Comparison O
with O
alkaline I-GENE
phosphatases I-GENE
and O
5 I-GENE
- I-GENE
nucleotidase RARE

Pharmacologic RARE
aspects O
of O
neonatal O
hyperbilirubinemia O
. O

When O
CSF O
[ O
HCO3 O
-] RARE
is O
shown O
as O
a O
function O
of O
CSF O
PCO2 O
the O
data O
of O
K O
- O
depleted O
rats O
are O
no O
longer O
displaced RARE
when O
compared O
to O
controls O
but O
still O
have O
a O
significantly O
greater O
slope O
( O
1 O
. O
21 O
+/- O
0 O
. O
23 O
vs O
. O

Flurazepam RARE
thus O
appears O
to O
be O
an O
effective O
hypnotic RARE
drug O
with O
the O
optimum RARE
dose O
for O
use O
in O
general O
practice O
being O
15 O
mg O
at O
night O
. O

Beta RARE
blocking O
agents O
. O

When O
extracorporeal RARE
CO2 O
removal O
approximated RARE
CO2 O
production O
( O
VCO2 NUMERIC
), O
alveolar O
ventilation O
almost O
ceased RARE
. O

Intravenous O
administration O
( O
25 O
mg O
/ O
kg O
) O
of O
carbonic RARE
anhydrase I-GENE
inhibitors O
( O
acetazolamide RARE
, O
methazolamide RARE
, O
dichlorphenamide RARE
, O
sulthiame RARE
) O
induced O
an O
early O
important O
rise O
of O
cortical O
p O
O2 O
, O
which O
is O
not O
dependent O
on O
increase O
of O
p O
O2 O
and O
p O
CO2 O
and O
decrease O
of O
pH O
in O
arterial O
blood O
. O

Teratological RARE
study O
of O
etoperidone RARE
in O
the O
rat O
and O
rabbit O
. O

Colorectal RARE
polyps O
should O
be O
removed O
endoscopically RARE
whenever RARE
possible O
. O

The O
variable O
HMG I-GENE
dosage O
regimen O
was O
found O
to O
offer O
no O
advantages O
when O
compared O
with O
our O
standard O
daily O
dosage O
regimen O
. O

When O
the O
CO2 O
content O
reached O
9 O
Vol RARE
% O
the O
animals O
became O
apathic RARE
and O
lost O
body O
weight O
. O

Serum I-GENE
gamma I-GENE
glutamyltransferase RARE
in O
the O
diagnosis O
of O
liver O
disease O
in O
cattle O
. O

By O
contrast O
, O
secretory I-GENE
HI ALLCAPS
antibodies I-GENE
were O
not O
demonstrated O
at O
the O
onset O
of O
illness O
in O
any O
of O
the O
patients O
, O
but O
their O
formation O
started O
early O
and O
the O
antibodies O
reached O
maximal O
levels O
about O
10 O
days O
after O
onset O
of O
illness O
. O

With O
the O
exception O
of O
virus O
assay O
and O
quantitation RARE
, O
these O
methods O
are O
simple O
and O
inexpensive RARE
enough O
to O
be O
done O
in O
typical O
shellfish RARE
microbiology RARE
laboratories O
. O

Characteristics RARE
of O
lipase I-GENE
activity O
. O

Takayasu RARE
' O
s O
disease O
: O
association O
with O
HLA I-GENE
- I-GENE
B5 NUMERIC
. O

SGPT ALLCAPS
, O
SGOT ALLCAPS
, O
and O
alkaline I-GENE
phosphatase I-GENE
concentrations O
were O
essentially O
normal O
in O
all O
subjects O
. O

Gamma RARE
glutamyl I-GENE
transpeptidase RARE
( O
GGTP ALLCAPS
) O
activity O
in O
the O
seminal O
fluid O

Patients O
with O
Parkinson O
' O
s O
disease O
showed O
a O
relatively O
high O
incidence O
to O
psychoses RARE
during O
drug O
treatment O
( O
51 O
. O
47 O
%). O

Selective O
stimulation O
of O
central O
alpha I-GENE
- I-GENE
autoreceptors RARE
following O
treatment O
with O
alpha O
- O
methyldopa RARE
and O
FLA ALLCAPS
136 O
. O

Anti O
- O
anxiety O
action O
of O
diazepam O
after O
intra O
- O
amygdaloid RARE
application O
in O
the O
rat O
. O

Abstracts RARE
. O

Removal O
of O
thick O
, O
permanently RARE
altered O
mucoas RARE
is O
recommended O
even O
in O
the O
absence O
of O
squamous O
epithelium O
. O

An O
IgG I-GENE
monoclonal O
gammopathy RARE
was O
present O
in O
the O
serum O
of O
4 O
patients O
and O
Bence RARE
- O
Joanes RARE
proteinuria RARE
was O
found O
in O
1 O
patient O
. O

Studies O
on O
immunoglobulin I-GENE
E I-GENE
: O
the O
impact O
of O
a O
sojourn RARE
with O
Professor RARE
Dan RARE
H O
. O

Peroxydase RARE
reaction O
stains RARE
were O
negative O
, O
chloroacetate RARE
esterase I-GENE
were O
strongly O
positive O
. O

Ten O
out O
- O
patients O
with O
pustulosis RARE
palmaris RARE
et O
plantaris RARE
were O
examined O
with O
direct O
immunofluorescence O
( O
IF O
) O
technique O
for O
deposition O
of O
fibrinogen I-GENE
, O
fibrin I-GENE
or O
its O
degradation O
products O
( O
FR I-GENE
- I-GENE
antigen I-GENE
) O
in O
affected O
and O
unaffected O
skin O
, O
together O
with O
heparin O
- O
precipitable RARE
fraction O
( O
HPF ALLCAPS
), O
cryoglobulin RARE
and O
total O
plasma O
fibrinogen I-GENE
in O
the O
blood O
. O

Of O
600 O
mediastinoscopies RARE
carried O
out O
from O
1966 NUMERIC
to O
1973 NUMERIC
, O
479 NUMERIC
were O
performed O
to O
assess O
the O
operability RARE
of O
a O
pulmonary O
carcinoma O
. O

A O
mixture O
of O
human I-GENE
albumin I-GENE
5 O
% O
and O
hydroxy O
- O
ethyl O
- O
starch RARE
was O
used O
as O
a O
solution O
for O
dilution O
. O

In O
the O
matched O
control O
group O
the O
acquisition O
- O
rate O
of O
both O
symptomatic O
and O
asymptomatic O
0acteriuria NUMERIC
was O
over O
12 O
%, O
a O
figure RARE
similar O
to O
the O
percentage O
of O
women O
present O
in O
the O
practice O
population O
during O
one O
year O
with O
transient O
, O
symptomatic O
, O
and O
persistent O
A O
. O
B O
. O

Late RARE
complications O
of O
catheterisation RARE
for O
intravenous O
nutrition O
. O

Prenatal RARE
diagnosis O
of O
galactosaemia RARE
. O

Sings RARE
which O
are O
indicative O
of O
metaplastic RARE
erythropoiesis RARE
are O
absent O
. O

False RARE
positive O
amniotic I-GENE
fluid I-GENE
alpha I-GENE
fetoprotein I-GENE
levels O
resulting O
from O
contamination O
with O
fetal O
blood O
: O
results O
of O
an O
experiment O
. O

Serum O
- O
ferritin I-GENE
in O
diagnosis O
of O
haemochromatosis RARE
. O

In O
2 O
subjects O
the O
phytomitogen RARE
reactivity O
of O
the O
lymphocytes O
was O
improved O
after O
treatment O
. O

Patients O
at O
risk O
of O
hypothyroidism O
. O

Albumin RARE
and O
cyclic O
AMP O
levels O
in O
peritoneal O
fluids O
in O
the O
child O

Preface RARE
. O

Thirty O
- O
five O
strains O
of O
Legionnaires RARE
' O
disease O
bacteria O
were O
shown O
to O
belong O
in O
four O
distinct O
serologic O
groups O
on O
the O
basis O
of O
findings O
obtained O
with O
direct O
fluorescent O
antibody O
testing O
. O

On O
the O
other O
hand O
factor I-GENE
IX I-GENE
activity O
is O
decreased O
in O
coumarin RARE
treatment O
with O
factor I-GENE
IX I-GENE
antigen O
remaining O
normal O
. O

The O
concentration O
of O
alpha I-GENE
2 I-GENE
- I-GENE
macroglobulin RARE
, O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
, O
plasminogen I-GENE
, O
C3 I-GENE
- I-GENE
complement I-GENE
, O
fibrinogen I-GENE
degradation I-GENE
products I-GENE
( O
FDP ALLCAPS
) O
and O
fibrinolytic RARE
activity O
, O
were O
studied O
in O
the O
aqueous O
humour RARE
and O
serum O
from O
nine O
patients O
with O
Fuchs RARE
' O
endothelial O
dystrophy O
, O
17 O
patients O
with O
uncomplicated RARE
senile O
cataract RARE
and O
in O
the O
secondary O
aqueous O
from O
six O
cataract RARE
patients O
. O

Only O
17 O
% O
of O
all O
patients O
admitted RARE
it O
at O
all O
times O
. O

Prazosin RARE
alone O
was O
effective O
in O
volume O
responsive O
patients O
at O
a O
dose O
of O
5 O
+/- O
1 O
. O
0 O
mg O
daily O
. O

T4 O
and O
FT4I NUMERIC
followed O
parallel O
courses O
in O
both O
groups O
; O
during O
the O
first O
45 O
days O
, O
however O
, O
the O
values O
were O
significantly O
lower O
in O
premature O
infants O
under O
34 O
weeks O
' O
EGA ALLCAPS
than O
in O
term O
infants O
( O
P O
less O
than O
0 O
. O
001 O
). O

A O
three O
- O
phased RARE
analysis O
of O
treatment O
plans RARE
for O
45 O
patients O
was O
undertaken O
. O

Aspirin RARE
intolerance RARE
: O
unaltered O
susceptibility O
of O
platelet I-GENE
cyclo RARE
- I-GENE
oxygenase I-GENE
to O
inhibition O
by O
aspirin O
in O
vitro O
. O

These O
results O
indicate O
that O
cynomolgus RARE
monkeys O
are O
either O
less O
sensitive O
or O
respond O
differently O
than O
rhesus O
monkeys O
to O
some O
of O
the O
pharmacological O
effects O
of O
norcocaine RARE
. O

59 O
cases O
of O
surgically O
resectable RARE
cancers O
( O
T1 O
, O
T2 O
, O
T3 O
, O
N0 NUMERIC
, O
N1 O
) O
had O
a O
minimum O
followup RARE
of O
two O
years O
( O
average O
4 O
years O
+/- O
3 O
months O
). O

The O
effect O
of O
CBZ ALLCAPS
and O
DPH ALLCAPS
can O
be O
explained O
by O
interference O
with O
thyroid O
hormone O
binding O
to O
TBG ALLCAPS
combined O
with O
enzyme O
- O
induced O
increased O
metabolic O
clearance O
rate O
of O
thyroid O
hormones O
without O
homeostatic RARE
maintenance O
of O
premedication RARE
levels O
of O
FT4 NUMERIC
and O
FT3 NUMERIC
. O

The O
present O
research O
evaluated O
the O
possibility O
that O
polyethylene RARE
glycol O
400 O
( O
PEG ALLCAPS
400 O
) O
might O
be O
efficacious RARE
, O
toxic O
, O
or O
both O
. O

According O
to O
their O
functional O
properties O
the O
latter O
neurons O
were O
subdivided RARE
into O
: O
( O
a O
) O
neurons O
responding O
to O
stimuli O
near O
the O
eyes O
; O
( O
b O
) O
neurons O
triggered O
by O
complex O
visual O
stimuli O
; O
( O
c O
) O
neurons O
inhibited O
by O
visual O
stimuli O
. O

Pentobarbital RARE
( O
1 O
, O
3 O
, O
10 O
, O
and O
17 O
. O
5 O
mg O
/ O
kg O
) O
was O
also O
tested O
in O
combination O
with O
rate O
- O
decreasing O
doses O
of O
normeperidine RARE
( O
17 O
. O
5 O
mg O
/ O
kg O
), O
anileridine RARE
( O
10 O
mg O
/ O
kg O
), O
alphaprodine RARE
( O
10 O
mg O
/ O
kg O
), O
and O
fentanyl O
( O
0 O
. O
3 O
mg O
/ O
kg O
). O

Pb RARE
foil RARE
( O
0 O
. O
55 O
gcm RARE
- O
2 O
) O
provided O
the O
best O
overall O
improvement O
. O

An O
anatomical O
and O
histochemical RARE
study O
has O
been O
undertaken O
and O
as O
a O
result O
emphasis RARE
is O
given O
to O
recent O
hypotheses RARE
that O
suggest O
there O
are O
similarities O
with O
Type O
IV O
glycogen O
storage O
disease O
( O
Andersen RARE
' O
s O
disease O
) O
which O
, O
although O
clinically O
distinct O
, O
has O
the O
same O
enzyme O
defect O
. O

All O
groups O
were O
tested O
in O
a O
Hebb RARE
- O
Williams RARE
maze RARE
at O
100 O
approximately O
10 O
days O
of O
age O
. O

Erythromycin RARE
and O
clindamycin O
resistance O
in O
Corynebacterium RARE
diphtheriae RARE
from O
skin O
lesions O
. O

Imposed RARE
angular RARE
displacements RARE
of O
monkey O
' O
s O
wrist O
produce O
three O
major O
peaks O
of O
activity O
( O
terms O
M1 O
, O
M2 NUMERIC
, O
and O
M3 NUMERIC
peaks O
) O
in O
the O
averaged O
gross O
EMG O
activity O
ot RARE
the O
stretched RARE
muscles O
. O

Hemolytic RARE
disease O
of O
African O
newborn O
. O

In O
this O
animal O
, O
infected O
with O
what O
was O
judged O
previously O
to O
be O
the O
less O
virulent O
of O
the O
two O
T O
. O
cruzi RARE
stocks RARE
used O
(' RARE
strain O
7 O
'), RARE
there O
was O
severe O
myocarditis RARE
, O
with O
myofibre RARE
degeneration O
, O
and O
lesions O
of O
the O
oesophagus RARE
. O

The O
majority O
of O
MRF ALLCAPS
units O
were O
behaviorally RARE
incongruent RARE
; O
in O
the O
most O
frequently O
observed O
case O
, O
their O
activity O
failed O
to O
change O
reliably RARE
when O
behavior O
habituated RARE
. O

Variability RARE
within O
Down RARE
' O
s O
syndrome O
( O
trisomy RARE
- O
21 O
): O
empirically RARE
observed O
sex O
differences O
in O
IQs RARE
. O

VII O
. O

Several O
demographic RARE
indices O
of O
isolated O
populations O
in O
Uzbekistan RARE

2 O
.-- RARE
concepts RARE
of O
higher O
nervous O
function O
in O
the O
USSR ALLCAPS
. O

The O
maintenance O
of O
increased O
myocardial O
capillary O
density O
required O
a O
similar O
amount O
of O
exercise O
, O
and O
at O
least O
1 O
h O
of O
exercise O
once O
a O
week O
was O
necessary O
to O
maintain O
the O
enlargement O
of O
ECA ALLCAPS
. O
20 O

These O
observations O
have O
led O
us O
to O
conclude O
that O
an O
elevated O
VIII O
- O
ratio O
is O
a O
very O
sensitive O
indicator O
of O
intravascular O
coagulation O
. O

Eight O
hours O
after O
the O
administration O
of O
colchicine RARE
, O
the O
serum I-GENE
ceruloplasmin RARE
level O
began RARE
to O
rise O
again O
in O
female O
rats O
, O
but O
not O
in O
male O
rats O
. O

Radioimmunoassays RARE
of O
pregnenolone RARE
, O
progesterone O
, O
dehydroepiandrosterone RARE
( O
DHA ALLCAPS
) O
16 O
alpha O
- O
hydroxy O
- O
DHA ALLCAPS
, O
estriol RARE
, O
and O
cortisol O
were O
performed O
on O
a O
total O
of O
0 O
; O
1 O
ml O
; O
of O
fetal O
plasma O
, O
collected O
during O
the O
course O
of O
normal O
vaginal O
delivery O
. O

In O
only O
two O
patients O
were O
we O
able O
to O
demonstrate O
changes O
suggestive O
of O
pulmonary O
metastases O
any O
earlier O
with O
a O
99mTc O
- O
EHDP ALLCAPS
scan O
than O
with O
chest O
radiographs O
and O
one O
of O
these O
resolved O
spontaneously O
. O

The O
majority O
of O
tumors O
occurred O
in O
the O
nasal O
cavities RARE
, O
although O
significant O
incidences RARE
were O
also O
found O
in O
the O
larynx O
, O
trachea RARE
and O
stem O
bronchi RARE
. O

Prediction RARE
of O
the O
times O
of O
sandfly RARE
development O

Native RARE
human I-GENE
fibrinogen I-GENE
was O
brought RARE
to O
coagulation O
by O
adding O
thrombin I-GENE
. O

No O
post O
- O
operative O
haemorrhages RARE
from O
the O
prostheses RARE
were O
observed O
. O

The O
Southern O
technique O
allowed O
a O
further O
localization O
of O
the O
region O
of O
most O
extensive O
transcription O
to O
a O
1 O
. O
8 O
kb O
HindIII I-GENE
- O
EcoRI I-GENE
fragment O
. O

Accepting RARE
arbitrarily RARE
chosen O
limits O
of O
maximized RARE
errors RARE
of O
+/- O
10 O
%, O
it O
could O
be O
shown O
that O
the O
system O
did O
not O
work O
acceptably RARE
when O
the O
mean O
carbon O
dioxide O
concentration O
was O
below O
1 O
. O
5 O
vol RARE
.% RARE
within O
the O
fresh O
gas O
flow O
rates O
( O
2 O
. O
2 O
-- O
7 O
. O
7 O
1 O
min O
- O
1 O
) O
and O
the O
range O
of O
minute O
ventilation O
( O
4 O
-- O
10 O
1 O
min O
- O
1 O
) O
employed O
. O

SV O
increased O
less O
in O
SHR ALLCAPS
, O
mainly O
reflecting O
the O
reduced O
diastolic O
compliance O
of O
the O
hypertrophied RARE
SHR ALLCAPS
left O
ventricle O
and O
the O
consequent RARE
rightward RARE
shift O
of O
its O
Frank RARE
- O
Starling RARE
curve O
. O

The O
carcass RARE
of O
a O
great O
horned RARE
owl RARE
( O
Bubo RARE
virginianus RARE
), O
which O
had O
been O
found O
moribund RARE
in O
southern O
Ontario RARE
, O
was O
presented O
for O
necropsy RARE
. O

The O
inner O
ears O
were O
exposed O
by O
microdissection RARE
, O
and O
the O
vestibular O
sensory O
regions O
were O
either O
sectioned RARE
and O
studied O
with O
light O
or O
electron O
microscopy O
, O
or O
prepared O
and O
studied O
with O
the O
surface O
specimen RARE
technique O
. O

Patulin RARE
is O
extracted O
from O
apple RARE
butter RARE
samples O
with O
ethyl O
acetate O
and O
the O
extract O
is O
cleaned RARE
up O
on O
a O
silica RARE
gel O
column O
, O
using O
benzene RARE
- O
ethyl O
acetate O
( O
75 O
+ O
25 O
) O
as O
the O
eluant RARE
. O

Steroid RARE
glucuronides RARE
in O
amniotic O
fluid O
at O
term O
. O

The O
matrix O
surrounding O
the O
clusters O
either O
showed O
a O
normal O
morphology O
or O
a O
homogeneous RARE
appearance O
, O
within O
which O
faint RARE
cross O
striations RARE
but O
no O
distinctly O
fibrillar RARE
outlines RARE
could O
be O
identified O
. O

Riboflavin RARE
did O
not O
affect O
the O
percentage O
of O
aflatoxin RARE
- O
treated O
animals O
with O
abnormal O
urinary O
excretion O
patterns O
, O
but O
did O
increase O
the O
magnitude O
of O
the O
disturbances O
in O
elimination O
of O
kynurenic RARE
and O
xanthurenic RARE
acids O
. O

Polyglactin RARE
910 NUMERIC
suture RARE
absorption O
and O
the O
role O
of O
cellular O
enzymes O
. O

The O
incidence O
of O
DNCB ALLCAPS
reactions O
was O
78 O
per O
cent O
for O
Stage O
I O
and O
II O
cancers O
( O
37 O
patinets RARE
), O
73 O
per O
cent O
for O
resectable RARE
Stage O
III O
cancer O
( O
22 O
patients O
), O
and O
66 O
per O
cent O
in O
patients O
with O
unresectable RARE
or O
inoperable RARE
Stage O
III O
cancer O
. O

Studies O
of O
lipoproteins O
should O
, O
however O
, O
be O
made O
in O
children O
from O
families O
known O
to O
have O
FH ALLCAPS
or O
early O
coronary O
heart O
disease O
. O

Sixteen RARE
other O
normal O
subjects O
with O
2 O
g O
of O
Metyrapone RARE
are O
best O
responses O
. O

EEG O
theta RARE
waves O
and O
psychological O
phenomena O
: O
a O
review O
and O
analysis O
. O

REM O
dream RARE
content O
was O
scored RARE
for O
categories O
suggesting O
the O
predominant O
influence O
of O
the O
left O
hemisphere O
, O
e O
. O
g O
., O
good O
ego RARE
functioning O
, O
verbalization RARE
, O
or O
the O
right O
hemisphere O
, O
e O
. O
g O
., O
music RARE
, O
spatial O
salience RARE
, O
bizarreness RARE
. O

Innervation RARE
of O
the O
ventral O
diaphragm O
of O
the O
locust RARE
( O
Locusta RARE
migratoria RARE
). O

Ectopic RARE
ACTH I-GENE
syndrome O
and O
medullary RARE
thyroid O
carcinoma O
. O

A O
striking O
finding O
in O
all O
of O
the O
studies O
was O
a O
positive O
correlation O
between O
PI O
ACTH I-GENE
and O
MSH I-GENE
contents O
. O

Chronic O
hypophosphatemia RARE
is O
the O
most O
common O
type O
of O
" O
resistant O
" O
rickets RARE
. O

There O
was O
no O
correlation O
between O
serum I-GENE
LH I-GENE
and O
chronological RARE
or O
bone O
age O
in O
this O
age O
group O
, O
which O
suggests O
that O
the O
correlation O
found O
is O
not O
due O
to O
age O
- O
related O
parallel O
phenomena O
. O

Molecular O
neurochemistry RARE
of O
addictive RARE
drugs O
. O

Efforts RARE
were O
made O
to O
determine O
the O
amount O
of O
time O
required O
for O
kidney O
lesions O
to O
develop O
and O
, O
if O
possible O
, O
to O
delineate RARE
the O
potential O
site O
of O
action O
of O
PBB ALLCAPS
. O

Effect O
of O
succimer RARE
on O
the O
intensity O
of O
tricarboxylic RARE
acid I-GENE
dehydrogenase I-GENE
reactions O
in O
the O
brain O
of O
rats O
poisoned RARE
with O
mercuric RARE
chloride O

Distribution RARE
and O
correlations O
of O
serum O
uric O
- O
acid O
in O
two O
French RARE
adult O
populations O
: O
13 O
, O
885 NUMERIC
men O
and O
6 O
, O
861 NUMERIC
women O

The O
incidence O
of O
hepatitis I-GENE
B I-GENE
antigen I-GENE
following O
transfusion O
was O
about O
2 O
. O
8 O
per O
cent O
. O

Technetium RARE
- O
99m O
stannous RARE
pyrophosphate RARE
myocardial O
scintigrams RARE
were O
obtained O
in O
138 NUMERIC
clinically O
stable O
patients O
32 O
. O
7 O
+/- O
47 O
. O
3 O
weeks O
( O
range O
6 O
to O
260 O
) O
after O
acute O
myocardial O
infarction O
. O

A O
similar O
phenomenon O
has O
been O
reported O
in O
a O
few O
humans O
. O

The O
decline O
in O
the O
activity O
of O
cytochrome I-GENE
oxidase I-GENE
, O
peroxidase I-GENE
and O
in O
the O
lipid O
content O
of O
peripheral O
neutrophils O
was O
followed O
by O
a O
decrease O
in O
the O
phagocytic O
activity O
. O

Treatment O
of O
2 O
patients O
with O
pseudohypoparathyroidism RARE
type O
I O
with O
vitamin O
- O
D O
- O
3 O
and O
1 O
alpha O
- O
Hydroxycholecalciferol RARE
consecutively RARE
resulted O
in O
a O
nonuniform RARE
response O
with O
regard O
to O
the O
normalisation RARE
of O
serum O
- O
calcium O
. O

Workers RARE
with O
" O
sensitivity O
" O
to O
toluene O
diisocyanate RARE
( O
TDI ALLCAPS
) O
studied O
in O
depth O
in O
an O
attempt O
to O
determine O
mechanisms O
of O
bronchial O
hyperreactivity RARE
. O

Total O
VO2 O
was O
decreased O
in O
both O
groups O
during O
severe O
hypoxia O
but O
limb O
VO2 O
was O
maintained O
in O
the O
beta O
- O
block O
group O
. O
beta O
- O
Block RARE
prevented O
the O
fall O
in O
total O
and O
limb O
peripheral O
resistance O
seen O
in O
severe O
hypoxia O
but O
did O
not O
alter O
the O
consistently O
more O
efficient O
utilization O
of O
total O
O2 O
delivery O
shown O
by O
the O
limb O
in O
comparison O
to O
the O
whole O
body O
by O
higher O
O2 O
extraction O
ratios O
and O
lower O
venous O
O2 O
pressure O
. O
beta I-GENE
- I-GENE
Vasodilator RARE
receptors I-GENE
evidently RARE
played O
an O
active O
part O
in O
the O
vasodilatation RARE
seen O
during O
severe O
hypoxia O
. O

Phenobarbital RARE
- O
induced O
alterations O
in O
the O
metabolism O
of O
[ O
3H O
] O
vitamin O
D3 O
by O
the O
perfused O
rachitic RARE
rat O
liver O
in O
vitro O
. O

Modulation RARE
of O
25 I-GENE
- I-GENE
hydroxyvitamin RARE
D3 I-GENE
- I-GENE
24 I-GENE
- I-GENE
hydroxylase I-GENE
by O
aminophylline RARE
: O
a O
cytochrome I-GENE
P I-GENE
- I-GENE
450 I-GENE
monooxygenase RARE
system O
. O

In O
both O
these O
respects RARE
, O
however O
, O
the O
DBP I-GENE
mRNA I-GENE
resembles O
the O
late O
messengers RARE
of O
SV40 O
and O
polyoma RARE
viruses O
. O

Effect O
of O
corticosteroid O
- O
containing O
antirheumatic RARE
combination O
drugs O
on O
endogenous O
ACTH I-GENE
and O
cortisol O
production O
. O

Serum I-GENE
ACTH I-GENE
did O
not O
respond O
to O
insulin I-GENE
and O
metyrapone RARE
. O

Anatomy RARE
of O
the O
RNA O
and O
gene O
products O
of O
MC29 NUMERIC
and O
MH2 NUMERIC
, O
two O
defective O
avian O
tumor O
viruses O
causing O
acute O
leukemia O
and O
carcinoma O
: O
evidence O
for O
a O
new O
class O
of O
transforming O
genes O
. O

Bertioga RARE
( O
Guama RARE
group O
) O
and O
Anhembi RARE
( O
Bunyamwera RARE
group O
), O
two O
new O
arboviruses RARE
isolated O
in O
Sao RARE
Paulo RARE
, O
Brazil RARE
. O

Gamma RARE
glutamyl I-GENE
transpeptidase RARE
activity O
was O
increased O
up O
to O
15 O
times O
above O
the O
upper O
normal O
limit O
in O
children O
, O
who O
received O
aminopyrine RARE
for O
two O
weeks O
or O
longer O
. O

XXI ALLCAPS
. O

A O
gas O
- O
liquid O
chromatographic O
method O
for O
the O
determination O
of O
p O
- O
chlorophenoxyisobutyric RARE
( O
CPIB ALLCAPS
) O
acid O
in O
blood O
plasma O
is O
described O
. O

Dopamine I-GENE
receptor I-GENE
blockade O
and O
the O
neuroleptics RARE
, O
a O
crystallographic RARE
study O
. O

V O
. O

A O
rapid O
fluorimetric RARE
procedure O
for O
the O
determination O
of O
the O
fungicide RARE
5 O
- O
fluorocytosine RARE
in O
serum O
is O
described O
. O

The O
' O
field O
of O
stress O
' O
of O
the O
supervisory RARE
nurse O

How RARE
do O
graduates RARE
of O
different O
types O
of O
programs O
perform O
on O
state O
boards RARE
? O

Similarly O
, O
maternal I-GENE
serum I-GENE
somatomedin RARE
A I-GENE
was O
significantly O
reduced O
in O
rats O
nursing O
large O
litters RARE
. O

The O
sequences O
following O
the O
X O
. O
borealis RARE
oocyte O
and O
somatic O
5S I-GENE
genes I-GENE
are O
identical O
in O
12 O
of O
the O
first O
14 O
residues O
and O
contain O
two O
or O
more O
T O
clusters O
, O
as O
does O
the O
corresponding O
region O
of O
X I-GENE
. I-GENE
laevis I-GENE
oocyte I-GENE
5S I-GENE
DNA I-GENE
. O

This O
mechanism O
is O
not O
due O
to O
the O
observed O
grain RARE
boundary O
precipitates RARE
. O

This O
report O
has O
reviewed O
some O
of O
the O
reasons RARE
for O
treatment O
failures RARE
and O
has O
presented O
a O
philosophy RARE
for O
their O
management O
. O

Diagnosis O
and O
treatment O
planning O
in O
Class O
II O
, O
division O
2 O

Because O
of O
serious O
infections O
( O
fever O
larger O
than O
or O
equal O
to O
101 O
degrees O
F O
. O
granulocytes RARE
less O
than O
1 O
, O
000 O
/ O
mm O
, O
3 O
and O
hospitalization RARE
) O
and O
1 O
drug O
death O
in O
the O
first O
4 O
patients O
, O
oral O
calcium O
leucovorin RARE
, O
20 O
to O
30 O
mg O
/ O
m2 O
orally O
, O
was O
given O
2 O
days O
after O
methotrexate O
in O
subsequent O
treatment O
cycles O
. O

It O
seems O
that O
the O
way O
in O
which O
drugs O
modify O
a O
patient O
' O
s O
serum O
chemistry O
may O
be O
used O
to O
assess O
the O
efficacy O
with O
which O
they O
control O
the O
inflammatory O
process O
. O

Here O
the O
conventional O
tests O
clearly O
pointed RARE
to O
the O
presence O
of O
retrocochlear RARE
disease O
. O

The O
end O
- O
stage O
or O
involutional RARE
phase O
of O
proliferative O
diabetic O
retinopathy RARE
may O
result O
in O
stabilization O
of O
vision O
for O
long O
periods O
of O
time O
. O

On O
the O
basis O
of O
serum I-GENE
alpha1AT NUMERIC
quantitation RARE
, O
newborn O
infants O
may O
be O
separated O
into O
two O
groups O
, O
characterized O
respectively O
by O
concentrations O
above O
or O
below O
150 O
mg O
%. O

In O
patients O
who O
were O
not O
vented RARE
, O
there O
was O
overall O
significant O
depression O
of O
function O
( O
67 O
+/- O
5 O
% O
of O
control O
; O
range O
, O
91 O
-- O
45 O
%, O
p O
less O
than O
0 O
. O
01 O
). O

Changes O
in O
body O
weight O
and O
agonistic RARE
behavior O
were O
also O
recorded O
. O

The O
uterine O
response O
to O
prostaglandin O
E2 O
( O
PGE2 O
) O
and O
prostaglandin O
F2alpha NUMERIC
( O
administered O
by O
intravenous O
and O
intrauterine O
routes O
) O
was O
evaluated O
during O
different O
phases O
of O
the O
menstrual O
cycle O
in O
five O
functionally O
infertile RARE
women O
. O

A O
total O
of O
26 O
BCG O
strains O
, O
out O
of O
them O
10 O
Czechoslovak RARE
strains O
( O
2 O
lyophilized RARE
cultures O
of O
BCG O
of O
different O
batch RARE
, O
6 O
strains O
isolated O
from O
abscesses RARE
of O
children O
after O
BCG O
- O
vaccination O
and O
2 O
strains O
from O
fatal O
cases O
after O
BCG O
- O
vaccination O
) O
and O
16 O
strains O
obtained O
from O
foreign O
laboratories O
, O
were O
used O
. O

High O
levels O
of O
serum O
calcitonin I-GENE
were O
found O
in O
patients O
with O
chronic O
renal O
failure O
. O

Detection O
of O
anti O
- O
lymphocyte O
antibodies O
using O
the O
immunoperoxidase RARE
antiglobulin RARE
technic RARE
. O

The O
response O
of O
serum I-GENE
GH I-GENE
to O
arginine O
infusion O
was O
normal O
, O
while O
that O
to O
insulin I-GENE
- O
induced O
hypoglycemia RARE
was O
poor O
. O

The O
mortality O
rate O
and O
histopathological O
features O
of O
Nocardia RARE
asteroides RARE
and O
Nocardia RARE
brasiliensis RARE
infections O
in O
congenitally RARE
athymic RARE
( O
nude O
) O
mice O
of O
ICR ALLCAPS
and O
C3H O
/ O
eB LASTCAP
origins O
were O
quite O
different O
from O
what O
we O
found O
for O
Swiss RARE
white O
mice O
and O
other O
inbred RARE
mouse O
strains O
( O
namely O
, O
C57 NUMERIC
/ O
BL ALLCAPS
/ O
6J NUMERIC
, O
New O
Zealand RARE
Black RARE
, O
BALB O
/ O
c O
, O
CBA ALLCAPS
/ O
LAC ALLCAPS
, O
and O
C3H O
/ O
eB LASTCAP
). O

Williams RARE
, O
2 O
August O
1977 NUMERIC
. O

Use O
of O
radioactive RARE
isotopes RARE
in O
the O
chemistry O
of O
proteins O

( O
Emeritus RARE
) O
John RARE
Henri RARE
Roosegaarde RARE
Bisschop RARE

Disrupted RARE
vaccines O
and O
whole O
- O
virus O
vaccines O
containing O
type I-GENE
B I-GENE
antigen I-GENE
only O
did O
not O
cause O
significant O
reactivity O
. O

255 NUMERIC
- O
61 O
. O

Antenatal RARE
diagnosis O
of O
haematological RARE
disorders O
--' RARE
1978 NUMERIC
'. O

Hepatic RARE
oxygen O
supply O
and O
selected O
blood O
parameters O
were O
recorded O
in O
fasted O
male O
rates O
given O
20 O
-- O
30 O
mg O
/ O
kg O
Escherichia I-GENE
coli I-GENE
endotoxin I-GENE
intraperitoneally RARE
. O

Gonadal RARE
dysfunction O
in O
patients O
with O
ataxia RARE
telangiectasia RARE
. O

The O
maximum O
period O
of O
treatment O
was O
73 O
( O
oral O
), O
73 O
( O
intraperitoneal RARE
) O
or O
75 O
( O
dermal O
) O
weeks O
. O

A O
study O
of O
the O
comparative O
efficacy O
of O
diflucortolone RARE
valerate RARE
0 O
. O
3 O
% O
ointment RARE
and O
clobetasol RARE
propionate RARE
0 O
. O
05 O
% O
ointment RARE
. O

Most O
of O
the O
phenomena O
of O
azotaemic RARE
osteodystrophy RARE
are O
encountered RARE
in O
simple O
vitamin O
D O
deficiency O
; O
as O
in O
that O
condition O
, O
deficiency O
of O
1 O
, O
25 O
- O
dihydroxycholecalciferol RARE
may O
be O
of O
primary O
significance O
in O
causing O
secondary O
hyperparathyroidism RARE
in O
renal O
failure O
. O

Basal O
FSH I-GENE
and O
LH I-GENE
levels O
were O
significantly O
lower O
in O
addicts O
; O
after O
GnRH I-GENE
stimulation O
the O
addicts O
' O
FSH I-GENE
and O
LH I-GENE
values O
increased O
but O
not O
significantly O
compared O
to O
controls O
. O

Adriamycin RARE
: O
comparison O
of O
a O
5 O
- O
week O
schedule O
with O
a O
3 O
- O
week O
schedule O
in O
the O
treatment O
of O
breast O
cancer O
. O

Follow RARE
- O
up O
controls O
of O
luteinizing RARE
hormone I-GENE
( O
LH I-GENE
), O
follicle I-GENE
stimulating I-GENE
hormone I-GENE
( O
FSH I-GENE
), O
prolactin I-GENE
( O
HPRL ALLCAPS
), O
oestradiol O
( O
E2 O
), O
progesterone O
( O
P O
) O
and O
testosterone O
( O
T O
) O
in O
the O
catabolic RARE
and O
healing O
phase O
of O
burn O
disease O
. O

Renin RARE
studies O
performed O
in O
34 O
hypertensive O
patients O
and O
in O
a O
control O
group O
of O
11 O
recipients O
showed O
that O
elevation O
of O
plasma I-GENE
renin I-GENE
activity O
and O
of O
plasma O
aldosterone O
level O
is O
frequent O
but O
difficult O
to O
interpret RARE
, O
particularly O
when O
a O
renal O
artery O
stenosis O
is O
observed O
. O

A O
randomized O
clinical O
trial O
in O
sixty RARE
- O
two O
adult O
patients O
suffering O
from O
typhoid RARE
fever O
, O
proved O
by O
blood O
and O
marrow O
culture O
, O
showed O
that O
amoxycillin RARE
in O
a O
dosage O
schedule O
of O
1 O
g O
8 O
- O
hourly RARE
orally O
for O
fourteen RARE
days O
was O
better O
than O
chloramphenicol O
with O
regard O
to O
clinical O
and O
temperature O
response O
and O
in O
respect O
of O
carriers O
and O
relapse O
rates O
. O

202 NUMERIC
- O
8 O
. O

Bone RARE
marrow O
transplantation O
- O
1979 NUMERIC
. O

In O
this O
article O
, O
the O
clinical O
actions O
of O
the O
principal O
dopamine I-GENE
receptor I-GENE
stimulating O
agents O
( O
apomorphine RARE
and O
its O
derivatives O
; O
piribedil RARE
, O
rye RARE
- O
ergot RARE
derivatives O
) O
are O
discussed O
on O
the O
basis O
of O
their O
biochemical O
and O
pharmacological O
properties O
. O

The O
unilateral O
vestibular O
hypofunction RARE
. O

Thus O
, O
the O
inhibition O
of O
pepsin RARE
in O
human O
gastric O
juice O
does O
not O
appear O
to O
have O
a O
major O
influence O
on O
the O
healing O
of O
duodenal O
ulcer O
. O

The O
IDF ALLCAPS
standard O
method O
for O
the O
detection O
of O
penicillin O
in O
milk O
is O
not O
suitable O
for O
the O
detection O
of O
sulphonamide RARE
residues O
in O
milk O
. O

Capsular RARE
antigens O
of O
Staphylococcus O
aureus O

The O
course O
of O
endotoxin O
fever O
remained O
uninfluenced RARE
by O
ALS ALLCAPS
. O

2 O
new O
Algerian RARE
cases O

Seventy O
- O
one O
percent O
of O
patients O
treated O
with O
ticarcillin RARE
alone O
responded O
favorably RARE
. O

Accurate RARE
pathologic O
staging RARE
identifies O
patients O
who O
are O
potentially O
curable RARE
with O
radiotherapy O
. O

Inherent RARE
hematology RARE
of O
old O
age O

Neomycin RARE
is O
fairly RARE
effective O
against O
staphylococci RARE
, O
less O
effective O
against O
streptococci RARE
, O
and O
fairly RARE
effective O
against O
gram O
- O
negative O
intestinal O
organisms O
. O

It O
was O
concluded O
, O
that O
on O
a O
given O
section O
, O
75 O
, O
7 O
per O
cent O
of O
the O
trabeculae RARE
were O
in O
contact O
with O
vascular O
cavities RARE
. O

2 O
. O

Changes O
in O
tissue O
PCO2 O
were O
less O
dramatic O
and O
did O
not O
vary O
significantly O
from O
those O
recorded O
in O
venous O
blood O
. O

Ultrasonic RARE
evaluation O
of O
renal O
calculi RARE
. O

Recognition RARE
of O
emphysema O
was O
poor O
when O
radiographs O
of O
inadequate RARE
quality O
were O
included O
( O
anteroposterior O
films O
or O
films O
from O
patients O
with O
acute O
or O
chronic O
lung O
disease O
). O

Isolation O
of O
T O
. O
gambiense RARE
strains O
in O
Zaire RARE
and O
their O
adaptation O
to O
laboratory O
animals O

Pharmacokinetic RARE
profile O
of O
clonazepam RARE
in O
rhesus O
monkeys O
. O

Immunologic RARE
mechanisms O
in O
chronic O
brucellosis RARE
in O
humans O
. O

Intestinal RARE
adaptation O
( O
first O
of O
two O
parts O
). O

In O
patients O
who O
had O
received O
no O
previous O
drug O
treatment O
, O
log O
baseline O
plasma I-GENE
renin I-GENE
activity O
and O
change O
in O
mean O
blood O
pressure O
after O
SQ ALLCAPS
20881 NUMERIC
correlated O
significantly O
( O
r O
= O
0 O
. O
651 NUMERIC
, O
P O
less O
than O
0 O
. O
05 O
). O

These O
techniques O
have O
been O
used O
by O
many O
people O
for O
many O
years O
and O
no O
claim RARE
is O
being O
made O
for O
any O
innovation RARE
in O
this O
regard O
. O

40 O
patients O
with O
chronic O
osteomyelitis RARE
were O
treated O
per O
os RARE
with O
the O
bactericidal O
beta O
- O
lactam RARE
- O
antibiotic O
cephalexin RARE
during O
3 O
to O
60 O
weeks O
. O

A O
total O
of O
57 O
patients O
with O
Hodgkin O
' O
s O
disease O
limited O
to O
above O
the O
diaphragm O
( O
Stages RARE
I O
and O
II O
, O
A O
and O
B O
) O
were O
treated O
with O
radiation O
therapy O
alone O
at O
the O
University O
of O
Florida RARE
between O
1964 NUMERIC
and O
1974 NUMERIC
. O

Year RARE
one O
of O
the O
first O
general O
practitioner RARE
medical O
unit O
in O
the O
greater O
Glasgow RARE
area O
. O

This O
multiple O
- O
electrode O
array RARE
for O
round O
window RARE
cochlear O
implantation O
is O
a O
robust RARE
, O
reliable O
system O
for O
inserting O
20 O
mm O
along O
the O
scala RARE
tympani RARE
with O
a O
minimum O
of O
trauma O
and O
can O
provide O
for O
bipolar O
stimulation O
. O

As O
authorized RARE
by O
the O
World RARE
Health O
Organization O
29th NUMERIC
Expert RARE
Committee O
on O
Biological O
Standardization RARE
, O
the O
preparation O
of O
human I-GENE
prolactin I-GENE
in O
ampoules RARE
coded O
75 O
/ O
504 NUMERIC
has O
been O
established O
as O
the O
International O
Reference RARE
Preparation RARE
( O
IRP ALLCAPS
) O
of O
human I-GENE
prolactin I-GENE
for O
immunoassay O
. O

i O
. O

Biliary RARE
- O
enteric O
fistulas RARE

Plasma O
ion O
changes O
in O
venous O
blood O
incubated O
with O
beta I-GENE
receptor I-GENE
blockers O
and O
subjected O
to O
tonometry RARE
in O
vitro O
. O

Such O
marked O
differences O
are O
found O
occasionally RARE
in O
the O
literature O
: O
heterophile RARE
antibodies O
against O
bovine I-GENE
gammaglobulin RARE
are O
regarded O
as O
responsible O
for O
the O
interference O
in O
the O
Sephadex RARE
system O
of O
RIST ALLCAPS
. O

" O
Let RARE
the O
hundred O
flowers RARE
bloom RARE
". O

Various O
treatment O
modalities O
are O
reviewed O
in O
the O
context O
of O
the O
psychology RARE
as O
well O
as O
the O
physiology O
of O
severe O
intractable RARE
pain O
. O

Lethal RARE
Tachmalcor RARE
( O
4 O
-( O
3 O
'- O
diethylamino RARE
- O
2 O
'- O
hydroxypropyl RARE
)- O
ajmaline RARE
) O
poisoning O
in O
childhood O

Ophthalmosonographic RARE
evaluation O
of O
blood O
flow O
velocity O
in O
arteriocavernous RARE
fistula RARE

Serum O
ferritin I-GENE
concentration O
and O
bone O
marrow O
iron O
stores RARE
. O

The O
systolic O
pressure O
gradient O
( O
SPG ALLCAPS
) O
between O
the O
left O
ventricle O
( O
LV O
) O
and O
left O
atrium O
( O
LA O
) O
was O
obtained O
from O
high O
- O
fidelity O
pressure O
transducers RARE
. O

A O
prospective O
trail RARE
comparing O
hysterectomy O
, O
hysterectomy O
plus O
vaginal O
radium RARE
, O
and O
uterine O
radium RARE
plus O
hysterectomy O
in O
stage O
I O
endometrial O
carcinoma O
. O

On O
the O
basis O
of O
a O
patient O
' O
s O
report O
of O
one O
inaccurate RARE
Clinitemp RARE
, O
we O
undertook RARE
to O
investigate O
the O
accuracy O
of O
this O
thermometer RARE
. O

Cryoglobulinemia RARE
in O
Raynaud RARE
' O
s O
syndrome O

Data O
were O
processed O
with O
a O
semi RARE
- O
automatic O
computer O
program O
which O
develops RARE
an O
averaged O
- O
volume O
curve O
from O
an O
assigned O
LV O
region O
- O
of O
- O
interest O
. O

The O
preferential O
serum I-GENE
IgA I-GENE
response O
observed O
in O
the O
patient O
population O
suggests O
that O
bronchial O
associated O
lymphoid O
tissue O
in O
the O
diseased O
lung O
is O
an O
important O
source O
of O
circulating O
IgA I-GENE
. O

Ultimate RARE
strengthes RARE
seem O
to O
be O
reached O
for O
cast RARE
cobalt RARE
alloys RARE
, O
whereas O
titanium RARE
alloys RARE
, O
such O
as O
Ta RARE
6 O
V O
, O
present O
very O
high O
fatigue RARE
limit O
under O
corrosion RARE
. O

The O
effects O
of O
intracisternal RARE
injection O
( O
i O
. O
c O
. O
i O
.) O
of O
clonidine RARE
( O
1 O
microgram O
kg O
- O
1 O
) O
on O
blood O
pressure O
and O
heart O
rate O
were O
studied O
in O
conscious O
rabbits O
with O
an O
implanted O
catheter O
in O
the O
cisterna RARE
magna RARE
. O

Platelet O
number O
and O
life O
span O
were O
determined O
in O
the O
last O
trimester RARE
of O
pregnancy O
in O
22 O
women O
who O
were O
delivered O
of O
small O
- O
for O
- O
gestational O
age O
( O
SGA ALLCAPS
) O
infants O
and O
in O
21 O
women O
with O
infants O
having O
normal O
birth O
weights O
. O

Serial RARE
measurements O
of O
total O
serum O
IgE I-GENE
appears O
to O
be O
a O
useful O
index O
of O
disease O
activity O
in O
ABPA ALLCAPS
. O

In O
the O
8 O
patients O
the O
difference O
betweent RARE
he RARE
mean O
diastolic O
values O
of O
delta O
PU O
and O
delta O
PM ALLCAPS
was O
- O
0 O
. O
54 O
+/- O
1 O
. O
0 O
( O
SD O
) O
mmHg O
. O

A O
rise O
of O
hemoglobin I-GENE
concentration O
accompanied O
by O
an O
increase O
of O
the O
total O
iron O
in O
the O
blood O
serum O
of O
white O
mice O
was O
found O
under O
oxygen O
pressure O
of O
4 O
atm RARE
for O
an O
hour O
( O
preconvulsive RARE
state O
) O
and O
6 O
atm RARE
( O
convulsive RARE
state O
). O

Nernst RARE
-- O
Planck RARE
analog O
equations RARE
and O
stationary O
state O
membrane O
electric RARE
potentials O
. O

Effects O
of O
methylene O
chloride O
, O
trichloroethane RARE
, O
trichloroethylene RARE
, O
tetrachloroethylene RARE
and O
toluene O
on O
the O
development O
of O
chick O
embryos O
. O

Effect O
of O
intraventricular RARE
administration O
of O
streptolysin RARE
O I-GENE
on O
the O
electroencephalogram RARE
of O
rabbits O
. O

In O
this O
situation RARE
the O
convlusion RARE
threshold O
for O
the O
8 O
substances O
is O
as O
follows O
: O
pethidine RARE
20 O
mg O
. O
kg O
- O
1 O
I O
. O
V O
., O
piritramide RARE
30 O
, O
morphine O
180 O
, O
phenoperidine RARE
4 O
, O
R O
39 O
209 NUMERIC
5 O
, O
fentanyl O
4 O
, O
sufentanil RARE
4 O
and O
R O
34 O
995 NUMERIC
10 O
mg O
. O
kg O
- O
1 O
I O
. O
V O
. O

The O
biochemistry RARE
of O
amniotic O
fluid O
with O
poor O
fetal O
growth O
. O

Roentgenographically RARE
, O
the O
lesion O
was O
usually O
a O
well O
- O
defined O
and O
benign O
appearing RARE
one O
, O
either O
purely RARE
lytic O
( O
3 O
cases O
) O
or O
with O
central O
radiodensity RARE
( O
2 O
cases O
). O

Effects O
of O
chronic O
descending RARE
tractotomy RARE
on O
the O
response O
patterns O
of O
neurons O
in O
the O
trigeminal RARE
nuclei O
principalis RARE
and O
oralis RARE
. O

Efficacy RARE
of O
a O
three O
- O
versus O
a O
five O
- O
week O
alcohol O
treatment O
program O
. O

Resistance O
to O
the O
simulated O
physiologic RARE
environment O
was O
tested O
by O
measured O
retention O
of O
mechanical O
properties O
after O
immersion O
times O
in O
pseudo RARE
- O
extracellular O
fluid O
( O
PECF ALLCAPS
) O
at O
37 O
degrees O
C O
for O
as O
long O
as O
three O
years O
. O

Isolated RARE
calcaneal RARE
tuberculous O
osteomyelitis RARE
. O

It O
is O
concluded O
that O
opiate I-GENE
receptors I-GENE
bordering RARE
the O
fourth O
cerebral O
ventricle O
mediate O
the O
cardiovascular O
and O
hypnotic RARE
action O
of O
fentanyl O
. O

In O
case O
of O
a O
pathologically RARE
convoluted RARE
internal O
carotid O
the O
common O
carotid O
artery O
was O
resected RARE
with O
an O
end O
- O
to O
- O
end O
anastomosis O
. O

This O
expression O
assumes RARE
: O
( O
1 O
) O
a O
laminar RARE
flow O
regimen O
during O
expiration RARE
, O
and O
( O
2 O
) O
a O
constant O
CT O
value O
over O
the O
range O
of O
VT O
. O

These O
data O
confirm O
the O
existence O
of O
hyperlipemic RARE
abdominal O
crisis RARE
as O
a O
distinct O
entity RARE
and O
testify RARE
to O
the O
importance O
of O
recognizing RARE
this O
syndrome O
in O
order O
to O
avoid O
the O
occurrence O
of O
acute O
pancreatitis O
and O
the O
performance O
of O
unnecessary RARE
and O
potentially O
harmful RARE
surgery O
. O

In O
addition O
a O
significant O
Treatment O
X O
Strain RARE
interaction O
was O
due O
to O
the O
larger O
defecation RARE
numbers O
displayed O
by O
the O
taurine RARE
- O
injected O
MR O
rats O
relative O
to O
the O
saline O
- O
injected O
MR O
rats O
. O

Their O
conduction O
velocity O
ranged O
from O
0 O
. O
23 O
to O
0 O
. O
98 O
m O
/ O
sec O
( O
group O
C O
). O

The O
failures RARE
frequently O
were O
related O
to O
patient O
intolerance RARE
or O
poor O
mechanical O
fit O
and O
occurred O
in O
the O
first O
few O
days O
or O
first O
few O
months O
after O
insertion O
. O

The O
major O
urinary O
metabolites O
were O
3 O
-( O
3 O
- O
carboxyphenyl RARE
)- O
5 O
- O
hydroxymethyl RARE
- O
2 O
- O
oxazolidinone RARE
and O
a O
glucuronide RARE
of O
toloxatone RARE
. O

These O
characteristics O
indicated O
the O
pronounced O
activity O
of O
collagenous RARE
fiber O
synthesis O
and O
the O
matrix O
of O
the O
osteoid RARE
tissue O
. O

The O
ventilation O
did O
not O
increase O
when O
PACO2 NUMERIC
was O
increased O
. O

Carbohydrate RARE
metabolism O
and O
the O
semen O
profile O
: O
glucose O
, O
insulin I-GENE
, O
and O
sperm O
studies O
. O

It O
has O
come RARE
out O
that O
CAEC ALLCAPS
is O
between O
CC O
and O
CIEC ALLCAPS
and O
that O
attacks O
of O
biliary O
fever O
and O
high O
levels O
of O
alkaline I-GENE
phosphatase I-GENE
and O
transaminases RARE
in O
the O
serum O
are O
the O
helpful O
findings O
for O
preoperative O
diagnosis O
. O

The O
sub O
- O
acute O
inhalation O
toxicity O
of O
furfural RARE
was O
studied O
in O
Syrian O
golden RARE
hamsters O
. O

Changes O
of O
thirtynine RARE
serum O
protein O
components O
following O
surgical O
stress O
. O

These O
differences O
are O
smaller O
than O
those O
described O
in O
standard O
textbooks RARE
. O

A O
study O
of O
the O
E O
. O
O O
. O
R O
. O
T O
. O
C O
. O

The O
present O
study O
examined O
the O
dependence O
of O
difference O
tone O
level O
[ O
L O
( O
f2 NUMERIC
- O
f1 O
)] O
on O
the O
following O
parameters O
of O
the O
two O
- O
tone O
input O
: O
f1 O
, O
f2 NUMERIC
/ O
f1 O
( O
f2 NUMERIC
greater O
than O
f1 O
), O
L1 O
, O
L2 O
, O
and O
L1 O
= O
L2 O
. O

An O
intravenous O
preparation O
of O
doxycycline RARE
( O
DOTC ALLCAPS
, O
Vibramycin RARE
' O
Pfizer RARE
'), RARE
a O
long O
- O
lasting O
tetracycline RARE
, O
was O
administered O
mainly O
by O
drip RARE
infusion O
for O
a O
series O
of O
study O
in O
the O
pediatrics RARE
field O
, O
and O
the O
results O
were O
as O
follows O
: O
1 O
) O
DOTC ALLCAPS
( O
100 O
mg O
) O
was O
dissolved RARE
in O
a O
100 O
ml O
of O
glucose O
solution O
and O
2 O
-- O
3 O
mg O
/ O
kg O
was O
administered O
intravenously O
. O

5 O
) O
Before RARE
and O
ten O
days O
after O
DOTC ALLCAPS
infusion O
, O
laboratory O
tests O
for O
liver O
and O
renal O
functions O
and O
blood O
were O
performed O
. O

Structural O
characteristics O
of O
the O
erythrocyte O
membrane O
, O
peroxidation O
processes O
and O
antioxidant O
function O
in O
children O
with O
diffuse O
glomerulonephritis O

The O
enteric O
route O
is O
the O
principal O
mode O
of O
transmission O
for O
hepatitis O
A O
, O
but O
maximal O
levels O
of O
hepatitis O
A O
virus O
excretion O
occur O
before O
the O
onset O
of O
jaundice O
. O

All O
13 O
patients O
showed O
endoscopic RARE
evidence O
of O
oesophagitis RARE
, O
moderate O
in O
4 O
and O
severe O
in O
9 O
. O

Urinary RARE
excretion O
of O
oestrone RARE
, O
oestradiol O
- O
17 O
beta O
and O
oestriol RARE
in O
pregnancies RARE
complicated O
by O
steroid I-GENE
sulphatase RARE
deficiency O
. O

Both O
reduced O
spontaneous O
locomotor O
activity O
in O
mice O
, O
protected O
them O
from O
death O
from O
amphetamine O
induced O
toxicity O
, O
prolonged O
hexobarbitone RARE
sleeping RARE
time O
and O
caused O
a O
depletion O
of O
catecholamines O
from O
various O
organs O
of O
the O
rat O
. O

On O
the O
role O
of O
transferrin I-GENE
in O
the O
uptake O
of O
gallium RARE
by O
tumor O
cells O
. O

Irradiation RARE
of O
human O
blood O
platelets O
with O
UV O
- O
A O
in O
vitro O
impairs RARE
their O
ability O
to O
aggregate RARE
after O
challenge O
with O
collagen I-GENE
. O

With O
certain O
exceptions RARE
the O
method O
was O
considered O
suitable O
in O
the O
routine O
intravenous O
cholangiography RARE
. O

Following O
the O
satisfactory O
results O
and O
taking O
into O
account O
that O
the O
complications O
had O
reduced O
to O
a O
very O
low O
rate O
( O
in O
2 O
cases O
lead O
tip O
displacement O
and O
pouch RARE
haematoma RARE
occurred O
respectively O
), O
the O
Authors RARE
consider O
the O
adopted O
method O
an O
useful O
approach O
for O
PMK ALLCAPS
implantation O
particularly O
when O
the O
use O
of O
the O
vena RARE
cephalica RARE
is O
deemed RARE
impossible RARE
. O

When O
two O
determinations O
were O
performed O
on O
12 O
samples O
of O
plasma O
taken O
from O
normal O
adults O
in O
October RARE
, O
the O
values O
were O
22 O
. O
6 O
+/- O
4 O
. O
8 O
and O
21 O
. O
0 O
+/- O
3 O
. O
6 O
( O
mean O
+/- O
SD O
) O
ng O
/ O
ml O
, O
respectively O
. O

The O
six O
commonest RARE
causes O
of O
death O
varied O
in O
the O
three O
ethnic RARE
groups O
. O

Although O
Grice RARE
' O
s O
operation O
has O
been O
used O
all O
over O
the O
world O
, O
no O
systematic O
account O
of O
it O
has O
been O
found O
in O
the O
literature O
( O
including O
publications RARE
dealing RARE
with O
technique O
), O
which O
presents O
it O
in O
terms O
related O
to O
the O
basic O
" O
classical O
" O
principles RARE
on O
which O
the O
operation O
was O
conceived RARE
. O

( O
5 O
) O
No O
changes O
were O
observed O
in O
the O
gastric O
venous O
blood O
flow O
by O
continuous O
intravenous O
injection O
of O
cimetidine O
, O
but O
by O
rapid O
injection O
both O
the O
flow O
was O
augmented O
and O
the O
systemic O
blood O
pressure O
decreased O
transiently O
. O

Study O
on O
re O
- O
establishment O
of O
ovulation O
after O
termination O
of O
sex O
- O
steroidal RARE
treatment O
-- O
compared O
with O
re O
- O
appearance O
of O
ovulation O
after O
abortion O
and O
premature O
delivery O
. O

Pharmacokinetics RARE
of O
Carbamazepine RARE
in O
man O
: O
a O
review O
. O

Of O
the O
compounds O
tested O
, O
alpha O
-( O
3 O
- O
methyl O
- O
2 O
- O
quinoxalinyl RARE
)- O
N O
- O
methylnitrone RARE
1 O
, O
4 O
- O
dioxide O
( O
2 O
) O
was O
the O
most O
active O
agent O
in O
vivo O
against O
the O
gram O
- O
negative O
and O
the O
gram O
- O
positive O
organisms O
. O

Changes O
in O
ionic O
content O
of O
the O
mucous RARE
suggest O
that O
cholinergic O
mechanisms O
affect O
pressure O
in O
the O
excretory RARE
duct O
of O
the O
gland O
. O

Calves RARE
fed O
MCT ALLCAPS
- O
milk O
had O
significantly O
lower O
blood O
cholesterol O
than O
calves O
fed O
T O
- O
or O
SBO ALLCAPS
- O
milk O
. O

Delayed RARE
mortality O
of O
mice O
following O
inhalation O
of O
acute O
doses O
of O
CH2O NUMERIC
, O
SO2Cl2 NUMERIC
, O
and O
Br2 NUMERIC
. O

Guinea RARE
pigs O
weighing RARE
300 O
approximately O
350 O
g O
were O
used O
. O

Under O
halothane O
anesthesia O
, O
the O
flow O
pneumocardiogram RARE
( O
PnCG LASTCAP
) O
and O
its O
time O
derivative O
( O
acceleration RARE
pneumocardiogram RARE
or O
dPn RARE
/ O
dt O
) O
were O
transduced RARE
during O
apnea O
by O
a O
small O
high O
- O
gain O
pneumotachograph RARE
. O

Sensory RARE
kindling O
: O
implications O
for O
development O
of O
sensory O
prostheses RARE
. O

It O
is O
concluded O
that O
stereotypy RARE
can O
be O
evoked O
also O
in O
the O
case O
when O
the O
striatal RARE
dopaminergic O
tone O
is O
normal O
or O
even O
below O
normal O
: O
it O
is O
the O
equilibrium O
of O
the O
striatal RARE
cholinergic O
- O
dopaminergic O
systems O
which O
must O
be O
shifted O
towards O
dopamine O
, O
which O
is O
necessary O
for O
the O
development O
of O
this O
behavioral O
manifestation O
. O

None O
of O
the O
cystometrograms RARE
showed O
uninhibited RARE
detrusor RARE
contractions O
. O

In O
the O
duodenum RARE
a O
small O
part O
of O
the O
administered O
dose O
was O
transformed O
to O
3H O
- O
alpha O
- O
acetyldigoxin RARE
. O

Functional O
effects O
following O
subacute O
administration O
. O

Treatment O
of O
Graves RARE
' O
disease O
. O

Although O
it O
has O
been O
shown O
that O
it O
is O
possible O
to O
use O
orally O
administered O
testosterone O
to O
maintain O
se RARE
- O
T O
levels O
in O
the O
normal O
male O
range O
, O
the O
convenience RARE
to O
the O
patient O
must O
be O
balanced RARE
against O
the O
cost O
and O
possible O
side O
effects O
of O
the O
large O
doses O
required O
. O

Contrary RARE
to O
1 O
, O
8 O
- O
dihydroxy RARE
- O
9 O
- O
anthrone RARE
, O
1 O
, O
8 O
, O
9 O
- O
triacetoxyanthracene RARE
and O
1 O
, O
8 O
- O
diacetoxy RARE
- O
9 O
- O
anthrone RARE
are O
effective O
against O
psoriatic RARE
lesions O
without O
accompanying O
inflammations RARE
of O
the O
skin O
. O

Etiopathogenetic RARE
and O
therapeutic O
problems O
in O
acute O
orbital RARE
inflammation O

Nursing RARE
of O
patients O
with O
gynecological RARE
diseases O

We O
measured O
basal O
plasma O
prolactin I-GENE
concentrations O
( O
in O
samples O
obtained O
during O
the O
early O
follicular O
phase O
) O
in O
25 O
normal O
( O
control O
) O
women O
and O
in O
a O
similar O
group O
of O
40 O
patients O
with O
a O
long O
- O
standing RARE
history O
of O
infertility O
. O

Ovarian RARE
allotransplantation RARE
in O
human O
. O

Allergic RARE
reaction O
to O
Patent RARE
Blue RARE
Violet RARE
during O
lymphography RARE
. O

Screening RARE
of O
asthma O
patients O
by O
determination O
of O
IgE I-GENE
and O
by O
comprehension RARE
of O
spectrum O
of O
allergospecific RARE
IgE I-GENE
antibodies I-GENE

The O
induction O
of O
seizures O
in O
" O
Papio RARE
papio RARE
" O
following O
allylglycine RARE
alone O
or O
in O
combination O
with O
intermittent O
photic RARE
stimulation O

A O
highly O
significant O
correlation O
was O
found O
between O
the O
presence O
of O
fibrinolytic RARE
degradation O
products O
( O
FDP ALLCAPS
) O
and O
the O
incidence O
of O
nephropathy O
and O
renal O
insufficiency O
, O
as O
well O
as O
between O
the O
presence O
of O
fibrin I-GENE
monomers RARE
( O
Godal RARE
' O
s O
ethanol O
- O
gelification RARE
test O
) O
and O
the O
evolutive RARE
signs O
of O
the O
primary O
disease O
( O
fever O
, O
accelerated O
ESR ALLCAPS
). O

One O
- O
third O
of O
the O
men O
with O
azoospermia RARE
and O
with O
sperm O
density O
of O
less O
than O
10 O
million O
had O
marked O
FSH I-GENE
elevation O
and O
our O
experience O
confirms RARE
the O
work O
of O
others O
that O
this O
indicates O
a O
poor O
prognosis O
. O

In O
girls O
prolactin I-GENE
levels O
rise O
at O
stage O
2 O
, O
and O
are O
higher O
after O
menarche RARE
; O
in O
boys O
there O
is O
no O
change O
in O
prolactin I-GENE
levels O
. O

It O
was O
concluded O
that O
both O
of O
these O
surgical O
procedures O
were O
as O
effective O
as O
pinealectomy RARE
in O
reversing RARE
the O
pineal O
- O
induced O
alterations O
in O
the O
reproductive O
physiology O
of O
the O
blind O
- O
anosmic RARE
female O
rat O
. O

2 O
cases O
of O
toxic O
lymphomononucleosis RARE

Such O
an O
hemoglobin I-GENE
solution O
was O
shown O
to O
exhibit O
a O
high O
affinity O
for O
oxygen O
and O
a O
low O
Bohr RARE
effect O
( O
assessed O
from O
the O
delta O
log O
Po2 NUMERIC
/ O
delta O
pH O
ratio O
). O

A O
one O
- O
week O
ulcer O
therapy O
with O
atropine O
and O
Vikalin RARE
( O
Roter RARE
) O
led O
to O
a O
significant O
( O
p O
less O
than O
0 O
. O
01 O
) O
reduction O
of O
the O
nocturnal RARE
proteolytic O
activity O
. O

In O
one O
patient O
with O
severe O
diarrhea RARE
the O
estriol RARE
concentration O
in O
serum O
was O
low O
until O
the O
intestinal O
function O
normalised RARE
and O
the O
estriol RARE
concentration O
went RARE
up O
exactly RARE
when O
the O
diarrhea RARE
stopped O
. O

Serum O
levels O
of O
IgG I-GENE
and O
IgM I-GENE
were O
also O
raised O
, O
but O
contrary RARE
to O
the O
findings O
of O
other O
observers RARE
IgA I-GENE
levels O
were O
normal O
. O

Experimental O
ischemic O
heart O
disease O
induced O
by O
thromboxane O
A2 O
in O
rabbits O
. O

Vitrectomy RARE
in O
ocular O
traumatology RARE

To O
study O
the O
sensitivity O
of O
some O
central O
brain O
structures O
to O
the O
action O
of O
an O
electromagnetic RARE
field O
of O
decimeter RARE
waves O
( O
EMF ALLCAPS
of O
DW ALLCAPS
) O
a O
dynamic O
investigation O
of O
single O
unit O
activity O
was O
undertaken O
. O

No O
systematic O
L O
- O
R O
differences O
were O
observed O
. O

A O
decrease O
of O
the O
lysozyme I-GENE
activity O
coincided RARE
with O
the O
clinical O
improvement O
of O
the O
bacterial O
meningitis O
. O

This O
implies RARE
that O
the O
groups O
do O
not O
just O
differ O
along O
one O
dimension RARE
, O
but O
along O
three O
dimensions O
. O

Deep RARE
tans RARE
were O
induced O
over O
the O
backs RARE
of O
volunteers O
with O
repeated O
exposure O
to O
longwave RARE
ultraviolet RARE
radiation O
( O
UV O
- O
A O
). O

1 O
The O
effects O
in O
normal O
subjects O
of O
a O
single O
oral O
dose O
of O
Motival RARE
( O
one O
tablet O
, O
containing O
fluphenazine RARE
0 O
. O
5 O
mg O
and O
nortriptyline RARE
10 O
mg O
) O
on O
the O
contingent RARE
negative O
variation O
( O
CNV O
), O
reaction O
time O
, O
heart O
rate O
, O
blood O
pressure O
and O
self O
- O
rating O
scales RARE
for O
alertness RARE
, O
anxiety O
, O
tension O
, O
detachment RARE
and O
depression O
were O
compared O
with O
those O
of O
diazepam O
( O
5 O
mg O
and O
7 O
. O
5 O
mg O
) O
and O
placebo O
or O
propranolol O
( O
60 O
mg O
). O

Stress RARE
effects O
on O
affiliation RARE
preferences RARE
among O
subjects O
possessing RARE
the O
type O
A O
coronary O
- O
prone O
behavior O
pattern O
. O

These O
show O
that O
the O
collagen I-GENE
in O
this O
tissue O
is O
modified O
compared O
with O
that O
in O
tendon O
. O

Smoking RARE
was O
regarded O
as O
the O
major O
contribution O
to O
pulmonary O
dysfunction O
. O

The O
malignity RARE
of O
nevoid RARE
lentigo RARE
. O

Elimination O
of O
bagassosis RARE
in O
Louisiana RARE
paper O
manufacturing RARE
plant O
workers O
. O

These O
responses O
were O
compared O
with O
others O
in O
the O
same O
subjects O
under O
the O
same O
conditions O
and O
it O
was O
concluded O
that O
the O
antihypertensive O
effect O
of O
labetalol RARE
is O
explained O
by O
concurrent O
blockade O
of O
alpha I-GENE
- I-GENE
and I-GENE
beta I-GENE
- I-GENE
adrenoceptors I-GENE
. O

Diuretics RARE
: O
basic O
clinical O
pharmacology RARE
and O
therapeutic O
use O
. O

Three O
patients O
with O
four O
renoureteral RARE
units O
have O
undergone O
single O
- O
stage O
reconstruction O
involving O
ureteroureterostomy RARE
and O
ipsilateral O
ureteroneocystostomy RARE
following O
temporary O
loop O
cutaneous O
ureterostomy RARE
. O

Evaluation O
of O
the O
Du RARE
Pont RARE
aca RARE
ammonia O
procedure O
. O

Internally RARE
oriented RARE
patients O
' O
scores O
on O
Rotter RARE
' O
s O
Internal RARE
- O
External RARE
Locus RARE
of O
Control O
Scale O
remained O
the O
same O
over O
treatment O
but O
those O
of O
externally RARE
oriented RARE
patients O
shifted O
toward O
greater O
internal O
control O
. O

Action RARE
of O
strontium RARE
- O
90 O
and O
metaphos RARE
on O
Cyprinus RARE
carpio RARE

Kodak RARE
XV ALLCAPS
- O
2 O
film RARE
is O
wrapped RARE
around O
a O
cylindrical RARE
water O
- O
filled O
phantom RARE
and O
the O
dose O
distribution O
is O
recorded O
. O

Diagnosis O
and O
differential O
diagnosis O

The O
multiple O
factors O
affecting O
plasma O
renin I-GENE
activity O
in O
essential O
hypertension O
. O

Cortisone RARE
induced O
bone O
changes O
and O
its O
response O
to O
lipid O
clearing RARE
agents O
. O

2 O
) O
The O
time O
- O
sharing RARE
principle RARE
was O
applied O
to O
gain O
high O
stability O
. O

When O
blood O
samples O
of O
patients O
with O
hyperbilirubinemia O
were O
analyzed O
, O
direct O
measurement O
of O
ZPP ALLCAPS
by O
this O
fluorimeter RARE
yielded O
significantly O
higher O
levels O
than O
did O
an O
alternate O
extraction O
method O
. O

Delayed RARE
hypersensitivity O
in O
man O
: O
effects O
of O
systemic O
anticoagulation RARE
. O

In O
three O
of O
the O
seven O
, O
inhalation O
of O
2 O
ml O
normal O
saline O
produced O
FEV1 O
falls RARE
of O
25 O
% O
to O
30 O
%, O
but O
these O
falls RARE
were O
not O
as O
great O
as O
each O
subject O
' O
s O
reactions O
to O
the O
test O
solutions O
. O

Experimental O
studies O
on O
virus O
excretion O
and O
non O
- O
arthropod RARE
transmission O
. O

Potency RARE
of O
enflurane RARE
in O
dogs O
: O
comparison O
with O
halothane O
and O
isoflurane O
. O

Prevention O
of O
acute O
paraquat RARE
toxicity O
in O
rats O
by O
superoxide I-GENE
dismutase I-GENE
. O

Measurement O
of O
magnesium O
absorption O
in O
man O
using O
stable O
26Mg NUMERIC
as O
a O
tracer O
. O

Increased O
urinary O
riboflavin RARE
excretion O
resulting O
from O
boric RARE
acid O
ingestion O
. O

Radionuclide RARE
angiography O
and O
static RARE
whole O
body O
imaging O
performed O
with O
technetium O
- O
99m O
- O
labeled O
particulates RARE
can O
clearly O
demonstrate O
differential O
shunting RARE
in O
patients O
with O
patent RARE
ductus RARE
arteriosus RARE
( O
PDA ALLCAPS
) O
with O
Eisenmenger RARE
physiology O
. O

Looming RARE
detectors RARE
in O
the O
human O
visual O
pathway O
. O

Escherichia O
of O
a O
single O
sero RARE
- O
anzymatic RARE
type O
( O
06a6b NUMERIC
: O
K13 NUMERIC
: O
H1 O
) O
were O
isolated O
in O
a O
group O
affection RARE
. O

The O
method O
described O
may O
prove O
useful O
in O
studying O
the O
physiology O
of O
the O
nasal O
cycle O
. O

At O
the O
same O
time O
we O
obtained O
easily O
understandable RARE
EEG O
- O
information O
which O
has O
never O
previously O
been O
available O
to O
us O
. O

Analysis O
of O
liver O
biopsy O
specimens O
from O
patients O
with O
hepatitis O
showed O
a O
large O
variation O
in O
the O
mean O
iron O
content O
of O
the O
liver O
ferritin I-GENE
molecules O
. O

Female O
mice O
were O
significantly O
more O
resistant O
to O
infection O
than O
males O
. O

During O
the O
following O
9 O
1 O
/ O
2 O
years O
three O
sequential O
liver O
biopsies O
were O
performed O
. O

Angiotensin RARE
effect O
in O
the O
human O
kidney O
. O

Procion RARE
yellow O
dye O
was O
injected O
intracellularly RARE
into O
large O
auditory O
fibers O
of O
goldfish RARE
to O
investigate O
the O
relationship O
between O
the O
response O
type O
of O
these O
fibers O
and O
their O
site O
of O
termination O
in O
the O
saccular RARE
macula RARE
. O

Incidental RARE
findings O
in O
the O
epidermis RARE
and O
in O
the O
intraepidermal RARE
eccrine RARE
sweat RARE
duct O
units O
. O

Silicosis RARE
mortality O

These O
consisted O
of O
beading RARE
and O
strictures RARE
mainly O
of O
the O
intrahepatic O
biliary O
tree RARE
( O
IHB ALLCAPS
). O

Pentane RARE
and O
ethane RARE
, O
which O
arise O
during O
lipid O
peroxidation O
in O
vivo O
, O
were O
measured O
by O
gas O
chromatography O
in O
breath RARE
samples O
of O
rats O
fed O
for O
8 O
weeks O
a O
vitamin O
E O
- O
deficient O
diet O
to O
which O
had O
been O
added O
0 O
, O
11 O
, O
or O
40 O
IU O
vitamin O
E O
acetate O
per O
kg O
. O

Thromboplastic RARE
and O
fibrynolytic RARE
activity O
of O
the O
blood O
after O
administration O
of O
intralipid RARE
in O
men O
with O
history O
of O
myocardial O
infarction O
up O
to O
45 O
year O
of O
life O

The O
authors O
report O
the O
clinicopathologic RARE
findings O
in O
four O
cases O
of O
adult O
women O
with O
rhabdomyosarcomas RARE
that O
originated RARE
in O
the O
endometrium RARE
or O
cervix O
, O
or O
both O
. O

The O
effect O
of O
pure O
natural O
porcine I-GENE
secretin RARE
on O
endocrine O
and O
exocrine RARE
pancreatic O
secretion O
was O
studied O
in O
the O
totally RARE
isolated O
perfused O
porcine O
pancreas O
. O

Biometric RARE
analysis O
of O
intraocular RARE
lens O
power O
required O
to O
produce O
emmetropia RARE
: O
results O
of O
450 O
implants O
. O

Urine RARE
antibodies O
could O
not O
be O
demonstrated O
in O
any O
other O
cases O
. O

Althoug RARE
RBF ALLCAPS
tended O
to O
increase O
after O
the O
therapy O
, O
there O
was O
no O
statistically O
significant O
change O
in O
RBF ALLCAPS
, O
GFR O
and O
cardiac O
output O
. O

99mTc O
phytate RARE
, O
198Au NUMERIC
colloid O
, O
and O
99mTc O
antimony RARE
sulfide RARE
have O
been O
used O
; O
the O
last O
appears O
to O
have O
been O
the O
most O
satisfactory O
. O

Six O
patients O
with O
glomerulonephritis O
in O
association O
with O
a O
ventriculovascular RARE
shunt O
were O
treated O
with O
three O
basic O
modes O
of O
therapy O
. O

The O
mass O
of O
UO2 NUMERIC
in O
the O
extrapulmonary RARE
bronchi RARE
and O
first O
bifurcation RARE
decreased O
more O
slowly O
over O
0 O
-- O
8 O
d O
after O
inhalation O
than O
the O
corresponding O
mass O
on O
the O
trachea RARE
. O

Synovial RARE
cysts O
of O
the O
hip O
joint O

A O
suspected O
hypothalamic RARE
dysfunction O
and O
a O
slightly O
impaired O
pituitary O
function O
manifested O
as O
GH I-GENE
deficiency O
were O
their O
common O
endocrinological RARE
features O
. O

A O
sharp RARE
outbreak O
of O
influenza O
A O
occurred O
on O
the O
base O
during O
February RARE
that O
was O
due O
to O
an O
A O
/ O
Texas RARE
/ O
1 O
/ O
77 O
- O
like O
virus O
, O
a O
variant O
of O
the O
A O
/ O
Victoria RARE
/ O
3 O
/ O
75 O
prototpye RARE
. O

Because O
decreases O
in O
the O
disfluency RARE
rates O
of O
stutterers RARE
were O
observed O
during O
the O
presentation O
of O
all O
three O
stimulus O
words RARE
, O
the O
data O
failed O
to O
support O
the O
operant RARE
model O
. O

Effect O
of O
time O
and O
dose O
on O
alterations O
following O
inhalation O
of O
plutonium O
- O
239 O
dioxide O
aerosol RARE
in O
rat O
. O

In O
biopsies O
CK I-GENE
- I-GENE
MB I-GENE
fraction O
of O
total O
myocardial O
CPK I-GENE
was O
37 O
%, O
the O
total I-GENE
- I-GENE
CPK I-GENE
activity O
of O
human O
skeletal O
muscles O
still O
shows O
a O
5 O
% O
fraction O
of O
CK I-GENE
- I-GENE
MB I-GENE
. O

Value O
of O
determination O
of O
alkaline I-GENE
phosphatase I-GENE
isoenzymes I-GENE
for O
differential O
diagnosis O
of O
obstructive RARE
jaundice O
and O
biliary O
liver O
cirrhosis O

A O
one O
- O
way O
analysis O
of O
variance RARE
, O
performed O
separately O
for O
men O
and O
women O
for O
differences O
among O
the O
three O
phobic RARE
groups O
on O
field O
dependence O
, O
showed O
significance O
( O
rho O
less O
than O
. O
05 O
) O
for O
the O
females O
, O
with O
the O
famale RARE
agoraphobic RARE
being O
more O
field O
dependent O
than O
the O
female O
simple O
phobic RARE
groups O
, O
but O
not O
for O
the O
males O
. O

Several O
free O
2nd NUMERIC
- O
generation O
schizonts RARE
, O
which O
varied O
in O
diameter O
from O
11 O
to O
21 O
. O
6 O
micrometer RARE
, O
were O
found O
on O
the O
epithelial O
surface O
of O
the O
cecum RARE
. O

The O
calculated O
pD2 NUMERIC
values O
were O
8 O
. O
8 O
for O
E O
, O
8 O
. O
6 O
for O
DHE ALLCAPS
and O
6 O
. O
6 O
for O
M O
. O

Newcastle RARE
disease O
virus O
surveillance RARE
in O
Hong RARE
Kong RARE
on O
local O
and O
imported RARE
poultry RARE
. O

It O
was O
postulated O
that O
persistent O
challenge O
by O
M O
. O
leprae RARE
or O
its O
antigens O
to O
the O
IgA I-GENE
immunocytes RARE
of O
the O
intestinal O
epithelium O
might O
have O
induced O
tolerance O
leading O
to O
IgA I-GENE
deficiency O
and O
subsequent O
subtotal O
atrophy O
of O
the O
intestinal O
villi RARE
in O
the O
patients O
with O
lepromatous RARE
leprosy RARE
. O

Treatment O
of O
hypertension O
with O
a O
combination O
of O
the O
adrenergic I-GENE
beta I-GENE
receptor I-GENE
blockader RARE
, O
obsidan RARE
, O
and O
the O
vasodilator O
, O
apressin RARE

Orthop RARE
. O

Thyroid RARE
disease O
and O
pregnancy O
. O

Residues RARE
removed O
from O
transcripts O
by O
splicing O
were O
identified O
. O

To O
minimize RARE
reflux O
into O
the O
blind O
loop O
, O
a O
number O
of O
technical RARE
steps O
are O
considered O
indispensable RARE
: O
1 O
) O
fluted RARE
section O
of O
the O
jejunal RARE
stump RARE
; O
2 O
) O
isoperistaltic RARE
construction O
of O
the O
anastomosis O
and O
, O
particularly O
, O
3 O
) O
the O
creation RARE
of O
a O
single O
or O
double O
valve O
system O
upstream O
from O
the O
anastomosis O
by O
spiral RARE
introflexion RARE
of O
the O
mucosa O
using O
seroserous RARE
stitches RARE
parallel O
and O
perpendicular RARE
to O
the O
ileal RARE
lumen RARE
. O

At O
this O
stage O
, O
the O
eventual RARE
high O
mortality O
of O
acute O
ischemia O
is O
established O
whatever RARE
the O
urgency RARE
of O
the O
operation O
or O
the O
skill RARE
with O
which O
it O
is O
performed O
. O

Pathogens RARE
( O
Staphylococcus O
aureus O
or O
Gram O
- O
negative O
bacilli O
) O
were O
isolated O
from O
only O
one O
member O
of O
staff RARE
in O
small O
numbers O
and O
irregularly RARE
and O
rarely O
in O
large O
numbers O
from O
patients O
. O

The O
histochemistry RARE
and O
ultrastructure RARE
of O
calcified RARE
cerebellar RARE
deposits RARE
described O
by O
Tonge RARE
et O
al O
. O

A O
36 O
year O
- O
old O
woman O
was O
given O
Ergotamine RARE
Tartrate RARE
4 O
. O
5 O
mg O
p O
. O
d O
. O
during O
seven O
days O
, O
after O
an O
abortion O
( O
a O
still O
birth O
). O

Reaction RARE
times O
to O
tachistoscopically RARE
presented O
stimuli O
in O
diabetics RARE

Two O
out O
of O
five O
patients O
undergoing O
selective O
spinal O
arteriography RARE
developed O
transient O
neurological O
complications O
during O
the O
injection O
of O
Urografin RARE
310 NUMERIC
M O
. O

The O
data O
indicate O
a O
three O
- O
phase O
reaction O
after O
B1 O
injection O
: O
Phase O
1 O
-- O
shortly RARE
after O
injection O
there O
is O
a O
drop O
of O
all O
parameters O
lasting O
for O
30 O
sec O
. O

Serum I-GENE
relaxin RARE
levels O
in O
prostaglandin O
E2 O
induced O
abortions RARE
. O

A O
-- O
A O
natural O
hydrostatic RARE
phenomenon O
, O
at O
the O
level O
of O
the O
ends O
of O
the O
plantar RARE
arcs RARE
, O
diffuses RARE
body O
weight O
, O
as O
PAIN ALLCAPS
plays O
the O
role O
of O
outsentry RARE
( O
fig RARE
.-- RARE
1 O
) O
( O
5 O
); O
B O
-- O
Plantar RARE
perforating RARE
ulceration O
( O
PPU ALLCAPS
) O
is O
caused O
by O
a O
combination O
of O
INSENSITIVITY ALLCAPS
and O
TRAUMATIS ALLCAPS
( O
1 O
); O
C O
-- O
The O
patient O
reposing RARE
, O
as O
body O
weight O
( O
traumatism RARE
) O
effects O
disappear RARE
, O
cicatrization RARE
process O
can O
be O
easily O
observed O
; O
D O
-- O
PNEUMATIC ALLCAPS
INSOLE ALLCAPS
, O
being O
elastic O
, O
diffuses RARE
localized O
compression O
at O
the O
ends O
of O
the O
plantar RARE
arcs RARE
, O
reduces O
attrition RARE
, O
makes O
easier RARE
blood O
circulation O
, O
as O
well O
as O
cure O
and O
prophylaxis O
of O
PPU ALLCAPS
( O
fig RARE
.-- RARE
6 O
) O
( O
3 O
). O

Effect O
of O
indoramin RARE
in O
small O
doses O
on O
the O
central O
vasomotor RARE
loci O
has O
been O
studied O
in O
chloralose RARE
anesthetized O
cats O
by O
localizing RARE
it O
to O
the O
central O
sites O
. O

As O
expected O
, O
the O
heparin O
did O
produce O
increased O
recalcification RARE
times O
and O
the O
development O
of O
occasional RARE
subcutaneous O
hematomas RARE
. O

Contingency RARE
contracting RARE
between O
clients RARE
and O
their O
parents O
/ O
caregivers RARE
was O
used O
to O
specify RARE
consequences O
for O
daily O
self O
- O
monitoring O
, O
reduced O
caloric RARE
intake O
, O
weight O
loss O
, O
and O
exercise O
. O

Dietetics RARE
of O
childhood O
- O
and O
juvenile O
diabetes O

The O
results O
of O
a O
quantitative O
study O
of O
vasculosyncytial RARE
membranes O
in O
123 O
placentas RARE
are O
presented O
. O

The O
micromethod RARE
uses O
microcuvettes RARE
and O
substitutes RARE
ferrozine RARE
for O
the O
bathophenanthroline RARE
chromogen RARE
of O
the O
ICSH ALLCAPS
. O

Platelet O
serotonin O
( O
5 O
- O
HT O
) O
and O
5 I-GENE
- I-GENE
HT I-GENE
releasing I-GENE
factor I-GENE
in O
plasma O
of O
migrainous RARE
patients O
. O

The O
overall O
incidence O
of O
SIDS ALLCAPS
was O
1 O
. O
43 O
per O
1 O
, O
000 O
live O
births O
. O

The O
vigilance RARE
task O
and O
the O
measurement O
of O
attentional RARE
deficits O
. O

The O
December RARE
armed RARE
revolt RARE
in O
Moscow RARE
and O
the O
paramedical RARE
personnel RARE

Significant O
increases O
in O
mean O
serum O
E2 O
concentration O
( O
100 O
to O
150 O
pg O
/ O
ml O
) O
were O
noted O
at O
6 O
and O
8 O
hours O
after O
administration O
on O
day O
1 O
and O
at O
8 O
hours O
on O
day O
4 O
. O

The O
motor O
unit O
viewed RARE
from O
above O
. O

Avian RARE
reproductive O
system O
: O
daily O
variations O
in O
responses O
to O
hormones O
. O

Biological O
properties O
of O
sumithion RARE
. O

Serological RARE
studies O
of O
antibodies O
to O
Epstein O
- O
Barr O
virus O
in O
infectious O
mononucleosis RARE

Carcinoembryonic RARE
antigen I-GENE
( O
CEA I-GENE
) O
procedures O
and O
clinical O
evaluation O
. O

We O
remain RARE
convinced RARE
that O
antilymphocyte RARE
globulin I-GENE
( O
ALG ALLCAPS
) O
is O
a O
potent O
immunosuppressive O
agent O
in O
humans O
. O

On O
the O
basis O
of O
a O
global O
assessment O
patients O
showed O
a O
highly O
significant O
preference O
for O
imipramine RARE
compared O
with O
placebo O
as O
adjunctive RARE
therapy O
. O

39 O
- O
47 O
. O

Patients O
were O
subclassified RARE
into O
age O
- O
matched O
groups O
of O
primary O
untreated O
cancer O
( O
21 O
), O
recurrent O
cancer O
( O
18 O
), O
and O
" O
cured RARE
" O
patients O
who O
had O
been O
free O
of O
disease O
for O
at O
least O
9 O
months O
( O
16 O
). O

Absorption RARE
varied O
between O
65 O
and O
95 O
per O
cent O
, O
with O
a O
mean O
absorption O
of O
80 O
per O
cent O
, O
in O
both O
pregnant O
and O
non O
- O
pregnant O
subjects O
. O

Bacteriostatic RARE
and O
bacteriacidal RARE
activity O
of O
hydroxy O
- O
9 O
ellipticine RARE
in O
vitro O

Advances RARE
in O
the O
management O
of O
gynecologic O
cancer O
-- O
radiation O
therapy O
. O

The O
clinico RARE
- O
pathological O
data O
from O
a O
patient O
with O
irreversible O
post O
- O
partum RARE
renal O
failure O
( O
IPRF ALLCAPS
) O
are O
presented O
. O

Personal RARE
satisfaction RARE
in O
nursing O
: O
an O
encounter RARE
with O
extremely O
hostile RARE
patients O

Dialyzable RARE
transfer I-GENE
factor I-GENE
. O

19 O
- O
32 O
. O

Rheumatoid RARE
factor I-GENE
and O
antinuclear RARE
antibody O
tests O
were O
frequently O
positive O
, O
and O
reactions O
to O
gold RARE
therapy O
were O
more O
frequent O
than O
in O
other O
rheumatoid O
populations O
. O

The O
effect O
of O
hydrostatic RARE
pressure O
on O
the O
swimming O
activity O
of O
three O
hyponeustonic RARE
crustacea RARE
, O
Anomalocera RARE
patersoni RARE
, O
Pontella RARE
mediterranea RARE
, O
Labidocera RARE
wollastoni RARE

This O
report O
presents O
an O
analysis O
of O
the O
vocal RARE
repertoire RARE
of O
howler RARE
monkeys O
( O
Alouatta RARE
palliata RARE
) O
observed O
during O
a O
field O
study O
in O
southwestern RARE
Panama RARE
. O

Up RARE
to O
now O
the O
number O
of O
patients O
examined O
is O
about O
300 O
, O
additionally O
6 O
persons O
who O
underwent O
binephrectomy RARE
. O

Deflunia RARE
was O
well O
tolerated O
by O
25 O
patients O
, O
very O
well O
tolerated O
by O
2 O
. O

III O
. O

A O
new O
instrument O
has O
been O
designed O
for O
freeze RARE
- O
fracturing RARE
of O
biological O
material O
in O
ultra RARE
high O
vacuum RARE
. O

Pancreatic RARE
and O
biliary O
secretion O
and O
gastric O
emptying O
rates O
of O
a O
liquid O
test O
meal O
( O
LTM ALLCAPS
) O
were O
determined O
in O
normal O
persons O
, O
in O
patients O
with O
subtotal O
gastrectomy RARE
with O
gastroduodenostomy RARE
( O
STG ALLCAPS
- O
BI O
) O
or O
with O
gastrojejunostomy RARE
( O
STG ALLCAPS
- O
BII ALLCAPS
), O
and O
in O
patients O
with O
truncal RARE
vagotomy O
and O
pyloroplasty RARE
( O
V O
& O
P O
). O

Abnormal O
calcium O
metabolism O
in O
normocalcaemic RARE
sarcoidosis RARE
. O

Also O
, O
except O
in O
one O
patient O
who O
developed O
gallstones RARE
following O
institution RARE
of O
colestipol RARE
, O
saturation O
of O
gallbladder O
bile O
with O
cholesterol O
was O
not O
markedly O
increased O
by O
this O
drug O
alone O
. O

A O
five O
- O
phase O
experiment O
was O
designed O
to O
investigate O
( O
a O
) O
whether O
contingent RARE
music RARE
- O
listening RARE
would O
act O
as O
a O
reinforcer RARE
to O
increase O
arithmetic RARE
performance O
of O
EMR ALLCAPS
children O
and O
( O
b O
) O
whether O
this O
contingent RARE
reinforcement RARE
would O
affect O
preference O
for O
that O
reinforcer RARE
. O

The O
responsiveness O
of O
visual O
cortex O
( O
VC ALLCAPS
) O
and O
superior O
colliculus RARE
( O
SC O
) O
was O
simultaneously O
compared O
following O
conditioning O
" O
ON ALLCAPS
" O
or O
" O
OFF ALLCAPS
" O
stimulation O
, O
in O
the O
rabbit O
. O

A O
diagnosis O
of O
MS O
was O
made O
based O
on O
subtle RARE
neurologic O
signs O
, O
spinal O
fluid O
gamma I-GENE
globulin I-GENE
elevations O
, O
and O
abnormalities O
in O
neuropsychological RARE
testing O
. O

If O
, O
however O
, O
the O
mean O
temperature O
rise O
was O
higher O
( O
0 O
. O
57 O
degrees O
C O
or O
0 O
. O
69 O
degrees O
C O
), O
such O
a O
selection O
practically RARE
resulted O
in O
the O
disappearance O
of O
' O
passable RARE
' O
qualifications RARE
in O
the O
triplet O
groups O
and O
a O
great O
predominance RARE
of O
' O
to O
be O
rejected RARE
' O
qualifications RARE
in O
the O
large O
groups O
. O

The O
elevated O
Viso RARE
V O
in O
the O
RDS ALLCAPS
group O
suggests O
an O
increase O
in O
small O
airway O
resistance O
secondary O
to O
the O
disease O
or O
to O
its O
therapy O
. O

The O
psychological O
tests O
consisted O
of O
a O
free O
- O
recall RARE
task O
, O
a O
test O
for O
visuomotor RARE
coordination O
and O
a O
recognition O
task O
. O

Selective O
bronchial O
intubation RARE
in O
the O
management O
of O
unilateral O
pulmonary O
interstitial O
emphysema O
. O

The O
background O
processes O
depending O
on O
the O
etiological RARE
factor O
and O
the O
character O
of O
lesion O
of O
the O
epithelium O
are O
divided O
into O
dyshormonal RARE
, O
inflammatory O
, O
and O
posttraumatic RARE
. O

The O
sense O
of O
self O
. O

Eleven RARE
strains O
of O
Fusarium RARE
poae RARE
and O
F O
. O
sporotrichioides RARE
from O
the O
U O
. O
S O
. O
S O
. O
R O
. O
and O
7 O
strains O
of O
these O
species O
and O
one O
of O
F O
. O
sporotrichioides RARE
var O
. O
tricinctum RARE
from O
U O
. O
S O
. O
A O
. O
and O
France RARE
have O
been O
compared O
as O
to O
their O
capacity O
to O
yield O
T I-GENE
- I-GENE
2 I-GENE
toxin I-GENE
. O

Current O
diagnostic O
uses O
of O
computerized O
tomography O
in O
clinical O
medicine O
. O

A O
follow O
- O
up O
study O
of O
22 O
patients O
with O
Ebstein RARE
' O
s O
anomaly RARE
has O
been O
performed O
. O

Deaths RARE
stopped O
11 O
hours O
after O
copper O
concentrations O
decreased O
below O
0 O
. O
2 O
ppm O
and O
signs O
of O
distress O
stopped O
in O
surviving RARE
pinfish RARE
by O
approximately O
6 O
hours O
after O
the O
last O
death O
. O

Recurrence RARE
of O
bladder O
tumors O
among O
the O
original O
9 O
cases O
has O
occurred O
only O
among O
the O
5 O
whose O
properdin RARE
levels O
remained O
below O
the O
median O
. O

Adaptation RARE
of O
taurocholate RARE
transport O
maximum O
to O
increased O
secretory O
load O
in O
the O
rat O
. O

Dangers RARE
in O
use O
of O
live O
- O
virus O
vaccines O
. O

Treatment O
with O
heparin O
, O
plasminogen I-GENE
activators O
and O
fibrinogenolytic RARE
agents O
was O
disappointing RARE
although O
renal O
function O
has O
stabilized O
in O
one O
patient O
on O
long O
term O
oral O
anticoagulant O
therapy O
. O

In O
diethyl RARE
ether O
solution O
the O
main O
peak O
is O
that O
of O
2 O
- O
benzylidenamio RARE
- O
1 O
- O
phenylpropane RARE
, O
which O
has O
a O
retention O
time O
of O
23 O
, O
2 O
minutes O
under O
the O
condition O
delineated RARE
. O

Amikacin RARE
was O
used O
in O
the O
treatment O
of O
56 O
serious O
gram O
- O
negative O
infections O
in O
54 O
patients O
of O
whom O
47 O
survived RARE
. O

The O
data O
normally O
available O
are O
insufficient O
and O
take O
no O
account O
of O
the O
direction O
of O
recirculation RARE
, O
which O
may O
be O
a O
determining O
factor O
. O

During O
activity O
III O
, O
one O
patient O
developed O
angina O
. O

Estimation RARE
of O
L O
- O
alanine O
in O
serum O
or O
plasma O
using O
the O
LKB ALLCAPS
reaction O
rate O
analyser RARE
. O

The O
acids O
were O
obtained O
by O
hydrolysis O
of O
the O
corresponding O
esters O
, O
and O
their O
anti O
- O
inflammatory O
activity O
was O
tested O
. O

Unrecognized RARE
amnionitis RARE
and O
prematurity RARE
: O
a O
preliminary O
report O
. O

Evaluation O
of O
the O
new O
Gravigard RARE
IUCD ALLCAPS
inserter RARE
. O

Bacterial RARE
meningitis O
secondary O
to O
abscess O
of O
the O
nasal O
septum RARE
. O

Serum I-GENE
amylase I-GENE
became O
markedly O
elevated O
( O
2 O
, O
624 NUMERIC
CU ALLCAPS
/ O
100 O
ml O
), O
as O
did O
the O
serum O
FFA ALLCAPS
( O
29 O
. O
19 O
mEq O
/ O
liter O
). O

In O
the O
control O
preparation O
before O
weight O
was O
allowed O
to O
increase O
, O
isogravimetric RARE
capillary O
pressure O
( O
Pci RARE
) O
averaged O
8 O
mmHg O
lower O
than O
colloid O
osmotic O
pressure O
of O
the O
plasma O
( O
IIp RARE
). O

Infants RARE
who O
died O
in O
the O
first O
12 O
hours O
from O
' O
IVH ALLCAPS
only O
' O
had O
suffered RARE
severe O
birth O
asphyxia RARE
but O
in O
those O
who O
died O
later O
the O
main O
symptom RARE
was O
recurrent O
apnoea RARE
. O

The O
morphological O
effects O
of O
two O
snake RARE
venoms RARE
, O
N O
. O
naja RARE
and O
A O
. O
piscivorus RARE
, O
and O
of O
the O
Direct I-GENE
Lytic RARE
Factor I-GENE
and O
Phospholipase RARE
- I-GENE
A I-GENE
, O
compounds O
purified O
from O
N O
. O
naja RARE
crude O
venom RARE
, O
were O
investigated O
on O
lung O
and O
cremaster RARE
vessels O
of O
rats O
. O

Since O
GAGs RARE
are O
the O
components O
of O
cartilage O
matrix O
, O
the O
depletion O
of O
which O
is O
associated O
with O
osteoarthrosis RARE
, O
a O
method O
for O
measuring O
sulphated RARE
GAG ALLCAPS
synthesis O
in O
culture O
has O
been O
investigated O
. O

The O
length O
scales RARE
of O
the O
turbulence RARE
were O
also O
estimated O
: O
at O
a O
Reynolds RARE
number O
near O
4 O
, O
000 O
the O
macroscale RARE
is O
about O
1 O
. O
25 O
mm O
, O
the O
Taylor RARE
microscale RARE
is O
about O
0 O
. O
85 O
mm O
, O
and O
the O
Kolmogoroff RARE
scale O
is O
near O
0 O
. O
075 NUMERIC
mm O
. O

Well RARE
- O
visualised RARE
arteriograms RARE
of O
the O
limbs RARE
can O
be O
obtained O
by O
xeroradiography RARE
after O
rapid O
manual RARE
injection O
of O
contrast O
- O
medium O
into O
an O
arm O
vein O
, O
as O
demonstrated O
in O
28 O
patients O
. O

No O
hypotension O
was O
noted O
in O
patients O
with O
toxemia RARE
and O
only O
2 O
ran RARE
a O
fever O
above O
37 O
. O
5 O
degrees O
C O
. O

The O
sera O
and O
nasal O
secretions RARE
of O
142 O
patients O
, O
who O
were O
positive O
in O
HD O
or O
mites RARE
skin O
test O
, O
were O
subjected O
to O
a O
radioallergosorbent RARE
test O
( O
RAST O
) O
for O
estimating O
the O
specific O
IgE I-GENE
antibody I-GENE
activity O
to O
mites RARE
. O

Wherever RARE
the O
site O
of O
the O
conditioning O
stimulation O
, O
these O
modifications O
disappeared O
after O
ischaemia O
of O
the O
leg O
. O

Diallylnitrosamine RARE
( O
DAN ALLCAPS
), O
one O
of O
the O
few O
nitrosamines RARE
tested O
thus O
far O
that O
has O
not O
induced O
neoplasms O
in O
rats O
, O
caused O
a O
high O
incidence O
of O
respiratory O
tract O
tumors O
in O
Syrian O
golden RARE
hamsters O
treated O
sc O
with O
single O
or O
weekly O
doses O
of O
the O
compound O
. O

Near RARE
term O
, O
under O
experimental O
conditions O
, O
maternal O
and O
fetal O
blood O
gases O
, O
pH O
, O
uterine O
and O
umbilical RARE
blood O
flows RARE
were O
measured O
or O
calculated O
. O

Haemodynamic RARE
responses O
to O
antagonism RARE
of O
bocurarine RARE
block O
with O
atropine O
- O
neostigmine RARE
mixture O
in O
children O
. O

The O
mechanism O
by O
which O
large O
molecules O
, O
such O
as O
the O
diphosphonate RARE
99mTc O
- O
labeled O
EHDP ALLCAPS
or O
99mTc O
- O
labeled O
pyrophosphate RARE
, O
pass RARE
through O
capillaries O
in O
bone O
is O
by O
passive O
diffusion O
. O

Twenty O
- O
nine O
days O
after O
injection O
of O
5 O
. O
8 O
mCi O
of O
Tc O
- O
99m O
, O
which O
gives O
28 O
rads RARE
to O
the O
testis O
, O
the O
number O
of O
sperm O
hads RARE
decreased O
to O
70 O
% O
of O
control O
. O

Self RARE
- O
emasculation RARE
is O
the O
end O
result O
of O
an O
unusual O
psychiatric O
disorder O
, O
which O
initially O
requires O
surgical O
treatment O
. O

Possibility RARE
of O
a O
TSH I-GENE
- O
Screening RARE
method O
for O
detection O
of O
hypothyroidism O
in O
the O
newborn O

Thus O
analysis O
indicated O
no O
reliable O
evidence O
that O
conscious O
presleep RARE
suggestions RARE
become O
incorporated O
into O
dream RARE
content O
. O

The O
prevalence O
of O
hepatitis I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
( O
HBsAg I-GENE
) O
and O
anti I-GENE
- I-GENE
HBs I-GENE
was O
determined O
by O
a O
sensitive O
double O
- O
antibody O
radio RARE
- O
immunoassay O
technique O
in O
a O
series O
of O
patients O
with O
chronic O
liver O
diseases O
. O

It O
was O
concluded O
that O
patients O
with O
acute O
respiratory O
failure O
requiring O
artificial O
ventilation O
have O
two O
componenents RARE
of O
the O
pulmonary O
shunt O
, O
one O
parallel O
with O
and O
the O
other O
inversely O
related O
with O
the O
PAO2 NUMERIC
. O

Decreased RARE
cardiac O
glycogen O
following O
phenformin RARE
injection O
in O
hyperglycemic RARE
, O
hyperinsulinemic RARE
anaesthetized RARE
rats O
. O

Biological O
evaluation O
of O
mibolerone RARE
in O
the O
female O
Beagle RARE
. O

Levels RARE
of O
both O
PGF ALLCAPS
and O
PGFM ALLCAPS
were O
significantly O
higher O
during O
early O
spontaneous O
labour O
, O
at O
a O
cervical O
dilatation O
of O
less O
than O
4 O
cm O
, O
than O
before O
the O
onset O
of O
labour O
. O

The O
most O
common O
cause O
of O
renal O
deterioration O
in O
the O
spinal O
cord O
injured RARE
patient O
is O
irreversible O
vesicoureteral RARE
reflux O
. O

Propranolol RARE
( O
Inderal RARE
) O
administered O
in O
a O
dose O
which O
blocks O
the O
beta O
- O
adrenergic O
apparatus O
of O
the O
heart O
prevents O
the O
development O
of O
the O
positive O
inotropic O
effect O
of O
therapeutic O
doses O
of O
strophanthin RARE
K O
on O
a O
hypodynamic RARE
left O
ventricular O
myocardium O
. O

Recent O
studies O
have O
shown O
the O
rat O
larynx O
to O
be O
an O
important O
organ O
in O
the O
evaluation O
of O
irritancy RARE
of O
inhaled O
materials O
. O

Scanning RARE
electron O
microscopic O
investigations O
on O
the O
formation O
of O
Reissner RARE
' O
s O
fiber O
in O
Rattus RARE
rattus RARE

Feeding RARE
behavior O
, O
circannual RARE
body O
weight O
and O
hibernation RARE
rhythms RARE
in O
European O
hamsters O
lesioned O
in O
the O
noradrenergic O
ascending O
bundles RARE

Role O
of O
the O
infectious O
- O
disease O
specialist RARE
of O
a O
polyclinic RARE
in O
reducing O
the O
incidence O
of O
communicable RARE
diseases O

These O
observed O
drug O
interactions O
, O
plus O
the O
known O
effect O
of O
probenecid RARE
to O
block O
secretion O
of O
PZA ALLCAPS
, O
have O
to O
be O
considered O
in O
evaluating O
the O
effect O
of O
the O
two O
drugs O
given O
together O
, O
compared O
to O
the O
effect O
of O
each O
drug O
given O
separately O
. O

Circulatory RARE
arrest O
in O
the O
operating O
room O
. O

At O
a O
systolic O
blood O
pressure O
( O
BP O
) O
of O
60 O
mmHg O
, O
C02 NUMERIC
responsiveness O
was O
abolished O
, O
but O
was O
maintained O
at O
higher O
levels O
of O
BP O
. O

Iodine RARE
- O
123 O
was O
satisfactorily RARE
imaged RARE
only O
with O
the O
MEC ALLCAPS
and O
pinhole RARE
collimators RARE
, O
which O
in O
turn O
yielded O
MTF ALLCAPS
values O
comparable O
to O
those O
measured O
for O
99mTc O
. O

Petrous RARE
meningioma RARE
en O
plaque O
presenting O
as O
a O
right O
middle O
ear O
tumor O
. O

The O
difficulties RARE
to O
analyse RARE
prostaglandins O
( O
PG ALLCAPS
) O
by O
gas O
- O
liquid O
chromatography O
are O
mainly O
due O
to O
the O
lack O
of O
sensitivity O
of O
the O
gas O
- O
chromatograph RARE
itself O
( O
higher O
than O
200 O
ng O
) O
and O
to O
the O
poor O
resolution O
of O
the O
packed RARE
columns RARE
. O

On O
cessation O
of O
steroid O
therapy O
the O
patient O
was O
noted O
to O
have O
radiologic RARE
manifestations O
of O
hypertrophic RARE
osteoarthropathy RARE
( O
HOA ALLCAPS
) O
as O
well O
as O
clinical O
and O
laboratory O
features O
of O
rheumatoid O
arthritis O
( O
RA O
). O

The O
effect O
of O
food O
on O
procainamide RARE
absorption O
. O

After O
giving O
a O
survey O
on O
the O
situation RARE
of O
antibiotic O
resistance O
in O
the O
region O
of O
Northern O
Bavaria RARE
during O
1973 NUMERIC
/ O
74 O
and O
comparing O
the O
activity O
of O
a O
sulfamethoxazole RARE
( O
SMZ ALLCAPS
) O
trimethoprim RARE
( O
TMP ALLCAPS
) O
combination O
to O
other O
commonly O
used O
antibiotics O
and O
chemotherapeutic O
agents O
, O
the O
results O
of O
tests O
with O
the O
new O
combination O
of O
N1 O
-( O
4 O
, O
5 O
- O
dimethyl O
- O
2 O
- O
oxazolyl RARE
)- O
sulfanilamide RARE
) O
( O
sulfamoxole RARE
) O
and O
2 O
, O
4 O
- O
diamino RARE
- O
5 O
-( O
3 O
, O
4 O
, O
5 O
- O
trimethoxy RARE
- O
benzyl RARE
)- O
pyrimidine O
( O
trimethoprim RARE
) O
at O
a O
ratio O
of O
5 O
: O
1 O
( O
CN ALLCAPS
3123 NUMERIC
; O
Nevin RARE
, O
Supristol RARE
) O
are O
compared O
to O
those O
of O
tests O
with O
TMP ALLCAPS
/ O
SMZ ALLCAPS
. O

RESULTS O
: O
Total O
IgE I-GENE
levels O
showed O
a O
tendency O
to O
diminish RARE
. O

Does RARE
afferent RARE
loop O
syndrome O
exist O
?] RARE
It O
is O
the O
author O
' O
s O
opinion RARE
that O
diagnosis O
of O
the O
" O
adducent RARE
loop O
syndrome O
" O
is O
unlikely O
to O
be O
correct O
in O
patients O
subjected O
to O
Billroth RARE
- O
II O
gastrectomy RARE
. O

Letter O
: O
Is O
actinic RARE
( O
solar RARE
) O
damage O
the O
provoking RARE
cause O
of O
' O
post O
- O
inflammatory O
elastolysis RARE
and O
cutis RARE
laxa RARE
( O
PECL ALLCAPS
)'? RARE

These O
data O
suggest O
that O
spontaneous O
recovery O
of O
central O
respiratory O
function O
after O
intoxication RARE
with O
Soman RARE
or O
Sarin RARE
may O
not O
be O
related O
to O
the O
return O
of O
AChE LASTCAP
activity O
. O

Batch RARE
cultures O
of O
S O
. O
mutans RARE
serotype O
a O
demonstrated O
no O
growth O
on O
MSB ALLCAPS
agar O
. O

Also O
, O
samples O
of O
serum O
were O
absorbed O
with O
the O
various O
solid O
- O
phase O
allergens O
and O
the O
reactivity O
of O
the O
remaining O
IgE I-GENE
antibodies I-GENE
was O
determined O
. O

Crisis RARE
of O
the O
therapeutic O
community O
in O
Great RARE
Britain RARE

Pregnant RARE
women O
at O
term O
had O
the O
lowest O
levels O
of O
antithrombin I-GENE
III I-GENE
. O

Hematology RARE
problem O
of O
the O
month O
: O
band O
or O
seg RARE
? O

It O
is O
possible O
that O
cyclic O
variations O
in O
heme O
turnover O
are O
related O
to O
changes O
in O
erythrocyte O
characteristics O
during O
the O
progesterone O
phase O
. O

Haemodilution RARE
in O
cardiopulmonary O
bypass O
using O
a O
gelatine RARE
derivative O
for O
priming RARE
. O

Extramedullary RARE
plasmacytoma RARE
of O
the O
parotid RARE
gland O

I O
. O

The O
recovered O
calves O
were O
tested O
for O
immunity O
to O
homologous O
severe O
challenge O
, O
50 O
or O
73 O
days O
after O
the O
first O
infection O
. O

The O
performance O
of O
three O
commonly O
used O
chemical O
cartridge RARE
respirators RARE
for O
SO2 NUMERIC
was O
measured O
under O
working O
conditions O
in O
a O
copper O
smelter RARE
. O

The O
neuroleptic O
- O
induced O
increase O
in O
central O
DA O
turnover O
( O
an O
indicator O
for O
the O
degree O
of O
DA I-GENE
receptor I-GENE
blocking O
) O
was O
found O
to O
be O
positively O
correlated O
with O
the O
therapeutic O
effect O
of O
neuroleptics RARE
and O
the O
development O
of O
hypokinetic RARE
- O
rigid RARE
symptoms O
. O

Rainbow RARE
trout O
were O
obtained O
from O
a O
commercial O
trout O
farm RARE
, O
kept O
in O
running RARE
water O
and O
feeding O
in O
experimental O
pellets O
for O
4 O
to O
8 O
weeks O
. O

Stimulation RARE
of O
macrophage O
function O
by O
killed O
Bordetella RARE
pertussis O
cells O
did O
not O
show O
any O
beneficial O
effect O
as O
an O
increased O
susceptibility O
became O
apparent O
. O

Primary O
amenorrhoea RARE
in O
a O
phenotypically RARE
female O
individual O
with O
a O
karyotype RARE
46 O
, O
xy RARE
and O
bilateral O
gonadoblastoma RARE

Toward RARE
absolute O
methods O
in O
clinical O
chemistry O
: O
application O
of O
mass O
fragmentography RARE
to O
high O
- O
accuracy O
analyses O
. O

Application RARE
of O
the O
2 O
- O
deoxy RARE
- O
D O
- O
glucose O
method O
to O
the O
coupling O
of O
cerebral O
metabolism O
and O
blood O
flow O
. O

Serum O
gastrin I-GENE
levels O
did O
not O
change O
in O
either O
group O
; O
however O
, O
background O
serum O
gastrin I-GENE
concentrations O
were O
significantly O
greater O
for O
V O
& O
P O
patients O
than O
V O
& O
A O
patients O
throughout O
the O
study O
. O

Efferent RARE
projections O
of O
the O
ventral O
portion O
of O
the O
putamen RARE
to O
the O
frontal O
, O
parietal RARE
and O
temporal O
regions O
of O
the O
cat O
cerebral O
cortex O

Preflight RARE
, O
inflight RARE
, O
and O
postflight RARE
exercise O
response O
tests O
were O
conducted O
on O
the O
astronauts RARE
of O
the O
second O
Skylab RARE
mission RARE
( O
Skylab RARE
3 O
) O
as O
part O
of O
an O
evaluation O
of O
physiological O
adaptation O
to O
long O
- O
term O
weightlessness RARE
. O

Mean O
corpuscular RARE
hemoglobin I-GENE
concentrations O
remained O
normal O
for O
48 O
h O
and O
then O
decreased O
in O
both O
groups O
, O
the O
CO2 O
group O
showing O
the O
larger O
decrease O
. O

All O
Cu O
values O
obtained O
from O
the O
organs O
investigated O
had O
reached O
a O
saturation O
level O
at O
8 O
mug RARE
Cu O
/ O
g O
diet O
with O
the O
exception O
of O
the O
values O
for O
body O
Cu O
found O
in O
the O
dams RARE
that O
were O
killed O
on O
the O
day O
of O
delivery O
. O

The O
effect O
of O
calcitonin I-GENE
, O
a O
large O
amount O
of O
calcium O
given O
orally O
, O
pentagastrin RARE
and O
glucagon I-GENE
on O
plasma O
47Ca NUMERIC
radioactivity RARE
curves O
in O
subjects O
pretreated O
with O
47Ca NUMERIC
was O
examined O
. O

State O
of O
the O
body O
in O
disorders O
of O
diurnal RARE
physiological O
rhythms RARE
and O
long O
- O
term O
hypokinesia RARE

Oxygen RARE
tension O
of O
the O
small O
lymph O
vessels O
( O
PLO2 NUMERIC
) O
of O
the O
rabbit O
hind RARE
limb O
was O
measured O
with O
both O
a O
flow O
- O
through O
micro O
chamber O
and O
a O
polarographic RARE
catheter O
- O
tip O
oxygen O
electrode O
to O
obtain O
experimental O
data O
on O
the O
source O
of O
oxygen O
in O
the O
lymph O
. O

The O
response O
of O
the O
plasma I-GENE
fibrinogen I-GENE
level O
to O
the O
subucutaneous RARE
injection O
of O
turpentine RARE
and O
to O
the O
intravenous O
injection O
of O
endotoxin O
was O
measured O
in O
normal O
rabbits O
and O
in O
rabbits O
made O
granulocytopenic RARE
and O
thrombocytopenic RARE
with O
busulfan RARE
. O

Constantly RARE
rectilinear RARE
pressure O
curves O
without O
uterine O
activities O
are O
interpreted O
as O
characteristic O
tocographic RARE
criteria O
of O
an O
advanced O
ectopic O
gravidity RARE
. O

Since O
myoglobin I-GENE
is O
co O
- O
extracted O
with O
the O
hemoglobin I-GENE
, O
the O
2 O
heme O
pigments RARE
are O
separated O
in O
one O
portion O
of O
the O
extract O
by O
precipitating O
the O
hemoglobin I-GENE
in O
an O
85 O
% O
( O
NH4 NUMERIC
) O
2SO4 NUMERIC
solution O
. O

Considering RARE
these O
sources O
of O
error O
some O
of O
the O
variability O
in O
the O
present O
investigation O
might O
be O
avoided RARE
by O
systematic O
instructions RARE
. O

E O
50 O
, O
843 NUMERIC
( O
1994 O
)]. O

Six O
patients O
with O
the O
diagnosis O
of O
acute O
mania RARE
were O
treated O
with O
high O
doses O
of O
the O
beta O
- O
adrenergic O
blocking O
agent O
propranolol O
. O

Effect O
of O
trauma O
on O
plasma I-GENE
glucagon I-GENE
and O
insulin I-GENE
concentrations O
in O
sheep O
. O

With O
the O
help O
of O
a O
nomogram RARE
one O
can O
read RARE
off O
the O
refraction RARE
, O
when O
axis O
length O
and O
corneal O
curvature RARE
are O
known O
. O

This O
up O
- O
grading RARE
of O
the O
final O
score O
by O
the O
CA O
component O
is O
greater O
( O
3 O
- O
8 O
%) O
in O
the O
less O
able O
students O
with O
scores O
below O
the O
mean O
level O
. O

Compared RARE
to O
controls O
, O
both O
UB ALLCAPS
and O
OCS ALLCAPS
rats O
showed O
a O
small O
but O
significant O
post O
- O
operative O
reduction O
in O
the O
nocturnality RARE
of O
drinking O
. O

Effect O
of O
indomethacin O
on O
coronary O
circulation O
: O
effect O
on O
ECG O
tracing RARE

Dual RARE
innervation RARE
of O
fast O
fibers O
in O
trunk O
muscles O
of O
lamprey RARE
larvae O

The O
feed O
consumed RARE
which O
was O
lowered O
by O
25 O
% O
initially O
, O
did O
not O
alter O
later O
. O

Certain RARE
characteristics O
of O
eye O
changes O
in O
patients O
with O
pheochromocytoma RARE
including O
Sipple RARE
' O
s O
syndrome O

The O
color O
- O
word RARE
interference O
effect O
previously O
reported O
with O
normal O
populations O
when O
given O
the O
Stroop O
test O
was O
demonstrated O
for O
this O
retarded O
sample O
using O
a O
special O
format RARE
. O

It O
was O
found O
that O
under O
the O
selected O
conditions O
a O
linear O
dependence O
exists O
between O
the O
betaI LASTCAP
% O
value O
and O
lgC LASTCAP
within O
the O
range O
of O
0 O
. O
5 O
-- O
10 O
mug RARE
ruscogenin RARE
. O

The O
influence O
of O
adrenergic O
nerves O
of O
the O
response O
of O
blood O
vessels O
in O
the O
rabbit O
ear O
to O
2 I-GENE
-- I-GENE
phenylalanine I-GENE
- I-GENE
8 I-GENE
- I-GENE
lysine I-GENE
vasopressin I-GENE
( O
Octapressin RARE
). O

Potscoital RARE
test O

I O
. O

When O
a O
tumour O
is O
present O
nipple RARE
discharge O
is O
of O
little O
importance O
for O
the O
diagnosis O
and O
treatment O
. O

Studies O
of O
biochemical O
and O
morphological O
changes O
( O
between O
normal O
and O
treated O
animals O
) O
show O
that O
chrysotile RARE
induces O
an O
increase O
in O
the O
lung O
free O
cell O
population O
and O
pulmonary O
surfactant O
levels O
. O

Infrared RARE
measurements O
of O
temperature O
changes O
and O
estimates O
of O
the O
heating RARE
produced O
at O
the O
mical RARE
. O

Who RARE
says RARE
' O
National O
Health O
Dis RARE
- O
service RARE
'. O

Is O
criticism RARE
of O
patient O
care O
justified RARE
and O
does O
it O
have O
educational RARE
value O
? O
Patients O
' O
criticism RARE
contributes O
to O
improved O
patient O
care O

Critique RARE
of O
" O
Interactive RARE
Effects O
of O
Test O
Anxiety RARE
and O
Credit RARE
/ O
No O
Credit RARE
or O
A O
- O
F O
Grade RARE
Condition RARE
upon O
Short O
- O
term O
and O
Long RARE
- O
term O
Recall RARE
of O
Course RARE
Information RARE
. O

These O
studies O
have O
shown O
that O
the O
majority O
of O
tested O
staphylococci RARE
were O
resistant O
to O
penicillin O
G O
, O
erythromycin RARE
, O
and O
produced O
beta I-GENE
- I-GENE
lactamase I-GENE
. O

Since O
1968 NUMERIC
, O
a O
steep RARE
decrease O
in O
the O
number O
of O
strains O
resistant O
to O
three O
or O
more O
antibiotics O
( O
multiple O
- O
resistant O
) O
and O
in O
strains O
of O
the O
83A NUMERIC
complex O
was O
noticed RARE
. O

Improvement RARE
of O
nursing O
instruction RARE
to O
be O
given O
at O
the O
time O
of O
discharge O
from O
the O
ward RARE
for O
premature O
infants O

No O
difference O
in O
the O
clinical O
acceptability RARE
could O
be O
ascertained RARE
between O
the O
two O
groups O
. O

After O
90 O
d O
a O
subsurface RARE
, O
radiolucent RARE
caries RARE
- O
like O
lesion O
was O
observed O
in O
two O
specimens O
only O
. O

The O
contraceptive RARE
pattern O
of O
157 NUMERIC
women O
was O
analysed O
and O
13 O
. O
8 O
percent O
were O
using O
inefficient O
methods O
. O

Plethysmographic RARE
technique O
and O
indirect O
blood O
pressure O
recordings O
were O
used O
. O

I O
. O

The O
second O
and O
third O
responded O
similarly O
to O
either O
a O
combined O
cyclophosphamide O
+ O
antilymphocyte RARE
globulin I-GENE
( O
ALG ALLCAPS
) O
treatment O
or O
to O
ALG ALLCAPS
administration O
preceded RARE
by O
a O
small O
dosage O
of O
cyclophosphamide O
, O
which O
had O
proved O
ineffective RARE
when O
administered O
alone O
. O

Evidence O
is O
presented O
that O
Leber RARE
' O
s O
military RARE
aneurysm RARE
retinitis RARE
is O
not O
a O
separate O
entity RARE
but O
a O
special O
form O
of O
Coats RARE
' O
disease O
. O

Fibrin RARE
cloaking RARE
along O
the O
catheter O
was O
found O
in O
20 O
patients O
studied O
by O
pull RARE
- O
out O
arteriography RARE
and O
was O
unassociated RARE
with O
clinical O
symptoms O
. O

The O
influence O
of O
a O
mobile O
pupil RARE
on O
the O
response O
in O
the O
DC O
- O
ERG ALLCAPS
is O
demonstrated O
. O

A O
newly O
synthesized O
anti O
- O
inflammatory O
agent O
, O
Y O
- O
8004 NUMERIC
demonstrated O
a O
greater O
inhibition O
than O
did O
indomethacin O
( O
IM O
). O
on O
inflammatory O
response O
such O
as O
ultraviolet RARE
erythema RARE
in O
guinea O
pigs O
, O
carrageenin RARE
edema O
, O
evans RARE
blue O
and O
carrageenin RARE
- O
induced O
pleuritis RARE
and O
acetic RARE
acid O
- O
induced O
peritonitis RARE
in O
rats O
. O

As O
stands RARE
shifted O
in O
dominance RARE
from O
pine RARE
to O
fir RARE
with O
age O
, O
subalpine RARE
fir RARE
appeared O
to O
maintain O
gradually O
increasing O
rates O
of O
whole O
- O
forest RARE
productivity RARE
until O
stands RARE
were O
approximately O
400 O
years O
old O
. O

Alpha RARE
- I-GENE
1 I-GENE
antitrypsin I-GENE
and O
Indian RARE
childhood O
cirrhosis O
. O

Lymphocyte RARE
subpopulations RARE
, O
serum I-GENE
IgE I-GENE
and O
total O
eosinophil O
counts O
in O
patients O
with O
bronchial O
asthma O
. O

A O
range O
of O
normal O
ventricular O
measurements O
for O
the O
EMI ALLCAPS
scan O
is O
suggested O
. O

A O
comparison O
of O
physical O
and O
cytogenetic O
estimates O
of O
radiation O
dose O
in O
patients O
treated O
with O
iodine O
- O
131 O
for O
thyroid O
carcinoma O
. O

Technique RARE
for O
obtaining O
refined RARE
ceramics RARE
with O
dense RARE
mass O

Mean O
total O
lung O
capacity O
, O
functional O
residual O
capacity O
, O
and O
residual O
volume O
increased O
significantly O
, O
and O
the O
mean O
closing RARE
volume O
, O
the O
lung O
volume O
above O
residual O
volume O
at O
which O
phase O
IV O
begins O
, O
decreased O
significantly O
with O
11 O
cm O
H20 NUMERIC
continuous O
positive O
airway O
pressure O
; O
differences O
at O
5 O
cm O
H20 NUMERIC
were O
not O
significant O
. O

Current O
status O
of O
zinc O
deficiency O
in O
the O
pathogenesis O
of O
neurological O
, O
dermatological RARE
and O
musculoskeletal RARE
disorders O
. O

Calcium RARE
and O
phosphorus O
metabolism O
in O
chronic O
uremia RARE
. O

Modern RARE
studies O
, O
conducted O
with O
Delta O
- O
9 O
- O
THC ALLCAPS
, O
in O
healthy O
voluntaries RARE
, O
again O
suggest O
the O
comparison O
or O
even O
the O
identity O
of O
the O
modifications O
caused O
by O
cannabis RARE
with O
sleep O
and O
dream RARE
. O

The O
correcting RARE
action O
of O
tropatepine RARE
hydrochloride RARE
upon O
the O
extrapyramidal RARE
effects O
induced O
by O
neuroleptics RARE
has O
been O
studied O
in O
32 O
acute O
psychotic RARE
states O
. O

Epididymal RARE
growth O
was O
retarded O
in O
animals O
maintained O
solely O
on O
chickpea RARE
haulm RARE
and O
improved O
with O
supplementation O
. O

Two O
patients O
were O
treated O
with O
both O
regimens O
. O

Results O
obtained O
for O
chloramphenicol O
- O
containing O
preparations O
are O
presented O
, O
and O
both O
dissolution O
curves O
and O
cup RARE
- O
plate O
assays O
demonstrate O
that O
chloramphenicol O
has O
far O
superior O
release O
( O
and O
hence O
activity O
) O
from O
creams RARE
than O
from O
ophthalmic O
ointments RARE
. O

IgG I-GENE
levels O
of O
1 O
/ O
100 O
were O
present O
in O
only O
four O
out O
of O
ten O
samples O
obtained O
150 O
days O
after O
the O
clinical O
onset O
. O

Letter O
: O
Perspectives RARE
in O
bone O
marrow O
transplantation O
. O

Assessment O
of O
the O
carcinogenicity RARE
of O
non O
- O
nutritive RARE
sweetners RARE
II O
: O
Cyclamates RARE
and O
cyclohexylamine RARE
. O

The O
discordant RARE
behaviour O
in O
weakly O
infected O
mice O
was O
due O
to O
the O
occurrence O
in O
some O
animals O
of O
a O
second O
phase O
of O
more O
rapid O
increase O
of O
the O
parasitemia RARE
. O

Residual RARE
amphotericin O
B O
was O
detected O
in O
the O
feces RARE
of O
the O
mice O
only O
while O
they O
were O
receiving O
the O
0 O
. O
3 O
mg O
/ O
ml O
dose O
level O
. O

There O
was O
a O
slight O
increase O
in O
total O
transferrin I-GENE
2 O
hr O
after O
1 O
tablet O
and O
values O
remained O
high O
throughout O
the O
experiment O
. O

Following O
intravenous O
administration O
, O
the O
myocardial O
concentration O
of O
tracer O
thallium O
- O
201 O
, O
potassium O
- O
43 O
, O
and O
rubidium RARE
- O
81 O
were O
determined O
in O
mice O
; O
thallium O
was O
present O
in O
the O
greatest O
concentration O
in O
the O
myocardium O
( O
2 O
. O
08 NUMERIC
% O
compared O
1 O
. O
25 O
% O
for O
potassium O
and O
1 O
. O
15 O
% O
for O
rubidium RARE
at O
10 O
minutes O
). O

Thromboplastin RARE
time O
, O
partial O
thromboplastin I-GENE
time O
, O
thrombin I-GENE
time O
, O
heat O
- O
dependent O
fibrin I-GENE
, O
clot RARE
retraction RARE
, O
and O
clotting I-GENE
factors I-GENE
II I-GENE
, I-GENE
V I-GENE
, I-GENE
VIII I-GENE
, I-GENE
IX I-GENE
, I-GENE
X I-GENE
, O
and O
the O
platelet O
count O
were O
determined O
. O

The O
data O
support O
the O
notion O
that O
suppression O
of O
images O
during O
binocular RARE
rivalry RARE
is O
independent O
in O
both O
eyes O
. O

Glycogen RARE
utilization O
was O
increased O
, O
but O
tissue O
levels O
of O
creatine O
phosphate O
, O
ATP O
, O
and O
lactate O
were O
similar O
to O
those O
in O
hearts O
receiving O
normal O
flow O
. O

The O
records O
from O
1948 NUMERIC
through O
1967 NUMERIC
of O
344 NUMERIC
previously O
untreated O
patients O
with O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
, O
oropharynx RARE
, O
supraglottic RARE
larynx O
and O
hypopharynx RARE
who O
had O
clinically O
positive O
cervical O
lymph O
node O
metastases O
staged RARE
N1 O
, O
N2A NUMERIC
, O
or O
N2B NUMERIC
, O
and O
whose O
initial O
neck O
treatment O
consisted O
of O
external O
radiation O
therapy O
alone O
were O
reviewed O
. O

With O
0 O
. O
5 O
vol RARE
.-%, RARE
the O
corresponding O
values O
were O
345 NUMERIC
mumol O
/ O
1 O
( O
5 O
. O
72 O
mg O
/ O
100 O
ml O
) O
and O
137 NUMERIC
mumol O
/ O
1 O
( O
2 O
. O
25 O
mg O
/ O
100 O
ml O
) O
respectively O
. O

The O
authors O
describe O
the O
technique O
of O
transverse O
axial O
tomography O
of O
the O
spine O
and O
give O
a O
detailed O
description O
of O
the O
axial O
anatomy RARE
of O
the O
normal O
lumbar O
spine O
from O
L O
- O
4 O
to O
the O
sacrum RARE
. O

Owing RARE
to O
parental O
attitude RARE
, O
a O
low O
protein O
diet O
( O
1 O
- O
5 O
g O
/ O
kg O
) O
was O
introduced O
only O
late O
. O

In O
none O
of O
the O
44 O
type O
I O
attacks O
and O
29 O
type O
II O
attacks O
which O
were O
recorded O
did O
circulatory O
changes O
; O
the O
latter O
were O
different O
in O
the O
two O
groups O
. O

A O
clinically O
useful O
diagnostic O
method O
has O
been O
developed O
for O
detecting O
and O
quantitating RARE
periods O
of O
apnea O
in O
pediatric O
patients O
. O

The O
other O
hypoglycaemic RARE
patient O
showed O
an O
exaggerated RARE
insulin I-GENE
release O
in O
response O
to O
tolbutamide RARE
. O

Nerve RARE
stimulation O
( O
1 O
. O
5 O
- O
12 O
cycles O
/ O
s O
) O
produced O
frequency O
- O
dependent O
reductions O
in O
CBF O
, O
a O
decrease O
of O
50 O
percent O
occurring O
with O
the O
highest O
frequency O
. O

Effect O
of O
ingestion O
of O
Norbiogest RARE
during O
the O
quiescent RARE
period O
of O
the O
genital O
organs O

Risk O
of O
infection O
in O
the O
treatment O
of O
fractures RARE

Bulbar RARE
pouches RARE
were O
perfused O
with O
solutions O
of O
0 O
. O
9 O
% O
Na O
C1 O
, O
0 O
. O
1 O
N O
HC1 NUMERIC
, O
40 O
% O
glucose O
, O
40 O
% O
NaC1 NUMERIC
, O
and O
40 O
% O
peptone RARE
or O
with O
0 O
. O
1 O
% O
solutions O
of O
acetylcholine O
chloride O
. O

Liver O
microsomes RARE
of O
the O
shag RARE
showed O
smaller O
than O
8 O
% O
of O
the O
epoxide RARE
hydrase RARE
activity O
and O
smaller O
than O
14 O
% O
of O
the O
hydroxylating RARE
capacity O
of O
liver O
microsomes RARE
from O
the O
rat O
. O

Prolonged RARE
heavy O
work O
effected RARE
an O
increase O
of O
10 O
. O
3 O
plus O
or O
minus O
0 O
. O
9 O
mmHg O
in O
in O
vivo O
P50 NUMERIC
( O
7 O
. O
30 O
PH O
- O
v O
, O
41 O
degrees O
C O
- O
v O
, O
and O
45 O
Pv RARE
- O
CO2 O
); O
due O
entirely O
to O
the O
additive O
effects O
of O
increased O
venous O
temperature O
and O
[ O
H O
+]. RARE

A O
clinical O
, O
serological O
and O
prognostic O
study O

The O
American O
Burkitt RARE
Lymphoma RARE
Registry RARE
: O
a O
progress O
report O
. O

Vitrectomy RARE
with O
an O
alternative O
instrument O
system O
. O

The O
metabolic O
clearance O
rate O
of O
progesterone O
was O
295 NUMERIC
+/- O
49 O
( O
S O
. O
E O
.) O
1 O
/ O
day O
. O

This O
sequence O
is O
almost O
identical O
with O
that O
of O
human I-GENE
luteinizing RARE
hormone I-GENE
( O
Sairam RARE
, O
M O
. O

The O
mean O
plasma O
sodium O
concentration O
which O
was O
135 O
. O
95 O
(+/- O
SD O
4 O
. O
14 O
) O
mEq O
/ O
kg O
before O
diuretic O
treatment O
was O
significantly O
decreased O
during O
treatment O
to O
129 NUMERIC
. O
19 O
(+/- O
SD O
2 O
. O
77 O
) O
mEq O
/ O
kg O
, O
P O
less O
than O
0 O
. O
001 O
. O

Editorial RARE
: O
Low O
- O
dose O
heparin O
and O
the O
prevention O
of O
venous O
thromboembolic RARE
disease O
. O

At O
the O
very O
high O
dose O
levels O
used O
, O
sodium O
saccharin O
and O
sodium O
cyclamate RARE
were O
weak O
solitary RARE
carcinogens RARE
producing O
4 O
/ O
253 NUMERIC
and O
3 O
/ O
228 NUMERIC
bladder O
tumours O
respectively O
, O
and O
the O
first O
of O
these O
tumours O
did O
not O
appear O
for O
more O
than O
80 O
weeks O
. O

Effects O
of O
perceptual RARE
salience RARE
on O
the O
matrix O
task O
performance O
of O
four O
- O
and O
six O
- O
year O
- O
old O
children O
. O

Glucose RARE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
( O
G I-GENE
- I-GENE
6 I-GENE
- I-GENE
PD I-GENE
) O
deficiency O
in O
the O
newborn O
. O

The O
eluting RARE
solvent O
was O
methanol RARE
- O
chloroform RARE
( O
10 O
+ O
90 O
) O
at O
a O
flow O
rate O
of O
2 O
. O
0 O
ml O
/ O
min O
. O

The O
bronchial O
epithelia RARE
of O
all O
smoke O
- O
exposed O
animals O
were O
hyperplastic RARE
, O
and O
their O
ultrastructure RARE
showed O
invaginations RARE
, O
tilt O
of O
nuclear O
axes RARE
, O
an O
increase O
in O
the O
number O
and O
size O
of O
lysosomes RARE
and O
multivesiculated RARE
bodies O
, O
and O
increased O
numbers O
of O
enlarged RARE
intramitochondrial RARE
granules O
. O

The O
routine O
administration O
of O
fat O
- O
soluble O
vitamins RARE
appears O
unnecessary RARE
but O
it O
is O
prudent RARE
to O
measure O
prothrombin I-GENE
time O
and O
serum O
vitamins RARE
A O
and O
E O
at O
intervals O
. O

Prostaglandins RARE
F O
( O
PGF ALLCAPS
) O
were O
measured O
in O
uterine O
vein O
, O
ovarian O
artery O
, O
and O
jugular RARE
vein O
plasma O
and O
in O
the O
endometrial O
tissues O
at O
various O
times O
during O
the O
bovine O
estrous RARE
cycle O
, O
and O
were O
compared O
to O
peripheral O
plasma O
progesterone O
levels O
. O

Before RARE
this O
date O
, O
the O
drug O
directly O
inhibits O
fetal O
weight O
gain O
, O
whereas O
the O
sensitivity O
of O
the O
placenta O
is O
only O
transient O
at O
day O
16 O
resulting O
in O
maximum O
weight O
decrease O
of O
this O
organ O
24 O
h O
later O
. O

Groups RARE
of O
ten O
dependent O
and O
ten O
saline O
mice O
were O
singly RARE
tested O
in O
both O
light O
and O
dark O
conditions O
in O
each O
of O
five O
covered RARE
cylinders RARE
( O
2 O
- O
23 O
in O
high O
). O

The O
effects O
initiated O
from O
the O
nucleus O
accumbens RARE
septi RARE
were O
most O
marked O
. O

The O
appearance O
of O
dyskinetic RARE
movement O
disorders O
in O
humans O
following O
the O
chronic O
use O
of O
levodopa RARE
or O
amphetamine O
may O
be O
a O
manifestation O
of O
similarly O
increased O
dopamine I-GENE
receptor I-GENE
site I-GENE
sensitivity O
within O
the O
striatum O
. O

Association O
with O
HL I-GENE
- I-GENE
A I-GENE
W I-GENE
- I-GENE
27 I-GENE
. O

Letter O
: O
Lactose RARE
tolerance O
tests O
as O
a O
predictor O
of O
milk O
tolerance O
. O

Retinoblastoma RARE
: O
a O
study O
of O
natural O
history O
and O
prognosis O
of O
268 NUMERIC
cases O
. O

Like O
pineal O
melatonin O
, O
serum O
melatonin O
was O
high O
at O
mid O
- O
dark O
and O
low O
at O
mid O
- O
light O
. O

D O
. O

Atherosclerosis RARE

The O
authors O
concluded O
that O
ultrasonic RARE
Doppler O
- O
cardiography RARE
can O
be O
used O
for O
measuring O
the O
relative O
changes O
in O
the O
stroke O
volume O
. O

The O
attainment RARE
of O
sexual O
maturity RARE
in O
terms O
of O
secondary O
sexual O
characteristics O
, O
the O
production O
of O
spermatozoa O
in O
the O
male O
, O
and O
the O
cyclical RARE
female O
pattern O
with O
release O
of O
ova RARE
are O
end O
- O
points O
of O
the O
developmental O
process O
. O

However O
, O
a O
10 O
-- O
15 O
% O
lengthening RARE
of O
the O
partial O
thromboplastin I-GENE
time O
is O
evident O
after O
24 O
hours O
of O
storage O
. O

Caution RARE
should O
be O
exercised RARE
in O
the O
use O
of O
these O
dyes RARE
for O
lymphograms RARE
. O

This O
reveals O
a O
new O
test O
for O
short O
saphenous RARE
incompetence RARE
and O
shows O
that O
14 O
per O
cent O
of O
varices RARE
stem O
from O
a O
saphenopopliteal RARE
reflux O
. O

Three O
groups O
of O
patients O
who O
had O
undergone O
subtotal O
thyroidectomy RARE
for O
Graves RARE
' O
s O
disease O
, O
toxic O
multinodular RARE
goitre RARE
, O
or O
euthyroid RARE
multinodular RARE
goitre RARE
12 O
to O
15 O
years O
before O
and O
in O
whom O
a O
normal O
serum O
thyroxine O
( O
T O
- O
4 O
) O
level O
was O
found O
were O
each O
divided O
into O
two O
subgroups O
on O
the O
basis O
of O
a O
normal O
or O
a O
raised O
serum O
thyrotrophin RARE
concentration O
. O

Routine RARE
isotope RARE
cystography RARE
using O
99M NUMERIC
Tc O
sulfur O
colloid O
for O
detection O
and O
follow O
- O
up O
of O
vesico RARE
- O
ureteral RARE
reflux O

Air RARE
ion O
action O
on O
bacteria O
. O

No O
evidence O
of O
either O
positive O
or O
negative O
chemography RARE
was O
found O
. O

The O
interpretation O
of O
antibiotic O
disc O
sensitivities RARE
. O

Following O
retransfusion RARE
, O
the O
affected O
epithelial O
lining RARE
appeared O
greatly O
distended RARE
over O
the O
oedematous RARE
lamina RARE
propria RARE
, O
with O
almost O
complete O
loss O
of O
structural O
detail O
. O

A O
study O
of O
chromosomes O
of O
lymphocytes O
from O
patients O
treated O
with O
hycanthone RARE
. O

Characteristics RARE
of O
anesthesia O
and O
resuscitation O
in O
emergency RARE
lung O
surgery O

Study O
of O
the O
physico RARE
- O
chemical O
state O
of O
plutonium O
- O
239 O
in O
a O
citrate O
solution O
- O
blood O
system O

Tobramycin RARE
60 O
mg O
did O
not O
show O
any O
remarkable O
effect O
, O
but O
dibecacin RARE
100 O
mg O
produced O
a O
slight O
potentiating RARE
effect O
on O
the O
action O
of O
d O
- O
tubocurarine RARE
. O

In O
about O
one O
third O
of O
the O
cases O
this O
operation O
results O
in O
tonal RARE
and O
vocal RARE
improvement O
for O
patients O
suffering O
from O
progressive O
perceptive RARE
deafness RARE
. O

The O
specific O
electrical O
resistance O
of O
the O
cerebrospinal O
fluid O
was O
measured O
by O
means O
of O
conductometry RARE
in O
14 O
cases O
of O
meningitis O
purulenta RARE
, O
17 O
cases O
of O
meningitis O
serosa RARE
, O
10 O
cases O
of O
encephalitis RARE
and O
in O
32 O
control O
subjects O
. O

2 O
- O
Chemical O
occlusion O
of O
vas O
is O
quite O
effective O
in O
producing O
a O
block O
in O
the O
vas O
deferens O
of O
dogs O
. O

Besides RARE
, O
we O
found O
in O
3 O
patients O
increased O
serum I-GENE
immunoglobulins I-GENE
, O
chiefly RARE
IgG I-GENE
, O
as O
first O
Russe RARE
, O
Busey RARE
and O
Barbeau RARE
demonstrated O
in O
a O
large O
French RARE
- O
Canadian RARE
family O
. O

We O
suggest O
that O
such O
occlusions RARE
occurred O
at O
the O
time O
of O
the O
infarction O
. O

Streptococcal RARE
preparation O
( O
OK ALLCAPS
- O
432 NUMERIC
), O
a O
new O
type O
of O
anti O
- O
cancer O
agent O
, O
was O
given O
to O
the O
patients O
with O
advanced O
cancer O
in O
combination O
with O
Mitomycin RARE
- O
C O
, O
5 O
- O
FU O
and O
Cytosine RARE
arabinoside RARE
. O

Generally RARE
, O
a O
correlation O
was O
observed O
between O
highest O
concentrations O
of O
CSF I-GENE
immunoglobulins I-GENE
and O
degree O
of O
meningeal RARE
inflammatory O
response O
, O
even O
if O
this O
was O
a O
component O
of O
other O
neurological O
diseases O
. O

Maternal RARE
lactation RARE

Experimental O
cardiotoxicity RARE
of O
adriamycin RARE

Muscular RARE
pathology O

Demonstration RARE
of O
the O
agent O
was O
performed O
from O
the O
6th NUMERIC
to O
the O
11th NUMERIC
day O
p O
. O
i O
. O
by O
direct O
microscopic O
methods O
( O
Stamp RARE
and O
auramine RARE
staining O
, O
fluorescent O
antibody O
technique O
); O
the O
Coxiella RARE
content O
was O
determined O
by O
titration O
in O
embryonated RARE
hen RARE
' O
s O
eggs O
. O

The O
patients O
were O
divided O
into O
4 O
groups O
receiving O
NLA ALLCAPS
II O
with O
or O
without O
nalorphine RARE
, O
morphine O
or O
Micoren RARE
. O

The O
alterations O
of O
5 O
- O
HT O
and O
5 O
- O
HIAA ALLCAPS
levels O
in O
several O
regions O
of O
the O
brain O
under O
the O
conditions O
examined O
may O
indicate O
that O
IDPN ALLCAPS
' O
s O
neurotoxicity O
primarily O
affects O
5 O
- O
HT O
- O
containing O
neurones O
. O

( O
5 O
) O
An O
increase O
in O
leukocyte O
- O
counts O
occurred O
on O
the O
administration O
of O
serum O
obtained O
from O
rabbit O
during O
phase O
- O
2 O
. O

The O
results O
obtained O
tend RARE
to O
prove O
that O
the O
reticuloendothelial RARE
system O
mainly O
participated RARE
in O
beryllium RARE
retention O
. O

In O
both O
cases O
, O
at O
the O
end O
of O
exposure O
the O
same O
level O
of O
blood I-GENE
carboxyhemoglobin RARE
( O
COHb RARE
) O
( O
about O
50 O
%) O
was O
reached O
. O

The O
results O
indicate O
that O
increased O
pulmonary O
blood O
flow O
and O
decreased O
pulmonary O
vascular O
resistance O
with O
advancing RARE
gestation O
are O
due O
to O
an O
increase O
in O
the O
total O
number O
of O
vessels O
and O
increased O
vasomotor RARE
reactivity O
is O
related O
to O
an O
increase O
in O
the O
total O
amount O
of O
smooth O
muscle O
while O
the O
thickness O
of O
muscle O
in O
individual O
vessels O
remains O
constant O
. O

Reduction RARE
in O
dosage O
restored O
normal O
taste O
sense O
in O
all O
three O
, O
but O
in O
two O
the O
drug O
had O
to O
be O
discontinued RARE
because O
of O
persisting RARE
high O
transaminase RARE
levels O
. O

The O
calcium O
ratio O
( O
mean O
ratio O
of O
the O
predicted O
to O
measured O
TBCa RARE
) O
in O
men O
was O
1 O
. O
000 O
+/- O
7 O
. O
8 O
% O
and O
in O
women O
0 O
. O
996 NUMERIC
+/- O
7 O
. O
1 O
%. O

A O
late O
diagnosis O
of O
retinoblastoma O
is O
an O
unquestionable RARE
fact O
that O
allows O
its O
growth O
and O
leads O
to O
a O
deterioration O
in O
the O
outlook RARE
. O

Total O
cholesterol O
was O
measured O
in O
amniotic O
fluids O
collected O
at O
different O
stages O
of O
gestation O
. O

Her RARE
serum O
FT3 NUMERIC
concentration O
was O
, O
however O
, O
much O
higher O
than O
the O
ranges RARE
in O
normal O
pregnancy O
or O
in O
GTD ALLCAPS
patients O
without O
clinical O
hyperthyroidism RARE
. O

The O
authors O
found O
that O
except O
for O
fear RARE
and O
pugnacity RARE
all O
husband RARE
- O
wife RARE
trait RARE
correlations O
were O
positive O
, O
in O
contrast O
to O
Winch RARE
' O
s O
principle RARE
of O
type O
I O
complementarity O
. O

A O
note RARE
on O
the O
phase O
- O
plane RARE
technique O
representation RARE
of O
cardiac O
action O
potentials O
. O

3 O
activities O
of O
the O
factor I-GENE
II I-GENE
molecule O
in O
the O
newborn O
infant O
at O
term O

The O
concept O
of O
" O
structural O
identifiability RARE
" O
is O
employed O
in O
this O
analysis O
to O
determine O
which O
model O
parameters O
can O
be O
and O
which O
cannot O
be O
determined O
" O
uniquely RARE
" O
from O
given O
input O
- O
output O
data O
; O
a O
step O
- O
by O
- O
step O
procedure O
based O
on O
an O
extension O
of O
this O
concept O
is O
presented O
for O
adapting O
the O
overall O
approach O
to O
the O
experimental O
design O
problem O
. O

However O
, O
we O
did O
detect O
lot RARE
- O
to O
- O
lot RARE
variation O
and O
differences O
in O
performance O
between O
narrow O
bandpass RARE
and O
wide O
bandpass RARE
spectrophotometers RARE
. O

The O
cochlear O
compromise RARE
. O

A O
case O
observed O
in O
Saigon RARE

Hypertonic RARE
glucose O
administered O
intrajejunally RARE
in O
Heidenhain RARE
pouch RARE
dogs O
resulted O
in O
an O
equal O
inhibition O
of O
pentagastrin RARE
- O
induced O
acid O
secretion O
from O
the O
pouch RARE
and O
the O
main O
stomach O
, O
whereas O
hypertonic RARE
saline O
had O
no O
effect O
. O

Acquired RARE
factor I-GENE
VIII I-GENE
inhibitor O
in O
non O
- O
hemophilic RARE
patients O

Biohydrogenation RARE
of O
linoleic RARE
acid O
into O
octadecenoic RARE
acid O
was O
observed O
. O

The O
study O
of O
calcium O
metabolism O
in O
ten O
thalassaemic RARE
children O
comperatively RARE
with O
controls O
after O
oral O
administration O
of O
47Ca NUMERIC
has O
shown O
diminished O
intestinal O
absorption O
. O

Chlamydial RARE
agents O
were O
isolated O
from O
the O
semen O
near O
the O
end O
of O
the O
chlamydemic RARE
phase O
. O

Because O
of O
the O
increased O
CPK I-GENE
activity O
found O
in O
normal O
newborns O
, O
screening O
for O
Duchenne RARE
- O
type O
muscular O
dystrophy O
should O
be O
postponed RARE
for O
a O
few O
weeks O
after O
delivery O
. O

In O
contrast O
, O
the O
insulin I-GENE
response O
had O
returned O
to O
the O
non O
- O
pregnant O
value O
by O
the O
second O
day O
of O
the O
puerperium RARE
. O

The O
authors O
report O
the O
results O
of O
a O
series O
of O
toxicological O
tests O
conducted O
on O
plastic RARE
materials O
( O
polyethylene RARE
) O
activated O
with O
tetraphenylbutadiene RARE
( O
TPB ALLCAPS
) O
an O
additive O
recently O
proposed O
as O
a O
sensitizer RARE
capable O
of O
photodegrading RARE
plastic RARE
materials O
. O

Mutational O
analysis O
of O
the O
major O
homology O
region O
of O
Mason RARE
- O
Pfizer RARE
monkey O
virus O
by O
use O
of O
saturation O
mutagenesis O
. O

One O
site O
, O
PAL I-GENE
, O
occurs O
within O
the O
10 O
bp O
sequence O
GGGGAGGAGG ALLCAPS
. O

Nuclear O
extracts O
prepared O
from O
both O
neural O
and O
non O
- O
neural O
cell O
lines O
, O
mouse O
brain O
, O
and O
mouse O
liver O
contain O
proteins O
that O
recognize O
and O
bind O
to O
the O
PROX ALLCAPS
and O
PAL O
sequences O
indicating O
that O
proteins O
which O
bind O
to O
these O
target O
sequences O
are O
widespread RARE
. O

To O
determine O
if O
the O
NF I-GENE
( I-GENE
H I-GENE
) I-GENE
promoter I-GENE
can O
be O
activated O
in O
a O
tissue O
specific O
manner O
during O
development O
transgenic O
mice O
containing O
the O
promoter O
region O
linked O
to O
a O
beta I-GENE
- I-GENE
galactosidase I-GENE
reporter I-GENE
gene I-GENE
were O
generated O
. O

Here O
we O
describe O
and O
map O
two O
more O
new O
genes O
identified O
as O
allele O
- O
specific O
suppressors O
that O
compensate RARE
for O
carboxy O
- O
terminal O
truncation RARE
of O
PET122 NUMERIC
. O

Previous O
studies O
have O
shown O
[ O
Hisanaga RARE
, O
S O
., O
Kusubata RARE
, O
M O
., O
Okumura RARE
, O
E O
. O
& O
Kishimoto RARE
, O
T O
. O

Treatment O
and O
staining O
of O
smears O
and O
sections O
for O
detection O
of O
microorganisms RARE

The O
apparent O
Kd RARE
of O
the O
MetRS LASTCAP
/ I-GENE
CAU ALLCAPS
operator I-GENE
complex I-GENE
is O
one O
order O
magnitude O
higher O
than O
that O
of O
the O
ThrRS LASTCAP
/ I-GENE
CGU ALLCAPS
operator I-GENE
complex I-GENE
. O

A O
significant O
direct O
relationship O
was O
observed O
between O
the O
percent O
area O
density O
of O
smooth O
muscle O
and O
the O
percent O
change O
in O
peak O
urinary O
flow O
rate O
. O

Rabbit RARE
skeletal I-GENE
muscle I-GENE
glycogenin RARE
. O

Characterization O
of O
the O
human I-GENE
gene I-GENE
encoding I-GENE
cytokeratin RARE
17 I-GENE
and O
its O
expression O
pattern O
. O

Animals O
that O
received O
DSP ALLCAPS
- O
4 O
were O
significantly O
retarded O
in O
motor O
recovery O
compared O
with O
the O
saline O
group O
. O

The O
prophylactic O
use O
of O
new O
medication O
for O
patients O
between O
the O
first O
and O
second O
cycle O
of O
chemotherapy O
, O
in O
agreement O
with O
the O
estimates O
calculated O
, O
does O
not O
save RARE
health O
care O
costs O
but O
may O
improve O
the O
quality O
of O
life O
in O
these O
patients O
and O
permit O
the O
continuation RARE
of O
a O
therapeutic O
schedule O
without O
interruption RARE
which O
may O
improve O
the O
life O
expectancy RARE
of O
the O
patient O
. O

AP O
was O
induced O
by O
intraductal RARE
infusion O
of O
two O
different O
concentrations O
of O
glycodeoxycholic RARE
acid O
( O
GDOC ALLCAPS
17 O
mmol O
and O
34 O
mmol O
). O

The O
isolation O
of O
this O
gene O
was O
based O
on O
the O
identification O
of O
the O
Y O
- O
231 O
cosmid O
that O
contains O
CpG O
rich O
sequences O
( O
HTF ALLCAPS
islands RARE
) O
in O
its O
human O
insert O
. O

Tissue I-GENE
plasminogen I-GENE
activator I-GENE
, O
its O
inhibitor O
and O
other O
parameters O
of O
fibrinolysis RARE
in O
blood O
of O
patients O
operated O
for O
mild O
hypertrophy O
of O
the O
prostate O

Gene O
constructs O
consisting O
of O
human I-GENE
growth I-GENE
hormone I-GENE
( O
hGH I-GENE
) O
gene O
driven O
by O
promoter O
/ O
regulatory O
sequence O
of O
mouse I-GENE
metallothionein RARE
( O
mMT LASTCAP
), O
viral I-GENE
thymidine I-GENE
kinase I-GENE
( O
vTK LASTCAP
), O
rat I-GENE
cholecystokinin RARE
( O
rCCK LASTCAP
), O
or O
chicken I-GENE
beta I-GENE
- I-GENE
actin I-GENE
( O
cBA LASTCAP
) O
gene O
were O
injected O
into O
the O
cytoplasm O
of O
fertilized RARE
medaka RARE
eggs O
via O
the O
micropyle RARE
. O

Serum O
gastrin I-GENE
and O
AFP I-GENE
levels O
had O
the O
same O
evolution O
and O
appear O
to O
have O
the O
same O
interest O
to O
follow O
the O
course O
of O
the O
disease O
. O

Prospects RARE
for O
controlled O
- O
delivery O
systems O
. O

The O
mean O
(+/- O
SD O
) O
PaO2 O
increased O
from O
80 O
. O
8 O
+/- O
26 O
. O
9 O
mmHg O
before O
to O
89 O
. O
8 O
+/- O
27 O
. O
3 O
mmHg O
after O
the O
infusion O
( O
P O
< O
0 O
. O
05 O
) O
and O
the O
PaCO2 O
decreased O
from O
42 O
. O
4 O
+/- O
8 O
. O
3 O
to O
39 O
. O
6 O
+/- O
7 O
. O
9 O
mmHg O
( O
P O
< O
0 O
. O
05 O
). O

Though RARE
hepatomegaly RARE
and O
mild O
elevation O
of O
enzymes O
can O
be O
observed O
in O
a O
significant O
proportion O
of O
patients O
, O
involvement O
of O
liver O
leading O
to O
acute O
hepatitis O
or O
liver O
cell O
necrosis O
is O
a O
relatively O
uncommon RARE
complication O
in O
P O
. O
falciparum O
malaria O
. O

For O
the O
first O
group O
, O
the O
maximal O
decrease O
in O
plasma O
potassium O
elicited O
by O
salbutamol RARE
was O
0 O
. O
80 O
+/- O
0 O
. O
19 O
, O
0 O
. O
48 O
+/- O
0 O
. O
22 O
, O
and O
0 O
. O
78 O
+/- O
0 O
. O
46 O
mmol O
/ O
l O
, O
and O
for O
the O
second O
group O
, O
maximal O
decrement RARE
was O
1 O
. O
31 O
+/- O
0 O
. O
37 O
, O
0 O
. O
70 O
+/- O
0 O
. O
24 O
, O
and O
0 O
. O
84 O
+/- O
0 O
. O
17 O
mmol O
/ O
l O
for O
the O
iv O
, O
po RARE
, O
and O
it O
routes O
, O
respectively O
. O

The O
two O
drugs O
increase O
the O
rate O
of O
early O
diastolic O
filling O
. O

A O
statistically O
significant O
improvement O
due O
to O
the O
administration O
of O
Bromergon RARE
was O
observed O
in O
symptoms O
associated O
with O
overreactiveness RARE
to O
normal O
prolactin I-GENE
levels O
, O
i O
. O
e O
. O
abdominal O
tension O
, O
edema O
, O
weight O
gain O
and O
breast O
tenderness RARE
. O

The O
magnitude O
of O
the O
early O
response O
was O
241 NUMERIC
+/- O
51 O
% O
in O
A O
(% RARE
baseline O
RL ALLCAPS
; O
mean O
+/- O
SE O
), O
and O
significantly O
less O
in O
B O
( O
119 O
+/- O
7 O
%) O
and O
C O
( O
131 O
+/- O
16 O
%) O
( O
p O
< O
0 O
. O
01 O
). O

Most O
of O
the O
patients O
presented O
with O
Transient O
Ischemic O
Attacks RARE
( O
64 O
%) O
or O
Reversible RARE
Ischemic O
Neurologic RARE
Deficits RARE
( O
19 O
%). O

We O
cloned O
the O
third O
human O
gene O
for O
the O
LD78 NUMERIC
, O
termed O
LD78 NUMERIC
gamma I-GENE
and O
the O
sequence O
analysis O
showed O
that O
it O
is O
a O
5 O
'- O
truncated O
pseudogene O
. O

This O
analysis O
, O
together O
with O
a O
consideration RARE
of O
the O
SCBs RARE
found O
upstream O
of O
known O
SWI4 I-GENE
, I-GENE
6 I-GENE
- O
dependent O
genes O
, O
leads O
to O
the O
proposal RARE
of O
a O
revised O
consensus O
sequence O
for O
this O
important O
regulatory O
element O
. O

Mutational O
analysis O
of O
a O
DNA O
sequence O
involved O
in O
linking O
gene O
expression O
to O
the O
cell O
cycle O
. O

The O
natural O
history O
of O
these O
lesions O
, O
locoregional RARE
efficiency O
of O
the O
different O
treatments O
used O
, O
the O
part O
played O
by O
chemotherapy O
, O
survival O
, O
causes O
of O
death O
and O
therapeutic O
modalities O
used O
as O
a O
last O
measure O
, O
have O
been O
analysed O
. O

The O
method O
was O
adapted O
for O
the O
determination O
of O
nadolol RARE
racemate RARE
A O
by O
a O
change O
in O
mobile O
phase O
composition O
. O

In O
general O
, O
however O
, O
this O
study O
provided O
little O
evidence O
of O
any O
effect O
of O
supplementation O
to O
athletic RARE
performance O
for O
athletes RARE
consuming RARE
the O
dietary O
RDIs RARE
. O

In O
the O
absence O
of O
histological O
criteria O
, O
which O
it O
is O
difficult O
to O
demand O
in O
view O
of O
the O
variability O
of O
results O
and O
potential O
dangers RARE
of O
endomyocardial RARE
biopsy O
involving O
such O
thin O
and O
fragile RARE
ventricular O
walls RARE
, O
the O
diagnosis O
of O
ACRV ALLCAPS
is O
based O
upon O
the O
concomitant O
existence O
of O
: O
( O
1 O
) O
electrophysiological RARE
criteria O
: O
ventricular O
arrhythmias O
, O
in O
particular O
sustained O
monomorphous RARE
VT O
, O
with O
the O
particular O
feature O
of O
a O
very O
high O
degree O
of O
sensitivity O
to O
adrenergic O
stimulation O
( O
exercise O
), O
the O
existence O
of O
late O
potentials O
on O
the O
high O
amplification O
ECG O
, O
a O
highly O
specific O
sign O
, O
though O
unfortunately RARE
of O
poor O
sensitivity O
in O
localized O
froms RARE
, O
those O
which O
are O
most O
difficult O
to O
identify O
( O
2 O
); O
segmentary RARE
morphological O
and O
kinetic O
RV O
abnormalities O
, O
most O
often O
resulting O
in O
localized O
akinetic RARE
or O
dyskinetic RARE
parietal RARE
vaulting RARE
, O
with O
stasis RARE
" O
in O
situ O
". O

In O
7 O
of O
9 O
cases O
, O
the O
enhancer O
is O
fused O
to O
the O
c I-GENE
- I-GENE
myc I-GENE
bearing I-GENE
sequences I-GENE
of O
chromosome O
8 O
. O

These O
components O
both O
had O
a O
median O
R2 O
of O
0 O
. O
84 O
, O
compared O
to O
median O
R2s NUMERIC
ranging O
from O
0 O
. O
37 O
to O
0 O
. O
83 O
for O
five O
commonly O
used O
ad RARE
hoc RARE
EEG O
components O
. O

The O
obtained O
results O
were O
compared O
with O
control O
group O
( O
10 O
female O
volunteers O
). O

100 O
years O
of O
dentistry RARE
at O
the O
Friedrich RARE
Schiller RARE
University O
in O
Jena RARE

The O
target O
contained O
between O
positions O
- O
403 NUMERIC
and O
- O
125 O
acts O
independently O
of O
orientation O
, O
in O
different O
cell O
types O
and O
species O
, O
and O
in O
the O
context O
of O
a O
heterologous O
promoter O
. O

66 O
: O
469 NUMERIC
- O
479 NUMERIC
, O
1992 O
). O

Synergistic RARE
transactivation O
of O
the O
BMRF1 NUMERIC
promoter I-GENE
by O
the O
Z I-GENE
/ O
c I-GENE
- I-GENE
myb I-GENE
combination O
appears O
to O
involve O
direct O
binding O
by O
the O
Z I-GENE
protein I-GENE
but O
not O
the O
c I-GENE
- I-GENE
myb I-GENE
protein I-GENE
. O

The O
UCR ALLCAPS
core O
sequence O
, O
CGCCATTTT ALLCAPS
, O
binds O
a O
ubiquitous O
nuclear O
factor O
and O
mediates O
negative O
regulation O
of O
MuLV O
promoter O
activity O
. O

These O
studies O
show O
that O
UCRBP ALLCAPS
binds O
to O
various O
target O
motifs O
that O
are O
distinct O
from O
the O
UCR ALLCAPS
motif O
: O
the O
adeno RARE
- I-GENE
associated I-GENE
virus I-GENE
P5 NUMERIC
promoter I-GENE
and O
elements O
in O
the O
immunoglobulin I-GENE
light I-GENE
- I-GENE
and I-GENE
heavy I-GENE
- I-GENE
chain I-GENE
genes O
, O
as O
well O
as O
elements O
in O
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

Possibly RARE
, O
the O
scr1 NUMERIC
- I-GENE
1 I-GENE
mutation I-GENE
does O
not O
affect O
signal O
recognition O
or O
translational O
arrest O
but O
instead O
results O
in O
maintenance O
of O
translational O
arrest O
of O
AEP ALLCAPS
synthesis O
. O

The O
cellular O
sequences O
5 O
' O
to O
the O
viral O
integration O
site O
exhibited O
85 O
to O
97 O
% O
identity O
to O
several O
sequences O
belonging O
to O
the O
mouse I-GENE
L1 I-GENE
family I-GENE
of O
long O
interspersed O
repetitive O
sequences O
. O

Both O
Rep78 NUMERIC
and O
Rep68 NUMERIC
cut O
the O
terminal O
AAV O
sequence O
at O
the O
same O
site O
( O
nucleotide O
124 O
). O

Nucleotide O
sequence O
analysis O
revealed O
that O
TAR I-GENE
- I-GENE
binding I-GENE
protein I-GENE
is O
very O
similar O
to O
the O
CREB2 NUMERIC
protein I-GENE
. O

These O
results O
indicate O
that O
both O
N O
- O
and O
C O
- O
terminal O
mutations O
are O
required O
to O
inhibit O
transrepression RARE
by O
FBR ALLCAPS
protein I-GENE
and O
that O
multiple O
structural O
mutations O
accompanied O
by O
posttranslational O
protein O
modification O
alter O
gene O
regulation O
by O
FBR ALLCAPS
protein I-GENE
. O

The O
JS78 NUMERIC
mutation O
changes O
Gln243 NUMERIC
in O
gp0 NUMERIC
. O
7 O
to O
an O
amber RARE
codon O
, O
which O
explains RARE
the O
production O
of O
the O
truncated O
, O
30 I-GENE
- I-GENE
kDa I-GENE
gp0 NUMERIC
. I-GENE
7 I-GENE
- I-GENE
related I-GENE
polypeptide I-GENE
, O
and O
implicates RARE
the O
11 O
- O
kDa O
C O
- O
terminal O
domain O
in O
host O
transcription O
shut RARE
- O
off O
. O

A O
patient O
suffering O
from O
heparin O
- O
associated O
thrombocytopenia O
( O
HAT ALLCAPS
), O
recurrent O
arteriothromboses RARE
, O
and O
acute O
renal O
failure O
after O
treatment O
with O
standard O
heparin O
is O
described O
. O

The O
predicted O
receptor O
structure O
includes O
a O
cysteine O
- O
rich O
extracellular O
domain O
, O
a O
single O
hydrophobic O
transmembrane O
domain O
, O
and O
a O
predicted O
cytoplasmic I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
domain I-GENE
. O

Drosophila I-GENE
UbcD1 NUMERIC
encodes O
a O
highly O
conserved O
ubiquitin I-GENE
- O
conjugating RARE
enzyme O
involved O
in O
selective O
protein O
degradation O
. O

Analysis O
of O
the O
entire O
16 O
. O
7 O
- O
kb O
mt RARE
genome O
determined O
that O
a O
MDP1 NUMERIC
mediates O
cleavage O
of O
chick O
mtDNA LASTCAP
in O
vitro O
at O
three O
H O
- O
and O
two O
L O
- O
strand O
sequence O
- O
specific O
target O
sites O
located O
within O
a O
90 O
- O
bp O
A O
+ O
T O
- O
rich O
genomic O
tract O
, O
theoretically RARE
capable O
of O
forming O
stable O
secondary O
structures O
, O
approximately O
200 O
bases O
upstream O
from O
the O
H O
- O
strand O
origin O
( O
OH O
) O
of O
replication O
. O

The O
goal O
of O
the O
present O
study O
was O
to O
determine O
the O
feasibility O
of O
retrovirus O
mediated O
expression O
of O
rp47phox NUMERIC
in O
the O
HL60 NUMERIC
and O
U937 O
human O
hematopoietic O
cell O
lines O
, O
and O
in O
an O
Epstein O
- O
Barr O
virus O
transformed O
B O
- O
lymphocyte O
cell O
line O
( O
EBV O
- O
BCL O
) O
derived O
from O
a O
p47phox NUMERIC
- O
deficient O
CGD ALLCAPS
patient O
. O

Comparison O
with O
the O
sequence O
databanks RARE
show O
that O
Tactile RARE
is O
a O
member O
of O
the O
immunoglobulin I-GENE
gene I-GENE
superfamily I-GENE
, O
with O
similarity O
to O
Drosophila I-GENE
amalgam RARE
, O
the O
melanoma I-GENE
Ag I-GENE
MUC ALLCAPS
- I-GENE
18 I-GENE
, O
members O
of O
the O
carcinoembryonic RARE
Ag I-GENE
family I-GENE
, O
the O
poliovirus RARE
receptor I-GENE
, O
and O
the O
neural I-GENE
cell I-GENE
adhesion I-GENE
molecule I-GENE
. O

A O
rather O
similar O
pattern O
of O
results O
was O
obtained O
with O
respect O
to O
LMP2B NUMERIC
mRNA I-GENE
expression O
, O
such O
transcripts O
being O
detectable O
only O
in O
a O
subset O
of O
tumors O
, O
and O
then O
at O
apparently O
low O
levels O
. O

The O
phenotypes O
of O
the O
ICP0 NUMERIC
nonsense O
mutants O
were O
intermediate O
between O
those O
of O
the O
wild O
- O
type O
virus O
and O
7134 NUMERIC
in O
that O
the O
more O
ICP0 NUMERIC
- I-GENE
coding I-GENE
sequence I-GENE
expressed O
by O
a O
given O
nonsense O
mutant O
, O
the O
more O
wild O
type O
- O
like O
was O
its O
phenotype O
. O

Analysis O
of O
nucleotide O
sequence O
of O
the O
rightmost RARE
43 O
kbp O
of O
herpesvirus O
saimiri RARE
( O
HVS O
) O
L O
- O
DNA O
: O
general O
conservation O
of O
genetic O
organization O
between O
HVS O
and O
Epstein O
- O
Barr O
virus O
. O

Treatment O
with O
MK O
- O
801 O
induced O
a O
burst O
suppression O
in O
the O
EEG O
and O
a O
transient O
drop O
( O
11 O
. O
4 O
+/- O
6 O
. O
5 O
mm O
Hg O
) O
in O
the O
mean O
arterial O
pressure O
. O

In O
contrast O
, O
gel O
mobility O
shift O
experiments O
have O
failed O
to O
reveal O
that O
HAP2 NUMERIC
or O
HAP3 NUMERIC
binds O
to O
domain O
1 O
or O
that O
hap3 NUMERIC
mutations O
affect O
the O
complexes O
bound O
to O
it O
. O

Myogenic RARE
differentiation O
can O
be O
inhibited O
by O
the O
adenovirus O
E1a I-GENE
protein I-GENE
in O
the O
rat O
L6 NUMERIC
muscle O
cell O
line O
. O

The O
experiment O
results O
showed O
: O
( O
i O
) O
not O
only O
1O2 NUMERIC
, O
but O
also O
free O
radicals O
( O
O2 O
-. O
. O
OH O
and O
YHPD O
-.) RARE
can O
be O
formed O
by O
the O
aid O
of O
YHPD O
; O
and O
( O
ii O
) O
as O
to O
the O
ability O
of O
producing O
1O2 NUMERIC
, O
YHPD O
less O
than O
BHPD ALLCAPS
, O
while O
for O
generating O
O2 O
-. O
and O
. O
OH O
, O
YHPD O
greater O
than O
BHPD ALLCAPS
. O

Two O
points O
are O
indicated O
: O
first O
, O
the O
photosensitized RARE
damage O
of O
YHPD O
is O
interrelated RARE
to O
not O
only O
1O2 NUMERIC
, O
but O
also O
free O
radicals O
( O
O2 O
-. O
. O
OH O
and O
YHPD O
-.); RARE
second O
, O
although O
the O
photosensitized RARE
damage O
of O
YHPD O
is O
stronger O
than O
that O
of O
BHPD ALLCAPS
, O
yet O
the O
photosensitized RARE
damage O
is O
negatively O
correlated O
to O
the O
yield O
of O
1O2 NUMERIC
but O
positively O
correlated O
to O
those O
of O
O2 O
-. O
and O
OH O
. O

Acad RARE
. O

Both O
in O
vitro O
- O
synthesized O
S2 I-GENE
protein I-GENE
and O
synthetic O
peptides O
corresponding O
to O
S2 I-GENE
are O
shown O
to O
react RARE
positively O
with O
sera O
obtained O
from O
EIAV ALLCAPS
- O
infected O
horses O
, O
providing O
the O
first O
direct O
evidence O
of O
expression O
of O
this O
protein O
in O
infected O
animals O
. O

Many O
canonical O
TATA O
sequences O
are O
present O
upstream O
from O
these O
VZV O
transcriptional O
start O
sites O
but O
, O
apparently O
, O
are O
not O
used O
. O

The O
ORF O
4 O
gene O
was O
minimally RARE
active O
, O
whereas O
the O
ORF O
62 O
gene O
gave O
twofold O
induction O
; O
both O
genes O
, O
acting O
together O
, O
gave O
fivefold RARE
induction O
. O

Interestingly O
, O
the O
IR5 NUMERIC
ORF I-GENE
of O
EHV O
- O
1 O
possesses O
a O
sequence O
of O
13 O
amino O
acids O
( O
CAYWCCLGHAFAC ALLCAPS
) O
that O
is O
a O
perfect O
match O
to O
the O
consensus O
zinc O
finger O
motif O
( O
C O
- O
X2 O
- O
4 O
- O
C O
- O
X2 O
- O
15 O
- O
C O
/ O
H O
- O
X2 O
- O
4 O
- O
C O
/ O
H O
). O

The O
DNA O
sequence O
of O
the O
sulfate I-GENE
activation I-GENE
locus I-GENE
from O
Escherichia O
coli O
K O
- O
12 O
has O
been O
determined O
. O

The O
unphosphorylated RARE
form O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
is O
designated O
IIA O
, O
whereas O
the O
phosphorylated O
form O
is O
designated O
IIO ALLCAPS
. O

RNA I-GENE
polymerase I-GENE
IIA I-GENE
was O
recovered O
in O
transcriptionally O
active O
complexes O
in O
reactions O
in O
which O
the O
input O
enzyme O
was O
RNA I-GENE
polymerase I-GENE
IIA I-GENE
. O

Fructokinase RARE
activity O
is O
elevated O
up O
to O
twofold O
when O
Z O
. O
mobilis RARE
was O
grown O
on O
fructose O
instead O
of O
glucose O
, O
and O
there O
was O
a O
parallel O
increase O
in O
frk RARE
mRNA I-GENE
levels O
. O

Plasma O
membranes O
of O
cultured O
cells O
contain O
high O
affinity O
receptors O
for O
high I-GENE
density I-GENE
lipoprotein I-GENE
( O
HDL I-GENE
) O
that O
appear O
to O
mediate O
removal O
of O
excess O
intracellular O
cholesterol O
. O

After O
the O
first O
28 O
patients O
vincristine O
was O
replaced O
by O
teniposide RARE
( O
VM ALLCAPS
- O
26 O
) O
due O
to O
neurotoxicity O
. O

These O
results O
indicate O
that O
an O
internal O
short O
element O
located O
at O
the O
very O
5 O
' O
terminal O
of O
L1 I-GENE
sequence I-GENE
and O
the O
nuclear O
factor O
binding O
to O
the O
element O
play O
a O
crucial O
role O
in O
the O
transcription O
of O
human I-GENE
L1 I-GENE
. O

Tumor O
cells O
were O
focally RARE
immunoreactive O
for O
neuron I-GENE
- I-GENE
specific I-GENE
enolase RARE
, O
insulin I-GENE
, O
glucagon I-GENE
and O
VIP ALLCAPS
. O

A O
recombinant O
with O
a O
5 O
' O
end O
from O
src I-GENE
and O
a O
3 O
' O
end O
from O
ros RARE
, O
called O
SRC I-GENE
x O
ROS I-GENE
, O
transformed O
chicken O
embryo O
fibroblasts O
( O
CEF ALLCAPS
) O
to O
a O
spindle O
shape O
morphology O
, O
mimicking RARE
that O
of O
UR2 NUMERIC
. O

ROS I-GENE
x O
SRC I-GENE
( O
R I-GENE
) O
contains O
a O
16 O
- O
amino O
- O
acid O
deletion O
that O
includes O
the O
3 O
' O
half O
of O
the O
transmembrane O
domain O
of O
ros RARE
. O

To O
define O
the O
number O
and O
nature O
of O
the O
E6 I-GENE
and O
E7 I-GENE
gene I-GENE
products O
expressed O
in O
BPV O
- O
1 O
- O
transformed O
cells O
, O
we O
performed O
immunoprecipitation O
experiments O
with O
antisera O
raised O
to O
bacterially O
expressed O
BPV I-GENE
- I-GENE
1 I-GENE
E6 I-GENE
and O
E7 I-GENE
fusion I-GENE
proteins I-GENE
. O

Transient O
transfection O
assays O
showed O
that O
site O
A O
is O
necessary O
and O
sufficient O
for O
RXR I-GENE
alpha I-GENE
- O
mediated O
transactivation O
of O
the O
apoAI LASTCAP
gene I-GENE
basal I-GENE
promoter I-GENE
in O
human O
hepatoma O
HepG2 O
cells O
in O
the O
presence O
of O
RA O
and O
that O
this O
transactivation O
is O
abolished O
by O
increasing O
amounts O
of O
cotransfected O
ARP ALLCAPS
- I-GENE
1 I-GENE
. O

The O
enhancer O
region O
of O
Akv RARE
murine O
leukemia O
virus O
contains O
the O
sequence O
motif O
ACAGATGG ALLCAPS
. O

Two O
splice O
variants O
of O
ALF1 NUMERIC
cDNA I-GENE
have O
been O
found O
, O
differing RARE
by O
a O
72 O
- O
bp O
insertion O
, O
coding O
for O
putative O
proteins O
of O
682 NUMERIC
and O
706 NUMERIC
amino O
acids O
. O

A O
third O
prominent O
component O
of O
apparent O
molecular O
mass O
16 O
kDa O
displayed O
several O
properties O
, O
including O
ability O
to O
bind O
45Ca2 NUMERIC
+, O
that O
are O
characteristic O
of O
the O
regulatory O
( O
B O
) O
subunit O
of O
mammalian I-GENE
calcineurin RARE
and O
was O
recognized O
by O
an O
antiserum O
raised O
against O
bovine I-GENE
calcineurin RARE
. O

As O
was O
observed O
previously O
for O
MATa RARE
cna1 NUMERIC
cna2 NUMERIC
double O
mutants O
, O
MATa RARE
cnb1 NUMERIC
mutants I-GENE
were O
defective O
in O
their O
ability O
to O
recover RARE
from O
alpha I-GENE
- I-GENE
factor I-GENE
- O
induced O
growth O
arrest O
. O

Antibodies O
against O
this O
purified O
protein O
localize O
RIM1 NUMERIC
to O
mitochondria O
. O

METHODS O
: O
IgG I-GENE
antibodies I-GENE
vs O
HHV ALLCAPS
- O
6 O
( O
anti I-GENE
- I-GENE
HHV ALLCAPS
- I-GENE
6 I-GENE
- I-GENE
IgG I-GENE
) O
were O
determined O
by O
indirect O
immunofluorescence O
in O
100 O
IVDA ALLCAPS
( O
29 O
seronegative RARE
and O
71 O
seropositive O
for O
HIV O
- O
1 O
of O
which O
45 O
were O
in O
stage O
II O
and O
26 O
in O
IV O
- O
C1 O
of O
CDC ALLCAPS
) O
as O
well O
as O
in O
100 O
healthy O
subjects O
of O
a O
similar O
age O
( O
control O
group O
). O

A O
position O
- O
independent O
activation O
domain O
which O
contained O
conserved O
regions O
II O
and O
III O
was O
identified O
at O
the O
carboxyl O
terminus O
of O
the O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
protein I-GENE
( O
amino O
acids O
361 NUMERIC
to O
458 NUMERIC
). O

HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
amino I-GENE
- I-GENE
terminal I-GENE
sequences I-GENE
defined O
by O
conserved O
region O
IV O
also O
contributed O
to O
transactivation O
, O
but O
region O
IV O
activity O
required O
the O
participation O
of O
the O
region O
II O
- O
III O
domain O
. O

Possible RARE
roles O
of O
RAD5 NUMERIC
putative O
ATPase I-GENE
/ O
DNA I-GENE
helicase I-GENE
activity O
in O
DNA O
repair O
and O
in O
the O
maintenance O
of O
wild O
- O
type O
rates O
of O
instability RARE
of O
simple O
repetitive O
sequences O
are O
discussed O
. O

Susceptibilities RARE
of O
540 NUMERIC
anaerobic O
gram O
- O
negative O
bacilli O
to O
amoxicillin O
, O
amoxicillin O
- O
BRL ALLCAPS
42715 NUMERIC
, O
amoxicillin O
- O
clavulanate RARE
, O
temafloxacin RARE
, O
and O
clindamycin O
. O

Nocodazole RARE
arrest O
of O
DU249 NUMERIC
cells O
was O
exploited RARE
for O
the O
detection O
of O
an O
M O
- O
phase O
- O
activated O
MBP I-GENE
kinase I-GENE
that O
was O
resolved O
from O
p41 NUMERIC
MAP I-GENE
kinase I-GENE
by O
phenyl RARE
- O
Superose RARE
chromatography O
. O

The O
hit1 NUMERIC
- I-GENE
1 I-GENE
mutation O
caused O
a O
defect O
in O
synthesis O
of O
a O
74 I-GENE
- I-GENE
kD I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
. O

The O
319 NUMERIC
base O
pair O
region O
immediately O
upstream O
of O
the O
CAP O
site O
is O
characterized O
by O
the O
lack O
of O
a O
proximal O
TATA O
box O
and O
the O
presence O
of O
sequences O
similar O
to O
GC O
boxes O
, O
CACCC ALLCAPS
boxes O
, O
CCAAT O
boxes O
, O
activator I-GENE
protein I-GENE
2 I-GENE
( O
Ap RARE
- I-GENE
2 I-GENE
) O
sites O
, O
partial O
glucocorticoid O
response O
elements O
( O
GREs RARE
), O
and O
partial O
cyclic O
AMP O
response O
elements O
( O
CREs RARE
). O

Cloning O
and O
primary O
structure O
of O
neurocan RARE
, O
a O
developmentally O
regulated O
, O
aggregating RARE
chondroitin RARE
sulfate O
proteoglycan O
of O
brain O
. O

In O
rats O
anaesthetized RARE
with O
+- O
chloralose RARE
the O
changes O
in O
extracellular O
pH O
and O
K O
+ O
in O
spinal O
cord O
dorsal O
horn RARE
were O
studied O
using O
pH O
and O
K O
+ O
ion O
- O
selective O
electrodes O
. O

Replication RARE
of O
bovine O
papillomavirus O
- O
1 O
( O
BPV O
- O
1 O
) O
DNA O
requires O
two O
viral O
gene O
products O
, O
the O
E1 I-GENE
protein I-GENE
and O
the O
full I-GENE
- I-GENE
length I-GENE
E2 I-GENE
protein I-GENE
. O

Insertional RARE
inactivation O
of O
sms RARE
led O
to O
increased O
sensitivity O
to O
the O
alkylating RARE
agent O
methylmethane RARE
sulfonate RARE
, O
but O
not O
to O
a O
requirement O
for O
serine O
or O
other O
metabolites O
. O

These O
findings O
suggest O
that O
the O
MAP I-GENE
kinase I-GENE
activator I-GENE
/ O
MAP I-GENE
kinase I-GENE
system O
may O
be O
the O
downstream O
components O
of O
ras I-GENE
signal O
transduction O
pathways O
. O

NSCL ALLCAPS
- I-GENE
1 I-GENE
is O
expressed O
in O
a O
larger O
number O
of O
these O
cell O
lines O
. O

Labile RARE
LTR I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
appear O
to O
be O
essential O
for O
c I-GENE
- I-GENE
myc I-GENE
hyperexpression RARE
, O
since O
both O
LTR O
- O
enhanced O
transcription O
and O
the O
activities O
of O
LTR I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
are O
specifically O
decreased O
after O
inhibition O
of O
protein O
synthesis O
( O
A O
. O

Ruddell RARE
, O
M O
. O

A O
single O
MEF I-GENE
- I-GENE
2 I-GENE
site I-GENE
is O
a O
major O
positive O
regulatory O
element O
required O
for O
transcription O
of O
the O
muscle O
- O
specific O
subunit O
of O
the O
human I-GENE
phosphoglycerate RARE
mutase RARE
gene I-GENE
in O
skeletal O
and O
cardiac O
muscle O
cells O
. O

Truncation RARE
variants O
of O
peptides O
isolated O
from O
MHC I-GENE
class I-GENE
II I-GENE
molecules I-GENE
suggest O
sequence O
motifs O
. O

Although O
the O
E O
- O
box O
consensus O
is O
minimally RARE
defined O
as O
CANNTG ALLCAPS
, O
the O
adjacent O
nucleotides O
of O
functional O
E O
- O
boxes O
are O
variable O
for O
genes O
regulated O
by O
the O
bHLH I-GENE
proteins I-GENE
. O

Intermediate RARE
levels O
of O
gene O
activity O
were O
observed O
for O
TnI I-GENE
enhancers I-GENE
containing O
E O
- O
boxes O
derived O
from O
the O
MCK ALLCAPS
left I-GENE
E I-GENE
- I-GENE
box I-GENE
site I-GENE
or O
from O
the O
Ig I-GENE
kappa I-GENE
E2 I-GENE
E I-GENE
- I-GENE
box I-GENE
. O

T I-GENE
- I-GENE
cell I-GENE
receptor I-GENE
beta I-GENE
( O
TCR I-GENE
beta I-GENE
) O
gene O
rearrangements O
occur O
in O
a O
third O
of O
early O
B O
- O
cell O
acute O
lymphoblastic RARE
leukemias O
( O
ALLs RARE
). O

The O
CANNTG ALLCAPS
motifs O
were O
found O
to O
bind O
MyoD I-GENE
and O
myogenin I-GENE
fusion I-GENE
proteins I-GENE
and O
to O
interact O
with O
proteins O
in O
nuclear O
extracts O
from O
cultured O
myotubes O
. O

Peripheral RARE
polyneuropathy RARE
associated O
with O
multiple O
myeloma O
. O

We O
have O
cloned O
and O
sequenced O
COX12 NUMERIC
, O
the O
nuclear O
gene O
for O
subunit I-GENE
VIb RARE
of O
Saccharomyces I-GENE
cerevisiae I-GENE
cytochrome I-GENE
c I-GENE
oxidase I-GENE
. O

The O
structure O
of O
the O
calcineurin RARE
A I-GENE
gene I-GENE
was O
determined O
by O
comparison O
of O
the O
genomic O
and O
cDNA O
sequences O
. O

The O
basal O
promoter O
elements O
of O
murine I-GENE
cytochrome I-GENE
c I-GENE
oxidase I-GENE
subunit I-GENE
IV I-GENE
gene I-GENE
consist O
of O
tandemly O
duplicated O
ets I-GENE
motifs O
that O
bind O
to O
GABP I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factors I-GENE
. O

Lastly RARE
, O
there O
are O
multiple O
instances O
in O
which O
short O
oligonucleotide O
direct O
repeats O
flank O
a O
region O
absent O
from O
either O
variola RARE
or O
vaccinia O
virus O
. O

Here O
we O
show O
that O
short O
synthetic O
peptides O
containing O
the O
pRB LASTCAP
- I-GENE
binding I-GENE
sequences I-GENE
of O
E1A I-GENE
are O
sufficient O
for O
interaction O
with O
p107 I-GENE
, O
cyclin I-GENE
A I-GENE
, O
and O
p130 I-GENE
. O

These O
mutants O
grow O
normally O
in O
3T6 NUMERIC
mouse O
fibroblast O
cells O
, O
and O
they O
do O
not O
complement O
the O
wild O
- O
type O
virus O
in O
coinfection RARE
experiments O
of O
C2 O
myoblasts O
. O

The O
MICs O
of O
this O
compound O
against O
90 O
% O
of O
these O
organisms O
, O
except O
for O
methicillin RARE
- O
resistant O
S O
. O
aureus O
, O
ranged O
from O
less O
than O
or O
equal O
to O
0 O
. O
006 NUMERIC
to O
3 O
. O
13 O
micrograms O
/ O
ml O
. O

The O
minimal O
promoter O
of O
the O
RII I-GENE
beta I-GENE
gene I-GENE
was O
composed O
of O
two O
adjacent O
functional O
elements O
. O

Mapping O
the O
cAMP I-GENE
receptor I-GENE
protein I-GENE
contact I-GENE
site I-GENE
on O
the O
alpha O
subunit O
of O
Escherichia I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

Here O
we O
show O
that O
epidermal I-GENE
growth I-GENE
factor I-GENE
or O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
stimulation O
of O
intact O
human O
or O
murine O
cells O
leads O
to O
phosphorylation O
of O
Nck RARE
protein I-GENE
on O
tyrosine O
, O
serine O
, O
and O
threonine O
residues O
. O

A O
major O
mechanism O
whereby RARE
steroid I-GENE
hydroxylase I-GENE
gene I-GENE
transcription O
is O
regulated O
in O
the O
adrenal O
cortex O
requires O
the O
pituitary O
peptide O
hormone O
, O
ACTH I-GENE
, O
which O
acts O
via O
cAMP O
. O

A O
combination O
of O
comparative O
sequence O
analysis O
and O
thermodynamic RARE
methods O
reveals O
the O
conservation O
of O
tertiary O
structure O
elements O
in O
the O
5 O
' O
untranslated O
region O
( O
UTR O
) O
of O
human O
enteroviruses RARE
and O
rhinoviruses RARE
. O

The O
- O
64 O
/- O
37 O
region O
interacted O
with O
purified O
Sp1 I-GENE
and O
an O
unidentified O
protein O
( O
s O
), O
proximal I-GENE
regulatory I-GENE
factor I-GENE
( I-GENE
s I-GENE
) I-GENE
I I-GENE
( O
PRF ALLCAPS
- I-GENE
I I-GENE
). O

Km RARE
and O
Vmax O
for O
two O
substrates O
, O
src I-GENE
- I-GENE
related I-GENE
peptide I-GENE
and O
poly O
( O
Glu O
, O
Tyr O
) O
( O
4 O
: O
1 O
), O
were O
2 O
. O
4 O
mM O
and O
2 O
. O
5 O
mumol O
min O
- O
1 O
mg O
- O
1 O
and O
0 O
. O
26 O
mM O
and O
1 O
. O
2 O
mumol O
min O
- O
1 O
mg O
- O
1 O
, O
respectively O
. O

This O
soluble O
form O
of O
the O
HGFr RARE
( O
sHGFr RARE
) O
bound O
HGF I-GENE
with O
an O
affinity O
similar O
to O
that O
of O
the O
authentic RARE
, O
membrane O
- O
associated O
receptor O
. O

Strategies RARE
for O
blood O
screening O
for O
the O
hepatitis O
C O
virus O
and O
for O
the O
human O
immunodeficiency O
virus O
in O
high O
risk O
groups O
. O

Also O
, O
the O
human I-GENE
glycoprotein I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
promoter I-GENE
was O
induced O
10 O
- O
fold O
by O
FSK ALLCAPS
in O
GH4 NUMERIC
rat O
pituitary O
cells O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Comparison O
of O
data O
obtained O
with O
the O
results O
of O
chronic O
treatment O
with O
the O
opioid O
antagonist O
permits O
to O
conclude O
that O
the O
chronic O
blockade O
increases O
the O
fatiguability RARE
to O
a O
great O
extent O
than O
chronic O
activation O
of O
opioid O
system O
. O

Laboratory O
studies O
using O
Ca45 NUMERIC
labeled O
teeth O
and O
biologically O
stained O
teeth O
confirmed O
that O
the O
dentifrice RARE
did O
not O
decalcify RARE
enamel RARE
or O
bleach RARE
teeth O
. O

Structure O
and O
expression O
of O
a O
gene O
from O
Arabidopsis O
thaliana O
encoding O
a O
protein O
related O
to O
SNF1 NUMERIC
protein O
kinase O
. O

We O
have O
cloned O
and O
characterized O
a O
55 O
- O
kb O
region O
of O
DNA O
surrounding O
HRAS1 NUMERIC
. O

The O
ORF1 O
protein O
was O
found O
to O
be O
highly O
homologous O
to O
the O
putative O
potexvirus RARE
RNA I-GENE
replicases RARE
; O
ORF2 O
, O
- O
3 O
, O
- O
5 O
and O
- O
6 O
proteins O
also O
have O
analogues O
among O
the O
potex RARE
- O
and O
/ O
or O
carlavirus RARE
- O
encoded O
proteins O
. O

A O
total O
of O
281 NUMERIC
patients O
were O
divided O
into O
groups O
according O
to O
their O
clinical O
diagnosis O
and O
were O
examined O
using O
capnography RARE
, O
spirometry RARE
and O
blood O
- O
gas O
analysis O
. O

The O
relationships O
between O
the O
partial O
pressures O
of O
O2 O
and O
CO2 O
as O
well O
as O
between O
their O
gradients RARE
, O
become O
stronger O
with O
the O
increase O
of O
the O
ventilation O
- O
perfusion O
ratio O
. O

No O
significant O
correlations O
of O
peak O
VO2 O
were O
observed O
between O
the O
3 O
tests O
. O

An O
RNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
( O
rbp1 NUMERIC
) O
from O
Drosophila O
melanogaster O
, O
encoding O
an O
RNA O
recognition O
motif O
and O
an O
Arg O
- O
Ser O
rich O
( O
RS O
) O
domain O
, O
has O
been O
characterized O
. O

Some O
research O
studies O
have O
related O
this O
kind RARE
of O
tumors O
with O
prolonged O
ingestion O
of O
H2 O
inhibitors O
and O
others O
antacid RARE
. O

A O
comparative O
study O
of O
the O
total O
protein O
profiles O
of O
wild O
- O
type O
S O
. O
entomophila RARE
UC9 NUMERIC
and O
mutant O
UC21 NUMERIC
revealed O
that O
the O
mutant O
lacked O
an O
approximately O
44 O
- O
kDa O
protein O
and O
overexpressed O
an O
approximately O
20 O
- O
kDa O
protein O
. O

Characterization O
of O
the O
regulon RARE
controlled O
by O
the O
leucine I-GENE
- I-GENE
responsive I-GENE
regulatory I-GENE
protein I-GENE
in O
Escherichia O
coli O
. O

Mapping O
of O
the O
mouse I-GENE
ornithine RARE
decarboxylase I-GENE
- I-GENE
related I-GENE
sequence I-GENE
family I-GENE
. O

This O
mutation O
also O
results O
in O
markedly O
decreased O
levels O
of O
CAD I-GENE
mRNA I-GENE
and O
protein O
in O
the O
mutant O
. O

The O
rationale RARE
for O
continuous O
dopaminergic O
stimulation O
in O
patients O
with O
Parkinson O
' O
s O
disease O
. O

Mutational O
studies O
revealed O
that O
it O
was O
the O
homeodomain I-GENE
binding I-GENE
site I-GENE
II I-GENE
sequence I-GENE
that O
was O
required O
for O
this O
regulation O
. O

Thus O
, O
the O
pol I-GENE
alpha I-GENE
- O
primase I-GENE
complex O
appears O
to O
act O
processively RARE
for O
only O
a O
short O
distance O
. O

Interestingly O
, O
the O
positions O
of O
these O
introns O
have O
been O
conserved O
in O
comparison O
with O
the O
genes O
of O
two O
other O
transglutaminase RARE
- O
like O
activities O
described O
in O
the O
literature O
, O
but O
the O
TGM1 NUMERIC
gene I-GENE
is O
by O
far O
the O
smallest O
characterized O
to O
date O
because O
its O
introns O
are O
relatively O
smaller O
. O

In O
a O
retrospective O
analysis O
of O
data O
from O
35 O
cases O
with O
malignant O
lymphoma O
from O
a O
cohort O
of O
2017 NUMERIC
HIV O
- O
infected O
patients O
, O
the O
stage O
of O
HIV O
- O
disease O
, O
the O
CD4 I-GENE
counts O
at O
the O
time O
of O
diagnosis O
, O
and O
the O
use O
of O
antineoplastic RARE
agents O
or O
radiotherapy O
were O
correlated O
with O
outcome O
. O

1 O
. O

Effects O
of O
dioxins RARE
on O
thyroid O
function O
in O
newborn O
babies O
. O

cDNA O
clones O
encoding O
Arabidopsis O
thaliana O
and O
Zea RARE
mays RARE
mitochondrial I-GENE
chaperonin RARE
HSP60 NUMERIC
and O
gene O
expression O
during O
seed O
germination RARE
and O
heat O
shock O
. O

Amino O
acid O
sequence O
comparison O
revealed O
significant O
homology O
between O
the O
yeast I-GENE
and I-GENE
Escherichia I-GENE
coli I-GENE
gamma I-GENE
- I-GENE
glutamyl I-GENE
kinases I-GENE
throughout O
their O
lengths O
. O

The O
single O
site O
of O
glycosylation O
is O
located O
near O
the O
C O
- O
terminus O
in O
the O
N O
- O
glycosylation O
sequon RARE
- O
Asn O
- O
Cys O
- O
Ser O
- O
in O
which O
Cys O
forms O
part O
of O
a O
disulphide RARE
bridge RARE
. O

The O
pulmonary O
toxic O
events O
induced O
by O
acute O
nitrogen O
dioxide O
( O
NO O
) O
2 O
exposure O
were O
studied O
in O
the O
rat O
to O
develop O
an O
inhalation O
model O
to O
investigate O
therapeutic O
measures O
. O

The O
pulmonary O
effects O
observed O
, O
became O
more O
pronounced O
with O
increasing O
NO2 O
concentrations O
( O
0 O
, O
25 O
, O
75 O
, O
125 O
, O
175 O
or O
200 O
ppm O
, O
1 O
ppm O
NO2 O
= O
1 O
. O
88 O
mg O
m O
- O
3 O
NO2 O
) O
and O
exposure O
times O
( O
5 O
, O
10 O
, O
20 O
or O
30 O
min O
). O

Interaction O
of O
H I-GENE
- I-GENE
2Eb NUMERIC
with O
an O
IAP ALLCAPS
retrotransposon I-GENE
in O
the O
A20 NUMERIC
/ O
2J NUMERIC
B O
cell O
lymphoma O
. O

Gestational RARE
trophoblastic RARE
diseases O
: O
recent O
advances RARE
in O
the O
understanding O
of O
cytogenetics RARE
, O
histopathology RARE
, O
and O
natural O
history O
. O

With O
the O
exception O
of O
mutants O
that O
remove RARE
the O
membrane O
anchor O
domain O
, O
all O
of O
the O
mutant O
glycoproteins O
retained O
the O
ability O
to O
cause O
fusion O
of O
CD4 I-GENE
- O
bearing O
cells O
. O

The O
subunit O
protein O
of O
curli RARE
was O
highly O
homologous O
at O
its O
amino O
terminus O
to O
SEF ALLCAPS
- I-GENE
17 I-GENE
, O
the O
subunit O
protein O
of O
thin O
, O
aggregative RARE
fimbriae RARE
of O
Salmonella O
enteritidis RARE
27655 NUMERIC
strain O
3b NUMERIC
, O
suggesting O
that O
these O
fibres O
form O
a O
novel O
class O
of O
surface O
organelles RARE
on O
enterobacteria RARE
. O

Substitution O
of O
the O
DR1 I-GENE
beta I-GENE
chain I-GENE
with O
H I-GENE
- I-GENE
2E NUMERIC
beta I-GENE
k RARE
led O
to O
a O
dramatic O
loss O
of O
recognition O
; O
alpha O
chain O
substitution O
had O
a O
less O
marked O
effect O
. O

This O
negative O
regulatory O
pathway O
may O
be O
important O
for O
determining O
cell O
fate O
or O
maintaining O
an O
inducible O
state O
in O
the O
ventroposterior RARE
region O
of O
the O
embryo O
. O

The O
distal O
portion O
of O
the O
rat I-GENE
insulin I-GENE
I I-GENE
gene I-GENE
5 I-GENE
'- I-GENE
flanking I-GENE
DNA I-GENE
contains O
two O
sequence O
elements O
, O
the O
Far RARE
and O
FLAT ALLCAPS
elements O
, O
that O
can O
function O
in O
combination O
, O
but O
not O
separately O
, O
as O
a O
beta O
- O
cell O
- O
specific O
transcriptional O
enhancer O
. O

The O
deduced O
amino O
acid O
sequence O
exhibited O
98 O
% O
identity O
to O
the O
human O
cellular O
transglutaminase RARE
sequence O
. O

This O
computation RARE
is O
performed O
by O
a O
parallel O
network O
of O
locally O
connected O
neuron O
- O
like O
elements O
. O

Repeated RARE
efforts RARE
to O
isolate O
recombinant O
baculoviruses RARE
containing O
a O
wild O
- O
type O
kinase O
failed O
, O
whereas O
recombinants O
expressing O
a O
nonfunctional RARE
kinase O
with O
a O
catalytic O
domain O
II O
mutation O
were O
readily O
isolated O
. O

Finally O
, O
we O
determined O
that O
the O
P68 NUMERIC
amino O
terminus O
was O
both O
necessary O
and O
sufficient O
for O
binding O
dsRNA O
as O
we O
were O
able O
to O
transfer O
dsRNA O
- O
binding O
properties O
to O
a O
reporter O
gene O
product O
previously O
unable O
to O
bind O
RNA O
. O

From O
August O
1989 O
to O
October RARE
1990 O
, O
83 O
pregnant O
Chinese O
women O
were O
the O
subjects O
for O
measuring O
the O
levels O
of O
plasma O
functional O
antithrombin I-GENE
III I-GENE
( O
AT I-GENE
III I-GENE
) O
activity O
. O

Visual RARE
acuity RARE
may O
be O
decreased O
by O
transient O
changes O
in O
refractive RARE
error O
caused O
by O
sulfonamides RARE
, O
the O
antifungal RARE
agent O
metronidazole RARE
, O
thiazide RARE
diuretics RARE
, O
and O
carbonic RARE
anhydrase I-GENE
inhibitors O
. O

Currents RARE
aspects O
of O
H2 I-GENE
receptor I-GENE
antagonists O
in O
the O
treatment O
of O
ulcers O

In O
addition O
, O
a O
21 O
- O
mer O
subrepeat RARE
structure O
is O
also O
present O
in O
each O
unit O
. O

Sequencing O
revealed O
one O
large O
open O
reading O
frame O
encoding O
a O
39 O
- O
kDa O
protein O
. O

These O
sites O
are O
also O
potential O
keratan RARE
sulfate O
attachment O
sites O
. O

We O
propose O
that O
plasmids O
of O
the O
pLS1 NUMERIC
family O
( O
pE194 NUMERIC
, O
pADB201 NUMERIC
, O
and O
pLB4 NUMERIC
) O
share O
functional O
and O
structural O
characteristics O
for O
the O
regulation O
of O
their O
copy O
numbers O
. O

Perturbation RARE
of O
dNTP LASTCAP
pools RARE
also O
affected O
the O
frameshift O
fidelity O
of O
the O
replicative O
yeast I-GENE
DNA I-GENE
polymerase I-GENE
alpha I-GENE
. O

Differential O
expression O
of O
the O
" O
B O
" O
subunit O
of O
the O
vacuolar I-GENE
H I-GENE
(+)- I-GENE
ATPase I-GENE
in O
bovine O
tissues O
. O

In O
addition O
, O
the O
hGCSFR LASTCAP
gene I-GENE
was O
chromosomally RARE
localized O
by O
Southern O
blot O
analysis O
of O
its O
segregation O
pattern O
in O
a O
panel O
of O
rodent O
- O
human O
hybrid O
DNAs O
using O
the O
radiolabeled O
cDNA O
probe O
. O

We O
have O
isolated O
and O
characterised RARE
a O
differentially O
- O
regulated O
gene O
family O
in O
the O
protozoan RARE
parasite O
Leishmania O
major O
. O

At O
some O
sites O
, O
% O
T O
is O
greatly O
increased O
by O
Cl O
- O
concentrations O
up O
to O
1 O
M O
, O
while O
at O
other O
sites O
% O
T O
is O
reduced O
or O
unaffected O
by O
these O
conditions O
. O

Necrosis RARE
appears O
6 O
h O
after O
TA O
infusion O
, O
being O
5 O
. O
77 O
% O
in O
extent O
after O
12 O
h O
, O
14 O
. O
9 O
% O
after O
24 O
h O
and O
animals O
die RARE
with O
an O
area O
of O
29 O
. O
5 O
% O
necrosis O
. O

In O
summary O
, O
the O
segments O
of O
C3 I-GENE
represented O
by O
amino O
acid O
residues O
1082 NUMERIC
- O
1118 NUMERIC
, O
1117 NUMERIC
- O
1155 NUMERIC
, O
1234 NUMERIC
- O
1294 NUMERIC
and O
1312 NUMERIC
- O
1404 NUMERIC
accommodate RARE
C3 I-GENE
( I-GENE
D I-GENE
) I-GENE
epitopes I-GENE
that O
are O
expressed O
by O
erythrocyte O
- O
bound O
C3 I-GENE
fragments I-GENE
, O
but O
not O
by O
the O
corresponding O
fluid O
- O
phase O
fragment O
, O
whereas O
the O
segments O
spanning O
residues O
973 NUMERIC
- O
1026 NUMERIC
and O
1477 NUMERIC
- O
1510 NUMERIC
contain O
C3 I-GENE
( I-GENE
D I-GENE
) I-GENE
epitopes I-GENE
that O
are O
exposed O
exclusively O
in O
denatured RARE
C3 I-GENE
and O
therefore O
hidden RARE
in O
physiological O
fragments O
of O
the O
protein O
. O

These O
exons O
, O
further O
identified O
as O
exons O
9 O
, O
10 O
, O
and O
11 O
, O
together O
encode O
the O
37 O
amino O
acid O
residues O
present O
in O
alpha I-GENE
s1 NUMERIC
- I-GENE
casein I-GENE
variant I-GENE
A I-GENE
but O
missing O
in O
variant O
F O
. O

We O
also O
report O
here O
the O
complete O
structural O
organization O
of O
the O
goat RARE
alpha I-GENE
s1 NUMERIC
- I-GENE
casein I-GENE
transcription I-GENE
unit I-GENE
, O
deduced O
from O
polymerase O
chain O
reaction O
experiments O
. O

Homodimers RARE
of O
the O
three O
proteins O
specifically O
recognize O
the O
G O
- O
box O
motif O
, O
with O
GBF1 NUMERIC
and O
GBF3 NUMERIC
binding O
symmetrically RARE
to O
this O
palindromic O
sequence O
. O

Neither O
gene O
possesses O
a O
distinct O
transcriptional O
start O
site O
as O
shown O
by O
nuclease I-GENE
S1 I-GENE
analysis O
. O

The O
hydrophobicity RARE
plot RARE
of O
NHE ALLCAPS
- I-GENE
3 I-GENE
is O
very O
similar O
to O
that O
of O
NHE ALLCAPS
- I-GENE
1 I-GENE
and O
NHE ALLCAPS
- I-GENE
2 I-GENE
. O

The O
initial O
translation O
protein O
encoded O
by O
the O
cDNA O
is O
53 O
, O
932 NUMERIC
kDa O
and O
possesses O
a O
hydrophilic O
amino O
acid O
composition O
with O
glutamic RARE
acid O
comprising RARE
22 O
% O
of O
the O
total O
amino O
acid O
residues O
. O

Each O
group O
received O
15 O
ml O
/ O
kg O
of O
either O
6 O
% O
pentafraction RARE
, O
6 O
% O
pentastarch RARE
, O
or O
plasma O
followed O
two O
hours O
later O
by O
1 O
. O
5 O
micrograms O
/ O
kg O
/ O
0 O
. O
5 O
hr O
E O
. O

Genetic O
and O
biochemical O
evidence O
suggests O
that O
v I-GENE
- I-GENE
Crk I-GENE
can O
induce O
transformation O
of O
chicken O
embryo O
fibroblasts O
by O
influencing O
the O
activity O
of O
cellular O
proteins O
involved O
in O
growth O
regulation O
. O

We O
have O
constructed O
, O
using O
synthetic O
DNA O
oligonucleotides O
, O
a O
U14 I-GENE
snRNA I-GENE
gene I-GENE
which O
has O
been O
positioned O
behind O
a O
T7 I-GENE
RNA I-GENE
polymerase I-GENE
promoter I-GENE
site I-GENE
and O
then O
inserted O
into O
a O
plasmid O
. O

Gene O
and O
pseudogene O
of O
the O
mouse O
cation RARE
- O
dependent O
mannose RARE
6 I-GENE
- I-GENE
phosphate I-GENE
receptor I-GENE
. O

The O
chick O
axon RARE
- O
associated O
surface O
glycoprotein O
neurofascin RARE
is O
implicated O
in O
axonal RARE
growth O
and O
fasciculation RARE
as O
revealed O
by O
antibody O
perturbation RARE
experiments O
. O

The O
carcinoma O
was O
restricted O
within O
the O
epithelium O
in O
one O
, O
the O
mucosal O
layer O
in O
five O
, O
and O
the O
submucosal RARE
layer O
in O
two O
. O

In O
addition O
, O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
gamma I-GENE
readily O
heterodimerize RARE
with O
each O
other O
as O
well O
as O
with O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
. O

In O
contrast O
, O
tobacco I-GENE
GS I-GENE
- I-GENE
2 I-GENE
is O
composed O
of O
subunits O
of O
identical O
size O
in O
all O
organs O
examined O
. O

Between RARE
acoR LASTCAP
and O
acoXABC LASTCAP
, O
two O
different O
types O
of O
sequences O
with O
dual O
rotational RARE
symmetry RARE
[ O
CAC ALLCAPS
-( O
N11 NUMERIC
to O
N18 NUMERIC
)- O
GTG ALLCAPS
and O
TGT ALLCAPS
-( O
N10 NUMERIC
to O
N14 NUMERIC
)- O
ACA O
] O
were O
found O
; O
these O
sequences O
are O
similar O
to O
NtrC LASTCAP
and O
NifA LASTCAP
upstream I-GENE
activator I-GENE
sequences I-GENE
, O
respectively O
. O

Although O
the O
effects O
of O
the O
calcium O
supplement RARE
or O
calcium O
antagonist O
alone O
were O
significant O
, O
such O
hypotensive O
responses O
were O
not O
optimal O
or O
predictable RARE
or O
clearly O
dose O
- O
dependent O
. O

C O
., O
Sun RARE
, O
J O
., O
Hsu RARE
, O
M O
.- RARE
Y O
., O
Vallejo RARE
- O
Ramirez RARE
, O
J O
., O
Inouye RARE
, O
S O
., O
and O
Inouye RARE
, O
M O
. O

Surprisingly O
, O
the O
full O
- O
deletion O
mutant O
showed O
a O
strong O
block O
in O
virus O
release O
, O
suggesting O
that O
NC ALLCAPS
is O
involved O
in O
virus O
assembly O
. O

Furthermore O
it O
was O
suggested O
that O
FK506 O
plasma O
levels O
were O
concerned RARE
with O
the O
appearance O
of O
side O
effect O
. O

Thirty O
percent O
of O
patients O
were O
tapered RARE
off O
all O
steroids O
, O
and O
the O
average O
steroid O
dose O
in O
the O
group O
who O
received O
steroids O
was O
8 O
. O
6 O
mg O
of O
prednisone O
per O
day O
. O

Thus O
, O
cibenzoline RARE
is O
an O
effective O
antiarrhythmic O
agent O
with O
a O
favourable O
pharmacokinetic O
profile O
that O
may O
be O
considered O
with O
other O
class O
I O
drugs O
in O
patients O
requiring O
therapy O
for O
high O
risk O
arrhythmias O
. O

T I-GENE
antigen I-GENE
contains O
four O
H O
- O
2Db NUMERIC
- O
restricted O
cytotoxic O
T O
lymphocyte O
( O
CTL O
) O
recognition O
epitopes O
that O
are O
targets O
for O
CTL O
clones O
Y O
- O
1 O
, O
Y O
- O
2 O
, O
Y O
- O
3 O
, O
and O
Y O
- O
5 O
. O

The O
method O
requires O
a O
reversed O
- O
phase O
column O
and O
a O
paired O
- O
ion O
technique O
to O
separate O
docusate RARE
sodium O
from O
other O
components O
. O

Here O
we O
demonstrate O
that O
the O
protein O
product O
of O
the O
ref RARE
- I-GENE
1 I-GENE
gene I-GENE
stimulates O
the O
DNA O
binding O
activity O
of O
Fos I-GENE
- O
Jun I-GENE
heterodimers O
, O
Jun I-GENE
- O
Jun I-GENE
homodimers O
and O
Hela RARE
cell O
AP I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
as O
well O
as O
that O
of O
several O
other O
transcription O
factors O
including O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
, O
Myb I-GENE
and O
members O
of O
the O
ATF I-GENE
/ O
CREB I-GENE
family O
. O

The O
pulpal RARE
tissues O
of O
the O
permanent O
mandibular O
molars RARE
were O
amputated RARE
and O
then O
dressed RARE
with O
calcium O
hydrate RARE
. O

Northern O
blot O
analyses O
demonstrate O
that O
3 O
. O
9 O
- O
and O
5 O
- O
kilobase O
mRNAs O
corresponding O
to O
the O
cDNA O
were O
present O
in O
all O
tissues O
examined O
, O
suggesting O
that O
the O
protein O
it O
encodes O
performs RARE
a O
housekeeping O
function O
. O

The O
ARG ALLCAPS
SH2 I-GENE
domain I-GENE
exhibited O
relatively O
weak O
affinity O
for O
BCR I-GENE
and O
was O
determined O
to O
bind O
about O
10 O
- O
fold O
less O
strongly O
than O
the O
ABL I-GENE
SH2 I-GENE
domain I-GENE
. O

We O
analyzed O
an O
EBV O
B O
- O
cell O
clone O
, O
E29 NUMERIC
. O
1 O
, O
derived O
from O
an O
11 O
week O
- O
old O
embryo O
, O
and O
secreting O
both O
IgM I-GENE
kappa I-GENE
and O
IgM I-GENE
lambda I-GENE
. O

Interestingly O
, O
this O
activation O
occurred O
only O
when O
the O
regions O
were O
cloned O
in O
the O
same O
relative O
orientation O
in O
which O
they O
exist O
on O
wild O
- O
type O
pCF10 NUMERIC
. O

In O
rats O
, O
we O
examined O
the O
effect O
of O
an O
omentum RARE
wrapping RARE
on O
the O
vascularization RARE
of O
the O
trachea RARE
and O
on O
regeneration O
of O
the O
mucosal O
epithelium O
in O
the O
very O
early O
stage O
after O
free O
tracheal O
grafting RARE
. O

To O
study O
a O
possible O
functional O
role O
of O
this O
putative O
chicken O
ICS ALLCAPS
, O
an O
oligonucleotide O
spanning O
the O
upstream O
sequences O
of O
the O
BF I-GENE
- I-GENE
IV I-GENE
gene I-GENE
(- O
174 NUMERIC
/- O
194 NUMERIC
) O
was O
cloned O
singly RARE
or O
in O
multiple O
copies O
before O
the O
herpes O
TK I-GENE
promoter I-GENE
controlling O
the O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
) O
gene O
( O
pBLCAT2 NUMERIC
). O

In O
general O
, O
two O
separate O
high O
- O
performance O
liquid O
chromatographic O
runs RARE
were O
performed O
, O
one O
for O
the O
gamma O
- O
aminobutyric RARE
acid O
determination O
and O
one O
for O
the O
determination O
of O
the O
monoamines RARE
. O

We O
report O
the O
successful O
use O
of O
electroconvulsive RARE
therapy O
for O
treatment O
of O
severe O
depression O
in O
a O
young O
man O
with O
adult O
GM2 NUMERIC
gangliosidosis RARE
. O

Entry RARE
of O
yeast O
cells O
into O
the O
mitotic O
cell O
cycle O
( O
Start RARE
) O
involves O
a O
form O
of O
the O
CDC28 NUMERIC
kinase I-GENE
that O
associates O
with O
G1 O
- O
specific O
cyclins RARE
encoded O
by O
CLN1 NUMERIC
and O
CLN2 NUMERIC
( O
ref RARE
. O

Through RARE
Southern O
blot O
analyses O
of O
DNA O
from O
backcross O
and O
cogenic RARE
mice O
, O
recombinant O
inbred RARE
strains O
, O
and O
somatic O
cell O
hybrids O
, O
the O
genetic O
loci O
that O
produce O
the O
cyclin I-GENE
B1 I-GENE
- I-GENE
related I-GENE
sequences I-GENE
( O
designated O
loci I-GENE
Cycb1 NUMERIC
- I-GENE
rs1 NUMERIC
to O
Cycb1 NUMERIC
- I-GENE
rs9 NUMERIC
) O
were O
mapped O
on O
mouse O
chromosomes O
5 O
, O
1 O
, O
17 O
, O
4 O
, O
14 O
, O
13 O
, O
7 O
, O
X O
, O
and O
8 O
, O
respectively O
. O

Again RARE
residue O
Glu O
- O
381 NUMERIC
of O
beta O
was O
notably RARE
reduced O
and O
no O
missing O
residue O
from O
the O
epsilon O
peptide O
could O
be O
identified O
, O
but O
the O
peptide O
sequence O
limited O
the O
possible O
choices RARE
to O
Ser O
- O
106 NUMERIC
, O
Ser O
- O
107 NUMERIC
, O
or O
Ser O
- O
108 NUMERIC
. O

Porcelain RARE
to O
dentin O
bond O
strength O
with O
a O
dentin O
adhesive O
. O

TBPf RARE
is O
defined O
as O
a O
quotient RARE
of O
the O
difference O
of O
the O
first O
and O
the O
second O
measurement O
: O
TBPf RARE
= O
( O
P1 O
- O
P2 O
)/( RARE
A1 O
- O
A2 O
). O

It O
was O
concluded O
that O
Scotchbond RARE
2 O
and O
Prisma RARE
Universal RARE
Bond RARE
2 O
are O
effective O
and O
are O
the O
dentine RARE
bonding RARE
agents O
of O
choice O
. O

From O
all O
clinically O
important O
yeasts RARE
species O
, O
a O
total O
of O
96 O
% O
were O
identified O
by O
ATB ALLCAPS
method O
according O
to O
conventional O
methods O
. O

The O
neurohypophysial RARE
vasopressin I-GENE
and O
oxytocin RARE
content O
was O
bioassayed RARE
by O
pressor O
effect O
following O
Dekanski RARE
or O
milk O
- O
ejection O
activity O
in O
vitro O
following O
van RARE
Dongen RARE
and O
Hays RARE
, O
respectively O
. O

Comments RARE
are O
given O
on O
the O
present O
status O
of O
regulations RARE
concerning O
water O
in O
swimming O
pools RARE
and O
baths RARE
-- O
1991 O
--( RARE
in O
connection RARE
with O
the O
KOK ALLCAPS
regulations RARE
-- O
1972 O
-- O
and O
the O
Federal RARE
German RARE
standard O
[ O
DIN ALLCAPS
] O
No O
. O

If O
no O
reply RARE
was O
received O
, O
telephone RARE
contact O
or O
home O
visits RARE
were O
made O
. O

The O
treatment O
group O
also O
showed O
in O
vivo O
T O
- O
cell O
activation O
with O
an O
initial O
lymphopenia RARE
followed O
by O
a O
rebound RARE
lymphocytosis RARE
and O
upregulation RARE
of O
the O
subset O
markers O
CD25 NUMERIC
( O
interleukin I-GENE
2 I-GENE
receptor I-GENE
) O
and O
CD45RO NUMERIC
( O
T O
- O
memory O
cells O
). O

Urease RARE
activity O
, O
judged O
as O
the O
amount O
of O
ammonia O
production O
from O
urea O
, O
could O
be O
measured O
at O
25 O
ng O
per O
tube O
( O
S O
/ O
N O
= O
1 O
. O
5 O
) O
with O
Jack RARE
bean I-GENE
meal I-GENE
urease I-GENE
. O

Consequently RARE
, O
significant O
differences O
between O
the O
measured O
and O
calculated O
methods O
were O
noted O
in O
oxygen O
uptake O
( O
213 NUMERIC
+/- O
41 O
ml O
/ O
min O
vs O
193 O
+/- O
25 O
ml O
/ O
min O
, O
p O
< O
0 O
. O
001 O
), O
oxygen O
delivery O
( O
780 NUMERIC
+/- O
297 NUMERIC
ml O
/ O
min O
vs O
716 NUMERIC
+/- O
296 O
ml O
/ O
min O
, O
p O
< O
0 O
. O
001 O
), O
and O
cardiac O
output O
( O
5 O
. O
8 O
+/- O
2 O
. O
2 O
L O
/ O
min O
vs O
5 O
. O
3 O
+/- O
1 O
. O
8 O
L O
/ O
min O
, O
p O
< O
0 O
. O
001 O
). O

Although O
a O
wide O
range O
of O
cognitive O
functions O
had O
been O
tested O
, O
all O
but O
one O
seizure O
occurred O
during O
assessment O
of O
memory O
performance O
. O

The O
experiments O
show O
that O
it O
is O
the O
micromilieu RARE
of O
the O
alveoli RARE
and O
the O
condition O
of O
the O
AM O
( O
certain O
physiological O
activation O
states O
, O
such O
as O
phagocytic O
activity O
) O
that O
essentially O
determine O
the O
degree O
of O
recovery O
. O

Negatively RARE
supercoiled RARE
plasmid O
pUC19 NUMERIC
did O
not O
compete O
, O
whereas O
an O
otherwise O
identical O
plasmid O
pUC19 NUMERIC
( O
CG O
), O
which O
contained O
a O
( O
dG LASTCAP
- O
dC LASTCAP
) O
7 O
segment O
in O
the O
Z O
- O
form O
was O
an O
excellent O
competitor O
. O

A O
cDNA O
library O
of O
tumour O
cells O
was O
screened O
with O
an O
interleukin I-GENE
2 I-GENE
gene O
- O
specific O
probe O
. O

Our O
experiments O
suggest O
that O
the O
SCL ALLCAPS
gene I-GENE
can O
be O
a O
target O
for O
the O
erythroid I-GENE
transcription I-GENE
factor I-GENE
GATA I-GENE
- I-GENE
1 I-GENE
and O
that O
the O
SCL ALLCAPS
gene I-GENE
product I-GENE
serves O
as O
a O
positive O
regulator O
of O
erythroid O
differentiation O
. O

In O
contrast O
, O
the O
lumenal RARE
domains O
of O
Sec12p NUMERIC
, O
Stl1p NUMERIC
and O
Stl2p NUMERIC
are O
very O
different O
in O
size O
and O
do O
not O
show O
any O
appreciable RARE
homology O
. O

Complexes RARE
containing O
wild O
- O
type O
and O
either O
his175 NUMERIC
or I-GENE
his273 NUMERIC
mutant I-GENE
p53 I-GENE
proteins I-GENE
are O
completely O
unable O
to O
bind O
to O
the O
RGC ALLCAPS
DNA I-GENE
sequence I-GENE
. O

These O
temperature O
- O
and O
cold O
- O
sensitive O
strains O
were O
used O
to O
prepare RARE
extracts O
deficient O
in O
BRF1 NUMERIC
activity O
and O
were O
tested O
for O
transcriptional O
activity O
by O
RNA I-GENE
polymerases I-GENE
I I-GENE
, I-GENE
II I-GENE
, I-GENE
and I-GENE
III I-GENE
in O
vitro O
. O

These O
results O
lead O
us O
to O
hypothesize RARE
that O
a O
single O
multisubunit I-GENE
TFIID I-GENE
protein I-GENE
supports O
transcriptional O
stimulation O
by O
diverse O
activation O
domains O
and O
from O
a O
TATA O
- O
less O
promoter O
. O

The O
gene O
sequence O
also O
identified O
a O
340 NUMERIC
- O
nucleotide O
RNA O
in O
total O
yeast O
RNA O
and O
in O
purified O
RNase I-GENE
MRP I-GENE
enzyme I-GENE
preparations O
. O

The O
RNase I-GENE
MRP I-GENE
RNA I-GENE
gene I-GENE
was O
deleted O
by O
insertional O
replacement O
and O
found O
to O
be O
essential O
for O
cellular O
viability O
, O
indicating O
a O
critical O
nuclear O
role O
for O
RNase I-GENE
MRP I-GENE
. O

Clone RARE
pSRc200 NUMERIC
hybrid O
selected O
an O
mRNA O
that O
on O
cell O
- O
free O
translation O
produced O
a O
38 O
- O
kDa O
polypeptide O
. O

From O
these O
results O
, O
CBF I-GENE
- I-GENE
A I-GENE
is O
a O
novel O
CArG O
box O
-, O
ssDNA I-GENE
- I-GENE
and I-GENE
RNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
as O
well O
as O
a O
repressive O
transcriptional O
factor O
. O

Cleavage RARE
by O
the O
intron O
- O
encoded O
enzyme O
( O
I I-GENE
- I-GENE
CreI LASTCAP
) O
occurs O
5 O
bp O
and O
1 O
bp O
3 O
' O
to O
the O
intron O
insertion O
site O
( O
in O
the O
3 O
'- O
exon O
) O
in O
the O
top O
(/) RARE
and O
bottom RARE
(,) RARE
strands RARE
, O
respectively O
, O
resulting O
in O
4 O
- O
nt O
single O
- O
stranded O
overhangs RARE
with O
3 O
'- O
OH O
termini O
. O

Surprisingly O
, O
the O
Xenopus I-GENE
U7 NUMERIC
gene I-GENE
contains O
two O
adjacent O
octamer O
- O
binding O
motifs O
located O
only O
12 O
and O
24 O
bp O
upstream O
from O
the O
PSE ALLCAPS
, O
instead O
of O
the O
usual RARE
location O
around O
150 O
- O
200 O
bp O
upstream O
. O

The O
results O
support O
earlier O
reports O
that O
collagenase RARE
inhibitors O
are O
useful O
in O
controlling O
blister RARE
formation O
in O
recessive O
dystrophic RARE
epidermolysis RARE
bullosa RARE
. O

Mutational O
analysis O
of O
essential O
IncP LASTCAP
alpha O
plasmid O
transfer O
genes O
traF LASTCAP
and O
traG LASTCAP
and O
involvement O
of O
traF LASTCAP
in O
phage O
sensitivity O
. O

The O
promoter O
was O
stimulated O
8 O
- O
20 O
- O
fold O
by O
phorbol O
esters O
accounting RARE
for O
the O
previously O
observed O
transcriptional O
activation O
of O
protein I-GENE
kinase I-GENE
C I-GENE
beta I-GENE
. O

In O
humans O
, O
four O
AMP I-GENE
deaminase I-GENE
variants I-GENE
, O
termed O
M I-GENE
( O
muscle O
), O
L I-GENE
( O
liver O
), O
E1 I-GENE
, O
and O
E2 I-GENE
( O
erythrocyte O
) O
can O
be O
distinguished O
by O
a O
variety O
of O
biochemical O
and O
immunological RARE
criteria O
. O

Western O
blot O
analyses O
detect O
anti I-GENE
- I-GENE
E I-GENE
- O
specific O
immunoreactivity O
in O
affinity O
- O
purified O
extracts O
derived O
from O
the O
bacterial O
expression O
of O
a O
truncated I-GENE
AMPD3 NUMERIC
cDNA I-GENE
. O

These O
results O
demonstrate O
that O
endogenous O
N O
- O
methylation O
of O
salsolinol RARE
into O
N O
- O
methylsalsolinol RARE
occurs O
in O
the O
brain O
in O
vivo O
. O

DR1 I-GENE
molecules I-GENE
purified O
from O
human O
lymphoblastoid RARE
cell O
lines O
could O
specifically O
bind O
to O
these O
peptide O
sequences O
expressed O
on O
the O
phage O
surface O
. O

This O
article O
describes O
the O
collaborative RARE
care O
of O
the O
woman O
participating RARE
in O
maternal O
blood O
donation RARE
for O
intrauterine O
transfusion O
. O

Chronic O
hepatitis O
B O
in O
adopted O
Romanian RARE
children O
. O

Behind RARE
the O
ATPase I-GENE
cluster I-GENE
, O
two O
open O
reading O
frames O
were O
detected O
that O
are O
not O
homologous O
to O
any O
known O
chloroplast O
gene O
. O

Therefore O
, O
recombinant O
human O
Ads RARE
that O
express O
noninfectious RARE
HIV O
or O
other O
microbial O
proteins O
are O
attractive RARE
vaccine O
candidates RARE
. O

Alignment RARE
of O
the O
selected O
sequences O
allowed O
us O
to O
predict O
a O
consensus O
sequence O
for O
binding O
of O
the O
individual O
homodimeric RARE
Rel I-GENE
- I-GENE
related I-GENE
proteins I-GENE
, O
and O
DNA O
- O
protein O
binding O
analysis O
of O
the O
selected O
DNA O
sequences O
revealed O
sequence O
specificity O
of O
the O
proteins O
. O

Using O
either O
a O
p50 I-GENE
- O
or O
p65 I-GENE
- I-GENE
selected I-GENE
kappa I-GENE
B I-GENE
motif I-GENE
, O
which O
displayed O
differential O
binding O
with O
respect O
to O
the O
other O
protein O
, O
little O
to O
no O
binding O
was O
observed O
with O
the O
heterodimeric I-GENE
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
complex I-GENE
. O

However O
, O
a O
cosmid O
clone O
containing O
the O
entire O
mouse I-GENE
alpha I-GENE
1 I-GENE
( I-GENE
I I-GENE
) I-GENE
gene I-GENE
, O
including O
3 O
. O
7 O
kb O
of O
5 O
'- O
and O
4 O
kb O
of O
3 O
'- O
flanking O
DNA O
, O
was O
expressed O
at O
reduced O
levels O
in O
fibroblasts O
overexpressing O
oncogenic I-GENE
ras I-GENE
. O

To O
define O
transcriptional O
control O
elements O
responsible O
for O
muscle O
- O
specific O
expression O
of O
the O
human I-GENE
myoglobin I-GENE
gene I-GENE
, O
we O
performed O
mutational O
analysis O
of O
upstream O
sequences O
( O
nucleotide O
positions O
- O
373 NUMERIC
to O
+ O
7 O
relative O
to O
the O
transcriptional O
start O
site O
) O
linked O
to O
a O
firefly RARE
luciferase I-GENE
gene I-GENE
. O

Sequencing O
analysis O
has O
shown O
that O
each O
rap1t NUMERIC
allele I-GENE
contains O
a O
nonsense O
mutation O
within O
a O
discrete O
region O
between O
amino O
acids O
663 NUMERIC
and O
684 NUMERIC
. O

By O
screening O
a O
Y1 NUMERIC
cell O
cDNA O
library O
with O
the O
DNA O
- O
binding O
region O
of O
the O
H I-GENE
- I-GENE
2RIIBP NUMERIC
nuclear I-GENE
hormone I-GENE
receptor I-GENE
cDNA I-GENE
, O
we O
isolated O
a O
cDNA O
that O
is O
selectively O
expressed O
in O
steroidogenic RARE
cells O
. O

Autopsy RARE
demonstrated O
good O
survival O
of O
the O
transplanted RARE
cells O
with O
good O
integration O
with O
the O
brain O
of O
the O
recipient O
and O
traces RARE
of O
positive O
immunocytochemical RARE
reaction O
for O
tyrosine I-GENE
hydroxylase I-GENE
. O

The O
technique O
of O
the O
TEE ALLCAPS
visualization O
of O
the O
proximal O
coronary O
arteries O
is O
described O
. O

The O
sequence O
of O
this O
region O
shows O
high O
G O
+ O
C O
content O
( O
62 O
%), O
which O
is O
particularly O
emphasized RARE
in O
the O
200 O
bp O
upstream O
from O
the O
mRNA O
start O
( O
80 O
% O
G O
+ O
C O
). O

In O
the O
eight O
patients O
with O
persistent O
generalized O
lymph O
- O
adenopathy RARE
( O
PGL ALLCAPS
) O
and O
nontender RARE
, O
nonenlarging RARE
nodes O
, O
pathologic O
analysis O
revealed O
lymphoid O
hyperplasia O
. O

PaO2 O
threshold O
was O
determined O
through O
an O
indwelling RARE
O2 O
sensor RARE
catheter O
. O

We O
found O
that O
both O
the O
E26 NUMERIC
virus O
- O
encoded O
v I-GENE
- I-GENE
ets I-GENE
and O
the O
myeloid I-GENE
/ I-GENE
B I-GENE
- I-GENE
cell I-GENE
- I-GENE
specific I-GENE
factor I-GENE
PU I-GENE
. I-GENE
1 I-GENE
bind O
efficiently O
to O
this O
site O
in O
vitro O
. O

By O
using O
lambda O
gt11 O
expression O
cloning O
with O
oligonucleotides O
corresponding O
to O
the O
human O
immunodeficiency O
virus O
1 O
TATA O
element O
, O
we O
report O
the O
identification O
of O
a O
cellular O
protein O
with O
a O
calculated O
molecular O
mass O
of O
123 O
kDa O
that O
we O
designate RARE
TATA I-GENE
element I-GENE
modulatory RARE
factor I-GENE
( O
TMF ALLCAPS
). O

Blood O
levels O
of O
melatonin O
, O
serotonin O
, O
cortisol O
, O
and O
prolactin I-GENE
in O
relation O
to O
the O
circadian O
rhythm O
of O
platelet O
serotonin O
uptake O
. O

We O
couldn RARE
' O
t O
detect O
any O
effect O
of O
n O
- O
3 O
FA ALLCAPS
supplementation O
on O
total O
cholesterol O
, O
HDL I-GENE
cholesterol I-GENE
, O
LDL I-GENE
cholesterol I-GENE
, O
apo I-GENE
A1 I-GENE
, O
Lp RARE
( O
a O
), O
HbA1C NUMERIC
, O
glucose O
, O
fibrinogen I-GENE
, O
factor I-GENE
VIII I-GENE
, O
antithrombin I-GENE
III I-GENE
, O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
, O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
and O
von I-GENE
Willebrand I-GENE
factor I-GENE
concentration O
, O
on O
bleeding O
time O
or O
on O
systolic O
or O
diastolic O
blood O
pressure O
. O

In O
8 O
healthy O
volunteers O
there O
were O
no O
significant O
differences O
in O
AUC O
, O
peak O
plasma O
concentrations O
or O
time O
to O
peak O
concentration O
when O
OXC ALLCAPS
was O
administered O
either O
with O
or O
without O
ERY ALLCAPS
. O

Using O
5 O
ng O
/ O
mL O
as O
the O
cutoff O
, O
the O
sensitivity O
of O
CEA I-GENE
was O
68 O
%. O

Rolandic RARE
spikes O
and O
cognitive O
function O
. O

The O
effect O
of O
sodium O
18 O
beta O
- O
glycyrrhetate RARE
( O
SGA ALLCAPS
) O
on O
experimental O
arrhythmia RARE
was O
investigated O
. O

Thus O
, O
chronic O
hematocrit O
decrease O
induced O
by O
H O
or O
P O
resulted O
in O
a O
significant O
fall O
in O
blood O
pressure O
compared O
to O
control O
( O
201 O
+/- O
3 O
v O
175 O
+/- O
4 O
, O
167 NUMERIC
+/- O
4 O
mm O
Hg O
, O
respectively O
; O
P O
< O
. O
05 O
). O

The O
effects O
of O
diltiazem O
were O
stereoselective RARE
, O
thus O
the O
potentiation O
induced O
by O
d O
- O
cis O
diltiazem O
was O
significantly O
greater O
in O
all O
cases O
than O
that O
induced O
by O
l O
- O
cis O
diltiazem O
, O
which O
suggests O
that O
calcium O
channel O
blockade O
plays O
a O
role O
in O
these O
interactions O
. O

Localization O
of O
the O
brachial RARE
plexus RARE
with O
the O
nerve O
stimulator RARE
is O
equally O
effective O
at O
the O
interscalene RARE
, O
supraclavicular RARE
, O
and O
axillary RARE
sites O
. O

Substitution O
of O
either O
Val33 NUMERIC
( O
by O
Gly O
) O
or O
Gly28 NUMERIC
( O
by O
Ser O
), O
two O
of O
the O
most O
conserved O
residues O
in O
all O
protein O
kinases O
, O
resulted O
in O
enzyme O
with O
marginally RARE
detectable O
activity O
. O

Significance O
of O
the O
biopsy O
site O
of O
the O
latissimus RARE
dorsi RARE
muscle O
for O
fiber O
typing RARE
. O

The O
TIMP I-GENE
(- O
59 O
/ O
- O
53 O
) O
AP1 I-GENE
site O
is O
a O
promiscuous RARE
motif O
that O
binds O
c I-GENE
- I-GENE
Fos I-GENE
/ O
c I-GENE
- I-GENE
Jun I-GENE
AP1 I-GENE
translated O
in O
vitro O
and O
is O
an O
effective O
competitor O
for O
binding O
of O
nuclear I-GENE
AP1 I-GENE
factors I-GENE
to O
the O
consensus O
TRE O
, O
but O
in O
addition O
it O
binds O
factors O
that O
do O
not O
associate O
with O
the O
consensus O
TRE O
. O

Involvement RARE
of O
AP1 I-GENE
and O
PEA3 I-GENE
binding I-GENE
sites I-GENE
in O
the O
regulation O
of O
murine I-GENE
tissue I-GENE
inhibitor I-GENE
of I-GENE
metalloproteinases RARE
- I-GENE
1 I-GENE
( O
TIMP I-GENE
- I-GENE
1 I-GENE
) O
transcription O
. O

Of O
the O
serum I-GENE
neutralizing RARE
( I-GENE
SN ALLCAPS
) I-GENE
antibody I-GENE
negative O
calves O
89 O
. O
7 O
% O
( O
26 O
/ O
29 O
) O
and O
92 O
. O
8 O
% O
( O
90 O
/ O
97 O
) O
developed O
SN ALLCAPS
antibody I-GENE
1 O
month O
after O
intranasal RARE
and O
intramuscular RARE
vaccination O
, O
respectively O
. O

Fractionation RARE
of O
crude O
nuclear O
extracts O
by O
heparin O
- O
agarose O
chromatography O
indicates O
that O
PCAT ALLCAPS
- I-GENE
1 I-GENE
is O
more O
prevalent RARE
in O
extracts O
prepared O
from O
salt O
- O
stressed O
leaf O
tissue O
. O

A O
controlled O
trial O
of O
recombinant I-GENE
human I-GENE
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
after O
total O
body O
irradiation O
, O
high O
- O
dose O
chemotherapy O
, O
and O
autologous O
bone O
marrow O
transplantation O
for O
acute O
lymphoblastic RARE
leukemia O
or O
malignant O
lymphoma O
. O

These O
data O
demonstrate O
that O
DMVA ALLCAPS
does O
not O
cause O
more O
myocardial O
trauma O
than O
CPB O
when O
used O
to O
provide O
resuscitative RARE
circulatory O
support O
. O

The O
IgG I-GENE
subclass RARE
profile O
of O
untreated O
coeliac RARE
disease O
was O
found O
to O
be O
the O
same O
as O
in O
healthy O
controls O
( O
IgG1 NUMERIC
approximately O
IgG2 NUMERIC
> O
IgG3 NUMERIC
> O
IgG4 NUMERIC
), O
with O
only O
the O
magnitude O
of O
the O
individual O
subclass RARE
responses O
being O
increased O
in O
coeliac RARE
patients O
. O

Examination O
of O
ANCA ALLCAPS
is O
not O
only O
a O
significant O
contribution O
towards O
a O
more O
accurate O
diagnosis O
of O
renal O
vasculitis O
, O
but O
also O
an O
indicator O
of O
the O
activity O
of O
the O
disease O
and O
thus O
of O
the O
effectiveness O
of O
immunosuppressive O
treatment O
. O

On O
the O
other O
hand O
, O
total O
pinealectomy RARE
in O
these O
already O
sympathectomized RARE
blinded RARE
rabbits O
always O
resulted O
in O
a O
substantial O
deceleration RARE
of O
the O
rhythms RARE
( O
mean O
delta O
tau O
= O
+ O
0 O
. O
23 O
h O
). O

Cicatricial RARE
pemphigoid RARE
is O
an O
autoimmune RARE
systemic O
disease O
characterized O
by O
chronic O
conjunctival RARE
cicatrization RARE
. O

The O
effects O
of O
two O
levels O
of O
caffeine O
ingestion O
on O
excess O
postexercise RARE
oxygen O
consumption O
in O
untrained RARE
women O
. O

The O
distinguishing RARE
features O
involved O
eight O
amino O
acid O
changes O
, O
including O
a O
single O
lysine O
deletion O
relative O
to O
a O
primate O
consensus O
sequence O
in O
the O
first O
complementary O
- O
determing RARE
region O
of O
V1J1 NUMERIC
. O

4 O
. O

The O
in O
vivo O
profile O
of O
ZFH ALLCAPS
- I-GENE
2 I-GENE
in O
the O
larval O
CNS O
shows O
intriguing RARE
overlap O
with O
DDC ALLCAPS
in O
specific O
serotonin O
and O
dopamine O
neurons O
. O

Unlike O
the O
introns O
of O
other O
duplicated O
ribosomal I-GENE
protein I-GENE
genes I-GENE
which O
are O
highly O
diverged O
, O
the O
duplicated O
S13 NUMERIC
genes I-GENE
have O
two O
nearly O
identical O
DNA O
sequences O
of O
25 O
and O
31 O
bp O
in O
length O
within O
their O
introns O
. O

In O
a O
prospective O
, O
randomized O
clinical O
trial O
we O
compared O
the O
efficacy O
of O
subcutaneously O
( O
SC O
) O
administered O
( O
every O
8 O
h O
) O
calcium O
heparin O
to O
intravenous O
( O
IV O
) O
sodium O
heparin O
in O
the O
treatment O
of O
proximal O
deep O
- O
vein O
thrombosis O
( O
DVT ALLCAPS
). O

The O
highest O
prevalence O
of O
reported O
pet RARE
allergy O
, O
chronic O
cough RARE
, O
wheeze RARE
, O
attacks O
of O
shortness RARE
of O
breath RARE
with O
wheezing RARE
, O
and O
doctor RARE
- O
diagnosed O
asthma O
was O
found O
in O
children O
who O
had O
pets RARE
in O
the O
past O
but O
not O
anymore RARE
. O

Therefore O
, O
it O
would O
be O
advantageous RARE
to O
identify O
such O
persons O
and O
treat O
them O
preferentially O
. O

On O
the O
basis O
of O
these O
unique O
properties O
, O
the O
newly O
characterized O
hemagglutinin I-GENE
has O
been O
termed O
Limulus RARE
18K NUMERIC
agglutination I-GENE
- I-GENE
aggregation I-GENE
factor I-GENE
( O
18K NUMERIC
- I-GENE
LAF ALLCAPS
). O

The O
shift O
to O
the O
nonpermissive RARE
temperature O
is O
accompanied O
by O
the O
loss O
of O
guanyl RARE
nucleotide O
- O
dependent O
activity O
of O
adenylylcyclase RARE
in O
vitro O
. O

Clin RARE
. O

The O
data O
indicate O
that O
the O
minimal O
catalytic O
domain O
of O
Nmt1p NUMERIC
is O
located O
between O
Ile59 NUMERIC
--> O
Phe96 NUMERIC
and O
Gly451 NUMERIC
--> O
Leu455 NUMERIC
. O

It O
corresponds O
to O
the O
complete O
mitochondrial O
presequence RARE
and O
the O
lipoyl RARE
- O
bearing O
domain O
that O
are O
encoded O
by O
exons O
I O
through O
IV O
of O
the O
functional O
E2 I-GENE
gene I-GENE
. O

Human O
neutrophil O
response O
to O
short O
- O
term O
exposure O
to O
F O
- O
75 O
cobalt RARE
- O
based O
alloy RARE
. O

Disruption O
of O
microtubules RARE
did O
not O
affect O
the O
fidelity O
or O
kinetics O
of O
vacuolar O
protein O
sorting O
, O
indicating O
that O
Vps1p NUMERIC
function O
is O
not O
dependent O
on O
microtubules RARE
. O

A O
mutant O
form O
of O
Vps1p NUMERIC
lacking O
the O
entire O
GTP O
- O
binding O
domain O
interfered RARE
with O
vacuolar O
protein O
sorting O
in O
wild O
- O
type O
cells O
. O

According O
to O
out O
field O
research O
, O
the O
tick RARE
fauna RARE
was O
very O
rich O
throughout O
that O
area O
, O
and O
it O
was O
permissible RARE
enough O
to O
determine O
ticks O
as O
the O
vectors O
, O
based O
on O
arising O
of O
anti I-GENE
- I-GENE
SF I-GENE
group I-GENE
rickettsiae RARE
( O
SFGR ALLCAPS
) O
antibody O
in O
mice O
inoculated O
with O
some O
tick RARE
emulsions RARE
, O
findings O
of O
rickettsiae RARE
reactive O
to O
patient O
sera O
or O
a O
species O
- O
specific O
monoclonal O
antibody O
to O
JSFR ALLCAPS
in O
the O
hemolymph RARE
cells O
of O
some O
ticks O
, O
and O
electron O
microscopical RARE
observations O
of O
SFGR ALLCAPS
in O
various O
internal O
organs O
including O
the O
salivary O
gland O
of O
ticks O
. O

The O
second O
method O
, O
the O
" O
macro RARE
" O
assay O
, O
has O
a O
sensitivity O
range O
of O
0 O
. O
03 O
- O
5 O
. O
0 O
micrograms O
phosphorus O
with O
100 O
- O
500 O
microliters RARE
HClO4 NUMERIC
. O

Nucleotide O
sequence O
and O
transcriptional O
analysis O
of O
the O
polyhedrin RARE
gene I-GENE
of O
Spodoptera RARE
exigua RARE
nuclear O
polyhedrosis RARE
virus O
. O

Validation RARE
of O
automated O
systems O
-- O
system O
definition O
. O

As O
a O
consequence O
of O
dark O
rearing RARE
, O
the O
numerical RARE
density O
of O
cortical O
neurons O
in O
area O
17 O
amounted RARE
to O
about O
double O
of O
the O
value O
observed O
in O
normally O
reared RARE
kittens RARE
and O
was O
also O
significantly O
higher O
in O
area O
18 O
. O

These O
results O
suggest O
that O
decreased O
class O
I O
enhancer O
activity O
in O
Ad12 NUMERIC
- O
transformed O
cells O
may O
, O
at O
least O
in O
part O
, O
be O
due O
to O
the O
higher O
levels O
of O
an O
enhancer O
- O
specific O
factor O
, O
possibly O
acting O
as O
a O
repressor O
. O

A O
second O
domain O
, O
located O
in O
the O
C O
- O
terminal O
437 NUMERIC
amino O
acids O
of O
IE1 I-GENE
, O
is O
required O
for O
inhibitory O
and O
DNA O
- O
binding O
activities O
. O

In O
order O
to O
investigate O
the O
blood O
compatibility O
of O
autogenous RARE
vein O
graft O
( O
AVG ALLCAPS
), O
changes O
in O
prostacyclin RARE
( O
PGI2 NUMERIC
) O
production O
following O
harvesting RARE
and O
arterial O
implantation O
were O
studied O
experimentally O
. O

Subcutaneous RARE
administration O
of O
the O
somatostatin I-GENE
analogue O
, O
octreotide RARE
, O
100 O
micrograms O
thrice RARE
daily O
, O
resulted O
in O
a O
sustained O
improvement O
in O
diarrhoea RARE
and O
disappearance O
of O
faecal RARE
incontinence RARE
without O
reducing O
calcitonin I-GENE
levels O
. O

Anti I-GENE
- I-GENE
CRK ALLCAPS
antibodies I-GENE
detect O
a O
53kDa NUMERIC
protein O
in O
extracts O
of O
C O
. O
fasciculata RARE
in O
agreement O
with O
the O
size O
predicted O
from O
the O
nucleotide O
sequence O
of O
the O
cloned O
gene O
. O

205 NUMERIC
, O
285 O
- O
290 NUMERIC
] O
and O
was O
subsequently O
cloned O
and O
sequenced O
[ O
J O
. O

Nonreplicating RARE
vaccinia O
vector O
efficiently O
expresses RARE
recombinant O
genes O
. O

Use O
of O
free O
- O
access O
minerals RARE
. O

Interferon I-GENE
type I-GENE
I I-GENE
in O
protective O
body O
reactions O
in O
an O
experimental O
Klebsiella O
infection O

No O
other O
changes O
in O
hematopoietic O
differentiation O
status O
were O
observed O
in O
association O
with O
Id RARE
- I-GENE
SCL ALLCAPS
expression O
. O

Respiratory RARE
interaction O
after O
spinal O
anesthesia O
and O
sedation O
with O
midazolam O
. O

For O
pressure O
greater O
than O
121 O
atm RARE
abs RARE
, O
an O
increased O
excitability RARE
of O
the O
tadpoles RARE
made O
it O
difficult O
to O
distinguish RARE
the O
righting RARE
reflex O
from O
involuntary RARE
movements O
. O

One O
air O
embolism RARE
occurred O
; O
this O
was O
the O
only O
filter O
- O
or O
retrieval RARE
- O
related O
complication O
. O

The O
5 O
' O
region O
of O
ADH5 NUMERIC
contains O
consensus O
binding O
sites O
for O
the O
transcriptional O
regulatory O
proteins O
, O
Sp1 I-GENE
, O
AP2 I-GENE
, O
LF ALLCAPS
- I-GENE
A1 I-GENE
, O
NF I-GENE
- I-GENE
1 I-GENE
, O
NF I-GENE
- I-GENE
A2 I-GENE
, O
and O
NF I-GENE
- I-GENE
E1 I-GENE
. O

V O
. O

These O
data O
indicate O
that O
RNK ALLCAPS
- I-GENE
Met I-GENE
- I-GENE
1 I-GENE
is O
a O
serine I-GENE
protease I-GENE
with O
unique O
activity O
that O
is O
expressed O
in O
the O
granules O
of O
large O
granular RARE
lymphocytes O
. O

Purification RARE
and O
cloning O
of O
a O
novel O
serine I-GENE
protease I-GENE
, O
RNK ALLCAPS
- I-GENE
Met I-GENE
- I-GENE
1 I-GENE
, O
from O
the O
granules O
of O
a O
rat O
natural O
killer O
cell O
leukemia O
. O

We O
describe O
here O
17 O
dominant I-GENE
GCN2 I-GENE
mutations I-GENE
that O
lead O
to O
derepression O
of O
GCN4 I-GENE
expression O
in O
the O
absence O
of O
amino O
acid O
starvation O
. O

Administration O
of O
growth I-GENE
hormone I-GENE
leads O
to O
faster O
growth O
, O
but O
also O
faster O
bone O
maturation O
. O

Comparisons RARE
with O
the O
available O
amino O
acid O
residue O
( O
aa O
) O
sequence O
information O
from O
the O
complete O
CPMV ALLCAPS
RNA I-GENE
1 I-GENE
sequence I-GENE
and O
the O
partial O
sequence O
of O
red I-GENE
clover RARE
mottle RARE
virus I-GENE
RNA I-GENE
1 I-GENE
suggest O
that O
CPSMV ALLCAPS
RNA I-GENE
1 I-GENE
specifies O
the O
expected O
set O
of O
five O
mature O
proteins O
: O
32K NUMERIC
proteinase I-GENE
cofactor I-GENE
, O
58K NUMERIC
presumed I-GENE
helicase I-GENE
, O
VPg RARE
5 I-GENE
'- I-GENE
linked I-GENE
protein I-GENE
of O
the O
genomic O
RNAs O
, O
24K NUMERIC
proteinase I-GENE
, O
and O
87K NUMERIC
presumed I-GENE
polymerase I-GENE
, O
separated O
by O
four O
cleavage O
sites O
. O

Rice RARE
dwarf RARE
phytoreovirus RARE
segment I-GENE
S12 NUMERIC
transcript I-GENE
is O
tricistronic RARE
in O
vitro O
. O

In O
addition O
, O
the O
utility RARE
of O
beta I-GENE
2 I-GENE
transferrin I-GENE
assay O
in O
the O
diagnosis O
of O
cerebrospinal O
fluid O
otorrhea RARE
is O
presented O
. O

Cold RARE
cardioplegia RARE
was O
administered O
at O
45 O
mm O
Hg O
every O
20 O
minutes O
for O
2 O
hours O
. O

The O
addition O
of O
diatrizoate RARE
to O
the O
IPRK ALLCAPS
led O
to O
a O
dose O
- O
dependent O
biphasic O
change O
in O
RPF ALLCAPS
and O
GFR O
characterized O
by O
an O
initial O
transient O
increase O
followed O
by O
a O
marked O
and O
sustained O
decrease O
. O

To O
prepare RARE
for O
analyses O
with O
the O
family O
variables O
, O
we O
next O
present O
descriptive RARE
data O
based O
on O
separate O
principal O
components O
analysis O
( O
PCA ALLCAPS
) O
and O
multidimensional RARE
scaling RARE
analysis O
( O
MDS ALLCAPS
) O
of O
14 O
self O
- O
reported O
health O
scores O
for O
husbands RARE
and O
for O
wives RARE
. O

The O
structural O
genes O
encoding O
glyceraldehyde RARE
- I-GENE
3 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
( O
GAPDH ALLCAPS
), O
3 I-GENE
- I-GENE
phosphoglycerate RARE
kinase I-GENE
( O
PGK ALLCAPS
) O
and O
the O
N O
- O
terminal O
part O
of O
triosephosphate RARE
isomerase I-GENE
( O
TIM ALLCAPS
) O
from O
mesophilic RARE
Bacillus O
megaterium RARE
DSM319 NUMERIC
have O
been O
cloned O
as O
a O
gene O
cluster O
( O
gap RARE
operon I-GENE
) O
by O
complementation O
of O
an O
Escherichia O
coli O
gap RARE
amber RARE
mutant I-GENE
. O

Pseudomonas I-GENE
aeruginosa I-GENE
exotoxin RARE
A I-GENE
: O
its O
role O
in O
retardation O
of O
wound O
healing O
: O
the O
1992 O
Lindberg RARE
Award RARE
. O

Laboratory O
studies O
showed O
that O
the O
direct O
fluorescent O
- O
antibody O
kits RARE
were O
the O
least O
sensitive O
in O
this O
case O
and O
did O
not O
detect O
fewer O
than O
10 O
( O
4 O
) O
elementary RARE
bodies O
per O
ml O
, O
while O
most O
ELISA O
kits RARE
detected O
between O
130 O
and O
600 O
elementary RARE
bodies O
per O
ml O
. O

To O
study O
the O
significance O
of O
these O
domains O
and O
the O
overall O
evolutionary O
conservation O
of O
the O
gene O
, O
the O
homolog O
from O
Drosophila O
melanogaster O
was O
isolated O
by O
low O
stringency RARE
hybridizations RARE
using O
two O
flanking O
probes O
of O
the O
human I-GENE
ERCC3 NUMERIC
cDNA I-GENE
. O

Mono RARE
- O
ADP O
- O
ribosylation RARE
is O
a O
reversible O
modification O
of O
proteins O
, O
with O
NAD O
: O
arginine I-GENE
ADP I-GENE
- I-GENE
ribosyltransferases RARE
( O
EC I-GENE
2 I-GENE
. I-GENE
4 I-GENE
. I-GENE
2 I-GENE
. I-GENE
31 I-GENE
) O
and O
ADP I-GENE
- I-GENE
ribosylarginine RARE
hydrolases RARE
( O
EC I-GENE
3 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
. I-GENE
19 I-GENE
) O
catalyzing RARE
the O
opposing RARE
reactions O
in O
an O
ADP O
- O
ribosylation RARE
cycle O
. O

For O
this O
reason RARE
, O
the O
particle O
forming O
capacity O
of O
derivatives O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
group I-GENE
specific I-GENE
core I-GENE
antigen I-GENE
p55 I-GENE
gag I-GENE
was O
assayed O
and O
compared O
dependent O
on O
various O
expression O
systems O
: O
recombinant O
bacteria O
, O
vaccinia O
- O
and O
baculoviruses RARE
were O
established O
encoding O
the O
entire O
core I-GENE
protein I-GENE
p55 I-GENE
either O
in O
its O
authentic RARE
sequence O
or O
lacking O
the O
myristylation RARE
consensus O
signal O
. O

The O
tramtrack RARE
( O
ttk RARE
) O
gene O
of O
Drosophila O
encodes O
69 O
- O
kDa O
and O
88 O
- O
kDa O
proteins O
through O
alternative O
splicing O
of O
the O
primary O
ttk RARE
transcript I-GENE
. O

Removal O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
by O
hemodialysis O
and O
hemofiltration RARE
: O
a O
four O
year O
follow O
up O
. O

Removal O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
by O
hemodialysis O
and O
hemofiltration RARE
: O
a O
four O
year O
follow O
up O
. O

Adapromine RARE
was O
established O
to O
evoke RARE
a O
decrease O
of O
the O
amplitude O
of O
the O
dominant O
peak O
and O
dominant O
theta RARE
- O
activity O
in O
power O
spectra O
of O
the O
EEG O
in O
the O
cortex O
and O
hippocamp RARE
, O
with O
an O
increase O
of O
rapid O
wave O
activity O
in O
the O
beta O
2 O
range O
in O
the O
right O
cortex O
and O
hippocamp RARE
. O

These O
sequences O
were O
then O
used O
to O
clone O
the O
full O
- O
length O
genes O
from O
a O
yeast O
genomic O
library O
. O

GAL4 I-GENE
- O
VP16 I-GENE
- O
mediated O
antirepression RARE
required O
an O
auxiliary O
factor O
, O
denoted RARE
as O
a O
co O
- O
antirepressor RARE
, O
which O
was O
partially O
purified O
from O
Drosophila O
embryos O
. O

After O
28 O
days O
of O
haloperidol O
treatment O
, O
similar O
changes O
were O
observed O
for O
delta O
, O
together O
with O
an O
increase O
of O
alpha O
1 O
, O
and O
a O
decrease O
of O
fast O
beta O
. O

Four O
ruminally RARE
and O
duodenally RARE
cannulated RARE
Hampshire RARE
wethers RARE
were O
used O
in O
a O
4 O
x O
4 O
Latin RARE
square O
experiment O
to O
determine O
whether O
linoleoyl RARE
methionine O
and O
calcium O
linoleate RARE
would O
increase O
duodenal O
flow O
of O
unsaturated RARE
fatty O
acids O
( O
C18 O
: O
2 O
+ O
cis O
C18 O
: O
1 O
). O

Truncated RARE
ICSBP ALLCAPS
lacking O
the O
first O
33 O
amino O
- O
terminal O
amino O
acids O
fails O
to O
bind O
to O
the O
ICS ALLCAPS
, O
indicating O
that O
at O
least O
part O
of O
the O
DNA O
binding O
domain O
is O
located O
within O
the O
well O
conserved O
amino O
terminus O
. O

Therefore O
, O
ICSBP ALLCAPS
may O
be O
involved O
in O
maintaining O
submaximal RARE
transcriptional O
activity O
of O
IFN I-GENE
- O
inducible O
genes O
in O
hematopoietic O
cells O
. O

A O
case O
of O
chronic O
hepatitis O
C O
with O
primary O
hypothyroidism O
manifested O
during O
interferon I-GENE
treatment O

Dynamic RARE
decision RARE
making O
: O
human O
control O
of O
complex O
systems O
. O

A O
coiled I-GENE
- I-GENE
coil I-GENE
related I-GENE
protein I-GENE
specific O
for O
synapsed RARE
regions O
of O
meiotic O
prophase RARE
chromosomes O
. O

Comparable RARE
amounts O
of O
alpha I-GENE
5 I-GENE
beta I-GENE
1 I-GENE
integrin I-GENE
were O
isolated O
from O
these O
cells O
by O
chromatography O
of O
detergent O
extracts O
on O
a O
fibronectin I-GENE
cell O
- O
binding O
fragment O
affinity O
column O
and O
elution RARE
with O
EDTA O
. O

Abstracts RARE
. O

These O
results O
indicate O
a O
possible O
involvement O
of O
endogenous O
opioid O
peptides O
in O
the O
cardiac O
effects O
due O
to O
myocardial O
ischaemia O
and O
reperfusion O
, O
mediated O
by O
opiate I-GENE
receptors I-GENE
through O
opiate O
antagonism RARE
. O

From O
this O
library O
, O
LEU2 I-GENE
and O
HIS3 I-GENE
cDNAs O
were O
recovered O
at O
a O
frequency O
of O
about O
1 O
in O
10 O
( O
4 O
) O
and O
in O
12 O
out O
of O
13 O
cases O
these O
were O
expressed O
in O
a O
galactose O
- O
dependent O
manner O
. O

Among O
these O
, O
ACT1 NUMERIC
was O
isolated O
four O
times O
, O
and O
NSR1 NUMERIC
three O
times O
. O

Since O
CENP ALLCAPS
- I-GENE
B I-GENE
gene I-GENE
is O
conserved O
in O
mammalian O
species O
and O
CENP ALLCAPS
- I-GENE
B I-GENE
boxes I-GENE
are O
found O
also O
in O
mouse O
centromere O
satellite O
DNA O
( O
minor O
satellite O
), O
this O
sequence O
- O
specific O
DNA O
- O
protein O
interaction O
may O
be O
important O
for O
some O
kind RARE
of O
common O
centromere O
function O
. O

Interestingly O
, O
a O
portion O
of O
the O
tail O
domain O
( O
aa O
, O
1 O
, O
094 NUMERIC
- O
1 O
, O
830 NUMERIC
) O
shares O
58 O
% O
amino O
acid O
sequence O
identity O
with O
a O
723 NUMERIC
- O
aa O
protein O
from O
mouse O
brain O
reported O
to O
be O
a O
glutamic RARE
acid I-GENE
decarboxylase I-GENE
. O

However O
, O
in O
the O
subgroup O
with O
normal O
Ht RARE
(< O
0 O
. O
45 O
l O
/ O
l O
; O
n O
= O
201 O
) O
there O
was O
a O
significant O
reduction O
( O
p O
< O
0 O
. O
05 O
) O
of O
the O
mortality O
after O
3 O
months O
( O
27 O
% O
and O
16 O
%, O
respectively O
) O
and O
an O
increase O
of O
independence RARE
at O
home O
( O
35 O
% O
and O
48 O
%, O
respectively O
) O
due O
to O
a O
reduction O
of O
the O
viscosity O
by O
means O
of O
haemodilution RARE
with O
albumin I-GENE
( O
a O
specific O
viscosity O
effect O
in O
the O
normovolaemic RARE
group O
). O

Distribution RARE
and O
changing O
morphological O
course O

The O
appropriate O
use O
and O
benefits O
of O
bile O
acid O
sequestrants RARE
, O
nicotinic RARE
acid O
, O
fibric RARE
acids O
, O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
methylglutaryl RARE
coenzyme I-GENE
A I-GENE
( I-GENE
HMG I-GENE
- I-GENE
CoA I-GENE
) I-GENE
reductase I-GENE
inhibitors O
, O
and O
probucol RARE
are O
individually O
discussed O
, O
whereas O
nonpharmacologic RARE
approaches O
used O
in O
conjunction O
with O
the O
drugs O
are O
recommended O
emphatically RARE
. O

This O
may O
result O
in O
more O
reabsorption RARE
and O
hence O
reduced O
renal O
clearance O
. O

The O
major O
pathological O
findings O
of O
the O
placenta O
were O
prematuration RARE
and O
hypoplasia RARE
. O

Green RARE
pepper RARE
significantly O
inhibited O
N O
- O
nitrosothiazolidine RARE
- O
carboxylic RARE
acid O
formation O
relative O
to O
ascorbic RARE
acid O
alone O
. O

A O
genomic O
clone O
, O
pTt21 NUMERIC
, O
containing O
DNA O
apparently O
transcribed O
specifically O
in O
Trypanosoma O
cruzi RARE
trypomastigotes RARE
, O
was O
obtained O
by O
differentially O
screening O
a O
genomic O
library O
with O
trypomastigote RARE
and O
epimastigote RARE
cDNA O
. O

Brucellosis RARE
-- O
1990 O

Assay RARE
of O
urea O
by O
immobilized RARE
urease I-GENE
coupled O
to O
a O
differential O
pH O
- O
meter RARE
. O

RESULTS O
: O
In O
the O
AGA ALLCAPS
group O
, O
both O
fetal O
and O
maternal O
serum O
prolactin I-GENE
concentration O
increased O
significantly O
with O
gestation O
( O
P O
< O
0 O
. O
001 O
and O
P O
< O
0 O
. O
01 O
, O
respectively O
). O

One O
phage O
clone O
contains O
a O
junction O
between O
alpha O
satellite O
DNA O
and O
a O
novel O
low O
- O
copy O
repeated O
sequence O
. O

The O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
lactoferrin RARE
gene I-GENE
was O
isolated O
from O
a O
human O
placental O
genomic O
library O
. O

Therefore O
, O
the O
molecular O
mechanisms O
of O
the O
estrogen O
action O
that O
govern O
the O
lactoferrin RARE
gene I-GENE
expression O
differ O
between O
mouse O
and O
human O
. O

BiP670 NUMERIC
retains O
basal O
and O
Ca2 O
+ O
ionophore RARE
A23187 NUMERIC
- O
inducible O
activities O
. O

The O
CEM ALLCAPS
receives RARE
registration RARE
updates RARE
via O
an O
HL7 NUMERIC
message O
and O
evaluates RARE
data O
dependencies RARE
in O
rules RARE
via O
an O
interface O
to O
the O
relational RARE
database O
. O

Magnetic O
resonance O
spectroscopy O
( O
MRS O
) O
and O
imaging O
( O
MRI O
) O
are O
now O
well O
established O
techniques O
for O
the O
study O
of O
cellular O
metabolism O
and O
gross O
structure O
of O
muscle O
. O

Simultaneously RARE
a O
greater O
NA O
was O
found O
with O
no O
change O
in O
plasma O
epinephrine O
response O
. O

We O
investigated O
the O
diagnostic O
value O
of O
a O
new O
in O
vitro O
test O
, O
Pharmacia O
CAP O
System RARE
( O
Pharmacia O
Diagnostics RARE
AB ALLCAPS
, O
Uppsala RARE
, O
Sweden RARE
), O
for O
the O
quantitative O
measurement O
of O
allergen I-GENE
- I-GENE
specific I-GENE
IgE I-GENE
antibodies I-GENE
by O
comparison O
with O
RAST O
in O
2 O
groups O
of O
patients O
, O
71 O
atopic O
and O
48 O
non O
- O
atopic O
. O

Patients O
receiving O
VPA ALLCAPS
showed O
differences O
in O
attention O
, O
visuomotor RARE
performance O
, O
verbal RARE
span O
and O
sensory O
discrimination O
tasks O
at O
T1 O
, O
in O
visuomotor RARE
performance O
at O
T2 O
and O
in O
spatial O
span O
at O
T3 O
, O
whereas O
no O
differences O
were O
detected O
at O
T4 O
. O

We O
found O
that O
the O
gene O
segment O
containing O
the O
mu O
m O
poly O
( O
A O
) O
signals O
, O
along O
with O
536 NUMERIC
bp O
of O
downstream O
flanking O
sequence O
, O
acted RARE
as O
a O
transcription O
terminator O
in O
both O
myeloma O
cells O
and O
L O
cell O
fibroblasts O
. O

As O
a O
part O
of O
a O
large O
examination O
, O
total O
and O
free O
serum O
cholesterol O
, O
total O
lipid O
and O
triglyceride RARE
levels O
were O
determined O
. O

Alena RARE
is O
a O
nurse O
in O
Prague RARE
-- O
she RARE
dreams RARE
of O
higher O
wages RARE
and O
a O
trip RARE
across O
the O
ocean RARE

Dopamine O
neurons O
in O
subjects O
that O
received O
6 O
- O
OHDA ALLCAPS
were O
protected O
by O
pre O
- O
treatment O
with O
GBR ALLCAPS
- O
12909 NUMERIC
. O

DIBA ALLCAPS
was O
more O
sensitive O
and O
had O
a O
better O
negative O
predictive O
value O
and O
a O
lower O
false O
negative O
percentage O
than O
DFAT ALLCAPS
. O

Caries RARE
and O
parodontitis RARE
have O
been O
one O
of O
the O
most O
spread O
diseases O
of O
mankind RARE
. O

The O
results O
of O
this O
study O
demonstrate O
that O
strongyloidiasis RARE
was O
the O
cause O
of O
sudden RARE
death O
. O

A O
second O
large O
group O
of O
disorders O
in O
pregnancy O
is O
caused O
by O
effects O
of O
infections O
of O
the O
mother RARE
without O
pathogens O
being O
transmitted O
to O
the O
embryo O
or O
the O
placenta O
. O

Four O
short O
nucleotide O
sequences O
( O
boxes O
I O
to O
IV O
) O
contribute O
to O
the O
light O
responsiveness O
of O
the O
parsley RARE
chalcone RARE
synthase I-GENE
promoter I-GENE
. O

The O
case O
described O
is O
that O
of O
a O
72 O
- O
year O
- O
old O
man O
with O
ochronosis RARE
who O
suffered RARE
a O
hyperextension RARE
injury O
to O
his O
spine O
in O
a O
fall O
, O
resulting O
in O
a O
fracture O
through O
an O
ankylosed RARE
L2 O
- O
L3 NUMERIC
disk RARE
space O
. O

The O
mean O
blood O
flow O
in O
the O
penile RARE
foreskin RARE
was O
estimated O
to O
be O
15 O
ml O
/ O
min O
/ O
100 O
g O
and O
it O
increased O
to O
150 O
- O
200 O
% O
after O
the O
induction O
of O
anesthesia O
, O
and O
then O
decreased O
to O
72 O
% O
at O
the O
tip O
of O
the O
created O
parameatal RARE
foreskin RARE
flap O
. O

ME1a1 NUMERIC
, O
a O
16 O
- O
base O
- O
pair O
nuclear O
factor O
binding O
site O
residing RARE
between O
the O
c I-GENE
- I-GENE
MYC ALLCAPS
P1 I-GENE
and I-GENE
P2 I-GENE
transcription I-GENE
initiation I-GENE
sites I-GENE
, O
is O
required O
for O
P2 O
activity O
. O

The O
next O
twenty RARE
years O
of O
prevention O
in O
Indian RARE
country RARE
: O
visionary RARE
, O
complex O
, O
and O
practical RARE
. O

Exogenous RARE
LHRH ALLCAPS
is O
also O
known O
to O
facilitate O
mating O
behavior O
in O
several O
species O
. O

The O
first O
146 NUMERIC
consecutive O
patients O
treated O
with O
EVL ALLCAPS
during O
the O
period O
from O
August O
, O
1986 O
to O
July RARE
, O
1989 O
are O
reported O
. O

Replacing RARE
the O
aspartic RARE
acid O
with O
a O
lysine O
but O
not O
with O
an O
alanine O
or O
valine RARE
residue O
allowed O
formation O
of O
disulfide O
- O
linked O
dimers O
. O

During O
V O
- O
A O
bypass O
, O
hemodynamics O
were O
stable O
. O

Greater RARE
rupture RARE
force O
was O
required O
in O
the O
adult O
pigs O
than O
in O
the O
young O
pigs O
. O

At O
rest O
AFF ALLCAPS
was O
significantly O
higher O
in O
UT O
( O
29 O
%) O
as O
compared O
to O
AT O
( O
25 O
%) O
and O
UEA ALLCAPS
( O
25 O
%). O

We O
investigated O
the O
smoking O
habits RARE
of O
relapsers RARE
1 O
year O
after O
quitting RARE
in O
a O
smoking O
cessation O
trial O
using O
nicotine O
or O
placebo O
patches RARE
. O

Exposure RARE
to O
hepatitis O
B O
virus O
in O
the O
general O
population O
of O
Hisayama RARE
, O
Japan O
: O
significance O
of O
isolated O
antibody O
to O
hepatitis I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
in O
general O
population O
. O

Because O
of O
this O
latter O
phenomenon O
, O
we O
were O
able O
to O
identify O
a O
particular O
cysteine O
motif O
that O
was O
repeated O
multiple O
times O
in O
Dfurin2 NUMERIC
but O
present O
only O
twice O
in O
mammalian I-GENE
furin RARE
. O

On O
the O
other O
hand O
, O
neither O
phosphate O
buffered RARE
saline O
injection O
into O
the O
ES O
nor O
primary O
KLH ALLCAPS
challenges RARE
of O
the O
ES O
were O
capable O
of O
elevating RARE
the O
threshold O
level O
and O
changing O
the O
latency O
. O

A O
newly O
developed O
broad O
- O
spectrum O
fluoroquinolone RARE
, O
levofloxacin RARE
( O
LVFX ALLCAPS
, O
DR O
- O
3355 NUMERIC
), O
was O
evaluated O
in O
vitro O
and O
in O
vivo O
in O
comparison O
with O
ciprofloxacin RARE
( O
CPFX ALLCAPS
), O
ofloxacin RARE
( O
OFLX ALLCAPS
) O
and O
norfloxacin RARE
( O
NFLX ALLCAPS
). O

The O
mean O
serum O
creatinine O
levels O
were O
similar O
at O
one O
year O
( O
SPK O
1 O
. O
8 O
, O
KTA ALLCAPS
1 O
. O
9 O
mg O
/ O
d O
).( RARE
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Model RARE
predictions O
were O
in O
accord RARE
with O
the O
nine O
- O
year O
survival O
experience O
of O
women O
in O
the O
HIP ALLCAPS
trial O
, O
and O
, O
with O
the O
exception O
of O
women O
40 O
- O
44 O
years O
old O
, O
with O
HIP ALLCAPS
data O
on O
18 O
- O
year O
survival O
. O

High O
- O
resolution O
computed O
tomography O
in O
the O
diagnosis O
of O
miliary RARE
tuberculosis O
. O

Previously O
, O
we O
showed O
that O
SNF2 NUMERIC
, O
SNF5 NUMERIC
, O
and O
SNF6 NUMERIC
function O
interdependently RARE
in O
transcriptional O
activation O
, O
possibly O
forming O
a O
heteromeric RARE
complex O
. O

We O
show O
that O
LexA I-GENE
- O
GAL4 I-GENE
and O
LexA I-GENE
- O
Bicoid RARE
fusion O
proteins O
are O
both O
dependent O
on O
SNF2 NUMERIC
, O
SNF5 NUMERIC
, O
and O
SNF6 NUMERIC
for O
activation O
of O
target O
genes O
containing O
one O
or O
multiple O
lexA LASTCAP
operators RARE
. O

George RARE
T O
. O

A O
lambda O
gt10 NUMERIC
cDNA O
library O
was O
constructed O
from O
poly O
( O
A O
)+ O
RNA O
of O
young O
green O
leaves O
of O
spinach RARE
. O

NE I-GENE
and O
PR3 NUMERIC
assist RARE
in O
the O
destruction RARE
of O
phagocytosed RARE
microorganisms RARE
, O
cleave RARE
the O
important O
connective I-GENE
- I-GENE
tissue I-GENE
protein I-GENE
elastin I-GENE
, O
and O
generate O
chemotactic O
activities O
by O
forming O
alpha I-GENE
1 I-GENE
- I-GENE
proteinase I-GENE
inhibitor I-GENE
complexes I-GENE
and O
elastin I-GENE
peptides I-GENE
. O

Selected RARE
topics RARE
in O
pediatric O
ultrasonography O
-- O
1992 O
. O

Methods RARE
included O
24 O
- O
hour O
dietary O
recall RARE
, O
menu RARE
weights O
, O
and O
recipe RARE
analysis O
. O

Factors O
associated O
with O
afterdrop RARE
included O
age O
, O
end O
- O
of O
- O
surgery O
temperature O
( O
both O
positively O
) O
and O
body O
mass O
( O
negatively O
). O

Both O
GH I-GENE
deficiency O
and O
impaired O
spinal O
growth O
may O
result O
in O
short O
stature RARE
, O
whereas O
the O
occurrence O
of O
early O
puberty RARE
in O
association O
with O
GH I-GENE
deficiency O
reduces O
the O
time O
available O
for O
GH I-GENE
therapy O
. O

By O
contrast O
, O
d I-GENE
( I-GENE
T2AG3T NUMERIC
) I-GENE
and O
d I-GENE
( I-GENE
T2G4T NUMERIC
) I-GENE
form O
only O
the O
G O
- O
quadruplex RARE
monomer RARE
structures O
independent O
of O
K O
cation RARE
concentration O
as O
reported O
previously O
[ O
Sen RARE
, O
D O
., O
& O
Gilbert RARE
, O
W O
. O

Differentiating RARE
among O
renal O
stones RARE
. O

IFI ALLCAPS
16 I-GENE
mRNA I-GENE
was O
found O
to O
be O
constitutively O
expressed O
in O
lymphoid O
cells O
and O
in O
cell O
lines O
of O
both O
the O
T O
and O
B O
lineages O
. O

Mitochondria RARE
- O
lytic O
action O
of O
warfarin RARE
in O
lymphocytes O
. O

Exon RARE
- O
intron O
junctions O
in O
the O
human O
and O
rat I-GENE
AdoMet RARE
decarboxylase I-GENE
genes I-GENE
were O
in O
identical O
positions O
except O
that O
exons O
6 O
and O
7 O
of O
the O
human O
gene O
formed O
a O
single O
exon O
in O
the O
rat O
gene O
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
- O
induced O
gene O
expression O
: O
evidence O
for O
a O
selective O
effect O
of O
ouabain RARE
on O
activation O
of O
the O
ISGF3 NUMERIC
transcription I-GENE
complex I-GENE
. O

The O
cDNA O
has O
an O
open O
reading O
frame O
of O
900 NUMERIC
amino O
acids O
capable O
of O
encoding O
a O
97 O
- O
kDa O
protein O
. O

Moreover O
, O
LD50 O
in O
mice O
of O
RP O
- O
170 O
( O
4 O
. O
3 O
g O
/ O
kg O
on O
i O
. O
v O
.) O
was O
increased O
to O
5 O
. O
2 O
g O
/ O
kg O
by O
oral O
administration O
. O

Among O
the O
few O
proteins O
of O
the O
eukaryotic O
nucleolus RARE
that O
have O
been O
characterized O
, O
four O
proteins O
, O
nucleolin RARE
, O
fibrillarin RARE
, O
SSB1 NUMERIC
and O
NSR1 NUMERIC
, O
possess O
a O
common O
structural O
motif O
, O
the O
GAR ALLCAPS
domain O
, O
which O
is O
rich O
in O
glycine O
and O
arginine O
residues O
. O

Thus O
, O
this O
study O
provides O
evidence O
that O
a O
novel O
, O
ubiquitous O
factor O
( O
HF I-GENE
- I-GENE
1a I-GENE
) O
and O
a O
muscle O
factor O
( O
HF I-GENE
- I-GENE
1b I-GENE
/ O
MEF I-GENE
- I-GENE
2 I-GENE
) O
can O
form O
a O
novel O
, O
E O
- O
box O
- O
independent O
pathway O
for O
muscle O
- O
specific O
expression O
in O
ventricular O
cardiac O
muscle O
cells O
. O

Mutations O
in O
either O
gene O
block O
some O
crucial O
late O
step O
in O
assembly O
of O
F1 I-GENE
, O
causing O
the O
alpha O
and O
beta O
subunits O
to O
accumulate O
in O
mitochondria O
as O
inactive O
aggregates O
( O
Ackerman RARE
, O
S O
. O

Expense RARE
limits O
the O
use O
of O
hepatitis O
B O
vaccines O
, O
but O
low O
- O
dose O
intradermal RARE
immunization O
has O
been O
evaluated O
as O
a O
cost O
- O
saving RARE
strategy O
in O
numerous O
studies O
. O

Estrogen RARE
replacement O
therapy O
and O
risk O
of O
breast O
cancer O
: O
results O
of O
two O
meta RARE
- O
analyses O
. O

Switching RARE
FDC ALLCAPS
- O
P1 O
/ O
MAC ALLCAPS
cells O
from O
growth O
in O
M I-GENE
- I-GENE
CSF I-GENE
to O
GM I-GENE
- I-GENE
CSF I-GENE
caused O
the O
selective O
degradation O
of O
c I-GENE
- I-GENE
fms I-GENE
mRNA I-GENE
within O
6 O
h O
after O
factor O
switching O
. O

There O
was O
however O
, O
no O
significant O
difference O
in O
the O
prevalence O
of O
chronic O
respiratory O
symptoms O
between O
animal O
food O
workers O
with O
positive O
and O
negative O
skin O
tests O
to O
house RARE
dust O
or O
to O
fish O
flour RARE
or O
among O
those O
with O
increased O
or O
normal O
IgE I-GENE
( O
except O
for O
dyspnea RARE
). O

An O
unexpected RARE
finding O
was O
the O
presence O
at O
position O
- O
403 NUMERIC
to O
- O
385 NUMERIC
of O
a O
putative O
dioxin O
responsive O
element O
, O
a O
sequence O
found O
to O
be O
responsible O
for O
the O
induction O
of O
transcription O
of O
the O
cytochrome I-GENE
P450IA1 NUMERIC
gene I-GENE
( O
CYPIA1 NUMERIC
) O
and O
other O
genes O
involved O
in O
detoxification RARE
/ O
activation O
of O
polycyclic RARE
aromatic O
hydrocarbons RARE
. O

The O
gene O
encoding O
TRP ALLCAPS
- I-GENE
2 I-GENE
maps O
to O
mouse O
chromosome O
14 O
, O
in O
the O
region O
of O
the O
coat I-GENE
colour I-GENE
mutation I-GENE
slaty RARE
. O

Using O
bovine I-GENE
and I-GENE
murine I-GENE
c I-GENE
- I-GENE
myb I-GENE
clones O
, O
no O
change O
in O
the O
rate O
of O
c I-GENE
- I-GENE
myb I-GENE
gene I-GENE
transcription O
or O
mRNA O
stability O
was O
detected O
during O
the O
cell O
cycle O
. O

A O
13 O
base O
- O
pair O
oligonucleotide O
spanning O
nucleotides O
+ O
80 O
to O
+ O
92 O
of O
the O
5 I-GENE
S I-GENE
RNA I-GENE
gene I-GENE
retained O
specific O
and O
high O
- O
affinity O
binding O
, O
although O
the O
latter O
was O
reduced O
sixfold RARE
relative O
to O
longer O
DNA O
fragments O
. O

Moreover O
, O
the O
reconstitution RARE
of O
eUSF LASTCAP
and O
TFIID I-GENE
- O
depleted O
transcription O
complexes O
with O
purified O
protein O
fractions O
demonstrate O
that O
not O
only O
TFIID I-GENE
but O
also O
eUSF LASTCAP
essentially O
participates O
in O
complex O
formation O
even O
on O
H5 NUMERIC
promoter I-GENE
mutations O
lacking O
the O
TATA O
- O
box O
. O

A O
comparison O
of O
the O
amino O
acid O
sequence O
of O
the O
T O
. O
thermophilus RARE
enzyme O
with O
that O
of O
the O
Escherichia O
coli O
enzyme O
showed O
( O
i O
) O
a O
37 O
% O
overall O
similarity O
; O
( O
ii O
) O
the O
conservation O
of O
the O
Ser O
residue O
, O
which O
is O
known O
to O
be O
phosphorylated O
in O
the O
E O
. O
coli O
enzyme O
, O
and O
of O
the O
surrounding O
sequence O
; O
and O
( O
iii O
) O
the O
presence O
of O
141 NUMERIC
extra O
residues O
at O
the O
C O
terminus O
of O
the O
T O
. O
thermophilus RARE
enzyme O
. O

Radiolabelled RARE
palmitate RARE
was O
not O
incorporated O
into O
the O
mutated O
protein O
, O
showing O
that O
lipid O
modification O
occurs O
at O
the O
Cys O
- O
22 O
residue O
. O

17 O
volunteer RARE
deaf RARE
Ss RARE
were O
compared O
with O
18 O
volunteer RARE
hearing O
Ss RARE
on O
the O
Stanford RARE
Hypnotic RARE
Clinical O
Scale O
( O
SHCS ALLCAPS
) O
of O
Morgan RARE
and O
J O
. O

Mature RARE
tobacco I-GENE
L12 I-GENE
protein I-GENE
has O
44 O
% O
amino O
acid O
identity O
with O
ribosomal O
protein O
L7 NUMERIC
/ O
L12 I-GENE
of O
Escherichia O
coli O
. O

Nuclear I-GENE
- I-GENE
encoded I-GENE
chloroplast I-GENE
ribosomal I-GENE
protein I-GENE
L12 I-GENE
of I-GENE
Nicotiana RARE
tabacum RARE
: O
characterization O
of O
mature O
protein O
and O
isolation O
and O
sequence O
analysis O
of O
cDNA O
clones O
encoding O
its O
cytoplasmic O
precursor O
. O

The O
gene O
encoding O
IFN I-GENE
- I-GENE
gamma I-GENE
was O
previously O
found O
to O
contain O
an O
intronic O
enhancer O
element O
that O
was O
not O
tissue O
- O
specific O
in O
its O
activity O
, O
despite O
the O
restricted O
expression O
of O
the O
intact O
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
encoding I-GENE
gene I-GENE
. O

Molecular O
cloning O
of O
the O
polypeptide O
component O
of O
the O
Rel I-GENE
- I-GENE
related I-GENE
human I-GENE
p75 NUMERIC
nucleoprotein I-GENE
complex I-GENE
has O
revealed O
its O
identity O
with O
the O
65 O
- O
kDa O
( O
p65 I-GENE
) O
subunit O
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
. O

Because O
single O
- O
chamber O
rate O
- O
adaptive O
atrial O
pacing O
leaves O
the O
patient O
exposed O
to O
the O
risk O
of O
future O
development O
of O
AV O
block O
and O
DDD ALLCAPS
pacing O
does O
not O
provide O
chronotropic RARE
support O
, O
it O
is O
likely O
that O
the O
new O
rate O
- O
adaptive O
dual O
- O
chamber O
( O
DDDR ALLCAPS
) O
devices RARE
will O
be O
used O
in O
a O
significant O
number O
of O
these O
patients O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

When O
transiently O
transfected O
into O
K562 O
cells O
, O
this O
Lg RARE
genomic O
clone O
is O
actively O
transcribed O
, O
suggesting O
that O
, O
although O
it O
possesses O
the O
characteristics O
of O
a O
processed O
pseudogene O
, O
it O
is O
likely O
to O
correspond O
to O
the O
gene O
encoding O
this O
new O
ferritin I-GENE
subunit I-GENE
. O

Of O
the O
drugs O
orally O
administered O
, O
WR O
- O
168643 NUMERIC
was O
the O
best O
protector RARE
with O
a O
DMF ALLCAPS
of O
1 O
. O
51 O
. O

Characterization O
of O
these O
R O
subunits O
by O
their O
8 O
- O
azido RARE
- O
cAMP O
photoaffinity RARE
labeling O
and O
immunoreactivity O
, O
as O
well O
as O
by O
a O
phosphorylation O
- O
dependent O
mobility O
shift O
on O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
( O
SDS O
- O
PAGE O
), O
indicated O
subunit O
sizes O
of O
RII I-GENE
beta I-GENE
( O
53 O
kDa O
) O
greater O
than O
RII I-GENE
alpha I-GENE
dephosphoform RARE
( O
51 O
kDa O
) O
greater O
than O
RI I-GENE
alpha I-GENE
( O
49 O
kDa O
). O

Comparison O
of O
the O
genomic O
DNA O
sequence O
with O
that O
of O
the O
four O
different O
mRNAs O
indicates O
that O
these O
transcripts O
are O
produced O
by O
alternative O
splicing O
of O
the O
murine O
pre O
- O
mRNA O
according O
to O
a O
cassette O
model O
. O

During O
the O
1980 O
' O
s O
, O
quantifications RARE
of O
immunoserological RARE
testings RARE
, O
especially O
C I-GENE
reactive I-GENE
protein I-GENE
, O
rheumatoid I-GENE
factor I-GENE
and O
antistreptolysin RARE
O I-GENE
, O
progressed O
rapidly O
. O

Within O
the O
human O
enhancer O
, O
these O
two O
sites O
are O
located O
within O
the O
previously O
defined O
DNase I-GENE
I I-GENE
footprints RARE
, O
NFAT I-GENE
- I-GENE
1 I-GENE
and O
NFIL ALLCAPS
- I-GENE
2B I-GENE
, O
respectively O
. O

The O
cardiac I-GENE
myosin I-GENE
light I-GENE
chain I-GENE
- I-GENE
2 I-GENE
( O
MLC ALLCAPS
- I-GENE
2 I-GENE
) O
gene O
promoter O
contains O
several O
positive O
and O
negative O
cis O
- O
acting O
sequences O
that O
are O
involved O
in O
the O
regulation O
of O
its O
expression O
. O

Deletion O
mutagenesis O
demonstrated O
that O
these O
two O
elements O
are O
involved O
in O
the O
positive O
regulation O
of O
MLC ALLCAPS
- I-GENE
2 I-GENE
gene I-GENE
transcription O
. O

Disruption O
mutations O
have O
been O
constructed O
in O
the O
SLK1 NUMERIC
gene I-GENE
. O
slk1 NUMERIC
null I-GENE
mutants I-GENE
cannot O
grow O
at O
37 O
degrees O
C O
, O
but O
many O
cells O
can O
grow O
at O
30 O
, O
24 O
, O
and O
17 O
degrees O
C O
. O

Molecular O
and O
genetic O
analysis O
of O
the O
yeast I-GENE
early I-GENE
meiotic I-GENE
recombination I-GENE
genes I-GENE
REC102 NUMERIC
and O
REC107 NUMERIC
/ O
MER2 NUMERIC
. O

The O
p130 I-GENE
and O
p62 I-GENE
tyrosine O
- O
phosphorylated O
proteins O
that O
complexed O
v I-GENE
- I-GENE
Src I-GENE
SH2 I-GENE
in O
vitro O
also O
associated O
with O
v I-GENE
- I-GENE
Src I-GENE
in O
v I-GENE
- I-GENE
src I-GENE
- O
transformed O
Rat O
- O
2 O
cells O
; O
this O
in O
vivo O
binding O
was O
dependent O
on O
the O
v I-GENE
- I-GENE
Src I-GENE
SH2 I-GENE
domain O
. O

Probable RARE
progressive O
multifocal RARE
leukoencephalopathy RARE
( O
PML ALLCAPS
) O
was O
diagnosed O
on O
the O
basis O
of O
clinical O
picture O
and O
magnetic O
resonance O
imaging O
in O
a O
63 O
- O
year O
- O
old O
man O
with O
a O
complete O
remission O
of O
a O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

These O
data O
support O
a O
possible O
biological O
significance O
of O
the O
frameshift O
to O
occur O
at O
this O
position O
of O
the O
large O
overlap O
by O
including O
the O
putative O
RNA O
template O
- O
binding O
site O
of O
the O
PLRV ALLCAPS
replicase RARE
in O
the O
ORF2a NUMERIC
/ I-GENE
ORF2b NUMERIC
transframe RARE
protein I-GENE
. O

Proprotein RARE
processing O
occurs O
intracellularly RARE
. O

A O
32P O
- O
labeled O
LAP ALLCAPS
DNA O
- O
binding O
and O
dimerization O
domain O
" O
zipper O
probe O
" O
was O
used O
to O
isolate O
a O
clone O
that O
encodes O
a O
new O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
homologous I-GENE
protein I-GENE
: O
CHOP I-GENE
- I-GENE
10 I-GENE
. O

Using O
a O
degenerate O
oligodeoxyribonucleotide RARE
( O
oligo RARE
) O
based O
on O
the O
N O
- O
terminal O
aa O
sequence O
, O
plus O
an O
internal O
oligo RARE
homologous O
to O
a O
conserved O
region O
within O
the O
portion O
of O
CYP1 NUMERIC
and O
CYP2 NUMERIC
that O
had O
been O
deleted O
in O
the O
genome O
, O
a O
CYP3 NUMERIC
- I-GENE
specific I-GENE
DNA I-GENE
fragment I-GENE
was O
generated O
by O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
using O
GL81 NUMERIC
genomic O
DNA O
as O
a O
substrate O
. O

Stringent RARE
hybridization O
of O
EHS ALLCAPS
- I-GENE
1 I-GENE
back O
to O
primate O
genomic O
DNA O
indicates O
two O
distinct O
EHS ALLCAPS
- I-GENE
1 I-GENE
loci I-GENE
in O
normal O
human O
DNA O
, O
an O
identical O
band O
pattern O
in O
chimpanzee RARE
DNA O
, O
and O
a O
single O
locus O
in O
rhesus O
monkey O
DNA O
. O

The O
level O
of O
carboxyl I-GENE
- I-GENE
terminal I-GENE
parathyroid I-GENE
hormone I-GENE
in O
the O
patients O
with O
thyroid O
carcinoma O
was O
higher O
than O
that O
in O
the O
patients O
without O
thyroid O
carcinoma O
( O
P O
less O
than O
0 O
. O
05 O
). O

The O
Caenorhabditis I-GENE
elegans I-GENE
vitellogenin RARE
genes I-GENE
are O
subject O
to O
sex O
-, O
stage O
-, O
and O
tissue O
- O
specific O
regulation O
: O
they O
are O
expressed O
solely O
in O
the O
adult O
hermaphrodite RARE
intestine O
. O

The O
MET4 NUMERIC
gene O
was O
cloned O
, O
and O
its O
sequence O
reveals O
that O
it O
encodes O
a O
protein O
related O
to O
the O
family O
of O
the O
bZIP I-GENE
transcriptional I-GENE
activators I-GENE
. O

The O
functions O
of O
isolated O
portions O
of O
the O
insulin I-GENE
, O
IAPP ALLCAPS
, O
and O
beta I-GENE
GK ALLCAPS
promoters I-GENE
were O
studied O
by O
using O
transient O
expression O
and O
DNA O
binding O
assays O
. O

It O
is O
believed O
that O
these O
domains O
are O
important O
for O
directing RARE
specific O
protein O
- O
protein O
interactions O
necessary O
for O
the O
proper O
functioning O
of O
Src I-GENE
. O

The O
c I-GENE
- I-GENE
Ets I-GENE
- I-GENE
1 I-GENE
oncoprotein I-GENE
is O
a O
transcription O
activator O
that O
specifically O
binds O
to O
DNA O
. O

Previous O
transactivation O
experiments O
indicated O
that O
three O
amino O
acids O
residing RARE
in O
this O
region O
, O
Gly O
, O
Ser O
and O
Val O
, O
appear O
to O
be O
critical O
for O
target O
- O
site O
discrimination O
. O

GR63178A NUMERIC
is O
a O
water O
- O
soluble O
analogue O
of O
mitoquidone RARE
, O
a O
pentacyclic RARE
pyrroloquinone RARE
. O

Marker RARE
rescue O
analysis O
has O
localized O
ts8 NUMERIC
to O
a O
910 NUMERIC
- O
bp O
internal O
segment O
of O
rpoB LASTCAP
that O
encodes O
the O
Rif RARE
domain I-GENE
. O

This O
vector O
transfected O
into O
the O
yeast O
Saccharomyces O
cerevisiae O
directs O
expression O
of O
a O
secreted O
mature O
protein O
at O
levels O
up O
to O
200 O
mg O
of O
LAPP ALLCAPS
/ O
liter O
of O
culture O
medium O
. O

Competition O
analysis O
by O
gel O
mobility O
shift O
electrophoresis O
indicates O
that O
this O
DNA O
- O
protein O
interaction O
is O
novel O
and O
not O
related O
to O
many O
transcription O
factors O
previously O
reported O
. O

This O
DNA O
motif O
represents O
a O
novel O
protein O
- O
binding O
sequence O
. O

OBJECTIVE O
: O
The O
study O
was O
designed O
to O
investigate O
the O
frequency O
of O
alterations O
in O
serum O
creatinine O
in O
patients O
with O
psoriasis O
receiving O
5 O
mg O
/ O
kg O
/ O
day O
of O
cyclosporine O
. O

Intrapocket RARE
chemotherapy O
in O
adult O
periodontitis RARE
using O
a O
new O
controlled O
- O
release O
insert O
containing O
ofloxacin RARE
( O
PT O
- O
01 O
). O

Electromagnetic RARE
blood O
flow O
( O
BF O
) O
probe O
was O
applied O
on O
the O
left O
anterior O
descending RARE
artery O
( O
LAD O
). O

Hence O
temperature O
and O
virF LASTCAP
are O
both O
required O
for O
the O
induction O
of O
the O
yop RARE
regulon RARE
. O

Problems RARE
remain RARE
to O
be O
resolved O
in O
the O
area O
of O
quantitative O
risk O
assessment O
. O

The O
recently O
developed O
gamma I-GENE
- I-GENE
interferon I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
assay O
system O
for O
the O
diagnosis O
of O
bovine O
tuberculosis O
in O
cattle O
has O
been O
accredited RARE
by O
the O
Standing RARE
Committee O
on O
Agriculture RARE
for O
use O
in O
Australia RARE
. O

Control O
Tmuscle RARE
was O
35 O
. O
8 O
+/- O
0 O
. O
7 O
degrees O
C O
, O
with O
control O
Wi RARE
, O
max O
being O
51 O
. O
6 O
( O
SD O
8 O
. O
7 O
) O
W O
. O
kg O
- O
1 O
. O

The O
Klebsiella I-GENE
aerogenes RARE
gene I-GENE
maoA LASTCAP
, O
which O
is O
involved O
in O
the O
synthesis O
of O
monoamine I-GENE
oxidase I-GENE
, O
was O
induced O
by O
tyramine RARE
and O
the O
related O
compounds O
, O
subjected O
to O
catabolite O
and O
ammonium RARE
ion O
repression O
, O
and O
cloned O
. O

However O
, O
other O
regions O
of O
the O
plasmid O
are O
also O
efficiently O
repaired RARE
. O

Eight O
of O
14 O
infectious O
or O
inflammatory O
lesions O
could O
be O
detected O
in O
the O
early O
scan O
( O
4 O
- O
6 O
h O
p O
. O
i O
.). O

Thus O
, O
the O
human I-GENE
D1A NUMERIC
gene I-GENE
belongs O
to O
the O
category O
of O
tissue O
- O
specific O
, O
regulated O
genes O
that O
have O
housekeeping O
- O
type O
promoters O
. O

Similar O
observations O
have O
been O
made O
previously O
for O
other O
genes O
. O

Preceptorship RARE
of O
CNS O
students O
: O
an O
exploratory RARE
study O
. O

To O
determine O
the O
genetic O
basis O
for O
the O
differences O
between O
the O
cardiac O
and O
brain I-GENE
AE3 NUMERIC
variants I-GENE
, O
we O
isolated O
and O
characterized O
the O
rat O
gene O
. O

The O
1 O
. O
7 O
kb O
cloned O
fragment O
was O
sequenced O
and O
shown O
to O
contain O
the O
entire O
fliA LASTCAP
gene I-GENE
. O

Institution RARE
of O
both O
intravenous O
and O
intracisternal RARE
administration O
of O
amphotericin O
B O
and O
possibly O
concomitant O
intravenous O
administration O
of O
dexamethasone O
may O
be O
warranted O
in O
situations O
in O
which O
the O
association O
of O
C O
. O
immitis RARE
with O
CNS O
vasculitis O
or O
encephalitis RARE
appears O
likely O
before O
serologic O
or O
cultural RARE
confirmation RARE
of O
C O
. O
immitis RARE
infection O
involving O
the O
CNS O
is O
available O
. O

Lac RARE
operators RARE
were O
introduced O
into O
several O
positions O
within O
the O
CAB ALLCAPS
promoter I-GENE
and O
operator O
- O
free O
plasmid O
was O
used O
as O
control O
. O

Overproduction RARE
, O
purification O
and O
characterization O
of O
M I-GENE
. I-GENE
HinfI LASTCAP
methyltransferase I-GENE
and O
its O
deletion O
mutant O
. O

Various O
companies RARE
produce O
this O
type O
of O
lens O
. O

From O
March RARE
5 O
through O
October RARE
26 O
, O
1991 O
, O
eight O
persons O
were O
diagnosed O
with O
elevated O
blood O
lead O
levels O
( O
BLLs RARE
) O
at O
a O
local O
hospital O
and O
were O
reported O
to O
the O
notifiable RARE
disease O
surveillance RARE
system O
maintained O
by O
the O
Alabama RARE
Department RARE
of O
Public RARE
Health O
( O
ADPH ALLCAPS
). O

According O
to O
the O
changes O
of O
perfusion O
defects O
between O
Ex RARE
, O
RD O
and O
ReI LASTCAP
images O
, O
they O
were O
classified O
into O
3 O
types O
: O
Type O
I O
; O
perfusion O
defect O
on O
the O
RD O
image O
was O
identical O
to O
ReI LASTCAP
image O
( O
75 O
%) O
Type O
I O
was O
divided O
into O
2 O
subgroups O
whether O
perfusion O
defect O
at O
Ex RARE
was O
unchanged O
( O
Ia RARE
, O
42 O
%) O
or O
improved O
( O
Ib RARE
, O
33 O
%) O
on O
the O
RD O
image O
. O

Keck RARE
, O
C O
. O
J O
. O

Twenty O
- O
eight O
( O
7 O
. O
0 O
%) O
infants O
without O
periventricular RARE
hemorrhage O
were O
revealed O
as O
having O
spastic RARE
cerebral O
palsy RARE
by O
neurodevelopmental RARE
evaluation O
in O
later O
infancy RARE
. O

A O
possible O
mechanism O
is O
that O
elevated O
alveolar O
pressure O
and O
decreased O
cardiac O
output O
eliminate RARE
blood O
flow O
from O
corner RARE
vessels O
in O
nondependent RARE
high O
VA O
/ O
Q O
regions O
. O

Computer RARE
- O
aided RARE
" O
FRAME ALLCAPS
" O
analysis O
revealed O
four O
possible O
open O
reading O
frames O
( O
ORFs O
), O
three O
in O
one O
direction O
and O
one O
in O
the O
opposite O
direction O
. O

Domain RARE
II O
is O
highly O
homologous O
to O
the O
LDL I-GENE
receptor I-GENE
and O
contains O
four O
repeats O
with O
perfect O
conservation O
of O
all O
6 O
consecutive O
cysteines RARE
. O

In O
both O
cities RARE
, O
HTLV O
- O
I O
/ O
II O
prevalence O
increased O
significantly O
with O
age O
, O
and O
the O
New O
Orleans RARE
age O
- O
and O
sex O
- O
adjusted O
HTLV O
- O
I O
/ O
II O
prevalence O
was O
significantly O
higher O
than O
that O
of O
Baltimore RARE
( O
P O
less O
than O
. O
001 O
). O

Here O
, O
we O
present O
evidence O
for O
a O
model O
in O
which O
mRNA O
sequences O
up O
to O
around O
100 O
nucleotides O
downstream O
from O
the O
start O
codon O
of O
21K NUMERIC
fold O
back O
and O
base O
- O
pair O
to O
the O
21K NUMERIC
translation O
initiation O
region O
, O
thereby O
decreasing O
the O
translation O
initiation O
frequency O
. O

Hybridization O
data O
indicate O
that O
6F6 NUMERIC
. I-GENE
2 I-GENE
corresponds O
to O
the O
previously O
characterized O
m6F6 NUMERIC
cDNA I-GENE
clone I-GENE
and O
that O
6F6 NUMERIC
. I-GENE
1 I-GENE
and O
6F6 NUMERIC
. I-GENE
3 I-GENE
, O
but O
not O
6F6 NUMERIC
. I-GENE
2 I-GENE
, O
are O
adjacent O
to O
alpha I-GENE
- I-GENE
type I-GENE
genes I-GENE
. O

The O
SEN1 NUMERIC
gene I-GENE
corresponds O
to O
a O
6 O
, O
336 NUMERIC
- O
bp O
open O
reading O
frame O
coding O
for O
a O
2 O
, O
112 O
- O
amino O
- O
acid O
protein O
( O
molecular O
mass O
, O
239 O
kDa O
). O

Protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
PTKs RARE
) O
are O
implicated O
in O
the O
control O
of O
cell O
growth O
by O
virtue RARE
of O
their O
frequent O
appearance O
as O
products O
of O
retroviral O
oncogenes O
, O
as O
intracellular O
signal O
transducers RARE
, O
and O
as O
growth I-GENE
factor I-GENE
receptors I-GENE
or O
components O
thereof RARE
. O

The O
IA4 NUMERIC
mAb I-GENE
was O
identified O
among O
a O
series O
of O
antibodies O
raised O
in O
BALB O
/ O
c O
mice O
after O
immunization O
against O
a O
HLA I-GENE
class O
I O
- O
deficient O
, O
lymphokine RARE
- O
activated O
killer O
( O
LAK ALLCAPS
)- O
susceptible O
EBV O
- O
B O
lymphocyte O
line O
. O

In O
a O
randomized O
double O
- O
blind O
cross O
- O
over O
study O
, O
the O
subjects O
received O
theophylline O
5 O
mg O
. O
kg O
- O
1 O
per O
day O
with O
omeprazole O
20 O
mg O
per O
day O
or O
identical O
placebo O
during O
two O
periods O
, O
each O
of O
7 O
days O
, O
separated O
by O
a O
washout O
period O
of O
7 O
days O
. O

Primer O
extension O
and O
mung RARE
bean I-GENE
and I-GENE
S1 I-GENE
nuclease I-GENE
mapping O
indicated O
multiple O
transcription O
initiation O
sites O
and O
were O
consistent O
with O
Northern O
analyses O
. O

Two O
variant O
PRP ALLCAPS
- I-GENE
precursor I-GENE
alleles I-GENE
occur O
which O
slightly O
differ O
in O
the O
number O
of O
repeats O
in O
domain O
C O
. O

Unlike O
the O
typical O
enhancer O
element O
, O
this O
region O
functions O
in O
an O
orientation O
- O
dependent O
manner O
. O

In O
the O
last O
20 O
years O
, O
the O
therapeutic O
uses O
of O
botulinum I-GENE
toxin I-GENE
, O
a O
potent O
neurotoxin RARE
, O
have O
been O
investigated O
. O

Allagille RARE
' O
s O
syndrome O
associated O
with O
antenatal RARE
ascites RARE

Sensitivity RARE
and O
specificity O
was O
established O
for O
the O
Pharmacia O
CAP O
System RARE
and O
the O
DPC ALLCAPS
AlaSTAT LASTCAP
System RARE
by O
comparison O
with O
results O
of O
the O
skin O
prick RARE
test O
. O

PSI I-GENE
- I-GENE
G I-GENE
and O
PSI I-GENE
- I-GENE
K I-GENE
probably O
have O
evolved O
from O
a O
gene O
duplication O
of O
an O
ancestral O
gene O
. O

At O
the O
C O
- O
terminus O
of O
the O
protein O
is O
a O
domain O
that O
contains O
sequences O
very O
similar O
to O
those O
found O
in O
the O
breakpoint O
cluster O
region O
gene O
product O
, O
n I-GENE
- I-GENE
chimerin RARE
, O
and O
rho I-GENE
GAP I-GENE
, O
all O
of O
which O
have O
been O
shown O
to O
possess O
intrinsic O
GAP I-GENE
activity O
on O
small I-GENE
GTPases I-GENE
. O

Site O
- O
directed O
mutagenesis O
revealed O
that O
two O
clusters O
of O
basic O
amino O
acids O
within O
a O
conserved O
basic O
region O
and O
two O
amphipathic RARE
helices O
within O
the O
adjacent O
HLH ALLCAPS
domain O
are O
essential O
for O
sequence O
- O
specific O
DNA O
binding O
and O
hetero RARE
- O
oligomerization O
, O
respectively O
. O

Dimerization RARE
of O
Myf RARE
- I-GENE
5 I-GENE
with O
the O
ubiquitously O
expressed O
bHLH O
protein O
E12 I-GENE
not O
only O
increases O
the O
affinity O
for O
DNA O
but O
also O
stimulates O
transactivation O
independently O
of O
DNA O
binding O
. O

The O
circadian O
rhythmicity RARE
of O
sleep O
was O
pronounced O
. O

SEA ALLCAPS
was O
recorded O
with O
bidirectional RARE
filters RARE
at O
25 O
- O
250 O
HZ ALLCAPS
and O
40 O
- O
250 O
Hz O
using O
Simson RARE
method O
. O

Neural RARE
- O
specific O
expression O
, O
genomic O
structure O
, O
and O
chromosomal O
localization O
of O
the O
gene O
encoding O
the O
zinc I-GENE
- I-GENE
finger I-GENE
transcription I-GENE
factor I-GENE
NGFI ALLCAPS
- I-GENE
C I-GENE
. O

An O
experiment O
examined O
the O
effects O
of O
treatment O
with O
gonadotrophin RARE
releasing I-GENE
hormone I-GENE
( O
100 O
micrograms O
GnRH I-GENE
injected O
24 O
h O
after O
progestagen RARE
sponge RARE
removal O
), O
season O
of O
treatment O
( O
autumn RARE
v O
. O
spring RARE
), O
the O
effect O
of O
supplementary O
feeding O
with O
lupin RARE
grain RARE
( O
in O
autumn RARE
only O
, O
from O
12 O
days O
before O
until O
8 O
days O
after O
sponge RARE
removal O
) O
on O
the O
time O
of O
ovulation O
in O
182 O
mature O
Merino RARE
ewes RARE
superovulated RARE
with O
a O
combination O
of O
400 O
I O
. O
U O
. O
pregnant I-GENE
mare RARE
serum I-GENE
gonadotrophin RARE
( O
PMSG ALLCAPS
) O
and O
12 O
mg O
follicle I-GENE
stimulating I-GENE
hormone I-GENE
( O
FSH I-GENE
- I-GENE
P I-GENE
). O

Drug O
- O
drug O
interactions O
are O
most O
likely O
to O
occur O
in O
patients O
receiving O
multiple O
medications RARE
and O
with O
drugs O
that O
have O
a O
narrow O
therapeutic O
window RARE
. O

The O
sequence O
data O
now O
permit O
a O
detailed O
interpretation O
of O
the O
X O
- O
ray O
crystallographic RARE
structure O
of O
the O
enzyme O
and O
the O
cloning O
and O
expression O
of O
the O
clostridial RARE
gene O
will O
facilitate O
site O
- O
directed O
mutagenesis O
. O

Total O
body O
irradiation O
was O
delivered O
according O
to O
a O
hyperfractionated RARE
scheme RARE
of O
12 O
fractions O
given O
three O
per O
day O
5 O
hr O
apart O
for O
4 O
days O
. O

A O
reduction O
in O
blood O
pressure O
was O
only O
observed O
at O
the O
end O
of O
the O
study O
, O
from O
142 O
+/- O
17 O
/ O
86 O
. O
6 O
+/- O
9 O
. O
1 O
to O
139 O
+/- O
13 O
/ O
82 O
. O
9 O
+/- O
8 O
. O
9 O
mmHg O
( O
P O
less O
than O
0 O
. O
05 O
for O
DBP O
). O

AgMNPV LASTCAP
and O
Orgyia RARE
pseudotsugata RARE
MNPV ALLCAPS
( O
OpMNPV LASTCAP
) O
are O
similar O
in O
terms O
of O
promoter O
structure O
and O
polyhedrin RARE
primary I-GENE
sequence I-GENE
, O
and O
the O
polyhedrin RARE
gene I-GENE
of O
both O
viruses O
is O
transcribed O
in O
the O
anti O
- O
clockwise RARE
direction O
in O
relation O
to O
their O
physical O
maps O
. O

A O
gene O
homologous O
to O
the O
Escherichia I-GENE
coli I-GENE
dnaA LASTCAP
gene I-GENE
was O
isolated O
from O
Pseudomonas O
putida O
and O
its O
transcription O
was O
investigated O
in O
E O
. O
coli O
as O
well O
as O
in O
P O
. O
putida O
. O

STP1 NUMERIC
is O
an O
unessential RARE
yeast O
gene O
involved O
in O
the O
removal O
of O
intervening O
sequences O
from O
some O
, O
but O
not O
all O
, O
families O
of O
intervening O
sequence O
- O
containing O
pre O
- O
tRNAs RARE
. O

Using O
these O
antibodies O
, O
we O
were O
able O
to O
define O
the O
conditions O
to O
completely O
solubilize RARE
the O
Cdc25 NUMERIC
protein I-GENE
. O

GCR1 NUMERIC
gene I-GENE
function O
is O
required O
for O
high O
- O
level O
glycolytic RARE
gene O
expression O
in O
Saccharomyces O
cerevisiae O
. O

The O
decay O
curves O
of O
chlorophyll RARE
fluorescence O
showed O
a O
superposition RARE
of O
three O
exponentially RARE
decaying RARE
components O
with O
time O
constants O
of O
T1 O
= O
100 O
- O
200 O
ps O
, O
T2 O
= O
300 O
- O
500 O
ps O
and O
T3 O
= O
2 O
. O
0 O
- O
3 O
. O
5 O
ns RARE
. O

After O
tilting RARE
, O
systolic O
blood O
pressure O
fell O
an O
average O
of O
17 O
% O
in O
patients O
who O
cramped RARE
infrequently RARE
( O
p O
= O
0 O
. O
0031 NUMERIC
) O
but O
only O
10 O
% O
in O
frequently O
cramping RARE
patients O
. O

These O
results O
are O
consistent O
with O
the O
roles O
that O
CCK ALLCAPS
and O
trypsin I-GENE
inhibitors O
are O
believed O
to O
play O
in O
the O
negative O
feedback RARE
control O
of O
pancreatic O
exocrine RARE
function O
. O

Most O
apneic RARE
events O
occurred O
during O
Stages RARE
I O
and O
II O
, O
and O
REM O
, O
but O
this O
proportion O
was O
less O
during O
the O
gamma O
OH O
study O
( O
77 O
. O
9 O
+/- O
8 O
. O
9 O
%) O
than O
during O
the O
control O
studies O
( O
92 O
. O
3 O
+/- O
1 O
. O
9 O
and O
95 O
. O
9 O
+/- O
2 O
. O
2 O
%), O
apneas RARE
occurring O
even O
during O
SWS ALLCAPS
with O
gamma O
OH O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Eight O
rabbits O
were O
exposed O
to O
0 O
. O
7 O
+/- O
0 O
. O
4 O
mg O
/ O
m3 O
Co2 NUMERIC
+ O
as O
CoCl2 NUMERIC
and O
1 O
. O
2 O
+/- O
0 O
. O
7 O
mg O
/ O
m3 O
Cr3 NUMERIC
+ O
as O
Cr O
( O
NO3 NUMERIC
) O
3 O
( O
group O
Co O
+ O
Cr O
), O
eight O
to O
0 O
. O
6 O
+/- O
0 O
. O
5 O
mg O
/ O
m3 O
Co2 NUMERIC
+ O
( O
group O
Co O
), O
and O
eight O
to O
filtered RARE
air O
( O
control O
group O
), O
for O
4 O
months O
, O
5 O
days O
/ O
week O
, O
and O
6 O
hr O
/ O
day O
. O

16 O
women O
were O
treated O
with O
methadone RARE
to O
prevent O
withdrawal O
symptoms O
. O

Disruption O
demonstrates O
that O
CDC14 NUMERIC
is O
an O
essential O
gene O
. O

Coronary O
flow O
was O
reduced O
by O
10 O
% O
in O
the O
phosphocreatine RARE
and O
by O
18 O
% O
in O
the O
control O
group O
. O

The O
60A NUMERIC
transcripts I-GENE
and O
protein O
are O
first O
detected O
at O
the O
onset O
of O
gastrulation RARE
, O
primarily O
in O
the O
mesoderm O
of O
the O
extending O
germ O
band O
. O

A O
724 NUMERIC
- O
bp O
segment O
of O
the O
5 O
'- O
flanking O
region O
consisting O
of O
the O
proximal O
E O
- O
box O
flanked O
upstream O
by O
a O
mammalian O
- O
specific O
352 NUMERIC
- O
bp O
region O
was O
sufficient O
for O
maximal O
transcriptional O
activation O
in O
postconfluent RARE
BC3H1 NUMERIC
myoblasts O
. O

These O
results O
indicate O
that O
baculovirus O
- O
expressed O
TR I-GENE
mediates O
transcriptional O
activation O
and O
repression O
in O
a O
promoter O
- O
specific O
manner O
in O
vitro O
. O

Influence O
of O
neural O
regulation O
on O
anti O
- O
arrhythmic RARE
effects O
of O
GABA O
in O
rats O

Recent O
investigations O
have O
detailed O
a O
selective O
dye O
release O
technique O
in O
which O
a O
pulse O
of O
laser O
light O
induces O
the O
release O
of O
a O
fluorescent O
dye O
from O
temperature O
- O
sensitive O
liposomes O
circulating O
in O
the O
retinal O
vasculature RARE
. O

And RARE
the O
natural O
barriers RARE
? O

Three O
pyridoxine RARE
derivatives O
have O
been O
isolated O
from O
the O
fresh O
stem O
bark RARE
of O
Albizzia RARE
julibrissin RARE
DURAZZ ALLCAPS
.. RARE

The O
serum O
erythropoietin I-GENE
( O
EPO I-GENE
) O
concentrations O
of O
15 O
male O
triathletes RARE
( O
26 O
. O
3 O
U O
. O
ml O
- O
1 O
) O
were O
significantly O
lower O
than O
those O
of O
45 O
male O
distance O
runners RARE
( O
31 O
. O
6 O
U O
. O
ml O
- O
1 O
; O
P O
less O
than O
0 O
. O
05 O
). O

The O
coating RARE
materials O
were O
poloxamine RARE
904 NUMERIC
, O
poloxamine RARE
908 NUMERIC
, O
poloxamine RARE
1508 NUMERIC
, O
poloxamer RARE
338 NUMERIC
, O
and O
Brij RARE
35 O
. O

The O
eating RARE
and O
drinking O
patterns O
of O
pygmy RARE
goats O
fed O
ad RARE
lib RARE
and O
kept O
on O
a O
12 O
h O
light O
/ O
12 O
h O
dark O
cycle O
were O
recorded O
and O
analyzed O
. O

The O
present O
study O
highlights RARE
the O
improvement O
in O
sputum O
amoxycillin RARE
( O
amoxy RARE
) O
levels O
when O
a O
combination O
tablet O
, O
amoxy RARE
500 O
mg O
plus O
bromhexeine RARE
8 O
mg O
, O
is O
administered O
as O
compared O
to O
plain RARE
amoxy RARE
500 O
mg O
. O

His O
HC ALLCAPS
II I-GENE
activity O
and O
antigen O
levels O
were O
49 O
% O
and O
50 O
%, O
respectively O
, O
and O
his O
daughter O
also O
showed O
similar O
low O
levels O
. O

Argatroban RARE
may O
be O
more O
effective O
under O
low O
HC ALLCAPS
II I-GENE
conditions O
because O
of O
its O
potent O
inhibition O
of O
thrombin I-GENE
activity O
at O
sites O
of O
vascular O
wall O
damage O
. O

These O
results O
support O
the O
diagnostic O
validity O
of O
NFPD ALLCAPS
in O
CP O
/ O
NCA ALLCAPS
patients O
, O
because O
such O
patients O
had O
a O
family O
history O
of O
panic RARE
disorder O
similar O
to O
patients O
with O
a O
more O
classical O
panic RARE
disorder O
presentation O
. O

FDA ALLCAPS
regulations RARE
for O
growth O
factors O
and O
related O
products O
. O

Because O
the O
adrenergic O
nervous O
system O
influences O
cardiac O
arrhythmias O
and O
myocardial O
infarction O
can O
directly O
affect O
sympathetic O
innervation RARE
in O
the O
heart O
, O
we O
investigated O
the O
role O
of O
the O
sympathetic O
nervous O
system O
on O
reentry RARE
in O
the O
canine O
heart O
4 O
days O
after O
infarction O
. O

DESIGN O
: O
Serum O
aldosterone O
and O
plasma I-GENE
renin I-GENE
activity O
were O
measured O
supine O
prior O
to O
and O
60 O
, O
90 O
, O
120 O
minutes O
after O
oral O
captopril O
, O
25 O
mg O
. O

Furthermore O
, O
no O
transcripts O
of O
the O
same O
size O
and O
having O
the O
same O
developmental O
profile O
as O
those O
generated O
by O
the O
wild I-GENE
- I-GENE
type I-GENE
E10 NUMERIC
fragment I-GENE
were O
identified O
by O
probes O
covering O
the O
remainder RARE
of O
the O
cloned O
region O
. O

Intravenous O
amine O
pressor O
tests O
in O
healthy O
volunteers O
. O

The O
mean O
minimum O
steady O
- O
state O
concentration O
after O
the O
oral O
regimen O
( O
23 O
micrograms O
. O
l O
- O
1 O
) O
was O
78 O
% O
of O
that O
after O
the O
intramuscular RARE
regime RARE
( O
29 O
micrograms O
. O
l O
- O
1 O
). O

In O
an O
ongoing RARE
study O
the O
performance O
of O
the O
SMSP ALLCAPS
is O
being O
compared O
with O
that O
of O
the O
Mini RARE
Speech RARE
Processor RARE
( O
MSP ALLCAPS
). O

Both O
parents O
are O
clinically O
normal O
and O
unrelated O
. O

These O
mutant O
proteins O
retained O
the O
ability O
to O
competitively RARE
inhibit O
kappa I-GENE
B I-GENE
- O
mediated O
transcriptional O
activation O
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
but O
failed O
to O
efficiently O
transform O
chicken O
lymphoid O
cells O
both O
in O
vitro O
and O
in O
vivo O
. O

The O
sequence O
- O
specific O
interaction O
of O
nuclear I-GENE
factor I-GENE
HiNF LASTCAP
- I-GENE
D I-GENE
with O
this O
key O
proximal O
promoter O
element O
of O
the O
H4 I-GENE
- I-GENE
FO108 NUMERIC
gene I-GENE
is O
cell O
cycle O
regulated O
in O
normal O
diploid O
cells O
( O
J O
. O

In O
conclusion O
, O
to O
study O
and O
overcome O
TI ALLCAPS
region O
- O
based O
expression O
problems O
it O
is O
worthwhile RARE
to O
start O
out O
with O
a O
versatile RARE
vector O
containing O
exhaustive RARE
mutations O
in O
the O
periShine RARE
- O
Dalgarno RARE
sequences O
; O
as O
a O
rule RARE
the O
coding O
MTI ALLCAPS
subregion RARE
can O
be O
kept O
unchanged O
. O

Four O
of O
these O
five O
subjects O
also O
performed O
mixed O
sequences O
under O
conditional O
control O
of O
the O
words RARE
( O
e O
. O
g O
., O
A1 O
---- O
B2 O
---- O
A3 O
---- O
B4 NUMERIC
---- O
A5 NUMERIC
and O
its O
reversal O
), O
verifying RARE
that O
the O
stimuli O
which O
occupied O
the O
same O
position O
in O
each O
sequence O
were O
members O
of O
the O
same O
class O
. O

UF ALLCAPS
- O
021 NUMERIC
ophthalmic O
solution O
( O
0 O
. O
03 O
to O
0 O
. O
24 O
%), O
when O
topically RARE
applied O
to O
the O
eyes O
of O
rabbits O
, O
caused O
dose O
- O
dependent O
IOP O
reduction O
( O
2 O
. O
8 O
to O
5 O
. O
2 O
mmHg O
), O
without O
transient O
IOP O
rise O
. O

While O
blood O
pressure O
and O
noradrenergic O
activity O
, O
assessed O
as O
changes O
in O
the O
plasma O
levels O
and O
urinary O
excretion O
of O
norepinephrine O
, O
remained O
unaffected O
in O
the O
Pl RARE
group O
, O
a O
significant O
drop O
in O
the O
supine O
systolic O
and O
diastolic O
blood O
pressures O
, O
as O
well O
as O
in O
the O
resting O
venous O
norepinephrine O
level O
and O
in O
urinary O
norepinephrine O
excretion O
was O
found O
after O
the O
first O
month O
of O
dF LASTCAP
administration O
. O

Wild O
- O
type O
protein O
bound O
azido RARE
- O
ATP O
well O
, O
but O
mutants O
with O
substitutions O
in O
the O
consensus O
amino O
acids O
were O
unable O
to O
bind O
azido RARE
- O
ATP O
. O

Therefore O
, O
with O
a O
biopsy O
from O
the O
stoma RARE
site O
there O
is O
a O
risk O
of O
missing O
early O
rejection O
. O

Whole RARE
blood O
serotonin O
levels O
were O
investigated O
in O
a O
control O
group O
( O
n O
= O
35 O
) O
and O
in O
a O
group O
of O
chronic O
renal O
failure O
patients O
( O
n O
= O
127 NUMERIC
) O
on O
various O
treatment O
regimen O
i O
. O
e O
. O
conservative O
treatment O
( O
n O
= O
39 O
), O
maintenance O
haemodialysis O
( O
n O
= O
35 O
) O
and O
after O
renal O
transplantation O
( O
n O
= O
53 O
). O

Tissues RARE
and O
exudates RARE
contain O
sufficient O
thymidine O
for O
growth O
of O
anaerobic O
bacteria O
in O
the O
presence O
of O
inhibitory O
levels O
of O
trimethoprim RARE
- O
sulfamethoxazole RARE
. O

The O
homologies O
between O
RAD16 NUMERIC
, O
RAD54 NUMERIC
and O
SNF2 NUMERIC
are O
also O
shared O
by O
several O
additional O
, O
recently O
isolated O
yeast O
and O
Drosophila O
genes O
. O

But RARE
the O
application O
solutions O
of O
instrument O
disinfectants RARE
should O
not O
be O
used O
longer O
than O
one O
day O
. O

In O
the O
Rett RARE
syndrome O
we O
, O
therefore O
, O
suspect RARE
there O
are O
disturbances O
in O
the O
brain O
stem O
functions O
especially O
in O
the O
ascending O
reticular RARE
activating O
system O
which O
is O
related O
to O
elevation O
of O
the O
conscious O
level O
. O

In O
a O
similar O
experiment O
, O
simultaneous O
nitrofurazone RARE
administration O
and O
S O
. O
enteritidis RARE
challenge O
resulted O
in O
no O
significant O
differences O
in O
S O
. O
enteritidis RARE
isolation O
frequency O
. O

In O
agreement O
with O
this O
southern O
blotting O
of O
mouse O
DNA O
with O
SmN LASTCAP
probes O
reveals O
bands O
, O
additional O
to O
those O
derived O
from O
the O
pseudogene O
, O
which O
are O
characteristic O
of O
an O
intron O
- O
containing O
SmN LASTCAP
gene I-GENE
. O

Two O
cDNAs O
encoding O
casein I-GENE
kinase I-GENE
- I-GENE
1 I-GENE
have O
been O
isolated O
from O
a O
yeast O
cDNA O
library O
and O
termed O
CKI1 NUMERIC
and O
CKI2 NUMERIC
. O

Incidence RARE
rate O
ranging O
between O
122 O
/ O
100 O
, O
000 O
/ O
year O
and O
190 O
/ O
100 O
, O
000 O
/ O
year O
were O
found O
( O
minimum O
, O
estimated O
and O
raw RARE
datasets RARE
). O

The O
observed O
sequence O
variation O
disrupts RARE
the O
first O
ORF O
in O
many O
Y I-GENE
' O
s O
while O
most O
of O
the O
second O
ORF O
including O
the O
putative O
helicase I-GENE
region I-GENE
is O
unaffected O
. O

The O
final O
screening O
yielded O
a O
clone O
containing O
a O
2 O
kilobase O
( O
kb O
) O
insert O
. O

Lesions RARE
were O
made O
by O
pressure O
injection O
of O
kainic RARE
acid O
into O
the O
SOC ALLCAPS
through O
a O
stereotaxically RARE
positioned O
glass O
micropipette RARE
. O

A O
38 O
- O
bp O
poly O
( O
dA LASTCAP
- O
dT O
) O
region O
was O
found O
to O
be O
a O
positive O
regulator O
of O
Act1 NUMERIC
promoter I-GENE
activity O
. O

We O
identified O
a O
protein O
, O
termed O
NFIL ALLCAPS
- I-GENE
1 I-GENE
beta I-GENE
A I-GENE
( O
NF I-GENE
beta I-GENE
A I-GENE
), O
that O
binds O
to O
a O
highly O
conserved O
12 O
- O
bp O
DNA O
sequence O
(- O
49 O
to O
- O
38 O
) O
located O
upstream O
of O
the O
TATA O
box O
motif O
in O
both O
the O
human I-GENE
and I-GENE
murine I-GENE
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
genes I-GENE
. O

We O
tried RARE
amphotericin O
B O
( O
AmB LASTCAP
), O
and O
remission O
of O
the O
tumor O
was O
obtained O
. O

Cutis RARE
aplasia RARE
. O

The O
DRF ALLCAPS
- I-GENE
2 I-GENE
nuclear I-GENE
protein I-GENE
has O
characteristics O
similar O
to O
those O
of O
the O
muscle O
- O
specific O
regulatory O
factor O
, O
MEF I-GENE
- I-GENE
2 I-GENE
( O
Buskin RARE
and O
Hauschka RARE
1989 O
; O
Gossett RARE
et O
al O
., O
1989 O
). O

From O
the O
15 O
- O
kb O
clone O
a O
4 I-GENE
- I-GENE
kb I-GENE
EcoRI I-GENE
fragment I-GENE
containing O
the O
first O
two O
exons O
and O
2 O
. O
6 O
kb O
of O
the O
5 O
' O
flanking O
region O
of O
the O
opn RARE
gene I-GENE
was O
sequenced O
, O
and O
the O
transcriptional O
start O
site O
determined O
by O
primer O
extension O
analysis O
and O
S1 I-GENE
nuclease I-GENE
mapping O
. O

Cardiovascular RARE
risk O
factors O
were O
measured O
by O
standardized O
techniques O
. O

Production RARE
costs O
included O
feed O
, O
non O
- O
feed O
operating O
, O
fixed O
, O
and O
replacement O
stock RARE
costs O
. O

We O
report O
a O
patient O
developing O
factor I-GENE
VII I-GENE
inhibitor I-GENE
possibly O
as O
a O
reaction O
to O
penicillin O
administration O
; O
it O
gave O
rise O
to O
fatal O
haemorrhage RARE
. O

This O
is O
in O
contrast O
with O
the O
classical O
' O
oxygen O
debt RARE
hypothesis O
', O
which O
states O
that O
the O
oxygen O
debt RARE
and O
lactate O
clearance O
are O
linked O
. O

Account RARE
was O
taken O
of O
noncellular RARE
and O
nonhuman RARE
elements O
in O
the O
smears O
; O
they O
included O
mucus O
, O
Charcot RARE
- O
Layden RARE
crystals RARE
, O
pollen O
grains RARE
, O
vegetal RARE
fragments O
and O
fungi RARE
. O

The O
results O
indicate O
that O
the O
carbon O
- O
perfused O
areas O
and O
MBF ALLCAPS
in O
the O
liver O
, O
renal O
cortex O
, O
spleen O
, O
and O
small O
intestinal O
serosa RARE
( O
only O
MBF ALLCAPS
) O
increased O
significantly O
5 O
h O
after O
CLP ALLCAPS
. O

In O
addition O
a O
greater O
proportion O
of O
women O
in O
the O
sweeping RARE
group O
had O
a O
cervical O
dilatation O
of O
4 O
cm O
or O
more O
at O
the O
first O
vaginal O
examination O
in O
the O
labour O
ward RARE
( O
16 O
/ O
33 O
( O
49 O
%) O
vs O
5 O
/ O
32 O
( O
16 O
%); RARE
OR O
4 O
. O
39 O
; O
95 O
% O
CI O
1 O
. O
56 O
to O
12 O
. O
32 O
; O
P O
= O
0 O
. O
005 O
). O

Lewis RARE
, O
N O
. O

A O
control O
group O
of O
nine O
women O
( O
age O
23 O
- O
40 O
years O
) O
on O
oral O
contraceptives RARE
( O
Nordette RARE
- O
28 O
) O
was O
also O
studied O
four O
times O
during O
a O
pill RARE
cycle O
. O

This O
accurate O
and O
rapid O
method O
makes O
the O
MLPA ALLCAPS
test O
logistically RARE
feasible RARE
for O
large O
- O
scale O
screening O
. O

The O
modalities O
for O
using O
reference O
values O
for O
individual O
subjects O
as O
well O
as O
for O
groups O
are O
then O
discussed O
and O
the O
main O
points O
of O
research O
which O
must O
be O
faced RARE
in O
the O
near O
future O
regarding O
reference O
values O
are O
highlighted RARE
. O

The O
clinical O
application O
of O
the O
antibody O
- O
targeted O
Phthalocyanine RARE
was O
performed O
in O
3 O
patients O
suffering O
from O
an O
advanced O
ovarian O
carcinoma O
( O
FIGO ALLCAPS
III O
). O

We O
found O
that O
lung O
cancer O
tissues O
of O
positive O
67Ga NUMERIC
scan O
expressed O
TFR ALLCAPS
, O
but O
those O
of O
a O
negative O
scan O
did O
not O
. O

This O
open O
reading O
frame O
was O
confirmed O
the O
correct O
one O
by O
direct O
amino O
- O
terminal O
sequence O
analysis O
of O
the O
overproduced RARE
msgB LASTCAP
gene I-GENE
product I-GENE
. O

In O
this O
study O
, O
we O
purified O
and O
characterized O
the O
recombinant I-GENE
furin RARE
from O
the O
conditioned O
medium O
of O
these O
cells O
. O

The O
virus O
encodes O
a O
40 O
- O
kDa O
protein O
, O
tax RARE
, O
that O
is O
important O
for O
the O
immortalization RARE
of O
T O
cells O
. O

However O
, O
butyrate RARE
was O
at O
least O
2 O
- O
fold O
more O
effective O
in O
stimulating O
CAT I-GENE
activity O
of O
fusion O
genes O
containing O
upstream O
sequences O
(- O
834 NUMERIC
to O
- O
576 NUMERIC
) O
than O
those O
containing O
proximal O
sequences O
(- O
456 NUMERIC
to O
- O
172 NUMERIC
), O
suggesting O
two O
regions O
in O
the O
PSG1 NUMERIC
- I-GENE
I I-GENE
gene I-GENE
that O
mediate O
the O
butyrate RARE
response O
. O

An O
examination O
of O
the O
role O
of O
the O
carboxyl O
terminus O
in O
regulating O
NGFI ALLCAPS
- I-GENE
B I-GENE
transcriptional O
activity O
revealed O
that O
, O
in O
accordance RARE
with O
other O
nuclear O
receptors O
, O
mutants O
lacking O
portions O
of O
the O
carboxyl O
terminus O
had O
greatly O
decreased O
activity O
. O

Altogether O
these O
results O
indicate O
that O
the O
Syn RARE
5 I-GENE
locus I-GENE
segregates RARE
from O
the O
gene O
specifying RARE
gH LASTCAP
, O
to O
a O
region O
encompassing O
portions O
of O
the O
TK I-GENE
and O
UL ALLCAPS
24 I-GENE
genes I-GENE
, O
and O
that O
the O
syn RARE
mutation I-GENE
does O
not O
affect O
the O
expression O
or O
activity O
of O
TK I-GENE
. O

Nucleoprotein RARE
( O
N O
) O
expressed O
by O
both O
recombinant O
vaccinia O
virus O
and O
TGEV ALLCAPS
had O
a O
relative O
molecular O
mass O
( O
Mr O
) O
of O
47 O
, O
000 O
and O
was O
susceptible O
to O
degradation O
at O
the O
C O
- O
terminus O
yielding RARE
discrete O
breakdown RARE
products O
. O

Recently O
, O
the O
3 I-GENE
. I-GENE
6 I-GENE
- I-GENE
kb I-GENE
full I-GENE
- I-GENE
length I-GENE
alpha I-GENE
- I-GENE
GalNAc RARE
cDNA I-GENE
sequence I-GENE
was O
isolated O
and O
found O
to O
have O
remarkable O
nucleotide O
and O
predicted O
amino O
acid O
homology O
( O
55 O
. O
8 O
and O
46 O
. O
9 O
%, O
respectively O
) O
with O
the O
human I-GENE
alpha I-GENE
- I-GENE
galactosidase I-GENE
A I-GENE
( O
alpha I-GENE
- I-GENE
Gal I-GENE
A I-GENE
) O
cDNA O
. O

Patients O
with O
an O
enzymatic O
activity O
below O
X O
-- O
1 O
manifested O
a O
decrease O
of O
the O
content O
of O
IgA I-GENE
, O
IgG I-GENE
, O
IgM I-GENE
, O
T O
and O
B O
lymphocytes O
, O
and O
of O
phagocytic O
activity O
of O
neutrophils O
as O
compared O
to O
patients O
exhibiting O
a O
high O
enzymatic O
activity O
. O

The O
reason RARE
that O
nitrous RARE
oxide O
does O
not O
produce O
hydroxyl RARE
radicals O
readily O
might O
be O
that O
the O
one O
- O
electron O
reduction O
proceeds RARE
through O
an O
N2O O
- O
intermediate O
which O
is O
energetically RARE
very O
unfavourable RARE
: O
EO ALLCAPS
( O
N2O O
/ O
N2O O
-) O
= O
- O
1 O
. O
1 O
V O
. O

All O
mutant I-GENE
JCV ALLCAPS
T I-GENE
antigens I-GENE
bound O
to O
JCV ALLCAPS
and O
SV40 O
origins O
of O
DNA O
replication O
. O

The O
relation O
between O
myocardial I-GENE
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
and O
left O
ventricular O
( O
LV O
) O
function O
was O
studied O
in O
10 O
patients O
, O
aged O
41 O
to O
61 O
years O
( O
average O
51 O
), O
with O
LV O
volume O
overload O
mainly O
due O
to O
chronic O
mitral O
regurgitation RARE
. O

Since O
each O
transcript O
appears O
to O
encode O
the O
same O
protein O
, O
this O
complexity O
may O
reflect O
the O
need O
for O
lineage O
- O
specific O
or O
differentiation O
- O
dependent O
control O
of O
expression O
. O

In O
patients O
with O
limited O
disease O
, O
the O
survival O
in O
the O
alternating RARE
arm O
was O
significantly O
superior O
to O
the O
survival O
in O
the O
CAV ALLCAPS
arm O
( O
P O
= O
. O
014 NUMERIC
) O
or O
the O
survival O
in O
the O
PE O
arm O
( O
P O
= O
. O
023 NUMERIC
). O

We O
identify O
the O
" O
M O
region O
" O
of O
the O
muscle I-GENE
- I-GENE
specific I-GENE
Xenopus I-GENE
cardiac I-GENE
actin I-GENE
gene I-GENE
promoter I-GENE
from O
- O
282 NUMERIC
to O
- O
348 NUMERIC
as O
necessary O
for O
the O
embryonic O
expression O
of O
a O
cardiac O
actin I-GENE
- O
beta I-GENE
- I-GENE
globin I-GENE
reporter O
gene O
injected O
into O
fertilized RARE
eggs O
. O

In O
addition O
to O
the O
previously O
identified O
and O
characterized O
attenuator RARE
1 I-GENE
situated O
93 O
nucleotides O
downstream O
from O
the O
major O
late O
transcription O
start O
site O
, O
a O
second O
attenuator RARE
, O
attenuator RARE
2 I-GENE
, O
situated O
55 O
nucleotides O
downstream O
from O
it O
, O
has O
been O
identified O
. O

EBNA I-GENE
- I-GENE
2 I-GENE
and O
the O
cis O
- O
acting O
CD23 I-GENE
element I-GENE
increased O
TK I-GENE
- O
promoted O
mRNA O
and O
did O
not O
alter O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
TK I-GENE
promoter I-GENE
transcription I-GENE
start I-GENE
site I-GENE
. O

These O
experiments O
delineate RARE
a O
186 O
- O
bp O
, O
EBNA I-GENE
- I-GENE
2 I-GENE
- O
responsive O
cell O
DNA O
fragment O
and O
provide O
firm RARE
evidence O
that O
EBNA I-GENE
- I-GENE
2 I-GENE
transactivates O
transcription O
of O
cell O
genes O
. O

Plasma O
vitamin O
E O
, O
total O
lipids O
and O
myeloperoxidase RARE
levels O
during O
spinal O
surgery O
. O

Transfecting RARE
the O
cloned O
bovine O
PBR ALLCAPS
/ O
IBP ALLCAPS
cDNA O
into O
COS O
- O
7 O
cells O
resulted O
in O
an O
11 O
- O
fold O
increase O
in O
the O
density O
of O
high O
affinity O
[ O
3H O
] O
PK O
11195 NUMERIC
binding O
sites O
which O
had O
only O
low O
affinity O
for O
Ro5 NUMERIC
- O
4864 NUMERIC
. O

The O
initial O
phase O
of O
increased O
vascular O
permeability O
in O
the O
peritoneal O
cavity O
and O
LTB4 NUMERIC
production O
was O
dose O
dependently O
inhibited O
by O
the O
5 O
- O
LO ALLCAPS
inhibitors O
phenidone RARE
, O
BW ALLCAPS
A4C NUMERIC
, O
A63162 NUMERIC
, O
and O
ICI ALLCAPS
207 NUMERIC
968 NUMERIC
but O
not O
by O
dexamethasone O
or O
colchicine RARE
. O

Discrepant RARE
results O
with O
a O
latex O
agglutination O
test O
in O
the O
assessment O
of O
cytomegalovirus O
antibody O
status O
of O
cardiac O
transplant O
donors O
. O

Each O
mRNA O
contained O
five O
or O
six O
internal O
uridine RARE
residues O
, O
which O
were O
transcribed O
using O
a O
mixture O
of O
UTP ALLCAPS
and O
thio RARE
- O
UTP ALLCAPS
. O

We O
have O
isolated O
and O
sequenced O
two O
overlapping O
cDNA O
fragments O
which O
could O
encode O
the O
complete O
amino O
acid O
sequence O
of O
rat I-GENE
testis I-GENE
fructose I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
, I-GENE
2 I-GENE
- I-GENE
kinase I-GENE
: O
fructose I-GENE
- I-GENE
2 I-GENE
, I-GENE
6 I-GENE
- I-GENE
bisphosphatase RARE
. O

We O
have O
identified O
SWI5 NUMERIC
' O
s O
nuclear O
localization O
signal O
( O
NLS O
) O
and O
show O
that O
it O
can O
confer O
cell O
cycle O
- O
dependent O
nuclear O
entry O
to O
a O
heterologous O
protein O
. O

In O
contrast O
to O
behavioral O
deviation O
( O
the O
avoidance RARE
conditioning O
lost O
), O
the O
haloperidol O
intrastriatal RARE
microinjections RARE
did O
not O
affect O
the O
DA O
synaptic O
level O
in O
rostral RARE
neostriatum RARE
. O

In O
similar O
transient O
transfection O
experiments O
in O
HeLa O
cells O
, O
overexpression O
of O
the O
wt I-GENE
human I-GENE
retinoblastoma I-GENE
susceptibility I-GENE
gene I-GENE
product I-GENE
, O
RB I-GENE
, O
was O
found O
to O
repress O
the O
serum O
- O
induced O
IL I-GENE
- I-GENE
6 I-GENE
(- O
225 NUMERIC
to O
+ O
13 O
), O
c I-GENE
- I-GENE
fos I-GENE
(- O
711 NUMERIC
to O
+ O
42 O
), O
and O
beta I-GENE
- I-GENE
actin I-GENE
(- O
3400 NUMERIC
to O
+ O
912 NUMERIC
) O
promoters O
but O
not O
the O
PRV ALLCAPS
- O
induced O
IL I-GENE
- I-GENE
6 I-GENE
(- O
110 O
to O
+ O
13 O
) O
or O
the O
serum O
- O
induced O
MHC I-GENE
(- O
528 NUMERIC
to O
- O
38 O
) O
promoters O
. O

This O
repression O
was O
mediated O
through O
binding O
to O
the O
E2 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
site I-GENE
immediately O
upstream O
of O
the O
P105 NUMERIC
promoter O
TATA O
box O
and O
could O
be O
abrogated O
by O
preincubation RARE
of O
the O
HPV I-GENE
- I-GENE
18 I-GENE
P105 NUMERIC
promoter I-GENE
template O
with O
the O
nuclear O
extract O
allowing O
the O
formation O
of O
the O
preinitiation RARE
complex O
. O

We O
did O
not O
detect O
p50 I-GENE
in O
association O
with O
native I-GENE
glucocorticoid I-GENE
receptor I-GENE
in O
L O
cells O
or O
with O
the O
overexpressed O
glucocorticoid I-GENE
receptor I-GENE
in O
Chinese O
hamster O
ovary O
cells O
. O

Two O
putative O
12 O
- O
O O
- O
tetradecanoyl RARE
- O
phorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
response O
elements O
, O
that O
might O
serve O
as O
binding O
sites O
for O
the O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
1 I-GENE
and O
a O
consensus O
sequence O
of O
a O
transforming I-GENE
growth I-GENE
factor I-GENE
beta I-GENE
1 I-GENE
( O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
) O
inhibitory O
element O
were O
found O
in O
the O
promoter O
region O
. O

TPA O
and O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
did O
not O
markedly O
affect O
the O
activities O
of O
the O
72 O
- O
kDa O
enzyme O
. O

They O
were O
almost O
regularly RARE
excited RARE
by O
pressure O
to O
the O
ipsilateral O
cornea RARE
or O
to O
both O
corneas RARE
at O
a O
strength O
well O
above O
the O
human O
corneal O
pain O
threshold O
. O

Feed RARE
intake O
was O
not O
affected O
by O
dietary O
KCl RARE
or O
NaHCO3 NUMERIC
supplementation O
, O
but O
average O
daily O
gain O
increased O
with O
increased O
K O
and O
tended O
to O
be O
reduced O
by O
dietary O
NaHCO3 NUMERIC
. O

Extraction RARE
procedure O
for O
the O
measurement O
of O
butyltin RARE
compounds O
in O
biological O
tissues O
using O
toluene O
, O
HBr RARE
, O
and O
tropolone RARE
. O

In O
this O
study O
, O
we O
have O
cloned O
a O
region O
that O
complements RARE
the O
exoenzyme RARE
S I-GENE
- O
deficient O
phenotype O
of O
strain O
388 NUMERIC
exs1 NUMERIC
:: O
Tn1 NUMERIC
, O
a O
chromosomal I-GENE
Tn1 NUMERIC
insertional I-GENE
mutation I-GENE
. O

axl RARE
, O
a O
transforming O
gene O
isolated O
from O
primary O
human O
myeloid O
leukemia O
cells O
, O
encodes O
a O
novel O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
. O

Alignment RARE
of O
the O
amino O
acid O
sequences O
surrounding O
Tyr O
- O
766 NUMERIC
with O
corresponding O
regions O
of O
other O
FGFRs RARE
revealed O
conserved O
tyrosine O
residues O
in O
all O
known O
members O
of O
the O
FGFR I-GENE
family I-GENE
. O

The O
single O
most O
important O
element O
, O
by O
linker O
- O
scanning O
analysis O
, O
is O
a O
10 O
- O
bp O
region O
that O
contains O
a O
CCAAT O
motif O
. O

Capnography RARE
curves O
of O
40 O
HVS O
patients O
, O
40 O
non O
- O
HVS O
patients O
with O
psycho RARE
- O
somatic O
complaints RARE
and O
26 O
healthy O
controls O
were O
analyzed O
. O

The O
transcription O
initiation O
site O
was O
determined O
to O
occur O
66 O
bp O
upstream O
of O
the O
initiating O
Met O
. O

All O
anti I-GENE
- I-GENE
I I-GENE
and O
anti I-GENE
- I-GENE
i I-GENE
CA I-GENE
were O
shown O
to O
express O
VH4 NUMERIC
heavy I-GENE
chains I-GENE
, O
and O
14 O
of O
17 O
CA I-GENE
expressed O
a O
previously O
described O
VH4 NUMERIC
second O
hypervariable RARE
region O
determinant O
, O
termed O
VH4 NUMERIC
- I-GENE
HV2a NUMERIC
. O

Intron O
K1 I-GENE
cox1 NUMERIC
. I-GENE
2 I-GENE
is O
not O
found O
in O
S O
. O
cerevisiae O
and O
appears O
at O
an O
unique O
location O
in O
K O
. O
lactis O
. O

We O
have O
determined O
that O
the O
mutants O
define O
two O
complementation O
groups O
, O
designated O
cgs1 NUMERIC
+ I-GENE
and O
cgs2 NUMERIC
+ I-GENE
( O
continues RARE
to O
grow O
in O
stationary O
). O

However O
, O
alterations O
in O
electrostatic RARE
and O
hydrophobic O
interactions O
created O
by O
the O
three O
amino O
acid O
substitutions O
prevent O
the O
conformational O
change O
in O
the O
enzyme O
usually O
produced O
by O
calmodulin I-GENE
binding O
. O

The O
results O
of O
induced O
coexpression O
were O
also O
supported O
by O
rapid O
generation O
of O
FeLV LASTCAP
recombinants O
when O
FeLV LASTCAP
- O
C O
was O
used O
to O
infect RARE
the O
feline O
3201B NUMERIC
cell O
line O
that O
constitutively O
expresses RARE
high O
levels O
of O
endogenous O
FeLV LASTCAP
- O
specific O
mRNAs O
. O

Recombination RARE
between O
feline O
leukemia O
virus O
subgroup O
B O
or O
C O
and O
endogenous O
env I-GENE
elements O
alters O
the O
in O
vitro O
biological O
activities O
of O
the O
viruses O
. O

The O
nucleotide O
sequences O
at O
the O
5 O
' O
and O
3 O
' O
ends O
of O
these O
introns O
are O
characteristic O
of O
spliced O
transcripts O
from O
eukaryotic O
protein O
- O
encoding O
genes O
, O
with O
one O
significant O
difference O
; O
i O
. O
e O
., O
the O
5 O
' O
end O
of O
the O
LAT ALLCAPS
intron I-GENE
is O
GC O
instead O
of O
the O
consensus O
sequence O
GT O
. O

At O
1 O
, O
5 O
, O
and O
9 O
months O
after O
initial O
isolation O
of O
C O
. O
kutscheri RARE
from O
the O
oral O
cavity O
, O
hamsters O
were O
euthanatized RARE
, O
and O
attempts O
were O
made O
to O
culture O
C O
. O
kutscheri RARE
from O
13 O
additional O
sites O
. O

The O
strategy O
has O
been O
used O
to O
determine O
2 O
. O
6 O
kilobases O
of O
nucleotide O
sequence O
in O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
ADE ALLCAPS
1 I-GENE
locus I-GENE
. O

Two O
independent O
promoters O
as O
well O
as O
5 O
' O
untranslated O
regions O
regulate O
Dd RARE
ras I-GENE
expression O
in O
Dictyostelium O
. O

The O
results O
suggested O
that O
, O
depending O
upon O
the O
cell O
type O
, O
gene O
cotransfer RARE
using O
aminoglycoside RARE
resistance O
as O
a O
selectable O
marker O
may O
seriously RARE
perturb RARE
important O
cellular O
control O
mechanisms O
such O
as O
the O
PKC I-GENE
pathway O
leading O
to O
activation O
of O
gene O
expression O
. O

Transfer RARE
RNA O
genes O
from O
Dictyostelium O
discoideum RARE
are O
frequently O
associated O
with O
repetitive O
elements O
and O
contain O
consensus O
boxes O
in O
their O
5 O
' O
and O
3 O
'- O
flanking O
regions O
. O

Therefore O
, O
the O
strD LASTCAP
and O
strE LASTCAP
genes I-GENE
could O
serve O
as O
universal RARE
probes O
indicative O
of O
the O
presence O
of O
biosynthetic O
capacity O
for O
6 O
- O
deoxyhexose RARE
moieties RARE
. O

The O
two O
genes O
code O
for O
polypeptides I-GENE
of I-GENE
420 NUMERIC
amino I-GENE
acids I-GENE
( I-GENE
M I-GENE
. I-GENE
HgiCI LASTCAP
) I-GENE
and O
345 NUMERIC
amino O
acids O
( O
R O
. O
HgiCI LASTCAP
). O

Expression O
of O
the O
wt1 NUMERIC
gene I-GENE
via O
transient O
transfection O
in O
COS O
- O
1 O
cells O
revealed O
a O
52 O
kDa O
protein O
which O
was O
immunoprecipitated O
by O
both O
the O
N O
- O
terminal O
- O
and O
C O
- O
terminal O
- O
specific O
antisera O
. O

The O
factor O
which O
binds O
to O
the O
TR I-GENE
promoter I-GENE
co O
- O
sedimented RARE
with O
SV40 O
chromosomes O
extracted O
late O
in O
infection O
. O

Temafloxacin RARE
400 O
mg O
b O
. O
i O
. O
d O
. O
administered O
orally O
for O
28 O
days O
represents O
a O
safe O
and O
effective O
treatment O
for O
chronic O
bacterial O
prostatitis RARE
. O

Its O
neuromuscular O
effects O
are O
similar O
to O
a O
single O
ED90 NUMERIC
dose O
of O
vecuronium RARE
. O

The O
patient O
with O
a O
prolonged O
fever O
caused O
by O
dissecting RARE
aneurysm RARE
of O
the O
aorta O
in O
whom O
pleuropneumonia RARE
masked RARE
the O
real O
diseases O
has O
been O
presented O
. O

The O
resulting O
clone O
pKB11 NUMERIC
, O
which O
has O
a O
1369 NUMERIC
- O
base O
pair O
( O
bp O
) O
cDNA O
insert O
, O
overlapping O
pCAD142 NUMERIC
by O
781 NUMERIC
bp O
, O
was O
identified O
by O
hybridization O
methods O
and O
sequence O
analysis O
and O
found O
to O
contain O
the O
entire O
cDNA O
sequence O
for O
the O
amino O
end O
of O
the O
CAD I-GENE
polypeptide I-GENE
. O

This O
conclusion O
was O
confirmed O
by O
Northern O
blotting O
analysis O
of O
the O
5 O
'- O
flanking O
region O
of O
CAD I-GENE
gene I-GENE
. O

We O
report O
the O
isolation O
of O
genomic O
and O
cDNA O
clones O
of O
the O
light O
- O
independent O
Sn RARE
: I-GENE
bol3 NUMERIC
allele I-GENE
. O

Histamine RARE
- O
2 O
blockade O
in O
psoriasis O

Its O
clearance O
has O
been O
found O
to O
be O
decreased O
( O
typically O
by O
around O
25 O
%, O
but O
often O
by O
far O
more O
) O
by O
erythromycin RARE
, O
troleandomycin RARE
( O
triacetyloleandomycin RARE
), O
roxithromycin RARE
, O
enoxacin RARE
, O
ciprofloxacin RARE
, O
pefloxacin RARE
, O
norfloxacin RARE
, O
ofloxacin RARE
, O
fluoroquinolone RARE
T O
- O
3262 NUMERIC
, O
pipemidic RARE
acid O
, O
cimetidine O
, O
etintidine RARE
, O
propranolol O
, O
verapamil O
, O
diltiazem O
, O
nifedipine O
, O
furosemide O
( O
frusemide RARE
), O
at O
least O
some O
anovulent RARE
agents O
, O
viloxazine RARE
, O
allopurinol RARE
, O
ticlopidine RARE
, O
idrocilamide RARE
, O
thiabendazole RARE
, O
disulfiram RARE
, O
influenza O
- O
and O
BCG O
- O
vaccination O
, O
interferon I-GENE
, O
and O
caffeine O
( O
half O
- O
life O
increase O
). O

A O
third O
is O
a O
partial O
element O
terminating RARE
at O
a O
probable O
internal O
restriction O
site O
used O
for O
cloning O
. O

We O
enrolled O
253 NUMERIC
HIV I-GENE
- I-GENE
antibody I-GENE
positive O
heroin RARE
addicts O
without O
HIV O
- O
related O
disease O
( O
n O
= O
81 O
) O
or O
with O
persistent O
generalized O
lymphadenopathy RARE
( O
n O
= O
172 NUMERIC
) O
in O
a O
prospective O
study O
to O
evaluate O
clinical O
progression O
to O
AIDS O
related O
complex O
( O
ARC O
) O
or O
AIDS O
and O
to O
identify O
factors O
of O
possible O
prognostic O
relevance O
. O

No O
homology O
was O
found O
between O
RNA14 NUMERIC
and O
RNA15 NUMERIC
or O
between O
RNA14 NUMERIC
and O
other O
proteins O
contained O
in O
data O
banks RARE
. O

Mutations O
in O
the O
yeast I-GENE
RNA14 NUMERIC
and O
RNA15 NUMERIC
genes I-GENE
result O
in O
an O
abnormal O
mRNA O
decay O
rate O
; O
sequence O
analysis O
reveals O
an O
RNA O
- O
binding O
domain O
in O
the O
RNA15 NUMERIC
protein I-GENE
. O

Myocardial O
infarction O
in O
patients O
with O
previous O
bypass O
surgery O
. O

The O
most O
striking O
difference O
in O
the O
birch RARE
NAD I-GENE
( I-GENE
P I-GENE
) I-GENE
H I-GENE
- I-GENE
NR ALLCAPS
sequence I-GENE
in O
comparison O
to O
NADH I-GENE
- I-GENE
NR ALLCAPS
sequences I-GENE
was O
found O
at O
the O
putative O
pyridine RARE
nucleotide O
binding O
site O
. O

A O
single O
amino O
acid O
difference O
in O
the O
C O
- O
terminal O
region O
influences O
dominant O
negative O
activity O
and O
receptor O
dimer O
formation O
. O

No O
such O
benefits O
were O
seen O
for O
children O
with O
CD4 I-GENE
+ I-GENE
counts O
below O
0 O
. O
2 O
x O
10 O
( O
9 O
) O
per O
liter O
at O
entry O
. O

Because O
the O
human I-GENE
Antp RARE
TATAA ALLCAPS
binding I-GENE
protein I-GENE
is O
expressed O
in O
both O
lymphoid O
and O
non O
- O
lymphoid O
cells O
, O
we O
suggest O
that O
this O
homeobox I-GENE
gene I-GENE
has O
evolved O
a O
more O
general O
transcriptional O
regulatory O
function O
in O
higher O
eukaryotic O
cells O
. O

The O
95 O
% O
confidence O
values O
( O
2SD NUMERIC
) O
for O
the O
change O
in O
Ros RARE
required O
to O
exclude RARE
natural O
variability O
were O
0 O
. O
39 O
, O
0 O
. O
50 O
and O
0 O
. O
53 O
cmH2O O
l O
- O
1 O
s O
, O
respectively O
. O

Among O
953 NUMERIC
infants O
in O
22 O
neonatal O
care O
units O
studied O
, O
23 O
% O
( O
median O
value O
, O
range O
0 O
- O
78 O
) O
were O
found O
to O
be O
faecally RARE
colonized RARE
with O
one O
of O
21 O
distinct O
nosocomial RARE
strains O
of O
Escherichia O
coli O
, O
Klebsiella O
or O
Enterobacter RARE
spp RARE
. O

Biochemical O
studies O
revealed O
the O
expected O
loss O
of O
ChAT LASTCAP
activity O
in O
the O
dorsal O
and O
ventral O
hippocampi RARE
of O
lesioned O
animals O
along O
with O
elevated O
levels O
of O
norepinephrine O
( O
NE O
) O
in O
the O
dorsal O
hippocampus O
of O
MS O
/ O
HSI ALLCAPS
animals O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

The O
localization O
of O
this O
proteoglycan O
locus O
in O
the O
human O
genome O
and O
the O
availability O
of O
new O
RFLPs RARE
provide O
the O
tools O
for O
future O
studies O
of O
human O
diseases O
where O
the O
HSPG2 NUMERIC
proteoglycan I-GENE
gene I-GENE
is O
suspected O
to O
be O
involved O
. O

After O
2 O
min O
of O
dobutamine RARE
injection O
, O
or O
after O
20 O
min O
of O
pimobendan RARE
injection O
, O
the O
myocardium O
was O
removed O
, O
and O
used O
for O
determination O
of O
the O
tissue O
levels O
of O
metabolites O
of O
energy O
and O
carbohydrate O
metabolism O
. O

During O
coronary O
stenosis O
, O
on O
the O
contrary RARE
, O
intracoronary RARE
procaterol RARE
at O
the O
same O
dose O
significantly O
deteriorated RARE
regional O
myocardial O
dysfunction O
without O
changing O
LCX ALLCAPS
flow O
, O
global O
hemodynamics O
and O
cardiac O
lactate O
metabolism O
. O

Here O
we O
present O
evidence O
that O
major I-GENE
IE I-GENE
proteins I-GENE
IE86 NUMERIC
, O
IE72 NUMERIC
, O
and O
IE55 NUMERIC
are O
capable O
of O
trans O
- O
activating O
the O
HIV I-GENE
LTR I-GENE
in O
a O
T O
- O
cell O
line O
, O
HUT ALLCAPS
- O
78 O
. O

In O
a O
country RARE
where O
general O
HIV O
prevalence O
is O
low O
, O
the O
strategy O
is O
cost O
- O
effective O
for O
location O
and O
counselling RARE
of O
unknowingly RARE
seropositive O
individuals O
. O

The O
cis O
- O
acting O
element O
mediating O
glucocorticoid O
inducibility O
of O
the O
chicken I-GENE
glutamine I-GENE
synthetase I-GENE
gene I-GENE
has O
been O
identified O
. O

However O
, O
the O
increase O
in O
biliary O
excretion O
did O
not O
compensate RARE
for O
the O
reduced O
elimination O
of O
bretylium RARE
and O
hexylsalicylic RARE
acid O
via O
the O
kidney O
. O

Diagnostic O
value O
of O
cerebrospinal I-GENE
fluid I-GENE
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
in O
pediatric O
neurological O
diseases O
. O

Expression O
of O
six O
genes O
, O
ipaB LASTCAP
, O
ipaC LASTCAP
, O
invE LASTCAP
, O
invG LASTCAP
, O
invJ LASTCAP
, O
and O
invK LASTCAP
, O
was O
apparently O
regulated O
by O
the O
positive O
regulator O
virF LASTCAP
. O

Inducible RARE
VT O
was O
suppressed O
entirely O
in O
one O
patient O
. O

Venkatesan RARE
, O
and O
D O
. O

The O
presence O
of O
the O
corresponding O
mature O
mRNA O
transcripts O
( O
3 O
. O
2 O
- O
3 O
. O
5 O
kilobase O
pairs O
( O
kb O
] O
in O
human O
fibroblasts O
was O
shown O
by O
Northern O
blot O
hybridization O
, O
S1 I-GENE
nuclease I-GENE
protection O
assay O
, O
and O
the O
polymerase O
chain O
reaction O
. O

Approximately O
50 O
% O
of O
the O
ribosomal O
DNA O
( O
rDNA O
) O
units O
of O
Drosophila O
melanogaster O
are O
inactivated O
by O
two O
different O
28 I-GENE
S I-GENE
RNA I-GENE
ribosomal I-GENE
gene I-GENE
insertions O
( O
type O
I O
and O
type O
II O
). O

Gap RARE
b3 NUMERIC
consists O
of O
two O
polypeptide O
chains O
( O
Mr O
= O
110 O
, O
000 O
and O
30 O
, O
000 O
), O
which O
seem O
to O
be O
proteolytic O
cleavage O
products O
connected O
by O
disulfide O
bonds O
from O
a O
precursor O
protein O
. O

However O
, O
the O
rtFc RARE
gamma I-GENE
R I-GENE
alpha I-GENE
cDNA I-GENE
clone O
is O
complementary O
to O
at O
least O
two O
different O
- O
sized O
mRNAs O
expressed O
by O
CRNK ALLCAPS
- O
16 O
cells O
, O
contrasting RARE
the O
single O
Fc I-GENE
gamma I-GENE
R I-GENE
- I-GENE
related I-GENE
mRNA I-GENE
species O
expressed O
by O
human O
and O
mouse O
natural O
killer O
cells O
. O

Both O
genes O
comprise O
three O
exons O
, O
two O
introns O
and O
an O
unusually O
long O
3 O
'- O
untranslated O
region O
( O
3 O
. O
2 O
kilobase O
pairs O
), O
specificying RARE
a O
mRNA O
of O
approximately O
4 O
. O
1 O
kilobases O
. O

Stable O
expression O
of O
the O
chimeric O
alpha I-GENE
i I-GENE
( I-GENE
54 I-GENE
)/ I-GENE
s I-GENE
polypeptide O
in O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
constitutively O
increased O
both O
cAMP O
synthesis O
and O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
activity O
. O

This O
exon O
, O
here O
named O
exon O
0 O
, O
contained O
the O
entire O
5 O
' O
untranslated O
region O
and O
the O
N O
- O
terminal O
signal O
sequence O
of O
the O
polypeptide O
. O

Treatment O
of O
human O
myeloid O
cell O
lines O
HL O
- O
60 O
and O
U937 O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
increased O
within O
2 O
h O
cellular O
levels O
of O
the O
RNA O
hybridizable RARE
to O
LD78 NUMERIC
cDNA I-GENE
. O

A O
new O
, O
flexible RARE
fiberoptic RARE
ventriculoscope RARE
for O
observation O
of O
the O
ventricles O
and O
major O
cisterns RARE
is O
reported O
. O

Isopenicillin RARE
N I-GENE
isomerase I-GENE
( O
epimerase RARE
) O
has O
been O
purified O
from O
Streptomyces O
clavuligerus RARE
, O
and O
the O
amino O
acid O
sequence O
of O
the O
N O
- O
terminus O
has O
been O
determined O
. O

Serum O
IgG I-GENE
was O
initially O
elevated O
in O
6 O
patients O
. O

The O
patient O
initially O
attained RARE
complete O
remission O
( O
CR1 NUMERIC
) O
with O
conventional O
chemotherapy O
and O
then O
relapsed RARE
14 O
months O
later O
. O

157 NUMERIC
+/- O
16 O
mg O
/ O
dl O
; O
NS O
), O
glucose O
levels O
, O
and O
basal O
( O
17 O
+/- O
4 O
vs O
. O

Platelet O
aggregation O
and O
metabolic O
control O
are O
not O
affected O
by O
calcium O
antagonist O
treatment O
in O
type O
II O
diabetes O
mellitus O
. O

Wnt I-GENE
- I-GENE
1 I-GENE
( O
int I-GENE
- I-GENE
1 I-GENE
) O
is O
a O
cellular O
oncogene O
often O
activated O
by O
insertion O
of O
proviral O
DNA O
of O
the O
mouse O
mammary O
tumor O
virus O
. O

Induction O
of O
Jurkat O
leukemic RARE
T O
cells O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
and O
ionomycin RARE
did O
not O
affect O
the O
level O
of O
FKBP ALLCAPS
mRNA I-GENE
. O

GLUT5 NUMERIC
mRNA I-GENE
is O
expressed O
at O
highest O
levels O
in O
small O
intestine O
and O
at O
much O
lower O
levels O
in O
kidney O
, O
skeletal O
muscle O
, O
and O
adipose O
tissue O
. O

e O
. O

We O
speculate RARE
that O
these O
tumors O
may O
represent O
congenital O
hamartomatous RARE
growths RARE
. O

Identification O
and O
characterization O
of O
the O
promoter O
for O
the O
cytotactin RARE
gene I-GENE
. O

Surprisingly O
, O
there O
is O
no O
sequence O
homology O
between O
this O
region O
of O
Ly RARE
- I-GENE
6E NUMERIC
and O
the O
established O
consensus O
for O
the O
interferon I-GENE
- I-GENE
stimulated I-GENE
response I-GENE
element I-GENE
, O
which O
has O
been O
shown O
functionally O
important O
to O
all O
previously O
characterized O
alpha I-GENE
/ I-GENE
beta I-GENE
interferon I-GENE
- O
inducible O
promoters O
. O

Relatively RARE
large O
DNA O
rearrangements O
spanning O
the O
region O
with O
tandem O
direct O
repeats O
encoding O
the O
carboxy O
- O
terminal O
histone I-GENE
H1 I-GENE
- I-GENE
like I-GENE
structure O
of O
AlgP LASTCAP
were O
detected O
in O
several O
strains O
upon O
conversion O
from O
the O
mucoid RARE
to O
the O
nonmucoid RARE
phenotype O
. O

( O
1988 O
) O
J O
. O

These O
results O
strongly O
suggested O
that O
similar O
, O
if O
not O
identical O
, O
the O
CArG I-GENE
box I-GENE
binding I-GENE
proteins I-GENE
interact O
with O
the O
functionally O
different O
promoter O
element O
in O
the O
VLC1 NUMERIC
, O
cardiac I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
and O
c I-GENE
- I-GENE
fos I-GENE
genes I-GENE
. O

Polyadenylation RARE
of O
B4 NUMERIC
RNA I-GENE
, O
which O
occurs O
very O
early O
during O
maturation O
, O
is O
limited O
to O
150 O
residues O
, O
and O
it O
is O
this O
number O
that O
is O
required O
for O
polysomal RARE
recruitment O
. O

Co O
- O
existence O
of O
these O
regulatory O
elements O
with O
other O
elements O
, O
such O
as O
the O
AP I-GENE
- I-GENE
2 I-GENE
element I-GENE
or O
CCAAT O
box O
, O
was O
also O
found O
. O

Recently O
, O
studies O
of O
agents O
that O
disrupt O
collagen I-GENE
synthesis O
and O
deposition O
have O
yielded O
several O
new O
angiogenesis O
inhibitors O
. O

Since O
the O
5 O
'- O
flanking O
region O
of O
this O
gene O
is O
likely O
involved O
in O
hormonal O
regulation O
of O
its O
expression O
, O
we O
have O
isolated O
and O
partially O
characterized O
an O
avian O
fatty I-GENE
acid I-GENE
synthase I-GENE
gene O
. O

A O
new O
set O
of O
cDNA O
clones O
spanning O
approximately O
3 O
. O
2 O
kb O
was O
isolated O
from O
a O
lambda O
- O
ZAP O
goose RARE
liver O
cDNA O
library O
using O
the O
5 O
'- O
most O
exon O
- O
containing O
fragment O
of O
the O
5 O
'- O
most O
genomic O
DNA O
clone O
. O

Northern O
blotting O
analysis O
indicates O
that O
expression O
of O
the O
genes O
corresponding O
to O
these O
clones O
is O
confined O
to O
pollen O
tissue O
. O

Whereas O
cDNA O
hybridization O
to O
genomic O
DNA O
blots O
indicated O
a O
small O
subfamily O
of O
G0S19 NUMERIC
genes I-GENE
, O
simple O
patterns O
of O
bands O
indicated O
that O
most O
cDNAs O
, O
including O
G0S30 NUMERIC
cDNA I-GENE
, O
corresponded O
to O
single O
- O
copy O
genes O
. O

Lymphoproliferative RARE
disorders O
arising O
under O
immunosuppression RARE
with O
FK O
506 NUMERIC
: O
initial O
observations O
in O
a O
large O
transplant O
population O
. O

The O
Drosophila I-GENE
suppressor I-GENE
of I-GENE
sable RARE
gene I-GENE
encodes O
a O
polypeptide O
with O
regions O
similar O
to O
those O
of O
RNA O
- O
binding O
proteins O
. O

2 O
: O
121 O
- O
133 O
, O
1988 O
). O

It O
is O
, O
however O
, O
extremely O
homologous O
to O
a O
third O
' O
non O
- O
classical O
' O
gene O
, O
HLA I-GENE
- I-GENE
5 I-GENE
. I-GENE
4 I-GENE
, O
and O
to O
the O
chimpanzee RARE
gene O
, O
Ch28 NUMERIC
. O

Although O
the O
N13 NUMERIC
- O
N20 NUMERIC
interpeak RARE
interval O
remained O
stable O
because O
of O
the O
parallel O
shift O
of O
the O
2 O
peaks O
, O
the O
central O
conduction O
time O
measured O
from O
onset O
latencies RARE
of O
N11 NUMERIC
and O
N20 NUMERIC
significantly O
increased O
. O

Using O
avidin RARE
- I-GENE
biotin RARE
complex O
DNA O
binding O
assays O
, O
a O
series O
of O
overlapping O
alpha I-GENE
promoter I-GENE
DNA I-GENE
sequences I-GENE
between O
- O
170 O
to O
29 O
basepairs RARE
were O
tested O
, O
but O
each O
failed O
to O
bind O
GR I-GENE
, O
whereas O
a O
control O
GRE O
avidly RARE
bound O
receptor O
. O

Sequence O
determination O
of O
isolated O
peptides O
suggested O
that O
Asn120 NUMERIC
is O
glycosylated O
, O
Asn65 NUMERIC
and O
Asn109 NUMERIC
glycosylated O
in O
some O
molecules O
but O
not O
in O
others O
, O
and O
Asn72 NUMERIC
not O
glycosylated O
. O

The O
DNA O
sequence O
conferring O
AP I-GENE
- I-GENE
1 I-GENE
activity O
was O
located O
in O
the O
proximal O
promoter O
region O
. O

The O
murine I-GENE
mutation I-GENE
dominant I-GENE
white I-GENE
spotting RARE
( O
W I-GENE
) O
is O
in O
the O
proto O
- O
oncogene O
, O
c I-GENE
- I-GENE
kit I-GENE
. O

Isolation O
and O
characterization O
of O
the O
rat O
chromosomal O
gene O
for O
a O
polypeptide O
( O
pS1 NUMERIC
) O
antigenically RARE
related O
to O
statin RARE
. O

The O
proteins O
differ O
in O
the O
presence O
or O
absence O
of O
a O
21 O
- O
amino O
- O
acid O
sequence O
located O
24 O
amino O
acids O
C O
terminal O
of O
the O
translational O
initiation O
codon O
. O

Our O
results O
also O
indicate O
the O
existence O
of O
sequences O
downstream O
of O
- O
0 O
. O
11 O
kb O
which O
can O
influence O
the O
pattern O
of O
tissue O
- O
specific O
expression O
of O
the O
HLA I-GENE
- I-GENE
B7 I-GENE
gene I-GENE
and O
the O
ability O
of O
this O
gene O
to O
respond O
to O
gamma I-GENE
interferon I-GENE
. O

The O
SH2 I-GENE
and O
SH3 I-GENE
domains I-GENE
of O
pp60src NUMERIC
direct O
stable O
association O
with O
tyrosine O
phosphorylated O
proteins O
p130 I-GENE
and O
p110 NUMERIC
. O

Chem O
. O

These O
clones O
overlapped RARE
and O
contained O
the O
structural O
gene O
encoding O
the O
complete O
C5 NUMERIC
alpha I-GENE
- I-GENE
chain I-GENE
and O
90 O
% O
of O
the O
beta O
- O
chain O
. O

The O
C5 NUMERIC
alpha I-GENE
- I-GENE
chain I-GENE
was O
encoded O
by O
49 O
kilobases O
containing O
26 O
exons O
; O
the O
beta O
- O
chain O
was O
encoded O
by O
29 O
kilobases O
containing O
16 O
exons O
. O

Heterozygous RARE
mutation O
in O
the O
G O
+ O
5 O
position O
of O
intron O
33 O
of O
the O
pro I-GENE
- I-GENE
alpha I-GENE
2 I-GENE
( I-GENE
I I-GENE
) I-GENE
gene I-GENE
( O
COL1A2 NUMERIC
) O
that O
causes O
aberrant O
RNA O
splicing O
and O
lethal O
osteogenesis RARE
imperfecta RARE
. O

The O
nucleotide O
sequences O
of O
these O
genes O
differ O
at O
only O
nine O
positions O
, O
resulting O
in O
three O
amino O
acid O
differences O
. O

The O
protein O
predicted O
by O
the O
sequence O
of O
the O
human I-GENE
pim RARE
- I-GENE
1 I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
shares O
extensive O
homology O
with O
known O
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinases I-GENE
, O
and O
yet O
the O
human I-GENE
Pim RARE
- I-GENE
1 I-GENE
enzyme I-GENE
has O
previously O
been O
reported O
to O
exhibit O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
both O
in O
vitro O
and O
in O
vivo O
. O

A O
full I-GENE
- I-GENE
length I-GENE
human I-GENE
pim RARE
- I-GENE
1 I-GENE
cDNA I-GENE
was O
subcloned O
into O
the O
bacterial O
vector O
pGEX LASTCAP
- O
2T NUMERIC
and O
the O
Pim RARE
- I-GENE
1 I-GENE
protein I-GENE
expressed O
as O
a O
fusion O
product O
with O
bacterial I-GENE
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
). O

This O
report O
substantiates RARE
that O
at O
least O
two O
of O
the O
18 O
kDa O
hsps RARE
in O
maize O
are O
products O
of O
different O
but O
related O
genes O
. O

The O
10 O
kDa O
polypeptide O
was O
phosphorylated O
in O
vitro O
by O
incubating RARE
wheat O
etioplast RARE
membranes O
with O
[ O
gamma O
32P O
] O
ATP O
. O

Homology RARE
with O
the O
human O
protein O
is O
only O
34 O
% O
in O
the O
tandem O
repeat O
domain O
, O
mainly O
showing O
conservation O
of O
serines RARE
and O
threonines RARE
, O
presumed O
sites O
of O
O O
- O
linked O
carbohydrate O
attachment O
. O

In O
addition O
to O
targeting O
partially O
assembled O
Ti RARE
alpha I-GENE
- I-GENE
beta I-GENE
CD3 I-GENE
gamma I-GENE
delta I-GENE
epsilon I-GENE
TCR I-GENE
complexes I-GENE
to O
the O
cell O
surface O
, O
CD3 I-GENE
zeta I-GENE
appears O
to O
be O
essential O
for O
interleukin I-GENE
- I-GENE
2 I-GENE
production O
after O
TCR I-GENE
stimulation O
with O
antigen I-GENE
/ I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
. O

When O
desipramine O
was O
injected O
16 O
hrs O
after O
fluoxetine RARE
injection O
, O
brain O
levels O
of O
desipramine O
were O
no O
longer O
elevated O
. O

Opposite RARE
effects O
of O
CYP1 NUMERIC
are O
observed O
in O
aerobic O
, O
heme O
- O
sufficient O
cells O
. O

A O
segmental O
analysis O
of O
the O
key O
regions O
of O
HLA I-GENE
- I-GENE
DR1 I-GENE
that O
control O
T O
cell O
allorecognition RARE
was O
performed O
by O
using O
a O
series O
of O
transfected O
cell O
lines O
expressing O
the O
products O
of O
recombinant O
DRB ALLCAPS
/ O
H I-GENE
- I-GENE
2Eb NUMERIC
genes O
, O
paired O
with O
either O
DR I-GENE
alpha I-GENE
or O
H I-GENE
- I-GENE
2E NUMERIC
alpha I-GENE
. O

We O
characterized O
cDNA O
clones O
specific O
for O
the O
extracellular O
matrix O
glycoprotein O
undulin RARE
. O

Finally O
, O
some O
point O
mutations O
in O
the O
Gag I-GENE
- O
Pol I-GENE
PR O
domain O
inhibited O
activation O
of O
RT I-GENE
in O
trans O
by O
a O
wild O
- O
type O
PR I-GENE
, O
suggesting O
that O
the O
correct O
conformation O
of O
the O
PR I-GENE
domain O
in O
Gag I-GENE
- O
Pol I-GENE
is O
prerequisite O
for O
activation O
of O
RT I-GENE
. O

The O
alpha I-GENE
inhibin RARE
promoter I-GENE
containing O
a O
mutated O
CRE O
was O
not O
regulated O
by O
forskolin O
in O
granulosa RARE
cells O
and O
did O
not O
bind O
the O
CREB I-GENE
protein I-GENE
. O

Regulation O
of O
the O
alpha I-GENE
inhibin RARE
gene I-GENE
by O
cyclic O
adenosine O
3 O
', O
5 O
'- O
monophosphate O
after O
transfection O
into O
rat O
granulosa RARE
cells O
. O

Comparison O
of O
the O
nucleotide O
sequences O
between O
the O
human O
and O
bovine O
DNA O
showed O
that O
the O
sequence O
similarity O
extended O
2400 NUMERIC
bp O
downstream O
from O
the O
coding O
region O
. O

Cloning O
of O
a O
human O
cDNA O
encoding O
a O
CDC2 NUMERIC
- I-GENE
related I-GENE
kinase I-GENE
by O
complementation O
of O
a O
budding I-GENE
yeast I-GENE
cdc28 NUMERIC
mutation O
. O

In O
patients O
with O
osteomyelitis RARE
and O
joint O
empyema RARE
( O
n O
= O
48 O
) O
PMN I-GENE
elastase I-GENE
had O
a O
sensitivity O
of O
77 O
%, O
which O
was O
only O
exceeded RARE
by O
that O
of O
the O
unspecific RARE
erythrocyte O
sedimentation O
rate O
( O
sensitivity O
89 O
%). O

E O
., O
Hession RARE
, O
C O
., O
Goff RARE
, O
D O
., O
Griffiths RARE
, O
B O
., O
Tizard RARE
, O
R O
., O
Newman RARE
, O
B O
., O
Chi O
- O
Rosso RARE
, O
G O
., O
and O
Lobb RARE
, O
R O
., O
( O
1990 O
) O
Cell O
63 O
, O
1349 NUMERIC
- O
1356 NUMERIC
). O

The O
above O
results O
mean O
that O
the O
increase O
in O
alpha I-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
makes O
the O
prostate O
, O
which O
has O
been O
already O
hypertrophied RARE
, O
less O
elastic O
, O
inhibiting O
external O
urinary O
sphincter RARE
function O
. O

An O
approximately O
2 I-GENE
- I-GENE
kilobase I-GENE
B2 I-GENE
transcript I-GENE
was O
expressed O
in O
all O
alfalfa RARE
organs O
tested O
. O

These O
results O
indicate O
that O
the O
sulfhydryl RARE
group O
of O
certain O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
can O
potentiate RARE
their O
effect O
on O
the O
endogenous O
nitrovasodilator RARE
EDRF ALLCAPS
. O

Pharmacokinetics RARE
of O
FK O
506 NUMERIC
in O
transplant O
patients O
. O

A O
second O
even O
more O
significant O
match O
to O
this O
E O
. O
coli O
region O
was O
found O
in O
the O
retroviral I-GENE
ribonuclease I-GENE
H I-GENE
( O
RNase I-GENE
H I-GENE
) O
domain O
, O
and O
corresponds O
precisely O
to O
a O
region O
that O
has O
been O
aligned RARE
by O
previous O
investigators RARE
with O
the O
E I-GENE
. I-GENE
coli I-GENE
RNase I-GENE
H I-GENE
, O
suggesting O
that O
Pol I-GENE
I I-GENE
helices O
O O
and O
P O
are O
homologous O
to O
helices O
A O
and O
D O
of O
the O
RNase I-GENE
H I-GENE
crystal O
structure O
, O
respectively O
. O

Analysis O
of O
the O
deduced O
amino O
acid O
sequence O
suggests O
that O
CHIP28 NUMERIC
protein I-GENE
contains O
six O
bilayer RARE
- O
spanning O
domains O
, O
two O
exofacial RARE
potential O
N O
- O
glycosylation O
sites O
, O
and O
intracellular O
N O
and O
C O
termini O
. O

The O
qualitative O
concentrations O
of O
HCG ALLCAPS
had O
a O
sensitivity O
of O
37 O
. O
5 O
% O
and O
a O
specificity O
of O
100 O
%. O

The O
reduced O
rate O
of O
F O
absorption O
and O
slower O
rise O
in O
plasma O
F O
concentration O
accompanying O
delayed O
gastric O
emptying O
indicate O
that O
passage O
of O
F O
into O
the O
small O
intestine O
is O
the O
major O
factor O
in O
rapid O
F O
absorption O
. O

The O
activity O
of O
serum I-GENE
lipase I-GENE
and O
amylase I-GENE
distinctly O
increased O
at O
3 O
h O
and O
went RARE
up O
to O
the O
maximum O
at O
12 O
h O
after O
injection O
of O
Na O
- O
Tc O
. O

They O
were O
checked RARE
for O
anti I-GENE
- I-GENE
HCV I-GENE
( O
anti I-GENE
- I-GENE
C100 NUMERIC
- I-GENE
3 I-GENE
) O
with O
HCV O
EIA O
kit O
( O
Abbott RARE
Lab RARE
., O
North RARE
Chicago RARE
, O
IL O
). O

Diltiazem RARE
resulted O
in O
a O
significant O
increase O
in O
epicardial RARE
diameter O
(+ O
10 O
%; O
p O
= O
0 O
. O
001 O
) O
and O
in O
coronary O
blood O
flow O
( O
CBF O
) O
(+ O
30 O
%; O
p O
= O
0 O
. O
0001 O
). O

The O
first O
transfusion O
resulted O
in O
a O
platelet O
increment RARE
to O
32 O
Gpt RARE
/ O
l O
( O
CCI ALLCAPS
11 O
). O

These O
risk O
factors O
can O
be O
divided O
into O
2 O
groups O
: O
local O
vessel O
wall O
- O
related O
factors O
, O
and O
local O
( O
focal O
action O
) O
systemic O
factors O
. O

Epidemiology RARE
and O
prevention O
of O
hospital O
infections O
in O
the O
Local RARE
Health O
Unit RARE
of O
Sassari RARE
: O
profile O
of O
bacterial O
resistance O
and O
antimicrobial O
agents O
of O
large O
usage O
. O

PRDII ALLCAPS
- I-GENE
BF1 NUMERIC
- I-GENE
derived I-GENE
cDNAs I-GENE
did O
not O
result O
in O
stimulation O
of O
either O
basal O
or O
tat I-GENE
- O
induced O
activated O
gene O
expression O
. O

Vaccinia RARE
virus O
( O
VV ALLCAPS
) O
is O
a O
potent O
immunogen RARE
, O
but O
the O
nature O
of O
VV ALLCAPS
proteins O
involved O
in O
the O
activation O
of O
the O
immune O
response O
of O
the O
host O
is O
not O
yet O
known O
. O

Max I-GENE
: O
functional O
domains O
and O
interaction O
with O
c I-GENE
- I-GENE
Myc I-GENE
. O

86 O
: O
3199 NUMERIC
- O
3203 NUMERIC
) O
or O
G1 O
to O
S O
phase O
( O
Reilly RARE
, O
C O
. O

Substitutions RARE
introduced O
at O
bases O
surrounding O
the O
ICR2 NUMERIC
motif I-GENE
yielded O
levels O
of O
pRNA LASTCAP
replication O
that O
differed O
, O
depending O
on O
the O
maintenance O
of O
a O
putative O
5 O
' O
stem O
- O
loop O
structure O
in O
the O
positive O
strand O
of O
the O
viral O
genome O
. O

Zn O
( O
II O
) O
coordination O
domain O
mutants O
of O
T4 O
gene I-GENE
32 I-GENE
protein O
. O

Zn O
( O
II O
) O
coordination O
domain O
mutants O
of O
T4 I-GENE
gene I-GENE
32 I-GENE
protein I-GENE
. O

The O
tissue O
specificity O
of O
gene O
expression O
was O
identical O
to O
that O
described O
previously O
for O
the O
CaMV LASTCAP
35S I-GENE
domain I-GENE
B I-GENE
enhancer I-GENE
element I-GENE
. O

The O
pathophysiology O
and O
clinical O
management O
of O
acute O
brain O
injury O
in O
infancy RARE
and O
childhood O
are O
presented O
using O
acute O
traumatic RARE
brain O
injury O
as O
a O
model O
. O

Transcripts RARE
from O
a O
second O
POU I-GENE
- I-GENE
domain I-GENE
gene I-GENE
, O
Oct I-GENE
- I-GENE
25 I-GENE
, O
were O
present O
at O
low O
levels O
in O
oocytes O
and O
early O
embryos O
and O
were O
dramatically O
upregulated RARE
during O
early O
gastrulation RARE
. O

In O
some O
early O
B O
cells O
and O
Abelson RARE
murine O
leukemia O
virus O
- O
transformed O
pre O
- O
B O
- O
cell O
lines O
, O
LT ALLCAPS
mRNA I-GENE
is O
constitutively O
expressed O
. O

The O
genome O
of O
Thogoto RARE
virus O
comprises O
six O
segments O
of O
single O
- O
stranded O
, O
negative O
sense O
RNA O
. O

These O
tumors O
were O
classified O
into O
three O
broad O
groups O
: O
I O
, O
cystadenoma RARE
; O
II O
, O
cystadenocarcinoma RARE
; O
and O
III O
, O
adenocarcinoma O
with O
mucin RARE
production O
or O
an O
associated O
cyst O
. O

Immunostaining RARE
of O
cells O
transfected O
with O
these O
constructs O
revealed O
that O
both O
the O
myristoylated RARE
and O
nonmyristoylated RARE
mutants O
were O
localized O
in O
nuclei O
, O
whereas O
wild I-GENE
- I-GENE
type I-GENE
PKC I-GENE
alpha I-GENE
was O
primarily O
cytoplasmic O
and O
perinuclear RARE
. O

We O
have O
partially O
sequenced O
the O
RAP74 NUMERIC
protein I-GENE
from O
purified O
HeLa O
cells O
, O
cloned O
its O
complementary O
DNA O
and O
shown O
that O
its O
translation O
product O
can O
interact O
with O
RAP30 NUMERIC
in O
vitro O
as O
well O
as O
in O
vivo O
. O

Effects O
of O
thromboxane I-GENE
synthetase I-GENE
inhibition O
on O
postburn RARE
mesenteric RARE
vascular O
resistance O
and O
the O
rate O
of O
bacterial O
translocation O
in O
a O
chronic O
porcine O
model O
. O

The O
primary O
pancreatic O
insult RARE
seemed RARE
to O
be O
unaffected O
by O
the O
treatment O
, O
because O
neither O
the O
rise O
in O
plasma I-GENE
lipase I-GENE
nor O
the O
development O
of O
ascites RARE
or O
the O
extension O
of O
the O
pancreatic O
necrosis O
were O
diminished O
. O

The O
size O
of O
the O
mutant O
molecule O
corresponds O
to O
the O
unprocessed RARE
cytoplasmic O
precursor O
( O
pre I-GENE
- I-GENE
super RARE
- I-GENE
pro I-GENE
- I-GENE
PrB LASTCAP
), O
as O
detected O
in O
sec61 NUMERIC
mutants I-GENE
, O
when O
translocation O
into O
the O
endoplasmic O
reticulum O
is O
blocked O
. O

Thus O
, O
the O
active O
- O
site O
mutation O
prevents O
the O
wild O
- O
type O
processing O
of O
the O
N O
- O
glycosylated O
73 O
- O
kDa O
precursor O
of O
PrB LASTCAP
to O
the O
41 I-GENE
. I-GENE
5 I-GENE
kDa I-GENE
pro I-GENE
- I-GENE
PrB LASTCAP
in O
the O
endoplasmic O
reticulum O
. O

The O
predicted O
amino O
acid O
sequence O
exhibited O
70 O
% O
identity O
to O
that O
of O
Bacillus I-GENE
stearothermophilus RARE
TyrTS LASTCAP
and O
55 O
% O
identity O
to O
that O
of O
E I-GENE
. I-GENE
coli I-GENE
TyrTS LASTCAP
, O
while O
identity O
to O
a O
second O
cryptic RARE
B I-GENE
. I-GENE
subtilis I-GENE
TyrTS LASTCAP
gene I-GENE
, O
designated O
tyrZ LASTCAP
, O
was O
only O
27 O
%. O

Heat RARE
- O
inducible O
CAT I-GENE
activity O
was O
detectable O
when O
additional O
sequences O
from O
the O
native O
promoter O
containing O
three O
CCAAT O
boxes O
and O
a O
single O
HSE O
were O
present O
in O
the O
constructions RARE
. O

SETTING O
-- O
Women RARE
, O
Infants RARE
, O
and O
Children O
clinics RARE
in O
Minneapolis RARE
, O
Minn RARE
. O

Testosterone RARE
, O
free O
testosterone O
, O
non I-GENE
- I-GENE
sex I-GENE
hormone I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
- O
bound O
testosterone O
, O
and O
free O
androgen O
index O
: O
which O
testosterone O
measurement O
is O
most O
relevant O
to O
reproductive O
and O
sexual O
function O
in O
men O
with O
epilepsy O
? O

BACKGROUND O
: O
The O
effectiveness O
of O
monoamine I-GENE
oxidase I-GENE
inhibitors O
( O
MAOIs RARE
) O
in O
tricyclic RARE
resistant O
depression O
has O
received O
surprisingly RARE
little O
systematic O
study O
. O

The O
upstream O
delta O
- O
alpha O
breakpoint O
is O
flanked O
by O
the O
direct O
repeats O
of O
the O
acceptor O
splice O
site O
, O
whereas O
the O
down O
- O
stream RARE
alpha O
- O
delta O
breakpoint O
is O
located O
in O
the O
adjacent O
intron O
. O

Patients O
with O
moderate O
PDDAT ALLCAPS
were O
impaired O
on O
all O
serial O
positions O
for O
both O
spatial O
order O
and O
spatial O
recognition O
memory O
. O

Bone RARE
and O
bones RARE
. O

One O
patients O
had O
plasma I-GENE
C I-GENE
- I-GENE
peptide I-GENE
greater O
than O
3 O
pM LASTCAP
and O
was O
therefore O
excluded O
from O
analysis O
. O

Complex RARE
repetitive O
discharges RARE
were O
observed O
in O
muscles O
of O
mdx RARE
mice O
but O
no O
complex O
repetitive O
discharges RARE
or O
other O
abnormalities O
were O
observed O
in O
muscles O
of O
normal O
control O
mice O
. O

Management RARE
often O
involves O
beta O
- O
and O
calcium O
channel O
blocking O
drugs O
or O
type O
IC ALLCAPS
antiarrhythmic O
drugs O
. O

To O
overcome O
this O
problem O
, O
we O
have O
overexpressed O
Kex2p NUMERIC
using O
the O
baculovirus O
/ O
insect O
cell O
expression O
system O
. O

J O
. O

The O
major I-GENE
49 I-GENE
- I-GENE
kDa I-GENE
core I-GENE
protein I-GENE
in O
the O
liver O
HSPG ALLCAPS
preparation O
was O
found O
to O
be O
reactive O
to O
an O
antibody O
that O
specifically O
recognizes O
the O
cytoplasmic O
domain O
of O
fibroglycan RARE
. O

While O
no O
obvious RARE
transmembrane O
regions O
were O
identified O
, O
several O
short O
hydrophobic O
amino O
acid O
stretches O
were O
found O
to O
be O
localized O
in O
and O
around O
the O
Pro O
II O
region O
, O
and O
these O
may O
be O
responsible O
for O
attachment O
of O
precursors O
to O
membranes O
. O

Toxicity RARE
was O
mild O
, O
mainly O
consisting O
of O
emesis RARE
( O
81 O
% O
of O
the O
patients O
; O
66 O
% O
of O
the O
courses O
), O
leukopenia RARE
of O
World RARE
Health O
Organization O
( O
WHO ALLCAPS
) O
grade O
1 O
to O
2 O
( O
47 O
% O
of O
the O
patients O
; O
18 O
% O
of O
the O
courses O
), O
and O
thrombocytopenia O
( O
12 O
% O
of O
the O
patients O
; O
3 O
% O
of O
the O
courses O
). O

W O
. O
G O
. O

This O
study O
confirms RARE
, O
although O
individual O
reaction O
is O
remarkably O
different O
, O
transportation RARE
as O
a O
potent O
stressor RARE
for O
Beagle RARE
dogs O
. O

A O
mouse I-GENE
brain I-GENE
beta I-GENE
- I-GENE
spectrin I-GENE
of O
cDNA O
was O
identified O
within O
a O
lambda O
Gt11 NUMERIC
expression O
library O
using O
an O
antibody O
which O
specifically O
binds O
with O
the O
235 NUMERIC
kDa I-GENE
spectrin I-GENE
beta I-GENE
- I-GENE
subunit I-GENE
. O

RESULTS O
: O
Plasma I-GENE
AVP I-GENE
responses O
to O
osmotic O
stimulation O
, O
and O
non O
- O
osmotic O
inhibition O
by O
drinking O
, O
were O
normal O
in O
patients O
with O
compulsive RARE
water O
drinking O
. O

The O
fragments O
of O
each O
region O
were O
amplified O
by O
polymerase O
chain O
reaction O
and O
analyzed O
by O
gel O
electrophoresis O
to O
detect O
single O
- O
strand O
conformation O
polymorphism O
. O

The O
csbA LASTCAP
fusion I-GENE
was O
maximally RARE
expressed O
during O
early O
stationary O
phase O
in O
cells O
grown O
in O
Luria RARE
broth RARE
containing O
5 O
% O
glucose O
and O
0 O
. O
2 O
% O
glutamine O
. O

The O
constraints RARE
of O
primase I-GENE
recognition I-GENE
sequences I-GENE
, O
nucleotide O
substrate O
requirements O
, O
and O
the O
effects O
of O
additional O
proteins O
on O
oligoribonucleotide RARE
synthesis O
by O
the O
63 I-GENE
- I-GENE
kDa I-GENE
gene I-GENE
4 I-GENE
protein I-GENE
have O
been O
examined O
using O
templates O
of O
defined O
sequence O
. O

Thrombolytic RARE
therapy O
in O
spontaneous O
coronary O
artery O
dissection O
. O

A O
prospective O
trial O
was O
carried O
out O
in O
156 O
unselected RARE
patients O
( O
41 O
men O
, O
mean O
age O
67 O
. O
5 O
years O
, O
115 O
women O
, O
mean O
age O
71 O
. O
4 O
years O
) O
who O
had O
undergone O
total O
hip O
joint O
replacement O
because O
of O
degenerative RARE
or O
inflammatory O
arthritis O
or O
fracture O
of O
the O
neck O
of O
the O
femur O
. O

When O
both O
lesions O
were O
complete O
lateral O
hemisections RARE
in O
weanling RARE
operates RARE
, O
little O
behavioral O
recovery O
was O
observed O
, O
similar O
to O
complete O
spinal O
cord O
transection RARE
( O
N O
= O
3 O
). O

Human O
SRF I-GENE
- I-GENE
related I-GENE
proteins I-GENE
: O
DNA O
- O
binding O
properties O
and O
potential O
regulatory O
targets O
. O

We O
have O
isolated O
cDNAs O
for O
a O
gene O
coding O
for O
a O
G I-GENE
protein I-GENE
alpha I-GENE
subunit I-GENE
from I-GENE
tomato I-GENE
( O
Lycopersicon RARE
esculentum RARE
, O
cv O
. O

Growth O
factor O
stimulation O
of O
cells O
causes O
the O
phosphorylation O
of O
the O
c I-GENE
- I-GENE
Myc I-GENE
transcriptional I-GENE
activation I-GENE
domain I-GENE
at O
Ser62 NUMERIC
within O
a O
proline O
- O
rich O
region O
that O
is O
highly O
conserved O
among O
members O
of O
the O
Myc I-GENE
family I-GENE
( O
Alvarez RARE
, O
E O
., O
Northwood RARE
, O
I O
. O
C O
., O
Gonzalez RARE
, O
F O
. O

The O
authors O
evaluated O
the O
potential O
for O
thrombotic O
complications O
arising O
from O
implantation O
of O
a O
ventricular O
assist RARE
device O
( O
Sarns RARE
/ O
3M NUMERIC
- O
VAD ALLCAPS
) O
in O
four O
calves O
. O

Cardiac O
output O
( O
CO O
) O
was O
significantly O
higher O
( O
p O
less O
than O
0 O
. O
0005 NUMERIC
) O
in O
the O
MBBF ALLCAPS
group O
. O

Amino O
acid O
residues O
147 NUMERIC
- O
167 NUMERIC
of O
the O
previously O
reported O
sequence O
are O
replaced O
by O
new O
residues O
147 NUMERIC
to O
150 O
. O

Transcriptional O
activation O
by O
the O
HIV I-GENE
- I-GENE
1 I-GENE
Tat I-GENE
protein I-GENE
requires O
specific O
residues O
in O
the O
hexanucleotide RARE
loop O
and O
trinucleotide RARE
bulge RARE
of O
the O
TAR I-GENE
RNA O
stem O
- O
loop O
structure O
found O
in O
the O
5 O
'- O
untranslated O
leader O
of O
all O
viral O
transcripts O
. O

We O
obtained O
quantitative O
evidence O
on O
the O
coding O
of O
interaural RARE
time O
differences O
( O
ITDs RARE
) O
of O
click RARE
stimuli O
by O
40 O
single O
neurons O
in O
the O
auditory O
cortex O
of O
anesthetized O
albino RARE
rats O
. O

These O
results O
strongly O
suggest O
that O
locally O
- O
applied O
TTC ALLCAPS
in O
combination O
with O
FDBA ALLCAPS
enhances O
new O
bone O
formation O
in O
experimental O
alveolar O
bone O
defects O
. O

As O
an O
initial O
step O
towards O
the O
characterization O
of O
replicative O
DNA I-GENE
polymerases I-GENE
of I-GENE
trypanosomes RARE
, O
we O
have O
cloned O
, O
sequenced O
and O
examined O
the O
expression O
of O
the O
Trypanosoma O
( O
Trypanozoon RARE
) O
brucei RARE
brucei RARE
gene O
that O
encodes O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
catalytic I-GENE
core I-GENE
( O
pol I-GENE
alpha I-GENE
). O

In O
addition O
, O
there O
was O
a O
significant O
increase O
in O
postdexamethasone RARE
cortical O
concentrations O
with O
age O
( O
p O
less O
than O
0 O
. O
01 O
; O
r O
= O
0 O
. O
31 O
). O

Pulmonary RARE
hypertension O
, O
with O
or O
without O
coronary O
arterial O
narrowing RARE
, O
is O
the O
major O
condition O
leading O
to O
isolated O
atrial O
infarction O
. O

The O
volume O
fraction O
( O
Vv RARE
) O
and O
number O
/ O
mm2 O
( O
Na O
) O
of O
all O
capillaries O
( O
perfused O
and O
nonperfused RARE
) O
in O
a O
given O
area O
of O
brain O
were O
determined O
after O
staining O
for O
alkaline I-GENE
phosphatase I-GENE
. O

Airway RARE
pressure O
and O
air O
flow O
were O
measured O
at O
the O
endotracheal RARE
tube O
in O
13 O
children O
on O
a O
variety O
of O
ventilators RARE
. O

Appl RARE
. O

Issues RARE
of O
distribution O
of O
kinetic O
energy O
of O
traumatizing RARE
object RARE
in O
direct O
contact O
interaction O
with O
head O
during O
impact O
are O
discussed O
from O
position O
of O
biomechanics RARE
. O

CONCLUSION O
: O
Monitoring RARE
SpO2 NUMERIC
at O
the O
nasal O
septum RARE
site O
is O
more O
reliable O
than O
monitoring O
it O
at O
the O
finger O
site O
in O
hypothermic RARE
patients O
. O

Diltiazem RARE
decreased O
the O
total O
body O
clearance O
from O
34 O
. O
0 O
+/- O
8 O
. O
0 O
to O
28 O
. O
6 O
+/- O
6 O
. O
1 O
mL O
/ O
min O
( O
P O
less O
than O
. O
01 O
), O
and O
prolonged O
the O
elimination O
half O
- O
life O
from O
12 O
. O
6 O
+/- O
3 O
. O
0 O
to O
14 O
. O
3 O
+/- O
2 O
. O
5 O
hours O
( O
P O
less O
than O
. O
01 O
) O
of O
antipyrine RARE
without O
any O
changes O
in O
volume O
of O
distribution O
. O

The O
granules O
grew RARE
as O
the O
melted RARE
material O
immersed RARE
into O
the O
void RARE
space O
among O
the O
adhered RARE
particles O
. O

Hence O
, O
the O
uPA I-GENE
promoter I-GENE
contains O
multiple O
weak O
cis O
- O
acting O
elements O
distributed O
over O
7 O
. O
0 O
kb O
5 O
' O
to O
the O
translation O
start O
site O
. O

Substituting RARE
a O
Ser O
for O
Gly69 NUMERIC
or O
a O
Glu O
for O
Lys O
71 O
in O
the O
conserved O
TGEK ALLCAPS
tetrapeptide RARE
in O
finger O
II O
of O
TFIIIA ALLCAPS
resulted O
in O
the O
loss O
of O
DNA O
binding O
. O

P O
. O

In O
one O
, O
exploratory RARE
behavior O
( O
assessed O
by O
hole RARE
pokes RARE
) O
and O
locomotion RARE
were O
assessed O
during O
a O
10 O
- O
min O
test O
session O
. O

The O
model O
is O
able O
to O
anticipate RARE
why RARE
the O
effect O
of O
water O
fluoridation RARE
on O
caries RARE
prevalence O
is O
most O
pronounced O
when O
caries RARE
is O
diagnosed O
at O
cavity O
level O
. O

12 O
- O
O O
- O
Tetradecanoylphorbol RARE
13 O
- O
acetate O
was O
found O
to O
inhibit O
rapidly O
and O
potently RARE
the O
expression O
of O
mRNAs O
coding O
for O
the O
myogenic O
regulators O
CMD1 NUMERIC
and O
myogenin I-GENE
. O

In O
Xenopus O
laevis O
, O
the O
gene O
encoding O
the O
elongation I-GENE
factor I-GENE
1 I-GENE
- I-GENE
alpha I-GENE
variant I-GENE
EF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
O I-GENE
, O
where O
O O
stands RARE
for O
oocyte O
, O
is O
expressed O
in O
oocytes O
and O
early O
embryos O
. O

These O
introns O
belong O
to O
the O
class O
of O
nuclear O
pre O
- O
mRNA O
introns O
and O
contain O
typical O
5 O
'- O
and O
3 O
'- O
consensus O
sequences O
, O
as O
well O
as O
unique O
features O
. O

The O
mRNA O
identified O
in O
both O
human O
and O
rat O
cells O
with O
the O
human I-GENE
clathrin I-GENE
clone O
revealed O
transcripts O
of O
approximately O
6 O
. O
5 O
kb O
, O
which O
is O
consistent O
with O
the O
predicted O
180 O
kDa O
molecular O
weight O
of O
the O
clathrin I-GENE
heavy I-GENE
chain I-GENE
. O

In O
this O
report O
, O
almost O
6 O
kb O
of O
DNA O
sequence O
is O
presented O
, O
including O
1251 NUMERIC
bp O
5 O
' O
to O
the O
gene O
, O
over O
4 O
kb O
of O
exon O
and O
exon O
- O
intron O
junctions O
, O
and O
583 NUMERIC
bp O
3 O
' O
to O
the O
gene O
. O

An O
8 O
- O
h O
exposure O
to O
10 O
mg O
DMEA ALLCAPS
/ O
m3 O
corresponds O
to O
a O
postexposure O
plasma O
concentration O
and O
2 O
- O
h O
postexposure O
urinary O
excretion O
of O
4 O
. O
9 O
mumol O
/ O
l O
and O
75 O
mmol O
/ O
mol O
creatinine O
, O
respectively O
. O

Antibodies O
specific O
to O
rE12 NUMERIC
and O
rNFIL LASTCAP
- I-GENE
6 I-GENE
disrupt O
nucleoprotein O
complexes O
with O
these O
DNA O
- O
binding O
sites O
, O
confirming O
the O
interaction O
of O
native O
in O
vivo O
factors O
. O

A O
method O
is O
described O
for O
detecting O
targeted O
events O
at O
the O
mu I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
which O
relies RARE
on O
co O
- O
conversion O
( O
or O
co O
- O
exchange O
) O
of O
a O
point O
mutation O
with O
a O
selectable O
marker O
contained O
on O
a O
replacement O
vector O
. O

Allergenic RARE
activity O
of O
allergen O
extract O
Ambrosia RARE
elatior RARE
( O
AE ALLCAPS
) O
was O
tested O
in O
fifteen RARE
volunteers O
extremely O
sensitive O
to O
the O
allergen O
. O

This O
study O
was O
aimed O
at O
assessing O
whether O
c O
- O
DDP O
administration O
immediately O
before O
radiotherapy O
could O
increase O
frequency O
and O
duration O
of O
objective O
responses O
, O
as O
well O
as O
survival O
, O
in O
patients O
affected O
with O
locally O
advanced O
stages O
of O
squamous O
carcinomas O
of O
the O
head O
and O
neck O
. O

Two O
potential O
regulatory O
sequences O
for O
DNA O
binding O
proteins O
were O
found O
in O
the O
non O
- O
coding O
5 O
' O
region O
: O
a O
HAP2 NUMERIC
/ O
HAP3 NUMERIC
consensus O
recognition O
sequence O
at O
nucleotide O
- O
154 O
and O
a O
BAF1 NUMERIC
consensus I-GENE
recognition I-GENE
sequence I-GENE
at O
nucleotide O
- O
136 O
. O

Marked O
thrombocytopenia O
, O
depletion O
of O
serum I-GENE
fibrinogen I-GENE
and O
prolonged O
prothrombin I-GENE
and O
activated O
partial O
thromboplastin I-GENE
time O
, O
were O
recorded O
at O
5 O
to O
10 O
and O
30 O
to O
40 O
minutes O
after O
intravenous O
envenomation RARE
. O

We O
exploit RARE
the O
properties O
of O
LexA I-GENE
fusion I-GENE
proteins I-GENE
to O
study O
the O
dimerization O
and O
DNA O
- O
contacting RARE
domains O
of O
cRel RARE
. O

Plasma O
lipid O
and O
lipoprotein O
profiles O
were O
compared O
in O
elderly O
female O
runners RARE
( O
RU ALLCAPS
: O
n O
= O
15 O
, O
aged O
66 O
+/- O
5 O
years O
, O
body O
fat O
20 O
+/- O
4 O
%, O
training O
distance O
35 O
+/- O
15 O
km RARE
week O
- O
1 O
, O
VO2max NUMERIC
36 O
+/- O
4 O
ml O
kg O
- O
1 O
min O
- O
1 O
, O
mean O
+/- O
SD O
) O
and O
age O
- O
matched O
untrained RARE
women O
( O
UT O
: O
n O
= O
28 O
, O
66 O
+/- O
4 O
years O
, O
body O
fat O
26 O
+/- O
6 O
%, O
VO2max NUMERIC
26 O
+/- O
3 O
ml O
kg O
- O
1 O
min O
- O
1 O
). O

Auditory RARE
threshold O
shifts O
, O
as O
measured O
by O
the O
auditory O
evoked O
brainstem RARE
response O
, O
were O
measured O
at O
2 O
, O
4 O
, O
8 O
, O
12 O
, O
16 O
, O
20 O
and O
24 O
kHz RARE
. O

Fundamental RARE
and O
clinical O
evaluation O
of O
equilibrium O
dialysis O
-- O
radioimmunoassay O
system O
for O
measurement O
of O
serum O
free O
thyroxine O

We O
conclude O
that O
TA O
caused O
a O
specific O
decrease O
in O
AGD ALLCAPS
on O
GD ALLCAPS
20 O
that O
was O
largely O
reversed O
by O
PCD ALLCAPS
23 O
. O

When O
examined O
as O
adults O
( O
8 O
weeks O
old O
), O
the O
external O
genitalia RARE
of O
TA O
- O
exposed O
offspring RARE
were O
normal O
. O

After O
PTCA O
, O
ejection O
fraction O
increased O
from O
54 O
+/- O
8 O
% O
to O
59 O
+/- O
8 O
% O
( O
p O
less O
than O
0 O
. O
05 O
) O
and O
regional O
function O
improved O
significantly O
( O
maximal O
standard O
deviation O
before O
PTCA O
: O
2 O
. O
8 O
+/- O
0 O
. O
8 O
; O
after O
PTCA O
: O
1 O
. O
9 O
+/- O
0 O
. O
9 O
- O
segments O
below O
the O
first O
standard O
deviation O
before O
PTCA O
: O
31 O
+/- O
16 O
; O
after O
PTCA O
: O
19 O
+/- O
17 O
). O

The O
alcoholic O
patient O
, O
his O
work O
and O
the O
subjectivity RARE
of O
the O
period O

These O
data O
suggest O
that O
the O
combined O
treatment O
with O
a O
thromboxane I-GENE
synthetase I-GENE
inhibitor O
and O
a O
thromboxane I-GENE
receptor I-GENE
antagonist O
provides O
a O
better O
protection O
against O
digoxin RARE
intoxication RARE
than O
with O
either O
agent O
alone O
. O

A O
330 NUMERIC
- O
kb O
YAC O
, O
A148A7 NUMERIC
, O
spanned RARE
from O
the O
HLA I-GENE
- O
DQA1 NUMERIC
locus O
through O
the O
Y3 NUMERIC
/ O
Ring RARE
4 I-GENE
locus O
and O
extended O
at O
least O
130 O
kb O
centromeric RARE
of O
YAC O
B1D12 NUMERIC
. O

Interspecific RARE
backcross O
analysis O
using O
progeny RARE
derived O
from O
matings RARE
of O
( O
C57BL O
/ O
6J NUMERIC
x O
Mus RARE
spretus RARE
) O
F1 O
x O
C57BL O
/ O
6J NUMERIC
mice O
indicates O
that O
the O
thrombospondin RARE
gene I-GENE
is O
tightly O
linked O
to O
the O
Fshb RARE
, O
Actcl RARE
, O
Ltk RARE
, O
and O
B2M NUMERIC
loci I-GENE
on O
murine O
chromosome O
2 O
. O

Adverse RARE
foetal RARE
outcome O
in O
specific O
IgM I-GENE
positive O
Chlamydia O
trachomatis RARE
infection O
in O
pregnancy O
. O

Using O
an O
image O
- O
processing O
computer O
, O
regional O
LV O
time O
- O
density O
curves O
were O
constructed O
for O
one O
cardiac O
cycle O
. O

In O
a O
second O
patient O
the O
VT O
became O
nonsustained RARE
. O

If O
delay O
has O
occurred O
between O
centrifugation RARE
and O
the O
measurement O
, O
causing O
substantial O
loss O
of O
CO2 O
, O
equilibration RARE
of O
the O
sample O
with O
a O
gas O
mixture O
corresponding O
to O
PCO2 O
= O
5 O
. O
3 O
kPa RARE
prior O
to O
the O
measurement O
is O
recommended O
. O

The O
possible O
mechanisms O
underlying O
differences O
in O
post O
- O
tetanic RARE
effects O
from O
muscle O
and O
cutaneous O
afferents O
in O
adults O
and O
neonates O
are O
discussed O
. O

We O
examined O
behavioral O
alterations O
in O
the O
brown O
cockroach RARE
, O
Periplaneta RARE
brunnea RARE
, O
infected O
with O
the O
acanthocephalan RARE
, O
Moniliformis RARE
moniliformis RARE
. O

First O
, O
the O
finding O
of O
a O
monomeric O
Alu I-GENE
family O
repeat O
at O
the O
junction O
between O
nonhomology RARE
block O
I O
and O
homology O
block O
Y O
of O
the O
alpha I-GENE
2 I-GENE
gene I-GENE
- I-GENE
containing I-GENE
unit I-GENE
in I-GENE
rhesus I-GENE
macaque RARE
suggests O
that O
the O
dimeric O
Alu I-GENE
family O
repeat O
, O
Alu I-GENE
3 I-GENE
, O
at O
the O
orthologous RARE
position O
in O
human O
was O
generated O
by O
insertion O
of O
a O
monomeric O
Alu I-GENE
family O
repeat O
into O
the O
3 O
' O
end O
of O
another O
preexisting RARE
Alu I-GENE
family O
repeat O
. O

The O
sequence O
of O
the O
repressor O
locus O
, O
c O
, O
of O
the O
Streptomyces O
temperate RARE
phage O
, O
phi O
C31 NUMERIC
, O
was O
shown O
previously O
to O
contain O
an O
open O
reading O
frame O
encoding O
a O
74 O
kDa O
protein O
. O

The O
EPO I-GENE
levels O
were O
distinctly O
increased O
before O
transfusion O
; O
they O
did O
not O
significantly O
change O
just O
after O
transfusion O
, O
but O
subsequently O
decreased O
. O

This O
differential O
sensitivity O
to O
DB ALLCAPS
, O
as O
measured O
by O
a O
lower O
concentration O
of O
DB ALLCAPS
which O
caused O
loss O
of O
righting RARE
in O
LS ALLCAPS
, O
was O
accompanied O
by O
an O
equal O
rate O
of O
water O
- O
soluble O
barbiturate RARE
brain O
distribution O
and O
elimination O
in O
the O
two O
lines O
. O

The O
existence O
of O
threshold O
concentrations O
, O
above O
which O
certain O
phenomena O
may O
occur O
, O
strengthens RARE
the O
role O
of O
sentinels RARE
. O

However O
, O
it O
was O
synthesized O
at O
both O
temperatures O
after O
addition O
of O
A23187 NUMERIC
. O

Felodipine RARE
did O
not O
alter O
the O
baseline O
FEV1 O
, O
but O
showed O
a O
small O
significant O
inhibitory O
effect O
upon O
histamine O
and O
AMP O
induced O
bronchoconstriction RARE
. O

Ten O
out O
of O
10 O
patients O
with O
progressive O
disease O
had O
mast O
cells O
greater O
than O
or O
equal O
to O
0 O
. O
5 O
%, O
hyaluronan RARE
greater O
than O
or O
equal O
to O
50 O
micrograms O
. O
l O
- O
1 O
and O
fibronectin I-GENE
greater O
than O
or O
equal O
to O
350 O
micrograms O
. O
l O
- O
1 O
compared O
to O
eight O
out O
of O
41 O
patients O
with O
stable O
or O
regressive RARE
disease O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Our O
mapping O
results O
did O
not O
suggest O
involvement O
of O
this O
gene O
in O
previously O
mapped O
genetic O
disorders O
or O
in O
known O
neoplasia RARE
- O
associated O
translocation O
breakpoints O
. O

Relatively RARE
little O
is O
known O
regarding O
the O
role O
of O
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
activity O
in O
male O
rat O
sexual O
behavior O
. O

These O
changes O
weren RARE
' O
t O
so O
significant O
in O
the O
group O
of O
obese O
children O
who O
didn RARE
' O
t O
lose RARE
weight O
. O

Arsenic RARE
contents O
in O
native O
copper O

In O
ten O
other O
experiments O
( O
5 O
experimental O
and O
5 O
control O
rats O
) O
99mTc O
- O
sulfur O
colloid O
was O
injected O
intravenously O
. O

Magnetotherapy RARE
of O
hepatitis O
A O
and O
B O
in O
children O

These O
results O
were O
superior O
to O
those O
in O
24 O
patients O
with O
conventional O
end O
- O
to O
- O
end O
sutures RARE
on O
clinical O
testing O
. O

Mutational O
analysis O
supports O
a O
role O
for O
multiple O
structural O
features O
in O
the O
C O
- O
terminal O
secretion O
signal O
of O
Escherichia I-GENE
coli I-GENE
haemolysin RARE
. O

Among O
blood O
donors O
in O
the O
Republic RARE
of O
Serbia RARE
, O
regardless O
the O
number O
of O
blood O
donations RARE
, O
the O
percentage O
of O
female O
donors O
is O
significantly O
lower O
compared O
to O
the O
percentage O
of O
male O
blood O
donors O
. O

Extramedullary RARE
relapse O
in O
childhood O
leukemia O
. O

Mycoplasma RARE
pneumoniae O
was O
isolated O
from O
the O
pleural O
fluid O
of O
this O
patient O
. O

RU486 NUMERIC
and O
ONO ALLCAPS
802 NUMERIC
in O
combination O
have O
been O
shown O
to O
be O
effective O
in O
early O
termination O
of O
pregnancy O
. O

The O
presence O
of O
local O
abnormalities O
in O
both O
patients O
can O
support O
the O
hypothesis O
that O
the O
cortex O
, O
especially O
of O
the O
temporal O
anterior O
lobe O
, O
is O
involved O
in O
the O
origin O
of O
the O
laughing RARE
seizures O
. O

In O
line O
with O
the O
small O
values O
for O
QS ALLCAPS
/ O
QC ALLCAPS
, O
our O
results O
further O
indicate O
that O
even O
large O
, O
well O
- O
perfused O
, O
occluded O
air O
spaces RARE
in O
the O
lung O
will O
hardly RARE
affect O
the O
recovered O
ventilation O
/ O
perfusion O
distribution O
obtained O
from O
inert RARE
gas O
data O
when O
CDCSF6 NUMERIC
exceeds RARE
0 O
. O
1 O
ml O
. O
min O
- O
1 O
. O
mmHg O
- O
1 O
. O

Many O
cells O
were O
negative O
for O
endothelial O
- O
cell O
markers O
, O
and O
they O
reacted O
with O
a O
monoclonal O
antibody O
against O
muscle O
actin I-GENE
. O

CT O
abnormalities O
noted O
in O
term O
babies O
included O
hemorrhage O
( O
subarachnoid RARE
5 O
. O
8 O
%, O
intracerebral RARE
11 O
. O
6 O
%), O
hypodensity RARE
( O
mild O
23 O
. O
2 O
%, O
moderate O
11 O
. O
6 O
% O
severe O
5 O
. O
8 O
%); RARE
hypodensity RARE
with O
hemorrhage O
5 O
. O
8 O
% O
and O
cerebral O
atrophy O
5 O
. O
8 O
%. O

The O
effects O
of O
contrast O
media O
on O
coagulation I-GENE
factor I-GENE
XII ALLCAPS
. O

Pigs RARE
were O
switched RARE
from O
the O
growing O
to O
the O
finishing RARE
diet O
at O
57 O
and O
61 O
kg O
in O
Exp RARE
. O

In O
sixteen RARE
patients O
with O
moderate O
essential O
hypertension O
the O
effects O
of O
10 O
- O
day O
nifedipine O
treatment O
on O
serum O
uric O
acid O
and O
renal O
excretion O
of O
uric O
acid O
were O
evaluated O
. O

TPTA ALLCAPS
produced O
brain O
congestion RARE
, O
and O
hepatic O
and O
pulmonary O
petechial RARE
and O
generalized O
hemorrhages RARE
. O

Examples RARE
are O
using O
more O
subjects O
or O
an O
improved O
research O
design O
, O
developing O
consensus O
statements RARE
or O
using O
meta RARE
- O
analysis O
. O

A O
two O
phase O
slug RARE
flow O
tubular O
heat O
exchanger RARE
was O
used O
for O
the O
thermal O
inactivation O
of O
Listeria RARE
monocytogenes O
in O
natural O
infected O
milk O
from O
seven O
cows O
. O

So RARE
far O
15 O
children O
have O
been O
studied O
. O

Regional RARE
cerebral O
blood O
flow O
( O
rCBF O
) O
measurements O
and O
psychiatric O
ratings RARE
were O
performed O
on O
seven O
schizophrenic O
patients O
( O
mean O
age O
= O
41 O
. O
4 O
years O
) O
who O
had O
been O
examined O
18 O
years O
previously O
in O
a O
study O
that O
used O
similar O
psychiatric O
ratings RARE
and O
a O
comparable O
rCBF O
technique O
. O

In O
the O
present O
study O
, O
we O
identified O
a O
strong O
positive O
cis O
- O
regulatory O
element O
at O
- O
70 O
bp O
to O
- O
75 O
bp O
in O
the O
LpS1 NUMERIC
beta I-GENE
promoter I-GENE
with O
the O
sequence O
( O
G O
) O
6 O
and O
a O
similar O
, O
more O
distal O
cis O
- O
element O
at O
- O
721 NUMERIC
bp O
to O
- O
726 NUMERIC
bp O
. O

The O
present O
study O
reports O
visual O
evoked O
potential O
responses O
to O
pattern O
reversal O
( O
VEP ALLCAPS
- O
P O
) O
in O
ten O
third O
trimester RARE
pregnant O
women O
and O
changes O
in O
latency O
of O
NPN ALLCAPS
complex O
when O
compared O
with O
these O
responses O
in O
the O
non O
pregnant O
state O
. O

No O
case O
of O
SMF ALLCAPS
demonstrated O
expansive RARE
tumorous RARE
growth O
. O

Different RARE
doses O
of O
15 O
- O
methyl O
- O
PGF2 O
alpha O
( O
0 O
. O
125 O
- O
10 O
mg O
) O
were O
used O
to O
induce O
luteolysis RARE
and O
oestrus RARE
in O
7 O
heifers O
with O
28 O
treatments O
on O
day O
8 O
- O
12 O
of O
the O
oestrous RARE
cycle O
. O

Review RARE
of O
the O
literature O
and O
report O
of O
a O
case O
of O
a O
dermoid RARE
cyst O
. O

Resolution RARE
of O
thermographic RARE
asymmetry O
and O
/ O
or O
decrease O
in O
Delta O
T O
was O
demonstrated O
in O
approximately O
81 O
% O
of O
the O
post O
- O
treatment O
population O
. O

In O
all O
instances O
the O
apparent O
alcohol O
responses O
were O
very O
small O
and O
never O
exceeded RARE
a O
reading O
of O
1 O
microgram O
/ O
100ml NUMERIC
for O
breath RARE
samples O
more O
than O
10min NUMERIC
post O
- O
exposure O
. O

Maize RARE
rbcS LASTCAP
promoter I-GENE
activity O
depends O
on O
sequence O
elements O
not O
found O
in O
dicot RARE
rbcS LASTCAP
promoters I-GENE
. O

Measurements O
were O
done O
with O
a O
commercial O
haematofluorometer RARE
Buchler RARE
ZF ALLCAPS
which O
was O
calibrated RARE
to O
the O
average O
haematocrit RARE
value O
of O
0 O
. O
42 O
. O

The O
relatively O
scanty RARE
number O
of O
examples O
, O
which O
could O
be O
justified RARE
by O
the O
variety O
and O
complexity O
of O
combined O
exposure O
, O
allows O
to O
conclude O
that O
life O
- O
style RARE
factors O
have O
considerable O
influence O
on O
interindividual RARE
differences O
in O
susceptibility O
to O
xenobiotics RARE
toxicity O
. O

The O
12S NUMERIC
E1A I-GENE
product I-GENE
does O
not O
activate O
a O
TRE O
sequence O
, O
but O
cotransfection O
with O
c I-GENE
- I-GENE
jun I-GENE
circumvents RARE
this O
lack O
of O
stimulation O
. O

After O
treatment O
with O
tunicamycin RARE
, O
the O
transfectants O
secreted O
unglycosylated RARE
18 O
- O
kDa O
polypeptides O
which O
could O
also O
bind O
IgE I-GENE
. O

PAS1 NUMERIC
, O
a O
yeast O
gene O
required O
for O
peroxisome O
biogenesis O
, O
encodes O
a O
member O
of O
a O
novel O
family O
of O
putative O
ATPases RARE
. O

The O
gene O
is O
1 O
, O
139 O
base O
pairs O
( O
bp O
) O
long O
, O
and O
, O
like O
other O
members O
of O
the O
SIG ALLCAPS
family I-GENE
, O
the O
beta I-GENE
TG I-GENE
gene I-GENE
is O
divided O
into O
3 O
exons O
. O

The O
pp90rsk NUMERIC
- I-GENE
protein I-GENE
kinase I-GENE
activity O
( O
referred O
to O
as O
rsk RARE
- I-GENE
kinase I-GENE
) O
is O
also O
not O
related O
to O
cofactor O
- O
dependent O
signal O
transducing RARE
protein O
kinases O
such O
as O
the O
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
, O
members O
of O
the O
protein I-GENE
kinase I-GENE
C I-GENE
family I-GENE
, O
or O
other O
Ca2 I-GENE
(+)- I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
. O

Human I-GENE
GATA I-GENE
- I-GENE
3 I-GENE
: O
a O
lineage O
- O
restricted O
transcription O
factor O
that O
regulates O
the O
expression O
of O
the O
T I-GENE
cell I-GENE
receptor I-GENE
alpha I-GENE
gene I-GENE
. O

Like O
many O
eukaryotic O
transcription O
factors O
, O
these O
proteins O
bind O
to O
DNA O
as O
dimers O
. O

Furthermore O
, O
the O
UvrA LASTCAP
protein I-GENE
interacts O
with O
the O
UvrB LASTCAP
protein I-GENE
to O
modulate O
its O
activities O
, O
both O
in O
solution O
and O
in O
association O
with O
DNA O
, O
where O
the O
UvrAB LASTCAP
complex I-GENE
possesses O
a O
helicase I-GENE
activity O
. O

The O
ED30 NUMERIC
values O
were O
2 O
. O
4 O
and O
2 O
. O
2 O
mg O
/ O
kg O
and O
similar O
to O
the O
respective O
values O
of O
nifedipine O
( O
ED ALLCAPS
30 O
: O
2 O
. O
4 O
, O
2 O
. O
1 O
mg O
/ O
kg O
). O

Southwestern RARE
blot O
analysis O
demonstrated O
that O
this O
phosphoprotein O
can O
bind O
the O
kappa I-GENE
B I-GENE
element I-GENE
directly O
and O
specifically O
. O

Thus O
, O
the O
positive O
effect O
of O
NS1 I-GENE
on O
the O
steady O
- O
state O
levels O
of O
P4 I-GENE
transcripts I-GENE
depends O
on O
the O
amplification O
of O
gene O
copy O
number O
and O
the O
integrity O
of O
the O
terminal O
repeats O
. O

The O
minus O
- O
end O
- O
directed O
microtubule O
motors RARE
, O
the O
dyneins RARE
, O
may O
also O
constitute O
a O
superfamily O
of O
force O
- O
generating O
proteins O
with O
distinct O
attachment O
domains O
. O

It O
is O
transparent RARE
, O
cheap RARE
to O
be O
made O
, O
and O
easy RARE
to O
empty RARE
and O
was O
tested O
in O
118 O
animals O
for O
two O
and O
four O
weeks O
. O

The O
incompatibility RARE
group O
W O
plasmid O
pSa RARE
suppresses O
Agrobacterium RARE
tumefaciens RARE
oncogenicity RARE
( O
J O
. O

Potential RARE
translational O
start O
signals O
are O
upstream O
of O
ORF1 O
and O
ORF2 O
. O

Imaging RARE
of O
D2 I-GENE
dopamine I-GENE
receptor I-GENE

The O
Thr161Val NUMERIC
mutation O
causes O
a O
lethal O
phenotype O
in O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
, O
while O
replacement O
of O
Thr161 NUMERIC
with O
glutamic RARE
acid O
, O
potentially O
mimicking RARE
phosphorylation O
, O
causes O
uncoordination RARE
of O
mitosis O
and O
multiple O
cytokinesis RARE
. O

The O
abundance O
of O
transcripts O
from O
several O
unrelated O
genes O
is O
decreased O
in O
cdc68 NUMERIC
- I-GENE
1 I-GENE
mutant I-GENE
cells O
after O
transfer O
to O
the O
restrictive O
temperature O
, O
while O
at O
least O
one O
transcript O
, O
from O
the O
HSP82 NUMERIC
gene I-GENE
, O
persists RARE
in O
an O
aberrant O
fashion O
. O

Deregulation RARE
of O
their O
expression O
may O
contribute O
to O
malignant O
transformation O
associated O
with O
HTLV O
- O
1 O
infection O
. O

The O
murine I-GENE
Mov RARE
- I-GENE
34 I-GENE
gene I-GENE
: O
full O
- O
length O
cDNA O
and O
genomic O
organization O
. O

CREB I-GENE
was O
identified O
as O
one O
of O
the O
protein O
components O
in O
several O
of O
the O
gel O
shift O
complexes O
formed O
with O
the O
variant O
CRE O
. O

The O
spectrum O
of O
histologically O
diagnosed O
malignant O
neoplasms O
in O
Sabah RARE
, O
1983 O
- O
1988 O
. O

When O
transfected O
into O
Drosophila O
SL ALLCAPS
- O
2 O
cells O
, O
pCAT LASTCAP
plasmid O
containing O
2 O
, O
090 NUMERIC
bp O
of O
5 O
'- O
flanking O
region O
shows O
a O
3 O
. O
0 O
- O
to O
3 O
. O
5 O
- O
fold O
increase O
in O
chloramphenicol I-GENE
acetyltransferase I-GENE
activity O
after O
induction O
with O
retinoic O
acid O
and O
/ O
or O
8 O
- O
bromo RARE
- O
cAMP O
. O

Two O
alternatively O
spliced O
5 O
' O
UTRs RARE
, O
designated O
type O
I O
and O
type O
II O
, O
of O
222 NUMERIC
and O
115 O
bp O
, O
respectively O
, O
were O
found O
associated O
with O
PFP ALLCAPS
. O

The O
N O
- O
terminus O
of O
another O
open O
reading O
frame O
was O
found O
3 O
' O
from O
nifA LASTCAP
and O
tentatively O
identified O
as O
nifB LASTCAP
by O
amino O
acid O
sequence O
comparison O
. O

The O
RNA O
genome O
of O
rabbit O
hemorrhagic O
disease O
virus O
( O
RHDV ALLCAPS
) O
was O
molecularly O
cloned O
. O

Therefore O
, O
we O
have O
developed O
a O
system O
to O
study O
nuclear O
targeting O
in O
plants O
and O
have O
established O
that O
the O
nuclear O
transport O
machinery O
is O
similar O
in O
monocots RARE
and O
dicots RARE
. O

A O
novel O
cDNA O
clone O
termed O
R2 O
was O
isolated O
by O
subtractive RARE
hybridization O
of O
a O
cDNA O
library O
of O
phytohemagglutinin I-GENE
( O
PHA I-GENE
)/ O
phorbol O
myristate O
acetate O
- O
stimulated O
Jurkat O
cells O
and O
by O
rescreening RARE
a O
cDNA O
library O
of O
PHA O
- O
stimulated O
peripheral O
blood O
lymphocytes O
. O

In O
conclusion O
, O
we O
observed O
a O
great O
regeneration O
ability O
following O
mechanical O
injury O
in O
the O
nasal O
mucosa O
. O

There O
occurred O
a O
linear O
relationship O
between O
the O
drop O
in O
glucose I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphatase I-GENE
dehydrogenase I-GENE
activity O
and O
in O
vitamin O
E O
level O
, O
on O
one O
hand O
, O
and O
the O
duration O
of O
poisoning O
with O
sodium O
nitrite O
. O

A O
vector O
containing O
a O
transcriptionally O
inactive O
neomycin I-GENE
phosphotransferase I-GENE
II I-GENE
gene I-GENE
was O
used O
to O
select O
promoter O
sequences O
from O
a O
pool O
of O
random O
genomic O
DNA O
fragments O
. O

Chagas RARE
' O
disease O
, O
visceral O
leishmaniasis RARE
, O
anti I-GENE
- I-GENE
nuclear I-GENE
factor I-GENE
, O
schistosomiasis RARE
, O
rheumatoid I-GENE
factor I-GENE
and O
normal O
controls O
. O

Previous O
analysis O
of O
the O
98 O
- O
bp O
sequence O
has O
delineated RARE
several O
protein O
- O
binding O
domains O
that O
are O
recognized O
by O
nuclear O
factors O
present O
in O
human O
brain O
cells O
. O

The O
second O
transcriptional O
unit O
, O
designated O
UL26 I-GENE
. I-GENE
5 I-GENE
, O
predicted O
to O
specify RARE
a O
protein O
of O
329 NUMERIC
amino O
acids O
, O
encodes O
the O
family I-GENE
35 I-GENE
proteins I-GENE
; O
it O
is O
transcribed O
by O
an O
mRNA O
which O
initiates RARE
at O
approximately O
nucleotide O
+ O
1000 O
of O
the O
UL26 I-GENE
transcription O
initiation O
site O
and O
is O
translated O
from O
the O
methionine O
initiation O
codon O
located O
at O
position O
+ O
1099 NUMERIC
of O
the O
UL26 I-GENE
transcriptional I-GENE
unit I-GENE
. O

The O
adeno RARE
- I-GENE
associated I-GENE
virus I-GENE
( I-GENE
AAV I-GENE
) I-GENE
rep RARE
gene I-GENE
encodes O
four O
proteins O
( O
Rep78 NUMERIC
, O
Rep68 NUMERIC
, O
Rep52 NUMERIC
, O
and O
Rep40 NUMERIC
) O
required O
for O
AAV O
DNA O
replication O
and O
AAV O
gene O
regulation O
. O

A O
larger O
region O
upstream O
of O
human I-GENE
CMV I-GENE
dbp RARE
also O
mediated O
replication O
in O
transient O
assays O
. O

It O
also O
contains O
a O
picornaviral RARE
3C I-GENE
- I-GENE
like I-GENE
protease I-GENE
domain I-GENE
and O
two O
papain RARE
- I-GENE
like I-GENE
protease I-GENE
domains I-GENE
. O

However O
, O
the O
relative O
positions O
of O
the O
VV ALLCAPS
genes O
( O
genus O
Orthopoxvirus RARE
) O
are O
different O
than O
those O
of O
the O
corresponding O
ORFs O
in O
SFV O
( O
genus O
Leporipoxvirus RARE
), O
indicating O
complex O
rearrangements O
of O
DNA O
in O
the O
genome O
of O
one O
or O
both O
of O
these O
viruses O
subsequent O
to O
their O
divergence O
from O
a O
common O
ancestor O
. O

This O
result O
suggests O
that O
phosphorylation O
of O
Thr O
14 O
and O
/ O
or O
Tyr O
15 O
inhibits O
p34cdc2 I-GENE
kinase I-GENE
activity O
, O
in O
line O
with O
the O
location O
of O
these O
residues O
within O
the O
putative O
ATP O
binding O
site O
of O
the O
kinase O
. O

In O
short O
- O
term O
cotransfections RARE
, O
a O
pFRTK LASTCAP
- O
CAT I-GENE
target O
containing O
EBNA I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
from O
the O
EBV O
origin O
of O
plasmid O
replication O
, O
ori RARE
- I-GENE
P I-GENE
, O
was O
transactivated O
by O
a O
carboxy I-GENE
- I-GENE
terminal I-GENE
EBNA I-GENE
- I-GENE
1 I-GENE
construction I-GENE
( O
amino O
acids O
450 O
to O
641 NUMERIC
) O
that O
also O
carried O
a O
c I-GENE
- I-GENE
myc I-GENE
nuclear I-GENE
localization I-GENE
signal I-GENE
. O

The O
findings O
are O
compatible O
with O
the O
idea O
that O
the O
genes O
encoding O
PDGF I-GENE
receptors I-GENE
in O
glioma O
cells O
are O
regulated O
in O
concert RARE
with O
other O
genes O
, O
the O
expression O
of O
which O
may O
reflect O
the O
developmental O
program O
of O
normal O
glia RARE
cell O
lineages O
. O

Suggestive RARE
evidence O
was O
obtained O
that O
cstA LASTCAP
is O
involved O
in O
peptide O
utilization O
. O

This O
study O
tested O
the O
hypothesis O
that O
sodium O
channel O
blocking O
drugs O
selectively O
prolong RARE
the O
late O
potential O
, O
or O
terminal O
low O
amplitude O
signal O
, O
portion O
of O
the O
signal O
- O
averaged O
QRS O
complex O
and O
that O
prolongation O
of O
the O
late O
potential O
would O
correlate O
with O
slowing RARE
of O
ventricular O
tachycardia O
. O

Identification O
and O
nucleotide O
sequence O
of O
Rhizobium I-GENE
meliloti RARE
insertion I-GENE
sequence I-GENE
ISRm3 NUMERIC
: O
similarity O
between O
the O
putative O
transposase RARE
encoded O
by O
ISRm3 NUMERIC
and O
those O
encoded O
by O
Staphylococcus I-GENE
aureus I-GENE
IS256 NUMERIC
and O
Thiobacillus RARE
ferrooxidans RARE
IST2 NUMERIC
. O

To O
determine O
the O
relationship O
of O
these O
viruses O
, O
the O
complete O
DNA O
sequence O
of O
KV ALLCAPS
consisting O
of O
4754 NUMERIC
bp O
was O
determined O
. O

Whereas O
a O
PR55 NUMERIC
beta I-GENE
transcript I-GENE
of O
about O
2 O
. O
3 O
kb O
was O
detected O
at O
high O
levels O
in O
the O
neuroblastoma O
derived O
cell O
line O
LA O
- O
N O
- O
1 O
, O
the O
level O
of O
the O
mRNA O
was O
very O
low O
in O
the O
other O
human O
cell O
lines O
analyzed O
. O

Heterodimers RARE
of O
myogenin I-GENE
and O
E12 I-GENE
( O
or O
MyoD I-GENE
and O
E12 I-GENE
) O
specifically O
bound O
a O
restriction O
fragment O
extending O
from O
- O
200 O
to O
- O
103 NUMERIC
relative O
to O
the O
start O
of O
cardiac I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
transcription O
. O

The O
effects O
of O
c I-GENE
- I-GENE
myc I-GENE
were O
further O
dissected RARE
by O
showing O
that O
c I-GENE
- I-GENE
myc I-GENE
can O
inhibit O
differentiation O
independently O
of O
Id RARE
, O
a O
negative O
regulator O
of O
muscle O
differentiation O
. O

Stable O
association O
of O
U2 I-GENE
snRNP I-GENE
with O
the O
branchpoint O
sequence O
of O
mammalian O
pre O
- O
mRNAs O
requires O
binding O
of O
a O
non O
- O
snRNP O
protein O
to O
the O
polypyrimidine RARE
tract O
. O

Naturally RARE
acquired O
antibodies O
were O
demonstrated O
in O
some O
rabbits O
kept O
on O
commercial O
farms RARE
. O

The O
Italian O
Lung O
Cancer O
Task RARE
Force RARE
( O
FONICAP ALLCAPS
). O

The O
promoter O
activity O
of O
the O
gene I-GENE
encoding I-GENE
Alzheimer I-GENE
beta I-GENE
- I-GENE
amyloid RARE
precursor I-GENE
protein I-GENE
( O
APP ALLCAPS
) O
is O
regulated O
by O
two O
blocks O
of O
upstream O
sequences O
. O

Biol O
. O

Nucleotide O
sequences O
between O
the O
env I-GENE
gene I-GENE
and O
the O
LTR I-GENE
of I-GENE
SFV I-GENE
- I-GENE
1 I-GENE
were O
determined O
. O

This O
element O
was O
used O
to O
screen O
an O
EMBL3 NUMERIC
mouse O
genomic O
library O
. O

The O
MVV ALLCAPS
- O
value O
is O
under O
the O
predicted O
level O
in O
the O
case O
of O
67 O
- O
76 O
percent O
. O

The O
rad9 NUMERIC
. I-GENE
192 I-GENE
DNA I-GENE
repair I-GENE
mutant I-GENE
from I-GENE
the I-GENE
fission I-GENE
yeast I-GENE
, I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
, O
is O
sensitive O
to O
both O
UV O
and O
ionising RARE
radiation O
. O

Review RARE
: O
deterioration O
of O
glucose O
tolerance O
with O
age O
: O
the O
role O
of O
insulin I-GENE
resistance O
. O

The O
5 O
' O
region O
shows O
strong O
sequence O
similarity O
to O
Escherichia O
coli O
consensus O
promoters O
and O
ribosome O
- O
binding O
sequences O
and O
allows O
high O
levels O
of O
expression O
in O
E O
. O
coli O
. O

Premature RARE
initiation O
of O
mitosis O
in O
yeast O
lacking O
RCC1 NUMERIC
or O
an O
interacting O
GTPase I-GENE
. O

The O
method O
has O
been O
routinely RARE
used O
in O
our O
laboratory O
for O
1 O
year O
and O
has O
proven O
to O
be O
a O
reliable O
procedure O
for O
the O
biological O
control O
of O
occupational RARE
exposure O
to O
toluene O
and O
/ O
or O
xylene O
. O

The O
patient O
was O
a O
78 O
- O
year O
- O
old O
male O
in O
whom O
skin O
lesions O
preceded RARE
the O
diagnosis O
of O
myelofibrosis RARE
. O

Oculus RARE
- O
500 O
is O
a O
group O
of O
high O
resolution O
imaging O
boards RARE
for O
use O
with O
IBM ALLCAPS
- O
AT O
and O
compatible O
computers RARE
. O

The O
human O
cDNA O
was O
used O
to O
demonstrate O
that O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
could O
rapidly O
stimulate O
MARCKS ALLCAPS
gene I-GENE
transcription O
in O
the O
human O
promyelocytic RARE
leukemia O
cell O
line O
HL60 NUMERIC
. O

After O
resection O
of O
the O
proximal O
fragment O
, O
all O
scaphoid RARE
contact O
area O
and O
pressure O
was O
born O
by O
the O
distal O
scaphoid RARE
fragment O
. O

Plate RARE
luting RARE
, O
a O
technique O
that O
uses O
polymethylmethacrylate RARE
( O
PMMA ALLCAPS
) O
interposed RARE
between O
the O
plate O
and O
the O
bone O
, O
as O
well O
as O
between O
the O
screw RARE
heads RARE
and O
the O
plate O
, O
to O
improve O
the O
stability O
of O
internal O
fixation O
was O
tested O
in O
vitro O
using O
20 O
paired O
equine O
third O
metacarpal RARE
bones RARE
with O
mid O
- O
diaphyseal RARE
osteotomies RARE
plated RARE
with O
six O
- O
hole RARE
broad O
ASIF ALLCAPS
compression O
plates O
. O

These O
features O
were O
considered O
consistent O
with O
a O
diagnosis O
of O
Rothmund RARE
- O
Thomson RARE
syndrome O
. O

Thyroid RARE
lymphoma O
and O
its O
management O
. O

The O
protein O
encoded O
by O
ORF113 NUMERIC
contains O
a O
transmembrane O
domain O
. O

Space RARE
limitations O
prevent O
an O
exhaustive RARE
review O
of O
all O
biologic RARE
pharmaceuticals RARE
, O
such O
as O
tissue I-GENE
plasminogen I-GENE
activating I-GENE
substance RARE
, O
hormones O
( O
e O
. O
g O
., O
thyroid O
, O
insulin I-GENE
, O
growth I-GENE
hormone I-GENE
, O
erythropoietin I-GENE
), O
clotting O
factors O
, O
and O
blood O
products O
. O

Dd RARE
PK1 NUMERIC
RNA I-GENE
decreases O
after O
6 O
h O
of O
starvation O
to O
re O
- O
accumulate O
once O
the O
cells O
have O
aggregated RARE
. O

The O
various O
forms O
of O
sickle RARE
cell O
disease O
share O
the O
common O
feature O
of O
an O
abnormal O
globin I-GENE
chain I-GENE
that O
, O
under O
certain O
conditions O
such O
as O
hypoxia O
, O
results O
in O
the O
sickling RARE
of O
red O
blood O
cells O
and O
obstruction O
of O
blood O
vessels O
. O

The O
primary O
structure O
of O
each O
of O
the O
three O
proteins O
has O
about O
70 O
% O
homology O
with O
that O
of O
mouse I-GENE
contrapsin RARE
, O
in O
contrast O
to O
43 O
- O
46 O
% O
homology O
with O
that O
of O
rat I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
protease I-GENE
inhibitor O
. O

Patterns RARE
of O
connections RARE
underlying O
cross O
- O
modality O
integration O
were O
studied O
by O
injecting O
distinguishable RARE
, O
retrograde RARE
tracers RARE
( O
Fluoro RARE
- O
Gold RARE
and O
diamidino RARE
yellow O
) O
in O
pairwise RARE
manner O
into O
different O
sensory O
representations RARE
( O
visual O
, O
somatosensory RARE
, O
and O
auditory O
) O
in O
the O
cerebral O
cortex O
of O
the O
rat O
. O

Young RARE
CD O
- O
1 O
mice O
, O
4 O
days O
old O
, O
exposed O
to O
0 O
. O
1 O
% O
nicotine O
sulfate O
on O
gestational O
days O
6 O
- O
20 O
were O
compared O
with O
untreated O
pups RARE
of O
the O
same O
age O
to O
determine O
its O
effect O
on O
the O
development O
of O
mandibular O
first O
molars RARE
. O

USF I-GENE
synthesized O
in O
an O
in O
vitro O
transcription O
and O
translation O
system O
also O
binds O
to O
the O
ADH I-GENE
promoter I-GENE
as O
well O
as O
to O
the O
MLP ALLCAPS
. O

The O
across O
- O
fiber O
pattern O
of O
the O
responses O
to O
hypotonic RARE
NaCl O
solutions O
correlated O
strongly O
to O
that O
elicited O
by O
distilled RARE
H2O NUMERIC
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Arterial RARE
radioactivity RARE
content O
after O
the O
intravenous O
administration O
of O
HMPAO O
in O
seven O
human O
subjects O
was O
analyzed O
. O

Linear RARE
regression O
analysis O
was O
performed O
and O
the O
following O
result O
was O
obtained O
: O
clearance O
( O
HMPAO O
) O
= O
0 O
. O
07 O
+ O
0 O
. O
43 O
. O
rCBF O
with O
a O
high O
significance O
( O
p O
less O
than O
0 O
. O
001 O
). O

Human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
IN ALLCAPS
, O
expressed O
in O
Escherichia O
coli O
, O
was O
purified O
to O
near O
homogeneity RARE
. O

Thigh RARE
girth RARE
correlated O
positively O
with O
HDL I-GENE
and O
HDL2 I-GENE
- I-GENE
C I-GENE
and O
mass O
, O
and O
with O
LDL I-GENE
particle O
size O
among O
women O
. O

Contributions RARE
from O
pairs O
of O
source O
and O
target O
volume O
elements O
are O
summed RARE
for O
the O
S O
values O
between O
the O
tumor O
and O
itself O
, O
between O
the O
remaining O
healthy O
host O
organ O
and O
itself O
, O
and O
between O
the O
tumor O
and O
the O
remaining O
healthy O
host O
organ O
, O
with O
the O
reciprocity RARE
theorem RARE
assumed O
for O
the O
last O
. O

Tests RARE
showed O
that O
an O
overall O
impression RARE
of O
the O
force O
applied O
could O
be O
obtained O
from O
a O
laboratory O
simulation RARE
, O
but O
that O
clearing RARE
cement RARE
and O
testing O
cement RARE
were O
not O
modelled RARE
by O
this O
method O
. O

The O
cDNA O
contained O
an O
open O
reading O
frame O
of O
1392 NUMERIC
bp O
that O
predicted O
a O
protein O
of O
464 NUMERIC
amino O
acids O
and O
a O
molecular O
mass O
of O
52 O
kDa O
; O
this O
protein O
has O
97 O
% O
identity O
to O
rat I-GENE
liver I-GENE
glucokinase RARE
. O

Analysis O
of O
viral O
mutants O
in O
vivo O
demonstrated O
that O
the O
NFIII ALLCAPS
/ O
OCT ALLCAPS
- I-GENE
1 I-GENE
binding O
site O
and O
a O
conserved O
ATF I-GENE
motif I-GENE
were O
important O
for O
efficient O
viral O
growth O
. O

Recovery RARE
of O
radiolabelled RARE
BA ALLCAPS
through O
urine O
( O
28 O
%) O
and O
faeces RARE
( O
22 O
%) O
up O
to O
96 O
hrs O
averaged O
50 O
%, O
whereas O
residual O
radioactivity RARE
in O
liver O
and O
testis O
experienced O
a O
recovery O
of O
29 O
% O
in O
scorbutic RARE
animals O
. O

Saccharomyces O
cerevisiae O
has O
been O
used O
widely O
both O
as O
a O
model O
system O
for O
unraveling RARE
the O
biochemical O
, O
genetic O
, O
and O
molecular O
details RARE
of O
gene O
expression O
and O
the O
secretion O
process O
, O
and O
as O
a O
host O
for O
the O
production O
of O
heterologous O
proteins O
of O
biotechnological RARE
interest O
. O

Paradoxically RARE
, O
however O
, O
the O
GH I-GENE
receptor I-GENE
cloned O
from O
liver O
exhibits O
no O
sequence O
similarity O
to O
receptors O
with O
known O
signal O
transduction O
mechanisms O
, O
including O
those O
exhibiting O
ligand O
- O
activated O
tyrosine I-GENE
kinase I-GENE
activity O
. O

This O
indicates O
that O
under O
certain O
experimental O
conditions O
cdc2 I-GENE
/ O
p58 NUMERIC
and O
cdc2 I-GENE
/ O
p62 I-GENE
may O
express O
some O
differences O
in O
their O
catalytic O
activity O
. O

Mutation O
analysis O
implicated O
multiple O
segments O
of O
the O
5 O
' O
untranslated O
region O
as O
contributing RARE
to O
the O
inhibitory O
effect O
. O

Identification O
of O
Ets I-GENE
- O
and O
notch RARE
- O
related O
subunits O
in O
GA I-GENE
binding I-GENE
protein I-GENE
. O

The O
enzymatic O
response O
of O
neutrophils O
and O
monocytes O
was O
similar O
although O
the O
magnitude O
of O
the O
NADPH ALLCAPS
oxidase I-GENE
activity O
was O
significantly O
higher O
in O
neutrophils O
than O
in O
monocytes O
. O

In O
the O
ileum RARE
, O
enterotoxin O
increased O
the O
luminal O
disappearance O
( O
P O
less O
than O
0 O
. O
05 O
) O
and O
peripheral O
blood O
appearance O
( O
P O
less O
than O
0 O
. O
001 O
) O
of O
chloroquine RARE
. O

Formalin RARE
activated O
both O
SNO ALLCAPS
NS O
and O
NnS LASTCAP
neurones O
, O
but O
, O
when O
they O
responded O
, O
NS O
neurones O
( O
n O
= O
5 O
) O
showed O
only O
the O
first O
phase O
of O
activity O
while O
NnS LASTCAP
neurones O
showed O
either O
one O
( O
n O
= O
13 O
) O
or O
two O
phases O
( O
n O
= O
6 O
). O

Uptake RARE
of O
ofloxacin RARE
by O
Escherichia O
coli O

It O
is O
concluded O
that O
attention O
to O
these O
issues O
can O
substantially O
improve O
the O
quality O
of O
research O
on O
AIDS O
related O
behaviors RARE
on O
Black RARE
communities RARE
. O

The O
effectiveness O
of O
alpha O
- O
mercapto RARE
- O
beta O
-( O
2 O
- O
furyl RARE
) O
acrylic RARE
acid O
( O
MFA ALLCAPS
) O
and O
N O
- O
benzyl RARE
- O
N O
- O
dithiocarboxy RARE
- O
D O
- O
glucamine RARE
( O
NaB LASTCAP
), O
used O
in O
combination O
, O
in O
the O
mobilization RARE
and O
excretion O
of O
lead O
was O
investigated O
in O
rats O
. O

These O
results O
suggest O
that O
beta I-GENE
- I-GENE
1 I-GENE
may O
act O
as O
a O
tissue O
- O
specific O
, O
trans O
- O
acting O
regulator O
of O
the O
expression O
of O
the O
beta I-GENE
- I-GENE
zein RARE
gene I-GENE
in O
developing O
maize O
endosperm RARE
. O

This O
study O
examines RARE
the O
effects O
of O
hypovolemia RARE
on O
the O
extracellular O
ptO2 NUMERIC
and O
ptH LASTCAP
distributions RARE
at O
multiple O
tissue O
sites O
using O
a O
recently O
developed O
multipoint RARE
microelectrode RARE
, O
that O
provides O
simultaneous O
measurements O
of O
ptO2 NUMERIC
and O
ptH LASTCAP
. O

All O
members O
are O
also O
capable O
of O
activating O
in O
vivo O
transcription O
from O
promoters O
that O
contain O
a O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

The O
domains O
involved O
in O
superactivation RARE
appear O
to O
be O
a O
subset O
of O
those O
necessary O
to O
achieve O
synergistic O
activation O
. O

Information RARE
on O
conserved O
noncoding O
sequences O
will O
help O
in O
studies O
on O
the O
regulation O
of O
the O
pro I-GENE
alpha I-GENE
1 I-GENE
( I-GENE
II I-GENE
) I-GENE
collagen I-GENE
gene I-GENE
. O

Chlamydia O
trachomatis RARE
and O
Chlamydia O
psittaci RARE
were O
not O
affected O
by O
methanol RARE
fixation O
. O

Although O
human O
infections O
with O
bacteraemia RARE
due O
to O
Pasteurella RARE
multocida RARE
are O
not O
uncommon RARE
, O
endocarditis RARE
associated O
with O
P O
. O
haemolytica RARE
is O
rare O
. O

For O
SMX ALLCAPS
at O
pH O
7 O
. O
0 O
, O
a O
1 O
: O
1 O
complex O
is O
formed O
, O
but O
at O
pH O
7 O
. O
5 O
HPCD ALLCAPS
has O
little O
effect O
on O
the O
solubility RARE
of O
the O
highly O
ionized RARE
SMX ALLCAPS
, O
presumably O
since O
only O
un RARE
- O
ionized RARE
molecules O
can O
form O
inclusion O
complexes O
with O
the O
HPCD ALLCAPS
. O

PO2 O
measurements O
using O
a O
double O
barrelled RARE
recess RARE
type O
microelectrodes RARE
were O
measured O
in O
the O
optic O
nerve O
head O
of O
miniature RARE
pigs O
in O
normoxia RARE
and O
hyperoxia RARE
. O

POU I-GENE
- O
specific O
and O
POU I-GENE
- O
homeo RARE
domains O
of O
Oct3 NUMERIC
were O
produced O
in O
Echerichia RARE
coli O
for O
characterization O
of O
DNA O
binding O
to O
the O
octamer O
sequence O
. O

A O
deletion O
series O
of O
the O
5 O
' O
flanking O
region O
was O
created O
from O
position O
- O
1329 NUMERIC
to O
- O
74 O
relative O
to O
the O
transcriptional O
initiation O
site O
and O
similarly O
examined O
in O
transgenic O
tobacco O
. O

The O
nucleotide O
( O
nt O
) O
sequences O
of O
the O
exons O
, O
exon O
/ O
intron O
boundaries O
and O
5 O
'- O
and O
3 O
'- O
untranslated O
regions O
were O
determined O
. O

Out RARE
of O
40 O
patients O
, O
who O
initially O
did O
not O
show O
eye O
complications O
due O
to O
leprosy RARE
, O
37 O
patients O
were O
essentially O
the O
same O
10 O
years O
later O
. O

Thus O
, O
two O
very O
different O
regulatory O
elements O
are O
used O
to O
mediate O
estrogen O
induction O
of O
related O
genes O
in O
chickens O
and O
amphibians RARE
. O

Toxicity RARE
was O
very O
mild O
with O
both O
regimens O
, O
although O
sedation O
was O
significantly O
higher O
in O
arm O
B O
( O
p O
less O
than O
0 O
. O
001 O
). O

Experimentally RARE
in O
green O
monkeys O
, O
Syrian O
hamsters O
and O
white O
mice O
the O
authors O
studied O
the O
pathogenic O
properties O
of O
a O
new O
virus O
Issyk RARE
- O
Kul RARE
. O

Increasing O
mean O
arterial O
pressure O
by O
phenylephrine RARE
infusion O
to O
levels O
much O
greater O
than O
produced O
by O
NMA ALLCAPS
and O
NNA ALLCAPS
caused O
only O
small O
reductions O
in O
cardiac O
output O
. O

J O
. O

Limits RARE
of O
energy O
turnover O
in O
relation O
to O
physical O
performance O
were O
addressed O
in O
terms O
of O
upper O
and O
lower O
limit O
, O
changes O
during O
a O
training O
programme RARE
and O
how O
to O
regulate O
energy O
balance O
at O
a O
changing O
energy O
turnover O
. O

With O
stepwise RARE
reductions O
in O
flow O
, O
the O
peak O
( O
S O
) O
and O
trough O
( O
D O
) O
points O
of O
the O
maximum O
shifted O
- O
frequency O
envelope O
fell O
in O
parallel O
in O
a O
linear O
fashion O
until O
D O
reached O
zero O
. O

The O
IE0 NUMERIC
gene I-GENE
product O
also O
transactivated O
the O
IE1 I-GENE
promoter I-GENE
but O
did O
not O
affect O
expression O
from O
its O
own O
promoter O
. O

Moreover O
, O
promoters O
containing O
a O
TATA O
box O
in O
the O
absence O
of O
Sp1 I-GENE
sites I-GENE
or O
Sp1 I-GENE
sites I-GENE
in O
the O
absence O
of O
a O
TATA O
box O
were O
equally O
inducible O
in O
vitro O
, O
as O
was O
an O
RNA I-GENE
polymerase I-GENE
III I-GENE
promoter I-GENE
. O

Evaluation O
of O
left O
ventricular O
function O
using O
gated O
planar RARE
myocardial O
imaging O
with O
Tc O
- O
99m O
- O
MIBI ALLCAPS

Ivermectin RARE
uptake O
and O
distribution O
in O
the O
plasma O
and O
tissue O
of O
Sudanese RARE
and O
Mexican RARE
patients O
infected O
with O
Onchocerca RARE
volvulus RARE
. O

Bone RARE
marrow O
abnormalities O
in O
Hodgkin O
' O
s O
disease O
are O
reviewed O
and O
the O
current O
understanding O
of O
the O
pathological O
mechanisms O
leading O
to O
aplastic RARE
anemia O
is O
discussed O
. O

The O
smaller O
uptake O
rate O
and O
faster O
clearance O
rate O
resulted O
in O
the O
lower O
BCF ALLCAPS
for O
SWA ALLCAPS
killifish RARE
. O

The O
currently O
proposed O
extended O
arch RARE
repair O
should O
be O
reserved RARE
for O
the O
small O
group O
of O
infants O
with O
transverse O
aortic O
arch RARE
to O
ascending O
aorta O
diameter O
ratios O
( O
arch RARE
indices O
) O
of O
less O
than O
0 O
. O
25 O
. O

DNA O
hybridization O
analysis O
revealed O
that O
both O
pigmented RARE
and O
nonpigmented RARE
cells O
of O
Y O
. O
pestis RARE
possess O
a O
DNA O
locus O
homologous O
to O
the O
Escherichia I-GENE
coli I-GENE
fur RARE
gene I-GENE
. O

Increases RARE
in O
the O
perfusate RARE
PCO2 O
but O
not O
in O
the O
perfusate RARE
H O
+ O
were O
highly O
correlated O
with O
decreases O
in O
both O
myocardial O
contractility O
and O
oxygen O
consumption O
( O
r2 NUMERIC
= O
. O
88 O
). O

Expression O
was O
cell O
cycle O
controlled O
, O
with O
steady O
- O
state O
RNA O
levels O
significantly O
higher O
in O
growth O
- O
arrested O
than O
in O
growth O
- O
stimulated O
cells O
. O

Determinants RARE
of O
recurrent O
ischaemia O
and O
revascularisation RARE
procedures O
after O
thrombolysis RARE
with O
recombinant O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
in O
primary O
coronary O
occlusion O
. O

Therefore O
, O
the O
rbcL LASTCAP
- O
rbcS LASTCAP
locus O
seems O
to O
be O
barely RARE
expressed O
under O
a O
standard O
condition O
for O
photoautotrophic RARE
growth O
. O

Relationship RARE
between O
mitochondrial I-GENE
NADH I-GENE
- I-GENE
ubiquinone RARE
reductase I-GENE
and O
a O
bacterial I-GENE
NAD I-GENE
- I-GENE
reducing I-GENE
hydrogenase RARE
. O

Analysis O
of O
mRNA O
expression O
shows O
that O
AT I-GENE
- I-GENE
BP1 NUMERIC
and O
AT I-GENE
- I-GENE
BP2 NUMERIC
are O
expressed O
in O
all O
the O
tissues O
examined O
. O

We O
report O
two O
patients O
receiving O
maintenance O
valproate RARE
, O
one O
with O
resolving RARE
acute O
hepatitis O
C O
and O
the O
other O
with O
chronic O
persistent O
hepatitis O
C O
, O
with O
incidental RARE
microvesicular RARE
steatosis RARE
demonstrated O
on O
oil O
- O
red O
O O
stains RARE
. O

3 O
cases O

UDP ALLCAPS
- I-GENE
Gal I-GENE
: I-GENE
Gal I-GENE
beta I-GENE
1 I-GENE
---- I-GENE
4GlcNAc NUMERIC
alpha I-GENE
1 I-GENE
---- I-GENE
3 I-GENE
- I-GENE
galactosyltransferase RARE
is O
a O
terminal I-GENE
glycosyltransferase RARE
that O
is O
widely O
expressed O
in O
a O
variety O
of O
mammalian O
species O
, O
with O
the O
notable RARE
exception O
of O
man O
, O
apes RARE
, O
and O
Old RARE
World RARE
monkeys O
. O

A O
synthetic O
oligonucleotide O
containing O
the O
SRE O
sequence O
from O
the O
mouse I-GENE
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
promoter I-GENE
(- O
299 NUMERIC
to O
- O
322 NUMERIC
) O
was O
radioactively RARE
labeled O
, O
used O
as O
a O
probe O
for O
the O
mobility O
shift O
assay O
and O
Southwestern RARE
( O
DNA O
- O
protein O
) O
blotting O
, O
and O
also O
used O
for O
sequence O
- O
specific O
affinity O
chromatography O
. O

Sequence O
requirements O
for O
premature O
transcription O
arrest O
within O
the O
first O
intron O
of O
the O
mouse I-GENE
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
. O

Infarct RARE
regional O
ejection O
fraction O
improved O
by O
10 O
. O
1 O
+/- O
2 O
. O
1 O
% O
between O
early O
and O
late O
studies O
when O
the O
infarct O
- O
related O
artery O
was O
patent RARE
and O
by O
4 O
. O
8 O
+/- O
1 O
. O
4 O
% O
if O
it O
was O
occluded O
( O
p O
= O
0 O
. O
048 NUMERIC
); O
changes O
in O
global O
and O
noninfarct RARE
regional O
ejection O
fraction O
were O
similar O
irrespective O
of O
perfusion O
status O
. O

One O
of O
its O
lysine O
residues O
is O
modified O
by O
spermidine RARE
to O
form O
hypusine RARE
, O
a O
posttranslational O
modification O
unique O
to O
eIF I-GENE
- I-GENE
5A NUMERIC
. O

The O
plasmid O
shuffle RARE
technique O
was O
used O
to O
replace O
the O
wild O
- O
type O
gene O
with O
the O
mutant O
form O
, O
resulting O
in O
failure O
of O
the O
yeast O
cells O
to O
grow O
. O

If O
this O
is O
the O
case O
, O
identification O
and O
characterization O
of O
transcripts O
from O
the O
Ig I-GENE
loci I-GENE
should O
permit O
a O
better O
understanding O
of O
the O
gene O
rearrangement O
process O
. O

Transcription O
of O
the O
metH LASTCAP
gene I-GENE
in I-GENE
Salmonella I-GENE
typhimurium RARE
and I-GENE
Escherichia I-GENE
coli I-GENE
is O
positively O
regulated O
by O
the O
metR LASTCAP
gene I-GENE
product I-GENE
, O
a O
DNA O
binding O
protein O
. O

Disruption O
of O
the O
chromosomal I-GENE
AAR1 NUMERIC
gene I-GENE
in O
alpha O
and O
a O
/ O
alpha O
cells O
conferred O
the O
nonmating RARE
phenotype O
, O
and O
the O
a O
/ O
alpha O
diploids RARE
could O
not O
sporulate RARE
. O

The O
effect O
of O
ICRF ALLCAPS
- O
187 NUMERIC
on O
the O
antitumor RARE
response O
induced O
by O
the O
combination O
of O
ADR O
and O
WBH ALLCAPS
was O
also O
investigated O
in O
order O
to O
assess O
alterations O
in O
the O
therapeutic O
index O
of O
this O
combined O
therapeutic O
modality O
treatment O
. O

The O
ORF O
was O
analyzed O
for O
secondary O
structural O
features O
, O
and O
the O
sequence O
data O
bases O
were O
searched RARE
for O
homologies O
. O

This O
study O
indicates O
that O
this O
dose O
- O
intense O
regimen O
can O
be O
safely RARE
administered O
, O
even O
with O
the O
use O
of O
purged RARE
marrow O
, O
with O
an O
acceptable O
toxicity O
profile O
. O

Mitomycin RARE
- O
C O
can O
cause O
severe O
necrosis O
and O
ulceration O
when O
extravasated RARE
inadvertently RARE
into O
skin O
and O
soft O
tissues O
following O
IV O
drug O
administration O
. O

In O
this O
study O
, O
we O
have O
cloned O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
nidogen RARE
gene I-GENE
. O

INTERVENTIONS ALLCAPS
: O
Patients O
received O
rt RARE
- I-GENE
PA I-GENE
, O
heparin O
, O
and O
aspirin O
. O

Consistent O
with O
the O
in O
vivo O
result O
, O
the O
pseudorevertant RARE
endonucleases RARE
in O
the O
crude O
cell O
extract O
display O
site O
- O
specific O
partial O
DNA O
cleavage O
activity O
. O

Additionally O
, O
I I-GENE
kappa I-GENE
B I-GENE
beta I-GENE
, O
but O
not O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
, O
also O
prevented O
the O
binding O
of O
Rel I-GENE
to O
the O
kappa I-GENE
B I-GENE
site I-GENE
. O

Sequence O
analysis O
reveals O
that O
the O
DNA O
binding O
domain O
of O
ILF ALLCAPS
has O
strong O
homology O
to O
the O
recently O
described O
fork I-GENE
head I-GENE
DNA I-GENE
binding I-GENE
domain I-GENE
found O
in O
the O
Drosophila I-GENE
homeotic I-GENE
protein I-GENE
fork I-GENE
head I-GENE
and O
a O
family O
of O
hepatocyte I-GENE
nuclear I-GENE
factors I-GENE
, O
HNF I-GENE
- I-GENE
3 I-GENE
. O

Lengthy RARE
and O
repeated O
hemodialyses RARE
were O
required O
to O
lower O
lithemia RARE
to O
nontoxic RARE
ranges RARE
. O

A O
single O
i O
. O
p O
. O
injection O
of O
d O
, O
l O
- O
baclofen RARE
10 O
mg O
/ O
kg O
both O
reduced O
noradrenaline O
( O
NA O
) O
biosynthesis O
in O
vivo O
( O
31 O
%) O
and O
the O
endogenous O
concentration O
of O
normetanephrine RARE
( O
NMN ALLCAPS
) O
( O
32 O
%) O
and O
increased O
NA O
levels O
( O
28 O
%). O

Fufang RARE
wuzi RARE
yanzong RARE
pills RARE
have O
strong O
leukogenic RARE
effect O
on O
cyclophosphamide O
induced O
leukopenia RARE
in O
mice O
. O

Mutations O
in O
the O
small O
subunit O
of O
ribulosebisphosphate RARE
carboxylase RARE
affect O
subunit O
binding O
and O
catalysis RARE
. O

The O
structural O
changes O
in O
intra O
- O
acinar RARE
artery O
manifested O
mainly O
by O
an O
increase O
in O
number O
of O
muscular O
artery O
resulting O
from O
muscularization RARE
of O
precursor O
cells O
( O
pericytes RARE
and O
intermediate O
cells O
) O
located O
within O
partially O
muscular O
and O
nonmuscular RARE
arterial O
wall O
to O
smooth O
muscle O
cell O
, O
and O
by O
the O
medial O
wall O
thickened RARE
due O
to O
hypertrophy O
and O
hyperplasia O
of O
smooth O
muscle O
cells O
as O
well O
as O
accumulation O
of O
a O
large O
amount O
of O
collagen I-GENE
, O
especially O
the O
type I-GENE
1 I-GENE
collagen I-GENE
. O

These O
results O
suggest O
that O
NZ ALLCAPS
- O
107 NUMERIC
may O
be O
a O
useful O
drug O
for O
the O
treatment O
of O
bronchial O
asthma O
by O
reducing O
late O
- O
phase O
airway O
responses O
and O
airway O
hyperreactivity RARE
. O

In O
study O
2 O
, O
the O
correlation O
coefficients O
between O
the O
ISO2 NUMERIC
measurements O
obtained O
at O
the O
ulcer O
margin O
and O
at O
the O
adjacent O
normal O
mucosa O
, O
and O
delta O
ISO2 NUMERIC
obtained O
by O
the O
experienced O
observer RARE
and O
one O
of O
the O
three O
learners RARE
were O
0 O
. O
94 O
, O
0 O
. O
97 O
, O
and O
0 O
. O
94 O
, O
respectively O
. O

Bronchial RARE
mucosa O
tattooing RARE
in O
persons O
exposed O
to O
different O
industrial RARE
aerosols RARE
did O
not O
depend O
on O
the O
forms O
of O
PC O
, O
DB ALLCAPS
and O
the O
diseases O
' O
stages O
. O

Anti I-GENE
- I-GENE
HBc RARE
production O
of O
PBMC ALLCAPS
was O
enhanced O
remarkably O
in O
this O
case O
. O

Sequence O
analysis O
of O
the O
sMtCK LASTCAP
genomic I-GENE
upstream I-GENE
sequences I-GENE
reveals O
a O
typical O
TATAA ALLCAPS
box O
within O
the O
80 O
base O
pairs O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
expression O
of O
chimeric O
plasmids O
with O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
. O

Sequence O
analysis O
of O
the O
sMtCK LASTCAP
genomic I-GENE
upstream I-GENE
sequences I-GENE
reveals O
a O
typical O
TATAA ALLCAPS
box O
within O
the O
80 O
base O
pairs O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
expression O
of O
chimeric O
plasmids O
with O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
. O

The O
cDNA O
segment O
is O
flanked O
by O
the O
immunoglobulin I-GENE
gene I-GENE
recombination I-GENE
signal I-GENE
sequences I-GENE
so O
that O
the O
cDNA O
segment O
can O
invert RARE
and O
the O
human I-GENE
IL I-GENE
- I-GENE
2R I-GENE
L I-GENE
chain I-GENE
is O
subsequently O
expressed O
under O
the O
control O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

Lipoprotein RARE
lipase I-GENE
( O
LPL ALLCAPS
), O
a O
key O
enzyme O
in O
normal O
lipoprotein O
metabolism O
, O
has O
a O
complex O
pattern O
of O
regulation O
and O
tissue O
- O
specific O
expression O
. O

Deletion O
of O
the O
proximal O
octanucleotide RARE
motif O
from O
the O
plasmid O
containing O
the O
- O
461 NUMERIC
fragment O
of O
the O
LPL ALLCAPS
promoter I-GENE
, O
resulted O
in O
a O
79 O
and O
76 O
% O
decrease O
in O
the O
level O
of O
expression O
in O
transfected O
3T3 O
- O
L1 O
adipocytes O
and O
HepG2 O
hepatocytes O
, O
respectively O
. O

We O
examined O
the O
binding O
of O
purified O
T3 I-GENE
receptor I-GENE
alpha I-GENE
( O
T3R I-GENE
alpha I-GENE
), O
overexpressed O
in O
Escherichia O
coli O
, O
to O
wild O
- O
type O
and O
up O
and O
down O
mutations O
of O
the O
rGH LASTCAP
T3RE NUMERIC
to O
evaluate O
whether O
transcriptional O
potency O
correlates O
with O
changes O
in O
T3R I-GENE
binding O
. O

Comparison O
of O
the O
cDNA O
- O
predicted O
avian I-GENE
TnIcardiac RARE
amino I-GENE
acid I-GENE
sequences I-GENE
with O
known O
TnI I-GENE
sequences I-GENE
indicated O
1 O
) O
that O
the O
presence O
of O
an O
N O
- O
terminal O
extension O
sequence O
carrying O
a O
dual O
protein I-GENE
kinase I-GENE
A I-GENE
phosphorylation O
target O
site O
and O
an O
adjacent O
proline O
- O
rich O
segment O
is O
an O
ancient RARE
cardiac O
- O
specific O
feature O
of O
TnI I-GENE
which O
has O
been O
conserved O
since O
the O
bird RARE
/ O
mammal RARE
divergence O
, O
2 O
) O
that O
features O
of O
the O
near O
- O
N O
- O
terminal O
troponin RARE
C I-GENE
( O
TnC LASTCAP
)- O
binding O
site O
sequence O
suggest O
isoform O
- O
specific O
adaptation O
of O
TnI I-GENE
and O
TnC LASTCAP
, O
and O
3 O
) O
that O
the O
avian O
TnIcardiac RARE
internal O
actin I-GENE
/ I-GENE
TnC LASTCAP
- I-GENE
binding I-GENE
, I-GENE
actomyosin RARE
- I-GENE
inhibitory I-GENE
, I-GENE
domain I-GENE
shows O
significant O
sequence O
divergence O
from O
mammalian I-GENE
TnIcardiac RARE
sequences I-GENE
, O
including O
the O
absence O
of O
a O
protein I-GENE
kinase I-GENE
C I-GENE
target O
site O
which O
is O
a O
cardiac O
- O
specific O
feature O
of O
TnI I-GENE
in O
mammals O
. O

Ventilatory RARE
management O
casebook RARE
. O

An O
ASSEMBLER ALLCAPS
routine O
for O
on O
- O
line O
graphic RARE
display O
and O
averaging RARE
of O
data O
acquired O
on O
a O
personal O
microcomputer RARE
. O

Expression O
of O
the O
mouse I-GENE
TSH I-GENE
beta I-GENE
gene I-GENE
, O
therefore O
, O
gives O
rise O
to O
multiple O
mRNAs O
, O
each O
with O
a O
unique O
5 O
'- O
untranslated O
region O
. O

Habituation RARE
of O
completely O
isolated O
neurons O
of O
the O
edible RARE
snail RARE
to O
electrical O
stimulation O
. O

It O
was O
found O
that O
the O
ROSP ALLCAPS
undergoes O
a O
number O
of O
fluctuations O
in O
the O
negative O
and O
positive O
directions RARE
with O
a O
gradually O
decreasing O
amplitude O
in O
the O
course O
of O
5 O
- O
25 O
days O
following O
the O
operation O
, O
after O
which O
relatively O
stable O
negative O
values O
of O
the O
ROSP ALLCAPS
are O
established O
on O
the O
average O
in O
electrodes O
implanted O
to O
the O
level O
of O
the O
dura RARE
mater RARE
, O
and O
positive O
values O
in O
electrodes O
implanted O
to O
the O
level O
of O
the O
pia RARE
mater RARE
. O

Blood O
flow O
velocity O
waveforms RARE
were O
recorded O
by O
pulsed O
Doppler O
examination O
of O
the O
fetal O
internal O
carotid O
and O
middle O
cerebral O
arteries O
using O
the O
established O
transabdominal RARE
route O
as O
well O
as O
a O
new O
transvaginal RARE
approach O
. O

Quantitative O
analysis O
of O
DNA O
using O
flow O
cytometry RARE
and O
immunocytochemical RARE
findings O
in O
16 O
cases O
of O
cardiac O
myxomas RARE

Sequence O
analysis O
revealed O
that O
in O
addition O
to O
the O
non O
- O
spliced O
variant O
, O
multiple O
mRNA O
species O
were O
generated O
by O
alternative O
splicing O
resulting O
in O
the O
exclusion O
of O
92 O
, O
166 NUMERIC
, O
170 O
, O
174 NUMERIC
and O
263 NUMERIC
nucleotides O
( O
nt O
), O
respectively O
, O
from O
exon O
1 O
. O

Position RARE
22 O
is O
an O
isoleucine RARE
in O
the O
complete I-GENE
SsoL12 NUMERIC
protein I-GENE
sequence I-GENE
, O
coded O
by O
an O
AUA ALLCAPS
codon O
. O

Symptoms RARE
due O
to O
the O
action O
of O
mastocyte RARE
mediators RARE
were O
observed O
. O

In O
the O
yeast O
Saccharomyces O
cerevisiae O
, O
copper O
levels O
exert O
some O
control O
over O
the O
level O
of O
SOD1 NUMERIC
expression O
. O

Of O
these O
179 NUMERIC
samples O
, O
Mobiluncus RARE
SP O
was O
observed O
in O
35 O
( O
19 O
. O
6 O
%) O
using O
Gram O
staining O
and O
in O
18 O
( O
10 O
. O
1 O
%) O
this O
microorganism RARE
was O
isolated O
in O
agar O
RLK ALLCAPS
and O
anaerobic O
atmosphere RARE
. O

Previous O
investigators RARE
have O
suggested O
that O
subretinal O
blood O
damages RARE
the O
retina O
in O
part O
because O
of O
its O
solid O
fibrin I-GENE
meshwork RARE
. O

Twenty O
- O
four O
hours O
later O
, O
the O
animals O
were O
randomized O
to O
subretinal O
treatment O
with O
2 O
. O
5 O
micrograms O
of O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
or O
a O
similar O
volume O
of O
physiologic RARE
saline O
. O

Neuro RARE
- O
otological RARE
examinations O
revealed O
spontaneous O
downbeat RARE
nystagmus O
, O
bilateral O
gaze RARE
nystagmus O
and O
rebound RARE
nystagmus O
. O

Since O
the O
morphology O
of O
the O
lesions O
can O
mimic O
that O
of O
other O
cutaneous O
disorders O
, O
Bowen RARE
' O
s O
disease O
is O
often O
not O
recognized O
initially O
. O

Equine RARE
amnion RARE
and O
live O
yeast O
cell O
derivative O
were O
evaluated O
as O
a O
biological O
dressing RARE
and O
as O
a O
topical RARE
wound O
medicament RARE
respectively O
, O
in O
the O
treatment O
of O
granulating RARE
wounds RARE
of O
the O
distal O
portion O
of O
the O
limbs RARE
of O
horses O
. O

To O
lower O
the O
current O
high O
incidence O
of O
NANB O
- O
induced O
PTH O
, O
in O
1986 O
, O
the O
American O
Association O
of O
Blood O
Banks RARE
( O
AABB ALLCAPS
) O
recommended O
testing O
for O
these O
PTH O
- O
associated O
" O
surrogate RARE
" O
markers O
on O
all O
donated RARE
units O
of O
blood O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
1 I-GENE
( O
IGF I-GENE
- I-GENE
1 I-GENE
) O
in O
burn O
patients O
. O

Fusion RARE
of O
ubiquitin I-GENE
to O
pADPRP LASTCAP
increased O
the O
yield O
of O
pADPRP LASTCAP
approximately O
10 O
- O
fold O
compared O
to O
that O
of O
the O
unfused RARE
enzyme O
. O

In O
group O
III O
, O
patients O
also O
received O
their O
own O
mediastinal RARE
drainage O
blood O
, O
shed RARE
for O
6 O
hours O
after O
operation O
, O
after O
concentration O
and O
washing RARE
in O
a O
MBRS ALLCAPS
. O

The O
suppression O
was O
also O
demonstrated O
in O
a O
transient O
expression O
assay O
in O
vivo O
using O
isolated O
barley O
endosperms RARE
. O

The O
effect O
of O
salmon RARE
calcitonin I-GENE
nasal O
spray RARE
in O
women O
with O
established O
osteoporosis RARE
has O
also O
been O
studied O
. O

Skeletal RARE
muscle O
metaboreceptor RARE
responses O
are O
impaired O
in O
heart O
failure O
. O

Skeletal RARE
muscle O
metaboreceptor RARE
exercise O
responses O
are O
attenuated O
in O
heart O
failure O
. O

Evaluation O
of O
antiepileptic RARE
drug O
effect O
on O
membrane O
fluidity RARE
. O

The O
examinations O
were O
performed O
on O
two O
groups O
of O
20 O
( O
using O
AmF LASTCAP
/ O
SnF2 NUMERIC
)-, RARE
resp RARE
. O

RNA O
gel O
retardation O
and O
competition O
analyses O
indicate O
that O
TRP ALLCAPS
- I-GENE
185 NUMERIC
binding O
is O
strongly O
dependent O
on O
the O
TAR O
RNA O
loop O
sequences O
. O

The O
vaccine O
used O
was O
known O
to O
be O
immunogenic RARE
for O
older O
children O
and O
adults O
. O

Both O
groups O
then O
underwent O
hypnotic RARE
induction O
, O
and O
completed O
the O
test O
again O
( O
R2 O
). O

Applications RARE
of O
three O
- O
dimensional O
analysis O
to O
the O
auditory O
P300 NUMERIC
. O

The O
construct O
was O
introduced O
into O
BW2001 NUMERIC
( O
xth RARE
- O
11 O
, O
nfo RARE
- O
2 O
) O
strain O
cells O
of O
Escherichia O
coli O
. O

Recombinant I-GENE
human I-GENE
TFIID I-GENE
supported O
weak O
basal O
transcription O
in O
heat O
- O
treated O
nuclear O
extracts O
whereas O
a O
partially O
purified O
TFIID I-GENE
fraction O
from O
HeLa O
cells O
reconstituted O
a O
maximal O
level O
of O
transcription O
. O

Only O
after O
a O
pretreatment O
aimed O
at O
increasing O
its O
oxide O
surface O
layer O
was O
titanium RARE
powder RARE
found O
to O
accelerate RARE
the O
precipitation O
from O
solutions O
containing O
2 O
mmol O
/ O
L O
CaCl2 NUMERIC
, O
2 O
mmol O
/ O
L O
KH2PO4 NUMERIC
, O
50 O
mmol O
/ O
L O
Hepes RARE
, O
pH O
7 O
. O
2 O
, O
and O
to O
induce O
precipitation O
from O
metastable RARE
solutions O
containing O
1 O
. O
2 O
mmol O
/ O
L O
CaCl2 NUMERIC
, O
1 O
. O
2 O
mmol O
/ O
L O
KH2PO4 NUMERIC
, O
50 O
mmol O
/ O
L O
Hepes RARE
, O
pH O
7 O
. O
2 O
, O
at O
37 O
degrees O
C O
. O

We O
conclude O
that O
solidification RARE
could O
occur O
in O
all O
feeds RARE
containing O
casein I-GENE
and O
that O
alternative O
feeds RARE
should O
be O
considered O
in O
patients O
with O
increased O
gastric O
acidity RARE
. O

Neither O
model O
, O
as O
applied O
, O
provided O
a O
satisfactory O
account O
of O
the O
effects O
of O
the O
main O
variables O
of O
number O
of O
tones RARE
and O
amount O
of O
perturbation RARE
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

This O
generalization RARE
of O
MFP ALLCAPS
involves O
defining RARE
an O
appropriate O
high O
- O
resolution O
cost O
function O
, O
parametrizing RARE
the O
search O
space O
of O
the O
environment O
and O
source O
, O
constructing RARE
solutions O
of O
the O
wave O
equation O
, O
and O
utilizing O
a O
nonlinear RARE
optimization RARE
method O
to O
search O
the O
parameter O
landscape RARE
for O
the O
global O
minimum O
of O
the O
cost O
function O
. O

Determination O
of O
an O
RNA O
structure O
involved O
in O
splicing O
inhibition O
of O
a O
muscle O
- O
specific O
exon O
. O

Endothelial RARE
cells O
stored O
with O
University O
of O
Wisconsin RARE
solution O
excluded O
trypan RARE
blue O
better O
( O
1 O
. O
0 O
% O
+/- O
0 O
. O
5 O
% O
cells O
stained O
, O
p O
less O
than O
0 O
. O
001 O
. O

The O
original O
technique O
was O
developed O
in O
the O
1960 NUMERIC
' O
s O
to O
analyze O
the O
inner O
ear O
fluid O
as O
a O
diagnostic O
procedure O
( O
i O
. O
e O
., O
diagnostic O
labyrinthotomy RARE
) O
in O
acoustic O
neuroma RARE
suspects RARE
. O

The O
effect O
of O
diffusion O
limitation O
was O
quantified RARE
in O
terms O
of O
the O
ratio O
O2 O
uptake O
/ O
O2 O
requirement O
(= RARE
fraction O
of O
cross O
- O
sectional O
area O
supplied O
with O
O2 O
), O
assuming RARE
local O
O2 O
requirement O
per O
unit O
volume O
to O
be O
constant O
and O
independent O
of O
PO2 O
at O
PO2 O
greater O
than O
0 O
. O

( O
2 O
) O
Diffusion RARE
limitation O
in O
the O
heterogeneous O
model O
sets O
in O
at O
a O
lower O
O2 O
requirement O
value O
, O
and O
increases O
more O
gradually O
with O
increasing O
O2 O
requirement O
, O
than O
in O
the O
corresponding O
homogeneous RARE
models O
with O
the O
same O
average O
cylinder RARE
diameter O
. O

The O
antihypertensive O
effect O
of O
Estulic RARE
has O
been O
examined O
over O
a O
12 O
- O
month O
period O
in O
101 O
hypertensive O
patients O
. O

At O
the O
time O
of O
the O
seizure O
, O
the O
patient O
was O
asked RARE
to O
read RARE
a O
test O
phrase RARE
aloud RARE
until O
it O
was O
read RARE
correctly O
and O
clearly O
. O

Monitoring RARE
patients O
with O
acute O
leukemia O
for O
IL I-GENE
- I-GENE
1 I-GENE
and O
TNF I-GENE
levels O
throughout O
the O
clinical O
course O
of O
disease O
may O
help O
clarify O
the O
causes O
of O
febrile RARE
episodes O
. O

Echinococcus RARE
granulosus RARE
was O
diagnosed O
by O
fine O
- O
needle RARE
aspiration RARE
cytology RARE
of O
a O
lung O
cyst O
in O
a O
6 O
- O
yr O
- O
old O
white O
female O
in O
central O
Missouri RARE
. O

The O
sequence O
was O
determined O
of O
6493 NUMERIC
nucleotides O
encompassing O
the O
bet RARE
genes I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
which O
encode O
the O
osmoregulatory RARE
choline RARE
- O
glycine O
betaine RARE
pathway O
. O

A O
7 O
- O
day O
treatment O
of O
amphotericin O
B O
( O
5 O
mg O
/ O
kg O
/ O
day O
i O
. O
p O
.) O
significantly O
reduced O
the O
glomerular O
filtration O
rate O
( O
GFR O
) O
measured O
as O
inuline RARE
clearance O
and O
creatinine O
clearance O
( O
0 O
. O
74 O
+/- O
0 O
. O
29 O
and O
0 O
. O
16 O
+/- O
0 O
. O
04 O
ml O
/ O
min O
, O
respectively O
) O
in O
comparison O
to O
vehicle O
- O
treated O
rats O
( O
2 O
. O
04 O
+/- O
0 O
. O
23 O
and O
1 O
. O
29 O
+/- O
0 O
. O
19 O
ml O
/ O
min O
, O
respectively O
). O

Evolution RARE
of O
lesions O
did O
not O
necessarily O
follow O
a O
regular O
progression O
through O
the O
later O
stages O
of O
the O
vitelliform RARE
classification O
. O

Confocal RARE
fluorescence O
microscopy O
in O
modern O
cell O
biology RARE
. O

Toluene RARE
is O
the O
chemical O
most O
frequently O
present O
in O
cases O
involving O
volatile O
solvents RARE
. O

Fortunately RARE
DDT ALLCAPS
-, O
HCH ALLCAPS
- O
and O
HCB O
- O
levels O
decreased O
in O
breast O
milk O
during O
the O
last O
years O
. O

A O
herpesvirus O
proteinase O
activity O
has O
been O
identified O
and O
partially O
characterized O
by O
using O
the O
cloned O
enzyme O
and O
substrate O
genes O
in O
transient O
transfection O
assays O
. O

Adult O
H O
, O
but O
not O
R O
, O
manifested O
the O
burrowing RARE
preference O
whenever RARE
offered O
the O
opportunity RARE
. O

The O
rear RARE
silver O
liquid O
chamber O
was O
threefold O
thick O
to O
17 O
MeV LASTCAP
protons RARE
in O
water O
and O
it O
efficiently O
produced O
either O
13N NUMERIC
by O
the O
16O NUMERIC
( O
p O
, O
alpha O
) O
13N NUMERIC
reaction O
or O
[ O
18F O
] O
fluoride O
ion O
by O
the O
18O NUMERIC
( O
p O
, O
n O
) O
18F O
reaction O
. O

Heterogeneous RARE
electron O
transfer O
of O
cytochrome I-GENE
c I-GENE
facilitated O
by O
polypyrrole RARE
and O
methylene O
blue O
polypyrrole RARE
film RARE
modified O
electrodes O
. O

Selective O
activation O
of O
adrenaline O
secretion O
by O
the O
rat O
adrenal O
in O
neuroglycopenia RARE
detected O
via O
microdialysis RARE

Urine RARE
specimens O
containing O
either O
phencyclidine RARE
( O
PCP ALLCAPS
) O
or O
11 O
- O
nor O
- O
delta O
9 O
- O
tetrahydrocannabinol RARE
- O
9 O
- O
carboxylic RARE
acid O
( O
9 O
- O
THC ALLCAPS
- O
COOH O
) O
were O
adulterated RARE
with O
sodium O
chloride O
, O
bleach RARE
, O
vinegar RARE
, O
potassium O
hydroxide RARE
, O
liquid O
soap RARE
, O
2 O
- O
propanol RARE
, O
and O
ammonia O
. O

The O
1489 NUMERIC
- O
base O
pair O
EFIA I-GENE
cDNA O
encodes O
a O
322 NUMERIC
- O
amino O
acid O
protein O
which O
is O
nearly O
identical O
to O
two O
previously O
described O
human O
DNA O
binding O
proteins O
. O

Four O
putative O
positive O
cDNA O
clones O
were O
isolated O
, O
and O
the O
largest O
insert O
( O
pASB LASTCAP
- I-GENE
1 I-GENE
) O
was O
sequenced O
in O
both O
orientations RARE
. O

Sci RARE
. O

Dose RARE
standardisation RARE
of O
botulinum I-GENE
toxin I-GENE
. O

The O
coding O
sequence O
for O
a O
260 O
- O
amino O
- O
acid O
residue O
polypeptide O
was O
interrupted O
by O
a O
single O
short O
intron O
of O
60 O
base O
pairs O
( O
bp O
), O
and O
about O
70 O
% O
of O
the O
deduced O
amino O
acid O
sequence O
of O
the O
Drosophila I-GENE
PCNA I-GENE
was O
identical O
to O
the O
rat O
and O
human I-GENE
PCNA I-GENE
polypeptides I-GENE
, O
with O
conserved O
unique O
repeats O
of O
leucine O
in O
the O
C O
- O
terminal O
region O
. O

Translational RARE
fusions O
of O
the O
aroF LASTCAP
regulatory I-GENE
regions I-GENE
to O
lacZ I-GENE
were O
constructed O
and O
then O
introduced O
in O
single O
copy O
into O
the O
E O
. O
coli O
chromosome O
. O
beta I-GENE
- I-GENE
Galactosidase RARE
assays O
for O
tyrR LASTCAP
- O
mediated O
regulation O
of O
aroF LASTCAP
- O
lacZ I-GENE
expression O
revealed O
that O
the O
E I-GENE
. I-GENE
coli I-GENE
TyrR LASTCAP
repressor I-GENE
apparently O
recognizes O
the O
operators RARE
of O
both O
organisms O
with O
about O
equal O
efficiency O
. O

Along RARE
with O
previously O
mapped O
genes O
including O
Ly RARE
- I-GENE
1 I-GENE
and O
CD20 NUMERIC
, O
OSBP ALLCAPS
defines O
a O
new O
conserved O
syntenic RARE
group O
on O
the O
long O
arm O
of O
chromosome O
11 O
in O
the O
human O
and O
the O
proximal O
end O
of O
chromosome O
19 O
in O
the O
mouse O
. O

During O
exercise O
K O
+ O
is O
released O
from O
contracting RARE
muscle O
and O
plasma O
K O
+ O
concentration O
rises RARE
. O

Following O
treatment O
, O
serum O
estradiol O
levels O
were O
higher O
in O
groups O
E O
+ O
T O
and O
E O
than O
in O
group O
C O
. O

We O
conclude O
that O
the O
beta O
- O
adrenergic O
agonist O
, O
isoproterenol O
, O
has O
little O
influence O
on O
vascular O
capacitance RARE
or O
liver O
volume O
of O
dogs O
, O
unless O
the O
hepatic O
outflow O
resistance O
is O
elevated O
by O
agents O
such O
as O
histamine O
. O

DNA O
sequence O
and O
evolution O
of O
the O
CPS ALLCAPS
domain I-GENE
of O
the O
Syrian I-GENE
hamster I-GENE
multifunctional RARE
protein I-GENE
CAD I-GENE
. O

Here O
we O
show O
that O
these O
synthetic O
binding O
sites O
have O
a O
more O
restricted O
and O
specific O
ability O
to O
enhance O
transcription O
when O
assayed O
in O
transformed O
embryos O
. O

After O
base O
- O
line O
CBF O
was O
established O
, O
hexamethonium RARE
bromide O
( O
2 O
mg O
/ O
kg O
iv O
), O
ipratropium RARE
bromide O
( O
0 O
. O
5 O
microgram O
/ O
kg O
iv O
), O
indomethacin O
( O
2 O
mg O
/ O
kg O
iv O
), O
or O
intravenous O
0 O
. O
9 O
% O
saline O
was O
administered O
. O

A O
high O
- O
frequency O
restriction O
fragment O
length O
polymorphism O
was O
evident O
in O
the O
DNA O
from O
29 O
unrelated O
individuals O
using O
the O
enzyme O
BglII LASTCAP
. O

The O
antilog RARE
transformation O
of O
pH O
did O
not O
improve O
the O
results O
. O

Telomeres RARE
prevent O
end O
- O
to O
- O
end O
fusions O
and O
exonucleolytic RARE
degradation O
, O
enable RARE
the O
end O
of O
the O
linear O
DNA O
molecule O
to O
replicate RARE
, O
and O
function O
in O
cell O
division O
. O

One O
of O
these O
is O
located O
in O
the O
5 O
'- O
untranslated O
region O
, O
and O
may O
encode O
regulatory O
sequences O
. O

The O
native O
enzyme O
purified O
from O
protease I-GENE
- I-GENE
B I-GENE
- O
deficient O
URA2 NUMERIC
- O
transformed O
cells O
, O
was O
phosphorylated O
in O
vitro O
using O
catalytic O
subunits O
of O
pure O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

This O
study O
suggests O
that O
BSPMs RARE
are O
useful O
in O
the O
assessment O
of O
AMI O
in O
terms O
of O
diagnosis O
, O
location O
and O
extent O
of O
myocardial O
infarct O
. O

A O
bovine O
abomasum RARE
lambda O
gt11 O
cDNA O
library O
was O
screened O
with O
a O
monoclonal O
antibody O
raised O
against O
the O
rabbit I-GENE
H I-GENE
, I-GENE
K I-GENE
- I-GENE
ATPase I-GENE
beta I-GENE
subunit I-GENE
. O

Judicious RARE
use O
of O
laboratory O
testing O
, O
including O
monitoring O
of O
CD4 I-GENE
cell O
counts O
, O
is O
recommended O
. O

There O
is O
no O
TATA O
box O
appropriately RARE
spaced RARE
upstream O
from O
the O
transcription O
initiation O
site O
. O

Characterization O
of O
the O
5 O
' O
end O
of O
the O
growth O
- O
regulated O
Syrian I-GENE
hamster I-GENE
CAD I-GENE
gene I-GENE
. O

Early O
cirrhosis O
, O
an O
early O
modality O
of O
the O
evolution O
of O
acute O
hepatitis O
. O

Examination O
of O
immediate I-GENE
- I-GENE
early I-GENE
transcription I-GENE
factor I-GENE
expression O
during O
the O
MDI ALLCAPS
regimen O
revealed O
that O
RA O
mediated O
an O
elevated O
, O
prolonged O
expression O
of O
c I-GENE
- I-GENE
Jun I-GENE
mRNA I-GENE
accompanied O
by O
diminished O
expression O
of O
c I-GENE
- I-GENE
Fos I-GENE
and O
Jun I-GENE
- I-GENE
B I-GENE
mRNAs I-GENE
. O

Although O
heart O
rate O
and O
diastolic O
pressure O
rose O
in O
some O
degree O
1 O
min O
after O
intubation RARE
, O
free O
and O
total O
CA O
concentrations O
did O
not O
increase O
during O
study O
period O
. O

Processing RARE
, O
secretion O
, O
and O
immunoreactivity O
of O
carboxy I-GENE
terminally I-GENE
truncated I-GENE
dengue RARE
- I-GENE
2 I-GENE
virus I-GENE
envelope I-GENE
proteins I-GENE
expressed O
in O
insect O
cells O
by O
recombinant O
baculoviruses RARE
. O

Combined O
therapy O
with O
MK O
- O
801 O
and O
nimodipine RARE
for O
protection O
of O
ischemic O
brain O
damage O
. O

Initial O
screening O
of O
a O
rat O
liver O
cDNA O
library O
with O
an O
oligonucleotide O
probe O
derived O
from O
the O
rat O
SCP2 NUMERIC
protein O
sequence O
revealed O
an O
825 NUMERIC
- O
base O
pair O
cDNA O
clone O
coding O
for O
the O
complete O
SCP2 NUMERIC
protein O
sequence O
. O

Cloning O
, O
expression O
, O
and O
nucleotide O
sequence O
of O
rat I-GENE
liver I-GENE
sterol I-GENE
carrier I-GENE
protein I-GENE
2 I-GENE
cDNAs I-GENE
. O

The O
addition O
of O
an O
equimolar RARE
complex O
of O
the O
fourth O
and O
seventh RARE
largest O
subunits O
, O
purified O
from O
pol I-GENE
II I-GENE
holoenzyme I-GENE
by O
ion O
- O
exchange O
chromatography O
in O
the O
presence O
of O
urea O
, O
restored O
promoter O
- O
directed O
initiation O
activity O
to O
pol I-GENE
II I-GENE
delta I-GENE
4 I-GENE
/ I-GENE
7 I-GENE
. O

We O
report O
here O
the O
identification O
of O
HSF I-GENE
in O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
. O

Induction O
requires O
the O
ACE1 NUMERIC
gene I-GENE
product I-GENE
, O
which O
binds O
to O
specific O
sites O
in O
the O
promoter O
region O
of O
the O
CUP1 NUMERIC
gene I-GENE
. O

Gel O
mobility O
shift O
assays O
using O
a O
synthetic O
E6 I-GENE
motif I-GENE
detected O
a O
B O
- O
cell O
- O
specific O
complex O
in O
addition O
to O
a O
ubiquitous O
band O
found O
also O
in O
T O
cells O
and O
HeLa O
cells O
. O

Seven RARE
clones O
encoding O
interferon I-GENE
response I-GENE
element I-GENE
binding I-GENE
factors I-GENE
have O
been O
isolated O
from O
a O
mouse O
fibroblast O
lambda O
gt11 O
cDNA O
library O
by O
using O
a O
32P O
end O
- O
labeled O
tandem O
trimer RARE
of O
the O
mouse I-GENE
( I-GENE
2 I-GENE
'- I-GENE
5 I-GENE
') I-GENE
oligoadenylate RARE
synthetase I-GENE
gene I-GENE
interferon O
response O
element O
as O
a O
probe O
. O

The O
sequence O
of O
four O
clones O
was O
sufficient O
to O
construct O
a O
3018 NUMERIC
- I-GENE
bp I-GENE
BAL I-GENE
cDNA I-GENE
structure O
. O

The O
application O
of O
these O
instruments O
allows O
occlusion O
of O
the O
ascending O
aorta O
traversed RARE
by O
the O
perfusion O
cannula RARE
inserted O
directly O
or O
through O
the O
apex O
of O
the O
heart O
as O
well O
as O
simultaneous O
left O
ventricular O
venting RARE
. O

Adenylosuccinate RARE
synthetase I-GENE
( O
IMP ALLCAPS
: O
L I-GENE
- I-GENE
aspartate I-GENE
ligase I-GENE
( O
GDP O
), O
EC I-GENE
6 I-GENE
. I-GENE
3 I-GENE
. I-GENE
4 I-GENE
. I-GENE
4 I-GENE
) O
plays O
an O
important O
role O
in O
purine RARE
biosynthesis O
catalyzing RARE
the O
GTP O
- O
dependent O
conversion O
of O
IMP ALLCAPS
to O
AMP O
. O

Immunophenotyping RARE
in O
four O
cases O
, O
demonstrated O
non O
- O
B O
, O
non O
- O
T O
cell O
origin O
in O
three O
and O
pre O
- O
B O
cell O
origin O
in O
one O
. O

DNA O
- O
protein O
UV O
cross O
- O
linking O
studies O
indicated O
that O
UHF ALLCAPS
- I-GENE
1 I-GENE
has O
an O
electrophoretic O
mobility O
on O
sodium O
dodecyl O
sulfate O
- O
acrylamide RARE
gels O
of O
approximately O
85 O
kDa O
and O
suggested O
that O
additional O
proteins O
, O
specific O
to O
each O
promoter O
, O
bind O
to O
each O
site O
. O

The O
results O
strengthen RARE
the O
conclusion O
that O
predominantly O
dynamic O
activity O
increases O
the O
G4 NUMERIC
content O
of O
mature O
innervated RARE
fast O
muscles O
. O

The O
specific O
interaction O
between O
a O
defined O
structural O
element O
of O
the O
human O
immunodeficiency O
virus O
mRNA O
( O
RRE ALLCAPS
, O
the O
Rev I-GENE
response I-GENE
element I-GENE
) O
and O
the O
virus I-GENE
- I-GENE
encoded I-GENE
protein I-GENE
Rev I-GENE
has O
been O
implicated O
in O
the O
regulation O
of O
the O
export O
of O
unspliced O
or O
singly RARE
spliced O
mRNA O
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

We O
reviewed O
the O
records O
of O
151 O
patients O
with O
optic O
neuritis RARE
examined O
over O
an O
eight O
- O
year O
period O
. O

Cut RARE
- O
off O
levels O
that O
define O
abnormality O
are O
rather O
arbitrary RARE
and O
this O
decreases O
the O
specificity O
of O
the O
test O
in O
apparently O
healthy O
patients O
. O

Alanine RARE
aminotransferase I-GENE
in O
clinical O
practice O
. O

Nucleotide O
sequence O
analysis O
of O
the O
Pseudomonas I-GENE
putida I-GENE
PpG7 NUMERIC
salicylate RARE
hydroxylase I-GENE
gene I-GENE
( O
nahG LASTCAP
) O
and O
its O
3 O
'- O
flanking O
region O
. O

All O
six O
ARF I-GENE
cDNAs I-GENE
are O
more O
similar O
to O
each O
other O
than O
to O
other O
approximately O
20 I-GENE
- I-GENE
kDa I-GENE
guanine I-GENE
nucleotide I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

The O
long O
terminal O
repeat O
( O
LTR O
) O
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
contains O
three O
binding O
sites O
for O
the O
transcriptional O
factor O
Sp1 I-GENE
. O

DNA O
from O
PCR O
was O
labeled O
and O
used O
to O
isolate O
several O
lambda O
gt11 O
cDNA O
clones O
, O
including O
one O
full O
- O
length O
one O
( O
Dd RARE
kinase I-GENE
- I-GENE
2 I-GENE
). O

Radiation RARE
- O
induced O
changes O
in O
the O
area O
of O
alveoli RARE
and O
septa RARE
as O
well O
as O
collagen I-GENE
content O
were O
seen O
11 O
weeks O
after O
irradiation O
. O

The O
first O
follow O
- O
up O
was O
at O
a O
nearly O
constant O
interval O
of O
5 O
. O
1 O
years O
in O
Caerphilly RARE
and O
3 O
. O
2 O
years O
in O
Speedwell RARE
; O
251 NUMERIC
major O
IHD ALLCAPS
events O
had O
occurred O
. O

A O
. O

Perilunar RARE
luxation RARE
-- O
an O
unusual O
injury O
demanding RARE
immediate O
and O
correct O
treatment O

Landsberg RARE
( O
La O
- O
O O
) O
and O
cv O
. O

In O
summary O
, O
at O
equianesthetic RARE
concentrations O
, O
desflurane RARE
and O
isoflurane O
produced O
similar O
hemodynamic O
effects O
; O
however O
, O
in O
the O
absence O
of O
drugs O
that O
inhibit O
autonomic RARE
reflexes RARE
, O
desflurane RARE
had O
less O
negative O
inotropic O
activity O
and O
produced O
less O
decrease O
in O
arterial O
pressure O
. O

We O
report O
here O
the O
isolation O
of O
a O
full O
- O
length O
cDNA O
clone O
coding O
for O
a O
hitherto O
undiscovered RARE
isoform O
of O
the O
bovine I-GENE
C I-GENE
- I-GENE
subunit I-GENE
. O

Isoform RARE
C I-GENE
beta I-GENE
2 I-GENE
, O
an O
unusual O
form O
of O
the O
bovine O
catalytic O
subunit O
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

Salient RARE
applications O
of O
PB ALLCAPS
- O
PK O
modeling RARE
to O
toxicological O
problems O
are O
illustrated RARE
with O
examples O
. O

Patients O
with O
apparently O
minor O
CT O
abnormalities O
may O
have O
significant O
epidural RARE
disease O
. O

The O
cdr1 NUMERIC
sequence I-GENE
includes O
an O
additional O
237 NUMERIC
amino O
acids O
of O
the O
contiguous O
fragment O
and O
encodes O
a O
product O
of O
predicted O
Mr O
67 O
, O
000 O
. O

Armed RARE
with O
a O
clear O
understanding O
of O
the O
pathophysiologic RARE
pathways O
that O
may O
cause O
and O
/ O
or O
contribute O
to O
the O
development O
of O
unconjugated RARE
hyperbilirubinemia O
and O
the O
associated O
jaundice O
, O
the O
practitioner RARE
will O
be O
successful O
in O
helping RARE
the O
family O
understand O
their O
child O
' O
s O
illness O
. O

Displacement RARE
thresholds RARE
of O
peripheral O
sites O
in O
monocular RARE
human O
vision O
were O
obtained O
. O

The O
authors O
report O
a O
case O
in O
which O
stereotactic RARE
irrigation O
of O
a O
brain O
cyst O
was O
temporally O
associated O
with O
respiratory O
distress O
. O

ELISA O
was O
found O
to O
make O
a O
contribution O
to O
the O
diagnosis O
of O
tuberculosis O
similar O
to O
that O
of O
sputum O
smear RARE
. O

In O
this O
paper O
, O
we O
report O
a O
detailed O
study O
of O
the O
structure O
and O
the O
functional O
role O
of O
the O
MalT LASTCAP
binding I-GENE
sites I-GENE
located O
in O
the O
adjacent O
and O
divergent O
pulAp RARE
and O
pulCp RARE
promoters I-GENE
. O

Despite O
the O
small O
number O
of O
patients O
, O
on O
the O
basis O
of O
this O
report O
, O
we O
can O
confirm O
that O
1 O
. O
5 O
MU ALLCAPS
/ O
day O
of O
alpha I-GENE
- I-GENE
IFN I-GENE
is O
an O
adequate O
treatment O
for O
patients O
with O
hairy RARE
cell O
leukemia O
. O

Paroxysmal RARE
fluctuations O
in O
observed O
parasitemia RARE
in O
Plasmodium RARE
falciparum O
malaria O
. O

No O
positive O
family O
history O
was O
obtained O
. O

Occupational RARE
asthma O
and O
rhinoconjunctivitis RARE
from O
inhalation O
of O
crystalline O
bovine I-GENE
serum I-GENE
albumin I-GENE
powder RARE
. O

A O
further O
subdivision RARE
of O
Category RARE
pN1 NUMERIC
into O
pN1a NUMERIC
( O
metastasis O
in O
single O
node O
) O
and O
pN1b NUMERIC
( O
two O
or O
more O
nodes O
) O
is O
recommended O
. O

Amino O
acid O
sequence O
comparisons O
of O
the O
E74A NUMERIC
protein I-GENE
reveal O
a O
highly O
conserved O
C O
- O
terminal O
region O
that O
is O
rich O
in O
basic O
amino O
acid O
residues O
and O
which O
has O
been O
proposed O
to O
possess O
sequence O
- O
specific O
DNA O
binding O
activity O
. O

We O
found O
that O
the O
relative O
strengths O
of O
the O
promoters O
were O
similar O
in O
different O
contexts RARE
. O

Grasso RARE
, O
and O
A O
. O

After O
6 O
months O
, O
definite O
improvement O
in O
strength O
occurred O
in O
4 O
of O
7 O
carnitine RARE
- O
treated O
patients O
and O
in O
none O
of O
7 O
controls O
. O

Age RARE
at O
POI ALLCAPS
and O
asymptote RARE
were O
achieved O
later O
for O
Line RARE
RBC2 NUMERIC
than O
for O
Line RARE
F O
. O

To O
identify O
the O
DNA O
sequences O
that O
cis O
- O
regulate O
the O
expression O
of O
the O
rat I-GENE
liver I-GENE
pyruvate RARE
kinase I-GENE
( O
L I-GENE
- I-GENE
PK I-GENE
) O
genes O
, O
a O
series O
of O
constructs O
in O
which O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
genes I-GENE
is O
driven O
by O
various O
deleted O
fragments O
of O
the O
3200 NUMERIC
base O
pairs O
( O
bp O
) O
upstream O
of O
the O
L I-GENE
- I-GENE
PK I-GENE
gene I-GENE
cap I-GENE
site I-GENE
have O
been O
assayed O
for O
transient O
expression O
after O
introduction O
into O
hepatoma O
HepG2 O
cells O
, O
rat O
hepatocytes O
in O
primary O
culture O
, O
fibroblast O
LTK ALLCAPS
- O
cells O
, O
myogenic O
C2C12 O
cells O
, O
and O
CHO O
cells O
. O

The O
disturbance O
of O
pulmonary O
gas O
exchange O
, O
as O
revealed O
by O
the O
high O
value O
of O
AaDO2 NUMERIC
, O
existed O
without O
left O
ventricular O
dysfunction O
, O
and O
AaDO2 NUMERIC
had O
no O
significant O
relationship O
with O
any O
of O
the O
hemodynamic O
parameters O
including O
the O
difference O
between O
plasma O
colloid O
osmotic O
pressure O
and O
PCW ALLCAPS
. O

A O
dose O
of O
3 O
and O
6 O
micrograms O
/ O
kg O
/ O
day O
GM I-GENE
- I-GENE
CSF I-GENE
reduces O
the O
severity O
of O
neutropenia O
and O
thrombocytopenia O
after O
carboplatin RARE
- O
cyclophosphamide O
chemotherapy O
, O
which O
may O
lead O
to O
more O
effective O
chemotherapy O
for O
ovarian O
cancer O
in O
the O
future O
. O

These O
differences O
involve O
specific O
hydrogen O
- O
bonding RARE
interactions O
between O
the O
protein O
and O
DNA O
, O
including O
guanine O
N7 NUMERIC
sites O
in O
the O
major O
groove O
of O
DNA O
, O
and O
alterations O
in O
DNA O
phosphodiester RARE
conformation O
induced O
by O
protein O
binding O
. O

Biochemical O
analysis O
demonstrates O
that O
the O
BJ1 NUMERIC
protein I-GENE
is O
associated O
with O
nucleosomes RARE
and O
is O
released O
from O
chromatin O
by O
agents O
which O
intercalate RARE
into O
DNA O
, O
as O
previously O
shown O
for O
the O
high I-GENE
mobility I-GENE
group I-GENE
proteins I-GENE
( O
HMGs RARE
). O

I O
propose O
that O
their O
gene O
products O
bind O
to O
the O
chromatin O
to O
establish O
or O
maintain O
a O
proper O
higher O
order O
structure O
as O
a O
prerequisite O
for O
a O
regulated O
gene O
expression O
. O

The O
C4BP NUMERIC
alpha I-GENE
gene I-GENE
is O
organized O
as O
follows O
: O
the O
first O
exon O
codes O
for O
the O
first O
198 O
nucleotides O
of O
the O
5 O
' O
UTR O
. O

The O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
Rev I-GENE
protein I-GENE
is O
a O
positive O
posttranscriptional O
regulator O
of O
viral O
structural O
gene O
expression O
and O
essential O
for O
virus O
replication O
. O

Once O
the O
proliferation O
of O
fibroblasts O
and O
collagen I-GENE
synthesis O
had O
led O
to O
an O
increase O
of O
mechanical O
strength O
, O
no O
negative O
effect O
on O
wound O
healing O
could O
be O
detected O
applying O
the O
same O
chemotherapeutic O
agents O
. O

The O
CDC7 NUMERIC
gene I-GENE
has O
two O
in O
- O
frame O
AUG O
codons O
as O
possible O
translation O
start O
sites O
, O
which O
would O
produce O
58 O
- O
and O
56 O
- O
kDa O
proteins O
, O
respectively O
. O

During O
the O
years O
1980 O
- O
87 O
a O
total O
of O
287 NUMERIC
persons O
received O
disability RARE
pensions RARE
in O
the O
municipality RARE
of O
Nordreisa RARE
in O
northern O
Norway RARE
. O

HeLa O
and O
Jurkat O
cell O
lines O
carrying O
the O
nef I-GENE
gene I-GENE
linked O
to O
the O
CMV O
promoter O
or O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
were O
isolated O
by O
coselection RARE
for O
neomycin O
resistance O
. O

Differences RARE
in O
the O
clinical O
presentation O
and O
the O
gross O
appearance O
of O
the O
two O
cases O
are O
described O
, O
and O
similarities O
in O
the O
microscopic O
features O
are O
discussed O
. O

MEASUREMENTS ALLCAPS
AND O
MAIN O
RESULTS O
: O
The O
two O
groups O
were O
similar O
on O
entry O
into O
the O
study O
, O
including O
mean O
FEV1 O
measurements O
( O
0 O
. O
70 O
L O
atropine O
/ O
0 O
. O
60 O
L O
metaproterenol RARE
, O
P O
greater O
than O
. O
05 O
). O

Using O
an O
ELISA O
, O
we O
found O
that O
surfactant I-GENE
protein I-GENE
A I-GENE
( O
SP I-GENE
- I-GENE
A I-GENE
) O
was O
markedly O
elevated O
in O
the O
pneumonia O
patients O
. O

In O
view O
of O
the O
short O
t1 O
/ O
2 O
, O
we O
used O
three O
doses O
/ O
day O
. O

Temporal RARE
control O
of O
GUS I-GENE
expression O
was O
found O
to O
involve O
two O
negative O
regulatory O
sequences O
, O
NRS1 NUMERIC
(- O
391 NUMERIC
to O
- O
295 NUMERIC
) O
and O
NRS2 NUMERIC
(- O
518 NUMERIC
to O
- O
418 NUMERIC
), O
as O
well O
as O
the O
positive O
domain O
UAS1 O
. O

We O
purified O
a O
Ca2 I-GENE
+/ I-GENE
calmodulin I-GENE
( I-GENE
CaM I-GENE
)- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
CaM I-GENE
kinase I-GENE
) O
from O
the O
yeast O
Saccharomyces O
cerevisiae O
with O
properties O
similar O
to O
mammalian I-GENE
type I-GENE
II I-GENE
CaM I-GENE
kinases I-GENE
. O

In O
most O
cases O
, O
DR4 NUMERIC
- O
homozygous O
, O
DRB1 NUMERIC
- O
heterozygous RARE
individuals O
could O
be O
genotyped RARE
with O
the O
panel O
of O
probes O
. O

Two O
patients O
had O
immediate O
adverse O
effects O
from O
NMF ALLCAPS
; O
one O
had O
a O
grand RARE
mal RARE
seizure O
and O
the O
other O
developed O
severe O
abdominal O
pain O
. O

The O
muscles O
from O
the O
ischemic O
group O
had O
significantly O
lower O
( O
P O
less O
than O
. O
05 O
) O
values O
for O
capillary O
density O
and O
capillary O
to O
fiber O
ratio O
and O
significantly O
higher O
intercapillary RARE
distance O
than O
those O
from O
the O
normal O
group O
. O

The O
prevalence O
of O
opportunistic RARE
infection O
among O
surviving RARE
AIDS O
patients O
and O
the O
probability RARE
of O
being O
in O
tumour O
response O
following O
cancer O
therapy O
conditional O
on O
being O
alive RARE
are O
two O
examples O
of O
such O
functions O
. O

Serum I-GENE
TNF I-GENE
concentrations O
were O
elevated O
at O
diagnosis O
and O
gradually O
decreased O
toward O
the O
reference O
limits O
by O
week O
16 O
. O

Genomic O
clones O
encompassing O
the O
human I-GENE
ETS1 NUMERIC
gene I-GENE
were O
isolated O
and O
utilized O
to O
define O
its O
molecular O
organization O
. O

Polymerase RARE
chain O
reaction O
analysis O
of O
ETS1 NUMERIC
cDNA I-GENE
identified O
several O
amplified O
products O
, O
indicating O
alternative O
splicing O
. O

Most O
of O
the O
expressed O
human I-GENE
E3 I-GENE
polypeptides I-GENE
( O
five O
bands O
) O
were O
found O
in O
the O
insoluble RARE
pellet RARE
while O
primarily O
full I-GENE
- I-GENE
length I-GENE
mature I-GENE
E3 I-GENE
was O
found O
in O
the O
soluble O
fraction O
. O

To O
test O
promotor RARE
function O
, O
chimeric O
genes O
were O
constructed O
linking O
fragments O
of O
chicken O
IGF I-GENE
- I-GENE
I I-GENE
5 O
'- O
flanking O
DNA O
to O
a O
promoterless O
reporter O
plasmid O
. O

The O
alpha I-GENE
4 I-GENE
gene I-GENE
5 O
' O
flanking O
region O
acted RARE
as O
a O
promoter O
in O
transfection O
assays O
. O

Characterization O
of O
the O
alpha I-GENE
4 I-GENE
integrin I-GENE
gene I-GENE
promoter I-GENE
. O

Only O
the O
3 O
. O
0 O
- O
kb O
transcript O
was O
detected O
in O
adult O
tissues O
, O
where O
its O
expression O
was O
restricted O
almost O
exclusively O
to O
the O
central O
nervous O
system O
. O

Two O
homologues O
of O
the O
rhombotin RARE
gene I-GENE
have O
now O
been O
isolated O
. O

Angina RARE
haemorrhagica RARE
bullosa RARE
causing O
respiratory O
obstruction O
postoperatively O
. O

We O
examined O
the O
effects O
of O
long O
- O
term O
perfusion O
with O
pyridoxalated RARE
hemoglobin I-GENE
polyoxyethylene RARE
conjugate RARE
( O
PHP ALLCAPS
) O
solution O
on O
cardiac O
function O
of O
isolated O
rat O
hearts O
. O

Conclusion RARE
: O
inlet RARE
type O
VSD ALLCAPS
and O
perimembranous RARE
type O
TOF O
have O
anatomic O
features O
in O
which O
the O
proximal O
His O
bundle O
tends RARE
to O
be O
jeopardized RARE
by O
suturing RARE
for O
VSD ALLCAPS
closure O
. O

The O
gcd2 NUMERIC
- I-GENE
503 NUMERIC
mutation O
also O
results O
in O
polysome RARE
runoff RARE
, O
accumulation O
of O
inactive O
80S NUMERIC
ribosomal I-GENE
couples RARE
, O
and O
accumulation O
of O
at O
least O
one O
of O
the O
subunits O
of O
the O
general I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
2 I-GENE
( O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
) O
in O
43S NUMERIC
- O
48S NUMERIC
particles O
following O
a O
shift O
to O
the O
restrictive O
temperature O
. O

Eight O
patients O
with O
ARC O
and O
renal O
failure O
were O
recently O
evaluated O
. O

To O
measure O
the O
enhancer O
activity O
of O
DR60 NUMERIC
, O
a O
reporter O
plasmid O
was O
constructed O
that O
contained O
DR60 NUMERIC
cloned O
upstream O
of O
the O
reporter O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
under O
the O
control O
of O
the O
delayed O
- O
early O
39K NUMERIC
promoter O
. O

A O
single O
case O
of O
an O
adenocarcinoma O
, O
arising O
in O
a O
retroperitoneal RARE
enterogenous RARE
cyst O
and O
which O
presented O
as O
a O
left O
renal O
cyst O
, O
is O
reported O
. O

Using O
the O
polymerase O
chain O
reaction O
, O
we O
analyzed O
the O
U6 I-GENE
RNA I-GENE
genes I-GENE
of O
52 O
organisms O
. O

Both O
tear O
volume O
and O
tear O
flow O
were O
found O
to O
be O
significantly O
( O
P O
less O
than O
0 O
. O
001 O
) O
decreased O
up O
to O
6 O
h O
after O
instillation RARE
, O
reaching RARE
a O
minimum O
90 O
min O
after O
application O
( O
tear O
volume O
: O
- O
63 O
%; O
tear O
flow O
: O
- O
71 O
%). O

Hydrophobicity RARE
analysis O
indicated O
that O
the O
KlaA LASTCAP
and O
KlaB LASTCAP
polypeptides I-GENE
are O
likely O
to O
be O
soluble O
, O
whereas O
the O
KlaC LASTCAP
polypeptide I-GENE
was O
predicted O
to O
have O
four O
potential O
membrane O
- O
spanning O
domains O
. O

To O
facilitate O
the O
availability O
of O
important O
new O
therapeutic O
agents O
, O
the O
Food RARE
and O
Drug O
Administration O
( O
FDA ALLCAPS
) O
in O
the O
mid O
- O
1970s NUMERIC
began RARE
assigning RARE
therapeutic O
ratings RARE
to O
investigational RARE
new O
drugs O
and O
holding RARE
end O
- O
of O
- O
phase O
II O
conferences RARE
with O
drug O
sponsors RARE
. O

In O
contrast O
, O
similar O
rates O
of O
B O
. O
sphaericus RARE
products O
, O
ABG ALLCAPS
- O
6184 NUMERIC
technical RARE
powder RARE
and O
BSP O
- O
2 O
flowable RARE
concentrate RARE
, O
produced O
no O
significant O
reduction O
. O

The O
remainder RARE
( O
18 O
. O
4 O
%) O
was O
with O
IgA I-GENE
nephropathy O
, O
which O
was O
histologically O
mild O
. O

Grossly RARE
, O
the O
experimental O
vulvitis RARE
was O
identical O
to O
the O
field O
condition O
, O
and O
bacteria O
indistinguishable O
from O
the O
inoculated O
strains O
were O
reisolated RARE
. O

3 O
. O

Furthermore O
, O
the O
DNA I-GENE
polymerase I-GENE
II I-GENE
complex I-GENE
was O
difficult O
to O
obtain O
from O
dpb2 NUMERIC
- I-GENE
1 I-GENE
mutant O
cells O
, O
suggesting O
that O
a O
stable O
DNA I-GENE
polymerase I-GENE
II I-GENE
complex I-GENE
requires O
DPB2 NUMERIC
and O
is O
essential O
for O
chromosomal O
replication O
. O

To O
determine O
whether O
mononuclear O
cell O
secretory O
products O
contribute O
to O
the O
changes O
in O
bone O
turnover O
that O
characterize O
the O
development O
of O
postmenopausal RARE
osteoporosis RARE
, O
we O
evaluated O
the O
effects O
of O
oophorectomy RARE
and O
subsequent O
estrogen O
replacement O
on O
the O
spontaneous O
secretion O
of O
interleukin I-GENE
1 I-GENE
( O
IL I-GENE
- I-GENE
1 I-GENE
) O
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
) O
and O
on O
the O
phytohemagglutinin I-GENE
A I-GENE
- O
induced O
secretion O
of O
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
GM I-GENE
- I-GENE
CSF I-GENE
) O
from O
peripheral O
blood O
mononuclear O
cells O
. O

There O
were O
45 O
to O
56 O
nt O
differences O
between O
the O
virulent O
and O
avirulent RARE
groups O
while O
there O
were O
6 O
to O
14 O
nt O
differences O
among O
four O
avirulent RARE
strains O
. O

The O
standard O
principles RARE
of O
surgical O
management O
must O
be O
adhered RARE
to O
when O
using O
Sandostatin RARE
to O
treat O
patients O
with O
these O
disorders O
. O

Some O
of O
the O
PCR O
products O
contained O
mutations O
in O
ATG1 NUMERIC
and O
/ O
or O
ATG2 NUMERIC
. O

Hemorrhagic RARE
shock O
and O
bacterial O
translocation O
in O
a O
swine O
model O
. O

These O
data O
suggest O
that O
the O
levels O
of O
oxygen O
free O
radicals O
were O
increased O
in O
hepatocytes O
and O
mitochondria O
. O

The O
sequence O
of O
the O
pMxL1 NUMERIC
plasmid O
containing O
the O
invertible RARE
region O
contains O
a O
perfect O
tandem O
repeat O
of O
19 O
bp O
in O
the O
orientation O
1 O
nonexpressed RARE
pilin RARE
gene I-GENE
at O
the O
middle O
of O
the O
recombination O
junction O
site O
. O

No O
evidence O
for O
the O
presence O
of O
introns O
within O
the O
acvA LASTCAP
gene I-GENE
has O
been O
found O
. O

These O
observations O
, O
together O
with O
the O
occurrence O
of O
putative O
4 O
'- O
phosphopantetheine RARE
- O
attachment O
sites O
and O
a O
putative O
thioesterase RARE
site I-GENE
, O
are O
discussed O
with O
reference O
to O
the O
reaction O
sequence O
leading O
to O
production O
of O
the O
ACV ALLCAPS
tripeptide RARE
. O

Pargyline RARE
, O
a O
monoamine I-GENE
oxidase I-GENE
inhibitor O
, O
reduces O
peak O
3 O
transiently O
( O
max O
. O

When O
given O
the O
choice O
between O
an O
estrous RARE
female O
and O
a O
sexually RARE
active O
male O
in O
the O
AOF ALLCAPS
, O
flutamide RARE
females O
, O
as O
well O
as O
controls O
, O
preferred O
the O
male O
partner O
. O

Hypoxic RARE
ventilatory RARE
responses O
were O
- O
1 O
. O
99 O
+/- O
0 O
. O
37 O
L O
/ O
min O
/% RARE
SaO2 O
in O
the O
relatives RARE
and O
- O
1 O
. O
54 O
+/- O
0 O
. O
25 O
L O
/ O
min O
/% RARE
SaO2 O
in O
the O
control O
subjects O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Very RARE
small O
deletions O
within O
the O
conserved O
region O
completely O
abolished O
transforming O
activity O
of O
dbl RARE
, O
while O
extensive O
deletion O
outside O
of O
this O
region O
had O
no O
effect O
. O

This O
computerized O
list RARE
was O
linked O
to O
the O
central O
files RARE
of O
the O
Massachusetts RARE
Cancer O
Registry RARE
and O
cases O
diagnosed O
between O
1982 O
and O
1988 O
were O
identified O
. O

We O
also O
present O
evidence O
for O
a O
negative O
regulatory O
element O
in O
the O
5 O
' O
flanking O
region O
of O
the O
Mlu RARE
I I-GENE
upstream I-GENE
activation I-GENE
sequence I-GENE
. O

A O
method O
for O
establishing RARE
stimulus O
control O
of O
ethanol O
responding O
was O
developed O
. O

Mechanism O
of O
activation O
of O
the O
vav RARE
protooncogene I-GENE
. O
vav RARE
is O
a O
human O
locus O
that O
appears O
to O
be O
specifically O
expressed O
in O
cells O
of O
hematopoietic O
origin O
regardless O
of O
their O
differentiation O
lineage O
. O

Endothelial RARE
cell O
seeding RARE
. O

Menetrier RARE
disease O
in O
a O
child O
. O

After O
hemodynamic O
stabilization O
, O
the O
goal O
of O
therapy O
is O
to O
diminish RARE
the O
chance RARE
that O
an O
ulcer O
will O
continue RARE
to O
bleed RARE
or O
will O
rebleed RARE
. O

Thirty O
seven O
patients O
( O
amitriptyline RARE
n O
= O
16 O
, O
moclobemide RARE
n O
= O
21 O
) O
completed O
the O
six O
week O
protocol O
, O
which O
was O
conducted O
under O
double O
blind O
conditions O
. O

The O
stimulus O
threshold O
for O
EER ALLCAPS
showed O
a O
less O
individual O
variation O
than O
amplitude O
. O

Analysis O
of O
electrically O
evoked O
response O
( O
EER ALLCAPS
) O
in O
relation O
to O
the O
central O
visual O
pathway O
of O
the O
cat O
( O
1 O
). O

Furthermore O
, O
plasma O
fibrinogen I-GENE
levels O
increased O
by O
a O
mean O
of O
17 O
. O
6 O
%, O
a O
potentially O
adverse O
effect O
of O
gemfibrozil RARE
that O
has O
not O
been O
previously O
reported O
. O

Gemfibrozil RARE
in O
hyperlipidaemic RARE
patients O
with O
peripheral O
arterial O
disease O
: O
some O
undiscovered RARE
actions O
. O

An O
RME1 NUMERIC
- O
independent O
pathway O
for O
sporulation O
control O
in O
Saccharomyces O
cerevisiae O
acts O
through O
IME1 I-GENE
transcript I-GENE
accumulation O
. O

The O
role O
of O
pharmacological O
profiling RARE
in O
safety O
assessment O
. O

Its O
application O
in O
Madagascar RARE
: O
advantages O
and O
disadvantages RARE

In O
all O
cases O
, O
high O
- O
level O
expression O
of O
the O
truncated I-GENE
avian I-GENE
integrins RARE
was O
obtained O
. O

The O
authors O
evaluate O
the O
clinical O
efficacy O
of O
EMB ALLCAPS
AZS ALLCAPS
in O
recurrent O
ulcer O
after O
operation O
on O
the O
stomach O
caused O
by O
a O
high O
level O
of O
acid O
production O
and O
ulcerative RARE
gastroduodenal RARE
bleeding O
. O

In O
adulthood RARE
these O
rats O
were O
hyperactive RARE
and O
learned RARE
the O
active O
avoidance RARE
response O
later O
than O
the O
controls O
. O

To O
investigate O
the O
regulation O
of O
Spec RARE
gene I-GENE
activity O
, O
the O
region O
around O
the O
Spec1 NUMERIC
transcriptional I-GENE
initiation I-GENE
site I-GENE
was O
analyzed O
for O
sites O
of O
protein O
- O
DNA O
interaction O
. O

Phosphopeptide RARE
mapping O
revealed O
the O
same O
autophosphorylation O
sites O
utilized O
by O
EGFR I-GENE
- I-GENE
IC ALLCAPS
as O
those O
identified O
in O
wild I-GENE
- I-GENE
type I-GENE
EGFR I-GENE
. O

The O
encoded O
sequence O
revealed O
a O
typical O
signal O
peptide O
, O
a O
predominantly O
hydrophilic O
707 NUMERIC
amino O
acid O
residue O
domain O
with O
8 O
N O
- O
glycosylation O
sites O
, O
a O
transmembrane O
domain O
, O
and O
a O
C O
- O
terminal O
domain O
of O
52 O
amino O
acids O
. O

The O
TCF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
binding I-GENE
site I-GENE
was O
also O
required O
for O
TCR I-GENE
alpha I-GENE
enhancer I-GENE
activity O
in O
transcriptionally O
active O
extracts O
from O
Jurkat O
but O
not O
HeLa O
cells O
, O
confirming O
that O
TCF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
is O
a O
T I-GENE
- I-GENE
cell I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
factor I-GENE
. O

A O
new O
semi RARE
- O
automatic O
method O
for O
quantifying RARE
regional O
cerebral O
uptake O
of O
99m O
technetium O
- O
hexamethylpropylene RARE
amine O
oxime RARE
( O
99mTc O
- O
HMPAO O
) O
was O
used O
to O
assess O
single O
photon O
emission O
tomograms RARE
from O
5 O
normal O
subjects O
, O
14 O
patients O
with O
Alzheimer O
' O
s O
disease O
, O
14 O
patients O
with O
dementia O
of O
frontal O
lobe O
type O
and O
4 O
patients O
with O
dementia O
with O
motor O
neurone RARE
disease O
. O

The O
results O
showed O
that O
fog RARE
, O
up O
to O
a O
level O
of O
base O
plus O
fog RARE
of O
0 O
. O
6 O
optical O
density O
units O
, O
had O
no O
influence O
on O
the O
diagnostic O
accuracy O
in O
the O
absence O
of O
any O
compensation RARE
. O

IdB LASTCAP
1031 NUMERIC
was O
first O
extracted O
by O
liquid O
- O
solid O
partition RARE
and O
the O
extracts O
were O
evaporated RARE
and O
analysed O
on O
a O
reversed O
- O
phase O
column O
under O
isocratic RARE
conditions O
, O
using O
either O
an O
electrochemical RARE
or O
a O
UV O
detector O
. O

In O
this O
model O
, O
eltoprazine RARE
has O
a O
very O
specific O
anti O
- O
aggressive O
( O
serenic RARE
) O
profile O
, O
inhibiting O
aggression O
while O
social O
interaction O
and O
exploration RARE
are O
not O
decreased O
but O
even O
enhanced O
; O
inactivity RARE
, O
a O
measure O
for O
sedation O
, O
is O
not O
affected O
. O

A O
new O
method O
for O
the O
in O
vitro O
transfer O
of O
delayed O
hypersensitivity O
by O
dialysed RARE
transfer I-GENE
factor I-GENE
. O

Effect O
of O
separate O
and O
combined O
effects O
of O
plutonium O
- O
239 O
, O
hexachlorobutadiene RARE
and O
tributyl RARE
phosphate O
on O
the O
thymus RARE
gland O
of O
rats O

Data O
collection O
was O
made O
with O
a O
query RARE
language O
, O
and O
data O
analysis O
performed O
with O
an O
interactive RARE
knowledge O
- O
based O
statistical O
tool O
, O
MAXITAB ALLCAPS
, O
employing O
a O
multivariate O
tabular RARE
analysis O
technique O
. O

ARPIA ALLCAPS
has O
been O
implemented RARE
by O
using O
a O
relational RARE
DBMS ALLCAPS
, O
very O
cheap RARE
and O
highly O
diffused RARE
on O
personal O
computers RARE
. O

Diuresis RARE
was O
induced O
by O
scheduled RARE
drinking O
of O
tea RARE
( O
150 O
ml O
/ O
h O
). O

Diagnostic O
value O
of O
adenosine I-GENE
deaminase I-GENE
activity O
in O
tuberculous O
effusions RARE
. O

Femoral RARE
strain O
adaptation O
after O
total O
hip O
replacement O
: O
a O
comparison O
of O
cemented RARE
and O
porous RARE
ingrowth RARE
components O
in O
canines RARE
. O

Immuno RARE
- O
cytochemistry RARE
, O
using O
antisera O
against O
Campylobacter RARE
jejuni RARE
, O
showed O
that O
the O
positive O
staining O
in O
altered O
epithelial O
cells O
were O
restricted O
to O
intracellular O
organisms O
having O
a O
structure O
resembling O
Campylobacter RARE
spp RARE
. O

Promoter O
activities O
were O
estimated O
using O
beta I-GENE
- I-GENE
glucuronidase I-GENE
and O
neomycin I-GENE
phosphotransferase I-GENE
II I-GENE
reporter I-GENE
gene I-GENE
systems I-GENE
. O

The O
5 O
' O
regions O
of O
these O
two O
soybean I-GENE
actin I-GENE
genes I-GENE
contain O
many O
unusual O
features O
including O
( O
CT O
) O
repeats O
and O
long O
stretches O
of O
pyrimidine O
- O
rich O
DNA O
. O

All O
8 O
( O
100 O
%) O
patients O
with O
fulminant RARE
hepatic O
failure O
who O
received O
grafts O
survived RARE
, O
including O
3 O
who O
received O
ABO ALLCAPS
- O
incompatible RARE
grafts O
, O
though O
2 O
of O
these O
subsequently O
required O
retransplantation RARE
. O

No O
patient O
had O
a O
history O
of O
excess O
alcohol O
intake O
, O
or O
prolonged O
intake O
of O
hepatotoxic RARE
drugs O
and O
steroids O
, O
and O
were O
not O
obese O
or O
malnourished RARE
. O

An O
evolutionary O
comparison O
of O
amino O
acid O
sequences O
of O
34 O
HSP70 I-GENE
proteins I-GENE
from O
17 O
species O
suggests O
that O
BiP LASTCAP
genes I-GENE
share O
a O
common O
ancestor O
, O
which O
diverged O
from O
other O
HSP70 I-GENE
genes I-GENE
near O
the O
time O
when O
eukaryotes O
first O
appeared O
. O

Spore RARE
inocula RARE
( O
approximately O
10 O
( O
6 O
)/ O
coupon RARE
) O
were O
dried RARE
onto O
0 O
. O
5 O
- O
in O
. O

However O
, O
overexpression O
of O
both O
the O
STE4 NUMERIC
and O
STE18 NUMERIC
proteins I-GENE
did O
not O
generate O
a O
stronger O
pheromone O
response O
than O
overexpression O
of O
STE4 NUMERIC
in O
the O
presence O
of O
wild O
- O
type O
levels O
of O
STE18 NUMERIC
. O

Reverse O
transcription O
- O
PCR O
was O
then O
used O
to O
clone O
from O
human O
poly O
( O
A O
)+ O
RNA O
the O
cDNA O
corresponding O
to O
the O
expressed O
homolog O
of O
psi I-GENE
ARF I-GENE
4 I-GENE
, O
referred O
to O
as O
human I-GENE
ARF I-GENE
4 I-GENE
. O

To O
evaluate O
the O
cost O
and O
benefits O
of O
screening O
tests O
for O
Chlamydia O
trachomatis RARE
in O
adolescent O
males O
, O
we O
developed O
a O
decision RARE
analysis O
model O
and O
compared O
the O
leukocyte I-GENE
esterase I-GENE
urine O
dipstick RARE
test O
with O
culture O
, O
with O
direct O
- O
smear RARE
fluorescent O
antibody O
( O
DFA ALLCAPS
), O
and O
with O
the O
option RARE
of O
no O
screening O
( O
no O
treatment O
). O

Sequencing O
the O
gene O
for O
an O
imipenem RARE
- O
cefoxitin RARE
- O
hydrolyzing RARE
enzyme O
( O
CfiA LASTCAP
) O
from O
Bacteroides RARE
fragilis RARE
TAL2480 NUMERIC
reveals O
strong O
similarity O
between O
CfiA LASTCAP
and O
Bacillus I-GENE
cereus RARE
beta I-GENE
- I-GENE
lactamase I-GENE
II I-GENE
. O

The O
cloned O
HindIII I-GENE
fragment I-GENE
, O
which O
was O
shown O
by O
DNA O
sequence O
analysis O
to O
encode O
the O
N O
- O
terminal O
half O
of O
the O
B I-GENE
. I-GENE
subtilis I-GENE
IF2 NUMERIC
protein I-GENE
and O
0 O
. O
2 O
kb O
of O
upstream O
flanking O
sequence O
, O
was O
utilized O
as O
a O
homologous O
probe O
to O
clone O
an O
overlapping O
2 I-GENE
. I-GENE
76 I-GENE
- I-GENE
kb I-GENE
ClaI LASTCAP
chromosomal I-GENE
fragment I-GENE
containing O
the O
entire I-GENE
IF2 NUMERIC
structural I-GENE
gene I-GENE
. O

The O
N O
- O
terminal O
115 O
amino O
acids O
correspond O
to O
a O
putative O
DNA O
- O
binding O
domain O
and O
show O
significant O
sequence O
similarity O
with O
other O
cloned O
IFN I-GENE
response I-GENE
factors I-GENE
( O
IRF I-GENE
- I-GENE
1 I-GENE
and O
IRF I-GENE
- I-GENE
2 I-GENE
). O

Maternal RARE
seizures O
had O
occurred O
during O
pregnancy O
in O
52 O
per O
cent O
. O

It O
encodes O
a O
protein O
with O
three O
zinc O
fingers O
similar O
to O
those O
of O
the O
transcription I-GENE
factor I-GENE
Sp1 I-GENE
. O

Krox I-GENE
- I-GENE
24 I-GENE
is O
therefore O
a O
sequence O
- O
specific O
transcriptional O
activator O
. O

The O
interindividual RARE
variability O
of O
the O
parameters O
is O
taken O
into O
consideration RARE
by O
interactively RARE
determining O
the O
threshold O
levels O
. O

The O
patients O
were O
divided O
into O
3 O
subgroups O
: O
1 O
) O
13 O
N O
+ O
patients O
with O
multiple O
hot O
spots O
( O
greater O
than O
2 O
) O
( O
N O
+ O
IM O
); O
2 O
) O
24 O
N O
+ O
patients O
with O
single O
hot O
spots O
( O
less O
than O
or O
equal O
to O
2 O
) O
( O
N O
+ O
IS ALLCAPS
); O
3 O
) O
12 O
N O
- O
patients O
with O
single O
hot O
spots O
( O
less O
than O
or O
equal O
to O
2 O
) O
( O
N O
- O
IS ALLCAPS
). O

Inspired RARE
CO2 O
causing O
changes O
from O
hypo RARE
- O
to O
normocapnia RARE
has O
previously O
been O
shown O
to O
improve O
arterial O
O2 O
tension O
( O
PaO2 O
) O
and O
to O
reduce O
alveolar O
- O
arterial O
O2 O
difference O
. O

Expression O
, O
nucleotide O
sequence O
and O
mutational O
analysis O
of O
two O
open O
reading O
frames O
in O
the O
nif RARE
gene I-GENE
region I-GENE
of I-GENE
Anabaena RARE
sp I-GENE
. I-GENE
strain I-GENE
PCC7120 NUMERIC
. O

Further O
, O
they O
are O
consistent O
with O
the O
suggestion RARE
that O
sites O
homologous O
to O
the O
CAR1 NUMERIC
URS ALLCAPS
may O
be O
situated O
in O
the O
5 O
'- O
flanking O
regions O
of O
multiple O
unrelated O
yeast O
genes O
. O

Our O
results O
suggest O
that O
a O
sequence O
match O
between O
enhancers O
and O
certain O
promoter O
elements O
is O
critical O
. O

This O
Mr O
is O
similar O
to O
those O
of O
the O
purified I-GENE
smg RARE
p25A NUMERIC
GDI ALLCAPS
estimated O
by O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
and O
sucrose O
density O
gradient O
ultracentrifugation RARE
, O
which O
are O
about O
54 O
, O
000 O
and O
65 O
, O
000 O
, O
respectively O
. O

Yeast O
mutants O
assigned O
to O
the O
pet RARE
complementation O
group O
G104 NUMERIC
were O
found O
to O
lack O
alpha I-GENE
- I-GENE
ketoglutarate RARE
dehydrogenase I-GENE
activity O
as O
a O
result O
of O
mutations O
in O
the O
dihydrolipoyl RARE
transsuccinylase RARE
( O
KE2 NUMERIC
) O
component O
of O
the O
complex O
. O

Critical RARE
residues O
required O
for O
repression O
are O
located O
within O
the O
C O
- O
terminal O
27 O
amino O
acids O
of O
c I-GENE
- I-GENE
Fos I-GENE
, O
since O
v I-GENE
- I-GENE
Fos I-GENE
and O
C O
- O
terminal O
truncations RARE
of O
c I-GENE
- I-GENE
Fos I-GENE
did O
not O
down O
regulate O
. O

We O
also O
discovered O
a O
V I-GENE
lambda I-GENE
pseudogene I-GENE
, O
called O
psi I-GENE
V I-GENE
lambda I-GENE
1 I-GENE
, O
3 O
kb O
upstream O
of O
the O
U266 NUMERIC
lambda I-GENE
gene I-GENE
. O

In O
this O
paper O
, O
we O
have O
analyzed O
the O
structure O
of O
human O
gene O
for O
Gx RARE
alpha I-GENE
, O
which O
spans O
more O
than O
60 O
kilobases O
. O

A O
long O
follow O
- O
up O
study O
revealed O
that O
convalescent RARE
stage O
children O
still O
have O
the O
potency O
to O
have O
an O
immediate O
type O
hypersensitivity O
reaction O
on O
exposure O
to O
mite O
antigen O
, O
with O
a O
high O
titer O
of O
mite I-GENE
specific I-GENE
IgE I-GENE
in O
their O
sera O
, O
but O
they O
are O
free O
from O
asthmatic O
attacks O
because O
of O
the O
reduction O
in O
the O
amount O
of O
mite O
antigen O
in O
the O
body O
, O
as O
shown O
by O
the O
reduction O
in O
the O
amount O
of O
mite I-GENE
specific I-GENE
IgG I-GENE
. O

But RARE
no O
influence O
was O
observed O
at O
lower O
concentrations O
than O
1 O
/ O
4 O
MIC ALLCAPS
of O
AMK ALLCAPS
. O

Uses RARE
of O
orthoclone RARE
OKT3 NUMERIC
for O
prophylaxis O
of O
rejection O
and O
induction O
in O
initial O
nonfunction RARE
in O
kidney O
transplantation O
. O

Uses RARE
of O
orthoclone RARE
OKT3 NUMERIC
for O
prophylaxis O
of O
rejection O
and O
induction O
in O
initial O
nonfunction RARE
in O
kidney O
transplantation O
. O

Furthermore O
, O
we O
notice RARE
two O
potential O
consensus O
motifs O
which O
are O
also O
found O
in O
corresponding O
positions O
in O
the O
genes O
for O
the O
nerve I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
and O
the O
68 I-GENE
- I-GENE
kDa I-GENE
neurofilament RARE
protein I-GENE
. O

In O
addition O
, O
the O
- O
119 O
to O
- O
81 O
fragment O
of O
the O
CCK ALLCAPS
promoter I-GENE
contains O
a O
transcriptional O
enhancer O
that O
potentiates O
the O
transcription O
from O
the O
herpes O
simplex O
virus O
thymidine I-GENE
kinase I-GENE
promoter I-GENE
in O
a O
position O
- O
and O
orientation O
- O
independent O
manner O
. O

Thirty O
minutes O
of O
supine O
restraint RARE
decreased O
DOPAC ALLCAPS
concentrations O
in O
the O
median O
eminence RARE
of O
female O
rats O
that O
were O
not O
exposed O
to O
ether O
, O
and O
brief O
exposure O
to O
ether O
enhanced O
this O
effect O
. O

Influence O
of O
metoprolol RARE
treatment O
on O
sympatho RARE
- O
adrenal O
activation O
of O
fibrinolysis RARE
. O

Five O
of O
10 O
scars RARE
studied O
decreased O
at O
least O
50 O
% O
in O
linear O
dimensions O
. O

Managing RARE
dysphagia RARE
in O
a O
chronic O
care O
setting O
: O
an O
introduction O
. O

Gel O
- O
mobility O
- O
shift O
assays O
confirmed O
that O
the O
Raji RARE
nuclear O
proteins O
that O
bound O
to O
W O
and O
V O
elements O
were O
competed RARE
with O
by O
an O
HLA I-GENE
- I-GENE
DRA ALLCAPS
X I-GENE
- I-GENE
box I-GENE
oligonucleotide I-GENE
. O

In O
Denmark RARE
only O
1 O
- O
3 O
cases O
of O
transfusion O
- O
associated O
hepatitis O
NANB O
( O
TAH ALLCAPS
- O
NANB O
) O
are O
registered RARE
annually RARE
or O
about O
1 O
case O
per O
100 O
, O
000 O
units O
transfused RARE
. O

The O
NF1 I-GENE
locus I-GENE
encodes O
a O
protein O
functionally O
related O
to O
mammalian I-GENE
GAP I-GENE
and O
yeast I-GENE
IRA ALLCAPS
proteins I-GENE
. O

Hence O
, O
the O
replacement O
of O
Phe O
- O
62 O
with O
Ser O
specifically O
affects O
a O
determinant O
on O
the O
lambda I-GENE
I I-GENE
light I-GENE
chain I-GENE
that O
is O
necessary O
for O
the O
intracellular O
transport O
of O
this O
molecule O
. O

A O
second O
isotype RARE
of O
Raja RARE
immunoglobulin I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
has O
been O
detected O
by O
screening O
a O
spleen O
cDNA O
library O
with O
homologous O
Raja RARE
VH I-GENE
- O
and O
CH1 NUMERIC
- O
specific O
probes O
complementing RARE
the O
respective O
regions O
of O
the O
mu I-GENE
- I-GENE
like I-GENE
isotype RARE
. O

Petko RARE
, O
and O
S O
. O

Disruption O
of O
ARF2 NUMERIC
causes O
no O
detectable O
phenotype O
. O

Human O
recombinant O
DNA O
- O
derived O
antihemophilic RARE
factor I-GENE
( O
factor I-GENE
VIII I-GENE
) O
in O
the O
treatment O
of O
hemophilia RARE
A O
. O
recombinant O
Factor I-GENE
VIII I-GENE
Study O
Group O
. O

Like O
other O
members O
of O
this O
family O
, O
the O
AP I-GENE
- I-GENE
4 I-GENE
HLH ALLCAPS
motif O
and O
the O
adjacent O
basic O
domain O
are O
necessary O
and O
sufficient O
to O
confer O
site O
- O
specific O
DNA O
binding O
. O

Furthermore O
, O
expression O
of O
the O
promoter O
in O
embryonic O
Drosophila O
melanogaster O
cells O
that O
lack O
MyoD1 NUMERIC
and O
Sp1 I-GENE
is O
strictly O
dependent O
on O
all O
three O
sites O
remaining O
intact O
and O
on O
the O
presence O
of O
exogenously RARE
supplied O
Sp1 I-GENE
and O
MyoD1 NUMERIC
. O

Effects O
of O
a O
selective O
monoamine I-GENE
oxidase I-GENE
( I-GENE
MAO I-GENE
)-- RARE
A I-GENE
inhibitor O
, O
clorgyline RARE
, O
a O
selective O
MAO I-GENE
- I-GENE
B I-GENE
inhibitor O
, O
deprenyl RARE
, O
and O
a O
non O
- O
selective O
MAO I-GENE
inhibitor O
, O
nialamide RARE
, O
were O
investigated O
on O
footshock RARE
- O
induced O
aggression O
( O
FIA ALLCAPS
) O
in O
paired O
rats O
. O

To O
identify O
structural O
features O
of O
residues O
flanking O
the O
c O
- O
region O
that O
influence O
the O
fidelity O
and O
efficiency O
of O
signal O
peptidase RARE
cleavage O
as O
well O
as O
co O
- O
translational O
translocation O
, O
we O
introduced O
six O
amino O
acid O
substitutions O
into O
the O
COOH O
terminus O
of O
the O
hydrophobic O
core O
and O
seven O
substitutions O
at O
the O
NH2 O
terminus O
of O
the O
mature O
region O
( O
the O
+ O
1 O
position O
) O
of O
a O
model O
eukaryotic I-GENE
preprotein RARE
- I-GENE
human I-GENE
pre I-GENE
( I-GENE
delta I-GENE
pro I-GENE
) I-GENE
apoA LASTCAP
- I-GENE
II I-GENE
. O

Additionally O
, O
although O
c I-GENE
- I-GENE
fos I-GENE
and O
egr RARE
- I-GENE
1 I-GENE
mRNAs I-GENE
are O
expressed O
at O
elevated O
levels O
in O
stimulated O
liver O
cells O
, O
fos I-GENE
- I-GENE
B I-GENE
, O
fra RARE
- I-GENE
1 I-GENE
, O
and O
egr RARE
- I-GENE
2 I-GENE
are O
not O
, O
which O
suggests O
that O
factors O
in O
addition O
to O
the O
serum I-GENE
response I-GENE
factor I-GENE
participate O
in O
the O
regulation O
of O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
induction O
. O

Of O
848 NUMERIC
patients O
, O
819 NUMERIC
cases O
with O
complete O
description O
of O
patient O
' O
s O
background O
were O
evaluable O
: O
Group O
A O
( O
surgery O
+ O
MMC O
+ O
5 O
- O
FU O
: O
chemotherapy O
) O
253 NUMERIC
cases O
, O
group O
B O
( O
surgery O
+ O
MMC O
+ O
5 O
- O
FU O
+ O
OK ALLCAPS
- O
432 NUMERIC
or O
PSK ALLCAPS
: O
immunochemotherapy RARE
) O
282 NUMERIC
and O
group O
C O
( O
surgery O
alone O
) O
284 NUMERIC
. O

The O
nuclear O
proteins O
encoded O
by O
the O
c I-GENE
- I-GENE
fos I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
protooncogenes RARE
are O
expressed O
during O
the O
proliferation O
period O
of O
osteoblast RARE
phenotype O
development O
. O

This O
model O
is O
further O
supported O
by O
binding O
of O
the O
Fos I-GENE
- O
Jun I-GENE
complex O
at O
an O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
in O
the O
type I-GENE
alpha I-GENE
I I-GENE
collagen I-GENE
promoter I-GENE
that O
is O
contiguous O
with O
, O
but O
not O
overlapping O
, O
the O
VDRE O
. O

PBSX ALLCAPS
is O
induced O
by O
agents O
which O
elicit O
the O
SOS ALLCAPS
response O
. O

A O
bacteriological RARE
relapse O
requiring O
treatment O
occurred O
by O
5 O
years O
in O
16 O
. O
8 O
% O
of O
113 O
R3 NUMERIC
, O
5 O
. O
2 O
% O
of O
97 O
R5 NUMERIC
, O
and O
20 O
. O
0 O
% O
of O
115 O
Z5 NUMERIC
patients O
with O
organisms O
sensitive O
to O
streptomycin RARE
and O
isoniazid RARE
initially O
. O

In O
the O
controls O
, O
it O
was O
found O
that O
all O
right O
- O
handed RARE
and O
10 O
out O
of O
14 O
left O
- O
handed RARE
control O
subjects O
showed O
a O
right O
VHF ALLCAPS
( O
i O
. O
e O
., O
left O
hemisphere O
) O
advantage O
. O

Although O
no O
Rh RARE
- I-GENE
antibodies I-GENE
were O
demonstrable RARE
, O
a O
similar O
mechanism O
can O
be O
postulated O
for O
the O
Rh RARE
- O
system O
. O

The O
deduced O
amino O
acid O
sequence O
has O
the O
greatest O
homology O
( O
61 O
%) O
to O
the O
green I-GENE
alga RARE
Scenedemus RARE
obliquus RARE
plastocyanin RARE
. O

Higher RARE
fasting O
serum O
gastrin I-GENE
concentration O
( O
102 NUMERIC
. O
0 O
+/- O
21 O
. O
1 O
vs O
63 O
. O
3 O
+/- O
8 O
. O
3 O
ng O
. O
l O
- O
1 O
), O
and O
greater O
postprandial RARE
gastrin I-GENE
release O
( O
AUC0 NUMERIC
- O
120 O
: O
16690 NUMERIC
+/- O
2648 NUMERIC
vs O
10654 NUMERIC
+/- O
1283 NUMERIC
ng O
. O
l O
- O
1 O
min O
) O
were O
observed O
after O
VTP ALLCAPS
- O
HM ALLCAPS
than O
after O
VTP ALLCAPS
- O
Cas O
. O

The O
experimental O
group O
consisted O
of O
61 O
examinees RARE
class O
II O
/ O
2 O
orthodontic RARE
anomalies O
. O

This O
study O
was O
performed O
to O
clarify O
the O
location O
of O
a O
transesophageal RARE
echocardiographic O
( O
TEE ALLCAPS
) O
transducer RARE
when O
obtaining O
the O
short O
- O
axis O
view O
of O
the O
left O
ventricle O
( O
S O
- O
LV O
). O

Subjects RARE
were O
16 O
male O
chronic O
schizophrenics RARE
consisting O
of O
8 O
DST ALLCAPS
suppressors O
and O
8 O
nonsuppressors RARE
. O

From O
S3 NUMERIC
( O
CBF O
: O
79 O
- O
60 O
%) O
to O
S5 NUMERIC
( O
CBF O
: O
39 O
- O
0 O
%), O
% O
WTh RARE
, O
1 O
/ O
TPC ALLCAPS
and O
1 O
/ O
T O
were O
significantly O
decreased O
from O
those O
of O
the O
control O
levels O
( O
all O
p O
less O
than O
0 O
. O
01 O
). O

In O
this O
article O
we O
propose O
to O
find O
out O
the O
percentage O
of O
normal O
occlusion O
and O
the O
distribution O
of O
maloclusions RARE
, O
according O
to O
the O
anteroposterior O
relationship O
between O
the O
dental O
archs RARE
( O
following O
the O
ANGLE3 NUMERIC
classification O
). O

In O
that O
case O
, O
the O
ratio O
of O
brush RARE
abrasion RARE
was O
0 O
. O
268 NUMERIC
, O
compressive RARE
and O
transverse O
strength O
, O
124 O
. O
3 O
and O
86 O
. O
3 O
MPa RARE
respectively O
, O
hardness RARE
, O
43 O
. O
2 O
Hk RARE
, O
water O
absorption O
14 O
. O
2 O
micrograms O
/ O
mm3 NUMERIC
and O
thermal O
expansion O
coefficient O
, O
47 O
. O
4 O
x O
10 O
(- O
6 O
)/ O
degrees O
C O
. O

9 O
, O
1498 NUMERIC
- O
1506 NUMERIC
). O

In O
a O
highly O
select O
group O
of O
stable O
hypertensive O
patients O
, O
we O
have O
assessed O
the O
strength O
of O
association O
between O
various O
blood O
pressure O
measurements O
( O
24 O
h O
average O
automated O
ambulatory O
blood O
pressure O
, O
4 O
h O
automated O
ambulatory O
morning RARE
average O
blood O
pressure O
, O
multiple O
office RARE
visit RARE
average O
blood O
pressure O
, O
and O
a O
single O
office RARE
visit RARE
average O
blood O
pressure O
) O
and O
various O
echocardiographic O
indices O
of O
hypertensive O
cardiac O
target O
organ O
damage O
( O
left O
atrial O
diameter O
, O
left O
ventricular O
end O
diastolic O
diameter O
, O
posterior O
wall O
thickness O
, O
combined O
wall O
thickness O
, O
relative O
wall O
thickness O
, O
left O
ventricular O
mass O
and O
mass O
index O
, O
and O
combined O
wall O
thickness O
/ O
left O
ventricular O
diastolic O
diameter O
ratio O
). O

We O
have O
previously O
identified O
, O
by O
screening O
a O
lambda O
gt11 O
expression O
library O
, O
murine I-GENE
protein I-GENE
mXBP LASTCAP
, O
which O
binds O
to O
a O
sequence O
which O
overlaps RARE
the O
3 O
' O
end O
of O
the O
murine I-GENE
class I-GENE
II I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
A I-GENE
alpha I-GENE
gene I-GENE
X I-GENE
box I-GENE
, O
a O
conserved O
transcription O
element O
found O
upstream O
of O
all O
class O
II O
genes O
. O

The O
p36 NUMERIC
gene I-GENE
is O
at O
least O
22 O
kb O
in O
length O
and O
has O
a O
coding O
sequence O
of O
approximately O
1 O
kb O
, O
representing O
only O
4 O
. O
5 O
% O
of O
the O
gene O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

This O
multimodality RARE
treatment O
for O
locally O
advanced O
gynecologic O
tumors O
appears O
feasible RARE
with O
modification O
, O
and O
continued O
work O
exploring RARE
this O
approach O
is O
encouraged RARE
. O

A O
contiguous O
and O
sequentially RARE
occupied O
secondary O
Fur I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
entC LASTCAP
was O
protected O
at O
higher O
Fur I-GENE
concentrations O
, O
extending O
the O
protected O
region O
to O
+ O
49 O
, O
and O
sequestering RARE
the O
putative O
Shine RARE
- O
Dalgarno RARE
sequence O
. O

The O
major O
promoter O
responds RARE
strongly O
to O
virus O
- O
encoded O
trans O
activators O
EIA I-GENE
and O
EIV ALLCAPS
and O
contains O
four O
elements O
: O
a O
TAGA ALLCAPS
motif O
analogous O
to O
the O
TATA O
box O
, O
two O
EIIF ALLCAPS
sites I-GENE
present O
in O
an O
inverted O
orientation O
, O
and O
an O
ATF I-GENE
/ O
CREB I-GENE
site O
. O

With O
the O
modified O
fingertip RARE
- O
to O
- O
floor O
( O
MFTF ALLCAPS
) O
method O
, O
patients O
stand RARE
on O
a O
stool RARE
and O
forward RARE
bend RARE
so O
that O
measurements O
can O
be O
taken O
on O
patients O
who O
are O
able O
to O
touch RARE
the O
floor O
or O
reach O
beyond O
the O
level O
of O
the O
floor O
. O

No O
significant O
differences O
could O
be O
seen O
in O
response O
rates O
according O
to O
the O
concentration O
of O
estrogen I-GENE
receptors I-GENE
or O
presence O
of O
progesteron RARE
receptors I-GENE
in O
this O
group O
of O
patients O
. O

Teicoplanin RARE
was O
given O
most O
often O
because O
of O
persistent O
fever O
or O
initial O
Gram O
- O
positive O
bacteraemia RARE
and O
only O
one O
- O
third O
of O
these O
cases O
responded O
. O

Luteinizing RARE
hormone I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
analog O
therapy O
of O
uterine O
fibroid RARE
: O
analysis O
of O
results O
obtained O
with O
buserelin RARE
administered O
intranasally RARE
and O
goserelin RARE
administered O
subcutaneously O
as O
a O
monthly O
depot RARE
. O

In O
Experiments O
1 O
and O
2 O
, O
infants O
, O
like O
adults O
, O
initially O
categorized RARE
novel O
objects O
on O
the O
basis O
of O
physical O
appearance O
, O
but O
only O
if O
trained RARE
with O
multiple O
exemplars RARE
, O
after O
delays RARE
of O
1 O
and O
7 O
days O
. O

The O
clinical O
picture O
of O
the O
disease O
was O
significantly O
different O
from O
anthropogenic RARE
cutaneous O
leishmaniasis RARE
caused O
by O
L O
. O
tropica RARE
but O
similar O
to O
cutaneous O
patterns O
caused O
by O
L O
. O
infantum RARE
which O
was O
a O
prevalent RARE
pattern O
in O
the O
southern O
France RARE
. O

Although O
there O
are O
no O
octamer O
elements O
in O
the O
adenovirus O
genome O
that O
are O
known O
to O
be O
important O
for O
transcription O
, O
there O
are O
octamer O
elements O
in O
the O
viral O
terminal O
repeat O
sequences O
. O

In O
comparison O
with O
the O
16 O
introns O
reported O
in O
AHA3 NUMERIC
, O
AHA2 NUMERIC
is O
missing O
one O
intron O
in O
the O
5 O
'- O
untranslated O
region O
and O
a O
second O
intron O
in O
the O
C O
- O
terminal O
coding O
region O
. O

Northern O
blot O
analysis O
indicates O
that O
AHA2 NUMERIC
mRNA I-GENE
relative O
to O
total O
cellular O
RNA O
is O
expressed O
at O
significantly O
higher O
levels O
in O
root O
tissue O
as O
compared O
with O
shoot RARE
tissue O
. O

Impaction RARE
of O
gastrostomy RARE
tube O
in O
the O
abdominal O
wall O
. O

Both O
antidepressants RARE
elevated O
the O
pain O
threshold O
acutely RARE
, O
while O
pretreatment O
with O
pCPA LASTCAP
largely O
blocked O
the O
analgesia O
. O

Sci RARE
. O

A O
needs O
assessment O
of O
these O
families O
was O
also O
done O
. O

TCR I-GENE
alpha I-GENE
and I-GENE
beta I-GENE
gene I-GENE
expression O
may O
be O
regulated O
by O
a O
common O
set O
of O
T I-GENE
- I-GENE
cell I-GENE
nuclear I-GENE
proteins I-GENE
in O
that O
the O
T I-GENE
beta I-GENE
2 I-GENE
element I-GENE
binding O
a O
set O
of O
cyclic I-GENE
AMP I-GENE
response I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
that O
are O
also O
bound O
by O
the O
T I-GENE
alpha I-GENE
1 I-GENE
element I-GENE
of O
the O
human O
TCR I-GENE
alpha I-GENE
enhancer O
and O
the O
decamer RARE
element O
present O
in O
a O
large O
number O
of O
human O
and O
murine O
TCR I-GENE
beta I-GENE
promoters O
. O

The O
3 O
' O
stem O
- O
loop O
is O
highly O
divergent O
in O
structure O
among O
species O
and O
lies O
immediately O
upstream O
of O
the O
binding O
site O
for O
Sm RARE
proteins I-GENE
. O

The O
deleted O
nucleotide O
sequence O
corresponded O
to O
sequences O
that O
, O
by O
analogy RARE
to O
the O
organization O
of O
the O
type I-GENE
I I-GENE
collagen I-GENE
genes I-GENE
, O
should O
be O
precisely O
encoded O
by O
exon O
41 O
of O
the O
COL3A1 NUMERIC
gene I-GENE
. O

These O
losses RARE
account O
for O
the O
resistance O
of O
EDS ALLCAPS
- O
IV O
collagen I-GENE
to O
cyanogen RARE
bromide O
and O
mammalian I-GENE
collagenase RARE
digestion O
. O

A O
4 O
. O
8 O
- O
kilobase O
BamHI I-GENE
- O
HindIII I-GENE
fragment O
encoding O
the O
entire I-GENE
Neurospora I-GENE
crassa I-GENE
CuZn RARE
superoxide I-GENE
dismutase I-GENE
gene I-GENE
( O
herein RARE
designated O
sod RARE
- I-GENE
1 I-GENE
) O
was O
isolated O
from O
a O
genomic O
library O
using O
two O
60 O
- O
base O
deoxyoligonucleotide RARE
probes O
corresponding O
to O
the O
published O
N O
. O
crassa O
amino O
acid O
sequence O
. O

Two O
other O
peptides O
, O
either O
partially O
or O
totally RARE
lacking O
the O
basic O
region O
, O
but O
containing O
the O
intact O
leucine O
zipper O
domain O
, O
readily O
form O
dimers O
but O
do O
not O
bind O
to O
the O
CRE O
. O

In O
contrast O
, O
the O
CRE O
of O
the O
human I-GENE
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
located O
at O
- O
60 O
was O
weakly O
induced O
by O
cAMP O
and O
E1a I-GENE
in O
both O
HeLa O
and O
PC12 O
cells O
. O

We O
have O
isolated O
and O
sequenced O
the O
gene O
encoding O
the O
human I-GENE
U1 I-GENE
- I-GENE
70K NUMERIC
snRNP I-GENE
protein I-GENE
. O

Although O
popular RARE
this O
hypothesis O
is O
far O
from O
explaining RARE
all O
the O
clinical O
facts RARE
, O
namely O
that O
rigidity RARE
is O
equal O
in O
extensor RARE
and O
flexor RARE
, O
proximal O
and O
distal O
muscles O
. O

Using O
appropriate O
synthetic O
HSE O
oligonucleotides O
, O
three O
types O
of O
clones O
with O
potential O
HSE O
binding O
domains O
were O
isolated O
from O
a O
tomato O
lambda O
gt11 O
expression O
library O
by O
DNA O
- O
ligand O
screening O
. O

Fluid RARE
( O
AVLF ALLCAPS
) O
31 O
. O

The O
results O
supported O
the O
therapeutic O
principle RARE
of O
TCM ALLCAPS
: O
Treating RARE
patients O
according O
to O
their O
pathophysiological RARE
patterns O
. O

The O
nmr RARE
gene I-GENE
is O
the O
major O
negative O
regulatory O
gene O
in O
the O
nitrogen O
control O
circuit O
of O
Neurospora O
crassa O
, O
which O
, O
together O
with O
positive O
regulatory O
genes O
, O
governs RARE
the O
expression O
of O
multiple O
unlinked RARE
structural O
genes O
of O
the O
circuit O
. O

The O
4 O
days O
dexamethasone O
suppression O
test O
showed O
more O
than O
80 O
% O
suppression O
of O
dehydroepiandrosterone RARE
- O
sulphate RARE
and O
a O
variable O
( O
40 O
- O
60 O
%) O
reduction O
of O
testosterone O
and O
androstenedione RARE
levels O
. O

The O
ratio O
of O
P O
- O
31 O
NMR O
- O
S O
derived O
inorganic O
phosphates RARE
[ O
Pi RARE
] O
to O
phosphocreatine RARE
[ O
PCr RARE
] O
was O
significantly O
greater O
at O
rest O
in O
LVH ALLCAPS
baboons RARE
[ O
0 O
. O
53 O
+/- O
0 O
. O
06 O
versus O
controls O
= O
0 O
. O
41 O
+/- O
0 O
. O
17 O
; O
P O
less O
than O
0 O
. O
05 O
]. O

Cutaneous RARE
necrosis O
associated O
with O
protein I-GENE
S I-GENE
deficiency O
. O

Critical RARE
study O

Regional RARE
cerebral O
blood O
flow O
was O
measured O
using O
N O
- O
isopropyl RARE
- O
123I NUMERIC
- O
iodoamphetamine RARE
with O
single O
- O
photon O
emission O
computed O
tomography O
( O
CT O
) O
in O
16 O
aged O
patients O
with O
noninsulin RARE
- O
dependent O
diabetes O
mellitus O
( O
NIDDM ALLCAPS
, O
average O
age O
72 O
. O
8 O
years O
, O
average O
fasting O
plasma O
glucose O
7 O
. O
7 O
mmol O
/ O
L O
), O
and O
12 O
nondiabetic RARE
subjects O
( O
71 O
. O
6 O
years O
, O
5 O
. O
3 O
mmol O
/ O
L O
). O

Mean O
ROI ALLCAPS
- O
A O
/ O
B O
ratio O
was O
49 O
. O
6 O
+/- O
1 O
. O
7 O
% O
in O
the O
diabetic O
group O
, O
significantly O
lower O
than O
the O
57 O
. O
9 O
+/- O
1 O
. O
6 O
% O
at O
the O
nondiabetic RARE
group O
( O
p O
less O
than O
0 O
. O
005 O
). O

These O
data O
strongly O
implicate RARE
the O
normal O
product O
of O
the O
int I-GENE
- I-GENE
2 I-GENE
gene I-GENE
, O
which O
is O
related O
to O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
family I-GENE
, O
as O
a O
contributory RARE
factor O
in O
virally RARE
induced O
mammary O
tumors O
. O

This O
result O
indicates O
that O
separate O
complexes O
exist O
containing O
ankyrin RARE
and O
fodrin RARE
with O
either O
uvomorulin RARE
or O
Na I-GENE
+, I-GENE
K I-GENE
+- I-GENE
ATPase I-GENE
. O

These O
genes O
are O
expressed O
within O
a O
few O
hours O
of O
the O
initiation O
of O
development O
; O
their O
mRNAs O
accumulate O
to O
a O
peak O
at O
12 O
hr O
and O
persist RARE
until O
culmination RARE
. O

The O
PC2 NUMERIC
protein I-GENE
also O
shows O
great O
similarity O
to O
the O
incomplete O
NH2 O
- O
terminal O
sequence O
of O
the O
human I-GENE
furin RARE
gene I-GENE
product I-GENE
, O
a O
putative O
membrane O
- O
inserted O
receptor O
- O
like O
molecule O
. O

Whether RARE
or O
not O
there O
are O
sequences O
conferring O
cAMP O
responsiveness O
which O
are O
common O
both O
to O
P I-GENE
- I-GENE
450scc NUMERIC
and O
the O
other O
steroidogenic RARE
P I-GENE
- I-GENE
450 I-GENE
genes I-GENE
remains O
to O
be O
established O
. O

In O
this O
study O
, O
we O
used O
footprinting O
and O
gel O
mobility O
retardation O
assays O
to O
reveal O
that O
bacterially O
synthesized O
Zta I-GENE
fusion I-GENE
proteins I-GENE
bound O
directly O
to O
six O
TGTGCAA ALLCAPS
- O
like O
motifs O
within O
DSL ALLCAPS
. O

The O
zta RARE
transactivator I-GENE
involved O
in O
induction O
of O
lytic O
cycle O
gene O
expression O
in O
Epstein O
- O
Barr O
virus O
- O
infected O
lymphocytes O
binds O
to O
both O
AP I-GENE
- I-GENE
1 I-GENE
and O
ZRE ALLCAPS
sites I-GENE
in O
target O
promoter O
and O
enhancer O
regions O
. O

It O
is O
the O
human O
homolog O
of O
the O
mouse I-GENE
Mx RARE
protein I-GENE
involved O
in O
resistance O
to O
influenza O
virus O
. O

Fragments RARE
containing O
the O
21 O
- O
base O
- O
pair O
repeat O
region O
, O
the O
enhancer I-GENE
of I-GENE
simian I-GENE
virus I-GENE
40 I-GENE
or O
both O
strongly O
stimulated O
beta I-GENE
- I-GENE
galactosidase I-GENE
synthesis O
, O
and O
three O
fragments O
from O
the O
polyomavirus RARE
enhancer I-GENE
region I-GENE
stimulated O
moderate O
levels O
. O

The O
sites O
targeted O
for O
mutagenesis O
, O
residues O
60 O
, O
61 O
, O
and O
66 O
, O
are O
located O
within O
a O
putative O
helical O
loop O
structure O
which O
may O
be O
involved O
in O
substrate O
recognition O
by O
the O
enzyme O
. O

The O
possible O
benefits O
of O
LMW ALLCAPS
heparin O
( O
reduced O
frequency O
of O
bleeding O
, O
alleviation RARE
of O
hypertriglyceridemia RARE
) O
were O
not O
, O
however O
, O
apparent O
, O
possibly O
because O
of O
the O
short O
observation O
period O
and O
the O
low O
incidence O
of O
hemorrhagic O
complications O
in O
routine O
dialyses RARE
. O

The O
deduced O
amino O
acid O
sequence O
of O
destrin RARE
is O
165 O
residues O
long O
and O
is O
very O
similar O
( O
71 O
% O
identical O
) O
to O
that O
of O
cofilin RARE
, O
a O
widely O
distributed O
, O
pH O
- O
sensitive O
actin I-GENE
- O
modulating RARE
protein O
. O

Summers RARE
, O
Virology RARE
89 O
: O
517 NUMERIC
- O
527 NUMERIC
, O
1978 NUMERIC
). O

With O
only O
purified O
T I-GENE
antigen I-GENE
in O
the O
presence O
of O
topoisomerase I-GENE
I I-GENE
to O
unwind RARE
purified O
DNA O
, O
ori RARE
- O
auxiliary O
sequences O
strongly O
facilitated O
T I-GENE
- I-GENE
antigen I-GENE
- O
dependent O
DNA O
conformational O
changes O
consistent O
with O
melting RARE
the O
first O
50 O
base O
pairs O
. O

A O
rabbit O
antiserum O
was O
raised O
against O
a O
synthetic O
peptide O
corresponding O
to O
a O
hydrophilic O
portion O
of O
the O
translated O
murine O
cDNA O
sequence O
. O

Conservation RARE
of O
function O
of O
Drosophila I-GENE
melanogaster I-GENE
abl I-GENE
and O
murine I-GENE
v I-GENE
- I-GENE
abl I-GENE
proteins I-GENE
in O
transformation O
of O
mammalian O
cells O
. O

In O
transient O
cotransfection O
assays O
using O
Chang RARE
liver O
cells O
( O
CCL ALLCAPS
13 O
), O
pM1 NUMERIC
DNA O
exerts O
a O
6 O
- O
to O
10 O
- O
fold O
trans O
- O
activating O
effect O
on O
the O
expression O
of O
the O
pSV2CAT NUMERIC
reporter O
plasmid O
. O

We O
have O
determined O
the O
nucleotide O
( O
nt O
) O
sequence O
of O
the O
7 I-GENE
. I-GENE
5 I-GENE
- I-GENE
kb I-GENE
COR ALLCAPS
segment I-GENE
that O
encompasses RARE
a O
cluster O
of O
six O
genes O
( O
CYC1 I-GENE
, O
UTR1 NUMERIC
, O
UTR3 NUMERIC
, O
OSM1 NUMERIC
, O
tRNA I-GENE
( I-GENE
Gly I-GENE
) I-GENE
and O
RAD7 NUMERIC
) O
located O
on O
chromosome O
X O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

Specific O
binding O
of O
the O
protein O
factors O
to O
the O
sites O
, O
possibly O
to O
the O
three O
Mt RARE
sequences O
, O
may O
play O
an O
important O
role O
in O
the O
coordinate O
regulation O
of O
the O
transcription O
of O
nuclear O
genes O
encoding O
subunits O
responsible O
for O
mitochondrial O
oxidative O
phosphorylation O
. O

This O
points O
to O
a O
specific O
interference O
with O
HSV O
- O
induced O
DNA O
amplification O
. O

No O
recombination O
signal O
sequences O
have O
been O
found O
contiguous O
to O
the O
recombination O
point O
. O

The O
antinociceptive RARE
properties O
, O
as O
measured O
by O
the O
tail O
- O
flick RARE
and O
hot O
- O
plate O
tests O
, O
and O
the O
motor O
effects O
of O
an O
intrathecally RARE
- O
administered O
benzodiazepine RARE
agonist O
midazolam O
, O
alone O
, O
and O
in O
combination O
with O
morphine O
, O
was O
examined O
in O
rats O
. O

Constructs RARE
were O
made O
in O
which O
an O
AATAAA ALLCAPS
and O
the O
GT O
- O
rich O
region O
were O
separated O
by O
various O
distances O
ranging O
from O
7 O
to O
43 O
bp O
. O

To O
address O
this O
issue RARE
, O
the O
gene O
for O
factor I-GENE
Y I-GENE
has O
been O
cloned O
molecularly O
and O
its O
DNA O
sequence O
has O
been O
determined O
. O

We O
cloned O
and O
sequenced O
the O
cDNAs O
against O
genomic O
RNA O
and O
mRNA O
for O
phosphoprotein I-GENE
( I-GENE
P I-GENE
) I-GENE
of O
human O
parainfluenza RARE
type O
2 O
virus O
( O
PIV ALLCAPS
- O
2 O
). O
cDNA O
clone O
from O
genomic O
RNA O
was O
1439 NUMERIC
nucleotides O
in O
length O
excluding O
poly O
( O
A O
) O
and O
was O
found O
to O
have O
two O
small O
open O
reading O
frames O
encoding O
proteins O
of O
233 O
and O
249 NUMERIC
amino O
acids O
. O

We O
show O
that O
cytR LASTCAP
expression O
is O
negatively O
controlled O
by O
the O
CytR LASTCAP
protein I-GENE
and O
positively O
affected O
by O
the O
cAMP I-GENE
/ I-GENE
CAP I-GENE
complex I-GENE
. O

To O
identify O
these O
sites O
, O
the O
deduced O
amino O
acid O
sequence O
of O
the O
3T3 O
- O
L1 O
adipocyte RARE
insulin I-GENE
receptor I-GENE
of O
the O
mouse O
was O
determined O
. O

PAO ALLCAPS
blocks O
turnover O
of O
the O
phosphoryl RARE
group O
of O
pp15 NUMERIC
, O
causing O
its O
accumulation O
, O
and O
thereby O
appears O
to O
interrupt RARE
signal O
transmission O
from O
the O
receptor O
to O
the O
glucose O
- O
transport O
system O
. O

It O
is O
likely O
that O
the O
sequence O
similarities O
reflect O
a O
common O
molecular O
architecture O
of O
the O
two O
heme O
binding O
sites O
and O
of O
a O
copper O
binding O
site O
in O
these O
enzymes O
. O

The O
cDNA O
sequence O
has O
an O
813 NUMERIC
- O
bp O
open O
reading O
frame O
( O
ORF O
) O
whose O
predicted O
amino O
acid O
sequence O
is O
97 O
. O
6 O
% O
identical O
to O
the O
272 O
carboxy O
- O
terminal O
amino O
acids O
of O
the O
human I-GENE
ets I-GENE
- I-GENE
1 I-GENE
protein I-GENE
. O

To O
characterize O
the O
O7 NUMERIC
- I-GENE
LPS I-GENE
region I-GENE
, O
the O
recombinant O
cosmids RARE
pJHCV31 NUMERIC
and O
pJHCV32 NUMERIC
were O
mutagenized RARE
by O
transposon O
mutagenesis O
with O
Tn3HoHo1 NUMERIC
, O
which O
carries O
a O
promoterless O
lac I-GENE
operon I-GENE
and O
can O
therefore O
generate O
lacZ I-GENE
transcriptional O
fusions O
with O
target O
DNA O
sequences O
. O

The O
sacT LASTCAP
gene I-GENE
regulating O
the O
sacPA LASTCAP
operon I-GENE
in I-GENE
Bacillus I-GENE
subtilis I-GENE
shares O
strong O
homology O
with O
transcriptional O
antiterminators RARE
. O

The O
TraD LASTCAP
protein I-GENE
( I-GENE
83 I-GENE
, I-GENE
899 NUMERIC
Da I-GENE
) I-GENE
contains O
three O
hydrophobic O
regions O
, O
of O
which O
two O
are O
located O
near O
the O
amino O
- O
terminal O
region O
. O

The O
protein O
product O
of O
orfD LASTCAP
, O
which O
is O
probably O
a O
new O
tra RARE
gene I-GENE
( O
named O
traX LASTCAP
), O
contains O
65 O
% O
hydrophobic O
amino O
acids O
, O
especially O
rich O
in O
alanine O
and O
leucine O
. O

Various O
mutant I-GENE
HN ALLCAPS
genes I-GENE
were O
constructed O
to O
examine O
the O
role O
of O
residues O
flanking O
the O
signal O
- O
anchor O
domain O
, O
including O
the O
cytoplasmic O
tail O
, O
on O
assembly O
and O
intracellular O
transport O
of O
the O
HN ALLCAPS
glycoprotein I-GENE
. O

Our O
studies O
extend O
these O
findings O
and O
show O
that O
the O
E2 I-GENE
transactivation I-GENE
gene I-GENE
is O
expressed O
from O
multiple O
promoters O
. O

Furthermore O
, O
analysis O
of O
the O
E2 I-GENE
proteins I-GENE
present O
in O
various O
cell O
lines O
harboring O
specific O
BPV O
- O
1 O
mutants O
, O
including O
the O
2558 NUMERIC
acceptor O
mutant O
, O
proves RARE
that O
alternate O
modes O
of O
E2 I-GENE
expression O
exist O
. O

Disruption O
of O
the O
IRA2 NUMERIC
gene I-GENE
resulted O
in O
( O
i O
) O
increased O
sensitivity O
to O
heat O
shock O
and O
nitrogen O
starvation O
, O
( O
ii O
) O
sporulation O
defects O
, O
and O
( O
iii O
) O
suppression O
of O
the O
lethality O
of O
the O
cdc25 NUMERIC
mutant I-GENE
. O

This O
cohort O
of O
patients O
was O
selected O
on O
the O
basis O
of O
clinical O
stage O
. O

A O
gene O
in O
Drosophila O
melanogaster O
that O
maps O
cytologically RARE
to O
2C1 NUMERIC
- O
3 O
on O
the O
distal O
portion O
of O
the O
X O
- O
chromosome O
encodes O
a O
member O
of O
the O
steroid I-GENE
/ I-GENE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
superfamily I-GENE
. O

A O
portion O
of O
Region RARE
II O
also O
resembles O
part O
of O
the O
human O
c I-GENE
- I-GENE
jun I-GENE
oncoprotein O
' O
s O
leucine O
zipper O
, O
which O
in O
turn O
, O
has O
been O
demonstrated O
to O
be O
the O
heterodimerization O
site O
between O
the O
jun I-GENE
and O
fos I-GENE
oncoproteins I-GENE
. O

To O
determine O
whether O
vanadate RARE
could O
inhibit O
PEPCK I-GENE
gene I-GENE
transcription O
, O
a O
series O
of O
chimeric O
genes O
containing O
several O
deletions O
in O
the O
P I-GENE
- I-GENE
enolypyruvate RARE
carboxykinase RARE
promoter I-GENE
between O
- O
550 NUMERIC
and O
- O
68 O
was O
linked O
to O
the O
structural O
genes O
for O
either O
amino I-GENE
- I-GENE
3 I-GENE
- I-GENE
glycosyl RARE
phosphotransferase I-GENE
( O
neo I-GENE
) O
or O
chloramphenicol I-GENE
acetyltransferase I-GENE
and O
introduced O
into O
hepatoma O
cells O
using O
three O
methods O
: O
( O
a O
) O
infection O
with O
a O
Moloney O
murine O
leukemia O
virus O
- O
based O
retrovirus O
, O
( O
b O
) O
transfection O
and O
stable O
selection O
for O
neo I-GENE
expression O
, O
or O
( O
c O
) O
transient O
expression O
of O
chloroamphenicol RARE
acetyltransferase I-GENE
. O

The O
diagnosis O
of O
miliary RARE
tuberculosis O
should O
be O
systematically O
considered O
in O
ARDS O
of O
unknown O
origin O
. O

In O
order O
to O
characterize O
the O
functional O
elements O
of O
the O
promoter O
that O
in O
some O
way O
must O
respond O
to O
these O
regulatory O
signals O
, O
a O
number O
of O
promoter O
mutations O
were O
constructed O
, O
including O
a O
set O
of O
linker O
- O
scanning O
mutations O
across O
the O
entire O
promoter O
region O
. O

A O
DNA O
motif O
related O
to O
the O
cAMP O
- O
responsive O
element O
and O
an O
exon I-GENE
- I-GENE
located I-GENE
activator I-GENE
protein I-GENE
- I-GENE
2 I-GENE
binding I-GENE
site I-GENE
in O
the O
human I-GENE
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
gene I-GENE
promoter I-GENE
cooperate O
in O
basal O
expression O
and O
convey RARE
activation O
by O
phorbol O
ester O
and O
cAMP O
. O

The O
26S NUMERIC
rRNA I-GENE
binding I-GENE
ribosomal I-GENE
protein I-GENE
equivalent O
to O
bacterial I-GENE
protein I-GENE
L11 NUMERIC
is O
encoded O
by O
unspliced O
duplicated O
genes O
in O
Saccharomyces O
cerevisiae O
. O

Five O
healthy O
male O
subjects O
inspired RARE
air O
for O
20 O
min O
and O
then O
5 O
% O
CO2 O
/ O
95 O
% O
O2 O
for O
30 O
min O
, O
of O
which O
the O
first O
10 O
min O
was O
used O
to O
achieve O
a O
steady O
- O
state O
end O
- O
tidal O
CO2 O
measurement O
. O

Significant O
correlations O
were O
obtained O
between O
changes O
in O
SSEP ALLCAPS
in O
response O
to O
AS O
and O
the O
presence O
of O
not O
deep O
residual O
- O
organic O
disturbances O
, O
so O
- O
called O
" O
ground RARE
" O
in O
psychogenic RARE
disorders O
. O

The O
transcripts O
were O
equally O
active O
with O
or O
without O
a O
5 O
' O
methylated RARE
capstructure RARE
as O
expected O
, O
since O
EMCV ALLCAPS
- O
RNA O
is O
one O
of O
the O
mRNAs O
capable O
of O
internal O
initiation O
. O

The O
E6 I-GENE
/ O
E7 I-GENE
promoter O
of O
all O
genital O
human O
papillomaviruses RARE
is O
responsible O
for O
expression O
of O
the O
viral O
transforming O
genes O
. O

A O
case O
of O
Goodpasture RARE
' O
s O
syndrome O
. O

Seventy O
- O
two O
of O
73 O
negative O
controls O
and O
all O
positive O
blocks O
as O
seen O
on O
soft O
tissue O
radiographs O
( O
STRs RARE
) O
were O
correctly O
coded O
( O
specificity O
98 O
. O
6 O
%, O
sensitivity O
100 O
%). O

No O
symptomatic O
abnormality O
has O
been O
noted O
in O
the O
neonatal O
period O
except O
periventricular RARE
calcifications RARE
. O

Immunohistochemical RARE
analysis O
of O
several O
rat O
organs O
also O
showed O
staining O
in O
epithelial O
cells O
. O

Both O
strains O
grew RARE
very O
poorly O
, O
or O
not O
at O
all O
, O
on O
nonfermentable RARE
carbon O
sources O
and O
exhibited O
, O
at O
most O
, O
only O
5 O
% O
of O
wild I-GENE
- I-GENE
type I-GENE
ubiquinol RARE
- I-GENE
cytochrome I-GENE
c I-GENE
oxidoreductase I-GENE
activity O
. O

Regulation O
of O
irgA LASTCAP
by O
iron O
in O
V O
. O
cholerae O
occurs O
at O
the O
transcriptional O
level O
, O
and O
there O
is O
an O
interrupted O
dyad RARE
symmetric RARE
sequence O
in O
the O
vicinity O
of O
the O
promoter O
that O
is O
homologous O
to O
Fur I-GENE
binding I-GENE
sites I-GENE
of O
E O
. O
coli O
. O

Transcription O
of O
the O
first O
operon O
coding O
for O
m O
- O
xylene O
- O
degrading RARE
enzymes O
on O
the O
TOL ALLCAPS
plasmid O
of O
Pseudomonas O
putida O
is O
activated O
by O
the O
xylR LASTCAP
gene I-GENE
product I-GENE
in O
the O
presence O
of O
m O
- O
xylene O
. O

The O
recombinant O
contains O
the O
normal O
beta I-GENE
A I-GENE
- I-GENE
globin I-GENE
gene I-GENE
, O
the O
mutant O
gene O
and O
Ylp RARE
vector O
sequences O
between O
the O
two O
copies O
. O

Some O
of O
the O
mutations O
obtained O
do O
not O
contain O
a O
copy O
of O
the O
Ulysses RARE
element I-GENE
at O
the O
mutant O
locus O
, O
suggesting O
that O
a O
different O
transposable RARE
element O
may O
be O
responsible O
for O
the O
mutation O
. O

Determination O
of O
diquat RARE
in O
biological O
materials O
by O
electron O
spin O
resonance O
spectroscopy O
. O

We O
show O
also O
that O
RA O
represses O
the O
transcriptional O
activity O
of O
a O
reporter O
gene O
containing O
a O
TPA O
responding O
AP1 I-GENE
binding I-GENE
site I-GENE
driving RARE
the O
HSV I-GENE
tk I-GENE
promoter I-GENE
. O

Moreover O
, O
radiolabeled O
EFI ALLCAPS
, O
NF I-GENE
- I-GENE
Y I-GENE
, O
or O
CBF I-GENE
DNAs I-GENE
give O
rise O
to O
identical O
gel O
retardation O
patterns O
in O
extracts O
from O
a O
variety O
of O
different O
cell O
types O
. O

Risk O
factors O
influencing O
lymph O
nodes O
metastasis O
in O
lung O
cancer O
with O
stage O
I O
, O
II O
or O
IIIA ALLCAPS

Multifunctional RARE
protein I-GENE
kinase I-GENE
( O
MFPK ALLCAPS
) O
phosphorylates O
ATP I-GENE
- I-GENE
citrate I-GENE
lyase I-GENE
on O
peptide I-GENE
B I-GENE
on O
two O
sites O
, O
BT ALLCAPS
and O
BS ALLCAPS
, O
on O
threonine O
and O
serine O
, O
respectively O
, O
inhibitor I-GENE
2 I-GENE
on O
a O
threonyl RARE
residue O
, O
and O
glycogen I-GENE
synthase I-GENE
at O
sites O
2 O
and O
3 O
. O

The O
characterized O
Y I-GENE
' I-GENE
repeated I-GENE
sequence I-GENE
families I-GENE
provide O
an O
experimental O
system O
in O
which O
repeated O
sequence O
interactions O
and O
subsequent O
evolution O
can O
be O
studied O
. O

The O
electrically O
induced O
motile RARE
responses O
were O
not O
suppressed O
in O
the O
presence O
of O
dinitrophenol RARE
or O
cytochalasin RARE
B O
. O

Unlike O
p59v NUMERIC
- O
rel I-GENE
, O
which O
is O
a O
nuclear O
protein O
in O
CEF ALLCAPS
, O
indirect O
immunofluorescence O
showed O
that O
p68c NUMERIC
- O
rel I-GENE
in O
JD214c NUMERIC
- O
rel O
infected O
CEF ALLCAPS
is O
located O
exclusively O
in O
the O
cytoplasm O
of O
these O
cells O
, O
even O
though O
the O
sequence O
of O
p68c NUMERIC
- O
rel I-GENE
showed O
that O
it O
contains O
a O
nuclear O
localizing RARE
sequence O
identical O
to O
the O
one O
previously O
identified O
in O
p59v NUMERIC
- O
rel I-GENE
. O

Kinetic RARE
experiments O
revealed O
that O
within O
10 O
min O
this O
radiolabeled O
precursor O
protein O
was O
converted O
in O
HL O
- O
60 O
cells O
into O
an O
Mr O
approximately O
150 O
, O
000 O
chondroitin RARE
sulfate O
proteoglycan O
intermediate O
. O

Blood O
flow O
and O
velocity O
( O
measured O
using O
Doppler O
ultrasound O
) O
gradually O
decreased O
during O
diastole RARE
and O
ultimately RARE
reversed O
in O
direction O
as O
cotyledon RARE
resistance O
was O
increased O
up O
to O
14 O
fold O
. O

A O
total O
of O
112 O
patients O
received O
anistreplase RARE
and O
119 O
received O
heparin O
within O
a O
mean O
period O
of O
188 NUMERIC
+/- O
62 O
min O
following O
the O
onset O
of O
symptoms O
. O

However O
, O
primary O
transcripts O
of O
a O
variant I-GENE
tRNA I-GENE
( I-GENE
Val I-GENE
)( I-GENE
UAC ALLCAPS
) I-GENE
gene I-GENE
are O
processing O
deficient O
under O
standard O
growth O
conditions O
( O
30 O
degrees O
C O
), O
due O
to O
a O
slightly O
altered O
5 O
' O
flanking O
region O
. O

The O
promoter O
activity O
was O
measured O
by O
a O
transient O
expression O
of O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene O
connected O
with O
various O
5 O
'- O
deletion O
mutants O
of O
the O
5 O
'- O
flanking O
region O
. O

Three O
of O
the O
short O
ORFs O
in O
the O
central O
region O
of O
BIV ALLCAPS
have O
been O
identified O
by O
location O
and O
structural O
similarity O
to O
the O
nonstructural RARE
/ O
regulatory O
genes O
( O
vif RARE
, O
tat I-GENE
, O
and O
rev I-GENE
) O
of O
other O
lentiviruses RARE
; O
we O
also O
discovered O
two O
unique O
ORFs O
, O
termed O
W O
and O
Y O
, O
which O
may O
serve O
as O
exons O
for O
novel O
genes O
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
14DM NUMERIC
gene I-GENE
, O
encoding O
cytochrome I-GENE
P450 I-GENE
lanosterol RARE
14 I-GENE
alpha I-GENE
- I-GENE
demethylase RARE
( O
14DM NUMERIC
), O
was O
overexpressed O
in O
various O
S O
. O
cerevisiae O
strains O
under O
the O
control O
of O
three O
strong O
heterologous O
yeast O
transcription O
promoters O
( O
pADC1 NUMERIC
, O
pGPD LASTCAP
, O
pPHO5 NUMERIC
) O
and O
under O
the O
control O
of O
its O
own O
promoter O
. O

Truncations RARE
composed O
of O
78 O
and O
64 O
amino O
acids O
were O
translocated RARE
across O
the O
endoplasmic O
reticulum O
membrane O
, O
and O
translocation O
was O
found O
to O
be O
strictly O
co O
- O
translational O
and O
SRP I-GENE
- O
dependent O
. O

Pulmonary RARE
vascular O
resistance O
was O
not O
altered O
, O
ejection O
fraction O
remained O
unchanged O
and O
isovolumic RARE
relaxation O
period O
was O
lengthened RARE
( O
119 O
+/- O
20 O
. O
1 O
to O
147 NUMERIC
. O
39 O
+/- O
21 O
. O
15 O
, O
P O
less O
than O
0 O
. O
05 O
). O

The O
ANB1 NUMERIC
locus I-GENE
of O
Saccharomyces O
cerevisiae O
encodes O
the O
protein I-GENE
synthesis I-GENE
initiation I-GENE
factor I-GENE
eIF I-GENE
- I-GENE
4D NUMERIC
. O

The O
contribution O
that O
alternative O
splicing O
events O
in O
c I-GENE
- I-GENE
myb I-GENE
expression O
may O
make O
on O
c I-GENE
- I-GENE
myb I-GENE
function O
remains O
to O
be O
elucidated RARE
. O

Serum I-GENE
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
levels O
( O
beta I-GENE
- I-GENE
2 I-GENE
- I-GENE
M I-GENE
) O
were O
studied O
in O
150 O
drug O
addicts O
, O
50 O
of O
them O
asymptomatic O
carriers O
of O
anti I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
antibodies I-GENE
, O
50 O
symptomatic O
carriers O
with O
persistent O
generalized O
lymphadenopathy RARE
( O
P O
. O
G O
. O
L O
.) O
and O
50 O
serum O
negative O
patients O
who O
had O
been O
living O
in O
a O
closed O
community O
for O
at O
least O
2 O
years O
. O

This O
emancipation RARE
of O
the O
ability O
to O
copulate RARE
from O
hormonal O
influence O
makes O
female O
sexual O
motivation RARE
the O
primary O
regulator O
of O
mating O
in O
primates O
. O

No O
therapy O
exists O
for O
halting RARE
the O
progression O
of O
the O
disease O
with O
the O
possible O
exception O
of O
laser O
photocoagulation RARE
treatment O
used O
to O
ablate RARE
subretinal O
neovascular RARE
membranes O
in O
an O
attempt O
to O
avoid O
complications O
of O
subretinal O
hemorrhages RARE
. O

R O
. O

Specific O
hyperimmune RARE
globulins RARE
to O
pathogens O
such O
as O
Haemophilus O
influenzae O
and O
Streptococcus O
pneumoniae O
have O
also O
been O
studied O
. O

Therapeutic RARE
effects O
of O
cefpirome RARE
( O
HR O
810 NUMERIC
) O
on O
experimental O
mixed O
infections O
with O
Enterococcus RARE
faecalis RARE
and O
Escherichia O
coli O
in O
mice O
. O

Regulation O
of O
yeast I-GENE
LEU2 I-GENE
. O

Homozygous O
individuals O
usually O
develop O
purpura O
fulminans RARE
as O
newborns O
; O
heterozygous RARE
protein I-GENE
C I-GENE
- O
deficient O
individuals O
are O
at O
increased O
risk O
for O
venous O
thrombosis O
and O
pulmonary O
embolism RARE
. O

Ischemic O
stroke O
due O
to O
protein I-GENE
C I-GENE
deficiency O
. O

TREB7 NUMERIC
and O
TREB36 NUMERIC
protected O
all O
three O
repeats O
of O
the O
21 O
bp O
, O
but O
TREB5 NUMERIC
protected O
only O
the O
second O
repeat O
. O

These O
results O
suggest O
that O
5 O
KE ALLCAPS
X O
3 O
/ O
W O
may O
be O
the O
optimal O
regimen O
to O
augment RARE
the O
antitumor RARE
immunity O
of O
RNL ALLCAPS
. O

Analysis O
of O
various O
deletion O
mutants O
indicates O
that O
the O
sequence O
requirements O
for O
binding O
by O
QBP ALLCAPS
in O
vitro O
are O
indistinguishable O
from O
those O
necessary O
for O
Q O
activity O
in O
vivo O
, O
strongly O
suggesting O
that O
QBP ALLCAPS
is O
required O
for O
the O
function O
of O
this O
TATA O
- O
independent O
promoter O
. O

Since O
general I-GENE
regulatory I-GENE
factor I-GENE
I I-GENE
( O
GRFI ALLCAPS
)/ O
repressor I-GENE
/ I-GENE
activator I-GENE
site I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
RAP1 NUMERIC
)/ O
translation I-GENE
upstream I-GENE
factor I-GENE
( O
TUF ALLCAPS
) O
is O
believed O
to O
be O
an O
activator O
of O
MAT ALLCAPS
alpha I-GENE
expression O
, O
we O
examined O
whether O
PYK1 NUMERIC
, O
which O
is O
known O
to O
be O
regulated O
by O
GRFI ALLCAPS
/ O
RAP1 NUMERIC
/ O
TUF ALLCAPS
, O
is O
also O
affected O
by O
the O
gal11 NUMERIC
mutation I-GENE
. O

Yeast I-GENE
Gal11 NUMERIC
protein I-GENE
mediates O
the O
transcriptional O
activation O
signal O
of O
two O
different O
transacting RARE
factors O
, O
Gal4 I-GENE
and O
general I-GENE
regulatory I-GENE
factor I-GENE
I I-GENE
/ O
repressor I-GENE
/ I-GENE
activator I-GENE
site I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
/ I-GENE
translation I-GENE
upstream I-GENE
factor I-GENE
. O

Deletion O
from O
either O
the O
N O
- O
or O
C O
- O
terminal O
ends O
of O
repA LASTCAP
( O
28 O
and O
69 O
codons O
, O
respectively O
, O
out O
of O
the O
286 NUMERIC
- O
codon O
open O
reading O
frame O
) O
affected O
the O
initiator O
but O
not O
the O
inhibitory O
activity O
. O

The O
two O
larger O
peptides O
, O
one O
containing O
amino O
acids O
1 O
- O
228 NUMERIC
and O
the O
other O
containing O
amino O
acids O
85 O
- O
228 NUMERIC
, O
formed O
dimers O
in O
solution O
and O
bound O
DNA O
specifically O
as O
a O
dimer O
. O

In O
vitro O
transcription O
extracts O
from O
ret1 NUMERIC
- I-GENE
1 I-GENE
cells O
terminate O
less O
efficiently O
at O
weak O
transcription O
termination O
signals O
than O
those O
from O
RET1 NUMERIC
cells O
, O
using O
a O
variety O
of O
tRNA O
templates O
. O

Guiding RARE
patients O
in O
the O
decision RARE
should O
involve O
a O
multidisciplinary RARE
team RARE
composed O
of O
a O
surgical O
oncologist RARE
, O
geneticist RARE
, O
pathologist RARE
, O
psychotherapist RARE
and O
plastic RARE
surgeon RARE
. O

IgG I-GENE
and O
IgM I-GENE
antibody O
activity O
was O
determined O
by O
adding O
a O
1 O
: O
100 O
dilution O
of O
serum O
to O
plates O
coated RARE
with O
A60 NUMERIC
antigen I-GENE
. O

These O
factors O
belong O
to O
a O
set O
of O
genetically O
distinct O
molecules O
, O
including O
AP I-GENE
- I-GENE
4 I-GENE
and O
MLTF ALLCAPS
, O
that O
bind O
to O
the O
CACCTGTC ALLCAPS
motif O
or O
related O
sequences O
. O

Among O
known O
flea RARE
larvae O
, O
the O
genus O
Anomiopsyllus RARE
( O
Anomiopsyllinae RARE
, O
Anomiopsyllini RARE
) O
is O
as O
distinctive O
in O
larval O
form O
as O
are O
the O
adults O
. O

Here O
, O
we O
have O
used O
specific O
antibody O
to O
identify O
and O
characterize O
the O
SSN6 NUMERIC
protein I-GENE
. O

These O
latter O
results O
showed O
that O
the O
ABFI ALLCAPS
protein I-GENE
, O
like O
the O
RAP1 NUMERIC
protein I-GENE
, O
bound O
sequences O
required O
for O
positive O
as O
well O
as O
negative O
regulation O
of O
gene O
expression O
. O

Clinical O
nutrition O
of O
adult O
horses O
. O

The O
computer O
- O
programmed O
cytocentrifuge RARE
is O
currently O
most O
popular RARE
. O

RNase I-GENE
protection O
assays O
reveal O
that O
this O
gene O
, O
unr RARE
, O
is O
transcribed O
in O
the O
same O
direction O
as O
N I-GENE
- I-GENE
ras I-GENE
and O
that O
its O
3 O
' O
end O
is O
located O
just O
130 O
base O
pairs O
away RARE
from O
the O
point O
at O
which O
N I-GENE
- I-GENE
ras I-GENE
transcription O
begins O
. O

Isolation O
of O
a O
temperature O
- O
sensitive O
mutant O
with O
an O
altered O
tRNA I-GENE
nucleotidyltransferase RARE
and O
cloning O
of O
the O
gene I-GENE
encoding I-GENE
tRNA I-GENE
nucleotidyltransferase RARE
in I-GENE
the I-GENE
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

The O
juxtamembrane O
region O
of O
the O
insulin I-GENE
receptor I-GENE
( I-GENE
IR I-GENE
) I-GENE
beta I-GENE
- I-GENE
subunit I-GENE
contains O
an O
unphosphorylated RARE
tyrosyl RARE
residue O
( O
Tyr960 NUMERIC
) O
that O
is O
essential O
for O
insulin I-GENE
- O
stimulated O
tyrosyl RARE
phosphorylation O
of O
some O
endogenous O
substrates O
and O
certain O
biological O
responses O
( O
White RARE
, O
M O
. O
F O
., O
Livingston RARE
, O
J O
. O
N O
., O
Backer RARE
, O
J O
. O
M O
., O
Lauris RARE
, O
V O
., O
Dull RARE
, O
T O
. O
J O
., O
Ullrich RARE
, O
A O
., O
and O
Kahn RARE
, O
C O
. O
R O
. O

This O
gene O
joins O
the O
group O
of O
genes O
whose O
members O
are O
rapidly O
transcribed O
in O
response O
to O
insulin I-GENE
and O
other O
mitogens RARE
. O

The O
3 O
' O
region O
, O
GA2 NUMERIC
, O
is O
necessary O
for O
maximal O
expression O
. O

1 O
, O
among O
which O
nine O
have O
been O
cloned O
and O
two O
( O
potentially O
functional O
) O
sequenced O
. O

Pups RARE
placed O
into O
the O
novel O
environment O
with O
their O
mothers O
exhibited O
an O
intermediate O
level O
of O
DA O
turnover O
. O

The O
efficacy O
and O
safety O
of O
a O
novel O
percutaneous RARE
anaesthetic RARE
preparation O
based O
on O
amethocaine RARE
has O
been O
investigated O
in O
the O
paediatric RARE
clinical O
environment O
. O

Homozygous O
protein I-GENE
C I-GENE
( O
PC I-GENE
) O
deficiency O
is O
reported O
in O
two O
siblings RARE
( O
girl RARE
and O
boy RARE
) O
who O
received O
their O
proper O
diagnoses RARE
at O
the O
ages O
of O
7 O
4 O
/ O
12 O
and O
1 O
3 O
/ O
12 O
years O
respectively O
. O

The O
grandfather RARE
and O
the O
granddaughter RARE
both O
had O
microtia RARE
and O
meatal RARE
atresia RARE
, O
whereas O
the O
daughter O
had O
a O
normal O
outer O
ear O
except O
for O
a O
narrow O
meatus RARE
and O
auricular RARE
appendages RARE
. O

Abnormal O
intrapulmonary RARE
shunting RARE
( O
IPS ALLCAPS
), O
which O
was O
proved O
in O
4 O
cases O
by O
whole O
- O
body O
radionuclide RARE
scanning O
with O
99mTc O
- O
MAA ALLCAPS
, O
is O
suggested O
as O
the O
major O
cause O
of O
cyanosis RARE
in O
liver O
cirrhosis O
. O

The O
urinary O
protein O
, O
serum O
albumin I-GENE
, O
BUN ALLCAPS
and O
SCr RARE
all O
had O
very O
significant O
improvement O
. O

More O
generally O
, O
Ets1 NUMERIC
and O
Ets2 NUMERIC
could O
regulate O
transcription O
of O
cellular O
genes O
. O

Within O
this O
sequence O
the O
MSAS ALLCAPS
gene I-GENE
was O
identified O
as O
a O
5322 NUMERIC
- O
bp O
- O
long O
open O
reading O
frame O
coding O
for O
a O
protein O
of O
1774 NUMERIC
amino O
acids O
and O
190 O
, O
731 NUMERIC
Da O
molecular O
mass O
. O

Horseradish RARE
peroxidase I-GENE
as O
a O
permeability O
marker O
in O
injured RARE
rat O
caudal RARE
and O
iliac O
arteries O
. O

Standardized RARE
gastric O
wall O
specimens O
from O
the O
area O
of O
grossly RARE
healed RARE
ulcers O
were O
obtained O
, O
processed O
, O
and O
evaluated O
by O
light O
microscopy O
and O
by O
transmission O
electron O
microscopy O
. O

2 O
. O

The O
effects O
of O
coenzyme O
Q10 NUMERIC
( O
CoQ LASTCAP
) O
and O
captopril O
on O
functional O
capacity O
, O
hemodynamics O
and O
survival O
were O
studied O
in O
154 O
rats O
that O
recovered O
after O
experimental O
myocardial O
infarction O
. O

Evidence O
that O
therapeutic O
alterations O
of O
a O
circadian O
rhythm O
for O
gastric O
emptying O
response O
may O
be O
possible O
. O

The O
interrelation RARE
of O
the O
levels O
of O
glucocorticoids O
and O
insulin I-GENE
in O
the O
blood O
of O
irradiated O
animals O

This O
last O
includes O
tissue O
O2 O
transfer O
( O
Ft O
') O
and O
mitochondrial O
O2 O
utilization O
( O
Fm RARE
'). RARE

Foveating RARE
saccades RARE
, O
therefore O
, O
can O
be O
distinguished O
from O
other O
FEMs RARE
on O
the O
basis O
of O
speed RARE
. O

Incidence RARE
correlated O
with O
the O
grade O
of O
oral O
hygiene RARE
und RARE
periodontal O
disease O
. O

Our O
study O
shows O
that O
the O
area O
of O
Alcoy RARE
is O
a O
medium O
MS O
risk O
region O
according O
to O
the O
thesis RARE
of O
Kurzke RARE
, O
although O
high O
MS O
areas O
may O
be O
found O
, O
thus O
confirming O
that O
MS O
distribution O
in O
southern O
Europe RARE
is O
not O
uniform O
. O

On O
an O
antithrombin I-GENE
unit O
basis O
, O
CY ALLCAPS
216 NUMERIC
and O
CY ALLCAPS
222 NUMERIC
were O
equivalent O
and O
more O
potent O
than O
UH ALLCAPS
. O

Chick RARE
brain I-GENE
actin I-GENE
depolymerizing RARE
factor I-GENE
( O
ADF ALLCAPS
) O
is O
a O
19 O
- O
kDa O
protein O
that O
severs RARE
actin I-GENE
filaments RARE
and O
binds O
actin I-GENE
monomers RARE
. O

Initial O
experience O
with O
a O
serotonin O
agonist O
. O

Comprehensive RARE
care O
of O
the O
patient O
exposed O
to O
a O
human O
teratogen RARE
may O
also O
include O
discussion O
of O
prenatal RARE
diagnostic O
procedures O
and O
other O
pregnancy O
management O
options RARE
. O

Primer O
extension O
analysis O
and O
RNA O
sequencing O
demonstrates O
that O
the O
transcription O
start O
point O
of O
rat I-GENE
ODC ALLCAPS
mRNA I-GENE
is O
located O
303 NUMERIC
nt O
upstream O
from O
the O
A O
residue O
in O
the O
start O
codon O
. O

For O
85Sr NUMERIC
, O
larger O
- O
than O
- O
expected O
distribution O
coefficients O
were O
obtained O
in O
the O
desorption RARE
experiments O
, O
an O
indication O
of O
the O
irreversible O
formation O
of O
metal O
- O
oxyhydroxides RARE
during O
a O
slow O
reaction O
. O

Gene O
constructs O
possessing RARE
the O
complete I-GENE
tat I-GENE
, O
rev I-GENE
( O
tat I-GENE
+ I-GENE
rev O
+) O
and O
env I-GENE
genes I-GENE
were O
transiently O
expressed O
in O
COS O
- O
1 O
cells O
as O
precursor I-GENE
SU I-GENE
- I-GENE
TM I-GENE
( O
gp160 NUMERIC
), O
SU I-GENE
. I-GENE
TM I-GENE
( O
gp120 I-GENE
x I-GENE
41 I-GENE
), O
and O
nucleolar I-GENE
rev I-GENE
protein I-GENE
. O

This O
growth O
arrest O
is O
partly O
suppressed O
on O
minimal O
medium O
or O
under O
conditions O
in O
which O
the O
cells O
are O
less O
dependent O
on O
mitochondrial O
metabolism O
. O

Patients O
with O
detectable O
serum O
TNF I-GENE
levels O
had O
significantly O
lower O
serum O
T3 O
concentrations O
compared O
to O
those O
with O
undetectable O
levels O
[ O
1 O
. O
072 NUMERIC
+/- O
0 O
. O
588 NUMERIC
vs O
. O

Giant RARE
pilomatrix RARE
carcinoma O
: O
report O
and O
review O
of O
the O
literature O
. O

Further O
studies O
of O
mandibular O
movement O
at O
initial O
tooth O
contact O
. O

Each O
parent RARE
interacted O
with O
their O
4 O
- O
or O
5 O
- O
year O
- O
old O
son RARE
or O
daughter O
in O
each O
of O
two O
conversations RARE
-- O
unstructured RARE
( O
social O
conversation RARE
) O
and O
structured O
( O
task O
activity O
). O

Droperidol RARE
- O
induced O
extrapyramidal RARE
symptoms O
in O
an O
adolescent O
following O
strabismus RARE
surgery O
. O

These O
results O
indicate O
that O
the O
cis O
- O
regulatory O
elements O
required O
for O
developmental O
control O
of O
the O
HaG3 NUMERIC
- I-GENE
A I-GENE
helianthinin RARE
gene I-GENE
are O
located O
in O
a O
2 O
. O
4 O
kb O
upstream O
region O
of O
this O
gene O
. O

The O
induction O
by O
pseudorabies O
virus O
of O
an O
IL I-GENE
- I-GENE
6 I-GENE
construct I-GENE
containing O
the O
IL I-GENE
- I-GENE
6 I-GENE
TATA I-GENE
box I-GENE
and O
the O
RNA O
start O
site O
(" O
initiator O
" O
or O
Inr RARE
element O
) O
but O
not O
the O
MRE ALLCAPS
region O
was O
also O
repressed O
by O
Dex RARE
in O
the O
presence O
of O
wild I-GENE
- I-GENE
type I-GENE
GR I-GENE
. O

Some O
mutations O
affected O
Dhfr RARE
in O
a O
qualitative O
manner O
, O
such O
as O
by O
changing O
the O
startpoint RARE
of O
one O
of O
the O
major O
Dhfr RARE
transcripts I-GENE
or O
changing O
the O
relative O
abundance O
of O
the O
two O
major O
Dhfr RARE
transcripts I-GENE
. O

The O
glial RARE
cyst O
wall O
was O
lined RARE
in O
part O
by O
flattened RARE
or O
cuboidal RARE
epithelium O
. O

We O
conclude O
that O
class O
I O
cytologic RARE
smears O
with O
moderate O
to O
severe O
inflammation O
may O
be O
associated O
with O
findings O
of O
condylomata RARE
and O
cervical O
dysplasia O
. O

As O
in O
mammals O
, O
considerable O
nucleotide O
diversity O
was O
observed O
at O
the O
junctions O
of O
the O
variable O
, O
diversity O
, O
and O
joining O
elements O
in O
chicken I-GENE
TCR I-GENE
beta I-GENE
cDNAs I-GENE
. O

The O
protooncogene O
c I-GENE
- I-GENE
myb I-GENE
encodes O
a O
nuclear O
transcription O
factor O
that O
binds O
to O
DNA O
in O
a O
sequence O
- O
specific O
manner O
and O
transactivates O
transcription O
of O
several O
viral O
and O
cellular O
genes O
. O

Modification RARE
by O
this O
latter O
compound O
was O
so O
extensive O
that O
the O
amount O
of O
membrane O
- O
associated O
N O
- O
myristoylated RARE
protein O
was O
decreased O
. O

S6 I-GENE
kinase I-GENE
activation O
requires O
displacement O
of O
this O
inhibitory O
segment O
, O
which O
is O
proposed O
to O
occur O
consequent RARE
to O
its O
multiple O
phosphorylation O
. O

Rats O
with O
one O
olfactory O
bulb O
removed O
and O
the O
contralateral O
naris RARE
closed O
can O
detect O
odors RARE
. O

Expression O
of O
the O
human O
T I-GENE
cell I-GENE
receptor I-GENE
( I-GENE
TCR I-GENE
) I-GENE
alpha I-GENE
gene I-GENE
is O
regulated O
by O
a O
T O
cell O
- O
specific O
transcriptional O
enhancer O
that O
is O
located O
4 O
. O
5 O
kilobases O
( O
kb O
) O
3 O
' O
to O
the O
C I-GENE
alpha I-GENE
gene I-GENE
segment I-GENE
. O

The O
Ets I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
was O
localized O
to O
a O
17 O
- O
base O
pair O
( O
bp O
) O
region O
from O
the O
3 O
' O
end O
of O
T I-GENE
alpha I-GENE
2 I-GENE
. O

Cerebral RARE
flow O
and O
resistance O
showed O
minor O
reductions O
with O
HD O
. O

Utilization RARE
of O
alternative O
polyadenylation O
signals O
was O
previously O
shown O
to O
generate O
two O
sialophorin RARE
mRNAs I-GENE
of I-GENE
1 I-GENE
. I-GENE
9 I-GENE
and I-GENE
4 I-GENE
. I-GENE
3 I-GENE
kb I-GENE
, O
which O
differ O
in O
the O
length O
of O
their O
3 O
' O
untranslated O
regions O
. O

Presidential RARE
address O
1990 O
-- O
coming RARE
in O
from O
the O
cold O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
encodes O
a O
40 O
- O
kDa O
nuclear O
protein O
, O
Tax I-GENE
, O
which O
stimulates O
transcription O
from O
three O
21 O
- O
base O
pair O
( O
bp O
) O
repeats O
in O
its O
U3 O
region O
. O

We O
have O
now O
identified O
, O
after O
21 O
serial O
undiluted RARE
passages RARE
of O
MHV ALLCAPS
, O
a O
small I-GENE
DI ALLCAPS
RNA I-GENE
, O
DIssF LASTCAP
, O
which O
is O
efficiently O
packaged RARE
into O
virions O
. O

The O
Jenkins RARE
Activity RARE
Survey RARE
and O
the O
CPI ALLCAPS
- O
revised O
: O
further O
evidence O
of O
adaptive O
and O
maladaptive RARE
type O
A O
traits RARE
. O

There O
was O
evidence O
of O
attenuated O
regression O
slopes RARE
relating RARE
recalled RARE
to O
observed O
portion O
sizes O
for O
4 O
of O
the O
10 O
food O
groups O
; O
adjusted O
r2 NUMERIC
values O
for O
the O
recalled RARE
portion O
sizes O
ranged O
from O
0 O
. O
02 O
to O
0 O
. O
94 O
. O

The O
result O
suggests O
that O
this O
non O
- O
invasive O
TTD ALLCAPS
method O
is O
easily O
available O
and O
useful O
in O
monitoring O
the O
intraoperative RARE
cardiac O
output O
. O

The O
TUP1 NUMERIC
gene I-GENE
was O
isolated O
in O
a O
screen O
for O
genes O
that O
regulate O
mating O
type O
( O
V O
. O
L O
. O

The O
SUP44 NUMERIC
suppressor I-GENE
mutation I-GENE
occurs O
near O
a O
region O
of O
the O
protein O
that O
corresponds O
to O
the O
known O
positions O
of O
alterations O
in O
E I-GENE
. I-GENE
coli I-GENE
S5 NUMERIC
ram RARE
mutations I-GENE
. O

Interestingly O
, O
disruption O
of O
the O
VPS34 NUMERIC
locus I-GENE
resulted O
in O
a O
temperature O
- O
sensitive O
growth O
defect O
, O
indicating O
that O
the O
VPS34 NUMERIC
gene I-GENE
is O
essential O
for O
vegetative RARE
growth O
only O
at O
elevated O
growth O
temperatures O
. O

We O
describe O
a O
case O
of O
a O
perinephric RARE
abscess O
treated O
with O
amphotericin O
B O
and O
nephrectomy RARE
. O

This O
, O
together O
with O
the O
data O
obtained O
with O
haloperidol O
, O
suggests O
that O
a O
minimal O
increase O
in O
the O
firing RARE
rate O
of O
LC ALLCAPS
cells O
(+ O
140 O
%) O
is O
required O
before O
it O
could O
influence O
the O
turnover O
of O
NA O
, O
as O
measured O
by O
DOPAC ALLCAPS
changes O
. O

This O
interaction O
occurs O
over O
a O
wide O
range O
of O
both O
parameters O
; O
for O
charge O
density O
from O
at O
least O
10 O
to O
800 O
microC LASTCAP
/ O
cm2 O
and O
, O
for O
charge O
per O
phase O
, O
from O
at O
least O
0 O
. O
05 O
to O
5 O
. O
0 O
microC LASTCAP
per O
phase O
. O

Perceptions RARE
of O
illness O
intrusiveness RARE
were O
significantly O
higher O
when O
both O
muscle O
cramp RARE
and O
headache O
symptoms O
occurred O
during O
one O
or O
more O
assessment O
intervals O
as O
compared O
to O
when O
muscle O
cramps RARE
or O
headaches RARE
, O
only O
, O
occurred O
. O

Results O
have O
surprisingly RARE
revealed O
the O
presence O
of O
three O
U14 I-GENE
snRNA I-GENE
- I-GENE
homologous I-GENE
regions I-GENE
positioned O
within O
introns O
5 O
, O
6 O
, O
and O
8 O
of O
the O
mouse O
cognate O
hsc70 NUMERIC
heat O
shock O
gene O
. O

65 O
- O
kilodalton O
protein O
phosphorylated O
by O
interleukin I-GENE
2 I-GENE
stimulation O
bears RARE
two O
putative O
actin I-GENE
- I-GENE
binding I-GENE
sites I-GENE
and O
two O
calcium O
- O
binding O
sites O
. O

The O
highly O
restrained RARE
girls O
had O
a O
significantly O
higher O
EAT ALLCAPS
score O
than O
the O
low O
- O
restrained RARE
girls O
, O
and O
shared O
with O
their O
mothers O
a O
susceptibility O
to O
the O
disinhibitory RARE
effects O
of O
negative O
mood RARE
states O
on O
their O
eating RARE
behaviour O
. O

The O
Mauriceville RARE
and O
Varkud RARE
mitochondrial O
plasmids O
are O
closely O
related O
, O
closed O
- O
circular O
DNAs O
( O
3 O
. O
6 O
and O
3 O
. O
7 O
kb O
, O
respectively O
) O
that O
have O
characteristics O
of O
mtDNA LASTCAP
introns O
and O
retroid RARE
elements O
. O

The O
circadian O
rhythm O
, O
however O
, O
was O
not O
affected O
and O
the O
difference O
between O
minimum O
( O
12 O
. O
00 O
h O
) O
and O
maximum O
( O
18 O
. O
50 O
h O
) O
serum O
concentrations O
was O
31 O
. O
3 O
%. O

Sequence O
and O
genetic O
organization O
of O
a O
Zymomonas RARE
mobilis RARE
gene O
cluster O
that O
encodes O
several O
enzymes O
of O
glucose O
metabolism O
. O

Most O
strains O
( O
95 O
%) O
of O
S O
. O
lugdunensis RARE
produced O
a O
delta I-GENE
hemolysin RARE
like O
that O
seen O
with O
nine O
other O
species O
of O
CNS O
. O

For O
this O
, O
cDNAs O
containing O
the O
60K NUMERIC
, O
87K NUMERIC
, O
110K NUMERIC
and O
170K NUMERIC
protein O
coding O
sequences O
were O
each O
provided O
with O
an O
ATG O
start O
codon O
and O
the O
cDNA O
containing O
the O
60K NUMERIC
coding O
sequence O
with O
a O
TAA ALLCAPS
stop O
codon O
immediately O
downstream O
of O
the O
coding O
sequence O
. O

Finally O
, O
a O
complementary O
footprinting O
analysis O
of O
the O
upstream O
region O
of O
the O
constitutively O
expressed O
HSC82 NUMERIC
gene I-GENE
reveals O
the O
presence O
of O
three O
discrete O
protein O
complexes O
. O

Pathophysiology RARE
of O
bone O
loss O
in O
castrated RARE
animals O
. O

Auditory RARE
- O
visual O
interaction O
in O
the O
generation O
of O
saccades RARE
in O
man O
. O

First O
, O
each O
lung O
was O
cut O
into O
slices RARE
, O
from O
which O
primary O
disectors RARE
were O
sampled RARE
systematically O
with O
a O
known O
sampling O
fraction O
. O

The O
upstream O
promoter O
is O
located O
within O
the O
coding O
sequence O
of O
a O
divergent O
gene O
expressing O
a O
protein O
of O
Mr O
39 O
kDa O
of O
unknown O
function O
. O

Assuming RARE
O2 O
consumption O
of O
the O
isolated O
skin O
to O
be O
same O
as O
in O
situ O
, O
calculations RARE
showed O
that O
when O
water O
PO2 O
was O
high O
( O
150 O
mm O
Hg O
), O
about O
40 O
% O
of O
total O
cutaneous O
O2 O
uptake O
was O
consumed RARE
by O
the O
skin O
. O

Experiments O
showed O
that O
temporary O
arrest O
of O
pulmonary O
circulation O
under O
conditions O
of O
extracorporeal RARE
circulation O
is O
attended RARE
by O
the O
development O
of O
ischemia O
of O
the O
respiratory O
pulmonary O
tissue O
. O

MCh RARE
infusion O
caused O
a O
concentration O
- O
dependent O
increase O
in O
airway O
resistance O
at O
constant O
QBA ALLCAPS
. O

Taste RARE
reactivity O
tests O
were O
used O
to O
examine O
the O
orofacial RARE
responses O
of O
alcohol O
preferring RARE
( O
P O
) O
rats O
and O
alcohol O
nonpreferring RARE
( O
NP O
) O
rats O
to O
the O
taste O
of O
alcohol O
. O

Plasma O
concentrations O
of O
atracurium RARE
and O
laudanosine RARE
were O
0 O
. O
73 O
- O
3 O
. O
11 O
micrograms O
ml O
- O
1 O
and O
0 O
. O
48 O
- O
8 O
. O
65 O
micrograms O
ml O
- O
1 O
, O
respectively O
; O
CSF O
concentration O
of O
laudanosine RARE
was O
70 O
- O
440 O
ng O
ml O
- O
1 O
. O

Plasma O
Al O
was O
obtained O
during O
each O
baseline O
and O
drug O
course O
. O

The O
survival O
in O
the O
case O
of O
these O
patients O
was O
studied O
five O
years O
later O
. O

The O
occurrence O
, O
maintenance O
and O
possible O
involvement O
of O
these O
repeated O
sequences O
, O
capable O
of O
forming O
stable O
secondary O
structures O
, O
are O
discussed O
in O
relation O
to O
their O
location O
in O
the O
region O
of O
control O
signals O
. O

IST ALLCAPS
is O
not O
the O
RNA O
target O
( O
TAR O
) O
for O
Tat I-GENE
trans O
- O
activation O
; O
however O
, O
because O
it O
relies RARE
entirely O
on O
cellular O
factors O
for O
activity O
, O
IST ALLCAPS
may O
serve O
to O
provide O
abundant O
RNA O
targets O
for O
Tat I-GENE
trans O
- O
activation O
without O
a O
requirement O
for O
full O
- O
length O
viral O
mRNA O
expression O
. O

Genotoxic RARE
activity O
of O
a O
tobacco O
- O
specific O
nitrosamine RARE
. O

The O
endodontal RARE
treatment O
need O
has O
been O
forming O
a O
clinical O
order O
of O
magnitude O
. O

1 O
(" O
long O
method O
") RARE
and O
the O
HML O
method O
. O

These O
results O
may O
suggest O
involvement O
of O
peripheral O
enkephalins RARE
in O
pain O
modulation O
in O
patients O
with O
episodic RARE
cluster O
headache O
. O

Effects O
of O
cisapride RARE
on O
upper O
- O
gastrointestinal O
motility O
and O
digestive RARE
hormones O

Common RARE
foot O
pathologies RARE
are O
heel RARE
pain O
, O
metatarsalgia RARE
, O
hammertoes RARE
and O
clawtoes RARE
, O
bunions RARE
, O
hallux RARE
rigidus RARE
, O
corns RARE
and O
calluses RARE
, O
nail RARE
pathologies RARE
, O
arthritis O
, O
and O
neuropathies RARE
. O

Liver O
dysfunction O
in O
the O
presence O
of O
different O
adverse O
reactions O
presented O
with O
a O
higher O
activity O
in O
the O
blood O
serum O
of O
indicator O
liver O
enzymes O
and O
its O
impaired O
protein O
- O
forming O
function O
. O

Coenzyme RARE
Q10 NUMERIC
: O
blood O
levels O
and O
metabolic O
demand O
. O

The O
CT O
characteristics O
are O
discussed O
and O
the O
recent O
literature O
is O
reviewed O
. O

Unfortunately RARE
, O
these O
preservatives RARE
may O
also O
interfere RARE
with O
microbiological RARE
assays O
used O
to O
determine O
product O
sterility RARE
or O
bioburden RARE
levels O
. O

In O
26 O
patients O
with O
angina O
pectoris O
, O
the O
changes O
of O
LVEF O
, O
LVESV ALLCAPS
and O
PSP ALLCAPS
/ O
LVESV ALLCAPS
were O
more O
sensitive O
for O
the O
detection O
of O
exercise O
- O
induced O
ischemia O
than O
the O
appearance O
of O
chest O
pain O
and O
the O
changes O
of O
ECG O
. O

In O
both O
groups O
there O
were O
5 O
management O
failure O
of O
therapy O
, O
so O
that O
alternative O
medication O
or O
a O
cesarean RARE
section O
lead O
to O
delivery O
. O

Serum O
Fibrin RARE
Degradation RARE
Products RARE
( O
FDP ALLCAPS
) O
were O
determined O
in O
50 O
oral O
cancer O
patients O
and O
50 O
normal O
individuals O
prior O
to O
any O
kind RARE
of O
treatment O
. O

The O
uteroglobin RARE
promoter I-GENE
contains O
a O
noncanonical RARE
estrogen O
responsive O
element O
. O

Prostaglandin RARE
synthesis O
inhibitors O
have O
been O
shown O
to O
delay O
healing O
of O
bone O
and O
this O
has O
led O
to O
limitations O
on O
their O
use O
clinically O
in O
some O
situations O
. O

The O
inspiratory O
oxygen O
concentration O
needed O
( O
FiO2 NUMERIC
) O
and O
the O
Horowitz RARE
quotient RARE
differed O
in O
a O
highly O
significant O
manner O
beginning O
on O
the O
1st NUMERIC
day O
after O
trauma O
. O

The O
corn RARE
and O
mineral O
oil O
emulsions RARE
were O
almost O
as O
effective O
as O
milk O
but O
less O
effective O
than O
sucrose O
( O
0 O
. O
3M NUMERIC
) O
in O
stimulating O
ingestion O
. O

Significance O
of O
thin O
glomerular O
basement RARE
membranes O
in O
hematuric RARE
children O
. O

Significance O
of O
cytokine O
production O
and O
adhesion O
molecules O
in O
malarial RARE
immunopathology RARE
. O

The O
former O
procedure O
is O
economical RARE
but O
complicated O
, O
whereas O
the O
latter O
is O
simple O
and O
labour O
- O
saving RARE
, O
but O
a O
special O
ultrafiltration RARE
tube O
is O
required O
. O

Simple RARE
method O
for O
determination O
of O
the O
cephalosporin RARE
DQ ALLCAPS
- O
2556 NUMERIC
in O
biological O
fluids O
by O
high O
- O
performance O
liquid O
chromatography O
. O

Since O
one O
group O
of O
adolescents RARE
more O
difficult O
to O
influence O
are O
those O
whose O
parents O
smoke O
, O
parental O
involvement O
in O
smoking O
prevention O
may O
be O
a O
powerful RARE
enhancer O
. O

Further O
research O
is O
recommended O
to O
identify O
the O
coping RARE
styles RARE
associated O
with O
the O
high O
EE ALLCAPS
/ O
low O
EE ALLCAPS
research O
classification O
. O

Staining RARE
with O
IF O
MoAB LASTCAP
alone O
of O
BAL O
fluid O
only O
seemed RARE
to O
be O
even O
more O
sensitive O
than O
silver O
methenamine RARE
staining O
of O
BAL O
, O
TBB ALLCAPS
and O
brushing RARE
material O
. O

Ultrastructural RARE
and O
morphometric RARE
study O
of O
the O
myeloid O
parenchyma O
cells O
of O
mice O
prior O
and O
after O
X O
- O
ray O
exposure O

Using O
an O
audiotape RARE
cassette O
and O
headphones RARE
the O
duration O
of O
the O
hallucinations RARE
decreased O
significantly O
. O

The O
mean O
change O
in O
HbA1 NUMERIC
, O
adjusted O
for O
the O
initial O
value O
, O
was O
- O
0 O
. O
4 O
% O
in O
the O
experimental O
and O
+ O
0 O
. O
5 O
% O
in O
the O
control O
group O
( O
p O
less O
than O
0 O
. O
05 O
). O

Effect O
of O
biliary O
obstruction O
and O
cholangitis RARE
on O
serum I-GENE
SPan RARE
- I-GENE
1 I-GENE
level O

Very RARE
good O
accuracy O
( O
r O
greater O
than O
0 O
. O
9 O
) O
was O
found O
when O
except O
comparing O
H O
* O
2 O
with O
the O
other O
machine O
and O
the O
reference O
methods O
, O
except O
for O
MCHCH ALLCAPS
and O
basophil RARE
count O
. O

The O
second O
part O
of O
this O
paper O
shows O
some O
medical O
applications O
of O
these O
two O
aspects O
of O
NMR O
, O
with O
help O
of O
some O
examples O
, O
taken O
from O
the O
literature O
, O
according O
to O
what O
is O
concerned RARE
with O
endocrinology RARE
. O

Interlimb RARE
coordination O
during O
fictive RARE
locomotion RARE
in O
the O
thalamic RARE
cat O
. O

Antileukoproteinase RARE
( O
ALP ALLCAPS
) O
is O
a O
low O
mol O
wt O
mucosal O
secretory O
protein O
which O
, O
in O
human O
tissues O
, O
inhibits O
the O
activities O
of O
the O
neutral O
serine I-GENE
lysosomal I-GENE
proteinases RARE
elastase I-GENE
and O
cathepsin RARE
- I-GENE
G I-GENE
. O

By O
introducing RARE
a O
series O
of O
deletions O
in O
the O
vimentin RARE
promoter O
, O
we O
further O
restrict RARE
these O
sequences O
to O
30 O
base O
pairs O
, O
located O
between O
241 NUMERIC
and O
210 O
base O
pairs O
upstream O
of O
the O
mRNA O
cap O
site O
. O

In O
particular O
, O
71 O
and O
69 O
% O
amino O
acid O
sequence O
similarities O
were O
identified O
with O
hsp70 I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
and I-GENE
Bacillus I-GENE
megaterium RARE
, O
respectively O
. O

No O
causal RARE
relations O
may O
be O
inferred RARE
from O
the O
correlation O
between O
the O
level O
of O
trapezius RARE
activity O
and O
complaints RARE
, O
though O
it O
indicates O
that O
individual O
, O
inexpedient RARE
muscle O
activity O
patterns O
may O
constitute O
an O
important O
risk O
factor O
for O
development O
of O
musculo RARE
- O
skeletal O
complaints RARE
. O

All O
89 O
participating RARE
household RARE
members O
were O
anti I-GENE
- I-GENE
HIV I-GENE
seronegative RARE
, O
and O
78 O
who O
were O
tested O
were O
serum I-GENE
p24 NUMERIC
antigen I-GENE
negative O
. O

Analysis O
with O
additional O
anti O
- O
peptide O
antibodies O
specific O
for O
alpha I-GENE
, I-GENE
beta I-GENE
, I-GENE
or I-GENE
gamma I-GENE
PKC I-GENE
indicated O
that O
all O
three O
types O
of O
PKC I-GENE
are O
expressed O
in O
JK ALLCAPS
cells O
; O
however O
, O
JKPE ALLCAPS
cells O
lost O
a O
major O
approximately O
82 O
kDa O
immunoreactive O
cytosolic O
protein O
detectable O
with O
anti I-GENE
- I-GENE
PKC I-GENE
alpha I-GENE
antibody I-GENE
. O

To O
those O
of O
us O
who O
are O
not O
satisfied RARE
with O
the O
present O
outlook RARE
there O
is O
much O
to O
be O
investigated O
and O
much O
to O
be O
contributed O
. O

To O
determine O
the O
effects O
on O
the O
pulmonary O
barrier O
of O
several O
surface O
active O
agents O
, O
a O
series O
of O
metered RARE
dose O
inhalers RARE
( O
MDIs RARE
) O
was O
prepared O
and O
used O
to O
dose O
aerosolized RARE
surfactant O
to O
the O
airways RARE
of O
isolated O
perfused O
rat O
lungs O
. O

The O
beta O
chain O
contains O
five O
potential O
N O
- O
linked O
glycosylation O
sites O
, O
and O
endoglycosidase RARE
digestion O
suggested O
that O
the O
beta O
chain O
contained O
multiple O
complex O
carbohydrate O
side O
chains O
. O

The O
therapeutic O
protocole RARE
used O
at O
the O
Gustave RARE
Roussy RARE
Institute O
for O
invasive O
epithelioma RARE
of O
the O
uterine O
cervix O
rests RARE
, O
for O
limited O
forms O
( O
T1B NUMERIC
- O
T2 O
proximal O
), O
on O
combined O
radiology RARE
and O
surgery O
. O

Thyrotropin RARE
- O
induced O
expression O
of O
a O
gene O
for O
a O
ribosomal I-GENE
protein I-GENE
related O
to O
the O
trk I-GENE
oncogene I-GENE
. O

The O
introns O
are O
1 O
. O
6 O
- O
1 O
. O
9 O
kbp O
long O
. O

After O
an O
initial O
titration O
period O
and O
adjustment O
of O
the O
therapeutic O
dose O
, O
the O
individual O
doses O
were O
from O
21 O
to O
500 O
micrograms O
/ O
24 O
hrs O
( O
mean O
160 O
micrograms O
/ O
24 O
hrs O
). O

In O
the O
first O
series O
of O
experiments O
, O
Sprague O
- O
Dawley O
male O
rats O
were O
implanted O
unilaterally RARE
with O
guide RARE
cannulas RARE
aimed O
at O
the O
lateral O
ventricle O
. O

Use O
of O
Selenastrum RARE
capricornutum RARE
and O
Microfeast RARE
as O
food O
for O
Daphnia RARE
pulex RARE
. O

The O
persistence RARE
of O
members O
of O
the O
prostigmatid RARE
families O
Tydeidae RARE
, O
Nanorchestidae RARE
and O
Tarsonemidae RARE
in O
the O
moisture RARE
- O
deficient O
90 O
%- RARE
concentration O
treatments O
supports O
previous O
evidence O
of O
adaptations RARE
to O
low O
- O
water O
- O
content O
habitats RARE
. O

To O
define O
the O
mechanism O
responsible O
for O
the O
loss O
of O
transcription O
elongation O
blockage RARE
and O
resulting O
c I-GENE
- I-GENE
myc I-GENE
deregulation RARE
in O
Burkitt RARE
' O
s O
lymphoma O
, O
we O
analyzed O
transcription O
patterns O
after O
transfer O
of O
normal O
and O
Burkitt RARE
' O
s O
lymphoma O
c I-GENE
- I-GENE
myc I-GENE
alleles O
into O
murine O
cells O
and O
Xenopus O
oocyte O
germinal RARE
vesicles O
. O

Erythrocyte RARE
protoporphyrin RARE
concentration O
increased O
significantly O
( O
P O
less O
than O
0 O
. O
05 O
) O
by O
14 O
days O
in O
dogs O
fed O
the O
basal O
diet O
, O
and O
remained O
significantly O
high O
relative O
to O
that O
in O
dogs O
of O
the O
other O
dietary O
groups O
for O
the O
remainder RARE
of O
the O
study O
. O

The O
coding O
sequences O
of O
the O
Crry RARE
gene I-GENE
encompass RARE
over O
25 O
kb O
of O
DNA O
, O
whereas O
the O
Crry RARE
- O
ps I-GENE
sequences O
are O
included O
within O
a O
single O
5 I-GENE
. I-GENE
6 I-GENE
- I-GENE
kb I-GENE
Eco RARE
- I-GENE
R1 I-GENE
fragment I-GENE
. O

The O
genomic O
and O
transcriptional O
complexity O
of O
the O
Crry RARE
and O
Crry RARE
- O
ps I-GENE
genes O
. O

From O
an O
RNK ALLCAPS
- O
16 O
lambda O
- O
gt11 O
library O
, O
we O
have O
isolated O
and O
sequenced O
a O
novel O
cDNA O
rat I-GENE
NK I-GENE
cell I-GENE
protease I-GENE
1 I-GENE
( O
RNKP ALLCAPS
- I-GENE
1 I-GENE
) O
that O
has O
characteristics O
unique O
to O
serine I-GENE
proteases I-GENE
. O

The O
induction O
of O
RNKP ALLCAPS
- I-GENE
1 I-GENE
expression O
in O
the O
Con RARE
A I-GENE
- O
cultured O
spleen O
cells O
is O
accompanied O
by O
increases O
in O
both O
NK O
and O
lymphokine RARE
- O
activated O
killer O
lymphocyte O
activities O
. O

The O
paper O
is O
concerned RARE
with O
the O
data O
on O
change O
in O
the O
blood O
level O
of O
ACTH I-GENE
, O
STH ALLCAPS
, O
TSH I-GENE
, O
cortisol O
, O
T3 O
, O
insulin I-GENE
, O
C I-GENE
- I-GENE
peptide I-GENE
during O
a O
25 O
- O
minute O
session O
of O
respiration O
using O
a O
gaseous RARE
hypoxic O
mixture O
with O
10 O
% O
oxygen O
( O
GHM ALLCAPS
- O
10 O
). O

The O
abscess O
was O
debrided RARE
and O
the O
septum RARE
was O
patched RARE
with O
a O
single O
layer O
of O
autologous O
pericardium RARE
. O

In O
18 O
% O
lymphography RARE
was O
clearly O
positive O
and O
CT O
negative O
. O

The O
present O
study O
examined O
the O
effect O
of O
intensity O
, O
rate O
, O
and O
polarity O
on O
the O
spectral O
content O
of O
ABRs RARE
of O
15 O
normal O
- O
hearing O
subjects O
. O

Similar O
memory O
impairments RARE
found O
in O
medial O
septal O
- O
vertical O
diagonal RARE
band O
of O
Broca RARE
and O
nucleus O
basalis RARE
lesioned O
rats O
: O
are O
memory O
defects O
induced O
by O
nucleus O
basalis RARE
lesions O
related O
to O
the O
degree O
of O
non O
- O
specific O
subcortical RARE
cell O
loss O
? O
The O
function O
of O
nucleus O
basalis RARE
( O
NB ALLCAPS
) O
and O
medial O
septal O
- O
vertical O
diagonal RARE
band O
of O
Broca RARE
( O
MS O
- O
VDBB ALLCAPS
) O
in O
a O
place O
navigation RARE
task O
requiring O
reference O
memory O
was O
investigated O
. O

Studies O
also O
have O
alluded RARE
to O
a O
relationship O
between O
the O
MSMR ALLCAPS
cyst O
and O
certain O
signs O
or O
symptoms O
of O
disease O
. O

The O
BAL O
- O
to O
- O
plasma O
specific O
activity O
of O
urea O
was O
about O
twice O
that O
of O
Na O
+, O
indicating O
that O
urea O
diffused RARE
into O
the O
ELF ALLCAPS
more O
rapidly O
than O
Na O
+ O
during O
the O
70 O
s O
that O
elapsed RARE
between O
the O
time O
the O
radioactive RARE
urea O
and O
Na O
+ O
were O
injected O
into O
the O
circulation O
and O
the O
time O
when O
lavage RARE
was O
complete O
. O

The O
kappa O
coefficient O
of O
agreement O
between O
the O
Patho RARE
Dx RARE
Kit RARE
and O
the O
standard O
method O
was O
0 O
. O
958 NUMERIC
. O

Senior RARE
systems O
-- O
45 O
; O
Mental RARE
health O
and O
illness O
in O
old O
age O
-- O
3 O
. O

When O
normalized O
for O
imaging O
time O
, O
all O
parameters O
are O
significantly O
higher O
with O
RASE ALLCAPS
, O
with O
a O
C O
/ O
A O
per O
unit O
time O
that O
was O
338 NUMERIC
% O
higher O
. O

Patients O
with O
acute O
myocardial O
infarction O
had O
higher O
plasma O
concentrations O
of O
neutrophil I-GENE
elastase I-GENE
and O
the O
non O
- O
peroxide RARE
diene RARE
conjugated O
isomer RARE
of O
linoleic RARE
acid O
than O
normal O
volunteers O
or O
patients O
with O
stable O
ischaemic O
heart O
disease O
. O

Determination O
of O
three O
- O
dimensional O
imaging O
properties O
of O
a O
light O
microscope RARE
system O
. O

The O
cis O
- O
acting O
element O
, O
identified O
as O
CACGTGACCCG ALLCAPS
, O
is O
located O
34 O
bp O
upstream O
from O
the O
transcription O
initiation O
site O
, O
and O
contains O
the O
core O
sequence O
of O
the O
upstream O
promoter O
sequence O
of O
Ad2MLP NUMERIC
. O

The O
clinical O
relevance O
of O
these O
findings O
is O
strengthened RARE
by O
the O
observation O
that O
similar O
results O
were O
obtained O
when O
P O
. O
HCl RARE
was O
given O
by O
the O
intravenous O
route O
. O

TMBr RARE
- I-GENE
1 I-GENE
is O
identical O
to O
striated RARE
muscle I-GENE
alpha I-GENE
- I-GENE
tropomyosin RARE
from O
amino O
acids O
1 O
through O
258 O
but O
contains O
a O
novel O
COOH O
- O
terminal O
region O
from O
amino O
acids O
259 NUMERIC
through O
281 NUMERIC
. O

The O
procedure O
has O
been O
applied O
to O
three O
materials O
: O
particle O
board RARE
with O
carpet RARE
; O
gypsum RARE
board RARE
with O
wallpaper RARE
; O
and O
plywood RARE
with O
polyurethane RARE
lacquer RARE
, O
for O
which O
the O
steady O
- O
state O
emission O
factors O
( O
mg O
m O
- O
2 O
h O
- O
1 O
) O
of O
several O
compounds O
are O
given O
. O

Intron O
1 O
is O
6 O
. O
5 O
kb O
long O
, O
and O
the O
minimal O
sizes O
of O
introns O
2 O
and O
3 O
are O
estimated O
to O
be O
32 O
kb O
each O
. O

After O
4 O
h O
, O
lesions O
in O
the O
secretory O
part O
of O
the O
stomach O
were O
scored RARE
and O
mucosal O
prostaglandin O
E2 O
synthesis O
was O
determined O
by O
the O
ex RARE
vivo O
prostaglandin O
generation O
technique O
. O

Comparison O
of O
transmembrane O
and O
cytoplasmic O
domains O
to O
a O
third O
cell O
- O
surface O
proteoglycan O
, O
48K5 NUMERIC
from O
human O
lung O
fibroblasts O
( O
Marynen RARE
, O
P O
., O
Zhang RARE
, O
J O
., O
Cassiman RARE
, O
J O
., O
Vanden RARE
Berghe RARE
, O
H O
., O
and O
David RARE
, O
C O
. O

Approximately O
65 O
% O
of O
the O
total O
cAMP I-GENE
- I-GENE
dependent I-GENE
phosphotransferase I-GENE
activity O
is O
recovered O
in O
particulate O
fractions O
of O
homogenates RARE
prepared O
from O
asynchronous RARE
populations O
of O
C O
. O
elegans O
. O

High O
levels O
of O
C I-GENE
subunits I-GENE
are O
observed O
in O
several O
subsequent O
larval O
and O
adult O
stages O
of O
development O
. O

A O
second O
, O
novel O
C O
subunit O
( O
CeCAT LASTCAP
alpha O
', O
374 NUMERIC
residues O
) O
has O
a O
unique O
56 O
- O
residue O
carboxyl O
- O
terminal O
region O
that O
is O
generated O
by O
the O
alternative O
splicing O
of O
the O
C I-GENE
pre I-GENE
- I-GENE
mRNA I-GENE
. O

The O
alternative O
exon O
introduces RARE
the O
novel O
carboxyl O
terminus O
and O
a O
new O
translation O
stop O
signal O
, O
while O
simultaneously O
converting O
the O
coding O
sequence O
for O
40 O
carboxyl O
- O
terminal O
residues O
in O
CeCAT LASTCAP
alpha I-GENE
into O
3 O
'- O
untranslated O
nucleotides O
. O

French RARE
, O
M O
. O

Slowly RARE
adapting O
type O
I O
mechanoreceptor RARE
discharge O
as O
a O
function O
of O
dynamic O
force O
versus O
dynamic O
displacement O
of O
glabrous RARE
skin O
of O
raccoon RARE
and O
squirrel RARE
monkey O
hand O
. O

Methods RARE
used O
include O
Cobb RARE
angle O
and O
a O
segmental O
evaluation O
( O
T7 O
- O
T12 NUMERIC
) O
of O
each O
of O
convex RARE
and O
concave RARE
rib RARE
- O
vertebra RARE
angles RARE
( O
RVAs RARE
), O
rib RARE
- O
vertebra RARE
angle O
differences O
( O
RVADs RARE
), O
vertebral O
rotation RARE
, O
tilt O
and O
displacement O
. O

Plasma O
lecithin RARE
/ I-GENE
cholesterol I-GENE
acyltransferase RARE
( O
LCAT ALLCAPS
) O
activity O
in O
multiple O
- O
organ O
donors O
: O
a O
predictor O
of O
allograft RARE
viability O
in O
clinical O
liver O
transplantation O
. O

Lars RARE
has O
AIDS O
-- O
a O
more O
dignified RARE
life O
with O
care O
at O
home O
. O

Axillary RARE
nodal O
status O
, O
tumour O
progesterone I-GENE
receptor I-GENE
status O
, O
and O
season O
of O
tumour O
detection O
significantly O
influenced O
survival O
in O
both O
older O
( O
greater O
than O
50 O
yrs RARE
) O
and O
younger RARE
( O
less O
than O
50 O
yrs RARE
) O
patients O
. O

The O
application O
of O
these O
microelectrodes RARE
to O
the O
measurement O
of O
rapid O
, O
transient O
changes O
in O
retinal O
[ O
K O
+] RARE
o O
is O
presented O
. O

Expression O
, O
cellular O
localization O
and O
in O
vitro O
transcription O
studies O
establish O
that O
cloned I-GENE
hUBF LASTCAP
encodes O
a O
nucleolar O
factor O
that O
binds O
specifically O
to O
the O
upstream O
control O
element O
and O
core O
of O
the O
rRNA O
gene O
promoter O
to O
activate O
transcription O
in O
a O
binding O
site O
- O
dependent O
manner O
. O

Combining RARE
multiple O
laboratory O
studies O
may O
be O
of O
value O
in O
predetermining RARE
the O
eventual RARE
outcome O
in O
near O
- O
drowning RARE
. O

Accumulations RARE
of O
Tl O
+ O
1 O
( O
202Tl NUMERIC
label RARE
) O
were O
6 O
times O
those O
for O
Ga O
or O
In O
in O
the O
brain O
and O
muscles O
, O
and O
. O
1 O
times O
in O
plasma O
. O

There O
was O
a O
gradual RARE
increase O
in O
the O
myocyte O
diameter O
according O
to O
age O
in O
the O
biopsy O
and O
autopsy O
specimens O
. O

Despite O
the O
absence O
of O
exercise O
- O
induced O
asthma O
( O
EIA O
) O
while O
breathing O
WH ALLCAPS
air O
, O
asthmatic O
patients O
still O
had O
significantly O
higher O
mean O
GH O
increments RARE
than O
normal O
subjects O
( O
9 O
. O
2 O
vs O
2 O
. O
3 O
ng O
/ O
ml O
, O
P O
less O
than O
0 O
. O
05 O
). O

The O
afferents O
' O
phase O
of O
response O
was O
unmodified RARE
by O
electrical O
EVS ALLCAPS
stimulation O
. O

Solving RARE
an O
age O
old O
problem O
. O

The O
distribution O
of O
their O
fibrinogen I-GENE
levels O
was O
Gaussian RARE
, O
but O
more O
wide O
- O
based O
than O
the O
distribution O
of O
our O
normal O
controls O
. O

In O
a O
stepwise RARE
logistic RARE
regression O
analysis O
of O
SPT ALLCAPS
and O
RAST O
data O
, O
the O
occurrence O
of O
serum I-GENE
IgE I-GENE
antibodies I-GENE
to I-GENE
P I-GENE
. I-GENE
orbiculare RARE
had O
the O
highest O
explanatory RARE
value O
for O
current O
eczema RARE
. O

The O
examination O
was O
focused O
on O
assessment O
of O
different O
types O
of O
drusen RARE
, O
on O
evaluation O
of O
the O
development O
and O
incidence O
of O
risk O
factors O
leading O
to O
complications O
and O
loss O
of O
central O
vision O
. O

They O
were O
then O
subjected O
to O
whole O
- O
body O
heat O
stress O
( O
water O
- O
perfused O
suits RARE
), O
and O
the O
3 O
minutes O
of O
LBNP ALLCAPS
was O
repeated O
. O

An O
NF1 I-GENE
- I-GENE
related I-GENE
vitellogenin RARE
activator I-GENE
element I-GENE
mediates O
transcription O
from O
the O
estrogen O
- O
regulated O
Xenopus I-GENE
laevis I-GENE
vitellogenin RARE
promoter I-GENE
. O

A O
poor O
correlation O
was O
also O
observed O
between O
PbB LASTCAP
and O
ALAD ALLCAPS
activity O
of O
the O
stearate RARE
workers O
. O

At O
the O
carboxyl O
terminus O
, O
deletion O
as O
far O
as O
residue O
388 NUMERIC
did O
not O
affect O
in O
vitro O
TRF ALLCAPS
. I-GENE
C I-GENE
assembly O
, O
although O
trans O
- O
activating O
activity O
was O
abolished O
. O

The O
effects O
of O
mean O
luminance RARE
were O
also O
measured O
and O
a O
general O
expression O
that O
would O
take O
them O
into O
account O
was O
derived O
. O

Effect O
of O
hyperglycemia RARE
on O
pain O
threshold O
in O
alloxan RARE
- O
diabetic O
rats O
. O

We O
have O
synthesized O
[ O
7 O
, O
7 O
- O
2H2 NUMERIC
]- RARE
19 O
- O
OHA ALLCAPS
with O
high O
deuterium RARE
content O
and O
, O
together O
with O
[ O
7 O
, O
7 O
- O
2H2 NUMERIC
] O
A O
and O
[ O
9 O
, O
11 O
- O
2H2 NUMERIC
] O
estrone RARE
( O
E1 O
), O
have O
developed O
a O
quantitative O
assay O
of O
serum O
level O
19 O
- O
OHA ALLCAPS
, O
A O
, O
and O
E1 O
using O
the O
gas O
chromatography O
/ O
mass O
spectrometry O
- O
mass O
fragmentography RARE
method O
to O
monitor O
individual O
subjects O
throughout O
pregnancy O
. O

Sequence O
analysis O
of O
these O
genes O
and O
their O
surrounding O
sequences O
are O
presented O
and O
compared O
with O
other O
known O
tRNA O
genes O
from O
plant O
mitochondria O
. O

Experiments O
were O
performed O
in O
which O
brain O
- O
stem O
auditory O
- O
evoked O
responses O
( O
BAERs RARE
) O
were O
elicited O
by O
two O
types O
of O
pseudorandom RARE
pulse O
trains RARE
: O
maximum O
length O
sequences O
( O
MLS ALLCAPS
) O
and O
Legendre RARE
sequences O
( O
LGS ALLCAPS
). O

Since O
the O
UfAP LASTCAP
and O
UTMP ALLCAPS
share O
many O
biosynthetic O
and O
structural O
features O
that O
include O
site O
of O
biosynthesis O
in O
the O
endometrium RARE
, O
P4 O
- O
responsiveness O
, O
the O
presence O
of O
the O
mannose RARE
6 O
- O
phosphate O
lysosomal O
recognition O
marker O
, O
and O
considerable O
sequence O
similarity O
, O
the O
UfAP LASTCAP
and O
the O
UTMP ALLCAPS
may O
have O
homologous O
function O
which O
for O
both O
still O
remains O
obscure RARE
. O

Fifteen RARE
light O
for O
dates RARE
infants O
and O
their O
placentae RARE
were O
compared O
to O
15 O
well O
- O
grown O
infants O
and O
their O
placentae RARE
. O

Treating RARE
renal O
anaemia RARE
with O
recombinant O
human O
erythropoietin I-GENE
. O

The O
pseudolymphoma RARE
syndrome O
is O
a O
reversible O
reactive O
condition O
consisting O
of O
fever O
, O
lymphadenopathy RARE
and O
generalized O
rash O
. O

In O
the O
local O
geomagnetic RARE
field O
, O
the O
animals O
preferred O
the O
SE O
- O
sector RARE
. O

In O
the O
artificial O
lung O
, O
like O
in O
the O
natural O
lung O
and O
peripheral O
tissues O
, O
gas O
exchanges RARE
depend O
on O
several O
parameters O
: O
blood O
inlet RARE
conditions O
, O
blood O
flow O
rate O
, O
temperature O
, O
composition O
of O
the O
gas O
mixture O
used O
for O
ventilation O
, O
blood O
tissue O
perfusion O
, O
O2 O
consumption O
, O
etc O
. O

Mean O
(+/- O
SE O
) O
measurements O
of O
clearance O
( O
24 O
. O
5 O
+/- O
2 O
. O
06 O
v O
26 O
. O
5 O
+/- O
2 O
. O
05 O
mL O
/ O
min O
/ O
m2 O
), O
half O
- O
life O
( O
5 O
. O
7 O
+/- O
0 O
. O
5 O
v O
6 O
. O
4 O
+/- O
0 O
. O
5 O
hours O
), O
and O
volume O
of O
distribution O
( O
12 O
. O
4 O
+/- O
1 O
. O
1 O
v O
13 O
. O
7 O
+/- O
1 O
. O
6 O
L O
/ O
m2 O
) O
were O
not O
significantly O
different O
in O
patients O
with O
jaundice O
when O
compared O
with O
controls O
. O

Attitudes RARE
were O
found O
to O
be O
multidimensional RARE
, O
with O
similar O
dimensions O
being O
identified O
in O
both O
samples O
. O

We O
conclude O
that O
DNA O
ploidy RARE
is O
a O
major O
objective O
prognostic O
factor O
and O
therapeutic O
determinant O
for O
endometrial O
carcinoma O
. O

A O
semiautomatic RARE
digital O
system O
( O
Videoplan RARE
2 O
) O
was O
used O
. O

Environmental RARE
factors O
were O
more O
important O
in O
the O
older O
cohorts RARE
( O
perhaps O
because O
of O
less O
reliable O
recall RARE
). O

Dopamine O
SERS ALLCAPS
spectra O
from O
these O
electrodes O
are O
similar O
to O
those O
obtained O
at O
uncoated RARE
electrodes O
. O

These O
findings O
indicate O
that O
hypergastrinemia RARE
induced O
by O
surgical O
removal O
of O
acid O
- O
producing O
mucosa O
in O
the O
rat O
has O
the O
same O
effects O
on O
oxyntical RARE
mucosal I-GENE
HDC ALLCAPS
activity O
, O
histamine O
concentration O
and O
ECL ALLCAPS
cell O
density O
as O
hypergastrinemia RARE
induced O
by O
continuous O
gastrin I-GENE
infusion O
or O
by O
long O
- O
term O
treatment O
with O
effective O
antisecretagogues RARE
. O

Basing RARE
on O
experimental O
toxicity O
research O
it O
was O
established O
that O
, O
out O
of O
50 O
atmosphere RARE
metal O
corrosion RARE
inhibitors O
, O
some O
14 O
per O
cent O
were O
found O
extremely O
hazardous O
, O
42 O
per O
cent O
-- O
of O
high O
level O
hazardous O
, O
33 O
percent O
-- O
of O
moderate O
and O
11 O
per O
cent O
-- O
of O
low O
hazardous O
. O

The O
order O
of O
the O
helicase I-GENE
motif I-GENE
and O
the O
nsP3 NUMERIC
homology I-GENE
region I-GENE
in O
the O
RUB ALLCAPS
genome O
is O
reversed O
with O
respect O
to O
the O
alphavirus RARE
genome O
indicating O
that O
a O
genetic O
rearrangement O
has O
occurred O
during O
the O
evolution O
of O
these O
viruses O
. O

The O
results O
suggest O
followings RARE
-- O
1 O
) O
both O
eosinophils O
and O
neutrophils O
participate O
in O
hypersecretion RARE
of O
type O
Ib RARE
in O
atopic O
cases O
, O
and O
only O
eosinophils O
in O
non O
- O
atopic O
cases O
. O

There O
were O
5 O
treatments O
: O
control O
( O
C O
); O
a O
wooden RARE
surround RARE
in O
one O
rear RARE
corner RARE
of O
the O
cage RARE
( O
S O
); O
a O
fiberglass RARE
rollaway RARE
hollow RARE
in O
one O
rear RARE
corner RARE
of O
the O
cage RARE
( O
H O
); O
a O
hollow RARE
and O
a O
surround RARE
( O
H O
/ O
S O
); O
a O
nest RARE
box O
attached O
to O
the O
back O
of O
the O
cage RARE
, O
containing O
a O
hollow RARE
( O
N O
). O

While O
no O
significant O
differences O
in O
the O
tensile RARE
responses O
or O
failure O
characteristics O
were O
noted O
for O
irradiated O
and O
nonirradiated RARE
grafts O
in O
the O
drip RARE
, O
in O
the O
bath RARE
environment O
the O
nonirradiated RARE
tissues O
had O
greater O
strength O
and O
modulus RARE
. O

The O
patient O
was O
treated O
with O
benzathine RARE
penicillin O
, O
2 O
, O
400 O
, O
000 O
U O
weekly O
for O
three O
weeks O
. O

A O
consensus O
binding O
site O
for O
the O
transcription O
factor O
SP1 I-GENE
was O
identified O
in O
intron O
As O
downstream O
of O
the O
proenkephalin RARE
germ I-GENE
cell I-GENE
cap I-GENE
site I-GENE
region I-GENE
. O

This O
proposed O
method O
is O
similar O
in O
principle RARE
to O
the O
sets O
technique O
but O
is O
shown O
to O
have O
much O
better O
expected O
time O
to O
alarm RARE
properties O
. O

The O
effects O
on O
reflex O
latencies RARE
but O
not O
on O
paCO2 NUMERIC
or O
pHa RARE
were O
blocked O
by O
naloxone O
( O
2 O
mg O
/ O
kg O
), O
and O
were O
not O
present O
in O
morphine O
- O
tolerant RARE
animals O
. O

Of O
the O
remaining O
seven O
, O
five O
reacted O
either O
with O
immediate O
and O
strong O
symptoms O
or O
had O
spontaneously O
reduced O
gluten RARE
intake O
, O
or O
had O
an O
acquired O
IgA I-GENE
deficiency O
. O

Drug O
and O
personnel RARE
costs O
were O
reduced O
when O
batch RARE
manufacturing RARE
with O
40 O
- O
mL O
multidose RARE
vials RARE
was O
compared O
with O
extemporaneous RARE
compounding RARE
with O
unit O
- O
dose O
vials RARE
. O

Changes O
in O
prognosis O
of O
twin RARE
births O
over O
20 O
years O
. O

Dermal RARE
toxicity O
and O
carcinogenicity RARE
of O
4 O
- O
vinyl O
- O
1 O
- O
cyclohexene RARE
diepoxide RARE
in O
Fischer RARE
rats O
and O
B6C3F1 NUMERIC
mice O
. O

Per RARE
kg O
FFM ALLCAPS
SMR ALLCAPS
was O
almost O
restored O
to O
baseline O
values O
for O
the O
EX ALLCAPS
group O
, O
whereas O
the O
non O
- O
exercising RARE
subjects O
still O
showed O
depressed O
values O
( O
EX ALLCAPS
3 O
. O
7 O
per O
cent O
and O
D O
+ O
DE ALLCAPS
15 O
. O
8 O
per O
cent O
lower O
than O
before O
treatment O
; O
P O
less O
than O
0 O
. O
05 O
). O

MK O
- O
927 NUMERIC
: O
a O
topically RARE
active O
ocular O
hypotensive O
carbonic RARE
anhydrase I-GENE
inhibitor O
. O

PCR O
- O
derived O
fragments O
were O
used O
as O
probes O
for O
the O
isolation O
of O
the O
U3 I-GENE
snRNA I-GENE
genes I-GENE
from O
a O
genomic O
library O
of O
Arabidopsis O
. O

In O
addition O
serum I-GENE
IgE I-GENE
concentrations O
were O
not O
statistically O
different O
. O

The O
findings O
suggest O
that O
, O
although O
iodine O
deficiency O
is O
the O
most O
probable O
cause O
of O
goiter RARE
among O
immigrants RARE
of O
the O
1928 NUMERIC
cohort O
, O
where O
the O
native O
population O
is O
concerned RARE
( O
both O
men O
and O
women O
), O
some O
other O
goitrogenic RARE
factor O
( O
s O
) O
must O
be O
involved O
. O

The O
transcriptional O
unit O
spans O
a O
chromosomal O
region O
of O
about O
55 O
kilobase O
pairs O
( O
kbp O
). O

100 O
of O
the O
patients O
who O
would O
have O
died O
survive RARE
. O

Co O
- O
administration O
of O
5FU NUMERIC
, O
angiotensin I-GENE
II I-GENE
and O
microspheres O
via O
the O
hepatic O
artery O
may O
reduce O
drug O
exposure O
in O
the O
systemic O
compartment O
and O
therefore O
may O
increase O
the O
therapeutic O
ratio O
of O
5FU NUMERIC
administration O
via O
the O
hepatic O
artery O
. O

The O
effects O
of O
tap O
( O
TW ALLCAPS
) O
or O
carbonated RARE
( O
CW ALLCAPS
) O
water O
on O
arterial O
pH O
, O
partial O
pressure O
of O
carbon O
dioxide O
( O
PCO2 O
) O
and O
plasma O
lactate O
were O
determined O
in O
heat O
- O
stressed O
broilers RARE
. O

Transient O
expression O
of O
human I-GENE
and I-GENE
chicken I-GENE
progesterone I-GENE
receptors I-GENE
does O
not O
support O
alternative O
translational O
initiation O
from O
a O
single O
mRNA O
as O
the O
mechanism O
generating O
two O
receptor O
isoforms O
. O

In O
contrast O
, O
2 O
, O
397 NUMERIC
( O
74 O
%) O
had O
one O
or O
more O
risk O
factors O
( O
not O
low O
risk O
); O
of O
these O
, O
5 O
. O
3 O
% O
died O
in O
6 O
weeks O
( O
p O
less O
than O
0 O
. O
001 O
). O

The O
Community RARE
Adjustment RARE
Scale O
provided O
outcome O
data O
related O
to O
the O
subjects O
' O
degree O
of O
productivity RARE
, O
ability O
to O
maintain O
close O
relationships O
, O
and O
presence O
/ O
absence O
of O
symptomatology RARE
an O
average O
of O
32 O
years O
after O
initial O
admission O
. O

However O
, O
at O
18 O
months O
of O
age O
, O
significantly O
higher O
levels O
of O
IgG1 NUMERIC
( O
P O
less O
than O
0 O
. O
05 O
) O
and O
of O
IgG4 NUMERIC
( O
P O
less O
than O
0 O
. O
01 O
) O
were O
found O
in O
infants O
with O
an O
elevated O
IgE I-GENE
( O
greater O
than O
or O
equal O
to O
8 O
. O
0 O
kU LASTCAP
/ O
l O
) O
than O
in O
those O
with O
a O
lower O
level O
. O

The O
protein O
sequence O
contains O
seven O
potential O
N O
- O
linked O
glycosylation O
sites O
and O
a O
threonine O
/ O
serine O
- O
rich O
region O
which O
is O
a O
potential O
site O
for O
attachment O
of O
O O
- O
linked O
carbohydrate O
. O

Thus O
adaptation O
to O
continuous O
mild O
stress O
has O
a O
potent O
antiarrhythmic O
effect O
which O
occurs O
due O
to O
the O
increased O
vagal RARE
tone O
. O

The O
eluent RARE
from O
the O
column O
was O
mixed O
with O
the O
chemiluminescent RARE
solution O
containing O
lucigenin RARE
and O
Triton RARE
X O
- O
100 O
and O
a O
0 O
. O
28 O
M O
KOH ALLCAPS
solution O
by O
pumps RARE
and O
monitored O
by O
a O
chemiluminescence RARE
detector O
. O

On O
histologic O
examination O
the O
cuboidal RARE
epithelium O
of O
the O
mucous RARE
membrane O
was O
found O
to O
be O
changed O
into O
columnar RARE
epithelium O
, O
with O
uneven RARE
distribution O
of O
enlarged RARE
nuclei O
in O
the O
vacuolized RARE
cytoplasm O
. O

These O
results O
suggest O
an O
increased O
risk O
of O
developing O
cancer O
among O
polyp RARE
patients O
and O
the O
possibility O
of O
prophylactic O
effect O
of O
polypectomy RARE
against O
subsequent O
cancer O
. O

The O
same O
trend O
was O
noted O
between O
YG ALLCAPS
4 O
. O
5 O
heifers O
and O
YG ALLCAPS
5 O
. O
5 O
steers O
, O
indicating O
a O
sex O
- O
related O
deposition O
of O
seam RARE
fat O
in O
fed O
cattle O
. O

The O
nucleotide O
sequence O
consists O
of O
48 O
bp O
of O
5 O
'- O
end O
non O
- O
coding O
region O
, O
1695 NUMERIC
bp O
of O
coding O
region O
and O
212 NUMERIC
bp O
of O
3 O
'- O
end O
non O
- O
coding O
region O
including O
a O
20 O
bp O
poly O
( O
A O
) O
tail O
. O

Toxicities RARE
included O
: O
nausea RARE
/ O
vomiting RARE
( O
69 O
%), O
headache O
( O
25 O
%), O
chills RARE
( O
69 O
%), O
pain O
at O
tumor O
sites O
( O
63 O
%), O
hypotension O
( O
31 O
%), O
and O
hypertension O
( O
38 O
%). O

The O
results O
also O
showed O
that O
although O
oyster RARE
shell RARE
supplementation O
generally O
increased O
alkaline I-GENE
phosphatase I-GENE
activity O
, O
bone O
mineralization RARE
was O
relatively O
uninfluenced RARE
as O
judged O
by O
the O
low O
coefficients O
of O
variation O
( O
CV ALLCAPS
) O
of O
3 O
. O
14 O
- O
3 O
. O
51 O
% O
and O
3 O
. O
39 O
- O
4 O
. O
82 O
% O
for O
calcium O
and O
phosphorus O
content O
in O
the O
femur O
and O
tibia RARE
respectively O
. O

In O
6 O
of O
24 O
infants O
studied O
( O
27th NUMERIC
- O
40th NUMERIC
weeks O
of O
gestation O
), O
acquired O
and O
congenital O
structural O
anomalies O
of O
the O
airways RARE
were O
detected O
with O
an O
ultrathin RARE
flexible RARE
fiberscope RARE
( O
Olympus RARE
PF18 NUMERIC
S O
, O
1 O
. O
8 O
mm O
). O

Fatal RARE
encephalitis RARE
in O
a O
patient O
with O
chronic O
graft O
- O
versus O
- O
host O
disease O
. O

Compared RARE
to O
its O
counterpart O
in O
the O
GPB ALLCAPS
gene I-GENE
, O
exon O
3 O
of O
the O
GPE ALLCAPS
gene I-GENE
contains O
several O
point O
mutations O
, O
an O
insertion O
of O
24 O
bp O
, O
and O
a O
stop O
codon O
which O
shortens RARE
the O
reading O
frame O
. O

Molecular O
cloning O
of O
a O
cDNA O
encoding O
rat I-GENE
NADH I-GENE
- I-GENE
cytochrome I-GENE
b5 NUMERIC
reductase I-GENE
and O
the O
corresponding O
gene O
. O

The O
results O
corroborate RARE
the O
idea O
that O
the O
structure O
of O
relaxation O
curves O
contains O
information O
on O
the O
distance O
scale O
and O
on O
the O
architecture O
of O
the O
pore O
space O
, O
even O
if O
it O
is O
difficult O
to O
extract O
it O
without O
ambiguities RARE
. O

Serotonin RARE
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
binding O
on O
blood O
platelets O
as O
a O
state O
dependent O
marker O
in O
major O
affective O
disorder O
. O

Although O
% O
BF O
was O
correlated O
with O
all O
the O
BMIs RARE
( O
r O
= O
0 O
. O
60 O
- O
0 O
. O
82 O
), O
applying O
objective O
definitions RARE
of O
obesity O
based O
on O
BMIs RARE
or O
% O
BF O
by O
densitometry RARE
often O
produced O
conflicting RARE
results O
. O

The O
RF ALLCAPS
values O
correlated O
well O
with O
the O
angiographic O
semiquantitative RARE
scale O
of O
severity O
of O
aortal RARE
insufficiency O
( O
r O
= O
0 O
. O
805 NUMERIC
; O
p O
less O
than O
0 O
. O
001 O
), O
although O
they O
enabled RARE
the O
authors O
only O
to O
make O
a O
partial O
differentiation O
of O
haemodynamically RARE
severe O
regurgitations RARE
and O
mild O
or O
insignificant RARE
ones O
. O

Promoter O
elements O
include O
an O
atypical O
TATA O
box O
( O
GTTA ALLCAPS
), O
one O
CCAAT O
box O
much O
further O
from O
the O
initiation O
site O
, O
three O
reverse O
compliments RARE
of O
CCAAT O
( O
ATTGG ALLCAPS
), O
and O
two O
pyrimidine O
- O
rich O
nucleotide O
stretches O
. O

The O
cloned O
genes O
were O
identified O
in O
genetic O
libraries O
by O
hybridization O
screening O
using O
four O
deoxyoligonucleotide RARE
probes O
which O
corresponded O
to O
the O
partial O
amino O
acid O
sequence O
of O
the O
purified O
enzyme O
. O

The O
pattern O
for O
catalytic O
zinc O
sites O
included O
two O
ligands O
close O
in O
sequence O
, O
a O
sequence O
- O
distant O
ligand O
, O
and O
a O
main O
- O
chain O
hydrogen O
bond O
joining O
two O
ligands O
. O

Results O
of O
the O
long O
- O
term O
observation O
and O
treatment O
of O
patients O
with O
arterial O
hypertension O

Eucaryotic RARE
transcription O
factors O
that O
stimulate O
RNA I-GENE
polymerase I-GENE
II I-GENE
by O
increasing O
the O
efficiency O
of O
elongation O
of O
specifically O
or O
randomly O
initiated O
RNA O
chains O
have O
been O
isolated O
and O
characterized O
. O

Sprague O
- O
Dawley O
newborn O
rats O
( O
n O
= O
85 O
) O
breathed RARE
100 O
% O
oxygen O
( O
O2 O
) O
or O
room O
air O
( O
RA O
) O
during O
the O
first O
8 O
days O
of O
life O
, O
and O
then O
RA O
. O

The O
Lm RARE
increased O
and O
the O
alveoli RARE
/ O
mm2 O
and O
elastic O
recoil RARE
pressure O
decreased O
. O

Comparison O
of O
propofol RARE
and O
thiopentone RARE
as O
anaesthetic RARE
agents O
for O
electroconvulsive RARE
therapy O
. O

In O
Experiment O
II O
, O
as O
performing RARE
moderate O
supine O
cycling RARE
( O
55 O
% O
VO2 O
max O
) O
for O
50 O
minutes O
under O
several O
LBNP ALLCAPS
conditions O
in O
5 O
sedentary RARE
women O
, O
there O
were O
correspondingly RARE
similar O
changing O
manners RARE
of O
the O
cardiovascular O
adjustments RARE
to O
each O
of O
the O
phases O
given O
in O
Experiment O
I O
. O

Commercially RARE
available O
formulations RARE
of O
2 O
. O
5 O
% O
and O
5 O
% O
lambdacyhalothrin RARE
can O
be O
diluted RARE
either O
with O
water O
for O
ULV ALLCAPS
cold O
aerosol RARE
space O
- O
spraying RARE
or O
with O
diesel RARE
/ O
kerosene RARE
for O
thermal O
fogging RARE
at O
recommended O
application O
rates O
of O
0 O
. O
5 O
- O
1 O
g O
ai RARE
/ O
ha RARE
for O
mosquito RARE
control O
and O
2 O
g O
ai RARE
/ O
ha RARE
for O
housefly RARE
control O
. O

Thus O
, O
this O
reading O
frame O
was O
concluded O
to O
encode O
the O
precursor O
of O
mitochondrial I-GENE
fumarase RARE
. O

Sequence O
analysis O
indicates O
that O
in O
addition O
to O
an O
ATA ALLCAPS
and O
GC O
box O
, O
this O
region O
contains O
domains O
that O
have O
been O
implicated O
in O
the O
regulation O
of O
other O
muscle O
- O
specific O
genes O
: O
a O
CArG O
box O
at O
- O
91 O
bp O
; O
myocyte I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
nuclear I-GENE
factor I-GENE
1 I-GENE
binding I-GENE
site I-GENE
homologies O
at O
- O
58 O
, O
- O
535 NUMERIC
, O
and O
- O
583 NUMERIC
bp O
; O
and O
a O
muscle O
- O
CAAT O
consensus O
sequence O
at O
- O
394 NUMERIC
bp O
relative O
to O
the O
cap O
site O
. O

The O
trk I-GENE
- I-GENE
2h NUMERIC
oncogene I-GENE
, O
isolated O
from O
the O
human O
breast O
carcinoma O
cell O
line O
MDA ALLCAPS
- O
MB O
231 O
by O
genomic O
DNA O
- O
transfection O
into O
NIH3T3 O
cells O
, O
consists O
of O
the O
trk I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
receptor I-GENE
kinase I-GENE
domain I-GENE
fused O
to O
a O
N O
- O
terminal O
41 O
amino O
acid O
activating O
sequence O
( O
Kozma RARE
, O
S O
. O
C O
., O
Redmond RARE
, O
S O
. O
M O
. O
S O
., O
Xiao RARE
- O
Chang RARE
, O
F O
., O
Saurer RARE
, O
S O
. O
M O
., O
Groner RARE
, O
B O
. O
and O
Hynes RARE
, O
N O
. O
E O
. O

Antibodies O
raised O
against O
a O
bacterially O
produced O
beta I-GENE
gal RARE
- O
trk I-GENE
receptor O
kinase O
fusion O
protein O
recognized O
a O
44 O
kd RARE
phosphoprotein O
phosphorylated O
on O
serine O
, O
threonine O
and O
tyrosine O
in O
extracts O
of O
trk I-GENE
- I-GENE
2h NUMERIC
transformed O
NIH3T3 O
cells O
. O

Since O
very O
recent O
scanning O
- O
deletion O
analysis O
indicates O
that O
there O
is O
a O
critical O
region O
for O
activity O
near O
Cys O
- O
118 O
and O
that O
Cys O
- O
118 O
is O
necessary O
for O
maximal O
activity O
, O
we O
conclude O
that O
the O
Cys O
- O
118 O
residue O
is O
necessary O
for O
proper O
glycosylation O
and O
maximal O
biologic RARE
activity O
of O
GM I-GENE
- I-GENE
CSF I-GENE
. O

Molecular O
and O
functional O
characterization O
of O
the O
promoter O
of O
ETS2 NUMERIC
, O
the O
human O
c I-GENE
- I-GENE
ets I-GENE
- I-GENE
2 I-GENE
gene O
. O

Information RARE
about O
immunologic O
drug O
interactions O
is O
needed O
by O
pharmacists RARE
to O
make O
rational RARE
drug O
- O
use O
decisions RARE
. O

Branch RARE
occlusion O
of O
Heubner RARE
' O
s O
artery O
, O
or O
perforators RARE
from O
the O
proximal O
anterior O
or O
middle O
cerebral O
arteries O
were O
the O
posited RARE
mechanism O
of O
infarction O
. O

All O
ABFI ALLCAPS
- I-GENE
binding I-GENE
sites I-GENE
, O
regardless O
of O
origin O
, O
provided O
weak O
UAS O
function O
in O
vivo O
when O
examined O
in O
test O
plasmids O
. O

An O
examination O
of O
the O
properties O
of O
sequences O
surrounding O
ARS1 NUMERIC
left O
open O
the O
possibility O
that O
ABFI ALLCAPS
enhances O
the O
initiation O
of O
DNA O
replication O
at O
ARS1 NUMERIC
by O
transcriptional O
activation O
. O

Nonvascular RARE
ophthalmic O
and O
neurologic O
disorders O
that O
can O
be O
confused RARE
with O
amaurosis RARE
fugax RARE
are O
listed RARE
, O
and O
an O
algorithm O
for O
evaluation O
( O
which O
includes O
ophthalmic O
examination O
, O
laboratory O
studies O
, O
and O
noninvasive RARE
carotid O
artery O
studies O
) O
is O
given O
. O

Likewise RARE
, O
whether O
or O
not O
the O
hypotensive O
action O
of O
converting O
enzyme O
inhibitors O
is O
age O
- O
related O
is O
as O
yet O
unknown O
. O

Polyclonal RARE
antiserum O
generated O
to O
the O
fusion O
protein O
was O
capable O
of O
detecting O
42 O
- O
and O
46 O
- O
kilodalton O
polypeptides O
from O
virus O
particles O
; O
both O
polypeptides O
were O
also O
shown O
to O
contain O
HBsAg I-GENE
determinants I-GENE
. O

These O
characteristics O
of O
N22 NUMERIC
/ O
P22 NUMERIC
indicate O
that O
it O
is O
a O
localized O
synaptically RARE
dependent O
event O
conforming RARE
to O
a O
transverse O
dipole RARE
with O
dorsal O
negativity RARE
and O
a O
simultaneous O
anterior O
positivity RARE
. O

Role O
of O
superoxide I-GENE
dismutase I-GENE
in O
cellular O
oxidative O
processes O
and O
method O
of O
its O
determination O
in O
biological O
materials O

At O
maximum O
photosensitivity RARE
the O
inhibitory O
amino O
acids O
gamma O
- O
aminobutyric RARE
acid O
and O
taurine RARE
were O
lower O
, O
and O
those O
of O
asparagine RARE
( O
metabolite O
of O
the O
excitatory RARE
amino O
acid O
aspartate O
) O
were O
higher O
, O
than O
when O
the O
animals O
were O
not O
photosensitive RARE
. O

We O
evaluated O
the O
likelihood O
of O
tissues O
to O
be O
positive O
for O
carcinoembryonic RARE
antigen I-GENE
and O
the O
intensity O
of O
carcinoembryonic RARE
antigen I-GENE
staining O
in O
specimens O
of O
villous RARE
adenomas RARE
, O
mixed O
polypoid RARE
villous RARE
adenomas RARE
, O
polypoid RARE
adenomas RARE
, O
and O
diverticulitis RARE
using O
the O
peroxidase I-GENE
- O
antiperoxidase RARE
technique O
. O

The O
priming RARE
activity O
of O
DNA O
incised RARE
by O
either O
of O
the O
Drosophila O
enzymes O
can O
be O
enhanced O
, O
however O
, O
by O
an O
additional O
incubation O
with O
E I-GENE
. I-GENE
coli I-GENE
endonuclease I-GENE
IV I-GENE
, O
which O
is O
known O
to O
cleave RARE
depurinated RARE
DNA O
on O
the O
5 O
'- O
side O
of O
an O
apurinic RARE
site O
. O

A O
. O

Therefore O
, O
in O
conjunction O
with O
a O
positive O
pregnancy O
test O
and O
the O
patient O
' O
s O
clinical O
history O
, O
a O
severely O
depressed O
or O
absent O
serum O
PAPP ALLCAPS
- I-GENE
A I-GENE
level O
may O
aid O
in O
the O
diagnosis O
of O
extrauterine RARE
pregnancy O
. O

The O
levels O
of O
both O
MAP1 NUMERIC
- I-GENE
specific I-GENE
and I-GENE
MAP2 NUMERIC
- I-GENE
specific I-GENE
mRNAs I-GENE
decline O
in O
the O
postnatal O
developing O
brain O
; O
the O
level O
of O
MAP1 NUMERIC
- I-GENE
specific I-GENE
mRNA I-GENE
also O
increases O
slightly O
in O
rat O
PC12 O
cells O
upon O
exposure O
to O
nerve I-GENE
growth I-GENE
factor I-GENE
. O

The O
cDNAs O
cross O
- O
hybridize RARE
with O
genomic O
sequences O
in O
rat O
, O
human O
, O
and O
chicken O
DNA O
, O
but O
not O
with O
DNA O
from O
frog RARE
, O
Drosophila O
, O
or O
sea O
urchin O
. O

Colorimetric RARE
method O
of O
determining O
glycerin RARE
in O
the O
blood O

Deletion O
analysis O
was O
carried O
out O
within O
a O
part O
of O
the O
5 O
'- O
flanking O
region O
showing O
homology O
to O
the O
upstream O
region O
of O
the O
yeast I-GENE
CYC1 I-GENE
gene I-GENE
. O

The O
N1 O
and O
P2 O
were O
comparable O
in O
amplitude O
and O
both O
had O
prolonged O
refractory O
periods O
. O

Tolerance RARE
to O
fenfluramine RARE
anorexia RARE
: O
fact O
or O
fiction RARE
? O
Recent O
findings O
in O
this O
laboratory O
with O
regard O
to O
tolerance O
to O
fenfluramine RARE
anorexia RARE
are O
reviewed O
with O
respect O
to O
generality RARE
of O
the O
behavioural RARE
phenomenon O
. O

In O
30 O
dogs O
the O
left O
limb O
( O
tail O
) O
of O
the O
pancreas O
was O
removed O
but O
left O
in O
the O
abdominal O
cavity O
after O
cessation O
of O
blood O
flow O
to O
produce O
warm RARE
ischemia O
for O
30 O
, O
60 O
, O
and O
120 O
min O
( O
10 O
dogs O
at O
each O
time O
point O
), O
and O
then O
was O
flushed RARE
with O
cold O
Ringers RARE
' O
lactate O
and O
transplanted RARE
to O
the O
iliac O
vessels O
. O

These O
results O
support O
the O
view O
that O
clonidine RARE
and O
6 O
- O
OHDA ALLCAPS
, O
but O
not O
alpha O
- O
MD ALLCAPS
, O
have O
central O
pressor O
actions O
in O
the O
rat O
that O
oppose RARE
their O
antihypertensive O
action O
. O

Furthermore O
, O
beta I-GENE
2 I-GENE
- I-GENE
adrenoceptor I-GENE
sensitivity O
appears O
to O
be O
unaltered O
in O
BHT ALLCAPS
. O

We O
conclude O
that O
Hansel RARE
' O
s O
stain O
substantially O
improves RARE
the O
recognition O
of O
eosinophiluria RARE
as O
compared O
with O
Wright RARE
' O
s O
stain O
. O

These O
results O
suggest O
that O
the O
negative O
inotropic O
action O
of O
nicorandil RARE
is O
caused O
by O
inhibition O
of O
Ca O
influx RARE
and O
intracellular O
mobilization RARE
of O
Ca O
. O

The O
study O
included O
139 O
eyes O
with O
presumed O
ocular O
histoplasmosis RARE
syndrome O
( O
POHS ALLCAPS
) O
and O
age O
- O
related O
macular RARE
degeneration O
( O
AMD ALLCAPS
). O

Comparison O
of O
elastase I-GENE
- I-GENE
1 I-GENE
with O
amylase I-GENE
, O
lipase I-GENE
, O
and O
trypsin I-GENE
- O
like O
immunoreactivity O
in O
the O
diagnosis O
of O
acute O
pancreatitis O
. O

A O
probe O
evoked O
potentials O
procedure O
was O
used O
to O
assess O
the O
relative O
engagement RARE
of O
both O
cerebral O
hemispheres RARE
during O
a O
language O
task O
in O
the O
following O
four O
groups O
of O
dextral RARE
adults O
: O
left O
hemisphere O
( O
LH O
)- O
damaged O
aphasics RARE
recovering RARE
from O
stroke O
, O
dysarthrics RARE
, O
right O
hemisphere O
( O
RH O
)- O
damaged O
nonaphasic RARE
patients O
, O
and O
normal O
control O
subjects O
. O

Mucolipidosis RARE
type O
IV O
: O
clinical O
spectrum O
and O
natural O
history O
. O

Two O
of O
the O
three O
groups O
were O
administered O
dauricine RARE
, O
as O
a O
new O
calcium O
channel O
blocker O
, O
and O
verapamil O
, O
as O
a O
generally O
recognized O
calcium O
channel O
blocker O
, O
respectively O
, O
from O
15 O
minutes O
pre O
- O
bypass O
to O
the O
end O
of O
the O
bypass O
procedure O
( O
a O
period O
of O
95 O
minutes O
). O

No O
reflow RARE
occurred O
in O
approximately O
30 O
percent O
of O
the O
muscle O
microvasculature RARE
upon O
reperfusion O
. O

Rarely RARE
, O
patients O
with O
locally O
advanced O
, O
uncontrollable RARE
, O
non O
- O
metastatic O
prostatic O
cancer O
enjoy RARE
prolonged O
survival O
. O

Lysozyme RARE
activity O
was O
evidently RARE
increased O
as O
well O
in O
undiluted RARE
as O
in O
diluted RARE
sera O
in O
all O
our O
tested O
patients O
. O

The O
first O
involved O
measurements O
of O
the O
steady O
state O
levels O
of O
mRNAs O
for O
subunit O
5 O
of O
cytochrome I-GENE
oxidase I-GENE
and O
the O
beta O
subunit O
of O
F1 I-GENE
ATPase I-GENE
in O
wild O
type O
and O
in O
a O
hem2 NUMERIC
mutant I-GENE
. O

A O
5 I-GENE
. I-GENE
8S NUMERIC
- I-GENE
like I-GENE
structure I-GENE
is O
present O
within O
the O
5 O
'- O
terminal O
region O
of O
all O
three O
fungal I-GENE
mitochondrial I-GENE
LSU ALLCAPS
rRNAs RARE
; O
in O
contrast O
, O
no O
4 I-GENE
. I-GENE
5S I-GENE
- I-GENE
like I-GENE
structure I-GENE
is O
evident O
at O
the O
3 O
' O
end O
of O
these O
molecules O
. O

ATP O
gamma O
S O
inhibition O
can O
be O
overcome O
by O
high O
concentrations O
of O
ATP O
, O
dATP LASTCAP
, O
araATP LASTCAP
, O
or O
ddATP LASTCAP
. O

The O
recovery O
of O
labelled O
methoxydextrane RARE
is O
98 O
+/- O
7 O
%. O

ASL ALLCAPS
- O
8123 NUMERIC
demonstrated O
weak O
competitive O
beta I-GENE
- I-GENE
adrenoreceptor RARE
blocking O
activity O
in O
isolated O
guinea O
pig O
right O
atria RARE
with O
a O
pA2 NUMERIC
of O
3 O
. O
73 O
+/- O
0 O
. O
07 O
; O
no O
agonist O
- O
like O
activity O
was O
observed O
in O
this O
tissue O
at O
concentrations O
of O
ASL ALLCAPS
- O
8123 NUMERIC
from O
3 O
X O
10 O
(- O
5 O
) O
to O
1 O
X O
10 O
(- O
2 O
) O
M O
. O

Enhancer RARE
and O
promoter O
elements O
directing RARE
activation O
and O
glucocorticoid O
repression O
of O
the O
alpha I-GENE
1 I-GENE
- I-GENE
fetoprotein I-GENE
gene I-GENE
in O
hepatocytes O
. O

We O
discuss O
the O
results O
in O
relation O
to O
previous O
systems O
for O
parcellating RARE
the O
posterior O
ectosylvian RARE
gyrus O
of O
the O
cat O
and O
consider O
the O
possibility O
that O
divisions RARE
of O
the O
feline O
posterior O
ectosylvian RARE
gyrus O
correspond O
directly O
to O
areas O
making O
up O
the O
superior O
temporal O
gyrus O
in O
primates O
. O

The O
gene O
is O
contained O
within O
a O
1 O
. O
8 O
- O
kilobase O
AccI LASTCAP
- O
EcoRI I-GENE
restriction O
fragment O
mapping O
at O
map O
coordinates RARE
0 O
. O
136 O
to O
0 O
. O
148 NUMERIC
in O
the O
UL ALLCAPS
region O
of O
the O
EHV O
- O
1 O
genome O
and O
is O
transcribed O
from O
right O
to O
left O
. O

The O
4 O
- O
AP O
( O
4 O
- O
20 O
mM O
) O
effect O
resulted O
in O
a O
decrease O
of O
the O
sensory O
activity O
, O
which O
was O
fully O
restored O
by O
TEA ALLCAPS
or O
Ba2 NUMERIC
+. RARE

Hybridization O
of O
a O
probe O
from O
this O
region O
to O
electrophoretic O
blots O
of O
RNAs O
from O
different O
human O
tissues O
showed O
a O
predominant O
2 O
. O
8 O
- O
kilobase O
( O
kb O
) O
message O
accompanied O
by O
weaker RARE
bands O
4 O
. O
1 O
and O
2 O
. O
1 O
kb O
in O
size O
. O

Prognosis RARE
of O
asymptomatic O
multiple O
myeloma O
. O

A O
new O
method O
for O
the O
quantitative O
analysis O
of O
sleep O
spindles RARE
during O
continuous O
overnight RARE
EEG O
recordings O
. O

Svensson RARE
et O
al O
. O

Endogenous RARE
release O
of O
neuronal O
serotonin O
and O
5 O
- O
hydroxyindoleacetic RARE
acid O
in O
the O
caudate RARE
- O
putamen RARE
of O
the O
rat O
as O
revealed O
by O
intracerebral RARE
dialysis O
coupled O
to O
high O
- O
performance O
liquid O
chromatography O
with O
fluorimetric RARE
detection O
. O

In O
this O
report O
we O
describe O
for O
the O
first O
time O
the O
complete O
primary O
structure O
of O
type I-GENE
X I-GENE
collagen I-GENE
, O
based O
on O
cloning O
and O
sequencing O
of O
cDNA O
and O
genomic O
DNA O
. O

Viable RARE
flap O
areas O
were O
established O
following O
vascular O
pedicle RARE
ligation O
( O
both O
vessels O
or O
only O
artery O
or O
vein O
), O
on O
the O
third O
day O
after O
flap O
replantation RARE
in O
both O
island O
and O
free O
flaps RARE
. O

The O
size O
discrepancy RARE
is O
not O
due O
to O
glycosylation O
or O
phosphorylation O
of O
Ag35 NUMERIC
but O
may O
result O
from O
a O
proline O
- O
rich O
sequence O
which O
occurs O
in O
this O
polypeptide O
. O

A O
9 O
. O
5 O
- O
kb O
KpnI LASTCAP
- O
SalI LASTCAP
fragment O
, O
where O
all O
the O
DNA O
changes O
associated O
with O
su RARE
( I-GENE
Hw RARE
) I-GENE
mutations I-GENE
were O
mapped O
, O
was O
able O
to O
rescue O
the O
su RARE
( I-GENE
Hw RARE
) I-GENE
mutant I-GENE
phenotype O
after O
P O
- O
element O
- O
mediated O
germ O
- O
line O
transformation O
. O

The O
corticosterone O
synthesis O
inhibitor O
metyrapone RARE
( O
75 O
mg O
/ O
kg O
i O
. O
p O
.) O
was O
given O
to O
attenuate RARE
the O
rise O
of O
corticosterone O
to O
a O
level O
typical O
of O
stressed O
males O
. O

The O
effects O
of O
L655 NUMERIC
, O
240 O
, O
a O
selective O
thromboxane O
and O
prostaglandin O
endoperoxide RARE
antagonist O
, O
on O
ischemia O
- O
and O
reperfusion O
- O
induced O
cardiac O
arrhythmias O
. O

In O
10 O
pentobarbitalized RARE
dogs O
, O
plasma O
viscosity O
( O
Ep RARE
) O
was O
raised O
fourfold O
while O
apparent O
blood O
viscosity O
( O
Ea RARE
) O
increased O
about O
twofold O
by O
two O
steps O
of O
exchange O
transfusion O
of O
200 O
ml O
of O
plasma O
with O
plasma O
containing O
high O
molecular O
weight O
dextran RARE
( O
mol O
wt O
500 O
, O
000 O
, O
20 O
% O
wt O
/ O
vol RARE
). O

The O
small I-GENE
IGF I-GENE
- I-GENE
binding I-GENE
protein I-GENE
is O
abundant O
in O
human O
amniotic O
fluid O
. O

Serum O
prostatic I-GENE
acid I-GENE
phosphatase I-GENE
levels O
showed O
a O
significantly O
weaker RARE
correlation O
with O
cancer O
volume O
( O
r O
equals RARE
0 O
. O
51 O
) O
and O
every O
other O
pathological O
parameter O
. O

The O
investigation O
was O
thereafter O
continued O
in O
an O
open O
fashion O
by O
administering RARE
a O
single O
10 O
mg O
dose O
of O
the O
MAO I-GENE
- I-GENE
B I-GENE
inhibitor O
deprenyl RARE
to O
the O
same O
subjects O
. O

Their O
studies O
have O
revealed O
a O
considerable O
increase O
of O
CSF I-GENE
AP I-GENE
activity O
in O
purulent RARE
meningitides RARE
whereas O
in O
serous RARE
meningitides RARE
it O
grows RARE
negligibly RARE
. O

A O
cDNA O
encoding O
a O
new O
human O
lymphocyte O
cell O
surface O
molecule O
has O
been O
isolated O
and O
shown O
to O
identify O
a O
fourth O
member O
of O
a O
recently O
discovered O
family O
of O
adhesion O
proteins O
. O

Dopamine O
caused O
a O
prominent O
potassium O
efflux RARE
measured O
as O
86Rb NUMERIC
+ O
efflux RARE
from O
control O
glands O
, O
but O
was O
without O
effect O
in O
denervated RARE
glands O
. O

Spontaneous RARE
sensitization O
to O
cross O
- O
reacting RARE
chemicals RARE
in O
a O
proportion O
of O
control O
animals O
is O
strongly O
suggested O
, O
somewhat RARE
akin RARE
to O
spontaneous O
sensitization O
in O
patients O
with O
anaphylactoid RARE
reactions O
to O
neuromuscular O
blockers O
on O
first O
exposure O
, O
and O
in O
whom O
IgE I-GENE
antibodies I-GENE
are O
detected O
. O

This O
approach O
was O
examined O
utilizing O
the O
fetal O
protein O
, O
HGB ALLCAPS
F I-GENE
. O

The O
investigation O
was O
apt RARE
at O
studying O
the O
relationship O
between O
urinary O
metabolites O
of O
serotonin O
and O
catecholamine RARE
( O
5 O
- O
HIAA ALLCAPS
and O
VMA ALLCAPS
), O
T O
- O
cells O
( O
OKT3 NUMERIC
+), O
T O
- O
helper RARE
( O
OKT4 NUMERIC
+), O
T O
- O
suppressor O
( O
OKT8 NUMERIC
+) O
and O
B O
- O
cells O
( O
EAC ALLCAPS
- O
rosette RARE
forming O
cells O
) O
in O
normal O
( O
10 O
subjects O
, O
1 O
female O
, O
9 O
male O
, O
age O
21 O
+/- O
5 O
years O
) O
and O
stress O
administered O
subjects O
( O
20 O
subjects O
, O
3 O
female O
, O
17 O
male O
, O
age O
20 O
+/- O
4 O
years O
). O

The O
84 I-GENE
. I-GENE
1C NUMERIC
mAb I-GENE
recognizes O
a O
site O
on O
IgE I-GENE
which O
is O
identical O
or O
very O
close O
to O
the O
Fc I-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
, O
and O
95 O
. O
3 O
recognizes O
a O
site O
on O
IgE I-GENE
which O
is O
related O
, O
but O
not O
identical O
to O
the O
Fc I-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
. O

Their O
hydropathic RARE
plots RARE
are O
very O
similar O
and O
both O
possess O
three O
hydrophobic O
segments O
that O
are O
likely O
alpha O
- O
helical O
transmembrane O
segments O
. O

Angiotensin RARE
converting I-GENE
enzyme I-GENE
inhibitors O
enhance O
the O
antihypertensive O
efficacy O
of O
diuretics RARE
and O
blunt RARE
or O
prevent O
adverse O
metabolic O
effects O
. O

In O
addition O
to O
the O
significant O
reduction O
in O
blood O
pressure O
, O
the O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
( O
ACE I-GENE
) O
inhibitor O
ramipril RARE
caused O
a O
significant O
regression O
of O
pathologic O
left O
ventricular O
hypertrophy O
demonstrated O
by O
magnetic O
resonance O
imaging O
and O
echocardiography O
. O

Endocrine RARE
cells O
were O
studied O
by O
means O
of O
Grimelius RARE
' O
silver O
staining O
and O
immunostaining RARE
for O
chromogranin RARE
, O
a O
general O
marker O
of O
endocrine O
cells O
. O

The O
ratio O
of O
radioactivity RARE
in O
tumour O
compared O
with O
normal O
tissue O
( O
T O
: O
N O
ratio O
) O
was O
determined O
after O
simultaneously O
injecting O
microspheres O
into O
the O
portal O
and O
arterial O
circulation O
of O
each O
animal O
. O

The O
mRNA O
was O
converted O
to O
cDNA O
and O
amplified O
by O
the O
polymerase O
chain O
reaction O
technique O
. O

Tissue O
necrosis O
was O
evaluated O
using O
triphenyltetrazolium RARE
staining O
and O
was O
related O
to O
two O
major O
baseline O
predictors O
of O
infarct O
size O
: O
anatomic O
risk O
zone O
size O
and O
coronary O
collateral O
flow O
. O

To O
study O
the O
retinal O
surface O
in O
the O
human O
eye O
in O
normal O
and O
diseased O
states O
we O
used O
laser O
scanning O
tomography O
. O

Previously O
, O
we O
reported O
the O
sequence O
of O
the O
gene I-GENE
encoding I-GENE
human I-GENE
K14 NUMERIC
( O
D O
. O

A O
potential O
TATA O
box O
is O
located O
29 O
base O
pairs O
upstream O
of O
the O
first O
transcription O
initiation O
site O
. O

Cotransfection O
of O
either O
construct O
with O
plasmids O
encoding O
PKI ALLCAPS
( I-GENE
1 I-GENE
- I-GENE
31 I-GENE
) I-GENE
inhibits O
cAMP O
- O
stimulated O
but O
not O
basal O
- O
or O
phorbol O
ester O
- O
stimulated O
expression O
. O

Sequence O
analysis O
of O
the O
5 O
' O
flanking O
region O
revealed O
several O
GC O
boxes O
but O
no O
identifiable RARE
TATA O
box O
. O

The O
underlying O
cirrhosis O
was O
alcoholic O
in O
11 O
( O
53 O
. O
3 O
%), O
cryptogenic RARE
in O
5 O
( O
23 O
. O
8 O
%), O
and O
hepatitis O
B O
chronic O
infection O
related O
in O
5 O
( O
23 O
. O
8 O
%). O

Once O
P I-GENE
- I-GENE
450scc NUMERIC
mRNA I-GENE
is O
induced O
as O
a O
consequence O
of O
the O
LH I-GENE
/ O
hCG I-GENE
surge RARE
it O
is O
constitutively O
maintained O
by O
luteinized RARE
cells O
in O
vivo O
( O
0 O
- O
4 O
days O
) O
and O
in O
vitro O
( O
0 O
- O
9 O
days O
) O
in O
the O
absence O
of O
gonadotropins RARE
, O
is O
susceptible O
to O
modulation O
by O
prolactin I-GENE
and O
is O
no O
longer O
regulated O
by O
cAMP O
. O

Similarly O
, O
a O
human O
but O
not O
a O
bovine I-GENE
alpha I-GENE
transgene RARE
was O
expressed O
in O
placenta O
in O
transgenic O
mice O
. O

A O
rapid O
staining O
technique O
for O
Leishmania O
parasites O
in O
splenic O
aspirate RARE
smears O
. O

NIK ALLCAPS
- O
244 NUMERIC
suppressed O
coronary O
ligation O
- O
and O
digitalis RARE
- O
induced O
arrhythmias O
, O
and O
the O
minimum O
effective O
plasma O
concentrations O
for O
arrhythmias O
induced O
by O
24 O
- O
h O
and O
48 O
- O
h O
coronary O
ligation O
and O
digitalis RARE
were O
0 O
. O
41 O
+/- O
0 O
. O
10 O
( O
by O
1 O
mg O
/ O
kg O
i O
. O
v O
.), RARE
0 O
. O
70 O
+/- O
0 O
. O
13 O
( O
by O
1 O
mg O
/ O
kg O
i O
. O
v O
.), RARE
and O
0 O
. O
21 O
+/- O
0 O
. O
08 NUMERIC
( O
by O
0 O
. O
5 O
mg O
/ O
kg O
i O
. O
v O
.) O
microgram O
/ O
ml O
, O
respectively O
( O
mean O
+/- O
SD O
of O
the O
mean O
, O
n O
= O
6 O
). O

In O
TNF I-GENE
- O
resistant O
T24 NUMERIC
bladder O
carcinoma O
cells O
, O
TNF I-GENE
failed O
to O
alter O
EGF I-GENE
- I-GENE
R I-GENE
tyrosine I-GENE
protein I-GENE
kinase I-GENE
activity O
although O
both O
EGF I-GENE
and O
phorbol O
ester O
were O
shown O
to O
modulate O
the O
enzymatic O
activity O
of O
the O
receptor O
in O
these O
cells O
. O

Thus O
, O
phosphodiesterase O
inhibitors O
that O
produce O
an O
opiate O
quasi RARE
- O
withdrawal O
syndrome O
potentiate RARE
interoceptive RARE
stimuli O
and O
weight O
loss O
associated O
with O
the O
withdrawal O
syndrome O
precipitated O
by O
naltrexone O
in O
morphine O
- O
dependent O
rats O
. O

The O
diagnostic O
value O
of O
blood O
serum O
and O
urinary I-GENE
amylase I-GENE
, O
lipase I-GENE
, O
and O
trypsin I-GENE
in O
exacerbations RARE
of O
chronic O
relapsing RARE
pancreatitis O
is O
discussed O
. O

On O
the O
basis O
of O
the O
mechanism O
of O
action O
, O
two O
groups O
of O
inodilators RARE
are O
distinguished O
, O
the O
phosphodiesterase O
inhibitors O
and O
the O
dopaminergic O
agents O
. O

Structural O
organization O
and O
expression O
of O
the O
mouse I-GENE
estrogen I-GENE
receptor I-GENE
. O

Intravenous O
gamma I-GENE
globulins RARE

Following O
chondroitinase RARE
AC I-GENE
and I-GENE
ABC ALLCAPS
digestion O
, O
staining O
reactions O
suggested O
that O
the O
highest O
levels O
of O
dermatan RARE
sulfate O
were O
in O
the O
diabetes O
resistant O
group O
( O
p O
less O
than O
0 O
. O
001 O
compared O
to O
diabetic O
, O
p O
less O
than O
0 O
. O
001 O
compared O
to O
diabetes O
prone O
) O
and O
the O
highest O
levels O
of O
chondroitin RARE
sulfates RARE
were O
in O
the O
diabetes O
prone O
group O
( O
p O
less O
than O
0 O
. O
001 O
). O

Myocardial O
perfusion O
was O
evaluated O
using O
the O
enhanced O
gray O
level O
after O
contrast O
injection O
, O
and O
the O
level O
was O
compared O
with O
the O
morphology O
and O
degree O
of O
collateral O
development O
. O

Once O
NGF ALLCAPS
administration O
is O
proven O
effective O
it O
will O
be O
possible O
to O
develop O
alternative O
ways O
of O
NGF ALLCAPS
administration O
. O

During O
the O
program O
' O
s O
use O
at O
the O
RSNA ALLCAPS
meeting RARE
, O
the O
program O
selected O
the O
correct O
diagnosis O
in O
the O
top O
five O
22 O
% O
of O
the O
time O
. O

Immunoglobulin RARE
light I-GENE
chain I-GENE
( O
IgL LASTCAP
) O
diversity O
is O
generated O
in O
the O
chicken O
by O
recombination O
between O
the O
single O
functional O
variable O
( O
VL ALLCAPS
) O
and O
joining O
( O
JL ALLCAPS
) O
gene O
segments O
and O
subsequent O
somatic O
diversification RARE
of O
the O
rearranged O
VL ALLCAPS
region O
. O

The O
results O
were O
as O
follows O
: O
1 O
) O
Total O
integrated O
EMG O
activity O
of O
FB O
group O
was O
approximately O
equal O
in O
any O
occluded O
position O
, O
whereas O
that O
of O
CG O
and O
GF ALLCAPS
group O
varied O
from O
position O
to O
position O
. O

Muscle RARE
action O
potential O
and O
masticatory RARE
rhythm O
of O
anterior O
temporal O
and O
masseter RARE
muscles O
in O
children O
and O
adults O

In O
76 O
% O
of O
59 O
lead O
- O
toxic O
children O
, O
bone O
lead O
values O
measured O
by O
LXRF ALLCAPS
were O
equal O
to O
or O
greater O
than O
those O
measured O
in O
normal O
and O
industrially RARE
exposed O
adults O
. O

When O
considered O
with O
the O
known O
neurotoxic RARE
effects O
on O
children O
of O
" O
low O
levels O
" O
of O
exposure O
to O
lead O
, O
these O
results O
also O
suggest O
that O
either O
an O
excessively RARE
narrow O
margin O
of O
safety O
or O
insufficient O
safety O
is O
provided O
by O
present O
U O
. O
S O
. O
guidelines O
, O
which O
classify RARE
an O
elevated O
blood O
lead O
concentration O
as O
25 O
micrograms O
/ O
dl O
or O
greater O
. O

In O
resting O
3T3 O
cells O
, O
jun I-GENE
- I-GENE
D I-GENE
is O
expressed O
at O
a O
higher O
level O
compared O
to O
c I-GENE
- I-GENE
jun I-GENE
and O
jun I-GENE
- I-GENE
B I-GENE
, O
and O
its O
transcription O
is O
stimulated O
only O
slightly O
by O
serum O
growth O
factors O
. O

The O
thrombolytic RARE
effects O
of O
native O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
AK ALLCAPS
- I-GENE
124 I-GENE
) O
on O
experimental O
canine O
coronary O
thrombosis O
. O

O2 O
and O
CO2 O
in O
the O
tracheostomy RARE
tube O
were O
continuously O
monitored O
by O
mass O
spectrometry O
using O
a O
special O
sample O
- O
hold RARE
phase O
- O
locked RARE
sampling O
technique O
. O

Enzyme RARE
- O
linked O
immunosorbent O
assay O
for O
screening O
aflatoxin RARE
B1 O
in O
cottonseed RARE
products O
and O
mixed O
feed O
: O
collaborative RARE
study O
. O

However O
, O
experiments O
with O
S1 I-GENE
mapping O
of O
in O
vivo O
transcripts O
, O
gene O
disruptions RARE
in O
the O
alpha O
region O
, O
and O
a O
single O
- O
copy O
transcriptional O
fusion O
vector O
all O
suggested O
that O
these O
possible O
promoters O
were O
largely O
inactive O
during O
logarithmic RARE
growth O
, O
that O
the O
major O
promoter O
for O
the O
alpha O
operon O
lay RARE
upstream O
from O
the O
region O
cloned O
, O
and O
that O
the O
genes O
in O
the O
IF1 NUMERIC
to O
L17 NUMERIC
interval O
were O
cotranscribed O
. O

Functional O
rearranged O
antibody O
genes O
were O
detected O
with O
JH ALLCAPS
and O
VH I-GENE
heavy I-GENE
chain I-GENE
probes O
and O
with O
Jk RARE
and O
Vk RARE
light I-GENE
chain I-GENE
probes O
. O

Two O
specific O
DNA O
- O
protein O
complexes O
were O
identified O
in O
gel O
retardation O
assays O
using O
HeLa O
cell O
nuclear O
extracts O
and O
an O
oligonucleotide O
probe O
spanning O
the O
footprinted RARE
region O
. O

After O
transfection O
, O
specific O
TSH I-GENE
beta I-GENE
promoter I-GENE
activity O
was O
evident O
in O
both O
TRH I-GENE
- O
responsive O
pituitary O
- O
derived O
GH3 NUMERIC
and O
primary O
pituitary O
cell O
cultures O
. O

In O
transformed O
E O
. O
coli O
, O
constitutive I-GENE
CAT I-GENE
expression O
is O
maintained O
when O
as O
little O
as O
0 O
. O
3 O
kilobase O
of O
DNA O
from O
the O
3 O
' O
end O
of O
the O
1 O
. O
6 O
- O
kilobase O
segment O
is O
inserted O
in O
the O
correct O
orientation O
in O
front O
of O
the O
CAT I-GENE
gene I-GENE
. O

Lowering RARE
of O
the O
renal O
blood O
flow O
alters O
the O
glomerular O
and O
tubular O
excretion O
processes O
. O

Tonometry RARE
of O
blood O
samples O
from O
patients O
may O
also O
be O
used O
in O
the O
determination O
of O
acid O
- O
base O
quantities RARE
and O
hemoglobin I-GENE
- O
oxygen O
affinity O
e O
. O
g O
. O
p50 O
. O

100 O
and O
14 O
p O
. O

Isolation O
of O
Weeksella RARE
virosa RARE
( O
formerly RARE
CDC ALLCAPS
group O
IIf RARE
) O
from O
a O
vaginal O
sample O
. O

Here O
, O
we O
alter O
the O
dimerization O
specificity O
of O
Fos I-GENE
by O
precisely O
replacing O
its O
leucine O
zipper O
with O
that O
from O
GCN4 I-GENE
. O

Growth O
of O
tracheal O
anastomoses RARE
in O
growing O
animals O

Fourth RARE
, O
sometime RARE
between O
4 O
and O
24 O
hours O
of O
recovery O
is O
necessary O
to O
reverse O
the O
effect O
of O
chronic O
hypoxia O
on O
cerebral O
blood O
flow O
. O

The O
ORF1 O
product O
was O
required O
for O
competence RARE
, O
while O
ORF2 O
, O
which O
was O
cotranscribed O
with O
ORF1 O
and O
encoded O
a O
predicted O
protein O
of O
126 O
amino O
acids O
, O
was O
not O
. O

Kindling RARE
of O
the O
primary O
visual O
cortex O
( O
VC ALLCAPS
) O
was O
compared O
with O
that O
of O
the O
amygdala O
in O
cats O
. O

Abundant RARE
infiltration RARE
of O
lymphocytes O
and O
plasma O
cells O
was O
also O
wide O
- O
spread O
beneath RARE
the O
carcinoma O
in O
situ O
, O
together O
with O
the O
lymphoid O
follicles RARE
. O

These O
case O
reports O
provide O
further O
evidence O
that O
LiCO3 NUMERIC
can O
be O
a O
useful O
medication O
in O
the O
treatment O
of O
aggressive O
behavior O
and O
affective O
instability RARE
after O
brain O
injury O
, O
but O
that O
it O
has O
significant O
potential O
for O
neurotoxicity O
in O
this O
population O
, O
particularly O
when O
used O
in O
conjunction O
with O
neuroleptic O
agents O
. O

In O
all O
sessions RARE
under O
IFN I-GENE
, O
the O
latency O
of O
the O
P100 NUMERIC
component O
of O
the O
VEP ALLCAPS
was O
shortened O
as O
compared O
to O
baseline O
conditions O
. O

Among O
100 O
cases O
of O
post O
- O
transfusion O
hepatitis O
, O
10 O
are O
due O
to O
the O
hepatitis O
B O
virus O
( O
despite O
systematic O
search O
for O
HBs I-GENE
Ag I-GENE
), O
89 O
are O
due O
to O
one O
of O
the O
non O
- O
A O
non O
- O
B O
viruses O
( O
not O
detectable O
by O
specific O
serological O
tests O
) O
and O
1 O
to O
several O
viruses O
, O
specially RARE
CMV O
. O

Recessive RARE
lethal O
mutations O
were O
isolated O
based O
upon O
failure O
to O
complement O
the O
recessive O
lethality O
of O
Df RARE
( O
3L NUMERIC
) O
RR2 NUMERIC
, O
a O
deletion O
of O
the O
DRE O
region O
that O
removes RARE
16 O
- O
18 O
polytene RARE
chromosome O
bands O
. O

Current O
status O
and O
future O
perspectives RARE

K O
. O

A O
215 O
- O
base O
- O
pair O
( O
bp O
) O
region O
of O
the O
mouse I-GENE
MOPC ALLCAPS
41 I-GENE
kappa I-GENE
light I-GENE
- I-GENE
chain I-GENE
immunoglobulin I-GENE
gene I-GENE
enhancer I-GENE
has O
been O
analyzed O
for O
specific O
binding O
of O
lymphoid O
and O
nonlymphoid RARE
nuclear O
factors O
. O

This O
paper O
presents O
the O
reasons RARE
why RARE
countries RARE
to O
which O
Chagas RARE
disease O
is O
endemic RARE
should O
carry O
out O
the O
relevant O
research O
themselves O
. O

The O
PETCO2 NUMERIC
measurement O
during O
precordial RARE
compression O
predicted O
the O
success O
of O
defibrillation RARE
with O
return O
of O
spontaneous O
circulation O
. O

Gastric RARE
CO2 O
/ O
HCO3 O
was O
determined O
in O
absence O
of O
simultaneous O
inhibition O
of O
acid O
secretion O
by O
intra O
- O
and O
extragastric RARE
pCO2 NUMERIC
/ O
pH O
measurements O
in O
23 O
persons O
and O
calculated O
using O
the O
equation O
of O
Henderson RARE
- O
Hasselbalch RARE
. O
pCO2 NUMERIC
was O
measured O
with O
use O
of O
a O
new O
electrode O
. O

Follow RARE
- O
up O
study O
showed O
85 O
% O
of O
these O
patients O
with O
effectiveness O
. O

The O
other O
patients O
continued O
the O
trial O
with O
single O
daily O
doses O
of O
monotherapy RARE
. O

Neonatal RARE
Chagas RARE
disease O
: O
laboratory O
diagnosis O
during O
the O
first O
year O
of O
life O

Using O
mutated I-GENE
IL2R NUMERIC
alpha I-GENE
promoter I-GENE
constructs I-GENE
in O
transient O
transfection O
and O
DNA O
binding O
assays O
, O
we O
now O
demonstrate O
that O
sequences O
located O
immediately O
upstream O
and O
downstream O
of O
the O
kappa I-GENE
B I-GENE
enhancer I-GENE
also O
contribute O
to O
the O
regulation O
of O
IL2R NUMERIC
alpha I-GENE
gene I-GENE
expression O
. O

Palindromic RARE
rheumatism RARE

Inefficacy RARE
of O
phosphine RARE
fumigation RARE
against O
ticks O
. O

Forty O
patients O
, O
divided O
according O
to O
their O
initial O
total O
gastrointestinal O
transit O
times O
and O
presenting O
symptoms O
, O
were O
treated O
with O
cimetropium RARE
bromide O
50 O
mg O
t O
. O
d O
. O
s O
. O
or O
placebo O
for O
1 O
month O
according O
to O
a O
double O
- O
blind O
, O
parallel O
group O
design O
. O

An O
immunologically RARE
related O
protein O
was O
detected O
in O
ribosome O
and O
membrane O
fractions O
of O
mitochondria O
from O
Saccharomyces O
cerevisiae O
. O

Mapping O
of O
RNA O
- O
temperature I-GENE
- I-GENE
sensitive I-GENE
mutants I-GENE
of I-GENE
Sindbis RARE
virus I-GENE
: I-GENE
complementation I-GENE
group I-GENE
F I-GENE
mutants I-GENE
have O
lesions O
in O
nsP4 NUMERIC
. O

The O
effect O
of O
the O
thromboxane I-GENE
A2 I-GENE
( I-GENE
TXA2 NUMERIC
)/ I-GENE
prostaglandin I-GENE
endoperoxide RARE
receptor I-GENE
antagonist O
, O
SQ ALLCAPS
29 O
, O
548 NUMERIC
on O
pacing O
- O
induced O
ischemia O
was O
determined O
in O
anesthetized O
open O
- O
chest O
dogs O
. O

According O
to O
the O
published O
sequence O
of O
the O
CHS1 NUMERIC
gene I-GENE
, O
this O
fragment O
contains O
four O
repeats O
of O
a O
TGAAACA ALLCAPS
consensus O
sequence O
previously O
identified O
in O
the O
alpha I-GENE
- I-GENE
factor I-GENE
- O
inducible O
BAR1 NUMERIC
promoter I-GENE
[ O
Kronstad RARE
, O
J O
. O

The O
recovery O
index O
( O
T25 NUMERIC
- O
T75 NUMERIC
) O
after O
the O
infusion O
stopped O
was O
similar O
in O
patients O
who O
received O
mivacurium RARE
and O
those O
who O
received O
suxamethonium RARE
. O

The O
sign O
of O
Leser RARE
- O
Trelat RARE
: O
does O
it O
exist O
? O
The O
sign O
of O
Leser RARE
- O
Trelat RARE
is O
usually O
regarded O
as O
a O
reliable O
cutaneous O
marker O
of O
internal O
malignancy O
. O

Xenopus I-GENE
homolog I-GENE
of I-GENE
the I-GENE
mos I-GENE
protooncogene I-GENE
transforms RARE
mammalian O
fibroblasts O
and O
induces O
maturation O
of O
Xenopus O
oocytes O
. O

Southern O
blot O
analyses O
demonstrated O
a O
low O
, O
if O
not O
single O
, O
copy O
number O
for O
this O
gene O
and O
conservation O
of O
this O
domain O
in O
other O
vertebrates RARE
. O

Three O
missense O
mutants O
in O
subunit O
a O
of O
the O
Escherichia I-GENE
coli I-GENE
F1F0 NUMERIC
- I-GENE
ATPase I-GENE
were O
isolated O
and O
characterized O
after O
hydroxylamine RARE
mutagenesis O
of O
a O
plasmid O
carrying O
the O
uncB LASTCAP
( I-GENE
subunit I-GENE
a I-GENE
) I-GENE
gene I-GENE
. O

Moreover O
, O
exons O
2a NUMERIC
and O
2b O
share O
the O
same O
5 O
' O
sequence O
but O
differ O
from O
each O
other O
by O
the O
use O
of O
two O
distinct O
donor O
splice O
sites O
171 NUMERIC
bp O
apart O
in O
the O
gene O
. O

S1 I-GENE
nuclease I-GENE
analysis O
of O
RNA O
prepared O
after O
transfection O
of O
these O
HIV O
constructs O
into O
HeLa O
cells O
infected O
with O
wild O
- O
type O
adenovirus O
indicated O
that O
the O
enhancer O
, O
SP1 I-GENE
, O
TATA O
, O
and O
a O
portion O
of O
the O
transactivation O
- O
responsive O
element O
were O
each O
required O
for O
complete O
E1A I-GENE
/ O
E1B I-GENE
- O
mediated O
activation O
of O
the O
HIV I-GENE
LTR I-GENE
. O

In O
supine O
position O
, O
plasma O
ANP I-GENE
levels O
ranged O
from O
12 O
pg O
/ O
ml O
to O
51 O
. O
5 O
pg O
/ O
ml O
, O
with O
an O
average O
level O
of O
35 O
. O
3 O
+/- O
11 O
. O
5 O
pg O
/ O
ml O
. O

The O
overall O
prevalence O
of O
HBV O
markers O
was O
higher O
among O
staff RARE
members O
than O
in O
the O
blood O
donors O
of O
our O
area O
. O

Quantitative O
predictions O
are O
confirmed O
for O
the O
positive O
responses O
, O
but O
not O
for O
the O
negatives RARE
, O
suggesting O
that O
the O
SSTS ALLCAPS
model O
is O
incorrect RARE
. O

Plasma O
concentrations O
of O
ANF ALLCAPS
( O
pANF LASTCAP
), O
aldosterone O
( O
PAC ALLCAPS
) O
and O
renin I-GENE
( O
PRC ALLCAPS
) O
were O
measured O
daily O
, O
as O
were O
hemodynamic O
parameters O
. O

The O
adenovirus I-GENE
E1A I-GENE
gene I-GENE
encodes O
a O
protein O
that O
transcriptionally O
activates O
viral I-GENE
early I-GENE
genes I-GENE
. O

Administration O
of O
dexamethasone O
was O
associated O
with O
progressive O
rises RARE
in O
plasma O
17 O
alpha O
OH O
progesterone O
, O
11 O
beta O
- O
desoxycortisol RARE
, O
DHEA ALLCAPS
sulphate RARE
, O
androstenedione RARE
and O
testosterone O
, O
together O
with O
increased O
urinary O
excretion O
of O
androsterone RARE
, O
11 O
beta O
OH O
androsterone RARE
, O
etiocholanolone RARE
, O
DHEA ALLCAPS
, O
and O
16 O
alpha O
OH O
DHEA ALLCAPS
. O

RNA O
transcripts O
that O
hybridize RARE
to O
the O
introduced O
foreign O
gene O
have O
been O
identified O
. O

In O
HeLa O
cells O
, O
it O
activated O
transcription O
from O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
1 I-GENE
thymidine I-GENE
kinase I-GENE
promoter I-GENE
linked O
to O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
when O
located O
in O
inverted O
orientation O
upstream O
of O
the O
thymidine I-GENE
kinase I-GENE
promoter I-GENE
or O
downstream O
of O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
coding I-GENE
sequence I-GENE
. O

At O
the O
basal O
unstimulated O
condition O
, O
Ren1d NUMERIC
5 I-GENE
' I-GENE
flanking I-GENE
sequence I-GENE
in O
the O
sense O
orientation O
inhibited O
basal O
CAT I-GENE
expression O
from O
the O
TK I-GENE
promoter I-GENE
of O
pUTKAT1 NUMERIC
, O
whereas O
the O
same O
sequence O
in O
the O
antisense O
orientation O
did O
not O
. O

None O
were O
restricted O
from O
clinical O
duties RARE
, O
were O
given O
varicella RARE
- I-GENE
zoster RARE
immune I-GENE
globulin I-GENE
, O
or O
developed O
disease O
. O

In O
the O
formalin O
test O
, O
however O
, O
naloxone O
attenuated O
morphine O
analgesia O
at O
the O
lower O
doses O
( O
0 O
. O
1 O
and O
0 O
. O
3 O
mg O
/ O
kg O
) O
and O
potentiated RARE
morphine O
analgesia O
at O
the O
highest O
dose O
( O
10 O
mg O
/ O
kg O
). O

We O
have O
isolated O
cDNA O
clones O
from O
rat O
brain O
and O
human O
liver O
encoding O
a O
putative O
isoform O
of O
the O
Na I-GENE
, I-GENE
K I-GENE
- I-GENE
ATPase I-GENE
beta I-GENE
subunit I-GENE
. O

We O
have O
determined O
that O
several O
E1 I-GENE
mutants I-GENE
mapping O
in O
both O
the O
M O
and O
R O
regions O
and O
a O
single O
mutant O
of O
the O
upstream O
regulatory O
region O
have O
a O
higher O
transforming O
activity O
on O
mouse O
C127 NUMERIC
cells O
than O
the O
wild O
- O
type O
genome O
does O
. O

UbiA LASTCAP
is O
also O
unique O
among O
known O
polyubiquitin RARE
genes I-GENE
in O
containing O
four O
cis O
- O
spliced O
introns O
within O
its O
coding O
sequence O
. O

That RARE
of O
the O
T2 I-GENE
gene I-GENE
contains O
numerous O
potential O
sites O
for O
binding O
the O
mammalian I-GENE
transcription I-GENE
factor I-GENE
SP1 I-GENE
, O
but O
no O
TATA O
or O
CCAAT O
sequences O
are O
evident O
near O
to O
its O
5 O
' O
end O
, O
although O
these O
latter O
features O
are O
associated O
with O
the O
human I-GENE
T1 I-GENE
gene I-GENE
. O

Radiation RARE
therapy O
was O
effective O
in O
controlling O
symptomatic O
metastasis O
in O
all O
three O
patients O
. O

These O
results O
indicate O
that O
patients O
who O
undergo O
postoperative O
irradiation O
for O
low O
grade O
spinal O
astrocytomas RARE
and O
localized O
spinal O
ependymomas RARE
achieve O
excellent O
survival O
. O

The O
methylation O
of O
nuclear O
and O
chloroplast O
DNAs O
has O
been O
examined O
in O
relation O
to O
the O
known O
differential O
expression O
of O
C4 I-GENE
photosynthesis RARE
genes I-GENE
in O
the O
bundle O
sheath RARE
and O
mesophyll RARE
cells O
of O
etiolated RARE
, O
greening RARE
, O
and O
fully O
green O
maize O
leaves O
. O

S1 I-GENE
nuclease I-GENE
analysis O
of O
RNA O
from O
chemically RARE
induced O
B95 NUMERIC
- O
8 O
cells O
and O
from O
Vero RARE
cells O
cotransfected O
with O
NotI LASTCAP
repeat I-GENE
promoter I-GENE
- O
CAT I-GENE
and O
Z I-GENE
showed O
that O
Z I-GENE
transactivation O
increased O
the O
level O
of O
correctly O
initiated O
, O
stable O
RNA O
transcripts O
. O

We O
conclude O
that O
( O
a O
) O
the O
likelihood O
of O
detecting O
carcinoma O
or O
atypical O
hyperplasia O
exclusively O
in O
the O
adipose O
tissue O
component O
of O
grossly RARE
benign O
breast O
biopsies O
is O
extremely O
low O
, O
and O
( O
b O
) O
a O
possible O
cost O
- O
effective O
method O
of O
sampling O
grossly RARE
benign O
breast O
biopsies O
consists O
of O
initially O
submitting RARE
a O
maximum O
of O
10 O
blocks O
of O
fibrous RARE
parenchyma O
for O
each O
case O
, O
then O
examining O
the O
remaining O
tissue O
histologically O
only O
if O
carcinoma O
or O
atypical O
hyperplasia O
is O
found O
among O
these O
blocks O
. O

Analysis O
of O
the O
DNA O
from O
15 O
cases O
of O
sporadic RARE
and O
familial O
Wilms RARE
' O
tumor O
did O
not O
reveal O
any O
changes O
, O
indicating O
that O
the O
translocation O
breakpoint O
does O
not O
reside O
in O
this O
gene O
. O

We O
also O
provide O
evidence O
that O
neither O
the O
lambda I-GENE
O I-GENE
and O
P I-GENE
initiators RARE
nor O
the O
E I-GENE
. I-GENE
coli I-GENE
DnaJ LASTCAP
and O
DnaK LASTCAP
heat O
shock O
proteins O
play O
a O
direct O
role O
in O
the O
propagation RARE
of O
lambda O
replication O
forks RARE
in O
vitro O
. O

Synthetic RARE
oligonucleotides O
representing O
the O
19 O
bp O
repeat O
unit O
strongly O
reduced O
the O
activity O
of O
the O
IE1 I-GENE
/ I-GENE
2 I-GENE
enhancer I-GENE
/ I-GENE
promoter I-GENE
in O
cotransfection O
assays O
after O
transient O
expression O
. O

Effects O
of O
nitrogen O
( O
PN2 NUMERIC
: O
5 O
and O
14 O
MPa RARE
) O
and O
helium RARE
( O
PHe RARE
: O
13 O
and O
14 O
MPa RARE
) O
were O
also O
tested O
. O

The O
mustard RARE
chloroplast I-GENE
gene I-GENE
rps16 NUMERIC
is O
split RARE
by O
an O
887 NUMERIC
bp O
group O
II O
( O
or O
III O
) O
intron O
. O

Antibodies O
raised O
to O
the O
expressed O
NS3 I-GENE
by O
immunization O
of O
mice O
detected O
both O
NS3 I-GENE
and O
NS3A NUMERIC
in O
BTV ALLCAPS
- O
10 O
- O
infected O
BHK ALLCAPS
cells O
but O
not O
in O
purified O
BTV ALLCAPS
- O
10 O
virus O
particles O
. O

Similarly O
, O
supraventricular RARE
tachycaydia RARE
following O
resuscitative RARE
efforts RARE
appeared O
to O
be O
associated O
with O
a O
negative O
outcome O
. O

The O
negative O
calcium O
balance O
with O
hyperparathyroidemia RARE
occurred O
after O
continuous O
oral O
administration O
of O
Cd O
and O
developed O
via O
increased O
urinary O
excretion O
of O
calcium O
. O

Clone RARE
4c NUMERIC
( O
2681 NUMERIC
bp O
) O
had O
a O
coding O
region O
identical O
to O
that O
of O
clone O
22c NUMERIC
but O
it O
included O
a O
putative O
intron O
of O
959 NUMERIC
bp O
. O

The O
application O
of O
ISH ALLCAPS
and O
IHC ALLCAPS
did O
not O
change O
significantly O
the O
routine O
histologic O
classification O
of O
pneumonias RARE
into O
CMV O
- O
IP ALLCAPS
and O
IIP ALLCAPS
. O

Validity RARE
of O
immunohistology RARE
and O
in O
situ O
hybridization O
in O
the O
differential O
diagnosis O
of O
cytomegalovirus O
pneumonia O
and O
idiopathic O
interstitial O
pneumonia O
after O
allogenic RARE
bone O
marrow O
transplantation O

The O
unique O
nature O
and O
arrangement O
of O
the O
ANT1 NUMERIC
transcriptional I-GENE
control I-GENE
elements I-GENE
may O
account O
for O
this O
differential O
expression O
. O

A O
brief O
account O
of O
the O
1988 O
seminar RARE
in O
Shanghai RARE
on O
viral O
hepatitis O
A O

The O
Bacillus I-GENE
subtilis I-GENE
phage I-GENE
phi I-GENE
105 I-GENE
repressor I-GENE
, O
a O
lambda I-GENE
repressor I-GENE
- O
like O
transcriptional O
regulatory O
protein O
, O
was O
overproduced RARE
in O
Escherichia O
coli O
and O
purified O
to O
near O
homogeneity RARE
in O
order O
to O
examine O
its O
in O
vitro O
DNA O
- O
binding O
properties O
. O

In O
consequence O
, O
the O
gpI LASTCAP
derived O
from O
cells O
infected O
with O
mO74 NUMERIC
showed O
antigenic O
characteristics O
similar O
to O
those O
of O
gpI LASTCAP
from O
VZV O
- O
infected O
cells O
as O
determined O
from O
the O
immunoprecipitation O
pattern O
, O
although O
the O
molecular O
weight O
of O
each O
polypeptide O
was O
different O
, O
and O
antibody O
produced O
in O
rabbits O
infected O
with O
recombinant O
virus O
had O
a O
high O
neutralizing RARE
activity O
, O
when O
the O
reaction O
was O
performed O
with O
complement O
. O

Erythrocytic RARE
stages O
of O
mammalian O
malarial RARE
parasites O
contain O
acristate RARE
mitochondria O
whose O
functions O
are O
not O
well O
understood O
. O

However O
, O
bilateral O
diffuse O
pulmonary O
infiltrations RARE
developed O
21 O
days O
later O
. O

Grossly RARE
, O
the O
incidence O
of O
a O
type O
IIc RARE
carcinoma O
was O
46 O
. O
5 O
% O
and O
that O
of O
a O
IIc RARE
+ O
III O
type O
was O
20 O
. O
5 O
%, O
respectively O
. O

Restriction O
maps O
of O
the O
cloned O
plasmids O
revealed O
that O
their O
chromosomal O
inserts O
consisted O
of O
overlapping O
fragments O
. O

VP5 NUMERIC
, O
which O
encodes O
the O
major I-GENE
capsid I-GENE
protein I-GENE
, O
each O
fused O
to O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
. O

Of O
202 NUMERIC
initially O
seronegative RARE
caretakers RARE
( O
observed O
for O
an O
average O
of O
305 NUMERIC
days O
per O
woman O
), O
19 O
seroconverted RARE
, O
for O
an O
annual O
seroconversion RARE
rate O
of O
11 O
percent O
. O

In O
contrast O
, O
a O
similar O
fragment O
lacking O
the O
38 O
- O
base O
- O
pair O
region O
had O
no O
such O
stabilizing RARE
effect O
. O

First O
, O
a O
pet54 NUMERIC
:: O
LEU2 I-GENE
cytoductant RARE
bearing O
the O
' O
short O
' O
mitochondrial O
genome O
that O
lacks O
both O
COX1 NUMERIC
introns I-GENE
aI5 NUMERIC
alpha I-GENE
and O
aI5 NUMERIC
beta I-GENE
is O
defective O
only O
in O
COX3 NUMERIC
gene I-GENE
expression O
and O
not O
in O
COX1 NUMERIC
mRNA I-GENE
splicing O
or O
mRNA O
translation O
. O

Insert2 NUMERIC
contains O
repetitive O
non O
- O
Ig I-GENE
- O
related O
sequences O
and O
a O
small I-GENE
Ig I-GENE
- I-GENE
related I-GENE
sequence I-GENE
. O

Since O
considerable O
variations O
in O
length O
and O
primary O
sequence O
in O
the O
CDR3 NUMERIC
( O
complementarity I-GENE
determining I-GENE
region I-GENE
) O
peptides O
of O
all O
the O
H I-GENE
- I-GENE
chains I-GENE
are O
evident O
, O
conservation O
of O
the O
D I-GENE
- I-GENE
region I-GENE
structure O
does O
not O
appear O
to O
be O
necessary O
for O
effective O
hapten RARE
binding O
. O

Tyrosine I-GENE
kinase I-GENE
oncogenes O
abrogate O
interleukin I-GENE
- I-GENE
3 I-GENE
dependence O
of O
murine O
myeloid O
cells O
through O
signaling O
pathways O
involving O
c I-GENE
- I-GENE
myc I-GENE
: O
conditional O
regulation O
of O
c I-GENE
- I-GENE
myc I-GENE
transcription O
by O
temperature O
- O
sensitive O
v I-GENE
- I-GENE
abl I-GENE
. O

This O
TC ALLCAPS
- I-GENE
II I-GENE
enhanson RARE
, O
which O
is O
identical O
to O
the O
kappa I-GENE
B I-GENE
motif I-GENE
from O
the O
kappa I-GENE
chain I-GENE
enhancer I-GENE
, O
was O
active O
in O
both O
lymphoid O
and O
non O
- O
lymphoid O
cells O
, O
which O
contrasts RARE
with O
the O
previously O
reported O
lymphoid O
cell O
specificity O
of O
the O
kappa I-GENE
B I-GENE
motif I-GENE
. O

The O
DNA O
helix O
at O
the O
tandemly O
repeated O
, O
13mer NUMERIC
sequence O
is O
thermodynamically RARE
unstable O
, O
as O
evidenced RARE
by O
hypersensitivity O
to O
single I-GENE
- I-GENE
strand I-GENE
- I-GENE
specific I-GENE
nuclease I-GENE
in O
a O
negatively O
supercoiled RARE
plasmid O
, O
and O
demonstrated O
by O
stable O
DNA O
unwinding RARE
seen O
after O
two O
- O
dimensional O
gel O
electrophoresis O
of O
topoisomers RARE
. O

There O
has O
been O
similar O
improvement O
in O
treating RARE
ampullary RARE
and O
periampullary RARE
cancer O
, O
gallbladder O
cancer O
, O
or O
extrahepatic RARE
bile O
duct O
cancer O
. O

Beta RARE
- I-GENE
endorphin I-GENE
, O
ACTH I-GENE
and O
cortisol O
secretion O
were O
measured O
in O
twelve RARE
healthy O
adult O
males O
after O
nasal O
spray RARE
administration O
200 O
IU O
salmon RARE
calcitonin I-GENE
. O

The O
data O
indicate O
that O
calcitonin I-GENE
induced O
a O
beta I-GENE
- I-GENE
endorphin I-GENE
increase O
independent O
of O
enhanced O
corticotrophin RARE
- O
cortisol O
release O
. O

The O
DNA O
sequences O
predict O
proteins O
for O
SRP54sc NUMERIC
and O
SRP54sp NUMERIC
that O
are O
47 O
% O
and O
52 O
% O
identical O
to O
SRP54mam NUMERIC
, O
respectively O
. O

Other O
hemostatic RARE
values O
evaluated O
were O
activated O
partial O
thromboplastin I-GENE
times O
, O
prothrombin I-GENE
times O
, O
thrombin I-GENE
times O
, O
fibrinogen I-GENE
, O
platelet O
counts O
, O
and O
fibrin I-GENE
/ O
fibrinogen I-GENE
degradation O
products O
. O

Rare RARE
neurogenic RARE
tumor O
with O
metastasis O
to O
mouth O
, O
jaw O
and O
face O
regions O

We O
have O
designated O
the O
protein O
" I-GENE
cellular I-GENE
NBP ALLCAPS
" I-GENE
( O
CNBP ALLCAPS
). O

Responsiveness RARE
to O
beta O
- O
2 O
agonist O
therapy O
was O
retained O
with O
both O
agents O
( O
p O
less O
than O
0 O
. O
05 O
). O

Drug O
use O
in O
trauma O
victims O
. O

A O
critical O
heart O
rate O
and O
/ O
or O
appropriate O
sympathetic O
state O
was O
found O
to O
provoke RARE
all O
instances O
of O
reentrant RARE
or O
automatic O
atrial O
tachycardia O
and O
atypical O
junctional RARE
tachycardia O
. O

In O
contrast O
, O
the O
neu I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
did O
not O
show O
kinase O
activity O
or O
transforming O
properties O
when O
expressed O
at O
similar O
levels O
in O
NIH O
3T3 O
cells O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

The O
65 O
- O
bp O
sequence O
contains O
the O
octameric RARE
cAMP O
- O
responsive O
enhancer O
( O
CRE O
) O
TGACGTCA ALLCAPS
( O
nucleotides O
- O
48 O
to O
- O
41 O
). O

Somatostatin RARE
gene I-GENE
expression O
in O
pancreatic O
islet O
cells O
is O
directed O
by O
cell O
- O
specific O
DNA O
control O
elements O
and O
DNA O
- O
binding O
proteins O
. O

In O
contrast O
, O
the O
full O
mu O
- O
opioid O
agonists O
fentanyl O
, O
morphine O
, O
I O
- O
methadone RARE
and O
levorphanol RARE
produced O
50 O
% O
fentanyl O
- O
appropriate O
responding O
at O
doses O
only O
1 O
. O
3 O
to O
10 O
. O
9 O
times O
smaller O
than O
those O
required O
to O
decrease O
response O
rates O
by O
50 O
%. O

After O
overtraining RARE
on O
the O
original O
discrimination O
, O
the O
controls O
showed O
the O
normal O
difficulty RARE
in O
learning O
the O
first O
reversal O
. O

Isolation O
and O
characterization O
of O
a O
cDNA O
encoding O
a O
putative O
cytokine O
which O
is O
induced O
by O
stimulation O
via O
the O
CD2 NUMERIC
structure I-GENE
on O
human O
T O
lymphocytes O
. O

After O
termination O
of O
medication O
the O
animals O
were O
kindled RARE
electrically O
in O
the O
nucleus O
amygdala O
. O

Haploid RARE
cells O
of O
mating O
type O
A O
of O
the O
basidiomycetous RARE
yeast O
Rhodosporidium RARE
toruloides RARE
secrete RARE
a O
mating O
pheromone O
, O
rhodotorucine RARE
A I-GENE
, O
which O
is O
an O
undecapeptide RARE
containing O
S O
- O
farnesyl RARE
cysteine O
at O
its O
carboxy O
terminus O
. O

Tumour RARE
necrosis I-GENE
factor I-GENE
and O
adult O
respiratory O
distress O
syndrome O
. O

Monitoring RARE
of O
rheumatoid O
arthritis O
. O

The O
decrease O
in O
left O
ventricular O
( O
LV O
) O
stroke O
volume O
during O
positive O
end O
- O
expiratory O
pressure O
( O
PEEP ALLCAPS
) O
has O
been O
attributed O
to O
reduced O
LV O
filling O
and O
a O
decreased O
contractile O
state O
. O

An O
experiment O
on O
the O
return O
- O
of O
- O
fear RARE
( O
ROF ALLCAPS
) O
was O
carried O
out O
on O
40 O
snake RARE
- O
or O
spider RARE
- O
phobic RARE
subjects O
in O
order O
to O
determine O
whether O
an O
arousing RARE
event O
that O
occurs O
shortly RARE
before O
retest RARE
influences O
the O
magnitude O
of O
the O
ROF ALLCAPS
. O

Evolutionary RARE
conservation O
of O
homeodomain I-GENE
- O
binding O
sites O
and O
other O
sequences O
upstream O
and O
within O
the O
major O
transcription O
unit O
of O
the O
Drosophila I-GENE
segmentation I-GENE
gene I-GENE
engrailed RARE
. O

To O
assess O
the O
functional O
importance O
of O
these O
NBS ALLCAPS
in O
the O
overall O
drug O
resistance O
phenotype O
conferred O
by O
mdr1 NUMERIC
, O
we O
introduced O
amino O
acid O
substitutions O
in O
the O
core O
consensus O
sequence O
for O
nucleotide O
binding O
, O
GXGKST ALLCAPS
. O

When O
the O
first O
twitch RARE
of O
TOF O
spontaneously O
recovered O
to O
10 O
% O
of O
control O
value O
, O
neostigmine RARE
was O
injected O
( O
40 O
micrograms O
/ O
kg O
in O
adults O
, O
30 O
micrograms O
/ O
kg O
in O
infants O
and O
children O
). O

No O
significant O
differences O
were O
found O
in O
relation O
to O
Type O
A O
behaviour O
and O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
blockade O
. O

Selection RARE
of O
the O
22 O
items RARE
of O
the O
Clinical O
Institute O
Withdrawal RARE
Assessment O
- O
Benzodiazepines RARE
( O
CIWA ALLCAPS
- O
B O
) O
was O
based O
on O
statistically O
significant O
differences O
between O
baseline O
and O
critical O
withdrawal O
periods O
in O
high O
- O
dose O
subjects O
and O
between O
symptoms O
associated O
with O
placebo O
and O
diazepam O
in O
low O
- O
dose O
subjects O
, O
using O
contingency RARE
tables RARE
and O
logistic RARE
regression O
analysis O
. O

Antihistamines RARE
in O
asthma O
. O

We O
have O
therefore O
evaluated O
the O
efficacy O
and O
safety O
of O
doxazosin RARE
, O
a O
new O
orally O
active O
selective O
alpha I-GENE
1 I-GENE
blocker O
, O
in O
patients O
with O
systemic O
hypertension O
with O
concomitant O
airflow RARE
limitation O
. O

Northern O
blot O
analysis O
revealed O
multiple O
oIGF LASTCAP
- I-GENE
I I-GENE
transcripts I-GENE
in O
a O
broad O
band O
at O
800 O
- O
1 O
, O
100 O
nucleotides O
and O
other O
transcripts O
of O
higher O
molecular O
weight O
in O
liver O
. O

Materials RARE
science RARE
studies O
on O
the O
soldering RARE
of O
different O
orthodontic RARE
wires RARE

The O
latency O
time O
for O
the O
lactate O
concentration O
to O
reach O
the O
top O
values O
was O
reduced O
by O
aerobic O
training O
( O
T2 O
). O

In O
patients O
resistant O
to O
VAD ALLCAPS
, O
high O
- O
dose O
therapies RARE
with O
intravenous O
melphalan RARE
, O
a O
CBV ALLCAPS
combination O
( O
cyclophosphamide O
- O
BCNU ALLCAPS
- O
VP ALLCAPS
- O
16 O
) O
or O
an O
EDAP ALLCAPS
regimen O
( O
VP ALLCAPS
- O
16 O
- O
platinum RARE
) O
produced O
responses O
in O
about O
40 O
% O
of O
patients O
. O

The O
discussion O
focuses RARE
primarily O
on O
the O
newer RARE
drugs O
like O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
, O
alpha I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
blockers O
, O
and O
calcium O
antagonists O
. O

The O
avian O
cellular O
homolog O
of O
the O
oncogene I-GENE
jun I-GENE
. O

A O
736 NUMERIC
- O
bp O
sequence O
of O
the O
5 O
' O
flanking O
region O
adjacent O
to O
the O
cap O
site O
of O
the O
human I-GENE
AFP I-GENE
gene I-GENE
shows O
a O
61 O
% O
similarity O
with O
the O
corresponding O
region O
of O
the O
mouse I-GENE
AFP I-GENE
gene I-GENE
. O

High O
ATP O
/ O
GTP O
ratios O
promoted O
initiation O
of O
RNA O
primer O
synthesis O
at O
3 O
'- O
dCTTT LASTCAP
sites O
, O
whereas O
low O
ATP O
/ O
GTP O
ratios O
promoted O
initiation O
at O
3 O
'- O
dCCC LASTCAP
sites O
. O

After O
hepatitis O
B O
vaccine O
immunization O
, O
serum O
antibody O
response O
was O
of O
primary O
type O
in O
33 O
cases O
with O
anti I-GENE
- I-GENE
HBs I-GENE
less O
than O
2 O
. O
1 O
S O
/ O
N O
( O
S O
/ O
N O
Ratio RARE
Unit RARE
) O
at O
T0 NUMERIC
, O
the O
anti I-GENE
- I-GENE
HBs I-GENE
positive O
rate O
was O
39 O
. O
4 O
%, O
84 O
. O
8 O
%, O
96 O
. O
7 O
% O
and O
96 O
. O
7 O
% O
in O
T1 O
, O
T2 O
, O
T0 NUMERIC
and O
T12 NUMERIC
respectively O
. O

The O
experimental O
design O
incorporated O
a O
multiple O
regression O
model O
, O
sequential O
treatments O
and O
a O
proportional RARE
end O
point O
( O
95 O
%) O
for O
protection O
time O
. O

Interspecific RARE
complementation O
tests O
showed O
that O
the O
P7 I-GENE
proteins I-GENE
are O
unable O
to O
complement O
P1 I-GENE
parA LASTCAP
or O
parB LASTCAP
mutants I-GENE
, O
and O
the O
P1 I-GENE
proteins I-GENE
fail O
to O
complement O
the O
P7 I-GENE
mutations I-GENE
. O

GN101 NUMERIC
, O
YC819 NUMERIC
- O
9 O
, O
and O
SB3 NUMERIC
. O

Analysis O
of O
the O
inferred RARE
1 I-GENE
, I-GENE
859 NUMERIC
- I-GENE
residue I-GENE
ama RARE
- I-GENE
1 I-GENE
product I-GENE
showed O
considerable O
identity O
with O
the O
largest O
subunit O
of O
RNAP I-GENE
II I-GENE
from O
other O
organisms O
, O
including O
the O
presence O
of O
a O
zinc O
finger O
motif O
near O
the O
amino O
terminus O
, O
and O
a O
carboxyl O
- O
terminal O
domain O
of O
42 O
tandemly O
reiterated RARE
heptamers RARE
with O
the O
consensus O
Tyr O
Ser O
Pro O
Thr O
Ser O
Pro O
Ser O
. O

Nodular RARE
involvement O
of O
the O
left O
lung O
and O
infiltration RARE
of O
the O
mucosa O
of O
the O
left O
lower O
lobe O
bronchus RARE
followed O
very O
gradually O
and O
a O
monoclonal O
gammopathy RARE
( O
IgA I-GENE
-- I-GENE
Type I-GENE
Kappa RARE
) O
was O
demonstrated O
. O

5 O
. O

None O
of O
the O
measured O
parameters O
( O
heart O
contents O
of O
neutral O
lipids O
, O
total O
phospholipids O
, O
phosphatidylcholine RARE
, O
phosphatidylethanolamine RARE
, O
diphosphatidylglycerol RARE
, O
sphingomyelin RARE
and O
fatty O
acid O
composition O
of O
each O
phospholipid O
class O
) O
appeared O
to O
be O
related O
with O
the O
grading RARE
of O
the O
lesions O
. O

Of O
165 O
women O
with O
non O
- O
malignant O
diagnoses RARE
26 O
( O
16 O
%) O
had O
CA I-GENE
125 I-GENE
levels O
in O
excess O
of O
35 O
U O
/ O
ml O
and O
8 O
( O
5 O
%) O
greater O
than O
65 O
U O
/ O
ml O
. O

We O
conclude O
that O
at O
steady O
state O
the O
timing O
of O
a O
light O
meal O
is O
unlikely O
to O
alter O
in O
any O
clinically O
important O
manner O
the O
pharmacokinetics O
of O
nifedipine O
released O
from O
' O
biphasic O
' O
tablets RARE
. O

The O
GALT ALLCAPS
- O
primed O
calves O
had O
increased O
serum O
IgG I-GENE
, O
lavage RARE
IgG I-GENE
and O
IgA I-GENE
and O
increased O
LNA ALLCAPS
titers RARE
in O
both O
lavage RARE
fluids O
and O
serum O
following O
the O
SC O
dose O
of O
killed O
bacteria O
. O

Recent O
investigations O
have O
shown O
that O
Grenz RARE
rays O
can O
suppress O
the O
allergic O
contact O
dermatitis O
reaction O
completely O
and O
that O
Langerhans RARE
cells O
, O
identified O
by O
OKT6 NUMERIC
antibodies I-GENE
and O
electron O
microscopy O
, O
disappear RARE
from O
the O
epidermis RARE
at O
the O
same O
time O
. O

The O
elements O
responsible O
for O
glucocorticoid O
stimulation O
of O
ADH I-GENE
gene I-GENE
transcription O
appear O
to O
reside O
outside O
of O
this O
region O
. O

1 O
. O

The O
present O
studies O
compare O
the O
biochemical O
characteristics O
, O
Kanagawa RARE
hemolysin RARE
reactions O
, O
and O
plasmid O
profiles O
of O
13 O
patient O
and O
221 NUMERIC
environmental O
isolates O
of O
the O
organism O
. O

High O
values O
of O
both O
retinol O
and O
beta O
- O
carotene RARE
were O
found O
in O
full O
fat O
cheeses RARE
and O
whipping RARE
cream O
: O
from O
179 NUMERIC
. O
0 O
( O
cheese RARE
, O
Edam RARE
- O
type O
) O
to O
318 NUMERIC
. O
7 O
micrograms O
/ O
100 O
g O
( O
whipping RARE
cream O
) O
and O
from O
86 O
. O
7 O
( O
cheese RARE
, O
Edam RARE
- O
type O
) O
to O
186 O
. O
5 O
micrograms O
/ O
100 O
g O
( O
whipping RARE
cream O
) O
for O
all O
- O
trans O
retinol O
and O
total O
beta O
- O
carotene RARE
, O
respectively O
. O

COGLAB ALLCAPS
includes O
measures O
of O
preattentional RARE
, O
attentional RARE
, O
conceptual RARE
, O
and O
psychomotor RARE
performance O
. O

These O
data O
locate RARE
the O
aniridia RARE
gene I-GENE
( O
AN2 NUMERIC
) O
and O
a O
recurrent O
T I-GENE
- I-GENE
cell I-GENE
leukemia I-GENE
breakpoint I-GENE
( O
TCL2 NUMERIC
) O
in O
the O
marker O
sequence O
, O
on O
opposite O
sides O
of O
MIC1 NUMERIC
. O

A O
fine O
- O
structure O
deletion O
map O
of O
human O
chromosome O
11p NUMERIC
: O
analysis O
of O
J1 NUMERIC
series O
hybrids O
. O

With O
respect O
to O
effective O
diffusivity RARE
of O
platelets O
( O
De RARE
) O
and O
the O
surface O
reactivity O
constant O
( O
K O
), O
less O
significant O
differences O
were O
found O
among O
artificial O
materials O
. O

The O
two O
most O
recent O
patients O
( O
35 O
and O
132 O
days O
) O
received O
only O
oral O
dipyridamole RARE
( O
75 O
mg O
X O
3 O
/ O
day O
) O
and O
aspirin O
( O
80 O
mg O
/ O
day O
) O
after O
the O
early O
recovery O
period O
( O
four O
- O
six O
days O
), O
resulting O
in O
normal O
prothrombin I-GENE
and O
partial O
thromboplastin I-GENE
times O
. O

Middle RARE
- O
latency O
auditory O
evoked O
potentials O
( O
MAEPs RARE
) O
were O
recorded O
in O
controls O
and O
patients O
with O
focal O
lesions O
in O
dorsolateral RARE
prefrontal RARE
cortex O
. O

Most O
of O
them O
were O
situated O
at O
Sylvius RARE
fissure RARE
( O
13 O
cases O
). O

Intracellular RARE
activity O
studies O
indicated O
that O
, O
at O
ten O
times O
MBC ALLCAPS
, O
only O
penicillin O
had O
any O
significant O
activity O
against O
intracellular O
staphylococci RARE
, O
reducing O
survival O
by O
28 O
%. O

Specifically O
, O
they O
were O
performed O
to O
determine O
whether O
detection O
of O
envelope O
phase O
disparity RARE
was O
consistent O
with O
processing O
within O
a O
single O
channel O
in O
which O
the O
AM O
tones RARE
were O
simply RARE
added O
. O

Gel O
retardation O
assays O
combined O
with O
DNase I-GENE
I I-GENE
footprinting O
and O
diethyl RARE
pyrocarbonate RARE
interference O
showed O
that O
a O
nuclear O
factor O
from O
differentiated O
C2 O
myotubes O
and O
BC3H1 NUMERIC
myocytes RARE
recognized O
a O
conserved O
A O
+ O
T O
- O
rich O
sequence O
within O
the O
peripheral O
activating O
region O
. O

Such O
transgenic O
plants O
should O
enable RARE
not O
only O
the O
mutational O
analysis O
of O
sequence O
elements O
within O
the O
replication O
origin O
region O
, O
but O
also O
the O
construction O
of O
a O
new O
generation O
of O
vectors O
for O
gene O
amplification O
in O
plants O
, O
based O
on O
a O
minimal O
virus O
replicon RARE
. O

Ventral RARE
rhinotomy RARE
is O
no O
more O
difficult O
than O
dorsal O
rhinotomy RARE
, O
has O
less O
patient O
morbidity O
and O
fewer O
postoperative O
complications O
, O
and O
is O
more O
cosmetically RARE
acceptable O
. O

Four O
full O
- O
thickness O
skin O
incisions RARE
were O
made O
in O
the O
back O
of O
10 O
female O
pigs O
that O
treated O
twice O
a O
day O
for O
14 O
days O
with O
2 O
ml O
of O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
300 O
ng O
/ O
ml O
) O
or O
2 O
ml O
of O
Ringer RARE
' O
s O
lactate O
solution O
in O
a O
single O
- O
blind O
, O
randomized O
fashion O
. O

During O
challenge O
, O
rebiopsy RARE
was O
done O
when O
reticulin RARE
antibodies I-GENE
turned O
positive O
( O
mean O
0 O
. O
6 O
years O
, O
range O
0 O
. O
2 O
- O
2 O
. O
0 O
) O
or O
at O
the O
end O
of O
the O
two O
year O
study O
. O

The O
effect O
of O
iron O
intake O
on O
59Fe NUMERIC
absorption O
throughout O
pregnancy O
, O
and O
on O
maternal O
and O
fetal O
Fe RARE
status O
towards O
the O
end O
of O
pregnancy O
, O
was O
investigated O
in O
rats O
. O

The O
deduced O
protein O
sequence O
is O
characterized O
by O
a O
putative O
16 O
- O
residue O
amino O
- O
terminal O
signal O
peptide O
that O
is O
cleaved O
, O
resulting O
in O
a O
239 O
- O
residue O
polypeptide O
. O

Analysis O
of O
the O
rate O
constants O
indicated O
that O
the O
isomerization RARE
rate O
k12 NUMERIC
was O
approximately O
equal O
to O
the O
apparent O
degradation O
rate O
of O
the O
delta O
3 O
ester O
kdeg RARE
, O
and O
slower O
than O
the O
hydrolysis O
rate O
of O
the O
delta O
2 O
ester O
k24 NUMERIC
. O

A O
protocol O
is O
elaborated RARE
for O
the O
preparation O
and O
characterization O
of O
a O
quality O
control O
material O
( O
QCM ALLCAPS
) O
containing O
intrinsic O
concentration O
of O
cadmium O
( O
Cd O
) O
( O
0 O
. O
8 O
microgram O
/ O
L O
) O
and O
lead O
( O
Pb RARE
) O
( O
13 O
. O
4 O
micrograms O
/ O
dL O
) O
from O
bovine O
blood O
and O
an O
elevated O
QCM ALLCAPS
containing O
Cd O
( O
5 O
. O
0 O
micrograms O
/ O
L O
), O
mercury RARE
( O
Hg O
) O
( O
11 O
. O
2 O
micrograms O
/ O
L O
), O
and O
Pb RARE
( O
34 O
. O
5 O
micrograms O
/ O
dL O
) O
from O
bovine O
blood O
spiked RARE
with O
aqueous O
spiking RARE
- O
solutions O
prepared O
with O
salts RARE
of O
Cd O
, O
Hg O
, O
and O
Pb RARE
. O

Reagent RARE
strips RARE
are O
frequently O
used O
in O
the O
practice O
of O
laboratory O
medicine O
as O
well O
as O
outside O
the O
professional RARE
laboratories O
. O

The O
lowest O
detectable O
concentration O
was O
1 O
. O
0 O
ng O
/ O
ml O
in O
the O
serum O
. O

Precipitating RARE
antibodies O
for O
Thermophilic RARE
actinomycetes RARE
and O
M O
. O
f O
. O
were O
negative O
. O

LON ALLCAPS
- O
72 O
( O
34 O
isolates O
), O
LON ALLCAPS
- O
73 O
( O
1 O
), O
LON ALLCAPS
- O
71 O
( O
2 O
) O
and O
LON ALLCAPS
- O
10 O
( O
2 O
) O
were O
found O
at O
altitudes RARE
around O
2000 O
m O
, O
3 O
of O
them O
in O
a O
single O
village RARE
. O

Animal RARE
experimental O
and O
clinical O
applications O
of O
plates O
, O
screws RARE
and O
spinal O
segmental O
replacement O
implants O
made O
of O
this O
composite O
material O
have O
shown O
good O
results O
so O
far O
. O

Significance O
of O
delta O
- O
aminolevulinic RARE
acid O
analysis O
in O
clinical O
tests O

No O
changes O
were O
evident O
in O
the O
FR O
- O
task O
performance O
of O
controls O
that O
received O
daily O
saline O
injections O
. O

The O
antigen I-GENE
- I-GENE
specific I-GENE
IgG4 NUMERIC
antibody I-GENE
seems O
to O
be O
an O
index O
in O
evaluating O
immunotherapy O
objectively RARE
. O

Although O
the O
fertility O
decline O
in O
the O
black O
population O
in O
the O
Mississippi RARE
Delta O
between O
the O
late O
1870 NUMERIC
' O
s O
and O
early O
1930 NUMERIC
' O
s O
closely O
paralleled RARE
that O
of O
the O
national O
black O
population O
, O
it O
rose O
much O
more O
dramatically O
in O
the O
1940 NUMERIC
' O
s O
and O
1950 NUMERIC
' O
s O
to O
almost O
1880 NUMERIC
levels O
. O

According O
to O
their O
staining O
affinity O
for O
anti I-GENE
- I-GENE
T I-GENE
antibodies I-GENE
, O
the O
glandular RARE
tissue O
cells O
were O
classified O
as O
T I-GENE
-, O
T I-GENE
+, O
T I-GENE
++, RARE
and O
T I-GENE
and O
the O
annual O
changes O
in O
the O
numbers O
of O
these O
cell O
populations O
, O
as O
well O
as O
in O
the O
volume O
occupied O
by O
the O
glandular RARE
tissue O
, O
were O
calculated O
. O

Ampicillin RARE
( O
AMP O
) O
alone O
or O
with O
an O
aminoglycoside RARE
( O
AMI O
) O
was O
the O
treatment O
in O
9 O
and O
16 O
cases O
, O
respectively O
. O

Alkoxymetgyl RARE
- O
3 O
, O
4 O
- O
dimethylpyridinium RARE
chlorides RARE
were O
synthetized RARE
by O
reacting RARE
3 O
, O
4 O
- O
dimethylpyridine RARE
with O
chloromethyl RARE
alkyl RARE
ethers RARE
, O
while O
1 O
- O
ethyloxymethyl RARE
- O
3 O
- O
alkylthiomethylimidazolium RARE
chlorides RARE
were O
obtained O
in O
reactions O
of O
1 O
- O
ethyloxymethylimidazol RARE
with O
chloromethyl RARE
alkyl RARE
sulfides RARE
. O

We O
investigated O
the O
incidence O
of O
congenital O
color O
deficiency O
among O
Koreans RARE
by O
the O
use O
of O
H O
- O
R O
- O
R O
pseudoisochromatic RARE
plates O
. O

Eighty RARE
patients O
presenting O
to O
HGGM ALLCAPS
with O
non O
- O
Hodgkin O
' O
s O
lymphomas O
between O
1962 NUMERIC
and O
1986 O
, O
were O
reviewed O
. O

The O
relation O
between O
VE O
/ O
VO2 O
and O
Q O
/ O
VO2 O
showed O
a O
significant O
negative O
correlation O
( O
r O
= O
- O
0 O
. O
93 O
, O
p O
less O
than O
0 O
. O
01 O
). O

The O
differential O
diagnosis O
of O
both O
affections RARE
is O
based O
on O
the O
clinical O
course O
, O
sialography RARE
and O
CT O
examination O
which O
along O
with O
modern O
ATB ALLCAPS
treatment O
significantly O
modify O
hitherto O
used O
surgical O
therapy O
. O

Retrograde RARE
filling O
consists O
in O
sealing RARE
endodontics RARE
system O
directly O
at O
the O
apical RARE
zone O
after O
surgical O
approach O
. O

Collaborative RARE
study O
of O
Japanese O
Pharmacopoeia RARE
Heparin O
Sodium O
Reference RARE
Standard RARE

Serological RARE
studies O
at O
the O
early O
relapse O
stage O
of O
this O
disease O
showed O
increased O
serum I-GENE
ANA ALLCAPS
, O
IgA I-GENE
and O
IgM I-GENE
level O
with O
normal O
IgG I-GENE
and O
decrease O
of O
C3 I-GENE
and O
C4 I-GENE
. O

The O
maximum O
stress O
due O
to O
the O
hygroscopic RARE
examination O
of O
the O
composite O
was O
0 O
. O
74 O
kg O
/ O
mm2 O
at O
equilibrium O
of O
the O
water O
absorbed O
of O
the O
composite O
. O

Ischemic O
heart O
disease O
evaluated O
by O
exercise O
stress O
thallium O
- O
201 O
myocardial O
scintigraphy O
: O
a O
comparison O
of O
SPECT O
and O
bull RARE
' O
s O
eye O
display O

Sequence O
analysis O
of O
the O
47 I-GENE
- I-GENE
kilodalton I-GENE
major I-GENE
integral I-GENE
membrane I-GENE
immunogen RARE
of I-GENE
Treponema RARE
pallidum RARE
. O

Potential RARE
consensus O
sequences O
for O
early O
and O
late O
regulatory O
elements O
were O
identified O
. O

An O
FP ALLCAPS
mutant I-GENE
, O
AcFP875 NUMERIC
- I-GENE
2 I-GENE
, O
had O
a O
1 O
. O
6 O
- O
kbp O
insertion O
of O
S O
. O
frugiperda RARE
DNA O
near O
the O
5 O
' O
end O
of O
these O
transcripts O
which O
by O
S1 I-GENE
analysis O
were O
shown O
to O
initiate O
within O
the O
host O
cell O
sequence O
. O

Construction RARE
of O
a O
RIP1 NUMERIC
deletion O
strain O
and O
isolation O
of O
temperature O
- O
sensitive O
mutants O
. O

These O
data O
suggest O
that O
hypocitraturia RARE
in O
type O
I O
renal O
tubular O
acidosis O
may O
be O
due O
to O
a O
defect O
in O
proximal O
tubule RARE
function O
. O

Concomitant RARE
chronic O
lymphocytic RARE
leukemia O
, O
acute O
myeloid O
leukemia O
, O
and O
thrombosis O
with O
protein I-GENE
C I-GENE
deficiency O
. O

Vivid RARE
visual O
hallucinations RARE
without O
other O
psychopathology RARE
have O
been O
reported O
for O
several O
hundred O
years O
. O

In O
the O
whole O
group O
, O
basal O
GH I-GENE
and O
somatomedin RARE
- I-GENE
C I-GENE
levels O
decreased O
from O
a O
mean O
(+/- O
standard O
error O
of O
the O
mean O
) O
of O
52 O
. O
3 O
+/- O
12 O
. O
7 O
to O
11 O
. O
1 O
+/- O
6 O
. O
3 O
ng O
/ O
ml O
and O
from O
7 O
. O
6 O
+/- O
0 O
. O
7 O
to O
2 O
. O
5 O
+/- O
0 O
. O
5 O
U O
/ O
ml O
, O
respectively O
. O

Application RARE
of O
different O
criteria O
of O
cure O
revealed O
that O
19 O
patients O
( O
66 O
%) O
had O
basal O
GH I-GENE
levels O
below O
5 O
ng O
/ O
ml O
, O
17 O
patients O
( O
59 O
%) O
had O
normal O
somatomedin RARE
- I-GENE
C I-GENE
values O
, O
16 O
patients O
( O
55 O
%) O
had O
complete O
GH I-GENE
suppression O
( O
less O
than O
1 O
ng O
/ O
ml O
) O
during O
OGTT ALLCAPS
, O
and O
13 O
patients O
( O
45 O
%) O
met O
the O
above O
- O
mentioned O
criteria O
with O
disappearance O
of O
the O
paradoxical RARE
GH I-GENE
response O
to O
TRH I-GENE
/ O
GnRH I-GENE
test O
. O

It O
suggests O
a O
sequence O
of O
surgical O
planning O
that O
can O
prevent O
them O
and O
also O
offers O
ways O
of O
dealing RARE
with O
the O
problems O
should O
they O
occur O
. O

In O
Rat O
- O
1a O
cells O
the O
expression O
of O
human I-GENE
c I-GENE
- I-GENE
jun I-GENE
mRNA I-GENE
was O
associated O
with O
the O
ability O
to O
clone O
in O
soft O
agarose O
and O
form O
tumors O
in O
nude O
mice O
. O

Furthermore O
, O
formation O
of O
foci RARE
of O
transformed O
RECs RARE
by O
the O
c I-GENE
- I-GENE
jun I-GENE
/ O
ras I-GENE
combination O
was O
augmented O
3 O
- O
fold O
by O
the O
tumor O
promoter O
phorbol O
12 O
- O
tetradecanoate RARE
13 O
- O
acetate O
. O

Platelet I-GENE
activating I-GENE
factor I-GENE
was O
given O
in O
six O
doses O
at O
15 O
minute O
intervals O
and O
airway O
response O
measured O
as O
change O
in O
partial O
expiratory O
flow O
at O
30 O
% O
of O
vital O
capacity O
( O
Vp30 NUMERIC
). O

There O
was O
no O
significant O
correlation O
between O
baseline O
PC40 NUMERIC
methacholine RARE
and O
the O
maximal O
fall O
in O
Vp30 NUMERIC
after O
either O
the O
first O
( O
12 O
micrograms O
) O
or O
the O
second O
dose O
( O
24 O
micrograms O
) O
of O
platelet I-GENE
activating I-GENE
factor I-GENE
. O

Both O
BG ALLCAPS
and O
IRI ALLCAPS
concentrations O
during O
the O
OGTT ALLCAPS
were O
the O
lowest O
in O
body O
builders RARE
, O
medium O
in O
controls O
, O
and O
the O
highest O
in O
obese O
men O
. O

Postcoital RARE
contraception RARE
: O
a O
family O
planning O
study O
. O

A O
0 O
. O
5 O
rating O
was O
intended RARE
to O
characterize O
subjects O
in O
whom O
mild O
cognitive O
impairment O
due O
to O
senile O
dementia O
of O
the O
Alzheimer O
type O
was O
suspected O
but O
was O
insufficient O
in O
degree O
to O
warrant RARE
a O
diagnosis O
of O
definite O
dementia O
. O

An O
implant O
may O
release O
a O
drug O
either O
by O
diffusion O
concurrent O
with O
dissolution O
of O
the O
polymeric RARE
implant O
material O
without O
depolymerization RARE
( O
Type O
A O
) O
or O
by O
bioerosion RARE
involving O
depolymerization RARE
( O
Type O
B O
). O

Although O
it O
is O
well O
known O
that O
calcium O
channel O
blockers O
can O
influence O
contraction O
of O
vascular O
smooth O
muscle O
, O
there O
is O
less O
knowledge O
on O
its O
effect O
on O
excitation RARE
contraction O
coupling O
in O
the O
endocrine O
glands O
and O
more O
specifically O
on O
insulin I-GENE
and O
glucagon I-GENE
release O
. O

Many O
studies O
have O
pointed RARE
out O
the O
possibility O
of O
" O
masked RARE
" O
organic O
factors O
in O
erectile RARE
impotence RARE
, O
detectable O
only O
by O
means O
of O
laboratory O
investigations O
: O
mild O
hypogonadism RARE
, O
hyperprolactinemia RARE
, O
occlusions RARE
selectively O
located O
at O
the O
site O
of O
the O
sexual O
arteries O
, O
venous O
incompetence RARE
, O
subclinical O
neuropathies RARE
. O

The O
site O
- O
specific O
DNA O
inversion O
system O
Cin RARE
encoded O
by O
the O
bacteriophage O
P1 O
consists O
of O
a O
recombinase RARE
, O
two O
inverted O
crossing RARE
- O
over O
sites O
and O
a O
recombinational RARE
enhancer O
. O

The O
terminator O
region O
supported O
termination O
of O
transcripts O
initiated O
by O
RNA I-GENE
polymerase I-GENE
I I-GENE
in O
vivo O
. O

US O
- O
Doppler O
has O
recently O
gained RARE
attention O
as O
a O
noninvasive RARE
method O
for O
the O
functional O
evaluation O
of O
arteriovenous RARE
fistulas RARE
( O
FAV ALLCAPS
). O

Doppler O
echo O
in O
evaluating O
arteriovenous RARE
fistulae RARE
for O
dialysis O

Improved RARE
cosmesis RARE
, O
extension O
of O
the O
scope RARE
of O
the O
problems O
that O
can O
be O
addressed O
with O
this O
repair O
( O
including O
treatment O
of O
a O
distal O
urethrocutaneous RARE
fistula RARE
) O
and O
the O
ease RARE
with O
which O
the O
Arap RARE
procedure O
can O
be O
performed O
are O
the O
advantages O
that O
this O
operation O
has O
over O
other O
1 O
- O
stage O
distal O
hypospadias RARE
repairs RARE
. O

Following O
the O
patients O
during O
a O
course O
of O
therapy O
with O
a O
selective O
vasodilator O
calcium O
antagonist O
, O
the O
beta O
- O
adrenergic O
reflex O
vasodilation O
became O
substantially O
attenuated O
but O
was O
preserved RARE
during O
a O
placebo O
course O
of O
therapy O
. O

The O
galactose I-GENE
transporter I-GENE
shows O
both O
sequence O
and O
structural O
homology O
with O
a O
superfamily O
of O
sugar I-GENE
transporters I-GENE
which O
includes O
the O
human I-GENE
HepG2 I-GENE
- I-GENE
erythrocyte I-GENE
and I-GENE
fetal I-GENE
muscle I-GENE
glucose I-GENE
transporters I-GENE
, O
the O
rat I-GENE
brain I-GENE
and I-GENE
liver I-GENE
glucose I-GENE
transporters I-GENE
, O
the O
Escherichia I-GENE
coli I-GENE
xylose RARE
and I-GENE
arabinose RARE
permeases RARE
, O
and O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
glucose I-GENE
, I-GENE
maltose RARE
, I-GENE
and I-GENE
galactose I-GENE
transporters I-GENE
. O

Of O
110 O
previously O
untreated O
patients O
who O
had O
entered RARE
the O
study O
of O
protocol O
TCL821 NUMERIC
, O
96 O
were O
evaluable O
. O

There O
were O
3 O
/ O
32 O
( O
9 O
. O
4 O
per O
cent O
) O
adverse O
reactions O
( O
ADRs RARE
), O
and O
one O
case O
each O
of O
nausea RARE
, O
dizziness RARE
and O
increased O
menstrual O
flow O
. O

More O
mRNA O
corresponding O
to O
nagB LASTCAP
and O
nagA LASTCAP
is O
detected O
than O
that O
corresponding O
to O
the O
distal O
genes O
, O
nagC LASTCAP
and O
nagD LASTCAP
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
( O
TNF I-GENE
) O
is O
reported O
to O
cause O
a O
shock O
syndrome O
similar O
to O
that O
produced O
by O
endotoxin O
( O
LPS O
). O

The O
calcium O
requirement O
for O
hypothermic RARE
storage O
of O
the O
cardiac O
explant RARE
. O

The O
seventh RARE
cysteine O
residue O
of O
CTSE ALLCAPS
is O
located O
within O
the O
activation O
peptide O
region O
of O
the O
proenzyme RARE
. O

The O
p34 NUMERIC
. I-GENE
8 I-GENE
gene I-GENE
has O
a O
strong O
codon O
usage O
bias RARE
which O
is O
strikingly O
different O
from O
that O
of O
the O
polyhedrin RARE
gene I-GENE
. O

Of O
the O
single O
- O
stranded O
DNA O
transformants O
, O
65 O
% O
resulted O
from O
replacement O
of O
the O
resident RARE
met2 NUMERIC
mutation I-GENE
by O
the O
exogenous O
wild O
- O
type O
allele O
. O

The O
results O
strongly O
support O
the O
notion O
that O
the O
OBF1 NUMERIC
- I-GENE
binding I-GENE
sites I-GENE
and O
the O
OBF1 NUMERIC
protein I-GENE
are O
important O
for O
normal O
ARS O
function O
as O
an O
origin O
of O
replication O
. O

On O
the O
basis O
of O
S1 I-GENE
nuclease I-GENE
protection O
analysis O
of O
RNA O
preparations O
from O
several O
mouse O
tissues O
, O
both O
dhfr RARE
and O
divergent O
genes O
showed O
similar O
levels O
of O
expression O
but O
did O
show O
some O
specificity O
in O
start O
site O
utilization O
. O

Four O
out O
of O
10 O
patients O
showed O
clinical O
improvement O
according O
to O
Ritchie RARE
- O
Index RARE
, O
pain O
score O
, O
ESR ALLCAPS
and O
CRP I-GENE
. O

62 O
: O
2491 NUMERIC
- O
2499 NUMERIC
, O
1987 O
). O

With O
both O
wild O
- O
type O
and O
the O
mutant O
enzymes O
, O
ATP O
activates O
both O
[ O
14C O
] O
Asp O
in O
equilibrium O
N O
- O
carbamyl RARE
- O
L O
- O
aspartate O
( O
C O
- O
Asp O
) O
and O
the O
[ O
32P O
] O
carbamyl RARE
phosphate O
( O
C O
- O
P O
) O
in O
equilibrium O
Pi RARE
exchanges RARE
. O

Survival RARE
rates O
for O
the O
original O
treatment O
group O
were O
84 O
. O
5 O
% O
and O
57 O
. O
6 O
% O
at O
12 O
and O
21 O
months O
, O
respectively O
; O
for O
the O
delayed O
treatment O
group O
, O
78 O
. O
8 O
% O
and O
64 O
. O
6 O
% O
at O
12 O
and O
21 O
months O
, O
respectively O
, O
and O
78 O
. O
8 O
% O
and O
47 O
. O
5 O
% O
at O
12 O
and O
21 O
months O
, O
respectively O
, O
for O
77 O
subjects O
with O
AIDS O
and O
93 O
. O
0 O
% O
and O
71 O
. O
8 O
%, O
respectively O
, O
for O
50 O
subjects O
with O
AIDS O
- O
related O
complex O
in O
the O
original O
treatment O
group O
. O

Mapping O
results O
suggested O
that O
the O
complementation O
group O
identified O
by O
these O
mutants O
is O
allelic O
to O
the O
ag RARE
alpha I-GENE
1 I-GENE
mutation O
identified O
previously O
. O

The O
products O
of O
genes O
ura10 NUMERIC
and O
ura3 NUMERIC
are O
proposed O
to O
participate O
in O
the O
channeling RARE
of O
orotidine RARE
monophosphate O
. O

After O
the O
application O
of O
RS O
86 O
, O
REM O
latency O
was O
shortened O
in O
all O
groups O
under O
investigation O
. O

Hybridization O
analysis O
showed O
that O
the O
size O
of O
the O
mRNA O
is O
about O
1 O
. O
4 O
kilobases O
. O

Agranulocytosis RARE
treatment O
with O
rhGM LASTCAP
- I-GENE
CSF I-GENE

The O
R I-GENE
. I-GENE
meliloti RARE
nifH LASTCAP
promoter I-GENE
but O
not O
the O
K I-GENE
. I-GENE
pneumoniae I-GENE
nifH LASTCAP
promoter I-GENE
showed O
sigma I-GENE
54 I-GENE
- O
dependent O
methylation O
protection O
of O
guanine O
residues O
at O
- O
14 O
, O
- O
25 O
and O
- O
26 O
, O
the O
most O
conserved O
nucleotides O
characteristic O
of O
sigma I-GENE
54 I-GENE
- I-GENE
dependent I-GENE
promoters I-GENE
. O

Major RARE
clinical O
symptoms O
of O
the O
disease O
were O
defined O
in O
this O
group O
of O
patients O
. O

Recently O
, O
an O
alternatively O
spliced O
form O
of O
c I-GENE
- I-GENE
myb I-GENE
- I-GENE
encoded I-GENE
mRNA I-GENE
has O
been O
identified O
in O
murine O
cells O
containing O
either O
normal O
or O
rearranged O
c I-GENE
- I-GENE
myb I-GENE
genes I-GENE
. O

Routine RARE
clinical O
analysis O
revealed O
lower O
hematocrit O
and O
hemoglobin I-GENE
, O
and O
elevated O
BUN ALLCAPS
and O
alkaline I-GENE
phosphatase I-GENE
in O
the O
treated O
group O
. O

To O
assess O
the O
health O
significance O
of O
the O
early O
renal O
changes O
after O
chronic O
exposure O
to O
cadmium O
, O
23 O
workers O
removed O
from O
exposure O
because O
of O
the O
discovery O
of O
an O
increased O
urinary O
excretion O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
or O
retinol I-GENE
binding I-GENE
protein I-GENE
, O
or O
both O
, O
have O
been O
examined O
once O
a O
year O
for O
five O
years O
. O

In O
order O
to O
study O
the O
structural O
and O
functional O
organization O
of O
the O
eukaryotic O
nucleolus RARE
, O
we O
have O
started O
to O
isolate O
and O
characterize O
nucleolar O
components O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

A O
transcription O
factor O
exclusion O
assay O
was O
used O
to O
show O
that O
the O
PCF1 NUMERIC
mutation I-GENE
affects O
two O
distinct O
stages O
in O
transcription O
: O
one O
prior O
to O
and O
one O
after O
stable O
complex O
formation O
; O
and O
that O
these O
effects O
are O
mediated O
by O
a O
component O
of O
the O
stable O
complex O
. O

Psychiatry RARE
and O
the O
skin O
. O

These O
adverse O
effects O
usually O
abate RARE
with O
time O
. O

The O
cytosolic O
glutathione I-GENE
S I-GENE
- I-GENE
transferases RARE
( O
GSTs RARE
, O
EC I-GENE
2 I-GENE
. I-GENE
5 I-GENE
. I-GENE
1 I-GENE
. I-GENE
18 I-GENE
) O
are O
a O
superfamily O
of O
dimeric O
isoenzymes O
which O
catalyze RARE
the O
conjugation O
of O
electrophilic RARE
substrates O
with O
glutathione O
. O

Furthermore O
, O
the O
3 O
'- O
untranslated O
regions O
of O
pmGT10 NUMERIC
display O
a O
marked O
degree O
of O
homology O
to O
the O
3 O
' O
region O
of O
the O
rat I-GENE
Yb1 NUMERIC
gene I-GENE
, O
while O
this O
region O
of O
pmGT2 NUMERIC
displays O
marked O
homology O
to O
the O
corresponding O
region O
of O
the O
rat I-GENE
Yb2 NUMERIC
gene I-GENE
. O

Model RARE
IV O
: O
primary O
abutments RARE
with O
the O
lateral O
incisor RARE
and O
the O
second O
molar RARE
as O
secondary O
abutments RARE
. O

The O
incidence O
of O
fetal O
breathing O
movements O
( O
06 O
. O
00 O
- O
10 O
. O
00 O
h O
) O
decreased O
with O
increasing O
gestational O
age O
while O
fetal O
arterial O
concentrations O
of O
plasma O
PGE ALLCAPS
increased O
significantly O
over O
the O
same O
period O
of O
gestation O
. O

During O
the O
first O
3 O
min O
of O
recovery O
, O
plasma O
potassium O
fell O
rapidly O
in O
spite RARE
of O
nearly O
unchanged O
blood O
acidosis O
and O
significantly O
decreasing O
bicarbonate RARE
concentration O
. O

The O
present O
data O
also O
suggest O
that O
when O
compared O
to O
the O
systemic O
vascular O
bed RARE
, O
the O
pulmonary O
vascular O
bed RARE
is O
less O
responsive O
to O
bolus O
administration O
of O
ET I-GENE
- I-GENE
1 I-GENE
. O

In O
comparison O
with O
normal O
pregnant O
women O
and O
normal O
non O
- O
pregnant O
women O
, O
women O
with O
PIH ALLCAPS
showed O
an O
increase O
in O
heart O
rate O
, O
suggesting O
an O
increased O
peripheral O
sympathetic O
tone O
, O
and O
an O
initial O
derangement RARE
in O
renal O
function O
as O
shown O
by O
the O
increase O
in O
serum O
uric O
acid O
and O
reduction O
in O
sodium O
excretion O
and O
total O
and O
fractional O
calcium O
excretion O
at O
any O
given O
level O
of O
sodium O
excretion O
. O

We O
have O
examined O
the O
role O
of O
two O
recombination O
- O
and O
repair O
- O
defective O
mutations O
, O
rad1 NUMERIC
and O
rad52 NUMERIC
, O
on O
direct O
repeat O
recombination O
in O
transcriptionally O
active O
and O
inactive O
sequences O
. O

The O
encoded O
protein O
has O
a O
leader O
sequence O
of O
27 O
amino O
acids O
. O

On O
the O
other O
hand O
, O
knowledge O
of O
the O
epidemiology RARE
of O
Parkinson O
' O
s O
disease O
is O
necessary O
in O
creating RARE
etiological RARE
hypotheses RARE
, O
since O
only O
hypotheses RARE
consistent O
with O
the O
epidemiological O
profile O
deserve RARE
careful RARE
testing O
. O

The O
stereoselectivity RARE
of O
drug O
action O
. O

Scotchbond RARE
2 O
showed O
the O
least O
dye O
penetration O
but O
not O
statistically O
less O
than O
the O
XR ALLCAPS
bond O
/ O
Silus RARE
Plus RARE
combination O
. O

A O
combination O
of O
cisplatin O
and O
5 O
- O
fluorouracil O
, O
both O
administered O
4 O
days O
continuously O
as O
infusion O
, O
was O
assessed O
in O
advanced O
head O
and O
neck O
cancer O
. O

Metformin RARE
plasma O
concentrations O
remained O
unchanged O
except O
for O
patients O
transferred O
from O
1 O
. O
5 O
to O
2 O
. O
0 O
g O
daily O
to O
850 NUMERIC
mg O
twice O
daily O
; O
in O
these O
patients O
plasma O
concentrations O
increased O
from O
1 O
. O
83 O
+/- O
0 O
. O
87 O
to O
2 O
. O
50 O
+/- O
0 O
. O
89 O
micrograms O
/ O
l O
( O
p O
less O
than O
0 O
. O
01 O
). O

Diagnosis O
of O
primary O
sclerosing RARE
cholangitis RARE
in O
a O
blood O
donor O
with O
elevated O
serum I-GENE
alanine I-GENE
aminotransferase I-GENE
. O

When O
statistically O
analyzed O
in O
various O
subgroupings RARE
, O
the O
obtained O
average O
sedimentation O
coefficients O
and O
polydispersity RARE
profiles O
supported O
the O
following O
conclusions O
: O
( O
a O
) O
loss O
of O
proteoglycan O
aggregation O
and O
sedimentability RARE
is O
confirmed O
to O
be O
a O
primary O
sign O
of O
cartilage O
matrix O
degradation O
; O
( O
b O
) O
higher O
S O
values O
for O
proteoglycans RARE
of O
the O
high O
weight O
( O
HW ALLCAPS
)- O
bearing O
areas O
and O
lower O
values O
for O
those O
of O
the O
low O
weight O
( O
LW ALLCAPS
)- O
bearing O
areas O
were O
a O
typical O
finding O
in O
normal O
cartilage O
samples O
; O
( O
c O
) O
inversion O
of O
this O
pattern O
was O
indicative O
of O
matrix O
degradation O
, O
suggesting O
that O
the O
HW ALLCAPS
regions O
are O
more O
affected O
than O
the O
LW ALLCAPS
- O
bearing O
areas O
; O
( O
d O
) O
the O
average O
S O
value O
distribution O
across O
cartilage O
thickness O
tended O
to O
resemble RARE
the O
corresponding O
proteoglycan O
content O
versus O
distance O
from O
articular RARE
surface O
; O
and O
( O
e O
) O
the O
deepest RARE
cartilage O
layer O
had O
, O
in O
most O
cases O
, O
the O
smallest O
amount O
of O
aggregates O
while O
the O
highest O
average O
sedimentability RARE
was O
observed O
at O
the O
middle O
zone O
of O
the O
normal O
samples O
. O

A O
significant O
relationship O
existed O
during O
the O
evolution O
of O
the O
disease O
between O
CRS O
/ O
BW ALLCAPS
and O
gas O
exchange O
parameters O
( O
FIO2 NUMERIC
and O
a O
/ O
AO2 NUMERIC
ratio O
) O
( O
P O
less O
than O
0 O
. O
01 O
), O
but O
gas O
exchange O
improved O
earlier O
than O
lung O
mechanics RARE
. O

End RARE
points O
measured O
were O
perioperative RARE
( O
30 O
- O
day O
) O
myocardial O
infarction O
( O
MI O
) O
rate O
and O
death O
. O

The O
predicted O
molecular O
weight O
of O
the O
polyprotein RARE
encoded O
by O
ORF1 O
is O
33 O
kilodaltons RARE
( O
kDa O
). O

Thus O
RV O
O2 O
demand O
fell O
when O
RC ALLCAPS
O2 O
supply O
was O
reduced O
, O
although O
a O
flow O
reserve O
was O
available O
. O

An O
alternative O
method O
of O
UKM ALLCAPS
is O
proposed O
based O
on O
collecting RARE
a O
small O
fraction O
of O
spent RARE
dialysate RARE
flow O
for O
3 O
consecutive O
dialyses RARE
. O

Liquid RARE
chromatography O
with O
amperometric RARE
detection O
( O
LC ALLCAPS
/ O
AD O
) O
is O
used O
to O
determine O
fluazifop RARE
acid O
produced O
from O
the O
metabolism O
or O
base O
hydrolysis O
of O
fluazifop RARE
- O
butyl RARE
in O
soybeans RARE
and O
soybean O
oil O
. O

The O
dichloromethane RARE
is O
removed O
, O
mobile O
phase O
solvent O
is O
added O
, O
and O
aliquots RARE
are O
injected O
onto O
a O
PRP ALLCAPS
- O
1 O
liquid O
chromatographic O
column O
; O
fluazifop RARE
acid O
is O
separated O
from O
coextracted RARE
compounds O
and O
detected O
at O
an O
applied O
potential O
of O
+ O
1 O
. O
25 O
V O
, O
using O
an O
amperometric RARE
electrochemical RARE
detector O
in O
the O
oxidation O
mode O
. O

Primer O
extension O
experiments O
indicated O
that O
the O
transcription O
initiation O
site O
mapped O
to O
a O
position O
on O
gene I-GENE
IV I-GENE
that O
was O
analogous O
to O
that O
reported O
for O
the O
structurally O
similar O
P I-GENE
- I-GENE
450e NUMERIC
gene I-GENE
. O

Significantly O
, O
the O
polymerase O
chain O
reaction O
results O
demonstrated O
that O
gene I-GENE
IV I-GENE
transcripts I-GENE
were O
associated O
with O
hepatic O
polysome RARE
fractions O
, O
indicating O
their O
active O
utilization O
in O
this O
tissue O
. O

Validation RARE
of O
the O
survey O
of O
work O
styles RARE
: O
a O
profile O
measure O
of O
the O
type O
A O
behaviour O
pattern O
. O

Only O
one O
ADR O
was O
related O
definitely RARE
to O
ciprofloxacin RARE
therapy O
. O

HIV O
infectiousness RARE
and O
the O
AIDS O
epidemic O
. O

From O
day O
30 O
after O
turnout RARE
, O
the O
PFB ALLCAPS
- O
group O
had O
significantly O
lower O
serum I-GENE
pepsinogen RARE
levels O
, O
which O
reflects RARE
the O
low O
degree O
of O
abomasal RARE
damage O
in O
these O
animals O
. O

The O
corresponding O
inhibition O
of O
acid I-GENE
phosphatase I-GENE
activity O
in O
control O
male O
and O
female O
guinea O
pigs O
was O
15 O
. O
91 O
% O
and O
20 O
. O
33 O
% O
respectively O
. O

Its O
clinical O
and O
histopathologic RARE
characteristics O
. O

Normocapnic RARE
( O
PACO2 NUMERIC
= O
40 O
mm O
Hg O
) O
ventilatory RARE
drive O
increased O
significantly O
( O
p O
less O
than O
0 O
. O
05 O
) O
in O
six O
subjects O
( O
Type O
1 O
response O
) O
and O
decreased O
substantially O
in O
the O
others O
( O
Type O
2 O
response O
); O
with O
hypercapnia O
, O
the O
changes O
in O
drive O
were O
attenuated O
in O
both O
groups O
. O

Fundus RARE
changes O
in O
( O
type O
II O
) O
mesangiocapillary RARE
glomerulonephritis O
simulating RARE
drusen RARE
: O
a O
histopathological O
report O
. O

Chronic O
dose O
effects O
of O
methyl O
parathion RARE
on O
nuthatches RARE
: O
cholinesterase I-GENE
and O
ptilochronology RARE
. O

The O
titer O
of O
anti I-GENE
HSV I-GENE
type I-GENE
1 I-GENE
and O
anti I-GENE
HSV I-GENE
type I-GENE
2 I-GENE
antibodies I-GENE
in O
the O
mothers O
' O
and O
cord O
blood O
was O
determined O
and O
compared O
. O

Kidney RARE
weight O
and O
kidney O
- O
to O
- O
body O
weight O
ratio O
were O
significantly O
elevated O
at O
the O
highest O
dose O
level O
after O
10 O
weeks O
and O
at O
the O
two O
higher O
dose O
levels O
after O
15 O
weeks O
of O
exposure O
. O

Allelic RARE
variation O
in O
HLA I-GENE
- I-GENE
B I-GENE
and O
HLA I-GENE
- I-GENE
C I-GENE
sequences I-GENE
and O
the O
evolution O
of O
the O
HLA I-GENE
- I-GENE
B I-GENE
alleles I-GENE
. O

A O
method O
for O
determining O
optimal O
development O
conditions O
by O
summary O
oxygen O
consumption O

Men RARE
were O
more O
positive O
about O
their O
physical O
fitness O
than O
women O
. O

Handgrip RARE
dynamometry RARE
was O
also O
carried O
out O
in O
249 NUMERIC
of O
the O
patients O
. O

In O
cerebrospinal O
fluid O
, O
an O
ADA ALLCAPS
catalytic O
concentration O
above O
0 O
. O
15 O
mu O
kat RARE
/ O
L O
strongly O
suggests O
tuberculous O
meningitis O
in O
patients O
older O
than O
7 O
years O
( O
sensitivity O
1 O
. O
00 O
, O
specificity O
0 O
. O
99 O
and O
efficiency O
0 O
. O
99 O
). O

NERVTRACK ALLCAPS
contains O
4000 NUMERIC
anatomical O
data O
items RARE
arranged O
in O
a O
tree RARE
- O
like O
manner O
reflecting O
structural O
and O
functional O
relationships O
. O

Swim RARE
- O
over O
: O
an O
alternative O
method O
for O
harvesting RARE
motile RARE
spermatozoa O
. O

Perfusion RARE
washout O
: O
increasing O
a O
microvascular O
free O
flap O
tolerance O
to O
ischemia O
. O

Similarly O
, O
the O
sequence O
of O
the O
U2 I-GENE
RNA I-GENE
region I-GENE
shown O
to O
be O
involved O
in O
pre O
- O
mRNA O
branchpoint O
recognition O
in O
yeast O
, O
and O
exactly RARE
conserved O
in O
metazoan I-GENE
U2 I-GENE
RNAs I-GENE
, O
was O
totally RARE
divergent O
in O
trypanosomes RARE
. O

It O
is O
striking O
that O
the O
active O
CHO O
spacer O
promoter O
violated RARE
the O
otherwise O
universal RARE
rule RARE
that O
metazoan I-GENE
RNA I-GENE
polymerase I-GENE
I I-GENE
promoters I-GENE
all O
have O
a O
G O
residue O
at O
position O
- O
16 O
. O

A O
raised O
amplitude O
of O
the O
aggregation O
of O
plates O
and O
a O
decrease O
in O
the O
threshold O
of O
their O
sensitivity O
to O
ADP O
were O
established O
in O
the O
persons O
with O
types O
IIa RARE
and O
IIb RARE
HLP ALLCAPS
and O
in O
CHD ALLCAPS
without O
HLP ALLCAPS
. O

Significant O
intergroup RARE
differences O
are O
highlighted RARE
for O
both O
selected O
dentoskeletal RARE
and O
soft O
tissue O
profile O
variables O
. O

The O
author O
provides O
a O
rationale RARE
for O
an O
interactional RARE
view O
and O
presents O
a O
case O
in O
which O
post O
- O
surgical O
hiccups RARE
were O
successfully O
treated O
, O
using O
principles RARE
developed O
by O
the O
Mental RARE
Research O
Institute O
. O

The O
relative O
toxicity O
of O
nickel O
oxide O
( O
NiO LASTCAP
), O
nickel O
sulfate O
hexahydrate RARE
( O
NiSO4 NUMERIC
. O
6H2O NUMERIC
), O
and O
nickel O
subsulfide RARE
( O
Ni3S2 NUMERIC
) O
was O
studied O
in O
F344 NUMERIC
/ O
N O
rats O
and O
B6C3F1 NUMERIC
mice O
after O
inhalation O
exposure O
for O
6 O
hr O
/ O
day O
, O
5 O
days O
/ O
week O
, O
for O
13 O
weeks O
. O

Light RARE
microscopical RARE
and O
routine O
immunohistochemical O
studies O
of O
a O
cervical O
neoplasm RARE
in O
a O
32 O
year O
old O
woman O
initially O
suggested O
a O
histiocytic RARE
lymphoma O
, O
but O
histochemical RARE
staining O
for O
chloroacetate RARE
esterase I-GENE
established O
the O
correct O
diagnosis O
. O

From O
the O
National O
Institutes RARE
of O
Health O
. O

Molecular O
cloning O
and O
characterisation RARE
of O
the O
two O
homologous O
genes O
coding O
for O
nitrate I-GENE
reductase I-GENE
in I-GENE
tobacco I-GENE
. O

In O
the O
final O
model O
, O
grade O
( O
p O
= O
0 O
. O
0002 NUMERIC
), O
peritoneal O
cytologic RARE
results O
( O
p O
= O
0 O
. O
0002 NUMERIC
), O
progesterone I-GENE
receptor I-GENE
status O
( O
p O
= O
0 O
. O
004 NUMERIC
), O
and O
age O
as O
a O
continuous O
variable O
( O
p O
= O
0 O
. O
008 NUMERIC
) O
were O
most O
closely O
associated O
with O
disease O
- O
free O
survival O
. O

In O
contrast O
, O
despite O
external O
radiation O
therapy O
, O
brain O
metastases O
proved O
fatal O
. O

COUP I-GENE
transcription I-GENE
factor I-GENE
is O
a O
member O
of O
the O
steroid I-GENE
receptor I-GENE
superfamily I-GENE
. O

In O
Experiment O
2 O
, O
we O
again O
used O
classification O
, O
but O
the O
fixed O
standard O
75 O
was O
not O
at O
the O
center O
of O
the O
range O
of O
target O
numbers O
( O
20 O
, O
21 O
, O
... RARE

Cosmid RARE
clones O
containing O
both O
VNTR ALLCAPS
sequences O
were O
identified O
, O
and O
restriction O
mapping O
showed O
them O
to O
be O
less O
than O
15 O
kb O
apart O
. O

The O
oxygen O
uptake O
( O
VO2 O
), O
carbon O
dioxide O
output O
( O
VCO2 NUMERIC
), O
respiratory O
rate O
( O
fR LASTCAP
), O
minute O
ventilation O
( O
VE O
), O
alveolar O
ventilation O
( O
VA O
), O
alveolar O
oxygen O
pressure O
( O
PAO2 NUMERIC
), O
and O
VE O
/ O
VO2 O
ratio O
were O
higher O
in O
the O
cows O
, O
while O
the O
tidal O
volume O
( O
VT O
) O
and O
physiological O
dead RARE
space O
( O
VD ALLCAPS
) O
were O
larger O
in O
the O
horses O
. O

Epithelial RARE
damage O
was O
not O
observed O
in O
any O
controls O
but O
was O
in O
all O
tissues O
exposed O
to O
SO2 NUMERIC
. O

Among O
booked RARE
patients O
the O
maternal O
mortality O
rate O
was O
0 O
. O
32 O
and O
among O
unbooked RARE
patients O
11 O
. O
13 O
per O
1000 O
deliveries RARE
. O

The O
present O
study O
investigates RARE
whether O
prostaglandins O
" O
cytoprotect RARE
" O
the O
gastric O
mucosa O
against O
hemorrhage O
- O
induced O
stress O
ulceration O
by O
assessing O
the O
influence O
of O
16 O
, O
16 O
- O
dimethyl O
prostaglandin O
E2 O
( O
16 O
, O
16 O
- O
dm RARE
PGE2 O
) O
on O
gross O
and O
microscopic O
lesion O
formation O
, O
intramucosal RARE
tissue O
pH O
, O
H O
+ O
back O
- O
diffusion O
, O
and O
mucosal O
blood O
flow O
in O
rat O
gastric O
mucosa O
exposed O
to O
luminal O
acid O
( O
100 O
mM O
HCl RARE
) O
during O
hemorrhagic O
shock O
( O
13 O
ml O
/ O
kg O
for O
20 O
min O
). O

Transcripts RARE
characterized O
include O
( O
i O
) O
abundant O
monocistronic RARE
L11e NUMERIC
and O
tricistronic RARE
L1e NUMERIC
- O
L10e NUMERIC
- O
L12e NUMERIC
transcripts O
; O
( O
ii O
) O
less O
abundant O
bicistronic RARE
NAB ALLCAPS
- O
L11e NUMERIC
and O
monocistronic RARE
NAB ALLCAPS
transcripts I-GENE
and O
( O
iii O
) O
a O
very O
rare O
ORF O
monocistronic RARE
transcript O
. O

Qualitatively RARE
, O
the O
results O
are O
similar O
for O
the O
two O
species O
: O
Both O
rhesus O
monkey O
and O
man O
have O
photopic RARE
and O
scotopic RARE
branches RARE
, O
which O
cross O
at O
approximately O
the O
same O
time O
in O
the O
dark O
and O
at O
approximately O
the O
same O
background O
luminance RARE
. O

Evidence O
from O
the O
structure O
of O
a O
number O
of O
cDNA O
clones O
, O
as O
well O
as O
S1 I-GENE
nuclease I-GENE
and O
primer O
extension O
studies O
supports O
the O
hypothesis O
that O
the O
PTHrP LASTCAP
gene I-GENE
contains O
at O
least O
two O
mRNA O
transcription O
start O
points O
that O
define O
two O
putative O
regulatory O
domains O
. O

At O
each O
level O
of O
PaO2 O
we O
obtained O
simultaneous O
measures O
of O
arterial O
and O
venous O
blood O
gases O
, O
venous O
lactate O
concentration O
, O
and O
changes O
in O
the O
relative O
concentrations O
of O
inorganic O
phosphate O
, O
phosphocreatine RARE
, O
and O
ATP O
measured O
with O
31P NUMERIC
magnetic O
resonance O
spectroscopy O
. O

The O
transcription O
initiation O
site O
was O
determined O
by O
S1 I-GENE
nuclease I-GENE
mapping O
. O

Endometrial RARE
biopsies O
and O
plasma O
oestradiol O
( O
E2 O
) O
and O
progesterone O
( O
P4 O
) O
levels O
in O
23 O
patients O
were O
evaluated O
during O
26 O
replacement O
therapy O
cycles O
for O
premature O
ovarian O
failure O
. O

The O
mobility O
of O
the O
upper O
and O
lower O
premolars RARE
under O
load O
was O
investigated O
in O
relation O
to O
the O
interproximal RARE
contact O
and O
occlusal RARE
facets RARE
. O

A O
larval I-GENE
albumin I-GENE
- I-GENE
like I-GENE
protein I-GENE
was O
not O
detectable O
by O
silver O
staining O
in O
serum O
of O
tadpoles RARE
before O
the O
beginning O
of O
metamorphosis RARE
at O
stage O
48 O
. O

Behaviorally RARE
, O
a O
pain O
- O
tolerant RARE
group O
( O
PT O
= O
29 O
Ss RARE
) O
tolerated O
the O
entire O
3 O
- O
min O
test O
( O
means O
= O
180 O
+/- O
0 O
sec O
), O
while O
a O
pain O
- O
sensitive O
group O
( O
PS O
= O
13 O
Ss RARE
) O
averaged O
only O
50 O
. O
31 O
+/- O
20 O
. O
81 O
sec O
of O
the O
cold O
- O
pressor O
test O
( O
t O
= O
16 O
. O
75 O
, O
P O
less O
than O
0 O
. O
0001 O
), O
replicating O
our O
earlier O
studies O
. O

This O
suggested O
that O
baboon RARE
liver I-GENE
class I-GENE
I I-GENE
ADH I-GENE
is O
of O
the O
same O
ancestral O
lineage O
as O
the O
human I-GENE
ADH I-GENE
- I-GENE
beta I-GENE
. O

Isolated RARE
proteinuria RARE
( O
i O
. O
e O
. O
without O
hematuria RARE
and O
/ O
or O
pyuria RARE
) O
is O
a O
frequent O
finding O
. O

Each O
individual O
shot RARE
25 O
bullets RARE
in O
about O
5 O
minutes O
, O
at O
an O
intensity O
level O
calculated O
at O
163 NUMERIC
dB LASTCAP
. O

Lithium RARE
delays RARE
the O
circadian O
rhythm O
of O
wheel RARE
- O
running RARE
in O
Syrian O
hamsters O
at O
plasma O
concentrations O
( O
0 O
. O
59 O
- O
0 O
. O
74 O
mM O
) O
that O
also O
cause O
toxic O
weight O
loss O
. O

Dynamic RARE
and O
static RARE
scintigrams RARE
, O
using O
99mtechnetium NUMERIC
methylene O
diphosphonate RARE
, O
were O
obtained O
at O
zero O
, O
six O
, O
and O
12 O
weeks O
after O
fracture O
. O

On O
admission O
to O
our O
department RARE
in O
September RARE
, O
1987 O
, O
the O
patient O
was O
alert RARE
and O
had O
spastic RARE
paraparesis RARE
, O
the O
impairment O
of O
all O
sensory O
modalities O
below O
the O
level O
of O
Th RARE
10 O
and O
urinary O
disturbance O
. O

Prostaglandins RARE
and O
gallstones RARE

The O
nature O
of O
the O
process O
formed O
by O
the O
successive O
occurrences RARE
of O
this O
arrhythmia RARE
was O
studied O
in O
8 O
patients O
with O
a O
history O
of O
symptomatic O
paroxysmal RARE
AF O
. O

This O
would O
have O
had O
the O
effect O
of O
positioning O
the O
genes O
currently O
on O
the O
long O
arm O
adjacent O
to O
the O
centromeric RARE
heterochromatin RARE
, O
perhaps O
resulting O
in O
a O
" O
position O
effect O
" O
on O
transcription O
of O
these O
genes O
. O

Initial O
experience O
with O
a O
microprocessor RARE
controlled O
current O
based O
defibrillator RARE
. O

Obesity RARE
was O
strongly O
associated O
with O
the O
proportions RARE
of O
nonprotein RARE
- O
bound O
and O
albumin I-GENE
- O
bound O
estradiol O
, O
and O
inversely O
associated O
with O
sex I-GENE
hormone I-GENE
binding I-GENE
globulin I-GENE
( O
SHBG I-GENE
) O
levels O
and O
the O
proportion O
of O
SHBG I-GENE
- O
bound O
estradiol O
. O

Heterogeneous RARE
nuclear I-GENE
ribonucleoprotein I-GENE
( I-GENE
hnRNP I-GENE
) I-GENE
core I-GENE
protein I-GENE
A1 I-GENE
is O
a O
major O
component O
of O
mammalian I-GENE
hnRNP I-GENE
40 I-GENE
S I-GENE
particles I-GENE
. O

Brain RARE
cholinesterase I-GENE
activity O
of O
nestling RARE
great O
egrets RARE
, O
snowy RARE
egrets RARE
and O
black O
- O
crowned RARE
night O
- O
herons RARE
. O
inhibition O
of O
brain I-GENE
cholinesterase I-GENE
( O
ChE LASTCAP
) O
activity O
in O
birds O
is O
often O
used O
to O
diagnose RARE
exposure O
or O
death O
from O
organophosphorus RARE
or O
carbamate RARE
pesticides RARE
. O

The O
effect O
of O
zinc O
deficiency O
on O
trace RARE
metals RARE
in O
the O
liver O
, O
spleen O
, O
kidney O
, O
pancreas O
and O
duodenum RARE
was O
investigated O
in O
the O
control O
and O
zinc O
- O
deficient O
rats O
at O
17 O
days O
and O
20 O
days O
of O
pregnancy O
. O

Our O
findings O
support O
the O
view O
of O
a O
multifactorial RARE
genesis RARE
of O
the O
cardiac O
involvement O
in O
uremic RARE
patients O
. O

Heating RARE
cells O
to O
43 O
degrees O
C O
decreased O
the O
amount O
of O
newly O
synthesized O
rRNA O
to O
less O
than O
5 O
% O
of O
the O
control O
level O
and O
led O
to O
greater O
than O
95 O
% O
inhibition O
of O
transcription O
termination O
at O
a O
region O
355 NUMERIC
to O
362 NUMERIC
nucleotides O
downstream O
of O
the O
3 O
' O
end O
of O
28S I-GENE
rRNA I-GENE
, O
with O
readthrough O
continuing RARE
into O
the O
next O
transcription O
unit O
. O

Deletion O
analysis O
showed O
that O
the O
NF I-GENE
- I-GENE
4FA NUMERIC
, O
NF I-GENE
- I-GENE
4FB NUMERIC
, O
and O
AP I-GENE
- I-GENE
1 I-GENE
sequences O
are O
each O
necessary O
for O
full O
enhancer O
activity O
. O

Cord RARE
swelling O
was O
observed O
in O
2 O
patients O
who O
developed O
complete O
lesions O
. O

Reye RARE
' O
s O
syndrome O
: O
reports O
of O
7 O
cases O
in O
the O
period O
1982 O
- O
1987 O

When O
two O
- O
dimensional O
polyacrylamide O
gel O
electrophoretic O
patterns O
of O
[ O
35S O
] O
methionine O
- O
labeled O
proteins O
secreted O
from O
cells O
infected O
with O
parental O
and O
recombinant O
viruses O
were O
compared O
, O
a O
spot RARE
missing O
from O
the O
latter O
corresponded O
in O
molecular O
weigh RARE
and O
isoelectric RARE
point O
with O
that O
predicted O
from O
the O
N1L NUMERIC
ORF I-GENE
. O

PULSE ALLCAPS
is O
used O
to O
set O
such O
NMR O
spectroscopic RARE
parameters O
as O
the O
delay O
and O
duration O
of O
rf RARE
transmit RARE
and O
receive O
gates RARE
, O
rf RARE
phase O
, O
sampling O
times O
, O
and O
such O
imaging O
parameters O
as O
rf RARE
pulse O
shape O
and O
gradient O
waveforms RARE
. O

Definite RARE
JPsA LASTCAP
( O
24 O
patients O
) O
was O
defined O
as O
arthritis O
associated O
, O
but O
not O
necessarily O
coincident RARE
, O
with O
a O
typical O
psoriatic RARE
rash O
, O
or O
arthritis O
plus O
at O
least O
3 O
of O
4 O
minor O
criteria O
: O
dactylitis RARE
, O
nail RARE
pitting RARE
, O
psoriasis O
- O
like O
rash O
, O
or O
family O
history O
of O
psoriasis O
. O

Hence O
follows O
Kurti RARE
' O
s O
demand O
to O
mete RARE
out O
appropriate O
importance O
to O
the O
arguments RARE
. O

The O
author O
gives O
an O
account O
of O
antipsychotic RARE
, O
analgetic RARE
, O
myorelaxing RARE
and O
vasodilatating RARE
effects O
of O
some O
calcium O
antagonists O
, O
and O
their O
clinical O
application O
is O
discussed O
. O

A O
correlation O
coefficient O
was O
used O
for O
assessing O
the O
similarity O
of O
each O
map O
pattern O
with O
the O
normal O
mean O
IQRST ALLCAPS
map O
. O

A O
hospital O
- O
based O
study O
of O
the O
relationship O
between O
retained O
placenta O
and O
mastitis RARE
in O
dairy RARE
cows O
. O

This O
indicates O
that O
lipid O
peroxidation O
may O
be O
involved O
in O
the O
development O
of O
senile O
cataract RARE
and O
, O
as O
a O
direct O
consequence O
of O
retinal O
damage O
, O
also O
in O
the O
pathogenesis O
of O
cataract RARE
in O
diabetes O
and O
in O
severe O
myopia RARE
. O

The O
histological O
grading RARE
was O
certified RARE
in O
68 O
cases O
: O
12 O
G1 O
, O
39 O
G2 O
, O
17 O
G3 NUMERIC
; O
extracapsular RARE
spread O
was O
found O
in O
20 O
/ O
54 O
cases O
( O
37 O
%). O

Asthma RARE
was O
significantly O
more O
often O
associated O
with O
ASA O
group O
( O
91 O
%) O
vs O
46 O
% O
at O
AT O
and O
in O
only O
16 O
% O
at O
INTR ALLCAPS
group O
. O

A O
value O
of O
1 O
. O
1 O
l O
/ O
kg O
was O
used O
for O
V O
in O
calculating RARE
all O
single O
sample O
estimates O
of O
clearance O
( O
CL O
), O
and O
a O
value O
of O
4 O
. O
3 O
l O
/ O
kg O
was O
used O
to O
calculate RARE
single O
sample O
estimates O
of O
clearance O
of O
plasma O
unbound RARE
drug O
( O
CLunb RARE
). O

The O
solitary RARE
kidney O
: O
a O
model O
of O
chronic O
hyperfiltration RARE
in O
humans O
. O

Halothane RARE
is O
metabolized RARE
by O
an O
oxidative O
pathway O
to O
stable O
, O
nonvolatile RARE
end O
products O
, O
trifluoroacetic RARE
acid O
( O
TFAA ALLCAPS
) O
and O
bromide O
( O
Br O
-), RARE
and O
by O
reductive RARE
pathways O
to O
Br O
- O
and O
inorganic O
fluoride O
( O
F O
-). RARE

The O
values O
were O
consistently O
lower O
( O
P O
less O
than O
0 O
. O
01 O
) O
during O
summer O
( O
3 O
. O
79 O
+/- O
0 O
. O
13 O
micrograms O
/ O
100 O
ml O
), O
as O
compared O
to O
winter RARE
( O
5 O
. O
06 O
+/- O
0 O
. O
27 O
). O

These O
results O
suggest O
that O
HAPE ALLCAPS
- O
S O
- O
S O
are O
prone O
to O
irregular RARE
nocturnal RARE
breathing O
patterns O
at O
high O
altitude O
, O
which O
is O
associated O
with O
the O
development O
of O
AMS ALLCAPS
, O
but O
it O
was O
not O
possible O
to O
determine O
whether O
these O
abnormal O
breathing O
patterns O
are O
a O
cause O
or O
an O
effect O
of O
AMS ALLCAPS
. O

Buflomedil RARE
( O
i O
. O
v O
.) O
induced O
a O
dose O
- O
dependent O
increase O
of O
cardiac O
output O
at O
0 O
. O
16 O
- O
0 O
. O
64 O
mg O
/ O
kg O
, O
biphasic O
changes O
at O
1 O
. O
28 O
and O
2 O
. O
56 O
mg O
/ O
kg O
and O
a O
marked O
decrease O
and O
subsequent O
slight O
increase O
at O
a O
large O
dose O
of O
5 O
. O
12 O
mg O
/ O
kg O
. O

It O
was O
possible O
to O
classify RARE
the O
animals O
into O
high O
and O
low O
responders O
according O
to O
the O
pattern O
of O
humoral RARE
immune O
response O
. O

Heart RARE
rate O
( O
HR O
), O
rectal O
temperature O
( O
Tre RARE
), O
blood O
pressure O
, O
temperature O
and O
relative O
humidity RARE
changes O
inside RARE
clothing RARE
were O
measured O
on O
18 O
professional RARE
firemen RARE
( O
mean O
age O
29 O
. O
4 O
+/- O
7 O
. O
4 O
yr O
, O
VO2 O
max O
41 O
. O
4 O
+ O
8 O
. O
8 O
ml O
kg O
- O
1 O
min O
- O
1 O
) O
wearing RARE
fire RARE
fighter RARE
' O
s O
uniforms RARE
( O
SU O
) O
or O
aluminized RARE
, O
fire RARE
resistant O
, O
impermeable RARE
clothing RARE
with O
self O
contained O
breathing O
apparatus O
( O
FE ALLCAPS
). O

The O
clinical O
tolerance O
and O
pharmacokinetics O
of O
FCE ALLCAPS
22101 NUMERIC
( O
sodium O
( O
5R NUMERIC
, O
6S NUMERIC
)- O
6 O
-[( RARE
1R NUMERIC
)- O
hydroxyethyl RARE
]- RARE
2 O
- O
carbamoyloxymethyl RARE
- O
2 O
- O
penem RARE
- O
3 O
- O
carboxylate RARE
), O
a O
new O
penem RARE
antibiotic O
, O
have O
been O
studied O
after O
giving O
a O
single O
i O
. O
v O
. O
dose O
of O
4 O
mg O
. O
kg O
- O
1 O
to O
ten O
healthy O
male O
volunteers O
. O

DNA O
blot O
hybridization O
suggests O
that O
the O
rat O
genome O
may O
contain O
more O
than O
one O
gene O
encoding O
PtdIns RARE
transfer I-GENE
protein I-GENE
. O

We O
use O
the O
term O
corticosteroid O
- O
dependent O
IA O
to O
refer RARE
to O
the O
serious O
problem O
of O
chronic O
IA O
requiring O
maintenance O
prednisone O
therapy O
. O

Another O
segment O
of O
CRL3 NUMERIC
(- O
296 O
to O
- O
184 NUMERIC
), O
also O
displaying RARE
enhancer O
function O
, O
contained O
tandem O
repeated O
sequences O
( O
DR O
- O
A1 O
and O
DR O
- O
A2 O
). O

1 O
-( O
1 O
- O
Naphthyl RARE
) O
piperazine RARE
( O
1 O
- O
NP O
) O
has O
been O
reported O
to O
have O
serotonin O
antagonist O
properties O
at O
the O
5 I-GENE
- I-GENE
HT2 I-GENE
subtype I-GENE
of O
receptor O
, O
and O
it O
has O
been O
suggested O
that O
it O
may O
have O
agonist O
actions O
at O
the O
5 I-GENE
- I-GENE
HT1 NUMERIC
site I-GENE
. O

1 O
-( O
m O
- O
Chlorophenyl RARE
) O
piperazine RARE
( O
mCPP LASTCAP
, O
0 O
. O
1 O
- O
3 O
. O
0 O
mg O
/ O
kg O
) O
and O
1 O
-( O
m O
- O
trifluoromethylphenyl RARE
) O
piperazine RARE
( O
TFMPP ALLCAPS
, O
0 O
. O
1 O
- O
3 O
. O
0 O
mg O
/ O
kg O
), O
both O
thought O
to O
act O
primarily O
at O
5 I-GENE
- I-GENE
HT1 NUMERIC
sites I-GENE
, O
also O
decreased O
responding O
and O
this O
effect O
was O
blocked O
by O
methysergide RARE
and O
by O
1 O
- O
NP O
, O
but O
not O
by O
ketanserin RARE
. O

The O
characteristic O
feature O
of O
liver O
and O
spleen O
MP O
function O
in O
patients O
with O
VHA ALLCAPS
associated O
with O
HBsAg I-GENE
carriership RARE
consisted O
in O
the O
lack O
of O
the O
compensatory RARE
reaction O
on O
the O
part O
of O
spleen O
MP O
, O
which O
was O
likely O
to O
be O
connected O
with O
overstrain RARE
of O
long O
standing RARE
and O
depletion O
of O
the O
MP O
system O
due O
to O
permanent O
antigenic O
stimulation O
of O
HBsAg I-GENE
. O

Changes O
in O
xanthine RARE
oxidase I-GENE
activity O
in O
patients O
with O
circulatory O
failure O

A O
soap RARE
and O
water O
( O
1 O
: O
1 O
, O
v O
/ O
v O
) O
solution O
effectively O
decontaminated RARE
powdered RARE
stratum RARE
corneum RARE
. O

The O
cytoprotective RARE
and O
antiulcer RARE
activities O
of O
the O
antacid RARE
magaldrate RARE
( O
ES O
Riopan RARE
) O
as O
well O
as O
its O
effects O
on O
gastric O
mucosal O
blood O
flow O
and O
mucus O
secretions RARE
, O
were O
determined O
in O
the O
rat O
. O

The O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
preferentially O
infects RARE
CD4 I-GENE
+ I-GENE
T O
lymphocytes O
and O
may O
exist O
as O
a O
latent O
provirus O
within O
these O
cells O
for O
extended O
periods O
. O

Histiocytic RARE
panniculitis RARE
was O
observed O
in O
biopsy O
specimens O
with O
cytophagocytosis RARE
. O

We O
have O
utilized O
the O
human I-GENE
4F2 NUMERIC
heavy I-GENE
chain I-GENE
( O
4F2HC NUMERIC
) O
gene O
as O
a O
model O
system O
in O
studies O
designed O
to O
elucidate O
the O
molecular O
events O
involved O
in O
regulating O
inducible O
gene O
expression O
during O
normal O
human O
T O
- O
cell O
activation O
. O

A O
cDNA O
encoding O
the O
NF I-GENE
- I-GENE
4FB NUMERIC
enhancer I-GENE
binding I-GENE
protein I-GENE
has O
been O
cloned O
by O
screening O
a O
lambda O
gt11 O
cDNA O
library O
with O
a O
rabiolabelled RARE
oligonucleotide O
corresponding O
to O
the O
NF I-GENE
- I-GENE
4FB NUMERIC
recognition I-GENE
sequence I-GENE
. O

Electrocardiographic RARE
right O
ventricular O
hypertrophy O
was O
seen O
in O
4 O
, O
and O
biventricular RARE
hypertrophy O
in O
5 O
patients O
. O

The O
two O
IL6 I-GENE
mRNA I-GENE
species O
are O
generated O
by O
alternative O
polyadenylation O
at O
sites O
separated O
by O
a O
distance O
of O
1 O
. O
2 O
kilobases O
. O

Sequencing O
analysis O
revealed O
that O
the O
0 O
. O
54 O
- O
and O
0 O
. O
4 O
- O
kb O
fragments O
are O
identical O
except O
for O
150 O
nucleotides O
missing O
at O
the O
5 O
' O
region O
of O
the O
0 O
. O
4 O
- O
kb O
fragment O
. O

The O
mature O
protein O
also O
contains O
a O
cysteine O
- O
rich O
, O
highly O
hydrophilic O
region O
homologous O
to O
the O
ovomucoid RARE
serine I-GENE
protease I-GENE
inhibitors I-GENE
( O
residues O
76 O
- O
132 O
). O

Oligosynaptic RARE
EPSP ALLCAPS
components O
were O
consistently O
modulated O
only O
in O
the O
superficial O
peroneal RARE
responses O
in O
flexor RARE
motoneurons RARE
, O
which O
exhibited O
enhanced O
amplitude O
during O
the O
flexion RARE
phase O
. O

Experiments O
on O
23 O
white O
rats O
and O
10 O
guinea O
pigs O
have O
shown O
that O
preliminarily RARE
indomethacin O
- O
induced O
inhibition O
of O
prostaglandins O
synthesis O
prevented O
development O
of O
pulmonary O
oedema RARE
, O
evoked O
by O
heterologous O
serum O
in O
rats O
and O
by O
vagotomy O
in O
guinea O
pigs O
. O

On O
the O
other O
hand O
, O
lack O
of O
conservation O
of O
the O
membrane O
attachment O
sequence O
arginine O
- O
glycine O
- O
aspartic RARE
acid O
argues RARE
against O
its O
functional O
importance O
in O
CgA LASTCAP
. O

Third RARE
- O
and O
later O
- O
parity RARE
cows O
were O
randomly O
assigned O
after O
each O
parturition RARE
to O
Charolais RARE
and O
Red RARE
Poll RARE
bulls RARE
in O
multiple O
- O
sire RARE
pastures RARE
. O

Within O
each O
lobe O
, O
the O
PA O
dispersion O
was O
up O
to O
10 O
cmH2O O
at O
CFV ALLCAPS
of O
90 O
l O
/ O
min O
; O
when O
flow O
decreased O
, O
PA O
at O
all O
sites O
decreased O
, O
as O
did O
the O
intralobar RARE
dispersion O
. O

The O
system O
consisted O
of O
the O
intact O
canine O
heart O
connected O
to O
a O
microcomputer RARE
that O
operated O
as O
the O
modulated O
parasystolic RARE
pacemaker RARE
. O

In O
order O
to O
identify O
and O
classify RARE
the O
basic O
CT O
appearances RARE
of O
interstitial O
pneumonia O
, O
radiologic RARE
- O
pathologic O
correlative RARE
study O
was O
performed O
using O
inflated RARE
and O
fixed O
lungs O
from O
autopsy O
and O
surgery O
. O

The O
disease O
ran RARE
an O
atypical O
course O
; O
with O
early O
jaundice O
syndrome O
, O
severe O
enterorrhagia RARE
and O
late O
appearance O
of O
roseola RARE
. O

The O
transcription O
factor O
Sp1 I-GENE
bound O
to O
eight O
sites O
, O
as O
demonstrated O
by O
footprinting O
assays O
and O
gel O
shift O
analysis O
with O
purified O
Sp1 I-GENE
. O

The O
combination O
PIP ALLCAPS
64 O
micrograms O
- O
PEF ALLCAPS
4 O
micrograms O
prevents O
the O
frequent O
secondary O
regrowth RARE
seen O
after O
6 O
hours O
with O
the O
antibiotics O
used O
alone O
. O

With O
a O
sample O
of O
mothers O
of O
healthy O
infants O
, O
all O
three O
subscales RARE
of O
the O
revised O
instrument O
, O
WPL ALLCAPS
- O
R O
, O
had O
acceptable O
levels O
of O
internal O
consistency RARE
at O
7 O
, O
30 O
, O
and O
90 O
days O
postpartum RARE
, O
and O
stability O
across O
administrations RARE
. O

Since O
1948 NUMERIC
, O
the O
use O
of O
saline O
- O
washed RARE
red O
cells O
( O
WRBCs RARE
) O
has O
been O
advocated RARE
to O
minimize RARE
hemolysis RARE
after O
transfusion O
to O
patients O
with O
PNH ALLCAPS
. O

In O
the O
group O
of O
asthmatics RARE
statistically O
significant O
correlation O
was O
found O
between O
PC20 NUMERIC
PGF2 O
alpha O
and O
histamine O
values O
( O
r O
= O
0 O
. O
538 NUMERIC
, O
p O
less O
than O
0 O
. O
05 O
). O

Acute O
experiments O
on O
nembutal RARE
- O
anesthetized O
cats O
( O
50 O
mg O
/ O
kg O
) O
were O
employed O
to O
investigate O
the O
effect O
of O
1 O
T O
pulsating RARE
magnetic O
field O
( O
PMF ALLCAPS
) O
on O
neuromuscular O
system O
of O
the O
leg O
. O

No O
significant O
differences O
were O
found O
between O
the O
TS ALLCAPS
and O
the O
PTS ALLCAPS
. O

The O
percentages RARE
of O
formed O
cysts O
and O
growth O
rates O
were O
monthly O
estimated O
and O
analyzed O
rhythmometrically RARE
by O
cosinor RARE
for O
5 O
clonal RARE
cultures O
of O
Scripsiella RARE
trochoidea RARE
Stein RARE
grown O
for O
2 O
years O
under O
laboratory O
conditions O
, O
rended RARE
as O
constant O
as O
possible O
from O
the O
view O
point O
of O
environmental O
temperature O
( O
24 O
+/- O
1 O
degree O
C O
), O
lighting RARE
( O
25 O
microEin RARE
m O
- O
2 O
s O
- O
1 O
), O
and O
artificial O
seawater RARE
. O

A O
genomic O
DNA O
clone O
encoding O
oryzacystatin RARE
( O
Oc RARE
), O
a O
cysteine I-GENE
proteinase I-GENE
inhibitor O
( O
cystatin RARE
) O
of O
rice O
, O
was O
isolated O
from O
a O
lambda O
EMBL3 NUMERIC
phage O
library O
constructed O
with O
Sau3AI NUMERIC
partial O
digests RARE
of O
rice O
chromosomal O
DNA O
, O
by O
screening O
with O
an O
oc RARE
cDNA I-GENE
as O
a O
probe O
. O

The O
use O
of O
an O
appropriate O
solution O
of O
methylene O
blue O
( O
0 O
. O
2 O
% O
in O
0 O
. O
9 O
M O
NaCl O
for O
15 O
min O
) O
permits O
the O
staining O
of O
premalignant RARE
areas O
and O
CIS ALLCAPS
, O
and O
their O
early O
diagnosis O
. O

Lower RARE
limits O
( O
to O
10 O
micrograms O
/ O
kg O
) O
were O
detectable O
, O
but O
with O
lower O
reliability O
( O
60 O
%). O

Instead O
, O
some O
small O
negative O
effects O
are O
observed O
, O
particularly O
involving O
effects O
of O
husbands RARE
' O
retirement RARE
on O
the O
marital RARE
satisfaction RARE
of O
employed O
wives RARE
. O

This O
in O
turn O
will O
further O
enhance O
the O
role O
of O
meta RARE
- O
analysis O
in O
helping RARE
clinicians RARE
and O
policy RARE
makers RARE
answer RARE
clinical O
questions O
. O

In O
one O
acromegalic RARE
patient O
visual O
improvement O
was O
obtained O
while O
the O
abnormal O
GH I-GENE
secretion O
remained O
unaltered O
. O

In O
contrast O
, O
the O
PPSF ALLCAPS
+ O
DBP O
side O
showed O
large O
amounts O
of O
bone O
formation O
, O
and O
bone O
almost O
covered RARE
the O
implant O
. O

The O
accuracies RARE
of O
presence O
or O
absence O
of O
neuroblastoma O
were O
compared O
between O
131I O
- O
MIBG ALLCAPS
imaging O
and O
several O
tumor O
markers O
. O

The O
congenital O
forms O
( O
7 O
cases O
) O
all O
occurred O
in O
female O
infants O
and O
involved O
the O
mucosa O
overlying RARE
either O
the O
anterior O
ridge RARE
of O
the O
maxilla RARE
or O
the O
mandible RARE
. O

Immunohistochemical RARE
studies O
revealed O
positive O
staining O
for O
S100 NUMERIC
protein I-GENE
in O
all O
the O
granular RARE
cell O
tumors O
of O
the O
adult O
but O
in O
none O
of O
the O
congenital O
granular RARE
cell O
epulides RARE
. O

We O
also O
found O
that O
the O
same O
males O
, O
breeding RARE
in O
different O
years O
on O
the O
same O
territories RARE
, O
had O
significantly O
larger O
harems RARE
in O
the O
years O
they O
had O
familiar RARE
neighbors RARE
. O

Male RARE
- I-GENE
enhanced I-GENE
antigen I-GENE
gene I-GENE
is O
phylogenetically RARE
conserved O
and O
expressed O
at O
late O
stages O
of O
spermatogenesis RARE
. O

In O
rats O
bearing O
Walker RARE
- O
256 O
- O
carcinosarcoma RARE
4 O
- O
EPI ALLCAPS
was O
effective O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Pacing RARE
the O
Roux RARE
limb O
abolished O
the O
ectopic O
pacemakers RARE
, O
restored O
the O
slow O
emptying O
of O
liquids RARE
to O
the O
more O
rapid O
rate O
found O
in O
the O
Billroth RARE
dogs O
( O
t1 O
/ O
2 O
: O
paced RARE
Roux RARE
, O
72 O
+/- O
15 O
minutes O
; O
Billroth RARE
, O
43 O
+/- O
9 O
minutes O
; O
p O
greater O
than O
0 O
. O
05 O
) O
and O
did O
not O
change O
emptying O
of O
solids RARE
. O

The O
treatments O
were O
60 O
mg O
t O
. O
i O
. O
d O
. O
and O
120 O
mg O
t O
. O
i O
. O
d O
. O
during O
14 O
days O
' O
treatment O
, O
with O
the O
last O
dose O
pulsed O
with O
1 O
. O
85 O
MBq O
[ O
14C O
] O
diltiazem O
. O

The O
subepicardial RARE
lymphatic RARE
capillaries O
were O
ramified RARE
and O
anastomosed RARE
with O
each O
other O
to O
form O
a O
relatively O
dense RARE
network O
which O
extended O
over O
the O
entire O
surface O
of O
both O
ventricles O
. O

The O
examination O
must O
include O
T1 O
and O
T2 O
sequences O
and O
scans O
in O
three O
planes RARE
. O

A O
great O
deal RARE
of O
information O
is O
available O
on O
the O
morphology O
of O
the O
claustrum RARE
in O
various O
animal O
species O
, O
as O
well O
as O
on O
its O
neuronal O
distribution O
and O
relationships O
with O
the O
cerebral O
cortex O
and O
other O
nuclei O
. O

Low O
- O
grade O
glioma O
. O

In O
terms O
of O
sequence O
repetitions RARE
, O
seven O
tandemly O
repeated O
copies O
of O
the O
hexanucleotide RARE
ATTGTT ALLCAPS
and O
three O
flanking O
regions O
of O
dyad RARE
symmetry RARE
were O
detected O
, O
all O
in O
ORF O
T3C NUMERIC
. O

The O
significance O
of O
these O
palindromic O
domains O
in O
this O
ORF O
is O
unclear O
but O
the O
coincidence RARE
of O
the O
end O
of O
one O
larger O
palindrome O
with O
the O
end O
of O
the O
translated O
protein O
sequence O
that O
has O
homology O
with O
the O
B O
chain O
of O
insulin I-GENE
suggests O
that O
the O
palindromes RARE
may O
divide RARE
the O
T2 I-GENE
protein I-GENE
into O
several O
functional O
units O
. O

During O
sub O
- O
maximal O
exercise O
, O
DCR ALLCAPS
in O
the O
UT O
dogs O
decreased O
from O
a O
resting O
value O
of O
4 O
. O
08 NUMERIC
+/- O
0 O
. O
18 O
mm O
Hg O
X O
ml O
- O
1 O
X O
min O
- O
1 O
to O
1 O
. O
91 O
+/- O
0 O
. O
17 O
mm O
Hg O
X O
ml O
- O
1 O
X O
min O
- O
1 O
at O
a O
workload RARE
of O
6 O
. O
4 O
kph RARE
( O
speed RARE
)/ O
16 O
% O
( O
grade O
). O

7 O
. O

These O
data O
suggest O
that O
the O
G I-GENE
- I-GENE
protein I-GENE
gene I-GENE
family I-GENE
may O
be O
distributed O
over O
at O
least O
two O
human O
chromosomes O
. O

The O
major O
inserted O
DNA O
has O
no O
significant O
homology O
to O
published O
human O
nucleic O
acid O
sequences O
. O

In O
44 O
evaluable O
patients O
the O
response O
rate O
was O
50 O
%, O
with O
one O
complete O
response O
. O

We O
have O
also O
found O
that O
the O
in O
vitro O
interaction O
between O
the O
SV40 O
octamer O
motif O
and O
the O
lymphoid I-GENE
cell I-GENE
- I-GENE
specific I-GENE
protein I-GENE
oct RARE
- I-GENE
B2 I-GENE
was O
negatively O
modulated O
by O
a O
component O
present O
in O
the O
nuclear O
extracts O
from O
several O
lymphoid O
cell O
lines O
. O

Anoxia RARE
was O
introduced O
by O
perfusing RARE
the O
gill RARE
with O
water O
deprived O
of O
oxygen O
or O
by O
halting RARE
the O
water O
flow O
to O
the O
gill RARE
. O

Growth O
, O
4 O
- O
PA O
and O
14C O
turnover O
data O
indicated O
that O
WB ALLCAPS
contributed O
to O
B O
- O
6 O
intake O
of O
these O
rats O
. O

Thus O
, O
multiple O
myogenic O
factors O
that O
vary O
qualitatively RARE
and O
quantitatively RARE
may O
be O
responsible O
for O
the O
different O
and O
complex O
modulatory RARE
programs O
of O
actin I-GENE
gene I-GENE
expression O
observed O
during O
in O
vivo O
muscle O
differentiation O
. O

DNA O
sequence O
analysis O
revealed O
that O
these O
clones O
encode O
two O
distinct O
forms O
of O
translocase RARE
. O

The O
effect O
of O
acetazolamide RARE
( O
ACZ ALLCAPS
) O
on O
HCO3 O
- O
and O
Cl O
- O
activities O
in O
inner O
ear O
fluid O
was O
investigated O
by O
ion O
- O
selective O
microelectrode RARE
methods O
. O

RPA190 NUMERIC
encodes O
a O
polypeptide O
chain O
of O
186 O
, O
270 O
daltons RARE
in O
a O
large O
uninterrupted RARE
reading O
frame O
. O

Both O
the O
intact I-GENE
A1 I-GENE
protein I-GENE
and O
its O
proteolytic O
fragment O
, O
the O
UP1 NUMERIC
protein I-GENE
, O
can O
be O
cleaved O
by O
Staphylococcus I-GENE
aureus I-GENE
V I-GENE
- I-GENE
8 I-GENE
protease I-GENE
to O
produce O
two O
polypeptides O
of O
92 O
amino O
acids O
. O

Irmiere RARE
, O
and O
W O
. O

These O
offspring RARE
of O
the O
alpha I-GENE
- I-GENE
MSH I-GENE
treated O
mothers O
were O
less O
sensitive O
to O
pain O
and O
as O
adults O
showed O
a O
reduced O
analgesic O
response O
to O
morphine O
. O

Simian RARE
immunodeficiency O
virus O
( O
SIV O
) O
is O
a O
lentivirus RARE
with O
morphological O
and O
antigenic O
similarities O
to O
human O
immunodeficiency O
virus O
, O
the O
causative RARE
agent O
of O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
of O
humans O
. O

The O
lack O
of O
change O
in O
the O
ratio O
of O
the O
two O
spliced O
products O
expressed O
from O
either O
the O
normal O
or O
the O
5 I-GENE
'- I-GENE
rearranged I-GENE
myb I-GENE
further O
indicates O
that O
the O
insertion O
of O
the O
unique O
121 O
amino O
acids O
in O
the O
larger O
myb I-GENE
transcripts I-GENE
is O
not O
a O
consequence O
of O
tumor O
- O
specific O
activation O
of O
the O
mouse I-GENE
myb I-GENE
oncogene I-GENE
. O

The O
use O
of O
CRF I-GENE
- I-GENE
41 I-GENE
in O
the O
differential O
diagnosis O
of O
Cushing RARE
' O
s O
syndrome O
and O
obesity O
. O

We O
detected O
mos I-GENE
transcripts I-GENE
by O
Northern O
( O
RNA O
) O
analyses O
in O
RNA O
prepared O
from O
chicken O
and O
quail RARE
ovaries RARE
and O
testes O
. O

The O
predicted O
L I-GENE
mRNA I-GENE
was O
6398 NUMERIC
nucleotides O
long O
and O
contained O
a O
single O
open O
reading O
frame O
corresponding O
to O
an O
L I-GENE
protein I-GENE
encompassing I-GENE
2109 NUMERIC
amino I-GENE
acids I-GENE
with O
a O
MW ALLCAPS
of O
241 NUMERIC
, O
546 NUMERIC
. O

The O
results O
suggest O
that O
the O
organization O
of O
functional O
units O
of O
the O
72 O
- O
bp O
repeat O
required O
for O
transcriptional O
enhancement O
of O
the O
early O
promoter O
is O
different O
from O
that O
required O
for O
late O
promoter O
function O
. O

Variations RARE
in O
the O
5 O
' O
half O
of O
U3 O
were O
primarily O
due O
to O
insertions O
and O
deletions O
. O

An O
analysis O
of O
the O
steady O
state O
RNA O
levels O
in O
T O
- O
lymphoid O
cell O
lines O
showed O
that O
at O
least O
three O
different O
incomplete O
proviral O
transcripts O
and O
their O
spliced O
products O
made O
up O
the O
majority O
of O
expressed O
RD I-GENE
- I-GENE
114 I-GENE
mRNA I-GENE
, O
and O
further O
demonstrated O
that O
partially O
deleted O
proviral O
loci O
have O
the O
potential O
to O
be O
transcriptionally O
vigorous RARE
in O
certain O
feline O
cell O
types O
. O

Aplastic RARE
crisis RARE
in O
sickle RARE
cell O
disorders O
: O
bone O
marrow O
necrosis O
and O
human O
parvovirus RARE
infection O
. O

Either RARE
two O
or O
more O
different O
sequences O
can O
promote O
cleavage O
, O
or O
a O
single O
element O
exists O
which O
is O
long O
and O
diffuse O
. O

Low O
molecular O
weight O
heparins RARE
have O
stimulated O
much O
interest O
because O
of O
their O
supposedly RARE
more O
selective O
action O
on O
Xa RARE
factor I-GENE
. O

The O
bactericidal O
activity O
of O
six O
new O
rifamycin RARE
derivatives O
-- O
rifabutin RARE
( O
RBU ALLCAPS
), O
FCE ALLCAPS
22250 NUMERIC
( O
F22 NUMERIC
), O
rifapentine RARE
( O
RPE ALLCAPS
), O
CGP O
29861 NUMERIC
( O
C29 NUMERIC
), O
CGP O
7040 NUMERIC
( O
C70 NUMERIC
) O
and O
CGP O
27557 NUMERIC
( O
C27 NUMERIC
) O
and O
rifampicin RARE
( O
RMP ALLCAPS
)-- RARE
have O
been O
measured O
against O
log O
phase O
and O
, O
as O
a O
better O
test O
of O
sterilising RARE
activity O
, O
against O
stationary O
phase O
cultures O
of O
Mycobacterium O
tuberculosis O
, O
H37Rv NUMERIC
. O

Mo RARE
+ O
SV O
M O
- O
MuLV O
- O
inoculated O
animals O
became O
moribund RARE
at O
3 O
to O
13 O
months O
postinoculation RARE
, O
whereas O
delta O
Mo RARE
+ O
SV O
M O
- O
MuLV O
- O
inoculated O
animals O
became O
moribund RARE
at O
6 O
to O
24 O
months O
postinoculation RARE
. O

Sodium O
dodecyl O
sulphate RARE
- O
induced O
cleavage O
by O
eukaryotic I-GENE
topoisomerase I-GENE
I I-GENE
is O
known O
to O
yield O
enzyme O
covalently O
attached O
to O
the O
3 O
' O
cut O
end O
of O
the O
DNA O
. O

Amino O
acid O
sequence O
of O
one O
human O
liver O
clone O
( O
HL O
- O
14 O
) O
was O
identical O
to O
the O
rabbit I-GENE
skeletal I-GENE
muscle I-GENE
phosphatase I-GENE
2A I-GENE
cDNA I-GENE
( O
with O
97 O
% O
nucleotide O
identity O
). O

Herpes RARE
virus O
infection O
was O
characterized O
by O
inversion O
of O
the O
T4 O
/ O
T8 NUMERIC
ratio O
below O
1 O
. O
0 O
( O
sensitivity O
90 O
%, O
specificity O
88 O
%), O
caused O
by O
proliferation O
of O
the O
T8 NUMERIC
subpopulation RARE
, O
which O
-- O
compared O
with O
the O
findings O
in O
patients O
with O
rejection O
crises RARE
-- O
was O
significantly O
raised O
( O
P O
less O
than O
0 O
. O
001 O
). O

RVEF ALLCAPS
and O
LVEF O
both O
increased O
by O
about O
14 O
% O
( O
p O
less O
than O
0 O
. O
05 O
and O
p O
less O
than O
0 O
. O
01 O
). O

The O
levels O
of O
NPY ALLCAPS
- O
ir RARE
in O
the O
rat O
vas O
deferens O
were O
not O
affected O
by O
either O
surgical O
or O
pharmacological O
treatment O
. O

Quantitative O
assays O
in O
which O
the O
activity O
of O
the O
synthetic I-GENE
alpha I-GENE
s I-GENE
- I-GENE
1 I-GENE
was O
compared O
to O
that O
of O
native O
purified O
human I-GENE
erythrocyte I-GENE
type I-GENE
- I-GENE
1 I-GENE
Gs I-GENE
, O
indicated O
that O
the O
two O
products O
are O
equipotent RARE
within O
a O
2 O
- O
fold O
margin O
of O
error O
. O

In O
these O
cells O
, O
E2 I-GENE
proteins I-GENE
had O
little O
or O
no O
stimulatory O
effect O
on O
the O
transcriptional O
activity O
of O
the O
HPV I-GENE
- I-GENE
11 I-GENE
enhancer I-GENE
- O
SV40 I-GENE
promoter I-GENE
. O

The O
mechanism O
by O
which O
E2 I-GENE
- I-GENE
C I-GENE
represses O
E2 I-GENE
- I-GENE
dependent I-GENE
enhancer I-GENE
activity O
most O
likely O
involves O
competition O
with O
E2 I-GENE
for O
binding O
to O
a O
common O
transcriptional O
regulatory O
site O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Accurate RARE
evaluation O
of O
the O
treatment O
results O
in O
unresectable RARE
lung O
cancer O
patients O
must O
take O
the O
strong O
prognostic O
factors O
into O
account O
. O

( O
anti I-GENE
- I-GENE
IIa RARE
) O
and O
Holmer RARE
et O
al O
. O

Introduction RARE
of O
v I-GENE
- I-GENE
fms I-GENE
into O
a O
CSF I-GENE
- I-GENE
1 I-GENE
dependent O
murine O
macrophage O
cell O
line O
induced O
factor O
independence RARE
and O
tumorigenicity RARE
by O
a O
nonautocrine RARE
mechanism O
. O

Chronic O
E O
- O
B O
virus O
infection O
terminated RARE
in O
malignant O
lymphoma O
: O
a O
case O
report O

The O
primary O
structure O
and O
cotranscription RARE
of O
the O
petCA LASTCAP
genes I-GENE
encoding O
the O
Rieske RARE
- I-GENE
FeS LASTCAP
( O
nuclear I-GENE
encoded I-GENE
in I-GENE
plants I-GENE
) O
and O
apocytochrome RARE
f I-GENE
proteins I-GENE
has O
been O
described O
previously O
( O
Kallas RARE
, O
T O
., O
Spiller RARE
, O
S O
., O
and O
Malkin RARE
, O
R O
. O

The O
Nostoc RARE
petBD LASTCAP
genes I-GENE
are O
not O
closely O
linked O
to O
the O
psbB LASTCAP
gene I-GENE
( O
encoding O
the O
51 O
- O
kDa O
photosystem RARE
II I-GENE
polypeptide I-GENE
) O
and O
do O
not O
contain O
introns O
as O
do O
the O
closely O
related O
chloroplast O
genes O
. O

RNA O
blot O
hybridizations RARE
identified O
an O
1 O
. O
8 O
- O
kb O
mRNA O
common O
to O
cytochrome I-GENE
b6 NUMERIC
and O
subunit O
IV O
, O
and O
an O
intensely RARE
hybridizing RARE
0 O
. O
8 O
- O
kb O
mRNA O
specific O
to O
the O
subunit O
IV O
gene O
probe O
. O

Whereas O
the O
muscle O
isoform O
consists O
of O
997 NUMERIC
amino O
acids O
and O
terminates RARE
with O
the O
sequence O
Ala O
- O
Ile O
- O
Leu O
- O
Glu O
, O
the O
second O
isoform O
is O
1043 NUMERIC
amino O
acids O
in O
length O
due O
to O
the O
replacement O
of O
these O
last O
4 O
amino O
acids O
with O
a O
50 O
- O
amino O
acid O
sequence O
that O
contains O
a O
potential O
transmembrane O
domain O
followed O
by O
a O
consensus O
sequence O
for O
an O
N O
- O
linked O
glycosylation O
site O
. O

Substitution O
of O
a O
threonine O
residue O
by O
an O
alanine O
residue O
at O
position O
- O
2 O
( O
P2 O
) O
of O
this O
cleavage O
site O
abolished O
cleavage O
, O
whereas O
substitution O
of O
a O
tyrosine O
residue O
by O
a O
phenylalanine O
residue O
at O
amino O
acid O
position O
- O
1 O
( O
P1 O
) O
of O
the O
cleavage O
site O
did O
not O
influence O
processing O
. O

All O
of O
the O
indigo RARE
- O
producing O
bacteria O
had O
an O
indoxyl RARE
phosphatase I-GENE
with O
a O
pI LASTCAP
of O
6 O
. O
4 O
. O

The O
number O
of O
polymerases O
active O
in O
vitro O
at O
the O
E O
strand O
promoter O
was O
similar O
to O
the O
number O
of O
polymerases O
at O
the O
L O
strand O
promoter O
. O

A O
family O
of O
RNA O
molecules O
in O
the O
2 O
. O
0 O
- O
2 O
. O
2 O
- O
kilobase O
range O
identified O
with O
a O
probe O
from O
this O
gene O
was O
overexpressed O
in O
the O
resistant O
cells O
. O

A O
highly O
hydrophobic O
sequence O
located O
near O
the O
carboxyl O
- O
terminal O
extremity RARE
of O
the O
molecule O
most O
likely O
constitutes O
the O
anchor O
to O
the O
plasma O
membrane O
. O

The O
SV40 I-GENE
enhancer I-GENE
augmented O
replication O
1 O
. O
5 O
- O
10 O
fold O
. O

One O
of O
these O
, O
the O
origin O
core O
, O
is O
required O
only O
for O
DNA O
replication O
. O

Induction O
of O
proto I-GENE
- I-GENE
oncogene I-GENE
fos I-GENE
transcription O
through O
the O
adenylate I-GENE
cyclase I-GENE
pathway O
: O
characterization O
of O
a O
cAMP O
- O
responsive O
element O
. O

A O
17 O
- O
mer O
oligodeoxynucleotide RARE
, O
corresponding O
to O
a O
region O
of O
the O
VtHb RARE
amino I-GENE
acid I-GENE
sequence I-GENE
was O
used O
as O
a O
hybridization O
probe O
to O
screen O
a O
Vitreoscilla RARE
genomic O
library O
constructed O
in O
broad O
- O
host O
- O
range O
cosmid O
vector O
pVK102 NUMERIC
. O

( O
total O
soluble O
solids RARE
) O
and O
organoleptic RARE
characteristics O
under O
the O
influence O
of O
different O
treatments O
. O

Causes RARE
of O
death O
found O
in O
an O
epidemiological O
study O
of O
native O
chickens O
in O
Thai RARE
villages RARE
. O

The O
progression O
of O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
to O
chronic O
diseases O
, O
and O
the O
transformation O
to O
hepatocellular RARE
carcinoma O

Elevated RARE
IOP O
developed O
in O
35 O
patients O
( O
44 O
eyes O
) O
during O
the O
study O
. O

Use O
of O
serum O
thyroglobulin RARE
determination O
in O
the O
follow O
- O
up O
of O
differentiated O
carcinomas O
of O
the O
thyroid O

Poor RARE
response O
when O
laboratory O
recommended O
range O
for O
serum O
lithium O
is O
changed O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
nebulized RARE
ipratropium RARE
in O
patients O
with O
acute O
asthma O
in O
order O
to O
determine O
whether O
it O
augments RARE
the O
bronchodilator RARE
effect O
of O
a O
beta O
agonist O
drug O
. O

Further O
analysis O
of O
this O
DNA O
fragment O
showed O
that O
four O
genes O
are O
present O
encoding O
proteins O
of O
16 O
, O
18 O
. O
5 O
, O
21 O
and O
89 O
kDal RARE
. O

Hantaan RARE
virus O
. O

Changes O
in O
dopamine I-GENE
receptor I-GENE
sensitivity O
in O
humans O
after O
heavy O
alcohol O
intake O
. O

No O
significant O
differences O
between O
the O
two O
treatment O
groups O
were O
found O
, O
but O
rapid O
responders O
had O
a O
smaller O
mean O
initial O
platelet I-GENE
- I-GENE
associated I-GENE
IgG I-GENE
index O
which O
returned O
more O
rapidly O
and O
more O
permanently RARE
to O
normal O
than O
that O
of O
slow O
responders O
. O

Replacement I-GENE
variant I-GENE
histone I-GENE
genes I-GENE
contain O
intervening O
sequences O
. O

Double O
- O
blind O
randomised O
trial O
of O
intravenous O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
versus O
placebo O
in O
acute O
myocardial O
infarction O
. O

The O
C O
- O
terminal O
domains O
( O
CTDs RARE
) O
of O
the O
RPase RARE
beta I-GENE
subunit I-GENE
and O
DNA I-GENE
primase I-GENE
( O
dnaG LASTCAP
protein I-GENE
) O
were O
not O
only O
strongly O
homologous O
to O
each O
other O
but O
also O
considerably O
homologous O
to O
the O
RPase RARE
alpha I-GENE
, O
suggesting O
that O
an O
alpha O
subunit O
- O
like O
enzyme O
must O
have O
been O
commonly O
ancestral O
to O
core I-GENE
enzyme I-GENE
subunits I-GENE
and O
primase I-GENE
. O

However O
, O
vancomycin O
and O
fosfomycin RARE
, O
which O
revealed O
suboptimal RARE
in O
vitro O
bactericidal O
activity O
, O
proved O
as O
efficacious RARE
as O
penicillin O
G O
and O
imipenem RARE
in O
an O
experimental O
mode O
of O
murine O
gas O
gangrene RARE
. O

Fentanyl RARE
, O
a O
prototypic RARE
mu I-GENE
- I-GENE
opiate I-GENE
receptor I-GENE
agonist O
, O
has O
been O
previously O
shown O
to O
produce O
a O
syndrome O
characterized O
by O
marked O
analgesia O
and O
locomotor O
stimulation O
as O
well O
as O
tachycardia O
, O
tachypnoea RARE
and O
behavioural RARE
arousal RARE
. O

Intravesical RARE
chemotherapy O
. O

Bisoprolol RARE
was O
found O
to O
be O
an O
effective O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
antagonist O
, O
the O
pA2 NUMERIC
values O
determined O
against O
isoprenaline RARE
in O
guinea O
pig O
atria RARE
and O
tracheal O
muscle O
being O
7 O
. O
45 O
and O
6 O
. O
41 O
, O
respectively O
. O

Output RARE
of O
99mTcO NUMERIC
- O
4 O
by O
the O
parotid RARE
gland O
closely O
mimicked O
fluctuations O
in O
parotid RARE
saliva RARE
flow O
rate O
. O

The O
Hagen RARE
- O
Poiseuille RARE
equation O
is O
used O
to O
assess O
the O
effects O
of O
attached O
parasites O
in O
the O
foregut RARE
of O
Leishmania O
- O
infected O
sandflies RARE
on O
blood O
flow O
. O

Moreover O
, O
in O
rats O
allowed O
to O
choose RARE
in O
a O
T O
- O
maze RARE
between O
immediate O
- O
but O
- O
small O
vs O
. O
delayed O
- O
but O
- O
large O
reward RARE
, O
BZP ALLCAPS
significantly O
decreased O
the O
frequency O
with O
which O
the O
delayed O
reward RARE
was O
chosen O
, O
with O
5 O
- O
HT O
uptake O
blockers O
producing O
opposite O
effects O
. O

An O
endometrial O
luteal O
phase O
deficiency O
was O
detected O
in O
15 O
( O
30 O
%) O
of O
aborting RARE
patients O
. O

Prenatal RARE
exposure O
to O
the O
fungicide RARE
dinocap RARE
causes O
behavioral O
torticollis RARE
, O
ballooning RARE
and O
cleft RARE
palate RARE
in O
mice O
, O
but O
not O
rats O
or O
hamsters O
. O

Reperfusion RARE
with O
normal O
blood O
in O
the O
beating RARE
, O
working O
hearts O
caused O
extensive O
structural O
damage O
, O
reduced O
reflow RARE
, O
and O
failed O
to O
restore RARE
contractility O
in O
any O
instance RARE
(- O
27 O
% O
systolic O
shortening O
, O
p O
less O
than O
0 O
. O
05 O
). O

The O
sensitivity O
of O
the O
vas O
deferens O
to O
adrenaline O
was O
also O
reduced O
in O
scorbutic RARE
guinea O
pigs O
, O
thus O
decreasing O
their O
fertility O
rate O
. O

In O
metabolic O
acidosis O
there O
was O
a O
marked O
stimulation O
when O
clamped RARE
at O
- O
10 O
to O
- O
100 O
mV LASTCAP
. O

On O
Days RARE
1 O
and O
14 O
, O
most O
young O
and O
elderly O
subjects O
exhibited O
monoexponential RARE
decline O
in O
bevantolol RARE
plasma O
concentrations O
after O
absorption O
phase O
. O

Mature RARE
and O
old O
B6AF1 NUMERIC
and O
B6D2F1 NUMERIC
mice O
were O
given O
acidified RARE
tap O
water O
or O
promethazine RARE
HCl RARE
( O
a O
phenothiazine RARE
with O
H1 I-GENE
receptor I-GENE
blocking O
activity O
), O
chlorpheniramine RARE
( O
an O
H1 I-GENE
blocker O
) O
or O
trifluoperazine RARE
( O
a O
phenothiazine RARE
with O
no O
H1 I-GENE
blocking O
activity O
) O
in O
their O
drinking O
water O
, O
and O
the O
effects O
of O
these O
agents O
on O
bone O
mineral O
content O
were O
assessed O
by O
intermittently RARE
measuring O
the O
24 O
- O
h O
whole O
body O
retention O
of O
Tc O
99m O
methylene O
diphosphonate RARE
( O
Tc O
99m O
MDP ALLCAPS
, O
an O
indicator O
of O
bone O
metabolism O
) O
and O
at O
the O
end O
of O
the O
studies O
by O
determining O
ash RARE
weights O
of O
femur O
, O
ilium RARE
and O
sacrum RARE
. O

Present RARE
results O
reveal O
a O
frequency O
- O
dependent O
inhibition O
of O
ganglionic RARE
transmission O
by O
diltiazem O
, O
and O
suggest O
that O
diltiazem O
may O
depress RARE
excessive O
sympathetic O
activity O
without O
affecting O
normal O
ganglionic RARE
transmission O
. O

Studies O
were O
performed O
on O
several O
superficial O
veins RARE
from O
the O
rabbit O
face O
to O
examine O
the O
relationship O
between O
beta I-GENE
adrenoceptor I-GENE
subtype I-GENE
distribution O
, O
intrinsic O
myogenic O
tone O
and O
sympathetic O
nerve O
innervation RARE
. O

Effects O
of O
a O
new O
antihypertensive O
agent O
, O
SGB ALLCAPS
- O
1534 NUMERIC
, O
on O
rat O
platelet O
aggregation O
. O

Since O
the O
stability O
of O
TF1 NUMERIC
resides O
in O
its O
primary O
structure O
, O
we O
cloned O
a O
gene O
coding O
for O
TF1 NUMERIC
, O
and O
the O
primary O
structure O
of O
the O
beta O
subunit O
was O
deduced O
from O
the O
nucleotide O
sequence O
of O
the O
gene O
to O
compare O
the O
sequence O
with O
those O
of O
beta O
' O
s O
of O
three O
major O
categories O
of O
F1 I-GENE
' O
s O
; O
prokaryotic O
membranes O
, O
chloroplasts RARE
, O
and O
mitochondria O
. O

Body RARE
temperature O
and O
overall O
conductance O
in O
the O
cold O
appear O
to O
be O
more O
variable O
in O
P O
. O
s O
. O
campbelli RARE
than O
in O
nominative RARE
sp O
. O

Two O
polyadenylation O
sites O
were O
used O
, O
one O
at O
the O
end O
of O
the O
early I-GENE
( I-GENE
E I-GENE
) I-GENE
region I-GENE
of O
the O
viral O
DNA O
, O
the O
other O
at O
the O
end O
of O
the O
late I-GENE
( I-GENE
L I-GENE
) I-GENE
region I-GENE
. O

A O
drug O
with O
ISA ALLCAPS
" O
down O
regulates O
" O
beta I-GENE
receptors I-GENE
; O
thus O
, O
when O
the O
drug O
is O
withdrawn RARE
there O
is O
no O
post O
- O
beta O
- O
blocking O
drug O
hypersensitivity O
in O
contrast O
to O
agents O
without O
ISA ALLCAPS
. O

Six O
patients O
with O
human O
T O
- O
cell O
lymphotropic RARE
virus O
type O
I O
( O
HTLV O
- O
I O
)- O
associated O
myelopathy RARE
( O
HAM ALLCAPS
) O
were O
studied O
by O
electrophysiologic RARE
methods O
. O

Terazosin RARE
, O
a O
structural O
analog O
of O
prazosin RARE
, O
also O
inhibits O
alpha I-GENE
1 I-GENE
adrenoceptors I-GENE
and O
is O
recommended O
as O
once O
or O
twice O
- O
daily O
therapy O
. O

Testing RARE
blood O
donors O
for O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
: O
irrational RARE
, O
perhaps O
, O
but O
inescapable RARE
. O

Most O
patients O
with O
high O
blood O
pressure O
( O
BP O
) O
can O
be O
managed RARE
by O
using O
one O
of O
4 O
classes O
of O
compounds O
: O
a O
diuretic O
, O
beta O
blocker O
, O
converting O
enzyme O
inhibitor O
or O
calcium O
antagonist O
. O

In O
a O
randomised O
double O
- O
blind O
study O
, O
46 O
first O
episode RARE
schizophrenics RARE
were O
given O
pimozide RARE
or O
flupenthixol RARE
for O
up O
to O
5 O
weeks O
; O
the O
mean O
daily O
dose O
at O
the O
end O
was O
18 O
. O
8 O
mg O
pimozide RARE
and O
20 O
mg O
flupenthixol RARE
. O

Somatostatin RARE
- O
producing O
endocrine O
pancreatic O
tumor O
in O
Recklinghausen RARE
' O
s O
neurofibromatosis RARE
. O

Direct O
and O
inverted O
repeat O
elements O
of O
10 O
, O
11 O
, O
16 O
, O
19 O
, O
and O
22 O
nucleotides O
( O
nt O
) O
flank O
the O
promoter O
site O
. O

We O
have O
been O
able O
to O
map O
specific O
DNA O
fragments O
at O
the O
bases O
of O
chromatin O
loops O
with O
the O
help O
of O
a O
novel O
extraction O
procedure O
by O
using O
lithium O
- O
3 O
', O
5 O
'- O
diiodosalicylate RARE
. O

Seventy O
- O
one O
supplementary O
doses O
of O
vecuronium RARE
were O
used O
for O
muscle O
relaxation O
during O
a O
22 O
- O
h O
- O
long O
NLA ALLCAPS
II O
anaesthesia O
. O

Finally O
, O
the O
recovery O
indexes RARE
represented O
by O
the O
times O
required O
for O
T1 O
/ O
T0 NUMERIC
and O
T4 O
/ O
T1 O
to O
rise O
from O
25 O
% O
to O
75 O
% O
respectively O
were O
studied O
. O

Transformed RARE
bacterial O
colonies O
were O
screened O
for O
recombinant O
plasmids O
containing O
cDNA O
coding O
for O
BiP LASTCAP
by O
hybrid O
- O
selected O
mRNA O
translation O
. O

DPA ALLCAPS
attenuated O
the O
increase O
of O
the O
intensity O
of O
the O
ischemic O
and O
pressure O
pain O
components O
with O
increasing O
ischemia O
duration O
, O
but O
only O
the O
effect O
on O
the O
pressure O
pain O
component O
was O
significant O
. O

Topical RARE
1 O
percent O
isoproterenol O
in O
the O
presence O
of O
the O
phosphodiesterase O
inhibitor O
theophylline O
was O
tested O
for O
its O
ability O
to O
stimulate O
the O
rate O
of O
aqueous O
humor RARE
flow O
through O
the O
anterior O
chamber O
of O
the O
normal O
and O
the O
partially O
adrenergically RARE
denervated RARE
human O
eye O
( O
Horner RARE
' O
s O
syndrome O
). O

Hyperthyroidism RARE
is O
one O
of O
the O
numerous O
causes O
of O
infertility O
and O
recurrent O
abortion O
. O

A O
strong O
correlation O
exists O
between O
the O
numbers O
of O
CFU ALLCAPS
- O
GM O
transfused RARE
and O
the O
rate O
of O
granulocytes RARE
and O
platelets O
recovery O
. O

We O
propose O
that O
the O
technique O
of O
low O
- O
frequency O
kindling O
is O
a O
useful O
experimental O
model O
in O
assessing O
the O
effects O
of O
antipsychotic RARE
or O
antiepileptic RARE
drugs O
on O
the O
excitability RARE
of O
the O
limbic RARE
regions O
. O

Oestrogen RARE
implant O
overdose RARE
. O

Three O
sequence O
elements O
are O
shown O
to O
be O
required O
for O
accurate O
and O
efficient O
transcription O
termination O
by O
RNA I-GENE
polymerase I-GENE
I I-GENE
( O
pol I-GENE
I I-GENE
) O
assayed O
both O
in O
a O
cell O
- O
free O
transcription O
system O
and O
in O
vivo O
after O
transfection O
of O
rDNA O
minigene RARE
constructs O
into O
3T6 NUMERIC
cells O
. O

The O
biosynthesis O
and O
stability O
of O
the O
three O
mutant O
proteins O
were O
similar O
to O
those O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
erbB I-GENE
protein I-GENE
, O
and O
all O
three O
retained O
the O
ability O
to O
transform O
chicken O
embryo O
fibroblasts O
. O

Codon RARE
usage O
in O
C O
. O
reinhardtii RARE
mitochondria O
is O
highly O
biased RARE
, O
with O
eight O
codons O
entirely O
absent O
from O
all O
protein O
- O
coding O
genes O
; O
however O
, O
even O
though O
codon O
usage O
is O
restricted O
, O
it O
appears O
that O
C O
. O
reinhardtii RARE
mtDNA LASTCAP
cannot O
encode O
the O
minimum O
number O
of O
tRNAs RARE
needed O
to O
support O
mitochondrial O
protein O
synthesis O
. O

A O
new O
physiopathological RARE
treatment O
of O
HBV O
- O
related O
polyarteritis RARE
inspired RARE
by O
advances RARE
in O
the O
treatment O
of O
chronic O
active O
hepatitis O
B O
was O
tested O
in O
7 O
patients O
. O

Like O
scrotal RARE
testes O
, O
undescended RARE
testes O
were O
hypointense RARE
to O
fat O
on O
sequences O
with O
a O
short O
repetition RARE
time O
( O
TR O
) O
and O
echo O
time O
( O
TE ALLCAPS
) O
in O
all O
cases O
, O
and O
hyperintense RARE
or O
isointense RARE
to O
fat O
on O
long O
TR O
/ O
TE ALLCAPS
sequences O
in O
all O
but O
two O
cases O
. O

The O
subunit I-GENE
- I-GENE
a I-GENE
gene I-GENE
is O
preceded RARE
by O
a O
gene O
coding O
for O
a O
small O
hydrophobic O
protein O
, O
as O
has O
been O
observed O
previously O
in O
the O
atp RARE
operons I-GENE
in O
E O
. O
coli O
, O
bacterium O
PS3 NUMERIC
and O
cyanobacteria RARE
. O

Here O
, O
we O
describe O
the O
isolation O
of O
bovine I-GENE
and I-GENE
rat I-GENE
GHF ALLCAPS
- I-GENE
1 I-GENE
cDNA I-GENE
clones O
. O

To O
explore O
the O
functional O
properties O
of O
the O
protein O
encoded O
by O
neu I-GENE
, O
we O
created O
a O
fusion O
gene O
that O
joins O
the O
cytoplasmic O
domain O
of O
neu I-GENE
to O
the O
extracellular O
portion O
of O
an O
immunoglobulin I-GENE
heavy I-GENE
chain I-GENE
. O

The O
East RARE
African O
dik RARE
- O
dik RARE
antelope RARE
represents O
a O
miniature RARE
model O
ruminant RARE
for O
comparative O
studies O
. O

By O
sequence O
comparison O
, O
42 O
blocks O
of O
homology O
are O
defined O
in O
the O
5 O
'- O
terminal O
region O
, O
of O
which O
36 O
appear O
in O
the O
CpG O
island O
and O
contain O
numerous O
conserved O
CpG O
dinucleotides RARE
. O

Among O
unusual O
features O
, O
we O
report O
numerous O
large O
G O
+ O
C O
- O
rich O
conserved O
sequences O
located O
in O
the O
first O
intron O
. O

In O
the O
first O
group O
, O
0 O
. O
02 O
% O
Prazosin RARE
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
was O
administered O
intravenously O
for O
1 O
. O
5 O
hours O
before O
the O
application O
of O
Oxy RARE
- O
Hb O
or O
PGF2 O
alpha O
. O

Efficacy RARE
and O
field O
evaluation O
of O
Bacillus O
thuringiensis RARE
( O
H O
- O
14 O
) O
and O
B O
. O
sphaericus RARE
against O
floodwater RARE
mosquitoes RARE
in O
California RARE
. O

2 O
cases O
of O
type O
II O
tyrosinosis RARE
( O
Richner RARE
- O
Hanhart RARE
syndrome O
) O

This O
loss O
was O
independent O
of O
drug O
concentration O
and O
a O
correction O
factor O
was O
employed O
to O
calculate RARE
the O
true O
free O
diazepam O
concentration O
. O

Effects O
of O
a O
perfluorochemical RARE
blood O
substitute O
on O
diazepam O
binding O
by O
human I-GENE
albumin I-GENE
. O

A O
second O
promoter O
activity O
was O
identified O
in O
the O
region O
between O
the O
two O
major O
transcriptional O
start O
sites O
. O

A O
decamer RARE
sequence O
, O
5 O
'- O
CGA ALLCAPS
- O
CCCCUCC ALLCAPS
- O
3 O
', O
complementary O
to O
a O
conserved O
sequence O
adjacent O
to O
the O
enzymatic O
cleavage O
site O
on O
the O
mitochondrial O
RNA O
substrate O
, O
is O
present O
in O
the O
RNAase RARE
MRP I-GENE
RNA I-GENE
. O

Effects O
of O
aging O
and O
beta O
- O
adrenergic O
- O
blockade O
on O
standing RARE
- O
induced O
QT O
/ O
QS2 NUMERIC
changes O
. O

A O
patient O
with O
an O
infected O
wound O
or O
one O
on O
a O
primary O
area O
( O
hands RARE
, O
feet RARE
, O
face O
, O
or O
perineum RARE
) O
may O
have O
to O
be O
hospitalized O
to O
ensure RARE
proper O
care O
. O

Pharmacology RARE
studies O
with O
potassium O
chloride O
and O
acetylcholine O
suggest O
that O
raveron RARE
acts O
as O
a O
calcium O
antagonist O
by O
blocking O
the O
influx RARE
of O
extracellular O
calcium O
. O

Computer RARE
analysis O
included O
digital O
averaging RARE
, O
followed O
by O
digital O
filtering RARE
in O
different O
frequency O
bands O
in O
order O
to O
determine O
the O
frequency O
range O
corresponding O
to O
notches RARE
and O
slurs RARE
. O

On O
admission O
to O
the O
ICU ALLCAPS
, O
117 O
patients O
( O
61 O
percent O
) O
had O
hypomagnesemia RARE
( O
serum O
Mg O
less O
than O
1 O
. O
5 O
mEq O
/ O
dl O
), O
66 O
patients O
( O
34 O
percent O
) O
had O
normomagnesemia RARE
( O
1 O
. O
5 O
to O
2 O
. O
0 O
mEq O
/ O
dl O
), O
and O
ten O
patients O
( O
5 O
percent O
) O
had O
hypermagnesemia RARE
( O
greater O
than O
2 O
. O
0 O
mEq O
/ O
dl O
). O

The O
risk O
factors O
studied O
were O
male O
sex O
, O
hypertension O
, O
diabetes O
mellitus O
, O
hypercholesterolemia RARE
, O
cigarette RARE
smoking O
, O
sedentary RARE
life O
- O
style RARE
, O
and O
family O
history O
. O

Neither O
verapamil O
nor O
nifedipine O
changed O
collateral O
myocardial O
blood O
flow O
from O
0 O
. O
10 O
+/- O
0 O
. O
02 O
in O
the O
subendocardium RARE
and O
0 O
. O
17 O
+/- O
0 O
. O
03 O
ml O
/ O
min O
/ O
g O
in O
the O
subepicardium RARE
. O

There O
were O
35 O
boys O
and O
15 O
girls O
, O
with O
a O
mean O
age O
of O
five O
and O
a O
half O
years O
. O

Controlled RARE
versus O
uncontrolled RARE
reperfusion O
of O
ischemic O
myocardium O
after O
experimental O
coronary O
artery O
occlusion O
was O
studied O
to O
determine O
the O
effect O
on O
regional O
ventricular O
wall O
motion O
and O
associated O
biochemical O
alterations O
. O

Cardiac O
disease O
was O
not O
detected O
with O
M O
- O
mode O
, O
2 O
- O
dimensional O
real O
- O
time O
or O
pulsed O
- O
wave O
Doppler O
echocardiography O
. O

Hemodynamic RARE
assessment O
was O
obtained O
before O
and O
following O
administration O
of O
digoxin RARE
10 O
micrograms O
/ O
kg O
IV O
or O
dopamine O
, O
5 O
to O
12 O
micrograms O
/ O
kg O
/ O
min O
IV O
. O

We O
also O
examined O
the O
relationship O
between O
the O
side O
of O
sinusitis RARE
and O
the O
cleft RARE
side O
in O
patients O
with O
unilateral O
cleft RARE
palate RARE
. O

We O
conclude O
that O
at O
these O
low O
levels O
studied O
, O
aluminum O
accumulates O
in O
intestinal O
tissue O
, O
and O
that O
this O
accumulation O
is O
enhanced O
by O
citrate O
ligand O
. O

Thus O
, O
the O
effects O
of O
father RARE
absence O
under O
routine O
conditions O
in O
relatively O
healthy O
samples O
may O
exert O
no O
significant O
effects O
independent O
of O
intervening O
family O
stressors RARE
or O
maternal O
psychopathology RARE
. O

Recently O
, O
an O
electrical O
- O
mechanical O
analog O
model O
of O
heat O
flow O
within O
the O
brain O
has O
been O
developed O
from O
which O
an O
expression O
for O
CBF O
has O
been O
derived O
: O
CBF O
= O
Cb RARE
/( RARE
tau O
rho O
c O
) O
where O
tau O
is O
the O
thermal O
decay O
constant O
, O
rho O
is O
the O
density O
of O
blood O
, O
and O
c O
is O
its O
specific O
heat O
. O

All O
of O
the O
newly O
acquired O
proviruses RARE
identified O
in O
mosaic O
founder RARE
SWR ALLCAPS
/ O
J O
- O
RF ALLCAPS
/ O
J O
mice O
that O
could O
be O
transmitted O
through O
the O
germ O
line O
were O
also O
present O
in O
somatic O
tissues O
, O
demonstrating O
that O
viral O
integration O
occurred O
before O
the O
germ O
line O
was O
set O
aside RARE
from O
the O
somatic O
lineages O
. O

Molecular O
cloning O
of O
the O
cDNA O
for O
the O
human I-GENE
U2 I-GENE
snRNA I-GENE
- I-GENE
specific I-GENE
A I-GENE
' I-GENE
protein I-GENE
. O

For O
the O
present O
work O
we O
used O
water O
saturated RARE
with O
a O
50 O
/ O
50 O
mixture O
of O
H2 O
and O
O2 O
gases O
, O
for O
which O
the O
heat O
defect O
is O
calculated O
to O
be O
- O
2 O
. O
1 O
%. O

Successful RARE
use O
of O
transureteroureterostomy RARE
to O
salvage RARE
ureterosigmoidostomy RARE
after O
anastomotic RARE
failure O
. O

During O
flexion RARE
whiplash RARE
, O
the O
torque RARE
at O
the O
occipital RARE
condyle RARE
reverses RARE
its O
direction O
at O
about O
25 O
ms O
after O
impact O
. O

The O
data O
indicates O
the O
presence O
of O
5 I-GENE
- I-GENE
HT2 I-GENE
serotonergic RARE
receptors I-GENE
in O
the O
bronchial O
artery O
of O
these O
species O
. O

Oxfendazole RARE
, O
which O
was O
active O
for O
the O
shortest RARE
time O
( O
about O
65 O
days O
) O
from O
the O
start O
of O
grazing RARE
( O
May RARE
1 O
), O
produced O
a O
78 O
. O
1 O
per O
cent O
reduction O
in O
Ostertagia RARE
species O
and O
an O
84 O
. O
4 O
per O
cent O
reduction O
in O
D O
viviparus RARE
. O

By O
adapting O
a O
method O
for O
DNA O
- O
footprinting O
using O
impure RARE
extracts O
of O
ner RARE
overproducing RARE
cells O
, O
we O
were O
able O
to O
determine O
that O
the O
ner RARE
- I-GENE
binding I-GENE
sites I-GENE
are O
located O
between O
nucleotides O
1026 NUMERIC
and O
1058 NUMERIC
from O
the O
Mu RARE
left O
end O
. O

We O
have O
identified O
and O
characterized O
the O
structure O
of O
the O
Spec1 NUMERIC
gene I-GENE
in O
the O
sea O
urchin O
Strongylocentrotus RARE
purpuratus RARE
. O

Platelet O
function O
and O
platelet O
- O
polymorphonuclear RARE
- O
neutrophil O
interaction O
in O
patients O
with O
deficient O
platelet I-GENE
lipoxygenase RARE
activity O
. O

Spontaneous RARE
degradation O
of O
atracurium RARE
in O
plasma O
is O
the O
major O
route O
of O
elimination O
in O
man O
and O
contributes O
to O
a O
short O
elimination O
half O
- O
life O
( O
approximatively RARE
20 O
min O
). O

Transformed RARE
cell O
lines O
expressing O
solely O
E1a I-GENE
or O
E1a I-GENE
and O
E1b NUMERIC
gene I-GENE
products I-GENE
derived O
from O
these O
viruses O
display O
enhanced O
anchorage O
- O
independent O
growth O
at O
37 O
degrees O
C O
versus O
32 O
degrees O
C O
and O
display O
a O
cytoskeletal O
architecture O
resembling O
untransformed RARE
fibroblastic RARE
CREF ALLCAPS
cells O
. O

Partial O
N O
- O
terminal O
amino O
acid O
sequence O
analysis O
showed O
that O
the O
43K NUMERIC
and I-GENE
42K NUMERIC
T I-GENE
antigens I-GENE
contain O
methionine O
at O
residues O
1 O
and O
5 O
, O
as O
predicted O
from O
the O
DNA O
sequence O
, O
whereas O
no O
methionine O
was O
released O
from O
the O
39K NUMERIC
T I-GENE
antigen I-GENE
during O
the O
first O
six O
cycles O
of O
Edman RARE
degradation O
. O

Group O
A O
was O
treated O
with O
three O
or O
four O
doses O
of O
hepatitis I-GENE
B I-GENE
immune I-GENE
globulin I-GENE
( O
HBIG ALLCAPS
) O
in O
one O
of O
three O
different O
schedules RARE
. O

In O
the O
former O
instance RARE
, O
in O
addition O
to O
serum O
calcium O
and O
phosphorous RARE
ion O
concentrations O
, O
tissue O
pH O
, O
blood O
supply O
, O
hormones O
, O
i O
. O
e O
., O
vitamin O
D O
, O
vitamin O
A O
, O
and O
various O
enzymes O
( O
e O
. O
g O
., O
alkaline I-GENE
phosphatase I-GENE
and O
pyrophosphatase RARE
) O
may O
all O
play O
significant O
, O
ancillary RARE
, O
time O
- O
dependent O
, O
but O
as O
yet O
undetermined RARE
roles O
. O

Penicillinase RARE
production O
in O
Staphylococcus O
aureus O
strains O
of O
clinical O
importance O
. O

Thus O
, O
quantitative O
analysis O
of O
thallium O
- O
201 O
uptake O
and O
washout O
provided O
objective O
evidence O
for O
improved O
myocardial O
perfusion O
after O
coronary O
angioplasty RARE
. O

This O
study O
reports O
the O
effects O
of O
a O
preparation O
with O
50 O
micrograms O
ethinyl RARE
estradiol O
and O
2 O
mg O
cyproterone RARE
acetate O
on O
gonadotropins RARE
, O
prolactin I-GENE
, O
testosterone O
, O
sex I-GENE
hormone I-GENE
binding I-GENE
globulin I-GENE
( O
SHBG I-GENE
), O
androstenedione RARE
, O
and O
calculated O
free O
testosterone O
index O
before O
and O
after O
six O
months O
of O
treatment O
. O

Functional O
flow O
was O
evaluated O
using O
laser O
Doppler O
flowmetry RARE
( O
LDF ALLCAPS
), O
for O
which O
the O
output O
signal O
, O
blood O
cell O
flux RARE
( O
BCF ALLCAPS
), O
is O
expressed O
in O
terms O
of O
volts RARE
. O

In O
nine O
patients O
with O
renal O
failure O
routine O
haemodialysis O
was O
accompanied O
by O
a O
30 O
per O
cent O
reduction O
in O
plasma O
ANP I-GENE
concentration O
. O

To O
investigate O
the O
effects O
of O
isotretinoin RARE
on O
HDL I-GENE
, O
we O
measured O
HDL I-GENE
- I-GENE
C I-GENE
, O
HDL I-GENE
phospholipids O
( O
HDL I-GENE
- I-GENE
PL I-GENE
), O
apoprotein RARE
A1 I-GENE
( O
apo I-GENE
A I-GENE
- I-GENE
1 I-GENE
), O
and O
HDL I-GENE
- I-GENE
C I-GENE
subfractions RARE
( O
HDL2 I-GENE
- I-GENE
C I-GENE
and O
HDL3 NUMERIC
- I-GENE
C I-GENE
) O
in O
24 O
healthy O
, O
male O
patients O
receiving O
a O
16 O
- O
week O
course O
of O
isotretinoin RARE
( O
1 O
. O
0 O
mg O
/ O
kg O
/ O
day O
) O
for O
treatment O
of O
severe O
acne RARE
vulgaris RARE
. O

The O
clinical O
picture O
and O
laboratory O
parameters O
were O
consistent O
with O
a O
serum O
sickness RARE
reaction O
. O

Our O
data O
, O
however O
, O
did O
not O
suggest O
the O
existence O
of O
a O
conversion O
factor O
for O
LDF ALLCAPS
signal O
to O
absolute O
flow O
values O
from O
experiment O
to O
experiment O
. O

Preventive RARE
effect O
of O
ONO ALLCAPS
- O
3708 NUMERIC
on O
thrombosis O
and O
vasospasms RARE
in O
vitro O
and O
in O
vivo O
. O

The O
frequency O
of O
PPNG ALLCAPS
strains O
increased O
from O
1 O
. O
7 O
% O
in O
1981 NUMERIC
to O
6 O
. O
7 O
% O
in O
1985 O
. O

Monospecific RARE
antibodies O
, O
eluted RARE
from O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
fusion O
protein O
of O
either O
clone O
reacted O
with O
the O
U1 I-GENE
snRNP I-GENE
- O
specific O
A I-GENE
antigen I-GENE
. O

Quantitative O
analysis O
of O
the O
coronary O
stenosis O
was O
assessed O
before O
and O
after O
PTCA O
, O
and O
the O
dilatation O
resulted O
in O
an O
increase O
in O
minimal O
luminal O
cross O
- O
sectional O
area O
from O
1 O
. O
1 O
+/- O
0 O
. O
8 O
to O
2 O
. O
7 O
+/- O
1 O
. O
2 O
mm2 O
. O

The O
pathogenesis O
of O
Limited RARE
Joint RARE
Mobility RARE
( O
LJM ALLCAPS
) O
in O
diabetes O
is O
unknown O
, O
but O
the O
abnormality O
is O
said RARE
to O
be O
associated O
with O
an O
increased O
incidence O
of O
microangiopathy RARE
. O

In O
a O
previous O
study O
( O
Brandl RARE
, O
C O
. O

The O
experimental O
end O
points O
were O
the O
time O
required O
for O
treated O
tumors O
to O
reach O
3 O
times O
their O
treatment O
size O
, O
the O
survival O
of O
stem O
cells O
in O
the O
duodenal O
crypts RARE
, O
and O
the O
breathing O
rate O
measured O
early O
( O
19 O
- O
23 O
weeks O
) O
and O
late O
( O
41 O
- O
46 O
weeks O
) O
after O
treatment O
. O

Schedule RARE
2 O
, O
in O
which O
2 O
. O
4 O
mg O
/ O
kg O
c O
- O
DDP O
was O
administered O
immediately O
before O
X O
- O
ray O
on O
5 O
consecutive O
days O
produced O
the O
highest O
degree O
of O
enhancement O
of O
radiation O
effect O
( O
expressed O
as O
dose O
- O
effect O
factor O
); O
and O
the O
next O
greatest O
enhancement O
was O
produced O
by O
12 O
mg O
/ O
kg O
c O
- O
DDP O
administered O
24 O
h O
before O
the O
start O
of O
fractionated RARE
daily O
radiotherapy O
. O

The O
cpc RARE
- I-GENE
1 I-GENE
- I-GENE
encoded I-GENE
transcript I-GENE
contains O
three O
open O
reading O
frames O
, O
two O
of O
which O
are O
located O
in O
the O
720 NUMERIC
- O
nucleotide O
leader O
segment O
preceding O
the O
cpc RARE
- I-GENE
1 I-GENE
coding I-GENE
region I-GENE
. O

The O
seco RARE
- O
steroid O
hormone O
1 O
, O
25 O
- O
dihydroxyvitamin RARE
D3 O
is O
known O
to O
induce O
the O
expression O
of O
a O
calcium O
binding O
protein O
termed O
calbindin RARE
- I-GENE
D28K NUMERIC
in O
a O
variety O
of O
target O
tissues O
. O

In O
addition O
, O
the O
calbindin RARE
- I-GENE
D28K NUMERIC
promoter I-GENE
is O
composed O
of O
a O
variety O
of O
simple O
repeated O
sequences O
, O
some O
of O
which O
are O
components O
of O
putative O
regulatory O
signals O
. O

The O
HOI ALLCAPS
induced O
a O
nearly O
fourfold O
increase O
in O
ANF ALLCAPS
in O
the O
elderly O
, O
whereas O
that O
for O
the O
young O
was O
threefold O
. O

To O
assess O
the O
ability O
of O
the O
atria RARE
to O
maintain O
elevated O
plasma O
concentrations O
of O
atrial I-GENE
natriuretic RARE
peptide I-GENE
( O
ANP I-GENE
), O
the O
temporal O
changes O
in O
plasma I-GENE
ANP I-GENE
concentrations O
were O
studied O
in O
seven O
chloralose RARE
- O
anaesthetized RARE
dogs O
during O
4 O
h O
of O
sustained O
rapid O
cardiac O
pacing O
. O

Ig I-GENE
D I-GENE
- O
JH ALLCAPS
recombinations RARE
may O
precede RARE
TcR LASTCAP
gene I-GENE
recombination O
in O
these O
early O
T O
cell O
lines O
, O
and O
some O
but O
not O
all O
express O
sterile RARE
Cmu RARE
transcripts I-GENE
. O

The O
RAD18 NUMERIC
gene I-GENE
open I-GENE
reading I-GENE
frame I-GENE
encodes O
a O
protein O
of O
487 NUMERIC
amino O
acids O
, O
with O
a O
calculated O
molecular O
weight O
of O
55 O
, O
512 NUMERIC
. O

Atomic RARE
absorption O
spectrophotometry RARE
applied O
to O
bacterially O
expressed O
E1A I-GENE
proteins I-GENE
revealed O
that O
the O
289 NUMERIC
- O
amino O
acid O
protein O
binds O
one O
zinc O
ion O
, O
whereas O
the O
243 NUMERIC
- O
amino O
acid O
protein O
binds O
no O
zinc O
. O

Most O
patients O
preferred O
tablets RARE
to O
injection O
both O
on O
day O
1 O
( O
313 NUMERIC
v O
200 O
) O
and O
at O
follow O
up O
( O
373 NUMERIC
v O
104 O
). O

Plots RARE
of O
RV O
, O
LV O
+ O
S O
and O
2A O
weight O
vs O
real O
hematocrit O
showed O
sharp RARE
upward RARE
inflections RARE
at O
real O
hematocrit O
65 O
%, O
suggesting O
a O
possible O
role O
of O
increased O
viscosity O
in O
CO O
cardiomegaly RARE
at O
the O
higher O
hematocrit O
. O

The O
absorbable RARE
perisplenic RARE
mesh RARE
is O
an O
important O
improvement O
, O
and O
in O
some O
cases O
it O
may O
replace O
other O
techniques O
for O
arresting RARE
splenic O
bleeding O
. O

A O
rare O
chronic O
course O
of O
Budd RARE
- O
Chiari RARE
syndrome O
associated O
with O
thrombosis O
of O
the O
portal O
vein O
was O
observed O
in O
a O
30 O
- O
year O
- O
old O
male O
patient O
suffering O
from O
postmyocarditic RARE
cardiosclerosis RARE
. O

After O
one O
accommodation RARE
night O
, O
sleep O
EEG O
recordings O
were O
performed O
during O
three O
consecutive O
nights RARE
in O
ten O
drug O
- O
free O
inpatients RARE
presenting O
generalized O
anxiety O
disorder O
( O
GAD ALLCAPS
) O
with O
significant O
depression O
, O
compared O
with O
a O
age O
- O
and O
sex O
- O
matched O
group O
of O
patients O
with O
GAD ALLCAPS
and O
a O
group O
of O
primary O
major O
depressive RARE
disorder O
( O
MDD ALLCAPS
) O
patients O
. O

Oligonucleotide RARE
mutagenesis O
of O
these O
binding O
domains O
indicated O
their O
importance O
in O
the O
transcriptional O
regulation O
of O
the O
E3 I-GENE
promoter I-GENE
in O
yeast O
cells O
. O

The O
concentration O
of O
PGI2 NUMERIC
on O
the O
newly O
- O
formed O
luminal O
surface O
remained O
low O
. O

Organ RARE
transplantation O
in O
Denmark RARE
. O

Effects O
of O
single O
and O
combined O
maltose RARE
tetrapalmitate RARE
immunotherapy O
, O
cyclophosphamide O
chemotherapy O
and O
radiotherapy O
on O
ethyl O
carbamate RARE
accelerated O
primary O
lung O
cancer O
in O
A O
/ O
J O
mice O
. O

D O
. O

A O
114 O
- O
base O
pair O
sequence O
of O
predominantly O
repeating O
purine RARE
- O
pyrimidine O
nucleotides O
separates RARE
these O
two O
d O
( O
AC O
) O
repeats O
. O

Phase O
II O
study O
of O
VP ALLCAPS
- O
16 O
( O
capsule RARE
) O
in O
solid O
tumors O
. O

When O
the O
coding O
segments O
, O
including O
both O
framework RARE
and O
complementarity O
- O
determining O
regions O
, O
of O
these O
genes O
and O
the O
murine O
probe O
sequences O
are O
compared O
by O
metric RARE
analysis O
, O
it O
is O
apparent O
that O
the O
caiman RARE
genes O
are O
only O
slightly O
more O
related O
to O
each O
other O
than O
to O
the O
mammalian O
sequence O
, O
consistent O
with O
significant O
preservation O
of O
nucleotide O
sequence O
over O
an O
extended O
period O
of O
phylogenetic O
time O
. O

Evidence O
for O
a O
role O
of O
endogenous I-GENE
corticotropin RARE
- I-GENE
releasing I-GENE
factor I-GENE
in O
cold O
, O
ether O
, O
immobilization RARE
, O
and O
traumatic RARE
stress O
. O

An O
unusual O
feature O
of O
these O
replicative O
genes O
is O
that O
the O
smaller O
mRNA O
begins O
within O
a O
long O
open O
reading O
frame O
of O
the O
larger O
mRNA O
. O

Different RARE
sequence O
elements O
of O
both O
the O
retroviral O
vectors O
and O
the O
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
recombined RARE
during O
genesis RARE
of O
highly O
oncogenic O
retroviruses RARE
CMII ALLCAPS
, O
MC29 NUMERIC
, O
or O
MH2 NUMERIC
. O

81 O
milk O
samples O
collected O
from O
35 O
donors O
3 O
days O
to O
7 O
months O
after O
delivery O
were O
examined O
for O
the O
occurrence O
of O
cytomegalovirus O
( O
CMV O
). O

Subcloning RARE
of O
DNA O
fragments O
from O
the O
8 O
. O
5 O
- O
kilobase O
( O
kb O
) O
insert O
of O
pAVO4 NUMERIC
defined O
a O
4 O
- O
kb O
DNA O
fragment O
which O
contained O
the O
functional I-GENE
FBP ALLCAPS
+ I-GENE
gene I-GENE
and O
its O
regulatory O
region O
. O

Three O
cases O
of O
primary O
signet RARE
- O
ring RARE
cell O
carcinoma O
of O
the O
rectum RARE
are O
described O
. O

The O
data O
obtained O
up O
to O
now O
only O
suggest O
the O
future O
potentiality RARE
of O
Bestatin RARE
treatment O
for O
these O
types O
of O
malignancy O
. O

These O
data O
suggest O
that O
dopaminergic O
regulation O
of O
adrenal O
zona RARE
glomerulosa RARE
corticosteroid O
and O
renal I-GENE
renin I-GENE
secretion O
is O
absent O
in O
patients O
with O
high O
spinal O
cord O
transections RARE
, O
suggesting O
that O
intact O
neural O
pathways O
from O
the O
central O
nervous O
system O
are O
necessary O
for O
metoclopramide RARE
stimulation O
of O
aldosterone O
and O
renin I-GENE
secretion O
in O
men O
. O

In O
the O
absence O
of O
enhancer O
sequences O
, O
the O
adenovirus I-GENE
E1A I-GENE
gene I-GENE
can O
not O
stimulate O
CATase RARE
synthesis O
. O

These O
IgG I-GENE
antibodies I-GENE
in O
the O
babies O
diminished O
rapidly O
after O
delivery O
, O
and O
were O
detectable O
only O
in O
3 O
cases O
at O
2 O
, O
3 O
, O
and O
5 O
months O
of O
ages O
out O
of O
38 O
babies O
up O
to O
21 O
months O
. O

Fine RARE
analysis O
at O
the O
nucleotide O
level O
of O
the O
early O
events O
in O
the O
digestion O
with O
nuclease I-GENE
S1 I-GENE
shows O
that O
the O
enzyme O
attacks O
preferentially O
the O
sequence O
( O
G O
- O
A O
) O
12 O
on O
the O
message O
complementary O
strand O
. O

Those RARE
dosages RARE
that O
inhibited O
mean O
NTE ALLCAPS
activity O
in O
spinal O
cord O
greater O
than O
or O
equal O
to O
72 O
% O
and O
brain O
greater O
than O
or O
equal O
to O
66 O
% O
of O
control O
values O
within O
44 O
hr O
postexposure O
produced O
marked O
spinal O
cord O
pathology O
14 O
days O
postexposure O
in O
greater O
than O
or O
equal O
to O
90 O
% O
of O
similarly O
dosed RARE
animals O
. O

FK O
33 O
- O
824 NUMERIC
, O
a O
methionine O
- O
enkephalin RARE
analogue O
, O
suppressed O
plasma O
ACTH I-GENE
to O
85 O
% O
of O
basal O
level O
, O
while O
bromocriptine RARE
( O
CB ALLCAPS
- O
154 O
) O
caused O
no O
significant O
change O
. O

A O
v I-GENE
- I-GENE
erbB I-GENE
- I-GENE
related I-GENE
protooncogene I-GENE
, O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
2 I-GENE
, O
is O
distinct O
from O
the O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
1 I-GENE
/ O
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
receptor I-GENE
gene O
and O
is O
amplified O
in O
a O
human O
salivary O
gland O
adenocarcinoma O
. O

The O
sequence O
analysis O
of O
both O
products O
of O
individual O
phi O
80 O
site O
- O
specific O
recombination O
events O
in O
vivo O
shows O
that O
recombination O
with O
a O
secondary O
attachment O
( O
att RARE
) O
site O
generates O
several O
different O
novel O
joints RARE
at O
the O
mismatched RARE
position O
: O
one O
recombination O
event O
resulted O
in O
a O
single O
base O
- O
pair O
deletion O
and O
two O
other O
recombination O
events O
resulted O
in O
two O
different O
single O
base O
- O
pair O
substitutions O
. O

This O
L I-GENE
- I-GENE
myc I-GENE
sequence I-GENE
is O
amplified O
10 O
- O
20 O
- O
fold O
in O
four O
SCLC ALLCAPS
cell O
line O
DNAs O
and O
in O
one O
SCLC ALLCAPS
tumour O
specimen RARE
taken O
directly O
from O
a O
patient O
. O

Temperature RARE
- O
shift O
experiments O
using O
synchronously RARE
grown O
cells O
of O
a O
delta I-GENE
top1 NUMERIC
top2 NUMERIC
temperature I-GENE
- I-GENE
sensitive I-GENE
( I-GENE
ts I-GENE
) I-GENE
double I-GENE
mutant I-GENE
and O
its O
isogenic RARE
top2 NUMERIC
ts O
strain O
show O
that O
, O
whereas O
mitotic O
blocks O
can O
prevent O
killing RARE
of O
the O
top2 NUMERIC
ts I-GENE
mutant I-GENE
at O
a O
nonpermissive RARE
temperature O
, O
the O
same O
treatments O
are O
ineffective RARE
in O
preventing O
cell O
death O
of O
the O
delta I-GENE
top1 NUMERIC
top2 NUMERIC
ts I-GENE
double I-GENE
mutant I-GENE
. O

The O
homology O
to O
v I-GENE
- I-GENE
mil RARE
starts RARE
within O
the O
coding O
sequence O
of O
exon O
1 O
and O
ends O
within O
the O
3 O
' O
untranslated O
region O
of O
exon O
11 O
, O
12 O
nucleotides O
downstream O
from O
the O
nonsense O
codon O
terminating RARE
the O
large O
open O
reading O
frame O
shared O
between O
c I-GENE
- I-GENE
mil RARE
and O
v I-GENE
- I-GENE
mil RARE
. O

Examination O
of O
the O
sequence O
of O
the O
Punta RARE
Toro RARE
M I-GENE
gene I-GENE
product I-GENE
reveals O
the O
presence O
of O
multiple O
hydrophobic O
sequences O
including O
a O
19 O
- O
amino O
acid O
, O
carboxy O
- O
proximal O
, O
hydrophobic O
region O
( O
G2 O
). O

Six O
( O
four O
FAP ALLCAPS
; O
two O
primary O
amyloidosis RARE
) O
also O
had O
diffusely RARE
positive O
myocardial O
uptakes RARE
, O
but O
the O
intensity O
was O
less O
than O
that O
of O
the O
sternum RARE
. O

The O
intensity O
of O
myocardial O
uptake O
of O
Tc O
- O
99m O
- O
PYP ALLCAPS
in O
patients O
with O
echocardiographic O
left O
ventricular O
hypertrophy O
and O
/ O
or O
highly O
refractile RARE
myocardial O
echoes RARE
, O
so O
- O
called O
granular RARE
sparkling RARE
appearance O
( O
GS O
) O
was O
slightly O
greater O
than O
that O
in O
patients O
with O
neither O
myocardial O
hypertrophy O
nor O
GS O
. O

The O
210 O
kDa O
precursor O
is O
converted O
slowly O
( O
t O
1 O
/ O
2 O
= O
2 O
h O
) O
by O
proteolytic O
processing O
into O
a O
125 O
kDa O
( O
alpha O
') O
and O
83 O
kDa O
( O
beta O
') O
species O
. O

Alveolar RARE
lymphocytes O
were O
surprisingly RARE
increased O
in O
most O
patients O
with O
AIDS O
( O
mean O
26 O
. O
1 O
+/- O
21 O
. O
9 O
%; O
range O
1 O
- O
76 O
%) O
and O
CGL ALLCAPS
( O
mean O
26 O
. O
6 O
+/- O
22 O
. O
6 O
%; O
range O
3 O
- O
76 O
%) O
with O
criteria O
of O
activation O
contrasting RARE
with O
the O
blood O
lymphopenia RARE
. O

We O
have O
determined O
that O
these O
nicks RARE
occur O
in O
both O
the O
wild O
- O
type O
and O
the O
mutant O
sites O
. O

The O
sequence O
was O
determined O
for O
a O
4024 NUMERIC
- O
base O
pair O
( O
bp O
) O
segment O
that O
extends RARE
from O
149 NUMERIC
bp O
5 O
' O
to O
the O
cap O
site O
of O
alpha I-GENE
1 I-GENE
to O
207 NUMERIC
bp O
3 O
' O
to O
psi I-GENE
alpha I-GENE
. O

Its O
predicted O
amino O
acid O
sequence O
shows O
extensive O
homology O
to O
those O
of O
Drosophila I-GENE
hsp70 I-GENE
, O
trout I-GENE
hsp70 I-GENE
, O
Xenopus I-GENE
hsp70 I-GENE
, O
yeast I-GENE
hsp70 I-GENE
, O
and O
some O
homology O
to O
the O
heat I-GENE
- I-GENE
inducible I-GENE
dnaK LASTCAP
gene I-GENE
product I-GENE
of O
Escherichia O
coli O
. O

When O
phosphorylation O
of O
exogenous O
peptide O
substrates O
was O
measured O
as O
a O
function O
of O
receptor O
self O
- O
phosphorylation O
, O
tyrosine I-GENE
kinase I-GENE
activity O
was O
found O
to O
be O
enhanced O
two O
to O
threefold O
at O
1 O
- O
2 O
mol O
of O
phosphate O
per O
mol O
of O
receptor O
. O

At O
temperatures O
permissive O
for O
transformation O
, O
6m2 NUMERIC
cells O
contain O
P58gag NUMERIC
produced O
from O
the O
4 O
. O
0 O
- O
kilobase O
( O
kb O
) O
viral O
RNA O
genome O
and O
P85gag NUMERIC
- O
mos I-GENE
translated O
from O
a O
3 O
. O
5 O
- O
kb O
spliced O
mRNA O
. O

The O
pet56 NUMERIC
and O
his3 NUMERIC
genes I-GENE
are O
transcribed O
divergently O
from O
initiation O
sites O
that O
are O
separated O
by O
only O
192 O
bp O
. O

Multistep RARE
transformation O
by O
defined O
fragments O
of O
herpes O
simplex O
virus O
type O
2 O
DNA O
: O
oncogenic O
region O
and O
its O
gene O
product O
. O

It O
is O
concluded O
that O
in O
patients O
with O
first O
- O
attack RARE
genital O
herpes O
, O
the O
type O
of O
HSV O
is O
the O
most O
important O
determinant O
of O
subsequent O
recurrences RARE
and O
that O
intravenous O
acyclovir RARE
has O
little O
effect O
on O
subsequent O
recurrences RARE
. O

Comparison O
of O
sequences O
of O
ovine RARE
and O
bovine O
, O
rat O
and O
guinea I-GENE
- I-GENE
pig I-GENE
alpha I-GENE
s1 NUMERIC
- I-GENE
casein I-GENE
mRNAs I-GENE
has O
revealed O
a O
greater O
homology O
in O
the O
3 O
' O
and O
especially O
5 O
' O
non O
coding O
regions O
. O

One O
group O
( O
n O
= O
9 O
) O
was O
premedicated RARE
with O
midazolam O
, O
0 O
. O
1 O
mg O
kg O
- O
1 O
, O
and O
atropine O
0 O
. O
2 O
- O
0 O
. O
4 O
mg O
i O
. O
m O
. O

Comparison O
with O
a O
recently O
described O
c I-GENE
- I-GENE
sis RARE
cDNA I-GENE
clone I-GENE
( O
Collins RARE
et O
al O
., O
Nature RARE
316 NUMERIC
, O
748 NUMERIC
- O
750 O
( O
1985 O
)) O
revealed O
that O
the O
1 O
. O
9 O
kbp O
DNA O
region O
contained O
a O
large O
5 I-GENE
' I-GENE
c I-GENE
- I-GENE
sis RARE
exon I-GENE
of O
at O
least O
1050 NUMERIC
bp O
. O

It O
was O
also O
suggested O
that O
the O
biological O
activities O
of O
5 O
- O
FU O
, O
ADM ALLCAPS
and O
MMC O
in O
FAMLIP ALLCAPS
were O
stable O
in O
FULIP ALLCAPS
, O
ADRLIP ALLCAPS
and O
MMCLIP ALLCAPS
. O

Surprisingly O
, O
a O
C O
to O
G O
transversion O
at O
the O
first O
residue O
of O
the O
CAT I-GENE
pentanucleotide RARE
, O
which O
severely O
impairs RARE
the O
activity O
of O
both O
promoters O
, O
appears O
to O
increase O
affinity O
of O
the O
CAT I-GENE
binding I-GENE
protein I-GENE
. O

The O
nucleotide O
sequence O
of O
3874 NUMERIC
bp O
of O
cloned O
R O
. O
sphaeroides RARE
chromosomal O
DNA O
, O
including O
the O
three O
structural O
genes O
fbcF LASTCAP
, O
fbcB LASTCAP
and O
fbcC LASTCAP
has O
been O
determined O
. O

The O
N O
- O
terminal O
sequence O
of O
one O
hydrophilic O
peptide O
of O
the O
FeS LASTCAP
protein I-GENE
has O
been O
also O
obtained O
confirming O
the O
fbcF LASTCAP
reading O
frame O
. O

The O
5 O
' O
and O
3 O
' O
untranslated O
sequences O
contain O
characteristic O
sequences O
that O
are O
involved O
in O
the O
initiation O
and O
termination O
of O
transcription O
, O
including O
two O
possible O
promoters O
, O
one O
of O
which O
may O
contain O
two O
overlapping O
- O
10 O
sequences O
. O

Unlike O
P135gag NUMERIC
- O
myb I-GENE
- O
ets I-GENE
and O
the O
Mr O
75 O
, O
000 O
translation O
product O
of O
c I-GENE
- I-GENE
myb I-GENE
( O
P75c NUMERIC
- I-GENE
myb I-GENE
), O
which O
are O
nuclear O
proteins O
, O
P54c NUMERIC
- I-GENE
ets I-GENE
was O
found O
to O
be O
predominantly O
cytoplasmic O
. O

The O
Dox RARE
- I-GENE
A2 I-GENE
locus I-GENE
is O
within O
3 O
. O
4 O
to O
4 O
. O
4 O
kb O
of O
the O
Df RARE
( I-GENE
2L NUMERIC
) I-GENE
OD15 NUMERIC
breakpoint I-GENE
, O
placing RARE
four O
of O
the O
vital O
loci O
within O
a O
maximum O
of O
15 O
. O
5 O
kb O
. O

The O
C O
- O
terminal O
end O
of O
this O
polypeptide O
harbors RARE
three O
types O
of O
repeated O
sequences O
. O

Further O
outbreaks RARE
of O
ocular O
disease O
in O
farmed RARE
red O
deer RARE
calves O
caused O
by O
HVC ALLCAPS
- O
1 O
were O
investigated O
. O

From O
our O
ultrastructural RARE
and O
biochemical O
studies O
, O
it O
is O
evident O
that O
Type O
II O
pneumocytes RARE
are O
an O
early O
target O
of O
radiation O
and O
the O
release O
of O
surfactant O
into O
the O
alveolus RARE
shortly RARE
after O
exposure O
persists RARE
for O
days O
and O
weeks O
. O

Thirty O
of O
the O
clones O
contained O
a O
complete O
340 NUMERIC
base O
- O
pair O
dimer O
unit O
of O
the O
repeat O
. O

Two O
copies O
of O
the O
72 O
- O
bp O
repeat O
provided O
efficient O
activation O
of O
gene O
expression O
. O

The O
open O
reading O
frames O
of O
rbsD LASTCAP
, O
rbsA LASTCAP
, O
and O
rbsC LASTCAP
encode O
proteins O
of O
139 O
, O
501 NUMERIC
, O
and O
321 NUMERIC
amino O
acid O
residues O
, O
respectively O
. O

In O
order O
to O
study O
the O
influence O
of O
iron O
overload O
on O
the O
polymorphonuclear RARE
leucocyte RARE
( O
PMN O
) O
metabolism O
of O
patients O
on O
chronic O
hemodialysis O
, O
generation O
of O
superoxide O
anion RARE
( O
O2 O
-) O
by O
PMN O
in O
whole O
blood O
was O
compared O
in O
two O
groups O
of O
hemodialyzed RARE
patients O
: O
group O
A O
consisted O
of O
twenty RARE
- O
one O
individuals O
with O
serum O
ferritin I-GENE
levels O
above O
1000 O
ng O
/ O
ml O
and O
group O
B O
of O
nineteen RARE
individuals O
with O
serum O
ferritin I-GENE
levels O
below O
1000 O
ng O
/ O
ml O
. O

Cattaneo RARE
, O
and O
J O
. O

Human I-GENE
alpha I-GENE
- I-GENE
galactosidase I-GENE
A I-GENE
: O
nucleotide O
sequence O
of O
a O
cDNA O
clone O
encoding O
the O
mature O
enzyme O
. O

Diazepam RARE
( O
3 O
mg O
/ O
kg O
) O
generalized O
to O
Ro O
11 O
- O
6896 NUMERIC
whereas O
the O
structurally O
related O
Ro O
5 O
- O
4864 NUMERIC
( O
3 O
mg O
/ O
kg O
and O
30 O
mg O
/ O
kg O
) O
did O
not O
. O

The O
amino O
acid O
sequence O
was O
determined O
to O
be O
residues O
716 NUMERIC
- O
724 NUMERIC
and O
hence O
lysine O
residue O
721 NUMERIC
is O
located O
within O
the O
ATP O
- O
binding O
site O
. O

Osteocalcin RARE
( O
and O
urinary O
hydroxyproline RARE
) O
were O
not O
elevated O
in O
isolated O
hyperphosphatasaemia RARE
, O
indicating O
that O
mechanisms O
other O
than O
increased O
bone O
turnover O
may O
account O
for O
the O
markedly O
elevated O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
activity O
in O
these O
subjects O
. O

Analysis O
of O
glucocorticoid O
unresponsive RARE
cell O
variants O
using O
a O
mouse I-GENE
glucocorticoid I-GENE
receptor I-GENE
complementary O
DNA O
clone O
. O

Among O
the O
v I-GENE
- I-GENE
myc I-GENE
codons O
, O
the O
first O
5 O
are O
derived O
from O
the O
noncoding O
5 O
' O
terminus O
of O
the O
second O
c I-GENE
- I-GENE
myc I-GENE
exon O
, O
and O
412 NUMERIC
codons O
correspond O
to O
the O
c I-GENE
- I-GENE
myc I-GENE
coding O
region O
. O

A O
recombinant O
vector O
, O
p410 NUMERIC
+, O
was O
constructed O
which O
carried O
the O
BamHI I-GENE
- I-GENE
K I-GENE
fragment I-GENE
( O
nucleotides O
107565 NUMERIC
to O
112625 NUMERIC
of O
the O
B95 NUMERIC
- O
8 O
strain O
, O
encoding O
the O
EBV O
- O
associated O
nuclear O
antigen O
EBNA I-GENE
- I-GENE
1 I-GENE
), O
the O
cis O
- O
acting O
sequence O
from O
the O
BamHI I-GENE
- I-GENE
C I-GENE
fragment I-GENE
, O
and O
a O
dominant O
selectable O
marker O
gene O
encoding O
G O
- O
418 NUMERIC
resistance O
in O
animal O
cells O
. O

13 O
men O
with O
a O
history O
of O
recurrent O
genital O
herpes O
simplex O
virus O
type O
2 O
( O
HSV O
- O
2 O
) O
infection O
were O
followed O
daily O
for O
4 O
weeks O
with O
samples O
taken O
from O
the O
urethra RARE
for O
virus O
isolation O
. O

Next RARE
, O
with O
carcinoma O
presenting O
a O
leather RARE
bottle RARE
( O
linitis RARE
plastica RARE
type O
) O
of O
the O
stomach O
itself O
, O
the O
II O
c O
portion O
of O
the O
stomach O
consisted O
of O
fundic RARE
glands O
( O
undifferentiated O
carcinoma O
) O
shall RARE
become O
the O
primary O
focus O
supporting O
Nakamura RARE
' O
s O
theory O
. O

During O
the O
biosynthesis O
of O
all O
three O
mutant O
polypeptides O
, O
the O
signal O
peptide O
is O
efficiently O
and O
accurately O
cleaved O
from O
the O
nascent RARE
protein O
, O
even O
though O
in O
mutants O
X2 O
and O
X3 NUMERIC
the O
cleavage O
site O
itself O
has O
been O
altered O
. O

The O
hexanucleotide RARE
5 O
'- O
TGTCCT ALLCAPS
- O
3 O
', O
thought O
to O
be O
important O
for O
GRE O
activity O
, O
not O
only O
was O
found O
in O
this O
sequence O
and O
in O
the O
5 O
'- O
flanking O
region O
, O
but O
also O
was O
present O
twice O
in O
the O
3 O
' O
end O
of O
the O
gene O
that O
did O
not O
show O
specific O
receptor O
binding O
. O

Five O
patients O
developed O
metastatic O
spread O
, O
and O
all O
of O
them O
died O
of O
tumor O
. O

The O
smallest O
of O
the O
mini RARE
- O
Mu RARE
elements O
is O
only O
7 O
. O
9 O
kilobase O
pairs O
long O
, O
allowing O
the O
cloning O
of O
DNA O
fragments O
of O
up O
to O
31 O
. O
1 O
kilobase O
pairs O
, O
and O
the O
largest O
of O
them O
is O
21 O
. O
7 O
kilobase O
pairs O
, O
requiring O
that O
clones O
carry O
insertions O
of O
less O
than O
17 O
. O
3 O
kilobase O
pairs O
. O

The O
52 O
- O
protein O
subunit O
of O
T4 I-GENE
DNA I-GENE
topoisomerase I-GENE
is O
homologous O
to O
the O
gyrA LASTCAP
- I-GENE
protein I-GENE
of O
gyrase RARE
. O

There O
were O
no O
interfering O
peaks O
in O
the O
quantitation RARE
of O
sulbactam RARE
. O

The O
latent O
periods O
from O
the O
antral RARE
exclusion O
to O
the O
occurrence O
of O
anastomotic RARE
ulcers O
after O
a O
subtotal O
gastrectomy RARE
with O
Billroth RARE
' O
s O
type O
II O
reconstruction O
varied O
from O
a O
few O
days O
to O
19 O
years O
, O
with O
an O
average O
of O
2 O
. O
8 O
years O
. O

The O
nucleosomal RARE
arrays O
detected O
by O
MPE ALLCAPS
X O
Fe RARE
( O
II O
) O
were O
characterized O
by O
a O
considerable O
loss O
of O
detail O
and O
significantly O
enhanced O
accessibility RARE
, O
the O
extent O
of O
which O
probably O
reflected O
the O
relative O
transcription O
rate O
of O
each O
gene O
. O

Translation RARE
of O
specific O
cellular O
genes O
from O
the O
chimeric O
viral O
- O
cellular O
transcripts O
seems O
to O
be O
unlikely O
. O

The O
molecular O
weight O
of O
in O
vivo O
- O
labeled O
proteins O
was O
increased O
relative O
to O
that O
of O
in O
vitro O
- O
translated O
proteins O
, O
indicating O
that O
a O
posttranslational O
modification O
had O
occurred O
. O

Insertion RARE
of O
4 O
bp O
reduced O
SV40 I-GENE
early I-GENE
promoter I-GENE
- O
dependent O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
expression O
by O
six O
- O
to O
eightfold RARE
. O

In O
the O
DNAs O
of O
all O
Ph1 NUMERIC
- O
positive O
chronic O
myelocytic RARE
leukemia O
patients O
studied O
to O
date O
, O
a O
breakpoint O
on O
chromosome O
22 O
( O
the O
Ph1 NUMERIC
chromosome O
) O
can O
be O
demonstrated O
with O
a O
probe O
from O
the O
bcr RARE
( O
breakpoint I-GENE
cluster I-GENE
region I-GENE
). O

Nuclease RARE
footprinting O
revealed O
that O
purified O
glucocorticoid I-GENE
receptor I-GENE
bound O
at O
multiple O
discrete O
sites O
within O
and O
at O
the O
borders RARE
of O
the O
tandemly O
repeated O
sequence O
motif O
that O
defines O
Sa RARE
. O

The O
96 O
- O
bp O
insert O
contained O
a O
termination O
signal O
which O
caused O
the O
premature O
termination O
of O
the O
protein O
, O
leading O
to O
the O
generation O
of O
a O
p53 I-GENE
product I-GENE
9 O
amino O
acids O
shorter O
than O
usual RARE
. O

All O
tumors O
proved O
histologically O
to O
be O
neuroendocrine RARE
in O
origin O
. O

The O
coding O
region O
of O
2385 NUMERIC
nucleotides O
corresponds O
to O
a O
polypeptide O
chain O
of O
795 NUMERIC
amino O
acids O
, O
giving O
a O
molecular O
weight O
of O
91 O
, O
555 NUMERIC
for O
the O
hsp108 NUMERIC
protein I-GENE
. O

Transcriptional O
control O
signals O
of O
a O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
1 I-GENE
late I-GENE
( I-GENE
gamma I-GENE
2 I-GENE
) I-GENE
gene I-GENE
lie RARE
within O
bases O
- O
34 O
to O
+ O
124 O
relative O
to O
the O
5 O
' O
terminus O
of O
the O
mRNA O
. O

A O
noncatalytic RARE
domain O
conserved O
among O
cytoplasmic I-GENE
protein I-GENE
- I-GENE
tyrosine I-GENE
kinases I-GENE
modifies RARE
the O
kinase O
function O
and O
transforming O
activity O
of O
Fujinami RARE
sarcoma I-GENE
virus I-GENE
P130gag NUMERIC
- O
fps RARE
. O

Gluzman RARE
, O
EMBO ALLCAPS
J O
. O

A O
single O
exon O
encodes O
the O
carboxyl O
- O
terminal O
26 O
amino O
acids O
of O
the O
ssd RARE
chain I-GENE
and O
the O
3 O
' O
untranslated O
region O
of O
its O
mRNA O
, O
ending RARE
with O
a O
poly O
( O
A O
)- O
addition O
site O
. O

The O
5 O
'- O
nontranslated RARE
sequences O
and O
parts O
of O
the O
coding O
sequences O
of O
various O
yeast O
genes O
have O
been O
cloned O
into O
representative O
lacZ I-GENE
fusion O
vectors O
. O

Two O
activities O
of O
the O
D I-GENE
protein I-GENE
of O
the O
miniF LASTCAP
plasmid O
have O
been O
found O
. O

SPECT O
examination O
of O
the O
TMJ ALLCAPS
using O
99m O
Tc O
- O
MDP ALLCAPS
was O
performed O
in O
43 O
patients O
with O
arthrographically RARE
proven O
anterior O
dislocation O
of O
the O
disc O
and O
in O
30 O
normals O
. O

Plasma I-GENE
renin I-GENE
activity O
rose O
and O
the O
plasma O
aldosterone O
level O
fell O
after O
taking O
lisinopril RARE
. O

Two O
mutants O
, O
each O
representative O
of O
a O
separate O
pet RARE
complementation O
group O
, O
have O
been O
analyzed O
. O

The O
second O
group O
of O
homologous O
elements O
is O
present O
in O
the O
upstream O
region O
of O
both O
genes O
. O

A O
centromere O
in O
S O
. O
cerevisiae O
consists O
of O
a O
region O
of O
DNA O
, O
approximately O
150 O
bp O
in O
length O
, O
containing O
three O
important O
sequence O
elements O
, O
which O
are O
folded O
with O
proteins O
into O
a O
specific O
conformation O
in O
the O
chromatin O
( O
the O
yeast O
kinetochore RARE
). O

Constitutive RARE
function O
of O
a O
positively O
regulated O
promoter O
reveals O
new O
sequences O
essential O
for O
activity O
. O

Two O
separate O
NF1 I-GENE
- I-GENE
binding I-GENE
loci I-GENE
were O
also O
found O
in O
the O
equivalent O
IE68 NUMERIC
gene I-GENE
of O
HCMV O
( O
Towne RARE
) O
DNA O
, O
but O
in O
this O
case O
the O
DNA O
sequence O
and O
competition O
filter O
binding O
experiments O
indicated O
a O
maximum O
of O
only O
four O
to O
five O
consensus O
binding O
sites O
encompassing O
the O
promoter O
- O
enhancer O
region O
. O

The O
previously O
described O
four O
sets O
of O
13 O
- O
to O
18 O
- O
base O
- O
pair O
interspersed O
repeat O
elements O
between O
- O
55 O
and O
- O
580 NUMERIC
provide O
most O
of O
the O
high O
basal O
transcriptional O
strength O
, O
whereas O
the O
arrangement O
of O
further O
upstream O
tandemly O
repeated O
NF1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
may O
contribute O
significantly O
to O
the O
expanded RARE
biological O
host O
range O
for O
expression O
of O
SCMV ALLCAPS
IE94 NUMERIC
compared O
with O
HCMV I-GENE
IE68 NUMERIC
. O

We O
inserted O
genes O
or O
gene O
segments O
, O
that O
code O
for O
the O
bacterial I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
, O
the O
bacterial O
gene O
conferring O
resistance O
against O
hygromycin RARE
, O
and O
the O
ORF O
E7 I-GENE
of O
the O
human O
papillomavirus O
type O
18 O
into O
these O
vectors O
. O

By O
contrast O
, O
their O
basal O
adrenal O
androgen O
levels O
were O
significantly O
decreased O
compared O
to O
those O
in O
normal O
subjects O
on O
both O
the O
day O
on O
and O
the O
day O
off O
prednisone O
( O
P O
less O
than O
0 O
. O
05 O
). O

Active RARE
lambda I-GENE
and I-GENE
kappa I-GENE
antibody I-GENE
gene I-GENE
rearrangement O
in O
Abelson RARE
murine O
leukemia O
virus O
- O
transformed O
pre O
- O
B O
cell O
lines O
. O

Identification O
of O
p40x NUMERIC
- O
responsive O
regulatory O
sequences O
within O
the O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
long O
terminal O
repeat O
. O

During O
pentobarbital RARE
anesthesia O
, O
the O
basal O
VO2 O
was O
5 O
. O
26 O
ml O
/ O
kg O
/ O
min O
and O
was O
increased O
by O
epinephrine O
in O
a O
dose O
dependent O
manner O
at O
plasma O
concentrations O
between O
3 O
. O
9 O
ng O
/ O
ml O
( O
VO2 O
= O
5 O
. O
68 O
ml O
/ O
kg O
/ O
min O
) O
and O
36 O
. O
5 O
ng O
/ O
ml O
( O
VO2 O
= O
6 O
. O
47 O
ml O
/ O
kg O
/ O
min O
). O

Influence O
of O
cyclo RARE
- I-GENE
oxygenase I-GENE
inhibition O
and O
of O
leukotriene RARE
receptor I-GENE
blockade O
on O
pulmonary O
vascular O
pressure O
/ O
cardiac O
index O
relationships O
in O
hyperoxic RARE
and O
in O
hypoxic O
dogs O
. O

Oligonucleotide RARE
- O
directed O
mutagenesis O
was O
used O
to O
create O
an O
NdeI LASTCAP
restriction I-GENE
site I-GENE
at O
the O
natural O
ATG O
of O
the O
yeast O
R O
. O

ACTH I-GENE
release O
is O
transiently O
suppressed O
in O
some O
children O
after O
exogenous O
ACTH I-GENE
treatment O
. O

We O
previously O
showed O
that O
the O
upstream O
promoter O
element O
of O
the O
yeast I-GENE
RP39A NUMERIC
gene I-GENE
consists O
of O
these O
identical O
sequence O
motifs O
. O

These O
data O
suggest O
that O
mammalian O
erythroid O
alpha I-GENE
- I-GENE
spectrin I-GENE
evolved O
by O
duplication O
and O
rapid O
divergence O
from O
an O
ancestral O
alpha I-GENE
- I-GENE
fodrin RARE
- I-GENE
like I-GENE
gene I-GENE
. O

Northern O
analyses O
of O
RNAs O
from O
mouse O
tissues O
and O
cell O
lines O
indicated O
that O
p11 NUMERIC
mRNA I-GENE
levels O
vary O
widely O
. O

One O
group O
of O
six O
cDNA O
clones O
was O
derived O
from O
a O
2 O
. O
9 O
- O
kilobase O
early O
transcript O
encoded O
by O
the O
IR2 NUMERIC
repeat O
element O
and O
showed O
restriction O
site O
polymorphism O
for O
the O
enzyme I-GENE
SmaI LASTCAP
. O

Combined O
immunochemotherapy RARE
with O
cyclophosphamide O
plus O
BCG O
gave O
a O
better O
enhancement O
of O
the O
antitumor RARE
effect O
of O
the O
cytostatic RARE
than O
that O
of O
the O
combination O
of O
methotrexate O
plus O
BCG O
and O
cyclophosphamide O
plus O
levamisole RARE
. O

Morphine RARE
produced O
a O
dose O
- O
dependent O
bradycardia RARE
followed O
by O
tachycardia O
. O

The O
PSS ALLCAPS
gene I-GENE
was O
subcloned O
into O
a O
1 O
. O
1 O
- O
kb O
fragment O
of O
the O
yeast O
DNA O
on O
the O
YEp13 NUMERIC
vector O
. O

Indeed O
, O
A O
- O
MuLV O
pseudotyped RARE
with O
some O
viruses O
, O
such O
as O
the O
Moloney O
MuLV O
, O
has O
been O
shown O
to O
be O
highly O
lymphogenic RARE
, O
whereas O
A O
- O
MuLV O
pseudotyped RARE
with O
other O
viruses O
, O
such O
as O
the O
BALB O
/ O
c O
endogenous O
N O
- O
tropic RARE
MuLV O
, O
has O
been O
shown O
to O
be O
devoid RARE
of O
lymphogenic RARE
potential O
( O
N O
. O

The O
presence O
of O
circulating O
platelet O
aggregates O
and O
elevated O
levels O
of O
fibrinopeptide RARE
A I-GENE
( O
a O
cleavage O
product O
of O
fibrin I-GENE
) O
suggests O
that O
platelet O
activation O
and O
fibrin I-GENE
deposition O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
this O
disorder O
. O

The O
gene O
is O
essential O
for O
yeast O
vegetative RARE
growth O
. O

4 O
. O

In O
general O
, O
the O
values O
obtained O
by O
the O
two O
methods O
were O
in O
agreement O
for O
each O
species O
of O
epidermal I-GENE
growth I-GENE
factor I-GENE
and O
followed O
the O
order O
: O
wild O
type O
greater O
than O
Glu24 NUMERIC
---- O
Gly O
greater O
than O
Asp27 NUMERIC
---- O
Gly O
much O
greater O
than O
Pro7 NUMERIC
---- O
Thr O
greater O
than O
Tyr29 NUMERIC
---- O
Gly O
greater O
than O
Leu47 NUMERIC
---- O
His O
. O

It O
is O
concluded O
that O
suppression O
of O
elevated O
prolactin I-GENE
levels O
in O
progressive O
metastatic O
breast O
cancer O
patients O
is O
not O
effective O
in O
restoring RARE
tumor O
sensitivity O
to O
chemotherapy O
. O

We O
report O
a O
prevalence O
study O
of O
the O
best O
visual O
acuity RARE
in O
the O
affected O
eye O
of O
100 O
selected O
patients O
with O
herpetic RARE
keratitis RARE
seen O
during O
a O
two O
- O
year O
period O
. O

We O
also O
found O
an O
eIF I-GENE
- I-GENE
4A NUMERIC
intronless O
retroposon RARE
which O
, O
when O
compared O
to O
the O
cDNA O
, O
contains O
a O
single O
nucleotide O
difference O
. O

Bacteriologic RARE
culture O
of O
pancreatic O
tissue O
was O
positive O
in O
6 O
/ O
8 O
IB ALLCAPS
and O
3 O
/ O
17 O
NIB ALLCAPS
rats O
( O
p O
less O
than O
0 O
. O
01 O
). O

These O
similarities O
suggest O
that O
these O
E2 I-GENE
proteins I-GENE
are O
structurally O
and O
evolutionarily O
related O
. O

After O
infection O
of O
293 O
cells O
( O
which O
provide O
complementary O
E1a I-GENE
- O
E1b NUMERIC
functions O
), O
both O
viruses O
directed O
equal O
amounts O
of O
P I-GENE
/ I-GENE
C I-GENE
- I-GENE
specific I-GENE
mRNA I-GENE
transcription O
. O

This O
observation O
cannot O
be O
explained O
by O
the O
scanning O
model O
for O
ribosomal O
initiation O
and O
suggests O
that O
ribosomes RARE
may O
be O
binding O
directly O
at O
an O
internal O
mRNA O
site O
at O
or O
near O
the O
initiator O
AUG O
codon O
for O
the O
C I-GENE
protein I-GENE
. O

In O
view O
of O
these O
results O
, O
simultaneous O
pancreas O
- O
kidney O
transplantation O
appears O
to O
be O
the O
treatment O
of O
choice O
for O
Type O
I O
diabetic O
patients O
. O

This O
makes O
these O
compounds O
attractive RARE
as O
vehicles RARE
for O
these O
and O
other O
gases O
in O
- O
vivo O
and O
in O
- O
vitro O
. O

DNA O
sequencing O
of O
the O
DPM1 NUMERIC
gene I-GENE
revealed O
an O
open O
reading O
frame O
of O
801 O
bases O
. O

The O
relationship O
between O
primary O
malignant O
lymphoma O
of O
the O
thyroid O
and O
chronic O
thyroiditis O
is O
discussed O
. O

Administration O
of O
anticoagulants RARE
, O
i O
. O
e O
., O
heparin O
, O
prostaglandin O
E1 O
and O
ticlopidine RARE
seems O
to O
be O
effective O
in O
alleviating RARE
symptoms O
and O
might O
prevent O
further O
deterioration O
. O

Mutational O
analysis O
of O
the O
L1 I-GENE
binding I-GENE
site I-GENE
of O
23S NUMERIC
rRNA I-GENE
in I-GENE
Escherichia I-GENE
coli I-GENE
. O

Animals O
may O
be O
immunized O
by O
oral O
vaccination O
, O
but O
natural O
mechanisms O
that O
also O
can O
terminate O
outbreaks RARE
are O
discussed O
. O

Prostacyclin RARE
formation O
, O
reflected O
by O
the O
excretion O
rate O
of O
its O
stable O
metabolite O
6 O
- O
keto RARE
- O
prostaglandin O
F1 O
alpha O
, O
was O
measured O
by O
means O
of O
radioimmunoassay O
in O
4 O
- O
hour O
urine O
specimens O
obtained O
during O
a O
smoking O
- O
free O
period O
and O
after O
participants RARE
had O
inhaled O
smoke O
from O
four O
high O
- O
nicotine O
cigarettes RARE
. O

However O
, O
excretion O
of O
6 O
- O
keto RARE
- O
prostaglandin O
F1 O
alpha O
was O
further O
reduced O
in O
the O
smokers O
who O
used O
oral O
contraceptives RARE
( O
133 O
+/- O
20 O
to O
86 O
+/- O
9 O
ng O
/ O
gm RARE
of O
creatinine O
, O
p O
less O
than O
0 O
. O
05 O
). O

The O
in O
vitro O
activity O
of O
mecillinam RARE
and O
amoxicillin O
/ O
clavulanic RARE
acid O
against O
Escherichia O
coli O
strains O
producing O
beta I-GENE
- I-GENE
lactamases RARE
of O
the O
TEM ALLCAPS
- I-GENE
1 I-GENE
, O
Oxa RARE
- I-GENE
1 I-GENE
and O
chromosomal O
type O
were O
studied O
using O
the O
broth RARE
and O
agar O
dilution O
technique O
. O

GCN4 I-GENE
encodes O
a O
transcriptional O
activator O
of O
amino O
acid O
biosynthetic O
genes O
in O
Saccharomyces O
cerevisiae O
. O

These O
results O
imply O
that O
the O
GCN3 NUMERIC
product I-GENE
can O
promote O
either O
repression O
or O
activation O
of O
GCN4 I-GENE
expression O
depending O
on O
amino O
acid O
availability O
. O

The O
efficacy O
of O
these O
immunosuppressive O
drugs O
is O
clinical O
proven O
. O

The O
amino O
acid O
sequence O
of O
the O
S O
. O
aureus O
peptide O
carrying O
the O
phosphoryl RARE
group O
was O
found O
to O
be O
Gln O
- O
Val O
- O
Val O
- O
Ser O
- O
Thr O
- O
Phe O
- O
Met O
- O
Gly O
- O
Asn O
- O
Gly O
- O
Leu O
- O
Ala O
- O
Ile O
- O
Pro O
- O
His O
- O
Gly O
- O
Thr O
- O
Asp O
- O
Asp O
. O

These O
mutations O
alter O
two O
regions O
of O
GAL4 I-GENE
protein I-GENE
: O
the O
DNA O
binding O
domain O
, O
and O
the O
transcription O
activation O
domain O
. O

The O
results O
indicated O
that O
two O
genes O
( O
citA LASTCAP
and O
citB LASTCAP
) O
have O
separate O
promoters O
, O
and O
the O
location O
of O
the O
promoter O
for O
the O
citB LASTCAP
gene I-GENE
in O
the O
Tn3411 NUMERIC
nucleotide O
sequence O
was O
different O
from O
that O
in O
pMS185 NUMERIC
. O

The O
rci RARE
gene I-GENE
was O
fused O
with O
lacZ I-GENE
and O
its O
gene O
product O
was O
identified O
by O
Western O
blot O
analysis O
. O

Structure O
and O
regulation O
of O
a O
nuclear O
gene O
in O
Saccharomyces O
cerevisiae O
that O
specifies O
MRP13 NUMERIC
, O
a O
protein O
of O
the O
small O
subunit O
of O
the O
mitochondrial O
ribosome O
. O

After O
a O
survey O
of O
the O
anatomical O
and O
physiological O
basis O
of O
operative O
treatment O
of O
behaviour O
disorders O
by O
stereotactic RARE
lesions O
in O
the O
amygdala O
and O
the O
posterior O
medial O
hypothalamus O
the O
author O
describes O
his O
own O
experiences RARE
with O
603 NUMERIC
operations RARE
for O
control O
of O
conservatively RARE
untreatable RARE
aggressiveness RARE
. O

Histological O
examination O
revealed O
a O
small O
simple O
renal O
cyst O
associated O
with O
renal O
cell O
carcinoma O
. O

Although O
large O
epidemiologic RARE
studies O
are O
best O
able O
to O
identify O
the O
relative O
contributions RARE
of O
specific O
risk O
factors O
while O
controlling O
for O
other O
risk O
factors O
, O
new O
studies O
need O
to O
focus O
on O
important O
unresolved RARE
questions O
. O

Thus O
, O
prostacyclin RARE
enhanced O
the O
autoregulative RARE
property RARE
of O
the O
inner O
ear O
vessels O
. O

The O
method O
is O
accurate O
, O
with O
good O
precision RARE
and O
adequate O
sensitivity O
. O

Factors O
influencing O
the O
bond O
strength O
between O
glass O
polyalkenoate RARE
( O
ionomer RARE
) O
cements RARE
and O
dentine RARE
. O

The O
amino O
acid O
sequences O
of O
the O
yeast O
and O
mammalian O
mitochondrial O
targeting O
sequences O
are O
similar O
but O
less O
related O
than O
the O
mature O
polypeptides O
. O

Van RARE
der RARE
Ende RARE
, O
R O
. O

During O
insulin I-GENE
infusion O
, O
a O
20 O
% O
dextrose RARE
solution O
was O
infused O
by O
a O
Biostator RARE
in O
order O
to O
maintain O
the O
patient O
' O
s O
glycemia RARE
at O
90 O
mg O
/ O
dl O
. O

Amounts RARE
of O
glucose O
infused O
during O
the O
last O
20 O
min O
of O
each O
2 O
hour O
insulin I-GENE
infusion O
were O
( O
at O
1 O
and O
10 O
m O
/ O
kg O
/ O
min O
respectively O
): O
before O
treatment O
( O
K O
+ O
= O
2 O
. O
7 O
mmol O
/ O
l O
): O
2 O
. O
4 O
and O
8 O
. O
4 O
mg O
/ O
kg O
/ O
min O
; O
after O
spironolactone RARE
( O
K O
+ O
= O
3 O
. O
9 O
mmol O
/ O
l O
): O
3 O
. O
3 O
and O
15 O
. O
4 O
mg O
/ O
kg O
/ O
min O
; O
after O
indomethacine RARE
( O
K O
+ O
= O
3 O
. O
7 O
mmol O
/ O
l O
): O
5 O
and O
19 O
mg O
/ O
kg O
/ O
min O
after O
stopping RARE
drugs O
( O
K O
+ O
= O
2 O
. O
9 O
mmol O
/ O
l O
): O
2 O
. O
5 O
and O
5 O
. O
3 O
mg O
/ O
kg O
/ O
min O
. O

Mycobacterium O
avium RARE
- O
intracellulare RARE
complex O
infections O
in O
the O
acquired O
immunodeficiency O
syndrome O
. O

Recurrence RARE
of O
oxalate RARE
deposition O
in O
a O
renal O
transplant O
during O
ciclosporin RARE
A O
therapy O
. O

The O
bile O
acid O
sequestrants RARE
( O
cholestyramine RARE
and O
colestipol RARE
), O
nicotinic RARE
acid O
, O
fenofibrate RARE
and O
inhibitors O
of O
hydroxymethylglutaryl RARE
coenzyme I-GENE
A I-GENE
( I-GENE
HMG I-GENE
CoA I-GENE
) I-GENE
reductase I-GENE
( O
e O
. O
g O
. O
lovastatin RARE
or O
simvastatin RARE
) O
are O
the O
most O
effective O
drugs O
for O
use O
in O
patients O
with O
primary O
hypercholesterolaemia RARE
; O
these O
agents O
reduce O
plasma O
concentrations O
of O
total O
and O
LDL I-GENE
- I-GENE
cholesterol I-GENE
by O
15 O
to O
45 O
%. O

Finally O
, O
the O
pathophysiological RARE
aspects O
of O
urinary O
acidification O
are O
discussed O
, O
focusing O
on O
renal O
tubular O
acidosis O
models O
( O
induced O
by O
maleate RARE
and O
amphotericin O
B O
treatment O
) O
and O
their O
cellular O
mechanisms O
, O
as O
well O
as O
the O
role O
of O
adrenal O
steroids O
in O
urinary O
acidification O
. O

Analysis O
in O
3 O
groups O
of O
patients O
suffering O
from O
simple O
acute O
and O
pernicious RARE
malarial RARE
flare RARE
- O
ups RARE

Statement RARE
on O
the O
development O
of O
guidelines O
for O
the O
prevention O
of O
AIDS O
transmission O
in O
the O
workplace RARE
. O

Modifications RARE
of O
the O
involuntary RARE
postcontraction RARE
in O
diseased O
people O
. O

Cocaine RARE
- O
treated O
rats O
acquired O
a O
preference O
for O
cocaine O
- O
associated O
contextual RARE
stimuli O
( O
CS O
) O
relative O
to O
saline O
- O
injected O
control O
rats O
. O

Under O
these O
schedules RARE
, O
a O
reinforced O
response O
run O
consisted O
of O
responding O
between O
eight O
and O
12 O
times O
on O
one O
response O
key O
( O
work O
key O
) O
and O
then O
responding O
once O
on O
a O
second O
response O
key O
( O
reinforced O
key O
). O

Intravenous O
glucose O
tolerance O
tests O
were O
performed O
before O
operation O
, O
before O
starting O
CyA LASTCAP
and O
after O
3 O
weeks O
. O

The O
effects O
of O
glutaraldehyde RARE
on O
dimensions O
and O
ultrastructure RARE
of O
microvascular O
beds RARE
in O
rat O
mesentery RARE
were O
studied O
in O
two O
kinds RARE
of O
experiment O
, O
administering RARE
the O
fixative RARE
by O
intra O
- O
arterial O
perfusion O
at O
a O
pressure O
of O
80 O
mm O
Hg O
and O
by O
superfusion RARE
of O
the O
exteriorized RARE
mesenteric RARE
membrane O
. O

This O
gave O
rise O
to O
RNA O
molecules O
with O
3 O
'- O
untranslated O
regions O
of O
roughly RARE
375 NUMERIC
, O
655 NUMERIC
, O
and O
945 NUMERIC
base O
pairs O
. O

Also O
, O
the O
BALB I-GENE
/ I-GENE
c I-GENE
gene I-GENE
contains O
a O
single O
substitution O
in O
a O
conserved O
octamer O
sequence O
approximately O
equal O
to O
100 O
nucleotides O
upstream O
of O
the O
coding O
region O
, O
which O
could O
affect O
its O
expression O
. O

Clinical O
findings O
were O
: O
height O
183 NUMERIC
cm O
, O
weight O
62 O
kg O
, O
increased O
length O
of O
lower O
limbs RARE
, O
P2 O
- O
A2 O
pilosity RARE
and O
micropenis RARE
. O

Our O
data O
suggest O
that O
it O
may O
be O
possible O
to O
individualize RARE
hCG I-GENE
administration O
at O
midcycle RARE
by O
determining O
the O
number O
of O
follicles RARE
greater O
than O
1 O
cm O
by O
ultrasound O
on O
cycle O
day O
12 O
or O
13 O
and O
giving O
hCG I-GENE
when O
serum O
E2 O
levels O
reach O
1100 NUMERIC
to O
1200 NUMERIC
pmol RARE
/ O
l O
per O
follicle O
. O

The O
8 O
patients O
receiving O
Ir192 NUMERIC
implant O
in O
addition O
to O
external O
radiation O
showed O
improved O
( O
p O
= O
0 O
. O
06 O
) O
survival O
compared O
to O
the O
9 O
receiving O
external O
only O
: O
median O
15 O
months O
( O
range O
1 O
. O
5 O
- O
34 O
+ O
months O
) O
versus O
7 O
months O
( O
range O
2 O
. O
5 O
- O
21 O
months O
). O

Within O
Stage O
IA O
, O
141 NUMERIC
patients O
had O
well O
differentiated O
tumor O
( O
G1 O
), O
20 O
had O
moderately O
well O
differentiated O
tumor O
( O
G2 O
), O
and O
12 O
patients O
had O
poorly O
differentiated O
( O
G3 NUMERIC
). O

Mechanism O
of O
the O
t O
( O
14 O
; O
18 O
) O
chromosomal O
translocation O
: O
structural O
analysis O
of O
both O
derivative O
14 O
and O
18 O
reciprocal O
partners O
. O

After O
age O
30 O
, O
mean O
hemoglobin I-GENE
levels O
for O
men O
gradually O
declined O
, O
while O
those O
in O
women O
rose O
, O
so O
that O
the O
sex O
difference O
diminished O
after O
60 O
years O
of O
age O
. O

Ritanserin RARE
is O
a O
new O
substance RARE
with O
highly O
selective O
blocking O
activity O
on O
S2 I-GENE
receptors I-GENE
for O
5 O
- O
HT O
in O
the O
central O
nervous O
system O
. O

Ethylene RARE
glycol O
and O
diethylene RARE
glycol O
were O
each O
administered O
once O
weekly O
subcutaneously O
to O
groups O
of O
100 O
female O
NMRI ALLCAPS
mice O
at O
3 O
dosages RARE
( O
30 O
; O
10 O
und RARE
3 O
mg O
single O
dose O
per O
mouse O
). O

Research O
on O
ethylene O
glycol O
and O
diethylene RARE
glycol O
for O
carcinogenic RARE
effects O

The O
results O
suggest O
that O
the O
greater O
estrogenic RARE
influence O
associated O
with O
the O
ethinyl RARE
estradiol O
- O
containing O
OC O
resulted O
in O
inhibition O
of O
coronary O
artery O
atherosclerosis O
despite O
a O
pronounced O
progestin RARE
- O
induced O
lowering O
of O
plasma O
HDL I-GENE
cholesterol I-GENE
concentration O
and O
, O
further O
, O
that O
hormonal O
balance O
may O
have O
a O
marked O
influence O
on O
the O
relationship O
between O
plasma O
lipids O
and O
atherogenesis RARE
. O

During O
BH ALLCAPS
the O
ventilator RARE
was O
disconnected RARE
and O
a O
bias RARE
flow O
of O
50 O
% O
O2 O
at O
4 O
- O
5 O
l O
/ O
min O
was O
delivered O
through O
the O
side O
ports RARE
of O
a O
small O
catheter O
whose O
tip O
was O
positioned O
1 O
cm O
cephalad RARE
of O
the O
carina RARE
. O

Comparison O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
removal O
using O
the O
same O
polysulphone RARE
membrane O
for O
haemodialysis O
and O
haemofiltration RARE
shows O
that O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
is O
more O
effectively O
removed O
by O
convection RARE
than O
by O
diffusion O
when O
both O
treatment O
modes O
are O
matched O
for O
blood O
flow O
and O
urea O
clearance O
. O

40 O
. O
3 O
+/- O
10 O
. O
1 O
mg O
/ O
l O
( O
SD O
) O
vs O
31 O
. O
2 O
+/- O
8 O
. O
0 O
, O
P O
less O
than O
0 O
. O
01 O
). O
beta I-GENE
2m NUMERIC
was O
not O
significantly O
higher O
in O
patients O
with O
bone O
cysts O
( O
37 O
. O
7 O
+/- O
11 O
. O
4 O
mg O
/ O
l O
vs O
37 O
. O
0 O
+/- O
10 O
. O
0 O
), O
but O
median O
duration O
of O
dialysis O
was O
significantly O
( O
P O
less O
than O
0 O
. O
01 O
) O
longer O
in O
patients O
with O
bone O
cysts O
( O
90 O
vs O
57 O
months O
). O
beta I-GENE
2m NUMERIC
was O
lower O
in O
patients O
maintained O
on O
dialysis O
for O
less O
than O
1 O
year O
and O
whose O
residual O
urine O
volume O
was O
greater O
than O
0 O
. O
1 O
litre RARE
per O
day O
. O

The O
mean O
percentage O
of O
linoleic RARE
acid O
in O
the O
triglycerides O
of O
the O
subcutaneous O
adipose O
tissue O
( O
PLASAT ALLCAPS
) O
of O
these O
subjects O
was O
substantially O
higher O
than O
that O
in O
a O
similar O
group O
examined O
in O
1975 NUMERIC
- O
1976 NUMERIC
. O

In O
overdoses RARE
up O
to O
2 O
g O
fluvoxamine RARE
no O
lasting O
toxic O
effects O
were O
observed O
. O

It O
is O
concluded O
that O
the O
plasma I-GENE
prolactin I-GENE
response O
to O
12 O
. O
5 O
micrograms O
i O
. O
v O
. O

No O
effect O
was O
found O
on O
grooming RARE
behavior O
. O

The O
remaining O
six O
patients O
had O
slightly O
decreased O
( O
n O
= O
3 O
) O
or O
normal O
( O
n O
= O
3 O
) O
seminal O
parameters O
. O

In O
addition O
, O
a O
wild O
- O
type O
strain O
containing O
a O
temperature I-GENE
- I-GENE
sensitive I-GENE
threonyl RARE
- I-GENE
tRNA I-GENE
synthetase I-GENE
mutation I-GENE
showed O
increased O
thr RARE
operon I-GENE
expression O
at O
the O
non O
- O
permissive O
temperature O
, O
whereas O
none O
of O
the O
mutants O
showed O
any O
change O
. O

Significant O
treatment O
- O
related O
problems O
appeared O
during O
the O
second O
decade RARE
in O
5 O
patients O
, O
including O
one O
chest O
wall O
sarcoma O
; O
all O
of O
these O
patients O
had O
received O
at O
least O
60 O
Gy O
to O
breast O
and O
regional O
nodal O
areas O
. O

Clinical O
and O
biological O
correlates O
of O
panic RARE
states O
. O

Effects O
of O
long O
- O
term O
parenteral RARE
nutrition O
on O
gastrin I-GENE
release O
in O
dogs O
. O

The O
mean O
weight O
and O
height O
velocities RARE
were O
148 NUMERIC
% O
and O
122 O
% O
of O
the O
standard O
, O
respectively O
. O

Of O
7 O
patients O
treated O
with O
cyclophosphamide O
, O
hexamethylmelamine RARE
, O
adriamycin RARE
and O
cisplatin O
( O
CHAP ALLCAPS
- O
5 O
), O
6 O
had O
measurable RARE
disease O
, O
of O
whom O
5 O
yielded O
a O
response O
( O
2 O
complete O
responses O
for O
19 O
+ O
and O
40 O
months O
and O
3 O
partial O
responses O
for O
4 O
, O
7 O
and O
8 O
months O
). O

Isolation O
and O
characterization O
of O
a O
vinculin RARE
cDNA I-GENE
from I-GENE
chick I-GENE
- I-GENE
embryo I-GENE
fibroblasts I-GENE
. O

A O
complementary O
study O
, O
showing O
a O
good O
agreement O
between O
surface O
and O
oesophageal RARE
EMGd RARE
seems O
to O
confirm O
that O
surface O
EMGd RARE
is O
a O
useful O
and O
promising RARE
tool O
for O
clinical O
investigation O
. O

No O
differences O
in O
fixation O
quality O
were O
observed O
between O
cochleas RARE
fixed O
by O
intravascular O
perfusion O
and O
cochleas RARE
fixed O
by O
intralabyrinthine RARE
perfusion O
. O

The O
DNA O
sequence O
encodes O
a O
protein O
of O
1520 NUMERIC
amino O
acids O
with O
sequence O
homology O
to O
the O
human I-GENE
c I-GENE
- I-GENE
abl I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
product I-GENE
, O
beginning O
at O
the O
amino O
terminus O
and O
extending O
656 NUMERIC
amino O
acids O
through O
the O
region O
essential O
for O
tyrosine I-GENE
kinase I-GENE
activity O
. O

The O
requirement O
of O
different O
essential O
fatty O
acids O
in O
patients O
with O
total O
parenteral RARE
nutrition O
after O
heavy O
injury O
is O
of O
special O
interest O
with O
respect O
to O
the O
development O
and O
prognosis O
of O
shock O
, O
sepsis O
or O
adult O
respiratory O
distress O
syndrome O
. O

In O
64 O
% O
a O
small O
cardiac O
vein O
does O
not O
exist O
, O
but O
its O
origin O
, O
the O
right O
marginal RARE
vein O
, O
joins O
the O
system O
of O
anterior O
cardiac O
veins RARE
. O

The O
Drosophila I-GENE
melanogaster I-GENE
Gart RARE
gene I-GENE
encodes O
three O
enzymatic O
activities O
in O
the O
pathway O
for O
purine RARE
de O
novo O
synthesis O
. O

The O
role O
of O
neuroplasticity RARE
in O
the O
response O
to O
drugs O
. O

Biol O
. O

The O
results O
of O
these O
experiments O
indicate O
that O
at O
least O
two O
upstream O
activator O
sequences O
( O
UAS O
) O
mediate O
maximum O
induction O
by O
galactose O
. O

Reversal RARE
of O
the O
increase O
in O
apomorphine RARE
- O
induced O
stereotypy RARE
and O
aggression O
in O
REM O
sleep O
deprived O
rats O
by O
dopamine O
agonist O
pretreatments RARE
. O

The O
heart O
rate O
, O
respiratory O
rate O
, O
arterial O
O2 O
and O
systemic O
vascular O
resistance O
were O
not O
significantly O
altered O
. O

Human I-GENE
rIL LASTCAP
- I-GENE
3 I-GENE
expressed O
in O
COS7 NUMERIC
cells O
has O
multipotential RARE
CSF I-GENE
activity O
in O
semisolid RARE
cultures O
of O
bone O
marrow O
cells O
, O
and O
selectively O
induced O
the O
proliferation O
of O
My RARE
- O
10 O
+ O
marrow O
or O
cord O
blood O
cells O
in O
liquid O
cultures O
. O

In O
14 O
patients O
whose O
PaCO2 O
was O
greater O
than O
or O
equal O
to O
39 O
torr O
( O
range O
39 O
to O
58 O
torr O
) O
and O
clinical O
asthma O
score O
was O
6 O
or O
greater O
, O
PaCO2 O
decreased O
a O
mean O
of O
11 O
. O
7 O
torr O
during O
a O
mean O
of O
8 O
. O
1 O
hours O
. O

A O
randomized O
, O
prospective O
study O
was O
conducted O
to O
compare O
ovarian O
stimulation O
with O
human I-GENE
menopausal I-GENE
gonadotropin I-GENE
( O
hMG LASTCAP
) O
and O
human I-GENE
follicle I-GENE
- I-GENE
stimulating I-GENE
hormone I-GENE
( O
hFSH LASTCAP
) O
in O
an O
in O
vitro O
fertilization O
and O
embryo O
transfer O
( O
IVF ALLCAPS
- O
ET O
) O
program O
. O

Our O
findings O
suggest O
that O
the O
mtr RARE
product I-GENE
causes O
both O
transcription O
attenuation O
and O
inhibition O
of O
translation O
of O
trpE LASTCAP
mRNA I-GENE
. O

Apropos RARE
of O
a O
case O

A O
prostaglandin O
analogue O
given O
in O
early O
pregnancy O
and O
human I-GENE
chorionic RARE
gonadotropin I-GENE
given O
near O
the O
end O
of O
the O
ensuing RARE
follicular O
phase O
were O
used O
for O
controlling O
the O
reproductive O
cycle O
, O
timing O
oocyte O
collection O
, O
and O
synchronizing RARE
the O
cycles O
of O
oocyte O
donors O
and O
embryo O
recipients O
. O

The O
nucleolin RARE
gene I-GENE
extends RARE
over O
9000 NUMERIC
base O
- O
pairs O
and O
is O
split RARE
into O
14 O
exons O
that O
encode O
the O
706 NUMERIC
amino O
acid O
residues O
of O
the O
protein O
. O

Although O
L O
- O
threo RARE
- O
dihydroxyphenylserine RARE
( O
DOPS ALLCAPS
), O
an O
artificial O
norepinephrine O
( O
NE O
) O
precursor O
, O
did O
not O
change O
immobility RARE
in O
intact O
mice O
, O
DOPS ALLCAPS
significantly O
reduced O
immobility RARE
in O
mice O
pretreated O
with O
the O
selective O
NE O
neurotoxin RARE
DSP4 NUMERIC
. O

Substantial RARE
amounts O
of O
liposomal RARE
ampicillin RARE
were O
recovered O
from O
isolated O
Kupffer RARE
cells O
, O
the O
target O
cells O
of O
L O
. O
monocytogenes O
after O
intravenous O
inoculation RARE
. O

This O
suggested O
that O
delta O
6 O
and O
delta O
5 O
desaturation RARE
activities O
are O
normal O
in O
these O
conditions O
with O
this O
C18 O
: O
2w6 NUMERIC
supply O
. O

The O
genetic O
basis O
for O
the O
expression O
of O
a O
latent O
VH I-GENE
allotype RARE
in O
the O
rabbit O
was O
investigated O
. O

Here O
we O
report O
the O
complete O
6 O
- O
kilobase O
cDNA O
sequence O
coding O
for O
a O
chain O
of O
1775 NUMERIC
amino O
acids O
, O
as O
well O
as O
the O
genomic O
structure O
. O

HDL I-GENE
- I-GENE
cholesterol I-GENE
(+ O
6 O
%, O
P O
less O
than O
. O
01 O
) O
and O
apolipoprotein I-GENE
A I-GENE
- I-GENE
I I-GENE
(+ O
6 O
%, O
P O
less O
than O
. O
01 O
) O
concentrations O
increased O
significantly O
only O
in O
the O
young O
. O

The O
Euglena RARE
ribosomal I-GENE
protein I-GENE
gene I-GENE
cluster I-GENE
resembles O
the O
S I-GENE
- I-GENE
10 I-GENE
ribosomal I-GENE
protein I-GENE
operon I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
in O
gene O
organization O
and O
follows O
the O
exact RARE
linear O
order O
of O
the O
analogous O
genes O
in O
the O
tobacco O
and O
liverwort RARE
chloroplast O
genomes O
. O

The O
distribution O
of O
the O
sites O
of O
recombinational RARE
resolution O
is O
inversely O
correlated O
with O
that O
of O
the O
gradient O
of O
sequence O
divergence O
, O
with O
only O
approximately O
7 O
% O
of O
the O
X O
recombinants O
resolved O
within O
the O
3 O
' O
third O
of O
the O
X O
blocks O
where O
two O
diverged O
Alu I-GENE
family O
repeats O
reside O
. O

The O
nucleotide O
sequence O
of O
the O
region O
upstream O
from O
M I-GENE
. I-GENE
voltae RARE
ORFtrpA LASTCAP
was O
determined O
and O
revealed O
the O
presence O
of O
an O
ORF O
of O
1227 NUMERIC
nucleotides O
( O
ORFtrpB LASTCAP
) O
encoding O
a O
409 NUMERIC
amino O
acid O
polypeptide O
of O
mol O
. O
wt O
. O

Potentiation RARE
of O
the O
thrombolytic RARE
efficacy O
of O
single I-GENE
- I-GENE
chain I-GENE
urokinase I-GENE
( O
Pro I-GENE
- I-GENE
urokinase I-GENE
) O
by O
heparin O
. O

Of O
49 O
receptors O
which O
fired RARE
in O
phase O
with O
ventilation O
, O
13 O
behaved RARE
like O
mammalian O
rapidly O
adapting O
pulmonary O
stretch O
receptors O
, O
19 O
like O
mammalian O
slowly O
adapting O
pulmonary O
stretch O
receptors O
( O
PSR ALLCAPS
), O
and O
17 O
like O
avian O
intrapulmonary RARE
CO2 O
- O
sensitive O
chemoreceptors RARE
( O
IPC ALLCAPS
). O

Symptomatic RARE
hyperventilators RARE
had O
a O
larger O
number O
of O
sighs RARE
and O
abnormally RARE
wide O
fluctuations O
in O
baseline O
for O
inspiratory O
time O
, O
expiratory O
time O
, O
and O
PETCO2 NUMERIC
. O

In O
the O
IA O
task O
, O
post O
- O
training O
intraperitoneal RARE
injections O
of O
picrotoxin RARE
and O
bicuculline RARE
induced O
a O
dose O
- O
dependent O
enhancement O
of O
retention O
measured O
24 O
h O
after O
the O
training O
, O
while O
retention O
was O
not O
affected O
by O
bicuculline RARE
methiodide RARE
( O
a O
GABA I-GENE
receptor I-GENE
antagonist O
that O
does O
not O
readily O
cross O
the O
blood O
- O
brain O
barrier O
). O

Clinical O
research O
of O
non O
- O
A O
, O
non O
- O
B O
post O
- O
transfusion O
hepatitis O

It O
is O
suggested O
that O
the O
use O
of O
endogenous O
creatinine O
clearance O
to O
estimate O
the O
glomerular O
filtration O
rate O
( O
GFR O
) O
requires O
caution RARE
and O
the O
recognition O
of O
the O
limitations O
of O
the O
method O
, O
and O
that O
simpler RARE
techniques O
( O
serum O
creatinine O
or O
estimated O
endogenous O
creatinine O
clearance O
) O
are O
preferable RARE
in O
routine O
practice O
. O

The O
protein O
mixtures RARE
of O
sesame RARE
flour RARE
and O
soybean O
flour RARE
were O
well O
accepted O
. O

The O
5 O
' O
end O
of O
the O
coding O
region O
was O
located O
precisely O
by O
comparing O
the O
deduced O
amino O
acid O
sequence O
to O
the O
actual O
N O
- O
terminal O
amino O
acid O
sequence O
of O
IHF ALLCAPS
. O

A O
protein O
footprint O
also O
was O
identified O
for O
a O
GC O
box O
element O
at O
nucleotides O
- O
59 O
to O
- O
45 O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
( O
IGFII ALLCAPS
) O
is O
a O
mitogenic O
polypeptide O
, O
the O
mRNAs O
of O
which O
are O
present O
in O
multiple O
forms O
, O
despite O
derivation RARE
from O
a O
single O
gene O
. O

The O
central O
visual O
fields O
of O
2165 NUMERIC
normal O
and O
106 NUMERIC
glaucoma O
eyes O
were O
measured O
using O
a O
threshold O
related O
suprathreshold RARE
strategy O
. O

The O
variability O
is O
most O
likely O
a O
result O
of O
alternative O
splicing O
of O
exons O
from O
the O
primary O
elastin I-GENE
transcripts I-GENE
. O

This O
led O
to O
the O
conclusion O
that O
the O
metatarsal RARE
artery O
should O
be O
used O
for O
toe O
MP O
joint O
grafts O
, O
while O
the O
unilateral O
proper O
digital O
artery O
is O
suitable O
for O
toe O
PIP ALLCAPS
joint O
grafts O
, O
together O
with O
concomitant O
or O
dorsal O
cutaneous O
vein O
. O

Effect O
of O
chronic O
undernutrition RARE
on O
susceptibility O
to O
cold O
stress O
in O
young O
adult O
and O
aged O
rats O
. O

This O
effect O
and O
the O
fact O
that O
all O
three O
doses O
were O
toxic O
to O
the O
dams RARE
dictated RARE
that O
a O
second O
experiment O
be O
carried O
out O
at O
lower O
doses O
. O

The O
CHARGE ALLCAPS
association O
is O
a O
collection O
of O
multisystem RARE
congenital O
anomalies O
including O
choanal RARE
atresia RARE
. O

Esophageal RARE
brush RARE
cytological RARE
screening O
was O
undertaken O
and O
blood O
concentrations O
of O
micronutrients RARE
( O
vitamin O
A O
, O
E O
, O
B12 NUMERIC
, O
folic RARE
acid O
and O
methionine O
) O
determined O
from O
adults O
at O
risk O
for O
esophageal O
carcinoma O
( O
EC O
) O
in O
Transkei RARE
and O
Ciskei RARE
, O
Southern O
Africa RARE
. O

Aviators RARE
from O
the O
Light RARE
Attack RARE
Wing RARE
, O
Pacific RARE
were O
surveyed RARE
and O
the O
results O
were O
categorized RARE
by O
aircraft RARE
type O
. O

Evaluation O
of O
human O
and O
bovine O
modified O
- O
hemoglobin I-GENE
solution O
as O
oxygen O
- O
carrying O
fluid O
for O
blood O
volume O
replacement O
. O

Delayed RARE
gallbladder O
visualization O
and O
reduction O
in O
ejection O
fraction O
were O
sensitive O
but O
nonspecific O
indicators O
of O
biliary O
disease O
. O

26 O
micrograms O
PAF ALLCAPS
or O
placebo O
was O
sprayed RARE
into O
each O
nasal O
cavity O
8 O
h O
and O
1 O
h O
before O
a O
nasal O
allergen O
challenge O
. O

Sci RARE
. O

Chem O
. O

Sequential RARE
MR O
examinations O
of O
the O
nasal O
cavity O
and O
paranasal RARE
sinuses RARE
were O
performed O
within O
a O
6 O
- O
8 O
h O
period O
in O
five O
normal O
volunteers O
. O

Comparison O
was O
made O
with O
other O
neuroradiological RARE
imaging O
modalities O
including O
CT O
, O
myelography RARE
, O
CT O
ventriculography RARE
, O
and O
CT O
myelocisternography RARE
. O

The O
feed O
given O
to O
young O
broiler RARE
chickens O
was O
contaminated O
artificially O
with O
Salmonella O
kedougou RARE
, O
a O
serotype O
associated O
with O
both O
subclinical O
infections O
in O
commercially RARE
reared RARE
chickens O
and O
food O
poisoning O
in O
humans O
. O

A O
poor O
correlation O
was O
found O
between O
a O
mildly RARE
- O
atypical O
( O
inflammatory O
) O
cytological RARE
result O
( O
class O
2 O
) O
and O
a O
benign O
histological O
diagnosis O
: O
48 O
% O
of O
class O
- O
2 O
smears O
were O
diagnosed O
histologically O
as O
dysplasia O
or O
worse RARE
. O

Factors O
involved O
in O
specific O
transcription O
by O
mammalian O
RNA I-GENE
polymerase I-GENE
II I-GENE
: O
purification O
, O
genetic O
specificity O
, O
and O
TATA O
box O
- O
promoter O
interactions O
of O
TFIID I-GENE
. O

Change RARE
in O
plasma I-GENE
cystyl RARE
aminopeptidase RARE
( O
oxytocinase RARE
) O
between O
30 O
- O
34 O
weeks O
' O
gestation O
as O
a O
predictor O
of O
pregnancy O
- O
induced O
hypertension O
. O

You RARE
make O
the O
diagnosis O
. O

The O
test O
for O
alpha I-GENE
- I-GENE
naphthyl RARE
esterase I-GENE
and O
quantitation RARE
of O
macrophages O
( O
absolute O
number O
) O
per O
infiltration RARE
area O
unit O
adjacent O
to O
the O
abscess O
suggest O
a O
direct O
correlation O
between O
the O
absolute O
number O
of O
macrophages O
and O
the O
width RARE
of O
the O
capsule RARE
. O

Determined RARE
as O
migration O
differentials RARE
, O
chemotactic O
and O
chemokinetic RARE
responsiveness O
tended O
to O
be O
higher O
in O
the O
neutropenic RARE
group O
. O

The O
deduced O
96 O
- O
residue O
amino O
acid O
coding O
sequence O
of O
the O
murine O
HMG I-GENE
- I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
cDNA O
is O
very O
similar O
to O
the O
reported O
amino O
acid O
sequence O
of O
human O
HMG I-GENE
- I-GENE
I I-GENE
, O
except O
that O
it O
lacks O
11 O
internal O
amino O
acids O
reported O
in O
the O
human O
protein O
. O

Interpersonal RARE
style RARE
differences O
among O
drug O
abusers RARE
were O
explored O
using O
Ryan RARE
' O
s O
( O
1977 NUMERIC
) O
typological RARE
system O
of O
FIRO ALLCAPS
- O
B O
interpretation O
. O

Statement RARE
of O
the O
American O
Academy RARE
of O
Implant RARE
Dentistry RARE
. O

Sera RARE
from O
euthyroid RARE
post O
- O
menopausal O
or O
pregnant O
women O
yielded O
TSH I-GENE
levels O
within O
the O
normal O
range O
. O

No O
UOxase RARE
mRNA I-GENE
was O
detected O
in O
11 O
nonhepatic RARE
tissues O
of O
rat O
, O
suggesting O
tissue O
specificity O
of O
expression O
of O
this O
UOxase RARE
gene I-GENE
. O

The O
platelet O
adhesion O
rate O
on O
these O
layers RARE
were O
tested O
concerning O
the O
valuation RARE
of O
the O
haemocompatibility RARE
of O
the O
basic O
- O
polymers O
polyurethane RARE
( O
PUR ALLCAPS
), O
polyvinylchloride RARE
( O
PVC ALLCAPS
), O
and O
polystyrene RARE
( O
PS O
) O
in O
two O
different O
worked RARE
test O
chambers RARE
. O

Conservative RARE
treatment O
of O
bladder O
carcinoma O
by O
partial O
cystectomy RARE
and O
interstitial O
iridium RARE
192 O
. O

In O
a O
112 O
- O
d O
feedlot RARE
trial O
, O
105 O
heifers O
were O
assigned O
to O
light O
, O
medium O
and O
heavy O
weight O
blocks O
on O
five O
treatments O
: O
dietary O
MGA O
(. RARE
5 O
mg O
. O
hd RARE
- O
1 O
. O
d O
- O
1 O
), O
control O
( O
no O
MGA O
) O
or O
DEPO ALLCAPS
- O
MGA O
on O
d O
1 O
at O
. O
5 O
, O
1 O
. O
0 O
or O
1 O
. O
5 O
ml O
/ O
hd RARE
( O
30 O
, O
60 O
or O
90 O
mg O
MGA O
/ O
hd RARE
, O
respectively O
). O

Existence RARE
and O
uniqueness RARE
of O
solutions O
of O
the O
appropriate O
boundary O
value O
problems O
are O
established O
, O
in O
the O
case O
of O
small O
permeability O
coefficients O
and O
transport O
rates O
, O
or O
large O
diffusion O
coefficients O
and O
small O
resistance O
to O
flow O
constants O
. O

There O
were O
gene O
clusters O
encoding O
photosynthesis RARE
components O
such O
as O
the O
psbB LASTCAP
- O
psbH LASTCAP
- O
petB LASTCAP
- O
petD LASTCAP
and O
the O
psbE LASTCAP
- O
psbF LASTCAP
clusters O
. O

The O
results O
presented O
suggest O
that O
TIQ ALLCAPS
reduces O
the O
turnover O
rate O
of O
the O
nigrostriatal RARE
dopamine O
neurons O
after O
repeated O
administration O
for O
a O
long O
period O
in O
mice O
. O

The O
partial O
sequence O
of O
the O
62 I-GENE
- I-GENE
kDa I-GENE
nuclear I-GENE
pore I-GENE
glycoprotein I-GENE
shows O
little O
similarity O
to O
other O
characterized O
proteins O
and O
elucidates RARE
structural O
features O
of O
a O
member O
of O
the O
family O
of O
nuclear I-GENE
pore I-GENE
glycoproteins I-GENE
. O

Seventy O
- O
two O
hours O
after O
administration O
of O
vitamin O
K1 O
, O
plasma O
concentrations O
of O
the O
vitamin O
were O
not O
different O
from O
normal O
. O

The O
glomerular O
filtration O
rate O
did O
not O
change O
but O
lithium O
clearance O
fell O
by O
30 O
%. O

During O
a O
28 O
- O
week O
promotion RARE
bioassay RARE
, O
groups O
of O
30 O
male O
CD O
- O
1 O
mice O
were O
treated O
once O
with O
50 O
microliter RARE
of O
either O
DMBA ALLCAPS
( O
1 O
. O
0 O
mg O
/ O
ml O
) O
or O
acetone RARE
, O
rested RARE
for O
2 O
weeks O
, O
and O
then O
treated O
twice O
per O
week O
with O
test O
material O
for O
the O
remaining O
25 O
weeks O
. O

The O
pathogenesis O
of O
Dupuytren RARE
' O
s O
contracture RARE

An O
ELISA O
procedure O
was O
developed O
for O
monitoring O
the O
specific O
IgE I-GENE
response O
in O
dogs O
to O
Dirofilaria RARE
immitis RARE
infection O
. O

Fifty O
min O
after O
release O
from O
stress O
, O
increases O
in O
plasma O
corticosterone O
levels O
induced O
by O
stress O
recovered O
in O
the O
biting RARE
group O
but O
remained O
high O
in O
the O
non O
- O
biting RARE
group O
. O

The O
only O
isolate O
of O
Aeromonas RARE
hydrophila RARE
produced O
cytotoxic O
enterotoxin O
and O
was O
invasive O
. O

An O
11 O
- O
month O
- O
old O
girl RARE
suffering O
from O
Dandy RARE
- O
Walker RARE
malformation RARE
( O
DWM ALLCAPS
) O
associated O
with O
tetralogy RARE
of O
Fallot RARE
( O
TOF O
) O
is O
presented O
. O

The O
incidence O
of O
early O
neonatal O
convulsions RARE
for O
inborn RARE
babies O
was O
3 O
. O
0 O
/ O
1000 O
live O
births O
. O

The O
median O
survival O
is O
not O
reached O
with O
a O
median O
follow O
- O
up O
time O
of O
9 O
. O
6 O
years O
. O

Critical RARE
evaluation O
of O
various O
methods O
of O
determining O
markers O
of O
fetal O
maturity RARE
in O
amniotic O
fluid O

Of O
the O
43 O
infants O
with O
a O
( O
probable O
) O
loss O
18 O
were O
examined O
again O
at O
3 O
months O
corrected O
age O
. O

Variety RARE
of O
cows O
and O
sires RARE
according O
to O
types O
of O
dermatoglyphics RARE
( O
patterns O
) O
of O
the O
nose RARE
- O
labial RARE
mirror RARE
of O
cattle O

Although O
not O
consistently O
identified O
in O
all O
samples O
, O
secondary O
Academic O
, O
Personal RARE
Responsibility RARE
, O
and O
Community RARE
/ O
Vocational RARE
dimensions O
were O
also O
identified O
. O

Recovery RARE
was O
characterized O
by O
rapid O
improvement O
such O
that O
all O
measured O
parameters O
normalized O
by O
1 O
week O
, O
except O
for O
cross O
- O
sectional O
cardiac O
area O
which O
remained O
dilated RARE
up O
to O
4 O
weeks O
( O
14 O
+/- O
3 O
cm2 O
, O
p O
less O
than O
0 O
. O
05 O
versus O
control O
).( RARE
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Not RARE
even O
extensive O
pancreatic O
resection O
could O
prevent O
pancreatic O
remnant RARE
infection O
. O

It O
has O
been O
calculated O
that O
600 O
, O
000 O
new O
cases O
of O
lung O
cancer O
occur O
worldwide RARE
every O
year O
, O
most O
of O
them O
due O
to O
smoking O
. O

Neuromyelitis RARE
optica RARE
( O
Devic RARE
' O
s O
syndrome O
): O
not O
always O
multiple O
sclerosis O
. O

Effect O
of O
the O
methods O
of O
cutaneous O
administration O
of O
methyl O
isobutyl RARE
ketone RARE
on O
its O
toxicity O

Incorporation RARE
of O
0 O
. O
1 O
or O
0 O
. O
2 O
M O
sodium O
dihydrogen RARE
phosphate O
in O
the O
sugar O
solutions O
resulted O
in O
a O
decrease O
in O
the O
shelf RARE
- O
life O
of O
diltiazem O
. O

None O
had O
a O
past O
history O
of O
opportunistic RARE
infections O
; O
neither O
did O
any O
have O
lymphopenia RARE
. O

Increasing O
the O
phosphorus O
content O
of O
the O
diet O
improved O
the O
reabsorption RARE
of O
calcium O
and O
magnesium O
. O

Post O
- O
transcriptional O
regulation O
of O
ribosomal I-GENE
protein I-GENE
gene I-GENE
expression O
during O
development O
in O
Dictyostelium O
discoideum RARE
. O

The O
temporal O
and O
static RARE
plasma O
concentration O
- O
effect O
relationships O
were O
evaluated O
by O
pharmacodynamic RARE
modeling RARE
and O
linear O
regression O
. O

The O
increase O
in O
amplitudes O
of O
the O
b O
- O
wave O
during O
the O
adaptation O
period O
was O
more O
prominent O
in O
lead O
- O
exposed O
subjects O
than O
in O
controls O
. O

Possible RARE
factors O
for O
the O
development O
of O
psychotic RARE
symptomatology RARE
during O
group O
activities O
and O
the O
role O
of O
group O
dynamics O
acting O
as O
stress O
factors O
precipitating O
functional O
psychoses RARE
, O
especially O
bipolar O
manifestations O
, O
are O
discussed O
. O

Baseline RARE
measurements O
of O
forced RARE
expiratory O
volume O
in O
1 O
s O
( O
FEV1 O
), O
specific O
airway O
conductance O
( O
SGaw RARE
) O
and O
the O
provocative RARE
dose O
of O
carbachol O
causing O
a O
35 O
% O
reduction O
in O
SGaw RARE
( O
PD35 NUMERIC
), O
and O
a O
20 O
% O
reduction O
in O
FEV1 O
( O
PD20 NUMERIC
) O
were O
established O
on O
entry O
while O
each O
subject O
was O
still O
smoking O
. O

Many O
children O
with O
BGC ALLCAPS
are O
delayed O
in O
their O
development O
, O
but O
calcifications RARE
are O
not O
directly O
related O
to O
specific O
forms O
of O
neurologic O
dysfunction O
. O

R O
- O
wave O
voltage O
in O
the O
right O
precordial RARE
leads O
in O
anthracycline RARE
cardiomyopathy O
: O
a O
clinical O
study O
. O

The O
results O
indicate O
that O
the O
pooling RARE
requirements O
are O
task O
dependent O
. O

These O
results O
indicate O
that O
CSFHU ALLCAPS
can O
increase O
neutrophil O
counts O
by O
increasing O
the O
number O
and O
maturity RARE
of O
the O
marrow O
neutrophil O
precursors O
in O
some O
types O
of O
childhood O
chronic O
neutropenia O
. O

The O
purposes RARE
of O
this O
study O
were O
1 O
) O
to O
examine O
the O
effect O
of O
high O
intensity O
, O
low O
frequency O
transcutaneous RARE
electrical O
nerve O
stimulation O
at O
auricular RARE
acupuncture RARE
points O
on O
experimental O
pain O
threshold O
measured O
at O
the O
wrist O
and O
2 O
) O
to O
determine O
the O
changes O
in O
effect O
over O
time O
. O

In O
the O
infected O
neonates O
serum O
alpha I-GENE
- I-GENE
amylase I-GENE
value O
, O
as O
determined O
by O
the O
blue O
starch RARE
method O
, O
was O
only O
40 O
% O
that O
of O
healthy O
controls O
; O
the O
mean O
value O
of O
175 O
. O
1 O
+/- O
64 O
. O
9 O
IU O
/ O
l O
for O
healthy O
neonates O
was O
significantly O
higher O
( O
p O
less O
than O
0 O
. O
0010 NUMERIC
) O
than O
the O
value O
of O
82 O
. O
8 O
+/- O
44 O
. O
4 O
IU O
/ O
l O
for O
the O
infected O
neonates O
. O

Records RARE
of O
31 O
children O
with O
AIDS O
or O
AIDS O
- O
related O
complex O
admitted RARE
to O
the O
pediatric O
intensive O
care O
unit O
for O
acute O
respiratory O
failure O
throughout O
a O
46 O
- O
month O
period O
were O
reviewed O
. O

Fourteen RARE
patients O
were O
in O
the O
multifocal RARE
disease O
group O
; O
13 O
were O
detected O
by O
SPECT O
and O
10 O
by O
TCT ALLCAPS
. O

SPECT O
is O
an O
important O
aid O
in O
the O
diagnosis O
of O
AIDS O
dementia O
complex O
and O
contributes O
to O
the O
understanding O
of O
the O
pathophysiological RARE
mechanisms O
of O
this O
disorder O
. O

We O
were O
interested RARE
in O
studying O
the O
relationship O
between O
the O
circadian O
rhythm O
in O
body O
temperature O
and O
24 O
- O
h O
variations O
in O
plasma O
concentrations O
of O
iron O
, O
zinc O
, O
circulating O
leukocyte O
counts O
, O
and O
plasma O
interleukin I-GENE
1 I-GENE
( O
IL I-GENE
- I-GENE
1 I-GENE
) O
activity O
. O

The O
murine I-GENE
MHC I-GENE
class I-GENE
I I-GENE
genes I-GENE
, O
H I-GENE
- I-GENE
2Dq NUMERIC
and O
H I-GENE
- I-GENE
2Lq NUMERIC
, O
are O
strikingly O
homologous O
to O
each O
other O
, O
H I-GENE
- I-GENE
2Ld NUMERIC
, O
and O
two O
genes O
reported O
to O
encode O
tumor O
- O
specific O
antigens O
. O

The O
active O
derivatives O
of O
the O
present O
series O
were O
also O
tested O
for O
their O
analgesic O
activity O
against O
aconitine RARE
- O
induced O
writhing RARE
in O
albino RARE
mice O
and O
ulcerogenic RARE
activity O
in O
albino RARE
rats O
. O

In O
untreated O
mice O
, O
bactericidal O
activity O
of O
peritoneal O
macrophages O
decreased O
from O
one O
day O
to O
3 O
days O
after O
ip RARE
injection O
of O
killed O
L O
. O
monocytogenes O
. O

Among O
a O
population O
of O
18 O
, O
175 O
children O
below O
7 O
years O
of O
age O
in O
medium O
sized O
towns RARE
and O
rural RARE
areas O
in O
south RARE
- O
western RARE
Germany RARE
552 NUMERIC
( O
3 O
. O
03 O
%) O
cases O
of O
croup RARE
were O
registered RARE
during O
a O
12 O
months O
period O
in O
1984 NUMERIC
- O
85 O
by O
their O
physicians O
. O

We O
concluded O
that O
Ga O
- O
fbg RARE
scintigraphy O
is O
a O
very O
simple O
method O
and O
sufficiently RARE
useful O
for O
detecting O
active O
left O
ventricular O
thrombi RARE
and O
for O
monitoring O
the O
effect O
of O
anticoagulant O
therapy O
. O

In O
vitro O
assessment O
of O
the O
biocompatibility RARE
of O
dental O
materials O
-- O
the O
millipore RARE
filter O
method O
. O

Hypomagnesemia RARE
was O
due O
to O
magnesium O
wasting RARE
by O
the O
kidney O
. O

Dentalplaque RARE
was O
controlled O
by O
the O
oral O
higienic RARE
index O
of O
the O
whole O
dentition RARE
daily O
, O
after O
staining O
with O
1 O
per O
cent O
alkaline O
fuxin RARE
. O

GRFI ALLCAPS
bound O
to O
sequences O
at O
the O
negative O
regulatory O
elements O
( O
silencers RARE
) O
of O
the O
silent I-GENE
mating I-GENE
type I-GENE
loci I-GENE
HML I-GENE
E I-GENE
and O
HMR I-GENE
E I-GENE
and O
to O
the O
upstream O
activating O
sequence O
( O
UAS O
) O
required O
for O
transcription O
of O
the O
MAT ALLCAPS
alpha I-GENE
genes I-GENE
. O

The O
effects O
of O
these O
mutations O
on O
RNA I-GENE
polymerase I-GENE
II I-GENE
activity O
were O
assayed O
by O
measuring O
the O
ability O
of O
mutant O
genes O
to O
confer O
alpha I-GENE
- I-GENE
amanitin RARE
resistance O
after O
transfection O
of O
susceptible O
rodent O
cells O
. O

We O
report O
the O
use O
of O
a O
new O
technetium O
- O
99m O
- O
albumin I-GENE
colloid O
white O
blood O
cell O
( O
TAC ALLCAPS
- O
WBC O
) O
scan O
in O
the O
evaluation O
of O
appendicitis RARE
. O

In O
one O
of O
these O
tumors O
the O
observed O
rearrangement O
was O
not O
due O
to O
the O
insertion O
of O
an O
intact O
MoMuLV LASTCAP
provirus O
. O

The O
indications RARE
for O
its O
use O
include O
every O
primary O
and O
secondary O
rhinoplasty RARE
candidate O
unless O
tip O
grafts O
are O
going RARE
to O
be O
under O
tension O
or O
if O
the O
deformity RARE
is O
minor O
. O

The O
SSB I-GENE
- O
poly O
( O
dT O
) O
affinity O
is O
too RARE
high O
to O
measure O
in O
buffers RARE
containing O
even O
5 O
M O
NaCl O
; O
however O
, O
in O
1 O
. O
8 O
- O
2 O
. O
5 O
M O
NaBr RARE
, O
we O
measure O
alpha O
log O
Kobsd RARE
/ O
alpha O
log O
[ O
NaBr RARE
] O
= O
- O
5 O
. O
7 O
+/- O
0 O
. O
7 O
, O
with O
a O
lower O
value O
of O
omega O
T O
/ O
O O
= O
130 O
+/- O
70 O
. O

Mutations O
at O
the O
suf12 NUMERIC
locus I-GENE
were O
isolated O
in O
Saccharomyces O
cerevisiae O
as O
extragenic RARE
suppressors O
of O
+ O
1 O
frameshift O
mutations O
in O
glycine O
( O
GGX ALLCAPS
) O
and O
proline O
( O
CCX ALLCAPS
) O
codons O
, O
as O
well O
as O
UGA O
and O
UAG ALLCAPS
nonsense O
mutations O
. O

The O
behavior O
of O
suf12 NUMERIC
- I-GENE
null I-GENE
/ I-GENE
SUF12 NUMERIC
+ I-GENE
heterozygotes RARE
indicates O
that O
suf12 NUMERIC
is O
co O
- O
dominantly RARE
expressed O
and O
suggests O
that O
suf12 NUMERIC
allele O
- O
specific O
suppression O
may O
result O
from O
functionally O
distinct O
mutant O
proteins O
rather O
than O
variation O
in O
residual O
wild I-GENE
- I-GENE
type I-GENE
SUF12 NUMERIC
+ I-GENE
activity O
. O

Antituberculosis RARE
agents O
. O

The O
putative O
immunity O
protein O
was O
detected O
among O
the O
[ O
35S O
] O
methionine O
- O
labelled O
proteins O
produced O
by O
minicells RARE
carrying O
cni RARE
cloned O
under O
lac I-GENE
promoter I-GENE
control O
, O
and O
when O
the O
gene O
was O
subcloned O
into O
expression O
vectors O
under O
the O
control O
of O
a O
bacteriophage O
T7 O
promoter O
. O

Antibodies O
made O
against O
fusion O
protein O
produced O
by O
the O
DP1A NUMERIC
clone O
reacted O
specifically O
with O
DP I-GENE
- I-GENE
I I-GENE
and I-GENE
- I-GENE
II I-GENE
on O
immunoblots RARE
. O

Finally O
, O
over O
a O
similar O
range O
of O
QO2 NUMERIC
, O
oxygen O
extraction O
was O
greater O
in O
patients O
with O
ARDS O
compared O
to O
patients O
with O
non O
- O
ARDS O
respiratory O
failure O
( O
r O
= O
- O
0 O
. O
67 O
and O
slope O
= O
- O
0 O
. O
62 O
vs O
r O
= O
- O
0 O
. O
45 O
and O
slope O
= O
- O
0 O
. O
35 O
; O
p O
less O
than O
0 O
. O
05 O
). O

Stable O
patients O
have O
mucous RARE
hypersecretion RARE
and O
little O
evidence O
of O
acute O
inflammation O
. O

Hyperprolactinaemia RARE
, O
moderate O
hypogonadism RARE
, O
infraclinical RARE
neuropathies RARE
, O
arterial O
stenoses RARE
and O
moderate O
venous O
leakages RARE
seem O
to O
play O
a O
partial O
role O
of O
organic O
starter RARE
or O
cofactor O
, O
the O
sexual O
consequences O
of O
which O
are O
amplified O
by O
psychological O
factors O
, O
partly O
secondary O
to O
the O
initial O
sexual O
failures RARE
. O

Yang RARE
and O
H O
. O

Secretory RARE
function O
of O
the O
prostate O
gland O
. O

Chronic O
endotoxemia RARE
appears O
to O
be O
associated O
with O
an O
elevated O
pulmonary O
microvascular O
permeability O
and O
a O
tendency O
toward O
a O
hyperdynamic RARE
circulation O
but O
with O
an O
appreciable RARE
degree O
of O
refractoriness RARE
associated O
with O
regional O
hemodynamics O
and O
eicosanoid RARE
biosynthesis O
. O

In O
contrast O
, O
we O
observed O
high O
concentrations O
in O
29 O
of O
75 O
patients O
with O
tumors O
of O
the O
central O
nervous O
system O
, O
especially O
in O
meningioma RARE
( O
6 O
/ O
9 O
), O
glioblastoma RARE
( O
9 O
/ O
23 O
), O
and O
neurinoma RARE
( O
5 O
/ O
5 O
). O

Diet RARE
and O
atopic O
eczema RARE
. O

Time RARE
delay O
effects O
on O
the O
tensile RARE
bond O
strength O
developed O
by O
the O
Silicoater RARE
. O

The O
future O
of O
research O
with O
interferon I-GENE
may O
be O
divided O
into O
three O
areas O
: O
Efforts RARE
must O
be O
made O
to O
determine O
how O
best O
to O
translate RARE
the O
in O
vitro O
synergy RARE
into O
clinically O
meaningful RARE
terms O
; O
in O
order O
to O
exploit RARE
the O
fullest RARE
potential O
of O
IFN I-GENE
, O
research O
is O
moving RARE
toward O
using O
this O
agent O
earlier O
in O
disease O
either O
as O
an O
adjuvant O
after O
tumor O
debulking RARE
or O
after O
initial O
diagnosis O
; O
the O
medical O
community O
must O
rethink RARE
the O
natural O
history O
of O
some O
diseases O
, O
because O
the O
fullest RARE
potential O
of O
the O
biologic RARE
agents O
will O
most O
likely O
manifest O
itself O
when O
these O
agents O
are O
used O
together O
. O

Minor RARE
differences O
were O
noted O
with O
latamoxef RARE
producing O
mild O
persistant RARE
elevation O
of O
prothrombin I-GENE
time O
( O
0 O
. O
7 O
second O
) O
associated O
with O
depression O
of O
factor I-GENE
II I-GENE
and O
factor I-GENE
VII I-GENE
. O

Six O
healthy O
male O
subjects O
received O
single O
oral O
doses O
of O
regular O
release O
( O
RR O
) O
quinidine RARE
sulfate O
, O
sustained O
release O
( O
SR O
) O
quinidine RARE
bisulfate RARE
and O
the O
same O
dose O
of O
the O
SR O
product O
with O
food O
( O
SR O
- O
F O
). O

This O
report O
expands RARE
on O
previous O
work O
with O
interferon I-GENE
alfa RARE
- I-GENE
2b I-GENE
( I-GENE
Intron I-GENE
A I-GENE
; I-GENE
Schering RARE
- I-GENE
Plough RARE
) I-GENE
in O
the O
treatment O
of O
hairy RARE
cell O
leukemia O
( O
HCL ALLCAPS
). O

Oxygen RARE
delivery O
and O
base O
excess O
decreased O
significantly O
and O
four O
pigs O
died O
. O

Clinical O
chemistry O
. O

Revascularization RARE
after O
anterior O
maxillary RARE
and O
mandibular O
osteotomy RARE

Static RARE
orthoses RARE
for O
the O
management O
of O
microstomia RARE
. O

The O
intrapancreatic RARE
spread O
of O
the O
carcinoma O
correlated O
with O
portal O
invasion O
of O
carcinoma O
, O
hardness RARE
of O
the O
body O
and O
tail O
, O
obstruction O
of O
main O
pancreatic O
duct O
and O
irregular RARE
pancreaticogram RARE
. O

Lysosomal RARE
enzymes O
that O
degrade RARE
cartilage O
are O
released O
. O

Contrary RARE
to O
the O
observation O
made O
with O
other O
S O
. O
pombe O
genes O
transcribed O
in O
the O
budding O
yeast O
, O
the O
heterologous O
actin I-GENE
gene I-GENE
transcript I-GENE
is O
initiated O
39 O
nucleotides O
upstream O
of O
the O
initiation O
start O
site O
used O
in O
the O
homologous O
yeast O
. O

A O
multicentre RARE
study O
involving O
9 O
Italian O
institutions RARE
was O
carried O
out O
to O
compare O
the O
efficacy O
and O
safety O
of O
ranitidine O
150 O
mg O
b O
. O
i O
. O
d O
. O
and O
ranitidine O
300 O
mg O
nocte RARE
in O
the O
treatment O
of O
reflux O
oesophagitis RARE
. O

Monotherapy RARE
with O
ceftazidime RARE
was O
clinically O
and O
bacteriologically RARE
as O
effective O
as O
a O
combination O
therapy O
with O
cefazolin RARE
and O
tobramycin RARE
. O

The O
N3 NUMERIC
wave O
of O
the O
SSEP ALLCAPS
' O
s O
, O
which O
has O
been O
found O
to O
correlate O
best O
with O
neurological O
recovery O
, O
returned O
to O
65 O
% O
+/- O
48 O
% O
of O
the O
preischemia RARE
amplitude O
in O
the O
insulin I-GENE
- O
treated O
animals O
, O
compared O
to O
40 O
% O
+/- O
34 O
% O
in O
the O
fasted O
group O
and O
26 O
% O
+/- O
24 O
% O
in O
the O
control O
animals O
. O

Proctoscopy RARE
and O
roentgenographic RARE
studies O
may O
be O
an O
important O
part O
of O
evaluation O
, O
especially O
in O
patients O
who O
present O
with O
perianal RARE
suppuration RARE
, O
masses O
, O
or O
anal RARE
fissures RARE
. O

In O
the O
control O
group O
the O
histological O
picture O
resembled RARE
osteoarthritis RARE
. O

In O
contrast O
to O
this O
mRNA O
, O
90 O
% O
of O
alpha I-GENE
and I-GENE
beta I-GENE
actin I-GENE
mRNAs I-GENE
were O
translated O
in O
both O
myoblasts O
and O
myotubes O
. O

Plasma I-GENE
renin I-GENE
activity O
does O
not O
predict O
the O
antihypertensive O
efficacy O
of O
chlorthalidone RARE
. O

Cephradine RARE
250 O
mg O
at O
night O
for O
12 O
months O
was O
given O
as O
a O
prophylactic O
measure O
to O
33 O
female O
patients O
of O
mean O
age O
41 O
. O
6 O
years O
, O
who O
had O
a O
history O
in O
the O
preceding O
12 O
months O
of O
between O
three O
and O
24 O
( O
median O
= O
7 O
) O
episodes O
of O
frequency O
and O
/ O
or O
dysuria RARE
. O

If O
this O
is O
unavailable RARE
, O
then O
Supramid RARE
has O
a O
proven O
record O
for O
good O
tissue O
compatibility O
and O
resistance O
to O
infection O
. O

The O
size O
of O
the O
group O
allocated O
to O
the O
good O
compliance O
category O
by O
the O
use O
of O
the O
digoxin RARE
marker O
was O
equivalent O
in O
size O
to O
a O
group O
of O
patients O
who O
had O
returned O
less O
than O
15 O
% O
of O
their O
prescribed RARE
dose O
or O
reported O
a O
deviation O
of O
less O
than O
6 O
% O
from O
their O
prescription RARE
. O

Bullous RARE
keratopathy RARE
was O
usually O
aphakic RARE
in O
origin O
in O
1982 O
, O
but O
after O
1983 O
pseudophakic RARE
bullous RARE
keratopathy RARE
( O
PBK ALLCAPS
) O
was O
the O
most O
common O
cause O
of O
bullous RARE
keratopathy RARE
. O

The O
ultrastructural RARE
findings O
, O
as O
well O
as O
the O
urinary O
C I-GENE
- I-GENE
peptide I-GENE
excretion O
, O
confirmed O
that O
the O
glycemic RARE
effects O
should O
not O
be O
thought O
to O
be O
due O
to O
a O
direct O
action O
of O
the O
drugs O
used O
on O
the O
endocrine O
pancreas O
. O

The O
activity O
of O
the O
EGF I-GENE
receptor I-GENE
promoter I-GENE
can O
be O
modulated O
by O
E1A I-GENE
protein I-GENE
and O
receptor O
RNA O
levels O
increased O
by O
stimulation O
with O
phorbol O
ester O
or O
fetal O
calf O
serum O
. O

In O
vitro O
antimalarial RARE
activity O
of O
neem RARE
( O
Azadirachta RARE
indica RARE
A O
. O

" O
In O
vitro O
" O
study O
of O
dentin O
adhesion O
to O
adhesives RARE
made O
from O
urethane RARE
molecules O
with O
free O
groups O
of O
isocyanate RARE

By O
Felix RARE
Lagrange RARE
, O
1918 NUMERIC
. O

There O
is O
a O
cysteine O
clustering RARE
region O
in O
an O
N O
- O
terminal O
region O
of O
the O
c I-GENE
- I-GENE
raf I-GENE
(- I-GENE
1 I-GENE
) I-GENE
product I-GENE
deduced O
from O
the O
nucleotide O
sequence O
, O
and O
this O
cysteine O
clustering RARE
region O
was O
found O
to O
be O
highly O
homologous O
to O
that O
present O
in O
an O
N O
- O
terminal O
region O
of O
protein I-GENE
kinase I-GENE
C I-GENE
, O
although O
, O
in O
the O
latter O
cysteine O
clusters O
are O
present O
in O
duplicate RARE
. O

Hand RARE
- O
held O
, O
continuous O
- O
wave O
Doppler O
probes O
, O
coupled O
with O
sound O
spectral O
analysis O
, O
can O
successfully O
predict O
carotid O
artery O
stenosis O
. O

The O
German RARE
Society RARE
of O
Pediatric RARE
Oncology RARE
in O
1981 NUMERIC
initiated O
the O
Cooperative RARE
Ewing RARE
' O
s O
Sarcoma RARE
Study O
( O
CESS ALLCAPS
81 O
) O
using O
a O
four O
- O
drug O
combination O
of O
chemotherapy O
prior O
to O
definitive O
local O
control O
with O
surgery O
and O
/ O
or O
radiation O
. O

The O
program O
has O
been O
written RARE
in O
a O
generic RARE
BASIC ALLCAPS
in O
order O
to O
make O
the O
procedure O
user RARE
- O
friendly RARE
. O

Since O
high O
levels O
of O
immunoglobulin I-GENE
G I-GENE
were O
demonstrated O
against O
the O
surface O
of O
the O
NVS ALLCAPS
after O
immunization O
, O
passive O
transfer O
experiments O
were O
initiated O
. O

A O
study O
was O
conducted O
of O
a O
human O
male O
who O
had O
inhaled O
a O
mixture O
of O
241Am NUMERIC
and O
Pu RARE
. O

An O
analytic RARE
method O
for O
comparative O
parameter O
weighting RARE
in O
magnetic O
resonance O
( O
MR O
) O
imaging O
has O
been O
developed O
using O
the O
concept O
of O
" O
fractional O
sensitivity O
." O
This O
new O
approach O
results O
in O
easily O
calculated O
indexes RARE
for O
T1 O
, O
T2 O
, O
and O
hydrogen O
weighting RARE
. O

Fifty O
- O
four O
patients O
were O
divided O
into O
groups O
according O
to O
their O
clinical O
presentation O
; O
seven O
asymptomatic O
volunteers O
, O
20 O
patients O
with O
duodenal O
- O
gastric O
reflux O
gastropathy RARE
( O
DRG ALLCAPS
), O
16 O
patients O
with O
recurrent O
ulcers O
of O
the O
duodenal O
bulb O
( O
RUD ALLCAPS
), O
and O
11 O
patients O
with O
Moynihan RARE
' O
s O
disease O
. O

No O
previous O
studies O
have O
determined O
the O
pharmaco RARE
- O
dynamics O
of O
intravenous O
procainamide RARE
when O
administered O
in O
a O
dose O
of O
15 O
mg O
/ O
kg O
and O
at O
a O
rate O
of O
50 O
mg O
/ O
min O
, O
as O
is O
common O
practice O
during O
electropharmacologic RARE
testing O
. O

High O
concentrations O
of O
tumor O
- O
associated O
trypsin I-GENE
inhibitor O
in O
hemodialyzed RARE
patients O
. O

In O
the O
chicken O
liver O
, O
levels O
of O
chicken I-GENE
MT ALLCAPS
mRNA I-GENE
were O
rapidly O
induced O
by O
metals RARE
( O
Cd2 NUMERIC
+, O
Zn2 NUMERIC
+, O
Cu2 NUMERIC
+), O
glucocorticoids O
and O
lipopolysaccharide O
. O

With O
histology RARE
and O
Evans RARE
blue O
injections O
, O
blood O
- O
brain O
barrier O
alterations O
were O
seen O
as O
early O
as O
4 O
days O
after O
a O
dose O
of O
50 O
Gy O
. O

Dosimetric RARE
estimates O
for O
these O
organs O
were O
2 O
. O
3 O
+/- O
1 O
. O
1 O
and O
2 O
. O
3 O
+/- O
1 O
. O
4 O
rad RARE
(. RARE
02 O
+/- O
. O
01 O
Gy O
), O
respectively O
, O
with O
a O
whole O
- O
body O
estimate O
of O
0 O
. O
28 O
rad RARE
(. RARE
003 NUMERIC
Gy O
). O

A O
significant O
association O
between O
a O
family O
history O
and O
a O
higher O
urinary O
pH O
was O
observed O
among O
the O
female O
calcium O
stone O
patients O
. O

New O
technologies RARE
in O
diagnosis O
and O
classification O
of O
malignancy O
. O

Thus O
the O
present O
data O
also O
suggest O
that O
BP O
and O
HR O
measurements O
are O
influenced O
not O
only O
by O
state O
- O
dependent O
factors O
but O
also O
by O
at O
least O
three O
different O
factors O
that O
are O
each O
independent O
of O
the O
state O
: O
one O
leads O
to O
BP O
and O
HR O
values O
that O
are O
influenced O
by O
the O
cycle O
the O
animal O
is O
in O
and O
the O
other O
two O
influence O
, O
respectively O
, O
the O
ranking RARE
of O
the O
individual O
' O
s O
BP O
and O
HR O
levels O
within O
the O
population O
. O

The O
correlation O
between O
PaCO2 O
and O
PtcO2 NUMERIC
in O
RDS ALLCAPS
was O
insufficient O
to O
make O
clinical O
judgement RARE
. O

Since O
1967 NUMERIC
at O
the O
times O
of O
their O
biennial RARE
ABCC ALLCAPS
/ O
RERF ALLCAPS
radiological RARE
examinations O
, O
all O
Adult O
Health O
Study O
( O
AHS ALLCAPS
) O
subjects O
have O
been O
interviewed RARE
to O
determine O
the O
exposures O
to O
medical O
x O
- O
rays O
they O
experienced O
in O
institutions RARE
other O
than O
RERF ALLCAPS
in O
order O
to O
estimate O
the O
numbers O
of O
examinations O
and O
corresponding O
doses O
which O
they O
received O
. O

The O
epidermal I-GENE
growth I-GENE
factor I-GENE
( I-GENE
EGF I-GENE
) I-GENE
receptor I-GENE
, O
which O
exhibits O
intrinsic O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
, O
undergoes O
a O
rapid O
, O
intramolecular RARE
self O
- O
phosphorylation O
reaction O
following O
EGF I-GENE
activation O
. O

One O
millimolar RARE
ouabain RARE
completely O
inhibited O
net RARE
HCO3 O
- O
secretion O
. O

There O
are O
regions O
with O
long O
runs RARE
of O
up O
to O
45 O
% O
C O
or O
35 O
% O
G O
residues O
. O

The O
same O
rhythmic RARE
structure O
enables O
a O
prediction O
to O
be O
made O
concerning O
when O
vowels RARE
of O
stressed O
syllables RARE
will O
be O
auditorily RARE
perceived O
. O

Vocal RARE
cord O
abduction RARE
rehabilitation RARE
by O
nervous O
selective O
anastomosis O
. O

UK ALLCAPS
' O
s O
biotechnology RARE
lacking O
specialists RARE
. O

A O
case O
of O
AIDS O
- O
related O
complex O
( O
ARC O
/ O
LAS ALLCAPS
) O
in O
a O
health O
worker RARE

Distant RARE
spread O
was O
found O
in O
46 O
patients O
( O
34 O
%), O
42 O
of O
whom O
had O
serum O
Tg RARE
greater O
than O
10 O
micrograms O
/ O
l O
. O

The O
glomerular O
filtration O
rate O
and O
effective O
renal O
plasma O
flow O
were O
determined O
by O
a O
standard O
clearance O
method O
, O
employing O
continuous O
infusion O
of O
inulin RARE
and O
para RARE
- O
aminohippuric RARE
acid O
. O

After O
the O
meal O
containing O
potato RARE
, O
plasma O
glucose O
levels O
rose O
sharply O
, O
peaked RARE
at O
30 O
- O
45 O
min O
and O
fell O
below O
initial O
levels O
2 O
to O
3 O
h O
later O
. O

The O
relations O
among O
various O
negative O
emotional RARE
and O
behavioral O
characteristics O
( O
e O
. O
g O
., O
aggression O
, O
anxiety O
, O
undercompliance RARE
, O
depressive RARE
mood RARE
) O
and O
adjustment O
were O
examined O
through O
use O
of O
data O
from O
the O
31 O
- O
year O
- O
old O
New O
York O
Longitudinal RARE
Study O
. O

To O
evaluate O
the O
effect O
of O
altitude O
on O
adolescent O
growth O
and O
development O
, O
three O
groups O
of O
healthy O
, O
well O
- O
nourished RARE
youth RARE
of O
similar O
socioeconomic RARE
status O
and O
ethnic RARE
grouping RARE
who O
resided RARE
at O
sea O
level O
( O
n O
= O
1262 NUMERIC
subjects O
), O
mid O
- O
altitude O
( O
n O
= O
1743 NUMERIC
subjects O
), O
and O
high O
altitude O
( O
n O
= O
1137 NUMERIC
subjects O
) O
were O
studied O
. O

Because O
the O
CAP O
measures O
variables O
predictive O
of O
abusive RARE
behavior O
, O
a O
substantial O
relationship O
was O
expected O
between O
the O
CAP O
and O
the O
MHI ALLCAPS
Loss RARE
of O
Behavioral RARE
/ O
Emotional RARE
Control O
scale O
. O

We O
have O
improved O
our O
system O
for O
nuclear O
contour RARE
digitization RARE
and O
determined O
its O
theoretical RARE
limitations O
by O
digitizing RARE
standardized O
objects O
. O

Such O
a O
change O
may O
involve O
increased O
mammary O
utilization O
of O
pre O
- O
formed O
long O
- O
chain O
fatty O
acid O
and O
increased O
metabolism O
of O
glucose O
via O
glycolysis RARE
. O

The O
skin O
site O
, O
6 O
- O
cm O
- O
distal O
and O
- O
proximal O
subcutaneous O
segments O
of O
the O
catheter O
, O
exudates RARE
, O
and O
blood O
were O
cultured O
. O

Because O
of O
its O
great O
reliability O
, O
conventional O
arteriography RARE
occupies RARE
a O
place O
of O
choice O
among O
the O
medical O
imaging O
techniques O
. O

Rapid RARE
detection O
of O
radioisotopically RARE
contaminated O
test O
serum O
before O
radioassay RARE
of O
vitamin O
B12 NUMERIC
. O

The O
former O
group O
did O
excrete RARE
less O
dry RARE
fecal O
material O
compared O
to O
both O
other O
groups O
. O

Electronic RARE
data O
processing O
( O
EDP ALLCAPS
) O
latex O
immunoassay O
using O
anti I-GENE
- I-GENE
human I-GENE
seminal I-GENE
acid I-GENE
phosphatase I-GENE
( O
anti I-GENE
- I-GENE
HSAP ALLCAPS
) O
immune O
serum O
was O
applied O
for O
the O
species O
and O
organ O
identification O
of O
human O
seminal O
stains RARE
. O

Vimentin RARE
positivity RARE
was O
noted O
in O
the O
undifferentiated O
and O
fibroblastic RARE
components O
. O

The O
maximum O
deflections RARE
of O
phase O
IV O
for O
Ar RARE
and O
N2 O
from O
extrapolated RARE
phase O
III O
slopes RARE
were O
smaller O
in O
the O
prone O
position O
, O
suggesting O
more O
uniform O
tracer O
gas O
concentrations O
across O
the O
lungs O
. O

Recent O
developments RARE
in O
drugs O
antagonistic O
to O
factors O
causing O
peptic RARE
ulcer O
-- O
clinical O
efficacy O
and O
problems O
; O
gastrin I-GENE
receptor I-GENE
blockaders RARE

The O
spermicide RARE
nonoxynol RARE
- O
9 O
is O
a O
member O
of O
a O
homologous O
series O
of O
alkylphenol RARE
- O
ethoxylates RARE
( O
polyethoxyethanols RARE
) O
of O
general O
formula O
C9H19 NUMERIC
- O
C6H6 NUMERIC
- O
O O
-( O
CH2CH2O NUMERIC
) O
n O
- O
1 O
CH2CH2OH NUMERIC
. O

Static RARE
magnetic O
fields O
affect O
the O
diffusion O
of O
biological O
particles O
in O
solutions O
through O
the O
Lorentz RARE
force O
and O
Maxwell RARE
stress O
. O

Psychological RARE
disturbance O
was O
greater O
in O
the O
high O
life O
stress O
group O
as O
indicated O
by O
significant O
elevations O
on O
the O
global O
severity O
index O
of O
the O
Symptom RARE
Checklist RARE
- O
90 O
and O
elevations O
on O
somatization RARE
, O
obsessive RARE
compulsive RARE
, O
interpersonal RARE
sensitivity O
, O
depression O
, O
anxiety O
and O
psychoticism RARE
subscales RARE
. O

Chronic O
administration O
of O
sodium O
cyanate RARE
decreases O
O2 O
extraction O
ratio O
in O
dogs O
. O

Nucleotide O
sequencing O
indicates O
that O
this O
E1 I-GENE
alpha I-GENE
cDNA I-GENE
clone O
is O
1821 NUMERIC
base O
pairs O
( O
bp O
) O
in O
length O
with O
an O
open O
reading O
frame O
of O
1365 NUMERIC
bp O
and O
a O
3 O
'- O
untranslated O
region O
of O
356 NUMERIC
bp O
. O

SPA ALLCAPS
from O
PAG ALLCAPS
sites O
was O
associated O
with O
aversion RARE
. O

In O
contrast O
, O
the O
MAN ALLCAPS
showed O
a O
unimodal RARE
, O
skewed RARE
distribution O
, O
with O
a O
range O
from O
approximately O
1 O
to O
14 O
micron O
and O
a O
maximum O
at O
3 O
- O
4 O
micron O
. O

Abnormal O
technetium O
Tc O
99m O
medronate RARE
scans O
in O
patients O
with O
previously O
undiagnosed RARE
polyarthralgias RARE
suggested O
inflammatory O
arthropathy RARE
and O
influenced O
management O
decisions RARE
with O
favorable RARE
therapeutic O
outcomes O
. O

Practical RARE
interest O
of O
such O
studies O
is O
limited O
since O
the O
pharmacokinetic O
parameters O
are O
systematically O
evaluated O
in O
man O
during O
phase O
I O
trials O
. O

The O
artery O
cuff RARE
was O
slightly O
superior O
to O
the O
fat O
wrap RARE
, O
particularly O
in O
having O
fewer O
adhesions O
and O
a O
better O
histological O
picture O
. O

Lithium RARE
- O
carbonate RARE
action O
during O
radiation O
therapy O
has O
been O
studied O
, O
valuing RARE
the O
positive O
effect O
on O
leukopoiesis RARE
and O
the O
consequent RARE
better O
clinical O
conditions O
of O
the O
patients O
in O
course O
of O
treatment O
. O

Of O
the O
53 O
units O
tested O
during O
sinusoidal RARE
motion O
at O
0 O
. O
05 O
Hz O
( O
9 O
. O
1 O
cm O
/ O
s O
), O
1 O
( O
1 O
. O
9 O
%) O
was O
responsive O
to O
the O
otolith RARE
input O
only O
, O
13 O
( O
24 O
. O
5 O
%) O
were O
influenced O
by O
the O
visual O
input O
only O
and O
23 O
( O
43 O
. O
4 O
%) O
responded O
to O
both O
modalities O
. O

Depending RARE
on O
the O
location O
and O
size O
of O
the O
mass O
, O
a O
wide O
range O
of O
clinical O
presentations RARE
is O
associated O
with O
the O
lesion O
. O

The O
development O
and O
distribution O
of O
Trypanosoma O
congolense RARE
, O
T O
vivax RARE
and O
T O
brucei RARE
in O
the O
skin O
of O
goats O
was O
examined O
after O
the O
animals O
were O
bitten RARE
by O
infected O
Glossina RARE
morsitans RARE
centralis RARE
. O

Electroglottography RARE
is O
a O
useful O
, O
non O
- O
invasive O
technique O
that O
can O
assist RARE
in O
the O
assessment O
of O
vocal RARE
fold O
dysfunction O
. O

Statistical RARE
analysis O
of O
the O
degrees O
of O
secondary O
spinal O
cord O
compression O
was O
performed O
in O
group O
- O
1 O
dogs O
by O
measuring O
and O
comparing O
ratios O
of O
the O
vertical O
to O
the O
horizontal O
diameters O
of O
the O
transverse O
spinal O
cord O
sections O
from O
locations O
within O
( O
T12 NUMERIC
to O
L1 O
) O
and O
out O
of O
( O
T11 NUMERIC
, O
T11 NUMERIC
- O
12 O
, O
L1 O
- O
2 O
, O
and O
L2 O
) O
the O
region O
of O
surgical O
intervention O
. O

The O
pharmacological O
effects O
of O
the O
novel O
compound O
WEB ALLCAPS
1881 NUMERIC
FU O
( O
4 O
- O
amino O
- O
methyl O
- O
1 O
- O
benzyl RARE
- O
pyrrolidine RARE
- O
2 O
- O
one O
- O
fumarate RARE
) O
were O
investigated O
. O

Histopathological RARE
examination O
revealed O
dose O
- O
related O
proliferation O
of O
type O
II O
pneumocytes RARE
in O
dams RARE
and O
proliferation O
of O
interstitial O
cells O
and O
delayed O
septal O
/ O
capillary O
development O
in O
neonates O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

So RARE
far O
no O
problems O
with O
multiply RARE
resistant O
strains O
have O
developed O
. O

During O
the O
observation O
period O
of O
0 O
. O
4 O
- O
30 O
weeks O
, O
cardiac O
white O
spots O
on O
the O
right O
ventricle O
of O
BALB O
/ O
c O
mice O
were O
first O
detected O
at O
three O
weeks O
( O
6 O
of O
20 O
mice O
; O
30 O
%), O
and O
the O
maximal O
incidence O
of O
cardiac O
white O
spots O
was O
obtained O
at O
nine O
weeks O
( O
39 O
of O
44 O
mice O
; O
88 O
%). O

The O
state O
of O
the O
liver O
in O
generalized O
forms O
of O
meningococcal RARE
infection O

Increasing O
the O
RH O
beyond O
32 O
% O
resulted O
in O
solvation RARE
of O
the O
peroxy RARE
radical O
, O
sterically RARE
hindering RARE
the O
radical O
from O
entering RARE
the O
propagation RARE
transition O
state O
. O

The O
effects O
produced O
by O
oral O
administration O
of O
500 O
mg O
/ O
kg O
p O
- O
xylene O
or O
toluene O
lasted RARE
at O
least O
8 O
hr O
, O
while O
the O
effect O
of O
inhaled O
p O
- O
xylene O
dissipated RARE
within O
75 O
min O
of O
removal O
from O
the O
exposure O
. O

PATIENTS O
and O
METHODS O
: O
Thallium RARE
- O
201 O
myocardial O
scintigraphy O
was O
performed O
at O
rest O
and O
after O
0 O
. O
56 O
mg O
/ O
kg O
intravenous O
dipyridamole RARE
during O
four O
minutes O
in O
16 O
patients O
with O
sarcoidosis RARE
. O

Thin RARE
melanomas O
can O
metastasize RARE
and O
be O
lethal O
. O

The O
TA O
muscle O
was O
fatigued RARE
by O
four O
forms O
of O
repeated O
isometric RARE
contractions O
: O
( O
1 O
) O
maximal O
voluntary RARE
contractions O
( O
MVC ALLCAPS
), O
( O
2 O
) O
MVC ALLCAPS
with O
circulation O
occluded O
, O
( O
3 O
) O
electrically O
evoked O
contractions O
with O
20 O
Hz O
supramaximal RARE
voltage O
stimulation O
and O
( O
4 O
) O
electrically O
evoked O
contractions O
with O
circulation O
occluded O
. O

The O
actuarial RARE
local O
control O
rates O
at O
10 O
years O
for O
the O
three O
treatment O
groups O
were O
as O
follows O
: O
subtotal O
excision O
alone O
, O
18 O
%; O
subtotal O
excision O
plus O
postoperative O
radiation O
therapy O
, O
82 O
%; O
and O
total O
excision O
alone O
, O
77 O
%. O

The O
effects O
of O
anabolic RARE
implants O
on O
rate O
, O
composition O
and O
energetic RARE
efficiency O
of O
growth O
were O
determined O
in O
steers O
fed O
diets O
varying O
in O
forage RARE
and O
grain RARE
content O
. O

Prolonged RARE
suspension RARE
induced O
a O
significant O
change O
in O
the O
geometric RARE
configuration O
of O
the O
femur O
middiaphysis RARE
by O
increasing O
the O
minimum O
diameter O
( O
12 O
%) O
without O
any O
significant O
alterations O
in O
cortical O
area O
, O
density O
, O
mineral O
, O
and O
collagen I-GENE
concentrations O
. O

Which RARE
cineangiographically RARE
assessed O
anatomic O
variable O
correlates O
best O
with O
functional O
measurements O
of O
stenosis O
severity O
? O
A O
comparison O
of O
quantitative O
analysis O
of O
the O
coronary O
cineangiogram RARE
with O
measured O
coronary O
flow O
reserve O
and O
exercise O
/ O
redistribution RARE
thallium O
- O
201 O
scintigraphy O
. O

Water RARE
content O
and O
equilibrium O
water O
partition RARE
in O
immature O
cartilage O
. O

Thyroid RARE
function O
tests O
were O
performed O
on O
300 O
admissions RARE
, O
leaving RARE
707 NUMERIC
untested RARE
. O

Data O
on O
the O
line O
spread O
function O
( O
LSF ALLCAPS
) O
were O
obtained O
from O
the O
image O
of O
a O
0 O
. O
2 O
mm O
wide O
slit RARE
between O
tungsten RARE
blocks O
that O
were O
positioned O
at O
the O
isocentre RARE
in O
front O
of O
a O
polystyrene RARE
phantom RARE
. O

Primary O
infection O
is O
usually O
managed RARE
conservatively RARE
. O

Papers RARE
of O
the O
Society RARE
for O
Clinical O
Vascular RARE
Surgery RARE
. O

Ischemic O
heart O
disease O
, O
age O
of O
more O
than O
75 O
years O
, O
and O
the O
fact O
that O
the O
patient O
was O
a O
woman O
were O
independent O
predictors O
of O
poor O
cardiac O
function O
. O

Prognosis RARE
in O
Bowen RARE
' O
s O
disease O
localized O
to O
the O
ano RARE
- O
genital O
region O
. O

Taken O
together O
, O
the O
results O
suggest O
that O
chlorphentermine RARE
may O
be O
capable O
of O
producing O
dual O
stimulus O
effects O
in O
animals O
. O

Liquid RARE
chromatographic O
method O
for O
determination O
of O
citreoviridin RARE
in O
corn RARE
and O
rice O
. O

These O
findings O
indicate O
that O
autophosphorylation O
of O
Thr286 NUMERIC
( O
alpha O
subunit O
) O
and O
Thr287 NUMERIC
( O
beta O
subunit O
) O
is O
responsible O
for O
transition O
of O
CaM I-GENE
- I-GENE
kinase I-GENE
II I-GENE
to O
the O
Ca2 O
+- O
independent O
form O
. O

This O
rapid O
and O
extensive O
penetration O
of O
intrathecally RARE
administered O
chemotherapy O
may O
offer O
insight O
into O
the O
myelopathy RARE
observed O
with O
these O
treatments O
. O

The O
interaction O
of O
radiation O
and O
hyperthermia RARE
was O
systematically O
studied O
in O
the O
Dunning RARE
R3327G NUMERIC
prostatic O
adenocarcinoma O
, O
the O
preeminent RARE
animal O
model O
for O
human O
prostatic O
cancer O
. O

Pregnant RARE
rats O
were O
exposed O
to O
one O
of O
the O
following O
: O
( O
1 O
) O
10 O
% O
O2 O
in O
N2 O
or O
100 O
% O
O2 O
for O
2 O
days O
beginning O
at O
day O
7 O
, O
11 O
, O
14 O
, O
or O
18 O
of O
pregnancy O
; O
( O
2 O
) O
10 O
% O
O2 O
in O
N2 O
or O
100 O
% O
O2 O
for O
10 O
h O
/ O
day O
beginning O
at O
day O
7 O
; O
or O
( O
3 O
) O
14 O
- O
11 O
% O
O2 O
in O
N2 O
continuously O
beginning O
at O
day O
14 O
till RARE
day O
21 O
when O
they O
were O
sacrificed RARE
. O

The O
incidence O
of O
cryptosporidiosis RARE
in O
young O
children O
was O
determined O
by O
staining O
of O
faecal RARE
specimens O
with O
a O
modified O
Kinyoun RARE
stain O
. O

Seven RARE
patients O
( O
8 O
. O
3 O
percent O
) O
had O
latent O
hypothyroidism O
only O
discovered O
by O
hormonal O
determinations O
. O

Addition O
of O
sucralfate RARE
or O
De RARE
- O
Nol RARE
resulted O
in O
increments RARE
of O
gastric O
HCO3 O
secretion O
, O
reaching RARE
about O
45 O
% O
and O
59 O
%, O
respectively O
, O
of O
the O
maximal O
HCO3 O
response O
to O
16 O
, O
16 O
- O
dimethyl O
PGE2 O
( O
dmPGE2 NUMERIC
). O

Moreover O
, O
unlike O
control O
rats O
operated O
animals O
did O
not O
show O
aversion RARE
to O
the O
highest O
concentrations O
of O
saccharin O
solutions O
. O

In O
Salmo RARE
gairdneri RARE
, O
no O
specialized O
system O
of O
portal O
vessels O
appears O
to O
exist O
between O
the O
pineal O
organ O
and O
other O
portions O
of O
the O
brain O
. O

The O
4 O
degrees O
stimuli O
were O
found O
to O
elicit O
scalp RARE
distributions RARE
for O
the O
pattern O
reversal O
P100 NUMERIC
and O
the O
pattern O
onset O
C1 O
consistent O
with O
striate RARE
and O
extrastriate RARE
visual O
cortical O
origins O
respectively O
. O

Nuclear I-GENE
factor I-GENE
III I-GENE
( O
NFIII ALLCAPS
) O
is O
a O
protein O
from O
HeLa O
cells O
that O
stimulates O
the O
initiation O
of O
adenovirus O
type O
2 O
( O
Ad2 NUMERIC
) O
DNA O
replication O
by O
binding O
to O
a O
specific O
nucleotide O
sequence O
in O
the O
origin O
, O
adjacent O
to O
the O
nuclear I-GENE
factor I-GENE
I I-GENE
recognition I-GENE
site I-GENE
. O

A O
Golgi O
study O
of O
the O
sixth RARE
layer O
of O
the O
cerebral O
cortex O
. O

We O
conclude O
that O
cephalothin RARE
clearance O
of O
S O
. O
aureus O
from O
a O
site O
accessible RARE
to O
phagocytes RARE
was O
delayed O
when O
compared O
to O
a O
phagocyte RARE
- O
inaccessible RARE
site O
. O

The O
findings O
are O
discussed O
in O
the O
context O
of O
known O
properties O
of O
cortical O
- O
bar RARE
detectors RARE
. O

Mean O
rCBF O
increased O
in O
some O
patients O
4 O
- O
8 O
weeks O
after O
surgery O
on O
the O
ipsilateral O
side O
. O

Quantitative O
computed O
tomography O
for O
measuring O
vertebral O
bone O
mineral O
content O
offers O
high O
sensitivity O
and O
reproducibility O
. O

The O
structure O
of O
the O
enhancer O
was O
also O
probed RARE
by O
inserting O
a O
pair O
of O
complementary O
synthetic O
oligodeoxynucleotides RARE
which O
represented O
the O
region O
between O
nt O
positions O
- O
235 NUMERIC
and O
- O
215 O
into O
a O
truncated O
template O
which O
lacked O
the O
enhancer O
. O

Kf RARE
, O
c O
and O
CT O
( O
referenced RARE
to O
the O
initial O
lung O
mass O
) O
decreased O
linearly RARE
with O
reductions O
in O
lung O
mass O
% O
delta O
Kf RARE
, O
c O
= O
1 O
. O
26 O
- O
0 O
. O
98 O
% O
mass O
removed O
( O
r O
= O
0 O
. O
90 O
, O
P O
less O
than O
0 O
. O
01 O
) O
and O
% O
delta O
CT O
= O
- O
3 O
. O
99 O
- O
0 O
. O
98 O
% O
mass O
removed O
( O
r O
= O
0 O
. O
82 O
, O
P O
less O
than O
0 O
. O
01 O
) O
relationships O
that O
were O
not O
altered O
by O
blocker O
pretreatment O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Two O
scintigraphic RARE
methods O
, O
resting O
dipyridamole RARE
and O
exercise O
thallium O
- O
201 O
myocardial O
perfusion O
imaging O
, O
to O
detect O
and O
localize O
coronary O
artery O
stenosis O
were O
compared O
in O
32 O
patients O
suffering O
from O
coronary O
artery O
disease O
. O

From O
these O
results O
, O
it O
is O
concluded O
that O
EDLF ALLCAPS
has O
clear O
vasoconstrictor RARE
properties O
which O
are O
not O
due O
to O
adrenergic O
or O
calcium O
entry O
mechanisms O
and O
that O
there O
are O
differences O
in O
the O
vasoconstrictor RARE
effects O
of O
EDLFs RARE
with O
respect O
to O
different O
vascular O
beds RARE
. O

Research O
was O
carried O
out O
on O
the O
rheumatoid I-GENE
factors I-GENE
in O
the O
serum O
of O
917 NUMERIC
patients O
by O
means O
of O
two O
tests O
( O
one O
using O
polystyrene RARE
and O
one O
with O
erythrocytes RARE
) O
and O
the O
results O
obtained O
were O
compared O
using O
a O
method O
of O
reference O
. O

A O
low O
aspirin I-GENE
esterase I-GENE
activity O
may O
be O
a O
contributory RARE
factor O
in O
precipitating O
these O
aspirin O
sensitive O
reactions O
. O

In O
both O
experiments O
, O
average O
daily O
gain O
and O
gain O
- O
to O
- O
feed O
ratio O
were O
similar O
for O
TR O
and O
CR O
. O

Overall O
least O
- O
squares RARE
means O
for O
uncooked RARE
and O
cooked RARE
longissimus RARE
muscle O
and O
subcutaneous O
fat O
were O
63 O
. O
32 O
, O
80 O
. O
27 O
and O
98 O
. O
90 O
mg O
of O
cholesterol O
/ O
100 O
g O
of O
tissue O
, O
respectively O
. O

The O
role O
of O
supercritical RARE
fluid O
chromatography O
( O
SFC ALLCAPS
) O
as O
a O
viable O
technique O
for O
analyzing O
agricultural RARE
products O
has O
been O
investigated O
using O
packed RARE
and O
capillary O
column O
methodology RARE
. O

Nitrofurazone RARE
significantly O
reduced O
the O
rise O
in O
LH I-GENE
induced O
by O
LHRH ALLCAPS
. O

Ovarian RARE
tumors O
in O
pregnancy O
. O

Ultrastructural RARE
study O
of O
polyarteritis RARE

X2 O
test O
, O
with O
Yates RARE
correction O
if O
need O
, O
was O
used O
as O
statistical O
. O
method O
. O

After O
a O
baseline O
study O
, O
WPW ALLCAPS
syndrome O
was O
simulated O
by O
stimulation O
at O
seven O
different O
sites O
around O
the O
base O
of O
the O
ventricles O
, O
and O
RNV ALLCAPS
' O
s O
were O
obtained O
. O

Man RARE
and O
insect O
, O
past O
, O
present O
, O
future O

All O
patients O
had O
the O
CA I-GENE
125 I-GENE
assay O
performed O
within O
one O
week O
before O
their O
second O
- O
look RARE
operation O
. O

Allergy RARE
and O
Tourette RARE
' O
s O
syndrome O
. O

The O
criterion O
was O
reached O
after O
two O
sessions RARE
and O
generalization RARE
to O
a O
variety O
of O
pills RARE
and O
capsules O
occurred O
. O

Clinical O
method O
for O
the O
treatment O
of O
Class O
II O
occlusal RARE
anomalies O
with O
open O
bite RARE

Enoxacin RARE
appears O
to O
be O
well O
suited RARE
for O
the O
treatment O
of O
complicated O
UTI ALLCAPS
. O

Mean O
fluorosis RARE
scores O
, O
however O
, O
were O
similar O
. O

Autonomic RARE
dysfunctions RARE
were O
restricted O
to O
tonic RARE
pupils RARE
. O

An O
industry RARE
- O
wide O
retrospective O
cohort O
mortality O
study O
was O
conducted O
on O
6 O
, O
152 NUMERIC
chemical O
workers O
( O
2 O
, O
460 NUMERIC
exposed O
and O
3 O
, O
692 NUMERIC
nonexposed RARE
) O
engaged RARE
in O
chloromethyl RARE
ether O
manufacture RARE
at O
7 O
major O
U O
. O
S O
. O
companies RARE
between O
1948 NUMERIC
and O
1980 O
. O

The O
diagnosis O
of O
amyloidosis RARE
was O
determined O
from O
a O
labial RARE
salivary O
gland O
biopsy O
. O

Hair RARE
and O
blood O
samples O
were O
taken O
before O
vitamin O
C O
or O
placebo O
supplementation O
was O
started O
and O
at O
monthly O
intervals O
thereafter O
for O
three O
months O
. O

In O
treated O
herds RARE
, O
cows O
more O
than O
40 O
d O
postpartum RARE
with O
a O
corpus RARE
luteum RARE
received O
prostaglandin O
F2 O
alpha O
. O

On O
the O
other O
hand O
, O
if O
the O
measured O
angle O
ANB ALLCAPS
is O
smaller O
than O
the O
calculated O
angle O
, O
the O
skeletal O
relation O
is O
Class O
III O
. O

Emergency RARE
treatment O
of O
facial O
and O
maxillary RARE
/ O
mandibular O
injuries O

In O
14 O
cases O
, O
isolates O
were O
biotyped RARE
yielding RARE
eight O
with O
biotype RARE
II O
, O
four O
with O
biotype RARE
III O
, O
and O
one O
each O
with O
biotypes RARE
IV O
and O
V O
. O

A O
total O
of O
117 O
EVS ALLCAPS
treatments O
were O
performed O
on O
34 O
patients O
. O

Most O
of O
the O
prepeptide RARE
portion O
of O
the O
precursor O
polypeptide O
is O
encoded O
by O
the O
next O
three O
exons O
, O
and O
the O
mature O
form O
of O
IL I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
is O
encoded O
by O
the O
remaining O
three O
exons O
. O

A O
stochastic RARE
version O
of O
Kernell RARE
' O
s O
( O
1968 NUMERIC
, O
1972 O
) O
model O
with O
cumulative O
afterhyperpolarization RARE
( O
AHP ALLCAPS
) O
was O
simulated O
. O

In O
a O
previous O
interim RARE
report O
we O
noted O
more O
prompt RARE
resolution O
of O
dermatomal RARE
signs O
and O
symptoms O
with O
acyclovir RARE
treatment O
. O

The O
detectability RARE
of O
the O
defects O
in O
RCA ALLCAPS
or O
LAD O
region O
was O
80 O
% O
in O
single O
- O
position O
scans O
in O
stress O
studies O
. O

Pharmacologic RARE
properties O
of O
serotonergic RARE
agents O
and O
antidepressant RARE
drugs O
. O

This O
brief O
hypercapnic RARE
challenge O
induced O
a O
rapid O
increase O
in O
CBF O
in O
the O
absence O
of O
any O
change O
in O
MABP ALLCAPS
. O

These O
data O
should O
be O
useful O
in O
developing O
reagents RARE
for O
heterozygote RARE
detection O
and O
prenatal RARE
diagnosis O
of O
11 I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
deficiency O
, O
the O
second O
most O
frequent O
cause O
of O
congenital O
adrenal O
hyperplasia O
. O

Osteocalcin RARE
( O
serum I-GENE
bone I-GENE
- I-GENE
Gla RARE
protein I-GENE
, O
sBGP LASTCAP
), O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
( O
sAP LASTCAP
) O
and O
urinary O
hydroxyproline RARE
/ O
creatinine O
ratio O
( O
uOH LASTCAP
- O
Prol RARE
/ O
creatinine O
) O
have O
been O
measured O
in O
21 O
patients O
with O
primary O
hyperparathyroidism RARE
( O
PHPT ALLCAPS
) O
and O
in O
nine O
patients O
with O
hypercalcaemia RARE
of O
malignancy O
( O
HM ALLCAPS
). O

Multivariate RARE
logistic RARE
regression O
analysis O
indicated O
that O
seropositivity RARE
was O
strongly O
associated O
with O
the O
prevalence O
of O
hepatitis O
B O
in O
an O
employee RARE
' O
s O
country RARE
of O
birth O
and O
with O
age O
. O

Hexsyn RARE
is O
the O
Goodyear RARE
Tire RARE
and O
Rubber RARE
Company RARE
tradename RARE
for O
a O
polyolefin RARE
rubber RARE
synthesized O
from O
1 O
- O
hexene RARE
with O
3 O
- O
5 O
% O
methylhexadiene RARE
as O
the O
source O
of O
residual O
double O
bonds O
for O
vulcanization RARE
. O

Chimeric RARE
phage O
- O
plasmid O
expression O
vectors O
were O
constructed O
from O
pUC18 NUMERIC
/ O
19 O
plasmids O
by O
cloning O
a O
single O
- O
stranded O
DNA O
( O
ssDNA O
) O
origin O
of O
replication O
from O
bacteriophage O
f1 O
and O
inserting O
a O
bacteriophage O
T7 O
promoter O
within O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
gene I-GENE
. O

By O
order O
of O
decreasing O
rate O
, O
finger O
flexors RARE
, O
jaw O
, O
crossed RARE
adductors RARE
, O
and O
triceps RARE
reflexes RARE
were O
less O
frequently O
elicited O
in O
both O
groups O
. O

Natl RARE
. O

Neither O
ethanol O
nor O
estrogen O
has O
been O
shown O
to O
cause O
UROD ALLCAPS
- O
deficiency O
in O
animals O
. O

Although O
not O
common O
, O
the O
disorder O
is O
the O
most O
frequently O
diagnosed O
disturbance O
of O
porphyrin O
metabolism O
in O
many O
countries RARE
, O
and O
further O
insight O
into O
its O
unusual O
pathogenesis O
may O
clarify O
the O
hepatotoxic RARE
effects O
of O
the O
4 O
etiologic RARE
agents O
. O

Five O
out O
of O
eight O
consecutive O
cases O
with O
initial O
symptoms O
of O
a O
' O
midline RARE
granuloma O
' O
were O
identified O
as O
malignant O
histiocytosis RARE
( O
histiocytic RARE
sarcoma O
) O
which O
within O
5 O
months O
to O
4 O
years O
led O
to O
generalization RARE
and O
death O
. O

All O
patients O
then O
received O
suxamethonium RARE
1 O
. O
5 O
mg O
kg O
- O
1 O
i O
. O
v O
. O

The O
highest O
postoperative O
CK I-GENE
- I-GENE
MB I-GENE
level O
was O
less O
after O
BC ALLCAPS
( O
BC ALLCAPS
, O
31 O
+/- O
17 O
U O
/ O
L O
; O
CC O
, O
56 O
+/- O
13 O
U O
/ O
L O
; O
p O
less O
than O
0 O
. O
05 O
). O

No O
relevant O
changes O
in O
heart O
rate O
, O
body O
weight O
, O
and O
plasma O
levels O
of O
renin I-GENE
activity O
and O
aldosterone O
concentration O
were O
observed O
. O

High O
trough O
serum O
TOB ALLCAPS
concentrations O
were O
associated O
with O
death O
and O
very O
low O
levels O
with O
recovery O
. O

State O
- O
approved RARE
schools RARE
of O
nursing O
R O
. O
N O
. O

In O
a O
maxicell RARE
system O
a O
protein O
with O
an O
approximate RARE
molecular O
weight O
of O
36 O
, O
000 O
was O
synthesized O
. O

This O
means O
that O
the O
loss O
of O
recessives RARE
must O
be O
calculated O
by O
using O
a O
hypergeometric RARE
and O
not O
a O
binomial RARE
model O
as O
Fisher RARE
did O
. O

The O
incidence O
of O
second O
malignant O
neoplasms O
was O
lower O
( O
1 O
. O
3 O
%) O
in O
the O
group O
treated O
with O
5 O
- O
fluorouracil O
, O
doxorubicin RARE
, O
and O
cyclophosphamide O
than O
in O
the O
historical RARE
control O
group O
( O
4 O
. O
8 O
%). O

Ovulation RARE
was O
induced O
in O
8 O
( O
56 O
. O
7 O
%) O
patients O
who O
conceived RARE
. O

In O
previous O
work O
( O
E O
. O

The O
small O
size O
and O
placement O
of O
the O
mutagenesis O
marker O
( O
the O
supF LASTCAP
suppressor I-GENE
tRNA I-GENE
gene I-GENE
from I-GENE
Escherichia I-GENE
coli I-GENE
) O
within O
the O
vector O
substantially O
reduced O
the O
frequency O
of O
spontaneous O
mutations O
normally O
observed O
after O
transfection O
of O
mammalian O
cells O
with O
plasmid O
DNA O
; O
hence O
, O
UV O
- O
induced O
mutations O
were O
easily O
identified O
above O
the O
spontaneous O
background O
. O

W O
. O

Tetrad RARE
analysis O
and O
mitotic O
recombination O
experiments O
localized O
the O
PEP4 NUMERIC
gene I-GENE
proximal O
to O
GAL4 I-GENE
on O
chromosome O
XVI ALLCAPS
. O

Based O
on O
our O
observations O
, O
we O
propose O
a O
model O
whereby RARE
inactive O
precursor O
molecules O
produced O
from O
the O
PEP4 NUMERIC
gene I-GENE
self O
- O
activate O
within O
the O
yeast O
vacuole RARE
and O
subsequently O
activate O
other O
vacuolar I-GENE
hydrolases RARE
. O

The O
poly O
( O
A O
) O
segment O
of O
the O
RNA O
was O
selectively O
cross O
- O
linked O
to O
the O
72 O
, O
000 O
- O
molecular O
- O
weight O
protein O
( O
72K NUMERIC
protein O
). O

In O
vitro O
translation O
of O
RNA O
synthesized O
from O
the O
cloned O
cDNAs O
predicts O
that O
P0 NUMERIC
transcripts I-GENE
are O
translated O
into O
a O
novel O
12 O
. O
5 O
- O
kilodalton O
protein O
corresponding O
to O
the O
first O
open O
reading O
frame O
. O

The O
N O
- O
terminal O
amino O
acid O
sequence O
of O
Mop RARE
has O
sequence O
homology O
with O
DNA O
binding O
proteins O
. O

Several O
new O
techniques O
are O
available O
for O
monitoring O
control O
of O
diabetes O
. O

Ciprofloxacin RARE
: O
an O
overview RARE
of O
adverse O
experiences RARE
. O

Possible RARE
pathogenetic RARE
mechanisms O
of O
hemopoietic RARE
changes O
in O
response O
to O
space O
flight RARE
effects O
are O
described O
. O

The O
rho I-GENE
genes I-GENE
comprise O
an O
evolutionarily O
conserved O
family O
with O
significant O
homology O
to O
the O
ras I-GENE
oncogene I-GENE
family I-GENE
. O

Also O
, O
component O
I O
significantly O
correlated O
with O
fasting O
insulin I-GENE
and O
VO2 O
max O
for O
both O
sexes RARE
and O
with O
basal O
metabolism O
and O
HDL I-GENE
- I-GENE
cholesterol I-GENE
for O
females O
and O
males O
, O
respectively O
. O

The O
glucose O
areas O
following O
the O
ingestion O
of O
the O
foods RARE
were O
: O
Study O
1 O
: O
glucose O
11 O
. O
7 O
, O
orange RARE
juice O
7 O
. O
3 O
, O
sucrose O
5 O
. O
2 O
, O
glucose O
+ O
fructose O
6 O
. O
3 O
, O
and O
fructose O
0 O
. O
7 O
mmol O
X O
h O
/ O
l O
; O
Study O
2 O
: O
glucose O
14 O
. O
6 O
, O
orange RARE
juice O
7 O
. O
3 O
, O
apples RARE
5 O
. O
5 O
, O
and O
apple RARE
juice O
4 O
. O
7 O
mmol O
X O
h O
/ O
l O
; O
Study O
3 O
: O
glucose O
12 O
. O
6 O
, O
ice RARE
cream O
8 O
. O
1 O
, O
milk O
3 O
. O
7 O
, O
and O
lactose RARE
4 O
. O
1 O
mmol O
X O
h O
/ O
l O
. O

The O
serum I-GENE
insulin I-GENE
response O
cannot O
. O

SCL ALLCAPS
prolonged O
promptly RARE
after O
verapamil O
, O
and O
sinus O
arrest O
developed O
in O
two O
of O
10 O
group O
2 O
and O
two O
of O
five O
group O
3 O
animals O
. O

Development RARE
of O
a O
yeast O
system O
to O
assay O
mutational O
specificity O
. O

Postglucose RARE
serum I-GENE
insulin I-GENE
levels O
showed O
no O
significant O
correlations O
with O
systolic O
or O
diastolic O
blood O
pressure O
levels O
in O
men O
, O
but O
in O
female O
diabetic O
and O
non O
- O
diabetic O
subjects O
significant O
correlations O
were O
found O
in O
particular O
with O
systolic O
blood O
pressure O
level O
. O

We O
used O
oligonucleotide O
- O
directed O
mutagenesis O
to O
alter O
a O
site O
in O
MucA LASTCAP
homologous O
to O
the O
Ala O
- O
Gly O
cleavage O
site O
of O
LexA I-GENE
. O

The O
latter O
was O
determined O
as O
follows O
: O
Type O
I O
- O
solid O
tumor O
tissue O
without O
significant O
peripheral O
isolated O
tumor O
cells O
; O
Type O
II O
- O
solid O
tumor O
tissue O
associated O
with O
peripheral O
isolated O
tumor O
cells O
; O
Type O
III O
- O
isolated O
tumor O
cells O
only O
. O

The O
pharmacology RARE
of O
carnitine RARE
. O

Acute O
inhalation O
toxicity O
of O
T O
- O
2 O
mycotoxin RARE
in O
mice O
. O

The O
present O
investigation O
sought O
to O
identify O
the O
principal O
dimensions O
of O
the O
Framingham RARE
Type O
A O
scale O
( O
FTAS ALLCAPS
) O
and O
then O
to O
examine O
their O
physiological O
and O
psychological O
correlates O
. O

A O
preliminary O
study O
on O
pyogenic RARE
arthritis O
. O

Legionella RARE
, O
microbial O
ecology RARE
, O
and O
inconspicuous RARE
consumption O
. O

Lymphatics RARE
in O
the O
aorta O
of O
rats O
treated O
with O
a O
soy RARE
- O
bean O
oil O
extract O
( O
lipofundin RARE
). O

As O
a O
last O
resort RARE
, O
it O
may O
be O
possible O
to O
maintain O
a O
patient O
on O
dialysis O
in O
reasonable O
health O
with O
a O
DiaTAP LASTCAP
button RARE
graft O
complex O
infected O
with O
Staphylococcus O
epidermidis RARE
and O
intermittent O
positive O
blood O
cultures O
using O
long O
term O
vancomycin O
therapy O
. O

For O
signal O
durations O
less O
than O
10 O
ms O
, O
however O
, O
the O
SoNo RARE
and O
S O
pi O
No O
threshold O
functions O
converged RARE
and O
the O
masking RARE
- O
level O
difference O
decreased O
. O

The O
spleen O
rate O
of O
about O
600 O
villagers RARE
of O
RK ALLCAPS
I O
examined O
was O
54 O
. O
3 O
% O
and O
the O
parasite O
rate O
13 O
. O
2 O
% O
before O
the O
drug O
intervention O
. O

Multiple O
dosing RARE
four O
times O
daily O
for O
7 O
days O
of O
indoprofen RARE
200 O
mg O
, O
a O
non O
- O
steroidal RARE
anti O
- O
inflammatory O
drug O
with O
a O
short O
half O
- O
life O
( O
t1 O
/ O
2 O
), O
revealed O
drug O
accumulation O
in O
eight O
elderly O
subjects O
. O

In O
10 O
patients O
with O
subacute O
cardiac O
tamponade RARE
, O
pulmonary O
wedge RARE
pressure O
( O
PWP ALLCAPS
), O
RAP ALLCAPS
, O
and O
IPP ALLCAPS
were O
measured O
along O
with O
indexes RARE
of O
systolic O
function O
. O

Encompassing RARE
tamponade RARE
and O
pericardiocentesis RARE
data O
, O
left O
ventricular O
stroke O
work O
index O
showed O
positive O
correlation O
with O
TMFP1 NUMERIC
( O
r O
= O
. O
59 O
) O
and O
TMFP2 NUMERIC
( O
r O
= O
. O
52 O
) O
but O
not O
with O
TMFP3 NUMERIC
. O

Rabbits RARE
developed O
profound O
hypocalcemia RARE
, O
with O
levels O
falling RARE
from O
15 O
. O
5 O
+/- O
0 O
. O
2 O
to O
7 O
. O
6 O
+/- O
0 O
. O
4 O
mg O
/ O
dl O
under O
the O
influence O
of O
TSST ALLCAPS
- I-GENE
1 I-GENE
. O

Reward RARE
value O
of O
prosodic RARE
features O
of O
language O
for O
autistic RARE
, O
mentally RARE
retarded O
, O
and O
normal O
children O
. O

Similarly O
, O
actuarial RARE
interpretations RARE
for O
the O
second O
protocols RARE
were O
not O
more O
frequently O
selected O
by O
therapists RARE
as O
more O
valid RARE
, O
regardless O
of O
treatment O
condition O
and O
elevation O
of O
the O
F O
and O
F O
- O
K O
indices O
on O
the O
first O
MMPI O
profile O
. O

Due RARE
to O
its O
relatively O
soluble O
chemical O
form O
, O
90Sr NUMERIC
was O
rapidly O
translocated RARE
from O
lung O
to O
bone O
where O
a O
substantial O
portion O
was O
retained O
for O
a O
long O
period O
of O
time O
. O

The O
study O
disclosed RARE
generalized O
atrophy O
and O
diffuse O
symmetric RARE
white O
matter O
hypodensities RARE
. O

The O
diagnosis O
of O
metachromatic RARE
leukodystrophy RARE
( O
MLD ALLCAPS
) O
was O
confirmed O
by O
the O
finding O
of O
low O
arylsulfatase RARE
A I-GENE
( O
ASA I-GENE
) O
levels O
in O
cultured O
fibroblasts O
in O
both O
sisters RARE
. O

Artificial RARE
ventilation O
was O
conducted O
using O
a O
tidal O
volume O
of O
10 O
ml O
X O
kg O
- O
1 O
and O
a O
rate O
of O
10 O
to O
12 O
c O
X O
min O
- O
1 O
. O

Significantly O
lower O
heart O
rate O
reactivity O
and O
significantly O
less O
pronounced O
left O
temporal O
artery O
pulse O
amplitude O
responses O
were O
found O
in O
non O
- O
medicated RARE
TH O
subjects O
than O
in O
controls O
. O

An O
epidemiological O
survey O
of O
rheumatic RARE
valve O
disease O
and O
rheumatic RARE
fever O
in O
primary O
and O
secondary O
school RARE
students O
in O
Jiangxi RARE
Province RARE

Drugs RARE
that O
are O
transformed O
via O
phase O
II O
reactions O
usually O
do O
not O
require O
dosage O
adjustment O
. O

A O
study O
of O
human O
genes O
coding O
for O
U4 I-GENE
small I-GENE
nuclear I-GENE
RNA I-GENE
is O
presented O
. O

Using O
the O
balloon RARE
- O
gas O
procedure O
with O
a O
single O
gas O
injection O
, O
a O
bubble RARE
was O
obtained O
that O
was O
large O
enough O
to O
tamponade RARE
a O
giant RARE
tear O
without O
prior O
drainage O
of O
subretinal O
fluid O
or O
vitrectomy RARE
. O

Heat RARE
- O
labile RARE
- O
like O
enterotoxin O
( O
LT ALLCAPS
) O
was O
produced O
by O
26 O
of O
42 O
stool RARE
isolates O
( O
62 O
%), O
while O
only O
1 O
of O
the O
42 O
isolates O
( O
2 O
%) O
produced O
enterotoxinlike RARE
activity O
in O
suckling RARE
mice O
; O
65 O
% O
of O
the O
cytotoxin RARE
- O
producing O
strains O
also O
produced O
an O
LT ALLCAPS
- I-GENE
like I-GENE
material O
. O

Development RARE
of O
a O
provisional RARE
information O
- O
retrieval RARE
descriptor RARE
language O
for O
" O
Roentgenology RARE
and O
Medical RARE
Radiology RARE
" O
for O
use O
in O
the O
Medinform RARE
system O

Persistent RARE
acantholytic RARE
dermatosis RARE
with O
increased O
light O
sensitivity O

Thus O
, O
a O
negative O
test O
is O
compatible O
with O
low O
disease O
activity O
and O
/ O
or O
efficacy O
of O
calcium O
antagonist O
treatment O
. O

Thus O
, O
a O
negative O
test O
is O
compatible O
with O
low O
disease O
activity O
and O
/ O
or O
efficacy O
of O
calcium O
antagonist O
treatment O
. O

Dorsal RARE
foot O
TcpO2 NUMERIC
was O
measured O
by O
using O
oxygen O
- O
sensing RARE
electrodes O
with O
surface O
temperatures O
of O
42 O
degrees O
C O
and O
45 O
degrees O
C O
; O
in O
theory O
, O
changes O
in O
sympathetic O
activity O
should O
affect O
vasomotor RARE
tone O
and O
TcpO2 NUMERIC
in O
skin O
beneath RARE
an O
electrode O
at O
42 O
degrees O
C O
( O
submaximal RARE
vasodilation O
), O
but O
not O
at O
45 O
degrees O
C O
( O
maximal O
vasodilation O
). O

In O
subjects O
( O
n O
= O
5 O
) O
with O
quadriplegia RARE
and O
reduced O
sympathetic O
tone O
secondary O
to O
cervical O
cord O
trauma O
, O
TcpO2 NUMERIC
at O
42 O
degrees O
C O
and O
vasodilation O
index O
were O
increased O
( O
45 O
. O
0 O
mmHg O
and O
0 O
. O
61 O
); O
TcpO2 NUMERIC
at O
45 O
degrees O
C O
did O
not O
change O
. O

The O
nucleotide O
sequences O
of O
the O
human I-GENE
and I-GENE
murine I-GENE
ornithine RARE
decarboxylase I-GENE
mRNAs I-GENE
share O
an O
85 O
% O
homology O
, O
even O
in O
their O
3 O
'- O
noncoding O
regions O
. O

The O
absolute O
concentrations O
of O
alpha I-GENE
2 I-GENE
- I-GENE
plasmin RARE
inhibitor O
, O
alpha I-GENE
2 I-GENE
- I-GENE
macroglobulin RARE
, O
and O
antithrombin I-GENE
III I-GENE
increased O
with O
exercise O
( O
all O
P O
less O
than O
0 O
. O
005 O
), O
but O
when O
concentrations O
were O
corrected O
for O
acute O
shifts O
of O
plasma O
water O
during O
exercise O
, O
the O
quantity RARE
of O
these O
inhibitors O
actually RARE
decreased O
( O
all O
P O
less O
than O
0 O
. O
005 O
). O

The O
other O
model O
was O
a O
continuous O
exponential RARE
plus O
constant O
of O
the O
form O
La O
- O
= O
a O
+ O
b O
[ O
exp RARE
( O
cVO2 NUMERIC
)]. O

Cell O
. O

Timing RARE
of O
symptoms O
and O
oocyst RARE
excretion O
in O
human O
cryptosporidiosis RARE
. O

After O
dopamine O
infusion O
in O
women O
with O
polycystic RARE
ovary O
syndrome O
and O
in O
matched O
controls O
, O
steady O
state O
levels O
of O
plasma O
dopamine O
, O
norepinephrine O
, O
and O
the O
ratio O
of O
dopamine O
/ O
norepinephrine O
were O
similar O
in O
the O
two O
groups O
. O

Diagnostic O
importance O
of O
determining O
the O
complement O
constituents RARE
in O
children O
with O
autoimmune RARE
thyroiditis O

In O
the O
normal O
, O
basal O
( O
unstimulated O
) O
condition O
there O
were O
no O
significant O
correlations O
( O
p O
greater O
than O
0 O
. O
05 O
) O
between O
the O
systolic O
blood O
pressure O
and O
dopamine O
( O
r O
= O
0 O
. O
09 O
), O
norepinephrine O
( O
r O
= O
0 O
. O
26 O
), O
or O
epinephrine O
( O
r O
= O
0 O
. O
27 O
), O
nor O
were O
there O
significant O
correlations O
between O
melatonin O
and O
dopamine O
( O
r O
= O
- O
0 O
. O
01 O
), O
norepinephrine O
( O
r O
= O
- O
0 O
. O
26 O
), O
or O
growth I-GENE
hormone I-GENE
( O
r O
= O
0 O
. O
17 O
). O

The O
4 O
patients O
with O
carboxyhemoglobin RARE
levels O
in O
excess O
of O
10 O
% O
may O
represent O
occult RARE
carbon O
monoxide RARE
poisoning O
in O
this O
population O
. O

All O
these O
processes O
were O
fully O
developed O
during O
the O
last O
month O
of O
pregnancy O
, O
offering RARE
the O
same O
picture O
as O
the O
controls O
. O

Hypoglycemic RARE
action O
of O
" O
he RARE
xiang RARE
zhuang RARE
qi RARE
gong RARE
" O
and O
its O
mechanism O
on O
diabetes O
mellitus O

In O
cases O
of O
1 O
degrees O
HPT ALLCAPS
, O
the O
plasma O
1 O
, O
25 O
-( O
OH O
) O
2D NUMERIC
level O
rose O
significantly O
in O
all O
cases O
( O
P O
less O
than O
0 O
. O
05 O
), O
although O
the O
pattern O
of O
the O
increase O
was O
not O
uniform O
. O

This O
region O
of O
60 O
amino O
acids O
may O
be O
involved O
in O
coiled O
- O
coil O
interactions O
similar O
to O
those O
that O
facilitate O
the O
filament RARE
formation O
in O
the O
rod RARE
region O
. O

This O
approach O
enables O
the O
sources O
of O
error O
in O
the O
calculation RARE
of O
nutrient O
utilization O
to O
be O
readily O
identified O
, O
and O
their O
effect O
on O
precision RARE
to O
be O
assessed O
in O
different O
nutritional O
and O
metabolic O
states O
. O

The O
effect O
of O
dietary O
zinc O
deficiency O
on O
the O
mossy RARE
fiber O
zinc O
content O
of O
the O
rat O
hippocampus O
. O

Weaned RARE
rats O
were O
fed O
a O
normal O
diet O
or O
a O
low O
- O
protein O
, O
low O
- O
energy O
diet O
, O
and O
injected O
with O
saline O
or O
thyroxine O
( O
5 O
micrograms O
/ O
100 O
g O
BW ALLCAPS
) O
for O
22 O
days O
. O

It O
is O
largely O
predicted O
by O
lupus O
anticoagulant O
( O
estimated O
by O
activated O
partial O
thromboplastin I-GENE
time O
) O
and O
/ O
or O
antibody O
to O
cardiolipin RARE
. O

The O
effects O
of O
several O
opioid O
agonists O
and O
the O
opioid O
antagonist O
naloxone O
were O
examined O
in O
rats O
responding O
under O
a O
fixed O
- O
consecutive O
- O
number O
( O
FCN ALLCAPS
) O
schedule O
. O

The O
rate O
- O
decreasing O
effects O
of O
morphine O
and O
U50488 NUMERIC
were O
reversed O
completely O
by O
a O
0 O
. O
01 O
and O
1 O
. O
0 O
mg O
/ O
kg O
dose O
of O
naloxone O
, O
respectively O
. O

Data O
from O
119 O
men O
and O
40 O
women O
undergoing O
coronary O
angiography O
provide O
an O
opportunity RARE
to O
compare O
these O
associations O
in O
relation O
to O
a O
direct O
and O
continuous O
measure O
of O
atherosclerosis O
while O
controlling O
for O
age O
, O
sex O
, O
income RARE
, O
hypertension O
, O
serum O
cholesterol O
, O
smoking O
, O
angina O
, O
diabetes O
, O
family O
history O
of O
heart O
disease O
, O
Type O
A O
behavior O
pattern O
, O
and O
hostility RARE
. O

An O
intralobar RARE
change O
in O
temperature O
above O
or O
below O
36 O
degrees O
C O
decreases O
only O
the O
lobar RARE
bronchial O
blood O
flow O
and O
does O
not O
influence O
blood O
flow O
to O
other O
nearby RARE
tissues O
including O
those O
vascularized RARE
by O
the O
bronchial O
circulation O
. O

Convulsive RARE
status O
epilepticus RARE
after O
infusion O
of O
cisplatin O

The O
presence O
in O
such O
patients O
of O
antibodies O
to O
adrenaline O
and O
noradrenaline O
is O
indicative O
of O
considerable O
disruption O
of O
catecholamine RARE
biotransformation RARE
. O

The O
following O
markers O
were O
looked RARE
for O
in O
the O
serum O
, O
skin O
and O
liver O
of O
all O
patients O
with O
chronic O
hepatitis O
: O
HBV O
( O
HBs I-GENE
Ag I-GENE
and O
HBe RARE
Ag I-GENE
, O
anti I-GENE
- I-GENE
HBs I-GENE
, O
anti I-GENE
- I-GENE
HBe RARE
and O
anti I-GENE
- I-GENE
HBc RARE
in O
the O
serum O
, O
HBs I-GENE
and I-GENE
HBc RARE
Ag I-GENE
in O
the O
liver O
); O
non I-GENE
- I-GENE
A I-GENE
non I-GENE
- I-GENE
B I-GENE
( O
non I-GENE
- I-GENE
A I-GENE
, I-GENE
non I-GENE
- I-GENE
B I-GENE
Ag I-GENE
and I-GENE
antibody I-GENE
, O
anti I-GENE
non I-GENE
- I-GENE
A I-GENE
non I-GENE
- I-GENE
Bc RARE
in O
the O
serum O
, O
non I-GENE
- I-GENE
A I-GENE
, I-GENE
non I-GENE
- I-GENE
Bc RARE
Ag I-GENE
in O
the O
liver O
). O

Groups RARE
of O
male O
and O
female O
Fischer RARE
344 NUMERIC
rats O
, O
B6C3F1 NUMERIC
mice O
, O
and O
Hartley RARE
guinea O
pigs O
were O
exposed O
once O
for O
6 O
hr O
to O
mean O
concentrations O
of O
10 O
. O
5 O
, O
5 O
. O
4 O
, O
2 O
. O
4 O
, O
1 O
. O
0 O
, O
or O
0 O
( O
control O
) O
ppm O
of O
methyl O
isocyanate RARE
( O
MIC ALLCAPS
) O
vapor RARE
. O

Radionuclide RARE
study O
and O
endomyocardial RARE
biopsy O
revealed O
remarkable O
degeneration O
of O
myocardium O
. O

Immobilization RARE
of O
the O
fracture O
in O
a O
collar RARE
and O
cuff RARE
sling RARE
was O
as O
effective O
as O
more O
elaborate RARE
methods O
. O

Comparison O
of O
patients O
receiving O
phenytoin O
and O
those O
who O
were O
not O
showed O
significantly O
lower O
serum O
folate O
in O
the O
sub O
- O
group O
receiving O
phenytoin O
, O
but O
there O
was O
no O
significant O
difference O
between O
the O
sub O
- O
groups O
with O
respect O
to O
vitamin O
B12 NUMERIC
or O
behaviour O
problem O
rating O
. O

Effects O
of O
a O
low O
- O
energy O
laser O
beam O
on O
the O
cells O
of O
the O
newt RARE
embryo O

Typical RARE
and O
atypical O
clinical O
features O
of O
this O
lacrimal RARE
sac RARE
cyst O
are O
emphasized RARE
. O

The O
role O
of O
saliva RARE
in O
sour RARE
taste O
perception RARE
was O
investigated O
in O
a O
series O
of O
4 O
experiments O
. O

Samples RARE
from O
1415 NUMERIC
neurological O
patients O
were O
used O
to O
study O
the O
diagnostic O
value O
of O
acid I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
glycoprotein I-GENE
in O
the O
lumbar O
cerebrospinal O
fluid O
. O

Separate RARE
experiments O
measured O
AIB ALLCAPS
and O
86RbCl NUMERIC
uptake O
in O
36B NUMERIC
- O
10 O
cells O
in O
vitro O
1 O
and O
2 O
days O
following O
20 O
Gy O
irradiation O
to O
assess O
whether O
this O
radiation O
dose O
reduced O
the O
capacity O
of O
tumor O
cells O
to O
trap RARE
AIB ALLCAPS
or O
Rb O
+. RARE

For O
patients O
with O
recurrent O
or O
metastatic O
disease O
, O
the O
data O
suggest O
that O
I O
- O
131 O
MIBG ALLCAPS
scintigraphy O
is O
the O
examination O
of O
choice O
. O

W O
. O

Comparison O
of O
the O
amino O
acid O
sequence O
of O
the O
M I-GENE
RNA I-GENE
product I-GENE
of I-GENE
Uukuniemi RARE
virus I-GENE
with O
that O
of O
Punta RARE
Toro RARE
and O
Rift RARE
Valley RARE
fever O
viruses O
showed O
in O
both O
cases O
a O
weak O
homology O
that O
was O
more O
pronounced O
for O
the O
proteins O
located O
at O
the O
COOH O
- O
terminal O
end O
of O
the O
precursor O
. O

Cyclosporine RARE
treatment O
for O
intractable RARE
polymyositis RARE
. O

In O
addition O
, O
on O
the O
Cohler RARE
' O
s O
maternal O
scale O
, O
Korean RARE
mothers O
were O
found O
to O
view O
their O
infants O
as O
more O
passive O
and O
dependent O
than O
American O
mothers O
did O
( O
P O
less O
than O
0 O
. O
00 O
). O

A O
preoperative O
teaching RARE
booklet RARE
for O
pediatric O
patients O
. O

Hyperthyroidism RARE

We O
conclude O
that O
for O
mono O
- O
intronic O
precursors O
in O
which O
there O
is O
only O
one O
choice O
of O
splice O
sites O
, O
most O
of O
the O
exon O
sequences O
are O
not O
mechanistically RARE
involved O
in O
the O
splicing O
process O
. O

UVA ALLCAPS
- O
induced O
melanocytic RARE
lesions O
. O

Ex RARE
vivo O
MAO I-GENE
inhibition O
data O
indicated O
DPGPEA ALLCAPS
to O
be O
an O
inhibitor O
of O
MAO I-GENE
- I-GENE
B I-GENE
, O
although O
the O
effect O
was O
much O
weaker RARE
than O
seen O
with O
tranylcypromine RARE
or O
pargyline RARE
. O

Thus O
in O
this O
region O
of O
the O
vessel O
pyridinoline RARE
represents O
the O
major O
stabilising RARE
crosslink RARE
of O
collagen I-GENE
. O

A O
careful RARE
, O
radiolabelled RARE
tissue O
- O
distribution O
study O
is O
warranted O
to O
elucidate O
the O
complicated O
metabolic O
fate O
of O
perhexiline RARE
. O

Systemic RARE
lupus O
erythematosus O
was O
diagnosed O
. O

In O
the O
evening RARE
, O
the O
amplitude O
of O
the O
responses O
to O
both O
O2 O
and O
CO2 O
increased O
but O
the O
increase O
in O
CO2 O
sensitivity O
was O
proportionally RARE
more O
important O
. O

The O
statistical O
significance O
of O
the O
prognosis O
factors O
was O
studied O
by O
uni RARE
- O
and O
multivariative RARE
methods O
, O
according O
to O
the O
model O
of O
Cox O
, O
with O
the O
help O
of O
an O
IMB ALLCAPS
computer O
. O

These O
changes O
at O
the O
site O
of O
injection O
consist O
of O
a O
focal O
abnormality O
characterized O
by O
a O
slight O
increase O
in O
signal O
intensity O
on O
T1 O
weighted O
images O
and O
markedly O
increased O
signal O
intensity O
on O
T2 O
weighted O
images O
. O

These O
results O
suggest O
that O
less O
antidopaminergic RARE
activity O
of O
RHAL ALLCAPS
in O
this O
neuroleptic O
test O
might O
be O
explained O
by O
the O
lesser O
conversion O
of O
RHAL ALLCAPS
to O
HAL ALLCAPS
. O

The O
purpose O
of O
this O
study O
is O
twofold O
: O
( O
1 O
) O
to O
present O
a O
parallel O
form O
of O
the O
Gudjonsson RARE
Suggestibility RARE
Scale O
( O
GSS ALLCAPS
, O
Form RARE
1 O
); O
( O
2 O
) O
to O
study O
test O
- O
retest RARE
reliabilities RARE
of O
interrogative RARE
suggestibility RARE
. O

Organisms RARE
were O
recovered O
from O
the O
conjunctiva RARE
for O
several O
weeks O
, O
and O
persistent O
genital O
and O
gastrointestinal O
infection O
also O
resulted O
from O
the O
ocular O
infection O
in O
some O
cats O
. O

In O
vivo O
epiluminescence RARE
microscopy O
of O
pigmented RARE
skin O
lesions O
. O

These O
equilibrium O
solutions O
are O
then O
shown O
to O
arise O
from O
the O
vertices RARE
of O
a O
particular O
convex RARE
polyhedron RARE
. O

The O
average O
deviations RARE
in O
the O
X O
- O
ray O
counts O
of O
the O
constant O
elements O
from O
the O
series O
means O
were O
used O
to O
correct O
the O
recorded O
count O
of O
the O
variable O
element O
in O
each O
block O
. O

Statistically RARE
significant O
effects O
were O
noted O
at O
doses O
which O
did O
not O
appear O
to O
be O
maternally RARE
toxic O
. O

Low O
MAO I-GENE
subjects O
showed O
a O
pattern O
of O
higher O
scores O
in O
KSP ALLCAPS
Impulsiveness RARE
, O
EPQ ALLCAPS
Neuroticism RARE
, O
and O
KSP ALLCAPS
Somatic RARE
Anxiety RARE
and O
Irritability RARE
and O
lower O
scores O
in O
KSP ALLCAPS
Socialization RARE
, O
in O
line O
with O
personality RARE
profiles O
found O
in O
alcoholics RARE
, O
psychopaths RARE
, O
and O
suicide O
attempters RARE
who O
also O
tend RARE
to O
have O
low O
platelet O
MAO I-GENE
activity O
. O

To O
evaluate O
the O
relative O
accuracy O
of O
continuous O
wave O
( O
CW ALLCAPS
) O
and O
high O
pulse O
repetition RARE
frequency O
( O
HPRF ALLCAPS
) O
Doppler O
for O
estimating O
aortic O
transvalvular RARE
pressure O
gradients RARE
, O
Doppler O
examinations O
with O
both O
devices RARE
were O
obtained O
in O
87 O
consecutive O
patients O
with O
aortic O
valve O
disease O
. O

In O
group O
I O
, O
Paw RARE
, O
delta O
V O
, O
PaO2 O
, O
Vinj RARE
and O
VT O
significantly O
decreased O
whereas O
operating O
pressure O
and O
E O
significantly O
increased O
when O
the O
internal O
diameter O
of O
the O
injector RARE
cannula RARE
was O
reduced O
. O

In O
calves O
receiving O
milk O
- O
substitute O
diets O
containing O
80 O
- O
260 O
g O
DM O
/ O
kg O
, O
milk O
intakes RARE
were O
reduced O
by O
up O
to O
30 O
% O
on O
the O
1st NUMERIC
day O
that O
calves O
were O
fed O
once O
daily O
instead O
of O
twice O
daily O
. O

Today RARE
there O
is O
no O
doubt RARE
that O
elevated O
plasma O
cholesterol O
levels O
should O
be O
lowered O
first O
by O
dietary O
modification O
even O
in O
early O
childhood O
, O
beginning O
at O
the O
age O
of O
two O
years O
. O

The O
number O
of O
fecal O
pellets O
ingested RARE
peaked RARE
at O
5 O
to O
6 O
weeks O
old O
( O
13 O
pellets O
/ O
day O
) O
and O
gradually O
decreased O
, O
thereafter O
( O
2 O
. O
1 O
pellets O
at O
78 O
weeks O
old O
, O
1 O
. O
5 O
pellets O
at O
104 O
weeks O
old O
). O

These O
results O
suggest O
that O
N O
- O
nitroso RARE
compounds O
can O
be O
formed O
in O
vivo O
in O
the O
infected O
bladder O
, O
which O
could O
explain O
the O
association O
between O
urinary O
- O
tract O
infections O
and O
increased O
risk O
for O
bladder O
cancer O
. O

Epithelial RARE
nerve O
fiber O
defects O
included O
absence O
or O
distorted RARE
architecture O
of O
the O
basal O
epithelial O
plexus RARE
and O
intra O
- O
epithelial O
terminals RARE
. O

The O
histologic O
grade O
for O
the O
same O
anatomic O
site O
varied O
among O
hearts O
and O
among O
different O
anatomic O
sites O
in O
the O
same O
heart O
. O

Serum O
levels O
of O
albumin I-GENE
, O
globulin I-GENE
, O
and O
coagulation I-GENE
protein I-GENE
activity O
were O
measured O
preshock RARE
, O
postshock RARE
, O
and O
daily O
for O
3 O
days O
; O
skin O
lymph O
levels O
were O
measured O
on O
Day O
3 O
. O

For O
colostral RARE
milk O
there O
was O
a O
significant O
correlation O
of O
vitamin O
K1 O
to O
cholesterol O
( O
r O
= O
0 O
. O
62 O
) O
but O
not O
to O
total O
lipid O
or O
phospholipid O
suggesting O
a O
role O
for O
cholesterol O
in O
the O
secretion O
of O
vitamin O
K1 O
into O
colostral RARE
milk O
. O

Endurance RARE
training O
resulted O
in O
an O
increase O
of O
stiffness O
associated O
with O
a O
decrease O
of O
type O
II O
fibers O
. O

A O
rate O
- O
decreasing O
dose O
of O
physostigmine RARE
, O
an O
acetylcholinesterase RARE
inhibitor O
, O
was O
studied O
in O
combination O
with O
the O
range O
of O
atropine O
doses O
. O

References RARE
for O
occupational RARE
fitness O
of O
adolescents RARE
with O
diseases O
of O
the O
respiratory O
tract O
and O
lungs O

Salzburg RARE
, O
9 O
- O
12 O
September RARE
1987 O
. O

Two O
new O
glucosidase RARE
inhibitors O
( O
BAY ALLCAPS
m O
1099 NUMERIC
and O
BAY ALLCAPS
o O
1248 NUMERIC
) O
were O
studied O
in O
volunteers O
and O
type O
II O
diabetics RARE
under O
various O
conditions O
. O

The O
models O
accurately O
localized O
the O
common O
boundaries O
between O
the O
PBB ALLCAPS
and O
CN ALLCAPS
. O

Two O
of O
these O
six O
cases O
showed O
mucosal O
spread O
without O
stromal RARE
invasion O
( O
type O
A O
); O
the O
remaining O
four O
cases O
presented O
a O
direct O
extension O
( O
type O
B O
) O
from O
muscle O
- O
invasive O
carcinomas O
of O
the O
bladder O
. O

However O
, O
conversions RARE
of O
12 O
mm O
or O
more O
from O
a O
documented RARE
negative O
result O
indicated O
spread O
of O
infection O
. O

The O
maximum O
amplitude O
of O
evoked O
responses O
in O
the O
cervical O
sympathetic O
trunk O
was O
obtained O
when O
the O
T2 O
white O
ramus RARE
was O
stimulated O
and O
decreased O
gradually O
when O
followed O
by O
the O
stimulation O
of O
T1 O
, O
T3 O
, O
T4 O
and O
T5 NUMERIC
white O
rami RARE
. O

It O
is O
concluded O
that O
contact O
allergy O
to O
K O
- O
CG O
is O
common O
. O

The O
effect O
of O
a O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
antagonist O
, O
pindolol RARE
, O
on O
uterine O
smooth O
muscle O
in O
term O
pregnant O
women O
was O
studied O
in O
vitro O
and O
in O
vivo O
( O
in O
hypertensive O
women O
). O

The O
less O
- O
polar RARE
mycolic RARE
acid O
- O
containing O
Rhodococcus RARE
species O
showed O
chromatographic O
patterns O
that O
partially O
overlapped RARE
( O
in O
elution RARE
times O
) O
the O
patterns O
of O
Nocardia RARE
asteroides RARE
, O
N O
. O
otitidiscaviarum RARE
, O
and O
N O
. O
brasiliensis RARE
, O
but O
the O
larger O
number O
of O
peaks O
in O
the O
last O
species O
made O
separation O
between O
the O
genera RARE
possible O
. O

The O
development O
of O
a O
data O
base O
is O
described O
which O
can O
be O
used O
as O
common O
reference O
for O
ECG O
computer O
programs O
analyzing O
12 O
or O
15 O
simultaneously O
recorded O
leads O
. O

Blood I-GENE
serum I-GENE
erythropoietin I-GENE
level O
and O
basic O
hematological RARE
indices O
during O
the O
adaptation O
of O
healthy O
newborn O
infants O

49 O
, O
XXXXY ALLCAPS
chromosome O
anomaly RARE
: O
an O
unusual O
variant O
of O
Klinefelter RARE
' O
s O
syndrome O
. O

Contraction RARE
of O
the O
tracheal O
muscle O
and O
the O
activity O
of O
stretch O
receptors O
in O
the O
trachea RARE

The O
selenium O
level O
and O
glutathione I-GENE
peroxidase I-GENE
activity O
in O
the O
blood O
, O
liver O
, O
and O
stomach O
mucosa O
were O
significantly O
higher O
in O
the O
high O
- O
selenium O
diet O
group O
than O
in O
the O
low O
- O
selenium O
diet O
group O
. O

Oxygen RARE
delivery O
and O
consumption O
and O
P50 NUMERIC
in O
patients O
with O
acute O
myocardial O
infarction O
. O

Infants RARE
of O
this O
sample O
had O
monocular RARE
PL O
visual O
acuities RARE
similar O
to O
those O
established O
by O
McDonald RARE
et O
al O
. O
in O
a O
laboratory O
setting O
. O

These O
results O
indicate O
that O
the O
effect O
of O
the O
isomers RARE
of O
pentobarbital RARE
and O
secobarbital RARE
on O
mult RARE
FR30 NUMERIC
FI600 NUMERIC
responding O
and O
on O
suppressed O
responding O
are O
qualitatively RARE
similar O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

The O
number O
of O
crystalline O
deposits RARE
is O
less O
in O
the O
advanced O
atrophic RARE
areas O
of O
the O
RPE ALLCAPS
- O
choriocapillaris RARE
complex O
. O

All O
33 O
subjects O
were O
given O
psychometric RARE
instruments O
for O
measuring O
various O
components O
of O
anger RARE
and O
anxiety O
: O
Spielberger RARE
' O
s O
State O
- O
Trait RARE
Personality RARE
Inventory RARE
, O
the O
Anger RARE
Expression O
Scale O
, O
and O
the O
State O
Anger RARE
Reaction RARE
Scale O
. O

It O
was O
found O
that O
the O
primary O
visual O
cortex O
of O
the O
rat O
is O
asymmetrical RARE
in O
volume O
, O
and O
that O
the O
asymmetry O
reflects RARE
side O
differences O
in O
the O
number O
of O
neurons O
. O

The O
subjects O
received O
a O
single O
500 O
mg O
dose O
of O
acetaminophen RARE
i O
. O
v O
. O
and O
concentrations O
in O
plasma O
were O
measured O
for O
360 NUMERIC
minutes O
and O
in O
urine O
for O
24 O
h O
in O
order O
to O
estimate O
the O
production O
of O
metabolites O
. O

Mean O
weighted O
skin O
temperature O
( O
Tsk RARE
) O
was O
lower O
( O
P O
less O
than O
0 O
. O
01 O
) O
following O
acclimation RARE
than O
before O
, O
and O
acclimation RARE
resulted O
in O
a O
larger O
( O
P O
less O
than O
0 O
. O
02 O
) O
Tre RARE
- O
to O
- O
Tsk RARE
gradient O
. O

Indium RARE
- O
111 O
leukocyte O
imaging O
in O
patients O
with O
rheumatoid O
arthritis O
. O

The O
effect O
of O
L O
- O
methionine O
supplementation O
on O
the O
utilization O
of O
a O
soy RARE
protein O
isolate O
( O
SPI ALLCAPS
) O
was O
evaluated O
by O
short O
- O
term O
nitrogen O
balance O
studies O
in O
young O
women O
. O

Primary O
invasive O
Haemophilus O
influenzae O
type O
b O
disease O
: O
a O
population O
- O
based O
assessment O
of O
risk O
factors O
. O

Overall O
, O
lesions O
infiltrating RARE
the O
deep O
lamina RARE
propria RARE
do O
not O
exhibit O
a O
reduced O
frequency O
of O
occurrence O
compared O
to O
lesions O
infiltrating RARE
the O
skeletal O
muscle O
; O
however O
, O
carcinomas O
affecting O
other O
oral O
sites O
showed O
a O
reduced O
frequency O
of O
deeply RARE
infiltrating RARE
lesions O
in O
comparison O
to O
more O
superficial O
lesions O
. O

Factors O
that O
showed O
significant O
correlation O
to O
elevated O
CIC O
' O
s O
in O
the O
highly O
elevated O
portion O
of O
our O
CIC O
population O
were O
poor O
NIH O
score O
, O
increased O
patient O
age O
, O
low O
peak O
expiratory O
flow O
rate O
, O
and O
elevated O
total O
serum I-GENE
IgG I-GENE
. O

Induction O
of O
both O
potential O
transcripts O
follows O
heat O
shock O
in O
vivo O
. O

New O
and O
successful O
steps O
have O
been O
made O
in O
immunodiagnostics RARE
, O
immunotherapy O
, O
and O
immunoprophylaxis RARE
of O
immunologically RARE
conditioned O
infertility O
. O

Amikacin RARE
was O
the O
most O
stable O
and O
tobramycin RARE
was O
the O
least O
stable O
aminoglycoside RARE
under O
the O
conditions O
tested O
. O

This O
may O
explain O
in O
part O
a O
secular RARE
trend O
towards O
reduced O
birthweight RARE
for O
gestation O
in O
preterm O
infants O
. O

Estimated RARE
nucleic O
acid O
N O
absorption O
is O
7 O
- O
8 O
% O
of O
N O
intake O
. O

Adhesion RARE
, O
phagocytosis RARE
, O
chemotactic O
and O
random O
migration O
, O
nitroblue RARE
tetrazolium RARE
dye O
reduction O
of O
peritoneal O
exudate RARE
neutrophils O
and O
macrophages O
, O
fibrinogen I-GENE
level O
, O
gelation RARE
of O
soluble O
fibrin I-GENE
and O
serial O
dilution O
protamine RARE
sulfate O
test O
were O
investigated O
in O
115 O
New O
Zealand RARE
white O
rabbits O
with O
experimentally O
induced O
Shwartzman RARE
phenomenon O
in O
the O
colon O
, O
and O
in O
control O
animals O
. O

Nickel RARE
is O
the O
most O
common O
cause O
of O
allergic O
contact O
dermatitis O
in O
Singapore RARE
, O
resulting O
in O
positive O
reactions O
in O
patch O
tests O
between O
7 O
and O
14 O
%. O

The O
FFA ALLCAPS
levels O
were O
not O
affected O
( O
P O
greater O
than O
. O
1 O
) O
by O
meal O
interval O
. O

He O
visited RARE
our O
hospital O
and O
left O
solitary RARE
renal O
cyst O
was O
suspected O
. O

However O
, O
further O
analyses O
of O
the O
data O
indicate O
that O
increasing O
VO2 O
AT O
( O
r O
= O
- O
0 O
. O
63 O
, O
P O
less O
than O
0 O
. O
05 O
) O
rather O
than O
VO2max NUMERIC
( O
r O
= O
- O
0 O
. O
15 O
) O
could O
result O
in O
improving RARE
the O
10 O
, O
000 O
m O
race RARE
performance O
to O
a O
larger O
extent O
, O
and O
that O
the O
absolute O
amount O
of O
change O
( O
delta O
) O
in O
the O
10 O
, O
000 O
m O
run O
time O
is O
best O
accounted RARE
for O
by O
a O
combination O
of O
delta O
VO2 O
AT O
and O
delta O
5 O
, O
000 O
m O
run O
time O
. O

A O
significant O
herd O
X O
period O
interaction O
existed O
for O
liver O
TG O
and O
serum O
dextran RARE
precipitable RARE
cholesterol O
concentrations O
. O

Liver O
TG O
and O
serum O
NEFA ALLCAPS
concentrations O
were O
positively O
correlated O
. O

The O
results O
show O
that O
nerve O
and O
roots O
differ O
considerably O
both O
in O
the O
force O
they O
sustain RARE
before O
failure O
and O
in O
the O
other O
biomechanics RARE
they O
exhibit O
. O

When O
the O
coronary O
sinus O
pressure O
reached O
15 O
torr O
, O
there O
was O
a O
significant O
decrease O
in O
cardiac O
index O
( O
3 O
. O
60 O
+/- O
0 O
. O
5 O
to O
2 O
. O
70 O
+/- O
0 O
. O
6 O
L O
/ O
min O
/ O
m2 O
, O
p O
less O
than O
0 O
. O
001 O
), O
coronary O
blood O
flow O
( O
13 O
. O
7 O
+/- O
3 O
. O
1 O
to O
7 O
. O
0 O
+/- O
2 O
. O
1 O
ml O
/ O
min O
, O
p O
less O
than O
0 O
. O
001 O
), O
rate O
of O
rise O
of O
left O
ventricular O
pressure O
( O
1 O
, O
567 NUMERIC
+/- O
275 NUMERIC
to O
1 O
, O
331 NUMERIC
+/- O
314 NUMERIC
, O
p O
less O
than O
0 O
. O
05 O
), O
and O
an O
increase O
in O
coronary O
arteriovenous RARE
difference O
( O
62 O
. O
8 O
% O
+/- O
9 O
. O
3 O
% O
to O
70 O
. O
5 O
% O
+/- O
5 O
. O
4 O
% O
saturation O
, O
p O
less O
than O
0 O
. O
03 O
). O

Calcifications RARE
in O
the O
thoracic RARE
aorta O
at O
the O
level O
of O
the O
11th NUMERIC
and O
the O
12th NUMERIC
thoracic RARE
vertebrae RARE
in O
592 NUMERIC
men O
and O
333 NUMERIC
women O
were O
studied O
using O
computed O
tomography O
. O

In O
a O
series O
of O
402 NUMERIC
consecutive O
autopsies RARE
, O
parietal RARE
pleural O
plaques RARE
( O
PP O
) O
were O
found O
in O
68 O
individuals O
above O
40 O
years O
of O
age O
. O

Approximately O
60 O
% O
of O
cell O
bodies O
of O
primary O
neurons O
innervating RARE
the O
intra O
and O
perioral RARE
structures O
through O
the O
inferior O
alveolar O
, O
lingual RARE
, O
mental O
, O
and O
buccal RARE
nerves O
were O
in O
the O
range O
between O
300 O
and O
600 O
micron O
2 O
in O
cross O
- O
sectional O
area O
: O
mean O
+/- O
SD O
509 NUMERIC
+/- O
243 NUMERIC
micron O
2 O
, O
420 NUMERIC
+/- O
181 NUMERIC
micron O
2 O
, O
469 NUMERIC
+/- O
200 O
micron O
2 O
, O
and O
444 NUMERIC
+/- O
186 O
micron O
2 O
, O
respectively O
. O

Pharmacological RARE
action O
of O
eptazocine RARE
( O
l O
- O
1 O
, O
4 O
- O
dimethyl O
- O
10 O
- O
hydroxy O
- O
2 O
, O
3 O
, O
4 O
, O
5 O
, O
6 O
, O
7 O
- O
hexahydro RARE
- O
1 O
, O
6 O
- O
methano RARE
- O
1H NUMERIC
- O
4 O
- O
benz RARE
azonine RARE
). O

On O
transition O
from O
high O
to O
low O
voltage O
there O
was O
a O
significant O
fall O
in O
arterial O
pressure O
( O
7 O
%) O
and O
an O
increase O
in O
flow O
( O
19 O
- O
38 O
%) O
to O
areas O
of O
the O
brain O
corresponding O
to O
the O
arborization RARE
of O
the O
reticular RARE
formation O
, O
i O
. O
e O
. O
excluding O
the O
cerebrum RARE
and O
cerebellum RARE
. O

Findings RARE
of O
positive O
potentials O
showed O
that O
N1 O
originated RARE
in O
the O
area O
of O
ventral O
gray O
matter O
through O
the O
ventro RARE
- O
lateral O
column O
and O
N2 O
through O
the O
dorsal O
column O
. O

One O
hundred O
and O
four O
( O
14 O
per O
cent O
) O
second O
primary O
tumours O
were O
reported O
. O

Failures RARE
of O
colorimetric RARE
additivity RARE
under O
these O
experimental O
conditions O
are O
discussed O
. O

There O
have O
been O
five O
problems O
( O
extravasation RARE
2 O
, O
suspected O
sepsis O
1 O
, O
and O
hematoma RARE
2 O
) O
during O
a O
total O
of O
2 O
, O
927 NUMERIC
days O
of O
exposure O
. O

It O
is O
suggested O
that O
these O
results O
may O
raise RARE
the O
interesting RARE
possibility O
of O
providing O
a O
means O
of O
identifying O
greater O
or O
lesser O
susceptibility O
to O
the O
coronary O
effects O
of O
Type O
A O
behavior O
. O

Two O
studies O
assessed O
two O
types O
of O
reliability O
of O
the O
student RARE
Jenkins RARE
Activity RARE
Survey RARE
( O
JAS ALLCAPS
; O
a O
questionnaire O
measure O
of O
Type O
A O
behavior O
). O

Splenectomized RARE
patients O
are O
predisposed RARE
toward O
developing O
overwhelming RARE
bacterial O
infections O
. O

When O
phencyclidine RARE
was O
administered O
alone O
, O
overall O
response O
rate O
decreased O
and O
percent O
errors RARE
increased O
with O
increasing O
doses O
. O

Possibilities RARE
and O
outlook RARE
for O
wrist O
joint O
endoprosthesis RARE

Study O
of O
the O
energy O
metabolism O
of O
the O
sensomotor RARE
cortex O
and O
hippocampus O
by O
the O
( O
14C O
) O
2 O
- O
deoxyglucose RARE
method O
during O
the O
development O
of O
dissociated RARE
states O

Malignant RARE
lymphoma O
is O
very O
heterogeneous O
in O
terms O
of O
its O
biological O
behavior O
. O

Further O
investigations O
are O
necessary O
to O
elucidate O
the O
biochemical O
and O
physiological O
properties O
of O
DLIS ALLCAPS
. O

Among O
them O
, O
26 O
cases O
were O
benign O
and O
34 O
malignant O
. O

Of O
the O
cases O
with O
PLD ALLCAPS
, O
50 O
% O
had O
associated O
renal O
cysts O
and O
10 O
% O
of O
the O
cases O
with O
APCD ALLCAPS
had O
associated O
liver O
cysts O
. O

Fast RARE
goal O
- O
directed O
voluntary RARE
movements O
of O
the O
human O
upper O
extremity RARE
are O
known O
to O
be O
associated O
with O
three O
distinct O
bursts RARE
of O
EMG O
activity O
in O
antagonistic O
muscles O
. O

The O
combination O
of O
F1 O
and O
F2 O
which O
was O
the O
best O
predictor O
of O
CHD ALLCAPS
in O
this O
population O
( O
G1 O
) O
might O
be O
interpreted O
as O
reflecting O
trunk O
adiposity RARE
mainly O
abdominal O
. O

Renal O
clearance O
fell O
from O
19 O
. O
0 O
+/- O
4 O
. O
9 O
ml O
/ O
min O
/ O
1 O
. O
73 O
m2 O
( O
group O
I O
) O
to O
1 O
. O
0 O
+/- O
0 O
. O
4 O
ml O
/ O
min O
/ O
1 O
. O
73 O
m2 O
( O
group O
IV O
). O

The O
relations O
between O
type O
A O
behavior O
, O
clinically O
relevant O
behavior O
, O
academic RARE
achievement RARE
, O
and O
IQ ALLCAPS
in O
children O
. O

The O
rats O
were O
used O
for O
the O
study O
of O
the O
effects O
of O
sepsis O
on O
the O
utilization O
of O
exogenous O
fat O
emulsion RARE
. O

She RARE
also O
had O
slight O
weakness RARE
of O
the O
upper O
extremities RARE
. O

Results O
of O
electron O
therapy O
of O
tumors O
in O
different O
sites O

The O
mechanism O
of O
action O
is O
explored O
in O
some O
detail O
, O
specifically O
as O
it O
relates RARE
to O
reticuloendothelial RARE
system O
( O
RES ALLCAPS
) O
Fc I-GENE
receptor I-GENE
blockade O
and O
suppression O
of O
antiplatelet RARE
antibody O
synthesis O
. O

Incidences RARE
of O
nonfatal RARE
stroke O
, O
myocardial O
infarction O
, O
angina O
pectoris O
und RARE
left O
ventricular O
hypertrophy O
could O
also O
be O
lowered O
. O

High O
radial RARE
r O
values O
with O
small O
standard O
deviations RARE
were O
observed O
in O
normal O
LV O
( O
0 O
. O
972 NUMERIC
+/- O
0 O
. O
016 NUMERIC
) O
and O
in O
non O
- O
MI O
regions O
( O
0 O
. O
964 NUMERIC
+/- O
0 O
. O
018 NUMERIC
), O
indicating O
temporally O
homogeneous RARE
radial RARE
shortening O
. O

These O
results O
indicate O
that O
during O
pregnancy O
there O
are O
increases O
in O
bone O
formation O
rates O
contributing RARE
to O
the O
increases O
in O
skeletal O
mass O
. O

We O
analyzed O
data O
from O
56 O
patients O
with O
Systemic RARE
Lupus RARE
Erythematosus RARE
( O
SLE O
) O
in O
whom O
renal O
biopsies O
were O
done O
systematically O
. O

The O
possibility O
of O
a O
hereditary O
disorder O
leading O
to O
a O
minor O
defect O
in O
elastic O
fibre O
structure O
which O
could O
be O
responsible O
for O
the O
spontaneous O
lesions O
is O
discussed O
. O

Prevention O
by O
a O
heparin O
- O
antithrombin I-GENE
III I-GENE
combination O

N O
- O
Substituted RARE
trimethylsilylcarbamates RARE
were O
tested O
as O
derivatizing RARE
reagents RARE
for O
gas O
chromatographic O
analysis O
. O

MICs O
of O
four O
antifungal RARE
agents O
( O
5 O
- O
fluorocytosine RARE
, O
miconazole RARE
, O
ketoconazole RARE
, O
and O
amphotericin O
B O
) O
for O
84 O
clinical O
isolates O
of O
various O
Candida O
species O
were O
then O
determined O
with O
both O
media O
in O
agar O
dilution O
and O
microtiter RARE
broth RARE
dilution O
systems O
. O

There O
were O
18 O
patients O
with O
Group O
II O
( O
a O
) O
tumors O
; O
although O
tumor O
biopsy O
was O
attempted RARE
on O
eight O
of O
these O
, O
pathological O
diagnosis O
at O
the O
time O
of O
surgery O
was O
made O
in O
only O
one O
case O
. O

Evidence O
that O
opiate O
addiction RARE
is O
in O
part O
an O
immune O
response O
. O

Parasitological RARE
post O
- O
mortem RARE
examination O
of O
all O
seropositive O
animals O
showed O
five O
and O
seven O
false O
- O
positive O
animals O
when O
E I-GENE
/ I-GENE
S I-GENE
and I-GENE
CWE ALLCAPS
antigens I-GENE
were O
used O
, O
respectively O
. O

Glucocorticoid RARE
induced O
hypertension O
has O
been O
regarded O
as O
independent O
of O
sodium O
( O
Na O
), O
in O
contrast O
to O
mineralocorticoid RARE
induced O
hypertension O
, O
which O
is O
Na O
+- O
dependent O
. O

Seventeen RARE
of O
them O
were O
on O
treatment O
with O
systemic O
steroids O
. O

Examples RARE
of O
its O
use O
in O
the O
intensive O
therapy O
unit O
are O
described O
. O

The O
growing O
drug O
problem O
is O
also O
reflected O
in O
the O
increasing O
number O
of O
cases O
of O
hepatitis O
B O
and O
of O
drug O
- O
related O
deaths O
. O

Only O
seven O
patients O
, O
five O
of O
whom O
have O
metastatic O
disease O
, O
survive RARE
more O
than O
10 O
years O
after O
first O
presentation O
; O
nine O
patients O
, O
one O
of O
whom O
has O
secondaries RARE
, O
survive RARE
for O
5 O
years O
or O
less O
. O

Although O
differences O
were O
not O
significant O
, O
infants O
in O
the O
experimental O
group O
had O
more O
changes O
in O
the O
intermittent O
mandatory RARE
ventilation O
( O
IMV ALLCAPS
) O
settings RARE
during O
transport O
, O
and O
more O
such O
infants O
arrived RARE
at O
the O
receiving O
hospital O
with O
acceptable O
pH O
and O
PCO2 O
values O
. O

Repetitive RARE
sequences O
are O
present O
in O
at O
least O
three O
introns O
of O
the O
cytochrome I-GENE
P I-GENE
- I-GENE
450PBc2 NUMERIC
gene I-GENE
, O
but O
not O
in O
exons O
or O
the O
5 O
'- O
flanking O
region O
. O

A O
large O
increase O
of O
serum O
ketones RARE
occurred O
under O
all O
conditions O
, O
and O
the O
exercise O
respiratory O
quotient RARE
suggested O
some O
increase O
of O
fat O
utilization O
, O
WW ALLCAPS
( O
0 O
. O
85 O
) O
through O
CW ALLCAPS
( O
0 O
. O
84 O
) O
to O
CC O
( O
0 O
. O
83 O
). O

This O
lack O
of O
correlation O
may O
be O
due O
to O
variations O
in O
the O
metabolic O
activity O
of O
the O
endometriotic RARE
implants O
present O
at O
different O
stages O
of O
the O
disease O
. O

Respiratory RARE
adaptation O
to O
chronic O
hypoxia O
in O
newborn O
rats O
. O

Compound RARE
1 O
is O
either O
21 O
- O
O O
- O
angeloyl RARE
, O
22 O
- O
O O
- O
tigloyl RARE
R1 O
- O
barrigenol RARE
, O
or O
21 O
- O
O O
- O
tigloyl RARE
, O
22 O
- O
O O
- O
angeloyl RARE
R1 O
- O
barrigenol RARE
. O

Human O
and O
Chinese I-GENE
hamster I-GENE
S14 NUMERIC
protein I-GENE
sequences I-GENE
deduced O
from O
the O
cDNAs O
are O
identical O
. O

RPS14 NUMERIC
introns O
3 O
and O
4 O
both O
contain O
Alu I-GENE
sequences O
. O

One O
of O
the O
most O
relevant O
aspects O
in O
achieving RARE
the O
consistent O
survival O
of O
an O
animal O
undergoing O
the O
experimental O
implantation O
of O
a O
total O
artificial O
heart O
is O
obviously RARE
related O
to O
the O
correct O
anatomic O
placement O
of O
prosthetic RARE
ventricles O
inside RARE
the O
chest O
. O

An O
exaggerated RARE
tissue O
response O
adjacent O
to O
the O
cyanoacrylate RARE
site O
suggested O
a O
potential O
toxic O
chemical O
or O
thermal O
reaction O
, O
or O
both O
, O
to O
the O
tissue O
adhesive O
, O
but O
there O
was O
no O
evidence O
of O
any O
distant O
ocular O
effects O
. O

These O
findings O
suggest O
that O
there O
may O
be O
a O
relationship O
between O
the O
pathogenesis O
of O
MAL ALLCAPS
, O
narcolepsy RARE
, O
and O
OSA ALLCAPS
. O

Among O
82 O
superficial O
lesions O
34 O
were O
classified O
as O
showing O
CR O
and O
another O
23 O
as O
showing O
PR O
, O
with O
a O
response O
rate O
of O
69 O
. O
5 O
%. O

Under O
the O
same O
hematocrit O
and O
flow O
conditions O
, O
the O
rate O
of O
oxygen O
saturation O
decrease O
was O
significantly O
higher O
for O
the O
sickle RARE
cells O
than O
for O
normal O
cells O
. O

While O
the O
examiner RARE
observed O
the O
interior RARE
of O
the O
eye O
with O
indirect O
ophthalmoscopy RARE
, O
the O
point O
source O
of O
light O
from O
the O
fiberoptic RARE
light O
pipe RARE
was O
moved RARE
along O
the O
margins RARE
of O
the O
episcleral RARE
plaque O
. O

These O
fusion O
proteins O
also O
allowed O
the O
localization O
of O
the O
transcriptional O
activation O
and O
DNA O
binding O
domains O
of O
the O
ToxR LASTCAP
protein I-GENE
to O
its O
cytoplasmically RARE
located O
N O
- O
terminal O
portion O
. O

From O
life O
- O
table RARE
analyses O
of O
these O
patients O
, O
we O
estimated O
that O
the O
incidence O
of O
secondary O
chondrosarcoma RARE
in O
patients O
who O
have O
Ollier RARE
disease O
is O
about O
25 O
per O
cent O
at O
the O
age O
of O
forty RARE
years O
, O
and O
that O
malignant O
degeneration O
is O
almost O
a O
certainty RARE
in O
patients O
who O
have O
Maffucci RARE
syndrome O
. O

The O
lethal O
toxicity O
of O
inorganic O
( O
HgCl2 NUMERIC
) O
and O
organic O
( O
CH3HgCl NUMERIC
) O
mercury RARE
chloride O
was O
compared O
for O
Coturnix RARE
( O
Japanese O
quail RARE
, O
Coturnix RARE
japonica RARE
) O
of O
different O
ages O
from O
hatch RARE
through O
adulthood RARE
by O
single O
- O
dose O
acute O
oral O
and O
intramuscular RARE
injections O
and O
by O
a O
5 O
- O
d O
dietary O
trial O
. O

Since O
the O
integrated O
13h00 NUMERIC
- O
16h00 NUMERIC
plasma O
cortisol O
estimation O
is O
cheaper RARE
and O
simpler RARE
than O
the O
mean O
13h00 NUMERIC
- O
16h00 NUMERIC
plasma O
cortisol O
estimation O
, O
we O
recommend RARE
it O
as O
an O
adjunct RARE
in O
the O
diagnosis O
of O
Cushing RARE
' O
s O
syndrome O
. O

Most O
of O
the O
patients O
had O
locally O
advanced O
lesions O
( O
63 O
T3 O
- O
4 O
: O
91 O
. O
5 O
%) O
according O
to O
the O
adopted O
TNM ALLCAPS
system O
( O
Lederman RARE
- O
Gadeberg RARE
, O
Sisson RARE
- O
Jesse RARE
). O

The O
risk O
for O
these O
complications O
is O
increased O
by O
the O
following O
factors O
: O
multiple O
gestation O
, O
the O
combination O
of O
magnesium O
sulfate O
and O
beta O
- O
adrenergic O
agonist O
, O
and O
the O
use O
of O
adrenocortico RARE
- O
steroids O
to O
hasten RARE
fetal O
pulmonary O
maturity RARE
. O

Chlorambucil RARE
and O
interferon I-GENE
for O
low O
grade O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

Selenium RARE
(. RARE
1 O
ppm O
) O
and O
E O
( O
50 O
IU O
/ O
kg O
) O
supplementation O
of O
the O
diet O
of O
the O
sow RARE
increased O
plasma O
tocopherol RARE
and O
Se RARE
concentrations O
, O
but O
did O
not O
increase O
plasma I-GENE
glutathione I-GENE
peroxidase I-GENE
( O
GSH ALLCAPS
- I-GENE
Px I-GENE
) O
activity O
. O

Framingham RARE
Type O
A O
behavior O
was O
positively O
associated O
with O
diastolic O
blood O
pressure O
( O
r O
= O
0 O
. O
17 O
, O
p O
less O
than O
0 O
. O
05 O
) O
among O
the O
women O
. O

The O
in O
vitro O
antibacterial RARE
potency O
is O
greatest O
when O
the O
1 O
- O
substituent RARE
is O
2 O
, O
4 O
- O
difluorophenyl RARE
and O
the O
7 O
- O
substituent RARE
is O
a O
3 O
- O
amino O
- O
1 O
- O
pyrrolidinyl RARE
group O
. O

The O
M I-GENE
reading I-GENE
frame I-GENE
differed O
from O
the O
reported O
sequence O
by O
a O
single O
nucleotide O
corresponding O
to O
a O
conservative O
lysine O
to O
arginine O
amino O
acid O
substitution O
near O
the O
carboxy O
- O
terminus O
conserved O
among O
the O
M I-GENE
proteins I-GENE
of O
paramyxoviruses RARE
. O

An O
ion O
chromatographic O
method O
was O
used O
to O
determine O
Br O
ion O
in O
the O
urine O
of O
Greyhounds RARE
. O

II O
. O

Laryngographic RARE
changes O
following O
endotracheal RARE
intubation RARE
in O
adults O
. O

Intensification RARE
of O
human O
myocardial O
contractile O
activity O
as O
affected O
by O
blood O
serum O

Autotransplantation RARE
of O
a O
vein O
segment O
with O
valve O
in O
the O
treatment O
of O
deep O
vein O
valvular RARE
insufficiency O
of O
the O
lower O
extremity RARE

The O
relationships O
among O
four O
descriptors RARE
of O
lactate O
increase O
: O
lactate O
threshold O
( O
LT ALLCAPS
) O
( O
the O
VO2 O
at O
which O
blood O
lactate O
concentration O
begins O
to O
increase O
above O
the O
resting O
level O
during O
an O
incremental RARE
exercise O
test O
), O
LT1 NUMERIC
( O
the O
VO2 O
at O
which O
blood O
lactate O
increases O
1 O
mM O
above O
the O
resting O
level O
), O
LT2 NUMERIC
( O
the O
VO2 O
at O
which O
blood O
lactate O
concentration O
reaches RARE
a O
fixed O
value O
of O
2 O
mM O
), O
onset O
of O
blood O
lactate O
accumulation O
( O
OBLA ALLCAPS
; O
the O
VO2 O
at O
which O
blood O
lactate O
reaches RARE
a O
concentration O
of O
4 O
mM O
), O
were O
compared O
with O
aerobic O
capacity O
( O
VO2max NUMERIC
) O
and O
12 O
min O
running RARE
performance O
in O
19 O
untrained RARE
female O
students O
. O

This O
is O
based O
on O
partitioning RARE
an O
underlying O
multivariate O
normal O
distribution O
. O

The O
observation O
of O
late O
effects O
after O
irradiations RARE
or O
after O
space O
flights RARE
show O
the O
difficulties RARE
encountered RARE
in O
assessing O
radiative RARE
risks RARE
during O
long O
duration O
space O
flights RARE
. O

Practical RARE
use O
and O
interpretation O
of O
viral O
hepatitis O
B O
markers O
and O
hepatic O
biopsy O
in O
HBs I-GENE
Ag I-GENE
carriers O
and O
at O
the O
chronic O
hepatitis O
stage O

The O
1 O
, O
2 O
, O
3 O
and O
4 O
year O
survival O
rates O
were O
94 O
%, O
84 O
%, O
76 O
% O
and O
63 O
%, O
respectively O
. O

Inhibition O
of O
histalog RARE
- O
stimulated O
gastric O
secretion O
by O
40 O
749 NUMERIC
RP O
, O
a O
new O
long O
- O
acting O
gastric O
antisecretory RARE
agent O
. O

Five O
- O
year O
prospective O
study O
of O
peripheral O
white O
blood O
cells O
in O
infectious O
mononucleosis RARE
. O

Northern O
blotting O
with O
a O
unique O
17 O
- O
mer O
oligonucleotide O
demonstrated O
the O
absence O
of O
the O
mutant O
sequence O
in O
the O
mRNA O
from O
which O
the O
cDNA O
library O
giving O
rise O
to O
the O
mutant O
cDNA O
was O
constructed O
. O

Novel RARE
multigene RARE
families O
encoding O
highly O
repetitive O
peptide O
sequences O
. O

Chemotherapy RARE
of O
metastasizing RARE
breast O
cancer O

In O
recent O
years O
, O
successful O
physiological O
models O
have O
been O
developed O
for O
a O
variety O
of O
volatile O
and O
nonvolatile RARE
chemicals RARE
, O
and O
their O
ability O
to O
perform O
the O
extrapolations RARE
needed O
in O
risk O
assessment O
has O
been O
demonstrated O
. O

Linear RARE
extrapolation RARE
is O
used O
below O
the O
experimental O
data O
range O
to O
establish O
an O
upper O
bound O
on O
carcinogenic RARE
risk O
at O
low O
doses O
. O

Hisako RARE
Minowa RARE
who O
has O
worked RARE
as O
a O
psychiatric O
counsellor RARE
in O
industry RARE
for O
the O
past O
20 O
years O

Deletion O
mapping O
studies O
revealed O
that O
the O
upstream O
DNA O
sequences O
up O
to O
- O
86 O
were O
sufficient O
for O
the O
optimal O
basal O
level O
transcription O
in O
HeLa O
cells O
and O
also O
for O
the O
EIA I-GENE
- O
induced O
transcription O
. O

Incorporation RARE
of O
the O
polyene RARE
antibiotic O
amphotericin O
B O
( O
AMB ALLCAPS
) O
in O
liposomes O
results O
in O
a O
marked O
reduction O
in O
drug O
toxicity O
with O
no O
loss O
of O
antifungal RARE
potency O
. O

Eleven RARE
healthy O
, O
normotensive RARE
males O
undergoing O
routine O
restorative RARE
dental O
care O
were O
evaluated O
during O
treatment O
for O
possible O
hemodynamic O
alterations O
in O
response O
to O
potential O
sympathetic O
nervous O
system O
stimulation O
. O

Serum I-GENE
IgM I-GENE
and O
IgE I-GENE
concentrations O
, O
allergen I-GENE
- I-GENE
specific I-GENE
IgE I-GENE
scores O
, O
and O
the O
tumor O
E2R NUMERIC
status O
were O
combined O
to O
construct O
a O
three O
- O
level O
risk O
classification O
that O
was O
more O
prognostic O
than O
any O
of O
the O
individual O
components O
. O

The O
M O
- O
3 O
subtype O
was O
an O
adverse O
prognostic O
factor O
. O

Within O
the O
Strep RARE
. O
mutans RARE
group O
there O
was O
a O
highly O
- O
significant O
difference O
between O
Strep RARE
. O
mutans RARE
/ O
Strep RARE
. O
cricetus RARE
( O
p O
less O
than O
0 O
. O
01 O
) O
with O
respect O
to O
mean O
clump RARE
size O
. O

These O
results O
indicate O
that O
T O
. O
C O
., O
LDL I-GENE
- I-GENE
C I-GENE
., O
HDL I-GENE
- I-GENE
C I-GENE
., O
HDL2 I-GENE
- I-GENE
C I-GENE
., O
apo I-GENE
B I-GENE
, O
apo I-GENE
A I-GENE
- I-GENE
I I-GENE
/ I-GENE
B I-GENE
ratio O
and O
apo I-GENE
A I-GENE
- I-GENE
II I-GENE
/ I-GENE
B I-GENE
ratio O
are O
predictive O
risk O
factors O
of O
the O
coronary O
heart O
disease O
. O

It O
is O
concluded O
that O
the O
unique O
suppository RARE
formulation O
of O
CZX ALLCAPS
- O
S O
is O
useful O
in O
the O
treatment O
of O
infections O
in O
children O
with O
heavy O
psychophysiologic RARE
disorders O
and O
in O
children O
who O
cannot O
take O
oral O
drugs O
because O
of O
severe O
vomiting RARE
. O

In O
addition O
, O
marked O
hypertension O
accompanied O
this O
disorder O
and O
all O
abnormalities O
, O
including O
the O
hypertension O
, O
responded O
to O
1 I-GENE
- I-GENE
desamino RARE
- I-GENE
8 I-GENE
- I-GENE
D I-GENE
- I-GENE
arginine I-GENE
vasopressin I-GENE
therapy O
. O

Single RARE
photon O
emission O
computerized O
tomography O
( O
SPECT O
), O
by O
providing O
three O
- O
dimensional O
representation RARE
of O
myocardial O
Tl O
- O
201 O
, O
offers O
promise RARE
for O
improved O
localization O
of O
CAD O
. O

Computer RARE
assisted RARE
mapping O
in O
quantitative O
analysis O
of O
cerebral O
positron RARE
emission O
tomograms RARE
. O

In O
19 O
patients O
vagotomy O
not O
only O
curbed RARE
the O
bleeding O
but O
provided O
definitive O
therapy O
( O
Visick RARE
I O
- O
II O
); O
4 O
patients O
died O
( O
mortality O
rate O
16 O
%). O

Documentation RARE
of O
a O
successful O
intrauterine O
fertilization O
with O
delivery O
of O
a O
term O
baby RARE
supports O
the O
theoretical RARE
feasibility O
of O
the O
EP ALLCAPS
; O
however O
, O
anovulation RARE
incurred RARE
by O
our O
procedure O
appears O
to O
be O
the O
major O
drawback RARE
. O

MRI O
disclosed RARE
one O
or O
more O
of O
the O
following O
abnormalities O
in O
24 O
( O
63 O
%) O
of O
38 O
treated O
kidneys O
: O
( O
1 O
) O
loss O
of O
corticomedullary RARE
differentiation O
, O
( O
2 O
) O
perirenal RARE
fluid O
, O
( O
3 O
) O
subcapsular RARE
hematoma RARE
, O
( O
4 O
) O
hemorrhage O
into O
a O
renal O
cyst O
, O
and O
( O
5 O
) O
unexplained RARE
abnormalities O
. O

The O
results O
obtained O
are O
similar O
to O
those O
described O
with O
the O
previous O
Cremophor RARE
formulation O
although O
greater O
variability O
in O
induction O
and O
recovery O
times O
was O
noted O
with O
the O
emulsion RARE
formulation O
. O

The O
percentage O
RFR ALLCAPS
reduction O
at O
the O
end O
of O
CPB O
showed O
significant O
correlation O
with O
1 O
) O
CPB O
duration O
( O
r O
= O
0 O
. O
49 O
), O
2 O
) O
oxygen O
flow O
rate O
index O
( O
OFRI ALLCAPS
), O
i O
. O
e O
. O
flow O
/ O
min O
in O
the O
bubble RARE
oxygenator RARE
/ O
m2 O
bsa RARE
( O
r O
= O
0 O
. O
38 O
), O
and O
3 O
) O
blood O
flow O
rate O
index O
( O
BFRI ALLCAPS
), O
i O
. O
e O
. O
average O
volume O
of O
blood O
pumped RARE
through O
the O
heart O
- O
lung O
machine O
/ O
min O
CPB O
time O
/ O
m2 O
bsa RARE
( O
r O
= O
0 O
. O
51 O
). O

Diagnosis O
of O
unilateral O
renal O
artery O
lesions O
after O
captopril O
administration O
. O

A O
yeast O
DNA O
fragment O
carrying O
the O
gene I-GENE
CP I-GENE
A1 I-GENE
encoding O
the O
small O
subunit O
of O
the O
arginine O
pathway O
carbamoyl RARE
- I-GENE
phosphate I-GENE
synthetase I-GENE
has O
been O
sequenced O
. O

A O
retrospective O
study O
of O
banked RARE
sera O
from O
19 O
cats O
with O
the O
eosinophilic RARE
granuloma O
complex O
revealed O
that O
68 O
% O
of O
affected O
cats O
had O
circulating O
antibodies O
to O
components O
of O
normal O
cat O
epithelium O
. O

In O
memory O
of O
Magdelaine RARE
Comtesse RARE

The O
H2 I-GENE
receptor I-GENE
antagonists O
and O
sucralfate RARE
cost O
about O
the O
same O
and O
have O
few O
side O
effects O
. O

These O
results O
suggest O
that O
indoramin RARE
may O
have O
Class O
III O
antiarrhythmic O
activity O
. O

A O
high O
efficacy O
of O
the O
combined O
use O
of O
nontoxic RARE
doses O
of O
two O
pharmaceuticals RARE
: O
cystamine RARE
( O
50 O
mg O
/ O
kg O
) O
and O
mexamine RARE
( O
25 O
mg O
/ O
kg O
) O
under O
the O
conditions O
of O
short O
- O
term O
exogenous O
hypoxia O
( O
7 O
. O
5 O
% O
O2 O
) O
was O
found O
in O
( O
CBA ALLCAPS
X O
C57Bl NUMERIC
) O
F1 O
mice O
. O

The O
Mean O
was O
74 O
, O
3 O
+/- O
53 O
, O
6 O
micrograms O
J O
/ O
g O
Cr O
, O
the O
Median RARE
61 O
micrograms O
J O
/ O
g O
Cr O
. O

In O
the O
region O
Walgau RARE
with O
mixed O
industrial RARE
- O
rural RARE
population O
an O
iodine O
deficiency O
I O
was O
found O
in O
81 O
% O
and O
an O
iodine O
deficiency O
II O
in O
45 O
%. O

The O
structural O
gene O
for O
hydrogenase RARE
encodes O
a O
protein O
product O
of O
molecular O
mass O
45820 NUMERIC
Da O
. O

Pancreaticoduodenal RARE
lymph O
node O
enlargement O
, O
regardless O
of O
cause O
, O
has O
been O
a O
source O
of O
imaging O
confusion RARE
because O
of O
its O
propensity O
to O
mimic O
pancreatic O
malignancy O
yet O
not O
cause O
biliary O
obstruction O
. O

Interference RARE
with O
rheumatoid I-GENE
factor I-GENE
was O
only O
observed O
in O
the O
ELISA O
enzygnost RARE
if O
sera O
were O
not O
pretreated O
with O
latex O
adsorbents RARE
. O

All O
patients O
had O
elevated O
levels O
of O
serum I-GENE
IgE I-GENE
antibodies I-GENE
to O
the O
crude O
soybean O
extract O
; O
binding O
values O
ranged O
from O
2 O
. O
3 O
to O
28 O
. O
1 O
times O
that O
of O
a O
negative O
control O
serum O
. O

New O
techniques O
for O
the O
mass O
spectrometry O
of O
natural O
products O
. O

Dual RARE
radionuclide RARE
subtraction RARE
imaging O
of O
the O
spleen O
using O
67Ga NUMERIC
citrate O
and O
99mTc O
is O
useful O
in O
further O
delineating RARE
lesions O
that O
are O
identified O
on O
either O
a O
routine O
radiogallium RARE
survey O
or O
on O
a O
conventional O
sulfur O
colloid O
liver O
- O
spleen O
image O
. O

Such O
studied O
acquired O
with O
low O
energy O
or O
medium O
energy O
collimation RARE
and O
a O
window RARE
centered O
on O
the O
159 NUMERIC
keV LASTCAP
123I NUMERIC
photopeak RARE
contain O
appreciable RARE
septal O
breakthrough RARE
signals O
originating RARE
from O
Compton RARE
scatter RARE
of O
high O
energy O
photons RARE
primarily O
from O
124I NUMERIC
. O

Nursing RARE
education O
-- O
the O
computer O
obligation RARE
. O

Shear RARE
bond O
strength O
of O
a O
composite O
resin O
to O
an O
etched RARE
glass O
ionomer RARE
. O

An O
additional O
advantage O
is O
that O
the O
resin O
can O
be O
removed O
and O
the O
immunoperoxidase RARE
technique O
carried O
out O
on O
thin O
sections O
. O

Such O
a O
concept O
is O
crucial O
to O
our O
understanding O
of O
the O
pathology O
of O
ageing RARE
in O
general O
. O

We O
consider O
that O
DIL ALLCAPS
- O
CP O
is O
a O
safe O
and O
excellent O
CP O
in O
CABG ALLCAPS
surgery O
and O
we O
are O
now O
utilizing O
this O
CP O
in O
all O
patients O
requiring O
CABG ALLCAPS
surgery O
. O

We O
have O
earlier O
evolved O
an O
experimental O
model O
by O
means O
of O
which O
changes O
identical O
to O
the O
microembolism RARE
syndrome O
can O
be O
induced O
from O
a O
reproducible RARE
musculo RARE
- O
skeletal O
trauma O
in O
pigs O
observed O
under O
long O
- O
term O
anesthesia O
under O
standardized O
conditions O
. O

Although O
no O
statistical O
significance O
was O
achieved O
, O
it O
is O
remarkable O
that O
there O
was O
a O
clear O
trend O
for O
the O
superiority RARE
of O
Galphimia RARE
D6 NUMERIC
while O
the O
Galphimia RARE
dilution O
10 O
(- O
6 O
) O
was O
about O
equally O
effective O
compared O
with O
placebo O
. O

The O
volume O
of O
blood O
to O
the O
flap O
ranges RARE
from O
1 O
to O
2 O
ml O
/ O
min O
, O
collateral O
circulation O
to O
the O
flap O
exists O
, O
but O
is O
negligible RARE
, O
and O
there O
is O
little O
change O
in O
the O
capillary O
blood O
flow O
as O
the O
flap O
ages O
. O

With O
aging O
, O
many O
aspects O
of O
immune O
function O
change O
. O

Oral RARE
candidiasis O

In O
addition O
, O
the O
gcd1 NUMERIC
- I-GENE
101 I-GENE
mutation I-GENE
suppressed O
the O
low O
translational O
efficiency O
of O
GCN4 I-GENE
- O
lacZ I-GENE
mRNA O
observed O
in O
gcn2 NUMERIC
- I-GENE
and O
gcn3 NUMERIC
- I-GENE
cells O
. O

This O
suggests O
that O
alaproclate RARE
acutely RARE
increases O
the O
responsiveness O
of O
postsynaptic RARE
muscarinic RARE
and I-GENE
alpha I-GENE
1 I-GENE
adrenoceptors I-GENE
. O

The O
concentrations O
of O
apo I-GENE
A I-GENE
- I-GENE
I I-GENE
and O
apo I-GENE
A I-GENE
- I-GENE
II I-GENE
of O
abstainers RARE
decreased O
significantly O
compared O
with O
the O
corresponding O
changes O
in O
controls O
. O

The O
distribution O
of O
patients O
was O
as O
follows O
: O
group O
1 O
-- O
complex O
gamma O
- O
therapy O
( O
55 O
cases O
), O
group O
2 O
-- O
complex O
gamma O
- O
therapy O
plus O
iliac O
lymphadenectomy RARE
( O
50 O
cases O
) O
and O
group O
3 O
-- O
complex O
radiation O
treatment O
with O
megavolt RARE
bremsstrahlung RARE
beam O
from O
the O
luc RARE
type O
installation RARE
and O
iliac O
lymphadenectomy RARE
( O
50 O
cases O
). O

The O
availability O
of O
cryoprecipitate RARE
and O
DDAVP ALLCAPS
offers O
an O
alternative O
and O
effective O
treatment O
for O
the O
temporary O
reversal O
of O
uremic RARE
bleeding O
in O
patients O
who O
require O
urgent RARE
invasive O
procedures O
. O

Thrombophlebitis RARE
and O
pulmonary O
embolism RARE
in O
congenital O
factor I-GENE
XII ALLCAPS
deficiency O

Biopsies RARE
of O
the O
jejunal RARE
mucosa O
have O
shown O
abnormal O
enzyme O
activity O
or O
deficiencies O
in O
transport O
mechanisms O
. O

Laboratory O
pyrolyses RARE
have O
indeed O
shown O
that O
PCBs RARE
give O
significant O
yields O
of O
PCDFs RARE
, O
and O
chlorobenzenes RARE
give O
both O
PCDFs RARE
and O
PCDDs RARE
. O

A O
significant O
degree O
of O
homology O
was O
also O
found O
among O
these O
genes O
and O
the O
Mtase RARE
gene I-GENE
of O
related O
phage O
SPR ALLCAPS
, O
which O
codes O
for O
an O
enzyme O
with O
different O
modification O
specificity O
. O

Thyrotropin RARE
- I-GENE
releasing I-GENE
hormone I-GENE
- O
induced O
contraction O
of O
urethral RARE
and O
vaginal O
muscle O
. O

In O
a O
blind O
controlled O
trial O
, O
15 O
patients O
with O
COCM ALLCAPS
( O
NYHA ALLCAPS
II O
- O
III O
) O
with O
sinus O
rhythm O
and O
a O
left O
ventricular O
ejection O
fraction O
( O
LV O
- O
EF O
) O
of O
34 O
. O
5 O
+/- O
2 O
. O
6 O
% O
received O
consecutively RARE
D O
( O
0 O
. O
25 O
- O
0 O
. O
5 O
mg O
/ O
d O
), O
placebo O
( O
PLAC ALLCAPS
), O
P O
( O
slow O
releases RARE
= O
SR O
) O
( O
80 O
mg O
/ O
d O
SR O
) O
and O
both O
drugs O
combined O
in O
respective O
doses O
. O

Mild RARE
orbital RARE
discomfort RARE
occurred O
in O
some O
patients O
. O

The O
sample O
is O
deproteinized RARE
and O
after O
centrifugation RARE
valproic RARE
acid O
in O
the O
supernatant O
is O
measured O
in O
the O
free O
form O
by O
direct O
injection O
into O
the O
gas O
chromatograph RARE
. O

Changes O
in O
muscarinic RARE
acetylcholine I-GENE
receptors I-GENE
in O
guinea O
- O
pig O
lung O
: O
effects O
of O
aging O
, O
inhalation O
of O
an O
allergen O
, O
administration O
of O
drugs O
, O
and O
vagotomy O
. O

In O
the O
absence O
of O
other O
stabilizers RARE
, O
increased O
sucrose O
can O
provide O
increased O
thermoresistance RARE
to O
the O
virus O
in O
2 O
. O
5 O
% O
albumin I-GENE
. O

The O
overall O
prevalence O
of O
psoriasis O
was O
4 O
. O
79 O
% O
in O
men O
and O
4 O
. O
85 O
% O
in O
women O
. O

Greek RARE
classicism RARE
in O
living O
structure O
? O
Some O
deductive RARE
pathways O
in O
animal O
morphology O
. O

The O
possible O
origin O
and O
role O
of O
CSF I-GENE
prolactin I-GENE
are O
discussed O
. O

Three O
chromosomal I-GENE
crsA LASTCAP
mutations I-GENE
, O
crsA1 NUMERIC
, O
crsA4 NUMERIC
, O
and O
crsA47 NUMERIC
, O
were O
transferred O
by O
the O
" O
gene O
conversion O
" O
process O
to O
B O
. O
subtilis O
plasmid O
pRPD11 NUMERIC
, O
which O
consists O
of O
the O
entire O
wild I-GENE
- I-GENE
type I-GENE
rpoD LASTCAP
coding I-GENE
sequence I-GENE
, O
encoding O
the O
major I-GENE
sigma I-GENE
43 I-GENE
factor I-GENE
of I-GENE
B I-GENE
. I-GENE
subtilis I-GENE
RNA I-GENE
polymerase I-GENE
, O
and O
pUB110 NUMERIC
. O

Selective O
effect O
of O
pulmonary O
oedema RARE
on O
prostaglandin O
E2 O
pharmacokinetics O
in O
rat O
lung O
. O

This O
article O
will O
briefly RARE
review O
the O
published O
data O
on O
the O
morphology O
, O
function O
, O
and O
biochemistry RARE
of O
the O
normal O
renal O
medulla RARE
and O
the O
pathology O
associated O
with O
RPN ALLCAPS
, O
together O
with O
the O
secondary O
changes O
which O
give O
rise O
to O
cortical O
degeneration O
or O
epithelial O
carcinoma O
. O

The O
data O
indicate O
that O
the O
five O
different O
( O
and O
partially O
overlapping O
) O
sry RARE
messenger I-GENE
RNAs I-GENE
detectable O
in O
early O
embryos O
are O
initiated O
at O
three O
separate O
sites O
, O
each O
directly O
upstream O
from O
one O
of O
the O
three O
protein O
- O
coding O
regions O
, O
designated O
( O
in O
5 O
' O
to O
3 O
' O
order O
) O
beta O
, O
alpha O
and O
delta O
. O

Chronic O
thyroiditis O
as O
a O
risk O
factor O
of O
B O
- O
cell O
lymphoma O
in O
the O
thyroid O
gland O
. O

Plasma I-GENE
secretin RARE
levels O
also O
augmented O
after O
the O
administration O
of O
ethanol O
solutions O
, O
with O
a O
delay O
of O
about O
one O
hour O
after O
the O
onset O
of O
acid O
secretion O
. O

Spectrophotometric RARE
microanalysis RARE
of O
ethylenediaminotetracetic RARE
acid O
in O
pharmaceutical RARE
preparations O

A O
comparison O
among O
the O
5 O
' O
flanking O
regions O
encompassing O
the O
presumptive RARE
HS I-GENE
promoter I-GENE
of O
the O
soybean I-GENE
HS I-GENE
- I-GENE
protein I-GENE
genes I-GENE
demonstrated O
this O
region O
to O
be O
extremely O
homologous O
. O

Results O
of O
this O
study O
indicate O
that O
GLC ALLCAPS
of O
short O
chain O
fatty O
acids O
produced O
on O
agar O
medium O
by O
anaerobes RARE
, O
combined O
with O
simple O
tests O
such O
as O
Gram O
' O
s O
stain O
and O
colonial RARE
morphology O
, O
may O
allow O
fir RARE
direct O
presumptive RARE
genus O
identification O
from O
an O
initial O
pure O
agar O
culture O
. O

Using O
this O
method O
, O
we O
measured O
absorption O
of O
low O
doses O
of O
vitamin O
A O
, O
which O
may O
provide O
a O
more O
physiological O
approach O
to O
assessment O
of O
fat O
malabsorption RARE
. O

Fulminant RARE
hepatitis O
A O
in O
chronic O
HBV O
carrier O
. O

Tissue O
pressure O
, O
rCBF O
, O
and O
water O
content O
were O
measured O
from O
gray O
matter O
in O
the O
central O
core O
and O
the O
peripheral O
margin O
of O
the O
MCA ALLCAPS
territory RARE
over O
6 O
h O
after O
MCAO ALLCAPS
. O

During O
this O
time O
, O
the O
patients O
all O
had O
the O
characteristic O
plasma O
thyroid O
hormone O
changes O
associated O
with O
amiodarone RARE
therapy O
, O
i O
. O
e O
. O
increased O
T4 O
, O
free O
T4 O
, O
and O
rT3 NUMERIC
and O
decreased O
T3 O
, O
while O
remaining O
clinically O
euthyroid RARE
. O

Drug O
and O
nutrient O
interactions O
. O

In O
each O
compartment O
O2 O
is O
removed O
by O
the O
tissues O
as O
a O
chemical O
reaction O
takes RARE
place O
between O
O2 O
and O
oxyhemoglobin RARE
( O
HbO2 NUMERIC
). O

To O
evaluate O
the O
effects O
of O
propranolol O
on O
myocardial O
metabolism O
after O
coronary O
reperfusion O
, O
serial O
measurements O
of O
myocardial I-GENE
creatine I-GENE
kinase I-GENE
( O
CK I-GENE
) O
and O
calcium O
( O
Ca O
) O
contents O
and O
CK I-GENE
and O
lactic RARE
acid O
( O
LA O
) O
concentrations O
in O
coronary O
sinus O
blood O
were O
carried O
out O
in O
33 O
open O
- O
chest O
dogs O
. O

Dissolution RARE
of O
the O
Pt RARE
- O
30 O
% O
Ir RARE
microelectrode RARE
tip O
was O
observed O
by O
scanning O
electron O
microscopy O
at O
charge O
densities RARE
as O
low O
as O
200 O
microC LASTCAP
/ O
cm2 O
X O
ph RARE
( O
1 O
A O
/ O
cm2 O
), O
whereas O
erosion RARE
of O
activated O
iridium RARE
microelectrodes RARE
occurred O
only O
at O
the O
highest O
charge O
and O
current O
densities RARE
( O
3200 NUMERIC
microC LASTCAP
/ O
cm2 O
X O
ph RARE
, O
16 O
A O
/ O
cm2 O
). O

Cortisol RARE
excretion O
, O
appeared O
to O
be O
markedly O
affected O
by O
the O
season O
although O
other O
factors O
such O
as O
social O
and O
environmental O
stress O
cannot O
be O
discounted RARE
. O

Two O
studies O
on O
the O
relationship O
between O
taking O
a O
commercial O
coaching RARE
course O
and O
performance O
on O
the O
Medical RARE
College RARE
Admission RARE
Test O
( O
MCAT ALLCAPS
) O
are O
reported O
. O

A O
total O
of O
90 O
patients O
were O
randomly O
allocated O
either O
to O
an O
MY ALLCAPS
- O
1 O
treated O
or O
an O
untreated O
group O
. O

Below RARE
50 O
% O
decrease O
of O
PaO2 O
, O
NADH O
was O
reduced O
largely O
. O

Angiography RARE
was O
performed O
following O
the O
rCBF O
study O
and O
the O
degree O
of O
vasospasm RARE
was O
measured O
on O
the O
angiograms RARE
. O

The O
results O
from O
the O
first O
five O
years O
of O
follow O
up O
in O
1972 O
showed O
a O
4 O
. O
7 O
- O
fold O
excess O
mortality O
for O
ischaemic O
and O
other O
heart O
diseases O
( O
ICD ALLCAPS
A83 NUMERIC
- O
A84 NUMERIC
) O
compared O
with O
a O
comparable O
reference O
cohort O
of O
paper O
mill RARE
workers O
. O

The O
financial RARE
impact O
of O
childhood O
asthma O
has O
not O
been O
assessed O
since O
Vance RARE
and O
Taylor RARE
reported O
their O
data O
in O
Annals RARE
of O
Allergy RARE
13 O
years O
ago RARE
. O

Hypersplenism RARE

Electrical RARE
activity O
was O
evaluated O
by O
monitoring O
the O
general O
electrocorticogram RARE
( O
ECoG LASTCAP
) O
as O
well O
as O
local O
DC O
steady O
potential O
( O
two O
sites O
). O

The O
topography RARE
and O
trajectories RARE
of O
the O
commissural RARE
fibers O
of O
the O
superior O
temporal O
region O
( O
STR ALLCAPS
) O
are O
studied O
using O
the O
autoradiographic RARE
technique O
. O

The O
diabetic O
state O
was O
characterized O
by O
mild O
insulin I-GENE
deficiency O
, O
plasma O
levels O
being O
73 O
% O
of O
controls O
, O
and O
mild O
hyperglycemia RARE
, O
with O
nonfasting RARE
plasma O
glucose O
levels O
of O
1 O
. O
5 O
times O
normal O
. O

The O
primary O
CT O
findings O
were O
misinterpreted RARE
as O
a O
brain O
infarct O
or O
possibly O
a O
tumour O
. O

No O
consistent O
correlation O
between O
blood O
pressure O
change O
and O
SCR ALLCAPS
- O
change O
was O
seen O
. O

Shoulder RARE
forearm RARE
support O
for O
the O
subluxed RARE
shoulder RARE
. O

Piroxicam RARE
produced O
a O
lower O
incidence O
of O
gastric O
ulcers O
than O
equivalent O
doses O
of O
indomethacin O
. O

These O
findings O
suggest O
that O
both O
in O
the O
early O
stages O
( O
0T NUMERIC
, O
0N NUMERIC
) O
and O
in O
more O
severe O
stages O
of O
VWF ALLCAPS
( O
stages O
1 O
- O
2 O
) O
cold O
induced O
hyperreactivity RARE
in O
the O
digital O
vessels O
and O
Raynaud RARE
' O
s O
syndrome O
are O
vascular O
disorders O
of O
functional O
origin O
occurring O
without O
any O
prethrombotic RARE
alterations O
. O

In O
MCCP ALLCAPS
functions O
of O
the O
source O
emission O
, O
surface O
reflection RARE
, O
photoacceptor RARE
sensitivity O
are O
approximated RARE
by O
the O
normal O
distribution O
curves O
. O

However O
, O
kidneys O
perfused O
for O
72 O
hr O
demonstrated O
more O
similar O
renal O
functions O
when O
tested O
by O
either O
IMPK ALLCAPS
or O
IBPK ALLCAPS
. O

To O
assess O
the O
effects O
of O
alveolar O
hypoxia O
and O
angiotensin I-GENE
II I-GENE
infusion O
on O
distribution O
of O
blood O
flow O
to O
the O
lung O
we O
performed O
perfusion O
lung O
scans O
on O
anesthetized O
mechanically RARE
ventilated O
lambs O
. O

A O
flow O
rate O
of O
at O
least O
5 O
mL O
/ O
h O
is O
required O
through O
the O
receptor O
( O
volume O
, O
0 O
. O
4 O
mL O
) O
for O
accurate O
results O
. O

We O
have O
now O
located O
the O
5 O
' O
ends O
of O
the O
two O
remaining O
late O
mRNAs O
. O

The O
efficacy O
of O
quantitative O
and O
qualitative O
chloride O
titrators RARE
in O
the O
estimation O
of O
human O
salt O
intake O
. O

Doctor RARE
Berglund RARE
warns RARE
members O
of O
union RARE
pitfalls RARE
. O

Acute O
appearance O
of O
hemiparesis RARE
or O
hemiplegia RARE
with O
initial O
marked O
spasticity RARE
was O
observed O
in O
8 O
stroke O
patients O
. O

Recurrent RARE
acute O
rhinosinusitis RARE
was O
common O
in O
both O
groups O
of O
patients O
, O
but O
the O
development O
of O
chronic O
rhinosinusitis RARE
was O
only O
found O
in O
patients O
with O
CVID ALLCAPS
, O
indicating O
the O
more O
severe O
nature O
of O
this O
condition O
compared O
with O
selective O
IgA I-GENE
deficiency O
. O

These O
data O
suggest O
that O
AP I-GENE
- I-GENE
A I-GENE
may O
be O
potentially O
useful O
in O
the O
management O
of O
heart O
failure O
. O

The O
various O
muscles O
of O
the O
pelvic RARE
floor O
region O
could O
be O
reflexly RARE
activated O
either O
individually O
or O
as O
a O
mass O
unit O
depending O
on O
the O
intensity O
of O
stimulation O
. O

It O
has O
been O
reported O
that O
rat O
blood O
chloroform RARE
levels O
were O
significantly O
decreased O
after O
treatment O
with O
ClO2 NUMERIC
. O

The O
frequency O
of O
lactase RARE
phenotypes I-GENE
in O
Aymara RARE
children O
. O

Activities RARE
of O
hepatic O
cytochrome I-GENE
P I-GENE
- I-GENE
450 I-GENE
- O
dependent O
metabolizing RARE
enzymes O
such O
as O
aminopyrine RARE
- I-GENE
and I-GENE
TMO ALLCAPS
N I-GENE
- I-GENE
demethylase RARE
and O
aniline RARE
hydroxylase I-GENE
activity O
were O
decreased O
by O
pretreatment O
of O
rats O
with O
cimetidine O
, O
whereas O
in O
the O
rats O
pretreated O
with O
ranitidine O
, O
these O
enzyme O
activities O
were O
not O
changed O
. O

Doxorubicin RARE
, O
dacarbazine RARE
, O
vincristine O
, O
and O
cyclophosphamide O
in O
the O
treatment O
of O
advanced O
gastrointestinal O
leiomyosarcoma RARE
. O

The O
effect O
of O
the O
opiate O
antagonist O
naloxone O
was O
evaluated O
in O
11 O
unselected RARE
patients O
with O
cerebral O
ischemia O
. O

Electrochemical RARE
detection O
of O
depressed O
circulating O
levels O
of O
vitamin O
K1 O
in O
osteoporosis RARE
. O

In O
the O
present O
experiments O
, O
we O
investigate O
the O
role O
played O
by O
the O
temporal O
pattern O
of O
neural O
activity O
during O
the O
ontogeny RARE
of O
frequency O
tuning RARE
in O
the O
mouse O
central O
auditory O
system O
. O

Ultrastructure RARE
of O
the O
tumor O
in O
1 O
patient O
in O
whom O
transurethral RARE
resection O
was O
performed O
2 O
weeks O
after O
alum RARE
irrigation O
revealed O
well O
preserved RARE
nuclear O
chromatin O
, O
thus O
, O
suggesting O
that O
whatever RARE
changes O
occur O
after O
alum RARE
irrigation O
are O
short O
- O
lived RARE
. O

The O
generally O
adopted O
criteria O
enabling RARE
to O
classify RARE
the O
examined O
persons O
into O
the O
following O
3 O
groups O
have O
been O
used O
: O
( O
a O
) O
diseased O
of O
BEN ALLCAPS
; O
( O
b O
) O
suspect RARE
to O
be O
diseased O
of O
BEN ALLCAPS
, O
and O
( O
c O
) O
individuals O
without O
signs O
of O
a O
renal O
disease O
. O

For O
this O
purpose O
, O
a O
simple O
respiration O
- O
control O
device O
has O
been O
developed O
that O
enables O
the O
patient O
to O
monitor O
breath RARE
- O
holding RARE
during O
successive O
scans O
. O

The O
POEMS ALLCAPS
syndrome O
( O
Polyneuropathy RARE
, O
Organomegaly RARE
, O
Endocrinopathy RARE
, O
Monoclonal RARE
component O
, O
Skin RARE
). O

During O
a O
disease O
remission O
there O
was O
an O
increase O
in O
GAG ALLCAPS
secretion O
with O
urine O
, O
linked O
with O
hyperheparinuria RARE
( O
13 O
. O
1 O
- O
fold O
, O
P O
less O
than O
0 O
. O
001 O
). O

In O
metastasis O
- O
free O
patients O
, O
the O
best O
results O
were O
obtained O
with O
tumor O
diameters O
under O
2 O
cm O
regardless O
of O
their O
localization O
in O
lung O
tissue O
and O
with O
2 O
-- O
4 O
. O
9 O
cm O
tumors O
embedded O
in O
lung O
parenchyma O
. O

Two O
siblings RARE
with O
hemolytic RARE
anemia O
caused O
by O
triosephosphate RARE
isomerase I-GENE
deficiency O
developed O
a O
progressive O
neurological O
syndrome O
featuring RARE
dystonic RARE
movements O
, O
tremor O
, O
pyramidal O
tract O
signs O
, O
and O
evidence O
of O
spinal O
motor O
neuron O
involvement O
. O

One O
extract O
with O
the O
lowest O
PCA ALLCAPS
content O
was O
non O
- O
carcinogenic RARE
. O

In O
the O
10 O
patients O
with O
a O
more O
severe O
degree O
of O
steatorrhea RARE
the O
decrease O
in O
fat O
loss O
approached RARE
20 O
% O
and O
a O
close O
relationship O
was O
found O
( O
r O
= O
0 O
. O
84 O
, O
p O
less O
than O
0 O
. O
01 O
) O
between O
the O
extent O
of O
the O
fatty O
acid O
loss O
on O
placebo O
and O
the O
decrease O
of O
this O
loss O
on O
taurine RARE
. O

Aortic RARE
diameters O
in O
infants O
and O
young O
children O
: O
normative RARE
angiographic O
data O
. O

The O
present O
investigation O
has O
revealed O
that O
the O
distribution O
of O
the O
main O
fatty O
acids O
in O
Leptospira RARE
phospholipids O
is O
similar O
to O
their O
distribution O
in O
Leptospira RARE
neutral O
lipids O
with O
the O
exception O
of O
unsaturated RARE
fatty O
acid O
with O
14 O
carbon O
atoms RARE
, O
occurring O
mainly O
in O
phospholipids O
. O

Since O
1970 NUMERIC
the O
frequency O
of O
potassium O
- O
induced O
ulceration O
has O
been O
low O
-- O
3 O
cases O
per O
100 O
000 O
patient O
- O
years O
of O
slow O
- O
release O
tablet O
use O
. O

Hydrocortisone RARE
caused O
lymphopenia RARE
and O
inhibited O
the O
blastogenic RARE
response O
of O
peripheral O
blood O
lymphocytes O
to O
phytohemagglutinin I-GENE
and O
concanavalin RARE
A I-GENE
mitogens RARE
. O

To O
test O
the O
feasibility O
of O
using O
liposomes O
to O
deliver RARE
therapeutic O
agents O
to O
the O
lungs O
, O
the O
effect O
of O
liposome RARE
- O
encapsulated RARE
superoxide I-GENE
dismutase I-GENE
( O
SOD I-GENE
) O
or O
catalase I-GENE
on O
pulmonary O
oxygen O
toxicity O
was O
studied O
in O
rats O
. O

Marrow RARE
cell O
necrosis O
in O
anorexia RARE
nervosa RARE
and O
involuntary RARE
starvation O
. O

For O
comparison O
conventional O
heparin O
was O
used O
during O
18 O
dialyses RARE
in O
the O
same O
patients O
. O

Chenodeoxycholic RARE
acid O
( O
cheno RARE
) O
and O
ursodeoxycholic RARE
acid O
( O
urso RARE
) O
dissolve RARE
cholesterol O
gallstones RARE
in O
man O
. O

Sensory RARE
evoked O
field O
potentials O
were O
recorded O
from O
the O
mesencephalic RARE
reticular RARE
formation O
( O
MRF ALLCAPS
), O
central O
gray O
( O
CG O
) O
and O
somatosensory RARE
cortex O
( O
SCX ALLCAPS
), O
following O
incremental RARE
doses O
of O
halothane O
in O
freely RARE
- O
moving RARE
rats O
. O

Ultrastructure RARE
of O
the O
heart O
muscle O
in O
experimental O
myocardial O
infarct O
following O
physical O
training O

Pharmacological RARE
desympathization RARE
leads O
to O
the O
development O
of O
hyper RARE
- O
reactivity O
of O
the O
true O
pacemakers RARE
to O
noradrenaline O
and O
dopamine O
and O
triggers O
off O
changes O
in O
the O
regulation O
of O
the O
electric RARE
activity O
of O
these O
cells O
by O
catecholamines O
. O

OODG ALLCAPS
is O
a O
diagnostic O
method O
permitting RARE
assessment O
of O
ocular O
pulse O
curves O
and O
objective O
determination O
of O
blood O
pressures O
in O
the O
ophthalmic O
circulatory O
system O
( O
retinal O
and O
ciliary RARE
arterial O
blood O
pressures O
) O
simultaneously O
for O
both O
eyes O
, O
without O
dilatation O
of O
the O
pupils RARE
. O

Viral RARE
infections O
have O
long O
been O
suspected O
to O
be O
causative RARE
agents O
in O
a O
number O
of O
inner O
ear O
dysfunctions RARE
. O

55 O
+/- O
11 O
%), O
all O
other O
parameters O
showed O
a O
significant O
increase O
: O
RS O
index O
5 O
. O
4 O
+/- O
1 O
. O
4 O
mVolt RARE
to O
6 O
. O
0 O
+/- O
1 O
. O
7 O
mVolt RARE
( O
p O
less O
than O
0 O
. O
01 O
); O
EDD ALLCAPS
6 O
. O
3 O
+/- O
0 O
. O
7 O
to O
6 O
. O
8 O
+/- O
0 O
. O
9 O
cm O
( O
p O
less O
than O
0 O
. O
001 O
); O
HV ALLCAPS
1017 NUMERIC
+/- O
151 O
ml O
to O
1099 NUMERIC
+/- O
261 NUMERIC
ml O
( O
p O
less O
than O
0 O
. O
01 O
); O
EDV ALLCAPS
371 NUMERIC
+/- O
131 O
ml O
to O
441 NUMERIC
+/- O
175 O
ml O
( O
p O
less O
than O
0 O
. O
001 O
); O
RBV ALLCAPS
117 O
+/- O
57 O
ml O
to O
151 O
+/- O
77 O
ml O
( O
p O
less O
than O
0 O
. O
001 O
). O

Retrospective RARE
analyses O
of O
this O
death O
revealed O
a O
significant O
decrease O
of O
the O
left O
ventricular O
( O
LV O
) O
end O
- O
diastolic O
volume O
index O
( O
EDVI ALLCAPS
) O
of O
21 O
ml O
/ O
m2 O
( O
36 O
% O
of O
normal O
). O

In O
group O
I O
adults O
both O
of O
these O
variables O
increased O
. O

Polysorbate RARE
80 O
did O
not O
have O
a O
direct O
stimulant RARE
or O
relaxant RARE
effect O
on O
either O
guinea O
pig O
ileum RARE
or O
rat O
uterus RARE
, O
however O
, O
it O
antagonised RARE
the O
contractions O
induced O
by O
acetylcholine O
, O
histamine O
, O
barium RARE
, O
5 O
- O
hydroxytryptamine RARE
and O
carbachol O
in O
a O
dose O
- O
dependent O
manner O
. O

Individual RARE
alcohol O
reaction O
profiles O
. O

Vitiligo RARE
in O
diabetes O
mellitus O
. O

The O
pharmacokinetics O
of O
each O
tetracycline RARE
in O
serum O
and O
dermal O
, O
suction RARE
blister RARE
fluid O
were O
determined O
after O
oral O
doses O
of O
300 O
mg O
lymecycline RARE
or O
100 O
mg O
doxycycline RARE
on O
the O
3rd NUMERIC
day O
. O

A O
high O
degree O
of O
correlation O
in O
the O
sense O
of O
the O
classic RARE
conception RARE
of O
brain O
localization O
of O
neuropsychological RARE
syndromes O
was O
found O
. O

Either RARE
a O
UV O
detector O
set O
at O
268 NUMERIC
nm O
or O
an O
electrochemical RARE
( O
EC O
) O
detector O
set O
at O
a O
potential O
of O
+ O
0 O
. O
9 O
V O
( O
versus O
Ag O
/ O
AgCl RARE
/ O
3 O
M O
NaCl O
) O
was O
used O
to O
monitor O
the O
drug O
. O

35 O
patients O
with O
acute O
arterial O
occlusions RARE
[ O
27 O
] O
and O
graft O
thromboses RARE
[ O
8 O
], O
responsible O
for O
severe O
and O
recent O
ischemia O
, O
were O
treated O
by O
fibrinolytic RARE
therapy O
( O
Urokinase RARE
: O
1 O
000 O
units O
/ O
kg O
/ O
hour O
, O
and O
Lys O
Plasminogen RARE
). O

The O
mean O
transfer O
ratios O
of O
the O
drug O
into O
the O
genital O
tissues O
to O
the O
concentration O
in O
the O
uterine O
arterial O
blood O
were O
such O
that O
the O
transfer O
ratio O
into O
the O
portio RARE
vaginalis RARE
was O
the O
highest O
, O
followed O
by O
the O
uterine O
cervix O
and O
the O
myometrium RARE
, O
and O
that O
into O
the O
oviduct RARE
was O
the O
lowest O
with O
about O
1 O
/ O
2 O
that O
into O
the O
portio RARE
vaginalis RARE
. O

We O
conclude O
that O
androgenic RARE
hormones O
reduce O
HDL I-GENE
- I-GENE
cholesterol I-GENE
concentrations O
and O
the O
HDL2 I-GENE
- I-GENE
cholesterol I-GENE
subfraction RARE
, O
possibly O
by O
enhancing O
hepatic I-GENE
triglyceride RARE
lipase I-GENE
activity O
. O

Because O
of O
its O
wide O
spectrum O
of O
activity O
particularly O
against O
ampicillin RARE
resistant O
strains O
of O
H O
. O
influenzae O
and O
because O
of O
its O
good O
tolerance O
Cefaclor RARE
is O
very O
useful O
in O
treatment O
of O
respiratory O
tract O
infections O
in O
children O
. O

Lower RARE
extremity RARE
weight O
bearing O
under O
various O
standing RARE
conditions O
in O
independently O
ambulatory O
patients O
with O
hemiparesis RARE
. O

Shape RARE
factor O
correlated O
well O
with O
hemodynamic O
data O
for O
RV O
/ O
LV O
systolic O
pressure O
ratios O
( O
r O
= O
0 O
. O
93 O
, O
p O
less O
than O
0 O
. O
001 O
) O
for O
normalized O
interventricular RARE
pressure O
differences O
( O
r O
= O
- O
0 O
. O
95 O
, O
p O
less O
than O
0 O
. O
001 O
). O

The O
effective O
and O
low O
toxic O
dose O
schedules RARE
of O
KW ALLCAPS
- O
2083 NUMERIC
should O
be O
investigated O
further O
. O

Furthermore O
, O
the O
initial O
plasma O
retinol O
level O
in O
conjunction O
with O
RBP ALLCAPS
was O
found O
to O
be O
even O
lower O
in O
12 O
patients O
( O
35 O
. O
1 O
micrograms O
dl O
- O
1 O
, O
3 O
. O
7 O
mg O
dl O
- O
1 O
) O
who O
subsequently O
had O
cancer O
recurrence O
than O
in O
those O
who O
remained O
free O
of O
apparent O
cancer O
( O
44 O
. O
5 O
micrograms O
dl O
- O
1 O
, O
4 O
. O
6 O
mg O
dl O
- O
1 O
). O

The O
results O
indicate O
that O
: O
1 O
) O
the O
initial O
response O
to O
tethering RARE
varies RARE
according O
to O
previous O
penning RARE
and O
handling RARE
experience O
, O
2 O
) O
although O
the O
circadian O
rhythm O
of O
cortisol O
was O
either O
altered O
or O
disrupted O
during O
estrus RARE
, O
such O
disruptions RARE
were O
not O
influenced O
by O
type O
of O
penning RARE
and O
3 O
) O
tether RARE
stalls RARE
may O
chronically RARE
increase O
cortisol O
concentrations O
in O
gilts RARE
. O

This O
laser O
provided O
sufficient O
power O
in O
an O
amniotic O
fluid O
medium O
to O
occlude RARE
placental O
vessels O
as O
large O
as O
7 O
mm O
in O
diameter O
within O
6 O
seconds RARE
at O
a O
power O
density O
of O
2000 O
W O
/ O
cm2 O
. O

On O
d O
112 O
, O
progesterone O
was O
higher O
( O
P O
less O
than O
. O
05 O
) O
in O
hysterectomized RARE
heifers O
than O
in O
other O
treatment O
groups O
. O

Male RARE
Japanese O
quail RARE
were O
chronically RARE
exposed O
to O
5000 NUMERIC
ppm O
manganese RARE
( O
Mn RARE
) O
as O
particulate O
manganese RARE
oxide O
( O
Mn3O4 NUMERIC
) O
in O
their O
diet O
from O
hatching RARE
to O
75 O
days O
of O
age O
. O

This O
study O
indicated O
that O
the O
Japanese O
quail RARE
was O
less O
sensitive O
to O
particulate O
Mn3O4 NUMERIC
exposure O
than O
rodents RARE
treated O
comparably RARE
. O

Plasma O
and O
bladder O
platinum RARE
concentration O
were O
measured O
following O
intravesical RARE
DDP O
, O
and O
also O
histopathological O
examination O
, O
urinalysis RARE
, O
complete O
blood O
count O
and O
blood O
chemistry O
were O
performed O
in O
order O
to O
know RARE
the O
toxicity O
of O
intravesical RARE
DDP O
. O

Scintigraphic RARE
visualisation RARE
of O
Walker RARE
carcinoma O
- O
256 O
in O
Sprague O
- O
Dawley O
rats O
by O
means O
of O
99mTc O
- O
labelled O
monocytes O
. O

These O
results O
were O
compared O
with O
those O
obtained O
in O
- O
D O
mothers O
and O
pups RARE
, O
after O
giving O
the O
mothers O
an O
oral O
supplement RARE
( O
10 O
i O
. O
u RARE
. O
vitamin O
D3 O
/ O
day O
) O
during O
the O
period O
of O
lactation RARE
( O
20 O
days O
). O

Rabbit RARE
eyes O
were O
removed O
and O
held O
in O
temperature O
- O
regulated O
chambers RARE
and O
irrigated RARE
with O
saline O
. O

Before RARE
birth O
, O
there O
were O
a O
few O
perivascular RARE
adrenergic O
nerves O
and O
correspondingly RARE
low O
ovarian O
NE O
levels O
. O

Monitoring RARE
changes O
in O
the O
heart O
rate O
of O
the O
premature O
fetus O
during O
tocolysis RARE
with O
the O
beta O
- O
adrenomimetics RARE
partusisten RARE
and O
Pre RARE
- O
par RARE

Since O
September RARE
1980 O
to O
June RARE
1983 O
we O
have O
treated O
32 O
patients O
with O
ovarian O
cancer O
. O

The O
results O
suggest O
that O
the O
calcium O
antagonist O
, O
diltiazem O
, O
may O
modify O
the O
effects O
of O
isoflurane O
on O
myocardial O
function O
. O

Supraventricular RARE
arrhythmias O
-- O
digoxin RARE
and O
quinidine RARE
revisited RARE
. O

Visidex RARE
I O
is O
unsuitable RARE
for O
storage O
and O
re O
- O
reading O
. O

Treatment O
with O
oxyphenylbutazone RARE
and O
hydrocortisone RARE
failed O
to O
inhibit O
the O
raised O
serum I-GENE
CPN ALLCAPS
levels O
. O

40 O
, O
000 O
). O

The O
Cox O
proportional RARE
hazards RARE
model O
was O
applied O
to O
the O
data O
in O
order O
to O
determine O
the O
prognostic O
factors O
for O
long O
- O
term O
survival O
. O

This O
suggests O
that O
mechanisms O
other O
than O
an O
excessive O
increase O
in O
myocardial O
oxygen O
demand O
may O
be O
responsible O
for O
the O
many O
episodes O
occurring O
outside O
the O
hospital O
. O

Duration RARE
of O
remission O
in O
advanced O
gastric O
cancer O
patients O
responding O
to O
sequential O
dose O
of O
MTX ALLCAPS
and O
5 O
- O
FU O

These O
data O
showed O
: O
that O
progesterone O
secretion O
is O
pulsatile RARE
throughout O
the O
human O
luteal O
phase O
, O
with O
maximum O
frequency O
in O
the O
mid O
- O
luteal O
phase O
; O
that O
during O
the O
mid O
- O
luteal O
phase O
most O
subjects O
had O
progesterone O
levels O
both O
above O
and O
below O
currently O
accepted O
ovulatory RARE
thresholds RARE
; O
the O
use O
of O
a O
single O
measurement O
of O
progesterone O
in O
the O
mid O
- O
luteal O
phase O
is O
not O
always O
a O
reliable O
indicator O
of O
ovulation O
; O
a O
threshold O
greater O
than O
20 O
nmol O
/ O
l O
may O
yield O
an O
unacceptable RARE
number O
of O
false O
negative O
results O
. O

The O
fast O
real O
- O
time O
digital O
processing O
of O
the O
N2 O
and O
flow O
signals O
incorporated O
filtering RARE
, O
delay O
compensation RARE
, O
and O
corrections RARE
for O
the O
effects O
of O
changes O
in O
gas O
composition O
and O
temperature O
. O

This O
slope O
tended O
to O
be O
higher O
( O
approximately O
1 O
. O
6 O
dB LASTCAP
/ O
dB LASTCAP
) O
for O
L1 O
= O
L2 O
greater O
than O
80 O
dB LASTCAP
. O

Histamine RARE
reactivity O
was O
significantly O
reduced O
after O
the O
nifedipine O
aerosol RARE
, O
the O
geometric RARE
mean O
provocative RARE
concentration O
causing O
a O
35 O
% O
fall O
in O
specific O
airway O
conductance O
, O
rising RARE
from O
5 O
. O
0 O
to O
10 O
. O
9 O
mg O
/ O
ml O
of O
histamine O
( O
p O
less O
than O
0 O
. O
05 O
). O

Pharmacologic RARE
doses O
of O
vitamin O
B6 O
administered O
to O
lactating RARE
women O
have O
been O
reported O
to O
suppress O
plasma I-GENE
prolactin I-GENE
. O

There O
was O
a O
significant O
but O
similar O
elevation O
of O
mean O
O2 O
uptake O
during O
40 O
min O
postexercise RARE
by O
13 O
. O
6 O
% O
in O
both O
the O
fasted O
( O
p O
less O
than O
0 O
. O
001 O
) O
and O
fed O
state O
( O
p O
less O
than O
0 O
. O
001 O
). O

National O
Institutes RARE
of O
Health O
Consensus RARE
Development RARE
Conference RARE
Statement RARE
. O

In O
controls O
, O
most O
of O
the O
output O
from O
the O
conduit RARE
occurred O
during O
type O
I O
activity O
( O
73 O
+/- O
14 O
%). O

Greater RARE
attenuation O
of O
the O
N1 O
- O
P2 O
and O
baseline O
- O
P2 O
amplitude O
of O
the O
probe O
EPs RARE
was O
observed O
when O
the O
probe O
stimulus O
was O
presented O
to O
the O
right O
ear O
and O
the O
verbal RARE
material O
presented O
to O
the O
left O
ear O
than O
when O
the O
opposite O
stimulation O
arrangement O
was O
used O
. O

Twenty O
- O
five O
patients O
( O
80 O
, O
6 O
%) O
with O
mixed O
neoplasms O
were O
operated O
on O
by O
total O
conservative O
parotidectomy RARE
( O
T O
. O
C O
. O
P O
.), RARE
3 O
( O
9 O
, O
7 O
%) O
by O
S O
. O
P O
. O
and O
3 O
( O
9 O
, O
7 O
%) O
by O
En RARE
. O

The O
comparisons O
revealed O
that O
female O
homicide RARE
- O
suicide O
perpetrators RARE
were O
more O
likely O
than O
female O
homicide RARE
- O
suicide O
victims O
to O
live O
in O
mobile O
homes RARE
, O
kill RARE
their O
lover RARE
or O
ex RARE
- O
lover RARE
, O
have O
their O
crime RARE
accidentally RARE
discovered O
, O
leave RARE
a O
suicide O
note RARE
, O
kill RARE
on O
a O
weekend RARE
, O
and O
be O
depressed O
, O
but O
are O
less O
likely O
than O
female O
homicide RARE
- O
suicide O
victims O
to O
live O
with O
a O
spouse RARE
. O

Germ RARE
- O
free O
rabbits O
given O
mouse O
CRF O
- O
flora RARE
showed O
values O
quite O
different O
from O
control O
animals O
for O
most O
parameters O
, O
indicating O
unsuitability RARE
of O
mouse O
CRF O
flora RARE
to O
' O
normalize RARE
' O
rabbits O
. O

The O
weak O
relationships O
between O
F O
and O
Zn O
to O
Mg O
clearly O
have O
no O
significant O
effect O
on O
the O
contents O
of O
these O
elements O
in O
bone O
. O

L3 NUMERIC
- O
L4 NUMERIC
compressive RARE
load O
was O
calculated O
using O
a O
model O
of O
the O
anatomy RARE
of O
the O
trunk O
musculoskeletal RARE
system O
. O

Diagnosis O
: O
progressive O
multifocal RARE
leukoencephalopathy RARE
. O

Component RARE
P100 NUMERIC
was O
associated O
with O
a O
frontal O
negativity RARE
of O
similar O
latency O
favoring RARE
the O
hypothesis O
of O
a O
dipolar RARE
occipital RARE
generator RARE
. O

Although O
no O
differences O
were O
noted O
in O
the O
decrease O
in O
platelet O
counts O
between O
the O
two O
groups O
, O
fibrinogen I-GENE
levels O
and O
alpha I-GENE
2 I-GENE
- I-GENE
antiplasmin RARE
levels O
declined O
less O
drastically RARE
in O
the O
antithrombin I-GENE
- O
treated O
group O
. O

Failure RARE
of O
stapedius RARE
reflexometry RARE
in O
the O
diagnosis O
of O
myasthenia RARE
gravis RARE
. O

Factors O
influencing O
semen O
characteristics O
in O
young O
boars RARE
reared RARE
in O
a O
subtropical RARE
environment O
were O
studied O
. O

[ O
14C O
]- RARE
beta O
- O
phenethylamine RARE
, O
its O
distribution O
after O
administration O
by O
various O
routes O
to O
cats O
, O
and O
the O
effects O
of O
monoamine I-GENE
oxidase I-GENE
inhibitors O
. O

All O
runners RARE
drank RARE
a O
total O
of O
1 O
. O
4 O
L O
of O
water O
during O
the O
race RARE
. O

The O
rates O
of O
total O
energy O
use O
( O
mean O
+/- O
SD O
= O
39 O
. O
3 O
+/- O
1 O
. O
2 O
vs O
35 O
. O
7 O
+/- O
1 O
. O
3 O
kJ LASTCAP
X O
min O
- O
1 O
; O
P O
less O
than O
0 O
. O
05 O
) O
were O
significantly O
higher O
at O
- O
10 O
degrees O
C O
than O
at O
22 O
degrees O
C O
. O

Clinical O
aspects O
and O
therapy O

Following O
seven O
days O
' O
incubation O
both O
at O
20 O
degrees O
C O
and O
28 O
degrees O
C O
, O
Ae RARE
. O
vexans RARE
nip RARE
. O
was O
capable O
of O
transmitting RARE
the O
virus O
. O

Blood O
eosinophils O
in O
patients O
with O
Taenia RARE
saginata RARE
taeniasis RARE
. O

The O
imino RARE
proton O
of O
T3 O
in O
the O
O6meG NUMERIC
. O
T O
12 O
- O
mer O
and O
G3 NUMERIC
in O
the O
O6meG NUMERIC
. O
N O
12 O
- O
mer O
helix O
, O
which O
are O
associated O
with O
the O
modification O
site O
, O
resonate RARE
at O
unusually O
high O
field O
( O
8 O
. O
5 O
to O
9 O
. O
0 O
ppm O
) O
compared O
to O
imino RARE
protons RARE
in O
Watson RARE
- O
Crick RARE
base O
pairs O
( O
12 O
. O
5 O
to O
14 O
. O
5 O
ppm O
). O

The O
recommendation RARE
is O
made O
that O
specific O
sub O
- O
groups O
of O
attempters RARE
need O
to O
be O
identified O
and O
may O
warrant RARE
specialized O
intervention O
strategies O
. O

There O
was O
no O
correlation O
between O
secretor RARE
status O
and O
clinical O
status O
, O
spirometry RARE
measurements O
, O
salivary I-GENE
and I-GENE
serum I-GENE
lysozyme I-GENE
levels O
or O
rates O
of O
respiratory O
tract O
colonization RARE
with O
P O
. O
aeruginosa O
and O
S O
. O
aureus O
. O

There O
was O
no O
correlation O
between O
secretor RARE
status O
and O
clinical O
status O
, O
spirometry RARE
measurements O
, O
salivary O
and O
serum I-GENE
lysozyme I-GENE
levels O
or O
rates O
of O
respiratory O
tract O
colonization RARE
with O
P O
. O
aeruginosa O
and O
S O
. O
aureus O
. O

Gains RARE
increased O
3 O
. O
5 O
% O
( O
P O
less O
than O
. O
10 O
) O
and O
feed O
conversion O
improved O
5 O
. O
9 O
% O
( O
P O
less O
than O
. O
07 O
) O
in O
steers O
fed O
. O
28 O
% O
AS O
- O
VFA ALLCAPS
compared O
with O
gain O
and O
feed O
conversion O
of O
the O
control O
steers O
. O

Postnatal RARE
volumetric RARE
development O
of O
the O
prefrontal RARE
cortex O
in O
the O
rat O
. O

Daily RARE
and O
seasonal RARE
rhythmicity RARE
in O
the O
methylation O
of O
pineal O
indolic RARE
compounds O
in O
adult O
male O
golden RARE
hamsters O
, O
kept O
under O
natural O
conditions O
. O

The O
transit O
time O
was O
significantly O
shortened O
. O

Among O
the O
patients O
grades RARE
1 O
- O
2 O
- O
3 O
, O
81 O
% O
had O
a O
good O
out O
come RARE
without O
any O
neurological O
abnormality O
, O
among O
the O
patients O
graded RARE
4 O
- O
5 O
, O
only O
27 O
% O
had O
a O
fair RARE
out O
come RARE
. O

Activity RARE
of O
acid I-GENE
hydrolases RARE
of O
peripheral O
blood O
leukocytes RARE
in O
focal O
and O
segmental O
pneumonia O
in O
children O

Comparative O
studies O
of O
the O
antithrombin I-GENE
III I-GENE
level O
and O
plasminogen I-GENE
activator I-GENE
activity O
in O
patients O
with O
thrombophlebitis RARE

We O
also O
observed O
that O
the O
predictive O
ability O
of O
the O
selected O
attitudes RARE
and O
orientations RARE
increased O
considerably O
from O
1975 NUMERIC
to O
1982 O
. O

Relations RARE
between O
cellular O
electrical O
activity O
and O
cardiac O
mechanical O
activity O
in O
man O
, O
the O
dog O
and O
the O
rabbit O

Treatment O
of O
Paget RARE
' O
s O
disease O
. O

Improvement RARE
of O
the O
CRT ALLCAPS
display O
of O
an O
averager RARE
. O

Is O
desensitization RARE
' O
for O
ragweed RARE
hay RARE
fever O
immunologically RARE
specific O
? O

Renal O
excretion O
of O
sulphadimidine RARE
in O
normal O
and O
uraemic RARE
subjects O
. O

Experiences RARE
with O
the O
clinical O
and O
experimental O
use O
of O
Urat RARE
- O
I O
lithotriptor RARE
. O

Formation RARE
of O
hyphae RARE
and O
chlamydospores RARE
by O
Cryptococcus RARE
laurentii RARE
. O

Evaluation O
of O
thyroid O
function O
. O

The O
effect O
of O
a O
tissue O
emulsion RARE
, O
vitamin O
A O
and O
nonspecific O
gamma I-GENE
- I-GENE
globulin I-GENE
on O
the O
blood O
clearance O
in O
rabbits O

HL I-GENE
- I-GENE
A I-GENE
antibodies I-GENE
in O
polytransfused RARE
patients O

Demonstration RARE
of O
fine O
structure O
of O
the O
guinea O
pig O
organ O
of O
Corti RARE
after O
electron O
microscopic O
silver O
staining O

Histamine RARE
metabolism O
in O
hemorrhagic O
- O
hypotensive O
shock O

They O
also O
discuss O
the O
existing O
nomenclature RARE
. O

Relaxation RARE
of O
catch RARE
in O
a O
molluscan RARE
smooth O
muscle O
. O

Studies O
on O
alcoholic O
liver O
injury O
. O

Hypothalamic RARE
control O
of O
coronary O
circulation O
in O
the O
dog O
. O

Evidence O
for O
two O
distinctive O
clinical O
, O
epidemiological O
, O
and O
immunological RARE
types O
of O
infection O
. O

Ultraviolet RARE
light O
- O
induced O
kinin RARE
formation O
in O
human O
skin O
. O

Poliomyelitis RARE
from O
a O
vaccine O
. O

To O
the O
problem O
of O
the O
stimulation O
of O
the O
growth O
of O
transplantable RARE
tumors O
of O
animals O
previously O
treated O
with O
antineoplastic RARE
antibiotics O

Assessment O
of O
nutrient O
media O
in O
the O
diagnosis O
of O
diptheria RARE

Aluminium RARE
resin O
for O
the O
treatment O
of O
the O
hyperkalamia RARE
of O
renal O
failure O
. O

Value O
of O
the O
EMG O
in O
the O
diagnosis O
of O
a O
cardiomyopathy O
associated O
with O
a O
myotonic RARE
myopathy RARE
. O

D O
. O

Prevention O
of O
maternal O
Rh RARE
sensitization O
: O
anti I-GENE
- I-GENE
Rh RARE
immune I-GENE
globulin I-GENE
. O

Serotonin RARE
levels O
in O
infant O
hypothyroidism O
. O

Cerebrospinal RARE
fluid O
transferrin I-GENE
II I-GENE
studies O
in O
ischemic O
disorders O
of O
the O
central O
nervous O
system O
. O

High O
dosages RARE
of O
D O
- O
penicillamine RARE
in O
pulmonary O
fibroses RARE

Inverse RARE
relation O
between O
serum O
IgG I-GENE
concentration O
and O
glucose O
and O
xylose RARE
absorption O
in O
Zambian RARE
African O
adults O
. O

Disorders RARE
of O
platelet O
function O
in O
chronic O
myeloid O
leukemias O

The O
effect O
of O
anticonvulsants RARE
on O
sodium I-GENE
- I-GENE
potassium I-GENE
- I-GENE
activated I-GENE
ATPase I-GENE
, O
sodium O
, O
and O
potassim RARE
in O
cortex O
. O

Effect O
of O
immune O
lymphocytes O
and O
of O
rabbit I-GENE
- I-GENE
anti I-GENE
- I-GENE
lymphocyte I-GENE
globulin I-GENE
( O
RAMLG ALLCAPS
) O
on O
infected O
macrophages O
exposed O
to O
increased O
incubation O
temperature O
in O
vitro O
. O

Estral RARE
cycle O
in O
white O
rats O
in O
the O
low O
and O
high O
mountains RARE
of O
Kirghizia RARE

Lactation RARE
of O
baboons RARE
fed O
a O
low O
protein O
maintenance O
diet O
. O

Studies O
on O
the O
organic O
matrix O
of O
human O
ear O
ossicles RARE

A O
medical O
- O
geographical RARE
review O

Age RARE
and O
sex O
structure O
of O
the O
natural O
population O
of O
Ornithodoros RARE
tatarovski RARE
Ol RARE
. O

Sensitization RARE
to O
hyperlactatemia RARE
induced O
by O
phenformin RARE
after O
subtotal O
ablation O
of O
the O
pancreas O
. O

Vitamin RARE
D3 O
and O
calcium O
absorption O
in O
the O
chick O
. O

The O
incidence O
of O
tumours O
in O
young O
chickens O
. O

Laboratory O
aspects O
with O
particular O
reference O
to O
chemotherapy O
and O
control O
. O

Their O
effect O
on O
the O
guinea O
pig O
vas O
deferens O
. O

Androgens RARE
and O
growth O
. O

Effect O
of O
variations O
in O
time O
interval O
between O
treatment O
with O
BCG O
and O
quartz RARE
dust O
on O
translocation O
of O
quartz RARE
dust O
from O
the O
lungs O
to O
their O
regional O
lymph O
nodes O
. O

Therapeutic RARE
action O
of O
a O
new O
antibiotic O
- O
corticoid RARE
association O
used O
for O
instillations RARE
in O
otology RARE

Clinico RARE
- O
physiological O
experiment O

Enzyme RARE
histochemical RARE
findings O
in O
the O
ultimobranchial RARE
body O
of O
the O
horse O

Familial RARE
glutathione I-GENE
reductase I-GENE
deficiency O
and O
disorder O
of O
glutathione O
synthesis O
in O
the O
erythrocyte O

Studies O
on O
swine O
enteroviruses RARE
. O

Serodiagnosis RARE
of O
ectromelia RARE
in O
laboratory O
mice O

Ultrasound RARE
effect O
on O
the O
cytochrome I-GENE
oxidase I-GENE
activity O

Metastasis RARE
of O
colon O
carcinoma O
to O
the O
lip RARE
. O

Genesis RARE
of O
foam RARE
cells O
: O
study O
in O
rats O
after O
administration O
of O
Cloforex RARE
. O

Pre RARE
- I-GENE
beta I-GENE
- I-GENE
1 I-GENE
lipoprotein I-GENE
and O
early O
detection O
of O
risk O
factors O
for O
coronary O
heart O
disease O
. O

Conditions RARE
influencing O
inhibitors O
of O
the O
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
CSF I-GENE
). O

Absence RARE
of O
action O
potentials O
in O
frog RARE
slow O
muscle O
fibres O
paralysed RARE
by O
botulinum I-GENE
toxin I-GENE
. O

An O
automated O
method O
for O
the O
quantitative O
analysis O
of O
the O
polyamines RARE
putrescine RARE
, O
spermidine RARE
and O
spermine RARE
in O
cerebrospinal O
fluid O
( O
CSF O
) O
was O
used O
to O
analyze O
CSF O
samples O
from O
37 O
patients O
with O
central O
nervous O
system O
( O
CNS O
) O
tumors O
and O
from O
13 O
patients O
without O
tumors O
. O

I O
. O

Disulfiram RARE
and O
the O
drug O
- O
induced O
effects O
on O
motility O
. O

Particles RARE
resembling O
microbodies RARE
in O
normal O
and O
neoplastic O
perianal RARE
glands O
of O
dogs O
. O

Natural RARE
and O
induced O
malarias RARE
in O
western RARE
hemisphere O
monkeys O
. O

A O
study O
in O
vivo O
of O
adrenergic I-GENE
receptors I-GENE
in O
the O
rectum RARE
and O
in O
the O
internal O
and O
sphincter RARE
of O
the O
cat O
. O

Intracranial RARE
arachnoid RARE
cyst O
of O
the O
middle O
fossa RARE
demonstrated O
by O
positive O
99mTc O
brainscintigraphy RARE
. O

Effects O
of O
estrogen O
and O
glucocorticoids O
on O
the O
adrenal O
development O
of O
the O
fetus O
. O

Copper RARE
and O
ceruloplasmin RARE
content O
in O
pregnant O
women O
and O
in O
women O
with O
certain O
gynecological RARE
diseases O

Effect O
of O
noise O
on O
CO O
- O
induced O
increases O
of O
LAP ALLCAPS
and O
GPT ALLCAPS
activity O
in O
the O
plasma O
of O
rats O

Kinetics RARE
of O
calcium O
metabolism O
. O

On O
the O
transport O
of O
mucus O
and O
its O
rheologic RARE
simulants RARE
in O
ciliated RARE
systems O
. O

A O
hydrodynamic RARE
description O
of O
the O
osmotic O
reflection RARE
coefficient O
with O
application O
to O
the O
pore O
theory O
of O
transcapillary RARE
exchange O
. O

Pathology RARE
of O
neuritis RARE
caudae RARE
equinae RARE
in O
the O
horse O

Abnormal O
characteristics O
and O
verticillation RARE
in O
Platynothrus RARE
peltifer RARE

Selected RARE
topics RARE
in O
laboratory O
animal O
medicine O
. O

Problems RARE
common O
to O
pediatrics RARE
and O
anesthesiology RARE

Clinical O
course O
and O
nursing O
care O
of O
patients O
with O
decubitus RARE
ulcer O
-- O
use O
of O
pillows RARE
stuffed RARE
with O
buckwheat RARE
chaff RARE

On O
parents O

From O
the O
Icelandic RARE
Red RARE
Cross O
activities O

Effects O
of O
alcoholism RARE
on O
the O
family O

Treatment O
and O
care O
of O
adult O
diabetes O
mellitus O
without O
coma RARE

Re O
- O
examining O
methylbenzene RARE
( O
toluene O
) O
as O
a O
treatment O
for O
Ancylostomum RARE
caninum RARE
. O

Junctions RARE
between O
cells O
of O
the O
human O
enamel RARE
organ O
. O

Electrocardiograms RARE
of O
the O
month O
. O

Composites RARE
as O
restoration RARE
materials O

Hodgkin O
' O
s O
disease O
. O

Value O
of O
Normotest RARE
and O
antithrombin I-GENE
3 I-GENE
in O
the O
assessment O
of O
liver O
function O
. O

Glutathione RARE
peroxidase I-GENE
in O
human O
red O
cells O
in O
health O
and O
disease O
. O

Histopathologic RARE
response O
of O
gingival RARE
tissues O
to O
hemodent RARE
and O
aluminum O
chloride O
solutions O
as O
tissue O
displacement O
materials O
. O

Changes O
following O
periodontal O
surgery O
. O

Intracellular RARE
pH O
, O
H O
ion O
flux RARE
and O
H O
ion O
permeability O
coefficient O
in O
bullfrog RARE
toe O
muscle O
. O

Teratological RARE
studies O
on O
SF O
- O
837 NUMERIC
. O

Directives RARE
concerning O
medical O
care O

Proceedings RARE
: O
Reversible RARE
complete O
heart O
block O
following O
surgery O
of O
congenital O
heart O
defects O

Method RARE
of O
synthesis O
of O
the O
rheumatoid I-GENE
factor I-GENE
in O
clinico RARE
- O
immunological RARE
studies O

Variations RARE
of O
the O
timing O
of O
deflections RARE
in O
the O
His O
bundle O
recordings O
. O

Extracellular RARE
fibril RARE
formation O
by O
neuroglial RARE
cells O
at O
the O
vitreoretinal RARE
junction O
of O
the O
human O
eye O
. O

Blood O
platelets O
, O
coagulation O
factors O
and O
morphologic O
organ O
changes O
following O
scalding RARE
shock O
in O
rhesus O
monkeys O

Cell O
viability O
and O
lysosomal I-GENE
enzymes I-GENE

State O
- O
approved RARE
schools RARE
of O
nursing O
-- O
R O
. O
N O
., O
1972 O
. O

Further O
investigation O
on O
the O
chemotactic O
influence O
of O
thymic I-GENE
hormone I-GENE
on O
lymphocytes O

1 O
, O
3 O
- O
bis RARE
( O
2 O
- O
chloroethyl RARE
)- O
1 O
- O
nitrosourea RARE
( O
bcnu RARE
) O
and O
other O
nitrosoureas RARE
in O
cancer O
treatment O
: O
a O
review O
. O

Pneumothorax RARE
following O
lung O
abscess O
in O
the O
renal O
transplant O
patient O
. O

Taxonomically RARE
significant O
colour O
changes O
in O
Brevibacterium RARE
linens RARE
probably O
associated O
with O
a O
carotenoid RARE
- O
like O
pigment RARE
. O

Temporal RARE
relationships O
and O
the O
development O
phase O
affected O
. O

A O
short O
history O
of O
dermatology RARE
in O
Lagos RARE
, O
Nigeria RARE
. O

Local RARE
graft O
irradiation O
as O
an O
adjunct RARE
to O
pharmacologic RARE
immunosuppression RARE
. O

Letter O
: O
Salmonella O
detection O

Role O
of O
biocenosis RARE
in O
the O
manifestation O
of O
Shigella RARE
virulence O

The O
effect O
of O
antilymphocyte RARE
sera O
on O
formation O
of O
transplantation O
and O
anti O
- O
infection O
immunity O
in O
mice O

60th NUMERIC
birthday RARE
of O
colonel RARE
prof RARE
. O
e O
. O
cerny RARE
m O
. O
d O
. O

Morphology RARE
of O
bacteriophages RARE
of O
Klebsiella O
bacilli O
. O

Cortical RARE
afferents O
to O
the O
entorhinal RARE
cortex O
of O
the O
Rhesus RARE
monkey O
. O

Mechanism O
of O
immunogenesis RARE
in O
vaccination O
with O
streptomycin RARE
- O
dependent O
mutants O
of O
salmonellae RARE
and O
shigellae RARE
. O

Resistance O
pattern O
of O
Mycobacterium O
tuberculosis O
( O
H O
37 O
Rv RARE
) O
to O
a O
new O
antibiotic O
, O
lividomycin RARE

Pulmonary RARE
arterial O
pressure O
and O
structure O
in O
the O
patas RARE
monkey O
after O
prolonged O
administration O
of O
aminorex RARE
fumarate RARE
. O

Effect O
of O
triftazin RARE
and O
aminazin RARE
on O
hippocampal O
bioelectric RARE
activity O

Sex RARE
ratio O
at O
birth O
. O

Pathological RARE
processes O
in O
the O
cervix O
uteri RARE

Benign RARE
intramural RARE
tumors O
of O
the O
esophagus RARE

General RARE
formulae RARE
for O
estimating O
heritability RARE
in O
a O
population O
with O
related O
parents O
. O

Measurement O
of O
open O
- O
loop O
responses O
to O
electrical O
stimulation O
in O
olfactory O
bulb O
of O
cat O
. O

Glucose RARE
disappearance O
rate O
and O
changes O
in O
plasma O
nutrients RARE
after O
intravenouly RARE
injected O
glucose O
in O
normoglycaemic RARE
and O
hypoglycaemic RARE
underweight RARE
newborns O
. O

Normal RARE
values O
for O
the O
peripheral O
blood O
and O
bone O
marrow O
of O
the O
grey RARE
( O
Armenian RARE
) O
hamster O

The O
relationship O
of O
human O
umbilical RARE
arterial O
and O
venous O
plasma O
levels O
of O
corticosteroids O
to O
gestational O
age O
. O

Antibiotic RARE
effect O
of O
the O
mud RARE
from O
heviz RARE

Sulfuric RARE
acid O
concentration O
in O
the O
catalyzed O
breathalyzer RARE
ampules RARE
. O

Role O
of O
histoclinical RARE
studies O
in O
the O
prophylaxis O
of O
spontaneous O
abortions RARE

Range RARE
behavior O
of O
Hereford RARE
, O
Hereford RARE
x O
Holstein RARE
and O
Holstein RARE
non O
- O
lactating RARE
heifers O
. O

Chemical O
constituents RARE
of O
the O
gentianaceae RARE
V O
: O
tetraoxygenated RARE
xanthones RARE
of O
Swertia RARE
chirata RARE
Buch RARE
.- RARE
Ham RARE
. O

Methyl RARE
mercury RARE
intoxication RARE
in O
rat O
kidneys O
. O

Microdetermination RARE
of O
adrenocortical RARE
steroids O
by O
double O
isotope RARE
method O
. O

Compensative RARE
justice RARE
and O
moral RARE
investment RARE
among O
Japanese O
, O
Chinese O
, O
and O
Koreans RARE
. O

Effects O
of O
cortisone RARE
, O
starvation O
, O
and O
rickets RARE
on O
oxidative O
enzyme O
activities O
of O
epiphyseal RARE
cartilage O
from O
rats O
. O

Metal RARE
coordination O
compounds O
of O
thiabendazole RARE
. O

Estimation RARE
of O
renin I-GENE
secretion O
rate O
and O
renal O
plasma O
flow O
from O
peripheral O
and O
renal I-GENE
vein I-GENE
renin I-GENE
levels O
. O

Disability RARE
insurance RARE
under O
social O
security RARE
. O

Choice RARE
of O
vessel O
. O

Suppression RARE
of O
food O
intake O
in O
the O
rat O
by O
tung RARE
oil O
. O

Studies O
of O
lipoprotein I-GENE
- I-GENE
X I-GENE
( O
LP ALLCAPS
- I-GENE
X I-GENE
) O
and O
bile O
acids O
in O
familial O
LCAT ALLCAPS
deficiency O
. O

Pneumothorax RARE
complicated O
by O
chronic O
steroid O
treatment O
. O

Polycythemia RARE
- O
1973 NUMERIC
. O

Manifest RARE
anxiety O
of O
Vietnam RARE
returnees RARE
and O
undergraduates RARE
. O

Familial RARE
juvenile O
nephronophthisis RARE

Early O
heparin O
therapy O
in O
60 O
children O
with O
acute O
meningococcemia RARE
. O

9 O
, O
11 O
- O
Seco RARE
steroids O
derived O
from O
estradiol O
3 O
- O
methyl O
ether O
. O

Psychological RARE
examinations O
in O
patients O
with O
chronic O
kidney O
insufficiency O

Possibilities RARE
of O
needleless RARE
administration O
of O
various O
substances O
to O
animals O

Change RARE
in O
the O
makeup RARE
of O
the O
blood O
following O
a O
short O
- O
term O
local O
action O
of O
a O
permanent O
magnetic O
field O
on O
the O
human O
body O

Observations RARE
on O
the O
flight RARE
activities O
of O
Chrysops RARE
caecutiens RARE
L O
. O

Combination RARE
of O
3 O
multiple O
primary O
malignant O
and O
benign O
tumors O
of O
the O
breasts RARE
and O
uterus RARE

Analysis O
of O
clearance O
curve O
of O
rose O
bengal RARE
- O
I O
- O
131 O

Proceedings RARE
: O
Barrels RARE
and O
somatotopy RARE
in O
S O
I O
neocortex RARE
of O
the O
brush RARE
- O
tailed RARE
possum RARE
. O

Antivitamin RARE
K O
agents O

Canine RARE
reproduction RARE
: O
effects O
of O
a O
single O
injection O
of O
medroxyprogesterone RARE
acetate O
on O
the O
reproductive O
organs O
of O
the O
bitch RARE
. O

3 O
. O

Hypoglycemic RARE
and O
antidiabetic RARE
properties O

Hematopoietic RARE
system O
in O
streptococcal O
allergy O
. O

Letter O
: O
Aryl RARE
hydrocarbon I-GENE
hydroxylase I-GENE
and O
smoking O
. O

Evaluation O
of O
1 O
, O
10 O
- O
phenanthroline RARE
as O
a O
reagent RARE
for O
sialic RARE
acid O
determinations O
. O

Delta O
- O
aminolevulinic RARE
acid O
in O
physiological O
conditions O
and O
some O
diseases O
in O
children O

Nonteratogenicity RARE
in O
rats O
of O
blighted RARE
potatoes RARE
and O
compounds O
contained O
in O
them O
. O

VII O
. O

Isolation O
of O
tha RARE
avian O
reticuloendothelial RARE
virus O
( O
strain O
T O
). O

Observations RARE
on O
saccules RARE
of O
rats O
exposed O
to O
long O
- O
term O
hypergravity RARE
. O

Effect O
of O
a O
high O
- O
intensity O
SHF ALLCAPS
field O
on O
the O
blood O
coagulation O
system O

The O
levels O
of O
galactosyltransferase RARE
activity O
in O
sera O
from O
normal O
children O
and O
patients O
with O
cystic O
fibrosis O
. O

Lack RARE
of O
effect O
of O
the O
appetite RARE
stimulant RARE
pizotifen RARE
( O
BC ALLCAPS
105 O
) O
on O
the O
absorption O
of O
isonicotinylhydrazine RARE
. O

Relationship RARE
between O
gross O
lesions O
and O
Escherichia O
coli O
serotypes RARE
in O
chronic O
respiratory O
disease O
( O
CRD ALLCAPS
) O
of O
poultry RARE
. O

Plastic RARE
solution O
of O
elbow RARE
joint O
ankylosis RARE
with O
a O
decorticated RARE
cylindrical RARE
flap O

Effects O
of O
ionizing RARE
radiation O
in O
the O
human O
oral O
cavity O
and O
oropharynx RARE
: O
results O
of O
a O
survey O
. O

The O
Twentieth RARE
Anniversary RARE
of O
the O
Pomeranian RARE
Medical RARE
Academy RARE
. O

Immunelectrophoretic RARE
pattern O
of O
Wassermann RARE
reagin RARE
and O
comparison O
of O
the O
appearance O
time O
between O
RPCF ALLCAPS
and O
FTA ALLCAPS
antibodies I-GENE

Motile RARE
nocardoid RARE
Actinomycetales RARE
. O

Electrocardiographic RARE
QRS O
complexes O
and O
vectorcardiographic RARE
QRS O
loop O

Study O
of O
antinuclear RARE
autoantibodies O
by O
immunofluorescence O
technic RARE
in O
collagen I-GENE
diseases O

Cardiac O
preservation O
. O

Labial RARE
bar RARE
. O

Yusuf RARE
Dawood RARE
Docrat RARE
L O
. O
R O
. O
C O
. O
P O
. O

Dr RARE
. O

The O
metabolism O
and O
pharmacology RARE
of O
5 O
- O
fluorouracil O
. O

Spleen RARE
weight O
in O
rats O
during O
tumour O
growth O
and O
in O
homograft RARE
rejection O
. O

Isolation O
of O
Proteus RARE
vulgaris RARE
MC O
- O
63 O
from O
carcinoma O
63 O
and O
its O
antitumor RARE
effect O
on O
Crocker RARE
sarcoma O
180 O
and O
Ehrlich RARE
carcinoma O
. O

Human O
synovial O
fluid O
: O
detection O
of O
a O
new O
component O
. O

Effects O
of O
temperature O
and O
moulting RARE
cycle O
on O
melanin RARE
synthesis O
in O
the O
newt RARE
, O
Triturus RARE
cristatus RARE
. O

Some O
reflexions RARE
apropos RARE
of O
a O
personal O
statistical O
study O
of O
513 NUMERIC
arterial O
embolisms RARE

LA O
- O
3848 NUMERIC
- O
MS O
. O

Immunochemical RARE
studies O
with O
filarial RARE
antigens O
. O

Morphological RARE
and O
functional O
alterations O
noted O
after O
baboon RARE
renal O
allotransplantation RARE
. O

Heterogeneity RARE
of O
human I-GENE
serum I-GENE
albumin I-GENE
. O

Analysis O
of O
corticosteroids O
. O

Reactivities RARE
to O
horse I-GENE
anti I-GENE
- I-GENE
lymphocyte I-GENE
globulin I-GENE
. O

Plasma I-GENE
histaminase RARE
in O
patients O
of O
bronchial O
asthma O
and O
the O
effect O
of O
prednisolone RARE
administration O
on O
it O
. O

A O
comparative O
study O
of O
the O
cortical O
end O
of O
the O
auditory O
analyzer RARE
during O
postnatal O
ontogenesis RARE
in O
lower O
monkeys O
and O
man O

The O
effect O
of O
osmotic O
flow O
on O
the O
distribution O
of O
horseradish RARE
peroxidase I-GENE
within O
the O
intercellular RARE
spaces RARE
of O
toad RARE
bladder O
epithelium O
. O

Immunogenicity RARE
of O
various O
mycobacteria O
and O
the O
corresponding O
levels O
of O
cross O
- O
protection O
developed O
between O
species O
. O

Ten O
- O
year O
experience O
with O
one O
- O
stage O
proctocolectomy RARE
and O
anal RARE
ileostomy RARE
. O

Nitrogen RARE
- O
hydrogen O
tautomerism RARE
in O
porphyrins RARE
and O
chlorins RARE
. O

Factors O
affecting O
the O
inhibition O
of O
phagocytosis RARE
by O
chlorpromazine RARE
. O

Photopic RARE
spectral O
sensitivity O
determined O
electroretinographically RARE
for O
the O
pigeon RARE
eye O
. O

Angiography RARE
of O
aneurysmal RARE
bone O
cyst O
. O

Cholinesterase RARE

Sodium O
restriction O
in O
cardiac O
failure O
. O

Clinical O
and O
angiographic O
examinations O
in O
occlusion O
disease O
of O
the O
great O
intestinal O
arteries O

Serum O
lipid O
changes O
during O
pregnancy O
due O
to O
oral O
calcium O
administration O

Successful RARE
treatment O
of O
candidiasis O
with O
transfer I-GENE
factor I-GENE
. O

A O
possible O
role O
for O
the O
mixed O
function O
oxidase I-GENE
enzyme O
system O
in O
the O
requirement O
for O
selenium O
in O
the O
rat O
. O

Periodic RARE
breathing O
and O
apnea O
in O
preterm O
infants O
. O

Working RARE
session O
report O
: O
in O
vivo O
- O
in O
vitro O
screening O
. O

Clinicopathologic RARE
studies O
in O
feminizing RARE
tumors O
of O
the O
ovary O
. O

On O
the O
constituents RARE
of O
Dryopteris RARE
polylepis RARE

Relation RARE
between O
mixing RARE
ratio O
of O
raw RARE
materials O
and O
composition O
of O
products O
in O
the O
synthesis O
of O
aluminosilicates RARE

Influence O
of O
diet O
on O
urinary O
VMA ALLCAPS
excretion O
. O

Oscilloscope RARE
triggering RARE
circuit O
for O
recording O
long O
transients RARE
at O
fast O
sweep RARE
speeds RARE
. O

Derivatives RARE
of O
boswellic RARE
acids O
. O

The O
status O
of O
education O
and O
training O
programs O
in O
speech O
pathology O
and O
audiology RARE
-- O
1971 NUMERIC
- O
72 O
. O

Coronary O
arteries O
-- O
old O
and O
new O
. O

Antiviral RARE
agents O
. O

Separation RARE
of O
ninhydrin RARE
- O
positive O
compounds O
in O
urine O
by O
the O
combined O
methods O
of O
medium O
- O
tension O
intophoresis RARE
and O
partition RARE
chromatography O

Conservative RARE
treatment O
of O
central O
nervous O
system O
injuries O

Spasmus RARE
nutans RARE
: O
a O
syndrome O
of O
auto RARE
- O
arousal RARE
. O

6 O
. O

1st NUMERIC
data O
on O
the O
immunosuppressive O
therapy O
of O
scleroderma RARE

Slowed RARE
lysosomal I-GENE
enzyme I-GENE
release O
and O
its O
normalization RARE
by O
drugs O
in O
adjuvant O
- O
induced O
polyarthritis RARE
. O

Treatment O
of O
ovarian O
neoplasms O

Experimental O
pancreatitis O
in O
pigs O
. O

Bacterial RARE
metabolism O
of O
4 O
- O
chlorophenoxyacetate RARE
. O

Dynamics RARE
of O
hospital O
stay RARE
in O
peptic RARE
ulcer O
patients O

I O
. O

Surgical RARE
treatment O
of O
pathologic O
scars RARE
of O
myocardial O
infarct O

The O
interaction O
of O
caffeine O
, O
theophylline O
and O
theobromine RARE
with O
monoamine I-GENE
oxidase I-GENE
inhibitors O
. O

Effect O
of O
phenformin RARE
on O
gluconeogenesis RARE
in O
perfused O
rat O
liver O
. O

New O
alkaloids RARE
from O
bark RARE
of O
Erythrophleum RARE
ivorense RARE
. O

A O
case O
of O
M O
hemoglobinosis RARE

Radiosensitive RARE
nature O
of O
paravascular RARE
infiltrate RARE
- O
producing O
potential O
of O
parental O
spleen O
cells O
. O

Sinusoidal RARE
oscillations RARE
of O
a O
gas O
dilution O
indicator O

The O
value O
of O
different O
sources O
of O
nitrogen O
in O
diets O
for O
the O
early O
- O
weaned RARE
calf O
. O

1 O
. O

Abdominal RARE
tumors O
in O
childhood O
. O

Results O
of O
the O
official RARE
inspection RARE
of O
the O
commercial O
anti O
- O
inflammatory O
enzyme O
preparations O
containing O
chymotrypsin RARE
and O
trypsin I-GENE
by O
means O
of O
modified O
NF O
13 O
methods O

Studies O
on O
the O
hereditary O
nature O
of O
sole RARE
prints RARE
-- O
with O
special O
reference O
to O
interdigital RARE
and O
triradii RARE

The O
problem O
of O
disablement RARE
due O
to O
pulmonary O
tuberculosis O
, O
on O
the O
basis O
of O
an O
analysis O
of O
the O
history O
of O
395 NUMERIC
cases O
as O
observed O
in O
Gdansk RARE
in O
the O
years O
1946 NUMERIC
- O
1965 NUMERIC

Cleidocranial RARE
dysostosis RARE

Proposals RARE
on O
authorization RARE
; O
by O
a O
group O
of O
nurses RARE
from O
psychiatric O
hospitals O

Successive RARE
abdominal O
scintillation RARE
with O
131 O
- O
I O
- O
tagged O
BSP O
-- O
description O
of O
the O
thyroid O
gland O
, O
kidney O
and O
spleen O
( O
comparison O
with O
131 O
- O
I O
- O
RB O
) O

Pneumonia RARE
in O
children O

Osteosarcoma RARE
caused O
by O
3 O
, O
4 O
- O
benzopyrene RARE

The O
content O
of O
glucosamine RARE
and O
galactosamine RARE
in O
tartar RARE

Relapse RARE
of O
leukemia O
after O
prolonged O
remission O
. O

Influence O
of O
cigarette RARE
smoking O
on O
some O
blood O
coagulation O
tests O
. O

The O
non O
- O
role O
of O
fluoride O
in O
the O
control O
of O
plasma O
calcium O
in O
the O
parathyroidectomized RARE
rat O
. O

Second O
report O
of O
the O
Norwegian RARE
Cancer O
Society RARE
. O

Modification RARE
of O
the O
growth O
of O
Tetrahymena RARE
by O
compounds O
which O
affect O
the O
adrenergic O
mechanism O
. O

SAM ALLCAPS
- O
TR O
- O
68 O
- O
54 O
. O

A O
brief O
discussion O
of O
color O
deficiencies O
. O

BIM ALLCAPS
130 O
. O

Problems RARE
in O
the O
determination O
of O
the O
antigenic O
content O
of O
influenza O
vaccines O
. O

Aedes RARE
aegypti RARE
( O
L O
.) O
and O
Aedes RARE
albopictus RARE
( O
Skuse RARE
) O
in O
Singapore RARE
City O
. O

Homograft RARE
response O
and O
hemagglutinin I-GENE
production O
by O
sensitized RARE
thymectomized RARE
irradiated O
adult O
mice O
. O

Comparative O
study O
on O
acute O
oral O
overload O
using O
tolbutamide RARE
and O
tolazamide RARE
in O
normal O
and O
diabetic O
subjects O
. O

Mycotoxins RARE
in O
feeds RARE
and O
foods RARE
. O

Factors O
influencing O
in O
vitro O
skin I-GENE
permeability I-GENE
factor I-GENE
production O
by O
Vibrio O
cholerae O
. O

Spinal RARE
cord O
representation RARE
of O
the O
micturition RARE
reflex O
. O

Biological O
action O
and O
kinetics O
of O
the O
elimination O
of O
tritium RARE
oxide O
in O
dogs O

Auto RARE
- O
and O
isotopy RARE
of O
the O
conjunctiva RARE

IX O
. O

Pitfalls RARE
in O
the O
use O
of O
chromosome O
aberration RARE
analysis O
for O
biological O
radiation O
dosimetry RARE
. O

Renin RARE
secretion O
in O
essential O
and O
accelerated O
hypertension O
. O

The O
need O
for O
including O
forensic RARE
medical O
expertise RARE
in O
the O
list RARE
of O
urgent RARE
criminal RARE
investigative RARE
actions O

Histopathology RARE
and O
pathogenesis O
of O
exanthematous RARE
viroses RARE

CNS O
effects O
of O
local O
anesthetics RARE
only O
partially O
dependent O
on O
biogenic RARE
amine O
mechanisms O
. O

Diethylene RARE
benzene RARE

Midge RARE
control O
in O
flood RARE
channels O
. O

The O
effects O
of O
taloximine RARE
and O
aminophylline RARE
on O
isolated O
human O
smooth O
muscle O
. O

The O
exploratory RARE
behaviour O
in O
normal O
and O
aggressive O
mice O
. O

Genitography RARE
in O
intersexual RARE
states O
. O

Tolerance RARE
test O
of O
HB O
419 NUMERIC
in O
animal O
experiments O

The O
role O
of O
ascorbic RARE
acid O
in O
the O
prevention O
of O
bladder O
tumor O
formation O
. O

The O
" O
28 O
percent O
" O
Venturi RARE
mask RARE
in O
obstructive RARE
airway O
disease O
. O

3 O
'- O
Methyl RARE
, O
8 O
- O
methyl O
, O
and O
8 O
- O
phenyl RARE
derivatives O
of O
5 O
, O
9 O
- O
dimethyl O
- O
6 O
, O
7 O
- O
benzomorphans RARE
. O

Antidromic RARE
invasion O
of O
impulses RARE
and O
recurrent O
collateral O
inhibition O
in O
pyramidal O
tract O
neurones O
. O

The O
distribution O
of O
body O
fluids O
following O
hemorrhage O
and O
resuscitation O
in O
combat RARE
casualties RARE
. O

Once O
more O
Hong RARE
Kong RARE
influenza O
in O
the O
Netherlands RARE

Early O
disagnosis RARE
of O
cancer O
-- O
50 O
per O
cent O
of O
all O
patients O
could O
be O
cured RARE

Difficulties RARE
bound O
to O
measuring O
of O
sputum O
viscosity O

Lipid RARE
concentration O
and O
lipase I-GENE
activity O
in O
the O
epiphysis RARE
of O
adrenalectomized RARE
rats O
consuming RARE
food O
with O
different O
sodium O
content O

Behavior RARE
of O
aspartate I-GENE
aminotransferase I-GENE
( O
EC I-GENE
2 I-GENE
. I-GENE
6 I-GENE
. I-GENE
1 I-GENE
. I-GENE
1 I-GENE
) O
and O
alanine I-GENE
aminotransferase I-GENE
( O
EC I-GENE
2 I-GENE
. I-GENE
6 I-GENE
. I-GENE
1 I-GENE
. I-GENE
2 I-GENE
) O
in O
rat O
serum O
during O
the O
course O
of O
acute O
radiation O
syndrome O
following O
whole O
body O
X O
- O
irradiation O

Diminished RARE
forearm RARE
arteriolar RARE
dilator RARE
capacity O
produced O
by O
mineralocorticoid RARE
- O
induced O
salt O
retention O
in O
man O
. O

Studies O
on O
the O
pathogenicity RARE
of O
ECHO O
9 O
( O
HILL ALLCAPS
) O
virus O
and O
its O
mutants O
for O
suckling RARE
mice O

Counter RARE
- O
current O
heat O
exchange O
in O
the O
respiratory O
passages RARE
: O
effect O
on O
water O
and O
heat O
balance O
. O

Calibration RARE
and O
a O
correction O
of O
blood O
O2 O
content O
measured O
by O
Po2 NUMERIC
and O
CO O
saturation O
. O

Mae RARE
West RARE
and O
the O
doctor RARE
shortage RARE
. O

Elimination O
of O
gamma O
- O
irradiation O
induced O
oxidation O
in O
aqueous O
drug O
preparations O

The O
absolute O
configuration O
at O
C O
- O
2 O
in O
monocrotalic RARE
acid O
. O

Teratogenic RARE
effects O
of O
actinomycin RARE
D O
in O
rats O

The O
plasma I-GENE
growth I-GENE
hormone I-GENE
concentration O
of O
the O
foetal RARE
lamb RARE
. O

Bimodal RARE
cochlear O
response O
curves O
in O
rodents RARE
. O

A O
new O
hemagglutination RARE
test O
for O
the O
on O
- O
slide RARE
assay O
of O
rheumatoid I-GENE
factor I-GENE

CO2 O
assimilation RARE
by O
chloroplasts RARE
illuminated RARE
on O
filter O
paper O
. O

The O
biology RARE
of O
Hyostrongylus RARE
ruidus RARE
. O

Foreign RARE
profiles O
in O
air O
pollution RARE
control O
activities O
. O

Effects O
of O
chronic O
metaraminol RARE
treatment O
on O
the O
sympathetic O
activity O
of O
intact O
and O
adrenal O
demedullated RARE
rats O
kept O
in O
warm RARE
or O
cold O
environments RARE
. O

The O
association O
of O
clopamide RARE
and O
hydergine RARE
( O
Brinedine RARE
) O
in O
the O
treatment O
of O
the O
vasculo RARE
- O
renal O
syndromes O
of O
pregnancy O

The O
effect O
of O
low O
dosage O
radiation O
on O
metabolism O
and O
function O
of O
the O
rat O
kidney O
damaged O
by O
ischemia O

Leukemia RARE
in O
twins RARE
: O
world O
- O
wide O
review O
of O
clinical O
cases O
. O

Preliminary RARE
report O
. O

Quantitation RARE
of O
exocrine RARE
IgA I-GENE
in O
human O
serum O
in O
health O
and O
disease O
. O

Gastrointestinal RARE
manifestations O
of O
systemic O
sclerosis O

Iodine RARE
metabolism O
in O
chronic O
thyroiditis O
. O

Total O
body O
water O
, O
rhodanide RARE
space O
and O
I I-GENE
- I-GENE
131 I-GENE
- I-GENE
albumin I-GENE
space O
under O
the O
acute O
effect O
of O
furosemide O

V O
. O

18F O
and O
85Sr NUMERIC
scintimetry RARE
in O
the O
study O
of O
primary O
arthropathies RARE
. O

Propagation RARE
and O
hormone O
production O
by O
human O
normal O
and O
malignant O
trophoblast RARE
in O
rats O
. O

Health O
: O
an O
integrative RARE
reticulum O
. O

Sensitive RARE
fluorometric RARE
method O
of O
determining O
SH O
- O
and O
S O
- O
S O
- O
groups O
when O
jointly RARE
present O

Morphogenesis RARE
of O
the O
trochanter RARE
produced O
by O
femoral O
regeneration O
in O
the O
phasmid RARE
Carausius RARE
morosus RARE
Br O

Behavioral RARE
and O
electrographic RARE
expression O
of O
natural O
sleep O
and O
wakefulness RARE
in O
reptiles RARE

Sensitivities RARE
of O
thromboplastins RARE
to O
factor I-GENE
VII I-GENE
deficiency O
. O

3 O
. O

Central RARE
venous O
catheter O
used O
for O
recording O
intracardiac RARE
electrocardiogram O
. O

Two O
Lab RARE
8 O
computer O
programmes RARE
for O
use O
in O
the O
study O
of O
the O
isometric RARE
and O
isotonic RARE
contractile O
characteristics O
of O
skeletal O
muscle O
. O

Open RARE
head O
- O
brain O
injuries O

The O
modification O
of O
P32 NUMERIC
uptake O
into O
the O
Jensen RARE
sarcoma O
in O
vitro O
by O
adding O
of O
peroxide RARE
to O
the O
nutritive RARE
medium O

Students RARE
, O
parents O
, O
teachers RARE
and O
hearing O
disorders O

Changing RARE
and O
predicting O
doses O
of O
Cs137 NUMERIC
irradiation O

Positive RARE
shifts O
of O
basal O
skin O
potentials O
during O
human O
sleep O
. O

Evaluating RARE
dietary O
department RARE
management O
. O

5 O
-( O
Dimethylaminopropyl RARE
)- O
19 O
, O
11 O
- O
dihydro RARE
- O
5H NUMERIC
- O
benzo RARE
[ O
2 O
, O
3 O
] O
pyrido RARE
[ O
6 O
, O
7 O
- O
b O
] O
azepine RARE
. O

Osteogenesis RARE
imperfecta RARE

Investigation RARE
on O
the O
exchange O
of O
Ca45 NUMERIC
in O
intact O
and O
burned RARE
rats O
by O
the O
kinetic O
analysis O
method O

Effect O
of O
thrombotic O
and O
antithrombotic RARE
drugs O
on O
the O
surface O
charge O
characteristics O
of O
canine O
blood O
vessels O
: O
in O
vivo O
and O
in O
vitro O
studies O
. O

Measurements O
of O
activity O
with O
the O
radioprotective RARE
chamber O
VA O
- O
K O
- O
254 NUMERIC
of O
the O
osimeter RARE
VA O
- O
J18 NUMERIC

3 O
-( O
N O
- O
Alkyl RARE
- O
N O
- O
2 O
- O
chloroethylaminomethyl RARE
)- O
5 O
- O
or O
7 O
- O
halogenobenzo RARE
[ O
b O
] O
thiophen RARE
hydrochlorides RARE
. O

Nephrectomy RARE
applied O
to O
cattle O

Evaluation O
of O
automatic O
blood O
cell O
counters RARE
. O

Determination O
of O
transaminases RARE
with O
an O
autoanalyzer RARE

Sterols RARE
in O
pollen O
. O

Dermoid RARE
cyst O
in O
a O
free O
skin O
flap O
as O
the O
complication O
after O
treatment O
of O
recurring RARE
hernia RARE

Histological O
observations O
on O
the O
decidua RARE
in O
the O
second O
half O
of O
pregnancy O

Endocardial RARE
fibro RARE
- O
elastosis RARE
, O
mitral O
incompetence RARE
, O
and O
coarctation RARE
of O
abdominal O
aorta O
. O

Studies O
on O
the O
method O
of O
size O
reduction O
of O
medicinal RARE
compounds O
. O

Children O
with O
defective O
vision O

Identification O
and O
estimation O
of O
monosaccharides RARE
and O
disaccharides RARE
in O
urine O
by O
gas O
- O
liquid O
chromatography O
. O

Steroids RARE
in O
germfree RARE
and O
conventional O
rats O
. O

The O
effects O
of O
loading O
the O
respiratory O
pumps RARE
on O
the O
oxygen O
consumption O
of O
Callionymus RARE
lyra RARE
. O

Trials RARE
of O
sevine RARE
activity O
against O
mosquito RARE
larvae O

The O
significance O
of O
structural O
integrity O
of O
lymphoid O
tissue O
for O
antibody O
production O
in O
culture O
in O
vivo O

The O
effect O
of O
a O
constant O
magnetic O
field O
on O
the O
phagocytic O
activity O
of O
Paramecia RARE

Studies O
carried O
out O
with O
the O
Glossina RARE
morsitans RARE
colony O
of O
Lisbon RARE
. O

Relations RARE
between O
adrenergic O
mechanisms O
and O
analgesic O
effects O

Transformations RARE
in O
the O
morphine O
series O
. O

Dissociative RARE
anesthetics RARE
2 O
-( O
o O
- O
chlorophenyl RARE
)- O
2 O
- O
methyl O
- O
amino O
cyclohexane RARE
HCL ALLCAPS
( O
CI O
- O
581 NUMERIC
) O

Estrus RARE
and O
copulative RARE
abilities O
of O
androgen O
- O
sterilized RARE
rats O

The O
bearing O
of O
season O
and O
sequence O
of O
calving RARE
on O
frequency O
of O
male O
, O
female O
and O
total O
calvings RARE
in O
Hariana RARE
cows O
. O

Hemodynamics RARE
changes O
in O
man O
during O
flight RARE

Caries RARE
prevention O
in O
the O
dental O
office RARE
. O

I O
. O

Clinical O
applications O
of O
inhibition O
of O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
with O
propranolol O
. O

Automatic RARE
view O
box O
. O

Measurement O
of O
gastric O
acid O
secretion O
by O
conductivity RARE
. O

Effect O
of O
castration RARE
on O
pituitary I-GENE
and I-GENE
serum I-GENE
LH I-GENE
and O
FSH I-GENE
in O
testosterone O
- O
sterilized RARE
rats O
. O

The O
significance O
of O
the O
phenolphthalein RARE
sulphatase RARE
test O
for O
the O
differentiation O
and O
identification O
of O
Nocardia RARE
species O
. O

Relationship RARE
of O
mast O
cells O
to O
sarcoidosis RARE
granuloma O
of O
the O
skin O

Long RARE
- O
term O
effects O
of O
clofibrate RARE
( O
Atromid RARE
- O
S O
) O
on O
serum O
lipids O
in O
man O
. O

Phosphate RARE
glucose I-GENE
dehydrogenase I-GENE
deficiency O
causing O
hyperbilirubinemia O
in O
the O
newborn O

Evidence O
forthe RARE
electroosmosis RARE
theory O
of O
transport O
in O
the O
phloem RARE
. O

Effects O
of O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
blockade O
on O
airway O
conductance O
and O
lung O
volume O
in O
normal O
and O
asthmatic O
subjects O
. O

Effect O
of O
heparin O
on O
the O
inactivation O
of O
serum I-GENE
lipoprotein I-GENE
lipase I-GENE
by O
the O
liver O
in O
unanesthetized RARE
dogs O
. O

Experimental O
chlorpromazine RARE
cataracts RARE
. O

I O
. O

Specialist RARE
in O
family O
practice O
-- O
prototype O
of O
a O
doctor RARE
. O

The O
possibility O
of O
selective O
chemotherapy O
of O
progressive O
recurring RARE
ovarian O
carcinoma O
with O
the O
aid O
of O
cytodiagnosis RARE
and O
incorporation O
of O
tagged O
idoxuridine RARE

Variation RARE
in O
the O
temporal O
- O
spatial O
distribution O
of O
228Ra NUMERIC
and O
224Ra NUMERIC
in O
the O
RES ALLCAPS
and O
marrow O
- O
free O
skeleton RARE
after O
incorporation O
of O
colloidal RARE
ThO2 NUMERIC

Oxidative RARE
degradation O
of O
adrenaline O
solutions O
: O
study O
of O
the O
intermediate O
stages O
and O
their O
analytic RARE
value O
for O
the O
control O
of O
this O
solute RARE

Absorption RARE
of O
electrolytes RARE
from O
the O
colon O
in O
cases O
of O
ulcerative RARE
colitis RARE
and O
in O
control O
subjects O
. O

Ion RARE
injection O
. O

Polyvinyl RARE
alcohol O
as O
a O
solution O
mediator RARE

Mining RARE
the O
diagnostic O
iron O
ore RARE
. O

The O
structure O
of O
digiprogenin RARE
. O

The O
need O
in O
the O
small O
hospital O
. O

I O
. O

On O
the O
character O
of O
changes O
in O
the O
enzyme O
activity O
in O
the O
brain O
tissue O
during O
reflex O
epilepsy O

A O
malignant O
true O
teratoma RARE
of O
liver O
in O
childhood O
. O

Methoxyflurane RARE
and O
renal O
function O

Histochemistry RARE
and O
electron O
microscopy O
of O
acute O
liver O
lesions O
induced O
by O
Aflatoxin RARE
B1 O
in O
ducklings RARE
. O

Functional O
disorders O
of O
the O
ureter RARE
following O
gynecologic O
surgery O

Study O
of O
the O
alterations O
of O
intestinal O
absorption O
, O
by O
means O
of O
I O
- O
131 O
- O
triolein RARE
, O
in O
the O
whole O
body O
irradiated O
rat O

Chemical O
histologic O
and O
immunologic O
responses O
in O
rats O
to O
CC1 NUMERIC
- O
4 O
by O
different O
routes O
of O
administration O
. O

Clinical O
trials O
with O
1 O
, O
3 O
- O
bis RARE
( O
2 O
- O
chloroethyl RARE
)- O
1 O
- O
nitrosourea RARE
, O
NSC ALLCAPS
- O
409962 NUMERIC
. O

Hydroxypropyl RARE
methacrylate RARE
, O
a O
new O
water O
- O
miscible RARE
embedding RARE
medium O
for O
electron O
microscopy O
. O

Statistics RARE
of O
the O
past O
5 O
years O

On O
the O
diagnosis O
of O
bovine O
leucosis RARE
and O
its O
control O
in O
southern O
Lower RARE
Saxony RARE

Experience RARE
with O
the O
restoration RARE
of O
agglutination O
properties O
of O
non O
- O
agglutinating RARE
dysenterial RARE
cultures O
with O
the O
use O
of O
Rzhaninov RARE
' O
s O
method O

Study O
on O
micromelias RARE
in O
the O
mouse O
fetus O
caused O
by O
x O
- O
radiation O
, O
hypoxia O
, O
trypan RARE
blue O
injection O
of O
hypervitaminosis RARE
- O
A O
upon O
mother RARE
animals O
during O
pregnancy O
. O

Human O
antitetanus RARE
serum O
: O
an O
unused RARE
wealth RARE

( O
3 O
). O

Studies O
on O
the O
intracutaneous RARE
infection O
of O
rabbits O
by O
Staphylococcus O
aureus O
. O

On O
catabolism O
of O
aminoketones RARE
in O
climacteric RARE
age O

The O
effect O
of O
feeding O
patterns O
on O
fat O
deposition O
in O
mice O
. O

Naphthalene RARE
and O
paradichlorobenzene RARE
in O
clinical O
toxicology RARE

IV O
. O

Studies O
on O
powdered RARE
preparations O
. O

A O
case O
report O
with O
angiographic O
follow O
- O
up O
study O
. O

Interactions RARE
between O
adrenergics RARE
, O
adrenolytics RARE
and O
monoamine I-GENE
oxidase I-GENE
inhibitors O

Further O
studies O
on O
a O
" O
new O
" O
human O
isoprecipitin RARE
system O
( O
Australia RARE
antigen O
). O

Pigmentary RARE
rhythms RARE
as O
indicators O
of O
neurosecretion RARE
. O

Story RARE
of O
a O
hospital O
that O
filmed RARE
its O
employee RARE
orientation O
program O
. O

When O
the O
cervical O
Pap RARE
smear RARE
is O
positive O
. O

I O
. O

The O
3 O
- O
hour O
test O
iodine O
( O
I O
- O
132 O
) O
uptake O
by O
the O
thyroid O
in O
children O
with O
growth O
deficiency O

Persistence RARE
of O
toxaphene RARE
in O
treated O
lakes RARE
. O

Studies O
on O
Coxsackie RARE
B O
Type O
5 O
virus O
infections O
. O

Value O
of O
the O
method O
of O
passive O
hemagglutination RARE
with O
polysaccharide RARE
C O
in O
detecting O
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
as O
compared O
to O
precipitation O
in O
capillaries O
and O
slide RARE
latex O
test O
with O
anti I-GENE
- I-GENE
CRP I-GENE
serum O

Adrenergic RARE
nerve O
function O
, O
noradrenaline O
level O
and O
noradrenaline O
uptake O
in O
cat O
nictitating RARE
membrane O
after O
reserpine RARE
treatment O
. O

Concussion RARE
of O
the O
spinal O
cord O

Study O
on O
the O
evagination RARE
of O
Cysticercus RARE
pisiformis RARE
. O

Antimicrobial RARE
substance RARE
isolated O
from O
an O
acorn RARE
extract O
. O

The O
pathogenicity RARE
of O
Achromobacter RARE
puntatum RARE
for O
cold O
blooded RARE
and O
warm RARE
blooded RARE
animals O

Consanguinity RARE
and O
migration O
in O
the O
marriages RARE
of O
the O
region O
of O
Nunoa RARE
, O
Santiago RARE
, O
1850 NUMERIC
- O
1960 NUMERIC

On O
the O
amount O
and O
significance O
of O
the O
effective O
glucose O
level O
in O
tumors O
. O

Studies O
of O
lipogenesis RARE
by O
labelled O
precursors O
in O
the O
pregnant O
rat O
. O

Pharmacodynamic RARE
studies O
on O
the O
cardiovascular O
system O
of O
spontaneously O
hypertensive O
rats O
. O

Nuclear O
spin O
of O
249Bk NUMERIC
from O
the O
hyperfine RARE
structure O
in O
its O
emission O
spectrum O
. O

Further O
observations O
on O
resorption O
in O
guinea O
pigs O
following O
injections O
of O
trypan RARE
blue O
. O

Derivatives RARE
of O
fluorene RARE
. O

Note RARE
on O
Slot RARE
' O
s O
method O
for O
the O
specific O
determination O
of O
creatinine O
. O

Retention RARE
behavior O
of O
steroids O
in O
gas O
chromatography O
with O
a O
series O
of O
combination O
columns RARE
. O

Compensatory RARE
renal O
hypertrophy O
in O
parabiotic RARE
rats O
. O

( O
3 O
). O

XXI ALLCAPS
. O

In O
vitro O
evaluation O
of O
the O
mucolytic RARE
action O
of O
urea O
. O

Electrophoretic O
characteriaztion RARE
of O
virus O
- O
induced O
interferon I-GENE
of O
the O
blood O
and O
urine O
in O
rabbits O

Iron RARE
and O
folate O
deficiency O
in O
pregnancy O

Symposium RARE
on O
presenile RARE
spongy RARE
encephalopathies RARE
. O

Twenty O
- O
two O
of O
the O
24 O
patients O
had O
a O
rise O
in O
the O
total O
serum O
amylase I-GENE
following O
ERCP ALLCAPS
. O

The O
immuno RARE
- O
purified O
mRNA O
in O
the O
polysome RARE
complex O
was O
used O
to O
prepare RARE
cDNA O
with O
which O
to O
probe O
a O
D O
. O
melanogaster O
genomic O
library O
. O

Elevated RARE
maternal I-GENE
alpha I-GENE
fetoproteins RARE
and O
oligoamnios RARE
: O
fetal O
prognosis O

Also O
discussed O
is O
the O
possibility O
of O
a O
combined O
genetic O
and O
environmental O
etiology O
. O

Courses RARE
were O
repeated O
monthly O
upon O
recovery O
of O
myelosuppression RARE
. O

Stimulation RARE
with O
MCh RARE
produced O
a O
Ca O
- O
dependent O
transient O
elevation O
of O
cGMP O
level O
from O
10 O
to O
80 O
fmol RARE
/ O
gland O
, O
peaking RARE
at O
1 O
- O
2 O
min O
but O
returning RARE
to O
the O
basal O
level O
by O
5 O
min O
. O

Two O
hundred O
forty RARE
- O
three O
patients O
have O
received O
WR O
- O
2721 O
in O
Phase O
I O
- O
II O
studies O
. O

The O
PEPCK I-GENE
promoter O
fragment O
was O
introduced O
either O
in O
the O
proper O
orientation O
for O
transcription O
of O
the O
TK I-GENE
gene I-GENE
or O
in O
the O
opposite O
orientation O
. O

Many O
mammary O
tumors O
induced O
by O
mouse O
mammary O
tumor O
virus O
( O
MMTV O
) O
contain O
a O
provirus O
in O
the O
same O
region O
of O
the O
host O
- O
cell O
genome O
, O
leading O
to O
expression O
of O
a O
putative O
cellular O
oncogene O
called O
int I-GENE
- I-GENE
1 I-GENE
. O

In O
these O
cases O
, O
asbestos RARE
or O
erionite RARE
- O
tissue O
burden O
followed O
by O
fibrosis O
was O
frequently O
observed O
. O

Hepatitis O
B O
virus O
and O
hepatoma O
. O

Eight O
recombinant O
DNA O
clones O
of O
endogenous O
murine O
leukemia O
virus O
( O
MuLV O
)- O
related O
DNA O
sequences O
have O
been O
isolated O
from O
a O
lambdaphage RARE
genomic O
library O
of O
Balb RARE
/ O
c O
mouse O
DNA O
. O

USA ALLCAPS
80 O
, O
3618 NUMERIC
- O
3622 NUMERIC
) O
The O
two O
proteins O
show O
36 O
% O
identities O
in O
their O
amino O
acid O
sequence O
, O
in O
an O
alignment O
requiring O
six O
gaps RARE
. O

The O
envelope O
glycoproteins O
of O
Rous O
sarcoma O
virus O
( O
RSV ALLCAPS
), O
gp85 NUMERIC
and O
gp37 NUMERIC
, O
are O
anchored O
in O
the O
membrane O
by O
a O
27 O
- O
amino O
acid O
, O
hydrophobic O
domain O
that O
lies O
adjacent O
to O
a O
22 O
- O
amino O
acid O
, O
cytoplasmic O
domain O
at O
the O
carboxy O
terminus O
of O
gp37 NUMERIC
. O

The O
drug O
was O
given O
in O
a O
daily O
oral O
dose O
of O
0 O
. O
5 O
g O
/ O
m2 O
, O
3 O
. O
5 O
h O
prior O
to O
each O
radiation O
treatment O
. O

Histogenetic RARE
aspects O
of O
mesoblastic RARE
nephroma RARE
. O

Effect O
of O
acute O
and O
chronic O
psychogenic RARE
stress O
on O
corticoadrenal RARE
and O
pituitary I-GENE
- I-GENE
thyroid I-GENE
hormones I-GENE
in O
male O
rats O
. O

Mature RARE
mRNA O
for O
cytosolic I-GENE
phosphoenolpyruvate I-GENE
carboxykinase RARE
of I-GENE
the I-GENE
chicken I-GENE
is O
2 O
. O
8 O
kilobases O
in O
length O
, O
similar O
to O
that O
previously O
noted O
for O
mRNA O
coding O
for O
the O
same O
enzyme O
in O
the O
rat O
. O

Upstream O
activation O
sites O
of O
the O
CYC1 I-GENE
gene I-GENE
of O
Saccharomyces O
cerevisiae O
are O
active O
when O
inverted O
but O
not O
when O
placed O
downstream O
of O
the O
" O
TATA O
box O
". O

An O
intact O
5 O
. O
7 O
- O
kb O
provirus O
of O
the O
avian O
erythroblastosis RARE
virus O
E26 NUMERIC
has O
been O
molecularly O
cloned O
for O
comparisons O
with O
avian O
myeloblastosis RARE
virus O
( O
AMV ALLCAPS
) O
and O
other O
avian O
tumor O
viruses O
. O

It O
is O
concluded O
that O
haloperidol O
selectively O
reduced O
the O
animal O
' O
s O
capacity O
to O
' O
programme RARE
non O
- O
stimulus O
directed O
motor O
behaviour O
'. O

Neither O
side O
effect O
nor O
abnormal O
laboratory O
findings O
due O
to O
this O
drug O
were O
observed O
. O

The O
results O
presented O
in O
this O
report O
suggest O
that O
the O
SV40 O
G O
- O
C O
- O
rich O
sequences O
can O
function O
as O
independent O
RNA I-GENE
polymerase I-GENE
II I-GENE
transcriptional O
- O
control O
elements O
. O

Construction RARE
of O
human O
cell O
lines O
which O
contain O
and O
express O
the O
adenovirus O
DNA O
binding O
protein O
gene O
by O
cotransformation RARE
with O
the O
HSV I-GENE
- I-GENE
1 I-GENE
tk I-GENE
gene I-GENE
. O

Diagnosis O
and O
treatment O
of O
insulin I-GENE
- O
secreting O
tumours O
. O

Theories RARE
proffered RARE
to O
account O
for O
the O
modality O
shift O
effect O
are O
critically RARE
evaluated O
. O

The O
effects O
of O
cardioselective RARE
beta O
- O
1 O
adrenergic O
agonist O
, O
1 O
-( O
4 O
- O
hydroxyphenoxy RARE
)- O
isopropylamino RARE
- O
2 O
- O
propanol RARE
), O
i O
. O
e O
., O
prenalterol RARE
, O
were O
examined O
on O
direct O
and O
continuous O
measurements O
of O
left O
ventricular O
( O
LV O
) O
pressure O
, O
diameter O
, O
dP LASTCAP
/ O
dt O
, O
velocity O
of O
shortening O
, O
arterial O
pressure O
, O
iliac O
blood O
flow O
and O
heart O
rate O
in O
10 O
conscious O
dogs O
. O

Endorphins RARE
at O
the O
approach O
of O
death O
. O

Trial RARE
treatment O
of O
schizophrenia O
with O
des RARE
- I-GENE
Tyr I-GENE
- I-GENE
gamma I-GENE
- I-GENE
endorphin I-GENE

Cardiac O
taurine RARE
levels O
and O
sarcolemmal RARE
calcium O
binding O
activity O
in O
furazolidone RARE
- O
induced O
cardiomyopathy O
. O

Separation RARE
of O
malaria O
- O
infected O
erythrocytes RARE
from O
whole O
blood O
: O
use O
of O
a O
selective O
high O
- O
gradient O
magnetic O
separation O
technique O
. O

The O
roll RARE
- O
over O
test O
to O
predict O
toxemia RARE
in O
pregnancy O
. O

Can RARE
thyroglobulin RARE
assay O
really RARE
supplant RARE
radioiodine RARE
scans O
in O
patients O
with O
differentiated O
thyroid O
cancer O
? O

3 O
Significant O
reductions O
in O
lying RARE
mean O
arterial O
blood O
pressure O
were O
observed O
with O
daily O
doses O
of O
200 O
mg O
(- O
9 O
%), O
400 O
mg O
(- O
10 O
%) O
and O
800 O
mg O
(- O
14 O
%), O
and O
were O
associated O
with O
significant O
decreases O
in O
heart O
rate O
and O
plasma I-GENE
renin I-GENE
activity O
. O

Isolation O
of O
Aeromonas RARE
from O
faeces RARE
. O

Plasma O
and O
erthrocyte RARE
lipid O
profile O
and O
lipoprotein I-GENE
lipase I-GENE
activity O
in O
postheparin RARE
plasma O
on O
vasectomized RARE
rabbits O
were O
studied O
and O
also O
the O
incidence O
of O
atherosclerosis O
in O
different O
arterial O
beds RARE
. O

( O
iii O
) O
The O
mRNA O
is O
not O
efficiently O
polyadenylated O
at O
sequences O
in O
the O
3 O
' O
end O
of O
the O
DHFR I-GENE
cDNA I-GENE
but O
rather O
uses O
polyadenylation O
signals O
downstream O
from O
the O
DHFR I-GENE
cDNA I-GENE
. O

At O
both O
water O
temperatures O
, O
VO2 O
increased O
linearly RARE
with O
increasing O
swimming O
velocity O
. O

Propranolol RARE
also O
effectively O
controlled O
her O
familial O
tremor O
. O

Brief RARE
report O
. O

The O
distribution O
phase O
is O
followed O
by O
an O
elimination O
phase O
with O
a O
much O
longer O
half O
- O
life O
( O
mean O
value O
375 NUMERIC
min O
) O
and O
a O
volume O
of O
distribution O
of O
approximately O
200 O
- O
400 O
l O
. O

Hybrid RARE
- O
selection O
experiments O
against O
total O
PB ALLCAPS
- O
inducible O
RNA O
were O
performed O
with O
plasmid O
DNA O
derived O
from O
clones O
enriched O
in O
PB ALLCAPS
- O
inducible O
information O
. O

Risk O
of O
HTLV O
infection O
in O
patients O
on O
haemodialysis O
. O

In O
vitro O
metabolism O
of O
progesterone O
by O
the O
human O
undescended RARE
testis O
. O

Two O
patients O
withdrew RARE
from O
therapy O
, O
one O
for O
personal O
reasons RARE
and O
one O
because O
a O
paraspinal RARE
mass O
developed O
. O

All O
patients O
received O
VCR ALLCAPS
1 O
. O
0 O
mg O
/ O
m2 O
weekly O
for O
6 O
weeks O
with O
dose O
modification O
for O
neurotoxicity O
. O

Glutamic RARE
acid O
in O
a O
dose O
of O
1 O
/ O
100 O
of O
the O
LD50 O
was O
injected O
in O
the O
form O
of O
sodium O
salt O
into O
male O
and O
female O
Wistar RARE
rats O
for O
7 O
days O
after O
8 O
- O
and O
12 O
- O
day O
injections O
of O
dexazone RARE
. O

Serum O
ascorbic RARE
acid O
had O
an O
inverse RARE
and O
the O
strongest O
association O
with O
systolic O
blood O
pressure O
among O
the O
risk O
factors O
including O
blood O
pressure O
, O
total O
cholesterol O
, O
triglyceride RARE
, O
gamma I-GENE
- I-GENE
GTP I-GENE
and O
obesity O
. O

Plasma I-GENE
secretin RARE
, O
pancreozymin RARE
, O
and O
somatostatin I-GENE
- I-GENE
like I-GENE
hormone I-GENE
in O
chronic O
renal O
failure O
patients O
. O

Effect O
of O
bromazepam RARE
on O
growth I-GENE
hormone I-GENE
and O
prolactin I-GENE
secretion O
in O
normal O
subjects O
. O

In O
several O
cases O
of O
definite O
SjS LASTCAP
, O
labial RARE
salivary O
gland O
examinations O
after O
more O
than O
a O
one O
year O
interval O
were O
performed O
on O
two O
occasions RARE
, O
and O
the O
clinical O
and O
histopathological O
changes O
were O
investigated O
. O

All O
radiologists RARE
using O
the O
machine O
found O
that O
the O
reporting RARE
terminal O
was O
simple O
to O
operate RARE
, O
but O
found O
that O
reporting RARE
abnormalities O
caused O
an O
increased O
effort O
and O
took RARE
a O
longer O
time O
. O

Thalamotomy RARE
aiming RARE
at O
the O
CM O
- O
Pf RARE
complex O
and O
using O
stereotactic RARE
gamma O
irradiation O
has O
been O
performed O
in O
a O
series O
of O
52 O
patients O
with O
severe O
pain O
due O
to O
malignancy O
. O

2 O
Silastic RARE
capsules O
, O
each O
containing O
22 O
- O
23 O
mg O
of O
ethinyl RARE
estradiol O
, O
were O
inserted O
subcutaneously O
in O
5 O
men O
with O
benign O
prostatic O
hypertrophy O
. O

When O
used O
subcutaneously O
or O
intravenously O
in O
maximum O
tolerated O
doses O
the O
antibiotic O
inhibited O
the O
development O
of O
lymphadenosis RARE
NK O
/ O
Li O
by O
90 O
and O
70 O
per O
cent O
respectively O
. O

Effect O
of O
2 O
-( O
p O
- O
chlorophenyl RARE
) O
cyclopropylamine RARE
on O
5 O
- O
hydroxyindole RARE
concentration O
and O
monoamine I-GENE
oxidase I-GENE
activity O
in O
rat O
brain O
. O

Then RARE
, O
pure O
pancreatic O
juice O
was O
infused O
into O
the O
duodenum RARE
. O

An O
experiment O
was O
carried O
on O
133 O
grown O
up O
fowls RARE
and O
broilers RARE
from O
4 O
industrial RARE
farms RARE
, O
vaccinated RARE
with O
spray RARE
lento RARE
and O
mesogenic RARE
vaccines O
for O
straining RARE
the O
immunity O
against O
pseodopest RARE
through O
RIHA ALLCAPS
and O
provoking RARE
pseudoplague RARE
with O
a O
pathogenic O
virus O
. O

( O
2 O
) O
The O
inappropriateness RARE
of O
adaptive O
segmentation O
for O
the O
isolation O
of O
spikes O
and O
sharp RARE
waves O
, O
which O
had O
been O
anticipated RARE
in O
view O
of O
the O
short O
duration O
of O
such O
transients RARE
in O
relation O
to O
the O
length O
of O
the O
window RARE
( O
1 O
. O
2 O
sec O
) O
used O
for O
the O
autocorrelation RARE
functions O
employed O
in O
the O
segmentation O
algorithm O
, O
was O
confirmed O
. O

The O
ability O
of O
chronic O
UM ALLCAPS
- O
272 O
( O
dimethylpropranolol RARE
) O
treatment O
to O
prevent O
the O
induction O
of O
reentrant RARE
ventricular O
tachyarrhythmias RARE
was O
assessed O
in O
the O
conscious O
dog O
subjected O
to O
serial O
programmed O
electrical O
stimulation O
on O
days O
3 O
-- O
5 O
after O
myocardial O
infarction O
. O

The O
effect O
of O
echothiophate RARE
on O
the O
biphasic O
response O
of O
rabbit O
ocular O
pressure O
to O
dipivefrin RARE
. O

In O
most O
cases O
of O
acute O
transmural RARE
infarction O
, O
the O
reciprocal O
ST O
segment O
depressions RARE
observed O
in O
contralateral O
leads O
are O
less O
marked O
than O
the O
primary O
ST O
segment O
elevations O
. O

Bacillus O
cereus RARE
cross O
- O
infection O
in O
a O
maternity RARE
- O
unit O
. O

We O
have O
followed O
37 O
phenytoin O
- O
treated O
patients O
with O
reduced O
serum I-GENE
IgA I-GENE
concentrations O
for O
2 O
- O
7 O
years O
. O

In O
the O
latter O
category O
particular O
emphasis RARE
is O
being O
placed O
on O
new O
anthracycline RARE
analogues O
of O
doxorubicin RARE
and O
analogues O
of O
cisplatinum RARE
diammine RARE
dichloride RARE
. O

Unusual RARE
course O
of O
plasmocytosis RARE
. O

Late RARE
mRNA O
selected O
by O
a O
cDNA O
homologous O
to O
the O
HindIII I-GENE
- I-GENE
P I-GENE
/ O
EcoRI I-GENE
- I-GENE
B I-GENE
region O
of O
the O
AcNPV LASTCAP
map O
directed O
the O
synthesis O
of O
31K NUMERIC
and O
30K NUMERIC
proteins O
which O
comigrated RARE
with O
the O
31K NUMERIC
and O
30K NUMERIC
proteins O
translated O
from O
RNA O
selected O
by O
the O
HindIII I-GENE
- I-GENE
A I-GENE
/ O
EcoRI I-GENE
- I-GENE
C I-GENE
/ O
SstI LASTCAP
- I-GENE
G I-GENE
cDNA O
. O

Intraoperatively RARE
the O
complement I-GENE
factor I-GENE
C3c NUMERIC
decreased O
by O
20 O
%, O
while O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
showed O
postoperatively O
an O
increase O
by O
30 O
%. O

A O
polypeptide O
chain O
of O
34 O
residues O
of O
the O
deduced O
yeast O
amino O
acid O
sequence O
closely O
resembles O
a O
peptide O
sequence O
at O
the O
ADP O
binding O
site O
of O
bovine I-GENE
muscle I-GENE
pyruvate RARE
kinase I-GENE
. O

The O
P165 NUMERIC
component O
, O
however O
, O
could O
be O
differentiated O
from O
the O
two O
later O
components O
since O
it O
increased O
in O
amplitude O
with O
increased O
task O
demands RARE
while O
the O
N2 O
and O
P3 O
amplitudes O
remained O
constant O
. O

Differential O
drawing RARE
size O
associated O
with O
unilateral O
brain O
damage O
. O

The O
intracoronary RARE
administration O
of O
both O
drugs O
markedly O
reduced O
the O
incidence O
of O
VF O
induced O
by O
the O
release O
of O
a O
40 O
- O
min O
coronary O
artery O
occlusion O
. O

These O
fusions O
are O
contained O
on O
plasmids O
which O
have O
both O
yeast O
and O
E O
. O
coli O
replication O
origins O
and O
selectable O
markers O
and O
, O
therefore O
, O
can O
be O
used O
to O
transform O
either O
yeast O
or O
E O
. O
coli O
cells O
. O

Therefore O
, O
it O
was O
concluded O
that O
thrombotic O
tendency O
certainly RARE
existed O
in O
patients O
with O
MS O
compared O
to O
those O
with O
non O
RHD ALLCAPS
and O
that O
it O
was O
one O
of O
the O
causes O
of O
the O
significantly O
high O
incidence O
of O
thromboembolism RARE
in O
comparison O
with O
non O
RHD ALLCAPS
. O

Toxicity RARE
was O
significant O
in O
selected O
cases O
; O
three O
patients O
developed O
WBC O
counts O
less O
than O
1 O
, O
000 O
/ O
mm3 NUMERIC
and O
one O
of O
these O
patients O
died O
with O
sepsis O
. O

Subdural RARE
electrodes O
may O
yield O
larger O
VEP ALLCAPS
amplitudes O
than O
skull RARE
or O
scalp RARE
electrodes O
. O

Products RARE
of O
immune O
cells O
such O
as O
transfer I-GENE
factor I-GENE
and O
lymphokines RARE
form O
the O
third O
and O
possibly O
most O
important O
group O
of O
immune O
- O
stimulating O
agents O
. O

Use O
of O
the O
immunofluorescence O
method O
for O
identification O
of O
enteroviruses RARE
in O
cell O
cultures O

This O
fraction O
is O
resistant O
to O
digestions RARE
by O
DNase I-GENE
I I-GENE
and O
RNase I-GENE
T1 I-GENE
and O
disappears RARE
completely O
upon O
alkali RARE
hydrolysis O
. O

The O
construction O
of O
a O
small O
library O
of O
mouse O
repetitive O
DNA O
has O
been O
previously O
reported O
( O
Pietras RARE
et O
al O
., O
Nucleic RARE
Acids RARE
Res RARE
. O

No O
direct O
repeats O
flank O
the O
pseudogene O
in O
the O
U2 I-GENE
/ I-GENE
4 I-GENE
locus I-GENE
. O

The O
direct O
effects O
of O
transmitter RARE
release O
were O
( O
a O
) O
an O
early O
fall O
in O
MAP O
followed O
by O
a O
late O
pressor O
effect O
; O
and O
( O
b O
) O
an O
early O
bradycardia RARE
followed O
by O
a O
late O
tachycardia O
. O

At O
Cabras RARE
( O
Oristano RARE
), O
a O
town RARE
characterized O
by O
a O
high O
incidence O
of O
thalassaemia RARE
and O
G6PD NUMERIC
deficiency O
less O
than O
half O
the O
people O
between O
18 O
and O
35 O
have O
a O
fair RARE
knowledge O
of O
genetic O
diseases O
and O
of O
their O
prevention O
. O

The O
number O
of O
elements O
and O
their O
sizes O
relative O
to O
the O
configuration O
were O
varied O
in O
a O
series O
of O
five O
experiments O
. O

In O
addition O
, O
the O
overall O
chance RARE
that O
a O
patient O
would O
undergo O
ET O
was O
greater O
in O
a O
cycle O
in O
which O
more O
than O
one O
follicle O
20 O
mm O
or O
larger O
was O
developing O
than O
in O
a O
cycle O
in O
which O
a O
single O
large O
follicle O
was O
developing O
. O

Experience RARE
with O
the O
tensor RARE
fasciae RARE
latae RARE
free O
flap O
. O

Five O
of O
the O
patients O
with O
increased O
L O
- O
L O
size O
had O
a O
normal O
A O
- O
P O
diameter O
. O

Immunochemotherapy RARE
with O
schizophyllan RARE
( O
SPG ALLCAPS
) O
combined O
with O
chemotherapeutic O
agents O
was O
evaluated O
in O
two O
syngeneic RARE
tumor O
- O
C3H O
/ O
He O
mouse O
systems O
. O

However O
, O
when O
combined O
with O
mitomycin RARE
C O
given O
with O
1 O
to O
5 O
- O
days O
interval O
, O
the O
concurrent O
administration O
of O
SPG ALLCAPS
prolonged O
significantly O
the O
life O
- O
span O
of O
the O
tumor O
- O
bearing O
mice O
. O

Data O
are O
presented O
hinting RARE
that O
the O
15 O
beta O
- O
hydroxy O
-, O
metabolite O
of O
CPA ALLCAPS
may O
actually RARE
be O
the O
biologically O
active O
agent O
. O

The O
abluminal RARE
surface O
is O
often O
almost O
entirely O
encircled RARE
by O
a O
thick O
layer O
of O
fibrillary RARE
connective O
tissue O
. O

In O
contrast O
, O
in O
LL ALLCAPS
patients O
during O
ENL ALLCAPS
the O
ConA LASTCAP
- O
induced O
suppressor O
response O
was O
markedly O
reduced O
. O

Functional O
characterization O
of O
a O
fraction O
identified O
by O
its O
activity O
in O
a O
second O
template O
rescue O
assay O
. O

It O
has O
been O
established O
that O
preoperative O
irradiation O
in O
the O
form O
of O
the O
fractionation O
of O
a O
single O
focal O
dose O
of O
6 O
Gy O
every O
other O
day O
, O
the O
summary O
dose O
of O
24 O
Gy O
within O
8 O
- O
10 O
days O
followed O
by O
surgery O
1 O
- O
3 O
days O
after O
irradiation O
does O
not O
either O
complicate RARE
its O
performance O
or O
the O
course O
of O
the O
postoperative O
period O
, O
and O
by O
the O
short O
- O
and O
long O
- O
term O
results O
it O
is O
no O
worse RARE
than O
the O
routine O
dose O
fractionation O
. O

Fibrin RARE
gels O
and O
their O
possible O
implication RARE
for O
surface O
hemorheology RARE
in O
health O
and O
disease O
. O

Hepatitis O
- O
B O
vaccination O
in O
the O
elderly O
. O

Radiogallium RARE
imaging O
is O
thus O
of O
limited O
use O
in O
evaluation O
of O
suspected O
giant RARE
cell O
tumors O
of O
bone O
. O

The O
customary RARE
coupling O
reagent RARE
sulfanilic RARE
acid O
has O
been O
replaced O
by O
1 O
, O
3 O
- O
dimethylbarbituric RARE
acid O
; O
CNCl RARE
is O
produced O
in O
the O
flow O
through O
system O
directly O
from O
KCN ALLCAPS
and O
chloramine RARE
T O
. O

Ventricular RARE
volume O
stiffness O
vs O
. O
the O
mean O
wall O
stress O
relationship O
of O
LVH ALLCAPS
shifted O
upward RARE
, O
whereas O
the O
normalized O
wall O
muscle O
stiffness O
vs O
. O
the O
mean O
wall O
stress O
relationship O
of O
LVH ALLCAPS
showed O
a O
smaller O
slope O
. O

Synthesis RARE
of O
(+)- O
lysergic RARE
acid O
diethylamide RARE
tartrate RARE

Weight RARE
loss O
reduces O
arterial O
pressure O
by O
a O
decrease O
in O
intravascular O
volume O
and O
cardiac O
output O
associated O
with O
a O
fall O
in O
sympathetic O
activity O
. O

The O
effect O
of O
treatment O
may O
thus O
be O
divided O
into O
two O
main O
phases O
-- O
an O
initial O
phase O
with O
a O
reduction O
in O
LV O
mass O
and O
a O
reduction O
in O
cardiac O
output O
and O
no O
change O
in O
total O
peripheral O
resistance O
-- O
and O
a O
second O
phase O
with O
a O
constant O
LV O
mass O
but O
an O
increase O
in O
cardiac O
output O
to O
the O
pretreatment O
level O
again O
and O
a O
concomitant O
decrease O
in O
total O
peripheral O
resistance O
. O

This O
study O
was O
undertaken O
to O
assess O
the O
effects O
of O
hypothermia O
and O
chemical O
cardioplegia RARE
on O
the O
functional O
recovery O
of O
hypertrophied RARE
non O
- O
failing RARE
rat O
hearts O
subjected O
to O
an O
extended O
period O
of O
global O
ischaemia O
. O

Oxygen RARE
profiles O
calculated O
for O
the O
Krogh RARE
model O
with O
excentric RARE
diffusion O
were O
similar O
to O
those O
derived O
for O
the O
two O
models O
of O
concentric RARE
diffusion O
. O

Cultivation RARE
technics RARE
for O
Codonopsis RARE
pilosula RARE

Radioimmunoassay RARE
of O
serum O
creatine I-GENE
kinase I-GENE
B I-GENE
isoenzyme RARE
in O
the O
diagnosis O
of O
acute O
myocardial O
infarction O
. O

Selective O
macrophage O
inhibition O
abolishes O
warfarin RARE
- O
induced O
reduction O
of O
metastasis O
. O

Restriction O
enzyme O
and O
heteroduplex RARE
analyses O
confirmed O
that O
sequences O
unique O
to O
FeSV LASTCAP
( O
src I-GENE
sequences I-GENE
) O
are O
located O
at O
the O
center O
of O
the O
FeSV LASTCAP
genome O
and O
are O
approximately O
1 O
. O
5 O
kilobase O
pairs O
in O
length O
. O

Among O
six O
different O
library O
isolates O
containing O
6 I-GENE
. I-GENE
5 I-GENE
- I-GENE
to I-GENE
7 I-GENE
- I-GENE
kb I-GENE
IAP ALLCAPS
units I-GENE
, O
some O
restriction O
sites O
were O
highly O
conserved O
whereas O
others O
varied O
in O
both O
occurrence O
and O
position O
. O

Catecholamines RARE
and O
aversive RARE
learning O
: O
a O
review O
. O

A O
haemolytic RARE
enterotoxigenic RARE
strain O
of O
E O
. O
coli O
( O
O149 NUMERIC
: O
K88 NUMERIC
: O
H10 NUMERIC
) O
was O
regularly RARE
recovered O
from O
piglets RARE
with O
PWD ALLCAPS
while O
rotavirus RARE
was O
demonstrated O
on O
a O
number O
of O
occasions RARE
. O

The O
antibody O
titer O
of O
202 NUMERIC
chickens O
to O
SA O
- O
11 O
rotavirus RARE
was O
determined O
by O
enzyme O
- O
linked O
immunosorbent O
blocking O
assay O
. O

Poly RARE
( O
dT O
) O
and O
denatured RARE
calf O
thymus RARE
DNA O
were O
more O
effective O
than O
were O
other O
polynucleotides RARE
tested O
in O
promoting O
accumulation O
of O
19 O
HDP ALLCAPS
*; RARE
( O
dT O
) O
8 O
was O
as O
effective O
as O
were O
longer O
molecules O
of O
( O
dT O
) O
n O
, O
but O
( O
dT O
) O
4 O
and O
( O
dT O
) O
6 O
were O
much O
less O
effective O
, O
indicating O
that O
the O
binding O
site O
involved O
in O
19 O
HDP ALLCAPS
* I-GENE
accumulation O
covered RARE
between O
6 O
and O
8 O
residues O
of O
( O
dT O
) O
n O
. O

A O
double O
- O
blind O
trial O
of O
half O
- O
strength O
Polybactrin RARE
Soluble RARE
GU ALLCAPS
bladder O
irrigation O
in O
cystoscopy RARE
. O

Thus O
it O
appears O
that O
insertion O
of O
a O
transposable RARE
element O
near O
the O
5 O
' O
terminus O
of O
the O
structural O
gene O
can O
produce O
constitutive O
expression O
of O
a O
normally O
glucose O
- O
repressed O
enzyme O
. O

Five O
experiments O
examined O
the O
influence O
of O
opiate O
antagonists O
on O
both O
the O
short O
- O
term O
analgesic O
reaction O
resulting O
30 O
min O
after O
exposure O
to O
inescapable RARE
shock O
and O
the O
long O
- O
term O
analgesic O
reaction O
resulting O
after O
reexposure RARE
to O
shock O
24 O
hr O
after O
inescapable RARE
shock O
exposure O
. O

Experiment O
3 O
showed O
that O
the O
long O
- O
term O
analgesic O
reaction O
could O
also O
be O
reduced O
by O
administration O
of O
naltrexone O
prior O
to O
reexposure RARE
to O
shock O
. O

During O
the O
period O
from O
May RARE
to O
August O
, O
1978 NUMERIC
, O
an O
epidemic O
of O
hand O
, O
foot O
and O
mouth O
disease O
( O
HFMD ALLCAPS
) O
occurred O
in O
Gifu RARE
prefecture RARE
. O

A O
22K NUMERIC
polypeptide O
was O
detected O
as O
a O
translation O
product O
of O
late O
RNA O
that O
hybridized O
to O
this O
DNA O
fragment O
. O

Replicating RARE
simian O
virus O
40 O
( O
SV40 O
) O
chromosomes O
were O
found O
to O
be O
similar O
to O
other O
eukaryotic O
chromosomes O
in O
that O
the O
rate O
and O
extent O
of O
micrococcal RARE
nuclease I-GENE
( O
MNase RARE
) O
digestion O
were O
greater O
with O
replicating O
than O
with O
nonreplicating RARE
mature O
SV40 O
chromatin O
. O

A O
hypothesis O
. O

We O
have O
investigated O
the O
requirements O
of O
the O
CH ALLCAPS
gene I-GENE
switch O
by O
characterizing O
two O
rearranged I-GENE
gamma I-GENE
2b I-GENE
genes I-GENE
from O
a O
gamma I-GENE
2b I-GENE
producing O
mouse O
myeloma O
( O
MPC ALLCAPS
- O
11 O
). O

Physiology RARE
and O
Physiopathology RARE

The O
genome O
of O
avian O
erythroblastosis RARE
virus O
contains O
two O
independently O
expressed O
genetic O
loci O
( O
v I-GENE
- I-GENE
erbA I-GENE
and O
v I-GENE
- I-GENE
erbB I-GENE
) O
whose O
activities O
are O
probably O
responsible O
for O
oncogenesis RARE
by O
the O
virus O
. O

Because O
RNase I-GENE
III I-GENE
host I-GENE
mutants I-GENE
are O
defective O
in O
sib RARE
regulation O
, O
processing O
of O
the O
PL I-GENE
mRNA I-GENE
at O
sib RARE
by O
this O
endoribonuclease RARE
may O
cause O
int I-GENE
mRNA I-GENE
decay O
and O
decrease O
int I-GENE
synthesis O
. O

At O
least O
one O
clone O
, O
lambda O
HHG ALLCAPS
41 O
, O
contains O
, O
in O
addition O
to O
the O
histone I-GENE
genes I-GENE
, O
a O
region O
that O
hybridizes RARE
with O
a O
cytoplasmic O
RNA O
approximately O
330 NUMERIC
nucleotides O
in O
length O
. O

Both O
neural O
and O
hormonal O
pathways O
and O
both O
opiate O
and O
nonopiate RARE
substances O
play O
roles O
in O
the O
complex O
modulation O
of O
pain O
transmission O
. O

Restoration RARE
of O
impaired O
immune O
functions O
in O
aging O
animals O
. O

Postoperative RARE
serum O
ACTH I-GENE
levels O
were O
normal O
. O

WR O
- O
2721 O
( O
S O
- O
2 O
-( O
3 O
aminopropylamino RARE
) O
ethylphosphorothioic RARE
acid O
) O
has O
been O
investigated O
for O
its O
ability O
to O
protect O
gut O
, O
lung O
, O
and O
testis O
, O
as O
well O
as O
fibrosarcoma RARE
( O
FSa RARE
) O
tumor O
nodules O
, O
in O
the O
lungs O
of O
mice O
from O
gamma O
- O
radiation O
injury O
. O

In O
fact O
, O
families O
of O
polypeptides O
were O
produced O
by O
initiation O
of O
translation O
at O
AUG O
codons O
within O
sequences O
coding O
for O
VP1 NUMERIC
and O
T I-GENE
, O
presumably O
as O
a O
result O
of O
transcription O
initiation O
events O
that O
generated O
5 O
' O
ends O
immediately O
upstream O
from O
these O
AUGs RARE
. O

In O
addition O
, O
TRP1 NUMERIC
RI O
Circle RARE
DNA O
is O
organized O
into O
nucleosomes RARE
whose O
size O
and O
spacing RARE
are O
indistinguishable O
from O
that O
of O
bulk O
yeast O
chromatin O
. O

The O
frequency O
of O
previous O
transfusion O
in O
chronic O
hepatitis O
, O
cirrhosis O
and O
hepatocellular RARE
carcinoma O
of O
type O
NANB O
was O
42 O
. O
8 O
, O
37 O
. O
1 O
and O
15 O
. O
1 O
%, O
respectively O
, O
whereas O
the O
incidence O
of O
early O
posttransfusion RARE
hepatitis O
was O
8 O
. O
5 O
, O
8 O
. O
6 O
and O
7 O
. O
5 O
%, O
respectively O
. O
in O
chronic O
liver O
diseases O
with O
a O
history O
of O
jaundice O
and O
/ O
or O
hepatitis O
, O
previous O
transfusions RARE
are O
more O
frequently O
associated O
with O
type O
NANB O
than O
with O
type O
B O
disease O
. O

Of O
115 O
hepatitis O
B O
patients O
seen O
at O
12 O
months O
, O
6 O
% O
had O
chronic O
hepatitis O
Bs RARE
antigenaemia RARE
, O
60 O
% O
had O
developed O
anti I-GENE
- I-GENE
HBs I-GENE
antibodies I-GENE
, O
and O
7 O
. O
3 O
% O
still O
had O
abnormal O
liver O
function O
. O

Survey RARE
on O
antibody O
against O
egg O
drop O
syndrome O
- O
1976 NUMERIC
virus O
among O
chicken O
flocks RARE
in O
Japan O
. O

In O
49 O
patients O
in O
whom O
gated O
equilibrium O
ventriculography RARE
and O
cardiac O
catheterization RARE
were O
performed O
within O
a O
6 O
day O
interval O
, O
total O
and O
fractional O
portions O
of O
global O
and O
regional O
right O
ventricular O
ejection O
fraction O
( O
RVEF ALLCAPS
) O
were O
correlated O
with O
pulmonary O
arterial O
systolic O
pressure O
. O

74 O
, O
193 O
- O
197 NUMERIC
). O

The O
combination O
of O
MISO ALLCAPS
and O
WR O
- O
2721 O
gave O
an O
intermediate O
response O
compared O
with O
either O
drug O
used O
alone O
, O
resulting O
in O
some O
sensitization O
with O
single O
doses O
and O
an O
overall O
protection O
with O
repeated O
small O
doses O
. O

Two O
mutations O
that O
affect O
larval I-GENE
cuticle RARE
protein I-GENE
gene I-GENE
expression O
in O
the O
2 O
/ O
3 O
variant O
Drosophila O
melanogaster O
strain O
were O
investigated O
. O

The O
ensembles RARE
are O
considered O
to O
be O
one O
of O
the O
forms O
of O
activity O
of O
the O
structured O
morphofunctional RARE
cortical O
units O
, O
i O
. O
e O
. O
the O
columns RARE
. O

The O
strong O
conservation O
of O
the O
inverted O
terminal O
repeat O
sequence O
may O
reflect O
a O
common O
integration O
mechanism O
for O
VL30 NUMERIC
elements I-GENE
and O
MuLV O
proviruses RARE
. O

A O
cDNA O
cloning O
vector O
that O
permits O
expression O
of O
cDNA O
inserts O
in O
mammalian O
cells O
. O

Hybridization O
of O
plasmid O
- O
transformed O
Escherichia O
coli O
RR1 NUMERIC
colonies O
with O
32P O
- O
labeled O
viral O
genome O
RNAs O
demonstrated O
the O
presence O
of O
DNA O
clones O
representative O
of O
each O
of O
the O
10 O
reovirus RARE
RNAs O
and O
10 O
of O
the O
11 O
constituent RARE
segments O
of O
the O
rotavirus RARE
genome O
. O

Another O
sequence O
, O
GGGXGGAG ALLCAPS
, O
which O
is O
repeated O
several O
times O
in O
many O
polyomaviruses RARE
and O
adenoviruses RARE
, O
and O
which O
is O
thought O
to O
play O
a O
role O
in O
DNA O
replication O
and O
/ O
or O
transcription O
, O
is O
not O
found O
in O
the O
JCV ALLCAPS
sequence O
presented O
. O

In O
conclusion O
, O
these O
studies O
indicate O
that O
LiCl RARE
( O
1 O
) O
decreases O
histamine O
- O
stimulated O
gastric O
acid O
secretion O
, O
and O
( O
2 O
) O
diminishes RARE
bile O
- O
induced O
disruption O
of O
the O
gastric O
mucosal O
barrier O
in O
the O
canine O
Heidenhain RARE
pouch RARE
. O

Lung O
density O
increased O
in O
quartz RARE
- O
exposed O
, O
but O
not O
in O
volcanic RARE
- O
ash RARE
- O
exposed O
animals O
. O

The O
hepatitis I-GENE
A I-GENE
virus I-GENE
antibody I-GENE
( O
anti I-GENE
- I-GENE
HAV ALLCAPS
) O
in O
chronic O
diffuse O
liver O
diseases O

The O
junctions O
between O
viral O
and O
cellular O
sequences O
were O
determined O
by O
DNA O
sequence O
analysis O
to O
be O
517 NUMERIC
nucleotides O
into O
the O
p30 NUMERIC
sequence I-GENE
and O
1 O
, O
920 NUMERIC
nucleotides O
into O
the O
polymerase O
sequence O
. O

Naloxone RARE
( O
2 O
mg O
/ O
kg O
bolus O
+ O
2 O
mg O
X O
kg O
- O
1 O
X O
h O
- O
1 O
) O
was O
given O
with O
one O
of O
the O
two O
doses O
of O
the O
lipopolysaccharide O
. O

Gel O
route O
preparation O
of O
low O
fusing RARE
dental O
porcelain RARE
frit RARE
. O

I O
. O

Viral RARE
RNA O
, O
molecularly O
cloned O
proviral O
DNA O
, O
and O
virus O
- O
specific O
protein O
of O
avian O
retrovirus O
MH2 NUMERIC
were O
analyzed O
. O

Intracellular RARE
recordings O
were O
performed O
on O
the O
optic O
tectum RARE
of O
the O
carp RARE
in O
vitro O
. O

Molecular O
structure O
and O
evolutionary O
origin O
of O
human I-GENE
cardiac I-GENE
muscle I-GENE
actin I-GENE
gene I-GENE
. O

The O
mutants O
were O
obtained O
by O
substitution O
into O
a O
molecular O
clone O
of O
M O
- O
MuLV O
DNA O
by O
DNA O
from O
two O
acutely RARE
transforming O
viruses O
, O
Ableson RARE
MuLV O
( O
Ab O
- O
MuLV O
) O
and O
Moloney O
murine O
sarcoma O
virus O
( O
M O
- O
MSV ALLCAPS
). O

Plasmids RARE
for O
the O
cloning O
and O
expression O
of O
full O
- O
length O
double O
- O
stranded O
cDNAs O
under O
control O
of O
the O
SV40 I-GENE
early I-GENE
or O
late I-GENE
gene I-GENE
promoter O
. O

Supplementing RARE
a O
soybean O
protein O
and O
sucrose O
- O
based O
diet O
with O
levels O
of O
2 O
. O
2 O
, O
11 O
, O
and O
55 O
ppm O
of O
the O
antibiotic O
, O
from O
the O
two O
sources O
each O
with O
two O
different O
purities RARE
, O
improved O
weight O
gain O
of O
chicks O
an O
average O
of O
23 O
% O
and O
improved O
feed O
efficiency O
an O
average O
of O
13 O
% O
at O
the O
higher O
levels O
( O
all O
P O
less O
than O
. O
01 O
). O

The O
dnaQ LASTCAP
- O
lacZ I-GENE
and O
the O
rnh RARE
- O
lacZ I-GENE
fused O
genes O
were O
constructed O
and O
hybrid O
proteins O
with O
beta I-GENE
- I-GENE
galactosidase I-GENE
activity O
were O
produced O
. O

Overall O
prevalences RARE
of O
antibody O
were O
70 O
per O
cent O
in O
cattle O
, O
67 O
per O
cent O
in O
sheep O
and O
76 O
per O
cent O
in O
goats O
as O
assessed O
by O
an O
immunodiffusion RARE
test O
. O

Expression O
of O
herpes O
simplex O
virus O
beta O
and O
gamma O
genes O
integrated O
in O
mammalian O
cells O
and O
their O
induction O
by O
an O
alpha O
gene O
product O
. O

The O
splice O
acceptor O
site O
is O
ca RARE
. O

This O
is O
consistent O
with O
a O
model O
proposing RARE
that O
SSV ALLCAPS
was O
generated O
by O
recombination O
between O
proviral O
DNA O
of O
a O
simian O
sarcoma O
associated O
virus O
and O
proto I-GENE
- I-GENE
sis RARE
and O
that O
introns O
were O
spliced O
out O
subsequently O
from O
a O
fused O
viral I-GENE
- I-GENE
sis RARE
messenger I-GENE
RNA I-GENE
. O

We O
conclude O
that O
, O
with O
autonomic RARE
nervous O
system O
activity O
intact O
, O
carotid O
chemoreceptor RARE
reflex O
activation O
can O
elicit O
an O
absolute O
reflexly RARE
mediated O
reduction O
in O
coronary O
blood O
flow O
in O
the O
normal O
, O
conscious O
dog O
, O
despite O
an O
increase O
in O
arterial O
pressure O
. O

Female O
subjects O
, O
including O
both O
normal O
subjects O
and O
idiopathic O
calcium O
stone O
- O
formers RARE
, O
have O
higher O
urinary O
cyclic O
AMP O
levels O
than O
their O
male O
counterparts O
, O
and O
this O
difference O
is O
significant O
when O
urinary O
cyclic O
AMP O
is O
expressed O
in O
the O
units O
mumol O
/ O
g O
of O
creatinine O
. O

We O
conclude O
that O
the O
' O
morning RARE
dip RARE
' O
observed O
in O
asthmatic O
patients O
cannot O
simply RARE
be O
explained O
by O
changes O
in O
cell O
receptor O
number O
or O
affinity O
, O
as O
our O
results O
suggest O
that O
both O
groups O
have O
intact O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
function O
. O

The O
effect O
of O
desipramine O
probably O
represents O
inhibition O
of O
neuronal O
uptake O
and O
that O
of O
amitriptyline RARE
and O
mianserin RARE
blockade O
of O
neuronal O
uptake O
and O
prejunctional RARE
alpha I-GENE
2 I-GENE
- I-GENE
adrenoreceptors RARE
. O

We O
conclude O
that O
the O
gp54 NUMERIC
structural I-GENE
gene I-GENE
is O
required O
for O
initiation O
or O
amplification O
of O
the O
splenic O
erythroblast RARE
hyperplasia O
which O
characterizes RARE
the O
preleukemic RARE
phase O
of O
Rauscher RARE
disease O
. O

Surgical RARE
treatment O
of O
pulmonary O
metastases O
. O

A O
promoter O
sequence O
( O
Goldberg RARE
- O
Hogness RARE
or O
TATA O
box O
) O
is O
situated O
28 O
base O
pairs O
upstream O
from O
the O
point O
of O
initiation O
of O
transcription O
which O
was O
found O
by O
S1 I-GENE
nuclease I-GENE
mapping O
and O
by O
oligonucleotide O
- O
primed O
reverse O
transcription O
of O
rat I-GENE
PTH I-GENE
mRNA I-GENE
. O

Each O
of O
these O
spliced O
mRNAs O
has O
an O
untranslated O
leader O
sequence O
of O
249 NUMERIC
bases O
and O
a O
single O
intron O
of O
approximately O
540 NUMERIC
bases O
which O
are O
contained O
entirely O
within O
TRs RARE
/ O
IRs RARE
sequences O
. O

The O
expression O
of O
chloramphenicol I-GENE
acetyltransferase I-GENE
was O
detected O
within O
1 O
h O
after O
infection O
of O
cells O
with O
recombinant O
virus O
, O
reflecting O
the O
early O
nature O
of O
the O
promoters O
used O
. O

NPT ALLCAPS
II I-GENE
synthesis O
, O
measured O
by O
agar O
plate O
assays O
of O
kanamycin RARE
resistance O
and O
by O
immunoprecipitation O
of O
the O
NPT ALLCAPS
II I-GENE
protein I-GENE
, O
was O
repressed O
in O
the O
presence O
of O
cysteine O
and O
derepressed RARE
in O
its O
absence O
. O

A O
computed O
tomographic RARE
scan O
obtained O
after O
EOE ALLCAPS
- O
13 O
infusion O
accurately O
showed O
the O
perfusion O
pattern O
of O
the O
implanted O
catheter O
. O

The O
primary O
structure O
of O
the O
GAL7 NUMERIC
5 I-GENE
' I-GENE
flanking I-GENE
region I-GENE
has O
many O
features O
common O
to O
those O
of O
multicellular RARE
eukaryotic O
genes O
. O

The O
12 I-GENE
, I-GENE
000 I-GENE
MW ALLCAPS
( I-GENE
12K NUMERIC
) I-GENE
IE I-GENE
polypeptide I-GENE
encoded O
by O
IEmRNA LASTCAP
- I-GENE
5 I-GENE
is O
translated O
from O
an O
88 O
codon O
open O
reading O
frame O
, O
leaving RARE
a O
1200 NUMERIC
base O
3 O
' O
non O
- O
translated O
region O
. O

The O
greatest O
difference O
between O
the O
Ad7 NUMERIC
and I-GENE
Ad5 I-GENE
DBPs RARE
is O
the O
absence O
, O
in O
the O
Ad7 NUMERIC
protein O
, O
of O
12 O
amino O
acids O
located O
between O
the O
two O
functional O
domains O
in O
the O
Ad5 O
protein O
( O
amino O
acids O
151 O
- O
162 NUMERIC
). O

No O
significant O
correlation O
was O
found O
between O
LVM ALLCAPS
or O
wall O
thickness O
and O
body O
surface O
area O
, O
age O
, O
blood O
pressure O
, O
heart O
rate O
, O
cardiac O
output O
, O
total O
peripheral O
resistance O
and O
left O
ventricular O
systolic O
wall O
stress O
, O
whereas O
CD25 NUMERIC
was O
correlated O
with O
urinary O
catecholamines O
only O
in O
hypertensive O
patients O
( O
r O
= O
0 O
. O
606 NUMERIC
, O
p O
less O
than O
0 O
. O
001 O
). O

Furthermore O
, O
no O
Shine RARE
- O
Dalgarno RARE
sequences O
are O
present O
upstream O
of O
the O
presumed O
translational O
start O
codons O
. O

The O
gene I-GENE
cat I-GENE
- I-GENE
86 I-GENE
, O
specifying RARE
chloramphenicol I-GENE
- I-GENE
inducible I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
, O
is O
located O
on O
the O
1 O
. O
1 O
- O
kilobase O
cloned O
DNA O
. O

The O
myeloproliferative RARE
sarcoma O
virus O
( O
MPSV ALLCAPS
) O
was O
derived O
by O
passage O
of O
Moloney O
sarcoma O
virus O
( O
Mo RARE
- O
MuSV LASTCAP
) O
in O
adult O
mice O
. O

The O
same O
- O
sized O
EBNA I-GENE
protein I-GENE
( I-GENE
approximately I-GENE
78 I-GENE
, I-GENE
000 I-GENE
) I-GENE
was O
made O
after O
transfection O
with O
BamHI I-GENE
- I-GENE
K I-GENE
( I-GENE
5 I-GENE
. I-GENE
2 I-GENE
kilobase I-GENE
pairs I-GENE
[ I-GENE
kbp I-GENE
]) I-GENE
or O
the O
I1f NUMERIC
subfragment RARE
( O
2 O
. O
9 O
kbp O
). O

They O
generated O
ca RARE
. O

Here O
we O
have O
determined O
the O
nucleotide O
sequence O
of O
3 O
. O
5 O
kb O
from O
the O
3 O
' O
end O
of O
delta I-GENE
gag I-GENE
to O
the O
3 O
' O
end O
of O
molecularly O
cloned O
proviral O
MH2 NUMERIC
DNA O
, O
in O
order O
to O
elucidate O
the O
genetic O
structure O
of O
the O
virus O
and O
to O
compare O
it O
with O
other O
mht RARE
- O
and O
myc I-GENE
- O
containing O
oncogenic O
viruses O
as O
well O
as O
with O
the O
chicken I-GENE
proto I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

USA ALLCAPS
80 O
, O
802 NUMERIC
- O
806 NUMERIC
] O
was O
used O
to O
isolate O
a O
genomic O
clone O
lambda O
PGK ALLCAPS
- I-GENE
1 I-GENE
containing O
a O
portion O
of O
an O
autosomal RARE
locus O
for O
phosphoglycerate RARE
kinase I-GENE
( O
PGK ALLCAPS
). O

A O
. O

188 NUMERIC
patients O
received O
cimetidine O
400 O
mg O
q O
. O
i O
. O
d O
. O
intravenously O
and O
1 O
, O
000 O
mg O
daily O
orally O
in O
divided O
doses O
. O

An O
immunologic O
test O
using O
stomach O
and O
tumor O
antigens O
for O
screening O
of O
those O
at O
high O
risk O
for O
stomach O
cancer O
is O
suggested O
. O

Thirty O
isolates O
of O
Haemophilus O
influenzae O
type O
b O
were O
obtained O
during O
an O
outbreak O
of O
invasive O
H O
. O
influenzae O
type O
b O
disease O
and O
were O
classified O
by O
the O
electrophoretic O
profile O
of O
their O
lipopolysaccharide O
( O
LPS O
). O

Tiaprofenic RARE
acid O
overdose RARE
. O

Frog RARE
type O
I O
( O
Ft O
I O
) O
and O
frog RARE
type O
II O
( O
Ft O
II O
) O
slowly O
adapting O
( O
SA O
) O
units O
produced O
spikes O
only O
at O
the O
indentation RARE
phase O
, O
and O
the O
threshold O
response O
phase O
( O
TRP ALLCAPS
), O
i O
. O
e O
.. RARE
the O
phase O
of O
the O
first O
spike RARE
was O
for O
ca RARE
. O

Frog RARE
type O
I O
( O
Ft O
I O
) O
and O
frog RARE
type O
II O
( O
Ft O
II O
) O
slowly O
adapting O
( O
SA O
) O
units O
produced O
spikes O
only O
at O
the O
indentation RARE
phase O
, O
and O
the O
threshold O
response O
phase O
( O
TRP ALLCAPS
), O
i O
. O
e O
.. RARE
the O
phase O
of O
the O
first O
spike RARE
was O
for O
ca RARE
. O

DMCM ALLCAPS
also O
permits O
extension O
of O
the O
possibilities O
of O
obtaining O
and O
transplanting RARE
donor O
organs O
. O

Grimelius RARE
stain O
was O
positive O
, O
Masson RARE
Fontana RARE
stain O
negative O
. O

Blood O
glucose O
and O
plasma O
insulin I-GENE
were O
measured O
at O
zero O
time O
and O
then O
at O
15 O
, O
30 O
, O
60 O
, O
90 O
and O
120 O
min O
after O
ingestion O
of O
25 O
g O
glucose O
, O
fructose O
or O
lactose RARE
, O
or O
30 O
g O
honey RARE
, O
50 O
g O
white O
bread RARE
, O
125 O
g O
white O
rice O
or O
potatoes RARE
, O
150 O
g O
apples RARE
or O
260 O
g O
carrots RARE
. O

Clinical O
use O
of O
absorbable RARE
polyglycolic RARE
acid O
suture RARE
in O
Blalock RARE
- O
Taussig RARE
' O
s O
operation O

Among O
these O
are O
: O
( O
1 O
) O
Is O
there O
sufficient O
understanding O
of O
family O
pathophysiology O
, O
of O
the O
sensitivity O
and O
specificity O
of O
diagnostic O
techniques O
and O
of O
the O
safety O
and O
efficacy O
of O
therapeutic O
modalities O
to O
make O
true O
family O
health O
care O
possible O
? O
( O
2 O
) O
If O
this O
type O
of O
care O
is O
possible O
, O
how O
are O
the O
needs O
of O
the O
family O
and O
its O
individual O
members O
met O
, O
or O
value O
judgements RARE
made O
about O
their O
relative O
importance O
? O
and O
( O
3 O
) O
What RARE
are O
the O
consequences O
for O
the O
health O
care O
delivery O
system O
of O
this O
type O
of O
care O
? O
An O
extensive O
literature O
review O
is O
used O
in O
an O
attempt O
to O
answer RARE
these O
queries RARE
, O
from O
which O
questions O
for O
further O
study O
are O
posed RARE
. O

In O
patients O
in O
group O
A O
(" O
normal O
" O
CI O
), O
the O
CI O
, O
heart O
rate O
and O
the O
mean O
circumferential RARE
fiber O
shortening O
velocity O
( O
mVCF LASTCAP
) O
were O
normal O
, O
but O
the O
TPR O
was O
increased O
significantly O
. O

Immunologically RARE
reactive O
insulin I-GENE
levels O
were O
determined O
in O
freely RARE
- O
moving RARE
normal O
rats O
offered O
three O
different O
test O
- O
meals RARE
. O

These O
results O
indicate O
that O
both O
naturally O
acquired O
and O
passive O
( O
modified O
immune I-GENE
serum I-GENE
globulin I-GENE
) O
antibodies O
to O
type I-GENE
III I-GENE
group I-GENE
B I-GENE
Streptococcus I-GENE
antigen I-GENE
are O
partially O
protective O
against O
intra O
- O
amniotic O
infection O
. O

In O
the O
posthospital RARE
phase O
of O
AMI O
, O
as O
well O
as O
in O
CCHD ALLCAPS
, O
the O
occurrence O
of O
high O
- O
grade O
VPBs RARE
usually O
indicates O
more O
advanced O
degrees O
of O
both O
coronary O
and O
left O
ventricular O
disease O
as O
well O
as O
the O
possibility O
of O
cardiac O
and O
/ O
or O
sudden RARE
death O
. O

Sweet RARE
oranges RARE
, O
mandarin RARE
, O
grapefruit RARE
, O
lemon RARE
, O
and O
lime RARE
are O
generally O
used O
for O
processing O
. O

The O
genes O
at O
each O
locus O
are O
divergently O
transcribed O
and O
the O
coding O
sequences O
are O
separated O
by O
646 NUMERIC
base O
- O
pairs O
at O
one O
locus O
and O
676 NUMERIC
base O
- O
pairs O
at O
the O
other O
. O

The O
enzymic RARE
hydrolysis O
of O
urea O
produces O
ammonia O
which O
causes O
a O
vivid RARE
yellow O
to O
purple RARE
colour O
change O
in O
the O
pH O
indicator O
. O

The O
clinical O
efficacy O
rates O
evaluated O
in O
151 O
cases O
( O
KS O
- O
R1 O
group O
in O
77 O
cases O
, O
oral O
group O
in O
74 O
cases O
) O
on O
standard O
criteria O
of O
committee RARE
members O
were O
88 O
. O
3 O
% O
for O
the O
KS O
- O
R1 O
group O
and O
86 O
. O
5 O
% O
for O
the O
oral O
group O
, O
respectively O
. O

Side RARE
effect O
including O
subjective RARE
and O
objective O
symptoms O
were O
strictly O
evaluated O
in O
163 NUMERIC
cases O
( O
KS O
- O
R1 O
group O
in O
83 O
cases O
, O
oral O
group O
in O
80 O
cases O
), O
but O
the O
incidence O
rate O
which O
was O
22 O
. O
9 O
% O
for O
the O
KS O
- O
R1 O
group O
and O
23 O
. O
8 O
% O
for O
the O
oral O
group O
showed O
no O
significant O
difference O
. O

Plasma O
renin I-GENE
activity O
did O
not O
change O
in O
response O
to O
head O
- O
up O
tilt O
or O
isoprenaline RARE
infusion O
in O
the O
patients O
. O

Martin RARE
Luther RARE
and O
his O
physicians O
. O

Enhancement RARE
of O
the O
immune O
response O
by O
aspecific RARE
action O
of O
vaccine O
additives RARE
in O
the O
aerogenic RARE
immunization O
of O
swine O
against O
swine O
plague RARE

Induced RARE
gamma O
- O
ray O
spectroscopy O

Bepridil RARE
, O
a O
calcium O
antagonist O
with O
a O
half O
- O
life O
of O
approximately O
42 O
hours O
, O
was O
compared O
with O
placebo O
in O
a O
double O
- O
blind O
, O
randomized O
, O
crossover RARE
trial O
. O

Analysis O
of O
proteins O
synthesized O
by O
plasmids O
containing O
deleted O
forms O
of O
the O
trfA LASTCAP
region I-GENE
indicates O
that O
the O
A2 I-GENE
protein I-GENE
is O
the O
essential O
trfA LASTCAP
- I-GENE
encoded I-GENE
replication I-GENE
protein I-GENE
of O
plasmid O
RK2 NUMERIC
. O

Effects O
of O
negative O
pleural O
pressure O
on O
left O
ventricular O
hemodynamics O
. O

Resting RARE
plasma O
norepinephrine O
( O
NE O
) O
and O
epinephrine O
( O
E O
) O
levels O
were O
lower O
during O
active O
therapy O
than O
2 O
wk O
after O
withdrawal O
( O
guanfacine RARE
and O
control O
: O
plasma O
NE O
, O
0 O
. O
27 O
+/- O
0 O
. O
03 O
/ O
0 O
. O
64 O
+/- O
0 O
. O
13 O
ng O
/ O
ml O
; O
plasma O
E O
, O
0 O
. O
09 O
+/- O
0 O
. O
02 O
/ O
0 O
. O
17 O
+/- O
0 O
. O
05 O
ng O
/ O
ml O
). O

Renal O
response O
to O
captopril O
in O
severe O
heart O
failure O
: O
role O
of O
furosemide O
in O
natriuresis RARE
and O
reversal O
of O
hyponatremia RARE
. O

Lauciello RARE
describes O
a O
technique O
for O
the O
placement O
of O
functionally O
generated O
amalgam RARE
stops RARE
as O
restorations O
within O
mandibular O
acrylic RARE
teeth O
. O

Eleven RARE
biopsy O
specimens O
( O
five O
papules RARE
and O
six O
dusky RARE
or O
crusted RARE
lesions O
) O
from O
four O
patients O
with O
pityriasis RARE
lichenoides RARE
et O
varioliformis RARE
acuta RARE
( O
PLEVA ALLCAPS
) O
were O
studied O
by O
direct O
immunofluorescence O
and O
immunoperoxidase RARE
technics RARE
. O

These O
data O
suggest O
that O
a O
major O
part O
of O
the O
reduction O
in O
food O
intake O
in O
hyperphagic RARE
rats O
eating RARE
a O
quinine RARE
- O
adulterated RARE
diet O
is O
due O
to O
postingestional RARE
events O
. O

The O
aspirate RARE
from O
a O
parathyroid O
cyst O
was O
watery RARE
clear O
and O
contained O
high O
amount O
of O
parathyroid I-GENE
hormone I-GENE
. O

EGV ALLCAPS
had O
no O
detectable O
effect O
on O
PP I-GENE
secretion O
under O
basal O
or O
stimulated O
conditions O
. O

The O
numerous O
tests O
demonstrate O
that O
the O
HDL O
- O
2M NUMERIC
can O
be O
extensively O
and O
successfully O
used O
for O
therapy O
of O
insulin I-GENE
- O
dependent O
diabetes O
mellitus O
in O
clinical O
practice O
. O

Lung O
prostacyclin RARE
production O
may O
be O
related O
to O
flow O
. O

For O
the O
first O
30 O
min O
following O
insulin I-GENE
administration O
, O
the O
rate O
of O
change O
in O
glucose O
levels O
was O
significantly O
less O
among O
the O
patients O
with O
major O
depressive RARE
disorder O
than O
among O
either O
the O
patients O
with O
dysthymic RARE
disorder O
or O
the O
normal O
control O
subjects O
. O

Management RARE
of O
hypertension O
in O
the O
elderly O
. O

Climatic RARE
treatment O
of O
children O
with O
respiratory O
allergy O

Transplantation RARE
of O
kidneys O
of O
juvenile O
donors O
in O
adult O
recipients O
. O

Ten O
patients O
with O
advanced O
, O
diffuse O
Hodgkin O
' O
s O
and O
non O
- O
Hodgkin O
' O
s O
lymphomas O
responding O
poorly O
to O
the O
most O
widely O
employed O
primary O
chemotherapy O
regimens O
were O
treated O
with O
a O
high O
- O
dose O
chemotherapy O
( O
HDC ALLCAPS
) O
followed O
by O
rescue O
with O
non O
- O
frozen RARE
autologous O
bone O
marrow O
infusion O
( O
ABMT ALLCAPS
). O

Effect O
of O
proteolytic O
enzymes O
and O
polypeptides O
on O
the O
antacid RARE
activity O
of O
almagate RARE
and O
other O
antacids RARE
. O

Results O
of O
a O
controlled O
study O

Hydrallazine RARE
also O
caused O
a O
slight O
increase O
in O
plasma I-GENE
renin I-GENE
activity O
and O
urinary O
excretion O
of O
noradrenaline O
. O

Urease RARE
activity O
of O
97 O
% O
of O
these O
organisms O
became O
evident O
within O
30 O
min O
. O

After O
description O
of O
his O
short O
life O
and O
an O
explanation O
of O
the O
light O
conductor RARE
Bozzini RARE
' O
s O
merit RARE
is O
emphasized RARE
, O
by O
his O
invention RARE
as O
first O
physician RARE
to O
have O
made O
accessible RARE
to O
medicine O
endoscopic RARE
diagnostic O
possibilities O
. O

The O
effect O
of O
lithium O
on O
the O
osmoregulation RARE
of O
arginine I-GENE
vasopressin I-GENE
secretion O
. O

The O
susceptibility O
of O
the O
PPNG ALLCAPS
strains O
to O
clinically O
relevant O
antibiotics O
varied O
with O
the O
plasmid O
pattern O
; O
this O
stresses O
the O
necessity RARE
of O
permanent O
surveillance RARE
of O
gonococcal RARE
infections O
and O
of O
regular O
evaluation O
of O
the O
recommendations RARE
for O
antimicrobial O
treatment O
. O

Antithrombin RARE
III I-GENE
( O
AT I-GENE
III I-GENE
) O
is O
a O
plasma O
protein O
which O
acts O
as O
the O
principal O
inhibitor O
of O
thrombin I-GENE
and O
is O
a O
major O
modulator RARE
of O
intravascular O
coagulation O
. O

Eighteen RARE
patients O
were O
untreated O
, O
and O
8 O
had O
been O
given O
previous O
treatment O
with O
depot RARE
testosterone O
100 O
mg O
intramuscularly RARE
every O
2 O
- O
3 O
weeks O
for O
an O
average O
duration O
of O
4 O
. O
7 O
years O
. O

195mPt NUMERIC
- O
labeled O
cisplatin O
was O
administered O
iv O
and O
ip RARE
to O
control O
mice O
and O
to O
mice O
bearing O
Sarcoma RARE
180 O
. O

New O
beta O
- O
blocking O
drugs O
have O
been O
introduced O
which O
may O
prove O
beneficial O
in O
certain O
clinical O
situations O
since O
they O
exert O
more O
selective O
blockade O
of O
the O
cardiac I-GENE
receptors I-GENE
( O
beta1 I-GENE
) O
as O
opposed O
to O
smooth I-GENE
muscle I-GENE
receptors I-GENE
( O
beta2 I-GENE
). O

If O
facilities RARE
for O
measurements O
of O
O2 O
consumption O
and O
hence O
metabolic O
rate O
are O
available O
, O
these O
should O
be O
utilized O
. O

This O
generally O
means O
an O
energy O
intake O
of O
1 O
. O
4 O
to O
1 O
. O
6 O
times O
the O
energy O
expenditure O
, O
with O
a O
N O
intake O
of O
250 O
to O
400 O
mg O
/ O
kg O
/ O
day O
. O

In O
the O
37 O
patients O
without O
lung O
disease O
respiratory O
muscle O
weakness RARE
was O
accompanied O
by O
significant O
decreases O
in O
vital O
capacity O
, O
total O
lung O
capacity O
, O
and O
maximum O
voluntary RARE
ventilation O
; O
by O
significant O
increases O
in O
residual O
volume O
and O
arterial O
carbon O
dioxide O
tension O
( O
PaCO2 O
); O
and O
greater O
likelihood O
of O
dependence O
on O
ventilators RARE
, O
atelectasis RARE
, O
and O
pneumonia O
. O

Commun RARE
. O

The O
statistical O
analysis O
of O
data O
of O
TRH I-GENE
test O
on O
a O
sample O
of O
57 O
healthy O
volunteers O
has O
permitted O
an O
evaluation O
of O
the O
upper O
limits O
of O
the O
normal O
thyrotropin I-GENE
response O
; O
the O
secretory O
area O
( O
As O
) O
was O
shown O
to O
be O
more O
discriminating RARE
. O

Total O
cumulative O
doses O
of O
doxorubicin RARE
ranged O
from O
145 NUMERIC
to O
625 NUMERIC
mg O
./ RARE
m O
. O
2 O
. O

Movement RARE
programming RARE
depends O
on O
understanding O
of O
behavioral O
requirements O
. O

Following O
20 O
min O
of O
steady O
state O
anaesthesia O
during O
which O
measurements O
of O
IOP O
, O
arterial O
pressure O
, O
heart O
rate O
, O
FIO2 NUMERIC
, O
FE ALLCAPS
' O
CO2 O
and O
CVP ALLCAPS
were O
recorded O
, O
one O
group O
of O
patients O
received O
atracurium RARE
0 O
. O
45 O
mg O
kg O
- O
1 O
and O
the O
other O
pancuronium RARE
0 O
. O
1 O
mg O
kg O
- O
1 O
. O

Transitory RARE
subclinical O
and O
permanent O
hypothyroidism O
in O
the O
course O
of O
subacute O
thyroiditis O
( O
de O
Quervain RARE
). O

Gonadotropin RARE
levels O
in O
mothers O
who O
have O
had O
two O
sets O
of O
DZ ALLCAPS
twins RARE
. O

Freezing RARE
of O
plasma O
to O
obtain O
better O
yield O
of O
factor I-GENE
VIII I-GENE
: O
C O
. O

These O
children O
were O
grouped RARE
into O
four O
diagnostic O
categories O
: O
1 O
) O
idiopathic O
GH I-GENE
deficiency O
( O
n O
= O
10 O
); O
2 O
) O
organic O
hypopituitarism RARE
( O
n O
= O
7 O
); O
3 O
) O
intrauterine O
growth O
retardation O
( O
n O
= O
5 O
); O
and O
4 O
) O
constitutional RARE
delay O
of O
growth O
and O
/ O
or O
familial O
short O
stature RARE
( O
n O
= O
18 O
), O
by O
standard O
clinical O
criteria O
and O
physiological O
and O
pharmacological O
tests O
of O
GH I-GENE
reserve O
. O

Each O
patient O
had O
measurable RARE
LH I-GENE
and O
FSH I-GENE
levels O
, O
with O
pulsed O
nocturnal RARE
secretion O
, O
and O
pubertal RARE
LH I-GENE
and O
FSH I-GENE
responses O
to O
LRH ALLCAPS
. O

These O
changes O
were O
the O
result O
of O
a O
decrease O
in O
afterload RARE
: O
mean O
aortic O
pressure O
fell O
from O
85 O
+/- O
11 O
. O
8 O
to O
68 O
+/- O
19 O
. O
6 O
mmHg O
( O
p O
less O
than O
0 O
. O
01 O
) O
and O
systemic O
arterial O
resistance O
fell O
from O
2 O
886 NUMERIC
+/- O
745 NUMERIC
to O
2 O
010 NUMERIC
+/- O
610 NUMERIC
dynes RARE
/ O
cm O
- O
5 O
/ O
sec O
/ O
m O
- O
2 O
( O
p O
less O
than O
0 O
. O
01 O
). O

Cimetidine RARE
800 O
mg O
given O
at O
night O
is O
as O
effective O
as O
400 O
mg O
twice O
daily O
; O
the O
single O
dose O
regimen O
may O
improve O
patient O
compliance O
, O
thus O
facilitating O
treatment O
. O

Ceftazidime RARE
shows O
promise RARE
as O
single O
- O
agent O
therapy O
for O
serious O
gram O
- O
negative O
bacillary RARE
infections O
. O

Regional RARE
CBF O
was O
determined O
by O
clearance O
of O
xenon RARE
133 O
in O
67 O
patients O
undergoing O
coronary O
bypass O
grafting RARE
procedures O
. O

Our O
results O
indicate O
that O
serum I-GENE
BGP ALLCAPS
is O
a O
valuable O
measurement O
of O
bone O
metabolism O
. O

The O
management O
of O
the O
" O
chronic O
" O
patient O
. O

Study O
of O
bacterial O
motility O
and O
rate O
of O
movement O
using O
a O
closed O
circuit O
television RARE

Finding RARE
of O
Rhodnius RARE
prolixus RARE
Stal RARE
, O
1859 NUMERIC
, O
in O
babassu RARE
palm RARE
trees RARE

Each O
causative RARE
organism O
has O
a O
species O
- O
specific O
preference O
and O
requirement O
for O
temperature O
, O
salinity RARE
, O
pH O
, O
the O
basic O
nutrients RARE
, O
and O
growth O
factors O
, O
and O
the O
toxin O
formation O
is O
affected O
by O
these O
environmental O
factors O
. O

It O
is O
concluded O
that O
axillo RARE
- O
axillary RARE
by O
- O
pass RARE
is O
a O
simple O
solution O
for O
a O
complex O
haemodynamic RARE
, O
clinical O
and O
therapeutic O
problem O
. O

Deformities RARE
of O
the O
tip O
of O
the O
olecranon RARE
and O
of O
the O
coronoid RARE
process O
are O
also O
described O
( O
De RARE
Palma RARE
1956 NUMERIC
, O
Jordan RARE
1958 NUMERIC
, O
Ahlberg RARE
1965 NUMERIC
, O
Weseloh RARE
1973 NUMERIC
). O

There O
was O
significant O
correlation O
of O
LVM ALLCAPS
/ O
M2 NUMERIC
and O
PWVn RARE
for O
pre O
- O
AVR ALLCAPS
and O
post O
AVR ALLCAPS
studies O
. O

Statokinesimetric RARE
recording O
in O
Huntington RARE
choreas RARE

The O
development O
and O
histostructural RARE
organization O
of O
intrahepatic O
biliary O
ducts RARE
were O
studied O
on O
a O
human O
embryofetal RARE
material O
6 O
to O
32 O
weeks O
old O
. O

It O
has O
been O
shown O
in O
an O
animal O
experiment O
that O
alterations O
of O
the O
renal O
vasculature RARE
and O
parenchyma O
after O
hemostasis O
performed O
by O
Infrared RARE
- O
Contact RARE
- O
Coagulation RARE
are O
best O
shown O
by O
intravital RARE
magnification O
angiography O
( O
magnification O
factor O
2 O
. O
22 O
). O

Cardiovascular RARE
and O
adrenal O
medullo RARE
- O
sympathetic O
reactions O
to O
acute O
tobacco O
poisoning O

Intravenous O
injections O
of O
SG O
- O
75 O
( O
0 O
. O
03 O
- O
1 O
mg O
/ O
kg O
) O
decreased O
systemic O
blood O
pressure O
( O
SBP ALLCAPS
) O
and O
increased O
peripheral O
( O
coronary O
, O
renal O
, O
mesenteric RARE
and O
femoral O
) O
blood O
flow O
( O
PBF ALLCAPS
) O
dose O
- O
dependently O
. O

In O
doses O
of O
0 O
. O
03 O
- O
0 O
. O
3 O
mg O
/ O
kg O
i O
. O
v O
., O
SG O
- O
75 O
did O
not O
significantly O
affect O
pulse O
pressure O
, O
heart O
rate O
, O
aortic O
blood O
flow O
, O
left O
ventricular O
pressure O
( O
LVP ALLCAPS
) O
and O
LVdP LASTCAP
/ O
dt O
max O
. O

Resting RARE
VE O
in O
the O
luteal O
phase O
was O
7 O
. O
8 O
% O
greater O
than O
that O
in O
the O
follicular O
phase O
. O

Exposure RARE
of O
endothelium O
to O
pulsatile RARE
shear O
stresses O
that O
followed O
a O
tape RARE
recording O
of O
physiological O
flow O
waveforms RARE
( O
electromagnetic RARE
flowmeter RARE
) O
did O
not O
cause O
gross O
injury O
or O
denudation RARE
even O
when O
peak O
shear O
exceeded RARE
1500 NUMERIC
dyne RARE
/ O
cm2 O
. O

Modern RARE
cancer O
therapy O
has O
included O
surgery O
, O
radiotherapy O
, O
chemotherapy O
, O
and O
most O
recently O
, O
immunotherapy O
and O
hyperthermia RARE
. O

There O
was O
a O
close O
correlation O
between O
plasma O
clearance O
of O
NT ALLCAPS
by O
10 O
- O
hydroxylation RARE
and O
the O
D O
metabolic O
ratio O
( O
D O
/ O
4 O
- O
OH O
- O
D O
in O
urine O
) O
in O
the O
Ghanaians RARE
( O
rs O
= O
- O
0 O
. O
95 O
; O
P O
less O
than O
0 O
. O
01 O
) O
and O
Swedes RARE
( O
rs O
= O
- O
0 O
. O
84 O
; O
P O
less O
than O
0 O
. O
01 O
). O

The O
response O
properties O
of O
cat O
horizontal O
canal RARE
afferents O
( O
N O
= O
81 O
) O
were O
characterized O
by O
three O
parameters O
: O
their O
long O
time O
constants O
( O
tau O
), O
low O
frequency O
gain O
constants O
( O
G1 O
), O
and O
middle O
frequency O
gain O
constants O
( O
Gm RARE
). O

Endothelium RARE
of O
the O
central O
ear O
artery O
of O
an O
anesthetized O
rabbit O
is O
damaged O
by O
placing RARE
artery O
forceps RARE
on O
the O
ear O
directly O
over O
the O
vessel O
. O

Despite O
supraphysiologic RARE
E2 O
concentrations O
, O
however O
, O
cervical O
mucus O
scores O
were O
significantly O
reduced O
in O
the O
CC O
- O
treated O
group O
( O
P O
less O
than O
0 O
. O
01 O
). O

Stimulation RARE
of O
the O
caudate RARE
nucleus O
' O
dophamine RARE
- O
reactive O
system O
in O
dogs O
by O
means O
of O
administration O
of O
dophamine RARE
( O
60 O
micrograms O
) O
and O
phenamine RARE
led O
to O
deterioration O
of O
conditioned O
and O
unconditioned RARE
components O
of O
feeding O
behaviour O
. O

Value O
of O
urine O
glucose O
tests O
in O
the O
management O
of O
type O
II O
diabetes O
mellitus O
. O

This O
experiment O
was O
conducted O
to O
determine O
if O
the O
sex O
or O
actual O
egg O
production O
was O
the O
important O
factor O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Hydrocortisone RARE
seems O
to O
be O
unable O
to O
hinder RARE
the O
postdenervation RARE
changes O
in O
the O
muscle O
membrane O
whereas O
high O
doses O
of O
the O
hormone O
are O
able O
to O
induce O
changes O
in O
the O
muscle O
membrane O
. O

Significant O
clinical O
differences O
between O
the O
patients O
treated O
with O
and O
without O
AMB ALLCAPS
were O
longer O
survival O
time O
following O
diagnosis O
of O
illness O
( O
P O
less O
than O
0 O
. O
05 O
) O
and O
more O
frequent O
cranial RARE
nerve O
signs O
in O
the O
treated O
patients O
( O
P O
= O
0 O
. O
089 NUMERIC
). O

A O
pharmacokinetic O
study O
of O
apalcillin RARE
was O
performed O
in O
12 O
patients O
in O
an O
intensive O
- O
care O
unit O
. O

Catch RARE
- O
up O
growth O
was O
observed O
only O
for O
a O
12 O
- O
month O
period O
in O
4 O
children O
with O
a O
bone O
age O
of O
7 O
to O
8 O
years O
. O

Thrombocyte RARE
function O
was O
impaired O
in O
all O
patients O
, O
characterized O
by O
a O
diminished O
platelet O
shape O
change O
. O

The O
findings O
demonstrate O
that O
AMPH ALLCAPS
administration O
induces O
a O
significant O
increase O
in O
the O
height O
of O
a O
major O
electroactive RARE
peak O
in O
the O
caudate RARE
nucleus O
of O
pigtail RARE
monkeys O
, O
and O
further O
that O
such O
amphetamine O
- O
induced O
increases O
can O
be O
manipulated RARE
by O
altering O
the O
affective O
and O
/ O
or O
emotional RARE
state O
of O
the O
animal O
. O

In O
two O
experiments O
, O
neonatal O
female O
BALB O
/ O
cCrgl RARE
or O
BALB O
/ O
cfC3HCrgl NUMERIC
mice O
were O
given O
subcutaneous O
injections O
of O
5 O
micrograms O
17 O
beta O
- O
estradiol O
or O
sesame RARE
oil O
for O
the O
first O
3 O
days O
of O
life O
and O
were O
ovariectomized RARE
at O
60 O
days O
of O
age O
, O
at O
which O
time O
vaginal O
concretions RARE
( O
Experiments O
I O
and O
II O
) O
or O
silica RARE
( O
Experiment O
II O
) O
were O
implanted O
intravaginally RARE
. O

For O
228 NUMERIC
of O
425 NUMERIC
deaths O
( O
54 O
%) O
occurring O
among O
26 O
100 O
people O
of O
known O
age O
in O
the O
Malumfashi RARE
area O
of O
northern O
Nigeria RARE
, O
data O
were O
collected O
on O
symptoms O
present O
prior O
to O
death O
. O

Salivary RARE
estradiol O
17 O
beta O
( O
E2 O
- O
17 O
beta O
) O
and O
progesterone O
( O
P O
) O
were O
determined O
by O
using O
radioimmunoassay O
techniques O
in O
30 O
pregnant O
females O
in O
the O
first O
, O
second O
and O
third O
trimesters RARE
as O
well O
as O
in O
10 O
non O
- O
pregnant O
controls O
during O
the O
luteal O
phase O
of O
the O
menstrual O
cycle O
. O

Other O
than O
d O
7 O
, O
there O
was O
no O
significant O
effect O
on O
the O
number O
of O
implants O
. O

Variable RARE
FHR ALLCAPS
decelerations RARE
or O
bradycardias RARE
were O
encountered RARE
on O
95 O
nonstress RARE
tests O
( O
18 O
. O
8 O
%) O
in O
80 O
( O
33 O
. O
5 O
%) O
postdate RARE
patients O
. O

The O
response O
chain O
in O
each O
component O
was O
maintained O
by O
food O
presentation O
under O
a O
fixed O
- O
ratio O
schedule O
. O

The O
results O
imply O
that O
kindling O
does O
not O
produce O
its O
facilitating O
effect O
on O
acquisition O
of O
HPC ALLCAPS
SS O
by O
removing O
a O
disruptive RARE
effect O
of O
the O
stimulation O
. O

The O
persistent O
fetal O
dispersion O
of O
nodal O
and O
Hiss RARE
bundle O
fragments O
within O
the O
ventricular O
septum RARE
is O
proposed O
as O
a O
possible O
explanation O
. O

According O
to O
the O
biochemical O
tests O
, O
high O
activity O
( O
over O
200 O
U O
/ O
l O
) O
of O
alkaline I-GENE
phosphatase I-GENE
was O
recorded O
exclusively O
in O
patients O
with O
the O
lymphogranulomatosis RARE
- O
induced O
liver O
damage O
. O

Changes O
of O
plasma O
cortisol O
level O
in O
late O
asthmatic O
responses O

Significant O
alterations O
in O
the O
vasectomized RARE
rats O
from O
sham O
rats O
included O
: O
testicular O
and O
epididymal RARE
hypertrophy O
, O
formation O
of O
pathologic O
vas O
deferens O
granulomas RARE
, O
decreased O
total O
serum O
protein O
, O
lowered O
alpha I-GENE
- I-GENE
globulin I-GENE
levels O
as O
shown O
by O
serum O
electrophoresis O
, O
and O
increased O
sperm O
agglutinin RARE
antibody O
titers RARE
. O

SFP ALLCAPS
was O
significantly O
elevated O
in O
Hn RARE
( O
s O
). O

The O
average O
birth O
mass O
of O
these O
newborns O
was O
3491 NUMERIC
. O
9 O
+/- O
2 O
SD O
780 NUMERIC
. O
5 O
g O
and O
that O
in O
the O
control O
group O
3 O
, O
767 NUMERIC
. O
5 O
+/- O
2 O
SD O
824 NUMERIC
. O
2 O
g O
( O
P O
less O
than O
0 O
. O
05 O
). O

This O
machine O
drift RARE
, O
which O
was O
not O
associated O
with O
a O
rise O
in O
water O
phantom RARE
temperature O
and O
did O
not O
consistently O
correlate O
with O
estimated O
x O
- O
ray O
tube O
heat O
, O
could O
result O
in O
a O
significant O
overestimation RARE
of O
regional O
cerebral O
blood O
flow O
( O
rCBF O
) O
for O
a O
xenon RARE
/ O
CT O
rCBF O
protocol O
involving O
5 O
- O
7 O
sequential O
scans O
obtained O
at O
1 O
- O
min O
interscan RARE
intervals O
. O

Other O
uncertainties RARE
in O
the O
dosimetry RARE
at O
Y O
- O
12 O
and O
Vinca RARE
are O
unaltered O
. O

E2 O
treatments O
elevated O
hen RARE
plasma O
TG O
7 O
. O
2X NUMERIC
, O
PL O
5 O
. O
1X NUMERIC
, O
and O
C O
7 O
. O
2X NUMERIC
; O
and O
pullet RARE
plasma O
TG O
6 O
. O
8X NUMERIC
, O
PL O
3 O
. O
7X NUMERIC
, O
and O
C O
2 O
. O
5X NUMERIC
. O

By O
contrast O
, O
kidneys O
from O
rats O
with O
chronic O
metabolic O
acidosis O
produced O
significantly O
more O
NH3 NUMERIC
than O
both O
these O
groups O
( O
2 O
. O
73 O
+/- O
0 O
. O
29 O
mumol O
X O
min O
- O
1 O
X O
g O
- O
1 O
). O

Serodiagnosis RARE
of O
trypanosomiasis RARE
in O
dromedary RARE
camels RARE
using O
a O
card RARE
agglutination O
test O
set O
( O
Testryp RARE
CATT ALLCAPS
). O

Adenyl RARE
cyclase I-GENE
activity O
of O
gastric O
mucosa O
in O
patients O
with O
duodenal O
ulcer O
before O
and O
after O
treatment O

Proteinuria RARE
-- O
selected O
physiopathological RARE
and O
clinical O
problems O

However O
, O
subcutaneously O
administered O
pneumococci RARE
gave O
a O
lower O
mortality O
than O
pneumococci RARE
given O
intravenously O
or O
intraperitoneally RARE
. O

Reaction RARE
of O
human O
organism O
to O
exercise O
. O

HA O
resulted O
in O
decreased O
( O
p O
less O
than O
0 O
. O
05 O
) O
Tre RARE
( O
0 O
. O
4 O
degrees O
C O
) O
and O
HR O
( O
17 O
b O
X O
min O
- O
1 O
), O
and O
increased O
( O
p O
less O
than O
0 O
. O
05 O
) O
Msw RARE
( O
16 O
g O
X O
m O
- O
2 O
X O
h O
- O
1 O
) O
during O
the O
saline O
experiments O
. O

The O
results O
obtained O
were O
as O
follows O
: O
The O
mitral O
valve O
orifice RARE
area O
( O
MVA ALLCAPS
) O
was O
significantly O
smaller O
in O
patients O
with O
type O
III O
of O
the O
LVIT ALLCAPS
flow O
velocity O
pattern O
than O
in O
patients O
with O
type O
I O
( O
p O
less O
than O
0 O
. O
001 O
). O

Scientific RARE
cooperation O
of O
CMEA ALLCAPS
member O
countries RARE
has O
been O
carried O
out O
since O
1974 NUMERIC
under O
the O
sponsorship RARE
of O
the O
Cancer O
Research O
Institute O
, O
Slovak RARE
Academy RARE
of O
Sciences RARE
( O
Czechoslovakia RARE
) O
within O
the O
framework RARE
of O
CMEA ALLCAPS
. O

This O
compares RARE
favorably RARE
to O
results O
of O
similarly O
sized O
melanomas O
treated O
by O
enucleation RARE
. O

A O
new O
variant O
of O
the O
EMG O
- O
BFB ALLCAPS
method O
( O
multichannel RARE
) O
is O
offered O
which O
has O
made O
it O
possible O
to O
use O
the O
method O
not O
only O
for O
training O
weakened RARE
muscles O
and O
reducing O
spasticity RARE
in O
their O
antagonists O
but O
also O
for O
improving RARE
motor O
coordination O
. O

Lymphocytes RARE
from O
all O
3 O
species O
yielded O
maximum O
responses O
with O
a O
48 O
- O
hour O
prelabel RARE
and O
12 O
- O
to O
- O
16 O
hour O
postlabel RARE
incubation O
period O
at O
41 O
C O
and O
1 O
: O
20 O
blood O
dilution O
. O

However O
, O
there O
was O
a O
difference O
in O
the O
quality O
of O
immunity O
: O
fever O
and O
body O
weight O
loss O
were O
seen O
in O
hamsters O
vaccinated RARE
with O
the O
killed O
- O
toxoplasma RARE
vaccine O
after O
they O
were O
challenge O
exposed O
with O
T O
- O
1 O
strain O
, O
whereas O
these O
changes O
were O
rarely O
seen O
in O
hamsters O
given O
the O
live O
- O
toxoplasma RARE
vaccine O
and O
then O
challenge O
exposed O
with O
RH O
strain O
. O

Alternating RARE
proline O
/ O
alanine O
sequence O
of O
beta I-GENE
B1 I-GENE
subunit I-GENE
originates RARE
from O
a O
repetitive O
DNA O
sequence O
. O

The O
segmental O
and O
regional O
projections O
of O
the O
sciatic RARE
, O
tibial RARE
and O
common O
peroneal RARE
nerves O
to O
the O
substantia RARE
gelatinosa RARE
of O
the O
spinal O
cord O
in O
rats O
-- O
an O
experimental O
study O
by O
means O
of O
an O
acid I-GENE
phosphatase I-GENE
( O
ACP ALLCAPS
) O
method O
. O

Removal O
of O
lipid O
fractions O
of O
plant O
extractions RARE
with O
hexane RARE
is O
recommended O
to O
avoid O
damage O
to O
the O
HPLC O
column O
. O

In O
the O
Arithmetic RARE
subtest RARE
one O
of O
the O
items RARE
would O
not O
meet RARE
the O
difficulty RARE
grading RARE
shown O
while O
the O
last O
two O
items RARE
offer O
very O
little O
possibility O
of O
success O
for O
all O
subjects O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

The O
toxicological O
evaluation O
of O
chlorofluorocarbon RARE
22 O
( O
CFC ALLCAPS
22 O
). O

All O
patients O
were O
evaluable O
for O
toxicity O
and O
9 O
for O
response O
. O

Methods RARE
of O
clinical O
and O
experimental O
algesimetry RARE
are O
described O
that O
have O
been O
used O
to O
evaluate O
effects O
of O
peripherally RARE
and O
centrally RARE
acting O
analgesics RARE
. O

The O
present O
paper O
elucidates RARE
the O
existing O
discrepancies RARE
, O
and O
offers O
a O
consistent O
terminology RARE
incorporating RARE
also O
such O
terms O
as O
" O
additivity RARE
", RARE
" O
potentiation O
", RARE
and O
" O
simple O
similarity O
". O

We O
propose O
that O
the O
ambiguous RARE
discrimination O
required O
a O
greater O
time O
for O
simulus RARE
evaluation O
and O
that O
this O
was O
reflected O
in O
the O
delayed O
P3 O
latencies RARE
. O

Ammonia RARE
concentration O
dropped RARE
significantly O
in O
all O
treatments O
, O
a O
finding O
which O
suggests O
a O
protective O
effect O
on O
protein O
nitrogen O
degradation O
to O
non O
- O
protein O
nitrogen O
( O
NH3 NUMERIC
). O

In O
this O
respect O
C I-GENE
reactive I-GENE
protein I-GENE
concentrations O
are O
superior O
to O
white O
cell O
count O
, O
erythrocyte O
sedimentation O
rate O
, O
and O
temperature O
and O
the O
concentrations O
of O
antiproteases RARE
. O

Human I-GENE
thyroid I-GENE
stimulator RARE
( O
HTS ALLCAPS
) O
in O
thyroid O
diseases O

We O
conclude O
that O
administration O
of O
the O
calcium O
antagonist O
Verapamil RARE
is O
of O
no O
additional O
value O
in O
tocolytic RARE
treatment O
with O
beta O
- O
mimetics RARE
. O

Brainstem RARE
auditory O
evoked O
responses O
( O
BAERs RARE
) O
and O
quantitative O
saccadic RARE
eye O
movement O
studies O
provide O
information O
on O
the O
integrity O
of O
pathways O
traversing RARE
the O
brainstem RARE
. O

Effects O
of O
ketamine RARE
on O
the O
circulatory O
functions O
and O
body O
tissue O
oxygenation O
in O
dogs O
under O
normal O
and O
hypovolemic RARE
conditions O
. O

The O
salient RARE
clinical O
features O
, O
the O
problems O
of O
management O
and O
the O
modern O
approaches O
to O
the O
reconstruction O
of O
facial O
deformities RARE
seen O
in O
this O
disease O
are O
described O
. O

Besides RARE
, O
it O
was O
considered O
that O
the O
NPF ALLCAPS
was O
a O
useful O
tool O
for O
activation O
of O
velopharyngeal RARE
activity O
by O
way O
of O
visual O
feed O
- O
back O
control O
. O

To O
evaluate O
the O
comparative O
safety O
of O
U O
- O
P O
and O
D O
& O
E O
, O
we O
analyzed O
2 O
, O
805 NUMERIC
U O
- O
P O
and O
9 O
, O
572 NUMERIC
D O
& O
E O
abortions RARE
at O
13 O
to O
24 O
menstrual O
weeks O
' O
gestation O
. O

Three O
radiologists RARE
without O
knowledge O
of O
patients O
' O
data O
and O
treatment O
analyzed O
30 O
angiograms RARE
with O
and O
30 O
examinations O
without O
PGF ALLCAPS
. O

In O
a O
man O
with O
myelomonocytic RARE
leukemia O
, O
the O
association O
of O
increased O
prostatic I-GENE
acid I-GENE
phosphatase I-GENE
activity O
in O
serum O
and O
the O
presence O
of O
typical O
bone O
lesions O
on O
roentgenography RARE
suggested O
the O
existence O
of O
disseminated RARE
prostatic O
carcinoma O
. O

The O
rational RARE
for O
the O
prophylactic O
treatment O
, O
the O
therapy O
of O
the O
meningopathy RARE
and O
AIL ALLCAPS
- O
AIEOP ALLCAPS
protocols RARE
are O
exposed O
. O

An O
experimental O
long O
- O
term O
study O
. O

No O
anisotropism RARE
was O
recorded O
in O
a O
tetrahydrofuran RARE
solution O
. O

Hepatitis O
B O
vaccine O

The O
calculated O
values O
of O
lambda O
tb RARE
at O
37 O
degrees O
C O
and O
50 O
per O
cent O
haematocrit RARE
were O
0 O
. O
650 NUMERIC
for O
the O
pulp RARE
, O
0 O
. O
674 NUMERIC
for O
the O
tongue RARE
, O
0 O
. O
828 NUMERIC
for O
the O
submandibular RARE
gland O
and O
0 O
. O
881 NUMERIC
for O
the O
gingiva RARE
of O
the O
dog O
. O
lambda O
cp RARE
increased O
and O
lambda O
tp RARE
decreased O
as O
the O
temperature O
was O
reduced O
from O
37 O
to O
4 O
degrees O
C O
. O

As O
pleural O
thickening RARE
is O
seen O
commonly O
in O
asbestosis RARE
and O
may O
influence O
lung O
volumes O
and O
the O
ratio O
of O
transfer I-GENE
factor I-GENE
to O
effective O
alveolar O
volume O
, O
the O
results O
of O
these O
measurements O
were O
compared O
only O
in O
the O
cases O
showing O
absent O
or O
minimal O
pleural O
thickening RARE
. O

The O
invasive O
pattern O
of O
squamous O
cell O
carcinoma O
in O
the O
mandibular O
gingiva RARE

Azygos RARE
vein O
abutting RARE
the O
posterior O
wall O
of O
the O
right O
main O
and O
upper O
lobe O
bronchi RARE
: O
a O
normal O
CT O
variant O
. O

However O
, O
the O
history O
of O
acute O
severe O
complications O
from O
otitis RARE
media O
revealed O
a O
higher O
frequency O
in O
those O
individuals O
with O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
deficiency O
as O
compared O
to O
normals O
. O

The O
Sarns RARE
51F NUMERIC
cavoatrial RARE
cannula RARE
decompressed RARE
the O
venous O
system O
as O
efficiently O
as O
the O
double O
caval RARE
cannulas RARE
. O

All O
other O
changes O
at O
the O
3 O
-, O
5 O
-, O
and O
6 O
- O
positions O
, O
as O
well O
as O
the O
replacement O
of O
the O
phenyl RARE
group O
at O
position O
2 O
, O
caused O
a O
marked O
decrease O
of O
activity O
. O

Three O
experiments O
contrasted RARE
the O
effects O
of O
6 O
- O
hydroxydopamine RARE
- O
induced O
lesions O
of O
the O
ventral O
noradrenergic O
and O
dorsal O
noradrenergic O
projections O
, O
predominantly O
to O
hypothalamus O
and O
cortex O
, O
respectively O
, O
upon O
body O
weight O
changes O
and O
food O
- O
related O
behaviour O
in O
the O
rat O
. O

Limb RARE
allografts RARE
in O
rats O
immunosuppressed RARE
with O
cyclosporin O
A O
. O

The O
method O
involved O
deproteinizing RARE
samples O
with O
two O
volumes O
of O
acetonitrile RARE
followed O
by O
injection O
of O
5 O
microliters RARE
of O
deproteinized RARE
supernatant O
onto O
a O
C18 O
reversed O
- O
phase O
column O
. O

Refractory RARE
periods O
of O
the O
AV O
junction O
were O
altered O
in O
a O
comparable O
fashion O
to O
conduction O
through O
the O
AV O
node O
. O

This O
paper O
brings RARE
together O
data O
, O
obtained O
from O
a O
variety O
of O
sources O
, O
on O
the O
extent O
of O
prescription RARE
and O
use O
of O
psychotropic RARE
drugs O
in O
the O
late O
1960s NUMERIC
and O
early O
1970s NUMERIC
. O

Sixteen RARE
patients O
were O
studied O
within O
24 O
hours O
of O
resuscitation O
and O
all O
showed O
depressed O
right O
ventricular O
ejection O
( O
RVEF ALLCAPS
) O
and O
/ O
or O
an O
increased O
end O
- O
diastolic O
volume O
( O
RVEDVI ALLCAPS
). O

During O
a O
single O
LAD O
occlusion O
lasting O
35 O
minutes O
( O
series O
I O
, O
n O
= O
10 O
) O
9 O
microns O
TMs RARE
were O
infused O
immediately O
and O
30 O
minutes O
after O
ligation O
, O
15 O
microns O
TMs RARE
being O
infused O
after O
15 O
- O
20 O
minutes O
. O

The O
population O
of O
between O
75 O
, O
000 O
and O
100 O
, O
000 O
was O
largely O
unstable O
, O
and O
cost O
per O
capita RARE
was O
$ RARE
0 O
. O
95 O
to O
$ RARE
1 O
. O
21 O
. O

Female O
Wistar RARE
rats O
were O
fed O
a O
liquid O
diet O
, O
Sustacal RARE
, O
which O
contained O
ethanol O
( O
40 O
% O
of O
calories RARE
) O
or O
isocaloric RARE
sucrose O
. O

HL O
02 O
type O
oculomotor RARE
stimulator RARE
. O

Four O
patients O
( O
group O
1 O
) O
had O
type O
I O
basement RARE
membrane O
nephropathy O
, O
characterized O
by O
marked O
thickening RARE
and O
lamellation RARE
of O
the O
basement RARE
membrane O
in O
a O
pattern O
resembling O
that O
of O
Alport RARE
' O
s O
syndrome O
. O

Brain RARE
pH O
following O
3 O
h O
of O
cerebral O
focal O
ischemia O
changed O
from O
a O
normal O
value O
of O
7 O
. O
0 O
to O
6 O
. O
5 O
and O
6 O
. O
2 O
in O
animals O
studied O
under O
barbiturate RARE
and O
halothane O
anesthesia O
, O
respectively O
. O

Our O
results O
demonstrate O
the O
importance O
of O
phosphate O
and O
calcium O
in O
influencing O
the O
secretion O
of O
PTH I-GENE
and O
CT I-GENE
in O
uremia RARE
. O

Thin RARE
- O
layer O
chromatographic O
methods O
were O
up O
- O
dated RARE
for O
pharmacokinetic O
studies O
of O
imipramine RARE
in O
plasma O
and O
urine O
. O

Introductory RARE
remarks RARE
. O

Increasing O
the O
cut O
- O
off O
point O
to O
3 O
positive O
responses O
decreased O
the O
sensitivity O
to O
81 O
% O
and O
increased O
the O
specificity O
to O
94 O
%. O

After O
clofelin RARE
administration O
the O
autoregulation O
borders RARE
shifted O
to O
the O
right O
i O
. O
e O
. O
towards O
higher O
AP O
levels O
. O

This O
phenomenon O
may O
be O
regarded O
as O
a O
variant O
of O
selective O
individual O
cell O
death O
, O
currently O
referred O
to O
as O
apoptosis O
, O
which O
has O
not O
been O
previously O
reported O
in O
a O
case O
of O
embryonal RARE
rhabdomyosarcoma RARE
. O

Combination RARE
of O
a O
Shwachman RARE
syndrome O
and O
a O
complex O
granulocyte O
function O
disorder O
in O
a O
girl RARE

A O
combined O
series O
of O
patients O
experienced O
a O
TOL ALLCAPS
after O
two O
or O
more O
previous O
cesarean RARE
deliveries RARE
; O
the O
rate O
of O
vaginal O
delivery O
was O
66 O
%, O
and O
there O
was O
virtually O
no O
morbidity O
. O

Nursing RARE
home O
discharges RARE
in O
clinical O
practice O
. O

Trial RARE
3 O
broiler RARE
chickens O
were O
maintained O
on O
control O
feed O
until O
they O
reached O
3 O
weeks O
of O
age O
at O
which O
time O
they O
were O
taken O
off O
of O
feed O
for O
2 O
. O
5 O
hr O
and O
then O
placed O
on O
either O
control O
feed O
or O
feed O
containing O
4 O
. O
0 O
ppm O
ochratoxin RARE
A O
, O
and O
heart O
rate O
and O
blood O
pressure O
were O
measured O
every O
half O
hour O
through O
7 O
hr O
. O

The O
carcinogen RARE
bioassay RARE
therefore O
is O
a O
very O
important O
component O
of O
the O
battery O
of O
toxicological O
tests O
used O
in O
hazard RARE
evaluation O
. O

Harmful RARE
effects O
in O
animals O
and O
man O
may O
result O
from O
both O
deficient O
or O
excessive O
amounts O
of O
intake O
. O

Angionephroscintigraphy RARE
in O
the O
diagnosis O
of O
diseases O
of O
the O
kidney O

The O
analysis O
of O
the O
structure O
of O
the O
sleep O
period O
as O
a O
whole O
reveals O
that O
with O
increasing O
of O
the O
age O
the O
delta O
- O
wave O
stage O
( O
DS ALLCAPS
) O
of O
the O
QS ALLCAPS
( O
determined O
by O
defined O
polygraphic RARE
parameters O
) O
increases O
, O
while O
the O
paradoxical RARE
phase O
of O
sleep O
( O
PS O
) O
decreases O
, O
this O
change O
being O
more O
pronounced O
during O
the O
first O
six O
months O
than O
during O
the O
second O
ones O
of O
the O
first O
year O
of O
the O
life O
. O

[ O
82Br NUMERIC
] O
MISO ALLCAPS
was O
prepared O
by O
irradiating RARE
samples O
of O
Br O
- O
MISO ALLCAPS
in O
a O
SLOWPOKE ALLCAPS
reactor RARE
for O
2 O
h O
at O
a O
thermal O
neutron RARE
flux RARE
of O
10 O
( O
12 O
) O
n O
cm O
- O
2 O
s O
- O
1 O
. O

While O
these O
findings O
may O
reflect O
the O
sensitivity O
of O
a O
thick O
myocardial O
wall O
to O
ischaemia O
during O
surgery O
, O
the O
postoperative O
recovery O
was O
not O
related O
to O
the O
serum I-GENE
CK I-GENE
- I-GENE
MB I-GENE
level O
. O

Morphofunctional RARE
status O
of O
the O
formed O
elements O
of O
the O
blood O
in O
rats O
subjected O
to O
different O
variants O
of O
combined O
and O
isolated O
exposure O
to O
BR ALLCAPS
- O
1 O
benzene RARE

Using O
a O
MOS ALLCAPS
- O
Hypersil RARE
reversed O
- O
phase O
column O
with O
a O
phosphate O
buffer RARE
-- O
acetonitrile RARE
mobile O
phase O
, O
baseline O
separation O
of O
antipyrine RARE
, O
its O
metabolites O
3 O
- O
hydroxymethylantipyrine RARE
, O
norantipyrine RARE
and O
4 O
- O
hydroxyantipyrine RARE
, O
and O
the O
internal O
standard O
, O
phenacetin RARE
, O
was O
achieved O
within O
6 O
min O
. O

The O
liver O
in O
the O
severely O
ill RARE

In O
a O
randomized O
study O
on O
150 O
patients O
( O
ASA O
1 O
) O
undergoing O
induction O
of O
anaesthesia O
, O
the O
effects O
of O
Fentanyl RARE
( O
0 O
. O
1 O
mg O
), O
the O
combination O
of O
Fentanyl RARE
( O
0 O
. O
1 O
mg O
) O
and O
Droperidol RARE
( O
5 O
mg O
) O
( O
Innovar RARE
, O
Thalamonal RARE
) O
and O
Atropine RARE
( O
0 O
. O
01 O
mg O
/ O
kg O
b O
. O
w O
.) O
alone O
on O
cardiocirculatory RARE
parameters O
were O
studied O
. O

These O
results O
confirming O
the O
high O
validity O
of O
NOM ALLCAPS
inhibiting O
test O
in O
the O
diagnosis O
of O
tumoural RARE
hyperprolactinemic RARE
states O
, O
reveal O
contradictory RARE
responses O
to O
CD O
/ O
LD ALLCAPS
, O
LD ALLCAPS
and O
DOM ALLCAPS
, O
with O
sustain RARE
the O
existence O
of O
2 O
sub O
- O
group O
of O
Prolactinomas RARE
: O
with O
or O
without O
a O
maintained O
DA O
central O
tonus RARE
supporting O
the O
possibility O
of O
different O
etiopathogenetical RARE
factors O
in O
inducing O
a O
tumoural RARE
hyperprolactinemic RARE
states O
. O

Serum O
lipids O
and O
lipoproteins O
of O
29 O
insulin I-GENE
dependent O
diabetic O
children O
have O
been O
determined O
and O
related O
to O
the O
metabolic O
status O
of O
the O
patients O
. O

Low O
NA O
and O
A O
may O
participate O
in O
lowering O
the O
plasma I-GENE
renin I-GENE
activity O
which O
in O
PA O
in O
suppressed O
, O
sometimes RARE
disproportionately RARE
to O
the O
actual O
body O
sodium O
content O
. O

Amikacin RARE
concentrations O
in O
serum O
and O
blister RARE
fluid O
in O
healthy O
volunteers O
and O
in O
patients O
with O
renal O
impairment O
. O

The O
subgroup O
innervating RARE
the O
medial O
rectus RARE
lies O
exclusively O
along O
the O
medial O
face O
of O
the O
oculomotor RARE
nucleus O
, O
with O
no O
aberrant O
neurons O
in O
the O
medial O
longitudinal O
fasciculus RARE
, O
as O
have O
been O
found O
in O
other O
mammals O
. O

Hepatitis O
B O
vaccination O
strategy O
for O
health O
- O
care O
workers O
in O
a O
country RARE
of O
intermediate O
hepatitis O
B O
endemicity RARE
. O

An O
intravenous O
drip RARE
infusion O
of O
AMK ALLCAPS
in O
adequate O
dosage O
would O
be O
beneficial O
to O
use O
against O
some O
infectious O
diseases O
of O
otorhinolaryngologic RARE
field O
. O

Out RARE
of O
these O
families O
74 O
, O
3 O
% O
planned RARE
next O
pregnancy O
( O
table RARE
IX O
), O
57 O
, O
6 O
% O
wanted RARE
to O
have O
prenatal RARE
diagnosis O
( O
table RARE
VI O
). O

The O
authors O
have O
tested O
the O
interference O
of O
the O
hemoglobin I-GENE
by O
two O
routine O
methods O
( O
Berthelot RARE
classic RARE
and O
Berthelot RARE
modified O
) O
for O
the O
determination O
of O
plasmatic RARE
urea O
. O

Parkinsonian RARE
patients O
had O
a O
significantly O
lower O
prevalence O
of O
alcohol O
use O
. O

These O
cells O
averaged O
17 O
microns O
in O
diameter O
and O
reproduced RARE
by O
fission O
, O
forming O
clusters O
of O
two O
or O
four O
daughter O
cells O
. O

Female O
but O
not O
male O
mortalities RARE
were O
significantly O
higher O
for O
cake RARE
- O
fed O
rats O
than O
for O
those O
fed O
diet O
41B NUMERIC
. O

Urinary RARE
N I-GENE
- I-GENE
acetylglucosaminidase RARE
activity O
per O
mg O
creatinine O
did O
not O
differ O
significantly O
between O
groups O
. O

The O
associations O
between O
sex I-GENE
- I-GENE
hormone I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
capacity O
( O
SHBG I-GENE
), O
age O
, O
body O
mass O
index O
( O
BMI O
), O
and O
physical O
fitness O
have O
been O
studied O
in O
34 O
men O
and O
36 O
women O
. O

Dipetalonema RARE
( O
Alafilaria RARE
) O
hydrochoerus RARE
subgen RARE
. O
et O
sp O
. O
n O
. O

After O
1 O
. O
5 O
years O
of O
such O
photoperiodic RARE
control O
, O
all O
ewes RARE
were O
blinded RARE
by O
bilateral O
orbital RARE
enucleation RARE
. O

The O
concentrations O
of O
C4 I-GENE
and O
C1 I-GENE
- I-GENE
INH ALLCAPS
increased O
with O
advancing RARE
stage O
of O
disease O
and O
were O
above O
normal O
mean O
values O
in O
all O
stages O
. O

Less RARE
antibacterial RARE
activity O
was O
shown O
toward O
the O
Gram O
- O
negative O
bacilli O
, O
i O
. O
e O
., O
Pseudomonas O
, O
Klebsiella O
- O
Enterobacter RARE
, O
Shigella RARE
, O
Escherichia O
coli O
, O
Serratia RARE
marcescens RARE
and O
Proteus RARE
. O

The O
mucosal O
defence RARE
capacity O
against O
proteolytic O
leukocyte O
enzymes O
. O

The O
apparatus O
consists O
of O
an O
Am RARE
- O
241 NUMERIC
exciting RARE
source O
( O
300 O
mCi O
) O
and O
pure O
Ge RARE
detector O
( O
50 O
mm2 O
X O
5 O
mm O
) O
for O
measuring O
K O
alpha O
fluorescent O
x O
- O
rays O
( O
28 O
. O
3 O
and O
28 O
. O
6 O
KeV LASTCAP
) O
emitted RARE
from O
exited RARE
iodine O
. O

Ultrastructural RARE
studies O
of O
retinopathy RARE
of O
premature O
infants O

The O
range O
of O
serum O
concentrations O
, O
mean O
values O
, O
median O
values O
, O
and O
standard O
deviations RARE
for O
each O
analyte RARE
are O
reported O
for O
males O
and O
females O
and O
for O
three O
age O
groups O
( O
25 O
- O
44 O
, O
45 O
- O
59 O
, O
60 O
- O
70 O
). O

The O
effects O
of O
antithrombotic RARE
drugs O
in O
patients O
with O
left O
ventricular O
thrombi RARE
: O
assessment O
with O
indium RARE
- O
111 O
platelet O
imaging O
and O
two O
- O
dimensional O
echocardiography O
. O

A O
stable O
interface O
depends O
on O
overall O
stress O
and O
microstress RARE
distribution O
on O
the O
bone O
, O
particularly O
trabecular RARE
bone O
. O

Plasma O
NE O
was O
also O
low O
in O
the O
anephric RARE
group O
( O
289 NUMERIC
mg O
/ O
liter O
+/- O
126 O
( O
1 O
SD O
) O
vs O
612 NUMERIC
+/- O
189 NUMERIC
, O
P O
= O
0 O
. O
033 NUMERIC
, O
resting O
).( RARE
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

10 O
long O
- O
term O
hemodialysis O
patients O
had O
immediate O
and O
redistribution RARE
thallium O
- O
201 O
myocardial O
imaging O
performed O
after O
a O
course O
of O
hemodialysis O
. O

The O
Prolactin RARE
levels O
were O
within O
the O
physiological O
norms RARE
; O
the O
responses O
to O
TRH I-GENE
were O
normal O
, O
and O
elevated O
only O
in O
a O
few O
cases O
. O

Despite O
total O
tumor O
resection O
, O
multiple O
intraperitoneal RARE
tumor O
nodules O
of O
varying O
sizes O
were O
found O
and O
resected RARE
six O
months O
and O
one O
year O
later O
. O

Private RARE
hospital O
accreditation RARE
. O

Antithrombin RARE
III I-GENE
in O
hip O
surgery O

In O
14 O
of O
21 O
infant O
hearts O
( O
66 O
%) O
with O
aortic O
arch RARE
interruption RARE
between O
the O
left O
common O
carotid O
and O
left O
subclavian RARE
arteries O
( O
type O
B O
of O
Celoria RARE
and O
Patton RARE
), O
the O
right O
subclavian RARE
artery O
( O
SA O
) O
arose RARE
anomalously RARE
. O

We O
suggest O
that O
sensitivity O
to O
photoperiod RARE
in O
pallid RARE
bats RARE
, O
as O
in O
several O
other O
mammals O
, O
is O
mediated O
by O
the O
pineal O
gland O
. O

Absorption RARE
was O
rapid O
, O
with O
a O
mean O
time O
to O
peak O
of O
39 O
min O
. O

Additionally O
, O
observations O
that O
patients O
with O
mitral O
versus O
aortic O
regurgitation RARE
respond O
differently O
to O
valve O
replacement O
suggest O
that O
differences O
exist O
preoperatively RARE
between O
these O
two O
types O
of O
volume O
overload O
. O

A O
case O
of O
manifest O
latent O
nystagmus O
of O
late O
onset O
in O
a O
13 O
- O
year O
- O
old O
girl RARE
is O
reported O
. O

Within O
the O
compartment O
or O
dimension RARE
of O
severity O
of O
depression O
a O
subscale RARE
of O
the O
Hamilton RARE
Depression RARE
Scale O
( O
or O
the O
Melancholia RARE
Scale O
) O
was O
shown O
to O
have O
reached O
an O
instrumental RARE
perfection RARE
, O
e O
. O
g O
. O
as O
an O
outcome O
measure O
of O
antidepressant RARE
treatment O
. O

Significant O
immunoglobulinuria RARE
developed O
prior O
to O
the O
development O
of O
azotemia RARE
, O
significantly O
decreased O
creatinine O
clearance O
, O
significant O
proteinuria RARE
( O
greater O
than O
or O
equal O
to O
3 O
+ O
dipstick RARE
or O
greater O
than O
or O
equal O
to O
5 O
gm RARE
per O
24 O
- O
hour O
urine O
collection O
), O
or O
oliguria RARE
. O

A O
total O
number O
of O
1628 NUMERIC
cases O
were O
collected O
from O
135 O
medical O
institutions RARE
. O

Epileptiform RARE
activity O
recorded O
from O
superficial O
laminae RARE
bordering RARE
layer O
4 O
, O
and O
into O
which O
layer O
4 O
' O
s O
primary O
projections O
terminate O
, O
is O
suppressed O
preferentially O
by O
phenytoin O
. O

The O
AD O
components O
were O
markedly O
more O
dependent O
on O
the O
affective O
state O
of O
the O
rat O
then O
was O
the O
V1 NUMERIC
component O
. O

Is O
nisoldipine RARE
capable O
of O
reducing O
left O
ventricular O
preload RARE
? O
In O
ten O
anesthetized O
pigs O
, O
nisoldipine RARE
( O
2 O
- O
4 O
micrograms O
X O
kg O
- O
1 O
X O
min O
- O
1 O
), O
a O
calcium O
channel O
blocker O
structurally O
related O
to O
nifedipine O
, O
reduced O
left O
ventricular O
systolic O
pressure O
( O
40 O
%) O
and O
systemic O
vascular O
resistance O
( O
35 O
%), O
whereas O
maxLVdP LASTCAP
/ O
dt O
decreased O
by O
20 O
% O
and O
cardiac O
output O
was O
unchanged O
. O

Monkeys RARE
were O
evaluated O
before O
and O
after O
unilateral O
and O
serial O
bilateral O
removal O
of O
superior O
temporal O
cortex O
. O

HBB ALLCAPS
concentration O
in O
the O
fetuses RARE
indicated O
little O
, O
if O
any O
accumulation O
. O

All O
samples O
exhibited O
a O
decline O
in O
ethanol O
concentration O
, O
with O
most O
losses RARE
falling RARE
within O
the O
expected O
20 O
to O
40 O
mg O
% O
range O
. O

Plasma I-GENE
lactoferrin RARE
and O
the O
blood O
count O
of O
polynuclear RARE
neutrophils O

The O
importance O
of O
selective O
renal O
vein O
phlebography RARE
in O
the O
evaluation O
of O
unexplained RARE
hematuria RARE
and O
filing RARE
defects O
in O
the O
excretory RARE
urogram RARE
is O
illustrated RARE
. O

Pilot RARE
study O
of O
blood O
coagulation O
in O
gout RARE
patients O
. O

The O
statistical O
analysis O
consist O
of O
the O
F O
test O
followed O
by O
Snedecor RARE
' O
s O
contrast O
test O
. O

The O
pyramidal O
tract O
and O
Mesencephalic RARE
Reticular RARE
Formation RARE
( O
MRF ALLCAPS
) O
were O
stimulated O
before O
and O
after O
the O
transection RARE
. O

Further O
, O
the O
reduction O
in O
5 O
- O
hydroxytryptophan RARE
( O
5 O
- O
HTP ALLCAPS
) O
accumulation O
by O
LSD ALLCAPS
showed O
regional O
differences O
in O
inhibition O
by O
methiothepin RARE
( O
hypothalamus O
greater O
than O
cortex O
greater O
than O
striatum O
) O
which O
paralleled RARE
the O
autoreceptor RARE
antagonist O
activity O
of O
methiothepin RARE
in O
vitro O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Effects O
of O
methiothepin RARE
and O
lysergic RARE
acid O
diethylamide RARE
on O
serotonin O
release O
in O
vitro O
and O
serotonin O
synthesis O
in O
vivo O
: O
possible O
relation O
to O
serotonin I-GENE
autoreceptor RARE
function O
. O

In O
a O
recent O
measles RARE
epidemic O
in O
El RARE
Paso RARE
, O
TX ALLCAPS
, O
120 O
, O
000 O
records O
were O
screened O
using O
these O
criteria O
, O
and O
as O
a O
result O
13 O
, O
000 O
students O
were O
vaccinated RARE
. O

No O
patient O
with O
bradyarrhythmia RARE
- O
related O
SCD ALLCAPS
had O
manifest O
atrioventricular RARE
block O
or O
bundle O
branch O
block O
. O

The O
measurement O
of O
the O
areas O
of O
fibrin I-GENE
, O
of O
tissue O
and O
fibrinolysis RARE
, O
at O
the O
above O
mentioned O
times O
, O
has O
been O
effected RARE
at O
standard O
magnification O
( O
15 O
X O
) O
by O
an O
image O
analyser RARE
( O
Videoplan RARE
) O
scale O
1 O
: O
8 O
. O

Diclofenac RARE
sodium O
- O
chlormezanone RARE
poisoning O
. O

Postprandial RARE
plasma I-GENE
enteroglucagon RARE
concentration O
after O
90 O
minutes O
in O
untreated O
patients O
correlated O
positively O
to O
the O
faecal RARE
fat O
excretion O
( O
r O
= O
0 O
. O
58 O
, O
p O
less O
than O
0 O
. O
02 O
). O

Blood O
pressure O
in O
children O
. O

In O
this O
study O
the O
splenectomized RARE
captive RARE
born O
cynomolgus RARE
appeared O
to O
be O
capable O
of O
supplementing RARE
rhesus O
as O
an O
antimalarial RARE
drug O
testing O
model O
. O

The O
results O
showed O
that O
the O
sensitivity O
of O
the O
3 O
given O
guinea O
pig O
strains O
was O
comparable O
. O

Adult O
Amblyomma RARE
lepidum RARE
ticks O
fed O
as O
nymphs RARE
on O
this O
goat RARE
transmitted O
heartwater RARE
to O
a O
Friesian RARE
( O
Bos RARE
taurus RARE
) O
calf O
. O

Twenty O
- O
one O
percent O
of O
these O
patients O
had O
neurologic O
disease O
that O
appeared O
to O
be O
responsible O
for O
the O
tinnitus RARE
. O

Morphine RARE
injected O
into O
the O
lateral O
ventricle O
of O
the O
rat O
produced O
unilateral O
analgesia O
in O
the O
formalin O
test O
, O
which O
involves O
continuous O
, O
moderate O
pain O
. O

The O
maps O
of O
Case RARE
2 O
showed O
that O
a O
maximum O
first O
appeared O
on O
the O
upper O
right O
back O
and O
then O
moved RARE
down O
the O
right O
side O
of O
the O
posterior O
thorax RARE
. O

Urinary RARE
urate RARE
excretion O
, O
urate RARE
clearance O
, O
and O
fractional O
excretion O
of O
urate RARE
all O
increased O
significantly O
during O
water O
immersion O
, O
and O
decreased O
in O
the O
hour O
following O
water O
immersion O
. O

Mutations O
in O
seven O
other O
lts RARE
genes I-GENE
do O
not O
result O
in O
the O
mak RARE
- I-GENE
phenotype I-GENE
. O

Twenty O
- O
eight O
were O
excluded O
as O
gallstones RARE
were O
not O
proved O
: O
of O
the O
remainder RARE
, O
21 O
patients O
received O
glucagon I-GENE
and O
22 O
placebo O
. O

4 O
Five O
patients O
died O
within O
one O
month O
of O
captopril O
and O
five O
between O
four O
and O
seven O
months O
, O
three O
of O
whom O
had O
improved O
to O
class O
IIM ALLCAPS
and O
one O
to O
IIS ALLCAPS
before O
death O
. O

Bullous RARE
angiolymphoid RARE
hyperplasia O
with O
eosinophilia RARE

Regions RARE
of O
the O
translated O
open O
reading O
frames O
of O
cobA LASTCAP
and O
the O
third O
intron O
of O
the O
cob RARE
gene I-GENE
in I-GENE
yeast I-GENE
show O
high O
amino O
acid O
homology O
. O

Multiresistant RARE
strains O
isolated O
from O
humans O
in O
enteral RARE
toxico RARE
- O
infections O
kill RARE
orally O
infected O
mice O
more O
frequently O
than O
strains O
isolated O
in O
hospital O
infections O
. O

Single RARE
tooth O
replacement O
with O
the O
aid O
of O
the O
ITI ALLCAPS
( O
International O
Team RARE
fur RARE
Implantologie RARE
) O
type O
F O
hollow RARE
- O
cylinder RARE
implant O

The O
13 O
, O
14 O
- O
dihydro RARE
- O
15 O
- O
keto RARE
- O
metabolites O
of O
PGE2 O
and O
PGF2 O
alpha O
had O
no O
statistically O
significant O
antiarrhythmic O
effect O
. O

Nucleotide O
sequence O
of O
DNA O
controlling O
expression O
of O
genes O
for O
maltosaccharide RARE
utilization O
in O
Streptococcus O
pneumoniae O
. O

The O
hypertension O
with O
elevated O
PRA ALLCAPS
, O
however O
, O
was O
resistant O
to O
the O
angiotensin I-GENE
II I-GENE
( O
AII ALLCAPS
) O
analog O
[ O
Sar1 NUMERIC
, O
Ile8 NUMERIC
] O
ALL O
. O

Colorimetric RARE
determination O
of O
urinary O
iron O
, O
chelated RARE
with O
deferoxamine RARE
B O
, O
using O
a O
single O
reagent RARE

Measurements O
of O
perfusion O
also O
showed O
significantly O
higher O
values O
under O
active O
therapy O
. O

Volume RARE
of O
distribution O
of O
total O
DMDZ ALLCAPS
( O
range O
, O
1 O
. O
33 O
to O
6 O
. O
30 O
l O
/ O
kg O
) O
and O
of O
unbound RARE
DMDZ ALLCAPS
after O
correction O
for O
protein O
binding O
( O
range O
, O
43 O
to O
243 NUMERIC
l O
/ O
kg O
) O
was O
larger O
in O
women O
than O
in O
men O
of O
all O
ages O
, O
and O
in O
the O
elderly O
as O
opposed O
to O
the O
young O
. O

Effects O
of O
dopamine O
and O
of O
a O
dopaminergic O
blocker O
, O
haloperidol O
, O
on O
the O
responses O
of O
carotid O
body O
chemoreceptors RARE
to O
hypoxia O
and O
hypercapnia O
were O
investigated O
in O
16 O
anesthetized O
cats O
. O

HLA I-GENE
- I-GENE
A I-GENE
and I-GENE
B I-GENE
phenotypes O
of O
105 O
patients O
suffering O
from O
malignant O
melanomas O
were O
determined O
, O
with O
special O
regard O
for O
metastatic O
form O
or O
relapse O
. O

Trypanosoma O
cruzi RARE
. O

The O
subjects O
of O
the O
study O
were O
10 O
normal O
subjects O
and O
64 O
patients O
with O
gastroduodenal RARE
disease O
. O

1 O
. O

This O
study O
represents O
the O
first O
published O
long O
- O
term O
follow O
- O
up O
regarding O
this O
mode O
of O
treatment O
in O
patients O
with O
alveolar O
hypoventilation RARE
. O

The O
alterations O
in O
differentiation O
of O
osteoprogenitor RARE
cells O
, O
together O
with O
the O
failure O
of O
mineralization RARE
, O
resulted O
in O
significantly O
lower O
rates O
of O
bone O
formation O
( O
as O
measured O
by O
fluorochrome RARE
labeling O
) O
in O
the O
magnesium O
- O
deficient O
rats O
. O

A O
convenient RARE
measure O
of O
this O
impairment O
may O
be O
obtained O
using O
the O
ratio O
of O
urine O
volume O
( O
V O
) O
divided O
by O
lithium O
clearance O
( O
CLi RARE
). O

Nitrogen RARE
balance O
was O
compared O
, O
and O
metabolic O
complications O
were O
monitored O
by O
evaluating O
BUN ALLCAPS
, O
serum O
creatinine O
, O
creatinine O
clearance O
, O
serum O
CO2 O
, O
SGOT ALLCAPS
, O
SGPT ALLCAPS
, O
serum I-GENE
LDH ALLCAPS
, O
and O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
. O

Production RARE
of O
C I-GENE
mu I-GENE
RNAs I-GENE
, O
unlike O
mu I-GENE
mRNAs I-GENE
, O
does O
not O
require O
recombination O
with O
the O
joining I-GENE
region I-GENE
( O
JH ALLCAPS
) O
locus O
. O

The O
1 O
. O
9 O
- O
kb O
C I-GENE
mu I-GENE
RNA O
contains O
the O
3 O
' O
sequence O
characteristic O
of O
secreted O
mu I-GENE
chain I-GENE
, O
whereas O
the O
longer O
species O
bear RARE
that O
of O
membrane O
- O
bound O
mu I-GENE
chin RARE
. O

Transcripts RARE
of O
the O
immunoglobulin I-GENE
C I-GENE
mu I-GENE
gene I-GENE
vary O
in O
structure O
and O
splicing O
during O
lymphoid O
development O
. O

Non O
- O
complement O
- O
dependent O
sperm O
- O
immobilizing RARE
activity O
was O
also O
detected O
in O
the O
cervical O
mucus O
of O
several O
patients O
. O

The O
role O
of O
DNA O
rearrangement O
and O
alternative O
RNA O
processing O
in O
the O
expression O
of O
immunoglobulin I-GENE
delta I-GENE
genes I-GENE
. O

Although O
the O
mechanism O
of O
action O
of O
ICRF ALLCAPS
- O
159 NUMERIC
and O
187 NUMERIC
has O
not O
been O
clearly O
defined O
, O
it O
is O
evident O
from O
both O
preclinical RARE
and O
early O
clinical O
studies O
that O
these O
compounds O
are O
of O
interest O
. O

All O
62 O
isolates O
were O
resistant O
to O
lincomycin RARE
, O
colistin RARE
, O
nystatin RARE
, O
amphotericin O
B O
, O
trimethoprim RARE
lactate O
, O
polymyxin RARE
B O
, O
and O
anisomycin RARE
. O

The O
evaluation O
of O
amniotic O
fluid O
delta O
OD450 NUMERIC
is O
considered O
to O
be O
the O
cornerstone RARE
of O
clinical O
management O
. O

Host RARE
lipids O
in O
tuberculous O
infection O
. O

There O
is O
now O
a O
significative RARE
difference O
between O
age O
group O
1 O
- O
5 O
and O
the O
others O
( O
p O
Less RARE
Than RARE
0 O
, O
02 O
). O

The O
sympathetic O
neuroeffector RARE
influence O
on O
the O
myocardium O
with O
ATCI ALLCAPS
depends O
to O
a O
large O
measure O
on O
the O
intensity O
of O
the O
neurotransmitter RARE
biosynthesis O
and O
function O
of O
cardiomyocyte RARE
adrenoreceptors RARE
. O

Lens RARE
aldose RARE
reductase I-GENE
in O
diabetic O
and O
galactosemic RARE
cataracts RARE
. O

Fenfluramine RARE
( O
in O
doses O
ranging O
from O
0 O
. O
0625 NUMERIC
- O
4 O
. O
0 O
mg O
/ O
kg O
/ O
infusion O
) O
did O
not O
maintain O
self O
- O
administration O
behavior O
at O
or O
above O
the O
minimum O
requirement O
( O
FR O
30 O
). O

In O
the O
course O
of O
Hepatitis I-GENE
A I-GENE
HBs I-GENE
- I-GENE
and I-GENE
HBe RARE
- I-GENE
antigen I-GENE
as O
well O
as O
HBc RARE
( I-GENE
IgM I-GENE
and I-GENE
IgG I-GENE
)-, RARE
HBs I-GENE
- I-GENE
and I-GENE
HBe RARE
- I-GENE
antibodies I-GENE
can O
be O
detected O
. O

The O
effect O
of O
the O
fatty I-GENE
acid I-GENE
cyclo RARE
- I-GENE
oxygenase I-GENE
inhibitor O
indomethacin O
on O
cerebral O
blood O
flow O
( O
CBF O
) O
and O
the O
metabolic O
rate O
for O
oxygen O
( O
CMRO2 NUMERIC
) O
was O
studied O
in O
paralyzed RARE
and O
artificially O
ventilated O
rats O
. O

The O
rat O
incisor RARE
is O
an O
excellent O
model O
system O
in O
which O
to O
study O
amelgenesis RARE
. O

The O
already O
elevated O
prolactin I-GENE
levels O
in O
nursing O
women O
were O
not O
influenced O
by O
chronic O
oestradiol O
administration O
. O

Factor I-GENE
VIII I-GENE
procoagulant RARE
activity O
, O
antigen O
concentration O
and O
von I-GENE
Willebrand I-GENE
activity O
as O
ristocetin RARE
cofactor I-GENE
were O
determined O
several O
times O
in O
10 O
patients O
with O
DIC ALLCAPS
. O

Morphine RARE
- O
dependent O
and O
control O
rats O
in O
an O
oral O
free O
- O
choice O
protocol O
were O
treated O
with O
gamma O
- O
vinyl O
GABA O
( O
GVG ALLCAPS
), O
60 O
, O
120 O
and O
240 O
mg O
/ O
kg O
IP ALLCAPS
, O
for O
3 O
days O
over O
three O
successive O
periods O
. O

Significance O
of O
the O
pulmonary O
gas O
exchange O
reaction O
to O
physical O
loading O
in O
evaluating O
the O
effectiveness O
of O
mitral O
commissurotomy RARE

Thyreoliberin RARE
VUFB ALLCAPS
in O
thyroid O
gammagraphy RARE

In O
silicosis RARE
, O
significant O
relationships O
between O
patients O
and O
sons RARE
were O
not O
seen O
with O
respect O
to O
arterial O
blood O
gas O
determinations O
and O
ventilatory RARE
responses O
except O
for O
Paco2 NUMERIC
of O
patients O
and O
hypercapnic RARE
ventilatory RARE
responses O
of O
sons RARE
. O

For O
steers O
the O
urinary O
N O
values O
were O
403 NUMERIC
and O
295 NUMERIC
mg O
/ O
kg O
W0 NUMERIC
. O
75 O
at O
200 O
and O
350 O
kg O
live O
weight O
respectively O
and O
total O
N O
excretion O
including O
faecal RARE
N O
was O
408 NUMERIC
and O
320 NUMERIC
mg O
/ O
kg O
W0 NUMERIC
. O
75 O
. O

Advances RARE
in O
hemophilia RARE
treatment O
: O
a O
hepatitis O
- O
safe O
factor I-GENE
VIII I-GENE
concentrate RARE

This O
study O
was O
designed O
to O
assess O
and O
compare O
the O
ability O
of O
three O
different O
forms O
of O
DSG ALLCAPS
to O
block O
EIB ALLCAPS
. O

Comparison O
of O
three O
different O
preparations O
of O
disodium RARE
cromoglycate RARE
in O
the O
prevention O
of O
exercise O
- O
induced O
bronchospasm RARE
: O
a O
double O
- O
blind O
study O
. O

LCBF ALLCAPS
in O
normal O
and O
hypoxic O
puppies RARE
was O
correlated O
with O
local O
cerebral O
glucose O
utilization O
( O
LCGU ALLCAPS
) O
obtained O
under O
the O
same O
experimental O
conditions O
( O
Duffy RARE
et O
al O
, O
1982 O
). O

Phagocytosis RARE
of O
tubercle RARE
bacilli O
by O
macrophages O
. O

Detection O
of O
hemophilia RARE
A O
carriers O
. O

The O
stability O
of O
isoniazid RARE
solutions O
increases O
markedly O
with O
increasing O
NTA ALLCAPS
or O
EDTA O
concentration O
up O
to O
1 O
mmol O
/ O
l O
. O

Bile RARE
bilirubin O
did O
not O
rise O
within O
12 O
h O
after O
haem RARE
infusion O
a O
finding O
which O
warrants RARE
further O
investigation O
. O

Autoimmune RARE
manipulation RARE
aids RARE
juvenile O
diabetes O
management O
. O

Other O
properties O
of O
Hg O
- O
and O
Cd O
- O
spores RARE
were O
similar O
to O
those O
of O
control O
spores RARE
. O

The O
decrease O
in O
HDL I-GENE
- I-GENE
cholesterol I-GENE
with O
increasing O
VLDL ALLCAPS
- I-GENE
triglycerides I-GENE
was O
relatively O
much O
larger O
than O
the O
concomitant O
decrease O
in O
apo I-GENE
A I-GENE
- I-GENE
I I-GENE
. O

Apo RARE
A I-GENE
- I-GENE
I I-GENE
level O
was O
unrelated O
to O
age O
, O
but O
increased O
with O
ethanol O
consumption O
and O
decreased O
with O
adiposity RARE
. O

TEMTU ALLCAPS
and O
DPTU ALLCAPS
were O
the O
most O
potent O
teratogens RARE
. O

The O
osmotic O
diuretic O
mannitol RARE
was O
administered O
to O
21 O
patients O
. O

Of O
270 O
patients O
with O
well O
- O
defined O
drug O
reactions O
, O
190 O
( O
70 O
per O
cent O
) O
gave O
a O
positive O
response O
to O
the O
mast O
cell O
test O
. O

Selenium RARE
, O
as O
a O
constituent RARE
of O
glutathione I-GENE
peroxidase I-GENE
, O
plays O
a O
role O
in O
the O
antioxidant O
defense O
systems O
of O
the O
body O
, O
but O
other O
metabolic O
roles O
for O
selenium O
may O
yet O
be O
discovered O
. O

Diagnostic O
value O
of O
serum I-GENE
myoglobin I-GENE
in O
cases O
of O
neuromuscular O
disease O

At O
43 O
% O
blood O
pressure O
reduction O
, O
PCO2 O
fell O
by O
0 O
. O
53 O
kPa RARE
, O
a O
decrease O
which O
could O
not O
explain O
the O
observed O
CBF O
fall O
of O
27 O
%. O

During O
the O
last O
6 O
months O
of O
the O
study O
a O
striking O
change O
in O
epidemiology RARE
concerning O
hepatitis O
A O
was O
seen O
, O
apparently O
caused O
by O
a O
steep RARE
increase O
in O
the O
incidence O
of O
this O
type O
of O
hepatitis O
among O
drug O
addicts O
. O

Asthmatic RARE
patients O
showed O
greater O
responses O
of O
both O
parameters O
to O
adrenaline O
than O
controls O
indicating O
that O
long O
- O
term O
corticosteroid O
treatment O
enhances O
the O
acute O
responses O
of O
plasminogen I-GENE
activator I-GENE
and O
clotting I-GENE
factor I-GENE
VIII I-GENE
to O
adrenaline O
infusion O
. O

Sulphur RARE
amino O
acids O
( O
g O
/ O
16 O
g O
N O
) O
were O
higher O
in O
the O
isolates O
than O
in O
the O
flours RARE
. O

Time RARE
shifts O
increase O
growth I-GENE
hormone I-GENE
release O
. O

It O
then O
merged RARE
with O
right O
ventricular O
wavefronts RARE
ending RARE
along O
the O
right O
ventricular O
anterior O
atrioventricular RARE
groove O
and O
outflow O
tract O
. O

Many O
of O
these O
landfill RARE
operations RARE
were O
undertaken O
in O
the O
early O
1950s NUMERIC
and O
1960s NUMERIC
, O
when O
knowledge O
regarding O
the O
safe O
and O
prolonged O
containment RARE
of O
the O
waste RARE
buried RARE
was O
nonexistent RARE
or O
minimal O
at O
best O
. O

Vesicles RARE
could O
be O
induced O
only O
with O
multiple O
exposures O
to O
UVA ALLCAPS
. O

The O
level O
of O
contamination O
in O
the O
wound O
can O
be O
determined O
with O
the O
rapid O
biopsy O
fixation O
technique O
. O

Self RARE
- O
heating RARE
after O
deep O
hypothermia O
( O
20 O
degrees O
C O
) O
causes O
a O
considerable O
increase O
in O
the O
brain O
tissues O
glutaminase RARE
activity O
at O
all O
studied O
incubation O
temperatures O
( O
37 O
, O
30 O
, O
20 O
and O
10 O
degrees O
C O
) O
as O
compared O
to O
control O
rats O
and O
rats O
under O
hypothermia O
. O

Similar O
observations O
were O
made O
with O
unilateral O
pneumothorax RARE
of O
15 O
cmH2O O
for O
30 O
min O
. O

According O
to O
Sugiura RARE
' O
s O
classification O
, O
they O
consisted O
of O
Type O
Ia RARE
in O
63 O
%, O
Type O
Ib RARE
in O
11 O
%, O
Type O
II O
in O
11 O
%, O
and O
Type O
III O
in O
16 O
%. O

This O
study O
was O
undertaken O
to O
define O
the O
mechanism O
for O
the O
respiratory O
inhibition O
observed O
during O
high O
- O
frequency O
oscillatory RARE
ventilation O
( O
HFOV ALLCAPS
). O

Determination O
of O
20 O
alpha O
- O
hydroxy O
- O
9 O
beta O
, O
10 O
alpha O
- O
pregna RARE
- O
4 O
, O
6 O
- O
dien RARE
- O
3 O
- O
one O
in O
plasma O
by O
selected O
ion O
monitoring O
. O

A O
case O
of O
a O
dense RARE
epidermoid RARE
cyst O
of O
the O
suprasellar RARE
cistern RARE
is O
presented O
. O

Copper RARE
treatments O
were O
assigned O
to O
simulate RARE
the O
different O
levels O
of O
copper O
intake O
that O
might O
result O
from O
differences O
in O
daily O
feed O
intake O
similar O
to O
the O
practice O
followed O
with O
commercial O
industry RARE
. O

Fibromuscular RARE
intimal RARE
thickening RARE
was O
seen O
in O
the O
ascending O
and O
thoracic RARE
aorta O
of O
the O
swine O
fed O
62 O
, O
500 O
IU O
of O
vitamin O
D3 O
/ O
kg O
of O
diet O
for O
three O
months O
duration O
; O
and O
after O
3 O
months O
of O
vitamin O
D3 O
withdrawal O
, O
atherosclerotic RARE
lesions O
were O
found O
. O

Because O
of O
a O
rapid O
development O
of O
the O
connective O
tissue O
scars RARE
, O
however O
, O
at O
the O
place O
of O
the O
destroyed RARE
glandular RARE
parenchyma O
areas O
, O
there O
is O
no O
normalization RARE
of O
the O
organ O
' O
s O
structure O
and O
function O
by O
the O
42d NUMERIC
day O
. O

Histological O
signs O
of O
the O
flare RARE
- O
up O
reaction O
were O
already O
present O
at O
6 O
hr O
after O
i O
. O
v O
. O
challenge O
and O
lasted RARE
for O
at O
least O
4 O
days O
. O

Significant O
GMBF ALLCAPS
reductions O
occurred O
in O
early O
shock O
in O
both O
treatment O
groups O
. O

Of O
254 NUMERIC
children O
with O
neuroblastoma O
treated O
at O
St RARE
. O

Penicillin RARE
- O
G O
degradation O
products O
inhibit O
in O
vitro O
granulopoiesis RARE
. O

Plasma O
fibrinogen I-GENE
was O
measured O
by O
the O
turbidimetric RARE
method O
in O
timol RARE
turbidimetric RARE
units O
. O

Five O
patients O
with O
type O
III O
musculoskeletal RARE
infection O
from O
nongonococcal RARE
Neisseria RARE
species O
were O
examined O
during O
a O
13 O
- O
month O
period O
. O

Distal RARE
tubular O
acidification O
and O
the O
threshold O
for O
proximal O
tubular O
bicarbonate RARE
reabsorption RARE
were O
normal O
, O
as O
was O
urine O
concentrating RARE
capacity O
. O

Detection O
of O
exercise O
- O
induced O
asynergy RARE
by O
M O
- O
mode O
echocardiography O
. O

The O
Tullio RARE
phenomenon O
, O
fistula RARE
test O
, O
and O
Hennebert RARE
' O
s O
sign O
: O
clinical O
significance O
. O

These O
results O
indicate O
that O
significant O
pulmonary O
metabolism O
of O
5 O
- O
HT O
followed O
by O
efflux RARE
of O
5 O
- O
HIAA ALLCAPS
into O
venous O
output O
occurs O
during O
single O
- O
pass RARE
circulation O
. O

Disturbances RARE
of O
placental O
maturation O
, O
2 O
. O

On O
the O
basis O
of O
histopathological O
findings O
, O
the O
origin O
of O
amyloid RARE
appeared O
to O
be O
closely O
related O
to O
the O
fibroblasts O
. O

Both O
groups O
were O
subjected O
to O
tests O
of O
delayed O
hypersensitivity O
with O
Candidin RARE
, O
Trycophytin RARE
and O
Tuberculin RARE
. O

Serum O
lactate I-GENE
dehydrogenase I-GENE
and O
haptoglobin RARE
levels O
were O
normal O
, O
and O
total O
bilirubin O
was O
only O
slightly O
elevated O
. O

Low O
- O
dose O
D O
( O
0 O
. O
4 O
- O
0 O
. O
8 O
mg O
) O
and O
DB ALLCAPS
( O
1 O
. O
0 O
- O
5 O
. O
0 O
mg O
) O
did O
not O
significantly O
alter O
any O
parameter O
from O
control O
. O

Efficacy RARE
of O
cervical O
spine O
immobilization RARE
methods O
. O

Leads RARE
from O
the O
MMWR ALLCAPS
. O

The O
presence O
of O
visna RARE
- O
maedi RARE
in O
Italy RARE
is O
reported O
for O
the O
first O
time O
. O

High O
levels O
of O
IC ALLCAPS
coincided RARE
with O
relative O
hypocomplementemia RARE
. O

Circulating RARE
platelets O
may O
be O
activated O
by O
exposed O
triple O
- O
helical O
collagen I-GENE
in O
atherosclerotic RARE
lesions O
in O
Mg O
- O
deficient O
ruminants RARE
. O

Acute O
type O
A O
hepatitis O
in O
three O
patients O
with O
chronic O
HBV O
infection O
. O

Pathogenetic RARE
relationships O
between O
renal O
tubular O
acidosis O
and O
sodium O
metabolism O
alterations O
in O
liver O
cirrhosis O
. O

5 O
microU LASTCAP
/ O
l O
thyrotropin I-GENE
: O
75 O
% O
( O
1974 NUMERIC
), O
45 O
% O
( O
1977 NUMERIC
) O
and O
20 O
% O
( O
1980 O
). O

Echosismography RARE
enables O
to O
improve O
the O
diagnosis O
when O
compared O
with O
classical O
sonography RARE
in O
about O
20 O
% O
of O
cases O
. O

Relationships RARE
with O
the O
acquired O
immune O
deficiency O
syndrome O
. O

The O
prevalence O
of O
CPAF ALLCAPS
was O
similar O
in O
type O
1 O
and O
type O
2 O
diabetes O
, O
was O
greater O
in O
women O
than O
in O
men O
, O
and O
was O
significantly O
greater O
after O
repeated O
administrations RARE
than O
after O
one O
single O
administration O
of O
chlorpropamide RARE
. O

A O
reassessment RARE
of O
the O
prevalence O
data O
was O
carried O
out O
in O
the O
southern O
province RARE
of O
Uusimaa RARE
and O
in O
the O
western RARE
province RARE
of O
Vaasa RARE
, O
the O
prevalence O
day O
being O
January O
1 O
, O
1979 NUMERIC
. O

The O
results O
confirm O
and O
extend O
previous O
work O
by O
other O
researchers RARE
. O

In O
the O
ultramarathon RARE
runner RARE
the O
testosterone O
levels O
sharply O
rose O
at O
the O
beginning O
of O
the O
training O
session O
( O
from O
the O
7 O
, O
20 O
ng O
/ O
ml O
to O
11 O
, O
50 O
ng O
/ O
ml O
after O
20 O
' O
training O
), O
and O
subsequently O
decrease O
after O
3 O
hours O
( O
9 O
, O
20 O
ng O
/ O
ml O
) O
and O
at O
the O
end O
of O
the O
6 O
hours O
training O
( O
4 O
, O
60 O
ng O
/ O
ml O
). O

In O
patients O
with O
complete O
or O
partial O
remission O
of O
the O
tumor O
, O
the O
neopterine RARE
excretion O
dropped RARE
to O
normal O
values O
. O

In O
visible RARE
tumours O
the O
best O
results O
were O
obtained O
with O
FB O
( O
85 O
%) O
while O
TBN ALLCAPS
was O
positive O
in O
65 O
%. O

Total O
PGE ALLCAPS
levels O
in O
synovial O
fluid O
remained O
significantly O
depressed O
in O
the O
patient O
group O
for O
24 O
hours O
after O
the O
400 O
- O
mg O
test O
dose O
of O
tolmetin RARE
on O
day O
8 O
. O

Normal RARE
rates O
of O
weight O
gain O
were O
seen O
once O
absorbed O
energy O
intakes RARE
reached O
100 O
- O
110 O
% O
of O
requirements O
. O

Its O
vasodilatory RARE
, O
anti O
- O
vasopressor RARE
, O
and O
platelet O
stabilizing RARE
effects O
could O
be O
expected O
to O
counteract RARE
the O
placental O
ischemia O
, O
hypertension O
and O
excessive O
coagulation O
that O
are O
seen O
in O
pre O
- O
eclampsia RARE
. O

Behcet RARE
' O
s O
syndrome O

Survival RARE
of O
111 O
Indium RARE
- O
labelled O
autologous O
platelets O
was O
studied O
in O
2 O
patients O
after O
correction O
of O
platelet O
count O
and O
was O
still O
found O
shortened O
. O

The O
effect O
of O
emotional RARE
- O
painful RARE
stress O
( O
EPS ALLCAPS
) O
on O
myocardial O
extensibility RARE
and O
contractility O
was O
studied O
on O
an O
isolated O
rat O
atrium O
. O

Terbutaline RARE
; O
a O
beta2 O
- O
adrenergic O
agonist O
, O
and O
aminophyllin RARE
, O
a O
phosphodiesterase O
inhibitor O
, O
were O
given O
separately O
, O
or O
in O
combination O
, O
to O
rabbit O
fetuses RARE
on O
the O
28th NUMERIC
day O
of O
gestation O
. O

When O
O2 O
therapy O
was O
controlled O
for O
, O
the O
association O
between O
RBT ALLCAPS
and O
RLF ALLCAPS
did O
not O
achieve O
statistical O
significance O
( O
P O
= O
. O
07 O
). O

This O
two O
- O
helix O
motif O
is O
thought O
to O
be O
involved O
in O
specific O
DNA O
sequence O
recognition O
by O
CAP I-GENE
. O

The O
hyperacute RARE
phase O
of O
posterolateral RARE
myocardial O
infarction O
. O

Statistics RARE
for O
nurse O
managers RARE
-- O
3 O
. O

The O
infection O
rate O
was O
five O
times O
greater O
in O
patients O
with O
Hickman RARE
catheters RARE
than O
in O
those O
with O
Broviac RARE
catheters RARE
( O
p O
= O
0 O
. O
01 O
). O

After O
a O
year O
of O
planning O
in O
the O
Laboratory O
Assistants RARE
' O
School RARE
in O
Stockholm RARE
: O
new O
education O
for O
laboratory O
assistants RARE
is O
now O
arranged O

The O
electrocardiogram O
. O

Setting RARE
takes RARE
place O
through O
complex O
formation O
of O
( O
NH4Mg NUMERIC
PO4 NUMERIC
. O
6H2O NUMERIC
) O
n O
, O
excess O
reactants RARE
, O
and O
water O
. O

The O
Authors RARE
have O
proposed O
to O
develop O
this O
research O
employing O
a O
preparation O
containing O
exclusively O
a O
cortisonic RARE
, O
the O
desametazone RARE
, O
in O
order O
to O
evaluate O
the O
alterations O
of O
the O
dentinogenesis RARE
to O
be O
attributed O
to O
such O
component O
. O

Secretory RARE
IgA I-GENE
and O
serum I-GENE
immunoglobulins I-GENE
as O
indices O
of O
the O
local O
immunity O
of O
the O
intestinal O
mucosa O
in O
acute O
leukemias O

Serum I-GENE
IgE I-GENE
levels O
in O
Tauranga RARE
children O
. O

Use O
of O
prostaglandin O
F2 O
alpha O
( O
PGF2 O
alpha O
) O
in O
cattle O
breeding RARE
. O

Thus O
it O
appears O
that O
the O
management O
of O
blood O
, O
including O
washing RARE
is O
of O
great O
importance O
. O

Range RARE
, O
variations O
and O
neoplastic O
potential O
. O

The O
scores O
are O
dependent O
in O
part O
on O
the O
reliability O
of O
faculty RARE
evaluations RARE
. O

Study O
on O
distribution O
of O
metal O
in O
the O
teeth O
treated O
by O
iontophoresis RARE
with O
transparent RARE
specimens O

Whereas O
creatine I-GENE
kinase I-GENE
activity O
declined O
exponentially RARE
from O
a O
single O
peak O
, O
myoglobin I-GENE
appeared O
in O
multiple O
episodes O
inadequately RARE
represented O
by O
a O
single O
peak O
value O
and O
having O
no O
clear O
clinical O
correlation O
. O

Utero RARE
- O
placental O
blood O
flow O
and O
the O
effect O
of O
beta I-GENE
2 I-GENE
- I-GENE
adrenoceptor I-GENE
stimulating O
drugs O
. O

Development RARE
of O
basophilic RARE
leukemia O
with O
trisomy RARE
8 O
and O
atypical O
erythroblastosis RARE
in O
a O
patient O
with O
a O
history O
of O
aplastic RARE
anemia O
22 O
years O
earlier O

The O
arginyl RARE
peptide O
bonds O
that O
are O
cleaved O
in O
the O
conversion O
of O
human I-GENE
factor I-GENE
IX I-GENE
to O
factor I-GENE
IXa RARE
by O
factor I-GENE
XIa RARE
were O
identified O
as O
Arg145 NUMERIC
- O
Ala146 NUMERIC
and O
Arg180 NUMERIC
- O
Val181 NUMERIC
. O

Alveolar RARE
growth O
, O
contemporary RARE
with O
dental O
eruption RARE
, O
is O
sufficient O
to O
compensate RARE
possible O
hypotrophy RARE
of O
maxillary RARE
bone O
bases O
. O

Fluorometric RARE
methods O
can O
also O
provide O
information O
about O
porphyrin O
binding O
sites O
that O
is O
useful O
in O
understanding O
porphyrin O
transport O
and O
clearance O
. O

Renal O
and O
extrarenal RARE
arterial O
fibromuscular RARE
hyperplasia O
with O
hypertension O
. O

The O
monoexponential RARE
rate O
of O
clearance O
of O
tracer O
-- O
obtained O
from O
the O
portion O
of O
the O
residue O
- O
detection O
curve O
reflecting O
metabolism O
of O
fatty O
acid O
incorporated O
into O
neutral O
lipids O
-- O
correlated O
directly O
with O
induced O
changes O
in O
tension O
- O
time O
index O
after O
injections O
into O
the O
left O
atrium O
( O
r O
= O
0 O
. O
96 O
, O
n O
= O
12 O
), O
right O
atrium O
( O
r O
= O
0 O
. O
86 O
, O
n O
= O
14 O
), O
and O
ear O
vein O
( O
r O
= O
0 O
. O
93 O
, O
n O
= O
14 O
). O

Both O
examinations O
are O
sensitive O
indicators O
of O
CNS O
abnormalities O
associated O
with O
bacterial O
meningeal RARE
infections O
and O
are O
important O
determinants O
of O
the O
therapy O
and O
ultimate RARE
prognosis O
of O
such O
complications O
. O

Specific O
IgE I-GENE
levels O
decreased O
slightly O
, O
but O
always O
remained O
within O
the O
pathological O
range O
. O

Similar O
clinical O
evaluation O
of O
an O
obligate RARE
carrier O
revealed O
no O
ocular O
abnormalities O
. O

Correlation RARE
between O
intraocular RARE
involvement O
and O
systemic O
outcome O
was O
poor O
. O

A O
case O
of O
anterior O
cleavage O
syndrome O
in O
a O
27 O
- O
year O
- O
old O
female O
patient O
is O
described O
. O

The O
daily O
administration O
of O
betamethasone RARE
for O
three O
weeks O
markedly O
reduced O
the O
absorption O
of O
calcium O
and O
phosphate O
as O
well O
as O
the O
growth O
rate O
. O

Endorphins RARE
and O
legal RARE
issues O
. O

At O
necropsy RARE
28 O
days O
post O
- O
inoculation RARE
, O
F344 NUMERIC
rats O
had O
no O
gross O
lung O
lesions O
, O
even O
those O
given O
the O
maximum O
dose O
of O
1 O
. O
4 O
X O
10 O
( O
9 O
) O
colony O
- O
forming O
units O
of O
M O
. O
pulmonis RARE
. O

Aneurysmectomy RARE
and O
the O
performance O
of O
CABG ALLCAPS
were O
not O
significantly O
associated O
with O
postoperative O
ECG O
changes O
, O
but O
more O
bypass O
grafts O
per O
patient O
grafted RARE
appeared O
in O
the O
group O
with O
postoperative O
ECG O
changes O
, O
suggesting O
that O
coronary O
artery O
disease O
may O
be O
more O
severe O
in O
that O
group O
. O

REV ALLCAPS
I O
: O
All O
vessels O
up O
to O
50 O
% O
stenosed RARE
have O
a O
patent RARE
graft O
. O

Complete RARE
sequences O
were O
obtained O
for O
the O
three O
large O
thrombic RARE
peptides O
, O
and O
these O
were O
aligned RARE
by O
using O
peptides O
from O
the O
V8 NUMERIC
protease I-GENE
digest RARE
. O

The O
extraction O
measurements O
were O
used O
to O
test O
for O
extracerebral RARE
contamination O
of O
venous O
outflow O
. O

Contractile RARE
responses O
to O
norepinephrine O
, O
serotonin O
and O
potassium O
( O
K O
+) O
and O
relaxant RARE
responses O
to O
isoproterenol O
and O
papaverine RARE
were O
studied O
in O
vitro O
with O
spirally RARE
cut O
thoracic RARE
aortic O
strips RARE
from O
aortic O
coarcted RARE
hypertensive O
rats O
( O
AHR ALLCAPS
) O
2 O
, O
6 O
, O
14 O
and O
28 O
days O
postoperatively O
and O
compared O
to O
time O
- O
matched O
, O
sham O
- O
operated O
normotensive RARE
controls O
. O

On O
line O
calculation RARE
of O
steroid O
concentrations O
by O
radioimmunoassay O

Detection O
of O
congenital O
hypothyroidism O
in O
26 O
, O
282 NUMERIC
newborn O
infants O

In O
rubella RARE
patients O
with O
serologic O
confirmation RARE
by O
HI ALLCAPS
, O
the O
IF O
test O
detected O
significant O
rises RARE
in O
219 NUMERIC
( O
99 O
. O
1 O
%) O
of O
221 NUMERIC
patients O
and O
the O
PHA I-GENE
test O
detected O
antibody O
conversion O
in O
68 O
( O
93 O
%) O
of O
73 O
patients O
. O

The O
results O
indicate O
that O
folate O
compounds O
decrease O
formate O
accumulation O
after O
methanol RARE
by O
stimulating O
formate O
oxidation O
or O
utilization O
and O
suggest O
a O
possible O
use O
for O
folates RARE
in O
the O
treatment O
of O
certain O
cases O
of O
human O
methanol RARE
poisoning O
. O

The O
effect O
of O
sodium O
saccharin O
in O
the O
diet O
on O
caecal RARE
microflora RARE
. O

The O
residue O
functions O
, O
R O
( O
t O
), O
for O
C O
- O
11 O
CPZ ALLCAPS
and O
In O
- O
113m NUMERIC
transferrin I-GENE
were O
plotted RARE
against O
time O
for O
selected O
areas O
of O
interest O
, O
and O
the O
CPZ ALLCAPS
area O
- O
weighted O
extraction O
, O
E O
( O
t O
), O
was O
computed O
for O
the O
same O
areas O
every O
250 O
msec O
using O
the O
formula O
: O
E O
( O
t O
) O
= O
[ O
RT O
( O
t O
) O
- O
RR O
( O
t O
)]/[ RARE
1 O
- O
RR O
( O
t O
)], RARE
where O
RT O
and O
RR O
are O
the O
normalized O
residue O
functions O
for O
CPZ ALLCAPS
and O
transferrin I-GENE
, O
respectively O
. O

Synchronous RARE
extracts O
showed O
no O
significant O
migration O
inhibition O
in O
allogeneic RARE
assays O
. O

Ten O
days O
of O
cefadroxil RARE
therapy O
was O
used O
to O
treat O
44 O
children O
with O
urinary O
tract O
infection O
and O
CRP I-GENE
values O
greater O
than O
or O
equal O
to O
28 O
microgram O
/ O
ml O
( O
CRP I-GENE
- O
positive O
group O
). O

Both O
resting O
blood O
flow O
( O
RBF ALLCAPS
) O
and O
maximal O
blood O
flow O
( O
NBF ALLCAPS
) O
were O
studied O
by O
Xenon RARE
133 O
clearance O
. O

Plasma I-GENE
renin I-GENE
concentration O
is O
significantly O
higher O
in O
the O
subcapsular RARE
venous O
outflow O
, O
which O
drains RARE
the O
superficial O
cortex O
, O
than O
in O
the O
deep O
venous O
outflow O
, O
which O
drains RARE
the O
inner O
half O
of O
the O
cortex O
and O
medulla RARE
of O
the O
cat O
kidney O
. O

After O
acclimation RARE
, O
resting O
supine O
and O
sitting RARE
DPB ALLCAPS
decreased O
( O
P O
less O
than O
0 O
. O
05 O
) O
by O
6 O
and O
9 O
mmHg O
, O
respectively O
. O

In O
the O
diabetics RARE
, O
Ca2 O
+ O
infusions RARE
induced O
a O
rise O
of O
plasma O
Ca2 O
+ O
up O
to O
3 O
. O
2 O
+/- O
0 O
. O
1 O
mmol O
/ O
1 O
and O
a O
fall O
of O
circulating O
glucagon I-GENE
(- O
26 O
. O
4 O
+/- O
5 O
. O
7 O
%; O
p O
less O
than O
0 O
. O
001 O
) O
and O
glucose O
(- O
23 O
. O
3 O
+/- O
3 O
. O
6 O
%; O
p O
less O
than O
0 O
. O
05 O
). O

Fifty O
- O
eight O
RMI ALLCAPS
' O
s O
occurred O
in O
the O
placebo O
group O
as O
compared O
to O
only O
twenty RARE
in O
the O
AC O
group O
( O
p O
less O
than O
0 O
. O
01 O
). O

The O
" O
cracked RARE
- O
tooth O
" O
syndrome O
. O

The O
foregoing RARE
results O
show O
that O
CXD ALLCAPS
has O
high O
efficacy O
and O
safety O
and O
it O
can O
be O
said RARE
that O
it O
is O
a O
drug O
required O
in O
the O
pediatric O
field O
. O

Based O
on O
peptide O
map O
similarities O
, O
partial O
amino O
- O
terminal O
sequence O
data O
, O
and O
common O
genetic O
origin O
, O
it O
is O
suggested O
that O
p60 NUMERIC
and O
p62 I-GENE
have O
identical O
amino O
acid O
sequences O
carboxy O
- O
terminal O
to O
the O
p60 NUMERIC
initiator O
methionine O
( O
residue O
21 O
of O
p62 I-GENE
). O

All O
patients O
in O
the O
control O
group O
showed O
a O
significant O
improvement O
in O
their O
PEFR ALLCAPS
while O
only O
3 O
patients O
in O
the O
treated O
group O
showed O
an O
improvement O
. O

Facts RARE
on O
the O
Economic RARE
Recovery RARE
Tax O
Act RARE
of O
1981 NUMERIC
for O
speech O
- O
language O
pathologists RARE
and O
audiologists RARE
. O

From O
Pap RARE
to O
ApUp RARE
. O

The O
relationship O
between O
the O
rare O
complications O
mentioned O
above O
and O
the O
pathophysiology O
of O
Bartter RARE
' O
s O
syndrome O
is O
still O
obscure RARE
. O

Using O
an O
opsonophagocytic RARE
bacterial O
assay O
and O
a O
suckling RARE
rat O
model O
of O
GBS ALLCAPS
sepsis O
, O
we O
analyzed O
a O
modified O
human I-GENE
immunoglobulin I-GENE
for O
opsonic RARE
and O
protective O
antibody O
. O

Glomerular RARE
lesions O
in O
renal O
allografts RARE
. O

Commonly RARE
observed O
systemic O
toxic O
effects O
( O
bone O
marrow O
, O
gastrointestinal O
tract O
, O
and O
heart O
) O
were O
not O
seen O
in O
this O
study O
. O

2 O
. O

When O
vascular O
pressure O
( O
Pvas RARE
) O
was O
raised O
abruptly RARE
from O
- O
5 O
to O
+ O
25 O
cmH2O O
by O
air O
inflation RARE
for O
60 O
min O
, O
Px O
( O
f O
) O
became O
abruptly RARE
less O
negative O
, O
then O
remained O
stable O
. O

( O
1980 O
): O
Science RARE
210 O
, O
77 O
- O
72 O
) O
that O
stimulating O
the O
crossed RARE
olivocochlear RARE
bundle O
( O
COCB ALLCAPS
) O
can O
change O
the O
magnitude O
of O
the O
distortion RARE
product O
( O
f2 NUMERIC
- O
f1 O
) O
in O
the O
ear O
- O
canal RARE
sound O
pressure O
. O

Rats O
underwent O
either O
a O
90 O
- O
95 O
% O
JIB ALLCAPS
or O
a O
sham O
operation O
. O

When O
the O
l O
- O
methadone RARE
- O
sensitive O
, O
opioid I-GENE
receptor I-GENE
is O
blocked O
by O
naloxone O
or O
tolerance O
has O
developed O
, O
than O
l O
- O
methadone RARE
can O
produce O
behavioral O
effects O
by O
a O
nonopioid RARE
mechanism O
. O

Microwave RARE
hyperthermia RARE
- O
induced O
blood O
- O
brain O
barrier O
alterations O
. O

Large O
and O
small O
medullary RARE
lesions O
inhibited O
the O
occurrence O
of O
target O
fibres O
in O
the O
tenotomized RARE
muscles O
, O
the O
smallest O
one O
being O
neurolysis RARE
of O
the O
dorsal O
roots O
. O

Diagnosis O
of O
phenylalanine I-GENE
hydroxylase I-GENE
deficiency O
( O
phenylketonuria RARE
). O

In O
10 O
control O
sheep O
mean O
plasma O
TXB2 NUMERIC
concentration O
increased O
from O
0 O
. O
39 O
ng O
/ O
ml O
prebypass RARE
to O
about O
1 O
. O
1 O
ng O
/ O
ml O
at O
8 O
and O
16 O
min O
of O
bypass O
. O

The O
respiratory O
rate O
was O
13 O
+/- O
1 O
breaths RARE
/ O
min O
with O
52 O
+/- O
4 O
% O
of O
the O
respiratory O
cycle O
spent RARE
in O
inspiration RARE
; O
end O
- O
tidal O
CO2 O
pressure O
increased O
by O
3 O
. O
3 O
+/- O
1 O
. O
0 O
Torr RARE
during O
runs RARE
at O
SIP ALLCAPS
. O

There O
was O
no O
further O
increase O
in O
oxygen O
consumption O
when O
these O
subjects O
breathed RARE
with O
inspiratory O
pressures O
above O
SIP ALLCAPS
. O

We O
compared O
the O
volume O
of O
the O
pulmonary O
extravascular RARE
, O
extracellular O
water O
space O
using O
sodium O
and O
sucrose O
indicators O
in O
8 O
normal O
and O
11 O
edematous RARE
rabbit O
lungs O
by O
steady O
- O
state O
techniques O
. O

Investigated RARE
the O
reliability O
, O
validity O
and O
dimensionality RARE
of O
scores O
obtained O
by O
acute O
psychiatric O
inpatients RARE
( O
N O
= O
120 O
) O
on O
the O
Michigan RARE
Alcoholism RARE
Screening RARE
Test O
adapted O
to O
assess O
lifetime RARE
and O
current O
symptomatology RARE
. O

A O
simple O
method O
for O
measuring O
urinary O
iron O
following O
the O
administration O
of O
desferrioxamine RARE
( O
DF ALLCAPS
) O
is O
described O
. O

During O
conventional O
hemofiltration RARE
using O
substitution O
fluid O
with O
a O
Na O
+ O
concentration O
of O
140 O
mEq O
/ O
L O
, O
a O
decrease O
in O
extracellular O
fluid O
volume O
was O
noted O
whereas O
the O
intracellular O
fluid O
volume O
was O
unaltered O
. O

The O
uncomplicated RARE
cases O
of O
typhoid RARE
fever O
were O
found O
to O
have O
an O
intact O
CMIR ALLCAPS
as O
compared O
to O
the O
complicated O
cases O
. O

Transvenous RARE
serial O
xeroradiography RARE
. O

Recommendations RARE
to O
deal RARE
with O
these O
and O
related O
issues O
are O
presented O
. O

Use O
of O
subcutaneous O
deferoxamine RARE
in O
a O
child O
with O
hemochromatosis RARE
associated O
with O
congenital O
dyserythropoietic RARE
anemia O
, O
type O
I O
. O

There O
was O
a O
significant O
correlation O
between O
tubular O
diameter O
and O
spg RARE
( O
r O
= O
0 O
. O
68 O
, O
P O
less O
than O
0 O
. O
001 O
) O
suggesting O
that O
tubular O
diameter O
measurements O
in O
histological O
sections O
could O
be O
used O
to O
predict O
sperm O
production O
. O

The O
differential O
investigation O
of O
lipoproteins O
, O
however O
, O
showed O
that O
the O
high I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
( O
HDL I-GENE
) O
fractions O
are O
absolutely RARE
or O
relatively O
decreased O
with O
respect O
to O
low I-GENE
- I-GENE
density I-GENE
lipoproteins I-GENE
( O
LDL I-GENE
) O
in O
cerebral O
infarcts RARE
and O
in O
transient O
ischaemic O
attacks O
. O

Although O
noninhibitory RARE
fluid O
had O
higher O
mean O
concentrations O
of O
phosphorus O
and O
zinc O
, O
these O
differences O
did O
not O
hold RARE
after O
meconium RARE
- O
stained O
samples O
were O
excluded O
. O

Selenium RARE
status O
of O
thoroughbreds RARE
in O
the O
United O
Kingdom RARE
. O

During O
an O
8 O
- O
wk O
follow O
- O
up O
, O
parasites O
reappeared RARE
in O
10 O
patients O
, O
5 O
after O
each O
drug O
, O
between O
1 O
and O
7 O
wk O
after O
treatment O
. O

Preparation RARE
of O
a O
stable O
phospholipid O
reagent RARE
for O
coagulation O
assays O
. O

A O
note RARE
on O
some O
consequences O
of O
UV O
vision O
in O
birds O
. O

Before RARE
turnout RARE
, O
a O
morantel RARE
sustained O
release O
bolus O
( O
MSRB ALLCAPS
) O
was O
administered O
to O
each O
animal O
in O
the O
" O
treated O
" O
category O
. O

In O
a O
longitudinal O
study O
, O
14 O
low O
- O
risk O
fetuses RARE
were O
studied O
at O
2 O
- O
week O
intervals O
from O
32 O
weeks O
of O
gestation O
onward RARE
. O

Further O
, O
intracerebroventricular RARE
injections O
of O
KA ALLCAPS
resulted O
in O
the O
substantial O
loss O
of O
pyramidal O
cells O
in O
the O
whole O
CA3 O
field O
of O
the O
hippocampus O
. O

Seventeen RARE
of O
the O
35 O
patients O
were O
randomly O
chosen O
to O
receive O
a O
training O
program O
( O
lasting O
approximately O
1 O
month O
) O
designed O
to O
establish O
a O
systematic O
strategy O
of O
organizing RARE
complex O
visual O
material O
. O

The O
duration O
and O
the O
amplitude O
of O
the O
negative O
potential O
were O
greatest O
for O
completely O
regenerating RARE
ears O
with O
overgrowth RARE
, O
smaller O
for O
partially O
regenerating RARE
ears O
, O
and O
smallest O
for O
the O
nonregenerating RARE
ears O
. O

Samples RARE
obtained O
from O
normal O
volunteers O
and O
from O
the O
great O
majority O
of O
the O
patients O
, O
excluding O
those O
with O
asthma O
, O
had O
no O
effect O
on O
ciliary RARE
beating RARE
. O

These O
results O
suggested O
the O
possibility O
that O
the O
fetus O
played O
some O
role O
in O
the O
production O
of O
E3 O
- O
16 O
- O
G O
in O
early O
pregnancy O
. O

In O
this O
way O
it O
is O
possible O
to O
simulate RARE
the O
growth O
function O
of O
the O
embryofetal RARE
curve O
of O
the O
length O
' O
increase O
of O
man O
and O
the O
curve O
of O
the O
mass O
' O
increase O
of O
rat O
. O

The O
highest O
doses O
were O
found O
for O
drivers RARE
who O
transported O
large O
numbers O
of O
99Mo NUMERIC
generators RARE
. O

The O
steepness RARE
of O
the O
standard O
O2 O
dissociation O
curve O
becomes O
greater O
during O
the O
training O
period O
( O
increase O
in O
Hill RARE
' O
s O
n O
from O
2 O
. O
68 O
+/- O
0 O
. O
10 O
to O
2 O
. O
96 O
+/- O
0 O
. O
15 O
). O

Conjugated RARE
and O
unconjugated RARE
phenylacetic RARE
acid O
and O
m O
- O
and O
p O
- O
hydroxyphenylacetic RARE
acid O
have O
been O
determined O
in O
the O
plasma O
of O
normal O
, O
healthy O
subjects O
after O
fasting O
, O
consumption O
of O
a O
meal O
and O
ingestion O
of O
deuterium RARE
labelled O
amine O
precursors O
, O
by O
high O
- O
resolution O
gas O
chromatography O
-- O
high O
resolution O
mass O
spectrometry O
with O
selected O
ion O
monitoring O
of O
their O
trifluoroethyl RARE
- O
pentafluoropropionyl RARE
derivatives O
. O

In O
concept O
II O
62 O
patients O
were O
treated O
with O
selective O
vagotomy O
and O
pyloroplasty RARE
. O

They O
consisted O
of O
behavioural RARE
disorders O
, O
tetraparesis RARE
, O
incontinence RARE
and O
oculomotor RARE
paralysis RARE
. O

CSF O
adenosine I-GENE
deaminase I-GENE
activity O
( O
ADA ALLCAPS
) O
was O
measured O
at O
the O
same O
time O
. O

Histamine RARE
reactivity O
had O
returned O
to O
normal O
in O
half O
the O
workers O
who O
had O
left O
their O
original O
factories RARE
, O
but O
in O
only O
one O
worker RARE
who O
had O
moved RARE
within O
her O
original O
factory RARE
. O

It O
was O
also O
found O
that O
there O
is O
no O
significant O
difference O
between O
the O
prevalence O
of O
nasal O
carriage RARE
of O
S O
. O
aureus O
amongst RARE
the O
hospital O
staff RARE
and O
the O
patients O
. O

Ficat RARE
and O
Bizou RARE
' O
s O
condylar RARE
depth O
index O
and O
the O
condylar RARE
- O
joint O
surface O
angle O
of O
Brattstrom RARE
are O
recommended O
as O
especially O
suitable O
methods O
of O
measurement O
. O

There O
were O
no O
significant O
differences O
in O
EF O
between O
the O
two O
studies O
, O
both O
at O
rest O
( O
56 O
. O
0 O
+/- O
13 O
. O
8 O
% O
vs O
58 O
. O
2 O
+/- O
11 O
. O
7 O
%, O
p O
= O
NS O
) O
and O
with O
exercise O
( O
51 O
. O
1 O
+/- O
17 O
. O
6 O
% O
vs O
54 O
. O
3 O
+/- O
17 O
. O
6 O
%, O
p O
= O
NS O
) O
and O
a O
highly O
significant O
correlation O
was O
shown O
between O
the O
two O
groups O
of O
values O
( O
rest O
r O
= O
0 O
. O
90 O
, O
exercise O
r O
= O
0 O
. O
93 O
, O
p O
less O
than O
0 O
. O
001 O
). O

After O
MOPP ALLCAPS
therapy O
, O
complete O
remission O
of O
Hodgkin O
' O
s O
disease O
was O
accompanied O
by O
normalization RARE
of O
the O
glucocerebrosidase RARE
level O
and O
disappearance O
of O
Gaucher RARE
' O
s O
cells O
. O

Specifically O
, O
by O
the O
type O
of O
adjuvant O
therapy O
, O
the O
median O
disease O
- O
free O
interval O
and O
survival O
from O
stage O
IVA ALLCAPS
for O
23 O
patients O
receiving O
Corynebacterium RARE
parvum RARE
were O
6 O
. O
9 O
and O
19 O
months O
; O
for O
39 O
patients O
receiving O
BCG O
, O
eight O
months O
and O
26 O
months O
; O
for O
24 O
patients O
receiving O
BCG O
+ O
DTIC ALLCAPS
, O
eight O
and O
17 O
. O
4 O
months O
; O
and O
for O
all O
51 O
DTIC ALLCAPS
treated O
patients O
6 O
. O
3 O
and O
17 O
. O
8 O
months O
, O
respectively O
. O

The O
COP ALLCAPS
- O
PAWP ALLCAPS
gradient O
was O
markedly O
decreased O
in O
both O
shock O
and O
non O
- O
shock O
patients O
with O
pulmonary O
edema O
. O

Re O
: O
A O
modified O
method O
for O
the O
in O
vivo O
labeling O
of O
red O
blood O
cells O
with O
Tc O
- O
99m O
. O

A O
limited O
study O
in O
a O
glassware RARE
factory RARE
( O
As2O3 NUMERIC
exposure O
) O
involving O
the O
measurement O
of O
total O
airborne RARE
arsenic RARE
, O
the O
determination O
of O
urinary O
arsenic RARE
, O
and O
the O
evaluation O
of O
hand O
and O
mouth O
contamination O
by O
arsenic RARE
before O
and O
after O
the O
workshift RARE
suggests O
that O
the O
high O
urinary O
arsenic RARE
levels O
( O
300 O
microgram O
/ O
g O
creatinine O
) O
are O
likely O
to O
be O
more O
related O
to O
an O
increased O
oral O
intake O
from O
contaminated O
hands RARE
than O
to O
an O
increased O
absorption O
from O
the O
lungs O
. O

Parasitological RARE
and O
pathological O
findings O
in O
capuchin RARE
monkeys O
infected O
with O
Schistosoma RARE
japonicum RARE
or O
Schistosoma RARE
mansoni RARE
. O

The O
pia RARE
mater RARE
at O
the O
site O
of O
the O
entry O
of O
blood O
vessels O
into O
the O
central O
nervous O
system O
. O

Experimental O
reproduction RARE
of O
malignant O
catarrhal RARE
fever O
in O
Bali RARE
cattle O

1 O
A O
colonic RARE
delivery O
system O
is O
described O
to O
deliver RARE
orally O
ingested RARE
drugs O
to O
the O
colon O
and O
release O
them O
at O
that O
site O
by O
coating RARE
with O
an O
acrylic RARE
based O
resin O
( O
Eudragit RARE
S O
). O

Administration O
of O
the O
dopamine O
agonist O
bromocriptine RARE
( O
2 O
. O
5 O
mg O
three O
times O
a O
day O
for O
4 O
days O
) O
suppressed O
( O
P O
less O
than O
0 O
. O
01 O
) O
mean O
24 O
- O
h O
plasma O
18 O
- O
OHB ALLCAPS
levels O
from O
21 O
. O
9 O
+/- O
2 O
. O
0 O
to O
14 O
. O
8 O
+/- O
1 O
. O
4 O
ng O
/ O
dl O
. O

Restarting RARE
time O
was O
not O
affected O
by O
magnesium O
cardioplegia RARE
. O

The O
most O
common O
types O
of O
malformations O
were O
eye O
defects O
and O
open O
coeloms RARE
. O

Repair RARE
of O
a O
cosmetic RARE
defect O
of O
the O
lower O
leg O
with O
a O
myocutaneous RARE
free O
flap O
. O

According O
to O
the O
literature O
, O
second O
malignant O
epithelial O
tumours O
are O
, O
in O
contrast O
to O
mesenchymal O
tumours O
such O
as O
osteosarcoma O
, O
very O
rare O
in O
retinoblastoma O
survivors RARE
. O

In O
Malmo RARE
, O
Sweden RARE
, O
17 O
, O
181 NUMERIC
school RARE
children O
born O
in O
the O
years O
1961 NUMERIC
- O
1965 NUMERIC
were O
screened O
for O
scoliosis RARE
once O
a O
year O
between O
the O
ages O
of O
7 O
and O
16 O
years O
, O
during O
1971 NUMERIC
- O
1980 O
. O

In O
the O
past O
, O
immunology RARE
in O
Singapore RARE
was O
mainly O
confined O
to O
serology RARE
for O
the O
diagnosis O
of O
certain O
infectious O
diseases O
. O

Intra RARE
- O
articular RARE
dislocation O
of O
the O
patella RARE
. O

This O
study O
demonstrates O
secretion O
of O
bicarbonate RARE
by O
the O
human O
stomach O
in O
vivo O
at O
a O
rate O
equivalent O
to O
10 O
-- O
20 O
% O
of O
basal O
acid O
secretion O
. O

Histological O
evaluation O
revealed O
a O
more O
than O
twofold O
increase O
in O
the O
number O
of O
interepithelial RARE
mononuclear O
cells O
( O
p O
less O
than O
0 O
. O
005 O
), O
while O
the O
number O
of O
epithelial O
cells O
/ O
100 O
microns O
of O
villous RARE
mucosa O
and O
the O
mean O
height O
of O
the O
epithelial O
cells O
were O
comparable O
in O
both O
groups O
. O

Cramps RARE
in O
extrapyramidal RARE
disorders O
. O

A O
suspected O
new O
storage O
disease O
in O
cattle O
. O

For O
various O
dog O
vessels O
in O
vivo O
, O
Q O
/ O
Dk RARE
ranged O
from O
0 O
. O
15 O
to O
47 O
X O
10 O
( O
5 O
) O
Torr RARE
/ O
cm2 O
. O

The O
tetraphasic RARE
action O
of O
lidocaine O
on O
CNS O
electrical O
activity O
and O
behavior O
in O
cats O
. O

Modification RARE
of O
enteral RARE
resorption O
by O
cytostatic RARE
therapy O

Asymptomatic RARE
bacteriospermia RARE
and O
fertility O

Triumph RARE
of O
Leninist RARE
national O
policy RARE

The O
favourable O
effect O
of O
thymic O
shielding RARE
was O
also O
reflected O
in O
a O
significant O
increase O
of O
LD50 O
/ O
30 O
, O
and O
the O
dose O
reduction O
factor O
was O
equal O
to O
2 O
. O

The O
application O
of O
ultrafiltration RARE
to O
sample O
preparation O
in O
the O
detection O
and O
quantification RARE
of O
ethylene O
glycol O
in O
plasma O
by O
gas O
chromatography O
is O
described O
. O

Mastocytosis RARE
. O

A O
new O
Onchocerca RARE
species O
, O
a O
parasite O
of O
domestic RARE
cattle O
, O
in O
Senegal RARE

It O
was O
suggested O
that O
the O
absence O
of O
pronounced O
differences O
between O
conditions O
may O
have O
been O
due O
to O
the O
complexity O
of O
the O
task O
or O
the O
type O
of O
prompts RARE
employed O
. O

A O
limiting O
factor O
were O
disturbances O
in O
the O
system O
of O
energy O
transport O
( O
creatine O
phosphate O
, O
creatine I-GENE
phosphokinase RARE
) O
and O
of O
the O
calcium O
pump O
( O
Ca I-GENE
++- RARE
ATPase I-GENE
of O
the O
sarcoplasmic RARE
reticulum O
, O
SPR ALLCAPS
), O
which O
evidently RARE
led O
to O
a O
decrease O
of O
the O
inotropic O
properties O
of O
the O
myocardium O
at O
70 O
% O
restriction O
of O
coronary O
blood O
flow O
. O

In O
vitro O
penetration O
tests O
of O
human O
sperm O
into O
cervical O
mucus O
were O
introduced O
in O
order O
to O
study O
the O
interaction O
between O
sperm O
and O
cervical O
mucus O
. O

Vibrio O
fluvialis RARE
( O
group O
F O
vibrio RARE
) O
in O
Maharashtra RARE
. O

Serum I-GENE
creatine I-GENE
kinase I-GENE
( O
SCK ALLCAPS
) O
was O
measured O
in O
ten O
subjects O
in O
the O
laboratory O
before O
and O
after O
the O
performance O
of O
bicycle RARE
ergometry RARE
and O
a O
lifting RARE
task O
. O

Organisms RARE
were O
not O
observed O
in O
the O
5 O
bobcats RARE
trapped RARE
in O
2 O
other O
counties RARE
. O

The O
cause O
of O
death O
is O
often O
quite O
apparent O
from O
the O
pathological O
and O
toxicological O
findings O
; O
however O
, O
the O
manner O
of O
death O
often O
gives O
the O
examining O
official RARE
some O
difficulty RARE
. O

The O
average O
annual O
cost O
per O
head O
of O
population O
was O
US O
+ O
0 O
X O
46 O
. O

It O
is O
postulated O
that O
altered O
blood O
flow O
, O
mediated O
through O
the O
well O
- O
known O
prostaglandin I-GENE
synthetase I-GENE
inhibitory O
effects O
of O
ibuprofen RARE
, O
resulted O
in O
tubular O
necrosis O
. O

Either RARE
20 O
mg O
mitomycin RARE
/ O
20 O
ml O
distilled RARE
water O
or O
40 O
mg O
/ O
40 O
ml O
distilled RARE
water O
was O
locally O
instilled RARE
into O
the O
bladder O
with O
a O
catheter O
after O
emptying O
it O
and O
was O
left O
for O
about O
25 O
- O
l20 NUMERIC
min O
. O

Both O
groups O
rejected RARE
pops RARE
with O
added O
SOA ALLCAPS
, O
decreasing O
mouthing RARE
times O
as O
SOA ALLCAPS
concentration O
increased O
. O

The O
mean O
extracted O
concentration O
of O
flucloxacillin RARE
obtained O
at O
operation O
was O
12 O
. O
9 O
micrograms O
/ O
ml O
( O
SD O
5 O
. O
25 O
) O
in O
synovial O
fluid O
; O
2 O
. O
9 O
micrograms O
/ O
g O
( O
SD O
3 O
. O
59 O
) O
in O
synovium RARE
; O
2 O
. O
0 O
micrograms O
/ O
g O
( O
SD O
1 O
. O
48 O
) O
in O
cancellous RARE
bone O
and O
1 O
. O
3 O
micrograms O
/ O
g O
( O
SD O
1 O
. O
25 O
) O
in O
cortical O
bone O
. O

A O
preliminary O
study O
of O
vincristine O
, O
methotrexate O
, O
and O
prednisolone RARE
( O
VM ALLCAPS
* O
P O
) O
combination O
chemotherapy O
for O
advanced O
adult O
non O
- O
Hodgkin O
' O
s O
lymphoma O

Lacrimal RARE
secretion O
in O
hyperthyroidism RARE

Re O
- O
examination O
of O
the O
ED01 NUMERIC
study O
. O

Based O
on O
213 NUMERIC
determinations O
, O
the O
control O
mean O
serum I-GENE
CPK I-GENE
activity O
was O
262 NUMERIC
+/- O
113 O
I O
. O
U O
./ RARE
liter O
. O

A O
further O
study O
on O
plasminogen I-GENE
activator I-GENE
release O
by O
vasoactive RARE
agents O
in O
the O
isolated O
perfused O
dog O
leg O
. O

CDDP ALLCAPS
is O
active O
as O
a O
single O
agent O
in O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

Treatment O
of O
meat O
muscle O
800 O
V O
for O
45 O
s O
reduced O
weeping RARE
but O
increased O
slightly O
the O
rate O
of O
autoxidation RARE
of O
lipids O
. O

The O
hormonal O
response O
to O
a O
standardized O
bicycle RARE
exercise O
test O
was O
studied O
in O
11 O
male O
cadets RARE
exposed O
to O
a O
course O
of O
107 NUMERIC
h O
of O
continuous O
activity O
with O
less O
than O
2 O
h O
sleep O
. O

At O
an O
ambient RARE
temperature O
of O
25 O
degrees O
C O
, O
the O
responses O
to O
spinal O
cooling RARE
are O
reduced O
during O
the O
dark O
phase O
. O

A O
method O
for O
determining O
cumulative O
behavioral O
toxicity O
after O
chronic O
oral O
administration O
of O
l O
- O
alpha O
- O
acetylmethadol RARE
to O
female O
rats O
. O

After O
successful O
subtotal O
parathyroidectomy RARE
, O
evident O
by O
the O
decrease O
of O
serum O
iPTH LASTCAP
levels O
, O
both O
the O
CL O
of O
group O
2 O
PMNs RARE
and O
the O
ability O
of O
group O
2 O
sera O
to O
induce O
augmented O
CL O
in O
normal O
PMNs RARE
decreased O
( O
p O
< O
0 O
. O
025 NUMERIC
). O

TCZ ALLCAPS
provides O
quick RARE
, O
inexpensive RARE
, O
noninvasive RARE
indication O
of O
tissue O
necrosis O
, O
moderate O
- O
to O
- O
severe O
intracranial RARE
hemorrhage O
, O
and O
delayed O
brain O
maturation O
. O

The O
number O
of O
muricidal RARE
rats O
increased O
with O
increase O
in O
the O
duration O
of O
Cd O
administration O
in O
association O
with O
greater O
accumulation O
of O
Cd O
in O
the O
olfactory O
bulb O
than O
in O
any O
other O
region O
of O
the O
brain O
. O

This O
test O
should O
provide O
another O
practical RARE
means O
to O
study O
leprosy RARE
. O

The O
preferences RARE
were O
for O
intact O
vis RARE
- O
a O
- O
vis RARE
castrated RARE
males O
, O
though O
injections O
of O
TP ALLCAPS
restored O
the O
castrates RARE
' O
attractiveness RARE
to O
the O
females O
. O

Each O
trial O
consisted O
of O
light O
and O
buzzer RARE
for O
five O
seconds RARE
as O
conditioned O
stimuli O
and O
electric RARE
shock O
for O
five O
seconds RARE
as O
an O
unconditioned RARE
stimulus O
. O

Ulcer RARE
appeared O
on O
the O
angulus RARE
of O
the O
stomach O
at O
the O
28th NUMERIC
week O
and O
resulted O
in O
ulcer O
scar RARE
at O
the O
42nd NUMERIC
week O
. O

Family RARE
visits RARE
and O
involvement O
in O
treatment O
of O
patients O
at O
a O
state O
hospital O
. O

A O
transparent RARE
overlay RARE
for O
assessing O
amplitude O
of O
ECG O
wave O
forms O
. O

Adverse RARE
reaction O
of O
the O
apparently O
healthy O
partner O
in O
response O
to O
improvement O
in O
the O
overtly RARE
dysfunctional RARE
partner O
. O

Brain RARE
scan O
with O
99mTc O
- O
labelled O
macroaggregated RARE
albumin I-GENE
( O
MAA ALLCAPS
brain O
scan O
) O
and O
computed O
tomography O
studies O
( O
CT O
) O
were O
performed O
on O
78 O
patients O
with O
intracranial RARE
diseases O
. O

Inhibition O
of O
Fusarium RARE
moniliforme RARE
var O
. O
subglutinans RARE
, O
the O
causal RARE
agent O
of O
pine RARE
pitch RARE
canker RARE
, O
by O
the O
soil RARE
bacterium O
Arthrobacter RARE
sp O
. O

The O
five O
- O
drug O
combination O
of O
fluorouracil O
imidazole RARE
carboxamide RARE
dimethyl O
triazeno RARE
, O
vincristine O
, O
bis RARE
- O
chloroethyl RARE
nitrosourea RARE
, O
and O
prednisone O
( O
FIVB ALLCAPS
+ O
P O
) O
was O
given O
to O
120 O
women O
with O
metastatic O
breast O
cancer O
. O

A O
method O
is O
described O
for O
the O
simultaneous O
determination O
of O
1 O
, O
alpha O
- O
acetylmethadol RARE
( O
LAAM ALLCAPS
) O
and O
five O
active O
metabolites O
-- O
noracetylmethadol RARE
, O
dinoracetylmethadol RARE
, O
methadol RARE
, O
normethadol RARE
, O
and O
dinormethadol RARE
-- O
in O
biofluids RARE
by O
high O
- O
performance O
liquid O
chromatography O
using O
a O
normal O
- O
phase O
column O
and O
a O
UV O
detector O
at O
218 NUMERIC
nm O
. O

Results O
of O
the O
recognition O
task O
revealed O
significant O
effects O
of O
consonant RARE
voicing RARE
, O
position O
and O
vowel RARE
context O
on O
syllable RARE
recognition O
. O

Visual RARE
response O
properties O
of O
neurons O
in O
four O
extrastriate RARE
visual O
areas O
of O
the O
owl RARE
monkey O
( O
Aotus RARE
trivirgatus RARE
): O
a O
quantitative O
comparison O
of O
medial O
, O
dorsomedial RARE
, O
dorsolateral RARE
, O
and O
middle O
temporal O
areas O
. O

A O
unified RARE
approach O
to O
the O
standardization RARE
of O
allergens O
. O

Clinical O
and O
anatomical O
considerations RARE

A O
dose O
- O
dependent O
fall O
in O
GABA O
content O
was O
observed O
; O
GABA O
decrease O
was O
evident O
15 O
min O
after O
the O
administration O
, O
reached O
its O
nadir RARE
at O
60 O
min O
and O
disappeared O
at O
120 O
minutes O
. O

Theory RARE
and O
applications O
of O
pulse O
dosing RARE
: O
a O
summary O
of O
the O
symposium RARE
. O

These O
results O
show O
that O
the O
neonate RARE
differs O
from O
the O
adult O
in O
respect O
of O
both O
the O
nature O
of O
effects O
of O
the O
drug O
and O
sensitivity O
to O
it O
. O

To O
evaluate O
the O
gas O
chromatographic O
electron O
capture RARE
detection O
method O
described O
earlier O
, O
23 O
plasma O
samples O
have O
been O
analysed O
by O
both O
techniques O
. O

The O
hemodynamics O
of O
isoproterenol O
- O
induced O
cardiac O
failure O
in O
the O
rat O
. O

Several O
authors O
have O
recently O
reported O
interference O
in O
theophylline O
analysis O
by O
paraxanthine RARE
( O
1 O
, O
7 O
- O
dimethylxanthine RARE
), O
an O
important O
metabolite O
of O
caffeine O
. O

Multi RARE
drug O
regimens O
like O
C O
- O
MOPP ALLCAPS
, O
CHOP O
and O
BACOP ALLCAPS
led O
to O
high O
remission O
rates O
and O
in O
some O
cases O
probably O
also O
to O
a O
cure O
of O
the O
disease O
. O

For O
monocytes O
, O
as O
measured O
on O
the O
Hematrak RARE
, O
it O
was O
13 O
. O
4 O
%. O

Morphological RARE
features O
of O
Jat RARE
dentition RARE
. O

Clinical O
accuracy O
of O
updated RARE
version O
of O
the O
Phadebas RARE
RAST O
test O
. O

Five O
control O
subjects O
with O
COPD O
, O
who O
performed O
the O
same O
sequence O
of O
tests O
without O
breathing O
30 O
% O
O2 O
, O
showed O
no O
change O
in O
flow O
rates O
or O
density O
dependence O
. O

Following O
extended O
recovery O
hippocampal O
EEG O
was O
normal O
despite O
extensive O
cellular O
loss O
in O
areas O
CA3 O
and O
CA4 NUMERIC
. O

Evoked RARE
potential O
and O
single O
unit O
responses O
to O
olfactory O
nerve O
volleys RARE
in O
the O
isolated O
turtle RARE
olfactory O
bulb O
. O

While O
all O
deletions O
within O
the O
sequence O
coding O
for O
the O
mature O
tRNA O
led O
to O
inactivity RARE
of O
the O
mutated O
genes O
, O
substitution O
of O
the O
central O
portion O
by O
concatenated RARE
Hind RARE
III I-GENE
linkers RARE
produced O
gene O
units O
active O
in O
transcription O
. O

Cross O
reactivity O
in O
theophylline O
RIA ALLCAPS
kit O
decreased O
. O

Strontium RARE
- O
90 O
was O
inject RARE
i O
. O
v O
. O
into O
pregnant O
rats O
on O
day O
18 O
post O
conception RARE
( O
p O
. O
c O
.). O

Recording RARE
of O
the O
digital O
sphygmic RARE
activity O
in O
the O
lower O
extremities RARE
with O
the O
photoplethysmographic RARE
and O
strain O
- O
gauge RARE
methods O
. O

Eight O
hr O
of O
acidosis O
caused O
a O
significant O
( O
P O
less O
than O
0 O
. O
01 O
) O
decrease O
in O
P50 NUMERIC
in O
vitro O
which O
fell O
from O
29 O
. O
0 O
to O
24 O
. O
4 O
torr O
. O

Catheter RARE
transit O
slows RARE
the O
response O
to O
a O
step O
increase O
in O
concentration O
by O
about O
0 O
. O
13 O
s O
( O
from O
10 O
per O
cent O
- O
90 O
per O
cent O
) O
and O
prolongs RARE
the O
transit O
time O
through O
the O
catheter O
for O
a O
volatile O
anesthetic RARE
by O
about O
0 O
. O
04 O
s O
more O
than O
N2 O
. O

These O
women O
should O
not O
be O
given O
the O
current O
estrogen O
PPI ALLCAPS
, O
which O
was O
designed O
to O
warn RARE
women O
of O
the O
risks RARE
of O
long O
- O
term O
estrogen O
use O
; O
a O
PPI ALLCAPS
should O
be O
written RARE
specifically O
for O
patients O
receiving O
short O
courses O
. O

The O
oral O
temperature O
rose O
and O
the O
serum I-GENE
creatine I-GENE
kinase I-GENE
levels O
fell O
only O
in O
those O
patients O
who O
were O
actively O
warmed RARE
. O

Determination O
of O
aortic O
distensibility RARE
and O
its O
variations O
in O
arterial O
hypertension O
. O

We O
studied O
the O
role O
of O
prostaglandins O
in O
acid O
- O
induced O
esophagitis RARE
and O
the O
associated O
LES ALLCAPS
hypotension O
by O
simultaneous O
treatment O
of O
some O
animals O
with O
indomethacin O
( O
150 O
micrograms O
/ O
kg O
intravenous O
), O
a O
specific O
inhibitor O
of O
prostaglandin O
synthesis O
, O
either O
during O
production O
of O
esophagitis RARE
or O
during O
recovery O
. O

Since O
only O
58 O
% O
of O
our O
sample O
could O
be O
adequately RARE
classified O
with O
one O
diagnosis O
, O
we O
expect RARE
that O
the O
ASDC ALLCAPS
nosology RARE
will O
need O
to O
evolve RARE
further O
. O

A O
surgical O
technique O
for O
correcting RARE
this O
problem O
is O
described O
. O

Effects O
of O
prostaglandin O
inhibitors O
on O
the O
onset O
of O
proteinuria RARE
and O
stroke O
in O
stroke O
- O
prone O
spontaneously O
hypertensive O
rats O
. O

In O
this O
study O
, O
the O
general O
clinical O
criteria O
for O
inhalation O
injury O
-- O
presence O
of O
facial O
or O
oropharyngeal RARE
burns RARE
, O
carboxyhemoglobin RARE
levels O
, O
carbonaceous RARE
sputum O
, O
or O
closed O
space O
injury O
-- O
did O
not O
differentiate O
patients O
with O
airway O
injury O
only O
from O
those O
with O
parenchymal RARE
injury O
. O

Survival RARE
was O
calculated O
both O
from O
the O
date O
of O
onset O
and O
from O
the O
date O
of O
diagnosis O
. O

Methisergide RARE
( O
0 O
. O
5 O
mg O
/ O
kg O
, O
i O
. O
p O
.), RARE
a O
blocker O
of O
serotonin I-GENE
receptors I-GENE
, O
prevented O
the O
development O
of O
the O
antinociceptive RARE
effect O
of O
serotonin O
. O

The O
plasma O
half O
- O
life O
of O
slow O
disposition RARE
phase O
t1 O
/ O
2 O
beta O
, O
increases O
from O
0 O
. O
26 O
hour O
in O
rabbits O
with O
normal O
renal O
function O
to O
5 O
. O
41 O
hours O
in O
rabbits O
with O
severe O
renal O
impairment O
. O

Effects O
of O
early O
monocular RARE
deprivation O
on O
development O
of O
cortico RARE
- O
geniculate RARE
projections O
in O
the O
cat O
. O

Corticosteroid RARE
therapy O
is O
known O
to O
be O
hazardous O
in O
patients O
with O
occult RARE
infection O
but O
the O
mechanism O
by O
which O
the O
host O
parasite O
relationship O
is O
altered O
by O
steroids O
is O
not O
known O
. O
We O
have O
used O
an O
intestinal O
protozoal RARE
parasite O
, O
Giardia RARE
muris RARE
, O
to O
examine O
the O
effects O
of O
corticosteroids O
on O
the O
number O
of O
parasites O
in O
the O
intestine O
in O
the O
course O
of O
a O
primary O
infection O
. O

Static RARE
lung O
function O
in O
puppies RARE
after O
pneumonectomy RARE
. O

With O
Sair RARE
and O
So2 NUMERIC
, O
mean O
vital O
capacity O
was O
reduced O
by O
44 O
% O
from O
control O
. O

Bilateral RARE
Charnley RARE
arthroplasty RARE
as O
a O
single O
procedure O
. O

Of O
the O
117 O
patients O
( O
out O
of O
the O
136 O
) O
with O
serologic O
evidence O
of O
chronic O
thyroiditis O
who O
could O
be O
studied O
, O
eight O
( O
7 O
%) O
had O
hyperthyroidism RARE
and O
45 O
( O
38 O
%) O
were O
hypothyroid RARE
. O

The O
relationship O
between O
estrogenic RARE
properties O
of O
Tamoxifen RARE
and O
breast O
cancer O
management O
is O
discussed O
. O

The O
new O
semi RARE
- O
synthetic O
oral O
cephalosporin RARE
, O
CGP O
9 O
, O
000 O
, O
has O
been O
evaluated O
in O
a O
large O
number O
of O
hospitalized O
patients O
with O
urinary O
infections O
. O

A O
fluoroimmunoassay RARE
for O
the O
determination O
of O
serum O
of O
plasma O
levels O
of O
propranolol O
was O
developed O
using O
antibodies O
to O
propranolol O
coupled O
to O
magnetizable RARE
solid O
- O
phase O
particles O
and O
fluorescein RARE
- O
labeled O
propranolol O
as O
tracer O
. O

The O
syncytial RARE
microvillous RARE
projections O
seemed RARE
to O
be O
more O
numerous O
and O
longer O
in O
CNF ALLCAPS
, O
otherwise O
the O
structure O
of O
the O
trophoblastic RARE
layer O
of O
the O
villi RARE
and O
the O
lining RARE
of O
the O
subtrophoblastic RARE
vessels O
were O
identical O
in O
CNF ALLCAPS
and O
controls O
. O

When O
pollen O
allergen O
from O
three O
grass RARE
species O
were O
used O
, O
The O
RAST O
- O
test O
results O
did O
not O
differ O
from O
duplicate RARE
values O
either O
. O

DMI ALLCAPS
and O
2 O
- O
OH O
- O
DMI ALLCAPS
concentrations O
were O
determined O
in O
a O
similar O
group O
of O
61 O
DMI ALLCAPS
- O
treated O
patients O
. O

It O
has O
been O
shown O
in O
experiments O
in O
vitro O
that O
the O
hepatotrophic RARE
organic O
anions RARE
, O
the O
radiographic RARE
contrast O
agent O
( O
RCA ALLCAPS
) O
bilignost RARE
used O
in O
cholecystography RARE
and O
Bengal RARE
pink RARE
, O
have O
an O
affinity O
, O
unlike O
the O
urographic RARE
RCA ALLCAPS
triombrin RARE
and O
renotrophic RARE
dye O
indigo RARE
- O
carmine RARE
, O
for O
the O
plasmatic RARE
membranes O
( O
PM ALLCAPS
) O
of O
liver O
cells O
. O

33 O
out O
of O
90 O
neurons O
of O
the O
cat O
medial O
geniculate RARE
body O
revealed O
the O
selectivity O
of O
their O
afterdischarges RARE
to O
movement O
of O
sound O
when O
velocity O
of O
the O
movement O
changed O
from O
30 O
to O
180 O
deg RARE
/ O
s O
. O

In O
controls O
, O
only O
modest RARE
differences O
were O
observed O
. O

Assay RARE
of O
serum I-GENE
immunoreactive I-GENE
trypsin I-GENE
in O
dried RARE
blood O
spots O
and O
the O
early O
detection O
of O
cystic O
fibrosis O
. O

Similar O
waves O
were O
seen O
on O
cross O
- O
correlating RARE
a O
motor O
unit O
with O
an O
electronic RARE
oscillator RARE
, O
confirming O
that O
their O
occurrence O
does O
not O
necessarily O
demonstrate O
the O
existence O
of O
active O
neural O
interactions O
. O

Leukocyte RARE
enzyme O
activity O
and O
blood O
lymphocyte O
blast RARE
transformation O
in O
chronic O
bronchitis RARE

Current O
status O
of O
chemotherapy O
for O
Hodgkin O
' O
s O
disease O

In O
literature O
, O
the O
HBE ALLCAPS
has O
been O
displayed O
by O
application O
of O
the O
averaging RARE
method O
. O

Forty O
- O
five O
cases O
were O
surgically O
by O
direct O
approach O
to O
the O
tumour O
, O
while O
two O
cases O
were O
treated O
only O
with O
a O
shunt O
. O

In O
Group O
V O
, O
the O
salvaged RARE
tissue O
was O
primarily O
subepicardial RARE
with O
virtually O
no O
lateral O
zone O
of O
salvaged RARE
tissue O
( O
ratio O
of O
salvaged RARE
subepicardium RARE
to O
salvaged RARE
subendocardium RARE
14 O
. O
8 O
+/- O
1 O
. O
9 O
to O
1 O
). O

Progressive RARE
100 O
- O
mmHg O
stepwise RARE
decreases O
in O
superfusate RARE
oxygen O
partial O
pressure O
( O
PO2 O
) O
from O
control O
( O
95 O
% O
O2 O
aeration RARE
, O
PO2 O
, O
620 NUMERIC
- O
650 NUMERIC
mmHg O
) O
were O
produced O
, O
and O
subsequent O
changes O
in O
isometric RARE
active O
and O
resting O
tension O
were O
measured O
. O

The O
known O
B1 O
- O
deficiency O
reaches RARE
excessive O
high O
values O
with O
light O
exercise O
. O

Based O
on O
AUC O
infinity RARE
analyses O
, O
the O
pharmacokinetics O
of O
buflomedil RARE
were O
found O
to O
be O
linear O
within O
the O
dose O
ranges RARE
studied O
( O
50 O
to O
200 O
mg O
for O
i O
. O
v O
. O
injection O
and O
150 O
to O
450 O
mg O
for O
oral O
administration O
). O

Gastrin RARE
secretion O
during O
food O
stimulation O
in O
digestive RARE
system O
diseases O

Fibrinogen RARE
determination O
using O
the O
KZM ALLCAPS
- O
1 O
meter RARE

Over RARE
a O
period O
of O
15 O
days O
16 O
% O
of O
the O
dose O
administered O
was O
excreted RARE
with O
faeces RARE
and O
0 O
. O
9 O
% O
in O
the O
urine O
. O

Delayed RARE
or O
paradoxically RARE
emptying O
regions O
of O
the O
left O
ventricle O
were O
detected O
by O
a O
relatively O
new O
nuclear O
technique O
-- O
phase O
imaging O
. O

Responses RARE
to O
brainstem RARE
of O
nuclei O
medialis RARE
dorsalis RARE
, O
lateralis RARE
posterior O
were O
of O
considerably O
longer O
latency O
. O

Nineteen RARE
patients O
with O
non O
- O
visualized RARE
gallbladder O
with O
OCG ALLCAPS
subsequently O
had O
Tc O
- O
99m O
- O
PyG LASTCAP
cholescintigraphy RARE
performed O
. O

One O
was O
allowed O
fresh O
drinking O
water O
ad RARE
libitum RARE
whilst RARE
the O
other O
received O
Aludrox RARE
in O
their O
drinking O
water O
. O

Anamnestic RARE
data O
were O
obtained O
from O
case O
history O
, O
smoking O
habits RARE
were O
not O
known O
in O
collective RARE
A O
and O
C O
. O

The O
determination O
of O
physical O
performance O
capacity O
was O
based O
on O
W170 NUMERIC
, O
W85 NUMERIC
% O
and O
on O
predicted O
VO2 O
max O
measured O
with O
continuously O
increasing O
work O
load O
on O
a O
bicycle RARE
ergometer RARE
. O

Determination O
of O
lead O
in O
blood O
. O

Effect O
of O
indomethacin O
and O
prostaglandin O
F2 O
alpha O
on O
parturition RARE
in O
swine O
. O

LD50 O
values O
of O
terms O
of O
KP O
were O
84 O
mg O
/ O
kg O
in O
male O
rats O
and O
122 O
mg O
/ O
kg O
in O
female O
rats O
when O
KP O
- O
CMC ALLCAPS
was O
administered O
intrarectally RARE
, O
and O
117 O
mg O
/ O
kg O
in O
male O
and O
92 O
mg O
/ O
kg O
in O
female O
when O
KP O
- O
T10 NUMERIC
was O
administered O
intrarectally RARE
., O
while O
peroral RARE
administration O
of O
KP O
- O
CMC ALLCAPS
showed O
LD50 O
values O
of O
68 O
mg O
/ O
kg O
in O
males O
and O
78 O
mg O
/ O
kg O
in O
females O
in O
terms O
of O
KP O
. O

Autotransfusion RARE
was O
performed O
as O
follows O
: O
Heparin O
- O
ACD ALLCAPS
- O
B O
- O
Heparin O
- O
DPD ALLCAPS
- O
Heparin O
- O
ACD ALLCAPS
- O
B O
etc O
. O

Electron RARE
microscopic O
picture O
of O
the O
cerebral O
cortex O
in O
rats O
cooled RARE
to O
22 O
degrees O
C O

Generally RARE
the O
differences O
between O
short O
gut O
and O
sham O
operation O
animals O
disappeared O
when O
the O
data O
were O
normalised RARE
for O
mucosal O
weight O
. O

A O
simplified RARE
thin O
- O
layer O
chromatographic O
determination O
of O
hippuric RARE
acid O
and O
methylhippuric RARE
acids O
. O

The O
architecture O
of O
microvasculature RARE
in O
these O
two O
regions O
was O
also O
examined O
by O
scanning O
electron O
microscopy O
, O
using O
the O
resin O
casting RARE
method O
. O

MSMS ALLCAPS
Council RARE
hears RARE
new O
public RARE
health O
director RARE
. O

Chordoma RARE
of O
the O
spinal O
cord O
in O
a O
F344 NUMERIC
rat O
. O

Micro RARE
high O
- O
performance O
liquid O
chromatographic O
system O
with O
micro O
precolumn RARE
and O
dual O
electrochemical RARE
detector O
for O
direct O
injection O
analysis O
of O
catecholamines O
in O
body O
fluids O
. O

Thirty O
- O
one O
age O
- O
matched O
, O
conscious O
, O
virgin RARE
, O
male O
Sprague O
- O
Dawley O
rats O
and O
spontaneously O
hypertensive O
rats O
( O
SHRs RARE
) O
were O
individually O
injected O
with O
a O
single O
subcutaneous O
dose O
of O
85 O
mg O
/ O
kg O
dl O
- O
isoproterenol O
to O
determine O
the O
degree O
and O
time O
course O
of O
drug O
- O
induced O
cardiac O
failure O
and O
functional O
recovery O
. O

A O
narrow O
zone O
of O
myelin O
- O
axonal RARE
dissociation O
was O
also O
observed O
. O

The O
IgA I-GENE
deficiency O
is O
combined O
with O
the O
IgE I-GENE
one O
. O

In O
PB ALLCAPS
mice O
, O
there O
was O
only O
a O
small O
deficit O
in O
the O
number O
of O
the O
hippocampal O
pyramidal O
neurons O
compared O
to O
controls O
( O
15 O
%, O
p O
less O
than O
0 O
. O
01 O
), O
and O
no O
deficit O
in O
the O
granule RARE
cells O
. O

Nutritional RARE
cataracts RARE
in O
timber RARE
wolves RARE
. O

Prevention O
of O
transfusion O
reactions O
by O
the O
use O
of O
saline O
washed RARE
red O
blood O
cells O
. O

The O
geometric RARE
mean O
hemagglutination RARE
- O
inhibition O
antibody O
titers RARE
( O
GMT ALLCAPS
) O
of O
non O
- O
immunized O
, O
once O
- O
immunized O
, O
and O
twice O
- O
immunized O
chickens O
were O
compared O
at O
2 O
- O
week O
intervals O
following O
primary O
immunization O
, O
secondary O
immunization O
, O
and O
challenge O
. O

The O
quantitative O
determination O
of O
HBSAG ALLCAPS
-- O
a O
valuable O
aid O
in O
evaluating O
the O
infectiousness RARE
of O
hepatitis O
B O
virus O
carriers O

2 O
. O
numerous O
narrow O
shunt O
vessels O
departing RARE
continuously O
from O
the O
primary O
arteries O
to O
feed O
a O
secondary O
arterial O
system O
which O
parallels RARE
the O
primary O
one O
. O

Urological RARE
complications O
are O
frequent O
during O
and O
after O
the O
treatment O
of O
gynecological RARE
malignancy O
. O

Arachnoid RARE
cyst O
. O

100 O
more O
than O
in O
the O
summer O
coat O
). O

Hypotension RARE
was O
produced O
by O
head O
up O
tilt O
. O

Therefore O
the O
procedure O
of O
Lich RARE
- O
Gregoir RARE
is O
not O
to O
be O
recommended O
in O
adults O
. O

Mucoepidermoid RARE
and O
acinous RARE
cell O
carcinomas O
of O
salivary O
tissues O
. O

Twenty O
patients O
aged O
45 O
or O
older O
with O
the O
diagnosis O
of O
endogenous O
depression O
were O
evaluated O
in O
terms O
of O
safety O
and O
efficacy O
in O
their O
response O
to O
multiple O
monitored O
electroconvulsive RARE
therapy O
( O
MMECT ALLCAPS
) O
versus O
single O
electroconvulsive RARE
therapy O
( O
SECT ALLCAPS
). O

Two O
new O
artifacts RARE
in O
automated O
coagulation O
testing O
. O

This O
relatively O
simple O
and O
easily O
performed O
technique O
of O
measuring O
deep O
muscle O
temperature O
appears O
to O
be O
a O
useful O
adjunct RARE
in O
choosing RARE
the O
amputation RARE
level O
. O

Longitudinal RARE
force O
- O
length O
relationships O
of O
guinea O
pig O
ureter RARE
were O
studied O
in O
vitro O
in O
animals O
3 O
weeks O
, O
3 O
months O
, O
and O
3 O
years O
of O
age O
. O

Tests RARE
of O
the O
method O
indicate O
( O
1 O
) O
the O
Mossbauer RARE
source O
can O
be O
placed O
on O
the O
basilar RARE
membrane O
without O
altering O
the O
signal O
- O
transmission O
properties O
of O
the O
cochlea RARE
, O
and O
( O
2 O
) O
the O
source O
adheres RARE
to O
the O
basilar RARE
membrane O
. O

Angiographic RARE
work O
- O
up O
in O
a O
patient O
with O
late O
vaginal O
metastasis O
from O
a O
renal O
carcinoma O
. O

The O
authors O
conclude O
that O
nonspecificity RARE
of O
low O
platelet I-GENE
MAO I-GENE
as O
a O
possible O
correlate O
of O
bipolar O
affective O
disorder O
, O
as O
well O
as O
schizophrenia O
, O
increases O
the O
burden O
of O
proof RARE
necessary O
before O
findings O
of O
low O
platelet I-GENE
MAO I-GENE
can O
be O
accepted O
as O
primary O
. O

Ecthyma RARE
, O
a O
known O
disease O
, O
of O
which O
little O
is O
known O

Estrogen RARE
replacement O
, O
either O
as O
17 O
beta O
- O
estradiol O
or O
beta O
- O
estradiol O
- O
3 O
- O
benzoate RARE
via O
subcutaneous O
Silastic RARE
capsules O
, O
was O
associated O
with O
elevated O
rates O
of O
heat O
production O
and O
dry RARE
heat O
loss O
relative O
to O
untreated O
ovariectomized RARE
controls O
. O

The O
following O
aspects O
were O
assessed O
: O
( O
1 O
) O
The O
effect O
on O
the O
cardiovascular O
system O
in O
terms O
of O
brachial RARE
arterial O
pressure O
, O
pulse O
rate O
, O
and O
oxygen O
consumption O
( O
VO2 O
) O
during O
exercise O
in O
5 O
health O
volunteers O
; O
( O
2 O
) O
emg RARE
activity O
of O
the O
tibialis RARE
anterior O
and O
gastrocnemius RARE
muscles O
during O
exercise O
in O
the O
same O
5 O
volunteers O
; O
and O
( O
3 O
) O
postexercise RARE
ankle RARE
pressure O
changes O
in O
10 O
subjects O
with O
angiographically RARE
proven O
occlusive RARE
arterial O
diseases O
of O
the O
lower O
extremities RARE
. O

Changes O
in O
immunologic O
reactivity O
in O
subjects O
receiving O
transfer I-GENE
factor I-GENE
could O
not O
be O
distinguished O
from O
those O
in O
subjects O
receiving O
placebo O
. O

It O
was O
argued RARE
that O
this O
arose RARE
from O
the O
possibility O
that O
the O
nature O
of O
blue O
collar RARE
jobs RARE
was O
physical O
, O
and O
that O
loss O
of O
myocardial O
tissue O
might O
be O
expected O
to O
more O
markedly O
interfere RARE
with O
their O
work O
efficiency O
( O
on O
returning RARE
to O
work O
) O
than O
it O
would O
the O
efficiency O
of O
the O
more O
sedentary RARE
jobs RARE
of O
white O
collar RARE
workers O
. O

Importance RARE
of O
determining O
the O
blood O
sulfhydryl RARE
groups O
in O
fractures RARE
of O
the O
long O
tubular O
bones RARE
complicated O
by O
infection O

The O
results O
revealed O
increased O
blood O
lead O
level O
associated O
with O
decreased O
blood I-GENE
haemoglobin RARE
and O
increased O
urinary O
excretion O
of O
delta O
amino O
levulinic RARE
acid O
. O

Following O
iv O
injection O
of O
0 O
. O
5 O
g O
galactose O
per O
kg O
body O
weight O
, O
together O
with O
2 O
mu O
Ci RARE
generally O
14C O
- O
labelled O
galactose O
, O
14CO2 NUMERIC
is O
collected O
in O
regular O
intervals O
during O
one O
hour O
. O

Specific O
clotting O
factor O
assays O
showed O
an O
isolated O
deficiency O
of O
factor I-GENE
X I-GENE
ranging O
from O
7 O
to O
12 O
per O
cent O
on O
three O
determinations O
. O

Charcoal RARE
- O
facilitated O
dialysis O
. O

Blood O
variables O
measured O
at O
eight O
intervals O
before O
, O
during O
, O
and O
after O
operation O
were O
as O
follows O
: O
seven O
plasma O
proteins O
, O
free O
hemoglobin I-GENE
, O
formed O
elements O
, O
and O
clotting O
functions O
. O

Retinal RARE
changes O
in O
pigmentary RARE
retinopathy RARE
in O
children O

As O
a O
result O
, O
beta O
- O
apo O
- O
8 O
'- O
carotenoic RARE
acid O
ethyl O
ester O
( O
apo O
- O
EE ALLCAPS
) O
was O
used O
as O
a O
reference O
standard O
in O
Experiments O
4 O
to O
6 O
. O

The O
ability O
of O
sodium O
phenobarbital RARE
( O
60 O
mg O
/ O
kg O
) O
and O
sodium O
barbital RARE
( O
80 O
mg O
/ O
kg O
) O
to O
produce O
a O
taste O
aversion RARE
in O
23 O
hr O
fluid O
deprived O
rats O
was O
examined O
using O
a O
discrimination O
or O
two O
bottle RARE
taste O
aversion RARE
task O
( O
0 O
. O
125 O
% O
sodium O
saccharin O
solution O
or O
water O
). O

It O
appears O
that O
the O
pulmonary O
gas O
exchange O
parenchyma O
of O
these O
smallest O
mammals O
is O
well O
suited RARE
to O
supply O
the O
organism O
with O
the O
comparatively RARE
high O
levels O
of O
O2 O
required O
by O
the O
high O
metabolic O
rates O
, O
exhibiting O
a O
structural O
adaptation O
of O
the O
lung O
to O
higher O
VO2 O
. O

Underestimations RARE
by O
as O
much O
as O
35 O
% O
may O
occur O
due O
to O
the O
problems O
in O
the O
existing O
methodologies RARE
. O

Chemotherapy RARE
was O
administered O
without O
altering O
the O
course O
of O
the O
disorder O
. O

Drug O
inhibition O
of O
whole O
blood O
aspirin I-GENE
esterase I-GENE
. O

However O
, O
at O
lower O
temperature O
the O
positive O
staircase RARE
was O
not O
clear O
and O
rather O
negative O
staircase RARE
appeared O
( O
1 O
-- O
3 O
Hz O
). O

Visual RARE
averaged O
evoked O
responses O
and O
platelet I-GENE
monoamine I-GENE
oxidase I-GENE
in O
patients O
suffering O
from O
alcoholism RARE
. O

At O
the O
end O
of O
the O
experiment O
the O
urinary O
porphyrin O
excretion O
and O
the O
porphyrin O
content O
in O
lijver RARE
and O
skin O
were O
diminished O
in O
HCB O
- O
CQ ALLCAPS
- O
treated O
animals O
by O
about O
50 O
% O
compared O
to O
the O
HCB O
controls O
. O

Six O
hours O
after O
the O
last O
administration O
, O
uterus RARE
of O
Gf RARE
and O
Cv RARE
mice O
were O
weight O
337 NUMERIC
. O
6 O
mg O
% O
and O
423 NUMERIC
. O
5 O
mg O
% O
respectively O
, O
the O
difference O
was O
statistically O
significant O
( O
p O
less O
than O
0 O
. O
01 O
). O

Although O
stone O
- O
formers RARE
were O
not O
found O
to O
display O
any O
features O
of O
magnesium O
metabolism O
that O
were O
different O
from O
those O
in O
the O
control O
group O
, O
their O
lower O
urinary O
excretion O
of O
magnesium O
in O
relation O
to O
calcium O
may O
be O
a O
factor O
in O
their O
increased O
stone O
- O
forming O
propensity O
. O

Analysis O
of O
an O
autopsy O
population O
. O

A O
16 O
- O
year O
follow O
- O
up O
study O
of O
69 O
paraplegics RARE
with O
complete O
lesions O
from O
T1 O
- O
L3 NUMERIC
is O
presented O
. O

Autoradiographic RARE
localisation RARE
of O
its O
cellular O
distribution O
in O
the O
kidney O
. O

Hippocampal RARE
stimulation O
overlapping O
conditioned O
stimulus O
preexposure RARE
produced O
attenuation O
of O
latent O
inhibition O
, O
as O
did O
stimulation O
presented O
during O
conditioning O
after O
preexposure RARE
. O

The O
centromedial RARE
amygdala O
and O
gastric O
pathology O
in O
rats O
. O

Cataract RARE
extraction O
in O
primary O
glaucoma O

Number RARE
and O
size O
of O
the O
myelin O
structures O
in O
the O
pneumocytes RARE
typ RARE
II O
increased O
simultaneously O
. O

In O
the O
intact O
animal O
, O
postextrasystolic RARE
potentiation O
depended RARE
on O
the O
basic O
pacing O
interval O
, O
t0 NUMERIC
, O
and O
the O
timing O
of O
the O
extrasystole RARE
, O
t1 O
: O
when O
t0 NUMERIC
was O
held O
constant O
and O
t1 O
was O
increased O
, O
potentiation O
decreased O
; O
when O
t1 O
was O
held O
constant O
and O
t0 NUMERIC
was O
increased O
, O
potentiation O
increased O
. O

In O
spite RARE
of O
this O
and O
other O
complications O
of O
corticosteroids O
, O
she RARE
made O
a O
full O
recovery O
from O
the O
fungal O
infection O
following O
treatment O
with O
amphotericin O
B O
and O
surgical O
excision O
of O
the O
lung O
abscess O
. O

Implications RARE
of O
this O
observation O
for O
pediatrics RARE
are O
discussed O
. O

For O
the O
study O
of O
the O
transition O
of O
long O
to O
short O
waves O
( O
deep O
- O
water O
waves O
) O
a O
closed O
- O
form O
solution O
is O
advantageous RARE
; O
this O
can O
, O
however O
, O
only O
be O
obtained O
at O
the O
cost O
of O
further O
simplification RARE
. O

Treatment O
of O
suppurative RARE
peritonitis RARE

We O
report O
a O
case O
of O
pheochromocytoma RARE
manifesting RARE
during O
the O
third O
trimester RARE
of O
pregnancy O
. O

Fasting RARE
plasma O
and O
lipoprotein O
lipid O
concentrations O
, O
adipose I-GENE
tissue I-GENE
lipoprotein I-GENE
lipase I-GENE
activity O
, O
anthropometric RARE
data O
, O
alcohol O
consumption O
, O
smoking O
habits RARE
, O
weekly O
mileage RARE
run O
and O
performance O
on O
a O
bicycle RARE
ergometer RARE
were O
recorded O
before O
and O
after O
the O
training O
period O
. O

The O
C18 O
: O
1 O
: O
C10 NUMERIC
value O
is O
a O
convenient RARE
measure O
of O
these O
changes O
and O
can O
be O
determined O
more O
rapidly O
than O
determining O
all O
the O
lower O
fatty O
acids O
. O

A O
progressive O
growth O
of O
blood O
erythrocyte O
membrane O
injury O
has O
been O
demonstrated O
after O
rats O
were O
exposed O
to O
gamma O
- O
irradiaton RARE
at O
a O
dose O
of O
100 O
to O
500 O
Gy O
. O

Within O
the O
3 O
' O
terminal O
50 O
nucleotides O
, O
the O
mouse I-GENE
mt RARE
12S NUMERIC
rRNA I-GENE
contains O
a O
potential O
10 O
bp O
hairpin O
structure O
and O
a O
sequence O
of O
15 O
consecutive O
nucleotides O
common O
to O
the O
RNA O
of O
the O
small O
ribosomal O
subunit O
in O
all O
systems O
, O
but O
does O
not O
contain O
the O
mRNA O
binding O
site O
( O
ACCUCC ALLCAPS
) O
found O
in O
E O
. O
coli O
and O
corn RARE
chloroplast O
rRNAs RARE
. O

Microscopic RARE
anatomy RARE
and O
cell O
population O
dynamics O
. O

Thirty O
cadaver RARE
brains RARE
were O
examined O
under O
X O
6 O
to O
16 O
magnification O
in O
order O
to O
define O
the O
microsurgical RARE
anatomy RARE
of O
the O
pineal O
region O
, O
particularly O
the O
relationship O
of O
the O
pineal O
body O
, O
posterior O
cerebral O
artery O
, O
superior O
cerebellar RARE
artery O
, O
vein O
of O
Galen RARE
, O
basal O
vein O
of O
Rosenthal RARE
, O
internal O
cerebral O
vein O
, O
straight RARE
sinus O
, O
bridging RARE
vein O
, O
the O
size O
of O
the O
tentorial RARE
notch RARE
, O
and O
the O
third O
and O
the O
fourth O
cranial RARE
nerves O
. O

Serum O
antibody O
titre RARE
was O
not O
significantly O
associated O
with O
the O
recurrence O
rate O
or O
the O
duration O
of O
infection O
. O

We O
propose O
that O
refeeding RARE
may O
be O
an O
important O
mechanism O
for O
activation O
of O
certain O
viral O
infections O
previously O
suppressed O
by O
famine RARE
. O

One O
hundred O
twenty RARE
units O
of O
deglycerolized RARE
red O
blood O
cells O
, O
some O
with O
glycerol RARE
added O
so O
as O
to O
exceed RARE
an O
acceptable O
1 O
% O
glycerol RARE
content O
, O
had O
measurements O
made O
of O
the O
post O
- O
wash RARE
supernatant O
fluid O
by O
refractive RARE
index O
and O
osmometry RARE
. O

The O
symptoms O
and O
objective O
findings O
were O
caused O
by O
a O
malignant O
lymphoma O
, O
and O
the O
diagnosis O
was O
established O
from O
a O
drill RARE
biopsy O
. O

Our O
study O
differs O
from O
previous O
studies O
in O
that O
it O
is O
limited O
to O
one O
diagnostic O
entity RARE
, O
yet O
at O
the O
same O
time O
evaluates RARE
a O
broad O
range O
of O
social O
and O
work O
- O
related O
factors O
in O
disability RARE
. O

It O
is O
suggested O
that O
a O
raised O
hydroxykynurenine RARE
/ O
hydroxyanthranilic RARE
acid O
ratio O
does O
not O
necessarily O
indicate O
vitamin O
B6 O
deficiency O
but O
may O
represent O
a O
nonspecific O
response O
of O
tryptophan O
metabolism O
to O
stress O
. O

All O
control O
persons O
had O
a O
normal O
reaction O
to O
DNFB ALLCAPS
. O

In O
a O
control O
group O
both O
common O
carotid O
arteries O
( O
CCA ALLCAPS
) O
were O
ligated O
. O

At O
pH O
6 O
. O
9 O
, O
the O
same O
lidocaine O
concentrations O
significantly O
reduced O
resting O
potential O
( O
3 O
- O
10 O
%), O
action O
potential O
amplitude O
( O
3 O
- O
8 O
%) O
and O
Vmax O
( O
14 O
- O
22 O
%). O

Simultaneous RARE
right O
and O
left O
adrenal O
and O
peripheral O
blood O
samples O
were O
collected O
for O
determination O
of O
oestrone RARE
( O
E1 O
) O
and O
oestradiol O
( O
E2 O
). O

Arm RARE
function O
tests O
. O

All O
lambs O
with O
B O
breeding RARE
had O
significantly O
higher O
Hb I-GENE
levels O
at O
the O
end O
of O
the O
experiment O
than O
did O
NB ALLCAPS
lambs O
. O
b O
and O
S O
x O
B O
lambs O
had O
higher O
( O
P O
< O
. O
05 O
) O
Hb I-GENE
levels O
than O
the O
D O
x O
B O
lambs O
, O
and O
B O
lambs O
had O
the O
highest O
( O
P O
< O
. O
05 O
) O
mean O
corpuscular RARE
hemoglobin I-GENE
concentrations O
. O

The O
same O
response O
occurs O
whether O
acrylamide RARE
is O
given O
immediately O
after O
nerve O
ligation O
or O
1 O
week O
later O
. O

The O
operation O
recommended O
is O
excision O
of O
3 O
mm O
of O
central O
slip RARE
followed O
by O
end O
- O
to O
- O
end O
repair O
of O
the O
tendon O
. O

In O
the O
unclipped RARE
group O
arterial O
pressure O
decreased O
50 O
mmHg O
to O
normal O
by O
24 O
h O
and O
was O
associated O
with O
increased O
diuresis RARE
and O
a O
small O
decrease O
in O
blood O
volume O
( O
9 O
. O
8 O
%). O

Marked O
sedative RARE
activity O
was O
observed O
with O
9 O
- O
methoxy RARE
- O
5 O
- O
phenylpyrrolo RARE
[ O
2 O
, O
1 O
- O
d O
][ RARE
1 O
, O
5 O
] O
benzothiazepin RARE
- O
6 O
, O
6 O
- O
dioxide O
( O
NF19 NUMERIC
) O
and O
9 O
- O
chloro RARE
- O
5 O
- O
p O
- O
nitrophenylpyrrolo RARE
[ O
2 O
, O
1 O
- O
d O
][ RARE
1 O
, O
5 O
] O
benzothiazepin RARE
- O
6 O
, O
6 O
- O
dioxide O
( O
NF20 NUMERIC
). O

In O
patients O
, O
the O
effect O
of O
CCK ALLCAPS
- O
PZ ALLCAPS
on O
the O
movement O
of O
the O
terminal O
part O
of O
the O
bile O
duct O
was O
measured O
with O
a O
pressure O
sensor RARE
using O
a O
duodenofiberscope RARE
. O

In O
11 O
patients O
with O
Horton RARE
' O
s O
headache O
morphological O
investigations O
( O
differential O
white O
blood O
cell O
count O
), O
cytoenzymatic RARE
determinations O
( O
alkaline I-GENE
and I-GENE
acid I-GENE
phosphatase I-GENE
, O
non I-GENE
- I-GENE
specific I-GENE
esterase I-GENE
) O
and O
cytoimmunological RARE
tests O
( O
IgM I-GENE
and O
IgG I-GENE
binding O
) O
were O
carried O
out O
on O
capillary O
blood O
neutrophils O
obtained O
from O
the O
area O
of O
pain O
, O
non O
- O
painful RARE
area O
of O
the O
skin O
on O
the O
head O
on O
the O
contralateral O
side O
, O
and O
from O
the O
finger O
. O

As O
high O
- O
speed RARE
, O
volumetric RARE
imaging O
, O
computed O
tomographic RARE
scan O
machines RARE
such O
as O
the O
Dynamic RARE
Spatial RARE
Reconstructor RARE
become O
available O
with O
higher O
density O
resolution O
, O
perhaps O
a O
single O
injection O
of O
contrast O
agent O
into O
the O
right O
atrium O
or O
even O
a O
peripheral O
vein O
may O
be O
adequate O
to O
obtain O
all O
these O
measurements O
. O

The O
ESEG ALLCAPS
' O
s O
are O
a O
direct O
result O
of O
the O
NEXT ALLCAPS
study O
. O

The O
potentially O
SLE O
- O
inducing O
drugs O
are O
reviewed O
. O

A O
third O
series O
of O
mice O
were O
given O
a O
single O
injection O
of O
5 O
- O
OH O
- O
DA O
, O
sacrificed RARE
, O
and O
prepared O
for O
ultrastructural RARE
study O
. O

Fourteen RARE
different O
species O
( O
eight O
Platyhelmintha RARE
, O
one O
Nematoda RARE
and O
five O
Crustacea RARE
) O
have O
been O
inventorized RARE
. O

No O
symptoms O
other O
than O
hot O
flush RARE
showed O
such O
significant O
correlation O
with O
plasma O
epinephrine O
or O
norepinephrine O
levels O
. O

The O
mean O
values O
of O
the O
concentrations O
of O
the O
components O
due O
to O
tobacco O
smoke O
are O
: O
CO O
= O
1 O
. O
1 O
ppm O
, O
NO O
= O
32 O
ppb O
, O
NO2 O
= O
24 O
ppb O
, O
nicotine O
= O
0 O
. O
9 O
micrograms O
/ O
m3 O
, O
particulate O
matter O
= O
133 O
micrograms O
/ O
m3 O
. O

The O
average O
backscatter RARE
coefficient O
was O
six O
time O
larger O
in O
regions O
of O
infarct O
studied O
8 O
-- O
10 O
weeks O
after O
occlusion O
than O
that O
in O
regions O
of O
infarct O
studied O
5 O
-- O
6 O
weeks O
after O
occlusion O
. O

At O
4 O
wk O
however O
, O
tumor O
relapse O
was O
noted O
in O
6 O
of O
7 O
group O
4 O
responders O
, O
10 O
of O
12 O
in O
group O
5 O
, O
13 O
of O
16 O
in O
group O
7 O
, O
but O
only O
4 O
of O
19 O
group O
8 O
responders O
( O
p O
less O
than O
. O
001 O
group O
8 O
versus O
4 O
, O
5 O
, O
7 O
). O

Early O
infection O
was O
detected O
in O
one O
of O
50 O
control O
women O
who O
gave O
birth O
to O
a O
healthy O
infant O
. O

Pentachlorophenol RARE
accelerates RARE
the O
onset O
of O
HCB O
porphyria RARE
, O
in O
other O
words RARE
it O
increases O
the O
total O
urinary O
porphyrin O
excretion O
and O
causes O
an O
earlier O
disturbance O
of O
the O
porphyrin O
pattern O
. O

Family RARE
planning O
continues RARE
to O
play O
a O
minor O
role O
, O
and O
only O
25 O
. O
3 O
per O
cent O
of O
all O
patients O
reviewed O
took RARE
to O
oral O
contraceptives RARE
for O
shorter O
or O
longer O
periods O
of O
time O
. O
- O
The O
percentages RARE
of O
primiparae RARE
and O
secundiparae RARE
in O
all O
births O
as O
well O
as O
the O
high O
percentage O
of O
multigravidity RARE
are O
parameters O
by O
which O
the O
approach O
to O
reproduction RARE
differs O
substantively RARE
from O
behaviour O
patterns O
in O
Europe RARE
. O

The O
term O
osteomesopycnosis RARE
is O
proposed O
for O
a O
sclerosing RARE
bone O
disease O
with O
dominant O
inheritance RARE
that O
has O
been O
discovered O
in O
five O
members O
of O
four O
different O
families O
. O

The O
87K NUMERIC
protein O
, O
together O
with O
proteins O
of O
105 O
, O
000 O
and O
75 O
, O
000 O
daltons RARE
, O
are O
translated O
from O
leftward RARE
transcribed O
( O
1 O
- O
strand O
) O
messenger O
RNAs O
that O
are O
complementary O
to O
the O
viral O
genome O
between O
positions O
11 O
. O
2 O
and O
31 O
. O
5 O
. O

The O
identification O
of O
viable O
myocardium O
with O
both O
99mTc O
- O
tetrofosmin O
and O
201Tl NUMERIC
can O
be O
greatly O
enhanced O
to O
a O
similar O
degree O
if O
the O
severity O
of O
reduction O
in O
activity O
within O
nonreversible RARE
defects O
is O
considered O
. O

The O
temporal O
component O
lacked O
a O
mandibular O
fossa RARE
as O
well O
as O
articular RARE
eminence RARE
. O

EUK ALLCAPS
- O
8 O
is O
a O
novel O
, O
synthetic O
, O
low O
- O
molecular O
- O
weight O
salen RARE
- O
manganese RARE
complex O
that O
exhibits O
both O
superoxide I-GENE
dismutase I-GENE
and O
catalase I-GENE
activities O
in O
vitro O
. O

The O
protein I-GENE
ELT ALLCAPS
- I-GENE
1 I-GENE
, O
encoded O
by O
a O
single O
- O
copy O
gene O
homologous O
to O
the O
GATA I-GENE
family I-GENE
of I-GENE
vertebrate I-GENE
transcription I-GENE
factors I-GENE
, O
is O
potentially O
capable O
of O
interacting O
with O
this O
element O
. O

However O
, O
in O
contrast O
with O
previous O
in O
vitro O
cell O
- O
free O
integration O
studies O
, O
alteration O
of O
the O
highly O
conserved O
CA O
dinucleotide O
resulted O
in O
a O
mutant O
which O
still O
retained O
40 O
% O
of O
wild O
- O
type O
integration O
activity O
. O

The O
resulting O
R I-GENE
protein I-GENE
terminates RARE
five O
codons O
downstream O
of O
the O
frameshift O
site O
at O
the O
V I-GENE
protein I-GENE
stop O
codon O
. O

These O
results O
demonstrate O
that O
although O
PI2 NUMERIC
and O
PI3 NUMERIC
viruses O
belong O
to O
the O
same O
parainfluenza RARE
virus O
genus O
, O
these O
viruses O
show O
marked O
differences O
with O
respect O
to O
functional O
requirements O
for O
the O
cytoplasmic O
tail O
of O
the O
F I-GENE
glycoprotein I-GENE
. O

By O
site O
- O
specific O
mutagenesis O
, O
we O
also O
show O
that O
individual O
ICP27 NUMERIC
C I-GENE
- I-GENE
terminal I-GENE
amino I-GENE
acid I-GENE
residues I-GENE
that O
are O
positionally RARE
conserved O
in O
ICP27 NUMERIC
homologs I-GENE
in O
other O
herpesviruses RARE
( O
D O
- O
357 NUMERIC
, O
E O
- O
358 NUMERIC
, O
H O
- O
479 NUMERIC
, O
C O
- O
400 O
, O
C O
- O
483 NUMERIC
, O
and O
C O
- O
488 NUMERIC
) O
are O
critical O
for O
trans O
- O
regulatory O
activity O
. O

Magnetic O
resonance O
imaging O
( O
MRI O
) O
has O
enabled RARE
us O
to O
see RARE
the O
spinal O
intramedullary RARE
pathology O
as O
differences O
in O
signal O
intensity O
. O

Patients O
with O
psychotropic RARE
drugs O
showed O
significantly O
higher O
PRL I-GENE
levels O
. O

The O
Laser RARE
Scanning RARE
Ophthalmoscope RARE
enables O
a O
fundus RARE
- O
based O
examination O
and O
therefore O
allows O
exact RARE
comparison O
between O
morphologic O
appearance O
and O
corresponding O
function O
. O

Malaria RARE
, O
anaemia RARE
, O
and O
HIV O
- O
1 O
transmission O
in O
central O
Africa RARE
. O

BSE ALLCAPS
and O
farmworkers RARE
. O

In O
addition O
, O
two O
- O
dimensional O
nuclear O
magnetic O
resonance O
studies O
with O
F17A NUMERIC
, O
K13Q NUMERIC
, O
F15Y NUMERIC
and O
F27Y NUMERIC
revealed O
that O
the O
mutants O
have O
the O
same O
overall O
structure O
as O
the O
wild I-GENE
- I-GENE
type I-GENE
CspB LASTCAP
protein I-GENE
. O

Considerably RARE
high O
levels O
of O
IgE I-GENE
antibodies I-GENE
was O
also O
established O
while O
other O
pollens RARE
did O
not O
show O
such O
correspondence RARE
. O

Peroxisome RARE
proliferator I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
PPARs RARE
) O
and O
retinoid I-GENE
X I-GENE
receptors I-GENE
( O
RXRs RARE
) O
are O
nuclear I-GENE
hormone I-GENE
receptors I-GENE
that O
are O
activated O
by O
fatty O
acids O
and O
9 O
- O
cis O
- O
retinoic O
acid O
, O
respectively O
. O

This O
is O
particularly O
intriguing RARE
because O
SKUT ALLCAPS
- O
1B O
- O
20 O
cells O
lack O
the O
transcription O
factor O
Pit I-GENE
- I-GENE
1 I-GENE
. O

The O
number O
of O
lactotropes RARE
, O
somatotropes RARE
, O
thyrotropes RARE
, O
and O
gonadotropes RARE
was O
not O
altered O
compared O
with O
controls O
, O
indicating O
that O
in O
the O
adult O
pituitary O
, O
POMC ALLCAPS
products I-GENE
are O
not O
required O
to O
maintain O
the O
distribution O
of O
cell O
types O
. O

Some O
strains O
of O
A O
. O
parasiticus RARE
produced O
all O
four O
aflatoxins RARE
B1 O
B2 O
G1 O
G2 O
, O
while O
the O
other O
ones O
produced O
AF O
B1 O
+ O
G1 O
only O
, O
with O
concentrations O
of O
aflatoxins RARE
from O
0 O
. O
1 O
to O
450 O
mg O
/ O
kg O
. O

We O
have O
isolated O
a O
new O
, O
larger O
rat I-GENE
B I-GENE
- I-GENE
myc I-GENE
genomic I-GENE
clone I-GENE
. O

In O
addition O
to O
the O
nine O
and O
51 O
terminal O
amino O
acid O
forms O
already O
known O
, O
we O
identified O
a O
third O
with O
43 O
terminal O
amino O
acids O
predicted O
to O
encode O
a O
novel O
RET I-GENE
protein I-GENE
isoform I-GENE
. O

Both O
classes O
of O
MHBst RARE
proteins I-GENE
were O
found O
to O
form O
dimers O
; O
an O
which O
is O
involved O
in O
mediating O
the O
dimerization O
. O

In O
electrophoretic O
mobility O
shift O
assays O
, O
the O
PERE ALLCAPS
formed O
three O
major O
complexes O
( O
P1 O
, O
P2 O
and O
P3 O
) O
with O
proteins O
in O
nuclear O
extracts O
from O
HeLa O
or O
293 O
cells O
. O

She RARE
had O
been O
receiving O
MTX ALLCAPS
7 O
. O
5 O
mg O
/ O
week O
for O
2 O
. O
5 O
months O
because O
of O
her O
vasculitis O
symptoms O
. O

Analysis O
of O
the O
sequence O
identified O
four O
open O
reading O
frames O
( O
ORFs O
) O
which O
are O
designated O
UL1 NUMERIC
, O
UL2 NUMERIC
, O
UL3 NUMERIC
, O
and O
UL3 NUMERIC
. I-GENE
5 I-GENE
based O
on O
their O
homology O
with O
proteins O
of O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
), O
pseudorabies O
virus O
( O
PRV ALLCAPS
), O
equine O
herpesvirus O
- O
1 O
, O
and O
varicella RARE
- O
zoster RARE
virus O
. O

These O
HPV16 NUMERIC
E6 I-GENE
/ O
E7 I-GENE
cDNAs O
were O
cloned O
under O
the O
SV40 I-GENE
enhancer I-GENE
/ I-GENE
promoter I-GENE
and O
the O
MMTV I-GENE
LTR I-GENE
to O
examine O
the O
activities O
of O
ras I-GENE
- O
collaborative RARE
transformation O
and O
induction O
of O
cellular O
DNA O
synthesis O
, O
both O
of O
which O
depend O
on O
the O
E7 I-GENE
gene I-GENE
product O
. O

Correlation RARE
coefficients O
between O
the O
reference O
methods O
and O
NIT ALLCAPS
were O
> O
or O
= O
0 O
. O
95 O
for O
water O
, O
fat O
, O
crude O
protein O
and O
connective O
- O
tissue O
- O
protein O
frei RARE
meat O
protein O
, O
and O
> O
or O
= O
0 O
. O
86 O
for O
connective O
- O
tissue O
- O
protein O
. O

The O
translation O
products O
of O
both O
clones O
are O
highly O
homologous O
to O
APS1 NUMERIC
( O
66 O
and O
86 O
% O
identity O
, O
respectively O
) O
over O
their O
entire O
lengths O
, O
including O
amino O
terminal O
sequences O
resembling O
transit O
peptides O
for O
plastid RARE
localization O
. O

The O
serum O
levels O
of O
IgE I-GENE
, O
and O
asIgE LASTCAP
and O
IgG I-GENE
- I-GENE
4 I-GENE
against O
14 O
common O
food O
allergens O
were O
determined O
. O

Two O
experiments O
investigating RARE
the O
effects O
of O
short O
- O
term O
spaceflight RARE
on O
cancellous RARE
bone O
turnover O
were O
carried O
out O
: O
Physiological RARE
Systems RARE
Experiment O
- O
1 O
( O
PSE ALLCAPS
- O
1 O
) O
( O
a O
4 O
- O
d O
orbital RARE
spaceflight RARE
) O
and O
PSE ALLCAPS
- O
2 O
( O
a O
10 O
- O
d O
flight RARE
). O

That RARE
sequence O
strongly O
promoted O
the O
transcription O
of O
the O
promotorless RARE
chloramphenicol I-GENE
acetyltranferase RARE
( O
CAT I-GENE
) O
gene O
in O
cells O
of O
pancreatic O
origin O
( O
AR O
- O
42J NUMERIC
) O
but O
not O
in O
cells O
of O
non O
- O
pancreatic O
origin O
( O
Rat O
2 O
and O
IEC ALLCAPS
6 O
). O

Functional O
analysis O
of O
aryl RARE
hydrocarbon I-GENE
receptor I-GENE
nuclear I-GENE
translocator RARE
interactions O
with O
aryl RARE
hydrocarbon I-GENE
receptor I-GENE
in O
the O
yeast O
two O
- O
hybrid O
system O
. O

Histopathologic RARE
observations O
showed O
that O
both O
somatostatin I-GENE
and O
triamcinolone RARE
acetonide RARE
reduced O
the O
inflammatory O
signs O
in O
the O
joint O
structures O
, O
although O
triamcinolone RARE
acetonide RARE
appeared O
to O
be O
more O
effective O
. O

An O
approach O
to O
a O
biomathematical RARE
model O
of O
lymphocytopoiesis RARE
. O

The O
influenza O
virus O
NS1 I-GENE
protein O
is O
a O
unique O
posttranscriptional O
regulator O
that O
has O
two O
activities O
: O
inhibition O
of O
the O
nuclear O
export O
of O
poly O
A O
- O
containing O
mRNAs O
and O
inhibition O
of O
pre O
- O
mRNA O
splicing O
. O

These O
are O
two O
regions O
of O
known O
conserved O
synteny RARE
, O
providing O
further O
evidence O
that O
the O
human I-GENE
STEP ALLCAPS
is O
a O
true O
homolog O
of O
the O
murine I-GENE
STEP ALLCAPS
gene I-GENE
. O

Molecular O
cloning O
of O
the O
human O
homolog O
of O
a O
striatum I-GENE
- I-GENE
enriched I-GENE
phosphatase I-GENE
( I-GENE
STEP ALLCAPS
) I-GENE
gene I-GENE
and O
chromosomal O
mapping O
of O
the O
human O
and O
murine O
loci O
. O

Carbonic RARE
anhydrase I-GENE
V I-GENE
( O
CA I-GENE
V I-GENE
) O
is O
expressed O
in O
mitochondrial O
matrix O
in O
liver O
and O
several O
other O
tissues O
. O

Vitamin RARE
D3 O
plus O
nicotine O
treatment O
produced O
parallel O
increases O
in O
cardiac O
mass O
and O
elastic O
modulus RARE
, O
with O
a O
significant O
correlation O
between O
the O
two O
. O

The O
latter O
domain O
appears O
to O
be O
involved O
in O
targeting O
Num1p NUMERIC
to O
the O
mother RARE
cell O
cortex O
. O

This O
finding O
is O
consistent O
with O
the O
notion O
that O
the O
dsRNA O
binding O
domains O
may O
be O
composed O
of O
two O
separate O
functional O
subdomains O
. O

Preferential RARE
heterodimeric O
parallel O
coiled O
- O
coil O
formation O
by O
synthetic I-GENE
Max I-GENE
and O
c I-GENE
- I-GENE
Myc I-GENE
leucine I-GENE
zippers I-GENE
: O
a O
description O
of O
putative O
electrostatic RARE
interactions O
responsible O
for O
the O
specificity O
of O
heterodimerization O
. O

Comparison O
to O
other O
coxI LASTCAP
genes I-GENE
revealed O
a O
966 NUMERIC
- O
bp O
group O
I O
intron O
, O
which O
, O
based O
on O
homology O
with O
the O
related O
yeast I-GENE
coxI LASTCAP
intron I-GENE
aI4 NUMERIC
, O
potentially O
encodes O
a O
279 NUMERIC
- O
amino O
- O
acid O
site O
- O
specific O
DNA I-GENE
endonuclease I-GENE
. O

We O
studied O
the O
GR I-GENE
in O
DMS ALLCAPS
- O
79 O
cells O
derived O
from O
a O
human O
ACTH I-GENE
- O
secreting O
small O
cell O
lung O
cancer O
. O

This O
study O
analyzed O
whether O
the O
localization O
of O
an O
accessory O
pathway O
could O
be O
predicted O
by O
using O
the O
polarity O
of O
the O
QRS O
complex O
during O
sinus O
rhythm O
on O
the O
surface O
ECG O
, O
instead O
of O
the O
delta O
wave O
polarity O
as O
used O
in O
many O
reports O
. O

The O
promoter O
mutation O
is O
complemented O
in O
trans O
by O
E1A I-GENE
products O
of O
the O
heterologous O
helper RARE
adenovirus O
type O
5 O
( O
Ad5 O
). O

Thus O
, O
as O
expected O
, O
trans O
- O
splicing O
depends O
on O
the O
integrity O
of O
U2 I-GENE
, O
U4 I-GENE
, O
and O
U6 I-GENE
snRNAs RARE
. O

Treatment O
of O
PCC4 NUMERIC
. O
aza1R NUMERIC
cells O
with O
an O
RAR I-GENE
- O
selective O
agonist O
also O
repressed O
the O
expression O
of O
EC I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
while O
treatment O
with O
an O
RXR I-GENE
- O
selective O
agonist O
reduced O
EC I-GENE
- I-GENE
1 I-GENE
expression O
slightly O
. O

In O
the O
absence O
of O
E1A243 NUMERIC
, O
YY1 I-GENE
represses O
CRE O
- O
dependent O
transcription O
of O
c I-GENE
- I-GENE
fos I-GENE
by O
physically O
interacting O
with O
ATF I-GENE
/ O
CREB I-GENE
proteins O
bound O
to O
the O
- O
67 O
CRE O
. O

Shift RARE
- O
down O
experiments O
indicated O
that O
the O
10 O
( O
4 O
)- O
to O
10 O
( O
5 O
)- O
fold O
reduction O
in O
virus O
yield O
at O
the O
nonpermissive RARE
temperature O
was O
due O
to O
the O
disfunction RARE
of O
alpha I-GENE
TIF I-GENE
late O
in O
infection O
, O
presumably O
in O
virion O
maturation O
. O

These O
results O
demonstrate O
that O
tip I-GENE
acts O
at O
an O
early O
stage O
of O
the O
T O
- O
cell O
signal O
transduction O
cascade O
by O
associating RARE
with O
Lck I-GENE
and O
downregulating RARE
Lck O
- O
mediated O
activation O
. O

Human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
Vpr RARE
is O
a O
virion O
- O
associated O
, O
regulatory O
protein O
that O
is O
required O
for O
efficient O
viral O
replication O
in O
monocytes O
/ O
macrophages O
. O

Here O
we O
examine O
the O
potential O
for O
VP16 I-GENE
protein O
- O
protein O
interactions O
specific O
to O
virus O
- O
infected O
cells O
and O
show O
that O
VP16 I-GENE
copurifies RARE
in O
a O
highly O
enriched O
fraction O
with O
a O
single O
major O
polypeptide O
which O
we O
identify O
as O
the O
virus O
- O
encoded O
structural O
protein O
VP22 NUMERIC
. O

Thus O
, O
transcriptional O
regulation O
, O
splicing O
, O
kinase O
interaction O
sites O
, O
and O
tyrosine O
phosphorylation O
of O
the O
LMP2A NUMERIC
homologs I-GENE
have O
been O
conserved O
despite O
significant O
sequences O
heterogeneity O
in O
the O
preterminal RARE
repeat O
regions O
of O
these O
human O
and O
nonhuman RARE
primate O
EBVs RARE
. O

Results O
of O
the O
ECAT ALLCAPS
Angina RARE
Pectoris RARE
Study O
Group O
. O

Therefore O
, O
a O
prospective O
Phase O
II O
trial O
was O
conducted O
to O
determine O
the O
safety O
and O
efficacy O
of O
cryosurgery RARE
following O
radiation O
therapy O
in O
men O
with O
local O
recurrence O
. O

These O
motifs O
include O
a O
Chi O
motif O
and O
a O
Chi O
- O
like O
element O
previously O
found O
in O
the O
recombination O
hotspot RARE
region O
of O
the O
Bcl I-GENE
- I-GENE
2 I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
and O
close O
to O
chromosomal O
breakpoints O
in O
T O
- O
ALL O
lines O
. O

Common RARE
history O
and O
prospects RARE
in O
surgical O
gynecology RARE
of O
the O
Charite RARE
and O
the O
Vienna RARE
University O
Clinic RARE

In O
contrast O
with O
the O
previously O
reported O
HMGR1 NUMERIC
mRNA I-GENE
( O
HMGR1S NUMERIC
mRNA I-GENE
), O
which O
is O
detected O
at O
high O
levels O
in O
all O
tissues O
of O
the O
plant O
, O
HMGR1L NUMERIC
mRNA I-GENE
is O
present O
at O
relatively O
low O
levels O
and O
its O
expression O
is O
restricted O
mostly O
to O
seedlings O
, O
roots O
and O
inflorescences RARE
. O

However O
, O
the O
requirement O
of O
rev3 NUMERIC
for O
the O
production O
of O
G O
. O
C O
--> O
T O
. O
A O
transversions RARE
by O
the O
rad18 NUMERIC
mutator RARE
, O
which O
induces O
only O
these O
substitutions O
, O
was O
similar O
to O
that O
for O
rad6 NUMERIC
- O
mediated O
G O
. O
C O
--> O
T O
. O
A O
transversion O
. O

The O
second O
mutation O
present O
in O
the O
original O
mutant O
proved O
to O
be O
an O
allele O
of O
a O
known O
gene O
, O
PBS2 NUMERIC
, O
which O
encodes O
a O
putative O
protein O
kinase O
that O
functions O
in O
the O
high O
osmolarity RARE
stress O
pathway O
. O

In O
adult O
tissues O
, O
it O
was O
less O
restricted O
, O
indicating O
that O
RAFTK ALLCAPS
expression O
is O
developmentally O
up O
- O
regulated O
. O

As O
hGM LASTCAP
- I-GENE
CSF I-GENE
receptor I-GENE
( O
hGMR LASTCAP
) O
does O
not O
contain O
a O
consensus O
sequence O
for O
binding O
of O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
hGMR LASTCAP
must O
use O
a O
distinct O
mechanism O
for O
its O
association O
with O
and O
activation O
of O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

J O
. O

The O
identity O
between O
hnRNPs RARE
H I-GENE
and O
H I-GENE
' I-GENE
is O
96 O
%, O
between O
H I-GENE
and O
F I-GENE
78 O
%, O
and O
between O
H I-GENE
' I-GENE
and O
F I-GENE
75 O
%, O
respectively O
. O

TPBF ALLCAPS
has O
two O
potential O
coiled O
- O
coil O
regions O
, O
a O
basic O
region O
, O
a O
proline O
- O
rich O
region O
, O
a O
histidine O
- O
rich O
N O
terminus O
, O
and O
a O
nuclear O
targeting O
sequence O
. O

In O
the O
present O
study O
, O
we O
transiently O
expressed O
in O
primary O
cultures O
of O
rat O
hepatocytes O
plasmids O
consisting O
of O
CYP3A1 NUMERIC
5 I-GENE
'- I-GENE
flanking I-GENE
sequences I-GENE
fused O
to O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
plasmid O
. O

We O
show O
that O
stimulation O
of O
resting O
splenic O
B O
cells O
with O
CD40L NUMERIC
- O
expressing O
Sf9 O
cells O
induces O
germ O
- O
line O
gamma O
1 O
and O
epsilon O
transcripts O
independently O
of O
cytokines O
. O

To O
confirm O
the O
GapIII LASTCAP
protein I-GENE
activity O
, O
constructs O
containing O
different O
GapIII LASTCAP
- O
GRD ALLCAPS
domains O
were O
transformed O
into O
iral RARE
mutant O
yeast O
to O
determine O
their O
relative O
ability O
to O
replace O
IRA1 NUMERIC
functionally O
. O

At O
the O
time O
of O
the O
13 O
latest RARE
BPVs RARE
, O
age O
ranged O
from O
three O
days O
to O
13 O
. O
1 O
years O
( O
mean O
5 O
. O
7 O
+/- O
SD O
4 O
. O
8 O
years O
). O

A O
tobacco O
homologue O
( O
trolC LASTCAP
) O
of O
the O
rolC LASTCAP
gene I-GENE
of I-GENE
the I-GENE
Agrobacterium RARE
rhizogenes RARE
Ri RARE
- I-GENE
plasmid I-GENE
was O
cloned O
and O
sequenced O
from O
Nicotiana RARE
tabacum RARE
L O
. O
cv O
. O

High O
ADR1 I-GENE
gene I-GENE
dosage O
increased O
the O
transcription O
of O
genes O
encoding O
peroxisomal RARE
proteins O
as O
compared O
to O
one O
copy O
of O
the O
ADR1 I-GENE
gene I-GENE
. O

A O
water O
- O
vapour RARE
giga RARE
- O
maser RARE
in O
the O
active O
galaxy RARE
TXFS2226 NUMERIC
- O
184 NUMERIC
. O

Of O
the O
three O
known O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
inhibitors O
, O
Ig I-GENE
/ I-GENE
EBP I-GENE
, O
LIP ALLCAPS
and O
CHOP I-GENE
- I-GENE
10 I-GENE
, O
only O
Ig I-GENE
/ I-GENE
EBP I-GENE
is O
ubiquitously O
expressed O
. O

The O
effects O
of O
a O
1 O
- O
or O
24 O
- O
hour O
pretreatment O
regimen O
with O
monophosphoryl RARE
lipid O
A O
( O
MLA ALLCAPS
, O
35 O
micrograms O
/ O
kg O
i O
. O
v O
.) O
on O
myocardial O
stunning RARE
produced O
by O
repetitive O
coronary O
occlusions RARE
were O
studied O
in O
barbital RARE
- O
anesthetized O
dogs O
. O

These O
incisors RARE
were O
studied O
by O
scanning O
electron O
microscopy O
- O
energy O
dispersive RARE
spectroscopy O
analysis O
( O
SEM ALLCAPS
- O
EDS ALLCAPS
) O
and O
light O
microscopy O
to O
examine O
the O
calciotraumatic RARE
lines O
of O
strontium RARE
in O
the O
rat O
incisor RARE
labial RARE
dentin O
. O

A O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
( O
PDGF I-GENE
- I-GENE
R I-GENE
) O
phosphopeptide O
containing O
Tyr O
- O
857 NUMERIC
does O
not O
bind O
appreciably RARE
to O
the O
Src I-GENE
SH2 I-GENE
domain I-GENE
, O
suggesting O
it O
is O
not O
the O
PDGF I-GENE
- I-GENE
R I-GENE
binding O
site O
for O
Src I-GENE
as O
previously O
reported O
. O

We O
have O
also O
tested O
Src I-GENE
SH2 I-GENE
mutants O
for O
their O
binding O
properties O
and O
have O
interpreted O
our O
results O
in O
light O
of O
the O
recent O
crystal O
structure O
solution O
for O
the O
Src I-GENE
SH2 I-GENE
domain O
. O

These O
observations O
link O
actin I-GENE
plaque O
assembly O
to O
increased O
cell O
substrate O
adhesion O
. O

The O
early O
lethality O
of O
the O
left O
- O
sided RARE
resectio RARE
was O
0 O
% O
and O
the O
postoperative O
survival O
-- O
5 O
- O
10 O
months O
. O

There O
are O
two O
immunogenic RARE
sites O
on O
the O
type O
A O
influenza O
A O
/ O
Japan O
/ O
57 O
( O
H2N2 NUMERIC
) O
hemagglutinin I-GENE
( O
HA I-GENE
) O
that O
can O
be O
recognized O
by O
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
( O
MHC I-GENE
), O
H I-GENE
- I-GENE
2Kd NUMERIC
- O
restricted O
cytolytic RARE
T O
lymphocytes O
( O
CTLs RARE
). O

This O
enhancer O
activates O
both O
the O
K19 NUMERIC
and O
TK I-GENE
basal I-GENE
promoters I-GENE
in O
HeLa O
cells O
. O

Mechanism O
of O
enhancement O
of O
DNA O
expression O
consequent RARE
to O
cointernalization RARE
of O
a O
replication O
- O
deficient O
adenovirus O
and O
unmodified RARE
plasmid O
DNA O
. O

Interestingly O
, O
one O
IRF I-GENE
binding I-GENE
site I-GENE
was O
found O
within O
the O
IRF I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
, O
and O
expression O
of O
the O
IRF I-GENE
- I-GENE
2 I-GENE
gene I-GENE
was O
affected O
by O
both O
transient O
and O
stable O
IRF I-GENE
- I-GENE
1 I-GENE
expression O
. O

Therefore O
, O
we O
studied O
ninety RARE
coagulopathic RARE
patients O
with O
the O
aim O
of O
determining O
the O
prevalence O
of O
hepatitis I-GENE
C I-GENE
virus I-GENE
( I-GENE
HCV I-GENE
) I-GENE
antibodies I-GENE
using O
the O
ELISA O
and O
RIBA ALLCAPS
methods O
. O

The O
highest O
decrease O
in O
mutagenic RARE
activity O
was O
observed O
when O
enzymatic O
bleaching RARE
was O
used O
together O
with O
chlorine RARE
. O

Hepatitis I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
was O
detected O
in O
2 O
patients O
, O
with O
negative O
hepatitis I-GENE
C I-GENE
virus I-GENE
antibody I-GENE
. O

There O
was O
also O
a O
highly O
significant O
correlation O
between O
total O
selenium O
intake O
and O
liver O
selenium O
concentration O
( O
r O
= O
0 O
. O
99 O
, O
p O
< O
0 O
. O
01 O
) O
after O
1 O
mo O
of O
treatment O
, O
but O
this O
time O
liver O
selenium O
did O
not O
change O
with O
time O
, O
and O
the O
correlation O
remained O
highly O
significant O
throughout O
the O
investigation O
. O

Antibodies O
affinity O
- O
purified O
using O
the O
bacterially O
expressed O
recombinant O
protein O
recognized O
the O
56K NUMERIC
autoantigen RARE
in O
a O
HeLa O
cell O
extract O
. O
cDNA O
sequencing O
revealed O
that O
the O
56K NUMERIC
cDNA I-GENE
shares O
a O
high O
degree O
of O
homology O
in O
both O
nucleotide O
( O
87 O
%) O
and O
amino O
acid O
sequence O
( O
92 O
. O
5 O
%) O
with O
bovine I-GENE
annexin RARE
XI ALLCAPS
, O
indicating O
that O
the O
56K NUMERIC
cDNA I-GENE
encodes O
the O
human I-GENE
homologue I-GENE
of I-GENE
annexin RARE
XI ALLCAPS
, O
a O
member O
of O
the O
Ca I-GENE
( I-GENE
2 I-GENE
+)- I-GENE
dependent I-GENE
phospholipid I-GENE
binding I-GENE
protein I-GENE
family I-GENE
. O

The O
avidin RARE
- I-GENE
biotin RARE
complex I-GENE
peroxidase I-GENE
( O
ABC ALLCAPS
- I-GENE
P I-GENE
) O
method O
was O
used O
to O
detect O
Mycobacterium O
bovis RARE
, O
and O
the O
results O
were O
compared O
with O
those O
obtained O
by O
the O
Ziehl RARE
- O
Neelsen RARE
( O
ZN ALLCAPS
) O
technique O
. O

Its O
role O
in O
these O
processes O
suggests O
that O
the O
function O
of O
c I-GENE
- I-GENE
Myb I-GENE
may O
be O
important O
early O
in O
the O
establishment O
of O
the O
hematopoietic O
lineage O
. O

The O
transforming O
gene O
of O
the O
avian I-GENE
sarcoma I-GENE
virus I-GENE
CT10 NUMERIC
encodes O
a O
fusion O
protein O
( O
p47gag NUMERIC
- O
crk RARE
or O
v I-GENE
- I-GENE
Crk I-GENE
) O
containing O
viral I-GENE
Gag I-GENE
sequences I-GENE
fused O
to O
cellular O
sequences O
consisting O
primarily O
of O
Src I-GENE
homology I-GENE
regions I-GENE
2 I-GENE
and I-GENE
3 I-GENE
( O
SH2 I-GENE
and O
SH3 I-GENE
sequences I-GENE
). O

This O
specific O
methylation O
pattern O
caused O
inactivation O
of O
the O
HSV I-GENE
tk I-GENE
gene I-GENE
, O
while O
methylation O
of O
the O
cytosine O
residues O
within O
the O
nucleotide O
sequence O
from O
+ O
811 NUMERIC
to O
+ O
1309 NUMERIC
had O
no O
effect O
on O
HSV I-GENE
tk I-GENE
gene I-GENE
activity O
. O

CONCLUSION O
: O
This O
study O
documents RARE
that O
regression O
of O
choroidal RARE
neovascularization RARE
that O
occurred O
with O
alpha I-GENE
interferon I-GENE
treatment O
was O
minimal O
. O

Long RARE
- O
range O
mapping O
of O
the O
11q23 NUMERIC
region O
involved O
in O
chromosome O
aberrations RARE
in O
human O
tumors O
by O
pulsed O
- O
field O
gel O
electrophoresis O
with O
a O
yeast O
artificial O
chromosome O
. O

GTRE ALLCAPS
, O
TRE O
, O
and O
CRE O
oligonucleotides O
all O
compete O
more O
efficiently O
for O
protein O
binding O
to O
their O
labeled O
congeners RARE
than O
for O
protein O
binding O
to O
either O
of O
the O
other O
labeled O
oligonucleotides O
, O
suggesting O
that O
the O
GTRE ALLCAPS
, O
TRE O
, O
and O
CRE O
oligonucleotides O
, O
suggesting O
that O
the O
GTRE ALLCAPS
, O
TRE O
, O
and O
CRE O
oligonucleotides O
each O
bind O
unique O
as O
well O
as O
common O
proteins O
, O
likely O
to O
be O
members O
of O
the O
Jun I-GENE
/ O
Fos I-GENE
and O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
/ O
activating I-GENE
transcription I-GENE
factors I-GENE
( O
CREB I-GENE
/ O
ATF I-GENE
) O
families O
of O
transcription O
factors O
, O
in O
chromaffin RARE
cells O
. O

One O
patient O
only O
had O
any O
test O
abnormalities O
. O

One O
antibody O
, O
mAb1C2 NUMERIC
, O
and O
a O
synthetic O
peptide O
comprising RARE
its O
epitope O
selectively O
inhibited O
in O
vitro O
transcription O
from O
TATA O
- O
containing O
, O
but O
not O
from O
TATA O
- O
less O
promoters O
, O
irrespective O
of O
whether O
they O
were O
transcribed O
by O
Pol I-GENE
II I-GENE
or O
Pol I-GENE
III I-GENE
. O

The O
lymph O
nodes O
from O
two O
of O
the O
patients O
with O
rheumatoid O
arthritis O
contained O
numerous O
sarcoid RARE
like O
granulomata RARE
, O
further O
indicating O
a O
possible O
association O
between O
sarcoidosis RARE
and O
rheumatoid O
arthritis O
. O

HCV O
infection O
acquired O
during O
or O
after O
BMT ALLCAPS
caused O
only O
mild O
acute O
hepatitis O
C O
, O
which O
progressed O
to O
chronic O
hepatitis O
C O
in O
one O
patient O
surviving RARE
10 O
years O
after O
BMT ALLCAPS
. O

Hepatitis O
C O
virus O
infection O
is O
a O
risk O
factor O
for O
liver O
failure O
from O
veno RARE
- O
occlusive RARE
disease O
after O
bone O
marrow O
transplantation O
. O

High O
plasma O
concentrations O
of O
soluble O
E I-GENE
- I-GENE
selectin I-GENE
were O
closely O
associated O
with O
multiple O
- O
organ O
dysfunction O
and O
death O
. O

These O
human O
IFN I-GENE
- I-GENE
beta I-GENE
- O
transformed O
cell O
populations O
have O
acquired O
a O
low O
, O
constitutive O
production O
of O
human I-GENE
IFN I-GENE
, O
while O
replicating O
at O
a O
rate O
similar O
to O
that O
of O
untransformed RARE
cells O
and O
of O
cells O
transformed O
with O
the O
control O
vector O
carrying O
a O
human I-GENE
IFN I-GENE
- I-GENE
beta I-GENE
sequence I-GENE
encoding O
an O
inactive O
, O
mutated O
protein O
. O

Improvement RARE
of O
the O
polypyrimidine RARE
tract O
also O
increased O
the O
splicing O
efficiency O
, O
but O
to O
a O
degree O
slightly O
less O
than O
that O
obtained O
with O
the O
branchpoint O
mutation O
. O

Liver O
transplantation O
in O
one O
patient O
resolved O
metabolic O
complications O
but O
did O
not O
improve O
PMN O
count O
or O
the O
infectious O
status O
, O
while O
neutropenia O
was O
corrected O
by O
G I-GENE
- I-GENE
CSF I-GENE
. O

Joys RARE
and O
F O
. O

Activation O
of O
the O
SH2 I-GENE
- I-GENE
containing I-GENE
protein I-GENE
tyrosine I-GENE
phosphatase I-GENE
, O
SH I-GENE
- I-GENE
PTP2 NUMERIC
, O
by O
phosphotyrosine O
- O
containing O
peptides O
derived O
from O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
. O

Tyrosine O
phosphorylation O
of O
cellular O
proteins O
is O
the O
earliest RARE
identifiable RARE
event O
following O
T I-GENE
- I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
( O
TCR I-GENE
) O
stimulation O
and O
is O
essential O
for O
activating O
downstream O
signaling O
machinery O
. O

The O
interferon I-GENE
- O
induced O
RNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
is O
considered O
to O
play O
an O
important O
role O
in O
the O
cellular O
defense O
against O
viral O
infection O
and O
, O
in O
addition O
, O
has O
been O
suggested O
to O
be O
a O
tumor O
suppressor O
gene O
because O
of O
its O
growth O
- O
suppressive RARE
properties O
. O

Moreover O
, O
Lck I-GENE
was O
reversibly RARE
co O
- O
immunoprecipitated O
with O
p95Vav NUMERIC
, O
and O
the O
stoichiometry RARE
of O
binding O
increased O
in O
anti I-GENE
- I-GENE
CD3 I-GENE
- O
treated O
Jurkat O
cells O
. O

In O
contrast O
, O
injection O
of O
a O
plasmid O
encoding O
simian I-GENE
virus I-GENE
40 I-GENE
small I-GENE
t I-GENE
antigen I-GENE
, O
which O
interacts O
with O
PP2A I-GENE
to O
inhibit O
its O
activity O
towards O
several O
phosphoprotein O
substrates O
, O
had O
no O
effect O
on O
the O
phosphorylation O
state O
of O
CREB I-GENE
in O
stimulated O
or O
unstimulated O
NIH O
3T3 O
cells O
. O

Several O
Src I-GENE
SH3 I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
were O
phosphorylated O
in O
Src I-GENE
- O
transformed O
cells O
. O

We O
also O
examined O
the O
effect O
of O
proteolytic O
processing O
in O
the O
MVE ALLCAPS
nonstructural RARE
polyprotein RARE
segment O
mediated O
by O
the O
viral I-GENE
proteinase I-GENE
NS3 I-GENE
on O
antigen O
processing O
and O
presentation O
of O
the O
MVE ALLCAPS
H O
- O
2Kk NUMERIC
- O
restricted O
T O
cell O
determinant O
. O

A O
full I-GENE
- I-GENE
length I-GENE
PRL I-GENE
receptor I-GENE
( O
PRLR ALLCAPS
) O
complementary O
DNA O
from O
pigeons RARE
was O
obtained O
by O
screening O
pigeon RARE
crop RARE
sac RARE
libraries O
and O
by O
reverse O
transcription O
coupled O
with O
polymerase O
chain O
reaction O
. O

After O
7 O
days O
, O
a O
spontaneous O
regression O
of O
the O
morphologic O
alterations O
caused O
by O
caerulein RARE
- O
induced O
acute O
pancreatitis O
occurs O
; O
however O
, O
recovery O
of O
the O
secretory O
function O
of O
the O
pancreas O
was O
only O
reached O
after O
this O
period O
of O
time O
when O
L O
- O
364 NUMERIC
, O
718 NUMERIC
was O
administered O
therapeutically RARE
( O
0 O
. O
1 O
mg O
/ O
kg O
/ O
day O
). O

We O
observed O
that O
dephosphorylation RARE
severely O
inhibits O
the O
DNA O
- O
binding O
ability O
of O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
delta I-GENE
and O
its O
transactivating O
potential O
increases O
in O
the O
presence O
of O
cellular O
phosphatase O
inhibitors O
, O
such O
as O
okadaic RARE
acid O
and O
sodium O
orthovanadate RARE
. O

Two O
promoters O
were O
identified O
by O
S1 I-GENE
nuclease I-GENE
mapping O
: O
P1 O
, O
which O
lies O
about O
72 O
bp O
upstream O
from O
the O
structural O
gene O
; O
and O
P2 O
, O
which O
lies O
about O
35 O
bp O
upstream O
. O

Interleukin I-GENE
- I-GENE
8 I-GENE
( O
IL I-GENE
- I-GENE
8 I-GENE
) O
is O
a O
potent O
inflammatory O
mediator RARE
that O
belongs O
to O
the O
family O
of O
C I-GENE
- I-GENE
X I-GENE
- I-GENE
C I-GENE
chemokines RARE
. O

On O
the O
other O
hand O
, O
cells O
containing O
a O
PTP1C NUMERIC
in O
which O
the O
catalytic O
site O
had O
been O
inactivated O
through O
mutagenesis O
, O
stably O
phosphorylated O
the O
phosphatase O
. O

We O
recently O
found O
that O
the O
p72syk NUMERIC
protein I-GENE
tyrosine I-GENE
kinase I-GENE
is O
physically O
associated O
with O
the O
TCR I-GENE
/ O
CD3 I-GENE
complex O
and O
is O
rapidly O
tyrosine O
phosphorylated O
and O
activated O
by O
receptor O
triggering RARE
also O
in O
T O
cells O
lacking O
p56lck NUMERIC
. O

The O
transforming O
protein O
of O
Rous O
sarcoma O
virus O
, O
pp60v NUMERIC
- I-GENE
src I-GENE
, O
and O
its O
normal O
cellular O
homolog O
, O
pp60c NUMERIC
- I-GENE
src I-GENE
, O
differ O
not O
only O
in O
oncogenic O
potential O
but O
also O
in O
their O
subcellular O
localization O
and O
cytoskeletal O
binding O
ability O
. O
pp60v NUMERIC
- I-GENE
src I-GENE
has O
been O
shown O
to O
stably O
associate O
with O
a O
detergent O
- O
insoluble RARE
cytoskeletal O
matrix O
, O
whereas O
pp60c NUMERIC
- I-GENE
src I-GENE
does O
not O
. O

Organization O
of O
the O
bovine O
gene O
encoding O
the O
endothelial I-GENE
nitric I-GENE
oxide I-GENE
synthase I-GENE
. O

We O
determined O
whether O
regional O
myocardial O
work O
efficiency O
( O
segment O
work O
/ O
regional O
O2 O
consumption O
) O
would O
be O
elevated O
by O
surgically O
- O
augmented O
inflow RARE
. O

In O
female O
Sl RARE
( I-GENE
pan RARE
)/ I-GENE
Sl RARE
( I-GENE
pan RARE
) I-GENE
mice O
, O
ovarian O
follicle O
development O
is O
arrested O
at O
the O
one O
layered RARE
cuboidal RARE
stage O
as O
a O
result O
of O
reduced O
KL ALLCAPS
expression O
in O
follicle O
cells O
, O
indicating O
a O
role O
for O
c I-GENE
- I-GENE
kit I-GENE
in O
oocyte O
growth O
. O

Anti I-GENE
- I-GENE
NPROSP ALLCAPS
- I-GENE
C I-GENE
also O
exclusively O
detected O
time O
- O
dependent O
appearances RARE
of O
5 I-GENE
- I-GENE
10 I-GENE
- I-GENE
kDa I-GENE
proSP LASTCAP
- I-GENE
C I-GENE
forms O
in O
lamellar RARE
bodies O
and O
homogenates RARE
. O

In O
the O
B6 O
- O
derived O
Db RARE
mutant I-GENE
B6 I-GENE
. I-GENE
CH ALLCAPS
- I-GENE
2bm13 NUMERIC
( I-GENE
bm13 NUMERIC
) I-GENE
strain O
, O
part O
of O
the O
class I-GENE
I I-GENE
Db RARE
antigen I-GENE
- I-GENE
presenting I-GENE
groove I-GENE
is O
shaped O
by O
a O
class I-GENE
I I-GENE
Kb RARE
- I-GENE
encoded I-GENE
sequence I-GENE
. O

Three O
mutants O
( O
pms1 NUMERIC
, O
pms2 NUMERIC
and O
pms3 NUMERIC
) O
isolated O
earlier O
from O
MW104 NUMERIC
- O
1B O
were O
shown O
to O
correct O
in O
vitro O
constructed O
plasmids O
with O
defined O
DNA O
mismatches RARE
( O
G O
/ O
T O
, O
A O
/ O
C O
, O
G O
/ O
G O
, O
etc O
.) O
poorly O
( O
Kramer RARE
et O
al O
., O
1989a NUMERIC
). O

Our O
findings O
confirm O
the O
high O
frequency O
of O
proximal O
nerve O
lesions O
in O
early O
GBS ALLCAPS
and O
CIDP ALLCAPS
, O
not O
all O
of O
which O
are O
associated O
with O
distal O
motor O
conduction O
abnormalities O
, O
and O
suggest O
that O
assessment O
of O
multiple O
F O
wave O
parameters O
, O
in O
particular O
chronodispersion RARE
, O
mean O
latency O
and O
mean O
amplitude O
( O
in O
addition O
to O
absence O
and O
minimum O
latency O
), O
increases O
the O
yield O
of O
F O
wave O
studies O
. O

Hematopoietic RARE
growth I-GENE
factors I-GENE
are O
being O
used O
to O
accelerate RARE
the O
recovery O
of O
myelopoiesis RARE
following O
high O
- O
dose O
chemotherapy O
in O
cancer O
patients O
. O

Effects O
of O
alterations O
of O
primer O
- O
binding O
site O
sequences O
on O
human O
immunodeficiency O
virus O
type O
1 O
replication O
. O

Presentation RARE
of O
a O
horse I-GENE
cytochrome I-GENE
c I-GENE
peptide I-GENE
by O
multiple O
H I-GENE
- I-GENE
2b I-GENE
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
( O
MHC I-GENE
) O
molecules O
to O
C57BL O
/ O
6 O
- O
and O
bm1 NUMERIC
- O
derived O
cytotoxic O
T O
lymphocytes O
: O
presence O
of O
a O
single O
MHC I-GENE
anchor I-GENE
residue I-GENE
may O
confer O
efficient O
peptide O
- O
specific O
CTL O
recognition O
. O

A O
particularly O
striking O
HpaII LASTCAP
tiny RARE
fragment O
island O
, O
extending O
over O
nearly O
2 O
, O
000 O
base O
pairs O
, O
surrounds RARE
the O
USF2 NUMERIC
translation I-GENE
initiation I-GENE
site I-GENE
. O

Diagnosis O
of O
prostatic O
carcinoma O
: O
the O
yield O
of O
serum I-GENE
prostate I-GENE
specific I-GENE
antigen I-GENE
, O
digital O
rectal O
examination O
and O
transrectal RARE
ultrasonography O
. O

Increased O
granulocyte I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
G I-GENE
- I-GENE
CSF I-GENE
) O
levels O
in O
neonates O
with O
perinatal RARE
complications O
. O

The O
results O
revealed O
a O
hierarchy RARE
of O
ligand O
affinities O
that O
mirrored RARE
their O
adhesive O
activity O
( O
rsVCAM LASTCAP
- I-GENE
1 I-GENE
> O
fibronectin I-GENE
variants I-GENE
containing O
CS1 NUMERIC
>> RARE
other O
fibronectin I-GENE
variants I-GENE
). O

When O
expressed O
in O
and O
purified O
from O
Escherichia O
coli O
, O
both O
full I-GENE
- I-GENE
length I-GENE
Fpr3 NUMERIC
and O
its O
isolated O
COOH O
- O
terminal O
domain O
exhibit O
readily O
detectable O
PPIase RARE
activity O
. O

Dilutions RARE
of O
H I-GENE
- I-GENE
2b I-GENE
or I-GENE
H I-GENE
- I-GENE
2d NUMERIC
NP I-GENE
peptides I-GENE
indicated O
that O
3 O
- O
4 O
logs RARE
less O
H I-GENE
- I-GENE
2b I-GENE
NP I-GENE
peptide I-GENE
was O
required O
to O
sensitize RARE
syngeneic RARE
target O
cells O
for O
CTL O
- O
specific O
lysis O
, O
suggesting O
that O
the O
differing RARE
affinities O
of O
H O
- O
2b O
and O
H O
- O
2d NUMERIC
major I-GENE
histocompatibility I-GENE
complex I-GENE
molecules I-GENE
for O
their O
peptides O
likely O
account O
for O
the O
total O
removal O
of O
NP O
CTL O
in O
the O
H O
- O
2b O
mice O
but O
only O
partial O
removal O
in O
H O
- O
2d NUMERIC
mice O
made O
to O
express O
thymic O
NP O
. O

However O
, O
expression O
of O
sigma I-GENE
3 I-GENE
from O
S4 I-GENE
( O
3 I-GENE
' I-GENE
UTR I-GENE
/ I-GENE
S1 I-GENE
), O
which O
included O
the O
PKR I-GENE
activator I-GENE
sequence I-GENE
from O
S1 I-GENE
within O
the O
3 I-GENE
'- I-GENE
UTR I-GENE
of I-GENE
S4 I-GENE
, O
was O
comparable O
to O
that O
from O
wild I-GENE
- I-GENE
type I-GENE
S4 I-GENE
. O

Microvessels RARE
were O
counted RARE
in O
a O
x200 NUMERIC
field O
( O
0 O
. O
754 NUMERIC
mm2 O
) O
in O
the O
area O
of O
maximal O
angiogenesis O
. O

Although O
both O
transfected O
cell O
lines O
contain O
FGF I-GENE
- I-GENE
1 I-GENE
cell I-GENE
surface I-GENE
receptors I-GENE
as O
judged O
by O
crosslinking RARE
studies O
, O
the O
wild O
- O
type O
transfectants O
are O
refractory O
to O
exogenous O
FGF I-GENE
- I-GENE
1 I-GENE
, O
whereas O
the O
mutant O
transfectants O
respond O
normally O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Recent O
studies O
have O
demonstrated O
that O
the O
activated O
GH I-GENE
receptor I-GENE
can O
stimulate O
Stat1 NUMERIC
, O
a O
cytoplasmic O
transcription O
factor O
that O
becomes O
tyrosine O
phosphorylated O
and O
translocates RARE
to O
the O
nucleus O
, O
where O
it O
can O
interact O
with O
specific O
DNA O
sequences O
to O
modulate O
gene O
expression O
. O

In O
viral O
infections O
, O
G I-GENE
- I-GENE
CSF I-GENE
was O
correlated O
with O
mononuclear O
cells O
( O
rs O
= O
0 O
. O
41 O
, O
P O
< O
0 O
. O
05 O
), O
white O
blood O
cell O
counts O
( O
rs O
= O
0 O
. O
56 O
, O
P O
< O
0 O
. O
01 O
), O
neutrophils O
( O
rs O
= O
0 O
. O
41 O
, O
P O
< O
0 O
. O
05 O
) O
and O
CRP I-GENE
( O
rs O
= O
0 O
. O
47 O
, O
P O
< O
0 O
. O
05 O
). O

Minor RARE
initiation O
sites O
were O
found O
at O
positions O
- O
128 O
, O
- O
111 O
, O
- O
91 O
, O
and O
- O
74 O
. O

Phosphoamino RARE
acid O
analysis O
of O
radiolabeled O
ASGPR ALLCAPS
subunits I-GENE
identified O
Ser O
( O
P O
) O
as O
the O
predominant O
( O
approximately O
95 O
%) O
and O
Thr O
( O
P O
) O
as O
a O
minor O
( O
approximately O
5 O
%) O
phosphoamino RARE
acid O
in O
each O
polypeptide O
and O
confirmed O
the O
presence O
of O
Tyr O
( O
P O
) O
( O
approximately O
1 O
%) O
in O
RHL1 NUMERIC
. O

To O
further O
define O
the O
structural O
requirements O
for O
ZAP I-GENE
- I-GENE
70 I-GENE
interaction O
with O
the O
TCR I-GENE
, O
we O
developed O
a O
binding O
assay O
using O
immobilized RARE
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
proteins I-GENE
containing O
the O
NH2 O
- O
and O
/ O
or O
COOH I-GENE
- I-GENE
terminal I-GENE
SH2 I-GENE
domains I-GENE
of O
ZAP I-GENE
- I-GENE
70 I-GENE
, O
and O
soluble O
synthetic O
peptides O
with O
the O
sequence O
of O
the O
cytoplasmic O
region O
of O
the O
TCR I-GENE
zeta I-GENE
chain I-GENE
( O
TCR I-GENE
zeta I-GENE
cyt I-GENE
) O
or O
individual O
TCR I-GENE
zeta I-GENE
and O
CD3 I-GENE
epsilon I-GENE
TAM ALLCAPS
motifs I-GENE
. O

All O
four O
doubly RARE
tyrosine O
phosphorylated O
TAM ALLCAPS
peptides O
cross O
- O
compete O
with O
each O
other O
for O
binding O
to O
the O
tandem O
SH2 I-GENE
domains I-GENE
of O
ZAP I-GENE
- I-GENE
70 I-GENE
. O

The O
three O
- O
dimensional O
structure O
of O
RT I-GENE
shows O
that O
it O
is O
a O
strikingly O
asymmetric O
heterodimer O
consisting O
of O
two O
differently O
folded O
subunits O
( O
molecular O
weights O
66 O
kDa O
and O
51 O
kDa O
) O
with O
identical O
amino O
- O
terminal O
amino O
acid O
sequences O
( O
residues O
1 O
- O
428 NUMERIC
). O

Pharmacological RARE
and O
pharmacokinetic O
characteristics O
of O
the O
non O
- O
ionic O
monomeric O
X O
- O
ray O
contrast O
agent O
iopromide RARE
( O
Ultravist RARE
, O
CAS O
73334 NUMERIC
- O
07 O
- O
3 O
) O
were O
evaluated O
in O
preclinical RARE
studies O
. O

All O
subsequent O
patients O
were O
treated O
at O
the O
maximal O
tolerated O
dose O
of O
EDXR ALLCAPS
( O
35 O
mg O
/ O
m2 O
/ O
day O
). O

The O
median O
post O
- O
treatment O
, O
pre O
- O
operative O
serum I-GENE
PSA I-GENE
was O
0 O
. O
4 O
ng O
/ O
ml O
. O

Addition O
of O
soluble O
recombinant I-GENE
human I-GENE
SLF ALLCAPS
to O
SI4 NUMERIC
- O
h220 NUMERIC
cultures O
enhanced O
reduction O
of O
cell O
- O
surface O
c I-GENE
- I-GENE
kit I-GENE
expression O
and O
its O
protein O
degradation O
. O

Membrane RARE
- O
bound O
Steel RARE
factor I-GENE
induces O
more O
persistent O
tyrosine I-GENE
kinase I-GENE
activation O
and O
longer O
life O
span O
of O
c I-GENE
- I-GENE
kit I-GENE
gene O
- O
encoded O
protein O
than O
its O
soluble O
form O
. O

Analysis O
of O
the O
sequences O
with O
the O
BLAST ALLCAPS
and O
GRAIL ALLCAPS
programs O
provided O
additional O
independent O
evidence O
that O
15 O
of O
these O
17 O
clones O
contain O
coding O
sequences O
and O
that O
nine O
other O
clones O
are O
likely O
to O
contain O
sequences O
coding O
for O
portions O
of O
new O
genes O
. O

Patients O
with O
more O
than O
250 O
PVC ALLCAPS
/ O
24 O
hours O
were O
selected O
for O
distribution O
of O
PVC ALLCAPS
and O
CI O
evaluation O
. O

Horvath RARE
, O
I O
. O

Cell O
lines O
derived O
from O
the O
tumors O
were O
examined O
by O
fluorescent O
in O
situ O
hybridization O
for O
the O
status O
of O
the O
transferred O
human O
chromosome O
and O
by O
PCR O
for O
marker O
loss O
. O

The O
amino O
acid O
sequences O
of O
the O
predicted O
RfbA LASTCAP
and O
RfbB LASTCAP
homologs I-GENE
showed O
identities O
of O
75 O
. O
7 O
% O
( O
87 O
. O
9 O
% O
total O
similarity O
) O
and O
78 O
. O
0 O
% O
( O
86 O
. O
5 O
% O
total O
similarity O
), O
respectively O
. O

However O
, O
multiple O
alanine O
substitutions O
or O
proline O
( O
helix O
- O
destabilizing RARE
) O
substitutions O
disrupted O
both O
oligomerization O
and O
transport O
of O
GP64 NUMERIC
EFP ALLCAPS
. O

The O
FinO LASTCAP
protein I-GENE
of O
IncF LASTCAP
plasmids O
binds O
FinP LASTCAP
antisense I-GENE
RNA I-GENE
and O
its O
target O
, O
traJ LASTCAP
mRNA I-GENE
, O
and O
promotes O
duplex O
formation O
. O

In O
this O
paper O
we O
report O
that O
ligand O
binding O
induced O
tyrosine O
phosphorylation O
in O
BaF3 NUMERIC
cells O
engineered O
to O
express O
the O
murine I-GENE
Mpl RARE
receptor I-GENE
( O
BaF3 NUMERIC
/ O
mMpl RARE
). O

A O
chicken I-GENE
paxillin I-GENE
cDNA I-GENE
was O
also O
cloned O
and O
is O
predicted O
to O
encode O
a O
protein O
approximately O
90 O
% O
identical O
to O
human I-GENE
paxil RARE
- I-GENE
lin RARE
. O

We O
linked O
a O
4 O
. O
1 O
- O
kilobase O
pair O
HindIII I-GENE
DNA I-GENE
fragment I-GENE
from O
the O
region O
upstream O
of O
the O
human I-GENE
AP I-GENE
endonuclease I-GENE
gene I-GENE
( O
APE ALLCAPS
) O
to O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene O
. O

The O
overexpressed O
His6 NUMERIC
- I-GENE
tagged I-GENE
GrsA LASTCAP
derivatives I-GENE
were O
affinity O
- O
purified O
, O
and O
the O
catalytic O
properties O
of O
the O
deletion O
mutants O
were O
examined O
by O
biochemical O
studies O
including O
ATP O
- O
dependent O
amino O
acid O
activation O
, O
carboxyl O
thioester RARE
formation O
, O
and O
the O
ability O
to O
racemize RARE
the O
covalently O
bound O
phenylalanine O
from O
L O
- O
to O
the O
D O
- O
isomer RARE
. O

CD7 NUMERIC
+/ O
CD3 I-GENE
- O
T O
- O
cell O
precursors O
exhibit O
V I-GENE
delta I-GENE
2D NUMERIC
delta I-GENE
3 I-GENE
rearrangements I-GENE
. O

HVH2 NUMERIC
mRNA I-GENE
showed O
an O
expression O
pattern O
distinct O
from O
CL100 NUMERIC
( O
human I-GENE
homologue I-GENE
of I-GENE
mouse I-GENE
MKP1 NUMERIC
) O
and O
PAC1 NUMERIC
, O
two O
previously O
identified O
MAP I-GENE
kinase I-GENE
phosphatases I-GENE
. O

These O
data O
suggest O
that O
these O
sequences O
located O
immediately O
3 O
' O
to O
the O
breakpoint O
of O
the O
HPFH ALLCAPS
- I-GENE
3 I-GENE
deletion I-GENE
, O
exhibit O
both O
the O
structure O
and O
the O
function O
of O
an O
enhancer O
, O
and O
can O
modify O
the O
developmental O
specificity O
of O
the O
fetal I-GENE
gamma I-GENE
- I-GENE
globin I-GENE
genes I-GENE
, O
resulting O
in O
their O
continued O
expression O
during O
adult O
life O
. O

In O
vivo O
association O
between O
Shb RARE
- O
SH3 I-GENE
domain O
proteins O
v I-GENE
- I-GENE
Src I-GENE
and O
Eps8 NUMERIC
was O
detected O
by O
coimmunoprecipitation RARE
. O

Our O
results O
indicate O
that O
interaction O
between O
Jak2 NUMERIC
and O
PRLR ALLCAPS
requires O
a O
proline O
- O
rich O
sequence O
in O
the O
membrane O
proximal O
region O
of O
the O
receptor O
, O
which O
is O
conserved O
among O
the O
different O
members O
of O
the O
cytokine I-GENE
receptor I-GENE
superfamily I-GENE
. O

Transcription O
of O
the O
vascular I-GENE
cell I-GENE
adhesion I-GENE
molecule I-GENE
1 I-GENE
( O
VCAM ALLCAPS
- I-GENE
1 I-GENE
) O
gene O
in O
endothelial O
cells O
is O
induced O
by O
lipopolysaccharide O
and O
the O
inflammatory O
cytokines I-GENE
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
). O

Experiments O
with O
recombinant O
proteins O
showed O
that O
p50 I-GENE
/ O
p65 I-GENE
and O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
protein I-GENE
cooperatively RARE
facilitated O
the O
binding O
of O
IRF I-GENE
- I-GENE
1 I-GENE
to O
the O
VCAM1 NUMERIC
IRF I-GENE
binding I-GENE
site I-GENE
and O
that O
IRF I-GENE
- I-GENE
1 I-GENE
physically O
interacted O
with O
p50 I-GENE
and O
with O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
protein I-GENE
. O

Based O
on O
these O
results O
the O
minimal O
control O
element O
( O
AX ALLCAPS
470 NUMERIC
) O
specifying RARE
the O
anterior O
boundary O
of O
Hox I-GENE
expression O
was O
designated O
as O
Hoxa RARE
- I-GENE
7 I-GENE
enhancer I-GENE
. O

In O
this O
report O
we O
describe O
the O
isolation O
of O
a O
Fab RARE
fragment I-GENE
( O
Fab RARE
A8 NUMERIC
) O
showing O
a O
high O
relative O
affinity O
for O
the O
receptor O
( O
0 O
. O
5 O
nM O
). O

MBP I-GENE
- O
Rep68 NUMERIC
delta I-GENE
- O
mediated O
DNA O
- O
RNA O
helicase O
activity O
required O
ATP O
hydrolysis O
and O
the O
presence O
of O
Mg2 NUMERIC
+ O
ions O
and O
was O
inhibited O
by O
high O
ionic O
strength O
. O

To O
identify O
critical O
regions O
mediating O
growth O
signal O
transduction O
by O
hG LASTCAP
- I-GENE
CSFR ALLCAPS
, O
deletions O
or O
site O
- O
directed O
amino O
acid O
substitutions O
were O
introduced O
into O
the O
cytoplasmic O
domain O
of O
hG LASTCAP
- I-GENE
CSFR ALLCAPS
, O
and O
the O
mutant O
cDNAs O
were O
transfected O
into O
the O
murine I-GENE
interleukin I-GENE
- I-GENE
3 I-GENE
( O
IL I-GENE
- I-GENE
3 I-GENE
)- O
dependent O
Ba RARE
/ O
F3 NUMERIC
and O
FDCP ALLCAPS
cell O
lines O
. O

When O
combined O
with O
independent O
activating O
mutations O
in O
the O
c I-GENE
- I-GENE
abl I-GENE
kinase I-GENE
domain I-GENE
or O
NH2 O
- O
terminus O
, O
the O
G128R NUMERIC
mutation O
blocked O
transformation O
by O
the O
double O
mutant O
, O
suggesting O
that O
the O
G128R NUMERIC
mutant I-GENE
was O
unable O
to O
transform O
cells O
for O
trivial RARE
reasons RARE
. O

Both O
mutations O
completely O
abolished O
binding O
of O
the O
Abl I-GENE
SH3 I-GENE
domain O
to O
proline O
- O
rich O
target O
proteins O
in O
a O
filter O
- O
binding O
assay O
. O

Changes O
induced O
in O
the O
gills RARE
of O
milkfish RARE
( O
Chanos RARE
chanos RARE
Forsskal RARE
) O
fingerlings RARE
after O
acute O
exposure O
to O
nifurpirinol RARE
( O
Furanace RARE
; O
P O
- O
7138 NUMERIC
). O

Retreatment RARE
of O
these O
2 O
dogs O
resulted O
in O
a O
similar O
, O
but O
blunted RARE
, O
response O
to O
human I-GENE
immunoglobulin I-GENE
. O

The O
levels O
of O
NSE ALLCAPS
and O
MBP I-GENE
in O
the O
IJVB ALLCAPS
were O
compared O
to O
those O
in O
the O
PVB ALLCAPS
. O

As O
expected O
, O
the O
insulin I-GENE
effect O
to O
increase O
ras I-GENE
GTP I-GENE
formation O
and O
MAP I-GENE
kinase I-GENE
activity O
was O
negligible RARE
in O
A O
/ O
K1018 NUMERIC
cells O
but O
normal O
, O
or O
supernormal RARE
, O
in O
Y O
/ O
F2 O
cells O
. O

Morphologic RARE
variables O
included O
cancer O
volume O
, O
histologic O
grade O
, O
capsular RARE
penetration O
, O
seminal O
vesicle O
invasion O
, O
and O
lymph O
node O
metastasis O
. O

Sequence O
analysis O
of O
these O
regions O
showed O
a O
CAAT O
box O
upstream O
of O
exon O
1a O
and O
high O
G O
- O
C O
content O
regions O
within O
both O
P1 O
and O
P2 O
. O

The O
fusion O
proteins O
were O
tested O
by O
ELISA O
for O
reactivity O
with O
a O
panel O
of O
human I-GENE
anti I-GENE
- I-GENE
La I-GENE
sera I-GENE
in O
order O
to O
define O
the O
nature O
of O
the O
epitopes O
. O

GCD10 NUMERIC
was O
first O
identified O
genetically O
as O
a O
translational O
repressor O
of O
GCN4 I-GENE
. O

GCD10 NUMERIC
binds O
RNA O
in O
vitro O
and O
we O
present O
strong O
biochemical O
evidence O
that O
it O
is O
identical O
to O
the O
RNA O
- O
binding O
subunit O
of O
yeast I-GENE
initiation I-GENE
factor I-GENE
- I-GENE
3 I-GENE
( O
eIF I-GENE
- I-GENE
3 I-GENE
). O
eIF I-GENE
- I-GENE
3 I-GENE
is O
a O
multisubunit O
complex O
that O
stimulates O
translation O
initiation O
in O
vitro O
at O
several O
different O
steps O
. O

Sources RARE
of O
noise O
in O
these O
signals O
were O
evaluated O
in O
preparations O
stained O
with O
the O
potentiometric RARE
probe O
RH O
- O
414 NUMERIC
. O

1993 O
. O

A O
transformation O
- O
competent O
mutant O
, O
like O
the O
wild I-GENE
- I-GENE
type I-GENE
E5 NUMERIC
protein I-GENE
, O
bound O
the O
receptor O
and O
induced O
receptor O
tyrosine O
phosphorylation O
and O
down O
- O
regulation O
. O

We O
conclude O
that O
cAMP O
, O
acting O
through O
PKA I-GENE
, O
is O
an O
essential O
regulator O
of O
basal O
CFTR I-GENE
gene I-GENE
expression O
and O
may O
mediate O
an O
induction O
of O
CFTR I-GENE
in O
responsive O
cell O
types O
. O

Appropriate RARE
restriction O
sites O
allow O
one O
to O
insert O
virtually O
any O
desired RARE
cDNA O
fragment O
directly O
behind O
the O
epitope O
- O
specific O
sequence O
and O
before O
a O
long O
poly O
( O
A O
) O
tail O
. O

Both O
PPC ALLCAPS
- O
1 O
and O
ALVA ALLCAPS
- O
31 O
cells O
display O
tumorigenesis O
and O
invasiveness RARE
in O
nude O
mice O
, O
whereas O
LNCap RARE
cells O
exhibit O
a O
less O
malignant O
phenotype O
, O
suggesting O
a O
correlation O
between O
CD44 I-GENE
variant I-GENE
( O
CD44v NUMERIC
) O
expression O
and O
aggressive O
prostate O
tumor O
behavior O
. O

The O
gene O
product O
of O
cotS LASTCAP
was O
confirmed O
to O
be O
identical O
to O
Cot40 NUMERIC
- I-GENE
2 I-GENE
by O
SDS O
- O
PAGE O
and O
immunoblotting RARE
from O
Escherichia O
coli O
transformed O
with O
a O
plasmid O
containing O
the O
cotS LASTCAP
region I-GENE
. O

Two O
such O
genes O
, O
designated O
hsiggll150 NUMERIC
and O
hsiggll295 NUMERIC
, O
were O
cloned O
and O
sequenced O
from O
genomic O
DNA O
. O

A O
retrospective O
epidemiological O
study O
is O
reported O
concerning O
burn O
injuries O
in O
775 NUMERIC
children O
hospitalized O
at O
the O
unit O
of O
burn O
care O
of O
Casablanca RARE
between O
1985 O
and O
1993 O
. O

Our O
results O
suggest O
that O
protein O
binding O
to O
the O
E2F I-GENE
- I-GENE
like I-GENE
sequences I-GENE
may O
act O
to O
reduce O
expression O
. O

The O
RAD6 NUMERIC
/ O
UBC2 NUMERIC
gene O
from O
Saccharomyces O
cerevisiae O
encodes O
a O
ubiquitin I-GENE
- I-GENE
conjugating RARE
enzyme I-GENE
involved O
in O
DNA O
repair O
, O
induced O
mutagenesis O
, O
and O
sporulation O
. O

Echocardiography RARE
revealed O
right O
ventricular O
diastolic O
collapse RARE
( O
RVDC ALLCAPS
) O
without O
physical O
signs O
of O
cardiac O
tamponade RARE
. O

In O
on O
- O
going RARE
screening O
programmes RARE
, O
the O
Haemoccult RARE
test O
consists O
of O
six O
slides RARE
and O
a O
test O
is O
considered O
positive O
if O
at O
least O
one O
slide RARE
is O
coloured RARE
. O

We O
showed O
previously O
that O
a O
fusion O
protein O
( O
GAL4 I-GENE
- O
p40 I-GENE
) O
containing O
the O
DNA O
- O
binding O
domain O
of O
GAL4 I-GENE
and O
sequences O
of O
chicken I-GENE
l I-GENE
kappa I-GENE
B I-GENE
- I-GENE
alpha I-GENE
( O
p40 I-GENE
) O
inhibits O
growth O
in O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

We O
have O
demonstrated O
previously O
that O
two O
binding O
sites O
in O
the O
- I-GENE
184 NUMERIC
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
promoter I-GENE
are O
recognized O
by O
widely O
distributed O
factors O
and O
that O
there O
is O
also O
a O
critical O
autoregulatory RARE
site O
, O
we O
identified O
a O
binding O
site O
for O
a O
cell O
- O
specific O
factor O
, O
LF ALLCAPS
- I-GENE
H3 I-GENE
beta I-GENE
, O
that O
may O
function O
in O
restricting RARE
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
gene I-GENE
expression O
to O
hepatocytes O
. O

In O
4 O
spinalized RARE
cats O
, O
the O
effects O
of O
afferent RARE
inputs O
from O
hindlimb RARE
cutaneous O
nerves O
( O
sural RARE
cutaneous O
nerve O
: O
Sur RARE
) O
on O
mono O
- O
and O
poly O
- O
synaptic O
reflex O
recorded O
from O
tail O
muscle O
motoneurons RARE
were O
studied O
before O
and O
after O
spinal O
lesioning RARE
at O
S2 O
- O
3 O
level O
. O

The O
flow O
rate O
of O
phosphate O
buffered RARE
saline O
through O
dermis RARE
was O
measured O
as O
a O
function O
of O
applied O
pressure O
. O

However O
, O
parallax RARE
measurements O
showed O
that O
at O
150K NUMERIC
, O
collapse RARE
of O
Epon RARE
sections O
does O
not O
take O
place O
. O

Although O
within O
normal O
limits O
, O
latency O
was O
high O
. O

The O
outcome O
of O
the O
optimization RARE
of O
the O
seven O
- O
field O
plan RARE
prompted RARE
an O
investigation O
into O
the O
best O
results O
that O
could O
be O
achieved O
by O
an O
" O
ideal RARE
" O
conformal RARE
radiotherapy O
technique O
. O

Specific O
requirements O
for O
branched O
- O
chain O
amino O
acids O
, O
glutamine O
, O
and O
arginine O
are O
evaluated O
. O

The O
pea RARE
rps10 NUMERIC
intron I-GENE
is O
homologous O
to O
introns O
in O
rrn26 NUMERIC
and O
cox3 NUMERIC
in O
the O
Marchantia RARE
mitochondrial O
genome O
, O
while O
the O
Marchantia RARE
rps10 NUMERIC
gene I-GENE
lacks O
an O
intron O
. O

The O
optimal O
care O
of O
CHF ALLCAPS
patient O
includes O
the O
recognition O
and O
management O
of O
these O
electrolyte RARE
disturbances O
. O

Serum O
magnesium O
in O
79 O
patients O
of O
gynecologic O
neoplasms O
treated O
with O
cisplatin O
and O
their O
controls O
was O
measured O
. O

METHODS O
: O
rHb1 NUMERIC
. I-GENE
1 I-GENE
or O
human I-GENE
serum I-GENE
albumin I-GENE
was O
administered O
intravenously O
to O
fasting O
male O
volunteers O
. O

Alanine RARE
aminotransferase I-GENE
( O
ALT ALLCAPS
) O
levels O
had O
been O
elevated O
for O
six O
months O
in O
all O
patients O
and O
hepatitis O
B O
viral O
infection O
was O
replicative O
. O

In O
this O
study O
we O
have O
investigated O
the O
role O
of O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
in O
initiating O
the O
adipogenic RARE
program O
by O
overexpressing O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
in O
multipotential RARE
NIH O
- O
3T3 O
fibroblasts O
. O

XYL1 NUMERIC
was O
isolated O
as O
a O
highly O
expressed O
fusion O
clone O
from O
a O
' I-GENE
lacZ I-GENE
translational O
fusion O
library O
. O

Various O
transcripts O
are O
generated O
from O
the O
VCSA1 NUMERIC
gene I-GENE
by O
alternative O
splicing O
and O
poly O
( O
A O
) O
processing O
in O
the O
rat O
submandibular RARE
gland O
. O

However O
, O
division O
of O
the O
chest O
wall O
muscles O
, O
usually O
with O
diathermy RARE
, O
contributes O
to O
prolonged O
pain O
and O
morbidity O
. O

Closure RARE
of O
an O
open O
high O
below O
- O
knee RARE
guillotine RARE
amputation RARE
wound O
using O
a O
skin O
- O
stretching RARE
device O
. O

Our O
study O
was O
addressed O
to O
the O
synthesis O
of O
some O
derivatives O
of O
this O
sequence O
in O
order O
to O
obtain O
both O
peptide O
substrates O
suitable O
for O
the O
detection O
of O
the O
Src I-GENE
- O
like O
tyrosine I-GENE
kinase I-GENE
activity O
and O
active O
site O
- O
directed O
inhibitors O
specific O
for O
this O
class O
of O
enzymes O
. O

Citrate RARE
synthase I-GENE
activity O
was O
increased O
in O
the O
medial O
head O
( O
81 O
%, O
P O
< O
0 O
. O
001 O
) O
and O
the O
red O
long O
head O
( O
88 O
%, O
P O
< O
0 O
. O
001 O
) O
of O
the O
triceps RARE
brachii RARE
muscle O
in O
R O
rats O
but O
not O
in O
the O
white O
long O
head O
( O
25 O
%, O
P O
= O
0 O
. O
06 O
). O

The O
expression O
of O
the O
putative O
operon O
bglPH LASTCAP
of O
Bacillus O
subtilis O
was O
studied O
by O
using O
bglP LASTCAP
'- O
lacZ I-GENE
transcriptional O
fusions O
. O

Although O
eight O
contiguous O
genes O
necessary O
for O
urease I-GENE
activity O
have O
been O
cloned O
and O
sequenced O
, O
the O
transcriptional O
organization O
and O
regulation O
of O
specific O
genes O
within O
the O
Proteus RARE
gene I-GENE
cluster I-GENE
has O
not O
been O
investigated O
in O
detail O
. O

The O
hypBFCDE LASTCAP
operon I-GENE
from O
Rhizobium O
leguminosarum RARE
biovar RARE
viciae RARE
is O
expressed O
from O
an O
Fnr RARE
- I-GENE
type I-GENE
promoter I-GENE
that O
escapes RARE
mutagenesis O
of O
the O
fnrN LASTCAP
gene I-GENE
. O

We O
demonstrate O
that O
a O
VT O
+ O
peptide O
was O
specifically O
phosphorylated O
by O
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
) O
in O
vitro O
, O
but O
not O
by O
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
). O

R O
. O

15 O
, O
2500 NUMERIC
- O
2508 NUMERIC
; O
O O
' O
Neill RARE
, O
T O
. O

Control O
experiments O
showed O
that O
each O
fusion O
protein O
had O
a O
high O
affinity O
binding O
site O
for O
estradiol O
- O
17 O
beta O
and O
could O
transactivate O
an O
ERE ALLCAPS
- O
LacZ LASTCAP
reporter O
gene O
in O
yeast O
similar O
to O
the O
wild I-GENE
type I-GENE
ER I-GENE
. O

Although O
Micrococcus RARE
luteus RARE
UV I-GENE
endonuclease I-GENE
has O
been O
reported O
to O
be O
an O
18 O
- O
kDa O
enzyme O
with O
possible O
homology O
to O
the O
16 I-GENE
- I-GENE
kDa I-GENE
endonuclease I-GENE
V I-GENE
from I-GENE
bacteriophage I-GENE
T4 I-GENE
( O
Gordon RARE
, O
L O
. O

Several O
different O
oncogenes O
and O
growth O
factors O
promote O
G1 O
phase O
progression O
. O

Cyclin I-GENE
D1 I-GENE
promoter I-GENE
activity O
was O
stimulated O
by O
overexpression O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
p41MAPK NUMERIC
) O
or O
c I-GENE
- I-GENE
Ets I-GENE
- I-GENE
2 I-GENE
through O
the O
proximal O
22 O
base O
pairs O
. O

Indeed O
, O
ERM ALLCAPS
and O
c I-GENE
- I-GENE
Jun I-GENE
synergistically O
activated O
the O
EBS ALLCAPS
- O
CRE O
without O
making O
an O
apparent O
ternary O
complex O
. O

A O
mutant O
( O
residues O
1 O
- O
332 NUMERIC
) O
showed O
complete O
Ca2 O
+/ O
CaM I-GENE
- O
dependent O
activity O
. O

In O
addition O
, O
the O
R206S NUMERIC
HSF I-GENE
substitution O
exhibits O
constitutive O
transcriptional O
activation O
from O
a O
consensus O
HSE O
( O
HSE2 NUMERIC
). O

The O
two O
bases O
immediately O
flanking O
the O
5 O
' O
end O
of O
the O
element O
proved O
to O
be O
very O
important O
to O
its O
function O
as O
a O
UAS O
element O
as O
did O
the O
two O
bases O
immediately O
3 O
' O
of O
the O
bHLH O
core O
motif O
. O

These O
results O
indicate O
that O
the O
PCNA I-GENE
gene I-GENE
is O
a O
likely O
target O
gene O
of O
E2F I-GENE
. O

Differential O
sensitivity O
of O
the O
MMPI O
- O
2 O
depression O
scales RARE
and O
subscales RARE
. O

After O
recovery O
, O
a O
hypertonic RARE
saline O
challenge O
was O
performed O
. O

The O
range O
of O
eosinophils O
was O
22 O
- O
56 O
% O
of O
the O
number O
of O
peripheral O
white O
blood O
cells O
( O
mean O
nadir RARE
33 O
%). O

Comparisons RARE
of O
rrnB LASTCAP
P1 I-GENE
- O
lacZ I-GENE
expression O
at O
different O
ppGpp RARE
levels O
is O
interpreted O
for O
the O
rpoD LASTCAP
( I-GENE
P504L NUMERIC
) I-GENE
mutant I-GENE
as O
resulting O
from O
a O
hypersensitivity O
to O
ppGpp RARE
. O

These O
intron O
chimeras RARE
show O
that O
peripheral O
sequences O
and O
the O
elements O
that O
define O
the O
splice O
sites O
are O
adequate O
for O
self O
- O
splicing O
activity O
but O
that O
the O
central O
portions O
containing O
the O
catalytic O
cores RARE
of O
ai4 NUMERIC
and O
bi4 NUMERIC
are O
deficient O
; O
these O
cores RARE
are O
the O
likely O
targets O
of O
the O
splicing O
proteins O
. O

Here O
we O
demonstrate O
genetically O
that O
plus O
- O
strand O
DNA O
synthesis O
of O
the O
yeast I-GENE
Ty1 I-GENE
element I-GENE
is O
initiated O
at O
two O
sites O
located O
at O
the O
5 O
' O
boundary O
of O
the O
3 O
' O
long O
terminal O
repeat O
( O
PPT1 NUMERIC
) O
and O
near O
the O
middle O
of O
the O
pol I-GENE
gene I-GENE
in O
the O
integrase I-GENE
coding I-GENE
sequence I-GENE
( O
PPT2 NUMERIC
). O

Characterization O
of O
the O
3 O
' O
ends O
of O
the O
plus O
- O
strand O
DNA O
fragments O
reveals O
( O
1 O
) O
that O
the O
upstream O
fragment O
is O
elongated RARE
beyond O
PPT2 NUMERIC
creating RARE
a O
plus O
- O
strand O
overlap O
and O
( O
2 O
) O
that O
the O
majority O
of O
plus O
- O
strand O
strong O
- O
stop O
DNA O
fragments O
bear RARE
a O
copy O
of O
the O
minus O
- O
strand O
primer O
binding O
site O
in O
agreement O
with O
the O
accepted O
model O
of O
retroviral O
genomic O
RNA O
reverse O
transcription O
. O

The O
patients O
undergoing O
VTLB ALLCAPS
had O
significantly O
shorter O
operative O
times O
( O
VTLB ALLCAPS
, O
100 O
. O
2 O
+/- O
27 O
. O
2 O
min O
. O
vs O
OLB ALLCAPS
, O
119 O
. O
8 O
+/- O
42 O
. O
6 O
min O
; O
p O
< O
0 O
. O
01 O
) O
and O
less O
blood O
loss O
( O
VTLB ALLCAPS
, O
4 O
. O
7 O
+/- O
14 O
. O
6 O
ml O
vs O
OLB ALLCAPS
, O
65 O
. O
7 O
+/- O
77 O
. O
0 O
ml O
; O
p O
< O
0 O
. O
001 O
). O

By O
150 O
minutes O
after O
Cr2O3 NUMERIC
inhalation O
, O
FEV1 O
. O
0 O
had O
decreased O
by O
32 O
%. O

This O
combined O
intravenous O
anaesthetic RARE
regimen O
gave O
good O
anaesthesia O
and O
analgesia O
to O
pigs O
for O
up O
to O
2 O
h O
as O
monitored O
by O
clinical O
signs O
. O

Twenty O
food O
products O
were O
contaminated O
with O
V O
. O
cholerae O
O1 NUMERIC
, O
Ogawa RARE
, O
toxigenic RARE
and O
not O
toxigenic RARE
strains O
: O
yoghurt RARE
, O
cream O
cheese RARE
, O
apricot RARE
marmelade RARE
, O
hip O
rose O
marmelade RARE
, O
mayonnaise RARE
, O
italian RARE
pasta RARE
for O
" O
empanadas RARE
", RARE
" O
dulce RARE
de O
leche RARE
", RARE
meat O
sausage RARE
, O
meat O
and O
spinach RARE
ravioli RARE
, O
margarine RARE
, O
milk O
dessert RARE
( O
made O
with O
cocoa RARE
, O
milk O
confiture RARE
, O
starch RARE
and O
additives RARE
), O
lettuce RARE
, O
tuna RARE
fish O
, O
ricotta RARE
and O
sterilized RARE
milk O
. O

It O
is O
impossible RARE
to O
define O
only O
one O
clinical O
outline RARE
because O
both O
symptomatic O
and O
asymptomatic O
infected O
NB ALLCAPS
may O
be O
found O
with O
gestational O
age O
at O
term O
and O
pre O
- O
term O
and O
when O
born O
with O
a O
weight O
above O
or O
below O
2000 O
g O
. O

The O
expression O
of O
the O
pilin RARE
gene I-GENE
, O
tcpA LASTCAP
, O
is O
dependent O
upon O
ToxR LASTCAP
and O
upon O
ToxT LASTCAP
. O

The O
chloramphenicol I-GENE
- I-GENE
resistance I-GENE
transposon I-GENE
Tn4451 NUMERIC
undergoes O
precise O
conjugative RARE
deletion O
from O
its O
parent RARE
plasmid O
plP401 NUMERIC
in O
Clostridium RARE
perfringens RARE
and O
precise O
spontaneous O
excision O
from O
multicopy O
plasmids O
in O
Escherichia O
coli O
. O

Ras I-GENE
p21Val NUMERIC
inhibits O
myogenesis RARE
without O
altering O
the O
DNA O
binding O
or O
transcriptional O
activities O
of O
the O
myogenic I-GENE
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
factors I-GENE
. O

In O
cells O
limited O
for O
His O
, O
increased O
expression O
of O
arg RARE
- I-GENE
2 I-GENE
and O
cpc RARE
- I-GENE
1 I-GENE
, O
and O
decreased O
expression O
of O
cox RARE
- I-GENE
5 I-GENE
, O
also O
had O
translational O
and O
transcriptional O
components O
. O

The O
peptide O
sequences O
reveal O
that O
the O
factor O
consists O
of O
GABP I-GENE
alpha I-GENE
and O
GABP I-GENE
beta I-GENE
1 I-GENE
with O
Ets I-GENE
and O
Notch I-GENE
motifs I-GENE
, O
respectively O
. O

Immunofluorescence RARE
microscopy O
and O
cell O
fractionation O
analyses O
showed O
that O
the O
110 O
- O
kDa O
protein O
was O
exclusively O
nuclear O
, O
whereas O
the O
150 O
- O
kDa O
protein O
was O
present O
in O
both O
the O
cytoplasm O
and O
nucleus O
of O
human O
cells O
. O

Expression O
and O
regulation O
by O
interferon I-GENE
of O
a O
double I-GENE
- I-GENE
stranded I-GENE
- I-GENE
RNA I-GENE
- I-GENE
specific I-GENE
adenosine I-GENE
deaminase I-GENE
from O
human O
cells O
: O
evidence O
for O
two O
forms O
of O
the O
deaminase O
. O

T O
- O
cell O
hybridomas RARE
, O
thymocytes RARE
, O
and O
T O
cells O
can O
be O
induced O
to O
undergo O
apoptotic O
cell O
death O
by O
activation O
through O
the O
T I-GENE
- I-GENE
cell I-GENE
receptor I-GENE
. O

Deletions RARE
were O
examined O
in O
the O
LYS2 NUMERIC
gene I-GENE
, O
using O
a O
set O
of O
31 O
- O
to O
156 O
- O
bp O
inserts O
that O
included O
inserts O
with O
no O
apparent O
potential O
for O
secondary O
structure O
as O
well O
as O
two O
quasipalindromes RARE
. O

Overexpression O
of O
SCS1 NUMERIC
could O
not O
complement O
an O
HSP60 NUMERIC
- I-GENE
null I-GENE
allele I-GENE
, O
indicating O
that O
suppression O
was O
not O
due O
to O
the O
bypassing RARE
of O
Hsp60 NUMERIC
activity O
. O

The O
DNA O
binding O
domain O
of O
NirA LASTCAP
was O
expressed O
as O
a O
fusion O
protein O
with O
the O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
of O
Schistosoma RARE
japonicum RARE
. O

The O
kinase O
is O
essential O
in O
vivo O
for O
normal O
phosphorylation O
of O
the O
CTD O
and O
for O
normal O
growth O
and O
differentiation O
. O

A O
general O
model O
for O
ARE ALLCAPS
- O
mediated O
mRNA O
degradation O
involving O
a O
potential O
role O
for O
certain O
heterogeneous O
nuclear O
ribonucleoproteins RARE
and O
ARE ALLCAPS
- I-GENE
binding I-GENE
proteins I-GENE
is O
proposed O
. O

Finally O
, O
we O
demonstrate O
that O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
can O
also O
active O
the O
GM I-GENE
- I-GENE
CSF I-GENE
receptor I-GENE
alpha I-GENE
promoter O
in O
nonmyeloid RARE
cells O
. O

Endocytosis RARE
and O
vacuolar O
degradation O
of O
the O
plasma O
membrane O
- O
localized O
Pdr5 NUMERIC
ATP I-GENE
- I-GENE
binding I-GENE
cassette I-GENE
multidrug I-GENE
transporter I-GENE
in O
Saccharomyces O
cerevisiae O
. O

Individual RARE
mutations O
in O
motifs O
III O
, O
IV O
, O
and O
V O
had O
distinctive O
effects O
on O
the O
affinity O
of O
enzyme O
for O
GTP O
, O
the O
rate O
of O
covalent RARE
catalysis RARE
( O
EpG LASTCAP
formation O
), O
or O
the O
transfer O
of O
GMP ALLCAPS
from O
enzyme O
to O
RNA O
. O

Mutational O
analysis O
of O
mRNA I-GENE
capping I-GENE
enzyme I-GENE
identifies O
amino O
acids O
involved O
in O
GTP O
binding O
, O
enzyme O
- O
guanylate RARE
formation O
, O
and O
GMP ALLCAPS
transfer O
to O
RNA O
. O

Disruption O
of O
the O
HOG1 NUMERIC
and O
PBS2 NUMERIC
genes I-GENE
leads O
to O
a O
dramatic O
decrease O
of O
the O
HSP12 NUMERIC
inducibility O
in O
osmostressed RARE
cells O
, O
whereas O
overproduction RARE
of O
Hog1 NUMERIC
produces O
a O
fivefold RARE
increase O
in O
wild O
- O
type O
induced O
levels O
upon O
a O
shift O
to O
a O
high O
salt O
concentration O
. O

Deletion O
or O
inactivation O
of O
CRY1 NUMERIC
leads O
to O
5 O
- O
to O
10 O
- O
fold O
- O
increased O
levels O
of O
CRY2 NUMERIC
mRNA I-GENE
. O

( O
1986 O
) O
method O
of O
separation O
of O
Cryptosporidium RARE
spp RARE
. O
oocysts RARE
from O
feces RARE
by O
using O
a O
percoll RARE
discontinuous RARE
density O
gradient O
appeared O
a O
method O
of O
choice O
for O
obtaining O
large O
numbers O
of O
oocysts RARE
of O
C O
. O
parvum RARE
free O
of O
fecal O
contamination O
. O

Staphylococcal RARE
enterotoxin I-GENE
A I-GENE
involvement O
in O
the O
illness O
of O
a O
20 O
- O
month O
- O
old O
burn O
patient O
. O

METHODS O
: O
We O
obtained O
maximal O
inspiratory O
and O
expiratory O
flow O
- O
volume O
curves O
in O
41 O
unselected RARE
patients O
with O
essential O
tremor O
( O
14 O
males O
, O
27 O
females O
, O
age O
61 O
. O
7 O
+/- O
2 O
. O
14 O
years O
). O

Our O
findings O
also O
provide O
the O
basis O
for O
the O
development O
of O
assays O
to O
screen O
for O
the O
ligands O
to O
testis I-GENE
receptor I-GENE
2 I-GENE
and O
hERR1 NUMERIC
. O

Four O
p53 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
peptides I-GENE
bind O
natural O
p53 I-GENE
- I-GENE
response I-GENE
elements I-GENE
and O
bend RARE
the O
DNA O
. O

The O
Stat5b NUMERIC
mRNA I-GENE
has O
a O
size O
of O
5 O
. O
6 O
kb O
and O
encodes O
a O
protein O
of O
786 NUMERIC
amino O
acids O
. O

The O
hydropathy RARE
plot RARE
revealed O
a O
rather O
hydrophilic O
N O
- O
terminal O
region O
and O
the O
absence O
of O
a O
hydrophobic O
signal O
peptide O
. O

These O
results O
suggest O
that O
G I-GENE
beta I-GENE
gamma I-GENE
- O
stimulated O
Shc I-GENE
phosphorylation O
represents O
an O
early O
step O
in O
the O
pathway O
leading O
to O
p21ras I-GENE
activation O
, O
similar O
to O
the O
mechanism O
utilized O
by O
growth I-GENE
factor I-GENE
tyrosine I-GENE
kinase I-GENE
receptors I-GENE
. O

This O
report O
focused O
on O
the O
relationship O
between O
Type O
A O
behavior O
and O
eight O
basic O
emotion RARE
dimensions O
. O

All O
carcasses RARE
resulted O
in O
contamination O
with O
aerobic O
mesophilic RARE
bacteria O
in O
the O
range O
from O
6 O
x O
10 O
( O
3 O
) O
to O
1 O
. O
2 O
x O
10 O
( O
6 O
) O
CFU ALLCAPS
/ O
ml O
liquid O
washed RARE
, O
and O
94 O
% O
them O
with O
sporulate RARE
bacteria O
, O
the O
threshold O
being O
under O
100 O
CFU ALLCAPS
/ O
ml O
( O
Figure RARE
1 O
). O

As O
for O
31 O
stage O
I O
- O
II O
lung O
cancer O
patients O
, O
CR O
has O
been O
observed O
in O
82 O
. O
8 O
% O
of O
them O
and O
PR O
in O
13 O
. O
8 O
%; O
the O
response O
was O
always O
assessed O
with O
chest O
radiography RARE
, O
CT O
, O
FBS ALLCAPS
, O
cytology RARE
and O
/ O
or O
histology RARE
. O

Pediatric RARE
medical O
emergencies RARE
in O
a O
regional O
hospital O
: O
appropriate O
locale RARE
? O

Protein O
electrophoresis O
showed O
decreased O
albumin I-GENE
levels O
in O
both O
groups O
, O
with O
lower O
values O
in O
G2 O
. O

METHODS O
: O
All O
these O
30 O
non O
- O
responders O
received O
an O
extra O
dose O
of O
the O
same O
vaccine O
2 O
months O
after O
primary O
immunization O
and O
a O
booster RARE
dose O
with O
a O
yeast O
- O
derived O
vaccine O
6 O
years O
later O
. O

An O
abnormally RARE
high O
percentage O
of O
hypertensive O
patients O
( O
approximately O
30 O
%) O
undergoing O
cardiac O
catheterization RARE
because O
of O
anginal RARE
pain O
and O
/ O
or O
exercise O
- O
induced O
ST O
- O
segment O
depressions RARE
has O
angiographically RARE
normal O
coronary O
arteries O
. O

Negative RARE
- O
staining O
, O
refractile RARE
mycobacteria O
in O
Romanowsky RARE
- O
stained O
smears O
. O

Mibefradil RARE
( O
Ro O
40 O
- O
5967 NUMERIC
) O
is O
a O
novel O
calcium O
antagonist O
from O
a O
new O
chemical O
class O
and O
is O
the O
first O
that O
selectively O
blocks O
the O
T O
- O
type O
calcium O
channel O
. O

However O
, O
2 O
minimum O
alveolar O
concentration O
anesthesia O
did O
significantly O
decrease O
the O
calculated O
VE O
at O
a O
PCO2 O
of O
60 O
mmHg O
( O
from O
7 O
. O
4 O
+/- O
1 O
. O
2 O
to O
4 O
. O
0 O
+/- O
0 O
. O
6 O
l O
. O
min O
- O
1 O
), O
indicating O
a O
rightward RARE
shift O
in O
the O
response O
relationship O
. O

cDNA O
encoding O
a O
functional O
feline I-GENE
liver I-GENE
/ I-GENE
bone I-GENE
/ I-GENE
kidney I-GENE
- I-GENE
type I-GENE
alkaline I-GENE
phosphatase I-GENE
. O

Protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
), O
a O
widely O
- O
distributed O
enzyme O
implicated O
in O
the O
regulation O
of O
many O
physiological O
processes O
, O
consists O
of O
a O
family O
of O
at O
least O
twelve RARE
isoenzymes O
which O
differ O
in O
tissue O
distribution O
, O
subcellular O
localization O
, O
regulatory O
properties O
, O
etc O
. O

This O
work O
, O
therefore O
, O
also O
emphasizes O
the O
importance O
of O
careful RARE
choice O
of O
oligonucleotide O
and O
cDNA O
probes O
to O
study O
PKC I-GENE
zeta I-GENE
mRNA I-GENE
. O

This O
action O
is O
dependent O
on O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
factors I-GENE
bound O
to O
the O
E1 I-GENE
element O
. O

The O
debate RARE
over O
electives RARE
-- O
1899 NUMERIC
. O

Polypeptide RARE
growth O
factors O
and O
cytokines O
mediate O
their O
biochemical O
functions O
through O
their O
responsive O
receptors O
. O

However O
, O
a O
strongly O
increased O
frequency O
of O
CpG O
dinucleotides RARE
was O
found O
. O

Here O
we O
focused O
on O
the O
role O
of O
the O
5 O
' O
proximal O
regulatory O
cassette O
(- O
190 O
; O
+ O
53 O
bp O
) O
of O
the O
rat I-GENE
enkephalin RARE
( O
rENK LASTCAP
) O
gene O
in O
the O
developmental O
regulation O
of O
the O
enkephalin RARE
phenotype O
. O

Unexpectedly RARE
, O
all O
ENK ALLCAPS
- I-GENE
specific I-GENE
motifs I-GENE
formed O
specific O
and O
highly O
abundant O
protein O
- O
DNA O
complexes O
when O
nuclear O
extracts O
from O
the O
human O
tumor O
cell O
line O
( O
HeLa O
), O
which O
does O
not O
express O
ENK ALLCAPS
, O
were O
used O
. O

Infant RARE
aged O
3 O
. O
5 O
years O
presents O
persistence RARE
of O
primordial RARE
vitreous O
body O
with O
crystalline O
dislocation O
in O
the O
camera RARE
aquosa RARE
and O
secondary O
buphthalmos RARE
of O
the O
left O
eye O
and O
microphthalmos RARE
with O
dislocation O
of O
the O
crystalline O
in O
the O
vitreous O
body O
of O
the O
right O
eye O
. O

During O
the O
dose O
- O
finding O
, O
two O
patients O
were O
temporarily RARE
withdrawn RARE
from O
medication O
and O
one O
patient O
was O
excluded O
because O
of O
elevated O
levels O
of O
liver O
enzymes O
. O

In O
comparison O
of O
cDNA O
and O
genomic O
sequences O
four O
RNA O
editing RARE
events O
were O
found O
in O
both O
atp9 NUMERIC
genes I-GENE
. O

MZF ALLCAPS
- I-GENE
1 I-GENE
represses O
CAT I-GENE
reporter I-GENE
gene I-GENE
expression O
via O
GAL4 I-GENE
binding I-GENE
sites I-GENE
in O
the O
nonhematopoietic RARE
cell O
lines O
NIH O
3T3 O
and O
293 O
. O

As O
with O
the O
heterologous O
DNA O
binding O
domain O
, O
MZF ALLCAPS
- I-GENE
1 I-GENE
represses O
reporter O
gene O
expression O
in O
nonhematopoietic RARE
cell O
lines O
and O
activates O
expression O
in O
hematopoietic O
cell O
lines O
. O

Analyses RARE
of O
hGMR LASTCAP
beta I-GENE
subunit I-GENE
mutants I-GENE
revealed O
two O
cytoplasmic O
regions O
involved O
in O
activation O
of O
the O
c I-GENE
- I-GENE
myc I-GENE
promoter I-GENE
, O
one O
is O
essential O
and O
the O
other O
is O
dispensable O
but O
enhances O
the O
activity O
. O

Similarly O
, O
we O
observed O
synthetic O
phenotypes O
between O
mutations O
in O
MIF2 NUMERIC
and O
trans O
- O
acting O
mutations O
in O
three O
known O
yeast O
centromere O
protein O
genes O
- O
CEP1 NUMERIC
/ O
CBF1 I-GENE
/ O
CPF1 NUMERIC
, O
NDC10 NUMERIC
/ O
CBF2 I-GENE
, O
and O
CEP3 NUMERIC
/ O
CBF3B NUMERIC
. O

Taken O
together O
, O
these O
data O
suggest O
that O
the O
Mif2 NUMERIC
protein I-GENE
interacts O
with O
Cep1p NUMERIC
at O
the O
centromere O
and O
that O
the O
yeast O
centromere O
indeed O
exists O
as O
a O
higher O
order O
protein O
- O
DNA O
complex O
. O

To O
accomplish RARE
this O
, O
actin I-GENE
cables RARE
and O
patches RARE
are O
redistributed RARE
during O
the O
cell O
cycle O
to O
direct O
secretory O
components O
to O
appropriate O
sites O
for O
cell O
growth O
. O

The O
effects O
of O
Codonopsis RARE
pilosula RARE
oral O
liquor RARE
( O
CPOL ALLCAPS
) O
on O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
t I-GENE
- I-GENE
PA I-GENE
) O
and O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
( O
PAI I-GENE
) O
in O
the O
plasma O
of O
25 O
patients O
of O
coronary O
heart O
disease O
with O
blood O
stasis RARE
were O
studied O
. O

Estimated RARE
daily O
intakes RARE
( O
EDIs RARE
) O
per O
person RARE
were O
0 O
. O
56 O
microgram O
for O
total O
HCH ALLCAPS
, O
0 O
. O
20 O
microgram O
for O
gamma O
- O
HCH ALLCAPS
, O
0 O
. O
09 O
microgram O
for O
dieldrin RARE
, O
1 O
. O
42 O
micrograms O
for O
total O
DDT ALLCAPS
, O
and O
0 O
. O
15 O
microgram O
for O
HCB O
. O

Imaging RARE
features O
of O
splenic O
epidermoid RARE
cyst O
with O
pathologic O
correlation O
. O

In O
two O
further O
cases O
( O
one O
type O
I O
and O
one O
type O
III O
SMA ALLCAPS
), O
de O
novo O
deletions O
of O
only O
one O
copy O
of O
Ag1 NUMERIC
- I-GENE
CA I-GENE
and O
C212 NUMERIC
were O
found O
. O

With O
each O
of O
the O
three O
pairs O
of O
isolates O
( O
case O
and O
suspicious RARE
case O
), O
identical O
IS6110 NUMERIC
banding RARE
patterns O
were O
found O
suggesting O
identical O
MTB ALLCAPS
strains O
. O

HRES ALLCAPS
has O
been O
found O
to O
be O
clinically O
useful O
in O
assessing O
histologic O
damage O
following O
pneumatic RARE
dilatation O
and O
in O
localizing RARE
the O
LES ALLCAPS
during O
the O
administration O
of O
intrasphincter RARE
botulinum I-GENE
toxin I-GENE
injection O
in O
the O
treatment O
of O
achalasia RARE
. O

These O
early O
structural O
processes O
are O
assumed O
to O
be O
subserved RARE
by O
the O
anterior O
parts O
of O
the O
left O
hemisphere O
, O
as O
event O
- O
related O
brain O
potentials O
show O
this O
area O
to O
be O
maximally RARE
activated O
when O
phrase RARE
structure O
violations RARE
are O
processed O
and O
as O
circumscribed RARE
lesions O
in O
this O
area O
lead O
to O
an O
impairment O
of O
the O
on O
- O
line O
structural O
assignment O
. O

In O
men O
with O
BMI O
< O
30 O
, O
the O
OR O
was O
1 O
. O
83 O
for O
postprandial RARE
TG O
( O
P O
= O
. O
041 NUMERIC
) O
and O
2 O
. O
77 O
for O
postprandial RARE
RP O
( O
P O
= O
. O
032 NUMERIC
) O
in O
models O
that O
included O
fasting O
TG O
, O
LDL I-GENE
- I-GENE
C I-GENE
, O
and O
hypertension O
. O

SL1 NUMERIC
trans O
- O
splicing O
specified O
by O
AU ALLCAPS
- O
rich O
synthetic O
RNA O
inserted O
at O
the O
5 O
' O
end O
of O
Caenorhabditis O
elegans O
pre O
- O
mRNA O
. O

A O
pyrazolo RARE
- O
quinoline RARE
compound O
, O
6 O
- O
methoxy RARE
- O
4 O
-[ O
2 O
-[( RARE
2 O
- O
hydroxyethoxyl RARE
)- O
ethyl O
] O
amino O
]- RARE
3 O
- O
methyl O
- O
1M NUMERIC
- O
pyrazo RARE
lo RARE
[ O
3 O
, O
4 O
- O
b O
] O
quinoline RARE
( O
SCH ALLCAPS
51344 NUMERIC
), O
was O
identified O
based O
on O
its O
ability O
to O
derepress RARE
human O
smooth O
muscle O
alpha I-GENE
- I-GENE
actin I-GENE
promoter I-GENE
activity O
in O
ras I-GENE
- O
transformed O
cells O
. O

On O
the O
basis O
of O
these O
relations O
, O
a O
risk O
factor O
- O
selection O
scale O
( O
RFSS ALLCAPS
) O
( O
range O
, O
0 O
to O
10 O
) O
was O
developed O
by O
computing RARE
appropriate O
weights O
for O
each O
risk O
factor O
. O

The O
Caenorhabditis I-GENE
elegans I-GENE
death I-GENE
susceptibility I-GENE
gene I-GENE
, O
ced RARE
- I-GENE
3 I-GENE
, O
has O
a O
number O
of O
homologs O
in O
vertebrate O
species O
, O
including O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
( I-GENE
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
)- I-GENE
converting I-GENE
enzyme I-GENE
( O
ICE I-GENE
), O
Ich RARE
- I-GENE
1long NUMERIC
, O
and O
CPP32 NUMERIC
. O

Repression RARE
of O
glucocorticoid I-GENE
receptor I-GENE
- O
mediated O
transcriptional O
activation O
by O
unliganded RARE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
is O
TR I-GENE
isoform O
- O
specific O
. O

The O
results O
indicate O
considerable O
flexibility RARE
in O
the O
spacing RARE
between O
DH ALLCAPS
regulatory O
sites O
. O

Obstruction RARE
of O
the O
ERF ALLCAPS
repressor I-GENE
function O
by O
the O
transactivating O
members O
of O
the O
ets I-GENE
family I-GENE
of O
genes O
( O
i O
. O
e O
. O
gag I-GENE
- O
myb I-GENE
- O
ets I-GENE
) O
may O
be O
essential O
for O
the O
control O
of O
genes O
involved O
in O
cell O
proliferation O
and O
may O
also O
underlie RARE
their O
tumorigenic O
effects O
. O

Overexpression O
of O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
also O
induces O
apoptosis O
in O
an O
LCL ALLCAPS
. O

We O
show O
that O
c I-GENE
- I-GENE
Fos I-GENE
( O
the O
c I-GENE
- I-GENE
fos I-GENE
protooncogene I-GENE
product I-GENE
), O
which O
is O
an O
intrinsically RARE
unstable O
nuclear O
protein O
, O
is O
metabolically RARE
highly O
stabilized O
, O
and O
greatly O
enhances O
the O
transforming O
efficiency O
of O
NIH O
3T3 O
cells O
, O
by O
Mos RARE
. O

Cloning O
, O
sequencing O
and O
expression O
of O
the O
3 I-GENE
- I-GENE
phosphoglycerate RARE
kinase I-GENE
gene I-GENE
of O
Pyrococcus RARE
woesei RARE
in O
Escherichia O
coli O
and O
characterization O
of O
the O
protein O
. O

These O
observations O
lead O
to O
the O
proposal RARE
that O
the O
RNAP I-GENE
II I-GENE
CTD I-GENE
might O
be O
an O
in O
vivo O
target O
for O
the O
activated O
p42mapk NUMERIC
and O
p44mapk NUMERIC
MAP I-GENE
kinases I-GENE
. O

We O
also O
isolated O
two O
alternatively O
spliced O
forms O
of O
human I-GENE
CD6 NUMERIC
cDNA I-GENE
lacking O
sequences O
encoding O
membrane O
- O
proximal O
regions O
of O
the O
cytoplasmic O
domain O
which O
maintain O
the O
same O
reading O
frame O
as O
CD6 NUMERIC
- O
PB1 NUMERIC
. O

We O
sought O
to O
determine O
whether O
such O
differences O
in O
polyadenylation O
affect O
the O
steady O
- O
state O
levels O
of O
DHFR I-GENE
and O
mRNAs O
expressed O
from O
either O
allele O
and O
, O
in O
a O
more O
general O
sense O
, O
to O
ask RARE
whether O
differences O
in O
3 O
' O
end O
RNA O
processing O
in O
a O
gene O
containing O
multiple O
poly O
( O
A O
) O
sites O
affects O
the O
final O
level O
of O
gene O
expression O
. O

We O
have O
isolated O
a O
Drosophila O
melanogaster O
( O
Dm RARE
) O
cDNA O
encoding O
a O
polypeptide O
that O
has O
extensive O
sequence O
similarity O
to O
the O
mammalian I-GENE
MAPKAPK ALLCAPS
- I-GENE
2 I-GENE
. O

A O
2 I-GENE
. I-GENE
4 I-GENE
- I-GENE
kb I-GENE
MAPKAPK ALLCAPS
- I-GENE
2 I-GENE
message I-GENE
is O
expressed O
throughout O
development O
, O
while O
two O
shorter O
transcripts O
of O
2 O
. O
3 O
and O
1 O
. O
8 O
kb O
appear O
to O
be O
specifically O
expressed O
in O
the O
germline O
. O

The O
finding O
that O
the O
chimeric I-GENE
TdT LASTCAP
:: O
Pol I-GENE
beta I-GENE
protein I-GENE
possessed O
significant O
template O
- O
dependent O
polymerase O
activity O
suggests O
that O
aa O
1 O
- O
60 O
of O
Pol I-GENE
beta I-GENE
are O
involved O
in O
template O
utilization O
during O
the O
polymerization RARE
reaction O
, O
as O
suggested O
by O
the O
previous O
finding O
that O
the O
8 O
- O
kDa O
N O
- O
terminal O
domain O
of O
Pol I-GENE
beta I-GENE
possesses O
ssDNA O
- O
binding O
activity O
[ O
Kumar RARE
et O
al O
., O
J O
. O

The O
average O
values O
were O
199 NUMERIC
and O
424 NUMERIC
revertants RARE
/ O
g O
for O
the O
hamburgers RARE
and O
hot O
dogs O
, O
respectively O
. O

Cholangiography RARE
was O
performed O
in O
all O
cases O
and O
classified O
by O
a O
scoring RARE
system O
specifically O
developed O
for O
pediatric O
patients O
. O

The O
integrity O
of O
the O
cDNA O
sequence O
was O
confirmed O
by O
analysis O
of O
several O
overlapping O
genomic O
clones O
that O
span O
the O
GAR1 NUMERIC
gene I-GENE
. O

In O
Trial RARE
1 O
, O
eight O
sows RARE
were O
allowed O
to O
farrow RARE
naturally O
( O
d O
114 O
, O
NF O
sows RARE
) O
and O
eight O
sows RARE
were O
induced O
to O
farrow RARE
( O
IF O
sows RARE
) O
prematurely RARE
by O
injection O
of O
prostaglandin O
F2 O
alpha O
on O
d O
112 O
of O
gestation O
. O

End RARE
- O
tidal O
PO2 O
and O
the O
ratio O
of O
minute O
ventilation O
to O
oxygen O
consumption O
( O
VE O
/ O
VO2 O
) O
were O
lower O
while O
PETCO2 NUMERIC
was O
higher O
for O
Hyp RARE
( O
P O
< O
or O
= O
0 O
. O
01 O
). O

These O
results O
suggested O
that O
NfxB LASTCAP
negatively O
autoregulates RARE
the O
expression O
of O
nfxB LASTCAP
itself O
. O

A511 NUMERIC
is O
a O
broad O
- O
host O
- O
range O
, O
virulent O
myovirus RARE
for O
Listeria RARE
monocytogenes O
. O

The O
mechanism O
of O
peroxisome O
proliferation O
is O
poorly O
understood O
. O

If O
NCR O
- O
sensitive O
gene O
expression O
occurs O
exclusively O
by O
this O
pathway O
, O
as O
has O
been O
thought O
to O
be O
the O
case O
, O
then O
the O
NCR O
sensitivity O
of O
a O
gene O
' O
s O
expression O
should O
be O
abolished O
by O
a O
ure2 NUMERIC
delta I-GENE
mutation I-GENE
. O

The O
single O
- O
stranded O
DNA O
Pur RARE
alpha I-GENE
recognition I-GENE
element I-GENE
disrupts RARE
these O
complexes O
. O

Association O
of O
human I-GENE
Pur RARE
alpha I-GENE
with O
the O
retinoblastoma I-GENE
protein I-GENE
, O
Rb I-GENE
, O
regulates O
binding O
to O
the O
single O
- O
stranded O
DNA O
Pur RARE
alpha I-GENE
recognition I-GENE
element I-GENE
. O

The O
insulin I-GENE
- O
induced O
DNA O
- O
binding O
complex O
was O
identified O
as O
the O
p50 I-GENE
/ O
p65 I-GENE
heterodimer O
. O

Using O
varying O
conditions O
, O
three O
distinct O
complexes O
were O
shown O
to O
interact O
specifically O
with O
the O
NIP ALLCAPS
region I-GENE
, O
although O
only O
one O
correlates O
with O
repressor O
activity O
. O

Exchange RARE
of O
the O
LPL ALLCAPS
and O
HL I-GENE
lids RARE
resulted O
in O
a O
reversal O
of O
the O
phospholipase I-GENE
/ O
neutral O
lipase I-GENE
ratio O
, O
establishing RARE
the O
important O
role O
of O
this O
region O
in O
mediating O
substrate O
specificity O
. O

The O
interferon I-GENE
- O
inducible O
protein I-GENE
kinase I-GENE
PKR I-GENE
modulates RARE
the O
transcriptional O
activation O
of O
immunoglobulin I-GENE
kappa I-GENE
gene I-GENE
. O

Truncated RARE
forms O
of O
a O
novel O
yeast O
protein O
suppress O
the O
lethality O
of O
a O
G I-GENE
protein I-GENE
alpha I-GENE
subunit I-GENE
deficiency O
by O
interacting O
with O
the O
beta O
subunit O
. O

Another O
common O
mutation O
involved O
amino O
acids O
that O
are O
thought O
to O
make O
specific O
contacts O
with O
DNA O
. O

Phorbol RARE
esters O
stimulated O
phosphorylation O
of O
CSK ALLCAPS
35H NUMERIC
proteins I-GENE
, O
thus O
emphasizing RARE
that O
sequences O
isolated O
according O
to O
PKC I-GENE
binding O
activity O
in O
vitro O
are O
also O
PKC I-GENE
substrates O
in O
vivo O
. O

Levels RARE
of O
TSG ALLCAPS
- I-GENE
14 I-GENE
protein I-GENE
( O
also O
termed O
PTX ALLCAPS
- I-GENE
3 I-GENE
) O
become O
elevated O
in O
the O
serum O
of O
mice O
and O
humans O
after O
injection O
with O
bacterial O
lipopolysaccharide O
, O
but O
in O
contrast O
to O
conventional O
acute O
phase O
proteins O
, O
the O
bulk O
of O
TSG ALLCAPS
- I-GENE
14 I-GENE
synthesis O
in O
the O
intact O
organism O
occurs O
outside O
the O
liver O
. O

The O
mouse I-GENE
beta I-GENE
2 I-GENE
- I-GENE
syntrophin RARE
gene I-GENE
( O
> O
33 O
kilobases O
) O
contains O
seven O
exons O
, O
all O
of O
which O
have O
homologues O
at O
the O
corresponding O
position O
in O
the O
alpha I-GENE
1 I-GENE
- I-GENE
syntrophin RARE
gene I-GENE
. O

Altogether O
our O
data O
indicate O
that O
PEDF ALLCAPS
belongs O
to O
the O
subgroup O
of O
noninhibitory RARE
serpins RARE
and O
that O
its O
N O
- O
terminal O
region O
confers O
a O
neurite RARE
- O
promoting O
activity O
to O
the O
protein O
. O

We O
report O
here O
the O
cloning O
of O
the O
murine O
p44 I-GENE
MAP I-GENE
kinase I-GENE
( O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
1 I-GENE
) O
gene O
, O
the O
determination O
of O
its O
intron O
/ O
exon O
boundaries O
, O
and O
the O
characterization O
of O
its O
promoter O
. O

It O
contains O
three O
putative O
TATA O
boxes O
far O
upstream O
of O
the O
main O
start O
sites O
region O
, O
one O
AP I-GENE
- I-GENE
1 I-GENE
box I-GENE
, O
one O
AP I-GENE
- I-GENE
2 I-GENE
box I-GENE
, O
one O
Malt RARE
box I-GENE
, O
one O
GAGA ALLCAPS
box O
, O
one O
half O
serum O
- O
responsive O
element O
, O
and O
putative O
binding O
sites O
for O
Sp1 I-GENE
( O
five O
), O
GC I-GENE
- I-GENE
rich I-GENE
binding I-GENE
factor I-GENE
( O
five O
), O
CTF ALLCAPS
- I-GENE
NF1 I-GENE
( O
one O
), O
Myb I-GENE
( O
one O
), O
p53 I-GENE
( O
two O
), O
Ets I-GENE
- I-GENE
1 I-GENE
( O
one O
), O
NF I-GENE
- I-GENE
IL6 I-GENE
( O
two O
), O
MyoD I-GENE
( O
two O
), O
Zeste RARE
( O
one O
), O
and O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
5 I-GENE
( O
one O
). O

One O
of O
these O
is O
surrounded RARE
by O
an O
adenine O
- O
uridine RARE
rich O
region O
that O
can O
form O
an O
11 O
- O
base O
pair O
stem O
structure O
. O

We O
conclude O
that O
this O
new O
measurement O
technique O
provides O
an O
easy RARE
and O
accurate O
P0 NUMERIC
. O
1 O
measurement O
using O
standard O
respiratory O
equipment RARE
when O
tested O
in O
a O
lung O
model O
. O

Effects O
of O
verapamil O
and O
propranolol O
on O
early O
afterdepolarizations RARE
and O
ventricular O
arrhythmias O
induced O
by O
epinephrine O
in O
congenital O
long O
QT O
syndrome O
. O

Deletion O
of O
the O
NF I-GENE
- I-GENE
IL6 I-GENE
beta I-GENE
leucine I-GENE
zipper I-GENE
domain I-GENE
also O
greatly O
diminished O
the O
interaction O
between O
these O
two O
proteins O
. O

After O
cells O
were O
stably O
transfected O
with O
CIITA ALLCAPS
, O
endogenous O
MHC I-GENE
class I-GENE
II I-GENE
genes I-GENE
were O
constitutively O
expressed O
, O
and O
MHC I-GENE
class I-GENE
II I-GENE
promoters I-GENE
, O
delivered O
by O
transfection O
, O
were O
actively O
transcribed O
in O
CIITA ALLCAPS
- O
expressing O
cells O
. O

Two O
domains O
of O
EBNA2 I-GENE
defined O
by O
deletion O
of O
amino O
acids O
247 NUMERIC
- O
337 NUMERIC
and O
437 NUMERIC
- O
476 NUMERIC
were O
found O
to O
be O
important O
for O
the O
activation O
of O
both O
promoters O
, O
while O
two O
different O
domains O
corresponding O
to O
residues O
4 O
- O
18 O
and O
118 O
- O
198 O
were O
required O
solely O
for O
the O
LMP1 I-GENE
promoter I-GENE
. O

The O
peak O
velocities RARE
of O
the O
atrial O
systolic O
waves O
of O
the O
transmitral RARE
and O
pulmonary O
venous O
flow O
velocities RARE
( O
A O
and O
PVA ALLCAPS
, O
respectively O
) O
and O
first O
systolic O
wave O
( O
PVS1 NUMERIC
) O
of O
pulmonary O
venous O
flow O
, O
durations O
of O
both O
atrial O
systolic O
waves O
, O
and O
amplitude O
of O
interatrial RARE
septal O
motion O
during O
atrial O
systole RARE
increased O
significantly O
ten O
days O
after O
cardioversion RARE
compared O
with O
those O
measured O
within O
a O
day O
of O
cardioversion RARE
in O
all O
patients O
except O
the O
5 O
patients O
with O
dilated RARE
cardiomyopathy O
. O

Additionally O
, O
the O
enzyme O
shows O
activity O
towards O
triglycerides O
such O
as O
olive RARE
oil O
and O
tributyrin RARE
and O
towards O
egg O
- O
yolk RARE
emulsions RARE
. O

The O
nucleotide O
sequence O
directly O
upstream O
of O
fimA LASTCAP
contains O
two O
open O
reading O
frames O
, O
ORF5 NUMERIC
and O
ORF1 O
, O
whose O
deduced O
protein O
products O
are O
homologous O
to O
members O
of O
a O
superfamily O
of O
ATP I-GENE
- I-GENE
binding I-GENE
cassette I-GENE
membrane I-GENE
transport I-GENE
proteins I-GENE
, O
including O
both O
prokaryotic O
and O
eukaryotic O
uptake O
and O
export O
systems O
. O

The O
ORF3 O
probe O
also O
hybridized O
to O
a O
540 NUMERIC
bp O
transcript O
consistent O
with O
the O
size O
of O
ORF3 O
alone O
and O
supportive RARE
of O
the O
mutagenesis O
data O
of O
non O
- O
linkage O
. O

These O
results O
suggest O
that O
low O
concentrations O
of O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
may O
be O
useful O
for O
nonsurgical RARE
treatment O
of O
human O
vitreous O
hemorrhage O
. O

We O
conclude O
that O
pancreatic O
polypeptide O
and O
motilin RARE
responses O
to O
a O
meal O
are O
different O
in O
encopretic RARE
children O
than O
in O
children O
in O
the O
control O
group O
. O

Here O
we O
report O
the O
cloning O
, O
expression O
, O
and O
biochemical O
characterization O
of O
the O
32 O
- O
kDa O
subunit O
of O
human O
( O
h O
) O
TFIID I-GENE
, O
termed O
hTAFII32 NUMERIC
. O

Hemolytic RARE
jaundice O
due O
to O
G6PD NUMERIC
deficiency O
causing O
kernicterus RARE
in O
a O
female O
newborn O
. O

Two O
transcripts O
of O
1 O
. O
6 O
kb O
and O
5 O
. O
8 O
kb O
are O
5 O
' O
coterminal RARE
and O
may O
both O
encode O
the O
novel O
glycoprotein I-GENE
gene I-GENE
EUS4 NUMERIC
. O

Mean O
growth O
changes O
in O
this O
Class O
II O
sample O
were O
comparable O
to O
those O
previously O
reported O
for O
male O
subjects O
with O
Class O
I O
malocclusions RARE
over O
the O
same O
age O
period O
, O
suggesting O
a O
similarity O
in O
postpubertal RARE
development O
between O
these O
two O
groups O
. O

However O
, O
the O
few O
studies O
that O
address O
antimicrobial O
prophylaxis O
in O
bone O
marrow O
transplantation O
have O
not O
always O
shown O
a O
survival O
benefit O
. O

The O
fracture O
groups O
were O
significantly O
older O
and O
had O
more O
years O
since O
menopause RARE
than O
the O
control O
groups O
. O

In O
addition O
, O
we O
found O
differences O
in O
the O
binding O
of O
nuclear O
factors O
from O
shoots RARE
versus O
from O
roots O
, O
in O
agreement O
with O
the O
different O
activities O
of O
the O
promoter O
in O
these O
two O
organs O
. O

The O
prevalence O
and O
incidence O
of O
human O
immunodeficiency O
virus O
types O
1 O
and O
2 O
( O
HIV O
- O
1 O
, O
HIV O
- O
2 O
), O
human O
T O
- O
lymphotropic RARE
virus O
types O
I O
and O
II O
( O
HTLV O
- O
I O
/ O
II O
), O
and O
syphilitic RARE
infections O
and O
the O
association O
between O
these O
infections O
were O
determined O
in O
a O
cohort O
of O
police RARE
officers RARE
in O
Guinea RARE
- O
Bissau RARE
. O

By O
in O
vitro O
immunoprecipitations RARE
and O
gel O
shift O
assays O
, O
we O
identified O
two O
classes O
of O
high O
affinity O
Engrailed RARE
- I-GENE
binding I-GENE
sites I-GENE
upstream O
of O
each O
of O
the O
two O
polyhomeotic RARE
transcription O
units O
. O

Subjects RARE
with O
a O
short O
postexposure O
time O
and O
a O
dioxin O
burden O
> O
0 O
. O
6 O
pg O
/ O
m3 O
had O
a O
significantly O
higher O
risk O
of O
hypoergy RARE
than O
unexposed RARE
subjects O
( O
hypoergy RARE
I O
: O
OR O
= O
9 O
. O
51 O
, O
95 O
% O
CI O
= O
1 O
. O
96 O
- O
42 O
. O
02 O
; O
hypoergy RARE
II O
: O
OR O
= O
2 O
. O
92 O
, O
95 O
% O
CI O
= O
1 O
. O
14 O
- O
7 O
. O
5 O
). O

Analysis O
of O
this O
sequence O
combined O
with O
that O
previously O
reported O
for O
the O
5 O
'- O
flanking O
region O
directly O
proximal O
to O
the O
start O
of O
transcription O
revealed O
several O
putative O
regulatory O
sequences O
. O

We O
now O
show O
that O
the O
BAT1 NUMERIC
translation I-GENE
product I-GENE
is O
the O
homolog O
of O
the O
rat I-GENE
p47 NUMERIC
nuclear I-GENE
protein I-GENE
, O
the O
WM6 NUMERIC
Drosophila I-GENE
gene I-GENE
product I-GENE
, O
and O
probably O
also O
Ce08102 NUMERIC
of O
Caenorhabditis O
elegans O
, O
all O
members O
of O
the O
DEAD ALLCAPS
protein I-GENE
family I-GENE
of O
ATP I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
helicases RARE
. O

By O
using O
lacZ I-GENE
fusions I-GENE
, O
it O
was O
possible O
to O
localize O
the O
DNA O
sequences O
required O
to O
mediate O
nitrate O
repression O
to O
the O
pfl RARE
promoter I-GENE
- I-GENE
regulatory I-GENE
region I-GENE
. O

In O
this O
report O
, O
we O
describe O
the O
characterization O
of O
two O
early O
class I-GENE
II I-GENE
flagellar RARE
genes I-GENE
contained O
in O
the O
orfX LASTCAP
- O
fliP LASTCAP
locus O
. O

Vestibular RARE
adaptation O
exercises RARE
and O
recovery O
: O
acute O
stage O
after O
acoustic O
neuroma RARE
resection O
. O

The O
experimental O
design O
represents O
a O
2 O
x O
3 O
factorial RARE
arrangement O
of O
treatments O
with O
three O
dietary O
levels O
of O
incorporation O
of O
RSB ALLCAPS
( O
0 O
, O
50 O
, O
and O
100 O
%), O
and O
chickens O
either O
infected O
or O
uninfected RARE
. O

A O
cDNA O
clone O
corresponding O
to O
the O
putative O
GA I-GENE
20 I-GENE
- O
oxidase I-GENE
genomic O
sequence O
was O
constructed O
with O
the O
reverse O
transcription O
- O
PCR O
method O
, O
and O
the O
identity O
of O
the O
cDNA O
clone O
was O
confirmed O
by O
analyzing O
the O
capability RARE
of O
the O
fusion O
protein O
expressed O
in O
Escherichia O
coli O
to O
convert RARE
GA53 NUMERIC
to O
GA44 NUMERIC
and O
GA19 NUMERIC
to O
GA20 NUMERIC
. O

There O
were O
no O
significant O
changes O
in O
either O
the O
fatty O
acid O
composition O
of O
biliary O
lecithin RARE
or O
in O
the O
bile O
acid O
composition O
of O
bile O
. O

Total O
cholesterol O
was O
also O
reduced O
at O
week O
12 O
by O
17 O
. O
0 O
% O
( O
20 O
mg O
/ O
day O
) O
and O
15 O
. O
7 O
% O
( O
20 O
- O
30 O
mg O
/ O
day O
), O
and O
at O
week O
52 O
by O
20 O
. O
4 O
% O
(< O
or O
= O
20 O
mg O
/ O
day O
) O
and O
19 O
. O
2 O
% O
(> O
or O
= O
30 O
mg O
/ O
day O
). O

Although O
further O
studies O
are O
required O
to O
determine O
the O
precise O
role O
of O
PEBP2 NUMERIC
in O
the O
GM I-GENE
- I-GENE
CSF I-GENE
promoter I-GENE
activity O
, O
the O
present O
findings O
suggested O
the O
importance O
of O
the O
relative O
ratio O
of O
different O
PEBP2 NUMERIC
isoforms I-GENE
in O
regulating O
the O
levels O
of O
the O
promoter O
activity O
. O

Benefits RARE
of O
obtaining O
board RARE
certification RARE
in O
pharmacotherapy RARE
. O

Piperacillin RARE
- O
tazobactam RARE
can O
be O
used O
for O
the O
treatment O
of O
infections O
caused O
by O
gram O
- O
negative O
, O
gram O
- O
positive O
, O
aerobic O
, O
and O
anaerobic O
bacteria O
. O

Basal O
plasma O
renin I-GENE
activity O
( O
PRA ALLCAPS
) O
was O
slightly O
raised O
prior O
to O
training O
( O
P O
< O
0 O
. O
07 O
) O
compared O
to O
the O
controls O
and O
post O
- O
training O
. O

This O
apparently O
anomalous RARE
structure O
/ O
activity O
relationship O
raises RARE
important O
issues O
for O
understanding O
the O
evolution O
of O
regulatory O
peptides O
and O
the O
mechanisms O
that O
control O
their O
expression O
. O

The O
structural O
gene O
encoding O
the O
novel O
lantibiotic RARE
epilancin RARE
K7 NUMERIC
from O
Staphylococcus O
epidermidis RARE
K7 NUMERIC
was O
cloned O
and O
its O
nucleotide O
sequence O
was O
determined O
. O

This O
paper O
summarises RARE
the O
experimental O
evidence O
upon O
which O
the O
clinical O
trials O
of O
aldose RARE
reductase I-GENE
inhibitors O
in O
diabetic O
patients O
have O
been O
initiated O
and O
the O
results O
of O
published O
drug O
trials O
in O
these O
patients O
. O

The O
spectrum O
of O
phenotypes O
caused O
by O
these O
mutations O
was O
strikingly O
different O
than O
mutations O
in O
the O
adaptor O
for O
the O
VP16 I-GENE
activation I-GENE
domain I-GENE
. O

Increase RARE
in O
urinary O
calcium O
and O
oxalate RARE
after O
fructose O
infusion O
. O

The O
5 O
' O
flanking O
region O
is O
highly O
GC O
rich O
, O
with O
multiple O
CpG O
doublets RARE
, O
and O
contains O
multiple O
binding O
sites O
for O
Sp1 I-GENE
. O

To O
discern RARE
whether O
these O
disorders O
of O
GnRH I-GENE
deficiency O
are O
associated O
with O
altered O
melatonin O
secretion O
profiles O
, O
we O
compared O
untreated O
young O
males O
IGD ALLCAPS
( O
n O
= O
7 O
) O
and O
DP O
( O
n O
= O
7 O
) O
to O
normal O
pubertal RARE
male O
controls O
( O
n O
= O
6 O
). O

Increased O
blood O
pressure O
during O
CyA LASTCAP
treatment O
was O
independent O
of O
circulating O
ET I-GENE
- I-GENE
1 I-GENE
levels O
. O

Analysis O
of O
several O
Tat I-GENE
mutants I-GENE
indicated O
that O
both O
the O
cysteine O
- O
rich O
and O
the O
core O
domains O
of O
this O
transactivator O
are O
necessary O
and O
sufficient O
to O
activate O
transcription O
when O
TBP I-GENE
is O
overexpressed O
. O

In O
addition O
, O
depletion O
of O
Oct I-GENE
- I-GENE
1 I-GENE
from O
the O
nuclear O
extract O
by O
using O
Oct I-GENE
- I-GENE
1 I-GENE
- O
specific O
antiserum O
or O
a O
sequence O
- O
specific O
DNA O
affinity O
resin O
decreased O
in O
vitro O
transcription O
from O
the O
wild O
- O
type O
MMTV O
promoter O
to O
a O
level O
identical O
to O
that O
obtained O
from O
a O
promoter O
in O
which O
all O
three O
octamer O
- O
related O
sequences O
were O
mutated O
. O

Transactivation RARE
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
by O
T3R I-GENE
alpha I-GENE
and O
several O
receptor O
mutants O
revealed O
that O
the O
50 O
- O
amino O
- O
acid O
N O
- O
terminal O
A O
/ O
B O
region O
of O
T3R I-GENE
alpha I-GENE
, O
known O
to O
interact O
with O
the O
basal I-GENE
transcription I-GENE
factor I-GENE
TFIIB ALLCAPS
, O
is O
critical O
for O
activation O
of O
both O
Tat I-GENE
- O
dependent O
and O
Tat I-GENE
- O
independent O
responsive O
sequences O
of O
the O
LTR O
. O

M O
. O
M O
. O
C O
. O
was O
used O
for O
2 O
. O
5 O
minutes O
in O
44 O
cases O
( O
20 O
HR O
patients O
, O
24 O
LR ALLCAPS
patients O
), O
and O
for O
5 O
minutes O
in O
66 O
cases O
( O
46 O
HR O
patients O
, O
20 O
LR ALLCAPS
patients O
). O

Finally O
, O
we O
show O
that O
complexes O
similar O
to O
the O
C25 NUMERIC
, O
C30 NUMERIC
and O
C35 NUMERIC
complexes I-GENE
are O
formed O
by O
rat O
cortex O
nuclear O
extracts O
and O
the O
SAA ALLCAPS
element O
in O
EMSA O
experiments O
, O
suggesting O
the O
relevance O
of O
our O
in O
vitro O
observations O
to O
the O
in O
vivo O
functioning O
of O
the O
rat I-GENE
APP ALLCAPS
promoter I-GENE
. O

Oncological RARE
, O
clinical O
and O
psychological O
aspects O
are O
evaluated O
according O
to O
experience O
accumulated O
in O
recent O
years O
, O
with O
immediate O
and O
delayed O
reconstruction O
, O
carried O
out O
in O
the O
most O
diverse O
specialized O
centers O
. O

The O
analysis O
of O
the O
prevalence O
values O
shows O
clearly O
that O
the O
global O
MS O
- O
frequency O
is O
closer RARE
related O
to O
the O
geomagnetic RARE
than O
to O
the O
geographic RARE
latitude RARE
. O

Diltiazem RARE
caused O
significant O
decrease O
in O
the O
ventricular O
response O
without O
conversion O
to O
sinus O
rhythm O
. O

Subhuman RARE
primates O
appear O
to O
be O
more O
sensitive O
to O
reproductive O
and O
other O
adverse O
effects O
of O
PCBs RARE
than O
humans O
. O

When O
excluding O
children O
with O
ocular O
and O
cerebral O
pathology O
, O
32 O
matched O
pairs O
of O
premature O
and O
control O
children O
remained O
. O

The O
cryptococcal RARE
antigen I-GENE
test O
was O
positive O
at O
1 O
: O
125 O
by O
latex O
agglutination O
. O

Functional O
analysis O
of O
DNase I-GENE
- I-GENE
I I-GENE
hypersensitive O
sites O
at O
the O
mouse I-GENE
porphobilinogen RARE
deaminase I-GENE
gene I-GENE
locus I-GENE
. O

These O
transcripts O
have O
a O
unique O
5 O
' O
untranslated O
region O
and O
NH2 O
- O
terminal O
sequence O
and O
encode O
a O
predicted O
protein O
of O
121 O
kD O
. O

Both O
mu I-GENE
and I-GENE
gamma I-GENE
2b I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
cause O
this O
feedback RARE
inhibition O
of O
heavy O
chain O
gene O
rearrangement O
. O

Purified O
CarP LASTCAP
binds O
in O
vitro O
to O
the O
carAB LASTCAP
control I-GENE
region I-GENE
and O
protects RARE
against O
DNase I-GENE
I I-GENE
two O
approximately O
25 O
bp O
long O
stretches O
, O
one O
of O
which O
is O
located O
just O
downstream O
of O
the O
GATC ALLCAPS
sequence O
. O

They O
include O
genes O
encoding O
three O
subunits O
of O
the O
cytochrome I-GENE
oxidase I-GENE
( O
cox1 NUMERIC
to I-GENE
3 I-GENE
), O
apocytochrome RARE
b I-GENE
( O
cob RARE
), O
seven O
subunits O
of O
the O
NADH I-GENE
dehydrogenase I-GENE
complex I-GENE
( O
nad1 NUMERIC
to I-GENE
6 I-GENE
, O
nad4L NUMERIC
), O
two O
ATPase I-GENE
subunits O
( O
atp6 NUMERIC
and O
atp9 NUMERIC
), O
three O
ribosomal O
RNAs O
( O
rrn5 NUMERIC
, O
srn RARE
and O
lrn RARE
), O
23 O
tRNAs RARE
and O
four O
ribosomal O
proteins O
( O
rps3 NUMERIC
, O
rps11 NUMERIC
, O
rps12 NUMERIC
and O
rpl16 NUMERIC
). O

From O
day O
10 O
, O
a O
significant O
increase O
in O
platelet O
count O
was O
observed O
in O
eight O
of O
the O
ten O
patients O
treated O
with O
heparin O
( O
p O
< O
0 O
. O
05 O
), O
with O
return O
to O
the O
initial O
value O
after O
heparin O
cessation O
in O
six O
of O
the O
responders O
. O

These O
" O
nucleocapsid RARE
- O
like O
" O
structures O
were O
readily O
purified O
by O
density O
gradient O
centrifugation RARE
. O

The O
Babcock RARE
Surgical RARE
Clinic RARE
. O

Resources RARE
for O
helping RARE
patients O
to O
quit RARE
smoking O
. O

The O
PEBP2 NUMERIC
alpha I-GENE
proteins I-GENE
contain O
a O
128 O
- O
amino O
- O
acid O
( O
aa O
) O
region O
highly O
homologous O
to O
the O
Drosophila I-GENE
melanogaster I-GENE
segmentation I-GENE
gene I-GENE
runt RARE
. O

In O
human O
proliferative O
cells O
, O
the O
NADP ALLCAPS
- O
dependent O
ME ALLCAPS
activity O
is O
poorly O
expressed O
and O
barely RARE
inducible O
by O
thyroid O
hormones O
. O

Based O
on O
previous O
mapping O
of O
the O
G I-GENE
beta I-GENE
gamma I-GENE
binding I-GENE
region I-GENE
of O
beta I-GENE
ARK ALLCAPS
, O
and O
conserved O
residues O
within O
the O
PH I-GENE
domain I-GENE
, O
we O
have O
constructed O
a O
series O
of O
mutants O
in O
the O
carboxyl O
terminus O
of O
beta I-GENE
ARK ALLCAPS
in O
order O
to O
determine O
important O
residues O
involved O
in O
G I-GENE
beta I-GENE
gamma I-GENE
and O
PIP2 O
binding O
. O

Histopathological RARE
features O
of O
relapsed RARE
leprosy RARE
. O

To O
dissect RARE
these O
mechanisms O
, O
wild O
- O
type O
and O
mutant I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
were O
studied O
in O
an O
in O
vitro O
system O
with O
purified O
plasma O
membranes O
from O
v I-GENE
- I-GENE
Ras I-GENE
- O
and O
v I-GENE
- I-GENE
Src I-GENE
- O
transformed O
cells O
( O
transformed O
membranes O
). O

In O
CV ALLCAPS
- O
1 O
cells O
, O
cotransfection O
of O
the O
retinoid I-GENE
and I-GENE
estrogen I-GENE
receptors I-GENE
led O
to O
mutual RARE
inhibition O
of O
the O
other O
' O
s O
activity O
, O
while O
an O
RA O
- O
dependent O
inhibition O
of O
ER I-GENE
activity O
was O
observed O
in O
breast O
cancer O
cells O
. O

One O
of O
these O
factors O
, O
HRF ALLCAPS
- I-GENE
1 I-GENE
, O
recognizes O
a O
cis O
element O
consisting O
of O
an O
inverted O
palindromic O
motif O
. O

Regulation O
of O
Gax RARE
homeobox I-GENE
gene I-GENE
transcription O
by O
a O
combination O
of O
positive O
factors O
including O
myocyte I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
factor I-GENE
2 I-GENE
. O

The O
carboxyl O
- O
terminal O
transactivation O
domain O
of O
heat I-GENE
shock I-GENE
factor I-GENE
1 I-GENE
is O
negatively O
regulated O
and O
stress O
responsive O
. O

D O
. O

It O
was O
proposed O
that O
the O
synthetase O
- O
related O
sequences O
of O
GCN2 I-GENE
stimulate O
the O
activity O
of O
the O
kinase O
by O
interacting O
directly O
with O
uncharged RARE
tRNA O
that O
accumulates O
during O
amino O
acid O
limitation O
. O

However O
, O
unlike O
Bcl I-GENE
- I-GENE
2 I-GENE
and O
the O
E1B I-GENE
19K NUMERIC
proteins I-GENE
, O
which O
completely O
block O
apoptosis O
but O
not O
p53 I-GENE
- O
dependent O
growth O
arrest O
, O
H I-GENE
- I-GENE
ras I-GENE
expression O
permitted O
DNA O
synthesis O
and O
cell O
proliferation O
in O
the O
presence O
of O
high O
levels O
of O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
. O

To O
compare O
the O
PAX3 NUMERIC
and O
putative O
PAX3 NUMERIC
- O
FKHR ALLCAPS
transactivation O
domains O
, O
we O
fused O
C O
- O
terminal O
test O
fragments O
to O
the O
heterologous O
GAL4 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
and O
tested O
activation O
of O
a O
reporter O
gene O
co O
- O
transfected O
into O
four O
cell O
types O
. O

All O
subjects O
were O
submitted O
to O
ECG O
and O
arterial O
blood O
pressure O
determination O
and O
were O
assayed O
for O
TSH I-GENE
, O
thyroid O
hormone O
, O
PRL I-GENE
, O
glucose O
, O
creatinine O
, O
nitrogen O
, O
glutamine I-GENE
transaminase RARE
, O
cholesterol O
and O
triglycerides O
plasma O
levels O
before O
therapy O
( O
T0 NUMERIC
), O
after O
30 O
treatment O
days O
( O
T30 NUMERIC
) O
and O
after O
a O
15 O
days O
washout O
( O
T45 NUMERIC
). O

Acute O
decrease O
in O
body O
temperature O
( O
TB O
) O
lowered O
PaCO2 O
( O
32 O
. O
5 O
to O
14 O
. O
5 O
mmHg O
) O
and O
[ O
HCO3 O
-] RARE
a O
( O
24 O
. O
20 O
mEq O
/ O
L O
to O
17 O
. O
56 O
mEq O
/ O
L O
), O
increased O
pHa RARE
( O
7 O
. O
481 NUMERIC
to O
7 O
. O
608 NUMERIC
) O
and O
diminished O
the O
[ O
OH O
-]/[ RARE
H O
+] RARE
ratio O
, O
but O
had O
no O
significant O
effect O
on O
[ O
SID ALLCAPS
] O
or O
[ O
Atot RARE
], O
although O
both O
total O
phosphorus O
[ O
PT O
] O
and O
inorganic O
phosphate O
[ O
Pi RARE
] O
increased O
. O

Hepatitis O
B O
vaccine O
: O
still O
has O
its O
problems O
. O

Basal O
promoter O
activity O
is O
enhanced O
by O
a O
functional O
M1 O
domain O
in O
LHR I-GENE
- O
expressing O
mouse O
Leydig RARE
tumor O
cells O
( O
MLTC ALLCAPS
) O
but O
not O
in O
non O
- O
expressing O
CHO O
cells O
. O

The O
RAT3 NUMERIC
gene I-GENE
encodes O
an O
1157 NUMERIC
- O
amino O
acid O
protein O
without O
similarity O
to O
other O
known O
proteins O
. O

For O
Al O
, O
the O
exposure O
to O
1 O
. O
36 O
mg O
/ O
m3 O
during O
the O
shift O
corresponded O
to O
a O
urinary O
concentration O
at O
the O
end O
of O
the O
shift O
of O
200 O
microgram O
/ O
g O
creatinine O
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
alpha I-GENE
), O
a O
proinflammatory RARE
cytokine O
, O
inhibits O
cAMP O
- O
stimulated O
testosterone O
production O
in O
mouse O
Leydig RARE
cells O
. O

The O
Drosophila I-GENE
insulin I-GENE
receptor I-GENE
homolog I-GENE
: O
a O
gene O
essential O
for O
embryonic O
development O
encodes O
two O
receptor O
isoforms O
with O
different O
signaling O
potential O
. O

We O
show O
here O
that O
RA O
and O
E1A I-GENE
induce O
phosphorylation O
of O
the O
E1A I-GENE
- I-GENE
associated I-GENE
300 I-GENE
kDa I-GENE
protein I-GENE
( O
p300 I-GENE
) O
during O
the O
differentiation O
of O
F9 O
cells O
. O

The O
double O
- O
stranded O
RNA O
binding O
domain O
( O
dsRBD LASTCAP
) O
is O
an O
approximately O
65 O
amino O
acid O
motif O
that O
is O
found O
in O
a O
variety O
of O
proteins O
that O
interact O
with O
double O
- O
stranded O
( O
ds RARE
) O
RNA O
, O
such O
as O
Escherichia O
coli O
RNase I-GENE
III I-GENE
and O
the O
dsRNA I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
, O
PKR I-GENE
. O

CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
isoforms I-GENE
beta I-GENE
and I-GENE
delta I-GENE
are O
expressed O
in O
mammary O
epithelial O
cells O
and O
bind O
to O
multiple O
sites O
in O
the O
beta I-GENE
- I-GENE
casein I-GENE
gene I-GENE
promoter I-GENE
. O

SCA ALLCAPS
was O
resistant O
to O
inhibitors O
of O
serine O
, O
aspartyl RARE
, O
and O
metalloproteases RARE
, O
but O
it O
was O
sensitive O
to O
N O
- O
ethylmaleimide RARE
. O

Mutational O
analysis O
of O
potential O
activating O
phosphorylation O
sites O
found O
in O
NIMA ALLCAPS
, O
NIM ALLCAPS
- I-GENE
1 I-GENE
, O
and O
related O
protein O
kinases O
was O
performed O
on O
NIMA ALLCAPS
. O

However O
, O
a O
similar O
mutation O
of O
a O
leucine O
residue O
to O
arginine O
at O
position O
422 NUMERIC
showed O
no O
alteration O
of O
heterodimerization O
, O
DNA O
binding O
, O
or O
transcriptional O
activation O
. O

Expression O
of O
the O
CYP11A1 NUMERIC
gene I-GENE
is O
increased O
by O
hormones O
, O
such O
as O
adrenocorticotropin RARE
and O
luteinizing RARE
hormone I-GENE
, O
as O
well O
as O
by O
a O
number O
of O
growth O
factors O
, O
suggesting O
that O
its O
promoter O
may O
contain O
regulatory O
elements O
that O
respond O
to O
multiple O
signal O
transduction O
pathways O
. O

NH2 O
- O
and O
COOH O
- O
terminal O
deletion O
analysis O
revealed O
that O
both O
the O
PH I-GENE
and O
putative O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
domains I-GENE
are O
required O
, O
but O
the O
zinc O
butterfly RARE
is O
dispensable O
, O
for O
transformation O
. O

We O
have O
found O
that O
the O
expression O
of O
GTPase I-GENE
- O
deficient O
mutants O
of O
alpha I-GENE
12 I-GENE
( O
alpha I-GENE
12Q229L NUMERIC
) O
or O
alpha I-GENE
13 I-GENE
( O
alpha I-GENE
13Q226L NUMERIC
) O
leads O
to O
robust RARE
activation O
of O
the O
Jun I-GENE
kinase I-GENE
/ O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
JNK I-GENE
/ O
SAPK I-GENE
) O
pathway O
. O

The O
objective O
of O
our O
study O
was O
to O
evaluate O
the O
age O
, O
sex O
, O
clinical O
conditions O
, O
family O
history O
, O
site O
, O
catheter O
association O
, O
means O
of O
radiologic RARE
evaluation O
, O
development O
of O
pulmonary O
involvement O
, O
prevalence O
of O
antithrombin I-GENE
III I-GENE
, O
protein I-GENE
C I-GENE
and O
protein I-GENE
S I-GENE
deficiencies O
, O
and O
lupus O
anticoagulants RARE
in O
children O
who O
suffered RARE
a O
thrombotic O
event O
. O

Harel RARE
, O
E O
. O
M O
. O

Radiotherapy RARE
and O
early O
orchiectomy RARE
in O
stage O
D1 O
prostatic O
carcinoma O

Structural O
organization O
and O
developmental O
expression O
pattern O
of O
the O
mouse I-GENE
WD I-GENE
- I-GENE
repeat I-GENE
gene I-GENE
DMR ALLCAPS
- I-GENE
N9 NUMERIC
immediately O
upstream O
of O
the O
myotonic RARE
dystrophy I-GENE
locus I-GENE
. O

The O
ARX2 NUMERIC
procedure O
models O
the O
recorded O
signal O
as O
the O
sum O
of O
three O
signals O
: O
( O
a O
) O
the O
background O
EEG O
activity O
, O
modelled RARE
as O
an O
autoregressive RARE
process O
driven O
by O
a O
white O
noise O
; O
( O
b O
) O
a O
filtered RARE
version O
of O
a O
reference O
signal O
carrying O
the O
average O
information O
contained O
in O
each O
sweep RARE
; O
( O
c O
) O
a O
signal O
due O
to O
the O
ocular O
artefact RARE
propagation RARE
. O

The O
expression O
of O
the O
gene O
encoding O
the O
enzyme O
( O
CYP19 NUMERIC
) O
is O
regulated O
, O
in O
part O
, O
by O
tissue O
- O
specific O
promoters O
through O
the O
use O
of O
alternative O
- O
splicing O
mechanisms O
. O

Using O
mutagenesis O
, O
we O
have O
identified O
two O
mutations O
of O
the O
second O
actin I-GENE
- I-GENE
binding I-GENE
domain I-GENE
that O
can O
also O
suppress O
the O
act1 NUMERIC
mutations O
of O
interest O
. O

CIITA ALLCAPS
mRNA I-GENE
is O
normally O
inducible O
by O
IFN I-GENE
- I-GENE
gamma I-GENE
in O
class O
II O
non O
- O
inducible O
, O
RB O
- O
defective O
lines O
, O
and O
in O
one O
line O
, O
re O
- O
expression O
of O
RB I-GENE
has O
no O
effect O
on O
CIITA ALLCAPS
mRNA I-GENE
induction O
levels O
. O

The O
normal O
cell O
cycle O
is O
regulated O
by O
several O
molecules O
, O
such O
as O
the O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
pRb I-GENE
, O
the O
G1 I-GENE
cyclins RARE
, O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
and O
their O
inhibitors O
. O

Consistent O
with O
the O
protein O
expression O
data O
, O
V I-GENE
beta I-GENE
8 I-GENE
. I-GENE
3 I-GENE
gene I-GENE
transcripts I-GENE
were O
found O
only O
in O
the O
transgenic O
lines O
with O
the O
wild O
- O
type O
promoter O
. O

These O
results O
are O
very O
useful O
for O
deciding RARE
on O
the O
doses O
of O
hormones O
and O
the O
expected O
serum O
estradiol O
level O
in O
HRT ALLCAPS
for O
Japanese O
women O
. O

Comparison O
of O
1 O
. O
5 O
Tesla RARE
and O
0 O
. O
35 O
Tesla RARE
field O
strength O
magnetic O
resonance O
imaging O
scans O
in O
the O
morphometric RARE
evaluation O
of O
the O
lumbar O
intervertebral RARE
foramina RARE
. O

One O
month O
after O
the O
DTaP LASTCAP
booster RARE
vaccination O
, O
both O
groups O
had O
6 O
- O
to O
40 O
- O
fold O
increases O
in O
serum O
antibody O
concentrations O
to O
all O
antigens O
tested O
; O
the O
concentrations O
against O
the O
three O
pertussis I-GENE
antigens I-GENE
were O
higher O
in O
the O
DTaP LASTCAP
- O
primed O
children O
( O
p O
< O
0 O
. O
05 O
). O

Interestingly O
, O
this O
amino O
- O
terminal O
determinant O
appears O
not O
to O
reside O
in O
the O
HSV O
- O
alpha I-GENE
TIF I-GENE
, O
which O
displays O
no O
independent O
amino O
- O
terminal O
activity O
. O

We O
also O
show O
that O
in O
fusions O
with O
the O
DNA O
binding O
domain O
of O
GAL4 I-GENE
, O
full O
activity O
requires O
the O
entire O
BHV ALLCAPS
- I-GENE
alpha I-GENE
TIF I-GENE
, O
although O
both O
amino O
and O
carboxyl O
termini O
display O
some O
activity O
on O
their O
own O
. O

To O
investigate O
the O
potential O
role O
of O
SP1 I-GENE
, O
we O
examined O
nuclear O
extracts O
from O
HCMV O
- O
infected O
cells O
. O

Here O
we O
show O
that O
messenger O
RNAs O
encoding O
trans O
- O
sialidases RARE
containing O
the O
repeats O
are O
not O
present O
in O
epimastigotes RARE
but O
are O
abundant O
in O
trypomastigotes RARE
. O

From O
May RARE
1985 O
to O
May RARE
1989 O
, O
126 O
necropsies RARE
were O
performed O
at O
the O
Sao RARE
Paulo RARE
City O
Morgue RARE
on O
cadavers RARE
of O
individuals O
AIDS O
victims O
whose O
unnatural RARE
deaths O
had O
prompted RARE
police RARE
investigations O
. O

A O
model O
with O
age O
and O
weight O
described O
the O
best O
fit O
for O
TBBMD ALLCAPS
, O
whereas O
age O
, O
weight O
, O
and O
height O
described O
the O
best O
fit O
for O
total O
body O
TBBMC ALLCAPS
. O

As O
retinoic O
acid O
and O
thyroid O
hormone O
are O
frequently O
involved O
in O
developmental O
regulatory O
processes O
, O
it O
is O
possible O
that O
this O
element O
may O
be O
important O
in O
the O
process O
of O
islet O
cell O
differentiation O
. O

The O
C O
- O
terminal O
peptide O
sequences O
of O
the O
human I-GENE
lymphocyte I-GENE
- I-GENE
specific I-GENE
high I-GENE
mobility I-GENE
group I-GENE
( I-GENE
HMG I-GENE
)- I-GENE
box I-GENE
transcription I-GENE
factor I-GENE
TCF I-GENE
- I-GENE
1 I-GENE
are O
determined O
by O
alternative O
splice O
mechanisms O
affecting O
the O
exons O
VIII O
to O
X O
. O

Thromboxane RARE
B2 O
increased O
( O
97 O
+/- O
105 O
versus O
40 O
+/- O
26 O
pg O
/ O
ml O
) O
and O
was O
significantly O
higher O
during O
heparin O
free O
hemodialysis O
than O
during O
hemodialysis O
with O
heparin O
( O
p O
= O
0 O
. O
01 O
, O
Wilcoxon RARE
matched O
pairs O
signed RARE
rank RARE
test O
). O

A O
new O
vector O
, O
pHBK280 NUMERIC
, O
was O
designed O
to O
facilitate O
this O
analysis O
. O

To O
explore O
the O
mechanism O
of O
RSK ALLCAPS
activation O
, O
a O
cloned O
human O
RSK ALLCAPS
cDNA O
( O
RSK3 NUMERIC
) O
was O
used O
to O
generate O
and O
characterize O
several O
site O
- O
directed O
RSK ALLCAPS
mutants I-GENE
; O
K91A NUMERIC
( O
N O
- O
Lys O
, O
NH2 O
- O
terminal O
ATP O
- O
binding O
mutant O
), O
K444A NUMERIC
( O
C O
- O
Lys O
, O
COOH O
- O
terminal O
ATP O
- O
binding O
mutant O
), O
N O
/ O
C O
- O
Lys O
( O
double O
ATP O
- O
binding O
mutant O
) O
T570A NUMERIC
( O
C O
- O
Thr O
, O
mutant O
of O
the O
putative O
MAPK I-GENE
phosphorylation O
site O
in O
subdomain O
VIII O
of O
the O
C O
- O
domain O
), O
S218A NUMERIC
( O
N O
- O
Ser O
, O
mutant O
of O
the O
corresponding O
NH2 O
- O
terminal O
residue O
). O

In O
contrast O
, O
both O
C O
- O
Lys O
and O
C O
- O
Thr O
retained O
high O
levels O
of O
kinase O
activity O
and O
were O
capable O
of O
responding O
to O
stimulation O
. O

Conversely O
, O
treatment O
of O
human I-GENE
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
alpha I-GENE
- O
overexpressing O
cells O
with O
phenylarsine RARE
oxide O
led O
to O
a O
loss O
of O
the O
constitutive O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
activity O
. O

A O
TATA O
- O
less O
promoter O
containing O
binding O
sites O
for O
ubiquitous O
transcription O
factors O
mediates O
cell O
type O
- O
specific O
regulation O
of O
the O
gene O
for O
transcription I-GENE
enhancer I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
TEF I-GENE
- I-GENE
1 I-GENE
). O

Since O
electrical O
stimulation O
of O
neurones O
may O
activate O
not O
only O
cell O
bodies O
but O
also O
neuronal O
fibres O
, O
this O
study O
aimed O
to O
test O
a O
selectively O
cholinergic O
neurochemical RARE
stimulation O
of O
the O
rat O
substantia RARE
innominata RARE
( O
SI ALLCAPS
) O
by O
the O
local O
microinjection O
of O
carbachol O
; O
the O
effects O
of O
this O
acetylcholine O
agonist O
were O
compared O
with O
glutamate O
. O

Here O
we O
describe O
an O
in O
vitro O
assay O
where O
the O
NS3 I-GENE
- I-GENE
4A NUMERIC
polyprotein RARE
, O
NS3 I-GENE
, O
the O
serine O
proteinase O
domain O
( O
the O
N O
- O
terminal O
181 NUMERIC
residues O
of O
NS3 O
), O
and O
the O
NS4A NUMERIC
cofactor I-GENE
were O
produced O
by O
cell O
- O
free O
translation O
and O
tested O
for O
trans O
- O
processing O
of O
radiolabeled O
substrates O
. O

In O
contrast O
, O
over O
- O
expression O
of O
RAR I-GENE
beta I-GENE
only O
poorly O
restored O
differentiation O
, O
although O
it O
could O
replace O
RAR I-GENE
gamma I-GENE
for O
the O
activation O
of O
target O
genes O
. O

We O
purified O
both O
proteins O
from O
human O
platelet O
membranes O
using O
DEAE ALLCAPS
- O
Sepharose RARE
chromatography O
followed O
by O
mAb I-GENE
F11 NUMERIC
affinity O
chromatography O
. O

The O
homeobox I-GENE
gene I-GENE
ATK1 NUMERIC
of O
Arabidopsis O
thaliana O
is O
expressed O
in O
the O
shoot RARE
apex O
of O
the O
seedling RARE
and O
in O
flowers RARE
and O
inflorescence RARE
stems RARE
of O
mature O
plants O
. O

The O
most O
likely O
explanation O
for O
this O
is O
that O
gold RARE
principally RARE
accumulates O
in O
the O
Kupffer RARE
cells O
and O
renal O
cortex O
and O
these O
cells O
do O
not O
express O
Type I-GENE
I I-GENE
deiodinase I-GENE
. O

These O
results O
suggest O
that O
different O
models O
of O
intestinal O
ischemia O
have O
different O
cytokine O
profiles O
and O
that O
the O
early O
TNF I-GENE
response O
associated O
with O
SMA ALLCAPS
occlusion O
model O
is O
primarily O
due O
to O
the O
laparotomy RARE
. O

Our O
evidence O
derives RARE
from O
three O
principal O
observations O
: O
1 O
) O
a O
transfection O
construct O
containing O
only O
122 O
nucleotides O
( O
nt O
) O
of O
promoter O
1 O
and O
328 NUMERIC
nt O
of O
the O
5 O
'- O
UTR O
retained O
full O
PGE2 O
- O
stimulated O
reporter O
expression O
; O
2 O
) O
maximal O
PGE2 O
- O
driven O
reporter O
expression O
required O
the O
presence O
of O
nt O
196 NUMERIC
to O
328 NUMERIC
of O
exon O
1 O
when O
tested O
within O
the O
context O
of O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
1 I-GENE
; O
3 O
) O
cotransfection O
of O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
- O
luciferase I-GENE
- O
reporter O
constructs O
with O
a O
plasmid O
encoding O
the O
alpha O
- O
isoform O
of O
the O
catalytic O
subunit O
of O
murine I-GENE
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKA I-GENE
) O
produced O
results O
comparable O
to O
those O
seen O
with O
PGE2 O
treatment O
, O
whereas O
cotransfection O
with O
a O
plasmid O
encoding O
a O
mutant O
regulatory O
subunit O
of O
PKA I-GENE
that O
cannot O
bind O
cAMP O
blocked O
PGE2 O
- O
induced O
reporter O
expression O
. O

The O
changes O
after O
treatment O
were O
observed O
chiefly RARE
by O
electromyography RARE
while O
sensory O
and O
motor O
improvement O
were O
also O
recorded O
as O
auxiliary O
indicators O
. O

Band RARE
- O
shift O
assays O
and O
DNase I-GENE
I I-GENE
footprinting O
experiments O
using O
purified O
42 O
kDa O
repressor O
isoform O
confirmed O
that O
CIRs RARE
5 I-GENE
and I-GENE
6 I-GENE
were O
indeed O
the O
targets O
for O
binding O
of O
this O
protein O
. O

The O
5 O
'- O
terminus O
of O
the O
p I-GENE
- I-GENE
gvpF LASTCAP
- I-GENE
M I-GENE
mRNA I-GENE
was O
located O
169 NUMERIC
nucleotides O
upstream O
of O
p I-GENE
- I-GENE
gvpF LASTCAP
within O
p I-GENE
- I-GENE
gvpE LASTCAP
. O

Retransformation RARE
of O
uvsH77 NUMERIC
mutants I-GENE
with O
the O
rescued RARE
cosmids RARE
from O
the O
MMS ALLCAPS
- O
resistant O
transformants O
resulted O
in O
restoration RARE
of O
both O
UV O
and O
MMS ALLCAPS
resistance O
to O
wild O
- O
type O
levels O
. O

Furthermore O
, O
this O
element O
confers O
p53 I-GENE
induction O
to O
the O
otherwise O
nonresponsive RARE
adenovirus O
major O
late O
promoter O
. O

In O
flies RARE
, O
the O
dShc RARE
protein I-GENE
physically O
associates O
with O
the O
activated O
Drosophila I-GENE
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
homolog I-GENE
( O
DER I-GENE
) O
and O
is O
inducibly RARE
phosphorylated O
on O
tyrosine O
by O
DER I-GENE
. O

A O
potential O
binding O
site O
for O
the O
dShc RARE
PTB O
domain O
is O
located O
at O
Tyr O
- O
1228 NUMERIC
of O
DER I-GENE
. O

A O
Drosophila I-GENE
shc RARE
gene I-GENE
product I-GENE
is O
implicated O
in O
signaling O
by O
the O
DER I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
. O

This O
inhibition O
can O
be O
overcome O
by O
mutating RARE
either O
the O
exon O
' O
s O
5 O
' O
or O
3 O
' O
splice O
site O
to O
make O
it O
correspond O
more O
closely O
to O
the O
relevant O
consensus O
sequence O
. O

Biochemical O
analysis O
shows O
that O
Ssm1p NUMERIC
is O
a O
structural O
protein O
that O
forms O
part O
of O
the O
largest O
60S NUMERIC
ribosomal I-GENE
subunit I-GENE
, O
which O
does O
not O
exist O
in O
a O
pool O
of O
free O
proteins O
. O

In O
wild O
- O
type O
cells O
, O
SSM1b NUMERIC
transcripts I-GENE
accumulate O
to O
twice O
the O
level O
of O
SSM1a NUMERIC
transcripts I-GENE
, O
suggesting O
that O
SSM1b NUMERIC
is O
responsible O
for O
the O
majority O
of O
the O
Ssm1p NUMERIC
pool O
. O

Northern O
blot O
analysis O
revealed O
the O
expression O
of O
LIMK ALLCAPS
- I-GENE
1 I-GENE
mRNA I-GENE
predominantly O
in O
the O
brain O
and O
the O
expression O
of O
LIMK ALLCAPS
- I-GENE
2 I-GENE
mRNA I-GENE
in O
various O
tissues O
in O
the O
rat O
. O

However O
, O
the O
relative O
binding O
affinity O
for O
the O
motifs O
is O
different O
. O

On O
the O
basis O
of O
this O
anatomic O
concept O
, O
the O
brachioplasty RARE
procedure O
was O
modified O
to O
provide O
secure RARE
anchoring RARE
of O
the O
arm O
flap O
to O
the O
axillary RARE
fascia RARE
along O
with O
strong O
superficial O
fascial RARE
system O
repair O
of O
incisions RARE
, O
reducing O
the O
risk O
of O
widening RARE
or O
migration O
of O
scars RARE
and O
unnatural RARE
contours RARE
. O

Furthermore O
, O
microinjection O
of O
dominant O
negative O
forms O
of O
Rac I-GENE
and O
Cdc42 I-GENE
or O
of O
the O
Rho I-GENE
inhibitor O
C3 I-GENE
transferase I-GENE
blocked O
serum O
- O
induced O
DNA O
synthesis O
. O

INF ALLCAPS
- I-GENE
alpha I-GENE
therapy O
has O
been O
a O
major O
development O
in O
the O
treatment O
of O
CML O
. O

A O
series O
of O
amino O
terminal O
deletion O
mutants O
( O
d10 NUMERIC
, O
d20 NUMERIC
, O
d27 NUMERIC
, O
d31 NUMERIC
, O
d40 NUMERIC
, O
d44 NUMERIC
, O
and O
d73 NUMERIC
) O
were O
compared O
for O
processing O
, O
cell O
surface O
expression O
, O
and O
maintenance O
of O
their O
biological O
attributes RARE
by O
recombinant O
expression O
of O
mutant O
genes O
using O
a O
plasmid O
vector O
( O
pcDL LASTCAP
- O
SR O
alpha O
- O
296 O
) O
in O
CV ALLCAPS
- O
1 O
and O
HeLa O
cells O
. O

Intrathecal RARE
acetyl I-GENE
cholinesterase I-GENE
inhibitors O
produce O
analgesia O
that O
is O
synergistic O
with O
morphine O
and O
clonidine RARE
in O
rats O
. O

After O
determining O
isoflurane O
MAC ALLCAPS
in O
triplicate RARE
, O
birds O
were O
given O
a O
mu O
- O
opioid O
agonist O
( O
morphine O
, O
n O
= O
9 O
) O
or O
a O
kappa O
- O
opioid O
agonist O
( O
U50488H NUMERIC
, O
n O
= O
9 O
). O

Max I-GENE
was O
constantly RARE
transcribed O
at O
a O
relatively O
low O
level O
during O
cell O
cycle O
progression O
. O

The O
yeast O
enzyme O
was O
6 O
- O
fold O
slower O
than O
the O
mammalian O
enzymes O
, O
which O
made O
it O
amenable RARE
to O
pre O
- O
steady O
- O
state O
stopped O
- O
flow O
spectroscopic RARE
kinetic O
analysis O
at O
30 O
degrees O
C O
and O
pH O
6 O
. O
0 O
. O

Key RARE
areas O
of O
the O
selection O
process O
including O
medical O
and O
surgical O
alternatives RARE
to O
transplantation O
, O
the O
composition O
of O
the O
transplant O
work O
- O
up O
, O
specific O
inclusion O
criteria O
as O
well O
as O
specific O
psychosocial RARE
factors O
and O
specific O
disease O
etiologies RARE
and O
co O
- O
morbidities RARE
that O
might O
represent O
contraindications RARE
were O
extensively O
reviewed O
. O

The O
transport O
of O
a O
genetically O
engineered O
chimeric O
transmembrane O
protein O
connected O
to O
this O
ER O
leader O
sequence O
was O
as O
efficient O
as O
that O
of O
the O
original O
protein O
from O
which O
the O
ER O
sequence O
has O
been O
derived O
. O

In O
both O
shoots RARE
and O
roots O
, O
GT I-GENE
- I-GENE
2 I-GENE
protein I-GENE
is O
undetectable O
in O
meristematic RARE
tissue O
but O
becomes O
expressed O
at O
later O
stages O
of O
cellular O
development O
, O
consistent O
with O
a O
role O
in O
contributing RARE
to O
the O
pattern O
of O
phytochrome RARE
A I-GENE
gene I-GENE
expression O
. O

A O
polymorphic O
bipartite O
motif O
signals O
nuclear O
targeting O
of O
early O
auxin RARE
- O
inducible O
proteins O
related O
to O
PS O
- O
IAA4 NUMERIC
from O
pea RARE
( O
Pisum RARE
sativum RARE
). O

Comparative O
DNA O
sequence O
analysis O
showed O
the O
Genethon RARE
microsatellite I-GENE
D19S596 NUMERIC
lies O
2 O
. O
2 O
kb O
downstream O
of O
the O
coding O
region O
of O
FUT1 NUMERIC
, O
indicating O
that O
the O
cluster O
comprising RARE
the O
closely O
linked O
FUT1 NUMERIC
and O
FUT2 NUMERIC
genes I-GENE
is O
located O
4 O
cM LASTCAP
distal O
to O
D19S412 NUMERIC
( O
lod RARE
score O
13 O
. O
7 O
) O
and O
9 O
cM LASTCAP
proximal O
to O
D19S571 NUMERIC
( O
lod RARE
score O
11 O
. O
7 O
). O

We O
conclude O
that O
transcription O
activation O
by O
LEF ALLCAPS
- I-GENE
1 I-GENE
in O
vitro O
is O
a O
chromatin O
- O
dependent O
process O
that O
requires O
a O
functional O
trans O
- O
activation O
domain O
in O
addition O
to O
the O
HMG I-GENE
domain I-GENE
. O

TH I-GENE
- O
SH3 I-GENE
binding O
in O
vitro O
is O
abolished O
by O
specific O
, O
single O
amino O
acid O
substitutions O
within O
the O
Btk RARE
TH I-GENE
domain I-GENE
or O
the O
Fyn I-GENE
SH3 I-GENE
domain I-GENE
. O

These O
results O
indicate O
that O
K I-GENE
- I-GENE
glypican RARE
is O
a O
novel O
GPI I-GENE
- I-GENE
anchored I-GENE
HSPG ALLCAPS
involved O
in O
embryonic O
development O
. O

Protein I-GENE
S I-GENE
levels O
were O
virtually O
undetectable O
at O
the O
time O
of O
admission O
and O
failed O
to O
respond O
to O
infusions RARE
of O
fresh O
frozen RARE
plasma O
, O
despite O
correction O
of O
other O
procoagulant RARE
and O
anticoagulant O
factors O
. O

The O
plant O
hormone O
auxin RARE
transcriptionally O
activates O
early I-GENE
genes I-GENE
. O

The O
test O
was O
not O
performed O
in O
3923 NUMERIC
patients O
because O
of O
contraindications RARE
. O

The O
ubiquitous O
transcription O
factor O
Oct I-GENE
- I-GENE
1 I-GENE
forms O
complexes O
with O
an O
octamer O
motif O
present O
within O
FPIV ALLCAPS
by O
gel O
shift O
analysis O
with O
liver O
and O
kidney O
extracts O
, O
making O
Oct I-GENE
- I-GENE
1 I-GENE
an O
intriguing RARE
candidate O
for O
partnership RARE
in O
androgen O
regulation O
. O

A O
new O
non O
- O
LTR O
retrotransposon O
provides O
evidence O
for O
multiple O
distinct O
site O
- O
specific O
elements O
in O
Crithidia RARE
fasciculata RARE
miniexon RARE
arrays O
. O

We O
used O
deletion O
analysis O
and O
transfection O
assays O
with O
reporter O
gene O
constructs O
to O
examine O
the O
transcription O
control O
elements O
in O
the O
5 O
' O
flanking O
region O
of O
the O
human I-GENE
EpoR LASTCAP
gene I-GENE
. O

The O
CVA16 NUMERIC
. I-GENE
4 I-GENE
proteolipid RARE
transcript I-GENE
is O
the O
most O
prevalent RARE
of O
the O
two O
proteolipid RARE
messages RARE
in O
expanding RARE
ovules RARE
harvested RARE
10 O
d O
post O
- O
anthesis RARE
. O

Incubation RARE
of O
the O
purified O
fusion O
proteins O
with O
[ O
gamma O
- O
32P O
] O
ATP O
in O
an O
in O
vitro O
assay O
showed O
that O
both O
proteins O
were O
capable O
of O
autophosphorylation O
. O

The O
character O
of O
specific O
immune O
response O
in O
101 O
immunized O
children O
and O
in O
12 O
adults O
belonging O
to O
a O
high O
risk O
group O
with O
respect O
to O
VHB ALLCAPS
. O

After O
nadolol RARE
, O
heart O
rate O
decreased O
(- O
22 O
+/- O
8 O
%), O
and O
so O
did O
PBV ALLCAPS
and O
PBF ALLCAPS
( O
8 O
. O
8 O
+/- O
3 O
. O
4 O
vs O
. O

The O
synthetic O
DNA O
sequence O
was O
constructed O
to O
achieve O
efficient O
base O
pairing RARE
with O
Escherichia I-GENE
coli I-GENE
16S NUMERIC
ribosomal I-GENE
RNA I-GENE
, O
avoidance RARE
of O
internal O
secondary O
structure O
, O
and O
optimal O
codon O
usage O
for O
high O
- O
level O
protein O
expression O
in O
accord RARE
with O
the O
known O
preferences RARE
in O
E O
. O
coli O
. O

Adrenergic RARE
system O
activation O
, O
indicated O
by O
metanephrine RARE
/ O
epinephrine O
ratio O
, O
increased O
with O
time O
in O
losing RARE
males O
, O
except O
that O
after O
one O
month O
of O
cohabitation RARE
, O
turnover O
returned O
to O
levels O
that O
equaled RARE
those O
of O
control O
animals O
. O

Transabdominal RARE
repair O
of O
type O
IV O
thoraco RARE
- O
abdominal O
aortic O
aneurysms RARE
. O

A O
. O

Transcription O
factors O
containing O
a O
basic O
helix O
- O
loop O
- O
helix O
( O
bHLH O
) O
motif O
regulate O
the O
expression O
of O
tissue O
- O
specific O
genes O
in O
a O
number O
of O
mammalian O
and O
insect O
systems O
. O

Primer O
extension O
and O
cDNA O
cloning O
were O
used O
to O
isolate O
the O
complete O
5 O
' O
end O
of O
the O
Nramp1 NUMERIC
mRNA I-GENE
. O

Primer O
extension O
and O
S1 I-GENE
nuclease I-GENE
mapping O
experiments O
were O
used O
to O
locate RARE
the O
transcription O
initiation O
site O
of O
Nramp1 NUMERIC
and O
revealed O
the O
presence O
of O
one O
major O
and O
several O
minor O
initiation O
sites O
. O

EsaR LASTCAP
can O
repress O
its O
own O
expression O
but O
seems O
not O
to O
regulate O
the O
expression O
of O
esaI LASTCAP
. O

Sequence O
analysis O
of O
the O
5 O
'- O
flanking O
region O
of O
the O
CD69 NUMERIC
gene I-GENE
revealed O
the O
presence O
of O
a O
potential O
TATA O
element O
30 O
base O
pairs O
upstream O
of O
the O
major O
transcription O
initiation O
site O
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription O
factors O
( O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
, O
Egr RARE
- I-GENE
1 I-GENE
, O
AP I-GENE
- I-GENE
1 I-GENE
), O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

The O
plasmin RARE
- I-GENE
derived I-GENE
D I-GENE
( I-GENE
approximately I-GENE
105 I-GENE
- I-GENE
kDa I-GENE
) I-GENE
product I-GENE
, O
however O
, O
could O
be O
cross O
- O
linked O
into O
DD ALLCAPS
dimers O
. O

All O
clinical O
isolates O
were O
concomitantly RARE
tested O
by O
disk RARE
diffusion O
and O
agar O
dilution O
procedures O
as O
outlined RARE
by O
the O
National O
Committee O
for O
Clinical O
Laboratory O
Standards RARE
. O

IgE I-GENE
levels O
showed O
higher O
values O
compared O
to O
normal O
individuals O
and O
IgE I-GENE
levels O
were O
higher O
in O
children O
groups O
than O
in O
adults O
regardless O
of O
the O
intensity O
of O
infection O
. O

Tissue O
- O
specific O
expression O
of O
the O
tmy RARE
- I-GENE
1 I-GENE
gene I-GENE
was O
determined O
by O
microinjection O
of O
a O
promoter I-GENE
/ I-GENE
lacZ I-GENE
fusion I-GENE
gene I-GENE
and O
with O
immunohistochemistry RARE
by O
using O
affinity O
- O
purified O
tissue I-GENE
- I-GENE
specific I-GENE
anti I-GENE
- I-GENE
tropomyosins RARE
. O

The O
nucleotide O
sequence O
of O
the O
chloroplast O
( O
cp RARE
) O
DNA O
from O
maize O
( O
Zea RARE
mays RARE
) O
has O
been O
completed O
. O

Investigation RARE
of O
the O
control O
of O
coronavirus O
subgenomic RARE
mRNA O
transcription O
by O
using O
T7 O
- O
generated O
negative O
- O
sense O
RNA O
transcripts O
. O

Initiation RARE
of O
translation O
of O
the O
human O
hepatitis O
C O
virus O
( O
HCV O
) O
RNA O
genome O
occurs O
by O
internal O
ribosome O
entry O
into O
the O
5 O
' O
noncoding O
region O
( O
5 O
' O
NCR O
) O
in O
a O
cap O
- O
independent O
manner O
. O

Mean O
longitudinal O
extension O
of O
the O
epidural RARE
lesion O
was O
2 O
. O
6 O
vertebral O
segments O
. O

The O
association O
of O
p255 NUMERIC
with O
splicing O
complexes O
is O
suggested O
by O
the O
finding O
that O
mAb I-GENE
CC3 NUMERIC
can O
inhibit O
in O
vitro O
splicing O
and O
immunoprecipitate RARE
pre O
- O
messenger O
RNA O
and O
splicing O
products O
. O

L O
- O
735 NUMERIC
, O
524 NUMERIC
free O
base O
or O
sulfate O
salt O
was O
administered O
orally O
as O
suspension RARE
, O
solution O
or O
in O
solid O
dosage O
forms O
to O
fasted O
or O
fed O
Beagle RARE
dogs O
. O

Doppler O
ultrasound O
studies O
of O
long O
- O
term O
follow O
- O
up O
of O
children O
with O
hemolytic RARE
- O
uremic RARE
syndrome O

Thus O
, O
endemic RARE
cumlations RARE
of O
hepatitis O
A O
diseases O
are O
possible O
. O

( O
1991 O
). O

The O
properties O
of O
the O
phi O
29 O
SSB I-GENE
- I-GENE
ssDNA I-GENE
complex O
are O
described O
. O

This O
shows O
that O
the O
characteristically RARE
diffuse O
banding RARE
pattern O
of O
plant O
nuclear O
proteins O
interacting O
with O
the O
G O
- O
box O
is O
also O
observed O
in O
a O
binding O
assay O
using O
only O
one O
recombinant I-GENE
GBF ALLCAPS
. O

We O
studied O
120 O
male O
and O
42 O
female O
patients O
with O
early O
CAD O
who O
were O
unrelated O
to O
each O
other O
but O
were O
from O
families O
in O
which O
at O
least O
one O
other O
sibling RARE
had O
early O
CAD O
. O

The O
physical O
linkage O
of O
the O
FHR2 NUMERIC
and O
the O
factor I-GENE
H I-GENE
genes I-GENE
provides O
additional O
evidence O
for O
a O
close O
relatedness RARE
of O
complement I-GENE
factor I-GENE
H I-GENE
and O
the O
factor I-GENE
H I-GENE
- I-GENE
related I-GENE
proteins I-GENE
. O

Genomic O
structure O
and O
chromosomal O
location O
of O
the O
mouse I-GENE
pre I-GENE
- I-GENE
T I-GENE
- I-GENE
cell I-GENE
receptor I-GENE
alpha I-GENE
gene I-GENE
. O

The O
third O
domain O
had O
the O
motif O
of O
a O
cAMP O
response O
element O
( O
CRE O
). O

The O
tyrosine O
- O
phosphorylated O
state O
of O
CAK I-GENE
beta I-GENE
was O
not O
reduced O
on O
trypsinization RARE
, O
nor O
enhanced O
in O
response O
to O
plating RARE
3Y1 NUMERIC
cells O
onto O
fibronectin I-GENE
. O

Our O
results O
suggest O
that O
while O
many O
muscle O
gene O
E O
- O
boxes O
are O
capable O
of O
binding O
the O
previously O
characterized O
spectrum O
of O
MDF ALLCAPS
/ I-GENE
bH LASTCAP
- I-GENE
L I-GENE
- I-GENE
H I-GENE
heterodimers I-GENE
in O
vitro O
, O
MCK ALLCAPS
- I-GENE
L I-GENE
type O
E O
- O
boxes O
probably O
bind O
qualitatively RARE
different O
factors O
in O
vivo O
. O

A O
single O
- O
case O
experimental O
ABAB ALLCAPS
multiple O
baseline O
design O
was O
employed O
to O
test O
for O
treatment O
effectiveness O
. O

These O
clones O
were O
found O
to O
share O
a O
common O
domain O
encoded O
by O
p O
( O
CA O
) O
n O
repeats O
; O
a O
simple O
sequence O
length O
polymorphism O
( O
SSLP ALLCAPS
). O

In O
one O
glioblastoma RARE
cell O
line O
, O
a O
Shc I-GENE
- O
associated O
p190 I-GENE
was O
identified O
as O
the O
activated O
PDGFR ALLCAPS
. O

We O
conclude O
that O
, O
in O
comparison O
to O
reports O
from O
other O
regions O
, O
Scandinavian RARE
renal O
transplant O
recipients O
are O
at O
high O
risk O
of O
dying RARE
of O
IHD ALLCAPS
. O

Veterinary RARE
certification RARE
for O
livestock RARE
export O
. O

The O
serum O
concentration O
of O
iP LASTCAP
before O
dialysis O
( O
HD O
) O
was O
on O
average O
3 O
. O
06 O
(+/- O
0 O
. O
81 O
) O
mmol O
/ O
l O
and O
D O
was O
on O
average O
55 O
. O
6 O
(+/- O
10 O
. O
0 O
) O
mmol O
. O

A O
significant O
correlation O
between O
a O
number O
of O
functional O
parameters O
of O
gastric O
secretion O
, O
incretion RARE
and O
histological O
changes O
of O
gastric O
mucosa O
was O
found O
in O
patients O
with O
chronic O
gastritis RARE
. O

The O
TAF O
factor O
appears O
to O
be O
particularly O
significant O
in O
OCD ALLCAPS
. O

Diffuse RARE
white O
matter O
injury O
can O
be O
attributed O
to O
radiation O
and O
associated O
with O
neurological O
deficits O
, O
but O
leukoencephalopathy RARE
is O
rarely O
observed O
in O
the O
absence O
of O
chemotherapy O
. O

RNase I-GENE
protection O
analyses O
indicate O
that O
either O
61 I-GENE
- I-GENE
kDa I-GENE
CaM I-GENE
PDE ALLCAPS
mRNA I-GENE
or O
structurally O
related O
transcripts O
encoding O
different O
CaM I-GENE
PDE ALLCAPS
isoforms I-GENE
are O
expressed O
in O
a O
tissue O
- O
specific O
manner O
. O

Little RARE
or O
no O
protection O
was O
detected O
using O
adrenal O
cortex O
, O
adrenal O
medulla RARE
, O
liver O
, O
kidney O
cortex O
, O
spleen O
, O
or O
T O
- O
lymphocyte O
total O
RNA O
. O

The O
PDGFR ALLCAPS
mutants I-GENE
that O
failed O
to O
associate O
with O
PLC I-GENE
gamma I-GENE
were O
not O
able O
to O
mediate O
the O
PDGF I-GENE
- O
dependent O
production O
of O
inositol O
phosphates RARE
. O

We O
found O
a O
direct O
correlation O
between O
the O
levels O
of O
transcription O
of O
the O
acc RARE
genes I-GENE
and O
the O
rate O
of O
cellular O
growth O
. O

The O
hybridizing RARE
clone O
of O
V O
. O
vulnificus RARE
chromosomal O
DNA O
complemented O
a O
V I-GENE
. I-GENE
cholerae I-GENE
fur RARE
mutant I-GENE
. O

We O
generated O
transformed O
B O
lymphoblast RARE
cell O
lines O
from O
controls O
, O
from O
four O
patients O
with O
p47 NUMERIC
- O
phox RARE
- O
deficient O
chronic O
granulomatous RARE
disease O
, O
and O
from O
three O
parents O
. O

The O
ectopic O
expression O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
in O
hybrid O
cells O
under O
a O
constitutive O
promoter O
is O
sufficient O
for O
transcriptional O
activation O
of O
an O
octamer O
- O
dependent O
promoter O
. O

RNase I-GENE
protection O
and O
primer O
extension O
assays O
confirmed O
that O
the O
5 O
' O
non O
- O
coding O
exon O
is O
included O
in O
the O
DDT1 NUMERIC
aFGF LASTCAP
mRNA I-GENE
and O
that O
a O
major O
transcription O
start O
site O
is O
approximately O
136 O
bp O
upstream O
of O
the O
5 O
' O
non O
- O
coding O
splice O
junction O
of O
this O
exon O
. O

These O
results O
suggest O
that O
FK O
506 NUMERIC
is O
a O
useful O
immunosuppressive O
agent O
in O
kidney O
transplantation O
. O

The O
roles O
of O
phorbol O
esters O
and O
cyclic O
AMP O
in O
mediating O
the O
GnRH I-GENE
response O
were O
also O
investigated O
. O

RT O
- O
PCR O
using O
1 O
. O
D O
- O
specific O
primers O
showed O
that O
kidney O
, O
brain O
and O
prostate O
do O
not O
express O
1 O
. O
D O
mRNA O
even O
though O
kidney O
and O
brain O
are O
the O
most O
abundant O
source O
for O
aFGF LASTCAP
protein I-GENE
. O

Molecular O
cloning O
and O
characterization O
of O
two O
genes I-GENE
encoding I-GENE
gp138 NUMERIC
, O
a O
cell O
surface O
glycoprotein O
involved O
in O
the O
sexual O
cell O
fusion O
of O
Dictyostelium O
discoideum RARE
. O

Two O
- O
dimensional O
phosphotryptic RARE
analyses O
indicate O
that O
phosphorylation O
on O
Ser O
- O
12 O
and O
Ser O
- O
48 O
in O
unstimulated O
cells O
is O
associated O
with O
the O
ability O
of O
overexpressed O
pp60c NUMERIC
- I-GENE
src I-GENE
to O
potentiate RARE
beta O
- O
adrenergic O
signalling O
. O

Piroximone RARE
is O
a O
new O
phosphodiesterase I-GENE
III I-GENE
inhibitor O
that O
combines RARE
inotropic O
and O
vasodilator O
properties O
. O

Cytogenetic RARE
studies O
were O
performed O
in O
lymphocytes O
from O
hospital O
workers O
exposed O
to O
low O
doses O
of O
radiation O
( O
1 O
. O
6 O
- O
42 O
. O
71 O
mSv RARE
). O

To O
study O
the O
origin O
of O
different O
fMLF LASTCAP
- I-GENE
R I-GENE
transcripts I-GENE
, O
the O
genetic O
linkage O
of O
chemotactic O
receptor O
genes O
, O
and O
the O
regulation O
of O
fMLF LASTCAP
- I-GENE
R I-GENE
gene I-GENE
expression O
, O
we O
determined O
the O
copy O
number O
, O
chromosomal O
location O
, O
structural O
organization O
, O
and O
5 O
'- O
flanking O
sequence O
of O
the O
human I-GENE
fMLF LASTCAP
- I-GENE
R I-GENE
gene I-GENE
. O

The O
first O
exon O
encodes O
66 O
bp O
of O
the O
5 O
'- O
untranslated O
sequence O
, O
while O
exon O
2 O
encodes O
the O
coding O
and O
3 O
'- O
untranslated O
sequences O
. O

The O
genomic O
structure O
of O
four O
members O
of O
the O
SRC I-GENE
- I-GENE
family I-GENE
revealed O
nearly O
identical O
exon O
/ O
intron O
boundaries O
within O
the O
catalytic O
domain O
of O
this O
family O
. O

Since O
we O
have O
observed O
effects O
of O
growth O
factors O
and O
cAMP O
as O
well O
as O
estradiol O
( O
E2 O
) O
on O
regulation O
of O
expression O
of O
some O
genes O
stimulated O
by O
the O
estrogen I-GENE
receptor I-GENE
( O
ER I-GENE
), O
we O
have O
undertaken O
studies O
to O
examine O
directly O
whether O
activators O
of O
protein O
kinases O
can O
modulate O
transcriptional O
activity O
of O
the O
ER I-GENE
. O

Using O
the O
polymerase O
chain O
reaction O
, O
Whipple RARE
- O
specific O
DNA O
fragments O
of O
284 NUMERIC
base O
pairs O
from O
the O
genome O
of O
the O
Whipple RARE
bacterium O
( O
Tropheryma RARE
whippelii RARE
) O
were O
demonstrated O
. O

RNA I-GENE
polymerase I-GENE
bound O
to O
the O
+ O
10A NUMERIC
promoter O
partially O
protects RARE
a O
20 O
base O
- O
pair O
sequence O
from O
DNase I-GENE
I I-GENE
digestion O
upstream O
of O
the O
start O
site O
. O

Salivary RARE
sodium O
, O
calcium O
, O
and O
magnesium O
concentrations O
were O
significantly O
higher O
in O
the O
SLE O
patients O
with O
systemic O
lupus O
erythematosus O
, O
whereas O
potassium O
and O
total O
protein O
concentrations O
and O
amylase I-GENE
activity O
did O
not O
differ O
significantly O
from O
the O
controls O
. O

Chem O
. O

Recombinant O
plasmid O
pFV100 NUMERIC
was O
subsequently O
isolated O
by O
its O
ability O
to O
complement O
B O
- O
band O
expression O
in O
ge6 NUMERIC
. O

We O
here O
demonstrate O
that O
a O
temperature O
- O
sensitive O
fission O
yeast O
mutant O
which O
has O
a O
mutation O
in O
a O
homologous O
gene O
, O
and O
two O
of O
three O
additional O
( O
mtr1 NUMERIC
/ O
prp20 NUMERIC
/ O
srm1 NUMERIC
) O
mutants O
accumulate O
nuclear O
poly O
( O
A O
)+ O
RNA O
at O
37 O
degrees O
C O
. O

Since O
RCC1p NUMERIC
acts O
as O
GNRP ALLCAPS
for O
Ran I-GENE
, O
a O
small I-GENE
nuclear I-GENE
GTPase I-GENE
of O
the O
ras I-GENE
superfamily I-GENE
, O
we O
have O
identified O
two O
homologs O
of O
Ran I-GENE
in O
S O
. O
cerevisiae O
( O
CNR1 NUMERIC
and O
CNR2 NUMERIC
). O

The O
immunosuppressant RARE
FK506 O
inhibits O
amino O
acid O
import O
in O
Saccharomyces O
cerevisiae O
. O

Prostate RARE
specific I-GENE
antigen I-GENE
shows O
the O
metastatic O
cases O
better O
[ O
correction O
of O
worse RARE
] O
than O
prostatic I-GENE
acid I-GENE
phosphatase I-GENE
. O

Protein O
phosphorylation O
appears O
to O
play O
a O
critical O
role O
in O
uPA I-GENE
gene I-GENE
expression O
in O
these O
cells O
; O
protein I-GENE
kinase I-GENE
C I-GENE
- O
activating O
phorbol O
esters O
cooperate O
with O
pp60v NUMERIC
- I-GENE
src I-GENE
to O
synergistically O
increase O
uPA I-GENE
mRNA I-GENE
, O
whereas O
cyclic I-GENE
AMP I-GENE
( I-GENE
cAMP I-GENE
)- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
- O
activating O
agents O
( O
e O
. O
g O
., O
8 O
- O
bromo RARE
cAMP O
) O
repress O
uPA I-GENE
mRNA I-GENE
levels O
. O

Of O
these O
carriers O
149 NUMERIC
were O
diagnosed O
to O
be O
asymptomatic O
clinically O
, O
biochemically RARE
and O
echographically RARE
. O

This O
300 O
bp O
5 O
'- O
upstream O
sequence O
of O
K3 NUMERIC
keratin RARE
gene I-GENE
, O
which O
can O
function O
in O
vitro O
as O
a O
keratinocyte RARE
- O
specific O
promoter O
, O
contains O
two O
clusters O
of O
partially O
overlapping O
motifs O
, O
one O
with O
an O
NFkB LASTCAP
consensus O
sequence O
and O
another O
with O
a O
GC O
box O
. O

Identification O
of O
mutations O
in O
the O
coding O
sequence O
of O
the O
proto I-GENE
- I-GENE
oncogene I-GENE
c I-GENE
- I-GENE
kit I-GENE
in O
a O
human O
mast O
cell O
leukemia O
cell O
line O
causing O
ligand O
- O
independent O
activation O
of O
c I-GENE
- I-GENE
kit I-GENE
product I-GENE
. O

BACKGROUND O
: O
Delineation RARE
of O
the O
morphologic O
aspects O
of O
age O
- O
related O
macular RARE
degeneration O
( O
ARMD ALLCAPS
) O
is O
helpful O
in O
correlation O
with O
the O
clinical O
features O
and O
may O
contribute O
to O
understanding O
the O
pathogenesis O
. O

An O
abundant O
1 O
. O
1 O
- O
kb O
virion O
- O
sense O
polyadenylated O
RNA O
and O
four O
complementary O
- O
sense O
polyadenylated O
RNAs O
of O
1 O
. O
7 O
, O
1 O
. O
5 O
, O
1 O
. O
3 O
, O
and O
0 O
. O
7 O
kb O
have O
been O
identified O
by O
northern O
blot O
hybridization O
, O
confirming O
the O
bidirectional RARE
transcription O
strategy O
implied RARE
by O
the O
arrangement O
of O
ORFs O
. O

Risk O
factors O
associated O
with O
a O
high O
seroprevalence RARE
of O
hepatitis O
C O
virus O
infection O
in O
Egyptian RARE
blood O
donors O
. O

Here O
the O
cloning O
and O
molecular O
analysis O
of O
the O
Zm RARE
- I-GENE
ERabp1 NUMERIC
, O
Zm RARE
- I-GENE
ERabp4 NUMERIC
, O
and O
Zm RARE
- I-GENE
ERabp5 NUMERIC
genes I-GENE
is O
presented O
. O

This O
agent O
, O
isolated O
from O
the O
fungus O
Streptomyces O
tsukubaensis RARE
, O
has O
a O
mechanism O
of O
action O
similar O
to O
that O
of O
cyclosporine O
. O

DNase I-GENE
I I-GENE
footprinting O
of O
the O
proximal O
promoter O
revealed O
four O
regions O
of O
protection O
. O

Finally O
, O
the O
stability O
of O
the O
nucleotide O
binding O
function O
of O
the O
two O
proteins O
is O
similar O
as O
assessed O
by O
sensitivity O
to O
urea O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
2 I-GENE
( O
IGF I-GENE
- I-GENE
BP I-GENE
- I-GENE
2 I-GENE
) O
transcription O
in O
rat O
liver O
varies RARE
with O
developmental O
age O
and O
fasting O
. O

The O
presence O
of O
the O
RV O
5 O
'(+) RARE
SL ALLCAPS
sequence O
had O
the O
primary O
enhancing O
effect O
on O
translation O
. O

By O
contrast O
, O
all O
proteins O
initiated O
with O
a O
methionine O
placed O
one O
residue O
upstream O
of O
the O
natural O
N O
terminus O
of O
PR I-GENE
failed O
to O
show O
specific O
proteolysis O
. O

Reverse I-GENE
transcriptase I-GENE
and O
protease O
activities O
of O
avian O
leukosis RARE
virus O
Gag I-GENE
- O
Pol I-GENE
fusion O
proteins O
expressed O
in O
insect O
cells O
. O

In O
addition O
, O
an O
mck1 NUMERIC
mds1 NUMERIC
mrk1 NUMERIC
triple O
disruptant RARE
was O
viable O
. O

However O
, O
there O
were O
some O
properties O
of O
Rak RARE
that O
are O
distinct O
from O
Src I-GENE
- I-GENE
like I-GENE
kinases I-GENE
: O
( O
a O
) O
expression O
of O
Rak RARE
was O
predominantly O
in O
epithelial O
- O
derived O
cell O
lines O
and O
tissues O
, O
especially O
normal O
liver O
and O
kidney O
, O
and O
cell O
lines O
of O
breast O
and O
colon O
origin O
; O
( O
b O
) O
Rak RARE
does O
not O
harbor O
the O
NH2 O
- O
terminal O
glycine O
essential O
for O
myristylation RARE
and O
membrane O
localization O
; O
and O
( O
c O
) O
Rak RARE
possesses O
a O
putative O
bipartite O
nuclear O
localization O
signal O
in O
the O
SH2 I-GENE
domain I-GENE
, O
and O
subcellular O
fractionation O
studies O
revealed O
that O
p54rak NUMERIC
resides O
predominantly O
in O
the O
nucleus O
. O

PATIENTS O
AND O
METHODS O
: O
We O
report O
our O
experience O
with O
seven O
children O
with O
active O
small O
bowel O
Crohn O
' O
s O
disease O
given O
a O
casein I-GENE
- O
based O
, O
polymeric RARE
feed O
rich O
in O
TGF I-GENE
- I-GENE
beta I-GENE
2 I-GENE
( O
Specific O
Polymeric RARE
Diet RARE
; O
Nestle RARE
- O
Clintec RARE
; O
Vevey RARE
, O
Switzerland RARE
) O
as O
complete O
nutrition O
for O
8 O
weeks O
. O

The O
leader O
sequence O
of O
the O
isolated O
cDNA O
clone O
contains O
several O
small O
open O
reading O
frames O
upstream O
of O
the O
initiation O
codon O
of O
the O
largest O
open O
reading O
frame O
coding O
for O
the O
homeodomain I-GENE
protein I-GENE
. O

A O
small O
amount O
of O
HSP81 NUMERIC
- I-GENE
1 I-GENE
mRNA I-GENE
was O
detected O
only O
in O
roots O
. O

Cell O
adhesion O
and O
migration O
assays O
demonstrate O
that O
alpha I-GENE
6 I-GENE
beta I-GENE
1 I-GENE
is O
the O
major O
laminin RARE
receptor I-GENE
in O
undifferentiated O
F9 O
cells O
as O
well O
as O
F9 O
- O
derived O
PE O
cells O
. O

No O
local O
destruction RARE
by O
tumor O
or O
infection O
could O
be O
demonstrated O
apart O
from O
HIV O
infection O
. O

Among O
the O
mixed O
race RARE
persons O
one O
Chukcha RARE
- O
Eskimo RARE
had O
AS O
, O
one O
Eskimo RARE
- O
Russian RARE
had O
psoriatic RARE
arthritis O
( O
PsA LASTCAP
). O

Our O
data O
complement O
other O
studies O
of O
circumpolar RARE
populations O
and O
reinforce RARE
the O
reported O
high O
prevalences RARE
of O
SPA ALLCAPS
and O
HLA I-GENE
- I-GENE
B27 NUMERIC
among O
those O
populations O
. O

Clinical O
studies O
SY5555 NUMERIC
was O
administered O
to O
45 O
patients O
with O
various O
infectious O
diseases O
( O
2 O
with O
acute O
pharyngitis RARE
, O
8 O
with O
acute O
tonsillitis RARE
, O
4 O
with O
lacunar RARE
tonsillitis RARE
, O
3 O
each O
with O
acute O
bronchitis RARE
, O
pneumonia O
and O
pertussis O
, O
7 O
with O
scarlet RARE
fever O
, O
3 O
with O
impetigo RARE
contagiosa RARE
, O
6 O
with O
acute O
urinary O
tract O
infections O
, O
2 O
with O
balanoposthitis RARE
and O
1 O
each O
with O
cervical O
lymphadenitis RARE
, O
S O
. O
S O
. O
S O
. O
S O
., O
vulvitis RARE
and O
acute O
colitis RARE
) O
at O
daily O
doses O
between O
3 O
. O
4 O
- O
10 O
mg O
/ O
kg O
, O
t O
. O
i O
. O
d O
., O
for O
3 O
- O
14 O
days O
. O

Although O
most O
SH2 I-GENE
- O
pTyr RARE
interactions O
occur O
between O
two O
different O
types O
of O
molecules O
, O
some O
appear O
to O
involve O
only O
a O
single O
molecular O
type O
. O

RESULTS O
: O
Closure RARE
time O
of O
fistulas RARE
in O
patients O
receiving O
TPN O
+ O
somatostatin I-GENE
was O
significantly O
shorter O
( O
13 O
. O
86 O
+/- O
1 O
. O
84 O
versus O
20 O
. O
4 O
+/- O
2 O
. O
89 O
days O
) O
than O
in O
those O
receiving O
TPN O
alone O
. O

Experimental O
adhesion O
prophylaxis O
with O
recombinant I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
. O

Scratching RARE
during O
sleep O
in O
children O
with O
atopic O
dermatitis O
is O
associated O
with O
increased O
VO2 O
. O

To O
determine O
which O
sequences O
in O
the O
rat I-GENE
P450c17 NUMERIC
promoter I-GENE
may O
be O
responsible O
for O
basal O
and O
cAMP O
- O
stimulated O
gene O
transcription O
, O
deletion O
constructs O
containing O
between O
- O
1 O
, O
560 NUMERIC
and O
- O
53 O
base O
pairs O
of O
5 O
'- O
flanking O
DNA O
from O
the O
rat I-GENE
P450c17 NUMERIC
gene I-GENE
were O
ligated O
to O
plasmids O
expressing O
the O
reporter O
gene O
luciferase I-GENE
and O
transfected O
into O
two O
mouse O
cell O
lines O
, O
adrenal O
Y O
- O
1 O
cells O
, O
and O
testicular O
Leydig RARE
MA O
- O
10 O
cells O
. O

Within O
- O
subject O
BP O
differences O
between O
fish O
oil O
and O
corn RARE
oil O
treatment O
were O
similar O
for O
Dinamap RARE
( O
3 O
. O
2 O
+/- O
1 O
. O
8 O
/ O
2 O
. O
5 O
+/- O
1 O
. O
0 O
mm O
Hg O
) O
and O
for O
24 O
- O
h O
ABP ALLCAPS
( O
2 O
. O
5 O
+/- O
1 O
. O
0 O
/ O
2 O
. O
3 O
+/- O
0 O
. O
8 O
mm O
Hg O
), O
but O
were O
more O
significant O
with O
the O
latter O
. O

We O
have O
cloned O
and O
sequenced O
the O
mouse I-GENE
NMO1 NUMERIC
cDNA I-GENE
, O
which O
encodes O
the O
NAD I-GENE
( I-GENE
P I-GENE
) I-GENE
H I-GENE
: I-GENE
menadione RARE
oxidoreductase I-GENE
[ O
also O
called O
NAD I-GENE
( I-GENE
P I-GENE
) I-GENE
H I-GENE
:( RARE
quinone RARE
acceptor I-GENE
) I-GENE
oxidoreductase I-GENE
; O
quinone RARE
reductase I-GENE
; O
azo RARE
dye I-GENE
reductase I-GENE
; O
DT I-GENE
diaphorase RARE
; O
EC I-GENE
1 I-GENE
. I-GENE
6 I-GENE
. I-GENE
99 I-GENE
. I-GENE
2 I-GENE
]. O

Escherichia O
coli O
JRG582 NUMERIC
is O
an O
ampD LASTCAP
ampE LASTCAP
deletion O
derivative O
of O
strain O
HfrH LASTCAP
and O
accordingly RARE
it O
is O
derepressed RARE
for O
expression O
of O
the O
cloned O
inducible O
beta I-GENE
- I-GENE
lactamase I-GENE
gene I-GENE
of O
Citrobacter RARE
freundii RARE
, O
carried O
on O
plasmid O
pNU305 NUMERIC
. O

Such O
a O
mechanism O
may O
allow O
acceleration RARE
of O
degenerative RARE
joint O
conditions O
, O
and O
may O
account O
for O
the O
increased O
prevalence O
of O
such O
conditions O
seen O
with O
HMS ALLCAPS
subjects O
. O

Solitary RARE
thyroid O
nodule RARE
. O

Male RARE
contraception RARE
: O
ideas RARE
for O
the O
future O
. O

While O
daily O
food O
intake O
was O
almost O
constant O
regardless O
of O
the O
dietary O
protein O
level O
, O
water O
intake O
and O
urine O
volume O
increased O
with O
increasing O
the O
dietary O
protein O
. O

We O
propose O
that O
Mad RARE
and O
Medea RARE
encode O
rate O
- O
limiting O
components O
integral O
to O
dpp RARE
pathways O
throughout O
development O
. O

Transcriptional O
regulation O
of O
the O
vacuolar I-GENE
H I-GENE
(+)- I-GENE
ATPase I-GENE
B2 I-GENE
subunit I-GENE
gene I-GENE
in O
differentiating O
THP ALLCAPS
- O
1 O
cells O
. O

However O
, O
the O
inability RARE
to O
export O
RNA O
from O
the O
nucleus O
to O
the O
cytoplasm O
was O
not O
limited O
to O
a O
particular O
phase O
of O
the O
cell O
division O
cycle O
. O

An O
E O
box O
element O
is O
required O
for O
the O
expression O
of O
the O
ad4bp NUMERIC
gene I-GENE
, O
a O
mammalian I-GENE
homologue I-GENE
of I-GENE
ftz RARE
- I-GENE
f1 I-GENE
gene I-GENE
, O
which O
is O
essential O
for O
adrenal O
and O
gonadal RARE
development O
. O

Inhibition O
assays O
performed O
with O
over O
30 O
different O
natural O
and O
synthetic O
sialylated RARE
and O
/ O
or O
sulfated RARE
compounds O
are O
utilized O
to O
define O
in O
greater O
detail O
specific O
structural O
features O
involved O
in O
oligosaccharide RARE
- O
protein O
binding O
. O

The O
amino O
acid O
sequence O
of O
the O
protein O
in O
the O
region O
of O
the O
specificity O
pocket O
is O
similar O
to O
that O
of O
S I-GENE
. I-GENE
griseus RARE
proteases I-GENE
A I-GENE
, I-GENE
B I-GENE
, I-GENE
and I-GENE
C I-GENE
. O

Mutations O
in O
the O
VPS45 NUMERIC
gene I-GENE
, O
a O
SEC1 NUMERIC
homologue O
, O
result O
in O
vacuolar O
protein O
sorting O
defects O
and O
accumulation O
of O
membrane O
vesicles O
. O

In O
293 O
cells O
, O
expression O
of O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
inhibitor O
, O
I I-GENE
kappa I-GENE
B I-GENE
- I-GENE
alpha I-GENE
, O
reduced O
the O
stimulatory O
activity O
of O
LMP I-GENE
. O

This O
experimental O
design O
was O
used O
to O
determine O
the O
effect O
of O
displacement O
of O
the O
alpha I-GENE
4 I-GENE
- I-GENE
2 I-GENE
binding I-GENE
site I-GENE
on O
the O
repression O
of O
alpha I-GENE
4 I-GENE
gene I-GENE
transcription O
by O
ICP4 I-GENE
. O

Immediate RARE
- O
early O
transcription O
from O
the O
channel O
catfish RARE
virus O
genome O
: O
characterization O
of O
two O
immediate I-GENE
- I-GENE
early I-GENE
transcripts I-GENE
. O

The O
GRE O
at O
nucleotide O
7640 NUMERIC
is O
a O
composite O
GRE O
( O
cGRE LASTCAP
) O
containing O
an O
overlapping O
activator I-GENE
protein I-GENE
- I-GENE
1 I-GENE
( O
AP I-GENE
- I-GENE
1 I-GENE
) O
motif O
for O
the O
c I-GENE
- I-GENE
jun I-GENE
homodimer I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
/ O
c I-GENE
- I-GENE
fos I-GENE
heterodimer O
. O

In O
contrast O
to O
some O
results O
previously O
published O
for O
a O
very O
close O
sequence O
variant O
( O
see RARE
ref RARE
. O

Transcriptional O
activation O
by O
thyroid O
hormone O
( O
T3 O
) O
requires O
interactions O
between O
the O
T3 I-GENE
receptor I-GENE
( O
TR I-GENE
) O
and O
T3 O
response O
elements O
( O
TREs RARE
) O
composed O
of O
two O
copies O
of O
sequences O
related O
to O
AGGTCA ALLCAPS
. O

A O
multivariate O
analysis O
of O
risk O
factors O
for O
relapse O
examined O
age O
, O
WBC O
at O
diagnosis O
, O
blast RARE
count O
at O
diagnosis O
, O
percentage O
of O
marrow O
blasts RARE
, O
FAB ALLCAPS
subtype O
, O
the O
number O
of O
remission O
induction O
courses O
to O
achieve O
a O
remission O
, O
maintenance O
therapy O
, O
consolidation RARE
therapy O
, O
marrow O
cell O
dose O
, O
donor O
- O
recipient O
sex O
, O
GVHD ALLCAPS
prophylaxis O
regimen O
and O
isolation O
and O
decontamination RARE
in O
laminar RARE
airflow RARE
rooms RARE
. O

Carnitine RARE
palmitoyltransferase RARE
( I-GENE
CPT I-GENE
) I-GENE
II I-GENE
deficiency O
is O
the O
most O
common O
inherited O
disorder O
of O
lipid O
metabolism O
affecting O
skeletal O
muscle O
. O

We O
show O
that O
these O
three O
gain O
- O
of O
- O
function O
mutants O
differ O
considerably O
in O
their O
ability O
to O
bypass O
the O
sex O
determination O
signal O
, O
with O
SxlM4 NUMERIC
being O
the O
strongest O
and O
SxlM1 NUMERIC
the O
weakest RARE
. O

We O
show O
that O
these O
three O
gain O
- O
of O
- O
function O
mutants O
differ O
considerably O
in O
their O
ability O
to O
bypass O
the O
sex O
determination O
signal O
, O
with O
SxlM4 NUMERIC
being O
the O
strongest O
and O
SxlM1 NUMERIC
the O
weakest RARE
. O

Binding O
of O
meAda RARE
is O
necessary O
to O
activate O
transcription O
of O
the O
adaptive O
response O
genes O
; O
accordingly RARE
, O
in O
vitro O
transcription O
of O
aidB LASTCAP
is O
dependent O
on O
the O
presence O
of O
meAda RARE
. O

No O
significant O
differences O
were O
identified O
between O
groups O
for O
pH O
, O
PaCO2 O
, O
intracranial RARE
pressure O
, O
heart O
rate O
, O
brain O
temperature O
, O
or O
glucose O
levels O
. O

Blood O
pressure O
also O
was O
increased O
by O
lidocaine O
( O
6 O
mg O
kg O
- O
1 O
). O

Anesthesiologists RARE
often O
use O
more O
than O
one O
drug O
in O
a O
patient O
to O
achieve O
a O
target O
response O
, O
such O
as O
a O
desired RARE
blood O
pressure O
. O

We O
suggest O
that O
this O
gene O
cluster O
codes O
for O
( O
parts O
of O
) O
a O
multisubunit I-GENE
cytochrome I-GENE
c I-GENE
haem RARE
lyase I-GENE
. O

In O
this O
paper O
, O
a O
comparison O
between O
the O
number O
and O
shape O
of O
corneal O
endothelial O
cells O
has O
been O
performed O
in O
25 O
patients O
before O
and O
6 O
months O
after O
PRK O
. O

Standard RARE
reference O
sources O
indicate O
that O
an O
able O
- O
bodied RARE
11 O
- O
year O
- O
old O
child O
of O
comparable O
height O
requires O
1 O
, O
493 NUMERIC
kcal RARE
/ O
d O
for O
support O
of O
basal O
metabolic O
functions O
. O

Weak RARE
allergenicity RARE
of O
recombinant I-GENE
hirudin RARE
CGP I-GENE
39393 NUMERIC
( O
REVASC ALLCAPS
) O
in O
immunocompetent RARE
volunteers O
. O

In O
contrast O
to O
the O
myoD I-GENE
promoter I-GENE
, O
the O
myoD I-GENE
enhancer I-GENE
shows O
striking O
conservation O
between O
humans O
and O
mice O
both O
in O
its O
sequence O
and O
its O
distal O
position O
. O

However O
, O
a O
clear O
difference O
exists O
between O
myoblasts O
and O
10T1 NUMERIC
/ O
2 O
cells O
( O
and O
other O
non O
- O
muscle O
cell O
types O
) O
in O
the O
chromatin O
structure O
of O
the O
chromosomal O
myoD I-GENE
core I-GENE
enhancer I-GENE
, O
suggesting O
that O
the O
myoD I-GENE
enhancer I-GENE
is O
repressed O
by O
epigenetic RARE
mechanisms O
in O
10T1 NUMERIC
/ O
2 O
cells O
. O

Using O
Ki RARE
- I-GENE
ras I-GENE
- O
transformed O
3T3 O
cells O
as O
a O
model O
system O
, O
we O
show O
that O
both O
RA O
and O
the O
' O
dissociating RARE
' O
retinoids RARE
inhibit O
anchorage O
- O
independent O
cell O
proliferation O
, O
suggesting O
that O
retinoid O
- O
induced O
growth O
inhibition O
may O
be O
related O
to O
AP1 I-GENE
transrepression RARE
. O

The O
Oct I-GENE
and O
HMG2 NUMERIC
proteins I-GENE
also O
interact O
in O
vivo O
. O

Atopic RARE
dermatitis O
is O
an O
" O
itch RARE
which O
rashes RARE
and O
not O
a O
rash O
which O
itches RARE
" O
and O
therefore O
, O
any O
patient O
treatment O
program O
should O
address O
the O
multiplicity RARE
of O
potential O
trigger RARE
factors O
that O
provoke RARE
this O
itching RARE
. O

Primer O
extension O
experiments O
showed O
that O
there O
are O
two O
transcription O
initiation O
sites O
16 O
bp O
apart O
in O
the O
mouse I-GENE
type I-GENE
2 I-GENE
receptor I-GENE
gene I-GENE
. O

The O
beta O
subunit O
of O
the O
Fc I-GENE
epsilon I-GENE
R1 I-GENE
is O
a O
33 O
- O
kDa O
tyrosine O
phosphoprotein O
, O
but O
the O
p33 NUMERIC
Grb2 I-GENE
- I-GENE
binding I-GENE
protein I-GENE
described O
in O
the O
present O
report O
is O
not O
the O
Fc I-GENE
epsilon I-GENE
R1 I-GENE
beta I-GENE
chain I-GENE
and O
its O
identity O
is O
unknown O
. O

To O
study O
the O
mechanisms O
as O
well O
as O
magnitude O
of O
the O
transmembrane O
transfer O
of O
bacterial O
products O
from O
the O
dialysate RARE
, O
we O
developed O
a O
computerized O
in O
vitro O
dialysis O
model O
which O
provides O
continuous O
pressure O
recording O
from O
the O
arterial O
, O
venous O
, O
dialysate RARE
inflow RARE
and O
outflow O
ports RARE
. O

After O
24 O
hour O
incubation O
, O
total O
cell O
- O
associated O
IL I-GENE
- I-GENE
1Ra NUMERIC
and O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
were O
measured O
by O
specific O
radioimmunoassay O
. O

Each O
dietary O
treatment O
was O
fed O
to O
six O
pen RARE
replicates RARE
of O
five O
chicks O
per O
pen RARE
for O
21 O
d O
. O

1972 O
. O

In O
contrast O
, O
recent O
evidence O
suggests O
that O
children O
with O
sickle RARE
- I-GENE
hemoglobin I-GENE
C I-GENE
disease O
do O
not O
develop O
functional O
asplenia RARE
before O
3 O
to O
4 O
years O
of O
age O
and O
thus O
may O
not O
benefit O
from O
penicillin O
prophylaxis O
. O

Deletion O
analysis O
indicates O
that O
TBP I-GENE
and O
hTAFII18 NUMERIC
bind O
to O
distinct O
domains O
of O
hTAFII28 NUMERIC
. O
hTAFII18 NUMERIC
also O
interacts O
with O
TBP I-GENE
, O
but O
it O
interacts O
more O
strongly O
with O
hTAFII28 NUMERIC
and O
hTAFII30 NUMERIC
. O

The O
NarX LASTCAP
and O
NarQ LASTCAP
proteins I-GENE
with O
amino O
acid O
substitutions O
at O
the O
first O
conserved O
histidine O
position O
were O
also O
unable O
to O
dephosphorylate RARE
NarL LASTCAP
- O
phosphate O
in O
vitro O
. O

Vascular RARE
endothelial O
cells O
undergo O
profound O
changes O
upon O
cellular O
activation O
including O
expression O
of O
a O
spectrum O
of O
cell O
activation O
- O
associated O
genes O
. O

Because O
ATF I-GENE
- I-GENE
1 I-GENE
and O
CREM ALLCAPS
are O
known O
to O
bind O
to O
cAMP O
response O
elements O
( O
CRE O
), O
this O
functional O
sequence O
was O
named O
the O
kappa O
E3 O
'- O
CRE O
. O

The O
Ng RARE
/ I-GENE
RC3 NUMERIC
and O
PKC I-GENE
- I-GENE
gamma I-GENE
genes I-GENE
have O
a O
similar O
expression O
pattern O
in O
the O
brain O
during O
development O
. O

Structure O
and O
regulation O
of O
the O
gene O
encoding O
the O
neuron O
- O
specific O
protein I-GENE
kinase I-GENE
C I-GENE
substrate O
neurogranin RARE
( O
RC3 NUMERIC
protein I-GENE
). O

The O
amino O
acid O
sequences O
of O
the O
known O
largest O
subunits O
of O
DdRPs RARE
from O
different O
species O
contain O
highly O
conserved O
regions O
. O

The O
TTG ALLCAPS
- I-GENE
2 I-GENE
gene I-GENE
has O
been O
identified O
at O
the O
site O
of O
chromosomal O
translocations RARE
in O
acute O
T O
- O
cell O
leukemia O
' O
s O
( O
T O
- O
ALL O
). O

In O
vitro O
studies O
with O
blood O
cells O
incubated O
with O
acetate O
or O
bicarbonate RARE
ions O
in O
concentrations O
, O
which O
are O
observed O
in O
vivo O
during O
hemodialysis O
, O
suggest O
that O
probably O
these O
ions O
do O
not O
directly O
affect O
superoxide O
anions RARE
generation O
, O
erythrocyte O
SOD I-GENE
- I-GENE
1 I-GENE
and O
catalase I-GENE
activities O
and O
erythrocyte O
membrane O
lipid O
peroxidation O
. O

Short O
therapy O
with O
omeprazole O
20 O
mg O
/ O
b O
. O
i O
. O
d O
., O
clarithromycin RARE
500 O
mg O
/ O
b O
. O
i O
. O
d O
., O
and O
CBS ALLCAPS
120 O
mg O
/ O
q O
. O
i O
. O
d O
. O
is O
a O
safe O
, O
well O
tolerated O
combination O
that O
achieves RARE
a O
80 O
. O
6 O
% O
eradication O
rate O
of O
H O
. O
pylori O
and O
duodenal O
ulcer O
healing O
rates O
as O
good O
as O
those O
achieved O
by O
omeprazole O
20 O
mg O
/ O
d O
when O
given O
for O
4 O
wk O
. O

The O
concentration O
of O
mite O
allergen O
was O
very O
low O
( O
mean O
0 O
. O
18 O
micrograms O
Der RARE
p O
milligrams RARE
sieved RARE
house RARE
dust O
), O
whereas O
that O
of O
cat O
allergen O
was O
high O
in O
homes RARE
with O
a O
cat O
( O
80 O
. O
8 O
micrograms O
Fel RARE
d O
milligrams RARE
) O
but O
also O
in O
homes RARE
with O
no O
cat O
( O
3 O
. O
2 O
micrograms O
Fel RARE
d O
milligrams RARE
). O

CONCLUSIONS O
: O
A O
comparison O
of O
the O
LysU LASTCAP
crystal O
structure O
with O
the O
structures O
of O
seryl RARE
- I-GENE
and I-GENE
aspartyl RARE
- I-GENE
tRNA I-GENE
synthetases I-GENE
enables O
a O
conserved O
core O
to O
be O
identified O
. O

Whole RARE
bowel O
irrigation O
is O
a O
recently O
described O
technique O
to O
enhance O
the O
passage O
of O
drugs O
already O
beyond O
the O
pylorus RARE
. O

The O
MPS1 NUMERIC
open I-GENE
reading I-GENE
frame I-GENE
has O
been O
fused O
to O
those O
that O
encode O
the O
LexA I-GENE
protein I-GENE
or O
the O
GST I-GENE
protein I-GENE
and O
both O
of O
these O
constructs O
function O
in O
yeast O
. O

As O
in O
Tb RARE
, O
U6 I-GENE
is O
a O
single O
- O
copy O
gene O
and O
two O
tRNA O
genes O
, O
tRNAGln RARE
and O
tRNAIle RARE
, O
are O
found O
upstream O
to O
the O
gene O
. O

Hematopoietic RARE
growth I-GENE
factors I-GENE
have O
already O
had O
an O
enormous RARE
impact O
on O
transfusion O
practice O
by O
eliminating RARE
or O
reducing O
the O
need O
for O
red O
blood O
cell O
transfusions RARE
in O
a O
variety O
of O
anemic RARE
states O
characterized O
by O
an O
absolute O
or O
relative O
decrease O
in O
erythropoietin I-GENE
. O

However O
, O
the O
mouse O
has O
previously O
been O
shown O
to O
possess O
only O
three O
forms O
of O
ADH I-GENE
. O

During O
IC ALLCAPS
breaths RARE
and O
following O
EC O
and O
VC ALLCAPS
breaths RARE
at O
rest O
, O
end O
- O
tidal O
CO2 O
pressure O
( O
PET O
, O
CO2 O
) O
fell O
by O
7 O
. O
5 O
, O
8 O
. O
5 O
and O
9 O
. O
5 O
mmHg O
, O
respectively O
. O

2 O
. O

Phylogenetic RARE
analyses O
of O
19 O
amino O
acid O
sequences O
of O
6 O
related O
protein O
types O
indicate O
that O
actin I-GENE
- O
associated O
proteins O
related O
to O
gelsolin RARE
are O
monophyletic RARE
to O
a O
common O
ancestor O
and O
include O
flightless RARE
proteins I-GENE
. O

No O
homologs O
of O
other O
members O
of O
the O
Surfeit RARE
gene I-GENE
cluster I-GENE
were O
detected O
in O
close O
proximity RARE
to O
the O
D O
. O
melanogaster O
Surf I-GENE
- I-GENE
3 I-GENE
/ O
rpL7a NUMERIC
gene O
. O

Moreover O
, O
we O
found O
that O
cyclin I-GENE
E I-GENE
, O
in O
contrast O
to O
cyclin I-GENE
D1 I-GENE
, O
was O
required O
for O
the O
G1 O
/ O
S O
transition O
even O
in O
cells O
lacking O
retinoblastoma I-GENE
protein I-GENE
function O
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
SGC1 NUMERIC
gene I-GENE
product I-GENE
includes O
a O
region O
with O
substantial O
similarity O
to O
the O
basic O
- O
helix O
- O
loop O
- O
helix O
domain O
of O
the O
Myc I-GENE
family I-GENE
of O
DNA O
- O
binding O
proteins O
. O

By O
creating RARE
Pax I-GENE
- I-GENE
6 I-GENE
- O
BSAP ALLCAPS
fusion O
proteins O
, O
we O
were O
able O
to O
identify O
a O
short O
amino O
acid O
stretch O
in O
the O
N O
- O
terminal O
part O
of O
the O
paired I-GENE
domain O
which O
is O
responsible O
for O
these O
differences O
in O
DNA O
- O
binding O
specificity O
. O

To O
establish O
a O
possible O
association O
between O
familial O
dysfibrinogenemia RARE
and O
thrombophilia RARE
, O
data O
on O
cases O
with O
both O
affections RARE
were O
collected O
in O
a O
study O
within O
the O
framework RARE
of O
the O
SSC ALLCAPS
Subcommittee RARE
on O
Fibrinogen RARE
of O
the O
International O
Society RARE
on O
Thrombosis RARE
and O
Haemostasis RARE
. O

Conjugated RARE
estrogens RARE
shorten RARE
bleeding O
time O
in O
uraemia RARE
: O
a O
possible O
role O
of O
serotonin O
? O

These O
six O
districts RARE
have O
an O
area O
of O
34 O
, O
000 O
km2 NUMERIC
and O
hold RARE
a O
population O
of O
30 O
million O
. O

According O
to O
symptoms O
, O
signs O
, O
imaging O
features O
, O
operation O
findings O
, O
the O
original O
places RARE
and O
the O
expansive RARE
directions RARE
of O
the O
tumor O
, O
they O
were O
divided O
into O
four O
clinical O
types O
: O
sellar RARE
, O
clival RARE
, O
occipito RARE
- O
temporal O
and O
extent O
. O

Two O
mammalian O
enzymes O
, O
the O
haem RARE
- I-GENE
controlled I-GENE
repressor I-GENE
( O
HCR ALLCAPS
) O
and O
the O
double I-GENE
- I-GENE
stranded I-GENE
RNA I-GENE
- I-GENE
activated I-GENE
inhibitor I-GENE
( O
dsI LASTCAP
), O
phosphorylate O
Ser O
- O
51 O
of O
the O
alpha O
subunit O
, O
thereby O
inhibiting O
the O
exchange O
of O
bound O
nucleotides O
on O
, O
and O
thus O
the O
recycling RARE
of O
, O
eIF I-GENE
- I-GENE
2 I-GENE
. O

A O
triple O
Ser O
--> O
Ala O
mutant O
form O
of O
yeast O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
was O
found O
to O
be O
no O
longer O
phosphorylated O
by O
either O
of O
the O
yeast O
( O
or O
mammalian O
) O
casein I-GENE
kinase I-GENE
activities O
in O
vitro O
. O

The O
cases O
included O
35 O
de O
novo O
diffuse O
aggressive O
lymphomas O
( O
DAL ALLCAPS
; O
19 O
large O
- O
cell O
, O
4 O
mixed O
- O
cell O
, O
and O
12 O
large O
- O
cell O
immunoblastic RARE
), O
52 O
transformed O
aggressive O
lymphomas O
derived O
from O
follicular O
lymphomas O
( O
TFL ALLCAPS
), O
42 O
indolent RARE
follicular O
lymphomas O
( O
FL O
), O
14 O
mantle RARE
cell O
lymphomas O
( O
MCL ALLCAPS
), O
and O
27 O
small O
noncleaved RARE
cell O
lymphomas O
( O
SNCL ALLCAPS
). O

Icterus RARE
and O
beta O
- O
thalassemia RARE
in O
Congolese RARE
children O
in O
Brazzaville RARE

Female O
patients O
with O
breast O
cancer O
diagnosed O
between O
1982 O
and O
1991 O
at O
Roswell RARE
Park RARE
Cancer O
Institute O
( O
RPCI ALLCAPS
) O
in O
Buffalo RARE
, O
New O
York O
, O
who O
provided O
information O
on O
their O
cigarette RARE
smoking O
history O
at O
the O
time O
of O
their O
diagnosis O
were O
included O
. O

Upon O
analysis O
of O
the O
tissue O
distribution O
of O
AAMP ALLCAPS
, O
it O
was O
found O
to O
be O
expressed O
strongly O
in O
endothelial O
cells O
, O
cytotrophoblasts RARE
, O
and O
poorly O
differentiated O
colon O
adenocarcinoma O
cells O
found O
in O
lymphatics RARE
. O

Data O
from O
the O
V O
- O
HeFT LASTCAP
II O
show O
that O
at O
2 O
- O
year O
follow O
- O
up O
, O
a O
progressive O
rise O
of O
plasma O
norepinephrine O
was O
observed O
in O
both O
treatment O
arms RARE
, O
suggesting O
that O
disease O
progresses RARE
despite O
treatment O
with O
either O
an O
angiotensin I-GENE
- I-GENE
converting I-GENE
enzyme I-GENE
inhibitor O
, O
enalapril RARE
, O
or O
vasodilator O
therapy O
with O
hydralazine RARE
/ O
isosorbide RARE
dinitrate RARE
. O

Binding O
activity O
in O
rat O
liver O
nuclear O
extracts O
includes O
these O
orphan O
receptors O
as O
judged O
from O
electromobility RARE
supershift O
experiments O
and O
from O
results O
obtained O
with O
expressed O
receptors O
, O
although O
the O
element O
in O
CYP2C11 NUMERIC
did O
not O
bind O
HNF I-GENE
- I-GENE
4 I-GENE
. O

Transcript RARE
analysis O
reveals O
that O
lethal O
B I-GENE
block I-GENE
substitutions O
reduce O
U6 I-GENE
RNA I-GENE
synthesis O
at O
least O
10 O
- O
fold O
in O
vivo O
and O
20 O
- O
fold O
in O
vitro O
. O

Analysis O
of O
Bcl I-GENE
- I-GENE
2 I-GENE
/ O
Bcl I-GENE
- I-GENE
2 I-GENE
homodimerization RARE
using O
both O
in O
vitro O
binding O
assays O
as O
well O
as O
a O
yeast O
two O
- O
hybrid O
method O
provided O
evidence O
in O
support O
of O
a O
head O
- O
to O
- O
tail O
model O
for O
Bcl I-GENE
- I-GENE
2 I-GENE
/ O
Bcl I-GENE
- I-GENE
2 I-GENE
homodimerization RARE
and O
revealed O
that O
sequences O
within O
the O
NH2 O
- O
terminal O
A O
domain O
interact O
with O
a O
structure O
that O
requires O
the O
presence O
of O
both O
the O
carboxyl O
B O
and O
C O
domains O
in O
combination O
. O

The O
protein O
is O
composed O
of O
a O
central O
alpha O
- O
helical O
portion O
with O
globular O
domains O
at O
both O
NH2 O
and O
COOH O
termini O
, O
and O
the O
epitope O
to O
the O
monoclonal O
antibody O
resides O
in O
the O
central O
alpha O
- O
helical O
stalk RARE
. O

Radioligand RARE
binding O
was O
indistinguishable O
for O
both O
transiently O
expressed O
constructs O
. O

Diagnosis O
of O
FHCS ALLCAPS
has O
been O
weighed RARE
upon O
laparoscopic O
findings O
. O

Human I-GENE
papillomavirus I-GENE
type I-GENE
31b NUMERIC
late I-GENE
gene I-GENE
expression O
is O
regulated O
through O
protein I-GENE
kinase I-GENE
C I-GENE
- O
mediated O
changes O
in O
RNA O
processing O
. O

Interestingly O
, O
virions O
also O
contained O
smaller O
proteins O
that O
reacted O
with O
antibodies O
specific O
for O
the O
accessory O
proteins O
as O
well O
as O
SN ALLCAPS
and O
CAT I-GENE
fusion I-GENE
partners O
. O

Studies O
using O
an O
inhibitor O
or O
a O
mutant I-GENE
Lb RARE
proteinase I-GENE
indicated O
that O
stimulation O
of O
IRES ALLCAPS
- O
driven O
translation O
is O
mediated O
via O
proteolysis O
of O
some O
cellular O
component O
( O
s O
). O

Restriction O
mapping O
analysis O
localized O
this O
cDNA O
to O
the O
HHV ALLCAPS
- I-GENE
6A NUMERIC
( I-GENE
U1102 NUMERIC
) I-GENE
genomic I-GENE
BamHI I-GENE
G I-GENE
fragment I-GENE
, O
at O
the O
right O
end O
of O
the O
unique O
long O
segment O
of O
the O
genome O
and O
to O
the O
SalI LASTCAP
L I-GENE
and O
SalI LASTCAP
O I-GENE
fragments I-GENE
within O
the O
left O
and O
right O
terminal O
direct O
repeat O
regions O
, O
respectively O
. O

For O
replication O
reporter O
constructs O
where O
E1 I-GENE
and O
E2 I-GENE
are O
supplied O
in O
trans O
by O
the O
respective O
expression O
vectors O
, O
distance O
between O
the O
half O
sites O
seems O
to O
play O
a O
major O
role O
, O
yet O
the O
phasing RARE
relationships O
are O
measurable RARE
. O

As O
it O
had O
been O
previously O
reported O
that O
the O
18 O
- O
bp O
palindrome O
contains O
sufficient O
nucleotide O
sequence O
information O
for O
E1 I-GENE
binding O
, O
we O
speculate RARE
that O
a O
minimal O
E1 I-GENE
recognition O
motif O
is O
presented O
in O
each O
half O
site O
. O

METHODS O
: O
Out RARE
of O
171 NUMERIC
patients O
receiving O
anticoagulation RARE
between O
July RARE
1992 O
and O
December RARE
1993 O
, O
83 O
patients O
with O
hemispheric RARE
embolisms RARE
received O
heparin O
within O
72 O
hours O
from O
onset O
( O
activated O
partial O
thromboplastin I-GENE
time O
[ O
aPTT LASTCAP
] O
1 O
. O
5 O
times O
control O
value O
). O

In O
the O
commercially RARE
available O
intravenous O
formulation O
of O
Cyclosporin RARE
A O
( O
Sandimmun RARE
), O
polyoxyethylated RARE
castor RARE
oil O
( O
Cremophor RARE
EL ALLCAPS
) O
is O
used O
as O
a O
solubilizing RARE
agent O
. O

Lung O
function O
tests O
( O
EFR ALLCAPS
) O
were O
performed O
on O
these O
patients O
for O
a O
period O
of O
19 O
. O
2 O
+/- O
3 O
. O
4 O
months O
. O

Sequence O
comparisons O
of O
prokaryotic I-GENE
RCR ALLCAPS
initiators RARE
has O
revealed O
a O
set O
of O
three O
common O
motifs O
, O
two O
of O
which O
, O
a O
putative O
metal O
coordination O
site O
and O
a O
downstream O
active O
- O
site O
tyrosine O
motif O
, O
could O
be O
tentatively O
identified O
in O
parvoviral RARE
replicator RARE
proteins I-GENE
. O

The O
mean O
marginal RARE
discrepancy RARE
of O
provisional RARE
restorations O
was O
compared O
for O
restorations O
fabricated RARE
from O
stone O
, O
low O
- O
viscosity O
poly O
( O
vinyl O
siloxane RARE
), O
and O
medium O
- O
viscosity O
poly O
( O
vinyl O
siloxane RARE
). O

The O
characterized O
Aplysia RARE
Afurin2 NUMERIC
is O
a O
candidate O
PC I-GENE
that O
may O
play O
an O
important O
role O
in O
the O
processing O
of O
egg I-GENE
- I-GENE
laying RARE
hormone I-GENE
( O
ELH ALLCAPS
)- O
related O
precursors O
in O
the O
secretory O
cells O
of O
the O
atrial O
gland O
. O

Rats O
treated O
with O
8 O
- O
OH O
- O
DPAT ALLCAPS
were O
not O
impaired O
in O
their O
ability O
to O
learn RARE
a O
visual O
discrimination O
in O
a O
water O
maze RARE
. O

The O
term O
endovascular RARE
papillary RARE
haemangioma RARE
is O
suggested O
. O

In O
addition O
, O
two O
internal O
promoters O
, O
PmiaA LASTCAP
and O
P1hfq NUMERIC
were O
identified O
and O
mapped O
to O
201 O
and O
837 NUMERIC
nucleotides O
upstream O
from O
the O
respective O
translation O
start O
sites O
. O

These O
results O
indicate O
that O
mutL LASTCAP
, O
miaA LASTCAP
, O
and O
hfq RARE
expression O
could O
be O
regulated O
by O
multiple O
mechanisms O
, O
including O
degree O
of O
cotranscription RARE
from O
upstream O
genes O
, O
modulation O
of O
internal O
promoter O
strength O
, O
and O
by O
RNase I-GENE
E I-GENE
activity O
. O

Coronary O
T1 O
and O
T2 O
weighted O
images O
were O
obtained O
. O

The O
2 O
kb O
of O
5 O
'- O
flanking O
region O
and O
the O
1 O
. O
1 O
kb O
of O
the O
entire O
sGTH LASTCAP
alpha I-GENE
subunit I-GENE
coding O
region O
were O
sequenced O
from O
the O
genomic O
clone O
, O
sGTH LASTCAP
alpha I-GENE
- I-GENE
G1 I-GENE
. O

Functional O
analysis O
of O
the O
sGTH LASTCAP
alpha I-GENE
subunit I-GENE
promoter I-GENE
by O
the O
transient O
transfection O
of O
several O
sGTH LASTCAP
alpha I-GENE
/ O
CAT I-GENE
chimeric O
plasmids O
into O
rainbow RARE
trout O
pituitary O
cells O
suggests O
that O
its O
pituitary O
- O
specific O
expression O
is O
GSE ALLCAPS
- O
dependent O
. O

Indium RARE
- O
111 O
OncoScint RARE
CR O
/ O
OV ALLCAPS
and O
F O
- O
18 O
FDG O
in O
colorectal RARE
and O
ovarian O
carcinoma O
recurrences RARE
. O

His O
carnitine RARE
palmitoyltransferase RARE
( I-GENE
CPT I-GENE
) I-GENE
I I-GENE
and I-GENE
II I-GENE
activities O
were O
0 O
. O
06 O
and O
0 O
. O
12 O
nmol O
/ O
min O
/ O
mg O
protein O
, O
as O
compared O
with O
a O
mean O
value O
of O
0 O
. O
22 O
+/- O
0 O
. O
14 O
and O
0 O
. O
27 O
+/- O
0 O
. O
07 O
nmol O
/ O
min O
/ O
mg O
protein O
, O
respectively O
, O
in O
control O
subjects O
. O

The O
Myc I-GENE
LZ ALLCAPS
was O
found O
to O
prevent O
homodimeric RARE
interactions O
, O
thus O
explaining RARE
Myc I-GENE
inability RARE
to O
homodimerize RARE
efficiently O
. O

Staphylococcus O
aureus O
and O
CNS O
showed O
high O
or O
moderate O
resistance O
rates O
to O
methicillin RARE
( O
DMPPC ALLCAPS
). O

Thus O
, O
VF O
resistant O
to O
defibrillation RARE
is O
not O
necessarily O
associated O
with O
both O
toxic O
plasma O
drug O
level O
and O
remarkably O
decreased O
conduction O
. O

The O
smallest O
active I-GENE
FecR LASTCAP
derivative I-GENE
contained O
59 O
amino O
acid O
residues O
as O
compared O
to O
the O
317 NUMERIC
residues O
of O
wild I-GENE
- I-GENE
type I-GENE
FecR LASTCAP
. O

The O
gene O
pairs O
psbB LASTCAP
- O
psbT LASTCAP
and O
psbH LASTCAP
- O
psbN LASTCAP
are O
cotranscribed O
from O
opposite O
strands RARE
. O

Hybridization O
signals O
were O
also O
detected O
with O
total O
DNAs O
of O
Rhizobium O
leguminosarum RARE
bv RARE
. O
phaseoli RARE
, O
Rhodobacter RARE
capsulatus RARE
and O
Escherichia O
coli O
, O
but O
not O
those O
of O
Xanthomonas RARE
campestris RARE
pv RARE
. O
campestris RARE
and O
Pseudomonas O
putida O
. O

The O
predicted O
amino O
acid O
sequence O
contains O
regions O
identical O
to O
the O
sequences O
of O
peptides O
derived O
from O
bovine I-GENE
liver I-GENE
eIF I-GENE
- I-GENE
2B I-GENE
alpha I-GENE
subunit I-GENE
. O

Expression O
of O
this O
cDNA O
in O
vitro O
yields O
a O
peptide O
which O
comigrates RARE
with O
natural I-GENE
eIF I-GENE
- I-GENE
2B I-GENE
alpha I-GENE
in O
SDS O
/ O
polyacrylamide O
gels O
. O

When O
RNA O
encoding O
the O
tail O
domain O
of O
desmoglein RARE
was O
coinjected RARE
with O
plakoglobin I-GENE
RNA I-GENE
, O
both O
the O
dorsalizing RARE
effect O
and O
nuclear O
accumulation O
of O
plakoglobin I-GENE
were O
suppressed O
. O

Six O
of O
them O
, O
NUC1 NUMERIC
, O
PRP21 NUMERIC
( O
also O
called O
SPP91 NUMERIC
), O
CDC6 NUMERIC
, O
CRY2 NUMERIC
, O
the O
gene O
encoding O
the O
ribosomal I-GENE
protein I-GENE
S24 NUMERIC
and O
the O
gene O
coding O
for O
a O
hypothetical RARE
protein O
of O
599 NUMERIC
amino O
acids O
, O
have O
been O
sequenced O
previously O
. O

Intrastriatal RARE
grafts O
of O
nigral RARE
and O
adrenal O
tissues O
have O
been O
found O
to O
be O
effective O
in O
alleviating RARE
many O
of O
the O
simple O
motor O
and O
sensorimotor RARE
deficits O
associated O
with O
lesions O
of O
the O
nigrostriatal RARE
dopamine O
system O
. O

OBJECTIVE O
: O
To O
determine O
the O
impact O
of O
the O
introduction O
of O
clarithromycin RARE
and O
azithromycin RARE
on O
the O
treatment O
and O
survival O
of O
patients O
with O
AIDS O
and O
disseminated RARE
Mycobacterium O
avium RARE
complex O
( O
DMAC ALLCAPS
). O

Thereafter RARE
, O
the O
aggregation O
rose O
to O
the O
initial O
100 O
% O
value O
4 O
h O
after O
drug O
application O
and O
remained O
at O
this O
level O
during O
the O
observation O
period O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Growth O
curves O
indicated O
that O
proliferation O
of O
clone O
CA9 NUMERIC
in O
the O
presence O
of O
10 O
% O
serum O
was O
reduced O
by O
60 O
% O
compared O
with O
clone O
ME10 NUMERIC
. O

The O
protein O
coding O
region O
, O
1 O
, O
696 NUMERIC
bps RARE
long O
, O
is O
divided O
by O
an O
intron O
into O
two O
exons O
. O

The O
UAS O
of O
the O
AAC2 NUMERIC
gene I-GENE
contains O
at O
least O
two O
distinct O
motifs O
for O
DNA O
- O
binding O
transcriptional O
activators O
, O
including O
one O
which O
is O
identical O
with O
the O
core O
HAP2 NUMERIC
/ I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
binding I-GENE
motif I-GENE
, O
and O
a O
second O
one O
with O
the O
ABF1 NUMERIC
consensus I-GENE
binding I-GENE
sequence I-GENE
. O

The O
emerging RARE
complexity O
of O
the O
5 O
' O
regulatory O
region O
of O
the O
GH I-GENE
receptor I-GENE
gene I-GENE
was O
emphasised RARE
by O
the O
observation O
that O
probes O
derived O
from O
exon O
1B O
and O
the O
distal O
3 O
' O
intron O
boundary O
do O
not O
hybridise RARE
with O
previously O
cloned O
genomic O
sequences O
that O
span O
the O
liver O
- O
specific O
P1 O
promoter O
and O
exon O
2 O
. O

A O
polymorphic O
dinucleotide O
( O
GT O
/ O
CA O
) O
n O
repeat O
contained O
in O
the O
NHE5 NUMERIC
cosmid O
was O
identified O
and O
developed O
into O
a O
microsatellite O
PCR O
marker O
. O

The O
proteins O
are O
more O
than O
90 O
% O
identical O
to O
each O
other O
within O
the O
protein O
kinase O
domain O
but O
only O
51 O
- O
59 O
% O
identical O
to O
other O
casein I-GENE
kinase I-GENE
I I-GENE
isoforms I-GENE
within O
this O
region O
. O

We O
used O
two O
approaches O
to O
ascertain RARE
whether O
CDP I-GENE
/ O
cut I-GENE
serves O
as O
a O
repressor O
of O
gp91 NUMERIC
- O
phox RARE
gene O
expression O
. O

Serum O
induction O
of O
a O
MEF2 I-GENE
reporter I-GENE
gene I-GENE
was O
not O
observed O
in O
a O
line O
of O
NIH O
3T3 O
cells O
which O
contain O
low O
MEF2 I-GENE
site I-GENE
binding O
activity O
. O

Despite O
the O
activation O
of O
these O
intracellular O
signaling O
molecules O
, O
PDGF I-GENE
beta I-GENE
receptor I-GENE
activation O
elicited O
no O
detectable O
effect O
on O
cell O
proliferation O
or O
differentiation O
. O

UAS1 O
is O
the O
binding O
site O
for O
the O
transcriptional O
regulator O
Adr1p NUMERIC
. O

In O
the O
context O
of O
the O
ADH2 NUMERIC
upstream I-GENE
regulatory I-GENE
region I-GENE
, O
including O
UAS1 O
, O
working O
in O
concert RARE
with O
the O
ADH2 NUMERIC
basal I-GENE
promoter I-GENE
elements I-GENE
, O
UAS2 NUMERIC
- O
dependent O
gene O
activation O
was O
dependent O
on O
orientation O
, O
copy O
number O
, O
and O
helix O
phase O
. O

Induction O
in O
AP I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
correlates O
with O
a O
concomitant O
GH I-GENE
trans O
- O
activation O
of O
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
genes I-GENE
described O
previously O
. O

Inactivation RARE
of O
MAP I-GENE
kinases I-GENE
occurs O
via O
a O
specific O
phosphatase O
, O
MKP I-GENE
- I-GENE
1 I-GENE
. O

Short O
- O
course O
amphotericin O
B O
therapy O
for O
candidemia RARE
in O
pediatric O
patients O
. O

Furthermore O
, O
45Ca NUMERIC
- O
binding O
assays O
revealed O
that O
CCaMK LASTCAP
directly O
binds O
Ca2 O
+. RARE

Since O
AP I-GENE
- I-GENE
1 I-GENE
is O
an O
important O
mediator RARE
of O
tumor O
promoter O
action O
, O
these O
findings O
may O
explain O
the O
anti O
- O
tumor O
- O
promoting O
activity O
of O
phenolic RARE
antioxidants RARE
. O

The O
second O
complex O
, O
when O
purified O
, O
contained O
four O
protein O
components O
including O
the O
36 O
- O
kDa O
protein O
. O

The O
protein O
expressed O
from O
the O
cloned O
cDNA O
is O
secreted O
into O
the O
culture O
medium O
and O
yields O
of O
up O
to O
40 O
mg O
per O
litre RARE
have O
been O
obtained O
. O

The O
study O
was O
repeated O
after O
administration O
of O
oral O
amiodarone RARE
, O
50 O
mg O
/ O
kg O
/ O
day O
for O
2 O
days O
in O
8 O
divided O
doses O
( O
mean O
dose O
6 O
. O
9 O
+/- O
0 O
. O
4 O
g O
). O

Plasmids RARE
pAMS12 NUMERIC
, O
pAMS13 NUMERIC
and O
pAMS14 NUMERIC
were O
transformed O
into O
a O
laboratory O
strain O
of O
Saccharomyces O
cerevisiae O
, O
whereas O
pAMS15 NUMERIC
was O
stably O
introduced O
into O
two O
commercial O
wine RARE
yeast O
strains O
. O

The O
maximum O
induction O
of O
ACC ALLCAPS
- I-GENE
oxidase I-GENE
transcripts I-GENE
occurred O
at O
about O
6 O
h O
after O
excision O
, O
while O
the O
maximum O
enzyme O
activity O
was O
observed O
at O
24 O
h O
. O

Within O
their O
polypeptide O
chain O
, O
they O
all O
contain O
those O
conserved O
features O
that O
define O
a O
plant O
CDPK ALLCAPS
; O
kinase O
catalytic O
sequences O
are O
linked O
to O
a O
calmodulin I-GENE
- I-GENE
like I-GENE
regulatory I-GENE
domain I-GENE
through O
a O
junction O
region O
. O

Repair RARE
of O
this O
insertion O
by O
homologous O
recombination O
restores O
the O
activity O
of O
the O
hprt RARE
locus I-GENE
, O
thus O
confirming O
the O
site O
of O
mutation O
. O

The O
timing O
of O
fla RARE
gene I-GENE
expression O
in O
the O
cell O
cycle O
is O
determined O
by O
specialized O
forms O
of O
RNA I-GENE
polymerase I-GENE
and O
the O
appearance O
and O
/ O
or O
activation O
of O
regulatory O
proteins O
. O

Primer O
extension O
experiments O
revealed O
a O
strong O
transcription O
initiation O
site O
102 NUMERIC
bp O
upstream O
of O
the O
translational O
start O
site O
. O

Polypeptides RARE
of O
the O
same O
apparent O
sizes O
are O
detected O
in O
spores RARE
of O
a O
cotE LASTCAP
null O
mutant O
, O
on O
which O
basis O
we O
infer RARE
that O
the O
products O
of O
the O
cotJ LASTCAP
operon I-GENE
are O
required O
for O
the O
normal O
formation O
of O
the O
inner O
layers RARE
of O
the O
coat O
or O
are O
themselves O
structural O
components O
of O
the O
coat O
. O

Based O
on O
the O
estimated O
values O
of O
divergence O
of O
apobec1 NUMERIC
sequences I-GENE
in O
terms O
of O
the O
numbers O
of O
synonymous RARE
and O
non O
- O
synonymous RARE
suhstitutions RARE
per O
site O
, O
we O
found O
that O
apobec1 NUMERIC
is O
a O
fairly RARE
rapidly O
evolving RARE
protein O
. O

EEA1 NUMERIC
is O
a O
conserved O
alpha O
- O
helical O
peripheral O
membrane O
protein O
flanked O
by O
cysteine O
" O
fingers O
" O
and O
contains O
a O
calmodulin I-GENE
- I-GENE
binding I-GENE
IQ ALLCAPS
motif I-GENE
. O

Nucleotide O
sequences O
of O
the O
clones O
revealed O
that O
one O
clone O
, O
cap3 NUMERIC
, O
contained O
an O
open O
reading O
frame O
( O
ORF O
) O
that O
would O
code O
for O
a O
26 O
- O
amino O
acid O
, O
cysteine O
- O
rich O
peptide O
with O
significant O
homology O
to O
Neurospora I-GENE
crassa I-GENE
copper I-GENE
metallothionein RARE
. O

Sensing RARE
with O
chemically RARE
and O
biologically O
modified O
carbon O
electrodes O
. O

Elevation RARE
of O
the O
tissues O
of O
the O
face O
is O
essentially O
vertical O
and O
acts O
on O
the O
forehead RARE
, O
temporal O
region O
, O
gaze RARE
and O
cheekbones RARE
. O

This O
region O
binds O
two O
ubiquitous O
nuclear O
factors O
, O
USF I-GENE
/ O
MLTF ALLCAPS
and O
the O
CAAT I-GENE
- I-GENE
binding I-GENE
transcription I-GENE
factor I-GENE
/ O
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
CTF ALLCAPS
/ O
NF1 I-GENE
). O

The O
potential O
impact O
of O
using O
a O
rapid O
diagnostic O
test O
( O
Strep RARE
A O
OIA ALLCAPS
) O
on O
detection O
and O
treatment O
of O
group O
A O
beta O
- O
hemolytic RARE
streptococcal O
( O
GABHS ALLCAPS
) O
pharyngitis RARE
in O
a O
large O
- O
volume O
pediatric O
and O
adolescent O
clinic RARE
was O
examined O
. O

The O
bHLH I-GENE
proteins I-GENE
function O
as O
potent O
transcriptional O
activators O
of O
tissue O
- O
specific O
genes O
by O
forming O
heterodimers O
between O
ubiquitous O
and O
cell O
- O
restricted O
family O
members O
. O

YAC O
and O
cosmid O
contigs RARE
spanning O
the O
BRCA1 I-GENE
region I-GENE
were O
used O
to O
select O
cDNA O
clones O
from O
pools RARE
of O
cDNAs O
derived O
from O
human O
placenta O
, O
HeLa O
cells O
, O
activated O
T O
cells O
, O
and O
fetal O
head O
. O

The O
other O
two O
clones O
, O
Ash RARE
- I-GENE
m I-GENE
and I-GENE
- I-GENE
s I-GENE
, O
had O
nucleotide O
sequences O
identical O
with O
Ash RARE
- I-GENE
l I-GENE
cDNA O
in O
the O
amino O
- O
terminal O
region O
. O

This O
study O
assesses RARE
the O
feasibility O
and O
toxicity O
of O
adoptive RARE
immunotherapy O
with O
tumor O
infiltrating RARE
lymphocytes O
and O
recombinant I-GENE
interleukin I-GENE
- I-GENE
2 I-GENE
in O
29 O
patients O
who O
underwent O
resection O
for O
stage O
III O
non O
- O
small O
- O
cell O
lung O
cancer O
. O

MATERIAL ALLCAPS
AND O
METHODS O
: O
Of O
the O
17 O
men O
and O
17 O
women O
, O
who O
were O
21 O
to O
80 O
years O
of O
age O
, O
27 O
had O
hereditary O
motor O
and O
sensory O
neuropathy O
type O
I O
and O
7 O
had O
acquired O
demyelinating RARE
polyneuropathy RARE
. O

The O
present O
study O
describes O
the O
cell O
volume O
dynamics O
in O
intact O
rat O
hearts O
, O
during O
ischemia O
and O
after O
reperfusion O
. O

In O
contrast O
, O
COUP I-GENE
- I-GENE
TF I-GENE
alone O
had O
no O
effect O
on O
repCRS2 NUMERIC
- O
dependent O
reporter O
gene O
activity O
. O

DNA O
sequencing O
and O
Southern O
blot O
analyses O
established O
that O
the O
cDNA O
clones O
are O
derived O
from O
two O
different O
genes O
. O

Muscle RARE
GSH ALLCAPS
- I-GENE
Px I-GENE
activity O
after O
prolonged O
exercise O
, O
training O
, O
and O
selenium O
supplementation O
. O

Mutation O
of O
the O
Sp1 I-GENE
element I-GENE
, O
which O
abolishes O
Sp1 I-GENE
binding O
, O
results O
in O
a O
6 O
- O
10 O
- O
fold O
reduction O
in O
reporter O
activity O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
is O
overexpressed O
in O
a O
variety O
of O
tumor O
types O
and O
appears O
to O
play O
an O
important O
role O
in O
the O
abnormal O
growth O
of O
a O
number O
of O
cell O
types O
. O

We O
found O
that O
PML ALLCAPS
was O
expressed O
at O
a O
lower O
level O
in O
S O
, O
G2 O
, O
and O
M O
phases O
and O
at O
a O
significantly O
higher O
level O
in O
G1 O
phase O
. O

Schooling RARE
is O
found O
to O
be O
related O
to O
good O
health O
even O
after O
controlling O
for O
differences O
in O
observable RARE
health O
inputs O
. O

With O
this O
bisected RARE
diastolic O
driving RARE
, O
the O
abnormal O
echo O
disappeared O
completely O
. O

It O
acts O
on O
Cdks RARE
in O
the O
G1 O
and O
S O
phases O
of O
the O
cell O
cycle O
, O
and O
also O
binds O
to O
proliferating I-GENE
cell I-GENE
nuclear I-GENE
antigen I-GENE
( O
PCNA I-GENE
), O
blocking O
DNA O
replication O
in O
vitro O
. O

Two O
major O
and O
one O
minor O
transcription O
initiation O
sites O
were O
assigned O
to O
positions O
+ O
1 O
and O
+ O
24 O
and O
position O
+ O
14 O
, O
respectively O
, O
by O
a O
combination O
of O
ribonuclease O
protection O
, O
primer O
extension O
, O
and O
5 O
' O
RACE O
analyses O
. O

The O
roxithromycin RARE
doses O
that O
were O
chosen O
for O
these O
studies O
were O
less O
than O
achievable RARE
blood O
levels O
. O

We O
demonstrate O
here O
that O
the O
- O
DEDDDL ALLCAPS
sequence O
stabilizes O
GDP O
binding O
to O
Ran I-GENE
, O
and O
that O
the O
domain O
is O
required O
for O
high O
affinity O
interaction O
with O
a O
Ran I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
HTF9A NUMERIC
/ O
RanBP1 NUMERIC
. O

Further O
, O
the O
ORFs O
of O
components O
3 O
and O
5 O
potentially O
encoded O
proteins O
of O
about O
20 O
kDa O
, O
the O
size O
of O
the O
BBTV ALLCAPS
coat I-GENE
protein I-GENE
. O

Serial RARE
followup RARE
strength O
data O
for O
2 O
patients O
were O
compared O
to O
change O
in O
creatinine I-GENE
kinase I-GENE
( O
CK I-GENE
) O
levels O
. O

CodY LASTCAP
does O
not O
have O
any O
homologues O
in O
the O
data O
- O
bases O
. O

OBJECTIVE O
: O
To O
investigate O
the O
incidence O
and O
presentation O
of O
acute O
pernicious RARE
or O
fulminating RARE
beriberi RARE
in O
a O
general O
district RARE
hospital O
. O

Unlike O
most O
other O
small I-GENE
G I-GENE
proteins I-GENE
which O
are O
expressed O
ubiquitously O
, O
TTF I-GENE
was O
transcribed O
only O
in O
hemopoietic RARE
cells O
as O
a O
2 O
. O
2 O
kb O
transcript O
. O

An O
explanation O
explored O
for O
this O
lack O
of O
gene O
expression O
was O
that O
increased O
levels O
of O
RAR I-GENE
alpha I-GENE
or O
PML ALLCAPS
might O
suppress O
APL ALLCAPS
cell O
growth O
. O

Transfection O
of O
non O
- O
deleted O
expression O
vector O
into O
NIH3T3 O
cells O
results O
in O
acquisition O
of O
focus O
- O
forming O
activity O
while O
a O
deleted O
form O
of O
expression O
vector O
fails O
to O
show O
this O
activity O
even O
in O
the O
presence O
of O
basic I-GENE
FGF I-GENE
. O

Cytosolic RARE
extracts O
from O
a O
variety O
of O
mammalian O
cell O
lines O
( O
monkey O
Cos7 NUMERIC
, O
several O
mouse O
fibrosarcomas RARE
and O
human O
HeLa O
S3 NUMERIC
) O
demonstrated O
similar O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
dependent O
RNA O
- O
protein O
band O
shifts O
as O
cell O
extract O
from O
BALB O
/ O
c O
3T3 O
mouse O
fibroblasts O
. O

All O
ribosomal I-GENE
protein I-GENE
( O
rp RARE
) O
gene O
promoters O
from O
Saccharomyces O
cerevisiae O
studied O
so O
far O
contain O
either O
( O
usually O
two O
) O
binding O
sites O
for O
the O
global O
gene O
regulator O
Rap1p NUMERIC
or O
one O
binding O
site O
for O
another O
global O
factor O
, O
Abf1p NUMERIC
. O

The O
provisional RARE
reports O
are O
based O
mainly O
upon O
macroscopic RARE
findings O
, O
whereas O
the O
final O
reports O
include O
the O
information O
provided O
by O
supplementary O
investigations O
such O
as O
microscopy O
, O
histochemistry RARE
, O
more O
rarely O
electron O
microscopy O
, O
immunohistochemistry RARE
and O
/ O
or O
microbiology RARE
. O

Circulating RARE
thrombomodulin RARE
: O
current O
knowledge O
and O
future O
prospects RARE

CPT O
- O
11 O
was O
administered O
as O
a O
30 O
- O
minute O
i O
. O
v O
. O
infusion O
at O
a O
dose O
of O
350 O
mg O
/ O
m2 O
diluted RARE
in O
250 O
ml O
normal O
saline O
every O
3 O
weeks O
. O

CONCLUSION O
: O
The O
MTD ALLCAPS
for O
CPT O
- O
11 O
administered O
in O
a O
3 O
consecutive O
- O
days O
- O
every O
- O
3 O
weeks O
schedule O
in O
this O
patient O
population O
is O
115 O
mg O
/ O
m2 O
/ O
day O
. O

A O
73 O
bp O
fragment O
( O
X1 NUMERIC
region O
) O
of O
the O
PRB ALLCAPS
- I-GENE
1b I-GENE
promoter I-GENE
, O
located O
between O
positions O
- O
213 NUMERIC
and O
- O
141 NUMERIC
, O
was O
sufficient O
to O
confer O
ethylene O
responsiveness O
to O
the O
reporter O
gene O
. O

To O
assess O
the O
function O
( O
s O
) O
of O
E74 NUMERIC
during O
metamorphosis RARE
, O
we O
have O
isolated O
and O
characterized O
recessive O
loss O
- O
of O
- O
function O
mutations O
specific O
to O
each O
transcription O
unit O
. O

Although O
the O
extracellular O
domain O
of O
the O
TSH I-GENE
- I-GENE
R I-GENE
is O
sufficient O
for O
high O
affinity O
binding O
of O
TSH I-GENE
, O
we O
conclude O
that O
the O
hyt RARE
mutation O
in O
the O
fourth O
transmembrane O
domain O
eliminates RARE
TSH I-GENE
binding O
. O

Lipiodol RARE
was O
covalently O
conjugated O
with O
EDTB ALLCAPS
. O

Moreover O
, O
Western O
blots O
demonstrated O
at O
least O
six O
types O
of O
Ypt RARE
in O
both O
Cr O
and O
Vc RARE
, O
suggesting O
that O
these O
Ypt RARE
are O
used O
for O
household RARE
functions O
responsible O
for O
vesicle O
transport O
rather O
than O
for O
cellular O
differentiation O
. O

The O
absence O
of O
other O
regions O
of O
hybridization O
suggests O
that O
there O
are O
no O
closely O
related O
sequences O
( O
e O
. O
g O
., O
reverse O
transcribed O
pseudogenes RARE
) O
scattered RARE
throughout O
the O
genome O
and O
that O
if O
there O
are O
closely O
related O
genes O
, O
they O
must O
be O
clustered O
near O
GSTT2 NUMERIC
. O

However O
, O
the O
lens O
dose O
( O
3 O
. O
6 O
Gy O
/ O
25 O
fractions O
) O
was O
higher O
compared O
to O
the O
other O
techniques O
. O

Antibodies O
to O
the O
human I-GENE
PTS1R NUMERIC
recognize O
this O
protein O
in O
human O
, O
monkey O
, O
rat O
, O
and O
hamster O
cells O
. O

There O
is O
a O
national O
effort O
to O
begin O
to O
ask RARE
all O
female O
patients O
about O
family O
violence RARE
. O

GnRH I-GENE
treatment O
was O
found O
to O
increase O
the O
phosphorylation O
of O
tyrosine O
residues O
of O
MAPK I-GENE
and O
to O
increase O
MAPK I-GENE
activity O
, O
as O
determined O
by O
an O
immune O
complex O
kinase O
assay O
. O

Molecular O
cloning O
of O
an O
amphibian RARE
insulin I-GENE
receptor I-GENE
substrate I-GENE
1 I-GENE
- I-GENE
like I-GENE
cDNA I-GENE
and O
involvement O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
in O
insulin I-GENE
- O
induced O
Xenopus O
oocyte O
maturation O
. O

We O
report O
here O
that O
in O
cultured O
Jurkat O
T O
cells O
, O
Cbl I-GENE
is O
coprecipitated RARE
with O
antibody O
against O
the O
adapter I-GENE
protein I-GENE
Grb2 I-GENE
. O

The O
effect O
of O
these O
cell O
cycle O
regulators O
is O
not O
specific O
to O
the O
rap1s NUMERIC
or O
hmr RARE
delta I-GENE
A I-GENE
mutation I-GENE
, O
since O
swi6 NUMERIC
, O
swi4 NUMERIC
, O
and O
clb5 NUMERIC
mutations I-GENE
also O
suppress O
mutations O
in O
SIR1 NUMERIC
, O
another O
gene O
implicated O
in O
the O
establishment O
of O
silencing O
. O

ICP4 I-GENE
has O
been O
shown O
to O
form O
tripartite RARE
complexes O
cooperatively RARE
with O
the O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
and O
TFIIB ALLCAPS
on O
DNA O
containing O
an O
ICP4 I-GENE
binding I-GENE
site I-GENE
and O
a O
TATA O
box O
( O
C O
. O

Otte RARE
, O
Mol RARE
. O

Characterization O
of O
fus1 NUMERIC
of O
Schizosaccharomyces O
pombe O
: O
a O
developmentally O
controlled O
function O
needed O
for O
conjugation O
. O

SRY ALLCAPS
- I-GENE
related I-GENE
cDNA I-GENE
encoding O
a O
protein O
with O
a O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
( O
HMG I-GENE
) O
box O
and O
a O
leucine O
zipper O
motif O
, O
which O
was O
designated O
SOX ALLCAPS
- I-GENE
LZ ALLCAPS
, O
was O
isolated O
from O
a O
rainbow RARE
trout O
testis O
cDNA O
library O
. O

Scalp RARE
flaps RARE
can O
be O
expanded RARE
just O
to O
the O
point O
of O
becoming RARE
noticeable RARE
over O
4 O
to O
6 O
weeks O
followed O
by O
scalp RARE
flap O
transposition RARE
and O
easy RARE
closure O
of O
the O
donor O
site O
. O

In O
the O
Center RARE
for O
Human O
Genetics RARE
in O
Leuven RARE
, O
predictive O
DNA O
- O
testing O
for O
Huntington RARE
' O
s O
disease O
is O
available O
as O
a O
clinical O
service RARE
since O
November RARE
1987 O
, O
initially O
by O
DNA O
- O
linkage O
and O
since O
mid O
1993 O
by O
direct O
mutation O
analysis O
. O

Risks RARE
of O
chronicity RARE
following O
acute O
hepatitis O
B O
virus O
infection O
: O
a O
review O
. O

Examination O
of O
neurohumoral RARE
factors O
revealed O
a O
hyperactive RARE
sympathetic O
nervous O
system O
and O
an O
increase O
in O
plasma O
renin I-GENE
activity O
. O

We O
compared O
the O
inhibitory O
effect O
of O
naturally O
occurring O
mutant I-GENE
hTR LASTCAP
beta I-GENE
1 I-GENE
, O
artificially O
created O
hTR LASTCAP
alpha I-GENE
1 I-GENE
mutants I-GENE
, O
c I-GENE
- I-GENE
erbA I-GENE
alpha I-GENE
2 I-GENE
and O
the O
human I-GENE
peroxisome I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
( O
hPPAR LASTCAP
) O
on O
three O
prototypic RARE
T3 O
- O
response O
elements O
( O
TREs RARE
), O
TRE O
- O
PAL O
, O
DR O
+ O
4 O
and O
TRE O
- O
LAP ALLCAPS
. O

The O
amino O
- O
terminal O
DNA O
- O
binding O
domain O
of O
Pip RARE
exhibits O
a O
high O
degree O
of O
homology O
to O
the O
DNA O
- O
binding O
domains O
of O
members O
of O
the O
interferon I-GENE
regulatory I-GENE
factor I-GENE
( O
IRF I-GENE
) O
family O
, O
which O
includes O
IRF I-GENE
- I-GENE
1 I-GENE
, O
IRF I-GENE
- I-GENE
2 I-GENE
, O
ICSBP ALLCAPS
, O
and O
ISGF3 NUMERIC
gamma I-GENE
. O

An O
outbreak O
of O
hepatitis O
A O
among O
homosexual RARE
men O
in O
Amsterdam RARE
, O
1991 O
- O
1993 O
. O

The O
RAP74 NUMERIC
subunit I-GENE
of O
TFIIF ALLCAPS
alone O
contained O
the O
stimulatory O
activity O
and O
the O
minimal O
region O
sufficient O
for O
stimulation O
corresponds O
to O
COOH O
- O
terminal O
residues O
358 NUMERIC
- O
517 NUMERIC
. O

We O
have O
generated O
various O
base O
substitutions O
and O
internal O
deletions O
in O
and O
around O
DRE O
( O
nucleotide O
positions O
- O
93 O
to O
- O
100 O
with O
respect O
to O
the O
transcription O
initiation O
site O
) O
of O
the O
PCNA I-GENE
gene I-GENE
in O
vitro O
and O
subsequently O
examined O
their O
effects O
on O
the O
binding O
to O
DREF ALLCAPS
( O
DRE I-GENE
- I-GENE
binding I-GENE
factor I-GENE
) O
and O
PCNA I-GENE
gene I-GENE
promote O
activity O
in O
cultured O
Drosophila O
Kc RARE
cells O
as O
well O
as O
in O
living O
flies RARE
. O

The O
hsp70 I-GENE
gene I-GENE
family I-GENE
of O
Neurospora O
crassa O
: O
cloning O
, O
sequence O
analysis O
, O
expression O
, O
and O
genetic O
mapping O
of O
the O
major O
stress O
- O
inducible O
member O
. O

The O
deduced O
amino O
acid O
sequences O
of O
each O
of O
the O
W3A1 NUMERIC
ETF ALLCAPS
subunits I-GENE
exhibit O
only O
approximately O
30 O
% O
identity O
with O
the O
corresponding O
subunits O
of O
the O
ETF ALLCAPS
from O
human O
, O
rat O
, O
and O
Paracoccus RARE
denitrificans RARE
, O
which O
as O
a O
group O
are O
greater O
than O
50 O
% O
identical O
. O

A O
secondary O
phosphorylation O
of O
CREB341 NUMERIC
at O
Ser129 NUMERIC
is O
required O
for O
the O
cAMP O
- O
mediated O
control O
of O
gene O
expression O
. O

A O
role O
for O
glycogen I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
in O
the O
control O
of O
gene O
expression O
. O

This O
last O
region O
contains O
two O
sites O
that O
bind O
Ets I-GENE
- I-GENE
related I-GENE
proteins I-GENE
present O
in O
liver O
nuclear O
extracts O
as O
well O
as O
recombinant I-GENE
purified I-GENE
Ets I-GENE
- I-GENE
1 I-GENE
protein I-GENE
. O

Other O
assays O
also O
distinguished O
the O
processive RARE
replication O
of O
pNeo RARE
. O
Myc O
- O
2 O
. O
4 O
from O
the O
dispersive RARE
labeling O
of O
control O
plasmids O
. O

Reconstitution RARE
of O
complexes O
containing O
p62 I-GENE
and O
the O
src I-GENE
family I-GENE
kinase I-GENE
p59fyn NUMERIC
in O
HeLa O
cells O
demonstrated O
that O
complex O
formation O
resulted O
in O
tyrosine O
phosphorylation O
of O
p62 I-GENE
and O
was O
mediated O
by O
both O
the O
SH3 I-GENE
and O
SH2 I-GENE
domains I-GENE
of O
p59fyn NUMERIC
. O

Therefore O
, O
it O
is O
hoped RARE
that O
by O
defining RARE
the O
transcriptional O
control O
of O
the O
L7 NUMERIC
gene I-GENE
insights RARE
into O
the O
mechanisms O
that O
control O
functional O
fate O
and O
organization O
in O
the O
nervous O
system O
can O
be O
gained RARE
. O

In O
contrast O
, O
a O
Maf I-GENE
- I-GENE
related I-GENE
protein I-GENE
, O
Nrl RARE
, O
completely O
mimicked O
c I-GENE
- I-GENE
Maf I-GENE
actions O
. O

The O
27 O
- O
base O
element O
interacts O
with O
a O
PDGF I-GENE
- O
activated O
serine O
/ O
threonine O
phosphoprotein O
that O
is O
detected O
only O
within O
the O
nucleus O
of O
PDGF O
- O
treated O
3T3 O
cells O
. O

By O
contrast O
, O
deletion O
of O
this O
Ras I-GENE
- I-GENE
binding I-GENE
site I-GENE
did O
not O
diminish RARE
activation O
of O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
by O
Src I-GENE
, O
implying O
that O
Src I-GENE
and O
Ras I-GENE
can O
activate O
Raf I-GENE
- I-GENE
1 I-GENE
through O
independent O
mechanisms O
. O

In O
studies O
of O
many O
different O
phenotypically RARE
distinct O
cells O
, O
the O
CRE O
of O
the O
somatostatin I-GENE
gene I-GENE
promoter I-GENE
is O
a O
prototype O
of O
a O
highly O
cAMP O
- O
responsive O
element O
regulated O
by O
CREB I-GENE
. O

The O
first O
gene O
, O
NSR1 NUMERIC
, O
a O
previously O
identified O
gene O
, O
encodes O
a O
protein O
involved O
in O
ribosomal O
RNA O
maturation O
and O
possibly O
in O
transport O
of O
proteins O
into O
the O
nucleus O
. O

Characterization O
of O
the O
promoter O
for O
the O
human I-GENE
85 I-GENE
kDa I-GENE
cytosolic I-GENE
phospholipase I-GENE
A2 I-GENE
gene I-GENE
. O

This O
paper O
describes O
the O
advantages O
and O
limitations O
of O
the O
main O
study O
approaches O
used O
. O

Comparative O
study O
of O
the O
differential O
white O
blood O
cell O
count O
using O
three O
automated O
analyzers RARE
: O
Coulter RARE
STKS ALLCAPS
, O
Sysmex RARE
NE O
8000 NUMERIC
and O
Technicon RARE
H O
- O
1 O
. O

Characterization O
of O
FIII ALLCAPS
/ O
YY1 I-GENE
, O
a O
Xenopus I-GENE
laevis I-GENE
conserved I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
binding O
to O
the O
first O
exon O
of O
L1 I-GENE
and O
L14 NUMERIC
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

Further O
studies O
established O
that O
the O
Ep RARE
- O
induced O
increase O
in O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
could O
be O
inhibited O
by O
the O
tyrosine I-GENE
kinase I-GENE
inhibitor O
genistein RARE
and O
the O
protein I-GENE
kinase I-GENE
C I-GENE
inhibitor O
Compound RARE
3 O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

This O
structure O
of O
cucumisin RARE
suggests O
that O
it O
is O
probably O
synthesized O
as O
an O
inactive O
precursor O
. O

Molecular O
dissection O
of O
the O
multimeric RARE
CD3 I-GENE
- O
TCR I-GENE
complex O
revealed O
that O
at O
least O
two O
associated O
polypeptides O
, O
CD3 I-GENE
zeta I-GENE
and O
CD3 I-GENE
epsilon I-GENE
, O
autonomously O
couple RARE
antigenic O
recognition O
event O
to O
early O
and O
late O
events O
of O
the O
intracytoplasmic RARE
activation O
cascade O
. O

Protein I-GENE
cHMGI LASTCAP
binds O
preferentially O
to O
AT O
- O
rich O
DNA O
with O
a O
half O
- O
saturation O
value O
of O
1 O
. O
1 O
nM O
. O

This O
study O
investigated O
the O
degree O
to O
which O
racial RARE
identity O
influences O
Mexican RARE
- O
Americans RARE
' O
performance O
on O
the O
L O
, O
K O
, O
and O
MF ALLCAPS
scales RARE
of O
the O
MMPI O
- O
2 O
. O

Both O
can O
be O
elevated O
on O
a O
single O
vascular O
pedicle RARE
based O
on O
the O
superficial O
temporal O
artery O
, O
the O
double O
- O
layered RARE
temporal O
fascia RARE
flap O
. O

To O
do O
this O
, O
segments O
of O
DNA O
from O
the O
5 O
' O
flank O
of O
the O
initiation O
sites O
for O
germline O
epsilon O
RNA O
were O
ligated O
to O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
and O
transfected O
into O
two O
mouse O
B O
cell O
lines O
, O
one O
of O
which O
can O
be O
induced O
to O
switch O
to O
IgE I-GENE
. O

The O
negative O
predictive O
value O
is O
92 O
%, O
vs O
80 O
% O
for O
the O
NCEP ALLCAPS
I O
. O

Oncogenic RARE
capacity O
of O
the O
E2F1 I-GENE
gene I-GENE
. O

In O
some O
of O
the O
cases O
of O
solitary RARE
lesion O
, O
serum I-GENE
TSH I-GENE
levels O
, O
serum I-GENE
thyroglobulin RARE
values O
, O
and O
131I O
protein O
bounded RARE
iodine O
( O
131I O
- O
PBI ALLCAPS
) O
were O
measured O
, O
but O
there O
were O
no O
significant O
differences O
between O
successful O
and O
unsuccessful RARE
therapy O
. O

Endo16 NUMERIC
transcripts I-GENE
are O
confined O
to O
the O
definitive O
vegetal RARE
plate O
in O
blastula RARE
stage O
embryos O
; O
at O
gastrula RARE
stage O
this O
gene O
is O
expressed O
throughout O
the O
archenteron RARE
, O
but O
later O
only O
in O
the O
midgut RARE
. O

A O
unique O
leucine O
- O
proline O
repeat O
element O
found O
N O
- O
terminal O
to O
the O
DNA O
- O
binding O
domain O
of O
EmBP LASTCAP
- I-GENE
1 I-GENE
does O
not O
appear O
to O
play O
a O
role O
in O
DNA O
- O
binding O
or O
dimerization O
. O

Another O
full O
ORF O
was O
found O
on O
the O
opposite O
strand O
downstream O
from O
the O
nspC LASTCAP
gene I-GENE
. O

The O
U14 I-GENE
genes I-GENE
of O
mouse O
as O
well O
as O
rat O
, O
hamster O
, O
human O
, O
Xenopus O
and O
trout O
are O
encoded O
within O
introns O
of O
the O
constitutively O
expressed O
70 I-GENE
- I-GENE
kDa I-GENE
- I-GENE
cognate I-GENE
- I-GENE
heat I-GENE
- I-GENE
shock I-GENE
protein I-GENE
gene I-GENE
( O
hsc70 NUMERIC
). O

Two O
related O
cDNAs O
were O
isolated O
that O
encode O
proteins O
that O
recognize O
the O
XMyoDa RARE
TATA I-GENE
motif I-GENE
. O

Deletion O
of O
both O
prfA LASTCAP
and O
ponA LASTCAP
resulted O
in O
extremely O
slow O
growth O
and O
a O
reduction O
in O
sporulation O
efficiency O
. O

Inclusion RARE
in O
this O
family O
of O
proteins O
suggests O
that O
FliQ LASTCAP
and O
FliR LASTCAP
may O
participate O
in O
an O
export O
pathway O
required O
for O
flagellum RARE
assembly O
. O

In O
broken RARE
L O
- O
cell O
membranes O
expressing O
wild O
type O
or O
mutant I-GENE
M6P NUMERIC
/ I-GENE
IGF I-GENE
II I-GENE
receptors I-GENE
, O
30 O
nM O
IGF I-GENE
II I-GENE
also O
failed O
to O
affect O
the O
pertussis I-GENE
toxin I-GENE
substrate O
activity O
. O

Chem O
. O

For O
the O
first O
time O
we O
describe O
deletion O
and O
point O
mutations O
within O
the O
plasma I-GENE
membrane I-GENE
family I-GENE
of I-GENE
guanylyl RARE
cyclase I-GENE
receptors I-GENE
that O
result O
in O
the O
formation O
of O
effective O
dominant O
negative O
proteins O
. O

Increase RARE
in O
blood O
NEFA ALLCAPS
was O
further O
augmented O
by O
fat O
plus O
AA O
supplementation O
, O
but O
no O
changes O
in O
concentrations O
of O
Lys O
or O
Met O
in O
blood O
were O
found O
. O

Virol RARE
. O

Coronary O
vasoconstriction RARE
caused O
by O
endothelin I-GENE
- I-GENE
1 I-GENE
is O
enhanced O
by O
ischemia O
- O
reperfusion O
and O
by O
norepinephrine O
present O
in O
concentrations O
typically O
observed O
after O
neonatal O
cardiopulmonary O
bypass O
. O

Comparison O
of O
the O
deduced O
amino I-GENE
acid I-GENE
sequence I-GENE
of I-GENE
gamma I-GENE
- I-GENE
kafirin RARE
with O
the O
published O
sequences I-GENE
of I-GENE
gamma I-GENE
- I-GENE
prolamins RARE
of I-GENE
maize I-GENE
, I-GENE
and I-GENE
Coix RARE
revealed O
highly O
conserved O
domains O
. O

Atcys1 NUMERIC
, O
Athyp1 NUMERIC
, O
AKin10 NUMERIC
and O
the O
ORF O
are O
very O
close O
to O
each O
other O
and O
organized O
in O
the O
same O
polarity O
; O
hence O
, O
the O
intergenic O
regions O
probably O
contain O
, O
within O
less O
than O
0 O
. O
5 O
kb O
, O
all O
the O
regulatory O
elements O
necessary O
to O
govern O
initiation O
and O
termination O
of O
transcription O
. O

Southern O
blot O
hybridization O
experiments O
suggest O
the O
presence O
of O
one O
copy O
of O
Atcys1 NUMERIC
, O
Athyp1 NUMERIC
and O
AKin10 NUMERIC
per O
haploid RARE
genome O
, O
and O
Northern O
blot O
analysis O
demonstrates O
that O
the O
three O
genes O
are O
differentially O
expressed O
in O
roots O
, O
shoots RARE
and O
leaves O
. O

These O
results O
suggest O
that O
HAC1 NUMERIC
may O
also O
be O
one O
of O
the O
meiotic O
genes O
. O

We O
characterized O
three O
Arabidopsis O
thaliana O
cDNA O
clones O
that O
could O
rescue O
the O
sterile RARE
phenotype O
of O
the O
Schizosaccharomyces I-GENE
pombe I-GENE
pde1 NUMERIC
mutant I-GENE
, O
which O
is O
defective O
in O
cAMP I-GENE
phosphodiesterase I-GENE
. O

Furthermore O
, O
the O
identification O
of O
a O
Dr1 NUMERIC
- I-GENE
like I-GENE
protein I-GENE
in O
A O
. O
thaliana O
strongly O
argues RARE
for O
the O
ubiquity RARE
of O
this O
protein O
among O
eukaryotic O
genera RARE
and O
for O
a O
conserved O
mechanism O
to O
regulate O
transcription O
initiation O
that O
involves O
Dr1 NUMERIC
. O

Similarly O
approximately O
300 O
bp O
of O
sequence O
downstream O
of O
the O
translation O
terminator O
TGA ALLCAPS
of O
the O
beta I-GENE
- I-GENE
tubulin RARE
2 I-GENE
( O
BTU2 NUMERIC
) O
gene O
could O
substitute O
for O
the O
3 O
' O
region O
of O
the O
H4 I-GENE
- I-GENE
I I-GENE
gene I-GENE
. O

These O
data O
demonstrate O
that O
the O
STR ALLCAPS
family I-GENE
of O
genes O
is O
represented O
in O
a O
nematode O
whose O
ancestor O
appeared O
well O
before O
the O
branching RARE
that O
gave O
rise O
to O
the O
Arthropoda RARE
and O
Chordata RARE
. O

The O
pre O
- O
and O
postoperative O
haemoglobin RARE
concentrations O
in O
the O
autologous O
group O
were O
lower O
by O
15 O
and O
10 O
g O
/ O
L O
, O
respectively O
, O
after O
primary O
THR ALLCAPS
and O
by O
10 O
g O
/ O
L O
in O
both O
instances O
after O
revision RARE
THR ALLCAPS
. O

The O
introduction O
of O
an O
acidic O
residue O
at O
the O
second O
site O
was O
essential O
for O
suppression O
of O
the O
Asn O
- O
285 O
mutation O
because O
Lys O
- O
220 O
and O
Gln O
- O
220 O
second O
- O
site O
mutants O
of O
the O
Asn O
- O
285 O
mutant O
showed O
very O
low O
tetracycline RARE
resistance O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
, O
the O
cytokine O
that O
participates O
in O
the O
autocrine O
growth O
control O
of O
hairy RARE
cell O
leukemia O
has O
strong O
bone O
resorptive RARE
properties O
. O

( O
iv O
) O
Although O
UCRBP ALLCAPS
has O
been O
previously O
shown O
to O
act O
as O
a O
transcriptional O
repressor O
, O
we O
show O
here O
that O
UCRBP ALLCAPS
can O
also O
act O
as O
a O
positive O
transactivator O
of O
a O
reporter O
driven O
by O
UCR ALLCAPS
elements O
when O
used O
in O
co O
- O
transfection O
assays O
. O

The O
sequence O
of O
monkey I-GENE
opsin RARE
closely O
resembles O
the O
human O
sequence O
at O
the O
nucleotide O
and O
the O
amino O
acid O
levels O
, O
with O
the O
latter O
having O
only O
7 O
differences O
out O
of O
348 NUMERIC
residues O
. O

One O
complex O
appears O
to O
be O
ubiquitous O
but O
enriched O
in O
lymphoid O
cells O
and O
represents O
the O
binding O
of O
a O
potentially O
novel O
factor O
with O
an O
apparent O
molecular O
mass O
of O
approximately O
50 O
kDa O
. O

Chem O
. O

Conversely O
, O
activation O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
promoter I-GENE
by O
RAR I-GENE
: O
RXR I-GENE
heterodimers I-GENE
was O
completely O
abolished O
by O
EAR ALLCAPS
- I-GENE
3 I-GENE
/ O
COUP I-GENE
- I-GENE
TFI I-GENE
and O
by O
ARP ALLCAPS
- I-GENE
1 I-GENE
/ O
COUP I-GENE
- I-GENE
TFII ALLCAPS
. O

These O
results O
demonstrate O
that O
EKLF ALLCAPS
provides O
a O
crucial O
transactivation O
function O
for O
globin I-GENE
expression O
and O
further O
reinforce RARE
the O
idea O
that O
EKLF ALLCAPS
is O
an O
important O
regulator O
of O
CACCC ALLCAPS
element O
- O
directed O
transcription O
in O
erythroid O
cells O
. O

Using O
a O
battery O
of O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
mutants I-GENE
, O
we O
show O
that O
( O
i O
) O
a O
dimer O
binds O
a O
single O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
molecule I-GENE
, O
( O
ii O
) O
the O
acidic O
C O
- O
terminal O
region O
of O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
is O
not O
required O
for O
protein O
- O
protein O
binding O
and O
does O
not O
mask RARE
the O
nuclear O
localization O
signal O
of O
the O
dimer O
, O
( O
iii O
) O
the O
same O
C O
- O
terminal O
region O
is O
required O
for O
inhibition O
of O
DNA O
binding O
, O
and O
( O
iv O
) O
this O
inhibition O
may O
be O
accomplished RARE
by O
direct O
interaction O
between O
the O
PEST ALLCAPS
- O
like O
region O
and O
the O
DNA O
- O
binding O
region O
of O
one O
of O
the O
subunits O
of O
the O
dimer O
. O

The O
negative O
regulatory O
activity O
of O
the O
N O
- O
terminal O
domain O
was O
antagonized RARE
by O
a O
C O
- O
terminal O
segment O
of O
Pho81p NUMERIC
supplied O
in O
trans O
. O

At O
different O
times O
of O
the O
surgical O
procedures O
( O
thorax RARE
opening RARE
and O
closure O
, O
period O
of O
cardiopulmonary O
bypass O
) O
67 O
to O
100 O
% O
of O
the O
patients O
in O
group O
1 O
had O
vancomycin O
concentrations O
in O
the O
studied O
tissues O
above O
the O
MIC ALLCAPS
90 O
for O
Staphylococcus O
aureus O
( O
1 O
microgram O
/ O
g O
) O
and O
Staphylococcus O
epidermidis RARE
( O
2 O
micrograms O
/ O
g O
). O

On O
- O
line O
angioscopic RARE
images O
of O
tissue O
flaps RARE
floating RARE
in O
the O
lumen RARE
, O
recent O
or O
structured O
thrombi RARE
, O
artery O
wall O
dissections RARE
, O
plaque O
ruptures RARE
, O
deep O
fissurations RARE
and O
sub O
- O
intimal RARE
haemorrhages RARE
demonstrate O
, O
in O
live O
colour O
, O
the O
pathophysiological RARE
mechanisms O
of O
coronary O
artery O
stenosis O
. O

The O
enhanced O
cysteine O
formation O
in O
a O
pCSK4F NUMERIC
plant O
responding O
to O
sulfite RARE
was O
also O
observed O
in O
leaf O
discs RARE
. O

Each O
type O
was O
divided O
into O
two O
subgroups O
on O
the O
basis O
of O
whether O
the O
body O
and O
tail O
of O
the O
pancreas O
showed O
intense O
fatty O
replacement O
( O
type O
a O
= O
negative O
for O
intense O
fatty O
replacement O
, O
type O
b O
= O
positive O
for O
intense O
fatty O
replacement O
). O

Between RARE
the O
subgroups O
of O
dementia O
disorders O
there O
were O
no O
significant O
differences O
in O
basal O
cortisol O
levels O
. O

A O
new O
hypothesis O
on O
mechanisms O
for O
inhibiting O
catalytic O
subunits O
by O
gamma O
- O
subunits O
and O
activation O
of O
a O
holoenzyme O
by O
transducin RARE

Basal O
components O
of O
the O
transcription O
apparatus O
( O
RNA I-GENE
polymerase I-GENE
II I-GENE
, O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
contain O
activation O
domains O
: O
is O
the O
repetitive O
C O
- O
terminal O
domain O
( O
CTD O
) O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
a O
" O
portable RARE
enhancer O
domain O
"? RARE
Regions RARE
rich O
in O
serine O
, O
threonine O
, O
and O
proline O
residues O
can O
be O
found O
in O
transcriptional O
activation O
domains O
, O
as O
well O
as O
in O
the O
N O
- O
terminal O
parts O
of O
mammalian I-GENE
TATA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
, O
where O
they O
are O
interrupted O
by O
polyglutamine RARE
stretches O
. O

Mutagenesis RARE
of O
IM1 NUMERIC
enhances O
the O
ability O
of O
c I-GENE
- I-GENE
Fos I-GENE
to O
activate O
an O
AP1 I-GENE
bearing I-GENE
promoter I-GENE
. O

Binding O
of O
SSP ALLCAPS
to O
the O
stage I-GENE
selector RARE
element I-GENE
( O
SSE ALLCAPS
) O
in O
the O
proximal O
gamma I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
is O
integral O
to O
the O
competitive O
silencing O
of O
a O
linked O
beta I-GENE
- I-GENE
promoter I-GENE
in O
embryonic O
/ O
fetal O
stage O
erythroleukemia RARE
( O
K562 O
) O
cells O
. O

This O
failure O
to O
execute RARE
regulated O
G1 O
/ O
S O
arrest O
is O
correlated O
with O
enhanced O
thermosensitivity RARE
of O
colony O
- O
forming O
ability O
. O

Mutations O
that O
alter O
photoreceptor RARE
cell O
structure O
and O
development O
were O
isolated O
that O
fail O
to O
complement O
these O
deletions O
. O

It O
is O
possible O
that O
the O
telomeres RARE
of O
the O
two O
nuclei O
have O
different O
functions O
. O

The O
marker O
orders RARE
from O
the O
genetic O
and O
RH O
maps O
were O
consistent O
. O

Integrated RARE
mapping O
analysis O
of O
the O
Werner RARE
syndrome O
region O
of O
chromosome O
8 O
. O

The O
region O
between O
DXS52 NUMERIC
and O
Factor I-GENE
VIII I-GENE
gene I-GENE
in O
the O
human O
Xq28 NUMERIC
chromosomal O
band O
contains O
a O
G O
+ O
C O
- O
rich O
isochore RARE
to O
which O
many O
genes O
have O
been O
mapped O
. O

Haplotype RARE
mapping O
and O
sequence O
analysis O
of O
the O
mouse O
Nramp RARE
gene I-GENE
predict O
susceptibility O
to O
infection O
with O
intracellular O
parasites O
. O

This O
utilization O
of O
an O
intronic O
polyadenylation O
site O
without O
alternative O
exon O
usage O
is O
comparable O
to O
the O
mechanism O
whereby RARE
both O
secreted O
and O
membrane O
- O
bound O
forms O
of O
the O
immunoglobulin I-GENE
mu I-GENE
heavy I-GENE
chain I-GENE
are O
made O
from O
a O
single O
genetic O
locus O
. O

To O
further O
our O
knowledge O
about O
the O
systemic O
humoral RARE
immune O
system O
response O
to O
weak O
hapten RARE
- O
syngeneic RARE
or O
allogeneic RARE
protein O
conjugates RARE
( O
corrosion RARE
and O
wear RARE
products O
of O
metallic RARE
orthopedic RARE
devices RARE
), O
a O
sensitive O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
method O
for O
testing O
for O
antibody O
( O
humoral RARE
immunity O
) O
to O
metals RARE
was O
developed O
. O

In O
contrast O
, O
peak O
filling O
rate O
( O
PFR ALLCAPS
), O
normalized O
to O
end O
diastolic O
volume O
( O
EDV ALLCAPS
), O
or O
stroke O
volume O
( O
SV O
), O
or O
expressed O
as O
the O
ratio O
of O
PFR ALLCAPS
- O
to O
- O
PER ALLCAPS
was O
reduced O
( O
p O
< O
0 O
. O
01 O
), O
time O
to O
PFR ALLCAPS
( O
TPFR ALLCAPS
) O
was O
prolonged O
( O
p O
< O
0 O
. O
01 O
), O
and O
echocardiographic O
left O
ventricular O
mass O
index O
was O
higher O
( O
p O
< O
0 O
. O
001 O
) O
in O
patients O
with O
acromegaly RARE
compared O
to O
normals O
. O

A O
genetic O
complementation O
system O
was O
developed O
in O
which O
tobacco I-GENE
etch RARE
virus I-GENE
( I-GENE
TEV ALLCAPS
) I-GENE
polymerase I-GENE
( O
NIb RARE
)- O
expressing O
transgenic O
plants O
or O
protoplasts RARE
were O
inoculated O
with O
NIb RARE
- O
defective O
TEV ALLCAPS
mutants I-GENE
. O

Nucleotide O
sequence O
and O
transcriptional O
analysis O
of O
the O
DNA I-GENE
polymerase I-GENE
gene I-GENE
of I-GENE
Bombyx RARE
mori RARE
nuclear I-GENE
polyhedrosis RARE
virus I-GENE
. O

Comparison O
of O
the O
genomes O
of O
PMTV ALLCAPS
, O
BNYVV ALLCAPS
, O
and O
SBWMV ALLCAPS
shows O
that O
furoviruses RARE
exhibit O
considerable O
heterogeneity O
in O
genome O
organization O
. O

The O
drug O
sensitivity O
was O
100 O
% O
for O
vancomycin O
( O
VCM ALLCAPS
), O
30 O
% O
for O
imipenam RARE
( O
IMP ALLCAPS
), O
31 O
% O
for O
minomycin RARE
( O
MINO ALLCAPS
), O
31 O
% O
for O
amikacin RARE
( O
AMK ALLCAPS
), O
and O
7 O
% O
for O
fosfomycin RARE
( O
FOM ALLCAPS
). O

Deglycosylation RARE
with O
endoglycosidase RARE
H I-GENE
showed O
that O
the O
mutant O
receptors O
had O
mainly O
high O
- O
mannose RARE
oligosaccharide RARE
chains O
. O

Dietary RARE
supplement RARE
with O
fish O
oil O
and O
related O
n O
- O
3 O
EFAs RARE
has O
been O
used O
to O
study O
their O
antihypertensive O
property RARE
in O
animals O
and O
humans O
with O
borderline RARE
and O
essential O
hypertension O
. O

The O
HSD3B1 NUMERIC
and O
HSD3B2 NUMERIC
genes I-GENE
encoding O
the O
types I-GENE
I I-GENE
and I-GENE
II I-GENE
3 I-GENE
beta I-GENE
- I-GENE
HSD ALLCAPS
isoenzymes I-GENE
, O
respectively O
, O
have O
been O
previously O
assigned O
by O
in O
situ O
hybridization O
to O
the O
chromosome O
1p13 NUMERIC
. O
1 O
region O
. O

Therefore O
the O
prevalences RARE
of O
total O
diabetes O
and O
GDM ALLCAPS
were O
1 O
. O
19 O
% O
and O
0 O
. O
56 O
%, O
respectively O
. O

Insulin I-GENE
- O
stimulated O
glucose O
transport O
in O
adipocytes O
is O
mediated O
by O
the O
insulin I-GENE
receptor I-GENE
. O

After O
selection O
and O
conversion O
to O
adipocytes O
, O
the O
level O
of O
EGFR I-GENE
expression O
was O
retained O
in O
infectant RARE
adipocytes O
( O
150 O
, O
000 O
and O
250 O
, O
000 O
/ O
cell O
, O
respectively O
), O
but O
not O
in O
the O
parental O
3T3 O
- O
L1 O
adipocytes O
(< O
5000 NUMERIC
/ O
cell O
). O

Intron O
- O
exon O
structure O
of O
the O
porcine I-GENE
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
- I-GENE
encoding I-GENE
gene I-GENE
. O

Fraction RARE
2 O
contains O
1 O
, O
25 O
( O
OH O
) O
2 O
- O
vitamin O
D3 O
, O
vitamin O
D3 O
, O
25 O
( O
OH O
)- O
vitamin O
D3 O
and O
1 O
, O
24 O
, O
25 O
( O
OH O
) O
3 O
- O
vitamin O
D3 O
. O

The O
kallistatin RARE
gene I-GENE
was O
localized O
by O
in O
situ O
hybridization O
to O
human O
chromosome O
14q31 NUMERIC
- O
q32 NUMERIC
. O
1 O
, O
close O
to O
the O
serpin RARE
genes I-GENE
encoding O
alpha I-GENE
1 I-GENE
- I-GENE
antichymotrypsin RARE
, O
protein I-GENE
C I-GENE
inhibitor I-GENE
, O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
, O
and O
corticosteroid I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
. O

The O
locus O
encoding O
the O
XD ALLCAPS
gene I-GENE
( O
designated O
Xd RARE
) O
was O
mapped O
to O
the O
distal O
part O
of O
mouse O
chromosome O
17 O
by O
haplotype RARE
analysis O
of O
114 O
interspecific RARE
backcross O
mice O
. O

Some O
studies O
of O
exercise O
have O
associated O
beta I-GENE
- I-GENE
endorphin I-GENE
release O
with O
increased O
exertion RARE
levels O
, O
but O
other O
evidence O
suggests O
that O
acidosis O
may O
stimulate O
the O
release O
of O
beta I-GENE
- I-GENE
endorphin I-GENE
. O

An O
interatrial RARE
communication RARE
mitigates RARE
the O
impairment O
of O
LV O
function O
after O
an O
acute O
and O
sustained O
drop O
of O
intrathoracic RARE
pressure O
. O

Self RARE
or O
foreign O
cellular O
proteins O
provide O
peptides O
for O
presentation O
by O
major I-GENE
histocompatibility I-GENE
complex I-GENE
( I-GENE
MHC I-GENE
) I-GENE
class I-GENE
I I-GENE
molecules I-GENE
on O
the O
surface O
of O
antigen O
presenting O
cells O
( O
APC O
). O

The O
characteristics O
of O
the O
VirD1 NUMERIC
/ O
VirD2 NUMERIC
- O
mediated O
cleavage O
reaction O
strongly O
resemble RARE
those O
observed O
with O
relaxosomes RARE
of O
IncP LASTCAP
plasmids O
involved O
in O
initiation O
of O
transfer O
DNA O
replication O
during O
bacterial O
conjugation O
. O

Isoelectric RARE
focusing O
of O
tryptic RARE
peptides O
generated O
from O
MHC I-GENE
- I-GENE
B I-GENE
phosphorylated O
with O
cdc2 I-GENE
kinase I-GENE
revealed O
one O
major O
phosphopeptide O
that O
was O
purified O
by O
reverse O
- O
phase O
high O
performance O
liquid O
chromatography O
and O
sequenced O
. O

The O
deduced O
protein O
sequence O
was O
88 O
% O
homologous O
to O
that O
of O
hNUC LASTCAP
I I-GENE
, O
isolated O
from O
human O
osteosarcoma O
cells O
. O

However O
, O
cotransfection O
studies O
indicate O
that O
RVR ALLCAPS
does O
not O
activate O
transcription O
when O
this O
hormone O
response O
element O
is O
linked O
to O
a O
reporter O
gene O
but O
rather O
acts O
as O
a O
potent O
competitive O
repressor O
of O
ROR ALLCAPS
alpha I-GENE
function O
. O

A O
comparison O
of O
the O
Flavobacterium RARE
glycosylasparaginase RARE
with O
a O
mammalian O
glycosylasparaginase RARE
revealed O
30 O
% O
structural O
identity O
and O
60 O
% O
overall O
similarity O
between O
the O
prokaryotic O
and O
eukaryotic O
forms O
of O
the O
enzyme O
. O

Dissociation RARE
and O
complexation RARE
of O
the O
fluoroquinolone RARE
antimicrobials RARE
-- O
an O
update RARE
. O

Superoxide RARE
dismutase I-GENE
( O
SOD I-GENE
) O
activity O
decreased O
significantly O
in O
sperm O
subjected O
to O
direct O
electric RARE
current O
in O
comparison O
to O
the O
control O
or O
the O
sample O
incubated O
with O
electrolyzed RARE
medium O
. O

These O
studies O
indicate O
that O
in O
vitro O
and O
in O
vivo O
electrical O
stimulation O
generate O
reactive O
oxygen O
species O
and O
affect O
SOD I-GENE
activity O
, O
which O
in O
part O
are O
responsible O
for O
decreased O
sperm O
motion O
and O
viability O
. O

Molecular O
cloning O
and O
sequencing O
of O
a O
cDNA O
encoding O
SR I-GENE
beta I-GENE
revealed O
that O
SR I-GENE
beta I-GENE
is O
a O
transmembrane O
protein O
and O
, O
like O
SR I-GENE
alpha I-GENE
and O
SRP54 NUMERIC
, O
is O
a O
member O
of O
the O
GTPase I-GENE
superfamily I-GENE
. O

To O
understand O
the O
function O
of O
receptor I-GENE
- I-GENE
linked I-GENE
tyrosine I-GENE
phosphatases I-GENE
in O
neural O
development O
, O
we O
sought O
to O
identify O
LAR ALLCAPS
isoforms I-GENE
preferentially O
expressed O
in O
the O
nervous O
system O
and O
cellular O
processes O
regulating O
LAR ALLCAPS
alternative O
splicing O
. O

Sex RARE
selection O
via O
albumin I-GENE
columns RARE
: O
20 O
years O
of O
results O
. O

135 O
students O
had O
a O
count O
of O
less O
than O
50 O
eggs O
/ O
10 O
ml O
. O
urine O
and O
56 O
had O
more O
than O
50 O
eggs O
/ O
10ml NUMERIC
. O

They O
also O
reported O
that O
E I-GENE
mu I-GENE
pim RARE
- I-GENE
1 I-GENE
transgenic O
mice O
show O
greatly O
accelerated O
lymphoma O
development O
when O
infected O
with O
wild O
- O
type O
M O
- O
MuLV O
at O
birth O
. O

Comparison O
of O
human I-GENE
and I-GENE
murine I-GENE
blk RARE
sequences I-GENE
indicated O
that O
they O
share O
86 O
% O
amino O
acid O
identity O
, O
the O
most O
conserved O
region O
being O
the O
catalytic O
domain O
( O
93 O
% O
identity O
). O

Chrispeels RARE
[ O
1993 O
] O
EMBO ALLCAPS
J O
12 O
: O
2241 NUMERIC
- O
2247 NUMERIC
). O

The O
mRNAs O
of O
the O
GRF ALLCAPS
genes I-GENE
are O
encoded O
by O
six O
exons O
interrupted O
by O
five O
introns O
. O

The O
effect O
of O
ethanol O
on O
human O
sensorimotor RARE
reactivity O
was O
assessed O
by O
examining O
the O
acoustic O
startle RARE
response O
. O

Digitalis RARE
glycosides RARE
or O
beta I-GENE
- I-GENE
receptor I-GENE
antagonists O
are O
not O
helpful O
in O
the O
therapy O
of O
this O
form O
of O
atrial O
fibrillation O
whereas O
class O
I O
antiarrhythmic O
drugs O
have O
been O
shown O
to O
be O
more O
effective O
. O

Atrial RARE
fibrillation O
and O
the O
autonomic RARE
nervous O
system O

VIII O
in O
doses O
2 O
- O
3 O
times O
higher O
than O
usually O
used O
in O
haemophiliacs RARE
without O
inhibitor O
were O
successful O
. O

A O
reduction O
of O
the O
aspartate I-GENE
aminotransferase I-GENE
activity O
was O
observed O
from O
800 O
mg O
/ O
kg O
b O
. O
w O
./ RARE
d O
onwards RARE
. O

Thus O
, O
these O
studies O
indicate O
that O
the O
104 O
- O
kDa O
isoform O
is O
required O
for O
normal O
proliferation O
of O
female O
germline O
cells O
and O
perhaps O
for O
oocyte O
differentiation O
. O

Physical RARE
analysis O
maps O
SAL6 NUMERIC
to O
chromosome O
XVI ALLCAPS
between O
TPK2 NUMERIC
and O
spt14 NUMERIC
. O

The O
newly O
devised RARE
DCT ALLCAPS
method O
yields O
reliable O
data O
in O
measuring O
TBF ALLCAPS
. O

Removal O
of O
PDMP ALLCAPS
from O
the O
cell O
medium O
resulted O
in O
reversal O
of O
the O
cell O
cycle O
changes O
, O
with O
cells O
re O
- O
entering RARE
the O
S O
phase O
. O

Rho I-GENE
GDP I-GENE
/ I-GENE
GTP I-GENE
exchange I-GENE
inhibitor I-GENE
, O
Rho I-GENE
GDI ALLCAPS
, O
comigrated RARE
with O
Rac2 NUMERIC
and O
RhoA I-GENE
, O
but O
not O
Rac1 I-GENE
. O

A O
major O
task O
for O
sports RARE
scientists RARE
may O
be O
to O
verify RARE
empirically RARE
the O
nature O
of O
an O
integrated O
model O
of O
the O
sport RARE
performer RARE
. O

Schnell RARE
, O
J O
. O

Encapsidation RARE
of O
poliovirus RARE
replicons RARE
encoding O
the O
complete O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
gag I-GENE
gene I-GENE
by O
using O
a O
complementation O
system O
which O
provides O
the O
P1 I-GENE
capsid I-GENE
protein I-GENE
in O
trans O
. O

Removal O
of O
the O
GST I-GENE
domain I-GENE
from O
GST I-GENE
- O
Tax I-GENE
by O
thrombin I-GENE
restores O
Tax I-GENE
' O
s O
ability O
to O
assemble RARE
a O
ternary O
Tax I-GENE
- O
CREB I-GENE
- O
21 O
- O
bp O
- O
repeat O
complex O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

The O
requirement O
of O
PilE LASTCAP
in O
pilus RARE
biogenesis O
was O
confirmed O
by O
demonstrating O
that O
chromosomal I-GENE
pilE LASTCAP
insertion I-GENE
mutants I-GENE
were O
pilus RARE
- O
and O
twitching RARE
- O
motility O
deficient O
. O

The O
pilE LASTCAP
gene I-GENE
product I-GENE
of I-GENE
Pseudomonas I-GENE
aeruginosa I-GENE
, O
required O
for O
pilus RARE
biogenesis O
, O
shares O
amino O
acid O
sequence O
identity O
with O
the O
N O
- O
termini O
of O
type I-GENE
4 I-GENE
prepilin RARE
proteins I-GENE
. O

Because O
of O
the O
functional O
conservation O
of O
cell O
cycle O
control O
elements O
, O
the O
expression O
of O
a O
vertebrate I-GENE
wee1 NUMERIC
or O
mik1 NUMERIC
homolog I-GENE
would O
be O
expected O
to O
rescue O
such O
lethal O
mutations O
in O
yeast O
. O

The O
expression O
of O
this O
clone O
in O
a O
wee1 NUMERIC
/ O
mik1 NUMERIC
- O
deficient O
mutant O
causes O
an O
elongated RARE
cell O
phenotype O
under O
non O
- O
permissive O
growth O
conditions O
. O

These O
data O
indicate O
that O
phosphorylation O
of O
M I-GENE
protein I-GENE
at O
the O
major O
in O
vivo O
sites O
is O
not O
essential O
for O
virus O
assembly O
. O

Near RARE
a O
third O
( O
31 O
. O
6 O
%) O
of O
Insulin I-GENE
Dependent RARE
and O
a O
third O
( O
33 O
. O
41 O
%) O
for O
Non O
Insulin I-GENE
Dependent RARE
were O
of O
D O
, O
F O
, O
H O
White RARE
' O
s O
Class O
. O

The O
activity O
of O
6 O
- O
fluoroquinolones RARE
and O
their O
nonfluorinated RARE
derivatives O
is O
compared O
in O
general O
. O

As O
the O
half O
- O
life O
of O
the O
compound O
did O
never O
exceed RARE
8 O
- O
9 O
h O
, O
the O
data O
do O
not O
support O
any O
change O
of O
pidotimod RARE
administration O
schedule O
( O
every O
24 O
- O
12 O
h O
). O

The O
MAP I-GENE
kinase I-GENE
cascade O
is O
highly O
conserved O
in O
all O
eukaryotes O
and O
involved O
in O
numerous O
cellular O
responses O
. O

A O
comparative O
study O
by O
holographic RARE
interferometry RARE
of O
ten O
porcine O
bioprosthetic RARE
valves RARE
( O
seven O
Carpentier RARE
- O
Edwards RARE
SAV ALLCAPS
, O
two O
BioImplant RARE
and O
one O
Valcor RARE
) O
with O
five O
human O
aortic O
valves RARE
before O
and O
after O
glutaraldehyde RARE
treatment O
is O
presented O
. O

No O
serious O
side O
effects O
were O
observed O
. O

This O
region O
constitutes O
the O
DNA O
- O
binding O
domain O
with O
basic O
- O
helix O
- O
loop O
- O
helix O
and O
leucine O
- O
zipper O
motifs O
, O
features O
common O
to O
the O
myc I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factor I-GENE
family I-GENE
. O

Specific O
binding O
was O
not O
observed O
with O
either O
the O
orthologous RARE
rat O
or O
mouse O
fragments O
using O
human O
or O
rodent O
extracts O
. O

The O
mean O
jitter RARE
and O
the O
fiber O
density O
did O
not O
change O
significantly O
from O
day O
0 O
( O
30 O
. O
1 O
+/- O
3 O
. O
6 O
microseconds RARE
; O
1 O
. O
4 O
+/- O
0 O
. O
07 O
) O
to O
day O
30 O
( O
34 O
. O
5 O
+/- O
2 O
. O
7 O
microseconds RARE
; O
1 O
. O
6 O
+/- O
0 O
. O
13 O
). O

Lack RARE
of O
cyclin I-GENE
D I-GENE
- O
Cdk I-GENE
complexes O
in O
Rb I-GENE
- O
negative O
cells O
correlates O
with O
high O
levels O
of O
p16INK4 NUMERIC
/ O
MTS1 NUMERIC
tumour O
suppressor O
gene O
product O
. O

Recombinant I-GENE
human I-GENE
serum I-GENE
albumin I-GENE
( O
rHSA LASTCAP
) O
produced O
by O
cultured O
fermentation RARE
has O
been O
prepared O
in O
the O
form O
of O
microcapsules RARE
nominally RARE
3 O
- O
5 O
microns O
in O
diameter O
and O
radiolabelled RARE
with O
technetium O
- O
99m O
following O
reduction O
with O
stannous RARE
chloride O
. O

We O
have O
measured O
the O
release O
of O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
( O
IL I-GENE
- I-GENE
1 I-GENE
) O
and O
tumour I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
) O
by O
unstimulated O
monocytes O
and O
monocytes O
stimulated O
with O
lipopolysaccharide O
( O
LPS O
) O
isolated O
from O
the O
peripheral O
blood O
of O
two O
patients O
with O
acute O
poststreptococcal RARE
glomerulonephritis O
( O
AGN ALLCAPS
) O
and O
16 O
healthy O
controls O
. O

Such O
an O
intervention O
may O
be O
of O
considerable O
use O
for O
the O
treatment O
of O
angiogenesis O
- O
dependent O
diseases O
involving O
FGF I-GENE
- I-GENE
2 I-GENE
. O

We O
have O
attempted RARE
to O
clone O
two O
recessive O
extragenic RARE
suppressors O
of O
such O
ts O
mutants O
( O
sdp1 NUMERIC
for O
mutation I-GENE
pol3 NUMERIC
- I-GENE
14 I-GENE
and O
sdp5 NUMERIC
- I-GENE
1 I-GENE
for O
mutation I-GENE
pol3 NUMERIC
- I-GENE
11 I-GENE
) O
by O
transforming O
thermoresistant RARE
haploid RARE
strains O
pol3 NUMERIC
- I-GENE
14 I-GENE
sdp1 NUMERIC
and O
pol3 NUMERIC
- I-GENE
11 I-GENE
sdp5 NUMERIC
- I-GENE
1 I-GENE
with O
wild O
- O
type O
genomic O
libraries O
in O
singlecopy RARE
or O
multicopy O
vectors O
. O

UV O
cross O
- O
linking O
experiments O
show O
that O
TEP ALLCAPS
has O
an O
apparent O
molecular O
mass O
of O
approximately O
65 O
kDa O
. O

In O
acute O
- O
phase O
livers RARE
, O
we O
observed O
a O
dramatic O
reduction O
in O
HNF I-GENE
- I-GENE
3 I-GENE
alpha I-GENE
expression O
which O
correlates O
with O
a O
decrease O
in O
the O
expression O
of O
its O
target O
gene O
, O
the O
TTR ALLCAPS
gene I-GENE
. O

Alternatively RARE
, O
loss O
- O
of O
- O
function O
alleles O
of O
genes O
that O
inhibit O
cAPK LASTCAP
lead O
to O
the O
inability RARE
to O
undergo O
sexual O
differentiation O
. O

One O
member O
of O
this O
family O
, O
RFX1 NUMERIC
, O
is O
a O
transcription O
factor O
for O
a O
variety O
of O
viral O
and O
cellular O
genes O
. O

This O
mutant O
was O
identified O
by O
screening O
with O
a O
TGF I-GENE
- I-GENE
beta I-GENE
- O
inducible O
vector O
a O
series O
of O
mink RARE
lung O
epithelial O
cell O
clones O
that O
have O
normal O
TGF I-GENE
- I-GENE
beta I-GENE
binding O
activity O
but O
have O
lost O
antiproliferative RARE
and O
transcriptional O
responses O
to O
TGF I-GENE
- I-GENE
beta I-GENE
. O

Cloning O
by O
complementation O
and O
subsequent O
physical O
and O
genetic O
analysis O
revealed O
that O
it O
maps O
to O
RAF1 NUMERIC
. O

In O
the O
presence O
of O
inositol O
and O
choline RARE
( O
repressing O
), O
the O
product O
of O
the O
OPI1 NUMERIC
gene I-GENE
represses O
transcription O
dictated RARE
by O
the O
UASINO ALLCAPS
element O
. O

By O
treating RARE
monkey O
COS O
cells O
with O
oligonucleotides O
linked O
to O
psoralen RARE
, O
we O
have O
generated O
targeted O
mutations O
in O
a O
simian O
virus O
40 O
( O
SV40 O
) O
vector O
contained O
within O
the O
cells O
via O
intracellular O
triple O
helix O
formation O
. O

The O
interleukin I-GENE
2 I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
chain I-GENE
( O
IL I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
) O
gene O
is O
rapidly O
and O
potently RARE
induced O
in O
T O
cells O
in O
response O
to O
mitogenic O
stimuli O
. O

The O
Wilms RARE
' I-GENE
tumour I-GENE
suppressor I-GENE
protein I-GENE
( O
WT1 I-GENE
) O
is O
a O
putative O
transcriptional O
regulatory O
protein O
with O
four O
zinc O
fingers O
, O
the O
last O
three O
of O
which O
have O
extensive O
sequence O
homology O
to O
the O
early I-GENE
growth I-GENE
response I-GENE
- I-GENE
1 I-GENE
( O
EGR ALLCAPS
- I-GENE
1 I-GENE
) O
protein O
. O

OBJECTIVES O
: O
1 O
) O
to O
determine O
serum I-GENE
ACE I-GENE
activity O
in O
patients O
with O
COPD O
treated O
with O
and O
without O
continuous O
ambulatory O
oxygen O
therapy O
( O
CAOT ALLCAPS
); O
2 O
) O
to O
verify RARE
whether O
there O
is O
a O
correlation O
between O
ACE I-GENE
and O
any O
hematological RARE
, O
spirometric RARE
or O
gasometric RARE
parameter O
. O

In O
order O
to O
infer RARE
shape O
from O
contour RARE
, O
the O
human O
visual O
system O
must O
selectively O
integrate RARE
fragments O
projecting RARE
from O
a O
common O
object RARE
while O
keeping RARE
fragments O
from O
different O
objects O
separate O
. O

Among O
9 O
group O
I O
patients O
with O
a O
positive O
result O
on O
head O
- O
up O
tilt O
- O
table RARE
testing O
and O
no O
evidence O
of O
structural O
heart O
disease O
( O
mean O
follow O
- O
up O
4 O
. O
3 O
years O
), O
7 O
are O
without O
further O
episodes O
of O
syncope RARE
; O
3 O
have O
discontinued RARE
medication O
and O
5 O
have O
resumed RARE
at O
least O
limited O
exercise O
. O

Constructs RARE
designed O
and O
expressed O
were O
E2L1 NUMERIC
( O
1 O
- O
98 O
), O
E2L1 NUMERIC
. O
H1 O
( O
1 O
- O
128 O
), O
E2L2 NUMERIC
( O
120 O
- O
233 O
), O
E2H1 NUMERIC
. O
L2 O
( O
98 O
- O
233 O
), O
and O
E2L1 NUMERIC
. O
H1 O
. O
L2 O
( O
1 O
- O
233 O
), O
where O
numbers O
in O
parentheses RARE
give O
the O
amino O
acid O
sequence O
for O
the O
portions O
of O
the O
E2 I-GENE
component O
incorporated O
into O
a O
construct O
. O

Thus O
, O
we O
have O
produced O
lipoyl RARE
domain O
constructs O
that O
can O
be O
employed O
in O
sorting O
the O
specific O
roles O
of O
E2L1 NUMERIC
and O
E2L2 NUMERIC
in O
facilitating O
catalytic O
and O
regulatory O
processes O
. O

METHODS O
: O
Ten O
influenza O
A O
( O
H3N2 NUMERIC
) O
viruses O
isolated O
during O
the O
outbreaks RARE
were O
examined O
for O
resistance O
to O
amantadine RARE
and O
rimantadine RARE
by O
means O
of O
an O
enzyme O
immunoassay O
and O
by O
sequencing O
of O
the O
viral O
nucleic O
acid O
that O
encodes O
the O
transmembrane O
domain O
of O
the O
M2 NUMERIC
protein I-GENE
. O

The O
first O
contains O
ATF I-GENE
/ O
CRE O
and O
TBP I-GENE
/ O
TATA O
sequence O
motifs O
within O
an O
87 O
- O
bp O
region O
. O

Gene O
expression O
occurs O
in O
a O
circadian O
rhythm O
and O
induced O
by O
light O
in O
leaves O
of O
dark O
- O
adapted O
plants O
. O

Our O
results O
suggested O
that O
the O
hexamer O
and O
the O
octamer O
motifs O
may O
play O
important O
role O
( O
s O
) O
in O
regulation O
of O
replication O
- O
dependent O
but O
not O
of O
replication O
- O
independent O
expression O
of O
the O
wheat I-GENE
histone I-GENE
H3 I-GENE
gene I-GENE
. O

The O
tissue O
- O
specific O
expression O
of O
DP I-GENE
family I-GENE
members I-GENE
suggests O
that O
the O
combination O
of O
DP I-GENE
/ O
E2F I-GENE
heterodimers O
that O
constitute O
DRTF1 NUMERIC
/ O
E2F I-GENE
is O
influenced O
by O
the O
phenotype O
of O
the O
cell O
. O

Similarly O
, O
in O
mammalian O
cells O
PBP74 NUMERIC
is O
synthesized O
as O
a O
pre O
- O
protein O
that O
requires O
membrane O
potential O
- O
dependent O
import O
into O
mitochondria O
for O
its O
maturation O
. O

In O
a O
second O
experiment O
involving O
an O
18 O
- O
h O
lung O
clearance O
assay O
, O
we O
used O
the O
mAb I-GENE
3 I-GENE
. I-GENE
2 I-GENE
. I-GENE
3 I-GENE
to O
deplete RARE
rats O
of O
LGL ALLCAPS
/ O
NK O
cells O
with O
the O
following O
rationale RARE
: O
if O
LGL ALLCAPS
/ O
NK O
cells O
are O
necessary O
to O
mediate O
an O
event O
, O
then O
in O
their O
absence O
, O
that O
event O
should O
not O
occur O
. O

Treatment O
of O
recurrent O
FSGS ALLCAPS
has O
included O
high O
- O
dose O
steroids O
, O
high O
- O
dose O
cyclosporine O
( O
CSA ALLCAPS
), O
plasmapheresis RARE
, O
and O
ACE I-GENE
inhibitors O
with O
mixed O
results O
. O

Our O
results O
concluded O
that O
1 O
) O
the O
two O
inhibin RARE
/ O
activin I-GENE
beta O
B O
- O
subunit O
mRNAs O
were O
transcribed O
from O
different O
initiation O
sites O
; O
2 O
) O
both O
promoters O
may O
be O
controlled O
by O
up O
- O
stream RARE
negative O
regulatory O
elements O
; O
and O
3 O
) O
neither O
of O
these O
promoters O
is O
responsive O
to O
cAMP O
and O
/ O
or O
phorbol O
esters O
under O
the O
conditions O
employed O
. O

Promoter O
region O
of O
the O
transcriptional O
unit O
for O
human I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
chimaerin RARE
, O
a O
neuron I-GENE
- I-GENE
specific I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
for O
p21rac NUMERIC
. O
alpha I-GENE
1 I-GENE
- I-GENE
chimaerin RARE
is O
a O
neuron I-GENE
- I-GENE
specific I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
for O
p21rac NUMERIC
, O
a O
protein O
involved O
in O
morphological O
events O
. O

Upstream O
from O
the O
transcription O
start O
point O
( O
tsp RARE
), O
a O
nucleotide O
sequence O
highly O
homologous O
to O
the O
consensus I-GENE
sequence I-GENE
motif I-GENE
for I-GENE
the I-GENE
sigma I-GENE
35 I-GENE
- I-GENE
recognized I-GENE
promoters I-GENE
was O
found O
. O

In O
this O
paper O
, O
an O
analysis O
of O
the O
dynamics O
in O
the O
closing RARE
phase O
of O
the O
occluder RARE
of O
a O
mechanical O
monoleaflet RARE
heart O
valve O
prosthesis RARE
is O
presented O
. O

During O
ISO ALLCAPS
+ O
AT O
infusion O
, O
abdominal O
fat O
blood O
flow O
was O
still O
significantly O
increased O
as O
compared O
with O
control O
values O
in O
lean O
and O
obese O
subjects O
. O

When O
expressed O
per O
kilogram RARE
body O
weight O
, O
mean O
GIT ALLCAPS
increased O
in O
the O
dF LASTCAP
group O
from O
0 O
. O
14 O
% O
to O
0 O
. O
16 O
% O
above O
RMR ALLCAPS
, O
with O
a O
significant O
decrease O
from O
0 O
. O
15 O
% O
to O
0 O
. O
13 O
% O
in O
the O
P O
group O
. O

In O
nucleus O
ventralis RARE
anterior O
thalami RARE
- O
nucleus O
ventralis RARE
lateralis RARE
thalami RARE
neurons O
with O
an O
inhibitory O
input O
from O
nucleus O
entopeduncularis RARE
, O
a O
shortening O
of O
inhibition O
from O
17 O
. O
5 O
+/- O
3 O
. O
6 O
to O
9 O
. O
1 O
+/- O
1 O
. O
8 O
ms O
( O
P O
< O
0 O
. O
05 O
) O
under O
the O
haloperidol O
influence O
was O
evident O
. O

However O
, O
inclusion O
of O
the O
neighboring RARE
CGGAAR ALLCAPS
motifs O
from O
the O
ICP4 I-GENE
promoter I-GENE
, O
which O
bind O
factors O
GABP I-GENE
alpha I-GENE
and I-GENE
beta I-GENE
, O
results O
in O
a O
strong O
synergistic O
activation O
. O

The O
first O
open O
reading O
frame O
of O
the O
blueberry RARE
scorch RARE
carlavirus RARE
( O
BBScV LASTCAP
) O
genome O
encodes O
a O
putative O
replication O
- O
associated O
protein O
of O
223 NUMERIC
kDa O
( O
p223 NUMERIC
). O

From O
sequence O
alignments RARE
with O
phylogenetically RARE
related O
viruses O
, O
including O
tymoviruses RARE
, O
we O
predicted O
that O
p223 NUMERIC
contained O
a O
papain RARE
- I-GENE
like I-GENE
proteinase I-GENE
domain I-GENE
with O
a O
putative O
catalytic O
cysteine994 NUMERIC
and O
histidine1075 NUMERIC
. O

This O
finding O
represents O
both O
a O
potentially O
important O
mechanism O
by O
which O
HPV O
gene O
expression O
can O
be O
regulated O
and O
an O
interesting RARE
model O
for O
the O
study O
of O
transcriptional O
cooperativity O
. O

Using O
this O
method O
, O
VLPs RARE
were O
obtained O
in O
quantities RARE
sufficient O
for O
further O
characterization O
. O

Analysis O
of O
the O
sequence O
upstream O
of O
this O
initiation O
codon O
reveals O
the O
presence O
of O
a O
promotor RARE
sequence O
. O

SUP46 NUMERIC
is O
implicated O
in O
translation O
fidelity O
and O
encodes O
the O
ribosomal I-GENE
protein I-GENE
S13 NUMERIC
. O

To O
explore O
the O
functional O
relationship O
between O
c I-GENE
- I-GENE
fos I-GENE
and O
Rb I-GENE
, O
a O
eukaryotic O
expression O
plasmid O
was O
constructed O
containing O
the O
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
under O
control O
of O
the O
SV40 I-GENE
promoter I-GENE
complex O
. O

The O
high O
degree O
of O
sequence O
identity O
( O
96 O
%) O
between O
hydrolase RARE
B I-GENE
and I-GENE
C I-GENE
, O
particularly O
in O
the O
3 O
' O
untranslated O
region O
, O
suggests O
that O
the O
genes O
encoding O
these O
two O
carboxylesterases RARE
evolved O
by O
duplication O
and O
divergence O
of O
a O
common O
ancestral O
gene O
. O

The O
regions O
of O
the O
tooth O
fracture O
are O
determined O
. O

Secondary RARE
pancreatic O
involvement O
of O
mycosis RARE
fungoides RARE
detected O
by O
a O
clinically O
palpable RARE
mass O
. O

The O
NR2 NUMERIC
hybrid O
is O
a O
powerful RARE
tool O
for O
the O
mapping O
of O
new O
probes O
of O
this O
region O
, O
as O
well O
as O
for O
obtaining O
new O
informative RARE
probes O
specific O
for O
the O
deletion O
by O
subtractive RARE
cloning O
of O
the O
region O
. O

TDEYA ALLCAPS
at O
doses O
of O
200 O
to O
500 O
mg O
/ O
kg O
significantly O
suppressed O
xanthine RARE
oxidase I-GENE
( O
XO ALLCAPS
) O
activity O
in O
the O
stomach O
tissue O
following O
its O
oral O
administration O
. O

Like O
humans O
, O
the O
PITSLRE ALLCAPS
PK I-GENE
genes I-GENE
in I-GENE
chickens I-GENE
must O
be O
closely O
linked O
, O
based O
on O
fluorescent O
in O
situ O
hybridization O
( O
FISH ALLCAPS
) O
localization O
of O
these O
genes O
to O
a O
single O
chicken O
microchromosome RARE
. O

Here O
, O
we O
report O
the O
characterization O
of O
an O
alternatively O
processed O
form O
of O
AFAP ALLCAPS
- I-GENE
110 I-GENE
that O
encodes O
an O
additional O
258 O
base O
pair O
( O
bp O
) O
of O
open O
reading O
frame O
. O

Expression O
of O
class I-GENE
IV I-GENE
ADH I-GENE
mRNA I-GENE
was O
detected O
in O
human O
stomach O
but O
not O
liver O
. O

In O
ICE I-GENE
gamma I-GENE
, O
most O
of O
the O
propeptide RARE
( O
amino O
acids O
20 O
- O
112 O
) O
is O
deleted O
, O
which O
suggests O
that O
it O
may O
function O
as O
a O
catalyst RARE
for O
ICE I-GENE
autoprocessing RARE
in O
vivo O
. O

Endocytosis RARE
and O
lysosomal O
targeting O
of O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptors I-GENE
are O
mediated O
by O
distinct O
sequences O
independent O
of O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
. O

It O
is O
now O
recognized O
that O
essentially O
all O
eukaryotic O
and O
prokaryotic O
genes O
whose O
5 O
'- O
flanking O
regions O
are O
known O
and O
that O
encode O
barbiturate RARE
- O
inducible O
proteins O
contain O
the O
Barbie RARE
box O
element O
. O

Mutation O
of O
the O
P450BM NUMERIC
- I-GENE
3 I-GENE
Barbie RARE
box I-GENE
significantly O
increased O
the O
expression O
of O
both O
P450BM NUMERIC
- I-GENE
3 I-GENE
and O
Bm3P1 NUMERIC
( O
another O
small O
gene O
located O
upstream O
of O
the O
P450BM NUMERIC
- I-GENE
3 I-GENE
gene I-GENE
that O
encodes O
a O
second O
putative O
regulatory O
protein O
) O
in O
response O
to O
pentobarbital RARE
induction O
but O
left O
the O
basal O
levels O
unaffected O
. O

The O
p97 NUMERIC
- O
depleted O
nuclei O
remained O
largely O
competent O
for O
nuclear O
protein O
import O
. O

A O
potential O
outcome O
of O
these O
biochemical O
effects O
may O
include O
the O
limited O
responsiveness O
of O
infected O
T O
cells O
to O
antigenic O
stimulation O
observed O
during O
HIV O
- O
1 O
infection O
. O

The O
full O
protocol O
was O
completed O
by O
33 O
patients O
( O
45 O
% O
of O
original O
cohort O
). O

In O
addition O
, O
we O
found O
that O
cell O
- O
specific O
suppression O
of O
RA O
- O
stimulated O
zif268 NUMERIC
gene I-GENE
expression O
can O
be O
attributed O
to O
a O
29 O
base O
pair O
nucleotide O
sequence O
, O
located O
downstream O
of O
the O
RA O
- O
responsive O
region O
in O
the O
zif268 NUMERIC
gene I-GENE
. O

We O
show O
that O
CBF I-GENE
- I-GENE
A I-GENE
and O
CBF I-GENE
- I-GENE
C I-GENE
interact O
with O
each O
other O
to O
form O
a O
CBF I-GENE
- I-GENE
A I-GENE
- O
CBF I-GENE
- I-GENE
C I-GENE
complex O
and O
that O
CBF I-GENE
- I-GENE
B I-GENE
does O
not O
interact O
with O
CBF I-GENE
- I-GENE
A I-GENE
or O
CBF I-GENE
- I-GENE
C I-GENE
individually O
but O
that O
it O
associates O
with O
the O
CBF I-GENE
- I-GENE
A I-GENE
- O
CBF I-GENE
- I-GENE
C I-GENE
complex O
. O

In O
the O
first O
, O
homologous O
sequences O
were O
deleted O
from O
a O
mouse O
enhancer O
, O
resulting O
in O
a O
tissue O
- O
specific O
loss O
of O
activity O
when O
assayed O
in O
transgenic O
mice O
. O

OKT3 NUMERIC
prophylaxis O
improves RARE
long O
- O
term O
renal O
graft O
survival O
in O
high O
- O
risk O
patients O
as O
compared O
to O
cyclosporine O
: O
combined O
results O
from O
the O
prospective O
, O
randomized O
Belgian RARE
and O
US O
studies O
. O

The O
major O
PKC I-GENE
beta I-GENE
transcription O
initiation O
site O
was O
identified O
by O
primer O
extension O
and O
S1 I-GENE
nuclease I-GENE
protection O
. O

In O
the O
course O
of O
a O
study O
of O
low O
dose O
X O
- O
rays O
effects O
, O
we O
found O
that O
male O
ICR ALLCAPS
white O
Swiss RARE
mice O
showed O
remarkable O
suppression O
of O
mounting RARE
behavior O
after O
whole O
body O
irradiation O
by O
5 O
to O
15 O
cGy RARE
X O
- O
rays O
. O

A O
quantitative O
analysis O
of O
the O
diffraction RARE
intensity O
as O
function O
of O
the O
accumulated O
electron O
dose O
suggests O
the O
possibility O
of O
recording O
up O
to O
250 O
diffraction RARE
patterns O
with O
3 O
. O
5 O
A O
resolution O
from O
a O
single O
crotoxin RARE
complex O
crystal O
128 O
A O
thick O
. O

Supplementary RARE
Phase O
Contraste RARE
RSE ALLCAPS
(" O
Rapid RARE
Sequential RARE
Excitation RARE
") RARE
sequences O
were O
carried O
out O
in O
29 O
patients O
. O

In O
yeast O
, O
the O
products O
of O
the O
UPF1 NUMERIC
and O
UPF3 NUMERIC
genes I-GENE
are O
required O
for O
this O
decay O
pathway O
, O
and O
in O
this O
report O
we O
focus O
on O
the O
identification O
and O
characterization O
of O
additional O
factors O
required O
for O
rapid O
decay O
of O
nonsense O
- O
containing O
mRNAs O
. O

Mutations O
in O
UPF1 NUMERIC
lead O
to O
the O
selective O
stabilization O
of O
mRNAs O
containing O
early O
nonsense O
mutations O
without O
affecting O
the O
decay O
rates O
of O
most O
other O
mRNAs O
. O

A O
DNA O
fragment O
encoding O
the O
DNA O
- O
binding O
domain O
( O
amino O
acids O
1 O
- O
60 O
) O
of O
the O
Escherichia I-GENE
coli I-GENE
fru RARE
transcriptional I-GENE
regulator I-GENE
was O
cloned O
into O
the O
pGEX LASTCAP
- O
KT ALLCAPS
vector O
and O
expressed O
in O
frame O
with O
the O
fused O
gene O
encoding O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
. O

Using O
gel O
retardation O
assays O
with O
HepG2 O
nuclear O
extract O
, O
we O
demonstrated O
the O
presence O
of O
a O
specific O
protein O
which O
bound O
to O
the O
NRE ALLCAPS
fragment O
. O

0 O
. O
61 O
+/- O
0 O
. O
04 O
). O

Several O
nuclear O
factors O
that O
interact O
with O
sequences O
in O
the O
5 O
' O
flanking O
region O
of O
the O
mouse I-GENE
tyrosinase RARE
gene I-GENE
were O
identified O
using O
band O
shift O
and O
methylation O
interference O
assays O
. O

With O
a O
population O
of O
853 NUMERIC
million O
there O
should O
be O
51 O
, O
204 NUMERIC
patients O
with O
hemophilia RARE
A O
in O
India RARE
assuming RARE
a O
prevalence O
of O
6 O
/ O
100 O
, O
000 O
population O
. O

When O
combined O
with O
serum O
ferritin I-GENE
and O
hemoglobin I-GENE
determinations O
, O
the O
serum O
transferrin I-GENE
receptor I-GENE
assay O
is O
a O
valuable O
addition O
in O
epidemiologic RARE
surveys RARE
because O
it O
provides O
a O
quantitative O
measure O
of O
functional O
iron O
deficiency O
and O
it O
distinguishes RARE
true O
IDA ALLCAPS
from O
the O
anemia O
of O
chronic O
disease O
. O

Twenty O
- O
two O
consecutive O
patients O
with O
ischaemic O
ulcers O
had O
tcPO2 NUMERIC
measured O
and O
the O
ankle RARE
/ O
brachial RARE
( O
ABI ALLCAPS
) O
and O
toe O
/ O
brachial RARE
( O
TBI ALLCAPS
) O
indices O
calculated O
. O

TcPO2 NUMERIC
measurement O
appears O
to O
be O
a O
reliable O
technique O
that O
can O
influence O
ischaemic O
ulcer O
management O
. O

Since O
1990 O
the O
University O
Hospital RARE
of O
Tromso RARE
has O
provided O
local O
hospitals O
in O
northern O
Norway RARE
with O
a O
remote RARE
frozen RARE
section O
service RARE
and O
with O
access O
to O
video RARE
conferences RARE
for O
the O
review O
of O
microscopic O
findings O
and O
for O
the O
discussion O
of O
major O
diagnostic O
issues O
. O

Current O
status O
of O
telepathology RARE
. O

Expression O
of O
h6 NUMERIC
. O
1 O
in O
COS O
- O
1 O
cells O
led O
to O
the O
production O
of O
a O
typical O
type I-GENE
IV I-GENE
PDE ALLCAPS
activity O
in O
that O
cAMP O
, O
but O
not O
cGMP O
, O
served RARE
as O
substrate O
and O
its O
activity O
was O
insensitive RARE
to O
either O
Ca2 O
+/ O
CaM I-GENE
or O
cGMP O
but O
was O
inhibited O
by O
low O
concentrations O
of O
rolipram RARE
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

PMEK1 NUMERIC
displays O
96 O
and O
80 O
% O
identity O
respectively O
with O
the O
tobacco I-GENE
NTF3 NUMERIC
and O
Arabidopsis I-GENE
ATMPK1 NUMERIC
kinases I-GENE
, O
and O
only O
50 O
% O
to O
the O
more O
distantly O
related O
plant O
MAP O
kinase O
MsERK1 NUMERIC
from O
alfalfa RARE
. O

Translation RARE
of O
the O
coding O
segment O
, O
which O
was O
designated O
MsPRP2 NUMERIC
, O
suggested O
it O
encodes O
a O
chimeric O
40 O
, O
569 NUMERIC
Da O
cell O
wall O
protein O
with O
an O
amino O
- O
terminal O
signal O
sequence O
, O
a O
repetitive O
proline O
- O
rich O
sequence O
, O
and O
a O
cysteine O
- O
rich O
carboxyl O
- O
terminal O
sequence O
homologous O
to O
nonspecific O
lipid O
transfer O
proteins O
. O

The O
presence O
of O
type O
I O
hypersensitivity O
in O
a O
subgroup O
of O
aspergillomas RARE
suggests O
an O
immunoallergic RARE
component O
to O
this O
disease O
which O
could O
contribute O
to O
a O
chronic O
inflammatory O
response O
to O
Aspergillus O
in O
some O
aspergillomas RARE
. O

This O
concept O
is O
supported O
by O
the O
identification O
of O
RH I-GENE
- I-GENE
like I-GENE
genes I-GENE
in O
non O
human O
primates O
. O

With O
steady O
illumination RARE
, O
outer O
retinal O
( O
photoreceptor RARE
) O
QO2 NUMERIC
decreased O
to O
1 O
. O
4 O
+/- O
0 O
. O
9 O
ml O
O2 O
/( RARE
100 O
g O
. O
min O
), O
but O
inner O
retinal O
QO2 NUMERIC
remained O
unchanged O
at O
3 O
. O
7 O
+/- O
1 O
. O
5 O
ml O
O2 O
/( RARE
100 O
g O
. O
min O
) O
( O
5 O
cats O
). O

We O
have O
screened O
the O
mouse O
cDNA O
library O
of O
an O
MIN6 NUMERIC
cell O
line O
, O
derived O
from O
pancreatic O
beta O
cells O
, O
for O
its O
novel O
isoform O
and O
have O
identified O
a O
cDNA O
encoding O
a O
593 NUMERIC
- O
amino O
acid O
protein O
having O
63 O
, O
53 O
, O
and O
30 O
% O
identity O
with O
munc RARE
- I-GENE
18 I-GENE
/ I-GENE
n I-GENE
- I-GENE
Sec1 NUMERIC
/ I-GENE
rbSec1 NUMERIC
, O
Caenorhabditis I-GENE
elegans I-GENE
unc18 NUMERIC
, O
and O
Saccharomyces I-GENE
cerevisiae I-GENE
Sec1p NUMERIC
, O
respectively O
. O

The O
catenins RARE
bind O
to O
APC I-GENE
and O
E I-GENE
- I-GENE
cadherin I-GENE
in O
a O
similar O
fashion O
, O
but O
APC I-GENE
and O
E I-GENE
- I-GENE
cadherin I-GENE
do O
not O
associate O
with O
each O
other O
either O
in O
the O
presence O
or O
absence O
of O
catenins RARE
. O

However O
, O
addition O
of O
core I-GENE
DNA I-GENE
polymerase I-GENE
III I-GENE
to O
preinitiation RARE
complex O
, O
fully O
reconstituting RARE
holoenzyme O
resulted O
in O
replacement O
of O
gamma O
by O
alpha O
at O
the O
primer O
terminus O
. O

The O
PSD2 NUMERIC
gene I-GENE
was O
heterologously RARE
expressed O
by O
infection O
of O
Sf RARE
- O
9 O
insect O
cells O
with O
recombinant O
baculovirus O
, O
resulting O
in O
a O
10 O
- O
fold O
increase O
in O
PSD ALLCAPS
activity O
. O

Computerized RARE
detection O
of O
abnormal O
asymmetry O
in O
digital O
chest O
radiographs O
. O

These O
results O
suggest O
that O
gluconeogenic RARE
genes O
are O
derepressed RARE
upon O
binding O
of O
Cat8p NUMERIC
, O
whose O
synthesis O
depends O
on O
the O
release O
of O
Cat4p NUMERIC
( O
Mig1p NUMERIC
) O
from O
the O
CAT8 NUMERIC
promoter I-GENE
. O

Like O
Epo I-GENE
, O
HNF I-GENE
- I-GENE
4 I-GENE
is O
expressed O
in O
kidney O
, O
liver O
, O
and O
Hep3B NUMERIC
cells O
but O
not O
in O
HeLa O
cells O
. O

Moreover O
, O
the O
hypoxia O
- O
induced O
expression O
of O
the O
endogenous O
Epo I-GENE
gene I-GENE
was O
significantly O
inhibited O
in O
Hep3B NUMERIC
cells O
stably O
transfected O
with O
HNF I-GENE
- I-GENE
4 I-GENE
delta I-GENE
C I-GENE
. O

These O
observations O
indicate O
that O
there O
are O
multiple O
mechanisms O
by O
which O
an O
individual O
transcript O
can O
be O
degraded O
following O
deadenylation RARE
. O

Small RARE
Maf I-GENE
proteins I-GENE
heterodimerize RARE
with O
Fos I-GENE
and O
may O
act O
as O
competitive O
repressors RARE
of O
the O
NF I-GENE
- I-GENE
E2 I-GENE
transcription I-GENE
factor I-GENE
. O

We O
show O
here O
that O
the O
binding O
of O
C1F NUMERIC
in O
vitro O
is O
sensitive O
to O
the O
concentration O
of O
calcium O
ions O
. O

Survival RARE
after O
development O
of O
symptomatic O
infection O
( O
P O
- O
2 O
) O
did O
not O
differ O
by O
transmission O
mode O
. O

Both O
factors O
demonstrated O
significant O
correlations O
with O
rCBF O
in O
the O
medial O
prefrontal RARE
cortex O
and O
frontal O
polar RARE
cortex O
while O
for O
each O
factor O
there O
were O
also O
unique O
patterns O
of O
correlations O
with O
posterior O
brain O
regions O
. O

These O
data O
suggest O
that O
the O
function O
of O
the O
DS2 NUMERIC
may O
be O
the O
protection O
of O
the O
nuclear O
DNA O
from O
desiccation RARE
. O

Glomerular RARE
hemodynamics O
during O
abortion O
induced O
by O
RU ALLCAPS
486 NUMERIC
and O
sepsis O
in O
rats O
. O

The O
aim O
of O
this O
retrospective O
study O
was O
to O
demonstrate O
that O
in O
certain O
cases O
of O
expulsive RARE
choroidal RARE
hemorrhage O
( O
ECH ALLCAPS
) O
anatomical O
success O
and O
useful O
vision O
can O
be O
obtained O
with O
repeated O
vitreoretinal RARE
surgery O
. O

The O
function O
of O
the O
C O
- O
terminal O
tail O
in O
telomere O
maintenance O
is O
not O
mediated O
through O
the O
RAP1 NUMERIC
interacting I-GENE
factor I-GENE
RIF1 NUMERIC
: O
rap1 NUMERIC
alleles I-GENE
defective O
in O
both O
the O
C O
- O
terminal O
tail O
and O
RIF1 NUMERIC
interaction I-GENE
domains I-GENE
have O
additive O
effects O
on O
telomere O
length O
. O

The O
resulting O
integrated O
physical O
, O
genetic O
, O
and O
cytogenetic O
map O
constitutes O
a O
resource O
for O
the O
characterization O
of O
genes O
that O
may O
be O
involved O
in O
the O
WAGR ALLCAPS
syndrome O
. O

The O
contribution O
of O
skin O
flow O
to O
the O
changes O
in O
760 NUMERIC
- O
800 O
nm O
absorption O
was O
investigated O
by O
simultaneous O
measurement O
of O
skin O
flow O
by O
laser O
flow O
Doppler O
and O
NIR ALLCAPS
recordings O
during O
hot O
water O
immersion O
. O

Proteins RARE
immunoprecipitated O
from O
lysates O
of O
control O
- O
and O
VEGF I-GENE
- O
stimulated O
BAEC ALLCAPS
with O
antisera O
to O
phospholipase I-GENE
C I-GENE
- I-GENE
gamma I-GENE
( O
PLC I-GENE
- I-GENE
gamma I-GENE
) O
were O
fractionated RARE
by O
SDS O
- O
polyacrylamide O
gel O
electrophoresis O
and O
transferred O
to O
Immobilon RARE
- O
P O
. O

Alternatively RARE
processed O
isoforms O
of O
cellular I-GENE
nucleic I-GENE
acid I-GENE
- I-GENE
binding I-GENE
protein I-GENE
interact O
with O
a O
suppressor O
region O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
myosin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
. O

Involvement RARE
of O
early I-GENE
growth I-GENE
response I-GENE
factor I-GENE
Egr RARE
- I-GENE
1 I-GENE
in O
apolipoprotein I-GENE
AI ALLCAPS
gene I-GENE
transcription O
. O

The O
wild O
- O
type O
and O
altered O
forms O
of O
the O
F I-GENE
protein I-GENE
were O
expressed O
in O
BHK ALLCAPS
- O
21 O
and O
HeLa O
T4 O
cells O
by O
use O
of O
the O
recombinant I-GENE
vaccinia I-GENE
virus I-GENE
- I-GENE
encoding I-GENE
T7 I-GENE
polymerase I-GENE
system O
. O

Erythrocyte RARE
delta I-GENE
- I-GENE
aminolevulinic RARE
acid I-GENE
dehydratase RARE
( O
ALAD ALLCAPS
) O
activity O
, O
erythrocyte O
zinc O
protoporphyrin RARE
( O
ZPP ALLCAPS
)/ O
heme O
ratio O
, O
and O
urinary O
coproporphyrin RARE
( O
UC ALLCAPS
) O
concentration O
have O
been O
employed O
as O
biological O
indicators O
of O
moderate O
- O
to O
high O
- O
level O
lead O
exposure O
, O
corresponding O
to O
blood O
levels O
in O
excess O
of O
50 O
micrograms O
/ O
dl O
, O
in O
human O
subjects O
. O

The O
relative O
risk O
of O
graft O
loss O
after O
conversion O
to O
azathioprine RARE
compared O
with O
graft O
loss O
after O
conversion O
to O
azathioprine RARE
compared O
with O
cyclosporin O
maintenance O
was O
0 O
. O
71 O
( O
0 O
. O
37 O
- O
1 O
. O
38 O
) O
and O
the O
relative O
risk O
of O
patient O
death O
was O
0 O
. O
57 O
( O
0 O
. O
23 O
- O
1 O
. O
41 O
). O

Three O
classes O
of O
test O
objects O
were O
considered O
: O
( O
1 O
) O
a O
multicompartment RARE
test O
object RARE
for O
31P NUMERIC
MRS O
measurements O
performed O
with O
slice RARE
- O
selective O
sequences O
; O
( O
2 O
) O
a O
two O
- O
compartment O
test O
object RARE
for O
volume O
- O
selection O
1H NUMERIC
MRS O
; O
and O
( O
3 O
) O
two O
- O
compartment O
test O
objects O
for O
assessing O
the O
performance O
of O
experimental O
systems O
using O
ISIS ALLCAPS
as O
volume O
localization O
sequence O
in O
31P NUMERIC
MRS O
. O

The O
" O
tobacco O
issue RARE
". O

Pregnancy RARE
screening O
by O
uterine O
artery O
Doppler O
velocimetry RARE
-- O
which O
criterion O
performs RARE
best O
? O
OBJECTIVE O
: O
To O
test O
whether O
repeating O
Doppler O
studies O
of O
the O
uteroplacental RARE
circulation O
late O
in O
gestation O
will O
improve O
the O
test O
' O
s O
power O
for O
predicting O
pregnancy O
- O
induced O
hypertension O
and O
fetal O
growth O
restriction O
( O
FGR ALLCAPS
), O
and O
whether O
analysis O
based O
on O
a O
combination O
of O
quantitative O
and O
qualitative O
assessments RARE
of O
the O
uterine O
arterial O
waveforms RARE
will O
yield O
better O
results O
than O
analysis O
based O
on O
either O
alone O
. O

The O
effect O
of O
the O
Ca O
entry O
blocker O
nitrendipine RARE
, O
the O
antioxidant O
superoxide I-GENE
dismutase I-GENE
( O
SOD I-GENE
), O
and O
a O
combination O
of O
nitrendipine RARE
and O
superoxide I-GENE
dismutase I-GENE
on O
postischemic RARE
renal O
function O
was O
studied O
in O
four O
groups O
( O
n O
= O
24 O
) O
of O
rats O
. O

PURPOSE O
: O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
bony RARE
anchorage O
of O
a O
new O
implant O
( O
orderly RARE
wired RARE
surface O
effect O
with O
alloy RARE
Ti RARE
Al O
Va RARE
and O
ordered RARE
pores RARE
of O
488 NUMERIC
mu O
). O

To O
determine O
whether O
food O
and O
/ O
or O
water O
in O
the O
gastrointestinal O
tract O
affects O
restitution RARE
of O
blood O
volume O
and O
plasma O
protein O
after O
hemorrhage O
, O
fed O
and O
24 O
- O
h O
- O
fasted O
awake RARE
rats O
received O
a O
20 O
ml O
. O
kg O
- O
1 O
x O
3 O
min O
- O
1 O
hemorrhage O
, O
and O
restitution RARE
of O
blood O
volume O
was O
measured O
by O
Evans RARE
blue O
dye O
and O
dilution O
of O
hematocrit O
. O

Cooperative RARE
dimerization O
of O
paired I-GENE
class O
homeo RARE
domains O
on O
DNA O
. O

We O
took RARE
advantage O
of O
the O
high O
degree O
of O
aa O
sequence O
homology O
between O
DAHPSs RARE
from O
several O
species O
to O
isolate O
ARO3 NUMERIC
homologues I-GENE
from O
the O
pathogenic O
yeast O
Candida O
albicans O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
BOX ALLCAPS
DNA O
enhances O
transcription O
from O
the O
thymidine I-GENE
kinase I-GENE
( O
TK I-GENE
) O
promoter O
in O
various O
EC O
cells O
. O

Deletion O
analyses O
of O
the O
construct O
revealed O
that O
the O
transcription O
of O
BOXF1 NUMERIC
gene I-GENE
is O
regulated O
by O
BOX ALLCAPS
DNA O
, O
preferentially O
in O
undifferentiated O
EC O
cells O
versus O
differentiated O
cells O
. O

Analysis O
of O
disassociation RARE
rates O
indicates O
that O
the O
Grf10 NUMERIC
- O
Swi5 NUMERIC
- O
DNA O
complex O
has O
a O
longer O
half O
- O
life O
than O
protein O
- O
DNA O
complexes O
that O
contain O
only O
Swi5 NUMERIC
or O
Grf10 NUMERIC
. O

The O
presence O
of O
an O
unusual O
transcript O
possessing RARE
IVS2C NUMERIC
beta I-GENE
1 I-GENE
at O
the O
5 O
' O
terminus O
suggests O
that O
cleavage O
of O
its O
splice O
acceptor O
is O
inefficient O
or O
negatively O
regulated O
. O

The O
mutant O
allele O
of O
the O
alpha I-GENE
1 I-GENE
- I-GENE
tubulin RARE
gene I-GENE
was O
designated O
tua1 NUMERIC
- I-GENE
1 I-GENE
. O

During O
chronic O
treatment O
, O
when O
plasma O
concentrations O
fluctuated RARE
between O
23 O
. O
5 O
ng O
. O
ml O
- O
1 O
at O
8 O
h O
and O
14 O
ng O
. O
ml O
- O
1 O
at O
24 O
h O
post O
- O
dosing RARE
, O
ST O
segment O
depression O
at O
an O
individually O
comparable O
workload RARE
was O
significantly O
decreased O
by O
28 O
% O
compared O
with O
placebo O
( O
P O
< O
0 O
. O
005 O
) O
at O
both O
points O
in O
time O
. O

Results O
from O
in O
vitro O
transcription O
- O
translation O
analysis O
and O
maxicell RARE
experiments O
suggested O
that O
the O
447 NUMERIC
- O
bp O
ORF O
was O
the O
one O
being O
actively O
expressed O
. O

Preliminary RARE
experiments O
demonstrated O
that O
it O
was O
possible O
to O
produce O
fasD LASTCAP
mutants I-GENE
, O
whose O
products O
remain RARE
functional O
for O
fimbrial RARE
export O
and O
assembly O
. O

Evoked RARE
electromyographic RARE
response O
to O
indirect O
supramaximal RARE
stimulation O
at O
1 O
Hz O
was O
monitored O
in O
ten O
adult O
goats O
under O
thiopentone RARE
- O
halothane O
anaesthesia O
. O

313 NUMERIC
, O
98 O
- O
102 NUMERIC
). O

Group O
6 O
was O
given O
physostigmine RARE
, O
0 O
. O
1 O
mg O
/ O
kg O
i O
. O
v O
., O
known O
to O
inhibit O
cholinesterase I-GENE
degradation O
, O
5 O
min O
before O
bupivacaine RARE
administration O
, O
and O
Group O
7 O
received O
a O
combination O
of O
physostigmine RARE
pretreatment O
and O
electrical O
vagal RARE
stimulation O
. O

To O
examine O
the O
possibility O
that O
LNNB ALLCAPS
performance O
of O
the O
schizophrenic O
groups O
may O
have O
been O
related O
to O
neuroleptic O
medication O
, O
analyses O
were O
completed O
on O
the O
relationship O
between O
medication O
levels O
and O
LNNB ALLCAPS
scores O
. O

ISIS ALLCAPS
5 O
possibilities O
. O

The O
use O
of O
specific O
antibodies O
allowed O
the O
identification O
of O
at O
least O
RAR I-GENE
beta I-GENE
in O
some O
of O
the O
DNA O
- O
protein O
complexes O
, O
although O
the O
four O
sequences O
bind O
single O
RARs RARE
transfected O
in O
COS O
cells O
much O
less O
efficiently O
, O
or O
not O
at O
all O
, O
when O
compared O
to O
a O
canonical O
RAR I-GENE
responsive I-GENE
element I-GENE
. O

The O
present O
treatment O
strategy O
in O
progressive O
disorders O
is O
mainly O
based O
on O
the O
complementary O
effect O
of O
intensive O
radiochemotherapy RARE
, O
autologous O
stem O
- O
cell O
transplantation O
and O
the O
rational RARE
use O
of O
cytokines O
, O
mostly O
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
. O

Our O
study O
cohorts RARE
consisted O
of O
15 O
patients O
who O
received O
SC O
rIL LASTCAP
- I-GENE
2 I-GENE
at O
doses O
of O
4 O
. O
8 O
- O
14 O
. O
4 O
million O
IU O
/ O
m2 O
/ O
day O
on O
5 O
days O
per O
week O
for O
a O
total O
of O
8 O
weeks O
, O
20 O
patients O
who O
received O
rIFN LASTCAP
- I-GENE
alpha I-GENE
2b I-GENE
at O
3 O
. O
0 O
- O
6 O
. O
0 O
million O
U O
/ O
m2 O
/ O
day O
thrice RARE
weekly O
for O
a O
total O
of O
6 O
weeks O
, O
and O
72 O
patients O
who O
were O
given O
SC O
rIFN LASTCAP
- I-GENE
alpha I-GENE
2b I-GENE
at O
6 O
. O
0 O
million O
U O
/ O
m2 O
/ O
day O
thrice RARE
weekly O
plus O
SC O
rIL LASTCAP
- I-GENE
2 I-GENE
at O
14 O
. O
4 O
- O
18 O
. O
0 O
million O
IU O
/ O
m2 O
/ O
day O
on O
days O
1 O
and O
2 O
, O
followed O
by O
4 O
. O
8 O
million O
IU O
/ O
m2 O
/ O
day O
, O
5 O
days O
per O
week O
for O
6 O
consecutive O
weeks O
. O

Analysis O
of O
a O
set O
of O
deletion O
constructs O
in O
transient O
transfection O
assays O
measuring O
heterologous O
reporter O
gene O
( O
luciferase I-GENE
) O
activity O
demonstrated O
that O
the O
182 O
- O
bp O
5 O
'- O
flanking O
region O
provides O
full O
promoter O
activity O
in O
IL I-GENE
- I-GENE
2 I-GENE
- O
stimulated O
L2 O
cells O
. O

At O
the O
MTD ALLCAPS
( O
8 O
mg O
/ O
m2 O
/ O
day O
), O
the O
dose O
- O
limiting O
toxicity O
of O
this O
agent O
is O
myelosuppression RARE
. O

Mitogen RARE
- O
induced O
lymphocyte O
proliferation O
was O
diminished O
. O

A O
decanucleotide RARE
promoter O
sequence O
homologous O
to O
those O
found O
in O
humans O
and O
mice O
was O
located O
in O
the O
5 O
' O
untranslated O
region O
of O
one O
horse O
gene O
. O

Some O
of O
these O
targets O
were O
reported O
to O
code O
for O
molecules O
involved O
in O
cell O
- O
cell O
interactions O
, O
whereas O
no O
relationship O
has O
yet O
been O
demonstrated O
between O
Hox I-GENE
genes I-GENE
and O
other O
transcription O
factors O
involved O
in O
determining O
and O
/ O
or O
maintaining O
tissue O
specificity O
. O

Northern O
analysis O
of O
RNA O
samples O
isolated O
from O
ammonium RARE
- O
grown O
cultures O
of O
the O
ntcA LASTCAP
mutant I-GENE
showed O
reduced O
amounts O
of O
glnA LASTCAP
message I-GENE
and O
the O
absence O
of O
a O
1 O
. O
7 O
- O
kb O
transcript O
. O

HER2 NUMERIC
overexpressing O
cells O
showed O
a O
single O
prominent O
DNase I-GENE
I I-GENE
hypersensitive O
site O
near O
a O
conserved O
and O
hitherto O
unrecognized RARE
ets I-GENE
response O
element O
( O
GAGGAA ALLCAPS
), O
located O
38 O
bases O
down O
- O
stream RARE
from O
the O
CAAT O
box O
and O
directly O
5 O
' O
of O
the O
TATA O
box O
in O
the O
human I-GENE
HER2 NUMERIC
promoter I-GENE
. O

Gel O
- O
shift O
assays O
with O
nuclear O
extracts O
and O
oligonucleotide O
sequences O
spanning O
the O
0 O
. O
125 O
- O
kb O
promoter O
region O
detected O
an O
ETS I-GENE
- O
immunoreactive O
complex O
, O
present O
most O
abundantly O
in O
cells O
overexpressing O
HER2 NUMERIC
, O
whose O
high O
- O
affinity O
binding O
depended RARE
on O
the O
GAGGAA ALLCAPS
response O
element O
. O

Comparison O
of O
cDNA O
sequences O
revealed O
that O
the O
two O
mRNA O
species O
arise O
as O
a O
result O
of O
alternate O
use O
of O
poly O
( O
A O
)- O
addition O
sites O
. O

The O
gene O
for O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
was O
isolated O
from O
mouse O
genomic O
DNA O
and O
characterized O
. O

High O
- O
frequency O
electrical O
stimulation O
in O
the O
hippocampus O
leads O
to O
an O
increase O
in O
synaptic O
efficacy O
that O
lasts RARE
for O
many O
hours O
. O

Similar O
to O
the O
mouse O
gene O
, O
the O
5 O
' O
flanking O
region O
of O
human I-GENE
CD79 NUMERIC
alpha I-GENE
lacks O
a O
TATA O
box O
; O
however O
, O
unlike O
mouse I-GENE
CD79 NUMERIC
alpha I-GENE
, O
a O
classical O
octamer O
motif O
could O
not O
be O
identified O
in O
the O
human O
gene O
. O

Detailed RARE
molecular O
organization O
of O
the O
coding O
and O
upstream O
regulatory O
regions O
of O
the O
murine O
homeodomain I-GENE
- I-GENE
containing I-GENE
gene I-GENE
, O
Msx RARE
- I-GENE
1 I-GENE
, O
is O
reported O
. O

We O
report O
here O
the O
cloning O
of O
the O
human I-GENE
goosecoid RARE
gene I-GENE
( O
GSC ALLCAPS
) O
from O
a O
genomic O
library O
and O
the O
sequence O
of O
its O
encoded O
protein O
. O

In O
order O
to O
define O
potential O
candidate O
genes O
for O
inherited O
disorders O
characterized O
by O
aberrant O
gene O
expression O
, O
we O
utilized O
Kruppel RARE
- I-GENE
related I-GENE
sequences I-GENE
to O
isolate O
zinc O
finger O
- O
containing O
cDNAs O
. O

This O
virus O
is O
not O
merely RARE
a O
South RARE
African O
strain O
of O
passion RARE
fruit RARE
woodiness RARE
virus O
( O
PWV ALLCAPS
): O
the O
deduced O
CP I-GENE
sequence I-GENE
is O
only O
distantly O
related O
to O
CPs RARE
of O
other O
sequenced O
strains O
of O
PWV ALLCAPS
, O
although O
it O
is O
part O
of O
a O
distinct O
subgroup O
of O
potyviruses RARE
related O
to O
PWV ALLCAPS
. O

The O
ratio O
of O
the O
activity O
of O
arogenate RARE
dehydrogenase I-GENE
to O
that O
of O
prephenate RARE
dehydrogenase I-GENE
( O
approximately O
3 O
: O
1 O
) O
remained O
constant O
throughout O
purification O
, O
and O
the O
two O
activities O
were O
therefore O
inseparable RARE
. O

The O
isolated O
POT1 NUMERIC
clones O
hybridized O
to O
a O
1 O
. O
4 O
kb O
RNA O
species O
, O
which O
was O
induced O
approximately O
30 O
- O
fold O
when O
oleate RARE
was O
the O
carbon O
source O
. O

The O
Y O
. O
lipolytica RARE
genomic O
POT1 NUMERIC
gene O
was O
disrupted O
by O
replacing O
120 O
bp O
of O
its O
coding O
sequence O
with O
2 O
. O
7 O
kbp O
of O
DNA O
including O
the O
Y O
. O
lipolytica RARE
LEU2 I-GENE
gene I-GENE
. O

A O
leucine O
zipper O
domain O
of O
the O
suppressor I-GENE
of I-GENE
Hairy RARE
- I-GENE
wing RARE
protein I-GENE
mediates O
its O
repressive O
effect O
on O
enhancer O
function O
. O

It O
is O
concluded O
that O
CT O
should O
be O
routinely RARE
employed O
in O
patients O
with O
N1 O
- O
N3 NUMERIC
neck O
disease O
to O
determine O
the O
proper O
electron O
- O
energy O
prescription RARE
. O

The O
predicted O
DNA O
- O
binding O
, O
zinc I-GENE
finger I-GENE
domain I-GENE
protein I-GENE
sequence O
was O
strictly O
conserved O
. O

60 O
patients O
were O
entered RARE
into O
a O
randomised O
study O
comparing O
vindesine RARE
( O
3 O
mg O
/ O
m2 O
/ O
week O
) O
plus O
interferon I-GENE
- I-GENE
alpha I-GENE
2b I-GENE
( O
6 O
U O
/ O
m2 O
3 O
times O
per O
week O
) O
to O
vindesine RARE
alone O
or O
to O
interferon I-GENE
alone O
for O
the O
treatment O
of O
metastatic O
malignant O
melanoma O
. O

The O
novel O
Notch I-GENE
homologue I-GENE
mouse I-GENE
Notch I-GENE
3 I-GENE
lacks O
specific O
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
repeats I-GENE
and O
is O
expressed O
in O
proliferating O
neuroepithelium RARE
. O

BACKGROUND O
: O
We O
conducted O
a O
phase O
I O
study O
with O
MDL ALLCAPS
73 O
, O
147EF NUMERIC
, O
a O
new O
5 I-GENE
hydroxytryptamine RARE
3 I-GENE
( I-GENE
5 I-GENE
- I-GENE
HT3 I-GENE
) I-GENE
receptor I-GENE
antagonist O
, O
in O
25 O
patients O
requiring O
emetogenic RARE
chemotherapy O
. O

In O
the O
presence O
of O
the O
in O
vivo O
reducing O
system O
( O
thioredoxin RARE
, O
thioredoxin RARE
reductase I-GENE
, O
and O
NADPH ALLCAPS
), O
however O
, O
each O
of O
these O
mutants O
catalyzed O
the O
formation O
of O
only O
0 O
. O
6 O
- O
0 O
. O
8 O
dCTPs RARE
per O
mole RARE
of O
enzyme O
. O

These O
genetic O
alterations O
do O
not O
affect O
synthesis O
of O
the O
major O
c I-GENE
- I-GENE
myc I-GENE
protein I-GENE
, O
p64 NUMERIC
, O
which O
is O
initiated O
from O
the O
first O
AUG O
codon O
in O
exon O
2 O
. O

In O
addition O
, O
both O
the O
exon O
1 O
- O
and O
exon O
2 O
- O
initiated O
forms O
of O
the O
c I-GENE
- I-GENE
Myc I-GENE
protein I-GENE
stimulated O
transcription O
of O
a O
Myc I-GENE
/ O
Max I-GENE
- O
responsive O
reporter O
construct O
to O
a O
similar O
level O
. O

Biological O
activities O
of O
hematopoietic I-GENE
growth I-GENE
factors I-GENE
that O
lead O
to O
future O
clinical O
application O
. O

Expression O
is O
exclusively O
limited O
to O
the O
CNS O
at O
this O
and O
later O
stages O
. O

Immunoreactive RARE
AR I-GENE
content O
in O
transfected O
COS O
- O
1 O
cells O
was O
not O
influenced O
by O
exposure O
to O
8 O
- O
Br O
- O
cAMP O
. O

Disruption O
of O
any O
one O
of O
the O
four O
genes O
encoding O
the O
newly O
identified O
SRP I-GENE
proteins I-GENE
results O
in O
slow O
cell O
growth O
and O
inefficient O
protein O
translocation O
across O
the O
ER O
membrane O
. O

Genetic O
alterations O
in O
elements O
of O
normal O
signal O
transduction O
mechanisms O
are O
known O
to O
be O
oncogenic O
events O
often O
resulting O
in O
aberrant O
activation O
of O
programs O
of O
gene O
transcription O
. O

The O
expression O
pattern O
of O
GL2 NUMERIC
, O
as O
demonstrated O
by O
in O
situ O
hybridization O
, O
indicated O
that O
the O
gene O
is O
expressed O
in O
trichome RARE
progenitor O
cells O
and O
at O
stages O
associated O
with O
trichome RARE
development O
. O

NOT4 NUMERIC
interacts O
with O
NOT1 NUMERIC
and O
NOT3 NUMERIC
in O
the O
two O
- O
hybrid O
assay O
, O
and O
overexpression O
of O
NOT3 NUMERIC
or O
NOT4 NUMERIC
suppresses O
not1 NUMERIC
and O
not2 NUMERIC
mutations O
. O

Binding O
site O
selection O
using O
in O
vitro O
- O
synthesized O
proteins O
reveals O
that O
the O
ROR ALLCAPS
alpha I-GENE
1 I-GENE
and O
ROR ALLCAPS
alpha I-GENE
2 I-GENE
isoforms I-GENE
bind O
DNA O
as O
monomers RARE
to O
hormone O
response O
elements O
composed O
of O
a O
6 O
- O
bp O
AT O
- O
rich O
sequence O
preceding O
a O
half O
- O
site O
core O
motif O
PuGGTCA LASTCAP
( O
RORE ALLCAPS
). O

The O
p73pct1 NUMERIC
/ O
p85cdc10 NUMERIC
complex O
binds O
both O
in O
vitro O
and O
in O
vivo O
to O
MCB ALLCAPS
but O
not O
SCB ALLCAPS
or O
E2F I-GENE
sites I-GENE
. O

We O
show O
that O
the O
en I-GENE
stripes RARE
expand RARE
anteriorly RARE
in O
slp RARE
mutant O
embryos O
and O
that O
slp RARE
activity O
is O
an O
absolute O
requirement O
for O
maintenance O
of O
wg RARE
expression O
at O
the O
same O
time O
that O
wg RARE
transcription O
is O
dependent O
on O
hh RARE
. O

The O
DNA O
sequence O
adjacent O
to O
the O
lacZ I-GENE
gene I-GENE
has O
been O
determined O
for O
91 O
vegetative RARE
fusion O
genes O
whose O
products O
have O
been O
localized O
and O
for O
43 O
meiotically RARE
induced O
fusions O
. O

CMV O
hyperimmunoglobulin RARE
treatment O
( O
Cytotect RARE
, O
Biotest RARE
) O
was O
started O
( O
2 O
ml O
/ O
kg O
bw RARE
on O
day O
1 O
and O
3 O
, O
and O
1 O
ml O
/ O
kg O
on O
days O
5 O
, O
7 O
and O
9 O
), O
which O
led O
to O
the O
eradication O
of O
the O
residual O
infiltrate RARE
and O
CMV O
- O
DNA O
in O
the O
myocardium O
. O

Internal RARE
biliary O
drainage O
, O
unlike O
external O
drainage O
, O
does O
not O
suppress O
the O
regeneration O
of O
cholestatic RARE
rat O
liver O
after O
partial O
hepatectomy RARE
. O

ORF O
2 O
potentially O
encoded O
a O
hydrophobic O
protein O
of O
29 O
, O
705 NUMERIC
Da O
with O
six O
potential O
membrane O
- O
spanning O
regions O
. O

In O
eight O
groups O
of O
subjects O
operating O
various O
hand O
- O
held O
vibrating RARE
tools O
and O
aged O
from O
30 O
to O
59 O
years O
, O
the O
prevalence O
rates O
of O
vibration O
- O
induced O
white O
finger O
( O
VWF ALLCAPS
) O
and O
numbness RARE
, O
pain O
, O
or O
stiffness O
in O
the O
upper O
and O
lower O
extremities RARE
were O
investigated O
. O

DNA O
sequence O
analysis O
showed O
that O
the O
gene O
was O
525 NUMERIC
bp O
long O
and O
encoded O
a O
175 O
- O
amino O
- O
acid O
protein O
with O
a O
molecular O
weight O
of O
19 O
, O
094 NUMERIC
containing O
a O
21 O
- O
residue O
typical O
lipoprotein O
signal O
peptide O
and O
consensus O
prolipoprotein RARE
processing O
site O
. O

DNA O
sequence O
and O
functions O
of O
the O
actVI LASTCAP
region I-GENE
of O
the O
actinorhodin RARE
biosynthetic O
gene O
cluster O
of O
Streptomyces O
coelicolor RARE
A3 O
( O
2 O
). O

( O
1992 O
) O
Genomics RARE
12 O
, O
58 O
- O
62 O
). O

A O
comparison O
of O
the O
predicted O
polypeptide O
sequence O
of O
the O
Drosophila O
protein O
with O
the O
equivalent O
subunits O
from O
mouse O
and O
yeast O
suggests O
that O
they O
are O
closely O
related O
and O
defines O
three O
conserved O
regions O
which O
are O
likely O
to O
be O
important O
for O
enzyme O
activity O
. O

Plasmids RARE
were O
constructed O
with O
the O
mouse O
promoter O
region O
linked O
to O
the O
reporter I-GENE
gene I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
), O
and O
transiently O
and O
stably O
transfected O
in O
the O
INS ALLCAPS
- O
1 O
cells O
. O

Cytoplasmic RARE
dynein I-GENE
is O
a O
multisubunit O
, O
microtubule O
- O
dependent O
mechanochemical RARE
enzyme O
that O
has O
been O
proposed O
to O
function O
in O
a O
variety O
of O
intracellular O
movements O
, O
including O
minus O
- O
end O
- O
directed O
transport O
of O
organelles RARE
. O

Identification O
of O
the O
plakoglobin I-GENE
- O
binding O
domain O
in O
desmoglein RARE
and O
its O
role O
in O
plaque O
assembly O
and O
intermediate O
filament RARE
anchorage O
. O

PATIENTS O
AND O
METHODS O
: O
One O
hundred O
eighty RARE
- O
four O
chemotherapy O
- O
naive RARE
patients O
receiving O
high O
- O
dose O
cisplatin O
( O
81 O
to O
120 O
mg O
/ O
m2 O
) O
were O
randomized O
to O
receive O
one O
of O
four O
granisetron RARE
doses O
( O
5 O
, O
10 O
, O
20 O
, O
or O
40 O
micrograms O
/ O
kg O
) O
administered O
before O
chemotherapy O
. O

Nine RARE
new O
naphthalene RARE
related O
compounds O
( O
I O
, O
IV O
, O
V O
, O
VII O
- O
XII ALLCAPS
) O
together O
with O
four O
known O
compounds O
( O
II O
, O
III O
, O
VI O
, O
XIII ALLCAPS
) O
were O
isolated O
from O
the O
root O
bark RARE
of O
Oroxylum RARE
indicum RARE
Vent RARE
. O

Specifically O
, O
this O
study O
determined O
the O
influence O
of O
: O
( O
1 O
) O
an O
awareness RARE
strategy O
, O
( O
2 O
) O
a O
non O
- O
awareness RARE
strategy O
, O
( O
3 O
) O
a O
Five O
- O
Step RARE
Approach RARE
strategy O
and O
( O
4 O
) O
a O
control O
condition O
. O

Mutually RARE
exclusive RARE
interaction O
of O
the O
adenovirus I-GENE
E4 NUMERIC
- I-GENE
6 I-GENE
/ I-GENE
7 I-GENE
protein I-GENE
and O
the O
retinoblastoma I-GENE
gene I-GENE
product I-GENE
with O
internal O
domains O
of O
E2F I-GENE
- I-GENE
1 I-GENE
and O
DP I-GENE
- I-GENE
1 I-GENE
. O

As O
shown O
previously O
, O
EBNA2 I-GENE
transactivates O
the O
promoters O
of O
the O
viral I-GENE
latent I-GENE
membrane I-GENE
proteins I-GENE
. O

We O
previously O
showed O
that O
v I-GENE
- I-GENE
Rel I-GENE
, O
the O
oncoprotein O
of O
the O
avian O
retrovirus O
Rev O
- O
T O
, O
can O
increase O
expression O
from O
promoters O
containing O
binding O
sites O
for O
the O
cellular O
transcription O
factor O
Sp1 I-GENE
in O
chicken O
embryo O
fibroblasts O
( O
S O
. O

Previous O
studies O
have O
demonstrated O
that O
the O
TATA O
element O
is O
critical O
for O
basal O
and O
Tat I-GENE
- O
induced O
HIV O
- O
1 O
gene O
expression O
. O

A O
comparison O
of O
the O
nucleotide O
sequence O
of O
the O
p54 I-GENE
gene I-GENE
carried O
by O
two O
virulent O
ASFV ALLCAPS
strains O
( O
E70 NUMERIC
and O
E75 NUMERIC
) O
with O
that O
obtained O
from O
virus O
Ba71V NUMERIC
showed O
100 O
% O
similarity O
. O

The O
p55 I-GENE
mRNA I-GENE
is O
undetectable O
in O
non O
- O
EBV O
- O
infected O
B O
- O
and O
T O
- O
cell O
lines O
or O
in O
a O
myelomonocytic RARE
cell O
line O
( O
U937 O
). O

A O
simple O
registration RARE
as O
an O
incentive RARE
for O
improvement O

The O
transverse O
magnetization RARE
decays RARE
mentioned O
above O
exhibited O
two O
components O
, O
a O
T2 O
fast O
( O
T2f NUMERIC
) O
and O
a O
T2 O
slow O
( O
T2s NUMERIC
) O
component O
. O

RESULTS O
: O
The O
diagnostic O
quality O
of O
FDG O
images O
was O
at O
least O
as O
good O
as O
that O
of O
their O
Tl O
- O
201 O
counterparts O
, O
with O
less O
liver O
background O
in O
all O
but O
one O
FDG O
study O
. O

The O
coordinated RARE
expression O
of O
CD4 I-GENE
and O
CD8 I-GENE
during O
T O
- O
cell O
development O
is O
tightly O
coupled O
with O
the O
maturation O
state O
of O
the O
T O
cell O
. O

Expression O
of O
a O
dominant I-GENE
- I-GENE
negative I-GENE
ras I-GENE
gene I-GENE
also O
blocks O
TIS10 NUMERIC
/ O
PGS2 NUMERIC
induction O
by O
v I-GENE
- I-GENE
src I-GENE
. O

The O
dying RARE
tTG LASTCAP
- O
transfected O
cells O
exhibit O
both O
cytoplasmic O
and O
nuclear O
changes O
characteristic O
of O
cells O
undergoing O
apoptosis O
. O

Using O
an O
RNase I-GENE
H I-GENE
- O
mediated O
mapping O
technique O
, O
we O
show O
that O
the O
64 O
- O
kDa O
subunit O
of O
CstF LASTCAP
can O
be O
photo RARE
cross O
- O
linked O
to O
pre O
- O
mRNAs O
at O
U O
- O
rich O
regions O
located O
downstream O
of O
the O
cleavage O
site O
of O
the O
simian O
virus O
40 O
late O
and O
adenovirus I-GENE
L3 NUMERIC
pre I-GENE
- I-GENE
mRNAs I-GENE
. O

The O
protein O
encoded O
is O
114 O
kDa O
and O
contains O
eight O
zinc O
finger O
motifs O
, O
seven O
of O
which O
are O
present O
in O
two O
clusters O
at O
opposite O
ends O
of O
the O
molecule O
. O

Tissue O
- O
specific O
expression O
of O
the O
diazepam I-GENE
- I-GENE
binding I-GENE
inhibitor I-GENE
in O
Drosophila O
melanogaster O
: O
cloning O
, O
structure O
, O
and O
localization O
of O
the O
gene O
. O

Using O
a O
v I-GENE
- I-GENE
erbA I-GENE
probe O
, O
we O
obtained O
a O
cDNA O
which O
encodes O
a O
novel O
445 NUMERIC
- O
amino O
- O
acid O
protein O
, O
RLD ALLCAPS
- I-GENE
1 I-GENE
, O
that O
contains O
the O
characteristic O
domains O
of O
nuclear O
receptors O
. O

Only O
two O
of O
the O
isoforms O
possess O
the O
N O
- O
terminal O
zinc O
finger O
domain O
that O
is O
necessary O
and O
sufficient O
for O
TdT LASTCAP
promoter I-GENE
binding O
. O

This O
study O
provides O
direct O
evidence O
that O
USF I-GENE
, O
a O
member O
of O
the O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
leucine I-GENE
zipper I-GENE
family I-GENE
, O
binds O
to O
MLE1 NUMERIC
, O
HF I-GENE
- I-GENE
1a I-GENE
, O
and O
PRE ALLCAPS
B I-GENE
sites I-GENE
and O
suggests O
that O
it O
is O
a O
component O
of O
protein O
complexes O
that O
may O
coordinately RARE
control O
the O
expression O
of O
MLC ALLCAPS
- I-GENE
2v NUMERIC
and O
alpha I-GENE
- I-GENE
myosin I-GENE
heavy I-GENE
- I-GENE
chain I-GENE
genes I-GENE
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
Tax I-GENE
activation O
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
/ O
Rel I-GENE
involves O
phosphorylation O
and O
degradation O
of O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
and O
RelA O
( O
p65 O
)- O
mediated O
induction O
of O
the O
c I-GENE
- I-GENE
rel I-GENE
gene I-GENE
. O

Activation O
of O
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
expression O
by O
a O
kinase O
- O
deficient O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
. O

Because O
endogenous O
HSF I-GENE
DNA O
- O
binding O
activity O
is O
low O
and O
anti I-GENE
- I-GENE
hHSF1 NUMERIC
antibody I-GENE
does O
not O
recognize O
Xenopus I-GENE
HSF I-GENE
, O
we O
employed O
this O
system O
for O
mapping O
regions O
in O
hHSF1 NUMERIC
that O
are O
required O
for O
the O
maintenance O
of O
the O
monomeric O
state O
. O

Enhancers RARE
containing O
disrupted O
Ets I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
were O
tested O
in O
transient O
expression O
assays O
in O
the O
murine O
T O
- O
cell O
line O
EL4 NUMERIC
. O
E1 O
; O
alterations O
in O
the O
LVb RARE
element O
affected O
constitutive O
enhancer O
activity O
, O
while O
mutation O
of O
either O
the O
LVb RARE
or O
LVc RARE
element O
disrupted O
phorbol O
ester O
- O
induced O
enhancer O
activity O
. O

The O
predominant O
binding O
activity O
was O
not O
Ets I-GENE
- I-GENE
1 I-GENE
but O
rather O
two O
independent O
DNA O
- O
protein O
complexes O
that O
comigrated RARE
in O
mobility O
shift O
assays O
. O

These O
RZR ALLCAPS
subtypes O
represent O
members O
of O
a O
new O
family O
of O
orphan I-GENE
nuclear I-GENE
receptors I-GENE
that O
most O
likely O
regulate O
specific O
gene O
expression O
. O

Interestingly O
, O
these O
response O
elements O
display O
dramatically O
reduced O
affinity O
for O
retinoic I-GENE
acid I-GENE
receptor I-GENE
- O
retinoid I-GENE
- I-GENE
X I-GENE
receptor I-GENE
heterodimers O
. O

Treatment O
with O
amphotericin O
B O
and O
flucytosine RARE
led O
to O
improvement O
of O
the O
symptoms O
but O
did O
not O
eradicate RARE
the O
micro O
- O
organisms O
from O
the O
cerebrospinal O
fluid O
( O
CSF O
). O

The O
unexpected RARE
presence O
of O
the O
tRNA I-GENE
( I-GENE
trp RARE
)( I-GENE
CCA ALLCAPS
)- I-GENE
gene I-GENE
transcript I-GENE
in I-GENE
mitochondria I-GENE
is O
also O
reported O
. O

The O
parameters O
of O
nonspecific O
humoral RARE
immunity O
-- O
serum I-GENE
immunoglobulins I-GENE
and O
immune O
complexes O
-- O
were O
evaluated O
in O
irradiated O
group O
of O
patients O
with O
uterine O
cervix O
carcinoma O
( O
Stages RARE
IIB ALLCAPS
and O
IIIB O
), O
during O
one O
year O
follow O
up O
. O

Mutation O
of O
KRKR ALLCAPS
to O
NGER ALLCAPS
retains O
MO15 NUMERIC
in O
the O
cytoplasmic O
compartment O
, O
whilst RARE
the O
wild O
- O
type O
protein O
is O
detected O
exclusively O
in O
the O
nucleus O
. O

To O
confirm O
the O
binding O
of O
protein O
to O
these O
sites O
in O
cells O
, O
we O
carried O
out O
an O
in O
vivo O
genomic O
footprinting O
analysis O
of O
this O
portion O
of O
the O
TGF I-GENE
alpha I-GENE
promoter I-GENE
in O
normal O
and O
transformed O
rat O
liver O
epithelial O
cell O
lines O
that O
express O
the O
endogenous O
gene O
at O
varying O
levels O
. O

Strikingly RARE
, O
this O
subdomain O
is O
also O
present O
in O
the O
otherwise O
unrelated O
N O
- O
terminal O
activating O
region O
of O
p58c NUMERIC
- I-GENE
ets I-GENE
- I-GENE
2 I-GENE
and O
was O
thus O
named O
BEC ALLCAPS
for O
Ets I-GENE
- I-GENE
1 I-GENE
- I-GENE
beta I-GENE
/ O
Ets I-GENE
- I-GENE
2 I-GENE
- I-GENE
Conserved RARE
sequence I-GENE
. O

This O
work O
unravels RARE
a O
new O
model O
for O
the O
ets I-GENE
- I-GENE
1 I-GENE
/ O
ets I-GENE
- I-GENE
2 I-GENE
gene I-GENE
' O
s O
evolution O
, O
based O
for O
the O
first O
time O
on O
both O
structural O
and O
functional O
evidences RARE
. O

The O
v I-GENE
- I-GENE
ets I-GENE
oncogene I-GENE
of O
the O
avian O
retrovirus O
E26 NUMERIC
differs O
from O
its O
cellular O
progenitor O
p68c NUMERIC
- I-GENE
ets I-GENE
- I-GENE
1 I-GENE
by O
two O
amino O
acid O
substitutions O
( O
alanine O
285 O
and O
isoleucine RARE
445 NUMERIC
in O
c I-GENE
- I-GENE
ets I-GENE
- I-GENE
1 I-GENE
both O
substituted O
by O
valine RARE
in O
v I-GENE
- I-GENE
ets I-GENE
, O
mutations O
A O
and O
B O
respectively O
) O
and O
its O
carboxy O
- O
terminal O
end O
( O
mutation O
C O
). O

Consequently RARE
functional O
mRNAs O
can O
be O
produced O
by O
endogenous I-GENE
RNA I-GENE
polymerase I-GENE
I O
. O

The O
individual O
subunits O
of O
Ku RARE
have O
been O
difficult O
to O
isolate O
from O
human O
cells O
without O
denaturation RARE
and O
attempts O
to O
produce O
functional I-GENE
recombinant I-GENE
Ku RARE
have O
been O
largely O
unsuccessful RARE
. O

Using O
this O
method O
, O
we O
were O
able O
to O
select O
strong O
enhancer O
- O
type O
activation O
domains O
from O
the O
immediate I-GENE
early I-GENE
regions I-GENE
of O
two O
herpesviruses RARE
, O
namely O
pseudorabies O
virus O
and O
bovine O
herpesvirus O
1 O
. O

Remarkably RARE
, O
U21 NUMERIC
contains O
a O
long O
stretch O
( O
13 O
nt O
.) O
of O
complementarity O
to O
a O
highly O
conserved O
sequence O
in O
28S I-GENE
rRNA I-GENE
. O

A O
genetic O
system O
was O
devised RARE
to O
select O
for O
pi I-GENE
protein I-GENE
mutants I-GENE
which O
discriminate RARE
between O
IR O
and O
DR O
( O
York O
et O
al O
., O
Gene O
( O
Amst RARE
.) O
116 NUMERIC
, O
7 O
- O
12 O
, O
1992 O
; O
York O
and O
Filutowicz RARE
, O
J O
. O

Univariate RARE
statistical O
analysis O
based O
on O
Kaplan RARE
- O
Meier RARE
- O
estimates O
and O
Log RARE
- O
Rank RARE
- O
Test O
showed O
the O
following O
prognostically RARE
beneficial O
factors O
: O
Limited RARE
disease O
stage O
( O
p O
= O
0 O
. O
009 NUMERIC
), O
NSE ALLCAPS
serum O
level O
less O
than O
25 O
micrograms O
/ O
l O
( O
p O
= O
0 O
. O
016 NUMERIC
), O
serum O
alkaline I-GENE
phosphatase I-GENE
less O
than O
200 O
U O
/ O
l O
( O
p O
= O
0 O
. O
035 NUMERIC
), O
normal O
serum O
albumin I-GENE
( O
p O
= O
0 O
. O
003 NUMERIC
) O
and O
activity O
index O
of O
minimum O
of O
70 O
( O
p O
< O
0 O
. O
001 O
). O

These O
results O
provide O
evidence O
of O
a O
bypass O
of O
p53 I-GENE
- O
induced O
Waf1 NUMERIC
/ O
Cip1 I-GENE
- O
mediated O
cell O
cycle O
regulatory O
pathways O
by O
a O
member O
of O
the O
myb I-GENE
oncogene I-GENE
family I-GENE
. O

HBx RARE
strongly O
elevates RARE
levels O
of O
GTP O
- O
bound O
Ras I-GENE
, O
activated O
and O
phosphorylated O
Raf I-GENE
, O
and O
tyrosine O
- O
phosphorylated O
and O
activated O
MAP I-GENE
kinase I-GENE
. O

Role O
of O
c I-GENE
- I-GENE
myc I-GENE
in O
simian I-GENE
virus I-GENE
40 I-GENE
large I-GENE
tumor I-GENE
antigen I-GENE
- O
induced O
DNA O
synthesis O
in O
quiescent RARE
3T3 O
- O
L1 O
mouse O
fibroblasts O
. O

All O
groups O
were O
challenged RARE
subsequently O
with O
naloxone O
( O
0 O
. O
4 O
mg O
/ O
kg O
) O
in O
the O
distinctive O
environment O
and O
then O
observed O
for O
signs O
of O
opiate O
withdrawal O
. O

Laser RARE
therapy O
of O
penile RARE
carcinoma O

A O
15 O
. O
1 O
kb O
fragment O
of O
the O
yeast O
genome O
was O
allocated O
to O
the O
centromeric RARE
region O
of O
chromosome O
XIV ALLCAPS
by O
genetic O
mapping O
. O

A O
third O
one O
is O
homologous O
in O
half O
of O
its O
length O
to O
the O
prokaryotic I-GENE
hydantoinase RARE
HyuA LASTCAP
and O
in O
the O
other O
half O
to O
hydatoinase RARE
HyuB LASTCAP
. O

It O
was O
shown O
that O
estradiol O
concentrations O
obtained O
after O
estradiol O
valerate RARE
and O
micronized RARE
estradiol O
ingestion O
were O
dependent O
on O
the O
patient O
' O
s O
age O
as O
well O
as O
on O
the O
constitutional RARE
type O
. O

There O
were O
9 O
patients O
in O
NYHA ALLCAPS
class O
III O
and O
8 O
in O
class O
IV O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Constipation RARE
is O
not O
a O
risk O
factor O
for O
hemorrhoids RARE
: O
a O
case O
- O
control O
study O
of O
potential O
etiological RARE
agents O
. O

Of O
419 NUMERIC
persons O
surveyed RARE
, O
207 NUMERIC
( O
49 O
. O
4 O
%) O
were O
antigen O
- O
positive O
with O
the O
Og4C3 NUMERIC
assay O
. O

TG O
- O
day O
and O
TG O
- O
night O
were O
19 O
. O
4 O
+/- O
6 O
. O
1 O
%, O
26 O
. O
6 O
+/- O
5 O
. O
3 O
%, O
( O
750 O
mm3 NUMERIC
< O
T O
. O

Vibrio O
cholerae O
O139 NUMERIC
in O
Calcutta RARE
. O

Ten O
volunteers O
were O
tested O
at O
18 O
, O
000 O
ft RARE
( O
5 O
, O
486 NUMERIC
m O
), O
and O
through O
12 O
, O
000 O
, O
8 O
, O
000 O
, O
and O
5 O
, O
000 O
ft RARE
( O
3 O
, O
657 NUMERIC
, O
2 O
, O
438 NUMERIC
, O
and O
1 O
, O
524 NUMERIC
m O
) O
with O
directional RARE
sounds RARE
recorded O
via O
a O
dummy RARE
head O
microphone RARE
and O
presented O
binaurally RARE
. O

Upon O
differentiation O
with O
retinoic O
acid O
( O
RA O
), O
transcription O
of O
the O
Rex I-GENE
- I-GENE
1 I-GENE
gene I-GENE
decreases O
rapidly O
. O

Sequence O
analysis O
of O
the O
zebrafish RARE
egr1 NUMERIC
coding I-GENE
region I-GENE
revealed O
a O
high O
level O
of O
homology O
to O
the O
mouse O
, O
rat O
, O
and O
human I-GENE
Egr1 NUMERIC
genes I-GENE
with O
the O
notable RARE
exception O
of O
a O
polymorphic O
, O
triplet O
nucleotide O
repeat O
sequence O
in O
the O
region O
coding O
for O
the O
amino O
terminus O
of O
the O
Egr1 NUMERIC
protein I-GENE
. O

The O
fibrinogen I-GENE
, O
serum O
proteins O
, O
sodium O
heparin O
and O
membrane O
contributed O
to O
Cm RARE
by O
20 O
%, O
14 O
%, O
2 O
% O
and O
64 O
%, O
respectively O
. O

In O
these O
vectors O
the O
chimeric I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
( O
chLTR LASTCAP
) O
drives RARE
the O
expression O
of O
the O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
) O
reporter O
gene O
that O
is O
followed O
by O
an O
internal O
SV40 I-GENE
virus I-GENE
early I-GENE
region I-GENE
promoter I-GENE
linked O
to O
the O
neomycin I-GENE
phosphotransferase I-GENE
II I-GENE
( O
NEO ALLCAPS
) O
gene O
. O

Optima RARE
) O
genomic O
library O
by O
hybridizing RARE
with O
elicitor RARE
- O
induced O
stilbene RARE
synthase I-GENE
cDNA I-GENE
as O
a O
probe O
. O

A O
total O
of O
125 O
acute O
leukemia O
adult O
patients O
were O
autografted RARE
with O
bone O
marrow O
( O
BM ALLCAPS
) O
purged RARE
by O
mafosfamide RARE
( O
ASTA ALLCAPS
Z O
) O
during O
the O
period O
of O
January O
1983 O
to O
January O
1993 O
. O

The O
pretransplant RARE
regimen O
consisted O
of O
cyclophosphamide O
( O
120 O
mg O
/ O
kg O
) O
and O
total O
body O
irradiation O
. O

The O
site O
- O
directed O
mutation O
of O
the O
kappa I-GENE
B I-GENE
motif I-GENE
in O
IL I-GENE
- I-GENE
6 I-GENE
/ O
CAT I-GENE
plasmid O
resulted O
in O
the O
complete O
abrogation RARE
of O
IL I-GENE
- I-GENE
6 I-GENE
promoter I-GENE
activity O
in O
these O
cells O
. O

Curiously RARE
, O
testololactone RARE
was O
earlier O
and O
more O
widely O
used O
than O
aminoglutethimide RARE
in O
treating RARE
advanced O
breast O
carcinoma O
. O

Use O
of O
the O
vena RARE
cava RARE
to O
extend O
the O
right O
renal O
vein O
for O
cadaver RARE
transplantation O
is O
controversial RARE
. O

Enhanced RARE
hepatic O
portal O
blood O
flow O
induced O
by O
prostaglandin O
E1 O
following O
liver O
transplantation O
in O
pigs O
. O

One O
gene O
appears O
ubiquitously O
expressed O
while O
the O
other O
is O
prominently RARE
expressed O
in O
muscle O
. O

For O
HeLa O
, O
293 O
, O
U937 O
, O
and O
A549 NUMERIC
cells O
, O
participation O
of O
E2F I-GENE
- I-GENE
1 I-GENE
, O
DP I-GENE
- I-GENE
1 I-GENE
, O
cyclin I-GENE
A I-GENE
, O
and O
RB I-GENE
was O
involved O
in O
formation O
of O
some O
complexes O
only O
, O
assuming RARE
participation O
of O
factors O
different O
from O
E2F I-GENE
- I-GENE
1 I-GENE
or O
DP I-GENE
- I-GENE
1 I-GENE
in O
others O
. O

E1A I-GENE
autoactivation RARE
mediated O
by O
these O
sites O
was O
about O
twofold O
compared O
with O
a O
ninefold RARE
activation O
described O
for O
the O
complete O
E1A I-GENE
promoter I-GENE
. O

Cestode RARE
invasion O
in O
irradiated O
host O
organism O
increases O
the O
negative O
effect O
of O
ionizing RARE
radiation O
on O
the O
hamster O
immune O
system O
. O

During O
heat O
exposure O
, O
chicks O
that O
had O
been O
subjected O
to O
early O
60 O
% O
restriction O
with O
non O
- O
metyrapone RARE
- O
treated O
food O
had O
lower O
H O
/ O
L O
ratios O
and O
improved O
resistance O
to O
marble RARE
spleen O
disease O
infection O
. O

Analyses RARE
of O
additional O
tumors O
induced O
in O
mice O
from O
two O
reciprocal O
crosses RARE
, O
A O
/ O
J O
x O
C3H O
/ O
HeJ LASTCAP
F1 O
( O
hereafter RARE
called O
AC3F1 NUMERIC
) O
and O
C3H O
/ O
HeJ LASTCAP
x O
A O
/ O
J O
F1 O
( O
hereafter RARE
called O
C3AF1 NUMERIC
), O
provided O
evidence O
for O
the O
inactivation O
of O
one O
allele O
of O
the O
putative O
chromosome O
4 O
tumor O
suppressor O
gene O
by O
parental O
imprinting O
. O

ERV1 NUMERIC
is O
involved O
in O
the O
cell O
- O
division O
cycle O
and O
the O
maintenance O
of O
mitochondrial O
genomes O
in O
Saccharomyces O
cerevisiae O
. O

Lesion RARE
diameters O
of O
greater O
than O
20 O
mm O
and O
the O
large O
sessile RARE
- O
type O
configurations RARE
were O
factors O
that O
were O
associated O
with O
incomplete O
removal O
. O

Routinely RARE
collected O
, O
processed O
and O
stored O
breast O
cancer O
tissue O
blocks O
recovered O
from O
the O
archives RARE
of O
the O
Pathology RARE
laboratory O
in O
Dar RARE
es RARE
Salaam RARE
after O
storage O
of O
up O
to O
3 O
years O
were O
analysed O
by O
a O
flow O
cytometry RARE
for O
DNA O
ploidy RARE
and O
S O
- O
phase O
fraction O
. O

Cbf3 NUMERIC
contains O
three O
proteins O
, O
Cbf3a NUMERIC
, O
Cbf3b NUMERIC
and O
Cbf3c NUMERIC
. O

Such O
an O
interaction O
could O
be O
detected O
using O
a O
GST I-GENE
- O
POU I-GENE
fusion O
protein O
bound O
to O
glutathione O
- O
agarose O
beads RARE
. O

These O
mutations O
are O
localized O
in O
the O
same O
region O
where O
the O
HSV I-GENE
transactivator I-GENE
VP16 I-GENE
binds O
, O
but O
did O
not O
coincide RARE
with O
the O
VP16 I-GENE
contacts O
. O

In O
general O
, O
the O
filtration O
rate O
in O
relevant O
areas O
appears O
to O
be O
an O
integrative RARE
and O
easily O
determined O
parameter O
, O
reflecting O
hormonal O
and O
neurogenic RARE
vascular O
as O
well O
as O
local O
interstitial O
control O
of O
the O
Starling RARE
forces RARE
. O

Notably RARE
, O
these O
residues O
are O
located O
in O
different O
domains O
. O

However O
, O
rapamycin RARE
inhibited O
proliferation O
of O
Ba RARE
/ O
F3 NUMERIC
- O
EpoRgp55 NUMERIC
but O
not O
of O
MEL ALLCAPS
cells O
despite O
inhibition O
of O
p70 I-GENE
S6 I-GENE
kinase I-GENE
activity O
in O
both O
cells O
. O

Intraventricular RARE
injection O
of O
( O
2S NUMERIC
, O
1 O
' O
R O
, O
2 O
' O
R O
, O
3 O
' O
R O
)- O
2 O
-( O
2 O
, O
3 O
- O
dicarboxycyclopropyl RARE
) O
glycine O
( O
DCG ALLCAPS
- O
IV O
), O
a O
potent O
agonist O
for O
metabotropic RARE
glutamate I-GENE
receptors I-GENE
, O
to O
rats O
retarded O
dose O
- O
dependently O
the O
recovery O
from O
halothane O
anesthesia O
at O
a O
dose O
range O
from O
30 O
to O
300 O
pmol RARE
/ O
rat O
. O

The O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
3 I-GENE
( O
HNF I-GENE
- I-GENE
3 I-GENE
)/ O
forkhead RARE
( O
fkh RARE
) O
proteins O
consist O
of O
an O
extensive O
family O
of O
tissue O
- O
specific O
and O
developmental O
gene O
regulators O
which O
share O
homology O
within O
the O
winged RARE
helix O
DNA O
binding O
motif O
. O

Homozygous O
null O
embryos O
also O
displayed O
abnormalities O
in O
heart O
development O
, O
consistent O
with O
the O
conclusion O
that O
Tek RARE
is O
necessary O
for O
endocardial RARE
/ O
myocardial O
interactions O
during O
development O
. O

Interestingly O
, O
dTFIIA LASTCAP
- I-GENE
L I-GENE
/ I-GENE
S I-GENE
is O
also O
able O
to O
significantly O
enhance O
transcriptional O
activation O
by O
upstream O
transcription O
factors O
including O
Sp1 I-GENE
, O
VP16 I-GENE
, O
and O
NTF ALLCAPS
- I-GENE
1 I-GENE
. O

A O
strong O
trithorax RARE
binding I-GENE
site I-GENE
was O
found O
at O
the O
cytological RARE
location O
of O
the O
fork I-GENE
head I-GENE
gene I-GENE
, O
a O
region O
- O
specific O
homeotic I-GENE
gene I-GENE
not O
located O
within O
a O
homeotic I-GENE
complex I-GENE
. O

In O
particular O
, O
changes O
in O
intracellular O
Ca2 O
+ O
have O
the O
potential O
to O
either O
inhibit O
or O
augment RARE
the O
ability O
of O
cAMP O
to O
stimulate O
transcription O
, O
depending O
on O
the O
presence O
of O
specific O
forms O
of O
Ca2 I-GENE
+/ I-GENE
calmodulin I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
. O

Antibodies O
directed O
against O
the O
SNM1 NUMERIC
protein I-GENE
immunoprecipitated O
RNase I-GENE
MRP I-GENE
RNA I-GENE
from O
whole O
- O
cell O
extracts O
without O
precipitating O
the O
structurally O
and O
functionally O
related O
RNase I-GENE
P I-GENE
RNA I-GENE
. O

C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
also O
activates O
the O
promoter O
of O
the O
rat I-GENE
class I-GENE
- I-GENE
I I-GENE
ADH I-GENE
gene I-GENE
in O
a O
sequence O
- O
specific O
manner O
[ O
Potter RARE
et O
al O
., O
Arch RARE
. O

C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
also O
activates O
the O
promoter O
of O
the O
rat I-GENE
class I-GENE
- I-GENE
I I-GENE
ADH I-GENE
gene I-GENE
in O
a O
sequence O
- O
specific O
manner O
[ O
Potter RARE
et O
al O
., O
Arch RARE
. O

Our O
results O
show O
that O
the O
ORF O
of O
hAMPK LASTCAP
encodes O
552 NUMERIC
amino O
acids O
( O
aa O
) O
( O
62 O
. O
250 O
kDa O
) O
and O
is O
highly O
conserved O
with O
rAMPK LASTCAP
with O
identities O
of O
97 O
. O
3 O
and O
90 O
% O
at O
the O
aa O
and O
nt O
levels O
, O
respectively O
. O

In O
human O
brain O
, O
contactin RARE
was O
first O
identified O
by O
amino O
terminal O
and O
peptide O
sequencing O
of O
the O
lentil RARE
- I-GENE
lectin RARE
- I-GENE
binding I-GENE
glycoprotein I-GENE
Gp135 NUMERIC
. O

The O
centromeric RARE
YAC O
contig O
, O
which O
consists O
of O
23 O
overlapping O
YACs O
and O
orders RARE
19 O
sequence O
- O
tagged O
sites O
( O
STSs RARE
), O
covers RARE
a O
minimum O
of O
2 O
. O
2 O
Mb O
and O
spans O
the O
Ewing RARE
sarcoma O
breakpoint O
. O
c I-GENE
- I-GENE
ets I-GENE
1 I-GENE
and O
Fli RARE
- I-GENE
1 I-GENE
, O
two O
members O
of O
the O
ets I-GENE
family I-GENE
, O
have O
been O
linked O
within O
400 O
kb O
of O
intervening O
DNA O
within O
this O
contig O
, O
which O
also O
comprises O
a O
polymorphic O
microsatellite O
, O
D11S912 NUMERIC
( O
CA O
) O
n O
, O
which O
we O
have O
localized O
within O
the O
Fli RARE
- I-GENE
1 I-GENE
gene I-GENE
. O

A O
cDNA O
for O
a O
newly O
discovered O
pseudogene O
, O
closely O
related O
to O
the O
mouse I-GENE
mast I-GENE
cell I-GENE
chymases RARE
was O
isolated O
by O
polymerase O
chain O
reaction O
amplification O
from O
a O
mouse O
connective O
tissue O
- O
like O
mast O
cell O
line O
. O

IFI16 NUMERIC
consists O
of O
ten O
exons O
and O
nine O
intervening O
introns O
spanning O
at O
least O
28 O
kilobases O
( O
kb O
) O
of O
DNA O
. O

Courses RARE
were O
repeated O
every O
four O
weeks O
. O

Peter RARE
Elfer RARE
explores RARE
the O
implications O
of O
the O
ruling RARE
. O

Other O
adverse O
events O
with O
incidences RARE
significantly O
higher O
than O
with O
placebo O
were O
dizziness RARE
, O
constipation RARE
, O
sweating RARE
, O
nervousness RARE
, O
and O
abnormal O
ejaculation RARE
. O

Homology RARE
was O
also O
detected O
between O
the O
putative O
transit O
peptide O
sequence O
of O
cysteine I-GENE
synthase I-GENE
C I-GENE
and O
other O
mitochondrion RARE
- O
targeting O
leader O
sequences O
. O

Furthermore O
, O
our O
data O
also O
show O
that O
, O
in O
addition O
to O
TEF I-GENE
- I-GENE
1 I-GENE
, O
another O
HF I-GENE
- I-GENE
1a I-GENE
- I-GENE
related I-GENE
factor I-GENE
may O
be O
recognized O
by O
the O
alpha I-GENE
- I-GENE
MHC I-GENE
gene I-GENE
EM O
element O
. O

Rat I-GENE
kidney I-GENE
carboxylesterase RARE
. O

Recombinant I-GENE
I I-GENE
- I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
inhibited O
kappa I-GENE
B I-GENE
motif I-GENE
binding O
by O
nuclear I-GENE
factor I-GENE
- I-GENE
kappa I-GENE
B1 I-GENE
, O
RelA I-GENE
, O
and O
c I-GENE
- I-GENE
Rel I-GENE
as O
indicated O
by O
studies O
using O
UV O
radiation O
- O
induced O
covalent RARE
cross O
- O
linking O
to O
a O
bromodeoxyuridine RARE
- O
substituted O
kappa I-GENE
B I-GENE
oligonucleotide I-GENE
. O

The O
physical O
and O
chemical O
stability O
of O
a O
combination O
of O
drugs O
commonly O
administered O
into O
the O
epidural RARE
or O
intrathecal RARE
space O
for O
the O
treatment O
of O
chronic O
pain O
was O
investigated O
. O

Therefore O
, O
mechanisms O
that O
control O
activation O
of O
the O
MAP I-GENE
kinase I-GENE
cascade O
temporally O
and O
spatially O
may O
be O
important O
for O
specification RARE
of O
cellular O
responses O
. O

A O
candidate O
gene O
for O
Bcg RARE
, O
designated O
natural I-GENE
resistance I-GENE
- I-GENE
associated I-GENE
macrophage I-GENE
protein I-GENE
( O
Nramp RARE
), O
has O
been O
isolated O
and O
shown O
to O
encode O
a O
novel O
macrophage O
- O
specific O
membrane O
protein O
, O
which O
is O
altered O
in O
susceptible O
animals O
. O

This O
motif O
is O
similar O
to O
but O
distinct O
from O
the O
LIM I-GENE
domain I-GENE
and O
the O
RING I-GENE
finger I-GENE
family I-GENE
, O
and O
is O
reminiscent RARE
of O
known O
metal O
- O
binding O
regions O
. O

The O
P131 NUMERIC
ORF O
is O
followed O
in O
- O
frame O
by O
a O
second O
ORF O
which O
is O
probably O
expressed O
by O
partial O
readthrough O
of O
the O
UGA O
termination O
codon O
of O
the O
P131 NUMERIC
ORF O
to O
produce O
a O
polypeptide O
of O
M O
( O
r O
) O
191044 NUMERIC
( O
P191 NUMERIC
). O

One O
hundred O
fifty RARE
patients O
were O
reviewed O
at O
1 O
year O
after O
arthroplasty RARE
. O

Elementary RARE
visual O
hallucinations RARE
in O
migraine RARE
and O
epilepsy O
. O

The O
influence O
of O
patient O
- O
related O
factors O
on O
inter RARE
- O
observer RARE
variability O
in O
the O
evaluation O
of O
neurological O
signs O
was O
investigated O
. O

Segments RARE
with O
more O
reduced O
BMIPP ALLCAPS
uptake O
than O
MIBI ALLCAPS
uptake O
( O
mismatching RARE
) O
showed O
either O
normal O
wall O
motion O
or O
demonstrated O
inotropic O
reserve O
during O
dobutamine RARE
stimulation O
. O

The O
defined O
length O
of O
the O
mRNA O
, O
1 O
, O
838 NUMERIC
nucleotides O
, O
was O
in O
agreement O
with O
that O
of O
a O
1 O
. O
9 O
- O
kb O
RNA O
expressed O
throughout O
the O
replication O
cycle O
, O
starting O
at O
the O
early O
stages O
of O
infection O
. O

Infect RARE
. O

Transient O
transfections O
of O
a O
construct O
expressing O
the O
RNA O
transcript O
defined O
by O
clone O
B1 O
. O
1 O
into O
D17 NUMERIC
cells O
led O
to O
the O
expression O
of O
an O
Env I-GENE
/ O
Mlvi RARE
- I-GENE
4 I-GENE
fusion O
protein O
with O
an O
apparent O
molecular O
mass O
of O
33 O
kDa O
. O

Roizman RARE
, O
J O
. O

Articles RARE
addressing RARE
valvular RARE
heart O
disease O
or O
heart O
failure O
secondary O
to O
acute O
myocardial O
infarction O
or O
Chagas RARE
' O
disease O
were O
excluded O
. O

The O
present O
data O
also O
indicate O
that O
patients O
with O
TGBM ALLCAPS
nephropathy O
often O
have O
concomitant O
IgA I-GENE
nephropathy O
and O
mesangial RARE
proliferative O
glomerulonephritis O
. O

All O
nuclear O
receptors O
have O
several O
well O
- O
characterized O
structural O
domains O
, O
including O
a O
conserved O
DNA O
- O
binding O
domain O
, O
and O
a O
ligand O
binding O
domain O
at O
the O
carboxyl O
terminus O
of O
the O
receptor O
. O

The O
sample O
includes O
all O
the O
HIV O
- O
infected O
- O
patients O
continuously O
referred O
to O
the O
Outpatient RARE
Service RARE
of O
the O
Infectious RARE
Diseases RARE
dept RARE
. O
of O
Bologna RARE
' O
s O
" O
Ospedale RARE
Maggiore RARE
" O
General RARE
Hospital RARE
during O
some O
five O
days O
( O
19 O
- O
23rd NUMERIC
, O
July RARE
1993 O
). O

Using O
in O
organello RARE
footprint O
analysis O
, O
we O
demonstrate O
that O
within O
human O
placental O
mitochondria O
there O
is O
a O
high O
level O
of O
protein O
- O
DNA O
binding O
at O
regularly RARE
phased RARE
intervals O
throughout O
a O
500 O
- O
bp O
region O
encompassing O
the O
D O
- O
loop O
DNA O
origins O
and O
two O
promoter O
regions O
. O

The O
Nur77 NUMERIC
protein I-GENE
can O
act O
as O
a O
potent O
transcription O
activator O
and O
may O
function O
to O
regulate O
the O
expression O
of O
downstream O
genes O
in O
response O
to O
extracellular O
stimuli O
. O

One O
class O
of O
plasmids O
contained O
tRNA I-GENE
( I-GENE
His I-GENE
) I-GENE
genes I-GENE
and O
conferred O
efficient O
suppression O
only O
when O
cells O
were O
starved RARE
for O
histidine O
; O
these O
plasmids O
suppressed O
a O
gcn2 NUMERIC
deletion O
much O
less O
efficiently O
than O
they O
suppressed O
gcn2 NUMERIC
- I-GENE
507 NUMERIC
. O

Thus O
, O
the O
presence O
of O
the O
Cln2 NUMERIC
PEST ALLCAPS
domain I-GENE
was O
sufficient O
to O
destabilize RARE
a O
heterologous O
protein O
. O

Electrophoretic O
mobility O
shift O
assays O
with O
each O
of O
these O
sequences O
demonstrated O
complexes O
with O
mobilities RARE
identical O
to O
those O
of O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
site I-GENE
from O
the O
kappa I-GENE
light I-GENE
- I-GENE
chain I-GENE
gene I-GENE
. O

Although O
a O
carboxyl O
- O
terminal O
HSF I-GENE
transcriptional O
activation O
domain O
is O
critical O
for O
the O
activation O
of O
CUP1 NUMERIC
transcription O
in O
response O
to O
both O
heat O
shock O
stress O
and O
glucose O
starvation O
, O
this O
region O
is O
dispensable O
for O
transient O
heat O
shock O
activation O
of O
at O
least O
two O
genes O
encoding O
members O
of O
the O
S O
. O
cerevisiae O
hsp70 I-GENE
family I-GENE
. O

We O
have O
recently O
detected O
high O
levels O
of O
CKB ALLCAPS
mRNA I-GENE
in O
HeLa O
cells O
and O
, O
in O
this O
study O
, O
have O
tested O
whether O
this O
may O
be O
due O
to O
the O
extremely O
low O
amounts O
of O
p53 I-GENE
protein I-GENE
present O
in O
HeLa O
cells O
. O

Distal RARE
lower O
motor O
neuron O
syndrome O
with O
high O
- O
titer O
serum I-GENE
IgM I-GENE
anti I-GENE
- I-GENE
GM1 NUMERIC
antibodies I-GENE
: O
improvement O
following O
immunotherapy O
with O
monthly O
plasma O
exchange O
and O
intravenous O
cyclophosphamide O
. O

Regulators RARE
responsible O
for O
the O
pervasive RARE
, O
nonsex RARE
- O
specific O
alternative O
pre O
- O
mRNA O
splicing O
characteristic O
of O
metazoans RARE
are O
almost O
entirely O
unknown O
or O
uncertain RARE
. O

A O
normal O
systemic O
response O
was O
obtained O
after O
IF O
, O
indicating O
that O
rhG LASTCAP
- I-GENE
CSF I-GENE
retains O
activity O
in O
the O
solid O
state O
. O

A O
full O
- O
length O
cDNA O
clone O
isolated O
from O
a O
rat O
lung O
library O
was O
predicted O
to O
encode O
a O
55 O
- O
kDa O
protein O
containing O
at O
its O
amino O
terminus O
a O
targeting O
domain O
that O
binds O
to O
the O
ANP I-GENE
- I-GENE
receptor I-GENE
kinase I-GENE
- I-GENE
like I-GENE
domain I-GENE
and O
containing O
at O
its O
carboxyl O
terminus O
a O
putative O
protein I-GENE
- I-GENE
serine I-GENE
phosphatase I-GENE
domain O
. O

A O
high O
- O
resolution O
restriction O
map O
of O
over O
200 O
kb O
of O
contiguous O
DNA O
containing O
N I-GENE
- I-GENE
myc I-GENE
has O
been O
generated O
by O
subcloning RARE
YACs O
into O
cosmids RARE
. O

PAI I-GENE
- I-GENE
1 I-GENE
levels O
increased O
significantly O
in O
patients O
who O
received O
iohexol RARE
but O
not O
in O
those O
who O
received O
ioxaglate RARE
. O

In O
the O
present O
article O
, O
the O
causes O
of O
death O
or O
ill RARE
- O
being O
as O
found O
in O
10 O
consecutive O
carcinogenicity RARE
studies O
-- O
5 O
studies O
with O
2400 NUMERIC
OFA ALLCAPS
( O
Sprague O
- O
Dawley O
- O
derived O
) O
and O
Wistar RARE
rats O
and O
5 O
studies O
with O
2400 NUMERIC
OF1 NUMERIC
and O
NMRI ALLCAPS
mice O
-- O
were O
re O
- O
examined O
. O

Determination O
of O
potassium O
iodide RARE
in O
Polish RARE
edible RARE
salt O

The O
recovery O
value O
of O
systolic O
pressure O
was O
higher O
than O
diastolic O
pressure O
and O
pulse O
pressure O
increased O
. O

The O
importance O
of O
hepatitis O
C O
virus O
( O
HCV O
) O
infection O
as O
a O
cause O
of O
chronic O
liver O
disease O
has O
become O
clear O
with O
the O
introduction O
of O
serologic O
detection O
methods O
. O

Human O
adenovirus O
type O
41 O
contains O
two O
fibers O
. O

Outflow RARE
obstruction O
of O
pancreatic O
juice O
, O
i O
. O
e O
., O
" O
relative O
stenosis O
of O
the O
minor O
papilla RARE
," O
was O
considered O
to O
be O
present O
in O
the O
patients O
with O
type O
II O
papilla RARE
, O
and O
, O
therefore O
, O
the O
patients O
with O
type O
II O
papilla RARE
might O
suffer RARE
from O
acute O
pancreatitis O
resulting O
from O
poor O
drainage O
of O
pancreatic O
juice O
and O
excessive O
pressure O
in O
the O
dorsal O
duct O
. O

Sequencing O
of O
the O
TP53 NUMERIC
transcripts I-GENE
from O
exons O
2 O
to O
10 O
, O
however O
, O
did O
not O
reveal O
mutations O
of O
the O
remaining O
allele O
in O
any O
of O
these O
tumors O
. O

An O
unusual O
complication O
in O
an O
unsuitable RARE
patient O
. O

In O
the O
ISO ALLCAPS
group O
, O
at O
pre O
- O
DEX ALLCAPS
, O
CBF O
increased O
from O
86 O
+/- O
8 O
to O
166 NUMERIC
+/- O
19 O
mL O
. O
min O
- O
1 O
. O
100 O
g O
- O
1 O
in O
response O
to O
hypercapnia O
( O
PCO2 O
approximately O
90 O
mmHg O
).( RARE
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

All O
other O
ejaculate RARE
parameters O
( O
density O
, O
motility O
, O
swelling O
test O
, O
penetration O
test O
) O
remained O
unchanged O
, O
and O
there O
was O
only O
one O
post O
- O
therapeutic O
pregnancy O
. O

KRN2391 NUMERIC
and O
cromakalim RARE
produced O
a O
dose O
- O
dependent O
increase O
in O
aortic O
and O
coronary O
blood O
flow O
. O

In O
H4IIE NUMERIC
rat O
hepatoma O
cells O
, O
glucocorticoids O
, O
retinoic O
acid O
and O
cyclic O
AMP O
( O
cAMP O
) O
increase O
PEPCK I-GENE
gene I-GENE
transcription O
whereas O
insulin I-GENE
and O
phorbol O
esters O
have O
the O
opposite O
effect O
. O

Acta RARE
572 NUMERIC
, O
113 O
- O
120 O
]. O

Basal O
plasma O
AVP I-GENE
levels O
and O
AVP I-GENE
release O
after O
postural RARE
change O
were O
assessed O
, O
and O
plasma O
NPY ALLCAPS
levels O
were O
measured O
in O
the O
same O
samples O
. O

A O
stretch O
of O
16 O
nucleotides O
just O
upstream O
of O
the O
IL I-GENE
- I-GENE
4RE NUMERIC
contributed O
to O
IL I-GENE
- I-GENE
4 I-GENE
inducibility O
and O
formed O
nucleoprotein O
complexes O
with O
constitutive O
factors O
. O

Our O
previous O
study O
suggested O
that O
pertussis I-GENE
toxin I-GENE
( O
IAP ALLCAPS
)- O
sensitive O
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
s I-GENE
) I-GENE
( O
G I-GENE
- I-GENE
protein I-GENE
) O
is O
involved O
in O
the O
process O
of O
differentiation O
by O
hormones O
/ O
IBMX ALLCAPS
, O
accompanied O
by O
c I-GENE
- I-GENE
fos I-GENE
induction O
. O

ATX ALLCAPS
, O
like O
PC I-GENE
- I-GENE
1 I-GENE
, O
was O
found O
to O
hydrolyze RARE
the O
type I-GENE
I I-GENE
phosphodiesterase I-GENE
substrate O
p O
- O
nitrophenyl RARE
thymidine O
- O
5 O
'- O
monophosphate O
. O

The O
effect O
of O
site O
- O
specific O
mutations O
in O
the O
mouse I-GENE
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
( I-GENE
PDGF I-GENE
) I-GENE
beta I-GENE
- I-GENE
receptor I-GENE
on O
activation O
of O
the O
Na I-GENE
+/ I-GENE
H I-GENE
+ I-GENE
exchanger RARE
was O
examined O
in O
normal O
murine O
mammary O
gland O
epithelial O
( O
NMuMG LASTCAP
) O
and O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
. O

Sequence O
analysis O
revealed O
: O
1 O
) O
a O
kinase O
catalytic O
domain O
most O
characteristic O
of O
serine I-GENE
/ I-GENE
threonine I-GENE
kinases I-GENE
but O
hybrid O
between O
members O
of O
the O
family O
of O
microtubule I-GENE
- I-GENE
associated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
kinases I-GENE
and O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
family I-GENE
; O
2 O
) O
two O
putative O
alpha O
- O
helical O
leucine O
zipper O
motifs O
separated O
by O
a O
25 O
- O
amino O
acid O
charged O
intermediate O
segment O
but O
lacking O
an O
NH2 O
- O
terminal O
basic O
domain O
; O
and O
3 O
) O
COOH O
- O
terminal O
and O
NH2 O
- O
terminal O
proline O
- O
rich O
domains O
suggestive O
of O
src I-GENE
homology I-GENE
3 I-GENE
( O
SH3 I-GENE
) O
domain O
binding O
regions O
. O

Type O
2 O
genomes O
containing O
this O
sequence O
presumably O
more O
closely O
reflect O
the O
structure O
of O
the O
infectious O
, O
replication O
- O
competent O
retrovirus O
ancestors RARE
of O
the O
HERV ALLCAPS
- O
K O
family O
than O
do O
type O
1 O
genomes O
that O
lack O
the O
sequence O
. O

However O
, O
when O
domain O
I O
and O
domain O
II O
were O
linked O
on O
the O
same O
plasmid O
, O
high O
levels O
of O
replication O
were O
observed O
. O

Point RARE
mutations O
that O
suppressed O
the O
in O
vitro O
binding O
of O
NF I-GENE
- I-GENE
Y I-GENE
to O
the O
internal O
palindromic O
arm O
reduced O
the O
activity O
of O
the O
resident RARE
P4 O
promoter O
, O
while O
those O
preventing O
complex O
formation O
with O
USF I-GENE
did O
not O
, O
as O
determined O
by O
transient O
expression O
assays O
using O
the O
luciferase I-GENE
reporter O
gene O
. O

Surprisingly O
, O
Northern O
( O
RNA O
) O
blot O
analysis O
and O
reverse I-GENE
transcriptase I-GENE
- O
PCRs RARE
performed O
after O
transfection O
of O
COS O
- O
7 O
or O
HeLa O
cells O
with O
these O
viral O
RNAs O
revealed O
that O
Y88S NUMERIC
and O
Y88L NUMERIC
RNAs I-GENE
replicated RARE
at O
only O
very O
low O
levels O
. O

Surprisingly O
, O
nuclear O
forms O
of O
IE110 NUMERIC
were O
found O
to O
move RARE
a O
cytoplasmic O
form O
of O
IE175 NUMERIC
into O
nuclear O
punctate RARE
structures O
, O
and O
a O
cytoplasmic O
form O
of O
IE110 NUMERIC
was O
able O
to O
retain RARE
nuclear O
forms O
of O
IE175 NUMERIC
in O
cytoplasmic O
punctate RARE
structures O
. O

Transcription O
of O
the O
gene O
for O
ivanolysin RARE
O I-GENE
and O
expression O
of O
other O
genes O
of O
the O
virulence I-GENE
gene I-GENE
cluster I-GENE
in I-GENE
L I-GENE
. I-GENE
ivanovii RARE
were O
dependent O
on O
PrfA LASTCAP
. O

Moreover O
, O
by O
complementation O
of O
the O
WA ALLCAPS
fyuA LASTCAP
mutant I-GENE
by O
the O
cloned O
fyuA LASTCAP
gene I-GENE
, O
yersiniabactin RARE
uptake O
and O
mouse O
virulence O
were O
restored O
. O

The O
ICBF ALLCAPS
in O
the O
ischaemic O
cortex O
revealed O
a O
graded RARE
reduction O
from O
the O
ischaemic O
centre RARE
to O
the O
surrounding O
tissues O
. O

The O
treatment O
of O
hydronephrosis RARE
in O
children O

The O
inflation RARE
hub RARE
of O
the O
probe O
is O
recreated RARE
by O
modifying RARE
a O
standard O
USCI ALLCAPS
Tuohy RARE
- O
Borst RARE
Y O
adaptor O
and O
attaching RARE
this O
to O
the O
transected RARE
probe O
hypotube RARE
. O

The O
other O
element O
bound O
RBP ALLCAPS
- I-GENE
J I-GENE
kappa I-GENE
with O
low O
affinity O
. O

The O
basal O
promoter O
strength O
of O
constructs O
that O
contained O
deletions O
in O
the O
U5 I-GENE
region I-GENE
of O
the O
LTR O
was O
analyzed O
by O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
assays O
following O
transfection O
of O
HeLa O
cells O
or O
Jurkat O
T O
- O
cells O
in O
the O
presence O
or O
absence O
of O
viral O
transactivator O
tax RARE
protein O
. O

In O
reviewing RARE
a O
number O
of O
the O
most O
intensely RARE
studied O
environmentally RARE
inducible O
promoters O
it O
becomes O
clear O
that O
the O
presence O
of O
two O
cis O
- O
acting O
elements O
are O
critical O
for O
promoter O
activity O
, O
one O
of O
which O
is O
the O
G O
- O
box O
( O
CCACGTGG ALLCAPS
). O

Recently O
, O
a O
protein O
designated O
GF14 NUMERIC
has O
been O
isolated O
that O
is O
associated O
with O
the O
GBF ALLCAPS
protein I-GENE
complex I-GENE
. O

New O
diagnostic O
strategies O
for O
lupus O
anticoagulants RARE
and O
antiphospholipid RARE
antibodies O
. O

Moreover O
, O
the O
ability O
to O
selectivity O
arrest O
elongation O
by O
polIII LASTCAP
at O
defined O
positions O
within O
the O
tRNA O
gene O
transcription O
unit O
has O
permitted O
the O
identification O
of O
discrete O
functional O
properties O
of O
paused RARE
mammalian I-GENE
polIII LASTCAP
ternary I-GENE
complexes I-GENE
. O

Propafenone RARE
is O
well O
tolerated O
in O
the O
majority O
of O
young O
patients O
. O

Mutational O
analysis O
of O
yeast I-GENE
CEG1 NUMERIC
demonstrated O
that O
four O
of O
the O
five O
conserved O
motifs O
are O
essential O
for O
capping I-GENE
enzyme I-GENE
function O
in O
vivo O
. O

2 O
patients O
( O
11 O
%) O
had O
significant O
morbidity O
502 NUMERIC
and O
529 NUMERIC
days O
respectively O
after O
transplantation O
. O

A O
recent O
index O
( O
Fluorosis RARE
Risk O
Index RARE
) O
developed O
by O
Pendrys RARE
( O
1990 O
) O
is O
also O
included O
in O
this O
review O
. O

Alternative O
splicing O
of O
the O
cytoplasmic O
tail O
appears O
to O
generate O
multiple O
PECAM ALLCAPS
- I-GENE
1 I-GENE
isoforms I-GENE
that O
may O
regulate O
phosphorylation O
, O
cytoskeletal O
association O
, O
and O
affinity O
modulation O
of O
the O
mature O
protein O
. O

Transfer RARE
also O
correlated O
inversely O
with O
gastric O
juice O
pH O
( O
r O
= O
- O
0 O
. O
619 NUMERIC
, O
P O
< O
0 O
. O
02 O
). O

This O
technique O
has O
a O
sensitivity O
and O
a O
specificity O
of O
almost O
100 O
%, O
and O
is O
currently O
the O
best O
way O
to O
diagnose RARE
nodal O
involvement O
, O
apart O
from O
laparotomy RARE
. O

The O
data O
show O
conclusively RARE
that O
phosphorylation O
of O
His O
- O
304 NUMERIC
is O
not O
essential O
for O
any O
of O
the O
known O
functions O
of O
A I-GENE
. I-GENE
vinelandii RARE
NifL LASTCAP
. O

The O
role O
of O
HIV I-GENE
tat I-GENE
, O
which O
is O
the O
main O
enhancing O
factor O
for O
viral I-GENE
LTR I-GENE
, O
in O
the O
regulation O
of O
IL I-GENE
- I-GENE
2 I-GENE
gene I-GENE
transcription O
has O
been O
studied O
following O
transient O
expression O
of O
the O
tat I-GENE
gene I-GENE
in O
phorbol O
ester O
and O
calcium O
ionophore RARE
- O
activated O
Jurkat O
cells O
transfected O
with O
IL I-GENE
- I-GENE
2 I-GENE
promoter O
- O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter O
constructs O
. O

Splice RARE
variations O
in O
genes O
coding O
for O
the O
transmembrane I-GENE
FGF I-GENE
receptor I-GENE
( O
FGFR I-GENE
) O
result O
in O
isoforms O
that O
vary O
in O
the O
ectodomain RARE
, O
intracellular O
juxtamembrane O
domain O
, O
and O
the O
intracellular O
kinase O
domain O
. O

If O
this O
is O
present O
, O
such O
patients O
should O
be O
closely O
monitored O
, O
and O
any O
atypical O
lesions O
biopsied RARE
. O

Cumulated RARE
maximum O
lod RARE
scores O
between O
FRDA ALLCAPS
and O
D9S5 NUMERIC
and O
between O
FRDA ALLCAPS
and O
D9S15 NUMERIC
are O
above O
36 O
and O
61 O
, O
respectively O
, O
at O
a O
recombination O
fraction O
of O
0 O
, O
indicating O
that O
recombination O
events O
needed O
to O
orient RARE
the O
search O
of O
the O
gene O
are O
very O
difficult O
to O
identify O
and O
ascertain RARE
. O

A O
receptor I-GENE
- I-GENE
like I-GENE
protein I-GENE
kinase I-GENE
, O
OsPK10 NUMERIC
, O
has O
been O
cloned O
from O
rice O
( O
Oryza RARE
sativa RARE
). O

A O
sequence O
representing O
about O
50 O
% O
of O
the O
expected O
complete O
sequence O
was O
obtained O
by O
translation O
of O
the O
two O
open O
reading O
frames O
present O
on O
a O
1 O
. O
6 O
kb O
DNA O
genomic O
fragment O
. O

Goodpasture RARE
' O
s O
- O
like O
syndrome O
and O
effect O
of O
extracorporeal RARE
membrane O
oxygenator RARE
support O
. O

A O
cDNA O
clone O
pCZ1 NUMERIC
, O
with O
a O
1 O
. O
1 O
kb O
insert O
, O
was O
isolated O
from O
a O
NaCl O
- O
adapted O
tobacco O
cell O
cDNA O
library O
that O
encodes O
an O
apparently O
full O
- O
length O
29 O
kDa O
protein O
( O
251 NUMERIC
amino O
acids O
) O
with O
a O
calculated O
pI LASTCAP
of O
5 O
. O
7 O
. O

METHODS O
-- O
16 O
volunteered RARE
for O
spirometry RARE
with O
methacholine RARE
provocation RARE
test O
including O
a O
test O
for O
small O
airways RARE
function O
by O
volume O
of O
trapped RARE
gas O
( O
VTG ALLCAPS
). O

Relationship RARE
of O
CDK I-GENE
- I-GENE
activating I-GENE
kinase I-GENE
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
CTD O
kinase O
TFIIH ALLCAPS
/ O
TFIIK ALLCAPS
. O

The O
git1 NUMERIC
, O
git3 NUMERIC
, O
git5 NUMERIC
, O
git7 NUMERIC
, O
git8 NUMERIC
and O
git10 NUMERIC
genes I-GENE
act O
upstream O
of O
adenylate I-GENE
cyclase I-GENE
, O
presumably O
encoding O
an O
adenylate I-GENE
cyclase I-GENE
activation O
pathway O
. O

These O
same O
regions O
showed O
remarkable O
homology O
to O
two O
invertebrate RARE
proteins O
, O
CNC ALLCAPS
and O
skin I-GENE
- I-GENE
1 I-GENE
, O
postulated O
to O
regulate O
embryonic O
development O
in O
Drosophila O
melanogaster O
and O
Caenorhabditis O
elegans O
, O
respectively O
. O

DNA O
sequence O
analysis O
has O
confirmed O
that O
this O
mutation O
affects O
the O
C O
- O
terminal O
region O
of O
the O
alpha O
subunit O
, O
changing O
a O
leucine O
residue O
at O
position O
290 NUMERIC
to O
a O
histidine O
( O
rpoAL290H NUMERIC
). O

CONCLUSIONS O
: O
These O
findings O
indicate O
a O
physical O
barrier O
of O
oesophageal RARE
surfactant O
which O
could O
offer O
some O
degree O
of O
protection O
against O
gastro RARE
- O
oesophageal RARE
reflux O
but O
one O
which O
is O
particularly O
prone O
to O
attack RARE
by O
bile O
. O

Differential O
screening O
of O
mitochondrial O
cDNA O
libraries O
from O
male O
- O
fertile RARE
and O
cytoplasmic O
male O
- O
sterile RARE
sugar O
- O
beet RARE
reveals O
genome O
rearrangements O
at O
atp6 NUMERIC
and O
atpA LASTCAP
loci I-GENE
. O

The O
effects O
of O
social O
isolation O
on O
morphine O
- O
induced O
locomotor O
activity O
were O
compared O
in O
: O
( O
i O
) O
animals O
with O
an O
intact O
hypothalamo RARE
- O
pituitary O
- O
adrenal O
( O
HPA ALLCAPS
) O
axis O
; O
( O
ii O
) O
animals O
in O
which O
stress O
- O
induced O
corticosterone O
secretion O
was O
blocked O
by O
adrenalectomy RARE
. O

Using O
this O
reporter O
gene O
system O
, O
we O
previously O
showed O
that O
EPO I-GENE
- O
induced O
activation O
of O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
can O
be O
detected O
rapidly O
and O
sensitively RARE
as O
an O
elevation O
of O
cellular I-GENE
luciferase I-GENE
activity O
. O

I O
hypothesize RARE
that O
white I-GENE
gene I-GENE
expression O
from O
P I-GENE
[ I-GENE
en I-GENE
] I-GENE
is O
repressed O
by O
the O
formation O
of O
a O
protein O
complex O
which O
is O
initiated O
at O
the O
engrailed RARE
PS I-GENE
sites I-GENE
and O
also O
requires O
interactions O
with O
flanking O
genomic O
DNA O
. O

SPP41 NUMERIC
was O
cloned O
and O
sequenced O
and O
found O
to O
be O
essential O
. O
spp43 NUMERIC
is O
allelic O
to O
the O
previously O
identified O
suppressor I-GENE
srn1 NUMERIC
, O
which O
encodes O
a O
negative O
regulator O
of O
gene O
expression O
. O

Standard RARE
curve O
correlation O
coefficients O
of O
0 O
. O
995 NUMERIC
or O
greater O
were O
obtained O
during O
validation RARE
experiments O
and O
analysis O
of O
study O
samples O
. O

To O
see RARE
if O
a O
pulse O
oximeter RARE
can O
monitor O
the O
fetus O
during O
labour O
we O
recruited O
100 O
Caucasian RARE
women O
in O
normal O
uncomplicated RARE
labour O
. O

There O
was O
no O
difference O
in O
plasma O
concentrations O
of O
PGI2 NUMERIC
( O
figure RARE
4 O
) O
and O
TxA2 NUMERIC
in O
patients O
with O
normal O
blood O
pressure O
, O
mild O
preeclampsia RARE
and O
hypotension O
, O
whereas O
in O
severe O
preeclampsia RARE
, O
the O
plasma O
concentration O
of O
PGI2 NUMERIC
was O
significantly O
lower O
( O
p O
< O
0 O
. O
001 O
) O
and O
of O
TxA2 NUMERIC
significantly O
higher O
( O
p O
< O
0 O
. O
001 O
). O

A O
causal RARE
analysis O
of O
secondary O
variables O
showed O
that O
the O
formation O
of O
FB O
memories RARE
was O
primarily O
associated O
with O
the O
level O
of O
importance O
attached O
to O
the O
event O
and O
level O
of O
affective O
response O
to O
the O
news RARE
. O

Deletion O
studies O
identified O
a O
distal O
response O
element O
that O
is O
responsible O
for O
the O
cytokine O
response O
and O
has O
properties O
of O
an O
inducible O
transcriptional O
enhancer O
. O

The O
IPL1 NUMERIC
gene I-GENE
is O
required O
for O
high O
- O
fidelity O
chromosome O
segregation O
in O
the O
budding O
yeast O
Saccharomyces O
cerevisiae O
. O

2 O
. O

No O
drop O
in O
oxygen O
saturation O
( O
SaO2 O
) O
or O
visual O
evidence O
of O
transient O
electroencephalographic RARE
( O
EEG O
) O
arousals RARE
can O
be O
found O
at O
repeat O
polysomnography RARE
. O

The O
complete O
gene O
organization O
was O
obtained O
by O
combining RARE
the O
results O
of O
the O
sequence O
of O
these O
clones O
and O
those O
of O
the O
characterization O
of O
polymerase O
chain O
reaction O
- O
amplified O
genomic O
segments O
. O

INO2 NUMERIC
, O
a O
regulatory O
gene O
in O
yeast O
phospholipid O
biosynthesis O
, O
affects O
nuclear O
segregation O
and O
bud RARE
pattern O
formation O
. O

The O
pentafluorobenzyl RARE
derivative O
of O
clonidine RARE
yields O
an O
intense O
ion O
fragment O
at O
m O
/ O
z O
354 NUMERIC
, O
and O
the O
lower O
limit O
of O
detection O
is O
0 O
. O
025 NUMERIC
ng O
/ O
ml O
for O
a O
1 O
- O
ml O
plasma O
sample O
. O

Mammalian RARE
ABPs RARE
and O
SHBGs RARE
bind O
sex O
steroids O
with O
high O
affinity O
, O
but O
some O
binding O
properties O
differ O
among O
species O
. O

Src I-GENE
homology I-GENE
( O
SH I-GENE
) O
domain O
dependent O
protein O
- O
protein O
interactions O
are O
important O
to O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
signal O
transduction O
. O

Sample RARE
treatment O
was O
optimized RARE
in O
order O
to O
achieve O
a O
complete O
extraction O
of O
labetalol RARE
diastereoisomers RARE
and O
to O
avoid O
racemization RARE
during O
extraction O
. O

Under O
resting O
conditions O
, O
activity O
levels O
of O
cardiac O
vagal RARE
and O
sympathetic O
outflows RARE
are O
not O
related O
across O
young O
, O
healthy O
human O
subjects O
and O
peripheral O
interaction O
is O
not O
manifest O
between O
the O
autonomic RARE
divisions RARE
. O

Both O
proprioceptive RARE
and O
electroreceptive RARE
units O
showed O
a O
progression O
of O
receptive RARE
fields O
from O
anterior O
to O
posterior O
body O
in O
the O
rostral RARE
to O
caudal RARE
direction O
along O
the O
length O
of O
DGR ALLCAPS
. O

In O
control O
patients O
, O
baseline O
images O
presented O
Type O
I O
in O
25 O
, O
Type O
II O
in O
7 O
, O
and O
the O
Type O
III O
& O
IV O
in O
0 O
, O
and O
the O
Type O
after O
loading O
was O
the O
same O
as O
the O
Type O
at O
baseline O
. O

A O
more O
complete O
analysis O
of O
dose O
response O
, O
time O
and O
mode O
of O
Ga O
administration O
( O
preinjury RARE
or O
postinjury RARE
), O
and O
availability O
of O
Ga O
across O
the O
blood O
- O
brain O
barrier O
is O
needed O
to O
further O
evaluate O
the O
efficacy O
of O
this O
compound O
. O

The O
presence O
of O
regulatory O
sequences O
for O
the O
binding O
of O
transcription O
factors O
such O
as O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
and O
AP I-GENE
- I-GENE
2 I-GENE
, O
whose O
activation O
is O
associated O
with O
the O
immediate O
response O
of O
the O
cell O
to O
an O
injury O
, O
may O
be O
an O
indication O
of O
the O
important O
role O
which O
HO ALLCAPS
- I-GENE
1 I-GENE
may O
play O
in O
defense O
mechanisms O
against O
tissue O
injury O
. O

Granisetron RARE
, O
but O
not O
saline O
, O
abolished O
vomiting RARE
and O
nausea RARE
when O
given O
as O
intervention O
after O
this O
combined O
emetic RARE
regimen O
. O

The O
femoroarterial RARE
coronary O
sinus O
difference O
in O
lactate O
turned O
negative O
, O
and O
pH O
, O
PCO2 O
and O
potassium O
differences O
increased O
in O
group O
2 O
during O
pacing O
. O

This O
was O
obtained O
with O
the O
thermal O
neutron RARE
fluency RARE
2 O
. O
0 O
x O
10 O
( O
10 O
) O
n O
/ O
cm2 O
. O

Endotoxemia RARE
induced O
by O
gram O
- O
negative O
bacteria O
leads O
to O
endotoxic RARE
shock O
pathogenetically RARE
stemming RARE
from O
the O
integral O
component O
of O
the O
bacterial O
wall O
-- O
lipid O
A O
. O

The O
study O
made O
to O
define O
the O
ability O
of O
lipid I-GENE
A I-GENE
monoclonal I-GENE
antibodies I-GENE
to O
correct O
hemodynamic O
disturbances O
due O
to O
endotoxemia RARE
in O
dog O
experiments O
showed O
the O
efficacy O
of O
the O
antibodies O
administration O
. O

A O
randomised O
, O
controlled O
trial O
was O
undertaken O
in O
40 O
patients O
with O
active O
Crohn O
' O
s O
disease O
to O
evaluate O
clinical O
and O
nutritional O
outcomes O
after O
an O
amino O
acid O
based O
diet O
containing O
3 O
% O
fat O
was O
given O
by O
a O
feeding O
tube O
compared O
with O
a O
peptide O
based O
diet O
containing O
33 O
% O
fat O
. O

This O
sequenced O
region O
of O
the O
V O
beta O
locus O
contains O
an O
average O
number O
of O
repetitive O
DNA O
elements O
( O
21 O
Alu I-GENE
, O
three O
L1 I-GENE
, O
three O
MER ALLCAPS
, O
and O
three O
retrovirus O
- O
related O
elements O
. O

The O
sequenced O
genomic O
region O
thus O
accounts RARE
for O
essentially O
all O
of O
the O
longest RARE
known O
transcript O
( O
4 O
. O
5 O
kb O
), O
although O
the O
precise O
ends O
of O
this O
transcript O
have O
not O
been O
defined O
. O

The O
pexB LASTCAP
upstream I-GENE
region I-GENE
contained O
245 NUMERIC
nucleotides O
within O
which O
sequences O
approximating RARE
the O
consensus O
for O
cyclic I-GENE
AMP I-GENE
receptor I-GENE
protein I-GENE
and O
integration I-GENE
host I-GENE
factor I-GENE
binding O
sites O
were O
discernible RARE
. O

The O
fepA LASTCAP
- O
entD LASTCAP
and O
fes RARE
- O
entF LASTCAP
operons O
in O
the O
enterobactin RARE
synthesis O
and O
transport O
system O
are O
divergently O
transcribed O
from O
overlapping O
promoters O
, O
and O
both O
are O
inhibited O
by O
the O
Fur I-GENE
repressor I-GENE
protein I-GENE
under O
iron O
- O
replete RARE
conditions O
. O

Sequence O
analysis O
of O
a O
6 O
. O
3 O
- O
kbp O
genomic O
EcoRI I-GENE
- O
fragment O
of O
Alcaligenes RARE
eutrophus RARE
, O
which O
was O
recently O
identified O
by O
using O
a O
dihydrolipoamide RARE
dehydrogenase I-GENE
- O
specific O
DNA O
probe O
( O
A O
. O

Using O
a O
previously O
published O
two O
- O
frequency O
( O
AC O
excitation RARE
) O
three O
- O
electrode O
method O
, O
the O
admittance RARE
locus O
plot RARE
( O
ALP ALLCAPS
) O
in O
the O
low O
- O
frequency O
region O
(< O
1000 O
Hz O
) O
has O
been O
shown O
to O
be O
very O
well O
approximated RARE
by O
a O
straight RARE
line O
and O
can O
be O
described O
with O
frequency O
- O
independent O
parameters O
; O
phase O
angle O
alpha O
pi O
/ O
2 O
, O
conductance O
at O
extrapolated RARE
zero O
frequency O
G0 NUMERIC
= O
1 O
/ O
R0 NUMERIC
, O
and O
ion O
relaxation O
time O
tau O
. O

Intraoperative RARE
measurement O
of O
activated O
partial O
thromboplastin I-GENE
time O
and O
prothrombin I-GENE
time O
with O
a O
new O
compact RARE
monitor O
. O

In O
addition O
, O
we O
sought O
to O
test O
the O
hypothesis O
that O
, O
when O
equal O
volumes O
are O
administered O
intrathecally RARE
, O
significant O
differences O
exist O
in O
the O
potential O
to O
three O
commonly O
used O
anesthetic RARE
solutions O
to O
induce O
sensory O
impairment O
. O

In O
an O
in O
vitro O
study O
, O
10 O
/ O
0 O
nylon RARE
was O
found O
to O
require O
a O
significantly O
lower O
laser O
energy O
density O
to O
produce O
suture RARE
lysis O
following O
a O
single O
shot RARE
than O
either O
10 O
/ O
0 O
Dacron RARE
or O
10 O
/ O
0 O
prolene RARE
. O

The O
proteins O
encoded O
downstream O
of O
rpoN LASTCAP
are O
known O
to O
negatively O
regulate O
sigma I-GENE
54 I-GENE
activity O
. O

We O
report O
here O
that O
microinjection O
of O
an O
anti I-GENE
- I-GENE
CBP I-GENE
antiserum I-GENE
into O
fibroblasts O
can O
inhibit O
transcription O
from O
a O
cAMP O
responsive O
promoter O
. O

These O
results O
demonstrate O
that O
a O
class O
of O
proline O
- O
rich O
activator O
proteins O
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
possess O
a O
common O
structural O
and O
functional O
component O
which O
can O
interact O
with O
the O
same O
target O
in O
the O
general O
transcription O
machinery O
. O

Cloning O
of O
higher I-GENE
plant I-GENE
omega I-GENE
- I-GENE
3 I-GENE
fatty I-GENE
acid I-GENE
desaturases RARE
. O

65 O
, O
3829 NUMERIC
- O
3838 NUMERIC
, O
1991 O
), O
a O
truncated O
form O
of O
the O
IE I-GENE
polypeptide I-GENE
lacking O
IE I-GENE
amino I-GENE
acid I-GENE
residues I-GENE
1 I-GENE
- I-GENE
322 NUMERIC
( O
and O
, O
therefore O
lacks O
the O
deduced O
transcriptional O
activation O
domain O
), O
fails O
to O
transactivate O
the O
EHV I-GENE
- I-GENE
1 I-GENE
tk I-GENE
promoter I-GENE
, O
but O
retains O
the O
ability O
to O
down O
- O
regulate O
the O
EHV I-GENE
- I-GENE
1 I-GENE
IE I-GENE
promoter I-GENE
. O

However O
, O
by O
an O
NS35 NUMERIC
- I-GENE
specific I-GENE
RNA I-GENE
capture RARE
assay O
, O
the O
multimers RARE
were O
shown O
to O
possess O
the O
RNA O
- O
binding O
activity O
previously O
demonstrated O
for O
NS35 NUMERIC
. O

CONCLUSION O
: O
Human O
preterm O
birth O
is O
associated O
with O
significantly O
lower O
progesterone O
/ O
17 O
beta O
- O
estradiol O
ratios O
than O
those O
of O
women O
with O
preterm O
labor RARE
delivered O
at O
term O
. O

Ketamine RARE
in O
the O
treatment O
of O
bronchospasm RARE
during O
mechanical O
ventilation O
. O

In O
conclusion O
, O
the O
disposition RARE
of O
venlafaxine RARE
and O
O O
- O
desmethylvenlafaxine RARE
is O
markedly O
altered O
in O
renal O
disease O
; O
therefore O
dosage O
adjustment O
is O
warranted O
for O
patients O
with O
creatinine O
clearance O
values O
below O
30 O
ml O
/ O
min O
. O

The O
availability O
of O
sequence O
from O
multiple O
species O
has O
permitted O
us O
to O
determine O
that O
the O
UBE ALLCAPS
site O
has O
close O
similarity O
to O
motifs O
that O
bind O
members O
of O
the O
NF I-GENE
- I-GENE
1 I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
. O

The O
incidence O
of O
HSV O
- O
2 O
positive O
subjects O
( O
HSV I-GENE
- I-GENE
2 I-GENE
/ I-GENE
HSV I-GENE
- I-GENE
1 I-GENE
antibody I-GENE
ratio O
> O
or O
= O
1 O
) O
was O
low O
in O
the O
Jewish RARE
Israeli RARE
population O
, O
compared O
to O
other O
demographic RARE
areas O
. O

The O
mechanism O
whereby RARE
zeta I-GENE
PKC I-GENE
regulates O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
most O
probably O
involves O
the O
activation O
of O
a O
putative O
I I-GENE
kappa I-GENE
B I-GENE
kinase I-GENE
of O
molecular O
mass O
approximately O
50 O
kDa O
, O
which O
phosphorylates O
and O
inactivates RARE
I I-GENE
kappa I-GENE
B I-GENE
. O

Stable O
expression O
of O
truncated I-GENE
inositol I-GENE
1 I-GENE
, I-GENE
4 I-GENE
, I-GENE
5 I-GENE
- I-GENE
trisphosphate RARE
receptor I-GENE
subunits I-GENE
in O
3T3 O
fibroblasts O
. O

The O
molecular O
basis O
for O
commitment RARE
of O
progenitors RARE
to O
the O
eosinophil O
lineage O
and O
mechanisms O
by O
which O
eosinophil O
- O
specific O
genes O
are O
expressed O
and O
regulated O
during O
differentiation O
is O
unknown O
. O

We O
report O
the O
identification O
and O
characterization O
of O
myr RARE
4 I-GENE
( O
myosin I-GENE
from I-GENE
rat I-GENE
), O
the O
first O
mammalian I-GENE
myosin I-GENE
I I-GENE
that O
is O
not O
closely O
related O
to O
brush RARE
border RARE
myosin I-GENE
I I-GENE
. O

M O
., O
and O
D O
. O

In O
addition O
, O
computer O
analysis O
suggests O
that O
sequences O
similar O
to O
the O
A O
stem O
element O
are O
present O
within O
the O
three O
AAV I-GENE
promoter I-GENE
regions O
. O

At O
least O
some O
of O
the O
difference O
in O
stability O
of O
the O
two O
kinds RARE
of O
complexes O
was O
due O
to O
the O
fact O
that O
the O
dissociation O
rate O
of O
the O
A O
stem O
substrate O
from O
the O
protein O
- O
DNA O
complexes O
was O
approximately O
fourfold O
faster O
than O
that O
of O
the O
complete O
TR I-GENE
. O

Processing RARE
of O
the O
NS3 O
'- O
5B NUMERIC
polyprotein RARE
was O
complex O
and O
occurred O
rapidly O
. O

However O
, O
each O
promoter O
activated O
by O
IEP86 NUMERIC
was O
synergistically O
affected O
by O
the O
addition O
of O
IEP72 NUMERIC
. O

32Pi NUMERIC
labeling O
or O
isoelectric RARE
focusing O
analysis O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
from O
conditional O
casein I-GENE
kinase I-GENE
II I-GENE
mutants I-GENE
indicated O
that O
phosphorylation O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
is O
abolished O
or O
dephosphorylated RARE
forms O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
are O
detected O
when O
these O
strains O
are O
grown O
at O
the O
restrictive O
growth O
conditions O
. O

Thus O
, O
YMIP ALLCAPS
is O
a O
functional O
homolog O
of O
RMIP ALLCAPS
and O
represents O
a O
new O
component O
of O
the O
yeast O
mitochondrial O
import O
machinery O
. O

The O
R2 O
region O
within O
the O
class O
I O
enhancer O
acts O
as O
a O
negative O
element O
in O
Ad12 NUMERIC
- O
transformed O
cells O
and O
exhibits O
a O
stronger O
binding O
activity O
than O
is O
observed O
in O
nontumorigenic RARE
Ad5 O
- O
transformed O
cells O
, O
which O
are O
not O
reduced O
in O
class O
I O
expression O
. O

PURPOSE O
: O
To O
evaluate O
the O
kinetics O
of O
erythropoietin I-GENE
( O
EPO I-GENE
) O
production O
and O
address O
the O
pathogenesis O
of O
anemia O
of O
prematurity RARE
, O
we O
measured O
EPO I-GENE
levels O
in O
infants O
during O
the O
first O
year O
of O
life O
. O

The O
nerve I-GENE
growth I-GENE
factor I-GENE
beta I-GENE
gene I-GENE
( O
NGFB ALLCAPS
) O
belongs O
to O
a O
conserved O
syntenic RARE
group O
on O
human O
chromosome O
1 O
and O
mouse O
Chromosome RARE
3 O
. O

Furthermore O
, O
an O
upstream O
element O
, O
collagen O
element O
I O
(- O
370 NUMERIC
/- O
344 NUMERIC
), O
which O
shares O
homology O
with O
the O
LAP ALLCAPS
binding O
cis O
- O
element O
of O
the O
albumin I-GENE
promoter I-GENE
( O
9 O
of O
13 O
bp O
) O
is O
described O
. O

Number RARE
and O
size O
of O
silver O
- O
stained O
nucleoli RARE
( O
Ag O
- O
NOR ALLCAPS
clusters O
) O
in O
canine O
seminomas RARE
: O
correlation O
with O
histological O
features O
and O
tumour O
behaviour O
. O

We O
speculate RARE
that O
mast O
cell O
degranulation RARE
may O
be O
involved O
in O
the O
pathogenesis O
of O
necrobiosis RARE
by O
altering O
fibroblast O
enzyme O
activity O
and O
/ O
or O
producing O
prolonged O
inflammatory O
reactions O
. O

Molecular O
cloning O
of O
a O
cysteine I-GENE
synthase I-GENE
cDNA I-GENE
from O
Citrullus RARE
vulgaris RARE
( O
watermelon RARE
) O
by O
genetic O
complementation O
in O
an O
Escherichia O
coli O
Cys O
- O
auxotroph RARE
. O

In O
earlier O
studies O
we O
identified O
several O
regulatory O
elements O
that O
control O
transcriptional O
activation O
and O
aerobic O
repression O
of O
one O
of O
these O
genes O
, O
COX5b NUMERIC
. O

Although O
elevated O
serum O
levels O
of O
antibodies O
to O
the O
nicotinic RARE
acetylcholine I-GENE
receptor I-GENE
( O
nAChR LASTCAP
) O
have O
been O
reported O
in O
neuroleptic O
treated O
patients O
with O
tardive RARE
dyskinesia RARE
, O
such O
antibodies O
have O
not O
been O
determined O
in O
comparable O
nondyskinetic RARE
patients O
. O

The O
tumor O
suppressor O
and O
transcriptional O
factor O
p53 I-GENE
is O
a O
phosphorylated O
protein O
. O

This O
DNA O
containing O
promoter O
activity O
has O
been O
sequenced O
in O
its O
entirety RARE
and O
found O
to O
contain O
multiple O
putative O
regulatory O
sites O
. O

However O
, O
Southern O
blot O
and O
karyotype RARE
analyses O
did O
not O
reveal O
any O
significant O
changes O
in O
copy O
number O
or O
gross O
rearrangements O
of O
the O
p53 I-GENE
gene I-GENE
in O
any O
of O
the O
p53 I-GENE
- I-GENE
cell O
lines O
. O

HupI LASTCAP
showed O
strong O
identity O
to O
rubredoxin RARE
and O
rubredoxin RARE
- I-GENE
like I-GENE
proteins I-GENE
from O
many O
other O
bacteria O
. O

The O
PCr RARE
resynthesis RARE
rate O
( O
P O
< O
0 O
. O
01 O
) O
and O
the O
effective O
maximal O
rate O
of O
mitochondrial O
ATP O
synthesis O
( O
P O
< O
0 O
. O
05 O
) O
also O
improved O
. O

An O
examination O
was O
performed O
in O
15 O
patients O
who O
had O
developed O
pronounced O
osteomalacia RARE
following O
gastric O
resection O
. O

However O
, O
regional O
MVO2 NUMERIC
increased O
to O
about O
the O
same O
extent O
in O
the O
CFX ALLCAPS
( O
from O
6 O
. O
0 O
+/- O
0 O
. O
7 O
to O
12 O
. O
4 O
+/- O
0 O
. O
9 O
ml O
O2 O
. O
min O
- O
1 O
times O
100 O
g O
- O
1 O
) O
and O
the O
LAD O
region O
( O
from O
7 O
. O
0 O
+/- O
0 O
. O
6 O
to O
14 O
. O
5 O
+/- O
1 O
. O
3 O
ml O
O2 O
. O
min O
- O
1 O
times O
100 O
g O
- O
1 O
). O

IGF I-GENE
I I-GENE
and O
insulin I-GENE
receptors I-GENE
are O
homologous O
proteins O
that O
function O
in O
distinct O
physiological O
pathways O
. O

Immunodepression RARE
was O
combined O
with O
the O
increase O
of O
glucocorticoid O
activity O
of O
adrenal O
cortex O
, O
while O
no O
significant O
changes O
in O
thyroid O
hormones O
were O
registered RARE
. O

Tryptic RARE
cleavage O
and O
peptide O
sequence O
analysis O
demonstrated O
that O
the O
98 O
- O
kD O
protein O
is O
identical O
to O
a O
recently O
cloned O
protein O
, O
special I-GENE
A I-GENE
- I-GENE
T I-GENE
- I-GENE
rich I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
SATB1 NUMERIC
), O
that O
binds O
selectively O
to O
nuclear O
matrix O
/ O
scaffold RARE
- O
associated O
regions O
of O
DNA O
( O
MARs RARE
/ O
SARs RARE
). O

Aberrant RARE
protein O
phosphorylation O
at O
tyrosine O
is O
responsible O
for O
the O
growth O
- O
inhibitory O
action O
of O
pp60v NUMERIC
- I-GENE
src I-GENE
expressed O
in O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

Acute O
pancreatitis O
: O
a O
multisystem RARE
disease O
. O

Alginate RARE
biosynthesis O
is O
controlled O
by O
a O
complex O
regulatory O
mechanism O
. O

The O
sequence O
upstream O
of O
the O
rhlA LASTCAP
promoter I-GENE
contains O
two O
inverted O
repeats O
which O
define O
putative O
binding O
sites O
for O
the O
RhlR LASTCAP
regulator I-GENE
. O

We O
have O
examined O
by O
in O
vitro O
footprinting O
a O
region O
located O
downstream O
of O
the O
human O
immunodeficiency O
virus O
, O
type O
1 O
( O
HIV O
- O
1 O
) O
promoter O
found O
to O
be O
hypersensitive O
to O
DNase I-GENE
I I-GENE
digestion O
in O
vivo O
. O

Heparin O
had O
no O
effect O
on O
rAC LASTCAP
- I-GENE
st RARE
myosin I-GENE
light I-GENE
chain I-GENE
phosphatase I-GENE
activity O
, O
while O
the O
B O
subunit O
- O
containing O
forms O
were O
stimulated O
2 O
- O
3 O
- O
fold O
. O

The O
relative O
abundance O
of O
each O
alternatively O
spliced O
mRNA O
was O
determined O
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
in O
various O
human O
tissues O
and O
cell O
lines O
. O

BACKGROUND O
AND O
DESIGN O
: O
Fifty O
- O
nine O
melanocytic RARE
nevi RARE
with O
eccentric RARE
foci RARE
of O
hyperpigmentation RARE
(" O
small O
dark O
dots RARE
") RARE
that O
measured O
primarily O
1 O
to O
2 O
mm O
in O
diameter O
were O
prospectively RARE
examined O
to O
determine O
the O
histologic O
correlates O
of O
the O
dark O
dots RARE
. O

The O
retention O
index O
of O
201Tl NUMERIC
SPECT O
is O
a O
useful O
indicator O
of O
metastatic O
potential O
, O
thereby O
facilitating O
the O
prediction O
of O
prognosis O
, O
and O
provides O
insight O
into O
the O
relationship O
between O
201Tl NUMERIC
uptake O
and O
malignancy O
. O

The O
central O
globular O
domain O
is O
highly O
similar O
to O
those O
regions O
from O
other O
H1 I-GENE
molecules I-GENE
, O
and O
the O
carboxyl O
- O
terminal O
domain O
contains O
a O
repeating O
hexapeptide RARE
motif O
, O
variants O
of O
which O
are O
conserved O
among O
H1 I-GENE
molecules I-GENE
. O

The O
location O
and O
approximate RARE
length O
of O
the O
intron O
are O
conserved O
in O
both O
the O
tomato O
and O
Arabidopsis O
genes O
, O
with O
the O
intron O
separating RARE
the O
' O
nose RARE
' O
region O
( O
encoded O
by O
exon O
1 O
) O
from O
the O
central O
globular O
domain O
( O
exon O
2 O
). O

The O
topology O
and O
chain O
folding O
of O
the O
beta O
subunits O
in O
the O
artifactual RARE
beta O
60 O
capsid O
are O
similar O
to O
the O
native I-GENE
alpha I-GENE
3 I-GENE
beta I-GENE
60 I-GENE
enzyme I-GENE
. O

A O
single O
NMSC ALLCAPS
was O
present O
in O
69 O
. O
4 O
%, O
two O
in O
16 O
%, O
three O
in O
6 O
. O
4 O
%, O
four O
in O
3 O
. O
5 O
%, O
five O
to O
nine O
in O
4 O
. O
2 O
%, O
and O
0 O
. O
5 O
% O
had O
ten O
or O
more O
. O

A O
constitutive O
mutant O
form O
with O
a O
single O
substitution O
( O
V88A NUMERIC
) O
in O
the O
amino O
- O
terminal O
( O
response O
regulator O
) O
region O
was O
used O
. O

Comparisons RARE
of O
the O
four O
operon O
control O
regions O
studied O
indicate O
that O
the O
NarL LASTCAP
heptamers RARE
are O
arranged O
with O
diverse O
orientations RARE
and O
spacing RARE
. O

Direct O
binding O
and O
competition O
assays O
using O
30 O
- O
mer O
oligonucleotide O
probes O
representing O
the O
individual O
CBF1 I-GENE
binding I-GENE
sites I-GENE
indicated O
that O
CBF1 I-GENE
bound O
less O
efficiently O
to O
the O
CD23 I-GENE
promoter I-GENE
and O
the O
EBV I-GENE
LMP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
sites I-GENE
than O
to O
the O
Cp I-GENE
site I-GENE
. O

We O
have O
found O
a O
satisfactory O
reproducibility O
in O
vitro O
( O
T1 O
: O
1 O
. O
9 O
%; O
T2 O
: O
6 O
. O
2 O
%), O
while O
the O
reproducibility O
was O
less O
satisfactory O
in O
vivo O
( O
T1 O
: O
16 O
. O
4 O
%; O
T2 O
: O
13 O
. O
4 O
%). O

The O
two O
ParA LASTCAP
proteins I-GENE
that O
are O
produced O
as O
a O
result O
of O
independent O
translation O
initiation O
at O
two O
different O
start O
codons O
within O
the O
same O
open O
reading O
frame O
were O
overexpressed O
in O
Escherichia O
coli O
and O
partially O
purified O
. O

To O
get RARE
further O
insights RARE
into O
the O
molecular O
mechanisms O
that O
control O
tal I-GENE
- I-GENE
1 I-GENE
expression O
, O
we O
have O
isolated O
5 O
' O
sequences O
of O
the O
murine O
gene O
and O
compared O
them O
to O
their O
human O
counterparts O
. O

CONCLUSION O
: O
Sonographic RARE
angiography O
has O
a O
possible O
role O
in O
the O
detection O
of O
small O
nodules O
in O
patients O
with O
CRF O
. O

Each O
expressed O
domain O
, O
as O
well O
as O
FKBP ALLCAPS
- I-GENE
33 I-GENE
itself O
, O
possesses O
peptidyl RARE
- I-GENE
prolyl RARE
cis I-GENE
- I-GENE
trans I-GENE
isomerase I-GENE
activity O
, O
though O
with O
much O
lower O
specific O
activities O
than O
FKBP ALLCAPS
- I-GENE
12 I-GENE
. O

The O
first O
85 O
nt O
upstream O
of O
the O
transcription O
initiation O
site O
of O
the O
mouse I-GENE
desmin RARE
gene I-GENE
, O
which O
contain O
an O
E O
box O
( O
E1 O
), O
the O
binding O
site O
of O
the O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
myogenic I-GENE
regulators I-GENE
, O
are O
sufficient O
to O
confer O
low O
level O
muscle O
- O
specific O
expression O
. O

The O
acfD LASTCAP
gene I-GENE
encompasses RARE
254 NUMERIC
nt O
that O
are O
predicted O
to O
encode O
an O
88 O
- O
amino O
- O
acid O
( O
aa O
) O
protein O
. O

We O
find O
that O
beta I-GENE
II I-GENE
PKC I-GENE
phosphorylates O
nuclear I-GENE
envelope I-GENE
lamin RARE
B I-GENE
at O
10 O
- O
20 O
times O
the O
rate O
of O
alpha I-GENE
PKC I-GENE
, O
whereas O
both O
kinases O
phosphorylate O
soluble I-GENE
lamin RARE
B I-GENE
at O
similar O
rates O
. O

Regulation O
of O
parathyroid I-GENE
hormone I-GENE
- I-GENE
related I-GENE
protein I-GENE
( O
PTHrP LASTCAP
) O
gene O
expression O
. O

These O
results O
demonstrate O
that O
a O
diverse O
set O
of O
carboxyl O
- O
terminal O
sequence O
motifs O
and O
posttranslational O
modifications O
lead O
to O
functional O
Ras I-GENE
proteins I-GENE
in O
yeast O
. O

We O
conclude O
that O
c I-GENE
- I-GENE
Abl I-GENE
activates O
c I-GENE
- I-GENE
myc I-GENE
transcription O
indirectly O
with O
no O
requirement O
for O
DNA O
binding O
by O
c I-GENE
- I-GENE
Abl I-GENE
. O

Long RARE
- O
latency O
: O
locked RARE
units O
responded O
to O
shocks RARE
with O
little O
jitter RARE
and O
long O
latency O
( O
4 O
- O
11 O
ms O
). O

The O
highly O
conserved O
ninth RARE
heptad O
, O
which O
is O
involved O
in O
heterodimerization O
, O
appears O
to O
participate O
in O
the O
receptor O
- O
inhibitor O
interaction O
, O
suggesting O
that O
the O
inhibitor O
is O
a O
related O
member O
of O
the O
receptor O
gene O
family O
. O

Here O
we O
show O
that O
for O
expression O
of O
snRNA O
genes O
in O
maize O
, O
a O
monocotyledonous RARE
plant O
, O
the O
USE ALLCAPS
and O
TATA O
elements O
are O
essential O
, O
but O
not O
sufficient O
, O
for O
transcription O
. O

Extensive RARE
DNA O
rearrangement O
occurs O
during O
the O
development O
of O
the O
somatic O
macronucleus RARE
from O
the O
germ O
line O
micronucleus RARE
in O
ciliated RARE
protozoans RARE
. O

An O
in O
vitro O
binding O
site O
selection O
procedure O
was O
used O
to O
determine O
DNA O
sequences O
preferentially O
bound O
by O
wild I-GENE
- I-GENE
type I-GENE
HLF ALLCAPS
and O
chimeric O
E2A NUMERIC
- O
HLF ALLCAPS
proteins O
isolated O
from O
various O
t O
( O
17 O
; O
19 O
)- O
bearing O
leukemias O
. O

The O
Oct I-GENE
- I-GENE
2 I-GENE
glutamine O
- O
rich O
and O
proline O
- O
rich O
activation O
domains O
can O
synergize RARE
with O
each O
other O
or O
duplicates RARE
of O
themselves O
to O
activate O
transcription O
. O

Binding O
of O
U2 I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
( O
snRNP O
) O
to O
the O
pre O
- O
mRNA O
is O
an O
early O
and O
important O
step O
in O
spliceosome O
assembly O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
Dbf8p NUMERIC
plays O
an O
essential O
role O
in O
chromosome O
segregation O
. O

Ariga RARE
, O
Biochem RARE
. O

Our O
results O
indicate O
that O
the O
KRAB I-GENE
domain I-GENE
present O
in O
the O
non O
- O
finger O
region O
of O
many O
ZFP ALLCAPS
genes I-GENE
quenches RARE
transcription O
possibly O
due O
to O
specific O
protein O
- O
protein O
interactions O
between O
the O
KRAB I-GENE
- I-GENE
A I-GENE
domain I-GENE
and O
components O
of O
the O
proximal O
transcriptional O
apparatus O
. O

Marine RARE
oils RARE
and O
cardiovascular O
reactivity O
. O

The O
diagnostic O
significance O
of O
creatine I-GENE
phosphokinase RARE
antibodies O
in O
the O
cardiac O
muscle O
in O
non O
- O
coronarogenic RARE
myocardial O
diseases O

According O
to O
the O
results O
of O
assays O
obtained O
with O
the O
use O
of O
assay O
systems O
ORTHO ALLCAPS
ELISA O
and O
ABBOTT ALLCAPS
HCV O
EIA O
( O
USA ALLCAPS
), O
the O
detection O
rate O
of O
anti I-GENE
- I-GENE
HCV I-GENE
- I-GENE
C100 NUMERIC
- I-GENE
3 I-GENE
among O
primary O
blood O
donors O
in O
Moscow RARE
was O
1 O
. O
37 O
% O
and O
was O
not O
different O
from O
that O
among O
HBsAg I-GENE
carriers O
( O
1 O
. O
8 O
%) O
and O
among O
donors O
with O
anti I-GENE
- I-GENE
HCV I-GENE
- I-GENE
C100 NUMERIC
- I-GENE
3 I-GENE
in O
the O
blood O
( O
1 O
. O
6 O
%) O
( O
p O
< O
0 O
. O
01 O
). O

We O
examined O
the O
hypothesis O
that O
the O
coronary O
vasomotor RARE
responses O
to O
etomidate RARE
( O
ETO ALLCAPS
), O
propofol RARE
( O
PRO ALLCAPS
), O
and O
sodium O
thiopental RARE
( O
STP ALLCAPS
) O
are O
mediated O
through O
contrasting RARE
effects O
on O
the O
resting O
nitric O
oxide O
( O
NO O
)- O
dependent O
vasodilator O
tone O
that O
opposes RARE
adrenergic O
vasoconstrictor RARE
activity O
in O
the O
intact O
dog O
. O

Significant O
alterations O
in O
CBC ALLCAPS
results O
and O
serum I-GENE
CRP I-GENE
concentration O
, O
compared O
with O
baseline O
values O
, O
were O
lacking O
in O
dogs O
of O
the O
control O
group O
. O

These O
alternative O
splice O
variants O
were O
detected O
in O
RNA O
isolated O
from O
several O
sources O
, O
including O
primary O
leptomeningeal RARE
tissue O
and O
an O
established O
line O
of O
leptomeningeal RARE
cells O
( O
LMC ALLCAPS
). O

Roux RARE
- O
en O
- O
Y O
gastroenterostomy RARE
severely O
disturbs RARE
emptying O
of O
the O
gallbladder O
. O

Surface RARE
- O
coil O
experiments O
on O
phantoms RARE
and O
on O
human O
calf O
muscles O
in O
vivo O
are O
presented O
. O

Large O
interpatient RARE
variation O
in O
peak O
PCZ ALLCAPS
plasma O
levels O
( O
91 O
- O
3215 NUMERIC
ng O
/ O
ml O
) O
was O
seen O
, O
with O
the O
plasma O
half O
- O
life O
( O
t1 O
/ O
2 O
alpha O
) O
being O
approximately O
57 O
min O
in O
patients O
given O
135 O
- O
180 O
mg O
/ O
m2 O
PCZ ALLCAPS
. O

The O
maximal O
effect O
was O
seen O
at O
100 O
ng O
/ O
ml O
EGF I-GENE
, O
with O
a O
time O
lag RARE
of O
about O
5 O
h O
. O

KAR1 NUMERIC
encodes O
an O
essential O
component O
of O
the O
yeast O
spindle O
pole O
body O
( O
SPB O
) O
that O
is O
required O
for O
karyogamy RARE
and O
SPB O
duplication O
. O

CDC31 NUMERIC
is O
required O
for O
SPB O
duplication O
and O
encodes O
a O
calmodulin I-GENE
- I-GENE
like I-GENE
protein I-GENE
that O
is O
most O
closely O
related O
to O
caltractin RARE
/ O
centrin RARE
, O
a O
protein O
associated O
with O
the O
Chlamydomonas RARE
basal O
body O
. O

During O
transcript O
elongation O
, O
the O
sizes O
of O
the O
DNA O
footprint O
and O
the O
single O
- O
stranded O
transcription O
bubble RARE
vary O
markedly O
among O
transcription O
complexes O
halted RARE
at O
different O
template O
positions O
. O

The O
newly O
recognised RARE
skeletogenital RARE
syndrome O
. O

All O
our O
patients O
had O
polyps O
, O
23 O
( O
54 O
%) O
had O
asthma O
, O
12 O
( O
27 O
%) O
had O
aspirin O
sensitivity O
, O
20 O
( O
65 O
%) O
had O
eosinophilia RARE
, O
and O
9 O
( O
69 O
%) O
had O
increased O
total O
IgE I-GENE
levels O
. O

Ras I-GENE
- I-GENE
and I-GENE
ultra RARE
- I-GENE
violet RARE
- I-GENE
responsive I-GENE
protein I-GENE
kinases I-GENE
that O
phosphorylate O
c I-GENE
- I-GENE
Jun I-GENE
on O
serine O
residues O
at O
positions O
63 O
and O
73 O
and O
stimulate O
its O
transcriptional O
activity O
have O
been O
identified O
. O

A O
short O
sequence O
surrounding O
the O
major O
JNK I-GENE
phosphorylation O
site O
of O
c I-GENE
- I-GENE
Jun I-GENE
is O
conserved O
in O
c I-GENE
- I-GENE
Fos I-GENE
and O
is O
part O
of O
its O
activation O
domain O
, O
suggesting O
that O
c I-GENE
- I-GENE
Fos I-GENE
may O
be O
similarly O
regulated O
. O

c I-GENE
- I-GENE
Fos I-GENE
transcriptional O
activity O
stimulated O
by O
H I-GENE
- I-GENE
Ras I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
distinct O
from O
JNK I-GENE
and O
ERK I-GENE
. O

A O
new O
generation O
of O
information O
retrieval RARE
tools O
for O
biologists RARE
: O
the O
example O
of O
the O
ExPASy RARE
WWW ALLCAPS
server RARE
. O

Essential RARE
features O
of O
this O
model O
are O
bending RARE
of O
the O
DNA O
double O
helix O
and O
contact O
of O
operator O
sites O
with O
repressor O
domains O
bearing O
sequence O
homologies O
with O
the O
helix O
- O
turn O
- O
helix O
( O
HTH ALLCAPS
) O
motifs O
of O
other O
DNA O
- O
binding O
proteins O
. O

The O
partial O
ORF O
was O
found O
to O
be O
identical O
to O
the O
C O
terminus O
of O
HrpJ2 NUMERIC
. O

The O
partial O
ORF O
was O
found O
to O
be O
identical O
to O
the O
C O
terminus O
of O
HrpJ2 NUMERIC
. O

The O
binding O
of O
transcription O
factor O
AP I-GENE
- I-GENE
1 I-GENE
and O
vitamin I-GENE
D I-GENE
receptor I-GENE
( O
VDR I-GENE
) O
to O
the O
composite O
AP I-GENE
- I-GENE
1 I-GENE
plus I-GENE
vitamin I-GENE
- I-GENE
D I-GENE
- I-GENE
responsive I-GENE
promoter I-GENE
region O
( O
AP I-GENE
- I-GENE
1 I-GENE
+ I-GENE
VDRE I-GENE
) O
of O
the O
human I-GENE
osteocalcin RARE
gene I-GENE
was O
characterized O
in O
osteocalcin RARE
- O
producing O
( O
MG ALLCAPS
- O
63 O
) O
and O
non O
- O
producing O
( O
U2 O
- O
Os RARE
, O
SaOs RARE
- O
2 O
) O
human O
osteosarcoma O
cell O
lines O
. O

Rapid RARE
detection O
of O
this O
mutation O
is O
achieved O
by O
restriction O
digestion O
of O
PCR O
- O
amplified O
genomic O
DNA O
; O
a O
mismatch RARE
primer O
combined O
with O
the O
point O
mutation O
creates RARE
a O
Tru9I NUMERIC
restriction I-GENE
site I-GENE
. O

Wild I-GENE
type I-GENE
and I-GENE
mutant I-GENE
Epo I-GENE
cDNAs I-GENE
were O
transiently O
expressed O
at O
high O
levels O
in O
COS1 NUMERIC
and O
COS7 NUMERIC
cells O
. O

OBJECTIVE O
-- O
To O
assess O
the O
risk O
of O
hepatitis O
A O
in O
international RARE
travelers RARE
and O
to O
recommend RARE
preventive RARE
measures O
. O

The O
bactericidal O
effect O
of O
disinfectants RARE
against O
biofilm RARE
cells O
was O
found O
to O
be O
considerably O
enhanced O
by O
increasing O
the O
concentrations O
of O
the O
disinfectants RARE
. O

Expression O
of O
ME31B NUMERIC
cDNA I-GENE
in O
S O
. O
pombe O
suppresses O
the O
ste13 NUMERIC
mutation O
. O

Use O
of O
Medi RARE
- O
Jector RARE
EZ ALLCAPS
dermojet RARE
for O
anesthesia O
in O
minor O
surgery O

2 O
. O

The O
immune O
response O
of O
past O
- O
infection O
of O
cytomegalovirus O
in O
the O
patients O
of O
RTID ALLCAPS
is O
rather O
remarkable O
. O

Acupuncture RARE
effect O
on O
deep O
receptors O
was O
not O
limited O
to O
one O
point O
but O
within O
a O
certain O
area O
, O
namely O
distant O
effect O
existed O
. O

Reduced RARE
NK O
activity O
correlates O
with O
active O
disease O
in O
HIV O
- O
patients O
with O
multidrug O
- O
resistant O
pulmonary O
tuberculosis O
. O

Smoking RARE
history O
and O
awake RARE
oxygen O
saturation O
( O
SaO2 O
) O
was O
recorded O
in O
all O
of O
them O
. O

( O
LH I-GENE
P O
< O
0 O
. O
05 O
, O
LH I-GENE
/ O
FSH I-GENE
P O
< O
0 O
. O
01 O
). O

The O
relative O
R O
- O
and O
L O
- O
brain O
weights O
were O
found O
to O
be O
inversely O
related O
to O
the O
relative O
R O
- O
L O
brain O
weight O
only O
in O
the O
RH O
female O
cats O
with O
R O
- O
L O
brain O
weight O
smaller O
than O
zero O
( O
testosterone O
in O
males O
, O
estrogen O
in O
females O
). O

This O
mode O
of O
ternary O
complex O
formation O
is O
in O
contrast O
to O
the O
one O
seen O
in O
the O
promoter O
of O
the O
c I-GENE
- I-GENE
fos I-GENE
protooncogene I-GENE
, O
where O
formation O
of O
the O
ternary O
complex O
is O
dependent O
on O
the O
prior O
assembly O
of O
the O
serum I-GENE
response I-GENE
factor I-GENE
- I-GENE
DNA I-GENE
binary RARE
complex I-GENE
. O

The O
LTR O
- O
binding O
activities O
of O
VBP ALLCAPS
, O
a1 NUMERIC
/ I-GENE
EBP I-GENE
, O
and O
B I-GENE
- I-GENE
cell I-GENE
nuclear I-GENE
extract I-GENE
protein I-GENE
were O
compared O
and O
mapped O
by O
gel O
shift O
, O
DNase I-GENE
I I-GENE
footprinting O
, O
and O
methylation O
interference O
assays O
. O

These O
results O
suggest O
that O
leader O
- O
mRNA O
fusion O
in O
coronavirus O
transcription O
does O
not O
require O
direct O
RNA O
- O
RNA O
interaction O
between O
complementary O
sequences O
. O

These O
results O
suggest O
that O
leader O
- O
mRNA O
fusion O
in O
coronavirus O
transcription O
does O
not O
require O
direct O
RNA O
- O
RNA O
interaction O
between O
complementary O
sequences O
. O

Vaccinia RARE
virus O
- O
expressed O
, O
purified O
full I-GENE
- I-GENE
length I-GENE
HPV I-GENE
- I-GENE
16 I-GENE
and I-GENE
BPV I-GENE
- I-GENE
1 I-GENE
E2 I-GENE
proteins I-GENE
bound O
a O
consensus O
E2 I-GENE
site I-GENE
with O
high O
specific O
affinities O
( O
Kd RARE
= O
approximately O
10 O
(- O
9 O
) O
M O
) O
and O
stimulated O
in O
vitro O
transcription O
up O
to O
six O
- O
to O
eightfold RARE
. O

This O
alternatively O
spliced O
transcript O
contained O
an O
open O
reading O
frame O
extending O
from O
the O
upstream O
J O
alpha O
11 O
- O
2 O
region O
to O
82 O
nucleotides O
downstream O
of O
the O
beginning O
of O
the O
TCR I-GENE
C I-GENE
alpha I-GENE
region I-GENE
, O
and O
potentially O
encoded O
a O
36 O
amino O
acid O
polypeptide O
. O

In O
HeLa O
x O
fibroblast O
cell O
hybrids O
its O
expression O
correlates O
with O
tumorigenicity RARE
. O

Demographic RARE
characteristics O
and O
risk O
factor O
data O
for O
76 O
, O
672 NUMERIC
clients RARE
were O
studied O
to O
characterize O
the O
distribution O
of O
infection O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
and O
the O
use O
of O
counseling RARE
and O
testing O
facilities RARE
in O
Houston RARE
, O
Tex RARE
. O

Results O
indicate O
that O
KNM ALLCAPS
- O
LU ALLCAPS
335 NUMERIC
differs O
from O
both O
human O
and O
chimpanzee RARE
M1s NUMERIC
in O
relative O
distances O
( O
measured O
in O
three O
dimensions O
) O
between O
crown RARE
fissure RARE
termini O
. O

We O
describe O
49 O
cases O
with O
papillary RARE
tumor O
< O
1 O
cm O
. O

Comparison O
with O
the O
bovine O
gene O
showed O
that O
the O
5 O
'- O
flanking O
region O
of O
the O
hATP1 NUMERIC
gene I-GENE
has O
an O
unconserved RARE
guanine O
- O
cytosine O
( O
GC O
) O
rich O
region O
, O
including O
several O
binding O
motifs O
of O
transcriptional O
factors O
, O
such O
as O
Sp1 I-GENE
, O
AP I-GENE
- I-GENE
2 I-GENE
, O
and O
GCF ALLCAPS
. O

Structure O
, O
promoter O
analysis O
and O
chromosomal O
assignment O
of O
the O
human I-GENE
APEX ALLCAPS
gene I-GENE
. O

The O
polyubiquitin RARE
gene I-GENE
was O
transcribed O
throughout O
the O
Volvox RARE
life O
cycle O
with O
peaks O
in O
the O
1 O
. O
6 O
- O
kb O
mRNA O
levels O
during O
pre O
- O
cleavage O
, O
cleavage O
, O
and O
post O
- O
inversion O
. O

Thus O
, O
in O
stress O
- O
induced O
arrhythmic RARE
disease O
as O
well O
as O
in O
ischemic O
heart O
disease O
, O
the O
main O
pathogenetic RARE
links O
are O
outside O
the O
heart O
, O
but O
they O
differ O
from O
those O
observed O
in O
ischemia O
. O

Here O
, O
we O
present O
genetic O
evidence O
in O
Saccharomyces O
cerevisiae O
for O
a O
functional O
interaction O
between O
the O
DEAH ALLCAPS
protein I-GENE
Prp16 NUMERIC
, O
and O
the O
U6 I-GENE
and O
U2 I-GENE
spliceosomal RARE
snRNAs RARE
. O

The O
consensus O
gene O
order O
deduced O
by O
combining RARE
data O
from O
both O
crosses RARE
is O
D2Mit1 NUMERIC
-( O
Dbh RARE
, O
Notch1 NUMERIC
)-( RARE
Col5a1 NUMERIC
, O
Rxra RARE
)- O
Spna2 NUMERIC
- O
Ab I-GENE
l I-GENE
-( O
Ak1 NUMERIC
, O
Fpgs RARE
)- O
( O
Grp78 NUMERIC
, O
Pbx3 NUMERIC
)-( RARE
Epb7 NUMERIC
. I-GENE
2 I-GENE
, I-GENE
Hc RARE
, I-GENE
Gsn RARE
)- O
Acra RARE
. O

The O
high O
level O
of O
transformation O
- O
associated O
deletions O
in O
the O
human O
YACs O
was O
reduced O
over O
10 O
- O
fold O
when O
the O
host O
was O
a O
recombination O
- O
deficient O
strain O
deleted O
for O
the O
RAD52 NUMERIC
gene I-GENE
. O

In O
addition O
, O
the O
megabase RARE
region O
surrounding O
the O
dagA LASTCAP
locus I-GENE
was O
mapped O
. O

These O
mutants O
had O
deletions O
of O
the O
extreme O
amino O
- O
terminal O
residues O
as O
far O
as O
amino O
acid O
residue O
30 O
. O

SECONDARY ALLCAPS
OUTCOME O
MEASURE ALLCAPS
-- O
Double O
- O
blind O
caffeine O
- O
withdrawal O
evaluation O
. O

Elimination O
of O
natural O
antibodies O
in O
discordant RARE
xenografts RARE

An O
8 O
- O
bp O
sequence O
( O
ATTTCAAA ALLCAPS
) O
within O
the O
protected O
region O
shares O
significant O
homology O
with O
promoter O
sequences O
required O
for O
ethylene O
responsiveness O
from O
the O
tomato O
fruit RARE
- O
ripening RARE
E4 NUMERIC
gene I-GENE
. O

We O
present O
evidence O
that O
DNA I-GENE
polymerase I-GENE
delta I-GENE
of I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
, O
an O
enzyme O
that O
is O
essential O
for O
viability O
and O
chromosomal O
replication O
, O
is O
also O
required O
for O
base O
excision O
repair O
of O
exogenous O
DNA O
methylation O
damage O
. O

We O
have O
identified O
two O
Marek RARE
' O
s O
Disease RARE
Virus RARE
( O
MDV O
) O
genes O
within O
the O
EcoRI I-GENE
- I-GENE
B I-GENE
fragment I-GENE
of O
MDV O
- O
GA O
genomic O
DNA O
. O

Cowpox RARE
virus O
contains O
two O
copies O
of O
an O
early I-GENE
gene I-GENE
encoding O
a O
soluble O
secreted O
form O
of O
the O
type I-GENE
II I-GENE
TNF I-GENE
receptor I-GENE
. O

To O
determine O
whether O
P35 NUMERIC
could O
activate O
the O
39k NUMERIC
promoter O
in O
the O
absence O
of O
IE1 I-GENE
, O
the O
p35 NUMERIC
open O
reading O
frame O
was O
cloned O
under O
the O
control O
of O
the O
ie1 NUMERIC
promoter I-GENE
. O

Mutagenesis RARE
of O
each O
NRF ALLCAPS
- I-GENE
1 I-GENE
motif I-GENE
in O
the O
ALAS ALLCAPS
promoter I-GENE
gave O
substantially O
lowered O
levels O
of O
chloramphenicol I-GENE
acetyltransferase I-GENE
expression O
, O
whereas O
mutagenesis O
of O
both O
NRF ALLCAPS
- I-GENE
1 I-GENE
motifs I-GENE
resulted O
in O
the O
almost O
complete O
loss O
of O
expression O
. O

DNase I-GENE
I I-GENE
footprinting O
analysis O
indicated O
that O
DREF ALLCAPS
binds O
to O
the O
24 O
- O
bp O
DRE O
region O
of O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
gene I-GENE
in O
which O
8 O
- O
bp O
palindromic O
sequences O
are O
centered O
. O

Novel RARE
8 O
- O
base O
pair O
sequence O
( O
Drosophila O
DNA O
replication O
- O
related O
element O
) O
and O
specific O
binding O
factor O
involved O
in O
the O
expression O
of O
Drosophila O
genes O
for O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
and O
proliferating I-GENE
cell I-GENE
nuclear I-GENE
antigen I-GENE
. O

In O
addition O
, O
a O
microsatellite O
repeat O
polymorphism O
with O
a O
heterozygosity O
of O
71 O
% O
at O
the O
RET I-GENE
locus I-GENE
and O
a O
restriction O
fragment O
length O
polymorphism O
with O
a O
heterozygosity O
of O
42 O
% O
detected O
by O
a O
lambda O
clone O
from O
the O
D10S94 NUMERIC
locus I-GENE
have O
been O
developed O
for O
high O
- O
resolution O
genetic O
linkage O
mapping O
and O
predictive O
diagnostic O
testing O
. O

However O
, O
tyrA LASTCAP
can O
be O
expressed O
efficiently O
from O
an O
internal O
promoter O
which O
appears O
to O
lie RARE
within O
the O
3 O
' O
portion O
of O
aroF LASTCAP
. O

Within O
the O
span O
of O
attenuator RARE
region O
encoding O
the O
three O
stem O
- O
loop O
structures O
of O
mRNA O
secondary O
configuration O
, O
hot O
spots O
of O
base O
- O
residue O
divergence O
were O
localized O
to O
looped RARE
- O
out O
regions O
. O

Most O
, O
however O
, O
would O
tell RARE
the O
spouse RARE
the O
full O
truth RARE
about O
both O
diagnosis O
and O
prognosis O
. O

Previous O
studies O
showed O
that O
mutations O
in O
the O
6K NUMERIC
protein O
led O
to O
the O
slow O
release O
of O
aberrant O
, O
multi O
- O
cored RARE
infectious O
virions O
. O

Metabolism RARE
of O
calcium O
and O
vitamin O
D3 O
in O
patients O
with O
acute O
tubulointerstitial RARE
nephritis RARE
: O
a O
study O
of O
41 O
patients O
with O
nephropathia RARE
epidemica RARE
. O

Furthermore O
, O
this O
study O
demonstrates O
that O
reduced O
inotropy RARE
with O
timolol RARE
helped RARE
uniform O
local O
contraction O
as O
estimated O
by O
the O
increased O
LONG ALLCAPS
/ O
CIRC ALLCAPS
ratio O
, O
a O
transition O
that O
could O
improve O
contraction O
efficacy O
. O

Effects O
of O
moderate O
hypercapnia O
on O
hypothermia O
induced O
by O
cold O
He O
- O
O2 O
in O
rats O
. O

The O
RFLP ALLCAPS
patterns O
of O
the O
isolates O
from O
six O
of O
these O
patients O
remained O
essentially O
unchanged O
( O
two O
strains O
showed O
one O
additional O
band O
) O
despite O
the O
development O
of O
drug O
resistance O
. O

We O
recommend RARE
that O
ovarian O
stimulation O
is O
done O
only O
if O
there O
is O
a O
valid RARE
indication O
after O
proper O
assessment O
of O
the O
ovaries RARE
, O
and O
that O
women O
who O
have O
had O
ovarian O
stimulation O
are O
followed O
for O
longer O
than O
at O
present O
. O

A23187 NUMERIC
did O
not O
induce O
any O
modifications O
of O
the O
endolymphatic RARE
potential O
, O
the O
ampullar RARE
direct O
current O
or O
the O
frequency O
of O
the O
evoked O
afferent RARE
spikes O
. O

Activation O
of O
the O
aboral RARE
ectoderm RARE
- I-GENE
specific I-GENE
Spec2a NUMERIC
gene I-GENE
in O
blastula RARE
- O
stage O
sea O
urchin O
embryos O
requires O
an O
upstream O
regulatory O
region O
that O
is O
part O
of O
a O
repetitive O
sequence O
element O
( O
RSR ALLCAPS
) O
associated O
with O
all O
Spec1 NUMERIC
/ O
Spec2 NUMERIC
genes O
. O

A O
transcript O
of O
about O
2 O
kb O
is O
expected O
for O
each O
PPO ALLCAPS
. O

Mutations O
in O
a O
region O
located O
15 O
to O
30 O
bp O
downstream O
from O
the O
major O
transcription O
start O
site O
that O
shows O
good O
homology O
to O
a O
sequence O
in O
the O
first O
exon O
of O
c I-GENE
- I-GENE
fos I-GENE
implicated O
as O
a O
negative O
regulatory O
element O
resulted O
in O
a O
significant O
increase O
in O
basal O
gene O
expression O
but O
did O
not O
affect O
regulation O
. O

Salazopyrine RARE
desensitization RARE

During O
exercise O
, O
the O
Pes RARE
- O
Ves RARE
relation O
was O
shifted O
toward O
the O
left O
and O
the O
slope O
[ O
end O
- O
systolic O
elastance RARE
( O
Ees RARE
)] O
increased O
from O
7 O
. O
7 O
+/- O
2 O
. O
8 O
to O
12 O
. O
7 O
+/- O
4 O
. O
2 O
( O
SD O
) O
mmHg O
/ O
ml O
( O
P O
< O
0 O
. O
05 O
). O

We O
show O
that O
HRI ALLCAPS
and O
dsRNA I-GENE
- I-GENE
PK I-GENE
phosphorylate O
yeast I-GENE
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
in O
vitro O
and O
in O
vivo O
and O
functionally O
substitute O
for O
GCN2 I-GENE
protein I-GENE
to O
stimulate O
GCN4 I-GENE
translation O
in O
yeast O
. O

Double O
- O
staining O
confirmed O
that O
there O
were O
separate O
populations O
of O
CD68 NUMERIC
- O
positive O
macrophages O
and O
XIIIa RARE
- O
positive O
dendrocytes RARE
. O

Interestingly O
, O
in O
the O
adult O
, O
transgene RARE
expression O
patterns O
within O
the O
cerebellum RARE
in O
two O
lines O
appeared O
to O
mark RARE
distinct O
anterior O
- O
posterior O
compartments RARE
. O

Southern O
analysis O
on O
genomic O
DNA O
isolated O
from O
tissues O
and O
cell O
lines O
from O
several O
mouse O
strains O
using O
mCD22 NUMERIC
cDNA I-GENE
demonstrated O
that O
the O
Cd22 NUMERIC
locus I-GENE
encoding O
mCD22 NUMERIC
is O
a O
single O
copy O
gene O
of O
< O
or O
= O
30 O
kb O
. O

The O
concentrations O
of O
plasma O
ACTH I-GENE
and O
cortisol O
increased O
by O
40 O
% O
and O
60 O
% O
after O
MPTP ALLCAPS
treatment O
, O
respectively O
. O

Instead O
, O
the O
results O
support O
the O
idea O
that O
Pc RARE
group I-GENE
products I-GENE
provide O
stable O
memory O
or O
imprinting O
of O
boundaries O
which O
are O
initially O
specified O
by O
gap RARE
and O
pair O
- O
rule RARE
regulators O
. O

To O
investigate O
the O
regulation O
of O
expression O
of O
the O
human I-GENE
mdr1 NUMERIC
gene I-GENE
, O
the O
response O
of O
the O
mdr1 NUMERIC
promoter I-GENE
to O
signals O
involved O
in O
cell O
proliferation O
was O
examined O
. O

The O
tyrosine I-GENE
hydroxylase I-GENE
gene I-GENE
( O
TH I-GENE
) O
contains O
a O
single O
copy O
of O
a O
consensus O
CRE O
at O
- O
45 O
to O
- O
38 O
base O
pair O
( O
bp O
) O
upstream O
of O
the O
transcription O
initiation O
site O
. O

Tobacco RARE
mosaic O
virus O
- O
infected O
tobacco O
( O
Nicotiana RARE
tabacum RARE
var O
. O

Through RARE
a O
stretch O
of O
56 O
amino O
acids O
, O
constituting RARE
the O
MADS I-GENE
domain I-GENE
, O
the O
two O
proteins O
are O
identical O
except O
for O
two O
conservative O
amino O
acid O
substitutions O
. O

Isolation O
and O
characterization O
of O
SRF I-GENE
accessory I-GENE
proteins I-GENE
. O

These O
data O
suggest O
that O
: O
( O
a O
) O
proSRIF LASTCAP
cleavage O
is O
initiated O
in O
the O
TGN ALLCAPS
, O
and O
( O
b O
) O
this O
reaction O
requires O
an O
acidic O
pH O
which O
is O
facilitated O
by O
a O
Golgi I-GENE
- I-GENE
associated I-GENE
vacuolar I-GENE
- I-GENE
type I-GENE
ATPase I-GENE
. O

Fenoldopam RARE
, O
a O
dopamine I-GENE
receptor I-GENE
agonist O
, O
has O
been O
shown O
, O
in O
animal O
experiments O
, O
to O
improve O
renal O
perfusion O
. O

Clinical O
aspects O
of O
early O
increase O
in O
serum O
gamma I-GENE
- I-GENE
glutamyl I-GENE
transferase I-GENE
in O
cerebral O
infarction O
. O

In O
the O
3 O
' O
flanking O
region O
of O
the O
27 I-GENE
kDa I-GENE
zein RARE
gene I-GENE
, O
several O
AATAAA ALLCAPS
- O
like O
sequences O
and O
a O
sequence O
resembling O
the O
mammalian O
GT O
- O
rich O
sequence O
are O
present O
around O
the O
polyadenylation O
sites O
. O

The O
indoor RARE
radon RARE
concentration O
in O
the O
summer O
( O
1990 O
) O
period O
ranged O
between O
8 O
and O
81 O
Bq RARE
m O
- O
3 O
, O
while O
in O
the O
winter RARE
( O
1989 O
- O
1990 O
) O
it O
ranged O
between O
20 O
and O
143 O
Bq RARE
m O
- O
3 O
for O
the O
first O
year O
of O
measurements O
or O
between O
8 O
and O
92 O
Bq RARE
m O
- O
3 O
in O
the O
summer O
( O
1991 O
) O
period O
and O
between O
12 O
and O
119 O
Bq RARE
m O
- O
3 O
in O
the O
winter RARE
( O
1990 O
- O
1991 O
) O
for O
the O
second O
year O
of O
measurements O
. O

The O
results O
indicate O
that O
hrpRS LASTCAP
and O
hrpL LASTCAP
are O
part O
of O
a O
regulatory O
cascade O
in O
which O
HrpR LASTCAP
and O
HrpS LASTCAP
activate O
expression O
of O
hrpL LASTCAP
and O
HrpL LASTCAP
, O
a O
putative O
sigma I-GENE
factor I-GENE
, O
induces O
expression O
of O
HrpL LASTCAP
- I-GENE
responsive I-GENE
genes I-GENE
. O

DtxR LASTCAP
is O
an O
iron O
- O
dependent O
sequence O
- O
specific O
DNA O
- O
binding O
protein O
that O
binds O
to O
the O
tox RARE
operator I-GENE
, O
an O
inverted O
- O
repeat O
nucleotide O
sequence O
located O
upstream O
from O
the O
diphtheria RARE
toxin I-GENE
gene I-GENE
. O

Vasopressin RARE
( O
AVP I-GENE
), O
the O
antidiuretic RARE
hormone O
, O
is O
a O
cyclic O
nonapeptide RARE
that O
acts O
through O
binding O
to O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
specific I-GENE
membrane I-GENE
receptors I-GENE
pharmacologically RARE
divided O
into O
three O
subtypes O
( O
V1a NUMERIC
, O
V1b NUMERIC
, O
and O
V2 I-GENE
) O
linked O
to O
distinct O
second O
messengers RARE
. O

These O
results O
confirmed O
that O
cleavage O
of O
the O
leader O
peptide O
is O
the O
last O
step O
in O
nisin RARE
maturation O
and O
is O
necessary O
to O
generate O
a O
biologically O
active O
peptide O
. O

When O
the O
promoter O
region O
was O
linked O
with O
a O
heterologous O
reporter O
gene O
, O
we O
found O
that O
the O
promoter O
region O
is O
inducible O
by O
both O
interferons RARE
( O
interferon I-GENE
- I-GENE
alpha I-GENE
and I-GENE
- I-GENE
gamma I-GENE
) O
and O
interferon I-GENE
regulatory I-GENE
factor I-GENE
1 I-GENE
. O

Anti I-GENE
- I-GENE
B I-GENE
. I-GENE
burgdorferi RARE
, O
anti I-GENE
- I-GENE
B I-GENE
. I-GENE
turicatae RARE
and O
anti I-GENE
- I-GENE
B I-GENE
. I-GENE
parkeri RARE
antibodies I-GENE
, O
tested O
by O
the O
indirect O
immunofluorescent RARE
assay O
( O
IFA ALLCAPS
), O
were O
detected O
in O
10 O
. O
8 O
, O
16 O
. O
1 O
and O
8 O
. O
2 O
% O
of O
the O
serum O
samples O
tested O
, O
and O
confirmed O
by O
IFA ALLCAPS
- O
ABS ALLCAPS
in O
1 O
. O
3 O
, O
1 O
. O
3 O
and O
1 O
. O
0 O
%, O
respectively O
. O

The O
approach O
derives RARE
from O
a O
recently O
described O
strategy O
for O
making O
recombinants O
from O
five O
overlapping O
EBV O
cosmid O
- O
cloned O
DNAs O
( O
B O
. O

Evaluation O
of O
desmopressin RARE
for O
dental O
extractions RARE
in O
patients O
with O
hemostatic RARE
disorders O
. O

Comparative O
analysis O
with O
an O
antiandrogen RARE
niftolid RARE
and O
synthetic I-GENE
GnRH I-GENE
was O
carried O
out O
in O
22 O
normal O
subjects O
, O
14 O
patients O
with O
primary O
and O
20 O
ones O
with O
secondary O
hypogonadism RARE
, O
and O
in O
5 O
patients O
with O
clinical O
signs O
of O
gonadal RARE
insufficiency O
and O
obscure RARE
diagnosis O
in O
order O
to O
elucidate O
the O
pituitary I-GENE
gonadotropin I-GENE
reserves RARE
. O

All O
other O
normal O
and O
transformed O
lymphoid O
and O
nonlymphoid RARE
cell O
lines O
and O
normal O
tissues O
were O
negative O
for O
PANG ALLCAPS
expression O
except O
for O
the O
brain O
, O
wherein RARE
unique O
4 O
. O
0 O
- O
and O
6 O
. O
1 O
- O
kb O
transcripts O
were O
detected O
. O

The O
cis O
- O
acting O
regulatory O
properties O
of O
an O
872 NUMERIC
bp O
promoter O
fragment O
of O
a O
B O
. O
napus O
oleosin RARE
gene I-GENE
were O
examined O
by O
analysis O
of O
beta I-GENE
- I-GENE
glucuronidase I-GENE
( O
GUS I-GENE
) O
expression O
in O
transgenic O
tobacco O
plants O
containing O
an O
oleosin RARE
promoter I-GENE
- O
GUS I-GENE
transcriptional O
fusion O
. O

This O
indicates O
that O
the O
mechanism O
by O
which O
CX ALLCAPS
blocks O
rapid O
degradation O
of O
tubulin RARE
mRNA I-GENE
in O
vivo O
is O
not O
simply RARE
by O
preventing O
its O
translation O
and O
suggests O
the O
involvement O
of O
an O
altered O
trans O
- O
factor O
. O

L O
., O
Greer RARE
, O
J O
. O
& O
Carter RARE
, O
G O
. O

Increasing O
the O
extracellular O
calcium O
concentration O
enhanced O
detrusor RARE
contractility O
in O
a O
dose O
- O
dependent O
manner O
in O
both O
control O
and O
obstructed RARE
bladders RARE
. O

Structural O
organization O
of O
the O
gene O
encoding O
the O
human I-GENE
lipocalin RARE
tear I-GENE
prealbumin RARE
and O
synthesis O
of O
the O
recombinant O
protein O
in O
Escherichia O
coli O
. O

The O
sequence O
has O
a O
1092 NUMERIC
- O
bp O
open O
reading O
frame O
encoding O
a O
protein O
of O
364 NUMERIC
amino O
acids O
. O

Western O
blotting O
( O
immunoblotting RARE
) O
with O
an O
antiserum O
to O
a O
partial O
SOD I-GENE
expressed O
in O
Escherichia O
coli O
revealed O
two O
proteins O
with O
estimated O
molecular O
masses O
of O
19 O
and O
29 O
kDa O
. O

The O
gene O
organization O
of O
CRSV ALLCAPS
RNA I-GENE
- I-GENE
1 I-GENE
is O
similar O
to O
those O
of O
red O
clover RARE
necrotic RARE
mosaic O
( O
RCNMV ALLCAPS
) O
and O
sweet RARE
clover RARE
necrotic RARE
mosaic O
( O
SCNMV ALLCAPS
) O
dianthoviruses RARE
with O
the O
exception O
that O
CRSV ALLCAPS
RNA I-GENE
- I-GENE
1 I-GENE
contains O
the O
additional O
3 O
'- O
terminal O
ORF O
. O

Members O
of O
the O
myocyte I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
factor I-GENE
2 I-GENE
( O
MEF2 I-GENE
) O
family O
of O
transcription O
factors O
bind O
a O
conserved O
A O
/ O
T O
- O
rich O
sequence O
in O
the O
control O
regions O
of O
numerous O
muscle O
- O
specific O
genes O
. O

We O
have O
previously O
shown O
that O
LBP ALLCAPS
- I-GENE
1 I-GENE
represses O
HIV O
- O
1 O
transcription O
by O
inhibiting O
the O
binding O
of O
TFIID I-GENE
to O
the O
TATA O
box O
. O

These O
results O
illustrate RARE
an O
important O
role O
for O
La I-GENE
in O
RNA O
production O
by O
demonstrating O
its O
ability O
to O
clear O
the O
termination O
sites O
of O
class O
III O
templates O
, O
thereby O
promoting O
efficient O
use O
of O
transcription O
complexes O
by O
pol I-GENE
III I-GENE
. O

The O
films O
were O
analyzed O
using O
a O
scanning O
helium RARE
- O
neon RARE
laser O
densitometer RARE
with O
a O
small O
aperture RARE
of O
5 O
- O
10 O
microns O
. O

The O
GafChromic RARE
method O
has O
proven O
to O
be O
an O
accurate O
and O
rapid O
method O
of O
analysis O
and O
could O
be O
easily O
incorporated O
into O
a O
quality O
assurance RARE
program O
. O

Viral RARE
genomic O
RNA O
for O
these O
reactions O
was O
obtained O
directly O
from O
fecal O
specimens O
of O
infected O
infant O
rats O
. O

GATA I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
was O
present O
in O
equivalent O
levels O
in O
both O
erythroid O
cell O
lines O
, O
but O
at O
a O
low O
level O
in O
FDC ALLCAPS
- O
P1 O
cells O
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
alpha I-GENE
) O
is O
one O
of O
several O
autocrine O
/ O
paracrine RARE
factors O
known O
to O
exert O
potent O
inhibitory O
effects O
on O
bone O
. O

We O
have O
investigated O
the O
role O
of O
cellular I-GENE
p21ras I-GENE
protein I-GENE
in O
insulin I-GENE
and O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
signaling O
pathways O
. O

The O
lack O
of O
the O
C2 I-GENE
domain O
of O
the O
Ca I-GENE
( I-GENE
2 I-GENE
+)- I-GENE
dependent I-GENE
PKCs RARE
and O
the O
presence O
of O
a O
unique O
NH2 O
- O
terminal O
sequence O
with O
a O
potential O
signal O
peptide O
and O
a O
transmembrane O
domain O
suggest O
that O
PKC I-GENE
mu I-GENE
is O
a O
novel O
member O
of O
the O
subgroup O
of O
atypical O
PKCs RARE
. O

Moreover O
, O
we O
observed O
that O
the O
function O
of O
T3R I-GENE
- O
RXR I-GENE
heterodimers O
on O
response O
elements O
composed O
of O
two O
half O
- O
sites O
in O
a O
directly O
repeated O
orientation O
spaced RARE
by O
4 O
nucleotides O
is O
determined O
in O
major O
parts O
by O
the O
5 O
'- O
flanking O
sequence O
of O
the O
upstream O
half O
- O
site O
. O

However O
, O
three O
Hm1 NUMERIC
mutants I-GENE
that O
were O
moderately O
deficient O
in O
stimulating O
PI O
turnover O
displayed O
normal O
sequestration RARE
, O
suggesting O
distinct O
mechanisms O
. O

Furthermore O
, O
in O
vitro O
decay O
reaction O
mixtures RARE
supplemented O
with O
the O
20 O
- O
nt O
sense O
RNA O
transcript O
resulted O
in O
stabilization O
of O
R2 I-GENE
message I-GENE
. O

Deletion O
analyses O
of O
the O
pCD41 NUMERIC
ORF I-GENE
- I-GENE
A I-GENE
and O
the O
use O
of O
promoter O
constructs O
further O
mapped O
an O
internal O
functional O
promoter O
within O
the O
pCD41 NUMERIC
sequence I-GENE
that O
can O
direct O
the O
synthesis O
of O
the O
trans O
- O
activating O
protein O
. O

Seven RARE
of O
these O
had O
counterparts O
in O
the O
US O
of O
herpes O
simplex O
type O
1 O
( O
HSV O
- O
1 O
), O
pseudorabies O
virus O
( O
PRV ALLCAPS
), O
and O
equine O
herpesvirus O
type O
1 O
( O
EHV O
- O
1 O
). O

The O
inferred RARE
amino O
acid O
sequence O
of O
the O
cyanobacterial RARE
HemB LASTCAP
protein I-GENE
indicates O
a O
significant O
difference O
in O
the O
metal O
cofactor O
requirement O
from O
the O
higher O
- O
plant O
enzymes O
, O
which O
was O
confirmed O
by O
overexpression O
and O
biochemical O
analysis O
. O

METHODS O
AND O
RESULTS O
: O
In O
25 O
open O
- O
chest O
, O
anesthetized O
dogs O
, O
progressive O
circumflex RARE
artery O
stenosis O
led O
to O
a O
concordant RARE
decrease O
of O
circumflex RARE
artery O
resting O
and O
hyperemic RARE
flow O
, O
coronary O
flow O
reserve O
, O
and O
inverse RARE
angiographic O
mean O
transit O
time O
Tmicro RARE
- O
1 O
( O
P O
< O
. O
01 O
). O

However O
, O
a O
correlation O
was O
observed O
between O
SF O
levels O
of O
IL I-GENE
- I-GENE
8 I-GENE
with O
those O
of O
lactate O
, O
LDH ALLCAPS
, O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
and O
glucose O
. O

Sodium O
- O
taurocholate RARE
- O
induced O
acute O
necrotizing RARE
pancreatitis O
does O
not O
affect O
jejunal RARE
oxygenation O
in O
pigs O
. O

Although O
inactive O
in O
cells O
under O
normal O
conditions O
, O
the O
CHOP I-GENE
gene I-GENE
is O
markedly O
induced O
by O
a O
variety O
of O
cellular O
stresses O
, O
including O
nutrient O
deprivation O
and O
metabolic O
perturbations RARE
. O

The O
ipiO LASTCAP
genes I-GENE
code O
for O
two O
almost O
identical O
152 NUMERIC
- O
aa O
proteins O
which O
do O
not O
have O
any O
homology O
with O
sequences O
present O
in O
data O
libraries O
. O

Sterol RARE
analysis O
of O
the O
disrupted O
mutant O
demonstrated O
the O
accumulation O
of O
ignosterol RARE
, O
indicating O
a O
loss O
of O
Erg24p NUMERIC
activity O
. O

The O
previously O
described O
enhanced O
translation O
of O
spinach RARE
L12 I-GENE
mRNA I-GENE
from O
its O
two O
tandem O
AUG O
codons O
and O
the O
two O
functional O
rpl12 NUMERIC
genes I-GENE
in O
Arabidopsis O
probably O
provide O
two O
mechanisms O
for O
generating O
the O
four O
copies O
of O
L12 I-GENE
/ I-GENE
chloroplast I-GENE
ribosome I-GENE
, O
qualitatively RARE
different O
from O
those O
attempted RARE
in O
eubacteria RARE
. O

In O
these O
experiments O
we O
begin O
to O
study O
the O
potential O
functions O
of O
the O
alpha I-GENE
7 I-GENE
cytoplasmic I-GENE
domain I-GENE
by O
analyzing O
homologies O
between O
the O
rat O
and O
human O
sequences O
, O
by O
immunologic O
studies O
using O
an O
anti O
- O
cytoplasmic O
domain O
antiserum O
, O
and O
by O
identifying O
two O
alternate O
forms O
. O

The O
alpha O
7A NUMERIC
form O
RNA O
contains O
an O
additional O
113 O
nucleotides O
compared O
to O
the O
B O
form O
, O
and O
a O
common O
coding O
region O
in O
the O
A O
and O
B O
form O
RNAs O
is O
used O
in O
alternate O
reading O
frames O
. O

In O
order O
to O
evaluate O
the O
function O
of O
the O
hypothalamic RARE
- O
pituitary O
- O
thyroid O
( O
HPT ALLCAPS
)- O
axis O
in O
unipolar RARE
depression O
, O
the O
authors O
measured O
basal O
0800h NUMERIC
plasma O
levels O
of O
free O
thyroxine O
( O
FT4 NUMERIC
), O
free O
triiodothyronine RARE
( O
FT3 NUMERIC
), O
and O
thyroid I-GENE
stimulating I-GENE
hormone I-GENE
( O
TSH I-GENE
) O
by O
means O
of O
the O
new O
, O
ultrasensitive RARE
assays O
( O
TSH O
- O
IRMA ALLCAPS
) O
in O
69 O
healthy O
controls O
, O
62 O
minor O
, O
101 O
simple O
major O
, O
and O
57 O
melancholic RARE
depressed O
subjects O
. O

CRS I-GENE
function O
in O
a O
5 O
' O
LTR O
- O
linked O
gene O
expression O
assay O
correlates O
with O
the O
ability O
of O
both O
p60CRS NUMERIC
and O
p40CRS NUMERIC
to O
interact O
with O
5 O
' O
LTR O
RNA O
in O
vitro O
. O

Serial RARE
levels O
of O
troponin RARE
T I-GENE
and O
the O
activity O
of O
CK I-GENE
- I-GENE
MB I-GENE
were O
measured O
6 O
, O
12 O
, O
24 O
and O
48 O
h O
after O
aortic O
unclamping RARE
. O

Regionalization RARE
of O
drug O
delivery O
is O
a O
potential O
method O
to O
avoid O
this O
problem O
. O

The O
epidemic O
occurred O
in O
a O
group O
of O
26 O
community O
members O
( O
23 O
men O
and O
3 O
women O
, O
mean O
age O
, O
28 O
. O
9 O
-- O
3 O
years O
) O
living O
and O
working O
together O
, O
who O
underwent O
acute O
and O
convalescent RARE
serologic O
tests O
for O
Mycoplasma RARE
pneumoniae O
, O
Legionella RARE
pneumophila RARE
, O
cytomegalovirus O
, O
adenovirus O
, O
Coxiella RARE
burnetii RARE
, O
and O
Chlamydia O
pneumoniae O
. O

MEK I-GENE
itself O
is O
activated O
via O
serine O
phosphorylation O
by O
upstream I-GENE
activator I-GENE
kinases I-GENE
, O
including O
c I-GENE
- I-GENE
raf I-GENE
, O
mos I-GENE
and O
MEK I-GENE
kinase I-GENE
. O

Genomic O
DNA O
clones O
containing O
the O
T I-GENE
- I-GENE
cell I-GENE
- I-GENE
specific I-GENE
human I-GENE
MAL ALLCAPS
gene I-GENE
were O
isolated O
. O

Members O
of O
SVA ALLCAPS
are O
also O
present O
in O
the O
complement I-GENE
C2 I-GENE
gene I-GENE
located O
about O
20 O
kilobases O
upstream O
of O
RP1 NUMERIC
in O
the O
HLA I-GENE
and O
in O
the O
cytochrome I-GENE
CYP1A1 NUMERIC
gene I-GENE
. O

Expression O
of O
the O
dibasic RARE
proprotein RARE
processing O
enzyme O
furin RARE
is O
directed O
by O
multiple O
promoters O
. O

European O
Community RARE
Huntington RARE
' O
s O
Disease RARE
Collaborative RARE
Study O
Group O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
and O
skeletal I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
gene I-GENE
promoters I-GENE
contain O
YY1 I-GENE
binding I-GENE
sites I-GENE
thought O
to O
act O
either O
as O
positive O
or O
negative O
cis O
- O
acting O
elements O
. O

MSSP ALLCAPS
- I-GENE
1 I-GENE
produced O
in O
E O
. O
coli O
as O
a O
fusion O
protein O
with O
GST I-GENE
specifically O
interacted O
with O
single O
- O
stranded O
TCTTAT ALLCAPS
( O
plus O
myc I-GENE
( O
H O
- O
P O
) O
21 O
) O
and O
ACT ALLCAPS
- O
ATT ALLCAPS
( O
in O
minus O
myc I-GENE
( O
H O
- O
P O
) O
21 O
), O
the O
consensus O
of O
which O
can O
be O
referred O
to O
as O
A O
/ O
TCTA ALLCAPS
/ O
TA O
/ O
TT ALLCAPS
. O

Within O
12 O
hours O
after O
MR O
tomography O
the O
patients O
were O
surgically O
explored O
, O
biopsied RARE
and O
if O
necessary O
orchiectomised RARE
. O

Certain RARE
spt10 NUMERIC
spontaneous O
alleles O
are O
good O
suppressors O
but O
have O
a O
normal O
growth O
rate O
, O
suggesting O
that O
the O
SPT10 NUMERIC
protein I-GENE
may O
have O
two O
distinct O
functions O
. O

Varieties RARE
of O
envious RARE
experience O
. O

The O
results O
show O
that O
both O
the O
amino O
and O
carboxy O
termini O
of O
the O
NS1 I-GENE
protein I-GENE
molecule I-GENE
and O
the O
cysteines RARE
at O
residues O
337 NUMERIC
and O
340 NUMERIC
are O
essential O
for O
tubule RARE
formation O
. O

The O
3 O
' O
UTR O
has O
several O
stable O
hairpins RARE
that O
are O
flanked O
by O
single O
- O
stranded O
( O
A O
/ O
U O
) O
UGC ALLCAPS
sequences O
. O

Moreover O
, O
the O
major O
site O
of O
transcriptional O
initiation O
, O
which O
was O
localized O
by O
primer O
extension O
250 O
bp O
upstream O
of O
the O
5 O
' O
end O
of O
the O
Ets I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
clone I-GENE
, O
was O
shown O
to O
be O
identical O
in O
normal O
cells O
and O
tumors O
carrying O
a O
provirus O
in O
the O
Tpl RARE
- I-GENE
1 I-GENE
locus I-GENE
. O

Specifically O
, O
by O
oligonucleotide O
- O
directed O
site O
- O
specific O
mutagenesis O
, O
we O
demonstrate O
that O
of O
10 O
cysteine O
residues O
in O
the O
ORF4 NUMERIC
polypeptide O
, O
only O
C O
- O
421 NUMERIC
and O
C O
- O
426 NUMERIC
are O
essential O
for O
transactivator O
function O
and O
suggest O
that O
these O
cysteine O
residues O
may O
participate O
in O
critical O
protein O
- O
protein O
interactions O
rather O
than O
protein O
- O
nucleic O
acid O
interactions O
to O
mediate O
ORF4 NUMERIC
inducibility O
. O

In O
Rat O
1a O
cells O
, O
m1R NUMERIC
stimulation O
of O
phospholipase I-GENE
C I-GENE
beta I-GENE
and O
the O
marked O
rise O
in O
intracellular O
calcium O
stimulated O
cyclic O
AMP O
( O
cAMP O
) O
synthesis O
, O
resulting O
in O
the O
activation O
of O
protein I-GENE
kinase I-GENE
A I-GENE
. O

The O
mutations O
did O
not O
affect O
the O
repression O
of O
CPA1 NUMERIC
by O
arginine O
. O

A O
segment O
of O
mRNA O
encoding O
the O
leader O
peptide O
of O
the O
CPA1 NUMERIC
gene I-GENE
confers O
repression O
by O
arginine O
on O
a O
heterologous O
yeast O
gene O
transcript O
. O

To O
search O
for O
genes O
that O
interact O
with O
the O
SLK1 NUMERIC
- O
SLT2 NUMERIC
pathway O
, O
a O
synthetic O
lethal O
suppression O
screen O
was O
carried O
out O
. O

Genetic O
and O
phenotypic RARE
analysis O
indicates O
that O
NHP6A NUMERIC
and O
NHP6B NUMERIC
function O
downstream O
of O
SLT2 NUMERIC
. O

In O
this O
report O
, O
we O
present O
two O
lines O
of O
evidence O
that O
all O
ribosomes RARE
which O
synthesize RARE
GCN4 I-GENE
have O
previously O
translated O
uORF1 NUMERIC
, O
resumed RARE
scanning O
, O
and O
reinitiated RARE
at O
the O
GCN4 I-GENE
start O
site O
. O

Identical RARE
components O
of O
yeast O
transcription I-GENE
factor I-GENE
IIIB I-GENE
are O
required O
and O
sufficient O
for O
transcription O
of O
TATA O
box O
- O
containing O
and O
TATA O
- O
less O
genes O
. O

Concordantly RARE
, O
it O
was O
shown O
that O
the O
dnHLH LASTCAP
protein I-GENE
Id1 NUMERIC
inhibits O
differentiation O
of O
muscle O
and O
myeloid O
cells O
in O
vitro O
. O

RNP1 NUMERIC
, O
a O
new O
ribonucleoprotein O
gene O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

Crohn O
' O
s O
disease O
in O
prolonged O
remission O
: O
should O
one O
augment RARE
protein O
- O
calorie RARE
intake O
as O
compared O
to O
healthy O
subjects O
?] RARE
The O
aim O
of O
our O
two O
year O
prospective O
study O
was O
to O
evaluate O
whether O
adult O
Crohn O
' O
s O
disease O
patients O
in O
prolonged O
remission O
( O
CDAI ALLCAPS
< O
150 O
), O
in O
order O
to O
maintain O
their O
body O
weight O
as O
close O
as O
possible O
to O
the O
ideal RARE
one O
, O
need O
a O
protein O
- O
calorie RARE
intake O
higher O
than O
the O
predicted O
one O
and O
that O
of O
healthy O
controls O
. O

To O
achieve O
complete O
dissection O
of O
the O
anterior O
vitreous O
, O
we O
remove RARE
even O
a O
clear O
lens O
during O
the O
first O
surgical O
intervention O
in O
selected O
cases O
. O

Restoration RARE
of O
opponens RARE
function O
with O
transplantation O
of O
free O
composites RARE
dorsal O
pedal RARE
skin O
flap O
containing O
m O
. O
extensor RARE
hallucis RARE
brevis RARE

Neither O
ethanol O
regimen O
impaired O
spontaneous O
alternation RARE
, O
but O
the O
4 O
g O
ethanol O
. O
kg O
- O
1 O
x O
day O
- O
1 O
regimen O
increased O
the O
percent O
completed O
trials O
. O

The O
mean O
(+/- O
sd RARE
) O
intra O
- O
vesicular O
pressure O
( O
IVP ALLCAPS
) O
and O
maximal O
urethral RARE
closure O
pressures O
( O
MUCP ALLCAPS
) O
were O
10 O
. O
3 O
(+/- O
1 O
. O
7 O
) O
and O
129 NUMERIC
. O
8 O
(+/- O
19 O
. O
6 O
) O
cmH2O O
, O
respectively O
, O
and O
the O
ratio O
between O
MUCP ALLCAPS
and O
IVP ALLCAPS
was O
13 O
. O
2 O
(+/- O
2 O
. O
5 O
). O

Several O
highly O
conserved O
regions O
were O
identified O
at O
the O
near O
N O
terminus O
, O
middle O
and O
C O
terminus O
. O

Thioredoxin RARE
( O
TR I-GENE
) O
is O
a O
small O
ubiquitous O
dithiol RARE
- I-GENE
reductase I-GENE
enzyme I-GENE
first O
identified O
in O
bacteria O
and O
plants O
. O

The O
mutation O
within O
the O
asgB480 NUMERIC
allele I-GENE
was O
identified O
as O
an O
A O
- O
to O
- O
G O
transition O
that O
results O
in O
a O
threonine O
- O
to O
- O
alanine O
substitution O
in O
the O
predicted O
protein O
product O
. O

The O
cysteine O
- O
rich O
region O
of O
raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
contains O
zinc O
, O
translocates RARE
to O
liposomes O
, O
and O
is O
adjacent O
to O
a O
segment O
that O
binds O
GTP I-GENE
- I-GENE
ras I-GENE
. O

Kinetic RARE
coupling O
and O
requirement O
for O
ATP O
hydrolysis O
. O

ATP O
by O
itself O
also O
reduced O
polypeptide O
binding O
to O
Ssb1 NUMERIC
/ I-GENE
2p NUMERIC
to O
a O
level O
that O
was O
intermediate O
between O
that O
observed O
for O
the O
Ssa RARE
Hsp70 NUMERIC
proteins I-GENE
tested O
and O
BiP LASTCAP
and O
DnaK LASTCAP
. O

Digestion RARE
of O
NF I-GENE
- I-GENE
IL6 I-GENE
with O
endoprotease RARE
Asp I-GENE
- I-GENE
N I-GENE
produced O
a O
domain O
smaller O
than O
the O
TCD ALLCAPS
( O
NF I-GENE
- I-GENE
IL6 I-GENE
bZIP I-GENE
domains I-GENE
( O
NFBD ALLCAPS
) O
( O
272 O
- O
345 NUMERIC
)), RARE
a O
domain O
identified O
either O
in O
the O
absence O
or O
the O
presence O
of O
DNA O
. O

Signaling RARE
by O
tyrosine I-GENE
kinases I-GENE
involves O
direct O
associations O
between O
proteins O
with O
Src I-GENE
homology I-GENE
2 I-GENE
( O
SH2 I-GENE
) O
domains O
and O
sites O
of O
tyrosine O
phosphorylation O
. O

Rather RARE
, O
complete O
skipping RARE
of O
exon O
V O
and O
subsequent O
joining O
of O
exon O
IV O
to O
exon O
VI O
caused O
a O
shift O
in O
the O
open O
reading O
frame O
, O
which O
remodeled RARE
GPHe RARE
( I-GENE
P2 I-GENE
) I-GENE
with O
an O
elongated RARE
new O
hydrophobic O
sequence O
for O
membrane O
anchoring RARE
. O

The O
responses O
of O
the O
" O
stress O
hormones O
" O
cortisol O
, O
11 O
- O
deoxycortisol RARE
, O
ACTH I-GENE
, O
vasopressin I-GENE
( O
AVP I-GENE
), O
and O
corticotropin RARE
releasing I-GENE
factor I-GENE
( O
CRF I-GENE
) O
were O
studied O
in O
6 O
normal O
males O
in O
response O
to O
acute O
cortisol O
deficiency O
induced O
by O
the O
11 I-GENE
- I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
inhibitor O
, O
metyrapone RARE
. O

Structure O
and O
expression O
of O
the O
alternative O
sigma I-GENE
factor I-GENE
, O
RpoN LASTCAP
, O
in O
Rhodobacter RARE
capsulatus RARE
; O
physiological O
relevance O
of O
an O
autoactivated RARE
nifU2 NUMERIC
- O
rpoN LASTCAP
superoperon RARE
. O

Thus O
our O
observations O
establish O
a O
functional O
link O
between O
the O
PKC I-GENE
and O
retinoid O
pathways O
, O
which O
are O
generally O
considered O
to O
have O
antagonistic O
activities O
on O
differentiation O
processes O
. O

The O
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
( O
CSFs RARE
) O
principally RARE
involved O
in O
the O
production O
of O
neutrophils O
and O
monocytes O
are O
granulocyte I-GENE
CSF I-GENE
, O
granulocyte I-GENE
- I-GENE
macrophage I-GENE
CSF I-GENE
, O
macrophage I-GENE
CSF I-GENE
, O
and O
interleukin I-GENE
3 I-GENE
( O
sometimes RARE
called O
multi I-GENE
- I-GENE
CSF I-GENE
). O

The O
degree O
of O
lung O
destruction RARE
, O
reflected O
by O
interstitial O
hemorrhage O
was O
assessed O
by O
measuring O
hemoglobin I-GENE
content O
in O
the O
fluid O
of O
the O
lavaged RARE
lungs O
. O

Expression O
plasmids O
harboring O
full O
- O
length O
or O
kinase O
domain O
of O
PKC I-GENE
alpha I-GENE
and O
PKC I-GENE
delta I-GENE
( O
PKC I-GENE
alpha I-GENE
K I-GENE
and O
PKC I-GENE
delta I-GENE
K I-GENE
) O
were O
constructed O
. O

These O
results O
indicate O
that O
both O
PKC I-GENE
alpha I-GENE
( O
calcium O
dependent O
) O
and O
PKC I-GENE
delta I-GENE
( O
calcium O
independent O
) O
may O
mediate O
the O
transcription O
of O
TPA O
- O
inducible O
genes O
through O
both O
AP I-GENE
- I-GENE
1 I-GENE
and O
non O
- O
AP I-GENE
- I-GENE
1 I-GENE
sequences O
. O

With O
a O
cutoff O
level O
for O
TSST ALLCAPS
- I-GENE
1 I-GENE
of O
less O
than O
100 O
pg O
/ O
ml O
, O
28 O
samples O
obtained O
from O
12 O
patients O
were O
positive O
for O
TSST ALLCAPS
- I-GENE
1 I-GENE
. O

Insertion RARE
of O
short O
oligonucleotides O
encoding O
the O
basic O
amino O
acid O
motifs O
726 NUMERIC
- O
GRKRKSP ALLCAPS
- O
732 NUMERIC
from O
IE175 NUMERIC
and O
500 O
- O
VRPRKRR ALLCAPS
- O
506 NUMERIC
from O
IE110 NUMERIC
into O
deleted O
cytoplasmic O
forms O
of O
the O
two O
proteins O
restored O
the O
karyophilic RARE
phenotype O
and O
confirmed O
that O
these O
motifs O
are O
both O
necessary O
and O
sufficient O
for O
proper O
nuclear O
localization O
. O

Mapping O
of O
intracellular O
localization O
domains O
and O
evidence O
for O
colocalization RARE
interactions O
between O
the O
IE110 NUMERIC
and O
IE175 NUMERIC
nuclear O
transactivator O
proteins O
of O
herpes O
simplex O
virus O
. O

The O
revertant RARE
TATA O
boxes O
accelerated O
the O
kinetics O
of O
HIV O
replication O
when O
present O
in O
the O
context O
of O
an O
LTR O
containing O
a O
Sp1 I-GENE
mutation O
( O
deletion O
or O
site O
specific O
); O
no O
effect O
was O
observed O
on O
the O
infectivity RARE
of O
wild O
- O
type O
HIV O
. O

Panlobular RARE
emphysema O

Since O
the O
ETS I-GENE
domain I-GENE
, O
which O
is O
localized O
in O
the O
carboxy O
terminal O
region O
of O
the O
encoded O
protein O
, O
is O
95 O
% O
and O
96 O
% O
identical O
to O
that O
of O
PEA3 I-GENE
and O
ER81 NUMERIC
, O
respectively O
, O
we O
named O
this O
new O
member O
' I-GENE
Ets I-GENE
Related RARE
Molecule RARE
PEA3 I-GENE
- I-GENE
like I-GENE
' I-GENE
( O
ERM ALLCAPS
). O

Gel O
shift O
analysis O
indicates O
that O
the O
full I-GENE
- I-GENE
length I-GENE
ERM ALLCAPS
protein I-GENE
is O
able O
to O
bind O
specifically O
to O
an O
oligonucleotide O
containing O
the O
consensus O
nucleotide O
core O
sequence O
GGAA ALLCAPS
recognized O
by O
the O
Ets I-GENE
proteins O
. O

Effects O
of O
estradiol O
on O
worm RARE
burden O
and O
peripheral O
leukocytes RARE
in O
Parastrongylus RARE
malaysiensis RARE
- O
infected O
rats O
. O

Dotarizine RARE
produced O
arterial O
dilation RARE
in O
both O
systemic O
and O
pulmonary O
circulation O
: O
the O
total O
peripheral O
resistance O
dropped RARE
, O
and O
femoral O
artery O
flow O
rose O
; O
aortic O
and O
pulmonary O
artery O
mean O
and O
diastolic O
pressures O
declined O
, O
and O
systolic O
pressures O
remained O
almost O
stable O
. O

These O
issues O
include O
the O
use O
of O
LMWHs RARE
in O
patients O
with O
arterial O
thrombosis O
or O
myocardial O
infarction O
( O
e O
. O
g O
. O
in O
conjunction O
with O
thrombolytic RARE
treatment O
), O
and O
in O
patients O
with O
pulmonary O
embolism RARE
. O

The O
usefulness RARE
of O
the O
lambda O
PG15 NUMERIC
and O
the O
lambda O
AD5 NUMERIC
cloning O
vectors O
was O
demonstrated O
by O
constructing RARE
large O
Neurospora O
crassa O
cDNA O
libraries O
. O

Endoscopic RARE
transthoracic RARE
sympathectomy RARE
as O
adjuvant O
treatment O
for O
critical O
upper O
- O
limb O
ischaemia O
. O

Sequence O
comparisons O
have O
shown O
that O
Aps1p NUMERIC
is O
more O
similar O
to O
the O
sigma O
subunit O
of O
the O
Golgi O
- O
localized O
mammalian O
AP I-GENE
- I-GENE
1 I-GENE
complex I-GENE
than O
Aps2p NUMERIC
, O
which O
is O
more O
related O
to O
the O
plasma O
membrane O
AP I-GENE
- I-GENE
2 I-GENE
sigma I-GENE
subunit O
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
APS1 NUMERIC
gene I-GENE
encodes O
a O
homolog O
of O
the O
small O
subunit O
of O
the O
mammalian I-GENE
clathrin I-GENE
AP I-GENE
- I-GENE
1 I-GENE
complex I-GENE
: O
evidence O
for O
functional O
interaction O
with O
clathrin I-GENE
at O
the O
Golgi O
complex O
. O

These O
results O
are O
the O
first O
to O
demonstrate O
the O
structural O
organization O
of O
a O
vertebrate O
gene O
encoding O
an O
integral O
membrane O
protein O
of O
the O
nuclear O
envelope O
that O
may O
be O
a O
member O
of O
a O
family O
of O
polypeptides O
conserved O
in O
evolution O
. O

Biochemical O
characterization O
of O
valosin RARE
- I-GENE
containing I-GENE
protein I-GENE
, O
a O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
substrate O
in O
hematopoietic O
cells O
. O

The O
presence O
of O
the O
foreign O
gene O
was O
confirmed O
by O
Southern O
analysis O
. O

All O
patients O
with O
deterioriation RARE
in O
mental O
status O
showed O
a O
marked O
increase O
in O
liver O
enzymes O
( O
aspartate I-GENE
and I-GENE
alanine I-GENE
aminotransaminases RARE
) O
and O
severe O
coagulopathy RARE
. O

Functional O
postnatal O
development O
of O
the O
rat O
primary O
visual O
cortex O
and O
the O
role O
of O
visual O
experience O
: O
dark O
rearing RARE
and O
monocular RARE
deprivation O
. O

Eleven RARE
patients O
tested O
positive O
for O
the O
hepatitis I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
( O
HBsAg I-GENE
). O

The O
xylose RARE
isomerase I-GENE
- I-GENE
encoding I-GENE
gene I-GENE
( O
xylA LASTCAP
) O
of O
Clostridium RARE
thermosaccharolyticum RARE
: O
cloning O
, O
sequencing O
and O
phylogeny RARE
of O
XylA LASTCAP
enzymes I-GENE
. O

Two O
phosphopeptides O
, O
identified O
as O
RS O
-[ O
32P O
] O
SGASGLLTSEHHSR ALLCAPS
and O
S O
-[ O
32P O
] O
SGASGLLTSEHHSR ALLCAPS
, O
were O
obtained O
after O
stoichiometric RARE
phosphorylation O
and O
trypsinization RARE
of O
the O
peptide O
. O

Mitochondrial RARE
Mas70p NUMERIC
signal I-GENE
anchor I-GENE
sequence I-GENE
. O

Altogether O
, O
these O
data O
suggest O
that O
Ypt51p NUMERIC
, O
Ypt52p NUMERIC
, O
and O
Ypt53p NUMERIC
are O
required O
for O
transport O
in O
the O
endocytic O
pathway O
and O
for O
correct O
sorting O
of O
vacuolar I-GENE
hydrolases RARE
suggesting O
a O
possible O
intersection RARE
of O
the O
endocytic O
with O
the O
vacuolar O
sorting O
pathway O
. O

All O
of O
the O
basal O
TPN O
solutions O
were O
isonitrogenous RARE
and O
identical O
in O
nutrient O
composition O
, O
except O
for O
the O
difference O
in O
energy O
level O
, O
which O
was O
adjusted O
with O
glucose O
. O

Surprisingly O
, O
TFIIIC ALLCAPS
alpha I-GENE
has O
no O
homology O
to O
any O
of O
the O
yeast I-GENE
TFIIIC ALLCAPS
subunits I-GENE
already O
cloned O
, O
suggesting O
a O
significant O
degree O
of O
evolutionary O
divergence O
for O
RNA I-GENE
polymerase I-GENE
III I-GENE
factors I-GENE
. O

Transactivation RARE
domain O
is O
located O
downstream O
of O
the O
128 I-GENE
- I-GENE
amino I-GENE
- I-GENE
acid I-GENE
runt RARE
homology I-GENE
region I-GENE
, O
referred O
to O
as O
the O
Runt RARE
domain I-GENE
. O

We O
estimate O
that O
the O
protease O
activity O
is O
at O
least O
35 O
- O
fold O
greater O
in O
mature O
B O
cells O
than O
in O
pre O
- O
B O
cells O
. O

The O
ligand O
for O
RXR I-GENE
, O
9 O
- O
cis O
retinoic O
acid O
, O
has O
the O
opposite O
effect O
of O
destabilizing RARE
the O
heterodimeric O
- O
DNA O
complex O
. O

Cerebral125 NUMERIC
albumin I-GENE
was O
increased O
to O
similar O
proportions RARE
in O
those O
groups O
submitted O
to O
hyperosmolality RARE
. O

Retrogradely RARE
labelled O
neurons O
significantly O
prevailed RARE
in O
the O
ipsilateral O
substantia RARE
nigra RARE
pars RARE
compacta RARE
. O

Response O
to O
treatment O
was O
better O
in O
patients O
with O
less O
pretreatment O
( O
one O
- O
two O
prior O
treatments O
) O
than O
in O
heavily RARE
pretreated O
ones O
( O
more O
than O
three O
) O
and O
this O
relation O
was O
found O
to O
be O
statistically O
significant O
( O
p O
< O
0 O
. O
05 O
). O

Therefore O
, O
the O
amino O
- O
terminal O
sequence O
of O
the O
purified O
carA LASTCAP
product I-GENE
is O
identical O
to O
that O
derived O
from O
the O
nucleotide O
sequence O
in O
both O
organisms O
, O
P O
. O
stutzeri RARE
having O
four O
additional O
amino O
acids O
. O

Aneurysmal RARE
bone O
cyst O
of O
the O
jaws RARE
: O
analysis O
of O
11 O
cases O
. O

Location RARE
and O
orientation O
of O
an O
activating O
region O
in O
the O
Escherichia O
coli O
transcription O
factor O
, O
FNR ALLCAPS
. O

Moxidectin RARE
( O
at O
3 O
times O
the O
therapeutic O
dose O
) O
did O
not O
have O
deleterious RARE
effects O
on O
cow RARE
reproductive O
performance O
as O
examined O
( O
eg RARE
, O
at O
folliculogenesis RARE
, O
ovulation O
, O
and O
the O
early O
embryonic O
phase O
of O
development O
). O

Northern O
- O
blot O
analysis O
of O
mRNA O
from O
Avicel RARE
- O
grown O
N O
. O
patriciarum RARE
showed O
that O
xynB LASTCAP
hybridized O
to O
a O
3 O
. O
4 O
kb O
mRNA O
species O
. O

The O
variable O
regions O
of O
vertebrate O
striated RARE
TnT LASTCAP
isoforms I-GENE
reflect O
the O
subsequent O
addition O
and O
modification O
of O
genomic O
sequences O
to O
give O
rise O
to O
members O
of O
the O
TnT LASTCAP
multigene RARE
family I-GENE
. O

The O
class I-GENE
II I-GENE
Escherichia I-GENE
coli I-GENE
alanine I-GENE
tRNA I-GENE
synthetase I-GENE
aminoacylates RARE
RNA I-GENE
miniduplexes RARE
, O
which O
reconstruct RARE
the O
acceptor O
end O
of O
alanine I-GENE
tRNA I-GENE
with O
the O
critical O
G3 NUMERIC
: O
U70 NUMERIC
base O
pair O
. O

Simple RARE
reaction O
time O
( O
RT O
) O
to O
a O
peripheral O
visual O
target O
( O
S2 O
) O
is O
shortened O
when O
a O
non O
- O
informative RARE
cue RARE
( O
S1 O
) O
is O
flashed RARE
at O
the O
S2 O
location O
100 O
- O
150 O
ms O
before O
target O
onset O
( O
early O
facilitation RARE
). O

A O
second O
study O
group O
, O
with O
intact O
cardiac O
innervation RARE
, O
consisted O
of O
19 O
patients O
with O
stable O
angina O
pectoris O
class O
I O
to O
III O
. O

These O
viruses O
depend O
on O
the O
host O
cell O
machinery O
for O
their O
existence O
, O
and O
interference O
with O
these O
processes O
typically O
interferes RARE
with O
other O
important O
host O
physiology O
. O

Treatment O
was O
well O
- O
tolerated O
. O

A O
concentration O
of O
12 O
. O
5 O
ppm O
SO2 NUMERIC
induced O
a O
decrease O
from O
baseline O
values O
of O
approximately O
80 O
% O
in O
mean O
MCA ALLCAPS
and O
of O
roughly RARE
70 O
% O
in O
mean O
CBF O
. O

We O
have O
used O
these O
modified O
assay O
conditions O
to O
extend O
studies O
on O
the O
transposition RARE
pathway O
. O

Renal O
cell O
carcinoma O
in O
children O
: O
a O
single O
institution RARE
' O
s O
experience O
. O

The O
data O
suggest O
that O
ICP10 NUMERIC
constitutively O
increases O
ras I-GENE
activity O
, O
and O
its O
TM O
segment O
plays O
a O
critical O
role O
in O
transformation O
- O
related O
signaling O
pathways O
. O

Thus O
, O
we O
have O
separated O
the O
signal O
function O
from O
the O
anchor O
function O
of O
the O
6 O
. O
7K NUMERIC
SA O
domain O
. O

Five O
concensus RARE
poly O
A O
addition O
sites O
are O
located O
in O
the O
350 O
base O
pairs O
immediately O
following O
the O
protein I-GENE
IX I-GENE
coding O
region O
. O

Factors O
associated O
with O
intrafamilial RARE
transmission O
of O
hepatitis O
B O
virus O
infection O
in O
Korea RARE
. O

Exposure RARE
to O
higher O
TPA O
concentrations O
decreased O
the O
content O
of O
these O
transcripts O
. O

Northern O
analysis O
, O
to O
search O
for O
a O
pcbAB LASTCAP
transcript I-GENE
, O
showed O
no O
distinct O
transcript O
and O
indicated O
severely O
degraded O
mRNA O
. O

Our O
results O
indicate O
that O
the O
minimal O
requirements O
for O
induction O
of O
PEPCK I-GENE
by O
PKA I-GENE
and O
inhibition O
by O
insulin I-GENE
include O
: O
1 O
) O
the O
CREB I-GENE
activation I-GENE
domain I-GENE
, O
2 O
) O
the O
PEPCK I-GENE
TATA I-GENE
sequence I-GENE
, O
and O
3 O
) O
insulin I-GENE
- O
responsive O
hepatoma O
cells O
. O

The O
high O
degree O
of O
conservation O
between O
NQO2 NUMERIC
and O
NQO1 NUMERIC
gene I-GENE
organization O
and O
sequence O
confirmed O
that O
NQO2 NUMERIC
gene I-GENE
encodes O
for O
a O
second O
member O
of O
the O
NQO ALLCAPS
gene I-GENE
family I-GENE
in O
human O
. O

The O
efficacy O
of O
a O
Propionibacterium RARE
acnes RARE
product O
for O
treatment O
of O
coliform RARE
mastitis RARE
was O
evaluated O
following O
intramammary RARE
infusion O
of O
Escherichia O
coli O
. O

The O
human I-GENE
eps15 NUMERIC
gene I-GENE
, O
encoding O
a O
tyrosine I-GENE
kinase I-GENE
substrate O
, O
is O
conserved O
in O
evolution O
and O
maps O
to O
1p31 NUMERIC
- O
p32 NUMERIC
. O

The O
gene O
encoding O
the O
105 I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
( I-GENE
p105 NUMERIC
) I-GENE
precursor I-GENE
of O
the O
p50 I-GENE
subunit I-GENE
of O
transcription O
factor O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
also O
encodes O
a O
p70 I-GENE
I I-GENE
kappa I-GENE
B I-GENE
protein I-GENE
, O
I I-GENE
kappa I-GENE
B I-GENE
gamma I-GENE
, O
which O
is O
identical O
to O
the O
C O
- O
terminal O
607 NUMERIC
amino O
acids O
of O
p105 NUMERIC
. O

Alternative O
splicing O
of O
RNA O
transcripts O
encoded O
by O
the O
murine O
p105 NUMERIC
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
gene O
generates O
I I-GENE
kappa I-GENE
B I-GENE
gamma I-GENE
isoforms I-GENE
with O
different O
inhibitory O
activities O
. O

Topical RARE
L O
- O
NNA ALLCAPS
attenuated O
the O
hypercapnic RARE
increase O
of O
CoBF LASTCAP
by O
52 O
+/- O
6 O
% O
and O
CeBF LASTCAP
by O
29 O
+/- O
5 O
% O
after O
45 O
- O
min O
exposure O
. O

The O
experiment O
included O
6 O
male O
and O
4 O
female O
healthy O
subjects O
who O
, O
during O
a O
24 O
- O
hour O
stay RARE
in O
the O
respiration O
chambers RARE
, O
performed O
, O
in O
the O
morning RARE
and O
afternoon RARE
, O
15 O
min O
cycling RARE
with O
the O
total O
work O
of O
6 O
, O
750 O
kg O
m O
. O

These O
rearrangements O
result O
in O
the O
formation O
of O
chimeric O
genes O
showing O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
of O
ret RARE
fused O
with O
the O
5 O
' O
end O
sequences O
of O
different O
genes O
. O

Frequent RARE
loss O
of O
heterozygosity O
( O
LOH ALLCAPS
) O
of O
> O
30 O
% O
of O
the O
informative RARE
cases O
was O
observed O
on O
chromosomes O
3p NUMERIC
( O
41 O
. O
1 O
%), O
5q NUMERIC
( O
52 O
. O
6 O
%), O
6p NUMERIC
( O
30 O
. O
4 O
%), O
8p NUMERIC
( O
33 O
. O
3 O
%), O
9p NUMERIC
( O
35 O
. O
7 O
%), O
9q NUMERIC
( O
30 O
. O
8 O
%), O
11p NUMERIC
( O
32 O
. O
4 O
%), O
13q NUMERIC
( O
52 O
. O
7 O
%), O
17p NUMERIC
( O
55 O
. O
2 O
%), O
17q NUMERIC
( O
33 O
. O
3 O
%), O
18q NUMERIC
( O
45 O
. O
7 O
%), O
and O
19q NUMERIC
( O
30 O
. O
4 O
%). O

A O
single O
amino O
acid O
change O
in O
the O
CPY ALLCAPS
vacuolar I-GENE
sorting I-GENE
signal I-GENE
prevents O
this O
interaction O
. O

Glutamyl RARE
- I-GENE
tRNA I-GENE
synthetase I-GENE
and O
prolyl RARE
- I-GENE
tRNA I-GENE
synthetase I-GENE
belong O
to O
different O
classes O
of O
aminoacyl RARE
- I-GENE
tRNA I-GENE
synthetases I-GENE
that O
are O
thought O
to O
have O
evolved O
along O
independent O
evolutionary O
pathways O
. O

Using O
the O
sequence O
data O
obtained O
from O
the O
human O
TCRAC ALLCAPS
/ O
TCRDC ALLCAPS
region O
, O
we O
have O
extended O
a O
polymerase O
chain O
reaction O
- O
based O
assay O
to O
test O
for O
the O
expression O
of O
the O
individual O
TCRAJ ALLCAPS
gene I-GENE
segments I-GENE
. O

This O
analysis O
revealed O
an O
intact O
gene O
( O
arg4 NUMERIC
) O
showing O
a O
high O
degree O
of O
homology O
with O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
CPA2 NUMERIC
gene I-GENE
encoding O
the O
large O
subunit O
of O
carbamoyl RARE
- I-GENE
phosphate I-GENE
synthetase I-GENE
( O
CPS ALLCAPS
- I-GENE
A I-GENE
). O

Restriction O
analysis O
and O
Southern O
hybridization O
revealed O
the O
presence O
of O
Tn5422 NUMERIC
in O
all O
the O
plasmid O
- O
mediated O
cadmium O
- O
resistant O
L O
. O
monocytogenes O
strains O
tested O
but O
not O
in O
strains O
encoding O
cadmium O
resistance O
on O
the O
chromosome O
. O

The O
baroreflex RARE
latency O
( O
from O
the O
ECG O
R O
- O
wave O
to O
the O
integrated O
MSNA ALLCAPS
burst O
peak O
) O
was O
constant O
at O
approximately O
1 O
. O
20 O
s O
during O
sleep O
, O
suggesting O
that O
pulse O
- O
synchronicity RARE
was O
maintained O
. O

DESIGN O
-- O
A O
randomised O
study O
was O
conducted O
in O
all O
women O
aged O
50 O
- O
70 O
years O
who O
were O
eligible RARE
for O
breast O
cancer O
screening O
and O
living O
in O
the O
city RARE
of O
Utrecht RARE
. O

Identification O
of O
an O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
in O
the O
Marek RARE
' O
s O
disease O
virus O
long O
internal O
repeat O
region O
which O
encodes O
a O
unique O
14 O
- O
kilodalton O
polypeptide O
. O

We O
have O
used O
a O
full O
- O
length O
cDNA O
clone O
of O
a O
mouse O
hepatitis O
virus O
strain O
A59 NUMERIC
defective O
interfering O
( O
DI ALLCAPS
) O
RNA O
, O
pMIDI LASTCAP
- I-GENE
C I-GENE
, O
and O
cassette O
mutagenesis O
to O
study O
the O
mechanism O
of O
coronavirus O
subgenomic RARE
mRNA O
synthesis O
. O

To O
study O
the O
structure O
- O
function O
of O
the O
gene I-GENE
5 I-GENE
product I-GENE
, O
wild O
- O
type O
and O
mutant O
forms O
of O
NS53 NUMERIC
were O
produced O
by O
using O
a O
recombinant O
baculovirus O
expression O
system O
and O
a O
recombinant O
vaccinia O
virus O
/ O
T7 O
( O
vTF7 NUMERIC
- O
3 O
) O
expression O
system O
. O

Gel O
electrophoresis O
and O
Western O
immunoblot RARE
analyses O
of O
intracellular O
fractions O
derived O
from O
infected O
cells O
revealed O
that O
large O
amounts O
of O
NS53 NUMERIC
were O
present O
in O
the O
cytosol O
and O
in O
association O
with O
the O
cytoskeletal O
matrix O
. O

The O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
2 I-GENE
is O
encoded O
by O
a O
gene O
located O
on O
chromosome O
6 O
near O
the O
HLA I-GENE
locus I-GENE
. O

The O
mature O
AP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
is O
spliced O
from O
7 O
exons O
distributed O
over O
a O
region O
of O
18 O
kb O
genomic O
DNA O
. O

San RARE
Martin RARE
' O
s O
psychological O
traits RARE
coupled O
to O
his O
work O
with O
masonic RARE
lodges RARE
that O
allowed O
him RARE
to O
display O
his O
abilities O
as O
strategist RARE
and O
political RARE
ruler RARE
. O

The O
participants RARE
were O
homosexual RARE
men O
in O
hepatitis O
B O
vaccine O
trials O
in O
Amsterdam RARE
( O
n O
= O
74 O
), O
New O
York O
City O
( O
n O
= O
120 O
), O
and O
San RARE
Francisco RARE
( O
n O
= O
168 NUMERIC
). O

The O
7 O
- O
day O
treatment O
resulted O
in O
a O
decrease O
in O
mitochondrial O
uptake O
of O
Rh123 NUMERIC
and O
an O
increase O
in O
NAO ALLCAPS
uptake O
. O

Thrombotic RARE
thrombocytopenic RARE
purpura O
in O
systemic O
lupus O
erythematosus O
. O

Comparison O
with O
the O
crystal O
structure O
of O
Desulfovibrio RARE
gigas RARE
, O
Dg RARE
, O
Fd RARE
( O
Kissinger RARE
et O
al O
., O
1991 O
) O
reveals O
a O
very O
similar O
folding O
topology O
, O
although O
several O
secondary O
structural O
elements O
are O
extended O
in O
Pf RARE
relative O
to O
Dg RARE
Fd RARE
. O

CONCLUSIONS O
: O
Serum I-GENE
prolactin I-GENE
concentrations O
show O
age O
related O
variations O
in O
presumably O
fertile RARE
men O
. O

Eight O
highly O
trained RARE
male O
kayakers RARE
were O
studied O
to O
determine O
the O
relationship O
between O
critical O
power O
( O
CP O
) O
and O
the O
onset O
of O
blood O
lactate O
accumulation O
( O
OBLA ALLCAPS
). O

As O
in O
S O
. O
cerevisiae O
, O
the O
sequence O
of O
rhp51 NUMERIC
+ I-GENE
showed O
two O
MluI LASTCAP
cell I-GENE
- I-GENE
cycle I-GENE
boxes I-GENE
and O
a O
putative O
DNA O
damage O
- O
responsive O
element O
in O
its O
upstream O
region O
. O

Women RARE
' O
s O
opportunities RARE
for O
paid RARE
work O
outside O
the O
home O
are O
constrained RARE
by O
their O
role O
as O
primary O
carer RARE
within O
the O
family O
, O
writes RARE
Trudy RARE
Wynne RARE
. O

A O
partial O
cDNA O
sequence O
indicated O
that O
the O
T I-GENE
lymphocyte I-GENE
early I-GENE
- I-GENE
activation I-GENE
gene I-GENE
( O
Tea RARE
) O
encodes O
a O
protein O
related O
to O
the O
dual O
- O
function O
ecotropic RARE
retrovirus I-GENE
receptor I-GENE
/ O
cationic RARE
amino I-GENE
acid I-GENE
transporter I-GENE
( O
ecoR LASTCAP
/ O
CAT1 NUMERIC
), O
and O
RNA O
blots O
suggested O
highest O
Tea RARE
expression O
in O
T O
lymphocytes O
and O
liver O
( O
MacLeod RARE
, O
C O
. O
L O
., O
Finley RARE
, O
K O
., O
Kakuda RARE
, O
D O
. O

Furthermore O
, O
unlike O
the O
case O
for O
HIS3 I-GENE
where O
only O
a O
limited O
subset O
of O
TATA O
- O
like O
sequences O
can O
activate O
transcription O
in O
conjunction O
with O
GCN4p NUMERIC
, O
many O
divergent O
TATA O
- O
like O
sequences O
allowed O
GCN4p NUMERIC
activation O
of O
TRP3 NUMERIC
. O

Bacterially RARE
expressed O
protein O
, O
as O
well O
as O
the O
in O
vitro O
reticulocyte RARE
lysate RARE
translation O
product O
, O
comigrated RARE
with O
the O
purified O
37 O
- O
kDa O
protein O
on O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gels O
. O

In O
addition O
, O
this O
kinase O
is O
well O
conserved O
evolutionarily O
, O
ubiquitously O
expressed O
, O
and O
its O
genes O
map O
to O
a O
position O
on O
human O
chromosome O
1 O
frequently O
deleted O
in O
the O
late O
stages O
of O
tumorigenesis O
. O

Deletion O
analysis O
of O
the O
ICL1 NUMERIC
promoter I-GENE
led O
to O
the O
identification O
of O
an O
upstream O
activating O
sequence O
element O
, O
UASICL1 NUMERIC
( O
5 O
' O
CATTCATCCG ALLCAPS
3 O
'), RARE
necessary O
and O
sufficient O
for O
conferring O
carbon O
source O
- O
dependent O
regulation O
on O
a O
heterologous O
reporter O
gene O
. O

Interestingly O
, O
the O
interaction O
of O
ZAP I-GENE
- I-GENE
70 I-GENE
with O
the O
motif O
was O
dependent O
on O
the O
presence O
of O
both O
ZAP I-GENE
- I-GENE
70 I-GENE
SH2 I-GENE
domains I-GENE
and O
both O
of O
the O
tyrosine O
residues O
in O
the O
motif O
, O
suggesting O
that O
ZAP I-GENE
- I-GENE
70 I-GENE
interacts O
with O
two O
phosphotyrosine O
residues O
and O
that O
the O
binding O
of O
the O
two O
SH2 I-GENE
domains I-GENE
is O
cooperative O
. O

PRL I-GENE
- I-GENE
1 I-GENE
is O
able O
to O
dephosphorylate RARE
phosphotyrosine O
substrates O
, O
and O
mutation O
of O
the O
active O
- O
site O
cysteine O
residue O
abolishes O
this O
activity O
. O

In O
Mv1Lu NUMERIC
lung O
epithelial O
cells O
, O
ActR LASTCAP
- I-GENE
IB ALLCAPS
and O
T I-GENE
beta I-GENE
R I-GENE
- I-GENE
I I-GENE
signal O
a O
common O
set O
of O
growth O
- O
inhibitory O
and O
transcriptional O
responses O
in O
association O
with O
their O
corresponding O
ligands O
and O
type I-GENE
II I-GENE
receptors I-GENE
. O

50 O
kDa O
and O
130 O
- O
170 O
kDa O
were O
detected O
. O

H O
- O
7 O
, O
which O
specifically O
, O
although O
weakly O
, O
inhibited O
PKC I-GENE
activation O
, O
had O
no O
effect O
on O
tyrosine O
phosphorylation O
and O
PtdIns RARE
( O
3 O
, O
4 O
) O
P2 O
production O
. O

The O
effects O
of O
systemic O
glucose O
concentration O
on O
brain O
metabolism O
following O
repeated O
brain O
ischemia O
. O

This O
strategy O
was O
used O
to O
place O
both O
the O
Tn903 NUMERIC
neo I-GENE
gene I-GENE
and O
the O
Rhodosporidium RARE
toruloides RARE
phenylalanine I-GENE
ammonia I-GENE
lyase I-GENE
( O
PAL I-GENE
)- O
encoding O
gene O
under O
the O
transcriptional O
control O
of O
pPGK LASTCAP
:: O
REP2 NUMERIC
. O

In O
the O
case O
of O
congenital O
protein I-GENE
C I-GENE
deficiency O
, O
vitamin O
K O
antagonists O
must O
be O
started O
cautiously RARE
due O
to O
the O
risk O
of O
skin O
necrosis O
. O

A O
- O
69 O
- O
year O
- O
old O
patient O
with O
postoperative O
small O
- O
bowel O
obstruction O
underwent O
laparotomy RARE
three O
times O
. O

On O
physical O
examination O
a O
mild O
symmetrical RARE
polyarthritis RARE
of O
small O
and O
large O
joints RARE
was O
seen O
. O

In O
addition O
, O
we O
observe O
that O
the O
hUBF LASTCAP
- I-GENE
promoter I-GENE
interaction O
is O
highly O
sensitive O
to O
the O
antagonistic O
effects O
of O
cisplatin O
- O
DNA O
adducts RARE
. O

We O
conclude O
that O
the O
SIMV ALLCAPS
is O
useful O
in O
weaning RARE
neonates O
from O
the O
ventilator RARE
. O

VP ALLCAPS
- O
16 O
, O
ifosfamide RARE
and O
cisplatin O
( O
VIP ALLCAPS
) O
for O
extensive O
small O
cell O
lung O
cancer O
. O

A O
total O
of O
7 O
( O
4 O
males O
and O
3 O
females O
) O
patients O
were O
included O
in O
this O
retrospective O
study O
to O
determine O
the O
sensitivity O
of O
radioimmunoscintigraphy RARE
with O
I O
- O
131 O
labeled O
anti I-GENE
CEA I-GENE
/ O
CA I-GENE
19 I-GENE
- I-GENE
9 I-GENE
monoclonal O
antibodies O
. O

Simultaneous RARE
, O
bilateral O
and O
permanent O
ventilation O
with O
a O
diaphragm O
pacing O
in O
childhood O
: O
the O
implantation O
technique O
and O
indications RARE

A O
genomic O
clone O
for O
the O
cyc07 NUMERIC
gene I-GENE
, O
which O
is O
expressed O
specifically O
at O
the O
S O
phase O
during O
the O
cell O
cycle O
in O
synchronous RARE
cultures O
of O
periwinkle RARE
( O
Catharanthus RARE
roseus RARE
) O
cells O
, O
was O
isolated O
. O

CONCLUSIONS O
: O
Translocation RARE
of O
bacteria O
or O
endotoxin O
from O
the O
gastrointestinal O
tract O
into O
the O
bloodstream RARE
has O
been O
noted O
in O
animal O
experiments O
; O
however O
, O
translocation O
was O
not O
detected O
in O
our O
patients O
with O
hemorrhagic O
shock O
. O

The O
pyrR LASTCAP
and O
pyrP LASTCAP
genes I-GENE
encoded O
polypeptides O
with O
calculated O
molecular O
masses O
of O
19 O
. O
9 O
and O
45 O
. O
2 O
kDa O
, O
respectively O
. O

Southern O
blotting O
analysis O
implied RARE
the O
occurrence O
of O
multiple O
COXVb RARE
genes I-GENE
in O
the O
rat O
genome O
. O

Acylation RARE
with O
the O
palmitate RARE
analog O
was O
prevented O
when O
Gly O
- O
2 O
was O
mutated O
to O
alanine O
, O
implying O
that O
N O
- O
myristylation RARE
is O
required O
for O
palmitylation RARE
, O
and O
when O
either O
Cys O
- O
3 O
or O
Cys O
- O
6 O
was O
mutated O
to O
serine O
. O

Subunit RARE
composition O
and O
domain O
structure O
of O
the O
Spo0A NUMERIC
sporulation I-GENE
transcription I-GENE
factor I-GENE
of I-GENE
Bacillus I-GENE
subtilis I-GENE
. O

Electrophoretic O
mobility O
shift O
analysis O
indicates O
that O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
, O
as O
well O
as O
other O
related O
members O
of O
this O
family O
, O
bind O
specifically O
to O
the O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
site O
in O
the O
IL I-GENE
- I-GENE
8 I-GENE
promoter I-GENE
. O

BYV ALLCAPS
, O
citrus RARE
tristeza RARE
virus O
( O
CTV ALLCAPS
), O
beet RARE
yellow O
stunt RARE
virus O
( O
BYSV ALLCAPS
) O
and O
carnation RARE
necrotic RARE
fleck RARE
virus O
templates O
produced O
1 O
kb O
amplification O
products O
, O
which O
were O
shown O
by O
sequencing O
to O
represent O
fragments O
of O
the O
respective O
HSP70 I-GENE
genes I-GENE
. O

To O
identify O
the O
precise O
location O
of O
the O
phosphorylation O
site O
on O
the O
64 O
- O
kDa O
protein O
, O
a O
step O
- O
by O
- O
step O
mutagenesis O
procedures O
was O
followed O
. O

The O
p53 I-GENE
tumor I-GENE
suppressor I-GENE
gene I-GENE
product I-GENE
, O
a O
sequence O
- O
specific O
DNA O
- O
binding O
protein O
, O
has O
been O
shown O
to O
act O
as O
a O
transcriptional O
activator O
and O
repressor O
both O
in O
vitro O
and O
in O
vivo O
. O

Mutational O
analysis O
of O
chromosomal O
segment O
64AB NUMERIC
, O
a O
region O
containing O
the O
glutamic RARE
acid I-GENE
decarboxylase I-GENE
gene I-GENE
. O

Rearrangements RARE
of O
the O
NFKB2 NUMERIC
gene I-GENE
are O
associated O
with O
lymphoid O
malignancies RARE
, O
but O
the O
functional O
significance O
of O
these O
alterations O
is O
not O
known O
. O

Cloning O
and O
sequencing O
of O
the O
corresponding O
cDNAs O
indicates O
that O
, O
via O
alternative O
splicing O
, O
the O
rearranged O
gene O
codes O
for O
two O
proteins O
of O
84 O
and O
85 O
kD O
( O
p84 NUMERIC
/ I-GENE
85 I-GENE
) O
which O
retain RARE
the O
DNA O
- O
binding O
rel I-GENE
domain I-GENE
and O
the O
first O
five O
ankyrin RARE
repeats O
, O
but O
have O
lost O
their O
carboxy O
- O
terminus O
including O
the O
seventh RARE
ankyrin RARE
repeat O
. O

Transient O
co O
- O
transfection O
assays O
involving O
NFKB2 NUMERIC
expression O
vectors O
and O
kappa I-GENE
B I-GENE
- O
driven O
reporter O
plasmids O
indicate O
that O
NFKB2 NUMERIC
p85 I-GENE
has O
lost O
the O
transcriptional O
repressor O
functions O
typical O
of O
normal O
NFKB2 NUMERIC
p52 NUMERIC
. O

Also O
, O
HR21ap NUMERIC
as O
well O
as O
HR21Xap NUMERIC
are O
specific O
in O
their O
inhibition O
of O
Sp1 I-GENE
binding O
. O

Intravenous O
antibiotic O
therapy O
in O
cystic O
fibrosis O
: O
in O
hospital O
or O
at O
home O
? O

Open RARE
reading O
frames O
in O
a O
4556 NUMERIC
nucleotide O
sequence O
within O
MDV I-GENE
- I-GENE
1 I-GENE
BamHI I-GENE
- I-GENE
D I-GENE
DNA I-GENE
fragment I-GENE
: O
evidence O
for O
splicing O
of O
mRNA O
from O
a O
new O
viral O
glycoprotein O
gene O
. O

The O
ns2 NUMERIC
gene I-GENE
comprises O
an O
open O
reading O
frame O
( O
ORF O
) O
encoding O
a O
putative O
nonstructural RARE
( O
ns RARE
) O
protein O
of O
279 NUMERIC
amino O
acids O
with O
a O
predicted O
molecular O
mass O
of O
32 O
- O
kDa O
. O

Co O
- O
transfection O
of O
a O
tat I-GENE
expressing O
plasmid O
with O
these O
viruses O
containing O
the O
tat I-GENE
ORF I-GENE
mutations O
resulted O
in O
higher O
levels O
of O
virus O
production O
demonstrating O
that O
the O
effects O
of O
both O
mutants O
are O
tat I-GENE
specific O
. O

Analysis O
of O
the O
gag I-GENE
and O
rev I-GENE
proteins I-GENE
in O
the O
transfected O
cells O
demonstrated O
that O
these O
proteins O
were O
not O
detectable O
in O
cells O
transfected O
with O
the O
tat I-GENE
mutants I-GENE
but O
could O
be O
readily O
detected O
when O
the O
mutations O
were O
complemented O
in O
trans O
with O
a O
tat I-GENE
expression O
vector O
. O

The O
hydrophobicity RARE
profile O
of O
the O
methyltransferase O
reveals O
the O
presence O
of O
at O
least O
five O
potential O
transmembrane O
domains O
. O

Measurement O
of O
SaO2 O
at O
moderate O
altitude O
can O
be O
helpful O
in O
the O
care O
of O
both O
healthy O
and O
ill RARE
newborns O
or O
infants O
. O

To O
determine O
whether O
the O
excess O
prevalence O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
in O
US O
black O
and O
Hispanic RARE
homosexual RARE
men O
relative O
to O
white O
men O
can O
be O
explained O
by O
differences O
in O
sociodemographic RARE
factors O
, O
history O
of O
sexually RARE
transmitted O
diseases O
, O
or O
sexual O
and O
drug O
- O
use O
behaviors RARE
, O
the O
authors O
conducted O
a O
cross O
- O
sectional O
analysis O
of O
baseline O
HIV O
- O
1 O
seroprevalence RARE
and O
HIV O
- O
1 O
risk O
factors O
among O
4 O
, O
475 NUMERIC
non O
- O
Hispanic RARE
white O
, O
234 NUMERIC
Hispanic RARE
white O
, O
and O
194 NUMERIC
black O
homosexual RARE
men O
from O
four O
centers O
in O
the O
United O
States RARE
( O
Baltimore RARE
/ O
Washington RARE
, O
DC O
, O
Pittsburgh RARE
, O
Chicago RARE
, O
and O
Los RARE
Angeles RARE
). O

The O
patients O
in O
one O
group O
had O
intrauterine O
catheters RARE
inserted O
and O
oxytocin RARE
was O
titrated RARE
to O
achieve O
the O
75th NUMERIC
percentile RARE
of O
uterine O
activity O
observed O
in O
spontaneous O
normal O
labour O
according O
to O
parity RARE
. O

Continued RARE
development O
of O
the O
rat O
conditioning O
paradigm RARE
is O
especially O
warranted O
because O
of O
the O
ability O
to O
record O
sympathetic O
nerve O
activity O
in O
intact O
, O
awake RARE
subjects O
and O
the O
large O
number O
of O
readily O
available O
genetic O
strains O
, O
which O
model O
human O
pathological O
states O
. O

The O
ultrastructure RARE
of O
retinal O
vessels O
was O
examined O
in O
three O
eyes O
from O
diabetic O
patients O
and O
two O
eyes O
from O
control O
subjects O
. O

The O
regulatory O
region O
also O
has O
a O
sequence O
similar O
to O
the O
binding O
site O
for O
a O
liver O
- O
specific O
transcription O
factor O
, O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
HNF I-GENE
- I-GENE
1 I-GENE
), O
at O
positions O
- O
120 O
to O
- O
132 O
. O

Thus O
, O
we O
have O
identified O
a O
GRE O
sufficient O
to O
account O
for O
full O
glucocorticoid O
inducibility O
and O
an O
HNF I-GENE
- I-GENE
1 I-GENE
site I-GENE
close O
to O
the O
promoter O
that O
are O
major O
determinants O
of O
transcriptional O
control O
of O
the O
Xenopus I-GENE
fibrinogen I-GENE
B I-GENE
beta I-GENE
subunit I-GENE
gene I-GENE
in O
cells O
from O
normal O
liver O
tissue O
. O

Acad RARE
. O

The O
PRB ALLCAPS
- I-GENE
1b I-GENE
gene I-GENE
encodes O
for O
a O
basic O
- O
type O
component O
of O
the O
pathogenesis O
- O
related O
PR I-GENE
- I-GENE
1 I-GENE
protein I-GENE
family I-GENE
. O

Replacement O
of O
the O
CRE O
with O
a O
second O
copy O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
results O
in O
a O
level O
of O
transcriptional O
activity O
comparable O
with O
that O
of O
the O
wild O
- O
type O
sequence O
, O
but O
replacement O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
with O
a O
CRE O
abolishes O
activity O
. O

The O
T I-GENE
- I-GENE
cyt I-GENE
promoter I-GENE
, O
although O
of O
bacterial O
origin O
is O
active O
in O
planta RARE
and O
the O
30 I-GENE
bp I-GENE
cyt I-GENE
- I-GENE
1 I-GENE
element I-GENE
is O
located O
within O
a O
region O
that O
is O
essential O
for O
T I-GENE
- I-GENE
cyt I-GENE
promotor RARE
activity O
in O
leaf O
, O
stem O
and O
root O
cells O
of O
tobacco O
plants O
. O

Reviewing RARE
manuscripts RARE
: O
developing O
an O
efficient O
system O
. O

We O
suggest O
that O
CT O
scan O
be O
preferable RARE
in O
diagnosis O
of O
tumors O
in O
that O
area O
. O

SIN ALLCAPS
- O
1 O
had O
no O
influence O
on O
either O
the O
ischemic O
parameters O
in O
the O
surface O
electrocardiogram O
( O
ECG O
) O
or O
the O
intracoronary RARE
ECG O
. O

Effect O
of O
aging O
on O
respiratory O
skeletal O
muscles O
. O

Two O
BASIC ALLCAPS
computer O
programs O
using O
logit RARE
transformation O
for O
the O
analysis O
of O
S O
- O
shaped O
curves O
are O
presented O
. O

The O
yeast I-GENE
SSS1 NUMERIC
gene I-GENE
is O
essential O
for O
secretory O
protein O
translocation O
and O
encodes O
a O
conserved O
protein O
of O
the O
endoplasmic O
reticulum O
. O

The O
lengths O
of O
the O
complete O
polypeptide O
chain O
of O
the O
recombinant O
enzyme O
and O
its O
transit O
peptide O
are O
388 NUMERIC
and O
53 O
residues O
, O
respectively O
. O

The O
absence O
of O
H4PteGlun NUMERIC
bound O
to O
the O
T I-GENE
protein I-GENE
in O
our O
experimental O
conditions O
demonstrates O
that O
H4PteGlun NUMERIC
is O
not O
covalently O
linked O
to O
the O
T I-GENE
protein I-GENE
. O

TATA O
and O
CCAAT O
boxes O
are O
located O
34 O
- O
bp O
and O
68 O
- O
bp O
, O
respectively O
, O
upstream O
of O
the O
transcription O
start O
site O
, O
the O
5 O
'- O
untranslated O
leader O
is O
78 O
nucleotides O
long O
, O
and O
the O
intronless O
gene O
has O
at O
least O
two O
different O
polyadenylation O
sites O
. O

GGS1 NUMERIC
is O
the O
same O
gene O
as O
TPS1 NUMERIC
which O
was O
identified O
as O
encoding O
a O
subunit O
of O
the O
trehalose RARE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
synthase I-GENE
/ I-GENE
phosphatase I-GENE
complex I-GENE
and O
it O
is O
allelic O
to O
the O
fdp1 NUMERIC
, O
byp1 NUMERIC
, O
glc6 NUMERIC
and O
cif1 NUMERIC
mutations O
. O

We O
also O
compared O
the O
sequence O
with O
the O
partly O
homologous O
products O
of O
the O
S O
. O
cerevisiae O
genes O
TPS2 NUMERIC
and O
TSL1 NUMERIC
which O
code O
for O
the O
larger O
subunits O
of O
the O
trehalose RARE
synthase I-GENE
complex I-GENE
and O
with O
a O
TSL1 NUMERIC
homologue I-GENE
, O
TPS3 NUMERIC
, O
of O
unknown O
function O
. O

Stroop O
interference O
: O
aging O
effects O
assessed O
with O
the O
Stroop O
Color RARE
- O
Word RARE
Test O
. O

Stimulation RARE
of O
[ O
3H O
] O
PA O
production O
upon O
CD3 I-GENE
cross O
- O
linking O
was O
77 O
% O
lower O
in O
permeabilized RARE
CD45 NUMERIC
- I-GENE
cells O
than O
in O
CD45 NUMERIC
+ I-GENE
cells O
, O
consistent O
with O
the O
reduced O
activity O
of O
p59fyn NUMERIC
in O
CD45 NUMERIC
- I-GENE
cells O
. O

CONCLUSION O
: O
The O
study O
demonstrates O
that O
transvaginal RARE
ultrasonography O
has O
an O
efficiency O
of O
88 O
% O
in O
differentiating O
endometriomas RARE
from O
other O
ovarian O
masses O
with O
a O
specificity O
of O
90 O
%. O

Genomic O
Southern O
blot O
analysis O
of O
rat I-GENE
EFIA I-GENE
( O
gene O
encoding O
enhancer I-GENE
factor I-GENE
I I-GENE
subunit I-GENE
A I-GENE
) O
reveals O
a O
complex O
band O
pattern O
when O
cDNA O
subfragment RARE
probes O
are O
used O
. O

The O
effect O
of O
ibopamine RARE
and O
furosemide O
in O
130 O
patients O
with O
NYHA ALLCAPS
Class O
I O
and O
II O
heart O
failure O
were O
studied O
in O
a O
parallel O
, O
double O
- O
blind O
, O
randomized O
placebo O
- O
controlled O
multi O
- O
centre RARE
trial O
. O

The O
nit RARE
- I-GENE
3 I-GENE
gene I-GENE
of I-GENE
the I-GENE
filamentous I-GENE
fungus I-GENE
Neurospora I-GENE
crassa I-GENE
encodes O
nitrate I-GENE
reductase I-GENE
, O
the O
enzyme O
which O
catalyzes O
the O
first O
step O
in O
nitrate O
assimilation RARE
. O

Unfolding RARE
can O
be O
described O
by O
a O
two O
- O
state O
process O
since O
a O
ratio O
of O
delta O
Hcalorimetric RARE
to O
delta O
Hvan RARE
' O
t O
Hoff RARE
equals RARE
0 O
. O
96 O
. O

A O
Dictyostelium O
transformant RARE
overexpressing O
DdPTPa RARE
does O
not O
develop O
normally O
. O

This O
motif O
has O
been O
shown O
to O
mediate O
protein O
interactions O
in O
the O
case O
of O
ankyrin RARE
as O
well O
as O
several O
other O
repeat O
- O
bearing O
proteins O
. O

[ I-GENE
Ala85 NUMERIC
] I-GENE
Dk RARE
( I-GENE
69 I-GENE
- I-GENE
85 I-GENE
) I-GENE
retains O
full O
biological O
activity O
. O

We O
postulate RARE
that O
CaM I-GENE
binding O
by O
HIV I-GENE
envelope I-GENE
proteins I-GENE
is O
likely O
to O
exert O
diverse O
modulatory RARE
effects O
, O
and O
the O
mechanism O
for O
HIV O
- O
induced O
cytotoxicity O
may O
involve O
, O
in O
part O
, O
inhibition O
of O
CaM I-GENE
- O
regulated O
cellular O
functions O
. O

There O
was O
no O
apparent O
effect O
of O
growth O
temperature O
on O
the O
steady O
- O
state O
levels O
of O
fad7 NUMERIC
mRNA I-GENE
in O
wild O
type O
plants O
. O

The O
major O
myosin I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
skeletal I-GENE
muscle I-GENE
MyBP LASTCAP
- I-GENE
C I-GENE
( O
C I-GENE
protein I-GENE
) O
resides O
in O
the O
COOH O
- O
terminal O
, O
immunoglobulin I-GENE
C2 I-GENE
motif I-GENE
. O

A O
second O
important O
molecule O
in O
TCR I-GENE
signal O
transduction O
is O
the O
guanine I-GENE
nucleotide I-GENE
binding I-GENE
protein I-GENE
, O
p21ras I-GENE
, O
which O
is O
coupled O
to O
the O
TCR I-GENE
by O
a O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
dependent O
mechanism O
. O

Our O
results O
indicate O
that O
periseizure RARE
lipid O
accumulation O
is O
related O
to O
cortical O
oxygenation O
. O

We O
conclude O
that O
the O
QLMI ALLCAPS
questionnaire O
has O
good O
potential O
as O
an O
instrument O
for O
assessing O
QL ALLCAPS
in O
post O
- O
AMI O
patients O
and O
that O
it O
can O
be O
successfully O
self O
- O
administered O
. O

Most O
smokers O
would O
prefer RARE
to O
quit RARE
smoking O
on O
their O
own O
. O

The O
inhibitory O
response O
to O
taps RARE
is O
essentially O
a O
protective O
reflex O
which O
probably O
serves O
to O
reduce O
the O
activity O
of O
the O
jaw O
- O
closing RARE
muscles O
when O
one O
bites RARE
unexpectedly RARE
on O
hard RARE
objects O
. O

The O
action O
of O
nef I-GENE
was O
specific O
to O
the O
LTR O
, O
as O
expression O
of O
nef I-GENE
had O
no O
effect O
on O
the O
activity O
of O
the O
simian O
virus O
40 O
, O
c I-GENE
- I-GENE
fms I-GENE
, O
urokinase I-GENE
plasminogen I-GENE
activator I-GENE
, O
or O
type I-GENE
5 I-GENE
acid I-GENE
phosphatase I-GENE
promoter I-GENE
. O
trans O
- O
activating O
activity O
was O
also O
manifested O
by O
a O
frameshift O
mutant O
expressing O
only O
the O
first O
35 O
amino O
acids O
of O
the O
protein O
. O

The O
product O
of O
the O
vpr RARE
open I-GENE
reading I-GENE
frame I-GENE
of I-GENE
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
is O
a O
15 O
- O
kDa O
, O
arginine O
- O
rich O
protein O
that O
is O
present O
in O
virions O
in O
molar RARE
quantities RARE
equivalent O
to O
that O
of O
Gag I-GENE
. O

The O
recombinant I-GENE
vaccinia I-GENE
virus I-GENE
- I-GENE
expressed I-GENE
mutant I-GENE
P1 I-GENE
polyproteins RARE
were O
analyzed O
for O
proteolytic O
processing O
defects O
in O
cells O
coinfected RARE
with O
a O
recombinant O
vaccinia O
virus O
( O
VVP3 NUMERIC
) O
that O
expresses RARE
the O
poliovirus RARE
3CD NUMERIC
protease I-GENE
and O
for O
processing O
and O
assembly O
defects O
by O
using O
a O
trans O
complementation O
system O
in O
which O
P1 I-GENE
- O
expressing O
recombinant O
vaccinia O
viruses O
provide O
capsid I-GENE
precursor I-GENE
to O
a O
defective O
poliovirus RARE
genome O
that O
does O
not O
express O
functional O
capsid I-GENE
proteins I-GENE
( O
D O
. O

In O
contrast O
, O
capsid I-GENE
proteins I-GENE
derived O
from O
the O
P1 I-GENE
precursor I-GENE
with O
a O
valine RARE
substitution O
at O
the O
amino O
terminus O
of O
VP1 NUMERIC
( O
VP1 NUMERIC
- I-GENE
G001V NUMERIC
) O
assembled O
empty RARE
capsid O
particles O
but O
were O
deficient O
in O
assembling RARE
RNA O
- O
containing O
virions O
. O

RESULTS O
: O
In O
an O
18 O
moth RARE
period O
and O
out O
of O
a O
total O
of O
284 NUMERIC
positive O
blood O
cultures O
( O
154 O
significant O
isolations RARE
) O
14 O
episodes O
of O
bacteremia RARE
by O
M O
. O
tuberculosis O
were O
studied O
in O
12 O
prison RARE
patients O
coinfected RARE
by O
the O
human O
immunodeficiency O
virus O
with O
associated O
severe O
immunosuppression RARE
( O
mean O
of O
CD4 I-GENE
= O
0 O
. O
068 NUMERIC
x O
10 O
( O
9 O
)/ O
l O
). O

Acid RARE
instilled RARE
on O
the O
larynx O
of O
maturing RARE
rabbits O
resulted O
in O
significant O
obstructive RARE
, O
central O
, O
and O
mixed O
apnea O
. O

By O
using O
total O
- O
protein O
extracts O
from O
mycelia RARE
grown O
under O
penicillin O
producing O
conditions O
we O
have O
detected O
a O
DNA O
- O
binding O
activity O
that O
specifically O
shifts O
a O
promoter O
fragment O
located O
between O
- O
654 NUMERIC
and O
- O
455 NUMERIC
( O
relative O
to O
IPNS ALLCAPS
tsp RARE
). O

A O
series O
of O
5 O
'- O
deletions O
revealed O
that O
the O
fragment O
- O
218 NUMERIC
to O
+ O
4 O
from O
the O
TSS ALLCAPS
had O
the O
highest O
promoter O
activity O
, O
nearly O
1000 O
- O
fold O
greater O
than O
the O
promoterless O
chloramphenicol I-GENE
acetyltransferase I-GENE
construct I-GENE
. O

The O
lemdr1 NUMERIC
gene I-GENE
was O
cloned O
in O
the O
expression O
vector O
pALTNEO LASTCAP
and O
transfected O
into O
wild O
- O
type O
L O
. O
enriettii RARE
and O
the O
resulting O
transfected O
cells O
were O
resistant O
to O
vinblastine RARE
but O
at O
lower O
levels O
than O
in O
the O
selected O
mutant O
cells O
. O

The O
bioavailability RARE
of O
etodolac RARE
from O
capsules O
exposed O
to O
stressed O
conditions O
was O
compared O
in O
both O
dogs O
and O
humans O
to O
capsules O
stored O
at O
RT O
conditions O
. O

Similar O
synergistic O
activation O
was O
observed O
in O
the O
IL I-GENE
- I-GENE
8 I-GENE
promoter I-GENE
, O
which O
also O
contains O
both O
NF I-GENE
- I-GENE
IL6 I-GENE
and O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
binding I-GENE
sites I-GENE
. O

Notice RARE
of O
retraction RARE
. O

No O
homology O
was O
found O
between O
the O
36K NUMERIC
protein O
and O
known O
structures O
of O
proteins O
. O

We O
report O
an O
odd RARE
case O
of O
marked O
enlargement O
of O
suprapineal RARE
recess RARE
in O
a O
patient O
with O
triventricular RARE
hydrocephalus RARE
. O

As O
regards RARE
lipid O
metabolism O
, O
the O
mean O
values O
for O
total O
triglycerides O
, O
cholesterol O
, O
LDL I-GENE
- I-GENE
cholesterol I-GENE
and O
HDL I-GENE
- I-GENE
cholesterol I-GENE
seen O
at O
the O
end O
of O
five O
years O
of O
Norplant RARE
- O
2 O
rod RARE
use O
and O
six O
months O
postremoval RARE
were O
similar O
to O
the O
preinsertion RARE
mean O
. O

At O
a O
PaCO2 O
of O
40 O
mmHg O
, O
baseline O
brain O
pHi RARE
measured O
7 O
. O
03 O
+/- O
0 O
. O
04 O
, O
while O
regional O
cortical O
blood O
flow O
was O
47 O
. O
0 O
+/- O
4 O
. O
3 O
ml O
. O
100 O
g O
- O
1 O
. O
min O
- O
1 O
. O

CPAP ALLCAPS
reduced O
isotime RARE
( O
defined O
as O
the O
last O
common O
minute O
of O
exercise O
) O
VO2 O
and O
dyspnea RARE
in O
those O
patients O
with O
more O
severe O
lung O
disease O
, O
but O
these O
values O
tended O
to O
increase O
slightly O
in O
the O
patients O
with O
only O
mild O
lung O
disease O
. O

Effects O
of O
diltiazem O
on O
netilmicin RARE
- O
induced O
nephrotoxicity RARE
in O
rabbits O
. O

Four O
forms O
of O
salmonellosis RARE
were O
recognised RARE
in O
feedlots RARE
and O
during O
transport O
by O
sea O
: O
septicaemic RARE
, O
and O
acute O
, O
subacute O
and O
chronic O
enteric O
. O

About RARE
20 O
% O
of O
single O
- O
stranded O
DNA O
binding O
was O
observed O
in O
the O
presence O
of O
MgdTDP LASTCAP
, O
but O
none O
was O
detectable O
in O
the O
absence O
of O
nucleotides O
. O

To O
our O
knowledge O
this O
is O
the O
first O
case O
in O
which O
a O
probable O
association O
between O
cholelithiasis RARE
and O
Wildervanck RARE
' O
s O
syndrome O
has O
been O
recorded O
. O

Both O
4 O
, O
8 O
- O
DiMeIQx RARE
and O
A O
alpha O
C O
were O
found O
at O
< O
1 O
p O
. O
p O
. O
b O
. O

Three O
cysteine O
and O
four O
tryptophan O
residues O
, O
previously O
identified O
as O
conserved O
amongst RARE
nitrous RARE
- I-GENE
oxide I-GENE
reductases RARE
, O
are O
found O
in O
the O
Paracoccus RARE
enzyme O
. O

Recombinant I-GENE
Leishmania I-GENE
surface I-GENE
glycoprotein I-GENE
GP63 NUMERIC
is O
secreted O
in O
the O
baculovirus O
expression O
system O
as O
a O
latent O
metalloproteinase RARE
. O

Delineating RARE
the O
molecular O
basis O
for O
agonist O
- O
induced O
destabilization RARE
of O
mRNA O
of O
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
linked I-GENE
receptors I-GENE
that O
contributes O
to O
receptor O
down O
- O
regulation O
is O
fundamental RARE
to O
our O
understanding O
of O
long O
- O
term O
regulation O
of O
receptors O
by O
agonist O
. O

Addition O
of O
phalloidin RARE
- O
stabilized O
F I-GENE
- I-GENE
actin I-GENE
nuclei O
and O
phalloidin RARE
restored O
L266D NUMERIC
actin I-GENE
' O
s O
ability O
to O
polymerize RARE
at O
4 O
degrees O
C O
. O

These O
cells O
produce O
a O
low O
level O
of O
IL I-GENE
- I-GENE
5 I-GENE
when O
stimulated O
with O
PMA O
alone O
; O
however O
, O
N6 NUMERIC
, O
O2 O
- O
dibutyryl RARE
cAMP O
( O
Bt2cAMP NUMERIC
), O
in O
combination O
with O
PMA O
, O
augmented O
by O
more O
than O
tenfold RARE
the O
IL I-GENE
- I-GENE
5 I-GENE
production O
at O
the O
mRNA O
and O
the O
protein O
levels O
. O

Hu RARE
- I-GENE
Met I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
expression O
in O
a O
small O
number O
of O
human O
T O
cell O
tumor O
lines O
did O
not O
correlate O
with O
any O
particular O
phenotype O
or O
stage O
of O
development O
. O

Partial O
engorgement RARE
was O
higher O
in O
the O
treatments O
. O

Northern O
( O
RNA O
) O
analysis O
demonstrated O
expression O
of O
human O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
in O
all O
tissues O
and O
cell O
lines O
tested O
. O

These O
results O
demonstrate O
the O
existence O
of O
different O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
isoforms I-GENE
and O
define O
a O
family O
of O
genes O
encoding O
distinct O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
catalytic I-GENE
subunits I-GENE
that O
can O
associate O
with O
p85 I-GENE
. O

In O
addition O
to O
the O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinase I-GENE
domain I-GENE
, O
p56lck NUMERIC
possesses O
Src I-GENE
homology I-GENE
2 I-GENE
and I-GENE
3 I-GENE
( O
SH2 I-GENE
and O
SH3 I-GENE
) O
domains O
as O
well O
as O
a O
unique O
N O
- O
terminal O
region O
. O

Strains RARE
bearing O
the O
drs2 NUMERIC
mutation I-GENE
process O
the O
20S I-GENE
precursor I-GENE
of O
the O
mature I-GENE
18S NUMERIC
rRNA I-GENE
slowly O
and O
are O
deficient O
in O
40S NUMERIC
ribosomal I-GENE
subunits I-GENE
. O

Hepatitis O
B O
and O
liver O
transplantation O
. O

One O
complex O
most O
likely O
contained O
Sp1 I-GENE
, O
and O
another O
complex O
showed O
S O
- O
phase O
- O
specific O
binding O
, O
suggesting O
a O
direct O
role O
in O
the O
cell O
- O
cycle O
- O
dependent O
R1 I-GENE
gene I-GENE
expression O
. O

These O
combined O
observations O
define O
a O
promoter O
and O
an O
enhancer O
for O
the O
chicken I-GENE
L I-GENE
- I-GENE
CAM ALLCAPS
gene I-GENE
. O

The O
rate O
of O
enzymic RARE
stimulation O
induced O
by O
a O
given O
nitrate O
correlates O
closely O
with O
the O
rate O
of O
measured O
NO O
production O
from O
the O
nitrate O
molecule O
. O

Clipping RARE
resulted O
in O
a O
serious O
mislocalization RARE
of O
the O
position O
of O
the O
peak O
of O
the O
epicortical RARE
potential O
field O
. O

The O
duration O
of O
diabetes O
mellitus O
in O
these O
patients O
was O
from O
5 O
months O
to O
6 O
years O
, O
and O
in O
all O
patients O
this O
was O
the O
first O
myocardial O
infarction O
. O

The O
247 NUMERIC
- O
kDa O
complex O
appears O
to O
contain O
two O
distinct O
protein O
- O
DNA O
complexes O
of O
approximately O
232 NUMERIC
and O
256 O
kDa O
and O
represents O
two O
proteins O
covalently O
cross O
- O
linked O
to O
a O
single O
DRE O
oligonucleotide O
, O
while O
the O
97 O
, O
105 O
, O
and O
115 O
- O
kDa O
complexes O
represent O
single O
protein O
- O
DRE O
cross O
- O
links O
. O

The O
promoter O
and O
upstream O
region O
of O
the O
Brassica RARE
napus I-GENE
2S NUMERIC
storage I-GENE
protein I-GENE
napA LASTCAP
gene I-GENE
were O
studied O
to O
identify O
cis O
- O
acting O
sequences O
involved O
in O
developmental O
seed O
- O
specific O
expression O
. O

However O
, O
limited O
comparisons O
reveal O
domains O
in O
the O
NH2 O
and O
COOH O
termini O
that O
have O
a O
high O
degree O
of O
similarity O
suggesting O
functional O
conservation O
. O

Rinit RARE
reflects RARE
the O
Newtonian RARE
resistances RARE
and O
Rdiff RARE
represents O
the O
viscoelastic RARE
/ O
inhomogeneous RARE
pressure O
dissipations RARE
in O
the O
system O
. O

We O
have O
explored O
the O
mechanism O
of O
action O
of O
the O
fibronectin I-GENE
splicing I-GENE
enhancer I-GENE
and O
found O
that O
the O
SE O
element O
is O
required O
for O
efficient O
assembly O
of O
early O
splicing O
complexes O
, O
allowing O
a O
more O
efficient O
interaction O
of O
the O
U2 I-GENE
snRNP I-GENE
with O
branch O
site O
sequences O
. O

Inspection RARE
of O
enhancer O
mutants O
suggests O
that O
trans O
- O
activation O
by O
hLEF LASTCAP
/ O
GAL4 I-GENE
is O
especially O
dependent O
on O
TCF I-GENE
- I-GENE
2 I-GENE
, O
a O
distinct O
T O
- O
cell O
- O
enriched O
protein O
that O
binds O
to O
sequences O
flanking O
the O
hLEF LASTCAP
- I-GENE
binding I-GENE
site I-GENE
in O
the O
enhancer O
. O

We O
conclude O
that O
sequences O
outside O
of O
the O
hLEF LASTCAP
HMG I-GENE
box I-GENE
mediate O
cell O
- O
and O
context O
- O
specific O
activation O
of O
the O
TCR I-GENE
alpha I-GENE
enhancer I-GENE
and O
may O
facilitate O
interactions O
between O
hLEF LASTCAP
and O
other O
T O
- O
cell O
- O
specific O
factors O
recruited O
to O
the O
enhancer O
. O

A O
cAMP O
response O
element O
( O
CRE O
) O
consensus O
signal O
was O
identified O
in O
the O
5 O
'- O
noncoding O
region O
. O
cAMP O
regulates O
the O
expression O
of O
Kv1 NUMERIC
. I-GENE
5 I-GENE
gene I-GENE
in O
a O
cell O
- O
specific O
manner O
. O

A O
number O
of O
serological O
tests O
measuring O
the O
presence O
of O
Helicobacter RARE
pylori O
- O
specific O
serum O
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
are O
now O
commercially RARE
available O
. O

Using O
a O
series O
of O
mutant I-GENE
T I-GENE
antigens I-GENE
expressed O
by O
recombinant O
baculoviruses RARE
in O
Sf9 O
cells O
, O
we O
find O
that O
the O
origin O
unwinding RARE
activities O
of O
both O
TS677 NUMERIC
--> O
A O
and O
TS677 NUMERIC
, O
679 NUMERIC
--> O
A O
are O
inhibited O
by O
the O
T I-GENE
- I-GENE
antigen I-GENE
kinase I-GENE
, O
as O
is O
wild I-GENE
- I-GENE
type I-GENE
T I-GENE
antigen I-GENE
. O

The O
degree O
of O
hypoperfusion RARE
was O
slightly O
related O
to O
decrease O
in O
FEV1 O
. O
0 O
%, O
V25 NUMERIC
and O
PaO2 O
and O
increase O
in O
circulating O
blood O
volume O
and O
peripheral O
red O
blood O
cell O
counts O
. O

Two O
patients O
were O
treated O
successfully O
with O
a O
combination O
of O
metronidazole RARE
( O
a O
tissue O
amoebicide RARE
) O
and O
diloxanide RARE
( O
a O
lumenal RARE
amoebicide RARE
). O

We O
have O
identified O
in O
the O
5 O
' O
untranslated O
region O
of O
the O
Drosophila I-GENE
copia RARE
retrotransposon I-GENE
, O
3 O
' O
to O
the O
left O
LTR O
, O
a O
sequence O
for O
transcriptional O
regulation O
by O
homeoproteins RARE
. O

In O
the O
present O
study O
, O
lesions O
of O
the O
OPT ALLCAPS
complex O
( O
the O
thalamic RARE
source O
of O
afferents O
to O
IHA ALLCAPS
and O
HD O
) O
were O
found O
to O
have O
no O
effect O
on O
color O
- O
reversal O
learning O
performance O
. O

The O
fourth O
dose O
produced O
favorable RARE
results O
( O
66 O
. O
7 O
%) O
in O
individuals O
with O
HB I-GENE
antibodies I-GENE
between O
10 O
and O
100 O
IU O
/ O
ml O
and O
unfavorable RARE
ones O
( O
3 O
. O
8 O
%) O
where O
the O
HB I-GENE
antibodies I-GENE
were O
below O
10 O
IU O
/ O
ml O
. O

CONCLUSIONS O
: O
In O
our O
patients O
and O
within O
the O
range O
of O
treatment O
variables O
studied O
, O
age O
, O
Karnofsky RARE
index O
, O
and O
graft O
- O
versus O
- O
host O
disease O
are O
the O
most O
important O
factors O
related O
with O
early O
mortality O
. O

Nucleotide O
sequence O
analysis O
of O
the O
HA I-GENE
gene I-GENE
in O
these O
two O
mutants O
confirmed O
the O
HA I-GENE
- I-GENE
phenotype O
. O

This O
intron O
occupies RARE
a O
conserved O
position O
corresponding O
to O
that O
of O
intron O
1 O
in O
the O
transit O
peptide O
region O
of O
chloroplast I-GENE
GAPDH ALLCAPS
genes I-GENE
( O
GapA LASTCAP
and O
GapB LASTCAP
) O
of O
higher O
plants O
. O

The O
drug O
- O
resistant O
cell O
lines O
P388 O
/ O
ADR O
/ O
3 O
and O
P388 O
/ O
ADR O
/ O
7 O
express O
a O
shortened O
topo RARE
II I-GENE
alpha I-GENE
mRNA I-GENE
transcript I-GENE
in O
addition O
to O
the O
native O
transcript O
present O
in O
the O
drug O
- O
sensitive O
P388 O
/ O
4 O
cell O
line O
. O

Using O
a O
3 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
strategy O
, O
we O
have O
cloned O
cDNAs O
representing O
the O
3 O
'- O
termini O
of O
both O
the O
native O
and O
mutant O
transcripts O
from O
both O
P388 O
/ O
ADR O
/ O
3 O
and O
P388 O
/ O
ADR O
/ O
7 O
cells O
. O

The O
phi I-GENE
AP3 NUMERIC
factor I-GENE
is O
a O
nuclear O
phosphoprotein O
; O
the O
extent O
of O
its O
phosphorylation O
is O
regulated O
during O
the O
cell O
cycle O
. O

Similarly O
, O
the O
N O
- O
terminal O
cytoplasmic O
domain O
of O
the O
latent I-GENE
membrane I-GENE
protein I-GENE
2A I-GENE
( O
LMP2A NUMERIC
) O
of O
the O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
contains O
a O
single O
copy O
of O
the O
Tyr O
- O
X O
- O
X O
- O
Leu O
/ O
Ile O
- O
containing O
motif O
which O
could O
play O
a O
critical O
role O
in O
B O
cell O
transformation O
. O

The O
functional O
homology O
of O
Cwg2 NUMERIC
with O
Cdc43 NUMERIC
, O
which O
has O
been O
implicated O
in O
the O
control O
of O
cell O
polarity O
, O
suggests O
a O
link O
between O
two O
morphogenetic RARE
events O
such O
as O
establishment O
of O
cell O
polarity O
and O
cell O
wall O
biosynthesis O
. O

Molecular O
cloning O
of O
a O
P I-GENE
- I-GENE
type I-GENE
ATPase I-GENE
gene I-GENE
from O
the O
cyanobacterium RARE
Synechocystis RARE
sp O
. O

The O
cloning O
of O
PTR2 NUMERIC
represents O
the O
first O
example O
of O
the O
molecular O
genetic O
characterization O
of O
a O
eucaryotic RARE
peptide O
transport O
gene O
. O

By O
using O
the O
full O
- O
length O
cytoplasmic O
domain O
and O
mutants O
with O
progressive O
carboxy O
- O
terminal O
deletions O
, O
internal O
deletions O
, O
or O
point O
mutations O
, O
we O
identified O
the O
first O
150 O
amino O
acid O
residues O
of O
LIFR ALLCAPS
as O
the O
minimal O
region O
necessary O
for O
signaling O
. O

To O
examine O
the O
biochemical O
basis O
of O
the O
end O
joining O
, O
nuclear O
extracts O
were O
prepared O
from O
a O
wide O
variety O
of O
mammalian O
cell O
lines O
and O
tested O
for O
their O
ability O
to O
join RARE
test O
plasmid O
substrates O
. O

These O
data O
indicate O
that O
the O
largest O
subunit O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
and O
TFIIB ALLCAPS
are O
important O
determinants O
of O
transcription O
start O
site O
selection O
in O
S O
. O
cerevisiae O
and O
suggest O
that O
this O
function O
might O
be O
conferred O
by O
interaction O
between O
these O
two O
proteins O
. O

Recombinant O
expression O
of O
a O
chimeric O
EGFR I-GENE
/ O
ErbB I-GENE
- I-GENE
3 I-GENE
receptor I-GENE
in O
NIH O
3T3 O
fibroblasts O
allowed O
us O
to O
investigate O
cytoplasmic O
events O
associated O
with O
ErbB I-GENE
- I-GENE
3 I-GENE
signal O
transduction O
upon O
ligand O
activation O
. O

Oligonucleotide RARE
competitors RARE
were O
used O
to O
evaluate O
the O
accessibility RARE
of O
the O
TATA O
- O
binding O
site O
in O
TIF I-GENE
- I-GENE
IB ALLCAPS
, O
TFIID I-GENE
, O
and O
TFIIIB ALLCAPS
. O

The O
227 NUMERIC
- O
to O
- O
239 O
region O
blocked O
ADR1 I-GENE
activity O
independently O
of O
the O
TAD ALLCAPS
present O
on O
ADR1 I-GENE
, O
ADR1 I-GENE
DNA O
binding O
, O
and O
specific O
ADH2 NUMERIC
promoter I-GENE
sequences I-GENE
. O

Analysis O
of O
strains O
harboring O
an O
mds1 NUMERIC
null I-GENE
mutation I-GENE
demonstrates O
that O
MDS1 NUMERIC
is O
not O
essential O
during O
normal O
vegetative RARE
growth O
but O
appears O
to O
be O
required O
for O
meiosis O
. O

TGF I-GENE
beta I-GENE
1 I-GENE
expression O
is O
largely O
governed RARE
by O
three O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
located O
in O
two O
different O
promoters O
of O
this O
gene O
. O

Val O
--> O
Ala O
mutations O
selectively O
alter O
helix O
- O
helix O
packing RARE
in O
the O
transmembrane O
segment O
of O
phage I-GENE
M13 NUMERIC
coat I-GENE
protein I-GENE
. O

Strategic RARE
change O
in O
the O
NHS ALLCAPS
. O

A O
much O
less O
expensive RARE
solution O
than O
UW ALLCAPS
, O
containing O
only O
K O
(+)- O
lactobionate RARE
, O
KH2PO4 NUMERIC
, O
MgSO4 NUMERIC
and O
raffinose RARE
, O
can O
be O
used O
successfully O
for O
preservation O
of O
rat O
hepatocytes O
for O
24 O
hr O
for O
drug O
transport O
studies O
. O

Repeated RARE
administration O
of O
GRg2 NUMERIC
20 O
mg O
/ O
kg O
i O
. O
p O
. O
significantly O
improved O
the O
CYP ALLCAPS
- O
induced O
recognitional RARE
deficits O
by O
increasing O
the O
CYP ALLCAPS
- O
decreased O
rate O
from O
55 O
. O
8 O
+/- O
9 O
. O
6 O
to O
80 O
. O
8 O
+/- O
4 O
. O
2 O
in O
d O
3 O
learning O
acquisition O
( O
F O
( O
1 O
, O
14 O
) O
= O
5 O
. O
6 O
, O
p O
< O
0 O
. O
05 O
), O
from O
53 O
. O
4 O
+/- O
8 O
. O
4 O
to O
60 O
. O
0 O
+/- O
8 O
. O
2 O
in O
48 O
h O
memory O
acquisition O
( O
F O
( O
1 O
, O
14 O
) O
= O
7 O
. O
5 O
, O
p O
< O
0 O
. O
05 O
) O
and O
from O
55 O
. O
0 O
+/- O
5 O
. O
5 O
to O
88 O
. O
3 O
+/- O
2 O
. O
5 O
in O
24 O
h O
memory O
retention O
( O
F O
( O
1 O
, O
12 O
) O
27 O
. O
5 O
, O
p O
< O
0 O
. O
01 O
) O
as O
well O
as O
from O
60 O
. O
0 O
+/- O
6 O
. O
8 O
to O
85 O
. O
6 O
+/- O
6 O
. O
9 O
in O
48 O
h O
memory O
retrieval RARE
( O
F O
( O
1 O
, O
12 O
) O
= O
5 O
. O
2 O
, O
p O
< O
0 O
. O
05 O
), O
respectively O
. O

Human I-GENE
bcl3 NUMERIC
protein I-GENE
specifically O
displaces RARE
( I-GENE
p50 I-GENE
) I-GENE
2 I-GENE
- I-GENE
DNA I-GENE
complexes I-GENE
. O

The O
therapeutic O
action O
of O
cyclosporin O
A O
( O
Sandimmun RARE
): O
its O
application O
in O
rheumatoid O
arthritis O
. O

In O
vitro O
translation O
experiments O
show O
that O
human O
cDNA O
derived O
RNA O
translates RARE
into O
a O
protein O
with O
a O
mobility O
of O
44 O
- O
46 O
kD O
on O
SDS O
polyacrylamide O
gels O
. O

After O
peripheral O
administration O
of O
both O
CRF I-GENE
and O
TRH I-GENE
, O
ACTH I-GENE
levels O
were O
significantly O
higher O
on O
the O
tumor O
side O
in O
all O
patients O
. O

Pentazocine RARE
analgesia O
: O
is O
there O
a O
niche RARE
for O
Talwin RARE
Nx RARE
? O
Pentazocine RARE
can O
be O
a O
useful O
analgesic O
agent O
for O
the O
management O
of O
acute O
dental O
pain O
. O

A O
sequence O
homology O
analysis O
between O
human I-GENE
nm23 NUMERIC
- I-GENE
H1 I-GENE
and O
the O
homolog O
gene O
of O
the O
rat O
( O
NDP ALLCAPS
- I-GENE
K I-GENE
beta I-GENE
) O
shows O
that O
exon O
- O
intron O
boundaries O
are O
well O
conserved O
between O
these O
two O
species O
. O

A O
favourable O
response O
was O
achieved O
with O
a O
combination O
of O
amphotericin O
B O
and O
cotrimoxazole RARE
. O

Response O
durations O
were O
short O
. O

RESULTS O
: O
At O
the O
beginning O
of O
the O
QA ALLCAPS
/ O
QI ALLCAPS
process O
, O
monitoring O
of O
blood O
administration O
practices RARE
revealed O
that O
a O
variance RARE
from O
institutional RARE
blood O
administration O
policy RARE
occurred O
during O
50 O
percent O
of O
blood O
and O
component O
transfusions RARE
. O

In O
addition O
, O
REP21 NUMERIC
plants O
were O
resistant O
to O
an O
unusually O
broad O
range O
of O
tobamoviruses RARE
including O
tomato O
mosaic O
virus O
, O
tobacco O
mild O
green O
mosaic O
virus O
, O
TMV ALLCAPS
- O
U5 O
, O
green O
tomato O
atypical O
mosaic O
virus O
, O
and O
ribgrass RARE
mosaic O
virus O
. O

Drug O
effect O
, O
measured O
as O
postural RARE
sway RARE
, O
was O
also O
similar O
in O
the O
patients O
with O
cirrhosis O
and O
control O
subjects O
; O
therefore O
the O
ratio O
of O
effect O
area O
under O
the O
curve O
to O
concentration O
area O
under O
the O
curve O
, O
a O
measure O
of O
sensitivity O
, O
did O
not O
differ O
significantly O
between O
the O
patients O
with O
cirrhosis O
and O
the O
control O
subjects O
. O

We O
present O
evidence O
that O
YY1 I-GENE
, O
a O
ubiquitously O
expressed O
DNA O
- O
binding O
protein O
, O
regulates O
the O
activity O
of O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
primarily O
through O
an O
effect O
on O
DNA O
structure O
. O

In O
a O
retrospective O
analysis O
of O
first O
- O
time O
total O
colonoscopies RARE
in O
685 NUMERIC
patients O
, O
we O
investigated O
the O
relationship O
between O
hyperplastic RARE
and O
adenomatous RARE
polyps O
. O

The O
rate O
of O
decrement RARE
in O
DPOAE ALLCAPS
amplitude O
over O
a O
prescribed RARE
time O
period O
was O
utilized O
as O
a O
measure O
of O
susceptibility O
to O
the O
acoustic O
trauma O
. O

Effect O
of O
single O
base O
substitutions O
at O
glycine O
- O
870 NUMERIC
codon O
of O
gramicidin RARE
S I-GENE
synthetase I-GENE
2 I-GENE
gene I-GENE
on O
proline O
activation O
. O

The O
predicted O
Pay4p NUMERIC
sequence I-GENE
contains O
two O
putative O
ATP O
- O
binding O
domains O
and O
shows O
structural O
relationships O
to O
other O
potential O
ATP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
involved O
in O
biological O
processes O
as O
diverse O
as O
peroxisome O
biogenesis O
, O
vesicle O
- O
mediated O
protein O
transport O
, O
cell O
cycle O
control O
, O
and O
transcriptional O
regulation O
. O

The O
results O
show O
that O
the O
structure O
of O
the O
decorin RARE
gene I-GENE
promoter I-GENE
is O
different O
from O
that O
of O
any O
other O
proteoglycan O
promoter O
characterized O
so O
far O
and O
indicate O
that O
the O
pur RARE
/ O
pyr RARE
segment O
plays O
a O
role O
in O
the O
regulation O
of O
gene O
transcription O
. O

The O
kinase O
inhibitor O
staurosporine RARE
( O
1 O
microM O
) O
blocks O
LPA ALLCAPS
- O
induced O
, O
but O
not O
epidermal O
growth O
factor O
- O
induced O
, O
activation O
of O
p21ras I-GENE
and O
MAP I-GENE
kinase I-GENE
, O
consistent O
with O
an O
intermediate O
protein O
kinase O
linking O
the O
LPA ALLCAPS
receptor I-GENE
to O
p21ras I-GENE
activation O
. O

267 NUMERIC
, O
4870 NUMERIC
- O
4877 NUMERIC
)) O
indicates O
an O
overall O
identity O
of O
58 O
and O
56 O
%, O
respectively O
, O
with O
a O
91 O
and O
92 O
% O
identity O
in O
the O
highly O
conserved O
transmembrane O
and O
cytoplasmic O
domains O
. O

S O
., O
K O
. O

The O
survival O
rate O
at O
forty RARE
months O
in O
15 O
patients O
with O
N2 O
disease O
who O
underwent O
R2b NUMERIC
operation O
was O
51 O
%. O

Mothers RARE
with O
severe O
anatomical O
abnormalities O
, O
who O
are O
HIV O
positive O
, O
have O
active O
TB O
or O
whose O
children O
have O
inherited O
mono O
- O
or O
disaccharide RARE
intolerances RARE
should O
not O
breastfeed RARE
. O

G O
. O

The O
psaD LASTCAP
, O
psaF LASTCAP
, O
psaH LASTCAP
, O
and O
psaL LASTCAP
products I-GENE
have O
two O
isoforms O
each O
that O
are O
distinguished O
by O
different O
mobilities RARE
in O
polyacrylamide O
gel O
electrophoresis O
, O
and O
the O
psaE LASTCAP
product I-GENE
has O
four O
isoforms O
. O

When O
Hy RARE
- O
Vac RARE
SPF ALLCAPS
type O
V O
embryos O
were O
exposed O
to O
either O
0 O
. O
20 O
ml O
50 O
% O
ethanol O
in O
CRS O
or O
to O
0 O
. O
20 O
ml O
CRS O
( O
controls O
), O
ethanol O
- O
treated O
embryos O
showed O
a O
VSD ALLCAPS
incidence O
of O
34 O
. O
1 O
% O
compared O
with O
a O
3 O
. O
6 O
% O
incidence O
in O
the O
controls O
( O
P O
= O
0 O
. O
0017 NUMERIC
). O

Peripheral RARE
vitreochorioretinal RARE
dystrophies RARE
in O
myopia RARE
patients O

In O
our O
studies O
, O
we O
utilized O
HIV O
- O
1 O
HXB2 NUMERIC
and O
HIV O
- O
1 O
Z2Z6 NUMERIC
core I-GENE
enhancers I-GENE
because O
the O
Z2Z6 NUMERIC
strain O
has O
a O
single O
point O
mutation O
flanking O
the O
right O
ETS I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

The O
secondary O
, O
but O
not O
the O
primary O
, O
antibody O
responses O
of O
male O
C57Bl NUMERIC
/ O
6 O
mice O
were O
higher O
among O
mice O
housed RARE
alone O
compared O
to O
mice O
housed RARE
in O
groups O
; O
differences O
were O
observed O
for O
both O
IgM I-GENE
and O
IgG I-GENE
anti I-GENE
- I-GENE
KLH ALLCAPS
antibodies I-GENE
. O

However O
, O
a O
surprisingly RARE
high O
degree O
of O
conservation O
of O
intron O
sequences O
was O
observed O
between O
both O
species O
. O

Interleukin I-GENE
- I-GENE
6 I-GENE
may O
possibly O
potentiate RARE
metastasis O
of O
cardiac O
myxoma RARE
. O

Other O
parameters O
of O
iron O
metabolism O
, O
including O
ferritin I-GENE
, O
were O
not O
found O
to O
contribute O
to O
the O
risk O
. O

Responses RARE
to O
the O
Plowright RARE
Rinderpest RARE
vaccine O
by O
43 O
calves O
and O
70 O
adult O
cattle O
in O
Uganda RARE
in O
1990 O
, O
through O
the O
production O
of O
IgG I-GENE
antibodies I-GENE
, O
were O
monitored O
for O
4 O
weeks O
using O
the O
ELISA O
assay O
. O

Because O
of O
the O
small O
number O
of O
visceral O
angiography O
procedures O
performed O
( O
38 O
), O
no O
definitive O
conclusions O
could O
be O
drawn RARE
as O
to O
the O
differences O
between O
ionic O
and O
nonionic RARE
agents O
regarding O
grade O
- O
2 O
and O
grade O
- O
3 O
adverse O
events O
. O

Tumours RARE
of O
the O
cavum RARE
oris RARE
and O
oropharynx RARE
of O
T1 O
- O
stage O
are O
possible O
only O
in O
1 O
of O
3 O
cases O
. O

Thomas RARE
' O
Hospital RARE
solution O
( O
with O
95 O
% O
O2 O
: O
5 O
% O
CO2 O
) O
can O
meet RARE
the O
metabolic O
demand O
of O
the O
ischaemic O
myocardium O
and O
thus O
increase O
the O
safe O
duration O
of O
cardiac O
arrest O
. O

Plasma O
, O
LDL I-GENE
and O
liver O
cholesterol O
concentrations O
were O
higher O
in O
the O
hyperlipidemic RARE
control O
than O
the O
nonhyperlipidemic RARE
control O
and O
lower O
in O
the O
groups O
fed O
diets O
containing O
pectin RARE
or O
prune RARE
fiber O
than O
in O
the O
hyperlipidemic RARE
control O
group O
. O

The O
Stryker RARE
frame O
modification O
to O
the O
standard O
Dornier RARE
HM3 NUMERIC
lithotriptor RARE
allows O
for O
improved O
visualization O
and O
easier RARE
localization O
of O
distal O
ureteral RARE
calculi RARE
compared O
to O
the O
standard O
gantry RARE
. O

Glomerular RARE
mesangial RARE
cells O
expressed O
an O
abundant O
1 O
. O
1 O
kb O
mRNA O
transcript O
for O
Id1 NUMERIC
, O
but O
in O
contrast O
to O
other O
cell O
types O
Id1 NUMERIC
mRNA I-GENE
was O
expressed O
in O
both O
randomly O
cycling RARE
cells O
and O
in O
serum O
- O
deprived O
, O
quiescent RARE
cultures O
. O

Routine RARE
psychometric RARE
screening O
of O
IHD ALLCAPS
patients O
may O
provide O
a O
cost O
- O
effective O
means O
of O
alerting RARE
cardiologists RARE
and O
internists RARE
to O
the O
relatively O
high O
levels O
of O
distress O
among O
their O
patients O
. O

A O
single O
1 O
. O
8 O
- O
kb O
transcript O
mRNA O
was O
detected O
by O
Northern O
( O
RNA O
) O
blot O
analysis O
, O
and O
its O
5 O
' O
end O
maps O
to O
a O
position O
51 O
bp O
upstream O
from O
the O
site O
of O
initiation O
of O
protein O
synthesis O
. O

Employing RARE
this O
sequence O
information O
from O
c11 NUMERIC
/ O
1 O
, O
the O
c11 NUMERIC
/ O
1 O
- O
specific O
cDNA O
was O
generated O
from O
poly O
( O
A O
)+ O
RNA O
of O
bovine O
PMNLs RARE
by O
reverse O
transcription O
and O
a O
combination O
of O
polymerase O
chain O
reaction O
( O
PCR O
) O
methods O
. O

The O
sequence O
similarity O
has O
suggested O
that O
SCG10 NUMERIC
and O
stathmin RARE
have O
been O
derived O
from O
structurally O
and O
evolutionarily O
related O
genes O
. O

These O
data O
are O
consistent O
with O
the O
idea O
that O
the O
neuron I-GENE
- I-GENE
specific I-GENE
SCG10 NUMERIC
gene I-GENE
evolved O
by O
duplication O
and O
modification O
of O
the O
more O
broadly O
expressed O
stathmin RARE
/ O
Lap18 NUMERIC
gene O
. O

The O
deduced O
amino O
acid O
sequence O
of O
the O
mouse I-GENE
HO ALLCAPS
- I-GENE
1 I-GENE
gene I-GENE
is O
identical O
to O
that O
of O
p32 NUMERIC
, O
initially O
identified O
as O
a O
stress O
- O
induced O
protein O
in O
mouse O
BALBc RARE
/ O
3T3 O
cells O
. O

We O
found O
that O
T3 O
( O
10 O
(- O
8 O
) O
M O
) O
selectively O
stimulates O
transcription O
from O
rGH LASTCAP
- O
TRE O
- O
and O
TREpal RARE
-, O
but O
not O
ME ALLCAPS
- O
TRE O
- O
and O
F2 O
- O
TRE O
-, O
containing O
templates O
in O
which O
these O
TREs RARE
are O
linked O
in O
front O
of O
the O
rGH LASTCAP
minimal I-GENE
promoter I-GENE
containing O
only O
the O
TATA I-GENE
box I-GENE
binding I-GENE
protein I-GENE
, O
but O
not O
any O
other O
proximal O
binding O
protein O
, O
sequence O
. O

Using O
a O
polymerase O
chain O
reaction O
- O
based O
approach O
, O
we O
cloned O
a O
150 O
- O
base O
pair O
fragment O
of O
a O
new O
sialymotif RARE
from O
human O
placenta O
mRNA O
, O
which O
was O
then O
used O
as O
a O
probe O
to O
clone O
the O
complete O
coding O
sequence O
of O
the O
corresponding O
gene O
from O
a O
cDNA O
library O
. O

The O
structural O
analysis O
also O
demonstrated O
that O
the O
heterogeneity O
of O
the O
HDC ALLCAPS
mRNA I-GENE
is O
caused O
by O
an O
insertion O
of O
the O
seventh RARE
intron O
sequence O
and O
alternative O
use O
of O
the O
splicing O
acceptor O
site O
at O
the O
12th NUMERIC
exon O
. O

A O
complementary O
DNA O
was O
isolated O
from O
Caenorhabditis O
elegans O
that O
encoded O
a O
polypeptide O
of O
1438 NUMERIC
amino O
acid O
residues O
, O
CeGAP LASTCAP
, O
which O
contains O
a O
domain O
with O
sequence O
similarity O
to O
the O
COOH I-GENE
- I-GENE
terminal I-GENE
segment I-GENE
( I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
region I-GENE
) I-GENE
of O
Bcr RARE
and O
other O
known O
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
of O
the O
Rho I-GENE
subfamily I-GENE
. O

Additional RARE
exonuclease I-GENE
III I-GENE
protection O
was O
observed O
beyond O
the O
core O
region O
on O
both O
the O
5 O
' O
and O
3 O
' O
sides O
, O
suggesting O
that O
E1 I-GENE
interacted O
with O
more O
distal O
sequences O
as O
well O
. O

Repression RARE
is O
alleviated RARE
when O
the O
two O
( O
for O
E2 I-GENE
) O
or O
three O
( O
for O
E2 I-GENE
- I-GENE
C I-GENE
) O
promoter O
- O
proximal O
copies O
of O
E2 I-GENE
- O
RS O
are O
mutated O
. O

A O
mutant O
in O
the O
AAV O
terminal O
resolution O
site O
( O
trs RARE
) O
was O
defective O
for O
DNA O
replication O
in O
the O
in O
vitro O
assay O
. O

The O
results O
indicate O
that O
rep RARE
strongly O
enhances O
the O
function O
of O
negative O
regulatory O
elements O
of O
the O
LTR O
. O

However O
, O
artificially O
ventilated O
rats O
, O
pretreated O
with O
MK O
- O
801 O
, O
were O
more O
sensitive O
( O
lethal O
cocaine O
dose O
, O
76 O
. O
6 O
+/- O
8 O
. O
0 O
mg O
/ O
kg O
, O
n O
= O
5 O
) O
than O
vehicle O
pretreated O
rats O
( O
129 NUMERIC
. O
4 O
+/- O
15 O
. O
8 O
mg O
/ O
kg O
, O
n O
= O
6 O
), O
indicating O
that O
MK O
- O
801 O
may O
increase O
both O
the O
respiratory O
and O
the O
cardiac O
toxicity O
of O
cocaine O
in O
urethane RARE
anesthetized O
rats O
. O

The O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
gene I-GENE
product I-GENE
, O
which O
belongs O
to O
the O
POU I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
, O
is O
a O
good O
candidate O
for O
regulating O
initial O
differentiation O
decisions RARE
. O

Using O
site O
- O
directed O
mutagenesis O
, O
we O
show O
that O
the O
RAREoct RARE
contributes O
to O
the O
transcriptional O
activation O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
promoter I-GENE
in O
P19 O
cells O
and O
, O
most O
interestingly RARE
, O
mediates O
the O
RA O
- O
induced O
repression O
in O
RA O
- O
differentiated O
EC O
cells O
. O

176 NUMERIC
: O
787 NUMERIC
- O
792 NUMERIC
, O
1992 O
; O
M O
. O

Furthermore O
, O
the O
negative O
transcriptional O
effect O
of O
COUP I-GENE
- I-GENE
TFs RARE
is O
dominant O
over O
the O
activating O
effect O
of O
the O
Oct4 NUMERIC
embryonic I-GENE
stem I-GENE
cell I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
. O

Analysis O
of O
mig RARE
/ O
CAT I-GENE
chimeric O
constructs O
transiently O
transfected O
into O
the O
RAW ALLCAPS
264 O
. O
7 O
mouse O
monocytic O
cell O
line O
revealed O
a O
unique O
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
responsive I-GENE
element I-GENE
( O
gamma I-GENE
RE ALLCAPS
- I-GENE
1 I-GENE
). O

When O
expressed O
alone O
in O
test O
cells O
, O
Atr RARE
- I-GENE
I I-GENE
is O
unable O
to O
bind O
TGF I-GENE
- I-GENE
beta I-GENE
, O
activin I-GENE
, O
or O
bone I-GENE
morphogenetic RARE
protein I-GENE
2 I-GENE
. O

Therefore O
, O
Mxi1 NUMERIC
and O
Mad RARE
might O
antagonize RARE
Myc I-GENE
function O
and O
are O
candidate O
tumor O
suppressor O
genes O
. O

To O
our O
knowledge O
, O
type O
IV O
renal O
tubular O
acidosis O
has O
not O
been O
reported O
previously O
in O
association O
with O
Alport RARE
' O
s O
syndrome O
in O
an O
adult O
patient O
. O

A O
cDNA O
clone O
was O
isolated O
from O
a O
chicken O
embryo O
cDNA O
library O
employing O
a O
PCR O
- O
generated O
radiolabeled O
probe O
specific O
for O
the O
U3 I-GENE
region I-GENE
of O
the O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
LTR I-GENE
. O

Two O
basic O
patterns O
of O
locomotor O
behavior O
and O
corresponding O
torso RARE
morphology O
exist O
among O
extant RARE
anthropoids RARE
. O

Animal RARE
age O
and O
sex O
had O
no O
significant O
effects O
on O
CSF O
composition O
, O
but O
serum O
IgG I-GENE
concentration O
increased O
with O
age O
. O

Fast RARE
continuous O
expansion O
. O

A O
randomized O
, O
multicenter RARE
study O
comparing O
the O
efficacy O
and O
tolerability RARE
of O
tropisetron RARE
, O
a O
new O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonist O
, O
with O
a O
metoclopramide RARE
- O
containing O
antiemetic RARE
cocktail RARE
in O
the O
prevention O
of O
cisplatin O
- O
induced O
emesis RARE
. O

Each O
repeat O
consists O
of O
12 O
nt O
, O
coding O
for O
the O
reiterated RARE
sequence O
, O
K O
/ O
NPAG ALLCAPS
. O

ENV ALLCAPS
also O
was O
secreted O
from O
P O
. O
pastoris RARE
using O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
alpha I-GENE
- I-GENE
factor I-GENE
prepro RARE
secretion I-GENE
leader I-GENE
and O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
invertase RARE
signal I-GENE
sequence I-GENE
. O

BACKGROUND O
: O
To O
determine O
the O
predictors O
of O
desipramine O
- O
refractory O
depression O
, O
the O
authors O
examined O
the O
outcome O
in O
patients O
with O
major O
depression O
who O
were O
admitted RARE
to O
a O
general O
hospital O
and O
treated O
with O
desipramine O
adjusted O
to O
an O
adequate O
blood O
level O
. O

Analysis O
of O
the O
intact O
hGH I-GENE
gene I-GENE
or O
hGH I-GENE
5 I-GENE
'- I-GENE
flanking I-GENE
DNA I-GENE
( I-GENE
5 I-GENE
'- I-GENE
FR I-GENE
) I-GENE
coupled O
to O
the O
hGh RARE
cDNA I-GENE
or O
chloramphenicol I-GENE
acetyltransferase I-GENE
or O
luciferase I-GENE
genes I-GENE
, O
indicated O
that O
cAMP O
primarily O
stimulated O
hGH I-GENE
promoter I-GENE
activity O
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
SAP ALLCAPS
- I-GENE
1 I-GENE
cDNA I-GENE
showed O
that O
mature I-GENE
SAP ALLCAPS
- I-GENE
1 I-GENE
consisted O
of O
1093 NUMERIC
amino O
acids O
and O
a O
transmembrane I-GENE
- I-GENE
type I-GENE
PTP I-GENE
, O
which O
possessed O
a O
single O
PTP I-GENE
- I-GENE
conserved I-GENE
domain I-GENE
in O
the O
cytoplasmic O
region O
. O

The O
following O
evidence O
indicates O
that O
the O
69 O
- O
kD O
protein O
is O
a O
common O
, O
rather O
than O
a O
U1 I-GENE
- O
specific O
, O
protein O
, O
possibly O
associating RARE
with O
the O
snRNP O
core O
particles O
by O
protein O
- O
protein O
interaction O
. O

Several O
features O
of O
10 O
. O
24 O
. O
6 O
cells O
suggest O
that O
the O
mutation O
disrupts RARE
normal O
intracellular O
formation O
of O
peptide I-GENE
/ I-GENE
DR I-GENE
complexes I-GENE
. O

This O
distribution O
parallels RARE
that O
of O
the O
neurotransmitters RARE
glutamate O
and O
aspartate O
; O
however O
, O
neither O
of O
these O
excitatory RARE
amino O
acids O
is O
a O
substrate O
for O
transport O
. O

The O
Harleco RARE
apparatus O
is O
a O
simple O
, O
useful O
, O
cost O
- O
effective O
adjunct RARE
to O
the O
diagnosis O
and O
treatment O
of O
this O
life O
- O
threatening RARE
condition O
. O

Co O
- O
transfection O
of O
expression O
vectors O
for O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
( I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
) I-GENE
alpha I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
trans O
- O
activated O
the O
rat I-GENE
uncoupling RARE
protein I-GENE
gene I-GENE
promoter I-GENE
due O
to O
sequences O
in O
the O
5 O
' O
proximal O
region O
. O

It O
was O
not O
possible O
to O
study O
the O
basis O
for O
tissue O
- O
specific O
expression O
of O
this O
gene O
, O
because O
the O
beta I-GENE
3 I-GENE
gene I-GENE
promoter I-GENE
had O
not O
been O
isolated O
previously O
. O

Isolation O
and O
characterization O
of O
a O
TATA O
- O
less O
promoter O
for O
the O
human I-GENE
beta I-GENE
3 I-GENE
integrin I-GENE
gene I-GENE
. O

Subretinal RARE
fluid O
was O
punctured RARE
on O
the O
poorer RARE
eye O
in O
19 O
eyes O
( O
52 O
. O
7 O
%) O
and O
on O
the O
better O
eye O
in O
7 O
eyes O
( O
19 O
. O
4 O
%). O

These O
data O
indicate O
that O
activation O
of O
these O
enzymes O
is O
not O
sufficient O
for O
the O
acute O
stimulation O
of O
glucose O
transport O
. O

The O
inserted O
region O
, O
which O
represents O
an O
intron O
in O
brain O
and O
muscle O
, O
is O
expressed O
in O
the O
tumor O
cell O
lines O
either O
as O
a O
" O
readthrough O
" O
form O
or O
with O
78 O
residues O
deleted O
from O
its O
5 O
' O
end O
. O

Concordance RARE
of O
IBDQ ALLCAPS
scores O
was O
tested O
in O
280 NUMERIC
stable O
subjects O
. O

Regression RARE
line O
slopes RARE
of O
IBDQ ALLCAPS
scores O
were O
significantly O
different O
in O
patients O
who O
deteriorated RARE
from O
those O
who O
remained O
stable O
([ RARE
b O
] O
< O
0 O
. O
15 O
; O
P O
< O
0 O
. O
0001 O
). O

Praziquantel RARE
and O
Albendazole RARE
were O
found O
effective O
in O
the O
treatment O
of O
neurocysticercosis RARE
, O
but O
because O
of O
serious O
side O
effects O
encountered RARE
in O
some O
cases O
, O
the O
drugs O
should O
be O
used O
cautiously RARE
in O
selected O
cases O
only O
. O

Inhibition O
of O
erythromycin RARE
synthesis O
by O
disruption O
of O
malonyl RARE
- I-GENE
coenzyme I-GENE
A I-GENE
decarboxylase I-GENE
gene I-GENE
eryM LASTCAP
in O
Saccharopolyspora RARE
erythraea RARE
. O

This O
region O
is O
required O
for O
activation O
of O
DNA O
binding O
of O
MyoD I-GENE
and O
E12 I-GENE
homodimers I-GENE
and O
E12 I-GENE
/ O
MyoD I-GENE
heterodimers O
. O

Transcriptional O
analysis O
of O
a O
series O
of O
deletion O
mutants O
of O
the O
gene O
in O
the O
nuclear O
extracts O
prepared O
from O
the O
middle O
silk RARE
gland O
of O
2 O
- O
day O
- O
old O
fifth RARE
instar RARE
larvae O
revealed O
the O
presence O
of O
multiple O
cis O
- O
regulatory O
elements O
located O
both O
upstream O
and O
downstream O
of O
the O
initiation O
site O
. O

One O
of O
these O
elements O
, O
the O
homeodomain I-GENE
- I-GENE
binding I-GENE
element I-GENE
, O
was O
identified O
to O
mediate O
negative O
regulation O
. O

Site O
- O
directed O
mutagenesis O
of O
the O
traI LASTCAP
structural I-GENE
gene I-GENE
and O
application O
of O
purified O
mutant O
TraI LASTCAP
proteins I-GENE
for O
in O
vitro O
assays O
served RARE
to O
evaluate O
the O
functional O
importance O
of O
conserved O
amino O
acid O
residues O
. O

Concerted RARE
action O
of O
three O
distinct O
domains O
in O
the O
DNA O
cleaving RARE
- O
joining O
reaction O
catalyzed O
by O
relaxase RARE
( O
TraI LASTCAP
) O
of O
conjugative RARE
plasmid O
RP4 NUMERIC
. O

The O
COOH O
- O
terminal O
46 O
codons O
of O
slyD LASTCAP
encode O
a O
remarkable O
histidine O
- O
rich O
peptide O
sequence O
which O
is O
at O
least O
partly O
dispensable O
for O
slyD LASTCAP
function O
in O
E I-GENE
- O
mediated O
lysis O
. O

Monospecific RARE
antibodies O
raised O
against O
rat I-GENE
cytochrome I-GENE
P I-GENE
- I-GENE
450 I-GENE
1A1 NUMERIC
recognized O
a O
protein O
in O
the O
hepatic O
microsomes RARE
of O
the O
double O
- O
crested RARE
cormorant RARE
, O
and O
also O
in O
those O
of O
the O
great O
blue O
heron RARE
( O
Ardea RARE
herodias RARE
), O
using O
immunoblotting RARE
. O

We O
studied O
GSH ALLCAPS
- O
Px O
enzyme O
activity O
in O
serum O
after O
acute O
myocardial O
infarction O
( O
AMI O
) O
and O
unstable O
angina O
pectoris O
( O
UAP ALLCAPS
). O

The O
HGF I-GENE
- O
induced O
cell O
motility O
was O
mimicked O
by O
12 O
- O
0 O
- O
tetradecanoyl RARE
- O
phorbol O
- O
13 O
- O
acetate O
, O
a O
protein I-GENE
kinase I-GENE
C I-GENE
- O
activating O
phorbol O
ester O
, O
but O
not O
by O
Ca2 O
+ O
ionophore RARE
. O

In O
addition O
, O
lexical RARE
priming RARE
was O
examined O
by O
presenting O
an O
identity O
prime RARE
earlier O
in O
the O
text RARE
. O

METHODS O
: O
Forty O
- O
nine O
cases O
with O
intrahepatic O
multiple O
nodules O
of O
HCC ALLCAPS
, O
by O
gross O
examination O
, O
among O
184 NUMERIC
consecutive O
resected RARE
HCCs RARE
were O
examined O
clinicopathologically RARE
. O

In O
the O
present O
report O
, O
66 O
hemochromatosis RARE
families O
yielding RARE
151 O
hemochromatosis RARE
chromosomes O
and O
182 O
normal O
chromosomes O
were O
RFLP ALLCAPS
- O
typed RARE
with O
a O
battery O
of O
probes O
, O
including O
two O
newly O
derived O
polymorphic O
markers O
from O
the O
6 O
. O
7 O
and O
HLA I-GENE
- I-GENE
F I-GENE
loci I-GENE
located O
150 O
and O
250 O
kb O
telomeric O
to O
HLA I-GENE
- I-GENE
A I-GENE
, O
respectively O
. O

Pneumothorax RARE
during O
laparoscopic O
dissection O
of O
the O
diaphragmatic RARE
hiatus RARE
. O

Different RARE
cortical O
malformations O
were O
produced O
in O
rats O
by O
a O
single O
dose O
of O
X O
- O
rays O
( O
200 O
cGy RARE
) O
given O
on O
different O
days O
during O
gestation O
. O

T2 O
cancers O
should O
not O
be O
excluded O
from O
the O
benefit O
of O
preoperative O
irradiation O
. O

IFN I-GENE
alpha I-GENE
and O
IFN I-GENE
gamma I-GENE
inducibility O
is O
mediated O
by O
a O
single O
element O
: O
a O
high O
affinity O
, O
nearly O
palindromic O
version O
of O
the O
IFN I-GENE
gamma I-GENE
activation I-GENE
site I-GENE
( O
GAS ALLCAPS
). O

Mutations O
in O
the O
nuclear I-GENE
gene I-GENE
CBP1 NUMERIC
of I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
result O
in O
degradation O
of O
mitochondrially RARE
encoded I-GENE
cytochrome I-GENE
b I-GENE
( O
cob RARE
) O
RNA O
; O
thus O
, O
the O
cells O
are O
unable O
to O
respire RARE
. O

Twenty O
- O
three O
sequence O
- O
tagged O
sites O
( O
STSs RARE
) O
were O
mapped O
within O
the O
contig O
, O
a O
density O
of O
approximately O
1 O
per O
200 O
kb O
. O

In O
this O
paper O
, O
we O
demonstrate O
that O
binding O
of O
the O
GA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
GABP I-GENE
) O
to O
ets I-GENE
sequence I-GENE
motifs I-GENE
within O
each O
repeated O
unit O
is O
required O
for O
transcriptional O
activation O
of O
the O
COXIV ALLCAPS
promoter I-GENE
. O

To O
gain O
further O
insight O
into O
the O
pathogenesis O
of O
the O
adult O
respiratory O
distress O
syndrome O
( O
ARDS O
), O
the O
authors O
studied O
possible O
relationships O
among O
the O
activation O
status O
of O
circulating O
polymorphonuclear RARE
neutrophils O
( O
PMN O
), O
cytokine O
levels O
, O
and O
the O
severity O
of O
lung O
injury O
in O
31 O
patients O
: O
15 O
with O
ARDS O
, O
9 O
with O
severe O
pneumonia O
uncomplicated RARE
by O
ARDS O
, O
and O
7 O
mechanically RARE
ventilated O
patients O
with O
neither O
ARDS O
nor O
pneumonia O
. O

Amiodarone RARE
, O
seldom RARE
used O
as O
first O
- O
line O
treatment O
, O
appears O
to O
be O
the O
most O
effective O
drug O
. O

These O
results O
demonstrate O
that O
dopamine I-GENE
receptor I-GENE
stimulation O
by O
different O
dopamine O
agonists O
produces O
a O
different O
pattern O
of O
effects O
on O
the O
characteristics O
of O
the O
reaction O
time O
response O
. O

Two O
experiments O
were O
conducted O
to O
study O
the O
vacuous RARE
jaw O
movements O
induced O
in O
rats O
by O
acute O
administration O
of O
the O
monoamine O
- O
depleting RARE
agent O
reserpine RARE
. O

Depletion RARE
of O
dopamine O
in O
the O
nucleus O
accumbens RARE
led O
to O
a O
dramatic O
shift O
in O
behavior O
in O
which O
there O
was O
a O
significant O
decrease O
in O
lever RARE
pressing RARE
but O
a O
significant O
increase O
in O
consumption O
of O
lab RARE
chow RARE
. O

We O
have O
investigated O
the O
influence O
of O
NaFe3 NUMERIC
+ O
EDTA O
, O
and O
of O
increasing O
dietary O
levels O
of O
Na2EDTA NUMERIC
, O
on O
Zn O
, O
Cu O
and O
Ca O
metabolism O
in O
rats O
fed O
on O
Zn O
- O
sufficient O
and O
Zn O
- O
deficient O
soya RARE
- O
bean O
- O
isolate O
- O
based O
diets O
. O

Recovery RARE
of O
carbimazole RARE
- O
induced O
agranulocytosis RARE
following O
recombinant I-GENE
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
rhGM LASTCAP
- I-GENE
CSF I-GENE
) O
administration O
. O

Thus O
, O
the O
system O
can O
be O
used O
to O
detect O
and O
study O
dynamic O
perfusion O
changes O
from O
the O
brain O
surface O
with O
minimal O
tissue O
damage O
. O

The O
neglect RARE
of O
Richards RARE
' O
s O
theory O
demonstrates O
the O
range O
of O
factors O
, O
other O
than O
the O
strictly O
scientific RARE
, O
which O
can O
be O
important O
in O
determining O
the O
influence O
or O
otherwise O
of O
a O
psychological O
theory O
. O

The O
positive O
- O
acting O
global O
sulfur O
regulatory O
protein O
, O
CYS3 NUMERIC
, O
of O
Neurospora O
crassa O
turns RARE
on O
the O
expression O
of O
a O
family O
of O
unlinked RARE
structural O
genes O
that O
encode O
enzymes O
of O
sulfur O
catabolism O
. O

Analysis O
of O
the O
upstream O
untranslated O
region O
of O
CHL15 NUMERIC
revealed O
the O
presence O
of O
the O
hexamer O
element O
, O
ACGCGT ALLCAPS
( O
an O
MluI LASTCAP
restriction I-GENE
site I-GENE
) O
controlling O
both O
the O
periodic O
expression O
and O
coordinate O
regulation O
of O
the O
DNA O
synthesis O
genes O
in O
budding O
yeast O
. O

The O
C O
- O
terminal O
region O
of O
the O
150 O
- O
kDa O
protein O
contains O
an O
NTP ALLCAPS
- O
binding O
helicase I-GENE
motif I-GENE
and O
the O
readthrough O
region O
, O
an O
RNA I-GENE
polymerase I-GENE
motif I-GENE
, O
indicating O
that O
these O
two O
overlapping O
proteins O
may O
form O
an O
RNA O
replication O
complex O
similar O
to O
those O
of O
tobamo RARE
- O
and O
tobraviruses RARE
. O

The O
5 O
' O
ends O
of O
F3R NUMERIC
late O
transcripts O
were O
located O
to O
an O
A O
within O
the O
sequence O
5 O
'- O
TAAAG ALLCAPS
, O
41 O
nt O
downstream O
from O
the O
early O
promoter O
and O
17 O
nt O
upstream O
from O
the O
initiation O
codon O
. O

On O
T2 O
weighted O
images O
, O
low O
intensity O
areas O
in O
the O
thalamus RARE
, O
the O
striatum O
, O
the O
anterior O
limb O
of O
the O
internal O
capsule RARE
, O
the O
tegmentum RARE
of O
midbrain RARE
, O
high O
intensity O
areas O
in O
middle O
cerebellar RARE
peduncle RARE
, O
the O
posterior O
limb O
of O
the O
internal O
capsule RARE
, O
the O
lateral O
part O
of O
the O
cerebral O
peduncle RARE
, O
and O
the O
cerebral O
white O
matter O
were O
noted O
. O

Using O
the O
rap1t NUMERIC
alleles I-GENE
to O
generate O
wild O
- O
type O
cells O
differing RARE
only O
in O
telomere O
tract O
lengths O
, O
we O
also O
show O
that O
telomere O
position O
effects O
are O
highly O
sensitive O
to O
changes O
in O
the O
size O
( O
or O
structure O
) O
of O
the O
telomeric O
tract O
. O

Pronounced RARE
microangiopathy RARE
characterized O
by O
avascular RARE
fields O
, O
enlarged RARE
and O
tortuous RARE
capillaries O
and O
increased O
transcapillary RARE
diffusion O
of O
sodium O
fluorescein RARE
, O
was O
clearly O
demonstrable RARE
in O
the O
area O
of O
the O
nodules O
. O

Epigenetic RARE
switching O
of O
transcriptional O
states O
: O
cis O
- O
and O
trans O
- O
acting O
factors O
affecting O
establishment O
of O
silencing O
at O
the O
HMR I-GENE
locus I-GENE
in O
Saccharomyces O
cerevisiae O
. O

NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
p65 I-GENE
, O
p50 I-GENE
, O
and O
Rel I-GENE
functionally O
synergize RARE
with O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
, O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
, O
and O
C I-GENE
/ I-GENE
EBP I-GENE
delta I-GENE
. O

It O
could O
be O
detected O
exclusively O
in O
the O
culture O
medium O
of O
cDNA O
- O
transfected O
COS O
cells O
. O

The O
first O
group O
of O
sequential O
BMB ALLCAPS
showed O
a O
significant O
progress O
to O
myelofibrosis RARE
in O
so O
- O
called O
" O
Chronic O
Megakaryocytic RARE
- O
Granulocytic RARE
Myelosis RARE
"-- RARE
CMGM ALLCAPS
-, O
which O
corresponds O
to O
Agnogenic RARE
Myeloid RARE
Metaplasia RARE
- O
AMM ALLCAPS
- O
in O
72 O
. O
4 O
% O
( O
21 O
/ O
29 O
patients O
), O
as O
well O
as O
in O
CML O
with O
megakaryocytic RARE
increase O
- O
CML O
. O
MI O
- O
in O
39 O
. O
2 O
% O
( O
20 O
/ O
51 O
). O

The O
two O
methods O
identify O
the O
same O
patients O
only O
if O
micturitional RARE
pressures O
are O
normal O
( O
40 O
to O
60 O
cmH2O O
) O
to O
high O
( O
over O
60 O
cmH2O O
) O
and O
the O
Sussett RARE
formula O
is O
used O
with O
a O
higher O
( O
95th NUMERIC
centile RARE
) O
cutoff O
. O

There O
was O
no O
clear O
correlation O
between O
the O
MFA ALLCAPS
and O
the O
severity O
of O
the O
UTS ALLCAPS
phenotype O
. O

Chicken RARE
sterol I-GENE
carrier I-GENE
protein I-GENE
2 I-GENE
/ O
sterol I-GENE
carrier I-GENE
protein I-GENE
x I-GENE
: O
cDNA O
cloning O
reveals O
evolutionary O
conservation O
of O
structure O
and O
regulated O
expression O
. O

The O
plasmatic RARE
albumin I-GENE
concentration O
( O
3 O
. O
5 O
- O
4 O
. O
5 O
g O
/ O
dl O
) O
represents O
about O
60 O
% O
of O
the O
total O
plasma O
protein O
. O

These O
lesions O
were O
asymptomatic O
, O
but O
both O
were O
characterized O
clinically O
by O
central O
ulceration O
. O

A O
single O
five O
minute O
period O
of O
rapid O
atrial O
pacing O
fails O
to O
limit O
infarct O
size O
in O
the O
in O
situ O
rabbit O
heart O
. O

Neither O
RD19 NUMERIC
nor O
RD21 NUMERIC
mRNA I-GENE
synthesis O
was O
responsive O
to O
cold O
or O
to O
heat O
stress O
. O

Previous O
studies O
indicated O
that O
the O
20S I-GENE
proteasome I-GENE
is O
a O
catalytic O
core O
of O
the O
26S NUMERIC
proteolytic I-GENE
complex I-GENE
that O
possesses O
a O
latent O
multicatalytic RARE
proteinase O
activity O
and O
catalyzes O
an O
ATP O
- O
dependent O
, O
selective O
breakdown RARE
of O
proteins O
ligated O
to O
ubiquitin I-GENE
. O

The O
O2 O
deficit O
was O
not O
related O
to O
blood O
lactate O
during O
submaximal RARE
exercise O
, O
muscle O
enzyme O
activity O
( O
citrate I-GENE
synthase I-GENE
, O
3 I-GENE
- I-GENE
hydroxyacyl RARE
- I-GENE
CoA I-GENE
- I-GENE
dehydrogenase I-GENE
, O
lactate I-GENE
dehydrogenase I-GENE
), O
number O
of O
muscle O
capillaries O
, O
% O
ST O
fibres O
or O
muscle O
buffer RARE
capacity O
. O

The O
sequence O
of O
the O
putative O
RBP1 NUMERIC
protein I-GENE
contains O
two O
copies O
of O
an O
RNA O
recognition O
motif O
, O
two O
glutamine O
stretches O
, O
an O
asparagine RARE
- O
rich O
region O
, O
a O
methionine O
- O
rich O
region O
, O
and O
two O
long O
potential O
alpha O
- O
helixes RARE
. O

One O
defective O
RNA O
with O
a O
large O
deletion O
in O
the O
p70 I-GENE
coding I-GENE
region I-GENE
was O
able O
to O
replicate RARE
efficiently O
, O
both O
when O
inoculated O
with O
the O
helper RARE
genome O
and O
when O
inoculated O
with O
a O
second O
complementing RARE
defective O
RNA O
that O
supplied O
a O
wild I-GENE
- I-GENE
type I-GENE
p70 I-GENE
. O

Release RARE
of O
this O
selective O
pressure O
, O
however O
, O
gave O
way O
to O
homologous O
resolution O
of O
the O
cointegrate RARE
structures O
. O

Complete RARE
nucleotide O
sequence O
of O
the O
bacteriophage I-GENE
K1F NUMERIC
tail I-GENE
gene I-GENE
encoding O
endo RARE
- I-GENE
N I-GENE
- I-GENE
acylneuraminidase RARE
( O
endo RARE
- I-GENE
N I-GENE
) O
and O
comparison O
to O
an O
endo RARE
- I-GENE
N I-GENE
homolog I-GENE
in O
bacteriophage O
PK1E NUMERIC
. O

Binding O
of O
U2 I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
was O
partially O
inhibited O
. O

Morphometrical RARE
quantification RARE
of O
brain O
edema O
related O
to O
experimental O
multiple O
micro O
- O
infarcts RARE
in O
mice O
: O
assessment O
of O
neurotropin RARE
effect O
. O

One O
member O
of O
this O
multigene RARE
family O
, O
GATA I-GENE
- I-GENE
3 I-GENE
, O
is O
most O
abundantly O
expressed O
in O
T O
lymphocytes O
, O
a O
cellular O
target O
for O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
and O
replication O
. O

Indeed O
, O
significant O
level O
of O
CAT I-GENE
activity O
was O
observed O
in O
human O
lung O
adenocarcinoma O
( O
A549 NUMERIC
- O
1 O
) O
cells O
which O
had O
been O
incubated O
with O
a O
complex O
of O
T7 I-GENE
RNA I-GENE
polymerase I-GENE
, O
pT7 NUMERIC
- I-GENE
EMC ALLCAPS
- I-GENE
CAT I-GENE
DNA I-GENE
and O
DC O
- O
chol RARE
cationic RARE
liposomes O
. O

Pneumoscrotum RARE
is O
a O
rare O
condition O
that O
receives RARE
little O
discussion O
in O
standard O
texts RARE
of O
urology RARE
. O

The O
first O
gene O
codes O
for O
a O
protein O
containing O
11 O
cystein RARE
residues O
in O
an O
arrangement O
typical O
for O
Fe RARE
/ I-GENE
S I-GENE
proteins I-GENE
. O

Triton RARE
- O
disrupted O
cells O
retained O
capacity O
for O
activation O
of O
the O
pathway O
by O
both O
peptide O
growth O
factors O
and O
by O
addition O
of O
GTP O
- O
loaded RARE
p21 I-GENE
rasVal12 NUMERIC
. O

To O
begin O
to O
examine O
the O
mechanism O
controlling O
expression O
of O
this O
gene O
during O
the O
cell O
- O
cycle O
, O
a O
mouse I-GENE
B I-GENE
- I-GENE
myb I-GENE
5 I-GENE
' I-GENE
flanking I-GENE
sequence I-GENE
was O
isolated O
from O
a O
cosmid O
library O
and O
shown O
to O
promote O
efficiently O
the O
transcription O
of O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
when O
transfected O
into O
NIH3T3 O
fibroblasts O
. O

The O
influence O
of O
a O
high O
ionic O
strength O
on O
the O
resolution O
was O
clearly O
shown O
. O

The O
number O
of O
bacteria O
in O
the O
lung O
, O
peripheral O
white O
blood O
cell O
and O
BAL O
fluid O
cell O
also O
decreased O
by O
the O
administration O
of O
FN I-GENE
. O

In O
mice O
, O
three O
major O
families O
of O
L1 O
elements O
, O
termed O
" O
A O
," O
" O
F O
," O
and O
" O
V O
," O
have O
been O
defined O
on O
the O
basis O
of O
the O
sequence O
found O
at O
the O
5 O
' O
terminus O
. O

TFEC ALLCAPS
, O
a O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
protein I-GENE
, O
forms O
heterodimers O
with O
TFE3 NUMERIC
and O
inhibits O
TFE3 NUMERIC
- O
dependent O
transcription O
activation O
. O

The O
equivalent O
of O
the O
third O
ligand O
, O
H O
- O
87 O
, O
is O
T O
- O
47 O
in O
the O
PSTAIRE ALLCAPS
sequence O
motif O
. O

Similar O
results O
were O
seen O
on O
Western O
blots O
of O
Autographa RARE
californica RARE
MNPV ALLCAPS
( O
AcMNPV LASTCAP
)- O
infected O
Spodoptera RARE
frugiperda RARE
cells O
. O

In O
infected O
mammalian O
cells O
, O
the O
ARV ALLCAPS
G I-GENE
and O
GNS ALLCAPS
genes I-GENE
are O
transcribed O
primarily O
as O
a O
polycistronic RARE
mRNA O
which O
appears O
to O
extend O
from O
the O
consensus O
sequence O
( O
AACAG ALLCAPS
) O
at O
the O
start O
of O
the O
G I-GENE
gene I-GENE
to O
the O
next O
recognized O
polyadenylation O
signal O
( O
CATG ALLCAPS
[ O
A O
] O
7 O
) O
located O
697 NUMERIC
nucleotides O
downstream O
of O
the O
GNS ALLCAPS
protein I-GENE
termination O
codon O
. O

Molecular O
cloning O
and O
expression O
of O
RPE65 NUMERIC
, O
a O
novel O
retinal O
pigment RARE
epithelium O
- O
specific O
microsomal RARE
protein O
that O
is O
post O
- O
transcriptionally O
regulated O
in O
vitro O
. O

The O
mean O
power O
( O
in O
mu O
W O
) O
required O
to O
produce O
the O
observed O
flow O
rate O
was O
estimated O
at O
each O
outflow O
pressure O
as O
the O
product O
of O
the O
flow O
rate O
and O
the O
pressure O
across O
the O
lymphatic RARE
vessel O
. O

Although O
antisperm RARE
antibodies O
are O
associated O
with O
infertility O
, O
many O
hospital O
laboratories O
do O
not O
test O
for O
these O
antibodies O
. O

PPD ALLCAPS
- O
specific O
IgG I-GENE
subclass RARE
responses O
were O
evident O
to O
all O
four O
IgG I-GENE
subclasses RARE
. O

Anterior RARE
body O
pattern O
in O
Drosophila O
is O
specified O
by O
the O
graded RARE
distribution O
of O
the O
bicoid RARE
protein I-GENE
( O
bcd RARE
), O
which O
activates O
subordinate RARE
genes O
in O
distinct O
anterior O
domains O
. O

GAP I-GENE
- I-GENE
N I-GENE
bound O
constitutively O
to O
p190 I-GENE
in O
both O
serum O
- O
deprived O
and O
growth O
factor O
- O
stimulated O
cells O
. O

The O
peptide O
sequence O
contains O
a O
region O
of O
80 O
amino O
acids O
that O
shows O
similarity O
to O
bcl I-GENE
- I-GENE
2 I-GENE
and O
to O
the O
recently O
described O
bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
related I-GENE
gene I-GENE
, O
MCL1 NUMERIC
. O

The O
phosphorylation O
efficiency O
is O
improved O
by O
increasing O
the O
number O
of O
N O
- O
terminal O
arginine O
residues O
and O
by O
moving RARE
the O
arginyl RARE
cluster O
one O
residue O
further O
away RARE
from O
the O
serine O
, O
the O
nonapeptide RARE
( O
Arg O
) O
4 O
- O
Ala O
- O
Ala O
- O
Ser O
- O
Val O
- O
Ala O
being O
the O
best O
substrate O
among O
all O
the O
short O
peptides O
tested O
( O
Km RARE
= O
15 O
microM O
). O

Botulinum RARE
toxin I-GENE
: O
preferred O
treatment O
for O
hemifacial RARE
spasm RARE
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
GAL1 NUMERIC
and O
GAL10 NUMERIC
genes I-GENE
are O
controlled O
in O
response O
to O
the O
availability O
of O
galactose O
and O
glucose O
by O
multiple O
activating O
and O
repressing O
proteins O
bound O
at O
adjacent O
or O
overlapping O
sites O
in O
UASG ALLCAPS
. O

Surprisingly O
, O
the O
results O
of O
several O
experiments O
suggest O
that O
the O
TSF ALLCAPS
genes I-GENE
encode O
global O
regulatory O
factors O
. O
tsf1 NUMERIC
to O
tsf6 NUMERIC
mutations O
derepressed RARE
expression O
from O
yeast O
CYC ALLCAPS
- O
GAL ALLCAPS
hybrid O
promoters O
( O
fused O
to O
lacZ I-GENE
) O
that O
harbor O
a O
variety O
of O
operator O
sequences O
, O
and O
caused O
pleiotropic O
defects O
in O
cell O
growth O
, O
mating O
, O
and O
sporulation O
. O

Sex RARE
of O
calf O
( O
variate RARE
2 O
) O
was O
associated O
most O
closely O
with O
width RARE
of O
muzzle RARE
and O
head O
. O

Sequence O
comparison O
indicates O
that O
exons O
5 O
'/ RARE
L O
and O
L O
/ O
N O
in O
PSG12 NUMERIC
and O
PSG12 NUMERIC
psi I-GENE
are O
99 O
% O
identical O
, O
except O
that O
the O
L O
/ O
N O
exon O
in O
the O
PSG12 NUMERIC
psi I-GENE
gene I-GENE
contains O
a O
stop O
codon O
. O

The O
mechanisms O
that O
govern O
the O
activation O
or O
suppression O
of O
the O
CD8 I-GENE
gene I-GENE
are O
likely O
to O
be O
central O
to O
the O
T O
cell O
development O
program O
. O

We O
suggest O
that O
the O
ER O
lumenal RARE
variable O
domain O
of O
gp19K NUMERIC
has O
a O
specific O
tertiary O
structure O
that O
is O
important O
for O
binding O
to O
the O
polymorphic O
alpha O
1 O
and O
alpha O
2 O
domains O
of O
class I-GENE
I I-GENE
heavy I-GENE
( I-GENE
alpha I-GENE
) I-GENE
chains I-GENE
. O

We O
recently O
found O
that O
17 O
beta O
- O
estradiol O
( O
E2 O
) O
not O
only O
suppresses O
bone O
resorption O
but O
also O
stimulates O
bone O
formation O
in O
the O
cancellous RARE
bone O
of O
female O
rats O
. O

Recombinant I-GENE
human I-GENE
erythropoietin I-GENE
( O
epoetin RARE
) O
is O
approved RARE
to O
be O
administered O
by O
the O
intravenous O
( O
i O
. O
v O
.) O
or O
subcutaneous O
( O
SC O
) O
route O
. O

Single RARE
- O
photon O
emission O
computed O
tomography O
( O
SPECT O
) O
with O
99mTc O
- O
hexamethylpropyleneamine RARE
oxime RARE
( O
HMPAO O
) O
was O
used O
to O
investigate O
changes O
in O
cerebral O
blood O
flow O
in O
seven O
patients O
with O
cortical O
visual O
impairment O
. O

The O
rCBF O
ratio O
was O
mainly O
reduced O
in O
frontal O
lobes RARE
( O
65 O
%). O

METHODS O
: O
Twenty O
- O
two O
patients O
were O
grouped RARE
according O
to O
their O
etiology O
based O
on O
the O
study O
of O
antiadrenal RARE
antibodies O
at O
diagnosis O
of O
the O
disease O
: O
7 O
were O
positive O
( O
autoimmune RARE
etiology O
or O
EAA ALLCAPS
), O
11 O
were O
negative O
( O
tuberculous O
etiology O
or O
EAT ALLCAPS
) O
and O
in O
four O
serologic O
study O
was O
not O
available O
( O
undetermined RARE
etiology O
or O
EAI ALLCAPS
). O

2 O
- O
AP O
induced O
marked O
, O
steady O
rises RARE
in O
mRNA O
accumulation O
from O
both O
transfected O
and O
chromosomally RARE
integrated O
HIV O
- O
1 O
constructs O
but O
no O
increases O
from O
an O
endogenous O
gene O
encoding O
gamma I-GENE
- I-GENE
actin I-GENE
or O
glucose I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
. O

The O
UV O
induction O
of O
c I-GENE
- I-GENE
jun I-GENE
is O
mediated O
by O
two O
UV O
response O
elements O
consisting O
of O
AP I-GENE
- I-GENE
1 I-GENE
- I-GENE
like I-GENE
sequences I-GENE
within O
its O
5 O
' O
control O
region O
. O

Protein I-GENE
tyrosine I-GENE
phosphatases I-GENE
( O
PTPs RARE
), O
together O
with O
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
PTKs RARE
), O
are O
involved O
in O
the O
regulation O
of O
cell O
activation O
, O
growth O
, O
and O
differentiation O
. O

ST O
elevation O
occurs O
in O
5 O
patients O
( O
55 O
. O
5 O
%) O
of O
subgroup O
A O
and O
in O
no O
patient O
of O
the O
subgroup O
B O
. O

Furthermore O
, O
a O
p21X NUMERIC
protein I-GENE
lacking O
the O
N O
- O
terminus O
of O
Rex1 NUMERIC
was O
expressed O
at O
high O
levels O
; O
our O
data O
indicate O
that O
p21X NUMERIC
is O
translated O
from O
the O
1 O
. O
6 O
- O
kb O
mRNA O
which O
is O
derived O
primarily O
from O
deleted O
proviruses RARE
. O

HTLV O
- O
1 O
gene O
expression O
by O
defective O
proviruses RARE
in O
an O
infected O
T O
- O
cell O
line O
. O

Thus O
, O
it O
was O
confirmed O
that O
the O
sodium O
lauryl RARE
sulfate O
method O
of O
estimating O
hemoglobin I-GENE
concentration O
is O
an O
appropriate O
alternative O
to O
the O
cyanmethemoglobin RARE
method O
and O
avoids RARE
the O
generation O
of O
toxic O
wastes RARE
. O

A O
comparison O
of O
the O
predicted O
amino O
acid O
sequences O
of O
the O
two O
human I-GENE
PKC I-GENE
- I-GENE
delta I-GENE
clones O
with O
the O
rat O
and O
mouse O
homologues O
indicated O
a O
greater O
degree O
of O
sequence O
divergence O
( O
89 O
- O
90 O
% O
homology O
) O
compared O
to O
the O
high O
degree O
of O
sequence O
conservation O
observed O
with O
other O
human I-GENE
PKC I-GENE
family I-GENE
members I-GENE
and O
their O
mammalian O
counterparts O
. O

XII ALLCAPS
. O

When O
comparing O
the O
barley I-GENE
PSI I-GENE
- I-GENE
K I-GENE
and O
PSI I-GENE
- I-GENE
G I-GENE
with O
the O
reported O
PSI I-GENE
- I-GENE
K I-GENE
sequence I-GENE
from I-GENE
Synechococcus RARE
vulcanus RARE
, O
the O
degree O
of O
similarity O
is O
equal O
, O
suggesting O
that O
an O
ancestral O
gene O
has O
been O
duplicated O
in O
a O
chloroplast O
progenitor O
but O
not O
in O
a O
cyanobacterial RARE
. O

On O
the O
other O
hand O
, O
the O
structures O
of O
the O
b O
- O
Zip O
domain O
are O
well O
conserved O
among O
these O
Maf I-GENE
- I-GENE
related I-GENE
proteins I-GENE
. O

Under O
these O
conditions O
, O
transfections O
with O
cDNAs O
of O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
p50 I-GENE
and O
serum I-GENE
response I-GENE
factor I-GENE
( O
SRF I-GENE
) O
produced O
a O
factor O
( O
s O
) O
that O
mediated O
Tax I-GENE
binding O
to O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
site I-GENE
and O
the O
CArG O
box O
respectively O
. O

We O
show O
here O
that O
v I-GENE
- I-GENE
Rel I-GENE
specifically O
increased O
expression O
from O
a O
reporter O
plasmid O
containing O
multiple O
Sp1 I-GENE
binding I-GENE
sites I-GENE
approximately O
sixfold RARE
in O
chicken O
embryo O
fibroblasts O
( O
CEFs RARE
), O
even O
though O
v I-GENE
- I-GENE
Rel I-GENE
did O
not O
bind O
directly O
to O
these O
sites O
. O
v I-GENE
- I-GENE
Rel I-GENE
also O
increased O
expression O
from O
a O
reporter O
plasmid O
containing O
a O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
( O
LTR O
) O
in O
which O
the O
kappa I-GENE
B I-GENE
binding I-GENE
sites I-GENE
were O
mutated O
but O
which O
still O
contained O
intact O
Sp1 I-GENE
binding I-GENE
sites I-GENE
. O

The O
simultaneous O
recording O
of O
electrical O
activity O
from O
the O
surface O
electrocardiogram O
, O
right O
ventricular O
apex O
, O
His O
bundle O
, O
high O
right O
atrium O
, O
coronary O
sinus O
, O
with O
or O
without O
a O
roving RARE
mapping O
catheter O
, O
enables O
us O
to O
precisely O
map O
the O
electrical O
activation O
sequence O
in O
the O
heart O
. O

CONCLUSION O
: O
This O
retrospective O
analysis O
does O
not O
confirm O
the O
efficacy O
of O
one O
course O
of O
simultaneous O
Mitomycin RARE
- O
C O
and O
5 O
- O
fluorouracil O
, O
at O
least O
in O
association O
with O
full O
- O
dose O
radiotherapy O
incorporating RARE
Iridium RARE
- O
192 O
boost RARE
. O

Despite O
the O
existence O
of O
30 O
cysteine O
residues O
, O
carboxymethylation RARE
prevented O
the O
formation O
of O
most O
if O
not O
all O
disulfide O
bonds O
that O
otherwise O
occurred O
when O
the O
cells O
were O
sonicated RARE
. O

Cerebro RARE
- O
oculo RARE
- O
facioskeletal RARE
syndrome O
( O
Pena RARE
- O
Shokeir RARE
syndrome O
II O
) O

Most O
importantly RARE
, O
the O
addition O
of O
purified O
17S NUMERIC
U2 I-GENE
snRNPs I-GENE
, O
but O
not O
of O
12S NUMERIC
U2 I-GENE
snRNPs I-GENE
, O
to O
HeLa O
splicing O
extracts O
in O
which O
the O
endogeneous RARE
U2 I-GENE
snRNPs I-GENE
have O
been O
functionally O
neutralized RARE
with O
anti I-GENE
- I-GENE
PRP9 NUMERIC
antibodies I-GENE
fully O
restores O
the O
mRNA O
- O
splicing O
activity O
of O
the O
extracts O
. O

Differences RARE
in O
profiles O
of O
viscosity O
variables O
between O
subgroups O
of O
EAD ALLCAPS
in O
RA O
patients O
were O
observed O
. O

These O
contain O
a O
single O
1977 NUMERIC
- O
bp O
exon O
that O
encodes O
900 NUMERIC
bp O
of O
the O
5 O
' O
and O
3 O
' O
untranslated O
sequences O
in O
addition O
to O
a O
1077 NUMERIC
- O
bp O
open O
reading O
frame O
identical O
to O
that O
found O
in O
vascular I-GENE
smooth I-GENE
muscle I-GENE
cell I-GENE
AT1a NUMERIC
receptor I-GENE
cDNAs I-GENE
. O

Deletion O
of O
a O
53 O
- O
bp O
early O
promoter O
region O
containing O
the O
transcription O
start O
site O
and O
a O
putative O
TATA O
box O
completely O
abolishes O
the O
ability O
of O
upstream O
elements O
to O
drive O
transcription O
of O
the O
luciferase I-GENE
cDNA I-GENE
. O

One O
chimpanzee RARE
reliably RARE
selected O
the O
larger O
numeral RARE
4 O
during O
testing O
with O
a O
nonadjacent RARE
pair O
( O
2 O
- O
4 O
), O
and O
2 O
chimps RARE
showed O
no O
preference O
. O

Dissipation RARE
of O
claudication RARE
pain O
after O
walking RARE
: O
implications O
for O
endurance RARE
training O
. O

Alternative O
transcript O
of O
the O
nonselective RARE
- O
type O
endothelin I-GENE
receptor I-GENE
from O
rat O
brain O
. O

The O
Functional O
Independence RARE
Measure RARE
: O
a O
comparative O
study O
of O
clinician RARE
and O
self O
ratings RARE
. O

Polymyxin RARE
B O
was O
given O
intravenously O
for O
1 O
week O
postburn RARE
in O
doses O
designed O
to O
neutralize RARE
circulating O
endotoxemia RARE
. O

SvO2 NUMERIC
can O
be O
determined O
in O
vitro O
and O
in O
vivo O
. O

The O
transverse O
relaxation O
time O
( O
T2 O
) O
and O
apparent O
diffusion O
coefficient O
of O
water O
were O
determined O
. O

The O
Drosophila O
clathrin I-GENE
heavy I-GENE
chain I-GENE
gene O
: O
clathrin I-GENE
function O
is O
essential O
in O
a O
multicellular RARE
organism O
. O

The O
binding O
specificity O
of O
this O
protein O
was O
compared O
to O
that O
of O
human I-GENE
E2F I-GENE
using O
a O
number O
of O
mutant I-GENE
E2F I-GENE
sites I-GENE
as O
competitors RARE
. O

To O
analyze O
the O
VH O
regions O
of O
polyreactive RARE
antibodies O
, O
with O
particular O
attention O
at O
their O
somatically RARE
mutated O
status O
, O
we O
generated O
five O
IgG I-GENE
( O
three O
IgG1 NUMERIC
and O
two O
IgG3 NUMERIC
) O
mAb O
( O
using O
B O
cells O
from O
a O
healthy O
subject O
, O
a O
patient O
with O
insulin I-GENE
- O
dependent O
diabetes O
mellitus O
and O
a O
patient O
with O
SLE O
), O
which O
bound O
with O
various O
efficiencies RARE
a O
number O
of O
different O
self O
and O
foreign O
Ag O
. O

It O
is O
possible O
that O
the O
patch O
determines RARE
the O
proper O
conformation O
of O
the O
site O
and O
thereby O
contributes O
to O
recognition O
indirectly O
. O

These O
findings O
suggest O
a O
functional O
cross O
- O
talk RARE
between O
RB I-GENE
protein I-GENE
and O
p21ras I-GENE
, O
which O
balances RARE
the O
cell O
phenotype O
between O
normal O
and O
transformed O
states O
. O

The O
7 O
- O
kb O
mRNA O
differs O
by O
alternative O
splicing O
such O
that O
it O
encodes O
a O
protein O
with O
a O
distinct O
amino O
terminus O
. O

Kinetics RARE
of O
the O
inhibition O
indicated O
that O
this O
polymerase O
domain O
can O
inhibit O
viral O
replication O
only O
during O
the O
preinitiation RARE
stage O
. O

The O
other O
transmembrane O
regions O
as O
well O
as O
the O
nucleoplasmic RARE
domain O
are O
not O
required O
for O
sorting O
. O

3 O
. O

McCann RARE
III O
, O
F O
. O

These O
cell O
lines O
, O
selected O
for O
the O
ability O
to O
support O
the O
replication O
of O
a O
temperature O
- O
sensitive O
VP5 NUMERIC
mutant I-GENE
, O
were O
used O
to O
isolate O
VP5 NUMERIC
and O
VP23 NUMERIC
null O
mutants O
. O

The O
E1 I-GENE
nuclear I-GENE
transport I-GENE
motif I-GENE
is O
highly O
conserved O
in O
the O
animal O
and O
human O
papillomaviruses RARE
and O
is O
encoded O
in O
a O
similar O
region O
in O
the O
related O
E1 I-GENE
genes I-GENE
. O

The O
E1 I-GENE
replication I-GENE
protein I-GENE
of O
bovine O
papillomavirus O
type O
1 O
contains O
an O
extended O
nuclear O
localization O
signal O
that O
includes O
a O
p34cdc2 I-GENE
phosphorylation O
site O
. O

In O
order O
to O
investigate O
to O
what O
extent O
this O
interaction O
might O
contribute O
to O
tumor O
induction O
by O
the O
virus O
, O
we O
have O
introduced O
two O
different O
point O
mutations O
within O
the O
putative O
pRb I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
of O
large I-GENE
T I-GENE
antigen I-GENE
, O
and O
as O
a O
preliminary O
to O
in O
vivo O
experiments O
we O
have O
studied O
their O
effects O
in O
vitro O
on O
some O
biological O
activities O
relevant O
to O
tumor O
induction O
. O

We O
conclude O
that O
the O
conservation O
of O
nucleotides O
154 O
to O
156 O
is O
likely O
to O
be O
a O
consequence O
of O
their O
role O
as O
a O
sequence O
- O
specific O
recognition O
element O
for O
the O
SRP54 NUMERIC
protein I-GENE
. O

A O
region O
of O
the O
deduced O
protein O
shares O
extensive O
homology O
with O
a O
catalytic O
region O
of O
Raf I-GENE
kinases I-GENE
, O
a O
feature O
shared O
only O
with O
TFIIE ALLCAPS
among O
transcription O
factors O
. O

The O
low O
molecular O
mass O
polypeptide O
complex O
is O
assumed O
to O
be O
involved O
in O
antigen O
presentation O
, O
generating O
peptides O
from O
cytosolic O
protein O
antigens O
, O
which O
are O
subsequently O
presented O
to O
cytotoxic O
T O
- O
lymphocytes O
on O
the O
cell O
surface O
. O

Secondary RARE
cleavage O
of O
RT I-GENE
at O
Trp RARE
- O
595 NUMERIC
- O
Tyr O
- O
596 NUMERIC
of O
Pol I-GENE
yields O
a O
truncated O
form O
lacking O
the O
C I-GENE
- I-GENE
terminal I-GENE
RNase I-GENE
H I-GENE
domain I-GENE
. O

The O
C O
- O
terminal O
approximately O
50 O
amino O
acids O
of O
Bel RARE
- I-GENE
1 I-GENE
are O
shown O
to O
be O
essential O
for O
Bel RARE
- I-GENE
1 I-GENE
activity O
but O
can O
be O
effectively O
substituted O
by O
the O
C O
- O
terminal O
activation O
domain O
of O
VP16 I-GENE
. O

Since O
the O
- O
172 NUMERIC
/- O
148 NUMERIC
element O
also O
conferred O
estrogen O
and O
thyroid O
hormone O
responsiveness O
, O
it O
can O
be O
considered O
a O
composite O
hormone O
response O
element O
. O

Optimal RARE
activation O
of O
T O
cells O
requires O
at O
least O
two O
signals O
. O

Together O
with O
a O
considerably O
shortened O
and O
interrupted O
aromatic O
aa O
stretch O
in O
this O
region O
, O
these O
differences O
are O
discussed O
in O
terms O
of O
the O
peculiar RARE
affinity O
of O
cyanobacterial RARE
cytochrome I-GENE
oxidases RARE
for O
acidic O
c I-GENE
- I-GENE
type I-GENE
cytochromes RARE
. O

All O
four O
of O
the O
genes O
have O
a O
similar O
structure O
, O
with O
the O
receptor O
protein O
encoded O
in O
a O
single O
exon O
. O

Identity RARE
of O
GABP I-GENE
with O
NRF ALLCAPS
- I-GENE
2 I-GENE
, O
a O
multisubunit O
activator O
of O
cytochrome I-GENE
oxidase I-GENE
expression O
, O
reveals O
a O
cellular O
role O
for O
an O
ETS I-GENE
domain I-GENE
activator O
of O
viral O
promoters O
. O

In O
the O
present O
study O
, O
beta O
- O
funaltrexamine RARE
( O
beta O
- O
FNA ALLCAPS
) O
and O
naltrindole RARE
( O
NTI ALLCAPS
) O
( O
nonequilibrium RARE
mu O
- O
and O
delta O
- O
antagonist O
, O
respectively O
) O
were O
used O
to O
precipitate RARE
withdrawal O
in O
butorphanol RARE
- O
dependent O
rats O
. O

The O
intracellular O
basic I-GENE
region I-GENE
/ I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
( I-GENE
bHLH I-GENE
) I-GENE
dioxin I-GENE
receptor I-GENE
mediates O
signal O
transduction O
by O
dioxin O
( O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo RARE
- O
p O
- O
dioxin O
) O
and O
functions O
as O
a O
ligand O
- O
activated O
DNA O
binding O
protein O
directly O
interacting O
with O
target O
genes O
by O
binding O
to O
dioxin O
response O
elements O
. O

The O
alpha I-GENE
2A I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
( O
alpha I-GENE
2AAR NUMERIC
) O
is O
coupled O
to O
a O
variety O
of O
effectors O
via O
pertussis I-GENE
toxin I-GENE
- O
sensitive O
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

A O
sequence O
comparison O
reveals O
two O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
) O
consensus O
sequences O
, O
basic O
DNA O
binding O
region O
and O
leucine O
zippers O
1 O
and O
2 O
( O
bZIP1 NUMERIC
and O
bZIP2 NUMERIC
), O
within O
this O
region O
. O

One O
of O
these O
genes O
, O
REC114 NUMERIC
, O
is O
described O
here O
, O
and O
the O
data O
confirm O
that O
REC114 NUMERIC
is O
a O
meiosis O
- O
specific O
recombination O
gene O
with O
no O
detectable O
function O
in O
mitosis O
. O

The O
transactivation O
function O
of O
EBNA2 I-GENE
was O
also O
observed O
in O
the O
HeLa O
epithelial O
cell O
line O
, O
which O
suggests O
that O
EBV O
and O
HIV O
- O
1 O
infection O
of O
non O
- O
B O
cells O
may O
result O
in O
HIV I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
activation O
. O

Mutation O
of O
the O
C I-GENE
/ I-GENE
EBP I-GENE
binding I-GENE
sites I-GENE
in O
the O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
and O
gag I-GENE
enhancers I-GENE
. O

Nuclear I-GENE
protein I-GENE
phosphatase I-GENE
2A I-GENE
dephosphorylates RARE
protein I-GENE
kinase I-GENE
A I-GENE
- O
phosphorylated O
CREB I-GENE
and O
regulates O
CREB I-GENE
transcriptional O
stimulation O
. O

We O
show O
that O
IL I-GENE
- I-GENE
6 I-GENE
activates O
JRE ALLCAPS
- I-GENE
IL6 I-GENE
through O
an O
H7 NUMERIC
- O
sensitive O
pathway O
that O
does O
not O
involve O
protein I-GENE
kinase I-GENE
C I-GENE
, O
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
, O
Ca I-GENE
( I-GENE
2 I-GENE
+)- I-GENE
or I-GENE
calmodulin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
Ras I-GENE
, O
Raf I-GENE
- I-GENE
1 I-GENE
, O
or O
NF I-GENE
- I-GENE
IL6 I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
). O

Mutation O
of O
the O
presumptive RARE
phosphorylated O
tyrosine O
and O
threonine O
residues O
of O
Mpk1p NUMERIC
individually O
to O
phenylalanine O
and O
alanine O
, O
respectively O
, O
severely O
impaired O
Mpk1p NUMERIC
function O
. O

Growth O
factor O
stimulation O
rapidly O
induces O
a O
reversible O
change O
in O
the O
electrophoretic O
mobility O
of O
the O
ternary O
complex O
, O
accompanied O
by O
increased O
phosphorylation O
of O
the O
Elk I-GENE
- I-GENE
1 I-GENE
C I-GENE
- I-GENE
terminal I-GENE
region I-GENE
and O
by O
the O
activation O
of O
a O
42 I-GENE
kd RARE
cellular I-GENE
Elk I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
. O

In O
contrast O
to O
the O
situation RARE
in O
mammalian O
cells O
, O
prolonged O
exposure O
of O
the O
agonist O
( O
24 O
h O
) O
does O
not O
result O
in O
down O
regulation O
of O
the O
remaining O
70 O
% O
of O
the O
receptors O
. O

This O
stimulatory O
effect O
could O
also O
be O
elicited O
by O
c I-GENE
- I-GENE
Jun I-GENE
, O
which O
interacts O
with O
topo RARE
II I-GENE
, O
but O
not O
by O
c I-GENE
- I-GENE
Fos I-GENE
, O
which O
does O
not O
bind O
topo RARE
II I-GENE
in O
our O
in O
vitro O
assay O
. O

The O
regulation O
of O
Myf RARE
- I-GENE
5 I-GENE
and O
MyoD I-GENE
function O
by O
a O
cAMP O
- O
dependent O
pathway O
may O
partly O
explain O
how O
external O
signals O
generated O
by O
serum O
and O
certain O
peptide O
growth O
factors O
can O
be O
transduced RARE
to O
the O
nucleus O
and O
inhibit O
dominant O
- O
acting O
factors O
that O
are O
responsible O
for O
myoblast RARE
differentiation O
. O

16 O
, O
99 O
- O
104 O
). O

We O
have O
previously O
reported O
that O
high O
level O
human I-GENE
desmin RARE
expression O
depends O
on O
a O
280 NUMERIC
- O
base O
pair O
muscle O
- O
specific O
enhancer O
which O
can O
function O
not O
only O
in O
myotubes O
, O
but O
can O
also O
activate O
gene O
expression O
in O
myoblasts O
. O

After O
surgery O
, O
patients O
self O
administered O
one O
of O
three O
possible O
postsurgical RARE
medications RARE
, O
which O
included O
placebo O
, O
codeine RARE
60 O
mg O
, O
and O
ibuprofen RARE
400 O
mg O
, O
when O
their O
pain O
reached O
a O
moderate O
or O
severe O
intensity O
. O

Replacement O
of O
the O
wild O
- O
type O
5 O
'- O
regulatory O
region O
with O
either O
of O
the O
mutants O
' O
cis O
- O
acting O
regulatory O
element O
resulted O
in O
the O
anaerobic O
expression O
of O
active I-GENE
Mn RARE
- I-GENE
superoxide I-GENE
dismutase I-GENE
. O

The O
orf61 NUMERIC
gene I-GENE
product I-GENE
, O
when O
expressed O
from O
an O
exogenous O
promoter O
, O
inhibited O
int I-GENE
- O
mediated O
integration O
at O
the O
chromosomal I-GENE
attB LASTCAP
site I-GENE
. O

Expression O
in O
established O
LCLs RARE
, O
occurring O
irrespective O
of O
virus O
producer RARE
status O
, O
was O
not O
a O
consequence O
of O
continued O
in O
vitro O
passage O
; O
thus O
, O
appropriately RARE
spliced O
BamHI I-GENE
- I-GENE
A I-GENE
transcripts I-GENE
could O
be O
amplified O
from O
normal O
B O
cells O
within O
1 O
day O
of O
their O
experimental O
infection O
in O
vitro O
, O
along O
with O
BamHI I-GENE
- I-GENE
C I-GENE
/ I-GENE
W I-GENE
promoter O
- O
initiated O
but O
not O
BamHI I-GENE
- I-GENE
F I-GENE
promoter I-GENE
- I-GENE
initiated I-GENE
mRNAs I-GENE
. O

Analysis O
by O
cell O
surface O
immunofluorescence O
showed O
that O
the O
UL28 NUMERIC
gene I-GENE
is O
not O
required O
for O
expression O
of O
viral O
glycoproteins O
on O
the O
surface O
of O
infected O
cells O
. O

Furthermore O
, O
a O
mutant O
receptor O
( O
Y977F NUMERIC
/ O
Y989F NUMERIC
[ O
PLC I-GENE
gamma I-GENE
- O
binding O
sites O
]) O
could O
fully O
activate O
Ras I-GENE
, O
and O
the O
direct O
activation O
of O
protein I-GENE
kinase I-GENE
C I-GENE
and O
calcium O
mobilization RARE
had O
almost O
no O
effect O
on O
the O
GDP O
/ O
GTP O
state O
of O
Ras I-GENE
in O
this O
cell O
line O
. O

Estrogen RARE
treatment O
in O
high O
doses O
is O
effective O
in O
reducing O
adult O
stature RARE
in O
constitutionally RARE
tall RARE
girls O
. O

Mutations O
at O
the O
extreme O
C O
- O
terminus O
of O
EIAV ALLCAPS
Tat I-GENE
impaired O
both O
RNA O
binding O
and O
activation O
domain O
functions O
, O
suggesting O
effects O
on O
secondary O
or O
tertiary O
structure O
. O

This O
observation O
suggests O
that O
the O
methyl O
- O
directed O
repair O
system O
utilizes RARE
the O
proximal O
d O
( O
GATC ALLCAPS
) O
sequence O
to O
direct O
correction O
. O

Uracil RARE
DNA I-GENE
glycosylase I-GENE
catalyzes O
the O
initial O
step O
in O
the O
repair O
pathway O
that O
removes RARE
potentially O
mutagenic RARE
uracil RARE
from O
duplex O
DNA O
. O

Current O
clinical O
trials O
should O
answer RARE
the O
question O
of O
which O
of O
the O
therapeutic O
options RARE
impairs RARE
quality O
of O
life O
less O
. O

Lithium RARE
phthalocyanine RARE
( O
LiPc RARE
) O
is O
a O
prototype O
of O
another O
generation O
of O
synthetic O
, O
metallic RARE
- O
organic O
, O
paramagnetic RARE
crystallites RARE
that O
appear O
very O
useful O
for O
in O
vitro O
and O
in O
vivo O
electron O
paramagnetic RARE
resonance O
oximetry RARE
. O

In O
this O
report O
, O
we O
focus O
on O
the O
genetics RARE
of O
the O
region O
of O
the O
17 I-GENE
hep RARE
syn RARE
gB LASTCAP
gene I-GENE
that O
conferred O
both O
the O
syncytial RARE
and O
pathogenic O
phenotypes O
to O
17 O
syn RARE
+. RARE

Recipients RARE
with O
acute O
leukaemia RARE
in O
first O
remission O
or O
chronic O
myeloid O
leukaemia RARE
in O
first O
chronic O
phase O
were O
analysed O
as O
good O
risk O
, O
and O
those O
beyond O
these O
stages O
, O
as O
poor O
risk O
patients O
. O

Elledge RARE
, O
P O
. O

Drugs RARE
suppressed O
> O
or O
= O
75 O
% O
of O
the O
total O
premature O
ventricular O
contractions O
in O
all O
patients O
who O
had O
both O
use O
- O
dependent O
QRS O
prolongation O
and O
reverse O
use O
- O
dependent O
QT O
prolongation O
, O
in O
79 O
% O
of O
patients O
with O
use O
- O
dependent O
QRS O
prolongation O
alone O
, O
in O
70 O
% O
with O
reverse O
use O
- O
dependent O
QT O
prolongation O
alone O
, O
and O
in O
11 O
% O
with O
neither O
use O
- O
dependent O
QRS O
prolongation O
nor O
reverse O
use O
- O
dependent O
QT O
prolongation O
. O

Losses RARE
during O
the O
complete O
procedure O
are O
corrected O
for O
using O
radioactive RARE
estrogen O
conjugates RARE
during O
the O
first O
steps O
and O
later O
by O
adding O
deuterated RARE
internal O
standards RARE
of O
all O
compounds O
measured O
( O
matairesinol RARE
, O
enterodiol RARE
, O
enterolactone RARE
, O
daidzein RARE
, O
O O
- O
desmethylangolensin RARE
, O
equol RARE
, O
and O
genistein RARE
). O

IE2 I-GENE
- O
IE2 I-GENE
interactions O
were O
mapped O
to O
a O
domain O
containing O
a O
putative O
helix O
- O
turn O
- O
helix O
motif O
located O
near O
the O
C O
terminus O
of O
IE2 I-GENE
, O
between O
amino O
acids O
456 NUMERIC
and O
539 NUMERIC
. O

The O
Sp1 I-GENE
region I-GENE
, O
however O
, O
is O
converted O
to O
a O
functionally O
strong O
TRE O
by O
the O
viral I-GENE
tat I-GENE
factor I-GENE
. O

Precipitation RARE
using O
GST I-GENE
fusion I-GENE
proteins I-GENE
containing O
Fyn I-GENE
SH2 I-GENE
, O
SH3 I-GENE
, O
and O
SH2 I-GENE
/ O
SH3 I-GENE
domains O
revealed O
that O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
bound O
principally RARE
to O
the O
SH3 I-GENE
domain I-GENE
of O
Fyn I-GENE
. O

A O
sheep O
testicular O
cDNA O
library O
constructed O
in O
pcDNA1 NUMERIC
vector O
was O
screened O
with O
a O
probe O
generated O
by O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
corresponding O
to O
a O
1 O
. O
6 O
kb O
fragment O
of O
the O
rat I-GENE
luteinizing RARE
hormone I-GENE
receptor I-GENE
cDNA I-GENE
. O

Two O
putative O
Rev I-GENE
proteins I-GENE
with O
apparent O
molecular O
masses O
of O
18 O
and O
16 O
kDa O
were O
expressed O
by O
p2 NUMERIC
/ I-GENE
2 I-GENE
and O
p176 NUMERIC
, O
while O
p20 NUMERIC
expressed O
only O
a O
16 O
- O
kDa O
species O
. O

Three O
group O
1 O
patients O
developed O
CMV O
disease O
; O
1 O
group O
2 O
patient O
developed O
CMV O
hepatitis O
. O

The O
ability O
of O
spt2 NUMERIC
mutations I-GENE
to O
suppress O
the O
transcriptional O
interference O
caused O
by O
the O
delta I-GENE
promoter I-GENE
insertion I-GENE
his I-GENE
- I-GENE
4 I-GENE
- I-GENE
912 NUMERIC
delta I-GENE
correlates O
with O
an O
increase O
in O
wild I-GENE
- I-GENE
type I-GENE
HIS4 NUMERIC
mRNA I-GENE
levels O
. O

Nuclear O
localization O
and O
protein O
sequence O
similarities O
suggested O
that O
the O
SPT2 NUMERIC
/ O
SIN1 NUMERIC
protein O
may O
be O
related O
to O
the O
nonhistone RARE
chromosomal I-GENE
protein I-GENE
HMG1 NUMERIC
. O

The O
conserved O
ninth RARE
C O
- O
terminal O
heptad O
in O
thyroid O
hormone O
and O
retinoic I-GENE
acid I-GENE
receptors I-GENE
mediates O
diverse O
responses O
by O
affecting O
heterodimer O
but O
not O
homodimer O
formation O
. O

Genetic O
interactions O
between O
BCK2 NUMERIC
and O
other O
pathway O
components O
suggested O
that O
BCK2 NUMERIC
functions O
on O
a O
common O
pathway O
branch O
with O
PPZ1 NUMERIC
and O
PPZ2 NUMERIC
. O

Steroidogenic RARE
factor I-GENE
1 I-GENE
, O
an O
orphan I-GENE
nuclear I-GENE
receptor I-GENE
, O
regulates O
the O
expression O
of O
the O
rat I-GENE
aromatase I-GENE
gene I-GENE
in O
gonadal RARE
tissues O
. O

To O
study O
the O
functional O
differences O
between O
cutaneous O
HPV5 NUMERIC
and O
HPV8 NUMERIC
E7s NUMERIC
and O
genital I-GENE
HPV16 NUMERIC
E7 I-GENE
, O
we O
cloned O
each O
of O
the O
E7 I-GENE
open O
reading O
frames O
and O
tested O
their O
immortalizing RARE
and O
transforming O
activities O
, O
the O
binding O
ability O
of O
their O
products O
with O
retinoblastoma I-GENE
protein I-GENE
( O
RB I-GENE
) O
and O
their O
complementation O
activity O
of O
a O
RB I-GENE
- I-GENE
nonbinding RARE
adenovirus I-GENE
E1A I-GENE
mutant I-GENE
. O

The O
rhaB LASTCAP
transcription I-GENE
start I-GENE
site I-GENE
was O
mapped O
to O
- O
24 O
relative O
to O
the O
start O
of O
translation O
. O

Several O
lines O
of O
evidence O
demonstrate O
that O
this O
growth O
inhibition O
requires O
active O
PKA I-GENE
subunits I-GENE
and O
cAMP O
: O
( O
i O
) O
this O
phenotype O
is O
dependent O
on O
cAMP O
since O
it O
is O
not O
seen O
in O
a O
strain O
lacking O
adenylyl RARE
cyclase I-GENE
activity O
, O
but O
the O
growth O
rate O
of O
these O
transformants O
is O
slower O
when O
exogenous O
cAMP O
is O
added O
; O
( O
ii O
) O
normal O
growth O
occurs O
when O
wild O
- O
type O
RI I-GENE
cDNA O
is O
replaced O
by O
a O
mutant I-GENE
RI I-GENE
cDNA I-GENE
encoding O
a O
RI I-GENE
protein I-GENE
with O
reduced O
cAMP O
binding O
; O
and O
( O
iii O
) O
the O
growth O
- O
inhibited O
phenotype O
of O
the O
transformed O
BL21 NUMERIC
( O
DE3 NUMERIC
) O
cells O
requires O
soluble O
, O
active O
C I-GENE
alpha I-GENE
protein I-GENE
. O

Liu RARE
, O
B O
. O

BCR I-GENE
- O
ABL I-GENE
and O
v I-GENE
- I-GENE
abl I-GENE
oncogenes I-GENE
induce O
distinct O
patterns O
of O
thymic O
lymphoma O
involving O
different O
lymphocyte O
subsets RARE
. O

These O
experiments O
confirm O
that O
the O
6 O
- O
S O
liganded RARE
form O
of O
the O
receptor O
identified O
in O
nuclear O
extracts O
of O
cells O
treated O
with O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo RARE
- O
p O
- O
dioxin O
( O
TCDD ALLCAPS
) O
contains O
the O
Ah RARE
receptor I-GENE
protein I-GENE
and O
ARNT ALLCAPS
but O
not O
the O
90 I-GENE
- I-GENE
kDa I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
. O

LDL I-GENE
cholesterol I-GENE
decreased O
from O
4 O
. O
74 O
+/- O
0 O
. O
87 O
to O
3 O
. O
78 O
+/- O
0 O
. O
78 O
mmol O
/ O
l O
after O
8 O
weeks O
on O
simvastatin RARE
( O
P O
< O
0 O
. O
001 O
), O
and O
apo I-GENE
B I-GENE
fell O
from O
142 O
+/- O
31 O
to O
112 O
+/- O
22 O
mg O
/ O
dl O
( O
P O
< O
0 O
. O
001 O
). O

LDL I-GENE
cholesterol I-GENE
decreased O
from O
4 O
. O
74 O
+/- O
0 O
. O
87 O
to O
3 O
. O
78 O
+/- O
0 O
. O
78 O
mmol O
/ O
l O
after O
8 O
weeks O
on O
simvastatin RARE
( O
P O
< O
0 O
. O
001 O
), O
and O
apo I-GENE
B I-GENE
fell O
from O
142 O
+/- O
31 O
to O
112 O
+/- O
22 O
mg O
/ O
dl O
( O
P O
< O
0 O
. O
001 O
). O

This O
negative O
element O
may O
, O
at O
least O
in O
part O
, O
be O
responsible O
for O
the O
cell O
type O
- O
specific O
expression O
of O
the O
DGK ALLCAPS
gene I-GENE
. O

Regulated RARE
activity O
of O
the O
distal O
promoter O
- O
like O
element O
of O
the O
human I-GENE
corticotropin RARE
- I-GENE
releasing I-GENE
hormone I-GENE
gene I-GENE
and O
secondary O
structural O
features O
of O
its O
corresponding O
transcripts O
. O

A O
new O
bioencapsulation RARE
technology O
for O
microbial O
inoculants RARE
. O

We O
linked O
hypersensitivity O
site O
2 O
( O
HS2 NUMERIC
) O
from O
the O
locus O
control O
region O
( O
LCR O
) O
to O
a O
A I-GENE
gamma I-GENE
- I-GENE
globin I-GENE
gene O
( O
A O
gamma O
*) RARE
mutationally RARE
marked O
to O
allow O
its O
transcript O
to O
be O
distinguished O
from O
endogenous O
gamma I-GENE
- I-GENE
globin I-GENE
mRNA O
. O

INTERVENTIONS ALLCAPS
-- O
Patients O
allocated O
to O
treatment O
with O
levodopa RARE
/ I-GENE
dopa RARE
decarboxylase I-GENE
inhibitor O
alone O
( O
arm O
1 O
), O
levodopa RARE
/ I-GENE
decarboxylase I-GENE
inhibitor O
/ O
selegiline RARE
in O
combination O
( O
arm O
2 O
), O
or O
bromocriptine RARE
( O
arm O
3 O
). O

It O
contains O
three O
putative O
binding O
sites O
for O
transcription I-GENE
factor I-GENE
Sp1 I-GENE
as O
well O
as O
several O
short O
sequences O
that O
are O
similar O
to O
known O
cis O
- O
acting O
enhancers O
or O
binding O
sites O
for O
transcription O
factors O
. O

French RARE
bean O
contains O
a O
small O
family O
of O
genes I-GENE
encoding I-GENE
PAL I-GENE
and O
two O
of O
these O
genes O
, O
PAL2 NUMERIC
and O
PAL3 NUMERIC
, O
have O
been O
shown O
to O
be O
differentially O
expressed O
at O
the O
mRNA O
level O
in O
bean O
tissues O
. O

Plasma O
thromboxane O
B2 O
levels O
in O
the O
older O
group O
were O
about O
double O
those O
in O
younger RARE
piglets RARE
. O

By O
stepwise RARE
linear O
multiple O
regression O
analysis O
, O
ionized RARE
magnesium O
was O
significantly O
related O
to O
cyclosporin O
trough O
level O
and O
total O
cholesterol O
but O
not O
to O
serum O
creatinine O
, O
time O
after O
transplant O
or O
the O
dose O
of O
cyclosporin O
. O

The O
human I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
( O
IGF I-GENE
- I-GENE
II I-GENE
) O
gene O
contains O
four O
promoters O
( O
P1 O
, O
P2 O
, O
P3 O
and O
P4 O
). O

Moreover O
, O
in O
transient O
transfection O
assays O
, O
PU I-GENE
. I-GENE
1 I-GENE
alone O
activated O
reporter O
constructs O
containing O
the O
JB ALLCAPS
cis O
- O
element O
, O
and O
the O
activation O
was O
shown O
to O
be O
dependent O
on O
a O
glutamine O
- O
rich O
sequence O
in O
the O
amino O
- O
terminal O
portion O
of O
PU I-GENE
. I-GENE
1 I-GENE
. O

Army RARE
veterans RARE
given O
yellow O
fever O
vaccine O
contaminated O
with O
hepatitis O
B O
virus O
in O
1942 NUMERIC
and O
controls O
and O
( O
b O
) O
a O
case O
- O
control O
study O
comparing O
veterans RARE
with O
hepatocellular RARE
carcinoma O
in O
Veterans RARE
Affairs RARE
hospitals O
with O
matched O
controls O
with O
respect O
to O
receipt RARE
of O
contaminated O
vaccine O
in O
1942 NUMERIC
. O

They O
were O
found O
to O
be O
seropositive O
for O
antibodies O
to O
hepatitis O
C O
virus O
by O
second O
- O
generation O
testing O
( O
RIBA ALLCAPS
2 O
, O
Ortho RARE
Diagnostic O
Systems RARE
Inc RARE
, O
Westwood RARE
, O
MA O
). O

Defects RARE
of O
fibrillin RARE
( O
FBN1 NUMERIC
), O
a O
glycoprotein O
component O
of O
the O
extracellular O
microfibril RARE
, O
cause O
Marfan RARE
syndrome O
. O

When O
introduced O
into O
recJ LASTCAP
+ I-GENE
strains O
, O
srjA LASTCAP
mutations O
conferred O
hyperrecombinational RARE
and O
hyper RARE
- I-GENE
UVr RARE
phenotypes O
. O

Distinguishing RARE
roles O
of O
the O
membrane O
- O
cytoskeleton O
and O
cadherin I-GENE
mediated O
cell O
- O
cell O
adhesion O
in O
generating O
different O
Na I-GENE
+, I-GENE
K I-GENE
(+)- I-GENE
ATPase I-GENE
distributions RARE
in O
polarized RARE
epithelia RARE
. O

Neonatal RARE
lupus O
erythematosus O
is O
most O
often O
associated O
with O
autoantibodies O
against O
Ro I-GENE
and O
La I-GENE
antigens O
. O

Genetic O
abnormalities O
that O
could O
lead O
to O
mutagenesis O
include O
chromosomal O
abnormalities O
and O
single O
- O
gene O
mutations O
. O

Hops RARE
, O
and O
L O
. O

Continued RARE
absorption O
of O
amino O
acids O
by O
the O
NBB ALLCAPS
carrier O
( O
for O
neutral O
amino O
acids O
), O
the O
Y O
+ O
system O
( O
for O
dibasic RARE
amino O
acids O
), O
and O
the O
PHE ALLCAPS
carrier O
were O
operative O
even O
during O
the O
actively O
purging RARE
stage O
of O
watery RARE
diarrhoea RARE
due O
to O
cholera RARE
. O

1 O
) O
CFDN ALLCAPS
, O
AMPC ALLCAPS
and O
MNZ ALLCAPS
showed O
a O
potent O
antimicrobial O
activity O
against O
H O
. O
pylori O
, O
and O
especially O
, O
AMPC ALLCAPS
showed O
a O
marked O
bactericidal O
activity O
in O
a O
short O
time O
. O

Creutzfeldt RARE
- O
Jakob RARE
disease O
and O
lyophilised RARE
dura RARE
mater RARE
grafts O
: O
report O
of O
two O
cases O
. O

A O
high O
mean O
intensity O
of O
CLTPA ALLCAPS
( O
standardized O
multivariate O
regression O
coefficient O
beta O
- O
0 O
. O
059 NUMERIC
, O
p O
= O
0 O
. O
020 NUMERIC
) O
and O
a O
high O
maximal O
oxygen O
uptake O
( O
beta O
- O
0 O
. O
163 NUMERIC
, O
p O
< O
0 O
. O
001 O
) O
were O
associated O
with O
reduced O
plasma I-GENE
fibrinogen I-GENE
when O
adjusting RARE
for O
the O
strongest O
covariates RARE
. O

What RARE
young O
people O
think RARE
and O
do O
when O
the O
option RARE
for O
cystic O
fibrosis O
carrier O
testing O
is O
available O
. O

A O
patient O
matches O
a O
PIC ALLCAPS
patient O
if O
both O
have O
the O
same O
mechanism O
of O
injury O
, O
the O
same O
coding O
of O
Revised RARE
Trauma RARE
Score RARE
variables O
( O
Glascow RARE
Coma RARE
Scale O
score O
, O
systolic O
blood O
pressure O
, O
respiratory O
rate O
), O
the O
same O
coded O
age O
per O
A O
Severity RARE
Characterization O
of O
Trauma RARE
) O
( O
ASCOT ALLCAPS
), O
and O
if O
they O
differ O
by O
no O
more O
than O
0 O
. O
5 O
for O
A O
, O
B O
, O
and O
C O
( O
the O
ASCOT ALLCAPS
components O
for O
serious O
injuries O
). O

Skin RARE
and O
bowel O
TPO2 NUMERIC
varied O
with O
DO2 NUMERIC
and O
each O
other O
( O
P O
< O
0 O
. O
05 O
). O

A O
region O
approximately O
100 O
bp O
upstream O
from O
the O
transcription O
start O
point O
of O
virB LASTCAP
was O
identified O
as O
being O
necessary O
for O
full O
activation O
of O
this O
promoter O
by O
VirF LASTCAP
. O

We O
have O
isolated O
a O
cosmid O
containing O
DNA O
that O
corresponds O
to O
the O
site O
of O
transposon O
insertion O
in O
257DH4 NUMERIC
and O
have O
localized O
Tn5 NUMERIC
on O
an O
8 I-GENE
. I-GENE
0 I-GENE
kb I-GENE
EcoRI I-GENE
fragment I-GENE
. O

The O
scr RARE
regulon RARE
of O
pUR400 NUMERIC
and O
the O
chromosomally RARE
encoded I-GENE
scr RARE
regulon RARE
of I-GENE
Klebsiella I-GENE
pneumoniae I-GENE
KAY2026 NUMERIC
are O
both O
negatively O
controlled O
by O
a O
specific O
repressor O
( O
ScrR LASTCAP
). O

Although O
the O
molecular O
mechanisms O
involved O
in O
this O
regulation O
are O
currently O
being O
elucidated RARE
, O
very O
little O
is O
known O
about O
the O
trans O
- O
acting O
factors O
that O
allow O
expression O
of O
the O
nitrate I-GENE
and I-GENE
nitrite I-GENE
reductase I-GENE
genes I-GENE
which O
code O
for O
the O
first O
enzymes O
in O
the O
pathway O
. O

The O
Ntl1 NUMERIC
gene I-GENE
is O
present O
as O
a O
unique O
copy O
in O
the O
diploid O
N O
. O
plumbaginifolia RARE
species O
. O

Transient O
transfection O
experiments O
revealed O
that O
Pax I-GENE
- I-GENE
8 I-GENE
isoforms I-GENE
a I-GENE
and I-GENE
b I-GENE
, O
but O
not O
c O
and O
d O
, O
strongly O
stimulate O
transcription O
from O
a O
promoter O
containing O
six O
copies O
of O
a O
paired I-GENE
- I-GENE
domain I-GENE
recognition I-GENE
sequence I-GENE
. O

The O
amino O
- O
terminal O
third O
of O
the O
protein O
contains O
a O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
motif I-GENE
characteristic O
of O
DNA O
- O
binding O
proteins O
. O

We O
have O
examined O
the O
ability O
of O
various O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
subunits I-GENE
to O
bind O
to O
, O
and O
activate O
transcription O
from O
, O
the O
IL I-GENE
- I-GENE
8 I-GENE
promoter I-GENE
. O

When O
multiple O
copies O
of O
the O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
site I-GENE
were O
linked O
to O
an O
enhancerless RARE
simian I-GENE
virus I-GENE
40 I-GENE
promoter I-GENE
, O
this O
element O
was O
able O
to O
mediate O
phorbol O
ester O
- O
or O
lipopolysaccharide O
- O
inducible O
gene O
expression O
. O

We O
found O
that O
the O
3 O
'- O
end O
- O
adjacent O
sequence O
CA O
( O
N O
) O
3 O
- O
10AGTNNAA NUMERIC
, O
conserved O
in O
plant O
Pol I-GENE
II I-GENE
- O
specific O
U I-GENE
snRNA I-GENE
genes I-GENE
, O
is O
essential O
for O
the O
3 O
'- O
end O
formation O
of O
U2 I-GENE
transcripts I-GENE
and O
, O
similar O
to O
the O
vertebrate O
3 O
' O
box O
, O
is O
highly O
tolerant RARE
to O
mutation O
. O

These O
results O
indicate O
that O
Rb I-GENE
protein I-GENE
is O
interacting O
with O
some O
component O
( O
s O
) O
of O
the O
cell O
cycle O
- O
regulatory O
machinery O
during O
G2 O
phase O
. O

MDBP ALLCAPS
from O
HeLa O
and O
Raji RARE
cells O
formed O
DNA O
- O
protein O
complexes O
with O
X O
- O
box O
oligonucleotides O
that O
coelectrophoresed RARE
with O
those O
containing O
standard O
MDBP ALLCAPS
sites I-GENE
. O

Transgenic RARE
mice O
harboring O
the O
rat O
TnI I-GENE
- O
CAT I-GENE
fusion O
gene O
expressed O
the O
reporter O
specifically O
in O
the O
skeletal O
muscle O
. O

METHODS O
: O
Fifty O
- O
one O
healthy O
eyes O
, O
169 NUMERIC
ocular O
hypertensive O
eyes O
with O
normal O
visual O
fields O
, O
and O
132 O
glaucomatous RARE
eyes O
with O
early O
visual O
field O
defects O
were O
evaluated O
with O
qualitative O
and O
quantitative O
measures O
of O
structural O
damage O
to O
the O
optic O
nerve O
and O
nerve O
fiber O
layer O
. O

Consistent O
with O
the O
hypothesis O
that O
it O
acts O
as O
transcriptional O
regulator O
, O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
protein I-GENE
binds O
DNA O
and O
activates O
transcription O
of O
several O
promoters O
. O

The O
ADP I-GENE
- I-GENE
ribosylation RARE
factor I-GENE
( O
ARF I-GENE
) O
family O
is O
one O
of O
four O
subfamilies RARE
of O
the O
RAS ALLCAPS
superfamily I-GENE
of O
low I-GENE
molecular I-GENE
weight I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
G I-GENE
proteins I-GENE
). O

The O
E1 I-GENE
gene I-GENE
is O
located O
within O
the O
first O
intron O
of O
the O
gene O
for O
RCC1 NUMERIC
, O
a O
protein O
that O
regulates O
onset O
of O
mitosis O
. O

Genomic O
Southern O
blot O
analysis O
and O
chromosome O
mapping O
showed O
that O
GPRK6 NUMERIC
hybridizes RARE
to O
two O
closely O
related O
genes O
located O
on O
chromosomes O
5 O
and O
13 O
and O
are O
, O
therefore O
, O
distinct O
from O
the O
GPRK ALLCAPS
located O
near O
the O
Huntington RARE
disease I-GENE
locus I-GENE
on O
chromosome O
4 O
. O

Metabolic RARE
labeling O
studies O
in O
S O
. O
cerevisiae O
and O
co O
- O
expression O
of O
nmt72p NUMERIC
with O
several O
protein O
substrates O
of O
Nmt1p NUMERIC
in O
Escherichia O
coli O
indicate O
that O
the O
Leu99 NUMERIC
--> O
Pro O
substitution O
causes O
a O
reduction O
in O
the O
acylation RARE
of O
some O
but O
not O
all O
protein O
substrates O
. O

These O
CTD I-GENE
kinases I-GENE
, O
designated O
CTDK1 NUMERIC
and O
CTDK2 NUMERIC
, O
are O
fractionated RARE
by O
chromatography O
on O
Mono RARE
Q O
. O

Instead O
, O
mRNA O
of O
2 O
. O
0 O
and O
2 O
. O
8 O
kb O
are O
detected O
in O
varying O
abundance O
. O

Previously O
, O
we O
identified O
a O
51 O
- O
bp O
promoter O
fragment O
, O
oligo31 NUMERIC
/ O
32 O
, O
which O
conferred O
heat O
shock O
inducibility O
on O
the O
heterologous O
CYC1 I-GENE
- O
lacZ I-GENE
reporter O
gene O
in O
S O
. O
cerevisiae O
( O
N O
. O

The O
sequence O
of O
the O
HIR1 NUMERIC
gene I-GENE
predicts O
an O
88 O
- O
kDa O
protein O
with O
three O
repeats O
of O
a O
motif O
found O
in O
the O
G I-GENE
beta I-GENE
subunit I-GENE
of O
retinal I-GENE
transducin RARE
and O
in O
a O
yeast O
transcriptional O
repressor O
, O
Tup1 NUMERIC
. O

All O
of O
these O
data O
suggest O
that O
replication O
of O
UV O
- O
damaged O
templates O
occurs O
in O
vitro O
as O
it O
does O
in O
vivo O
and O
that O
this O
replication O
results O
in O
mutation O
fixation O
. O

To O
identify O
factors O
that O
may O
modify O
the O
heterosexual RARE
transmission O
of O
human O
T O
cell O
leukemia O
/ O
lymphoma O
virus O
type O
I O
( O
HTLV O
- O
I O
), O
534 NUMERIC
married RARE
couples RARE
enrolled O
in O
the O
Miyazaki RARE
Cohort RARE
Study O
between O
November RARE
1984 NUMERIC
and O
April RARE
1989 O
were O
studied O
: O
95 O
husband RARE
HTLV O
- O
I O
- O
seropositive O
( O
H O
+)/ RARE
wife RARE
seropositive O
( O
W O
+), O
33 O
H O
+/ O
W O
-, O
64 O
H O
-/ RARE
W O
+, O
and O
342 NUMERIC
H O
-/ RARE
W O
-. O

Biol O
. O

To O
characterize O
the O
expression O
of O
this O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
we O
have O
isolated O
the O
corresponding O
genomic O
clone O
. O

L O
., O
Stange RARE
, O
G O
., O
Markovich RARE
, O
D O
., O
Biber RARE
, O
J O
., O
Testar RARE
, O
X O
., O
Zorzano RARE
, O
A O
., O
Palacin RARE
, O
M O
., O
and O
Murer RARE
, O
H O
. O

The O
nucleotide O
sequence O
of O
the O
gene O
predicts O
a O
polypeptide O
of O
215 O
amino O
acids O
( O
25 O
. O
2 O
kDa O
) O
with O
two O
putative O
membrane O
- O
spanning O
domains O
. O

SAECG ALLCAPS
, O
echocardiography O
and O
thallium O
- O
201 O
imaging O
were O
performed O
before O
and O
1 O
month O
after O
attempted RARE
angioplasty RARE
. O

They O
were O
called O
PACE4 NUMERIC
and O
PC4 NUMERIC
. O

265 NUMERIC
, O
1102 NUMERIC
- O
1110 NUMERIC
). O

Both O
fusion O
proteins O
form O
stable O
specific O
complexes O
with O
a O
short O
DNA O
duplex O
harboring O
the O
CTGT ALLCAPS
( O
at O
) O
4ACAG NUMERIC
consensus O
sequence O
of O
the O
LexA I-GENE
repressor I-GENE
. O

Ten O
selenocysteine O
residues O
( O
deduced O
) O
are O
present O
. O

CONCLUSIONS O
: O
Free RARE
protein I-GENE
S I-GENE
deficiency O
is O
common O
among O
hospitalized O
patients O
, O
even O
in O
the O
absence O
of O
a O
recognized O
predisposing RARE
condition O
. O

During O
the O
past O
decade RARE
, O
different O
types O
of O
endogenous O
retroviral O
sequences O
have O
been O
defined O
in O
the O
human O
genome O
usually O
by O
low O
stringency RARE
hybridization O
employing O
DNA O
probes O
of O
evolutionary O
conserved O
animal O
retrovirus O
genes O
. O

As O
the O
components O
of O
these O
complexes O
, O
at O
least O
five O
TRBPs RARE
( O
p30 NUMERIC
, O
p37 NUMERIC
, O
p46 NUMERIC
, O
p50 I-GENE
, O
and O
p56 NUMERIC
) O
showing O
specific O
binding O
to O
the O
TAR O
RNA O
were O
detected O
in O
the O
uv RARE
cross O
- O
linking O
assay O
. O

The O
obvious RARE
functional O
necessity RARE
for O
editing RARE
in O
kinetoplastid RARE
mitochondria O
is O
the O
formation O
of O
translatable RARE
mRNAs O
. O

The O
use O
of O
this O
model O
for O
investigating RARE
pathophysiologically RARE
significant O
issues O
in O
denervating RARE
diseases O
is O
illustrated RARE
with O
five O
different O
sets O
of O
parameters O
. O

An O
extensive O
inverted O
repeat O
is O
present O
3 O
' O
of O
rpeA LASTCAP
; O
inverted O
repeats O
are O
found O
downstream O
of O
all O
PE I-GENE
operons I-GENE
sequenced O
to O
date O
, O
although O
the O
sequence O
is O
not O
conserved O
. O

We O
describe O
a O
novel O
cytoplasmic I-GENE
tyrosine I-GENE
kinase I-GENE
, O
termed O
BPK ALLCAPS
( O
B I-GENE
cell I-GENE
progenitor I-GENE
kinase I-GENE
), O
which O
is O
expressed O
in O
all O
stages O
of O
the O
B O
lineage O
and O
in O
myeloid O
cells O
. O

Large O
differences O
between O
the O
groups O
were O
not O
observed O
in O
HA I-GENE
- I-GENE
synthesizing RARE
enzyme I-GENE
activity O
, O
but O
degradative RARE
enzyme O
activity O
was O
much O
higher O
in O
aspirin O
- O
induced O
asthma O
- O
related O
polyps O
than O
in O
other O
types O
of O
nasal O
polyps O
tested O
. O

In O
the O
multivariate O
analysis O
, O
six O
variables O
were O
independently O
correlated O
with O
survival O
: O
blood O
urea O
nitrogen O
level O
, O
serum I-GENE
aspartate I-GENE
aminotransferase I-GENE
level O
, O
community O
- O
acquired O
vs O
. O
hospital O
- O
acquired O
peritonitis RARE
, O
age O
, O
Child RARE
- O
Pugh RARE
score O
and O
ileus RARE
. O

Localization O
of O
the O
intronless O
gene O
coding O
for O
calmodulin I-GENE
- I-GENE
like I-GENE
protein I-GENE
CLP ALLCAPS
to O
human O
chromosome O
10p13 NUMERIC
- O
ter RARE
. O

In O
wandering RARE
stage O
larvae O
, O
the O
OBP ALLCAPS
transcript I-GENE
appeared O
to O
be O
at O
least O
250 O
- O
fold O
less O
abundant O
than O
ribosomal O
RNA O
. O

One O
such O
mutant O
also O
affects O
the O
overlapping O
- O
10 O
hexamer O
of O
PR O
and O
results O
in O
reduced O
occupancy RARE
by O
both O
MerR LASTCAP
and O
RNA I-GENE
polymerase I-GENE
, O
likely O
as O
a O
result O
of O
inefficient O
transcriptional O
initiation O
of O
merR LASTCAP
mRNA I-GENE
. O

However O
, O
L I-GENE
- I-GENE
plastin I-GENE
has O
been O
found O
in O
many O
types O
of O
malignant O
human O
cells O
of O
non O
- O
hemopoietic RARE
origin O
suggesting O
that O
its O
expression O
is O
induced O
accompanying O
tumorigenesis O
in O
solid O
tissues O
. O

Finally O
, O
we O
present O
evidence O
that O
fimbrin RARE
is O
a O
third O
distinct O
plastin I-GENE
isoform I-GENE
which O
is O
specifically O
expressed O
at O
high O
levels O
in O
the O
small O
intestine O
. O

This O
promoter O
could O
direct O
the O
constitutive O
expression O
of O
the O
reporter O
beta I-GENE
- I-GENE
galactosidase I-GENE
at O
high O
frequency O
in O
transfected O
colonies O
of O
transformed O
cells O
that O
express O
L I-GENE
- I-GENE
plastin I-GENE
constitutively O
; O
by O
contrast O
, O
this O
promoter O
was O
virtually O
inactive O
in O
transfected O
colonies O
of O
normal O
fibroblasts O
and O
it O
exhibited O
a O
low O
frequency O
of O
constitutive O
activation O
in O
transfected O
colonies O
of O
in O
vitro O
SV40 O
- O
transformed O
fibroblasts O
which O
did O
not O
exhibit O
L I-GENE
- I-GENE
plastin I-GENE
expression O
. O

The O
half O
- O
life O
of O
the O
serum O
- O
induced O
CBP I-GENE
/ O
tk I-GENE
binding O
activity O
was O
estimated O
to O
be O
less O
than O
1 O
h O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

The O
DNase I-GENE
I I-GENE
footprint O
extended O
5 O
' O
in O
the O
silencer O
region O
to O
include O
an O
inverted O
repeat O
of O
a O
six O
- O
nucleotide O
motif O
( O
epsilon O
- O
267 NUMERIC
to O
- O
278 NUMERIC
bp O
) O
which O
shares O
5 O
of O
6 O
bases O
with O
the O
GATA I-GENE
- I-GENE
1 I-GENE
consensus I-GENE
sequence I-GENE
. O

Furthermore O
, O
competitor O
containing O
the O
YY1 I-GENE
consensus I-GENE
sequence I-GENE
competed RARE
for O
protein I-GENE
B I-GENE
binding O
, O
whereas O
competitor O
containing O
a O
perfect O
yeast I-GENE
ABF ALLCAPS
- I-GENE
1 I-GENE
consensus I-GENE
sequence I-GENE
did O
not O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

The O
gene O
includes O
three O
exons O
and O
two O
introns O
within O
1 O
. O
6 O
kilobases O
of O
DNA O
, O
and O
the O
entire O
open O
reading O
frame O
for O
glycoprotein I-GENE
IX I-GENE
is O
included O
within O
the O
third O
exon O
. O

Rhizobium O
meliloti RARE
large O
plasmid O
pRmeGR4b NUMERIC
carries O
the O
nodulation RARE
competitiveness RARE
locus O
nfe RARE
responsible O
for O
the O
nodulation RARE
efficiency O
and O
competitive O
ability O
of O
strain O
GR4 NUMERIC
on O
alfalfa RARE
roots O
. O

Further O
, O
the O
ability O
of O
recombinant O
beta O
and O
/ O
or O
gamma O
chains O
to O
function O
in O
defined O
biochemical O
assays O
of O
beta O
gamma O
activity O
was O
assessed O
for O
membrane O
extracts O
and O
supernatant O
fractions O
from O
infected O
Sf9 O
cells O
. O

This O
report O
describes O
the O
identification O
of O
a O
gene O
of O
related O
function O
, O
SMD1 NUMERIC
, O
located O
immediately O
3 O
' O
to O
PRP38 NUMERIC
. O

These O
data O
establish O
Smd1p NUMERIC
as O
a O
required O
component O
of O
the O
cellular O
splicing O
apparatus O
and O
a O
factor O
in O
snRNA O
maturation O
and O
stability O
. O

This O
study O
compared O
the O
gross O
and O
fine O
motor O
performance O
of O
14 O
traumatically RARE
brain O
- O
injured RARE
children O
( O
five O
to O
15 O
years O
old O
, O
with O
loss O
of O
consciousness RARE
for O
at O
least O
24 O
hours O
) O
to O
14 O
normal O
children O
group O
matched O
for O
age O
and O
sex O
. O

We O
compared O
the O
parameters O
pleural I-GENE
adenosine I-GENE
deaminase I-GENE
( O
PADA ALLCAPS
, O
determined O
in O
405 NUMERIC
patients O
), O
the O
PADA ALLCAPS
/ O
serum I-GENE
ADA ALLCAPS
ratio O
( O
P I-GENE
/ O
SADA ALLCAPS
; O
276 NUMERIC
cases O
), O
pleural I-GENE
lysozyme I-GENE
( O
PLYS ALLCAPS
, O
276 NUMERIC
cases O
), O
the O
PLYS ALLCAPS
/ O
serum I-GENE
LYS ALLCAPS
ratio O
( O
P I-GENE
/ O
SLYS ALLCAPS
; O
276 NUMERIC
cases O
), O
and O
pleural I-GENE
interferon I-GENE
gamma I-GENE
( O
IFN I-GENE
, O
145 NUMERIC
cases O
) O
regarding O
their O
ability O
to O
differentiate O
tuberculous O
pleural O
effusions RARE
from O
others O
. O

These O
exons O
were O
identified O
by O
cloning O
and O
sequencing O
cDNAs O
obtained O
by O
polymerase O
chain O
reaction O
amplification O
of O
a O
fibroblast O
cDNA O
library O
. O

Deletion O
of O
the O
apeA LASTCAP
gene I-GENE
, O
either O
with O
or O
without O
deletion O
of O
other O
proteinases RARE
( O
protease I-GENE
IV I-GENE
and O
aminopeptidase RARE
N I-GENE
), O
did O
not O
have O
any O
effect O
on O
cell O
growth O
in O
the O
various O
media O
tested O
. O

In O
Experiment O
2 O
scopolamine RARE
hydrobromide RARE
, O
0 O
. O
5 O
and O
1 O
. O
0 O
mg O
/ O
kg O
i O
. O
p O
., O
was O
administered O
1 O
h O
before O
each O
electrical O
stimulation O
until O
each O
rat O
showed O
the O
stage O
- O
3 O
seizure O
. O

PNT ALLCAPS
, O
ADD ALLCAPS
and O
BSS ALLCAPS
in O
the O
initial O
stage O
of O
kindling O
, O
kindling O
rate O
for O
the O
stage O
- O
3 O
and O
- O
5 O
seizures O
, O
seizure O
parameters O
at O
the O
first O
stage O
- O
3 O
and O
- O
5 O
were O
recorded O
and O
compared O
to O
the O
values O
of O
saline O
- O
treated O
, O
control O
group O
. O

CONCLUSIONS O
. O

There O
was O
a O
positive O
correlation O
between O
pyridinium RARE
cross O
- O
link O
excretion O
and O
thyroid O
hormone O
concentrations O
. O

Mutations O
truncating RARE
as O
many O
as O
143 O
C O
- O
terminal O
residues O
from O
the O
transcriptional O
activator O
encoded O
by O
the O
areA LASTCAP
gene I-GENE
, O
mediating O
nitrogen O
metabolite O
repression O
in O
Aspergillus O
nidulans RARE
, O
do O
not O
significantly O
reduce O
the O
ability O
of O
the O
areA LASTCAP
product I-GENE
to O
activate O
expression O
of O
most O
genes O
under O
areA LASTCAP
control O
. O

Naval RARE
personnel RARE
who O
exceed RARE
standards RARE
for O
% O
BF O
can O
be O
separated O
from O
active O
duty RARE
. O

Weak RARE
promoter O
activity O
was O
observed O
for O
the O
promoter O
of O
the O
C1 I-GENE
and O
C2 I-GENE
ORFs O
( O
C1 I-GENE
- O
C2 I-GENE
gene O
) O
and O
for O
the O
promoter O
of O
the O
V1 NUMERIC
ORF I-GENE
. O

The O
activity O
of O
the O
coat I-GENE
protein I-GENE
promoter I-GENE
of O
chloris RARE
striate RARE
mosaic O
virus O
is O
enhanced O
by O
its O
own O
and O
C1 I-GENE
- O
C2 I-GENE
gene O
products O
. O

The O
amino O
acid O
sequence O
alignment O
of O
TC ALLCAPS
II I-GENE
with O
that O
of O
other O
Cbl I-GENE
binding I-GENE
proteins I-GENE
( O
rat I-GENE
intrinsic I-GENE
factor I-GENE
, O
human I-GENE
transcobalamin RARE
I I-GENE
and O
porcine I-GENE
haptocorrin RARE
) O
revealed O
only O
33 O
% O
overall O
homology O
. O

This O
short O
communication RARE
compares RARE
a O
novel O
fluorimetric RARE
microplate RARE
enzyme O
immunoassay O
( O
FEIA ALLCAPS
) O
with O
a O
commercial O
time O
- O
resolved O
fluoroimmunoassay RARE
for O
the O
determination O
of O
thyrotropin I-GENE
in O
dried RARE
blood O
spots O
. O

The O
evaluation O
was O
performed O
using O
a O
retrospective O
study O
design O
with O
newborn O
blood O
samples O
from O
three O
screening O
centres RARE
. O

A O
region O
in O
the O
C O
- O
terminus O
of O
adenovirus I-GENE
2 I-GENE
/ I-GENE
5 I-GENE
E1a I-GENE
protein I-GENE
is O
required O
for O
association O
with O
a O
cellular O
phosphoprotein O
and O
important O
for O
the O
negative O
modulation O
of O
T24 NUMERIC
- O
ras I-GENE
mediated O
transformation O
, O
tumorigenesis O
and O
metastasis O
. O

These O
studies O
demonstrate O
that O
both O
G I-GENE
alpha I-GENE
i I-GENE
genes I-GENE
are O
dynamically RARE
regulated O
in O
LLC ALLCAPS
- O
PK1 NUMERIC
cells O
by O
both O
growth O
, O
differentiation O
, O
and O
hormone O
signals O
. O

Constructs RARE
containing O
the O
full I-GENE
- I-GENE
length I-GENE
PfCPK LASTCAP
cDNA I-GENE
have O
been O
expressed O
in O
Escherichia O
coli O
at O
a O
high O
level O
to O
generate O
a O
60 O
- O
kDa O
recombinant O
protein O
. O

When O
ligated O
to O
the O
proIL LASTCAP
- I-GENE
1 I-GENE
beta I-GENE
cap I-GENE
site I-GENE
- I-GENE
proximal I-GENE
region I-GENE
( O
located O
between O
- O
131 O
to O
+ O
12 O
), O
both O
the O
proIL LASTCAP
- I-GENE
1 I-GENE
beta I-GENE
and O
the O
simian I-GENE
virus I-GENE
40 I-GENE
enhancer I-GENE
elements I-GENE
functioned O
more O
efficiently O
in O
monocytes O
than O
in O
HeLa O
cells O
, O
which O
are O
not O
normally O
competent O
for O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
expression O
. O

Therefore O
, O
PC I-GENE
- I-GENE
PLC I-GENE
is O
a O
component O
of O
a O
signal O
transduction O
pathway O
leading O
to O
transcription O
of O
c I-GENE
- I-GENE
fos I-GENE
and O
junB I-GENE
that O
collaborates RARE
with O
c I-GENE
- I-GENE
myc I-GENE
and O
is O
independent O
of O
PKC I-GENE
- I-GENE
delta I-GENE
and O
Ras I-GENE
activation O
. O

In O
mitogen O
- O
stimulated O
splenocytes RARE
, O
Gfi RARE
- I-GENE
1 I-GENE
expression O
begins O
to O
rise O
at O
12 O
h O
after O
stimulation O
and O
reaches RARE
very O
high O
levels O
after O
50 O
h O
, O
suggesting O
that O
it O
may O
be O
functionally O
involved O
in O
events O
occurring O
after O
the O
interaction O
of O
IL I-GENE
- I-GENE
2 I-GENE
with O
its O
receptor O
, O
perhaps O
during O
the O
transition O
from O
the O
G1 O
to O
the O
S O
phase O
of O
the O
cell O
cycle O
. O

We O
have O
isolated O
and O
characterized O
the O
GCD6 NUMERIC
and O
GCD7 NUMERIC
genes I-GENE
and O
shown O
that O
their O
products O
are O
required O
to O
repress O
GCN4 I-GENE
translation O
under O
nonstarvation RARE
conditions O
. O

The O
plateau RARE
MO2 NUMERIC
value O
was O
that O
predicted O
by O
allometric RARE
relation O
. O

While O
the O
latter O
corresponded O
to O
a O
protein O
of O
824 NUMERIC
amino O
acids O
, O
an O
upstream O
open O
reading O
frame O
( O
uORF O
) O
within O
the O
5 O
' O
leader O
could O
potentially O
encode O
a O
54 O
amino O
acid O
peptide O
. O

The O
SCH9 NUMERIC
protein I-GENE
kinase I-GENE
mRNA I-GENE
contains O
a O
long O
5 O
' O
leader O
with O
a O
small O
open O
reading O
frame O
. O

In O
contrast O
to O
T O
cells O
, O
in O
fibroblasts O
PILOT ALLCAPS
gene I-GENE
expression O
requires O
only O
one O
signal O
( O
PMA O
) O
and O
is O
not O
affected O
by O
CyA LASTCAP
. O

Histochemical RARE
localization O
of O
GUS I-GENE
revealed O
promoter O
function O
in O
leaf O
epidermis RARE
, O
mesophyll RARE
and O
vascular O
bundles RARE
, O
in O
the O
cortex O
and O
vascular O
cylinder RARE
of O
the O
root O
. O

In O
order O
to O
investigate O
how O
these O
expression O
patterns O
are O
established O
, O
we O
fused O
promoter O
regions O
of O
an O
acidic O
and O
a O
basic O
glucanase RARE
gene I-GENE
to O
the O
beta I-GENE
- I-GENE
glucuronidase I-GENE
( O
GUS I-GENE
) O
reporter O
gene O
and O
examined O
expression O
of O
these O
constructs O
in O
transgenic O
tobacco O
plants O
. O

Southern O
blot O
analysis O
using O
probes O
from O
the O
3 O
' O
portions O
of O
the O
genomic O
and O
B I-GENE
. I-GENE
napus I-GENE
MA I-GENE
and O
MB I-GENE
cDNA I-GENE
clones O
showed O
that O
MA I-GENE
type I-GENE
myrosinases RARE
are O
encoded O
by O
approximately O
4 O
genes O
, O
while O
MB I-GENE
type I-GENE
myrosinases RARE
are O
encoded O
by O
more O
than O
10 O
genes O
in O
B O
. O
napus O
. O

Sudomoina RARE
, O
A O
. O

Zinc RARE
fingers O
( O
Zf RARE
) O
are O
a O
common O
structural O
motif O
found O
in O
many O
nucleic O
acid O
- O
binding O
proteins O
. O

The O
deduced O
bovine O
EFIA I-GENE
# RARE
1 I-GENE
amino O
acid O
( O
aa O
) O
sequence O
is O
98 O
% O
identical O
to O
rat O
EFIA I-GENE
and O
100 O
% O
identical O
to O
human O
EFIA I-GENE
/ O
DbpB LASTCAP
/ O
YB ALLCAPS
- I-GENE
1 I-GENE
family O
member O
DNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
B I-GENE
( O
DbpB LASTCAP
). O

Effect O
of O
tracheal O
insufflation RARE
of O
deferoxamine RARE
on O
acute O
ozone RARE
toxicity O
in O
rats O
. O

Localization O
of O
the O
insertion O
locus O
in O
the O
yeast O
genome O
and O
complementation O
studies O
with O
the O
temperature O
- O
sensitive O
mutant O
indicate O
that O
the O
two O
mutations O
are O
allelic O
. O

Replacement O
of O
the O
spacer O
sequence O
between O
the O
two O
ARMs RARE
with O
a O
shorter O
stretch O
of O
sequence O
also O
reduced O
RNA O
binding O
in O
vitro O
. O

Type O
II O
could O
be O
divided O
further O
into O
two O
forms O
( O
IIA O
and O
IIB ALLCAPS
) O
that O
may O
represent O
two O
underscribed RARE
species O
or O
developmental O
stages O
of O
the O
same O
species O
. O

Second O
, O
the O
transcription I-GENE
factor I-GENE
Gal I-GENE
- I-GENE
ER I-GENE
was O
rendered RARE
more O
potent O
and O
less O
susceptible O
to O
cell O
type O
- O
specific O
variation O
by O
fusing RARE
the O
strong O
activating O
domain O
of O
the O
herpesvirus I-GENE
protein I-GENE
VP16 I-GENE
onto O
its O
C O
terminus O
. O

The O
exogenous O
fos I-GENE
gene I-GENE
was O
rapidly O
induced O
to O
maximal O
levels O
within O
1 O
- O
2 O
hr O
of O
estrogen O
addition O
. O

Elimination O
of O
Haemophilus O
influenzae O
type O
b O
meningitis O
after O
introduction O
of O
vaccination O

Endosonography RARE
accurately O
assessed O
tumor O
extension O
in O
two O
T2 O
tumors O
, O
14 O
T3 O
tumors O
, O
and O
seven O
T4 O
tumors O
. O

In O
the O
present O
study O
we O
demonstrated O
a O
unique O
mechanism O
of O
action O
of O
8 O
- O
Cl O
- O
cAMP O
in O
the O
regulation O
of O
these O
kinase O
isozymes RARE
in O
HL O
- O
60 O
human O
promyelocytic RARE
leukemia O
cells O
. O

Analysis O
of O
cell O
cycle O
regulation O
in O
the O
budding O
yeast O
Saccharomyces O
cerevisiae O
has O
shown O
that O
a O
central O
regulatory O
protein O
kinase O
, O
Cdc28 I-GENE
, O
undergoes O
changes O
in O
activity O
through O
the O
cell O
cycle O
by O
associating RARE
with O
distinct O
groups O
of O
cyclins RARE
that O
accumulate O
at O
different O
times O
. O

Overlapping RARE
clones O
representing O
full O
- O
length O
cDNAs O
for O
MMI ALLCAPS
alpha I-GENE
were O
obtained O
from O
mouse O
brain O
. O

The O
method O
involves O
preliminary O
isolation O
of O
oxiracetam RARE
and O
internal O
standard O
from O
plasma O
by O
solid O
- O
phase O
extraction O
prior O
to O
the O
formation O
of O
their O
n O
- O
propyl RARE
carbamate RARE
derivatives O
. O

There O
are O
, O
however O
, O
several O
differences O
between O
the O
two O
new O
ars RARE
sequences O
. O

Pathways RARE
linking O
the O
olfactory O
bulbs RARE
with O
the O
medial O
preoptic RARE
anterior O
hypothalamus O
are O
important O
for O
intermale RARE
aggression O
in O
mice O
. O

Pokeweed RARE
mitogen I-GENE
( O
PWM ALLCAPS
) O
or O
anti I-GENE
- I-GENE
CD3 I-GENE
significantly O
increases O
c I-GENE
- I-GENE
jun I-GENE
messenger I-GENE
RNA I-GENE
( I-GENE
mRNA I-GENE
) I-GENE
levels O
in O
T O
cells O
. O

Following O
seizure O
induction O
, O
MABP ALLCAPS
increased O
to O
105 O
mm O
Hg O
and O
brain O
pHi RARE
fell O
to O
6 O
. O
79 O
+/- O
0 O
. O
03 O
within O
15 O
min O
and O
remained O
at O
this O
level O
for O
1 O
h O
( O
P O
< O
0 O
. O
001 O
). O

In O
contrast O
, O
rats O
receiving O
U74500A NUMERIC
( O
2 O
mg O
/ O
kg O
i O
. O
v O
. O
infusion O
commencing RARE
30 O
min O
prior O
to O
revascularisation RARE
) O
exhibited O
enhanced O
GMBF ALLCAPS
throughout O
reperfusion O
[ O
PI O
10 O
min O
: O
3 O
. O
26 O
( O
2 O
. O
56 O
- O
3 O
. O
63 O
); O
120 O
min O
: O
2 O
. O
03 O
( O
1 O
. O
73 O
- O
2 O
. O
25 O
); O
240 O
min O
: O
2 O
. O
13 O
( O
1 O
. O
75 O
- O
2 O
. O
44 O
), O
p O
< O
0 O
. O
01 O
vs O
. O
controls O
and O
normals O
] O
with O
complete O
muscle O
salvage RARE
[ O
GMV ALLCAPS
100 O
% O
in O
all O
reperfused RARE
muscles O
, O
p O
< O
0 O
. O
01 O
vs O
. O
controls O
, O
not O
significant O
( O
NS O
) O
vs O
. O
normals O
and O
6 O
h O
ischaemia O
].( RARE
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Sequencing O
of O
a O
1 O
. O
3 O
- O
kilobase O
fragment O
of O
the O
5 O
'- O
flanking O
region O
of O
the O
TSG6 NUMERIC
gene I-GENE
identified O
TATA O
- O
like O
and O
CAAT O
sequences O
near O
the O
transcription O
start O
site O
. O

The O
region O
that O
imparts RARE
inducibility O
by O
IL I-GENE
- I-GENE
1 I-GENE
or O
TNF I-GENE
( O
positions O
- O
165 O
to O
- O
58 O
) O
contains O
potential O
binding O
sites O
for O
IRF I-GENE
- I-GENE
1 I-GENE
and I-GENE
- I-GENE
2 I-GENE
, O
AP I-GENE
- I-GENE
1 I-GENE
, O
and O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
. O

Ig I-GENE
- I-GENE
alpha I-GENE
and O
Ig I-GENE
- I-GENE
beta I-GENE
contain O
extended O
cytoplasmic O
structure O
( O
61 O
and O
48 O
amino O
acids O
, O
respectively O
) O
and O
associate O
with O
cytoplasmic O
effectors O
indicating O
that O
they O
are O
directly O
involved O
in O
signal O
transduction O
. O

Sterile RARE
mutants O
of O
Saccharomyces O
cerevisiae O
were O
isolated O
from O
alpha O
* O
cells O
having O
the O
a I-GENE
/ I-GENE
alpha I-GENE
aar1 NUMERIC
- I-GENE
6 I-GENE
genotype RARE
( O
exhibiting O
alpha O
mating O
ability O
and O
weak O
a O
mating O
ability O
as O
a O
result O
of O
a O
defect O
in O
a1 NUMERIC
- I-GENE
alpha I-GENE
2 I-GENE
repression O
). O

We O
studied O
the O
functional O
interaction O
between O
human O
embryonic O
zeta I-GENE
2 I-GENE
globin I-GENE
promoter O
and O
the O
alpha I-GENE
globin I-GENE
regulatory I-GENE
element I-GENE
( O
HS I-GENE
- I-GENE
40 I-GENE
) O
located O
40 O
kb O
upstream O
of O
the O
zeta I-GENE
2 I-GENE
globin I-GENE
gene I-GENE
. O

It O
was O
shown O
by O
transient O
expression O
assay O
that O
HS I-GENE
- I-GENE
40 I-GENE
behaved RARE
as O
an O
authentic RARE
enhancer O
for O
high O
- O
level O
zeta I-GENE
2 I-GENE
globin I-GENE
promoter I-GENE
activity O
in O
K562 O
cells O
, O
an O
erythroid O
cell O
line O
of O
embryonic O
and O
/ O
or O
fetal O
origin O
. O

Initial O
results O
indicate O
that O
this O
23S NUMERIC
pre I-GENE
- I-GENE
rRNA I-GENE
is O
the O
same O
as O
the O
species O
detected O
on O
depletion O
of O
the O
small I-GENE
nucleolar I-GENE
RNA I-GENE
- I-GENE
associated I-GENE
proteins I-GENE
NOP1 NUMERIC
and O
GAR1 NUMERIC
and O
in O
an O
snr10 NUMERIC
mutant I-GENE
strain O
. O

Breitbart RARE
, O
L O
. O

This O
study O
evaluates RARE
the O
feasibility O
of O
indirect O
mesenteric RARE
lymphangiography RARE
as O
a O
colonoscopic RARE
technique O
in O
a O
canine O
model O
. O

OBJECTIVE O
: O
Our O
purpose O
was O
to O
determine O
the O
simultaneous O
concentrations O
of O
serum O
cotinine RARE
in O
both O
fetal O
and O
maternal O
blood O
. O

Internal RARE
amino O
acid O
sequence O
has O
now O
been O
obtained O
from O
this O
protein O
which O
shares O
50 O
- O
100 O
% O
sequence O
identity O
with O
sequences O
encoded O
by O
mammalian I-GENE
G I-GENE
alpha I-GENE
11 I-GENE
and O
G I-GENE
alpha I-GENE
q I-GENE
cDNAs I-GENE
. O

Estradiol RARE
is O
known O
to O
induce O
expression O
of O
certain O
proto O
- O
oncogenes O
, O
and O
this O
led O
us O
to O
examine O
potential O
regulatory O
regions O
of O
the O
cellular I-GENE
c I-GENE
- I-GENE
fos I-GENE
oncogene I-GENE
. O

Air RARE
lead O
was O
not O
a O
significant O
explanatory RARE
variable O
. O

We O
now O
show O
that O
regulation O
of O
flaN LASTCAP
transcription O
in O
vivo O
depends O
on O
a O
sigma I-GENE
54 I-GENE
promoter I-GENE
and O
two O
ftr RARE
elements O
located O
downstream O
of O
the O
transcription O
start O
site O
at O
+ O
86 O
( O
ftr2 NUMERIC
) O
and O
+ O
120 O
( O
ftr3 NUMERIC
). O

5 O
micrograms O
/ O
l O
was O
detected O
in O
urine O
from O
some O
non O
- O
occupationally RARE
exposed O
persons O
. O

Fibular RARE
dimelia RARE
with O
deficiency O
of O
the O
tibia RARE
. O

This O
prospective O
study O
compared O
the O
measured O
energy O
expenditures RARE
of O
30 O
patients O
using O
indirect O
calorimetry RARE
with O
their O
predicted O
basal O
energy O
expenditure O
according O
to O
the O
Harris RARE
- O
Benedict RARE
equation O
, O
or O
their O
calculated O
energy O
expenditure O
derived O
from O
basal O
energy O
expenditure O
times O
, O
an O
activity O
factor O
, O
and O
a O
stress O
factor O
. O

However O
, O
after O
repeated O
infections O
, O
hypobiotic RARE
larvae O
were O
numerous O
. O

This O
was O
performed O
in O
a O
double O
blinded RARE
, O
randomized O
, O
placebo O
- O
controlled O
study O
. O

Group O
I O
consisted O
of O
six O
noncholestatic RARE
patients O
; O
group O
II O
consisted O
of O
nine O
mildly RARE
cholestatic RARE
patients O
with O
mild O
hepatic O
impairment O
( O
conjugated O
bilirubin O
, O
47 O
mumol O
liter O
- O
1 O
; O
alkaline I-GENE
phosphatase I-GENE
, O
280 NUMERIC
IU O
liter O
- O
1 O
; O
gamma I-GENE
- I-GENE
glutamyltranspeptidase RARE
, O
190 O
IU O
liter O
- O
1 O
); O
group O
III O
consisted O
of O
six O
benign O
intrahepatic O
cholestatic RARE
patients O
with O
high O
isolated O
conjugated O
hyperbilirubinemia O
( O
98 O
. O
1 O
mumol O
liter O
- O
1 O
). O

There O
was O
either O
no O
change O
or O
an O
improvement O
in O
renographic RARE
findings O
( O
t1 O
/ O
2 O
time O
and O
/ O
or O
split RARE
function O
) O
in O
40 O
patients O
( O
93 O
%). O

We O
discuss O
the O
need O
to O
use O
animals O
older O
than O
3 O
months O
for O
the O
study O
of O
' O
adult O
' O
regeneration O
phenomena O
since O
3 O
- O
month O
- O
old O
rats O
may O
be O
somewhat RARE
immature O
. O

Nuclear I-GENE
beta I-GENE
II I-GENE
PKC I-GENE
, O
like O
p34cdc2 I-GENE
kinase I-GENE
, O
may O
function O
to O
regulate O
nuclear O
lamina RARE
structural O
stability O
during O
cell O
cycle O
. O

In O
situ O
copper O
- O
phenanthroline RARE
footprinting O
of O
individual O
gel O
shift O
assembly O
intermediates RARE
shows O
that O
on O
the O
302 NUMERIC
- O
nucleotide O
G4oric NUMERIC
, O
the O
first O
two O
SSB I-GENE
tetramers RARE
assemble RARE
at O
random O
, O
but O
the O
addition O
of O
more O
SSB I-GENE
tetramers RARE
results O
in O
formation O
of O
a O
unique O
structure O
. O

Effects O
of O
intramammary RARE
endotoxin O
infusion O
on O
milking RARE
- O
induced O
oxytocin RARE
release O
. O

Finger RARE
associated I-GENE
box I-GENE
- I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
( O
FAX ALLCAPS
- I-GENE
ZFPs RARE
) O
constitute O
a O
subfamily O
of O
the O
many O
C2H2 NUMERIC
type I-GENE
ZFPs RARE
in O
Xenopus O
laevis O
. O

Further O
evidence O
for O
a O
clustered O
organization O
of O
FAX ALLCAPS
- O
ZFP ALLCAPS
transcription O
units O
is O
provided O
by O
Southern O
blot O
analysis O
of O
large O
genomic O
restriction O
fragments O
separated O
by O
transverse O
field O
gel O
electrophoresis O
, O
and O
by O
in O
situ O
hybridization O
on O
intact O
chromosomes O
. O

A O
rat O
cDNA O
that O
encodes O
eIF I-GENE
- I-GENE
5 I-GENE
has O
been O
isolated O
and O
expressed O
in O
Escherichia O
coli O
to O
yield O
a O
catalytically O
active O
eIF I-GENE
- I-GENE
5 I-GENE
protein I-GENE
. O

Mutational O
analyses O
have O
demonstrated O
the O
importance O
of O
sequences O
within O
the O
327 NUMERIC
bp O
segment O
that O
contain O
a O
putative O
cyclic I-GENE
AMP I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
binding O
site O
for O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
and O
PMA O
responsiveness O
and O
putative O
PU I-GENE
- I-GENE
1 I-GENE
and O
Sp1 I-GENE
binding I-GENE
sites I-GENE
for O
basal O
promoter O
activity O
. O

( O
1992 O
) O
J O
. O

In O
F42A NUMERIC
- O
stimulated O
internalization O
assays O
on O
forskolin O
- O
induced O
YT ALLCAPS
- O
1 O
cells O
, O
the O
IL I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
chain I-GENE
is O
consistently O
endocytosed RARE
together O
with O
the O
IL I-GENE
- I-GENE
2R I-GENE
beta I-GENE
subunit I-GENE
indicating O
that O
IL I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
is O
stably O
associated O
with O
the O
F42A NUMERIC
- I-GENE
IL I-GENE
- I-GENE
2R I-GENE
beta I-GENE
complex I-GENE
even O
though O
the O
alpha O
- O
subunit O
contributes O
little O
if O
any O
affinity O
to O
the O
F42A NUMERIC
binding O
reaction O
. O

The O
microcirculatory RARE
dynamics O
of O
prostaglandin O
E1 O
and O
/ O
or O
nicardipine RARE
and O
their O
different O
reactions O
in O
the O
hyper RARE
- O
and O
hypodynamic RARE
state O
of O
septic RARE
shock O
in O
a O
rat O
model O

We O
obtained O
the O
prevalence O
of O
IgG I-GENE
antibodies I-GENE
against O
Trypanosoma O
cruzi RARE
among O
1076 NUMERIC
blood O
donors O
at O
the O
Instituto RARE
Nacional RARE
de O
Cardiologia RARE
" O
Ignacio RARE
Chavez RARE
" O
in O
Mexico RARE
City O
. O

Examination O
of O
the O
immediate O
sequence O
5 O
' O
to O
the O
mRNA O
start O
site O
reveals O
no O
TATA O
box O
and O
multiple O
known O
enhancer O
sequences O
. O

The O
short O
- O
term O
synthesis O
and O
infant O
- O
regulated O
removal O
of O
milk O
in O
lactating RARE
women O
. O

Pseudosubstrate RARE
( O
19 O
- O
36 O
), O
derived O
from O
the O
C O
- O
terminus O
of O
Ca I-GENE
- I-GENE
dependent I-GENE
PKC I-GENE
isotypes RARE
, O
inhibited O
beta I-GENE
- I-GENE
PKC I-GENE
but O
not O
nPKC LASTCAP
activity O
using O
either O
Histone RARE
IIIS ALLCAPS
or O
peptide O
( O
19 O
- O
31 O
) O
as O
substrate O
. O

Based O
on O
these O
results O
, O
a O
new O
model O
for O
the O
regulation O
of O
nif RARE
/ O
fix RARE
gene O
expression O
in O
A O
. O
caulinodans RARE
is O
proposed O
. O

Nitric RARE
oxide O
inhalation O
selectively O
reduces O
pulmonary O
hypertension O
in O
porcine O
endotoxin O
shock O
and O
improves RARE
arterial O
oxygenation O
and O
pH O
with O
a O
marked O
attenuation O
of O
sympathetic O
activation O
. O

B O
cell O
- O
specific O
mb RARE
- I-GENE
1 I-GENE
and O
B29 NUMERIC
genes I-GENE
encode O
the O
alpha O
/ O
beta O
components O
of O
the O
BCR I-GENE
- I-GENE
associated I-GENE
complex I-GENE
in O
mature O
sIgM LASTCAP
+ I-GENE
B O
cells O
. O

Bipolarity RARE
in O
Jungian RARE
type O
theory O
and O
the O
Myers RARE
- O
Briggs RARE
Type O
Indicator RARE
. O

A O
variety O
of O
nuclear O
ribonucleoproteins RARE
are O
believed O
to O
associate O
directly O
with O
nascent RARE
RNA I-GENE
polymerase I-GENE
II I-GENE
transcripts I-GENE
and O
remain RARE
associated O
during O
subsequent O
nuclear O
RNA O
processing O
reactions O
, O
including O
pre O
- O
mRNA O
polyadenylation O
and O
splicing O
as O
well O
as O
nucleocytoplasmic RARE
mRNA O
transport O
. O

Mutations O
at O
three O
sites O
have O
larger O
effects O
in O
muscle O
than O
nonmuscle RARE
cells O
; O
an O
A O
/ O
T O
- O
rich O
site O
mutation O
has O
a O
pronounced O
effect O
in O
both O
striated RARE
muscle O
types O
, O
mutations O
at O
the O
MEF1 NUMERIC
( I-GENE
Right RARE
E I-GENE
- I-GENE
box I-GENE
) I-GENE
site I-GENE
are O
relatively O
specific O
to O
expression O
in O
skeletal O
muscle O
, O
and O
mutations O
at O
the O
CArG O
site O
are O
relatively O
specific O
to O
expression O
in O
cardiac O
muscle O
. O

Transient O
transfection O
analysis O
with O
these O
mutations O
revealed O
that O
only O
a O
10 O
- O
bp O
region O
, O
containing O
precisely O
the O
Ets I-GENE
and O
proximal O
LyF LASTCAP
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
, O
was O
needed O
for O
D O
' O
activity O
. O

However O
, O
despite O
its O
relationship O
to O
the O
TR I-GENE
, O
Rev I-GENE
- O
Erb RARE
bound O
poorly O
to O
TR I-GENE
binding I-GENE
sites I-GENE
. O

We O
report O
here O
that O
a O
25 O
- O
bp O
promoter O
element O
previously O
shown O
to O
be O
important O
for O
the O
G1 O
- O
S O
activation O
of O
the O
human I-GENE
thymidine I-GENE
kinase I-GENE
( O
htk RARE
) O
promoter O
in O
growth O
- O
stimulated O
cells O
is O
a O
cellular O
target O
of O
cyclin I-GENE
A I-GENE
and O
the O
p33cdk2 NUMERIC
complexes I-GENE
. O

These O
protective O
influences O
were O
observed O
throughout O
the O
range O
of O
filling O
pressures O
measured O
, O
from O
0 O
to O
30 O
mmHg O
. O

DNase I-GENE
I I-GENE
footprinting O
with O
rat O
liver O
nuclear O
extracts O
identified O
7 O
major O
protein O
- O
binding O
domains O
termed O
P1 O
through O
P7 O
in O
a O
796 NUMERIC
base O
pair O
DNA O
fragment O
( O
base O
pairs O
- O
763 NUMERIC
to O
+ O
33 O
). O

This O
may O
account O
, O
at O
least O
in O
part O
, O
for O
the O
ability O
of O
excess O
wt I-GENE
p53 I-GENE
to O
inhibit O
cell O
proliferation O
and O
to O
interfere RARE
with O
neoplastic O
processes O
. O

Neither O
clone O
encoded O
the O
cognate O
endonuclease O
. O

Northern O
blot O
analysis O
of O
total O
cellular O
RNA O
indicated O
that O
xylP LASTCAP
encodes O
a O
1 O
. O
3 O
- O
kb O
transcript O
which O
is O
induced O
by O
xylan RARE
. O

The O
nifJ LASTCAP
and O
nifH LASTCAP
promoters I-GENE
of I-GENE
Klebsiella I-GENE
pneumoniae I-GENE
are O
divergently O
transcribed O
sigma I-GENE
54 I-GENE
- I-GENE
dependent I-GENE
promoters I-GENE
that O
are O
positively O
activated O
by O
the O
NifA LASTCAP
protein I-GENE
. O

These O
data O
show O
that O
PTH I-GENE
and O
cAMP O
can O
repress O
collagen I-GENE
promoter I-GENE
activity O
in O
calvariae RARE
from O
transgenic O
mice O
, O
suggesting O
that O
the O
alpha I-GENE
1 I-GENE
( I-GENE
I I-GENE
) I-GENE
collagen I-GENE
promoter I-GENE
may O
contain O
cis O
elements O
down O
- O
stream RARE
of O
- O
2 O
. O
3 O
kilobases O
that O
mediate O
PTH I-GENE
and O
cAMP O
repression O
of O
collagen I-GENE
gene I-GENE
expression O
in O
bone O
. O

Both O
inhaled O
and O
superfused RARE
isoflurane O
dilated RARE
the O
baseline O
vein O
diameter O
before O
stimulation O
. O

Prevalence RARE
of O
rheumatoid O
arthritis O
and O
rheumatoid I-GENE
factor I-GENE
in O
women O
: O
evidence O
for O
a O
secular RARE
decline O
. O

Although O
olfactory O
associative RARE
conditioning O
in O
newborn O
rats O
produces O
marked O
structural O
and O
functional O
changes O
in O
the O
olfactory O
bulb O
, O
recent O
evidence O
suggests O
that O
extrabulbar RARE
circuits RARE
must O
be O
involved O
in O
storing RARE
these O
early O
memories RARE
. O

The O
fission I-GENE
yeast I-GENE
dsk1 NUMERIC
+ I-GENE
gene I-GENE
, O
a O
multicopy O
suppressor O
for O
cold O
- O
sensitive O
dis1 NUMERIC
mutants I-GENE
, O
encodes O
a O
novel O
61 O
- O
kd RARE
protein O
kinase O
. O

Closure RARE
of O
the O
patent RARE
ductus RARE
arteriosus RARE
with O
a O
Ligaclip RARE
through O
a O
minithoracotomy RARE
. O

Sequence O
comparison O
between O
the O
translated O
ORF O
and O
a O
protein O
database O
reveal O
between O
26 O
. O
5 O
and O
23 O
. O
4 O
% O
aa O
sequence O
homology O
to O
bacterial I-GENE
transmembrane I-GENE
( I-GENE
TM I-GENE
) I-GENE
proteins I-GENE
including O
those O
mediating O
chloramphenicol O
( O
Cm RARE
) O
and O
tetracycline RARE
( O
Tc O
) O
resistance O
and O
an O
arabinose RARE
- O
proton O
symport RARE
protein O
. O

The O
yeast O
gene O
that O
encodes O
eIF I-GENE
- I-GENE
5 I-GENE
, O
designated O
TIF5 NUMERIC
, O
has O
been O
isolated O
and O
expressed O
in O
Escherichia O
coli O
to O
yield O
a O
catalytically O
active O
eIF I-GENE
- I-GENE
5 I-GENE
protein I-GENE
. O

The O
strategies O
by O
which O
hepatitis O
B O
and O
hepatitis O
D O
can O
be O
diminished O
and O
eventually RARE
eliminated RARE
are O
: O
immunization O
, O
measures O
to O
prevent O
exposure O
to O
infective RARE
blood O
or O
blood O
derivatives O
and O
education O
( O
in O
particular O
awareness RARE
that O
hepatitis O
B O
is O
a O
sexually RARE
transmitted O
disease O
). O

Xylose RARE
- O
and O
arabinose RARE
- O
containing O
polymers O
were O
better O
digested RARE
than O
was O
cellulose RARE
for O
both O
breads RARE
. O

The O
technical RARE
construction O
of O
the O
mouth O
protectors RARE
is O
illustrated RARE
, O
as O
is O
the O
need O
for O
instrumentation RARE
and O
its O
costs O
and O
the O
materials O
required O
to O
manufacture RARE
these O
mouth O
protectors RARE
. O

The O
alpha O
- O
subunit O
by O
itself O
binds O
to O
telomeric O
DNA O
. O

We O
conclude O
that O
the O
alpha O
- O
subunit O
of O
the O
telomere I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
like O
many O
transcription O
factors O
, O
has O
separable RARE
DNA O
- O
binding O
and O
protein O
- O
protein O
interaction O
domains O
. O

Three O
patients O
had O
well O
-, O
6 O
patients O
had O
moderately O
-, O
and O
5 O
patients O
had O
poorly O
- O
differentiated O
adenocarcinoma O
of O
the O
prostate O
. O

Spontaneous RARE
burst O
firing RARE
in O
cat O
primary O
auditory O
cortex O
: O
age O
and O
depth O
dependence O
and O
its O
effect O
on O
neural O
interaction O
measures O
. O

By O
applying O
the O
potentiometric RARE
method O
, O
in O
aqueous O
medium O
of O
ionic O
strength O
mu O
= O
0 O
. O
2 O
, O
the O
stability O
constants O
, O
log O
beta O
1 O
= O
4 O
. O
42 O
and O
log O
beta O
2 O
= O
8 O
. O
57 O
were O
obtained O
. O

Cryopreservation RARE
straws RARE
filled O
with O
media O
plus O
additive O
are O
emersed RARE
below O
the O
surface O
of O
an O
unprocessed RARE
donor O
ejaculate RARE
. O

The O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
can O
potentially O
encode O
26 O
- O
and O
22 O
- O
kDa O
proteins O
that O
differ O
only O
in O
their O
carboxyl O
tails O
because O
of O
an O
alternative O
splicing O
mechanism O
. O

The O
active O
open O
reading O
frame O
in O
the O
clone O
maps O
at O
27 O
min O
on O
the O
E O
. O
coli O
chromosome O
and O
is O
identical O
in O
sequence O
to O
a O
wild O
type O
counterpart O
. O

Subsequent RARE
cloning O
and O
nucleotide O
sequence O
analysis O
of O
the O
S I-GENE
. I-GENE
pombe I-GENE
adenylate I-GENE
kinase I-GENE
gene I-GENE
, O
adk1 NUMERIC
, O
revealed O
a O
coding O
region O
of O
660 NUMERIC
nucleotides O
. O

Calcification RARE
of O
a O
cariogenic RARE
Streptococcus O
and O
of O
Corynebacterium RARE
( O
Bacterionema RARE
) O
matruchotii RARE
. O

As O
a O
result O
of O
alternative O
splicing O
, O
the O
BGP ALLCAPS
gene I-GENE
is O
transcribed O
into O
at O
least O
seven O
distinct O
mRNA O
species O
. O

A O
comparison O
of O
the O
promoters O
for O
muMIP LASTCAP
- I-GENE
1 I-GENE
beta I-GENE
and O
muMIP LASTCAP
- I-GENE
1 I-GENE
alpha I-GENE
reveals O
a O
conserved O
CK O
- O
1 O
element O
, O
but O
transient O
expression O
studies O
in O
RAW ALLCAPS
264 O
. O
7 O
macrophages O
with O
proximal O
fragments O
of O
either O
the O
muMIP LASTCAP
- I-GENE
1 I-GENE
beta I-GENE
or O
the O
muMIP LASTCAP
- I-GENE
1 I-GENE
alpha I-GENE
5 I-GENE
' I-GENE
promoter I-GENE
fused O
to O
a O
human I-GENE
growth I-GENE
hormone I-GENE
reporter I-GENE
gene I-GENE
link O
LPS O
- O
inducibility O
in O
both O
to O
promoter O
segments O
near O
to O
, O
but O
not O
identical O
with O
, O
the O
consensus O
CK O
- O
1 O
sequence O
. O

However O
, O
essential O
contrast O
differences O
existing O
between O
the O
FSE ALLCAPS
sequences O
and O
their O
routine O
asymmetric O
dual O
SE O
counterpart O
can O
be O
identified O
. O

Sequence O
analysis O
and O
identification O
of O
two O
hyp RARE
regulatory I-GENE
mutants I-GENE
. O

The O
gene O
encoding O
the O
receptor O
for O
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
1 I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
), O
the O
c I-GENE
- I-GENE
fms I-GENE
protooncogene I-GENE
, O
is O
selectively O
expressed O
in O
immature O
and O
mature O
mononuclear O
phagocytes RARE
and O
trophoblasts RARE
. O

The O
level O
of O
the O
SUP4A53T61 NUMERIC
transcript I-GENE
was O
threefold O
higher O
in O
the O
tap1 NUMERIC
- I-GENE
1 I-GENE
mutant I-GENE
than O
in O
the O
wild O
type O
. O

This O
sequence O
similarity O
raises RARE
the O
possibility O
that O
GCN1 NUMERIC
interacts O
with O
ribosomes RARE
or O
tRNA O
molecules O
and O
functions O
in O
conjunction O
with O
GCN2 I-GENE
in O
monitoring O
uncharged RARE
tRNA O
levels O
during O
the O
process O
of O
translation O
elongation O
. O

NF I-GENE
- I-GENE
HB I-GENE
( O
BSAP ALLCAPS
) O
is O
a O
repressor O
of O
the O
murine I-GENE
immunoglobulin I-GENE
heavy I-GENE
- I-GENE
chain I-GENE
3 I-GENE
' I-GENE
alpha I-GENE
enhancer I-GENE
at O
early O
stages O
of O
B O
- O
cell O
differentiation O
. O

Since O
the O
regulation O
of O
SWI4 I-GENE
is O
required O
for O
normal O
cell O
cycle O
progression O
, O
we O
have O
characterized O
cis O
- O
and O
trans O
- O
acting O
regulators O
of O
SWI4 I-GENE
transcription O
. O

It O
also O
suggests O
that O
there O
is O
another O
pathway O
which O
can O
activate O
SWI4 I-GENE
transcription O
in O
the O
absence O
of O
SWI6 NUMERIC
. O

Multiple O
SWI6 NUMERIC
- O
dependent O
cis O
- O
acting O
elements O
control O
SWI4 I-GENE
transcription O
through O
the O
cell O
cycle O
. O

In O
conclusion O
, O
changes O
in O
carotid O
sinus O
stimulation O
alters O
blood O
flow O
to O
the O
hindlimb RARE
through O
changes O
in O
both O
Pcrit RARE
and O
Ra RARE
. O

Multizone RARE
PRK O
has O
been O
suggested O
to O
increase O
the O
predictability RARE
of O
higher O
myopic RARE
corrections RARE
. O

In O
17 O
patients O
with O
deletions O
, O
the O
parental O
origin O
of O
deletion O
was O
determined O
. O

The O
COL7A1 NUMERIC
gene I-GENE
, O
which O
encodes O
type I-GENE
VII I-GENE
collagen I-GENE
, O
has O
been O
implicated O
as O
a O
candidate O
gene O
for O
dominantly RARE
and O
recessively RARE
inherited O
forms O
of O
dystrophic RARE
epidermolysis RARE
bullosa RARE
. O

However O
, O
study O
of O
the O
productive RARE
gamma O
gene O
showed O
that O
the O
skipped RARE
variable O
exon O
was O
bounded RARE
by O
normal O
splicing O
signals O
and O
that O
the O
adjacent O
intron O
organization O
was O
not O
altered O
. O

We O
conclude O
that O
grade O
III O
BGCT ALLCAPS
can O
be O
treated O
by O
modified O
intralesional RARE
excision O
provided O
the O
articular RARE
surfaces RARE
and O
part O
of O
the O
metaphysis RARE
are O
intact O
. O

Second O
, O
nitrate O
induction O
of O
aeg RARE
- I-GENE
46 I-GENE
. I-GENE
5 I-GENE
operon I-GENE
expression O
is O
substantially O
enhanced O
in O
narL LASTCAP
null O
strains O
( O
M O
. O
H O
. O

This O
new O
knowledge O
has O
contributed O
to O
the O
development O
of O
a O
successful O
immunoprophylactic RARE
strategy O
for O
eliminating RARE
Hib RARE
disease O
. O

The O
HMG I-GENE
CoA I-GENE
reductase I-GENE
inhibitors O
are O
the O
most O
effective O
cholesterol O
- O
lowering O
agents O
currently O
available O
. O

The O
etiology O
, O
pathology O
, O
brain O
CT O
scan O
features O
, O
clinical O
manifestations O
and O
treatment O
of O
these O
accidents RARE
were O
discussed O
. O

Drosophila O
230 NUMERIC
- O
kD O
TFIID I-GENE
subunit O
, O
a O
functional O
homolog O
of O
the O
human O
cell O
cycle O
gene O
product O
, O
negatively O
regulates O
DNA O
binding O
of O
the O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
subunit I-GENE
of I-GENE
TFIID I-GENE
. O

One O
enigmatic RARE
aspect RARE
of O
GATA I-GENE
factor I-GENE
expression O
is O
that O
several O
GATA I-GENE
proteins I-GENE
, O
which O
ostensibly RARE
share O
the O
same O
DNA O
- O
binding O
site O
specificity O
, O
are O
coexpressed O
in O
erythroid O
cells O
. O

Pit I-GENE
- I-GENE
1 I-GENE
is O
a O
tissue O
- O
specific O
POU I-GENE
domain I-GENE
factor I-GENE
obligatory RARE
for O
the O
appearance O
of O
three O
cell O
phenotypes O
in O
the O
anterior O
pituitary O
gland O
. O

Maximum RARE
number O
of O
strains O
( O
39 O
. O
1 O
%) O
were O
resistant O
in O
S O
. O
bareilly RARE
serotype O
, O
followed O
by O
S O
. O
typhimurium RARE
( O
21 O
. O
7 O
%) O
and O
least O
in O
S O
. O
typhi RARE
( O
17 O
. O
4 O
%). O

Biol O
. O

Characterization O
and O
hormonal O
regulation O
of O
the O
promoter O
of O
the O
rat I-GENE
prostaglandin I-GENE
endoperoxide RARE
synthase I-GENE
2 I-GENE
gene I-GENE
in O
granulosa RARE
cells O
. O

The O
retention O
of O
75SeHCAT NUMERIC
was O
low O
. O

Patient RARE
characteristics O
associated O
with O
deep O
wounds RARE
as O
well O
as O
patient O
and O
wound O
characteristics O
predictive O
of O
the O
extent O
of O
healing O
and O
time O
required O
for O
healing O
were O
identified O
. O

Members O
of O
the O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
of O
basic I-GENE
- I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
bZip RARE
) I-GENE
transcription I-GENE
factors I-GENE
form O
heterodimers O
and O
bind O
to O
the O
CAAT O
box O
and O
other O
sequence O
- O
related O
enhancer O
motifs O
. O

In O
mammalian O
cells O
, O
phosphorylation O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
inhibits O
the O
activity O
of O
eIF I-GENE
- I-GENE
2B I-GENE
, O
the O
GDP I-GENE
- I-GENE
GTP I-GENE
exchange I-GENE
factor I-GENE
for O
eIF I-GENE
- I-GENE
2 I-GENE
. O

In O
conclusion O
, O
these O
observations O
demonstrated O
that O
stratification RARE
of O
acute O
MI O
patients O
by O
plasma O
ANF ALLCAPS
level O
is O
a O
useful O
non O
- O
invasive O
method O
for O
predicting O
prognosis O
and O
for O
identifying O
individuals O
at O
high O
risk O
of O
cardiac O
death O
. O

Analysis O
of O
the O
binding O
of O
Lrp RARE
to O
a O
set O
of O
circularly RARE
permuted RARE
DNA O
fragments O
from O
this O
region O
indicates O
that O
Lrp RARE
induces O
DNA O
bending RARE
. O

Yeast O
mutants O
lacking O
a O
functional O
NOP1 NUMERIC
gene I-GENE
can O
be O
complemented O
by O
human I-GENE
fibrillarin RARE
but O
are O
temperature O
sensitive O
for O
growth O
and O
impaired O
in O
pre O
- O
rRNA O
processing O
. O

The O
patients O
were O
divided O
into O
ischaemia O
and O
non O
- O
ischaemia O
groups O
on O
the O
basis O
of O
the O
change O
in O
lactate O
extraction O
ratio O
during O
balloon RARE
inflation RARE
. O

Seven RARE
out O
of O
34 O
patients O
died O
, O
giving O
a O
mortality O
rate O
of O
21 O
%. O

A O
36 O
- O
kDa O
protein O
that O
was O
localized O
to O
the O
membrane O
fraction O
was O
detected O
in O
minicells RARE
containing O
plasmids O
with O
the O
ftsN LASTCAP
gene I-GENE
, O
confirming O
that O
FtsN LASTCAP
was O
a O
membrane O
protein O
. O

SSG1 NUMERIC
, O
a O
gene O
encoding O
a O
sporulation I-GENE
- I-GENE
specific I-GENE
1 I-GENE
, I-GENE
3 I-GENE
- I-GENE
beta I-GENE
- I-GENE
glucanase RARE
in O
Saccharomyces O
cerevisiae O
. O

Expression O
of O
this O
protein O
in O
E O
. O
coli O
demonstrated O
that O
tyrosine O
was O
incorporated O
during O
suppression O
and O
that O
yeast I-GENE
cytoplasmic I-GENE
TyrRS LASTCAP
activity O
was O
produced O
. O

The O
first O
involved O
complementation O
of O
a O
nonphotosynthetic RARE
mutant O
of O
Chlamydomonas RARE
, O
CC O
- O
2341 NUMERIC
( O
ac RARE
- O
u RARE
- O
g O
- O
2 O
. O
3 O
), O
which O
has O
a O
frameshift O
mutation O
in O
the O
psaB LASTCAP
gene I-GENE
, O
and O
selection O
of O
photosynthetic RARE
transformants O
on O
minimal O
medium O
. O

Against RARE
200 O
strains O
of O
methicillin RARE
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA ALLCAPS
) O
isolated O
from O
1990 O
to O
1991 O
, O
minimum O
inhibitory O
concentrations O
( O
MICs O
) O
of O
a O
total O
of O
15 O
antibacterial RARE
agents O
including O
arbekacin RARE
( O
ABK ALLCAPS
) O
were O
determined O
. O

It O
is O
reported O
that O
, O
at O
present O
, O
most O
of O
the O
MRSAs RARE
spreading RARE
in O
Japan O
are O
acceleratedly RARE
acquiring RARE
resistance O
to O
many O
drugs O
, O
and O
especially O
, O
they O
are O
developing O
high O
resistance O
against O
beta O
- O
lactams RARE
. O

Beg2 NUMERIC
and O
Beg1 NUMERIC
are O
regulated O
differently O
which O
may O
indicate O
variation O
in O
storage O
or O
utilization O
properties O
among O
the O
barley I-GENE
globulins RARE
. O

Here O
, O
we O
have O
more O
closely O
investigated O
transactivation O
of O
the O
human I-GENE
HSP70 I-GENE
promoter I-GENE
by O
Myb I-GENE
proteins I-GENE
. O

We O
have O
found O
out O
that O
one O
- O
year O
- O
old O
carps RARE
are O
extremely O
sensitive O
to O
ichthiomycin RARE
in O
concentrations O
between O
25 O
- O
125 O
micrograms O
/ O
dm3 NUMERIC
. O

RESULTS O
: O
Statistically RARE
significant O
differences O
were O
obtained O
between O
group O
I O
and O
II O
concerning O
the O
number O
of O
patients O
in O
whom O
induced O
atrial O
fibrillation O
with O
conduction O
by O
the O
accessory O
pathway O
and O
RR O
< O
or O
= O
250 O
msec O
was O
found O
( O
0 O
vs O
6 O
, O
p O
= O
0 O
. O
0045 NUMERIC
). O

We O
studied O
the O
effect O
of O
skinfold RARE
thickness O
on O
the O
correlation O
between O
serum O
total O
bilirubin O
level O
and O
transcutaneous RARE
bilirubin O
( O
TcB LASTCAP
) O
readings RARE
. O

Both O
immunophilins RARE
may O
have O
important O
roles O
in O
receptor O
assembly O
and O
may O
represent O
a O
new O
category O
of O
ligand O
- O
and O
calcium O
- O
dependent O
modulators RARE
of O
protein O
function O
. O

The O
GTPase I-GENE
activity O
of O
CDC42Ce NUMERIC
is O
moderately O
stimulated O
by O
human I-GENE
n I-GENE
- I-GENE
chimaerin RARE
, O
a O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
for O
the O
related O
p21 I-GENE
rac1 NUMERIC
. O

Tl O
- O
201 O
uptake O
ratio O
of O
the O
right O
ventricle O
, O
which O
represents O
the O
ratio O
of O
total O
counts O
of O
the O
right O
ventricle O
to O
counts O
of O
the O
administered O
dose O
of O
Tl O
- O
201 O
, O
was O
higher O
in O
COPD O
, O
especially O
in O
pulmonary O
emphysema O
and O
B O
type O
COPD O
by O
Burrows RARE
classification O
than O
in O
controls O
. O

A O
second O
hydrophobic O
domain O
, O
bordered RARE
by O
two O
hydrophilic O
regions O
strongly O
suggests O
a O
transmembrane O
region O
. O

This O
gene O
spans O
23 O
kb O
and O
is O
composed O
of O
five O
exons O
and O
four O
introns O
. O

The O
remaining O
RAD ALLCAPS
+ I-GENE
cells O
progressed O
to O
form O
microcolonies RARE
(< O
30 O
cells O
) O
containing O
aberrantly RARE
shaped O
inviable RARE
cells O
. O

The O
11 O
; O
22 O
chromosomal O
translocation O
specifically O
linked O
to O
Ewing RARE
sarcoma O
and O
primitive RARE
neuroectodermal RARE
tumor O
results O
in O
a O
chimeric O
molecule O
fusing RARE
the O
amino O
- O
terminal O
- O
encoding O
portion O
of O
the O
EWS I-GENE
gene I-GENE
to O
the O
carboxyl O
- O
terminal O
DNA O
- O
binding O
domain O
encoded O
by O
the O
FLI1 I-GENE
gene I-GENE
. O

These O
findings O
suggest O
that O
a O
range O
of O
microenvironmental RARE
conditions O
exist O
within O
purified O
water O
systems O
, O
leading O
to O
variable O
populations O
of O
bacteria O
. O

X O
- O
linked O
liver O
glycogenosis RARE
: O
localization O
and O
isolation O
of O
a O
candidate O
gene O
. O

This O
conclusion O
is O
based O
on O
the O
observations O
of O
the O
immunologic O
changes O
that O
characterize O
the O
acute O
stages O
of O
illness O
as O
well O
as O
on O
the O
demonstrated O
association O
with O
toxin O
- O
producing O
bacteria O
in O
the O
pharynx RARE
and O
gastrointestinal O
tract O
. O

Measurement O
of O
anti I-GENE
- I-GENE
HCV I-GENE
IgM I-GENE
antibodies I-GENE
with O
an O
experimental O
kit O

Embryo RARE
coculture RARE
system O
may O
contribute O
to O
understand O
the O
mechanisms O
underlying O
the O
decrease O
of O
fertility O
with O
aging O
. O

These O
cell O
lines O
displayed O
methylation O
of O
the O
CpG O
island O
surrounding O
the O
first O
exon O
of O
p16INK4A NUMERIC
and O
expressed O
abundant O
levels O
of O
a O
nontranslated RARE
mRNA O
containing O
an O
alternative O
first O
exon O
( O
E1 O
beta O
), O
as O
did O
all O
other O
cell O
lines O
in O
which O
the O
p16INK4A NUMERIC
locus I-GENE
was O
not O
deleted O
. O

An O
immunoperoxidase RARE
reaction O
, O
PAP ALLCAPS
method O
, O
with O
the O
antiserum O
of O
Factor I-GENE
VIII I-GENE
as O
the O
primary O
antibody O
, O
was O
carried O
out O
in O
the O
endometrial O
biopsies O
to O
detect O
the O
Factor I-GENE
VIII I-GENE
activity O
in O
the O
endometrial O
endothelium O
before O
and O
after O
insertion O
of O
LNG ALLCAPS
- O
IUD ALLCAPS
- O
20 O
. O

Umweltchem RARE
. O

Egd1p NUMERIC
is O
homologous O
to O
human I-GENE
BTF3b NUMERIC
, O
recently O
identified O
as O
the O
beta O
subunit O
of O
the O
heterodimeric I-GENE
nascent RARE
- I-GENE
polypeptide I-GENE
- I-GENE
associated I-GENE
complex I-GENE
( O
NAC ALLCAPS
) O
involved O
in O
ensuring RARE
signal O
- O
sequence O
- O
specific O
protein O
sorting O
and O
translocation O
[ O
Wiedmann RARE
et O
al O
., O
Nature RARE
370 NUMERIC
( O
1994 O
) O
434 NUMERIC
- O
440 O
]. O

Purified O
PLB ALLCAPS
showed O
optimal O
lyase I-GENE
activity O
at O
pH O
10 O
. O
0 O
. O

The O
5 O
' O
flanking O
regions O
of O
both O
pelA LASTCAP
and O
pelB LASTCAP
were O
translationally RARE
fused O
to O
the O
beta I-GENE
- I-GENE
glucuronidase I-GENE
gene I-GENE
and O
introduced O
into O
F O
. O
solani RARE
f O
. O
sp O
. O
pisi RARE
, O
and O
beta I-GENE
- I-GENE
glucuronidase I-GENE
activities O
of O
the O
transformants O
were O
measured O
. O

When O
nifA LASTCAP
mRNA I-GENE
5 O
' O
start O
points O
were O
mapped O
by O
primer O
extension O
, O
both O
a O
minor O
upstream O
transcript O
( O
s O
) O
starting O
45 O
bp O
distal O
to O
the O
anaerobox RARE
and O
a O
major O
downstream O
transcript O
starting O
10 O
bp O
distal O
to O
the O
sigma I-GENE
54 I-GENE
box O
were O
observed O
. O

We O
failed O
to O
find O
these O
data O
to O
be O
useful O
in O
predicting O
the O
time O
of O
onset O
of O
initial O
seizures O
after O
acute O
ischemic O
stroke O
and O
recurrence O
. O

The O
human I-GENE
papillomavirus I-GENE
type I-GENE
16 I-GENE
E7 I-GENE
protein I-GENE
complements RARE
adenovirus I-GENE
type I-GENE
5 I-GENE
E1A I-GENE
amino O
- O
terminus O
- O
dependent O
transactivation O
of O
adenovirus I-GENE
type I-GENE
5 I-GENE
early I-GENE
genes I-GENE
and O
increases O
ATF I-GENE
and O
Oct I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
activity O
. O

A O
chaotropic RARE
detergent O
, O
0 O
. O
1 O
% O
Nonidet RARE
P O
- O
40 O
, O
also O
abolished O
the O
interaction O
, O
further O
supporting O
the O
hydrophobic O
nature O
of O
the O
interaction O
. O

Contrary RARE
to O
expectations RARE
, O
we O
find O
a O
relatively O
high O
level O
of O
variation O
in O
the O
stripe RARE
2 I-GENE
enhancer O
region O
, O
including O
point O
substitutions O
and O
insertion O
/ O
deletions O
in O
binding O
sites O
, O
and O
a O
comparable O
level O
of O
variation O
in O
the O
other O
noncoding O
regions O
. O

Degradation RARE
of O
the O
soybean I-GENE
ribulose RARE
- I-GENE
1 I-GENE
, I-GENE
5 I-GENE
- I-GENE
bisphosphate RARE
carboxylase RARE
small I-GENE
- I-GENE
subunit I-GENE
mRNA I-GENE
, O
SRS4 NUMERIC
, O
initiates RARE
with O
endonucleolytic RARE
cleavage O
. O

Cloning O
and O
sequencing O
revealed O
that O
dMax RARE
contains O
a O
deletion O
spanning O
the O
basic O
region O
and O
helix O
1 O
and O
the O
loop O
of O
the O
helix O
- O
loop O
- O
helix O
region O
, O
presumably O
as O
a O
result O
of O
alternative O
splicing O
of O
max I-GENE
RNA I-GENE
. O

I O
report O
here O
that O
induction O
of O
HSP82 NUMERIC
is O
regulated O
by O
the O
early O
meiotic O
IME1 I-GENE
- O
IME2 NUMERIC
transcriptional O
cascade O
. O

The O
domain O
structure O
of O
bovine I-GENE
LTBP ALLCAPS
- I-GENE
2 I-GENE
is O
very O
similar O
to O
that O
of O
the O
human I-GENE
LTBP ALLCAPS
- I-GENE
2 I-GENE
, O
containing O
20 O
examples O
of O
6 O
- O
cysteine O
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
like I-GENE
repeats I-GENE
, O
16 O
of O
which O
have O
the O
consensus O
sequence O
for O
calcium O
binding O
, O
together O
with O
4 O
examples O
of O
8 O
- O
cysteine O
motifs O
characteristic O
of O
fibrillins RARE
and O
LTBP ALLCAPS
- I-GENE
1 I-GENE
. O

Similarly O
, O
expression O
of O
a O
transiently O
transfected O
wild I-GENE
- I-GENE
type I-GENE
prothymosin RARE
alpha I-GENE
gene I-GENE
as O
the O
reporter O
was O
not O
affected O
by O
a O
repertoire RARE
of O
myc I-GENE
- I-GENE
derived I-GENE
genes I-GENE
, O
including O
myc I-GENE
itself O
and O
dominant O
or O
recessive O
negative O
myc I-GENE
mutants I-GENE
. O

Differential O
regulation O
of O
the O
alpha I-GENE
/ I-GENE
beta I-GENE
interferon I-GENE
- O
stimulated O
Jak I-GENE
/ O
Stat I-GENE
pathway O
by O
the O
SH2 I-GENE
domain O
- O
containing O
tyrosine I-GENE
phosphatase I-GENE
SHPTP1 NUMERIC
. O

We O
now O
report O
the O
isolation O
and O
expression O
of O
cDNAs O
encoding O
PTF ALLCAPS
gamma I-GENE
and O
PTF ALLCAPS
delta I-GENE
, O
as O
well O
as O
functional O
studies O
with O
cognate O
antibodies O
that O
recognize O
the O
native O
PTF ALLCAPS
complex I-GENE
in O
HeLa O
extracts O
. O

Results O
from O
the O
mechanism O
study O
have O
revealed O
that O
YY1 I-GENE
is O
able O
to O
inhibit O
transactivation O
mediated O
by O
either O
AP1 I-GENE
or O
the O
Sp1 I-GENE
- I-GENE
related I-GENE
protein I-GENE
, O
and O
YY1 I-GENE
suppressive RARE
activity O
is O
DNA O
binding O
dependent O
. O

The O
skp1 NUMERIC
+ I-GENE
gene I-GENE
is O
not O
essential O
. O

The O
TEA1 NUMERIC
( O
Ty RARE
enhancer I-GENE
activator I-GENE
) O
gene O
sequence O
predicts O
a O
protein O
of O
86 O
. O
9 O
kDa O
whose O
N O
terminus O
contains O
a O
zinc O
cluster O
and O
dimerization O
motif O
typical O
of O
the O
Gal4 I-GENE
- I-GENE
type I-GENE
family I-GENE
of O
DNA O
- O
binding O
proteins O
. O

Refugees RARE
living O
in O
Lund RARE
and O
repatriated RARE
to O
Chile RARE
considered O
their O
health O
as O
bad RARE
in O
a O
higher O
proportion O
than O
their O
Swedish RARE
counterparts O
, O
with O
an O
odds O
ratio O
of O
3 O
. O
48 O
( O
2 O
. O
03 O
- O
5 O
. O
66 O
) O
and O
4 O
. O
78 O
( O
2 O
. O
1 O
- O
10 O
. O
25 O
) O
respectively O
. O

This O
study O
underlines RARE
the O
importance O
of O
terminal O
SC5b NUMERIC
- I-GENE
9 I-GENE
complement I-GENE
complex I-GENE
as O
a O
suitable O
marker O
in O
the O
evaluation O
of O
complement O
activation O
during O
cardiopulmonary O
bypass O
. O

Videonystagmoscopy RARE
has O
been O
used O
to O
subjectively RARE
observe O
the O
responses O
of O
the O
vestibular O
system O
in O
a O
population O
of O
patients O
with O
vestibular O
deficits O
. O

The O
MCA ALLCAPS
and O
UA ALLCAPS
PI O
values O
showed O
the O
greatest O
deviation O
for O
any O
single O
- O
vessel O
parameter O
. O

Striking RARE
sequence O
similarities O
( O
57 O
and O
53 O
%) O
were O
observed O
with O
yeast O
mitochondrial O
proteins O
, O
SMF1 NUMERIC
and O
SMF2 NUMERIC
, O
especially O
within O
putative O
functional O
domains O
: O
exon O
6 O
encoding O
the O
second O
transmembrane O
spanning O
domain O
, O
site O
of O
the O
murine I-GENE
susceptibility I-GENE
mutation O
; O
and O
exon O
11 O
encoding O
a O
conserved O
transport O
motif O
. O

Stems RARE
contain O
distinctly O
less O
P I-GENE
protein I-GENE
mRNA I-GENE
and O
the O
relative O
level O
in O
roots O
is O
very O
low O
but O
still O
clearly O
detectable O
. O

The O
B I-GENE
. I-GENE
germanica RARE
cyclophilin RARE
amino I-GENE
acid I-GENE
sequence I-GENE
shares O
83 O
% O
identity O
with O
the O
cytosolic I-GENE
cyclophilin RARE
isoform I-GENE
from I-GENE
Drosophila I-GENE
melanogaster I-GENE
( O
Cyp RARE
- I-GENE
1 I-GENE
). O

Furthermore O
, O
we O
have O
identified O
a O
soluble O
form O
of O
ERp57 NUMERIC
/ O
GRP58 NUMERIC
by O
Western O
blotting O
and O
biosynthetic O
labeling O
. O

The O
minimal O
region O
of O
overlap O
of O
Langer RARE
- O
Giedion RARE
syndrome O
deletions O
, O
previously O
identified O
by O
analysis O
of O
15 O
patients O
, O
was O
placed O
on O
the O
map O
by O
analysis O
of O
2 O
patients O
whose O
deletions O
define O
the O
endpoints RARE
. O

Consistent O
with O
the O
hepatic O
and O
epidermal O
expression O
of O
histidase RARE
, O
this O
finding O
suggests O
that O
histidase RARE
transcription O
may O
be O
regulated O
by O
these O
factors O
. O

Comparison O
of O
promoters O
repressed O
by O
c I-GENE
- I-GENE
myc I-GENE
reveals O
a O
weak O
consensus O
sequence O
of O
the O
initiator O
( O
Inr RARE
) O
element O
: O
TCA ALLCAPS
(+ O
1 O
) O
YYYNY ALLCAPS
. O

The O
human I-GENE
gp39 NUMERIC
promoter I-GENE
. O

Transfection O
analyses O
indicate O
that O
mutation O
of O
any O
one O
of O
these O
TGACCT ALLCAPS
motifs O
or O
truncation RARE
of O
the O
entire O
HD I-GENE
PPRE ALLCAPS
into O
a O
separate O
DR1 O
and O
DR2 NUMERIC
element O
significantly O
reduced O
the O
transcriptional O
response O
of O
HD I-GENE
PPRE ALLCAPS
to O
peroxisome O
proliferators RARE
. O

The O
site O
of O
autophosphorylation O
is O
Tyr397 NUMERIC
which O
corresponds O
to O
the O
consensus O
autophosphorylation O
site O
of O
other O
Src I-GENE
family I-GENE
tyrosine I-GENE
kinases I-GENE
. O

This O
protein O
- O
protein O
interaction O
does O
not O
require O
the O
simultaneous O
binding O
of O
Oct I-GENE
proteins I-GENE
to O
DNA O
, O
and O
high O
resolution O
footprinting O
of O
the O
Oct I-GENE
- I-GENE
DNA I-GENE
interaction O
reveals O
that O
binding O
of O
BOB ALLCAPS
. I-GENE
1 I-GENE
/ O
OBF ALLCAPS
. I-GENE
1 I-GENE
to O
Oct1 NUMERIC
or O
Oct2 NUMERIC
does O
not O
alter O
the O
interaction O
with O
DNA O
. O

Together O
, O
our O
data O
suggest O
that O
the O
TR2 NUMERIC
orphan I-GENE
receptor I-GENE
may O
be O
a O
master RARE
regulator O
in O
modulating RARE
the O
activation O
of O
two O
key O
HREs RARE
, O
RARE ALLCAPS
beta O
and O
CRBPIIp RARE
, O
involved O
in O
the O
retinoic O
acid O
signal O
transduction O
pathway O
. O

Using O
a O
series O
of O
mutant O
proteins O
, O
we O
have O
characterized O
domains O
responsible O
for O
activation O
or O
repression O
. O

Unlike O
ARF I-GENE
, O
the O
ARP ALLCAPS
immunoreactivity O
was O
detected O
in O
plasma O
membranes O
but O
not O
in O
cytosol O
of O
fractionated RARE
3T3 O
- O
L1 O
cells O
. O

It O
is O
considered O
that O
the O
recurrent O
annular RARE
erythema RARE
is O
a O
specific O
skin O
manifestation O
of O
SjS LASTCAP
with O
anti I-GENE
SS I-GENE
- I-GENE
A I-GENE
/ O
SS I-GENE
- I-GENE
B I-GENE
antibodies I-GENE
. O

Competition O
needs O
to O
be O
better O
studied O
, O
since O
in O
Central RARE
America RARE
and O
Caribean RARE
islands RARE
this O
kind RARE
of O
study O
has O
favored RARE
the O
biological O
control O
of O
planorbid RARE
species O
. O

In O
this O
paper O
we O
describe O
properties O
of O
the O
cdc10 NUMERIC
- O
C4 O
mutant O
of O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
. O

TIEG ALLCAPS
expression O
in O
hFOB LASTCAP
cells O
was O
highly O
induced O
by O
TGF I-GENE
- I-GENE
beta I-GENE
and O
bone I-GENE
morphogenetic RARE
protein I-GENE
- I-GENE
2 I-GENE
( O
BMP I-GENE
- I-GENE
2 I-GENE
), O
with O
a O
moderate O
induction O
by O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
), O
but O
no O
induction O
by O
other O
growth O
factors O
/ O
cytokines O
was O
observed O
. O

An O
infectious O
origin O
should O
always O
be O
excluded O
since O
specific O
etiologic RARE
therapy O
may O
be O
implemented RARE
. O

The O
predicted O
protein O
products O
of O
ORFs I-GENE
N2417 NUMERIC
and O
N2403 NUMERIC
present O
similarities O
with O
domains O
from O
proteins O
of O
other O
organisms O
: O
the O
Candida O
maltosa RARE
cycloheximide I-GENE
- I-GENE
resistance I-GENE
protein I-GENE
, O
the O
human O
interleukin I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
factor I-GENE
( O
ILF ALLCAPS
- I-GENE
2 I-GENE
). O

In O
particular O
, O
the O
highly O
expressed O
ADH1 NUMERIC
gene I-GENE
is O
represented O
in O
this O
database O
by O
no O
less O
than O
20 O
EST O
sequences O
. O

Five O
families O
of O
Ashkenazi RARE
Jewish RARE
descent RARE
carried O
the O
185delAG NUMERIC
mutation O
and O
shared O
the O
same O
haplotype RARE
at O
eight O
polymorphic O
markers O
spanning O
approximately O
850 NUMERIC
kb O
at O
BRCA1 I-GENE
. O

The O
subjects O
from O
the O
two O
regions O
with O
a O
higher O
pollution RARE
level O
had O
lower O
FVC ALLCAPS
and O
FEV1 O
values O
than O
those O
from O
the O
Viskovo RARE
region O
. O

PTP I-GENE
- I-GENE
S3 NUMERIC
differs O
from O
PTP I-GENE
- I-GENE
S4 I-GENE
in O
having O
a O
deletion O
of O
19 O
amino O
acids O
corresponding O
to O
exon O
E1 O
. O

All O
three O
NR ALLCAPS
isoforms I-GENE
are O
expressed O
in O
cv O
. O

All O
three O
NR ALLCAPS
isoforms O
are O
expressed O
in O
cv O
. O

The O
Arabidopsis I-GENE
FAD7 NUMERIC
gene I-GENE
encodes O
a O
chloroplast I-GENE
omega I-GENE
- I-GENE
3 I-GENE
fatty I-GENE
acid I-GENE
desaturase RARE
that O
catalyzes O
the O
desaturation RARE
of O
lipid O
- O
linked O
dienoic RARE
fatty O
acids O
( O
18 O
: O
2 O
and O
16 O
: O
2 O
). O

When O
differentiated O
G0 NUMERIC
- O
arrested O
leaf O
cells O
were O
induced O
to O
resume RARE
cell O
division O
by O
treatment O
with O
plant O
hormones O
, O
cycMs4 NUMERIC
transcription O
was O
induced O
before O
the O
onset O
of O
DNA O
synthesis O
. O

A O
survey O
is O
given O
of O
the O
pharmacological O
backgrounds RARE
that O
are O
relevant O
for O
the O
drug O
treatment O
of O
essential O
hypertension O
in O
the O
elderly O
. O

Protein O
kinases O
play O
pivotal O
roles O
in O
the O
control O
of O
many O
cellular O
processes O
. O

Interestingly O
, O
internal O
and O
5 O
' O
deletions O
revealed O
tha RARE
the O
distal O
promoter O
was O
not O
required O
for O
full O
transcriptional O
activity O
and O
that O
the O
first O
631 NUMERIC
base O
pairs O
of O
WNT ALLCAPS
- I-GENE
5A NUMERIC
harbored RARE
the O
strongest O
promoter O
activity O
. O

The O
protein O
kinase O
domains O
of O
LIMK1 NUMERIC
and O
LIMK2 NUMERIC
are O
unique O
in O
that O
they O
contain O
an O
unusual O
sequence O
motif O
Asp O
- O
Leu O
- O
Asn O
- O
Ser O
- O
His O
- O
Asn O
in O
subdomain O
VIB ALLCAPS
and O
a O
highly O
basic O
insert O
between O
subdomains O
VII O
and O
VIII O
. O

A O
human O
recombinant O
cDNA O
clone O
that O
encoded O
253 NUMERIC
amino O
acids O
residues O
of O
a O
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
( O
THZif RARE
- I-GENE
1 I-GENE
) O
was O
cloned O
by O
screening O
a O
cDNA O
library O
prepared O
from O
human O
promyelocytic RARE
leukemia O
HL60 NUMERIC
cells O
with O
synthetic O
oligodeoxynucleotide RARE
probes O
that O
corresponded O
to O
the O
amino O
acid O
sequences O
of O
tryptic RARE
peptides O
derived O
from O
the O
DNA O
- O
binding O
protein O
specific O
for O
the O
nuclease I-GENE
- I-GENE
hypersensitive I-GENE
element I-GENE
( O
NHE ALLCAPS
) O
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

Erythrocyte RARE
AA O
in O
FO ALLCAPS
+ O
EPO I-GENE
- O
supplemented O
infants O
remained O
low O
and O
below O
breast O
- O
and O
placebo O
formula O
- O
fed O
levels O
. O

Taking RARE
into O
consideration RARE
weight O
and O
seasonal RARE
changes O
in O
bone O
mass O
, O
total O
( O
TBBMC ALLCAPS
) O
and O
regional O
body O
bone O
mineral O
content O
were O
measured O
in O
38 O
women O
treated O
with O
GnRH I-GENE
agonists O
for O
6 O
months O
for O
endometriosis RARE
or O
leiomyomata RARE
. O

The O
encoded O
polypeptide O
is O
similar O
in O
sequence O
to O
the O
ABA I-GENE
- I-GENE
1 I-GENE
allergen I-GENE
of I-GENE
Ascaris RARE
, O
the O
gp15 NUMERIC
/ I-GENE
400 I-GENE
' I-GENE
ladder RARE
' I-GENE
protein I-GENE
of I-GENE
Brugia RARE
malayi RARE
, I-GENE
Brugia RARE
pahangi RARE
and I-GENE
Wuchereria RARE
bancrofti RARE
, O
and O
a O
15 I-GENE
- I-GENE
kDa I-GENE
antigen I-GENE
of I-GENE
Dirofilaria RARE
immitis RARE
. O

Certain RARE
transcript O
patterns O
in O
Epifagus RARE
plastids RARE
are O
highly O
complex O
and O
similar O
to O
those O
of O
tobacco O
operons O
. O

Spontaneous RARE
recovery O
occurs O
within O
30 O
min O
to O
2 O
hrs O
. O

DAF ALLCAPS
is O
a O
70 O
kD O
glycoprotein O
containing O
complement O
regulatory O
short O
consensus O
repeats O
( O
SCRs RARE
); O
its O
gene O
is O
located O
in O
the O
regulation I-GENE
of I-GENE
complement I-GENE
activation I-GENE
( O
RCA ALLCAPS
) O
gene O
cluster O
on O
chromosome O
1 O
and O
is O
about O
40 O
kb O
in O
size O
. O

The O
XS2 NUMERIC
gene I-GENE
down O
- O
regulates O
but O
does O
not O
abolish RARE
expression O
of O
LU ALLCAPS
genes I-GENE
and O
does O
not O
affect O
expression O
of O
CD44 I-GENE
. O

Diabetes RARE
care O
: O
a O
guideline RARE
to O
the O
facilities RARE
needed O
to O
support O
internationally RARE
endorsed RARE
standards RARE
. O

There O
is O
no O
TATA O
box O
around O
the O
transcriptional O
start O
points O
( O
tsp RARE
), O
as O
determined O
by O
primer O
extension O
analysis O
. O

According O
to O
the O
investigation O
, O
the O
recent O
burst O
of O
pseudoterranovosis RARE
in O
this O
area O
can O
be O
attributed O
to O
the O
increased O
presence O
of O
sea O
lions RARE
, O
which O
proliferate RARE
in O
the O
Arctic RARE
region O
, O
then O
migrate RARE
to O
the O
northern O
Japan O
Sea RARE
and O
eat RARE
the O
intermediate O
host O
fish O
. O

In O
summary O
, O
the O
efficacies RARE
of O
adjuvant O
carboplatin RARE
and O
of O
abdominal O
radiotherapy O
seem O
to O
be O
identical O
. O

To O
identify O
some O
of O
the O
genes O
expressed O
in O
LPS O
- O
activated O
coelomocytes RARE
, O
we O
sequenced O
randomly O
chosen O
clones O
from O
a O
directionally RARE
constructed O
cDNA O
library O
to O
produce O
a O
set O
of O
expressed O
sequence O
tags O
( O
ESTs O
). O

Characterization O
of O
an O
EcR LASTCAP
/ O
USP ALLCAPS
heterodimer O
target O
site O
that O
mediates O
ecdysone O
responsiveness O
of O
the O
Drosophila I-GENE
Lsp RARE
- I-GENE
2 I-GENE
gene I-GENE
. O

Thus O
, O
SPECT O
was O
not O
as O
sensitive O
as O
PET O
in O
this O
activation O
task O
. O

Transcriptional O
activation O
of O
the O
chicken I-GENE
lysozyme I-GENE
gene I-GENE
by O
NF I-GENE
- I-GENE
kappa I-GENE
Bp65 NUMERIC
( O
RelA I-GENE
) O
and O
c I-GENE
- I-GENE
Rel I-GENE
, O
but O
not O
by O
NF I-GENE
- I-GENE
kappa I-GENE
Bp50 NUMERIC
. O

The O
results O
indicate O
that O
the O
bradycardic RARE
agents O
alinidine RARE
and O
zatebradine RARE
do O
not O
exert O
antiarrhythmic O
efficacy O
against O
SVT ALLCAPS
induced O
during O
subacute O
myocardial O
infarction O
in O
conscious O
dogs O
. O

In O
vivo O
, O
selective O
activation O
of O
SAPKs RARE
stimulates O
formation O
of O
the O
ternary O
complex O
containing O
Elk I-GENE
- I-GENE
1 I-GENE
, O
serum I-GENE
response I-GENE
factor I-GENE
and O
the O
serum O
response O
element O
, O
and O
enhances O
Elk I-GENE
- I-GENE
1 I-GENE
- O
dependent O
transcription O
. O

An O
epidemic O
of O
hepatitis O
B O
virus O
infection O
among O
intravenous O
drug O
users O
in O
Iceland RARE
. O

The O
gene O
was O
uniquely RARE
mapped O
with O
odds O
> O
1 O
, O
000 O
: O
1 O
on O
chromosome O
3p NUMERIC
in O
Centre RARE
d O
' O
Etude RARE
du RARE
Polymorphisme RARE
Humain RARE
pedigrees RARE
. O

Three O
of O
these O
subunits O
are O
also O
homologous O
to O
the O
dimeric O
POR ALLCAPS
from O
a O
mesophilic RARE
archaeon RARE
, O
Halobacterium RARE
halobium RARE
( O
21 O
% O
identity O
). O

The O
transposon O
- O
inactivated O
gene O
, O
designated O
pilP LASTCAP
, O
is O
525 NUMERIC
bp O
long O
, O
potentially O
encoding O
a O
19 O
. O
1 O
- O
kDa O
protein O
precursor O
that O
contains O
a O
typical O
membrane O
lipoprotein O
leader O
sequence O
. O

Cheung RARE
and O
S O
. O

Upstream O
of O
the O
dra RARE
gene I-GENE
an O
open O
reading O
frame O
of O
313 NUMERIC
amino O
acids O
was O
identified O
. O

Sucrose RARE
- O
specific O
regulation O
of O
scrB LASTCAP
was O
also O
lost O
upon O
deletion O
of O
4 O
bp O
of O
a O
palindromic O
sequence O
( O
OB ALLCAPS
) O
covering O
positions O
+ O
6 O
to O
+ O
21 O
downstream O
of O
the O
scrB LASTCAP
transcriptional O
start O
site O
. O

In O
E O
. O
coli O
, O
CheW LASTCAP
mediates O
the O
physical O
coupling O
of O
the O
receptors O
to O
the O
kinase O
CheA LASTCAP
. O

The O
promoter O
of O
the O
first O
gene O
, O
epiF LASTCAP
, O
responded O
to O
the O
activator I-GENE
protein I-GENE
EpiQ LASTCAP
and O
contained O
a O
palindromic O
sequence O
similar O
to O
the O
EpiQ LASTCAP
binding I-GENE
site I-GENE
of O
the O
epiA LASTCAP
promoter I-GENE
, O
which O
is O
also O
activated O
by O
EpiQ LASTCAP
. O

CXC ALLCAPS
chemokines RARE
bind O
to O
unique O
sets O
of O
selectivity O
determinants O
that O
can O
function O
independently O
and O
are O
broadly O
distributed O
on O
multiple O
domains O
of O
human O
interleukin I-GENE
- I-GENE
8 I-GENE
receptor I-GENE
B I-GENE
. O

Oligodeoxynucleotides RARE
antisense O
to O
the O
predicted O
translation O
initiation O
regions O
of O
ICP4 I-GENE
and O
pp38 NUMERIC
mRNAs I-GENE
inhibited O
proliferation O
of O
MSB1 NUMERIC
cells O
but O
not O
MDCC ALLCAPS
- O
CU91 NUMERIC
( O
CU91 NUMERIC
) O
reticuloendotheliosis RARE
virus O
- O
transformed O
cells O
. O

Retroviral RARE
replication O
requires O
that O
a O
portion O
of O
the O
primary O
transcripts O
generated O
from O
proviral O
DNA O
be O
spliced O
to O
serve O
as O
mRNA O
for O
the O
envelope I-GENE
protein I-GENE
and O
in O
Rous O
sarcoma O
virus O
as O
src I-GENE
mRNA I-GENE
. O

In O
this O
case O
the O
degree O
of O
promoter O
methylation O
, O
which O
could O
extend O
beyond O
the O
T O
- O
DNA O
borders RARE
, O
was O
not O
correlated O
with O
the O
reduction O
in O
steady O
- O
state O
poly O
( O
A O
)+ O
mRNA O
levels O
, O
the O
silenced RARE
state O
was O
transmitted O
through O
meiosis O
and O
reactivation RARE
lasted RARE
several O
generations RARE
. O

Thus O
, O
the O
consensus O
sequences O
for O
phosphatase O
regulation O
are O
5 O
'- O
GCACGTGGG ALLCAPS
- O
3 O
' O
and O
5 O
'- O
GCACGTTTT ALLCAPS
- O
3 O
' O
which O
differ O
from O
the O
binding O
sequences O
for O
the O
Cpflp RARE
protein O
required O
for O
transcription O
of O
the O
genes O
in O
methionine O
biosynthesis O
and O
for O
centromere O
function O
. O

Here O
we O
report O
that O
the O
proline O
- O
rich O
region O
of O
CAP I-GENE
is O
recognized O
by O
the O
SH3 I-GENE
domains I-GENE
of O
several O
proteins O
, O
including O
the O
yeast I-GENE
actin I-GENE
- I-GENE
associated I-GENE
protein I-GENE
Abp1p NUMERIC
. O

We O
have O
identified O
and O
characterized O
a O
vitamin O
D O
response O
element O
( O
VDRE O
) O
in O
the O
promoter O
of O
c I-GENE
- I-GENE
fos I-GENE
. O

In O
addition O
to O
protein O
binding O
at O
sequences O
known O
to O
be O
involved O
in O
the O
regulation O
of O
transcription O
, O
genomic O
footprinting O
of O
the O
entire O
promoter O
region O
also O
showed O
that O
a O
protein O
factor O
is O
constitutively O
bound O
to O
the O
first O
intron O
of O
the O
rep3 NUMERIC
gene I-GENE
. O

Differentiation RARE
was O
not O
observed O
after O
cellular O
expression O
of O
GTPase I-GENE
- O
deficient O
forms O
of O
alpha I-GENE
i2 NUMERIC
or O
alpha I-GENE
0 I-GENE
, O
indicating O
selectivity O
for O
the O
Gq RARE
family I-GENE
of O
G I-GENE
proteins I-GENE
. O

Consistent O
with O
a O
possible O
role O
in O
transcription O
, O
Paf1p NUMERIC
is O
localized O
to O
the O
nucleus O
. O

By O
comparing O
the O
abundances RARE
of O
many O
yeast O
transcripts O
in O
isogenic RARE
wild O
- O
type O
and O
paf1 NUMERIC
mutant I-GENE
strains O
, O
we O
have O
identified O
genes O
whose O
expression O
is O
affected O
by O
PAF1 NUMERIC
. O

Paf1p NUMERIC
may O
therefore O
be O
required O
for O
both O
positive O
and O
negative O
regulation O
of O
subsets RARE
of O
yeast O
genes O
. O

Using O
a O
high O
- O
copy O
suppression O
strategy O
, O
we O
have O
identified O
a O
yeast O
gene O
( O
UBS1 NUMERIC
) O
whose O
elevated O
expression O
suppresses O
the O
conditional O
cell O
cycle O
defects O
associated O
with O
cdc34 NUMERIC
mutations O
. O

Molecular O
characterization O
of O
malignant O
melanoma O
of O
soft O
parts O
or O
soft O
tissue O
clear O
cell O
sarcoma O
which O
shares O
t O
( O
12 O
; O
22 O
) O
chromosome O
translocation O
revealed O
fusion O
of O
EWS I-GENE
with O
a O
transcriptional O
factor O
gene I-GENE
ATF I-GENE
- I-GENE
1 I-GENE
. O

Clones RARE
that O
expressed O
DBD ALLCAPS
exhibited O
a O
dominant O
negative O
phenotype O
and O
did O
not O
elicit O
antiviral RARE
activity O
against O
vesicular O
stomatitis O
virus O
( O
VSV ALLCAPS
) O
infection O
upon O
IFN I-GENE
treatment O
. O

Abp1 NUMERIC
preferentially O
binds O
to O
multiple O
sites O
in O
ARS I-GENE
3002 NUMERIC
and O
to O
the O
DNA O
polymer RARE
poly O
[ O
d O
( O
A O
. O
T O
)]. O

Identification O
, O
purification O
, O
and O
molecular O
cloning O
of O
autonomously I-GENE
replicating I-GENE
sequence I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
from I-GENE
fission I-GENE
yeast I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
. O

A O
short O
open O
reading O
frame O
( O
ORF2 O
), O
of O
unknown O
function O
, O
is O
present O
in O
all O
FIV ALLCAPS
isolates O
. O

The O
patient O
was O
homozygous O
for O
the O
underlying O
mutation O
, O
which O
was O
found O
to O
be O
a O
G O
--> O
T O
transversion O
within O
the O
acceptor O
splice O
site O
between O
intron O
e O
and O
exon O
6 O
, O
abolishing RARE
normal O
RNA O
splicing O
. O

These O
regions O
overlap O
with O
the O
HIT ALLCAPS
protein I-GENE
similarity I-GENE
regions I-GENE
. O

We O
tested O
10 O
rats O
with O
electrophysiologically RARE
guided RARE
, O
ibotenic RARE
acid O
lesions O
of O
the O
PBN ALLCAPS
( O
PBNx RARE
) O
to O
determine O
whether O
they O
could O
acquire RARE
a O
LiCl RARE
- O
induced O
CTA ALLCAPS
to O
l O
- O
alanine O
( O
0 O
. O
3 O
M O
) O
or O
demonstrate O
a O
sodium O
appetite RARE
following O
furosemide O
treatment O
and O
overnight RARE
access O
to O
sodium O
deficient O
chow RARE
. O

Liposomal RARE
Amphotericin RARE
- O
B O
failed O
in O
6 O
/ O
7 O
patients O
with O
culture O
- O
proven O
mycosis RARE
who O
died O
from O
infection O
with O
Aspergillus O
( O
n O
= O
2 O
) O
and O
Candida O
( O
n O
= O
4 O
), O
respectively O
. O

Mg2 NUMERIC
+ O
and O
Mn2 NUMERIC
+ O
compete O
for O
binding O
sites O
, O
with O
the O
former O
having O
lower O
affinity O
. O

Magnetic O
storm RARE
indicators O
could O
be O
used O
in O
medicine O
, O
in O
geophysics RARE
and O
for O
special O
purposes RARE
. O

Transgenic RARE
tobacco O
plants O
( O
ppa RARE
- I-GENE
1 I-GENE
) O
constitutively O
expressing O
Escherichia I-GENE
coli I-GENE
pyrophosphatase RARE
behind O
the O
35S I-GENE
CaMV LASTCAP
promoter I-GENE
accumulate O
high O
levels O
of O
soluble O
sugars O
in O
their O
leaves O
[ O
27 O
]. O

Human I-GENE
LAF ALLCAPS
- I-GENE
4 I-GENE
readily O
hybridized O
with O
genes O
in O
mouse O
and O
chicken O
, O
thus O
showing O
that O
this O
gene O
family O
has O
been O
highly O
conserved O
during O
vertebrate O
evolution O
. O

Hb I-GENE
levels O
remained O
adequate O
( O
Hb I-GENE
= O
10 O
. O
68 O
+/- O
0 O
. O
77 O
g O
/ O
dl O
) O
after O
14 O
. O
6 O
+/- O
7 O
. O
64 O
months O
. O

CBT ALLCAPS
is O
discussed O
in O
comparison O
with O
the O
Wisconsin RARE
Card RARE
Sorting RARE
Test O
as O
a O
potential O
cognitive O
activation O
task O
for O
functional O
neuroimaging RARE
of O
the O
frontal O
lobes RARE
. O

These O
data O
indicate O
that O
although O
218leu NUMERIC
retains O
normal O
transactivation O
activity O
on O
a O
p53 I-GENE
promoter I-GENE
in O
yeast O
at O
physiological O
temperatures O
, O
it O
is O
not O
capable O
of O
normal O
p53 I-GENE
function O
in O
the O
presence O
of O
a O
248trp NUMERIC
allele I-GENE
in O
SNU ALLCAPS
- O
C5 NUMERIC
cells O
. O

Cycles RARE
were O
repeated O
every O
3 O
weeks O
. O

Neither O
class O
II O
nor O
IV O
infections O
precluded RARE
transplantation O
. O

Although O
a O
great O
deal RARE
is O
understood O
about O
how O
bHLH I-GENE
factors I-GENE
activate O
gene O
transcription O
via O
E O
- O
box O
DNA O
consensus O
sequences O
, O
studies O
of O
bHLH I-GENE
factor I-GENE
function O
in O
higher O
eukaryotes O
often O
have O
been O
hindered RARE
by O
the O
presence O
of O
multiple O
family O
members O
. O

Mobility RARE
and O
supershift O
assays O
demonstrated O
that O
upstream I-GENE
stimulatory I-GENE
factor I-GENE
( O
USF I-GENE
) O
and O
Sp1 I-GENE
bind O
to O
the O
former O
elements O
and O
competition O
experiments O
confirmed O
that O
CREB I-GENE
/ O
ATF I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
bind O
to O
the O
CRE O
/ O
TRE O
element O
. O

Upstream O
of O
- O
37 O
, O
the O
5 O
' O
untranslated O
sequences O
of O
the O
isolates O
differ O
in O
both O
length O
and O
sequence O
. O

In O
these O
cases O
, O
greatly O
increased O
human I-GENE
chorionic RARE
gonadotropin I-GENE
( O
hCG I-GENE
) O
levels O
and O
suppressed O
TSH I-GENE
levels O
suggest O
that O
hCG I-GENE
has O
thyrotropic RARE
activity O
. O

High O
fibrinogen I-GENE
levels O
could O
thus O
be O
a O
risk O
for O
perioperative RARE
thrombosis O
. O

Strontium RARE
chloride O
Sr RARE
89 O
is O
costly RARE
, O
but O
preliminary O
analysis O
indicates O
that O
it O
may O
reduce O
management O
expenditures RARE
overall O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

We O
propose O
that O
epigenetic RARE
features O
of O
tissue O
- O
specific O
control O
and O
of O
the O
control O
of O
allelic O
expression O
are O
intricately RARE
linked O
. O

This O
study O
determined O
the O
arthritogenic RARE
potential O
of O
silicone RARE
gel O
by O
either O
mixing RARE
it O
with O
bovine I-GENE
collagen I-GENE
II I-GENE
( O
BII ALLCAPS
) O
or O
by O
injecting O
silicone RARE
gel O
alone O
in O
DA O
rats O
. O

SBF I-GENE
binds O
to O
the O
promoter O
prior O
to O
the O
activation O
of O
transcription O
in O
late O
G1 O
, O
suggesting O
that O
Cln RARE
/ O
Cdc28 I-GENE
kinase O
regulates O
the O
ability O
of O
previously O
bound O
SBF I-GENE
to O
activate O
transcription O
. O

However O
, O
it O
remains O
an O
open O
question O
whether O
vertebrate I-GENE
Hox I-GENE
genes I-GENE
expressed O
under O
the O
control O
of O
Drosophila O
regulatory O
sequences O
can O
substitute O
the O
function O
of O
Drosophila I-GENE
Hox I-GENE
genes I-GENE
. O

This O
approach O
places RARE
gHoxb RARE
- I-GENE
1 I-GENE
into O
the O
normal O
embryonic O
spatiotemporal RARE
context O
in O
which O
lab RARE
acts O
. O

This O
5 O
' O
splice O
site O
sequence O
was O
required O
for O
enhanced O
polyadenylation O
and O
was O
recognized O
by O
both O
U1 I-GENE
small I-GENE
nuclear I-GENE
ribonucleoproteins RARE
( O
snRNPs O
) O
and O
alternative I-GENE
splicing I-GENE
factor I-GENE
/ O
splicing I-GENE
factor I-GENE
2 I-GENE
( O
ASF ALLCAPS
/ O
SF2 NUMERIC
). O

This O
analysis O
revealed O
that O
SAP ALLCAPS
145 NUMERIC
, O
together O
with O
four O
other O
SF3a NUMERIC
/ O
SF3b NUMERIC
subunits O
, O
UV O
cross O
- O
links O
to O
pre O
- O
mRNA O
in O
a O
20 O
- O
nucleotide O
region O
upstream O
of O
the O
BPS ALLCAPS
. O

We O
propose O
that O
CTS1 NUMERIC
and I-GENE
CTS2 NUMERIC
of I-GENE
Ci RARE
are O
members O
of O
two O
distinct O
classes O
of O
fungal I-GENE
chitinases RARE
, O
an O
observation O
not O
previously O
reported O
for O
a O
single O
fungus O
. O

Although O
the O
consumption O
of O
myoglobin I-GENE
- O
bound O
O2 O
( O
MbO2 NUMERIC
) O
stores RARE
in O
seal RARE
muscles O
has O
been O
demonstrated O
in O
seal RARE
muscles O
during O
laboratory O
simulations RARE
of O
diving RARE
, O
this O
may O
not O
be O
a O
feature O
of O
normal O
field O
diving RARE
in O
which O
measurements O
of O
heart O
rate O
and O
lactate O
production O
show O
marked O
differences O
from O
the O
profound O
diving RARE
response O
induced O
by O
forced RARE
immersion O
. O

The O
human I-GENE
purH LASTCAP
cDNA I-GENE
is O
1776 NUMERIC
base O
pairs O
in O
length O
encoding O
for O
a O
591 NUMERIC
- O
amino O
acid O
polypeptic RARE
( O
Mr O
= O
64 O
, O
425 NUMERIC
). O

The O
Saccharomyces O
cerevisiae O
spindle O
pole O
body O
duplication O
gene I-GENE
MPS1 NUMERIC
is O
part O
of O
a O
mitotic O
checkpoint O
. O

In O
our O
opinion RARE
, O
the O
SM ALLCAPS
- O
CMA ALLCAPS
system O
is O
, O
despite O
some O
shortcomings RARE
in O
its O
user RARE
- O
interface O
, O
a O
useful O
and O
versatile RARE
instrument O
for O
examination O
of O
human O
semen O
samples O
, O
with O
desirable RARE
features O
. O

The O
purpose O
of O
the O
study O
reported O
here O
was O
to O
investigate O
whether O
differences O
in O
T1 O
and O
T2 O
between O
tumors O
are O
mainly O
a O
consequence O
of O
differences O
in O
the O
fractional O
volume O
of O
the O
extracellular O
compartment O
. O

A O
mutant I-GENE
areA LASTCAP
product I-GENE
truncated O
immediately O
after O
the O
last O
residue O
of O
the O
highly O
conserved O
GATA I-GENE
( I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
) I-GENE
domain I-GENE
retains O
partial O
function O
. O

Oligonucleotides RARE
, O
designed O
on O
the O
basis O
of O
conserved O
flanking O
amino O
acid O
sequence O
segments O
within O
the O
catalytic O
domain O
of O
eukaryotic I-GENE
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
) O
proteins O
, O
were O
used O
as O
primers O
for O
polymerase O
chain O
reactions O
to O
amplify RARE
a O
427 NUMERIC
- O
bp O
chromosomal O
DNA O
fragment O
from O
the O
filamentous O
fungus O
Trichoderma RARE
reesei RARE
. O

Disruption O
of O
RB I-GENE
/ O
E2F I-GENE
- I-GENE
1 I-GENE
interaction O
by O
single O
point O
mutations O
in O
E2F I-GENE
- I-GENE
1 I-GENE
enhances O
S O
- O
phase O
entry O
and O
apoptosis O
. O

Apparent RARE
loss O
of O
differentiation O
markers O
characterizes RARE
advanced O
malignant O
neoplasms O
. O

This O
region O
contains O
a O
motif O
with O
partial O
identity O
with O
the O
binding O
site O
for O
the O
ubiquitous O
transcription O
factor O
upstream I-GENE
stimulatory I-GENE
factor I-GENE
( O
USF I-GENE
), O
which O
binds O
to O
the O
human I-GENE
insulin I-GENE
promoter I-GENE
. O

The O
method O
has O
been O
satisfactorily RARE
applied O
to O
the O
determination O
of O
paracetamol RARE
in O
pharmaceutical RARE
formulations RARE
and O
biological O
fluids O
. O

These O
primers O
yielded O
a O
PCR O
product O
of O
a O
characteristic O
length O
within O
most O
Xanthomonas RARE
species O
and O
pathovars RARE
tested O
. O

The O
Clb5 NUMERIC
kinase I-GENE
, O
which O
promotes O
S O
phase O
, O
remains O
active O
during O
the O
G2 O
- O
phase O
arrest O
of O
cells O
of O
the O
parental O
strain O
, O
but O
its O
activity O
declines RARE
rapidly O
in O
sim RARE
mutants I-GENE
. O

The O
C O
/ O
D O
ratio O
was O
equal O
to O
or O
over O
0 O
. O
6 O
in O
9 O
cases O
( O
16 O
eyes O
), O
and O
the O
values O
were O
inconsistent RARE
between O
both O
eyes O
in O
55 O
% O
of O
the O
patients O
. O

Rad6 NUMERIC
mutants I-GENE
display O
a O
remarkably O
pleiotropic O
phenotype O
, O
implicating RARE
the O
protein O
in O
DNA O
damage O
- O
induced O
mutagenesis O
, O
postreplication RARE
repair O
, O
repression O
of O
retrotransposition RARE
, O
and O
sporulation O
. O

RNase I-GENE
protection O
assays O
revealed O
a O
correlation O
between O
the O
levels O
of O
dorsal O
and O
ventral O
skin O
expression O
with O
pigmentation RARE
/ O
phaeomelanin RARE
phenotypes O
. O

Molecular O
cloning O
, O
expression O
pattern O
, O
and O
chromosomal O
localization O
of O
human O
CDKN2D NUMERIC
/ O
INK4d NUMERIC
, O
an O
inhibitor O
of O
cyclin I-GENE
D I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
. O

Overproduction RARE
of O
HrcA LASTCAP
protein I-GENE
from O
a O
second O
copy O
of O
hrcA LASTCAP
derived O
from O
a O
plasmid O
( O
phrcA LASTCAP
+) O
in O
B O
. O
subtilis O
wild O
- O
type O
and O
delta O
hrcA LASTCAP
strains O
prevented O
heat O
shock O
induction O
of O
the O
dnaK LASTCAP
and O
groE LASTCAP
operons I-GENE
at O
the O
level O
of O
transcription O
almost O
completely O
and O
strongly O
reduced O
the O
amounts O
of O
mRNA O
at O
a O
low O
temperature O
as O
well O
. O

We O
report O
the O
molecular O
cloning O
and O
functional O
characterization O
of O
USF2 NUMERIC
isoforms I-GENE
, O
corresponding O
to O
a O
44 O
- O
kDa O
subunit O
, O
USF2a NUMERIC
, O
and O
a O
new O
38 O
- O
kDa O
subunit O
, O
USF2b NUMERIC
, O
generated O
by O
differential O
splicing O
. O

The O
preferential O
heterodimerization O
of O
USF I-GENE
subunits I-GENE
was O
reproduced RARE
ex RARE
vivo O
, O
while O
the O
in O
vitro O
association O
of O
cotranslated RARE
subunits O
, O
or O
recombinant I-GENE
USF I-GENE
proteins I-GENE
, O
appeared O
to O
be O
random O
. O

Activated RARE
PKR I-GENE
may O
exist O
as O
a O
dimer O
and O
phosphorylates O
the O
eukaryotic I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
2 I-GENE
alpha I-GENE
subunit I-GENE
( O
cIF LASTCAP
- I-GENE
2 I-GENE
alpha I-GENE
) O
to O
inhibit O
polypeptide O
chain O
initiation O
. O

GRP78 NUMERIC
, O
a O
molecular O
chaperone RARE
expressed O
in O
the O
endoplasmic O
reticulum O
, O
is O
a O
" O
glucose O
- O
regulated O
protein O
" O
induced O
by O
stress O
responses O
that O
deplete RARE
glucose O
or O
intracisternal RARE
calcium O
or O
otherwise O
disrupt O
glycoprotein O
trafficking O
. O

The O
IL I-GENE
- I-GENE
8 I-GENE
receptor I-GENE
is O
a O
seven O
- O
transmembrane O
spanning O
receptor O
coupled O
to O
specific O
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
including O
Gi RARE
and O
G16 NUMERIC
. O

In O
a O
second O
series O
of O
experiments O
, O
the O
efficacy O
of O
PDC ALLCAPS
/ O
HDC ALLCAPS
Ac O
was O
evaluated O
in O
both O
single O
and O
multiple O
dose O
regiments RARE
. O

To O
elucidate O
the O
functional O
significance O
of O
Fyn I-GENE
in O
the O
expression O
of O
viral O
promoters O
, O
we O
transfected O
a O
Fyn I-GENE
- O
expression O
vector O
together O
with O
a O
reporter O
plasmid O
containing O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
driven O
by O
HIV I-GENE
LTR I-GENE
into O
a O
human O
T O
cell O
line O
, O
Jurkat O
. O

We O
conducted O
a O
prospective O
, O
randomized O
controlled O
trial O
of O
metoprolol RARE
, O
a O
selective O
beta O
- O
blocker O
for O
prevention O
of O
gastrointestinal O
bleeding O
from O
portal O
hypertension O
in O
29 O
non O
- O
selected O
patients O
with O
liver O
disease O
and O
previous O
gastrointestinal O
bleeding O
. O

A O
genetic O
and O
molecular O
analysis O
of O
non O
- O
inducible O
qutA LASTCAP
mutants I-GENE
showed O
that O
all O
23 O
mutations O
analysed O
map O
within O
the O
N O
- O
terminal O
half O
of O
the O
encoded O
QUTA ALLCAPS
protein I-GENE
. O

These O
studies O
indicate O
that O
the O
acidimetric RARE
test O
was O
less O
sensitive O
than O
the O
chromogenic RARE
cephalosporin RARE
substrates O
and O
that O
nitrocefin RARE
and O
S1 O
could O
be O
used O
to O
screen O
for O
beta I-GENE
- I-GENE
lactamase I-GENE
production O
in O
these O
tested O
species O
. O

Suppressors RARE
of O
defective O
silencing O
in O
yeast O
: O
effects O
on O
transcriptional O
repression O
at O
the O
HMR I-GENE
locus I-GENE
, O
cell O
growth O
and O
telomere O
structure O
. O

Although O
ANP I-GENE
induced O
systemic O
capillary O
filtration O
, O
in O
the O
calf O
, O
filtration O
was O
reduced O
with O
ANP I-GENE
. O

Recent O
literature O
has O
suggested O
that O
beta I-GENE
- I-GENE
2 I-GENE
transferrin I-GENE
can O
also O
be O
used O
as O
a O
clinical O
marker O
for O
perilymph RARE
. O

With O
current O
methodology RARE
beta I-GENE
- I-GENE
2 I-GENE
transferrin I-GENE
does O
not O
appear O
to O
be O
a O
reliable O
clinical O
marker O
for O
perilymph RARE
in O
the O
operative O
setting O
. O

The O
hIGF LASTCAP
- I-GENE
I I-GENE
gene I-GENE
has O
two O
promoters O
, O
P1 O
and O
P2 O
. O

Gel O
mobility O
shift O
assays O
indicated O
that O
at O
least O
four O
nuclear O
proteins O
with O
distinct O
biochemical O
and O
binding O
properties O
possess O
the O
ability O
to O
bind O
the O
3 O
beta O
I O
- O
A O
element O
to O
produce O
four O
DNA O
- O
protein O
complexes O
( O
R1 O
to O
R4 NUMERIC
). O

Sixty RARE
- O
five O
patients O
( O
aged O
between O
3 O
years O
5 O
months O
and O
60 O
years O
) O
suffering O
from O
medically RARE
resistant O
temporal O
lobe O
epilepsy O
( O
TLE ALLCAPS
) O
were O
operated O
on O
over O
a O
period O
of O
33 O
months O
in O
Bethel RARE
Epilepsy RARE
Center RARE
. O

Significant O
correlations O
existed O
between O
FEV1 O
and O
the O
corresponding O
values O
of O
Raw RARE
, O
MEF50 NUMERIC
and O
MEF25 NUMERIC
, O
although O
there O
were O
considerable O
individual O
differences O
between O
test O
results O
. O

( O
1989 O
), O
which O
is O
identical O
to O
the O
SSC1 NUMERIC
gene I-GENE
( O
Smith RARE
et O
al O
., O
1988 O
). O

This O
region O
also O
contains O
a O
gene O
specifying RARE
a O
Leu I-GENE
- I-GENE
tRNA I-GENE
precursor I-GENE
and O
a O
remnant RARE
of O
a O
tau O
element O
. O

Occupational RARE
exposure O
to O
hepatitis O
B O
virus O
and O
human O
immunodeficiency O
virus O
: O
a O
comparative O
risk O
analysis O
. O

Hybrid RARE
female O
mice O
( O
C57BL O
x O
CBA ALLCAPS
) O
were O
paired O
with O
breeder RARE
males O
( O
CD O
- O
1 O
) O
and O
LNG ALLCAPS
pellets O
were O
implanted O
on O
day O
0 O
, O
the O
day O
on O
which O
copulation RARE
plugs RARE
were O
found O
, O
or O
on O
day O
2 O
or O
day O
3 O
in O
the O
postcoital RARE
period O
. O

This O
gene O
encodes O
a O
putative O
transcription O
factor O
with O
regions O
of O
homology O
to O
several O
other O
proteins O
including O
the O
zinc O
fingers O
and O
other O
domains O
of O
the O
Drosophila I-GENE
trithorax RARE
gene I-GENE
product I-GENE
, O
and O
the O
" O
AT O
- O
hook RARE
" O
DNA O
- O
binding O
motif O
of O
high I-GENE
mobility I-GENE
group I-GENE
proteins I-GENE
. O

Using O
reference O
probes O
as O
internal O
standards RARE
, O
we O
show O
that O
the O
ost RARE
transcription I-GENE
unit I-GENE
is O
located O
within O
the O
cytogenetic O
band O
interval O
89A1 NUMERIC
, O
2 O
on O
the O
right O
arm O
of O
the O
third O
chromosome O
, O
and O
that O
it O
exerts O
diagnostic O
segmentation O
gene O
expression O
patterns O
in O
the O
embryo O
. O

The O
purified O
recombinant O
enzyme O
catalyzed O
specific O
phosphoryl RARE
transfer O
from O
ATP O
to O
UMP ALLCAPS
and O
CMP ALLCAPS
. O

Studies O
on O
the O
life O
cycle O
of O
Haplorchis RARE
pumilio RARE
( O
Looss RARE
, O
1896 NUMERIC
) O
Looss RARE
, O
1899 NUMERIC
with O
morphological O
redescription RARE
of O
larval O
and O
adult O
stages O
. O

Regressing RARE
microaneurysms RARE
in O
5 O
cases O
of O
hepatitis O
B O
virus O
related O
polyarteritis RARE
nodosa RARE
. O

During O
the O
following O
pregnancy O
ultrasonographic RARE
studies O
of O
the O
male O
fetus O
in O
the O
16th NUMERIC
week O
of O
gestation O
revealed O
severe O
micrognathia RARE
, O
short O
and O
wide O
thumbs RARE
, O
and O
big RARE
toes RARE
, O
and O
bowed RARE
tibiae RARE
. O

Despite O
an O
overall O
survival O
rate O
of O
43 O
%, O
survival O
to O
discharge O
varied O
greatly O
( O
0 O
to O
100 O
%) O
among O
the O
24 O
diagnostic O
groups O
: O
tumor O
lysis O
syndrome O
and O
systemic O
lupus O
erythematosus O
( O
3 O
/ O
3 O
patients O
each O
, O
100 O
%), O
hemolytic RARE
uremic RARE
syndrome O
( O
8 O
/ O
9 O
patients O
, O
89 O
%). O

One O
hundred O
units O
/ O
kg O
of O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
( O
rhEPO LASTCAP
) O
was O
given O
subcutaneously O
3 O
times O
a O
week O
for O
3 O
weeks O
. O

A O
3 O
- O
week O
regimen O
of O
erythropoietin I-GENE
may O
help O
prevent O
the O
donor O
' O
s O
need O
to O
receive O
allogeneic RARE
blood O
transfusion O
, O
when O
the O
initial O
Hb I-GENE
levels O
were O
below O
130 O
milligrams RARE
. O

In O
these O
constructs O
, O
GUS I-GENE
expression O
was O
driven O
by O
promoter O
regions O
derived O
from O
the O
Arabidopsis I-GENE
alcohol I-GENE
dehydrogenase I-GENE
( O
Adh1 NUMERIC
), O
maize I-GENE
ubiquitin I-GENE
( O
Ubi1 NUMERIC
), O
rice I-GENE
actin I-GENE
( O
Act1 NUMERIC
) O
and O
CaMV LASTCAP
35S I-GENE
genes I-GENE
. O

Its O
organization O
and O
regulation O
indicate O
that O
the O
S I-GENE
. I-GENE
pombe I-GENE
URA1 NUMERIC
gene I-GENE
product I-GENE
appears O
very O
similar O
to O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
URA2 NUMERIC
gene I-GENE
product I-GENE
. O

The O
mean O
body O
mass O
index O
( O
BMI O
) O
was O
31 O
. O
8 O
+/- O
6 O
. O
3 O
kg O
/ O
m2 O
and O
28 O
. O
5 O
+/- O
6 O
. O
3 O
kg O
/ O
m2 O
in O
women O
and O
men O
, O
respectively O
. O

These O
findings O
demonstrate O
that O
haemodialysis O
patients O
with O
chronic O
hepatitis O
C O
respond O
well O
to O
interferon I-GENE
treatment O
and O
that O
a O
long O
- O
term O
response O
is O
achieved O
in O
a O
high O
proportion O
of O
patients O
. O

Synthetic RARE
enantiomers RARE
of O
drugs O

Polysome RARE
analysis O
further O
indicated O
that O
these O
germ I-GENE
cell I-GENE
- I-GENE
specific I-GENE
Sp1 I-GENE
mRNAs I-GENE
are O
translated O
, O
albeit RARE
with O
a O
lower O
efficiency O
than O
the O
somatic O
transcript O
. O

In O
nondiabetics RARE
the O
response O
of O
tcPO2 NUMERIC
but O
not O
of O
LDF ALLCAPS
was O
influenced O
by O
the O
values O
at O
rest O
. O

This O
study O
proposes RARE
an O
estimator RARE
for O
such O
global O
synchronizing RARE
effects O
upon O
unit O
- O
pair O
correlations O
based O
on O
local O
field O
potentials O
( O
LFPs RARE
). O

The O
assembly O
of O
sequence O
ready RARE
, O
high O
- O
resolution O
physical O
maps O
and O
construction O
of O
minimally RARE
overlapping O
contigs RARE
for O
the O
human O
as O
well O
as O
model O
genomes O
requires O
accurate O
determination O
of O
the O
extent O
of O
overlap O
between O
adjacent O
clones O
as O
well O
as O
their O
relative O
orientation O
. O

( O
ii O
) O
opening RARE
of O
KATP ALLCAPS
attenuates O
, O
inhibition O
of O
the O
channel O
exacerbates RARE
functional O
consequences O
of O
coronary O
occlusion O
, O
and O
( O
iii O
) O
KATP ALLCAPS
opening RARE
attenuates O
reperfusion O
- O
induced O
VF O
, O
but O
it O
triggers O
ischemia O
- O
induced O
VF O
. O

The O
DNA O
sequences O
upstream O
of O
these O
termini O
exhibit O
homology O
to O
plant O
mitochondrial O
- O
processing O
sites O
, O
therefore O
the O
proximal O
5 O
' O
ends O
are O
most O
probably O
generated O
by O
RNA O
processing O
. O

Curing RARE
shrinkage RARE
and O
volumetric RARE
changes O
of O
resin O
- O
modified O
glass O
ionomer RARE
restorative RARE
materials O
. O

Here O
we O
present O
genetic O
evidence O
suggesting O
that O
PP2A I-GENE
functions O
downstream O
of O
Ras1 NUMERIC
in O
the O
Sevenless RARE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
( O
RTK ALLCAPS
) O
signal O
transduction O
pathway O
that O
specifies O
R7 NUMERIC
photoreceptor RARE
cell O
fate O
in O
the O
developing O
Drosophila O
eye O
. O

QBMDs RARE
for O
a O
5 O
% O
change O
in O
response O
( O
QBMD05 NUMERIC
) O
were O
6 O
- O
fold O
lower O
, O
on O
average O
, O
than O
the O
corresponding O
NOAEL ALLCAPS
. O

Effects O
of O
repeated O
exposures O
of O
hydrogen O
sulphide RARE
on O
rat O
hippocampal O
EEG O
. O

The O
gene O
encodes O
an O
ATP I-GENE
- I-GENE
binding I-GENE
cassette I-GENE
, O
ABC ALLCAPS
transporter I-GENE
. O

The O
T O
- O
box O
motif O
is O
present O
in O
a O
family O
of O
genes O
whose O
structural O
features O
and O
expression O
patterns O
support O
their O
involvement O
in O
developmental O
gene O
regulation O
. O

Molecular O
analysis O
of O
a O
novel O
schizosaccharomyces RARE
pombe O
gene O
containing O
two O
RNP O
consensus O
- O
sequence O
RNA O
- O
binding O
domains O
. O

Do RARE
overall O
treatment O
time O
, O
field O
size O
, O
and O
treatment O
energy O
influence O
local O
control O
of O
T1 O
- O
T2 O
squamous O
cell O
carcinomas O
of O
the O
glottic RARE
larynx O
? O
PURPOSE O
: O
To O
evaluate O
treatment O
and O
patient O
related O
prognostic O
factors O
that O
may O
influence O
local O
control O
in O
the O
treatment O
of O
T1 O
- O
T2 O
squamous O
cell O
carcinoma O
of O
the O
glottic RARE
larynx O
. O

In O
contrast O
to O
the O
signaling O
triggered O
by O
surface O
Ig I-GENE
engagement RARE
in O
B O
lymphocytes O
, O
CD38 NUMERIC
ligation O
did O
not O
appear O
to O
induce O
tyrosine O
phosphorylation O
of O
the O
src I-GENE
- I-GENE
like I-GENE
protein I-GENE
tyrosine I-GENE
kinases I-GENE
lyn RARE
, O
fyn RARE
, O
and O
btk RARE
, O
or O
of O
vav RARE
- I-GENE
and I-GENE
ras I-GENE
- I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
, O
nor O
did O
it O
induce O
detectable O
changes O
in O
cytosolic O
CA2 NUMERIC
+ O
concentrations O
. O

Mutations O
in O
the O
alpha I-GENE
- I-GENE
amanitin RARE
conserved O
domain O
of O
the O
largest O
subunit O
of O
yeast I-GENE
RNA I-GENE
polymerase I-GENE
III I-GENE
affect O
pausing RARE
, O
RNA O
cleavage O
and O
transcriptional O
transitions RARE
. O

The O
evidence O
presented O
here O
suggests O
that O
the O
p40 I-GENE
complex I-GENE
is O
a O
ribonucleoprotein O
complex O
containing O
L1Hs NUMERIC
RNA I-GENE
( I-GENE
s I-GENE
) I-GENE
and O
that O
protein O
- O
protein O
interactions O
in O
which O
alpha O
- O
helix O
structures O
participate O
, O
for O
example O
coiled O
- O
coils RARE
, O
may O
occur O
in O
the O
complex O
. O

Our O
data O
suggest O
that O
trans O
- O
activation O
from O
the O
prothymosin RARE
intron I-GENE
enhancer I-GENE
is O
a O
faithful RARE
reflection RARE
of O
the O
transforming O
properties O
of O
the O
Myc I-GENE
protein I-GENE
. O

Pseudomembranous RARE
conjunctivitis RARE
following O
bone O
marrow O
transplantation O
: O
immunopathological RARE
and O
ultrastructural RARE
study O
of O
one O
case O
. O

In O
view O
of O
the O
presence O
of O
SECIS O
elements O
in O
the O
open O
reading O
frames O
( O
ORFs O
) O
of O
bacterial I-GENE
selenoproteins RARE
, O
we O
examine O
the O
effects O
in O
the O
type I-GENE
1 I-GENE
deiodinase I-GENE
of O
extending O
the O
ORF O
into O
the O
SECIS O
element O
, O
and O
find O
that O
this O
dramatically O
inhibits O
SECIS O
function O
. O

The O
5 O
' O
external O
transcribed O
spacer O
( O
ETS O
) O
region O
of O
the O
pre O
- O
rRNA O
in O
Saccharomyces O
cerevisiae O
contains O
a O
sequence O
with O
10 O
bp O
of O
perfect O
complementarity O
to O
the O
U3 I-GENE
snoRNA LASTCAP
. O

These O
animals O
were O
viable O
and O
fertile RARE
. O

This O
spindle O
defect O
of O
pds1 NUMERIC
mutants I-GENE
results O
from O
a O
temperature O
- O
sensitive O
step O
that O
occurs O
around O
the O
G1 O
/ O
S O
boundary O
about O
the O
time O
of O
spindle O
assembly O
. O

These O
data O
suggest O
that O
RPF ALLCAPS
- I-GENE
1 I-GENE
is O
likely O
to O
be O
involved O
in O
early O
steps O
in O
the O
differentiation O
of O
amacrine RARE
and O
ganglion RARE
cells O
. O

In O
the O
point O
mutant O
we O
observed O
normal O
repair O
of O
endonuclease I-GENE
III I-GENE
site I-GENE
( O
i O
. O
e O
. O
as O
wild O
type O
), O
but O
no O
removal O
of O
CPDs RARE
at O
the O
MAT ALLCAPS
alpha I-GENE
and O
HML I-GENE
alpha I-GENE
loci I-GENE
. O

However O
, O
for O
the O
evaluable O
cases O
, O
the O
performances RARE
of O
the O
CD3500 NUMERIC
and O
the O
STKS ALLCAPS
were O
broadly O
similar O
and O
generally O
correlated O
well O
with O
the O
manual RARE
reference O
procedure O
. O

Carboxy RARE
- O
terminal O
Spc110p NUMERIC
truncations RARE
lacking O
the O
calmodulin I-GENE
binding O
site O
can O
support O
growth O
and O
are O
also O
phosphorylated O
in O
a O
cell O
cycle O
- O
specific O
manner O
. O

Both O
EWS I-GENE
- O
FLI I-GENE
- I-GENE
1 I-GENE
and O
FLI I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
function O
as O
transcription O
factors O
that O
bind O
specifically O
to O
ets I-GENE
sequences O
( O
the O
ets I-GENE
boxes O
) O
present O
in O
promoter O
elements O
. O

In O
electromobility RARE
shift O
assays O
, O
EWS I-GENE
- O
FLI I-GENE
- I-GENE
1 I-GENE
binding O
to O
the O
SRE O
is O
detectable O
in O
the O
absence O
of O
SRF I-GENE
whereas O
the O
binding O
of O
FLI I-GENE
- I-GENE
1 I-GENE
is O
not O
, O
suggesting O
that O
the O
interaction O
with O
DNA O
is O
the O
step O
which O
limits O
ternary O
complex O
formation O
by O
FLI I-GENE
- I-GENE
1 I-GENE
. O

Additional RARE
studies O
with O
new O
and O
reprocessed RARE
regenerated RARE
cellulose RARE
dialyzers RARE
comparing O
450 O
and O
220 O
mL O
/ O
min O
blood O
flow O
rates O
at O
10 O
minutes O
showed O
no O
change O
in O
BTG ALLCAPS
. O

DNA O
methylation O
, O
especially O
of O
either O
one O
or O
both O
of O
the O
deoxyadenosines RARE
at O
the O
two O
GATC ALLCAPS
motifs O
( O
one O
in O
the O
first O
exon O
and O
the O
other O
in O
the O
first O
intron O
of O
the O
rice O
CatA LASTCAP
gene I-GENE
), O
appeared O
to O
be O
responsible O
for O
the O
CatA LASTCAP
promoter I-GENE
activity O
identified O
in O
the O
transient O
assay O
. O

The O
viral I-GENE
LTR I-GENE
was O
used O
as O
the O
promoter O
. O

Overlapping RARE
cDNA O
clones O
were O
isolated O
and O
sequenced O
. O

In O
conclusion O
, O
IgM I-GENE
class O
CIC O
is O
the O
predominant O
CIC O
in O
acute O
hepatitis O
A O
and O
correlated O
with O
disease O
activity O
. O

Epitope RARE
mapping O
revealed O
that O
these O
three O
clones O
appear O
to O
recognize O
an O
identical O
epitope O
domain O
present O
on O
the O
C O
- O
terminal O
RNP O
motif O
of O
the O
U1A NUMERIC
protein I-GENE
. O

Variables RARE
evaluated O
were O
number O
of O
weekly O
anginal RARE
events O
, O
data O
from O
ergometric RARE
exercise O
testing O
with O
simultaneous O
electrocardiographic RARE
registration RARE
, O
semiquantitative RARE
evaluation O
of O
Tc O
- O
99m O
2 O
- O
methoxy RARE
isobutyl RARE
isonitrile RARE
( O
MIBI ALLCAPS
) O
scans O
and O
rheologic RARE
variables O
. O

As O
the O
length O
of O
the O
fatty O
acid O
decreased O
, O
the O
binding O
affinity O
was O
reduced O
; O
myristic RARE
acid O
( O
14 O
: O
0 O
) O
bound O
with O
a O
K O
( O
d O
) O
of O
1409 NUMERIC
+/- O
423 NUMERIC
nM O
, O
but O
medium O
- O
chain O
( O
decanoic RARE
acid O
, O
10 O
: O
0 O
) O
and O
short O
- O
chain O
( O
octanoic RARE
acid O
, O
8 O
: O
0 O
) O
lipids O
were O
not O
bound O
at O
all O
. O

The O
membrane O
- O
distal O
cytoplasmic O
region O
of O
human I-GENE
granulocyte I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
receptor I-GENE
is O
required O
for O
STAT3 I-GENE
but O
not O
STAT1 I-GENE
homodimer I-GENE
formation O
. O

However O
, O
whether O
or O
not O
nonsense O
codon O
recognition O
within O
TPI ALLCAPS
transcripts I-GENE
takes RARE
place O
prior O
to O
or O
after O
splicing O
remained O
unresolved RARE
. O

Although O
some O
residues O
are O
found O
reactive O
toward O
dimethylsulphate RARE
and O
kethoxal RARE
in O
regions O
predicted O
to O
be O
unpaired RARE
by O
the O
phylogenetic O
secondary O
structure O
model O
of O
4 I-GENE
. I-GENE
5S I-GENE
RNA I-GENE
, O
generally O
the O
reactivity O
is O
low O
, O
and O
some O
residues O
in O
internal O
loops O
are O
not O
reactive O
at O
all O
. O

Ongoing RARE
and O
future O
investigations O
may O
better O
define O
the O
optimal O
approach O
for O
local O
control O
, O
the O
optimal O
duration O
of O
maintenance O
chemotherapy O
, O
and O
the O
possible O
role O
of O
biologic RARE
response O
modifiers RARE
and O
growth O
factors O
in O
further O
improving RARE
the O
outcome O
for O
patients O
with O
this O
disease O
. O

SUMMARY ALLCAPS
OF ALLCAPS
REVIEW ALLCAPS
: O
We O
discuss O
the O
criteria O
that O
make O
such O
studies O
comparable O
, O
drawing RARE
on O
the O
experiences RARE
of O
recent O
studies O
performed O
around O
the O
world O
. O

Forty O
- O
five O
patients O
with O
pleural O
lesions O
identified O
on O
CT O
scans O
were O
subsequently O
examined O
by O
MR O
imaging O
at O
0 O
. O
5 O
T O
. O

Left RARE
atrial O
volumes O
were O
greater O
in O
old O
compared O
with O
young O
subjects O
( O
maximal O
: O
31 O
+/- O
10 O
cm3 O
/ O
m2 O
vs O
24 O
+/- O
8 O
cm3 O
/ O
m2 O
, O
p O
= O
0 O
. O
02 O
; O
at O
onset O
of O
atrial O
systole RARE
: O
23 O
+/- O
8 O
cm3 O
/ O
m2 O
vs O
15 O
+/- O
5 O
cm3 O
/ O
m2 O
, O
p O
= O
0 O
. O
0002 NUMERIC
; O
minimal O
: O
13 O
+/- O
5 O
cm3 O
/ O
m2 O
vs O
9 O
+/- O
4 O
cm3 O
/ O
m2 O
, O
p O
= O
0 O
. O
001 O
). O

RESULTS O
: O
Basal O
plasma I-GENE
IGF I-GENE
- I-GENE
I I-GENE
levels O
as O
well O
as O
body O
mass O
index O
( O
BMI O
) O
were O
lower O
in O
amenorrheic RARE
patients O
than O
in O
healthy O
controls O
. O

We O
observed O
abundant O
levels O
of O
Rev I-GENE
- O
erbA I-GENE
alpha I-GENE
mRNA O
in O
dividing RARE
C2C12 O
myoblasts O
, O
which O
were O
suppressed O
when O
the O
cells O
differentiated O
into O
postmitotic RARE
multinucleated RARE
myotubes O
. O

We O
then O
demonstrated O
that O
1 O
) O
GAL4 I-GENE
- O
REV ALLCAPS
- O
erbA I-GENE
alpha I-GENE
chimeras RARE
that O
contain O
the O
' O
AB ALLCAPS
' O
region O
and O
lack O
the O
' O
E O
' O
region O
activated O
transcription O
of O
GAL4 I-GENE
response I-GENE
elements I-GENE
in O
the O
presence O
of O
8 O
- O
Br O
- O
cAMP O
and O
2 O
) O
the O
ligand O
- O
binding O
domain O
( O
LBD ALLCAPS
) O
contains O
an O
active O
transcriptional O
silencer O
. O

The O
alpha O
T3 O
- O
1 O
cell O
line O
, O
a O
GnRH I-GENE
- O
responsive O
gonadotroph RARE
cell O
line O
developed O
by O
targeted O
oncogenesis RARE
in O
transgenic O
mice O
, O
was O
used O
to O
study O
regulation O
of O
the O
glycoprotein I-GENE
hormone I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
by O
activin I-GENE
. O

Cotransfection O
with O
the O
ie1 NUMERIC
gene I-GENE
resulted O
in O
a O
dramatic O
increase O
in O
the O
amount O
of O
the O
two O
enzymes O
expressed O
in O
the O
transfected O
cells O
. O

As O
expected O
, O
glycosylation O
of O
Env I-GENE
produced O
from O
mutants O
was O
affected O
but O
, O
irrespective O
of O
the O
glycosylation O
phenotype O
, O
( O
i O
) O
similar O
quantities RARE
of O
Env I-GENE
were O
synthesized O
, O
( O
ii O
) O
the O
immunoreactivity O
of O
V3 NUMERIC
was O
similar O
, O
( O
iii O
) O
gp160 NUMERIC
was O
efficiently O
cleaved O
into O
gp120 I-GENE
and O
gp41 NUMERIC
, O
( O
vi RARE
) O
Env I-GENE
was O
exposed O
at O
the O
cell O
membrane O
, O
( O
v O
) O
secreted O
gp120 I-GENE
bound O
CD4 I-GENE
, O
and O
( O
vi RARE
) O
membrane O
gp41 NUMERIC
was O
able O
to O
induce O
membrane O
fusion O
with O
CD4 I-GENE
+ I-GENE
cells O
. O

Effects O
of O
posteroventral RARE
pallidotomy RARE
on O
Parkinson O
' O
s O
disease O
. O

On O
the O
trail RARE
of O
Dr RARE
. O

However O
, O
only O
complete I-GENE
DnaJ LASTCAP
can O
cooperate O
with O
DnaK LASTCAP
and O
a O
third O
protein O
, O
GrpE LASTCAP
, O
in O
refolding RARE
denatured RARE
firefly RARE
luciferase I-GENE
. O

The O
two O
different O
phosphoforms RARE
of O
STAT5 I-GENE
have O
identical O
in O
vitro O
DNA O
binding O
specificity O
and O
reactivity O
with O
tyrosine O
phosphopeptides O
, O
but O
differ O
in O
their O
cellular O
localization O
. O

TNF I-GENE
Treatment O
of O
cell O
activated O
the O
p38 I-GENE
MAP I-GENE
kinase I-GENE
pathway O
, O
as O
revealed O
by O
increased O
phosphorylation O
of O
p38 I-GENE
MAP I-GENE
kinase I-GENE
itself O
, O
activation O
of O
the O
substrate O
protein O
MAPKAP ALLCAPS
kinase I-GENE
- I-GENE
2 I-GENE
, O
and O
culminating RARE
in O
the O
phosphorylation O
of O
the O
heat I-GENE
shock I-GENE
protein I-GENE
27 I-GENE
( O
hsp27 NUMERIC
). O

We O
have O
isolated O
a O
novel O
protein O
from O
Drosophila O
nuclear O
extracts O
which O
binds O
specifically O
to O
a O
site O
in O
this O
second O
region O
. O

However O
, O
while O
the O
sequence O
similarity O
between O
the O
membrane O
exons O
of O
avian I-GENE
mIgY LASTCAP
and O
mammalian I-GENE
mIgG LASTCAP
and I-GENE
IgE I-GENE
is O
striking O
, O
the O
overall O
similarity O
with O
Xenopus I-GENE
mIgY LASTCAP
is O
very O
low O
. O

Control O
of O
transcription O
of O
the O
erbB I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
an O
important O
determinant O
of O
receptor O
expression O
. O

DNase I-GENE
I I-GENE
footprinting O
and O
electrophoretic O
mobility O
shift O
assays O
indicate O
that O
PBP ALLCAPS
binds O
to O
the O
half O
- O
site O
of O
each O
palindrome O
with O
the O
core O
recognition O
sequence O
TGGGAG ALLCAPS
. O

These O
results O
demonstrate O
that O
sequences O
in O
the O
SH2 I-GENE
/ O
SH3 I-GENE
/ O
SH2 I-GENE
region O
of O
p120 NUMERIC
GAP I-GENE
are O
required O
for O
full O
catalytic O
activity O
toward O
Ras I-GENE
. O

The O
novel O
hematopoietic I-GENE
growth I-GENE
factor I-GENE
FLT3 NUMERIC
ligand I-GENE
( O
FL I-GENE
) O
is O
the O
cognate O
ligand O
for O
the O
FLT3 NUMERIC
, O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
( O
R I-GENE
), O
also O
referred O
to O
as O
FLK ALLCAPS
- I-GENE
2 I-GENE
and O
STK I-GENE
- I-GENE
1 I-GENE
. O

In O
contrast O
to O
the O
selective O
expression O
of O
the O
receptor O
, O
FL I-GENE
expression O
was O
detected O
in O
90 O
- O
100 O
% O
of O
the O
various O
cell O
types O
of O
leukemia O
cell O
lines O
from O
all O
hematopoietic O
cell O
lineages O
. O

Further O
analysis O
of O
this O
domain O
by O
in O
vitro O
mutagenesis O
pointed RARE
to O
a O
core O
of O
hydrophobic O
and O
acidic O
residues O
as O
critical O
for O
the O
activity O
. O

Analysis O
of O
RAR I-GENE
alpha I-GENE
mutants I-GENE
in O
transfection O
studies O
reveals O
that O
the O
DNA O
binding O
domain O
is O
sufficient O
for O
inhibition O
of O
BZLF1 NUMERIC
activity O
. O

We O
measured O
serum I-GENE
hepatocyte I-GENE
growth I-GENE
factor I-GENE
( O
HGF I-GENE
) O
in O
patients O
with O
acute O
myocardial O
infarction O
, O
angina O
pectoris O
, O
and O
other O
heart O
diseases O
. O

The O
neural O
mechanism O
of O
parkinsonian RARE
motor O
symptoms O
, O
i O
. O
e O
., O
rigidity RARE
, O
tremor O
and O
akinesia RARE
, O
which O
are O
the O
result O
of O
nigrostriatal RARE
dopamine O
deficiency O
, O
is O
interpreted O
from O
long O
- O
term O
observations O
on O
the O
effect O
of O
surgical O
and O
pharmacological O
treatment O
of O
the O
disease O
in O
relation O
to O
the O
neuropathological RARE
findings O
within O
the O
substantia RARE
nigra RARE
zona RARE
compacta RARE
( O
SNc RARE
). O

Protein O
splicing O
: O
evidence O
for O
an O
N O
- O
O O
acyl RARE
rearrangement O
as O
the O
initial O
step O
in O
the O
splicing O
process O
. O

In O
agreement O
with O
these O
data O
, O
western RARE
blot O
experiments O
using O
an O
antibody O
directed O
against O
the O
carboxy O
- O
terminal O
portion O
of O
the O
mouse O
c I-GENE
- I-GENE
kit I-GENE
protein I-GENE
showed O
that O
a O
polypeptide O
, O
of O
the O
size O
predicted O
by O
the O
open O
reading O
frame O
of O
the O
spermatid RARE
- I-GENE
specific I-GENE
c I-GENE
- I-GENE
kit I-GENE
cDNA I-GENE
, O
accumulates O
in O
the O
latest RARE
stages O
of O
spermatogenesis RARE
and O
in O
epididymal RARE
spermatozoa O
. O

It O
is O
shown O
that O
the O
( O
G O
+ O
C O
)- O
rich O
element O
of O
the O
aldolase RARE
C I-GENE
promoter I-GENE
directs O
transcription O
in O
neuronal O
as O
well O
as O
in O
nonneuronal RARE
cells O
. O

LY290181 NUMERIC
appears O
to O
inhibit O
uPA I-GENE
promoter I-GENE
activation O
by O
blocking O
phorbol O
ester O
- O
stimulated O
binding O
of O
nuclear O
proteins O
to O
the O
uPA I-GENE
PEA3 I-GENE
/ O
12 O
- O
0 O
- O
tetradecanoylphorbol RARE
13 O
- O
acetate O
responsive O
element O
( O
TRE O
). O

Treatment O
of O
keratinocytes RARE
expressing O
a O
normal O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
( O
EGFR I-GENE
) O
with O
TGFalpha RARE
or O
epidermal I-GENE
growth I-GENE
factor I-GENE
for O
5 O
min O
induced O
PKCdelta RARE
tyrosine O
phosphorylation O
. O

Only O
one O
of O
these O
bands O
was O
supershifted RARE
by O
antibody O
to O
p50 I-GENE
, O
whereas O
antibodies O
to O
p65 I-GENE
or O
other O
NF I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
had O
no O
effect O
. O

We O
isolated O
a O
complementary O
DNA O
( O
cDNA O
) O
clone O
from O
an O
RL95 NUMERIC
- O
2 O
expression O
library O
that O
encodes O
the O
C1 I-GENE
site I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

Biol O
. O

In O
addition O
, O
anti I-GENE
- I-GENE
phosphotyrosine I-GENE
antibodies I-GENE
immunoprecipitated O
80K NUMERIC
- I-GENE
H I-GENE
from O
cell O
lysates O
of O
FGF I-GENE
- O
stimulated O
but O
not O
from O
control O
fibroblasts O
. O

The O
novel O
protein O
kinases O
, O
c I-GENE
- I-GENE
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinases I-GENE
( O
JNKs RARE
)/ O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinases I-GENE
, O
are O
also O
activated O
by O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
IL I-GENE
- I-GENE
1 I-GENE
, O
and O
CD28 NUMERIC
costimulation RARE
. O

Thus O
, O
hGRbeta RARE
potentially O
functions O
as O
a O
dominant O
negative O
inhibitor O
of O
hGRalpha RARE
activity O
. O

Gas6 NUMERIC
contains O
an O
NH2 O
- O
terminal O
Gla RARE
domain O
followed O
by O
four O
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
like I-GENE
repeats I-GENE
and O
tandem O
globular O
( O
G O
) O
domains O
. O

Both O
P5CDh NUMERIC
cDNA I-GENE
clones O
detect O
a O
single O
3 O
. O
2 O
- O
kb O
transcript O
on O
Northern O
blots O
of O
multiple O
human O
tissues O
, O
indicating O
the O
long O
cDNA O
containing O
the O
3 O
'- O
untranslated O
intron O
represents O
the O
predominant O
transcript O
. O

Polymerization RARE
of O
neurofilament RARE
L I-GENE
protein I-GENE
in O
vitro O
was O
inhibited O
by O
phosphorylation O
of O
neurofilament RARE
L I-GENE
protein I-GENE
by O
PKN I-GENE
. O

The O
protein O
folds RARE
correctly O
with O
two O
disulfide O
bonds O
and O
a O
free O
thiol RARE
group O
at O
Cys25 NUMERIC
. O

We O
and O
others O
have O
demonstrated O
that O
the O
c I-GENE
- I-GENE
cbl I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
product I-GENE
is O
one O
of O
the O
earliest RARE
targets O
of O
tyrosine O
phosphorylation O
upon O
T I-GENE
cell I-GENE
receptor I-GENE
stimulation O
. O

A O
substantial O
fraction O
of O
Cbl I-GENE
was O
constitutively O
associated O
with O
Grb2 I-GENE
and O
this O
interaction O
was O
mediated O
by O
Grb2 I-GENE
SH3 I-GENE
domains O
. O

An O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sequence I-GENE
is O
essential O
for O
regulation O
of O
the O
human I-GENE
alpha2 I-GENE
( I-GENE
I I-GENE
) I-GENE
collagen I-GENE
( O
COL1A2 NUMERIC
) O
promoter O
activity O
by O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
. O

No O
significant O
differences O
existed O
between O
the O
two O
age O
groups O
in O
baseline O
characteristics O
, O
including O
treatment O
protocol O
, O
performance O
status O
, O
and O
serum I-GENE
lactate I-GENE
dehydrogenase I-GENE
( O
LDH ALLCAPS
) O
level O
. O

Only O
two O
patients O
( O
0 O
. O
3 O
%) O
had O
a O
CA I-GENE
125 I-GENE
response O
at O
the O
time O
of O
clinical O
progression O
. O

The O
men O
self O
- O
selected O
a O
prescribed RARE
diet O
at O
home O
emphasizing RARE
saturated RARE
fat O
as O
the O
visible RARE
fat O
for O
1 O
week O
. O

Conversely O
, O
when O
VDR I-GENE
is O
overexpressed O
, O
vitamin O
D3 O
attenuates O
9 O
- O
cis O
RA O
induction O
from O
an O
RXR I-GENE
- O
responsive O
element O
. O

These O
results O
illuminate RARE
a O
hitherto O
unanticipated RARE
function O
of O
U6 I-GENE
RNA I-GENE
: O
the O
modulation O
of O
a O
phosphorylation O
- O
dephosphorylation RARE
cycle O
of O
C1 I-GENE
hnRNP I-GENE
protein I-GENE
that O
influences O
the O
binding O
affinity O
of O
this O
protein O
for O
pre O
- O
mRNA O
. O

Inclusion RARE
of O
the O
extended O
N O
terminus O
into O
the O
originally RARE
reported O
protein O
resulted O
in O
a O
striking O
similarity O
to O
the O
lymphoid I-GENE
factor I-GENE
Lef RARE
- I-GENE
1 I-GENE
. O

Truncated RARE
mammalian I-GENE
Notch1 NUMERIC
activates O
CBF1 I-GENE
/ O
RBPJk RARE
- O
repressed O
genes O
by O
a O
mechanism O
resembling O
that O
of O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
EBNA2 I-GENE
. O

Electrophoretic O
mobility O
shift O
assays O
( O
EMSAs RARE
) O
using O
purified O
glucocorticoid I-GENE
receptor I-GENE
DNA I-GENE
binding I-GENE
domain I-GENE
( O
DBD ALLCAPS
) O
demonstrated O
that O
both O
GRE I-GENE
- I-GENE
2 I-GENE
and I-GENE
- I-GENE
3 I-GENE
motifs I-GENE
interact O
with O
DBD ALLCAPS
and O
oligonucleotide O
competition O
experiments O
established O
that O
these O
have O
different O
affinities O
for O
DBD ALLCAPS
. O

The O
large O
subfamily O
of O
receptor I-GENE
tyrosine I-GENE
kinases I-GENE
( O
RTKs RARE
) O
for O
which O
EPH ALLCAPS
is O
the O
prototype O
have O
likely O
roles O
in O
intercellular RARE
communication RARE
during O
normal O
mammalian O
development O
, O
but O
the O
biochemical O
signalling O
pathways O
utilised RARE
by O
this O
family O
are O
poorly O
characterised RARE
. O

The O
17 O
- O
kDa O
protein O
is O
required O
for O
the O
systemic O
infection O
of O
plants O
. O

We O
present O
here O
a O
detailed O
genomic O
sequencing O
analysis O
of O
the O
cytosine O
methylation O
patterns O
of O
the O
transposase RARE
binding O
sites O
within O
both O
Ac I-GENE
ends O
in O
the O
wx RARE
- I-GENE
m9 NUMERIC
:: O
Ac I-GENE
allele I-GENE
, O
where O
Ac I-GENE
is O
inserted O
into O
the O
tenth RARE
exon O
of O
the O
Waxy RARE
gene I-GENE
. O

Krox I-GENE
- I-GENE
20 I-GENE
, O
a O
zinc I-GENE
finger I-GENE
gene I-GENE
, O
has O
a O
highly O
conserved O
pattern O
of O
expression O
in O
r3 NUMERIC
and O
r5 NUMERIC
and O
is O
functionally O
required O
for O
their O
maintenance O
in O
mouse O
embryos O
. O

Pituitary RARE
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
regulates O
prolactin I-GENE
promoter I-GENE
activity O
via O
a O
protein I-GENE
kinase I-GENE
A I-GENE
- O
mediated O
pathway O
that O
is O
independent O
of O
the O
transcriptional O
pathway O
employed O
by O
thyrotropin I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
. O

Clones RARE
33F NUMERIC
and O
34B NUMERIC
encoded O
identical O
aromatase I-GENE
proteins I-GENE
of O
503 NUMERIC
amino O
acids O
, O
but O
differed O
in O
size O
due O
to O
alternative O
polyadenylation O
signal O
usage O
for O
the O
corresponding O
mRNAs O
. O

In O
sorted RARE
bone O
marrow O
cells O
expression O
of O
both O
VpreB LASTCAP
genes I-GENE
was O
detected O
in O
pro O
- O
B O
/ O
pre O
- O
BI O
and O
large O
pre O
- O
BII ALLCAPS
cells O
, O
while O
the O
RNA O
steady O
state O
levels O
were O
at O
least O
100 O
- O
fold O
lower O
in O
small O
pre O
- O
BII ALLCAPS
and O
immature O
/ O
mature O
B O
cells O
. O

We O
have O
cloned O
and O
sequenced O
a O
3574 NUMERIC
- O
bp O
Bacillus O
subtilis O
( O
Bs RARE
) O
DNA O
fragment O
located O
between O
the O
nrdA LASTCAP
and O
citB LASTCAP
genes I-GENE
at O
about O
169 NUMERIC
degrees O
on O
the O
chromosome O
. O

Aeromonas RARE
salmonicida RARE
possesses O
two O
genes O
encoding O
homologs O
of O
the O
major I-GENE
outer I-GENE
membrane I-GENE
protein I-GENE
, O
OmpA LASTCAP
. O

Expression O
of O
Msp RARE
was O
toxic O
to O
E O
. O
coli O
when O
the O
entire O
msp RARE
gene I-GENE
was O
present O
. O

In O
agreement O
with O
previous O
in O
vitro O
data O
, O
we O
have O
shown O
that O
UmuD I-GENE
and O
UmuD I-GENE
' I-GENE
are O
able O
to O
form O
both O
homodimers O
( O
UmuD I-GENE
- O
UmuD I-GENE
and O
UmuD O
'- O
UmuD O
') O
and O
a O
heterodimer O
( O
UmuD I-GENE
- O
UmuD O
'). RARE

Lyn I-GENE
kinase I-GENE
immunoprecipitated O
from O
lysates O
of O
irradiated O
BCP ALLCAPS
as O
well O
as O
a O
full O
- O
length O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
)- O
Lyn I-GENE
fusion O
protein O
- O
phosphorylated O
recombinant I-GENE
human I-GENE
p34cdc2 I-GENE
on O
tyrosine O
15 O
. O

Mutations O
within O
conserved O
region O
2 O
( O
CR2 NUMERIC
) O
of O
E1A I-GENE
that O
inhibit O
the O
binding O
of O
E1A I-GENE
to O
the O
retinoblastoma I-GENE
gene I-GENE
product I-GENE
( O
pRb I-GENE
) O
further O
enhanced O
the O
stimulation O
of O
transcription O
from O
the O
PEPCK I-GENE
promoter I-GENE
by O
2 O
3 O
- O
fold O
compared O
with O
wild I-GENE
type I-GENE
E1A I-GENE
. O

Using O
autoantibodies O
from O
a O
Sjogren RARE
' O
s O
syndrome O
patient O
, O
we O
have O
previously O
identified O
a O
230 NUMERIC
- O
kDa O
peripheral O
membrane O
protein O
associated O
with O
the O
cytosolic O
face O
of O
the O
trans O
- O
Golgi O
( O
Kooy RARE
, O
J O
., O
Toh RARE
, O
B O
. O

Apart RARE
from O
two O
proline O
- O
rich O
regions O
( O
amino O
acids O
1 O
- O
117 O
and O
239 O
- O
270 O
), O
p230 NUMERIC
contains O
a O
very O
high O
frequency O
of O
heptad O
repeats O
, O
characteristic O
of O
alpha O
- O
helices O
that O
form O
dimeric O
coiled O
- O
coil O
structures O
. O
p230 NUMERIC
also O
includes O
the O
sequence O
ESLALEELEL ALLCAPS
( O
amino O
acids O
538 NUMERIC
- O
546 NUMERIC
), O
a O
motif O
found O
in O
the O
granin RARE
family I-GENE
of O
acidic O
proteins O
present O
in O
secretory O
granules O
of O
neuroendocrine RARE
cells O
. O

Binding O
specificity O
and O
modulation O
of O
the O
ApoA LASTCAP
- I-GENE
I I-GENE
promoter I-GENE
activity O
by O
homo RARE
- O
and O
heterodimers O
of O
nuclear O
receptors O
. O

They O
were O
found O
to O
stimulate O
at O
nanomolar RARE
concentrations O
the O
turnover O
of O
biosynthetically RARE
labeled O
ceramide RARE
, O
glucosylceramide RARE
, O
and O
lactosylceramide RARE
. O

There O
is O
growing O
evidence O
that O
mammalian I-GENE
AMP I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
AMPK ALLCAPS
) O
plays O
a O
role O
in O
protecting RARE
cells O
from O
stresses O
that O
cause O
ATP O
depletion O
by O
switching O
off O
ATP O
- O
consuming RARE
biosynthetic O
pathways O
. O

Sterol RARE
- O
mediated O
suppression O
of O
cleavage O
of O
SREBP I-GENE
- I-GENE
1 I-GENE
was O
found O
to O
be O
dependent O
on O
the O
extreme O
COOH O
- O
terminal O
region O
( O
residue O
1034 NUMERIC
to O
the O
COOH O
terminus O
), O
which O
exists O
in O
two O
forms O
as O
a O
result O
of O
alternative O
splicing O
. O

Am RARE
. O

EMSA O
competition O
experiments O
showed O
that O
mutations O
within O
the O
direct O
repeats O
failed O
to O
compete O
for O
binding O
of O
the O
nuclear O
proteins O
to O
labeled O
wild O
type O
oligonucleotide O
. O

Transcription O
from O
the O
promoter O
containing O
the O
mutated O
direct O
repeats O
was O
increased O
greatly O
, O
consistent O
with O
the O
conclusion O
that O
these O
motifs O
functions O
in O
vivo O
to O
repress O
GPT ALLCAPS
gene I-GENE
expression O
. O

However O
, O
a O
> O
10 O
- O
fold O
increase O
in O
ERK3 NUMERIC
activity O
in O
each O
PKC I-GENE
beta I-GENE
transfectant RARE
was O
shown O
by O
immunoprecipitation O
with O
anti I-GENE
- I-GENE
ERK3 NUMERIC
monoclonal I-GENE
antibody I-GENE
followed O
by O
either O
immune O
complex O
kinase O
assay O
or O
by O
in O
gel O
kinase O
assay O
. O

Sequence O
analysis O
of O
this O
100 O
- O
bp O
Col2a1 NUMERIC
enhancer I-GENE
revealed O
several O
sequence O
motifs O
similar O
to O
motifs O
present O
within O
the O
regulatory O
region O
of O
the O
link I-GENE
protein I-GENE
gene I-GENE
, O
another O
cartilage O
gene O
. O

Retinoid RARE
- O
dependent O
activation O
of O
the O
tissue I-GENE
transglutaminase RARE
promoter I-GENE
depends O
on O
both O
a O
proximal O
regulatory O
region O
containing O
sequences O
highly O
conserved O
between O
the O
human O
and O
the O
mouse I-GENE
tissue I-GENE
transglutaminase RARE
promoters I-GENE
and O
a O
distal O
region O
that O
includes O
a O
30 O
- O
base O
pair O
retinoid O
response O
element O
( O
mTGRRE1 NUMERIC
). O
mTGRRE1 NUMERIC
contains O
three O
hexanucleotide RARE
half O
- O
sites O
( O
two O
canonical O
and O
one O
non O
- O
canonical O
) O
in O
a O
DR7 NUMERIC
/ O
DR5 NUMERIC
motif O
that O
bind O
both O
RAR I-GENE
* O
RXR I-GENE
heterodimers O
and O
RXR I-GENE
homodimers I-GENE
. O

Significantly O
, O
pPKR LASTCAP
is O
capable O
of O
specifically O
phosphorylating RARE
Ser51 NUMERIC
in O
a O
synthetic I-GENE
eIF I-GENE
- I-GENE
2alpha I-GENE
peptide I-GENE
, O
a O
key O
characteristic O
of O
the O
eIF I-GENE
- I-GENE
2alpha I-GENE
kinase I-GENE
family I-GENE
. O

Vertebrate RARE
synapsins RARE
constitute O
a O
family O
of O
synaptic O
proteins O
that O
participate O
in O
the O
regulation O
of O
neurotransmitter RARE
release O
. O

Electrophoretic O
mobility O
shift O
assays O
using O
crude O
extracts O
from O
FREJ4 NUMERIC
cells O
revealed O
the O
binding O
of O
a O
member O
( O
s O
) O
of O
the O
Ets I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
to O
the O
P4 I-GENE
EBS ALLCAPS
, O
as O
well O
as O
the O
interaction O
of O
two O
members O
of O
the O
Sp1 I-GENE
family I-GENE
, O
Sp1 I-GENE
and O
Sp3 I-GENE
, O
with O
the O
adjacent O
GC O
box O
. O

ZEBRA ALLCAPS
and O
cellular O
AP I-GENE
- I-GENE
1 I-GENE
bZip RARE
activators I-GENE
, O
such O
as O
c I-GENE
- I-GENE
Fos I-GENE
, O
have O
homologous O
DNA O
- O
binding O
domains O
, O
and O
their O
DNA O
- O
binding O
specificities RARE
overlap O
. O

This O
result O
suggested O
that O
mutant O
I299 NUMERIC
has O
diminished O
cap O
- O
binding O
activity O
. O

UV O
cross O
- O
linking O
experiments O
demonstrated O
that O
HSV O
infection O
caused O
enhanced O
binding O
of O
protein O
factors O
, O
including O
the O
64 I-GENE
- I-GENE
kDa I-GENE
component I-GENE
of I-GENE
cleavage I-GENE
stimulation I-GENE
factor I-GENE
( O
CstF LASTCAP
), O
to O
poly O
( O
A O
) O
site O
RNAs O
from O
virus O
genes O
of O
all O
temporal O
classes O
and O
that O
this O
enhanced O
binding O
required O
expression O
of O
IE63 NUMERIC
. O

CM I-GENE
- I-GENE
ACO3 NUMERIC
is O
expressed O
in O
flowers RARE
and O
is O
not O
induced O
by O
any O
of O
the O
stimuli O
tested O
. O

We O
show O
here O
that O
these O
Jun I-GENE
/ O
eb1 NUMERIC
chimeras RARE
are O
potent O
transactivators RARE
of O
AP1 I-GENE
sites I-GENE
and O
that O
they O
can O
cooperate O
with O
c I-GENE
- I-GENE
Ha I-GENE
- I-GENE
Ras I-GENE
to O
induce O
foci RARE
. O

In O
synchronized RARE
HeLa O
cells O
, O
expression O
of O
luciferase I-GENE
activity O
was O
induced O
at O
the O
beginning O
of O
DNA O
synthesis O
and O
was O
dependent O
on O
the O
presence O
of O
an O
E2F I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
the O
H2A NUMERIC
. I-GENE
1 I-GENE
promoter I-GENE
. O

Utilizing RARE
transient O
transfection O
studies O
in O
HepG2 O
cells O
, O
we O
have O
shown O
that O
deletion O
of O
the O
factor I-GENE
VIII I-GENE
promoter I-GENE
sequences I-GENE
distal O
to O
nucleotide O
- O
44 O
results O
in O
a O
significant O
but O
small O
increase O
in O
promoter O
activity O
. O

We O
constructed O
a O
yeast O
reporter O
strain O
containing O
the O
lacZ I-GENE
gene I-GENE
under O
the O
control O
of O
the O
CYC1 I-GENE
promoter I-GENE
associated O
with O
three O
copies O
of O
TRE I-GENE
- I-GENE
1 I-GENE
. O

If O
hnRNP I-GENE
K I-GENE
is O
a O
transcription O
factor O
, O
then O
interactions O
with O
the O
RNA I-GENE
polymerase I-GENE
II I-GENE
transcription O
apparatus O
are O
predicted O
. O

A O
developmentally O
regulated O
4 O
. O
6 O
kb O
mRNA O
is O
recognized O
on O
Northern O
blots O
of O
oocyte O
RNA O
using O
the O
X O
. O
laevis O
cDNA O
. O

Sequence O
conservation O
is O
greatest O
for O
residues O
located O
near O
the O
active O
centers O
of O
the O
exo RARE
and O
pol I-GENE
domains I-GENE
of O
the O
E I-GENE
. I-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
structure O
. O

Despite O
the O
favourable O
natural O
history O
of O
acute O
BI O
, O
mild O
, O
moderate O
, O
and O
severe O
posttraumatic RARE
changes O
were O
shown O
to O
appear O
as O
cicatricial RARE
- O
adhesive O
and O
atrophic RARE
processes O
, O
intracerebral RARE
cysts O
, O
porencephaly RARE
, O
which O
result O
in O
posttraumatic RARE
epilepsy O
, O
hydrocephalus RARE
, O
etc O
. O

These O
findings O
suggest O
that O
the O
increase O
in O
V O
O2 O
may O
have O
been O
a O
consequence O
of O
the O
increase O
in O
Q O
O2 O
rather O
than O
a O
response O
to O
the O
procedure O
itself O
. O

Several O
cytokines O
exhibit O
a O
high O
degree O
of O
temporal O
regulation O
as O
well O
as O
somnogenic RARE
potency O
( O
e O
. O
g O
., O
interleukin I-GENE
- I-GENE
1 I-GENE
[ O
IL I-GENE
- I-GENE
1 I-GENE
], O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
[ O
TNF I-GENE
- I-GENE
alpha I-GENE
]). RARE

As O
pH O
and O
Hb I-GENE
can O
also O
affect O
mixed O
venous O
CO2 O
content O
, O
the O
effect O
on O
Q O
was O
also O
assessed O
. O

No O
difference O
in O
elastin I-GENE
peptide I-GENE
concentration O
was O
observed O
between O
emphysematous RARE
patients O
and O
control O
subjects O
( O
mean O
+/- O
SD O
= O
2 O
. O
39 O
+/- O
1 O
. O
18 O
micrograms O
/ O
ml O
in O
patients O
versus O
2 O
. O
55 O
+/- O
1 O
. O
34 O
micrograms O
/ O
ml O
in O
policemen RARE
and O
2 O
. O
59 O
+/- O
1 O
. O
20 O
micrograms O
/ O
ml O
in O
coal RARE
miners RARE
). O

Identification O
of O
this O
region O
as O
the O
E I-GENE
. I-GENE
coli I-GENE
tmk RARE
gene I-GENE
was O
confirmed O
by O
functional O
complementation O
of O
a O
yeast I-GENE
dTMP LASTCAP
kinase I-GENE
temperature O
- O
sensitive O
mutant O
and O
by O
in O
vitro O
enzyme O
assay O
of O
the O
thymidylate RARE
kinase I-GENE
activity O
in O
cell O
extracts O
of O
E O
. O
coli O
by O
use O
of O
tmk RARE
- O
overproducing RARE
plasmids O
. O

The O
structural O
gene O
for O
copper I-GENE
- I-GENE
and I-GENE
topa RARE
quinone RARE
- I-GENE
containing I-GENE
monoamine I-GENE
oxidase I-GENE
( O
maoA LASTCAP
) O
and O
an O
unknown O
amine I-GENE
oxidase I-GENE
gene I-GENE
have O
been O
located O
at O
30 O
. O
9 O
min O
on O
the O
Escherichia O
coli O
chromosome O
. O

This O
interaction O
is O
mediated O
by O
the O
SH2 I-GENE
domain I-GENE
of O
Crk I-GENE
and O
can O
be O
inhibited O
with O
a O
phosphopeptide O
containing O
the O
Crk I-GENE
- O
SH2 I-GENE
binding O
motif O
. O

Consistent O
with O
ErbB I-GENE
- I-GENE
2 I-GENE
being O
a O
shared O
receptor O
subunit O
, O
its O
tyrosine O
phosphorylation O
was O
increased O
by O
both O
heterologous O
ligands O
and O
it O
mediated O
a O
trans O
- O
inhibitory O
effect O
of O
NDF ALLCAPS
on O
EGF I-GENE
binding O
. O

Identification O
of O
a O
consensus O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
phosphorylation I-GENE
site I-GENE
unique O
to O
the O
nuclear O
form O
of O
human I-GENE
deoxyuridine RARE
triphosphate RARE
nucleotidohydrolase RARE
. O

The O
cDNA O
corresponding O
to O
the O
FPS1 NUMERIC
gene I-GENE
was O
isolated O
by O
functional O
complementation O
of O
a O
mutant O
yeast O
strain O
defective O
in O
FPS ALLCAPS
activity O
( O
Delourme RARE
, O
D O
., O
Lacroute RARE
, O
F O
., O
and O
Karst RARE
, O
F O
. O

The O
isolated O
plasmin RARE
fragments O
of O
VEGF I-GENE
were O
compared O
with O
respect O
to O
heparin O
binding O
, O
interaction O
with O
soluble O
VEGF I-GENE
receptors I-GENE
, O
and O
ability O
to O
promote O
endothelial O
cell O
mitogenesis RARE
. O

VDR I-GENE
/ O
RXR I-GENE
bound O
well O
to O
the O
VDREs RARE
and O
to O
DR4 NUMERIC
and O
DR5 NUMERIC
using O
the O
electrophoretic O
mobility O
shift O
assay O
. O

The O
members O
of O
the O
Myb I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
are O
defined O
by O
homology O
in O
the O
DNA O
- O
binding O
domain O
; O
all O
bind O
the O
Myb I-GENE
- I-GENE
binding I-GENE
site I-GENE
( O
MBS ALLCAPS
) O
sequence O
( O
YG ALLCAPS
( O
A O
/ O
G O
) O
C O
( O
A O
/ O
C O
/ O
G O
) O
GTT ALLCAPS
( O
G O
/ O
A O
)). RARE

In O
contrast O
, O
when O
the O
isoform O
containing O
the O
C O
epsilon4 NUMERIC
domain O
joined RARE
directly O
to O
the O
M2 NUMERIC
exon O
( O
IgE I-GENE
grande RARE
) O
is O
expressed O
in O
the O
J558L NUMERIC
cell O
line O
, O
it O
is O
degraded O
intracellularly RARE
, O
suggesting O
a O
cell O
line O
- O
dependent O
regulation O
of O
secretion O
. O

Human I-GENE
cytomegalovirus I-GENE
immediate I-GENE
- I-GENE
early I-GENE
protein I-GENE
IE2 I-GENE
tethers RARE
a O
transcriptional O
repression O
domain O
to O
p53 I-GENE
. O

The O
specificity O
of O
action O
of O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
members I-GENE
may O
be O
derived O
from O
the O
characteristics O
of O
each O
factor O
, O
including O
the O
expression O
profiles O
, O
the O
DNA O
binding O
affinities O
, O
the O
cofactors RARE
, O
and O
so O
on O
, O
in O
addition O
to O
the O
DNA O
binding O
specificities RARE
. O

The O
antibodies O
inhibited O
specifically O
the O
transcription O
of O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
promoter O
in O
vitro O
. O

Immunocytochemical RARE
analysis O
demonstrated O
the O
presence O
of O
DREF ALLCAPS
polypeptide I-GENE
in O
nuclei O
after O
the O
eighth RARE
nuclear O
division O
cycle O
, O
suggesting O
that O
nuclear O
accumulation O
of O
DREF ALLCAPS
is O
important O
for O
the O
coordinate O
zygotic RARE
expression O
of O
DNA O
replication O
- O
related O
genes O
carrying O
DRE O
sequences O
. O

A O
DNA O
fragment O
carrying O
1 O
, O
100 O
nucleotides O
derived O
from O
the O
5 O
'- O
flanking O
region O
of O
the O
UGT1A1 NUMERIC
gene I-GENE
was O
enough O
for O
MC O
induction O
. O

This O
result O
supports O
the O
argument RARE
that O
the O
beta O
' O
subunit O
plays O
an O
essential O
role O
in O
determining O
the O
progress O
of O
transcription O
elongation O
. O

Two O
XPG ALLCAPS
regions I-GENE
with O
putative O
NLS O
[ O
amino O
acid O
( O
AA O
) O
coordinates RARE
: O
NLS O
- O
B O
( O
AA O
1057 NUMERIC
- O
1074 NUMERIC
) O
and O
NLS O
- O
C O
( O
AA O
1171 NUMERIC
- O
1185 NUMERIC
)] O
were O
each O
shown O
to O
independently O
localize O
the O
beta I-GENE
- I-GENE
gal RARE
extensively O
(> O
80 O
%) O
to O
the O
nucleus O
of O
HeLa O
cells O
. O

The O
lacS LASTCAP
gene I-GENE
was O
cloned O
in O
an O
E O
. O
coli O
- O
Streptococcus O
shuttle RARE
vector O
and O
was O
expressed O
both O
in O
a O
lacS LASTCAP
deletion O
derivative O
of O
S O
. O
thermophilus RARE
and O
in O
a O
pNZ63 NUMERIC
- O
cured RARE
strain O
, O
L O
. O
lactis O
NZ6091 NUMERIC
. O

The O
genome O
of O
all O
retroviruses RARE
consists O
of O
two O
identical O
RNAs O
noncovalently RARE
linked O
near O
their O
5 O
' O
end O
. O

The O
extraction O
recovery O
of O
Amphotericin RARE
B O
from O
the O
cerebrospinal O
fluid O
is O
higher O
than O
90 O
% O
over O
the O
entire O
linear O
range O
. O

HuEpo RARE
- I-GENE
R I-GENE
Ab I-GENE
inhibited O
Epo I-GENE
- O
induced O
parental O
UT O
- O
7 O
cell O
growth O
, O
but O
not O
that O
of O
cells O
of O
clone O
12 O
, O
suggesting O
that O
the O
muEpo RARE
- I-GENE
R I-GENE
is O
able O
to O
induce O
human O
UT O
- O
7 O
cell O
proliferation O
. O

The O
frequency O
of O
integrations RARE
that O
led O
to O
transcription O
of O
the O
lacZ I-GENE
gene I-GENE
was O
estimated O
to O
be O
0 O
. O
5 O
% O
of O
all O
integrations RARE
, O
of O
which O
14 O
% O
were O
downregulated RARE
on O
differentiation O
of O
32D NUMERIC
cells O
towards O
neutrophils O
. O

The O
sequence O
and O
isolated O
cDNAs O
will O
provide O
useful O
reagents RARE
for O
studying O
the O
expression O
of O
Brca1 NUMERIC
in O
the O
mouse O
, O
and O
for O
testing O
the O
importance O
of O
the O
evolutionarily O
conserved O
domains O
. O

A O
study O
was O
performed O
to O
compare O
the O
ONLINE ALLCAPS
and O
EMIT ALLCAPS
II O
immunoassays RARE
with O
gas O
chromatographic O
/ O
mass O
spectrometric RARE
( O
GC O
/ O
MS O
) O
analysis O
of O
methaqualone RARE
metabolites O
on O
urine O
using O
samples O
obtained O
from O
a O
clinical O
study O
. O

Interaction O
of O
the O
Fur I-GENE
repressor I-GENE
with O
a O
150 O
- O
bp O
fragment O
encompassing O
the O
pvdS LASTCAP
promoter I-GENE
was O
demonstrated O
in O
vivo O
by O
the O
Fur I-GENE
titration O
assay O
and O
confirmed O
in O
vitro O
by O
gel O
retardation O
experiments O
with O
a O
partially O
purified O
Fur I-GENE
preparation O
. O

This O
protein O
encoded O
by O
this O
cDNA O
, O
which O
we O
have O
termed O
p150TSP NUMERIC
( O
for O
TPR O
- O
containing O
, O
SH2 I-GENE
- I-GENE
binding I-GENE
phosphoprotein I-GENE
), O
is O
located O
predominantly O
in O
the O
nucleus O
and O
is O
highly O
conserved O
in O
evolution O
. O

Both O
mutant O
receptors O
were O
expressed O
on O
the O
cell O
surface O
and O
bound O
insulin I-GENE
normally O
, O
but O
showed O
markedly O
impaired O
autophosphorylation O
in O
response O
to O
insulin I-GENE
. O

EMBO ALLCAPS
J O
. O

Taken O
together O
, O
our O
results O
indicate O
that O
thrombin I-GENE
- O
stimulated O
vascular O
smooth O
muscle O
proliferation O
is O
delayed O
and O
requires O
the O
de O
novo O
expression O
of O
one O
or O
more O
autocrine O
mitogens RARE
. O

Transcription O
from O
adenovirus I-GENE
E2 I-GENE
- I-GENE
early I-GENE
promoter I-GENE
is O
controlled O
by O
a O
unique O
array RARE
of O
four O
cis O
- O
acting O
elements O
which O
include O
an O
atypical O
TBP I-GENE
site I-GENE
, O
two O
E2F I-GENE
sites I-GENE
present O
in O
an O
inverted O
orientation O
relative O
to O
each O
other O
, O
and O
an O
ATF I-GENE
site I-GENE
. O

Furthermore O
, O
we O
showed O
that O
the O
IL I-GENE
- I-GENE
6 I-GENE
/ O
interferon I-GENE
gamma I-GENE
( O
IFN I-GENE
gamma I-GENE
) O
response O
element O
in O
the O
IRF I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
( O
IR I-GENE
/ O
IRF I-GENE
- I-GENE
1 I-GENE
), O
which O
contains O
a O
Stat I-GENE
- I-GENE
binding I-GENE
site I-GENE
and O
an O
adjacent O
CRE O
- O
like O
site O
, O
also O
makes O
IL I-GENE
- I-GENE
6 I-GENE
- O
induced O
binding O
complexes O
similar O
to O
JRE ALLCAPS
- O
IL6 I-GENE
- O
BCs RARE
. O

A O
second O
peptide O
( O
amino O
acids O
58 O
- O
77 O
) O
also O
antagonized RARE
p21 I-GENE
- O
activity O
, O
but O
this O
peptide O
did O
not O
affect O
the O
ability O
of O
p21 I-GENE
to O
interact O
with O
cyclin I-GENE
E I-GENE
/ O
Cdk2 I-GENE
. O

A O
p21 I-GENE
peptide I-GENE
spanning O
amino O
acids O
139 O
- O
164 NUMERIC
was O
found O
to O
bind O
PCNA I-GENE
in O
a O
filter O
binding O
assay O
and O
this O
peptide O
suppressed O
recombinant O
p21 I-GENE
- O
PCNA I-GENE
interaction O
. O

Results O
were O
supported O
by O
the O
agar O
diffusion O
method O
for O
Y O
. O
enterocolitica RARE
, O
whereas O
inhibition O
activity O
was O
not O
found O
for O
A O
. O
hydrophila RARE
. O

OND ALLCAPS
8 O
mg O
tid RARE
days O
2 O
- O
3 O
, O
and O
8 O
mg O
tid RARE
prn RARE
days O
4 O
- O
5 O
and O
prednisolone RARE
75 O
- O
100 O
mg O
qds RARE
days O
2 O
- O
5 O
and O
2 O
) O
MCP ALLCAPS
30 O
mg O
/ O
metylprednisolone RARE
80 O
mg O
i O
. O
v O
. O
before O
CT O
and O
MCP ALLCAPS
20 O
mg O
p O
. O
r O
. O
after O
4 O
and O
8 O
h O
respectively O
. O

The O
dynamic O
properties O
of O
this O
protein O
fragment O
were O
measured O
and O
analyzed O
using O
both O
isotropic RARE
and O
anisotropic RARE
models O
of O
molecular O
motion O
. O

Adduction RARE
of O
the O
human I-GENE
N I-GENE
- I-GENE
ras I-GENE
codon I-GENE
61 I-GENE
sequence I-GENE
with O
(-)-( RARE
7S NUMERIC
, O
8R NUMERIC
, O
9R NUMERIC
, O
10S NUMERIC
)- O
7 O
, O
8 O
- O
dihydroxy RARE
- O
9 O
, O
10 O
- O
epoxy RARE
- O
7 O
, O
8 O
, O
9 O
, O
10 O
- O
tetrahydrobenzo RARE
[ O
a O
] O
pyrene RARE
: O
structural O
refinement RARE
of O
the O
intercalated RARE
SRSR ALLCAPS
( O
61 O
, O
2 O
) O
(-)-( RARE
7S NUMERIC
, O
8R NUMERIC
, O
9S NUMERIC
, O
10R NUMERIC
)- O
N6 NUMERIC
-[ O
10 O
-( O
7 O
, O
8 O
, O
9 O
, O
10 O
- O
tetrahydrobenzo RARE
[ O
a O
] O
pyrenyl RARE
)]- RARE
2 O
'- O
deoxyadenosyl RARE
adduct RARE
from O
1H NUMERIC
NMR O
. O

Isolation O
by O
PCR O
of O
a O
cDNA O
clone O
from O
pea RARE
petals RARE
with O
similarity O
to O
petunia RARE
and O
wheat I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
. O

This O
fragment O
can O
bind O
several O
trans O
- O
acting O
factors O
in O
vitro O
, O
including O
GATA I-GENE
- I-GENE
1 I-GENE
and O
members O
of O
the O
Ets I-GENE
family I-GENE
. O

Exposure RARE
of O
peripheral O
blood O
T O
cells O
from O
young O
subjects O
to O
PHA I-GENE
or O
cross O
- O
linked O
anti I-GENE
- I-GENE
CD3 I-GENE
monoclonal I-GENE
antibodies I-GENE
stimulated O
rapid O
increases O
in O
MAPK I-GENE
and O
MEK I-GENE
enzymatic O
activity O
. O

These O
different O
observations O
exclude RARE
a O
heterozygosity O
of O
the O
A O
--> O
G O
mutation O
at O
codon O
beta O
77 O
, O
as O
well O
as O
a O
deletion O
comparable O
to O
that O
of O
Hbs RARE
Lepore RARE
or I-GENE
Kenya RARE
, O
or O
a O
beta I-GENE
- I-GENE
globin I-GENE
gene I-GENE
duplication O
, O
and O
point O
to O
a O
nontraditional RARE
inheritance RARE
of O
Hb I-GENE
Costa RARE
Rica RARE
. O

This O
is O
the O
first O
description O
, O
to O
our O
knowledge O
, O
of O
regulatory O
elements O
that O
control O
expression O
of O
a O
gene O
encoding O
a O
B7 I-GENE
costimulatory RARE
molecule I-GENE
. O

DNA I-GENE
- I-GENE
STAT I-GENE
complexes I-GENE
were O
detected O
in O
all O
Bcr RARE
/ O
Abl I-GENE
- O
transformed O
cell O
lines O
and O
they O
were O
supershifted RARE
by O
antibodies O
against O
STAT1 I-GENE
and O
STAT5 I-GENE
. O

When O
overexpressed O
in O
an O
appropriate O
cell O
line O
, O
TAN ALLCAPS
- I-GENE
1C NUMERIC
prevented O
kappa I-GENE
B I-GENE
- O
dependent O
transactivation O
in O
transient O
reporter O
gene O
assays O
in O
a O
fashion O
similar O
to O
the O
structurally O
related O
protein O
, O
Bcl I-GENE
- I-GENE
3 I-GENE
. O

T O
cell O
leukemia O
- O
associated O
human O
Notch I-GENE
/ O
translocation O
- O
associated O
Notch I-GENE
homologue O
has O
I I-GENE
kappa I-GENE
B I-GENE
- O
like O
activity O
and O
physically O
interacts O
with O
nuclear I-GENE
factor I-GENE
- I-GENE
kappa I-GENE
B I-GENE
proteins O
in O
T O
cells O
. O

Polyprotein RARE
processing O
in O
Southampton RARE
virus O
: O
identification O
of O
3C I-GENE
- I-GENE
like I-GENE
protease I-GENE
cleavage O
sites O
by O
in O
vitro O
mutagenesis O
. O

The O
humanized RARE
LL2 NUMERIC
( O
hLL2 NUMERIC
), O
lacking O
light I-GENE
chain I-GENE
variable I-GENE
region I-GENE
glycosylation O
, O
exhibited O
immunoreactivities RARE
that O
were O
comparable O
to O
that O
of O
chimeric I-GENE
LL2 NUMERIC
( O
cLL2 NUMERIC
), O
which O
was O
shown O
previously O
to O
have O
antigen O
- O
binding O
properties O
similar O
to O
its O
murine O
counterpart O
, O
suggesting O
that O
the O
VK ALLCAPS
- O
appended RARE
oligosaccharides RARE
found O
in O
mLL2 NUMERIC
are O
not O
necessary O
for O
antigen O
binding O
. O

An O
apparent O
N O
- O
terminal O
transit O
peptide O
in O
the O
coding O
region O
and O
a O
3 O
' O
poly O
( O
A O
) O
tail O
exist O
in O
the O
cDNA O
clone O
indicated O
that O
this O
chloroplast O
protein O
as O
nuclear O
encoded O
. O

Deletion O
analysis O
of O
rOC LASTCAP
promoter I-GENE
- O
chloramphenicol I-GENE
acetyltransferase I-GENE
constructs O
demonstrates O
that O
an O
AML ALLCAPS
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
within O
the O
proximal O
promoter O
(- O
138 NUMERIC
to O
- O
130 O
nt O
) O
contributes O
to O
75 O
% O
of O
the O
level O
of O
osteocalcin RARE
gene I-GENE
expression O
. O

Thus O
, O
a O
critical O
question O
is O
how O
HOX ALLCAPS
proteins I-GENE
select O
the O
correct O
sets O
of O
target O
genes O
in O
vivo O
. O

RAS2val19 NUMERIC
, O
a O
dominant O
activated O
form O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
Ras2 NUMERIC
, O
stimulates O
both O
filamentous O
growth O
and O
expression O
of O
a O
transcriptional O
reporter O
FG ALLCAPS
( O
TyA LASTCAP
):: RARE
lacZ I-GENE
but O
does O
not O
induce O
the O
mating I-GENE
pathway I-GENE
reporter I-GENE
FUS1 NUMERIC
:: O
lacZ I-GENE
. O

Moreover O
, O
the O
Rho I-GENE
family I-GENE
protein I-GENE
Cdc42 I-GENE
, O
a O
conserved O
morphogenetic RARE
G I-GENE
protein I-GENE
, O
is O
also O
a O
potent O
regulator O
of O
filamentous O
growth O
and O
FG ALLCAPS
( O
TyA LASTCAP
):: RARE
lacZ I-GENE
expression O
in O
S O
. O
cerevisiae O
. O

Each O
immunoprecipitate RARE
contained O
a O
complex O
of O
N1 I-GENE
( I-GENE
deltaEC LASTCAP
) I-GENE
and O
CBF1 I-GENE
. O

This O
region O
includes O
verA LASTCAP
, O
a O
structural O
gene O
previously O
shown O
to O
be O
required O
for O
ST O
biosynthesis O
, O
and O
24 O
additional O
closely O
spaced RARE
transcripts O
ranging O
in O
size O
from O
0 O
. O
6 O
to O
7 O
. O
2 O
kb O
that O
are O
coordinately RARE
induced O
only O
under O
ST O
- O
producing O
conditions O
. O

Subcellular RARE
localizations RARE
of O
the O
wild I-GENE
- I-GENE
type I-GENE
CBFbeta RARE
and O
the O
CBFbeta RARE
- O
SMMHC ALLCAPS
fusion O
protein O
were O
determined O
by O
immunofluorescence O
of O
NIH O
3T3 O
cells O
that O
overexpress RARE
wild O
- O
type O
or O
fusion O
protein O
. O

Menstrual RARE
- O
cycle O
phase O
did O
not O
significantly O
affect O
personality RARE
variables O
in O
either O
group O
. O

We O
report O
the O
isolation O
of O
human O
cDNAs O
homologous O
to O
the O
Drosophila I-GENE
dishevelled RARE
( O
dsh RARE
) O
segment O
- O
polarity O
gene O
. O

Escherichia O
coli O
BL21 NUMERIC
( O
DE3 NUMERIC
) O
plysS LASTCAP
, O
harbouring RARE
a O
recombinant O
plasmid O
containing O
the O
catalase I-GENE
- O
peroxidase I-GENE
gene O
, O
produced O
a O
large O
amount O
of O
proteins O
that O
co O
- O
migrated RARE
on O
SDS O
/ O
PAGE O
with O
the O
native O
enzyme O
. O

Ca2 O
+ O
decreased O
Zn2 NUMERIC
+ O
binding O
in O
S100 NUMERIC
beta I-GENE
but O
it O
did O
not O
influence O
binding O
to O
MRP14 NUMERIC
, O
suggesting O
that O
the O
Zn2 NUMERIC
+ O
binding O
site O
was O
distinct O
from O
and O
independent O
of O
the O
two O
Ca2 O
+ O
binding O
domains O
. O

Cdk2 I-GENE
formed O
a O
complex O
with O
cyclin I-GENE
D1 I-GENE
in O
this O
system O
. O

The O
Cdk2 I-GENE
- O
cyclin I-GENE
- I-GENE
D1 I-GENE
complex O
did O
not O
phosphorylate O
any O
tested O
substrates O
, O
such O
as O
H1 I-GENE
histone I-GENE
, O
pRB LASTCAP
, O
SV40 I-GENE
large I-GENE
T I-GENE
antigen I-GENE
, O
p53 I-GENE
, O
E2F I-GENE
- I-GENE
1 I-GENE
or O
a O
preparation O
of O
nuclear O
proteins O
from O
HeLa O
cells O
; O
in O
contrast O
, O
Cdk2 I-GENE
- O
cyclin I-GENE
- I-GENE
E I-GENE
and O
Cdk2 I-GENE
- O
cyclin I-GENE
- I-GENE
A I-GENE
phosphorylated O
these O
proteins O
. O

Cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
( O
Cdk2 I-GENE
) O
forms O
an O
inactive O
complex O
with O
cyclin I-GENE
D1 I-GENE
since O
Cdk2 I-GENE
associated O
with O
cyclin I-GENE
D1 I-GENE
is O
not O
phosphorylated O
by O
Cdk7 NUMERIC
- O
cyclin I-GENE
- I-GENE
H I-GENE
. O

Two O
overlapping O
clones O
contained O
the O
complete O
Adh RARE
- I-GENE
2 I-GENE
gene I-GENE
composed O
of O
nine O
exons O
in O
a O
12 O
- O
kb O
region O
, O
with O
the O
placement O
of O
introns O
matching RARE
that O
observed O
in O
other O
mammalian I-GENE
ADH I-GENE
genes I-GENE
. O

Ligation RARE
of O
CD40 I-GENE
rescues RARE
Ramos RARE
- O
Burkitt RARE
lymphoma O
B O
cells O
from O
calcium O
ionophore RARE
- O
and O
antigen O
receptor O
- O
triggered O
apoptosis O
by O
inhibiting O
activation O
of O
the O
cysteine I-GENE
protease I-GENE
CPP32 NUMERIC
/ O
Yama RARE
and O
cleavage O
of O
its O
substrate O
PARP ALLCAPS
. O

Large I-GENE
T I-GENE
antigen I-GENE
was O
coimmunoprecipitated RARE
by O
antibodies O
to O
epitope O
- O
tagged O
TBP I-GENE
, O
endogenous O
TBP I-GENE
, O
hTAF LASTCAP
( I-GENE
II I-GENE
) I-GENE
100 I-GENE
, O
hTAF LASTCAP
( I-GENE
II I-GENE
) I-GENE
130 I-GENE
, O
and O
hTAF LASTCAP
( I-GENE
II I-GENE
) I-GENE
250 I-GENE
, O
under O
conditions O
where O
holo RARE
- I-GENE
TFIID I-GENE
would O
be O
precipitated O
. O

Northern O
blot O
hybridization O
demonstrated O
that O
HEP ALLCAPS
- O
COP ALLCAPS
was O
expressed O
in O
a O
wide O
range O
of O
human O
adult O
and O
fetal O
tissues O
. O

A O
human O
cytoplasmic O
signaling O
protein O
has O
been O
cloned O
that O
possesses O
the O
same O
structural O
arrangement O
of O
SH3 I-GENE
- O
SH2 I-GENE
- O
SH3 I-GENE
domains O
as O
Grb2 I-GENE
. O

A O
direct O
role O
for O
sterol I-GENE
regulatory I-GENE
element I-GENE
binding I-GENE
protein I-GENE
in O
activation O
of O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
methylglutaryl RARE
coenzyme I-GENE
A I-GENE
reductase I-GENE
gene I-GENE
. O

E3 I-GENE
/ I-GENE
19K NUMERIC
resides O
in O
the O
endoplasmic O
reticulum O
where O
it O
binds O
to O
MHC I-GENE
class I-GENE
I I-GENE
molecules I-GENE
, O
thereby O
preventing O
their O
transport O
to O
the O
cell O
surface O
. O

When O
the O
PHT ALLCAPS
and O
CSA ALLCAPS
groups O
were O
compared O
, O
Hyp RARE
levels O
were O
significantly O
higher O
in O
the O
PHT ALLCAPS
- O
GO ALLCAPS
+ O
group O
than O
in O
the O
CSA ALLCAPS
- O
GO ALLCAPS
+ O
group O
. O

Among O
the O
LE6 NUMERIC
deletions O
, O
only O
one O
had O
a O
reduced O
transformation O
efficiency O
, O
while O
seven O
transformed O
cells O
at O
least O
as O
efficiently O
as O
wild I-GENE
- I-GENE
type I-GENE
LE6 NUMERIC
. O

ORF I-GENE
E8 NUMERIC
colinear RARE
with O
ORF I-GENE
E6 I-GENE
, O
which O
could O
generate O
a O
50 O
- O
amino O
- O
acid O
protein O
with O
a O
hydrophobic O
segment O
, O
did O
not O
transform O
cells O
when O
cloned O
into O
the O
pZipNeo RARE
vector O
. O

Cloning O
of O
individual O
ZI ALLCAPS
domains O
upstream O
of O
a O
minimal O
promoter O
demonstrated O
that O
the O
ZIA ALLCAPS
, O
ZIC ALLCAPS
, O
and O
ZID ALLCAPS
domains O
, O
but O
not O
the O
ZIB ALLCAPS
domain O
, O
are O
TPA O
responsive O
. O

Clb2 NUMERIC
/ O
Cdc28 I-GENE
kinase O
is O
not O
required O
for O
the O
repression O
of O
MCB ALLCAPS
- I-GENE
binding I-GENE
factor I-GENE
transcriptional O
activity O
in O
G2 O
and O
M O
phase O
. O

The O
carboxy O
terminus O
of O
Mbp1 NUMERIC
is O
sufficient O
for O
interaction O
with O
Swi6 NUMERIC
, O
and O
the O
carboxy O
terminus O
of O
Swi6 NUMERIC
is O
required O
for O
interaction O
with O
Mbp1 NUMERIC
. O

Multiple O
single O
- O
stranded O
cis O
elements O
are O
associated O
with O
activated O
chromatin O
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
in O
vivo O
. O

A O
new O
UASH ALLCAPS
consensus O
sequence O
derived O
from O
this O
mutational O
analysis O
closely O
matches O
a O
consensus O
Abf1 NUMERIC
binding I-GENE
site I-GENE
. O

We O
have O
isolated O
and O
analyzed O
human I-GENE
CTCF I-GENE
cDNA I-GENE
clones O
and O
show O
here O
that O
the O
ubiquitously O
expressed O
11 I-GENE
- I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
factor I-GENE
CTCF I-GENE
is O
an O
exceptionally RARE
highly O
conserved O
protein O
displaying RARE
93 O
% O
identity O
between O
avian O
and O
human O
amino O
acid O
sequences O
. O

Mutational O
analysis O
of O
the O
P2 I-GENE
- I-GENE
proximal I-GENE
CTCF I-GENE
binding I-GENE
site I-GENE
and O
transient O
- O
cotransfection O
experiments O
demonstrate O
that O
CTCF I-GENE
is O
a O
transcriptional O
repressor O
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

A O
chromosome I-GENE
transmission I-GENE
fidelity I-GENE
( O
ctf RARE
) O
mutant O
, O
s138 NUMERIC
, O
of O
Saccharomyces O
cerevisiae O
was O
identified O
by O
its O
centromere O
( O
CEN ALLCAPS
) O
transcriptional O
readthrough O
phenotype O
, O
suggesting O
perturbed RARE
kinetochore RARE
integrity O
in O
vivo O
. O

The O
growth O
defect O
of O
a O
reg1 NUMERIC
reg2 NUMERIC
double I-GENE
mutant I-GENE
is O
alleviated RARE
by O
a O
loss O
- O
of O
- O
function O
mutation O
in O
the O
SNF1 NUMERIC
- I-GENE
encoded I-GENE
protein I-GENE
kinase I-GENE
. O

Sp1 I-GENE
binds O
two O
sites O
in O
the O
CD11c NUMERIC
promoter I-GENE
in O
vivo O
specifically O
in O
myeloid O
cells O
and O
cooperates RARE
with O
AP1 I-GENE
to O
activate O
transcription O
. O

Expression O
of O
the O
phenylalanine I-GENE
hydroxylase I-GENE
gene I-GENE
in O
livers RARE
and O
kidneys O
of O
rodents RARE
is O
activated O
at O
birth O
and O
is O
induced O
by O
glucocorticoids O
and O
cyclic O
AMP O
in O
the O
liver O
. O

We O
found O
that O
120 O
bp O
of O
the O
enhancer O
' O
s O
transcriptional O
core O
becomes O
DNase I-GENE
I I-GENE
hypersensitive O
early O
in O
B O
- O
cell O
development O
. O

A O
developmentally O
modulated O
chromatin O
structure O
at O
the O
mouse I-GENE
immunoglobulin I-GENE
kappa I-GENE
3 I-GENE
' I-GENE
enhancer I-GENE
. O

We O
report O
here O
the O
identification O
of O
a O
cDNA O
that O
encodes O
a O
new O
member O
of O
the O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
( O
GAP I-GENE
) O
family O
of O
GTPase I-GENE
regulators O
. O

In O
this O
study O
, O
we O
further O
investigated O
the O
regulation O
of O
the O
synthesis O
of O
the O
c I-GENE
- I-GENE
mos I-GENE
oncogene I-GENE
product I-GENE
, O
which O
is O
necessary O
for O
the O
activation O
of O
Cdc2 I-GENE
. O

The O
heterogeneity O
of O
bovine I-GENE
IgG2 NUMERIC
-- I-GENE
VIII I-GENE
. O

The O
ability O
of O
BCL I-GENE
- I-GENE
6 I-GENE
to O
function O
as O
a O
transcriptional O
repressor O
may O
contribute O
to O
its O
ability O
to O
transform O
B O
lymphocytes O
in O
diffuse O
large O
cell O
lymphoma O
. O

Positioning RARE
this O
uORF O
, O
together O
with O
its O
accompanying O
Kozak RARE
sequences O
, O
between O
a O
heterologous O
promoter O
from O
SV40 O
and O
a O
CAT I-GENE
reporter I-GENE
gene I-GENE
resulted O
in O
marked O
inhibition O
of O
CAT I-GENE
protein I-GENE
production O
without O
a O
decrease O
in O
CAT I-GENE
mRNA I-GENE
. O

A O
secondary O
spread O
of O
an O
imported RARE
methicillin RARE
- O
resistant O
Staphylococcus O
aureus O
strain O
( O
MRSA ALLCAPS
) O
to O
two O
other O
patients O
occurred O
within O
a O
Danish RARE
surgical O
ward RARE
in O
spite RARE
of O
isolation O
of O
a O
multitraumatized RARE
index O
- O
patient O
immediately O
after O
arrival RARE
from O
a O
hospital O
in O
the O
Mediterranean RARE
area O
. O

Mesial RARE
temporal O
sclerosis O
was O
characterized O
by O
severe O
neuronal O
loss O
accompanied O
by O
gliosis RARE
occurring O
in O
the O
CA1 NUMERIC
/ O
prosubiculum RARE
( O
27 O
patients O
, O
100 O
%), O
focally RARE
in O
the O
dentate RARE
gyrus O
( O
12 O
patients O
, O
44 O
%), O
and O
in O
the O
CA4 NUMERIC
region O
( O
11 O
patients O
, O
41 O
%). O

Mesial RARE
temporal O
sclerosis O
. O

More O
specific O
adverse O
events O
, O
also O
frequently O
considered O
as O
dose O
- O
limiting O
toxicities RARE
, O
include O
hypotension O
with O
IL I-GENE
- I-GENE
1 I-GENE
, O
severe O
headache O
or O
skin O
rash O
with O
IL I-GENE
- I-GENE
3 I-GENE
, O
and O
nasal O
congestion RARE
and O
gastroduodenal RARE
lesions O
with O
IL I-GENE
- I-GENE
4 I-GENE
. O

Therefore O
, O
magnetic O
resonance O
imaging O
was O
used O
to O
determine O
liver O
volume O
in O
pediatric O
and O
adolescent O
patients O
, O
in O
whom O
systemic O
clearance O
of O
three O
model O
substrates O
[ O
lorazepam RARE
( O
0 O
. O
03 O
mg O
/ O
kg O
), O
antipyrine RARE
( O
10 O
mg O
/ O
kg O
), O
and O
indocyanine RARE
green O
( O
ICG ALLCAPS
; O
0 O
. O
5 O
mg O
/ O
kg O
)] O
was O
also O
determined O
. O

A O
mutational O
analysis O
has O
resolved O
a O
region O
of O
seven O
amino O
acids O
( O
amino O
acids O
26 O
- O
32 O
) O
in O
the O
N O
- O
terminus O
of O
Bob1 NUMERIC
that O
are O
important O
for O
contacting RARE
the O
DNA I-GENE
binding I-GENE
POU I-GENE
domain I-GENE
of O
Oct I-GENE
- I-GENE
1 I-GENE
or O
Oct I-GENE
- I-GENE
2 I-GENE
. O

Heme RARE
oxygenase I-GENE
1 I-GENE
is O
an O
essential O
enzyme O
in O
heme O
catabolism O
that O
cleaves RARE
heme O
to O
form O
biliverdin RARE
, O
iron O
, O
and O
carbon O
monoxide RARE
. O

An O
inactive O
analog O
of O
wortmannin O
, O
WM12 NUMERIC
, O
did O
not O
affect O
TCR I-GENE
/ O
CD3 I-GENE
- O
induced O
Erk2 NUMERIC
activation O
, O
and O
wortmannin O
had O
no O
effect O
on O
the O
activity O
of O
Erk2 NUMERIC
when O
added O
directly O
to O
the O
in O
vitro O
assays O
. O

155 NUMERIC
aa O
, O
shares O
78 O
% O
identity O
with O
the O
analogous O
region O
of O
Xenopus O
laevis O
FGF3 NUMERIC
and O
72 O
% O
identity O
with O
the O
product O
of O
the O
more O
distantly O
related O
human O
gene O
. O

The O
transcription O
start O
point O
of O
the O
proximal O
promoter O
aligns RARE
to O
that O
of O
mouse O
promoter O
P3 O
and O
lies O
within O
a O
conserved O
region O
of O
sequence O
. O

Defects RARE
in O
the O
Schizosaccharomyces O
pombe O
( O
Sp RARE
) O
cell O
cycle O
- O
controlling O
genes O
prevent O
the O
cell O
cycle O
progression O
. O

To O
determine O
the O
signal I-GENE
recognition I-GENE
particle I-GENE
( O
SRP I-GENE
)- O
SRP I-GENE
receptor I-GENE
( O
Srb RARE
) O
system O
in O
Bacillus O
subtilis O
( O
Bs RARE
), O
we O
cloned O
the O
Bs RARE
srb RARE
gene I-GENE
, O
which O
encodes O
a O
homologue O
of O
the O
mammalian I-GENE
SRP I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
[ O
Oguro RARE
et O
al O
., O
DNA O
Res RARE
. O

A O
novel O
gene O
designated O
cmr RARE
, O
which O
mapped O
to O
18 O
. O
8 O
min O
of O
the O
Escherichia O
coli O
K O
- O
12 O
genome O
, O
was O
shown O
to O
mediate O
resistance O
to O
chloramphenicol O
when O
it O
was O
expressed O
from O
a O
multicopy O
vector O
. O

In O
addition O
, O
5 O
' O
deletions O
removing O
all O
but O
34 O
bp O
upstream O
of O
the O
transcription O
start O
point O
retained O
greater O
than O
90 O
% O
promoter O
activity O
, O
suggesting O
that O
the O
- O
35 O
hexamer O
was O
not O
essential O
for O
promoter O
activity O
. O

The O
DNA O
sequence O
immediately O
upstream O
from O
the O
- O
10 O
hexamer O
contained O
the O
TGn RARE
motif O
described O
as O
an O
extended O
- O
10 O
region O
in O
prokaryotic O
promoters O
. O

An O
apparent O
ufo RARE
mRNA I-GENE
overexpression O
was O
not O
found O
in O
any O
of O
the O
positive O
leukemia O
cell O
lines O
, O
but O
was O
identified O
in O
the O
drug O
- O
resistant O
subclones RARE
of O
the O
cervix O
carcinoma O
cell O
line O
HeLa O
. O

We O
conclude O
from O
these O
studies O
that O
CKII ALLCAPS
may O
act O
as O
a O
positive O
regulator O
of O
myogenesis RARE
by O
preventing O
E I-GENE
protein I-GENE
homodimers I-GENE
from O
binding O
to O
muscle O
gene O
regulatory O
elements O
. O

The O
role O
of O
negative O
regulators O
such O
as O
NCE3 NUMERIC
, O
as O
well O
as O
the O
previously O
described O
SIN5 NUMERIC
gene I-GENE
, O
in O
determining O
the O
promoter O
specificity O
of O
homologous O
activators O
is O
discussed O
. O

Transcriptional O
regulators O
utilizing O
the O
POU I-GENE
domain I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
motif I-GENE
have O
been O
shown O
to O
form O
multi O
- O
protein O
complexes O
dependent O
on O
the O
POU I-GENE
domain I-GENE
itself O
and O
its O
flexible RARE
recognition O
of O
various O
octamer O
sequence O
elements O
. O

We O
found O
strand O
selective O
repair O
in O
DNA O
fragments O
within O
two O
active O
genes O
, O
DHFR I-GENE
and O
an O
unknown O
gene O
adjacent O
to O
DHFR I-GENE
. O

MATERIALS ALLCAPS
AND O
METHODS O
: O
Coronal RARE
3D NUMERIC
GRE O
imaging O
was O
used O
to O
study O
the O
volar RARE
, O
middle O
, O
and O
dorsal O
portions O
of O
the O
SLL ALLCAPS
in O
14 O
patients O
with O
an O
arthroscopically RARE
normal O
SLL ALLCAPS
and O
in O
five O
cadaveric RARE
wrists RARE
that O
had O
a O
normal O
SLL ALLCAPS
proved O
with O
dissection O
. O

In O
an O
effort O
to O
contribute O
to O
the O
transcript O
map O
of O
human O
chromosome O
21 O
and O
the O
understanding O
of O
the O
pathophysiology O
of O
trisomy RARE
21 O
, O
we O
have O
used O
exon O
trapping RARE
to O
identify O
fragments O
of O
chromosome O
21 O
genes O
. O

Reproducing RARE
populations O
of O
this O
aphid RARE
were O
first O
detected O
in O
Puerto RARE
Rico RARE
in O
April RARE
1992 O
. O

The O
model O
captures RARE
the O
essence RARE
of O
predator RARE
- O
prey RARE
dynamics O
to O
provide O
reasonable O
predictions O
of O
population O
patterns O
. O

At O
cuticular RARE
positions O
exhibiting O
the O
Brd RARE
bristle RARE
loss I-GENE
phenotype I-GENE
, O
we O
have O
found O
that O
the O
progeny RARE
of O
the O
multiplied RARE
SOPs RARE
develop O
aberrantly RARE
, O
in O
that O
neurons O
and O
thecogen RARE
( O
sheath RARE
) O
cells O
appear O
but O
not O
trichogen RARE
( O
shaft RARE
) O
and O
tormogen RARE
( O
socket RARE
) O
cells O
. O

Transcriptional O
blockade O
was O
reversed O
by O
co O
- O
transfections O
of O
a O
wild I-GENE
- I-GENE
type I-GENE
SRF I-GENE
expression O
vector O
, O
but O
was O
not O
rescued RARE
by O
the O
expression O
of O
other O
myogenic O
factors O
, O
such O
as O
MyoD I-GENE
and O
Mef RARE
- I-GENE
2C NUMERIC
. O

The O
mMIWC1 NUMERIC
promoter I-GENE
was O
identified O
and O
contained O
TATA O
, O
CAAT O
, O
GATA O
, O
and O
AP I-GENE
- I-GENE
2 I-GENE
elements I-GENE
; O
primer O
extension O
revealed O
mMIWC LASTCAP
transcription O
initiation O
at O
621 NUMERIC
bp O
upstream O
from O
the O
mMIWC1 NUMERIC
translational O
initiation O
site O
. O

Human I-GENE
MN ALLCAPS
/ I-GENE
CA9 NUMERIC
gene I-GENE
, O
a O
novel O
member O
of O
the O
carbonic RARE
anhydrase I-GENE
family I-GENE
: O
structure O
and O
exon O
to O
protein O
domain O
relationships O
. O

The O
exon O
- O
intron O
distribution O
of O
Cdebp RARE
appears O
strikingly O
similar O
to O
that O
of O
the O
App RARE
gene I-GENE
in O
the O
regions O
encoding O
the O
conserved O
domains O
, O
with O
a O
divergent O
structure O
in O
the O
other O
parts O
. O

DNA O
sequence O
analysis O
reveals O
that O
the O
gene O
encodes O
a O
protein O
highly O
homologous O
to O
rat I-GENE
CRP1 NUMERIC
. O

The O
gene O
was O
expressed O
as O
an O
approximately O
1 O
. O
5 O
- O
kb O
mRNA O
in O
most O
nonlymphoid RARE
human O
cells O
/ O
tissues O
including O
prostate O
, O
lung O
, O
liver O
, O
and O
colon O
. O

Both O
of O
these O
domains O
have O
striking O
sequence O
homology O
with O
human O
SIM ALLCAPS
and O
Drosophila O
SIM ALLCAPS
proteins O
. O

Promoter O
activity O
was O
high O
in O
cell O
lines O
that O
expressed O
high O
levels O
of O
endogenous O
D3 I-GENE
mRNA I-GENE
, O
as O
indicated O
by O
Northern O
blot O
analyses O
, O
and O
was O
significantly O
reduced O
when O
the O
promoter O
was O
truncated O
to O
- O
122 O
bp O
. O

We O
have O
obtained O
the O
human I-GENE
EP4 NUMERIC
receptor I-GENE
gene I-GENE
sequence I-GENE
and O
determined O
its O
structure O
relative O
to O
EP4R NUMERIC
cDNA I-GENE
synthesized O
from O
peripheral O
blood O
lymphocytes O
. O

Some O
users O
will O
willingly RARE
comply RARE
with O
management O
measures O
, O
other O
users O
will O
comply RARE
in O
response O
to O
education O
, O
but O
there O
will O
be O
another O
group O
who O
will O
only O
respond O
to O
enforcement RARE
activities O
. O

Three O
separate O
activation O
subdomains O
, O
and O
one O
negative O
- O
acting O
region O
, O
which O
function O
in O
yeast O
were O
located O
in O
the O
carboxyl O
- O
terminal O
region O
of O
NIT4 NUMERIC
. O

The O
front O
( O
F O
) O
interaction O
occurs O
ahead RARE
of O
the O
growing O
end O
of O
RNA O
. O

Collectively O
, O
these O
data O
indicate O
that O
HIP ALLCAPS
is O
a O
membrane O
- O
associated O
HP ALLCAPS
- I-GENE
binding I-GENE
protein I-GENE
expressed O
on O
the O
surface O
of O
normal O
human O
uterine O
epithelia RARE
and O
uterine O
epithelial O
cell O
lines O
. O

The O
corresponding O
gene O
was O
identified O
in O
the O
GenBankTM LASTCAP
data O
base O
by O
sequence O
alignment O
and O
termed O
RPS30A NUMERIC
. O

The O
location O
of O
multiple O
GRK2 NUMERIC
and O
GRK5 NUMERIC
phosphoacceptor RARE
sites I-GENE
at O
the O
extreme O
carboxyl O
terminus O
of O
the O
beta2AR NUMERIC
is O
highly O
reminiscent RARE
of O
GRK1 NUMERIC
- O
mediated O
phosphorylation O
of O
rhodopsin RARE
. O

This O
regulation O
could O
not O
be O
appreciably RARE
modified O
by O
enhanced O
expression O
of O
STAT I-GENE
proteins I-GENE
. O

Receptors RARE
for O
interleukin I-GENE
( I-GENE
IL I-GENE
)- I-GENE
10 I-GENE
and O
IL I-GENE
- I-GENE
6 I-GENE
- I-GENE
type I-GENE
cytokines I-GENE
use O
similar O
signaling O
mechanisms O
for O
inducing O
transcription O
through O
IL I-GENE
- I-GENE
6 I-GENE
response O
elements O
. O

Specifically O
, O
the O
deduced O
FR I-GENE
- I-GENE
19 I-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
has O
approximately89 NUMERIC
, O
77 O
, O
and O
68 O
% O
overall O
identity O
to O
chicken I-GENE
TEF I-GENE
- I-GENE
1A NUMERIC
, O
mouse I-GENE
TEF I-GENE
- I-GENE
1 I-GENE
, O
and O
mouse I-GENE
embryonic I-GENE
TEA ALLCAPS
domain I-GENE
- I-GENE
containing I-GENE
factor I-GENE
, O
respectively O
. O

This O
phenomenon O
did O
not O
require O
DNA O
binding O
by O
the O
" O
interfering O
" O
receptor O
but O
required O
it O
to O
be O
hormone O
- O
bound O
, O
indicating O
that O
a O
transcriptionally O
active O
form O
of O
the O
interfering O
receptor O
is O
essential O
for O
the O
interfering O
effect O
. O

The O
receptor I-GENE
for I-GENE
hyaluronan RARE
mediated I-GENE
motility I-GENE
( I-GENE
RHAMM ALLCAPS
) I-GENE
gene I-GENE
expression O
is O
markedly O
elevated O
in O
fibrosarcomas RARE
exposed O
to O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta1 I-GENE
( O
TGF I-GENE
- I-GENE
beta1 I-GENE
). O

Oncogenic RARE
Raf I-GENE
- I-GENE
1 I-GENE
activates O
p70 I-GENE
S6 I-GENE
kinase I-GENE
via O
a O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- O
independent O
pathway O
. O

Hydropathy RARE
analysis O
of O
KCC1 NUMERIC
indicates O
structural O
homology O
to O
NKCC ALLCAPS
, O
including O
12 O
transmembrane O
domains O
, O
a O
large O
extracellular O
loop O
with O
potential O
N O
- O
linked O
glycosylation O
sites O
, O
and O
cytoplasmic O
N O
- O
and O
C O
- O
terminal O
regions O
. O

A O
cis O
- O
acting O
DNA O
element O
located O
between O
TATA O
box O
and O
transcription O
initiation O
site O
is O
critical O
in O
response O
to O
regulatory O
sequences O
in O
human O
angiotensinogen RARE
gene I-GENE
. O

This O
protein O
with O
a O
hydrophobic O
amino O
terminus O
appears O
to O
be O
a O
secreted O
protein O
. O

The O
promoter O
of O
the O
rat I-GENE
PGS ALLCAPS
- I-GENE
2 I-GENE
gene I-GENE
contains O
a O
CAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
consensus I-GENE
site I-GENE
( I-GENE
CAAT I-GENE
box I-GENE
) I-GENE
which O
can O
confer O
hormone O
inducibility O
to O
a O
PGS ALLCAPS
- I-GENE
2 I-GENE
. O
CAT I-GENE
reporter O
gene O
, O
as O
well O
as O
a O
putative O
E O
- O
box O
region O
. O

Notably RARE
, O
SRF I-GENE
has O
been O
found O
to O
be O
a O
key O
regulator O
of O
members O
of O
a O
class O
of O
cellular O
response O
genes O
termed O
immediate I-GENE
- I-GENE
early I-GENE
genes I-GENE
( O
IEGs RARE
), O
many O
of O
which O
are O
believed O
to O
be O
involved O
in O
regulating O
cell O
growth O
and O
differentiation O
. O

The O
final O
sigma54 NUMERIC
- I-GENE
dependent I-GENE
DmpR LASTCAP
activator I-GENE
regulates O
transcription O
of O
the O
dmp RARE
operon I-GENE
that O
encodes O
the O
enzymes O
for O
catabolism O
of O
( O
methyl O
) O
phenols RARE
. O

In O
this O
study O
, O
we O
have O
cloned O
the O
human I-GENE
DSG3 NUMERIC
gene I-GENE
and O
examined O
the O
transcriptional O
regulation O
of O
its O
expression O
. O

Clinical O
evaluation O
of O
the O
Allergan RARE
Humphrey RARE
500 O
autorefractor RARE
and O
the O
Nidek RARE
AR O
- O
1000 O
autorefractor RARE
. O

None O
of O
the O
five O
proprotein RARE
processing O
proteases O
tested O
were O
capable O
of O
cleaving RARE
human I-GENE
pro I-GENE
- I-GENE
LPH ALLCAPS
, O
strongly O
suggesting O
that O
they O
are O
not O
involved O
in O
the O
maturation O
of O
this O
enzyme O
. O

These O
changes O
may O
be O
the O
result O
of O
, O
on O
the O
one O
hand O
, O
an O
increased O
sensitivity O
of O
the O
neuromuscular O
transmission O
and O
/ O
or O
decreased O
muscle O
contractility O
and O
, O
on O
the O
other O
hand O
, O
the O
result O
of O
a O
reduced O
plasma O
clearance O
during O
hypothermia O
. O

SETTING O
-- O
Delhi RARE
, O
urban RARE
India RARE
, O
1985 O
- O
6 O
. O

By O
using O
interleukin I-GENE
- I-GENE
3 I-GENE
- O
dependent O
cells O
that O
ectopically RARE
express O
the O
three O
ErbB I-GENE
proteins I-GENE
or O
their O
combinations O
, O
we O
found O
that O
ErbB I-GENE
- I-GENE
3 I-GENE
is O
devoid RARE
of O
any O
biological O
activity O
but O
both O
ErbB I-GENE
- I-GENE
1 I-GENE
and O
ErbB I-GENE
- I-GENE
2 I-GENE
can O
reconstitute RARE
its O
extremely O
potent O
mitogenic O
activity O
. O

ZIOS ALLCAPS
was O
significantly O
more O
sensitive O
than O
all O
subsequent O
methods O
, O
and O
Ptc RARE
, O
O2 O
was O
significantly O
more O
sensitive O
than O
FEV1 O
. O

Selective O
translation O
initiation O
by O
ribosome O
jumping RARE
in O
adenovirus O
- O
infected O
and O
heat O
- O
shocked RARE
cells O
. O

Furthermore O
, O
we O
have O
identified O
a O
43 O
- O
bp O
region O
of O
the O
24p3 NUMERIC
promoter I-GENE
required O
for O
the O
Dex RARE
responsiveness O
. O

These O
findings O
suggest O
that O
direct O
cDNA O
mapping O
using O
fluorescence O
in O
situ O
hybridization O
provides O
an O
accurate O
and O
rapid O
approach O
to O
the O
definition O
of O
a O
transcribed O
map O
of O
the O
human O
genome O
. O

YAC O
and O
cosmid O
contigs RARE
spanning O
the O
Batten RARE
disease I-GENE
( O
CLN3 NUMERIC
) O
region O
at O
16p12 NUMERIC
. O
1 O
- O
p11 NUMERIC
. O
2 O
. O

Isolation O
of O
a O
near O
full O
- O
length O
cDNA O
from O
a O
human O
fetal O
brain O
cDNA O
library O
revealed O
a O
protein I-GENE
serine I-GENE
- I-GENE
threonine I-GENE
phosphatase I-GENE
with O
a O
tetratricopeptide RARE
motif O
, O
almost O
identical O
to O
human I-GENE
PPP5C NUMERIC
( O
PP5 NUMERIC
) O
and O
highly O
homologous O
to O
rat I-GENE
PPT ALLCAPS
. O

Ly RARE
- I-GENE
49 I-GENE
is O
a O
family I-GENE
type I-GENE
II I-GENE
transmembrane I-GENE
proteins I-GENE
encoded O
by O
a O
gene O
cluster O
on O
murine O
chromosome O
6 O
. O

The O
Dox RARE
- I-GENE
A2 I-GENE
ORF I-GENE
driven O
by O
the O
TDH3 NUMERIC
promoter I-GENE
complemented O
the O
phenotype O
of O
a O
strain O
deleted O
for O
sun2 NUMERIC
. O

The O
introduction O
of O
hARF4 NUMERIC
to O
the O
cells O
maintained O
the O
balance O
between O
cytosolic O
and O
membrane O
- O
associated O
Sec7p NUMERIC
pools RARE
. O

Our O
data O
demonstrate O
directly O
that O
Rpm1r NUMERIC
is O
transcribed O
with O
its O
substrates O
, O
tRNA I-GENE
met I-GENE
f I-GENE
and O
tRNAPro RARE
, O
from O
a O
promoter O
located O
upstream O
of O
the O
tRNA I-GENE
met I-GENE
f I-GENE
gene I-GENE
and O
suggest O
that O
a O
portion O
also O
originates RARE
from O
a O
second O
promoter O
, O
located O
between O
the O
tRNA I-GENE
met I-GENE
f I-GENE
gene I-GENE
and O
RPM1 NUMERIC
. O

Furthermore O
, O
strains O
with O
mutant I-GENE
RPM1 NUMERIC
genes I-GENE
also O
accumulate O
precursor I-GENE
Rpm1r NUMERIC
, O
suggesting O
that O
mutations O
in O
either O
gene O
can O
lead O
to O
similar O
biogenesis O
defects O
. O

Vacuolar RARE
membrane O
vesicles O
from O
hum1 NUMERIC
mutants I-GENE
lack O
all O
Ca2 O
+/ O
H O
+ O
antiport RARE
activity O
, O
demonstrating O
that O
Hum1p NUMERIC
catalyzes O
the O
exchange O
of O
Ca2 O
+ O
for O
H O
+ O
across O
the O
yeast O
vacuolar O
membrane O
. O

Detailed RARE
mutagenesis O
of O
the O
element O
' O
s O
rare O
- O
codon O
/ O
AU ALLCAPS
- O
rich O
sequence O
boundary O
revealed O
that O
the O
destabilizing RARE
activity O
of O
the O
MATalpha1 NUMERIC
IE I-GENE
is O
observed O
when O
the O
terminal O
codon O
of O
the O
element O
' O
s O
rare O
- O
codon O
interval O
is O
translated O
. O

FTF ALLCAPS
is O
also O
abundantly O
expressed O
in O
the O
pancreas O
and O
may O
exert O
differentiation O
functions O
in O
endodermal RARE
sublineages RARE
, O
similar O
to O
SF I-GENE
- I-GENE
1 I-GENE
in O
steroidogenic RARE
tissues O
. O

Merlie RARE
, O
Cold RARE
Spring RARE
Harbor RARE
Symp RARE
. O

Substantial RARE
evidence O
supports O
a O
critical O
role O
for O
the O
activation O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
/ O
MEK I-GENE
/ O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
in O
oncogenic O
Ras I-GENE
- O
mediated O
transformation O
. O

Stylohyoid RARE
chain O
ossification RARE
: O
choice O
of O
the O
surgical O
approach O
. O

The O
incidence O
of O
cardiac O
death O
( O
one O
per O
group O
), O
Q O
wave O
MI O
( O
propofol RARE
, O
n O
= O
7 O
; O
midazolam O
, O
n O
= O
3 O
; O
P O
= O
0 O
. O
27 O
), O
or O
non O
Q O
wave O
MI O
( O
propofol RARE
, O
n O
= O
16 O
; O
midazolam O
, O
n O
= O
18 O
; O
P O
= O
0 O
. O
81 O
) O
did O
not O
differ O
between O
treatment O
groups O
. O

63 O
. O
3 O
micromol RARE
/ O
1 O
, O
p O
< O
0 O
. O
01 O
) O
and O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
extrapolated RARE
to O
infinity RARE
AUC O
9 O
( O
0 O
- O
infinity RARE
)( O
518 NUMERIC
. O
7 O
vs O
. O

Cluster RARE
formation O
of O
E I-GENE
- I-GENE
cadherin I-GENE
on O
the O
cell O
surface O
is O
believed O
to O
be O
of O
major O
importance O
for O
cell O
- O
cell O
adhesion O
. O

DNA I-GENE
polymerase I-GENE
E I-GENE
, O
DNA I-GENE
ligase I-GENE
III I-GENE
and O
a O
DNA O
structure O
- O
specific O
endonuclease O
co O
- O
purify RARE
with O
the O
five O
polypeptide O
complex O
. O

By O
using O
reporter O
gene O
constructs O
, O
it O
is O
shown O
that O
upstream O
sequences O
of O
the O
P1 O
promoter O
contain O
several O
regions O
that O
modulate O
the O
expression O
either O
positively O
or O
negatively O
. O

The O
factor O
structure O
of O
" O
schizotypal RARE
' O
traits RARE
: O
a O
large O
replication O
study O
. O

Interestingly O
, O
however O
, O
it O
is O
homologous O
to O
several O
expressed O
sequence O
tags O
( O
EST O
) O
of O
unknown O
function O
from O
Caenorhabditis O
elegans O
, O
Oryza RARE
sativa RARE
and O
Homo RARE
sapiens RARE
. O

RESULTS O
: O
The O
bilinear RARE
model O
provided O
a O
significantly O
better O
fit O
to O
the O
acuity RARE
outcome O
data O
. O

Outcome RARE
of O
severe O
congenital O
hypothyroidism O
. O

Mean O
increase O
of O
milk O
protein O
yield O
was O
46 O
g O
/ O
d O
with O
Met O
plus O
Lys O
, O
and O
mean O
increase O
of O
true O
protein O
content O
was O
1 O
. O
1 O
g O
/ O
kg O
of O
milk O
. O

Nonreturn RARE
rates O
can O
be O
used O
to O
derive RARE
more O
elementary RARE
biological O
measures O
for O
reproductive O
efficiency O
, O
such O
as O
conception RARE
rate O
and O
calving RARE
rate O
, O
which O
separately O
might O
be O
more O
reliable O
than O
nonreturn RARE
rate O
itself O
to O
evaluate O
the O
fertility O
of O
a O
bull RARE
or O
the O
performance O
of O
an O
AI ALLCAPS
technician RARE
. O

However O
, O
if O
EMPD ALLCAPS
involves O
the O
glans RARE
penis RARE
or O
perianal RARE
area O
, O
a O
search O
for O
internal O
malignancy O
is O
still O
warranted O
. O

The O
mean O
values O
of O
protease O
activity O
were O
significantly O
higher O
in O
the O
test O
groups O
than O
in O
the O
control O
group O
at O
baseline O
. O

Each O
half O
molecule O
contains O
four O
disulfide O
linkages RARE
and O
four O
cis O
peptides O
. O

Only O
fully O
processed O
Pra I-GENE
( O
N0 NUMERIC
and O
Nb RARE
) O
and O
ICP35 NUMERIC
( O
ICP35 NUMERIC
e I-GENE
, I-GENE
f I-GENE
) O
are O
present O
in O
B O
capsids RARE
, O
which O
are O
believed O
to O
be O
precursors O
of O
mature O
virions O
. O

A O
chimeric O
VP16 I-GENE
- O
Tat I-GENE
construct O
containing O
the O
leucine O
mutations O
showed O
no O
increased O
AP I-GENE
- I-GENE
1 I-GENE
responsiveness O
in O
comparison O
with O
that O
of O
the O
VP16 I-GENE
activation I-GENE
domain I-GENE
alone O
. O

However O
, O
one O
3 O
' O
splice O
site O
, O
located O
at O
nucleotide O
( O
nt O
) O
3225 NUMERIC
, O
is O
used O
for O
the O
processing O
of O
most O
BPV O
- O
1 O
pre O
- O
mRNAs O
in O
BPV O
- O
1 O
- O
transformed O
C127 NUMERIC
cells O
and O
at O
early O
to O
intermediate O
times O
in O
productively RARE
infected O
warts RARE
. O

Here O
, O
the O
cloning O
and O
characterization O
of O
S I-GENE
- I-GENE
RNase I-GENE
genes I-GENE
from O
two O
species O
of O
Rosaceae RARE
, O
apple RARE
( O
Malus RARE
x O
domestica RARE
) O
and O
Japanese O
pear RARE
( O
Pyrus RARE
serotina RARE
) O
is O
described O
and O
these O
sequences O
are O
compared O
with O
those O
of O
other O
T2 I-GENE
- I-GENE
type I-GENE
RNases RARE
. O

A O
phylogenetic O
tree RARE
of O
members O
of O
the O
T2 I-GENE
/ I-GENE
S I-GENE
- I-GENE
RNase I-GENE
superfamily I-GENE
in O
plants O
was O
obtained O
. O

In O
a O
Hoosier RARE
Oncology RARE
Group O
randomized O
study O
involving O
extensive O
- O
disease O
SCLC ALLCAPS
patients O
, O
VIP ALLCAPS
was O
superior O
to O
etoposide RARE
/ O
cisplatin O
with O
regard O
to O
median O
time O
to O
progression O
( O
6 O
. O
6 O
v O
5 O
. O
8 O
months O
), O
median O
survival O
times O
( O
9 O
. O
1 O
v O
7 O
. O
3 O
months O
), O
and O
2 O
- O
and O
3 O
- O
year O
survival O
rates O
( O
13 O
% O
v O
5 O
% O
and O
5 O
% O
v O
0 O
%, O
respectively O
). O

It O
was O
shown O
that O
administration O
of O
immunomodulator RARE
neurotropin RARE
( O
NSP ALLCAPS
) O
results O
in O
more O
steady O
consolidation RARE
and O
retention O
of O
feeding O
and O
avoidance RARE
behavior O
, O
and O
some O
neurophysiological RARE
mechanisms O
of O
that O
phenomena O
were O
revealed O
. O

Sestamibi RARE
scintigraphy O
, O
performed O
in O
70 O
patients O
, O
was O
less O
sensitive O
than O
ultrasonography O
( O
80 O
%). O

Atopic RARE
allergy O
and O
other O
hypersensitivities RARE
. O

Despite O
significant O
lethality O
and O
cardiovascular O
dysfunction O
, O
in O
the O
septic RARE
group O
on O
Days RARE
1 O
and O
2 O
, O
septic RARE
versus O
control O
animals O
had O
no O
significant O
differences O
in O
mean O
metabolic O
cart RARE
measured O
( O
Vo2DIR NUMERIC
, O
ml O
/ O
kg O
/ O
min O
; O
Day O
1 O
: O
11 O
. O
9 O
versus O
12 O
. O
4 O
, O
p O
= O
0 O
. O
81 O
; O
Day O
2 O
: O
14 O
. O
2 O
versus O
13 O
. O
5 O
, O
p O
= O
0 O
. O
72 O
, O
respectively O
) O
and O
intravascular O
catheter O
calculated O
( O
Vo2INDIR NUMERIC
, O
ml O
/ O
kg O
/ O
min O
; O
Day O
1 O
: O
11 O
. O
2 O
versus O
11 O
. O
2 O
, O
p O
= O
0 O
. O
99 O
; O
Day O
2 O
: O
12 O
. O
8 O
versus O
15 O
. O
4 O
, O
p O
= O
0 O
. O
49 O
, O
respectively O
). O

After O
6 O
h O
of O
reperfusion O
, O
PO2 O
/ O
FlO2 NUMERIC
ratio O
was O
significantly O
better O
after O
Combined O
Therapy RARE
( O
372 NUMERIC
+/- O
52 O
mm O
Hg O
) O
than O
in O
the O
Recipient RARE
Instilled RARE
( O
117 O
+/- O
47 O
mm O
Hg O
) O
and O
Control O
groups O
( O
87 O
+/- O
26 O
mm O
Hg O
), O
with O
intermediate O
values O
in O
Donor RARE
Aerosol RARE
dogs O
( O
232 NUMERIC
+/- O
64 O
mm O
Hg O
). O

The O
euglobulin RARE
clot RARE
lysis O
time O
was O
slightly O
longer O
in O
the O
smokers O
than O
in O
the O
non O
- O
smokers O
in O
all O
three O
experimental O
situations O
, O
but O
the O
differences O
were O
not O
significant O
. O

HS O
inducibility O
required O
the O
HSE O
which O
was O
bound O
by O
HS I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
HSF I-GENE
- I-GENE
1 I-GENE
) O
present O
in O
extracts O
prepared O
from O
cells O
exposed O
to O
HS O
. O

Although O
the O
DSK2 NUMERIC
- I-GENE
1 I-GENE
mutation I-GENE
alters O
a O
conserved O
residue O
in O
the O
Dsk2p NUMERIC
ubiquitin I-GENE
- I-GENE
like I-GENE
domain I-GENE
, O
we O
detect O
no O
differences O
in O
Dsk2p NUMERIC
or O
Cdc31p NUMERIC
stability O
. O

Although O
IL I-GENE
- I-GENE
2 I-GENE
and O
IFN I-GENE
- I-GENE
alpha I-GENE
activated O
STAT1 I-GENE
alpha I-GENE
and O
STAT5 I-GENE
, O
IL I-GENE
- I-GENE
2 I-GENE
predominantly O
activated O
STAT5 I-GENE
, O
while O
IFN I-GENE
- I-GENE
alpha I-GENE
predominantly O
activated O
STAT1 I-GENE
alpha I-GENE
. O

Consistent O
with O
this O
interpretation O
, O
recombinant I-GENE
CREB I-GENE
and O
activating I-GENE
transcription I-GENE
factor I-GENE
proteins I-GENE
bound O
the O
junB I-GENE
CRE O
- O
like O
site O
, O
but O
did O
not O
interact O
with O
a O
mutant O
CRE O
- O
like O
site O
. O

Collectively O
, O
these O
results O
suggest O
that O
components O
of O
the O
protein I-GENE
kinase I-GENE
A I-GENE
signaling O
pathway O
are O
recruited O
by O
mIg RARE
to O
induce O
junB I-GENE
transcription O
. O

One O
complex O
containing O
a O
70 O
D O
protein O
was O
found O
to O
be O
associated O
specifically O
with O
transcriptionally O
active O
leukemia O
cells O
. O

Our O
results O
confirm O
the O
participation O
of O
intron O
1 O
in O
transcriptional O
regulation O
of O
the O
c I-GENE
- I-GENE
myb I-GENE
gene I-GENE
( O
in O
mouse O
and O
human O
) O
and O
implicate RARE
multiple O
and O
complex O
regulatory O
mechanisms O
of O
activation O
during O
myelomonocytic RARE
differentiation O
and O
leukemic RARE
cell O
growth O
control O
. O

Immunofluorescence RARE
microscopy O
revealed O
extensive O
deposition O
of O
such O
extracellular O
matrices RARE
as O
type I-GENE
IV I-GENE
collagen I-GENE
and O
laminin RARE
in O
the O
vascular O
wall O
. O

OBJECTIVE O
: O
To O
compare O
pregnancy O
complications O
in O
women O
having O
genetic O
amniocentesis RARE
at O
11 O
- O
14 O
weeks O
versus O
those O
undergoing O
amniocentesis RARE
at O
16 O
- O
19 O
weeks O
' O
gestation O
. O

Three O
ORFs O
( O
9765orfR002 NUMERIC
, O
9765orfR011 NUMERIC
and O
9765orfR013 NUMERIC
) O
were O
found O
to O
be O
homologous O
with O
Schizosaccharomyces O
pombe O
polyadenylate RARE
binding I-GENE
protein I-GENE
, O
Escherichia O
coli O
hypothetical RARE
38 O
. O
1 O
- O
kDa O
protein O
in O
the O
BCR I-GENE
5 O
' O
region O
, O
and O
transcription O
regulatory O
protein O
Swi3 NUMERIC
, O
respectively O
. O

Two O
new O
flavone RARE
glucosides RARE
, O
nevadensin RARE
5 O
- O
O O
- O
beta O
- O
D O
- O
glucoside RARE
and O
nevadensin RARE
5 O
- O
O O
- O
beta O
- O
D O
- O
glucosyl RARE
( O
1 O
--> O
6 O
) O
beta O
- O
D O
- O
glucoside RARE
, O
have O
been O
isolated O
from O
the O
aerial RARE
parts O
of O
Lysionotus RARE
pauciflorus RARE
. O

Recently O
, O
our O
laboratory O
developed O
a O
screen O
that O
identified O
five O
multicopy O
suppressors O
that O
can O
rescue O
lethal O
strains O
of O
clathrin I-GENE
heavy O
chain O
- O
deficient O
yeast O
( O
Chc RARE
- O
scd1 NUMERIC
- I-GENE
i I-GENE
) O
to O
viability O
. O

Reproductive RARE
period O
affects O
water O
intake O
in O
heat O
- O
stressed O
dehydrated RARE
goats O
. O

The O
logistic RARE
regression O
analysis O
of O
the O
manual RARE
method O
( O
percentage O
normal O
morphology O
) O
and O
IVOS ALLCAPS
indicated O
that O
both O
were O
predictors O
of O
fertilization O
. O

METHODS O
: O
Rats O
received O
continuous O
intragastric RARE
infusion O
of O
elemental RARE
diet O
or O
with O
supplementation O
of O
oatbase RARE
, O
Lactobacillus RARE
reuteri RARE
R2LC NUMERIC
, O
and O
Lactobacillus RARE
plantarum RARE
DSM ALLCAPS
9843 NUMERIC
, O
with O
and O
without O
fermentation RARE
, O
from O
the O
beginning O
of O
the O
study O
. O

However O
, O
D8 NUMERIC
binding O
was O
observed O
by O
nuclease O
protection O
with O
lactotroph RARE
- I-GENE
as I-GENE
well I-GENE
as I-GENE
somatotroph RARE
- I-GENE
like I-GENE
cell I-GENE
nuclear I-GENE
protein I-GENE
. O

Limited RARE
role O
for O
PCR O
- O
based O
diagnosis O
of O
Whipple RARE
' O
s O
disease O
from O
peripheral O
blood O
mononuclear O
cells O
. O

The O
ability O
of O
A20 NUMERIC
to O
block O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
was O
mapped O
to O
its O
C O
- O
terminal O
zinc O
finger O
domain O
. O

The O
Pro O
- O
258 O
--> O
Leu O
( O
P258L NUMERIC
) O
mutation O
caused O
constitutive O
receptor O
signaling O
that O
was O
equivalent O
to O
about O
45 O
% O
of O
the O
maximum O
level O
observed O
in O
wild O
- O
type O
cells O
stimulated O
with O
alpha I-GENE
- I-GENE
factor I-GENE
. O

By O
using O
a O
DNA O
sequence O
selected O
for O
its O
ability O
to O
bind O
recombinant I-GENE
BCL I-GENE
- I-GENE
6 I-GENE
in O
vitro O
, O
we O
show O
here O
that O
BCL I-GENE
- I-GENE
6 I-GENE
is O
present O
in O
DNA O
- O
binding O
complexes O
in O
nuclear O
extracts O
from O
various O
B O
- O
cell O
lines O
. O

The O
predictive O
value O
of O
a O
positive O
flag RARE
was O
77 O
. O
7 O
%. O

CONCLUSIONS O
: O
Our O
findings O
suggest O
that O
pre O
- O
treatment O
with O
coenzyme O
Q10 NUMERIC
may O
play O
a O
protective O
role O
during O
routine O
vascular O
procedures O
requiring O
abdominal O
aortic O
cross O
clamping RARE
by O
attenuating RARE
the O
degree O
of O
peroxidative RARE
damage O
. O

Because O
chromosome O
X O
is O
frequently O
involved O
in O
structural O
alterations O
in O
neoplastic O
Syrian O
hamster O
cells O
transformed O
by O
chemical O
carcinogens RARE
and O
oncogenic O
viruses O
, O
the O
localization O
of O
the O
cph RARE
locus I-GENE
on O
this O
chromosome O
supports O
the O
notion O
that O
the O
cph RARE
oncogene I-GENE
plays O
a O
role O
in O
the O
malignant O
conversion O
of O
chemically RARE
transformed O
hamster O
fibroblasts O
. O

In O
a O
screen O
for O
genes O
with O
oncogenic O
potential O
expressed O
by O
the O
murine O
B6SUtA1 NUMERIC
myeloid O
progenitor O
cell O
line O
, O
we O
isolated O
a O
2 O
. O

Gap1 NUMERIC
( O
IP4BP NUMERIC
), O
one O
of O
a O
member O
of O
Ras I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
, O
has O
been O
identified O
as O
a O
specific O
inositol I-GENE
1 I-GENE
, I-GENE
3 I-GENE
, I-GENE
4 I-GENE
, I-GENE
5 I-GENE
- I-GENE
tetrakisphosphate RARE
( I-GENE
IP4 NUMERIC
)- I-GENE
binding I-GENE
protein I-GENE
( O
Cullen RARE
, O
P O
. O

We O
previously O
described O
the O
purification O
of O
an O
83 I-GENE
- I-GENE
kDa I-GENE
phosphatidic RARE
acid I-GENE
phosphatase I-GENE
( O
PAP ALLCAPS
) O
from O
the O
porcine O
thymus RARE
membranes O
( O
Kanoh RARE
, O
H O
., O
Imai RARE
, O
S O
.- RARE
i O
., O
Yamada RARE
, O
K O
. O
and O
Sakane RARE
, O
F O
.( O
1992 O
) O
J O
. O

The O
mechanism O
involves O
Gbetagamma I-GENE
subunit O
- O
mediated O
increases O
in O
tyrosine O
phosphorylation O
of O
the O
Shc I-GENE
adapter I-GENE
protein I-GENE
, O
Shc I-GENE
* O
Grb2 I-GENE
complex O
formation O
, O
and O
recruitment O
of O
Ras I-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
activity O
. O

A O
cDNA O
encoding O
the O
amino O
- O
terminal O
17 O
% O
of O
apoB LASTCAP
( O
apoB17 NUMERIC
) O
was O
fused O
to O
a O
cDNA O
coding O
for O
the O
last O
37 O
amino O
acids O
of O
decay I-GENE
- I-GENE
accelerating RARE
factor I-GENE
( O
DAF ALLCAPS
), O
which O
contains O
the O
signal O
for O
glycosylphosphatidylinositol RARE
anchor O
attachment O
. O

Next RARE
, O
we O
stably O
overexpressed O
wild I-GENE
- I-GENE
type I-GENE
Shc I-GENE
or O
Y317F NUMERIC
mutant I-GENE
Shc I-GENE
into O
HIRc RARE
cells O
. O

The O
small I-GENE
GTPase I-GENE
Rho I-GENE
is O
implicated O
in O
physiological O
functions O
associated O
with O
actin I-GENE
- O
myosin I-GENE
filaments RARE
such O
as O
cytokinesis RARE
, O
cell O
motility O
, O
and O
smooth O
muscle O
contraction O
. O

Conversely O
, O
activation O
of O
this O
signaling O
pathway O
by O
expression O
of O
a O
constitutively O
active O
MKK1 NUMERIC
mutant I-GENE
dramatically O
increased O
cyclin I-GENE
D1 I-GENE
promoter O
activity O
and O
cyclin I-GENE
D1 I-GENE
protein I-GENE
expression O
, O
in O
a O
growth O
factor O
- O
independent O
manner O
. O

Furthermore O
, O
upstream O
insertion O
of O
the O
GSTP1 NUMERIC
silencer I-GENE
element I-GENE
failed O
to O
inhibit O
activity O
of O
a O
heterologous O
promoter O
in O
MCF7 NUMERIC
cells O
. O

In O
order O
to O
delineate RARE
structural O
motifs O
regulating O
substrate O
affinity O
and O
recognition O
for O
the O
human I-GENE
dopamine I-GENE
transporter I-GENE
( O
DAT ALLCAPS
), O
we O
assessed O
[ O
3H O
] O
dopamine O
uptake O
kinetics O
and O
[ O
3H O
] O
CFT ALLCAPS
binding O
characteristics O
of O
COS O
- O
7 O
cells O
transiently O
expressing O
mutant I-GENE
DATs RARE
in O
which O
the O
COOH O
terminus O
was O
truncated O
or O
substituted O
. O

An O
expression O
library O
was O
constructed O
by O
inserting O
5 O
' O
portion O
- O
enriched O
cDNAs O
from O
phytohemagglutinin I-GENE
- O
stimulated O
peripheral O
blood O
mononuclear O
cells O
into O
upstream O
of O
signal I-GENE
sequence I-GENE
- I-GENE
deleted I-GENE
CD4 I-GENE
cDNA I-GENE
in O
an O
Epstein O
- O
Barr O
virus O
shuttle RARE
vector O
. O

Radiolabeled RARE
recombinant I-GENE
TARC ALLCAPS
specifically O
bound O
to O
T O
cell O
lines O
and O
peripheral O
T O
cells O
but O
not O
to O
monocytes O
or O
granulocytes RARE
. O

The O
cis O
- O
acting O
elements O
that O
control O
promoter O
activity O
include O
binding O
sites O
for O
transcription O
factors O
Sp1 I-GENE
and O
alphaCbf RARE
, O
a O
60 I-GENE
- I-GENE
kDa I-GENE
CCAAT I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

Therefore O
, O
we O
have O
identified O
a O
cis O
- O
acting O
element O
, O
the O
E1 O
E O
- O
box O
, O
located O
in O
the O
GAP I-GENE
- I-GENE
43 I-GENE
promoter O
region O
that O
modulates RARE
either O
positively O
or O
negatively O
the O
expression O
of O
the O
GAP I-GENE
- I-GENE
43 I-GENE
gene I-GENE
depending O
on O
which O
E I-GENE
- I-GENE
box I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
occupy RARE
this O
site O
. O

Collectively O
, O
our O
findings O
demonstrate O
that O
SF I-GENE
- I-GENE
1 I-GENE
plays O
a O
key O
role O
in O
controlling O
the O
basal O
and O
cAMP O
- O
stimulated O
expression O
of O
the O
StAR LASTCAP
gene I-GENE
. O

There O
was O
a O
general O
broadening RARE
of O
proton O
resonances RARE
for O
a O
three O
- O
nucleotide O
segment O
centered O
about O
the O
lesion O
site O
which O
resulted O
in O
a O
tentative RARE
assignment O
for O
the O
sugar O
protons RARE
of O
the O
C7 NUMERIC
residue O
in O
the O
spectrum O
of O
the O
adduct RARE
duplex O
. O

Using O
one O
of O
the O
six O
fragments O
( O
CPK3 NUMERIC
- I-GENE
8 I-GENE
), O
we O
isolated O
a O
2022 NUMERIC
bp I-GENE
cDNA I-GENE
( I-GENE
VrCDPK LASTCAP
- I-GENE
1 I-GENE
) I-GENE
from O
a O
Vigna RARE
radiata RARE
lambda O
gt11 O
library O
. O

However O
, O
in O
TF O
- O
1 O
cells O
grown O
on O
GM I-GENE
- I-GENE
CSF I-GENE
before O
starvation O
, O
CREB I-GENE
phosphorylation O
was O
observed O
10 O
minutes O
after O
PIXY321 NUMERIC
stimulation O
. O

Workplace RARE
violence RARE
-- O
nurses RARE
at O
risk O
. O

RESULTS O
: O
The O
LV O
maximum O
brightness RARE
and O
area O
under O
the O
curve O
showed O
significant O
negative O
correlations O
( O
p O
= O
< O
0 O
. O
004 NUMERIC
) O
with O
the O
FIO2 NUMERIC
, O
while O
the O
minimum O
brightness RARE
showed O
a O
significant O
positive O
correlation O
( O
p O
= O
< O
0 O
. O
002 NUMERIC
). O

The O
results O
also O
imply O
that O
the O
absence O
of O
perforin RARE
expression O
in O
non O
- O
cytotoxic O
cells O
may O
be O
due O
to O
the O
suppression O
of O
the O
induction O
of O
the O
killer O
- O
cell O
- O
specific O
trans O
- O
acting O
factor O
NF I-GENE
- I-GENE
P2 I-GENE
. O

We O
identify O
considerable O
spatio RARE
- O
temporal O
similarities O
between O
reported O
expression O
patterns O
of O
Ypr10 NUMERIC
genes I-GENE
and O
ribonuclease O
genes O
, O
which O
, O
together O
with O
the O
significant O
sequence O
similarity O
to O
the O
ginseng RARE
ribonuclease I-GENE
, O
support O
the O
hypothesis O
of O
a O
ribonuclease O
function O
for O
PR I-GENE
- I-GENE
10 I-GENE
proteins I-GENE
and O
allow O
the O
prediction O
of O
possible O
biological O
roles O
. O

The O
expression O
of O
ERV3 NUMERIC
env I-GENE
mRNA I-GENE
was O
found O
to O
be O
differentiation O
- O
associated O
, O
with O
high O
expression O
detected O
in O
the O
late O
stages O
of O
monocytic O
development O
. O

Initial O
estimates O
indicate O
that O
27 O
, O
193 O
people O
are O
either O
in O
receipt RARE
of O
or O
in O
need O
of O
mental O
handicap RARE
services RARE
. O

It O
is O
exclusively O
observed O
in O
smooth O
muscle O
cells O
by O
Northern O
blotting O
and O
immunohistochemical O
analysis O
and O
therefore O
designated O
" I-GENE
smoothelin RARE
." I-GENE
A O
human O
smooth O
muscle O
cDNA O
library O
was O
screened O
with O
the O
monoclonal I-GENE
antibody I-GENE
R4A NUMERIC
, O
and O
a O
full O
- O
size O
cDNA O
of O
the O
protein O
was O
selected O
. O

Using O
immunogold RARE
electron O
microscopy O
, O
we O
found O
that O
p58 NUMERIC
/ O
p45 NUMERIC
and O
p54 I-GENE
are O
localized O
on O
both O
sides O
of O
the O
nuclear O
pore O
complex O
, O
like O
p62 I-GENE
. O

Concurrent RARE
with O
ligand O
- O
dependent O
uptake O
, O
we O
now O
show O
that O
the O
receptor O
undergoes O
ligand O
- O
induced O
ubiquitination O
, O
suggesting O
that O
receptor O
ubiquitination O
may O
function O
in O
the O
ligand O
- O
dependent O
endocytosis RARE
of O
the O
a I-GENE
- I-GENE
factor I-GENE
receptor I-GENE
as O
well O
as O
in O
its O
constitutive O
endocytosis RARE
. O

Transcription O
initiation O
sites O
of O
the O
rat O
II I-GENE
beta I-GENE
-, I-GENE
III I-GENE
beta I-GENE
, I-GENE
and I-GENE
O I-GENE
beta I-GENE
- I-GENE
globin I-GENE
genes O
were O
determined O
to O
be O
52 O
base O
pairs O
( O
bp O
) O
5 O
'- O
upstream O
of O
the O
translation O
initiation O
codon O
( O
ATG O
), O
in O
each O
gene O
by O
primer O
extension O
analysis O
. O

Aggravating RARE
process O
induced O
by O
indomethacin O
on O
chronic O
gastric O
lesion O
in O
rat O
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
nuclear I-GENE
protein I-GENE
2 I-GENE
( O
EBNA2 I-GENE
) O
binds O
to O
a O
component O
of O
the O
human O
SNF ALLCAPS
- O
SWI ALLCAPS
complex O
, O
hSNF5 NUMERIC
/ O
Ini1 NUMERIC
. O

Our O
studies O
also O
excluded O
the O
possibility O
that O
the O
phosphorylation O
of O
Ser O
- O
2 O
, O
Ser O
- O
123 O
, O
or O
Ser O
- O
210 O
, O
had O
roles O
in O
the O
trans O
- O
suppression O
activity O
of O
the O
large I-GENE
HDAg RARE
, O
in O
the O
assembly O
of O
empty RARE
virus I-GENE
- I-GENE
like I-GENE
HDAg RARE
particle I-GENE
, O
and O
in O
the O
nuclear O
transport O
of O
HDAgs RARE
. O

Homologous RARE
recombination O
between O
the O
Autographa RARE
californica RARE
nuclear O
polyhedrosis RARE
virus O
( O
AcNPV LASTCAP
) O
genome O
and O
a O
0 O
. O
6 O
- O
kbp O
- O
long O
DNA O
fragment O
derived O
from O
the O
putative O
DNA I-GENE
helicase I-GENE
gene I-GENE
of I-GENE
Bombyx RARE
mori RARE
nuclear I-GENE
polyhedrosis RARE
virus I-GENE
generates O
eh2 NUMERIC
- O
AcNPV LASTCAP
, O
an O
expanded RARE
- O
host O
- O
range O
AcNPV LASTCAP
mutant O
( O
S O
. O

The O
data O
further O
indicate O
that O
the O
IL I-GENE
- I-GENE
7R NUMERIC
alpha I-GENE
chains I-GENE
are O
directly O
involved O
in O
the O
activation O
of O
JAKs RARE
and O
STATs RARE
and O
have O
a O
major O
role O
in O
proliferative O
signaling O
in O
precursor O
B O
cells O
. O

Furthermore O
, O
the O
potency O
of O
Dacarbacine RARE
in O
the O
treatment O
of O
carcinoid RARE
tumors O
seems O
to O
be O
underestimated RARE
up O
to O
now O
. O

5 O
) O
We O
' O
ve RARE
noticed RARE
that O
the O
mean O
value O
of O
the O
cost O
for O
episode RARE
of O
pnx RARE
s O
. O
in O
class O
A O
was O
more O
than O
15 O
% O
compared O
to O
class O
B O
and O
the O
cost O
for O
patient O
in O
class O
A O
was O
nearly O
double O
than O
in O
class O
B O
. O

We O
have O
been O
studying O
the O
interaction O
of O
the O
oncogenic O
human O
polyomavirus RARE
BK ALLCAPS
( O
BKV ALLCAPS
) O
with O
the O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
p53 I-GENE
to O
understand O
the O
biology RARE
of O
this O
virus O
as O
well O
as O
to O
understand O
the O
basic O
mechanisms O
of O
p53 I-GENE
transactivation O
. O

Site O
S O
- O
II O
also O
spans O
a O
23 O
bp O
sequence O
containing O
two O
tandem O
consensus O
binding O
sites O
with O
three O
base O
pair O
mismatches RARE
in O
each O
and O
a O
one O
base O
pair O
deletion O
. O

Cbl I-GENE
constitutively O
interacts O
with O
the O
SH3 I-GENE
domains I-GENE
of O
Grb2 I-GENE
, O
with O
a O
preference O
for O
the O
amino O
- O
terminal O
domain O
, O
and O
is O
in O
this O
way O
recruited O
to O
Shc I-GENE
upon O
BCR I-GENE
stimulation O
. O

Activation O
mediated O
by O
Cat8p NUMERIC
was O
no O
longer O
detectable O
in O
a O
cat1 NUMERIC
mutant I-GENE
. O

Treatment O
is O
instituted RARE
with O
prednisone O
and O
cyclophosphamide O
. O

Unaided RARE
attempts O
to O
quit RARE
smoking O
are O
generally O
unsuccessful RARE
. O

Laboratory O
evaluation O
was O
normal O
, O
and O
neuroimaging RARE
failed O
to O
confirm O
obstruction O
of O
venous O
or O
lymphatic RARE
drainage O
. O

Microcomputer RARE
management O
of O
chronic O
hepatitis O
B O
virus O
asymptomatic O
patients O

While O
fusion O
to O
the O
N O
- O
terminus O
required O
a O
linker O
to O
become O
surface O
accessible RARE
, O
both O
fusion O
to O
the O
N O
- O
terminus O
and O
to O
the O
C O
- O
terminus O
was O
compatible O
with O
particle O
assembly O
and O
preserved RARE
the O
native O
antigenicity RARE
and O
immunogenicity RARE
of O
HBcAg RARE
. O

The O
standard O
dosage O
of O
anti I-GENE
- I-GENE
D I-GENE
currently O
given O
at O
all O
gestational O
ages O
is O
1 O
ampoule RARE
containing O
125 O
micrograms O
of O
anti I-GENE
- I-GENE
D I-GENE
. O

We O
report O
here O
the O
molecular O
cloning O
of O
a O
putative O
adhesive O
molecule O
from O
P O
. O
falciparum O
that O
shares O
both O
sequence O
and O
structural O
similarities O
with O
a O
sporozoite RARE
surface O
molecule O
from O
Plasmodium RARE
termed O
the O
thrombospondin RARE
- I-GENE
related I-GENE
anonymous RARE
protein I-GENE
( O
TRAP ALLCAPS
) O
and O
, O
to O
a O
lesser O
extent O
, O
with O
the O
circumsporozoite RARE
( I-GENE
CS I-GENE
) I-GENE
protein I-GENE
. O

There O
are O
no O
introns O
within O
the O
gene O
, O
which O
contains O
a O
9360 NUMERIC
- O
bp O
open O
reading O
frame O
and O
encodes O
a O
377 NUMERIC
- O
kDa O
protein O
. O

METHODS O
: O
DSF ALLCAPS
was O
instilled RARE
in O
one O
eye O
chosen O
at O
random O
and O
CF ALLCAPS
in O
the O
fellow RARE
eye O
of O
13 O
normal O
subjects O
and O
in O
13 O
patients O
with O
KCS O
. O

The O
experience O
of O
the O
lateral O
rhinotomy RARE
approach O
in O
transsphenoidal RARE
surgery O
of O
acromegaly RARE
has O
been O
favourable O
. O

CONCLUSION O
: O
The O
results O
demonstrate O
that O
at O
the O
site O
of O
lumbar O
disc O
herniation RARE
, O
inflammatory O
cytokines O
such O
as O
interleukin I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
are O
produced O
, O
which O
increases O
prostaglandin O
E2 O
production O
. O

The O
predominant O
sensitizing RARE
allergens O
in O
Swedish RARE
asthmatic O
children O
are O
furred RARE
pet RARE
animals O
. O

Our O
results O
demonstrate O
that O
distinct O
cytoplasmic O
domains O
of O
these O
cytokine O
receptors O
elicit O
convergent RARE
signaling O
pathways O
and O
provide O
evidence O
that O
beta I-GENE
c I-GENE
and O
IL I-GENE
- I-GENE
2R I-GENE
beta I-GENE
function O
as O
a O
complete O
signal O
transducer RARE
. O

In O
addition O
, O
they O
display O
common O
features O
that O
make O
them O
strikingly O
related O
to O
snoRNA LASTCAP
U14 I-GENE
. O

U24 NUMERIC
has O
two O
separate O
12 O
nt O
long O
complementarities RARE
to O
a O
highly O
conserved O
tract O
of O
28S I-GENE
rRNA I-GENE
. O

This O
complex O
interacts O
at O
the O
GTPase I-GENE
domain I-GENE
in O
the O
large O
subunit O
rRNA O
, O
overlapping O
the O
binding O
site O
of O
the O
protein I-GENE
L11 NUMERIC
- I-GENE
like I-GENE
eukaryotic I-GENE
counterpart I-GENE
( O
Saccharomyces I-GENE
cerevisiae I-GENE
protein I-GENE
L15 NUMERIC
and O
mammalian I-GENE
protein I-GENE
L12 I-GENE
). O

Chromatin RARE
repression O
of O
these O
replacement O
genes O
would O
be O
avoided RARE
, O
consistent O
with O
the O
high O
, O
constitutive O
expression O
of O
replacement O
H3 I-GENE
histone I-GENE
genes I-GENE
in O
plants O
. O

This O
transition O
is O
regulated O
positively O
by O
G1 I-GENE
- I-GENE
specific I-GENE
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
cdks RARE
) O
and O
negatively O
by O
the O
product O
of O
the O
retinoblastoma I-GENE
tumour I-GENE
suppressor I-GENE
gene I-GENE
, O
pRb I-GENE
. O

Possible RARE
relationship O
between O
hyperinsulinemia RARE
and O
glomerular O
hypertrophy O
in O
nephrosclerosis RARE
. O

Blood O
GSH ALLCAPS
- I-GENE
Px I-GENE
activity O
was O
measured O
with O
a O
spectrophotometer RARE
, O
using O
a O
modification O
of O
a O
previously O
described O
assay O
. O

The O
concentrations O
of O
vitamin O
A O
precursors O
and O
vitamin O
E O
in O
the O
hay RARE
were O
below O
currently O
recommended O
dietary O
levels O
for O
llamas RARE
, O
and O
alfalfa RARE
hay RARE
appears O
to O
provide O
an O
unreliable RARE
source O
of O
vitamins RARE
A O
and O
E O
in O
this O
species O
. O

Eight O
cats O
infected O
with O
H O
. O
pylori O
were O
used O
in O
the O
study O
. O

However O
, O
as O
determined O
by O
PCR O
with O
primers O
specific O
for O
the O
26 O
- O
kDa O
product O
, O
the O
majority O
of O
cats O
at O
2 O
and O
4 O
weeks O
p O
. O
t O
. O
had O
gastric O
fluid O
samples O
which O
were O
positive O
for O
H O
. O
pylori O
and O
three O
of O
three O
cats O
at O
2 O
weeks O
p O
. O
t O
. O
had O
dental O
plaque O
which O
was O
positive O
for O
H O
. O
pylori O
. O

To O
derive RARE
quantitative O
concentration O
changes O
from O
measurements O
of O
light O
attenuation O
, O
the O
optical O
path RARE
length O
must O
be O
known O
. O

STUDY ALLCAPS
DESIGN O
. O

Following O
the O
injection O
of O
PGF2 O
alpha O
, O
heifers O
were O
observed O
visually RARE
for O
signs O
of O
estrus RARE
at O
0730 NUMERIC
and O
1630 NUMERIC
( O
45 O
min O
each O
). O

Differential O
activation O
of O
the O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
, O
Jun I-GENE
kinase I-GENE
and O
Janus I-GENE
kinase I-GENE
- O
Stat I-GENE
pathways O
by O
oncostatin RARE
M I-GENE
and O
basic I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
in O
AIDS O
- O
derived O
Kaposi O
' O
s O
sarcoma O
cells O
. O

There O
is O
general O
agreement O
that O
the O
hepatitis O
C O
virus O
is O
efficiently O
transmitted O
parenterally RARE
, O
while O
data O
on O
viral O
transmission O
from O
mothers O
to O
babies O
or O
by O
sexual O
or O
non O
- O
sexual O
household RARE
contact O
are O
conflicting RARE
. O

Ten O
weeks O
after O
reconstruction O
, O
the O
regenerating RARE
nerves O
already O
resembled RARE
normal O
nerves O
. O

The O
distribution O
and O
organization O
of O
projections O
from O
the O
spinal O
cervical O
enlargement O
to O
subnucleus RARE
reticularis RARE
dorsalis RARE
( O
SRD ALLCAPS
) O
and O
the O
neighbouring RARE
Cuneate RARE
nucleus O
( O
Cu O
) O
area O
was O
studied O
in O
the O
rat O
by O
using O
microinjections RARE
of O
Phaseolus RARE
vulgaris RARE
leucoagglutinin RARE
( O
PHA I-GENE
- I-GENE
L I-GENE
) O
into O
different O
laminae RARE
around O
the O
C7 NUMERIC
level O
. O

The O
levels O
of O
fibrinogen I-GENE
as O
well O
as O
antithrombin I-GENE
III I-GENE
( O
ATIII ALLCAPS
) O
and O
heparin I-GENE
cofactor I-GENE
II I-GENE
( O
HCII ALLCAPS
) O
activities O
were O
steadily RARE
increased O
in O
loop O
- O
bearing O
animals O
. O

Amplification RARE
and O
overexpression O
of O
the O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
2 I-GENE
gene I-GENE
in O
21MT NUMERIC
- O
2 O
and O
21MT NUMERIC
- O
1 O
human O
breast O
carcinoma O
cells O
results O
in O
progressively RARE
elevated O
levels O
of O
constitutively O
tyrosine I-GENE
- I-GENE
phosphorylated I-GENE
p185erbB NUMERIC
- I-GENE
2 I-GENE
and O
is O
associated O
with O
progressive O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
( O
IGF I-GENE
) O
and O
combined O
IGF I-GENE
/ O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
) O
independence RARE
in O
culture O
. O

Facioscapulohumeral RARE
muscular O
dystrophy O
( O
FSHD ALLCAPS
) O
is O
an O
autosomal RARE
dominant O
, O
neuromuscular O
disorder O
characterized O
by O
progressive O
weakness RARE
of O
muscles O
in O
the O
face O
, O
shoulder RARE
and O
upper O
arm O
. O

The O
mature O
chromosome O
4 O
FRG1 NUMERIC
transcript I-GENE
is O
1042 NUMERIC
bp O
in O
length O
and O
contains O
nine O
exons O
which O
encode O
a O
putative O
protein O
of O
258 O
amino O
acid O
residues O
. O

Patients O
who O
have O
undergone O
thyroidectomy RARE
for O
thyroid O
carcinoma O
are O
frequently O
subjected O
to O
periods O
of O
induced O
severe O
hypothyroidism O
in O
preparation O
for O
131I O
whole O
body O
scanning O
and O
measurement O
of O
serum O
TG I-GENE
. O

Full RARE
thyroid O
function O
testing O
was O
performed O
on O
600 O
randomly O
selected O
samples O
with O
normal O
TSH I-GENE
values O
and O
also O
on O
subjects O
with O
abnormal O
TSH I-GENE
levels O
. O

In O
a O
third O
experiment O
, O
crossover RARE
AM O
between O
dissimilar RARE
textures RARE
was O
investigated O
, O
and O
it O
was O
found O
that O
the O
more O
salient RARE
textures RARE
carried O
the O
AM O
. O

The O
relative O
tumor O
FDG O
- O
uptake O
( O
Q O
- O
MRGlu RARE
) O
( O
tumor O
/ O
contralateral O
cortex O
) O
of O
all O
meningiomas RARE
was O
calculated O
with O
0 O
. O
73 O
+/- O
0 O
. O
37 O
( O
0 O
. O
24 O
- O
1 O
. O
79 O
). O

Zatebradine RARE
weakly O
depressed O
the O
ectopic O
ventricular O
rate O
but O
not O
the O
arrhythmic RARE
ratio O
of O
the O
ventricular O
arrhythmias O
induced O
by O
two O
- O
stage O
coronary O
ligation O
24 O
h O
after O
the O
ligation O
in O
conscious O
dogs O
. O

Catha RARE
edulis RARE
, O
a O
plant O
that O
has O
amphetamine O
effects O
. O

The O
predicted O
protein O
, O
Seb1p NUMERIC
, O
consists O
of O
82 O
amino O
acids O
and O
contains O
one O
potential O
membrane O
- O
spanning O
region O
at O
the O
C O
- O
terminus O
but O
no O
N O
- O
terminal O
signal O
sequence O
. O

The O
SEB1 NUMERIC
homologue O
thus O
isolated O
, O
SEB2 NUMERIC
, O
encodes O
a O
protein O
53 O
% O
identical O
to O
Seb1p NUMERIC
. O

Nonetheless RARE
, O
that O
ventricular O
afferents O
, O
in O
certain O
special O
settings RARE
, O
are O
able O
to O
induce O
e O
. O
g O
. O
generalised RARE
vasodilation O
and O
hypotension O
cannot O
be O
excluded O
. O

Large O
ones O
were O
similar O
in O
size O
to O
the O
main O
lobe O
and O
small O
ones O
were O
approximately O
1 O
/ O
4 O
of O
the O
length O
of O
the O
main O
lobe O
. O

Fragments RARE
and O
analogs RARE
of O
the O
hormone O
ACTH I-GENE
were O
previously O
shown O
to O
have O
beneficial O
effect O
on O
the O
outcome O
of O
head O
injury O
, O
while O
elevated O
levels O
of O
corticosterone O
( O
CS O
) O
exacerbate RARE
it O
. O

The O
most O
frequent O
causes O
of O
the O
meningitis O
was O
the O
external O
ventricular O
drainage O
( O
14 O
. O
8 O
%), O
post O
- O
neurosurgical RARE
( O
0 O
. O
8 O
%) O
and O
head O
injury O
( O
0 O
. O
0007 NUMERIC
%). O

Fifty O
- O
one O
patients O
with O
primary O
refractory O
or O
relapsed RARE
malignant O
lymphoma O
( O
47 O
non O
- O
Hodgkin O
' O
s O
lymphoma O
and O
four O
Hodgkin O
' O
s O
disease O
) O
were O
treated O
with O
a O
new O
chemotherapeutic O
regimen O
( O
cisplatinum RARE
, O
methyl O
GAG ALLCAPS
, O
bleomocyin RARE
, O
methyl O
prednisolon RARE
). O

With O
the O
increasing O
use O
of O
ACE I-GENE
inhibitors O
, O
the O
incidence O
of O
rare O
adverse O
effects O
such O
as O
potentially O
lethal O
pancreatitis O
is O
likely O
to O
increase O
. O

In O
3 O
treatments O
the O
diet O
was O
supplemented O
with O
0 O
, O
100 O
and O
150 O
mg O
probiotic RARE
/ O
kg O
food O
. O

Low O
- O
dose O
aspirin O
and O
recurrent O
miscarriage RARE
. O

Protein O
films O
are O
distinctly O
different O
in O
mechanical O
profiles O
from O
those O
films O
made O
of O
other O
materials O
. O

Furthermore O
, O
cpxA LASTCAP
* I-GENE
mutations O
suppress O
the O
toxicity O
conferred O
by O
the O
LamB LASTCAP
- O
LacZ LASTCAP
hybrid O
protein O
, O
which O
exerts O
its O
effects O
in O
the O
cytoplasm O
, O
sequestered RARE
from O
DegP LASTCAP
. O

The O
PI3K_68D NUMERIC
cDNA I-GENE
encodes O
a O
protein O
of O
210 O
kDa O
, O
which O
lacks O
sequences O
implicated O
in O
linking O
p110 NUMERIC
PI I-GENE
3 I-GENE
- I-GENE
kinases I-GENE
to O
p85 I-GENE
adaptor I-GENE
proteins I-GENE
, O
but O
contains O
an O
amino O
- O
terminal O
proline O
- O
rich O
sequence O
, O
which O
could O
bind O
to O
SH3 I-GENE
domains I-GENE
, O
and O
a O
carboxy O
- O
terminal O
C2 I-GENE
domain O
. O

In O
vitro O
interaction O
studies O
, O
using O
proteins O
fused O
to O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
, O
showed O
that O
RBP ALLCAPS
- I-GENE
J I-GENE
kappa I-GENE
and O
Su RARE
( I-GENE
H I-GENE
) I-GENE
bind O
directly O
to O
the O
RAM23 NUMERIC
regions I-GENE
of O
mouse I-GENE
Notch1 NUMERIC
and O
Drosophila I-GENE
Notch I-GENE
, O
respectively O
. O

AIMS ALLCAPS
/ O
METHODS O
: O
Reticuloendothelial RARE
system O
function O
, O
as O
assessed O
by O
clearance O
of O
radiolabelled RARE
bacteria O
, O
was O
evaluated O
in O
acute O
liver O
injury O
induced O
by O
D O
- O
galactosamine RARE
in O
rats O
, O
and O
compared O
with O
that O
after O
70 O
% O
liver O
resection O
model O
. O

Our O
laboratory O
and O
others O
have O
shown O
alternative O
splicing O
of O
up O
to O
ten O
exons O
at O
a O
discrete O
extracellular O
site O
to O
be O
primarily O
responsible O
for O
the O
generation O
of O
CD44 I-GENE
variant I-GENE
( O
CD44v NUMERIC
) O
isoforms O
. O

Study O
groups O
were O
control O
, O
and O
those O
treated O
with O
the O
alpha1 I-GENE
- I-GENE
adrenoceptor I-GENE
- I-GENE
subtype I-GENE
blockers O
WB4101 NUMERIC
( O
0 O
. O
5 O
mg O
/ O
kg O
i O
. O
v O
.) O
or O
chloroethylclonidine RARE
( O
1 O
. O
9 O
mg O
/ O
kg O
i O
. O
v O
.). O

This O
caused O
severe O
cortical O
damage O
and O
neuronal O
loss O
in O
hippocampus O
subfields RARE
CA1 NUMERIC
, O
CA3 O
, O
and O
hilus RARE
. O

The O
occurrence O
of O
multiple O
malignancy O
was O
studied O
in O
674 NUMERIC
patients O
with O
hematologic RARE
malignancies RARE
who O
were O
admitted RARE
to O
this O
department RARE
during O
the O
past O
10 O
years O
. O

The O
upTRE LASTCAP
binds O
more O
T3R I-GENE
homodimers I-GENE
and O
less O
T3R I-GENE
- O
RXR I-GENE
heterodimers O
than O
the O
dnTRE LASTCAP
, O
and O
T3 O
more O
readily O
facilitates RARE
heterodimer O
binding O
to O
the O
dn RARE
- O
than O
to O
the O
upTRE LASTCAP
. O

Transcriptional O
control O
of O
a O
nuclear O
gene O
encoding O
a O
mitochondrial O
fatty O
acid O
oxidation O
enzyme O
in O
transgenic O
mice O
: O
role O
for O
nuclear O
receptors O
in O
cardiac O
and O
brown O
adipose O
expression O
. O

Hoeben RARE
, O
F O
. O
J O
. O

Twelve RARE
genomic O
fragments O
containing O
novel O
response O
elements O
are O
described O
, O
and O
the O
transcription O
unit O
associated O
with O
one O
of O
them O
, O
NN ALLCAPS
- I-GENE
84AG NUMERIC
, O
was O
characterized O
in O
detail O
. O

Moreover O
, O
glucan RARE
synthase I-GENE
activity O
, O
which O
is O
activated O
by O
Rho1p NUMERIC
, O
was O
significantly O
reduced O
in O
the O
deltabem4 NUMERIC
mutant I-GENE
. O

In O
gel O
retardation O
assays O
, O
an O
RCS ALLCAPS
cell O
- O
specific O
protein O
and O
another O
closely O
related O
protein O
expressed O
only O
in O
RCS ALLCAPS
cells O
and O
primary O
chondrocytes RARE
bound O
to O
a O
10 O
- O
bp O
sequence O
within O
the O
18 O
- O
mer O
. O

Two O
classes O
of O
Xanthomonas RARE
pathogens O
evading RARE
Bs2 NUMERIC
host O
resistance O
and O
displaying RARE
reduced O
fitness O
were O
found O
to O
be O
specifically O
mutated O
in O
avrBs2 NUMERIC
. O

Members O
of O
the O
Ras I-GENE
subfamily I-GENE
of O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
have O
been O
shown O
to O
be O
promiscuous RARE
towards O
a O
variety O
of O
putative O
effector O
molecules O
such O
as O
the O
protein I-GENE
kinase I-GENE
c I-GENE
- I-GENE
Raf I-GENE
and O
the O
Ral RARE
- I-GENE
specific I-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
Ral RARE
- I-GENE
GEF ALLCAPS
). O

Thus O
, O
the O
characterization O
of O
the O
promoter O
region O
should O
help O
to O
define O
regulatory O
elements O
that O
control O
neuron O
- O
specific O
and O
developmental O
expression O
of O
the O
MAP1B NUMERIC
gene I-GENE
. O

The O
cDNA O
encoded O
a O
mature O
protein O
of O
240 O
amino O
acids O
, O
including O
a O
29 O
- O
amino O
acid O
signal O
sequence O
. O

Mutants RARE
lacking O
the O
3 O
' O
stem O
- O
loop O
exhibited O
a O
75 O
% O
reduction O
in O
the O
level O
of O
psaB LASTCAP
mRNA O
. O

The O
deduced O
amino O
acid O
sequence O
was O
highly O
conserved O
across O
the O
wide O
range O
of O
eukaryotes O
( O
vertebrates RARE
, O
invertebrates RARE
, O
fungi RARE
, O
plants O
and O
protozoa RARE
) O
in O
which O
this O
gene O
has O
now O
been O
identified O
. O

Biol O
. O

Semidominant RARE
mutations O
in O
the O
yeast I-GENE
Rad51 NUMERIC
protein I-GENE
and O
their O
relationships O
with O
the O
Srs2 NUMERIC
helicase I-GENE
. O

Alterations RARE
of O
the O
5q23 NUMERIC
- O
q31 NUMERIC
interval O
are O
frequently O
observed O
in O
myelodysplasia RARE
and O
myeloid O
leukemia O
. O

Previous O
studies O
have O
suggested O
that O
the O
616 NUMERIC
amino O
acid O
, O
70 I-GENE
- I-GENE
kDa I-GENE
subunit I-GENE
of I-GENE
RPA I-GENE
( O
RPA I-GENE
70 I-GENE
) O
is O
composed O
of O
multiple O
structural O
/ O
functional O
domains O
. O

Neurons RARE
were O
held O
at O
- O
67 O
mV LASTCAP
to O
equate RARE
voltage O
- O
dependent O
effects O
. O

This O
site O
acts O
as O
a O
negative O
element O
when O
transferred O
to O
the O
thymidine I-GENE
kinase I-GENE
promoter I-GENE
, O
but O
does O
not O
confer O
inducibility O
. O

The O
extent O
of O
the O
fbpA LASTCAP
operator O
sequence O
( O
42 O
bp O
), O
as O
defined O
by O
our O
footprinting O
analysis O
, O
would O
suggest O
the O
binding O
of O
two O
Fur I-GENE
repressor I-GENE
dimers I-GENE
. O

The O
structural O
similarity O
between O
Vav RARE
and O
other O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factors I-GENE
for O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
, O
together O
with O
the O
recent O
identification O
of O
biochemical O
routes O
specific O
for O
members O
of O
the O
Ras I-GENE
and O
Rho I-GENE
family I-GENE
of O
GTPases I-GENE
, O
prompted RARE
us O
to O
explore O
whether O
MAPK I-GENE
or O
JNK I-GENE
are O
downstream O
components O
of O
the O
Vav RARE
signaling O
pathways O
. O

CONCLUSION O
: O
Twice RARE
daily O
treatment O
with O
inhaled O
fluticasone RARE
propionate RARE
50 O
micrograms O
or O
100 O
micrograms O
was O
significantly O
more O
effective O
than O
theophylline O
in O
the O
treatment O
of O
mild O
- O
to O
- O
moderate O
asthma O
. O

Our O
results O
support O
a O
model O
where O
both O
E2F I-GENE
- O
and O
CDE ALLCAPS
- O
mediated O
repression O
, O
acting O
at O
different O
stages O
in O
the O
cell O
cycle O
, O
are O
dependent O
on O
promoter O
- O
specific O
CHR ALLCAPS
elements O
. O

The O
cDNA O
clone O
was O
used O
as O
a O
homologous O
probe O
to O
isolate O
a O
truncated O
genomic O
clone O
encoding O
H2A1 NUMERIC
. O

Comparison O
of O
the O
deduced O
amino O
acid O
sequences O
with O
protein O
sequences O
of O
T O
. O
pyriformis RARE
H2As NUMERIC
showed O
only O
two O
and O
three O
differences O
respectively O
, O
in O
a O
total O
of O
137 NUMERIC
amino O
acids O
for O
H2A1 NUMERIC
, O
and O
132 O
amino O
acids O
for O
H2A2 NUMERIC
, O
indicating O
the O
two O
genes O
arose RARE
before O
the O
divergence O
of O
these O
two O
species O
. O

Cognitive RARE
visual O
dysfunction O
in O
a O
child O
with O
cerebral O
damage O
. O

Interaction O
was O
apparently O
determined O
by O
the O
N O
- O
terminal O
splice O
region O
of O
RPDE ALLCAPS
- I-GENE
6 I-GENE
, O
as O
the O
PDE4A NUMERIC
splice O
variant O
RPDE ALLCAPS
- I-GENE
39 I-GENE
, O
which O
differs O
from O
RPDE ALLCAPS
- I-GENE
6 I-GENE
at O
the O
extreme O
N O
- O
terminus O
, O
failed O
to O
associate O
with O
v I-GENE
- I-GENE
Src I-GENE
- O
SH3 I-GENE
; O
met26RD1 NUMERIC
( O
where O
RD1 NUMERIC
is O
rat I-GENE
' I-GENE
dunc RARE
- I-GENE
like I-GENE
' I-GENE
PDE ALLCAPS
), O
which O
has O
the O
N O
- O
terminal O
splice O
region O
deleted O
, O
failed O
to O
associate O
with O
v I-GENE
- I-GENE
Src I-GENE
- O
SH3 I-GENE
, O
and O
the O
association O
of O
RPDE ALLCAPS
- I-GENE
6 I-GENE
and O
v I-GENE
- I-GENE
Src I-GENE
- O
SH3 I-GENE
was O
blocked O
by O
a O
fusion O
protein O
formed O
from O
the O
N O
- O
terminal O
splice O
region O
. O

Potentially RARE
load O
- O
insensitive RARE
measures O
of O
ventricular O
performance O
were O
therefore O
evaluated O
in O
10 O
open O
- O
and O
closed O
- O
chested RARE
, O
anesthetized O
rabbits O
. O

Large O
strain O
differences O
were O
found O
for O
all O
variables O
recorded O
, O
i O
. O
e O
., O
the O
proportion O
of O
attacking RARE
males O
, O
the O
time O
spent RARE
in O
the O
brightly RARE
lit RARE
box O
, O
and O
the O
number O
of O
transitions RARE
between O
the O
lit RARE
and O
the O
dark O
boxes O
. O

The O
effect O
of O
ligustrazine RARE
hydrochloride RARE
( O
LTH ALLCAPS
) O
on O
depressing RARE
pulmonary O
artery O
hypertension O
has O
been O
proved O
in O
recent O
studies O
. O

It O
is O
the O
oxidation O
peak O
of O
this O
product O
, O
arising O
in O
acidic O
media O
at O
0 O
. O
42 O
V O
, O
which O
was O
analysed O
using O
DPV ALLCAPS
, O
again O
following O
the O
accumulation O
of O
clenbuterol RARE
at O
the O
Nafion RARE
- O
modified O
CPE ALLCAPS
. O

Phenylephrine RARE
is O
a O
pure O
alpha I-GENE
- I-GENE
1 I-GENE
adrenoreceptor RARE
agonist O
known O
to O
produce O
marked O
systemic O
vasoconstriction RARE
and O
associated O
hypertension O
with O
occasional RARE
profound O
reflex O
bradycardia RARE
. O

The O
expression O
of O
the O
first O
two O
genes O
located O
in O
this O
unit O
( O
c I-GENE
- I-GENE
gvpD LASTCAP
and O
c I-GENE
- I-GENE
gvpE LASTCAP
) O
was O
also O
monitored O
by O
Western O
blot O
( O
immunoblot RARE
) O
analyses O
using O
antisera O
raised O
against O
these O
proteins O
synthesized O
in O
Escherichia O
coli O
. O

One O
unit O
encodes O
traA LASTCAP
, O
traF LASTCAP
, O
and O
traB LASTCAP
, O
while O
the O
second O
encodes O
traC LASTCAP
, O
traD LASTCAP
, O
and O
traG LASTCAP
. O

A O
. O

In O
an O
effort O
to O
isolate O
genes O
with O
down O
- O
regulated O
expression O
at O
the O
mRNA O
level O
during O
oncogenic O
transformation O
of O
human O
mammary O
epithelial O
cells O
( O
MECs RARE
), O
we O
performed O
subtractive RARE
hybridization O
between O
normal O
MEC ALLCAPS
strain O
76N NUMERIC
and O
its O
radiation O
- O
transformed O
tumorigenic O
derivative O
76R NUMERIC
- O
30 O
. O

CASE ALLCAPS
REPORT ALLCAPS
: O
Referred RARE
because O
of O
a O
right O
corneal O
perforation RARE
with O
cellular O
reaction O
in O
anterior O
chamber O
, O
a O
patient O
was O
sutured RARE
and O
treated O
with O
a O
single O
intravitreal RARE
injection O
of O
0 O
. O
2 O
ml O
( O
1 O
mg O
) O
Amikacin RARE
and O
0 O
. O
2 O
ml O
( O
1 O
mg O
) O
Vancomycin RARE
. O

In O
the O
same O
period O
we O
pointed RARE
out O
an O
increase O
of O
hematocrit O
( O
from O
29 O
% O
to O
35 O
%) O
and O
of O
the O
Hb I-GENE
( O
from O
9 O
. O
3 O
to O
11 O
. O
2 O
g O
/ O
dl O
). O

The O
P I-GENE
- I-GENE
wr RARE
and O
P I-GENE
- I-GENE
rr RARE
cDNA I-GENE
sequences I-GENE
are O
very O
similar O
in O
their O
5 O
' O
regions O
. O

Because O
the O
hcf109 NUMERIC
locus I-GENE
was O
mapped O
at O
a O
distance O
< O
0 O
. O
1 O
centimorgans RARE
from O
the O
phytochrome RARE
C I-GENE
gene I-GENE
, O
its O
molecular O
characterization O
by O
positional RARE
cloning O
is O
possible O
. O

The O
human I-GENE
MSH I-GENE
- I-GENE
2 I-GENE
gene I-GENE
product I-GENE
is O
a O
member O
of O
a O
highly O
conserved O
family O
of O
proteins O
which O
are O
involved O
in O
post O
- O
replication O
mismatch RARE
repair O
. O
hMSH LASTCAP
- I-GENE
2 I-GENE
is O
homologous O
to O
Escherichia O
coli O
( O
E O
. O
coli O
) O
MutS LASTCAP
and O
Sacchromyces RARE
cerevisiae I-GENE
MSH I-GENE
- I-GENE
1 I-GENE
and O
MSH I-GENE
- I-GENE
2 I-GENE
proteins I-GENE
, O
which O
recognise RARE
heteroduplex RARE
DNA O
at O
the O
sites O
of O
all O
single O
base O
mismatches RARE
and O
deletions O
or O
insertions O
up O
to O
4 O
base O
pairs O
. O
hMSH LASTCAP
- I-GENE
2 I-GENE
is O
one O
of O
the O
hereditary I-GENE
non I-GENE
- I-GENE
polyposis RARE
colorectal RARE
cancer I-GENE
( I-GENE
HNPCC ALLCAPS
) I-GENE
tumor I-GENE
suppressor I-GENE
genes I-GENE
, O
and O
maps O
to O
human O
chromosome O
2p16 NUMERIC
. O

We O
have O
recently O
shown O
that O
the O
tissue O
- O
specific O
expression O
of O
the O
RAR I-GENE
beta I-GENE
2 I-GENE
gene I-GENE
in I-GENE
mouse I-GENE
embryos I-GENE
is O
regulated O
at O
the O
translational O
level O
by O
short O
upstream O
open O
reading O
frames O
( O
uORFs RARE
) O
In O
the O
5 O
'- O
untranslated O
region O
( O
Zimmer RARE
, O
A O
., O
A O
. O
M O
. O

We O
have O
previously O
isolated O
a O
cDNA O
for O
a O
transcription O
factor O
referred O
to O
as O
Zfhep RARE
( O
zinc I-GENE
finger I-GENE
homeodomain I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
containing O
two O
separate O
zinc O
finger O
domains O
, O
ZD1 NUMERIC
and O
ZD2 NUMERIC
, O
each O
of O
which O
binds O
DNA O
, O
and O
a O
homeodomain O
. O

The O
structure O
of O
these O
genes O
suggests O
a O
common O
ancestor O
for O
all O
viperid RARE
PLA2 NUMERIC
genes I-GENE
. O

Increased O
PTHRP ALLCAPS
production O
by O
a O
tyrosine I-GENE
kinase I-GENE
oncogene I-GENE
, O
Tpr RARE
- I-GENE
Met I-GENE
: O
role O
of O
the O
Ras I-GENE
signaling O
pathway O
. O

Subsequent RARE
to O
their O
secretion O
, O
the O
IGF I-GENE
- I-GENE
II I-GENE
in O
xz97 NUMERIC
and O
G11 NUMERIC
cells O
accumulated O
in O
the O
conditioned O
medium O
mostly O
as O
two O
partially O
processed O
species O
with O
appMr RARE
, O
of O
17K NUMERIC
and O
14K NUMERIC
, O
respectively O
. O

Paradoxically RARE
, O
coexpression O
of O
the O
transcriptionally O
inactive O
, O
amino O
- O
terminally O
deleted O
IDX ALLCAPS
- I-GENE
1 I-GENE
mutant I-GENE
proteins I-GENE
, O
either O
with O
the O
wild I-GENE
- I-GENE
type I-GENE
IDX ALLCAPS
- I-GENE
1 I-GENE
or O
with O
themselves O
, O
results O
in O
a O
marked O
enhancement O
of O
transactivation O
of O
the O
transcriptional O
TAAT ALLCAPS
- I-GENE
1 I-GENE
element I-GENE
reporter I-GENE
. O

All O
patients O
had O
abnormal O
von I-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
fragmentation RARE
as O
reflected O
by O
decreased O
high O
molecular O
weight O
and O
increased O
low O
molecular O
weight O
vWF I-GENE
multimers RARE
in O
the O
circulation O
. O

In O
an O
attempt O
to O
investigate O
whether O
the O
intergenic O
region O
between O
the O
oleosin RARE
and O
a O
second O
open O
reading O
frame O
( O
ORFII ALLCAPS
) O
in O
Brassica RARE
napus O
( O
L O
.) O
is O
a O
divergent O
promoter O
, O
and O
also O
to O
characterize O
the O
ORFII ALLCAPS
, O
cDNA I-GENE
clones I-GENE
homologous I-GENE
to I-GENE
ORFII ALLCAPS
were O
isolated O
from O
a O
leaf O
cDNA O
library O
. O

The O
ORFII ALLCAPS
gene I-GENE
product I-GENE
is O
targeted O
to O
the O
chloroplast O
, O
which O
is O
consistent O
with O
previous O
data O
indicating O
the O
presence O
of O
PMSR ALLCAPS
activity O
in O
the O
chloroplast O
. O

Characterization O
of O
LRP ALLCAPS
, O
a O
leucine I-GENE
- I-GENE
rich I-GENE
repeat I-GENE
( I-GENE
LRR ALLCAPS
) I-GENE
protein I-GENE
from I-GENE
tomato I-GENE
plants I-GENE
that O
is O
processed O
during O
pathogenesis O
. O

To O
test O
whether O
Sp1 I-GENE
and O
zif268 NUMERIC
/ O
egr RARE
- I-GENE
1 I-GENE
interact O
with O
this O
motif O
, O
gel O
retardation O
assays O
were O
performed O
. O

OBJECTIVES O
: O
The O
aim O
of O
the O
study O
was O
to O
analyze O
the O
clinical O
characteristics O
, O
treatment O
and O
outcome O
of O
310 NUMERIC
patients O
with O
hydatidiform RARE
mole RARE
. O

Stably RARE
transfected O
human O
kidney O
293 O
cells O
expressing O
the O
wild I-GENE
type I-GENE
rat I-GENE
LH I-GENE
/ I-GENE
CG I-GENE
receptor I-GENE
( O
rLHR LASTCAP
) O
or O
receptors O
with O
C O
- O
terminal O
tails O
truncated O
at O
residues O
653 NUMERIC
, O
631 NUMERIC
, O
or O
628 NUMERIC
( O
designated O
rLHR LASTCAP
- I-GENE
t653 NUMERIC
, O
rLHR LASTCAP
- I-GENE
t631 NUMERIC
, O
and O
rLHR LASTCAP
- I-GENE
t628 NUMERIC
) O
were O
used O
to O
probe O
the O
importance O
of O
this O
region O
on O
the O
regulation O
of O
hormonal O
responsiveness O
. O

Are RARE
low O
P300 NUMERIC
amplitudes O
a O
marker O
for O
schizophrenia O
. O

Sleep RARE
was O
determined O
again O
for O
an O
additional O
3 O
days O
and O
6 O
hours O
. O

The O
patients O
are O
two O
healthy O
adult O
males O
. O

Chloroplast RARE
mutator RARE
( O
chm RARE
) O
of O
Arabidopsis O
is O
a O
recessive O
nuclear O
mutation O
that O
causes O
green O
and O
white O
variegation RARE
in O
leaves O
and O
is O
inherited O
in O
a O
non O
- O
Mendelian RARE
fashion O
. O

Indoor RARE
concentrations O
were O
only O
weakly O
correlated O
with O
outdoor RARE
concentrations O
, O
however O
, O
and O
personal O
exposures O
were O
even O
more O
poorly O
correlated O
with O
outdoor RARE
concentrations O
. O

A O
neuropsychological RARE
test O
battery O
was O
used O
that O
contained O
the O
Wisconsin RARE
card RARE
sorting O
test O
, O
Street RARE
completion RARE
test O
, O
Stroop O
test O
, O
a O
dichotic RARE
memory O
listening RARE
test O
, O
and O
a O
facial O
recognition O
test O
. O

We O
present O
this O
case O
because O
of O
the O
rarity RARE
of O
left O
ventricular O
involvement O
associated O
with O
ARVD ALLCAPS
. O

In O
a O
randomized O
single O
- O
blind O
3 O
x O
3 O
Latin RARE
- O
square O
study O
with O
corrections RARE
for O
any O
carryover RARE
effects O
, O
27 O
males O
and O
30 O
females O
consumed RARE
supplements RARE
containing O
glucose O
or O
resistant O
starch RARE
( O
RS O
) O
from O
raw RARE
high O
- O
amylose RARE
cornstarch RARE
( O
RS2 NUMERIC
) O
or O
from O
retrograded RARE
high O
- O
amylose RARE
cornstarch RARE
( O
RS3 NUMERIC
). O

The O
5 O
' O
flanking O
region O
of O
the O
mouse I-GENE
Met I-GENE
- I-GENE
ase RARE
- I-GENE
1 I-GENE
gene I-GENE
also O
shares O
considerable O
regions O
of O
identity O
with O
the O
5 O
' O
flanking O
region O
of O
the O
rat I-GENE
Met I-GENE
- I-GENE
ase RARE
- I-GENE
1 I-GENE
gene I-GENE
. O

The O
[ O
18F O
] O
FMISO ALLCAPS
TMRR ALLCAPS
is O
a O
simple O
and O
clinically O
useful O
index O
for O
detecting O
tumour O
hypoxia O
in O
NPC ALLCAPS
. O

Improved RARE
methods O
have O
been O
developed O
for O
maintaining O
and O
breeding RARE
the O
neotropical RARE
short O
- O
tailed RARE
fruit RARE
bat RARE
, O
Carollia RARE
perspicillata RARE
, O
in O
an O
easily O
- O
reproduced RARE
, O
laboratory O
setting O
. O

In O
addition O
, O
the O
time O
to O
engraftment RARE
was O
significantly O
shorter O
in O
the O
amifostine RARE
arm O
in O
both O
cohorts RARE
. O

Also O
like O
the O
thrombin I-GENE
receptor I-GENE
, O
PAR2 NUMERIC
can O
be O
activated O
by O
the O
hexapeptide RARE
corresponding O
to O
its O
tethered RARE
ligand O
sequence O
independent O
of O
receptor O
cleavage O
. O

We O
conclude O
that O
CPET ALLCAPS
is O
a O
useful O
investigation O
in O
the O
management O
of O
patients O
with O
cardiopulmonary O
disease O
and O
complements RARE
the O
various O
other O
investigations O
offered O
by O
a O
pulmonary O
function O
laboratory O
. O

Using O
fluorescence O
in O
situ O
hybridization O
, O
we O
mapped O
the O
chromosome O
- O
17 O
breakpoint O
in O
a O
patient O
with O
acampomelic RARE
CMPD ALLCAPS
and O
sex O
reversal O
, O
who O
carries O
a O
de O
novo O
constitutional RARE
t O
( O
12 O
; O
17 O
) O
translocation O
, O
between O
two O
known O
cosmid O
markers O
in O
the O
17q24 NUMERIC
- O
q25 NUMERIC
region O
. O

This O
is O
concluded O
from O
the O
isolation O
of O
cDNAs O
from O
spinach RARE
( O
Spinacia RARE
oleracea RARE
) O
and O
barley O
( O
Hordeum RARE
vulgare RARE
cv O
. O

The O
data O
presented O
in O
this O
work O
indicate O
that O
thi1 NUMERIC
may O
also O
be O
involved O
in O
DNA O
damage O
tolerance O
in O
plant O
cells O
. O

In O
the O
rat I-GENE
rnu RARE
allele I-GENE
described O
here O
, O
a O
nonsense O
mutation O
in O
exon O
8 O
of O
the O
whn RARE
gene I-GENE
was O
identified O
. O

Such O
an O
increase O
in O
the O
steady O
- O
state O
testicular I-GENE
TIMP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
level O
apparently O
is O
not O
the O
result O
of O
an O
up O
- O
regulation O
by O
germ O
cells O
because O
germ O
cells O
cocultured RARE
with O
Sertoli RARE
cells O
failed O
to O
elicit O
an O
increase O
in O
the O
Sertoli RARE
cell O
steady O
- O
state O
TIMP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
level O
. O

Control O
intact O
rats O
were O
age O
- O
matched O
to O
the O
different O
treated O
groups O
. O

DESIGN O
: O
A O
cross O
- O
sectional O
study O
. O

In O
the O
SPK O
and O
PTA ALLCAPS
category O
, O
anti O
- O
T O
- O
cell O
therapy O
significantly O
lowered O
the O
risk O
of O
graft O
loss O
. O

We O
have O
identified O
a O
strong O
Tas RARE
- I-GENE
responsive I-GENE
element I-GENE
, O
designated O
TRE I-GENE
( O
GP ALLCAPS
), O
near O
the O
3 O
' O
end O
of O
the O
gag I-GENE
gene I-GENE
and O
preceding O
the O
pol I-GENE
gene I-GENE
of O
SFV O
- O
1 O
. O

Although O
the O
binding O
of O
IE2 I-GENE
86 I-GENE
to O
nonphosphorylated RARE
full I-GENE
- I-GENE
length I-GENE
CREB I-GENE
or O
deltaCREB LASTCAP
is O
minimal O
, O
IE2 I-GENE
86 I-GENE
does O
form O
complexes O
with O
p300 I-GENE
and O
the O
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CBP I-GENE
), O
which O
in O
turn O
bind O
to O
CREB I-GENE
and O
can O
serve O
as O
adaptor O
proteins O
for O
CREB I-GENE
function O
. O

A O
transgenic O
complementation O
assay O
was O
used O
to O
test O
whether O
NIa RARE
supplied O
in O
trans O
could O
rescue O
amplification O
- O
defective O
viral O
genomes O
encoding O
altered O
NIa RARE
proteins I-GENE
. O

On O
the O
basis O
of O
its O
bZIP O
structural O
homology O
, O
meq RARE
is O
perhaps O
the O
only O
member O
of O
the O
jun I-GENE
- O
fos I-GENE
gene O
family O
completely O
viral O
in O
origin O
. O

The O
rCBF O
and O
vasomotion RARE
were O
recorded O
by O
laser O
- O
doppler RARE
fluxmetry RARE
. O

Although O
basal O
vessels O
may O
constrict RARE
distal O
parenchymal RARE
vessels O
tend RARE
to O
dilate RARE
after O
SAH ALLCAPS
. O

The O
triple O
combination O
of O
nizatidine RARE
, O
clarithromycin RARE
, O
and O
bismuth RARE
subcitrate RARE
resulted O
in O
an O
ulcer O
healing O
rate O
of O
98 O
% O
and O
an O
H O
. O
pylori O
eradication O
rate O
of O
90 O
%. O

Several O
lines O
of O
evidence O
presented O
here O
suggest O
that O
PKC I-GENE
- I-GENE
zeta I-GENE
plays O
a O
role O
in O
alpha I-GENE
2 I-GENE
integrin I-GENE
gene I-GENE
expression O
. O

Plasma O
thrombomodulin RARE
: O
a O
marker O
for O
microvascular O
complications O
in O
diabetes O
mellitus O
. O

Update RARE
: O
diphtheria RARE
epidemic O
in O
the O
newly O
independent O
states O
of O
the O
former O
USSR ALLCAPS
, O
January O
1995 O
- O
March RARE
1996 O
. O

The O
characterization O
of O
the O
promoter O
region O
indicated O
that O
three O
distinct O
regulatory O
elements O
corresponding O
to O
an O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
( O
or O
TRE O
), O
a O
PRDII ALLCAPS
/ O
kappaB I-GENE
domain O
, O
and O
a O
CAAT O
box O
are O
involved O
in O
the O
activation O
by O
pp60 NUMERIC
( I-GENE
v I-GENE
-) I-GENE
src I-GENE
. O

Serine RARE
528 NUMERIC
is O
phosphorylated O
in O
vivo O
in O
several O
cell O
lines O
, O
and O
substitution O
of O
serine O
528 NUMERIC
to O
alanine O
( O
S528A NUMERIC
) O
resulted O
in O
an O
increased O
ability O
of O
Myb I-GENE
to O
transactivate O
a O
synthetic O
promoter O
containing O
five O
copies O
of O
the O
mim RARE
- I-GENE
1A NUMERIC
Myb I-GENE
- O
responsive O
element O
and O
a O
minimal O
herpes I-GENE
tk I-GENE
promoter I-GENE
. O

The O
DNA O
binding O
and O
multimerization RARE
activities O
of O
c I-GENE
- I-GENE
Myb I-GENE
appear O
to O
be O
unaffected O
by O
the O
S528A NUMERIC
substitution O
, O
suggesting O
that O
phosphorylation O
of O
serine O
528 NUMERIC
may O
mediate O
its O
effect O
on O
the O
transcription O
transactivating O
activity O
of O
c I-GENE
- I-GENE
Myb I-GENE
by O
regulating O
interactions O
with O
other O
proteins O
. O

The O
amount O
of O
these O
factors O
was O
reduced O
in O
GEO ALLCAPS
cells O
in O
which O
the O
u RARE
- I-GENE
PAR ALLCAPS
gene I-GENE
is O
only O
weakly O
transcriptionally O
activated O
. O

PIP2 O
, O
when O
incorporated O
into O
phosphatidylcholine RARE
carrier O
vesicles O
, O
binds O
tightly O
to O
the O
guanine O
nucleotide O
- O
depleted O
form O
of O
Cdc42Hs NUMERIC
and O
weakly O
to O
the O
GDP O
- O
bound O
form O
of O
the O
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
but O
does O
not O
bind O
to O
GTP O
- O
bound O
Cdc42Hs NUMERIC
, O
similar O
to O
what O
was O
observed O
for O
the O
Dbl RARE
oncoprotein I-GENE
. O

Purified O
spleen O
GAP I-GENE
accelerated O
hydrolysis O
of O
GTP O
bound O
to O
recombinant I-GENE
ARF1 NUMERIC
, O
ARF3 NUMERIC
, O
ARF5 NUMERIC
, O
and O
ARF6 NUMERIC
; O
no O
effect O
of O
NH2 O
- O
terminal O
myristoylation RARE
was O
observed O
. O

Biol O
. O

A O
novel O
phosphotyrosine O
- O
binding O
domain O
in O
the O
N O
- O
terminal O
transforming O
region O
of O
Cbl I-GENE
interacts O
directly O
and O
selectively O
with O
ZAP I-GENE
- I-GENE
70 I-GENE
in O
T O
cells O
. O

Cys O
- O
757 NUMERIC
within O
the O
( O
Fe4S4 NUMERIC
)- O
siroheme RARE
- O
binding O
domain O
was O
essential O
for O
native O
enzyme O
activity O
. O

Its O
transcription O
has O
been O
shown O
to O
be O
induced O
40 O
- O
50 O
- O
fold O
in O
response O
to O
oxygen O
or O
heme O
deficiency O
, O
in O
part O
through O
relief RARE
of O
repression O
exerted RARE
by O
Rox1p NUMERIC
and O
in O
part O
by O
activation O
mediated O
by O
an O
upstream O
activation O
sequence O
( O
UAS O
). O

Altogether O
, O
our O
results O
indicate O
that O
the O
transcriptional O
activity O
of O
Cut RARE
proteins I-GENE
is O
modulated O
by O
PKC I-GENE
. O

Lck I-GENE
has O
been O
postulated O
to O
dimerize RARE
through O
the O
SH2 I-GENE
and O
SH3 I-GENE
domains I-GENE
. O

Furthermore O
, O
freezing RARE
in O
the O
presence O
of O
bovine I-GENE
lactalbumin RARE
resulted O
in O
a O
good O
maintenance O
of O
the O
cellular O
viability O
and O
of O
the O
CCCD ALLCAPS
heterogeneity O
in O
respect O
to O
fresh O
cells O
. O

Myelomatous RARE
pleural O
effusion RARE
as O
presentation O
form O
of O
multiple O
myeloma O

Five O
- O
year O
survivals RARE
amounted RARE
to O
100 O
%, O
86 O
. O
2 O
%, O
59 O
. O
4 O
%, O
29 O
. O
8 O
%, O
and O
20 O
% O
for O
stages O
I O
, O
II O
, O
III O
, O
IVA ALLCAPS
and O
IVB ALLCAPS
respectively O
. O

The O
presence O
of O
unidentified O
macroscopic RARE
or O
microscopic O
clusters O
of O
neoplastic O
cells O
, O
lying RARE
around O
, O
more O
or O
less O
close O
to O
, O
the O
line O
of O
insertion O
of O
lesion O
, O
could O
render RARE
any O
attempt O
to O
gain O
a O
" O
radical O
" O
excision O
useless RARE
. O

The O
partial O
categories O
of O
the O
SIP ALLCAPS
that O
were O
more O
affected O
were O
work O
, O
recreation RARE
and O
pastimes RARE
, O
home O
management O
, O
and O
sleep O
and O
rest O
. O

Northern O
blot O
analysis O
, O
using O
the O
Ltp4 NUMERIC
- O
specific O
probe O
, O
indicated O
that O
Xanthomonas RARE
campestris RARE
pv RARE
. O
translucens RARE
induced O
an O
increase O
over O
basal O
levels O
of O
Ltp4 NUMERIC
mRNA I-GENE
, O
while O
Pseudomonas O
syringae RARE
pv RARE
. O
japonica RARE
caused O
a O
decrease O
. O

Targeted RARE
disruption O
of O
the O
OGG1 NUMERIC
gene I-GENE
in O
yeast O
revealed O
a O
second O
OG ALLCAPS
glycosylase I-GENE
/ I-GENE
lyase I-GENE
protein I-GENE
, O
tentatively O
named O
Ogg2 NUMERIC
, O
which O
differs O
from O
Ogg1 NUMERIC
in O
that O
it O
preferentially O
acts O
on O
OG ALLCAPS
: O
G O
. O

Furthermore O
, O
the O
use O
of O
zero O
- O
loss O
filtering RARE
in O
combination O
with O
exit RARE
wavefront RARE
reconstruction O
is O
considerably O
more O
effective O
at O
removing O
the O
effects O
of O
multiple O
elastic O
and O
inelastic RARE
scattering RARE
and O
microscope RARE
objective O
lens O
aberrations RARE
than O
either O
technique O
by O
itself O
. O

Transcripts RARE
for O
both O
ODV ALLCAPS
- I-GENE
E18 NUMERIC
and O
ODV ALLCAPS
- I-GENE
EC27 NUMERIC
initiate O
from O
conserved O
TAAG ALLCAPS
motifs O
, O
and O
transcripts O
are O
detected O
from O
16 O
through O
72 O
hr O
p O
. O
i O
. O

In O
order O
to O
determine O
which O
sequences O
in O
the O
GATA I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
are O
crucial O
for O
activation O
by O
the O
ME26 NUMERIC
viral I-GENE
protein I-GENE
, O
we O
made O
deletions O
of O
the O
promoter O
, O
cloned O
them O
into O
a O
luciferase I-GENE
expression O
vector O
and O
tested O
their O
activity O
in O
mouse O
fibroblasts O
, O
which O
do O
not O
express O
GATA I-GENE
- I-GENE
1 I-GENE
. O

Sequence O
analysis O
of O
the O
isolated O
genomic O
clone O
revealed O
that O
the O
DNA O
binding O
domain O
of O
this O
orphan O
receptor O
is O
most O
homologous O
to O
the O
human I-GENE
TR2 NUMERIC
receptor I-GENE
. O

Genomic O
DNA O
hybridization O
suggests O
that O
SpSHR2 NUMERIC
is O
a O
single O
- O
copy O
gene O
in O
the O
S O
. O
purpuratus RARE
genome O
. O

A O
3 O
- O
yr O
retrospective O
review O
is O
effective O
and O
detects RARE
94 O
% O
of O
the O
undercalls RARE
. O

Isolation O
and O
identification O
of O
genes O
activating O
UAS2 NUMERIC
- I-GENE
dependent I-GENE
ADH2 NUMERIC
expression O
in O
Saccharomyces O
cerevisiae O
. O

METHODS O
AND O
RESULTS O
: O
A O
64 O
- O
year O
- O
old O
woman O
with O
confirmed O
AV O
nodal O
reentrant RARE
tachycardia O
underwent O
a O
successful O
" O
slow O
pathway O
" O
AV O
modification O
with O
a O
single O
radiofrequency RARE
application O
. O

Patients O
with O
low O
probability RARE
of O
having O
aluminum O
overload O
( O
serum O
iron O
levels O
< O
40 O
micrograms O
/ O
L O
and O
DAI ALLCAPS
< O
150 O
micrograms O
/ O
L O
) O
had O
significantly O
higher O
values O
of O
serum O
iron O
, O
iron O
transferrin I-GENE
saturation O
, O
and O
serum I-GENE
ferritin I-GENE
levels O
compared O
with O
those O
patients O
with O
a O
high O
probability RARE
of O
having O
aluminum O
overload O
( O
serum O
aluminum O
levels O
> O
40 O
micrograms O
/ O
L O
and O
DAI ALLCAPS
> O
150 O
micrograms O
/ O
L O
). O

Although O
the O
RAD23 NUMERIC
equivalents RARE
are O
well O
conserved O
during O
evolution O
, O
the O
mammalian O
genes O
did O
not O
express O
the O
UV O
- O
inducible O
phenotype O
of O
their O
yeast O
counterpart O
. O

Ha I-GENE
- I-GENE
RasV12 NUMERIC
and O
activated O
proteins O
in O
both O
the O
extra I-GENE
- I-GENE
cellular I-GENE
regulated I-GENE
kinase I-GENE
( O
ERK I-GENE
) O
and O
the O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
) O
or O
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
) O
cascades O
independently O
stimulated O
PEA3 I-GENE
- O
mediated O
gene O
expression O
. O

Sequence O
analysis O
of O
reverse O
transcribed O
, O
amplified O
cDNA O
generated O
from O
total O
RNA O
isolated O
from O
transfected O
cells O
demonstrated O
the O
presence O
of O
abnormally RARE
spliced O
products O
containing O
13 O
and O
78 O
additional O
bases O
as O
well O
as O
the O
accumulation O
of O
unspliced O
mRNA O
. O

Its O
hydropathy RARE
profile O
predicts O
seven O
transmembrane O
spans O
and O
a O
hydrophilic O
amino O
terminus O
of O
approximately O
100 O
residues O
, O
and O
it O
suggests O
the O
presence O
of O
an O
amphiphilic RARE
alpha O
- O
helix O
( O
L O
- O
61 O
to O
F O
- O
97 O
) O
in O
close O
proximity RARE
to O
the O
first O
strongly O
hydrophobic O
segment O
of O
ProW LASTCAP
. O

A O
1 O
. O
5 O
- O
kb O
HindIII I-GENE
genomic O
fragment O
carrying O
the O
vspA LASTCAP
gene O
from O
M O
. O
bovis RARE
PG45 NUMERIC
was O
cloned O
and O
sequenced O
. O

Carbon RARE
catabolite O
repression O
of O
the O
gnt RARE
operon I-GENE
of I-GENE
Bacillus I-GENE
subtilis I-GENE
is O
mediated O
by O
the O
catabolite O
control O
protein O
CcpA LASTCAP
and O
by O
HPr RARE
, O
a O
phosphocarrier RARE
protein O
of O
the O
phosphotransferase O
system O
. O

Melatonin RARE
and O
seasonality RARE
: O
filling O
the O
gap RARE
. O

A O
subsequent O
screen O
for O
the O
loss O
of O
the O
positively O
selectable O
target O
locus O
marker O
detects RARE
the O
desired RARE
replacement O
at O
modest RARE
frequency O
(> O
2 O
%). O

Here O
we O
demonstrate O
that O
another O
cellular O
protein O
linked O
to O
BCR I-GENE
/ O
ABL I-GENE
through O
the O
CRKL ALLCAPS
- O
SH2 I-GENE
domain O
is O
p130 I-GENE
( O
CAS I-GENE
). O
p130 I-GENE
( O
CAS I-GENE
) O
was O
found O
to O
be O
tyrosine O
phosphorylated O
and O
associated O
with O
CRKL ALLCAPS
in O
BCR I-GENE
/ O
ABL I-GENE
expressing O
cell O
lines O
and O
in O
samples O
obtained O
from O
CML O
and O
ALL O
patients O
, O
but O
not O
in O
samples O
from O
controls O
. O

There O
are O
four O
polyglutamine RARE
motifs O
interspersed O
with O
histidine O
- O
rich O
regions O
. O

The O
effects O
of O
procedural RARE
variations O
on O
lateralized RARE
Stroop O
effects O
. O

In O
a O
third O
experiment O
, O
a O
Chessmaster RARE
gradually O
increases O
the O
number O
of O
boards RARE
he RARE
can O
reproduce RARE
with O
higher O
than O
70 O
% O
average O
accuracy O
to O
nine O
, O
replacing O
as O
many O
as O
160 O
pieces RARE
correctly O
. O

PCNA I-GENE
mRNA I-GENE
has O
a O
3 O
' O
UTR O
antisense O
to O
yellow O
crescent RARE
RNA O
and O
is O
localized O
in O
ascidian RARE
eggs O
and O
embryos O
. O

A O
1 O
. O
8 O
- O
kb O
cDNA O
clone O
( O
designed O
hKID LASTCAP
, O
gene I-GENE
symbol RARE
AQP2L NUMERIC
) O
with O
homology O
to O
the O
aquaporins RARE
was O
isolated O
from O
a O
human O
kidney O
cDNA O
library O
. O

PCR O
/ O
Southern O
blot O
analysis O
of O
human O
kidney O
cDNA O
using O
primers O
flanking O
the O
hKID LASTCAP
coding I-GENE
sequence I-GENE
revealed O
expression O
of O
a O
full O
- O
length O
mRNA O
and O
short O
transcripts O
with O
partial O
exon O
1 O
and O
partial O
exon O
4 O
deletions O
. O

The O
high O
sequence O
homology O
, O
similar O
genomic O
structure O
, O
and O
identical O
chromosomal O
loci O
of O
hKID LASTCAP
, O
MIP I-GENE
, O
and O
AQP ALLCAPS
- I-GENE
2 I-GENE
suggest O
a O
MIP I-GENE
family I-GENE
gene I-GENE
cluster I-GENE
at O
chromosome O
locus O
12q13 NUMERIC
. O

The O
third O
ORF O
generates O
a O
transcript O
of O
1 O
. O
6 O
kb O
and O
encodes O
a O
protein O
of O
382 NUMERIC
residues O
including O
a O
perfect O
match O
to O
the O
consensus O
sequence O
of O
a O
C2H2 NUMERIC
zinc O
finger O
domain O
; O
it O
shares O
a O
strong O
homology O
with O
yeast I-GENE
Mig1p NUMERIC
and O
Cre RARE
- I-GENE
A I-GENE
from I-GENE
Aspergillus I-GENE
, I-GENE
Emericella RARE
and I-GENE
E I-GENE
. I-GENE
coli I-GENE
. O

Adding RARE
phytase RARE
and O
nP LASTCAP
improved O
the O
orderliness RARE
of O
development O
, O
mineralization RARE
and O
arrangement O
of O
cartilage O
and O
bone O
cells O
, O
and O
alleviated RARE
the O
effects O
of O
P O
deficiency O
on O
the O
histological O
and O
gross O
structure O
of O
the O
tibias RARE
. O

The O
importance O
of O
temporal O
factors O
on O
the O
presence O
and O
severity O
of O
ethanol O
withdrawal O
signs O
in O
the O
rat O
was O
quantified RARE
using O
rating O
scale O
, O
tremor O
, O
and O
acoustic O
startle RARE
paradigms RARE
. O

Data O
supported O
the O
brevity RARE
of O
the O
WISC ALLCAPS
- O
III O
short O
form O
and O
the O
criterion O
- O
related O
validity O
of O
both O
the O
K O
- O
FAST ALLCAPS
and O
and O
Kaufman RARE
Short O
Neuropsychological RARE
Assessment O
Procedure RARE
( O
K O
- O
SNAP ALLCAPS
). O

Quantitative O
analysis O
of O
plasmid O
loss O
rates O
in O
cdc28 NUMERIC
- I-GENE
1N NUMERIC
strains O
carrying O
plasmids O
with O
multiple O
replication O
origins O
suggests O
that O
a O
defect O
in O
initiating O
DNA O
replication O
probably O
causes O
this O
plasmid O
loss O
phenotype O
. O

Thus O
, O
the O
multidomained RARE
ROK ALLCAPS
alpha I-GENE
appears O
to O
be O
involved O
in O
reorganization RARE
of O
the O
cytoskeleton O
, O
with O
the O
N O
and O
C O
termini O
acting O
as O
positive O
and O
negative O
regulators O
, O
respectively O
, O
of O
the O
kinase O
domain O
whose O
activity O
is O
crucial O
for O
formation O
of O
stress O
fibers O
and O
focal O
adhesion O
complexes O
. O

These O
findings O
and O
the O
differential O
tissue O
distribution O
of O
p54 I-GENE
suggest O
that O
this O
novel O
SR I-GENE
protein I-GENE
may O
participate O
in O
regulation O
of O
alternative O
splicing O
in O
a O
tissue O
- O
and O
substrate O
- O
dependent O
manner O
. O

The O
elevation O
of O
cyclic O
AMP O
( O
cAMP O
) O
levels O
in O
the O
cell O
downregulates RARE
the O
activity O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
. O

An O
interaction O
screen O
with O
the O
repression O
domain O
of O
the O
orphan I-GENE
receptor I-GENE
RevErb RARE
identified O
N I-GENE
- I-GENE
CoR LASTCAP
, O
the O
corepressor RARE
for O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
and O
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RAR I-GENE
). O

These O
results O
indicate O
that O
inhibition O
of O
Jun I-GENE
kinase I-GENE
activation O
was O
sufficient O
to O
inhibit O
Ras I-GENE
transformation O
even O
in O
the O
presence O
of O
activated O
Erk RARE
- I-GENE
2 I-GENE
. O

Our O
analysis O
suggests O
that O
Upf1p NUMERIC
is O
a O
multifunctional RARE
protein O
with O
separable RARE
activities O
that O
can O
affect O
mRNA O
turnover O
and O
nonsense O
suppression O
. O

Identification O
of O
Ste4 NUMERIC
as O
a O
potential O
regulator O
of O
Byr2 NUMERIC
in O
the O
sexual O
response O
pathway O
of O
Schizosaccharomyces O
pombe O
. O

Two O
closely O
related O
variants O
of O
Stat5 I-GENE
, O
Stat5a I-GENE
and O
Stat5b NUMERIC
, O
are O
encoded O
by O
distinct O
genes O
. O

Mutations O
in O
three O
loci O
( O
SIC1 NUMERIC
, O
SWI5 NUMERIC
, O
and O
RIC3 NUMERIC
) O
were O
identified O
. O

The O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
functions O
downstream O
of O
Rats I-GENE
in O
a O
signal O
transduction O
cascade O
which O
transmits RARE
mitogenic O
stimuli O
from O
the O
plasma O
membrane O
to O
the O
nucleus O
. O

Platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
- O
dependent O
activation O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
is O
regulated O
by O
receptor O
binding O
of O
SH2 I-GENE
- I-GENE
domain I-GENE
- I-GENE
containing I-GENE
proteins I-GENE
which O
influence O
Ras I-GENE
activity O
. O

In O
transient O
cotransfections RARE
E1A I-GENE
could O
induce O
the O
activity O
of O
the O
p53 I-GENE
promoter I-GENE
to O
a O
high O
level O
; O
12S NUMERIC
E1A I-GENE
was O
threefold O
as O
efficient O
as O
13S NUMERIC
E1A I-GENE
in O
this O
activity O
, O
and O
YY1 I-GENE
bound O
to O
the O
composite O
element O
was O
shown O
to O
mediate O
55 O
% O
of O
this O
induction O
. O

The O
retinoid I-GENE
Z I-GENE
receptor I-GENE
beta I-GENE
( O
RZR ALLCAPS
beta I-GENE
), O
an O
orphan O
receptor O
, O
is O
a O
member O
of O
the O
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RAR I-GENE
)/ O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
subfamily O
of O
nuclear O
receptors O
. O

DNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
DNA I-GENE
- I-GENE
PK I-GENE
) O
consists O
of O
a O
heterodimeric O
protein O
( O
Ku RARE
) O
and O
a O
large O
catalytic O
subunit O
( O
DNA I-GENE
- I-GENE
PKcs RARE
). O

Almost RARE
complete O
sequence O
identity O
was O
found O
between O
the O
3 O
' O
end O
of O
the O
DXS6673E NUMERIC
gene I-GENE
and O
two O
expressed O
sequence O
tags O
( O
ESTs O
) O
and O
between O
the O
5 O
' O
end O
of O
the O
DXS6673E NUMERIC
gene I-GENE
and O
a O
third O
EST O
. O

Sequencing O
of O
the O
16p NUMERIC
11 O
. O
1 O
/ O
Xq28 NUMERIC
duplication O
breakpoints O
has O
revealed O
the O
presence O
of O
repetitive O
immunoglobulin I-GENE
- I-GENE
like I-GENE
CAGGG ALLCAPS
pentamer RARE
sequences I-GENE
at O
or O
near O
the O
paralogy RARE
boundaries O
. O

However O
, O
in O
a O
multivariate O
analysis O
considering RARE
age O
, O
gender O
, O
and O
a O
previous O
history O
of O
cardiovascular O
diseases O
, O
female O
gender O
was O
not O
independently O
associated O
with O
death O
. O

Moreover O
, O
following O
a O
single O
intravenous O
injection O
of O
the O
bicistronic RARE
vector O
complexed O
to O
cationic RARE
liposomes O
into O
recipient O
mice O
, O
delivery O
of O
MDR1 NUMERIC
and O
GC I-GENE
cDNAs I-GENE
was O
achieved O
in O
all O
the O
organs O
we O
tested O
. O

The O
limits O
of O
agreement O
between O
DBS ALLCAPS
and O
TOF O
responses O
were O
so O
wide O
that O
they O
cannot O
be O
used O
interchangeably RARE
. O

The O
harpin RARE
- O
encoding O
hrpZ LASTCAP
gene I-GENE
is O
located O
in O
an O
operon O
that O
also O
encodes O
Hrp RARE
secretion I-GENE
pathway I-GENE
components I-GENE
and O
is O
part O
of O
the O
functional O
cluster O
of O
hrp RARE
genes I-GENE
carried O
on O
cosmid O
pHIR11 NUMERIC
that O
enables O
saprophytic RARE
bacteria O
like O
Escherichia O
coli O
and O
Pseudomonas O
fluorescens RARE
to O
elicit O
the O
HR O
in O
tobacco O
leaves O
. O

Despite O
the O
presence O
of O
one O
additional O
ribonucleotide RARE
reductase I-GENE
, O
the O
nrdAB LASTCAP
- I-GENE
encoded I-GENE
enzyme I-GENE
is O
essential O
to O
the O
aerobic O
growth O
of O
the O
cell O
because O
nrdAB LASTCAP
- I-GENE
defective I-GENE
mutants I-GENE
of O
both O
species O
are O
not O
viable O
in O
the O
presence O
of O
oxygen O
. O

Altogether O
, O
the O
results O
demonstrate O
that O
the O
two O
isoforms O
elicit O
similar O
responses O
in O
vivo O
despite O
differences O
in O
their O
regulation O
. O

Motivational RARE
factors O
focusing O
on O
attitudes RARE
, O
perceived O
susceptibility O
to O
pregnancy O
, O
and O
normative RARE
factors O
were O
also O
relevant O
. O

High O
- O
resolution O
structure O
of O
the O
diphtheria RARE
toxin I-GENE
repressor I-GENE
complexed O
with O
cobalt RARE
and O
manganese RARE
reveals O
an O
SH3 I-GENE
- I-GENE
like I-GENE
third O
domain O
and O
suggests O
a O
possible O
role O
of O
phosphate O
as O
co O
- O
corepressor RARE
. O

Titration RARE
of O
the O
human O
and O
porcine O
proteins O
with O
2 O
- O
nitro RARE
- O
5 O
- O
thiosulfabenzoate RARE
indicates O
that O
membrane I-GENE
dipeptidase RARE
additionally O
possesses O
two O
intrachain RARE
disulfide O
bonds O
. O

FEV1 O
did O
not O
fall O
significantly O
in O
patients O
without O
acute O
or O
chronic O
GVHD ALLCAPS
and O
recovered O
earlier O
than O
in O
patients O
without O
posttransplant RARE
pulmonary O
infection O
. O

Administration O
of O
adrenaline O
resulted O
in O
a O
large O
overestimation RARE
of O
the O
SaO2 O
in O
6 O
of O
the O
7 O
measurements O
. O

Therapy RARE
with O
dietary O
modification O
and O
triglyceride RARE
lowering O
drugs O
resulted O
in O
resolution O
of O
symptoms O
and O
parotid RARE
swelling O
in O
one O
patient O
. O

Chernoff RARE
, O
submitted O
for O
publication RARE
). O

We O
have O
cloned O
a O
novel O
protein O
kinase O
, O
termed O
hematopoietic I-GENE
progenitor I-GENE
kinase I-GENE
1 I-GENE
( O
HPK1 NUMERIC
), O
that O
is O
expressed O
predominantly O
in O
hematopoietic O
cells O
, O
including O
early O
progenitor O
cells O
. O

Human O
ESP1 NUMERIC
/ O
CRP2 NUMERIC
protein O
has O
two O
LIM I-GENE
domains O
, O
and O
each O
shares O
35 O
. O
1 O
% O
and O
77 O
or O
79 O
% O
identical O
residues O
with O
human I-GENE
cysteine I-GENE
- I-GENE
rich I-GENE
protein I-GENE
( O
CRP I-GENE
) O
and O
rat I-GENE
CRIP ALLCAPS
, O
respectively O
. O

The O
fragments O
are O
separated O
and O
directly O
sized O
by O
agarose O
gel O
electrophoresis O
. O

Several O
of O
the O
exon O
boundaries O
correspond O
to O
the O
boundaries O
of O
functional O
domains O
in O
the O
p55 I-GENE
protein I-GENE
. O

Linkage RARE
studies O
have O
shown O
locus O
heterogeneity O
with O
one O
TSC ALLCAPS
gene I-GENE
mapped O
to O
chromosome O
9q34 NUMERIC
and O
a O
second O
to O
16p13 NUMERIC
. O
3 O
. O

The O
cytogenetic O
expression O
of O
the O
folate O
sensitive O
fragile RARE
site O
, O
FRAXE ALLCAPS
, O
is O
due O
to O
the O
expansion O
of O
a O
GCC ALLCAPS
repeat O
in O
proximal O
Xq28 NUMERIC
of O
the O
human O
X O
chromosome O
and O
is O
associated O
with O
a O
mild O
form O
of O
mental O
handicap RARE
. O

DNA O
sequence O
analysis O
of O
a O
3213 NUMERIC
bp O
BamHI I-GENE
- O
ClaI LASTCAP
fragment O
revealed O
that O
three O
open O
reading O
frames O
( O
ORFs O
) O
were O
encoded O
in O
the O
same O
orientation O
. O

The O
initial O
inpatient RARE
experience O
for O
individuals O
with O
HIV O
- O
related O
TB O
may O
be O
pivotal O
to O
the O
acceptance RARE
of O
and O
participation O
in O
ongoing RARE
TB O
care O
. O

Tristetraprolin RARE
( O
TTP ALLCAPS
) O
is O
the O
prototype O
of O
a O
group O
of O
potential O
transcription O
factors O
that O
contain O
two O
or O
more O
unusual O
CCCH ALLCAPS
zinc O
fingers O
. O

This O
element O
, O
termed O
CREsp RARE
- O
a O
( O
TGACCTCA ALLCAPS
), O
differs O
by O
one O
nucleotide O
from O
a O
palindromic O
CRE O
( O
CREpal RARE
, O
TGACGTCA ALLCAPS
), O
which O
is O
known O
to O
bind O
CREB I-GENE
as O
a O
homodimer O
. O

Analysis O
of O
human O
genomic O
DNA O
reveals O
an O
intronless O
sequence O
with O
strong O
homology O
to O
human I-GENE
G I-GENE
alpha I-GENE
q I-GENE
cDNA I-GENE
. O

The O
complete O
exon O
- O
intron O
structure O
of O
the O
156 I-GENE
- I-GENE
kb I-GENE
human I-GENE
gene I-GENE
NFKB1 NUMERIC
, O
which O
encodes O
the O
p105 NUMERIC
and O
p50 I-GENE
proteins I-GENE
of O
transcription O
factors O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
and O
I I-GENE
kappa I-GENE
B I-GENE
- I-GENE
gamma I-GENE
: O
implications O
for O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
- O
mediated O
signal O
transduction O
. O

An O
inverted O
Alu I-GENE
repeat O
element O
, O
flanked O
by O
nonamer RARE
direct O
repeats O
, O
was O
identified O
within O
the O
region O
- O
913 NUMERIC
/- O
620 NUMERIC
, O
relative O
to O
the O
cap O
site O
. O

The O
ewes RARE
were O
returned O
to O
normoxia RARE
, O
and O
monitoring O
was O
continued O
for O
1 O
h O
. O

Feline RARE
leukemia O
viruses O
( O
FeLVs RARE
), O
which O
are O
replication O
- O
competent O
oncoretroviruses RARE
of O
the O
domestic RARE
cat O
species O
, O
are O
contagiously RARE
transmitted O
in O
natural O
environments RARE
. O

Comparison O
of O
the O
amino O
acid O
sequences O
of O
the O
RPO1 NUMERIC
polypeptides I-GENE
of I-GENE
IIV6 NUMERIC
, I-GENE
LCDV ALLCAPS
, I-GENE
and I-GENE
MCV ALLCAPS
- I-GENE
1 I-GENE
with O
the O
corresponding O
prokaryotic O
, O
eukaryotic O
, O
and O
viral O
proteins O
revealed O
differences O
in O
amino O
acid O
similarity O
and O
phylogenetic O
relationships O
. O

The O
RPO1 NUMERIC
of O
LCDV ALLCAPS
shows O
the O
highest O
similarity O
to O
the O
RPO1 NUMERIC
of O
IIV6 NUMERIC
and O
significant O
lower O
similarity O
to O
the O
eukaryotic I-GENE
polymerases I-GENE
II I-GENE
and I-GENE
III I-GENE
as O
well O
as O
to O
the O
archaebacteral RARE
subunit O
. O

The O
use O
of O
primary O
GE ALLCAPS
cells O
thus O
provides O
a O
convenient RARE
in O
vitro O
system O
for O
further O
study O
of O
the O
endocrine O
, O
paracrine RARE
, O
and O
autocrine O
factors O
regulating O
endometrial O
gene O
expression O
during O
pregnancy O
. O

We O
performed O
dipole RARE
estimation O
of O
spikes O
and O
SEP ALLCAPS
components O
in O
identical O
patients O
. O

Both O
verapamil O
and O
propranolol O
can O
exhibit O
additive O
effects O
with O
adenosine O
in O
prolonging RARE
AV O
nodal O
conduction O
time O
; O
however O
, O
only O
verapamil O
can O
reduce O
the O
dose O
of O
adenosine O
required O
to O
produce O
AV O
nodal O
block O
. O

Proximal RARE
CBD ALLCAPS
was O
inversely O
correlated O
with O
bone I-GENE
alkaline I-GENE
phosphatase I-GENE
( O
r O
= O
- O
0 O
. O
71 O
, O
p O
< O
0 O
. O
01 O
) O
and O
intact O
PTH I-GENE
( O
r O
= O
- O
0 O
. O
59 O
, O
p O
< O
0 O
. O
05 O
). O

In O
addition O
, O
a O
comparison O
of O
the O
hCHLR LASTCAP
gene I-GENE
sequences I-GENE
with O
available O
databases RARE
indicates O
that O
a O
large O
portion O
of O
these O
genes O
, O
including O
exons O
encoding O
two O
functional O
domains O
of O
the O
carboxyl O
- O
terminal O
region O
of O
these O
proteins O
, O
has O
been O
duplicated O
as O
part O
of O
a O
larger O
human O
telomeric O
repeat O
sequence O
found O
on O
many O
human O
chromosomes O
. O

We O
show O
here O
that O
the O
LIM I-GENE
domain I-GENE
homeobox I-GENE
protein I-GENE
isl RARE
- I-GENE
1 I-GENE
activates O
the O
rat I-GENE
amylin RARE
promoter I-GENE
in O
both O
fibroblast O
and O
islet O
cell O
lines O
. O

Although O
isl RARE
- I-GENE
1 I-GENE
binds O
to O
both O
the O
insulin I-GENE
and O
amylin RARE
gene I-GENE
promoter I-GENE
elements I-GENE
in O
vitro O
, O
these O
sequences O
display O
marked O
differences O
in O
their O
relative O
transcriptional O
properties O
when O
ligated O
adjacent O
to O
a O
heterologous O
promoter O
and O
transfected O
into O
InR1 NUMERIC
- O
G9 NUMERIC
islet O
cells O
. O

It O
is O
likely O
that O
other O
pathways O
involve O
alternate O
signal O
transduction O
events O
( O
e O
. O
g O
., O
calcium O
mobilization RARE
) O
and O
promoter O
response O
elements O
( O
e O
. O
g O
., O
SRE O
). O

The O
CD4 I-GENE
count O
at O
which O
remission O
occurs O
may O
reflect O
severe O
immunodeficiency O
such O
that O
risk O
for O
AIDS O
- O
related O
infection O
is O
high O
. O

Although O
diagnostic O
laparoscopy RARE
is O
still O
considered O
the O
standard O
reference O
in O
the O
diagnosis O
of O
ectopic O
pregnancy O
( O
EP ALLCAPS
), O
use O
of O
high O
- O
resolution O
endovaginal RARE
sonography RARE
, O
in O
conjunction O
with O
qualitative O
serum O
assays O
of O
the O
beta O
subunit O
of O
human I-GENE
chorionic RARE
gonadotropin I-GENE
( O
beta I-GENE
- I-GENE
hCG I-GENE
), O
allows O
detection O
of O
earlier O
and O
smaller O
EPs RARE
. O

Bifunctionality RARE
of O
the O
AcMNPV LASTCAP
homologous I-GENE
region I-GENE
sequence I-GENE
( O
hr1 NUMERIC
): O
enhancer O
and O
ori RARE
functions O
have O
different O
sequence O
requirements O
. O

RVR ALLCAPS
' O
loss O
of O
function O
' O
studies O
by O
constitutive O
over O
- O
expression O
of O
a O
dominant O
negative O
RVR ALLCAPS
delta I-GENE
E I-GENE
resulted O
in O
increased O
levels O
of O
p21Cip1 NUMERIC
/ O
Waf1 NUMERIC
and O
myogenin I-GENE
mRNAs I-GENE
after O
serum O
withdrawal O
. O

Neither O
CES1 NUMERIC
nor O
CES4 NUMERIC
is O
essential O
for O
cell O
growth O
, O
and O
a O
double O
deletion O
mutant O
is O
viable O
. O

These O
two O
repeat O
motifs O
are O
organized O
in O
an O
extremely O
well O
- O
ordered RARE
pattern O
in O
each O
domain O
, O
which O
suggests O
that O
SbHRGP3 NUMERIC
belongs O
to O
a O
new O
group O
of O
proteins O
having O
the O
repeat O
motifs O
of O
two O
distinct O
groups O
of O
dicot RARE
extensins RARE
. O

Their O
use O
established O
that O
the O
BrAAP LASTCAP
activity O
catalyzed O
both O
a O
postproline RARE
and O
a O
postglutamate RARE
cleavage O
and O
therefore O
has O
a O
broader RARE
specificity O
than O
previously O
recognized O
. O

To O
explore O
the O
functional O
significance O
of O
these O
subdomains O
in O
PRL I-GENE
binding O
and O
signal O
transduction O
, O
deletion O
mutants O
of O
S1 O
or O
/ O
and O
S2 O
subdomains O
were O
constructed O
. O

A O
stable O
heterologous O
cell O
line O
containing O
the O
mouse I-GENE
TRH I-GENE
receptor I-GENE
was O
constructed O
by O
transfection O
of O
nonexcitable RARE
293 O
cells O
, O
which O
lack O
L O
channel O
activity O
. O

To O
understand O
further O
the O
expression O
and O
regulation O
of O
the O
V1aR NUMERIC
, O
we O
now O
describe O
the O
genomic O
characteristics O
, O
tissue O
expression O
, O
chromosomal O
localization O
, O
and O
regional O
mapping O
of O
the O
human I-GENE
V1aR NUMERIC
gene I-GENE
, O
AVPR1A NUMERIC
. O

The O
final O
predicted O
structure O
has O
an O
overall O
backbone RARE
deviation O
of O
0 O
. O
7 O
A O
from O
that O
of O
ras I-GENE
- O
p21 I-GENE
. O

Genomic O
organization O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
catenin I-GENE
gene I-GENE
( O
CTNNB1 NUMERIC
). O

Furthermore O
, O
although O
the O
regional O
distribution O
of O
lean O
tissue O
mass O
in O
the O
trunk O
and O
legs RARE
remained O
fairly RARE
constant O
at O
different O
pubertal RARE
stages O
, O
the O
regional O
distribution O
of O
fat O
was O
altered O
significantly O
, O
becoming RARE
more O
central O
and O
less O
peripheral O
. O

Thus O
, O
the O
predicted O
CD30v NUMERIC
protein I-GENE
retains O
most O
of O
the O
cytoplasmic O
region O
, O
but O
lacks O
the O
extracellular O
and O
transmembrane O
domains O
. O

Constitutive RARE
phosphorylation O
of O
the O
CD30v NUMERIC
protein I-GENE
was O
demonstrated O
by O
in O
vitro O
labeling O
with O
[ O
32P O
]. O

17 O
. O
5 O
% O
of O
cycles O
). O

We O
report O
here O
the O
discovery O
of O
a O
new O
actin I-GENE
- I-GENE
related I-GENE
gene I-GENE
in O
this O
organism O
, O
which O
we O
have O
named O
ACT4 NUMERIC
. O

Two O
of O
the O
ORFs O
are O
completely O
internal O
to O
longer O
ones O
and O
a O
third O
is O
partially O
embedded O
in O
G2850 NUMERIC
. O

MVR ALLCAPS
typing RARE
of O
rare O
- O
length O
alleles O
indicates O
that O
they O
are O
comprised O
of O
disorganized RARE
sequences O
, O
although O
they O
usually O
bear RARE
a O
resemblance RARE
to O
one O
of O
the O
common O
alleles O
at O
the O
5 O
'- O
most O
end O
. O

Plasmid RARE
pAL618 NUMERIC
contains O
the O
genetic O
determinants O
for O
H2 O
uptake O
( O
hup RARE
) O
from O
Rhizobium O
leguminosarum RARE
bv RARE
. O
viciae RARE
, O
including O
a O
cluster O
of O
17 O
genes O
named O
hupSLCDEFGHIJK LASTCAP
- I-GENE
hypABFCDE LASTCAP
. O

Two O
classes O
of O
inactive O
receptors O
were O
identified O
: O
one O
in O
which O
both O
transcriptional O
activation O
and O
dimerization O
were O
compromised RARE
and O
a O
second O
in O
which O
only O
transcriptional O
activation O
was O
abolished O
. O

Here O
we O
localize O
a O
transferable RARE
40 O
- O
amino O
acid O
region O
within O
the O
LBDs RARE
of O
RXR I-GENE
, O
RAR I-GENE
, O
TR I-GENE
, O
and O
chicken I-GENE
ovalbumin RARE
upstream I-GENE
promoter I-GENE
transcription I-GENE
factor I-GENE
that O
is O
critical O
for O
determining O
identity O
in O
the O
heterodimeric O
interaction O
and O
for O
high O
- O
affinity O
DNA O
binding O
. O

OKA ALLCAPS
and O
calyculin RARE
A O
do O
not O
decrease O
OCFRE ALLCAPS
DNA O
- O
protein O
interactions O
, O
suggesting O
that O
important O
protein O
- O
protein O
interactions O
are O
phosphatase O
regulated O
. O

An O
open O
- O
label RARE
, O
placebo O
- O
controlled O
, O
randomized O
, O
two O
- O
way O
crossover RARE
study O
was O
performed O
in O
12 O
healthy O
volunteers O
( O
between O
20 O
and O
44 O
years O
of O
age O
) O
to O
assess O
the O
effect O
of O
orlistat RARE
, O
a O
gastrointestinal I-GENE
lipase I-GENE
inhibitor O
that O
reduces O
dietary O
fat O
absorption O
and O
is O
being O
developed O
for O
weight O
control O
in O
obesity O
, O
on O
the O
absorption O
of O
vitamins RARE
A O
and O
E O
. O

Tilmicosin RARE
is O
a O
novel O
macrolide RARE
antibiotic O
developed O
for O
exclusive RARE
use O
in O
veterinary RARE
medicine O
. O

Effect O
of O
nitrous RARE
oxide O
( O
N2O O
) O
on O
the O
somatosympathetic RARE
A O
- O
and O
C O
- O
reflexes RARE
was O
investigated O
using O
artificially O
ventilated O
rats O
anesthetized O
with O
alpha O
- O
chloralose RARE
and O
urethane RARE
. O

Restriction O
enzyme O
mapping O
and O
Southern O
analysis O
indicated O
further O
that O
the O
human I-GENE
MZF ALLCAPS
- I-GENE
1 I-GENE
gene I-GENE
is O
a O
single O
- O
copy O
gene O
. O

In O
the O
absence O
of O
Swi4 NUMERIC
and O
Swi6 NUMERIC
cell O
viability O
is O
lost O
, O
but O
can O
be O
regained RARE
by O
ectopic O
expression O
of O
the O
G1 I-GENE
cyclin I-GENE
encoding I-GENE
genes I-GENE
, O
CLN1 NUMERIC
or O
CLN2 NUMERIC
. O

The O
detection O
ratio O
peaked RARE
at O
ages O
30 O
to O
34 O
and O
decreased O
heavily RARE
during O
the O
next O
15 O
years O
of O
age O
. O

How RARE
many O
embryos O
to O
transfer O
in O
patients O
undergoing O
IVF ALLCAPS
? O

IMPLICATIONS ALLCAPS
: O
Given RARE
the O
small O
size O
of O
this O
study O
and O
the O
inconsistency RARE
of O
results O
among O
the O
few O
prospective O
studies O
of O
ovarian O
cancer O
conducted O
to O
test O
these O
associations O
, O
replications RARE
of O
these O
findings O
are O
highly O
desirable RARE
. O

The O
nonconsensus RARE
TATA O
box O
in O
promoter O
B O
plays O
a O
more O
important O
role O
in O
promoter O
activity O
than O
the O
TATA O
box O
in O
promoter O
A O
. O

These O
properties O
indicate O
that O
Gle1 NUMERIC
is O
an O
RNA O
- O
export O
factor O
and O
that O
Rev I-GENE
may O
mediate O
viral O
RNA O
export O
by O
mimicking RARE
the O
function O
of O
Gle1 NUMERIC
. O

Demispan RARE
is O
a O
reliable O
and O
reproducible RARE
measure O
of O
stature RARE
in O
the O
elderly O
. O

Two O
techniques O
based O
on O
assay O
coefficients O
of O
variation O
were O
employed O
to O
characterize O
a O
normal O
circadian O
pattern O
of O
cortisol O
. O

We O
have O
performed O
toeprinting RARE
analyses O
on O
repA LASTCAP
mRNA I-GENE
of O
plasmid O
R1 O
, O
both O
free O
and O
in O
duplex O
with O
the O
antisense O
RNA O
, O
CopA LASTCAP
. O

Previous O
work O
showed O
that O
repA LASTCAP
( O
initiator O
protein O
) O
expression O
requires O
tap I-GENE
( O
leader O
peptide O
) O
translation O
. O

A O
system O
is O
described O
in O
which O
the O
volume O
flow O
rate O
of O
blood O
in O
a O
vessel O
is O
determined O
using O
transverse O
colour O
Doppler O
ultrasound O
imaging O
. O

The O
enzyme O
activities O
studied O
are O
important O
elements O
in O
the O
pathophysiology O
of O
dental O
caries RARE
and O
may O
even O
be O
addressed O
as O
virulence O
factors O
. O

Tonsillectomy RARE
is O
an O
effective O
means O
of O
prophylaxis O
for O
upper O
respiratory O
infection O
in O
habitual RARE
angina O
patients O
. O

In O
lean O
mice O
, O
the O
fat O
/ O
water O
intensity O
ratio O
was O
about O
1 O
: O
4 O
, O
about O
half O
that O
in O
normal O
mice O
. O

Pharmacokinetic RARE
parameters O
were O
similar O
to O
values O
given O
in O
the O
literature O
for O
intravenous O
( O
IV O
) O
or O
intraarterial RARE
( O
IA O
) O
bolus O
MMC O
injections O
( O
Tmax RARE
= O
7 O
. O
0 O
min O
following O
the O
beginning O
of O
MMC O
infusion O
, O
Vss RARE
= O
0 O
. O
57 O
1 O
/ O
kg O
, O
C1 O
= O
8 O
. O
9 O
ml O
/ O
min O
. O
kg O
, O
T1 O
/ O
2 O
alpha O
= O
8 O
. O
3 O
min O
, O
T1 O
/ O
2 O
beta O
= O
58 O
. O
6 O
min O
). O

In O
this O
study O
, O
we O
identified O
four O
distinct O
E2F I-GENE
complexes I-GENE
present O
in O
aged O
and O
senescent RARE
normal O
, O
human O
diploid O
fibroblasts O
. O

This O
paper O
gives O
an O
overview RARE
of O
the O
global O
pattern O
of O
casualties RARE
in O
earthquakes RARE
which O
occurred O
during O
the O
30 O
- O
month O
period O
from O
1 O
September RARE
1993 O
to O
29 O
February RARE
1996 O
. O

If O
we O
apply RARE
the O
finding O
of O
non O
- O
visualization O
of O
the O
GB ALLCAPS
at O
4 O
h O
post O
injection O
as O
the O
criterion O
for O
the O
diagnosis O
of O
AC O
, O
the O
diagnostic O
accuracy O
was O
only O
40 O
. O
7 O
% O
( O
11 O
/ O
27 O
). O

These O
results O
were O
corroborated RARE
in O
a O
subsequent O
study O
in O
which O
30 O
hypogonadal RARE
men O
were O
supplemented O
with O
SLT ALLCAPS
5 O
mg O
three O
times O
daily O
for O
6 O
months O
. O

Alternative O
processing O
of O
the O
tryptophanyl RARE
- I-GENE
tRNA I-GENE
synthetase I-GENE
mRNA I-GENE
from O
interferon I-GENE
- O
treated O
human O
cells O
. O

Evidence O
for O
the O
promoting O
role O
of O
the O
intra I-GENE
- I-GENE
uterine I-GENE
kinin RARE
release O
in O
the O
development O
of O
late O
hypertonic RARE
saline O
- O
induced O
abortion O
. O

This O
GAP I-GENE
activity O
was O
observed O
in O
3T3 O
- O
L1 O
adipocyte RARE
lysates O
, O
and O
was O
able O
to O
accelerate RARE
the O
hydrolysis O
of O
the O
[ O
alpha O
- O
32P O
] O
GTP O
bound O
to O
GST I-GENE
- O
Rab4 NUMERIC
into O
[ O
alpha O
- O
32P O
] O
GDP O
. O

CONCLUSION O
: O
During O
chronic O
treatment O
, O
the O
haemodynamic RARE
response O
to O
oral O
cilazapril RARE
was O
attenuated O
, O
indicating O
that O
continued O
clinical O
improvement O
in O
patients O
with O
CHF ALLCAPS
on O
CLZ ALLCAPS
is O
independent O
of O
to O
its O
acute O
haemodynamic RARE
effects O
. O

We O
conclude O
that O
, O
in O
AIDS O
patients O
with O
cryptococcosis RARE
, O
tolerance O
to O
ILd RARE
- O
AmB LASTCAP
was O
acceptable O
when O
the O
daily O
dosage O
did O
not O
exceed RARE
1 O
mg O
/ O
kg O
, O
but O
the O
higher O
1 O
. O
5 O
mg O
/ O
kg O
daily O
dosage O
was O
associated O
with O
an O
unacceptable RARE
rate O
of O
nephrotoxicity RARE
. O

Moreover O
, O
the O
second O
RCC1 NUMERIC
- I-GENE
like I-GENE
motif I-GENE
located O
at O
the O
amino O
- O
terminus O
of O
p619 NUMERIC
stimulates O
guanine O
nucleotide O
exchange O
on O
ARF1 NUMERIC
and O
on O
members O
of O
the O
related O
Rab RARE
proteins I-GENE
, O
but O
not O
on O
other O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
such O
as O
Ran I-GENE
or O
R I-GENE
- I-GENE
Ras2 NUMERIC
/ O
TC21 NUMERIC
. O

The O
reconstituted O
RNA I-GENE
polymerases I-GENE
containing O
the O
mutant O
alpha O
subunits O
were O
examined O
for O
their O
response O
to O
transcription O
activation O
by O
cAMP I-GENE
- I-GENE
CRP I-GENE
and O
the O
rrnBP1 NUMERIC
UP ALLCAPS
element I-GENE
. O

Transcription O
factor O
recognition O
surface O
on O
the O
RNA I-GENE
polymerase I-GENE
alpha I-GENE
subunit I-GENE
is O
involved O
in O
contact O
with O
the O
DNA O
enhancer O
element O
. O

Consistent O
with O
this O
similarity O
, O
the O
cdc28 NUMERIC
- O
P8 NUMERIC
mutant O
accumulates O
unspliced O
precursors O
at O
the O
restrictive O
temperature O
. O

A O
decrease O
of O
erythrocyte O
Mn RARE
with O
age O
, O
expressed O
in O
nmol O
/ O
L O
, O
was O
noted O
( O
p O
< O
0 O
. O
02 O
). O

Cloning O
and O
sequence O
analyses O
revealed O
a O
second O
cDNA O
with O
a O
95 O
- O
nt O
deletion O
in O
the O
region O
coding O
for O
the O
putative O
second O
intracellular O
loop O
and O
the O
fourth O
transmembrane O
domain O
of O
the O
5 I-GENE
- I-GENE
HT2C NUMERIC
- I-GENE
R I-GENE
. O

Expression O
of O
thymidine I-GENE
kinase I-GENE
gene I-GENE
in O
normal O
human O
diploid O
cells O
is O
both O
cell O
cycle O
- O
and O
age O
- O
dependent O
and O
appears O
to O
be O
transcriptionally O
regulated O
. O

The O
minimum O
inhibitory O
concentrations O
( O
MICs O
) O
of O
ketoconazole RARE
, O
miconazole RARE
, O
itraconazole RARE
, O
fluconazole RARE
, O
and O
amphotericin O
B O
were O
significantly O
influenced O
by O
the O
inoculum RARE
size O
, O
regardless O
of O
the O
techniques O
used O
. O

These O
bacteria O
produce O
and O
export O
proteins O
capable O
of O
specific O
interactions O
with O
key O
mammalian O
cell O
regulatory O
molecules O
in O
order O
to O
derail RARE
the O
normal O
functions O
of O
the O
cells O
. O

The O
elevations O
achieved O
by O
LDEE ALLCAPS
given O
s O
. O
c O
. O
were O
higher O
than O
those O
achieved O
after O
i O
. O
p O
. O
administration O
and O
lasted RARE
for O
longer O
periods O
. O

Thus O
, O
although O
p28 NUMERIC
may O
play O
only O
a O
limited O
role O
during O
the O
early O
embryonic O
cleavages RARE
, O
it O
may O
function O
later O
in O
development O
to O
establish O
a O
somatic O
type O
of O
cell O
cycle O
. O

The O
main O
aim O
of O
the O
contribution O
, O
which O
opens RARE
an O
arena RARE
for O
discussion O
on O
the O
Rivista RARE
dell RARE
' O
Infermiere RARE
is O
to O
critically RARE
appraise RARE
published O
research O
works RARE
focusing O
both O
on O
strengths O
and O
novelty RARE
and O
weaknesses RARE
in O
the O
hypothesis O
formulation O
, O
methods O
and O
instruments O
used O
, O
discussion O
of O
results O
. O

Moreover O
, O
it O
also O
discusses RARE
the O
effects O
of O
antihypertensive O
drugs O
currently O
regarded O
as O
first O
- O
choice O
agents O
, O
i O
. O
e O
. O
calcium O
antagonists O
and O
the O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
, O
on O
intrarenal RARE
hemodynamics O
. O

Many O
human O
viruses O
are O
able O
to O
develop O
suitable O
strategies O
for O
modifying RARE
apoptosis O
in O
virus O
- O
infected O
cells O
and O
in O
virus O
- O
primed O
T O
cells O
. O

It O
is O
suggested O
that O
the O
observed O
clinical O
phenomena O
in O
response O
to O
morphine O
can O
be O
explained O
by O
differences O
in O
expression O
and O
sensitivity O
of O
some O
opioid I-GENE
receptor I-GENE
subtypes O
in O
migraine RARE
. O

Previous O
studies O
demonstrated O
that O
the O
flavin RARE
- I-GENE
containing I-GENE
monooxygenases RARE
( O
FMO ALLCAPS
) O
are O
expressed O
in O
a O
tissue O
- O
specific O
manner O
. O

Taken O
together O
, O
these O
observations O
indicate O
that O
the O
C O
- O
terminal O
24 O
amino O
acids O
are O
sufficient O
for O
NodO LASTCAP
secretion O
although O
the O
region O
adjacent O
to O
this O
domain O
appears O
to O
affect O
secretion O
efficiency O
. O

Thus O
, O
despite O
the O
potential O
for O
common O
regulatory O
mechanisms O
, O
the O
available O
evidence O
indicates O
that O
the O
Mtx RARE
minimal I-GENE
promoter I-GENE
does O
not O
significantly O
affect O
Thbs3 NUMERIC
gene I-GENE
expression O
. O

MSSP ALLCAPS
proteins I-GENE
have O
been O
identified O
by O
their O
binding O
to O
an O
upstream O
element O
of O
c I-GENE
- I-GENE
myc I-GENE
. O

Gene I-GENE
1 I-GENE
has O
been O
completely O
sequenced O
. O

B I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
( O
BCR I-GENE
)- O
induced O
apoptosis O
in O
the O
WEHI ALLCAPS
- O
231 O
B O
lymphoma O
cell O
line O
can O
be O
prevented O
by O
engaging RARE
CD40 I-GENE
. O

Both O
alleles O
are O
functionally O
expressed O
and O
are O
distributed O
within O
CD4 I-GENE
+/ O
CD8 I-GENE
+ O
T O
cell O
subsets RARE
. O

The O
model O
also O
predicts O
that O
blood O
flow O
shunt O
fraction O
( O
Qs RARE
/ O
QT O
) O
is O
directly O
related O
to O
the O
oxygen O
sine RARE
- O
wave O
amplitude O
perturbations RARE
transmitted O
to O
end O
- O
expired RARE
air O
and O
arterial O
and O
mixed O
- O
venous O
blood O
through O
two O
simple O
equations RARE
. O

The O
deduced O
amino O
acid O
sequence O
of O
LvUSF2 NUMERIC
is O
nearly O
identical O
to O
LvUSF1 NUMERIC
except O
at O
the O
amino O
end O
, O
where O
they O
are O
sharply O
divergent O
. O

ECM ALLCAPS
disruption O
in O
Lytechinus RARE
embryos O
caused O
a O
relative O
drop O
in O
USF I-GENE
RNA I-GENE
accumulation O
levels O
to O
approximately O
60 O
% O
of O
control O
embryos O
, O
while O
LpS1 NUMERIC
RNA I-GENE
accumulation O
levels O
dropped RARE
to O
less O
than O
5 O
%. O

Five O
of O
these O
eight O
patients O
in O
group O
II O
also O
received O
8 O
- O
in O
- O
1 O
chemotherapy O
. O

Sixty RARE
days O
after O
the O
intervention O
, O
twitch RARE
and O
tetanic RARE
tensions RARE
remained O
dependent O
upon O
the O
extracellular O
Ca2 O
+ O
concentration O
([ RARE
Ca O
] O
o O
) O
both O
in O
groups O
A O
and O
B O
. O

Discrimination RARE
between O
HIV O
- O
1 O
and O
HIV O
- O
2 O
showed O
evidence O
for O
the O
presence O
of O
HIV O
- O
1 O
only O
. O

However O
, O
an O
intrinsic O
DNA O
- O
binding O
subunit O
for O
HiNF LASTCAP
- I-GENE
D I-GENE
was O
not O
identified O
. O

The O
HiNF LASTCAP
- I-GENE
D I-GENE
( O
CDP I-GENE
/ O
cut I-GENE
) O
complex O
with O
the O
H4 I-GENE
promoter I-GENE
is O
immunoreactive O
with O
antibodies O
against O
CDP I-GENE
/ O
cut I-GENE
and O
pRB LASTCAP
but O
not O
p107 I-GENE
, O
whereas O
the O
CDP I-GENE
/ O
cut I-GENE
complex O
with O
a O
nonhistone RARE
promoter O
( O
gp91 NUMERIC
- O
phox RARE
) O
reacts RARE
only O
with O
CDP I-GENE
and O
p107 I-GENE
antibodies O
. O

Recently O
, O
a O
distantly O
related O
UmuC LASTCAP
- I-GENE
homolog I-GENE
, O
DinB LASTCAP
, O
has O
also O
been O
identified O
in O
E O
. O
coli O
. O

To O
study O
the O
regulation O
of O
mdr2 NUMERIC
expression O
, O
the O
promoter O
of O
the O
mdr2 NUMERIC
gene I-GENE
has O
been O
isolated O
from O
a O
murine O
vinblastine RARE
- O
resistant O
cell O
line O
, O
J7 NUMERIC
. O
V2 O
- O
1 O
, O
and O
characterized O
. O

The O
amplification O
was O
achieved O
using O
two O
primers O
which O
correspond O
to O
TRH I-GENE
progenitor I-GENE
sequence I-GENE
( O
Lys O
/ O
Arg O
- O
Arg O
- O
Gln O
- O
His O
- O
Pro O
- O
Gly O
- O
Lys O
/ O
Arg O
- O
Arg O
). O

The O
intranodal RARE
mesothelial RARE
cells O
occupied O
the O
sinusoids RARE
of O
the O
lymph O
nodes O
and O
were O
initially O
suspected O
of O
being O
metastatic O
from O
the O
ovarian O
tumor O
in O
each O
case O
. O

The O
gene I-GENE
ccpA LASTCAP
encoding O
the O
catabolite I-GENE
control I-GENE
protein I-GENE
CcpA LASTCAP
of O
Staphylococcus O
xylosus RARE
has O
been O
cloned O
and O
characterized O
. O

An O
InlC LASTCAP
deletion I-GENE
mutant I-GENE
shows O
reduced O
virulence O
when O
tested O
in O
an O
intravenous O
mouse O
model O
, O
but O
intracellular O
replication O
of O
the O
mutant O
in O
Caco RARE
- O
2 O
and O
J774 NUMERIC
cells O
appears O
to O
be O
comparable O
with O
that O
of O
the O
wild O
- O
type O
strain O
. O

Thus O
, O
the O
N I-GENE
- O
Nus RARE
complex O
may O
be O
affected O
through O
contacts O
with O
the O
CTD O
of O
the O
alpha O
subunit O
of O
RNA I-GENE
polymerase I-GENE
, O
as O
is O
a O
group O
of O
regulatory O
proteins O
that O
influences O
initiation O
of O
transcription O
. O

Administration O
of O
RIFA ALLCAPS
at O
200 O
mg O
/ O
kg O
/ O
day O
in O
combination O
with O
ATO ALLCAPS
at O
100 O
mg O
/ O
kg O
/ O
day O
resulted O
in O
a O
marked O
prolongation O
of O
survival O
compared O
with O
that O
for O
mice O
that O
received O
ATO ALLCAPS
or O
RIFA ALLCAPS
alone O
. O

Eight O
- O
four O
ACOAs RARE
were O
tested O
in O
order O
to O
examine O
the O
fit O
of O
the O
model O
to O
the O
data O
by O
path RARE
analysis O
with O
LISREL ALLCAPS
VII O
. O

Two O
of O
seven O
initiation O
sites O
were O
flanked O
by O
a O
sequence O
homologous O
to O
the O
consensus O
promoter O
motif O
that O
includes O
the O
CRTA ALLCAPS
motif O
( O
where O
R O
is O
A O
or O
G O
) O
of O
the O
rice O
mitochondrion RARE
. O

Selection RARE
using O
SC O
EPD ALLCAPS
was O
more O
effective O
than O
phenotypic RARE
selection O
in O
reducing O
age O
at O
puberty RARE
in O
daughters RARE
. O

Using O
anchored O
PCR O
, O
a O
VL ALLCAPS
element I-GENE
rearranged O
to O
CL2 NUMERIC
was O
isolated O
. O

Sodium O
polystyrene RARE
sulfonate RARE
treatment O
for O
lithium O
toxicity O
: O
effects O
on O
serum O
potassium O
concentrations O
. O

The O
mammalian I-GENE
homeodomain I-GENE
proteins I-GENE
encoded O
by O
Hox I-GENE
genes I-GENE
play O
an O
important O
role O
in O
embryonic O
development O
by O
providing O
positional RARE
queues RARE
which O
define O
developmental O
identities O
along O
the O
anteroposterior O
axis O
of O
developing O
organisms O
. O

Interferon I-GENE
stimulated I-GENE
gene I-GENE
factor I-GENE
3 I-GENE
( O
ISGF3 NUMERIC
) O
is O
a O
trimeric RARE
transcription O
factor O
activated O
on O
treatment O
of O
cells O
with O
interferon I-GENE
- I-GENE
alpha I-GENE
and I-GENE
beta I-GENE
( O
type I-GENE
I I-GENE
IFNs RARE
). O

The O
TYAC ALLCAPS
/ O
P1 O
resource O
, O
derivative O
STSs RARE
, O
and O
polymorphisms RARE
constitute O
an O
enabling RARE
resource O
to O
further O
studies O
of O
telomere O
structure O
and O
function O
and O
a O
means O
for O
physical O
and O
genetic O
map O
integration O
and O
closure O
. O

Confirmatory RARE
statistics RARE
included O
item RARE
2 O
of O
the O
Clinical O
Global RARE
Impression RARE
( O
CGI ALLCAPS
), O
the O
total O
score O
of O
the O
Sandoz RARE
Clinical O
Assessment O
Geriatric RARE
( O
SCAG ALLCAPS
) O
scale O
, O
the O
subscale RARE
' O
need O
for O
help O
' O
of O
the O
nurse O
' O
s O
rating O
of O
geriatric RARE
patients O
( O
Beurteilungsskala RARE
fur RARE
geriatrische RARE
Patienten RARE
; O
BGP ALLCAPS
) O
and O
the O
total O
score O
of O
the O
Short O
Cognitive RARE
Performance RARE
Test O
( O
Syndrom RARE
- O
Kurztest RARE
; O
SKT ALLCAPS
). O

Three O
mutants O
were O
isolated O
from O
the O
widely O
used O
strain O
, O
PAO1 NUMERIC
. O

As O
extensively O
examined O
with O
the O
myogenin I-GENE
promoter I-GENE
, O
presence O
of O
one O
or O
multiple O
copies O
of O
Me RARE
in O
the O
vectors O
elevated O
the O
expression O
activity O
in O
myotubes O
by O
4 O
. O
5 O
- O
to O
19 O
- O
fold O
over O
those O
without O
Me RARE
, O
but O
not O
significantly O
in O
myoblasts O
. O

We O
conclude O
that O
common O
upstream O
signals O
cause O
activation O
of O
Ras I-GENE
and O
TC21 NUMERIC
, O
but O
activated O
TC21 NUMERIC
controls O
cell O
growth O
via O
distinct O
Raf I-GENE
- O
independent O
downstream O
signaling O
pathways O
. O

Fission RARE
yeast I-GENE
mal2 NUMERIC
+ I-GENE
is O
required O
for O
chromosome O
segregation O
. O

Selection RARE
was O
based O
on O
expression O
of O
an O
integrated O
DNA O
fragment O
containing O
the O
con RARE
- I-GENE
10 I-GENE
promoter I-GENE
- I-GENE
regulatory I-GENE
region I-GENE
followed O
by O
the O
initial O
segment O
of O
the O
con RARE
- I-GENE
10 I-GENE
open I-GENE
reading I-GENE
frame I-GENE
fused O
in O
frame O
with O
the O
bacterial I-GENE
hygromycin RARE
B I-GENE
phosphotransferase I-GENE
structural I-GENE
gene I-GENE
( O
con10 NUMERIC
'-' RARE
hph RARE
). O

Mutations O
at O
two O
neighboring RARE
sites O
, O
serine O
242 NUMERIC
and O
threonine O
255 NUMERIC
, O
exacerbated RARE
the O
effect O
. O

IRF I-GENE
- I-GENE
1 I-GENE
acts O
as O
a O
transcriptional O
activator O
, O
while O
IRF I-GENE
- I-GENE
2 I-GENE
acts O
as O
a O
repressor O
. O

In O
contrast O
, O
cotransfection O
of O
TFIIB ALLCAPS
and O
IRF I-GENE
- I-GENE
1 I-GENE
into O
NIH O
3T3 O
cells O
resulted O
in O
a O
dose O
- O
dependent O
repression O
of O
promoter O
activation O
which O
occurred O
in O
a O
TATA O
- O
dependent O
manner O
. O

The O
requirement O
of O
Tyr O
- O
19 O
dephosphorylation RARE
for O
spindle O
assembly O
is O
also O
observed O
under O
conditions O
in O
which O
spindle O
formation O
is O
independent O
of O
mitosis O
, O
suggesting O
that O
the O
involvement O
of O
Cdc28 I-GENE
/ O
Clb RARE
kinase O
in O
SPB O
separation O
is O
direct O
. O

A O
subset O
of O
these O
DMP1 NUMERIC
recognition I-GENE
sequences I-GENE
containing O
a O
GGA ALLCAPS
trinucleotide RARE
core O
can O
also O
function O
as O
Ets I-GENE
- I-GENE
responsive I-GENE
elements I-GENE
. O

In O
both O
settings RARE
, O
it O
can O
be O
phosphorylated O
by O
cyclin I-GENE
D I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
suggesting O
that O
its O
transcriptional O
activity O
may O
normally O
be O
regulated O
through O
such O
mechanisms O
. O

Expression O
of O
the O
proapoptotic RARE
protein I-GENE
Bax RARE
under O
the O
control O
of O
a O
GAL10 NUMERIC
promoter I-GENE
in O
Saccharomyces O
cerevisiae O
resulted O
in O
galactose O
- O
inducible O
cell O
death O
. O

This O
technique O
was O
employed O
in O
12 O
patients O
with O
a O
unicameral RARE
bone O
cyst O
. O

Enterococcus RARE
faecium RARE
strains O
with O
vanA LASTCAP
- O
mediated O
glycopeptide RARE
resistance O
were O
isolated O
by O
enrichment RARE
culture O
from O
the O
intestines RARE
and O
feces RARE
of O
several O
animal O
species O
, O
mainly O
horses O
and O
dogs O
( O
8 O
% O
positive O
), O
chickens O
( O
7 O
% O
positive O
), O
and O
pigs O
( O
6 O
% O
positive O
). O

The O
amino O
- O
terminal O
region O
of O
E1A I-GENE
binds O
several O
high O
molecular O
weight O
proteins O
and O
inhibits O
the O
transcriptional O
coactivator O
function O
of O
p300 I-GENE
and O
the O
homologous O
cAMP I-GENE
response I-GENE
element I-GENE
( I-GENE
CRE I-GENE
)- I-GENE
binding I-GENE
protein I-GENE
. O

Transient O
transfection O
assays O
using O
reporter O
gene O
constructs O
containing O
various O
lengths O
of O
the O
5 I-GENE
' I-GENE
mdr1b NUMERIC
sequences I-GENE
revealed O
that O
the O
sequence O
located O
between O
- O
247 NUMERIC
to O
- O
126 O
bp O
was O
important O
for O
the O
expression O
of O
the O
reporter O
gene O
in O
many O
different O
cell O
lines O
. O

We O
show O
that O
the O
5 O
' O
UTR O
characteristic O
of O
testis I-GENE
- I-GENE
specific I-GENE
c I-GENE
- I-GENE
mos I-GENE
mRNA I-GENE
strongly O
represses O
translation O
relative O
to O
the O
translation O
of O
transcripts O
that O
contain O
a O
5 O
' O
UTR O
derived O
from O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
, O
and O
this O
is O
mainly O
due O
to O
the O
four O
uORFs RARE
. O

To O
address O
the O
biological O
effect O
of O
specific O
isoform O
expression O
, O
NIH3T3 O
cells O
were O
transfected O
with O
a O
eukaryotic O
expression O
vector O
containing O
cDNA O
for O
FGF8a NUMERIC
, O
FGF8b NUMERIC
, O
or O
FGF8e NUMERIC
. O

These O
findings O
suggest O
that O
the O
F O
- O
wave O
may O
be O
elicited O
in O
motoneuron RARE
of O
different O
depolarization RARE
threshold O
but O
primarily O
in O
larger O
and O
faster O
nerve O
fibers O
, O
with O
a O
lower O
threshold O
of O
depolarization RARE
. O

In O
addition O
, O
carp RARE
JAK1 NUMERIC
shows O
higher O
sequence O
homology O
to O
mammalian I-GENE
JAK1 NUMERIC
in O
both O
the O
kinase O
- O
like O
( O
JH2 NUMERIC
) O
and O
kinase O
( O
JH1 NUMERIC
) O
domains O
( O
approximately O
70 O
% O
identity O
). O

When O
this O
DNA O
fragment O
was O
placed O
upstream O
of O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
reporter O
gene O
and O
transfected O
into O
a O
carp RARE
CF ALLCAPS
cell O
line O
, O
it O
could O
drive O
the O
synthesis O
of O
CAT I-GENE
enzyme I-GENE
16 O
times O
more O
efficiently O
than O
the O
promoterless O
pCAT LASTCAP
- I-GENE
Basic RARE
. O

Molecular O
cloning O
of O
Elk I-GENE
- I-GENE
3 I-GENE
, O
a O
new O
member O
of O
the O
Ets I-GENE
family I-GENE
expressed O
during O
mouse O
embryogenesis O
and O
analysis O
of O
its O
transcriptional O
repression O
activity O
. O

We O
report O
an O
example O
of O
an O
MDV O
- O
transformed O
T O
- O
lymphoblastoid RARE
cell O
line O
( O
T9 NUMERIC
) O
expressing O
high O
levels O
of O
a O
truncated I-GENE
C I-GENE
- I-GENE
MYB ALLCAPS
protein I-GENE
as O
a O
result O
of O
RAV ALLCAPS
integration O
within O
one O
c I-GENE
- I-GENE
myb I-GENE
allele I-GENE
. O

Frozen RARE
/ O
thawed RARE
extensor RARE
digitorum RARE
longus RARE
muscle O
tendon O
units O
had O
significantly O
lower O
values O
for O
load O
to O
failure O
( O
p O
< O
0 O
. O
01 O
), O
energy O
absorbed O
to O
failure O
( O
p O
< O
0 O
. O
01 O
), O
and O
strain O
at O
failure O
( O
p O
< O
0 O
. O
01 O
), O
and O
they O
tended O
to O
fail O
at O
a O
different O
anatomic O
location O
( O
p O
< O
0 O
. O
01 O
) O
( O
broadly O
at O
the O
fascia RARE
- O
muscle O
interface O
as O
compared O
with O
horizontally RARE
at O
the O
musculotendinous RARE
junction O
) O
than O
fresh O
units O
. O

Northern O
analysis O
of O
the O
3 I-GENE
. I-GENE
1 I-GENE
- I-GENE
kb I-GENE
PWP2H NUMERIC
cDNA I-GENE
revealed O
that O
a O
3 O
. O
3 O
- O
kb O
major O
transcript O
is O
ubiquitously O
expressed O
in O
human O
adult O
tissues O
. O

Forty O
- O
eight O
10 O
- O
12 O
- O
week O
- O
old O
male O
Sprague O
- O
Dawley O
rats O
were O
randomized O
to O
receive O
, O
daily O
for O
28 O
days O
: O
( O
1 O
) O
CsA O
vehicle O
p O
. O
o O
. O
plus O
FB O
vehicle O
sc O
; O
( O
2 O
) O
CsA O
( O
15 O
mg O
/ O
kg O
) O
p O
. O
o O
. O
plus O
FB O
vehicle O
sc O
, O
( O
3 O
) O
CsA O
vehicle O
p O
. O
o O
. O
plus O
FB O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
sc O
; O
and O
( O
4 O
) O
CsA O
( O
15 O
mg O
/ O
kg O
) O
p O
. O
o O
. O
plus O
FB O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
sc O
. O

CsA O
alone O
resulted O
in O
elevated O
bone O
turnover O
. O

Individuals RARE
attending RARE
the O
GUM ALLCAPS
Department RARE
in O
the O
Royal RARE
Infirmary RARE
of O
Edinburgh RARE
between O
1990 O
and O
1994 O
with O
the O
diagnosis O
of O
HIV O
infection O
, O
genital O
warts RARE
, O
genital O
herpes O
, O
non O
- O
specific O
genital O
infection O
( O
NSGI ALLCAPS
), O
gonorrhoea RARE
and O
syphilis RARE
were O
included O
in O
the O
study O
. O

Oncogenic RARE
activation O
of O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
of O
the O
human I-GENE
trk I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
by O
fusion O
to O
a O
cell O
adhesion O
molecule O
. O

Northern O
blotting O
showed O
that O
MDMX ALLCAPS
, O
like O
MDM2 NUMERIC
, O
is O
expressed O
in O
all O
tissues O
tested O
, O
and O
that O
several O
mRNAs O
for O
MDMX ALLCAPS
can O
be O
detected O
. O

Physiol RARE
. O

The O
nucleotide O
sequence O
of O
22 O
, O
846 NUMERIC
bp O
of O
the O
left O
arm O
of O
chromosome O
IV O
is O
described O
. O

They O
suggest O
that O
decreased O
steady O
- O
state O
levels O
of O
IME1 I-GENE
and O
IME2 NUMERIC
mRNA I-GENE
were O
not O
merely RARE
the O
result O
of O
non O
- O
specific O
adverse O
affects O
on O
nucleic O
acid O
metabolism O
caused O
by O
the O
yvh1 NUMERIC
disruption O
. O

Natural RARE
FL I-GENE
protein I-GENE
has O
been O
purified O
from O
a O
stromal RARE
cell O
line O
and O
shown O
to O
be O
a O
65 O
kD O
nondisulfide RARE
- O
linked O
homodimeric RARE
glycoprotein O
comprised O
of O
30 O
kD O
subunits O
, O
each O
containing O
12 O
kD O
of O
N O
- O
and O
O O
- O
linked O
sugars O
. O

The O
objective O
of O
this O
study O
was O
to O
examine O
the O
influence O
of O
HHCA ALLCAPS
and O
other O
serological O
factors O
upon O
the O
development O
of O
VGS ALLCAPS
. O

Spliced RARE
exons O
of O
adenovirus O
late O
RNAs O
colocalize RARE
with O
snRNP O
in O
a O
specific O
nuclear O
domain O
. O

Using O
Spurr RARE
' O
s O
resin O
as O
a O
mounting RARE
medium O
, O
we O
could O
observe O
thick O
specimens O
with O
oil O
immersion O
objective O
lens O
without O
the O
use O
of O
coverslips RARE
, O
then O
avoid O
air O
bubbles RARE
near O
the O
specimen RARE
. O

The O
present O
study O
investigated O
dose O
dependence O
and O
time O
course O
effects O
of O
the O
benzodiazepine RARE
( O
BDZ ALLCAPS
) O
partial O
inverse RARE
agonist O
, O
RO19 NUMERIC
- O
4603 NUMERIC
( O
0 O
. O
005 O
- O
0 O
. O
30 O
mg O
/ O
kg O
) O
alone O
, O
and O
in O
combination O
with O
the O
BDZ ALLCAPS
receptor I-GENE
antagonists O
flumazenil RARE
, O
ZK ALLCAPS
93426 NUMERIC
, O
and O
CGS ALLCAPS
8216 NUMERIC
( O
20 O
mg O
/ O
kg O
) O
in O
selectively O
bred RARE
alcohol O
- O
preferring RARE
( O
P O
) O
rats O
provided O
a O
two O
- O
bottle RARE
choice O
test O
between O
ethanol O
( O
EtOH LASTCAP
) O
( O
10 O
% O
v O
/ O
v O
), O
and O
a O
palatable RARE
saccharin O
( O
0 O
. O
0125 NUMERIC
% O
g O
/ O
v O
) O
solution O
. O

Beyond RARE
the O
Tower RARE
of O
Babel RARE
: O
a O
nomenclature RARE
for O
suicidology RARE
. O

Infection RARE
with O
Neisseria RARE
meningitidis RARE
group O
B O
has O
been O
difficult O
to O
detect O
, O
partly O
because O
this O
bacterial O
group O
' O
s O
polysaccharide RARE
is O
a O
weak O
immunogen RARE
. O

RNase I-GENE
protection O
analysis O
of O
two O
rRNA O
fragments O
whose O
genes O
are O
adjacent O
provided O
evidence O
for O
a O
polycistronic RARE
transcript O
containing O
sequences O
from O
both O
, O
as O
well O
as O
separate O
small O
RNAs O
. O

Rss1p NUMERIC
encodes O
a O
novel O
essential O
protein O
of O
538 NUMERIC
amino O
acids O
, O
which O
contains O
an O
extended O
predicted O
coiled O
- O
coil O
domain O
and O
is O
located O
both O
at O
nuclear O
pore O
complexes O
( O
NPCs RARE
) O
and O
in O
the O
cytoplasm O
. O

To O
map O
this O
regulatory O
serine O
phosphorylation O
site O
we O
developed O
a O
baculovirus O
- O
mediated O
expression O
system O
for O
wild I-GENE
- I-GENE
type I-GENE
annexin RARE
II I-GENE
and O
for O
a O
series O
of O
annexin RARE
II I-GENE
mutants I-GENE
which O
contained O
substitutions O
in O
one O
or O
more O
serine O
residues O
present O
in O
the O
N O
- O
terminal O
domain O
. O

The O
PAI I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
one O
of O
the O
most O
TNF I-GENE
- I-GENE
responsive I-GENE
genes I-GENE
known O
and O
is O
also O
highly O
induced O
by O
the O
phorbol O
ester O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
and O
the O
phosphatase O
inhibitor O
, O
okadaic RARE
acid O
, O
in O
both O
HT O
- O
1080 NUMERIC
fibrosarcoma RARE
and O
U O
- O
937 NUMERIC
histiocytic RARE
cells O
. O

220 O
, O
263 NUMERIC
- O
273 NUMERIC
). O

These O
two O
contigs RARE
contain O
a O
total O
of O
163 NUMERIC
open O
reading O
frames O
( O
ORFs O
) O
in O
26 O
- O
29 O
putative O
operons O
; O
56 O
ORFs O
could O
be O
identified O
with O
reasonable O
certainty RARE
. O

T O
., O
Patel RARE
, O
S O
. O

Growth O
factors O
induce O
the O
expression O
of O
the O
immediate I-GENE
early I-GENE
gene I-GENE
products I-GENE
MAP I-GENE
kinase I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
( O
MKP I-GENE
- I-GENE
1 I-GENE
), O
c I-GENE
- I-GENE
Fos I-GENE
and O
c I-GENE
- I-GENE
Jun I-GENE
. O

The O
up O
- O
regulation O
of O
E I-GENE
- I-GENE
selectin I-GENE
, O
one O
of O
the O
adhesion O
molecules O
on O
the O
endothelium O
, O
is O
an O
important O
event O
in O
the O
mediation RARE
of O
the O
inflammatory O
response O
. O

The O
NIT2 NUMERIC
protein I-GENE
is O
localised RARE
in O
nuclei O
and O
could O
not O
be O
detected O
in O
the O
cytoplasmic O
fraction O
of O
cells O
subjected O
to O
nitrogen O
derepression O
or O
nitrogen O
repression O
, O
indicating O
that O
the O
nuclear O
import O
of O
NIT2 NUMERIC
is O
not O
regulated O
. O

In O
spite RARE
of O
much O
effort O
, O
no O
one O
has O
succeeded RARE
in O
isolating RARE
and O
characterizing O
the O
enzyme O
( O
s O
) O
responsible O
for O
synthesis O
of O
cellulose RARE
, O
the O
major O
cell O
wall O
polymer RARE
of O
plants O
. O

Vascular RARE
responses O
to O
reactive O
hyperemia RARE
( O
with O
flow O
increase O
leading O
to O
endothelium O
- O
dependent O
dilation RARE
) O
and O
to O
sublingual RARE
glyceryl RARE
trinitrate RARE
( O
GTN ALLCAPS
; O
endothelium O
- O
independent O
dilation RARE
) O
were O
recorded O
. O

During O
this O
period O
, O
administration O
of O
additional O
exogenous I-GENE
PRL I-GENE
did O
not O
stimulate O
further O
activation O
( O
binding O
) O
of O
the O
Stat I-GENE
factors I-GENE
. O

Intraperitoneal RARE
administration O
of O
L O
- O
5 O
- O
hydroxytryptophan RARE
( O
L O
- O
5 O
- O
HTP ALLCAPS
) O
at O
doses O
of O
25 O
to O
100 O
mg O
/ O
kg O
dramatically O
increase O
defecation RARE
in O
mice O
. O

In O
the O
VA O
- O
SMV ALLCAPS
mode O
, O
the O
connection RARE
was O
made O
with O
valved RARE
conduits RARE
from O
the O
LV O
apex O
( O
inflow RARE
) O
to O
the O
ascending O
aorta O
( O
outflow O
) O
( O
n O
= O
11 O
) O
or O
to O
the O
DAo RARE
( O
n O
= O
12 O
). O

The O
evidence O
in O
support O
of O
this O
was O
derived O
from O
the O
fact O
that O
the O
affinity O
or O
interaction O
between O
the O
two O
subunits O
was O
impaired O
as O
indicated O
by O
the O
first O
order O
rate O
constant O
of O
hCG I-GENE
alpha I-GENE
1 I-GENE
beta I-GENE
( O
km RARE
= O
4 O
. O
1 O
x O
10 O
(- O
2 O
) O
min O
- O
1 O
) O
at O
pH O
3 O
. O
0 O
at O
23 O
degrees O
C O
which O
is O
one O
order O
of O
magnitude O
greater O
relative O
to O
rehCG LASTCAP
( O
kw RARE
= O
4 O
. O
6 O
x O
10 O
(- O
3 O
) O
min O
- O
1 O
). O

Factor O
V O
Leiden RARE
is O
a O
genetic O
disorder O
associated O
with O
an O
increased O
risk O
of O
venous O
thrombosis O
. O

This O
is O
the O
first O
determination O
of O
the O
complete O
secondary O
structure O
of O
an O
RNA O
spliced O
in O
a O
spliceosome O
. O

The O
majority O
of O
the O
cases O
with O
0 O
- O
I O
or O
0 O
- O
III O
components O
were O
sm RARE
. O
cancer O
. O

These O
patients O
appear O
to O
have O
slightly O
better O
pulmonary O
function O
and O
nutritional O
status O
; O
yet O
, O
they O
seem O
to O
have O
a O
higher O
degree O
of O
health O
care O
utilization O
. O

This O
observation O
calls RARE
for O
careful RARE
monitoring O
of O
calcium O
and O
alkaline I-GENE
phosphatase I-GENE
values O
and O
possible O
adjustments RARE
of O
vitamin O
D O
intake O
when O
fortifiers RARE
are O
used O
for O
extended O
periods O
. O

We O
have O
found O
that O
PEA2 NUMERIC
is O
also O
required O
for O
the O
bipolar O
budding O
pattern O
and O
that O
it O
encodes O
a O
novel O
protein O
with O
a O
predicted O
coiled O
- O
coil O
domain O
. O

Signaling RARE
from O
the O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
Rac1 I-GENE
and O
Cdc42 I-GENE
to O
the O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
/ O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
. O

Percent RARE
identities O
of O
the O
mouse I-GENE
PP2 NUMERIC
to O
mouse I-GENE
Y1 NUMERIC
, O
mouse O
Y4 NUMERIC
/ O
PP1 NUMERIC
and O
human I-GENE
Y2 NUMERIC
receptors I-GENE
are O
53 O
, O
42 O
, O
and O
31 O
, O
respectively O
. O

Correlating RARE
with O
the O
previous O
observation O
that O
CBF I-GENE
binding O
to O
the O
78C1 NUMERIC
site O
is O
enhanced O
by O
EGTA ALLCAPS
and O
EDTA O
, O
these O
divalent RARE
cation RARE
chelators RARE
specifically O
stimulate O
78C1 NUMERIC
- O
directed O
transcription O
. O

The O
human O
gene O
fragment O
ligated O
to O
the O
minimal O
rat O
liver O
glucokinase RARE
promoter O
was O
shown O
to O
work O
as O
an O
enhancer O
in O
the O
hepatocyte O
transfection O
system O
. O

To O
test O
the O
role O
of O
ML ALLCAPS
in O
human O
reproductive O
axis O
, O
128 O
healthy O
children O
, O
68 O
boys O
and O
60 O
girls O
, O
were O
studied O
. O

However O
, O
the O
truncated O
deer RARE
receptor I-GENE
lacks O
the O
most O
C O
- O
terminal O
tyrosine O
residue O
in O
the O
intracellular O
domain O
which O
is O
believed O
to O
be O
essential O
for O
activation O
of O
the O
beta I-GENE
- I-GENE
casein I-GENE
promoter I-GENE
. O

This O
report O
provides O
further O
evidence O
for O
the O
riMLF LASTCAP
in O
the O
control O
of O
downgaze RARE
, O
and O
a O
synkinesis RARE
is O
postulated O
for O
the O
development O
of O
the O
convergence RARE
retraction RARE
nystagmus O
. O

Rifabutin RARE
has O
substantial O
efficacy O
when O
combined O
with O
other O
agents O
. O

Ninety RARE
- O
four O
percent O
of O
the O
EPs RARE
were O
tubal RARE
, O
and O
90 O
% O
of O
the O
tubes RARE
exhibited O
some O
pathologic O
changes O
, O
including O
chronic O
salpingitis RARE
( O
49 O
. O
5 O
%) O
and O
follicular O
salpingitis RARE
( O
10 O
%), O
among O
others O
. O

The O
assessment O
using O
7 O
H O
9 O
liquid O
medium O
by O
the O
former O
author O
demonstrated O
the O
potent O
activities O
of O
both O
CS O
- O
940 NUMERIC
* O
and O
sparfloxacin RARE
( O
SPFX ALLCAPS
), O
followed O
by O
AM O
- O
1155 NUMERIC
*, RARE
ciprofloxacin RARE
( O
CPFX ALLCAPS
), O
levofloxacin RARE
( O
LVFX ALLCAPS
), O
OPC ALLCAPS
- O
17116 NUMERIC
*, RARE
NM ALLCAPS
- O
394 NUMERIC
* O
in O
sequence O
. O

The O
STE20 NUMERIC
gene I-GENE
, O
encoding O
a O
protein O
kinase O
required O
for O
pheromone O
signal O
transduction O
, O
has O
recently O
been O
identified O
in O
a O
genetic O
screen O
for O
high O
- O
gene O
- O
dosage O
suppressors O
of O
a O
partly O
defective O
G I-GENE
beta I-GENE
mutation O
. O

This O
enzyme O
is O
designated O
( I-GENE
1 I-GENE
--> I-GENE
4 I-GENE
)- I-GENE
beta I-GENE
- I-GENE
xylan RARE
endohydrolase RARE
isoenzyme RARE
X I-GENE
- I-GENE
I I-GENE
. O

Magnetic O
resonance O
imaging O
in O
coccidioidal RARE
arthritis O
. O

Moloney O
murine O
leukemia O
virus O
( O
MMLV ALLCAPS
)- O
derived O
pUCMoTiN LASTCAP
- O
based O
retroviral O
vectors O
were O
engineered O
to O
allow O
constitutive O
and O
Tat I-GENE
( O
trans I-GENE
- I-GENE
activator I-GENE
of I-GENE
transcription I-GENE
)- O
inducible O
expression O
of O
five O
hammerhead RARE
ribozymes RARE
targeted O
against O
highly O
conserved O
sequences O
within O
the O
group I-GENE
antigen I-GENE
( O
Gag I-GENE
), O
protease I-GENE
( O
Pro I-GENE
), O
reverse I-GENE
transcriptase I-GENE
( O
RT I-GENE
), O
tat I-GENE
, O
and O
envelope I-GENE
( O
Env I-GENE
) O
coding O
regions O
of O
human O
immunodeficiency O
virus O
type O
- O
1 O
( O
HIV O
- O
1 O
) O
RNA O
. O

REM O
sleep O
deprivation O
was O
performed O
using O
the O
platform RARE
technique O
. O

The O
same O
ligands O
also O
exhibit O
a O
similar O
inhibitory O
effect O
on O
PDGF I-GENE
- I-GENE
BB I-GENE
- O
dependent O
[ O
3H O
] O
thymidine O
incorporation O
in O
PAE ALLCAPS
cells O
expressing O
the O
PDGF I-GENE
beta I-GENE
- I-GENE
receptors I-GENE
. O

We O
analyzed O
serial O
biopsy O
specimens O
from O
eight O
patients O
with O
FL O
for O
secondary O
alterations O
of O
the O
rearranged I-GENE
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
in O
the O
breakpoint O
and O
open O
reading O
frame O
( O
ORF O
) O
regions O
. O

In O
all O
eight O
cases O
, O
neither O
FL O
nor O
DLL ALLCAPS
cells O
showed O
alterations O
of O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
sequences I-GENE
in O
the O
breakpoint O
region O
, O
suggesting O
high O
conservation O
of O
the O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
during O
both O
t O
( O
14 O
; O
18 O
) O
translocation O
and O
morphologic O
transformation O
of O
the O
FL O
cells O
. O

BACKGROUND O
: O
The O
Bazett RARE
- O
corrected O
QT O
( O
QTc RARE
) O
interval O
during O
exercise O
has O
been O
used O
as O
a O
marker O
for O
ischemic O
disease O
, O
arrhythmogenic RARE
substrate O
and O
the O
long O
QT O
syndrome O
. O

An O
essential O
role O
of O
c I-GENE
- I-GENE
Jun I-GENE
and O
c I-GENE
- I-GENE
Fos I-GENE
in O
basal O
and O
PMA O
- O
stimulated O
transcription O
of O
the O
PAI I-GENE
- I-GENE
1 I-GENE
gene I-GENE
is O
demonstrated O
by O
our O
finding O
that O
antisense O
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
oligodeoxynucleotides RARE
both O
strongly O
reduced O
basal O
and O
PMA O
- O
stimulated O
PAI I-GENE
- I-GENE
1 I-GENE
synthesis O
. O

Leukemia RARE
- I-GENE
inhibitory I-GENE
factor I-GENE
( O
LIF ALLCAPS
) O
is O
a O
neuropoietin RARE
able O
to O
regulate O
the O
differentiation O
and O
the O
survival O
of O
many O
cell O
types O
, O
which O
include O
some O
neuronal O
populations O
. O

To O
analyze O
the O
mechanism O
of O
fos I-GENE
/ O
jun I-GENE
activation O
by O
TCDD ALLCAPS
we O
have O
used O
electrophoretic O
mobility O
shift O
and O
transient O
expression O
assays O
of O
reporter O
gene O
constructs O
containing O
response O
elements O
for O
12 O
- O
O O
- O
tetradecanoyl RARE
- O
phorbol O
- O
13 O
- O
acetate O
( O
TRE O
), O
serum O
( O
SRE O
), O
cAMP O
( O
CRE O
), O
and O
aromatic O
hydrocarbons RARE
( O
AhRE LASTCAP
) O
from O
the O
fos I-GENE
and O
jun I-GENE
genes I-GENE
fused O
to O
the O
firefly RARE
luciferase I-GENE
gene I-GENE
under O
the O
control O
of O
the O
SV40 I-GENE
minimal I-GENE
promoter I-GENE
. O

The O
optimal O
sequence O
for O
interaction O
with O
mu I-GENE
2 I-GENE
and O
with O
AP I-GENE
- I-GENE
2 I-GENE
has O
tyrosine O
as O
an O
anchor O
and O
prefers RARE
arginine O
at O
position O
Y O
+ O
2 O
and O
leucine O
at O
position O
Y O
+ O
3 O
. O

STK I-GENE
/ O
RON ALLCAPS
- O
expressing O
Ba RARE
/ O
F3 NUMERIC
pro O
- O
B O
cells O
( O
BaF LASTCAP
/ O
STK I-GENE
) O
exhibited O
MSP ALLCAPS
- O
dependent O
growth O
, O
whereas O
STK I-GENE
/ O
RON ALLCAPS
- O
expressing O
mouse O
erythroleukaemia RARE
cells O
( O
MEL ALLCAPS
/ O
STK I-GENE
) O
displayed O
MSP ALLCAPS
- O
induced O
apoptosis O
. O

In O
vitro O
DNase I-GENE
I I-GENE
footprinting O
showed O
that O
OxyR I-GENE
- I-GENE
C199S NUMERIC
protected O
Pmom RARE
from O
- O
104 O
to O
- O
46 O
on O
the O
top O
strand O
and O
produced O
a O
protection O
pattern O
characteristic O
of O
reduced I-GENE
wild I-GENE
- I-GENE
type I-GENE
OxyR I-GENE
. O

Kss1 NUMERIC
binds O
specifically O
to O
a O
GST I-GENE
- O
Dig1 NUMERIC
fusion O
in O
the O
absence O
of O
any O
other O
yeast O
protein O
. O

In O
contrast O
, O
dig1 NUMERIC
dig2 NUMERIC
cells O
constitutively O
invade RARE
agar O
medium O
, O
whereas O
a O
dig1 NUMERIC
dig2 NUMERIC
ste12 NUMERIC
triple O
mutant O
does O
not O
, O
indicating O
that O
Dig1 NUMERIC
and O
Dig2 NUMERIC
share O
a O
role O
in O
negatively O
regulating O
the O
invasive O
growth O
pathway O
. O

Paracrine RARE
activation O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
promoter I-GENE
by O
the O
viral I-GENE
Tat I-GENE
protein I-GENE
is O
mechanistically RARE
similar O
to O
trans O
- O
activation O
within O
a O
cell O
. O

Comparison O
of O
the O
sequences O
of O
the O
xFxFG LASTCAP
repeat O
regions O
of O
p62 I-GENE
and O
Nsplp RARE
indicated O
that O
NTF2 NUMERIC
was O
probably O
interacting O
with O
the O
phenylalanine O
- O
containing O
core O
of O
these O
repeats O
and O
not O
the O
intervening O
hydrophilic O
linkers RARE
. O

This O
is O
the O
first O
report O
of O
the O
successful O
resection O
of O
a O
MFH ALLCAPS
originating RARE
in O
the O
renal O
capsular RARE
tissue O
and O
extending O
into O
the O
inferior O
vena RARE
cava RARE
. O

Transient O
expression O
of O
VSF ALLCAPS
- I-GENE
1 I-GENE
in O
protoplasts RARE
stimulated O
vs I-GENE
- I-GENE
1 I-GENE
dependent O
activation O
of O
the O
- I-GENE
76 I-GENE
/ I-GENE
grp1 NUMERIC
. I-GENE
8 I-GENE
minimal I-GENE
promoter I-GENE
. O

Keeping RARE
in O
mind RARE
the O
limited O
range O
of O
age O
and O
dosages RARE
, O
advantages O
and O
disadvantages RARE
of O
the O
drug O
are O
discussed O
, O
comparing O
the O
experimental O
results O
with O
those O
derived O
from O
the O
literature O
. O

Blood O
sampling O
procedures O
were O
videotaped RARE
. O

Analysis O
of O
one O
cDNA O
revealed O
an O
unusual O
splicing O
event O
involving O
EZH1 NUMERIC
and O
a O
tandemly O
linked O
gene O
GPR2 NUMERIC
and O
suggests O
a O
potential O
mechanism O
for O
modifying RARE
the O
EZH1 NUMERIC
protein I-GENE
in O
the O
conserved O
C O
- O
terminal O
domain O
. O

A O
given O
standard O
input O
function O
and O
a O
given O
value O
of O
distribution O
volume O
( O
Vd RARE
) O
used O
for O
the O
rCBF O
measurement O
of O
this O
method O
were O
calculated O
from O
the O
dynamic O
study O
by O
six O
normal O
volunteers O
. O

They O
lack O
a O
predicted O
single O
stranded O
( O
ss RARE
) O
DNA O
binding O
motif O
that O
is O
unique O
the O
large O
terminase I-GENE
proteins I-GENE
in O
T4 I-GENE
gp17 NUMERIC
, O
and O
that O
has O
been O
implicated O
in O
recognizing RARE
ssDNA O
regions O
in O
replicating O
and O
recombining RARE
T4DNA NUMERIC
destined RARE
to O
be O
packaged RARE
. O

It O
can O
be O
concluded O
that O
in O
normotensive RARE
subjects O
, O
uric O
acid O
and O
xanthine RARE
oxidase I-GENE
have O
significant O
association O
with O
blood O
pressure O
and O
thus O
are O
one O
of O
the O
many O
factors O
which O
are O
involved O
in O
the O
cause O
or O
effect O
of O
hypertension O
. O

Immunoblotting RARE
of O
expressed O
recombinant O
proteins O
with O
the O
monoclonal I-GENE
08L NUMERIC
antibody I-GENE
localized O
the O
08L NUMERIC
epitope O
to O
the O
carboxyl O
end O
of O
the O
protein O
. O

We O
infer RARE
that O
the O
dominant O
negative O
inhibition O
results O
from O
both O
direct O
proteolysis O
of O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
tetramer I-GENE
by O
the O
fusion O
subunit O
and O
detour RARE
of O
the O
tetramer O
to O
the O
lysosome RARE
. O

The O
current O
study O
defines O
the O
vinculin RARE
- O
and O
FAK I-GENE
- I-GENE
interaction I-GENE
domains I-GENE
on O
paxillin I-GENE
and O
identifies O
the O
principal O
paxillin I-GENE
focal O
adhesion O
targeting O
motif O
. O

These O
data O
demonstrate O
the O
presence O
of O
a O
single O
binding O
site O
for O
vinculin RARE
, O
and O
at O
least O
two O
binding O
sites O
for O
FAK I-GENE
that O
are O
separated O
by O
an O
intervening O
stretch O
of O
100 O
amino O
acids O
. O

These O
data O
demonstrate O
that O
paxillin I-GENE
localizes O
to O
focal O
adhesions O
independent O
of O
interactions O
with O
vinculin RARE
and O
/ O
or O
FAK I-GENE
, O
and O
represents O
the O
first O
definitive O
demonstration RARE
of O
LIM I-GENE
domains I-GENE
functioning O
as O
a O
primary O
determinant O
of O
protein O
subcellular O
localization O
to O
focal O
adhesions O
. O

A O
single O
protease O
- O
resistant O
structure O
formed O
by O
the O
entirety RARE
of O
both O
PDZ I-GENE
repeats I-GENE
1 I-GENE
and I-GENE
2 I-GENE
( O
PDZ1 NUMERIC
- I-GENE
2 I-GENE
) O
contains O
the O
protein I-GENE
4 I-GENE
. I-GENE
1 I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

Several O
agents O
have O
been O
tried RARE
for O
treatment O
, O
often O
limited O
by O
toxic O
side O
effects O
. O

Jerseys RARE
had O
higher O
hepatic O
Cu O
concentrations O
than O
did O
Holsteins RARE
on O
d O
60 O
( O
346 NUMERIC
vs O
. O

RUSH ALLCAPS
- I-GENE
1 I-GENE
beta I-GENE
is O
a O
95 O
- O
kDa O
truncated O
version O
of O
RUSH ALLCAPS
- I-GENE
1 I-GENE
alpha I-GENE
that O
results O
from O
alternative O
splicing O
of O
a O
57 O
- O
bp O
exon O
as O
confirmed O
by O
genomic O
cloning O
. O

These O
results O
are O
consistent O
with O
the O
well O
established O
polarity O
of O
RXR I-GENE
heterodimer O
binding O
to O
bipartite O
hormone O
response O
elements O
, O
with O
the O
VDR I-GENE
recognizing RARE
the O
3 O
'- O
half O
- O
element O
. O

PPAR ALLCAPS
gamma I-GENE
mRNA I-GENE
levels O
were O
reduced O
by O
95 O
% O
with O
3 O
nM O
TNF I-GENE
alpha I-GENE
treatment O
for O
24 O
h O
. O

Exons RARE
III O
to O
VIII O
, O
which O
cover RARE
the O
coding O
region O
and O
the O
3 O
' O
untranslated O
region O
, O
are O
almost O
identical O
in O
all O
types O
of O
PST ALLCAPS
or O
AST ALLCAPS
cDNAs I-GENE
. O

Growth O
factor O
allows O
effective O
dose O
- O
intensive O
regimen O
in O
advanced O
breast O
cancer O
patients O
. O

Recombinant I-GENE
erythropoietin I-GENE
( O
r I-GENE
- I-GENE
HuEPO LASTCAP
) O
in O
the O
treatment O
of O
anemia O
in O
multiple O
myeloma O

In O
1993 O
and O
1994 O
and O
infection O
with O
body O
lice RARE
was O
registered RARE
41 O
times O
in O
31 O
patients O
at O
the O
clinic RARE
for O
homeless RARE
of O
the O
Community RARE
Health O
Service RARE
of O
Utrecht RARE
. O

Ki RARE
- I-GENE
ras I-GENE
and O
p53 I-GENE
mutations I-GENE
in O
pancreatic O
ductal RARE
adenocarcinoma O
. O

Epidemiological RARE
data O
are O
quite O
controversial RARE
but O
sudden RARE
death O
occurring O
during O
sporting RARE
activity O
is O
probably O
not O
a O
rare O
occurrence O
. O

However O
, O
the O
ratio O
M O
/ O
Pc RARE
provides O
a O
useful O
index O
that O
seems O
to O
be O
independent O
of O
the O
metabolic O
demand O
. O

Rat I-GENE
liver I-GENE
catalase I-GENE
is O
sorted RARE
to O
peroxisomes RARE
by O
its O
C O
- O
terminal O
tripeptide RARE
Ala O
- O
Asn O
- O
Leu O
, O
not O
by O
the O
internal O
Ser O
- O
Lys O
- O
Leu O
motif O
. O

The O
mobility O
shift O
assay O
of O
the O
65 O
bp O
(- O
318 NUMERIC
/ O
- O
254 NUMERIC
) O
fragment O
with O
nuclear O
extract O
from O
the O
dark O
- O
adapted O
sample O
showed O
an O
additional O
band O
, O
not O
seen O
with O
the O
light O
- O
grown O
sample O
. O

These O
data O
provide O
strong O
evidence O
that O
E2F I-GENE
or O
an O
E2F I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factor I-GENE
is O
involved O
in O
the O
regulation O
of O
nonmuscle RARE
myosin I-GENE
expression O
. O

When O
the O
E1A I-GENE
N I-GENE
- I-GENE
terminus I-GENE
is O
used O
as O
a O
competitor O
in O
squelshing RARE
experiments O
it O
abolishes O
CBP I-GENE
- O
induced O
activation O
of O
E2F1 I-GENE
/ O
DP1 NUMERIC
, O
whereas O
an O
E1A I-GENE
mutant I-GENE
lacking O
CBP I-GENE
binding O
ability O
fails O
to O
do O
so O
. O

Small RARE
Maf I-GENE
proteins I-GENE
interact O
with O
the O
human O
transcription O
factor O
TCF11 NUMERIC
/ O
Nrf1 NUMERIC
/ O
LCR I-GENE
- I-GENE
F1 I-GENE
. O

On O
the O
third O
occasion RARE
water O
( O
W O
) O
was O
ingested RARE
throughout O
the O
run O
. O

The O
effect O
of O
maternal O
ingestion O
of O
the O
reduced O
energy O
sweetener RARE
erythritol RARE
was O
investigated O
in O
KBL ALLCAPS
: O
JW ALLCAPS
strain O
pregnant O
rabbits O
. O

Moreover O
, O
the O
same O
mutations O
alter O
the O
structure O
of O
junB I-GENE
5 O
' O
flanking O
DNA O
within O
chromatin O
. O

The O
nm23 NUMERIC
- I-GENE
H1 I-GENE
/ O
nm23 NUMERIC
- I-GENE
H2 I-GENE
gene O
transcriptional O
activity O
ratio O
varied O
depending O
on O
the O
cell O
line O
. O

CONCLUSION O
: O
Intravenous O
diazepam O
administration O
before O
EGD ALLCAPS
produces O
a O
significant O
fall O
in O
SpO2 NUMERIC
during O
the O
procedure O
, O
and O
so O
should O
be O
avoided RARE
; O
continuous O
monitoring O
of O
SpO2 NUMERIC
should O
be O
done O
during O
EGD ALLCAPS
. O

The O
nucleotide O
sequence O
alignment O
between O
mouse O
and O
human I-GENE
CA I-GENE
IV I-GENE
shows O
69 O
% O
identity O
in O
the O
coding O
region O
and O
all O
of O
the O
exon O
- O
intron O
boundaries O
are O
conserved O
, O
as O
are O
the O
sizes O
of O
the O
introns O
. O

Discordance RARE
on O
the O
cost O
dimension RARE
correlated O
negatively O
with O
G I-GENE
Hb I-GENE
, O
suggesting O
better O
glycemic RARE
control O
with O
greater O
disagreement RARE
. O

DATA ALLCAPS
SOURCES ALLCAPS
: O
Epidemiologic RARE
studies O
, O
research O
studies O
, O
review O
articles RARE
, O
and O
government RARE
reports O
pertaining RARE
to O
epidemiology RARE
of O
lung O
cancer O
. O

RESULTS O
: O
The O
age O
distribution O
was O
28 O
to O
83 O
years O
old O
( O
mean O
was O
54 O
. O
1 O
years O
). O

Histological O
changes O
, O
including O
cortical O
cell O
involution RARE
and O
hemorrhage O
occurring O
during O
the O
neonatal O
period O
, O
would O
seem O
to O
have O
crucial O
relevance O
to O
the O
remodeling O
of O
the O
adrenal O
vasculature RARE
. O

Furthermore O
, O
co O
- O
expression O
of O
both O
p46 NUMERIC
and O
p54 I-GENE
subunits I-GENE
markedly O
altered O
the O
subcellular O
distribution O
of O
p46 NUMERIC
; O
co O
- O
expressed O
p46 NUMERIC
was O
transported O
into O
the O
nucleus O
as O
efficiently O
as O
p54 I-GENE
. O

The O
results O
suggest O
that O
, O
although O
both O
the O
N O
- O
and O
C O
- O
terminal O
regions O
of O
talin RARE
bind O
actin I-GENE
, O
the O
properties O
of O
these O
two O
regions O
of O
the O
protein O
are O
distinct O
. O

Merr RARE
.) O
embryo O
library O
. O

The O
accumulation O
of O
both O
LHA4 NUMERIC
and O
LHA2 NUMERIC
mRNAs I-GENE
is O
induced O
by O
the O
addition O
of O
exogenous O
sugars O
and O
this O
induction O
appears O
to O
be O
dependent O
on O
sugar O
uptake O
and O
metabolism O
, O
because O
mannitol RARE
and O
3 O
- O
O O
- O
methylglucose RARE
do O
not O
stimulate O
mRNA O
accumulation O
. O

Using O
the O
yeast O
one O
- O
hybrid O
screen O
with O
integrated O
NRE ALLCAPS
and O
flanking O
DNA O
as O
bait RARE
, O
the O
predominant O
clone O
obtained O
was O
bovine I-GENE
Nrl RARE
. O

As O
the O
rate O
of O
protein O
synthesis O
decreases O
during O
late O
embryogenesis O
, O
levels O
of O
SEC ALLCAPS
- I-GENE
1 I-GENE
and O
its O
cognate O
mRNA O
decline O
precipitously RARE
. O

These O
findings O
suggest O
that O
fodrin RARE
proteolysis O
in O
vivo O
may O
reflect O
the O
activity O
of O
multiple O
ICE I-GENE
/ O
Ced RARE
- I-GENE
3 I-GENE
proteases O
whose O
partial O
sensitivity O
to O
DEVD ALLCAPS
- O
CHO O
reflects RARE
a O
limited O
contribution O
from O
CPP32 NUMERIC
, O
or O
an O
ICE I-GENE
/ O
Ced RARE
- I-GENE
3 I-GENE
protease O
less O
sensitive O
than O
CPP32 NUMERIC
to O
DEVD ALLCAPS
- O
CHO O
inhibition O
. O

In O
3Y1 NUMERIC
and O
3Y1 NUMERIC
v I-GENE
- I-GENE
crk RARE
- O
transformed O
fibroblasts O
, O
almost O
all O
of O
the O
total O
PTP1B NUMERIC
and O
about O
40 O
% O
of O
total O
p130 I-GENE
( O
Cas I-GENE
) O
co O
- O
sediment RARE
with O
membranes O
composed O
primarily O
of O
endoplasmic O
reticulum O
. O

Replacing RARE
residues O
405 NUMERIC
- O
419 NUMERIC
on O
delta419 NUMERIC
with O
the O
conserved O
AF O
- O
2 O
domain O
from O
the O
vitamin I-GENE
D3 I-GENE
receptor I-GENE
or O
the O
estrogen I-GENE
receptor I-GENE
results O
in O
a O
receptor O
with O
wild O
- O
type O
or O
low O
transcriptional O
activity O
, O
respectively O
. O

Recurrent RARE
G O
- O
to O
- O
A O
substitution O
in O
a O
single O
codon O
of O
SREBP I-GENE
cleavage I-GENE
- I-GENE
activating I-GENE
protein I-GENE
causes O
sterol O
resistance O
in O
three O
mutant O
Chinese O
hamster O
ovary O
cell O
lines O
. O

The O
Escherichia I-GENE
coli I-GENE
tet RARE
- I-GENE
repressor I-GENE
( O
TetR LASTCAP
) O
operator O
system O
was O
used O
to O
develop O
a O
variation O
of O
the O
yeast O
two O
- O
hybrid O
assay O
in O
which O
disruptions RARE
of O
protein O
- O
protein O
interactions O
can O
be O
identified O
by O
a O
positive O
selection O
. O

Recent O
studies O
have O
suggested O
that O
SHP I-GENE
- I-GENE
1 I-GENE
regulates O
the O
function O
of O
Jak I-GENE
family O
tyrosine I-GENE
kinases I-GENE
, O
as O
shown O
by O
its O
constitutive O
association O
with O
the O
Tyk2 NUMERIC
kinase I-GENE
and O
the O
hyperphosphorylation RARE
of O
Jak I-GENE
kinases I-GENE
in O
the O
motheaten RARE
cells O
that O
lack O
functional O
SHP I-GENE
- I-GENE
1 I-GENE
. O

Administration O
of O
a O
second O
dose O
of O
vaccine O
during O
the O
outbreak O
was O
not O
protective O
. O

But RARE
, O
as O
Theriault RARE
explains RARE
, O
improvements RARE
in O
assessing O
exposure O
have O
not O
yet O
translated O
into O
clear O
and O
consistent O
findings O
. O

Biol O
. O

Structural O
basis O
for O
activation O
of O
human I-GENE
lymphocyte I-GENE
kinase I-GENE
Lck I-GENE
upon O
tyrosine O
phosphorylation O
. O

Evolutive RARE
morphology O
of O
the O
olfactory O
bulb O
in O
man O
and O
certain O
non O
- O
human O
mammals O

From O
these O
results O
, O
we O
concluded O
that O
this O
ORF O
is O
the O
FRDS ALLCAPS
gene I-GENE
. O

FK506 O
is O
10 O
- O
to O
100 O
- O
fold O
more O
potent O
than O
cyclosporin O
A O
in O
preventing O
organ O
rejection O
and O
in O
toxicity O
. O

These O
results O
suggest O
that O
Rho1p NUMERIC
regulates O
cytoskeletal O
reorganization RARE
at O
least O
through O
Bni1p NUMERIC
and O
Pkc1p NUMERIC
. O

The O
ERH ALLCAPS
expression O
profile O
is O
similar O
, O
to O
that O
of O
An3 NUMERIC
, O
which O
localizes O
to O
the O
animal O
hemisphere O
of O
oocytes O
and O
is O
abundantly O
expressed O
in O
the O
embryo O
. O

Waves RARE
N1 O
, O
P3 O
and O
CNV O
were O
recorded O
during O
a O
CNV O
paradigm RARE
in O
a O
simple O
reaction O
time O
task O
with O
a O
constant O
interstimulus RARE
interval O
( O
ISI ALLCAPS
) O
of O
1 O
sec O
. O

Therefore O
, O
both O
the O
Chilean RARE
and O
the O
Japanese O
samples O
collected O
in O
high O
- O
risk O
areas O
showed O
higher O
mutagenic RARE
rates O
than O
the O
Japanese O
ones O
in O
a O
low O
- O
risk O
area O
, O
with O
a O
statistical O
significance O
( O
p O
< O
0 O
. O
001 O
), O
chi RARE
- O
square O
test O
). O

Regulation O
of O
ASN1 NUMERIC
and O
ASN2 NUMERIC
expression O
was O
studied O
using O
lacZ I-GENE
fusions I-GENE
and O
both O
genes O
were O
found O
to O
be O
several O
times O
less O
expressed O
in O
the O
absence O
of O
the O
transcription O
activator O
Gcn4p NUMERIC
. O

Several O
particular O
features O
of O
this O
polypeptide O
fragment O
from O
the O
hamster I-GENE
lysyl RARE
- I-GENE
tRNA I-GENE
synthetase I-GENE
suggest O
that O
it O
is O
implicated O
in O
the O
assembly O
of O
that O
enzyme O
within O
the O
multisynthetase RARE
complex O
. O

He O
is O
well O
, O
five O
years O
after O
relapse O
. O

Comparison O
of O
the O
proportion O
of O
nonsynonymous RARE
( O
pN LASTCAP
) O
and O
synonymous RARE
( O
pS LASTCAP
) O
substitutions O
occurring O
per O
site O
within O
tamarin RARE
variable I-GENE
region I-GENE
genes I-GENE
demonstrated O
a O
reduction O
in O
pN LASTCAP
in O
the O
framework RARE
regions O
compared O
with O
pN LASTCAP
in O
the O
presumed O
MHC I-GENE
contact I-GENE
regions I-GENE
( O
CDR1 NUMERIC
and O
CDR2 NUMERIC
). O

The O
effects O
of O
oral O
vanadyl RARE
sulfate O
( O
VOSO4 NUMERIC
) O
( O
0 O
. O
5 O
mg O
/ O
kg O
/ O
day O
) O
on O
anthropometry RARE
, O
body O
composition O
, O
and O
performance O
were O
investigated O
in O
a O
12 O
- O
week O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
involving O
weight O
- O
training O
volunteers O
. O

Later RARE
in O
development O
, O
Tbx6 NUMERIC
expression O
is O
restricted O
to O
presomitic RARE
, O
paraxial RARE
mesoderm O
and O
to O
the O
tail O
bud RARE
, O
which O
replaces RARE
the O
streak RARE
as O
the O
source O
of O
mesoderm O
. O

Disruption O
of O
re O
- O
replication O
control O
by O
overexpression O
of O
human I-GENE
ORC1 NUMERIC
in O
fission O
yeast O
. O

Our O
results O
demonstrate O
that O
the O
promoter O
and O
enhancer O
regions O
identified O
here O
are O
essential O
for O
maintaining O
the O
efficient O
promoter O
activity O
of O
the O
human I-GENE
activin I-GENE
betaA LASTCAP
subunit I-GENE
gene I-GENE
. O

Recombinant O
, O
bacterially O
expressed O
PIP5KIalpha NUMERIC
possessed O
PIP5K NUMERIC
activity O
and O
was O
immunoreactive O
with O
erythroid I-GENE
PIP5KI NUMERIC
antibodies I-GENE
. O

Human I-GENE
acid I-GENE
ceramidase RARE
(( RARE
AC O
) O
N O
- O
acylsphingosine RARE
amidohydrolase RARE
, O
EC I-GENE
3 I-GENE
. I-GENE
5 I-GENE
. O

The O
0 O
. O
22 O
- O
kb O
NheI LASTCAP
/ O
BglII LASTCAP
promoter O
exhibited O
PMA O
inducibility O
in O
myeloid O
cells O
and O
contained O
a O
PMA O
- O
responsive O
element O
recognized O
by O
Sp1 I-GENE
and O
EGR ALLCAPS
- I-GENE
1 I-GENE
transcription I-GENE
factors I-GENE
. O

Northern O
( O
RNA O
) O
blot O
analyses O
indicated O
that O
the O
cdh RARE
genes I-GENE
encoding O
the O
five O
subunits O
and O
an O
open O
reading O
frame O
( O
ORF1 O
) O
with O
unknown O
function O
are O
cotranscribed O
during O
growth O
on O
acetate O
. O

Two O
classes O
of O
mutations O
were O
obtained O
: O
( O
i O
) O
those O
that O
altered O
the O
coding O
region O
of O
HOL1 NUMERIC
, O
conferring O
the O
ability O
to O
take O
up O
histidinol RARE
; O
and O
( O
ii O
) O
cis O
- O
acting O
mutations O
( O
selected O
in O
a O
mutant O
HOL1 NUMERIC
- I-GENE
1 I-GENE
background O
) O
that O
increased O
expression O
of O
the O
Hol1 NUMERIC
protein I-GENE
. O

Damage RARE
to O
the O
BBB ALLCAPS
was O
judged O
by O
extravasation RARE
of O
Evans RARE
Blue RARE
( O
EB ALLCAPS
) O
dye O
, O
which O
was O
administered O
either O
2 O
, O
3 O
, O
24 O
or O
48 O
h O
after O
onset O
of O
MCAo RARE
. O

Lipid RARE
hydroperoxide RARE
levels O
in O
plasma O
and O
LDL I-GENE
remained O
unchanged O
throughout O
the O
study O
. O

When O
the O
degree O
of O
exercise O
was O
maximal O
, O
mPAP LASTCAP
was O
maintained O
, O
SVI ALLCAPS
decreased O
, O
HR O
was O
unchanged O
, O
and O
CO O
and O
VO2 O
decreased O
. O

We O
report O
a O
case O
of O
vasculitis O
( O
cutaneous O
and O
neurologic O
) O
which O
led O
to O
the O
discovery O
of O
a O
selective O
immunodeficit RARE
towards O
EBV O
, O
similar O
to O
Purtilo RARE
' O
s O
syndrome O
. O

To O
elucidate O
whether O
potential O
endocrine O
changes O
resulted O
from O
acute O
hypoxaemia RARE
alone O
, O
the O
underlying O
disease O
, O
or O
unspecific RARE
influences O
connected O
with O
the O
ICU ALLCAPS
setting O
, O
all O
measurements O
were O
compared O
to O
those O
of O
a O
completely O
healthy O
reference O
group O
( O
REF ALLCAPS
) O
with O
comparable O
acute O
experimental O
hypoxaemia RARE
. O

There O
were O
no O
significant O
differences O
in O
graft O
survival O
between O
groups O
with O
early O
graft O
function O
( O
EGF O
) O
and O
DGF ALLCAPS
, O
either O
in O
first O
transplantations RARE
or O
retransplantations RARE
. O

These O
results O
suggested O
that O
the O
GG ALLCAPS
motifs O
contributed O
to O
the O
cell O
- O
specific O
transcription O
of O
the O
human I-GENE
insulin I-GENE
gene I-GENE
in O
association O
with O
the O
binding O
of O
the O
sequence O
- O
specific O
nuclear O
factor O
. O

Abnormal O
urinary O
coproporphyrin RARE
levels O
in O
patients O
infected O
by O
hepatitis O
C O
virus O
with O
or O
without O
human O
immunodeficiency O
virus O
. O

The O
determination O
of O
immunoglobulin I-GENE
E I-GENE
( O
IgE I-GENE
) O
antibodies O
by O
one O
of O
several O
laboratory O
tests O
, O
by O
skin O
- O
prick RARE
tests O
or O
by O
appropriate O
challenge O
procedures O
is O
useful O
either O
to O
identify O
atopic O
individuals O
or O
as O
outcome O
predictors O
in O
wheezy RARE
children O
. O

Thrombosis RARE
of O
the O
renal O
vein O
may O
be O
dramatic O
and O
include O
renal O
failure O
. O

Filter RARE
and O
cytocentrifuge RARE
preparations O
of O
the O
urine O
were O
studied O
and O
all O
cases O
displayed O
numerous O
scattered RARE
aggregates O
or O
single O
tumor O
cells O
in O
an O
inflammatory O
background O
. O

327 NUMERIC
and O
736 NUMERIC
protocols RARE
of O
postmortem RARE
examinations O
from O
Moscow RARE
hospitals O
N O
31 O
and O
57 O
, O
respectively O
, O
were O
evaluated O
statistically O
. O

The O
promoter O
segment O
was O
inactive O
when O
introduced O
into O
the O
rat O
glioma O
cell O
line O
C6B4 NUMERIC
, O
the O
rat O
submandibular RARE
cell O
line O
RSMT ALLCAPS
- O
A5 NUMERIC
, O
and O
the O
rat O
pancreatic O
beta O
cell O
line O
RIN ALLCAPS
- O
5AH NUMERIC
, O
all O
of O
which O
do O
not O
express O
the O
endogenous O
alpha2c NUMERIC
- I-GENE
AR I-GENE
gene I-GENE
. O

The O
sequencing O
of O
the O
conditional O
lethal O
mutation O
ts O
- O
A13 NUMERIC
, O
localized O
in O
the O
nrdE LASTCAP
cistron RARE
, O
and O
the O
lethality O
of O
insertional O
mutations O
targeted O
in O
the O
internal O
region O
of O
nrdE LASTCAP
and O
nrdF LASTCAP
, O
demonstrated O
the O
essential O
role O
of O
this O
locus O
. O

The O
microdensitometric RARE
scores O
and O
their O
side O
- O
to O
- O
side O
differences O
in O
patients O
correlated O
negatively O
with O
the O
serum O
25 O
- O
OHD ALLCAPS
concentration O
and O
positively O
with O
the O
degree O
of O
paralysis RARE
. O

These O
data O
do O
not O
support O
the O
use O
of O
LDD ALLCAPS
to O
reduce O
risk O
of O
progression O
to O
MSOF ALLCAPS
in O
sepsis O
. O

This O
correlated O
with O
reduced O
levels O
of O
secreted O
hepatitis I-GENE
B I-GENE
e I-GENE
antigen I-GENE
and O
increased O
intracellular O
levels O
of O
core I-GENE
and O
Pol I-GENE
proteins I-GENE
and O
replicative O
HBV O
DNA O
intermediates RARE
. O

In O
contrast O
, O
extracts O
of O
the O
mutant O
virions O
catalyze RARE
the O
wild O
- O
type O
level O
of O
transcription O
from O
an O
exogenous O
template O
containing O
an O
early O
promoter O
. O

The O
SCMV ALLCAPS
SNE ALLCAPS
sites I-GENE
contain O
potential O
overlapping O
core O
recognition O
binding O
motifs O
for O
SRF I-GENE
, O
Rel I-GENE
/ O
NFkappaB LASTCAP
, O
ETS I-GENE
, O
and O
YY1 I-GENE
class I-GENE
transcription I-GENE
factors I-GENE
but O
fail O
to O
respond O
to O
either O
serum O
or O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
. O

Upon O
serum O
withdrawal O
at O
the O
permissive O
temperature O
, O
p53 I-GENE
- O
mediated O
apoptosis O
was O
induced O
in O
50 O
to O
60 O
% O
of O
the O
cells O
. O

To O
circumvent RARE
this O
problem O
, O
a O
simple O
two O
- O
step O
strategy O
was O
devised RARE
by O
which O
essential O
cis O
- O
acting O
sites O
like O
the O
a O
sequence O
can O
be O
readily O
deleted O
from O
their O
natural O
loci O
in O
large O
viral O
DNA O
genomes O
. O

On O
the O
basis O
of O
serological O
studies O
, O
the O
highly O
conserved O
A O
domain O
of O
HspA LASTCAP
was O
found O
to O
be O
the O
immunodominant RARE
domain O
. O

In O
Group O
IV O
dogs O
that O
received O
alpha I-GENE
- I-GENE
MSH I-GENE
only O
during O
reperfusion O
, O
BAEPs RARE
were O
increased O
approximately O
10 O
to O
14 O
% O
more O
than O
in O
Group O
II O
during O
the O
late O
reperfusion O
period O
. O

The O
Fas I-GENE
receptor I-GENE
mediates O
a O
signalling O
cascade O
resulting O
in O
programmed O
cell O
death O
( O
apoptosis O
) O
within O
hours O
of O
receptor O
cross O
- O
linking O
. O

Fas I-GENE
has O
been O
shown O
to O
require O
ICE I-GENE
( O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
- I-GENE
converting I-GENE
enzyme I-GENE
) O
family O
proteases O
to O
induce O
apoptosis O
from O
studies O
utilizing O
the O
cowpox RARE
ICE I-GENE
inhibitor I-GENE
protein I-GENE
CrmA LASTCAP
, O
the O
synthetic O
tetrapeptide RARE
ICE I-GENE
inhibitor O
YVAD ALLCAPS
- I-GENE
CMK ALLCAPS
, O
and O
the O
tripeptide RARE
pan RARE
- O
ICE I-GENE
inhibitor O
Z I-GENE
- I-GENE
VAD ALLCAPS
- I-GENE
FMK ALLCAPS
. O

The O
imprinted O
expression O
of O
the O
endogenous O
gene O
can O
be O
recapitulated RARE
in O
mice O
by O
using O
a O
14 O
- O
kb O
transgene RARE
encompassing O
4 O
kb O
of O
5 O
'- O
flanking O
sequence O
, O
8 O
kb O
of O
3 O
'- O
flanking O
sequence O
, O
which O
includes O
the O
two O
endoderm O
- O
specific O
enhancers O
, O
and O
an O
internally RARE
deleted O
structural O
gene O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
hGCN5 NUMERIC
is O
also O
an O
HAT ALLCAPS
and O
has O
the O
same O
substrate O
specificity O
as O
yGCN5 NUMERIC
. O

The O
effect O
of O
six O
arginine O
mutations O
of O
oxidative O
phosphorylation O
and O
AAC ALLCAPS
expression O
. O

Complementary RARE
DNAs O
encompassing O
the O
coat I-GENE
protein I-GENE
coding O
and O
adjacent O
regions O
of O
Agropyron RARE
mosaic O
virus O
( O
AgMV LASTCAP
) O
and O
Hordeum RARE
mosaic O
virus O
( O
HoMV LASTCAP
) O
were O
cloned O
and O
sequenced O
. O

In O
some O
cases O
, O
factor O
- O
induced O
Rac I-GENE
activation O
results O
in O
Rho I-GENE
activation O
, O
and O
factor O
- O
induced O
Cdc42 I-GENE
activation O
leads O
to O
Rac I-GENE
activation O
, O
as O
determined O
by O
specific O
morphological O
changes O
. O

Several O
cDNAs O
corresponding O
to O
the O
human I-GENE
PWP2 NUMERIC
gene I-GENE
were O
identified O
and O
partially O
sequenced O
. O

Isolation O
and O
genomic O
structure O
of O
a O
human O
homolog O
of O
the O
yeast I-GENE
periodic I-GENE
tryptophan I-GENE
protein I-GENE
2 I-GENE
( O
PWP2 NUMERIC
) O
gene O
mapping O
to O
21q22 NUMERIC
. O
3 O
. O

Patterns RARE
defined O
by O
combinations O
of O
normal O
and O
abnormal O
laboratory O
results O
had O
decreased O
the O
likelihood O
of O
PEM ALLCAPS
from O
an O
all O
- O
2 O
to O
all O
- O
0 O
pattern O
. O

To O
examine O
whether O
thiamine RARE
( O
vitamin O
B1 O
) O
deficiency O
is O
associated O
with O
recurrent O
aphthous RARE
stomatitis O
, O
we O
studied O
vitamin O
B1 O
levels O
in O
70 O
patients O
with O
recurrent O
aphthous RARE
stomatitis O
and O
in O
50 O
members O
of O
a O
control O
group O
. O

Liver O
injuries O

By O
screening O
a O
cDNA O
library O
with O
a O
probe O
derived O
from O
sequences O
downstream O
of O
the O
p53p2 NUMERIC
start O
site O
, O
we O
have O
cloned O
and O
characterized O
a O
cDNA O
that O
represents O
a O
mRNA O
that O
appears O
to O
have O
been O
initiated O
from O
the O
p53p2 NUMERIC
promoter I-GENE
. O

However O
, O
we O
did O
not O
observe O
a O
correlation O
between O
serum O
and O
seminal I-GENE
plasma I-GENE
PSA I-GENE
levels O
. O

The O
implications O
for O
estimates O
of O
cortical O
magnification O
and O
possible O
differences O
in O
the O
specializations RARE
of O
foveal RARE
and O
peripheral O
vision O
are O
discussed O
. O

G I-GENE
- I-GENE
CSF I-GENE
activates O
multiple O
signaling O
molecules O
, O
including O
the O
JAK1 NUMERIC
and O
JAK2 NUMERIC
kinases I-GENE
and O
the O
STAT I-GENE
transcription O
factors O
. O

Mutants RARE
lacking O
any O
tyrosine O
residues O
in O
the O
cytoplasmic O
domain O
maintain O
their O
ability O
to O
activate O
STAT5 I-GENE
and O
STAT1 I-GENE
but O
cannot O
activate O
STAT3 I-GENE
, O
implying O
that O
STAT5 I-GENE
and O
STAT1 I-GENE
activation O
does O
not O
require O
receptor O
tyrosine O
phosphorylation O
. O

The O
RI I-GENE
alpha I-GENE
gene I-GENE
is O
composed O
of O
nine O
coding O
exons O
of O
varying O
lengths O
, O
separated O
by O
introns O
, O
giving O
the O
gene O
a O
total O
length O
of O
at O
least O
21 O
kb O
. O
our O
recent O
cloning O
of O
a O
processed O
RI I-GENE
alpha I-GENE
pseudogene I-GENE
with O
a O
5 O
'- O
noncoding O
region O
different O
from O
the O
previously O
reported O
RI I-GENE
alpha I-GENE
complementary I-GENE
RNA I-GENE
indicated O
that O
the O
RI I-GENE
alpha I-GENE
gene I-GENE
may O
have O
multiple O
leader O
exons O
giving O
rise O
to O
alternately RARE
spliced O
messenger O
RNAs O
( O
mRNAs O
). O

This O
establishes RARE
Rad3 NUMERIC
/ O
Mec1 NUMERIC
as O
the O
only O
conserved O
protein O
which O
is O
required O
for O
all O
the O
DNA O
structure O
checkpoints RARE
in O
both O
yeast O
model O
systems O
. O

In O
addition O
, O
double O
mutants O
with O
either O
dim1 NUMERIC
- I-GENE
delta I-GENE
or O
dim2 NUMERIC
- I-GENE
1 I-GENE
and O
the O
endocytosis RARE
mutants I-GENE
end4 NUMERIC
- I-GENE
1 I-GENE
or O
act1 NUMERIC
- I-GENE
1 I-GENE
displayed O
synthetic O
growth O
defects O
, O
indicating O
that O
the O
DIM ALLCAPS
gene I-GENE
products I-GENE
function O
in O
a O
common O
or O
parallel O
endocytic O
pathway O
. O

The O
identification O
of O
the O
hepatitis O
C O
virus O
as O
the O
major O
cause O
of O
liver O
disease O
both O
in O
dialysis O
patients O
and O
in O
transplant O
patients O
has O
focused O
attention O
on O
the O
epidemiology RARE
and O
the O
impact O
of O
continuing RARE
infection O
in O
these O
patient O
groups O
. O

Stable O
transfection O
of O
the O
BL ALLCAPS
cell O
line O
Raji RARE
with O
constructs O
containing O
core O
promoter O
mutations O
confirmed O
that O
the O
proximal O
Sp1 I-GENE
site I-GENE
and O
the O
TATA O
box O
are O
essential O
for O
the O
activation O
of O
promoter O
P1 O
by O
the O
Ig I-GENE
kappa I-GENE
enhancers I-GENE
. O

Such O
multisensory RARE
interactions O
can O
be O
significant O
for O
behavior O
. O

The O
P13 NUMERIC
and O
N22 NUMERIC
of O
ppSEPs RARE
had O
phase O
reversal O
relationship O
with O
the O
P2 O
and O
N2 O
recorded O
from O
the O
PES ALLCAPS
, O
respectively O
. O

The O
cDNA O
of O
cpm7 NUMERIC
encodes O
a O
closely O
related O
protein O
of O
36 O
. O
8 O
kDa O
. O

Finally O
, O
the O
C O
- O
terminal O
region O
of O
ENBP1 NUMERIC
shows O
strong O
homology O
to O
a O
protein O
from O
rat O
that O
is O
specifically O
expressed O
in O
testis O
tissue O
. O

The O
conservation O
of O
both O
the O
G O
- O
box O
and O
H O
- O
box O
in O
different O
CHS ALLCAPS
promoters I-GENE
emphasizes O
their O
importance O
as O
regulatory O
motifs O
. O

Mortality RARE
on O
the O
last O
ranch RARE
was O
particularly O
severe O
among O
certain O
segregated RARE
groups O
of O
turkeys RARE
that O
included O
toms RARE
, O
heavier RARE
birds O
, O
and O
birds O
undergoing O
a O
stressful RARE
event O
such O
as O
artificial O
insemination RARE
. O

Further O
, O
the O
PIP2 O
content O
of O
the O
85 O
- O
90 O
kDa O
protein O
appeared O
to O
decrease O
with O
CSF I-GENE
- I-GENE
1 I-GENE
treatment O
. O

Further O
, O
the O
PIP2 O
content O
of O
the O
85 O
- O
90 O
kDa O
protein O
appeared O
to O
decrease O
with O
CSF I-GENE
- I-GENE
1 I-GENE
treatment O
. O

Just RARE
before O
inserting O
on O
the O
anterior O
margin O
and O
apex O
of O
the O
iliac O
crest RARE
it O
widens RARE
, O
assuming RARE
the O
aspect RARE
of O
a O
small O
cone RARE
. O

The O
first O
identification O
of O
the O
active O
37LRP NUMERIC
/ O
p40 I-GENE
gene O
presented O
in O
this O
study O
is O
a O
critical O
step O
toward O
the O
isolation O
of O
the O
corresponding O
human O
gene O
and O
the O
understanding O
of O
the O
molecular O
mechanisms O
involved O
in O
the O
up O
- O
regulation O
of O
its O
expression O
during O
tumor O
invasion O
and O
metastasis O
. O

The O
promoter O
region O
( O
P1 O
) O
corresponding O
to O
the O
main O
group O
of O
transcription O
initiation O
sites O
is O
devoid RARE
of O
TATA O
and O
CAAT O
boxes O
but O
has O
putative O
binding O
sites O
for O
the O
transcription I-GENE
factor I-GENE
SP1 I-GENE
and O
is O
embedded O
in O
a O
large O
G O
+ O
C O
- O
rich O
domain O
of O
a O
CpG O
island O
, O
features O
shared O
by O
the O
promoters O
of O
constitutively O
expressed O
housekeeping O
genes O
. O

The O
STAT I-GENE
- I-GENE
1 I-GENE
signaling O
pathway O
provides O
at O
least O
one O
mechanism O
for O
activation O
of O
the O
CAEV ALLCAPS
LTR I-GENE
by O
IFN I-GENE
- I-GENE
gamma I-GENE
in O
monocytes O
. O

Reperfusion RARE
caused O
a O
transient O
reduction O
in O
lactate O
production O
and O
a O
significant O
increase O
in O
LDH ALLCAPS
release O
. O

To O
evaluate O
the O
hepatic O
regenerative RARE
response O
in O
patients O
with O
alcoholic O
liver O
disease O
, O
sera O
from O
263 NUMERIC
patients O
with O
severe O
alcoholic O
hepatitis O
and O
/ O
or O
cirrhosis O
were O
analyzed O
for O
hepatocyte I-GENE
growth I-GENE
factor I-GENE
( O
HGF I-GENE
) O
and O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
( O
AFP I-GENE
). O

Children O
born O
from O
chronic O
alcoholic O
mothers O
have O
shown O
behavioral O
teratogenic RARE
effects O
more O
frequently O
than O
morphological O
malformations O
. O

INTERVENTION ALLCAPS
( O
S O
): O
Twenty O
- O
six O
hemostasis O
parameters O
evaluated O
repeatedly RARE
in O
patients O
undergoing O
IVF ALLCAPS
- O
ET O
. O

Here O
we O
report O
that O
expression O
of O
the O
I I-GENE
- I-GENE
POU I-GENE
/ O
tI LASTCAP
- I-GENE
POU I-GENE
message O
is O
maximal O
late O
in O
the O
embryonic O
phase O
of O
Drosophila O
development O
, O
and O
I I-GENE
- I-GENE
POU I-GENE
is O
the O
preferred O
splice O
variant O
. O

Unlike O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
, O
the O
delta I-GENE
proAE LASTCAP
mutant I-GENE
cDNA I-GENE
can O
be O
stably O
expressed O
in O
tumor O
derived O
cell O
lines O
with O
few O
immediate O
detrimental RARE
effects O
. O

The O
patient O
' O
s O
role O
, O
organized O
by O
the O
prerequisites RARE
of O
expressive RARE
freedom RARE
, O
is O
counter RARE
posed RARE
with O
the O
psychoanalyst RARE
' O
s O
, O
which O
is O
structured O
to O
empower RARE
listening RARE
and O
understanding O
. O

The O
most O
common O
risk O
factor O
reported O
for O
both O
recent O
and O
all O
other O
hepatitis O
C O
cases O
was O
a O
history O
of O
injecting O
drug O
use O
, O
although O
the O
proportion O
of O
cases O
with O
that O
history O
was O
different O
in O
NT ALLCAPS
from O
ACT ALLCAPS
and O
Queensland RARE
. O

Silencing RARE
can O
be O
restored O
by O
creation RARE
of O
a O
telomere O
at O
13 O
kb O
from O
the O
reporter O
construct O
, O
or O
by O
insertion O
of O
340 NUMERIC
bp O
of O
yeast O
telomeric O
repeat O
sequence O
at O
this O
site O
without O
chromosomal O
truncation RARE
. O

In O
contrast O
with O
previous O
two O
- O
pool O
models O
, O
provisions RARE
were O
made O
for O
folate O
turnover O
by O
urinary O
folate O
excretion O
( O
as O
measured O
here O
) O
and O
by O
fecal O
excretion O
and O
catabolic RARE
processes O
. O

When O
voltage O
- O
operated O
Ca2 O
+ O
channels O
( O
VOC ALLCAPS
) O
were O
blocked O
by O
nifedipine O
, O
midazolam O
, O
in O
concentrations O
more O
than O
1 O
microM O
, O
attenuated O
both O
phasic RARE
and O
tonic RARE
responses O
. O

Several O
artifacts RARE
occurred O
that O
interfered RARE
with O
visualization O
of O
the O
diaphragm O
. O

Although O
p48 NUMERIC
gene I-GENE
induction O
is O
dependent O
on O
STAT1 I-GENE
and O
JAK1 NUMERIC
, O
activated O
STAT1 I-GENE
does O
not O
bind O
to O
GATE ALLCAPS
. O

The O
syndrome O
of O
resistance O
to O
thyroid O
hormone O
is O
characterized O
by O
elevated O
serum O
free O
thyroid O
hormones O
, O
failure O
to O
suppress O
pituitary I-GENE
thyrotropin I-GENE
secretion O
, O
and O
variable O
peripheral O
refractoriness RARE
to O
hormone O
action O
. O

Finally O
, O
nonphotosynthetic RARE
mutants O
, O
including O
the O
tscA LASTCAP
- I-GENE
lacking I-GENE
photosystem RARE
I I-GENE
mutant I-GENE
, O
H13 NUMERIC
, O
did O
not O
show O
evidence O
of O
light O
- O
stimulated O
RNA O
processing O
. O

The O
progression O
of O
acute O
bronchitis RARE
is O
associated O
with O
elevated O
blood O
concentrations O
of O
acute O
- O
phase O
proteins O
, O
KKS ALLCAPS
activation O
in O
the O
blood O
and O
high O
serotonin O
and O
lactic RARE
acid O
content O
in O
the O
humor RARE
condensated RARE
from O
the O
exhaled RARE
air O
. O

Because O
of O
the O
potential O
implications O
of O
these O
findings O
in O
human O
physiology O
, O
we O
cloned O
the O
hPACAP LASTCAP
- I-GENE
R I-GENE
gene I-GENE
. O

Differential O
signaling O
and O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
activation O
by O
four O
splice O
variants O
of O
the O
human I-GENE
pituitary I-GENE
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
receptor I-GENE
( O
hPACAP LASTCAP
- I-GENE
R I-GENE
). O

During O
skeletal O
muscle O
development O
, O
different O
types O
of O
muscle O
fibers O
are O
generated O
, O
which O
express O
different O
combinations O
of O
muscle O
- O
specific O
gene O
products O
. O

We O
discuss O
these O
results O
with O
respect O
to O
the O
transcriptional O
induction O
of O
the O
HNF I-GENE
- I-GENE
3 I-GENE
alpha I-GENE
gene I-GENE
in O
respiratory O
epithelium O
during O
embryogenesis O
. O

BACKGROUND O
: O
Mitosis RARE
is O
regulated O
by O
MPF ALLCAPS
( O
maturation I-GENE
promoting I-GENE
factor I-GENE
), O
the O
active O
form O
of O
Cdc2 I-GENE
/ I-GENE
28 I-GENE
- O
cyclin I-GENE
B I-GENE
complexes O
. O

Ectopic RARE
expression O
of O
Apo RARE
- I-GENE
3 I-GENE
in O
HEK293 NUMERIC
or O
HeLa O
cells O
induced O
marked O
apoptosis O
. O

An O
N O
- O
terminal O
arm O
from O
each O
subunit O
wraps RARE
around O
the O
dinucleotide O
- O
binding O
domain O
of O
an O
adjacent O
subunit O
, O
covering O
the O
adenine O
ring RARE
of O
NADP ALLCAPS
. O

Similarity RARE
is O
most O
striking O
in O
the O
zinc O
knuckle RARE
region O
, O
a O
region O
characteristic O
of O
gag I-GENE
genes I-GENE
of O
most O
replication O
- O
competent O
retroelements RARE
. O

D O
. O
melanogaster O
HeT LASTCAP
- I-GENE
A I-GENE
coding O
sequences O
have O
a O
polymorphic O
region O
with O
insertions O
/ O
deletions O
of O
1 O
- O
31 O
codons O
and O
many O
nucleotide O
changes O
. O

Eukaryotic RARE
initiation I-GENE
factor I-GENE
3 I-GENE
( O
eIF3 I-GENE
) O
is O
a O
large O
multisubunit O
complex O
that O
stabilizes O
the O
ternary O
complex O
, O
eIF2 NUMERIC
x O
GTP O
x O
tRNA I-GENE
( I-GENE
Met I-GENE
) I-GENE
i I-GENE
and O
promotes O
mRNA O
binding O
to O
the O
40 I-GENE
S I-GENE
ribosomal I-GENE
subunit I-GENE
. O
eIF3 I-GENE
also O
functions O
as O
a O
ribosome O
subunit O
anti O
- O
association O
factor O
. O

Our O
data O
, O
combined O
with O
those O
of O
Hershey RARE
and O
co O
- O
workers O
, O
suggest O
that O
mammalian I-GENE
eIF3 I-GENE
is O
composed O
of O
at O
least O
10 O
subunits O
: O
p170 NUMERIC
, O
p116 NUMERIC
( O
hPrt1 NUMERIC
), O
p110 NUMERIC
, O
p66 NUMERIC
, O
p48 NUMERIC
, O
p47 NUMERIC
, O
p44 I-GENE
, O
p40 I-GENE
, O
p36 NUMERIC
, O
and O
p35 NUMERIC
. O

Identification O
of O
a O
cis O
- O
acting O
element O
in O
the O
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
gene I-GENE
promoter I-GENE
responsive O
to O
activation O
by O
retroviral O
sequences O
. O

The O
results O
demonstrate O
that O
( O
i O
) O
no O
intact O
capsids RARE
were O
assembled O
when O
the O
full O
- O
length O
or O
a O
truncated O
( O
missing O
the O
C O
- O
terminal O
65 O
amino O
acids O
) O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
was O
tested O
; O
( O
ii O
) O
when O
the O
C O
- O
terminal O
65 O
amino O
acids O
of O
the O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
were O
replaced O
with O
the O
C O
- O
terminal O
25 O
amino O
acids O
of O
the O
UL26 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
, O
intact O
capsids RARE
were O
made O
and O
direct O
interaction O
of O
the O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
with O
VP5 NUMERIC
was O
detected O
; O
( O
iii O
) O
assembly O
of O
intact O
capsids RARE
was O
demonstrated O
when O
the O
sequence O
of O
the O
last O
12 O
amino O
acids O
of O
the O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
was O
changed O
from O
RRIFVA ALLCAPS
ALNKLE ALLCAPS
to O
RRIFVAAMMKLE ALLCAPS
; O
( O
iv O
) O
self O
- O
interaction O
of O
the O
scaffold RARE
proteins O
is O
mediated O
by O
sequences O
N O
terminal O
to O
the O
maturation O
cleavage O
site O
; O
and O
( O
v O
) O
the O
UL26 I-GENE
. I-GENE
5 I-GENE
and O
UL80 I-GENE
. I-GENE
5 I-GENE
proteins I-GENE
will O
not O
coassemble RARE
into O
scaffold RARE
structures O
. O

Fourth RARE
, O
the O
3 O
'- O
region O
splice O
junctions O
of O
the O
MSRs RARE
during O
latent O
and O
productive RARE
infection O
were O
determined O
by O
sequencing O
RNA O
- O
PCR O
products O
generated O
with O
primers O
that O
flank O
the O
3 O
' O
splice O
region O
. O

( O
ii O
) O
ICP27 NUMERIC
binds O
preferentially O
to O
less O
modified O
forms O
of O
ICP4 I-GENE
, O
a O
protein O
that O
is O
extensively O
modified O
posttranslationally RARE
. O

Lack RARE
of O
sufficient O
data O
on O
vibration O
measurements O
and O
employment RARE
durations O
add RARE
to O
the O
uncertainty RARE
, O
as O
do O
variations O
in O
tool O
conditions O
( O
grinder RARE
wheels RARE
, O
etc O
) O
and O
inherent RARE
difficulties RARE
in O
measurement O
. O

C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
V I-GENE
> O
A O
selectively O
binds O
only O
the O
subset O
of O
C I-GENE
/ I-GENE
EBP I-GENE
sites I-GENE
that O
are O
also O
DBP I-GENE
sites I-GENE
, O
both O
as O
oligonucleotides O
and O
within O
the O
natural O
contexts RARE
of O
the O
albumin I-GENE
and O
cholesterol I-GENE
hydroxylase I-GENE
promoters I-GENE
. O

Specific O
IgG I-GENE
, O
specific O
IgE I-GENE
and O
total O
IgE I-GENE
immunoglobulins I-GENE
against O
Toxocara RARE
canis RARE
excretory RARE
/ I-GENE
secretory I-GENE
antigens I-GENE
( O
TES ALLCAPS
) O
were O
detected O
by O
using O
ELISA O
technique O
. O

SUMMARY ALLCAPS
BACKGROUND O
DATA ALLCAPS
: O
Melanoma RARE
care O
has O
not O
changed O
significantly O
in O
the O
last O
20 O
years O
, O
and O
the O
controversy RARE
of O
elective RARE
lymph O
node O
dissections RARE
in O
this O
disease O
continues RARE
to O
be O
discussed O
. O

The O
differences O
among O
subgenera RARE
of O
the O
genus O
Dermacentor RARE
are O
more O
significant O
. O

Mutating RARE
the O
E O
- O
box O
in O
the O
context O
of O
the O
3 O
'- O
flanking O
region O
confirmed O
that O
it O
contributes O
to O
the O
enhancement O
of O
transcriptional O
activity O
of O
the O
alpha1 I-GENE
( I-GENE
I I-GENE
) I-GENE
collagen I-GENE
gene I-GENE
promoter I-GENE
. O

Expression O
of O
neuronal O
traits RARE
in O
pancreatic O
beta O
cells O
. O

We O
propose O
that O
Mnt RARE
: O
Max I-GENE
: O
Sin3 NUMERIC
complexes O
normally O
function O
to O
restrict RARE
Myc I-GENE
: O
Max I-GENE
activities O
associated O
with O
cell O
proliferation O
. O

Its O
transcription O
product O
, O
a O
1 O
. O
3 O
kb O
mRNA O
, O
is O
polyadenylated O
at O
a O
site O
containing O
consensus O
eukaryotic O
polyadenylation O
signals O
and O
mapping O
87 O
bp O
downstream O
of O
the O
translation O
termination O
codon O
for O
CG30 NUMERIC
. O

Phenotypic RARE
changes O
induced O
by O
wild I-GENE
type I-GENE
and I-GENE
variant I-GENE
c I-GENE
- I-GENE
src I-GENE
genes I-GENE
carrying O
C O
- O
terminal O
sequence O
alterations O
. O

The O
resurgence RARE
of O
drug O
- O
resistant O
malaria O
makes O
urgent RARE
the O
evaluation O
of O
new O
antimalarial RARE
agents O
. O

In O
the O
p51 NUMERIC
subunit I-GENE
, O
the O
Cys181 NUMERIC
side O
- O
chain O
is O
oriented RARE
in O
a O
similar O
direction O
to O
the O
Tyr181 NUMERIC
side O
- O
chain O
in O
the O
wild O
- O
type O
complex O
. O

The O
relatively O
high O
level O
transcription O
from O
this O
gene O
shows O
that O
the O
polymorphic O
chromosome O
ends O
of O
P O
. O
falciparum O
, O
which O
have O
been O
proposed O
to O
be O
transcriptionally O
silent O
, O
can O
be O
active O
expression O
sites O
for O
var I-GENE
genes I-GENE
. O

NUP145 NUMERIC
was O
previously O
identified O
by O
using O
a O
genetic O
synthetic O
lethal O
screen O
( O
E O
. O

Prevalence RARE
of O
sleep O
- O
disordered RARE
breathing O
( O
SDB ALLCAPS
) O
is O
reported O
to O
increase O
in O
menopausal O
women O
. O

In O
all O
cases O
the O
antigenemia RARE
was O
transient O
and O
cleared RARE
by O
28th NUMERIC
day O
post O
- O
vaccination O
. O

A O
total O
of O
1459 NUMERIC
men O
aged O
48 O
to O
84 O
years O
, O
who O
were O
diagnosed O
for O
the O
first O
time O
by O
physicians O
as O
having O
BPH ALLCAPS
in O
1994 O
and O
who O
had O
not O
received O
treatment O
, O
participated RARE
in O
the O
study O
. O

BCL I-GENE
- I-GENE
2 I-GENE
, O
an O
inhibitor O
of O
apoptosis O
in O
a O
wide O
variety O
of O
cell O
types O
, O
has O
been O
reported O
to O
prevent O
oxidative O
stress O
- O
induced O
cell O
death O
. O

In O
vitro O
translation O
of O
the O
mTRF1 NUMERIC
cDNA I-GENE
resulted O
in O
a O
56 O
kDa O
protein O
that O
binds O
to O
TTAGGG ALLCAPS
repeat O
arrays O
. O
mTRF1 NUMERIC
displayed O
the O
same O
sequence O
specificity O
as O
hTRF1 NUMERIC
, O
preferring RARE
arrays O
of O
TTAGGG ALLCAPS
repeats O
as O
a O
binding O
substrate O
over O
TTAGGC ALLCAPS
and O
TTGGGG ALLCAPS
repeats O
. O

The O
ubiquitously O
expressed O
E12 I-GENE
bHLH I-GENE
protein I-GENE
dimerizes RARE
with O
numerous O
cell O
- O
specific O
bHLH I-GENE
factors I-GENE
. O

The O
E O
- O
box O
sequence O
in O
the O
SE2 NUMERIC
fragment I-GENE
of O
the O
transferrin I-GENE
promoter I-GENE
was O
CATCTG ALLCAPS
and O
was O
similar O
in O
gel O
shifts O
to O
the O
consensus O
E O
- O
box O
elements O
( O
CANNTG ALLCAPS
) O
previously O
characterized O
. O

A O
5 O
. O
3 O
- O
kb O
DNA O
fragment O
, O
which O
included O
the O
entire O
structural O
porin RARE
gene I-GENE
( O
named O
porCa RARE
) O
and O
its O
flanking O
regions O
, O
was O
identified O
. O

Full RARE
- I-GENE
length I-GENE
AT I-GENE
- I-GENE
PHH1 NUMERIC
, O
and O
both O
AT I-GENE
- I-GENE
PHH1 NUMERIC
and O
AT I-GENE
- I-GENE
PHH1 NUMERIC
delta I-GENE
C I-GENE
- I-GENE
513 NUMERIC
( O
truncated O
to O
be O
approximately O
the O
size O
of O
microbial I-GENE
photolyase RARE
genes I-GENE
) O
cDNAs O
, O
were O
overexpressed O
, O
respectively O
, O
in O
yeast O
and O
Escherichia O
coli O
mutants O
hypersensitive O
to O
ultraviolet RARE
light O
. O

The O
human I-GENE
p100 NUMERIC
protein I-GENE
was O
recently O
identified O
as O
a O
coactivator O
of O
the O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
nuclear I-GENE
antigen I-GENE
2 I-GENE
. O

However O
, O
five O
new O
mutation O
sites O
( O
S61 NUMERIC
, O
SL1 NUMERIC
, O
S29 NUMERIC
, O
SL11 NUMERIC
, O
SL196 NUMERIC
and O
SL126 NUMERIC
) O
are O
unique O
to O
the O
nrdB LASTCAP
intron O
and O
disrupt O
self O
- O
splicing O
. O

This O
report O
presents O
the O
isolation O
and O
characterization O
of O
the O
5 O
'- O
flanking O
region O
( O
1 O
. O
2 O
kb O
) O
and O
exon O
1 O
of O
the O
human I-GENE
RII I-GENE
alpha I-GENE
gene I-GENE
. O

A O
cohort O
of O
Swedish RARE
children O
was O
monitored O
from O
6 O
months O
to O
11 O
years O
of O
age O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
reproducibility O
of O
a O
number O
of O
simplified RARE
clearance O
methods O
using O
chromium RARE
- O
51 O
ethylenediamine RARE
tetraacetic RARE
acid O
( O
51Cr NUMERIC
- O
EDTA O
) O
and O
to O
compare O
these O
with O
the O
multiple O
blood O
sample O
technique O
. O

The O
primary O
structure O
of O
a O
2671 NUMERIC
bp O
DNA O
fragment O
between O
the O
pla RARE
gene I-GENE
( O
encoding O
plasminogen I-GENE
activator I-GENE
) O
and O
the O
origin O
of O
replication O
of O
the O
wild O
- O
type O
Yersinia RARE
pestis RARE
plasmid O
pYP358 NUMERIC
was O
determined O
. O

Serotonin RARE
concentration O
in O
the O
blood O
of O
patients O
with O
hemorrhagic O
fever O
with O
renal O
syndrome O

MAIN O
OUTCOME O
MEASURES ALLCAPS
: O
Associations RARE
of O
factor O
analysis O
- O
derived O
syndromes O
with O
risk O
factors O
for O
chemical O
interactions O
that O
inhibit O
butyrylcholinesterase RARE
and O
neuropathy O
target O
esterase I-GENE
. O

CONCLUSION O
: O
Some O
Gulf RARE
War RARE
veterans RARE
may O
have O
delayed O
, O
chronic O
neurotoxic RARE
syndromes O
from O
wartime RARE
exposure O
to O
combinations O
of O
chemicals RARE
that O
inhibit O
butyrylcholinesterase RARE
and O
neuropathy I-GENE
target I-GENE
esterase I-GENE
. O

Control O
examination O
was O
performed O
at O
the O
end O
of O
each O
period O
. O

No O
correlation O
between O
the O
age O
of O
the O
horses O
and O
the O
antibody O
level O
could O
be O
found O
. O

The O
GHR ALLCAPS
mRNA I-GENE
: O
GHBP ALLCAPS
mRNA I-GENE
ratio O
was O
1 O
. O
1 O
+/- O
0 O
. O
12 O
and O
remained O
unchanged O
during O
differentiation O
. O

The O
results O
demonstrate O
( O
i O
) O
that O
the O
selenocysteine O
- O
specific O
UGA O
codon O
is O
readily O
suppressed O
under O
conditions O
where O
the O
homologous I-GENE
SelB LASTCAP
protein I-GENE
is O
absent O
and O
( O
ii O
) O
that O
apart O
from O
the O
specificity O
of O
the O
SelB LASTCAP
- I-GENE
mRNA I-GENE
interaction O
, O
a O
structural O
compatibility O
of O
the O
quaternary RARE
complex O
with O
the O
ribosome O
is O
required O
. O

One O
linker O
- O
peptide O
insertion O
in O
the O
RsaA LASTCAP
C I-GENE
terminus I-GENE
( I-GENE
amino I-GENE
acid I-GENE
784 NUMERIC
) I-GENE
had O
no O
effect O
on O
S O
- O
layer O
biogenesis O
, O
while O
another O
( O
amino O
acid O
907 NUMERIC
) O
disrupted O
secretion O
of O
the O
protein O
, O
suggesting O
that O
RsaA LASTCAP
possesses O
a O
secretion O
signal O
lying RARE
C O
terminal O
to O
amino O
acid O
784 NUMERIC
, O
near O
or O
including O
amino O
acid O
907 NUMERIC
. O

To O
characterize O
the O
gene O
products O
, O
the O
cvaA LASTCAP
gene I-GENE
was O
subcloned O
and O
expressed O
under O
the O
control O
of O
T7 I-GENE
RNA I-GENE
polymerase I-GENE
promoter I-GENE
. O

PrpB LASTCAP
showed O
homology O
to O
carboxyphosphonoenolpyruvate RARE
phosphonomutase RARE
of I-GENE
Streptomyces I-GENE
hygroscopicus RARE
and O
to O
its O
homolog O
in O
the O
carnation RARE
Dianthus RARE
caryophyllus RARE
; O
PrpC LASTCAP
was O
homologous O
to O
both O
archaeal RARE
and I-GENE
bacterial I-GENE
citrate I-GENE
synthases RARE
; O
PrpD LASTCAP
showed O
homology O
to O
yeast O
and O
Bacillus O
subtilis O
proteins O
of O
unknown O
function O
; O
PrpE LASTCAP
showed O
homology O
to O
acetyl I-GENE
coenzyme I-GENE
A I-GENE
synthetases I-GENE
. O

MAIN O
OUTCOME O
MEASURES ALLCAPS
: O
Systemic RARE
and O
pulmonary O
hemodynamics O
, O
arterial O
blood O
gas O
determination O
, O
bronchoalveolar RARE
lavage RARE
protein O
and O
neutrophil O
content O
, O
neutrophil O
oxidant RARE
burst O
, O
lung I-GENE
myeloperoxidase RARE
content O
, O
and O
scanning O
electron O
micrographic RARE
studies O
. O

We O
have O
isolated O
a O
cDNA O
encoding O
human I-GENE
MEKK3 NUMERIC
. O

To O
investigate O
the O
mechanisms O
involved O
in O
the O
transcriptional O
control O
of O
retinoid I-GENE
X I-GENE
receptor I-GENE
( O
RXR I-GENE
) O
gene O
expression O
, O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
RXRgamma2 NUMERIC
isoform I-GENE
was O
characterized O
. O

JNK I-GENE
and O
p38 I-GENE
are O
constitutively O
present O
in O
the O
nucleus O
, O
and O
DNA O
- O
bound O
c I-GENE
- I-GENE
JUN ALLCAPS
and O
ATF I-GENE
- I-GENE
2 I-GENE
are O
stably O
contacted RARE
by O
JNK I-GENE
and O
p38 I-GENE
, O
respectively O
. O

The O
effects O
of O
dominant O
interfering O
forms O
of O
the O
JNK I-GENE
/ O
p38 I-GENE
signaling O
pathway O
demonstrate O
that O
activation O
of O
these O
kinases O
is O
critical O
for O
cytokine O
- O
induced O
E I-GENE
- I-GENE
selectin I-GENE
gene I-GENE
expression O
. O

Sp1 I-GENE
binds O
the O
CTC ALLCAPS
repeat O
with O
an O
affinity O
, O
KD ALLCAPS
= O
0 O
. O
37 O
nM O
, O
at O
least O
as O
high O
as O
the O
consensus O
GC O
box O
. O

Identification O
of O
the O
region O
in O
actin I-GENE
- I-GENE
binding I-GENE
protein I-GENE
that O
binds O
to O
the O
cytoplasmic O
domain O
of O
glycoprotein I-GENE
IBalpha RARE
. O

Mutant RARE
enzyme O
forms O
were O
prepared O
to O
eliminate RARE
the O
initial O
autoprocessing RARE
site O
and O
thus O
form O
an O
active O
single O
- O
chain O
protein O
for O
structure O
- O
function O
studies O
. O

The O
primer O
is O
generated O
by O
a O
cleavage O
that O
occurs O
between O
bases O
11 O
and O
12 O
of O
the O
Tf1 NUMERIC
mRNA I-GENE
. O

Similarly O
, O
we O
examined O
whether O
the O
ELK1 NUMERIC
, O
SAP1a NUMERIC
, O
FLI1 I-GENE
, O
EWS I-GENE
- O
FLI1 I-GENE
, O
ETS1 NUMERIC
, O
ETS2 NUMERIC
, O
PEA3 I-GENE
and O
PU I-GENE
. I-GENE
1 I-GENE
proteins I-GENE
can O
form O
ternary O
complexes O
with O
SRF I-GENE
on O
the O
Egr1 NUMERIC
SREI ALLCAPS
and I-GENE
II I-GENE
. O

This O
R O
- O
domain O
may O
modulate O
the O
interaction O
with O
SRF I-GENE
, O
providing O
a O
mechanism O
that O
would O
be O
unique O
to O
FLI1 I-GENE
and O
EWS I-GENE
- O
FLI1 I-GENE
, O
thus O
implicating RARE
a O
novel O
function O
for O
these O
ETS I-GENE
transcription I-GENE
factors I-GENE
in O
the O
regulation O
of O
the O
Egr1 NUMERIC
gene I-GENE
. O

The O
total O
number O
of O
specimens O
was O
131 O
with O
78 O
nonsmokers RARE
and O
53 O
smokers O
. O

The O
murine O
chromosomal O
locations O
of O
the O
five O
NMDA ALLCAPS
receptor I-GENE
channel I-GENE
subunits I-GENE
, O
the O
epsilon I-GENE
1 I-GENE
( O
Grin2a NUMERIC
), O
epsilon I-GENE
2 I-GENE
( O
Grin2b NUMERIC
), O
epsilon I-GENE
3 I-GENE
( O
Grin2c NUMERIC
), O
epsilon I-GENE
4 I-GENE
( O
Grin2d NUMERIC
) O
and O
zeta I-GENE
1 I-GENE
( O
Grinl RARE
) O
subunits O
, O
were O
determined O
using O
an O
interspecific RARE
backcross O
mapping O
panel O
derived O
from O
crosses RARE
of O
[( RARE
C57BL O
/ O
6JxM NUMERIC
. O
spretus RARE
) O
F1xC57BL NUMERIC
/ O
6J NUMERIC
] O
mice O
. O

CDNA ALLCAPS
cloning O
of O
chick I-GENE
brain I-GENE
alpha I-GENE
- I-GENE
amino I-GENE
- I-GENE
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
5 I-GENE
- I-GENE
methyl I-GENE
- I-GENE
4 I-GENE
- I-GENE
isoxazolepropionic RARE
acid I-GENE
receptors I-GENE
reveals O
conservation O
of O
structure O
, O
function O
and O
post O
- O
transcriptional O
processes O
with O
mammalian O
receptors O
. O

Remarkably RARE
, O
both O
TTD ALLCAPS
- O
A O
and O
XP ALLCAPS
- O
D O
defects O
are O
associated O
with O
subunits O
of O
TFIIH ALLCAPS
, O
a O
basal O
transcription O
factor O
with O
a O
second O
function O
in O
DNA O
repair O
. O

Adjustment RARE
for O
age O
, O
total O
cholesterol O
, O
HDL I-GENE
cholesterol I-GENE
, O
triglycerides O
, O
current O
smoking O
, O
and O
systolic O
pressure O
slightly O
reduced O
the O
association O
between O
fibrinogen I-GENE
and O
atherosclerosis O
. O

In O
Experiment O
1 O
, O
pups RARE
that O
had O
received O
an O
injection O
of O
the O
noncompetitive RARE
N I-GENE
- I-GENE
methyl I-GENE
- I-GENE
D I-GENE
- I-GENE
aspartate I-GENE
receptor I-GENE
antagonist O
MK O
- O
801 O
( O
0 O
. O
1 O
mg O
/ O
kg O
, O
i O
. O
p O
.) O
either O
30 O
min O
before O
or O
immediately O
after O
conditioning O
spent RARE
less O
time O
over O
the O
conditioned O
odor RARE
than O
saline O
- O
treated O
controls O
. O

Cholesterol RARE
side I-GENE
- I-GENE
chain I-GENE
cleavage I-GENE
cytochrome I-GENE
P450 I-GENE
( O
CYP11A NUMERIC
; O
P450scc NUMERIC
) O
gene O
expression O
is O
regulated O
by O
gonadotropins RARE
via O
cAMP O
in O
the O
ovary O
and O
by O
ACTH I-GENE
via O
cAMP O
in O
adrenal O
cortical O
cells O
. O

One O
possible O
solution O
is O
a O
thin O
radial RARE
forearm RARE
free O
flap O
. O

Structural O
analysis O
and O
characterization O
of O
tissue O
and O
hormonal O
responsive O
expression O
of O
the O
avian I-GENE
bone I-GENE
sialoprotein RARE
( O
BSP I-GENE
) O
gene O
. O

Serotonin RARE
receptors I-GENE
in O
suicide O
victims O
with O
major O
depression O
. O

The O
Y O
- O
type O
structural O
motif O
is O
also O
conserved O
among O
a O
number O
of O
divergent O
BiP LASTCAP
mRNAs I-GENE
. O

A O
false O
positive O
marker O
screen O
was O
associated O
with O
the O
occurrence O
of O
hand O
- O
foot O
syndrome O
even O
when O
the O
effect O
of O
regimen O
was O
accounted RARE
for O
by O
stratification RARE
( O
p O
= O
. O
01 O
). O

The O
detection O
of O
ORF I-GENE
- I-GENE
1 I-GENE
sequences O
in O
human O
tumors O
, O
while O
not O
proof RARE
per O
se RARE
, O
is O
a O
prerequisite O
for O
establishing RARE
its O
role O
in O
tumor O
development O
. O

Phylogenetic RARE
analysis O
gave O
evidence O
for O
a O
close O
evolutionary O
relationship O
between O
PhHV LASTCAP
- O
1 O
and O
members O
of O
the O
Varicellovirus RARE
genus O
of O
the O
alpha O
- O
Herpesvirinae RARE
and O
canid RARE
herpesvirus O
in O
particular O
. O

In O
this O
method O
, O
PLP O
in O
plasma O
can O
be O
determined O
with O
high O
sensitivity O
using O
derivatization RARE
with O
sodium O
bisulfite RARE
in O
the O
mobile O
phase O
. O

Both O
HEF1 I-GENE
and O
Cas I-GENE
were O
found O
to O
complex O
with O
the O
related I-GENE
adhesion I-GENE
focal I-GENE
tyrosine I-GENE
kinase I-GENE
( O
RAFTK ALLCAPS
), O
and O
when O
tyrosine O
phosphorylated O
, O
with O
the O
adapter O
molecule O
CrkL LASTCAP
. O

SIM1 NUMERIC
and O
SIM2 NUMERIC
do O
not O
form O
homodimers O
, O
and O
they O
do O
not O
interact O
with O
AHR ALLCAPS
. O

Complexes RARE
of O
qTBP42 NUMERIC
with O
each O
complementary O
strand O
of O
telomeric O
DNA O
and O
with O
quadruplex RARE
forms O
of O
the O
guanine O
- O
rich O
strand O
had O
3 O
. O
7 O
- O
14 O
. O
6 O
nM O
dissociation O
constants O
, O
Kd RARE
, O
whereas O
complexes O
with O
double O
- O
stranded O
telomeric O
DNA O
had O
up O
to O
100 O
- O
fold O
higher O
Kd RARE
values O
. O

Moreover O
, O
the O
effect O
exerted RARE
by O
TIS1 NUMERIC
appeared O
to O
be O
selective O
for O
the O
MCK ALLCAPS
promoter I-GENE
. O

Experimental O
data O
showed O
that O
these O
abnormal O
proteins O
are O
constitutively O
localized O
in O
the O
nucleus O
, O
have O
lost O
the O
transcriptional O
repressor O
functions O
typical O
of O
normal O
NF I-GENE
- I-GENE
kappa I-GENE
B2p52 NUMERIC
and O
may O
be O
capable O
of O
transactivation O
activity O
. O

Because O
L I-GENE
- I-GENE
plastin I-GENE
expression O
in O
tissue O
- O
specifically O
regulated O
in O
both O
humans O
and O
rodents RARE
, O
it O
is O
likely O
that O
similar O
mechanisms O
regulate O
L I-GENE
- I-GENE
plastin I-GENE
gene I-GENE
expression O
in O
human O
and O
rodent O
cells O
and O
that O
they O
could O
be O
identified O
by O
comparing O
the O
function O
and O
nucleotide O
sequences O
of O
the O
human O
and O
murine O
L I-GENE
- I-GENE
plastin I-GENE
gene O
promoters O
. O

What RARE
' O
s O
new O
in O
gynecologic O
and O
obstetrical RARE
surgery O
. O

The O
dnaK LASTCAP
operon I-GENE
of I-GENE
Bacillus I-GENE
subtilis I-GENE
is O
heptacistronic RARE
. O

Moreover O
, O
expression O
of O
CBF1 I-GENE
in O
yeast O
was O
found O
to O
activate O
transcription O
of O
reporter O
genes O
containing O
the O
C O
- O
repeat O
/ O
DRE O
as O
an O
upstream O
activator O
sequence O
but O
not O
mutant O
versions RARE
of O
the O
DNA O
element O
. O

Forty O
- O
one O
ASA O
physical O
status O
I O
or O
II O
adult O
patients O
undergoing O
a O
variety O
of O
1 O
- O
1 O
. O
5 O
h O
surgical O
procedures O
were O
randomly O
allocated O
to O
receive O
CCA ALLCAPS
with O
desflurane RARE
or O
isoflurane O
with O
ventilation O
being O
either O
spontaneous O
or O
controlled O
. O

OBJECTIVE O
: O
Our O
goal O
was O
to O
determine O
whether O
chlamydia RARE
- O
infected O
women O
have O
a O
higher O
rate O
of O
febrile RARE
complications O
after O
postpartum RARE
tubal RARE
ligation O
. O

In O
the O
electrophoresis O
mobility O
shift O
assay O
using O
nuclear O
extracts O
of O
the O
myogenic O
cells O
, O
MyoD I-GENE
and O
myogenin I-GENE
bound O
to O
the O
right O
E O
- O
box O
in O
the O
enhancer O
region O
of O
the O
MCK ALLCAPS
gene I-GENE
even O
in O
the O
presence O
of O
BMP I-GENE
- I-GENE
2 I-GENE
. O

A O
heterologous O
promoter O
construct O
containing O
three O
repeats O
of O
a O
consensus O
Sp1 I-GENE
site I-GENE
, O
cloned O
upstream O
of O
a O
single O
copy O
of O
the O
ZII ALLCAPS
( O
CREB I-GENE
/ I-GENE
AP1 I-GENE
) O
element O
from O
the O
BZLF1 NUMERIC
promoter I-GENE
linked O
to O
the O
beta I-GENE
- I-GENE
globin I-GENE
TATA O
box O
, O
exhibited O
phorbol O
ester O
inducibility O
. O

Subsequent RARE
experiments O
showed O
that O
motoric RARE
tasks O
rather O
than O
cognitive O
aspects O
of O
the O
COWA ALLCAPS
task O
were O
critical O
in O
potentiating RARE
finger O
- O
tapping RARE
performance O
. O

How RARE
does O
a O
nurse O
go RARE
about O
maintaining O
her O
level O
of O
competence RARE
when O
she RARE
is O
one O
of O
the O
few O
local O
practitioners RARE
in O
her O
field O
? O
Vancouver RARE
sex O
therapist RARE
Bianca RARE
Rucker RARE
is O
doing RARE
it O
by O
cultivating RARE
a O
network O
of O
colleagues RARE
and O
mentors RARE
in O
related O
fields O
both O
at O
home O
and O
across O
the O
continent RARE
. O

Finally O
, O
antibody O
binding O
to O
site O
IIIa RARE
on O
the O
hCG I-GENE
- I-GENE
ectodomain RARE
complex I-GENE
was O
also O
hindered RARE
by O
an O
anti O
- O
peptide O
mAb O
directed O
against O
a O
peptide O
encoded O
by O
the O
eighth RARE
exon O
( O
pE LASTCAP
x O
8 O
) O
of O
the O
LHR I-GENE
. O

cDNA O
cloning O
, O
expression O
analysis O
, O
and O
chromosomal O
localization O
of O
a O
gene O
with O
high O
homology O
to O
wheat I-GENE
eIF I-GENE
-( I-GENE
iso RARE
) I-GENE
4F NUMERIC
and O
mammalian I-GENE
eIF I-GENE
- I-GENE
4G NUMERIC
. O

Therefore O
, O
it O
is O
important O
to O
control O
hypertension O
and O
keep RARE
appropriate O
renal O
blood O
flow O
during O
living O
renal O
transplantation O
surgery O
. O

The O
initial O
patients O
treated O
with O
AZQ ALLCAPS
and O
mitroxantrone RARE
experienced O
prolonged O
bone O
marrow O
suppression O
and O
, O
therefore O
, O
subsequent O
cohorts RARE
were O
treated O
with O
G I-GENE
- I-GENE
CSF I-GENE
, O
5 O
micrograms O
/ O
kg O
, O
beginning O
the O
day O
after O
completion RARE
of O
the O
third O
cycle O
of O
chemotherapy O
. O

Human I-GENE
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
hGM LASTCAP
- I-GENE
CSF I-GENE
) O
activates O
a O
set O
of O
genes O
such O
as O
c I-GENE
- I-GENE
fos I-GENE
, O
jun I-GENE
, O
myc I-GENE
, O
and O
early I-GENE
growth I-GENE
response I-GENE
gene I-GENE
1 I-GENE
( O
egr RARE
- I-GENE
1 I-GENE
). O

In O
order O
to O
provide O
adequate O
local O
control O
without O
compromising RARE
cosmetic RARE
outcome O
, O
the O
amount O
of O
breast O
tissue O
that O
must O
be O
excised RARE
in O
BCT ALLCAPS
needs O
to O
be O
individualized RARE
. O

Surprisingly O
, O
however O
, O
TCR I-GENE
- O
mediated O
tyrosine O
phosphorylation O
of O
phospholipase I-GENE
C I-GENE
gamma I-GENE
1 I-GENE
remains O
intact O
in O
the O
Jurkat O
cells O
expressing O
the O
A2 I-GENE
/ O
HCP ALLCAPS
chimera O
. O

The O
14 I-GENE
. I-GENE
1 I-GENE
( I-GENE
IGLL1 NUMERIC
) I-GENE
gene I-GENE
is O
expressed O
in O
a O
lineage O
- O
and O
stage O
- O
restricted O
manner O
. O

The O
interferon I-GENE
( O
IFN I-GENE
)- O
induced O
double I-GENE
- I-GENE
stranded I-GENE
RNA I-GENE
( I-GENE
dsRNA I-GENE
)- I-GENE
activated I-GENE
Ser I-GENE
/ I-GENE
Thr I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
plays O
a O
role O
in O
the O
antiviral RARE
and O
antiproliferative RARE
effects O
of O
IFN I-GENE
. O

Together O
, O
the O
data O
suggest O
that O
cAMP O
- O
dependent O
control O
of O
the O
amounts O
of O
the O
activator O
SF I-GENE
- I-GENE
1 I-GENE
vs O
. O
the O
repressor O
COUP I-GENE
- I-GENE
TF I-GENE
could O
influence O
CRS2 NUMERIC
- O
dependent O
transcription O
. O

Object RARE
relations O
, O
affect O
management O
, O
and O
psychic RARE
structure O
formation O
. O

When O
expressed O
in O
COS O
- O
7 O
cells O
, O
MKP I-GENE
- I-GENE
4 I-GENE
blocks O
activation O
of O
MAP I-GENE
kinases I-GENE
with O
the O
selectivity O
ERK I-GENE
> O
p38 I-GENE
= O
JNK I-GENE
/ O
SAPK I-GENE
. O

In O
rlf2 NUMERIC
mutants I-GENE
, O
telomeric O
chromatin O
is O
perturbed RARE
: O
Telomeric RARE
silencing O
is O
reduced O
and O
Rap1p NUMERIC
localization O
is O
altered O
. O

Most O
kinases O
are O
not O
significantly O
inhibited O
by O
roscovitine RARE
. O
cdc2 I-GENE
/ O
cyclin I-GENE
B I-GENE
, O
cdk2 I-GENE
/ O
cyclin I-GENE
A I-GENE
, O
cdk2 I-GENE
/ O
cyclin I-GENE
E I-GENE
and O
cdk5 NUMERIC
/ O
p35 NUMERIC
only O
are O
substantially O
inhibited O
( O
IC50 NUMERIC
values O
of O
0 O
. O
65 O
, O
0 O
. O
7 O
, O
0 O
. O
7 O
and O
0 O
. O
2 O
microM O
, O
respectively O
). O
cdk4 NUMERIC
/ O
cyclin I-GENE
D1 I-GENE
and O
cdk6 NUMERIC
/ O
cyclin I-GENE
D2 I-GENE
are O
very O
poorly O
inhibited O
by O
roscovitine RARE
( O
IC50 NUMERIC
> O
100 O
microM O
). O

This O
0 O
. O
74 O
kb O
cDNA O
contains O
an O
open O
reading O
frame O
( O
ORF O
) O
of O
477 NUMERIC
bp O
encoding O
a O
polypeptide O
of O
159 NUMERIC
amino O
acids O
( O
aa O
) O
which O
differs O
at O
only O
one O
position O
( O
position O
65 O
) O
from O
the O
human I-GENE
U1 I-GENE
- I-GENE
C I-GENE
protein I-GENE
. O

Interaction O
of O
Ets I-GENE
- I-GENE
1 I-GENE
and O
the O
POU I-GENE
- I-GENE
homeodomain I-GENE
protein I-GENE
GHF ALLCAPS
- I-GENE
1 I-GENE
/ O
Pit I-GENE
- I-GENE
1 I-GENE
reconstitutes RARE
pituitary O
- O
specific O
gene O
expression O
. O

Although O
Pho85 NUMERIC
is O
not O
essential O
for O
viability O
, O
Pcl1 NUMERIC
, I-GENE
2 I-GENE
- O
Pho85 NUMERIC
kinase O
complexes O
become O
essential O
for O
Start RARE
in O
the O
absence O
of O
Cln1 NUMERIC
, I-GENE
2 I-GENE
- O
Cdc28 I-GENE
kinases O
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
to O
screen O
for O
proteins O
which O
interact O
with O
Tax1 NUMERIC
, O
we O
isolated O
the O
B O
subunit O
of O
the O
CCAAT O
binding O
protein O
NF I-GENE
- I-GENE
Y I-GENE
from O
a O
HeLa O
cDNA O
library O
. O

Enhancer RARE
activity O
requires O
both O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
and O
these O
adjacent O
sequences O
. O

Studies O
using O
HLA I-GENE
- I-GENE
DR I-GENE
- O
B7 I-GENE
- I-GENE
1 I-GENE
- O
LFA ALLCAPS
- I-GENE
3 I-GENE
triple O
transfectants O
showed O
that O
the O
LFA ALLCAPS
- I-GENE
3 I-GENE
- O
induced O
NF I-GENE
- I-GENE
AT I-GENE
DNA O
binding O
activity O
was O
negatively O
regulated O
by O
B7 I-GENE
- I-GENE
1 I-GENE
costimulation RARE
. O

Constitutive RARE
activation O
of O
Rac1 I-GENE
and O
RhoA I-GENE
causes O
tumorigenic O
transformation O
of O
NIH O
3T3 O
cells O
, O
and O
their O
functions O
may O
be O
required O
for O
full O
Ras I-GENE
transformation O
. O

Furthermore O
, O
Rac1 I-GENE
activation O
of O
JNK I-GENE
or O
SRF I-GENE
, O
or O
induction O
of O
lamellipodia RARE
, O
was O
neither O
necessary O
nor O
sufficient O
for O
Rac1 I-GENE
transforming O
activity O
. O

Overexpression O
of O
the O
bZip RARE
interaction O
domain O
of O
CBP I-GENE
specifically O
abolishes O
the O
positive O
cross O
talk RARE
between O
TR I-GENE
and O
p45 NUMERIC
/ O
NF I-GENE
- I-GENE
E2 I-GENE
. O

This O
inhibitory O
domain O
has O
been O
deleted O
in O
all O
naturally O
occurring O
AHC ALLCAPS
deletion I-GENE
mutants I-GENE
described O
to O
date O
. O

Identification O
of O
a O
promoter O
- O
specific O
transactivation O
domain O
in O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
regulatory I-GENE
protein I-GENE
ICP4 I-GENE
. O

DNA O
sequencing O
of O
a O
17 O
- O
kb O
segment O
encompassing O
a O
gammaherpesvirus RARE
divergent O
locus O
( O
DL ALLCAPS
- O
B O
) O
between O
ORF11 NUMERIC
and O
ORF17 NUMERIC
revealed O
the O
presence O
of O
nine O
viral O
ORFs O
with O
predicted O
gene O
products O
related O
to O
cellular O
proteins O
. O

Studies O
in O
mammalian O
cells O
have O
correlated O
induction O
of O
inhibitory O
tyrosine O
15 O
( O
Y15 NUMERIC
) O
phosphorylation O
on O
p34cdc2 I-GENE
with O
the O
response O
to O
DNA O
damage O
. O

We O
report O
herein RARE
the O
case O
of O
a O
30 O
- O
year O
- O
old O
man O
in O
whom O
ectopic O
mediastinal RARE
parathyroid O
adenoma RARE
was O
detected O
by O
99mTc O
- O
methoxyisobutylisonitrile RARE
scintigraphy O
( O
99mTc O
- O
MIBI ALLCAPS
). O

Cardiac I-GENE
endothelin I-GENE
release O
and O
infarct O
size O
, O
myocardial O
blood O
flow O
, O
and O
ventricular O
function O
in O
canine O
infarction O
and O
reperfusion O
. O

The O
workup RARE
included O
skin O
tests O
( O
up O
to O
1 O
microgram O
/ O
ml O
, O
Pharmacia O
), O
measurement O
of O
specific O
serum O
IgE I-GENE
with O
RAST O
- O
CAP O
( O
Pharmacia O
), O
and O
CAST ALLCAPS
with O
three O
concentrations O
of O
bee RARE
( O
Apis RARE
mellifera RARE
) O
and O
wasp RARE
( O
Vespula RARE
spec RARE
.) O
venom RARE
( O
Aquagen RARE
ALK ALLCAPS
). O

The O
proliferation I-GENE
potential I-GENE
protein I-GENE
- I-GENE
related I-GENE
( O
P2P NUMERIC
- I-GENE
R I-GENE
) O
gene O
with O
domains O
encoding O
heterogeneous O
nuclear O
ribonucleoprotein O
association O
and O
Rb1 NUMERIC
binding O
shows O
repressed O
expression O
during O
terminal O
differentiation O
. O

Recent O
application O
of O
recombinant O
canarypox RARE
ALVAC ALLCAPS
/ O
HIV O
- O
1 O
vectors O
as O
vaccine O
immunogens RARE
in O
HIV O
- O
1 O
,- RARE
noninfected RARE
volunteers O
has O
produced O
CTL O
responses O
in O
a O
significant O
number O
of O
vaccinees RARE
. O

The O
relevance O
of O
these O
elements O
in O
conferring O
anaerobic O
induction O
of O
gpc4 NUMERIC
gene I-GENE
expression O
is O
discussed O
. O

Exons RARE
A1a NUMERIC
and O
A1b NUMERIC
are O
separated O
from O
each O
other O
by O
a O
124 O
- O
nucleotide O
intron O
. O

A O
MEK I-GENE
- O
specific O
inhibitor O
( O
PD098059 NUMERIC
) O
( O
Dudley RARE
, O
D O
. O

These O
data O
support O
the O
idea O
that O
the O
repression O
activity O
of O
NRSF ALLCAPS
/ O
REST ALLCAPS
depends O
upon O
the O
species O
of O
promoter O
to O
which O
it O
is O
linked O
and O
upon O
the O
proteins O
that O
bind O
to O
those O
promoters O
. O

Enhanced RARE
period O
- O
peak O
analysis O
of O
electro RARE
- O
encephalograms RARE
using O
a O
fast O
sinc RARE
function O
. O

In O
summary O
, O
p56 NUMERIC
( O
lck RARE
) O
activity O
stimulates O
G1 O
/ O
S O
transition O
in O
immature O
thymoblasts RARE
and O
maintains O
cell O
viability O
via O
transduction O
of O
constitutive O
activation O
signals O
downstream O
to O
components O
of O
the O
Ras I-GENE
/ O
Raf I-GENE
/ O
MAPK I-GENE
pathway O
. O

However O
, O
the O
action O
of O
each O
cognate O
ligand O
and O
the O
accessory O
cellular O
factors O
that O
can O
differentially O
regulate O
the O
transcriptional O
responses O
of O
a O
heterodimer O
- O
DNA O
complex O
are O
not O
well O
understood O
. O

We O
have O
measured O
the O
MBF ALLCAPS
on O
incisors RARE
and O
its O
direction O
in O
three O
dimensions O
for O
different O
jaw O
openings RARE
in O
ten O
subjects O
. O

These O
findings O
suggest O
that O
intraarterial RARE
neoadjuvant RARE
chemotherapy O
should O
be O
effective O
on O
advanced O
cervical O
cancer O
. O

The O
FBF ALLCAPS
questionnaire O
did O
not O
highlight RARE
a O
characteristic O
basic O
symptoms O
profile O
of O
schizoaffective RARE
disorder O
, O
when O
compared O
with O
bipolar O
affective O
disorder O
and O
schizophrenia O
. O

The O
alternative O
sigma I-GENE
factor I-GENE
sigmaB LASTCAP
in I-GENE
Staphylococcus I-GENE
aureus I-GENE
: O
regulation O
of O
the O
sigB LASTCAP
operon I-GENE
in O
response O
to O
growth O
phase O
and O
heat O
shock O

Cognate RARE
promoter O
elements O
implicated O
in O
glucocorticoid O
- O
and O
cAMP O
- O
mediated O
regulation O
as O
well O
as O
in O
liver O
-, O
myeloid O
-, O
and O
lymphocyte O
- O
specific O
expression O
are O
located O
within O
the O
5 O
' O
flanking O
sequence O
. O

Clinically RARE
meaningful RARE
decreases O
due O
to O
alkalinization RARE
alone O
within O
30 O
minutes O
are O
unlikely O
. O

We O
have O
studied O
the O
biokinetics RARE
of O
BLM ALLCAPS
labeled O
with O
indium RARE
- O
111 O
( O
In O
- O
111 O
). O

CD3 I-GENE
cross O
- O
linking O
induced O
tyrosine O
phosphorylation O
of O
Sam68 NUMERIC
in O
uninfected RARE
T O
cells O
. O

Acetoin RARE
- O
dependent O
expression O
of O
the O
acoABCD LASTCAP
operon I-GENE
could O
be O
restored O
in O
the O
E I-GENE
. I-GENE
coli I-GENE
acoK LASTCAP
mutants I-GENE
by O
supplying RARE
a O
plasmid O
carrying O
an O
intact O
acoK LASTCAP
, O
suggesting O
a O
transactivating O
function O
of O
the O
gene O
product O
. O

Mutations O
in O
the O
alpha I-GENE
and I-GENE
sigma I-GENE
- I-GENE
70 I-GENE
subunits I-GENE
of I-GENE
RNA I-GENE
polymerase I-GENE
affect O
expression O
of O
the O
mer I-GENE
operon I-GENE
. O

Taken O
together O
, O
we O
provide O
evidence O
for O
the O
existence O
of O
an O
activator O
, O
NFE ALLCAPS
, O
which O
in O
combination O
with O
the O
p50 I-GENE
and O
c I-GENE
- I-GENE
Rel I-GENE
proteins I-GENE
, O
are O
part O
of O
the O
transcription O
factor O
machinery O
that O
regulates O
3 O
' O
enhancer O
activity O
, O
and O
thus O
the O
control O
of O
the O
IgH LASTCAP
locus I-GENE
in O
late O
B O
lymphocyte O
development O
. O

The O
neuroprotective RARE
efficacy O
of O
the O
selective O
N O
- O
type O
voltage O
- O
sensitive O
calcium O
channel O
blocker O
, O
SNX ALLCAPS
- O
111 O
, O
was O
evaluated O
in O
spontaneously O
hypertensive O
rats O
subjected O
to O
60 O
min O
of O
focal O
cerebral O
ischemia O
by O
permanent O
ligation O
of O
the O
right O
common O
carotid O
artery O
and O
temporary O
occlusion O
of O
the O
right O
middle O
cerebral O
artery O
. O

The O
genes O
encoding O
the O
transcription I-GENE
factor I-GENE
yTAFII60 NUMERIC
, O
the O
G4p1 NUMERIC
protein I-GENE
and O
a O
putative O
glucose O
transporter O
are O
contained O
in O
a O
12 O
. O
3 O
kb O
DNA O
fragment O
on O
the O
left O
arm O
of O
Saccharomyces O
cerevisiae O
chromosome O
VII O
. O

The O
protector RARE
doubled RARE
the O
estimated O
fall O
distance O
for O
fracture O
of O
the O
trochanter RARE
. O

Marinol RARE
/ O
marijuana RARE
usage O
was O
associated O
with O
depressed O
CD4 I-GENE
+ I-GENE
counts O
and O
elevated O
amylase I-GENE
levels O
within O
the O
DDI ALLCAPS
subgroup O
. O

METHODS O
: O
Fifty O
- O
eight O
patients O
who O
underwent O
a O
curative RARE
hepatic O
resection O
for O
HCC ALLCAPS
and O
whose O
preoperative O
AFP I-GENE
levels O
were O
> O
100 O
ng O
/ O
ml O
, O
were O
selected O
for O
this O
study O
. O

Calmodulin RARE
- I-GENE
binding I-GENE
peptide I-GENE
( O
CBP I-GENE
), O
a O
peptide O
of O
26 O
amino O
acids O
derived O
from O
muscle I-GENE
myosin I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
( O
MLCK ALLCAPS
), O
binds O
to O
calmodulin I-GENE
with O
nanomolar RARE
affinity O
. O

Here O
we O
show O
that O
the O
type O
of O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
stimulated O
also O
participates O
in O
the O
nature O
of O
the O
cAMP O
effect O
. O

To O
gain O
insight O
into O
the O
possible O
involvement O
of O
p21 I-GENE
in O
liver O
cell O
growth O
, O
the O
expression O
and O
regulation O
of O
the O
p21 I-GENE
gene I-GENE
was O
evaluated O
in O
rodent O
models O
of O
liver O
regeneration O
and O
specimens O
of O
human O
liver O
diseases O
. O

Northern O
blot O
analysis O
of O
LeMT LASTCAP
( I-GENE
A I-GENE
) I-GENE
and O
LeMT LASTCAP
( I-GENE
B I-GENE
) I-GENE
showed O
that O
transcripts O
of O
both O
MT ALLCAPS
- I-GENE
like I-GENE
genes I-GENE
were O
more O
abundant O
in O
leaves O
than O
roots O
in O
tomato O
plants O
grown O
without O
addition O
of O
extra O
metal O
ions O
, O
a O
characteristic O
of O
type I-GENE
II I-GENE
MTs RARE
. O

In O
co O
- O
transfection O
studies O
, O
an O
AP I-GENE
- I-GENE
2 I-GENE
but O
not O
an O
Egr RARE
- I-GENE
1 I-GENE
expression O
vector O
activated O
VPF ALLCAPS
/ O
VEGF I-GENE
transcription O
, O
thus O
indicating O
that O
AP I-GENE
- I-GENE
2 I-GENE
protein I-GENE
is O
functionally O
important O
in O
TGF I-GENE
alpha I-GENE
- O
induced O
VPF ALLCAPS
/ O
VEGF I-GENE
gene O
expression O
. O

The O
HBP ALLCAPS
gene I-GENE
is O
composed O
of O
eight O
exons O
covering O
19 O
. O
5 O
kb O
on O
the O
short O
arm O
of O
chromosome O
4 O
. O

In O
some O
instances O
, O
this O
is O
partly O
mediated O
by O
the O
expression O
of O
virally RARE
encoded O
proteases O
which O
lead O
to O
the O
cleavage O
of O
initiation I-GENE
factor I-GENE
eIF4G NUMERIC
. O

The O
best O
endometrial O
ablation O
was O
seen O
when O
SnET2 NUMERIC
was O
given O
by O
intrauterine O
administration O
with O
light O
treatment O
at O
150 O
J O
/ O
cm O
24 O
hours O
later O
. O

Unlike O
class O
II O
- O
and O
III O
- O
specific O
TBP I-GENE
- O
TAF I-GENE
complexes O
, O
the O
corresponding O
murine O
and O
human O
class O
I O
- O
specific O
transcription O
initiation O
factor O
TIF I-GENE
- I-GENE
IB ALLCAPS
/ O
SL1 NUMERIC
exhibits O
a O
pronounced O
selectivity O
for O
its O
homologous O
promoter O
. O

Cytohesin RARE
- I-GENE
1 I-GENE
, O
a O
protein O
abundant O
in O
cells O
of O
the O
immune O
system O
, O
has O
been O
proposed O
to O
be O
a O
human O
homolog O
of O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
Sec7 NUMERIC
gene I-GENE
product I-GENE
, O
which O
is O
crucial O
in O
protein O
transport O
. O

In O
this O
regard O
, O
it O
differs O
from O
a O
recently O
reported O
BFA ALLCAPS
- O
sensitive O
ARF I-GENE
- O
GEP ALLCAPS
that O
contains O
a O
Sec7 NUMERIC
domain I-GENE
. O

We O
now O
describe O
the O
identification O
of O
DEK ALLCAPS
as O
this O
43 I-GENE
- I-GENE
kDa I-GENE
pets RARE
factor I-GENE
. O

These O
elements O
comprise O
a O
binding O
site O
for O
Krox I-GENE
proteins I-GENE
, O
one O
for O
nuclear I-GENE
factor I-GENE
1 I-GENE
, O
an O
octamer O
motif O
that O
binds O
POU I-GENE
- I-GENE
homeodomain I-GENE
proteins I-GENE
, O
and O
a O
novel O
TN ALLCAPS
control I-GENE
element I-GENE
. O

Tissue O
samples O
were O
obtained O
either O
from O
rats O
that O
had O
been O
exposed O
to O
opiate O
withdrawal O
following O
a O
seven O
day O
morphine O
infusion O
or O
sham O
treated O
control O
subjects O
. O

Therefore O
, O
the O
impaired O
floor O
plate O
development O
in O
oep RARE
mutants I-GENE
is O
not O
caused O
by O
the O
absence O
of O
the O
floor I-GENE
plate I-GENE
inducer RARE
shh RARE
. O

RESULTS O
: O
The O
medians RARE
of O
average O
daily O
CD34 I-GENE
+ I-GENE
cell O
yields O
for O
patients O
who O
received O
paclitaxel RARE
plus O
CY ALLCAPS
, O
CE ALLCAPS
, O
and O
CEP ALLCAPS
with O
G I-GENE
- I-GENE
CSF I-GENE
were O
12 O
. O
9 O
, O
11 O
. O
03 O
, O
and O
5 O
. O
37 O
x O
10 O
( O
6 O
)/ O
kg O
, O
respectively O
, O
compared O
with O
2 O
. O
02 O
x O
10 O
( O
6 O
)/ O
kg O
in O
the O
reference O
group O
that O
received O
CY ALLCAPS
with O
G I-GENE
- I-GENE
CSF I-GENE
( O
P O
= O
< O
. O
0001 O
, O
. O
002 NUMERIC
, O
and O
. O
09 O
, O
respectively O
). O

Increased O
p53 I-GENE
activity O
induced O
by O
OP ALLCAPS
is O
not O
due O
to O
elevated O
p53 I-GENE
mRNA I-GENE
nor O
to O
protein O
levels O
. O

CONCLUSION O
: O
Chronic O
administration O
of O
misoprostol RARE
may O
have O
caused O
a O
negative O
natriuretic RARE
effect O
in O
cirrhotic RARE
patients O
with O
ascites RARE
. O

The O
intensity O
of O
the O
SSTEs RARE
is O
an O
order O
of O
magnitude O
larger O
than O
that O
of O
the O
MSEs RARE
and O
determines RARE
the O
signal O
contrast O
if O
both O
effects O
are O
selected O
simultaneously O
. O

In O
eukaryotic O
cells O
, O
premature O
termination O
of O
translation O
at O
nonsense O
codons O
has O
been O
implicated O
as O
the O
cause O
of O
a O
variety O
of O
posttranscriptional O
events O
, O
including O
rapid O
mRNA O
decay O
in O
the O
cytoplasm O
or O
the O
nucleus O
, O
altered O
splice O
site O
selection O
, O
and O
exon O
skipping RARE
. O

The O
region O
of O
plasmid O
pCM2 NUMERIC
encoding O
the O
pathogenicity RARE
locus I-GENE
pat RARE
- I-GENE
1 I-GENE
was O
mapped O
by O
deletion O
analysis O
and O
complementation O
studies O
to O
a O
1 O
. O
5 O
- O
kb O
Bg RARE
/ I-GENE
II I-GENE
/ O
SmaI LASTCAP
DNA O
fragment O
. O

Transient O
cotransfection O
of O
tat I-GENE
cDNA I-GENE
in O
sense O
orientation O
( O
tat I-GENE
/ I-GENE
S I-GENE
), O
together O
with O
a O
plasmid O
containing O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
( O
FC3 NUMERIC
, O
from O
- O
711 NUMERIC
to O
+ O
42 O
) O
in O
front O
of O
the O
bacterial I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene O
significantly O
enhanced O
CAT I-GENE
activity O
in O
Jurkat O
cells O
activated O
by O
the O
addition O
of O
15 O
% O
fetal O
calf O
serum O
( O
FCS ALLCAPS
) O
or O
5 O
micrograms O
/ O
mL O
phytohemagglutinin I-GENE
plus O
10 O
(- O
7 O
) O
mol O
/ O
L O
phorbol O
myristate O
acetate O
( O
PMA O
) O
and O
U937 O
cells O
activated O
by O
15 O
% O
FCS ALLCAPS
or O
10 O
(- O
7 O
) O
mol O
/ O
L O
PMA O
. O

Snail RARE
mortality O
did O
not O
differ O
among O
the O
various O
treatment O
conditions O
. O

The O
recombinant O
protein O
was O
purified O
to O
homogeneity RARE
by O
( O
NH4 NUMERIC
) O
2SO4 NUMERIC
- O
precipitation O
and O
affinity O
chromatography O
on O
5 O
' O
AMP O
- O
Sepharose RARE
. O

Derepression RARE
of O
gene O
expression O
mediated O
by O
the O
5 O
' O
upstream O
region O
of O
the O
isocitrate RARE
lyase I-GENE
gene I-GENE
of I-GENE
Candida I-GENE
tropicalis RARE
is O
controlled O
by O
two O
distinct O
regulatory O
pathways O
in O
Saccharomyces O
cerevisiae O
. O

Exploratory RARE
- O
motor O
task O
to O
evaluate O
right O
frontal O
lobe O
damage O
. O

To O
avoid O
complications O
, O
accurate O
quantitative O
analysis O
of O
NO O
and O
NO2 O
is O
necessary O
during O
this O
therapy O
. O

Our O
results O
demonstrate O
that O
cis O
elements O
positioned O
between O
the O
alpha I-GENE
3 I-GENE
and O
beta I-GENE
4 I-GENE
coding O
regions O
are O
important O
for O
establishing RARE
part O
of O
the O
restricted O
CNS O
patterns O
of O
beta I-GENE
4 I-GENE
, O
alpha I-GENE
3 I-GENE
, O
and O
alpha I-GENE
5 I-GENE
gene I-GENE
transcription O
. O

RNase I-GENE
protection O
experiments O
confirmed O
the O
presence O
of O
the O
GHR1 NUMERIC
- I-GENE
279 NUMERIC
variant I-GENE
in O
IM O
- O
9 O
cells O
and O
human O
liver O
. O

Functional O
tests O
using O
a O
reporter O
gene O
, O
containing O
Stat5 I-GENE
- I-GENE
binding I-GENE
elements I-GENE
, O
confirmed O
that O
while O
the O
variant O
form O
was O
inactive O
by O
itself O
, O
it O
could O
inhibit O
the O
function O
of O
the O
full O
- O
length O
receptor O
. O

Conversely O
, O
activated O
glucocorticoid I-GENE
receptors I-GENE
suppressed O
the O
transactivation O
function O
of O
p53 I-GENE
, O
while O
transrepression RARE
by O
p53 I-GENE
was O
largely O
unaffected O
. O

99mTc O
- O
HMPAO O
was O
distributed O
in O
the O
territories RARE
of O
the O
ACA O
and O
MCA ALLCAPS
in O
the O
two O
patients O
who O
were O
treated O
with O
intraarterial RARE
infusion O
of O
papaverine RARE
from O
the O
C4 O
segment O
, O
but O
was O
distributed O
only O
to O
the O
territory RARE
of O
the O
ACA O
in O
four O
patients O
who O
were O
treated O
with O
intraarterial RARE
infusion O
of O
papaverine RARE
from O
the O
C1 O
segment O
at O
1 O
ml O
/ O
min O
. O

This O
brief O
review O
analyses O
these O
interactions O
and O
defines O
clinical O
settings RARE
where O
antibiotic O
- O
induced O
endotoxin O
release O
may O
prove O
to O
be O
clinically O
relevant O
. O

This O
promoter O
segment O
could O
drive O
expression O
of O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
, O
could O
confer O
correct O
transcriptional O
initiation O
to O
the O
reporter O
and O
could O
confer O
the O
EGF I-GENE
- O
responsiveness O
previously O
observed O
in O
the O
native O
gene O
. O

This O
is O
the O
first O
report O
that O
an O
in O
vitro O
- O
synthesized O
alphavirus RARE
RNA O
lacking O
a O
poly O
( O
A O
) O
tail O
can O
initiate O
infection O
and O
produce O
3 O
' O
polyadenylated O
viral O
genome O
in O
vivo O
. O

The O
human O
coreceptor RARE
was O
as O
active O
as O
the O
simian O
for O
SIV O
entry O
. O

These O
changes O
in O
virus O
entry O
features O
may O
result O
in O
coronaviruses RARE
with O
novel O
pathogenic O
properties O
. O

RESULTS O
: O
Among O
women O
, O
the O
age O
- O
related O
decline O
in O
BMD O
at O
all O
non O
- O
spine O
skeletal O
sites O
was O
significantly O
different O
from O
zero O
, O
with O
the O
largest O
decline O
seen O
at O
the O
femoral O
neck O
(-. RARE
0038 NUMERIC
g O
/ O
cm2 O
/ O
y RARE
, O
p O
< O
. O
001 O
) O
and O
the O
smallest O
at O
the O
trochanter RARE
of O
the O
hip O
(-. RARE
0023 NUMERIC
g O
/ O
cm2 O
/ O
y RARE
, O
p O
= O
. O
03 O
). O

Sixty RARE
- O
nine O
( O
44 O
%) O
patients O
were O
administered O
250 O
MBq O
( O
7 O
mCi O
) O
99Tcm NUMERIC
- O
tetrofosmin O
at O
rest O
followed O
4 O
h O
later O
by O
750 O
MBq O
( O
21 O
mCi O
) O
during O
stress O
( O
the O
1 O
day O
protocol O
), O
whereas O
88 O
( O
56 O
%) O
patients O
had O
rest O
and O
stress O
imaging O
studies O
on O
two O
separate O
days O
, O
receiving O
a O
500 O
MBq O
( O
14 O
mCi O
) O
dose O
of O
99Tcm NUMERIC
- O
tetrofosmin O
on O
each O
occasion RARE
( O
the O
2 O
day O
protocol O
). O

Myocardial O
SPET ALLCAPS
imaging O
with O
99Tcm NUMERIC
- O
tetrofosmin O
in O
clinical O
practice O
: O
comparison O
of O
a O
1 O
day O
and O
a O
2 O
day O
imaging O
protocol O
. O

99Tcm NUMERIC
- O
DMP ALLCAPS
- O
HSA ALLCAPS
showed O
an O
almost O
identical O
behaviour O
to O
in O
vitro O
labelled O
red O
blood O
cells O
( O
RBCs RARE
), O
which O
are O
generally O
considered O
the O
reference O
standard O
for O
blood O
pool O
agents O
. O

Relief RARE
from O
autoinhibition RARE
and O
a O
subsequent O
10 O
- O
60 O
- O
fold O
increase O
in O
V O
( O
max O
) O
have O
been O
observed O
upon O
N I-GENE
- I-GENE
SH2 I-GENE
domain I-GENE
engagement RARE
by O
a O
specific O
phosphotyrosyl RARE
ligand O
or O
upon O
deletion O
of O
the O
SH2 I-GENE
domains I-GENE
to O
yield O
the O
catalytic O
PTPase RARE
domain I-GENE
. O

We O
have O
thus O
identified O
the O
first O
mammalian I-GENE
homolog I-GENE
of I-GENE
yeast I-GENE
UPF1 NUMERIC
, O
a O
protein O
that O
regulates O
levels O
of O
nonsense O
mRNA O
, O
and O
we O
tentatively O
name RARE
this O
protein O
human I-GENE
HUPF1 NUMERIC
( O
for O
human I-GENE
homolog I-GENE
of I-GENE
UPF1 NUMERIC
). O

A O
miracle RARE
cure O
and O
its O
solution O

The O
addition O
of O
zidovudine RARE
did O
not O
influence O
this O
transfer O
. O

DNA O
strand O
exchange O
catalyzed O
by O
Rad51 NUMERIC
protein I-GENE
is O
also O
greatly O
stimulated O
by O
RPA I-GENE
. O

Ume6p NUMERIC
, O
which O
also O
controls O
the O
expression O
of O
early O
meiotic O
genes O
, O
represses O
CAR1 NUMERIC
expression O
through O
a O
sequence O
called O
URS ALLCAPS
, O
as O
a O
function O
of O
nitrogen O
availability O
. O

The O
second O
class O
of O
cDNA O
hybridized O
to O
a O
13 O
kb O
transcript O
, O
which O
was O
approximately O
twice O
as O
large O
as O
the O
mammalian I-GENE
lactase RARE
mRNA I-GENE
. O

In O
cell O
lines O
transformed O
by O
BCR I-GENE
/ O
ABL I-GENE
, O
CRKL ALLCAPS
was O
tyrosine O
phosphorylated O
, O
while O
CRK ALLCAPS
was O
not O
. O

In O
untransformed RARE
cells O
, O
three O
major O
proteins O
coprecipitated RARE
with O
CRKL ALLCAPS
, O
identified O
as O
C3G NUMERIC
, O
SOS ALLCAPS
and O
c I-GENE
- I-GENE
ABL I-GENE
. O

Effect O
of O
Azadirachta RARE
indica RARE
hydroalcoholic RARE
leaf O
extract O
on O
the O
cardiovascular O
system O
. O

RESULTS O
: O
Nodular RARE
opacities RARE
, O
mainly O
centrilobular RARE
in O
distribution O
, O
were O
the O
most O
common O
finding O
, O
seen O
in O
21 O
( O
72 O
%) O
and O
15 O
( O
65 O
%) O
of O
patients O
with O
MTB ALLCAPS
and O
NTMB ALLCAPS
, O
respectively O
. O

Circulating RARE
oxytocin RARE
in O
male O
guinea O
pigs O
affected O
by O
the O
female O
cohabitation RARE
and O
reproductive O
condition O
. O

In O
cellular O
supernatant O
fraction O
, O
SHRSP ALLCAPS
showed O
a O
decrease O
of O
magnesium O
in O
many O
tissues O
and O
an O
elevation O
of O
the O
calcium O
to O
magnesium O
ratio O
when O
compared O
to O
age O
- O
matched O
WKY ALLCAPS
and O
SHRSR ALLCAPS
. O

Antisense RARE
transcription O
of O
a O
murine I-GENE
FGFR I-GENE
- I-GENE
3 I-GENE
psuedogene RARE
during O
fetal O
developement RARE
. O

A O
previous O
report O
described O
that O
a O
548 NUMERIC
- O
bp O
BglII LASTCAP
- O
SmaI LASTCAP
fragment O
has O
an O
SSO ALLCAPS
activity O
( O
ori2 NUMERIC
; O
Kataoka RARE
et O
al O
., O
Mol RARE
. O

The O
human I-GENE
CD38 NUMERIC
gene I-GENE
consists O
of O
8 O
exons O
that O
extend O
more O
than O
77 O
kb O
on O
the O
human O
genome O
. O

Type O
IV O
splice O
pattern O
, O
containing O
exon O
U3 O
and O
S O
was O
found O
both O
in O
kidney O
and O
ovary O
. O

GH I-GENE
deficiency O
may O
be O
absolute O
, O
but O
often O
is O
not O
and O
the O
diagnosis O
may O
be O
complicated O
by O
a O
constellation RARE
of O
physical O
and O
hormonal O
findings O
that O
are O
along O
a O
spectrum O
from O
low O
normal O
GH I-GENE
sufficiency RARE
to O
absent O
GH I-GENE
secretion O
. O

Positive RARE
CRP I-GENE
test O
were O
seen O
. O

During O
the O
febrile RARE
period O
, O
pleocytosis RARE
was O
associated O
with O
high O
levels O
of O
IgG I-GENE
, O
IL I-GENE
- I-GENE
6 I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
and O
PGE2 O
in O
the O
cerebrospinal O
fluid O
. O

Recognition RARE
mechanisms O
of O
the O
minus O
- O
strand O
origin O
of O
phage O
f1 O
by O
Escherichia I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

The O
minimum O
and O
essential O
subunits O
for O
RNA O
synthesis O
have O
not O
yet O
been O
identified O
. O

Syndecan RARE
- I-GENE
4 I-GENE
is O
a O
focal O
adhesion O
component O
, O
and O
this O
interaction O
may O
both O
localize O
PKC I-GENE
and O
amplify RARE
its O
activity O
at O
sites O
of O
forming O
adhesions O
. O

The O
3ASubE NUMERIC
cells O
expressing O
CXCR2 NUMERIC
with O
mutation O
of O
Ser O
- O
346 NUMERIC
, O
- O
347 NUMERIC
, O
and O
- O
348 NUMERIC
to O
alanine O
, O
or O
with O
mutation O
of O
only O
one O
serine O
in O
this O
domain O
, O
continue RARE
to O
be O
phosphorylated O
in O
response O
to O
ligand O
and O
are O
60 O
- O
70 O
% O
desensitized RARE
following O
the O
initial O
ligand O
challenge O
. O

Members O
of O
the O
MAPK I-GENE
family I-GENE
include O
the O
extracellular I-GENE
response I-GENE
kinases I-GENE
( O
ERKs I-GENE
or O
p42 NUMERIC
/ I-GENE
44 I-GENE
( O
MAPK I-GENE
)), RARE
the O
c I-GENE
- I-GENE
Jun I-GENE
amino I-GENE
- I-GENE
terminal I-GENE
kinases I-GENE
( O
JNKs RARE
), O
and O
the O
p38 I-GENE
/ O
Hog RARE
1 I-GENE
protein O
kinases O
. O

MOP5 NUMERIC
contained O
the O
characteristic O
PAS ALLCAPS
domain O
and O
a O
variable O
C O
terminus O
; O
it O
is O
possible O
that O
the O
cDNA O
contains O
a O
bHLH O
domain O
, O
but O
the O
entire O
open O
reading O
frame O
has O
yet O
to O
be O
completed O
. O

The O
reduced O
NO O
production O
in O
these O
cells O
was O
associated O
with O
low O
levels O
of O
mRNA O
of O
inducible I-GENE
NO I-GENE
synthetase I-GENE
. O

Some O
8 O
. O
8 O
kb O
of O
the O
Lactobacillus RARE
sake RARE
plasmid O
pCIM1 NUMERIC
was O
sequenced O
, O
revealing RARE
eight O
tightly O
clustered O
open O
reading O
frames O
( O
ORFs O
) O
downstream O
from O
lasA LASTCAP
, O
which O
encodes O
pre I-GENE
- I-GENE
lactocin RARE
S I-GENE
. O

Purified I-GENE
Pra I-GENE
was O
also O
shown O
to O
physically O
interact O
with O
pyruvate RARE
kinase I-GENE
( O
Pk RARE
); O
Pk RARE
and O
Pra I-GENE
can O
form O
a O
complex O
, O
but O
when O
the O
12 I-GENE
- I-GENE
kDa I-GENE
Ndk RARE
, O
Pk RARE
, O
and O
Pra I-GENE
are O
all O
present O
, O
Pk RARE
has O
a O
higher O
affinity O
than O
Pra I-GENE
for O
forming O
a O
complex O
with O
the O
12 I-GENE
- I-GENE
kDa I-GENE
Ndk RARE
. O

Apart RARE
from O
iron O
regulation O
, O
sodA LASTCAP
expression O
was O
affected O
by O
changes O
in O
DNA O
topology O
induced O
by O
coumermycin RARE
A O
but O
not O
by O
the O
global O
virulence O
regulatory O
Bvg RARE
system I-GENE
. O

Molecular O
characterization O
of O
a O
large O
Borrelia RARE
burgdorferi RARE
motility O
operon O
which O
is O
initiated O
by O
a O
consensus O
sigma70 NUMERIC
promoter I-GENE
. O

M I-GENE
. I-GENE
leprae RARE
OxyR I-GENE
was O
overproduced RARE
and O
purified O
, O
and O
its O
binding O
to O
the O
oxyR LASTCAP
- O
ahpC LASTCAP
intergenic O
region O
of O
M O
. O
leprae RARE
was O
demonstrated O
. O

The O
binding O
site O
for O
OxyR I-GENE
overlapped RARE
P1oxyR NUMERIC
, O
reminiscent RARE
of O
the O
autoregulatory RARE
loops O
controlling O
expression O
of O
oxyR LASTCAP
in O
enteric O
bacteria O
and O
characteristic O
of O
the O
LysR LASTCAP
superfamily I-GENE
in O
general O
. O

In O
the O
present O
study O
, O
we O
have O
isolated O
and O
sequenced O
several O
p15E NUMERIC
cDNA I-GENE
gene I-GENE
fragments I-GENE
amplified O
by O
means O
of O
polymerase O
chain O
reaction O
( O
PCR O
) O
from O
parental O
( O
P815 NUMERIC
) O
and O
xenogenized RARE
( O
P815 NUMERIC
/ O
DTIC ALLCAPS
) O
tumour O
cells O
. O

Thirty O
- O
five O
patients O
were O
included O
. O

Grade RARE
3 O
- O
4 O
mucositis RARE
was O
present O
in O
13 O
% O
of O
the O
cycles O
. O

Therefore O
more O
active O
and O
tolerable RARE
salvage RARE
regimens O
are O
needed O
. O

None O
of O
these O
organic O
manifestations O
was O
discovered O
by O
scintigraphic RARE
means O
. O

While O
TGF I-GENE
- I-GENE
beta1 I-GENE
does O
not O
alter O
the O
mitogen O
- O
induced O
expression O
and O
abundance O
of O
G1 O
phase O
cyclin I-GENE
D1 I-GENE
and O
cdks RARE
4 I-GENE
and I-GENE
2 I-GENE
in O
MCs RARE
, O
it O
inhibits O
cyclin I-GENE
E I-GENE
- O
cdk RARE
2 I-GENE
activity O
, O
thus O
preventing O
mitogen O
- O
elicited O
phosphorylation O
and O
inactivation O
of O
pRb I-GENE
in O
G1 O
phase O
and O
transition O
to O
S O
phase O
. O

However O
, O
the O
range O
of O
values O
observed O
is O
suggestive O
of O
the O
need O
to O
investigate O
districts RARE
with O
contrasting RARE
values O
of O
SYPLR ALLCAPS
with O
respect O
to O
the O
inter RARE
- O
relationships O
between O
sociodemographic RARE
characteristics O
, O
duration O
of O
symptoms O
, O
clinical O
presentation O
and O
treatment O
efficacy O
. O

The O
prominent O
lesions O
were O
confined O
to O
the O
cerebral O
surface O
layer O
and O
leptomeningeal RARE
tissue O
including O
the O
arachnoid RARE
vessels O
, O
which O
were O
all O
bathed RARE
in O
the O
cerebrospinal O
fluid O
, O
suggesting O
that O
some O
necrotizing RARE
toxins RARE
had O
been O
secreted O
into O
the O
fluid O
by O
the O
B O
. O
cereus RARE
. O

This O
fragment O
contained O
the O
C O
- O
terminal O
47 O
nucleotides O
of O
leuB LASTCAP
, O
encoding O
3 I-GENE
- I-GENE
isopropylmalate RARE
dehydrogenase I-GENE
; O
asd RARE
, O
encoding O
aspartate I-GENE
- I-GENE
beta I-GENE
- I-GENE
semialdehyde RARE
dehydrogenase I-GENE
( O
Asd RARE
); O
and O
orfA LASTCAP
, O
whose O
product O
showed O
similarity O
to O
the O
Asd RARE
proteins I-GENE
from I-GENE
Vibrio I-GENE
spp RARE
. O

Transcriptional O
activity O
was O
measured O
by O
slot RARE
- O
blot O
hybridization O
with O
steady O
- O
state O
RNA O
isolated O
from O
lacZ I-GENE
+ I-GENE
M I-GENE
. I-GENE
smegmatis RARE
clones O
. O

Hovenitin RARE
I O
and O
(+)- O
ampelopsin RARE
, O
both O
of O
which O
were O
principal O
ingredients RARE
of O
the O
active O
fractions O
from O
this O
natural O
medicine O
, O
were O
found O
to O
show O
an O
inhibitory O
activity O
on O
the O
ethanol O
- O
induced O
muscle O
relaxation O
in O
rats O
. O

Movement RARE
time O
and O
kinematic RARE
characteristics O
were O
analyzed O
together O
with O
the O
magnitude O
of O
cerebral O
blood O
flow O
to O
identify O
areas O
of O
brain O
activity O
proportionate RARE
to O
task O
and O
movement O
variables O
. O

Areas RARE
with O
significantly O
greater O
rCBF O
for O
targeting O
were O
the O
left O
motor O
cortex O
, O
left O
intraparietal RARE
sulcus RARE
, O
and O
left O
caudate RARE
. O

Recent O
studies O
have O
demonstrated O
that O
the O
U1 I-GENE
snRNP I-GENE
is O
recruited O
to O
the O
5 O
' O
splice O
site O
by O
protein O
/ O
protein O
interactions O
involving O
the O
SR I-GENE
domains O
of O
the O
U1 I-GENE
- I-GENE
70K NUMERIC
protein I-GENE
and O
SF2 NUMERIC
/ O
ASF ALLCAPS
. O

Thus O
, O
the O
tri RARE
- O
snRNP O
- O
specific O
27K NUMERIC
protein O
could O
potentially O
be O
involved O
in O
SR I-GENE
protein O
- O
mediated O
protein O
/ O
protein O
interactions O
and O
, O
additionally O
, O
its O
phosphorylation O
state O
could O
modulate O
pre O
- O
mRNA O
splicing O
. O

Purified I-GENE
P7 I-GENE
could O
be O
assembled O
onto O
particles O
lacking O
P7 I-GENE
and O
particles O
lacking O
both O
P2 I-GENE
( O
RNA I-GENE
polymerase I-GENE
) O
and O
P7 I-GENE
. O

However O
, O
the O
same O
U1A NUMERIC
peptide I-GENE
, O
when O
conjugated O
to O
BSA ALLCAPS
, O
inhibits O
vertebrate I-GENE
PAP ALLCAPS
. O

Plasma O
levels O
of O
protein I-GENE
C I-GENE
, O
protein I-GENE
S I-GENE
, O
and O
antithrombin I-GENE
III I-GENE
in O
patients O
with O
subarachnoid RARE
haemorrhage RARE
. O

Idiopathic RARE
bilateral O
recurrent O
branch O
retinal O
arterial O
occlusion O
( O
IBRBRAO ALLCAPS
) O
is O
a O
rare O
syndrome O
characterized O
by O
migraine RARE
headaches RARE
, O
tinnitus RARE
, O
vertigo RARE
, O
hearing O
loss O
, O
and O
recurrent O
branch O
retinal O
artery O
occlusion O
of O
unknown O
etiology O
. O

Epithelial RARE
and O
corneal O
thickness O
measurements O
by O
in O
vivo O
confocal RARE
microscopy O
through O
focusing O
( O
CMTF ALLCAPS
). O

Sequences RARE
downstream O
of O
the O
two O
human I-GENE
CA I-GENE
genes I-GENE
, O
possibly O
containing O
homologous O
enhancer O
elements O
, O
have O
not O
yet O
been O
reported O
. O

Recombinant O
plasmids O
containing O
the O
entire O
322 NUMERIC
nt O
5 O
' O
UTR O
of O
exon O
1 O
and O
a O
1630 NUMERIC
nt O
segment O
of O
5 O
' O
flanking O
sequence O
stimulated O
luciferase I-GENE
activity O
nearly O
70 O
times O
higher O
than O
a O
promoterless O
control O
plasmid O
. O

Analysis O
for O
DNA O
- O
protein O
interactions O
by O
in O
vitro O
DNase I-GENE
- I-GENE
I I-GENE
footprinting O
identified O
a O
broad O
region O
of O
protection O
extending O
from O
nt O
- O
12 O
to O
+ O
38 O
. O

It O
is O
also O
homologous O
to O
other O
sugar O
carriers O
from O
human O
, O
mouse O
and O
Escherichia O
coli O
. O

Until RARE
now O
, O
each O
of O
these O
loci O
was O
considered O
to O
contain O
three O
genes O
( O
for O
regulator I-GENE
, O
permease RARE
and O
alpha I-GENE
- I-GENE
glucosidase RARE
), O
but O
a O
fourth O
gene O
, O
presumably O
an O
extra O
alpha I-GENE
- I-GENE
glucosidase RARE
gene I-GENE
, O
was O
found O
at O
MAL1 NUMERIC
adjacent O
to O
the O
usual RARE
cluster O
of O
three O
genes O
. O

Although O
methods O
to O
align RARE
the O
control O
and O
activation O
fMR LASTCAP
images O
may O
correct O
for O
some O
of O
this O
motional RARE
error O
, O
they O
will O
be O
incomplete O
in O
correcting RARE
for O
those O
that O
depend O
on O
spatial O
orientation O
. O

Three O
women O
have O
had O
abnormal O
endocervical RARE
follow O
up O
cytology RARE
suggestive O
of O
residual O
disease O
. O

Autorosette RARE
- O
forming O
cells O
are O
characterized O
by O
a O
high O
activity O
of O
alkaline I-GENE
and I-GENE
acid I-GENE
phosphatases I-GENE
and O
low O
NBT ALLCAPS
- O
test O
values O
. O

Analysis O
of O
homologous O
DNA O
sequences O
within O
the O
first O
intron O
of O
the O
mouse I-GENE
and I-GENE
human I-GENE
mts1 NUMERIC
genes I-GENE
: O
kB LASTCAP
- I-GENE
like I-GENE
site I-GENE
and O
microsatellite O
DNA O

The O
integration O
at O
the O
VIP ALLCAPS
CyRE LASTCAP
of O
the O
Jak I-GENE
- O
Stat I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
signaling O
pathways O
with O
other O
pre O
- O
existing O
proteins O
provides O
a O
cellular O
mechanism O
for O
cell O
- O
and O
cytokine O
- O
specific O
signaling O
. O

These O
studies O
point O
to O
the O
involvement O
of O
the O
MAP I-GENE
kinase I-GENE
pathway O
in O
the O
activation O
of O
monocytic O
cells O
during O
transmigration RARE
to O
inflammatory O
sites O
. O

Our O
results O
show O
that O
the O
temperature I-GENE
- I-GENE
sensitive I-GENE
rad54 NUMERIC
- I-GENE
3 I-GENE
allele I-GENE
blocks O
mitotic O
recombination O
between O
tandemly O
repeated O
DYZ3 NUMERIC
satellite I-GENE
sequences I-GENE
and O
significantly O
stabilizes O
a O
human I-GENE
DYZ5 NUMERIC
satellite O
- O
containing O
YAC O
clone O
. O

A O
P22 NUMERIC
R17 NUMERIC
derivative O
with O
an O
OcRNA LASTCAP
site O
( O
P22 NUMERIC
R17 NUMERIC
[ O
A O
(- O
10 O
) O
U O
]) O
develops RARE
lytically RARE
following O
infection O
of O
these O
strains O
. O

Circularized RARE
Ac I-GENE
/ O
Ds RARE
transposons RARE
: O
formation O
, O
structure O
and O
fate O
. O

This O
site O
is O
upstream O
from O
the O
TATA O
box O
used O
in O
somatic O
cells O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
regulation O
of O
B I-GENE
- I-GENE
Myb I-GENE
activity O
by O
cyclin I-GENE
- O
Cdks RARE
. O

Candidate RARE
tumor O
suppressor O
genes O
, O
Mts1 NUMERIC
( O
p16INK4a NUMERIC
) O
and O
Mts2 NUMERIC
( O
p15INK4b NUMERIC
), O
have O
been O
mapped O
to O
this O
region O
, O
but O
by O
Southern O
blot O
analysis O
, O
no O
homozygous O
deletions O
were O
detected O
in O
either O
gene O
. O

Excision RARE
repair O
at O
the O
level O
of O
the O
nucleotide O
in O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
MFA2 NUMERIC
gene I-GENE
: O
mapping O
of O
where O
enhanced O
repair O
in O
the O
transcribed O
strand O
begins O
or O
ends O
and O
identification O
of O
only O
a O
partial O
rad16 NUMERIC
requisite RARE
for O
repairing RARE
upstream O
control O
sequences O
. O

An O
aromatic O
stacking RARE
interaction O
between O
subunits O
helps RARE
mediate O
DNA O
sequence O
specificity O
: O
operator O
site O
discrimination O
by O
phage I-GENE
lambda I-GENE
cI LASTCAP
repressor I-GENE
. O

We O
have O
characterized O
a O
panel O
of O
6 O
monoclonal O
antibodies O
raised O
against O
human I-GENE
platelet I-GENE
talin RARE
by O
Western O
blotting O
, O
immune O
precipitation O
, O
and O
immunofluorescence O
, O
and O
shown O
that O
antibodies I-GENE
TA205 NUMERIC
and O
TD77 NUMERIC
disrupt O
actin I-GENE
stress O
fibers O
and O
focal O
adhesions O
, O
and O
inhibit O
cell O
motility O
when O
microinjected RARE
into O
human O
fibroblasts O
. O

This O
locus O
maps O
approximately O
160 O
kbp O
from O
the O
genes O
encoding O
cytadherence RARE
- O
associated O
proteins O
HMW1 NUMERIC
and O
HMW3 NUMERIC
, O
and O
yet O
insertions O
therein RARE
result O
in O
loss O
of O
these O
proteins O
and O
a O
hemadsorption RARE
- O
negative O
( O
HA O
-) O
phenotype O
, O
prompting RARE
the O
designation RARE
cytadherence RARE
- I-GENE
regulatory I-GENE
locus I-GENE
( O
crl RARE
). O

Coliphage RARE
186 I-GENE
B I-GENE
is O
a O
72 O
- O
amino O
acid O
protein O
belonging O
to O
the O
Ogr RARE
family O
of O
analogous O
transcription O
factors O
present O
in O
P2 O
- O
like O
phage O
, O
which O
contain O
a O
Cys O
- O
X2 O
- O
Cys O
- O
X22 NUMERIC
- O
Cys O
- O
X4 NUMERIC
- O
Cys O
presumptive RARE
zinc O
- O
finger O
motif O
. O

The O
UV O
absorption O
spectrum O
revealed O
a O
shoulder RARE
at O
250 O
nm O
, O
characteristic O
of O
CysS LASTCAP
- O
Cd O
( O
II O
) O
ligand O
- O
to O
- O
metal O
charge O
- O
transfer O
transitions RARE
, O
and O
the O
difference O
absorption O
coefficient O
after O
acidification O
( O
delta O
epsilon O
248 NUMERIC
, O
24 O
mM O
- O
1 O
cm O
- O
1 O
) O
indicated O
the O
presence O
of O
a O
Cd O
( O
Cys O
- O
S O
) O
4 O
center O
. O

Diacylglycerol RARE
kinase I-GENE
( O
DGK ALLCAPS
) O
attenuates O
levels O
of O
second O
messenger O
diacylglycerol RARE
in O
cells O
and O
produces O
another O
( O
putative O
) O
messenger O
, O
phosphatidic RARE
acid O
. O

Recently O
, O
we O
have O
reported O
the O
cloning O
of O
the O
germ O
cell O
- O
specific O
, O
nuclear O
orphan O
receptor O
germ I-GENE
cell I-GENE
nuclear I-GENE
factor I-GENE
( O
GCNF ALLCAPS
)/ O
RTR ALLCAPS
. O

Based O
on O
the O
sequence O
of O
the O
conRTRE LASTCAP
, O
we O
located O
a O
putative O
RTRE ALLCAPS
, O
referred O
to O
as O
P2 I-GENE
- I-GENE
RE ALLCAPS
, O
in O
the O
5 O
' O
promoter O
- O
flanking O
region O
of O
the O
mouse I-GENE
protamine RARE
2 I-GENE
gene I-GENE
, O
which O
is O
induced O
during O
the O
same O
stage O
of O
spermatogenesis RARE
as O
RTR ALLCAPS
. O

Here O
we O
report O
the O
purification O
of O
this O
larger O
form O
as O
an O
approximately O
320 NUMERIC
- O
kDa O
particle O
that O
contains O
mRNP3 NUMERIC
+ I-GENE
4 I-GENE
and O
nine O
additional O
polypeptides O
, O
including O
mRNA O
- O
binding O
polypeptides O
of O
34 O
and O
36 O
kDa O
and O
a O
doublet RARE
of O
110 O
/ O
105 O
kDa O
that O
proved O
to O
be O
nucleolin RARE
. O

Active RARE
complexes O
eluted RARE
at O
a O
higher O
molecular O
weight O
than O
inactive O
complexes O
, O
were O
relatively O
deficient O
in O
both O
p21 I-GENE
and O
p27 I-GENE
, O
and O
contained O
Cdk2 I-GENE
with O
increased O
threonine O
160 O
phosphorylation O
, O
consistent O
with O
a O
mechanism O
of O
activation O
of O
cyclin I-GENE
E I-GENE
- O
Cdk2 I-GENE
involving O
both O
reduced O
CDK I-GENE
inhibitor O
association O
and O
CDK I-GENE
- I-GENE
activating I-GENE
kinase I-GENE
- O
mediated O
phosphorylation O
of O
Cdk2 I-GENE
. O

Thirty O
Class O
I O
and O
Class O
II O
recessions RARE
in O
30 O
patients O
were O
treated O
with O
a O
modified O
subepithelial RARE
connective O
tissue O
graft O
procedure O
. O

The O
derivatives O
of O
the O
latter O
two O
cell O
lines O
showed O
increased O
expression O
of O
the O
p27Kip1 NUMERIC
protein I-GENE
and O
inhibition O
of O
cell O
growth O
. O

The O
perioperative RARE
mortality O
of O
all O
patients O
was O
1 O
. O
9 O
%, O
the O
mortality O
of O
patients O
older O
than O
70 O
years O
was O
4 O
. O
3 O
%. O

Chronic O
renal O
failure O
patients O
essentially O
die RARE
from O
cardiovascular O
causes O
, O
and O
the O
frequency O
of O
malignant O
disease O
responsible O
for O
death O
is O
estimated O
to O
be O
10 O
%. O

The O
new O
FIGO ALLCAPS
definition O
of O
cervical O
cancer O
stage O
IA O
: O
a O
critique RARE
. O

The O
effect O
of O
Vpu RARE
on O
class O
I O
biogenesis O
was O
analyzed O
in O
more O
detail O
using O
a O
Vpu RARE
- O
expressing O
recombinant O
vaccinia O
virus O
( O
VV ALLCAPS
). O

This O
study O
indicates O
that O
the O
phenotype O
of O
myofibrillar RARE
disarray RARE
seen O
in O
HCM ALLCAPS
patients O
which O
harbor O
either O
of O
these O
two O
mutations O
may O
not O
be O
directly O
due O
to O
the O
failure O
of O
the O
mutant I-GENE
myosin I-GENE
heavy I-GENE
chain I-GENE
protein I-GENE
to O
assemble RARE
and O
form O
normal O
sarcomeres RARE
, O
but O
may O
rather O
be O
a O
secondary O
effect O
possibly O
resulting O
from O
the O
chronic O
stress O
of O
decreased O
beta I-GENE
MHC I-GENE
function O
. O

Inductively RARE
coupled O
plasma O
atomic RARE
emission O
spectroscopy O
was O
employed O
to O
obtain O
the O
tissue O
silicon RARE
measurements O
. O

An O
egg O
protein O
, O
lysozyme I-GENE
, O
is O
a O
still O
unlabeled RARE
additive O
currently O
used O
in O
cheese RARE
preparation O
. O

A O
method O
for O
the O
simultaneous O
determination O
of O
de O
( O
N O
- O
methyl O
)- O
N O
- O
ethyl O
- O
8 O
, O
9 O
- O
anhydroerythromycin RARE
A O
6 O
, O
9 O
- O
hemiacetal RARE
( O
EM523 NUMERIC
, O
I O
) O
and O
its O
three O
metabolites O
in O
human O
plasma O
and O
urine O
has O
been O
developed O
using O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
with O
chemiluminescence RARE
( O
CL O
) O
detection O
. O

Similarly O
, O
the O
DNA O
- O
binding O
activity O
of O
activator I-GENE
protein I-GENE
1 I-GENE
( O
AP I-GENE
- I-GENE
1 I-GENE
) O
is O
modified O
by O
a O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
redox RARE
factor I-GENE
1 I-GENE
( O
Ref RARE
- I-GENE
1 I-GENE
), O
which O
is O
identical O
to O
a O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
AP I-GENE
endonuclease I-GENE
. O

Having RARE
an O
LRR ALLCAPS
domain I-GENE
and O
an O
SH3 I-GENE
- I-GENE
binding I-GENE
domain I-GENE
, O
Acan125 NUMERIC
and O
the O
C O
. O
elegans O
homologue O
define O
a O
novel O
family O
of O
bifunctional RARE
binding O
proteins O
. O

However O
, O
its O
participation O
in O
gagging RARE
induced O
by O
oropharyngeal RARE
irritation RARE
is O
unclear O
. O

The O
capacity O
to O
repair O
8 O
- O
OxoG LASTCAP
has O
been O
measured O
in O
cell O
- O
free O
extracts O
of O
wild O
- O
type O
and O
ogg1 NUMERIC
strains O
using O
a O
34mer NUMERIC
DNA O
fragment O
containing O
a O
single O
8 O
- O
OxoG LASTCAP
residue O
paired O
with O
a O
cytosine O
( O
8 O
- O
OxoG LASTCAP
/ O
C O
) O
as O
a O
substrate O
. O

Results O
from O
our O
and O
other O
laboratories O
have O
suggested O
that O
UCN ALLCAPS
- O
01 O
induces O
preferential O
G1 O
- O
phase O
accumulation O
in O
several O
human O
tumor O
cell O
lines O
tested O
. O

Northern O
and O
RT O
- O
PCR O
analysis O
of O
Ube3a NUMERIC
expression O
in O
mouse O
tissues O
from O
animals O
with O
segmental O
, O
paternal RARE
uniparental RARE
disomy RARE
failed O
to O
detect O
substantially O
reduced O
or O
absent O
expression O
compared O
to O
control O
animals O
, O
failing RARE
to O
provide O
any O
evidence O
for O
maternal O
- O
specific O
expression O
from O
this O
locus O
. O

Two O
predominant O
effects O
were O
noted O
: O
( O
i O
) O
the O
Xaa RARE
residue O
in O
the O
dual O
phosphorylation O
motif O
Thr O
- O
Xaa RARE
- O
Tyr O
as O
well O
as O
the O
length O
of O
L12 O
influence O
p38 I-GENE
substrate O
specificity O
, O
and O
( O
ii O
) O
the O
length O
of O
L12 O
plays O
a O
major O
role O
in O
controlling O
autophosphorylation O
. O

A O
novel O
, O
testis I-GENE
- I-GENE
specific I-GENE
mRNA I-GENE
transcript I-GENE
encoding O
an O
NH2 I-GENE
- I-GENE
terminal I-GENE
truncated I-GENE
nitric I-GENE
- I-GENE
oxide I-GENE
synthase I-GENE
. O
mRNA O
diversity O
represents O
a O
major O
theme RARE
of O
neuronal I-GENE
nitric I-GENE
- I-GENE
oxide I-GENE
synthase I-GENE
( O
nNOS LASTCAP
) O
gene O
expression O
in O
somatic O
cells O
/ O
tissues O
. O

Unlike O
the O
MAR ALLCAPS
- O
binding O
domain O
, O
the O
homeodomain I-GENE
when O
isolated O
binds O
poorly O
and O
with O
low O
specificity O
to O
DNA O
. O

Cotransfection O
of O
Ets I-GENE
- I-GENE
2 I-GENE
and O
p44 I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
expression O
vectors O
strongly O
potentiated RARE
HB I-GENE
- O
EGF I-GENE
promoter O
activation O
in O
response O
to O
deltaRaf RARE
- I-GENE
1 I-GENE
: O
ER I-GENE
. O

Cyclin I-GENE
D1 I-GENE
could O
not O
be O
displaced RARE
from O
cdk4 NUMERIC
in O
the O
resistant O
184A1L5R NUMERIC
cell O
lysates O
. O

The O
importance O
of O
posttranslational O
regulation O
of O
p15INK4B NUMERIC
by O
TGF I-GENE
- I-GENE
beta I-GENE
is O
underlined RARE
by O
the O
observation O
that O
in O
TGF I-GENE
- I-GENE
beta I-GENE
- O
resistant O
184A1L5R NUMERIC
, O
although O
the O
p15 NUMERIC
transcript I-GENE
increased O
, O
p15INK4B NUMERIC
protein I-GENE
was O
not O
stabilized O
and O
did O
not O
accumulate O
, O
and O
cyclin I-GENE
D1 I-GENE
- O
cdk RARE
association O
and O
kinase O
activation O
were O
not O
inhibited O
. O

The O
Rlm1 NUMERIC
protein I-GENE
, O
a O
member O
of O
the O
MADS I-GENE
box I-GENE
family I-GENE
of O
transcription O
factors O
, O
functions O
downstream O
of O
Mpk1 NUMERIC
in O
the O
pathway O
. O

To O
identify O
cis O
- O
acting O
elements O
that O
target O
c I-GENE
- I-GENE
myc I-GENE
mRNA I-GENE
for O
downregulation RARE
during O
myogenesis RARE
, O
we O
stably O
transfected O
C2C12 O
cells O
with O
mutant I-GENE
myc I-GENE
genes I-GENE
or O
chimeric O
genes O
in O
which O
various O
myc I-GENE
sequences I-GENE
were O
fused O
to O
the O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
gene I-GENE
or O
to O
the O
bacterial I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene O
. O

Furthermore O
, O
experiments O
with O
32D NUMERIC
temperature O
- O
sensitive O
p53 I-GENE
cells O
indicate O
that O
aberrant O
tal I-GENE
- I-GENE
1 I-GENE
expression O
at O
the O
permissive O
temperature O
does O
not O
exert O
a O
proliferative O
effect O
but O
causes O
p53 I-GENE
- O
mediated O
apoptosis O
, O
i O
. O
e O
., O
the O
tal I-GENE
- I-GENE
1 I-GENE
proliferative O
effect O
depends O
on O
the O
integrity O
of O
the O
cell O
cycle O
checkpoints RARE
of O
the O
host O
cell O
, O
as O
observed O
for O
c I-GENE
- I-GENE
myc I-GENE
and O
other O
oncogenes O
. O
tal I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
experiments O
indicate O
that O
ectopic O
tal I-GENE
- I-GENE
1 I-GENE
effects O
are O
mediated O
by O
both O
the O
DNA O
- O
binding O
and O
the O
heterodimerization O
domains O
, O
while O
the O
N I-GENE
- I-GENE
terminally I-GENE
truncated I-GENE
tal I-GENE
- I-GENE
1 I-GENE
variant I-GENE
( O
M3 NUMERIC
) O
expressed O
in O
T O
- O
ALL O
malignant O
cells O
mimics RARE
the O
effects O
of O
the O
wild O
- O
type O
protein O
. O

The O
likelihood O
that O
a O
common O
region O
of O
deletions O
would O
contain O
a O
tumor O
suppressor O
is O
strongly O
enhanced O
by O
coincidence RARE
of O
that O
region O
with O
a O
chromosome O
fragment O
suppressing RARE
tumorigenicity RARE
upon O
introduction O
in O
tumor O
cells O
. O

DNA O
- O
binding O
activity O
was O
not O
increased O
by O
the O
addition O
of O
forskolin O
to O
thecal RARE
or O
luteal O
cells O
. O

However O
, O
in O
some O
of O
them O
either O
pattern O
may O
predominate RARE
or O
be O
exclusively O
present O
. O

Upon O
induction O
of O
SOS ALLCAPS
, O
viability O
increased O
2 O
- O
6 O
- O
fold O
. O

In O
particular O
, O
Western O
, O
supershift O
, O
and O
promoter O
deletion O
analyses O
suggested O
a O
role O
for O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
beta I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
beta I-GENE
) O
binding O
site O
between O
- O
2010 NUMERIC
and O
- O
1954 NUMERIC
in O
regulating O
transcription O
of O
collagenase RARE
- I-GENE
1 I-GENE
in O
monocytic O
cells O
. O

11 O
- O
Aminoundecanoyl RARE
- O
SK ALLCAPS
- O
NH2 O
and O
11 O
- O
aminoundecanoyl RARE
- O
SH O
- O
NH2 O
establish O
that O
a O
simple O
alkyl RARE
backbone RARE
can O
maintain O
an O
appropriate O
distance O
between O
three O
elements O
critical O
for O
recognition O
by O
the O
fungal O
enzyme O
' O
s O
peptide O
- O
binding O
site O
: O
a O
simple O
omega O
- O
terminal O
amino O
group O
, O
a O
beta O
- O
hydroxyl RARE
, O
and O
an O
epsilon O
- O
amino O
group O
or O
an O
imidazole RARE
. O

The O
carboxyl O
- O
terminal O
CCCC ALLCAPS
module RARE
is O
structurally O
related O
to O
the O
DNA O
- O
binding O
domain O
of O
the O
erythroid I-GENE
transcription I-GENE
factor I-GENE
GATA I-GENE
- I-GENE
1 I-GENE
. O

Cdc2 I-GENE
co O
- O
precipitates RARE
with O
Pch1 NUMERIC
in O
S O
. O
pombe O
cell O
lysates O
, O
although O
Cdc2 I-GENE
may O
not O
be O
the O
major O
catalytic O
partner O
of O
a O
Pch1 NUMERIC
kinase I-GENE
in O
vivo O
. O

Little RARE
is O
known O
about O
the O
mechanism O
, O
but O
the O
availability O
of O
rapid O
facile RARE
assays O
for O
monitoring O
immunoglobulin I-GENE
hypermutation RARE
would O
greatly O
aid O
the O
development O
of O
culture O
systems O
for O
hypermutating RARE
B O
cells O
as O
well O
as O
the O
screening O
for O
individuals O
deficient O
in O
the O
process O
. O

Expression O
of O
the O
human I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
70 I-GENE
gene I-GENE
( O
hsp70 I-GENE
) O
is O
induced O
by O
various O
kinds RARE
of O
stress O
and O
by O
oncogenes O
. O

Of O
these O
proteins O
, O
five O
have O
previously O
been O
shown O
to O
be O
phosphorylated O
during O
mitosis O
( O
epithelial I-GENE
- I-GENE
microtubule I-GENE
associated I-GENE
protein I-GENE
- I-GENE
115 I-GENE
, O
Oct91 NUMERIC
, O
Elongation RARE
factor I-GENE
1gamma NUMERIC
, O
BRG1 NUMERIC
and O
Ribosomal RARE
protein I-GENE
L18A NUMERIC
), O
five O
are O
related O
to O
proteins O
postulated O
to O
have O
roles O
in O
mitosis O
( O
epithelial I-GENE
- I-GENE
microtubule I-GENE
associated I-GENE
protein I-GENE
- I-GENE
115 I-GENE
, O
Schizosaccharomyces I-GENE
pombe I-GENE
Cdc5 NUMERIC
, O
innercentrosome RARE
protein I-GENE
, O
BRG1 NUMERIC
and O
the O
RNA I-GENE
helicase I-GENE
WM6 NUMERIC
), O
and O
nine O
are O
related O
to O
transcription O
factors O
( O
BRG1 NUMERIC
, O
negative I-GENE
co I-GENE
- I-GENE
factor I-GENE
2alpha I-GENE
, O
Oct91 NUMERIC
, O
S O
. O
pombe O
Cdc5 NUMERIC
, O
HoxD1 NUMERIC
, O
Sox3 NUMERIC
, O
Vent2 NUMERIC
, O
and O
two O
isoforms O
of O
Xbr1b NUMERIC
). O

Thus O
, O
depending O
on O
their O
location O
, O
psoralen RARE
cross O
- O
links O
affected O
different O
steps O
in O
the O
initiation O
process O
. O

Activation O
of O
alpha I-GENE
4 I-GENE
beta I-GENE
1 I-GENE
with O
TS2 NUMERIC
/ I-GENE
16 I-GENE
inhibited O
the O
cytoplasmic O
protrusions RARE
and O
cell O
migration O
but O
did O
not O
affect O
the O
pattern O
of O
phosphorylation O
. O

Performance RARE
on O
two O
verbal RARE
measures O
- O
the O
National O
Adult O
Reading RARE
Test O
- O
Revised RARE
( O
NART ALLCAPS
- O
R O
) O
and O
the O
Vocabulary RARE
subtest RARE
from O
the O
Wechsler RARE
Adult O
Intelligence RARE
Scale O
- O
Revised RARE
( O
WAIS ALLCAPS
- O
R O
)- O
showed O
strong O
correlations O
with O
level O
of O
education O
. O

L O
- O
canavanine RARE
, O
a O
selective O
inhibitor O
of O
the O
inducible O
nitric I-GENE
oxide I-GENE
synthase I-GENE
, O
increases O
the O
mean O
systemic O
filling O
pressure O
, O
thereby O
improving RARE
venous O
return O
, O
under O
these O
conditions O
. O

RESULTS O
: O
Of O
the O
29 O
patients O
who O
received O
concurrent O
chemotherapy O
and O
G I-GENE
- I-GENE
CSF I-GENE
, O
ten O
( O
34 O
%; O
95 O
% O
confidence O
interval O
[ O
CI O
], O
17 O
. O
9 O
to O
54 O
. O
3 O
%) O
were O
believed O
to O
have O
clinically O
significant O
bleomycin RARE
toxicity O
. O

The O
different O
holoenzyme I-GENE
RNA I-GENE
polymerases I-GENE
generated O
upon O
reconstituting RARE
these O
mutants O
independently O
with O
core I-GENE
RNA I-GENE
polymerase I-GENE
( O
alpha2beta NUMERIC
beta O
') O
have O
shown O
reduced O
transcriptional O
activity O
in O
comparison O
to O
the O
enzyme O
containing O
wild I-GENE
- I-GENE
type I-GENE
sigma I-GENE
factor I-GENE
. O

These O
data O
are O
consistent O
with O
a O
model O
in O
which O
GATA I-GENE
- I-GENE
5 I-GENE
performs RARE
a O
unique O
temporally O
and O
spatially O
restricted O
function O
in O
the O
embryonic O
heart O
and O
lung O
. O

The O
exonic RARE
sequence O
encodes O
a O
protein O
of O
495 NUMERIC
amino O
acids O
that O
is O
nearly O
identical O
to O
the O
previously O
reported O
protein O
sequence O
of O
human I-GENE
GPT ALLCAPS
- I-GENE
1 I-GENE
. O

Here O
we O
characterize O
an O
S I-GENE
. I-GENE
cerevisiae I-GENE
Swi3 NUMERIC
homolog I-GENE
( O
Swh3 NUMERIC
) O
and O
present O
evidence O
that O
it O
associates O
in O
a O
complex O
with O
a O
Snf2 NUMERIC
homolog I-GENE
, O
Sthl RARE
. O

Shc I-GENE
stimulates O
Ras I-GENE
/ O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
through O
forming O
a O
complex O
with O
Grb2 I-GENE
at O
the O
phosphorylated O
tyrosine O
( O
Y O
) O
residue O
317 NUMERIC
. O

In O
contrast O
, O
Y239 NUMERIC
/ I-GENE
240F NUMERIC
Shc I-GENE
, O
but O
not O
Y317F NUMERIC
Shc I-GENE
, O
reduced O
the O
EGF I-GENE
- O
induced O
c I-GENE
- I-GENE
myc I-GENE
message O
. O

The O
Ras I-GENE
guanine I-GENE
nucleotide I-GENE
- I-GENE
binding I-GENE
protein I-GENE
functions O
as O
a O
molecular O
switch O
in O
signalling O
downstream O
of O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinases I-GENE
. O

We O
show O
that O
Rlm1 NUMERIC
and O
Smp1 NUMERIC
have O
MEF2 I-GENE
- O
related O
DNA O
- O
binding O
specificities RARE
: O
Rlm1 NUMERIC
binds O
with O
the O
same O
specificity O
as O
MEF2 I-GENE
, O
CTA ALLCAPS
( I-GENE
T I-GENE
/ I-GENE
A I-GENE
) I-GENE
4TAG NUMERIC
, O
while O
SMP1 NUMERIC
binds O
a O
more O
extended O
consensus O
sequence O
, O
ACTACTA ALLCAPS
( O
T O
/ O
A O
) O
4TAG NUMERIC
. O

Domains RARE
I O
and O
II O
of O
B I-GENE
" I-GENE
are O
buried RARE
upon O
assembly O
of O
the O
TFIIIB ALLCAPS
- I-GENE
DNA I-GENE
complex I-GENE
, O
as O
determined O
by O
protein O
footprinting O
. O

Domain RARE
switch O
experiments O
reveal O
that O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
proteins I-GENE
containing O
either O
the O
leucine O
zipper O
or O
the O
activation O
domain O
of O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
are O
unable O
to O
stimulate O
the O
2D5 NUMERIC
promoter I-GENE
yet O
are O
fully O
capable O
of O
transactivating O
an O
artificial O
promoter O
bearing O
a O
high O
- O
affinity O
C I-GENE
/ I-GENE
EBP I-GENE
site I-GENE
. O

The O
similar O
phenotypes O
of O
bur6 NUMERIC
and O
bur3 NUMERIC
( O
mot1 NUMERIC
) O
mutations O
suggest O
that O
Bur6p NUMERIC
and O
Mot1p NUMERIC
have O
related O
, O
but O
not O
identical O
, O
functions O
in O
modulating RARE
the O
activity O
of O
the O
general O
transcription O
machinery O
in O
vivo O
. O

PRH75 NUMERIC
, O
a O
new O
nucleus O
- O
localized O
member O
of O
the O
DEAD ALLCAPS
- I-GENE
box I-GENE
protein I-GENE
family I-GENE
from O
higher O
plants O
. O

These O
activities O
are O
all O
required O
for O
stimulation O
of O
cell O
growth O
by O
middle I-GENE
- I-GENE
T I-GENE
and O
activate O
members O
of O
the O
MAP I-GENE
kinase I-GENE
family I-GENE
. O

A O
role O
for O
the O
small I-GENE
GTPase I-GENE
Rac I-GENE
in O
polyomavirus RARE
middle I-GENE
- I-GENE
T I-GENE
antigen I-GENE
- O
mediated O
activation O
of O
the O
serum O
response O
element O
and O
in O
cell O
transformation O
. O

Time RARE
- O
activity O
curves O
from O
the O
gastric O
region O
of O
interest O
were O
used O
, O
after O
subjection RARE
to O
appropriate O
corrective RARE
procedures O
, O
to O
calculate RARE
the O
mean O
gastric O
transit O
time O
( O
MTT ALLCAPS
90 O
) O
and O
the O
fraction O
of O
the O
test O
meal O
retained O
in O
the O
stomach O
after O
90 O
min O
( O
F90 NUMERIC
). O

This O
study O
provides O
a O
direct O
demonstration RARE
of O
a O
role O
for O
G I-GENE
betagamma RARE
in O
mediating O
the O
agonist O
- O
stimulated O
translocation O
of O
GRK2 NUMERIC
and O
GRK3 NUMERIC
in O
an O
intact O
cellular O
system O
and O
demonstrates O
isoform O
specificity O
in O
the O
interaction O
of O
these O
components O
. O

Our O
results O
indicate O
that O
RA O
- O
mediated O
repression O
of O
the O
hMGP LASTCAP
gene I-GENE
is O
due O
to O
binding O
of O
liganded RARE
RAR I-GENE
/ O
RXR I-GENE
to O
a O
novel O
negative O
RA O
response O
element O
. O

Point RARE
mutations O
of O
the O
five O
tyrosine O
residues O
in O
the O
cytoplasmic O
domain O
of O
the O
receptor O
were O
subsequently O
used O
to O
confirm O
our O
conclusions O
. O

We O
describe O
a O
novel O
method O
using O
Saccharomyces O
cerevisiae O
for O
detecting O
protein O
- O
truncating RARE
mutations O
in O
any O
gene O
of O
interest O
. O

Hepatocellular RARE
injury O
during O
preservation O
of O
human O
livers RARE
with O
UW ALLCAPS
and O
HTK ALLCAPS
solution O
. O

The O
electromyographically RARE
recorded O
responses O
consisted O
of O
an O
early O
R1 O
response O
in O
the O
orbicularis RARE
oculi RARE
muscle O
ipsilateral O
to O
the O
side O
of O
stimulation O
, O
a O
bilateral O
late O
response O
( O
ipsilateral O
R2 O
and O
contralateral O
Rc RARE
) O
and O
a O
third O
, O
R3 NUMERIC
response O
, O
in O
the O
ipsilateral O
orbicularis RARE
oculi RARE
muscle O
. O

The O
prognosis O
of O
seven O
patients O
who O
received O
ABSCT ALLCAPS
was O
significantly O
better O
than O
that O
of O
13 O
patients O
who O
received O
conventional O
therapy O
alone O
. O

( O
1994 O
, O
Hum RARE
. O

The O
pigment RARE
intensity O
of O
both O
melanized RARE
colonies O
and O
appressoria RARE
of O
CAL ALLCAPS
transformants O
was O
weaker RARE
than O
that O
of O
the O
wild O
type O
. O

Malonate RARE
decarboxylation RARE
in O
Malonomonas RARE
rubra RARE
involves O
the O
formation O
of O
malonyl RARE
- I-GENE
S I-GENE
-[ I-GENE
acyl RARE
- I-GENE
carrier I-GENE
protein I-GENE
] I-GENE
from O
acetyl I-GENE
- I-GENE
S I-GENE
-[ I-GENE
acyl RARE
- I-GENE
carrier I-GENE
protein I-GENE
] I-GENE
and O
malonate RARE
, O
carboxyltransfer RARE
to O
a O
biotin RARE
protein I-GENE
and O
its O
decarboxylation RARE
that O
is O
coupled O
to O
delta O
mu O
Na O
+ O
generation O
. O

The O
Jem RARE
peptide O
sequence O
shows O
a O
' O
leucine O
- O
zipper O
' O
dimerisation RARE
motif O
with O
limited O
homology O
to O
Fos I-GENE
/ O
Jun I-GENE
and O
ATF I-GENE
/ O
CREB I-GENE
proteins O
and O
several O
putative O
phosphorylation O
sites O
. O

Here O
we O
report O
the O
cloning O
of O
the O
protein O
that O
binds O
to O
enhancer O
site O
III O
. O

Further O
support O
for O
a O
direct O
interaction O
of O
Tub4p NUMERIC
, O
Spc98p NUMERIC
and O
Spc97p NUMERIC
comes RARE
from O
the O
toxicity O
of O
strong O
SPC97 NUMERIC
overexpression O
which O
is O
suppressed O
by O
co O
- O
overexpression O
of O
TUB4 NUMERIC
or O
SPC98 NUMERIC
. O

Sequences RARE
needed O
for O
iron O
- O
regulated O
expression O
of O
sid1 NUMERIC
were O
localized O
to O
a O
306 NUMERIC
bp O
region O
mapping O
2 O
. O
3 O
and O
2 O
. O
6 O
kb O
upstream O
of O
the O
ATG O
. O

A O
genetic O
screen O
applied O
to O
mutants O
in O
the O
branch O
site O
region O
shows O
that O
all O
positions O
in O
the O
conserved O
TACTAAC ALLCAPS
sequence O
are O
important O
for O
intron O
recognition O
. O

Implication RARE
of O
PAF ALLCAPS
and O
acetylhydrolase RARE
( O
PAF ALLCAPS
- I-GENE
AH ALLCAPS
) O
activity O
in O
periodontal O
disease O
. O

Comparison O
of O
the O
p50 I-GENE
sequence I-GENE
to O
other O
cloned O
proteins O
revealed O
89 O
% O
homology O
with O
a O
glycosaminoglycan RARE
- O
binding O
protein O
and O
54 O
% O
homology O
with O
Drosophila I-GENE
cell I-GENE
cycle I-GENE
control I-GENE
protein I-GENE
( I-GENE
cdc RARE
) I-GENE
37 O
. O

A O
polypeptide O
encoded O
by O
the O
NTS ALLCAPS
16 O
open O
reading O
frame O
has O
sequence O
similarity O
to O
the O
catalytic O
domain O
of O
several O
receptor I-GENE
protein I-GENE
kinases I-GENE
from I-GENE
plants I-GENE
including O
the O
S I-GENE
- I-GENE
receptor I-GENE
kinases I-GENE
implicated O
in O
the O
rejection O
of O
self O
- O
pollen O
in O
Brassica RARE
species O
and O
the O
Pto RARE
gene I-GENE
product I-GENE
of I-GENE
tomato I-GENE
which O
confers O
resistance O
to O
a O
bacterial O
pathogen RARE
. O

The O
atp RARE
1 I-GENE
and O
atp RARE
2 I-GENE
types O
of O
cDNA O
sequences O
were O
the O
most O
redundant RARE
among O
the O
28 O
different O
isoperoxidases RARE
identified O
among O
about O
200 O
peroxidase I-GENE
encoding I-GENE
ESTs I-GENE
. O

Additional RARE
information O
including O
echocardiographic O
sequences O
, O
perioperative RARE
video RARE
sequences O
, O
x O
- O
ray O
analysis O
, O
angiograms RARE
, O
etc O
. O
is O
represented O
in O
the O
program O
. O

We O
report O
here O
that O
constitutively O
active O
Mek1 NUMERIC
could O
activate O
p96h2bk NUMERIC
in O
the O
absence O
of O
oncogenic I-GENE
Ras I-GENE
. O

In O
Schizosaccharomyces O
pombe O
, O
the O
activity O
of O
the O
M O
- O
phase O
- O
inducing O
Cdc2 I-GENE
/ O
Cdc13 NUMERIC
cyclin O
- O
dependent O
kinase O
is O
inhibited O
by O
Wee1 I-GENE
and O
Mik1 NUMERIC
tyrosine I-GENE
kinases I-GENE
, O
and O
activated O
by O
Cdc25 NUMERIC
and O
Pyp3 NUMERIC
tyrosine I-GENE
phosphatases I-GENE
. O

Glycemic RARE
response O
to O
malted RARE
, O
popped RARE
and O
roller RARE
dried RARE
wheat O
- O
legume RARE
based O
foods RARE
in O
normal O
subjects O
. O

4 O
. O
26 O
+/- O
1 O
. O
54 O
mmol O
/ O
l O
, O
P O
< O
0 O
. O
01 O
), O
and O
systolic O
BP O
responses O
to O
intravenous O
norepinephrine O
and O
angiotensin I-GENE
II I-GENE
were O
significantly O
higher O
on O
glibenclamide RARE
than O
on O
metformin RARE
( O
P O
< O
0 O
. O
02 O
and O
P O
< O
0 O
. O
05 O
, O
respectively O
). O

The O
sequencing O
of O
Stellate RARE
copies O
located O
along O
the O
discontinuous RARE
cluster O
revealed O
a O
complex O
pattern O
of O
diversification RARE
. O

The O
results O
indicate O
that O
DNA O
methylation O
, O
chromatin O
structure O
, O
and O
transactivation O
at O
an O
Sp1 I-GENE
site I-GENE
contribute O
to O
the O
highly O
restricted O
expression O
of O
this O
myelomonocytic RARE
lineage O
specific O
gene O
. O

In O
gel O
mobility O
shift O
assays O
, O
factors O
present O
in O
nuclear O
extracts O
derived O
from O
differentiated O
osteoblast RARE
bound O
to O
oligonucleotide O
probes O
containing O
the O
E O
- O
box O
1 O
and O
E O
- O
box O
2 O
elements O
. O

Laboratory O
exam RARE
: O
IDR ALLCAPS
of O
the O
tuberculin RARE
was O
high O
positive O
, O
chest O
radiography RARE
shows O
hilar RARE
bilateral O
calcifications RARE
, O
ORL ALLCAPS
exam RARE
shows O
a O
tumor O
at O
the O
foot O
of O
the O
epiglottis RARE
and O
anatomopathological RARE
exam RARE
shows O
low O
differentiated O
epidermoid RARE
carcinoma O
. O

Finally O
, O
we O
show O
that O
PhLP LASTCAP
complexes O
, O
at O
least O
partially O
, O
with O
Gbetagamma I-GENE
in O
vivo O
. O

CTF1alpha NUMERIC
, O
expressed O
in O
Escherichia O
coli O
, O
showed O
specific O
binding O
to O
the O
palindrome O
2 O
DNA O
fragment O
but O
not O
to O
palindrome O
1 O
or O
mutant O
palindrome O
2 O
DNA O
fragments O
, O
suggesting O
specific O
binding O
of O
CTF1alpha NUMERIC
to O
palindrome O
2 O
. O

Cyclin I-GENE
G2 I-GENE
is O
highly O
expressed O
in O
the O
immune O
system O
where O
immunologic O
tolerance O
subjects O
self O
- O
reactive O
lymphocytes O
to O
negative O
selection O
and O
clonal RARE
deletion O
via O
apoptosis O
. O

A O
sterol O
- O
regulated O
protease O
initiates RARE
release O
of O
the O
NH2 O
- O
terminal O
segments O
of O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
SREBPs RARE
) O
from O
cell O
membranes O
, O
thereby O
allowing O
them O
to O
enter RARE
the O
nucleus O
and O
to O
stimulate O
transcription O
of O
genes O
involved O
in O
the O
uptake O
and O
synthesis O
of O
cholesterol O
and O
fatty O
acids O
. O

Thus O
, O
the O
P O
. O
aeruginosa O
orfX LASTCAP
and O
vfr RARE
promoters I-GENE
are O
arranged O
in O
a O
back O
- O
to O
- O
back O
orientation O
rather O
than O
the O
face O
- O
to O
- O
face O
orientation O
of O
the O
dorf RARE
and O
crp RARE
promoters I-GENE
. O

Sequence O
analysis O
of O
cloned O
PCR O
products O
confirmed O
the O
presence O
of O
two O
different O
nifV LASTCAP
- I-GENE
like I-GENE
DNA I-GENE
fragments I-GENE
, O
which O
were O
subsequently O
used O
as O
nifV LASTCAP
- O
and O
leuA LASTCAP
- I-GENE
specific I-GENE
probes I-GENE
, O
respectively O
, O
to O
clone O
XbaI LASTCAP
fragments I-GENE
of O
2 O
. O
1 O
kbp O
( O
pOST4 NUMERIC
) O
and O
2 O
. O
6 O
kbp O
( O
pOST2 NUMERIC
). O

In O
contrast O
, O
the O
Anabaena RARE
strain O
7120 NUMERIC
leuA LASTCAP
gene O
did O
not O
complement O
the O
nifV LASTCAP
mutation I-GENE
of O
R229I NUMERIC
efficiently O
. O

( O
3 O
) O
This O
effect O
occurs O
without O
removing O
TRs RARE
from O
the O
TRE O
. O

Is O
leishmaniasis RARE
endemic RARE
on O
the O
island O
of O
Minorca RARE
( O
Spain RARE
)? RARE
A O
human O
visceral O
case O
after O
living O
13 O
years O
in O
Minorca RARE
. O

RESULTS O
: O
Surprisingly O
, O
PAF ALLCAPS
blockade O
increased O
mortality O
after O
trauma O
( O
5 O
of O
11 O
WEB ALLCAPS
- O
2086 NUMERIC
animals O
versus O
1 O
of O
9 O
vehicle O
animals O
; O
p O
= O
0 O
. O
15 O
) O
and O
depressed O
cardiac O
index O
and O
O2 O
delivery O
at O
72 O
hours O
( O
p O
< O
0 O
. O
05 O
). O

This O
finding O
is O
the O
first O
example O
of O
utilization O
of O
noncomplementary RARE
dinucleotide O
primer O
by O
an O
RNA I-GENE
polymerase I-GENE
. O

Pure RARE
T1 O
and O
dual O
- O
T1 O
images O
were O
visually RARE
evaluated O
for O
image O
quality O
( O
IQ ALLCAPS
) O
on O
a O
five O
- O
point O
scale O
( O
0 O
= O
unacceptable RARE
to O
4 O
= O
excellent O
). O

In O
a O
model O
of O
the O
ternary O
complex O
, O
the O
segment O
of O
NFAT I-GENE
nearest RARE
AP I-GENE
- I-GENE
1 I-GENE
is O
the O
Rel I-GENE
insert O
region O
( O
RIR ALLCAPS
), O
a O
feature O
that O
is O
notable RARE
for O
its O
hypervariability RARE
in O
size O
and O
in O
sequence O
amongst RARE
members O
of O
the O
Rel I-GENE
transcription I-GENE
factor I-GENE
family I-GENE
. O

We O
thus O
conclude O
that O
the O
NFAT I-GENE
RIR ALLCAPS
plays O
an O
essential O
dual O
role O
in O
DNA O
recognition O
and O
cooperative O
binding O
to O
AP I-GENE
- I-GENE
1 I-GENE
family I-GENE
transcription I-GENE
factors I-GENE
. O

Thus O
, O
the O
association O
of O
PS1 NUMERIC
fragments I-GENE
may O
be O
maintained O
during O
cycles O
of O
phosphorylation O
/ O
dephosphorylation RARE
of O
the O
PS1 NUMERIC
CTF ALLCAPS
. O

This O
conformer RARE
features O
a O
Type O
I O
beta O
- O
turn O
and O
has O
extensive O
hydrophobic O
contacts O
with O
the O
FKBP12 NUMERIC
binding O
surface O
. O

This O
protein O
can O
bind O
to O
a O
region O
of O
the O
promoter O
of O
an O
Arabidopsis I-GENE
light I-GENE
- I-GENE
harvesting RARE
chlorophyll RARE
a I-GENE
/ I-GENE
b I-GENE
protein I-GENE
gene I-GENE
, O
Lhcb1 NUMERIC
* I-GENE
3 I-GENE
, O
which O
is O
necessary O
for O
its O
regulation O
by O
phytochrome RARE
. O

A O
patient O
of O
Group O
B O
had O
severe O
athetoid RARE
CP O
with O
spasticity RARE
, O
being O
unable O
to O
right O
his O
trunk O
and O
neck O
. O

Dystonic RARE
movement O
of O
the O
left O
upper O
limb O
in O
a O
case O
of O
the O
right O
pontine RARE
hemorrhage O

It O
has O
repeatedly RARE
been O
shown O
that O
HCMV O
IE1 I-GENE
/ O
IE2 I-GENE
can O
independently O
transactivate O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
. O

TAR I-GENE
and O
Sp1 I-GENE
- O
independent O
transactivation O
of O
HIV I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
by O
the O
Tat I-GENE
protein I-GENE
in O
the O
presence O
of O
human O
cytomegalovirus O
IE1 I-GENE
/ O
IE2 I-GENE
. O

Respiratory RARE
chain O
enzyme O
activity O
was O
normal O
. O

Children O
' O
s O
temperament RARE
and O
maternal O
socialization RARE
at O
Time RARE
1 O
( O
n O
= O
103 NUMERIC
, O
aged O
2 O
- O
3 O
years O
) O
were O
considered O
predictors O
of O
future O
conscience RARE
, O
assessed O
using O
new O
observational RARE
and O
narrative RARE
measures O
. O

Cellular RARE
Csk I-GENE
was O
associated O
with O
several O
phosphoproteins RARE
, O
some O
of O
which O
were O
interacting O
with O
the O
Csk I-GENE
SH2 I-GENE
domain I-GENE
. O

Thus O
, O
our O
studies O
suggest O
that O
pV LASTCAP
- O
mediated O
activation O
of O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
activity O
is O
controlled O
by O
the O
nuclear O
translocation O
of O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
transcription I-GENE
factor I-GENE
, O
which O
is O
mediated O
by O
IkappaBalpha I-GENE
serine O
phosphorylation O
and O
degradation O
, O
but O
also O
by O
a O
still O
undefined RARE
NF I-GENE
- I-GENE
kappaB I-GENE
- O
independent O
pathway O
. O

One O
P1 O
genomic O
clone O
and O
six O
subsequent O
plasmid O
subclones RARE
were O
isolated O
and O
analyzed O
for O
the O
exon O
- O
intron O
organization O
of O
the O
Ctpct RARE
gene I-GENE
. O

FN I-GENE
- O
stimulated O
c I-GENE
- I-GENE
Src I-GENE
PTK ALLCAPS
activity O
was O
enhanced O
by O
wild O
type O
FAK I-GENE
expression O
, O
whereas O
FN I-GENE
- O
stimulated O
activation O
of O
ERK2 I-GENE
was O
blocked O
by O
expression O
of O
the O
c I-GENE
- I-GENE
Src I-GENE
binding I-GENE
site I-GENE
Phe I-GENE
- I-GENE
397 NUMERIC
mutant I-GENE
of O
FAK I-GENE
. O

A O
promising RARE
new O
cement RARE
, O
4 O
- O
META ALLCAPS
/ O
MMA ALLCAPS
- O
TBB ALLCAPS
opaque RARE
resin O
, O
has O
shown O
remarkable O
adhesive O
properties O
as O
a O
bone O
cement RARE
in O
vivo O
. O

Congruent RARE
with O
empirical RARE
predictions O
, O
the O
most O
homesick RARE
children O
perceived O
low O
control O
over O
homesickness RARE
and O
separation O
, O
and O
coped RARE
by O
relinquishing RARE
control O
. O

Each O
sample O
was O
analysed O
as O
soon RARE
as O
possible O
, O
and O
repeated O
15 O
, O
30 O
, O
60 O
and O
120 O
min O
after O
sampling O
. O

We O
also O
review O
the O
role O
of O
grains RARE
in O
the O
formation O
of O
complex O
molecules O
in O
interstellar RARE
molecular O
clouds RARE
. O

Like O
the O
elicitors RARE
of O
the O
hypersensitive O
reaction O
( O
HR O
) O
produced O
by O
E O
. O
chrysanthemi RARE
( O
HarpinEch RARE
) O
and O
E O
. O
amylovora RARE
( O
HarpinEa RARE
), O
the O
deduced O
36 O
- O
kDa O
protein O
does O
not O
possess O
a O
typical O
signal O
sequence O
, O
but O
it O
contains O
a O
putative O
membrane O
- O
spanning O
domain O
. O

Molecular O
characterization O
and O
expression O
of O
the O
Erwinia RARE
carotovora RARE
hrpNEcc RARE
gene I-GENE
, O
which O
encodes O
an O
elicitor RARE
of O
the O
hypersensitive O
reaction O
. O

The O
mRNA O
from O
this O
gene O
, O
termed O
HES1 NUMERIC
, O
is O
ubiquitously O
expressed O
, O
but O
strongly O
so O
in O
heart O
and O
skeletal O
muscle O
. O

Anesthesia RARE
was O
maintained O
with O
isoflurane O
( O
ISO ALLCAPS
)/ O
N2O O
/ O
O2 O
inhalation O
. O

They O
observed O
depressed O
protein I-GENE
C I-GENE
activity O
that O
significantly O
( O
p O
< O
0 O
. O
005 O
) O
increased O
and O
became O
normal O
immediately O
after O
hemodialysis O
while O
factor I-GENE
X I-GENE
and O
factor I-GENE
VII I-GENE
increased O
( O
p O
< O
0 O
. O
01 O
; O
p O
< O
0 O
. O
05 O
) O
despite O
heparinization RARE
together O
with O
amount O
of O
serum O
lipoprotein O
( O
a O
). O

We O
present O
a O
case O
of O
type O
II O
hyperbetalipoproteinemia RARE
in O
a O
patient O
whose O
diagnosis O
had O
been O
previously O
unrecognized RARE
, O
and O
who O
had O
previously O
been O
misdiagnosed RARE
with O
rheumatoid O
arthritis O
and O
later O
gout RARE
. O

These O
data O
provide O
evidence O
that O
the O
2 I-GENE
. I-GENE
0 I-GENE
- I-GENE
kb I-GENE
LAT ALLCAPS
is O
an O
intron O
of O
the O
mLAT LASTCAP
pre I-GENE
- I-GENE
mRNA I-GENE
with O
a O
unique O
branch O
point O
. O

The O
altered O
amino O
acid O
residues O
of O
the O
seven O
mutant I-GENE
9ORF1 NUMERIC
polypeptides I-GENE
clustered O
within O
three O
separate O
regions O
referred O
to O
as O
region O
I O
( O
residues O
34 O
to O
41 O
), O
region O
II O
( O
residues O
89 O
to O
91 O
), O
and O
C O
- O
terminal O
region O
III O
( O
residues O
122 O
to O
125 O
). O

Rep I-GENE
- O
Rep I-GENE
protein O
interaction O
was O
confirmed O
in O
vitro O
through O
coimmunoprecipitation RARE
experiments O
with O
a O
bacterially O
expressed O
maltose RARE
- I-GENE
binding I-GENE
protein I-GENE
- O
Rep78 NUMERIC
fusion O
protein O
in O
combination O
with O
[ O
35S O
] O
methionine O
- O
labeled O
Rep78 NUMERIC
synthesized O
in O
a O
coupled O
in O
vitro O
transcription O
- O
translation O
system O
. O

The O
C O
- O
LIP ALLCAPS
also O
was O
compared O
with O
transcather RARE
arterial O
embolization RARE
( O
TAE ALLCAPS
; O
C O
- O
LIP ALLCAPS
followed O
by O
gelatin RARE
sponge RARE
) O
and O
percutaneous RARE
ethanol O
injection O
therapy O
( O
PEIT ALLCAPS
). O

Fourteen RARE
patients O
with O
New O
York O
Heart RARE
Association O
class O
II O
congestive RARE
heart O
failure O
were O
enrolled O
in O
a O
double O
- O
blind O
, O
cross O
- O
over O
study O
. O

The O
main O
advantages O
of O
Multi RARE
- O
MUP ALLCAPS
analysis O
are O
: O
( O
1 O
) O
quick RARE
acquisition O
of O
many O
MUPs RARE
; O
( O
2 O
) O
simultaneous O
collection O
of O
several O
MUPs RARE
at O
one O
recording O
site O
; O
( O
3 O
) O
possibility O
to O
analyze O
not O
only O
low O
threshold O
MUPs RARE
; O
( O
4 O
) O
less O
bias RARE
in O
the O
selection O
of O
MUPs RARE
and O
( O
5 O
) O
the O
reproducibility O
of O
the O
results O
that O
allow O
the O
same O
reference O
values O
to O
be O
used O
in O
different O
laboratories O
. O

We O
also O
demonstrate O
that O
preformed RARE
triplexes RARE
are O
quite O
stable O
when O
precipitated O
with O
ethanol O
and O
resuspended RARE
in O
water O
. O

Transfection O
experiments O
using O
preformed RARE
triplexes RARE
with O
a O
reporter O
plasmid O
containing O
the O
collagen I-GENE
promoter I-GENE
sequence I-GENE
showed O
significant O
inhibition O
of O
transcription O
when O
compared O
with O
a O
control O
phosphorothioate RARE
ODN ALLCAPS
. O

Thus O
, O
an O
increase O
in O
plasma I-GENE
TBG ALLCAPS
and O
a O
shift O
from O
adrenal O
androgen O
and O
mineralocorticoid RARE
steroid O
secretion O
towards O
cortisol O
secretion O
may O
be O
endocrine O
markers O
for O
progression O
of O
the O
disease O
in O
patients O
with O
HIV O
- O
infection O
. O

In O
several O
studies O
the O
RDFS ALLCAPS
has O
shown O
evidence O
of O
reliability O
and O
validity O
. O

Latanoprost RARE
produces O
an O
additional O
reduction O
of O
intraocular RARE
pressure O
( O
IOP O
) O
when O
used O
in O
combination O
with O
timolol RARE
, O
pilocarpine RARE
, O
acetazolamide RARE
and O
dipivefrin RARE
. O

These O
results O
suggest O
that O
dietary O
safflower RARE
phospholipids O
may O
be O
a O
valuable O
ingredient RARE
to O
layers RARE
for O
reducing O
liver O
triglycerides O
and O
serum O
cholesterol O
without O
any O
adverse O
effects O
. O

Using O
various O
techniques O
, O
we O
have O
undertaken O
a O
systematic O
analysis O
of O
the O
natural O
TATA O
- O
less O
human I-GENE
DNA I-GENE
polymerase I-GENE
beta I-GENE
( O
beta I-GENE
- I-GENE
pol I-GENE
) O
gene O
promoter O
. O

Saturable RARE
spermidine RARE
transport O
in O
stk2 NUMERIC
:: O
lacZ I-GENE
mutants I-GENE
had O
an O
approximately O
fivefold RARE
- O
lower O
affinity O
and O
twofold O
- O
lower O
Vmax O
than O
in O
the O
parental O
strain O
. O

Transient O
overexpression O
of O
c I-GENE
- I-GENE
Jun I-GENE
induced O
tenascin RARE
- I-GENE
C I-GENE
expression O
in O
primary O
REF ALLCAPS
and O
in O
FR3T3 NUMERIC
, O
an O
established O
fibroblast O
cell O
line O
. O

Inhibition O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
by O
cyclic O
AMP O
agonists O
causes O
apoptosis O
of O
v I-GENE
- I-GENE
abl I-GENE
- O
transformed O
cells O
. O

Previous O
studies O
have O
indicated O
that O
a O
hamster O
cell O
line O
( O
ts13 NUMERIC
) O
with O
a O
point O
mutation O
in O
the O
TAF I-GENE
( I-GENE
II I-GENE
) I-GENE
250 I-GENE
/ O
CCG1 NUMERIC
( O
TAF I-GENE
( I-GENE
II I-GENE
) I-GENE
250 I-GENE
) O
gene O
shows O
temperature O
- O
sensitive O
expression O
of O
a O
subset O
of O
genes O
and O
arrests RARE
in O
late O
G1 O
at O
39 O
. O
5 O
degrees O
C O
. O

We O
show O
here O
that O
the O
protein O
kinase O
MEKK1 NUMERIC
can O
induce O
reporter O
gene O
expression O
from O
the O
atrial I-GENE
natriuretic RARE
factor I-GENE
( O
ANF ALLCAPS
) O
promoter O
, O
a O
genetic O
marker O
that O
is O
activated O
during O
in O
vivo O
hypertrophy O
. O

Overexpression O
of O
EFG1 NUMERIC
in O
C O
. O
albicans O
leads O
to O
enhanced O
filamentous O
growth O
in O
the O
form O
of O
extended O
pseudohyphae RARE
in O
liquid O
and O
on O
solid O
media O
. O

Selected RARE
parameters O
: O
heart O
rate O
( O
HR O
), O
arterial O
blood O
pressure O
( O
ABP ALLCAPS
) O
and O
arterial O
O2 O
saturation O
( O
SaO2 O
) O
monitored O
by O
pulsoximetry RARE
were O
measured O
during O
the O
procedure O
. O

To O
determine O
if O
signing RARE
, O
when O
established O
, O
would O
compete O
with O
SIB ALLCAPS
when O
both O
were O
reinforced O
, O
extinction RARE
was O
then O
withdrawn RARE
. O

The O
husband RARE
in O
one O
of O
the O
married RARE
couples RARE
was O
treated O
for O
hepatitis O
of O
unidentified O
etiology O
in O
an O
Infectology RARE
Department RARE
four O
years O
ago RARE
. O

Both O
quantitative O
and O
qualitative O
analysis O
of O
individual O
cytoarchitectonic RARE
peculiarities RARE
of O
Meynart RARE
' O
s O
nucleus O
as O
well O
as O
of O
external O
part O
of O
dorsomedial RARE
nucleus O
of O
thalamus RARE
was O
performed O
in O
mentally RARE
normal O
individuals O
. O

We O
have O
tested O
this O
proposal RARE
by O
carrying O
out O
circular O
dichroism RARE
( O
CD O
) O
and O
NMR O
experiments O
on O
the O
Skn RARE
domain I-GENE
and O
five O
truncated O
proteins O
. O

Positional RARE
cloning O
has O
already O
produced O
the O
sequences O
of O
more O
than O
70 O
human O
genes O
associated O
with O
specific O
diseases O
. O

Genes RARE
for O
ocs RARE
element I-GENE
binding I-GENE
factors I-GENE
( O
OBFs RARE
), O
belonging O
to O
a O
specific O
class O
of O
basic I-GENE
- I-GENE
region I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
bZIP I-GENE
) I-GENE
transcription I-GENE
factors I-GENE
, O
have O
been O
isolated O
in O
a O
number O
of O
plants O
. O

The O
30 O
- O
day O
mortality O
in O
the O
CPB O
group O
and O
the O
non O
- O
CPB O
group O
were O
20 O
% O
and O
4 O
. O
6 O
%, O
respectively O
which O
was O
not O
statistically O
significant O
( O
p O
= O
0 O
. O
06 O
). O

As O
opposed O
to O
in O
vitro O
co O
- O
precipitation O
studies O
, O
the O
yeast O
two O
- O
hybrid O
screen O
reveals O
in O
vivo O
protein O
- O
protein O
interactions O
. O

This O
association O
appears O
to O
be O
mediated O
by O
Src I-GENE
- O
SH2 I-GENE
domain O
, O
because O
PECAM ALLCAPS
- I-GENE
1 I-GENE
can O
be O
precipitated O
by O
a O
GST I-GENE
- O
Src I-GENE
- O
SH2 I-GENE
affinity O
matrix O
. O

MKK3 NUMERIC
autophosphorylation O
and O
activation O
of O
p38 I-GENE
was O
also O
observed O
following O
coexpression O
of O
MKK3 NUMERIC
with O
MEKK3 NUMERIC
, O
but O
not O
with O
MEKK2 NUMERIC
. O

An O
alternatively O
spliced O
MAdCAM LASTCAP
- I-GENE
1 I-GENE
variant O
was O
identified O
that O
lacks O
exon O
4 O
encoding O
the O
mucin RARE
domain O
, O
and O
may O
mediate O
leukocyte O
adhesion O
to O
LPAM ALLCAPS
- I-GENE
1 I-GENE
without O
adhesion O
to O
the O
alternate O
receptor O
, O
L I-GENE
- I-GENE
selectin I-GENE
. O

In O
summary O
, O
the O
data O
establish O
that O
the O
previously O
reported O
human I-GENE
MAdCAM LASTCAP
- I-GENE
1 I-GENE
cDNA I-GENE
does O
indeed O
encode O
the O
human O
homologue O
of O
mouse I-GENE
MAdCAM LASTCAP
- I-GENE
1 I-GENE
, O
despite O
gross O
dissimilarities RARE
in O
the O
MAdCAM LASTCAP
- I-GENE
1 I-GENE
C O
- O
terminal O
structures O
. O

We O
have O
used O
a O
site O
- O
directed O
mutagenesis O
approach O
to O
examine O
how O
the O
Xaa RARE
and O
hydroxy O
( O
Ser O
/ O
Thr O
) O
amino O
acid O
residues O
in O
sequons RARE
influence O
core O
- O
glycosylation O
efficiency O
. O

MATERIAL ALLCAPS
AND O
METHODS O
: O
The O
authors O
analyzed O
41 O
persons O
formerly RARE
submitted O
to O
surgery O
( O
after O
8 O
years O
and O
4 O
months O
, O
as O
a O
mean O
), O
31 O
to O
highly O
selective O
vagotomy O
, O
and O
10 O
to O
truncal RARE
or O
selective O
vagotomy O
plus O
gastroduodenal RARE
drainage O
. O

This O
region O
does O
not O
contain O
an O
identifiable RARE
TATA O
element O
, O
indicating O
that O
transcription O
of O
the O
glutaminase RARE
gene I-GENE
is O
driven O
by O
a O
TATA O
- O
less O
promoter O
. O

SRE O
activity O
is O
dependent O
upon O
the O
activation O
by O
phosphorylation O
of O
a O
ternary O
complex O
factor O
; O
included O
among O
the O
ternary O
complex O
factors O
is O
Elk I-GENE
- I-GENE
1 I-GENE
. O

Serum I-GENE
alkaline I-GENE
phosphatase I-GENE
activity O
, O
bone O
mass O
measurements O
, O
dual O
energy O
x O
- O
ray O
absortiometric RARE
analysis O
of O
mineral O
density O
, O
and O
mechanical O
testing O
values O
in O
vertebrae RARE
and O
femora RARE
of O
the O
- O
D O
Sal RARE
animals O
did O
not O
significantly O
differ O
from O
those O
in O
+ O
D O
Sal RARE
animals O
. O

The O
monkey I-GENE
LHR I-GENE
cDNA I-GENE
displayed O
83 O
- O
94 O
% O
overall O
sequence O
homology O
with O
the O
other O
mammalian I-GENE
LHR I-GENE
cDNAs I-GENE
. O

In O
conclusion O
, O
marmoset RARE
monkey I-GENE
LHR I-GENE
seems O
to O
lack O
the O
sequence O
corresponding O
to O
exon O
10 O
of O
the O
LHR I-GENE
gene I-GENE
in O
other O
mammalian O
species O
. O

In O
unc RARE
- I-GENE
4 I-GENE
mutants I-GENE
, O
VA O
motor O
neurons O
assume RARE
the O
pattern O
of O
synaptic O
input O
normally O
reserved RARE
for O
their O
lineal RARE
sister RARE
cells O
, O
the O
VB ALLCAPS
motor O
neurons O
; O
the O
loss O
of O
normal O
input O
to O
the O
VAs RARE
produces O
a O
distinctive O
backward RARE
movement O
defect O
. O

Intracavitary RARE
irradiation O
was O
carried O
out O
with O
a O
microSelectron RARE
HDR ALLCAPS
afterloading RARE
device O
and O
usually O
22 O
. O
5 O
Gy O
was O
given O
in O
three O
fractions O
repeated O
weekly O
. O

No O
patient O
in O
group O
2 O
developed O
HAT ALLCAPS
( O
P O
= O
0 O
. O
006 NUMERIC
versus O
group O
1 O
). O

Sequence O
comparison O
of O
the O
0 O
. O
38 O
kb O
promoter O
sequence O
with O
the O
promoters O
of O
the O
Sm RARE
- I-GENE
E I-GENE
gene O
and O
U1 I-GENE
snRNA I-GENE
genes I-GENE
revealed O
several O
homologous O
motifs O
, O
suggesting O
that O
genes O
encoding O
the O
snRNP O
components O
may O
be O
coordinately RARE
regulated O
. O

METHODS O
: O
The O
responses O
of O
a O
31 O
- O
year O
- O
old O
woman O
with O
complex O
regional O
pain O
syndrome O
type O
I O
( O
reflex O
sympathetic O
dystrophy O
) O
to O
a O
thermal O
grill RARE
were O
evaluated O
before O
and O
after O
stellate RARE
ganglion RARE
block O
. O

More O
recently O
, O
however O
, O
a O
number O
of O
developments RARE
such O
as O
the O
successful O
use O
of O
the O
inhaled O
steroid O
budesonide RARE
and O
oral O
dexamethasone O
have O
reinforced O
the O
argument RARE
for O
using O
steroids O
. O

A O
xylE LASTCAP
transcriptional I-GENE
fusion I-GENE
to O
the O
putative O
mxbD LASTCAP
promoter I-GENE
showed O
low O
- O
level O
expression O
in O
wild O
- O
type O
cells O
grown O
on O
one O
- O
carbon O
( O
C1 O
) O
compounds O
and O
no O
detectable O
expression O
in O
cells O
grown O
on O
succinate RARE
. O

In O
AcMNPV LASTCAP
- O
infected O
Sf9 O
cells O
, O
late O
transcription O
initiation O
is O
detected O
from O
only O
two O
upstream O
TAAG ALLCAPS
sites O
and O
not O
from O
three O
downstream O
TAAG ALLCAPS
sites O
. O

Mutation O
of O
nucleotides O
adjacent O
to O
the O
AP I-GENE
- I-GENE
1 I-GENE
cis I-GENE
- I-GENE
response I-GENE
elements I-GENE
had O
no O
effect O
on O
trans O
- O
activation O
. O

The O
close O
proximity RARE
of O
the O
two O
neuropeptide RARE
Y I-GENE
receptor I-GENE
genes I-GENE
suggests O
that O
they O
have O
evolved O
from O
a O
gene O
duplication O
event O
with O
the O
small O
intron O
interrupting RARE
the O
coding O
sequence O
of O
the O
y1 NUMERIC
gene I-GENE
being O
converted O
into O
a O
functional O
sequence O
within O
the O
y5 NUMERIC
gene I-GENE
, O
while O
the O
reverse O
complementary O
sequence O
was O
utilized O
as O
an O
alternatively O
spliced O
5 O
' O
exon O
for O
the O
y1 NUMERIC
gene I-GENE
. O

The O
mammalian I-GENE
phosphoinositide RARE
3 I-GENE
- I-GENE
kinases I-GENE
( O
PI3Ks NUMERIC
) O
p110alpha NUMERIC
, I-GENE
beta I-GENE
, I-GENE
and I-GENE
delta I-GENE
form O
heterodimers O
with O
Src I-GENE
homology I-GENE
2 I-GENE
( O
SH2 I-GENE
) O
domain O
- O
containing O
adaptors RARE
such O
as O
p85alpha NUMERIC
or O
p55 I-GENE
( O
PIK ALLCAPS
). O

In O
the O
studies O
reported O
here O
, O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
gp130 NUMERIC
gene I-GENE
was O
isolated O
and O
the O
transcription O
initiation O
sites O
were O
mapped O
. O

Localization O
of O
the O
cytokine O
response O
element O
by O
5 O
'- O
deletion O
analysis O
and O
site O
- O
directed O
mutagenesis O
revealed O
a O
cis O
- O
acting O
binding O
site O
for O
activated O
STAT I-GENE
complexes O
. O

Insulin I-GENE
regulation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
( O
MEK I-GENE
), O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
and O
casein I-GENE
kinase I-GENE
in O
the O
cell O
nucleus O
: O
a O
possible O
role O
in O
the O
regulation O
of O
gene O
expression O
. O

Sequencing O
of O
the O
three O
pag RARE
- I-GENE
3 I-GENE
alleles I-GENE
showed O
that O
two O
apparent O
null O
alleles O
encode O
a O
nonsense O
mutation O
before O
the O
zinc O
fingers O
and O
a O
missense O
mutation O
in O
the O
fourth O
zinc O
finger O
that O
changes O
a O
coordinating RARE
histidine O
to O
a O
tyrosine O
. O

Pax I-GENE
- I-GENE
3 I-GENE
is O
a O
paired I-GENE
- I-GENE
type I-GENE
homeobox I-GENE
gene I-GENE
that O
is O
specifically O
expressed O
in O
the O
dorsal O
and O
posterior O
neural O
tube O
. O

Instead O
, O
they O
contained O
dendritic RARE
cells O
that O
express O
melanogenic RARE
marker O
proteins O
such O
as O
tyrosinase RARE
and O
tyrosinase RARE
- I-GENE
related I-GENE
protein I-GENE
1 I-GENE
. O

These O
mutations O
create O
stop O
codons O
in O
exon O
7 O
and O
8 O
, O
respectively O
, O
and O
probably O
result O
in O
truncated O
proteins O
lacking O
HLH ALLCAPS
- O
Zip O
or O
Zip O
structure O
. O

Here O
, O
a O
case O
of O
Sjogren RARE
' O
s O
syndrome O
is O
presented O
that O
was O
initially O
diagnosed O
because O
of O
dental O
complaints RARE
, O
and O
long O
- O
term O
treatment O
of O
Sjogren RARE
' O
s O
patients O
is O
discussed O
. O

Cloning O
and O
characterization O
of O
a O
cDNA O
encoding O
a O
bacteriophage I-GENE
- I-GENE
type I-GENE
RNA I-GENE
polymerase I-GENE
from O
the O
higher O
plant O
Chenopodium RARE
album RARE
. O

Similarly O
, O
overexpression O
of O
increasing O
concentration O
of O
COUP I-GENE
- I-GENE
TFI I-GENE
, O
but O
not O
COUP I-GENE
- I-GENE
TFI I-GENE
delta35 NUMERIC
, O
can O
squelch RARE
the O
silencing O
activity O
of O
the O
unliganded RARE
TRbeta RARE
. O

These O
six O
amino O
acids O
are O
part O
of O
an O
amphipathic RARE
helix O
that O
is O
highly O
conserved O
among O
nuclear I-GENE
hormone I-GENE
receptors I-GENE
and O
contains O
the O
core O
domain O
of O
the O
ligand O
- O
dependent O
transactivation O
function O
, O
AF O
- O
2 O
. O

Surprisingly O
, O
the O
RXR I-GENE
- O
specific O
ligand O
9 O
- O
cis O
- O
retinoic O
acid O
induced O
binding O
of O
SRC I-GENE
- I-GENE
1 I-GENE
to O
the O
RXR I-GENE
component I-GENE
of O
the O
TRE O
- O
bound O
heterodimer O
. O

In O
ciliates RARE
, O
both O
mechanisms O
are O
readily O
observed O
. O

Based O
on O
the O
occurrence O
of O
several O
transcription O
signals O
in O
the O
Thermus RARE
pyr RARE
promoter I-GENE
region I-GENE
and O
strong O
amino O
acid O
sequence O
identities O
( O
about O
60 O
%) O
between O
Thermus RARE
PyrR LASTCAP
and O
the O
PyrR LASTCAP
attenuation I-GENE
proteins I-GENE
of O
two O
Bacillus O
sp O
., O
we O
propose O
a O
regulatory O
mechanism O
involving O
transcriptional O
attenuation O
to O
control O
pyr RARE
gene I-GENE
expression O
in O
Thermus RARE
. O

Diver RARE
respiratory O
responses O
to O
a O
tunable RARE
closed O
- O
circuit O
breathing O
apparatus O
. O

Measurement O
of O
the O
time O
constant O
of O
VO2 O
and O
oxygen O
pulse O
during O
constant O
work O
rate O
exercise O
are O
useful O
for O
the O
objective O
evaluation O
of O
the O
training O
effect O
of O
patients O
with O
COPD O
. O

Characterization O
of O
CR1 NUMERIC
repeat O
random O
PCR O
markers O
for O
mapping O
the O
chicken O
genome O
. O

A O
reversed O
- O
phase O
high O
- O
performance O
liquid O
chromatographic O
( O
HPLC O
) O
method O
for O
the O
determination O
of O
cocaine O
metabolites O
produced O
in O
vitro O
by O
serum I-GENE
and I-GENE
liver I-GENE
esterases RARE
is O
described O
. O

Mutational O
studies O
provide O
evidence O
to O
this O
end O
and O
indicate O
that O
the O
side O
chains O
of O
subdomain O
4 O
. O
2 O
make O
specific O
contacts O
with O
the O
nucleotides O
at O
- O
35 O
. O

It O
is O
concluded O
that O
fludarabine RARE
is O
a O
highly O
useful O
agent O
in O
CLL ALLCAPS
. O

Three O
different O
techniques O
of O
EA ALLCAPS
analysis O
were O
used O
in O
the O
study O
: O
1 O
) O
fast O
Fourier RARE
transformation O
( O
FFT ALLCAPS
) O
of O
EA ALLCAPS
in O
a O
broad O
band O
, O
2 O
) O
developed O
by O
us O
alternative O
method O
of O
non O
- O
harmonic RARE
expansion O
of O
the O
EEG O
curves O
taking O
into O
account O
their O
shape O
, O
3 O
) O
factor O
analysis O
of O
the O
EA ALLCAPS
spectral O
densities RARE
. O

Concomitantly RARE
, O
p34CDC2 NUMERIC
histone I-GENE
H1 I-GENE
kinase O
activity O
increases O
in O
the O
former O
, O
but O
not O
in O
the O
latter O
cell O
lines O
, O
hence O
suggesting O
a O
role O
for O
this O
protein O
in O
radiation O
- O
induced O
cell O
death O
. O

Using O
PRL I-GENE
- I-GENE
R I-GENE
tagged O
both O
in O
the O
N O
- O
terminal O
or O
C O
- O
terminal O
regions O
of O
the O
mature O
receptor O
excludes RARE
the O
possibility O
of O
a O
cleaved O
fragment O
which O
could O
have O
been O
subsequently O
imported RARE
into O
the O
nucleus O
. O

Thus O
, O
the O
B O
- O
S O
mutant O
does O
not O
mimic O
efficiently O
the O
chloroplastic RARE
GAPDHs RARE
, O
and O
long O
- O
range O
and O
/ O
or O
second O
- O
layer O
effects O
, O
not O
easily O
predictable RARE
from O
visual O
inspection RARE
of O
three O
- O
dimensional O
structures O
, O
need O
to O
be O
taken O
into O
account O
for O
designing RARE
a O
true O
" O
chloroplastic RARE
- O
like O
" O
mutant O
of O
cytosolic I-GENE
GAPDH ALLCAPS
. O

Transcription O
of O
these O
genes O
was O
also O
elevated O
in O
gut O
and O
lung O
during O
freezing RARE
, O
but O
mRNA O
levels O
in O
these O
tissues O
were O
lower O
than O
in O
liver O
. O

Computer RARE
software RARE
assisted RARE
ordering RARE
( O
CSAO ALLCAPS
) O
was O
developed O
to O
integrate RARE
PN ALLCAPS
Ca O
: O
P O
solubility RARE
with O
clinical O
data O
to O
improve O
parenteral RARE
Ca O
and O
P O
administration O
. O

A O
similar O
chimera O
was O
assembled O
from O
the O
two O
halves RARE
of O
the O
molecule O
expressed O
separately O
in O
different O
bacteria O
and O
refolded RARE
together O
. O

The O
conditions O
for O
obtaining O
titanium RARE
dioxide O
from O
the O
substrates O
titanium RARE
tetrachloride RARE
and O
oxygen O
and O
applying O
this O
to O
a O
surgical O
stainless RARE
steel RARE
of O
the O
type O
316L NUMERIC
by O
the O
plasma O
assisted RARE
chemical O
vapour RARE
deposition O
method O
have O
been O
determined O
. O

All O
six O
genes O
were O
cloned O
and O
characterised RARE
. O

We O
analysed O
two O
regions O
involved O
in O
preS2 NUMERIC
/ O
S I-GENE
gene I-GENE
transcription O
of O
the O
HBV O
adw RARE
subtype O
: O
the O
diverged O
TATA O
box O
and O
a O
putative O
initiator O
element O
. O

Indeed O
the O
predicted O
folding O
of O
the O
5 O
' O
and O
3 O
'- O
untranslated O
regions O
revealed O
patterns O
of O
stem O
and O
loop O
structures O
conserved O
for O
all O
tick RARE
- O
borne RARE
flaviviruses RARE
suggesting O
a O
purifying RARE
selection O
for O
preservation O
of O
essential O
RNA O
secondary O
structures O
which O
could O
be O
involved O
in O
translational O
control O
and O
replication O
. O

EGF I-GENE
acts O
primarily O
by O
means O
of O
transactivation O
domain O
AF O
- O
1 O
, O
whereas O
cAMP O
acts O
via O
transactivation O
domain O
AF O
- O
2 O
of O
the O
ER I-GENE
. O

To O
determine O
which O
region O
of O
SulA LASTCAP
is O
essential O
for O
the O
inhibition O
of O
cell O
division O
, O
we O
constructed O
a O
series O
of O
N O
- O
terminal O
and O
C O
- O
terminal O
deletions O
of O
SulA LASTCAP
and O
a O
series O
of O
alanine O
substitution O
mutants O
. O

We O
have O
inactivated O
Krox I-GENE
- I-GENE
20 I-GENE
by O
homologous O
recombination O
in O
ES O
cells O
and O
demonstrated O
that O
the O
mutation O
leads O
to O
the O
deletion O
of O
r3 NUMERIC
and O
r5 NUMERIC
. O

Recently O
we O
have O
performed O
a O
detailed O
analysis O
of O
specific O
neuronal O
populations O
affected O
by O
the O
mutation O
which O
shed RARE
new O
light O
on O
the O
role O
of O
Krox I-GENE
- I-GENE
20 I-GENE
in O
the O
segmentation O
and O
on O
the O
physiological O
consequences O
of O
its O
inactivation O
. O

The O
most O
important O
one O
among O
them O
is O
Cyclosporin RARE
A O
, O
which O
is O
a O
selective O
immunosuppressive O
drug O
. O

Consistent O
with O
its O
role O
in O
p53 I-GENE
ubiquitination O
, O
mE6 NUMERIC
- I-GENE
AP I-GENE
was O
found O
both O
in O
the O
nucleus O
and O
cytosol O
, O
while O
Nedd RARE
- I-GENE
4 I-GENE
was O
found O
only O
in O
the O
cytosol O
. O

SPP ALLCAPS
also O
induced O
transient O
tyrosine O
phosphorylation O
of O
focal I-GENE
adhesion I-GENE
kinase I-GENE
( O
p125 NUMERIC
( O
FAK I-GENE
)), RARE
a O
cytosolic I-GENE
tyrosine I-GENE
kinase I-GENE
that O
localizes O
in O
focal O
adhesions O
, O
and O
of O
the O
cytoskeleton I-GENE
- I-GENE
associated I-GENE
protein I-GENE
paxillin I-GENE
. O

Using O
a O
conditional O
- O
lethal O
mutant O
allele O
of O
SUP45 NUMERIC
( O
sup45 NUMERIC
- I-GENE
2 I-GENE
) O
and O
a O
combination O
of O
in O
vivo O
and O
in O
vitro O
approaches O
, O
we O
demonstrate O
that O
the O
product O
of O
the O
SUP45 NUMERIC
gene I-GENE
( O
Sup45p NUMERIC
or O
eRF1 NUMERIC
) O
is O
a O
factor O
required O
for O
translation O
termination O
in O
yeast O
. O

Evaluation O
of O
myocardial O
perfusion O
by O
99mTc O
- O
tetrofosmin O
SPECT O
before O
and O
after O
emergent RARE
percutaneous RARE
transluminal RARE
coronary O
angioplasty RARE
for O
acute O
myocardial O
infarction O

A O
neonatal O
alloimmune RARE
thrombocytopenia O
with O
an O
HPA ALLCAPS
- I-GENE
3a NUMERIC
( O
Baka RARE
) O
incompatibility RARE
was O
confirmed O
. O

She RARE
was O
able O
to O
stand RARE
unaided RARE
by O
3 O
years O
of O
age O
with O
then O
progressive O
worsening RARE
of O
motor O
abilities O
. O

Merosin RARE
positive O
congenital O
muscular O
dystrophy O
with O
mental O
deficiency O
, O
epilepsy O
and O
MRI O
changes O
in O
the O
cerebral O
white O
matter O
. O

Most O
eukaryotic O
mRNAs O
are O
translated O
by O
a O
" O
scanning O
ribosome O
" O
mechanism O
. O

Comparison O
of O
Tc O
- O
99m O
sestamibi RARE
perfusion O
imaging O
and O
echocardiography O
using O
an O
arbutamine RARE
infusion O
for O
the O
detection O
of O
coronary O
artery O
disease O
. O

Also O
, O
transient O
overexpression O
of O
this O
protein O
in O
C2C12 O
cells O
reduced O
the O
transcription O
of O
a O
CAT I-GENE
- O
reporter O
regulated O
by O
an O
E12 I-GENE
/ O
MyoD I-GENE
driven O
enhancer O
. O

Five O
of O
these O
have O
ocular O
or O
oculocutaneous RARE
albinism RARE
. O

Comprising RARE
a O
126 O
- O
nucleotide O
5 O
' O
untranscribed RARE
genomic O
sequence O
and O
a O
466 NUMERIC
- O
nucleotide O
5 O
' O
noncoding O
cDNA O
sequence O
, O
the O
592 NUMERIC
- O
nucleotide O
5 O
' O
CpG O
island O
lacked O
TATA O
and O
CAAT O
boxes O
but O
displayed O
a O
high O
G O
+ O
C O
content O
, O
was O
enriched O
for O
CpG O
dinucleotides RARE
, O
and O
contained O
a O
potential O
Sp1 I-GENE
- I-GENE
binding I-GENE
site I-GENE
, O
i O
. O
e O
., O
features O
compatible O
with O
a O
housekeeping O
gene O
. O

SSeCKS LASTCAP
( O
pronounced O
essex RARE
) O
encodes O
a O
major O
protein I-GENE
kinase I-GENE
C I-GENE
substrate O
, O
the O
expression O
of O
which O
is O
down O
- O
regulated O
in O
src I-GENE
- O
and O
ras I-GENE
- O
transformed O
rodent O
fibroblasts O
but O
not O
in O
raf O
- O
transformed O
rodent O
fibroblasts O
( O
X O
. O

Type O
I O
position O
- O
vestibular O
- O
pause RARE
( O
PVP ALLCAPS
I O
) O
and O
vestibular O
- O
only O
( O
V O
I O
) O
neurons O
, O
as O
well O
as O
a O
smaller O
number O
of O
other O
type O
I O
and O
type O
II O
eye O
- O
plus O
- O
vestibular O
neurons O
were O
studied O
. O

The O
1 O
. O
1 O
- O
and O
1 O
. O
3 O
- O
kb O
mRNA O
species O
were O
found O
only O
in O
the O
heart O
, O
and O
the O
2 O
. O
6 O
- O
kb O
species O
was O
found O
in O
the O
heart O
, O
kidney O
and O
brain O
, O
but O
not O
in O
skeletal O
muscle O
or O
liver O
. O

Taurine RARE
deficiency O
significantly O
depressed O
the O
amplitude O
of O
OP1 NUMERIC
and O
OP4 NUMERIC
. O

We O
have O
found O
that O
mcs4 NUMERIC
- O
cells O
are O
defective O
at O
activation O
of O
Spc1 NUMERIC
in O
response O
to O
various O
forms O
of O
stress O
. O

The O
extended O
rat I-GENE
SP I-GENE
- I-GENE
A I-GENE
isoforms I-GENE
were O
enriched O
in O
the O
more O
fully O
glycosylated O
and O
multimeric RARE
SP I-GENE
- I-GENE
A I-GENE
species O
separated O
on O
SDS O
- O
PAGE O
gels O
. O

Alternative O
splicing O
of O
CDC25B NUMERIC
may O
therefore O
contribute O
to O
the O
control O
of O
cell O
proliferation O
. O

This O
investigation O
was O
undertaken O
to O
determine O
whether O
consuming RARE
several O
small O
feedings RARE
of O
preexercise RARE
carbohydrate O
( O
CHO O
), O
rather O
than O
a O
single O
bolus O
, O
would O
affect O
blood O
glucose O
and O
insulin I-GENE
responses O
during O
rest O
and O
exercise O
. O

The O
findings O
suggest O
that O
ERP ALLCAPS
effects O
of O
distinct O
memory O
processes O
are O
differentially O
influenced O
by O
the O
encoding O
instructions RARE
. O

This O
coat I-GENE
protein I-GENE
consists O
of O
Sar1p NUMERIC
, O
the O
Sec23p NUMERIC
protein I-GENE
complex I-GENE
containing O
Sec23p NUMERIC
and O
Sec24p NUMERIC
, O
and O
the O
Sec13p NUMERIC
protein I-GENE
complex I-GENE
containing O
Sec13p NUMERIC
and O
a O
novel O
150 I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
, I-GENE
p150 NUMERIC
. O

The O
second O
primary O
mutant O
contained O
a O
proline O
- O
to O
- O
leucine O
change O
at O
position O
243 NUMERIC
( O
P243L NUMERIC
). O

Induction O
of O
correctly O
spliced O
germline O
transcripts O
is O
necessary O
to O
target O
a O
switch O
region O
for O
recombination O
and O
switching O
. O

Thus O
, O
the O
PCE ALLCAPS
binds O
a O
Pbx RARE
dimer I-GENE
partner I-GENE
that O
behaves RARE
unlike O
Class I-GENE
I I-GENE
Hox I-GENE
proteins I-GENE
. O

Furthermore O
, O
the O
NH2 O
- O
terminal O
portion O
of O
the O
homologue O
was O
not O
translocated RARE
into O
the O
outer O
membrane O
without O
its O
COOH O
- O
terminal O
part O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA O
, O
CHEMR1 NUMERIC
, O
encoding O
a O
chemokine O
receptor O
with O
a O
homology O
to O
the O
human I-GENE
C I-GENE
- I-GENE
C I-GENE
chemokine I-GENE
receptor I-GENE
, O
CCR ALLCAPS
- I-GENE
4 I-GENE
. O

Organization O
of O
the O
human I-GENE
LU ALLCAPS
gene I-GENE
and O
molecular O
basis O
of O
the O
Lu RARE
( O
a O
)/ O
Lu RARE
( I-GENE
b I-GENE
) I-GENE
blood O
group O
polymorphism O
. O

Using O
mouse O
- O
human O
somatic O
hybrids O
and O
FISH ALLCAPS
analysis O
, O
the O
PE I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
localized O
to O
human O
chromosome O
19q13 NUMERIC
. O
2 O
, O
a O
region O
involved O
in O
translocations RARE
and O
deletions O
in O
leukemias O
and O
several O
solid O
tumors O
, O
suggesting O
that O
this O
novel O
ETS I-GENE
factor I-GENE
may O
play O
a O
role O
in O
carcinogenesis RARE
. O

Whereas O
the O
mutant O
enzymes O
terminate O
normally O
at O
the O
late O
terminator O
in O
T7 O
DNA O
( O
T O
( O
phi O
)) O
and O
rrnB LASTCAP
T2 O
, O
they O
fail O
to O
terminate O
at O
one O
of O
the O
termination O
sites O
of O
rrnB LASTCAP
T1 O
, O
and O
also O
fail O
to O
recognize O
the O
PTH I-GENE
and O
CJ ALLCAPS
signals O
. O

Cytological RARE
data O
suggest O
that O
the O
transgenes RARE
associate O
with O
a O
nucleolus RARE
. O

Light RARE
regulatory I-GENE
unit I-GENE
1 I-GENE
( O
LRU1 NUMERIC
) O
is O
necessary O
for O
and O
sufficient O
to O
mediate O
light O
- O
dependent O
activation O
of O
the O
chalcone RARE
synthase I-GENE
( I-GENE
CHS ALLCAPS
) I-GENE
minimal I-GENE
promoter I-GENE
in O
Petroselinum RARE
crispum RARE
. O

Sequence O
divergence O
is O
observed O
in O
untranslated O
regions O
which O
allows O
the O
definition O
of O
gene O
- O
specific O
probes O
. O

The O
active O
state O
is O
terminated RARE
by O
hydrolysis O
of O
bound O
GTP O
, O
producing O
inactive O
ARF I-GENE
- I-GENE
GDP I-GENE
. O

We O
suggest O
that O
apart O
from O
the O
World RARE
Summit RARE
for O
Children O
' O
s O
under O
- O
five O
mortality O
target O
for O
the O
year O
2000 O
, O
intraregional RARE
targets O
to O
reduce O
geographical RARE
inequalities RARE
in O
under O
- O
five O
mortality O
should O
be O
specified O
. O

The O
immunophilin RARE
, O
which O
can O
be O
of O
the O
FK506 O
- O
or O
cyclosporin O
A O
- O
binding O
class O
, O
binds O
to O
hsp90 I-GENE
via O
its O
tetratricopeptide RARE
repeat O
( O
TPR O
) O
domain O
, O
and O
different O
receptor O
heterocomplexes RARE
exist O
depending O
upon O
which O
immunophilin RARE
occupies RARE
the O
TPR O
- O
binding O
region O
of O
hsp90 I-GENE
. O

In O
adherent RARE
macrophages O
, O
absence O
of O
CD45 NUMERIC
led O
to O
the O
hyperphosphorylation RARE
and O
hyperactivation RARE
of O
p56 NUMERIC
/ I-GENE
59 I-GENE
( O
hck RARE
) O
and O
p53 I-GENE
/ I-GENE
56 I-GENE
( O
lyn RARE
), O
but O
not O
of O
p58 NUMERIC
( O
c I-GENE
- I-GENE
fgr RARE
). O

Secretion RARE
in O
milk O
and O
transplacental RARE
transfer O
of O
two O
iodized RARE
oils RARE
, O
Lipiodol RARE
UF ALLCAPS
and O
Oriodol RARE
, O
in O
rabbits O
. O

Sequencing O
of O
the O
facB LASTCAP
gene I-GENE
revealed O
that O
it O
encodes O
a O
protein O
that O
contains O
an O
N O
- O
terminal O
GAL4 I-GENE
- O
like O
Zn O
( O
II O
) O
2Cys6 NUMERIC
( O
or O
C6 O
zinc O
) O
binuclear RARE
cluster O
for O
DNA O
binding O
, O
leucine O
zipper O
- O
like O
heptad O
repeat O
motifs O
and O
central O
and O
C O
- O
terminal O
acidic O
alpha O
- O
helical O
regions O
, O
consistent O
with O
a O
function O
as O
a O
DNA O
- O
binding O
transcriptional O
activator O
. O

Overexpression O
of O
Sed5p NUMERIC
allowed O
growth O
in O
the O
absence O
of O
Vti1p NUMERIC
. O

The O
coding O
region O
of O
mkh1 NUMERIC
is O
contained O
within O
a O
single O
exon O
encoding O
a O
1 O
, O
116 NUMERIC
- O
amino O
- O
acid O
protein O
. O

Strikingly RARE
, O
stoichiometric RARE
association O
of O
p107 I-GENE
or O
p130 I-GENE
with O
either O
cyclin I-GENE
E I-GENE
- O
cdk2 I-GENE
or O
cyclin I-GENE
A I-GENE
- O
cdk2 I-GENE
negated RARE
the O
activities O
of O
these O
kinases O
. O

Furthermore O
, O
p150 NUMERIC
suppresses O
actin I-GENE
gelation RARE
, O
which O
is O
induced O
by O
smooth I-GENE
muscle I-GENE
alpha I-GENE
- I-GENE
actinin RARE
. O

Denaturation RARE
of O
the O
simian O
virus O
40 O
origin O
of O
replication O
mediated O
by O
human I-GENE
replication I-GENE
protein I-GENE
A I-GENE
. O

This O
effect O
was O
abolished O
once O
the O
EM O
motif O
in O
the O
promoter O
- O
reporter O
construct O
was O
mutated O
, O
thus O
suggesting O
that O
the O
synergistic O
transactivation O
function O
of O
the O
TEF I-GENE
- I-GENE
1 I-GENE
- O
Max I-GENE
heterotypic RARE
complex O
is O
mediated O
through O
binding O
of O
the O
complex O
to O
the O
EM O
motif O
. O

Interdigitated RARE
residues O
within O
a O
small O
region O
of O
VP16 I-GENE
interact O
with O
Oct I-GENE
- I-GENE
1 I-GENE
, O
HCF ALLCAPS
, O
and O
DNA O
. O

With O
a O
view O
to O
identifying O
other O
important O
U14 I-GENE
interactions O
, O
a O
stem O
- O
loop O
domain O
required O
for O
activity O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
U14 I-GENE
RNAs I-GENE
( O
the O
Y O
domain O
) O
was O
first O
subjected O
to O
detailed O
mutational O
analysis O
. O

Based O
on O
these O
results O
and O
because O
Cdc68 NUMERIC
has O
been O
implicated O
as O
a O
regulator O
of O
chromatin O
structure O
, O
we O
postulate RARE
that O
polymerase I-GENE
alpha I-GENE
may O
interact O
with O
these O
proteins O
to O
gain O
access O
to O
its O
template O
or O
to O
origins O
of O
replication O
in O
vivo O
. O

Even RARE
when O
the O
inoculum RARE
size O
was O
reduced O
sixfold RARE
( O
i O
. O
e O
., O
6 O
x O
10 O
( O
6 O
) O
CFU ALLCAPS
/ O
mouse O
), O
50 O
% O
of O
the O
RB6 NUMERIC
- I-GENE
8C5 NUMERIC
- O
treated O
animals O
died O
within O
6 O
days O
. O

In O
12 O
cases O
( O
3 O
. O
1 O
%), O
a O
change O
in O
stage O
resulted O
. O

Promoter O
recognition O
algorithms RARE
identified O
divergent O
promoter O
elements O
within O
the O
CpG O
island O
, O
which O
lies O
between O
the O
ATM ALLCAPS
and O
E14 NUMERIC
/ O
NPAT ALLCAPS
genes O
, O
and O
provide O
evidence O
for O
a O
putative O
second O
ATM ALLCAPS
promoter I-GENE
located O
within O
intron O
3 O
, O
immediately O
upstream O
of O
the O
first O
coding O
exon O
. O

Recombinant I-GENE
soluble I-GENE
pMCP LASTCAP
that O
lacked O
transmembrane O
and O
cytoplasmic O
domains O
had O
factor I-GENE
I I-GENE
cofactor I-GENE
activity O
in O
C3b NUMERIC
cleavage O
, O
indicating O
that O
it O
is O
functionally O
, O
as O
well O
as O
structurally O
homologous O
to O
MCP ALLCAPS
. O

Clinical O
and O
haematological RARE
signs O
are O
not O
specific O
in O
this O
setting O
, O
and O
the O
diagnosis O
relies RARE
on O
histological O
features O
, O
mainly O
bone O
marrow O
examination O
. O

Spatial RARE
zones RARE
for O
muscle O
coactivation RARE
and O
the O
control O
of O
postural RARE
stability O
. O

Liquid RARE
chromatographic O
separation O
was O
achieved O
on O
a O
Zorbax RARE
RX ALLCAPS
C8 NUMERIC
analytical RARE
column O
using O
gradient O
elution RARE
. O

The O
linear O
plasmid O
pDHL1 NUMERIC
from O
Debaryomyces RARE
hansenii RARE
encodes O
a O
protein O
highly O
homologous O
to O
the O
pGKL1 NUMERIC
- I-GENE
plasmid I-GENE
DNA I-GENE
polymerase I-GENE
. O

The O
RNA O
- O
binding O
and O
RNA I-GENE
- I-GENE
DNA I-GENE
helicase I-GENE
activities O
of O
the O
Escherichia I-GENE
coli I-GENE
transcription I-GENE
termination I-GENE
factor I-GENE
rho I-GENE
have O
been O
investigated O
using O
natural O
RNA O
molecules O
that O
are O
255 NUMERIC
and O
391 NUMERIC
nucleotide O
residues O
in O
length O
and O
that O
contain O
the O
trp RARE
t I-GENE
' I-GENE
rho I-GENE
- I-GENE
dependent I-GENE
termination I-GENE
sequence I-GENE
of O
E O
. O
coli O
. O

The O
p20 NUMERIC
- I-GENE
CGGBP ALLCAPS
gene I-GENE
is O
conserved O
among O
mammals O
but O
shows O
no O
homology O
to O
non O
- O
vertebrate O
species O
. O

The O
data O
suggest O
that O
like O
in O
yeast O
, O
in O
plants O
a O
certain O
subfamily O
of O
UBC ALLCAPS
is O
specifically O
involved O
in O
the O
proteolytic O
degradation O
of O
abnormal O
proteins O
as O
result O
of O
stress O
. O

The O
pWP LASTCAP
- I-GENE
19 I-GENE
also O
encodes O
the O
AAV O
inverted O
terminal O
repeats O
for O
integration O
and O
replication O
and O
the O
herpes O
virus O
thymidine I-GENE
kinase I-GENE
promoter O
- O
driven O
gene O
for O
neomycin O
resistance O
( O
neoR LASTCAP
). O

We O
have O
developed O
a O
rAAV LASTCAP
- O
mediated O
gene O
transfer O
system O
for O
the O
rat I-GENE
preproinsulin RARE
II I-GENE
gene I-GENE
. O

The O
serum O
levels O
of O
beta I-GENE
- I-GENE
human I-GENE
chorionic RARE
gonadotropin I-GENE
( O
HCG ALLCAPS
) O
and O
placental I-GENE
alkaline I-GENE
phosphatase I-GENE
( O
PLAP ALLCAPS
) O
were O
not O
elevated O
. O

A O
striking O
feature O
of O
the O
recombinant I-GENE
H19 I-GENE
allele I-GENE
is O
the O
occurrence O
of O
a O
parental O
imprint RARE
set O
on O
the O
neo I-GENE
replacement I-GENE
cassette I-GENE
. O

This O
indicates O
that O
recruitment O
of O
large I-GENE
T I-GENE
antigen I-GENE
to O
the O
rRNA O
promoter O
by O
SL1 NUMERIC
constitutes O
a O
crucial O
step O
in O
the O
activation O
process O
. O

In O
1990 O
, O
an O
International O
Commission RARE
for O
the O
Certification RARE
of O
Eradication RARE
of O
Poliomyelitis RARE
Eradication RARE
( O
ICCPE ALLCAPS
) O
was O
established O
by O
the O
Pan RARE
American O
Health O
Organization O
to O
eventually RARE
determine O
if O
transmission O
was O
interrupted O
. O

Functional O
and O
regulatory O
analysis O
of O
the O
two O
copies O
of O
the O
fixNOQP LASTCAP
operon I-GENE
of O
Rhizobium O
leguminosarum RARE
strain O
VF39 NUMERIC
. O

This O
study O
describes O
a O
new O
MADS I-GENE
box I-GENE
gene I-GENE
, O
nmhC5 NUMERIC
, O
which O
along O
with O
nmh7 NUMERIC
( O
J O
. O

Thus O
E14 NUMERIC
. O
1TG3B1 NUMERIC
is O
a O
useful O
ES O
cell O
line O
for O
modifying RARE
the O
mouse O
genome O
using O
the O
HPRT ALLCAPS
gene I-GENE
as O
a O
selection O
marker O
and O
for O
transmission O
at O
a O
high O
frequency O
into O
the O
mouse O
germ O
line O
. O

Lung O
and O
multi O
- O
system O
damage O
were O
early O
indicators O
of O
poor O
outcome O
in O
severe O
non O
- O
fatal O
disease O
. O

The O
results O
suggest O
that O
the O
bulbospinal RARE
micturition RARE
reflex O
evoked O
by O
bladder O
filling O
and O
L O
- O
dopa RARE
involves O
a O
descending RARE
pathway O
where O
transmission O
is O
partly O
mediated O
by O
spinal I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
adrenoceptors I-GENE
. O

OBJECTIVE O
: O
This O
study O
was O
designed O
to O
analyze O
the O
common O
cause O
of O
asthenopia RARE
, O
mixed O
astigmatism RARE
. O

Disturbance RARE
of O
regeneration O
in O
the O
above O
pathological O
condition O
results O
from O
the O
damage O
to O
tunica RARE
propria RARE
and O
loss O
of O
its O
function O
for O
the O
support O
of O
structural O
homeostasis RARE
. O

Sternocleidomastoid RARE
, O
neck O
or O
facial O
muscles O
wasting RARE
were O
also O
found O
in O
three O
cases O
. O

Identification O
of O
five O
new O
genes O
, O
closely O
related O
to O
the O
interleukin I-GENE
- I-GENE
1beta I-GENE
converting I-GENE
enzyme I-GENE
gene I-GENE
, O
that O
do O
not O
encode O
functional O
proteases O
. O

The O
C O
- O
terminal O
mature O
region O
is O
highly O
conserved O
in O
other O
serine I-GENE
carboxypeptidases RARE
. O

One O
RNA O
construct O
which O
consisted O
of O
112 O
nucleotides O
( O
nt O
) O
from O
nt O
639 NUMERIC
to O
nt O
750 O
formed O
a O
heterodimeric O
complex O
with O
the O
RNA O
which O
consisted O
of O
200 O
nucleotides O
from O
nt O
551 NUMERIC
to O
nt O
750 O
. O

Here O
we O
demonstrate O
that O
AML1a NUMERIC
, O
which O
solely O
has O
no O
effects O
as O
a O
transcriptional O
regulator O
, O
dominantly RARE
suppresses O
transcriptional O
activation O
by O
AML1b NUMERIC
, O
and O
that O
AML1a NUMERIC
exhibits O
the O
higher O
affinity O
for O
DNA O
- O
binding O
than O
AML1b NUMERIC
. O

However O
, O
we O
could O
not O
find O
the O
homologous O
regions O
with O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factors I-GENE
or O
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
in O
the O
c I-GENE
- I-GENE
cbl I-GENE
gene I-GENE
. O

However O
, O
using O
ATL ALLCAPS
- O
16T NUMERIC
nuclear O
extract O
, O
we O
demonstrated O
that O
GATA I-GENE
- I-GENE
4 I-GENE
is O
the O
only O
GATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
that O
forms O
specific O
DNA O
- O
protein O
complex O
with O
the O
- O
70 O
GATA O
site O
. O

The O
impact O
of O
social O
support O
on O
the O
relationships O
of O
gay RARE
male O
couples RARE
is O
examined O
. O

The O
ubiquitously O
expressed O
hypoxia I-GENE
- I-GENE
inducible I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
HIF I-GENE
- I-GENE
1 I-GENE
) O
is O
involved O
in O
expression O
of O
a O
large O
number O
of O
oxygen O
- O
regulated O
genes O
. O

Stromelysin RARE
- I-GENE
1 I-GENE
, O
matrix I-GENE
metalloproteinase RARE
- I-GENE
3 I-GENE
( O
MMP ALLCAPS
- I-GENE
3 I-GENE
), O
is O
an O
important O
endopeptidase RARE
selectively O
expressed O
by O
somatic O
cells O
in O
organ O
tissues O
. O

Tendon RARE
also O
shows O
a O
degree O
of O
extensibility RARE
. O

Surveillance RARE
for O
preeclampsia RARE
was O
conducted O
by O
personnel RARE
unaware RARE
of O
treatment O
- O
group O
assignments RARE
, O
using O
standardized O
measurements O
of O
blood O
pressure O
and O
urinary O
protein O
excretion O
at O
uniformly RARE
scheduled RARE
prenatal RARE
visits RARE
, O
protocols RARE
for O
monitoring O
these O
measurements O
during O
the O
hospitalization RARE
for O
delivery O
, O
and O
reviews RARE
of O
medical O
records O
of O
unscheduled RARE
outpatient RARE
visits RARE
and O
all O
hospitalizations RARE
. O

Aryl RARE
hydrocarbon I-GENE
receptor I-GENE
nuclear I-GENE
translocator RARE
( O
ARNT ALLCAPS
) O
is O
a O
component O
of O
the O
transcription O
factors O
, O
aryl RARE
hydrocarbon I-GENE
receptor I-GENE
( O
AhR LASTCAP
) O
and O
hypoxia I-GENE
- I-GENE
inducible I-GENE
factor I-GENE
1 I-GENE
, O
which O
transactivate O
their O
target O
genes O
, O
such O
as O
CYP1A1 NUMERIC
and O
erythropoietin I-GENE
, O
in O
response O
to O
xenobiotic RARE
aromatic O
hydrocarbons RARE
and O
to O
low O
O2 O
concentration O
, O
respectively O
. O

DNase I-GENE
I I-GENE
footprint O
analysis O
identified O
a O
protected O
region O
from O
- O
37 O
to O
- O
53 O
. O

We O
also O
provide O
evidence O
that O
gar2 NUMERIC
is O
phosphorylated O
in O
vitro O
by O
a O
p13 NUMERIC
( O
suc1 NUMERIC
)- O
Sepharose RARE
- O
bound O
kinase O
from O
Schizosaccharomyces O
pombe O
extracts O
that O
displays O
cell O
cycle O
- O
regulated O
activity O
similar O
to O
that O
of O
the O
p34 NUMERIC
( O
cdc2 I-GENE
( O
kinase O
. O

However O
, O
by O
immobilized RARE
metal O
affinity O
chromatography O
assay O
, O
self O
- O
association O
of O
PR I-GENE
- I-GENE
A I-GENE
was O
3 O
. O
5 O
- O
fold O
more O
efficient O
than O
that O
of O
either O
the O
DhLBD LASTCAP
or O
hLBD LASTCAP
constructs O
. O

The O
overall O
results O
of O
this O
paper O
are O
consistent O
with O
the O
conclusion O
that O
the O
carboxyl O
- O
terminal O
LBD ALLCAPS
is O
not O
sufficient O
for O
mediating O
PR I-GENE
dimerization O
and O
that O
multiple O
regions O
, O
including O
the O
hinge RARE
and O
amino O
- O
terminal O
sequences O
, O
contribute O
either O
directly O
or O
indirectly O
to O
homodimerization RARE
of O
PR I-GENE
. O

We O
isolated O
several O
overlapping O
A O
- O
phage O
and O
cosmid O
clones O
that O
cover RARE
more O
than O
100 O
kb O
of O
human O
DNA O
and O
contained O
the O
entire O
VDR I-GENE
gene I-GENE
. O

Colorectal RARE
carcinoma O
: O
therapeutic O
approach O
in O
patients O
already O
treated O
with O
metastasis O
resection O

Here O
, O
we O
correlate O
Dox RARE
effects O
on O
cell O
cycle O
with O
changes O
of O
E2F I-GENE
/ O
DP I-GENE
complexes O
and O
activity O
in O
differentiating O
C2C12 O
myocytes RARE
. O

The O
products O
of O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
CIN1 NUMERIC
, O
CIN2 NUMERIC
and O
CIN4 NUMERIC
genes I-GENE
participate O
in O
a O
nonessential RARE
pathway O
required O
for O
normal O
microtubule O
function O
. O

Vitrectomy RARE
was O
still O
a O
significant O
risk O
factor O
when O
macular RARE
holes RARE
were O
excluded O
. O

Invited RARE
editorial RARE
on O
" O
Acute O
and O
chronic O
effects O
of O
exercise O
on O
leptin I-GENE
levels O
in O
humans O
". O

Both O
promoters O
lack O
a O
TATA O
box O
, O
and O
Pint RARE
belongs O
to O
the O
MED ALLCAPS
- I-GENE
1 I-GENE
class O
of O
promoters O
, O
which O
initiate O
transcription O
at O
multiple O
sites O
. O

Serum I-GENE
response I-GENE
factor I-GENE
( O
SRF I-GENE
), O
a O
member O
of O
an O
ancient RARE
family O
of O
DNA O
- O
binding O
proteins O
, O
is O
generally O
assumed O
to O
be O
a O
ubiquitous O
transcription O
factor O
involved O
in O
regulating O
growth O
factor O
- O
responsive O
genes O
. O

We O
have O
initiated O
studies O
to O
identify O
candidate O
signal O
transducers RARE
that O
associate O
with O
the O
cytosolic O
domain O
( O
cd RARE
) O
of O
the O
IL I-GENE
- I-GENE
1R NUMERIC
. O

In O
this O
study O
, O
we O
sought O
to O
identify O
mechanisms O
that O
could O
account O
for O
the O
antimitogenic RARE
effects O
of O
IL I-GENE
- I-GENE
4 I-GENE
. O

Pseudomonas O
aeruginosa O
strains O
infecting RARE
patients O
with O
cystic O
fibrosis O
( O
CF ALLCAPS
) O
acquire RARE
a O
mucoid RARE
phenotype O
due O
to O
overproduction RARE
of O
alginate RARE
. O

Activity RARE
of O
palgD LASTCAP
in O
the O
cysB LASTCAP
mutant I-GENE
, O
in O
CHA ALLCAPS
and O
in O
the O
non O
- O
mucoid RARE
strain O
PAO ALLCAPS
was O
assessed O
by O
the O
use O
of O
a O
transcriptional O
algD LASTCAP
- O
xylE LASTCAP
fusion O
. O

The O
Man9 NUMERIC
- I-GENE
mannosidase RARE
specificity O
of O
the O
cDNA O
construct O
was O
verified RARE
by O
the O
observation O
that O
all O
peptide O
sequences O
derived O
from O
a O
previously O
purified O
, O
catalytically O
active O
49 O
- O
kDa O
fragment O
were O
found O
within O
the O
coding O
region O
. O

A O
soluble O
62 O
- O
kDa O
protein O
was O
produced O
without O
the O
proteolytic O
processing O
by O
inserting O
the O
coding O
sequence O
of O
amino O
acids O
112 O
to O
660 NUMERIC
of O
ORF O
- O
2 O
in O
a O
baculovirus O
expression O
vector O
and O
using O
the O
corresponding O
virus O
to O
infect RARE
Sf9 O
cells O
. O

The O
CPK I-GENE
- I-GENE
MB I-GENE
isoenzyme RARE
showed O
no O
percentage O
increase O
of O
total O
CPK I-GENE
higher O
than O
5 O
%, O
measured O
at O
6 O
, O
12 O
, O
and O
24 O
h O
after O
the O
shock O
, O
independent O
of O
the O
number O
of O
attempts O
of O
cardioversion RARE
. O

Serum O
and O
peritoneal O
dialysis O
fluid O
( O
PDF ALLCAPS
) O
were O
collected O
for O
assay O
throughout O
the O
course O
of O
the O
study O
and O
for O
5 O
days O
thereafter O
. O

Results O
support O
the O
hypothesis O
that O
endogenous I-GENE
corticotropin RARE
- I-GENE
releasing I-GENE
factor I-GENE
, O
perhaps O
acting O
at O
a O
peripheral O
binding O
site O
, O
suppresses O
the O
active O
behavioral O
response O
characteristic O
of O
pups RARE
during O
the O
early O
phase O
of O
isolation O
in O
novel O
surroundings RARE
. O

Liver O
regional O
blood O
volume O
( O
LRBV ALLCAPS
) O
is O
altered O
by O
several O
disease O
states O
and O
various O
drugs O
. O

The O
gray O
matter O
NAA ALLCAPS
/ O
mI LASTCAP
ratio O
clearly O
separated O
the O
two O
groups O
. O

As O
with O
the O
murine I-GENE
and I-GENE
human I-GENE
mb RARE
- I-GENE
1 I-GENE
genes I-GENE
, O
the O
5 O
' O
region O
of O
the O
bovine I-GENE
mb RARE
- I-GENE
1 I-GENE
gene I-GENE
lacked O
a O
TATA O
box O
. O

Chloramphenicol RARE
acetyltransferase I-GENE
assays O
examining O
the O
ability O
of O
IE86 NUMERIC
to O
repress O
activity O
from O
the O
HCMV O
major O
IE I-GENE
promoter I-GENE
or O
activate O
the O
HCMV I-GENE
early I-GENE
promoter I-GENE
for O
the O
2 O
. O
2 O
- O
kb O
class O
of O
RNAs O
demonstrated O
the O
functional O
integrity O
of O
the O
IE86 NUMERIC
protein I-GENE
. O

ORF O
M1 O
has O
striking O
homology O
to O
poxvirus RARE
serpins RARE
, O
while O
ORF O
M11 NUMERIC
encodes O
a O
potential O
homolog O
of O
Bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
like I-GENE
molecules I-GENE
encoded O
by O
other O
gammaherpesviruses RARE
( O
gene I-GENE
16 I-GENE
of O
HVS O
and O
KSHV O
and O
the O
BHRF1 NUMERIC
gene I-GENE
of O
EBV O
). O

Transcription O
factor O
binding O
sites O
downstream O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
start O
site O
are O
important O
for O
virus O
infectivity RARE
. O

Crystal RARE
structure O
of O
an O
oligomer RARE
of O
proteolytic O
zymogens RARE
: O
detailed O
conformational O
analysis O
of O
the O
bovine O
ternary O
complex O
and O
implications O
for O
their O
activation O
. O

Through RARE
transient O
transfection O
of O
NIH3T3 O
fibroblast O
cells O
and O
gel O
mobility O
shift O
assays O
, O
the O
functional O
binding O
site O
was O
localized O
to O
a O
short O
region O
(- O
318 NUMERIC
to O
- O
303 NUMERIC
bp O
from O
the O
transcription O
start O
site O
) O
which O
has O
a O
CTCCC ALLCAPS
sequence O
. O

We O
suppose RARE
that O
this O
injection O
speed RARE
( O
0 O
. O
1 O
- O
0 O
. O
2 O
ml O
. O
s O
- O
1 O
) O
is O
suitable O
for O
spinal O
anesthesia O
. O

Alternative O
splicing O
of O
ClC LASTCAP
- I-GENE
6 I-GENE
( O
a O
member O
of O
the O
CIC I-GENE
chloride I-GENE
- I-GENE
channel I-GENE
family I-GENE
) O
transcripts O
generates O
three O
truncated O
isoforms O
one O
of O
which O
, O
ClC LASTCAP
- I-GENE
6c NUMERIC
, O
is O
kidney O
- O
specific O
. O

The O
current O
study O
demonstrates O
that O
T3 O
- O
activated O
transcription O
of O
the O
NADPH ALLCAPS
: I-GENE
cytochrome I-GENE
P450 I-GENE
oxidoreductase I-GENE
( O
P450R NUMERIC
) O
gene O
is O
dependent O
on O
the O
thyroid O
hormonal O
status O
of O
the O
animal O
, O
with O
both O
transcriptional O
and O
post O
- O
transcriptional O
pathways O
being O
important O
in O
regulating O
the O
cellular O
P450R NUMERIC
mRNA O
level O
. O

The O
behavior O
of O
different O
types O
of O
polytetrafluoroethylene RARE
( O
PTFE ALLCAPS
) O
prostheses RARE
in O
the O
reparative RARE
scarring RARE
process O
of O
abdominal O
wall O
defects O
. O

The O
control O
group O
revealed O
significantly O
higher O
levels O
of O
coagulation I-GENE
factors I-GENE
II I-GENE
, I-GENE
V I-GENE
and I-GENE
VIII I-GENE
, O
compared O
to O
the O
index O
group O
. O

The O
frequency O
of O
positive O
anti I-GENE
- I-GENE
GM1 NUMERIC
antibody I-GENE
titers RARE
in O
the O
Guillain RARE
- O
Barre RARE
syndrome O
patients O
with O
PEN ALLCAPS
19 O
isolates O
was O
higher O
than O
that O
in O
the O
Guillain RARE
- O
Barre RARE
syndrome O
and O
Fisher RARE
' O
s O
syndrome O
patients O
without O
PEN ALLCAPS
19 O
isolates O
. O

Stereotactic RARE
radiofrequency RARE
lesioning RARE
of O
the O
hamartoma RARE
resulted O
in O
seizure O
remission O
without O
complications O
20 O
months O
after O
surgery O
. O

NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
/ O
Rel I-GENE
transcription O
factors O
participate O
in O
the O
activation O
of O
numerous O
genes O
involved O
in O
immune O
regulation O
/ O
inflammation O
including O
cytokines O
, O
cell O
surface O
receptors O
, O
adhesion O
molecules O
, O
and O
acute O
phase O
proteins O
. O

If O
E O
. O
coli O
is O
present O
in O
any O
source O
water O
sample O
, O
the O
borehole RARE
and O
any O
directly O
connected O
borehole RARE
should O
be O
embargoed RARE
. O

However O
, O
mean O
food O
intake O
in O
the O
40 O
% O
group O
was O
half O
that O
of O
the O
ACT ALLCAPS
group O
( O
p O
< O
0 O
. O
001 O
) O
and O
significantly O
less O
( O
p O
< O
0 O
. O
01 O
) O
than O
the O
SEP ALLCAPS
group O
, O
which O
consumed RARE
amounts O
equivalent O
to O
65 O
% O
of O
daily O
requirement O
. O

The O
following O
technique O
describes O
a O
modification O
to O
a O
bar RARE
superstructure RARE
that O
provided O
the O
advantages O
of O
convenience RARE
, O
security RARE
, O
and O
consistent O
positioning O
even O
though O
one O
implant O
was O
lost O
and O
the O
angulation RARE
of O
implants O
limited O
accuracy O
. O

In O
summary O
, O
DDC ALLCAPS
express O
receptors O
for O
a O
broad O
panel O
of O
cytokines O
, O
even O
receptors O
for O
cytokines O
whose O
effects O
on O
DC O
are O
still O
unknown O
( O
i O
. O
e O
. O

Its O
potential O
as O
a O
diagnostic O
tool O
for O
epidemiological O
surveillance RARE
was O
assessed O
in O
comparison O
with O
three O
other O
diagnostic O
tests O
: O
stool RARE
examination O
, O
ELISA O
with O
soluble I-GENE
egg I-GENE
antigen I-GENE
( O
SEA ALLCAPS
) O
and O
the O
circumoval RARE
precipitin RARE
test O
( O
COPT ALLCAPS
). O

We O
have O
separated O
a O
dermatan RARE
sulfate O
proteoglycan O
, O
epiphycan RARE
, O
from O
decorin RARE
and O
biglycan RARE
by O
using O
dissociative RARE
extraction O
of O
bovine O
fetal O
epiphyseal RARE
cartilage O
, O
followed O
by O
sequential O
ion O
- O
exchange O
, O
gel O
permeation RARE
, O
hydrophobic O
, O
and O
Zn2 NUMERIC
+ O
chelate RARE
chromatographic O
steps O
. O

These O
analyses O
demonstrate O
that O
the O
dUTPase RARE
isoforms O
are O
encoded O
by O
the O
same O
gene O
with O
isoform O
- O
specific O
transcripts O
arising O
through O
the O
use O
of O
alternative O
5 O
' O
exons O
. O

The O
selective O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonists O
ramosetron RARE
( O
YM060 NUMERIC
), O
YM114 NUMERIC
( O
KAE ALLCAPS
- O
393 NUMERIC
), O
granisetron RARE
and O
ondansetron RARE
, O
and O
the O
substituted O
benzamides RARE
( O
5 I-GENE
- I-GENE
HT4 NUMERIC
receptor I-GENE
agonist O
/ O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonists O
) O
cisapride RARE
mosapride RARE
and O
SC O
- O
53116 NUMERIC
dose O
- O
dependently O
enhanced O
gastric O
emptying O
in O
normal O
rats O
. O

Re O
- O
evaluation O
of O
the O
biopsy O
specimen RARE
from O
the O
right O
hip O
taken O
at O
the O
time O
of O
the O
initial O
operation O
showed O
areas O
of O
chondrosarcoma RARE
arising O
in O
the O
background O
of O
synovial O
chondromatosis RARE
. O

All O
corneal O
buttons RARE
were O
processed O
for O
histopathologic RARE
and O
electron O
microscopic O
studies O
. O

3600 NUMERIC
- O
fold O
to O
apparent O
homogeneity RARE
with O
a O
41 O
% O
yield O
by O
affinity O
chromatography O
utilizing O
DNA O
- O
cellulose RARE
; O
the O
purity RARE
of O
the O
final O
preparation O
was O
assessed O
by O
SDS O
/ O
PAGE O
, O
lack O
of O
contamination O
by O
other O
nucleases RARE
and O
production O
of O
a O
monospecific RARE
antibody O
against O
the O
enzyme O
. O

Human I-GENE
thymine RARE
- I-GENE
DNA I-GENE
glycosylase I-GENE
maps O
at O
chromosome O
12q22 NUMERIC
- O
q24 NUMERIC
. O
1 O
: O
a O
region O
of O
high O
loss O
of O
heterozygosity O
in O
gastric O
cancer O
. O

FOG ALLCAPS
is O
coexpressed O
with O
GATA I-GENE
- I-GENE
1 I-GENE
during O
embryonic O
development O
and O
in O
erythroid O
and O
megakaryocytic RARE
cells O
. O

The O
mean O
times O
to O
detection O
of O
all O
mycobacteria O
with O
BACTEC ALLCAPS
9000 NUMERIC
MB O
and O
BACTEC ALLCAPS
460 NUMERIC
TB O
were O
similar O
( O
10 O
. O
3 O
and O
10 O
. O
0 O
days O
, O
respectively O
). O

Though RARE
the O
BACTEC ALLCAPS
9000 NUMERIC
MB O
system O
is O
recommended O
for O
respiratory O
specimens O
, O
we O
demonstrated O
that O
it O
can O
be O
successfully O
used O
also O
for O
recovery O
of O
mycobacteria O
from O
clinical O
specimens O
from O
various O
extrapulmonary RARE
sites O
. O

We O
further O
found O
that O
KmMig1p NUMERIC
is O
fully O
functional O
when O
expressed O
in O
S O
. O
cerevisiae O
. O

A O
pre O
- O
boutonniere RARE
deformity RARE
was O
simulated O
by O
dividing RARE
the O
central O
slip RARE
. O

Autoimmune RARE
neutropenia O
( O
AIN ALLCAPS
) O
is O
a O
frequent O
cause O
of O
chronic O
neutropenia O
especially O
in O
youngest RARE
children O
. O

With O
regard O
to O
the O
characteristic O
expression O
pattern O
of O
DJ ALLCAPS
protein I-GENE
and O
its O
conspicuous RARE
repeat O
units O
possible O
functional O
roles O
are O
discussed O
. O

Future RARE
analysis O
of O
long O
- O
term O
outcome O
measures O
of O
performance O
with O
the O
implant O
will O
confirm O
or O
dispute RARE
the O
benefit O
of O
ear O
selection O
using O
the O
Prom RARE
- O
EABR ALLCAPS
. O

This O
protein O
, O
designated O
p532 NUMERIC
based O
on O
its O
predicted O
molecular O
weight O
( O
EMBO ALLCAPS
J O
15 O
: O
5738 NUMERIC
, O
1996 O
), O
contains O
multiple O
structural O
domains O
including O
two O
regions O
of O
seven O
internal O
repeats O
highly O
related O
to O
the O
cell O
cycle O
regulator O
RCC1 NUMERIC
, O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
for O
the O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
Ran I-GENE
, O
seven O
beta O
- O
repeat O
domains O
characteristic O
of O
the O
beta O
subunit O
of O
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
, O
three O
putative O
SH3 I-GENE
binding I-GENE
sites I-GENE
, O
a O
putative O
leucine O
- O
zipper O
and O
a O
carboxy I-GENE
- I-GENE
terminal I-GENE
HECT ALLCAPS
domain I-GENE
characteristic O
of O
E3 I-GENE
ubiquitin I-GENE
- I-GENE
protein I-GENE
ligases RARE
. O

Thus O
, O
the O
L45 NUMERIC
sequence O
between O
kinase O
subdomains O
IV O
and O
V O
specifies O
TGF I-GENE
- I-GENE
beta I-GENE
responsiveness O
of O
the O
type I-GENE
I I-GENE
receptor I-GENE
. O

The O
two O
mouse O
lines O
carrying O
the O
unfragmented RARE
Hnf3g NUMERIC
- O
lacZ I-GENE
YAC O
showed O
tissue O
- O
specific O
, O
copy O
number O
- O
dependent O
and O
position O
- O
independent O
expression O
, O
proving RARE
that O
170 O
kb O
of O
the O
Hnf3g NUMERIC
locus O
contain O
all O
elements O
important O
in O
the O
regulation O
of O
Hnf3g NUMERIC
. O

Second O
, O
plasmid O
- O
derived O
transgenes RARE
and O
gene O
targeting O
of O
the O
endogenous I-GENE
Hnf3g NUMERIC
gene I-GENE
locus I-GENE
were O
used O
to O
demonstrate O
that O
the O
3 O
'- O
flanking O
region O
of O
the O
gene O
is O
necessary O
and O
sufficient O
to O
direct O
reporter O
gene O
expression O
in O
liver O
, O
pancreas O
, O
stomach O
and O
small O
intestine O
. O

This O
regulation O
requires O
two O
HMG I-GENE
- I-GENE
box I-GENE
proteins I-GENE
: O
the O
ubiquitous O
Ste11 NUMERIC
transcription I-GENE
factor I-GENE
and O
the O
M O
cell O
- O
controlling O
protein O
Mat1 NUMERIC
- I-GENE
Mc RARE
. O

Here O
we O
have O
tested O
the O
hypothesis O
that O
the O
short O
transcripts O
, O
or O
proteins O
translated O
from O
the O
short O
transcripts O
, O
are O
also O
required O
for O
respiration O
. O

Upstream O
activating O
sequences O
( O
UASs RARE
) O
derived O
from O
known O
Ste12p NUMERIC
- O
dependent O
genes O
have O
previously O
been O
characterized O
to O
require O
either O
multiple O
PREs RARE
or O
a O
single O
PRE ALLCAPS
coupled O
to O
a O
binding O
site O
for O
a O
second O
protein O
. O

Prominent RARE
protein O
kinase O
cascades O
are O
those O
that O
activate O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinases I-GENE
. O

JNK I-GENE
is O
additionally O
regulated O
by O
the O
Ras I-GENE
- O
related O
G I-GENE
proteins I-GENE
Rac I-GENE
and O
Cdc42 I-GENE
. O

In O
this O
study O
, O
we O
tested O
this O
notion O
by O
using O
ligation O
- O
mediated O
PCR O
to O
assess O
the O
formation O
of O
recombination I-GENE
- I-GENE
activating I-GENE
gene I-GENE
( O
RAG ALLCAPS
)- O
dependent O
double O
- O
strand O
breaks RARE
( O
DSBs RARE
) O
at O
RSSs RARE
3 O
' O
of O
Ddelta3 NUMERIC
and O
5 O
' O
of O
Jdelta1 NUMERIC
. O

Recent O
studies O
have O
demonstrated O
that O
Cbl I-GENE
, O
the O
120 O
- O
kDa O
protein O
product O
of O
the O
c I-GENE
- I-GENE
cbl I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
, O
serves O
as O
a O
substrate O
of O
a O
number O
of O
receptor I-GENE
- I-GENE
coupled I-GENE
tyrosine I-GENE
kinases I-GENE
and O
forms O
complexes O
with O
SH3 I-GENE
and O
SH2 I-GENE
domain O
- O
containing O
proteins O
, O
pointing RARE
to O
its O
role O
in O
signal O
transduction O
. O

Although O
neither O
constitutively O
activated O
MEK I-GENE
( O
MEK I-GENE
- I-GENE
2E NUMERIC
) O
nor O
v I-GENE
- I-GENE
Src I-GENE
was O
sufficient O
individually O
to O
differentiate O
the O
H19 O
- O
7 O
cells O
, O
coexpression O
of O
constitutively O
activated O
MEK I-GENE
and O
v I-GENE
- I-GENE
Src I-GENE
induced O
neurite RARE
outgrowth RARE
. O

This O
mechanism O
is O
in O
contrast O
to O
other O
cases O
of O
splicing O
regulation O
by O
PTB I-GENE
, O
in O
which O
the O
protein O
represses O
the O
splice O
site O
to O
which O
it O
binds O
. O

While O
important O
for O
ligand O
- O
dependent O
transactivation O
, O
this O
interaction O
surface O
is O
not O
directly O
involved O
in O
transrepression RARE
of O
AP I-GENE
- I-GENE
1 I-GENE
activity O
. O

Gal4 I-GENE
- O
Eed RARE
fusion O
protein O
represses O
transcription O
of O
a O
reporter O
gene O
driven O
by O
a O
promoter O
that O
contains O
Gal4 I-GENE
- I-GENE
binding I-GENE
DNA I-GENE
elements I-GENE
. O

In O
situ O
hybridization O
analysis O
in O
adult O
rat O
tissue O
reveals O
good O
correlation O
with O
this O
pattern O
and O
indicates O
that O
drm RARE
mRNA I-GENE
is O
most O
highly O
expressed O
in O
nondividing RARE
and O
terminally O
differentiated O
cells O
, O
such O
as O
neurons O
, O
type O
1 O
lung O
cells O
, O
and O
goblet RARE
cells O
. O

Neither O
of O
these O
proteins O
, O
individually O
or O
as O
a O
pair O
, O
can O
bind O
the O
alpha I-GENE
- I-GENE
globin I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
unless O
they O
are O
complexed O
with O
the O
remaining O
non O
- O
poly O
( O
C O
) O
binding O
proteins O
of O
the O
alpha I-GENE
- I-GENE
complex I-GENE
. O

A O
2 O
years O
and O
9 O
months O
old O
female O
patient O
, O
with O
the O
diagnosis O
of O
Weaver RARE
syndrome O
is O
reported O
. O

Confirming RARE
measures O
made O
by O
nurses RARE
and O
additionally O
, O
ABPM ALLCAPS
for O
women O
, O
seem O
to O
lessen RARE
this O
effect O
. O

In O
a O
series O
of O
patients O
with O
neuroinfection RARE
, O
Lyme RARE
disease O
, O
Guillain RARE
Barre RARE
syndrome O
, O
demyelinization RARE
, O
partial O
or O
generalized O
, O
epilepsy O
, O
we O
have O
investigated O
antiphospholipid RARE
antibodies O
of O
IgG I-GENE
and O
IgM I-GENE
subtypes O
, O
together O
with O
anticoagulant O
factors O
, O
member O
of O
thrombocytes RARE
, O
sedimentation O
rate O
of O
erythrocytes RARE
. O

( O
1996a NUMERIC
) O
Biochemistry RARE
35 O
, O
1589 NUMERIC
- O
1598 NUMERIC
]. O

Second O
, O
the O
membrane O
expression O
of O
alpha O
and O
beta O
subunits O
was O
mimicked O
by O
cholesterol O
and O
17 O
- O
ketocholesterol RARE
, O
both O
of O
which O
inhibit O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
. O

Our O
results O
suggest O
that O
Lrp RARE
binds O
a O
central O
palindromic O
site O
, O
interacting O
predominantly O
with O
the O
major O
groove O
of O
its O
DNA O
target O
, O
and O
that O
additional O
dimers O
bind O
to O
flanking O
sites O
to O
form O
a O
nucleoprotein O
activation O
complex O
. O

Sustained RARE
activation O
of O
p21 I-GENE
expression O
is O
proposed O
to O
be O
a O
distinguishing RARE
feature O
of O
the O
activity O
of O
NGF ALLCAPS
that O
contributes O
to O
PC12 O
growth O
arrest O
during O
differentiation O

The O
remaining O
80 O
patients O
underwent O
recordings O
of O
ECG O
, O
beat RARE
- O
to O
- O
beat RARE
arterial O
oxygen O
saturation O
( O
SaO2 O
), O
and O
respiration O
during O
both O
spontaneous O
and O
controlled O
breathing O
. O

The O
mean O
total O
white O
cell O
count O
increased O
from O
a O
baseline O
of O
11 O
. O
3 O
x O
10 O
( O
9 O
)/ O
L O
( O
SD O
2 O
. O
3 O
) O
to O
16 O
. O
2 O
x O
10 O
( O
9 O
)/ O
L O
( O
SD O
4 O
. O
6 O
) O
on O
day O
1 O
, O
normalising RARE
thereafter O
. O

A O
prospective O
observational RARE
study O
was O
conducted O
to O
identify O
early O
indicators O
of O
acute O
dengue RARE
virus O
infection O
. O

In O
all O
experimental O
eyes O
, O
there O
was O
a O
marked O
reduction O
, O
but O
never O
a O
complete O
absence O
of O
adrenergic O
nerves O
in O
the O
iris RARE
. O

These O
lesions O
may O
be O
treated O
by O
propranolol O
or O
phentolamine RARE
. O

Furthermore O
, O
ICER ALLCAPS
negatively O
autoregulates RARE
the O
alternative O
promoter O
, O
thus O
generating O
a O
feedback RARE
loop O
. O

This O
night O
- O
day O
oscillation RARE
is O
driven O
by O
the O
endogenous O
clock RARE
( O
located O
in O
the O
suprachiasmatic RARE
nucleus O
, O
SCN ALLCAPS
). O

It O
is O
present O
in O
the O
nucleus O
of O
the O
cells O
in O
which O
it O
is O
expressed O
and O
can O
phosphorylate O
and O
activate O
the O
cyclic I-GENE
AMP I-GENE
response I-GENE
element I-GENE
binding I-GENE
proteins I-GENE
CREB I-GENE
and O
CREM ALLCAPS
tau I-GENE
in O
a O
manner O
analogous O
to O
protein I-GENE
kinase I-GENE
A I-GENE
. O

These O
cells O
fail O
to O
generate O
the O
signals O
to O
phosphorylate O
CREB I-GENE
and O
produce O
significantly O
less O
of O
the O
cytokine O
Interleukin I-GENE
- I-GENE
2 I-GENE
( O
IL I-GENE
- I-GENE
2 I-GENE
) O
in O
response O
to O
agents O
that O
either O
increase O
intracellular O
Ca2 O
+ O
and O
/ O
or O
activate O
protein I-GENE
kinase I-GENE
C I-GENE
. O

Both O
of O
these O
dogs O
had O
low O
serum O
IgG I-GENE
( O
3 O
. O
5 O
to O
7 O
. O
2 O
mg O
/ O
ml O
) O
and O
the O
second O
littermate RARE
also O
had O
reduced O
serum O
IgA I-GENE
(< O
0 O
. O
1 O
to O
0 O
. O
15 O
mg O
/ O
ml O
). O

CONCLUSIONS O
: O
Valproate RARE
appears O
to O
inhibit O
the O
glucuronidation RARE
of O
carbamazepine RARE
- O
10 O
, O
11 O
- O
trans O
- O
diol RARE
, O
and O
probably O
also O
inhibits O
the O
conversion O
of O
carbamazepine RARE
- O
10 O
, O
11 O
- O
epoxide RARE
to O
this O
trans O
- O
diol RARE
derivative O
, O
rather O
than O
simply RARE
inhibiting O
the O
latter O
reaction O
only O
. O

The O
Ogg1 NUMERIC
protein I-GENE
efficiently O
cleaves RARE
a O
DNA O
duplex O
where O
a O
preformed RARE
AP I-GENE
site I-GENE
is O
placed O
opposite O
a O
cytosine O
( O
AP O
/ O
C O
). O

A O
consensus O
sequence O
indicates O
a O
highly O
conserved O
lysine O
residue O
, O
K120 NUMERIC
of O
endonuclease I-GENE
III I-GENE
or O
K241 NUMERIC
of O
Ogg1 NUMERIC
, O
respectively O
. O

Overall O
, O
these O
findings O
demonstrate O
that O
mutations O
E768D NUMERIC
and O
V804L NUMERIC
are O
gain O
- O
of O
- O
function O
mutations O
that O
confer O
to O
the O
long I-GENE
RET I-GENE
isoform I-GENE
the O
capacity O
to O
exert O
a O
biological O
effect O
, O
although O
these O
mutations O
are O
more O
weakly O
activating O
than O
the O
MEN2A NUMERIC
and O
MEN2B NUMERIC
mutations O
. O

Volunteers RARE
were O
irradiated O
on O
their O
backs RARE
with O
suberythemal RARE
UV O
daily O
for O
5 O
d O
after O
application O
of O
the O
sunscreens RARE
and O
their O
base O
lotion RARE
to O
different O
sites O
. O

E2F I-GENE
is O
a O
heterodimeric O
complex O
consisting O
of O
E2F I-GENE
family I-GENE
members I-GENE
( I-GENE
1 I-GENE
- I-GENE
5 I-GENE
) I-GENE
and O
DP O
proteins O
( O
1 O
- O
3 O
). O

EBER1 NUMERIC
mRNA I-GENE
, O
a O
consistent O
marker O
of O
viral O
latency O
, O
was O
positive O
in O
all O
PEL ALLCAPS
cases O
, O
although O
at O
lower O
levels O
than O
in O
the O
non O
- O
PEL ALLCAPS
controls O
due O
to O
EBER1 NUMERIC
expression O
by O
only O
a O
variable O
subset O
of O
lymphoma O
cells O
. O

METHODS O
: O
Four O
hundred O
fifty RARE
patients O
with O
the O
diagnosis O
of O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
received O
their O
primary O
treatment O
at O
Roswell RARE
Park RARE
Cancer O
Center RARE
( O
RPCI ALLCAPS
) O
from O
1971 NUMERIC
to O
1991 O
. O

Therefore O
, O
use O
of O
presaturation RARE
is O
recommended O
for O
myocardial O
motion O
studies O
using O
cine RARE
PC O
velocity O
data O
. O

In O
addition O
, O
the O
DNA O
- O
binding O
experiments O
show O
that O
either O
one O
of O
the O
two O
MADS I-GENE
domains I-GENE
of O
a O
dimer O
can O
be O
sufficient O
to O
confer O
a O
particular O
DNA O
- O
binding O
specificity O
to O
the O
complex O
and O
that O
sequences O
outside O
the O
amino O
- O
terminal O
basic O
region O
of O
the O
MADS I-GENE
domain O
can O
, O
in O
some O
cases O
, O
contribute O
to O
the O
DNA O
- O
binding O
specificity O
of O
the O
proteins O
. O

PURPOSE O
/ O
OBJECTIVES O
: O
To O
examine O
the O
question O
of O
whether O
an O
early O
first O
full O
- O
term O
pregnancy O
( O
FFTP ALLCAPS
) O
protects RARE
against O
breast O
cancer O
and O
whether O
interruption RARE
of O
the O
pregnancy O
with O
an O
induced O
abortion O
increases O
breast O
cancer O
risk O
. O

Two O
related O
studies O
conducted O
over O
a O
five O
week O
period O
measured O
and O
typed RARE
HLA I-GENE
- I-GENE
DQA1 NUMERIC
from O
accumulated O
DNA O
on O
autopsy O
room O
and O
Forensic RARE
DNA O
Laboratory O
structures O
. O

Thirty O
- O
two O
rats O
were O
divided O
into O
four O
groups O
. O

Mutagenesis RARE
of O
the O
pecT LASTCAP
regulatory O
region O
revealed O
the O
presence O
of O
two O
sites O
in O
which O
insertions O
reproduced RARE
the O
pec RARE
- I-GENE
1 I-GENE
phenotype O
. O

BRCA1 I-GENE
, O
a O
familial O
breast O
and O
ovarian O
cancer O
susceptibility O
gene O
encodes O
nuclear O
phosphoproteins RARE
that O
function O
as O
tumor O
suppressors O
in O
human O
breast O
cancer O
cells O
. O

The O
alternative O
splice O
sites O
for O
the O
smallest O
adducin RARE
isoform O
, O
beta I-GENE
- I-GENE
3 I-GENE
, O
are O
alternative O
donor O
and O
acceptor O
sites O
within O
exons O
7 O
and O
12 O
. O

Proteinuria RARE
in O
a O
young O
man O
. O

Neural RARE
blockade O
in O
chronic O
and O
cancer O
pain O
. O

Two O
new O
temperature O
- O
sensitive O
alleles O
of O
SEC3 NUMERIC
, O
1 O
of O
10 O
late O
- O
acting O
SEC ALLCAPS
genes I-GENE
required O
for O
targeting O
or O
fusion O
of O
post O
- O
Golgi O
secretory O
vesicles O
to O
the O
plasma O
membrane O
in O
Saccharomyces O
cerevisiae O
, O
were O
isolated O
in O
a O
screen O
for O
temperature O
- O
sensitive O
secretory O
mutants O
that O
are O
synthetically RARE
lethal O
with O
sec4 NUMERIC
- I-GENE
8 I-GENE
. O

Five O
cell O
strains O
of O
human O
dermal O
fibroblasts O
were O
each O
treated O
with O
three O
samples O
of O
burn O
blister RARE
fluid O
and O
the O
effect O
compared O
with O
the O
rate O
of O
contraction O
of O
free O
floating RARE
fibroblast O
populated RARE
collagen I-GENE
lattices RARE
( O
FPCL ALLCAPS
). O

It O
is O
thus O
one O
of O
the O
key O
enzymes O
involved O
in O
the O
triiodothyronine RARE
- O
mediated O
control O
of O
growth O
, O
differentiation O
and O
basal O
metabolism O
in O
vertebrates RARE
. O

Cell O
49 O
, O
753 NUMERIC
- O
761 NUMERIC
]. O

Twenty O
- O
one O
ELISA O
- O
positive O
sera O
were O
tested O
and O
confirmed O
positive O
by O
plaque O
reduction O
neutralization RARE
testing O
. O

Patients O
received O
either O
diltiazem O
CD O
180 O
mg O
or O
placebo O
once O
/ O
day O
in O
combination O
with O
existing O
antianginal RARE
therapy O
. O

Reactive RARE
lymphoid O
hyperplasia O
was O
found O
in O
15 O
cases O
, O
2 O
cases O
had O
angiofollicular RARE
lymphoid O
hyperplasia O
or O
Castleman RARE
' O
s O
disease O
, O
atypical O
lymphoid O
hyperplasia O
suggestive O
of O
malignant O
lymphoma O
was O
observed O
in O
3 O
cases O
, O
and O
malignant O
lymphoma O
was O
diagnosed O
in O
the O
remaining O
4 O
cases O
. O

We O
had O
previously O
analyzed O
repair O
rates O
of O
cyclobutane RARE
pyrimidine O
dimers O
at O
nucleotide O
resolution O
along O
the O
human I-GENE
JUN ALLCAPS
gene I-GENE
in O
normal O
fibroblasts O
and O
found O
very O
efficient O
repair O
of O
sequences O
near O
the O
transcription O
initiation O
site O
but O
slow O
repair O
along O
the O
promoter O
. O

Tyrosine O
1356 NUMERIC
forms O
a O
multisubstrate RARE
binding O
site O
for O
the O
Grb2 I-GENE
and O
Shc I-GENE
adaptor I-GENE
proteins I-GENE
, O
the O
p85 I-GENE
subunit I-GENE
of O
phosphatidylinositol I-GENE
3 I-GENE
'- I-GENE
kinase I-GENE
, O
phospholipase I-GENE
Cgamma RARE
, O
and O
a O
phosphatase O
, O
SHP2 NUMERIC
. O

Then RARE
we O
correlated O
HRCT ALLCAPS
findings O
with O
the O
clinical O
features O
, O
pulmonary O
functions O
and O
methacholine RARE
PC20 NUMERIC
( O
PC20M NUMERIC
) O
and O
studied O
their O
clinical O
significance O
. O

Gtx RARE
mRNA I-GENE
accumulates O
in O
parallel O
with O
the O
RNAs O
encoding O
the O
major O
structural O
proteins O
of O
myelin O
, O
myelin I-GENE
basic I-GENE
protein I-GENE
( O
MBP I-GENE
), O
and O
proteolipid RARE
protein I-GENE
( O
PLP I-GENE
) O
during O
postnatal O
brain O
development O
; O
Gtx RARE
mRNA I-GENE
decreases O
in O
parallel O
with O
MBP I-GENE
and O
PLP I-GENE
mRNAs I-GENE
in O
the O
brains RARE
of O
myelin O
- O
deficient O
rats O
, O
which O
have O
a O
point O
mutation O
in O
the O
PLP I-GENE
gene I-GENE
. O

Contacts RARE
between O
Bacillus O
subtilis O
catabolite O
regulatory O
protein O
CcpA LASTCAP
and O
amyO LASTCAP
target O
site O
. O

They O
also O
interact O
with O
GTPase I-GENE
activating I-GENE
proteins I-GENE
encoded O
by O
IRA1 NUMERIC
and O
IRA2 NUMERIC
. O

For O
E2 O
, O
each O
cat O
was O
given O
either O
5 O
( O
group O
[ O
G O
] O
1 O
) O
or O
10 O
( O
G2 O
) O
mg O
of O
itraconazole RARE
/ O
kg O
( O
capsules O
) O
twice O
daily O
for O
6 O
weeks O
. O

RESULTS O
: O
For O
E1 O
, O
itraconazole RARE
plasma O
drug O
concentration O
extrapolated RARE
to O
time O
zero O
( O
IV O
dose O
) O
was O
5 O
. O
2 O
+/- O
1 O
. O
4 O
micrograms O
/ O
ml O
, O
and O
mean O
residence RARE
time O
( O
MRT ALLCAPS
) O
was O
37 O
+/- O
16 O
hours O
. O

The O
human O
U4 I-GENE
/ O
U6 I-GENE
snRNP O
contains O
60 O
and O
90kD NUMERIC
proteins O
that O
are O
structurally O
homologous O
to O
the O
yeast O
splicing O
factors O
Prp4p NUMERIC
and O
Prp3p NUMERIC
. O

G I-GENE
- I-GENE
CSF I-GENE
was O
started O
on O
day O
3 O
of O
each O
cycle O
( O
5 O
microg O
/ O
kg O
/ O
day O
) O
and O
was O
stopped O
the O
day O
before O
the O
last O
apheresis RARE
or O
when O
absolute O
neutrophil O
count O
was O
above O
0 O
. O
5 O
x O
10 O
( O
9 O
)/ O
l O
. O

The O
used O
expression O
system O
could O
allow O
to O
produce O
mutated O
forms O
of O
SsEF LASTCAP
- I-GENE
2 I-GENE
obtained O
by O
mutagenesis O
of O
the O
corresponding O
gene O
. O

Crosstalk RARE
among O
the O
pathways O
may O
explain O
how O
some O
forms O
of O
stress O
can O
contribute O
to O
the O
development O
of O
a O
malignancy O
. O

Supershift RARE
assays O
, O
using O
Jun I-GENE
and I-GENE
Fos I-GENE
family I-GENE
member I-GENE
- I-GENE
specific I-GENE
antibodies I-GENE
, O
showed O
that O
protein O
complexes O
formed O
by O
AtT LASTCAP
- O
20 O
cell O
nuclear O
extracts O
bound O
to O
the O
c I-GENE
- I-GENE
jun I-GENE
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
were O
comprised O
of O
Jun I-GENE
family O
members O
, O
JunD LASTCAP
, O
JunB LASTCAP
, O
and O
cJun RARE
. O

The O
majority O
of O
PI I-GENE
kinase I-GENE
activity O
appeared O
to O
be O
cbl I-GENE
- O
associated O
after O
PRL I-GENE
stimulation O
. O

Mutation O
of O
Enh4 NUMERIC
, O
an O
essential O
GT I-GENE
- I-GENE
IIC ALLCAPS
- I-GENE
like I-GENE
enhanson RARE
in O
the O
context O
of O
the O
intact O
enhancer O
, O
abolishes O
silencer O
activity O
, O
and O
multimerized RARE
GT I-GENE
- I-GENE
IIC ALLCAPS
enhansons RARE
mimic O
the O
intact O
CSEn RARE
enhancer I-GENE
/ I-GENE
silencer I-GENE
activities O
in O
BeWo RARE
and O
GC O
cells O
, O
respectively O
. O

Using O
lectin RARE
- O
affinity O
chromatography O
, O
discordance RARE
between O
the O
pattern O
of O
O O
- O
glycosylation O
of O
SSBP ALLCAPS
and O
DSBP ALLCAPS
was O
demonstrated O
. O

Deletion O
mapping O
experiments O
determined O
that O
the O
sequences O
required O
for O
full O
activity O
in O
MSC ALLCAPS
- O
1 O
cells O
were O
included O
within O
619 NUMERIC
bp O
of O
the O
start O
site O
and O
identified O
several O
regions O
that O
demonstrated O
increased O
luciferase I-GENE
activity O
: O
the O
- O
583 NUMERIC
bp O
to O
- O
564 NUMERIC
bp O
, O
- O
503 NUMERIC
bp O
to O
- O
484 NUMERIC
bp O
, O
and O
- O
114 O
bp O
to O
- O
65 O
regions O
. O

Furthermore O
, O
the O
PH I-GENE
and O
PTB O
domains O
are O
highly O
homologous O
( O
at O
least O
40 O
% O
identical O
) O
to O
those O
found O
in O
insulin I-GENE
receptor I-GENE
substrates I-GENE
1 I-GENE
, I-GENE
2 I-GENE
, I-GENE
and I-GENE
3 I-GENE
( O
IRS I-GENE
- I-GENE
1 I-GENE
, O
IRS I-GENE
- I-GENE
2 I-GENE
, O
and O
IRS I-GENE
- I-GENE
3 I-GENE
). O

The O
mouse O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
2 I-GENE
gene I-GENE
. O

As O
demonstrated O
by O
gel O
mobility O
shift O
analysis O
and O
supershift O
experiments O
, O
FIRE1 NUMERIC
, O
located O
between O
- O
516 NUMERIC
and O
- O
498 NUMERIC
, O
is O
responsible O
for O
binding O
NF I-GENE
- I-GENE
Y I-GENE
. O

MR O
imaging O
of O
traumatic RARE
head O
injuries O
using O
FLAIR ALLCAPS
technique O

Gag I-GENE
protein O
sequence O
motifs O
of O
the O
NC ALLCAPS
domain I-GENE
of O
primate O
foamy RARE
viruses O
assumed O
to O
be O
involved O
in O
genome O
encapsidation RARE
are O
not O
conserved O
in O
FeFV LASTCAP
. O

Induction O
of O
B O
cell O
apoptosis O
by O
co O
- O
cross O
- O
linking O
CD23 I-GENE
and O
sIg RARE
involves O
aberrant O
regulation O
of O
c I-GENE
- I-GENE
myc I-GENE
and O
is O
inhibited O
by O
bcl I-GENE
- I-GENE
2 I-GENE
. O

MEASUREMENTS ALLCAPS
AND O
MAIN O
RESULTS O
: O
Lung O
elastance RARE
( O
EL ALLCAPS
) O
and O
resistance O
( O
RL ALLCAPS
) O
were O
calculated O
from O
measurements O
of O
airway O
pressure O
, O
esophageal O
pressure O
, O
and O
airway O
flow O
in O
five O
anesthetized O
, O
paralyzed RARE
dogs O
during O
sinusoidal RARE
forcing RARE
at O
a O
constant O
mean O
airway O
pressure O
of O
10 O
cmH2O O
in O
a O
wide O
range O
of O
breathing O
frequencies O
( O
0 O
. O
2 O
to O
1 O
. O
0 O
Hz O
in O
intervals O
of O
0 O
. O
2 O
) O
and O
tidal O
volumes O
( O
50 O
, O
100 O
, O
200 O
, O
and O
to O
300 O
mL O
). O

Here O
, O
we O
report O
theoretical RARE
models O
for O
the O
Gla RARE
and O
EGF I-GENE
- I-GENE
1 I-GENE
modules I-GENE
of O
human I-GENE
PS I-GENE
constructed O
using O
prothrombin I-GENE
and O
factor I-GENE
X I-GENE
experimental O
structures O
. O

The O
Cut9 NUMERIC
subunit I-GENE
is O
likely O
to O
be O
a O
target O
for O
regulating O
APC I-GENE
/ I-GENE
cyclosome RARE
function O
through O
protein O
- O
protein O
interactions O
and O
phosphorylation O
. O

The O
dose O
was O
50 O
Gy O
/ O
20 O
fractions O
/ O
5 O
weeks O
. O

Because O
the O
biosynthetic O
pathway O
to O
the O
vacuole RARE
intersects RARE
with O
the O
endocytic O
pathway O
, O
internalization O
of O
a O
bulk O
membrane O
endocytic O
marker O
FM ALLCAPS
4 O
- O
64 O
was O
assayed O
in O
the O
sop RARE
mutants I-GENE
. O

All O
the O
women O
received O
13 O
. O
5 O
mg O
plain RARE
bupivacaine RARE
via O
subarachnoid RARE
injection O
at O
the O
L2 O
- O
3 O
interspace RARE
. O

Far RARE
from O
this O
being O
the O
case O
, O
however O
, O
the O
measurement O
of O
apo I-GENE
B I-GENE
has O
met O
every O
reasonable O
standard O
of O
laboratory O
precision RARE
and O
reliability O
to O
allow O
its O
widespread RARE
introduction O
in O
clinical O
laboratories O
. O

Two O
soybean O
cDNA O
clones O
, O
SPK I-GENE
- I-GENE
3 I-GENE
and O
SPK I-GENE
- I-GENE
4 I-GENE
, O
encoding O
putative O
protein O
kinases O
were O
isolated O
and O
characterized O
. O

Genes RARE
belonging O
to O
the O
ras I-GENE
superfamily I-GENE
encode O
low I-GENE
- I-GENE
molecular I-GENE
- I-GENE
weight I-GENE
GTP I-GENE
/ I-GENE
GDP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
that O
are O
highly O
conserved O
in O
wide O
variety O
of O
organisms O
. O

Naltrexone RARE
has O
been O
recently O
approved RARE
by O
the O
Food RARE
and O
Drug O
Administration O
for O
the O
treatment O
of O
alcohol O
dependence O
. O

Ent RARE
- I-GENE
kaurene RARE
synthase I-GENE
from I-GENE
the I-GENE
fungus I-GENE
Phaeosphaeria RARE
sp O
. O

In O
this O
report O
, O
we O
identify O
and O
characterize O
two O
overlapping O
ELL ALLCAPS
functional I-GENE
domains I-GENE
that O
govern O
its O
interaction O
with O
RNA I-GENE
polymerase I-GENE
II I-GENE
and O
the O
ternary O
elongation O
complex O
. O

Eight O
induced O
cDNA O
sequences O
were O
identified O
and O
designated O
message I-GENE
up I-GENE
- I-GENE
regulated I-GENE
during I-GENE
death I-GENE
( I-GENE
mud RARE
)- I-GENE
1 I-GENE
- I-GENE
8 I-GENE
. O

The O
position O
, O
transcription O
orientation O
, O
and O
imprinted O
status O
of O
the O
genes O
immediately O
flanking O
Igf2r NUMERIC
have O
been O
assessed O
. O

Here O
, O
we O
describe O
directional RARE
chromosome O
walking RARE
studies O
starting O
from O
D8S260 NUMERIC
as O
well O
as O
D8S285 NUMERIC
. O

We O
describe O
a O
novel O
zinc I-GENE
finger I-GENE
protein I-GENE
, O
dsRBP LASTCAP
- I-GENE
ZFa RARE
, O
isolated O
by O
screening O
an O
expression O
library O
with O
dsRNA O
. O

Our O
results O
indicate O
that O
the O
retroplasmid RARE
reverse I-GENE
transcriptase I-GENE
is O
uniquely RARE
adapted O
to O
initiate O
cDNA O
synthesis O
by O
recognizing RARE
a O
3 O
' O
CCA ALLCAPS
sequence O
. O

Nasal RARE
absorption O
was O
rapid O
, O
nasal O
bioavailability RARE
was O
43 O
%, O
and O
the O
iv O
and O
nasal O
elimination O
profiles O
were O
similar O
. O

Together O
, O
these O
results O
suggest O
that O
EGF I-GENE
/ O
Ras I-GENE
/ O
Raf I-GENE
induces O
transcription O
via O
combined O
activation O
of O
ATF3 NUMERIC
/ O
c I-GENE
- I-GENE
Jun I-GENE
and O
a O
52 O
- O
kDa O
nuclear O
factor O
, O
whereas O
JunD LASTCAP
acts O
as O
a O
repressor O
of O
this O
response O
. O

Together O
, O
these O
data O
support O
a O
model O
in O
which O
Tax I-GENE
anchors RARE
CBP I-GENE
to O
the O
HTLV I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
, O
with O
strong O
transcriptional O
activation O
resulting O
from O
the O
CBP I-GENE
- O
associated O
activities O
of O
nucleosome RARE
remodeling O
and O
recruitment O
of O
the O
general O
transcription O
machinery O
. O

DNase I-GENE
I I-GENE
and O
1 O
, O
10 O
- O
phenanthroline RARE
- O
copper O
footprinting O
of O
MURA ALLCAPS
- O
Mu1 NUMERIC
TIR ALLCAPS
complexes O
indicate O
that O
MURA ALLCAPS
binds O
to O
a O
conserved O
approximately O
32 O
- O
bp O
region O
in O
the O
TIR ALLCAPS
of O
Mu1 NUMERIC
. O

Consistent O
with O
this O
model O
, O
a O
synthetic O
construct O
containing O
three O
tandem O
copies O
of O
the O
native O
LDL I-GENE
receptor I-GENE
SREBP I-GENE
site O
linked O
to O
a O
single O
Sp1 I-GENE
site I-GENE
was O
also O
significantly O
activated O
in O
a O
buttonhead RARE
- O
independent O
fashion O
. O

Various O
assays O
demonstrate O
promoter O
activity O
in O
this O
sequence O
that O
reproduces RARE
the O
normal O
control O
of O
E2F2 NUMERIC
expression O
during O
a O
growth O
stimulation O
. O

In O
the O
adult O
mouse O
, O
ERR ALLCAPS
alpha I-GENE
is O
most O
highly O
expressed O
in O
kidney O
, O
heart O
, O
and O
brown O
adipocytes O
, O
tissues O
which O
preferentially O
metabolize RARE
fatty O
acids O
. O

The O
MCAD ALLCAPS
nuclear I-GENE
receptor I-GENE
response I-GENE
element I-GENE
1 I-GENE
( O
NRRE ALLCAPS
- I-GENE
1 I-GENE
) O
interacts O
in O
vitro O
with O
ERR ALLCAPS
alpha I-GENE
expressed O
in O
COS O
- O
7 O
cells O
. O

Mapping O
features O
of O
HIV I-GENE
- I-GENE
1 I-GENE
integrase I-GENE
near O
selected O
sites O
on O
viral O
and O
target O
DNA O
molecules O
in O
an O
active O
enzyme O
- O
DNA O
complex O
by O
photo RARE
- O
cross O
- O
linking O
. O

Analysis O
of O
the O
5 O
' O
flanking O
region O
of O
the O
gene O
also O
revealed O
the O
presence O
of O
multiple O
TATA O
and O
CAAT O
sequences O
. O

Analysis O
of O
the O
5 O
' O
flanking O
region O
of O
the O
gene O
also O
revealed O
the O
presence O
of O
multiple O
TATA O
and O
CAAT O
sequences O
. O

The O
complete O
response O
( O
CR O
) O
rate O
was O
34 O
% O
in O
the O
CODE ALLCAPS
with O
rhG LASTCAP
- I-GENE
CSF I-GENE
group O
and O
23 O
% O
in O
the O
CODE ALLCAPS
alone O
group O
; O
the O
median O
survival O
was O
59 O
and O
32 O
weeks O
, O
respectively O
, O
in O
these O
groups O
( O
P O
= O
0 O
. O
004 NUMERIC
). O

Heterogeneous RARE
nuclear I-GENE
ribonucleoprotein I-GENE
A1 I-GENE
binds O
to O
the O
transcription O
- O
regulatory O
region O
of O
mouse O
hepatitis O
virus O
RNA O
. O

The O
m7GpppN NUMERIC
cap O
structure O
of O
eukaryotic O
mRNA O
is O
formed O
cotranscriptionally RARE
by O
the O
sequential O
action O
of O
three O
enzymes O
: O
RNA I-GENE
triphosphatase RARE
, O
RNA I-GENE
guanylyltransferase RARE
, O
and O
RNA I-GENE
( I-GENE
guanine I-GENE
- I-GENE
7 I-GENE
)- I-GENE
methyltransferase I-GENE
. O

In O
the O
first O
part O
of O
our O
study O
, O
the O
highest O
mutagenicity RARE
was O
revealed O
by O
TA98 NUMERIC
strain O
without O
enzymatic O
activation O
, O
suggesting O
a O
direct O
- O
acting O
mutagenicity RARE
prevalence O
in O
diesel RARE
particulate O
. O

The O
addition O
of O
culture O
to O
the O
CC O
and O
CC O
: O
SW ALLCAPS
by O
- O
products O
resulted O
in O
pH O
values O
lower O
( O
P O
< O
0 O
. O
05 O
) O
than O
those O
without O
culture O
on O
Day O
21 O
, O
and O
the O
15 O
% O
carbohydrate O
treatment O
significantly O
reduced O
pH O
beyond O
the O
5 O
% O
carbohydrate O
. O

Myocardial O
interstitial O
edema O
is O
more O
likely O
a O
potential O
mechanism O
of O
diastolic O
dysfunction O
after O
DC O
shocks RARE
. O

Two O
experiments O
( O
N O
= O
20 O
each O
) O
were O
carried O
out O
to O
explore O
the O
nature O
of O
ERP ALLCAPS
negativities RARE
in O
a O
visuospatial RARE
memory O
task O
and O
in O
an O
auditory O
spatial O
memory O
task O
, O
respectively O
. O

Biol O
. O

The O
pattern O
and O
timing O
of O
CARP ALLCAPS
mRNA I-GENE
expression O
, O
including O
transient O
expression O
in O
the O
tongue RARE
at O
14 O
. O
5 O
days O
p O
. O
c O
., O
coincides RARE
with O
that O
of O
Nkx2 NUMERIC
. I-GENE
5 I-GENE
/ O
Csx RARE
( O
a O
putative O
homolog O
of O
tinman RARE
, O
the O
Drosophila O
melanogaster O
gene O
responsible O
for O
cardiac O
development O
). O

Overexpression O
of O
CARP ALLCAPS
in O
cardiomyocytes RARE
suppresses O
cardiac I-GENE
troponin RARE
C I-GENE
and O
atrial I-GENE
natriuretic RARE
factor I-GENE
transcription O
. O

Substrate RARE
specificity O
of O
the O
RNase I-GENE
activity O
of O
yeast I-GENE
RNA I-GENE
polymerase I-GENE
III I-GENE
. O

Electrophoretic O
mobility O
shift O
assays O
and O
competition O
experiments O
showed O
that O
site O
A O
is O
recognized O
by O
an O
NF1 I-GENE
protein I-GENE
. O

Examination O
of O
the O
MMP ALLCAPS
- I-GENE
2 I-GENE
RE1 NUMERIC
sequence I-GENE
revealed O
an O
incomplete O
Y O
- O
box O
sequence O
( O
CTGCTGGGCAAG ALLCAPS
), O
which O
specifically O
interacted O
with O
recombinant I-GENE
YB ALLCAPS
- I-GENE
1 I-GENE
on O
DMS ALLCAPS
protection O
footprinting O
analysis O
. O

Hence O
, O
scs32 NUMERIC
only O
partially O
suppressed O
the O
ts O
phenotype O
and O
was O
unable O
to O
suppress O
the O
Ino RARE
- O
phenotype O
of O
rpo26 NUMERIC
- I-GENE
31 I-GENE
. O

In O
contrast O
, O
both O
Sp1 I-GENE
and O
ETS I-GENE
proteins I-GENE
are O
required O
to O
bring RARE
about O
full O
promoter O
activity O
in O
the O
Surf I-GENE
- I-GENE
1 I-GENE
direction O
. O

CONCLUSION O
: O
Patients O
wit RARE
clinically O
palpable RARE
neck O
disease O
( O
N1 O
- O
3 O
), O
histological O
evidence O
of O
metastatic O
nodal O
disease O
, O
extracapsular RARE
spread O
, O
and O
three O
or O
more O
positive O
lymph O
nodes O
are O
at O
greater O
risk O
of O
developing O
failure O
at O
distant O
sites O
. O

We O
have O
subcloned O
into O
pBR322 NUMERIC
deoxyribonucleic RARE
acid O
( O
DNA O
) O
sequences O
mapping O
either O
in O
the O
coding O
region O
, O
the O
5 O
' O
spacer O
, O
or O
the O
3 O
' O
spacer O
of O
the O
H2B NUMERIC
histone I-GENE
gene I-GENE
. O

4 O
. O

Area RARE
under O
the O
drug O
concentration O
- O
time O
curves O
( O
AUC0 NUMERIC
- O
24 O
hr O
) O
for O
MTX ALLCAPS
were O
2379 NUMERIC
and O
3534 NUMERIC
ng O
* O
hr O
/ O
ml O
from O
PG ALLCAPS
- O
2 O
. O
5 O
% O
Azone RARE
and O
PG ALLCAPS
- O
7 O
. O
5 O
% O
Azone RARE
systems O
respectively O
. O

The O
combination O
of O
hydralazine RARE
hydrochloride RARE
and O
isosorbide RARE
dinitrate RARE
also O
improves RARE
survival O
, O
but O
direct O
comparison O
of O
both O
regimens O
provided O
evidence O
for O
a O
less O
favourable O
effect O
than O
that O
of O
the O
ACE I-GENE
inhibitors O
. O

To O
address O
mechanisms O
that O
define O
interactions O
of O
Site I-GENE
II I-GENE
regulatory I-GENE
factors I-GENE
with O
this O
cell O
cycle O
control O
element O
, O
we O
have O
investigated O
these O
determinants O
of O
transcriptional O
regulation O
at O
the O
G1 O
/ O
S O
phase O
transition O
in O
FDC ALLCAPS
- O
P1 O
hematopoietic O
progenitor O
cells O
. O

The O
goal O
of O
this O
study O
was O
to O
identify O
neuronal O
cell O
cultures O
that O
express O
RC3 NUMERIC
/ O
neurogranin RARE
, O
to O
check RARE
whether O
they O
are O
sensitive O
to O
T3 O
, O
and O
to O
examine O
the O
mechanism O
of O
regulation O
. O

There O
were O
differences O
between O
males O
( O
p O
< O
0 O
. O
05 O
) O
for O
most O
of O
the O
characteristics O
studied O
. O

Their O
circadian O
responses O
to O
both O
photic RARE
and O
non O
- O
photic RARE
cues RARE
were O
then O
tested O
. O

Although O
previous O
data O
have O
suggested O
that O
Rev I-GENE
uses O
the O
same O
export O
pathway O
as O
uracil RARE
- O
rich O
small O
nuclear O
RNAs O
and O
5S I-GENE
ribosomal I-GENE
RNA I-GENE
, O
the O
CTE ALLCAPS
seems O
to O
interact O
with O
evolutionarily O
conserved O
factors O
that O
are O
essential O
for O
cellular O
mRNA O
export O
. O

Human I-GENE
Duo RARE
contains O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
GEF ALLCAPS
) O
domain O
that O
is O
likely O
to O
be O
rac1 NUMERIC
- O
specific O
, O
a O
pleckstrin I-GENE
homology I-GENE
( O
PH I-GENE
) O
domain O
and O
spectrin I-GENE
- I-GENE
like I-GENE
repeat I-GENE
units I-GENE
. O

S2F NUMERIC
, O
a O
leaf O
- O
specific O
trans O
- O
acting O
factor O
, O
binds O
to O
a O
novel O
cis O
- O
acting O
element O
and O
differentially O
activates O
the O
RPL21 NUMERIC
gene I-GENE
. O

ArgR LASTCAP
was O
shown O
to O
be O
a O
dimer O
of O
two O
equal O
subunits O
, O
each O
with O
a O
molecular O
mass O
of O
37 O
, O
000 O
Da O
. O

Plasma I-GENE
leptin I-GENE
concentrations O
were O
higher O
in O
women O
than O
men O
, O
even O
after O
the O
adjustment O
for O
differences O
in O
fat O
mass O
( O
28 O
+/- O
3 O
ng O
/ O
ml O
for O
women O
vs O
. O

Consistent O
with O
effects O
on O
STAT I-GENE
activation O
, O
altered O
SHP I-GENE
- I-GENE
1 I-GENE
expression O
also O
affected O
EGF I-GENE
- O
induced O
activation O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
; O
expression O
of O
SHP I-GENE
- I-GENE
1 I-GENE
-( I-GENE
Cys I-GENE
--> I-GENE
Ser I-GENE
) I-GENE
inhibited O
activity O
of O
MEK I-GENE
by O
approximately O
25 O
%, O
whereas O
expression O
of O
SHP I-GENE
- I-GENE
1 I-GENE
resulted O
in O
a O
approximately O
25 O
% O
increase O
. O

This O
interaction O
involved O
the O
SH3 I-GENE
region I-GENE
of O
p50 I-GENE
( O
csk RARE
) O
and O
a O
proline O
- O
rich O
region O
( O
PPPLPERTPESFVLADM ALLCAPS
) O
outside O
the O
catalytic O
region O
of O
PTP I-GENE
- O
PEST ALLCAPS
. O

Following O
2 O
. O
5 O
Gy O
, O
HbO2 NUMERIC
changes O
were O
minimal O
. O

Polarised RARE
expression O
of O
human O
intestinal O
N I-GENE
- I-GENE
benzoyl RARE
- I-GENE
L I-GENE
- I-GENE
tyrosyl RARE
- I-GENE
p I-GENE
- I-GENE
aminobenzoic RARE
acid I-GENE
hydrolase RARE
( O
human I-GENE
meprin RARE
) O
alpha O
and O
beta O
subunits O
in O
Madin RARE
- O
Darby RARE
canine O
kidney O
cells O
. O

Neither O
mutant O
exhibited O
derepression O
of O
the O
silent I-GENE
mating I-GENE
type I-GENE
loci I-GENE
. O

Among O
38 O
patients O
with O
inducible O
reentrant RARE
VTs RARE
who O
underwent O
electrophysiologic RARE
study O
( O
EPS ALLCAPS
), O
10 O
VTs RARE
of O
six O
patients O
were O
selected O
. O

The O
cycle O
length O
of O
induced O
VT O
( O
n O
= O
10 O
VTs RARE
) O
was O
380 NUMERIC
+/- O
41 O
msec O
. O

Transient O
hyperammonaemia RARE
in O
an O
adult O
German RARE
shepherd RARE
dog O
. O

We O
established O
that O
the O
2 O
. O
6 O
kb O
mRNA O
V O
- O
1 O
and O
the O
2 O
. O
3 O
kb O
GGT ALLCAPS
mRNA O
V O
- O
2 O
derive RARE
, O
by O
alternate O
splicing O
, O
from O
a O
primary O
transcript O
initiated O
on O
a O
distal O
promoter O
on O
the O
rat I-GENE
GGT ALLCAPS
gene I-GENE
. O

A O
specific O
distal O
promoter O
controls O
gamma I-GENE
- I-GENE
glutamyl I-GENE
transpeptidase RARE
gene I-GENE
expression O
in O
undifferentiated O
rat O
transformed O
liver O
cells O
. O

These O
repressor O
sites O
are O
pyrimidine O
rich O
and O
bind O
avidly RARE
to O
the O
polypyrimidine RARE
tract I-GENE
binding I-GENE
protein I-GENE
( O
PTB I-GENE
) O
in O
HeLa O
nuclear O
extracts O
as O
determined O
by O
UV O
crosslinking RARE
/ O
competition O
assays O
. O

For O
higher O
expression O
of O
lipA LASTCAP
in O
S O
. O
lividans RARE
, O
the O
gene O
was O
cloned O
next O
to O
the O
strong O
aphII LASTCAP
promoter I-GENE
. O

Within O
a O
135 O
- O
bp O
core O
homology O
region O
, O
the O
human I-GENE
HS12 NUMERIC
enhancers I-GENE
are O
approximately O
90 O
% O
identical O
to O
the O
murine O
homolog O
and O
include O
several O
motifs O
previously O
demonstrated O
to O
be O
important O
for O
function O
of O
the O
murine O
enhancer O
; O
additional O
segments O
of O
high O
sequence O
conservation O
suggest O
the O
possibility O
of O
previously O
unrecognized RARE
functional O
motifs O
. O

In O
contrast O
to O
the O
wild O
- O
type O
protein O
, O
expression O
of O
p45 NUMERIC
NF I-GENE
- I-GENE
E2 I-GENE
lacking O
this O
activation O
domain O
in O
an O
NF I-GENE
- I-GENE
E2 I-GENE
null O
cell O
line O
fails O
to O
support O
enhancer O
- O
dependent O
transcription O
in O
transient O
assays O
. O

These O
findings O
suggest O
one O
potential O
mechanism O
for O
direct O
recruitment O
of O
distal O
regulatory O
regions O
of O
the O
globin I-GENE
loci I-GENE
to O
the O
individual O
promoters O
. O

The O
promoter O
region O
showed O
no O
consensus O
TATA O
box O
but O
it O
contains O
CCAAT O
and O
CreA LASTCAP
boxes O
known O
to O
be O
involved O
in O
both O
stress O
and O
carbon O
- O
catabolite O
regulation O
of O
fungal O
promoters O
. O

The O
two O
cysteine O
residues O
located O
in O
this O
additional O
region O
may O
be O
involved O
in O
the O
formation O
of O
a O
disulfide O
bridge RARE
associated O
with O
the O
activation O
process O
of O
the O
catalytic O
activity O
. O

The O
por RARE
gene I-GENE
has O
been O
expressed O
, O
for O
the O
first O
time O
, O
in O
anaerobically RARE
grown O
Escherichia O
coli O
behind O
the O
isopropyl RARE
- O
beta O
- O
D O
- O
thiogalactopyranoside RARE
- O
inducible O
tac RARE
promoter I-GENE
, O
resulting O
in O
the O
production O
of O
POR ALLCAPS
in O
its O
active O
form O
. O

When O
the O
downstream O
operator O
was O
altered O
, O
there O
was O
a O
fourfold O
reduction O
in O
reporter O
enzyme O
levels O
. O

The O
ORF3 O
mutant O
produced O
reduced O
levels O
of O
tabtoxin RARE
, O
indicating O
that O
ORF3 O
may O
have O
a O
role O
in O
T I-GENE
beta I-GENE
L I-GENE
biosynthesis O
. O

Refined RARE
Cox O
models O
using O
a O
CD4 I-GENE
count O
of O
150 O
/ O
microL LASTCAP
rather O
than O
200 O
/ O
microL LASTCAP
to O
distinguish RARE
I0 NUMERIC
and O
I1 NUMERIC
yielded O
a O
simplified RARE
model O
with O
better O
fit O
to O
the O
observed O
data O
. O

However O
, O
the O
published O
reports O
consist O
of O
a O
small O
number O
of O
patients O
and O
limited O
data O
. O

These O
transcripts O
contain O
the O
5 O
' O
ends O
of O
mature O
UbCRBP LASTCAP
mRNAs I-GENE
; O
extend O
through O
UbCRBP LASTCAP
, O
across O
the O
intergenic O
region O
, O
and O
a O
significant O
distance O
3 O
' O
into O
the O
enolase RARE
gene I-GENE
. O

The O
distribution O
of O
cryptosporidia RARE
in O
the O
intestine O
and O
number O
of O
cryptosporidia RARE
per O
ileal RARE
villus RARE
on O
different O
DPI ALLCAPS
were O
also O
estimated O
for O
detailed O
characterization O
of O
the O
infection O
in O
kids RARE
as O
a O
model O
for O
experimental O
cryptosporidiosis RARE
. O

As O
a O
result O
, O
the O
subendocardial RARE
/ O
subepicardial RARE
blood O
flow O
ratio O
( O
ENDO ALLCAPS
/ O
EPI ALLCAPS
) O
increased O
from O
0 O
. O
44 O
+/- O
0 O
. O
09 O
during O
control O
stenosis O
to O
0 O
. O
85 O
+/- O
0 O
. O
13 O
after O
ITF ALLCAPS
1129 NUMERIC
( O
10 O
micrograms O
/ O
kg O
/ O
min O
i O
. O
v O
.) O
and O
to O
0 O
. O
81 O
+/- O
0 O
. O
12 O
after O
NTG ALLCAPS
. O

Proteasomes RARE
are O
the O
multisubunit O
protease O
involved O
in O
the O
generation O
of O
peptides O
presented O
by O
MHC I-GENE
class I-GENE
I I-GENE
molecules I-GENE
. O

In O
support O
of O
this O
interpretation O
we O
demonstrate O
that O
MQ9b NUMERIC
binds O
strongly O
5 O
of O
17 O
motif O
- O
positive O
, O
pathogen RARE
- O
derived O
synthetic O
peptides O
. O

Takahashi RARE
, O
H O
. O

For O
sputum I-GENE
interleukin I-GENE
- I-GENE
8 I-GENE
there O
was O
an O
estimated O
true O
treatment O
median O
difference O
of O
142 O
pg O
/ O
ml O
( O
95 O
% O
confidence O
interval O
( O
CI O
) O
8 O
to O
2866 NUMERIC
pg O
/ O
ml O
) O
in O
favour RARE
of O
placebo O
; O
while O
for O
maximal O
expiratory O
flow O
at O
25 O
% O
( O
MEF25 NUMERIC
%) O
remaining O
forced RARE
vital O
capacity O
predicted O
for O
sex O
and O
height O
there O
was O
a O
15 O
percentage O
points O
( O
pp RARE
) O
( O
95 O
% O
CI O
4 O
to O
26 O
pp RARE
) O
mean O
treatment O
difference O
in O
favour RARE
of O
placebo O
. O

However O
, O
although O
deletion O
of O
Fp1 NUMERIC
in O
the O
hCRBP1 NUMERIC
gene I-GENE
yielded O
increased O
CAT I-GENE
activity O
, O
pointing RARE
toward O
a O
negative O
regulatory O
function O
exerted RARE
by O
this O
element O
, O
its O
insertion O
upstream O
of O
the O
p12 NUMERIC
basal I-GENE
promoter I-GENE
results O
in O
an O
impressive RARE
positive O
stimulation O
of O
CAT I-GENE
gene I-GENE
expression O
. O

Gaucher RARE
' O
s O
disease O
is O
a O
rare O
metabolic O
disorder O
characterized O
by O
the O
lack O
of O
beta I-GENE
- I-GENE
glucocerebrosidase RARE
enzyme I-GENE
. O

These O
discoloration RARE
' O
s O
can O
be O
treated O
in O
several O
ways O
but O
up O
to O
lately RARE
tooth O
structure O
had O
to O
be O
removed O
in O
an O
irreversible O
manner O
in O
order O
to O
provide O
sufficient O
bulk O
for O
the O
new O
restorative RARE
material O
. O

The O
9 O
; O
22 O
chromosomal O
translocation O
characteristic O
of O
CML O
results O
in O
a O
fused O
bcr RARE
/ O
abl I-GENE
gene O
and O
an O
abnormal O
fusion O
protein O
, O
p210bcr NUMERIC
/ O
abl I-GENE
. O

Overexpression O
of O
BAG ALLCAPS
- I-GENE
1 I-GENE
also O
protected O
certain O
cell O
lines O
from O
heat O
shock O
- O
induced O
cell O
death O
. O

The O
5 O
' O
flanking O
region O
contains O
potential O
binding O
sites O
for O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
Sp1 I-GENE
, O
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
NF1 I-GENE
), O
CAAT I-GENE
- I-GENE
box I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
), O
hepatocyte I-GENE
nuclear I-GENE
factors I-GENE
1 I-GENE
and I-GENE
5 I-GENE
( O
HNF1 NUMERIC
, O
HNF5 NUMERIC
) O
and O
activator I-GENE
proteins I-GENE
1 I-GENE
and I-GENE
2 I-GENE
( O
AP1 I-GENE
, O
AP2 I-GENE
). O

The O
recognition O
specificity O
of O
the O
p55 I-GENE
PDZ I-GENE
domain I-GENE
appears O
to O
be O
unique O
, O
since O
the O
three O
PDZ I-GENE
domains I-GENE
of O
hDlg RARE
( O
human O
lymphocyte O
homologue O
of O
the O
Drosophila I-GENE
discs RARE
large I-GENE
tumor I-GENE
suppressor I-GENE
) O
do O
not O
bind O
the O
cytoplasmic O
domain O
of O
glycophorin RARE
C I-GENE
. O

By O
analyzing O
the O
RanGAP LASTCAP
activity O
of O
a O
series O
of O
recombinantly RARE
expressed O
rna1p NUMERIC
mutant I-GENE
derivatives O
, O
we O
show O
that O
the O
highly O
acidic O
sequence O
in O
the O
C O
- O
terminal O
domain O
of O
both O
yeast O
proteins O
is O
indispensable RARE
for O
activating O
Ran I-GENE
- O
mediated O
GTP O
hydrolysis O
. O

In O
the O
absence O
of O
MHC I-GENE
class I-GENE
II I-GENE
, O
purified I-GENE
soluble I-GENE
D10 NUMERIC
TCR I-GENE
bound O
to O
Staphylococcus I-GENE
aureus I-GENE
enterotoxin I-GENE
C2 I-GENE
with O
an O
association O
rate O
of O
1 O
. O
69 O
+/- O
0 O
. O
12 O
x O
10 O
( O
4 O
) O
M O
(- O
1 O
) O
sec O
(- O
1 O
) O
and O
a O
dissociation O
rate O
of O
1 O
. O
9 O
+/- O
0 O
. O
47 O
x O
10 O
(- O
2 O
) O
sec O
(- O
1 O
), O
giving O
a O
dissociation O
constant O
of O
1 O
. O
1 O
microM O
. O

Evidence O
for O
such O
peak O
shifts O
has O
been O
found O
in O
the O
responses O
of O
auditory O
nerve O
fibers O
, O
cochlear O
microphonics RARE
, O
and O
the O
responses O
of O
outer O
hair RARE
cells O
and O
supporting O
cells O
in O
the O
cochlea RARE
, O
as O
well O
as O
in O
basilar RARE
membrane O
vibration O
measurements O
, O
and O
indirectly O
, O
in O
psychophysical RARE
data O
. O

Mnt RARE
: O
Max I-GENE
complexes O
also O
efficiently O
suppress O
Myc I-GENE
- O
dependent O
activation O
from O
the O
same O
promoter O
. O

In O
the O
United O
States RARE
high O
- O
MW ALLCAPS
HES ALLCAPS
480 NUMERIC
which O
is O
difficult O
to O
degrade RARE
is O
most O
frequently O
used O
and O
results O
in O
a O
larger O
in O
vivo O
MW ALLCAPS
and O
subsequent O
decrease O
in O
factor I-GENE
VIII I-GENE
/ O
von I-GENE
Willebrand I-GENE
factor I-GENE
levels O
. O

Assays RARE
of O
total O
cholesterol O
as O
well O
as O
the O
HDL I-GENE
, O
HDL2 I-GENE
, O
LDL I-GENE
, O
triglycerides O
, O
endothelin I-GENE
- I-GENE
1 I-GENE
, O
lipoprotein O
( O
a O
), O
estradiol O
and O
FSH I-GENE
were O
also O
obtained O
at O
baseline O
before O
receiving O
ERT ALLCAPS
and O
after O
3 O
months O
of O
ERT ALLCAPS
. O

Six O
tandem O
repeats O
of O
the O
P I-GENE
element I-GENE
linked O
to O
the O
SV40 I-GENE
promoter I-GENE
responded O
to O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
, O
while O
that O
of O
other O
elements O
did O
not O
. O

The O
distributed O
current O
density O
J O
is O
calculated O
within O
the O
volume O
defined O
by O
the O
motor O
unit O
. O

The O
cleavage O
dipeptides RARE
of O
C1YVV NUMERIC
NIa RARE
protease I-GENE
are O
Q O
( O
E O
)/ O
S O
( O
A O
, O
G O
). O

In O
our O
previous O
studies O
, O
transcriptional O
activation O
was O
shown O
to O
correlate O
with O
IEP86 NUMERIC
binding O
to O
both O
the O
TATA I-GENE
- I-GENE
box I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
and O
the O
transcription O
factor O
bound O
upstream O
. O

However O
, O
we O
were O
unable O
to O
identify O
a O
p4 NUMERIC
molecule O
. O

( O
iv O
) O
The O
accumulation O
of O
cyclin I-GENE
D3 I-GENE
protein I-GENE
in O
Vero RARE
cells O
infected O
with O
an O
alpha0 NUMERIC
deletion I-GENE
mutant I-GENE
was O
reduced O
relative O
to O
that O
of O
cells O
infected O
with O
wild O
- O
type O
virus O
or O
a O
recombinant O
virus O
in O
which O
the O
deleted O
alpha0 NUMERIC
sequences I-GENE
were O
restored O
. O

We O
report O
the O
preliminary O
biochemical O
characterization O
of O
the O
T I-GENE
antigens I-GENE
encoded O
by O
three O
SV40 O
mutants O
, O
5030 NUMERIC
, O
5031 NUMERIC
, O
and O
5061 NUMERIC
, O
each O
of O
which O
have O
altered O
residues O
within O
or O
near O
the O
ATP O
binding O
pocket O
. O

These O
effects O
were O
abrogated O
by O
co O
- O
expression O
of O
kinase I-GENE
- I-GENE
deficient I-GENE
PKC I-GENE
zeta I-GENE
and O
inhibition O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
p85alpha NUMERIC
- O
p110 NUMERIC
by O
wortmannin O
, O
LY294002 NUMERIC
and O
a O
dominant O
- O
negative O
mutant O
of O
p85alpha NUMERIC
. O

Protein I-GENE
phosphatase I-GENE
2A I-GENE
is O
a O
critical O
regulator O
of O
protein I-GENE
kinase I-GENE
C I-GENE
zeta I-GENE
signaling O
targeted O
by O
SV40 I-GENE
small I-GENE
t I-GENE
to O
promote O
cell O
growth O
and O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

Interestingly O
, O
the O
RXRalphaF318A NUMERIC
constitutive O
activity O
generated O
within O
heterodimers O
in O
the O
presence O
of O
BMS614 NUMERIC
requires O
the O
integrity O
of O
both O
RXR I-GENE
and O
RAR I-GENE
AF O
- O
2 O
domains O
. O

These O
introns O
contain O
only O
single O
snoRNA LASTCAP
genes I-GENE
and O
their O
processing O
involves O
exonucleolytic RARE
release O
of O
the O
snoRNA LASTCAP
from O
debranched RARE
intron O
lariats RARE
. O

Recent O
studies O
have O
shown O
that O
the O
Src I-GENE
homology I-GENE
- I-GENE
2 I-GENE
( O
SH2 I-GENE
) O
domain O
- O
containing O
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
, O
SHP I-GENE
- I-GENE
2 I-GENE
, O
associates O
with O
the O
cytoplasmic O
domain O
of O
PECAM ALLCAPS
- I-GENE
1 I-GENE
as O
it O
becomes O
tyrosine O
- O
phosphorylated O
during O
platelet O
aggregation O
: O
a O
process O
that O
can O
be O
mimicked O
in O
part O
by O
small O
synthetic O
phosphopeptides O
corresponding O
to O
the O
cytoplasmic O
domain O
of O
PECAM ALLCAPS
- I-GENE
1 I-GENE
encompassing O
tyrosine O
residues O
Tyr O
- O
663 NUMERIC
or O
Tyr O
- O
686 NUMERIC
. O

Underlying RARE
the O
clustering RARE
of O
these O
risk O
variables O
were O
three O
factors O
. O

Supplementation RARE
was O
stopped O
when O
pl RARE
- I-GENE
ALB ALLCAPS
reached O
2 O
. O
0 O
g O
/ O
dL O
. O

Detection O
of O
airborne RARE
Mycobacterium O
tuberculosis O
by O
air O
filtration O
and O
polymerase O
chain O
reaction O
. O

These O
findings O
show O
that O
EBP50 NUMERIC
is O
a O
physiologically RARE
relevant O
ezrin RARE
binding I-GENE
protein I-GENE
. O

Previously O
, O
we O
reported O
that O
scanthrough RARE
translation O
, O
where O
the O
initiating O
AUG O
of O
a O
primary O
open O
reading O
frame O
is O
bypassed RARE
, O
is O
most O
likely O
to O
account O
for O
the O
presentation O
of O
cryptic RARE
epitopes O
from O
alternative O
reading O
frames O
within O
the O
influenza I-GENE
A I-GENE
PR I-GENE
/ I-GENE
8 I-GENE
/ I-GENE
34 I-GENE
nucleoprotein I-GENE
gene I-GENE
. O

This O
family O
of O
proteins O
binds O
GC O
- O
rich O
motifs O
widely O
distributed O
in O
gene O
promoters O
, O
resulting O
in O
distinct O
activation O
or O
repression O
of O
transcriptional O
activities O
. O

Deletion O
of O
the O
POR2 NUMERIC
gene I-GENE
alone O
had O
no O
detectable O
phenotype O
, O
while O
yeasts RARE
with O
deletions O
of O
both O
the O
POR1 NUMERIC
and O
POR2 NUMERIC
genes I-GENE
were O
viable O
and O
able O
to O
grow O
on O
glycerol RARE
at O
30 O
degrees O
C O
, O
albeit RARE
more O
slowly O
than O
delta I-GENE
por1 NUMERIC
single I-GENE
mutants I-GENE
. O

Furthermore O
, O
our O
novel O
observation O
that O
expression O
of O
a O
highly O
activated O
FGFR3 NUMERIC
kinase I-GENE
domain I-GENE
is O
able O
to O
morphologically RARE
transform O
fibroblasts O
suggests O
that O
dysregulation RARE
of O
FGFR3 NUMERIC
has O
the O
potential O
to O
play O
a O
role O
in O
human O
neoplasia RARE
. O

The O
deduced O
amino O
acid O
sequence O
of O
the O
gene O
has O
significant O
homology O
to O
the O
interferon I-GENE
regulatory I-GENE
factors I-GENE
( O
IRFs RARE
). O

Involvement RARE
of O
AP I-GENE
- I-GENE
2 I-GENE
in O
regulation O
of O
the O
R I-GENE
- I-GENE
FABP ALLCAPS
gene I-GENE
in O
the O
developing O
chick O
retina O
. O

However O
, O
Cbf5p NUMERIC
was O
found O
to O
be O
nucleolar O
and O
is O
highly O
homologous O
to O
the O
rat I-GENE
nucleolar I-GENE
protein I-GENE
NAP57 NUMERIC
, O
which O
coimmunoprecipitates RARE
with O
Nopp140 NUMERIC
and O
which O
is O
postulated O
to O
be O
involved O
in O
nucleolar O
- O
cytoplasmic O
shuttling RARE
( O
U O
. O

This O
newly O
described O
organism O
was O
difficult O
to O
identify O
due O
to O
discrepancies RARE
between O
the O
Vitek RARE
and O
API ALLCAPS
20E NUMERIC
identification O
systems O
. O

Ig I-GENE
heavy I-GENE
chain I-GENE
class O
switching O
is O
directed O
by O
cytokines O
inducing O
transcription O
from O
unrearranged RARE
CH ALLCAPS
genes I-GENE
. O

The O
available O
data O
suggest O
that O
the O
NF I-GENE
kappa I-GENE
B2 I-GENE
nucleoprotein I-GENE
complex I-GENE
may O
cooperate O
with O
DNA O
- O
bound O
STAT6 NUMERIC
to O
achieve O
IL I-GENE
- I-GENE
4 I-GENE
- O
dependent O
activation O
of O
the O
human I-GENE
IgE I-GENE
germline I-GENE
gene I-GENE
. O

EXERCISE ALLCAPS
IN ALLCAPS
THE ALLCAPS
TERRESTRIAL ALLCAPS
CHRISTMAS ALLCAPS
ISLAND ALLCAPS
RED ALLCAPS
CRAB ALLCAPS
GECARCOIDEA ALLCAPS
NATALIS ALLCAPS
- O
ENERGETICS ALLCAPS
OF ALLCAPS
LOCOMOTION ALLCAPS

THE ALLCAPS
SCALING ALLCAPS
OF ALLCAPS
SONG ALLCAPS
FREQUENCY ALLCAPS
IN ALLCAPS
CICADAS ALLCAPS

The O
pheromone O
response O
pathway O
activates O
transcription O
of O
Ty5 NUMERIC
retrotransposons RARE
located O
within O
silent O
chromatin O
of O
Saccharomyces O
cerevisiae O
. O

In O
this O
study O
we O
have O
introduced O
mutations O
into O
the O
corresponding O
elements O
of O
two O
cox3 NUMERIC
promoters I-GENE
and O
show O
that O
while O
the O
core O
element O
is O
essential O
for O
cox3 NUMERIC
promoter I-GENE
activity O
, O
upstream O
element O
mutations O
have O
little O
or O
no O
effect O
. O

We O
found O
that O
multiple O
tumor O
suppressor O
genes O
( O
e O
. O
g O
., O
p53 I-GENE
, O
DCC ALLCAPS
, O
APC I-GENE
, O
MCC ALLCAPS
, O
BRCA1 I-GENE
, O
and O
WAF1 I-GENE
/ O
CIP1 NUMERIC
) O
were O
inactivated O
at O
different O
frequencies O
via O
various O
mechanisms O
[ O
e O
. O
g O
., O
loss O
of O
heterozygosity O
( O
LOH ALLCAPS
), O
loss O
of O
expression O
( O
LOE ALLCAPS
), O
mutation O
, O
and O
inactivation O
by O
cellular O
binding O
protein O
]. O

The O
histidine O
- O
tagged O
gene O
, O
rpoCHIS LASTCAP
, O
was O
used O
to O
replace O
the O
wild O
- O
type O
allele O
in O
the O
chromosome O
of O
S O
. O
coelicolor RARE
and O
S O
. O
lividans RARE
. O

Because O
the O
deletion O
included O
the O
TK I-GENE
gene I-GENE
, O
selection O
with O
gancyclovir RARE
against O
cells O
not O
having O
undergone O
recombination O
was O
possible O
. O

The O
malate RARE
synthase I-GENE
gene I-GENE
, O
MLS1 NUMERIC
, O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
is O
transcriptionally O
regulated O
by O
the O
carbon O
source O
in O
the O
growth O
medium O
. O

By O
deletion O
analysis O
of O
the O
MLS1 NUMERIC
control O
region O
, O
we O
identified O
two O
sites O
, O
UAS1 O
and O
UAS2 NUMERIC
, O
as O
important O
for O
efficient O
derepression O
of O
the O
gene O
. O

Lack RARE
of O
controlled O
prospective O
studies O
of O
sleep O
electroencephalograms RARE
( O
EEG O
), O
and O
the O
use O
of O
medication O
, O
in O
children O
with O
developmental O
dysphasia RARE
, O
may O
deny RARE
appropriate O
treatment O
strategies O
to O
children O
with O
severe O
developmental O
speech O
and O
language O
disorders O
. O

Prior RARE
to O
meals RARE
2 O
to O
3 O
times O
daily O
, O
1 O
- O
2 O
tablespoons RARE
of O
Alzoon RARE
are O
recommended O
. O

Widening RARE
of O
the O
abdominal O
aortic O
wall O
on O
an O
ultrasound O
examination O
was O
the O
key O
to O
the O
incidental RARE
diagnosis O
of O
a O
clinically O
unsuspected RARE
type O
B O
dissection O
. O

Fermentation RARE
process O
after O
supplementation O
of O
nitrate O
, O
nitrite O
, O
lactic RARE
acid O
bacteria O
and O
formic RARE
acid O

Substrates RARE
include O
the O
p21 I-GENE
( O
ras I-GENE
) O
proteins O
, O
nuclear I-GENE
lamins RARE
, O
and O
a O
series O
of O
retinal O
proteins O
. O

Ovaries RARE
of O
10 O
animals O
per O
group O
from O
16 O
studies O
in O
CD O
- O
1 O
mice O
and O
1 O
study O
each O
in O
C3H O
and O
C57BL O
/ O
6 O
mice O
were O
sectioned RARE
serially RARE
at O
6 O
microm O
. O

The O
Trx RARE
- O
CT I-GENE
fusion O
protein O
was O
produced O
less O
efficiently O
( O
20 O
% O
of O
total O
soluble O
cellular O
protein O
). O

These O
results O
suggest O
that O
UBP41 NUMERIC
may O
play O
an O
important O
role O
in O
the O
recycling RARE
of O
ubiquitin I-GENE
by O
hydrolysis O
of O
branched I-GENE
poly I-GENE
- I-GENE
ubiquitin I-GENE
chains I-GENE
generated O
by O
the O
action O
of O
26 I-GENE
S I-GENE
proteasome I-GENE
on O
poly O
- O
ubiquitinated RARE
protein O
substrates O
, O
as O
well O
as O
in O
the O
production O
of O
free O
ubiquitin I-GENE
from O
linear I-GENE
poly I-GENE
- I-GENE
ubiquitin I-GENE
chains I-GENE
and O
of O
certain O
ribosomal O
proteins O
from O
ubiquitin I-GENE
fusion I-GENE
proteins I-GENE
. O

A O
data O
base O
homology O
search O
revealed O
that O
the O
predicted O
ER1 NUMERIC
amino O
acid O
sequence O
contains O
three O
regions O
of O
similarity O
to O
the O
rat O
and O
human O
proteins O
encoded O
by O
the O
metastasis O
- O
associated O
gene O
, O
mta1 NUMERIC
, O
and O
two O
regions O
of O
similarity O
to O
the O
Caenorhabditis O
elegans O
sequence O
that O
is O
similar O
to O
mta1 NUMERIC
. O

The O
sequenced O
cDNA O
predicts O
a O
704 NUMERIC
- O
amino O
acid O
protein O
80 O
% O
identical O
to O
human I-GENE
progelatinase RARE
B I-GENE
. O

The O
inhibition O
by O
cytosolic O
Ca2 O
+ O
was O
caused O
by O
a O
decrease O
in O
cooperativity O
and O
by O
a O
shift O
in O
EC50 NUMERIC
toward O
higher O
InsP3 NUMERIC
concentrations O
. O

RESULTS O
: O
The O
standardised RARE
mortality O
ratio O
( O
SMR ALLCAPS
) O
for O
all O
malignant O
neoplasms O
was O
94 O
( O
95 O
% O
CI O
74 O
to O
118 O
). O

Sequence O
analysis O
of O
this O
region O
revealed O
three O
eight O
- O
bp O
repetitive O
elements O
, O
the O
deletion O
of O
which O
restored O
wild O
- O
type O
levels O
of O
luciferase I-GENE
activity O
to O
the O
- O
916 NUMERIC
- O
bp O
reporter O
plasmid O
. O

Using O
5 O
' O
RACE O
and O
reverse O
transcription O
- O
PCR O
( O
RT O
- O
PCR O
) O
methodologies RARE
, O
we O
cloned O
these O
sequences O
from O
brain O
and O
placenta O
and O
found O
this O
material O
to O
be O
composed O
of O
alternatively O
spliced O
exons O
using O
a O
previously O
reported O
noncoding O
exon O
( O
1A NUMERIC
) O
and O
a O
novel O
97 O
- O
bp O
noncoding O
exon O
( O
1B O
). O

This O
is O
the O
first O
study O
in O
which O
mutation O
screening O
has O
been O
performed O
for O
both O
the O
EXT1 NUMERIC
and O
EXT2 NUMERIC
genes I-GENE
prior O
to O
any O
linkage O
analysis O
. O

The O
regurgitation RARE
of O
large O
vitreous O
injections O
. O

Positron RARE
emission O
tomography O
radioligands RARE
for O
dopamine I-GENE
transporters I-GENE
and O
studies O
in O
human O
and O
nonhuman RARE
primates O
. O

Attenuation RARE
from O
the O
vit RARE
A2 I-GENE
consensus O
ERE ALLCAPS
is O
not O
necessarily O
dependent O
on O
DNA O
binding O
as O
the O
TR I-GENE
alpha I-GENE
DNA O
binding O
mutant O
was O
still O
able O
to O
inhibit O
E O
- O
dependent O
transactivation O
. O

Expression O
from O
this O
element O
is O
regulated O
by O
a O
heteromeric RARE
protein O
complex O
containing O
ubiquitous O
( O
i O
. O
e O
. O
the O
E2A NUMERIC
- O
and O
HEB ALLCAPS
- I-GENE
encoded I-GENE
proteins I-GENE
) O
and O
islet O
- O
enriched O
members O
of O
the O
bHLH I-GENE
family I-GENE
. O

Thus O
, O
the O
CCAAT O
box O
also O
has O
tissue O
- O
specific O
characteristics O
that O
assist RARE
in O
targeting O
expression O
of O
the O
alpha I-GENE
- I-GENE
subunit I-GENE
gene I-GENE
to O
trophoblasts RARE
. O

U4 I-GENE
/ O
U6 I-GENE
snRNP O
is O
one O
of O
four O
essential O
small O
nuclear O
ribonucleoprotein O
( O
snRNP O
) O
particles O
( O
U1 I-GENE
, O
U2 I-GENE
, O
U5 I-GENE
and O
U4 I-GENE
/ O
U6 I-GENE
) O
present O
in O
the O
spliceosome O
. O

Hprp3p NUMERIC
is O
a O
77 O
kDa O
protein O
, O
which O
is O
homologous O
to O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
splicing I-GENE
factor I-GENE
Prp3p NUMERIC
. O

The O
growth O
- O
promoting O
properties O
of O
the O
retroviral I-GENE
v I-GENE
- I-GENE
erbA I-GENE
oncogene I-GENE
, O
a O
highly O
mutated O
version O
of O
the O
chicken I-GENE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( I-GENE
TR I-GENE
) I-GENE
alpha I-GENE
, O
have O
so O
far O
exclusively O
been O
linked O
to O
dominant O
repression O
of O
the O
antimitogenic RARE
roles O
of O
TR I-GENE
and O
retinoic I-GENE
acid I-GENE
receptors I-GENE
. O

We O
cloned O
a O
complete O
cDNA O
( O
2 O
. O
9 O
kb O
) O
for O
HET ALLCAPS
from O
an O
MCF ALLCAPS
- O
7 O
cDNA O
library O
. O

The O
most O
common O
grade O
3 O
toxicity O
was O
neutropenia O
, O
thrombocytopenia O
, O
and O
parasthesias RARE
( O
observed O
in O
< O
10 O
% O
of O
cycles O
). O

Serum O
concentrations O
of O
E2 O
and O
TBOH ALLCAPS
were O
measured O
on O
d O
0 O
, O
1 O
, O
3 O
, O
5 O
, O
7 O
, O
13 O
, O
21 O
, O
28 O
, O
42 O
, O
56 O
, O
84 O
, O
112 O
, O
and O
140 O
in O
finishing RARE
heifers O
administered O
the O
following O
treatments O
: O
1 O
) O
control O
; O
2 O
) O
MGA O
, O
. O
5 O
mg O
per O
heifer RARE
daily O
; O
3 O
) O
Revalor RARE
- O
H O
( O
140 O
mg O
TBA ALLCAPS
+ O
14 O
mg O
E2 O
); O
4 O
) O
Revalor RARE
- O
H O
+ O
MGA O
; O
5 O
) O
Finaplix RARE
- O
H O
( O
200 O
mg O
TBA ALLCAPS
); O
and O
6 O
) O
Finaplix RARE
- O
H O
+ O
MGA O
. O

Serum O
E2 O
concentrations O
increased O
numerically RARE
two O
- O
to O
threefold O
from O
d O
56 O
to O
140 O
in O
controls O
fed O
MGA O
, O
compared O
with O
controls O
not O
fed O
MGA O
. O

Interferon I-GENE
Regulatory RARE
Factor I-GENE
( I-GENE
IRF I-GENE
)- I-GENE
1 I-GENE
has O
been O
characterized O
as O
an O
important O
growth O
regulatory O
and O
immunomodulatory RARE
transcription O
factor O
. O

The O
genomic O
structure O
of O
brk RARE
consists O
of O
8 O
exons O
, O
whose O
boundaries O
are O
distinct O
from O
other O
non O
- O
receptor O
PTK ALLCAPS
family I-GENE
members O
, O
again O
indicating O
a O
structural O
and O
functional O
divergence O
. O

We O
have O
previously O
reported O
that O
expression O
of O
a O
tumour O
derived O
brk RARE
cDNA I-GENE
in O
mouse O
embryonic O
fibroblasts O
and O
human O
mammary O
epithelial O
cells O
supports O
anchorage O
independent O
growth O
, O
and O
in O
the O
latter O
potentiates O
the O
mitogenic O
response O
to O
epidermal I-GENE
growth I-GENE
factor I-GENE
. O

Anti I-GENE
- I-GENE
hepatitis I-GENE
A I-GENE
virus O
( O
HAV ALLCAPS
) O
titer O
after O
vaccination O
was O
measured O
in O
83 O
HIV O
- O
positive O
and O
39 O
HIV O
- O
negative O
men O
. O

One O
skull RARE
does O
not O
a O
species O
make O
. O

Surprisingly O
, O
calf I-GENE
thymus RARE
CstF LASTCAP
contained O
an O
additional O
, O
novel O
form O
of O
the O
64 O
- O
kDa O
subunit O
with O
a O
molecular O
mass O
of O
70 O
kDa O
. O

Null RARE
mutations O
in O
daf RARE
- I-GENE
3 I-GENE
suppress O
mutations O
in O
genes O
encoding O
this O
TGF I-GENE
- I-GENE
beta I-GENE
signal O
, O
its O
receptors O
, O
and O
associated O
Smad I-GENE
signal I-GENE
transduction I-GENE
proteins I-GENE
. O
daf RARE
- I-GENE
3 I-GENE
encodes O
a O
Smad I-GENE
protein I-GENE
that O
is O
most O
closely O
related O
to O
mammalian I-GENE
DPC4 NUMERIC
, O
and O
is O
expressed O
throughout O
development O
in O
many O
of O
the O
tissues O
that O
are O
remodeled RARE
during O
dauer RARE
development O
. O

Our O
results O
favor RARE
the O
possibility O
that O
the O
Drosophila I-GENE
EGF I-GENE
receptor I-GENE
DER I-GENE
/ O
Egfr RARE
expressed O
by O
the O
EMA ALLCAPS
cells O
functions O
as O
a O
receptor O
for O
Vein RARE
. O

PATIENTS O
AND O
METHODS O
: O
In O
807 NUMERIC
consecutive O
patients O
from O
the O
Chilean RARE
National O
Registry RARE
of O
Acute O
Myocardial O
Infarction RARE
we O
analyzed O
the O
resolution O
of O
chest O
pain O
and O
ST O
segment O
elevation O
over O
50 O
% O
within O
the O
first O
90 O
min O
, O
abrupt RARE
CK I-GENE
rise O
within O
8 O
h O
and O
T O
wave O
inversion O
in O
infarct O
related O
EKG ALLCAPS
leads O
within O
the O
first O
24 O
h O
after O
thrombolysis RARE
. O

Because O
of O
the O
operon O
structure O
of O
this O
organism O
, O
traditional RARE
methods O
such O
as O
insertional O
mutagenesis O
run O
the O
risk O
of O
introducing RARE
polar RARE
effects O
on O
downstream O
genes O
or O
creating RARE
secondary O
mutations O
elsewhere RARE
in O
the O
genome O
. O

It O
has O
been O
proposed O
that O
the O
parCBA LASTCAP
operon I-GENE
encodes O
a O
plasmid O
partitioning RARE
system O
( O
M O
. O

Furthermore O
, O
the O
insertion O
of O
the O
ColE1 NUMERIC
cer RARE
site I-GENE
into O
the O
RK2 NUMERIC
plasmid O
deleted O
for O
the O
par RARE
region O
failed O
to O
stabilize RARE
the O
plasmid O
in O
the O
MC1061K NUMERIC
strain O
, O
indicating O
that O
the O
multimer RARE
resolution O
activity O
encoded O
by O
parCBA LASTCAP
is O
not O
by O
itself O
responsible O
for O
the O
stabilization O
activity O
observed O
for O
this O
operon O
. O

To O
examine O
the O
basis O
for O
the O
apparent O
differences O
in O
postsegregational RARE
killing RARE
between O
the O
two O
E O
. O
coli O
strains O
, O
transformation O
assays O
were O
carried O
out O
to O
determine O
the O
relative O
sensitivities RARE
of O
the O
strains O
to O
the O
ParE LASTCAP
toxin I-GENE
protein I-GENE
. O

Splice RARE
- O
junction O
elements O
and O
intronic O
sequences O
regulate O
alternative O
splicing O
of O
the O
Drosophila O
myosin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
transcript O
. O

Nucleotide O
sequence O
analysis O
of O
R O
has O
revealed O
similarities O
to O
the O
R1 O
plasmid O
found O
in O
some O
South RARE
American O
maize O
races RARE
with O
RU ALLCAPS
cytoplasm O
, O
to O
the O
M1 O
plasmid O
found O
in O
one O
source O
of O
Zea RARE
luxurians RARE
teosinte RARE
, O
to O
the O
atp9 NUMERIC
mitochondrial I-GENE
gene I-GENE
and O
its O
3 O
' O
flanking O
sequence O
, O
and O
also O
to O
a O
region O
3 O
' O
to O
the O
orf221 NUMERIC
gene I-GENE
. O

We O
have O
measured O
the O
kinetics O
of O
the O
recovery O
of O
mRNA O
synthesis O
in O
the O
inducible O
GAL10 NUMERIC
and O
RNR3 NUMERIC
genes I-GENE
after O
exposure O
of O
yeast O
cells O
to O
ultraviolet RARE
( O
UV O
) O
radiation O
. O

Cloning O
of O
a O
human I-GENE
phosphoinositide RARE
3 I-GENE
- I-GENE
kinase I-GENE
with O
a O
C2 I-GENE
domain O
that O
displays O
reduced O
sensitivity O
to O
the O
inhibitor O
wortmannin O
. O

Ea RARE
value O
was O
calculated O
as O
the O
ratio O
of O
the O
steady O
- O
state O
end O
- O
systolic O
aortic O
pressure O
( O
ESAP ALLCAPS
) O
to O
stroke O
volume O
( O
thermodilution RARE
). O

Functional O
analysis O
of O
promoter O
activity O
of O
the O
5 O
'- O
flanking O
region O
of O
cyclin I-GENE
D2 I-GENE
suggested O
that O
the O
region O
- O
1 O
, O
100 O
to O
- O
805 NUMERIC
including O
C I-GENE
/ I-GENE
EBP I-GENE
, O
PEA3 I-GENE
, O
AP2 I-GENE
, O
NF I-GENE
- I-GENE
Y I-GENE
, O
c I-GENE
- I-GENE
Myc I-GENE
, O
and O
Sp1 I-GENE
may O
have O
a O
major O
positive O
regulatory O
activity O
for O
expression O
of O
cyclin I-GENE
D2 I-GENE
. O

Effect O
of O
alcohol O
on O
minimal O
effective O
nCPAP LASTCAP
pressure O

In O
contrast O
, O
resensitization RARE
of O
a O
sequestration RARE
- O
impaired O
beta2AR NUMERIC
mutant O
( O
Y326A NUMERIC
) O
was O
reestablished RARE
following O
the O
overexpression O
of O
either O
GRK2 NUMERIC
or O
beta I-GENE
- I-GENE
arrestin RARE
1 I-GENE
. O

The O
medium O
chains O
of O
these O
complexes O
, O
mu1 NUMERIC
and O
mu2 NUMERIC
, O
have O
been O
implicated O
in O
two O
types O
of O
interaction O
: O
assembly O
with O
the O
beta1 I-GENE
and I-GENE
beta2 I-GENE
chains I-GENE
of O
the O
corresponding O
complexes O
and O
recognition O
of O
tyrosine O
- O
based O
sorting O
signals O
. O

We O
have O
overexpressed O
, O
purified O
, O
characterized O
, O
and O
crystallized RARE
the O
BTB I-GENE
/ O
POZ O
domain O
from O
PLZF I-GENE
( O
PLZF I-GENE
- O
BTB I-GENE
/ O
POZ O
). O

Osmotic RARE
shock O
stimulates O
GLUT4 NUMERIC
translocation O
in O
3T3L1 NUMERIC
adipocytes O
by O
a O
novel O
tyrosine I-GENE
kinase I-GENE
pathway O
. O

We O
also O
identified O
Sp1 I-GENE
, O
Sp3 I-GENE
, O
and O
NGFI ALLCAPS
- I-GENE
A I-GENE
/ O
Egr RARE
- I-GENE
1 I-GENE
as O
the O
primary O
nuclear O
transcription O
factors O
binding O
to O
TRE1 NUMERIC
which O
mediate O
Tax I-GENE
responsiveness O
. O

Interestingly O
, O
segment O
nesting RARE
differentially O
increases O
the O
copy O
number O
of O
genes O
encoded O
by O
segment O
W O
, O
suggesting O
that O
the O
unusual O
genomic O
organization O
of O
PDVs RARE
may O
be O
directly O
linked O
to O
the O
unique O
functions O
of O
this O
virus O
in O
its O
obligate RARE
mutualistic RARE
association O
with O
parasitic RARE
wasps RARE
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM ALLCAPS
- I-GENE
1 I-GENE
promoter I-GENE
performed O
with O
chloramphenicol I-GENE
acetyltransferase I-GENE
constructs I-GENE
revealed O
that O
Tax I-GENE
was O
trans O
activating O
the O
VCAM ALLCAPS
- I-GENE
1 I-GENE
promoter I-GENE
via O
two O
NF I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM ALLCAPS
- I-GENE
1 I-GENE
gene I-GENE
promoter I-GENE
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax I-GENE
- O
induced O
expression O
of O
this O
adhesion O
molecule O
. O

The O
AGM ALLCAPS
and I-GENE
NIH I-GENE
/ I-GENE
Swiss RARE
mouse I-GENE
CCR5 NUMERIC
proteins I-GENE
are O
97 O
. O
7 O
to O
98 O
. O
3 O
% O
and O
79 O
. O
8 O
% O
identical O
to O
the O
human O
protein O
, O
respectively O
. O

Processivity RARE
of O
DNA O
synthesis O
by O
the O
mutant O
holoenzyme O
containing O
pcna RARE
- I-GENE
79 I-GENE
was O
unaffected O
on O
poly O
( O
dA LASTCAP
) O
x O
oligo RARE
( O
dT O
) O
but O
was O
dramatically O
reduced O
on O
a O
natural O
template O
with O
secondary O
structure O
. O

Alanine RARE
substitution O
mutations O
in O
the O
Zta I-GENE
activation I-GENE
domain I-GENE
which O
eliminate RARE
the O
ability O
of O
Zta I-GENE
to O
stimulate O
the O
D I-GENE
- I-GENE
A I-GENE
complex I-GENE
were O
examined O
. O

The O
Scm RARE
and O
ph RARE
proteins O
share O
a O
homology O
domain O
with O
38 O
% O
identity O
over O
a O
length O
of O
65 O
amino O
acids O
, O
termed O
the O
SPM ALLCAPS
domain O
, O
that O
is O
located O
at O
their O
respective O
C O
termini O
. O

It O
has O
been O
previously O
shown O
that O
genes O
transcribed O
by O
RNA I-GENE
polymerase I-GENE
II I-GENE
( O
RNAP I-GENE
II I-GENE
) O
are O
subject O
to O
position O
effect O
variegation RARE
when O
located O
near O
yeast O
telomeres RARE
. O

Likewise RARE
, O
rad6 NUMERIC
- I-GENE
delta I-GENE
reduces O
silencing O
of O
the O
telomere I-GENE
- I-GENE
located I-GENE
RNAP I-GENE
II I-GENE
- I-GENE
transcribed I-GENE
genes I-GENE
URA3 NUMERIC
and O
ADE2 NUMERIC
. O

The O
amplitude O
of O
detrusor RARE
contractions O
at O
6 O
, O
12 O
, O
and O
24 O
hours O
showed O
no O
significant O
difference O
from O
that O
in O
the O
controls O
. O

In O
the O
predicted O
transmembrane O
domain O
, O
Casr RARE
- I-GENE
rs2 NUMERIC
and O
Casr RARE
- I-GENE
rs3 NUMERIC
are O
95 O
% O
identical O
to O
Casr RARE
- I-GENE
rs1 NUMERIC
. O

Recently O
, O
roles O
also O
have O
been O
suggested O
for O
the O
nuclear O
trans O
- O
factor O
GATA I-GENE
- I-GENE
1 I-GENE
in O
regulating O
progenitor O
cell O
proliferation O
. O

PET O
activation O
studies O
are O
performed O
widely O
to O
study O
human O
brain O
function O
. O

F I-GENE
- I-GENE
box I-GENE
proteins I-GENE
are O
receptors O
that O
recruit O
phosphorylated O
substrates O
to O
the O
SCF ALLCAPS
ubiquitin I-GENE
- O
ligase I-GENE
complex O
. O

In O
the O
context O
of O
liver O
allograft RARE
shortage RARE
, O
our O
results O
suggest O
that O
an O
ELT ALLCAPS
should O
not O
be O
performed O
in O
patients O
with O
cardiac O
failure O
, O
more O
than O
two O
OSF ALLCAPS
, O
or O
an O
APACHE ALLCAPS
II O
score O
higher O
than O
30 O
. O

The O
SH3 I-GENE
domains I-GENE
of O
Grb2 I-GENE
bound O
in O
vitro O
to O
specific O
proline O
- O
rich O
motifs O
in O
the O
HPK1 NUMERIC
tail O
and O
functioned O
synergistically O
to O
direct O
the O
stable O
binding O
of O
Grb2 I-GENE
to O
HPK1 NUMERIC
in O
transfected O
Cos1 NUMERIC
cells O
. O

By O
far O
- O
Western O
analysis O
and O
coimmunoprecipitation RARE
studies O
, O
we O
demonstrate O
that O
ZNF74 NUMERIC
interacts O
, O
via O
its O
zinc O
finger O
domain O
, O
with O
the O
hyperphosphorylated RARE
largest O
subunit O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
( O
pol I-GENE
IIo RARE
) O
but O
not O
with O
the O
hypophosphorylated RARE
form O
. O

Thus O
, O
ZNF74 NUMERIC
sublocalization RARE
in O
nuclear O
domains O
enriched O
in O
pre O
- O
mRNA O
maturating RARE
factors O
, O
its O
RNA O
binding O
activity O
, O
and O
its O
direct O
phosphodependent RARE
interaction O
with O
the O
pol I-GENE
IIo RARE
, O
a O
form O
of O
the O
RNA I-GENE
polymerase I-GENE
functionally O
associated O
with O
pre O
- O
mRNA O
processing O
, O
suggest O
a O
role O
for O
this O
member O
of O
the O
KRAB I-GENE
multifinger RARE
protein I-GENE
family I-GENE
in O
RNA O
processing O
. O

Ki RARE
- I-GENE
ras4BVal NUMERIC
- I-GENE
12 I-GENE
transfectant RARE
cells O
expressed O
2 O
- O
fold O
elevated O
protein O
levels O
of O
the O
lysosomal I-GENE
cysteine I-GENE
protease I-GENE
cathepsin RARE
B I-GENE
but O
did O
not O
up O
- O
regulate O
cathepsin RARE
B I-GENE
mRNA I-GENE
expression O
. O

The O
cellular O
rate O
of O
anticoagulant I-GENE
heparan RARE
sulfate I-GENE
proteoglycan I-GENE
( O
HSPGact RARE
) O
generation O
is O
determined O
by O
the O
level O
of O
a O
kinetically RARE
limiting O
microsomal RARE
activity O
, O
HSact RARE
conversion O
activity O
, O
which O
is O
predominantly O
composed O
of O
the O
long O
sought O
heparan RARE
sulfate I-GENE
D I-GENE
- I-GENE
glucosaminyl RARE
3 I-GENE
- I-GENE
O I-GENE
- I-GENE
sulfotransferase RARE
( O
3 I-GENE
- I-GENE
OST ALLCAPS
) O
( O
Shworak RARE
, O
N O
. O

Interestingly O
, O
EGF I-GENE
, O
but O
not O
insulin I-GENE
, O
stimulated O
tyrosine O
phosphorylation O
of O
c I-GENE
- I-GENE
cbl I-GENE
and O
its O
association O
with O
Crk I-GENE
- I-GENE
II I-GENE
. O

An O
end O
to O
the O
lottery RARE
. O

We O
previously O
showed O
that O
the O
N O
- O
terminal O
portion O
common O
to O
various O
chimeric I-GENE
MLL ALLCAPS
products I-GENE
, O
as O
well O
as O
to O
MLL ALLCAPS
- I-GENE
LTG9 NUMERIC
and O
MLL ALLCAPS
- I-GENE
LTG19 NUMERIC
, O
localizes O
in O
the O
nuclei O
, O
and O
therefore O
suggested O
that O
it O
might O
play O
an O
important O
role O
in O
leukemogenesis RARE
. O

Our O
results O
suggest O
that O
the O
pattern O
of O
blood O
supply O
is O
relevant O
to O
the O
structural O
organisation RARE
of O
mature O
lamellar RARE
bone O
around O
the O
implant O
. O

Induction O
of O
AtP5CS1 NUMERIC
mRNA I-GENE
accumulation O
in O
salt O
- O
treated O
seedlings O
involves O
an O
immediate O
early O
transcriptional O
response O
regulated O
by O
ABA O
signalling O
that O
is O
not O
inhibited O
by O
cycloheximide O
, O
but O
abolished O
by O
the O
deficiency O
of O
ABA O
biosynthesis O
in O
the O
aba1 NUMERIC
Arabidopsis I-GENE
mutant I-GENE
. O

It O
thus O
appears O
that O
MAPK I-GENE
functions O
in O
meiotic O
maturation O
by O
preventing O
unfertilized RARE
eggs O
from O
proceeding RARE
into O
parthenogenetic RARE
development O
. O

( O
ii O
) O
An O
AF O
G I-GENE
- I-GENE
CSF I-GENE
level O
> O
2000 O
pg O
/ O
ml O
is O
a O
strong O
positive O
predictor O
of O
CAM ALLCAPS
. O

A O
positive O
correlation O
between O
serum I-GENE
myoglobin I-GENE
and O
CA I-GENE
III I-GENE
concentrations O
( O
rs O
= O
0 O
. O
933 NUMERIC
, O
P O
< O
0 O
. O
001 O
) O
was O
observed O
in O
hemodialyzed RARE
patients O
with O
chronic O
renal O
failure O
. O

Furthermore O
, O
the O
over O
- O
replication O
phenotype O
produced O
by O
this O
mutant I-GENE
p65cdc18 NUMERIC
is O
resistant O
to O
increased O
mitotic O
cyclin I-GENE
/ O
CDK I-GENE
activity O
, O
a O
known O
inhibitor O
of O
over O
- O
replication O
. O

Rip1p NUMERIC
is O
inessential RARE
, O
associated O
with O
nuclear O
pore O
complexes O
, O
and O
structurally O
related O
to O
the O
FG ALLCAPS
- I-GENE
nucleoporin RARE
family I-GENE
of O
pore O
proteins O
. O

The O
CNXA ALLCAPS
domain O
is O
similar O
at O
the O
amino O
acid O
level O
to O
the O
Escherichia I-GENE
coli I-GENE
moaA LASTCAP
gene I-GENE
product I-GENE
, O
while O
CNXC ALLCAPS
is O
similar O
to O
the O
E I-GENE
. I-GENE
coli I-GENE
moaC LASTCAP
product I-GENE
, O
with O
both O
E O
. O
coli O
products O
encoded O
by O
different O
cistrons RARE
. O

Deletions RARE
in O
each O
of O
these O
regions O
abolish RARE
membrane O
localization O
of O
Tiam1 NUMERIC
and O
membrane O
ruffling RARE
, O
suggesting O
that O
they O
function O
cooperatively RARE
. O

However O
, O
besides RARE
the O
kinase O
catalytic O
domain O
and O
double O
leucine O
/ O
isoleucine RARE
zippers O
, O
there O
was O
no O
significant O
homology O
with O
known O
proteins O
. O

RNA I-GENE
polymerase I-GENE
II I-GENE
inhibition O
increased O
the O
binding O
of O
ARE ALLCAPS
( O
AUBP ALLCAPS
activity O
) O
and O
poly O
( O
U O
)- O
Sepharose RARE
by O
cytoplasmic I-GENE
hnRNP I-GENE
A1 I-GENE
, O
while O
nuclear I-GENE
hnRNP I-GENE
A1 I-GENE
binding O
was O
unaffected O
. O

Modulation RARE
of O
AUUUA ALLCAPS
response O
element O
binding O
by O
heterogeneous I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
A1 I-GENE
in O
human O
T O
lymphocytes O
. O

Histological O
slides RARE
of O
one O
biopsy O
of O
each O
patient O
( O
formalin O
- O
fixed O
and O
paraffin RARE
- O
embedded O
) O
were O
stained O
with O
a O
Modified RARE
Giemsa RARE
( O
MG ALLCAPS
), O
the O
Warthin RARE
- O
Starry RARE
( O
WS ALLCAPS
), O
and O
an O
immunohistochemical O
method O
( O
IMM ALLCAPS
) O
using O
purified O
polyclonal RARE
H O
. O
pylori O
antiserum O
( O
DAKO ALLCAPS
B471 NUMERIC
). O

Their O
biosynthesis O
proceeds RARE
via O
linear O
precursors O
that O
become O
branched O
by O
beta1 I-GENE
, I-GENE
6 I-GENE
- I-GENE
GlcNAc I-GENE
transferases RARE
( O
IGnT6 NUMERIC
, O
GlcNAc O
to O
Gal O
). O

These O
findings O
indicate O
that O
the O
t O
( O
4 O
; O
14 O
)( O
p16 O
. O
3 O
; O
q32 NUMERIC
) O
represents O
a O
novel O
, O
recurrent O
chromosomal O
translocation O
in O
MM ALLCAPS
, O
and O
suggest O
that O
the O
FGFR3 NUMERIC
gene I-GENE
may O
be O
the O
target O
of O
this O
abnormality O
and O
thus O
contribute O
to O
tumorigenesis O
in O
MM ALLCAPS
. O

In O
addition O
, O
mutation O
of O
the O
Sp1 I-GENE
site I-GENE
also O
significantly O
reduced O
promoter O
activity O
. O

Amino O
acid O
residues O
of O
beta O
1 O
', O
alpha O
A O
', O
alpha O
B O
', O
and O
the O
loop O
containing O
His539 NUMERIC
of O
the O
RNase I-GENE
H I-GENE
domain I-GENE
interact O
with O
the O
primer O
strand O
of O
the O
dsDNA LASTCAP
. O

Moreover O
, O
in O
one O
patient O
with O
a O
sarcoma O
who O
underwent O
a O
leg O
- O
sparing RARE
procedure O
, O
no O
sciatic RARE
nerve O
enlargement O
was O
seen O
postoperatively O
. O

The O
full O
length O
cDNA O
sequence O
of O
a O
Type I-GENE
I I-GENE
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
( I-GENE
TGF I-GENE
- I-GENE
beta I-GENE
) I-GENE
receptor I-GENE
has O
been O
isolated O
from O
the O
filarial RARE
parasitic RARE
nematode O
Brugia RARE
pahangi RARE
. O

This O
sequence O
possessed O
homology O
with O
a O
methylation O
- O
sensitive O
promoter O
element O
, O
Enh2 NUMERIC
, O
present O
in O
the O
LTR O
of O
mouse O
intractisternal RARE
A O
- O
particles O
. O

Codon RARE
optimization RARE
for O
high O
- O
level O
expression O
of O
human I-GENE
erythropoietin I-GENE
( O
EPO I-GENE
) O
in O
mammalian O
cells O
. O

Parodoxical RARE
rise O
in O
urinary I-GENE
albumin I-GENE
levels O
after O
treatment O
of O
essential O
hypertension O
. O

20 O
% O
of O
total O
HSL ALLCAPS
transcripts I-GENE
in O
human O
subcutaneous O
adipocytes O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
Rat7p NUMERIC
/ O
Nup159p NUMERIC
is O
anchored O
within O
the O
NPC ALLCAPS
through O
its O
coiled O
- O
coil O
region O
and O
adjacent O
sequences O
. O

In O
a O
group O
of O
13 O
patients O
with O
obliterative RARE
arteriopathies RARE
of O
the O
lower O
limbs RARE
the O
plasma O
levels O
of O
thrombomodulin RARE
( O
TM I-GENE
), O
betathromboglobulin RARE
( O
beta I-GENE
- I-GENE
TG I-GENE
), O
D O
- O
dimer O
( O
DD ALLCAPS
) O
and O
plasminogen I-GENE
activator I-GENE
- I-GENE
inhibitor I-GENE
( O
pAI LASTCAP
- I-GENE
1 I-GENE
) O
were O
measured O
, O
and O
compared O
to O
the O
values O
obtained O
from O
10 O
healthy O
volunteers O
. O

These O
residues O
, O
Ile244 NUMERIC
at O
the O
extracellular O
end O
of O
transmembrane O
helix O
3 O
, O
and O
Tyr318 NUMERIC
at O
the O
COOH O
- O
terminal O
portion O
of O
extracellular O
loop O
2 O
, O
are O
replaced O
by O
Leu O
and O
Ile O
in O
the O
PTH I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
, O
respectively O
. O

We O
have O
now O
shown O
that O
in O
vivo O
phosphorylation O
of O
14 I-GENE
- I-GENE
3 I-GENE
- I-GENE
3 I-GENE
zeta I-GENE
at O
the O
CKIalpha RARE
site I-GENE
( I-GENE
Thr I-GENE
- I-GENE
233 I-GENE
) I-GENE
negatively O
regulates O
its O
binding O
to O
c I-GENE
- I-GENE
Raf I-GENE
, O
and O
may O
be O
important O
in O
Raf I-GENE
- O
mediated O
signal O
transduction O
. O

Mouse RARE
mast I-GENE
cell I-GENE
protease I-GENE
9 I-GENE
, O
a O
novel O
member O
of O
the O
chromosome O
14 O
family O
of O
serine I-GENE
proteases I-GENE
that O
is O
selectively O
expressed O
in O
uterine O
mast O
cells O
. O

A O
DNase I-GENE
I I-GENE
- I-GENE
hypersensitive I-GENE
site I-GENE
has O
also O
been O
mapped O
in O
the O
258 O
- O
base O
pair O
enhancer O
region O
. O

[ O
Pulmonary RARE
vascular O
resistance O
( O
PVR ALLCAPS
) O
during O
10 O
% O
O2 O
- O
PVR ALLCAPS
during O
21 O
% O
O2 O
/ O
PVR ALLCAPS
during O
21 O
% O
O2 O
] O
x O
100 O
was O
termed O
as O
hypoxic O
pulmonary O
vasoconstriction RARE
( O
HPV O
). O

Together O
, O
our O
results O
show O
that O
tinman RARE
is O
controlled O
by O
an O
array RARE
of O
discrete O
enhancer O
elements O
that O
are O
activated O
successively RARE
by O
differential O
genetic O
inputs O
, O
as O
well O
as O
by O
closely O
linked O
activator O
and O
repressor O
binding O
sites O
within O
an O
early O
- O
acting O
enhancer O
, O
which O
restrict RARE
twist RARE
activity O
to O
specific O
areas O
within O
the O
twist RARE
expression I-GENE
domain I-GENE
. O

An O
unusual O
cysteine O
triplet O
conserved O
in O
the O
sequences O
of O
TB I-GENE
domains I-GENE
is O
localized O
to O
the O
hydrophobic O
core O
, O
at O
the O
C O
- O
terminus O
of O
an O
alpha O
- O
helix O
. O

The O
Fis RARE
protein I-GENE
regulates O
site O
- O
specific O
DNA O
inversion O
catalyzed O
by O
a O
family O
of O
DNA I-GENE
invertases RARE
when O
bound O
to O
a O
cis O
- O
acting O
recombinational RARE
enhancer O
. O

Protein O
phosphatases O
play O
a O
critical O
role O
in O
the O
regulation O
of O
the O
eukaryotic O
cell O
cycle O
and O
signal O
transduction O
. O

The O
cell O
cycle O
- O
regulated O
transcription O
factor O
E2F I-GENE
is O
also O
known O
to O
bend RARE
DNA O
upon O
binding O
. O

Our O
study O
reveals O
that O
the O
modular RARE
structure O
of O
the O
FSH I-GENE
receptor I-GENE
gene O
generates O
motifs O
that O
allows O
coupling O
to O
different O
effectors O
. O

Transcriptional O
regulation O
of O
SUP35 NUMERIC
and O
SUP45 NUMERIC
in I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

These O
studies O
serve O
as O
the O
basis O
for O
the O
further O
characterization O
of O
the O
regulatory O
mechanism O
of O
aromatase I-GENE
expression O
in O
human O
breast O
cancer O
and O
ASCs RARE
. O

Xenopus I-GENE
Ran I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
: O
molecular O
interactions O
and O
effects O
on O
nuclear O
assembly O
in O
Xenopus O
egg O
extracts O
. O

She RARE
improved O
with O
a O
combination O
of O
benzodiazepines RARE
and O
the O
acetylcholinesterase RARE
inhibitor O
physostigmine RARE
. O

METHODS O
: O
Total O
muscle O
paralysis RARE
was O
induced O
under O
general O
anesthesia O
in O
a O
group O
of O
obese O
persons O
( O
n O
= O
9 O
; O
body O
mass O
index O
, O
32 O
+/- O
3 O
kg O
[- RARE
2 O
]) O
and O
in O
a O
group O
of O
nonobese RARE
persons O
( O
n O
= O
9 O
; O
body O
mas RARE
index O
, O
21 O
+/- O
2 O
kg O
[- RARE
2 O
]). RARE

PKA I-GENE
phosphorylated O
WT1 I-GENE
at O
Ser O
- O
365 NUMERIC
and O
Ser O
- O
393 NUMERIC
in O
vitro O
, O
as O
well O
as O
at O
additional O
sites O
, O
and O
this O
phosphorylation O
abolished O
the O
DNA O
- O
binding O
activity O
of O
WT1 I-GENE
in O
vitro O
. O

Our O
findings O
provide O
the O
first O
evidence O
that O
the O
function O
of O
WT1 I-GENE
can O
be O
modulated O
by O
its O
phosphorylation O
in O
vivo O
. O

Re O
: O
" O
Assessing RARE
the O
direction O
of O
causality RARE
in O
cross O
- O
sectional O
studies O
". O

A O
second O
aim O
was O
to O
determine O
whether O
the O
decrease O
in O
muscle O
- O
tendon O
unit O
rest O
length O
produced O
by O
prolonged O
immobilisation RARE
in O
a O
shortened O
position O
is O
mediated O
primarily O
by O
adaptations RARE
of O
the O
muscle O
or O
tendon O
. O

The O
presence O
of O
an O
additional O
sequence O
of O
nucleotides O
145 NUMERIC
- O
165 O
from O
the O
3 O
' O
end O
of O
RNA3 NUMERIC
enhanced O
template O
recognition O
by O
RdRp RARE
in O
vitro O
and O
accumulation O
of O
RNA3 NUMERIC
in O
vivo O
to O
wild O
- O
type O
levels O
. O

We O
argue RARE
that O
the O
primary O
role O
of O
hh RARE
in O
controlling O
polarity O
is O
to O
cause O
anterior O
compartment O
cells O
to O
reverse O
their O
interpretation O
of O
an O
underlying O
symmetric RARE
polarization RARE
. O

Restriction O
enzyme O
mapping O
, O
subcloning RARE
, O
and O
DNA O
sequencing O
analysis O
of O
recombinant O
phage O
lambda O
and O
P1 O
clones O
revealed O
that O
exons O
encoding O
the O
1 O
. O
9 O
- O
kb O
mouse I-GENE
TS ALLCAPS
mRNA I-GENE
are O
dispersed RARE
over O
> O
150 O
kb O
genomic O
DNA O
. O

Transfection O
analyses O
indicated O
that O
the O
expression O
of O
Tbxas1 NUMERIC
is O
controlled O
by O
a O
short O
( O
70 O
- O
bp O
) O
positive O
regulatory O
sequence O
and O
several O
upstream O
repressive O
elements O
. O

The O
results O
of O
this O
study O
suggest O
that O
NF I-GENE
- I-GENE
kappaB I-GENE
activity O
may O
be O
regulated O
by O
its O
interaction O
with O
the O
cell O
cycle O
regulatory O
protein O
, O
E2F I-GENE
- I-GENE
1 I-GENE
. O

The O
lysozyme I-GENE
FEF ALLCAPS
site O
is O
immediately O
5 O
' O
to O
a O
PU I-GENE
. O

Osteocalcin RARE
( O
OC I-GENE
) O
is O
a O
matrix I-GENE
calcium I-GENE
- I-GENE
binding I-GENE
protein I-GENE
expressed O
in O
osteoblasts RARE
and O
odontoblasts RARE
undergoing O
mineralization RARE
. O

In O
this O
study O
, O
we O
examine O
the O
effects O
of O
Msx2 NUMERIC
expression O
on O
OC I-GENE
promoter I-GENE
activation O
( O
luciferase I-GENE
reporter I-GENE
) O
by O
FGF2 NUMERIC
/ O
FSK ALLCAPS
and O
calcitriol RARE
in O
MC3T3 NUMERIC
- O
E1 O
osteoblasts RARE
. O

Thus O
, O
unlike O
other O
proteins O
reported O
to O
inhibit O
SRF I-GENE
activity O
, O
the O
repressor O
activity O
associated O
with O
the O
GC O
- O
rich O
element O
does O
not O
appear O
to O
function O
through O
direct O
inhibition O
of O
SRF I-GENE
binding O
. O

However O
, O
one O
CAK I-GENE
- O
phosphorylated O
phosphopeptide O
comigrates RARE
with O
a O
Cdc2 I-GENE
- O
phosphorylated O
phosphopeptide O
previously O
shown O
to O
be O
mitosis O
- O
specific O
, O
suggesting O
that O
, O
in O
vitro O
, O
CAK I-GENE
is O
able O
to O
phosphorylate O
at O
least O
one O
site O
that O
is O
also O
phosphorylated O
in O
vivo O
. O

The O
pen RARE
can O
heal RARE
. O

The O
mHIF LASTCAP
- I-GENE
1 I-GENE
alpha I-GENE
structural I-GENE
gene I-GENE
is O
composed O
of O
15 O
exons O
. O

However O
, O
when O
a O
second O
, O
upstream I-GENE
IRE ALLCAPS
- I-GENE
like I-GENE
sequence I-GENE
was O
evaluated O
by O
EMSA O
, O
a O
DNA O
binding O
pattern O
distinct O
from O
that O
seen O
following O
exposure O
to O
IFN I-GENE
- I-GENE
gamma I-GENE
alone O
was O
observed O
after O
prolonged O
stimulation O
with O
both O
IFN I-GENE
- I-GENE
alpha I-GENE
and O
IFN I-GENE
- I-GENE
gamma I-GENE
. O

In O
Arabidopsis O
, O
the O
induction O
of O
a O
dehydration RARE
- O
responsive O
gene O
, O
rd22 NUMERIC
, O
is O
mediated O
by O
abscisic RARE
acid O
( O
ABA O
) O
and O
requires O
protein O
biosynthesis O
for O
ABA O
- O
dependent O
gene O
expression O
. O

A O
cDNA O
encoding O
a O
MYC ALLCAPS
- I-GENE
related I-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
was O
isolated O
by O
DNA O
- O
ligand O
binding O
screening O
, O
using O
the O
67 O
- O
bp O
region O
as O
a O
probe O
, O
and O
designated O
rd22BP1 NUMERIC
. O

Human I-GENE
PDK1 NUMERIC
is O
homologous O
to O
the O
Drosophila I-GENE
protein I-GENE
kinase I-GENE
DSTPK61 NUMERIC
, O
which O
has O
been O
implicated O
in O
the O
regulation O
of O
sex O
differentiation O
, O
oogenesis RARE
and O
spermatogenesis RARE
. O

Thus O
, O
the O
synergistic O
effects O
of O
HNF I-GENE
- I-GENE
1beta I-GENE
and O
the O
GR I-GENE
on O
dexamethasone O
- O
stimulated O
promoter O
activity O
require O
that O
they O
are O
bound O
to O
the O
HNF I-GENE
- I-GENE
1 I-GENE
site I-GENE
and O
the O
GRE O
, O
respectively O
, O
and O
may O
involve O
protein O
- O
protein O
interactions O
between O
the O
transcription O
factors O
, O
or O
between O
them O
and O
the O
basal O
transcription O
machinery O
or O
a O
steroid I-GENE
receptor I-GENE
coactivator I-GENE
. O

Mutational O
analysis O
shows O
that O
both O
an O
AP I-GENE
- I-GENE
1 I-GENE
like I-GENE
sequence I-GENE
(- O
294 NUMERIC
/- O
285 O
, O
TGAATCATCA ALLCAPS
) O
and O
an O
A O
/ O
T O
- O
rich O
myocyte I-GENE
enhancer I-GENE
factor I-GENE
( I-GENE
MEF I-GENE
)- I-GENE
2 I-GENE
like I-GENE
sequence I-GENE
(- O
310 NUMERIC
/- O
298 NUMERIC
, O
TTAAAAATAAAAA ALLCAPS
) O
in O
the O
33 O
- O
bp O
region O
are O
necessary O
for O
the O
OP ALLCAPS
- I-GENE
1 I-GENE
effect O
. O

Unlike O
most O
other O
members O
of O
the O
Bcl I-GENE
- I-GENE
2 I-GENE
family I-GENE
, O
BAD ALLCAPS
( O
Bcl I-GENE
- I-GENE
xL LASTCAP
/ I-GENE
Bcl I-GENE
- I-GENE
2 I-GENE
associated I-GENE
death I-GENE
promoter I-GENE
), O
a O
death I-GENE
enhancer I-GENE
, O
has O
no O
C O
- O
terminal O
transmembrane O
domain O
for O
targeting O
to O
the O
outer O
mitochondrial O
membrane O
and O
nuclear O
envelope O
. O

Electromobility RARE
shift O
and O
cotransfection O
assays O
demonstrated O
that O
HNF1alpha NUMERIC
, O
but O
not O
HNF4 NUMERIC
, O
bound O
to O
its O
cognate O
site O
and O
transactivated O
G6Pase NUMERIC
gene I-GENE
expression O
. O

An O
open O
reading O
frame O
of O
2862 NUMERIC
bp O
encoding O
a O
954 NUMERIC
amino O
acid O
protein O
was O
identified O
. O

One O
of O
these O
, O
an O
AACA ALLCAPS
motif O
, O
has O
been O
shown O
to O
be O
a O
negative O
regulator O
in O
non O
- O
seed O
tissues O
and O
has O
a O
similarity O
to O
the O
barley O
gibberellin RARE
responsive O
element O
recognized O
by O
MYB ALLCAPS
- I-GENE
like I-GENE
DNA I-GENE
binding I-GENE
proteins I-GENE
. O

Strain RARE
CFN037 NUMERIC
is O
an O
R O
. O
etli RARE
mutant O
induced O
by O
a O
single O
Tn5mob NUMERIC
insertion O
in O
the O
promoter O
region O
of O
the O
thiCOGE LASTCAP
gene I-GENE
cluster I-GENE
. O

Expression O
of O
thiamin RARE
biosynthetic O
genes O
( O
thiCOGE LASTCAP
) O
and O
production O
of O
symbiotic RARE
terminal I-GENE
oxidase I-GENE
cbb3 NUMERIC
in O
Rhizobium O
etli RARE
. O

We O
have O
cloned O
and O
sequenced O
a O
region O
encoding O
a O
lipase I-GENE
operon I-GENE
and O
a O
putative O
, O
previously O
uncharacterized O
metalloprotease RARE
of I-GENE
Vibrio I-GENE
cholerae I-GENE
O1 NUMERIC
. O

Furthermore O
, O
the O
amount O
of O
tRNA I-GENE
( I-GENE
3Lys NUMERIC
) I-GENE
that O
was O
placed O
onto O
viral O
RNA O
in O
mutated O
viruses O
was O
significantly O
less O
than O
that O
placed O
in O
the O
wild O
- O
type O
virus O
. O

This O
protein O
is O
present O
in O
both O
HeLa O
nuclear O
extracts O
and O
S100 NUMERIC
extracts O
but O
absent O
from O
SR I-GENE
protein I-GENE
preparations O
, O
suggesting O
that O
it O
is O
not O
a O
classical O
SR I-GENE
protein I-GENE
. O

Differential O
regulation O
of O
the O
pre I-GENE
- I-GENE
C I-GENE
and O
pregenomic RARE
promoters O
of O
human O
hepatitis O
B O
virus O
by O
members O
of O
the O
nuclear I-GENE
receptor I-GENE
superfamily I-GENE
. O

Acad RARE
. O

Chimeras RARE
containing O
IE1 I-GENE
peptides I-GENE
dramatically O
activated O
transcription O
of O
the O
basal O
promoter O
only O
when O
lac I-GENE
operator I-GENE
sequences I-GENE
were O
present O
. O

The O
results O
of O
replicase RARE
assays O
performed O
with O
mutant I-GENE
VP2 NUMERIC
containing O
a O
deletion O
in O
its O
RNA O
- O
binding O
domain O
suggests O
that O
the O
essential O
role O
for O
VP2 NUMERIC
in O
replication O
is O
linked O
to O
the O
protein O
' O
s O
ability O
to O
bind O
the O
mRNA O
template O
for O
minus O
- O
strand O
synthesis O
. O

We O
previously O
described O
two O
alanine O
cluster O
mutations O
, O
R77 NUMERIC
to O
A O
( O
R77A NUMERIC
)- O
K79A NUMERIC
and O
E192A NUMERIC
- O
E194A NUMERIC
, O
which O
selectively O
inactivated O
the O
triphosphatase RARE
component O
. O

Transfection O
of O
HepG2 O
and O
SK ALLCAPS
- O
N O
- O
MC O
cells O
with O
constructs O
deleted O
of O
additional O
5 O
'- O
flanking O
fragments O
permitted O
the O
definition O
of O
a O
minimal O
200 O
bp O
promoter O
fragment O
containing O
the O
pseudo RARE
- O
TATA O
box O
and O
two O
putative O
SP1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

Both O
inserts O
are O
larger O
than O
their O
homologues O
in O
eIF I-GENE
- I-GENE
2alpha I-GENE
kinases I-GENE
. O

Three O
monopolar RARE
electrodes O
were O
inserted O
into O
the O
left O
and O
right O
lateral O
vestibulospinal RARE
tract O
( O
LVST ALLCAPS
) O
and O
medial O
vestibulospinal RARE
tract O
( O
MVST ALLCAPS
) O
of O
the O
C1 O
segment O
, O
to O
determine O
the O
pathway O
of O
axons RARE
. O

Epitopes RARE
of O
adhesion O
- O
perturbing RARE
monoclonal O
antibodies O
map O
within O
a O
predicted O
alpha O
- O
helical O
domain O
of O
the O
integrin I-GENE
beta I-GENE
1 I-GENE
subunit I-GENE
. O

Polyhomeotic RARE
and I-GENE
Posterior RARE
Sex RARE
Combs RARE
may O
participate O
in O
a O
more O
general O
transcriptional O
mechanism O
that O
causes O
modulated O
gene O
repression O
, O
whereas O
the O
inclusion O
of O
Polycomb RARE
protein I-GENE
in O
the O
complex O
at O
PREs RARE
leads O
to O
stable O
silencing O
. O

Furthermore O
, O
both O
rhHR23 NUMERIC
proteins I-GENE
function O
in O
a O
defined O
NER ALLCAPS
system O
reconstituted O
with O
purified O
proteins O
, O
indicating O
direct O
involvement O
of O
hHR23 NUMERIC
proteins I-GENE
in O
the O
DNA O
repair O
reaction O
via O
interaction O
with O
XPC ALLCAPS
. O

The O
yeast O
silent I-GENE
information I-GENE
regulator I-GENE
Sir4p NUMERIC
anchors RARE
and O
partitions RARE
plasmids O
. O

These O
results O
implicate RARE
a O
precursor O
- O
specific O
base O
- O
paired O
structure O
involving O
sequences O
on O
both O
sides O
of O
the O
mature O
cleavage O
site O
in O
the O
3 O
' O
processing O
of O
human I-GENE
U2 I-GENE
RNA I-GENE
. O

Polysome RARE
analyses O
in O
a O
temperature O
- O
sensitive O
fal1 NUMERIC
- I-GENE
1 I-GENE
mutant I-GENE
and O
a O
Fal1p NUMERIC
- O
depleted O
strain O
reveal O
a O
decrease O
in O
the O
number O
of O
40S NUMERIC
ribosomal I-GENE
subunits I-GENE
. O

Sequence O
analysis O
identified O
some O
of O
these O
cDNA O
clones O
as O
Dlc RARE
- I-GENE
1 I-GENE
, O
a O
sequence O
encoding O
a O
small O
, O
9 I-GENE
- I-GENE
kDa I-GENE
human I-GENE
homolog I-GENE
of I-GENE
the I-GENE
outer I-GENE
- I-GENE
arm I-GENE
dynein I-GENE
light I-GENE
- I-GENE
chain I-GENE
protein O
. O

Importantly RARE
, O
in O
HeLa O
and O
293 O
cells O
, O
endogenous O
and O
transfected O
I I-GENE
kappaB I-GENE
alpha I-GENE
coimmunoprecipitated RARE
with O
Myc I-GENE
- O
tagged O
or O
endogenous O
Dlc RARE
- I-GENE
1 I-GENE
. O

The O
mouse I-GENE
M I-GENE
- I-GENE
lysozyme I-GENE
downstream I-GENE
enhancer I-GENE
has O
been O
previously O
characterized O
on O
several O
levels O
of O
gene O
regulation O
. O

Identification O
of O
dynein I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
expressed O
in O
human O
and O
mouse O
testis O
: O
chromosomal O
localization O
of O
an O
axonemal RARE
dynein I-GENE
gene I-GENE
. O

Bitter RARE
cassava RARE
contains O
cyanogenic RARE
glycosides RARE
; O
processing O
breaks RARE
them O
down O
to O
acetone RARE
cyanohydrin RARE
and O
hydrogen O
cyanide RARE
. O

The O
proposed O
mechanism O
of O
effect O
states O
that O
mono O
( O
2 O
- O
ethylhexyl RARE
) O
phthalate RARE
( O
MEHP ALLCAPS
), O
the O
primary O
hydrolysis O
product O
of O
DEHP ALLCAPS
, O
mimics RARE
the O
inducing O
prostaglandins O
( O
PG ALLCAPS
) O
PGD ALLCAPS
( O
2 O
), O
9alpha NUMERIC
, O
11betaPGF2 NUMERIC
, O
and O
PGF2alpha NUMERIC
, O
and O
thromboxanes RARE
in O
the O
lungs O
, O
thereby O
increasing O
the O
risk O
of O
inducing O
inflammation O
in O
the O
airways RARE
, O
which O
is O
a O
characteristic O
of O
asthma O
. O

We O
found O
14 O
protein O
binding O
sites O
that O
were O
occupied O
in O
vivo O
. O

Constitutive RARE
protection O
of O
E2F I-GENE
recognition I-GENE
sequences I-GENE
in O
the O
human I-GENE
thymidine I-GENE
kinase I-GENE
promoter I-GENE
during O
cell O
cycle O
progression O
. O

Comparison O
of O
genomic O
sequence O
shows O
that O
the O
ph RARE
locus I-GENE
has O
been O
duplicated O
, O
and O
that O
it O
contains O
proximal O
and O
distal O
transcription O
units O
. O

Radiation RARE
decreased O
the O
levels O
of O
T4 O
and O
T3 O
6 O
h O
and O
72 O
h O
in O
group O
C O
, O
in O
group O
A O
at O
72 O
h O
, O
in O
group O
B O
at O
24 O
h O
postexposure O
. O

We O
have O
reviewed O
the O
experience O
of O
a O
major O
MMT ALLCAPS
general O
practice O
with O
hepatitis O
C O
virus O
( O
HCV O
) O
infection O
from O
1991 O
to O
1995 O
. O

The O
author O
analyzes RARE
extensive O
own O
data O
based O
on O
study O
into O
particular O
features O
of O
cardiovascular O
disorders O
in O
chronic O
renal O
impairement RARE
with O
making O
use O
of O
modern O
diagnostic O
tools O
. O

In O
this O
paper O
, O
characterization O
is O
given O
of O
clinical O
and O
biochemical O
features O
of O
VH O
B O
course O
against O
the O
background O
of O
narcomania RARE
. O

447 NUMERIC
microns O
for O
A O
. O
microcephalum RARE
and O
350 O
microns O
for O
A O
. O
wedli RARE
), O
and O
fewer O
testes O
per O
proglottis RARE
( O
44 O
- O
73 O
vs O
. O

The O
ZnF20 NUMERIC
cDNA I-GENE
hybridized O
to O
multiple O
transcripts O
in O
a O
thyroid O
cancer O
cell O
line O
( O
8 O
. O
0 O
, O
4 O
. O
5 O
and O
2 O
kb O
) O
that O
increased O
after O
cycloheximide O
treatment O
and O
decayed RARE
< O
2 O
h O
after O
addition O
of O
actinomycin RARE
D O
. O

Glutathione RARE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
)- O
E2F I-GENE
and O
GST I-GENE
- O
DP I-GENE
fusion O
proteins O
were O
found O
to O
cooperate O
in O
binding O
to O
the O
three O
E2F I-GENE
sites I-GENE
in O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
gene I-GENE
promoter I-GENE
in O
vitro O
. O

Two O
sterol O
regulatory O
element O
- O
like O
sequences O
mediate O
up O
- O
regulation O
of O
caveolin RARE
gene I-GENE
transcription O
in O
response O
to O
low I-GENE
density I-GENE
lipoprotein I-GENE
free O
cholesterol O
. O

Furthermore O
, O
DNA O
- O
bound O
LAZ3 NUMERIC
/ O
BCL6 NUMERIC
recruits RARE
SMRT I-GENE
in O
vivo O
, O
and O
both O
overexpressed O
proteins O
completely O
colocalize RARE
in O
nuclear O
dots RARE
. O

CONCLUSIONS O
: O
We O
obtained O
normal O
EPO I-GENE
levels O
for O
mothers O
and O
newborns O
for O
our O
area O
, O
similarly O
to O
the O
previously O
described O
ones O
. O

Ischaemia RARE
was O
induced O
by O
a O
low O
flow O
rate O
of O
0 O
. O
8 O
mL O
min O
- O
1 O
for O
30 O
min O
, O
and O
was O
followed O
by O
a O
40 O
- O
minute O
reperfusion O
. O

First O
, O
two O
MCTs RARE
using O
a O
long O
electrode O
, O
3 O
cm O
in O
size O
, O
were O
performed O
in O
the O
central O
area O
of O
the O
tumor O
, O
and O
eight O
MCTs RARE
by O
a O
short O
electrode O
, O
2 O
cm O
in O
size O
, O
were O
done O
in O
the O
peripheral O
and O
surrounding O
area O
of O
the O
tumor O
. O

BACKGROUND O
: O
Checkpoint RARE
pathways O
prevent O
cell O
- O
cycle O
progression O
in O
the O
event O
of O
DNA O
lesions O
. O

Direct O
proof RARE
that O
the O
heightened RARE
renal O
cellular O
apoptosis O
in O
PKD ALLCAPS
is O
not O
occurring O
through O
p53 I-GENE
was O
obtained O
by O
successive O
matings RARE
between O
SBM ALLCAPS
and O
p53 I-GENE
(-/-) RARE
mice O
. O

Accumulated RARE
evidence O
indicates O
that O
, O
upon O
stimulation O
with O
interferon I-GENE
- I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
), O
three O
beta O
- O
type O
subunits O
, O
designated O
LMP2 NUMERIC
, O
LMP7 NUMERIC
, O
and O
PSMB10 NUMERIC
, O
are O
incorporated O
into O
the O
20S I-GENE
proteasome I-GENE
by O
displacing RARE
the O
housekeeping O
beta O
- O
type O
subunits O
designated O
PSMB6 NUMERIC
, O
PSMB5 NUMERIC
, O
and O
PSMB7 NUMERIC
, O
respectively O
. O

The O
major O
RNase I-GENE
E I-GENE
cleavage O
product O
( O
denoted RARE
pSok RARE
- I-GENE
6 I-GENE
) O
is O
rapidly O
degraded O
by O
polynucleotide RARE
phosphorylase RARE
( O
PNPase RARE
). O

This O
difference O
may O
result O
from O
the O
lower O
match O
to O
the O
ARG ALLCAPS
box O
consensus O
of O
the O
O I-GENE
( I-GENE
rocD LASTCAP
) I-GENE
site I-GENE
. O

Ask RARE
AONE ALLCAPS
' O
s O
experts RARE
... RARE
about O
productivity RARE
indicators O
. O

All O
pigs O
had O
significant O
regional O
LV O
dysfunction O
and O
reduced O
LV O
ejection O
fraction O
( O
41 O
+/- O
11 O
%). O

The O
progress O
of O
morphological O
research O
on O
the O
parabrachial RARE
nucleus O

The O
amplitudes O
of O
DPOAE ALLCAPS
also O
recovered O
to O
a O
greater O
extent O
and O
outer O
hair RARE
cell O
losses RARE
were O
less O
severe O
in O
the O
R O
- O
PIA ALLCAPS
- O
treated O
ears O
. O

The O
data O
provide O
evidence O
both O
for O
a O
signal O
transduction O
pathway O
independent O
of O
JNK I-GENE
, O
ERK I-GENE
, O
and O
p38 I-GENE
MAP I-GENE
kinase I-GENE
to O
be O
involved O
in O
the O
induction O
of O
rhoB LASTCAP
by O
genotoxic RARE
stress O
, O
and O
furthermore RARE
, O
indicate O
autoregulation O
of O
rhoB LASTCAP
. O

In O
an O
effort O
to O
separate O
domains O
of O
FadR LASTCAP
required O
for O
DNA O
binding O
, O
dimerization O
, O
and O
ligand O
binding O
, O
chimeric O
protein O
fusions O
between O
the O
DNA O
binding O
domain O
of O
LexA I-GENE
and O
different O
regions O
of O
FadR LASTCAP
were O
constructed O
. O

Inhibition O
appears O
to O
result O
from O
titration O
of O
general O
transcription O
factors O
because O
MDM2 NUMERIC
overexpression O
inhibits O
c I-GENE
- I-GENE
fos I-GENE
as O
well O
as O
other O
promoters O
in O
vivo O
and O
basal O
transcription O
in O
vitro O
. O

4 O
) O
PU I-GENE
and O
PD I-GENE
lacked O
the O
canonical O
TATA O
or O
CAAT O
motifs O
, O
and O
are O
AT O
- O
rich O
. O

We O
also O
show O
by O
immunogold RARE
electron O
microscopy O
immunocytochemistry RARE
that O
amphiphysin RARE
I I-GENE
is O
localized O
in O
the O
nerve O
terminal O
cytomatrix RARE
and O
is O
partially O
associated O
with O
endocytic O
intermediates RARE
. O

The O
mobility O
shift O
of O
both O
of O
these O
proteins O
is O
abolished O
by O
treatment O
with O
inhibitors O
of O
PKC I-GENE
or O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
/ O
extracellular I-GENE
signal I-GENE
- I-GENE
related I-GENE
kinase I-GENE
kinase I-GENE
. O

The O
prescription RARE
for O
apoplexy RARE
includes O
C1 O
- O
7 O
, O
T1 O
- O
9 O
and O
L2 O
- O
4 O
. O

During O
the O
aftermath RARE
of O
excitation RARE
of O
the O
skin O
sympathetic O
nerve O
by O
mental O
arithmetics RARE
, O
3 O
/ O
12 O
A O
delta O
units O
were O
turned O
to O
the O
active O
state O
with O
decreased O
mechanical O
threshold O
. O

In O
a O
similar O
fashion O
to O
adipose O
stromal RARE
cells O
, O
serum O
potentiated RARE
the O
response O
to O
dexamethasone O
but O
had O
no O
effect O
on O
phorbol O
ester O
- O
stimulated O
activity O
. O

Thus O
, O
Hex RARE
expression O
marks RARE
the O
earliest RARE
unequivocal RARE
molecular O
anteroposterior O
asymmetry O
in O
the O
mouse O
embryo O
and O
indicates O
that O
the O
anteroposterior O
axis O
of O
the O
embryo O
develops RARE
from O
conversion O
of O
a O
proximodistal RARE
asymmetry O
established O
in O
the O
primitive RARE
endoderm O
lineage O
. O

Thus O
, O
dpp RARE
and O
omb RARE
promote O
both O
dorsal O
leg O
cell O
fate O
as O
well O
as O
transdetermination RARE
- O
competent O
leg O
disc O
cells O
. O

CONCLUSIONS O
: O
While O
INR ALLCAPS
correction O
may O
be O
achieved O
by O
all O
the O
above O
methods O
, O
that O
relating RARE
log O
reference O
INR ALLCAPS
to O
log O
local O
prothrombin I-GENE
time O
by O
linear O
regression O
analysis O
is O
the O
simplest RARE
to O
perform O
. O

RESULTS O
: O
The O
overall O
FNF ALLCAPS
for O
1992 O
was O
12 O
. O
3 O
% O
and O
was O
19 O
. O
1 O
%, O
22 O
. O
2 O
%, O
3 O
. O
8 O
% O
and O
6 O
. O
1 O
% O
per O
successive O
quarters RARE
in O
1992 O
. O

Western O
blot O
analysis O
of O
various O
bovine O
tissues O
with O
human O
NMT ALLCAPS
peptide I-GENE
antibody I-GENE
indicated O
a O
common O
prominent O
immunoreactive O
band O
with O
an O
apparent O
molecular O
mass O
of O
48 O
. O
5 O
- O
50 O
kDa O
in O
all O
tissues O
. O

Transcription O
start O
sites O
of O
the O
plastid RARE
ACCase RARE
genes I-GENE
were O
estimated O
from O
the O
longest RARE
cDNA O
clones O
obtained O
by O
5 O
'- O
RACE O
( O
rapid O
amplification O
of O
cDNA O
ends O
). O

AIDS O
- O
related O
disseminated RARE
histoplasmosis RARE
in O
San RARE
Francisco RARE
, O
California RARE
. O

Thus O
, O
Fis RARE
acts O
as O
an O
accessory O
transcriptional O
activator O
at O
the O
mar RARE
promoter I-GENE
. O

These O
observations O
provide O
strong O
support O
for O
the O
idea O
that O
expression O
of O
mutant O
tRNA O
can O
confer O
a O
mutator RARE
phenotype O
, O
including O
the O
UVM ALLCAPS
- O
constitutive O
phenotype O
observed O
in O
mutA LASTCAP
and O
mutC LASTCAP
cells O
. O

TNF I-GENE
- I-GENE
alpha I-GENE
exposure O
markedly O
increased O
activity O
of O
several O
RNA O
- O
binding O
proteins O
, O
especially O
a O
novel O
Mr O
50 O
, O
000 O
- O
55 O
, O
000 O
RNA O
- O
binding O
protein O
. O

We O
speculate RARE
that O
the O
human O
papillomavirus O
late O
mRNAs O
, O
produced O
from O
several O
hundred O
copies O
of O
the O
virus O
genome O
present O
in O
infected O
cells O
, O
compete O
with O
the O
c I-GENE
- I-GENE
fos I-GENE
mRNAs I-GENE
for O
destabilizing RARE
cellular O
factors O
and O
that O
this O
may O
lead O
to O
elevated O
Fos I-GENE
protein I-GENE
levels O
in O
human O
papillomavirus O
infected O
cells O
. O

Two O
closely O
related O
IgH LASTCAP
constant O
region O
genes O
, O
CHA ALLCAPS
and O
CHB ALLCAPS
, O
have O
been O
sequenced O
completely O
. O

The O
aim O
of O
this O
study O
was O
to O
find O
out O
whether O
it O
was O
possible O
to O
detect O
normal O
lymph O
nodes O
by O
high O
- O
resolution O
mediastinal RARE
US O
. O

To O
study O
the O
role O
of O
heavy O
chain O
motifs O
in O
substrate O
recognition O
, O
secreted O
variants O
of O
recombinant I-GENE
bovine I-GENE
proenteropeptidase RARE
were O
constructed O
by O
replacing O
the O
transmembrane O
domain O
with O
a O
signal O
peptide O
. O

CKbeta4GT NUMERIC
- I-GENE
II I-GENE
is O
predicted O
to O
encode O
a O
type I-GENE
II I-GENE
transmembrane I-GENE
glycoprotein I-GENE
of O
43 O
kDa O
with O
five O
potential O
N O
- O
linked O
glycosylation O
sites O
. O

We O
now O
demonstrate O
that O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
) I-GENE
delta I-GENE
is O
a O
major O
component O
of O
a O
PGE2 O
- O
stimulated O
DNA O
- O
protein O
complex O
involving O
HS3D NUMERIC
and O
find O
that O
C I-GENE
/ I-GENE
EBPdelta RARE
transactivates O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
1 I-GENE
through O
this O
site O
. O

PATIENTS O
AND O
METHODS O
: O
Semen RARE
analyses O
were O
performed O
on O
58 O
patients O
with O
stages O
I O
- O
III O
HD O
before O
, O
during O
, O
and O
after O
chemotherapy O
and O
after O
the O
sperm O
count O
recovered O
from O
the O
effects O
of O
abdominal O
radiotherapy O
that O
was O
given O
after O
chemotherapy O
. O

Thus O
, O
the O
absence O
of O
residual O
infarct O
- O
zone O
viability O
discriminates RARE
patients O
who O
develop O
progressive O
left O
ventricular O
dilation RARE
after O
reperfused RARE
AMI O
from O
those O
who O
maintain O
normal O
left O
ventricular O
geometry RARE
. O

With O
a O
BMI O
cutoff O
of O
27 O
, O
mean O
cardiac O
NE O
spillover RARE
was O
46 O
% O
lower O
in O
the O
obese O
subjects O
when O
compared O
with O
the O
lean O
subjects O
( O
P O
=. O
017 NUMERIC
). O

The O
gene O
( O
ApxII LASTCAP
) O
encoding O
both O
chloroplastic RARE
ascorbate RARE
peroxidase I-GENE
isoenzymes I-GENE
was O
isolated O
and O
the O
organization O
of O
the O
gene O
was O
determined O
. O

This O
emphasizes O
the O
conclusion O
that O
CDF ALLCAPS
- I-GENE
1 I-GENE
is O
not O
an O
E2F I-GENE
family I-GENE
member I-GENE
and O
points O
to O
profound O
differences O
in O
the O
cell O
cycle O
regulation O
of O
CDF ALLCAPS
- I-GENE
1 I-GENE
and O
E2F I-GENE
. O

The O
proofreading RARE
domain O
of O
Escherichia I-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
and O
other O
DNA I-GENE
and I-GENE
/ I-GENE
or I-GENE
RNA I-GENE
exonuclease I-GENE
domains I-GENE
. O

Interleukin I-GENE
- I-GENE
1 I-GENE
levels O
remained O
low O
throughout O
the O
course O
. O

Responsibility RARE
matters RARE
-- O
this O
is O
a O
scientific RARE
council RARE

Southern O
blot O
analysis O
of O
endonuclease O
- O
digested RARE
genomic O
DNA O
from O
primary O
chick O
embryo O
fibroblasts O
( O
CEF ALLCAPS
) O
suggested O
that O
MEK2 NUMERIC
is O
a O
single O
- O
copy O
gene O
in O
this O
vertebrate O
species O
. O

Sequences RARE
required O
for O
interaction O
of O
mu2 NUMERIC
and O
CTLA ALLCAPS
- I-GENE
4 I-GENE
were O
localized O
to O
residues O
, O
161TTGVY NUMERIC
in O
CTLA ALLCAPS
- I-GENE
4 I-GENE
; O
this O
sequence O
is O
N O
- O
terminal O
to O
, O
but O
overlaps RARE
with O
, O
a O
previously O
identified O
SH2 I-GENE
binding I-GENE
motif I-GENE
, O
165YVKM NUMERIC
, O
involved O
in O
CTLA ALLCAPS
- I-GENE
4 I-GENE
signaling O
. O

Here O
, O
we O
report O
that O
a O
transfected O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cell O
line O
expressing O
a O
murine I-GENE
CD4 I-GENE
fragment I-GENE
containing O
the O
first O
two O
N O
- O
terminal O
domains O
secretes RARE
both O
monomeric O
molecules O
and O
disulfide O
- O
linked O
multimers RARE
. O

SCID ALLCAPS
V I-GENE
( O
D I-GENE
) O
J I-GENE
recombination O
can O
be O
partly O
rescued RARE
in O
T O
- O
lymphocytes O
by O
either O
DNA O
- O
damaging RARE
agents O
( O
gamma O
- O
irradiation O
and O
bieomycin RARE
) O
or O
a O
null O
mutation O
of O
the O
p53 I-GENE
gene I-GENE
, O
possibly O
because O
of O
transiently O
elevated O
DNA O
repair O
activity O
in O
response O
to O
DNA O
damage O
or O
to O
delayed O
apoptosis O
in O
the O
absence O
of O
p53 I-GENE
. O

Coexpression RARE
of O
mouse O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
515 NUMERIC
) I-GENE
WT ALLCAPS
as O
a O
Gal4 I-GENE
DNA O
- O
binding O
domain O
fusion O
with O
either O
the O
catalytic O
- O
deficient O
human O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
551 NUMERIC
) I-GENE
K296R NUMERIC
mutant O
, O
the O
RNA O
- O
binding O
- O
deficient O
human O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
551 NUMERIC
) I-GENE
K64E NUMERIC
/ I-GENE
K296R NUMERIC
double O
mutant O
, O
or O
wild O
- O
type O
mouse O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
515 NUMERIC
) I-GENE
WT ALLCAPS
as O
full O
- O
length O
PKR I-GENE
- O
Gal4 I-GENE
activation O
domain O
fusions O
resulted O
in O
activation O
of O
the O
HIS3 I-GENE
and O
lacZ I-GENE
reporters RARE
. O

Using O
GST I-GENE
- O
PKR I-GENE
fusion O
chromatography O
, O
direct O
physical O
interaction O
between O
the O
mouse O
and O
human I-GENE
PKR I-GENE
homologs I-GENE
was O
established O
. O

An O
even O
greater O
inflammatory O
response O
was O
observed O
after O
intratracheal RARE
instillation RARE
of O
ufCB LASTCAP
, O
but O
not O
after O
CB ALLCAPS
instillation RARE
. O

Interestingly O
, O
the O
avirulent RARE
strain O
H37Ra NUMERIC
showed O
weak O
hybridization O
with O
these O
two O
probes O
, O
suggesting O
that O
these O
genes O
might O
have O
been O
deleted O
in O
the O
avirulent RARE
strain O
or O
are O
present O
in O
limited O
copy O
numbers O
as O
opposed O
to O
those O
in O
the O
virulent O
strain O
H37Rv NUMERIC
. O

These O
defects O
no O
doubt RARE
impair RARE
the O
folding O
and O
configuration O
necessary O
for O
normal O
processing O
of O
the O
AVP I-GENE
gene I-GENE
precursor I-GENE
. O

Similarities RARE
between O
the O
hIGFBP LASTCAP
- I-GENE
1 I-GENE
and O
phosphoenolpyruvate I-GENE
kinase I-GENE
( O
PEPCK I-GENE
) O
promoters O
, O
including O
regions O
conferring O
insulin I-GENE
, O
glucocorticoid O
, O
and O
cyclic O
adenosine O
- O
monophosphate O
responses O
, O
are O
consistent O
with O
our O
previous O
hypothesis O
that O
IGFBP ALLCAPS
- I-GENE
1 I-GENE
is O
involved O
in O
regulation O
of O
glucose O
metabolism O
. O

This O
binary RARE
repeat O
contains O
repetitive O
DNA O
elements O
that O
include O
LINES ALLCAPS
, O
SINES ALLCAPS
, O
medium O
reiteration RARE
frequency O
repeats O
, O
and O
a O
transposon O
- O
like O
element O
. O

At O
60 O
days O
the O
amount O
of O
gangliosides RARE
was O
on O
average O
lower O
in O
females O
than O
in O
males O
, O
even O
if O
with O
some O
exception O
. O

Large O
genomic O
constructs O
integrate RARE
at O
the O
endogenous O
locus O
by O
homologous O
recombination O
, O
but O
cDNA O
- O
derived O
sequences O
lacking O
long O
stretches O
of O
contiguous O
genomic O
DNA O
( O
due O
to O
intron O
excision O
) O
typically O
integrate RARE
into O
chromosomal O
DNA O
by O
nonhomologous RARE
recombination O
. O

The O
existence O
of O
these O
two O
categories O
of O
strains O
offers O
a O
new O
genetic O
system O
in O
which O
the O
properties O
of O
a O
potential O
invertebrate RARE
retrovirus O
can O
be O
tested O
. O

During O
the O
conditioning O
procedure O
, O
the O
C O
- O
fiber O
reflex O
was O
facilitated O
( O
wind RARE
- O
up O
) O
in O
a O
stimulus O
- O
dependent O
fashion O
in O
intact O
, O
anesthetized O
animals O
during O
the O
application O
of O
the O
first O
seven O
conditioning O
stimuli O
; O
thereafter O
, O
the O
magnitude O
of O
the O
responses O
reached O
a O
plateau RARE
and O
then O
decreased O
. O

As O
a O
sequence O
- O
specific O
DNA O
binding O
transcription O
factor O
, O
p53 I-GENE
specifically O
binds O
to O
a O
20 O
- O
bp O
consensus O
motif O
5 O
'- O
PuPuPuC LASTCAP
( O
A O
/ O
T O
) O
( O
T O
/ O
A O
) O
GPyPyPyPuPuPuC LASTCAP
( O
A O
/ O
T O
)( O
T O
/ O
A O
) O
GPyPyPy RARE
- O
3 O
'. O

TSA ALLCAPS
treatment O
, O
however O
, O
did O
not O
detectably RARE
alter O
enhancer O
factor O
binding O
or O
the O
positioning O
of O
nuc RARE
- I-GENE
1 I-GENE
on O
the O
majority O
of O
the O
chromatin O
templates O
indicating O
that O
protein O
acetylation O
and O
chromatin O
remodeling O
may O
be O
limiting O
steps O
that O
occur O
only O
on O
transcriptionally O
competent O
templates O
, O
or O
that O
remodeling O
of O
nuc RARE
- I-GENE
1 I-GENE
requires O
additional O
factors O
. O

Upon O
UV O
damage O
, O
Crb2 NUMERIC
is O
transiently O
modified O
, O
probably O
phosphorylated O
, O
with O
a O
similar O
timing O
of O
phosphorylation O
in O
Chk1 NUMERIC
kinase I-GENE
, O
which O
is O
reported O
to O
restrain RARE
Cdc2 I-GENE
activation O
. O

Moreover O
, O
moderate O
overexpression O
of O
Chk1 NUMERIC
suppresses O
the O
phenotypes O
of O
cut5 NUMERIC
and O
crb2 NUMERIC
mutants I-GENE
. O

Tcn1p NUMERIC
/ O
Crz1p NUMERIC
, O
a O
calcineurin RARE
- O
dependent O
transcription O
factor O
that O
differentially O
regulates O
gene O
expression O
in O
Saccharomyces O
cerevisiae O
. O

Structure O
and O
localization O
of O
the O
human O
gene O
encoding O
SR I-GENE
- I-GENE
BI I-GENE
/ O
CLA ALLCAPS
- I-GENE
1 I-GENE
. O

We O
introduced O
the O
gel O
technique O
as O
a O
routine O
assay O
for O
antibody O
detection O
and O
identification O
in O
1993 O
. O

Stability RARE
of O
pyrimethamine RARE
in O
a O
liquid O
dosage O
formulation O
stored O
for O
three O
months O
. O

Multiple O
regression O
analyses O
revealed O
that O
WAIS ALLCAPS
- O
R O
factor O
scores O
Verbal RARE
Comprehension RARE
and O
Freedom RARE
from O
Distractibility RARE
accounted RARE
for O
up O
to O
42 O
% O
of O
the O
variance RARE
in O
WMS ALLCAPS
- O
R O
and O
CVLT ALLCAPS
indices O
. O

Bilateral RARE
basal O
arteries O
were O
measured O
by O
the O
transtemporal RARE
approach O
with O
a O
2 O
MHz RARE
pulsed O
Doppler O
instrument O
( O
TC ALLCAPS
- O
2 O
64B NUMERIC
EME ALLCAPS
). O

At O
the O
genomic O
level O
, O
the O
sequences O
of O
two O
members O
of O
this O
family O
are O
known O
in O
the O
rat O
Rattus RARE
norvegicus RARE
: O
the O
VCSA1 NUMERIC
gene I-GENE
, O
encoding O
the O
prohormone RARE
- I-GENE
like I-GENE
polypeptide I-GENE
SMR1 NUMERIC
, O
and O
the O
VCSB1 NUMERIC
gene I-GENE
, O
encoding O
a O
salivary O
Pro O
- O
rich O
polypeptide O
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
RAD30 NUMERIC
gene I-GENE
, O
a O
homologue I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
dinB LASTCAP
and O
umuC LASTCAP
, O
is O
DNA O
damage O
inducible O
and O
functions O
in O
a O
novel O
error O
- O
free O
postreplication RARE
repair O
mechanism O
. O

However O
, O
in O
a O
new O
experiment O
in O
which O
the O
deletion O
task O
was O
presented O
as O
a O
puppet RARE
game RARE
, O
and O
with O
pretraining RARE
and O
selection O
on O
vowel RARE
deletion O
, O
a O
significantly O
higher O
level O
of O
success O
was O
achieved O
by O
the O
children O
working O
with O
the O
CVCC ALLCAPS
material O
. O

Diet RARE
therapy O
with O
soy RARE
proteins O
for O
chronic O
stomach O
ulcers O

In O
ICU ALLCAPS
patients O
, O
the O
LIS ALLCAPS
related O
to O
the O
postoperative O
rise O
in O
IL I-GENE
- I-GENE
6 I-GENE
level O
only O
, O
even O
though O
the O
rise O
in O
plasma O
concentrations O
of O
cytokines O
interrelated RARE
. O

Resistance O
training O
shifts O
the O
power O
curve O
in O
a O
positive O
direction O
when O
the O
measurements O
are O
determined O
with O
absolute O
loads RARE
, O
but O
the O
increased O
power O
may O
not O
be O
transferred O
to O
an O
absolute O
performance O
task O
like O
the O
SSP ALLCAPS
. O

Gel O
- O
shift O
assays O
identified O
two O
Sp1 I-GENE
binding I-GENE
sites I-GENE
within O
this O
element O
. O

Y15170 NUMERIC
( O
Surf I-GENE
- I-GENE
2 I-GENE
, O
Surf I-GENE
- I-GENE
4 I-GENE
), O
Y15171 NUMERIC
( O
Surf I-GENE
- I-GENE
3 I-GENE
, O
Surf I-GENE
- I-GENE
1 I-GENE
, O
Surf I-GENE
- I-GENE
6 I-GENE
), O
and O
Y15172 NUMERIC
( O
Surf I-GENE
- I-GENE
5 I-GENE
.)] RARE

Gel O
mobility O
shift O
and O
super RARE
- O
shift O
assays O
using O
liver O
nuclear O
extracts O
from O
either O
rat O
liver O
or O
DDT1MF NUMERIC
- O
2 O
cells O
demonstrated O
that O
the O
CRE O
in O
the O
alpha I-GENE
1B I-GENE
- I-GENE
AR I-GENE
gene I-GENE
bound O
CRE I-GENE
binding I-GENE
protein I-GENE
. O

These O
results O
suggest O
that O
, O
in O
this O
experimental O
model O
, O
ACE I-GENE
inhibitors O
limit O
the O
arrhythmias O
following O
ischemia O
- O
reperfusion O
and O
free O
radical O
scavenging RARE
action O
of O
these O
drugs O
does O
not O
have O
a O
major O
contributory RARE
role O
in O
their O
protective O
effect O
. O

The O
mean O
values O
of O
the O
first O
three O
components O
were O
not O
significantly O
different O
in O
ARVD ALLCAPS
patients O
and O
control O
subjects O
. O

However O
, O
the O
signaling O
cascade O
utilized O
by O
the O
urokinase I-GENE
receptor I-GENE
is O
only O
incompletely RARE
understood O
. O

The O
murine O
Htf9 NUMERIC
- I-GENE
a I-GENE
/ O
RanBP1 NUMERIC
and O
Htf9 NUMERIC
- I-GENE
c I-GENE
genes I-GENE
are O
divergently O
transcribed O
from O
a O
shared O
TATA O
- O
less O
promoter O
. O

In O
accordance RARE
with O
clinical O
improvement O
we O
found O
a O
decrease O
of O
laboratory O
indicators O
of O
inflammation O
( O
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
, O
alpha I-GENE
2 I-GENE
- I-GENE
globuline RARE
, O
prostaglandin O
E2 O
). O

We O
have O
previously O
reported O
that O
depletion O
of O
protein I-GENE
kinase I-GENE
C I-GENE
by O
long O
- O
term O
treatment O
of O
B16 NUMERIC
mouse O
melanoma O
cells O
with O
phorbol O
dibutyrate RARE
( O
PDBu RARE
) O
prevented O
cell O
density O
- O
dependent O
melanogenesis RARE
. O

Replacement O
of O
residues O
in O
positions O
+ O
3 O
( O
His128Asn NUMERIC
) O
and O
+ O
2 O
( O
Gln155Lys NUMERIC
) O
of O
the O
reading O
helices O
of O
fingers O
2 O
and O
3 O
, O
respectively O
, O
prevented O
binding O
. O

Two O
disulphide RARE
bridges RARE
, O
which O
are O
conserved O
in O
all O
spermadhesin RARE
molecules O
and O
many O
CUB ALLCAPS
domains O
, O
crosslink RARE
loop O
LA O
and O
strand O
beta O
4 O
and O
loops O
LE ALLCAPS
and O
LG ALLCAPS
, O
respectively O
, O
at O
opposite O
edges RARE
of O
the O
same O
face O
of O
the O
domain O
. O

Mg I-GENE
- I-GENE
chelatase RARE
of O
tobacco O
: O
identification O
of O
a O
Chl RARE
D I-GENE
cDNA I-GENE
sequence I-GENE
encoding O
a O
third O
subunit O
, O
analysis O
of O
the O
interaction O
of O
the O
three O
subunits O
with O
the O
yeast O
two O
- O
hybrid O
system O
, O
and O
reconstitution RARE
of O
the O
enzyme O
activity O
by O
co O
- O
expression O
of O
recombinant I-GENE
CHL ALLCAPS
D I-GENE
, O
CHL ALLCAPS
H I-GENE
and O
CHL ALLCAPS
I I-GENE
. O

One O
R O
- O
EST O
and O
one O
Pto RARE
- I-GENE
like I-GENE
sequence I-GENE
each O
mapped O
to O
two O
locations O
. O

The O
multidomain RARE
structure O
includes O
a O
cysteine O
- O
rich O
motif O
resembling O
those O
of O
protein I-GENE
kinase I-GENE
C I-GENE
and O
n I-GENE
- I-GENE
chimaerin RARE
and O
a O
putative O
pleckstrin I-GENE
homology I-GENE
domain I-GENE
. O

The O
interaction O
between O
DDB ALLCAPS
and O
E2F1 I-GENE
can O
also O
be O
detected O
by O
coimmunoprecipitation RARE
experiments O
. O

271 NUMERIC
: O
31290 NUMERIC
- O
31295 NUMERIC
, O
1996 O
). O

Nevertheless O
, O
antibodies O
directed O
against O
an O
epitope O
- O
tagged O
version O
of O
Prp42p NUMERIC
specifically O
precipitate RARE
U1 I-GENE
snRNA I-GENE
from O
yeast O
extracts O
. O

These O
results O
indicate O
that O
in O
addition O
to O
Grb2 I-GENE
- O
mediated O
activation O
of O
Ras I-GENE
, O
PLC I-GENE
- I-GENE
gamma1 NUMERIC
- O
mediated O
DAG ALLCAPS
production O
is O
required O
for O
EGF I-GENE
- O
and O
PDGF I-GENE
- O
induced O
S O
- O
phase O
entry O
and O
gene O
expression O
, O
possibly O
through O
activation O
of O
PKC I-GENE
. O

In O
this O
study O
, O
we O
investigated O
STAT I-GENE
activation O
in O
a O
panel O
of O
rodent O
fibroblast O
cell O
lines O
stably O
transformed O
by O
diverse O
viral O
oncoproteins O
. O

In O
serum O
- O
stimulated O
cells O
, O
the O
binding O
of O
NF I-GENE
- I-GENE
Y I-GENE
/ O
CBF I-GENE
to O
TKC1 NUMERIC
increased O
gradually O
, O
reaching RARE
a O
plateau RARE
at O
the O
S O
phase O
. O

CONCLUSION O
: O
In O
our O
animal O
model O
, O
blood O
- O
brain O
barrier O
disruption O
was O
a O
reproducible RARE
, O
integral O
finding O
of O
single O
- O
fraction O
, O
high O
- O
dose O
irradiation O
injury O
. O

To O
facilitate O
the O
investigation O
of O
parameters O
that O
govern O
selective O
export O
in O
adenovirus O
- O
infected O
cells O
, O
we O
constructed O
a O
marked O
human O
beta I-GENE
- I-GENE
actin I-GENE
minigene RARE
under O
the O
control O
of O
the O
glucocorticoid I-GENE
- I-GENE
inducible I-GENE
enhancer I-GENE
- I-GENE
promoter I-GENE
of O
mouse O
mammary O
tumor O
virus O
and O
introduced O
it O
into O
the O
left O
end O
of O
the O
adenovirus O
type O
5 O
( O
Ad5 O
) O
genome O
. O

Cell O
factor O
- O
mediated O
regulatory O
interactions O
are O
involved O
in O
regulating O
the O
restricted O
expression O
of O
the O
HCMV I-GENE
major I-GENE
immediate I-GENE
- I-GENE
early I-GENE
( I-GENE
IE I-GENE
) I-GENE
gene I-GENE
( O
J O
. O

MpB LASTCAP
GroEL LASTCAP
has O
extensive O
sequence O
similarity O
( O
92 O
%) O
with O
Escherichia I-GENE
coli I-GENE
GroEL LASTCAP
and O
other O
members O
of O
the O
chaperonin RARE
- I-GENE
60 I-GENE
family I-GENE
. O

The O
critical O
mutations O
were O
likely O
to O
have O
been O
multiple O
and O
dispersed RARE
, O
including O
elongation O
of O
the O
TM O
and O
Nef I-GENE
coding I-GENE
sequences I-GENE
; O
changes O
in O
RNA O
splice O
donor O
and O
acceptor O
sites O
, O
TATA O
box O
sites O
, O
and O
Sp1 I-GENE
sites I-GENE
; O
multiple O
changes O
in O
the O
V2 I-GENE
region O
of O
SU I-GENE
, O
including O
a O
consensus O
neutralization RARE
epitope O
; O
and O
five O
new O
N O
- O
linked O
glycosylation O
sites O
in O
SU I-GENE
. O

C O
. O

These O
are O
the O
long O
terminal O
repeat O
( O
LTR O
) O
promoter O
, O
which O
regulates O
expression O
of O
the O
viral O
structural O
proteins O
, O
and O
a O
second O
internal O
promoter O
, O
located O
towards O
the O
3 O
' O
end O
of O
the O
env I-GENE
gene I-GENE
, O
that O
directs O
expression O
of O
the O
viral O
auxiliary O
proteins O
. O

The O
5 O
' O
end O
of O
the O
genomic O
RNA O
of O
rubella RARE
virus O
( O
RUB ALLCAPS
) O
contains O
a O
14 O
- O
nucleotide O
( O
nt O
) O
single O
- O
stranded O
leader O
( O
ss RARE
- O
leader O
) O
followed O
by O
a O
stem O
- O
and O
- O
loop O
structure O
[ O
5 O
'(+) RARE
SL ALLCAPS
] O
( O
nt O
15 O
to O
65 O
), O
the O
complement O
of O
which O
at O
the O
3 O
' O
end O
of O
the O
minus O
- O
strand O
RNA O
[ O
3 O
'(-) RARE
SL ALLCAPS
] O
has O
been O
proposed O
to O
function O
as O
a O
promoter O
for O
synthesis O
of O
genomic O
plus O
strands RARE
. O

To O
investigate O
the O
requirements O
for O
CBF2 I-GENE
binding O
, O
we O
synthesized O
a O
series O
of O
oligonucleotides O
carrying O
double O
transversion O
mutations O
spanning O
both O
the O
conserved O
core O
sequence O
and O
outside O
flanking O
sequences O
. O

In O
addition O
, O
the O
affinities O
of O
CBF2 I-GENE
for O
binding O
to O
the O
LMP I-GENE
- I-GENE
1 I-GENE
, O
LMP I-GENE
- I-GENE
2 I-GENE
, O
and O
CD23 I-GENE
promoters I-GENE
were O
also O
measured O
. O

CONCLUSIONS O
: O
The O
myocardial O
uptake O
of O
99mTc O
sestamibi RARE
in O
normal O
subjects O
and O
patients O
with O
coronary O
artery O
disease O
is O
comparable O
after O
exercise O
, O
dipyridamole RARE
, O
and O
adenosine O
stress O
. O

The O
SR I-GENE
protein I-GENE
family I-GENE
is O
involved O
in O
constitutive O
and O
regulated O
pre O
- O
mRNA O
splicing O
and O
has O
been O
found O
to O
be O
evolutionarily O
conserved O
in O
metazoan O
organisms O
. O

To O
investigate O
the O
activity O
of O
TCF11 NUMERIC
through O
this O
selected O
site O
, O
both O
alone O
and O
in O
the O
presence O
of O
MafG LASTCAP
, O
we O
have O
used O
a O
transient O
transfection O
assay O
. O

These O
and O
other O
comparisons O
suggest O
that O
, O
during O
evolution O
, O
both O
the O
RNA I-GENE
- I-GENE
polymerase I-GENE
specificity O
of O
telomerase I-GENE
RNA I-GENE
- I-GENE
gene I-GENE
promoters I-GENE
and O
, O
more O
recently O
, O
the O
position O
of O
the O
template O
sequence O
in O
the O
telomerase I-GENE
RNA I-GENE
changed O
. O

Deadenylation RARE
and O
decay O
of O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
in O
K562 O
cells O
is O
extraordinarily RARE
slow O
compared O
with O
NIH O
3T3 O
cells O
, O
suggesting O
that O
the O
increased O
stability O
gained RARE
by O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
in O
K562 O
cells O
is O
mainly O
controlled O
at O
the O
deadenylation RARE
step O
. O

Holliday RARE
junction I-GENE
resolvase RARE
in O
Schizosaccharomyces O
pombe O
has O
identical O
endonuclease O
activity O
to O
the O
CCE1 NUMERIC
homologue O
YDC2 NUMERIC
. O

Ca2 I-GENE
+/ I-GENE
calmodulin I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
II I-GENE
( O
CaMK LASTCAP
II I-GENE
) O
is O
a O
multifunctional RARE
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
that O
regulates O
ion O
channels O
, O
metabolic O
enzymes O
, O
cytoskeletal O
proteins O
, O
and O
possibly O
transcription O
factors O
. O

A O
cAMP O
- O
responsive O
element O
- O
like O
( O
CRE O
- O
like O
, O
TGACGTGA ALLCAPS
) O
promoter O
sequence O
and O
a O
protein I-GENE
kinase I-GENE
A I-GENE
signaling O
pathway O
are O
involved O
in O
this O
induction O
, O
and O
activation O
of O
both O
CRE I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
and O
activating I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
2 I-GENE
( O
ATF I-GENE
- I-GENE
2 I-GENE
) O
is O
required O
in O
the O
above O
process O
. O

IVOX ALLCAPS
was O
named O
as O
an O
acronym RARE
for O
intravascular O
oxygenator RARE
. O

Histopathologically RARE
, O
a O
cystic O
lymphangioma RARE
was O
diagnosed O
because O
of O
the O
morphological O
features O
and O
the O
immunohistochemical O
stainings RARE
of O
CD34 I-GENE
and O
Factor I-GENE
VIII I-GENE
related I-GENE
antigen I-GENE
which O
were O
observed O
positive O
reactions O
in O
endothelial O
cells O
of O
the O
cysts O
. O

Protease RARE
activities O
in O
cultures O
of O
the O
streptococcal O
strains O
were O
associated O
with O
species O
of O
different O
molecular O
masses O
ranging O
from O
130 O
to O
200 O
kDa O
, O
suggesting O
posttranslational O
processing O
possibly O
as O
a O
result O
of O
autoproteolysis RARE
at O
post O
- O
proline O
peptide O
bonds O
in O
the O
N O
- O
terminal O
parts O
of O
the O
molecules O
. O

The O
mechanism O
underlying O
such O
analgesia O
has O
been O
suggested O
to O
involve O
the O
interaction O
between O
the O
two O
separate O
but O
interconnected RARE
motivational RARE
systems O
" O
defense O
" O
and O
" O
pain O
." O
To O
determine O
the O
developmental O
course O
of O
defense O
and O
nociception RARE
, O
these O
processes O
were O
analyzed O
during O
early O
ontogeny RARE
in O
rats O
. O

Three O
large O
field O
placement O
errors RARE
( O
two O
patients O
with O
11 O
. O
5 O
and O
16 O
. O
0 O
mm O
distances O
of O
the O
planned RARE
versus O
simulated O
isocenter RARE
, O
respectively O
and O
one O
patient O
with O
a O
7 O
degree O
rotational RARE
error O
) O
were O
detected O
and O
, O
as O
with O
the O
smaller O
errors RARE
, O
were O
immediately O
corrected O
. O

In O
addition O
, O
a O
catalytically O
inactive O
version O
of O
the O
Src I-GENE
family I-GENE
member O
, O
Lck I-GENE
( O
lymphoid I-GENE
cell I-GENE
kinase I-GENE
), O
was O
expressed O
, O
purified O
, O
and O
evaluated O
as O
a O
Csk I-GENE
substrate O
. O

A O
., O
Swift RARE
, O
A O
. O

Neuronal RARE
mechanisms O
underlying O
stimulus O
- O
response O
( O
S O
- O
R O
) O
associations O
in O
S O
- O
R O
compatibility O
tasks O
were O
identified O
in O
2 O
experiments O
with O
monkeys O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
/ O
TGF I-GENE
- I-GENE
alpha I-GENE
HCCs RARE
were O
also O
characterized O
by O
a O
particularly O
strong O
expression O
of O
TGF I-GENE
- I-GENE
alpha I-GENE
and O
very O
low O
apoptotic O
index O
in O
contrast O
to O
high O
levels O
of O
apoptosis O
in O
peritumorous RARE
tissues O
and O
c I-GENE
- I-GENE
myc I-GENE
HCCs RARE
. O

Taken O
together O
, O
our O
data O
suggest O
that O
the O
antagonistic O
effects O
of O
CRP I-GENE
and O
KdgR LASTCAP
on O
the O
expression O
of O
the O
pectinolysis RARE
genes I-GENE
occur O
by O
different O
mechanisms O
, O
including O
direct O
competition O
between O
the O
two O
regulators O
or O
between O
the O
repressor O
and O
RNA I-GENE
polymerase I-GENE
for O
the O
occupation RARE
of O
a O
common O
DNA O
region O
on O
the O
target O
genes O
. O

The O
well O
- O
known O
Rel I-GENE
/ O
NF I-GENE
- I-GENE
kappaB I-GENE
family O
of O
vertebrate O
transcription O
factors O
comprises O
a O
number O
of O
structurally O
related O
, O
interacting O
proteins O
that O
bind O
DNA O
as O
dimers O
and O
whose O
activity O
is O
regulated O
by O
subcellular O
location O
. O

The O
cglIM LASTCAP
gene I-GENE
is O
organized O
in O
an O
unusual O
operon O
which O
contains O
, O
in O
addition O
, O
two O
genes O
encoding O
stress O
- O
sensitive O
restriction O
enzymes O
. O

Lysine RARE
- I-GENE
ketoglutarate RARE
reductase I-GENE
and O
saccharopine RARE
dehydrogenase I-GENE
from O
Arabidopsis O
thaliana O
: O
nucleotide O
sequence O
and O
characterization O
. O

The O
purpose O
of O
this O
investigation O
was O
to O
describe O
a O
new O
formulation O
of O
silver O
sulfadiazine RARE
in O
a O
water O
soluble O
gel O
, O
poloxamer RARE
188 NUMERIC
. O

The O
study O
goals RARE
were O
to O
isolate O
a O
full O
- O
length O
clone O
encoding O
CO I-GENE
- I-GENE
Ag I-GENE
from O
a O
bovine O
corneal O
cDNA O
library O
and O
to O
express O
this O
clone O
in O
Escherichia O
coli O
( O
E O
. O
coli O
). O

The O
pel RARE
gene I-GENE
from O
an O
Amycolata RARE
sp O
. O
encoding O
a O
pectate RARE
lyase I-GENE
( O
EC I-GENE
4 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
) O
was O
isolated O
by O
activity O
screening O
a O
genomic O
DNA O
library O
in O
Streptomyces O
lividans RARE
TK24 NUMERIC
. O

The O
gene O
contains O
six O
exons O
separated O
by O
1 O
. O
1 O
- O
5 O
. O
8 O
kb O
introns O
and O
has O
been O
localized O
to O
the O
murine O
chromosome O
2 O
by O
linkage O
analysis O
. O

In O
Xenopus O
embryos O
, O
the O
engineered I-GENE
PDGF I-GENE
receptor I-GENE
protein I-GENE
induced O
the O
formation O
of O
mesoderm O
from O
animal O
- O
pole O
explants RARE
in O
an O
FK1012 NUMERIC
- O
dependent O
manner O
. O

A O
cytosolic O
variant O
of O
the O
protein O
underwent O
efficient O
transphosphorylation RARE
, O
yet O
failed O
to O
activate O
appreciably RARE
either O
p70 I-GENE
( O
S6k NUMERIC
) O
or O
MAP I-GENE
kinase I-GENE
following O
treatment O
with O
FK1012 NUMERIC
. O

Small RARE
- O
molecule O
control O
of O
insulin I-GENE
and O
PDGF I-GENE
receptor I-GENE
signaling O
and O
the O
role O
of O
membrane O
attachment O
. O

Conversely O
, O
the O
inactive O
dAK LASTCAP
subunit I-GENE
is O
progressively RARE
activated O
by O
1 O
) O
association O
with O
a O
dGK LASTCAP
or O
dCK LASTCAP
subunit I-GENE
and O
2 O
) O
the O
conformationally RARE
driven O
heterotropic RARE
affect O
of O
dGuo RARE
or O
dCyd RARE
bound O
to O
the O
opposing RARE
subunit O
. O

CONCLUSIONS O
: O
A O
50 O
- O
mg O
daily O
dose O
of O
bicalutamide RARE
is O
sufficient O
when O
given O
in O
combination O
with O
an O
agent O
, O
such O
as O
a O
LHRH ALLCAPS
- O
A O
, O
that O
lowers RARE
serum O
testosterone O
, O
but O
higher O
doses O
of O
bicalutamide RARE
may O
be O
needed O
when O
the O
drug O
is O
given O
as O
monotherapy RARE
. O

A O
genomic O
clone O
was O
isolated O
that O
contained O
12 O
. O
5 O
kb O
of O
the O
5 O
'- O
flanking O
region O
and O
the O
first O
exon O
of O
the O
p69 NUMERIC
/ I-GENE
71 I-GENE
2 I-GENE
- I-GENE
5A NUMERIC
synthetase I-GENE
gene I-GENE
. O

Although O
the O
gene O
is O
substantially O
smaller O
than O
the O
human O
genes O
for O
other O
mitochondrial O
enzymes O
, O
its O
intron O
/ O
exon O
organization O
is O
very O
similar O
, O
especially O
to O
that O
of O
P450scc NUMERIC
. O

RESULTS O
: O
Looking RARE
at O
the O
question O
of O
its O
benefits O
, O
we O
were O
unable O
to O
find O
any O
methodologically RARE
sound O
studies O
that O
have O
shown O
efficacy O
for O
EMDR ALLCAPS
in O
eating RARE
disorders O
, O
or O
, O
indeed O
, O
any O
psychiatric O
disorder O
. O

In O
the O
clinical O
study O
, O
the O
defect O
size O
shown O
by O
BMIPP ALLCAPS
imaging O
was O
greater O
in O
anterior O
than O
in O
inferior O
infarcts RARE
( O
p O
< O
0 O
. O
001 O
) O
and O
correlated O
well O
with O
the O
risk O
area O
revealed O
by O
contrast O
ventriculography RARE
( O
r O
= O
0 O
. O
80 O
, O
p O
< O
0 O
. O
0001 O
) O
CONCLUSION O
: O
The O
above O
preliminary O
data O
, O
admittedly RARE
from O
a O
small O
group O
of O
patients O
, O
suggest O
that O
tomographic RARE
BMIPP ALLCAPS
imaging O
provides O
an O
accurate O
quantification RARE
of O
defect O
size O
by O
means O
of O
a O
simple O
threshold O
technique O
and O
, O
in O
the O
subacute O
phase O
, O
permits O
determination O
of O
the O
amount O
of O
myocardium O
at O
risk O
after O
acute O
myocardial O
infarction O
. O

Transient O
overexpression O
of O
mutant I-GENE
EphB1 NUMERIC
receptors I-GENE
( O
Y594F NUMERIC
) O
blocked O
Nck RARE
recruitment O
to O
EphB1 NUMERIC
, O
attenuated O
downstream O
JNK I-GENE
activation O
, O
and O
blocked O
cell O
attachment O
responses O
. O

The O
promoter O
for O
HMG I-GENE
- I-GENE
CoA I-GENE
synthase I-GENE
contains O
two O
binding O
sites O
for O
the O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
SREBPs RARE
). O

S O
., O
and O
Walter RARE
, O
P O
. O

Here O
we O
demonstrate O
that O
Hh RARE
and O
Patched RARE
( O
Ptc RARE
) O
act O
through O
those O
Ci RARE
binding O
sites O
to O
modulate O
the O
level O
of O
Ci RARE
- O
dependent O
transcriptional O
activation O
in O
S2 O
cells O
. O

Furthermore O
the O
median O
increase O
in O
cyclosporine O
DR O
/ O
C O
( O
SS O
trough O
) O
was O
18 O
l O
h O
- O
1 O
(- O
3 O
. O
1 O
to O
42 O
. O
1 O
l O
h O
- O
1 O
, O
interquartile RARE
range O
). O

Patients O
and O
their O
relatives RARE
must O
be O
informed RARE
about O
the O
available O
effective O
treatment O
possibilities O
and O
about O
the O
right O
moment RARE
for O
their O
application O
in O
an O
individual O
patient O
. O

Several O
PTPases RARE
were O
expressed O
abundantly O
in O
the O
5 O
- O
FU O
- O
treated O
bone O
marrow O
stem O
cells O
. O

Expression O
of O
PTPRO ALLCAPS
was O
also O
observed O
in O
human I-GENE
CD34 I-GENE
+ I-GENE
bone O
marrow O
cells O
and O
5 O
- O
FU O
- O
treated O
murine O
primitive RARE
stem O
cells O
. O

The O
organization O
of O
SPP1 NUMERIC
genes I-GENE
involved O
in O
the O
replication O
, O
DNA O
packaging RARE
and O
phage O
assembly O
proteins O
resembles O
the O
organization O
of O
genes O
of O
equivalent O
regions O
of O
different O
E O
. O
coli O
double O
- O
stranded O
DNA O
phages RARE
. O

Our O
results O
showed O
that O
compared O
to O
the O
primary O
photon O
fluence RARE
, O
the O
extra O
- O
focal O
photon O
fluence RARE
from O
the O
primary O
collimator RARE
and O
the O
flattening RARE
filter O
was O
11 O
%- RARE
16 O
% O
at O
the O
isocenter RARE
, O
among O
which O
70 O
% O
was O
contributed O
by O
the O
flattening RARE
filter O
. O

The O
functional O
mature O
domain O
of O
pediocin RARE
AcH LASTCAP
( I-GENE
Lys I-GENE
+ I-GENE
1 I-GENE
to I-GENE
Cys I-GENE
+ I-GENE
44 I-GENE
) I-GENE
is O
targeted O
into O
the O
E O
. O
coli O
sec O
machinery O
and O
secreted O
to O
the O
periplasm RARE
in O
active O
form O
when O
fused O
in O
frame O
to O
the O
COOH O
terminus O
of O
the O
secretory I-GENE
protein I-GENE
maltose RARE
- I-GENE
binding I-GENE
protein I-GENE
( O
MBP I-GENE
). O

Isomers RARE
were O
differentiated O
based O
on O
the O
MS O
- O
MS O
data O
of O
the O
trofluoroacetyl RARE
- O
biphenylol RARE
derivatives O
. O

Although O
RAD17 NUMERIC
, O
RAD24 NUMERIC
and O
MEC3 NUMERIC
are O
not O
required O
for O
cell O
cycle O
arrest O
when O
S O
phase O
is O
inhibited O
by O
hydroxyurea RARE
( O
HU ALLCAPS
), O
they O
do O
contribute O
to O
the O
viability O
of O
yeast O
cells O
grown O
in O
the O
presence O
of O
HU ALLCAPS
, O
possibly O
because O
they O
are O
required O
for O
the O
repair O
of O
HU ALLCAPS
- O
induced O
DNA O
damage O
. O

Clinical O
value O
of O
the O
estimation O
of O
growth O
kinetics O
of O
primary O
ovarian O
cancer O
recurrences RARE
by O
CA125 NUMERIC
doubling RARE
time O

This O
review O
seeks RARE
to O
summarize RARE
the O
disease O
, O
to O
propose O
pathways O
of O
carcinogenesis RARE
and O
to O
suggest O
ways O
in O
which O
the O
" O
traditional RARE
" O
risk O
factors O
may O
be O
interpreted O
on O
the O
basis O
of O
evolving RARE
knowledge O
. O

The O
patient O
underwent O
two O
intracytoplasmic RARE
sperm O
injection O
cycles O
with O
thawed RARE
epididymal RARE
spermatozoa O
, O
in O
which O
, O
due O
to O
a O
pharmacist RARE
' O
s O
mistake RARE
, O
ovarian O
stimulation O
was O
carried O
out O
by O
a O
combination O
of O
long O
- O
acting O
gonadotrophin RARE
- I-GENE
releasing I-GENE
hormone I-GENE
agonist O
( O
leuprolide RARE
depot RARE
) O
and O
gonadotrophins RARE
. O

Protein I-GENE
C I-GENE
deficiency O
or O
protein I-GENE
S I-GENE
deficiency O
was O
the O
only O
identified O
risk O
factor O
for O
5 O
. O
4 O
% O
( O
2 O
patients O
) O
and O
13 O
. O
5 O
% O
( O
5 O
patients O
), O
respectively O
, O
of O
these O
37 O
children O
. O

Perhaps RARE
in O
addition O
to O
, O
or O
as O
part O
of O
, O
its O
essential O
function O
in O
late O
mitosis O
, O
MOB1 NUMERIC
is O
required O
for O
a O
cell O
cycle O
reset RARE
function O
necessary O
for O
the O
initiation O
of O
the O
spindle O
pole O
body O
duplication O
. O

In O
contrast O
, O
overproduction RARE
of O
Der3p NUMERIC
is O
lethal O
in O
a O
sec61 NUMERIC
- I-GENE
2 I-GENE
strain O
at O
the O
permissive O
temperature O
of O
25 O
degrees O
C O
. O

Normal RARE
baseline O
( O
day O
- O
8 O
) O
PC O
levels O
( O
86 O
and O
89 O
%) O
were O
markedly O
reduced O
in O
both O
patients O
at O
the O
time O
of O
VOD ALLCAPS
manifestation O
on O
day O
20 O
and O
40 O
, O
respectively O
( O
26 O
and O
31 O
%). O

To O
examine O
the O
role O
of O
this O
CE2 NUMERIC
element O
in O
regulating O
Hoxa1 NUMERIC
expression O
in O
vivo O
, O
transgenic O
mice O
were O
generated O
which O
express O
a O
Hoxa1 NUMERIC
beta I-GENE
- I-GENE
galactosidase I-GENE
reporter O
gene O
that O
contains O
a O
mutation O
in O
the O
CE2 NUMERIC
element O
. O

An O
evolutionary O
conserved O
element O
is O
essential O
for O
somite RARE
and O
adjacent O
mesenchymal O
expression O
of O
the O
Hoxa1 NUMERIC
gene I-GENE
. O

RESULTS O
: O
The O
bovine O
cDNA O
insert O
sequence O
was O
273 NUMERIC
nucleotides O
in O
length O
for O
the O
entire O
mRNA O
coding O
region O
, O
212 NUMERIC
nucleotides O
in O
the O
5 O
' O
untranslated O
region O
, O
83 O
nucleotides O
in O
the O
3 O
' O
untranslated O
region O
and O
a O
poly O
( O
A O
) O
tail O
. O

Altogether O
46 O
phase O
III O
activities O
were O
recorded O
. O

We O
have O
previously O
identified O
a O
liver O
- O
enriched O
transcription O
factor O
, O
HNF I-GENE
- I-GENE
6 I-GENE
, O
which O
is O
required O
for O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
promoter I-GENE
activity O
and O
also O
recognizes O
the O
regulatory O
region O
of O
numerous O
hepatocyte O
- O
specific O
genes O
. O

A O
cDNA O
clone O
was O
identified O
encoding O
a O
second O
GHS ALLCAPS
- I-GENE
R I-GENE
- I-GENE
related I-GENE
gene I-GENE
( O
GPR39 NUMERIC
). O

( O
1997 O
) O
Science RARE
275 NUMERIC
, O
1927 NUMERIC
- O
1930 NUMERIC
). O

P O
., O
Peyron RARE
, O
J O
. O

A O
hybridoma RARE
clone O
( O
7H1 NUMERIC
) O
resulting O
from O
the O
fusion O
between O
CEMLAI ALLCAPS
/ O
NP O
and O
human O
embryonic O
fibroblasts O
MRC5 NUMERIC
cells O
produced O
very O
large O
amounts O
of O
P47 NUMERIC
that O
was O
purified O
using O
Jacalin RARE
lectin RARE
( O
specific O
for O
O O
- O
glycans RARE
) O
and O
microsequenced RARE
. O

This O
information O
, O
together O
with O
estimation O
of O
the O
size O
of O
the O
deglycosylated RARE
A O
subunit O
relative O
to O
a O
series O
of O
C I-GENE
- I-GENE
terminal I-GENE
truncated I-GENE
TSHR ALLCAPS
ectodomain RARE
variants I-GENE
, O
places RARE
cleavage O
Site O
1 O
in O
the O
vicinity O
of O
, O
or O
closely O
upstream O
to O
, O
residue O
317 NUMERIC
. O

In O
vitro O
DNase I-GENE
I I-GENE
footprinting O
of O
the O
200 O
- O
bp O
proximal O
region O
of O
the O
promoter O
with O
a O
murine O
Hepa RARE
1 O
- O
6 O
cell O
nuclear O
extract O
revealed O
a O
clear O
footprint O
of O
a O
region O
corresponding O
to O
- O
80 O
to O
- O
28 O
bp O
of O
the O
murine I-GENE
fVII LASTCAP
gene I-GENE
, O
suggesting O
that O
liver O
factors O
interact O
with O
this O
region O
of O
the O
DNA O
. O

A O
reciprocal O
binding O
assay O
using O
IM O
- O
9 O
cells O
as O
a O
source O
of O
SHP I-GENE
- I-GENE
1 I-GENE
and O
SHP I-GENE
- I-GENE
2 I-GENE
revealed O
specific O
association O
of O
SHP I-GENE
- I-GENE
2 I-GENE
( O
but O
not O
SHP I-GENE
- I-GENE
1 I-GENE
) O
with O
a O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
incorporating RARE
GHR ALLCAPS
cytoplasmic I-GENE
domain I-GENE
residues I-GENE
485 NUMERIC
- I-GENE
620 NUMERIC
, O
but O
only O
if O
the O
fusion O
was O
first O
rendered RARE
tyrosine O
- O
phosphorylated O
. O

Both O
increasing O
basal O
FSH I-GENE
and O
age O
were O
associated O
significantly O
with O
increased O
total O
gonadotrophin RARE
dose O
, O
and O
reduced O
number O
of O
oocytes O
collected O
and O
pregnancy O
rate O
. O

A O
comparative O
study O
was O
undertaken O
between O
an O
enzymatic O
immunohistochemical O
technique O
( O
EIT ALLCAPS
) O
developed O
for O
the O
diagnosis O
of O
human O
trichinellosis RARE
and O
the O
indirect O
immunofluorescence O
test O
( O
IIF ALLCAPS
), O
analysing RARE
sera O
from O
outbreaks RARE
of O
human O
trichinellosis RARE
in O
Argentina RARE
. O

Our O
results O
establish O
GKLF ALLCAPS
as O
a O
sequence O
- O
specific O
transcription O
factor O
likely O
involved O
in O
regulation O
of O
expression O
of O
endogenous O
genes O
. O

CES4 NUMERIC
on O
a O
multicopy O
plasmid O
was O
unable O
to O
suppress O
tif1 NUMERIC
- I-GENE
A79V NUMERIC
. O

Here O
we O
report O
that O
in O
cultured O
cells O
from O
Drosophila O
melanogaster O
human I-GENE
Sp1 I-GENE
efficiently O
activates O
transcription O
from O
synthetic O
promoters O
containing O
TATA O
boxes O
, O
but O
not O
from O
promoters O
that O
contain O
an O
initiator O
instead O
of O
a O
TATA O
box O
. O

No O
apparent O
clinical O
signs O
indicative O
of O
systemic O
toxicity O
were O
observed O
in O
the O
F0 NUMERIC
and O
F1 O
animals O
of O
either O
sex O
. O

We O
have O
used O
mutation O
- O
directed O
chemical O
cross O
- O
linking O
with O
bis RARE
( O
sulfosuccinimidyl RARE
) O
suberate RARE
( O
BS3 NUMERIC
) O
to O
investigate O
the O
architecture O
of O
the O
gp41 NUMERIC
oligomer RARE
. O

In O
an O
effort O
to O
identify O
the O
USH1C NUMERIC
disease I-GENE
gene I-GENE
we O
have O
isolated O
the O
region O
between O
these O
markers O
in O
yeast O
artificial O
chromosomes O
( O
YACs O
) O
using O
a O
combination O
of O
STS ALLCAPS
content O
mapping O
and O
Alu I-GENE
- O
PCR O
hybridization O
. O

PowerBLAST LASTCAP
analysis O
identified O
six O
clusters O
of O
expressed O
sequence O
tags O
( O
ESTs O
), O
two O
known O
genes O
( O
BIR ALLCAPS
, O
SUR1 NUMERIC
) O
mapped O
previously O
to O
this O
region O
, O
and O
a O
previously O
characterized O
but O
unmapped RARE
gene I-GENE
NEFA ALLCAPS
( O
DNA I-GENE
binding I-GENE
/ I-GENE
EF I-GENE
hand I-GENE
/ I-GENE
acidic I-GENE
amino I-GENE
- I-GENE
acid I-GENE
- I-GENE
rich I-GENE
). O

A O
fusion O
protein O
composed O
of O
beta I-GENE
- I-GENE
galactosidase I-GENE
and O
full I-GENE
- I-GENE
length I-GENE
Ahr RARE
translocates RARE
from O
the O
cytoplasm O
to O
the O
nucleus O
in O
a O
ligand O
- O
dependent O
manner O
. O

Reconstitution RARE
of O
Raf I-GENE
- I-GENE
1 I-GENE
activity O
was O
observed O
only O
with O
kinase O
active O
Jak1 NUMERIC
in O
both O
cell O
lines O
. O

In O
addition O
, O
negatively O
regulatory O
region O
may O
exist O
from O
- O
1782 NUMERIC
to O
- O
1295 NUMERIC
bp O
. O

The O
hypothesis O
of O
Geisler RARE
( O
Brain RARE
Res RARE
. O

The O
second O
transcript O
, O
rhis4l NUMERIC
, O
is O
bicistronic RARE
. O

Consistent O
with O
this O
interpretation O
, O
a O
mutant O
form O
of O
XRN1 NUMERIC
, O
which O
encodes O
a O
5 O
'- O
3 O
' O
exonuclease O
, O
was O
identified O
as O
an O
extragenic RARE
suppressor O
that O
increases O
the O
half O
- O
life O
of O
rhis4 NUMERIC
mRNA I-GENE
, O
leading O
to O
a O
10 O
- O
fold O
increase O
in O
steady O
- O
state O
mRNA O
levels O
compared O
to O
the O
wild I-GENE
- I-GENE
type I-GENE
HIS4 NUMERIC
mRNA I-GENE
level O
. O

Sip1 NUMERIC
was O
initially O
identified O
by O
virtue RARE
of O
its O
interaction O
with O
SC35 NUMERIC
, O
a O
splicing O
factor O
of O
the O
SR I-GENE
family I-GENE
. O

Consistent O
with O
previous O
reports O
, O
addition O
of O
a O
myristoylation RARE
signal O
to O
mSos1 NUMERIC
( O
MyrSos1 NUMERIC
) O
rendered RARE
it O
transforming O
for O
NIH O
3T3 O
cells O
and O
deletion O
of O
the O
mSos RARE
C I-GENE
terminus I-GENE
( O
MyrSos1 NUMERIC
- I-GENE
deltaC LASTCAP
) O
did O
not O
interfere RARE
with O
this O
activity O
. O

Such O
mutations O
are O
thought O
to O
exert O
their O
dominant O
phenotype O
by O
sequestration RARE
of O
the O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
GNEF ALLCAPS
). O

Several O
studies O
have O
characterized O
the O
upstream O
regulatory O
region O
of O
c I-GENE
- I-GENE
fos I-GENE
, O
and O
identified O
cis O
- O
acting O
elements O
termed O
the O
cyclic O
AMP O
( O
cAMP O
) O
response O
elements O
( O
CREs RARE
) O
that O
are O
critical O
for O
c I-GENE
- I-GENE
fos I-GENE
transcription O
in O
response O
to O
a O
variety O
of O
extracellular O
stimuli O
. O

We O
have O
cloned O
a O
kinase O
, O
Nlk RARE
, O
that O
is O
a O
murine I-GENE
homolog I-GENE
of I-GENE
the I-GENE
Drosophila I-GENE
nemo RARE
( O
nmo RARE
) O
gene O
. O

Our O
findings O
suggest O
that O
striatal RARE
FDG O
and O
particularly O
RACLO ALLCAPS
are O
sensitive O
and O
effective O
measures O
of O
striatal RARE
function O
and O
may O
help O
characterizing O
patients O
with O
multiple O
system O
atrophy O
. O

Childhood RARE
misbehavior RARE
and O
the O
risk O
of O
injecting O
drug O
use O
. O

Genetic O
analysis O
has O
subsequently O
identified O
subpathways RARE
of O
the O
DNA O
structure O
checkpoints RARE
, O
including O
the O
reversible O
arrest O
of O
DNA O
synthesis O
. O

Thus O
, O
Esigma54 NUMERIC
promoters I-GENE
are O
responsive O
to O
CRP I-GENE
, O
a O
protein O
unrelated O
to O
sigma54 NUMERIC
activators I-GENE
, O
and O
the O
repression O
exerted RARE
is O
the O
direct O
result O
of O
an O
interaction O
between O
Esigma54 NUMERIC
and O
the O
CRP I-GENE
- I-GENE
cAMP I-GENE
complex I-GENE
. O

GlcNAc O
- O
and O
GlcNAc2 NUMERIC
- O
PP O
- O
Dolichol RARE
biosynthesis O
could O
be O
shown O
with O
isolated O
S O
. O
cerevisiae O
membranes O
from O
cells O
harboring O
the O
recombinant O
plasmid O
and O
grown O
on O
glucose O
thus O
suppressing RARE
transcription O
of O
the O
endogenous O
gene O
. O

Demonstration RARE
of O
tissue O
lesions O
after O
intramuscular RARE
injection O
by O
determination O
of O
creatine I-GENE
kinase I-GENE
in O
blood O

Antibodies O
raised O
against O
GST I-GENE
mSH2 NUMERIC
- I-GENE
B I-GENE
identified O
a O
cellular O
protein O
of O
92 O
kDa O
that O
was O
not O
found O
to O
be O
phosphorylated O
on O
Tyr O
. O

Interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
is O
a O
pleiotropic O
cytokine O
, O
which O
is O
involved O
in O
inflammatory O
and O
immune O
responses O
, O
acute O
phase O
reactions O
, O
and O
hematopoiesis RARE
. O

Upon O
analysis O
of O
various O
deletion O
and O
point O
- O
mutated O
variants O
of O
the O
human I-GENE
IL I-GENE
- I-GENE
6 I-GENE
gene I-GENE
promoter I-GENE
coupled O
to O
a O
reporter O
gene O
, O
we O
screened O
for O
possible O
cooperating RARE
transcription O
factors O
. O

This O
region O
, O
however O
, O
contains O
a O
CCAATC ALLCAPS
box O
in O
the O
reverse O
complement O
and O
several O
GC O
boxes O
that O
are O
recognition O
sites O
for O
SP1 I-GENE
. O

Our O
purpose O
was O
to O
determine O
if O
intact O
perianal RARE
( O
S4 O
- O
5 O
) O
pin RARE
sensation RARE
( O
PPS ALLCAPS
) O
and O
bulbocavernosus RARE
( O
S2 O
- O
4 O
) O
reflex O
( O
BCR O
) O
shortly RARE
after O
spinal O
cord O
injury O
( O
SCI ALLCAPS
) O
are O
predictive O
of O
bladder O
function O
recovery O
. O

The O
correct O
termination O
of O
retroviral O
transcripts O
at O
the O
3 O
' O
LTR O
R O
/ O
U5 O
junction O
is O
primarily O
dependent O
on O
the O
canonical O
AAUAAA ALLCAPS
polyadenylation O
signal O
, O
so O
we O
have O
analyzed O
the O
effect O
of O
mutating RARE
the O
polyadenylation O
signal O
sequences O
on O
the O
properties O
of O
a O
selectable O
murine O
retroviral O
vector O
. O

Levels RARE
of O
the O
MEK I-GENE
inhibitor O
PD98059 O
that O
block O
EGF I-GENE
- O
induced O
mitogenesis RARE
and O
MAP I-GENE
kinase I-GENE
phosphorylation O
also O
abrogate O
EGF I-GENE
- O
induced O
focal O
adhesion O
disassembly RARE
and O
cell O
motility O
. O

ALT ALLCAPS
levels O
in O
responders O
were O
lowered O
by O
46 O
% O
and O
AST ALLCAPS
levels O
were O
lowered O
by O
35 O
% O
after O
12 O
weeks O
of O
vitamin O
E O
treatment O
. O

Surprisingly O
, O
the O
COOH O
- O
terminal O
domain O
of O
RanGAP1 NUMERIC
was O
also O
found O
to O
harbor O
a O
nuclear O
localization O
signal O
. O

51 O
. O
9 O
% O
( O
P O
= O
0 O
. O
0006 NUMERIC
) O
in O
the O
MMF ALLCAPS
versus O
the O
AZA ALLCAPS
groups O
, O
respectively O
. O

Our O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
MMF ALLCAPS
on O
in O
vivo O
bone O
mineral O
metabolism O
. O

Pao2 NUMERIC
increased O
from O
15 O
. O
5 O
+/- O
5 O
. O
6 O
kPa RARE
( O
116 NUMERIC
+/- O
42 O
mm O
Hg O
) O
to O
17 O
. O
3 O
+/- O
6 O
. O
3 O
kPa RARE
( O
130 O
+/- O
47 O
mm O
Hg O
) O
( O
P O
< O
0 O
. O
05 O
). O

Typical RARE
configurations RARE
of O
psychosocial RARE
stress O
factors O
of O
psychiatrically RARE
conspicuous RARE
children O
and O
adolescents RARE

Nine RARE
cats O
received O
PMEA ALLCAPS
at O
a O
dosage O
of O
10 O
mg O
/ O
kg O
body O
weight O
, O
nine O
cats O
received O
FPMPA ALLCAPS
at O
a O
dosage O
of O
25 O
mg O
/ O
kg O
body O
weight O
. O

Resistance O
to O
thyroid O
hormone O
: O
implications O
for O
neurodevelopmental RARE
research O
on O
the O
effects O
of O
thyroid O
hormone O
disruptors RARE
. O

Here O
, O
we O
present O
evidence O
that O
exposure O
of O
DT40 NUMERIC
lymphoma O
B O
cells O
to O
low O
energy O
electromagnetic RARE
field O
( O
EMF ALLCAPS
) O
results O
in O
a O
tyrosine I-GENE
kinase I-GENE
- O
dependent O
activation O
of O
phospholipase I-GENE
Cgamma2 NUMERIC
( O
PLC I-GENE
- I-GENE
gamma2 NUMERIC
) O
leading O
to O
increased O
inositol O
phospholipid O
turnover O
. O

We O
present O
the O
preliminary O
results O
obtained O
on O
36 O
patients O
which O
were O
followed O
for O
a O
mean O
period O
of O
12 O
months O
. O

Moreover O
, O
xTAK1KN NUMERIC
could O
block O
the O
expression O
of O
ventral O
mesoderm O
marker O
genes O
induced O
by O
Smad1 NUMERIC
or I-GENE
5 I-GENE
. O

PATIENTS O
AND O
METHOD ALLCAPS
: O
Since O
1986 O
, O
62 O
patients O
were O
irradiated O
stereotactically RARE
. O

The O
assay O
exhibits O
a O
dynamic O
range O
of O
0 O
. O
1 O
- O
100 O
micrograms O
l O
- O
1 O
using O
a O
monoclonal O
antibody O
or O
alternatively O
10 O
micrograms O
l O
- O
1 O
to O
10 O
mg O
l O
- O
1 O
using O
commercially RARE
available O
antiserum O
. O

Training RARE
for O
audit RARE
. O

A O
canonical O
TATA O
box O
was O
not O
detected O
. O

Expression O
and O
characterization O
of O
recombinant I-GENE
single I-GENE
- I-GENE
chain I-GENE
Fv RARE
and O
Fv RARE
fragments I-GENE
derived O
from O
a O
set O
of O
catalytic O
antibodies O
. O

A O
putative O
inhibitor O
( O
s O
) O
appears O
to O
co O
- O
elute RARE
in O
the O
inactive O
fraction O
that O
blocked O
the O
L I-GENE
( I-GENE
alpha I-GENE
) I-GENE
activity O
. O

Platelet O
aggregation O
in O
response O
to O
10 O
micrograms O
collagen I-GENE
/ O
ml O
was O
decreased O
in O
parallel O
after O
treatment O
with O
ASA O
. O

Using O
himA LASTCAP
mutants I-GENE
, O
we O
confirmed O
that O
IHF ALLCAPS
plays O
a O
role O
in O
the O
molybdate RARE
- O
dependent O
regulation O
of O
dmsA LASTCAP
- O
lacZ I-GENE
expression O
in O
vivo O
. O

Cross O
- O
talking RARE
among O
Drosophila O
nuclear O
receptors O
at O
the O
promiscuous RARE
response O
element O
of O
the O
ng I-GENE
- I-GENE
1 I-GENE
and O
ng I-GENE
- I-GENE
2 I-GENE
intermolt RARE
genes I-GENE
. O

The O
ipsilateral O
breast O
tumor O
relapse O
rate O
was O
similar O
between O
the O
PALP ALLCAPS
and O
MGDET ALLCAPS
groups O
. O

Sibling RARE
aggregation O
of O
low I-GENE
- I-GENE
and I-GENE
high I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
cholesterol I-GENE
and O
apolipoproteins RARE
B I-GENE
and I-GENE
A I-GENE
- I-GENE
I I-GENE
levels O
in O
black O
and O
white O
children O
: O
the O
Bogalusa RARE
Heart RARE
Study O
. O

The O
CAPLC1 NUMERIC
protein I-GENE
also O
exhibited O
several O
unique O
features O
, O
including O
a O
novel O
stretch O
of O
18 O
- O
19 O
amino O
acid O
residues O
within O
the O
X O
domain O
and O
an O
unusually O
long O
N O
- O
terminus O
which O
did O
not O
contain O
a O
recognizable RARE
EF O
- O
hand O
Ca O
( O
2 O
+)- O
binding O
domain O
. O

This O
hypothesis O
is O
consistent O
with O
the O
occurrence O
of O
PEA3 I-GENE
binding I-GENE
sites I-GENE
in O
the O
PEA3 I-GENE
promoter I-GENE
and O
with O
the O
ability O
of O
PEA3 I-GENE
to O
transactivate O
this O
promoter O
. O

Pet RARE
- I-GENE
1 I-GENE
can O
bind O
specifically O
to O
a O
PEA3 I-GENE
ETS I-GENE
DNA O
- O
binding O
motif O
and O
can O
modulate O
transcription O
of O
synthetic O
promoter O
constructs O
in O
a O
sequence O
- O
specific O
manner O
. O

The O
protein O
expressed O
by O
F2771 NUMERIC
cDNA I-GENE
in O
transfected O
COS O
cells O
is O
localized O
in O
the O
cytoplasm O
. O

Northern O
analysis O
indicated O
differential O
expression O
by O
tissue O
with O
highest O
expression O
in O
the O
heart O
. O

As O
well O
, O
further O
deletion O
of O
the O
promoter O
region O
to O
nucleotide O
- O
110 O
, O
which O
contains O
only O
one O
SF I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
, O
still O
retained O
the O
ability O
to O
respond O
to O
exogenous O
SF I-GENE
- I-GENE
1 I-GENE
. O

The O
observation O
that O
beta I-GENE
2m NUMERIC
with O
covalently O
attached O
peptide O
can O
effectively O
create O
CTL O
target O
structures O
in O
vitro O
offers O
new O
possibilities O
for O
the O
in O
vivo O
induction O
of O
epitope O
- O
specific O
CTL O
responses O
by O
either O
DNA O
immunization O
or O
injection O
of O
the O
purified O
epitope O
- O
linked O
beta I-GENE
2m NUMERIC
. O

The O
mRNAs O
of O
these O
genes O
contain O
respectively O
one O
( O
YAP1 NUMERIC
uORF I-GENE
) O
and O
two O
( O
YAP2 NUMERIC
uORF1 NUMERIC
and O
uORF2 NUMERIC
) O
upstream O
open O
reading O
frames O
. O
uORF O
- O
mediated O
modulation O
of O
post O
- O
termination O
events O
on O
the O
5 O
'- O
untranslated O
region O
( O
5 O
'- O
UTR O
) O
directs O
differential O
control O
not O
only O
of O
translation O
but O
also O
of O
mRNA O
decay O
. O

To O
further O
investigate O
the O
nature O
of O
the O
site O
specificity O
a O
set O
of O
deletion O
mutants O
of O
the O
160 O
bp O
sequence O
were O
analysed O
. O

In O
the O
tissues O
tested O
, O
except O
brain O
, O
the O
message O
for O
CLIP ALLCAPS
- I-GENE
170 I-GENE
was O
more O
abundant O
than O
that O
for O
Restin RARE
. O

BACKGROUND O
: O
Chemicals RARE
vary O
considerably O
in O
their O
intrinsic O
ability O
to O
cause O
allergic O
contact O
dermatitis O
. O

Cytoskeletal RARE
polarization RARE
of O
T O
cells O
is O
regulated O
by O
an O
immunoreceptor RARE
tyrosine O
- O
based O
activation O
motif O
- O
dependent O
mechanism O
. O

Here O
we O
have O
examined O
the O
ability O
of O
the O
cellular O
protein O
YB ALLCAPS
- I-GENE
1 I-GENE
to O
modulate O
transcription O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
in O
a O
human O
astrocytic RARE
cell O
line O
( O
U O
- O
87MG NUMERIC
), O
a O
neuronal O
cell O
line O
( O
SK ALLCAPS
- O
N O
- O
MC O
) O
and O
lymphoid O
cells O
( O
Jurkat O
) O
by O
transfection O
assay O
. O

Also O
, O
the O
deduced O
amino O
acids O
of O
the O
antigenic I-GENE
regions I-GENE
A I-GENE
, I-GENE
B I-GENE
and I-GENE
C I-GENE
of I-GENE
VP7 NUMERIC
were O
nearly O
conserved O
within O
the O
phylogenetic O
lineages O
. O

The O
cloned O
alcR LASTCAP
gene I-GENE
provided O
in O
trans O
restored O
these O
siderophore RARE
system O
activities O
to O
the O
mutants O
. O

The O
cloned O
alcR LASTCAP
gene I-GENE
provided O
in O
trans O
restored O
these O
siderophore RARE
system O
activities O
to O
the O
mutants O
. O

Copyright O
1998 O
Academic O
Press O
. O

It O
may O
also O
be O
suggested O
that O
particular O
care O
should O
be O
taken O
when O
such O
a O
trans O
- O
dominant O
Rev I-GENE
mutant I-GENE
is O
considered O
to O
be O
used O
as O
a O
genetic O
therapy O
against O
HIV O
- O
I O
infection O
, O
in O
individuals O
infected O
with O
both O
HIV O
- O
I O
and O
HTLV O
- O
1 O
. O

PATIENTS O
AND O
METHODS O
: O
Between RARE
January O
1992 O
and O
June RARE
1994 O
at O
St RARE
. O

The O
frequency O
of O
SPs RARE
for O
both O
the O
moderate O
and O
severe O
groups O
was O
significantly O
higher O
than O
that O
in O
patients O
with O
a O
normal O
MMFCV ALLCAPS
( O
p O
< O
. O
01 O
); O
of O
154 O
arms RARE
with O
a O
normal O
MMFCV ALLCAPS
, O
only O
9 O
( O
6 O
%) O
had O
an O
SP O
. O

We O
analyzed O
the O
P O
- O
SAECG ALLCAPS
in O
the O
time O
and O
frequency O
domain O
in O
23 O
patients O
with O
Paf RARE
and O
19 O
controls O
. O

Competitive RARE
reverse O
transcription O
- O
polymerase O
chain O
reaction O
and O
HPLC O
analysis O
showed O
that O
RUSH ALLCAPS
- I-GENE
1alpha I-GENE
is O
the O
progesterone O
- O
dependent O
splice O
variant O
. O

TOR2 NUMERIC
is O
part O
of O
two O
related O
signaling O
pathways O
coordinating RARE
cell O
growth O
in O
Saccharomyces O
cerevisiae O
. O

Transcervical RARE
amnioinfusion RARE
. O

SETTING O
: O
A O
division O
of O
a O
large O
tea RARE
plantation RARE
in O
Kandy RARE
. O

Simple RARE
models O
of O
bimolecular RARE
interaction O
did O
not O
fully O
account O
for O
the O
kinetic O
profiles O
obtained O
with O
the O
parental O
antibodies O
and O
the O
hybrids O
, O
and O
this O
complexity O
suggested O
the O
existence O
of O
a O
conformational O
heterogeneity O
in O
these O
molecules O
. O

In O
order O
to O
decipher RARE
the O
pathway O
that O
leads O
to O
Hox I-GENE
gene I-GENE
induction O
, O
we O
have O
investigated O
whether O
a O
Hox I-GENE
gene I-GENE
regulator O
, O
the O
leucine O
zipper O
transcription O
factor O
MafB LASTCAP
/ O
Kr RARE
, O
is O
itself O
transcriptionally O
regulated O
by O
the O
environmental O
signals O
. O

Substrates RARE
for O
p210 NUMERIC
( O
bcr RARE
- O
abl I-GENE
) O
are O
likely O
to O
be O
involved O
in O
the O
pathogenesis O
of O
CML O
. O

Reporter RARE
constructs O
function O
in O
a O
parallel O
manner O
, O
demonstrating O
the O
key O
role O
of O
the O
AhR LASTCAP
in O
constitutive O
as O
well O
as O
TCDD ALLCAPS
- O
induced O
expression O
of O
Cyp1B1 NUMERIC
in O
mouse O
embryo O
fibroblasts O
. O

Transfection O
studies O
also O
showed O
that O
3 O
'- O
deletion O
of O
sequences O
downstream O
of O
the O
transcriptional O
start O
site O
(+ O
1 O
/+ RARE
47 O
) O
markedly O
reduced O
OSM ALLCAPS
- O
fold O
induction O
. O

Oncostatin RARE
M I-GENE
stimulates O
c I-GENE
- I-GENE
Fos I-GENE
to O
bind O
a O
transcriptionally O
responsive O
AP I-GENE
- I-GENE
1 I-GENE
element I-GENE
within O
the O
tissue I-GENE
inhibitor I-GENE
of I-GENE
metalloproteinase RARE
- I-GENE
1 I-GENE
promoter I-GENE
. O

We O
have O
isolated O
a O
new O
human I-GENE
RING I-GENE
- I-GENE
finger I-GENE
gene I-GENE
( O
RNF4 NUMERIC
) O
that O
encodes O
a O
190 O
- O
amino O
- O
acid O
protein O
. O

To O
elucidate O
the O
regulatory O
mechanism O
of O
human I-GENE
AM I-GENE
gene I-GENE
expression O
, O
functional O
elements O
of O
5 O
'- O
flanking O
region O
of O
AM I-GENE
gene I-GENE
were O
studied O
in O
human O
aortic O
endothelial O
cells O
( O
HAEC ALLCAPS
). O

The O
COOH O
- O
terminal O
region O
of O
the O
transcripts O
contained O
fifteen RARE
triplet O
repeats O
( O
GCT ALLCAPS
; O
alanine O
) O
at O
nucleotide O
465 NUMERIC
to O
509 NUMERIC
, O
which O
is O
significantly O
expanded RARE
compared O
to O
the O
rat I-GENE
RL14 NUMERIC
. O

Soluble RARE
FasR LASTCAP
ligand O
- O
binding O
domain O
: O
high O
- O
yield O
production O
of O
active O
fusion O
and O
non O
- O
fusion O
recombinant O
proteins O
using O
the O
baculovirus O
/ O
insect O
cell O
system O
. O

Control O
of O
fatty O
liver O
syndrome O
in O
a O
Jersey RARE
herd O
by O
a O
change O
of O
diet O
and O
the O
use O
of O
recombinant O
bovine O
somatotrophin RARE
. O

The O
inhibition O
of O
focus O
formation O
observed O
in O
the O
presence O
of O
C3G NUMERIC
was O
not O
due O
to O
toxic O
effects O
on O
cell O
viability O
, O
since O
transfected O
C3G NUMERIC
cells O
exhibited O
the O
same O
survival O
and O
growth O
rates O
as O
untransfected RARE
NIH3T3 O
cells O
or O
cells O
transfected O
with O
plasmid O
vector O
alone O
. O

C O
. O
D2 O
- O
Chr O
4 O
congenic RARE
strains O
harboring O
DBA ALLCAPS
/ O
2 O
alleles O
associated O
with O
the O
Pctr1 NUMERIC
locus I-GENE
contained O
DBA ALLCAPS
/ O
2 O
" O
resistant O
" O
alleles O
of O
the O
CDK4 NUMERIC
/ O
CDK6 NUMERIC
inhibitors O
p16 I-GENE
and O
p15 NUMERIC
. O

When O
tested O
with O
wild O
- O
type O
( O
DBA ALLCAPS
/ O
2 O
) O
p16 I-GENE
, O
both O
A134C NUMERIC
and O
G232A NUMERIC
BALB O
/ O
c O
- O
specific O
variants O
of O
p16 I-GENE
were O
inefficient O
in O
their O
ability O
to O
inhibit O
the O
activity O
of O
cyclin I-GENE
D2 I-GENE
/ O
CDK4 NUMERIC
in O
kinase O
assays O
with O
retinoblastoma I-GENE
protein I-GENE
, O
suggesting O
this O
defective O
, O
inherited O
allele O
plays O
an O
important O
role O
in O
the O
genetic O
susceptibility O
of O
BALB O
/ O
c O
mice O
for O
plasmacytoma RARE
induction O
and O
that O
p16 I-GENE
( O
INK4a NUMERIC
) O
is O
a O
strong O
candidate O
for O
the O
Pctr1 NUMERIC
locus I-GENE
. O

Despite O
this O
there O
was O
no O
difference O
in O
the O
intubating RARE
conditions O
at O
one O
minute O
with O
25 O
excellent O
/ O
5 O
good O
in O
the O
suxamethonium RARE
group O
and O
27 O
excellent O
/ O
3 O
good O
in O
the O
rocuronium RARE
group O
. O

Cloning O
and O
expression O
of O
two O
genes O
encoding O
auxin RARE
- I-GENE
binding I-GENE
proteins I-GENE
from O
tobacco O
. O

Furthermore O
, O
direct O
association O
with O
D3 O
phosphatidylinositides RARE
seems O
to O
be O
essential O
for O
activation O
of O
PKB I-GENE
/ O
Akt I-GENE
. O

The O
FMN ALLCAPS
moiety RARE
but O
not O
the O
[ O
3Fe NUMERIC
- O
4S NUMERIC
] O
cluster O
of O
the O
subunit O
appears O
to O
participate O
in O
this O
reaction O
. O

Alison RARE
Bell RARE
Memorial RARE
Award RARE
. O

METHODS O
: O
A O
population O
survey O
was O
undertaken O
in O
10 O
, O
148 NUMERIC
individuals O
to O
measure O
the O
prevalence O
and O
identify O
the O
causes O
of O
blindness RARE
in O
Lebanon RARE
. O

During O
organogenesis RARE
, O
HFH ALLCAPS
- I-GENE
8 I-GENE
expression O
is O
found O
in O
the O
splanchnic RARE
mesoderm O
in O
close O
apposition RARE
of O
the O
gut O
endoderm O
, O
suggesting O
a O
role O
in O
mesenchymal O
- O
epithelial O
induction O
of O
lung O
and O
gut O
morphogenesis RARE
. O

However O
, O
laparoscopy RARE
failed O
to O
establish O
inoperability RARE
in O
any O
cases O
of O
carcinoma O
spread O
to O
areas O
not O
accessible RARE
to O
laparoscopic O
visualization O
. O

No O
difference O
in O
telomere O
length O
was O
seen O
in O
mutants O
affected O
in O
the O
regulation O
of O
Cdc2 I-GENE
, O
whereas O
some O
of O
the O
DNA O
repair O
mutants O
examined O
had O
slightly O
longer O
telomeres RARE
than O
did O
the O
wild O
type O
. O

The O
mean O
duration O
of O
pain O
relief RARE
was O
4 O
- O
6 O
weeks O
. O

The O
ESEM ALLCAPS
differs O
from O
conventional O
SEM ALLCAPS
in O
that O
no O
sample O
preparation O
is O
needed O
, O
eliminating RARE
artifactual RARE
changes O
. O

Sp1 I-GENE
can O
activate O
transcription O
through O
immunoglobulin I-GENE
kappa I-GENE
- I-GENE
chain I-GENE
enhancer I-GENE
or O
P I-GENE
- I-GENE
selectin I-GENE
promoter I-GENE
NF I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
. O
p50 I-GENE
homodimers I-GENE
replace O
Sp1 I-GENE
from O
the O
P I-GENE
- I-GENE
selectin I-GENE
promoter I-GENE
by O
binding O
site O
competition O
and O
thereby O
either O
inhibit O
basal O
Sp1 I-GENE
- O
driven O
expression O
or O
, O
in O
concert RARE
with O
Bcl I-GENE
- I-GENE
3 I-GENE
, O
stimulate O
expression O
. O

The O
3 O
' O
fragment O
was O
shown O
to O
accumulate O
as O
full O
- O
length O
mRNA O
disappeared O
in O
actinomycin RARE
D O
- O
treated O
cells O
, O
indicating O
a O
precursor O
- O
product O
relationship O
. O

The O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
plays O
an O
essential O
role O
in O
transcription O
by O
all O
three O
eukaryotic O
nuclear I-GENE
RNA I-GENE
polymerases I-GENE
, O
polymerases I-GENE
( I-GENE
Pol I-GENE
) I-GENE
I I-GENE
, I-GENE
II I-GENE
, I-GENE
and I-GENE
III I-GENE
. O

A O
triple I-GENE
- I-GENE
mutant I-GENE
TBP I-GENE
( O
R231E NUMERIC
+ O
R235E NUMERIC
+ O
R239S NUMERIC
) O
had O
greatly O
reduced O
activity O
for O
yeast I-GENE
U6 I-GENE
snRNA I-GENE
gene I-GENE
transcription O
while O
remaining O
active O
for O
Pol I-GENE
II I-GENE
basal O
transcription O
. O

E2F I-GENE
activity O
is O
regulated O
in O
part O
by O
the O
retinoblastoma I-GENE
family I-GENE
of I-GENE
tumor I-GENE
suppressor I-GENE
proteins I-GENE
. O

This O
resulted O
in O
a O
complete O
inhibition O
of O
Site O
- O
1 O
cleavage O
that O
was O
restored O
by O
concomitant O
overexpression O
of O
full O
- O
length O
SCAP ALLCAPS
. O

To O
determine O
the O
true O
molecular O
identity O
of O
SFD ALLCAPS
, O
both O
the O
50 O
- O
and O
57 O
- O
kDa O
polypeptides O
were O
directly O
sequenced O
. O

Molecular O
characterization O
of O
the O
50 O
- O
and O
57 O
- O
kDa O
subunits O
of O
the O
bovine I-GENE
vacuolar I-GENE
proton I-GENE
pump I-GENE
. O

In O
C O
. O
albicans O
, O
HST6 NUMERIC
is O
expressed O
constitutively O
at O
high O
levels O
in O
the O
different O
cell O
types O
analysed O
( O
yeast O
, O
hyphae RARE
, O
white O
and O
opaque RARE
), O
demonstrating O
that O
HST6 NUMERIC
transcription O
is O
not O
repressed O
in O
this O
diploid O
yeast O
, O
unlike O
in O
diploid O
S O
. O
cerevisiae O
, O
and O
suggesting O
a O
basic O
biological O
function O
for O
the O
Hst6p NUMERIC
transporter O
in O
C O
. O
albicans O
. O

Furthermore O
, O
binding O
of O
recombinant I-GENE
Myb I-GENE
and O
Ets I-GENE
- I-GENE
2 I-GENE
protein I-GENE
to O
these O
fragments O
could O
be O
competed RARE
with O
an O
excess O
of O
double O
stranded O
oligodeoxynucleotides RARE
containing O
canonical O
, O
but O
not O
mutated O
, O
Myb I-GENE
- O
or O
Ets I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

This O
structure O
interconnects RARE
specific O
triplets RARE
of O
the O
basal O
bodies O
with O
the O
microtubular RARE
bundles RARE
that O
emerge RARE
from O
the O
basal O
apparatus O
. O

To O
understand O
the O
regulatory O
mechanism O
controlling O
its O
expression O
at O
low O
temperature O
, O
the O
promoter O
region O
has O
been O
characterized O
. O

In O
the O
current O
study O
, O
the O
roles O
of O
two O
putative O
cis O
- O
acting O
elements O
within O
the O
- O
73 O
to O
+ O
44 O
region O
in O
basal O
exon O
2 O
promoter O
activity O
were O
evaluated O
using O
mutagenesis O
and O
nuclear O
protein O
- O
DNA O
binding O
assays O
. O

For O
the O
5HT5A NUMERIC
receptor I-GENE
the O
addition O
of O
yohimbine RARE
resulted O
in O
a O
similar O
but O
smaller O
effect O
. O

We O
have O
examined O
reporter O
gene O
( O
beta I-GENE
- I-GENE
gal RARE
) O
expression O
directed O
by O
human I-GENE
heat I-GENE
shock I-GENE
transcription I-GENE
factors I-GENE
1 I-GENE
and I-GENE
2 I-GENE
( O
HSF1 I-GENE
and O
HSF2 NUMERIC
) O
in O
HeLa O
cells O
and O
in O
yeast O
( O
Saccharomyces O
cerevisiae O
). O

Localized RARE
fluorescence O
was O
detectable O
only O
in O
cells O
containing O
a O
visible RARE
midcell RARE
constriction RARE
, O
suggesting O
that O
FtsK LASTCAP
targeting O
normally O
occurs O
only O
at O
a O
late O
stage O
of O
septation RARE
. O

No O
TATA O
box O
was O
found O
in O
the O
putative O
promoter O
region O
, O
but O
multiple O
GC O
boxes O
were O
found O
around O
the O
cap O
sites O
, O
supporting O
the O
previously O
inferred RARE
housekeeping O
nature O
of O
CYP51 NUMERIC
gene I-GENE
and O
the O
existence O
of O
the O
multiple O
transcription O
initiation O
sites O
. O

Structural O
and O
evolutionary O
studies O
on O
sterol I-GENE
14 I-GENE
- I-GENE
demethylase RARE
P450 I-GENE
( O
CYP51 NUMERIC
), O
the O
most O
conserved O
P450 I-GENE
monooxygenase RARE
: O
I O
. O

Its O
expression O
pattern O
is O
representative O
of O
many O
B O
cell O
- O
specific O
proteins O
, O
which O
are O
essential O
for O
B O
cell O
development O
and O
activation O
but O
are O
down O
- O
regulated O
after O
B O
cells O
become O
terminally O
differentiated O
plasma O
cells O
. O

The O
intercistronic RARE
gene O
junctions O
of O
vesicular O
stomatitis O
virus O
( O
VSV ALLCAPS
) O
contain O
conserved O
sequence O
elements O
that O
are O
important O
for O
polyadenylation O
and O
transcription O
termination O
of O
upstream O
transcript O
as O
well O
as O
reinitiation RARE
of O
transcription O
of O
downstream O
transcript O
. O

Infectious RARE
mutant O
virus O
progeny RARE
was O
obtained O
only O
on O
complementing RARE
gK LASTCAP
- O
expressing O
cells O
, O
suggesting O
that O
gK LASTCAP
has O
an O
important O
function O
in O
the O
replication O
cycle O
. O

Cleavage RARE
and O
DNA O
joining O
reactions O
, O
carried O
out O
by O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
integrase I-GENE
, O
are O
necessary O
to O
effect O
the O
covalent RARE
insertion O
of O
HIV O
- O
1 O
DNA O
into O
the O
host O
genome O
. O

The O
DSF ALLCAPS
regimen O
appears O
to O
have O
significant O
activity O
in O
patients O
who O
have O
metastatic O
pancreatic O
islet O
- O
cell O
carcinoma O
, O
and O
patient O
tolerance O
of O
the O
regimen O
is O
excellent O
, O
thus O
warranting RARE
further O
investigation O
. O

Activation O
of O
the O
mitogen I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
is O
a O
primary O
consequence O
of O
Ras I-GENE
activation O
and O
plays O
a O
key O
role O
in O
mediating O
Ras I-GENE
signal O
transduction O
. O

Histone RARE
acetylation O
levels O
in O
cells O
result O
from O
a O
dynamic O
equilibrium O
between O
competing RARE
histone I-GENE
acetylases RARE
and I-GENE
deacetylases RARE
. O

CONCLUSIONS O
: O
XCoe2 NUMERIC
may O
play O
a O
pivotal O
role O
in O
the O
transcriptional O
cascade O
that O
specifies O
primary O
neurons O
in O
Xenopus O
embryos O
: O
by O
maintaining O
Delta I-GENE
- O
Notch I-GENE
signalling O
, O
XCoe2 NUMERIC
stabilises RARE
the O
higher O
neural O
potential O
of O
selected O
progenitor O
cells O
that O
express O
X I-GENE
- I-GENE
ngnr RARE
- I-GENE
1 I-GENE
, O
ensuring RARE
the O
transition O
between O
neural O
competence RARE
and O
irreversible O
commitment RARE
to O
a O
neural O
fate O
; O
and O
it O
promotes O
neuronal O
differentiation O
by O
activating O
XNeuroD LASTCAP
expression O
, O
directly O
or O
indirectly O
. O

RESULTS O
: O
Patients O
in O
Group O
A O
had O
a O
higher O
incidence O
of O
posterolateral RARE
wall O
motion O
abnormalities O
( O
p O
< O
0 O
. O
001 O
) O
on O
radionuclide RARE
ventriculography RARE
, O
a O
larger O
infarct O
area O
( O
as O
evidenced RARE
by O
higher O
peak O
creatine I-GENE
kinase I-GENE
levels O
) O
( O
p O
< O
0 O
. O
02 O
) O
and O
a O
lower O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
at O
hospital O
discharge O
( O
p O
< O
0 O
. O
008 NUMERIC
) O
than O
those O
in O
Group O
B O
. O

CyIIa RARE
transcription O
follows O
, O
and O
is O
therefore O
downstream O
of O
, O
the O
initial O
specification RARE
of O
these O
embryonic O
domains O
. O

Cis RARE
- O
regulation O
downstream O
of O
cell O
type O
specification RARE
: O
a O
single O
compact RARE
element O
controls O
the O
complex O
expression O
of O
the O
CyIIa RARE
gene I-GENE
in O
sea O
urchin O
embryos O
. O

We O
also O
present O
evidence O
that O
human I-GENE
HYAL1 NUMERIC
is O
identical O
to O
an O
uncharacterized O
gene O
positionally RARE
cloned O
by O
others O
from O
chromosome O
3p21 NUMERIC
. O
3 O
that O
is O
homozygously RARE
deleted O
in O
several O
small O
- O
cell O
lung O
carcinoma O
cell O
lines O
. O

In O
patients O
with O
myalgia RARE
, O
Raynaud RARE
' O
s O
syndrome O
, O
skin O
vasculitis O
and O
vascular O
diseases O
WFAg RARE
concentrations O
were O
higher O
than O
in O
patients O
without O
them O
. O

Although O
the O
expression O
of O
the O
4E NUMERIC
- I-GENE
BP1 NUMERIC
gene I-GENE
alone O
has O
not O
yet O
been O
accomplished RARE
, O
the O
gene O
was O
expressed O
in O
Escherichia O
coli O
[ O
BL21 NUMERIC
( O
DE3 NUMERIC
)] O
as O
a O
fusion O
gene O
with O
the O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
) O
gene O
using O
a O
prokaryotic O
gene O
fusion O
vector O
( O
pGEX LASTCAP
- O
4T NUMERIC
- O
2 O
), O
which O
contains O
a O
gene O
sequence O
coding O
the O
cleavage O
site O
for O
a O
specific O
protease O
, O
alpha I-GENE
- I-GENE
thrombin I-GENE
. O

Randomised RARE
comparison O
of O
addition O
of O
autologous O
bone O
- O
marrow O
transplantation O
to O
intensive O
chemotherapy O
for O
acute O
myeloid O
leukaemia RARE
in O
first O
remission O
: O
results O
of O
MRC ALLCAPS
AML ALLCAPS
10 O
trial O
. O

Therapeutic RARE
use O
of O
cannabis RARE
. O

Analysis O
of O
intragenic RARE
revertants RARE
shows O
that O
this O
function O
depends O
on O
the O
amino O
acid O
preceding O
the O
first O
cysteine O
residue O
of O
the O
DNA O
- O
binding O
domain O
of O
Hap1p NUMERIC
. O

Peripheral RARE
visual O
stimuli O
and O
monoaural RARE
auditory O
stimuli O
were O
used O
as O
targets O
. O

A O
review O
of O
studies O
published O
between O
1983 O
and O
1995 O
shows O
that O
there O
are O
some O
common O
factors O
as O
regards RARE
the O
psychological O
distress O
and O
social O
and O
functional O
limitations O
this O
group O
of O
patients O
has O
to O
deal RARE
with O
. O

PKC I-GENE
- I-GENE
gamma I-GENE
, O
which O
is O
not O
present O
in O
keratinocytes RARE
, O
also O
induces O
involucrin RARE
gene I-GENE
expression O
in O
a O
TPA O
- O
independent O
manner O
, O
when O
introduced O
into O
SVHK ALLCAPS
cells O
. O

Identification O
and O
characterization O
of O
specific O
DNA O
- O
binding O
complexes O
containing O
members O
of O
the O
Myc I-GENE
/ O
Max I-GENE
/ O
Mad RARE
network O
of O
transcriptional O
regulators O
. O

We O
further O
show O
that O
proteolytic O
targeting O
by O
calpain RARE
II I-GENE
and O
the O
proteasome O
involves O
different O
structural O
elements O
of O
YY1 I-GENE
. O

Primers RARE
for O
subsequent O
rounds RARE
of O
RACE O
were O
designed O
from O
the O
5 O
'- O
ends O
of O
amplified O
RACE O
products O
. O

Human O
ZFM1 NUMERIC
protein I-GENE
is O
a O
transcriptional O
repressor O
that O
interacts O
with O
the O
transcription I-GENE
activation I-GENE
domain I-GENE
of I-GENE
stage I-GENE
- I-GENE
specific I-GENE
activator I-GENE
protein I-GENE
. O

Surprisingly O
, O
the O
CSF1R NUMERIC
/ O
IRDelta960 NUMERIC
was O
as O
effective O
as O
the O
CSF1R NUMERIC
/ O
IR I-GENE
in O
mediating O
CSF I-GENE
- I-GENE
1 I-GENE
protection O
of O
cells O
from O
staurosporine RARE
- O
induced O
apoptosis O
. O

CONCLUSIONS O
: O
The O
special O
clinical O
presentation O
of O
our O
case O
of O
possible O
Gardner RARE
' O
s O
syndrome O
is O
discussed O
. O

These O
results O
would O
suggest O
that O
a O
high O
UV O
sensitivity O
is O
associated O
with O
high O
phaeomelanin RARE
and O
low O
eumelanin RARE
levels O
, O
and O
point O
to O
the O
eumelanin RARE
/ O
phaeomelanin RARE
ratio O
as O
a O
novel O
chemical O
parameter O
that O
could O
be O
used O
for O
predicting O
individuals O
at O
high O
risk O
for O
skin O
cancer O
and O
melanoma O
. O

In O
ferrets RARE
naturally O
infected O
with O
H O
. O
mustelae RARE
, O
a O
single O
dose O
( O
50 O
mg O
/ O
kg O
, O
per O
os RARE
) O
of O
fluorofamide RARE
completely O
inhibited O
bacterial I-GENE
urease I-GENE
. O

The O
cAMP O
- O
dependent O
mitogenic O
pathway O
is O
unique O
as O
it O
is O
independent O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
activation O
and O
differs O
from O
growth O
factor O
- O
dependent O
pathways O
at O
the O
level O
of O
the O
expression O
of O
several O
protooncogenes RARE
/ O
transcription O
factors O
. O

CONCLUSIONS O
: O
Use O
of O
the O
first O
method O
was O
associated O
with O
a O
reduction O
in O
the O
time O
patients O
remained O
in O
the O
ICU ALLCAPS
before O
transfer O
to O
another O
unit O
and O
savings RARE
in O
nursing O
time O
, O
but O
the O
two O
methods O
did O
not O
differ O
according O
to O
clinical O
outcomes O
. O

We O
have O
elucidated RARE
the O
exon O
- O
intron O
organization O
of O
the O
entire O
human O
CD58 NUMERIC
gene I-GENE
, O
including O
approximately O
2 O
. O
5 O
kilobases O
( O
kb O
) O
of O
5 O
'- O
flanking O
DNA O
. O

The O
risk O
factors O
for O
hematuria RARE
in O
patients O
with O
renal O
hypouricemia RARE
are O
the O
elevation O
of O
urinary O
urate RARE
concentration O
and O
the O
subtypes O
of O
Post O
and O
Secretion RARE
. O

Two O
hundred O
sixty RARE
- O
four O
patients O
scheduled RARE
for O
DCBM ALLCAPS
were O
randomized O
to O
receive O
intravenously O
geG LASTCAP
0 O
. O
25 O
mg O
( O
geG LASTCAP
- O
25 O
), O
or O
geG LASTCAP
0 O
. O
5 O
mg O
( O
geG LASTCAP
- O
50 O
), O
or O
HBB ALLCAPS
20 O
mg O
as O
hypotonic RARE
agent O
. O

If O
the O
haemoglobin RARE
concentration O
( O
Hb I-GENE
) O
was O
less O
than O
12 O
g O
dL O
- O
1 O
they O
were O
given O
a O
four O
week O
course O
of O
ferrous RARE
sulphate RARE
. O

In O
all O
cells O
, O
the O
accumulation O
of O
high O
Dsg RARE
protein I-GENE
levels O
required O
calcium O
and O
was O
not O
observed O
in O
low O
calcium O
( O
0 O
. O
05 O
- O
0 O
. O
07 O
mM O
) O
media O
. O

Based O
on O
restriction O
enzyme O
analysis O
, O
Southern O
blots O
, O
polymerase O
chain O
reaction O
analysis O
and O
DNA O
sequencing O
, O
it O
was O
confirmed O
that O
the O
three O
overlapping O
clones O
isolated O
cover RARE
the O
entire O
cHO LASTCAP
- I-GENE
1 I-GENE
gene I-GENE
, O
as O
well O
as O
approximately O
10 O
kb O
of O
the O
flanking O
regions O
on O
both O
ends O
. O

RESULTS O
: O
Using O
information O
in O
the O
dbEST LASTCAP
database O
of O
expressed O
sequence O
tags O
, O
we O
isolated O
an O
Arabidopsis O
thaliana O
gene O
( O
GCR1 NUMERIC
) O
that O
encodes O
a O
protein O
with O
seven O
predicted O
membrane O
- O
spanning O
domains O
and O
other O
features O
characteristic O
of O
7TM NUMERIC
receptors I-GENE
. O

E1A I-GENE
represses O
apolipoprotein I-GENE
AI ALLCAPS
enhancer I-GENE
activity O
in O
liver O
cells O
through O
a O
pRb I-GENE
- O
and O
CBP I-GENE
- O
independent O
pathway O
. O

Position RARE
- O
independent O
expression O
of O
a O
human O
nerve I-GENE
growth I-GENE
factor I-GENE
- O
luciferase I-GENE
reporter O
gene O
cloned O
on O
a O
yeast O
artificial O
chromosome O
vector O
. O

Calcitriol RARE
therapy O
was O
associated O
with O
a O
decrease O
in O
serum O
iPTH LASTCAP
levels O
( O
701 NUMERIC
+/- O
103 NUMERIC
. O
9 O
vs O
. O

Alterations RARE
in O
DNase I-GENE
I I-GENE
reactivity O
of O
the O
GC O
- O
response O
element O
region O
suggest O
that O
GC I-GENE
receptor I-GENE
- I-GENE
GC I-GENE
complexes I-GENE
may O
associate O
, O
in O
a O
transient O
manner O
, O
with O
the O
promoter O
in O
the O
actively O
transcribing RARE
control O
state O
. O

Most O
pituitary O
hormone O
- O
coding O
gene O
promoters O
are O
activated O
by O
Ptx1 NUMERIC
. O

One O
of O
these O
small I-GENE
inteins RARE
might O
be O
inactive O
or O
a O
" I-GENE
pseudo RARE
intein RARE
." I-GENE
The O
results O
suggest O
a O
modular RARE
architecture O
for O
inteins RARE
, O
clarify O
their O
origin O
and O
relationship O
to O
other O
protein O
families O
, O
and O
extend O
recent O
experimental O
findings O
on O
the O
functional O
roles O
of O
intein RARE
N I-GENE
, I-GENE
C I-GENE
, I-GENE
and I-GENE
EN ALLCAPS
motifs I-GENE
. O

Purification RARE
of O
MvaT LASTCAP
enriched O
for O
two O
polypeptides O
of O
approximate RARE
molecular O
mass O
15 O
kDa O
and O
16 O
kDa O
, O
designated O
P15 NUMERIC
and O
P16 NUMERIC
. O

M I-GENE
- I-GENE
66 I-GENE
identified O
the O
14 O
- O
kDa O
protein O
in O
another O
MMTV O
bearing O
T O
- O
cell O
lymphoma O
, O
EL ALLCAPS
- O
4 O
. O

These O
results O
indicate O
that O
TGF I-GENE
- I-GENE
betaf RARE
potentiates O
the O
c I-GENE
- I-GENE
fos I-GENE
SRE O
activated O
by O
PKC I-GENE
through O
the O
SRF I-GENE
binding I-GENE
site I-GENE
. O

RT O
- O
PCR O
indicated O
that O
p21 I-GENE
mRNA I-GENE
was O
induced O
1 O
. O
4 O
-, O
2 O
. O
0 O
-, O
and O
3 O
. O
1 O
- O
fold O
in O
the O
2 O
- O
day O
neonatal O
, O
7 O
- O
day O
neonatal O
, O
and O
adult O
stages O
, O
respectively O
, O
compared O
to O
the O
17 O
- O
day O
fetal O
stage O
. O

Ganciclovir RARE
and O
foscarnet RARE
efficacy O
in O
AIDS O
- O
related O
CMV O
polyradiculopathy RARE
. O

BACKGROUND O
: O
Defensins RARE
, O
also O
known O
as O
human I-GENE
neutrophil I-GENE
peptides I-GENE
, O
are O
antimicrobial O
peptides O
present O
in O
the O
azurophil RARE
granules O
of O
neutrophils O
. O

The O
spontaneous O
mutation O
blocking O
pca RARE
gene I-GENE
expression O
was O
located O
in O
the O
promoter O
for O
the O
pca RARE
operon I-GENE
. O

From O
250 O
g O
of O
cells O
, O
we O
isolated O
1 O
mg O
of O
PDH ALLCAPS
complex I-GENE
with O
a O
specific O
activity O
of O
12 O
. O
6 O
U O
/ O
mg O
of O
protein O
. O

The O
PDH ALLCAPS
complex I-GENE
- I-GENE
encoding I-GENE
genes I-GENE
were O
identified O
by O
hybridization O
experiments O
and O
sequence O
analysis O
in O
two O
separate O
gene O
regions O
in O
the O
genome O
of O
Z O
. O
mobilis RARE
. O

We O
have O
identified O
two O
functional O
elements O
, O
both O
located O
downstream O
from O
the O
TATA O
motif O
, O
that O
control O
Id4 NUMERIC
promoter I-GENE
activity O
. O

Azithromycin RARE
is O
a O
new O
generation O
macrolide RARE
antibiotic O
with O
unusual O
and O
favorable RARE
pharmacokinetics O
, O
and O
seems O
to O
be O
a O
very O
promising RARE
agent O
for O
innovative RARE
anti O
- O
H O
. O
pylori O
regimens O
. O

The O
study O
enrolled O
994 NUMERIC
people O
co O
- O
infected O
with O
CMV O
and O
HIV O
, O
with O
at O
least O
one O
CD4 I-GENE
count O
recorded O
< O
100 O
x O
10 O
( O
6 O
) O
cells O
/ O
l O
. O

BACKGROUND O
AND O
OBJECTIVES O
: O
The O
sexually RARE
transmitted O
diseases O
( O
STD ALLCAPS
) O
control O
program O
for O
female O
sex O
workers O
( O
FSW ALLCAPS
) O
in O
Lima RARE
, O
Peru RARE
, O
provided O
periodic O
serological O
tests O
for O
syphilis RARE
and O
cervical O
smears O
for O
gonococci RARE
, O
but O
not O
medication O
for O
STD ALLCAPS
or O
condoms RARE
. O

National O
certification RARE
: O
a O
vital O
component O
of O
quality O
assurance RARE
. O

Two O
rare O
novel O
mutations O
, O
D811N NUMERIC
in O
exon O
20 O
and O
R835C NUMERIC
in O
exon O
21 O
, O
were O
identified O
in O
the O
first O
nucleotide O
- O
binding O
fold O
( O
NBF ALLCAPS
), O
a O
functionally O
important O
region O
of O
SUR1 NUMERIC
, O
in O
one O
patient O
each O
, O
both O
heterozygotes RARE
. O

Chimaeric RARE
VP16 I-GENE
- O
E2 I-GENE
molecules O
suggest O
that O
the O
epithelial O
specific O
transcriptional O
activation O
of O
the O
BPV I-GENE
- I-GENE
4 I-GENE
LCR I-GENE
promoter I-GENE
is O
mediated O
by O
the O
E2 I-GENE
transactivation I-GENE
domain I-GENE
. O

In O
order O
to O
examine O
the O
potential O
role O
of O
transcriptional O
silencing O
during O
productive RARE
HSV O
- O
1 O
infection O
, O
recombinant O
viruses O
were O
generated O
in O
which O
wild I-GENE
- I-GENE
type I-GENE
or I-GENE
mutant I-GENE
ICP34 NUMERIC
. I-GENE
5 I-GENE
promoters I-GENE
controlling O
the O
expression O
of O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
gene I-GENE
were O
inserted O
into O
the O
thymidine I-GENE
kinase I-GENE
gene I-GENE
of O
the O
viral O
genome O
. O

These O
changes O
correlate O
directly O
with O
an O
increase O
in O
the O
acetylation O
levels O
of O
all O
four O
core I-GENE
histones RARE
in O
vivo O
. O

Drosophila I-GENE
orthodenticle RARE
( O
otd RARE
) O
and O
murine I-GENE
Otx RARE
genes I-GENE
exemplify RARE
this O
, O
both O
in O
terms O
of O
expression O
patterns O
and O
mutant O
phenotypes O
. O

APETALA3 NUMERIC
transcripts I-GENE
are O
first O
detected O
in O
a O
meristematic RARE
region O
that O
will O
give O
rise O
to O
the O
petal RARE
and O
stamen RARE
primordia RARE
, O
and O
expression O
is O
maintained O
in O
this O
region O
during O
subsequent O
development O
of O
these O
organs O
. O

We O
also O
recovered O
mutations O
in O
the O
60A NUMERIC
gene I-GENE
which O
encodes O
another O
TGF I-GENE
- I-GENE
beta I-GENE
- I-GENE
related I-GENE
factor I-GENE
in O
Drosophila O
. O

Cell O
lines O
are O
checked RARE
to O
find O
out O
whether O
they O
develop O
tumors O
in O
nude O
mice O
followed O
by O
an O
analysis O
of O
the O
karyotype RARE
. O

Cervicovaginal RARE
foetal RARE
fibronectin I-GENE
in O
the O
prediction O
of O
preterm O
labour O
in O
a O
low O
- O
risk O
population O
. O

In O
addition O
, O
IgM I-GENE
can O
be O
absent O
in O
children O
with O
congenital O
toxoplasmosis RARE
or O
subjects O
with O
secondary O
reactivation RARE
. O

Both O
variants O
display O
the O
seven O
- O
transmembrane O
topology O
that O
is O
typical O
for O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptors I-GENE
. O

A O
constitutive O
allele O
of O
GPA2 NUMERIC
could O
stimulate O
growth O
of O
a O
strain O
lacking O
both O
RAS ALLCAPS
genes I-GENE
. O

The O
COOH O
- O
terminus O
of O
this O
new O
isoform O
, O
which O
we O
designate RARE
beta I-GENE
4 I-GENE
, O
lacks O
a O
22 O
amino O
acid O
lysine O
- O
rich O
sequence O
common O
to O
both O
the O
human I-GENE
red I-GENE
cell I-GENE
alpha I-GENE
- I-GENE
and I-GENE
beta I-GENE
- I-GENE
adducin RARE
subunits I-GENE
and O
homologous O
to O
a O
highly O
conserved O
region O
in O
MARCKS ALLCAPS
, O
a O
filamentous O
actin I-GENE
- O
cross O
linking O
protein O
regulated O
by O
protein I-GENE
kinase I-GENE
C I-GENE
and O
calcium O
/ O
calmodulin I-GENE
. O
beta I-GENE
4 I-GENE
- I-GENE
adducin RARE
preserves RARE
a O
previously O
identified O
calmodulin I-GENE
binding I-GENE
domain I-GENE
. O

PCR O
analysis O
indicates O
that O
this O
new O
beta I-GENE
- I-GENE
adducin RARE
isoform I-GENE
is O
expressed O
in O
fetal O
brain O
and O
liver O
, O
bone O
marrow O
, O
and O
NT ALLCAPS
- O
2 O
( O
neuroepithelial RARE
) O
cells O
, O
but O
is O
not O
detected O
in O
several O
other O
tissues O
. O

The O
gene I-GENE
lac I-GENE
- I-GENE
1 I-GENE
, O
encoding O
the O
enzyme O
laccase RARE
, O
is O
the O
best O
characterized O
of O
a O
number O
of O
genes O
in O
the O
chestnut RARE
blight RARE
fungus O
, O
Cryphonectria RARE
parasitica RARE
, O
that O
are O
repressed O
by O
hypoviruses RARE
, O
a O
group O
of O
virulence O
- O
attenuating RARE
mycoviruses RARE
. O
lac I-GENE
- I-GENE
1 I-GENE
has O
also O
been O
shown O
to O
be O
transcriptionally O
activated O
by O
low O
concentrations O
of O
the O
translational O
inhibitor O
cycloheximide O
( O
CHX ALLCAPS
) O
and O
by O
the O
immunosuppressant RARE
cyclosporin O
A O
. O

Both O
TRE O
- O
like O
elements O
were O
capable O
of O
binding O
AP1 I-GENE
. O

The O
hp55 NUMERIC
gamma I-GENE
protein I-GENE
interacts O
strongly O
with O
the O
activated O
IGFIR ALLCAPS
but O
not O
with O
the O
kinase O
- O
negative O
mutant O
receptor O
. O
hp55 NUMERIC
gamma I-GENE
also O
interacts O
with O
the O
insulin I-GENE
receptor I-GENE
( O
IR I-GENE
) O
in O
the O
yeast O
two O
- O
hybrid O
system O
. O

The O
plant O
protein O
maintains O
all O
the O
functional O
domains O
found O
in O
the O
other O
proteins O
, O
including O
nuclear O
localization O
signal O
, O
DNA O
- O
binding O
domain O
and O
helicase I-GENE
motifs I-GENE
, O
suggesting O
that O
it O
might O
also O
act O
as O
part O
of O
the O
RNA O
transcription O
apparatus O
, O
as O
well O
as O
nucleotide O
excision O
repair O
in O
plant O
cells O
. O

This O
paper O
describes O
the O
genomic O
organization O
of O
mouse O
gC1qBP NUMERIC
and O
the O
characterization O
of O
its O
5 O
' O
flanking O
region O
. O

LysR LASTCAP
proteins I-GENE
have O
been O
shown O
to O
regulate O
urease I-GENE
in I-GENE
Klebsiella I-GENE
aerogenes RARE
( O
NAC ALLCAPS
), O
and O
catalase I-GENE
in I-GENE
Escherichia I-GENE
coli I-GENE
( O
OxyR I-GENE
), O
which O
offers O
the O
intracellular O
bacterium O
protection O
from O
phagolysosome RARE
damage O
. O

Also O
, O
the O
anti O
- O
inflammatory O
activities O
of O
an O
aqueous O
extract O
of O
Buddleia RARE
cordata RARE
and O
its O
principal O
glycoside RARE
linarin RARE
were O
evaluated O
. O

Regulation O
of O
the O
Raf I-GENE
kinase I-GENE
in O
T O
cells O
differs O
from O
findings O
with O
a O
variety O
of O
cell O
lines O
that O
the O
catalytic I-GENE
domain I-GENE
of I-GENE
Raf I-GENE
( O
Raf I-GENE
( O
delta26 NUMERIC
- O
303 NUMERIC
)) O
shows O
no O
activity O
. O

Full RARE
- I-GENE
length I-GENE
FLAP ALLCAPS
clones O
were O
isolated O
from O
a O
mouse O
skeletal O
muscle O
cDNA O
library O
. O

Members O
of O
the O
meis1 NUMERIC
and O
pbx RARE
homeodomain I-GENE
protein I-GENE
families I-GENE
cooperatively RARE
bind O
a O
cAMP O
- O
responsive O
sequence O
( O
CRS1 NUMERIC
) O
from O
bovine I-GENE
CYP17 NUMERIC
. O

We O
have O
visualized RARE
DNA O
- O
protein O
complexes O
by O
electron O
microscopy O
and O
a O
high O
- O
affinity O
binding O
site O
of O
WDV ALLCAPS
Rep I-GENE
protein I-GENE
within O
the O
core O
element O
has O
been O
mapped O
to O
approximately O
144 NUMERIC
+/- O
18 O
bp O
upstream O
from O
the O
initiation O
site O
, O
between O
the O
start O
site O
for O
complementary O
- O
sense O
transcription O
and O
the O
TATA O
box O
. O

Rex I-GENE
- I-GENE
1 I-GENE
, O
a O
gene O
encoding O
a O
transcription O
factor O
expressed O
in O
the O
early O
embryo O
, O
is O
regulated O
via O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
and O
Oct I-GENE
- I-GENE
6 I-GENE
binding O
to O
an O
octamer O
site O
and O
a O
novel O
protein O
, O
Rox RARE
- I-GENE
1 I-GENE
, O
binding O
to O
an O
adjacent O
site O
. O

However O
, O
inhibition O
of O
both O
the O
ERK I-GENE
/ O
RSK ALLCAPS
and O
the O
p38 I-GENE
/ O
MAPKAP ALLCAPS
kinase I-GENE
2 I-GENE
pathways O
completely O
abolished O
NGF ALLCAPS
- O
induced O
CREB I-GENE
Ser O
- O
133 O
phosphorylation O
. O

Cells RARE
respond O
to O
the O
accumulation O
of O
unfolded RARE
proteins O
in O
the O
endoplasmic O
reticulum O
( O
ER O
) O
by O
increasing O
the O
transcription O
of O
the O
genes O
encoding O
ER I-GENE
- I-GENE
resident RARE
chaperone RARE
proteins I-GENE
. O

The O
RAS ALLCAPS
- O
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
cAPK LASTCAP
pathway O
prevents O
the O
UAS O
activity O
of O
IREu RARE
in O
the O
presence O
of O
glucose O
as O
the O
sole RARE
carbon O
source O
, O
while O
the O
transcriptional O
activators O
Msn2p NUMERIC
and O
Msn4p NUMERIC
promote O
the O
UAS O
activity O
of O
this O
repeat O
in O
the O
presence O
of O
acetate O
. O

The O
mei4 NUMERIC
+ I-GENE
gene I-GENE
of O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
was O
cloned O
by O
functional O
complementation O
. O

Alternative O
splicing O
of O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
2 I-GENE
( O
FGF I-GENE
- I-GENE
R2 I-GENE
) O
is O
an O
example O
of O
highly O
regulated O
alternative O
splicing O
in O
which O
exons O
IIIb RARE
and O
IIIc RARE
are O
utilized O
in O
a O
mutually RARE
exclusive RARE
manner O
in O
different O
cell O
types O
. O

In O
some O
cases O
, O
the O
aberrant O
methylation O
of O
CpGs RARE
within O
5 O
' O
regulatory O
regions O
has O
led O
to O
suppression O
of O
gene O
activity O
. O

The O
genomic O
fragments O
were O
fused O
upstream O
of O
the O
luciferase I-GENE
reporter I-GENE
gene I-GENE
. O

Cotransfection O
analyses O
of O
the O
T I-GENE
/ I-GENE
EBP I-GENE
promoter I-GENE
- I-GENE
reporter I-GENE
constructs I-GENE
with O
a O
T I-GENE
/ I-GENE
EBP I-GENE
expression O
vector O
into O
human O
HepG2 O
cells O
, O
which O
do O
not O
express O
T I-GENE
/ I-GENE
EBP I-GENE
, O
suggested O
that O
autoregulation O
may O
be O
involved O
in O
controlling O
both O
rat O
and O
human I-GENE
T I-GENE
/ I-GENE
EBP I-GENE
gene I-GENE
expression O
. O

Deletion O
of O
the O
last O
two O
Ser O
residues O
, O
including O
one O
PKC I-GENE
consensus O
site O
in O
the O
receptor O
tail O
, O
prevented O
only O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
- O
induced O
desensitization RARE
by O
30 O
%. O

Flap RARE
survival O
depends O
on O
the O
development O
of O
a O
small O
number O
of O
vascular O
connections RARE
between O
vessels O
arising O
from O
the O
pedicle RARE
and O
preexisting RARE
dermal O
vessels O
. O

Jean RARE
Klig RARE
reviews RARE
recent O
literature O
about O
lower O
respiratory O
tract O
infection O
in O
children O
. O

Potential RARE
indicators O
were O
assessed O
for O
the O
two O
classifications RARE
of O
protein O
- O
energy O
malnutrition RARE
in O
the O
guidelines O
for O
integrated O
management O
of O
childhood O
illness O
: O
severe O
malnutrition RARE
, O
which O
requires O
immediate O
referral RARE
to O
hospital O
, O
and O
very O
low O
weight O
, O
which O
calls RARE
for O
feeding O
assessment O
, O
nutritional O
counselling RARE
and O
follow O
- O
up O
. O

SNAC ALLCAPS
or O
PBS ALLCAPS
was O
infused O
for O
6 O
. O
5 O
h O
, O
beginning O
30 O
min O
before O
ischemia O
and O
continuing RARE
throughout O
the O
duration O
of O
reperfusion O
. O

Despite O
its O
requirement O
for O
enhancer O
- O
dependent O
splicing O
activity O
in O
vitro O
, O
the O
dU2AF38 NUMERIC
RS I-GENE
domain I-GENE
was O
also O
inessential RARE
in O
vivo O
. O

In O
vitro O
binding O
studies O
using O
GST I-GENE
fusion O
proteins O
and O
yeast O
extracts O
defined O
distinct O
binding O
sites O
on O
yAP180A NUMERIC
for O
Pan1p NUMERIC
and O
clathrin I-GENE
. O
yAP180 NUMERIC
proteins I-GENE
and O
Pan1p NUMERIC
, O
like O
actin I-GENE
, O
localize O
to O
peripheral O
patches RARE
along O
the O
plasma O
membrane O
. O

In O
vitro O
affinity O
analyses O
demonstrated O
that O
recombinant O
130 O
- O
kD O
protein O
directly O
interacts O
with O
ZO ALLCAPS
- I-GENE
1 I-GENE
and O
the O
cytoplasmic O
domain O
of O
occludin RARE
, O
but O
not O
with O
ZO ALLCAPS
- I-GENE
2 I-GENE
. O

Cytochrome RARE
b I-GENE
in O
human I-GENE
complex I-GENE
II I-GENE
( O
succinate RARE
- I-GENE
ubiquinone RARE
oxidoreductase I-GENE
): O
cDNA O
cloning O
of O
the O
components O
in O
liver O
mitochondria O
and O
chromosome O
assignment O
of O
the O
genes O
for O
the O
large O
( O
SDHC ALLCAPS
) O
and O
small O
( O
SDHD ALLCAPS
) O
subunits O
to O
1q21 NUMERIC
and O
11q23 NUMERIC
. O

A O
possible O
decrease O
in O
theophylline O
' O
s O
volume O
of O
distribution O
at O
4 O
days O
, O
but O
not O
immediately O
, O
after O
administration O
of O
chloroquine RARE
was O
suggested O
, O
although O
this O
just O
failed O
to O
achieve O
statistical O
significance O
( O
p O
= O
0 O
. O
055 NUMERIC
). O

The O
addition O
of O
a O
Paf RARE
- O
containing O
extract O
does O
not O
lead O
to O
significant O
protein O
binding O
to O
these O
two O
hly RARE
target I-GENE
sequences I-GENE
in O
the O
absence O
of O
PrfA LASTCAP
but O
converts RARE
the O
complex O
( O
CIII ALLCAPS
) O
consisting O
of O
PrfA LASTCAP
and O
the O
109 NUMERIC
bp I-GENE
hly RARE
DNA I-GENE
fragment I-GENE
to O
a O
slower O
migrating RARE
PrfA LASTCAP
- O
Paf RARE
- O
DNA O
complex O
( O
CI O
). O

Moreover O
, O
it O
is O
the O
assumptions RARE
behind O
steady O
- O
state O
O2 O
uptake O
that O
do O
not O
permit O
proper O
interpretation O
of O
energy O
expenditure O
during O
EPOC ALLCAPS
; O
1 O
l O
O2 O
not O
= O
20 O
. O
9 O
kJ LASTCAP
. O

The O
predicted O
amino O
acid O
sequence O
of O
m I-GENE
- I-GENE
Staf RARE
is O
highly O
homologous O
to O
that O
of O
Staf RARE
, O
another O
selenocysteine I-GENE
tRNA I-GENE
gene I-GENE
transcription I-GENE
activating I-GENE
factor I-GENE
of O
Xenopus O
laevis O
. O

ROCK ALLCAPS
- I-GENE
I I-GENE
, O
Kinectin RARE
, O
and O
mDia2 NUMERIC
can O
bind O
the O
wild O
type O
forms O
of O
both O
RhoA I-GENE
and O
Cdc42 I-GENE
in O
a O
GTP O
- O
dependent O
manner O
in O
vitro O
. O

Among O
three O
isoforms O
, O
the O
beta O
isoform O
has O
the O
greatest O
Vmax O
value O
for O
the O
PtdIns RARE
( I-GENE
4 I-GENE
) I-GENE
P I-GENE
kinase I-GENE
activity O
and O
the O
gamma O
isoform O
is O
most O
markedly O
stimulated O
by O
phosphatidic RARE
acid O
. O

The O
beta O
subunit O
of O
the O
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
that O
transduce RARE
signals O
across O
the O
plasma O
membrane O
is O
made O
up O
of O
an O
amino O
- O
terminal O
alpha O
- O
helical O
segment O
followed O
by O
seven O
repeating O
units O
called O
WD O
( O
Trp RARE
- O
Asp O
) O
repeats O
that O
occur O
in O
about O
140 O
different O
proteins O
. O

Two O
differentially O
expressed O
LNX ALLCAPS
messages RARE
encode O
overlapping O
proteins O
with O
predicted O
molecular O
masses O
of O
80 I-GENE
kDa I-GENE
( I-GENE
LNX ALLCAPS
) I-GENE
and O
70 O
kDa O
( O
LNX ALLCAPS
- O
b O
). O

In O
contrast O
, O
the O
contractile O
action O
of O
arachidonic RARE
acid O
, O
via O
a O
presumed O
cyclooxygenase RARE
product O
that O
mediated O
the O
contractions O
caused O
by O
both O
TF I-GENE
and O
EGF I-GENE
, O
was O
not O
blocked O
by O
any O
of O
the O
signal O
pathway O
probe O
inhibitors O
. O

Recent O
studies O
have O
revealed O
unconventional RARE
myosin I-GENE
V I-GENE
to O
be O
an O
important O
actin I-GENE
- O
based O
molecular O
motor O
involved O
in O
vesicular O
movement O
. O

On O
a O
separate O
occasion RARE
the O
T1 O
weighted O
and O
T2 O
weighted O
sagittal RARE
and O
T2 O
weighted O
axial O
sequences O
were O
reported O
blind O
in O
relation O
to O
the O
initial O
assessment O
. O

Furthermore O
, O
a O
minor O
start O
site O
was O
localized O
179 NUMERIC
bp O
upstream O
of O
the O
major O
site O
using O
reverse I-GENE
transcriptase I-GENE
- O
polymerase O
chain O
reaction O
with O
various O
P1 O
primers O
( O
primer O
walking RARE
), O
primer O
extension O
, O
and O
cDNA O
cloning O
. O

Analysis O
of O
promoter O
and O
androgen O
regulatory O
sequences O
required O
for O
optimal O
transcription O
of O
the O
rat O
androgen I-GENE
- I-GENE
binding I-GENE
protein I-GENE
gene O
. O

The O
iron O
dependence O
of O
transcription O
and O
expression O
of O
cvaA LASTCAP
, O
which O
encodes O
a O
transporter O
accessory O
protein O
, O
and O
cvi RARE
, O
encoding O
the O
colicin RARE
V I-GENE
immunity I-GENE
protein I-GENE
, O
was O
assessed O
under O
conditions O
of O
iron O
excess O
or O
depletion O
. O

In O
a O
gntR LASTCAP
deletion I-GENE
mutant I-GENE
, O
the O
expression O
of O
a O
chromosomal O
gntT LASTCAP
:: O
lacZ I-GENE
fusion O
is O
both O
high O
and O
constitutive O
, O
confirming O
that O
GntR LASTCAP
is O
the O
negative O
regulator O
of O
gntT LASTCAP
. O

Furthermore O
, O
the O
deletion O
of O
bcp RARE
from O
the O
chromosome O
had O
no O
effect O
on O
gcv RARE
- O
lacZ I-GENE
expression O
. O

Of O
these O
sites O
, O
PEA3 I-GENE
and O
STAT I-GENE
contributed O
specifically O
to O
induction O
by O
v I-GENE
- I-GENE
src I-GENE
, O
whereas O
the O
remaining O
elements O
were O
also O
involved O
in O
induction O
by O
the O
phorbol O
ester O
phorbol O
myristate O
acetate O
( O
PMA O
). O

BRCA1 I-GENE
protein I-GENE
contains O
an O
amino O
- O
terminal O
zinc O
finger O
motif O
and O
a O
carboxy O
- O
terminal O
acidic O
region O
. O

The O
mitochondrial I-GENE
regulatory I-GENE
region I-GENE
( O
mrr RARE
) O
located O
between O
the O
tRNAPhe RARE
and O
tRNAPro RARE
genes I-GENE
of O
mitochondrial O
DNA O
( O
mtDNA LASTCAP
) O
is O
essential O
for O
regulation O
of O
replication O
and O
transcription O
of O
the O
mitochondrial O
genome O
. O

In O
this O
report O
, O
we O
investigate O
the O
mechanism O
underlying O
Ras I-GENE
activation O
upon O
stimulation O
of O
these O
two O
types O
of O
receptors O
in O
hematopoietic O
cells O
. O

Thus O
, O
Sir RARE
proteins I-GENE
from O
K O
. O
lactis O
have O
roles O
in O
both O
silencing O
and O
telomere O
length O
maintenance O
, O
reflecting O
conserved O
functional O
themes RARE
. O

Therefore O
, O
we O
conclude O
that O
DnaA LASTCAP
may O
contact O
the O
beta O
subunit O
of O
RNA I-GENE
polymerase I-GENE
during O
activation O
of O
the O
pR LASTCAP
promoter I-GENE
. O

Expression O
of O
Bcl I-GENE
- I-GENE
XL ALLCAPS
inhibited O
the O
association O
of O
Apaf RARE
- I-GENE
1 I-GENE
with O
caspase RARE
- I-GENE
9 I-GENE
in O
mammalian O
cells O
. O

Whole RARE
- O
mount RARE
in O
situ O
hybridization O
to O
early O
mouse O
embryos O
of O
9 O
. O
5 O
- O
10 O
. O
5 O
days O
indicated O
a O
complex O
pattern O
of O
Arp1 NUMERIC
expression O
spatially O
overlapping O
with O
the O
expression O
of O
All1 NUMERIC
. O

These O
mutants O
were O
tested O
for O
ability O
to O
bind O
each O
of O
the O
Site I-GENE
II I-GENE
cognate I-GENE
proteins I-GENE
, O
and O
subsequently O
evaluated O
for O
ability O
to O
confer O
H4 I-GENE
transcriptional O
activity O
using O
chimeric O
H4 I-GENE
promoter O
/ O
CAT I-GENE
fusion O
constructs O
in O
different O
cell O
types O
. O

Increased O
plasma O
IgE I-GENE
was O
also O
confirmed O
in O
the O
NC ALLCAPS
mice O
, O
and O
treatment O
with O
FK506 O
ointment RARE
reduced O
the O
plasma O
IgE I-GENE
level O
. O

Creatine RARE
kinase I-GENE
release O
after O
hepatic O
artery O
embolization RARE
in O
patients O
with O
carcinoid RARE
tumors O
. O

Furthermore O
, O
in O
the O
ischemia O
/ O
angiotension RARE
II I-GENE
- O
induced O
AHF ALLCAPS
model O
, O
NIC ALLCAPS
decreased O
left O
ventricular O
end O
- O
diastolic O
pressure O
( O
LVEDP ALLCAPS
). O

Group O
A O
( O
68 O
. O
7 O
+/- O
2 O
. O
7 O
years O
) O
consisted O
of O
patients O
with O
0 O
or O
1 O
risk O
factors O
; O
B O
( O
68 O
. O
3 O
+/- O
4 O
. O
2 O
years O
) O
those O
with O
2 O
risk O
factors O
; O
and O
C O
( O
69 O
. O
2 O
+/- O
3 O
. O
6 O
years O
) O
those O
with O
3 O
or O
more O
risk O
factors O
. O

We O
further O
demonstrate O
that O
RU486 NUMERIC
- O
PR I-GENE
- I-GENE
B I-GENE
interacts O
physically O
with O
NCoR LASTCAP
in O
vitro O
. O

PRL I-GENE
receptor I-GENE
also O
activates O
SHP I-GENE
- I-GENE
2 I-GENE
, O
a O
cytosolic I-GENE
tyrosine I-GENE
phosphatase I-GENE
. O

The O
dominant O
negative O
mutant O
of O
SHP I-GENE
- I-GENE
2 I-GENE
was O
found O
to O
inhibit O
the O
induction O
of O
tyrosine O
phosphorylation O
and O
DNA O
- O
binding O
activity O
of O
m I-GENE
- I-GENE
Stat5a I-GENE
, O
m I-GENE
- I-GENE
Stat5b NUMERIC
, O
and O
the O
carboxyl O
- O
terminal O
deletion O
variant O
m I-GENE
- I-GENE
Stat5adelta749 NUMERIC
, O
as O
well O
as O
the O
transactivation O
potential O
of O
m I-GENE
- I-GENE
Stat5a I-GENE
and O
m I-GENE
- I-GENE
Stat5b NUMERIC
. O

CONCLUSIONS O
: O
These O
routinely RARE
collected O
data O
provided O
quantitative O
estimates O
of O
changes O
in O
CBZ ALLCAPS
Cl O
/ O
F O
due O
to O
comedication RARE
and O
an O
age O
- O
related O
decrease O
in O
Cl O
/ O
F O
The O
derived O
regression O
equations RARE
reasonably RARE
predicted O
concentrations O
in O
a O
separate O
validation RARE
set O
. O

Sites RARE
1 O
and O
4 O
in O
lumican RARE
and O
keratocan RARE
are O
in O
a O
homologous O
location O
. O

Our O
observations O
suggest O
that O
members O
of O
the O
HMG I-GENE
- I-GENE
I I-GENE
family I-GENE
play O
an O
important O
role O
in O
SRF I-GENE
- O
dependent O
transcription O
and O
that O
their O
effect O
is O
mediated O
primarily O
by O
a O
protein O
- O
protein O
interaction O
. O

ATP O
- O
dependent O
assembly O
of O
a O
ternary O
complex O
consisting O
of O
a O
DNA O
mismatch RARE
and O
the O
yeast O
MSH2 NUMERIC
- O
MSH6 NUMERIC
and O
MLH1 NUMERIC
- O
PMS1 NUMERIC
protein O
complexes O
. O

Mutation O
of O
the O
central O
Tyr497 NUMERIC
to O
Phe O
blocks O
the O
tyrosine O
phosphorylation O
of O
the O
insulin I-GENE
receptor I-GENE
substrate I-GENE
1 I-GENE
( O
IRS1 NUMERIC
) O
and O
diminishes RARE
proliferation O
in O
response O
to O
IL I-GENE
- I-GENE
4 I-GENE
. O

Instead O
, O
it O
contained O
two O
tandem O
kappaB I-GENE
elements I-GENE
and O
a O
variant O
activating I-GENE
transcription I-GENE
factor I-GENE
/ I-GENE
cAMP I-GENE
response I-GENE
element I-GENE
site O
, O
which O
closely O
resembled RARE
sites O
in O
the O
E I-GENE
- I-GENE
selectin I-GENE
gene I-GENE
that O
are O
required O
for O
TNF I-GENE
- I-GENE
alpha I-GENE
- O
or O
LPS O
- O
inducible O
expression O
. O

We O
recently O
characterized O
a O
single O
yeast I-GENE
hnRNP I-GENE
methyltransferase I-GENE
( O
HMT1 NUMERIC
). O

We O
recently O
characterized O
a O
single O
yeast I-GENE
hnRNP I-GENE
methyltransferase I-GENE
( O
HMT1 NUMERIC
). O

Recombinant I-GENE
HRMT1L2 NUMERIC
protein I-GENE
encoded O
by O
the O
most O
common O
5 O
'- O
variant O
exhibited O
methyltransferase O
activity O
in O
vitro O
. O

The O
possible O
roles O
of O
HRMT1L1 NUMERIC
and O
HRMT1L2 NUMERIC
in O
human O
disease O
are O
currently O
unknown O
. O

Identification O
and O
characterization O
of O
two O
putative O
human I-GENE
arginine I-GENE
methyltransferases RARE
( O
HRMT1L1 NUMERIC
and O
HRMT1L2 NUMERIC
). O

Interestingly O
, O
the O
activated O
PDGF I-GENE
beta I-GENE
- I-GENE
receptor I-GENE
was O
found O
not O
to O
bind O
Crk I-GENE
proteins I-GENE
. O

Furthermore O
, O
interactions O
were O
identified O
between O
endogenous I-GENE
E I-GENE
- I-GENE
cadherin I-GENE
and O
the O
chimera O
containing O
the O
E I-GENE
- I-GENE
cadherin I-GENE
extracellular I-GENE
domain I-GENE
and O
the O
desmoglein RARE
1 I-GENE
intracellular I-GENE
domain I-GENE
providing O
in O
vivo O
evidence O
for O
previously O
predicted O
lateral O
interactions O
of O
E I-GENE
- I-GENE
cadherin I-GENE
extracellular I-GENE
domains I-GENE
. O

The O
ether O
phospholipid O
1 O
- O
O O
- O
octadecyl RARE
- O
2 O
- O
O O
- O
methyl O
- O
rac RARE
- O
glycero RARE
- O
3 O
- O
phosphocholine RARE
( O
ET O
- O
18 O
- O
OCH3 NUMERIC
; O
edelfosine RARE
) O
is O
a O
potent O
inducer RARE
of O
apoptosis O
in O
human O
tumor O
cells O
. O

In O
addition O
to O
a O
previously O
characterized O
promoter O
( O
P1 O
), O
we O
now O
show O
the O
existence O
of O
a O
second O
promoter O
for O
the O
human I-GENE
IL I-GENE
- I-GENE
5Ralpha NUMERIC
gene I-GENE
. O

Serum O
levels O
of O
testosterone O
also O
showed O
no O
significant O
changes O
by O
exposure O
to O
p O
, O
p O
'- O
DDE ALLCAPS
under O
the O
conditions O
of O
this O
study O
. O

Overall O
agreement O
between O
rest O
/ O
postnitroglycerin RARE
technetium O
- O
99m O
tetrofosmin O
SPET ALLCAPS
studies O
and O
rest O
/ O
redistribution RARE
or O
rest O
/ O
reinjection RARE
thallium O
- O
201 O
SPET ALLCAPS
studies O
, O
regarding O
the O
presence O
of O
myocardial O
viability O
, O
was O
87 O
% O
and O
90 O
%, O
respectively O
. O

Their O
use O
resulted O
in O
a O
sensitivity O
of O
73 O
% O
and O
a O
specificity O
of O
74 O
% O
with O
regard O
to O
predictability RARE
of O
ALT ALLCAPS
levels O
increasing O
during O
the O
trial O
. O

One O
hundred O
replicate RARE
data O
sets O
of O
100 O
subjects O
each O
were O
simulated O
for O
each O
missing O
data O
scenario RARE
. O

Spatial RARE
accuracy O
of O
primary O
and O
secondary O
memory O
- O
guided RARE
saccades RARE
in O
schizophrenic O
patients O
. O

Successful RARE
treatment O
with O
nasal O
continuous O
positive O
airway O
pressure O
( O
8 O
. O
3 O
+/- O
1 O
. O
5 O
cmH2O O
) O
for O
3 O
days O
caused O
a O
significant O
decrease O
in O
mean O
blood O
pressure O
in O
OSAS ALLCAPS
. O

When O
data O
were O
expressed O
in O
a O
cumulative O
manner O
, O
the O
response O
to O
intravenous O
adenosine O
3 O
mg O
, O
6 O
mg O
, O
9 O
mg O
and O
12 O
mg O
in O
the O
24 O
episodes O
of O
PSVT ALLCAPS
were O
5 O
episodes O
( O
21 O
%), O
16 O
episodes O
( O
67 O
%), O
20 O
episodes O
( O
83 O
%) O
and O
20 O
episodes O
( O
83 O
%) O
respectively O
. O

RNAs O
are O
not O
only O
essential O
components O
of O
both O
ribosomal O
subunits O
but O
also O
transiently O
interacting O
factors O
during O
particle O
formation O
. O

To O
study O
retinoid O
signalling O
in O
zebrafish RARE
embryos O
, O
we O
developed O
a O
novel O
method O
to O
detect O
endogenous O
retinoids RARE
in O
situ O
in O
embryos O
, O
using O
a O
fusion O
protein O
of O
the O
ligand O
inducible O
transactivation O
domain O
of O
a O
retinoic I-GENE
acid I-GENE
receptor I-GENE
and O
a O
heterologous O
DNA O
binding O
domain O
. O

To O
identify O
nuclear O
regulatory O
factors O
, O
we O
have O
located O
and O
functionally O
characterized O
the O
CCR5 NUMERIC
gene I-GENE
promoter I-GENE
. O

Fluorescence RARE
in O
situ O
hybridization O
of O
metaphase RARE
spreads RARE
of O
chromosome O
8 O
, O
containing O
hybrid O
cell O
line O
706 NUMERIC
- O
B6 O
clone O
17 O
( O
CL O
- O
17 O
) O
with O
cosmid O
c101F1 NUMERIC
, O
placed O
the O
9804 NUMERIC
gene I-GENE
close O
to O
the O
telomere O
at O
8q24 NUMERIC
. O
3 O
. O

The O
interaction O
between O
piroxicam RARE
and O
poloxamer RARE
was O
studied O
by O
x O
- O
ray O
diffractometry RARE
( O
XRD ALLCAPS
), O
infrared RARE
( O
IR O
) O
spectroscopy O
and O
differential O
thermal O
analysis O
( O
DTA ALLCAPS
) O
with O
a O
solid O
dispersion O
, O
coprecipitate RARE
, O
or O
physical O
mixture O
. O

Cell O
survival O
by O
Epo I-GENE
did O
not O
require O
activation O
of O
other O
known O
signaling O
pathways O
including O
PI I-GENE
- I-GENE
3 I-GENE
kinase I-GENE
, O
PLC I-GENE
- I-GENE
gamma I-GENE
, O
Ras I-GENE
or O
Stats RARE
. O

The O
N O
- O
syndecan RARE
- O
dependent O
neurite RARE
outgrowth RARE
is O
inhibited O
by O
the O
tyrosine I-GENE
kinase I-GENE
inhibitors O
herbimycin RARE
A O
and O
PP1 NUMERIC
. O

An O
in O
vivo O
ZAP I-GENE
- I-GENE
70 I-GENE
substrate O
, O
SLP ALLCAPS
- I-GENE
76 I-GENE
, O
implicated O
in O
Erk RARE
activation O
, O
also O
became O
rapidly O
tyrosine O
- O
phosphorylated O
in O
Jurkat O
cells O
, O
but O
not O
in O
P116 NUMERIC
cells O
, O
upon O
treatment O
with O
H2O2 NUMERIC
. O

The O
pharmacokinetic O
patterns O
of O
estradiol O
( O
CAS O
50 O
- O
28 O
- O
2 O
) O
and O
of O
estrone RARE
( O
CAS O
53 O
- O
16 O
- O
7 O
) O
were O
investigated O
in O
18 O
women O
in O
natural O
or O
surgical O
menopause RARE
during O
the O
application O
of O
a O
new O
estradiol O
transdermal RARE
patch O
with O
active O
matrix O
and O
without O
absorption O
enhancers O
designed O
for O
epicutaneous RARE
applications O
of O
7 O
days O
( O
hereinafter RARE
called O
" O
patch O
7D NUMERIC
"). RARE

The O
results O
confirm O
that O
a O
single O
base O
change O
in O
the O
branchpoint O
consensus O
sequence O
of O
an O
intron O
can O
cause O
human O
disease O
although O
this O
sequence O
is O
poorly O
conserved O
in O
mammals O
. O

Conversely O
, O
the O
central O
regions O
are O
highly O
variable O
. O

Among O
the O
H I-GENE
/ I-GENE
ACA I-GENE
snoRNAs RARE
associated O
with O
Gar1p NUMERIC
, O
one O
can O
distinguish RARE
a O
large O
group O
of O
snoRNAs RARE
that O
are O
not O
essential O
in O
yeast O
and O
serve O
as O
guides RARE
for O
pseudouridine RARE
synthesis O
onto O
the O
pre O
- O
rRNA O
molecule O
. O

It O
bound O
to O
vitamin I-GENE
D I-GENE
receptor I-GENE
( O
VDR I-GENE
) O
but O
not O
retinoic I-GENE
acid I-GENE
Xalpha RARE
receptor I-GENE
( O
RXRalpha RARE
) O
in O
the O
human O
T O
cell O
line O
MT2 NUMERIC
cells O
. O

Further O
studies O
demonstrated O
that O
the O
PPARalpha I-GENE
ligand O
8 O
( O
S O
)- O
hydroxyeicosatetraenoic RARE
acid O
strongly O
promotes O
the O
interaction O
of O
PPARalpha I-GENE
with O
the O
co O
- O
activator O
RIP ALLCAPS
- I-GENE
140 I-GENE
but O
decreases O
the O
interaction O
of O
PPARalpha I-GENE
with O
the O
co O
- O
repressor O
SMRT I-GENE
. O

Based O
on O
the O
current O
literature O
, O
the O
mechanisms O
involved O
in O
the O
toxicity O
of O
OA ALLCAPS
indicate O
three O
major O
effects O
: O
( O
1 O
) O
inhibition O
of O
mitochondrial O
respiration O
correlated O
with O
a O
depletion O
of O
ATP O
; O
( O
2 O
) O
inhibition O
of O
tRNA I-GENE
- I-GENE
synthetase I-GENE
accompanied O
by O
a O
reduced O
protein O
synthesis O
; O
and O
( O
3 O
) O
enhanced O
lipid O
peroxidation O
. O

We O
previously O
demonstrated O
that O
acute O
expression O
of O
the O
bovine O
papillomavirus O
type O
1 O
( O
BPV1 NUMERIC
) O
E2 I-GENE
protein I-GENE
in O
HeLa O
and O
HT O
- O
3 O
cervical O
carcinoma O
cell O
lines O
greatly O
reduced O
cellular O
proliferation O
by O
imposing RARE
a O
specific O
G1 O
/ O
S O
phase O
growth O
arrest O
. O

Four O
possible O
isoforms O
( O
hGli2 NUMERIC
alpha I-GENE
, I-GENE
beta I-GENE
, I-GENE
gamma I-GENE
, I-GENE
and I-GENE
delta I-GENE
) O
are O
formed O
by O
combinations O
of O
two O
independent O
alternative O
splicings RARE
, O
and O
all O
the O
isoforms O
could O
bind O
to O
a O
DNA O
motif O
, O
TRE2S NUMERIC
, O
in O
the O
LTR O
. O

Specialized RARE
actin I-GENE
tails O
that O
propel RARE
IEV ALLCAPS
particles O
to O
the O
periphery RARE
and O
virus O
- O
tipped RARE
microvilli RARE
( O
both O
common O
in O
wild O
- O
type O
- O
infected O
cells O
) O
were O
absent O
in O
cells O
infected O
with O
vA33delta NUMERIC
. O

Their O
mean O
IOP O
was O
15 O
. O
3 O
( O
SD O
3 O
. O
7 O
) O
mmHg O
prior O
to O
induction O
of O
anesthesia O
, O
13 O
. O
5 O
( O
SD O
3 O
. O
5 O
) O
mmHg O
after O
loss O
of O
eyelash RARE
reflex O
following O
injection O
of O
methohexitone RARE
, O
16 O
. O
1 O
( O
SD O
2 O
. O
4 O
) O
mmHg O
after O
cessation O
of O
muscle O
fasciculations RARE
induced O
by O
suxamethonium RARE
, O
19 O
. O
2 O
( O
SD O
5 O
. O
6 O
) O
mmHg O
after O
cessation O
of O
convulsion RARE
and O
15 O
. O
5 O
( O
SD O
4 O
. O
4 O
) O
mmHg O
following O
resumption RARE
of O
regular O
spontaneous O
respiration O
. O

A O
cDNA O
, O
cak1At NUMERIC
, O
was O
isolated O
that O
suppressed O
the O
CAK I-GENE
mutation I-GENE
in O
budding O
yeast O
, O
and O
it O
also O
complemented O
a O
fission I-GENE
yeast I-GENE
CAK I-GENE
mutant I-GENE
. O
cak1At NUMERIC
encodes O
a O
protein O
related O
to O
animal I-GENE
CAKs RARE
. O

Post O
- O
translational O
modifications O
such O
as O
glycosylation O
and O
phosphorylation O
could O
be O
excluded O
as O
potential O
explanations RARE
for O
the O
protein O
heterogeneity O
. O

In O
addition O
to O
restoring RARE
checkpoint O
control O
, O
overexpression O
of O
sum1 NUMERIC
+ I-GENE
inhibits O
the O
normal O
cell O
cycle O
response O
to O
osmotic O
stress O
. O

Ime1 NUMERIC
plays O
a O
pivotal O
role O
in O
the O
initiation O
of O
meiosis O
in O
a O
/ O
alpha O
diploid O
cells O
of O
Saccharomyces O
cerevisiae O
. O

Rhesus RARE
macaques RARE
and O
BALB O
/ O
c O
mice O
inoculated O
with O
the O
Mengo RARE
virus O
SIV O
recombinants O
failed O
to O
develop O
CTL O
responses O
against O
the O
SIV O
gene O
products O
, O
while O
one O
of O
the O
HIV I-GENE
- I-GENE
Nef I-GENE
recombinants I-GENE
induced O
a O
weak O
CTL O
response O
in O
mice O
directed O
to O
an O
HIV1 NUMERIC
Nef I-GENE
peptide I-GENE
spanning O
positions O
182 O
- O
198 O
. O

Deltamethrin RARE
was O
most O
effective O
on O
the O
thatched RARE
surface O
and O
produced O
100 O
% O
mortality O
of O
An O
. O
culicifacies RARE
adults O
up O
to O
12 O
weeks O
, O
even O
when O
exposed O
at O
the O
lowest O
dose O
/ O
12 O
. O
5 O
mg O
/ O
m2 O
. O

Trichloroethylene RARE
, O
in O
turn O
, O
increased O
the O
AUC O
5 O
. O
0 O
( O
1 O
. O
9 O
- O
13 O
. O
4 O
), O
25 O
. O
8 O
( O
8 O
. O
2 O
- O
80 O
. O
8 O
) O
and O
2 O
. O
9 O
( O
1 O
. O
6 O
- O
5 O
. O
4 O
), O
respectively O
, O
whereas O
the O
corresponding O
values O
for O
n O
- O
hexane RARE
were O
1 O
. O
9 O
( O
0 O
. O
7 O
- O
5 O
. O
1 O
), O
1 O
. O
5 O
( O
0 O
. O
5 O
- O
4 O
. O
6 O
), O
and O
3 O
. O
2 O
( O
1 O
. O
8 O
- O
5 O
. O
9 O
). O

Solution RARE
structure O
of O
the O
IRF I-GENE
- I-GENE
2 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
: O
a O
novel O
subgroup O
of O
the O
winged RARE
helix I-GENE
- I-GENE
turn I-GENE
- I-GENE
helix I-GENE
family I-GENE
. O

In O
contrast O
, O
receptor I-GENE
/ I-GENE
G I-GENE
protein I-GENE
coupling O
appeared O
unaffected O
by O
expression O
of O
loop O
3i NUMERIC
domains O
derived O
from O
two O
receptors O
coupled O
to O
G I-GENE
( I-GENE
i I-GENE
/ I-GENE
o I-GENE
) I-GENE
proteins I-GENE
( O
M2Ach NUMERIC
- I-GENE
muscarinic RARE
and I-GENE
alpha2A NUMERIC
- I-GENE
adrenergic I-GENE
receptors I-GENE
). O

These O
data O
indicate O
that O
the O
third O
intracellular O
loop O
of O
the O
rat I-GENE
GnRH I-GENE
- I-GENE
R I-GENE
is O
involved O
in O
receptor I-GENE
G I-GENE
( I-GENE
q I-GENE
/ I-GENE
11 I-GENE
) I-GENE
protein I-GENE
coupling O
and O
/ O
or O
selectivity O
, O
and O
in O
the O
GGH ALLCAPS
( O
3 O
) O
1 O
' O
cell O
line O
, O
this O
loop O
is O
also O
involved O
in O
signal O
transduction O
mediated O
through O
the O
Gs I-GENE
protein O
pathway O
. O

Decreased RARE
levels O
of O
alpha2 I-GENE
- I-GENE
antiplasmin RARE
were O
also O
observed O
in O
the O
mediastinum RARE
( O
0 O
. O
50 O
versus O
0 O
. O
61 O
U O
/ O
mL O
; O
p O
< O
0 O
. O
05 O
). O

A O
catalytic O
domain O
of O
eukaryotic I-GENE
DNA I-GENE
topoisomerase I-GENE
I I-GENE
. O

A O
cluster O
of O
basic O
amino O
acids O
, O
KKKR ALLCAPS
, O
generated O
by O
joining O
of O
the O
sequences O
encoded O
by O
the O
constitutive O
exon O
13 O
and O
the O
alternative O
exon O
16 O
, O
is O
necessary O
for O
the O
nuclear O
targeting O
of O
4 I-GENE
. I-GENE
1H NUMERIC
, O
as O
demonstrated O
by O
site O
- O
directed O
mutagenesis O
analysis O
. O

Another O
stem O
- O
loop O
called O
structure O
III O
near O
the O
3 O
'- O
end O
of O
repY LASTCAP
sequesters RARE
both O
the O
5 O
'- O
rCGCC LASTCAP
- O
3 O
' O
sequence O
and O
the O
repZ LASTCAP
ribosome I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

All O
three O
genes O
have O
been O
mapped O
precisely O
to O
a O
small O
region O
on O
human O
chromosome O
16p12 NUMERIC
. O
1 O
- O
p11 NUMERIC
. O
2 O
( O
homologous O
to O
mouse O
chromosome O
7 O
), O
using O
somatic O
cell O
hybrids O
and O
cosmid O
clones O
. O

In O
fus3 NUMERIC
mutants I-GENE
, O
the O
levels O
of O
Ty1 I-GENE
RNA I-GENE
, O
protein O
synthesis O
, O
and O
proteolytic O
processing O
were O
not O
altered O
relative O
to O
those O
in O
FUS3 NUMERIC
strains O
but O
steady O
- O
state O
levels O
of O
TyA LASTCAP
, O
integrase I-GENE
, O
and O
reverse I-GENE
transcriptase I-GENE
proteins O
and O
Ty1 I-GENE
cDNA I-GENE
were O
all O
increased O
. O

Posttranslational RARE
regulation O
of O
Ty1 I-GENE
retrotransposition RARE
by O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
Fus3 NUMERIC
. O

The O
general O
transcription I-GENE
factor I-GENE
IIA I-GENE
( O
TFIIA ALLCAPS
) O
interacts O
with O
the O
TATA I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
and O
promoter O
DNA O
to O
mediate O
transcription O
activation O
in O
vitro O
. O

Their O
function O
is O
not O
only O
to O
recruit O
Pho2 NUMERIC
to O
the O
promoter O
but O
to O
allow O
cooperative O
binding O
of O
Pho4 NUMERIC
together O
with O
Pho2 NUMERIC
. O

Substitution O
of O
the O
Ser O
- O
Thr O
sites O
with O
the O
phosphomimetic RARE
Asp O
generated O
a O
constitutively O
active O
form O
of O
IRF I-GENE
- I-GENE
3 I-GENE
that O
functioned O
as O
a O
very O
strong O
activator O
of O
promoters O
containing O
PRDI ALLCAPS
- O
PRDIII ALLCAPS
or O
ISRE ALLCAPS
regulatory I-GENE
elements I-GENE
. O

New O
- O
onset O
angina O
preceding O
acute O
myocardial O
infarction O
is O
associated O
with O
improved O
contractile O
recovery O
after O
thrombolysis RARE
. O

In O
this O
study O
, O
the O
effect O
of O
acute O
administration O
of O
various O
doses O
of O
malathion RARE
via O
oral O
and O
dermal O
routes O
to O
mice O
and O
rats O
on O
serum O
levels O
of O
histamine O
was O
evaluated O
. O

Fetal RARE
growth O
retardation O
as O
a O
cause O
of O
impaired O
ovarian O
development O
. O

Similarly O
, O
PCDFs RARE
/ O
PCDDs RARE
ratio O
in O
ESP ALLCAPS
ash RARE
was O
lower O
than O
that O
in O
boiler RARE
ash RARE
. O

In O
addition O
to O
DNA O
- O
protein O
interactions O
, O
protein O
- O
protein O
interactions O
with O
partner O
proteins O
often O
play O
major O
roles O
in O
targeting O
ETS I-GENE
- I-GENE
domain I-GENE
proteins I-GENE
to O
specific O
promoters O
. O

Localization O
of O
67 O
exons O
on O
a O
YAC O
contig O
spanning O
1 O
. O
5 O
Mb O
around O
the O
multidrug I-GENE
resistance I-GENE
gene I-GENE
region I-GENE
of O
human O
chromosome O
7q21 NUMERIC
. O
1 O
. O

The O
complete O
exon O
- O
intron O
organization O
of O
the O
murine O
gene O
encoding O
M I-GENE
- I-GENE
protein I-GENE
, O
a O
structural O
protein O
of O
sarcomeric RARE
myofibrils RARE
, O
was O
determined O
. O

PURPOSE O
: O
To O
introduce RARE
an O
image O
analysis O
of O
the O
cornea RARE
in O
photorefractive RARE
keratectomy RARE
( O
PRK O
) O
for O
preoperative O
and O
early O
postoperative O
determination O
of O
changes O
in O
the O
condition O
of O
the O
cornea RARE
. O

Mean O
+/- O
SD O
serum I-GENE
VEGF I-GENE
concentrations O
were O
significantly O
higher O
( O
P O
< O
0 O
. O
001 O
) O
in O
women O
with O
PCO ALLCAPS
and O
PCOS ALLCAPS
( O
3 O
. O
4 O
+/- O
0 O
. O
7 O
and O
3 O
. O
2 O
+/- O
0 O
. O
66 O
ng O
/ O
ml O
respectively O
) O
compared O
with O
women O
with O
normal O
ovaries RARE
( O
2 O
. O
3 O
+/- O
0 O
. O
5 O
ng O
/ O
ml O
). O

Strikingly RARE
, O
these O
cells O
contain O
a O
missense O
mutation O
of O
the O
p53 I-GENE
gene I-GENE
at O
codon O
242 NUMERIC
( O
p53 I-GENE
( O
242 NUMERIC
)), RARE
which O
substitutes RARE
alanine O
for O
glycine O
. O

The O
new O
algorithm O
, O
called O
RBI ALLCAPS
- O
MAP O
, O
is O
based O
on O
the O
rescaled RARE
block O
iterative RARE
EM O
( O
RBI ALLCAPS
- O
EM O
) O
algorithm O
. O

A O
third O
ORF O
, O
ORF5 NUMERIC
, O
shows O
homology O
with O
gene I-GENE
agrB LASTCAP
from O
Staphylococcus O
aureus O
, O
which O
is O
involved O
in O
the O
mechanism O
of O
regulation O
of O
the O
virulence O
phenotype O
in O
this O
species O
. O

An O
association O
between O
hSIE LASTCAP
and O
Stat I-GENE
- I-GENE
3 I-GENE
after O
MHC I-GENE
- I-GENE
I I-GENE
ligation O
was O
directly O
demonstrated O
by O
precipitating O
Stat I-GENE
- I-GENE
3 I-GENE
from O
nuclear O
extracts O
with O
biotinylated RARE
hSIE LASTCAP
probe O
and O
avidin RARE
- O
coupled O
agarose O
. O

Transcriptional O
repression O
mediated O
by O
LysR LASTCAP
- I-GENE
type I-GENE
regulator I-GENE
CatR LASTCAP
bound O
at O
multiple O
binding O
sites O
. O

Two O
of O
these O
resulted O
in O
increased O
levels O
of O
the O
alpha O
subunit O
, O
and O
one O
caused O
a O
substitution O
of O
glycine O
for O
the O
aspartic RARE
acid O
residue O
at O
position O
171 NUMERIC
, O
in O
the O
N O
- O
terminal O
domain O
. O

These O
two O
mRNA O
species O
are O
produced O
by O
differential O
polyadenylation O
site O
usage O
. O

Using O
Southern O
blot O
analysis O
and O
restriction O
mapping O
of O
genomic O
YAC O
( O
yeast O
artificial O
chromosome O
) O
and O
cosmid O
clones O
, O
we O
located O
the O
human I-GENE
RIL ALLCAPS
gene I-GENE
240 O
- O
260 O
kb O
telomeric O
to O
the O
IRF1 NUMERIC
gene I-GENE
and O
characterized O
its O
genomic O
structure O
. O

U73 NUMERIC
contains O
C O
, O
D O
and O
D O
' O
boxes O
and O
a O
12 O
- O
nucleotide O
antisense O
complementarity O
to O
the O
28S I-GENE
ribosomal I-GENE
RNA I-GENE
. O

However O
, O
mandibular O
position O
( O
S O
- O
N O
- O
B O
and O
S O
- O
N O
- O
Pog RARE
) O
was O
found O
to O
be O
significantly O
more O
retrusive RARE
in O
Class O
II O
when O
compared O
with O
Class O
I O
subjects O
. O

Echinostomiasis RARE
is O
aggravated RARE
by O
socioeconomic RARE
factors O
such O
as O
poverty RARE
, O
malnutrition RARE
, O
an O
explosively RARE
growing O
free O
- O
food O
market RARE
, O
a O
lack O
of O
supervised RARE
food O
inspection RARE
, O
poor O
or O
insufficient O
sanitation RARE
, O
other O
helminthiases RARE
, O
and O
declining RARE
economic RARE
conditions O
. O

The O
localization O
of O
ZAP I-GENE
- I-GENE
70 I-GENE
to O
the O
cell O
cortex O
is O
, O
therefore O
, O
regulated O
by O
the O
activity O
of O
SRC I-GENE
- I-GENE
family I-GENE
kinases I-GENE
, O
independently O
of O
their O
ability O
to O
phosphorylate O
immunoreceptor RARE
tyrosine O
- O
based O
activation O
motifs O
of O
the O
TCR I-GENE
. O

Finally O
, O
a O
role O
for O
NF I-GENE
- I-GENE
kappaB I-GENE
in O
preventing O
apoptosis O
induced O
by O
ER O
calcium O
release O
was O
demonstrated O
by O
data O
showing O
that O
sAPPalpha RARE
prevents O
thapsigargin RARE
- O
induced O
apoptosis O
, O
an O
effect O
blocked O
by O
kappaB I-GENE
decoy RARE
DNA O
. O

Many O
cytokine O
receptors O
employ RARE
Janus I-GENE
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
Jaks RARE
) O
and O
signal I-GENE
transducers RARE
and I-GENE
activators I-GENE
of I-GENE
transcription I-GENE
( O
Stats RARE
) O
for O
nuclear O
signaling O
. O

A O
site O
- O
directed O
R618K NUMERIC
mutation O
in O
the O
Stat5 I-GENE
SH2 I-GENE
domain I-GENE
abolished O
the O
phosphorylation O
by O
Jak2 NUMERIC
, O
while O
deletion O
of O
the O
C O
terminus O
led O
to O
Stat5 I-GENE
hyperphosphorylation RARE
. O

The O
effect O
of O
nitric I-GENE
oxide I-GENE
synthase I-GENE
inhibitor O
on O
reperfusion O
injury O
of O
the O
brain O
under O
hypothermic RARE
circulatory O
arrest O
. O

Specifically O
, O
recombination O
at O
HMR I-GENE
was O
used O
to O
produce O
rings RARE
that O
lacked O
the O
E O
and O
I O
silencers RARE
. O

In O
angiodysplasia RARE
, O
ectatic RARE
vessels O
in O
the O
mucosa O
appeared O
to O
contain O
less O
collagen I-GENE
type I-GENE
IV I-GENE
than O
similarly O
sized O
vessels O
in O
the O
submucosa RARE
, O
and O
perforating RARE
vessels O
appeared O
in O
many O
cases O
to O
lose RARE
staining O
at O
the O
level O
of O
the O
muscularis RARE
mucosae RARE
. O

We O
studied O
the O
human O
vestibulo RARE
- O
ocular O
reflex O
( O
VOR ALLCAPS
) O
in O
response O
to O
head O
' O
impulses RARE
': RARE
brief O
, O
unpredictable RARE
, O
passive O
, O
high O
- O
acceleration RARE
( O
up O
to O
4000 NUMERIC
degrees O
/ O
s2 NUMERIC
), O
low O
- O
amplitude O
( O
20 O
- O
30 O
degrees O
) O
head O
rotations RARE
. O

To O
clarify O
whether O
seizure O
- O
offset RARE
patterns O
are O
reliable O
in O
predicting O
seizure O
outcome O
, O
we O
studied O
SEEG ALLCAPS
/ O
ECoG LASTCAP
in O
a O
similar O
group O
of O
patients O
with O
temporal O
lobe O
epilepsy O
( O
TLE ALLCAPS
). O

In O
this O
study O
, O
to O
characterize O
the O
gene O
for O
protein I-GENE
Z I-GENE
, O
its O
organization O
and O
structure O
were O
determined O
by O
a O
combination O
of O
PCR O
amplification O
of O
leukocyte O
DNA O
and O
isolation O
of O
phage O
clones O
from O
a O
human O
genomic O
library O
. O

These O
modifications O
may O
improve O
the O
interlaboratory RARE
reproducibility O
of O
CD34 I-GENE
determinations O
due O
to O
the O
reduction O
in O
sample O
handling RARE
and O
calculation RARE
of O
results O
. O

The O
present O
results O
demonstrate O
that O
rats O
with O
relatively O
small O
remnants RARE
of O
one O
olfactory O
bulb O
can O
perform O
a O
variety O
of O
odor RARE
detection O
and O
discrimination O
tasks O
as O
well O
or O
nearly O
as O
well O
as O
controls O
. O

UDP ALLCAPS
- I-GENE
GlcNAc I-GENE
: O
alpha I-GENE
- I-GENE
6 I-GENE
- I-GENE
D I-GENE
- I-GENE
mannoside RARE
beta I-GENE
- I-GENE
1 I-GENE
, I-GENE
2 I-GENE
- I-GENE
N I-GENE
- I-GENE
acetylglucosaminyltransferase RARE
II I-GENE
( O
GnT LASTCAP
II I-GENE
; O
EC I-GENE
2 I-GENE
. I-GENE
4 I-GENE
. I-GENE
1 I-GENE
. I-GENE
143 I-GENE
) O
is O
essential O
for O
the O
normal O
assembly O
of O
complex O
Asn O
- O
linked O
glycans RARE
. O

These O
patients O
failed O
to O
respond O
to O
intravenous O
cyclophosphamide O
and O
steroids O
and O
were O
then O
changed O
to O
receive O
oral O
cyclosporine O
A O
, O
at O
a O
dose O
of O
5 O
mg O
/ O
kg O
/ O
day O
. O

The O
predicted O
amino O
acid O
sequence O
is O
78 O
. O
0 O
% O
identical O
to O
the O
cytoplasmic I-GENE
dynein I-GENE
heavy I-GENE
chain I-GENE
of I-GENE
Neurospora I-GENE
crassa I-GENE
, O
70 O
. O
2 O
% O
identical O
to O
that O
of O
Aspergillus O
nidulans RARE
and O
24 O
. O
8 O
% O
identical O
to O
that O
of O
Saccharomyces O
cerevisiae O
. O

The O
DNA O
binding O
activities O
of O
the O
three O
repressor O
preparations O
were O
studied O
using O
fragments O
containing O
CIRs RARE
( O
CIR3 NUMERIC
- O
CIR6 NUMERIC
) O
from O
the O
essential O
early O
region O
as O
templates O
for O
DNase I-GENE
I I-GENE
footprinting O
. O

Molecular O
modelling RARE
suggested O
that O
the O
tetramerization RARE
domain O
was O
a O
four O
- O
helix O
bundle O
, O
stabilized O
by O
interactions O
of O
seven O
conserved O
aromatic O
amino O
acids O
. O

In O
the O
present O
study O
, O
we O
sought O
to O
investigate O
whether O
constitutive O
NF I-GENE
- I-GENE
kappaB I-GENE
activity O
in O
chronically RARE
HIV O
- O
1 O
- O
infected O
promonocytic RARE
U937 O
( O
U9 NUMERIC
- O
IIIB O
) O
and O
myeloblastic RARE
PLB ALLCAPS
- O
985 NUMERIC
( O
PLB ALLCAPS
- O
IIIB O
) O
cells O
affects O
apoptotic O
signaling O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
silymarin RARE
may O
exert O
a O
strong O
anticarcinogenic RARE
effect O
against O
PCA ALLCAPS
and O
that O
this O
effect O
is O
likely O
to O
involve O
impairment O
of O
erbB1 NUMERIC
- O
SHC ALLCAPS
- O
mediated O
signaling O
pathway O
, O
induction O
of O
CDKIs RARE
, O
and O
a O
resultant RARE
G1 O
arrest O
. O

In O
connective O
tissue O
, O
cell O
structure O
contributes O
to O
type I-GENE
I I-GENE
collagen I-GENE
expression O
. O

To O
explore O
the O
function O
of O
human O
SINA ALLCAPS
- I-GENE
homologous I-GENE
( I-GENE
Siah RARE
) I-GENE
proteins I-GENE
, O
expression O
plasmids O
encoding O
Siah RARE
- I-GENE
1A NUMERIC
were O
transiently O
transfected O
into O
293 O
epithelial O
cells O
and O
GM701 NUMERIC
fibroblast O
cells O
, O
resulting O
in O
growth O
arrest O
without O
induction O
of O
apoptosis O
. O

A O
point O
mutation O
in O
Galphao RARE
and O
Galphai1 NUMERIC
blocks O
interaction O
with O
regulator O
of O
G I-GENE
protein I-GENE
signaling O
proteins O
. O

Indeed O
, O
it O
is O
shown O
that O
it O
mediates O
the O
formation O
of O
disulfide O
- O
linked O
homodimers O
and O
that O
the O
formation O
of O
homo RARE
- O
and O
heterodimers O
are O
mutually RARE
excluded O
. O

N O
., O
and O
Fanning RARE
, O
E O
. O

We O
have O
shown O
previously O
that O
GH3 NUMERIC
cells O
transfected O
with O
the O
rat I-GENE
GnRH I-GENE
receptor I-GENE
cDNA I-GENE
( O
GGH3 NUMERIC
- O
1 O
' O
cells O
) O
support O
the O
expression O
of O
a O
cotransfected O
fusion O
gene O
composed O
of O
797 NUMERIC
base O
pairs O
of O
rat I-GENE
LHbeta RARE
gene I-GENE
5 I-GENE
'- I-GENE
flanking I-GENE
sequence I-GENE
and O
the O
first O
5 O
base O
pairs O
of O
the O
5 O
'- O
untranslated O
region O
fused O
to O
a O
luciferase I-GENE
reporter I-GENE
(- I-GENE
797 NUMERIC
/+ RARE
5LHbetaLUC NUMERIC
) I-GENE
and O
respond O
to O
a O
GnRH I-GENE
agonist O
with O
a O
10 O
- O
fold O
stimulation O
of O
activity O
. O

The O
5 O
'- O
flanking O
region O
, O
from O
nucleotide O
- O
837 NUMERIC
to O
- O
336 NUMERIC
, O
contains O
TATA O
and O
inverted O
CAAT O
boxes O
as O
well O
as O
GATA I-GENE
- I-GENE
1 I-GENE
/ O
SP1 I-GENE
erythroid O
- O
specific O
cis O
- O
acting O
regulatory O
elements O
. O

We O
established O
the O
radiosensitive RARE
cell O
line O
SX9 NUMERIC
from O
mammary O
carcinoma O
cell O
line O
FM3A NUMERIC
. O

In O
patients O
with O
type O
IA O
maple RARE
syrup RARE
urine O
disease O
, O
the O
E1alpha NUMERIC
subunit I-GENE
is O
affected O
, O
resulting O
in O
the O
loss O
of O
E1 I-GENE
and O
branched I-GENE
- I-GENE
chain I-GENE
ketoacid RARE
dehydrogenase I-GENE
catalytic O
activities O
. O

Results O
showed O
that O
the O
mean O
bond O
strength O
of O
H O
. O
T O
. O
V O
. O
specimens O
ranged O
from O
9 O
. O
6 O
to O
13 O
. O
12 O
kg O
/ O
cm2 O
, O
while O
the O
mean O
bond O
strength O
of O
R O
. O
T O
. O
V O
. O
specimens O
ranged O
from O
0 O
. O
36 O
to O
1 O
. O
75 O
kg O
/ O
cm2 O
. O

OBJECTIVES O
: O
To O
measure O
coagulation I-GENE
factor I-GENE
VIII I-GENE
: I-GENE
coagulant RARE
( O
F I-GENE
. I-GENE
VIII I-GENE
: I-GENE
C I-GENE
) O
and O
C1 I-GENE
- I-GENE
esterase I-GENE
inhibitor I-GENE
( O
C1 I-GENE
- I-GENE
INH ALLCAPS
), O
hemostasis O
- O
associated O
acute O
- O
phase O
reactant RARE
proteins O
and O
coagulation I-GENE
factors I-GENE
VII I-GENE
( O
F I-GENE
. I-GENE
VII I-GENE
), O
IX O
( O
F I-GENE
. I-GENE
IX I-GENE
), O
and O
X O
( O
F I-GENE
. I-GENE
X I-GENE
), O
hemostasis O
proteins O
not O
associated O
with O
an O
acute O
- O
phase O
response O
, O
in O
a O
select O
population O
of O
horses O
with O
colic RARE
and O
hemostasis O
abnormalities O
, O
and O
presumed O
to O
have O
acute O
- O
phase O
changes O
. O

RESULTS O
: O
Horses RARE
with O
colic RARE
had O
significantly O
higher O
fibrinogen I-GENE
concentration O
, O
greater O
alpha I-GENE
2AP NUMERIC
and O
protein I-GENE
C I-GENE
activities O
, O
and O
longer O
PT O
and O
APTT ALLCAPS
than O
did O
healthy O
horses O
. O

The O
data O
suggest O
that O
plasminogen I-GENE
, O
alpha I-GENE
2AP NUMERIC
, O
and O
C1 I-GENE
- I-GENE
INH ALLCAPS
, O
should O
be O
considered O
equine O
acute O
- O
phase O
proteins O
. O

None O
of O
the O
patients O
was O
obese O
. O

Marked O
elevation O
of O
creatine I-GENE
kinase I-GENE
was O
observed O
while O
serum O
albumin I-GENE
, O
immunoglobulin I-GENE
, O
and O
complement O
were O
decreased O
. O

DESIGN O
AND O
METHODS O
: O
Case RARE
study O
. O

METHODS O
: O
A O
total O
of O
15 O
pigs O
were O
randomised O
to O
ligation O
of O
left O
marginal RARE
arteries O
( O
infarction O
group O
, O
n O
= O
5 O
), O
to O
TMLR ALLCAPS
of O
the O
left O
lateral O
wall O
using O
a O
holmium RARE
: O
yttrium RARE
- O
aluminium RARE
garnet RARE
( O
Ho RARE
: O
YAG ALLCAPS
) O
laser O
( O
laser O
group O
, O
n O
= O
5 O
), O
and O
to O
both O
( O
laser O
- O
infarction O
group O
, O
n O
= O
5 O
). O

RACK1 NUMERIC
, O
a O
receptor O
for O
activated I-GENE
C I-GENE
kinase I-GENE
and O
a O
homolog O
of O
the O
beta O
subunit O
of O
G I-GENE
proteins I-GENE
, O
inhibits O
activity O
of O
src I-GENE
tyrosine I-GENE
kinases I-GENE
and O
growth O
of O
NIH O
3T3 O
cells O
. O

Peptide RARE
sequences O
of O
the O
zinc I-GENE
finger I-GENE
protein I-GENE
Ttk RARE
and O
the O
transcription I-GENE
factor I-GENE
Adf RARE
- I-GENE
1 I-GENE
were O
obtained O
. O

The O
same O
IL I-GENE
- I-GENE
4 I-GENE
- O
inducible O
reporter O
gene O
is O
also O
synergistically O
activated O
by O
the O
endogenous I-GENE
Stat6 NUMERIC
and O
NF I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
in O
IL I-GENE
- I-GENE
4 I-GENE
- O
stimulated O
I O
. O
29mu NUMERIC
B O
lymphoma O
cells O
. O

HEF1 I-GENE
, O
p130 I-GENE
( O
Cas I-GENE
), O
and O
Efs RARE
/ O
Sin RARE
constitute O
a O
family O
of O
multidomain RARE
docking RARE
proteins O
that O
have O
been O
implicated O
in O
coordinating RARE
the O
regulation O
of O
cell O
adhesion O
. O

In O
support O
of O
a O
role O
at O
the O
spindle O
, O
two O
- O
hybrid O
library O
screening O
with O
HEF1 I-GENE
identifies O
the O
human O
homolog O
of O
the O
G2 I-GENE
/ I-GENE
M I-GENE
spindle I-GENE
- I-GENE
regulatory I-GENE
protein I-GENE
Dim1p NUMERIC
as O
a O
specific O
interactor RARE
with O
a O
region O
of O
HEF1 I-GENE
encompassed RARE
in O
p55 I-GENE
( O
HEF1 I-GENE
). O

Our O
data O
showed O
that O
activation O
of O
the O
raf I-GENE
- O
ERK I-GENE
pathway O
led O
to O
activation O
of O
TF I-GENE
expression O
in O
breast O
carcinoma O
cells O
and O
suggested O
that O
constitutive O
activation O
of O
this O
pathway O
leads O
to O
high O
TF I-GENE
expression O
in O
MDA ALLCAPS
- O
MB O
- O
231 O
cells O
. O

However O
, O
a O
zinc O
- O
depleted O
enzyme O
was O
obtained O
after O
prolonged O
dialysis O
against O
the O
specific O
chelating RARE
agent O
1 O
, O
10 O
- O
phenanthroline RARE
. O

All O
patients O
diagnosed O
of O
H O
. O
influenza O
type O
b O
meningitis O
were O
less O
than O
3 O
years O
old O
. O

The O
lines O
also O
differed O
in O
postsynaptic RARE
, O
but O
not O
presynaptic RARE
, O
5 I-GENE
- I-GENE
HT1A NUMERIC
receptors I-GENE
. O

Convulsive RARE
seizure O
during O
a O
treatment O
with O
interferon I-GENE
alpha I-GENE
for O
chronic O
viral O
hepatitis O
C O

Immunohistochemically RARE
, O
anticytokeratin RARE
19 I-GENE
antibody I-GENE
revealed O
strong O
staining O
in O
both O
epithelial O
and O
sarcomatous RARE
MPM ALLCAPS
tissues O
. O

Genetic O
studies O
in O
Drosophila O
have O
led O
to O
the O
identification O
of O
several O
components O
of O
the O
Notch I-GENE
pathway O
. O

The O
bZP2 NUMERIC
cDNA O
( O
115 O
- O
1914 NUMERIC
nt O
, O
1 O
. O
8 O
kb O
), O
excluding O
sequences O
coding O
for O
N O
- O
terminal O
signal O
sequence O
and O
C O
- O
terminal O
transmembranelike RARE
domain O
, O
was O
PCR O
amplified O
and O
Sac1 NUMERIC
- O
Sal1 NUMERIC
restricted O
fragment O
cloned O
in O
frame O
downstream O
of O
the O
T5 NUMERIC
promoter O
under O
the O
lac I-GENE
operator I-GENE
control O
in O
a O
pQE LASTCAP
- O
30 O
vector O
. O

Control O
subjects O
' O
evoked O
potentials O
( O
EPs RARE
) O
were O
characterized O
by O
an O
initial O
positivity RARE
in O
the O
90 O
- O
140 O
ms O
range O
( O
P1 O
) O
at O
the O
temporo RARE
- O
occipital RARE
site O
. O

Class I-GENE
I I-GENE
alpha1 I-GENE
, I-GENE
2 I-GENE
- I-GENE
mannosidases RARE
play O
an O
essential O
role O
in O
the O
elaboration RARE
of O
complex O
and O
hybrid O
N O
- O
glycans RARE
in O
mammalian O
cells O
. O

Structural O
features O
of O
the O
minimal O
DNA O
binding O
domain O
( O
M98 NUMERIC
- O
F219 NUMERIC
) O
of O
human I-GENE
nucleotide I-GENE
excision I-GENE
repair I-GENE
protein I-GENE
XPA ALLCAPS
. O

Amongst RARE
other O
qualities RARE
, O
the O
book RARE
' O
s O
importance O
lies O
in O
the O
fact O
that O
it O
associates O
an O
elaborate RARE
theoretical RARE
construction O
with O
the O
empirical RARE
data O
, O
working O
within O
the O
possibilities O
provided O
by O
late O
19th NUMERIC
- O
century RARE
moral RARE
statistics RARE
. O

The O
results O
point O
to O
the O
effectiveness O
of O
the O
educational RARE
intervention O
. O

The O
mechanistic RARE
implications O
of O
aromatic O
non O
- O
responsiveness O
of O
autonomously O
expressed O
A O
- O
domain O
, O
despite O
its O
demonstrated O
ability O
to O
bind O
phenol RARE
, O
are O
discussed O
. O

RESULTS O
: O
Acetabular RARE
index O
returned O
to O
normal O
gradually O
as O
the O
time O
went RARE
by O
and O
significantly O
within O
one O
year O
after O
the O
reduction O
of O
developmental O
dislocation O
of O
the O
hip O
. O

Recently O
, O
extremely O
high O
levels O
of O
endothelin I-GENE
- I-GENE
1 I-GENE
( O
ET I-GENE
- I-GENE
1 I-GENE
) O
were O
detected O
in O
the O
pericardial RARE
fluid O
of O
patients O
undergoing O
cardiac O
surgery O
. O

Consequently RARE
, O
it O
is O
not O
known O
how O
knee RARE
loading O
changes O
following O
ACL ALLCAPS
transection RARE
, O
and O
how O
it O
contributes O
to O
cartilage O
degeneration O
. O

We O
show O
that O
the O
surfaces RARE
of O
tracheal O
cartilage O
matrix O
are O
collagen I-GENE
- O
rich O
and O
surround RARE
a O
proteoglycan O
- O
rich O
core O
. O

Comparative O
mapping O
of O
the O
Brassica RARE
S I-GENE
locus I-GENE
region I-GENE
and O
its O
homeolog RARE
in O
Arabidopsis O
. O

Roles RARE
of O
the O
Candida I-GENE
albicans I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
homolog I-GENE
, O
Cek1p NUMERIC
, O
in O
hyphal RARE
development O
and O
systemic O
candidiasis O
. O

Neither O
the O
reaction O
of O
monosaccharides RARE
nor O
the O
disaccharides RARE
with O
beta O
- O
alanine O
resulted O
in O
the O
formation O
of O
maltol RARE
. O

In O
most O
subjects O
, O
markers O
of O
bone O
formation O
and O
resorption O
were O
normal O
. O

Analysis O
of O
a O
Mac1p NUMERIC
mutant I-GENE
, O
refractile RARE
for O
copper O
- O
dependent O
repression O
of O
the O
Cu I-GENE
( I-GENE
I I-GENE
) I-GENE
transport I-GENE
genes I-GENE
, O
showed O
an O
aberrant O
pattern O
of O
CUP1 NUMERIC
expression O
and O
copper O
sensitivity O
. O

The O
DNA O
sequencing O
of O
the O
recombinant O
clones O
revealed O
the O
expression O
of O
RXR I-GENE
alpha I-GENE
and O
RXR I-GENE
beta I-GENE
. O

A O
stratified RARE
random O
sample O
of O
20 O
active O
employees RARE
from O
a O
cohort O
of O
phenoxy RARE
herbicide RARE
workers O
was O
selected O
in O
1995 O
for O
determining O
PCDD ALLCAPS
and O
PCDF ALLCAPS
congeners RARE
in O
blood O
lipids O
to O
assess O
the O
extent O
of O
past O
PCDD ALLCAPS
and O
PCDF ALLCAPS
exposure O
in O
this O
cohort O
and O
whether O
that O
exposure O
might O
explain O
site O
- O
specific O
cancer O
findings O
in O
the O
total O
cohort O
. O

The O
clinical O
and O
laboratory O
features O
of O
72 O
children O
with O
Henoch RARE
- O
Schonlein RARE
purpura O
( O
HSP ALLCAPS
) O
were O
examined O
to O
determine O
if O
there O
were O
associations O
between O
the O
laboratory O
indices O
-- O
including O
white O
blood O
cell O
( O
WBC O
) O
counts O
, O
serum I-GENE
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
( O
CRP I-GENE
) O
levels O
, O
platelet O
( O
PLT ALLCAPS
) O
counts O
-- O
and O
the O
clinical O
manifestations O
of O
acute O
HSP ALLCAPS
. O

We O
provide O
community O
metabolic O
data O
that O
indicate O
that O
large O
changes O
in O
CO2 O
concentration O
can O
occur O
in O
coral RARE
reef RARE
waters RARE
via O
biogeochemical RARE
processes O
not O
directly O
associated O
with O
photosynthesis RARE
, O
respiration O
, O
calcification RARE
, O
and O
CaCO3 NUMERIC
dissolution O
. O

In O
contrast O
to O
other O
known O
retroviruses RARE
, O
the O
FV ALLCAPS
pol I-GENE
genes I-GENE
are O
expressed O
via O
spliced O
transcripts O
. O

Substitution O
of O
bulky RARE
hydrophobic O
residues O
with O
charged O
residues O
within O
PEP1 NUMERIC
affects O
the O
fusion O
activity O
of O
the O
S I-GENE
protein I-GENE
without O
affecting O
processing O
and O
surface O
expression O
. O

Tributyltin RARE
and O
its O
breakdown RARE
products O
, O
mono O
- O
and O
di RARE
- O
butyltin RARE
, O
were O
determined O
in O
water O
birds O
collected O
from O
Lake RARE
Huron RARE
( O
the O
Great RARE
Lakes RARE
), O
marine RARE
coastal RARE
United O
States RARE
, O
and O
the O
west RARE
coast RARE
of O
British RARE
Columbia RARE
, O
Canada RARE
. O

The O
5 O
' O
flanking O
region O
of O
the O
CD1 NUMERIC
gene I-GENE
contained O
the O
binding O
motifs O
for O
two O
cytokine O
- O
inducible O
transcription O
factors O
, O
NF I-GENE
- I-GENE
IL2 NUMERIC
- I-GENE
A I-GENE
and O
NF I-GENE
- I-GENE
IL6 I-GENE
. O

Fregnac RARE
, O
M O
. O

GLRaV LASTCAP
- O
2 O
is O
the O
only O
closterovirus RARE
, O
so O
far O
, O
that O
matches O
the O
genome O
organization O
of O
the O
type O
member O
of O
the O
group O
, O
BYV ALLCAPS
, O
and O
thus O
can O
be O
unambiguously RARE
classified O
as O
a O
definitive O
member O
of O
the O
genus O
Closterovirus RARE
. O

Demographic RARE
and O
clinical O
data O
were O
compared O
with O
a O
control O
group O
of O
339 NUMERIC
healthy O
age O
- O
matched O
women O
and O
with O
a O
sample O
of O
224 NUMERIC
women O
with O
wrist O
fracture O
. O

Combined O
expression O
of O
c I-GENE
- I-GENE
Jun I-GENE
and O
p65 I-GENE
induced O
vigorous RARE
transcription O
of O
IL I-GENE
- I-GENE
2 I-GENE
promoter O
- O
and O
CD28RE NUMERIC
- I-GENE
driven I-GENE
reporter I-GENE
constructs I-GENE
in O
both O
LFA ALLCAPS
- I-GENE
3 I-GENE
- O
and O
B7 I-GENE
- I-GENE
1 I-GENE
- O
costimulated RARE
Jurkat O
cells O
. O

Identical RARE
results O
were O
obtained O
when O
transfections O
and O
mobility O
shift O
assays O
were O
performed O
in O
primary O
rat O
hepatocytes O
in O
which O
the O
endogenous O
ALS ALLCAPS
gene I-GENE
is O
expressed O
. O

This O
E O
box O
sequence O
( O
CACGTG ALLCAPS
) O
is O
identical O
to O
the O
binding O
element O
for O
USF I-GENE
( O
upstream I-GENE
stimulatory I-GENE
factor I-GENE
), O
a O
member O
of O
the O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
. O

Interferon I-GENE
beta I-GENE
therapy O
was O
discontinued RARE
for O
4 O
weeks O
. O

Liquid RARE
chromatographic O
method O
for O
analysis O
of O
all O
- O
rac RARE
- O
alpha O
- O
tocopheryl RARE
acetate O
and O
retinyl RARE
palmitate RARE
in O
milk O
- O
based O
infant O
formula O
using O
matrix O
solid O
- O
phase O
dispersion O
. O

We O
specially RARE
devised RARE
3 O
types O
of O
turbo RARE
pumps RARE
, O
a O
centrifugal RARE
pump O
( O
CFP ALLCAPS
), O
a O
mixed O
flow O
pump O
( O
MFP ALLCAPS
), O
and O
an O
axial O
flow O
pump O
( O
AFP O
), O
and O
analyzed O
their O
in O
vitro O
performance O
. O

Examination O
of O
the O
mitochondrial I-GENE
bc1 NUMERIC
complex I-GENE
crystal I-GENE
structure I-GENE
[ O
Zhang RARE
, O
Z O
., O
Huang RARE
, O
L O
., O
Shulmeister RARE
, O
V O
. O

Two O
protease O
- O
resistant O
fragments O
spanning O
the O
N O
- O
and O
C O
- O
terminal O
halves RARE
of O
the O
nuclease O
were O
identified O
using O
different O
proteases O
which O
cleave RARE
the O
protein O
in O
the O
same O
region O
. O

The O
side O
- O
to O
- O
side O
difference O
was O
statistically O
significant O
at O
EXT ALLCAPS
30 O
degrees O
/ O
s O
and O
60 O
degrees O
/ O
s O
( O
p O
< O
0 O
. O
05 O
). O

CONCLUSION O
: O
In O
women O
who O
want RARE
or O
require O
conservative O
management O
of O
grade O
4 O
prolapse RARE
and O
are O
unable O
to O
retain RARE
a O
single O
pessary RARE
, O
the O
placement O
of O
two O
pessaries RARE
often O
will O
be O
successful O
. O

The O
ability O
to O
maintain O
expression O
of O
FAS1 NUMERIC
in O
nmt1 NUMERIC
- O
451Dino2 NUMERIC
Delta O
cells O
suggests O
the O
existence O
of O
another O
transcription O
factor O
, O
or O
factors O
, O
whose O
expression O
/ O
activity O
is O
inversely O
related O
to O
overall O
levels O
of O
cellular O
protein O
N O
- O
myristoy RARE
- O
lation RARE
. O

Rev I-GENE
- O
erbAalpha RARE
/ I-GENE
beta I-GENE
), O
Mxi RARE
- I-GENE
1 I-GENE
and O
Mad RARE
bHLH O
- O
zip RARE
proteins O
and O
the O
oncoproteins O
PLZF I-GENE
and O
LAZ3 NUMERIC
/ O
BCL6 NUMERIC
is O
mediated O
by O
the O
corepressors RARE
N I-GENE
- I-GENE
CoR LASTCAP
and O
SMRT I-GENE
. O

The O
identified O
isolates O
of O
CSF O
( O
20 O
of O
29 O
) O
were O
: O
ECHO O
30 O
( O
9 O
), O
ECHO O
11 O
( O
7 O
), O
ECHO O
9 O
( O
3 O
) O
and O
ECHO O
7 O
( O
1 O
). O

There O
was O
no O
evidence O
of O
any O
persistent O
oscillation RARE
within O
the O
ULF ALLCAPS
band O
. O

The O
ParaSight RARE
- O
F O
test O
alone O
was O
used O
to O
monitor O
serum O
antigen O
levels O
after O
treatment O
in O
24 O
patients O
. O

The O
purified O
recombinant O
protein O
was O
assayed O
for O
its O
enzyme O
activity O
by O
monitoring O
transfer O
of O
[ O
3H O
] O
methyl O
groups O
from O
the O
substrate O
DNA O
to O
the O
MGMT ALLCAPS
protein I-GENE
; O
the O
activity O
was O
found O
to O
be O
stable O
at O
90 O
degrees O
C O
for O
at O
least O
30 O
min O
. O

A O
deproteinization RARE
procedure O
was O
coupled O
with O
a O
reversed O
- O
phase O
HPLC O
separation O
using O
a O
250x4 NUMERIC
. O
6 O
mm O
I O
. O
D O
. O

Elimination O
of O
the O
inducible O
response O
requires O
simultaneous O
mutation O
of O
both O
sequences O
, O
however O
, O
in O
the O
presence O
of O
an O
intact O
EpRE LASTCAP
the O
upstream O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
is O
irrelevant RARE
to O
induction O
. O

Three O
high I-GENE
mobility I-GENE
group I-GENE
- I-GENE
like I-GENE
sequences I-GENE
within O
a O
48 O
- O
base O
pair O
enhancer O
of O
the O
Col2a1 NUMERIC
gene I-GENE
are O
required O
for O
cartilage O
- O
specific O
expression O
in O
vivo O
. O

The O
sequence O
contains O
an O
open O
reading O
frame O
of O
1744 NUMERIC
nt O
in O
the O
virus O
- O
sense O
strand O
, O
a O
3 O
' O
untranslated O
region O
of O
1360 NUMERIC
nt O
and O
a O
3 O
' O
poly O
( O
A O
) O
tail O
. O

A O
phylogenetic O
analysis O
of O
the O
reverse I-GENE
transcriptase I-GENE
domain I-GENE
confirms RARE
our O
differential O
genetic O
assessment O
that O
Cyclops RARE
from O
pea RARE
is O
a O
novel O
element O
with O
no O
specific O
relationship O
to O
the O
previously O
described O
Gypsy RARE
- I-GENE
like I-GENE
elements I-GENE
from O
plants O
. O

At O
physiological O
doses O
, O
either O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
or O
insulin I-GENE
turned O
out O
to O
be O
as O
potent O
as O
dibutyryl RARE
cAMP O
( O
dbcAMP LASTCAP
) O
in O
increasing O
UCP1 NUMERIC
gene I-GENE
transcription O
rate O
( O
1 O
h O
) O
and O
also O
UCP1 NUMERIC
mRNA I-GENE
accumulation O
( O
3 O
h O
), O
their O
maximal O
effect O
( O
15 O
- O
fold O
increase O
) O
reached O
upon O
treatment O
for O
24 O
h O
. O

In O
addition O
, O
insulin I-GENE
induced O
AP I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
activity O
, O
this O
effect O
being O
totally RARE
prevented O
in O
the O
presence O
of O
MEK I-GENE
- I-GENE
1 I-GENE
inhibitor O
. O

Essentially RARE
, O
2 O
'- O
O O
- O
methyl O
oligoribonucleotides RARE
( O
2 O
' O
OMeRNA LASTCAP
) O
were O
delivered O
to O
the O
nuclei O
of O
primary O
mdx RARE
myoblasts O
in O
culture O
. O

A O
large O
deletion O
in O
the O
CTD I-GENE
- I-GENE
binding I-GENE
motif I-GENE
blocks O
down O
- O
regulation O
but O
does O
not O
affect O
the O
essential O
function O
of O
Nrd1 NUMERIC
. O

Regulation O
of O
the O
human O
p21 I-GENE
/ O
WAF1 I-GENE
/ O
Cip1 I-GENE
promoter O
in O
hepatic O
cells O
by O
functional O
interactions O
between O
Sp1 I-GENE
and O
Smad I-GENE
family I-GENE
members I-GENE
. O

RESULTS O
: O
We O
isolated O
a O
C O
. O
elegans O
cDNA O
that O
encoded O
a O
protein O
which O
was O
similar O
to O
, O
but O
not O
exactly RARE
homologous O
with O
mammalian O
p120 NUMERIC
Ras I-GENE
- O
GAP I-GENE
. O

The O
weak O
base O
ketoconazole RARE
showed O
complete O
dissolution O
from O
a O
tablet O
formulation O
in O
Simulated RARE
Gastric RARE
Fluid RARE
without O
pepsin RARE
( O
SGFsp RARE
) O
within O
30 O
minutes O
, O
70 O
% O
dissolution O
in O
2 O
hours O
under O
fed O
state O
simulated O
upper O
jejunal RARE
conditions O
but O
only O
6 O
% O
dissolution O
in O
2 O
hours O
under O
fasted O
state O
conditions O
. O

In O
mammals O
, O
the O
Rb I-GENE
protein I-GENE
interacts O
specifically O
with O
D I-GENE
- I-GENE
type I-GENE
cyclins RARE
and O
regulates O
cell O
proliferation O
by O
binding O
and O
inhibiting O
E2F I-GENE
transcription I-GENE
factors I-GENE
. O

In O
addition O
to O
the O
signals O
obtained O
by O
ligation O
of O
the O
TCR I-GENE
, O
T O
cells O
need O
additional O
, O
co O
- O
stimulatory O
signals O
to O
be O
activated O
. O

Moreover O
, O
the O
observation O
of O
enhanced O
luteal I-GENE
HSP ALLCAPS
- I-GENE
27 I-GENE
phosphorylation O
in O
vivo O
, O
in O
late O
pregnancy O
, O
when O
PKC I-GENE
- I-GENE
delta I-GENE
is O
abundant O
and O
active O
, O
suggests O
that O
select O
PKC I-GENE
family I-GENE
members I-GENE
contribute O
to O
sHSP LASTCAP
phosphorylation O
events O
in O
vivo O
. O

We O
characterized O
the O
structure O
of O
this O
leader O
mRNA O
by O
using O
the O
program O
Mfold RARE
and O
a O
combination O
of O
nested RARE
and O
internal O
deletions O
transcriptionally O
fused O
to O
a O
promoterless O
lac I-GENE
operon I-GENE
. O

The O
importance O
of O
these O
sites O
for O
transcriptional O
activation O
was O
studied O
by O
site O
- O
directed O
mutagenesis O
followed O
by O
promoter O
function O
analysis O
of O
the O
mutants O
with O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
system O
. O

Routine RARE
blood O
examination O
showed O
leukocytosis RARE
, O
thrombocytopenia O
, O
positive O
CRP I-GENE
, O
and O
elevated O
myocardial O
enzymes O
. O

Previous O
studies O
have O
suggested O
that O
moderate O
cooling RARE
increases O
the O
responsiveness O
of O
vascular I-GENE
alpha2 I-GENE
- I-GENE
adrenoceptors I-GENE
. O

Two O
members O
of O
the O
Cbl I-GENE
family I-GENE
have O
since O
been O
defined O
in O
mammals O
( O
c I-GENE
- I-GENE
Cbl I-GENE
and O
Cbl I-GENE
- I-GENE
b I-GENE
), O
one O
in O
C O
. O
elegans O
( O
Sli RARE
- I-GENE
1 I-GENE
) O
and O
one O
in O
Drosophila O
( O
D I-GENE
- I-GENE
Cbl I-GENE
). O

Anti I-GENE
- I-GENE
PTB I-GENE
antibodies I-GENE
did O
not O
inhibit O
the O
binding O
of O
PTB I-GENE
to O
RNA O
because O
they O
were O
able O
to O
supershift O
RNA I-GENE
- I-GENE
PTB I-GENE
complexes I-GENE
. O

The O
use O
of O
antibodies O
to O
the O
polypyrimidine RARE
tract I-GENE
binding I-GENE
protein I-GENE
( O
PTB I-GENE
) O
to O
analyze O
the O
protein O
components O
that O
assemble RARE
on O
alternatively O
spliced O
pre O
- O
mRNAs O
that O
use O
distant O
branch O
points O
. O

The O
therapeutic O
use O
of O
botulinum I-GENE
toxin I-GENE
( O
Botox RARE
) O
is O
increasing O
in O
popularity RARE
. O

The O
viral I-GENE
oncoprotein I-GENE
E1A I-GENE
inhibits O
NFAT I-GENE
- O
dependent O
transactivation O
in O
a O
p300 I-GENE
- O
dependent O
manner O
. O

We O
have O
applied O
the O
mRNA O
differential O
display O
method O
to O
compare O
and O
analyze O
mRNAs O
prepared O
from O
five O
normal O
nasopharyngeal RARE
epithelial O
cell O
cultures O
and O
five O
nasopharyngeal RARE
carcinoma O
cell O
lines O
. O

Similar O
experiments O
with O
TR I-GENE
support O
the O
high O
affinity O
of O
RIP140 NUMERIC
to O
the O
RXR I-GENE
subunit I-GENE
and O
also O
suggest O
that O
either O
partner O
in O
the O
TR I-GENE
/ O
RXR I-GENE
heterodimer O
can O
independently O
respond O
to O
ligand O
. O

SETTING O
: O
University O
hospital O
- O
based O
, O
tertiary O
care O
infertility O
center O
. O

RESULT ALLCAPS
( O
S O
): O
In O
patients O
with O
elevated O
FSH I-GENE
levels O
on O
cycle O
day O
3 O
, O
a O
low O
oocyte O
yield O
was O
achieved O
( O
7 O
versus O
11 O
) O
and O
a O
high O
number O
of O
ampules RARE
of O
hMG LASTCAP
was O
necessary O
( O
56 O
versus O
33 O
). O

RESULTS O
: O
Of O
the O
patients O
with O
IS ALLCAPS
, O
67 O
% O
had O
significantly O
greater O
values O
of O
directional RARE
preponderance RARE
on O
the O
OVAR ALLCAPS
test O
( O
a O
measure O
of O
otolith RARE
system O
imbalance RARE
) O
compared O
with O
control O
subjects O
. O

In O
the O
ePTFE LASTCAP
specimens O
, O
tissue O
coverage RARE
had O
increased O
. O

As O
predicted O
by O
the O
Wing RARE
and O
Kristofferson RARE
model O
, O
the O
durations O
of O
successive O
ISIs RARE
tended O
to O
be O
negatively O
correlated O
. O

Thus O
, O
included O
in O
the O
KG1a NUMERIC
EST O
dataset RARE
are O
candidates RARE
for O
new O
human O
genes O
that O
may O
play O
roles O
in O
hematopoietic O
differentiative RARE
progression O
and O
lineage O
commitment RARE
. O

We O
found O
the O
following O
: O
Specific O
mutations O
affected O
the O
precise O
carbohydrate O
structure O
and O
folding O
of O
the O
HA I-GENE
trimer RARE
. O

The O
results O
show O
that O
ROS O
production O
by O
viable O
spermatozoa O
is O
highly O
correlated O
with O
the O
concentration O
of O
PMN I-GENE
elastase I-GENE
and O
the O
number O
of O
both O
peroxidase I-GENE
- O
positive O
and O
round O
cells O
. O

Yeast I-GENE
U1 I-GENE
snRNP I-GENE
is O
considerably O
more O
complex O
than O
its O
metazoan O
counterpart O
, O
which O
suggests O
possible O
differences O
between O
yeast O
and O
metazoa RARE
in O
early O
splicing O
events O
. O

Yeast I-GENE
U1 I-GENE
snRNP I-GENE
therefore O
contains O
16 O
different O
proteins O
, O
including O
seven O
snRNP I-GENE
core I-GENE
proteins I-GENE
, O
three O
homologues O
of O
the O
metazoan I-GENE
U1 I-GENE
snRNP I-GENE
- I-GENE
specific I-GENE
proteins I-GENE
, O
and O
six O
yeast I-GENE
- I-GENE
specific I-GENE
U1 I-GENE
snRNP I-GENE
proteins I-GENE
. O

After O
the O
first O
cycle O
, O
18 O
cases O
were O
treated O
at O
dose O
level O
1 O
, O
after O
a O
second O
cycle O
, O
13 O
cases O
were O
treated O
at O
dose O
level O
2 O
. O

The O
opioid O
antagonist O
naltrexone O
( O
0 O
. O
01 O
- O
1 O
. O
0 O
mg O
/ O
kg O
) O
antagonized RARE
the O
discriminative RARE
stimulus O
effects O
of O
heroin RARE
, O
but O
naltrexone O
at O
doses O
up O
to O
10 O
mg O
/ O
kg O
had O
no O
effect O
on O
the O
discriminative RARE
stimulus O
effects O
of O
cocaine O
. O

In O
this O
study O
we O
examined O
hepatic O
stellate RARE
cell O
regulation O
of O
M6P NUMERIC
/ O
IGFIIR ALLCAPS
expression O
and O
found O
that O
M6P NUMERIC
/ O
IGFIIR ALLCAPS
mRNA O
transcript O
levels O
increased O
in O
stellate RARE
cells O
from O
rats O
exposed O
to O
carbon O
tetrachloride RARE
( O
CCl4 NUMERIC
), O
a O
potent O
fibrogenic RARE
stimulant RARE
. O

One O
cDNA O
clone O
designated O
NCoA LASTCAP
- O
62 O
, O
encoded O
a O
62 O
, O
000 O
- O
Da O
protein O
that O
is O
highly O
related O
to O
BX42 NUMERIC
, O
a O
Drosophila O
melanogaster O
nuclear O
protein O
involved O
in O
ecdysone O
- O
stimulated O
gene O
expression O
. O

These O
widely O
expressed O
proteins O
share O
a O
C O
- O
terminal O
region O
that O
bears RARE
significant O
sequence O
homology O
to O
a O
group O
of O
GDP I-GENE
/ I-GENE
GTP I-GENE
exchange I-GENE
proteins I-GENE
for O
the O
Rab3 NUMERIC
family I-GENE
of O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
. O

Whereas O
p82 NUMERIC
expression O
had O
no O
effect O
on O
ERK2 I-GENE
activation O
by O
p126 NUMERIC
, O
p70 I-GENE
completely O
abrogated O
this O
activity O
. O

The O
pre O
- O
mRNA O
splicing O
factor O
U2AF NUMERIC
( O
U2 I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
particle I-GENE
[ I-GENE
snRNP I-GENE
] I-GENE
auxiliary I-GENE
factor I-GENE
) O
plays O
a O
critical O
role O
in O
3 O
' O
splice O
site O
selection O
. O

The O
brackets RARE
were O
bonded RARE
to O
100 O
freshly RARE
extracted O
bovine O
incisors RARE
, O
and O
, O
after O
storage O
in O
tap O
water O
at O
room O
temperature O
for O
24 O
hours O
, O
they O
were O
subsequently O
tested O
in O
a O
shear O
mode O
using O
a O
universal RARE
testing O
machine O
. O

Exercise RARE
training O
has O
become O
increasingly RARE
important O
in O
the O
treatment O
of O
heart O
failure O
patients O
. O

The O
growth O
of O
Aer RARE
. O
hydrophila RARE
in O
filter O
- O
sterilized RARE
lettuce RARE
extract O
was O
completely O
inhibited O
by O
0 O
. O
1 O
% O
( O
v O
/ O
v O
) O
BMC ALLCAPS
whereas O
that O
of O
Ps RARE
. O
fluorescens RARE
was O
not O
significantly O
affected O
by O
1 O
% O
( O
v O
/ O
v O
) O
BMC ALLCAPS
. O

Despite O
continuous O
compliance O
, O
unexplained RARE
resurgence RARE
of O
serum O
ferritin I-GENE
levels O
occurred O
in O
4 O
/ O
7 O
patients O
of O
the O
' O
veteran RARE
' O
group O
after O
4 O
- O
5 O
years O
on O
L1 O
. O

Hematocrit RARE
and O
PaO2 O
did O
not O
change O
. O

Regulation O
of O
myosin I-GENE
phosphatase I-GENE
activity O
involves O
changes O
in O
subunit O
interactions O
, O
although O
molecular O
mechanisms O
are O
not O
defined O
. O

Commutative RARE
saccadic RARE
generator RARE
is O
sufficient O
to O
control O
a O
3 O
- O
D O
ocular O
plant O
with O
pulleys RARE
. O

The O
virus O
- O
associated O
VAI ALLCAPS
RNA O
of O
adenovirus O
is O
a O
small O
highly O
structured O
RNA O
that O
is O
required O
for O
the O
efficient O
translation O
of O
cellular O
and O
viral O
mRNAs O
at O
late O
times O
after O
infection O
. O

Structure O
of O
the O
gene O
encoding O
the O
human O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor O
p18 NUMERIC
and O
mutational O
analysis O
in O
breast O
cancer O
. O

The O
YccA LASTCAP
protein I-GENE
was O
found O
to O
be O
degraded O
in O
an O
FtsH LASTCAP
- O
dependent O
manner O
in O
vivo O
and O
in O
vitro O
, O
whereas O
the O
YccA11 NUMERIC
mutant I-GENE
protein I-GENE
, O
lacking O
eight O
amino O
acid O
residues O
within O
the O
amino O
- O
terminal O
cytoplasmic O
domain O
, O
was O
refractory O
to O
the O
degradation O
. O

The O
major O
type O
involves O
activator O
proteins O
that O
bind O
to O
DNA O
adjacent O
to O
where O
the O
RNA I-GENE
polymerase I-GENE
( O
RNAP I-GENE
) O
holoenzyme O
binds O
, O
usually O
assisting RARE
in O
recruitment O
of O
the O
RNAP I-GENE
to O
the O
promoter O
. O

A O
conserved O
role O
for O
L1 I-GENE
as O
a O
transmembrane O
link O
between O
neuronal O
adhesion O
and O
membrane O
cytoskeleton O
assembly O
. O

Atmospheric RARE
benzene RARE
, O
urinary O
muconic RARE
acid O
( O
tt RARE
- O
MA O
) O
and O
leukocyte I-GENE
alkaline I-GENE
phosphatase I-GENE
activity O
( O
LAPA ALLCAPS
) O
were O
evaluated O
among O
66 O
car RARE
mechanics RARE
, O
34 O
road RARE
tanker RARE
drivers RARE
, O
and O
28 O
nonexposed RARE
workers O
. O

It O
contains O
a O
5 O
'- O
noncoding O
region O
( O
NCR O
) O
of O
73 O
nucleotides O
, O
five O
open O
reading O
frames O
( O
ORFs O
1 O
to O
5 O
) O
which O
encode O
proteins O
with O
M O
( O
r O
) O
160 O
kDa O
RNA O
- O
dependent O
RNA O
polymerase O
( O
ORF1 O
), O
26 O
kDa O
movement O
protein O
1 O
( O
ORF2 O
), O
13 O
kDa O
movement O
protein O
2 O
( O
ORF3 O
), O
10 O
kDa O
movement O
protein O
3 O
( O
ORF4 NUMERIC
), O
24 O
kDa O
coat O
protein O
( O
OFR5 NUMERIC
), O
and O
a O
3 O
' O
NCR O
of O
76 O
nucleotides O
. O

After O
profound O
normovolemic RARE
hemodilution RARE
( O
Hct RARE
9 O
%) O
superiority RARE
of O
LV O
MC O
and O
LV O
diastolic O
properties O
was O
found O
, O
when O
myocardial O
oxygenation O
was O
supported O
by O
i O
. O
v O
. O
perflubron RARE
emulsion RARE
, O
a O
temporary O
O2 O
carrier O
. O

Sp1 I-GENE
and O
two O
Sp3 I-GENE
isoforms I-GENE
were O
detected O
as O
the O
primary O
cellular O
constituents RARE
of O
DNA O
- O
protein O
complexes O
formed O
with O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
proximal I-GENE
site I-GENE
. O

These O
genes O
may O
represent O
interesting RARE
targets O
for O
new O
therapeutic O
strategies O
. O

It O
could O
also O
inhibit O
C1q NUMERIC
- O
dependent O
haemolysis RARE
of O
both O
IgG I-GENE
- O
and O
IgM I-GENE
- O
sensitized RARE
erythrocytes RARE
. O

3 O
) O
and O
one O
distal O
(- O
11 O
. O
8 O
/- O
10 O
. O
9 O
), O
presented O
an O
enhancer O
activity O
in O
pituitary O
cells O
when O
placed O
upstream O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

The O
second O
patient O
had O
received O
pituitary I-GENE
- I-GENE
derived I-GENE
growth I-GENE
hormone I-GENE
for O
treatment O
of O
growth I-GENE
hormone I-GENE
deficiency O
, O
secondary O
to O
a O
third O
ventricle O
teratoma RARE
, O
exised RARE
13 O
yr O
earlier O
. O

3 O
-- O
It O
is O
necessary O
to O
think RARE
about O
cosmetic RARE
consequences O
of O
the O
chinese RARE
flap O
and O
consider O
other O
possibilities O
of O
the O
flap O
choice O
. O

CONCLUSION O
: O
TNF I-GENE
alpha I-GENE
, O
TGF I-GENE
beta I-GENE
, O
PDGF I-GENE
and O
IL I-GENE
- I-GENE
1beta I-GENE
increased O
LDLr RARE
gene I-GENE
expression O
by O
increasing O
sterol O
- O
independent O
and O
mitogenesis RARE
- O
independent O
gene O
transcription O
. O

Binding O
affinities O
of O
different O
nucleotide O
mono O
-, O
di RARE
- O
and O
triphosphates RARE
and O
non O
- O
hydrolyzable RARE
analogs RARE
indicate O
that O
the O
beta O
- O
phosphate O
moiety RARE
is O
required O
for O
substrate O
binding O
. O

However O
, O
it O
is O
only O
one O
- O
half O
and O
one O
- O
third O
the O
size O
of O
the O
proteolipids RARE
from O
M O
. O
thermoautotrophicum RARE
and O
M O
. O
jannaschii RARE
, O
respectively O
. O
ahaK LASTCAP
is O
expressed O
in O
Escherichia O
coli O
, O
and O
it O
is O
incorporated O
into O
the O
cytoplasmic O
membrane O
despite O
the O
different O
chemical O
natures RARE
of O
lipids O
from O
archaea RARE
and O
bacteria O
. O

In O
this O
report O
we O
studied O
the O
role O
of O
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
SHP I-GENE
- I-GENE
2 I-GENE
in O
ErbB I-GENE
- O
mediated O
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
by O
overexpressing O
SHP I-GENE
- I-GENE
2 I-GENE
mutants I-GENE
in O
COS O
- O
7 O
cells O
. O

Osteoadherin RARE
is O
a O
recently O
described O
bone O
proteoglycan O
containing O
keratan RARE
sulfate O
. O

Intron O
8 O
harbored RARE
a O
strong O
erythroid O
- O
specific O
enhancer O
activity O
which O
was O
orientation O
- O
dependent O
. O

The O
intron O
8 O
enhancer O
region O
was O
not O
activated O
by O
GATA I-GENE
- I-GENE
1 I-GENE
together O
with O
Sp1 I-GENE
in O
transactivation O
experiments O
in O
COS O
- O
1 O
cells O
indicating O
the O
involvement O
of O
a O
related O
Sp1 I-GENE
protein I-GENE
or O
of O
another O
unidentified O
erythroid O
factor O
. O

The O
cleavage O
of O
Fak RARE
by O
caspases RARE
may O
thus O
play O
an O
important O
role O
in O
the O
execution RARE
of O
the O
suicide O
program O
by O
disabling RARE
the O
anti O
- O
apoptotic O
function O
of O
Fak RARE
. O

Moreover O
, O
the O
mass O
estimated O
with O
the O
QCM ALLCAPS
response O
through O
the O
Sauerbrey RARE
equation O
and O
the O
mass O
which O
can O
be O
measured O
thanks RARE
to O
other O
analytical RARE
techniques O
, O
in O
our O
case O
an O
enzymatic O
assay O
, O
are O
different O
: O
the O
deposited RARE
mass O
is O
generally O
overestimated RARE
by O
the O
QCM ALLCAPS
. O

[ O
Treatment O
of O
early O
T1 O
small O
T2N NUMERIC
breast O
cancers O
. O

Transcription O
initiation O
occurred O
predominantly O
at O
the O
putative O
sigmaA LASTCAP
- I-GENE
dependent I-GENE
promoter I-GENE
in O
exponentially RARE
growing O
cells O
and O
was O
induced O
under O
stress O
conditions O
. O

The O
genes O
encoding O
( I-GENE
2Fe NUMERIC
- I-GENE
2S NUMERIC
) I-GENE
plant I-GENE
- I-GENE
like I-GENE
ferredoxins RARE
were O
studied O
in O
the O
widely O
used O
cyanobacterium RARE
Synechocystis RARE
PCC6803 NUMERIC
. O

RNA O
of O
GBV ALLCAPS
- O
C O
was O
detected O
in O
14 O
( O
18 O
%) O
patients O
before O
BMT ALLCAPS
. O

A O
major O
pool O
of O
Dsg RARE
- O
plakoglobin I-GENE
complexes O
sedimented RARE
at O
8S NUMERIC
and O
exhibited O
a O
1 O
: O
1 O
stoichiometry RARE
. O

Our O
results O
indicate O
that O
the O
binding O
of O
CBF I-GENE
/ O
NF I-GENE
- I-GENE
Y I-GENE
to O
the O
inverted O
CCAAT O
box O
is O
responsible O
for O
transcriptional O
activation O
of O
the O
nTPH LASTCAP
gene I-GENE
. O

In O
macrophages O
, O
LPS O
- O
inducible O
HIV O
- O
1 O
gene O
expression O
is O
mediated O
in O
part O
by O
binding O
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
to O
identical O
tandem O
binding O
sites O
located O
within O
the O
long O
terminal O
repeat O
( O
LTR O
). O

The O
influence O
of O
p53 I-GENE
on O
cytokine O
- O
triggered O
Janus I-GENE
kinase I-GENE
- O
STAT I-GENE
signaling O
was O
investigated O
in O
human O
hepatoma O
Hep3B NUMERIC
cell O
lines O
engineered O
to O
constitutively O
express O
the O
temperature O
- O
sensitive O
Val135 NUMERIC
mutant I-GENE
of I-GENE
p53 I-GENE
. O

It O
can O
also O
be O
used O
to O
examine O
various O
laryngeal RARE
parameters O
obtained O
from O
videotaped RARE
endoscopic RARE
and O
stroboscopic RARE
examinations O
. O

CONCLUSIONS O
: O
Two O
consecutive O
sets O
of O
transrectal RARE
ultrasound O
guided RARE
sextant RARE
biopsies O
of O
the O
prostate O
performed O
in O
a O
single O
office RARE
visit RARE
represent O
a O
cost O
- O
effective O
biopsy O
strategy O
for O
men O
presenting O
with O
an O
abnormal O
digital O
rectal O
examination O
and O
/ O
or O
elevated O
serum I-GENE
PSA I-GENE
. O

Examination O
of O
nuclear O
magnetic O
resonance O
( O
NMR O
) O
spectra O
of O
a O
series O
of O
N I-GENE
- I-GENE
terminally I-GENE
truncated I-GENE
MIP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
variants I-GENE
reveals O
that O
these O
proteins O
possess O
a O
range O
of O
ability O
to O
dimerize RARE
. O

Interestingly O
, O
PKA I-GENE
activity O
is O
dispensable O
in O
a O
strain O
lacking O
Msn2p NUMERIC
and O
Msn4p NUMERIC
activity O
. O

They O
also O
indicate O
that O
direct O
interactions O
between O
C I-GENE
/ I-GENE
EBPs RARE
and O
specific O
Ets I-GENE
family O
members O
, O
together O
with O
GATA I-GENE
- I-GENE
1 I-GENE
, O
are O
important O
for O
eosinophil O
lineage O
determination O
. O

Recently O
, O
a O
human I-GENE
transcription I-GENE
elongation I-GENE
factor I-GENE
P I-GENE
- I-GENE
TEFb RARE
, O
consisting O
of O
CDK9 NUMERIC
kinase I-GENE
, O
cyclin I-GENE
T I-GENE
and O
other O
associated O
factors O
, O
has O
been O
shown O
to O
interact O
with O
Tat I-GENE
to O
restore RARE
Tat I-GENE
activation O
in O
HeLa O
nuclear O
extract O
depleted O
of O
P I-GENE
- I-GENE
TEFb RARE
. O

We O
have O
used O
the O
hydrophobic O
repeats O
of O
the O
HSF1 I-GENE
trimerization RARE
domain I-GENE
in O
the O
yeast O
two O
- O
hybrid O
protein O
interaction O
assay O
to O
identify O
heat I-GENE
shock I-GENE
factor I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
HSBP1 NUMERIC
), O
a O
novel O
, O
conserved O
, O
76 O
- O
amino O
- O
acid O
protein O
that O
contains O
two O
extended O
arrays O
of O
hydrophobic O
repeats O
that O
interact O
with O
the O
HSF1 I-GENE
heptad I-GENE
repeats I-GENE
. O

Genomic O
and O
cDNA O
clones O
homologous O
to O
the O
yeast O
GCN2 I-GENE
eIF I-GENE
- I-GENE
2alpha I-GENE
kinase O
( O
yGCN2 NUMERIC
) O
were O
isolated O
from O
Drosophila O
melanogaster O
. O

The O
general O
recombination O
at O
a O
polarizing RARE
voltage O
of O
300 O
V O
is O
less O
than O
2 O
% O
for O
dose O
- O
rates O
up O
to O
about O
100 O
mGy RARE
min O
- O
1 O
. O

The O
low O
number O
of O
false O
positives RARE
indicates O
that O
our O
scheme RARE
would O
not O
confuse RARE
the O
radiologist RARE
by O
suggesting O
normal O
regions O
as O
suspicious RARE
. O

Strengthening RARE
the O
biological O
weapons RARE
convention RARE
and O
implications O
on O
the O
pharmaceutical RARE
and O
biotechnology RARE
industry RARE
. O

VirD2 NUMERIC
is O
one O
of O
the O
key O
Agrobacterium RARE
tumefaciens RARE
proteins O
involved O
in O
T O
- O
DNA O
processing O
and O
transfer O
. O

Taken O
together O
, O
these O
data O
indicate O
that O
the O
VirD2 NUMERIC
omega I-GENE
domain I-GENE
is O
important O
for O
efficient O
T O
- O
DNA O
integration O
. O

The O
DHEAS ALLCAPS
levels O
in O
all O
stages O
of O
decreased O
BMD O
were O
significantly O
lower O
than O
those O
in O
the O
group O
with O
normal O
BMD O
. O

Orientation RARE
of O
the O
nuclear O
spin O
system O
by O
optical O
pumping RARE
causes O
an O
Overhauser RARE
shift O
of O
the O
excitonic RARE
energy O
levels O
proportional RARE
to O
the O
degree O
of O
nuclear O
orientation O
. O

Cystatin RARE
A I-GENE
, O
a O
cysteine I-GENE
proteinase I-GENE
inhibitor O
, O
is O
one O
of O
the O
precursor O
proteins O
of O
cornified RARE
cell I-GENE
envelope I-GENE
of O
keratinocytes RARE
and O
is O
expressed O
during O
the O
late O
stage O
of O
keratinocyte RARE
differentiation O
. O

A O
role O
for O
RalGDS LASTCAP
and O
a O
novel O
Ras I-GENE
effector O
in O
the O
Ras I-GENE
- O
mediated O
inhibition O
of O
skeletal O
myogenesis RARE
. O

GTPase I-GENE
activating O
specificity O
of O
RGS12 NUMERIC
and O
binding O
specificity O
of O
an O
alternatively O
spliced O
PDZ I-GENE
( O
PSD ALLCAPS
- I-GENE
95 I-GENE
/ O
Dlg RARE
/ O
ZO ALLCAPS
- I-GENE
1 I-GENE
) O
domain O
. O

However O
, O
mutations O
in O
the O
HNF I-GENE
- I-GENE
4 I-GENE
binding I-GENE
site I-GENE
on O
element I-GENE
CIIB ALLCAPS
and O
inhibition O
of O
HNF I-GENE
- I-GENE
4 I-GENE
synthesis O
in O
HepG2 O
cells O
by O
antisense O
HNF I-GENE
- I-GENE
4 I-GENE
constructs I-GENE
decreased O
the O
apoCII LASTCAP
promoter I-GENE
activity O
to O
25 O
- O
40 O
% O
of O
the O
control O
, O
indicating O
that O
HNF I-GENE
- I-GENE
4 I-GENE
is O
a O
positive O
regulator O
of O
the O
apoCII LASTCAP
gene I-GENE
. O

272 O
, O
19107 NUMERIC
- O
19110 NUMERIC
). O

In O
addition O
, O
we O
find O
that O
E2F I-GENE
- I-GENE
1 I-GENE
can O
cause O
apoptosis O
in O
p53 I-GENE
-/- RARE
tumour O
cells O
and O
further O
p300 I-GENE
, O
which O
also O
functions O
as O
a O
co O
- O
activator O
for O
the O
E2F I-GENE
/ O
DP I-GENE
heterodimer O
, O
enhances O
the O
apoptotic O
activity O
of O
E2F I-GENE
- I-GENE
1 I-GENE
. O

Blocked RARE
shift O
/ O
supershift O
analysis O
indicates O
that O
Fos I-GENE
family I-GENE
member O
proteins O
especially O
Fra RARE
- I-GENE
1 I-GENE
and O
Fra RARE
- I-GENE
2 I-GENE
are O
related O
to O
progression O
and O
no O
changes O
found O
in O
the O
Jun I-GENE
family I-GENE
member O
proteins O
although O
they O
are O
present O
in O
the O
AP I-GENE
- I-GENE
1 I-GENE
/ I-GENE
DNA I-GENE
binding I-GENE
complex I-GENE
. O

Initially RARE
, O
we O
observed O
that O
unmutated RARE
p53 I-GENE
is O
strongly O
expressed O
in O
premalignant RARE
mammary O
glands O
and O
in O
mammary O
tumors O
derived O
from O
the O
MMTV O
- O
c I-GENE
- I-GENE
myc I-GENE
strain O
. O

These O
data O
show O
that O
heterologous O
virus O
RNAs O
( O
BSMV ALLCAPS
) O
can O
serve O
as O
primer O
donors O
for O
MStV LASTCAP
mRNA O
capped RARE
RNA O
- O
primed O
transcription O
in O
doubly RARE
infected O
plants O
. O

Human O
isoforms O
, O
designated O
1 O
to O
4 O
, O
differ O
from O
each O
other O
by O
the O
start O
codon O
used O
. O

Comparison O
of O
cDNA O
and O
genomic O
sequences O
shows O
that O
the O
ZNF189 NUMERIC
gene I-GENE
spans O
approximately O
11 O
kb O
and O
is O
organized O
into O
at O
least O
four O
exons O
, O
the O
large O
3 O
'- O
end O
exon O
coding O
for O
the O
complete O
zinc O
finger O
domain O
and O
the O
3 O
' O
untranslated O
region O
. O

Malaria RARE
had O
diminished O
significantly O
by O
the O
early O
1940s NUMERIC
, O
and O
this O
paper O
queries RARE
whether O
that O
reduction O
was O
due O
to O
the O
control O
projects RARE
of O
the O
thirties RARE
, O
and O
, O
if O
so O
, O
whether O
such O
projects RARE
should O
be O
a O
model O
for O
the O
current O
developing O
world O
, O
where O
malaria O
is O
a O
growing O
problem O
today RARE
. O

The O
gp330 NUMERIC
/ O
Megalin RARE
/ O
LRP ALLCAPS
- I-GENE
2 I-GENE
protein O
belongs O
to O
the O
low I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
receptor I-GENE
gene I-GENE
family I-GENE
and O
is O
believed O
to O
function O
as O
an O
endocytic O
receptor O
for O
the O
uptake O
of O
lipoproteins O
and O
many O
other O
ligands O
. O

In O
the O
DNA O
recognition O
helix O
of O
finger O
II O
, O
the O
conserved O
Arg O
at O
position O
62 O
( O
N O
- O
terminal O
side O
of O
the O
first O
zinc O
- O
coordinating RARE
histidine O
) O
was O
changed O
to O
a O
Leu O
or O
Gln O
. O

Dosage RARE
in O
both O
cases O
was O
0 O
. O
2 O
g O
/ O
m2 O
. O

Five O
additional O
copies O
of O
Lian RARE
elements I-GENE
were O
isolated O
, O
mapped O
by O
restriction O
digestion O
, O
and O
partially O
sequenced O
. O

Evolutionary RARE
relationships O
among O
putative O
RNA I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
polymerases I-GENE
encoded O
by O
a O
mitochondrial O
virus O
- O
like O
RNA O
in O
the O
Dutch RARE
elm RARE
disease O
fungus O
, O
Ophiostoma RARE
novo O
- O
ulmi RARE
, O
by O
other O
viruses O
and O
virus O
- O
like O
RNAs O
and O
by O
the O
Arabidopsis O
mitochondrial O
genome O
. O

Role O
of O
the O
transcription O
start O
site O
core O
region O
and O
transcription I-GENE
factor I-GENE
YY1 I-GENE
in O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
promoter I-GENE
activity O
. O

Fowlpox RARE
virus O
encodes O
nonessential RARE
homologs O
of O
cellular I-GENE
alpha I-GENE
- I-GENE
SNAP ALLCAPS
, O
PC I-GENE
- I-GENE
1 I-GENE
, O
and O
an O
orphan O
human O
homolog O
of O
a O
secreted O
nematode O
protein O
. O

Addition O
of O
Rap RARE
or O
KN62 NUMERIC
after O
exposure O
of O
cells O
to O
progesterone O
agonist O
Org RARE
2058 NUMERIC
had O
no O
effect O
on O
induction O
of O
CAT I-GENE
activity O
. O

The O
Dax RARE
- I-GENE
1 I-GENE
gene I-GENE
encodes O
a O
protein O
that O
is O
structurally O
related O
to O
members O
of O
the O
orphan I-GENE
nuclear I-GENE
receptor I-GENE
superfamily I-GENE
. O

He O
was O
administered O
recombinant I-GENE
IFN I-GENE
alpha I-GENE
- I-GENE
2b I-GENE
under O
the O
diagnosis O
of O
chronic O
hepatitis O
C O
. O

Further O
, O
Ser O
/ O
Thr O
phosphorylation O
of O
downstream O
molecules O
Akt I-GENE
and O
p70 I-GENE
S6 I-GENE
kinase I-GENE
was O
inhibited O
. O

Quantitative O
evaluation O
of O
the O
steady O
state O
kinetics O
of O
MEK I-GENE
inhibition O
by O
these O
compounds O
reveals O
that O
U0126 NUMERIC
has O
approximately O
100 O
- O
fold O
higher O
affinity O
for O
deltaN3 NUMERIC
- I-GENE
S218E NUMERIC
/ I-GENE
S222D NUMERIC
MEK I-GENE
than O
does O
PD098059 NUMERIC
. O

Regulation O
at O
37 O
degrees O
C O
, O
therefore O
, O
involves O
the O
action O
of O
three O
protein O
kinase O
cascades O
that O
repress O
HSF1 I-GENE
through O
phosphorylation O
of O
serine O
residues O
303 NUMERIC
, O
307 NUMERIC
, O
and O
363 NUMERIC
and O
may O
promote O
growth O
by O
suppressing RARE
the O
heat O
shock O
response O
. O

Clinical O
implication RARE
of O
protein O
levels O
of O
IL I-GENE
- I-GENE
5 I-GENE
in O
induced O
sputum O
in O
asthmatic O
patients O
. O

In O
these O
cells O
, O
ras I-GENE
- O
induced O
transition O
is O
accompanied O
by O
a O
strong O
induction O
of O
AP I-GENE
- I-GENE
1 I-GENE
- O
binding O
activity O
along O
with O
increased O
expression O
of O
CD44 I-GENE
mRNA I-GENE
and O
protein O
. O

However O
, O
little O
is O
known O
regarding O
the O
genomic O
organization O
and O
developmental O
expression O
of O
the O
caveolin RARE
gene I-GENE
family I-GENE
. O

Tensile RARE
bond O
strengths O
between O
resin O
composite O
and O
bovine O
dentin O
using O
dentin O
adhesive O
systems O
( O
Clearfil RARE
Liner RARE
Bond RARE
II O
: O
LB ALLCAPS
II O
; O
Scotchbond RARE
Multi RARE
- O
Purpose RARE
: O
MP O
) O
bonding RARE
systems O
showed O
a O
large O
scatter RARE
among O
students O
and O
dentists RARE
. O

This O
distribution O
implies RARE
that O
the O
polycistronic RARE
precursor O
is O
imported RARE
into O
the O
nucleolus RARE
for O
processing O
to O
the O
mature O
snoRNAs RARE
, O
and O
that O
the O
import O
or O
processing O
pathway O
involves O
coiled O
bodies O
. O

Suppressive RARE
therapy O
for O
thyroid O
nodules O
. O

Fourteen RARE
healthy O
male O
volunteers O
completed O
the O
study O
. O

In O
the O
absence O
of O
Mg2 NUMERIC
+, O
a O
hydrophobic O
exonuclease O
site O
dominates RARE
over O
the O
polymerase O
site O
for O
possession RARE
of O
the O
primer O
terminus O
. O

As O
the O
high O
- O
affinity O
Mg2 NUMERIC
+ O
binding O
sites O
are O
filled O
, O
the O
primer O
terminus O
migrates RARE
from O
the O
exonuclease O
site O
to O
a O
highly O
based O
stacked RARE
polymerase O
active O
site O
. O

One O
missense O
allele O
( O
P236S NUMERIC
) O
with O
complete O
loss O
of O
function O
at O
30 O
degreesC LASTCAP
and O
four O
missense O
alleles O
( O
L173F NUMERIC
, O
E225K NUMERIC
, O
S269L NUMERIC
and O
E274K NUMERIC
) O
that O
conferred O
a O
temperature O
sensitive O
phenotype O
were O
identified O
. O

Structural O
analysis O
of O
the O
5 O
'- O
regulatory O
region O
reveals O
that O
the O
c I-GENE
- I-GENE
met I-GENE
promoter I-GENE
lacks O
TATA O
or O
CAAT O
elements O
but O
has O
an O
extremely O
high O
G O
- O
C O
content O
and O
multiple O
Sp1 I-GENE
binding I-GENE
sites I-GENE
. O

The O
report O
highlights RARE
the O
possible O
contribution O
of O
stress O
factors O
in O
the O
context O
of O
therapy O
resistant O
periodontal O
disease O
, O
and O
the O
results O
seem O
to O
be O
understandable RARE
within O
the O
context O
of O
a O
stress O
system O
disorder O
perspective RARE
. O

Acute O
pancreatitis O
is O
a O
rather O
common O
abdominal O
disorder O
. O

To O
better O
understand O
the O
role O
of O
Ets I-GENE
proteins I-GENE
in O
Ras I-GENE
transformation O
, O
we O
have O
now O
analyzed O
the O
effects O
of O
stably O
expressing O
a O
variety O
of O
Ets2 NUMERIC
constructs I-GENE
in O
Ras I-GENE
- O
transformed O
NIH3T3 O
( O
DT O
) O
cells O
. O

Each O
binding O
site O
, O
however O
, O
was O
different O
in O
its O
preference O
for O
binding O
partners O
. O

We O
isolated O
the O
human I-GENE
FGF I-GENE
- I-GENE
BP I-GENE
promoter I-GENE
and O
determined O
by O
deletion O
analysis O
that O
TPA O
regulatory O
elements O
were O
all O
contained O
in O
the O
first O
118 O
base O
pairs O
upstream O
of O
the O
transcription O
start O
site O
. O

Manipulation RARE
of O
the O
checkpoint O
regulators O
involved O
in O
cell O
cycle O
arrest O
and O
apoptosis O
may O
thus O
provide O
a O
novel O
strategy O
to O
cancer O
therapy O
. O

Electrophoretic O
mobility O
shift O
assays O
demonstrated O
specific O
nuclear O
protein O
binding O
to O
- O
85 O
/- O
64 O
, O
and O
single O
point O
mutations O
suggested O
important O
binding O
nucleotides O
between O
- O
79 O
/- O
68 O
with O
five O
critical O
bases O
between O
- O
74 O
/- O
70 O
( O
5 O
'- O
CTCCT ALLCAPS
- O
3 O
'). RARE

The O
diagnostic O
accuracy O
of O
serum O
PE I-GENE
- I-GENE
1 I-GENE
was O
0 O
. O
80 O
, O
and O
that O
of O
amylase I-GENE
0 O
. O
97 O
. O

We O
demonstrate O
that O
Ddc1p NUMERIC
interacts O
physically O
in O
vivo O
with O
Mec3p NUMERIC
, O
and O
this O
interaction O
requires O
Rad17p NUMERIC
. O

" O
Complex RARE
partial O
" O
seizures O
. O

B I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
( O
BCR I-GENE
)- O
mediated O
formation O
of O
a O
SHP I-GENE
- I-GENE
2 I-GENE
- O
pp120 NUMERIC
complex O
and O
its O
inhibition O
by O
Fc I-GENE
gamma I-GENE
RIIB1 NUMERIC
- O
BCR I-GENE
coligation RARE
. O

Chem O
., O
270 O
: O
7117 NUMERIC
- O
7124 NUMERIC
, O
1995 O
; O
and O
MT ALLCAPS
Hartsough RARE
et O
al O
., O
J O
. O

Deleting RARE
SNF1 NUMERIC
repressed O
meiosis O
at O
the O
same O
three O
steps O
that O
were O
inhibited O
by O
glucose O
, O
suggesting O
that O
glucose O
blocks O
meiosis O
by O
inhibiting O
Snf1 NUMERIC
. O

Here O
we O
investigate O
the O
role O
of O
c I-GENE
- I-GENE
Cbl I-GENE
in O
development O
and O
homeostasis RARE
in O
mice O
by O
targeted O
disruption O
of O
the O
c I-GENE
- I-GENE
Cbl I-GENE
locus I-GENE
. O
c I-GENE
- I-GENE
Cbl I-GENE
- O
deficient O
mice O
were O
viable O
, O
fertile RARE
, O
and O
outwardly RARE
normal O
in O
appearance O
. O

One O
is O
to O
act O
within O
the O
visceral O
endoderm O
to O
promote O
proper O
streak RARE
morphogenesis RARE
. O

We O
propose O
that O
noi RARE
/ O
pax2 NUMERIC
. I-GENE
1 I-GENE
participates O
in O
sequential O
signaling O
processes O
as O
a O
key O
integrator RARE
of O
midbrain RARE
- O
hindbrain RARE
boundary O
development O
. O

Ligand RARE
- O
independent O
activation O
of O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
is O
a O
necessary O
intermediate O
in O
lysophosphatidic RARE
, O
acid O
- O
stimulated O
mitogenic O
activity O
in O
L O
cells O
. O

METHODS O
: O
Fibrotic RARE
changes O
involving O
bone O
marrow O
were O
evaluated O
histologically O
semiquantitatively RARE
using O
reticulin RARE
fiber O
impregnation RARE
( O
method O
of O
Gomori RARE
). O

In O
canrenoate RARE
- O
treated O
rats O
, O
ANP I-GENE
infusion O
caused O
greater O
increases O
in O
sodium O
excretion O
( O
FENA ALLCAPS
from O
3 O
. O
05 O
+/- O
0 O
. O
71 O
to O
7 O
. O
21 O
+/- O
0 O
. O
45 O
%; O
P O
< O
0 O
. O
05 O
; O
n O
= O
8 O
) O
than O
saline O
infusion O
( O
FENA ALLCAPS
from O
4 O
. O
16 O
+/- O
1 O
. O
11 O
to O
5 O
. O
47 O
+/- O
0 O
. O
66 O
%; O
n O
= O
6 O
), O
despite O
the O
hypocapnia RARE
. O

We O
then O
studied O
four O
unrelated O
Japanese O
families O
with O
GSD ALLCAPS
- O
Ib RARE
, O
and O
found O
three O
novel O
mutations O
: O
a O
four O
- O
base O
deletion O
/ O
two O
- O
base O
insertion O
, O
a O
point O
mutation O
within O
a O
consensus O
splicing O
donor O
site O
, O
and O
a O
missense O
mutation O
( O
W118R NUMERIC
). O

Removal O
of O
the O
carboxyl O
region O
severely O
reduced O
transcriptional O
activation O
. O

A O
" O
Level RARE
A O
" O
in O
vitro O
/ O
in O
vivo O
correlation O
was O
established O
for O
a O
sustained O
release O
theophylline O
( O
CAS O
58 O
- O
55 O
- O
9 O
) O
preparation O
( O
Bronchoretard RARE
) O
under O
investigation O
. O

METHOD ALLCAPS
: O
50 O
consecutive O
children O
aged O
from O
6 O
months O
to O
17 O
years O
were O
included O
into O
the O
study O
which O
comprised O
questionnaires RARE
of O
patient O
and O
family O
histories RARE
, O
serological O
screening O
tests O
for O
common O
inhalational RARE
allergens O
( O
CAP O
SX1 NUMERIC
), O
and O
determination O
of O
total O
serum I-GENE
immunoglobulin I-GENE
E I-GENE
( O
IgE I-GENE
) O
and O
of O
latex O
- O
specific O
serum I-GENE
IgE I-GENE
by O
solid O
- O
phase O
immunoassays RARE
. O

The O
PDE4A NUMERIC
- I-GENE
subfamily I-GENE
- I-GENE
specific I-GENE
linker I-GENE
region I-GENE
LR1 NUMERIC
, O
which O
joins O
UCR1 NUMERIC
and O
UCR2 NUMERIC
, O
is O
encoded O
by O
two O
exons O
, O
whereas O
LR2 NUMERIC
, O
which O
joins O
UCR2 NUMERIC
to O
the O
catalytic O
unit O
, O
is O
encoded O
by O
a O
single O
exon O
. O

Pol32Delta NUMERIC
strains O
are O
weak O
antimutators RARE
and O
are O
defective O
for O
damage O
- O
induced O
mutagenesis O
. O

At O
the O
same O
time O
, O
the O
results O
indicate O
that O
p53 I-GENE
plays O
a O
defensive RARE
role O
against O
HBV O
by O
transcriptionally O
repressing O
the O
HBV I-GENE
core I-GENE
promoter I-GENE
through O
liver I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
II I-GENE
and O
HBx RARE
is O
required O
to O
counteract RARE
this O
inhibitory O
function O
of O
p53 I-GENE
. O

To O
gain O
insight O
into O
the O
expression O
of O
the O
AtCP1 NUMERIC
gene I-GENE
, O
northern O
blot O
analysis O
was O
carried O
out O
. O

The O
aim O
of O
the O
study O
was O
to O
correlate O
the O
responsiveness O
to O
bronchoprovocation RARE
with O
methacholine RARE
in O
subjects O
a O
with O
allergic O
rhinitis RARE
during O
and O
out O
of O
the O
pollen O
season O
with O
total O
serum O
IgE I-GENE
and O
blood O
eosinophils O
. O

These O
results O
provide O
the O
first O
demonstration RARE
that O
an O
SR I-GENE
protein I-GENE
can O
influence O
splicing O
of O
specific O
pre O
- O
mRNAs O
in O
vivo O
. O

In O
particular O
, O
the O
potential O
for O
prostate O
cancer O
chemoprevention RARE
using O
nonsteroidal RARE
anti O
- O
inflammatory O
drugs O
( O
cyclo RARE
- I-GENE
oxygenase I-GENE
inhibitors O
; O
NSAIDs RARE
) O
has O
received O
little O
attention O
. O

This O
study O
reports O
the O
isolation O
of O
a O
P O
. O
hybrida RARE
gene O
, O
jaf13 NUMERIC
, O
encoding O
a O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
protein I-GENE
that O
, O
on O
the O
basis O
of O
sequence O
homology O
and O
intron O
/ O
exon O
structure O
, O
represents O
the O
P O
. O
hybrida RARE
orthologue RARE
of O
the O
Z I-GENE
. I-GENE
mays RARE
r I-GENE
genes I-GENE
. O

Identical RARE
c I-GENE
- I-GENE
erbB3 NUMERIC
transcripts I-GENE
are O
expressed O
in O
normal O
human O
placental O
tissues O
. O

During O
the O
past O
4 O
years O
, O
a O
purposeful RARE
search O
was O
made O
for O
electrocardiograms RARE
with O
documented RARE
reversible O
QRS O
changes O
associated O
with O
all O
acute O
injury O
pattern O
. O

Mutating RARE
a O
potential O
cleavage O
site O
located O
N O
- O
terminal O
to O
the O
protease O
domain O
, O
Gln2526 NUMERIC
- O
Asp2527 NUMERIC
, O
diminished O
processing O
. O

METHODS O
: O
Millipore RARE
ultrafiltration RARE
membranes O
of O
three O
different O
pore O
sizes O
were O
used O
as O
model O
lenticule RARE
materials O
. O
The O
nominal RARE
membrane O
pore O
sizes O
were O
0 O
. O
1 O
microm O
, O
0 O
. O
45 O
microm O
, O
and O
3 O
microm O
; O
the O
surface O
roughness RARE
increased O
in O
the O
same O
order O
The O
membranes O
were O
coated RARE
with O
a O
thin O
layer O
of O
collagen I-GENE
I I-GENE
and O
implanted O
in O
a O
circular O
pocket O
of O
the O
anterior O
cornea RARE
of O
adult O
cats O
, O
and O
were O
clinically O
evaluated O
for O
the O
extent O
of O
epithelialization RARE
and O
the O
persistence RARE
of O
epithelial O
attachment O
. O

The O
role O
of O
calcitonin I-GENE
, O
and O
other O
agonists O
which O
activate O
the O
cAMP O
pathway O
, O
in O
regulating O
transcription O
of O
the O
human I-GENE
parathyroid I-GENE
hormone I-GENE
- I-GENE
related I-GENE
protein I-GENE
( O
PTHrP LASTCAP
) O
gene O
was O
investigated O
in O
a O
human O
lung O
cancer O
cell O
line O
( O
BEN ALLCAPS
). O

The O
combination O
of O
Pitx2 NUMERIC
and O
another O
homeodomain I-GENE
protein I-GENE
, O
Pit I-GENE
- I-GENE
1 I-GENE
, O
yielded O
a O
synergistic O
55 O
- O
fold O
activation O
of O
the O
prolactin I-GENE
promoter I-GENE
in O
transfection O
assays O
. O

The O
biochemical O
and O
molecular O
spectrum O
of O
ornithine RARE
transcarbamylase RARE
deficiency O
. O

To O
further O
understand O
the O
role O
of O
cis O
- O
acting O
elements O
in O
these O
regulatory O
mechanisms O
, O
we O
have O
characterized O
a O
transcriptional O
promoter O
that O
drives RARE
germline O
expression O
of O
TCR I-GENE
beta I-GENE
gene I-GENE
segments I-GENE
in O
vivo O
. O

Our O
results O
suggest O
that O
the O
crucial O
role O
of O
the O
mutations O
activating O
v I-GENE
- I-GENE
erbA I-GENE
as O
an O
oncogene O
is O
to O
' O
freeze RARE
' O
c I-GENE
- I-GENE
ErbA LASTCAP
/ O
TRalpha RARE
in O
its O
non O
- O
liganded RARE
, O
repressive O
conformation O
and O
to O
facilitate O
its O
overexpression O
. O

Downregulation RARE
of O
FUS ALLCAPS
expression O
in O
BCR I-GENE
/ O
ABL I-GENE
- O
expressing O
32Dcl3 NUMERIC
cells O
was O
associated O
with O
suppression O
of O
growth O
factor O
- O
independent O
colony O
formation O
, O
restoration RARE
of O
G I-GENE
- I-GENE
CSF I-GENE
- O
induced O
granulocytic RARE
differentiation O
and O
reduced O
tumorigenic O
potential O
in O
vivo O
. O

In O
this O
study O
, O
we O
describe O
a O
mammalian O
cell O
- O
free O
transcription O
system O
reconstituted O
with O
only O
recombinant O
proteins O
and O
epitope O
- O
tagged O
multiprotein RARE
complexes O
. O

This O
repressor O
is O
however O
unlikely O
to O
mediate O
spi RARE
2 I-GENE
. I-GENE
3 I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
silencer I-GENE
action O
since O
it O
was O
not O
detected O
in O
rat O
hepatocytes O
. O

A O
prerequisite O
for O
the O
synthesis O
of O
sialylated RARE
glycoconjugates RARE
is O
the O
activated O
sugar O
- O
nucleotide O
cytidine RARE
5 O
'- O
monophosphate O
N O
- O
acetylneuraminic RARE
acid O
( O
CMP ALLCAPS
- O
Neu5Ac NUMERIC
), O
which O
provides O
a O
substrate O
for O
Golgi I-GENE
sialyltransferases RARE
. O

Thus O
, O
the O
bovine I-GENE
PEDF ALLCAPS
cDNA I-GENE
isolated O
here O
codes O
for O
a O
functional O
soluble O
secreted I-GENE
PEDF ALLCAPS
glycoprotein I-GENE
. O

We O
propose O
a O
model O
in O
which O
Sro7 NUMERIC
function O
is O
involved O
in O
the O
targeting O
of O
the O
myosin I-GENE
proteins I-GENE
to O
their O
intrinsic O
pathways O
. O

We O
found O
sequences O
related O
to O
this O
insertion O
in O
wild O
- O
type O
strains O
of O
N O
. O
crassa O
and O
other O
Neurospora O
species O
. O

When O
cysteine O
is O
scanned RARE
through O
the O
helices O
, O
characteristic O
repeating O
patterns O
of O
solvent O
exposure O
and O
burial RARE
are O
observed O
. O

Human I-GENE
ULK1 NUMERIC
, O
a O
novel O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
related O
to O
UNC I-GENE
- I-GENE
51 I-GENE
kinase I-GENE
of O
Caenorhabditis O
elegans O
: O
cDNA O
cloning O
, O
expression O
, O
and O
chromosomal O
assignment O
. O

Specifically O
, O
I O
use O
molecular O
markers O
that O
identify O
particular O
neuroectodermal RARE
domains O
, O
all O
neuroblasts O
or O
individual O
neuroblasts O
, O
to O
show O
that O
in O
DER I-GENE
mutant I-GENE
embryos O
( O
1 O
) O
intermediate O
column O
neuroblasts O
do O
not O
form O
, O
( O
2 O
) O
medial O
column O
neuroblasts O
often O
acquire RARE
identities O
inappropriate RARE
for O
their O
position O
, O
while O
( O
3 O
) O
lateral O
neuroblasts O
develop O
normally O
. O

Cochlear RARE
microphonic RARE
potentials O
in O
patients O
with O
vestibular O
schwannomas RARE
. O

These O
results O
with O
clozapine RARE
illustrate RARE
that O
LI ALLCAPS
is O
sensitive O
to O
antipsychotics RARE
which O
differ O
in O
their O
mode O
of O
action O
and O
furthermore RARE
emphasize RARE
the O
value O
of O
LI ALLCAPS
as O
a O
test O
model O
for O
detecting O
the O
antipsychotic RARE
potential O
of O
novel O
drugs O
. O

The O
complement I-GENE
C3a NUMERIC
anaphylatoxin RARE
receptor I-GENE
( O
C3aR NUMERIC
) O
is O
a O
seven I-GENE
- I-GENE
transmembrane I-GENE
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
chemoattractant RARE
receptor I-GENE
that O
on O
binding O
the O
C3a NUMERIC
peptide I-GENE
ligand I-GENE
mediates O
numerous O
cellular O
responses O
, O
including O
histamine O
release O
from O
mast O
cells O
. O
smooth O
muscle O
contraction O
, O
and O
the O
directed O
migration O
of O
eosinophils O
. O

CONCLUSIONS O
: O
Significant O
elevations O
of O
IL I-GENE
- I-GENE
1alpha I-GENE
and O
IL I-GENE
- I-GENE
1beta I-GENE
occur O
in O
patients O
with O
bacterial O
cystitis RARE
and O
microscopic O
hematuria RARE
. O

Band RARE
- O
shift O
assays O
were O
performed O
using O
the O
LPS I-GENE
- I-GENE
and I-GENE
IL I-GENE
- I-GENE
1 I-GENE
- I-GENE
responsive I-GENE
element I-GENE
( O
LILRE ALLCAPS
) O
oligonucleotide O
, O
a O
gamma I-GENE
interferon I-GENE
activation I-GENE
site I-GENE
- I-GENE
like I-GENE
site I-GENE
that O
is O
present O
in O
the O
human I-GENE
IL I-GENE
- I-GENE
1beta I-GENE
promoter I-GENE
. O

The O
C O
- O
terminal O
region O
contains O
the O
PTP I-GENE
- I-GENE
like I-GENE
domain I-GENE
, O
whereas O
the O
N O
- O
terminal O
region O
shows O
no O
homology O
to O
any O
known O
mammalian O
protein O
. O

In O
addition O
, O
and O
in O
support O
of O
a O
mediating O
role O
of O
STATs RARE
in O
the O
activation O
of O
the O
p21 I-GENE
promoter I-GENE
, O
overexpression O
of O
Stat3 I-GENE
potentiated RARE
the O
cytokine O
effect O
on O
the O
p21 I-GENE
promoter I-GENE
; O
whereas O
a O
dominant I-GENE
negative I-GENE
Stat3 I-GENE
, O
or O
a O
mutation O
of O
the O
STAT I-GENE
response I-GENE
element I-GENE
on O
the O
promoter O
, O
significantly O
reduced O
the O
cytokine O
effect O
. O

The O
heterogeneous O
nuclear I-GENE
ribonucleoprotein I-GENE
C I-GENE
protein I-GENE
tetramer I-GENE
binds O
U1 I-GENE
, O
U2 I-GENE
, O
and O
U6 I-GENE
snRNAs RARE
through O
its O
high O
affinity O
RNA O
binding O
domain O
( O
the O
bZIP O
- O
like O
motif O
). O

On O
the O
comparison O
of O
correlated O
proportions RARE
for O
clustered O
data O
. O

A O
safe O
and O
simple O
system O
for O
the O
detection O
of O
sudden RARE
infant O
death O
syndrome O
( O
SIDS ALLCAPS
) O
is O
proposed O
. O

The O
resulting O
mutants O
were O
coexpressed O
with O
gE LASTCAP
in O
the O
vaccinia O
virus O
- O
based O
vTF7 NUMERIC
- O
3 O
system O
, O
and O
the O
formation O
and O
endoplasmic O
reticulum O
( O
ER O
)- O
to O
- O
Golgi O
transport O
of O
the O
hetero RARE
- O
oligomeric RARE
complex O
were O
monitored O
. O

Homozygous O
mutant O
mice O
, O
designated O
Cux RARE
/ O
CDPDeltaCR1 NUMERIC
, O
display O
a O
phenotype O
characterized O
by O
curly RARE
vibrissae RARE
and O
wavy RARE
hair RARE
. O

The O
mutant O
protein O
is O
present O
at O
levels O
slightly O
greater O
than O
wild O
- O
type O
, O
but O
exhibits O
the O
same O
tissue O
distribution O
as O
wild O
- O
type O
protein O
, O
and O
has O
approximately O
normal O
affinity O
for O
known O
target O
sequences O
( O
though O
no O
DNA O
targets O
identified O
to O
date O
require O
the O
first O
cut O
repeat O
for O
binding O
). O

METHODS O
: O
We O
retrospectively RARE
reviewed O
242 NUMERIC
adult O
cadaveric RARE
renal O
transplant O
recipients O
treated O
between O
11 O
/ O
91 O
and O
5 O
/ O
97 O
. O

The O
spectrum O
of O
age O
- O
associated O
brain O
abnormalities O
: O
their O
measurement O
and O
histopathological O
correlates O
. O

Our O
laboratory O
has O
recently O
identified O
two O
phosducin RARE
- I-GENE
like I-GENE
orphan I-GENE
proteins I-GENE
( O
PhLOP1 NUMERIC
and O
PhLOP2 NUMERIC
) O
that O
lack O
the O
ability O
to O
interact O
with O
Gbetagamma I-GENE
. O

Reverse I-GENE
transcriptase I-GENE
- O
polymerase O
chain O
reaction O
( O
RT I-GENE
- O
PCR O
) O
was O
performed O
using O
eyestalk RARE
complementary O
DNA O
of O
the O
sand RARE
shrimp RARE
Metapenaeus RARE
ensis RARE
. O

In O
contrast O
, O
transcription O
initiating O
from O
opuE LASTCAP
P I-GENE
- I-GENE
1 I-GENE
( O
sigma I-GENE
A I-GENE
) O
rose O
in O
proportion O
to O
the O
external O
osmolarity RARE
and O
was O
maintained O
at O
high O
levels O
. O

Randomly RARE
selected O
300 O
children O
aged O
3 O
months O
- O
3 O
yr O
were O
analysed O
over O
a O
period O
of O
one O
year O
for O
estimating O
prevalence O
of O
nutritional O
anaemia RARE
. O

In O
insects RARE
, O
arylalkylamine RARE
N I-GENE
- I-GENE
acetyltransferases RARE
( O
AANATs RARE
) O
have O
been O
implicated O
in O
several O
physiological O
processes O
, O
including O
sclerotization RARE
, O
inactivation O
of O
certain O
neurotransmitters RARE
, O
and O
, O
similar O
to O
the O
function O
in O
vertebrates RARE
, O
catalysis RARE
of O
the O
rate O
- O
limiting O
step O
in O
melatonin O
biosynthesis O
. O

In O
experiments O
with O
the O
D1 O
antagonist O
SCH ALLCAPS
23390 NUMERIC
, O
buprenorphine RARE
- O
induced O
depression O
was O
consistently O
blocked O
, O
but O
facilitation RARE
was O
unaffected O
. O

These O
results O
establish O
that O
hydroquinones RARE
lead O
to O
mutagenicity RARE
and O
carcinogenicity RARE
. O

IA O
- O
CT O
with O
cisplatin O
50 O
mg O
and O
doxorubicin RARE
30 O
mg O
was O
administered O
by O
one O
shot RARE
method O
in O
bilateral O
internal O
iliac O
arteries O
. O

Arnt3 NUMERIC
mRNA I-GENE
was O
expressed O
in O
brain O
, O
skeletal O
muscle O
, O
13 O
. O
5 O
- O
day O
embryos O
, O
and O
P19 O
cells O
treated O
with O
retinoic O
acid O
. O

Acute O
idiopathic O
thrombocytopenic RARE
purpura O
presenting O
a O
high O
serum O
level O
of O
immunoglobulin I-GENE
E I-GENE
and O
eosinophilia RARE
in O
an O
elderly O
patient O
. O

The O
genomic O
structure O
and O
chromosomal O
location O
of O
the O
human I-GENE
TR2 NUMERIC
orphan I-GENE
receptor I-GENE
, O
a O
member O
of O
the O
steroid I-GENE
receptor I-GENE
superfamily I-GENE
. O

Correlation RARE
of O
skin O
disorders O
with O
CD4 I-GENE
lymphocyte O
counts O
in O
patients O
with O
HIV O
/ O
AIDS O
. O

E2F I-GENE
- I-GENE
6 I-GENE
shares O
significant O
homology O
with O
E2Fs NUMERIC
1 I-GENE
- I-GENE
5 I-GENE
, O
especially O
within O
the O
DNA O
binding O
, O
heterodimerization O
and O
marked O
box O
domains O
. O

The O
IE13 NUMERIC
. O
1 O
cell O
line O
was O
able O
to O
complement O
a O
recombinant O
virus O
in O
which O
both O
copies O
of O
the O
IE I-GENE
gene I-GENE
were O
replaced O
by O
insertion O
of O
the O
Escherichia I-GENE
coli I-GENE
lacZ I-GENE
gene I-GENE
. O

DNase I-GENE
I I-GENE
footprinting O
and O
electrophoretic O
mobility O
shift O
analyses O
revealed O
two O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
HNF1 NUMERIC
), O
three O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
), O
and O
one O
consensus O
palindromic O
thyroid O
hormone O
response O
elements O
within O
the O
first O
215 O
base O
pairs O
( O
bp O
) O
of O
the O
promoter O
sequence O
of O
rat I-GENE
Std RARE
. O

Thus O
, O
these O
studies O
on O
rat I-GENE
Std RARE
promoter I-GENE
function O
indicate O
that O
( O
i O
) O
HNF1 NUMERIC
and O
C I-GENE
/ I-GENE
EBP I-GENE
are O
responsible O
for O
liver O
specificity O
of O
the O
rat I-GENE
Std RARE
gene I-GENE
; O
( O
ii O
) O
androgenic RARE
repression O
of O
the O
gene O
requires O
the O
presence O
of O
all O
of O
the O
OCT ALLCAPS
- I-GENE
1 I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
elements I-GENE
between O
positions O
- O
231 O
and O
- O
292 NUMERIC
; O
and O
( O
iii O
) O
AR I-GENE
may O
exert O
its O
negative O
regulatory O
effect O
indirectly O
through O
transcriptional O
interference O
of O
OCT ALLCAPS
- I-GENE
1 I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
rather O
than O
through O
a O
direct O
DNA I-GENE
- I-GENE
AR I-GENE
interaction O
. O

Purified O
Hsk1 NUMERIC
phosphorylates O
the O
Cdc19 NUMERIC
( O
Mcm2 NUMERIC
) O
subunit O
of O
the O
six I-GENE
- I-GENE
member I-GENE
minichromosome RARE
maintenance I-GENE
protein I-GENE
complex I-GENE
purified O
from O
fission O
yeast O
. O

The O
yeast I-GENE
MMS2 NUMERIC
gene I-GENE
was O
cloned O
by O
its O
ability O
to O
complement O
the O
methyl O
methanesulfonate RARE
sensitivity O
of O
the O
mms2 NUMERIC
- I-GENE
1 I-GENE
mutant I-GENE
and O
was O
later O
shown O
to O
be O
involved O
in O
DNA O
post O
- O
replication O
repair O
. O

Expression O
of O
the O
human I-GENE
papillomavirus I-GENE
type I-GENE
11 I-GENE
E5A NUMERIC
protein I-GENE
from O
the O
E1E4 NUMERIC
, I-GENE
E5 NUMERIC
transcript I-GENE
. O

Anesthesia RARE
with O
M O
/ O
K O
was O
reversed O
after O
41 O
. O
6 O
min O
of O
immobilization RARE
with O
atipamezole RARE
. O

There O
was O
no O
evident O
inciting RARE
agent O
of O
the O
disease O
. O

MK O
- O
801 O
administration O
resulted O
in O
a O
biphasic O
response O
in O
seizure O
latency O
. O

In O
contrast O
, O
the O
distribution O
of O
endocytic O
markers O
is O
not O
affected O
. O

Toxicity RARE
during O
the O
therapeutic O
period O
was O
not O
significant O
in O
the O
study O
group O
compared O
with O
the O
historical RARE
control O
, O
treated O
with O
the O
same O
regimen O
without O
G I-GENE
- I-GENE
CSF I-GENE
. O

The O
purpose O
of O
this O
article O
is O
to O
discuss O
the O
factors O
involved O
in O
the O
selection O
of O
antibodies O
, O
radionuclides RARE
and O
labeling O
methods O
in O
the O
development O
of O
radioimmunotherapy RARE
( O
RIT ALLCAPS
) O
for O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
NHL ALLCAPS
) O
from O
a O
single O
clinical O
study O
site O
through O
multicenter RARE
trials O
and O
commercialization RARE
. O

Both O
methods O
were O
employed O
for O
various O
focal O
- O
film RARE
distances O
, O
image O
intensifier RARE
tube O
modes O
and O
laser O
printer RARE
formats RARE
. O

The O
effect O
of O
Rho I-GENE
on O
AP I-GENE
- I-GENE
1 I-GENE
is O
independent O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
, O
as O
a O
dominant I-GENE
- I-GENE
negative I-GENE
MEK I-GENE
and O
a O
MEK I-GENE
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho I-GENE
- O
induced O
AP I-GENE
- I-GENE
1 I-GENE
activity O
. O

Site O
- O
directed O
mutagenesis O
of O
residues O
in O
this O
domain O
( O
R82A NUMERIC
, O
K85A NUMERIC
, O
K88A NUMERIC
, O
and O
V89A NUMERIC
) O
resulted O
in O
proteins O
which O
failed O
to O
transactivate O
from O
the O
HTLV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
in O
vivo O
. O

Mutations O
within O
the O
C O
terminus O
of O
c I-GENE
- I-GENE
fos I-GENE
at O
serine O
residues O
that O
are O
phosphorylation O
targets O
for O
growth O
factors O
and O
MAP I-GENE
kinase I-GENE
completely O
abrogate O
transactivation O
and O
block O
potentiation O
by O
MAP I-GENE
kinase I-GENE
. O

In O
the O
former O
cells O
, O
ets I-GENE
- I-GENE
2 I-GENE
was O
a O
CSF I-GENE
- I-GENE
1 I-GENE
immediate O
- O
early O
response O
gene O
, O
and O
phosphorylated O
ets I-GENE
- I-GENE
2 I-GENE
was O
detected O
after O
2 O
to O
4 O
h O
, O
coincident RARE
with O
expression O
of O
ets I-GENE
- I-GENE
2 I-GENE
protein I-GENE
. O

Persistent RARE
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinases I-GENE
p42 NUMERIC
and O
p44 I-GENE
and O
ets I-GENE
- I-GENE
2 I-GENE
phosphorylation O
in O
response O
to O
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
1 I-GENE
/ O
c I-GENE
- I-GENE
fms I-GENE
signaling O
. O

Identification O
of O
a O
proline O
- O
rich O
sequence O
in O
the O
CD2 NUMERIC
cytoplasmic I-GENE
domain I-GENE
critical O
for O
regulation O
of O
integrin I-GENE
- O
mediated O
adhesion O
and O
activation O
of O
phosphoinositide RARE
3 I-GENE
- I-GENE
kinase I-GENE
. O

Vam7p NUMERIC
, O
a O
SNAP ALLCAPS
- I-GENE
25 I-GENE
- I-GENE
like I-GENE
molecule I-GENE
, O
and O
Vam3p NUMERIC
, O
a O
syntaxin RARE
homolog I-GENE
, O
function O
together O
in O
yeast O
vacuolar O
protein O
trafficking O
. O

We O
have O
tested O
this O
possibility O
by O
constructing RARE
a O
consecutive O
series O
of O
cysteine O
substitutions O
in O
the O
Neu RARE
juxtamembrane I-GENE
domain I-GENE
in O
order O
to O
force O
dimerization O
along O
a O
series O
of O
interreceptor RARE
faces RARE
. O

It O
has O
been O
demonstrated O
previously O
that O
Pax I-GENE
- I-GENE
6 I-GENE
, O
a O
paired I-GENE
domain I-GENE
( O
PD I-GENE
)/ O
homeodomain I-GENE
( O
HD I-GENE
) O
transcription O
factor O
critical O
for O
eye O
development O
, O
contributes O
to O
the O
activation O
of O
the O
alphaB LASTCAP
-, I-GENE
alphaA LASTCAP
-, I-GENE
delta1 NUMERIC
-, I-GENE
and I-GENE
zeta I-GENE
- I-GENE
crystallin RARE
genes O
in O
the O
lens O
. O

Tctex RARE
- I-GENE
1 I-GENE
binding O
required O
the O
first O
19 O
amino O
acids O
of O
Fyn I-GENE
and O
integrity O
of O
two O
lysine O
residues O
within O
this O
sequence O
that O
were O
previously O
shown O
to O
be O
important O
for O
Fyn I-GENE
interactions O
with O
the O
immunoreceptor RARE
tyrosine O
- O
based O
activation O
motifs O
( O
ITAMs RARE
) O
of O
lymphocyte I-GENE
Ag I-GENE
receptors I-GENE
. O

The O
prothrombin I-GENE
gene I-GENE
G20210A NUMERIC
mutation I-GENE
is O
not O
found O
among O
Japanese O
patients O
with O
deep O
vein O
thrombosis O
and O
healthy O
individuals O
. O

Transcriptional O
regulation O
of O
the O
GluR2 NUMERIC
gene I-GENE
: O
neural O
- O
specific O
expression O
, O
multiple O
promoters O
, O
and O
regulatory O
elements O
. O

The O
binding O
of O
NF I-GENE
- I-GENE
ATp RARE
, O
although O
not O
NF I-GENE
- I-GENE
AT4 NUMERIC
, O
to O
this O
enhancer O
also O
occurs O
along O
with O
HTLV O
- O
I O
- O
mediated O
infection O
of O
human O
peripheral O
blood O
T O
- O
cells O
. O

Thus O
, O
TRAF2 I-GENE
initiates RARE
SAPK I-GENE
and O
p38 I-GENE
activation O
by O
binding O
two O
proximal O
protein O
kinases O
: O
GCK ALLCAPS
and O
RIP ALLCAPS
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
signaling O
to O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
)/ O
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
) O
and O
p38 I-GENE
. O

The O
activity O
of O
the O
minimal O
promoter O
was O
found O
to O
be O
controlled O
by O
a O
combination O
of O
the O
activities O
of O
the O
transcription O
factors O
Sp1 I-GENE
, O
Sp3 I-GENE
, O
and O
NF I-GENE
- I-GENE
Y I-GENE
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
investigated O
the O
signaling O
pathway O
( O
s O
) O
that O
are O
responsible O
for O
CREB I-GENE
activation O
in O
normal O
T O
cells O
. O

Respondents RARE
who O
lived RARE
with O
a O
spouse RARE
/ O
partner O
only O
were O
less O
likely O
to O
have O
an O
unfavorable RARE
BMI O
status O
than O
people O
in O
the O
other O
two O
groups O
. O

Isolation O
of O
a O
novel O
TP53 NUMERIC
target I-GENE
gene I-GENE
from O
a O
colon O
cancer O
cell O
line O
carrying O
a O
highly O
regulated O
wild I-GENE
- I-GENE
type I-GENE
TP53 NUMERIC
expression O
system O
. O

Overexpression O
of O
MDR1 NUMERIC
has O
been O
demonstrated O
in O
many O
cancers O
, O
both O
in O
patient O
tumors O
and O
in O
cell O
lines O
selected O
with O
a O
variety O
of O
chemotherapeutic O
agents O
. O

Cytogenetic RARE
and O
molecular O
characterization O
of O
random O
chromosomal O
rearrangements O
activating O
the O
drug O
resistance O
gene O
, O
MDR1 NUMERIC
/ O
P I-GENE
- I-GENE
glycoprotein I-GENE
, O
in O
drug O
- O
selected O
cell O
lines O
and O
patients O
with O
drug O
refractory O
ALL O
. O

BACKGROUND O
: O
It O
is O
generally O
accepted O
that O
smoking O
increases O
blood O
pressure O
and O
inhibits O
muscle O
sympathetic O
nerve O
activity O
( O
SNA ALLCAPS
). O

When O
the O
blood O
pressure O
increase O
in O
response O
to O
smoking O
was O
blunted RARE
by O
nitroprusside RARE
infusion O
, O
there O
was O
a O
striking O
increase O
in O
muscle O
SNA ALLCAPS
. O

After O
that O
report O
, O
carboxypeptidase RARE
D I-GENE
( O
CPD ALLCAPS
) O
was O
subsequently O
purified O
from O
bovine O
pituitary O
and O
characterized O
as O
a O
novel O
carboxypeptidase RARE
E I-GENE
( O
CPE ALLCAPS
)- O
like O
enzyme O
, O
with O
many O
characteristics O
in O
common O
with O
duck RARE
gp180 NUMERIC
( O
Song RARE
, O
L O
., O
Fricker RARE
, O
L O
. O
D O
., O
1995 O
. O

RA O
- O
treatment O
of O
these O
transfectants O
induced O
morphologic O
and O
immunophenotypic RARE
maturation O
, O
changes O
in O
RA O
- O
regulated O
genes O
, O
and O
a O
G1 O
cell O
cycle O
arrest O
in O
a O
manner O
similar O
to O
parental O
NT2 NUMERIC
/ O
D1 O
cells O
. O

The O
histopathology RARE
and O
neovascularization RARE
did O
not O
appreciably RARE
differ O
between O
xenograft RARE
tumors O
derived O
from O
FGF4 NUMERIC
over O
- O
expressing O
versus O
control O
transfectants O
. O

For O
smaller O
vessels O
up O
to O
a O
diameter O
of O
0 O
. O
5 O
mm O
, O
treatments O
at O
16 O
and O
18 O
J O
/ O
cm2 O
showed O
good O
results O
in O
60 O
and O
82 O
% O
respectively O
; O
for O
vessels O
up O
to O
1 O
mm O
in O
27 O
and O
33 O
%. O

Pressure RARE
ulcers O
. O

RXR I-GENE
- I-GENE
gamma I-GENE
expression O
produced O
significant O
reduction O
in O
levels O
of O
RA O
- O
responsive O
genes O
including O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitors O
p21Cip1 NUMERIC
/ O
WAF1 I-GENE
and O
p27Kip1 NUMERIC
, O
resulting O
in O
increased O
cdc2 I-GENE
and O
cdk2 I-GENE
kinase I-GENE
activity O
and O
RB I-GENE
phosphorylation O
. O

TBP I-GENE
can O
be O
phosphorylated O
in O
vitro O
by O
extracts O
of O
U937 O
cells O
or O
by O
bacterially O
expressed O
activated O
ERK2 I-GENE
; O
the O
phosphorylation O
sites O
were O
mapped O
to O
ERK I-GENE
kinase I-GENE
consensus I-GENE
sites I-GENE
in O
the O
TBP I-GENE
amino I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
. O

During O
the O
CR O
/ O
PP O
diet O
only O
the O
HS O
subjects O
did O
not O
show O
the O
stress O
- O
induced O
rise O
in O
depression O
, O
decline O
in O
vigour RARE
and O
cortisol O
elevation O
that O
they O
showed O
after O
the O
PR O
/ O
CP O
diet O
. O

Generally RARE
ILC ALLCAPS
and O
ILVF ALLCAPS
values O
decreased O
with O
increasing O
exposure O
time O
with O
rate O
constants O
ranging O
from O
0 O
. O
03 O
to O
0 O
. O
33 O
day O
- O
1 O
( O
wet RARE
and O
lipid O
weight O
) O
for O
ILC ALLCAPS
and O
0 O
. O
03 O
to O
0 O
. O
31 O
day O
- O
1 O
for O
ILVF ALLCAPS
. O

These O
sequence O
analyses O
suggest O
that O
xIRS LASTCAP
- I-GENE
u RARE
is O
a O
novel O
member O
of O
the O
IRS I-GENE
family I-GENE
rather O
than O
a O
Xenopus O
homolog O
of O
an O
existing O
member O
. O

The O
present O
study O
sought O
to O
develop O
an O
equation O
to O
estimate O
VO2peak NUMERIC
in O
peripheral O
arterial O
occlusive RARE
disease O
( O
PAOD ALLCAPS
) O
patients O
with O
intermittent O
claudication RARE
and O
to O
determine O
independent O
predictors O
of O
VO2peak NUMERIC
in O
this O
population O
. O

Evidence O
for O
a O
novel O
MAPKKK ALLCAPS
- O
independent O
pathway O
controlling O
the O
stress O
activated O
Sty1 NUMERIC
/ O
Spc1 NUMERIC
MAP O
kinase O
in O
fission O
yeast O
. O

The O
Abbreviated RARE
Injury RARE
Scale O
( O
AIS ALLCAPS
), O
Injury RARE
Severity RARE
Scale O
and O
TRISS ALLCAPS
methodology RARE
comprise O
a O
mathematically RARE
sound O
system O
for O
the O
analysis O
of O
injuries O
and O
injured RARE
patients O
. O

This O
hypothesis O
was O
tested O
by O
introducing RARE
mutations O
at O
each O
of O
the O
three O
histidine O
pairs O
, O
the O
H382 NUMERIC
- O
X2 O
- O
H385 NUMERIC
pair O
, O
the O
H411 NUMERIC
- O
X2 O
- O
H414 NUMERIC
pair O
and O
the O
H430 NUMERIC
- O
X5 NUMERIC
- O
H436 NUMERIC
pair O
, O
which O
constitute O
the O
histidine O
- O
rich O
region O
near O
the O
C O
terminus O
of O
gp17 NUMERIC
. O

Using O
backcross O
analysis O
, O
both O
exons O
1 O
and O
4 O
mapped O
to O
a O
proximal O
region O
of O
murine O
Chromosome RARE
4 O
indistinguishable O
from O
the O
vacillans RARE
gene I-GENE
. O

Seventy O
- O
five O
percent O
of O
children O
who O
received O
a O
second O
transplant O
for O
HCV O
hepatitis O
had O
early O
histologic O
recurrence O
that O
led O
to O
liver O
failure O
and O
death O
. O

However O
, O
both O
TPN O
groups O
showed O
a O
marked O
increase O
in O
activities O
of O
liver O
lysosomal I-GENE
enzymes I-GENE
. O

Regulation O
of O
embryonic O
growth O
and O
lysosomal O
targeting O
by O
the O
imprinted O
Igf2 NUMERIC
/ O
Mpr RARE
gene O
. O

Furthermore O
, O
we O
demonstrated O
that O
Galpha11 NUMERIC
Q209L NUMERIC
stimulated O
Src I-GENE
family I-GENE
kinase O
activity O
and O
induced O
tyrosine O
phosphorylation O
of O
several O
proteins O
in O
HEK ALLCAPS
- O
293 O
cells O
. O

The O
micturition RARE
pressure O
was O
significantly O
decreased O
only O
after O
injection O
with O
BUP ALLCAPS
- O
4 O
in O
both O
normal O
and O
obstructed RARE
rats O
. O

Peroxisome RARE
proliferator I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
PPAR ALLCAPS
) O
modulate O
transcription O
by O
binding O
to O
specific O
peroxisome O
proliferator O
- O
response O
elements O
( O
PPRE ALLCAPS
) O
through O
heterodimerization O
with O
the O
9 I-GENE
- I-GENE
cis I-GENE
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RXR I-GENE
). O

Furthermore O
, O
early O
- O
and O
late O
- O
firing RARE
origins O
differ O
not O
in O
the O
timing O
of O
their O
recruitment O
of O
an O
Mcm RARE
protein I-GENE
, O
but O
in O
the O
timing O
of O
RPA I-GENE
' I-GENE
s I-GENE
recruitment O
. O

Thus O
, O
in O
the O
presence O
of O
active I-GENE
S I-GENE
- I-GENE
CDKs RARE
and O
Dbf4 NUMERIC
/ O
Cdc7 NUMERIC
, O
Mcms RARE
may O
open O
origins O
and O
thereby O
facilitate O
the O
loading O
of O
RPA I-GENE
. O

Tyrosine O
phosphorylated O
STATs RARE
dimerize RARE
and O
translocate RARE
into O
the O
nucleus O
to O
activate O
specific O
genes O
. O

Nonsynonymous RARE
substitution O
in O
abalone RARE
sperm O
fertilization O
genes O
exceeds RARE
substitution O
in O
introns O
and O
mitochondrial O
DNA O
. O

Gel O
retardation O
assays O
detected O
ZiaR LASTCAP
- O
dependent O
complexes O
forming O
with O
the O
zia RARE
operator I-GENE
- I-GENE
promoter I-GENE
and O
ZiaR LASTCAP
- O
DNA O
binding O
was O
enhanced O
by O
treatment O
with O
a O
metal O
- O
chelator RARE
in O
vitro O
. O

CONCLUSION O
: O
Although O
quantitative O
and O
qualitative O
criteria O
for O
diagnosing RARE
fatty O
liver O
on O
helical O
CT O
can O
be O
determined O
, O
they O
are O
protocol O
- O
specific O
. O

The O
PC O
- O
based O
RTPS ALLCAPS
is O
designed O
to O
run O
in O
the O
Microsoft RARE
Windows RARE
3 O
. O
11 O
environment O
( O
and O
later O
versions RARE
), O
for O
computers RARE
equipped RARE
with O
486 NUMERIC
or O
Pentium RARE
processors RARE
. O

Alternatively RARE
, O
the O
similarity O
in O
apparent O
regulatory O
action O
of O
the O
genes O
may O
indicate O
allelic O
differences O
wherein RARE
the O
IS1112C NUMERIC
Rf3 NUMERIC
allele I-GENE
may O
differ O
from O
alleles O
of O
maintainer RARE
lines O
by O
the O
capability RARE
to O
regulate O
both O
orf107 NUMERIC
and O
urf209 NUMERIC
processing O
activities O
. O

JCAHO ALLCAPS
revised O
interpretation O

Molecular O
cloning O
and O
functional O
characterization O
of O
murine I-GENE
sphingosine RARE
kinase I-GENE
. O

A O
human O
SPT3 NUMERIC
- O
TAFII31 NUMERIC
- O
GCN5 NUMERIC
- O
L I-GENE
acetylase RARE
complex O
distinct O
from O
transcription I-GENE
factor I-GENE
IID ALLCAPS
. O

Oleate RARE
induced O
steady O
- O
state O
levels O
of O
M I-GENE
- I-GENE
CPT I-GENE
I I-GENE
mRNA I-GENE
4 O
. O
5 O
- O
fold O
. O

Mapping O
of O
the O
DNA O
binding O
domain O
of O
the O
copper O
- O
responsive O
transcription O
factor O
Mac1 NUMERIC
from I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

A O
further O
mechanism O
increasing O
specific O
activation O
was O
cooperation O
of O
receptors O
at O
multiple O
and O
weak O
HREs RARE
, O
which O
was O
accentuated RARE
in O
the O
presence O
of O
both O
the O
AR I-GENE
N O
terminus O
and O
ligand O
binding O
domain O
. O

Previously O
, O
we O
characterized O
a O
DNA O
- O
binding O
protein O
, O
HS2NF5 NUMERIC
, O
that O
bound O
tightly O
to O
a O
conserved O
region O
within O
hypersensitive O
site O
2 O
( O
HS2 NUMERIC
) O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
locus I-GENE
control I-GENE
region I-GENE
( O
LCR O
) O
( O
Lam RARE
, O
L O
. O

The O
CBF1 I-GENE
site I-GENE
within O
HS2 NUMERIC
resides O
near O
sites O
for O
hematopoietic O
regulators O
such O
as O
GATA I-GENE
- I-GENE
1 I-GENE
, O
NF I-GENE
- I-GENE
E2 I-GENE
, O
and O
TAL1 NUMERIC
. O

The O
rat I-GENE
branched I-GENE
- I-GENE
chain I-GENE
- I-GENE
2 I-GENE
- I-GENE
oxo RARE
- I-GENE
acid I-GENE
dehydrogenase I-GENE
( I-GENE
BCOD ALLCAPS
) I-GENE
kinase I-GENE
mRNA I-GENE
is O
transcribed O
from O
a O
TATA O
- O
less O
promoter O
that O
has O
GC O
- O
rich O
sequences O
and O
two O
putative O
Sp1 I-GENE
binding I-GENE
sites I-GENE
near O
the O
transcription O
start O
site O
. O

Co O
- O
transfection O
of O
the O
Sp1 I-GENE
expression O
plasmid O
and O
the O
- O
58 O
promoter O
construct O
into O
Drosophila O
Schneider RARE
cells O
revealed O
that O
Sp1 I-GENE
contributed O
to O
the O
kinase O
basal O
promoter O
activity O
by O
binding O
to O
the O
non O
- O
consensus O
site O
in O
the O
- O
58 O
region O
. O

Until RARE
such O
investigations O
are O
performed O
, O
we O
conclude O
that O
the O
role O
for O
adjuvant O
treatment O
is O
questionable RARE
and O
that O
TME ALLCAPS
surgery O
is O
preferred O
as O
the O
treatment O
option RARE
for O
Stage O
T1 O
- O
T3 O
rectal O
cancers O
. O

Likewise RARE
, O
at O
150 O
degrees O
C O
with O
2 O
% O
APS ALLCAPS
the O
surface O
density O
of O
NH2 O
groups O
reached O
a O
maximum O
at O
24 O
hr O
and O
remained O
relatively O
constant O
up O
to O
96 O
hr O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
the O
cooperation O
of O
transcription I-GENE
factors I-GENE
NF I-GENE
- I-GENE
kappaB I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
is O
essential O
for O
transactivation O
of O
IL I-GENE
- I-GENE
8 I-GENE
gene I-GENE
by O
HTLV I-GENE
- I-GENE
I I-GENE
Tax I-GENE
. O

This O
study O
examines RARE
the O
cooperative O
effects O
of O
a O
human O
estrogen I-GENE
receptor I-GENE
- I-GENE
alpha I-GENE
( O
ERalpha RARE
) O
isoform O
on O
estrogen O
( O
E2 O
)- O
mediated O
gene O
activation O
in O
U2 O
- O
OS ALLCAPS
osteosarcoma O
cells O
. O

Transfection O
of O
increasing O
amounts O
of O
delta5ERalpha NUMERIC
expression O
vector O
into O
[ O
ERalpha RARE
+] RARE
OS ALLCAPS
cells O
resulted O
in O
potentiation O
of O
E2 O
- O
stimulated O
ERELuc RARE
activity O
in O
a O
synergistic O
, O
dose O
- O
dependent O
manner O
. O

Studies O
using O
the O
yeast O
two O
- O
hybrid O
system O
also O
did O
not O
provide O
evidence O
for O
the O
formation O
of O
a O
VDR I-GENE
- O
TR I-GENE
protein O
- O
protein O
interaction O
. O

Our O
results O
show O
that O
, O
from O
a O
thermodynamical RARE
standpoint RARE
, O
melatonin O
may O
directly O
scavenge RARE
hydroxyl RARE
radicals O
both O
in O
vacuum RARE
and O
in O
aqueous O
solution O
. O

This O
sequence O
, O
Thr O
- O
Gly O
- O
X O
- O
X O
- O
Gly O
- O
Asp O
- O
Gly O
- O
Lys O
- O
Ile O
- O
Phe O
, O
forms O
part O
of O
the O
B O
- O
loop O
and O
is O
conserved O
in O
a O
wide O
variety O
of O
organisms O
that O
include O
bacteria O
, O
algae RARE
and O
archeabacteria RARE
. O

We O
did O
not O
observe O
any O
changes O
in O
Bcl I-GENE
- I-GENE
2 I-GENE
or O
Bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
related I-GENE
proteins I-GENE
( O
Bcl I-GENE
- I-GENE
x I-GENE
, O
Bax RARE
, O
and O
Bad RARE
) O
in O
control O
or O
KCREB ALLCAPS
- O
transfected O
cells O
before O
or O
after O
treatment O
with O
Tg RARE
. O

Tyrosine O
112 O
of O
latent I-GENE
membrane I-GENE
protein I-GENE
2A I-GENE
is O
essential O
for O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
loading O
and O
regulation O
of O
Epstein O
- O
Barr O
virus O
latency O
. O

The O
only O
abundant O
viral O
transcript O
expressed O
during O
latency O
is O
the O
latency I-GENE
- I-GENE
related I-GENE
( O
LR ALLCAPS
) O
RNA O
. O

To O
improve O
test O
efficiency O
, O
we O
modified O
our O
previously O
introduced O
contrast O
/ O
color O
card RARE
test O
by O
including O
a O
patterned RARE
test O
stimulus O
and O
reducing O
the O
number O
of O
stimuli O
in O
both O
experimental O
phases O
. O

The O
defect O
in O
these O
proteins O
was O
also O
uniformly RARE
suppressed O
by O
either O
Mn2 NUMERIC
+, O
or O
the O
Mu RARE
B I-GENE
protein I-GENE
in O
the O
presence O
of O
ATP O
and O
target O
DNA O
. O

Using O
homology O
cloning O
techniques O
, O
we O
identified O
a O
mouse O
homologue O
of O
E O
( O
Pc RARE
), O
termed O
Epc1 NUMERIC
, O
a O
yeast O
protein O
that O
we O
name RARE
EPL1 NUMERIC
, O
and O
as O
well O
as O
additional O
ESTs O
from O
Caenorhabditis O
elegans O
, O
mice O
and O
humans O
. O

Second O
, O
the O
wild I-GENE
- I-GENE
type I-GENE
m8 NUMERIC
3 I-GENE
' I-GENE
UTR I-GENE
strongly O
reduces O
accumulation O
of O
heterologous O
transcripts O
in O
vivo O
, O
an O
activity O
that O
requires O
its O
K O
box O
sequences O
. O

In O
particular O
, O
unc RARE
- I-GENE
86 I-GENE
encodes O
a O
POU I-GENE
- I-GENE
type I-GENE
homeodomain I-GENE
protein I-GENE
needed O
for O
the O
production O
of O
the O
touch RARE
cells O
, O
while O
mec RARE
- I-GENE
3 I-GENE
encodes O
a O
LIM I-GENE
- I-GENE
type I-GENE
homeodomain I-GENE
protein I-GENE
needed O
for O
the O
differentiation O
of O
the O
touch RARE
cells O
. O

During O
the O
2h NUMERIC
resuscitation O
period O
, O
extracellular O
aspartate O
and O
glutamate O
concentrations O
in O
the O
cerebral O
striatum O
were O
higher O
during O
hypoxaemic RARE
resuscitation O
( O
p O
= O
0 O
. O
044 NUMERIC
and O
p O
= O
0 O
. O
055 NUMERIC
, O
respectively O
) O
than O
during O
resuscitation O
with O
21 O
% O
O2 O
or O
100 O
% O
O2 O
, O
suggesting O
an O
unfavourable RARE
accumulation O
of O
potent O
excitotoxins RARE
during O
hypoxaemic RARE
resuscitation O
. O

Expression O
of O
constitutively O
active O
MEK1 NUMERIC
, O
the O
kinase O
that O
activates O
ERKs I-GENE
, O
or O
overexpression O
of O
ERK2 I-GENE
, O
but O
not O
JNK1 I-GENE
, O
inhibited O
Stat3 I-GENE
activation O
. O

MEKs RARE
and O
ERKs I-GENE
inhibited O
IL I-GENE
- I-GENE
6 I-GENE
activation O
of O
Stat3 I-GENE
harboring O
a O
mutation O
at O
serine O
- O
727 NUMERIC
, O
the O
major O
site O
for O
serine O
phosphorylation O
, O
similar O
to O
inhibition O
of O
wild I-GENE
- I-GENE
type I-GENE
Stat3 I-GENE
, O
and O
inhibited O
Janus I-GENE
kinases I-GENE
Jak1 NUMERIC
and O
Jak2 NUMERIC
upstream O
of O
Stat3 I-GENE
in O
the O
Jak I-GENE
- O
STAT I-GENE
- O
signaling O
pathway O
. O

Furthermore O
, O
phosphatidylinositol O
( O
3 O
, O
4 O
, O
5 O
) O
trisphosphate RARE
specifically O
stimulates O
the O
activity O
of O
ILK I-GENE
in O
vitro O
, O
and O
in O
addition O
, O
membrane O
targetted RARE
constitutively O
active O
Pi RARE
( I-GENE
3 I-GENE
) I-GENE
K I-GENE
activates O
ILK I-GENE
in O
vivo O
. O

Transfection O
and O
in O
vitro O
binding O
studies O
identified O
within O
HEFT1 NUMERIC
a I-GENE
promoter I-GENE
whose O
basal O
activity O
required O
a O
GC O
box O
activated O
by O
Sp1 I-GENE
or O
Sp3 I-GENE
. O

Plasma O
was O
tested O
before O
and O
after O
( O
14 O
+/- O
7 O
. O
5 O
[ O
SD O
] O
days O
) O
surgery O
for O
IgG I-GENE
antibodies I-GENE
to O
the O
complex O
of O
heparin I-GENE
/ I-GENE
platelet I-GENE
factor I-GENE
4 I-GENE
, O
using O
a O
standardized O
, O
validated RARE
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
). O

Genome RARE
plasticity RARE
in O
the O
distal O
tail O
fiber O
locus O
of O
the O
T O
- O
even O
bacteriophage O
: O
recombination O
between O
conserved O
motifs O
swaps RARE
adhesin RARE
specificity O
. O

The O
FAS ALLCAPS
promoter I-GENE
was O
up O
- O
regulated O
by O
insulin I-GENE
through O
the O
proximal O
insulin I-GENE
response I-GENE
sequence I-GENE
containing O
an O
E O
- O
box O
motif O
at O
the O
- O
65 O
- O
base O
pair O
position O
. O

The O
effect O
of O
independent O
predictors O
on O
survival O
was O
examined O
in O
a O
Cox O
regression O
model O
with O
adjustment O
for O
existing O
illnesses RARE
. O

Effects O
of O
rhG LASTCAP
- I-GENE
CSF I-GENE
on O
neutrophil O
functions O
and O
survival O
in O
sepsis O
induced O
diabetic O
rats O
. O

OBJECTIVE O
: O
The O
purpose O
of O
this O
article O
is O
to O
review O
balance O
instruments O
developed O
within O
the O
past O
10 O
years O
that O
can O
be O
used O
in O
the O
clinic RARE
or O
home O
environment O
. O

CASE ALLCAPS
REPORT ALLCAPS
: O
We O
observed O
a O
congenital O
skin O
defect O
located O
exclusively O
on O
the O
trunk O
. O

Whereas O
, O
in O
the O
single O
- O
chambered RARE
body O
box O
, O
PenH LASTCAP
units O
( O
Enhanced RARE
Pause RARE
) O
reflect O
" O
effort O
of O
breathing O
." O
This O
is O
measured O
as O
the O
pause RARE
between O
inspiration RARE
and O
expiration RARE
. O

Anastrozole RARE
is O
the O
first O
aromatase I-GENE
inhibitor O
to O
show O
a O
significant O
survival O
advantage O
over O
megestrol RARE
acetate O
in O
post O
- O
menopausal O
women O
with O
advanced O
breast O
cancer O
. O

W O
. O

Moritta RARE
) O
and O
contains O
Bis RARE
- O
GMA ALLCAPS
. O

Mutation O
of O
either O
the O
AP I-GENE
- I-GENE
1 I-GENE
or O
the O
ets I-GENE
component O
of O
this O
site O
also O
prevented O
promoter O
activity O
in O
SMCs RARE
. O

ANIMALS ALLCAPS
: O
Fifty O
dogs O
with O
naturally O
developing O
DM O
. O

Surprisingly O
, O
double O
mutants O
of O
the O
shy2 NUMERIC
- I-GENE
1D NUMERIC
mutant I-GENE
with O
the O
phytochrome RARE
- O
deficient O
mutants O
hy2 NUMERIC
, O
hy3 NUMERIC
( O
phyB LASTCAP
- I-GENE
1 I-GENE
) O
and O
fre1 NUMERIC
- I-GENE
1 I-GENE
( O
phyA LASTCAP
- I-GENE
201 I-GENE
) O
showed O
reduced O
photomorphogenic RARE
response O
in O
darkness RARE
with O
a O
longer O
hypocotyl RARE
, O
a O
longer O
inflorescence RARE
stem O
, O
and O
a O
lower O
level O
expression O
of O
the O
CAB ALLCAPS
gene I-GENE
than O
the O
shy2 NUMERIC
- I-GENE
1D NUMERIC
single I-GENE
mutant I-GENE
. O

This O
suggests O
that O
while O
underpredictions RARE
of O
pain O
do O
not O
hurt RARE
more O
, O
disruption O
on O
primary O
tasks O
and O
physiological O
impact O
are O
higher O
. O

Laser RARE
ablation O
has O
been O
employed O
as O
a O
therapeutic O
measure O
for O
chronic O
pulmonary O
emphysema O
. O

The O
SH2 O
- O
containing O
adapter O
protein O
GRB10 NUMERIC
interacts O
with O
BCR I-GENE
- O
ABL I-GENE
. O

Saccharomyces O
cerevisiae O
contains O
four O
known O
acyl RARE
- I-GENE
CoA I-GENE
synthetases I-GENE
( O
fatty I-GENE
acid I-GENE
activation I-GENE
proteins I-GENE
, O
Faaps RARE
). O

We O
recently O
reported O
a O
placenta O
- O
specific O
enhancer O
in O
the O
human I-GENE
leukemia I-GENE
inhibitory I-GENE
factor I-GENE
receptor I-GENE
( O
LIFR ALLCAPS
) O
gene O
and O
now O
show O
detailed O
characterization O
of O
the O
226 NUMERIC
- O
base O
pair O
enhancer O
(- O
4625 NUMERIC
/- O
4400 NUMERIC
nucleotides O
). O

Copyright O
1998 O
Elsevier RARE
Science RARE
B O
. O
V O
. O

It O
may O
be O
time O
to O
reevaluate RARE
the O
dichotomy RARE
between O
AD O
and O
VaD LASTCAP
. O

Clone RARE
39 O
was O
a O
homolog O
of O
CONSTANS ALLCAPS
, O
which O
is O
a O
gene O
involved O
in O
controlling O
the O
flowering RARE
time O
in O
Arabidopsis O
. O

Badcock RARE
and O
Westheimer RARE
( O
Spatial RARE
Vision RARE
1 O
( O
1 O
), O
3 O
- O
11 O
, O
1985 O
) O
showed O
that O
a O
thin O
vertical O
line O
induces O
nearby RARE
zones RARE
of O
attraction RARE
and O
repulsion RARE
; O
this O
study O
extends RARE
those O
results O
by O
more O
closely O
examining O
the O
horizontal O
and O
vertical O
extents RARE
of O
the O
repulsion RARE
zone O
and O
by O
using O
an O
illusory RARE
contour RARE
to O
induce O
repulsion RARE
. O

The O
effects O
of O
high O
intensity O
light O
emissions RARE
, O
produced O
by O
a O
novel O
pulsed O
power O
energization RARE
technique O
( O
PPET ALLCAPS
), O
on O
the O
survival O
of O
bacterial O
populations O
of O
verocytotoxigenic RARE
Escherichia O
coli O
( O
serotype O
0157 NUMERIC
: O
H7 NUMERIC
) O
and O
Listeria RARE
monocytogenes O
( O
serotype O
4b NUMERIC
) O
were O
investigated O
. O

Multiple O
chemical O
sensitivity O
( O
MCS ALLCAPS
) O
is O
a O
syndrome O
in O
which O
multiple O
symptoms O
reportedly RARE
occur O
with O
low O
- O
level O
chemical O
exposure O
. O

POU I-GENE
- I-GENE
domain I-GENE
proteins I-GENE
, O
such O
as O
the O
pituitary I-GENE
- I-GENE
specific I-GENE
factor I-GENE
Pit I-GENE
- I-GENE
1 I-GENE
, O
are O
members O
of O
the O
homeodomain I-GENE
family I-GENE
of O
proteins O
which O
are O
important O
in O
development O
and O
homeostasis RARE
, O
acting O
constitutively O
or O
in O
response O
to O
signal O
- O
transduction O
pathways O
to O
either O
repress O
or O
activate O
the O
expression O
of O
specific O
genes O
. O

Wild O
- O
type O
and O
mutant O
MyoD I-GENE
were O
introduced O
into O
cells O
using O
an O
E1 I-GENE
, O
E3 I-GENE
- O
deleted O
adenoviral RARE
vector O
. O

These O
results O
suggest O
that O
Thr115 NUMERIC
may O
play O
an O
important O
role O
in O
the O
regulation O
of O
MyoD I-GENE
function O
under O
conditions O
of O
high O
mitogenesis RARE
. O

This O
and O
previous O
results O
suggest O
that O
the O
CRE O
and O
Sp1 I-GENE
site I-GENE
may O
synergistically O
activate O
TH I-GENE
transcription O
in O
a O
promoter O
context O
- O
dependent O
manner O
. O

desmethyltrimebutine RARE
was O
inactive O
. O

Endoscopic RARE
examinations O
, O
peripheral O
white O
blood O
cell O
( O
WBC O
) O
counts O
, O
and O
assays O
of O
myeloperoxidase RARE
activity O
( O
MPO ALLCAPS
) O
in O
homogenates RARE
of O
colon O
mucosa O
were O
performed O
after O
one O
week O
( O
4 O
% O
DSS ALLCAPS
model O
) O
and O
eight O
weeks O
( O
1 O
% O
DSS ALLCAPS
model O
). O

T7 O
transcription O
could O
be O
manipulated RARE
to O
achieve O
different O
levels O
of O
constitutive O
expression O
, O
through O
the O
use O
of O
promoter O
mutations O
. O

The O
primers O
were O
degenerate O
sets O
of O
oligonucleotides O
derived O
from O
known O
amino O
acid O
sequences O
of O
the O
PBAN ALLCAPS
precursor I-GENE
. O

Plants RARE
transformed O
with O
the O
35S I-GENE
- O
1 I-GENE
- I-GENE
sst RARE
construct O
accumulated O
the O
oligofructans RARE
1 O
- O
kestose RARE
( O
GF2 NUMERIC
), O
1 O
, O
1 O
- O
nystose RARE
( O
GF3 NUMERIC
) O
and O
1 O
, O
1 O
, O
1 O
- O
fructosylnystose RARE
( O
GF4 NUMERIC
). O

Based O
on O
the O
comparison O
of O
the O
predicted O
amino O
acid O
sequences O
of O
1 I-GENE
- I-GENE
sst RARE
and O
1 I-GENE
- I-GENE
fft RARE
with O
those O
of O
other O
plant O
fructosyl RARE
transferase I-GENE
genes I-GENE
, O
we O
postulate RARE
that O
both O
plant O
fructan RARE
genes I-GENE
have O
evolved O
from O
plant O
invertase RARE
genes O
. O

However O
, O
ICK1 NUMERIC
was O
induced O
by O
ABA O
, O
and O
along O
with O
ICK1 NUMERIC
induction O
there O
was O
a O
decrease O
in O
Cdc2 I-GENE
- I-GENE
like I-GENE
histone I-GENE
H1 I-GENE
kinase I-GENE
activity O
. O

A O
5 O
. O
0 O
- O
kb O
transcript O
detected O
by O
the O
differential O
display O
amplicon RARE
3G1 NUMERIC
was O
found O
to O
correlate O
strongly O
with O
RAG1 NUMERIC
mRNA I-GENE
expression O
in O
various O
human O
cell O
lines O
. O

The O
hBRAG LASTCAP
gene I-GENE
was O
localized O
to O
the O
long O
arm O
of O
chromosome O
10 O
( O
10q26 NUMERIC
). O

Here O
, O
we O
report O
that O
swa5 NUMERIC
- I-GENE
1 I-GENE
is O
a O
new O
temperature O
- O
sensitive O
allele O
of O
the O
clathrin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
( O
chc1 NUMERIC
- I-GENE
5 I-GENE
), O
which O
carries O
a O
frameshift O
mutation O
near O
the O
3 O
' O
end O
of O
the O
CHC1 NUMERIC
open O
reading O
frame O
. O

We O
have O
determined O
the O
molecular O
lesions O
of O
nine O
Scm RARE
mutant I-GENE
alleles I-GENE
, O
which O
identify O
functional O
requirements O
for O
specific O
domains O
. O

Intriguingly RARE
, O
three O
hypomorphic RARE
Scm RARE
mutations O
, O
which O
map O
within O
an O
mbt RARE
repeat I-GENE
, O
interact O
with O
PcG LASTCAP
mutations I-GENE
more O
strongly O
than O
do O
Scm RARE
null O
alleles O
. O

Northern O
analysis O
revealed O
no O
detectable O
expression O
of O
the O
transcript O
in O
diapause RARE
- O
or O
nondiapause RARE
- O
programmed O
wandering RARE
larvae O
, O
and O
only O
trace RARE
expression O
in O
nondiapausing RARE
pupae RARE
. O

Besides RARE
the O
characterization O
and O
discussion O
of O
the O
experimental O
setup RARE
used O
, O
the O
rate O
constants O
obtained O
are O
discussed O
and O
compared O
with O
estimated O
values O
. O

Genomic O
locus O
of O
chCTCF LASTCAP
contains O
a O
GC O
- O
rich O
untranslated O
exon O
separated O
from O
seven O
coding O
exons O
by O
a O
long O
intron O
. O

The O
presence O
of O
PDZ I-GENE
and O
SAM ALLCAPS
domains O
in O
the O
KS5 NUMERIC
protein I-GENE
suggests O
that O
it O
may O
act O
as O
a O
molecular O
adaptor O
, O
promoting O
and O
relaying RARE
information O
in O
a O
signal O
transduction O
pathway O
. O

BACKGROUND O
: O
Fluoroquinolones RARE
( O
FQ ALLCAPS
) O
are O
contraindicated RARE
in O
children O
because O
of O
the O
risk O
of O
cartilage O
damage O
. O

In O
analyses O
with O
control O
for O
multiple O
variables O
, O
relative O
risk O
for O
microalbuminuria RARE
( O
urinary O
albumin I-GENE
excretion O
, O
20 O
- O
199 NUMERIC
microg O
/ O
min O
) O
in O
men O
and O
women O
was O
2 O
. O
51 O
and O
1 O
. O
62 O
, O
respectively O
, O
with O
18 O
mm O
Hg O
higher O
( O
1 O
SD O
) O
systolic O
blood O
pressure O
; O
2 O
. O
25 O
and O
2 O
. O
10 O
, O
respectively O
, O
with O
1 O
. O
0 O
- O
mmol O
/ O
L O
( O
40 O
mg O
/ O
dL O
) O
higher O
plasma O
cholesterol O
level O
; O
1 O
. O
99 O
and O
1 O
. O
91 O
, O
respectively O
, O
for O
smokers O
vs O
nonsmokers RARE
; O
and O
1 O
. O
83 O
and O
1 O
. O
33 O
, O
respectively O
, O
with O
4 O
kg O
/ O
m2 O
higher O
body O
mass O
index O
. O

However O
, O
while O
IL I-GENE
- I-GENE
1beta I-GENE
and O
TNF I-GENE
- I-GENE
alpha I-GENE
both O
induced O
nuclear O
binding O
of O
the O
Rel I-GENE
proteins I-GENE
p50 I-GENE
and O
p65 I-GENE
to O
an O
NF I-GENE
- I-GENE
kappaB I-GENE
consensus I-GENE
oligonucleotide I-GENE
in O
gel O
shift O
assays O
and O
caused O
transient O
degradation O
of O
inhibitor I-GENE
of I-GENE
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
alpha I-GENE
( O
IkappaB LASTCAP
- I-GENE
alpha I-GENE
) O
in O
the O
cytoplasm O
of O
myofibroblasts RARE
, O
only O
IL I-GENE
- I-GENE
1beta I-GENE
upregulated RARE
PDGF I-GENE
- I-GENE
Ralpha RARE
. O

Cotransfections RARE
with O
ATF I-GENE
- I-GENE
2 I-GENE
and O
HNF I-GENE
- I-GENE
4 I-GENE
expression O
plasmids O
resulted O
in O
additive O
transactivation O
of O
the O
apoCIII LASTCAP
promoter I-GENE
. O

Phosphocreatine RARE
hydrolysis O
during O
submaximal RARE
exercise O
: O
the O
effect O
of O
FIO2 NUMERIC
. O

Pseudocontact RARE
shifts O
arise O
from O
the O
isotropic RARE
reorientational RARE
average O
of O
the O
dipolar RARE
coupling O
between O
unpaired RARE
electron O
and O
nuclei O
, O
in O
the O
presence O
of O
magnetic O
susceptibility O
anisotropy RARE
. O

GETS ALLCAPS
- I-GENE
1 I-GENE
is O
expressed O
in O
many O
tissues O
, O
but O
is O
enriched O
in O
retina O
and O
brain O
. O

The O
interaction O
of O
U1 I-GENE
- I-GENE
70K NUMERIC
with O
the O
SRZ ALLCAPS
proteins I-GENE
is O
confirmed O
further O
in O
vitro O
using O
a O
blot O
overlay RARE
assay O
. O

The O
major O
phenotypes O
resulting O
from O
Fab1p NUMERIC
kinase I-GENE
inactivation O
include O
temperature O
- O
sensitive O
growth O
, O
vacuolar O
acidification O
defects O
, O
and O
dramatic O
increases O
in O
vacuolar O
size O
. O

Small RARE
GTPases I-GENE
of O
the O
Ypt RARE
/ O
Rab RARE
family O
are O
involved O
in O
the O
regulation O
of O
vesicular O
transport O
. O

The O
GEF ALLCAPS
and O
GAP I-GENE
activities O
for O
Ypt1p NUMERIC
localize O
to O
particulate O
cellular O
fractions O
. O

Dopamine I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
( O
DBH ALLCAPS
) O
catalyzes O
the O
conversion O
of O
dopamine O
to O
noradrenaline O
and O
is O
selectively O
expressed O
in O
noradrenergic O
and O
adrenergic O
neurons O
and O
neuroendocrine RARE
cells O
. O

Collectively O
, O
this O
study O
emphasizes O
a O
critical O
role O
of O
Phox2a NUMERIC
as O
well O
as O
its O
functional O
synergism RARE
with O
other O
transcription O
factors O
( O
e O
. O
g O
., O
CREB I-GENE
, O
AP2 I-GENE
, O
and O
Sp1 I-GENE
) O
in O
transcriptional O
activation O
of O
the O
DBH ALLCAPS
gene I-GENE
. O

Interestingly O
, O
an O
antibody O
against O
N I-GENE
- I-GENE
SMase RARE
can O
abrogate O
Ox RARE
- I-GENE
LDL I-GENE
- O
and O
TNF I-GENE
- I-GENE
alpha I-GENE
- O
induced O
apoptosis O
and O
therefore O
may O
be O
useful O
for O
in O
vivo O
studies O
of O
apoptosis O
in O
experimental O
animals O
. O

We O
found O
that O
virulent O
Ngo RARE
strains O
induce O
phosphorylation O
and O
activation O
of O
JNK I-GENE
but O
not O
of O
p38 I-GENE
kinase O
. O

Focused RARE
beams RARE
of O
classical O
light O
ablate RARE
elements O
of O
the O
cell O
division O
machinery O
and O
switch O
the O
beating RARE
of O
hearts O
on O
a O
cellular O
basis O
. O

The O
human O
T O
cell O
lymphotropic RARE
retrovirus O
type O
I O
( O
HTLV O
- O
I O
) O
trans O
- O
activator O
, O
Tax I-GENE
, O
interacts O
specifically O
with O
the O
basic I-GENE
- I-GENE
domain I-GENE
/ I-GENE
leucine I-GENE
- I-GENE
zipper I-GENE
( I-GENE
bZip RARE
) I-GENE
protein I-GENE
, O
cAMP I-GENE
response I-GENE
element I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
), O
bound O
to O
the O
viral I-GENE
Tax I-GENE
- I-GENE
responsive I-GENE
element I-GENE
consisting O
of O
three O
imperfect RARE
21 O
- O
base O
pair O
repeats O
, O
each O
with O
a O
cAMP O
response O
element O
core O
flanked O
by O
G O
/ O
C O
- O
rich O
sequences O
. O

This O
sequence O
is O
very O
similar O
to O
the O
insulin I-GENE
response I-GENE
sequence I-GENE
found O
in O
the O
regulatory O
region O
of O
other O
genes O
negatively O
regulated O
by O
insulin I-GENE
such O
as O
those O
encoding O
phosphoenolpyruvate I-GENE
carboxykinase RARE
, O
tyrosine I-GENE
aminotransferase I-GENE
, O
and O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
. O

The O
murine I-GENE
facilitative RARE
glucose I-GENE
transporter I-GENE
isoform I-GENE
3 I-GENE
( O
Glut RARE
3 I-GENE
) O
is O
developmentally O
regulated O
and O
is O
predominantly O
expressed O
in O
neurons O
and O
trophoblasts RARE
. O

However O
, O
changing O
the O
half O
- O
site O
to O
the O
consensus O
sequence O
AGGTCA ALLCAPS
( O
IRper RARE
- O
1 O
) O
increased O
binding O
of O
AaEcR LASTCAP
. I-GENE
AaUSP LASTCAP
10 O
- O
fold O
over O
IRhsp RARE
- O
1 O
and O
, O
at O
the O
same O
time O
, O
reduced O
the O
stringency RARE
of O
the O
spacer O
length O
requirement O
, O
with O
IRper RARE
- O
0 O
to O
IRper RARE
- O
5 O
showing O
detectable O
binding O
. O

The O
levels O
of O
transactivation O
are O
correlated O
with O
the O
respective O
binding O
affinities O
of O
the O
response O
elements O
( O
IRper RARE
- O
1 O
> O
DR O
- O
4 O
> O
IRhsp RARE
- O
1 O
). O

The O
high O
density O
of O
tegumental RARE
spines RARE
on O
posterior O
half O
of O
the O
body O
and O
the O
distribution O
of O
type O
II O
papillae RARE
on O
dorsal O
surface O
are O
considered O
to O
be O
characteristic O
of O
C O
. O
armatus RARE
. O

Inactivation RARE
of O
p53 I-GENE
but O
not O
p73 NUMERIC
by O
adenovirus I-GENE
type I-GENE
5 I-GENE
E1B I-GENE
55 I-GENE
- I-GENE
kilodalton I-GENE
and I-GENE
E4 NUMERIC
34 I-GENE
- I-GENE
kilodalton I-GENE
oncoproteins I-GENE
. O

The O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
transactivator I-GENE
Zta I-GENE
triggers O
lytic O
gene O
expression O
and O
is O
essential O
for O
replication O
of O
the O
lytic O
origin O
, O
oriLyt RARE
. O

Cotransfection O
of O
the O
helicase I-GENE
- O
primase I-GENE
proteins O
, O
one O
of O
which O
was O
fused O
to O
a O
heterologous O
activation O
domain O
, O
led O
to O
Zta I-GENE
- O
dependent O
superactivation RARE
of O
CAT I-GENE
expression O
. O

Sequence O
comparisons O
strongly O
suggest O
that O
the O
S27a NUMERIC
and O
the O
ubiquitin I-GENE
coding O
sequences O
found O
in O
the O
genome O
of O
CP O
Rit RARE
were O
both O
derived O
from O
a O
bovine O
mRNA O
encoding O
a O
hybrid O
protein O
with O
the O
structure O
NH2 O
- O
ubiquitin I-GENE
- O
S27a NUMERIC
- O
COOH O
. O

J O
. O

There O
was O
a O
trend O
in O
all O
studies O
favouring RARE
PVI ALLCAPS
. O

A O
single O
rectal O
dose O
of O
25 O
mg O
/ O
kg O
will O
obtain O
this O
lower O
concentration O
within O
1 O
h O
of O
administration O
and O
maintain O
it O
for O
up O
to O
6 O
h O
. O

This O
domain O
, O
although O
adjacent O
to O
the O
5 O
' O
edge RARE
of O
the O
SD O
sequence O
, O
does O
not O
inhibit O
ribosome O
binding O
as O
long O
as O
the O
single O
- O
stranded O
region O
of O
domain O
3 O
is O
present O
. O

Although O
YopH LASTCAP
is O
a O
highly O
active O
PTP I-GENE
, O
it O
preferentially O
targets O
a O
subset O
of O
tyrosine O
- O
phosphorylated O
proteins O
in O
host O
cells O
, O
including O
p130Cas NUMERIC
. O

Phylogenetic RARE
position O
of O
the O
Phacotaceae RARE
within O
the O
Chlamydophyceaeas RARE
revealed O
by O
analysis O
of O
18S NUMERIC
rDNA I-GENE
and O
rbcL LASTCAP
sequences I-GENE
. O

Previous O
genetic O
studies O
led O
to O
the O
conclusion O
that O
nitrate O
and O
nitrite O
induction O
of O
nasF LASTCAP
operon I-GENE
expression O
is O
determined O
by O
a O
transcriptional O
antitermination RARE
mechanism O
. O

The O
activation O
and O
injury O
of O
endothelial O
cells O
induced O
by O
TNF I-GENE
and O
other O
proinflammatory RARE
cytokines O
may O
underlie RARE
the O
local O
effects O
of O
these O
mediators RARE
in O
vivo O
. O

A O
technique O
for O
thermal O
imaging O
of O
the O
animal O
and O
human O
brain O
cortex O
using O
an O
infrared RARE
optical O
system O
is O
described O
. O

EGFR I-GENE
levels O
were O
found O
to O
be O
elevated O
5 O
-, O
3 O
. O

Here O
we O
demonstrate O
that O
THOV ALLCAPS
NP I-GENE
contains O
a O
motif O
( O
KRxxxxxxxxxKTKK LASTCAP
) O
at O
amino O
acid O
positions O
179 NUMERIC
- O
193 O
that O
represents O
a O
classical O
bipartite O
nuclear O
localization O
signal O
( O
NLS O
). O

As O
PP2A I-GENE
exerts O
a O
range O
of O
cellular O
functions O
including O
cell O
cycle O
regulation O
and O
cell O
fate O
determination O
, O
we O
were O
surprised RARE
to O
find O
that O
these O
embryos O
develop O
normally O
until O
postimplantation RARE
, O
around O
embryonic O
day O
5 O
. O
5 O
/ O
6 O
. O
0 O
. O

The O
most O
frequent O
risk O
factor O
for O
ischaemic O
was O
hypertension O
. O

The O
results O
indicate O
that O
anthraquinone RARE
sennoside RARE
B O
and O
rhein RARE
are O
weakly O
genotoxic RARE
. O

Furthermore O
, O
LB1 NUMERIC
gene I-GENE
mapped O
to O
chromosome O
13q14 NUMERIC
, O
a O
region O
that O
has O
been O
involved O
as O
a O
chromosomal O
breakpoint O
in O
DLBL ALLCAPS
. O

16 O
subjects O
were O
repatch RARE
tested O
to O
ethylmercury RARE
chloride O
( O
EtHgCl RARE
) O
and O
to O
solutions O
containing O
EtHgCl RARE
mixed O
with O
L O
- O
cysteine O
and O
glutathione O
, O
respectively O
. O

Wild I-GENE
- I-GENE
type I-GENE
AT1A NUMERIC
receptors I-GENE
, O
expressed O
in O
Chinese O
hamster O
ovary O
cells O
, O
rapidly O
internalized RARE
after O
Ang RARE
II I-GENE
stimulation O
[ O
t1 O
/ O
2 O
2 O
. O
3 O
min O
; O
maximal O
level O
of O
internalization O
( O
Ymax O
) O
78 O
. O
2 O
%], RARE
as O
did O
mutant O
receptors O
carrying O
single O
acidic O
substitutions O
( O
T332E NUMERIC
, O
t1 O
/ O
2 O
2 O
. O
7 O
min O
, O
Ymax O
76 O
. O
3 O
%; O
S335D NUMERIC
, O
t1 O
/ O
2 O
2 O
. O
4 O
min O
, O
Ymax O
76 O
. O
7 O
%; O
T336E NUMERIC
, O
t1 O
/ O
2 O
2 O
. O
5 O
min O
, O
Ymax O
78 O
. O
2 O
%; O
S338D NUMERIC
, O
t1 O
/ O
2 O
2 O
. O
6 O
min O
, O
Ymax O
78 O
. O
4 O
%). O

The O
activated O
glucocorticoid I-GENE
receptor I-GENE
forms O
a O
complex O
with O
Stat5 I-GENE
and O
enhances O
Stat5 I-GENE
- O
mediated O
transcriptional O
induction O
. O

T O
., O
Mahasneh RARE
, O
A O
., O
and O
Cote RARE
, O
G O
. O

The O
carboxyl O
- O
terminal O
portion O
of O
UKLF ALLCAPS
contains O
three O
zinc O
fingers O
of O
the O
Cys2 NUMERIC
- O
His2 NUMERIC
type O
and O
binds O
in O
vitro O
to O
the O
CACCC ALLCAPS
motif O
of O
the O
beta I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
and O
to O
the O
Sp1 I-GENE
recognition I-GENE
sequence I-GENE
. O

We O
have O
recently O
identified O
a O
mouse O
enzyme O
termed O
gamma I-GENE
- I-GENE
glutamyl I-GENE
leukotrienase RARE
( O
GGL ALLCAPS
) O
that O
converts RARE
leukotriene RARE
C4 O
( O
LTC4 NUMERIC
) O
to O
leukotriene RARE
D4 NUMERIC
( O
LTD4 NUMERIC
). O

UGA O
codon O
position O
affects O
the O
efficiency O
of O
selenocysteine O
incorporation O
into O
glutathione I-GENE
peroxidase I-GENE
- I-GENE
1 I-GENE
. O

Forskolin RARE
significantly O
enhanced O
heregulin RARE
- O
stimulated O
expression O
of O
cyclin I-GENE
D I-GENE
and O
phosphorylation O
of O
the O
retinoblastoma I-GENE
gene I-GENE
product I-GENE
. O

The O
ARF I-GENE
promoter I-GENE
was O
also O
found O
to O
be O
highly O
responsive O
to O
E2F1 I-GENE
expression O
, O
in O
keeping RARE
with O
previous O
results O
at O
the O
RNA O
level O
. O

RESULTS O
: O
The O
binding O
of O
99mTc O
d O
, O
1 O
- O
HMPAO O
to O
human O
placenta O
ranged O
from O
2 O
. O
95 O
% O
+/- O
1 O
. O
5 O
% O
to O
5 O
. O
82 O
% O
+/- O
0 O
. O
3 O
% O
per O
1 O
ml O
standard O
solution O
. O

CM O
reduced O
the O
nuclear O
binding O
activity O
of O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
1 I-GENE
. O

NF I-GENE
- I-GENE
kappaB I-GENE
, O
which O
is O
probably O
important O
for O
basal O
activity O
of O
the O
human I-GENE
NOS ALLCAPS
II I-GENE
promoter I-GENE
, O
is O
unlikely O
to O
function O
as O
a O
major O
effector O
of O
CM O
in O
DLD ALLCAPS
- O
1 O
cells O
. O

Observers RARE
with O
brain O
injury O
and O
control O
participants RARE
performed O
a O
vigilance RARE
task O
during O
which O
they O
received O
periodic O
whiffs RARE
of O
unscented RARE
air O
or O
air O
scented RARE
with O
peppermint RARE
. O

A O
simple O
analytical RARE
method O
for O
l O
- O
menthol RARE
by O
high O
- O
performance O
liquid O
chromatography O
with O
a O
polarized RARE
photometric RARE
detector O
was O
established O
. O

RESULTS O
: O
The O
cardiac O
index O
significantly O
changed O
with O
varying O
PaCO2 O
levels O
( O
hypocapnia RARE
, O
- O
9 O
%; O
hypercapnia O
, O
13 O
%). O

After O
measuring O
baseline O
Vmca RARE
at O
a O
partial O
pressure O
of O
carbon O
dioxide O
in O
arterial O
blood O
( O
PaCO2 O
) O
of O
37 O
. O
7 O
+/- O
4 O
. O
5 O
mmHg O
( O
mean O
+/- O
SD O
), O
measurements O
were O
repeated O
at O
a O
PaCO LASTCAP
of O
44 O
. O
2 O
+/- O
3 O
. O
8 O
mmHg O
, O
and O
the O
carbon O
dioxide O
reactivity O
( O
absolute O
value O
: O
cm O
x O
s O
(- O
1 O
) O
x O
mmHg O
(- O
1 O
); O
relative O
value O
: O
percentage O
of O
baseline O
Vmca RARE
/ O
mmHg O
) O
was O
calculated O
. O

Multivariate RARE
Cox O
survival O
analysis O
identified O
baseline O
EF O
< O
or O
= O
30 O
%, O
presence O
of O
significant O
mitral O
regurgitation RARE
(> O
2 O
+) O
before O
ablation O
, O
and O
failure O
to O
exhibit O
improved O
cardiac O
performance O
by O
1 O
month O
after O
ablation O
as O
the O
only O
independent O
predictors O
of O
death O
. O

We O
have O
developed O
a O
new O
method O
for O
estimation O
of O
regional O
CBF O
( O
rCBF O
) O
and O
cerebrovascular RARE
reserve O
capacity O
on O
a O
pixel RARE
- O
by O
- O
pixel RARE
basis O
by O
means O
of O
dynamic O
magnetic O
resonance O
imaging O
( O
MRI O
). O

Cost RARE
- O
effectiveness O
analysis O
provides O
a O
rational RARE
means O
of O
allocating RARE
limited O
health O
care O
resources RARE
by O
allowing O
the O
comparison O
of O
the O
costs O
of O
lipid O
- O
lowering O
therapy O
, O
in O
particular O
, O
therapy O
with O
beta I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
beta I-GENE
- I-GENE
methylglutaryl RARE
- I-GENE
CoA I-GENE
( I-GENE
coenzyme I-GENE
A I-GENE
) I-GENE
reductase I-GENE
inhibitors O
( O
statins RARE
), O
with O
the O
costs O
of O
atherosclerosis O
that O
could O
be O
prevented O
by O
lowering O
cholesterol O
. O

Although O
E2FBP1 NUMERIC
lacks O
the O
transactivation O
domain O
, O
it O
stimulates O
E2F I-GENE
site O
- O
dependent O
transcription O
in O
cooperation O
with O
E2F I-GENE
- I-GENE
1 I-GENE
. O

Sequencing O
of O
a O
40 O
- O
kb O
DNA O
segment O
of O
the O
FK506 O
gene O
cluster O
from O
Streptomyces O
sp O
. O

The O
predicted O
domain O
structures O
of O
FkbB LASTCAP
and O
FkbC LASTCAP
are O
analogous O
to O
that O
of O
FkbA LASTCAP
and O
comprise O
30 O
fatty I-GENE
- I-GENE
acid I-GENE
- I-GENE
synthase I-GENE
( O
FAS ALLCAPS
)- O
like O
domains O
arranged O
in O
6 O
modules O
. O

Analysis O
of O
Msy2 NUMERIC
mRNA I-GENE
expression O
in O
prepubertal RARE
and O
adult O
mouse O
testes O
, O
and O
in O
isolated O
populations O
of O
germ O
cells O
, O
reveals O
maximal O
expression O
in O
postmeiotic RARE
round O
spermatids RARE
, O
a O
cell O
type O
with O
abundant O
amounts O
of O
stored O
messenger O
ribonucleoproteins RARE
. O

1 O
in O
Ho RARE
Chi O
Minh RARE
City O
was O
studied O
by O
culture O
and O
latex O
agglutination O
of O
blood O
, O
cerebrospinal O
fluid O
, O
urine O
and O
pleural O
fluid O
. O

Glycogen RARE
synthesis O
and O
catabolism O
, O
gluconeogenesis RARE
, O
glycolysis RARE
, O
motility O
, O
cell O
surface O
properties O
and O
adherence RARE
are O
modulated O
by O
csrA LASTCAP
in I-GENE
Escherichia I-GENE
coli I-GENE
, O
while O
the O
production O
of O
several O
secreted O
virulence O
factors O
, O
the O
plant O
hypersensitive O
response O
elicitor RARE
HrpN LASTCAP
( O
Ecc RARE
) O
and O
, O
potentially O
, O
other O
secondary O
metabolites O
are O
regulated O
by O
rsmA LASTCAP
in I-GENE
Erwinia RARE
carotovora RARE
. O

The O
cwg2 NUMERIC
- I-GENE
1 I-GENE
mutation I-GENE
was O
identified O
as O
a O
guanine O
to O
adenine O
substitution O
at O
nucleotide O
604 NUMERIC
of O
the O
coding O
region O
, O
originating RARE
the O
change O
A202T NUMERIC
in O
the O
cwg2p NUMERIC
. O

Deletion O
analysis O
revealed O
that O
the O
essential O
domain O
of O
this O
promoter O
, O
termed O
the O
ORF5 NUMERIC
/ I-GENE
deltaX LASTCAP
transcript I-GENE
promoter I-GENE
, O
mapped O
to O
nucleotides O
1525 NUMERIC
- O
1625 NUMERIC
. O

Some O
of O
the O
peptide I-GENE
: I-GENE
MBP I-GENE
fusions I-GENE
were O
also O
analyzed O
using O
surface O
plasmon RARE
resonance O
. O

Cardiac I-GENE
myosin I-GENE
- I-GENE
binding I-GENE
protein I-GENE
C I-GENE
( O
MyBP LASTCAP
- I-GENE
C I-GENE
): O
identification O
of O
protein I-GENE
kinase I-GENE
A I-GENE
and O
protein I-GENE
kinase I-GENE
C I-GENE
phosphorylation O
sites O
. O

Handling RARE
on O
PND ALLCAPS
9 O
did O
not O
result O
in O
elevated O
CORT ALLCAPS
levels O
in O
any O
of O
the O
groups O
. O

Analysis O
of O
chromosomal O
DNA O
sequence O
immediately O
downstream O
of O
the O
transposon O
insertion O
identified O
two O
open O
reading O
frames O
, O
designated O
csrR LASTCAP
and O
csrS LASTCAP
, O
which O
exhibited O
sequence O
similarity O
to O
bacterial O
two O
- O
component O
regulatory O
systems O
. O

633 NUMERIC
+/- O
258 O
aggregates O
/ O
ml O
at O
0 O
rpm RARE
; O
P O
< O
0 O
. O
001 O
). O

We O
previously O
delineated RARE
a O
region O
in O
the O
fatty I-GENE
- I-GENE
acid I-GENE
synthase I-GENE
promoter I-GENE
, O
which O
was O
responsible O
for O
obesity O
- O
related O
overexpression O
of O
the O
fatty I-GENE
- I-GENE
acid I-GENE
synthase I-GENE
( O
FAS ALLCAPS
) O
gene O
, O
by O
negatively O
regulating O
the O
activity O
of O
the O
downstream O
promoter O
in O
lean O
but O
not O
obese O
rat O
fat O
cells O
. O

Finally O
, O
using O
in O
vitro O
binding O
studies O
, O
we O
showed O
that O
SREBP2 NUMERIC
was O
able O
to O
displace RARE
ADD1 NUMERIC
/ O
SREBP1 NUMERIC
binding O
from O
the O
sterol O
regulatory O
element O
( O
SRE O
) O
site O
. O

Thus O
, O
IRF I-GENE
- I-GENE
7 I-GENE
exhibits O
functional O
similarity O
to O
IRF I-GENE
- I-GENE
3 I-GENE
; O
however O
, O
the O
preferential O
expression O
of O
IRF I-GENE
- I-GENE
7 I-GENE
in O
lymphoid O
cells O
( O
the O
cell O
type O
that O
expresses RARE
IFNA ALLCAPS
) O
suggests O
that O
IRF I-GENE
- I-GENE
7 I-GENE
may O
play O
a O
critical O
role O
in O
regulating O
the O
IFNA ALLCAPS
gene I-GENE
expression O
. O

J O
. O

PURPOSE O
: O
The O
role O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
in O
the O
treatment O
of O
congenital O
thrombocytopenias RARE
is O
unknown O
. O

CKII ALLCAPS
as O
a O
CD44 I-GENE
- I-GENE
associated I-GENE
serine I-GENE
kinase I-GENE
therefore O
may O
serve O
as O
an O
important O
molecule O
in O
a O
signaling O
cascade O
that O
produces O
a O
variety O
of O
cellular O
responses O
in O
MDA231 NUMERIC
breast O
cancer O
cells O
. O

Galphaq RARE
, O
Galpha12 NUMERIC
, O
and O
Galpha13 NUMERIC
, O
but O
not O
Galphai RARE
, O
activate O
SRF I-GENE
through O
RhoA I-GENE
. O

Additionally O
in O
seven O
subjects O
adrenaline O
( O
A O
) O
and O
noradrenaline O
( O
NA O
) O
concentrations O
were O
determined O
. O

Northern O
blot O
analyses O
show O
that O
the O
hBub1 NUMERIC
mRNA I-GENE
level O
is O
abundantly O
expressed O
in O
tissues O
or O
cells O
with O
a O
high O
mitotic O
index O
. O

We O
mapped O
two O
overlapping O
expressed O
sequence O
tag O
clones O
within O
a O
genomic O
contig O
on O
human O
chromosome O
5 O
, O
band O
q31 NUMERIC
. O

Htra2 NUMERIC
- I-GENE
beta3 NUMERIC
is O
developmentally O
regulated O
and O
expressed O
predominantly O
in O
brain O
, O
liver O
testis O
, O
and O
weakly O
in O
kidney O
. O

Gng3lg NUMERIC
transcripts I-GENE
are O
expressed O
in O
a O
variety O
of O
tissues O
including O
both O
brain O
and O
testes O
. O

Using O
an O
interspecific RARE
backcross O
panel O
, O
we O
localized O
both O
Gng3 NUMERIC
and O
Gng3lg NUMERIC
to O
the O
same O
locus O
on O
chromosome O
19 O
. O

We O
also O
raised O
a O
polyclonal RARE
antibody O
against O
the O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
protein I-GENE
containing O
the O
NH2 O
- O
terminal O
86 O
amino O
acids O
of O
human I-GENE
NRAMP2 NUMERIC
. O

Inhibition O
of O
the O
apolipoprotein I-GENE
B I-GENE
mRNA I-GENE
editing RARE
enzyme O
- O
complex O
by O
hnRNP I-GENE
C1 I-GENE
protein I-GENE
and O
40S NUMERIC
hnRNP I-GENE
complexes I-GENE
. O

SRC I-GENE
- I-GENE
1 I-GENE
can O
relieve RARE
the O
NF I-GENE
- I-GENE
kappaB I-GENE
- O
mediated O
repression O
of O
GR I-GENE
activity O
. O

However O
the O
sequence O
surrounding O
the O
transcription O
start O
site O
CTCA ALLCAPS
(+ O
1 O
) O
TTCC ALLCAPS
was O
similar O
to O
the O
consensus O
CTCA ALLCAPS
(+ O
1 O
) O
NTCT ALLCAPS
( O
N O
is O
any O
nucleoside RARE
) O
for O
an O
initiator O
element O
found O
in O
terminal I-GENE
deoxynucleotidyltransferase RARE
and O
a O
number O
of O
other O
highly O
regulated O
genes O
. O

These O
results O
indicate O
that O
the O
total O
number O
of O
subunit O
c O
in O
F0 NUMERIC
should O
be O
a O
multiple O
of O
2 O
and O
3 O
. O

Expression O
of O
a O
dominant O
- O
negative O
mutant O
of O
JNK1 I-GENE
also O
suppressed O
glucose O
deprivation O
- O
induced O
JNK1 I-GENE
activation O
as O
well O
as O
HSP70 I-GENE
gene I-GENE
expression O
. O

The O
interaction O
of O
AF O
- O
1 O
with O
proteins O
that O
regulate O
distinct O
steps O
of O
transcription O
may O
provide O
a O
mechanism O
for O
synergistic O
activation O
of O
gene O
expression O
by O
AF O
- O
1 O
. O

The O
role O
of O
protein I-GENE
kinase I-GENE
C I-GENE
signaling O
in O
activated O
DRA ALLCAPS
transcription O
. O

Ligand RARE
binding O
to O
the O
receptor O
complex O
leads O
to O
tyrosine O
phosphorylation O
and O
activation O
of O
Janus I-GENE
kinases I-GENE
( O
Jak I-GENE
), O
phosphorylation O
of O
the O
signal I-GENE
transducing RARE
subunit I-GENE
gp130 NUMERIC
, O
followed O
by O
recruitment O
and O
phosphorylation O
of O
the O
signal I-GENE
transducer RARE
and I-GENE
activator I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
STAT3 I-GENE
and O
STAT1 I-GENE
and O
the O
src I-GENE
homology I-GENE
domain I-GENE
( O
SH2 I-GENE
)- O
containing O
protein I-GENE
tyrosine I-GENE
phosphatase I-GENE
( O
SHP2 NUMERIC
). O

Interestingly O
, O
an O
increase O
of O
distance O
per O
se RARE
did O
not O
have O
a O
deleterious RARE
effect O
on O
translation O
efficiency O
. O

We O
also O
mapped O
a O
3 O
'- O
polyadenylation O
site O
504bp NUMERIC
downstream O
of O
the O
TGA ALLCAPS
stop O
codon O
, O
consistent O
with O
the O
2 O
. O
5kb NUMERIC
transcript O
size O
. O

RBP56 NUMERIC
protein I-GENE
turned O
out O
to O
be O
hTAFII68 NUMERIC
which O
was O
isolated O
as O
a O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
associated I-GENE
factor I-GENE
( O
TAF I-GENE
) O
from O
a O
sub O
- O
population O
of O
TFIID I-GENE
complexes I-GENE
( O
Bertolotti RARE
A O
., O
Lutz RARE
, O
Y O
., O
Heard RARE
, O
D O
. O
J O
., O
Chambon RARE
, O
P O
., O
Tora RARE
, O
L O
., O
1996 O
. O
hTAFII68 NUMERIC
, O
a O
novel O
RNA O
/ O
ssDNA O
- O
binding O
protein O
with O
homology O
to O
the O
proto O
- O
oncoproteins O
TLS ALLCAPS
/ O
FUS ALLCAPS
and O
EWS I-GENE
is O
associated O
with O
both O
TFIID I-GENE
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
. O

An O
electrophoretic O
mobility O
shift O
assay O
was O
performed O
to O
characterize O
the O
binding O
property RARE
of O
TR2 NUMERIC
and O
its O
truncated O
isoform O
. O

Gel O
- O
mobility O
shift O
analysis O
was O
also O
performed O
for O
the O
CCAAT O
motif O
at O
- O
67 O
. O

BACKGROUND O
: O
The O
c I-GENE
- I-GENE
myc I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
has O
been O
suggested O
to O
play O
key O
roles O
in O
cell O
proliferation O
, O
differentiation O
, O
transformation O
and O
apoptosis O
. O

AMY ALLCAPS
- I-GENE
1 I-GENE
was O
localized O
in O
the O
cytoplasm O
in O
cells O
expressing O
c I-GENE
- I-GENE
myc I-GENE
at O
low O
levels O
, O
but O
in O
the O
nucleus O
in O
the O
cells O
of O
a O
high O
c I-GENE
- I-GENE
myc I-GENE
expression O
in O
transiently O
transfected O
cells O
. O

RESULTS O
: O
We O
identified O
a O
full O
- O
length O
cDNA O
with O
an O
open O
reading O
frame O
of O
2883 NUMERIC
bp O
corresponding O
to O
a O
predicted O
protein O
of O
961 NUMERIC
amino O
acids O
that O
shares O
greater O
than O
95 O
% O
homology O
with O
the O
rat I-GENE
gamma I-GENE
- I-GENE
aminobutyric RARE
acid I-GENE
B I-GENE
( I-GENE
GABAB ALLCAPS
) I-GENE
receptor I-GENE
. O

On O
Day O
8 O
, O
the O
CIDR ALLCAPS
- O
B O
was O
removed O
and O
500 O
micrograms O
cloprostenol RARE
injected O
, O
IM O
. O

Antidepressant RARE
- O
like O
properties O
of O
some O
serotonin I-GENE
receptor I-GENE
ligands O
and O
calcium O
channel O
antagonists O
measured O
with O
the O
forced RARE
swimming O
test O
in O
mice O
. O

Another O
tentative RARE
hotspot RARE
mutation O
in O
the O
third O
patient O
, O
a O
frame O
shift O
caused O
by O
a O
G O
nucleotide O
insertion O
in O
a O
monotonous RARE
repeat O
of O
six O
Gs O
in O
HPRT ALLCAPS
exon I-GENE
3 I-GENE
, O
has O
been O
reported O
previously O
in O
three O
other O
LN ALLCAPS
patients O
. O

SRF I-GENE
- O
deficient O
embryos O
( O
Srf RARE
-/-) RARE
have O
a O
severe O
gastrulation RARE
defect O
and O
do O
not O
develop O
to O
term O
. O

These O
characteristic O
structural O
features O
were O
used O
to O
create O
the O
abbreviation RARE
AZF1 NUMERIC
( O
Asparagine RARE
- I-GENE
rich I-GENE
Zinc RARE
Finger RARE
protein I-GENE
). O

Over RARE
- O
expression O
of O
Azf1p NUMERIC
in O
the O
yeast O
cell O
does O
not O
influence O
the O
expression O
level O
of O
the O
mitochondrial I-GENE
transcription I-GENE
factor I-GENE
Mtf1p NUMERIC
, O
indicating O
that O
the O
influence O
of O
Azf1p NUMERIC
on O
the O
suppression O
of O
the O
special O
mitochondrial I-GENE
RNA I-GENE
polymerase I-GENE
mutant I-GENE
is O
an O
indirect O
one O
. O

We O
have O
generated O
a O
computer O
model O
of O
the O
C O
- O
terminal O
domain O
of O
the O
434 NUMERIC
repressor O
based O
on O
the O
crystal O
structure O
of O
the O
homologous I-GENE
UmuD I-GENE
' I-GENE
protein I-GENE
. O

Large O
- O
scale O
sequencing O
of O
two O
regions O
in O
human O
chromosome O
7q22 NUMERIC
: O
analysis O
of O
650 NUMERIC
kb O
of O
genomic O
sequence O
around O
the O
EPO I-GENE
and O
CUTL1 NUMERIC
loci I-GENE
reveals O
17 O
genes O
. O

Because O
Trp53 NUMERIC
( O
the O
mouse I-GENE
homolog I-GENE
of I-GENE
human I-GENE
TP53 NUMERIC
) O
is O
located O
with O
Tk1 NUMERIC
on O
chromosome O
11 O
and O
is O
critical O
in O
regulating O
cellular O
responses O
following O
exposure O
to O
DNA O
damaging RARE
agents O
, O
we O
wanted RARE
to O
determine O
if O
these O
mouse O
lymphoma O
cells O
harbor O
mutations O
in O
Trp53 NUMERIC
. O

One O
of O
these O
fragments O
shows O
the O
highest O
amino O
acid O
sequence O
homology O
to O
the O
insect O
ecdysone O
inducible O
gene I-GENE
E75 NUMERIC
. O

The O
full O
- O
length O
N I-GENE
gene I-GENE
, O
encoded O
by O
open O
reading O
frame O
7 O
, O
was O
cloned O
from O
the O
Canadian RARE
PRRS ALLCAPS
virus O
, O
PA O
- O
8 O
. O

Based O
on O
sequence O
homology O
, O
the O
genes O
were O
identified O
as O
TEF I-GENE
, O
encoding O
translation I-GENE
elongation I-GENE
factor I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
and O
RPS7 NUMERIC
, O
encoding O
ribosomal O
protein O
S7 NUMERIC
. O

We O
have O
previously O
shown O
that O
ARNO ALLCAPS
localizes O
to O
the O
plasma O
membrane O
in O
vivo O
and O
efficiently O
catalyzes O
ARF6 NUMERIC
nucleotide O
exchange O
in O
vitro O
. O

Renal O
pathology O
and O
long O
- O
term O
outcome O
in O
childhood O
SLE O
. O

Transcription O
factors O
of O
the O
Stat I-GENE
family I-GENE
are O
controlled O
by O
protein O
kinases O
. O

We O
propose O
that O
two O
pathways O
regulate O
Stat5 I-GENE
serine O
phosphorylation O
, O
one O
that O
is O
prolactin I-GENE
- O
activated O
and O
PD98059 O
- O
resistant O
and O
one O
that O
is O
constitutively O
active O
and O
PD98059 O
- O
sensitive O
and O
preferentially O
targets O
Stat5a I-GENE
. O

An O
approximately O
37 O
- O
kDa O
cytoplasmic O
protein O
is O
rapidly O
tyrosine O
- O
phosphorylated O
in O
the O
response O
of O
mouse O
BAC1 NUMERIC
. O
2F5 NUMERIC
macrophages O
to O
colony I-GENE
stimulating I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
). O
pp37 NUMERIC
was O
purified O
from O
the O
cytosolic O
fraction O
by O
anti I-GENE
- I-GENE
Tyr I-GENE
( I-GENE
P I-GENE
) I-GENE
affinity O
chromatography O
, O
size O
exclusion O
chromatography O
, O
and O
C4 O
reverse O
phase O
high O
pressure O
liquid O
chromatography O
. O

Dose RARE
of O
20 O
ig RARE
were O
administered O
within O
a O
scheme RARE
from O
0 O
. O
1 O
to O
6 O
months O
in O
order O
to O
study O
its O
immunogenicity RARE
, O
which O
was O
evaluated O
at O
2 O
, O
7 O
, O
and O
12 O
months O
after O
the O
first O
dose O
. O

The O
various O
available O
data O
strongly O
suggesting O
an O
environmental O
toxic O
origin O
for O
the O
" O
sperm O
fall O
" O
will O
be O
presented O
as O
well O
as O
the O
most O
frequently O
suspected O
class O
of O
substances O
, O
the O
xenoestrogens RARE
. O

This O
association O
was O
independently O
significant O
for O
patients O
treated O
primarily O
( O
not O
for O
recurrence O
). O

CONCLUSION O
: O
Local RARE
control O
was O
highest O
with O
Preop RARE
in O
patients O
presenting O
primarily O
with O
gross O
disease O
, O
and O
with O
Postop RARE
in O
patients O
presenting O
primarily O
following O
gross O
total O
excision O
. O

Its O
interaction O
with O
RFX5 NUMERIC
and O
RFXAP ALLCAPS
is O
essential O
for O
binding O
of O
the O
RFX ALLCAPS
complex I-GENE
to O
MHC I-GENE
- I-GENE
II I-GENE
promoters I-GENE
. O

We O
have O
previously O
mapped O
the O
defect O
in O
RIIIS ALLCAPS
/ O
J O
to O
distal O
mouse O
Chr O
11 O
, O
distinct O
from O
the O
Vwf RARE
locus I-GENE
on O
Chr O
6 O
. O

These O
data O
may O
also O
aid O
in O
the O
localization O
of O
other O
disease O
loci O
mapped O
to O
this O
region O
, O
including O
the O
gene O
for O
tricho RARE
- O
dento RARE
- O
osseous RARE
syndrome O
and O
a O
murine O
locus O
for O
susceptibility O
to O
ozone RARE
- O
induced O
acute O
lung O
injury O
. O

Copyright O
1998 O
Academic O
Press O
. O

An O
open O
reading O
frame O
encoding O
a O
protein O
which O
shows O
significant O
similarity O
to O
invertases RARE
and O
resolvases RARE
was O
located O
immediately O
upstream O
of O
the O
Pac25I NUMERIC
R I-GENE
- I-GENE
M I-GENE
operon I-GENE
. O

Identification O
of O
a O
new O
gene O
in O
the O
streptococcal O
plasmid O
pLS1 NUMERIC
: O
the O
rnaI LASTCAP
gene I-GENE
. O

Rather RARE
, O
usp RARE
is O
required O
in O
late O
third O
instar RARE
larvae O
for O
appropriate O
developmental O
and O
transcriptional O
responses O
to O
the O
ecdysone O
pulse O
that O
triggers O
puparium RARE
formation O
. O

An O
intact O
neurovascular RARE
supply O
is O
essential O
for O
the O
viability O
of O
a O
muscle O
flap O
. O

Examination O
of O
DNA O
: O
protein O
binding O
complexes O
by O
gel O
- O
shift O
analysis O
indicated O
that O
nuclear O
factors O
from O
both O
proliferative O
and O
growth O
- O
arrested O
cells O
bound O
to O
the O
DNA O
fragment O
spanning O
- O
949 NUMERIC
- O
- O
722 NUMERIC
bp O
. O

BACKGROUND O
: O
Studies O
in O
lean O
men O
show O
poor O
regulation O
of O
energy O
( O
EB ALLCAPS
) O
and O
fat O
balance O
( O
FB O
) O
during O
manipulation RARE
of O
dietary O
ratios O
of O
fat O
to O
carbohydrate O
. O

Fatal RARE
apneusis RARE
was O
observed O
under O
following O
conditions O
: O
( O
1 O
) O
Persistent RARE
apnea O
was O
produced O
after O
a O
single O
KA ALLCAPS
microinjection O
in O
one O
side O
of O
the O
VRG ALLCAPS
- O
Apa RARE
( O
5 O
animals O
). O

A O
comparative O
analysis O
of O
the O
reported O
MOCT ALLCAPS
- O
associated O
malignant O
melanomas O
emphasizes O
the O
singularity RARE
of O
our O
case O
in O
the O
amelanotic RARE
character O
of O
the O
melanoma O
, O
its O
lymphotropism RARE
and O
the O
coexistence RARE
of O
invasive O
squamous O
cell O
carcinoma O
. O

RESULTS O
: O
An O
herpetic RARE
seroconversion RARE
is O
observed O
with O
presence O
of O
type O
I O
herpes O
simplex O
virus O
( O
HSV O
I O
) O
nucleic O
acids O
in O
the O
recipient O
' O
s O
aqueous O
humor RARE
. O

These O
results O
indicate O
that O
HIV O
- O
1 O
Gag I-GENE
sequences I-GENE
can O
influence O
the O
viral I-GENE
PR I-GENE
- O
mediated O
processing O
of O
the O
MuLV O
TM I-GENE
Env I-GENE
protein I-GENE
p15 NUMERIC
( O
E O
). O

These O
results O
demonstrate O
a O
specific O
association O
of O
SIV O
and O
HIV I-GENE
- I-GENE
2 I-GENE
nef I-GENE
, O
but O
not O
HIV I-GENE
- I-GENE
1 I-GENE
nef I-GENE
, O
with O
TCRzeta RARE
. O

Competition O
EMSA O
established O
that O
constitutively O
expressed O
nuclear O
proteins O
bound O
the O
KCS I-GENE
element I-GENE
selectively O
; O
KCS I-GENE
protein I-GENE
binding O
activity O
correlated O
with O
promoter O
activity O
in O
the O
transient O
transfection O
reporter O
assay O
. O

Mechanism O
of O
interferon I-GENE
action O
: O
identification O
of O
essential O
positions O
within O
the O
novel O
15 I-GENE
- I-GENE
base I-GENE
- I-GENE
pair I-GENE
KCS I-GENE
element I-GENE
required O
for O
transcriptional O
activation O
of O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
pkr RARE
gene I-GENE
. O

GH I-GENE
failed O
to O
stimulate O
phosphorylation O
or O
activation O
of O
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
under O
the O
conditions O
used O
. O

Expression O
of O
a O
novel O
murine I-GENE
phospholipase I-GENE
D I-GENE
homolog I-GENE
coincides RARE
with O
late O
neuronal O
development O
in O
the O
forebrain RARE
. O

We O
detected O
no O
effect O
of O
deleting RARE
YCL024W NUMERIC
, O
either O
alone O
or O
in O
combination O
with O
deletion O
of O
GIN4 NUMERIC
. O

Paralemmin RARE
is O
also O
phosphorylated O
, O
and O
its O
mRNA O
is O
differentially O
spliced O
in O
a O
tissue O
- O
specific O
and O
developmentally O
regulated O
manner O
. O

The O
deduced O
amino O
acid O
sequence O
of O
CBP90 NUMERIC
had O
no O
significant O
similarity O
to O
any O
other O
protein O
, O
but O
it O
had O
a O
proline O
- O
rich O
domain O
at O
the O
C O
- O
terminal O
region O
. O

The O
effect O
of O
low O
- O
profile O
serine O
substitutions O
in O
the O
V3 NUMERIC
loop O
of O
HIV O
- O
1 O
gp120 I-GENE
IIIB I-GENE
/ O
LAI ALLCAPS
on O
the O
immunogenicity RARE
of O
the O
envelope I-GENE
protein O
. O

Transcription O
start O
site O
mapping O
identified O
the O
presence O
of O
an O
aphidicolin RARE
- O
sensitive O
late O
transcript O
arising O
from O
a O
TAAG ALLCAPS
motif O
located O
at O
- O
352 NUMERIC
nucleotides O
and O
an O
aphidicolin RARE
- O
insensitive RARE
early O
transcript O
originating RARE
from O
a O
TTGT ALLCAPS
motif O
located O
35 O
nucleotides O
downstream O
to O
a O
TATA O
box O
at O
- O
312 NUMERIC
nucleotides O
, O
with O
respect O
to O
the O
+ O
1 O
ATG O
of O
lef2 NUMERIC
. O

The O
human I-GENE
2 I-GENE
', I-GENE
5 I-GENE
'- I-GENE
oligoadenylate RARE
( I-GENE
2 I-GENE
- I-GENE
5A NUMERIC
) I-GENE
synthetases I-GENE
are O
members O
of O
a O
family O
interferon I-GENE
( O
IFN I-GENE
)- O
inducible O
anti I-GENE
- I-GENE
viral I-GENE
proteins I-GENE
. O

Our O
findings O
demonstrate O
a O
dose O
- O
dependent O
blockade O
of O
the O
mechanical O
sensitivity O
caused O
by O
a O
mild O
thermal O
injury O
by O
both O
GBP ALLCAPS
and O
IBG ALLCAPS
. O

These O
striations RARE
were O
caused O
by O
contact O
between O
the O
sharp RARE
edge RARE
of O
the O
upper O
canine O
and O
the O
P3 O
during O
honing RARE
( O
canine O
/ O
premolar RARE
complex O
). O

Low O
PbrO2 NUMERIC
readings RARE
, O
however O
, O
could O
be O
caused O
by O
local O
microhemorrhages RARE
, O
undetectable O
on O
CT O
or O
MRI O
. O

The O
consequences O
of O
intensive O
swine O
production O
on O
the O
environment O
and O
possible O
solutions O
by O
means O
of O
nutrition O
are O
outlined RARE
. O

This O
study O
demonstrates O
that O
alteration O
of O
CDKN2 NUMERIC
is O
one O
of O
the O
most O
frequent O
genetic O
abnormalities O
in O
prostate O
cancer O
and O
may O
contribute O
to O
prostate O
carcinogenesis RARE
. O

The O
pharmacokinetic O
parameters O
which O
helped RARE
predict O
these O
toxicities RARE
included O
area O
under O
the O
curve O
and O
peak O
plasma O
level O
. O

A O
Chinese O
( O
HK ALLCAPS
) O
SF O
- O
36 O
survey O
form O
was O
developed O
by O
an O
iterative RARE
translation O
process O
. O

However O
, O
the O
use O
of O
cyclosporin O
A O
is O
associated O
with O
an O
increased O
prevalence O
of O
hypertension O
in O
kidney O
transplant O
recipients O
. O

PURPOSE O
: O
To O
determine O
the O
effects O
of O
hypercholesterolemia RARE
and O
atherosclerosis O
- O
induced O
chronic O
cavernosal RARE
arterial O
insufficiency O
on O
cavernosal RARE
smooth O
muscle O
tone O
, O
nitric I-GENE
oxide I-GENE
synthase I-GENE
( O
NOS ALLCAPS
) O
activity O
and O
cavernosal RARE
tissue O
synthesis O
of O
constrictor RARE
eicosanoids RARE
. O

Characterization O
of O
the O
regulatory O
regions O
of O
the O
human I-GENE
aromatase I-GENE
( O
P450arom NUMERIC
) O
gene O
involved O
in O
placenta O
- O
specific O
expression O
. O

Recombinant I-GENE
FVIIa RARE
was O
stable O
in O
the O
infusion O
pump O
for O
several O
days O
at O
room O
temperature O
and O
for O
24 O
h O
at O
body O
temperature O
. O

CD4 I-GENE
lymphocyte O
and O
viral O
load O
levels O
suggested O
an O
optimal O
response O
to O
ARV ALLCAPS
therapy O
at O
the O
time O
LD ALLCAPS
developed O
. O

( O
1992 O
) O
Biochemistry RARE
31 O
, O
3351 NUMERIC
- O
3358 NUMERIC
]. O

Levels RARE
of O
serum O
IgE I-GENE
were O
measured O
monthly O
, O
and O
nasal O
IgE I-GENE
was O
measured O
at O
the O
height O
and O
end O
of O
the O
season O
. O

A O
mutation O
in O
the O
5 O
' O
C2U4 NUMERIC
repeat O
causes O
underaccumulation RARE
of O
snR13F NUMERIC
, O
whereas O
mutations O
in O
the O
3 O
' O
C2U4 NUMERIC
repeat O
cause O
the O
accumulation O
of O
two O
novel O
RNAs O
that O
migrate RARE
in O
the O
500 O
- O
nt O
range O
. O

By O
directly O
interacting O
with O
both O
Arfs RARE
and O
tyrosine I-GENE
kinases I-GENE
involved O
in O
regulating O
cell O
growth O
and O
cytoskeletal O
organization O
, O
ASAP1 NUMERIC
could O
coordinate O
membrane O
remodeling O
events O
with O
these O
processes O
. O

By O
DNase I-GENE
I I-GENE
footprint O
analysis O
of O
the O
PNR ALLCAPS
element O
, O
a O
palindrome O
of O
two O
high O
- O
affinity O
Ets I-GENE
- I-GENE
binding I-GENE
sites I-GENE
( O
CTTCCCTGGAAG ALLCAPS
) O
was O
identified O
. O

These O
sorting I-GENE
nexins RARE
also O
associated O
with O
the O
long O
isoform O
of O
the O
leptin I-GENE
receptor I-GENE
but O
not O
with O
the O
short O
and O
medium O
isoforms O
. O

Cyclophilins RARE
are O
cis I-GENE
- I-GENE
trans I-GENE
- I-GENE
peptidyl RARE
- I-GENE
prolyl RARE
isomerases RARE
that O
bind O
to O
and O
are O
inhibited O
by O
the O
immunosuppressant RARE
cyclosporin O
A O
( O
CsA O
). O

In O
vitro O
protein O
retention O
experiments O
in O
which O
Hsp90 NUMERIC
heterocomplexes RARE
were O
precipitated O
resulted O
in O
coprecipitation RARE
of O
Cns1 NUMERIC
. O

The O
Ras I-GENE
- I-GENE
related I-GENE
GTPases I-GENE
are O
small O
, O
20 O
- O
to O
25 O
- O
kDa O
proteins O
which O
cycle O
between O
an O
inactive O
GDP O
- O
bound O
form O
and O
an O
active O
GTP O
- O
bound O
state O
. O

To O
modulate O
transcription O
, O
regulatory O
factors O
communicate RARE
with O
basal O
transcription O
factors O
and O
/ O
or O
RNA I-GENE
polymerases I-GENE
in O
a O
variety O
of O
ways O
. O

Endogenous RARE
RMP ALLCAPS
was O
immunologically RARE
detected O
interacting O
with O
assembled O
RPB5 NUMERIC
in O
RNA I-GENE
polymerase I-GENE
in O
mammalian O
cells O
. O

In O
this O
study O
, O
rabbits O
were O
used O
to O
evaluate O
the O
sutured RARE
wound O
reaction O
with O
Dexon RARE
or O
nylon RARE
in O
the O
conjunctival RARE
flap O
1 O
, O
4 O
, O
7 O
, O
14 O
and O
28 O
days O
after O
trabeculectomy RARE
surgery O
with O
or O
without O
the O
use O
of O
mitomycin RARE
- O
C O
. O

The O
mapping O
was O
completed O
with O
Southern O
blotting O
and O
restriction O
analysis O
. O

The O
zona RARE
pellucida RARE
( O
ZP ALLCAPS
), O
the O
extracellular O
glycocalyx RARE
that O
surrounds RARE
the O
oocyte O
, O
is O
well O
known O
to O
mediate O
homologous O
gamete RARE
interaction O
. O

Therapeutic RARE
use O
of O
continuous O
subcutaneous O
infusion O
of O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
in O
malnourished RARE
predialysis RARE
anemic RARE
patients O
with O
diabetic O
nephropathy O
. O

Although O
pathological O
thyroid O
function O
is O
related O
to O
changes O
in O
energy O
expenditure O
and O
body O
composition O
, O
its O
possible O
influence O
on O
leptin I-GENE
levels O
remains O
to O
be O
determined O
. O

These O
cognitive O
deficits O
were O
prevented O
in O
animals O
treated O
with O
MK O
- O
801 O
during O
SE O
. O

Here O
we O
demonstrate O
that O
the O
mechanism O
of O
activation O
of O
HIF I-GENE
- I-GENE
1alpha I-GENE
is O
a O
multi O
- O
step O
process O
which O
includes O
hypoxia O
- O
dependent O
nuclear O
import O
and O
activation O
( O
derepression O
) O
of O
the O
transactivation O
domain O
, O
resulting O
in O
recruitment O
of O
the O
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CBP I-GENE
)/ O
p300 I-GENE
coactivator I-GENE
. O

Thus O
, O
hypoxia O
- O
inducible O
nuclear O
import O
and O
transactivation O
by O
recruitment O
of O
CBP I-GENE
can O
be O
functionally O
separated O
from O
one O
another O
and O
play O
critical O
roles O
in O
signal O
transduction O
by O
HIF I-GENE
- I-GENE
1alpha I-GENE
. O

The O
rat I-GENE
aldolase RARE
C I-GENE
gene I-GENE
encodes O
a O
glycolytic RARE
enzyme O
strongly O
expressed O
in O
adult O
brain O
. O

A O
synergistic O
effect O
on O
HCK ALLCAPS
promoter I-GENE
activity O
was O
observed O
at O
high O
concentrations O
of O
Sp1 I-GENE
. O

Quinone RARE
- O
binding O
domain O
and O
amino O
acid O
residues O
involved O
in O
quinone RARE
binding O
. O

Western O
analyses O
with O
antisera O
raised O
against O
Lu RARE
- I-GENE
ECAM ALLCAPS
- I-GENE
1 I-GENE
peptides I-GENE
show O
that O
the O
N O
- O
terminal O
region O
of O
the O
predicted O
open O
reading O
frame O
is O
present O
only O
in O
the O
larger O
size O
proteins O
( O
i O
. O
e O
. O

Mammalian RARE
sperm O
motility O
is O
regulated O
by O
a O
cascade O
of O
cAMP O
- O
dependent O
protein O
phosphorylation O
events O
mediated O
by O
protein I-GENE
kinase I-GENE
A I-GENE
. O

In O
this O
paper O
, O
we O
show O
that O
, O
like O
BAP2 NUMERIC
, O
the O
expression O
of O
the O
BAP3 NUMERIC
gene I-GENE
in O
S O
. O
cerevisiae O
is O
induced O
by O
the O
addition O
of O
branched O
- O
chain O
amino O
acids O
to O
the O
medium O
. O

Effect O
of O
enteral RARE
nutritional O
products O
differing RARE
in O
carbohydrate O
and O
fat O
on O
indices O
of O
carbohydrate O
and O
lipid O
metabolism O
in O
patients O
with O
NIDDM ALLCAPS
. O

Low O
- O
grade O
gastric O
MALT ALLCAPS
lymphoma O
and O
helicobacter RARE
heilmannii RARE
( O
Gastrospirillum RARE
hominis RARE

These O
studies O
support O
the O
view O
that O
HMG I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
is O
an O
important O
cofactor O
for O
HLA I-GENE
- I-GENE
DRA ALLCAPS
gene I-GENE
activation O
by O
Oct I-GENE
- I-GENE
2A I-GENE
and O
provide O
insights RARE
into O
its O
mechanism O
of O
action O
. O

In O
contrast O
to O
hemodynamic O
and O
histopathological O
predictors O
of O
survival O
, O
vWF I-GENE
: O
Ag O
does O
not O
require O
invasive O
techniques O
to O
be O
determined O
. O

CONCLUSION O
: O
We O
were O
unable O
to O
identify O
features O
of O
disease O
likely O
to O
be O
associated O
with O
a O
clinically O
useful O
response O
to O
inhaled O
NO O
therapy O
using O
the O
parameters O
studied O
. O

We O
find O
that O
BCL I-GENE
- I-GENE
6 I-GENE
POZ O
domain O
mutations O
that O
disrupt O
the O
interaction O
with O
N I-GENE
- I-GENE
CoR LASTCAP
and O
SMRT I-GENE
no O
longer O
repress O
transcription O
. O

Partial O
characterization O
of O
the O
active O
site O
human I-GENE
platelet I-GENE
cAMP I-GENE
phosphodiesterase I-GENE
, O
PDE3A NUMERIC
, O
by O
site O
- O
directed O
mutagenesis O
. O

This O
core O
sequence O
, O
along O
with O
additional O
nonspecific O
downstream O
nucleotides O
, O
is O
sufficient O
for O
partial O
suppression O
of O
spliceosome O
assembly O
and O
splicing O
of O
BPV O
- O
1 O
pre O
- O
mRNAs O
. O

Over RARE
- O
expression O
of O
the O
cofactor O
p300 I-GENE
, O
which O
functions O
as O
a O
coactivator O
of O
myoD I-GENE
- O
mediated O
transcription O
, O
alleviated RARE
repression O
by O
COUP I-GENE
- I-GENE
TF I-GENE
II I-GENE
. O

Familial RARE
autoimmune RARE
hepatitis O
and O
C4 I-GENE
deficiency O

No O
mutations O
were O
found O
in O
follicular O
adenomas RARE
. O

Since O
glutathione I-GENE
peroxidase I-GENE
( O
GPX ALLCAPS
) O
and O
superoxide I-GENE
dismutase I-GENE
( O
SOD I-GENE
) O
play O
a O
significant O
role O
in O
erythrocyte O
antioxidative RARE
defence RARE
, O
it O
is O
very O
important O
to O
determine O
their O
activity O
in O
occupationally RARE
exposed O
workers O
. O

Retroviral RARE
nucleocapsid RARE
proteins I-GENE
( O
NCPs RARE
) O
are O
CCHC ALLCAPS
- I-GENE
type I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
that O
mediate O
virion O
RNA O
binding O
activities O
associated O
with O
retrovirus O
assembly O
and O
genomic O
RNA O
encapsidation RARE
. O

The O
Schizosaccharomyces I-GENE
pombe I-GENE
rad1 NUMERIC
+ I-GENE
cell I-GENE
cycle I-GENE
checkpoint I-GENE
control I-GENE
gene I-GENE
is O
required O
for O
S O
- O
phase O
and O
G2 O
/ O
M O
arrest O
in O
response O
to O
both O
DNA O
damage O
and O
incomplete O
DNA O
replication O
. O

It O
is O
now O
well O
established O
that O
progression O
through O
the O
eukaryotic O
cell O
cycle O
is O
controlled O
by O
oscillations RARE
in O
the O
activity O
of O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
CDKs RARE
). O

Positive RARE
genetic O
selections RARE
for O
inhibition O
of O
cyclin I-GENE
/ O
CDK I-GENE
function O
were O
characterized O
using O
the O
E I-GENE
. I-GENE
coli I-GENE
neo I-GENE
and O
yeast I-GENE
LEU2 I-GENE
genes I-GENE
. O

The O
hematopoietic I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
( O
CSF I-GENE
) O
have O
been O
introduced O
into O
clinical O
practice O
as O
additional O
supportive RARE
measures O
that O
can O
reduce O
the O
incidence O
of O
infectious O
complications O
in O
patients O
with O
cancer O
and O
neutropenia O
. O

All O
injections O
of O
CSF I-GENE
were O
given O
after O
the O
initiation O
of O
neutropenia O
and O
continued O
until O
the O
occurrence O
of O
an O
absolute O
neutrophil O
recovery O
. O
rHu RARE
GM I-GENE
- I-GENE
CSF I-GENE
and O
rHu RARE
G I-GENE
- I-GENE
CSF I-GENE
, O
administered O
once O
daily O
at O
the O
250 O
microg O
m O
(- O
2 O
) O
day O
(- O
1 O
) O
and O
5 O
microg O
kg O
(- O
1 O
) O
day O
(- O
1 O
) O
level O
, O
were O
effective O
in O
increasing O
the O
absolute O
neutrophil O
count O
and O
neutrophil O
function O
, O
as O
measured O
by O
an O
automated O
chemiluminescence RARE
system O
. O

Expression O
of O
lacZ I-GENE
from O
the O
promoter O
of O
the O
Escherichia I-GENE
coli I-GENE
spc RARE
operon I-GENE
cloned O
into O
vectors O
carrying O
the O
W205 NUMERIC
trp RARE
- O
lac I-GENE
fusion O
. O

We O
evaluated O
regional O
right O
ventricular O
wall O
motion O
during O
systole RARE
in O
patients O
with O
surgically O
repaired RARE
tetralogy RARE
of O
Fallot RARE
( O
TOF O
) O
using O
color O
kinesis RARE
imaging O
. O

RT O
- O
PCR O
analysis O
showed O
that O
PLP I-GENE
- I-GENE
H I-GENE
as O
well O
as O
PLP I-GENE
- I-GENE
C I-GENE
and O
PLP I-GENE
- I-GENE
D I-GENE
are O
expressed O
in O
all O
rat O
strains O
examined O
, O
confirming O
that O
PLP I-GENE
diversity O
is O
not O
due O
to O
strain O
differences O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
new O
member O
of O
the O
rat I-GENE
placental I-GENE
prolactin I-GENE
( O
PRL I-GENE
) O
family O
, O
PRL I-GENE
- O
like O
protein I-GENE
H I-GENE
. O

Interestingly O
, O
we O
find O
that O
the O
interaction O
between O
Tat I-GENE
and O
hCycT1 NUMERIC
requires O
zinc O
as O
well O
as O
essential O
cysteine O
residues O
in O
both O
proteins O
. O

Thus O
, O
we O
have O
identified O
an O
activation O
target O
of O
a O
human O
activator O
, O
Oct I-GENE
- I-GENE
1 I-GENE
, O
within O
its O
cognate O
basal O
transcription O
complex O
. O

During O
early O
neurogenesis RARE
, O
Vnd RARE
protein I-GENE
is O
restricted O
to O
ventral O
column O
neuroectoderm RARE
and O
neuroblasts O
; O
later O
it O
is O
detected O
in O
a O
complex O
pattern O
of O
neurons O
. O

The O
repression O
domain O
, O
and O
indeed O
the O
entire O
Cdc68 NUMERIC
protein I-GENE
, O
is O
highly O
conserved O
, O
as O
shown O
by O
the O
sequence O
of O
the O
Cdc68 NUMERIC
functional I-GENE
homolog I-GENE
from O
the O
yeast O
Kluyveromyces RARE
lactis O
and O
by O
database O
searches RARE
. O

The O
exodomain RARE
alone O
has O
the O
high O
affinity O
hormone O
binding O
site O
but O
is O
not O
capable O
of O
generating O
hormonal O
signal O
. O

Pyrrolidine RARE
dithiocarbamate RARE
, O
a O
potent O
transcriptional O
inhibitor O
of O
the O
viral I-GENE
LTR I-GENE
, O
abrogated O
the O
cytokine O
responses O
in O
both O
U1 O
and O
ACH ALLCAPS
- O
2 O
cells O
, O
suggesting O
a O
common O
TNF I-GENE
- I-GENE
alpha I-GENE
- O
mediated O
transcriptional O
mechanism O
in O
these O
cell O
types O
despite O
their O
different O
modes O
of O
provirus O
latency O
. O

Furthermore O
, O
synergistic O
activation O
of O
ERK2 I-GENE
occurred O
in O
the O
absence O
of O
changes O
in O
intracellular O
Ca2 O
+, O
and O
was O
not O
blocked O
by O
inhibition O
of O
protein I-GENE
kinase I-GENE
C I-GENE
activity O
and O
represents O
a O
separate O
pathway O
by O
which O
CD19 NUMERIC
regulates O
B O
cell O
function O
. O

The O
retrovesical RARE
hydatid RARE
cyst O
is O
a O
very O
rare O
site O
. O

Biochemical O
analysis O
reveals O
that O
KS1 NUMERIC
is O
a O
nuclear O
protein O
containing O
two O
transcriptional O
repressor O
domains O
, O
R1 O
and O
R2 O
. O

However O
, O
the O
BCH ALLCAPS
group O
showed O
inferior O
gross O
motor O
performance O
on O
the O
Bruininks RARE
- O
Oseretsky RARE
Test O
of O
Motor RARE
Proficiency RARE
( O
Bruininks RARE
1978 NUMERIC
). O

The O
results O
raise RARE
the O
possibility O
that O
pH O
induced O
post O
- O
translational O
modifications O
of O
DdRPA LASTCAP
are O
involved O
in O
events O
that O
halt RARE
cell O
proliferation O
and O
induce O
differentiation O
in O
Dictyostelium O
. O

We O
report O
here O
that O
, O
for O
a O
constant O
amount O
of O
transfected O
DNA O
, O
the O
level O
of O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
mRNA O
is O
increased O
in O
Vpr RARE
- O
expressing O
cells O
using O
either O
HIV O
- O
1 O
or O
a O
murine O
leukemia I-GENE
virus I-GENE
( I-GENE
MLV ALLCAPS
) I-GENE
SL3 NUMERIC
- I-GENE
3 I-GENE
LTR I-GENE
- O
CAT I-GENE
reporter O
construct O
. O

We O
identified O
telSMN LASTCAP
mutations O
in O
11 O
of O
these O
unrelated O
SMA ALLCAPS
- O
like O
individuals O
who O
carry O
a O
single O
copy O
of O
telSMN LASTCAP
: O
these O
include O
two O
frameshift O
mutations O
( O
800ins11 NUMERIC
and O
542delGT NUMERIC
) O
and O
three O
missense O
mutations O
( O
A2G NUMERIC
, O
S262I NUMERIC
, O
and O
T274I NUMERIC
). O

The O
decrease O
of O
TNF I-GENE
receptors I-GENE
by O
IL I-GENE
- I-GENE
4 I-GENE
was O
accompanied O
by O
down O
- O
regulation O
of O
TNF I-GENE
- O
induced O
activities O
, O
including O
cytotoxicity O
, O
caspase RARE
- I-GENE
3 I-GENE
activation O
, O
NF I-GENE
- I-GENE
kappaB I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
activation O
, O
and O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
induction O
. O

Type I-GENE
2 I-GENE
deiodinase I-GENE
( O
D2 I-GENE
) O
catalyzes O
the O
5 O
'- O
deiodination RARE
of O
thyroxine O
to O
form O
3 O
, O
5 O
, O
3 O
'- O
triiodothyronine RARE
. O

We O
have O
identified O
two O
overlapping O
expressed O
sequence O
tag O
clones O
, O
which O
contain O
the O
missing O
4 O
. O
4 O
- O
kb O
3 O
'- O
UTR O
of O
the O
human I-GENE
D2 I-GENE
( O
hD2 NUMERIC
) O
cDNA O
. O

Biol O
. O

Here O
we O
have O
investigated O
the O
structural O
requirements O
and O
consequences O
of O
regulatory O
phosphorylation O
for O
the O
interaction O
between O
c I-GENE
- I-GENE
Jun I-GENE
and O
JNK I-GENE
in O
vivo O
. O

P I-GENE
- I-GENE
CIP1 NUMERIC
, O
a O
novel O
protein O
that O
interacts O
with O
the O
cytosolic O
domain O
of O
peptidylglycine RARE
alpha I-GENE
- I-GENE
amidating RARE
monooxygenase RARE
, O
is O
associated O
with O
endosomes RARE
. O

Immunolocalization RARE
of O
Sop1p NUMERIC
revealed O
a O
cytoplasmic O
distribution O
and O
cell O
fractionation O
studies O
showed O
that O
a O
significant O
fraction O
of O
Sop1p NUMERIC
was O
recovered O
in O
a O
sedimentable RARE
fraction O
of O
the O
cytosolic O
material O
. O

Resultant RARE
activation O
of O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
/ O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
JNK I-GENE
/ O
SAPK I-GENE
). O

Here O
we O
report O
the O
full O
- O
length O
coding O
cDNA O
sequence O
of O
the O
mouse I-GENE
homologue I-GENE
of I-GENE
MPP3 NUMERIC
. O

The O
method O
also O
eliminates RARE
tagging RARE
of O
venous O
spins RARE
and O
concern RARE
about O
asymmetric O
magnetization RARE
transfer O
effects O
. O

Consistent O
with O
this O
, O
purified O
Dlk RARE
phosphorylated O
core O
histones RARE
H3 I-GENE
, O
H2A NUMERIC
and O
H4 I-GENE
as O
exogenous O
substrates O
and O
endogenous O
histone I-GENE
H3 I-GENE
in O
kinase O
assays O
with O
nuclear O
extracts O
. O

In O
this O
study O
we O
provide O
evidence O
that O
B I-GENE
- I-GENE
Myb I-GENE
is O
a O
direct O
physiological O
target O
for O
cyclin I-GENE
A I-GENE
/ O
Cdk2 I-GENE
. O

Neither O
Ha I-GENE
- I-GENE
Ras I-GENE
( O
G12V NUMERIC
, O
T35S NUMERIC
) O
( O
Ha I-GENE
- I-GENE
RasV12S35 NUMERIC
), O
which O
activates O
the O
Rafl RARE
signaling O
pathway O
, O
nor O
Ha I-GENE
- I-GENE
Ras I-GENE
( I-GENE
G12V NUMERIC
, I-GENE
E37G NUMERIC
) I-GENE
( O
Ha I-GENE
- I-GENE
RasV12G37 NUMERIC
), O
which O
stimulates O
the O
RalGDS LASTCAP
pathway O
, O
did O
not O
have O
significant O
effects O
on O
factor O
- O
withdrawal O
apoptosis O
of O
myeloid O
cells O
. O

We O
have O
isolated O
a O
novel O
human I-GENE
cyclin I-GENE
, O
cyclin I-GENE
E2 I-GENE
, O
that O
contains O
significant O
homology O
to O
cyclin I-GENE
E I-GENE
. O

Initial O
experience O
with O
the O
new O
technology O
indicates O
that O
SieScape RARE
is O
an O
alternative O
to O
other O
methods O
such O
as O
CT O
and O
MRI O
. O

The O
dopamine I-GENE
D4 NUMERIC
receptor I-GENE
as O
well O
as O
many O
other O
catecholaminergic RARE
receptors I-GENE
contain O
several O
putative O
SH3 I-GENE
binding I-GENE
domains I-GENE
. O

The O
highly O
amyloidogenic RARE
42 O
- O
residue O
form O
of O
Abeta RARE
( O
Abeta42 NUMERIC
) O
is O
the O
first O
species O
to O
be O
deposited RARE
in O
both O
sporadic RARE
and O
familial O
AD O
. O

This O
model O
is O
supported O
by O
experiments O
showing O
that O
Cdr2 NUMERIC
associates O
with O
the O
N I-GENE
- I-GENE
terminal I-GENE
regulatory I-GENE
domain I-GENE
of I-GENE
Wee1 I-GENE
in O
cell O
lysates O
and O
phosphorylates O
Wee1 I-GENE
in O
vitro O
. O

Schizosaccharomyces O
pombe O
cells O
respond O
to O
nutrient O
deprivation O
by O
altering O
G2 O
/ O
M O
cell O
size O
control O
. O

A O
- O
tracts RARE
functioned O
best O
when O
positioned O
close O
to O
the O
- O
35 O
hexamer O
rather O
than O
one O
helical O
turn O
farther RARE
upstream O
, O
similar O
to O
the O
positioning O
optimal O
for O
UP ALLCAPS
element O
function O
. O

Pyk2 NUMERIC
phosphorylation O
increased O
upon O
adherence RARE
of O
FLG ALLCAPS
29 O
. O
1 O
cells O
to O
fibronectin I-GENE
and O
to O
ST2 NUMERIC
stromal RARE
cells O
. O

Raf I-GENE
is O
a O
key O
serine I-GENE
- I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
which O
participates O
in O
the O
transmission O
of O
growth O
, O
anti O
- O
apoptotic O
and O
differentiation O
messages RARE
. O

The O
US O
National O
Institute O
on O
Alcohol RARE
Abuse RARE
and O
Alcoholism RARE
( O
NIAAA ALLCAPS
) O
recognizes O
two O
forms O
of O
problematic RARE
drinking O
: O
' O
willful RARE
alcohol O
abuse RARE
', O
a O
behavioural RARE
problem O
, O
and O
' O
alcohol O
dependence O
', O
a O
true O
medical O
disorder O
, O
which O
includes O
a O
genetic O
component O
, O
that O
can O
be O
scientifically RARE
understood O
and O
medically RARE
treated O
. O

Collagen RARE
was O
extracted O
from O
the O
skin O
, O
and O
the O
lack O
of O
type I-GENE
III I-GENE
collagen I-GENE
was O
determined O
by O
means O
of O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
( O
SDS O
- O
PAGE O
). O

RESULTS O
: O
During O
the O
7 O
- O
year O
period O
, O
10 O
, O
331 NUMERIC
symptomatic O
duodenal O
ulcer O
diseases O
were O
diagnosed O
. O

RESULTS O
: O
Significant O
changes O
from O
pretreatment O
to O
posttreatment RARE
were O
observed O
( O
p O
< O
0 O
. O
001 O
). O

In O
turn O
, O
assembly O
of O
this O
complex O
mediates O
the O
enzymatic O
activation O
of O
the O
p21 I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
1 I-GENE
and O
facilitates RARE
actin I-GENE
polymerization RARE
. O

The O
tip O
of O
the O
button RARE
caused O
a O
perforation RARE
of O
the O
posterior O
stomach O
wall O
, O
leading O
to O
death O
. O

Jembrana RARE
disease O
virus O
( O
JDV ALLCAPS
) O
is O
a O
newly O
identified O
bovine O
lentivirus RARE
that O
is O
closely O
related O
to O
the O
bovine O
immunodeficiency O
virus O
( O
BIV ALLCAPS
). O

Approximately O
50 O
% O
of O
the O
residues O
are O
conserved O
among O
all O
three O
sequences O
, O
yet O
all O
three O
viruses O
have O
retained O
response O
elements O
for O
glucocorticoids O
, O
two O
positionally RARE
conserved O
CCAAT O
boxes O
, O
and O
positionally RARE
conserved O
TATA O
boxes O
. O

Nhp2p NUMERIC
is O
a O
highly O
basic O
protein O
that O
belongs O
to O
a O
family O
of O
putative O
RNA O
- O
binding O
proteins O
. O

This O
survey O
included O
3000 NUMERIC
randomly O
selected O
Norwegians RARE
above O
18 O
years O
of O
age O
who O
received O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Core RARE
Quality RARE
of O
Life RARE
Questionnaire RARE
( O
EORTC ALLCAPS
QLQ ALLCAPS
- O
C30 NUMERIC
(+ O
3 O
) O
by O
mail RARE
. O

During O
presentation O
of O
happy RARE
facial O
expressions RARE
, O
we O
detected O
a O
signal O
increase O
predominantly O
in O
the O
left O
anterior O
cingulate RARE
gyrus O
, O
bilateral O
posterior O
cingulate RARE
gyri RARE
, O
medial O
frontal O
cortex O
and O
right O
supramarginal RARE
gyrus O
, O
brain O
regions O
previously O
implicated O
in O
visuospatial RARE
and O
emotion RARE
processing O
tasks O
. O

Down RARE
- O
regulation O
of O
IRS I-GENE
- I-GENE
1 I-GENE
is O
linked O
to O
its O
serine O
phosphorylation O
dependent O
on O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
activity O
and O
appears O
required O
for O
differentiation O
to O
occur O
, O
as O
IRS I-GENE
- I-GENE
1 I-GENE
is O
not O
modified O
and O
continues RARE
to O
accumulate O
in O
a O
nondifferentiating RARE
myoblast RARE
cell O
line O
. O

This O
study O
utilizes RARE
the O
mammalian O
two O
- O
hybrid O
system O
to O
examine O
the O
role O
of O
ligand O
in O
the O
dimerization O
of O
human I-GENE
progesterone I-GENE
receptor I-GENE
( O
hPR LASTCAP
). O

One O
of O
its O
unique O
features O
appears O
to O
be O
the O
unusually O
short O
5 O
'- O
untranslated O
regions O
( O
UTR O
) O
( O
1 O
- O
6 O
nucleotides O
( O
nts RARE
)) O
and O
the O
apparent O
absence O
of O
5 O
'- O
cap O
structures O
from O
its O
mRNAs O
. O

The O
gene I-GENE
encoding I-GENE
human I-GENE
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
t I-GENE
- I-GENE
PA I-GENE
) O
is O
regulated O
in O
a O
cell O
- O
type O
- O
specific O
manner O
. O

Both O
the O
presence O
of O
arginine O
and O
anaerobiosis RARE
are O
needed O
to O
trigger RARE
induction O
of O
the O
pathway O
. O

Competition O
with O
a O
putative O
MADS I-GENE
box I-GENE
consensus O
binding O
site O
from O
the O
promoter O
of O
the O
coordinately RARE
regulated O
opaque RARE
- I-GENE
phase I-GENE
- I-GENE
specific I-GENE
gene I-GENE
PEP1 NUMERIC
( O
SAP1 NUMERIC
) O
and O
the O
human I-GENE
MADS I-GENE
box I-GENE
consensus I-GENE
binding I-GENE
site I-GENE
for O
serum I-GENE
response I-GENE
factor I-GENE
demonstrated O
that O
one O
of O
the O
three O
complexes O
formed O
was O
specific O
to O
the O
OP4 NUMERIC
sequence I-GENE
. O

The O
human I-GENE
SHBG I-GENE
proximal I-GENE
promoter I-GENE
was O
analyzed O
by O
DNase I-GENE
I I-GENE
footprinting O
, O
and O
the O
functional O
significance O
of O
6 O
footprinted RARE
regions O
( O
FP1 NUMERIC
- O
FP6 NUMERIC
) O
within O
the O
proximal O
promoter O
was O
studied O
in O
human O
HepG2 O
hepatoblastoma RARE
cells O
. O

In O
vitro O
translation O
and O
in O
vivo O
polysome RARE
profile O
analysis O
indicated O
that O
transcripts I-GENE
C I-GENE
and I-GENE
E I-GENE
were O
translated O
with O
similar O
translational O
efficiencies RARE
that O
are O
substantially O
greater O
than O
that O
of O
transcript I-GENE
D I-GENE
, O
suggesting O
that O
5 O
'- O
untranslated O
regions O
play O
a O
role O
in O
translational O
control O
. O

We O
have O
introduced O
a O
mutation O
( O
Ser36 NUMERIC
--> O
Asn O
) O
into O
this O
domain O
of O
p190 I-GENE
that O
decreased O
its O
ability O
to O
bind O
guanine O
nucleotide O
when O
expressed O
as O
a O
hemagglutinin I-GENE
( O
HA I-GENE
)- O
tagged O
protein O
in O
COS O
cells O
. O

Wild O
type O
HA I-GENE
- O
p190 I-GENE
induced O
a O
phenotype O
of O
rounded RARE
cells O
with O
long O
, O
beaded RARE
extensions RARE
similar O
to O
that O
seen O
when O
Rho I-GENE
function O
is O
disrupted O
by O
ADP O
- O
ribosylation RARE
. O

We O
emphasize RARE
that O
ANCA ALLCAPS
- O
associated O
vasculitis O
is O
another O
important O
complication O
of O
RA O
. O

The O
downstream O
, O
TATA O
- O
less O
promoter O
has O
high O
G O
+ O
C O
content O
, O
and O
exon O
1b O
predominates RARE
among O
abundantly O
expressed O
mRNA O
species O
. O

Although O
we O
predicted O
that O
overexpression O
of O
the O
COOH O
- O
terminal O
domains O
, O
which O
were O
thought O
to O
be O
involved O
in O
the O
regulation O
of O
SREBP I-GENE
processing O
, O
would O
result O
in O
disruption O
of O
the O
SREBP I-GENE
- O
dependent O
transcriptional O
regulation O
of O
several O
genes O
, O
the O
mRNA O
levels O
for O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
methylglutaryl RARE
coenzyme I-GENE
A I-GENE
( I-GENE
HMG I-GENE
CoA I-GENE
) I-GENE
synthase I-GENE
in O
these O
two O
cell O
lines O
were O
regulated O
in O
a O
sterol O
- O
dependent O
manner O
. O

Dry RARE
matter O
intake O
, O
apparent O
nutrient O
digestibilities RARE
, O
serum O
chemistry O
profiles O
, O
sphingolipid RARE
concentrations O
, O
and O
persistency RARE
of O
FB1 NUMERIC
in O
tissues O
were O
evaluated O
. O

However O
, O
no O
studies O
have O
been O
conducted O
to O
further O
investigate O
this O
potentially O
hazardous O
effect O
of O
lidocaine O
. O

E O
., O
Scott RARE
, O
J O
. O

Yap1p NUMERIC
is O
constitutively O
nuclear O
in O
a O
crm1 NUMERIC
mutant I-GENE
, O
and O
Crm1p NUMERIC
binds O
to O
a O
nuclear O
export O
sequence O
( O
NES ALLCAPS
)- O
like O
sequence O
in O
Yap1p NUMERIC
in O
the O
presence O
of O
RanGTP LASTCAP
. O

Mean O
intake O
of O
vitamin O
A O
amounted RARE
to O
1 O
. O
1 O
and O
0 O
. O
9 O
mg O
RE ALLCAPS
/ O
day O
for O
men O
and O
women O
, O
respectively O
; O
the O
contributions RARE
of O
meat O
, O
fats RARE
and O
oils RARE
, O
vegetables RARE
and O
dairy RARE
products O
to O
total O
intake O
were O
35 O
%, O
24 O
%, O
16 O
%, O
and O
16 O
%, O
respectively O
. O

Also O
, O
the O
amplitude O
of O
the O
oscillatory RARE
potentials O
( O
O1 NUMERIC
+ O
O2 O
+ O
O3 NUMERIC
+ O
O4 NUMERIC
) O
was O
significantly O
reduced O
in O
the O
early O
postoperative O
period O
. O

Furthermore O
, O
RING1 NUMERIC
overexpression O
results O
in O
enhanced O
expression O
of O
the O
proto O
- O
oncogenes O
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
. O

The O
yeast I-GENE
RER2 NUMERIC
gene I-GENE
, O
identified O
by O
endoplasmic O
reticulum O
protein O
localization O
mutations O
, O
encodes O
cis I-GENE
- I-GENE
prenyltransferase RARE
, O
a O
key O
enzyme O
in O
dolichol RARE
synthesis O
. O

The O
yeast O
retrotransposon I-GENE
Ty5 NUMERIC
preferentially O
integrates RARE
into O
regions O
of O
silent O
chromatin O
. O

The O
loss O
of O
SKO1 NUMERIC
completely O
restored O
ENA1 NUMERIC
expression O
in O
a O
hog1 NUMERIC
mutant I-GENE
and O
partially O
suppressed O
the O
osmotic O
stress O
sensitivity O
, O
qualifying RARE
Sko1p NUMERIC
as O
a O
downstream O
effector O
of O
the O
HOG ALLCAPS
pathway O
. O

Elevated RARE
expression O
of O
a O
previously O
uncharacterized O
gene O
, O
SPP381 NUMERIC
, O
efficiently O
suppresses O
the O
growth O
and O
splicing O
defects O
of O
a O
temperature O
- O
sensitive O
( O
Ts RARE
) O
mutant I-GENE
prp38 NUMERIC
- I-GENE
1 I-GENE
. O

The O
slower O
- O
electrophoretic O
- O
mobility O
form O
of O
p68 NUMERIC
was O
absent O
in O
human O
cells O
in O
G1 O
/ O
S O
and O
appeared O
as O
the O
cells O
entered RARE
G2 O
/ O
M O
. O

We O
have O
identified O
amino O
acid O
sequences O
in O
mammalian O
and O
Xenopus O
NeuroD1 NUMERIC
/ O
BETA2 NUMERIC
that O
are O
necessary O
for O
insulin I-GENE
gene I-GENE
expression O
and O
ectopic O
neurogenesis RARE
. O

Both O
NUP98 NUMERIC
- O
HOXA9 NUMERIC
chimeras RARE
transformed O
NIH O
3T3 O
fibroblasts O
, O
and O
this O
transformation O
required O
the O
HOXA9 NUMERIC
domains I-GENE
for O
DNA O
binding O
and O
PBX ALLCAPS
interaction O
. O

Recent O
studies O
have O
suggested O
that O
Y319 NUMERIC
also O
positively O
regulate O
ZAP I-GENE
- I-GENE
70 I-GENE
function O
. O

Genetic O
and O
molecular O
data O
indicate O
that O
wild I-GENE
- I-GENE
type I-GENE
Pan RARE
and O
CiD LASTCAP
compete O
for O
binding O
to O
Arm RARE
, O
leading O
to O
a O
compromised RARE
transduction O
of O
the O
Wg RARE
signal O
in O
heterozygous RARE
ciD LASTCAP
/+ RARE
animals O
and O
to O
a O
dramatic O
enhancement O
of O
the O
gain O
- O
of O
- O
function O
activity O
of O
CiD LASTCAP
in O
homozygous O
mutants O
. O

Another O
ORF O
, O
dda RARE
. I-GENE
2 I-GENE
located O
between O
modA LASTCAP
and O
dda RARE
, O
shares O
sequence O
similarity O
with O
sigma70 NUMERIC
, O
and O
we O
call RARE
it O
srd RARE
. O

The O
location O
of O
the O
IBS ALLCAPS
within O
the O
catB LASTCAP
structural I-GENE
gene I-GENE
, O
the O
cooperativity O
observed O
in O
footprinting O
studies O
and O
phasing RARE
studies O
suggest O
that O
the O
IBS ALLCAPS
participates O
in O
the O
interaction O
of O
CatR LASTCAP
with O
the O
upstream O
binding O
sites O
by O
looping RARE
out O
the O
intervening O
DNA O
. O

In O
vitro O
transcription O
assays O
demonstrate O
that O
the O
TCA ALLCAPS
- O
cycle O
intermediate O
, O
fumarate RARE
, O
directly O
and O
specifically O
inhibits O
the O
formation O
of O
the O
clcA LASTCAP
transcript I-GENE
. O

BIAcore RARE
analysis O
gave O
a O
Kaff RARE
of O
4 O
. O
4 O
x O
10 O
( O
10 O
) O
M O
- O
1 O
for O
the O
binding O
of O
N I-GENE
- I-GENE
A3 I-GENE
to O
T84 NUMERIC
. I-GENE
1 I-GENE
and O
2 O
. O
2 O
x O
10 O
( O
10 O
) O
M O
- O
1 O
for O
the O
binding O
of O
N I-GENE
- I-GENE
A3 I-GENE
to O
T84 NUMERIC
. I-GENE
66 I-GENE
. O

Expression O
of O
p130 I-GENE
( O
Cas I-GENE
) O
( O
Cas I-GENE
), O
a O
major O
binding O
protein O
for O
the O
Crk I-GENE
SH2 I-GENE
- I-GENE
domain I-GENE
, O
also O
induced O
JNK I-GENE
activation O
, O
which O
was O
blocked O
by O
the O
SH2 I-GENE
- I-GENE
mutant I-GENE
of O
Crk I-GENE
. O

Positive RARE
correlations O
were O
seen O
between O
the O
measurements O
for O
protein O
intake O
( O
r O
=. O
58 O
, O
P O
=. O
0026 NUMERIC
) O
energy O
intake O
( O
r O
=. O
78 O
, O
P O
<. RARE
00001 NUMERIC
), O
with O
mean O
differences O
of O
. O
066 NUMERIC
g O
/ O
kg O
/ O
d O
( O
SD O
. O
38 O
) O
2 O
. O
04 O
kcal RARE
/ O
kg O
/ O
day O
( O
SD O
6 O
. O
67 O
), O
respectively O
. O

The O
Og4C3 NUMERIC
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
to O
detect O
circulating O
Wuchereria RARE
bancrofti RARE
antigen I-GENE
uses O
50 O
microL LASTCAP
of O
serum O
. O

We O
now O
show O
that O
gp200 NUMERIC
- O
MR6 NUMERIC
ligation O
can O
also O
mimic O
IL I-GENE
- I-GENE
4 I-GENE
and O
have O
an O
anti O
- O
proliferative O
pro O
- O
maturational RARE
influence O
within O
the O
immune O
system O
, O
causing O
up O
- O
regulation O
of O
co O
- O
stimulatory O
molecules O
on O
B O
lymphocytes O
. O

The O
Mig1 NUMERIC
repressor I-GENE
is O
a O
zinc I-GENE
finger I-GENE
protein I-GENE
that O
mediates O
glucose O
repression O
in O
yeast O
. O

Ethylene RARE
is O
involved O
in O
endosperm RARE
rupture RARE
and O
high O
- O
level O
betaGLU LASTCAP
I I-GENE
expression O
; O
but O
, O
it O
does O
not O
affect O
the O
spatial O
and O
temporal O
pattern O
of O
betaGLU LASTCAP
I I-GENE
expression O
. O

The O
divergence O
in O
primary O
structure O
between O
the O
sheep O
CRF1 NUMERIC
and O
the O
other O
mammalian I-GENE
CRF1s NUMERIC
is O
primarily O
localized O
to O
the O
extracellular O
amino O
terminal O
domain O
of O
the O
receptor O
( O
18 O
of O
22 O
divergent O
residues O
, O
ovine RARE
vs O
human I-GENE
CRF1 NUMERIC
). O

Agonist RARE
- O
induced O
receptor O
internalization O
, O
determined O
as O
the O
percent O
of O
total O
[ O
125I NUMERIC
] O
Tyr0 NUMERIC
- I-GENE
oCRF LASTCAP
bound O
located O
in O
the O
acid O
- O
resistant O
fraction O
of O
transfected O
Cos RARE
7 O
cells O
, O
increased O
with O
time O
( O
0 O
- O
60 O
min O
at O
37 O
degrees O
C O
) O
for O
both O
wild O
- O
type O
and O
variant O
oCRF1 NUMERIC
. O

Recurrent RARE
arterial O
thrombotic O
disease O
on O
young O
onset O
and O
protein I-GENE
S I-GENE
deficiency O
. O

We O
showed O
that O
Stat3 I-GENE
and O
Stat3beta NUMERIC
were O
affinity O
purified O
using O
phosphopeptides O
containing O
Y704 NUMERIC
and O
Y744 NUMERIC
but O
not O
by O
nonphosphorylated RARE
peptide O
analogues O
or O
by O
phosphopeptides O
containing O
Y729 NUMERIC
and O
Y764 NUMERIC
. O

Taken O
together O
, O
our O
results O
indicate O
that O
the O
FCR1 NUMERIC
gene I-GENE
behaves RARE
as O
a O
negative O
regulator O
of O
drug O
resistance O
in O
C O
. O
albicans O
and O
constitute O
the O
first O
evidence O
that O
FCZ ALLCAPS
resistance O
can O
result O
from O
the O
inactivation O
of O
a O
regulatory O
factor O
such O
as O
Fcr1p NUMERIC
. O

These O
findings O
suggest O
that O
late O
MYO ALLCAPS
/ O
M O
is O
more O
useful O
than O
washout O
rate O
to O
assess O
the O
effect O
of O
treatment O
on O
heart O
failure O
due O
to O
DCM ALLCAPS
. O

This O
study O
was O
undertaken O
to O
evaluate O
how O
couplers RARE
and O
their O
placement O
affect O
the O
ALGO2 NUMERIC
click RARE
spectral O
properties O
. O

CONCLUSIONS O
: O
Pretreatment RARE
with O
OCs RARE
prior O
to O
pituitary O
suppression O
in O
the O
early O
follicular O
phase O
decreases O
ovarian O
cyst O
formation O
, O
without O
an O
apparent O
effect O
on O
subsequent O
follicular O
recruitment O
or O
pregnancy O
rates O
. O

With O
regard O
to O
the O
optimal O
threshold O
values O
, O
sensitivity O
and O
specificity O
were O
100 O
%/ RARE
97 O
% O
and O
95 O
%/ RARE
95 O
% O
with O
FDG O
PET O
, O
compared O
to O
86 O
%/ RARE
92 O
% O
and O
77 O
%/ RARE
82 O
% O
with O
IS ALLCAPS
, O
respectively O
. O

This O
c I-GENE
- I-GENE
Jun I-GENE
activity O
is O
inhibited O
by O
c I-GENE
- I-GENE
Fos I-GENE
, O
another O
protooncoprotein RARE
that O
can O
dimerize RARE
with O
c I-GENE
- I-GENE
Jun I-GENE
to O
form O
the O
transcription O
factor O
AP I-GENE
- I-GENE
1 I-GENE
. O

Dorsal RARE
root O
ganglia RARE
neuron O
- O
specific O
promoter O
activity O
of O
the O
rabbit I-GENE
beta I-GENE
- I-GENE
galactoside RARE
alpha1 I-GENE
, I-GENE
2 I-GENE
- I-GENE
fucosyltransferase RARE
gene I-GENE
. O

CONCLUSION O
: O
Our O
study O
shows O
that O
( O
1 O
) O
total O
body O
BMD O
and O
femoral O
neck O
BMD O
were O
significantly O
higher O
in O
the O
study O
group O
that O
performed O
weight O
- O
bearing O
exercises RARE
than O
in O
control O
subjects O
, O
( O
2 O
) O
swimming O
exercise O
had O
no O
effect O
on O
BMD O
, O
and O
( O
3 O
) O
although O
swimming O
is O
not O
a O
bone O
- O
building RARE
exercise O
, O
it O
can O
significantly O
improve O
shoulder RARE
, O
back O
, O
and O
grip RARE
muscle O
strength O
. O

This O
suggests O
roles O
for O
both O
the O
CE1 NUMERIC
and O
CE2 NUMERIC
elements O
in O
regulating O
Hoxb1 NUMERIC
gene I-GENE
expression O
during O
development O
. O

CAL ALLCAPS
gain O
amounted RARE
to O
4 O
. O
2 O
+/- O
1 O
. O
3 O
mm O
, O
60 O
% O
of O
the O
defects O
showing O
CAL ALLCAPS
gain O
> O
or O
= O
4 O
mm O
. O

Comparisons RARE
with O
other O
known O
germins RARE
and O
germin RARE
- I-GENE
like I-GENE
proteins I-GENE
indicate O
that O
these O
Arabidopsis O
GLP ALLCAPS
subfamilies RARE
are O
unique O
from O
wheat O
germin RARE
. O

Lead RARE
fixation O
in O
dogs O
achieved O
with O
RF ALLCAPS
energy O
. O

However O
, O
there O
has O
not O
been O
any O
evidence O
of O
A O
. O
salmonicida RARE
infections O
, O
specifically O
furunculosis RARE
, O
associated O
with O
the O
fish O
in O
this O
loch RARE
. O

Further O
, O
we O
show O
that O
this O
EIA I-GENE
- O
inducible O
CBF O
/ O
cdc2 I-GENE
is O
related O
to O
the O
CBF I-GENE
which O
was O
shown O
to O
activate O
the O
heat I-GENE
shock I-GENE
protein I-GENE
70 I-GENE
promoter I-GENE
. O

The O
percutaneous RARE
absorption O
of O
clindamycin O
was O
studied O
in O
healthy O
male O
volunteers O
, O
comparing O
two O
investigative RARE
clindamycin O
(% RARE
w O
/ O
v O
)/ O
tretinoin RARE
( O
0 O
. O
025 NUMERIC
% O
w O
/ O
v O
) O
gels O
, O
containing O
clindamycin O
phosphate O
ester O
and O
clindamycin O
HCl RARE
, O
respectively O
, O
relative O
to O
a O
clindamycin O
phosphate O
lotion RARE
( O
1 O
% O
clindamycin O
; O
Dalacin RARE
T O
). O

The O
BAL O
concentrations O
of O
the O
nine O
cytokines O
evaluated O
for O
the O
more O
and O
less O
affected O
lungs O
were O
compared O
: O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
), O
IL I-GENE
- I-GENE
8 I-GENE
, O
IL I-GENE
- I-GENE
12 I-GENE
, O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
), O
and O
interferon I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
showed O
significant O
differences O
( O
p O
ranged O
between O
0 O
. O

Phosphorylation RARE
analyses O
indicated O
that O
inhibition O
of O
ERK I-GENE
- I-GENE
1 I-GENE
/ I-GENE
2 I-GENE
decreased O
okadaic RARE
acid O
- O
elevated O
phosphorylation O
of O
JunD LASTCAP
and O
FosB LASTCAP
. O

Two O
- O
way O
analysis O
of O
variance RARE
was O
used O
to O
determine O
whether O
composite O
knowledge O
score O
differed O
among O
patient O
groups O
. O

The O
human O
pathogenic O
bacterium O
group O
A O
Streptococcus O
produces O
an O
extracellular O
cysteine I-GENE
protease I-GENE
[ O
streptococcal I-GENE
pyrogenic RARE
exotoxin RARE
B I-GENE
( O
SpeB LASTCAP
)] O
that O
is O
a O
critical O
virulence O
factor O
for O
invasive O
disease O
episodes O
. O

The O
orbitofrontal RARE
, O
cingulate RARE
, O
and O
anteromedial RARE
part O
of O
the O
dorsal O
premotor RARE
areas O
were O
preferentially O
activated O
by O
the O
self O
- O
initiated O
hand O
movement O
task O
( O
SELF ALLCAPS
). O

Improving RARE
the O
evidence O
base O
for O
anaesthesia O
. O

Plasma O
CCK ALLCAPS
levels O
were O
determined O
at O
regular O
intervals O
. O

The O
peroxisome O
biogenesis O
disorders O
( O
PBDs RARE
) O
are O
a O
set O
of O
lethal O
genetic O
diseases O
characterized O
by O
peroxisomal RARE
metabolic O
deficiencies O
, O
multisystem RARE
abnormalities O
, O
mental O
retardation O
, O
and O
premature O
death O
. O

The O
active O
site O
includes O
the O
acidic O
triad RARE
Asp53 NUMERIC
( O
the O
site O
of O
phosphorylation O
), O
Asp10 NUMERIC
and O
Glu9 NUMERIC
. O

Consistent O
with O
these O
findings O
, O
relatively O
weak O
transcriptional O
silencing O
by O
the O
native O
VDR I-GENE
was O
observed O
using O
the O
osteopontin RARE
VDRE O
. O

In O
PAV ALLCAPS
- O
3 O
, O
the O
E1A I-GENE
region I-GENE
is O
located O
between O
1 O
. O
5 O
and O
3 O
. O
8 O
map O
units O
. O

Six O
putative O
MDV O
genome O
products O
, O
including O
one O
Rep I-GENE
and O
five O
non O
- O
Rep I-GENE
proteins O
, O
show O
high O
( O
70 O
. O
4 O
- O
90 O
. O
9 O
%) O
amino O
acid O
identity O
to O
the O
corresponding O
six O
FBNYV ALLCAPS
proteins I-GENE
, O
whereas O
two O
other O
Rep I-GENE
proteins I-GENE
encoded O
by O
MDV I-GENE
- I-GENE
C2 I-GENE
and O
C3 I-GENE
are O
82 O
. O
3 O
% O
and O
73 O
. O
0 O
% O
identical O
to O
those O
encoded O
by O
SCSV ALLCAPS
- I-GENE
C2 I-GENE
and O
C6 I-GENE
, O
respectively O
. O

MPO ALLCAPS
was O
labeled O
with O
1 O
mCi O
125I NUMERIC
by O
a O
technique O
of O
self O
- O
labeling O
in O
the O
presence O
of O
10 O
(- O
4 O
) O
M O
hydrogen O
peroxide RARE
. O

It O
is O
related O
to O
a O
variety O
of O
mammalian O
Golgi O
- O
associated O
proteins O
and O
to O
the O
yeast O
Uso1p NUMERIC
, O
an O
essential O
protein O
involved O
in O
docking RARE
of O
endoplasmic O
reticulum O
- O
derived O
vesicles O
to O
the O
cis O
- O
Golgi O
. O

The O
data O
indicate O
that O
Bmp2 NUMERIC
is O
directly O
regulated O
by O
retinoic O
acid O
- O
bound O
receptors O
and O
Sp1 I-GENE
. O

Both O
proteins O
were O
shown O
to O
be O
constitutively O
associated O
with O
tubulin RARE
. O

HEED ALLCAPS
was O
found O
to O
bind O
to O
MA I-GENE
protein I-GENE
in O
vitro O
, O
as O
efficiently O
as O
in O
vivo O
in O
yeast O
cells O
. O

Fas I-GENE
- O
resistant O
DT O
- O
40 O
lymphoma O
B O
- O
cells O
rendered RARE
BTK ALLCAPS
- O
deficient O
through O
targeted O
disruption O
of O
the O
btk RARE
gene I-GENE
by O
homologous O
recombination O
knockout RARE
underwent O
apoptosis O
after O
Fas I-GENE
ligation O
, O
but O
wild O
- O
type O
DT O
- O
40 O
cells O
or O
BTK ALLCAPS
- O
deficient O
DT O
- O
40 O
cells O
reconstituted O
with O
wild I-GENE
- I-GENE
type I-GENE
human I-GENE
btk RARE
gene I-GENE
did O
not O
. O

A O
motif O
( O
TGATGTCA ALLCAPS
) O
which O
matches O
a O
CREB I-GENE
site I-GENE
and O
is O
similar O
to O
an O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
is O
embedded O
within O
ER2 NUMERIC
. O

Conventionally RARE
, O
four O
nominal RARE
allotypic RARE
variants O
, O
b4 NUMERIC
, O
b5 NUMERIC
, O
b6 NUMERIC
and O
b9 NUMERIC
have O
been O
shown O
to O
be O
co O
- O
dominantly RARE
expressed O
at O
the O
Ckappa1 NUMERIC
gene I-GENE
locus I-GENE
. O

Therefore O
, O
in O
order O
to O
search O
for O
the O
latent O
genes O
, O
we O
used O
allotype RARE
- O
specific O
oligonucleotides O
for O
b5 NUMERIC
, O
b6 NUMERIC
and O
b9 NUMERIC
to O
probe O
DNAs O
from O
both O
normal O
and O
T O
. O
brucei RARE
- O
infected O
rabbits O
by O
Southern O
blotting O
. O

TRAF2 I-GENE
is O
known O
to O
associate O
with O
TRADD ALLCAPS
, O
and O
expression O
of O
a O
dominant O
- O
negative O
N O
- O
terminal O
deletion O
TRAF2 I-GENE
mutant I-GENE
was O
found O
to O
partially O
inhibit O
LMP1 I-GENE
- O
induced O
JNK I-GENE
activation O
in O
293 O
cells O
. O

These O
data O
further O
define O
a O
role O
for O
TRADD ALLCAPS
and O
TRAF2 I-GENE
in O
JNK I-GENE
activation O
and O
confirm O
that O
LMP1 I-GENE
utilizes RARE
signalling O
mechanisms O
used O
by O
the O
TNF I-GENE
receptor I-GENE
/ O
CD40 I-GENE
family O
to O
elicit O
its O
pleiotropic O
activities O
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
- I-GENE
encoded I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
activates O
the O
JNK I-GENE
pathway O
through O
its O
extreme O
C O
terminus O
via O
a O
mechanism O
involving O
TRADD ALLCAPS
and O
TRAF2 I-GENE
. O

In O
contrast O
, O
transiently O
transfected O
cells O
expressing O
EBNA I-GENE
- I-GENE
3 I-GENE
revealed O
a O
sixfold RARE
increase O
in O
EBNA I-GENE
- I-GENE
3 I-GENE
protein I-GENE
expression O
from O
the O
genomic O
EBNA I-GENE
- I-GENE
3 I-GENE
gene I-GENE
compared O
to O
EBNA I-GENE
- I-GENE
3 I-GENE
cDNA I-GENE
. O

However O
, O
serial O
passages RARE
of O
fetal O
lamb RARE
kidney O
( O
FLK ALLCAPS
) O
cells O
, O
which O
are O
sensitive O
to O
infection O
with O
BLV ALLCAPS
, O
after O
transient O
transfection O
revealed O
that O
mutation O
of O
a O
second O
tyrosine O
residue O
in O
the O
N O
- O
terminal O
motif O
completely O
prevented O
the O
propagation RARE
of O
the O
virus O
. O

Varicella RARE
- I-GENE
zoster RARE
virus I-GENE
( I-GENE
VZV I-GENE
) I-GENE
glycoprotein I-GENE
gI LASTCAP
is O
a O
type I-GENE
1 I-GENE
transmembrane I-GENE
glycoprotein I-GENE
which O
is O
one O
component O
of O
the O
heterodimeric O
gE LASTCAP
: O
gI LASTCAP
Fc I-GENE
receptor I-GENE
complex O
. O

To O
this O
end O
, O
we O
analyzed O
the O
phosphorylation O
status O
of O
a O
universal RARE
tyrosine I-GENE
kinase I-GENE
substrate O
, O
the O
transforming O
Shc I-GENE
adapter I-GENE
protein I-GENE
, O
in O
fibroblasts O
expressing O
the O
viral O
oncogene O
. O

These O
genes O
were O
expressed O
in O
a O
Saccharomyces O
cerevisiae O
mutant O
in O
which O
the O
endogenous I-GENE
ferrochelatase RARE
gene I-GENE
( O
HEM15 NUMERIC
) O
had O
been O
deleted O
, O
and O
the O
phenotypes O
of O
the O
transformants O
were O
characterized O
. O

In O
this O
study O
, O
evidence O
is O
presented O
that O
temporally O
and O
spatially O
specific O
mef2 NUMERIC
expression O
is O
controlled O
by O
a O
complex O
array RARE
of O
cis O
- O
acting O
regulatory O
modules O
that O
are O
responsive O
to O
different O
genetic O
signals O
. O

Furthermore O
, O
using O
transgenic O
mouse O
technology O
we O
localized O
independent O
cis O
- O
regulatory O
elements O
controlling O
the O
tissue O
- O
specific O
expression O
of O
Pax6 NUMERIC
. O

In O
the O
second O
experiment O
, O
a O
stable O
nickel O
isotope RARE
, O
61Ni NUMERIC
, O
was O
given O
in O
drinking O
water O
to O
20 O
nickel O
- O
sensitized RARE
women O
and O
20 O
age O
- O
matched O
controls O
, O
both O
groups O
having O
vesicular O
hand O
eczema RARE
of O
the O
pompholyx RARE
type O
. O

Folded RARE
tissue O
and O
crimped RARE
collagen I-GENE
fibers O
in O
the O
tunica RARE
albuginea RARE
permit O
its O
expansion O
during O
erection RARE
. O

Number RARE
of O
patients O
infected O
with O
nontuberculous RARE
mycobacteria O
( O
NTM ALLCAPS
) O
is O
increasing O
world O
- O
wide O
in O
recent O
years O
. O

Comparison O
of O
the O
sequences O
of O
attP LASTCAP
, O
attB LASTCAP
and O
bacteria O
- O
prophage RARE
junctions O
attL LASTCAP
and O
attR LASTCAP
showed O
a O
26 O
bp O
common O
core O
sequence O
, O
where O
recombination O
takes RARE
place O
, O
near O
the O
5 O
' O
end O
of O
the O
integrase I-GENE
gene I-GENE
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
treatment O
of O
posttransplant RARE
lymphoproliferative RARE
disorder O
in O
recipients O
of O
solid O
organ O
transplants RARE
. O

Immunological RARE
testing O
was O
performed O
on O
all O
brewery RARE
workers O
and O
some O
control O
volunteers O
using O
skin O
prick RARE
testing O
with O
hops RARE
, O
barley O
, O
and O
yeast O
antigens O
as O
well O
as O
other O
nonoccupational RARE
allergens O
, O
and O
by O
determining O
total O
serum I-GENE
IgE I-GENE
levels O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
accuracy O
of O
working O
casts RARE
for O
crown RARE
and O
bridge RARE
restorations O
made O
from O
twin RARE
mix RARE
putty RARE
/ O
wash RARE
silicone RARE
elastomeric RARE
impression RARE
materials O
using O
different O
types O
of O
stock RARE
tray RARE
. O

OBJECTIVES O
: O
To O
assess O
the O
ability O
of O
pretreatment O
and O
post O
- O
treatment O
prostate I-GENE
- I-GENE
specific I-GENE
antigen I-GENE
( O
PSA I-GENE
) O
measurements O
, O
clinical O
tumor O
stage O
, O
tumor O
grade O
, O
Gleason RARE
sum O
, O
race RARE
, O
age O
, O
and O
radiation O
dose O
to O
predict O
the O
recurrence O
of O
prostate O
cancer O
following O
external O
beam O
radiation O
therapy O
( O
XRT ALLCAPS
) O
since O
the O
introduction O
of O
PSA I-GENE
as O
a O
tumor O
marker O
at O
one O
tertiary O
care O
center O
. O

To O
evaluate O
whether O
the O
human O
gene O
is O
also O
a O
target O
of O
thyroid O
hormone O
we O
have O
searched RARE
for O
T3 O
- O
responsive O
elements O
in O
NRGN ALLCAPS
cloned O
genomic O
fragments O
spanning O
the O
whole O
gene O
. O

The O
transcriptional O
activity O
of O
PPARgamma I-GENE
is O
positively O
modulated O
by O
ligand O
binding O
and O
negatively O
regulated O
by O
phosphorylation O
mediated O
by O
the O
MEK I-GENE
/ O
ERK I-GENE
signaling O
pathway O
. O

BACKGROUND O
: O
Diazepam RARE
, O
one O
of O
the O
benzodiazepine RARE
group O
of O
tranquilizers RARE
, O
is O
used O
as O
an O
adjunctive RARE
drug O
for O
sedation O
and O
for O
relief RARE
of O
anxiety O
in O
the O
treatment O
of O
epilepsy O
. O

Bioplastique RARE
granuloma O
presents O
with O
irregularly RARE
shaped O
cystic O
spaces RARE
of O
varying O
size O
containing O
jagged RARE
, O
translucent RARE
, O
nonbirefringent RARE
foreign O
bodies O
whereas O
Artecoll RARE
granuloma O
shows O
numerous O
round O
vacuoles RARE
nearly O
identical O
in O
size O
and O
shape O
enclosing RARE
round O
and O
sharply O
circumscribed RARE
, O
translucent RARE
, O
nonbirefringent RARE
foreign O
bodies O
. O

This O
Tbx6 NUMERIC
- I-GENE
subfamily I-GENE
gene I-GENE
is O
likely O
to O
participate O
in O
paraxial RARE
mesoderm O
formation O
and O
somitogenesis RARE
in O
human O
embryo O
. O

Structure O
- O
function O
analysis O
of O
the O
Z O
- O
DNA O
- O
binding O
domain O
Zalpha RARE
of O
dsRNA I-GENE
adenosine I-GENE
deaminase I-GENE
type I-GENE
I I-GENE
reveals O
similarity O
to O
the O
( I-GENE
alpha I-GENE
+ I-GENE
beta I-GENE
) I-GENE
family I-GENE
of O
helix I-GENE
- I-GENE
turn I-GENE
- I-GENE
helix I-GENE
proteins I-GENE
. O

In O
addition O
, O
the O
regulation O
of O
Glvr RARE
- I-GENE
1 I-GENE
gene I-GENE
expression O
also O
has O
potential O
applications O
to O
gene O
therapy O
, O
since O
retroviral O
vectors O
carrying O
gibbon RARE
ape RARE
leukemia I-GENE
virus I-GENE
envelope I-GENE
proteins I-GENE
are O
used O
for O
gene O
delivery O
into O
different O
cell O
types O
. O

Carbohydrates RARE
and O
glycoconjugates RARE
biophysical RARE
methods O
. O

Molecular O
cloning O
of O
mouse I-GENE
glycolate RARE
oxidase I-GENE
. O

In O
such O
a O
manner O
, O
activated O
PKR I-GENE
inhibits O
cell O
growth O
and O
induces O
apoptosis O
, O
whereas O
disruption O
of O
normal O
PKR I-GENE
signaling O
results O
in O
unregulated RARE
cell O
growth O
. O

We O
isolated O
a O
ribosomal I-GENE
protein I-GENE
L18 NUMERIC
by O
interaction O
with O
PKR I-GENE
. O

Processing RARE
of O
the O
polycistronic RARE
precursor O
requires O
nucleases RARE
also O
involved O
in O
rRNA O
processing O
, O
i O
. O
e O
., O
Rnt1p NUMERIC
and O
Rat1p NUMERIC
. O

To O
search O
for O
transcriptional O
regulators O
, O
we O
used O
a O
fragment O
of O
the O
SpHE LASTCAP
promoter I-GENE
containing O
several O
individual O
elements O
instead O
of O
the O
conventional O
bait RARE
that O
contains O
a O
multimerized RARE
cis O
element O
. O

As O
expected O
for O
a O
positive O
SpHE LASTCAP
transcriptional I-GENE
regulator I-GENE
, O
the O
timing O
of O
SpEts4 NUMERIC
gene I-GENE
expression O
precedes RARE
the O
transient O
expression O
of O
SpHE LASTCAP
in O
the O
very O
early O
sea O
urchin O
blastula RARE
. O

Furthermore O
, O
rhoA LASTCAP
- O
mediated O
SRE O
activation O
was O
blocked O
by O
dominant O
negative O
mutants O
of O
PKC I-GENE
- I-GENE
alpha I-GENE
or O
PKC I-GENE
- I-GENE
epsilon I-GENE
. O

Nip7p NUMERIC
- O
depleted O
cells O
exhibited O
the O
same O
defects O
as O
Nop8p NUMERIC
- O
depleted O
cells O
, O
except O
that O
they O
accumulated O
27S NUMERIC
precursors I-GENE
. O

We O
show O
that O
the O
Sm RARE
- I-GENE
binding I-GENE
site I-GENE
and O
stem O
- O
loop O
III O
structures O
are O
necessary O
for O
correct O
3 O
'- O
end O
formation O
. O

Five O
different O
subtypes O
of O
spondyloarthropathy RARE
( O
SpA LASTCAP
) O
are O
now O
recognized O
. O

Further O
experiments O
will O
be O
required O
to O
highlight RARE
the O
in O
vivo O
role O
of O
ELE1 NUMERIC
in O
nuclear O
receptor O
functioning O
. O

Overexpression O
of O
PTTG ALLCAPS
in O
transfected O
NIH O
3T3 O
cells O
also O
stimulated O
expression O
and O
secretion O
of O
basic I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
, O
a O
human I-GENE
pituitary I-GENE
tumor I-GENE
growth I-GENE
- I-GENE
regulating I-GENE
factor I-GENE
. O

The O
perifascicular RARE
connective O
tissue O
sheath RARE
is O
important O
in O
organising RARE
the O
contraction O
of O
the O
myocardium O
by O
preventing O
lateral O
spread O
of O
conduction O
and O
by O
permitting RARE
transmission O
of O
the O
impulse RARE
only O
at O
the O
termination O
of O
the O
purkinje RARE
fibre O
. O

E1 I-GENE
, O
a O
DNA I-GENE
helicase I-GENE
, O
collaborates RARE
with O
the O
HPV I-GENE
E2 I-GENE
protein I-GENE
in O
ori RARE
- O
dependent O
replication O
. O

Here O
we O
describe O
a O
mutant O
alpha O
subunit O
designed O
to O
inhibit O
receptor O
- O
mediated O
hormonal O
activation O
of O
Gs I-GENE
, O
the O
stimulatory O
regulator O
of O
adenylyl RARE
cyclase I-GENE
. O

A O
gapped RARE
search O
with O
the O
C O
- O
terminal O
region O
of O
CDED ALLCAPS
/ O
LIOR ALLCAPS
revealed O
a O
36 O
- O
41 O
% O
similarity O
to O
several O
proteins O
related O
to O
signal O
transduction O
and O
cell O
replication O
, O
such O
as O
ORC1 NUMERIC
and O
KSR ALLCAPS
. O

Northern O
blot O
analysis O
demonstrated O
the O
ubiquitous O
expression O
of O
2 O
. O
9 O
kb O
and O
3 O
. O

Additionally O
, O
a O
variety O
of O
regulatory O
schemes RARE
contribute O
temporal O
and O
/ O
or O
spatial O
restriction O
to O
TGF I-GENE
- I-GENE
beta I-GENE
responses O
. O

Induction O
of O
anaesthesia O
was O
standardised RARE
: O
fentanyl O
( O
3 O
micrograms O
/ O
kg O
), O
thiopentone RARE
( O
5 O
mg O
/ O
kg O
), O
atracurium RARE
( O
0 O
. O
4 O
mg O
/ O
kg O
). O

A O
comparison O
of O
the O
clinical O
profile O
of O
cavernous RARE
malformations O
with O
and O
without O
associated O
venous O
malformations O
. O

Conserved RARE
and O
distinct O
roles O
of O
kreisler RARE
in O
regulation O
of O
the O
paralogous RARE
Hoxa3 NUMERIC
and O
Hoxb3 NUMERIC
genes I-GENE
. O

Magnetically RARE
induced O
optical O
self O
- O
pulsing RARE
in O
a O
nonlinear RARE
resonator RARE
. O

Wave RARE
cybernetics RARE
: O
A O
simple O
model O
of O
wave O
- O
controlled O
nonlinear RARE
and O
nonlocal RARE
cooperative O
phenomena O
. O

Autoionization RARE
rates O
and O
energy O
levels O
of O
triplet O
nf RARE
, O
v O
= O
1 O
Rydberg RARE
states O
of O
H2 O
. O

Unitary RARE
- O
group O
approach O
to O
spin O
- O
dependent O
operators RARE
. O

Nonlocal RARE
approach O
to O
scattering RARE
in O
a O
one O
- O
dimensional O
problem O
. O

Soft RARE
- O
x O
- O
ray O
lasing RARE
at O
32 O
. O
6 O
nm O
in O
Ne RARE
- O
like O
Ti RARE
ions O
driven O
by O
40 O
J O
of O
energy O
from O
two O
650 NUMERIC
- O
ps O
laser O
pulses RARE
. O

Next RARE
, O
to O
identify O
regions O
of O
the O
promoter O
involved O
, O
we O
examined O
a O
series O
of O
tenascin RARE
- I-GENE
C I-GENE
promoter I-GENE
constructs I-GENE
with O
5 O
' O
deletions O
and O
showed O
that O
denatured RARE
collagen I-GENE
- I-GENE
dependent I-GENE
promoter I-GENE
activity O
was O
retained O
by O
a O
122 O
- O
base O
pair O
element O
, O
located O
- O
43 O
to O
- O
165 O
bp O
upstream O
of O
the O
RNA O
start O
site O
. O

Nuclear I-GENE
factor I-GENE
kappa I-GENE
B I-GENE
( O
NF I-GENE
- I-GENE
kappaB I-GENE
) O
is O
an O
important O
transcription O
factor O
for O
the O
genes O
of O
many O
pro O
- O
inflammatory O
proteins O
and O
is O
strongly O
activated O
by O
the O
cytokines O
interleukin I-GENE
- I-GENE
1 I-GENE
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
( I-GENE
TNF I-GENE
) I-GENE
alpha I-GENE
under O
various O
pathological O
conditions O
. O

Moreover O
, O
this O
enhancement O
of O
transcriptional O
activation O
by O
COUP I-GENE
- I-GENE
TFI I-GENE
requires O
specifically O
the O
AF O
- O
1 O
transactivation O
function O
of O
ER I-GENE
and O
can O
be O
observed O
in O
the O
presence O
of O
E2 O
or O
4 O
- O
hydroxytamoxifen RARE
but O
not O
ICI ALLCAPS
164384 NUMERIC
. O

Recombinant I-GENE
Ffh RARE
has O
a O
melting RARE
point O
of O
tm RARE
= O
89 O
degreesC LASTCAP
. O

Unilateral RARE
naris RARE
occlusion O
and O
the O
rat O
accessory O
olfactory O
bulb O
. O

This O
region O
of O
hsp90 I-GENE
mediates O
ATP O
- O
independent O
chaperone RARE
activity O
, O
overlaps RARE
the O
hsp90 I-GENE
dimerization I-GENE
domain I-GENE
, O
and O
includes O
structural O
elements O
important O
for O
steroid I-GENE
receptor I-GENE
interaction O
. O

The O
promoter O
of O
the O
rat O
pgp2 NUMERIC
/ O
mdr1b NUMERIC
gene O
has O
a O
GC O
- O
rich O
region O
( O
pgp2GC NUMERIC
) O
that O
is O
highly O
conserved O
in O
mdr RARE
genes I-GENE
and O
contains O
an O
consensus O
Sp1 I-GENE
site I-GENE
. O

Sp1 I-GENE
' O
s O
role O
in O
transactivation O
of O
the O
pgp2 NUMERIC
/ O
mdr1b NUMERIC
promoter O
was O
tested O
in O
Drosophila O
Schneider RARE
cells O
. O

Measurements O
included O
bone O
mineral O
density O
of O
the O
lumbar O
spine O
and O
proximal O
femur O
( O
by O
dual O
- O
energy O
X O
- O
ray O
absorptiometry RARE
) O
and O
biochemical O
markers O
of O
bone O
remodeling O
( O
serum O
bone O
- O
specific O
alkaline I-GENE
phosphatase I-GENE
by O
immunoassay O
and O
urine O
deoxypyridinoline RARE
by O
high O
- O
pressure O
liquid O
chromatography O
). O

Human I-GENE
MGP ALLCAPS
is O
a O
10 I-GENE
- I-GENE
kD I-GENE
skeletal I-GENE
extracellular I-GENE
matrix I-GENE
( I-GENE
ECM ALLCAPS
) I-GENE
protein I-GENE
that O
consists O
of O
an O
84 O
- O
aa O
mature O
protein O
and O
a O
19 O
- O
aa O
transmembrane O
signal O
peptide O
. O

Dual RARE
roles O
of O
p82 NUMERIC
, O
the O
clam RARE
CPEB ALLCAPS
homolog I-GENE
, O
in O
cytoplasmic O
polyadenylation O
and O
translational O
masking RARE
. O

The O
RNA I-GENE
polymerase I-GENE
III I-GENE
- I-GENE
recruiting RARE
factor I-GENE
TFIIIB ALLCAPS
induces O
a O
DNA O
bend RARE
between O
the O
TATA O
box O
and O
the O
transcriptional O
start O
site O
. O

The O
pattern O
of O
RNase I-GENE
E I-GENE
digestion O
of O
finP305 NUMERIC
RNA I-GENE
differed O
from O
FinP LASTCAP
, O
and O
GST I-GENE
- O
FinO LASTCAP
did O
not O
protect O
finP305 NUMERIC
RNA I-GENE
from O
cleavage O
in O
vitro O
. O

Transcription O
readthrough O
into O
the O
inverted O
repeats O
has O
little O
effect O
on O
this O
event O
. O

Analysis O
of O
hematopoietic I-GENE
growth I-GENE
factor I-GENE
prescriptions RARE
in O
19 O
french RARE
cancer O
centers O

In O
the O
second O
case O
, O
an O
epidermal O
cyst O
was O
diagnosed O
. O

MotA LASTCAP
also O
binds O
a O
DNA O
sequence O
( O
a O
MotA LASTCAP
box I-GENE
), O
centered O
at O
position O
- O
30 O
. O

We O
suggest O
that O
MotA LASTCAP
and O
AsiA LASTCAP
may O
function O
like O
certain O
eukaryotic I-GENE
TAFs RARE
( O
TATA I-GENE
binding I-GENE
protein I-GENE
( I-GENE
TBP I-GENE
) I-GENE
associated I-GENE
factors I-GENE
) O
whose O
binding O
to O
TBP I-GENE
results O
in O
transcription O
from O
new O
core O
promoter O
sequences O
. O

The O
S229A NUMERIC
variant O
can O
better O
flip RARE
modified O
bases O
but O
does O
not O
tightly O
lock RARE
the O
flipped RARE
base O
into O
the O
adenine O
- O
binding O
pocket O
, O
suggesting O
that O
Ser229 NUMERIC
could O
form O
a O
contact O
to O
the O
flipped RARE
adenine O
. O

The O
high O
conservation O
of O
the O
3 O
' O
terminus O
suggests O
that O
this O
region O
directs O
the O
assembly O
of O
proteins O
required O
for O
the O
initiation O
of O
RNA O
replication O
. O

All O
stimulations RARE
were O
down O
- O
regulated O
with O
GnRH I-GENE
- I-GENE
a I-GENE
commenced RARE
on O
day O
21 O
in O
a O
long O
protocol O
before O
gonadotropin I-GENE
stimulation O
. O

The O
sequence O
up O
to O
- O
267 NUMERIC
bp O
relative O
to O
the O
transcription O
start O
site O
was O
sufficient O
to O
enhance O
reporter O
gene O
expression O
depending O
on O
the O
mesodermal RARE
differentiation O
of O
P19 O
cells O
. O

Chem O
. O

No O
significant O
differences O
between O
the O
substituted O
and O
wild O
type O
peptides O
were O
observed O
, O
suggesting O
that O
this O
substitution O
in O
the O
intact O
protein O
may O
cause O
disruption O
of O
global O
rather O
than O
local O
structures O
. O

These O
results O
suggest O
that O
the O
c I-GENE
- I-GENE
met I-GENE
gene I-GENE
is O
also O
a O
target O
of O
p53 I-GENE
gene I-GENE
regulation O
. O

C3 I-GENE
toxin I-GENE
completely O
inhibited O
RhoA I-GENE
function O
, O
partially O
inhibited O
SRE O
: O
Luc RARE
activity O
, O
but O
had O
no O
effect O
on O
LPA ALLCAPS
- O
stimulated O
c I-GENE
- I-GENE
Fos I-GENE
expression O
. O

However O
, O
C3 I-GENE
toxin I-GENE
alone O
or O
in O
combination O
with O
growth O
factors O
did O
not O
stimulate O
AP I-GENE
- I-GENE
1 I-GENE
: O
Luc RARE
activity O
and O
actually RARE
antagonized RARE
the O
synergistic O
activation O
of O
AP I-GENE
- I-GENE
1 I-GENE
: O
Luc RARE
observed O
in O
response O
to O
co O
- O
stimulation O
with O
growth O
factors O
and O
Ro O
- O
31 O
- O
8220 NUMERIC
. O

The O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
antimicrobial O
susceptibility O
to O
10 O
currently O
used O
antimicrobial O
agents O
of O
50 O
strains O
of O
P O
. O
acnes RARE
isolated O
from O
acne RARE
lesions O
and O
identified O
using O
a O
Rap RARE
ID ALLCAPS
ANA ALLCAPS
II O
panel O
. O

The O
role O
of O
intraoperative RARE
echocardiography O
in O
surgery O
of O
the O
heart O
and O
large O
vessels O

Taken O
together O
, O
our O
results O
demonstrate O
that O
CAP1 NUMERIC
is O
involved O
in O
multidrug O
resistance O
and O
oxidative O
stress O
response O
in O
C O
. O
albicans O
. O

Trinipatch RARE
is O
a O
small O
, O
transparent RARE
, O
matricial RARE
, O
monolayer RARE
patch O
with O
an O
absorption O
promoter O
, O
marketed RARE
in O
two O
dose O
- O
strengths O
( O
5 O
mg O
/ O
24 O
h O
and O
10 O
mg O
/ O
24 O
h O
) O
by O
Laboratoires RARE
Synthelabo RARE
. O

The O
RMRI ALLCAPS
was O
tested O
for O
interrater RARE
reliability O
using O
three O
simulated O
and O
10 O
actual O
patients O
. O

The O
starting O
point O
is O
the O
consideration RARE
that O
the O
conceptions RARE
underlying O
the O
ICIDH ALLCAPS
are O
not O
suitable O
to O
serve O
as O
a O
mainstay RARE
of O
a O
model O
for O
diagnostics RARE
in O
rehabilitation RARE
because O
they O
do O
not O
reflect O
essential O
characteristics O
of O
the O
diagnostic O
process O
which O
is O
the O
basis O
for O
intervention O
. O

Pokeweed RARE
antiviral RARE
protein I-GENE
( O
PAP ALLCAPS
) O
from O
Phytolacca RARE
americana RARE
is O
a O
highly O
specific O
N I-GENE
- I-GENE
glycosidase RARE
removing O
adenine O
residues O
( O
A4324 NUMERIC
in O
28S I-GENE
rRNA I-GENE
and O
A2660 NUMERIC
in O
23S NUMERIC
rRNA I-GENE
) O
from O
intact O
ribosomes RARE
of O
both O
eukaryotes O
and O
prokaryotes RARE
. O

OBJECTIVE O
: O
This O
meta RARE
- O
analysis O
of O
67 O
controlled O
trials O
was O
performed O
to O
quantify RARE
the O
cholesterol O
- O
lowering O
effect O
of O
major O
dietary O
fibers O
. O

Among O
these O
360 NUMERIC
ZFPs RARE
, O
a O
novel O
ZFP ALLCAPS
cDNA I-GENE
named O
HFHZ ALLCAPS
( O
human I-GENE
fetal I-GENE
heart I-GENE
ZFP ALLCAPS
) O
with O
sequence O
homology O
to O
a O
Kruppel RARE
- I-GENE
associated I-GENE
box I-GENE
( O
KRAB I-GENE
) O
was O
identified O
. O

The O
3 O
. O
3 O
- O
fold O
higher O
expression O
in O
the O
fetal O
heart O
than O
in O
the O
adult O
heart O
suggests O
that O
HFHZ ALLCAPS
mRNA I-GENE
is O
downregulated RARE
in O
the O
process O
of O
development O
. O

When O
the O
high O
affinity O
hnRNP I-GENE
A1 I-GENE
binding I-GENE
site I-GENE
was O
inserted O
into O
the O
beta I-GENE
- I-GENE
globin I-GENE
reporter I-GENE
, O
Rev I-GENE
was O
able O
to O
increase O
the O
cytoplasmic O
levels O
of O
unspliced O
mRNAs O
to O
14 O
%. O

To O
date O
, O
two O
such O
proteins O
, O
PLZF I-GENE
and O
LAZ ALLCAPS
- I-GENE
3 I-GENE
/ O
BCL I-GENE
- I-GENE
6 I-GENE
, O
have O
been O
implicated O
in O
oncogenesis RARE
. O

Overexpression O
of O
POG1 NUMERIC
inhibits O
alpha I-GENE
- I-GENE
factor I-GENE
- O
induced O
G1 O
arrest O
and O
transcriptional O
repression O
of O
the O
CLN1 NUMERIC
and O
CLN2 NUMERIC
genes I-GENE
. O

We O
now O
show O
that O
RNU2 NUMERIC
fragility RARE
can O
be O
induced O
by O
transfection O
with O
an O
expression O
vector O
encoding O
Ad12 NUMERIC
E1B I-GENE
55 O
kDa O
alone O
but O
not O
by O
an O
E1 I-GENE
vector O
encoding O
all O
E1 I-GENE
products I-GENE
( O
3 O
E1A I-GENE
proteins I-GENE
, O
as O
well O
as O
the O
E1B I-GENE
19 O
kDa O
and O
55 O
kDa O
proteins O
). O

Competitionsupershift RARE
EMSA O
assays O
revealed O
that O
multiple O
proteins O
were O
involved O
in O
bandshift RARE
complex O
formation O
with O
KCS I-GENE
, O
one O
of O
which O
was O
identified O
as O
factor O
Sp1 O
. O

Similarity RARE
of O
DNA O
binding O
and O
transcriptional O
regulation O
by O
Caenorhabditis I-GENE
elegans I-GENE
MAB ALLCAPS
- I-GENE
3 I-GENE
and O
Drosophila I-GENE
melanogaster I-GENE
DSX ALLCAPS
suggests O
conservation O
of O
sex O
determining O
mechanisms O
. O

CONTEXT ALLCAPS
: O
ThinPrep RARE
, O
AutoPap RARE
, O
and O
Papnet RARE
are O
3 O
new O
technologies RARE
that O
increase O
the O
sensitivity O
and O
cost O
of O
cervical O
cancer O
screening O
. O

Experiments O
on O
narcotized RARE
cats O
demonstrated O
that O
the O
derivatives O
of O
2 O
- O
mercaptobenzimidazole RARE
possessing RARE
the O
properties O
of O
specific O
bradycardic RARE
agents O
and O
coded O
as O
CM O
- O
251 NUMERIC
, O
CM O
- O
266 NUMERIC
, O
and O
CM O
- O
345 NUMERIC
, O
reduce O
the O
mean O
rise O
of O
segment O
ST O
on O
numerous O
leads O
of O
the O
epicardial RARE
electrogram RARE
during O
5 O
- O
min O
occlusion O
of O
the O
anterior O
descending RARE
branch O
of O
the O
left O
coronary O
artery O
. O

Neither O
the O
p42 NUMERIC
/ I-GENE
44 I-GENE
nor O
the O
JNK I-GENE
pathway O
was O
involved O
in O
the O
action O
of O
IL I-GENE
- I-GENE
1beta I-GENE
. O

In O
protocol O
2 O
, O
eight O
different O
subjects O
performed O
Con RARE
and O
Ecc RARE
arm O
curls RARE
to O
fatigue RARE
, O
followed O
by O
postexercise RARE
muscle O
ischemia O
, O
by O
using O
the O
same O
resistance O
as O
in O
protocol O
1 O
. O

Airflow RARE
was O
measured O
with O
a O
custom RARE
- O
designed O
turbine RARE
and O
a O
45 O
- O
ft RARE
.- RARE
long O
cable RARE
to O
reach O
the O
volume O
- O
measuring O
module RARE
. O

Both O
mutations O
confer O
amino O
acid O
substitutions O
in O
the O
viral I-GENE
coat I-GENE
protein I-GENE
but O
differ O
in O
their O
relative O
abilities O
to O
utilize RARE
the O
foreign O
scaffolding RARE
protein I-GENE
. O

Complete RARE
recovery O
of O
liver O
function O
after O
this O
surgery O
tended O
to O
be O
slow O
. O

Although O
both O
transcripts O
share O
the O
first O
nine O
exons O
, O
exon O
10 O
of O
ZIS ALLCAPS
- I-GENE
2 I-GENE
is O
lacking O
in O
ZIS ALLCAPS
- I-GENE
1 I-GENE
, O
and O
instead O
, O
exon O
11 O
( O
10th NUMERIC
exon O
) O
of O
ZIS ALLCAPS
- I-GENE
1 I-GENE
is O
larger O
in O
size O
, O
leading O
to O
the O
longer O
3 O
'- O
UTR O
. O

Expression O
of O
the O
second O
gene O
( O
XT3 NUMERIC
) O
was O
found O
to O
be O
conserved O
in O
human O
kidney O
, O
and O
partial O
sequence O
was O
obtained O
from O
a O
human O
cDNA O
library O
. O

IFN I-GENE
- I-GENE
gamma I-GENE
was O
elevated O
during O
active O
TB O
when O
compared O
with O
healthy O
controls O
, O
declining RARE
during O
and O
after O
treatment O
. O

The O
missing O
5 O
' O
sequences O
were O
obtained O
by O
5 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
and O
by O
analysis O
of O
an O
NHE5 NUMERIC
genomic I-GENE
clone I-GENE
, O
and O
the O
missing O
3 O
' O
sequences O
were O
obtained O
by O
3 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
. O

If O
no O
alloantibodies RARE
are O
detected O
, O
further O
analysis O
to O
define O
a O
role O
of O
drug O
- O
related O
or O
autoantibodies O
is O
required O
. O

This O
dependence O
, O
however O
, O
can O
be O
overcome O
to O
a O
large O
extent O
by O
dividing RARE
min O
LVdP LASTCAP
/ O
dt O
by O
mean O
aortic O
pressure O
. O

Genoa RARE
, O
Italy RARE
, O
24 O
- O
28 O
August O
1997 O
. O

Electronic RARE
structure O
of O
delta O
- O
plutonium O
and O
of O
single O
Al O
, O
Ga O
, O
and O
Sc RARE
impurities RARE
in O
delta O
- O
plutonium O
. O

Bound RARE
- O
exciton RARE
transfer O
and O
photoluminescence RARE
undulation RARE
spectra O
for O
acceptors RARE
in O
ZnTe RARE
. O

Unified RARE
theory O
of O
segregated RARE
- O
stack RARE
organic O
charge O
- O
transfer O
solids RARE
: O
Magnetic O
properties O
. O

Internal RARE
modes O
of O
a O
soliton RARE
. O

II O
. O

Envelope RARE
- O
function O
matching RARE
conditions O
for O
GaAs RARE
/( RARE
Al O
, O
Ga O
) O
As O
heterojunctions RARE
. O

Neutron RARE
scattering RARE
measurements O
of O
critical O
exponents RARE
in O
CsMnBr3 NUMERIC
: O
A O
Z2 NUMERIC
& O
gt RARE
;= RARE
1 O
antiferromagnet RARE
. O

( O
2 O
) O
Erythroid RARE
32D NUMERIC
Epo1 NUMERIC
cells O
showed O
a O
lower O
level O
of O
bulk O
PKC I-GENE
catalytic O
activity O
, O
lacked O
the O
expression O
of O
epsilon I-GENE
and I-GENE
eta RARE
PKC I-GENE
isoforms I-GENE
, O
and O
showed O
a O
weak O
or O
absent O
upregulation RARE
of O
the O
remaining O
isoforms O
, O
except O
betaI LASTCAP
, O
upon O
readdition RARE
of O
Epo I-GENE
to O
growth O
factor O
- O
starved RARE
cells O
. O

We O
used O
expression O
cloning O
to O
identify O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
as O
one O
factor O
that O
suppressed O
growth O
of O
a O
pre O
- O
B O
- O
cell O
variant O
line O
, O
1A9 NUMERIC
- O
M O
. O

Airflow RARE
through O
the O
dust O
trap RARE
was O
controlled O
with O
a O
vacuum RARE
pump O
. O

Thus O
, O
in O
normal O
intestinal O
epithelial O
goblet RARE
cells O
, O
TbetaRI LASTCAP
and O
TbetaRII LASTCAP
can O
respond O
to O
autocrine O
but O
not O
exogenous O
TGF I-GENE
- I-GENE
beta I-GENE
without O
the O
participation O
of O
TbetaRIII LASTCAP
. O

The O
history O
of O
exposure O
and O
carboxyhemoglobin RARE
levels O
should O
alert RARE
the O
physician RARE
to O
this O
diagnosis O
. O

The O
odds O
ratio O
for O
CHD ALLCAPS
was O
1 O
. O
21 O
( O
95 O
% O
confidence O
interval O
, O
0 O
. O
84 O
- O
1 O
. O
75 O
) O
given O
a O
positive O
serostatus RARE
of O
specific O
IgG I-GENE
antibodies O
after O
adjustment O
for O
covariates RARE
. O

Another O
group O
of O
HIPP ALLCAPS
- O
and O
HCX ALLCAPS
- O
lesioned O
animals O
trained RARE
on O
the O
tasks O
after O
the O
lesion O
showed O
reduced O
impairments RARE
of O
the O
type O
described O
above O
, O
suggesting O
that O
extrahippocampal RARE
structures O
trained RARE
after O
the O
lesion O
can O
assume RARE
the O
role O
of O
the O
hippocampus O
to O
some O
degree O
. O

The O
case O
for O
neutrinos RARE
from O
SN ALLCAPS
1987A NUMERIC
. O

Scaling RARE
of O
fluctuations O
in O
one O
- O
dimensional O
interface O
and O
hopping RARE
models O
. O

Model RARE
of O
spatiotemporal RARE
dynamics O
of O
stick RARE
- O
slip RARE
motion O
. O

NMR O
of O
diffusing RARE
atoms RARE
in O
a O
periodic O
porous RARE
medium O
in O
the O
presence O
of O
a O
nonuniform RARE
magnetic O
field O
. O

Microstructure RARE
and O
conductivity RARE
of O
hierarchical RARE
laminate RARE
composites RARE
. O

Anisotropic RARE
heat O
transport O
in O
the O
octylcyanobiphenyl RARE
( O
8CB NUMERIC
) O
liquid O
crystal O
. O

Direct O
approach O
to O
the O
study O
of O
soliton RARE
perturbations RARE
. O

Mutations O
affecting O
only O
CD4 I-GENE
regulation O
mapped O
to O
residues O
previously O
shown O
to O
mediate O
the O
binding O
of O
Nef I-GENE
to O
this O
receptor O
, O
such O
as O
W57 NUMERIC
and O
L58 NUMERIC
, O
as O
well O
as O
to O
an O
AP I-GENE
- I-GENE
recruiting RARE
dileucine RARE
motif I-GENE
and O
to O
an O
acidic O
dipeptide RARE
in O
the O
C O
- O
terminal O
region O
of O
the O
protein O
. O

Several O
mutations O
disrupted O
the O
endonuclease O
and O
helicase I-GENE
activities O
; O
however O
, O
only O
one O
amino I-GENE
- I-GENE
terminal I-GENE
- I-GENE
charge I-GENE
cluster I-GENE
mutant I-GENE
protein I-GENE
( O
D40A NUMERIC
- O
D42A NUMERIC
- O
D44A NUMERIC
) O
completely O
lost O
AAV O
hairpin O
DNA O
binding O
activity O
. O

The O
lytic O
cycle O
of O
KSHV O
, O
probably O
under O
the O
initial O
control O
of O
the O
KSHV I-GENE
/ I-GENE
Rta RARE
gene I-GENE
, O
may O
directly O
contribute O
to O
tumor O
pathogenesis O
. O

We O
conclude O
that O
( O
i O
) O
we O
have O
identified O
several O
candidate O
latency O
genes O
of O
murine O
gammaHV68 NUMERIC
, O
( O
ii O
) O
expression O
of O
genes O
during O
latency O
may O
be O
different O
in O
different O
organs O
, O
consistent O
with O
multiple O
latency O
programs O
and O
/ O
or O
multiple O
cellular O
sites O
of O
latency O
, O
and O
( O
iii O
) O
regions O
of O
the O
viral O
genome O
( O
v I-GENE
- I-GENE
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
, O
v I-GENE
- I-GENE
GCR ALLCAPS
gene I-GENE
, O
and O
gene I-GENE
73 I-GENE
) O
are O
transcribed O
during O
latency O
with O
both O
gammaHV68 NUMERIC
and O
primate O
gammaherpesviruses RARE
. O

These O
data O
indicate O
a O
functional O
role O
for O
U1 I-GENE
in O
NRS ALLCAPS
- O
mediated O
splicing O
inhibition O
. O

This O
suggests O
that O
the O
DcuS LASTCAP
- O
DcuR LASTCAP
system O
responds RARE
to O
external O
substrates O
. O

Here O
we O
describe O
the O
identification O
and O
characterization O
of O
several O
Sp100 NUMERIC
splice I-GENE
variant I-GENE
proteins I-GENE
and O
support O
their O
existence O
by O
elucidation RARE
of O
the O
3 O
'- O
end O
of O
the O
Sp100 NUMERIC
gene I-GENE
. O

Crossover RARE
in O
the O
specific O
heat O
of O
dilute RARE
magnets RARE
induced O
by O
critical O
spin O
- O
wave O
dynamics O
. O

Erratum RARE
: O
Absence RARE
of O
precursor O
effects O
above O
the O
martensitic RARE
transformation O
in O
a O
virgin RARE
crystal O
of O
Li O
metal O

Interplane RARE
coupling O
in O
the O
superconductor RARE
Y2Ba4Cu7O15 NUMERIC
as O
revealed O
by O
NQR ALLCAPS
spin O
- O
echo O
double O
resonance O
. O

Electronic RARE
structure O
of O
a O
buried RARE
NiSi2 NUMERIC
or O
CoSi2 NUMERIC
layer O
in O
bulk O
Si RARE
. O

Raman RARE
investigation O
of O
YBa2 NUMERIC
- O
xLaxCu3O7 NUMERIC
ceramics RARE
. O

Effects O
of O
point O
defects O
on O
lattice RARE
parameters O
of O
semiconductors RARE
. O

Chaotic RARE
electron O
dynamics O
around O
a O
single O
elliptically RARE
shaped O
antidot RARE
. O

However O
, O
deletions O
of O
the O
C O
terminal O
11 O
or O
14 O
amino O
acids O
had O
more O
substantial O
effects O
. O

Sixty RARE
months O
after O
the O
initial O
vaccination O
, O
all O
vaccinees RARE
who O
received O
annual O
follow O
- O
up O
still O
had O
protective O
levels O
of O
anti I-GENE
- I-GENE
HAV ALLCAPS
. O

However O
, O
after O
PRK O
at O
5 O
weeks O
of O
age O
, O
partial O
retreatment RARE
may O
be O
necessary O
due O
to O
regression O
of O
the O
PRK O
effect O
. O

Its O
early O
lesions O
were O
characterized O
by O
angiomatosis RARE
, O
vasculopathy RARE
, O
and O
proliferation O
of O
synoviocytes RARE
and O
fibroblasts O
. O

Molecular O
cloning O
of O
human O
cDNA O
encoding O
a O
novel O
beta1 I-GENE
, I-GENE
6 I-GENE
- I-GENE
N I-GENE
- I-GENE
acetylglucosaminyltransferase RARE
forming O
core O
2 O
and O
core O
4 O
. O

Interspecific RARE
mouse O
back O
- O
cross O
analysis O
identified O
the O
loci O
for O
mouse I-GENE
3Ost NUMERIC
genes I-GENE
and O
syntenic RARE
assignments RARE
of O
corresponding O
human O
isologs RARE
were O
confirmed O
by O
the O
identification O
of O
mapped O
sequence O
- O
tagged O
site O
markers O
. O

The O
Scales RARE
of O
Cognitive RARE
Impairment RARE
Rated RARE
From O
Institutional RARE
Records RARE
( O
SCIRFIR ALLCAPS
), O
a O
battery O
based O
on O
commonly O
used O
dementia O
rating O
instruments O
, O
was O
tested O
on O
the O
records O
of O
26 O
chronically RARE
institutionalized RARE
, O
elderly O
schizophrenia O
patients O
, O
for O
the O
purpose O
of O
retrospectively RARE
evaluating O
the O
long O
- O
term O
course O
of O
cognitive O
change O
in O
schizophrenia O
and O
relating RARE
it O
to O
available O
autopsy O
materials O
. O

It O
was O
demonstrated O
that O
the O
processing O
signals O
in O
the O
transcript O
, O
i O
. O
e O
. O
both O
donor O
splice O
sites O
and O
the O
polyadenylation O
site O
located O
in O
the O
muscle O
- O
specific O
intron O
, O
have O
to O
be O
weak O
. O

Most O
recently O
, O
the O
use O
of O
the O
product O
of O
brain O
weight O
and O
clearance O
has O
been O
proposed O
. O

Recombination RARE
and O
transcription O
of O
the O
endogenous I-GENE
Ig I-GENE
heavy I-GENE
chain I-GENE
locus I-GENE
is O
effected RARE
by O
the O
Ig I-GENE
heavy I-GENE
chain I-GENE
intronic I-GENE
enhancer I-GENE
core I-GENE
region I-GENE
in O
the O
absence O
of O
the O
matrix O
attachment O
regions O
. O

Two O
of O
these O
motifs O
are O
part O
of O
a O
highly O
conserved O
and O
inducible O
dyad RARE
symmetry RARE
element O
shown O
previously O
to O
control O
a O
remote RARE
IL I-GENE
- I-GENE
2 I-GENE
enhancer I-GENE
and O
the O
CD18 NUMERIC
promoter I-GENE
. O

In O
concert RARE
with O
the O
coactivator O
CREB I-GENE
binding I-GENE
protein I-GENE
/ O
p300 I-GENE
, O
which O
interacts O
with O
GABPalpha RARE
, O
the O
binding O
of O
GABPalpha RARE
and I-GENE
- I-GENE
beta I-GENE
to O
the O
dyad RARE
symmetry RARE
element O
controls O
the O
induction O
of O
IL I-GENE
- I-GENE
16 I-GENE
promoter I-GENE
in O
T O
cells O
. O

TPO ALLCAPS
by O
itself O
did O
not O
activate O
ERK1 I-GENE
, O
ERK2 I-GENE
and O
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
), O
whereas O
TPO ALLCAPS
directly O
enhanced O
the O
PKC I-GENE
- O
dependent O
activation O
of O
ERKs I-GENE
induced O
by O
other O
agonists O
including O
thrombin I-GENE
and O
phorbol O
esters O
, O
without O
affecting O
the O
PKC I-GENE
activation O
by O
those O
agonists O
. O

BACKGROUND O
: O
In O
the O
ubiquitin I-GENE
- O
dependent O
proteolysis O
pathway O
, O
a O
ubiquitin I-GENE
ligase I-GENE
( O
E3 I-GENE
) O
is O
responsible O
for O
substrate O
selectivity O
and O
timing O
of O
degradation O
. O

CONCLUSIONS O
: O
Fission RARE
yeast I-GENE
SCF ALLCAPS
is O
composed O
of O
Pop1 NUMERIC
and O
Pop2 NUMERIC
, O
two O
structurally O
related O
but O
functionally O
independent O
F I-GENE
- I-GENE
box I-GENE
/ I-GENE
WD I-GENE
- I-GENE
repeat I-GENE
proteins I-GENE
. O

19F NUMERIC
NMR O
studies O
in O
ABF4 NUMERIC
- O
type O
layered RARE
antiferromagnets RARE
. O

Optical RARE
- O
absorption O
spectra O
, O
crystal O
- O
field O
energy O
levels O
, O
and O
transition O
line O
strengths O
of O
holmium RARE
in O
trigonal RARE
Na3 NUMERIC

Observation RARE
of O
dipolar RARE
interactions O
between O
Pb0 NUMERIC
defects O
at O
the O
( O
111 O
) O
Si RARE
/ O
SiO2 NUMERIC
interface O
. O

Quantum RARE
- O
statistical O
theory O
of O
high O
- O
field O
transport O
phenomena O
. O

NH3 NUMERIC
and O
NO O
interaction O
with O
Si RARE
( O
100 O
)-( RARE
2 O
x O
1 O
) O
surfaces RARE
. O

Chirality RARE
- O
glass O
and O
spin O
- O
glass O
correlations O
in O
the O
two O
- O
dimensional O
random O
- O
bond O
XY ALLCAPS
model O
. O

Echo RARE
modulation O
in O
Pr3 NUMERIC
+: RARE
YAlO3 NUMERIC
. O

Mechanisms RARE
of O
visible RARE
- O
light O
emission O
from O
electro RARE
- O
oxidized RARE
porous RARE
silicon RARE
. O

Far RARE
- O
infrared RARE
hopping RARE
conductivity RARE
in O
the O
CuO LASTCAP
chains O
of O
a O
single O
- O
domain O
YBa2Cu3O7 NUMERIC
- O
delta O
crystal O
. O

Surface RARE
spin O
waves O
in O
a O
Heisenberg RARE
ferrimagnet RARE
with O
a O
single O
- O
ion O
anisotropy RARE
( O
uniaxial RARE
and O
nonuniaxial RARE
). O

Optically RARE
detected O
librons RARE
and O
phonons RARE
in O
crystalline O
C60 NUMERIC
. O

Multilayer RARE
- O
relaxation O
geometry RARE
and O
electronic RARE
structure O
of O
a O
W O
( O
111 O
) O
surface O
. O

Temperature RARE
dependence O
of O
the O
sublattice RARE
spontaneous O
magnetization RARE
of O
YBa2Cu3O6 NUMERIC
. O

GW ALLCAPS
Gamma RARE
approximation RARE
for O
electron O
self O
- O
energies RARE
in O
semiconductors RARE
and O
insulators RARE
. O

Precision RARE
measurement O
of O
the O
pion RARE
mass O
difference O
m O
pi O
-- O
m O
pi O
0 O
. O

Testing RARE
gravity RARE
to O
second O
post O
- O
Newtonian RARE
order O
: O
A O
field O
- O
theory O
approach O
. O

Genetic O
experiments O
using O
mutants O
defective O
in O
apontic RARE
and O
bruno RARE
reveal O
a O
functional O
interaction O
between O
these O
genes O
. O

In O
the O
current O
model O
, O
Wingless RARE
/ O
Wnt I-GENE
signal O
stabilizes O
Armadillo RARE
/ O
beta I-GENE
- I-GENE
catenin I-GENE
, O
which O
then O
accumulates O
in O
nuclei O
and O
binds O
TCF I-GENE
/ O
LEF ALLCAPS
family O
proteins O
, O
forming O
bipartite O
transcription O
factors O
which O
activate O
transcription O
of O
Wingless RARE
/ O
Wnt I-GENE
responsive O
genes O
. O

In O
support O
of O
clinical O
antianginal RARE
studies O
, O
the O
vasodilator O
nicorandil RARE
( O
NIC ALLCAPS
) O
was O
combined O
with O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
antagonists O
propranolol O
( O
PRO ALLCAPS
) O
and O
atenolol RARE
( O
ATN ALLCAPS
) O
and O
with O
the O
calcium O
channel O
blocker O
diltiazem O
( O
DTZ ALLCAPS
) O
to O
determine O
their O
cardiovascular O
and O
pharmacokinetic O
interactions O
. O

Factors O
influencing O
direct O
- O
immersion O
( O
DI ALLCAPS
)- O
SPME ALLCAPS
process O
were O
also O
checked RARE
and O
chosen O
experimentally O
. O

In O
contrast O
, O
an O
amino O
- O
terminal O
fragment O
containing O
the O
C O
/ O
H1 O
domain O
was O
sufficient O
for O
coactivation RARE
of O
Zta I-GENE
transcription O
and O
viral O
reactivation RARE
function O
. O

In O
addition O
, O
a O
potent O
splicing O
enhancer O
sequence O
isolated O
in O
the O
selection O
specifically O
binds O
a O
20 I-GENE
- I-GENE
kDa I-GENE
SR I-GENE
protein I-GENE
. O

Elimination O
of O
ETH1 NUMERIC
in O
apn1 NUMERIC
strains O
also O
increased O
spontaneous O
mutation O
rates O
9 O
- O
or O
31 O
- O
fold O
compared O
to O
the O
wild O
type O
as O
determined O
by O
reversion RARE
to O
adenine O
or O
lysine O
prototrophy RARE
, O
respectively O
. O

Elimination O
of O
ETH1 NUMERIC
in O
apn1 NUMERIC
strains O
also O
increased O
spontaneous O
mutation O
rates O
9 O
- O
or O
31 O
- O
fold O
compared O
to O
the O
wild O
type O
as O
determined O
by O
reversion RARE
to O
adenine O
or O
lysine O
prototrophy RARE
, O
respectively O
. O

These O
data O
suggest O
that O
other O
Ras I-GENE
effectors I-GENE
can O
collaborate RARE
with O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
with O
each O
other O
to O
activate O
Pak RARE
. O

Mammalian RARE
Ras I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
( O
GAP I-GENE
), O
p120 NUMERIC
Ras I-GENE
- O
GAP I-GENE
, O
has O
been O
implicated O
as O
both O
a O
downregulator RARE
and O
effector O
of O
Ras I-GENE
proteins I-GENE
, O
but O
its O
precise O
role O
in O
Ras I-GENE
- O
mediated O
signal O
transduction O
pathways O
is O
unclear O
. O

Three O
mog RARE
- I-GENE
1 I-GENE
alleles I-GENE
possess O
premature O
stop O
codons O
and O
are O
likely O
to O
be O
null O
alleles O
, O
and O
one O
is O
a O
missense O
mutation O
and O
is O
likely O
to O
retain RARE
residual O
activity O
. O
mog RARE
- I-GENE
1 I-GENE
mRNA I-GENE
is O
expressed O
in O
both O
germ O
line O
and O
somatic O
tissues O
and O
appears O
to O
be O
ubiquitous O
. O

However O
, O
unlike O
the O
SIN3 NUMERIC
gene I-GENE
of O
Saccharomyces O
cerevisiae O
, O
pst1 NUMERIC
(+) I-GENE
is O
essential O
for O
cell O
viability O
. O

The O
Nmd3 NUMERIC
protein I-GENE
sequence I-GENE
does O
not O
contain O
readily O
recognizable RARE
motifs O
of O
known O
function O
. O

The O
distribution O
of O
the O
various O
repeats O
suggests O
its O
organization O
is O
similar O
to O
the O
beta O
- O
heterochromatic RARE
regions O
near O
the O
base O
of O
the O
major O
chromosome O
arms RARE
. O

Calcitonin RARE
simultaneously O
regulates O
both O
periosteal RARE
hyperostosis RARE
and O
trabecular RARE
osteopenia RARE
in O
the O
spinal O
hyperostotic RARE
mouse O
( O
twy RARE
/ O
twy RARE
) O
in O
vivo O
. O

Electrophoretic O
mobility O
- O
shift O
assays O
performed O
with O
the O
HNF I-GENE
- I-GENE
3 I-GENE
X O
and O
Y O
sites O
demonstrated O
that O
both O
sites O
are O
capable O
of O
binding O
HNF I-GENE
- I-GENE
3alpha NUMERIC
and O
HNF I-GENE
- I-GENE
3beta NUMERIC
. O

In O
addition O
, O
we O
also O
show O
that O
cdk7 NUMERIC
may O
phosphorylate O
the O
carboxy O
- O
terminal O
domain O
( O
CTD O
) O
of O
RNA I-GENE
pol I-GENE
II I-GENE
in O
the O
absence O
of O
promoter O
opening RARE
. O

The O
therapy O
with O
a O
H2 I-GENE
- I-GENE
receptor I-GENE
antagonist O
is O
less O
effective O
than O
the O
triple O
therapies RARE
with O
omeprazole O
or O
lansoprazole RARE
. O

In O
humans O
, O
three O
tissue I-GENE
- I-GENE
specific I-GENE
plastin I-GENE
isoforms I-GENE
have O
been O
identified O
. O

No O
TATA O
or O
Inr RARE
sequence O
was O
found O
. O

The O
inhibition O
by O
the O
RIalpha RARE
subunit I-GENE
is O
reversed O
by O
addition O
of O
nanomolar RARE
concentrations O
of O
cAMP O
( O
Ka RARE
= O
40 O
nM O
), O
thus O
demonstrating O
that O
PrKX LASTCAP
is O
a O
novel O
, O
type I-GENE
I I-GENE
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
that O
is O
activated O
at O
lower O
cAMP O
concentrations O
than O
the O
holoenzyme O
with O
the O
Calpha RARE
subunit I-GENE
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

Proteins RARE
known O
to O
bind O
the O
PEPCK I-GENE
CRE O
include O
the O
CRE I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
and O
members O
of O
the O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
) O
family O
. O

This O
construct O
, O
termed O
pDeltaCREC LASTCAP
/ O
EBP I-GENE
, O
binds O
C I-GENE
/ I-GENE
EBPalpha RARE
and I-GENE
beta I-GENE
but O
not O
CREB I-GENE
, O
yet O
it O
confers O
a O
nearly O
complete O
glucocorticoid O
response O
when O
transiently O
transfected O
into O
H4IIE NUMERIC
rat O
hepatoma O
cells O
. O

In O
addition O
, O
in O
vitro O
mutagenesis O
of O
both O
Engrailed RARE
and O
Pbx1 NUMERIC
sites I-GENE
indicated O
that O
other O
unidentified O
sites O
are O
responsible O
for O
the O
transcriptional O
enhancement O
observed O
with O
the O
intronic O
fragment O
. O

Several O
secondary O
structure O
elements O
were O
identified O
. O

Here O
, O
we O
evidence O
that O
the O
developmental O
functions O
of O
the O
family O
of O
transcription O
factors O
characterized O
by O
the O
POU I-GENE
DNA I-GENE
binding I-GENE
motif I-GENE
exerts O
roles O
in O
mammalian O
development O
. O

High O
- O
affinity O
site O
- O
specific O
DNA O
binding O
by O
POU I-GENE
domain I-GENE
transcription I-GENE
factors I-GENE
requires O
both O
the O
POU I-GENE
- I-GENE
specific I-GENE
and O
the O
POU I-GENE
- I-GENE
homeodomain I-GENE
. O

In O
the O
Oct I-GENE
- I-GENE
1 I-GENE
crystal O
, O
the O
POU I-GENE
- I-GENE
specific I-GENE
domain I-GENE
recognizes O
a O
GCAT ALLCAPS
half O
- O
site O
, O
while O
the O
corresponding O
sequence O
recognized O
by O
the O
Pit I-GENE
- I-GENE
1 I-GENE
POU I-GENE
- O
specific O
domain O
, O
GTAT ALLCAPS
, O
is O
on O
the O
opposing RARE
strand O
. O

Systematic RARE
functional O
analysis O
of O
V1a NUMERIC
/ I-GENE
V2 I-GENE
hybrid I-GENE
receptors I-GENE
showed O
that O
the O
second O
intracellular O
loop O
of O
the O
V1a NUMERIC
receptor I-GENE
is O
required O
and O
sufficient O
for O
efficient O
coupling O
to O
Gq RARE
/ I-GENE
11 I-GENE
, O
whereas O
the O
third O
intracellular O
loop O
of O
the O
V2 I-GENE
receptor I-GENE
is O
required O
and O
sufficient O
for O
coupling O
to O
Gs I-GENE
. O

Most O
other O
end O
points O
were O
highly O
significant O
, O
and O
death O
, O
which O
was O
monitored O
across O
the O
U O
. O
S O
. O
program O
, O
was O
different O
with O
p O
< O
0 O
. O
0001 O
. O

The O
other O
is O
located O
at O
- O
1335 NUMERIC
, O
outside O
this O
highly O
conserved O
region O
. O

The O
fatigue RARE
exercise O
showed O
relatively O
high O
blood O
lactate O
concentration O
[ O
12 O
. O
5 O
( O
SD O
2 O
. O
6 O
) O
mmol O
x O
l O
(- O
1 O
)] O
and O
an O
increase O
of O
serum I-GENE
creatine I-GENE
kinase I-GENE
( O
CK I-GENE
) O
activity O
delayed O
by O
2 O
days O
[ O
540 NUMERIC
( O
SD O
407 NUMERIC
) O
U O
x O
l O
(- O
1 O
)]. O

Those RARE
radiological RARE
aspects O
were O
distributed O
in O
two O
categories O
: O
1 O
) O
type O
I O
- O
presenting O
variable O
sinusoidal RARE
filling O
. O

Results O
demonstrated O
that O
the O
presence O
of O
myofibroblasts RARE
varied O
considerably O
from O
case O
to O
case O
and O
was O
always O
related O
to O
smooth O
muscle O
cell O
dispersion O
, O
which O
occurred O
around O
medium O
- O
sized O
damaged O
portal O
vein O
branches RARE
. O

New O
Langevin RARE
equations RARE
for O
a O
translating RARE
and O
simultaneously O
rotating RARE
asymmetric O
top O
. O

Radiative RARE
corrections RARE
to O
beta O
decay O
and O
the O
possibility O
of O
a O
fourth O
generation O
. O

Depth RARE
- O
controlled O
grazing RARE
- O
incidence O
diffraction RARE
of O
synchrotron RARE
x O
radiation O
. O

Oscillatory RARE
exchange O
of O
atoms RARE
between O
traps RARE
containing O
Bose RARE
condensates RARE
. O

Structure O
determination O
of O
an O
adsorbate RARE
- O
induced O
multilayer RARE
reconstruction O
: O
( O
1 O
x O
2 O
)- O
H O
/ O
Ni RARE
( O
110 O
). O

Magnetic O
trapping RARE
of O
spin O
- O
polarized RARE
atomic RARE
hydrogen O
. O

Northern O
blot O
and O
in O
situ O
hybridization O
analyses O
revealed O
GPR34 NUMERIC
mRNA I-GENE
transcripts I-GENE
in O
several O
human O
and O
rat O
brain O
regions O
. O

The O
microphthalmia RARE
- I-GENE
TFE ALLCAPS
( O
MiT LASTCAP
) O
subfamily O
of O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
bHLH I-GENE
- I-GENE
ZIP ALLCAPS
) I-GENE
transcription I-GENE
factors I-GENE
, O
including O
TFE3 NUMERIC
, O
TFEB ALLCAPS
, O
TFEC ALLCAPS
, O
and O
Mitf RARE
, O
has O
been O
implicated O
in O
the O
regulation O
of O
tissue O
- O
specific O
gene O
expression O
in O
several O
cell O
lineages O
. O

Fifty O
- O
seven O
patients O
aged O
< O
55 O
years O
with O
acute O
lymphoblastic RARE
leukemia O
( O
ALL O
) O
in O
second O
or O
third O
bone O
marrow O
( O
BM ALLCAPS
) O
relapse O
or O
refractory O
to O
first O
- O
line O
therapy O
were O
enrolled O
in O
an O
Italian O
cooperative O
study O
. O

The O
dorsal O
nerves O
of O
the O
penis RARE
were O
anesthetized O
bilaterally RARE
with O
lidocaine O
. O

In O
the O
brain O
, O
muscarinic RARE
receptors I-GENE
mediate O
motor O
and O
memory O
function O
by O
interaction O
with O
their O
ligand O
acetylcholine O
. O

Early O
- O
onset O
scleral RARE
necrosis O
after O
iodine O
I O
125 O
plaque O
radiotherapy O
for O
ciliochoroidal RARE
melanoma O
. O

Successful RARE
interaction O
of O
ARF I-GENE
and O
PKC I-GENE
- I-GENE
alpha I-GENE
with O
PLD1 NUMERIC
was O
not O
achieved O
, O
but O
a O
C O
- O
terminal O
fragment O
of O
human I-GENE
PLD1 NUMERIC
( O
denoted RARE
" O
D4 NUMERIC
") RARE
interacted O
with O
the O
active O
mutant O
of O
RhoA I-GENE
, O
RhoAVal RARE
- I-GENE
14 I-GENE
. O

In O
this O
study O
, O
we O
investigated O
the O
signal O
transduction O
pathways O
that O
are O
involved O
in O
OM ALLCAPS
- O
induced O
LDLR ALLCAPS
transcription O
. O

Vacuum RARE
Rabi RARE
splitting RARE
as O
a O
feature O
of O
linear O
- O
dispersion O
theory O
: O
Analysis O
and O
experimental O
observations O
. O

High O
- O
pressure O
effects O
on O
ultrafast RARE
- O
relaxation O
kinetics O
of O
excitons RARE
in O
polydiacetylene RARE
4BCMU NUMERIC
. O

Drag RARE
reduction O
in O
turbulent RARE
flows RARE
by O
polymers O
. O

Large O
scale O
electronic RARE
structure O
calculations RARE
. O

Current O
world O
literature O
. O

These O
results O
show O
that O
Ski RARE
is O
a O
component O
of O
the O
HDAC ALLCAPS
complex I-GENE
and O
that O
Ski RARE
is O
required O
for O
the O
transcriptional O
repression O
mediated O
by O
this O
complex O
. O

Recombinant O
unr RARE
acts O
synergistically O
with O
recombinant O
PTB I-GENE
to O
stimulate O
translation O
dependent O
on O
the O
rhinovirus RARE
IRES ALLCAPS
. O

Analysis O
of O
the O
consensus O
binding O
sequence O
and O
the O
DNA O
- O
binding O
domain O
of O
ZF5 NUMERIC
. O

Mapping O
of O
the O
human I-GENE
Voltage RARE
- I-GENE
Dependent RARE
Anion RARE
Channel RARE
isoforms I-GENE
1 I-GENE
and I-GENE
2 I-GENE
reconsidered RARE
. O

Identification O
of O
RNase I-GENE
T I-GENE
as O
a O
high O
- O
copy O
suppressor O
of O
the O
UV O
sensitivity O
associated O
with O
single I-GENE
- I-GENE
strand I-GENE
DNA I-GENE
exonuclease I-GENE
deficiency O
in O
Escherichia O
coli O
. O

Inhibition O
of O
phosphatidylinositol I-GENE
- I-GENE
3 I-GENE
kinase I-GENE
did O
not O
have O
a O
significant O
effect O
on O
p53 I-GENE
conformation O
but O
did O
have O
a O
weak O
but O
significant O
effect O
on O
Tpo RARE
- O
enhanced O
viability O
. O

No O
difference O
in O
percentage O
of O
males O
in O
semen O
production O
was O
noted O
between O
strains O
, O
CP O
levels O
, O
or O
feeding O
regimens O
. O

The O
Lp RARE
mouse I-GENE
mutant I-GENE
provides O
a O
model O
for O
the O
severe O
human O
neural O
tube O
defect O
( O
NTD ALLCAPS
), O
cranio RARE
- O
rachischisis RARE
. O

Further O
analysis O
of O
AP I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
activities O
in O
7 O
- O
to O
14 O
- O
day O
culture O
activated O
HSCs RARE
led O
to O
the O
discovery O
of O
high I-GENE
mobility I-GENE
AP I-GENE
- I-GENE
1 I-GENE
complexes I-GENE
( O
HMAP ALLCAPS
- I-GENE
1 I-GENE
). O

Mutations O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
of O
the O
TIMP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
that O
prevented O
formation O
of O
HMAP ALLCAPS
- I-GENE
1 I-GENE
caused O
a O
70 O
% O
loss O
of O
activity O
in O
transfected O
activated O
HSCs RARE
. O

STUDY ALLCAPS
DESIGN O
: O
Salivary RARE
immunoglobulin I-GENE
A I-GENE
levels O
of O
each O
of O
20 O
subjects O
were O
determined O
on O
3 O
occasions RARE
: O
first O
, O
while O
the O
subject O
was O
still O
smoking O
; O
second O
, O
7 O
days O
after O
cessation O
of O
smoking O
; O
third O
, O
on O
the O
14th NUMERIC
day O
after O
cessation O
. O

Therefore O
, O
high O
set O
- O
up O
accuracy O
and O
reproducibility O
are O
mandatory RARE
. O

Role O
of O
g2 NUMERIC
in O
relating RARE
the O
Schwinger RARE
and O
Gerasimov RARE
- O
Drell RARE
- O
Hearn RARE
sum O
rules RARE
. O

Spectroscopy RARE
of O
negative O
ions O
utilizing O
multiphoton RARE
detachment RARE
in O
a O
Raman RARE
coupling O
regime RARE
. O

Band RARE
structure O
effects O
of O
transport O
properties O
in O
icosahedral RARE
quasicrystals RARE
. O

Acoustic RARE
transmission O
spectra O
in O
the O
Penrose RARE
lattice RARE
. O

Two O
- O
Channel RARE
Kondo RARE
Lattice RARE
: O
An O
Incoherent RARE
Metal RARE
. O

Basal O
midexpiratory RARE
lower O
esophageal O
sphincter RARE
pressure O
was O
similar O
in O
the O
study O
group O
( O
mean O
[ O
SD O
] O
20 O
. O
1 O
[ O
9 O
. O
1 O
] O
mmHg O
) O
and O
controls O
( O
17 O
. O
6 O
[ O
6 O
. O
0 O
] O
mmHg O
); O
the O
pressure O
did O
not O
change O
following O
EVS ALLCAPS
or O
EVL ALLCAPS
. O

CPDs RARE
at O
these O
three O
sites O
may O
partially O
displace RARE
TFIIIA ALLCAPS
, O
thereby O
enabling RARE
rapid O
repair O
. O

There O
was O
no O
difference O
in O
the O
hormone O
receptor O
status O
between O
the O
cases O
without O
lymph O
node O
metastases O
and O
with O
lymph O
node O
metastases O
, O
' O
clandestine RARE
' O
or O
macrometastases RARE
. O

On O
the O
other O
hand O
, O
subjects O
with O
air O
trapping RARE
( O
residual O
volume O
( O
RV O
)/ O
total O
lung O
capacity O
( O
TLC ALLCAPS
) O
> O
37 O
%) O
disclosed RARE
not O
only O
a O
higher O
n O
( O
mit RARE
) O
( O
0 O
. O
63 O
+/- O
0 O
. O
17 O
versus O
0 O
. O
43 O
+/- O
0 O
. O
07 O
mt RARE
x O
microm O
(- O
2 O
), O
p O
< O
0 O
. O
05 O
) O
but O
shorter O
sarcomeres RARE
( O
L O
( O
sar RARE
)) O
than O
subjects O
without O
this O
functional O
abnormality O
( O
2 O
. O
08 NUMERIC
+/- O
0 O
. O
16 O
to O
2 O
. O
27 O
+/- O
0 O
. O
15 O
microm O
, O
p O
< O
0 O
. O
05 O
). O

Gel O
filtration O
, O
sedimentation O
velocity O
, O
and O
immunoprecipitation O
experiments O
revealed O
that O
beta4 NUMERIC
is O
a O
component O
of O
a O
multisubunit O
complex O
( O
AP I-GENE
- I-GENE
4 I-GENE
) O
that O
also O
contains O
the O
sigma4 NUMERIC
polypeptide O
and O
two O
additional O
adaptor O
subunit O
homologs O
named O
mu4 NUMERIC
( O
mu O
- O
ARP2 NUMERIC
) O
and O
epsilon O
. O

Cyclin I-GENE
D1 I-GENE
- I-GENE
associated I-GENE
kinase I-GENE
activity O
and O
protein O
levels O
were O
increased O
in O
mammary O
tumors O
from O
murine O
mammary O
tumor O
virus O
- O
pp60 NUMERIC
( O
c I-GENE
- I-GENE
src527F NUMERIC
) O
transgenic O
mice O
. O

The O
SH2 I-GENE
domain I-GENE
- I-GENE
containing I-GENE
inositol I-GENE
5 I-GENE
'- I-GENE
phosphatase I-GENE
( O
SHIP ALLCAPS
) O
recruits RARE
the O
p85 I-GENE
subunit I-GENE
of O
phosphoinositide RARE
3 I-GENE
- I-GENE
kinase I-GENE
during O
FcgammaRIIb1 NUMERIC
- O
mediated O
inhibition O
of O
B I-GENE
cell I-GENE
receptor I-GENE
signaling O
. O

We O
show O
that O
the O
mouse O
genome O
contains O
four O
copies O
of O
the O
ubc RARE
- I-GENE
9 I-GENE
gene I-GENE
. O

An O
increase O
in O
bone O
mineral O
density O
at O
the O
spine O
, O
total O
hip O
, O
and O
total O
body O
has O
been O
reported O
with O
raloxifene RARE
but O
seems O
to O
be O
less O
than O
that O
seen O
with O
estrogen O
or O
alendronate RARE
therapy O
. O

However O
, O
in O
those O
studies O
due O
to O
the O
presence O
of O
thiol RARE
agents O
in O
the O
PKC I-GENE
preparations O
, O
the O
sensitive O
reaction O
of O
BPO ALLCAPS
with O
redox RARE
- O
active O
cysteine O
residues O
in O
PKC I-GENE
was O
not O
observed O
. O

Interestingly O
, O
Csx RARE
/ O
Nkx2 NUMERIC
. O

We O
also O
identified O
an O
alternative O
spliced O
form O
of O
Lyp RARE
RNA I-GENE
, O
Lyp2 NUMERIC
. O

The O
costs O
were O
DM O
11 O
, O
562 NUMERIC
for O
a O
PE O
, O
DM O
12 O
, O
477 NUMERIC
for O
a O
VR ALLCAPS
and O
DM O
7 O
, O
532 NUMERIC
for O
a O
MR O
. O

We O
now O
provide O
evidence O
for O
physical O
and O
functional O
interaction O
between O
Doa4 NUMERIC
and O
the O
proteasome O
. O

Independent RARE
splicing O
events O
involve O
three O
previously O
described O
cassette O
exons O
, O
which O
are O
predicted O
to O
encode O
most O
of O
the O
second O
transmembrane O
domain O
. O

Each O
of O
these O
genes O
contains O
a O
putative O
upstream O
ORF O
, O
while O
STA2 NUMERIC
has O
two O
additional O
in O
- O
frame O
AUG O
codons O
5 O
' O
to O
the O
major O
cistron RARE
. O

Nipponbare RARE
as O
well O
as O
O O
. O
australiensis RARE
. O

In O
addition O
, O
mapping O
of O
the O
promoter O
region O
and O
the O
identification O
of O
putative O
promoter O
regulatory O
sequences O
should O
give O
insight O
into O
the O
transcriptional O
regulation O
of O
UCP2 NUMERIC
expression O
-- O
in O
particular O
by O
anyone RARE
of O
the O
above O
mentioned O
factors O
-- O
in O
vitro O
and O
in O
vivo O
. O

The O
rate O
of O
resectability RARE
is O
low O
and O
5 O
- O
year O
survival O
is O
very O
poor O
. O

In O
order O
to O
better O
characterize O
the O
distribution O
of O
ML ALLCAPS
and O
MAP O
estimates O
under O
these O
conditions O
, O
we O
derive RARE
a O
point O
approximation RARE
to O
density O
values O
of O
the O
conditional O
distribution O
of O
such O
estimates O
. O

RT O
- O
PCR O
was O
performed O
using O
previously O
reported O
degenerate O
oligonucleotide O
primers O
to O
the O
ligand O
binding O
domain O
( O
LBD ALLCAPS
) O
of O
known O
beta I-GENE
integrin I-GENE
subunits I-GENE
and O
Bge RARE
cDNA I-GENE
. O

The O
lowest O
culture O
failure O
rate O
of O
0 O
. O
2 O
per O
cent O
was O
found O
after O
EAF ALLCAPS
compared O
with O
0 O
. O
9 O
per O
cent O
among O
CVS ALLCAPS
. O

Ectopic RARE
expression O
of O
d I-GENE
- I-GENE
axin RARE
inhibited O
Wingless RARE
signaling O
. O

The O
corresponding O
differences O
in O
FVIIa RARE
and O
PAI I-GENE
- I-GENE
1 I-GENE
were O
not O
statistically O
significant O
. O

Primary O
and O
secondary O
structural O
elements O
required O
for O
synthesis O
of O
barley O
yellow O
dwarf RARE
virus O
subgenomic RARE
RNA1 NUMERIC
. O

On O
the O
other O
side O
, O
when O
the O
aortic O
ring RARE
was O
perfused O
with O
L O
- O
NNA ALLCAPS
( O
NO O
- O
synthesis O
inhibitor O
) O
or O
methylene O
blue O
( O
soluble O
cGMPase RARE
inhibitor O
), O
the O
changes O
could O
be O
attenuated O
. O

Nevertheless O
, O
inactivation O
of O
the O
cyclin I-GENE
E I-GENE
- O
Cdk2 I-GENE
complex O
in O
response O
to O
mitogen O
starvation O
occurs O
normally O
in O
MEFs RARE
that O
have O
a O
homozygous O
deletion O
of O
the O
p27 I-GENE
gene I-GENE
. O

Identification O
and O
characterization O
of O
IS2404 NUMERIC
and O
IS2606 NUMERIC
: O
two O
distinct O
repeated O
sequences O
for O
detection O
of O
Mycobacterium O
ulcerans RARE
by O
PCR O
. O

Taken O
together O
, O
these O
results O
are O
consistent O
with O
the O
possibility O
that O
p202 NUMERIC
protein I-GENE
contributes O
to O
the O
cell O
growth O
retardation O
activity O
of O
the O
IFNs RARE
, O
at O
least O
in O
part O
, O
by O
modulating RARE
p21 I-GENE
protein I-GENE
levels O
. O

Similar O
results O
were O
also O
obtained O
with O
a O
HepG2 O
hepatoblastoma RARE
cell O
line O
carrying O
wt I-GENE
p53 I-GENE
. O

Partial O
sequencing O
of O
the O
region O
downstream O
of O
ORF I-GENE
- I-GENE
Pto RARE
revealed O
homology O
to O
the O
ru RARE
/ I-GENE
AB ALLCAPS
genes I-GENE
, O
involved O
in O
UV O
resistance O
, O
from O
plasmid O
pPSR1 NUMERIC
. O

The O
MSY2 NUMERIC
associated O
kinase O
is O
not O
casein I-GENE
kinase I-GENE
2 I-GENE
, O
the O
kinase O
believed O
to O
phosphorylate O
mRNP3 NUMERIC
+ I-GENE
4 I-GENE
in O
oocytes O
, O
but O
a O
yet O
unidentified O
kinase O
. O

This O
suggests O
that O
helicase I-GENE
- I-GENE
like I-GENE
genes I-GENE
may O
be O
involved O
in O
the O
biosynthesis O
of O
nucleic O
acids O
and O
proteins O
, O
and O
that O
the O
genes O
can O
be O
transcriptionally O
activated O
by O
heat O
shock O
to O
compensate RARE
for O
the O
repressed O
synthesis O
of O
mRNA O
and O
protein O
. O

These O
data O
provide O
the O
molecular O
tools O
for O
the O
final O
identification O
of O
the O
MKS ALLCAPS
and O
the O
MUL ALLCAPS
genes I-GENE
. O

The O
H O
- O
reflex O
recovery O
curve O
was O
obtained O
after O
stimulation O
of O
the O
median O
nerve O
at O
the O
elbow RARE
and O
recording O
from O
the O
flexor RARE
carpi RARE
radialis RARE
. O

The O
origins O
of O
reflected O
light O
changes O
associated O
with O
neuronal O
activity O
( O
optical O
signals O
) O
were O
investigated O
in O
rat O
somatosensory RARE
cortex O
with O
optical O
imaging O
, O
microspectrophotometry RARE
, O
and O
laser O
- O
Doppler O
flowmetry RARE
, O
and O
dynamic O
changes O
in O
local O
hemoglobin I-GENE
concentration O
and O
oxygenation O
were O
focused O
on O
. O

Human I-GENE
neuronal I-GENE
Elav RARE
- I-GENE
like I-GENE
proteins I-GENE
contain O
three O
RNP O
- O
type O
RNA O
recognition O
motifs O
( O
RRMs RARE
). O

Comparison O
of O
frequencies O
of O
atrial O
fibrillation O
after O
coronary O
artery O
bypass O
grafting RARE
with O
and O
without O
the O
use O
of O
cardiopulmonary O
bypass O
. O

The O
results O
of O
supershift O
analysis O
using O
specific O
antibodies O
against O
transcription O
factors O
suggested O
that O
both O
binding O
complexes O
contained O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
components O
p50 I-GENE
and O
p65 I-GENE
, O
and O
did O
not O
contain O
other O
NF I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
( O
p52 NUMERIC
, O
c I-GENE
- I-GENE
Rel I-GENE
, O
Rel I-GENE
B I-GENE
), O
AP I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
( O
c I-GENE
- I-GENE
Fos I-GENE
, O
C I-GENE
- I-GENE
Jun I-GENE
), O
CREB I-GENE
or O
C I-GENE
/ I-GENE
EBPbeta I-GENE
( O
NF I-GENE
- I-GENE
IL6 I-GENE
). O

A O
set O
of O
peptides O
corresponding O
to O
the O
individual O
elements O
of O
secondary O
structure O
derived O
from O
the O
N O
- O
terminal O
domain O
of O
the O
ribosomal I-GENE
protein I-GENE
L9 NUMERIC
have O
been O
synthesized O
. O

The O
results O
showed O
that O
IFN I-GENE
- I-GENE
gamma I-GENE
stimulated O
the O
rapid O
accumulation O
of O
interferon I-GENE
regulated I-GENE
factor I-GENE
( I-GENE
IRF I-GENE
)- I-GENE
1 I-GENE
mRNA I-GENE
, O
followed O
by O
a O
delayed O
and O
dose O
- O
dependent O
inhibition O
of O
alpha1 I-GENE
( I-GENE
I I-GENE
) I-GENE
procollagen RARE
mRNA I-GENE
expression O
in O
skin O
fibroblasts O
from O
several O
different O
donors O
. O

Functional O
domains O
of O
c I-GENE
- I-GENE
myc I-GENE
promoter I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
involved O
in O
transcriptional O
repression O
and O
cell O
growth O
regulation O
. O

Therefore O
, O
we O
have O
named O
this O
gene O
UBP43 NUMERIC
. O

These O
results O
continue RARE
to O
support O
the O
hypothesis O
that O
HS2 NUMERIC
, O
HS3 NUMERIC
, O
and O
HS4 NUMERIC
act O
as O
a O
single O
, O
integral O
unit O
to O
regulate O
human I-GENE
globin I-GENE
gene I-GENE
transcription O
as O
a O
holocomplex RARE
, O
but O
they O
can O
also O
be O
interpreted O
to O
say RARE
that O
formation O
of O
a O
DNase I-GENE
I I-GENE
hypersensitive O
holocomplex RARE
alone O
is O
not O
sufficient O
for O
mediating O
high O
- O
level O
globin I-GENE
gene I-GENE
transcription O
. O

To O
identify O
additional O
non O
- O
Sir RARE
factors I-GENE
that O
affect O
rDNA O
silencing O
, O
we O
performed O
a O
genetic O
screen O
designed O
to O
isolate O
mutations O
which O
alter O
the O
expression O
of O
reporter O
genes O
integrated O
within O
the O
rDNA O
. O

Because O
there O
is O
great O
need O
for O
iron O
in O
the O
EPO I-GENE
- O
stimulated O
erythroid O
progenitors RARE
, O
it O
is O
essential O
that O
serum I-GENE
ferritin I-GENE
and O
transferrin I-GENE
saturation O
levels O
should O
be O
maintained O
over O
300 O
microg O
/ O
liter O
and O
30 O
%, O
respectively O
. O

These O
results O
indicate O
that O
the O
p33 NUMERIC
subunit I-GENE
of O
eIF3 I-GENE
plays O
an O
important O
role O
in O
the O
initiation O
phase O
of O
protein O
synthesis O
and O
that O
its O
RNA O
- O
binding O
domain O
is O
required O
for O
optimal O
activity O
. O

In O
this O
study O
, O
we O
elucidate O
signaling O
pathways O
induced O
by O
photodynamic RARE
therapy O
( O
PDT ALLCAPS
) O
with O
hypericin RARE
. O

These O
results O
indicate O
that O
ATF I-GENE
- I-GENE
2 I-GENE
plays O
a O
central O
role O
in O
TGF I-GENE
- I-GENE
beta I-GENE
signaling O
by O
acting O
as O
a O
common O
nuclear O
target O
of O
both O
Smad I-GENE
and O
TAK1 NUMERIC
pathways O
. O

KEY ALLCAPS
WORDS O
: O
Melaleuca RARE
; O
Lake RARE
Okeechobee RARE
; O
Littoral RARE
zone O
; O
Water RARE
level O
; O
Regulation O
schedule O

The O
systolic O
peak O
of O
pulmonary O
vein O
was O
higher O
than O
the O
diastolic O
peak O
in O
45 O
out O
of O
56 O
cases O
. O

Specimens RARE
were O
assayed O
for O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
, O
unconjugated RARE
estriol RARE
, O
free O
alpha I-GENE
hCG I-GENE
, O
and O
total O
hCG I-GENE
. O

FASEB ALLCAPS
Federal RARE
Funding RARE
Consensus RARE
Conference RARE
FY ALLCAPS
2000 O
. O

The O
following O
data O
were O
recorded O
at O
arrival RARE
in O
the O
intensive O
care O
unit O
6 O
, O
12 O
, O
24 O
, O
and O
48 O
hours O
after O
termination O
of O
CPB O
: O
heart O
rate O
, O
blood O
pressure O
, O
left O
atrial O
pressure O
, O
central O
- O
peripheral O
temperature O
difference O
, O
arterial O
- O
central O
venous O
oxygen O
saturation O
difference O
, O
urine O
output O
, O
serum O
creatinine O
, O
lactate O
and O
neutrophil I-GENE
elastase I-GENE
levels O
, O
the O
Doppler O
echocardiographic O
factors O
shortening O
fraction O
and O
preejection RARE
period O
/ O
left O
- O
ventricular O
ejection O
time O
, O
and O
cumulative O
doses O
of O
catecholamines O
( O
epinephrine O
), O
enoximone RARE
, O
and O
furosemide O
. O

MDS1 NUMERIC
/ O
EVI1 NUMERIC
, O
located O
on O
chromosome O
3 O
band O
q26 NUMERIC
, O
encodes O
a O
zinc I-GENE
- I-GENE
finger I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
transcription I-GENE
activator I-GENE
not O
detected O
in O
normal O
hematopoietic O
cells O
but O
expressed O
in O
several O
normal O
tissues O
. O

Analysis O
of O
the O
protein O
sequences O
of O
these O
two O
replicases RARE
, O
together O
with O
previously O
characterized O
H I-GENE
. I-GENE
pylori I-GENE
plasmid I-GENE
replication I-GENE
proteins I-GENE
, O
supports O
the O
formation O
of O
a O
distinct O
class O
of O
H I-GENE
. I-GENE
pylori I-GENE
plasmid I-GENE
proteins I-GENE
. O

The O
JTc RARE
delta O
among O
the O
three O
groups O
did O
not O
differ O
as O
well O
: O
JTc RARE
delta O
of O
the O
VT O
group O
was O
70 O
ms O
+/- O
30 O
ms O
, O
the O
JTc RARE
delta O
of O
the O
PVC ALLCAPS
group O
was O
60 O
msec O
+/- O
25 O
msec O
, O
and O
the O
JTc RARE
delta O
of O
the O
control O
group O
was O
70 O
ms O
+/- O
30 O
ms O
. O

In O
contrast O
, O
deletion O
of O
the O
upstream O
portion O
of O
the O
delta O
promoter O
led O
to O
a O
10 O
fold O
decrease O
in O
expression O
. O

Site O
- O
directed O
mutagenesis O
of O
binding O
sites O
for O
the O
repressor I-GENE
proteins I-GENE
BP1 NUMERIC
and O
BP2 NUMERIC
in O
the O
upstream O
portion O
of O
the O
beta I-GENE
globin I-GENE
gene I-GENE
flanking I-GENE
region I-GENE
led O
to O
a O
4 O
- O
6 O
fold O
increase O
in O
promoter O
activity O
. O

However O
, O
with O
the O
alpha1 O
antagonist O
prazosin RARE
( O
5 O
x O
10 O
(- O
8 O
)- O
5 O
x O
10 O
(- O
7 O
) O
M O
), O
no O
relaxation O
occurred O
. O

Differential O
expression O
of O
AP I-GENE
- I-GENE
2alpha I-GENE
and O
AP I-GENE
- I-GENE
2beta NUMERIC
in O
the O
developing O
chick O
retina O
: O
repression O
of O
R I-GENE
- I-GENE
FABP ALLCAPS
promoter I-GENE
activity O
by O
AP I-GENE
- I-GENE
2 I-GENE
. O

The O
algorithm O
also O
limited O
TG O
to O
20 O
and O
64 O
%, O
apoB LASTCAP
to O
6 O
and O
20 O
%, O
and O
Lp RARE
( I-GENE
a I-GENE
) I-GENE
to O
15 O
and O
56 O
%, O
of O
low O
- O
and O
high O
- O
risk O
groups O
, O
respectively O
. O

The O
mean O
value O
of O
the O
CD79b NUMERIC
to O
the O
CD79b NUMERIC
internally RARE
deleted O
ratio O
was O
0 O
. O
64 O
+/- O
0 O
. O
20 O
SD O
in O
normal O
donors O
and O
0 O
. O
44 O
+/- O
0 O
. O
27 O
SD O
in O
B O
- O
CLL ALLCAPS
( O
P O
=. O
01 O
). O

As O
normal O
B O
cells O
also O
present O
this O
variant O
, O
the O
mechanism O
of O
CD79b NUMERIC
posttranscriptional O
regulation O
might O
reflect O
the O
activation O
stage O
of O
the O
normal O
B O
cell O
from O
which O
B O
- O
CLL ALLCAPS
derives RARE
. O

Conformational RARE
studies O
combining RARE
secondary O
structure O
predictions O
, O
CD O
and O
NMR O
spectroscopy O
together O
with O
ELISA O
assays O
, O
showed O
that O
the O
greater O
is O
the O
propensity O
of O
the O
epitope O
for O
helix O
formation O
the O
higher O
is O
the O
recognition O
by O
anti I-GENE
- I-GENE
K159 NUMERIC
. O

Schwab RARE
and O
England RARE
ADL ALLCAPS
scores O
in O
the O
" O
off O
" O
state O
were O
improved O
by O
18 O
% O
and O
in O
the O
" O
on O
" O
state O
the O
scores O
declined O
by O
2 O
%. O

High O
- O
level O
gains RARE
( O
HLGs RARE
) O
indicative O
of O
gene O
amplifications RARE
were O
identified O
at O
11q13 NUMERIC
in O
two O
cases O
, O
and O
in O
one O
case O
each O
at O
2q33 NUMERIC
- O
34 O
, O
3q25 NUMERIC
- O
29 O
, O
5p15 NUMERIC
. O
1 O
- O
15 O
. O
2 O
, O
7q21 NUMERIC
- O
22 O
, O
11p11 NUMERIC
. O
2 O
, O
12p11 NUMERIC
. O
2 O
- O
12 O
, O
and O
13q34 NUMERIC
. O

With O
respect O
to O
the O
distribution O
of O
active O
MREs RARE
over O
the O
promoter O
region O
, O
the O
hMT LASTCAP
- I-GENE
IIA I-GENE
gene I-GENE
is O
largely O
different O
from O
the O
mouse O
metallothionein RARE
- I-GENE
I I-GENE
gene I-GENE
, O
suggesting O
that O
MRE ALLCAPS
arrangement O
is O
not O
an O
important O
factor O
for O
metal O
regulation O
. O

The O
cDNA O
was O
expressed O
in O
Saccharomyces O
cerevisiae O
under O
the O
control O
of O
the O
yeast I-GENE
triose RARE
phosphate I-GENE
isomerase I-GENE
promoter I-GENE
. O

Interestingly O
, O
the O
RNA O
sequences O
selected O
by O
the O
mutated O
zinc I-GENE
knuckle RARE
9G8 NUMERIC
variant I-GENE
are O
efficiently O
recognized O
by O
SRp20 NUMERIC
, O
in O
agreement O
with O
the O
fact O
that O
the O
RBD ALLCAPS
of O
9G8 NUMERIC
and O
SRp20 NUMERIC
are O
similar O
. O

Topoisomerase RARE
II I-GENE
is O
a O
major O
target O
of O
the O
protein I-GENE
kinase I-GENE
casein I-GENE
kinase I-GENE
2 I-GENE
( O
PK I-GENE
CK2 NUMERIC
) O
in O
vivo O
. O

Recent O
work O
in O
this O
laboratory O
has O
shown O
that O
the O
gene O
coding O
for O
acetate I-GENE
kinase I-GENE
( O
ackA LASTCAP
) O
in O
Sinorhizobium RARE
meliloti RARE
is O
up O
- O
regulated O
in O
response O
to O
phosphate O
limitation O
. O

All O
numbers O
refer RARE
to O
nucleotide O
positions O
on O
the O
wild O
- O
type O
HIV O
- O
1 O
transcript O
. O

Sequence O
analysis O
revealed O
that O
the O
MEMA ALLCAPS
protein I-GENE
is O
identical O
with O
a O
160 I-GENE
kDa I-GENE
nuclear I-GENE
' I-GENE
domain I-GENE
rich I-GENE
in I-GENE
serines RARE
' I-GENE
( I-GENE
DRS ALLCAPS
) I-GENE
protein I-GENE
occurring O
free O
in O
the O
nucleoplasm RARE
and O
in O
U2 I-GENE
- I-GENE
ribonucleoprotein I-GENE
structures I-GENE
. O

Here O
, O
we O
report O
the O
complete O
structure O
of O
the O
human I-GENE
topoisomerase I-GENE
IIalpha RARE
gene I-GENE
, O
which O
consists O
of O
35 O
exons O
spanning O
27 O
. O
5 O
kb O
. O

Dopaminergic RARE
modulation O
of O
transcallosal RARE
activity O
of O
cat O
motor O
cortical O
neurons O
. O

Previous O
studies O
characterized O
a O
cytokine O
- O
inducible O
, O
functional O
nuclear I-GENE
factor I-GENE
( I-GENE
NF I-GENE
)- I-GENE
kappaB I-GENE
consensus I-GENE
element I-GENE
in O
the O
immediate O
5 O
' O
regulatory O
region O
of O
the O
MGSA ALLCAPS
/ O
GRO ALLCAPS
- I-GENE
alpha I-GENE
gene O
at O
- O
78 O
bp O
. O

An O
exon O
that O
prevents O
transport O
of O
a O
mature O
mRNA O
. O

Four O
CsA O
- O
treated O
patients O
developed O
persistently RARE
elevated O
UAER ALLCAPS
> O
30 O
mg O
/ O
24 O
h O
( O
n O
= O
3 O
with O
microalbuminuria RARE
), O
whereas O
all O
the O
17 O
placebo O
- O
treated O
patients O
had O
normal O
UAER ALLCAPS
(< O
30 O
mg O
/ O
24 O
h O
) O
after O
7 O
years O
of O
follow O
- O
up O
. O

Mutational O
analysis O
of O
the O
- O
84 O
/- O
55 O
DNA O
showed O
that O
JEG ALLCAPS
- O
3 O
nuclear O
proteins O
bound O
to O
a O
site O
containing O
, O
but O
not O
identical O
to O
, O
the O
SF I-GENE
- I-GENE
1 I-GENE
sequence I-GENE
. O

In O
contrast O
, O
no O
change O
was O
detected O
in O
the O
phenotype O
of O
' O
unstressed RARE
' O
clones O
, O
with O
respect O
to O
any O
of O
the O
following O
parameters O
: O
proliferation O
rate O
in O
monolayer RARE
, O
serum O
- O
dependence O
for O
proliferation O
or O
survival O
, O
tumorigenicity RARE
, O
cellular O
morphology O
, O
or O
tissue O
- O
specific O
differentiation O
markers O
. O

A O
high O
reactor RARE
pH O
(+/- O
8 O
), O
a O
short O
solid O
retention O
time O
(< O
150 O
days O
), O
and O
the O
presence O
of O
a O
substantial O
SRB ALLCAPS
population O
in O
the O
inoculum RARE
may O
considerably O
reduce O
the O
time O
required O
for O
acetate O
- O
utilising RARE
SRB ALLCAPS
to O
outcompete RARE
MB O
. O

In O
throttling RARE
valves RARE
, O
the O
aim O
is O
to O
correlate O
the O
effect O
of O
shear O
to O
a O
parameter O
related O
to O
the O
inner O
geometry RARE
of O
the O
valve O
and O
to O
operating O
conditions O
. O

The O
induced O
respiratory O
burst O
was O
investigated O
by O
the O
intracellular O
oxidative O
transformation O
of O
dihydrorhodamine RARE
123 O
to O
the O
fluorescent O
dye O
rhodamine RARE
123 O
via O
flow O
cytometry RARE
. O

A O
mutation O
linked O
to O
the O
SOC1 NUMERIC
gene I-GENE
, O
previously O
defined O
by O
recessive O
mutations O
that O
suppress O
cbp1 NUMERIC
ts I-GENE
alleles I-GENE
and O
stabilize RARE
many O
mitochondrial O
mRNAs O
, O
was O
also O
isolated O
. O

A O
deletion O
mutation O
analysis O
of O
the O
recombinant O
protein O
has O
shown O
that O
the O
N O
- O
terminal O
region O
and O
the O
two O
leucine O
zippers O
are O
necessary O
for O
the O
binding O
. O

A O
database O
search O
has O
revealed O
as O
the O
most O
significative RARE
homology O
a O
match O
with O
the O
human I-GENE
mitochondrial I-GENE
transcription I-GENE
termination I-GENE
factor I-GENE
( O
mTERF LASTCAP
), O
a O
protein O
that O
also O
binds O
DNA O
as O
a O
monomer RARE
and O
contains O
three O
leucine O
zippers O
forming O
intramolecular RARE
interactions O
. O

In O
all O
trials O
, O
antigen O
challenge O
followed O
1 O
h O
after O
the O
last O
treatment O
. O

31 O
, O
1997 O
, O
40 O
patients O
had O
died O
( O
35 O
in O
the O
ERA ALLCAPS
- O
II O
group O
and O
5 O
in O
the O
ERA ALLCAPS
- O
III O
group O
), O
for O
a O
crude O
mortality O
rate O
of O
8 O
. O
0 O
%. O

We O
found O
that O
total O
PSA I-GENE
can O
be O
detected O
in O
all O
cyst O
fluids O
and O
in O
about O
75 O
% O
of O
female O
sera O
. O

Type O
I O
cysts O
( O
with O
a O
high O
K O
+/ O
Na O
+ O
ratio O
) O
tend RARE
to O
have O
higher O
total O
PSA I-GENE
than O
Type O
II O
cysts O
. O

Despite O
this O
DNA O
binding O
activity O
, O
AP I-GENE
- I-GENE
1 I-GENE
reporter I-GENE
activity O
was O
suppressed O
in O
these O
cells O
. O

A O
single O
N O
- O
glycosylation O
site O
present O
in O
chicken I-GENE
gp42 NUMERIC
is O
conserved O
among O
all O
five O
of O
these O
proteins O
: O
carbohydrate O
analysis O
of O
gp42 NUMERIC
revealed O
the O
presence O
of O
a O
complex O
type O
glycan RARE
chain O
at O
this O
site O
. O

Here O
we O
describe O
the O
optimization RARE
and O
characterization O
of O
a O
140 O
- O
residue O
fragment O
, O
containing O
the O
Runt RARE
domain I-GENE
of O
AML1 NUMERIC
, O
which O
is O
suitable O
for O
structural O
studies O
. O

Judge RARE
OKs RARE
docs RARE
' O
bid RARE
for O
Chicago RARE
hospital O
. O

HANYS ALLCAPS
criticizes RARE
laparoscopic O
gall RARE
bladder O
guidelines O
. O

Groups RARE
dicker RARE
for O
price RARE
breaks RARE
as O
anesthetic RARE
gas O
goes RARE
multi O
- O
source O
. O

Troubled RARE
CareNetwork RARE
gets RARE
pact RARE
from O
largest O
teacher RARE
union RARE
in O
Wis RARE
. O

JCAHO ALLCAPS
asks RARE
for O
hospitals O
' O
patience RARE
. O

Ultrasonography RARE
provides O
excellent O
intraoperative RARE
evaluation O
of O
spinal O
cord O
injury O
. O

UPMC ALLCAPS
is O
not O
the O
only O
organization O
pursuing RARE
controlled O
NHBC ALLCAPS
organ O
procurement RARE
, O
however O
. O

Because O
of O
concerns RARE
regarding O
blood O
transfusion O
- O
related O
communicable RARE
disease O
( O
eg RARE
, O
acquired O
immune O
deficiency O
syndrome O
and O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
), O
there O
has O
been O
increasing O
research O
effort O
into O
postoperative O
hemorrhage O
related O
to O
cardiopulmonary O
bypass O
with O
extracorporeal RARE
circulation O
. O

They O
contrast O
trends RARE
in O
fertility O
, O
life O
expectancy RARE
ratios O
, O
and O
gender O
differences O
in O
these O
countries RARE
with O
the O
Hispanic RARE
population O
of O
the O
United O
States RARE
. O

Holger RARE
v O
. O

Hospital RARE
hit RARE
for O
hiring RARE
AHERF ALLCAPS
physicians O
. O

Overexpression O
of O
either O
DAP ALLCAPS
- I-GENE
1 I-GENE
or O
sentrin RARE
causes O
apoptosis O
of O
TNF I-GENE
- O
sensitive O
L929 NUMERIC
fibroblast O
cell O
line O
, O
as O
well O
as O
TNF I-GENE
- O
resistant O
osteosarcoma O
cell O
line O
, O
U2OS NUMERIC
. O

This O
is O
in O
contrast O
to O
PPARgamma2 NUMERIC
, O
which O
was O
previously O
shown O
to O
be O
phosphorylated O
at O
a O
single O
site O
in O
a O
motif O
that O
is O
not O
homologous O
to O
the O
sites O
now O
described O
in O
PPARalpha I-GENE
. O

These O
results O
suggest O
KCC3 NUMERIC
is O
a O
new O
member O
of O
the O
KCC ALLCAPS
family I-GENE
that O
is O
under O
distinct O
regulation O
from O
KCC1 NUMERIC
. O

We O
have O
screened O
the O
elastin I-GENE
gene I-GENE
for O
mutations O
responsible O
for O
supravalvular RARE
aortic O
stenosis O
( O
SVAS ALLCAPS
) O
in O
two O
large O
, O
independently O
collected O
families O
with O
isolated O
( O
nonsyndromic RARE
) O
SVAS ALLCAPS
. O

Spatiotemporal RARE
expression O
of O
the O
PAX3 NUMERIC
gene I-GENE
is O
tightly O
regulated O
during O
development O
. O

25 O
- O
OH O
- O
D3 O
did O
not O
adversely RARE
affect O
animal O
health O
at O
the O
proposed O
use O
level O
of O
99 O
micrograms O
/ O
kg O
feed O
when O
replacing O
vitamin O
D3 O
in O
turkey RARE
rations RARE
. O

A O
list RARE
of O
12 O
names RARE
for O
the O
disease O
and O
37 O
diagnostic O
criteria O
were O
proposed O
to O
a O
Consensus RARE
Panel RARE
of O
12 O
Italian O
experts RARE
who O
ranked RARE
them O
in O
order O
so O
as O
to O
identify O
a O
core O
set O
of O
criteria O
. O

Methanesulfonyl RARE
fluoride O
( O
MSF ALLCAPS
): O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
of O
safety O
and O
efficacy O
in O
the O
treatment O
of O
senile O
dementia O
of O
the O
Alzheimer O
type O
. O

METHODS O
: O
Between RARE
August O
1991 O
and O
June RARE
1994 O
, O
198 O
men O
with O
clinical O
T2 O
or O
T3 O
classified O
( O
TNM ALLCAPS
) O
prostate O
carcinoma O
( O
bone O
scan O
negative O
) O
who O
were O
at O
high O
risk O
of O
lymph O
node O
involvement O
underwent O
a O
111In NUMERIC
- O
capromab RARE
pendetide RARE
scan O
prior O
to O
staging RARE
lymphadenectomy RARE
. O

Voluntary RARE
wheel RARE
running RARE
did O
not O
significantly O
increase O
estimated O
alanine O
or O
pyruvate RARE
Gneo RARE
or O
absolute O
glycerol RARE
Ra RARE
. O

Immediately RARE
after O
surgery O
, O
dialysate RARE
PGE2 O
and O
adenosine O
concentrations O
were O
3 O
. O
7 O
+/- O
0 O
. O
7 O
and O
296 O
+/- O
127 NUMERIC
nM O
, O
respectively O
. O

Because O
of O
the O
probable O
causal RARE
relationship O
between O
constitutive O
p210 NUMERIC
( O
bcr RARE
/ O
abl I-GENE
) O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
and O
manifestations O
of O
chronic O
- O
phase O
chronic O
myelogenous RARE
leukemia O
( O
CML O
; O
myeloid O
expansion O
), O
a O
key O
goal O
is O
to O
identify O
relevant O
p210 NUMERIC
substrates O
in O
primary O
chronic O
- O
phase O
CML O
hematopoietic O
progenitor O
cells O
. O

In O
vitro O
precipitation O
with O
a O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
- I-GENE
fusion I-GENE
protein I-GENE
containing O
the O
C O
- O
terminal O
transactivation O
domain O
of O
STAT5a NUMERIC
showed O
GH I-GENE
- O
regulated O
association O
of O
ERK1 I-GENE
/ I-GENE
2 I-GENE
with O
the O
fusion O
protein O
, O
while O
this O
was O
not O
seen O
when O
serine O
780 NUMERIC
in O
STAT5a NUMERIC
was O
changed O
to O
alanine O
. O

One O
such O
element O
, O
1P NUMERIC
, O
was O
employed O
to O
clone O
from O
a O
rat O
pituitary O
cDNA O
expression O
library O
a O
novel O
417 NUMERIC
- I-GENE
amino I-GENE
acid I-GENE
WD I-GENE
protein I-GENE
, O
designated O
PREB ALLCAPS
( I-GENE
PRL I-GENE
regulatory I-GENE
element I-GENE
binding I-GENE
) I-GENE
protein I-GENE
. O

Characterization O
of O
the O
transcription I-GENE
factor I-GENE
MTF ALLCAPS
- I-GENE
1 I-GENE
from O
the O
Japanese O
pufferfish RARE
( O
Fugu RARE
rubripes RARE
) O
reveals O
evolutionary O
conservation O
of O
heavy O
metal O
stress O
response O
. O

The O
peroxisome I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
PPARs RARE
) O
are O
members O
of O
the O
nuclear I-GENE
hormone I-GENE
receptor I-GENE
superfamily I-GENE
. O

However O
, O
F I-GENE
- I-GENE
SRC I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
lacking O
CBP I-GENE
- I-GENE
interacting I-GENE
domain I-GENE
still O
preserved RARE
enhancing O
activity O
. O

The O
catalytic O
site O
has O
an O
S1 O
pocket O
lined RARE
with O
conserved O
hydrophobic O
residues O
to O
accommodate RARE
the O
pyroglutamyl RARE
residue O
. O

The O
complete O
circular O
TTV ALLCAPS
genome O
contained O
a O
novel O
sequence O
of O
113 O
nt O
( O
nt O
3740 NUMERIC
to O
3852 NUMERIC
[= RARE
0 O
]) O
in O
between O
the O
known O
3 O
'- O
and O
5 O
'- O
end O
arms RARE
, O
forming O
a O
117 O
- O
nt O
GC O
- O
rich O
stretch O
( O
GC O
content O
, O
90 O
. O
6 O
% O
at O
nt O
3736 NUMERIC
to O
3852 NUMERIC
). O

The O
Asian RARE
mouse O
Mus RARE
castaneus RARE
is O
resistant O
to O
infection O
by O
the O
polytropic RARE
mink RARE
cell O
focus O
- O
inducing O
( O
MCF ALLCAPS
) O
subgroup O
of O
murine O
leukemia O
viruses O
( O
MuLVs RARE
). O

To O
determine O
the O
function O
of O
VZV I-GENE
gK LASTCAP
in O
virus O
growth O
, O
a O
series O
of O
gK LASTCAP
deletion I-GENE
mutants I-GENE
were O
constructed O
with O
VZV O
cosmid O
DNA O
derived O
from O
the O
Oka RARE
strain O
. O

CCAAT I-GENE
displacement I-GENE
protein I-GENE
binds O
to O
and O
negatively O
regulates O
human O
papillomavirus O
type O
6 O
E6 I-GENE
, O
E7 I-GENE
, O
and O
E1 I-GENE
promoters O
. O

As O
such O
the O
findings O
support O
existing O
studies O
that O
have O
identified O
given O
social O
characteristics O
of O
drink RARE
drivers RARE
. O

Three O
different O
site O
- O
directed O
mutations O
of O
the O
cyclic O
AMP O
response O
element O
each O
reduced O
the O
nerve I-GENE
growth I-GENE
factor I-GENE
effect O
by O
> O
90 O
%. O

Using O
an O
RNase I-GENE
H I-GENE
protection O
assay O
and O
specific O
blocking O
oligonucleotides O
, O
we O
find O
that O
recognition O
of O
the O
5 O
' O
splice O
- O
site O
( O
5 O
' O
ss RARE
) O
and O
branchpoint O
sequence O
( O
BPS ALLCAPS
) O
elements O
by O
U11 NUMERIC
and O
U12 NUMERIC
snRNPs I-GENE
, O
respectively O
, O
displays O
strong O
cooperativity O
, O
requiring O
both O
sites O
in O
the O
pre O
- O
mRNA O
substrate O
for O
efficient O
complex O
formation O
. O

Analysis O
of O
lacZ I-GENE
transcriptional I-GENE
fusions I-GENE
shows O
that O
the O
KdgR LASTCAP
- I-GENE
binding I-GENE
sites I-GENE
negatively O
affect O
the O
expression O
of O
rsmB LASTCAP
. O

Many O
eukaryotic O
cell O
surface O
proteins O
are O
anchored O
in O
the O
lipid O
bilayer RARE
through O
glycosylphosphatidylinositol RARE
( O
GPI O
). O

In O
the O
cell O
- O
free O
import O
assay O
, O
beta I-GENE
- I-GENE
catenin I-GENE
rapidly O
migrates RARE
into O
the O
nucleus O
without O
the O
exogenous O
addition O
of O
cytosol O
, O
Ran I-GENE
, O
or O
ATP O
/ O
GTP O
. O

In O
ischemic O
and O
hypoxic O
hypoxia O
, O
a O
strong O
correlation O
was O
found O
between O
cyt O
a O
, O
a3 NUMERIC
oxidation O
level O
and O
VO2 O
in O
both O
ischemic O
and O
hypoxic O
hypoxia O
( O
r2 NUMERIC
=. O
90 O
and O
. O
87 O
, O
respectively O
). O

An O
endogenous O
mammalian O
regulator O
of O
this O
process O
, O
named O
Usurpin RARE
, O
has O
been O
identified O
( O
aliases RARE
for O
Usurpin RARE
include O
CASH ALLCAPS
, O
Casper RARE
, O
CLARP ALLCAPS
, O
FLAME ALLCAPS
- I-GENE
1 I-GENE
, O
FLIP ALLCAPS
, O
I I-GENE
- I-GENE
FLICE ALLCAPS
and O
MRIT ALLCAPS
). O

Plasma O
glucose O
, O
immunoreactive I-GENE
insulin I-GENE
( O
IRI ALLCAPS
), O
C I-GENE
- I-GENE
peptide I-GENE
, O
glucagon I-GENE
, O
and O
GLP ALLCAPS
- I-GENE
1 I-GENE
levels O
at O
each O
time O
point O
during O
OGTT ALLCAPS
were O
measured O
. O

Each O
recombinant O
product O
was O
a O
fusion O
protein O
with O
a O
B O
domain O
of O
Staphylococcal RARE
protein I-GENE
A I-GENE
( O
SPA ALLCAPS
). O

Polypyrimidine RARE
and O
ssDNA O
binding O
by O
the O
isolated O
VH I-GENE
domain I-GENE
of O
immunization O
- O
induced O
anti O
- O
Z O
- O
DNA O
Ab O
resembles O
the O
activity O
of O
natural O
autoantibodies O
and O
suggests O
that O
VH I-GENE
- O
dependent O
binding O
to O
a O
ligand O
mimicked O
by O
polypyrimidines RARE
may O
play O
a O
role O
in O
B O
cell O
selection O
before O
immunization O
with O
Z O
- O
DNA O
. O

Technetium RARE
- O
99m O
methylene O
diphosphonate RARE
scintimammography RARE
for O
evaluation O
of O
palpable RARE
breast O
masses O
. O

INTERVENTIONS ALLCAPS
: O
Study O
patients O
were O
randomly O
divided O
into O
four O
parallel O
groups O
to O
receive O
either O
terbinafine RARE
250 O
mg O
a O
day O
for O
12 O
or O
16 O
weeks O
( O
groups O
T12 NUMERIC
and O
T16 NUMERIC
) O
or O
itraconazole RARE
400 O
mg O
a O
day O
for O
1 O
week O
in O
every O
4 O
weeks O
for O
12 O
or O
16 O
weeks O
( O
groups O
I3 NUMERIC
and O
I4 NUMERIC
). O

Nuclear O
receptors O
( O
NRs RARE
) O
can O
function O
as O
ligandinducible RARE
transregulators RARE
in O
both O
mammalian O
and O
yeast O
cells O
, O
indicating O
that O
important O
features O
of O
transcriptional O
control O
have O
been O
conserved O
throughout O
evolution O
. O

When O
tethered RARE
to O
a O
heterologous O
DNA O
- O
binding O
domain O
, O
PSU1 NUMERIC
can O
activate O
transcription O
on O
its O
own O
. O

OBJECTIVE O
: O
To O
follow O
- O
up O
prospectively RARE
patients O
with O
arthritis O
after O
infection O
with O
beta O
- O
haemolytic RARE
streptococci RARE
of O
Lancefield RARE
group O
A O
( O
beta O
HSA ALLCAPS
), O
with O
emphasis RARE
on O
clinical O
characteristics O
and O
serological O
features O
. O

Bacteria RARE
can O
also O
cause O
a O
labyrinthitis RARE
acting O
directly O
on O
the O
inner O
ear O
: O
among O
these O
, O
Treponemas RARE
Pallidum RARE
, O
a O
spirochaete RARE
which O
causes O
syphilis RARE
and O
Borrelia RARE
Burgdorferi RARE
, O
a O
spirochaete RARE
that O
causes O
Lyme RARE
Disease RARE
, O
must O
be O
mentioned O
. O

We O
found O
that O
the O
expression O
of O
the O
protein O
was O
maximum O
in O
mitosis O
and O
minimum O
in O
G1 O
, O
which O
correlated O
with O
the O
expression O
of O
its O
messenger O
RNA O
. O

These O
findings O
demonstrate O
that O
signature RARE
- O
tagged O
mutagenesis O
is O
a O
viable O
approach O
to O
identify O
bacterial O
genes O
associated O
with O
the O
ability O
to O
infect RARE
the O
urinary O
tract O
. O

Pathol RARE
. O

The O
eukaryotic O
cell O
cycle O
is O
governed RARE
in O
part O
by O
the O
periodic O
transcription O
of O
cyclin I-GENE
genes I-GENE
, O
whose O
protein O
products O
associate O
with O
and O
positively O
regulate O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
. O

The O
GAC1 NUMERIC
gene I-GENE
encodes O
the O
regulatory O
subunit O
for O
a O
type I-GENE
1 I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
phosphoprotein I-GENE
phosphatase I-GENE
, O
Glc7 NUMERIC
. O

The O
results O
demonstrate O
that O
the O
Glc7 NUMERIC
phosphatase I-GENE
and O
its O
Gac1 NUMERIC
regulatory O
subunit O
play O
positive O
roles O
in O
HSF I-GENE
activation O
of O
CUP1 NUMERIC
transcription O
. O

MEF I-GENE
and O
AML1B NUMERIC
synergistically O
transactivated O
an O
interleukin I-GENE
3 I-GENE
promoter I-GENE
reporter I-GENE
gene I-GENE
construct I-GENE
, O
yet O
the O
activating O
activity O
of O
MEF I-GENE
was O
abolished O
when O
MEF I-GENE
was O
coexpressed O
with O
AML1 NUMERIC
/ O
ETO ALLCAPS
. O

Mechanistically RARE
, O
the O
presence O
of O
the O
GRR ALLCAPS
appears O
to O
stop O
further O
degradation O
of O
p50 I-GENE
and O
to O
stabilize RARE
the O
molecule O
. O

This O
phosphorylation O
can O
be O
catalyzed O
by O
a O
break RARE
- O
ended RARE
double O
- O
stranded O
DNA O
- O
activated O
protein O
kinase O
activity O
from O
the O
sea O
urchin O
nucleus O
in O
vitro O
. O

Concomitantly RARE
, O
the O
total O
cellular O
level O
of O
p21 I-GENE
increased O
severalfold RARE
via O
a O
posttranscriptional O
mechanism O
. O

Moreover O
, O
when O
added O
to O
the O
osteoclast RARE
cultures O
, O
mrIhh RARE
- I-GENE
N I-GENE
markedly O
stimulated O
the O
formation O
of O
resorption O
pits RARE
on O
dentine RARE
slices RARE
. O

Overall O
, O
our O
results O
suggest O
that O
resistant O
genotypes RARE
exist O
among O
the O
WAD ALLCAPS
goat RARE
population O
. O

The O
molecular O
mechanism O
by O
which O
Gle2p NUMERIC
and O
the O
Gle2p NUMERIC
- O
Nup116p NUMERIC
interaction O
function O
in O
mRNA O
export O
is O
unknown O
. O

The O
Fyn I-GENE
NH2 I-GENE
terminus I-GENE
was O
necessary O
but O
not O
sufficient O
for O
interaction O
with O
zeta O
and O
both O
Fyn I-GENE
kinase I-GENE
and O
SH2 I-GENE
domains I-GENE
were O
required O
, O
directing RARE
phosphorylation O
of O
zeta I-GENE
ITAM ALLCAPS
tyrosines RARE
and O
binding O
to O
zeta I-GENE
ITAM ALLCAPS
phosphotyrosines RARE
. O

In O
budding O
yeast O
, O
the O
protein O
Skp1p NUMERIC
, O
the O
cullin RARE
- I-GENE
family I-GENE
member I-GENE
Cdc53p NUMERIC
, O
and O
the O
F O
- O
box O
/ O
WD O
- O
repeat O
protein O
Cdc4p NUMERIC
form O
the O
SCFCdc4p NUMERIC
ubiquitin I-GENE
ligase I-GENE
complex O
, O
which O
targets O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
inhibitor O
Sic1p NUMERIC
for O
proteolysis O
[ O
3 O
] O
[ O
4 O
] O
[ O
5 O
] O
[ O
6 O
] O
[ O
7 O
] O
[ O
8 O
]. O

We O
show O
here O
that O
, O
despite O
their O
structural O
and O
functional O
similarities O
, O
the O
pop1 NUMERIC
and O
pop2 NUMERIC
genes I-GENE
fail O
to O
complement O
each O
other O
' O
s O
deletion O
phenotypes O
, O
indicating O
that O
they O
perform O
non O
- O
redundant RARE
, O
but O
potentially O
interdependent RARE
, O
functions O
in O
proteolysis O
. O

Antithrombin RARE
III I-GENE
prevents O
60 O
min O
warm RARE
intestinal O
ischemia O
reperfusion O
injury O
in O
rats O
. O

In O
retrospect RARE
, O
the O
diagnoses RARE
were O
reconsidered RARE
applying O
strict RARE
criteria O
. O

These O
observations O
of O
elevated O
serum I-GENE
lipase I-GENE
and O
serum O
CA I-GENE
19 I-GENE
- I-GENE
9 I-GENE
in O
Sjogren RARE
' O
s O
syndrome O
without O
evidence O
of O
malignancy O
may O
reflect O
pancreatic O
involvement O
in O
this O
disorder O
. O

Acute O
pancreatitis O
as O
a O
complication O
of O
polyarteritis RARE
nodosa RARE
. O

Significantly O
greater O
improvement O
( O
p O
< O
0 O
. O
05 O
) O
in O
the O
sertraline RARE
group O
first O
became O
apparent O
by O
the O
end O
of O
week O
3 O
on O
the O
Y O
- O
BOCS ALLCAPS
and O
the O
CGI ALLCAPS
Improvement RARE
scale O
, O
and O
by O
the O
end O
of O
weeks O
6 O
and O
8 O
, O
respectively O
, O
on O
the O
NIMH ALLCAPS
and O
CGI ALLCAPS
Severity RARE
scale O
. O

Stress RARE
- I-GENE
inducible I-GENE
protein I-GENE
kinases I-GENE
capable O
of O
activating O
c I-GENE
- I-GENE
jun I-GENE
expression O
include O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
/ O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
/ O
JNK I-GENE
) O
and O
p38 I-GENE
members O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
superfamily O
of O
signaling O
molecules O
. O

Transforming RARE
growth I-GENE
factor I-GENE
( I-GENE
TGF I-GENE
)- I-GENE
beta1 I-GENE
induces O
extracellular O
matrix O
deposition O
and O
proliferation O
of O
mesenchymal O
cells O
. O

Chronotherapeutics RARE
in O
cardiovascular O
disease O
. O

Group O
psychometric RARE
functions O
for O
listeners RARE
with O
hearing O
loss O
do O
not O
show O
a O
decrease O
in O
performance O
at O
the O
largest O
values O
of O
delta O
f O
included O
in O
this O
study O
. O

Uroflowmetry RARE
can O
detect O
dysuria RARE
, O
which O
may O
be O
poorly O
perceived O
or O
even O
unknown O
to O
the O
subjects O
themselves O
. O

Marked O
racial RARE
variation O
in O
birthweight RARE
percentiles RARE
by O
gestational O
age O
was O
evident O
. O

Significant O
correlations O
between O
mental O
status O
as O
measured O
by O
the O
Mini RARE
- O
Mental RARE
State O
Examination O
and O
NA O
/ O
mI LASTCAP
, O
mI LASTCAP
/ O
Cr O
and O
NA O
were O
found O
. O

Glucagon RARE
also O
induced O
LUC ALLCAPS
activity O
very O
strongly O
when O
the O
CRE1 NUMERIC
and O
CRE2 NUMERIC
sites O
were O
combined O
; O
induction O
of O
the O
( O
CRE1 NUMERIC
) O
3 O
( O
CRE2 NUMERIC
) O
2SV40 NUMERIC
- O
LUC ALLCAPS
constructs O
was O
positively O
modulated O
by O
the O
pO2 NUMERIC
. O

In O
this O
study O
, O
we O
report O
the O
isolation O
and O
characterization O
of O
the O
entire O
rat I-GENE
GSTA3 NUMERIC
( O
rGST LASTCAP
Yc1 NUMERIC
) O
subunit O
gene O
. O

Calcinosis RARE
cutis RARE
following O
intravenous O
infusion O
of O
calcium O
gluconate RARE
. O

Initial O
control O
of O
bleeding O
is O
similar O
, O
but O
eradication O
is O
achieved O
in O
fewer O
sessions RARE
with O
EVL ALLCAPS
. O

Finally O
, O
we O
determined O
the O
genomic O
organization O
of O
the O
human I-GENE
TrxR2 NUMERIC
gene I-GENE
, O
which O
consists O
of O
18 O
exons O
spanning O
about O
67 O
kb O
, O
and O
its O
chromosomal O
localization O
at O
position O
22q11 NUMERIC
. O
2 O
. O

The O
aims RARE
of O
this O
study O
were O
to O
determine O
and O
rank RARE
the O
frequency O
of O
self O
reported O
visual O
disability RARE
in O
daily O
tasks O
performed O
by O
glaucoma O
patients O
; O
to O
examine O
the O
interrelation RARE
between O
disabilities RARE
using O
factor O
analysis O
; O
to O
study O
the O
relation O
between O
perceived O
visual O
difficulty RARE
and O
a O
measure O
of O
the O
severity O
of O
visual O
field O
loss O
; O
to O
develop O
a O
glaucoma O
specific O
subgroup O
of O
questions O
; O
and O
examine O
the O
validity O
and O
reliability O
of O
this O
subgroup O
of O
questions O
. O

Furthermore O
, O
the O
validity O
of O
this O
new O
subset O
of O
questions O
was O
shown O
to O
be O
significant O
( O
r O
= O
0 O
. O
037 NUMERIC
, O
p O
< O
0 O
. O
05 O
) O
for O
the O
correlation O
between O
a O
measure O
of O
the O
severity O
of O
binocular RARE
visual O
field O
loss O
and O
the O
mean O
score O
of O
the O
variables O
used O
in O
the O
glaucoma O
specific O
subgroup O
of O
questions O
. O

Sequence O
comparison O
of O
cytochromes RARE
bd RARE
and O
their O
homologs O
from O
various O
organisms O
demonstrates O
that O
the O
proteins O
can O
be O
classified O
into O
two O
subfamilies RARE
, O
a O
proteobacterial RARE
type O
including O
E I-GENE
. I-GENE
coli I-GENE
bd RARE
and O
a O
more O
widely O
distributed O
type O
including O
the O
B O
. O
stearothermophilus RARE
enzyme O
, O
suggesting O
that O
the O
latter O
type O
is O
evolutionarily O
older O
. O

Canalith RARE
repositioning RARE
is O
the O
mainstay RARE
of O
treatment O
. O

Solution RARE
structure O
and O
mechanism O
of O
the O
MutT LASTCAP
pyrophosphohydrolase RARE
. O

In O
11 O
eyes O
that O
had O
been O
selected O
at O
random O
10 O
micrograms O
of O
recombinant I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
were O
injected O
midvitreally RARE
24 O
hrs O
later O
. O

RESULTS O
AND O
CONCLUSIONS O
: O
Brandt RARE
' O
s O
double O
cuff RARE
- O
tubes RARE
( O
G2 O
) O
succeed RARE
in O
avoiding RARE
uncontrolled RARE
increase O
of O
cuff RARE
- O
pressure O
during O
anaesthesia O
with O
N2O O
. O

Accordingly RARE
, O
we O
designated O
this O
gene I-GENE
CTL1 NUMERIC
( O
capping I-GENE
enzyme I-GENE
RNAtriphosphatase RARE
- I-GENE
like I-GENE
1 I-GENE
). O

The O
binding O
of O
PH I-GENE
domains I-GENE
to O
Gbetagamma I-GENE
was O
inhibited O
by O
preincubation RARE
of O
Gbetagamma I-GENE
with O
the O
GDP O
- O
bound O
but O
not O
the O
GTP O
- O
bound O
form O
of O
Gialpha RARE
. O

Their O
afterglows RARE
are O
brighter RARE
than O
supernovae RARE
and O
therefore O
are O
called O
hypernovae RARE
. O

Constrictive RARE
pericarditis RARE
and O
pleuropulmonary RARE
disease O
linked O
to O
ergot RARE
dopamine O
agonist O
therapy O
( O
cabergoline RARE
) O
for O
Parkinson O
' O
s O
disease O
. O

An O
undilated RARE
type O
of O
APBD ALLCAPS
is O
frequently O
associated O
with O
AMT ALLCAPS
and O
we O
believe RARE
, O
therefore O
, O
that O
clinicians RARE
should O
be O
aware RARE
of O
a O
possible O
coexistence RARE
of O
APBD ALLCAPS
and O
AMT ALLCAPS
. O

In O
addition O
, O
we O
also O
constructed O
and O
expressed O
chimeric O
fusion O
protein O
that O
contains O
HIV I-GENE
- I-GENE
2 I-GENE
gag I-GENE
with O
V3 NUMERIC
domains O
of O
HIV O
- O
1IIIB NUMERIC
, O
HIV O
- O
1MN NUMERIC
, O
HIV O
- O
1SF2 NUMERIC
and O
HIV O
- O
1RF NUMERIC
. O

Our O
results O
indicate O
that O
V3 NUMERIC
peptides O
from O
all O
major O
clades RARE
of O
HIV O
- O
1 O
carried O
by O
HIV I-GENE
- I-GENE
2 I-GENE
gag I-GENE
can O
be O
used O
as O
a O
potential O
HIV O
/ O
AIDS O
vaccine O
. O

Efficacy RARE
was O
determined O
by O
responses O
to O
question O
3 O
( O
ability O
to O
achieve O
an O
erection RARE
) O
and O
question O
4 O
( O
ability O
to O
maintain O
an O
erection RARE
) O
of O
the O
15 O
- O
item RARE
International O
Index RARE
of O
Erectile RARE
Function RARE
( O
IIEF ALLCAPS
). O

Evidence O
for O
the O
involvement O
of O
the O
Glc7 NUMERIC
- O
Reg1 NUMERIC
phosphatase O
and O
the O
Snf1 NUMERIC
- O
Snf4 NUMERIC
kinase O
in O
the O
regulation O
of O
INO1 NUMERIC
transcription O
in O
Saccharomyces O
cerevisiae O
. O

In O
XO ALLCAPS
males O
, O
two O
her I-GENE
- I-GENE
1 I-GENE
mRNAs I-GENE
, O
her I-GENE
- I-GENE
1a I-GENE
and O
her I-GENE
- I-GENE
1b I-GENE
, O
are O
transcribed O
from O
two O
separate O
promoters O
: O
P1 O
, O
located O
in O
the O
5 O
'- O
flanking O
region O
, O
and O
P2 O
, O
located O
in O
the O
large O
second O
intron O
. O

Induction O
of O
Fas I-GENE
ligand I-GENE
expression O
by O
HIV O
involves O
the O
interaction O
of O
Nef I-GENE
with O
the O
T I-GENE
cell I-GENE
receptor I-GENE
zeta I-GENE
chain I-GENE
. O

Receptor RARE
protein I-GENE
tyrosine I-GENE
phosphatases I-GENE
( O
RPTPs RARE
) O
comprise O
a O
family O
of O
proteins O
that O
feature O
intracellular O
phosphatase O
domains O
and O
an O
ectodomain RARE
with O
putative O
ligand O
- O
binding O
motifs O
. O

These O
well O
- O
characterized O
brain O
regions O
may O
provide O
a O
basis O
for O
future O
studies O
of O
RPTP ALLCAPS
- I-GENE
kappa I-GENE
function O
. O

Commonly RARE
used O
stressors RARE
are O
mental O
arithmetics RARE
, O
speech O
tasks O
, O
the O
Stroop O
test O
, O
videogame RARE
playing RARE
, O
films O
or O
videotapes RARE
and O
interviews RARE
. O

The O
control O
group O
included O
8 O
afterbirth RARE
samples O
from O
physiological O
full O
- O
term O
pregnancies RARE
. O

However O
, O
we O
identified O
a O
gene O
between O
the O
MDV2 NUMERIC
UL54 NUMERIC
and O
UL55 NUMERIC
genes I-GENE
with O
homology O
to O
the O
first I-GENE
ORF I-GENE
( I-GENE
ORF I-GENE
- I-GENE
1 I-GENE
) I-GENE
of I-GENE
equine I-GENE
herpesvirus I-GENE
type I-GENE
1 I-GENE
and O
corresponding O
gene O
identified O
in O
pseudorabies O
virus O
. O

In O
contrast O
, O
the O
loss O
of O
MAD2 NUMERIC
staining O
in O
meiosis O
was O
not O
correlated O
with O
initial O
microtubule O
attachment O
but O
was O
correlated O
with O
a O
measure O
of O
tension O
: O
the O
distance O
between O
homologous O
or O
sister RARE
kinetochores RARE
( O
in O
meiosis O
I O
and O
II O
, O
respectively O
). O

In O
epithelial O
cells O
, O
the O
PH I-GENE
domain I-GENE
of O
Akt I-GENE
/ O
PKB I-GENE
localised RARE
to O
sites O
of O
cell O
- O
cell O
and O
cell O
- O
matrix O
contact O
, O
distinct O
from O
focal O
contacts O
, O
even O
in O
the O
absence O
of O
serum O
. O

The O
5 O
' O
untranslated O
and O
coding O
regions O
are O
contained O
within O
12 O
exons O
, O
with O
the O
translation O
start O
site O
located O
within O
the O
first O
exon O
. O

The O
motility O
of O
sperm O
, O
except O
for O
those O
adjacent O
to O
both O
electrodes O
, O
did O
not O
change O
after O
stimulation O
for O
60s NUMERIC
, O
despite O
a O
high O
electrical O
energy O
. O

Induction O
of O
the O
CINC ALLCAPS
promoter I-GENE
by O
IL I-GENE
- I-GENE
17 I-GENE
in O
IEC ALLCAPS
- O
6 O
cells O
was O
TNF I-GENE
receptor I-GENE
- I-GENE
associated I-GENE
factor I-GENE
- I-GENE
6 I-GENE
( O
TRAF6 NUMERIC
), O
but O
not O
TRAF2 I-GENE
, O
dependent O
. O

SCFFWD1 NUMERIC
may O
be O
critical O
for O
tumor O
development O
and O
suppression O
through O
regulation O
of O
beta I-GENE
- I-GENE
catenin I-GENE
protein I-GENE
stability O
. O

A O
Bub2p NUMERIC
- O
dependent O
spindle O
checkpoint O
pathway O
regulates O
the O
Dbf2p NUMERIC
kinase I-GENE
in I-GENE
budding I-GENE
yeast I-GENE
. O

We O
analyzed O
the O
modular RARE
organization O
of O
DNA I-GENE
polymerase I-GENE
beta I-GENE
and O
found O
that O
residues O
making O
contact O
with O
DNA O
phosphates RARE
were O
localized O
to O
five O
modules O
. O

RESULTS O
: O
Cholinergic RARE
nerves O
are O
mainly O
involved O
in O
the O
regulation O
of O
enteric O
nerve O
responses O
to O
EFS ALLCAPS
in O
the O
normal O
IAS ALLCAPS
. O

Two O
- O
dimensional O
gel O
electrophoresis O
of O
anti I-GENE
- I-GENE
p59fyn NUMERIC
immunoprecipitates RARE
obtained O
from O
non O
- O
transformed O
resting O
human O
T O
lymphocytes O
resulted O
in O
the O
identification O
of O
an O
oligomeric RARE
protein O
complex O
which O
is O
constitutively O
formed O
between O
Fyn I-GENE
and O
several O
additional O
phosphoproteins RARE
( O
pp43 NUMERIC
, O
pp72 NUMERIC
, O
pp85 NUMERIC
, O
the O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
Pyk2 NUMERIC
, O
as O
well O
as O
the O
two O
recently O
cloned O
adaptor O
proteins O
, O
SKAP55 NUMERIC
and O
SLAP ALLCAPS
- I-GENE
130 I-GENE
). O

We O
show O
that O
other O
cdc33 NUMERIC
mutants I-GENE
also O
arrest O
in O
G1 O
. O

A O
cdc33 NUMERIC
- I-GENE
1 I-GENE
strain O
expressing O
either O
stable O
Cln3p NUMERIC
( O
Cln3 NUMERIC
- I-GENE
1p NUMERIC
) O
or O
a O
hybrid O
UBI4 NUMERIC
5 I-GENE
'- I-GENE
CLN3 NUMERIC
mRNA O
, O
whose O
translation O
displays O
decreased O
dependence O
on O
eIF4E NUMERIC
, O
arrested O
randomly O
in O
the O
cell O
cycle O
. O

Regulatory RARE
motifs O
for O
gene O
expression O
such O
as O
nuclear I-GENE
- I-GENE
factor I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
binding I-GENE
- I-GENE
site I-GENE
- I-GENE
like I-GENE
sequence I-GENE
( O
kappaB I-GENE
site I-GENE
) O
and O
nuclear I-GENE
- I-GENE
factor I-GENE
- I-GENE
interleukin I-GENE
- I-GENE
6 I-GENE
- I-GENE
binding I-GENE
- I-GENE
site I-GENE
- I-GENE
like I-GENE
sequence I-GENE
( O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
site I-GENE
) O
were O
found O
in O
the O
5 O
'- O
upstream O
regulatory O
region O
. O

The O
gene O
structure O
of O
Elk1 NUMERIC
spans O
15 O
. O
2 O
kb O
and O
consists O
of O
seven O
exons O
and O
six O
introns O
. O

Total O
serum O
calcium O
was O
7 O
. O
8 O
+/- O
0 O
. O
8 O
mg O
/ O
dl O
, O
whereas O
ionized RARE
calcium O
was O
5 O
. O
7 O
+/- O
0 O
. O
7 O
mg O
/ O
dl O
, O
phosphorus O
3 O
. O
2 O
+/- O
1 O
. O
2 O
mg O
/ O
dl O
, O
and O
alkaline I-GENE
phosphatase I-GENE
149 NUMERIC
+/- O
48 O
. O
6 O
U O
/ O
liter O
. O

Sequence O
analysis O
suggests O
that O
TtrA LASTCAP
contains O
a O
molybdopterin RARE
guanine O
dinucleotide O
cofactor O
and O
a O
[ O
4Fe NUMERIC
- O
4S NUMERIC
] O
cluster O
, O
that O
TtrB LASTCAP
binds O
four O
[ O
4Fe NUMERIC
- O
4S NUMERIC
] O
clusters O
, O
and O
that O
TtrC LASTCAP
is O
an O
integral O
membrane O
protein O
containing O
a O
quinol RARE
oxidation O
site O
. O

Cranio RARE
- O
caudal RARE
differences O
in O
granulation RARE
tissue O
formation O
: O
an O
experimental O
study O
in O
the O
rat O
. O

Site O
- O
directed O
mutagenesis O
showed O
that O
two O
adjacent O
SP1 I-GENE
sites I-GENE
proximal O
to O
exon O
1 O
were O
equally O
important O
in O
sustaining RARE
basal O
promoter O
activity O
. O

Breast RARE
- O
fed O
newborn O
infants O
synthesize RARE
n O
- O
6 O
long O
- O
chain O
polyunsaturated RARE
fatty O
acids O
already O
during O
the O
first O
week O
of O
life O
, O
but O
the O
contribution O
of O
endogenous O
synthesis O
to O
the O
total O
plasma O
long O
- O
chain O
polyunsaturated RARE
pool O
is O
small O
. O

Ischemia RARE
and O
reperfusion O
markedly O
increased O
the O
release O
of O
6 O
- O
keto RARE
- O
PGF1 NUMERIC
alpha O
and O
TXB2 NUMERIC
. O

Prostate RARE
- I-GENE
specific I-GENE
antigen I-GENE
( O
PSA I-GENE
) O
promoter O
- O
driven O
androgen O
- O
inducible O
expression O
of O
sodium I-GENE
iodide RARE
symporter RARE
in O
prostate O
cancer O
cell O
lines O
. O

It O
is O
clear O
that O
subclinical O
and O
silent O
CD O
exist O
in O
a O
large O
subgroup O
of O
the O
celiac RARE
population O
. O

Ras2p NUMERIC
activates O
invasive O
growth O
using O
either O
of O
two O
downstream O
signaling O
pathways O
, O
the O
filamentation RARE
MAPK I-GENE
( O
Cdc42p NUMERIC
/ O
Ste20p NUMERIC
/ O
MAPK I-GENE
) O
cascade O
or O
the O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
Cyr1p NUMERIC
/ O
cAMP O
/ O
PKA I-GENE
) O
pathway O
. O

Consistent O
with O
this O
prediction O
, O
transfections O
into O
the O
hematopoietic O
cell O
line O
Jurkat O
showed O
a O
9 O
. O
0 O
- O
and O
2 O
. O
5 O
- O
fold O
activation O
of O
the O
mim RARE
- I-GENE
1 I-GENE
promoter I-GENE
by O
the O
p32 NUMERIC
and O
p30 NUMERIC
isoforms I-GENE
, O
respectively O
. O

Previous O
work O
has O
shown O
that O
spleen I-GENE
necrosis I-GENE
virus I-GENE
( I-GENE
SNV ALLCAPS
) I-GENE
long I-GENE
terminal I-GENE
repeats I-GENE
( O
LTRs RARE
) O
are O
associated O
with O
Rex I-GENE
/ O
Rex I-GENE
- O
responsive O
element O
- O
independent O
expression O
of O
bovine O
leukemia O
virus O
RNA O
and O
supports O
the O
hypothesis O
that O
SNV ALLCAPS
RNA O
contains O
a O
cis O
- O
acting O
element O
that O
interacts O
with O
cellular I-GENE
Rex I-GENE
- I-GENE
like I-GENE
proteins I-GENE
. O

Despite O
the O
reported O
detrimental RARE
effects O
on O
CNS O
development O
, O
a O
number O
of O
animal O
studies O
have O
shown O
that O
pretreatment O
with O
corticosteroids O
nevertheless RARE
protect O
the O
brain O
from O
hypoxia O
- O
ischemic O
injury O
; O
however O
, O
clinically O
such O
treatment O
is O
no O
longer O
favored RARE
. O

In O
one O
mechanism O
, O
a O
specialized O
ubiquitin I-GENE
- O
dependent O
proteolytic O
system O
( O
called O
the O
APC O
- O
dependent O
proteolysis O
machinery O
) O
degrades RARE
the O
mitotic O
( O
Clb RARE
) O
cyclin I-GENE
subunit I-GENE
. O

Predictors RARE
of O
success O
in O
pharmacy RARE
school RARE
: O
PCAT ALLCAPS
vs O
. O
other O
admission O
criteria O
. O

Canadian RARE
survey O
reveals O
widespread RARE
dissatisfaction RARE
among O
physicians O
. O

In O
a O
series O
of O
16 O
full O
- O
scale O
fire RARE
tests O
, O
investigators RARE
at O
the O
IIT ALLCAPS
Research O
Institute O
have O
concluded O
that O
automatic O
door RARE
control O
in O
the O
room O
of O
fire RARE
origin O
can O
significantly O
reduce O
the O
spread O
of O
toxic O
smoke O
and O
gases O
. O

Online RARE
LATCH ALLCAPS
demonstrates O
a O
shift O
in O
identification O
of O
the O
library O
as O
an O
isolated O
unit O
to O
an O
interactive RARE
resource O
center O
. O

Reporting RARE
of O
adverse O
events O
occurring O
during O
clinical O
trials O
of O
investigational RARE
drugs O
is O
a O
complex O
and O
controversial RARE
issue RARE
. O

Medicare RARE
SNF ALLCAPS
benefits O
revised O
-- O
again O
. O

In O
this O
paper O
, O
the O
current O
status O
of O
the O
understanding O
of O
the O
interaction O
mechanisms O
of O
ultrasound O
with O
biological O
media O
and O
the O
factors O
that O
govern O
different O
biological O
effects O
are O
surveyed RARE
. O

Members O
of O
the O
mitogen I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
family I-GENE
, O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
, O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- I-GENE
1 I-GENE
/ O
c I-GENE
- I-GENE
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
, O
and O
p38 I-GENE
, O
are O
central O
elements O
that O
transduce RARE
the O
signal O
generated O
by O
growth O
factors O
, O
cytokines O
, O
and O
stressing RARE
agents O
. O

In O
the O
present O
study O
, O
we O
have O
investigated O
the O
functional O
role O
of O
the O
other O
MAP I-GENE
kinases I-GENE
in O
PDGF I-GENE
- O
mediated O
cellular O
responses O
. O

Analyses RARE
of O
tyrosine O
residue O
- O
mutated O
PDGF I-GENE
receptors I-GENE
show O
that O
Src I-GENE
homology I-GENE
2 I-GENE
domain I-GENE
- I-GENE
containing I-GENE
proteins I-GENE
including O
Src I-GENE
family I-GENE
kinases I-GENE
, O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
the O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
of O
Ras I-GENE
, O
the O
Src I-GENE
homology I-GENE
2 I-GENE
domain I-GENE
- I-GENE
containing I-GENE
phosphatase I-GENE
SHP I-GENE
- I-GENE
2 I-GENE
, O
phospholipase I-GENE
C I-GENE
- I-GENE
gamma I-GENE
, O
and O
Crk I-GENE
do O
not O
play O
a O
major O
role O
in O
mediating O
the O
PDGF I-GENE
- O
induced O
activation O
of O
p38 I-GENE
. O

Here O
we O
show O
that O
calpeptin RARE
inhibits O
tyrosine I-GENE
phosphatases I-GENE
, O
enhancing O
tyrosine O
phosphorylation O
particularly O
of O
paxillin I-GENE
. O

Three O
- O
dimensional O
structural O
studies O
using O
electron O
cryomicroscopy RARE
showed O
that O
the O
binding O
of O
one O
Fab RARE
( O
8H2 NUMERIC
/ O
G5 NUMERIC
) O
does O
not O
affect O
the O
conformation O
of O
the O
capsid O
, O
and O
the O
efficiency O
of O
mRNA O
production O
is O
similar O
to O
that O
of O
the O
native O
subviral RARE
particle O
. O

Further O
, O
mutational O
analysis O
of O
NS5A NUMERIC
assigned O
the O
SH3 I-GENE
- I-GENE
binding I-GENE
region I-GENE
to O
a O
proline O
- O
rich O
motif O
that O
is O
highly O
conserved O
among O
HCV O
genotypes RARE
. O

Taken O
together O
, O
these O
findings O
show O
that O
16K NUMERIC
hPRL LASTCAP
inhibits O
the O
VEGF I-GENE
- O
induced O
Ras I-GENE
activation O
; O
this O
antagonism RARE
represents O
a O
novel O
and O
potentially O
important O
mechanism O
for O
the O
control O
of O
angiogenesis O
. O

Analysis O
of O
SRE O
oligonucleotide O
gel O
mobility O
shift O
assays O
with O
nuclear O
extracts O
from O
Sertoli RARE
cells O
demonstrated O
the O
presence O
of O
both O
the O
SRF I-GENE
and O
the O
ubiquitously O
expressed O
bHLH O
protein O
E12 I-GENE
/ O
E47 NUMERIC
. O

We O
calculated O
differences O
in O
late O
occlusion O
rates O
by O
the O
chi2 NUMERIC
( O
chi RARE
- O
square O
) O
test O
, O
and O
found O
these O
differences O
were O
significant O
( O
P O
=. O
04 O
). O

Baseline RARE
electrocorticography RARE
over O
the O
surface O
of O
the O
temporal O
lobe O
and O
depth O
electrode O
recordings O
in O
the O
amygdala O
and O
hippocampus O
were O
obtained O
, O
followed O
by O
10 O
min O
of O
recording O
before O
and O
after O
the O
i O
. O
v O
. O
administration O
of O
both O
alfentanil RARE
50 O
microg O
/ O
kg O
and O
fentanyl O
10 O
microg O
/ O
kg O
. O

We O
describe O
a O
genetic O
system O
for O
further O
characterizing O
the O
role O
of O
the O
extreme O
C O
- O
terminus O
of O
the O
beta O
subunit O
of O
E I-GENE
. I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

We O
suggest O
that O
FlgN LASTCAP
and O
FliT LASTCAP
are O
substrate O
- O
specific O
flagellar RARE
chaperones RARE
that O
prevent O
oligomerization O
of O
the O
HAPs RARE
by O
binding O
to O
their O
helical O
domains O
before O
export O
. O

Post O
and O
core O
fabrication RARE
for O
divergent O
canals RARE
with O
a O
cast RARE
post O
and O
core O
and O
a O
prefabricated RARE
dowel RARE
. O

Rep63A NUMERIC
( O
513 NUMERIC
amino O
acids O
[ O
aa O
]), RARE
encoded O
by O
the O
largest O
ORF O
, O
displayed O
strong O
similarity O
( O
40 O
% O
identity O
) O
to O
the O
replication O
proteins O
from O
plasmids O
pAMbeta1 NUMERIC
, O
pIP501 NUMERIC
, O
and O
pSM19035 NUMERIC
, O
indicating O
that O
the O
pAW63 NUMERIC
replicon RARE
belongs O
to O
the O
pAMbeta1 NUMERIC
family O
of O
gram O
- O
positive O
theta RARE
- O
replicating O
plasmids O
. O

Here O
we O
report O
the O
cloning O
and O
characterization O
of O
Xenopus I-GENE
Pax I-GENE
- I-GENE
5 I-GENE
and O
Pax I-GENE
- I-GENE
8 I-GENE
, O
two O
orthologues RARE
of O
the O
Pax I-GENE
- I-GENE
2 I-GENE
/ I-GENE
5 I-GENE
/ I-GENE
8 I-GENE
gene I-GENE
family I-GENE
. O

Km RARE
values O
for O
ammonium RARE
, O
2 O
- O
oxoglutarate RARE
, O
NADH O
, O
glutamate O
and O
NAD O
+ O
were O
6 O
. O
5 O
, O
3 O
. O
5 O
, O
0 O
. O
06 O
, O
37 O
. O
1 O
and O
0 O
. O
046 NUMERIC
mM O
, O
respectively O
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
may O
exacerbate RARE
cryoblobulinemia RARE
- O
related O
ischemic O
manifestations O
: O
an O
adverse O
effect O
potentially O
related O
to O
its O
anti O
- O
angiogenic RARE
activity O
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
may O
exacerbate RARE
cryoblobulinemia RARE
- O
related O
ischemic O
manifestations O
: O
an O
adverse O
effect O
potentially O
related O
to O
its O
anti O
- O
angiogenic RARE
activity O
. O

In O
addition O
, O
we O
demonstrate O
that O
the O
production O
of O
active I-GENE
recombinant I-GENE
telomerase I-GENE
requires O
a O
factor O
in O
rabbit O
reticulocyte RARE
lysate RARE
that O
promotes O
ribonucleoprotein O
assembly O
. O

The O
enhanced O
binding O
of O
c I-GENE
- I-GENE
Abl I-GENE
to O
DNA O
containing O
5 O
- O
methylcytosine RARE
residues O
may O
result O
from O
an O
increased O
propensity O
of O
the O
double O
helix O
to O
denature RARE
locally O
coupled O
with O
a O
protein O
- O
induced O
reduction O
in O
the O
base O
stacking RARE
interaction O
. O

Homozygous O
mutation O
in O
two O
children O
led O
to O
amputation RARE
of O
legs RARE
due O
to O
purpura O
fulminans RARE
. O

According O
to O
pilot RARE
experiments O
which O
considered O
various O
durations O
of O
global O
no O
- O
flow O
ischemia O
ranging O
from O
10 O
to O
20 O
minutes O
, O
two O
durations O
were O
chosen O
for O
the O
present O
study O
: O
20 O
minutes O
( O
group O
20 O
) O
in O
which O
ventricular O
fibrillation O
( O
VF O
) O
was O
the O
predominant O
form O
of O
arrhythmias O
, O
and O
18 O
minutes O
( O
group O
18 O
) O
in O
which O
the O
prevalence O
of O
VF O
was O
markedly O
lower O
despite O
the O
small O
difference O
in O
the O
duration O
of O
ischemia O
. O

An O
end O
- O
to O
- O
end O
pancreaticojejunostomy RARE
using O
a O
mechanical O
purse RARE
- O
string RARE
device O
. O

We O
further O
demonstrate O
that O
the O
Stress RARE
- I-GENE
Activated RARE
- I-GENE
Protein I-GENE
- I-GENE
Kinase RARE
( O
SAPK I-GENE
) O
target O
sites O
of O
ATF2 NUMERIC
, O
Thr69 NUMERIC
and O
Thr71 NUMERIC
are O
not O
required O
for O
the O
formation O
of O
the O
p300 I-GENE
/ O
CBP I-GENE
- O
ATF2 NUMERIC
multiprotein RARE
complex O
. O

Blood O
samples O
were O
obtained O
daily O
during O
this O
supplementation O
period O
and O
5 O
d O
thereafter O
( O
d O
11 O
to O
15 O
). O

These O
results O
suggest O
that O
mitochondrial O
presequences RARE
interact O
with O
the O
mt RARE
- I-GENE
hsp70 I-GENE
during O
or O
after O
mitochondrial O
protein O
import O
. O

The O
3 O
' O
terminus O
of O
the O
genome O
can O
be O
folded O
into O
a O
tRNA O
- O
like O
secondary O
structure O
that O
has O
a O
valine RARE
anticodon RARE
; O
the O
tRNA O
- O
like O
structure O
lacks O
a O
pseudoknot RARE
in O
the O
aminoacyl RARE
stem O
, O
a O
feature O
common O
to O
both O
genera RARE
of O
tetraviruses RARE
. O

O I-GENE
. I-GENE
novo I-GENE
- I-GENE
ulmi RARE
RNA I-GENE
- I-GENE
7 I-GENE
, O
previously O
believed O
to O
be O
a O
satellite O
- O
like O
RNA O
, O
is O
shown O
to O
be O
a O
defective O
RNA O
, O
derived O
from O
OnuMV4 NUMERIC
- I-GENE
Ld RARE
RNA I-GENE
by O
multiple O
internal O
deletions O
. O

Only O
one O
gene O
, O
fibronectin I-GENE
( O
FN I-GENE
), O
was O
highly O
overexpressed O
(> O
60 O
- O
fold O
) O
in O
LNCaP LASTCAP
- O
r O
cells O
, O
consistent O
with O
previously O
reported O
overexpression O
of O
FN I-GENE
in O
prostate O
cancer O
. O

We O
also O
observed O
that O
cell O
surface O
CD4 I-GENE
(-) RARE
CD8 I-GENE
(-) RARE
CD3 I-GENE
(-) RARE
cells O
with O
rearranged I-GENE
TCR I-GENE
genes I-GENE
developed O
from O
Id3 NUMERIC
- O
transduced RARE
but O
not O
from O
control O
- O
transduced RARE
pre O
- O
T O
cells O
in O
an O
FTOC ALLCAPS
. O

As O
determined O
in O
a O
modified O
yeast O
two O
- O
hybrid O
system O
, O
mIRS3 NUMERIC
bound O
strongly O
to O
the O
p85 I-GENE
subunit I-GENE
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

Insulin I-GENE
stimulation O
promoted O
the O
association O
of O
mIRS3 NUMERIC
with O
p85 I-GENE
, O
SHP2 NUMERIC
, O
Nck RARE
, O
and O
Shc I-GENE
. O

The O
mRNA O
expression O
of O
RFX1 NUMERIC
, O
RFX2 NUMERIC
, O
and O
RFX3 NUMERIC
was O
detected O
ubiquitously O
, O
but O
in O
transient O
- O
transfection O
assays O
, O
multimerized RARE
RFX ALLCAPS
binding I-GENE
sites I-GENE
in O
front O
of O
a O
basal O
promoter O
efficiently O
functioned O
in O
a O
tissue O
- O
and O
lineage O
- O
specific O
manner O
. O

In O
the O
case O
of O
the O
unspliceable RARE
intron O
, O
repression O
of O
luciferase I-GENE
expression O
likely O
involved O
two O
AUF1 NUMERIC
- I-GENE
binding I-GENE
sequences I-GENE
, O
since O
luciferase I-GENE
expression O
was O
increased O
by O
deletion O
of O
these O
sites O
. O

Thus O
, O
VDR I-GENE
acts O
selectively O
on O
the O
two O
components O
required O
for O
activation O
of O
this O
promoter O
/ O
enhancer O
: O
it O
competes RARE
with O
NFAT1 NUMERIC
for O
binding O
to O
the O
composite O
site O
, O
positioning O
itself O
adjacent O
to O
Jun I-GENE
- O
Fos I-GENE
on O
the O
DNA O
. O

Two O
evolutionarily O
conserved O
kinases O
, O
the O
cyclin I-GENE
B I-GENE
( O
Clb RARE
)/ O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
/ O
Cdc28p NUMERIC
) O
and O
Cdc7p NUMERIC
along O
with O
its O
interacting O
factor O
Dbf4p NUMERIC
, O
are O
required O
late O
in O
G1 O
to O
initiate O
DNA O
replication O
. O

The O
RanQ69L NUMERIC
preincubation RARE
leads O
to O
accumulation O
of O
CRM1 NUMERIC
at O
the O
cytoplasmic O
periphery RARE
of O
the O
nuclear O
pore O
complex O
( O
NPC ALLCAPS
) O
in O
association O
with O
the O
p62 I-GENE
complex I-GENE
and O
Can RARE
/ O
Nup214 NUMERIC
. O

All O
of O
the O
elements O
exhibited O
a O
uniform O
structure O
. O

In O
contrast O
, O
the O
deduced O
amino O
acid O
sequence O
of O
a O
second O
family O
( O
ART5 NUMERIC
) O
of O
transferases RARE
, O
cloned O
from O
murine O
lymphoma O
cells O
and O
expressed O
in O
high O
abundance O
in O
testis O
, O
displays O
a O
hydrophobic O
amino O
terminus O
, O
consistent O
with O
a O
signal O
sequence O
, O
but O
lacks O
a O
hydrophobic O
signal O
sequence O
at O
its O
carboxyl O
terminus O
, O
suggesting O
that O
the O
protein O
is O
destined RARE
for O
export O
. O

RESULTS O
: O
Each O
year O
, O
on O
average O
39 O
% O
of O
cases O
seen O
in O
Sardinia RARE
are O
notified RARE
; O
646 NUMERIC
( O
40 O
%) O
of O
the O
1591 NUMERIC
patients O
notified RARE
during O
the O
study O
period O
were O
never O
seen O
by O
regional O
medical O
centres RARE
. O

This O
dimer O
interface O
is O
likely O
important O
for O
increasing O
the O
DNA O
- O
binding O
specificity O
and O
affinity O
of O
the O
trimeric RARE
form O
of O
HSF I-GENE
, O
as O
well O
as O
for O
increasing O
cooperativity O
between O
adjacent O
trimers RARE
. O

The O
paramyxovirus RARE
fusion I-GENE
( I-GENE
F I-GENE
) I-GENE
protein I-GENE
mediates O
membrane O
fusion O
. O

Additionally O
, O
deletion O
analysis O
of O
the O
UCP2 NUMERIC
promoter O
- O
PLAP ALLCAPS
constructs O
indicated O
that O
the O
minimal O
region O
exhibiting O
the O
promoter O
activity O
was O
located O
between O
nt O
- O
33 O
and O
+ O
100 O
, O
and O
that O
a O
strong O
enhancer O
was O
present O
within O
601 NUMERIC
bp O
of O
the O
5 O
'- O
promoter O
region O
. O

The O
hTERT LASTCAP
gene I-GENE
encompasses RARE
more O
than O
37kb NUMERIC
and O
consists O
of O
16 O
exons O
. O

Both O
betaAPP LASTCAP
mRNA I-GENE
and O
Abeta RARE
levels O
are O
increased O
in O
trisomy RARE
21 O
. O

In O
reperfusion O
B O
, O
only O
the O
diabetic O
group O
demonstrated O
a O
significant O
increase O
in O
IL I-GENE
- I-GENE
8 I-GENE
concentrations O
at O
1 O
and O
15 O
min O
compared O
to O
nondiabetics RARE
. O

This O
repression O
was O
reversed O
agonists O
of O
either O
receptor O
demonstrating O
a O
functional O
interaction O
between O
NCoR LASTCAP
and O
PPARalpha I-GENE
. O
RXRalpha RARE
heterodimeric O
complexes O
in O
mammalian O
cells O
. O

In O
the O
present O
study O
, O
we O
show O
that O
SRm160 NUMERIC
/ I-GENE
300 I-GENE
is O
required O
for O
a O
purine RARE
- O
rich O
ESE ALLCAPS
to O
promote O
the O
splicing O
of O
a O
pre O
- O
mRNA O
derived O
from O
the O
Drosophila I-GENE
doublesex RARE
gene I-GENE
. O

Spc42p NUMERIC
also O
was O
identified O
as O
a O
component O
of O
a O
cytoplasmic O
SPB O
subcomplex RARE
containing O
Spc94p NUMERIC
/ O
Nud1p NUMERIC
, O
Cnm67p NUMERIC
, O
and O
Spc42p NUMERIC
. O

The O
average O
coefficients O
of O
correlation O
were O
0 O
. O
9998 NUMERIC
and O
0 O
. O
9993 NUMERIC
for O
the O
QMF ALLCAPS
and O
the O
QIT ALLCAPS
system O
, O
respectively O
. O

The O
5 O
- O
year O
OS ALLCAPS
for O
stage O
IIIB O
was O
30 O
. O
9 O
%, O
compared O
to O
7 O
. O
8 O
% O
for O
stage O
IV O
. O

Furthermore O
, O
heparin I-GENE
lyase I-GENE
treatment O
of O
extracts O
of O
cells O
expressing O
recombinant I-GENE
YD ALLCAPS
- I-GENE
repeat I-GENE
protein I-GENE
releases RARE
this O
protein O
from O
high O
molecular O
mass O
aggregates O
. O

The O
coefficient O
of O
determination O
, O
r2 NUMERIC
, O
of O
the O
other O
scores O
ranged O
from O
0 O
. O
56 O
to O
0 O
. O
61 O
. O

While O
determination O
of O
the O
protein O
content O
of O
the O
formulae RARE
gave O
no O
valid RARE
information O
, O
RAST O
/ O
EAST ALLCAPS
inhibition O
was O
highest O
for O
cow RARE
' O
s O
milk O
, O
followed O
by O
the O
partially O
hydrolysed RARE
whey RARE
formula O
, O
partially O
hydrolysed RARE
whey RARE
/ O
casein I-GENE
formula O
, O
soy RARE
/ I-GENE
pork RARE
collagen I-GENE
formula O
, O
and O
the O
amino O
acid O
formula O
. O

In O
light O
of O
the O
importance O
of O
GnRHR LASTCAP
, O
the O
molecular O
mechanisms O
underlying O
the O
transcriptional O
regulation O
of O
the O
human I-GENE
GnRHR LASTCAP
( O
hGnRHR LASTCAP
) O
gene O
become O
a O
key O
issue RARE
in O
understanding O
human O
reproduction RARE
. O

Competitive RARE
mobility O
shift O
assays O
using O
either O
alphaT3 NUMERIC
- O
1 O
nuclear O
extract O
or O
recombinant I-GENE
SF I-GENE
- I-GENE
1 I-GENE
protein I-GENE
clearly O
indicated O
that O
SF I-GENE
- I-GENE
1 I-GENE
is O
able O
to O
interact O
specifically O
with O
this O
GSE ALLCAPS
element I-GENE
positioned O
at O
- O
134 NUMERIC
. O

Grade RARE
3 O
mucositis RARE
was O
reported O
in O
1 O
patient O
. O

CDK4 NUMERIC
kinase I-GENE
activities O
were O
unaffected O
, O
as O
were O
the O
levels O
of O
the O
CDK I-GENE
inhibitor O
p21Cip1 NUMERIC
present O
in O
cyclin I-GENE
E I-GENE
immunocomplexes RARE
. O

The O
recombinant O
purified O
protein O
expressed O
in O
the O
baculovirus O
system O
had O
an O
approximate RARE
molecular O
size O
20 O
kDa O
with O
amino O
- O
terminal O
sequence O
of O
AVQGP ALLCAPS
. O

Induction O
of O
the O
urokinase I-GENE
promoter I-GENE
by O
HGF I-GENE
/ O
SF I-GENE
via O
the O
Met I-GENE
receptor I-GENE
was O
blocked O
by O
co O
- O
expression O
of O
a O
dominant O
- O
negative O
Grb2 I-GENE
and O
Sos1 NUMERIC
expression O
construct O
. O

Serine RARE
phosphorylation O
of O
STAT3 I-GENE
was O
only O
apparent O
after O
somatostatin I-GENE
treatment O
and O
was O
abolished O
by O
pertussis I-GENE
toxin I-GENE
or O
PD O
98059 NUMERIC
, O
together O
with O
the O
associated O
increases O
in O
proliferation O
. O

Nevertheless O
, O
we O
demonstrate O
that O
the O
entire O
three O
- O
component O
yeast O
capping O
apparatus O
, O
consisting O
of O
RNA I-GENE
5 I-GENE
'- I-GENE
triphosphatase RARE
( O
Cet1p NUMERIC
), O
RNA I-GENE
guanylyltransferase RARE
( O
Ceg1p NUMERIC
), O
and O
Abd1p NUMERIC
could O
be O
replaced O
in O
vivo O
by O
the O
two O
- O
component O
mammalian O
apparatus O
consisting O
of O
a O
bifunctional RARE
triphosphatase RARE
- I-GENE
guanylyltransferase RARE
Mce1p NUMERIC
and O
the O
methyltransferase I-GENE
Hcm1 NUMERIC
( I-GENE
121 I-GENE
- I-GENE
476 NUMERIC
) I-GENE
p I-GENE
. O

The O
IC50 NUMERIC
values O
for O
rat O
and O
dog O
urinary O
bladder O
were O
3 O
. O
9 O
x O
10 O
(- O
6 O
) O
M O
and O
3 O
. O
8 O
x O
10 O
(- O
6 O
) O
M O
, O
respectively O
. O

Although O
it O
has O
two O
potential O
binding O
sites O
, O
the O
purified O
MerR LASTCAP
homodimer I-GENE
binds O
only O
one O
Hg O
( O
II O
) O
ion O
, O
employing O
Cys82 NUMERIC
from O
one O
monomer RARE
and O
Cys117 NUMERIC
and O
Cys126 NUMERIC
from O
the O
other O
. O

The O
influence O
of O
Epstein O
- O
Barr O
virus O
seropositivity RARE
on O
the O
efficacy O
of O
intravenous O
immune I-GENE
globulin I-GENE
in O
children O
with O
immune O
thrombocytopenic RARE
purpura O
. O

The O
results O
of O
the O
lab RARE
and O
field O
tests O
yielded O
high O
levels O
of O
infestation RARE
in O
larvae O
with O
values O
ranging O
from O
90 O
to O
100 O
% O
and O
from O
85 O
to O
95 O
%, O
respectively O
. O

Amisulpride RARE
400 O
mg O
had O
several O
adverse O
effects O
on O
psychomotor RARE
and O
, O
although O
less O
severe O
, O
on O
cognitive O
performance O
on O
the O
fifth RARE
day O
only O
. O

MutY LASTCAP
is O
an O
adenine I-GENE
- I-GENE
DNA I-GENE
glycosylase I-GENE
with O
specificity O
for O
mismatches RARE
involving O
8 O
- O
oxoguanine RARE
( O
oG LASTCAP
. O
A O
) O
or O
guanine O
( O
G O
. O
A O
). O

The O
kinetics O
of O
kinase O
activity O
within O
these O
complexes O
compared O
to O
CheA LASTCAP
alone O
indicate O
approximately O
a O
50 O
% O
decrease O
in O
the O
KM ALLCAPS
for O
ATP O
and O
a O
100 O
- O
fold O
increase O
in O
the O
Vmax O
. O

Latexin RARE
, O
a O
carboxypeptidase RARE
A I-GENE
inhibitor O
, O
is O
expressed O
in O
a O
cell O
type O
- O
specific O
manner O
in O
both O
central O
and O
peripheral O
nervous O
systems O
in O
the O
rat O
. O

Regression RARE
analyses O
identified O
7 O
risk O
and O
7 O
protective O
factors O
with O
minimal O
overlap O
. O

During O
1985 O
, O
1990 O
, O
and O
1995 O
, O
respectively O
, O
11 O
. O
7 O
, O
11 O
. O
3 O
, O
and O
11 O
. O
4 O
infants O
per O
100 O
, O
000 O
live O
births O
had O
a O
diagnosis O
of O
HSV O
( O
P O
=. O
98 O
). O

Subsets RARE
of O
patients O
were O
performed O
according O
to O
the O
severity O
of O
trauma O
( O
ISS ALLCAPS
< O
9 O
; O
9 O
- O
17 O
; O
18 O
- O
31 O
; O
> O
32 O
), O
based O
on O
the O
different O
injury O
pattern O
, O
and O
survivors RARE
versus O
nonsurvivors RARE
as O
well O
. O

The O
median O
age O
was O
33 O
years O
( O
range O
17 O
- O
56 O
years O
). O

Developmental RARE
follow O
- O
up O
at O
age O
2 O
years O
was O
performed O
. O

In O
the O
whole O
group O
of O
infected O
children O
, O
an O
age O
- O
specific O
z O
score O
< O
- O
2 O
for O
weight O
and O
for O
FFM ALLCAPS
was O
significantly O
associated O
with O
an O
increased O
risk O
of O
death O
[ O
relative O
risk O
( O
95 O
% O
CI O
) O
= O
11 O
. O
4 O
( O
3 O
. O
1 O
, O
41 O
. O
0 O
) O
and O
5 O
. O
1 O
( O
1 O
. O
5 O
, O
18 O
. O
2 O
), O
respectively O
]; RARE
when O
only O
children O
with O
more O
severe O
disease O
were O
considered O
, O
only O
z O
score O
for O
weight O
was O
significantly O
associated O
with O
an O
increased O
risk O
[ O
4 O
. O
6 O
( O
1 O
. O
4 O
, O
14 O
. O
9 O
)]. O

In O
addition O
, O
these O
cells O
contained O
one O
, O
two O
, O
or O
multiple O
nuclei O
indicative O
of O
a O
G2 O
/ O
M O
delay O
in O
nuclear O
division O
and O
also O
a O
defect O
in O
cytokinesis RARE
and O
/ O
or O
cell O
separation O
. O

DAF16 NUMERIC
is O
known O
to O
be O
a O
component O
of O
a O
signaling O
pathway O
that O
has O
been O
partially O
dissected RARE
genetically O
and O
includes O
homologues O
of O
the O
insulin I-GENE
/ O
IGF I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
, O
PtdIns RARE
3 I-GENE
- I-GENE
kinase I-GENE
and O
PKB I-GENE
. O

However O
, O
neu I-GENE
differentiation O
factor O
- O
induced O
heterodimers O
of O
ErbB2 NUMERIC
and O
ErbB4 NUMERIC
activated O
Stat5 I-GENE
. O

Although O
linker O
regions O
in O
transcription O
factors O
are O
known O
to O
modulate O
DNA O
binding O
specificity O
, O
our O
studies O
suggest O
that O
the O
human I-GENE
HSF1 I-GENE
linker O
plays O
no O
role O
in O
determining O
HSF1 I-GENE
binding O
preferences RARE
in O
vivo O
but O
is O
a O
critical O
determinant O
in O
regulating O
the O
HSF1 I-GENE
monomer RARE
- I-GENE
trimer RARE
equilibrium O
. O

Modulation RARE
of O
human I-GENE
heat I-GENE
shock I-GENE
factor I-GENE
trimerization RARE
by O
the O
linker O
domain O
. O

Both O
functional O
analyses O
in O
undifferentiated O
and O
differentiated O
F9 O
cells O
and O
characterization O
of O
DNA O
- O
protein O
complexes O
in O
vitro O
have O
identified O
the O
sequence O
motifs O
GTGACT ALLCAPS
( O
C O
), O
ATTGT ALLCAPS
, O
and O
GATA O
as O
the O
key O
transcription O
factor O
binding O
sites O
. O

These O
results O
suggest O
that O
the O
phenotype O
of O
XLP ALLCAPS
may O
result O
from O
perturbed RARE
signaling O
not O
only O
through O
SLAM ALLCAPS
, O
but O
also O
other O
cell O
surface O
molecules O
that O
utilize RARE
SAP ALLCAPS
as O
a O
signaling O
adaptor O
protein O
. O

We O
also O
localized O
the O
Fra RARE
- I-GENE
2 I-GENE
phosphorylation I-GENE
sites I-GENE
by O
MAPK I-GENE
to O
three O
threonine O
and O
three O
serine O
residues O
in O
the O
COOH O
- O
terminal O
region O
by O
means O
of O
site O
- O
directed O
mutagenesis O
and O
showed O
that O
the O
threonine O
residues O
were O
more O
susceptible O
to O
MAPK I-GENE
. O

Nevertheless O
, O
they O
are O
functionally O
distinct O
in O
that O
FcalphaRI LASTCAP
binds O
human I-GENE
IgA I-GENE
( O
hIgA LASTCAP
) O
but O
not O
bovine I-GENE
IgG2 NUMERIC
( O
bIgG2 NUMERIC
), O
whereas O
bFcgamma2R NUMERIC
binds O
bIgG2 NUMERIC
but O
not O
hIgA LASTCAP
. O

Vac1p NUMERIC
was O
found O
to O
bind O
the O
Sec1p NUMERIC
homologue I-GENE
Vps45p NUMERIC
. O

In O
a O
heterologous O
transcriptional O
system O
in O
which O
the O
upstream O
regions O
of O
oIFNtau RARE
were O
inserted O
in O
front O
of O
simian I-GENE
virus I-GENE
40 I-GENE
( I-GENE
SV40 I-GENE
) I-GENE
promoter I-GENE
, O
the O
regions O
between O
bases O
- O
654 NUMERIC
and O
- O
555 NUMERIC
were O
determined O
as O
being O
the O
enhancer O
region O
required O
for O
oIFNtau RARE
- O
SV40 O
- O
CAT I-GENE
transactivation O
. O

In O
co O
- O
transfection O
studies O
, O
the O
expression O
of O
c I-GENE
- I-GENE
Jun I-GENE
plus O
c I-GENE
- I-GENE
Fos I-GENE
enhanced O
the O
transactivation O
of O
oIFNtau RARE
- O
CAT I-GENE
but O
the O
expression O
of O
GATA I-GENE
- I-GENE
1 I-GENE
, O
GATA I-GENE
- I-GENE
2 I-GENE
or O
GATA I-GENE
- I-GENE
3 I-GENE
did O
not O
. O

To O
identify O
these O
sites O
, O
Cdk2 I-GENE
- O
phosphorylated O
MARCKS ALLCAPS
was O
digested RARE
with O
lysyl RARE
endoprotease RARE
and O
analysed O
by O
electrospray RARE
MS O
. O

The O
yeast I-GENE
LPD1 NUMERIC
gene I-GENE
encoding O
lipoamide RARE
dehydrogenase I-GENE
is O
subject O
to O
the O
general O
control O
of O
amino O
acid O
biosynthesis O
mediated O
by O
the O
GCN4 I-GENE
transcription I-GENE
factor I-GENE
. O

The O
relatively O
mild O
defects O
observed O
in O
Rpd3 NUMERIC
mutants I-GENE
suggest O
that O
the O
recently O
identified O
Groucho RARE
and O
dCtBP LASTCAP
corepressor RARE
proteins I-GENE
do O
not O
function O
solely O
through O
the O
recruitment O
of O
histone I-GENE
deacetylases RARE
. O

However O
, O
the O
serum I-GENE
TNF I-GENE
- I-GENE
a I-GENE
concentration O
decreased O
significantly O
in O
patients O
receiving O
pentoxifylline RARE
( O
basal O
623 NUMERIC
+/- O
366 NUMERIC
pg O
/ O
ml O
; O
6th NUMERIC
month O
562 NUMERIC
+/- O
358 NUMERIC
pg O
/ O
ml O
, O
p O
< O
0 O
. O
01 O
), O
but O
not O
in O
the O
control O
group O
. O

In O
addition O
, O
we O
show O
that O
the O
expression O
of O
individual O
members O
of O
one O
subfamily O
of O
KRAB I-GENE
zinc I-GENE
finger I-GENE
genes I-GENE
is O
restricted O
to O
specific O
hematopoietic O
cell O
lineages O
. O

Employing RARE
fluorescence O
spectroscopy O
and O
circular O
dichroism RARE
, O
we O
showed O
that O
the O
binding O
of O
Ca2 O
+ O
to O
ALG ALLCAPS
- I-GENE
2 I-GENE
induced O
significant O
conformational O
changes O
in O
both O
the O
N O
- O
terminal O
and O
C O
- O
terminal O
domains O
of O
the O
protein O
. O

They O
also O
occur O
in O
similar O
locations O
in O
the O
promoters O
of O
several O
other O
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

Both O
carbachol O
( O
100 O
microM O
) O
and O
EGF I-GENE
( O
10 O
nM O
) O
induced O
Ras I-GENE
activation O
. O

Dominant RARE
negative O
Sos I-GENE
did O
not O
affect O
carbachol O
stimulation O
of O
HA I-GENE
- O
ERK2 I-GENE
but O
inhibited O
the O
stimulatory O
effect O
of O
EGF I-GENE
by O
60 O
%. O

RESULTS O
: O
Transpulmonary RARE
passage O
of O
contrast O
occurred O
in O
sufficient O
amounts O
to O
enhance O
the O
intensity O
of O
the O
Doppler O
signal O
significantly O
, O
but O
the O
duration O
of O
this O
effect O
was O
short O
. O

In O
this O
paper O
, O
such O
lesions O
in O
two O
cases O
were O
evaluated O
by O
ultrasonography O
. O

These O
regions O
contain O
inverted O
E O
- O
box O
palindromic O
or O
direct O
repeat O
motifs O
and O
bind O
SREBP I-GENE
- I-GENE
1 I-GENE
with O
different O
affinities O
. O

To O
address O
these O
questions O
, O
a O
recombinant O
FRAP ALLCAPS
/ O
mTOR LASTCAP
protein O
and O
a O
FRAP ALLCAPS
/ O
mTOR LASTCAP
immunoprecipitate RARE
were O
utilized O
in O
in O
vitro O
kinase O
assays O
to O
phosphorylate O
4E NUMERIC
- I-GENE
BP1 NUMERIC
. O

Hrs RARE
has O
a O
FYVE ALLCAPS
double O
zinc O
finger O
domain O
, O
which O
specifically O
binds O
phosphatidylinositol O
( O
3 O
)- O
phosphate O
and O
is O
conserved O
in O
several O
proteins O
involved O
in O
vesicular O
traffic RARE
. O

The O
coexpression O
of O
full O
- O
length O
expression O
constructs O
for O
both O
DBP I-GENE
and O
hepatic I-GENE
leukemia I-GENE
factor I-GENE
resulted O
in O
a O
dramatic O
increase O
in O
activation O
mediated O
by O
the O
GAL4 I-GENE
- O
DBP I-GENE
fusion O
proteins O
, O
suggesting O
the O
involvement O
of O
a O
regulated O
coactivator O
in O
this O
process O
. O

Three O
subgenomes RARE
also O
comprised O
15 O
to O
75 O
nucleotides O
derived O
from O
the O
5 O
' O
part O
of O
the O
NS2 NUMERIC
gene I-GENE
. O

Cp I-GENE
is O
normally O
the O
main O
promoter O
for O
EBNA I-GENE
mRNA I-GENE
initiation O
, O
so O
it O
appears O
that O
EBNA3C NUMERIC
contributes O
to O
a O
negative O
autoregulatory RARE
control O
loop O
. O

These O
indications RARE
of O
deregulated RARE
signalling O
in O
the O
absence O
of O
tyrosine O
118 O
were O
substantiated RARE
by O
sustained O
activation O
of O
STAT3 I-GENE
. O

With O
exon O
trapping RARE
, O
we O
could O
isolate O
five O
potential O
exons O
from O
the O
YAC O
946E12 NUMERIC
that O
spans O
the O
region O
, O
four O
of O
which O
could O
be O
placed O
in O
the O
contig O
in O
the O
vicinity O
of O
the O
breakpoints O
. O

Campomelic RARE
dysplasia O
translocation O
breakpoints O
are O
scattered RARE
over O
1 O
Mb O
proximal O
to O
SOX9 NUMERIC
: O
evidence O
for O
an O
extended O
control O
region O
. O

The O
most O
common O
characteristics O
of O
VRE ALLCAPS
patients O
were O
recent O
prior O
vancomycin O
use O
, O
recent O
prior O
susceptible O
enterococcal RARE
infection O
, O
coinfection RARE
with O
other O
microbial O
pathogens O
, O
and O
concurrent O
fungal O
infection O
. O

A O
coiled O
- O
coil O
domain O
, O
conserved O
within O
each O
encoded O
protein O
, O
serves O
as O
a O
potential O
interaction O
motif O
for O
FLI I-GENE
LRR ALLCAPS
. O

Binding O
affinities O
of O
these O
recombinant O
phages RARE
as O
determined O
by O
the O
retention O
of O
these O
phages RARE
by O
a O
His O
- O
tag O
immobilized RARE
gp17 NUMERIC
column O
, O
and O
by O
co O
- O
immunoprecipitation O
with O
purified O
terminase I-GENE
supported O
the O
specific O
nature O
of O
the O
portal I-GENE
protein I-GENE
and O
terminase I-GENE
interaction I-GENE
sites I-GENE
. O

Although O
the O
terminase I-GENE
apparently O
interacts O
with O
this O
gp20 NUMERIC
portal I-GENE
peptide I-GENE
, O
polyclonal RARE
antibody O
against O
the O
portal O
peptide O
appears O
unable O
to O
access O
it O
in O
the O
native O
structure O
, O
suggesting O
intimate RARE
association O
of O
gp20 NUMERIC
and O
gp17 NUMERIC
possibly O
internalizes RARE
terminase I-GENE
regions I-GENE
within O
the O
portal O
in O
the O
packasome RARE
complex O
. O

The O
hybrid O
viruses O
were O
found O
to O
accumulate O
to O
high O
levels O
in O
infected O
plants O
, O
to O
form O
stable O
virions O
, O
and O
to O
be O
mechanically RARE
transmissible RARE
. O

cDNA O
and O
structural O
organization O
of O
the O
gene I-GENE
Pole1 NUMERIC
for O
the O
mouse I-GENE
DNA I-GENE
polymerase I-GENE
epsilon I-GENE
catalytic I-GENE
subunit I-GENE
. O

Nevertheless O
cryopreservation RARE
of O
spermatozoa O
in O
a O
medium O
containing O
neither O
SP O
nor O
biological O
substances O
could O
offer O
an O
acceptable O
cryoprotection RARE
of O
spermatozoa O
to O
be O
used O
in O
assisted RARE
fertilization O
procedures O
, O
especially O
for O
intracytoplasmic RARE
sperm O
injection O
. O

A O
liquid O
chromatographic O
method O
is O
described O
for O
analysis O
of O
beta O
- O
carotene RARE
in O
medical O
food O
. O

The O
FCMS ALLCAPS
conditions O
were O
as O
follows O
: O
2 O
kW LASTCAP
maximum O
electrical O
power O
consumption O
, O
800 O
V O
maximum O
capacitor RARE
voltage O
, O
720 NUMERIC
microseconds RARE
pulsewidth RARE
( O
180 O
microseconds RARE
rise O
time O
), O
and O
5 O
- O
30 O
Hz O
frequency O
. O

Severe RARE
hemolysis RARE
resulted O
in O
statistically O
significant O
changes O
in O
the O
mean O
values O
of O
the O
above O
analytes RARE
in O
addition O
to O
the O
following O
increases O
: O
alanine I-GENE
aminotransferase I-GENE
, O
calcium O
, O
and O
serum I-GENE
globulins RARE
( O
P O
< O
0 O
. O
001 O
) O
and O
albumin I-GENE
and O
total O
protein O
( O
P O
< O
0 O
. O
01 O
). O

EMSA O
with O
crude O
nuclear O
extracts O
demonstrated O
that O
stimulation O
with O
CD40L NUMERIC
results O
in O
the O
induction O
of O
NF I-GENE
- I-GENE
kappaB I-GENE
complexes I-GENE
that O
bind O
to O
each O
of O
the O
three O
NF I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
and O
are O
composed O
mainly O
of O
p50 I-GENE
and O
RelB LASTCAP
, O
but O
also O
include O
c I-GENE
- I-GENE
Rel I-GENE
and O
p65 I-GENE
. O

Optimal RARE
monitoring O
of O
ODA ALLCAPS
remains O
undefined RARE
. O

The O
major O
transcription O
factors O
controlling O
arginine O
metabolism O
in O
Escherichia O
coli O
and O
Bacillus O
subtilis O
, O
ArgR LASTCAP
and O
AhrC LASTCAP
, O
respectively O
, O
are O
homologous O
multimeric RARE
proteins O
that O
form O
l O
- O
arginine O
- O
dependent O
DNA O
- O
binding O
complexes O
capable O
of O
repressing O
transcription O
of O
the O
biosynthetic O
genes O
( O
both O
), O
activating O
transcription O
of O
catabolic RARE
genes O
( O
AhrC LASTCAP
only O
) O
or O
facilitating O
plasmid O
dimer O
resolution O
( O
both O
). O

The O
studied O
protein O
fragments O
consist O
of O
residues O
Arg183 NUMERIC
- O
His267 NUMERIC
of O
the O
human I-GENE
ER I-GENE
and O
residues O
Lys438 NUMERIC
- O
Gln520 NUMERIC
of O
the O
rat O
GR I-GENE
. O

The O
exon O
: O
intron O
structure O
of O
chicken I-GENE
IL8 NUMERIC
corresponds O
almost O
exactly RARE
to O
that O
of O
human I-GENE
IL8 NUMERIC
and O
differs O
from O
those O
of O
other O
known O
mammalian I-GENE
CXC ALLCAPS
chemokine I-GENE
genes I-GENE
. O

The O
Aa RARE
- I-GENE
Pri2 NUMERIC
gene I-GENE
, O
specifically O
expressed O
during O
basidiocarp RARE
differentiation O
of O
the O
mushroom RARE
Agrocybe RARE
aegerita RARE
, O
was O
cloned O
. O

The O
main O
causes O
of O
liver O
disease O
in O
the O
patients O
with O
HCC ALLCAPS
were O
hepatitis O
C O
virus O
( O
HCV O
) O
( O
77 O
%), O
alcohol O
abuse RARE
( O
73 O
%), O
and O
the O
combination O
of O
HCV O
and O
alcohol O
abuse RARE
( O
50 O
%). O

Three O
new O
aromatase I-GENE
inhibitors O
have O
recently O
completed O
phase O
III O
evaluation O
as O
treatment O
of O
metastatic O
breast O
cancer O
in O
post O
- O
menopausal O
women O
whose O
disease O
has O
progressed O
despite O
tamoxifen RARE
therapy O
: O
anastrozole RARE
( O
ARIMIDEX ALLCAPS
, O
Zeneca RARE
), O
letrozole RARE
( O
FEMARA ALLCAPS
, O
Novartis RARE
) O
and O
vorozole RARE
( O
RIVIZOR ALLCAPS
, O
Janssen RARE
). O

CONCLUSIONS O
: O
Turbutest RARE
is O
a O
valuable O
tool O
in O
asthmatic O
patients O
' O
training O
, O
allowing O
identification O
and O
improvement O
of O
an O
inadequate RARE
inhalation O
technique O
with O
Turbuhaler RARE
. O

Of O
those O
injuries O
, O
143 O
cases O
were O
snowboard RARE
related O
and O
158 NUMERIC
cases O
were O
ski RARE
related O
. O

The O
femoral O
artery O
/ O
vein O
and O
the O
soleus RARE
and O
gastrocnemius RARE
muscles O
were O
examined O
in O
healthy O
human O
male O
volunteers O
. O

SRFDelta5 NUMERIC
acts O
as O
a O
naturally O
occurring O
dominant O
negative O
regulatory O
mutant O
that O
blocks O
SRF I-GENE
- O
dependent O
skeletal I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
cardiac I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
smooth I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
SM22alpha NUMERIC
, O
and O
SRF I-GENE
promoter O
- O
luciferase I-GENE
reporter O
activities O
. O

In O
serum O
- O
free O
media O
, O
p50E4F NUMERIC
accelerated O
E1A I-GENE
- O
induced O
apoptosis O
. O

The O
potency O
of O
the O
effect O
of O
Nim RARE
( O
0 O
. O
5 O
mg O
. O
kg O
- O
1 O
i O
. O
p O
.) O
was O
similar O
to O
that O
of O
NBP ALLCAPS
( O
10 O
mg O
. O
kg O
- O
1 O
i O
. O
p O
.). O

CONCLUSION O
: O
NBP ALLCAPS
pre O
- O
treatment O
or O
post O
- O
treatment O
markedly O
enhanced O
the O
rCBF O
to O
striatum O
in O
RMCAO ALLCAPS
rats O
. O

Progression RARE
after O
first O
- O
line O
chemotherapy O
was O
associated O
with O
significantly O
worse RARE
survival O
for O
patients O
with O
metastasis O
. O

Mutations O
within O
human O
UTR1 NUMERIC
modulate O
NRF ALLCAPS
- I-GENE
1 I-GENE
expression O
by O
interfering O
with O
mRNA O
translational O
efficiency O
in O
transfected O
cells O
and O
in O
an O
in O
vitro O
translation O
system O
. O

As O
is O
deduced O
from O
the O
nucleotide O
sequence O
of O
the O
cDNA O
, O
CBS ALLCAPS
- I-GENE
1 I-GENE
contains O
an O
open O
reading O
frame O
consisting O
of O
182 O
amino O
acids O
, O
with O
a O
molecular O
weight O
of O
19 O
. O
5kDa NUMERIC
. O

Corticostriatal RARE
and O
corticosubthalamic RARE
input O
zones RARE
from O
the O
presupplementary RARE
motor O
area O
in O
the O
macaque RARE
monkey O
: O
comparison O
with O
the O
input O
zones RARE
from O
the O
supplementary O
motor O
area O
. O

Basic RARE
fibroblast I-GENE
growth I-GENE
factor I-GENE
( O
bFGF LASTCAP
) O
has O
been O
shown O
to O
induce O
angiogenesis O
in O
various O
animal O
models O
, O
but O
the O
methods O
of O
administration O
used O
experimentally O
are O
not O
clinically O
feasible RARE
. O

Both O
filters RARE
equally O
contributed O
to O
elevation O
of O
iliac O
venous O
pressure O
( O
median O
, O
9 O
. O
3 O
and O
7 O
. O
2 O
mm O
Hg O
[ O
n O
= O
9 O
] O
with O
the O
spring RARE
filter O
and O
RF02 NUMERIC
filter O
, O
respectively O
). O

12 O
healthy O
women O
( O
age O
18 O
- O
38 O
years O
) O
were O
examined O
using O
the O
2 O
- O
hour O
' O
s O
method O
of O
passive O
leg O
rising RARE
( O
PLR ALLCAPS
) O
in O
follicular O
( O
FP ALLCAPS
) O
and O
luteal O
( O
LP ALLCAPS
) O
phases O
of O
normal O
ovulatory RARE
cycle O
. O

Thus O
, O
sgRNA2 NUMERIC
has O
the O
3 O
' O
TE ALLCAPS
in O
its O
5 O
' O
UTR O
. O

These O
single O
mutational O
defects O
in O
the O
eRF1 NUMERIC
- O
eRF3 NUMERIC
interaction O
became O
evident O
when O
either O
truncated O
protein O
eRF3C NUMERIC
or O
C O
- O
terminally O
altered O
eRF1 NUMERIC
proteins O
were O
used O
for O
the O
authentic RARE
protein O
, O
providing O
further O
support O
for O
the O
presence O
of O
a O
C O
- O
terminal O
interaction O
. O

Removal O
of O
each O
of O
three O
contiguous O
segments O
from O
the O
N O
- O
terminal O
half O
specifically O
inhibits O
the O
formation O
of O
5 I-GENE
. I-GENE
8Ss NUMERIC
rRNA I-GENE
, O
whereas O
deleting RARE
part O
of O
the O
C O
- O
terminal O
region O
of O
the O
protein O
only O
blocks O
the O
production O
of O
18S NUMERIC
rRNA I-GENE
. O

Ras I-GENE
is O
not O
associated O
with O
the O
tegument RARE
. O

Green RARE
fluorescent O
protein O
- O
tagged O
UNC I-GENE
- I-GENE
49B NUMERIC
and O
UNC I-GENE
- I-GENE
49C NUMERIC
subunits I-GENE
are O
coexpressed O
in O
muscle O
cells O
and O
are O
colocalized RARE
to O
synaptic O
regions O
. O

We O
show O
that O
a O
protein O
, O
UBC9 NUMERIC
, O
interacts O
specifically O
with O
TEL ALLCAPS
in O
vitro O
and O
in O
vivo O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
spontaneous O
reports O
of O
suspected O
adverse O
drug O
reactions O
, O
observed O
in O
elderly O
patients O
( O
over O
65 O
years O
of O
age O
) O
in O
Sicily RARE
( O
Italy RARE
) O
during O
the O
period O
from O
1 O
January O
1995 O
to O
31 O
December RARE
1997 O
. O

Molecules RARE
of O
NH3 NUMERIC
are O
capable O
of O
emitting RARE
stimulated O
radiation O
( O
MASER ALLCAPS
). O

The O
major O
findings O
of O
our O
studies O
are O
as O
follows O
: O
1 O
) O
There O
are O
no O
detectable O
signals O
around O
GDF ALLCAPS
- I-GENE
9 I-GENE
- O
deficient O
follicles RARE
for O
several O
theca RARE
cell O
layer O
markers O
[ O
i O
. O
e O
. O

Interestingly O
, O
highly O
charged O
residues O
were O
abundantly O
possessed O
in O
the O
carboxy O
- O
terminal O
part O
of O
the O
MDV2 NUMERIC
UL10 NUMERIC
protein I-GENE
. O

Identification O
and O
structure O
of O
the O
Marek RARE
' I-GENE
s I-GENE
disease I-GENE
virus I-GENE
serotype I-GENE
2 I-GENE
glycoprotein I-GENE
M I-GENE
gene I-GENE
: O
comparison O
with O
glycoprotein I-GENE
M I-GENE
genes I-GENE
of O
Herpesviridae RARE
family O
. O

OBJECTIVE O
: O
To O
perform O
a O
cost O
- O
effectiveness O
analysis O
( O
CEA O
) O
between O
a O
standard O
antiemetic RARE
regimen O
- O
chlorpromazine RARE
+ O
dexamethasone O
( O
CPM ALLCAPS
- O
DEX ALLCAPS
)- O
and O
a O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonist O
- O
tropisetron RARE
( O
TROP ALLCAPS
)-- RARE
in O
the O
control O
of O
acute O
emesis RARE
induced O
by O
highly O
emetogenic RARE
chemotherapy O
in O
children O
, O
considering RARE
two O
analytic RARE
perspectives RARE
: O
hospital O
and O
patients O
. O

Baseline RARE
data O
were O
obtained O
from O
10 O
adults O
. O

A O
comparison O
of O
the O
nucleotide O
and O
deduced O
amino O
acid O
sequences O
of O
the O
core O
regions O
of O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
polymerase I-GENE
domains I-GENE
found O
in O
these O
three O
dsRNAs RARE
suggested O
that O
these O
dsRNAs RARE
probably O
evolved O
independently O
within O
each O
host O
plant O
from O
a O
common O
ancestor O
. O

Consistent O
with O
this O
possibility O
, O
a O
non O
- O
MBD ALLCAPS
region O
of O
Bin1 NUMERIC
was O
sufficient O
to O
recruit O
a O
repression O
function O
to O
DNA O
that O
was O
unrelated O
to O
histone I-GENE
deacetylase RARE
. O

Forty O
- O
eight O
sequences O
, O
30 O
not O
previously O
identified O
as O
IR O
- O
responsive O
, O
were O
significantly O
regulated O
by O
IR O
. O

A O
recently O
described O
protein O
, O
metaxin RARE
1 I-GENE
, O
serves O
as O
a O
component O
of O
a O
preprotein RARE
import O
complex O
in O
the O
outer O
membrane O
of O
the O
mammalian O
mitochondrion RARE
. O

Molecular O
cloning O
of O
rat I-GENE
SH2 I-GENE
- I-GENE
containing I-GENE
inositol I-GENE
phosphatase I-GENE
2 I-GENE
( O
SHIP2 NUMERIC
) O
and O
its O
role O
in O
the O
regulation O
of O
insulin I-GENE
signaling O
. O

Slp1 NUMERIC
represses O
transcription O
via O
this O
binding O
site O
in O
yeast O
cells O
, O
consistent O
with O
its O
role O
as O
a O
direct O
repressor O
of O
ftz RARE
stripes RARE
in O
interstripe RARE
regions O
during O
late O
stages O
of O
embryogenesis O
. O

The O
results O
of O
these O
studies O
support O
a O
model O
in O
which O
VirB4 NUMERIC
dimers I-GENE
or O
homomultimers RARE
contribute O
structural O
information O
for O
the O
assembly O
of O
a O
transenvelope RARE
channel O
competent O
for O
bidirectional RARE
DNA O
transfer O
, O
whereas O
an O
ATP O
- O
dependent O
activity O
is O
required O
for O
configuring RARE
this O
channel O
as O
a O
dedicated RARE
export O
machine O
. O

The O
penicillin I-GENE
binding I-GENE
proteins I-GENE
( O
PBPs RARE
) O
synthesize RARE
and O
remodel RARE
peptidoglycan RARE
, O
the O
structural O
component O
of O
the O
bacterial O
cell O
wall O
. O

TCR I-GENE
alpha I-GENE
( O
TCRA ALLCAPS
) O
expression O
was O
examined O
in O
RNA O
samples O
from O
PBMC ALLCAPS
and O
isolated O
populations O
of O
CD4 O
+, O
CD8 O
+, O
and O
DN ALLCAPS
T O
cells O
from O
15 O
healthy O
individuals O
. O

Similar O
results O
were O
obtained O
with O
xylitol RARE
, O
an O
activator O
of O
the O
pentose RARE
phosphate O
pathway O
. O

The O
high I-GENE
density I-GENE
lipoprotein I-GENE
( I-GENE
HDL I-GENE
) I-GENE
receptor I-GENE
mediates O
the O
uptake O
of O
cholesterol O
and O
cholesteryl RARE
esters O
, O
substrates O
for O
steroidogenesis RARE
, O
from O
an O
HDL I-GENE
particle O
in O
the O
adrenal O
gland O
and O
gonads RARE
. O

D3S1261 NUMERIC
is O
physically O
located O
at O
or O
near O
the O
MITF ALLCAPS
locus I-GENE
, O
while O
D3S2465 NUMERIC
and O
D3S1766 NUMERIC
are O
flanking O
the O
locus O
at O
about O
17 O
. O
5 O
cM LASTCAP
genetic O
distance O
each O
side O
. O

The O
percentages RARE
of O
recovery O
decreased O
with O
storage O
time O
, O
although O
the O
addition O
of O
dispersant RARE
( O
Tris RARE
- O
Tween RARE
80 O
) O
before O
storage O
appeared O
to O
partially O
prevent O
adhesion O
. O

Point RARE
mutations O
of O
the O
site O
that O
suppressed O
Pit I-GENE
- I-GENE
1 I-GENE
binding O
in O
vitro O
restored O
full O
tiGH LASTCAP
promoter I-GENE
activity O
. O

A O
human I-GENE
Raf I-GENE
- I-GENE
responsive I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
that O
binds O
to O
divergent O
sequences O
. O

We O
are O
reporting RARE
an O
autopsy O
case O
of O
so O
- O
called O
" O
acute O
multiple O
sclerosis O
" O
that O
was O
difficult O
to O
differentiate O
from O
a O
brain O
tumor O
on O
MRI O
findings O
. O

Furthermore O
, O
MOM ALLCAPS
- I-GENE
4 I-GENE
and O
TAK1 NUMERIC
bind O
related O
proteins O
that O
promote O
their O
kinase O
activities O
. O

BACKGROUND O
: O
The O
MAZE ALLCAPS
- O
III O
is O
the O
surgical O
treatment O
of O
choice O
for O
medically RARE
refractory O
atrial O
fibrillation O
. O

Gab2 NUMERIC
, O
a O
new O
pleckstrin I-GENE
homology O
domain O
- O
containing O
adapter O
protein O
, O
acts O
to O
uncouple RARE
signaling O
from O
ERK I-GENE
kinase I-GENE
to O
Elk I-GENE
- I-GENE
1 I-GENE
. O

The O
presence O
of O
cutaneous O
xanthomas RARE
with O
normal O
serum O
lipid O
levels O
is O
due O
to O
the O
antibetalipoproteic RARE
activity O
of O
the O
monoclonal I-GENE
immunoglobulin I-GENE
. O

In O
an O
attempt O
to O
reduce O
the O
incidence O
of O
NSAID O
- O
induced O
gastrointestinal O
lesions O
, O
the O
following O
approaches O
have O
been O
proposed O
: O
( O
i O
) O
use O
of O
the O
prostaglandin O
analogue O
misoprostol RARE
, O
which O
is O
an O
antiulcer RARE
drug O
which O
has O
been O
proven O
to O
be O
as O
effective O
in O
the O
prevention O
of O
NSAID O
- O
induced O
gastric O
and O
duodenal O
ulcers O
as O
in O
the O
reduction O
of O
serious O
upper O
gastrointestinal O
complications O
; O
( O
ii O
) O
histamine I-GENE
H2 I-GENE
receptor I-GENE
antagonists O
( O
H2 O
antagonists O
), O
e O
. O
g O
. O
ranitidine O
, O
cimetidine O
and O
famotidine RARE
, O
which O
are O
useful O
in O
the O
prevention O
of O
NSAID O
- O
induced O
duodenal O
ulcers O
during O
long O
term O
treatment O
, O
but O
not O
in O
the O
prevention O
of O
NSAID O
- O
induced O
gastric O
ulcers O
; O
( O
iii O
) O
proton O
pump O
inhibitors O
, O
e O
. O
g O
omeprazole O
, O
and O
pantoprazole RARE
, O
whose O
efficacy O
in O
preventing O
NSAID O
- O
associated O
ulcers O
has O
been O
recently O
demonstrated O
; O
and O
( O
iv O
) O
barrier O
agents O
, O
e O
. O
g O
. O
sucralfate RARE
, O
which O
cannot O
be O
recommended O
as O
prophylactic O
agents O
to O
prevent O
NSAID O
- O
induced O
gastropathy RARE
. O

Lung O
mesenchyme RARE
serves O
as O
a O
' O
compleat RARE
' O
inducer RARE
of O
lung O
morphogenesis RARE
by O
secreting O
soluble O
peptide O
growth O
factors O
. O

The O
activation O
of O
the O
HIV O
promoter O
required O
the O
nuclear O
localization O
of O
c I-GENE
- I-GENE
Abl I-GENE
and O
could O
be O
correlated O
with O
increased O
tyrosine O
phosphorylation O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
. O

The O
bovine I-GENE
papillomavirus I-GENE
E2 I-GENE
protein I-GENE
can O
inhibit O
the O
proliferation O
of O
HT O
- O
3 O
cells O
, O
a O
p53 I-GENE
- O
negative O
cervical O
carcinoma O
cell O
line O
containing O
integrated O
human O
papillomavirus O
type O
30 O
DNA O
. O

E2 I-GENE
point O
mutants O
unable O
to O
inhibit O
cell O
growth O
did O
not O
repress O
cdc25A NUMERIC
and O
cdc25B NUMERIC
expression O
, O
nor O
did O
the O
cell O
cycle O
inhibitors O
hydroxyurea RARE
and O
mimosine RARE
. O

BACKGROUND O
/ O
PURPOSE O
: O
Anomalous RARE
arrangement O
of O
the O
pancreaticobiliary RARE
duct O
( O
AAPBD ALLCAPS
) O
is O
closely O
related O
to O
congenital O
biliary O
dilatation O
and O
frequently O
associated O
with O
biliary O
tract O
malignancy O
. O

Neurospora O
crassa O
CYT ALLCAPS
- I-GENE
18 I-GENE
, O
can O
rescue O
the O
exonic RARE
trap RARE
and O
intron O
mutants O
which O
cause O
a O
structural O
defect O
. O

DDP1 NUMERIC
also O
localizes O
to O
heterochromatin RARE
in O
interphase RARE
nuclei O
of O
larval O
neuroblasts O
. O

In O
a O
reconstituted O
human O
DNA O
repair O
system O
containing O
DNA I-GENE
polymerase I-GENE
beta I-GENE
and O
DNA I-GENE
ligase I-GENE
III I-GENE
- O
XRCC1 NUMERIC
, O
accurate O
rejoining RARE
of O
a O
3 O
' O
mismatched RARE
base O
residue O
at O
a O
single O
- O
strand O
break RARE
is O
dependent O
on O
addition O
of O
the O
exonuclease O
. O

The O
PAC ALLCAPS
clone O
with O
an O
insert O
size O
of O
120kb NUMERIC
was O
isolated O
and O
mapped O
by O
restriction O
analysis O
. O

Sequence O
of O
10q24 NUMERIC
locus I-GENE
surrounding O
the O
HOX11 NUMERIC
oncogene I-GENE
reveals O
a O
new O
gene O
HUG1 NUMERIC
expressed O
in O
a O
T O
- O
ALL O
cell O
line O
. O

About RARE
20 O
kb O
upstream O
of O
LAMB2 NUMERIC
we O
found O
a O
gene O
encoding O
a O
transcribed O
, O
non O
- O
processed O
LAMB2 NUMERIC
- I-GENE
like I-GENE
pseudogene I-GENE
( O
LAMB2L NUMERIC
). O

Site O
- O
directed O
mutagenesis O
of O
the O
R2 I-GENE
protein I-GENE
was O
used O
to O
provide O
evidence O
that O
this O
motif O
is O
also O
part O
of O
the O
active O
site O
of O
the O
endonuclease O
encoded O
by O
this O
element O
. O

The O
infected I-GENE
cell I-GENE
protein I-GENE
no I-GENE
. I-GENE
0 I-GENE
( O
ICP0 NUMERIC
) O
of O
herpes O
simplex O
virus O
1 O
is O
a O
promiscuous RARE
transactivator O
shown O
to O
enhance O
the O
expression O
of O
genes O
introducted RARE
into O
cells O
by O
infection O
or O
transfection O
. O

Wrist RARE
measurement O
of O
blood O
pressure O
: O
some O
critical O
remarks RARE
to O
oscillometry RARE
. O

G O
- O
box O
- O
directed O
expression O
in O
leaves O
required O
the O
presence O
of O
an O
enhancer O
region O
from O
the O
cauliflower RARE
mosaic O
virus O
( O
CaMV LASTCAP
) O
35S I-GENE
promoter I-GENE
. O

Another O
element O
necessary O
for O
augmenting RARE
the O
amplitude O
of O
the O
oscillation RARE
lies O
between O
- O
178 NUMERIC
and O
- O
264 O
. O

This O
scFv RARE
was O
therefore O
used O
as O
control O
in O
experiments O
where O
another O
anti I-GENE
- I-GENE
Ras I-GENE
scFv RARE
( O
Y259 NUMERIC
scFv RARE
, O
derived O
from O
the O
neutralizing RARE
anti I-GENE
- I-GENE
Ras I-GENE
mAb I-GENE
Y13 NUMERIC
- I-GENE
259 NUMERIC
) O
blocked O
the O
Ras I-GENE
pathway O
in O
vitro O
and O
led O
to O
tumor O
regression O
in O
a O
nude O
mouse O
model O
[ O
Cochet RARE
, O
O O
., O
Kenigsberg RARE
, O
M O
., O
Delumeau RARE
, O
I O
., O
Virone RARE
- O
Oddos RARE
, O
A O
., O
Multon RARE
, O
M O
. O
C O
., O
Fridman RARE
, O
W O
. O
H O
., O
Schweighoffer RARE
, O
F O
., O
Teillaud RARE
, O
J O
. O
L O
., O
Tocque RARE
, O
B O
., O
1998 O
. O

There O
was O
no O
competition O
between O
activin I-GENE
A I-GENE
and O
OP ALLCAPS
- I-GENE
1 I-GENE
for O
availability O
of O
Smad4 NUMERIC
, O
indicating O
that O
the O
concentration O
of O
this O
common O
signal O
transducer RARE
is O
not O
limiting O
for O
generating O
the O
observed O
biological O
responses O
. O

Our O
data O
therefore O
indicate O
that O
it O
is O
possible O
to O
engineer RARE
the O
HA I-GENE
envelope I-GENE
glycoprotein I-GENE
by O
fusing RARE
ligands O
to O
its O
amino O
- O
terminal O
end O
without O
affecting O
its O
fusion O
activity O
. O

However O
, O
the O
favored RARE
, O
parallel O
beta O
helix O
model O
is O
a O
compact RARE
coil O
of O
ten O
helically RARE
arranged O
beta O
strands RARE
forming O
two O
parallel O
beta O
sheet RARE
faces RARE
. O

This O
is O
predicted O
to O
encode O
a O
315 NUMERIC
- O
residue O
protein O
containing O
seven O
hydrophobic O
helical O
regions O
and O
a O
17 O
amino O
acid O
motif O
characteristic O
of O
the O
R7G NUMERIC
family I-GENE
of O
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
membrane I-GENE
- I-GENE
bound I-GENE
receptors I-GENE
. O

Characterisation RARE
of O
the O
chicken I-GENE
apolipoprotein I-GENE
A I-GENE
- I-GENE
I I-GENE
gene I-GENE
5 O
'- O
flanking O
region O
. O

These O
results O
suggest O
that O
members O
of O
the O
ATF I-GENE
family I-GENE
are O
involved O
in O
mediating O
the O
transcriptional O
regulation O
of O
the O
KGF ALLCAPS
gene I-GENE
in O
response O
to O
extracellular O
stimuli O
via O
a O
novel O
CRE O
regulatory O
element O
. O

Moreover O
, O
a O
high O
proportion O
of O
blood O
samples O
from O
a O
random O
sample O
of O
the O
rest O
of O
the O
suspects RARE
tested O
positive O
for O
trypanosome RARE
- O
specific O
DNA O
by O
PCR O
( O
79 O
. O
9 O
% O
for O
T O
. O
b O
. O
gambiense RARE
and O
13 O
. O
9 O
% O
for O
T O
. O
b O
. O
rhodesiense RARE
). O

A O
multi O
- O
centre RARE
evaluation O
of O
the O
card RARE
indirect O
agglutination O
test O
for O
trypanosomiasis RARE
( O
TrypTect RARE
CIATT ALLCAPS
). O

Results O
for O
men O
who O
drank RARE
up O
to O
two O
drinks RARE
per O
day O
suggest O
that O
if O
the O
dependence O
criteria O
were O
invalid RARE
, O
reductions O
in O
the O
prevalence O
of O
specific O
indicators O
of O
alcohol O
dependence O
would O
range O
from O
0 O
. O
3 O
% O
to O
5 O
. O
2 O
%. O

Mutagenesis RARE
of O
the O
CDE ALLCAPS
/ O
CHR ALLCAPS
elements O
and O
Sp1 I-GENE
sites I-GENE
in O
this O
region O
, O
alone O
or O
in O
combination O
, O
reduced O
transcriptional O
activity O
by O
40 O
- O
60 O
% O
in O
asynchronously RARE
growing O
cells O
and O
abolished O
cell O
cycle O
periodicity RARE
in O
G2 O
- O
M O
- O
synchronized RARE
cells O
. O

Using O
Scheffe RARE
' O
s O
procedure O
as O
an O
illustration RARE
, O
comparisons O
are O
made O
to O
usual RARE
sample O
size O
methods O
that O
incorrectly RARE
ignore RARE
the O
stochastic RARE
nature O
of O
S2p NUMERIC
. O

The O
crystal O
structure O
of O
the O
VP16 I-GENE
core I-GENE
has O
been O
determined O
at O
2 O
. O
1 O
A O
resolution O
. O

Ozagrel RARE
, O
ifenprodil RARE
, O
cinnarizine RARE
and O
dilazep RARE
were O
more O
effective O
than O
pentoxifylline RARE
in O
increasing O
rCBF O
at O
the O
HPC ALLCAPS
. O

The O
latter O
method O
adds RARE
clamping RARE
of O
the O
inferior O
vena RARE
cava RARE
, O
which O
results O
in O
hypotension O
, O
requiring O
invasive O
anesthetic RARE
management O
. O

By O
contrast O
, O
PvirE LASTCAP
or O
Plac RARE
promoter I-GENE
constructs I-GENE
yielded O
functional O
VirE2 NUMERIC
only O
if O
virE1 NUMERIC
was O
coexpressed O
with O
virE2 NUMERIC
. O

Simian RARE
parainfluenza RARE
virus O
5 O
( O
SV5 NUMERIC
) O
is O
a O
prototype O
of O
the O
Paramyxoviridae RARE
family O
of O
nonsegmented RARE
negative O
- O
sense O
RNA O
viruses O
. O

To O
investigate O
the O
functions O
of O
GE ALLCAPS
, O
IG ALLCAPS
, O
and O
GS O
sequences O
in O
transcription O
, O
we O
constructed O
plasmids O
containing O
cDNAs O
of O
the O
full O
- O
length O
SV5 NUMERIC
genome O
in O
which O
the O
gene O
junction O
sequences O
( O
GE ALLCAPS
, O
IG ALLCAPS
, O
and O
GS O
sequences O
) O
located O
between O
the O
hemagglutinin I-GENE
- I-GENE
neuraminidase RARE
( O
HN ALLCAPS
) O
and O
the O
polymerase I-GENE
( I-GENE
L I-GENE
) I-GENE
genes I-GENE
were O
replaced O
with O
the O
counterpart O
sequences O
from O
other O
gene O
junctions O
. O

CXCR4 NUMERIC
is O
a O
chemokine O
receptor O
and O
a O
coreceptor RARE
for O
T O
- O
cell O
- O
line O
- O
tropic RARE
( O
X4 NUMERIC
) O
and O
dual O
- O
tropic RARE
( O
R5X4 NUMERIC
) O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
isolates O
. O

These O
data O
will O
help O
us O
to O
better O
detail O
the O
CXCR4 NUMERIC
structural O
requirements O
exhibited O
by O
different O
HIV O
- O
1 O
strains O
and O
will O
direct O
further O
mutagenesis O
efforts RARE
aimed O
at O
better O
defining RARE
the O
domains O
in O
CXCR4 NUMERIC
involved O
in O
the O
HIV O
- O
1 O
Env I-GENE
- O
mediated O
fusion O
process O
. O

The O
results O
of O
these O
analyses O
indicate O
that O
the O
proteinase O
cleaves RARE
at O
amino O
acid O
residues O
E960 NUMERIC
- O
A961 NUMERIC
, O
E1071 NUMERIC
- O
S1072 NUMERIC
, O
E1345 NUMERIC
- O
T1346 NUMERIC
, O
and O
E1419 NUMERIC
- O
G1420 NUMERIC
; O
however O
, O
the O
cleavage O
efficiency O
is O
varied O
. O

y RARE
. O

SM ALLCAPS
is O
also O
shown O
to O
be O
associated O
in O
vivo O
with O
other O
components O
of O
the O
CRM ALLCAPS
1 I-GENE
export O
pathway O
, O
including O
the O
small I-GENE
GTPase I-GENE
Ran I-GENE
and O
the O
nucleoporin RARE
CAN ALLCAPS
/ O
Nup214 NUMERIC
. O

Identification O
of O
a O
spliced O
gene O
from O
Kaposi O
' O
s O
sarcoma O
- O
associated O
herpesvirus O
encoding O
a O
protein O
with O
similarities O
to O
latent I-GENE
membrane I-GENE
proteins I-GENE
1 I-GENE
and I-GENE
2A I-GENE
of I-GENE
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
. O

Auditory RARE
clicks RARE
were O
given O
at O
a O
rate O
of O
20 O
s O
(- O
1 O
). O

Myosin RARE
light I-GENE
chain I-GENE
kinase I-GENE
functions O
downstream O
of O
Ras I-GENE
/ O
ERK I-GENE
to O
promote O
migration O
of O
urokinase I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
- O
stimulated O
cells O
in O
an O
integrin I-GENE
- O
selective O
manner O
. O

The O
inhibition O
of O
StAR LASTCAP
gene I-GENE
transcription O
by O
DAX ALLCAPS
- I-GENE
1 I-GENE
was O
dose O
- O
dependent O
reducing O
transcription O
to O
6 O
% O
of O
control O
levels O
. O

In O
a O
prospective O
randomized O
study O
, O
287 NUMERIC
patients O
with O
advanced O
non O
- O
small O
cell O
lung O
cancer O
( O
NSCLC ALLCAPS
) O
stage O
IIIb RARE
or O
IV O
with O
ECOG ALLCAPS
performance O
status O
( O
PS O
) O
0 O
- O
1 O
or O
2 O
were O
randomly O
assigned O
to O
receive O
either O
best O
supportive RARE
care O
( O
BSC ALLCAPS
) O
or O
supportive RARE
care O
plus O
combination O
chemotherapy O
( O
IEP ALLCAPS
regimen O
: O
ifosfamide RARE
3 O
gm RARE
/ O
m2 O
IV O
with O
mesna RARE
uroprotection RARE
, O
epirubicin RARE
60 O
mg O
/ O
m2 O
IV O
on O
day O
1 O
and O
cisplatin O
60 O
mg O
/ O
m2 O
IV O
on O
day O
2 O
; O
or O
MVP ALLCAPS
regimen O
: O
mitomycin RARE
- O
C O
8 O
mg O
/ O
m2 O
, O
cisplatin O
100 O
mg O
/ O
m2 O
IV O
on O
day O
1 O
, O
vinblastine RARE
4 O
mg O
/ O
m2 O
IV O
on O
days O
1 O
and O
15 O
). O

Using O
sequence O
information O
from O
human I-GENE
BMAL1 NUMERIC
( O
hBMAL1 NUMERIC
) O
cDNAs O
previously O
reported O
by O
our O
laboratory O
, O
we O
have O
isolated O
and O
characterized O
cDNAs O
encoding O
three O
splice O
variants O
of O
the O
mouse I-GENE
BMAL1 NUMERIC
( O
mBMAL1 NUMERIC
) O
gene O
. O

Comparison O
with O
the O
bHLH I-GENE
/ O
PAS ALLCAPS
family O
genes O
revealed O
that O
the O
intron O
/ O
exon O
splice O
pattern O
of O
mBMAL1 NUMERIC
most O
closely O
matches O
that O
of O
the O
mAhr RARE
, O
which O
suggests O
that O
BMAL1 NUMERIC
and O
Ahr RARE
belong O
to O
the O
same O
subclass RARE
and O
may O
be O
derived O
from O
a O
common O
primordial RARE
gene O
. O

The O
transcriptional O
activities O
of O
the O
full O
- O
length O
promoter O
(- O
295 NUMERIC
to O
+ O
85 O
) O
and O
of O
three O
deletion O
constructs O
(- O
197 NUMERIC
, O
- O
154 O
and O
- O
74 O
to O
+ O
85 O
) O
were O
significantly O
down O
- O
regulated O
in O
resistant O
cells O
. O

We O
were O
able O
to O
detect O
significant O
differences O
in O
functional O
residual O
capacity O
adjusted O
for O
weight O
or O
height O
, O
and O
compliance O
of O
the O
respiratory O
system O
adjusted O
for O
weight O
or O
lung O
volume O
in O
the O
ILD ALLCAPS
infants O
compared O
to O
the O
healthy O
controls O
or O
infants O
who O
had O
PPHN ALLCAPS
, O
indicating O
that O
these O
PFTs RARE
were O
sensitive O
enough O
to O
determine O
abnormal O
lung O
function O
in O
this O
age O
group O
. O

A O
13 O
- O
bp O
cis O
- O
regulatory O
element O
in O
the O
LTR O
promoter O
of O
the O
tobacco I-GENE
retrotransposon I-GENE
Tto1 NUMERIC
is O
involved O
in O
responsiveness O
to O
tissue O
culture O
, O
wounding RARE
, O
methyl O
jasmonate RARE
and O
fungal O
elicitors RARE
. O

In O
this O
study O
we O
describe O
that O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
( O
PDGF I-GENE
), O
12 O
- O
O O
- O
tetradecanoyl RARE
- O
phorbol O
- O
acetate O
( O
TPA O
), O
and O
forskolin O
induced O
CREB I-GENE
( O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
Ser O
- O
133 O
phosphorylation O
with O
comparable O
magnitude O
and O
kinetics O
in O
NIH O
3T3 O
cells O
. O

This O
constitutes O
evidence O
for O
an O
in O
vivo O
role O
of O
SRC I-GENE
- I-GENE
1 I-GENE
in O
dimerization O
- O
induced O
activation O
by O
OR1 NUMERIC
/ O
RXRalpha RARE
. O

By O
contrast O
, O
mTRAP100 NUMERIC
coprecipitates RARE
in O
vivo O
with O
another O
component O
of O
the O
TRAP ALLCAPS
complex I-GENE
( O
TRAP220 NUMERIC
), O
which O
directly O
contacts O
TR I-GENE
and O
the O
vitamin I-GENE
D I-GENE
receptor I-GENE
in O
a O
ligand O
- O
dependent O
manner O
. O

This O
sequence O
also O
confers O
VDR I-GENE
and O
vitamin O
D O
responsiveness O
to O
a O
heterologous O
promoter O
. O

Classical RARE
ligand O
- O
activated O
nuclear O
receptors O
( O
e O
. O
g O
. O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
, O
retinoic I-GENE
acid I-GENE
receptor I-GENE
), O
orphan I-GENE
nuclear I-GENE
receptors I-GENE
( O
e O
. O
g O
. O

Expression O
of O
GlcNAc I-GENE
- I-GENE
TI ALLCAPS
mRNA I-GENE
in O
tobacco O
leaves O
was O
detected O
using O
RT O
- O
PCR O
. O

Chemical O
stability O
tests O
and O
site O
- O
specific O
mutagenesis O
identified O
amino O
acids O
H219 NUMERIC
and O
D63 NUMERIC
of O
RegS LASTCAP
and O
RegR LASTCAP
, O
respectively O
, O
as O
the O
phosphorylated O
residues O
. O

An O
overexpression O
of O
the O
betaAPP LASTCAP
gene I-GENE
in O
certain O
areas O
of O
the O
AD O
brain O
has O
been O
suggested O
to O
be O
an O
important O
factor O
in O
the O
neuropathology RARE
of O
AD O
. O

For O
functional O
studies O
, O
two O
promoter O
regions O
were O
cloned O
upstream O
of O
the O
reporter O
gene O
, O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
): O
( O
i O
) O
phbetaE LASTCAP
- O
B O
- O
the O
plasmid O
that O
contains O
the O
human O
( O
h O
) O
promoter O
region O
(- O
2832 NUMERIC
to O
+ O
101 O
) O
including O
URE ALLCAPS
, O
and O
( O
ii O
) O
prhbetaE LASTCAP
- O
B O
- O
the O
plasmid O
that O
contains O
the O
rhesus O
( O
rh RARE
) O
promoter O
region O
excluding O
URE ALLCAPS
as O
it O
lacks O
a O
270 O
bp O
region O
of O
the O
hbetaAPP LASTCAP
promoter I-GENE
(- O
2435 NUMERIC
to O
- O
2165 NUMERIC
). O

67 O
393 NUMERIC
bp O
of O
contiguous O
DNA O
located O
between O
markers O
cdc18 NUMERIC
and O
cdc14 NUMERIC
on O
the O
right O
arm O
of O
fission O
yeast O
chromosome O
II O
has O
been O
sequenced O
as O
part O
of O
the O
European O
Union RARE
Schizosaccharomyces O
pombe O
genome O
sequencing O
project RARE
. O

67 O
393 NUMERIC
bp O
of O
contiguous O
DNA O
located O
between O
markers O
cdc18 NUMERIC
and O
cdc14 NUMERIC
on O
the O
right O
arm O
of O
fission O
yeast O
chromosome O
II O
has O
been O
sequenced O
as O
part O
of O
the O
European O
Union RARE
Schizosaccharomyces O
pombe O
genome O
sequencing O
project RARE
. O

G I-GENE
- I-GENE
CSF I-GENE
( O
480 NUMERIC
micrograms O
subcutaneously O
( O
s O
. O
c O
.)) RARE
were O
used O
in O
55 O
and O
GM I-GENE
- I-GENE
CSF I-GENE
( O
400 O
micrograms O
s O
. O
c O
.) O
in O
28 O
chemotherapeutic O
cycles O
. O

Overexpression O
of O
H411 NUMERIC
cDNA I-GENE
in O
the O
RAW ALLCAPS
264 O
. O
7 O
macrophage O
cell O
line O
promoted O
an O
increased O
growth O
rate O
, O
suggesting O
that O
expression O
of O
H411 NUMERIC
is O
part O
of O
the O
proliferative O
cell O
response O
to O
LPS O
. O

Human O
expressed O
sequence O
tag O
clones O
were O
identified O
by O
sequence O
similarity O
to O
mammalian I-GENE
and I-GENE
yeast I-GENE
oligosaccharide RARE
- I-GENE
processing I-GENE
mannosidases RARE
, O
and O
the O
full O
- O
length O
coding O
region O
of O
the O
putative O
mannosidase RARE
homolog I-GENE
was O
isolated O
by O
a O
combination O
of O
5 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
and O
direct O
polymerase O
chain O
reaction O
from O
human O
placental O
cDNA O
. O

Activation O
of O
ERK1 I-GENE
/ I-GENE
2 I-GENE
is O
correlated O
with O
induction O
of O
the O
immediate I-GENE
- I-GENE
early I-GENE
response I-GENE
genes I-GENE
. O

The O
transcription O
of O
most O
RP I-GENE
genes I-GENE
is O
activated O
by O
two O
Rap1p NUMERIC
binding I-GENE
sites I-GENE
, O
250 O
to O
400 O
bp O
upstream O
from O
the O
initiation O
of O
transcription O
. O

We O
have O
isolated O
three O
mutant O
alleles O
of O
CDC4 NUMERIC
( O
cdc4 NUMERIC
- I-GENE
10 I-GENE
, O
cdc4 NUMERIC
- I-GENE
11 I-GENE
, O
and O
cdc4 NUMERIC
- I-GENE
16 I-GENE
) O
which O
suppress O
the O
nuclear O
division O
defect O
of O
cdc20 NUMERIC
- I-GENE
1 I-GENE
cells O
. O

Role O
of O
secondary O
structure O
in O
discrimination O
between O
constitutive O
and O
inducible O
activators O
. O

In O
summary O
, O
Ca O
( O
2 O
+)- O
dependent O
activation O
of O
NO O
production O
mediates O
apoptosis O
after O
TG I-GENE
exposure O
in O
JT ALLCAPS
/ O
Neo RARE
cells O
. O

Accumulation RARE
of O
the O
U4 I-GENE
/ O
U6 I-GENE
duplex O
was O
relieved RARE
by O
overexpression O
of O
wild I-GENE
- I-GENE
type I-GENE
Prp44p NUMERIC
. O

Our O
results O
, O
when O
combined O
with O
previously O
published O
in O
vitro O
results O
, O
support O
a O
direct O
role O
for O
Prp44p NUMERIC
in O
unwinding RARE
of O
the O
U4 I-GENE
/ O
U6 I-GENE
helix O
. O

This O
approximately O
125 O
- O
nt O
RNA O
proved O
to O
arise O
via O
RNase I-GENE
E I-GENE
cleavage O
from O
the O
3 O
'- O
terminal O
region O
of O
the O
mRNAs O
bearing O
the O
terminator O
. O

The O
mysteries RARE
of O
geographic RARE
variability O
in O
nonmelanoma RARE
skin O
cancer O
incidence O
. O

In O
Saccharomyces O
cerevisiae O
the O
cAMP I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
PKAs RARE
) O
promote O
cytoplasmic O
growth O
and O
modulate O
the O
growth O
- O
regulated O
mechanism O
triggering RARE
the O
begin O
of O
DNA O
synthesis O
. O

We O
have O
shown O
previously O
that O
in O
contrast O
to O
other O
extracellular O
matrix O
molecules O
pepsin RARE
- O
solubilized RARE
collagen I-GENE
VI I-GENE
( O
CVI ALLCAPS
) O
can O
stimulate O
DNA O
synthesis O
of O
various O
mesenchymal O
cell O
types O
, O
apparently O
independent O
of O
integrin I-GENE
- O
mediated O
signal O
transduction O
. O

A O
recombinant O
derivative O
harboring O
the O
pMJ101 NUMERIC
replication O
region O
proved O
to O
be O
compatible O
with O
pJM1 NUMERIC
, O
a O
plasmid O
containing O
the O
iron O
acquisition O
system O
required O
for O
the O
virulence O
of O
V O
. O
anguillarum RARE
775 NUMERIC
, O
another O
important O
pathogen RARE
that O
causes O
vibriosis RARE
. O

FAK I-GENE
localizes O
to O
sites O
of O
transmembrane I-GENE
integrin I-GENE
receptor I-GENE
clustering RARE
and O
facilitates RARE
intracellular O
signaling O
events O
. O

Expression O
of O
various O
FAK I-GENE
mutants I-GENE
in O
the O
FAK I-GENE
- O
cells O
showed O
that O
FAK I-GENE
kinase I-GENE
activity O
, O
the O
Tyr I-GENE
- I-GENE
397 NUMERIC
/ I-GENE
SH2 I-GENE
domain I-GENE
binding I-GENE
site I-GENE
, O
and O
the O
first O
proline O
- O
rich O
SH3 I-GENE
binding I-GENE
region I-GENE
in O
the O
FAK I-GENE
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
were O
individually O
needed O
to O
promote O
full O
FAK I-GENE
- O
mediated O
FAK I-GENE
- O
cell O
migration O
to O
FN I-GENE
whereas O
direct O
paxillin I-GENE
binding O
to O
FAK I-GENE
was O
not O
required O
. O

This O
dominant O
- O
negative O
effect O
of O
FRNK ALLCAPS
was O
reversed O
by O
a O
point O
mutation O
( O
Leu O
- O
1034 NUMERIC
to O
Ser O
) O
which O
prevented O
FRNK ALLCAPS
localization O
to O
focal O
contact O
sites O
. O

Fifty O
six O
young O
patients O
( O
age O
< O
45 O
yr O
) O
with O
doppler RARE
- O
proven O
DVT ALLCAPS
were O
investigated O
for O
the O
presence O
of O
resistance O
to O
activated I-GENE
protein I-GENE
C I-GENE
( O
APC I-GENE
- I-GENE
R I-GENE
), O
lupus O
anticoagulant O
( O
LA O
), O
anticardiolipin RARE
antibodies I-GENE
and O
deficiencies O
of O
protein I-GENE
C I-GENE
, O
protein I-GENE
S I-GENE
, O
ATIII ALLCAPS
activities O
. O

DESIGN O
: O
Comparison O
of O
number O
of O
women O
with O
PKU ALLCAPS
aged O
15 O
- O
44 O
years O
on O
the O
NSW ALLCAPS
PKU ALLCAPS
database O
( O
observed O
number O
) O
with O
expected O
number O
derived O
from O
population O
data O
. O

PURPOSE O
: O
The O
purposes RARE
of O
the O
present O
study O
were O
to O
assess O
the O
effects O
of O
a O
12 O
- O
wk O
laboratory O
based O
aerobic O
exercise O
program O
on O
cardiopulmonary O
function O
, O
CD4 I-GENE
cell O
count O
, O
and O
physician RARE
- O
assessed O
health O
status O
among O
symptomatic O
pre O
- O
AIDS O
HIV O
- O
infected O
individuals O
( O
N O
= O
28 O
) O
and O
to O
assess O
the O
degree O
to O
which O
ill RARE
health O
was O
associated O
with O
exercise O
relapse O
. O

The O
enzyme O
displays O
optimal O
activity O
at O
about O
0 O
. O
5 O
mM O
pantoate RARE
( O
k RARE
( O
cat O
) O
0 O
. O
63 O
s O
(- O
1 O
)) O
and O
at O
pH O
7 O
. O
8 O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
the O
RP I-GENE
, O
like O
the O
20S I-GENE
proteasome I-GENE
, O
is O
functionally O
and O
structurally O
conserved O
among O
eukaryotes O
and O
indicate O
that O
the O
plant I-GENE
RPT ALLCAPS
subunits I-GENE
, O
like O
their O
yeast O
counterparts O
, O
have O
non O
- O
redundant RARE
functions O
. O

Epidemiologic RARE
evidence O
indicates O
that O
estrogen O
replacement O
therapy O
after O
menopause RARE
increases O
breast O
cancer O
risk O
. O

In O
addition O
to O
its O
elongation O
activity O
, O
ELL ALLCAPS
contains O
a O
novel O
type O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
interaction I-GENE
domain I-GENE
that O
is O
capable O
of O
repressing O
polymerase O
activity O
in O
promoter O
- O
specific O
transcription O
. O

A O
diagnosis O
of O
IgA I-GENE
lambda I-GENE
multiple O
myeloma O
with O
peritoneal O
involvement O
was O
made O
. O

The O
radiation O
burden O
associated O
with O
the O
majority O
of O
examinations O
in O
nuclear O
medicine O
expressed O
as O
the O
effective O
dose O
is O
comparable O
with O
the O
radiation O
burden O
of O
radiodiagnostic RARE
examinations O
, O
only O
after O
administration O
of O
preparations O
with O
131I O
, O
201Tl NUMERIC
, O
67Ga NUMERIC
and O
111In NUMERIC
it O
is O
markedly O
higher O
. O

Although O
the O
risk O
of O
malformation RARE
in O
children O
born O
after O
ICSI ALLCAPS
is O
not O
increased O
there O
is O
an O
increased O
risk O
to O
transmit RARE
genetic O
abnormalities O
in O
case O
of O
NOA ALLCAPS
( O
such O
as O
the O
rate O
of O
sex O
chromosome O
, O
or O
microdeletions RARE
of O
the O
Y O
chromosome O
) O
and O
in O
case O
of O
congenital O
OA ALLCAPS
( O
mutations O
of O
the O
cystic I-GENE
fibrosis I-GENE
gene I-GENE
). O

TaV LASTCAP
particles O
have O
a O
buoyant RARE
density O
of O
1 O
. O
296 O
g O
/ O
cm3 O
in O
CsCl RARE
and O
consist O
of O
two O
capsid I-GENE
proteins I-GENE
of O
56 O
and O
6 O
kDa O
. O

CONCLUSION O
: O
These O
results O
suggest O
that O
vibration O
- O
induced O
neural O
involvement O
can O
be O
considered O
neither O
pure O
digital O
neuropathy O
, O
nor O
definite O
CTS ALLCAPS
, O
as O
previously O
described O
. O

In O
about O
770 NUMERIC
bp O
upstream O
region O
of O
Spam1 NUMERIC
that O
has O
been O
cloned O
and O
sequenced O
, O
multiple O
transcription O
factor O
binding O
sites O
including O
a O
CRE O
( O
cAMP O
- O
responsive O
element O
) O
were O
found O
. O

The O
in O
vitro O
relaxivity RARE
of O
the O
complex O
is O
16 O
. O
24 O
s O
(- O
1 O
) O
mM O
(- O
1 O
). O

Structure O
and O
expression O
of O
the O
mouse I-GENE
growth I-GENE
hormone I-GENE
receptor I-GENE
/ O
growth I-GENE
hormone I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
. O

Bacterial RARE
recovery O
of O
SA O
from O
the O
liver O
/ O
spleen O
and O
the O
cecal RARE
tonsil RARE
in O
contact O
poults RARE
and O
SG O
from O
contact O
chicks O
treated O
with O
ILK I-GENE
was O
dramatically O
reduced O
when O
compared O
to O
non O
- O
treated O
contact O
poults RARE
and O
chicks O
. O

The O
results O
of O
the O
ISIS ALLCAPS
- O
2 O
trial O
and O
the O
data O
from O
the O
Antiplatelet RARE
Trialists RARE
' O
Collaboration RARE
indicated O
that O
aspirin O
is O
mandatory RARE
in O
patients O
with O
acute O
myocardial O
infarction O
and O
for O
secondary O
prevention O
. O

This O
study O
was O
performed O
to O
assess O
the O
role O
of O
additional O
diagnostic O
laparoscopy RARE
in O
the O
preoperative O
staging RARE
of O
patients O
with O
adenocarcinoma O
of O
the O
esophagus RARE
, O
gastric O
cancer O
and O
pancreatic O
cancer O
prior O
to O
intended RARE
curative RARE
surgery O
. O

This O
report O
presents O
state O
- O
specific O
MMRs RARE
for O
1987 O
- O
1996 O
, O
focusing O
on O
persistent O
disparities RARE
in O
maternal O
mortality O
between O
black O
and O
white O
women O
. O

Preheparin RARE
LPL ALLCAPS
mass O
level O
did O
not O
significantly O
differ O
in O
individuals O
from O
19 O
to O
70 O
years O
old O
, O
for O
both O
men O
and O
women O
. O

A O
decrease O
in O
insulin I-GENE
- O
induced O
receptor O
kinase O
activity O
was O
observed O
for O
solubilized RARE
chimeric O
receptors O
. O

Cat RARE
- I-GENE
1 I-GENE
is O
identical O
to O
the O
recently O
identified O
binding O
partner O
for O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
kinase I-GENE
( O
betaARK LASTCAP
or O
GRK ALLCAPS
- I-GENE
2 I-GENE
), O
which O
was O
shown O
to O
have O
Arf RARE
- O
GAP I-GENE
activity O
. O

Cat RARE
proteins I-GENE
are O
tyrosine O
- O
phosphorylated O
when O
co O
- O
expressed O
in O
cells O
with O
the O
focal I-GENE
adhesion I-GENE
kinase I-GENE
Fak RARE
and O
Src I-GENE
. O

Immunoprecipitation RARE
experiments O
using O
DokR LASTCAP
- I-GENE
specific I-GENE
antibodies I-GENE
revealed O
an O
interaction O
between O
endogenous I-GENE
DokR LASTCAP
and O
a O
150 O
- O
kDa O
protein O
that O
is O
tyrosine O
- O
phosphorylated O
in O
EGF I-GENE
- O
stimulated O
BaF LASTCAP
/ O
3 O
cells O
. O

Expansins RARE
are O
a O
family O
of O
proteins O
that O
catalyse RARE
long O
- O
term O
extension O
of O
isolated O
plant O
cell O
walls RARE
due O
to O
an O
as O
yet O
unknown O
biochemical O
mechanism O
. O

This O
review O
summarizes RARE
the O
clinical O
evidence O
to O
support O
current O
therapies RARE
in O
irritable RARE
bowel O
syndrome O
( O
IBS ALLCAPS
). O

The O
responsive O
region O
of O
the O
alpha I-GENE
2 I-GENE
( I-GENE
V I-GENE
) I-GENE
collagen I-GENE
gene I-GENE
was O
localized O
to O
a O
fragment O
including O
100 O
bp O
of O
basal O
promoter O
and O
150 O
bp O
of O
exon O
1 O
sequences O
, O
which O
contained O
two O
CRE O
- O
like O
elements O
. O

Furthermore O
, O
addition O
of O
B I-GENE
- I-GENE
Myb I-GENE
- O
glutathionine RARE
S I-GENE
- I-GENE
transferase I-GENE
fusion O
protein O
inhibited O
complex O
formation O
. O

APOE ALLCAPS
- O
epsilon4 NUMERIC
count O
predicts O
age O
when O
prevalence O
of O
AD O
increases O
, O
then O
declines RARE
: O
the O
Cache RARE
County RARE
Study O
. O

Repair RARE
of O
double O
- O
strand O
breaks RARE
( O
DSBs RARE
) O
in O
chromosomal O
DNA O
by O
nonhomologous RARE
end O
- O
joining O
( O
NHEJ ALLCAPS
) O
is O
not O
well O
characterized O
in O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

A O
new O
DNA I-GENE
repair I-GENE
gene I-GENE
from O
Schizosaccharomyces O
pombe O
with O
homology O
to O
RecA LASTCAP
was O
identified O
and O
characterized O
. O

Among O
mucus O
- O
secreting O
cells O
, O
the O
gastric O
gland O
mucous RARE
cells O
, O
Brunner RARE
' O
s O
glands O
, O
accessory O
glands O
of O
pancreaticobiliary RARE
tract O
, O
and O
pancreatic O
ducts RARE
exhibiting O
gastric O
metaplasia RARE
are O
unique O
in O
that O
they O
express O
class I-GENE
III I-GENE
mucin RARE
identified O
by O
paradoxical RARE
Con RARE
A I-GENE
staining O
composed O
of O
periodate RARE
oxidation O
, O
sodium O
borohydride RARE
reduction O
, O
Con RARE
A I-GENE
, O
and O
horseradish RARE
peroxidase I-GENE
reaction O
. O

The O
C O
- O
terminal O
mutants O
were O
strongly O
dominant O
over O
TraR LASTCAP
, O
suggesting O
that O
they O
can O
form O
heteromultimers RARE
with O
the O
wild O
- O
type O
activator O
. O

Thus O
, O
elongin RARE
C I-GENE
is O
found O
to O
oligomerize RARE
in O
solution O
and O
to O
undergo O
significant O
structural O
rearrangements O
upon O
binding O
of O
two O
different O
partner O
proteins O
. O

The O
data O
imply O
that O
JAK ALLCAPS
/ O
STAT I-GENE
signaling O
has O
a O
role O
in O
EBV O
- O
associated O
malignancies RARE
. O

There O
were O
27 O
men O
and O
156 O
women O
. O

A O
., O
Bowers RARE
, O
K O
. O
E O
, O
and O
Matthews RARE
, O
C O
. O

Spfkh1 NUMERIC
is O
transcribed O
in O
one O
open O
reading O
frame O
that O
contains O
the O
DNA O
binding O
domain O
, O
nuclear O
localization O
signal O
and O
transactivation O
domain O
. O

The O
molecular O
mechanism O
of O
Tax I-GENE
- O
mediated O
trans O
- O
activation O
has O
been O
well O
investigated O
. O

Gel O
filtration O
and O
co O
- O
immunoprecipitation O
analyses O
reveal O
that O
Mad2p NUMERIC
tightly O
associates O
with O
another O
spindle O
checkpoint O
component O
, O
Mad1p NUMERIC
. O

METHODS O
: O
109 NUMERIC
suspected O
cases O
with O
SS O
underwent O
the O
biopsies O
. O

We O
also O
identify O
several O
regulatory O
domain O
mutants O
in O
which O
Cd O
( O
2 O
+) O
tolerance O
of O
the O
mutant O
strain O
and O
transport O
activity O
of O
the O
protein O
are O
dissociated RARE
. O

The O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
- I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
Tat I-GENE
protein I-GENE
regulates O
transcription O
by O
stimulating O
RNA I-GENE
polymerase I-GENE
processivity RARE
. O

One O
of O
these O
SEBPs RARE
, O
SEBP2 NUMERIC
, O
was O
shown O
to O
be O
the O
product O
of O
the O
homeotic I-GENE
gene I-GENE
fork I-GENE
head I-GENE
. O

Identity RARE
elements O
in O
tRNA O
for O
mono O
- O
and O
dimethylation RARE
reactions O
by O
the O
recombinant I-GENE
pfTrm1p NUMERIC
were O
identified O
using O
in O
vitro O
T7 O
transcripts O
of O
33 O
variants O
of O
tRNA I-GENE
( I-GENE
Asp I-GENE
) I-GENE
and O
tRNA I-GENE
( I-GENE
Phe I-GENE
) I-GENE
from O
yeast O
. O

In O
insulin I-GENE
- O
responsive O
cells O
, O
Akt I-GENE
phosphorylates O
and O
inactivates RARE
the O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
glycogen I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
( O
GSK ALLCAPS
- I-GENE
3 I-GENE
). O

The O
B I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
activates O
the O
Akt I-GENE
( O
protein I-GENE
kinase I-GENE
B I-GENE
)/ O
glycogen I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
signaling O
pathway O
via O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

Fewer RARE
recombination O
events O
are O
detected O
in O
four O
different O
B O
and O
T O
cell O
lines O
that O
do O
not O
undergo O
switch O
recombination O
of O
their O
endogenous O
genes O
. O

IL I-GENE
- I-GENE
1 I-GENE
and O
TNF I-GENE
increase O
AND I-GENE
- I-GENE
34 I-GENE
transcript I-GENE
levels O
in O
thymic O
cortical O
reticular RARE
, O
thymic O
nurse O
, O
and O
fibroblast O
cell O
lines O
. O

To O
determine O
what O
role O
eIF4E NUMERIC
might O
play O
in O
c I-GENE
- I-GENE
myc I-GENE
expression O
, O
the O
c I-GENE
- I-GENE
myc I-GENE
5 I-GENE
' I-GENE
untranslated I-GENE
region I-GENE
( I-GENE
UTR I-GENE
) I-GENE
was O
fused O
in O
- O
frame O
to O
CAT I-GENE
reporters RARE
, O
and O
several O
more O
derivative O
constructs O
were O
made O
. O

Analysis O
of O
cell O
cycle O
proteins O
showed O
that O
24 O
h O
of O
lovastatin RARE
treatment O
in O
the O
control O
cells O
caused O
an O
elevation O
in O
the O
levels O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor O
p27 I-GENE
( O
kip1 NUMERIC
), O
inhibition O
of O
both O
cyclin I-GENE
E I-GENE
- I-GENE
and I-GENE
cyclin I-GENE
A I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
activity O
, O
and O
decreased O
levels O
of O
hyperphosphorylated RARE
retinoblastoma I-GENE
protein I-GENE
( O
pRb I-GENE
). O

RESULTS O
: O
Circulating RARE
leptin I-GENE
concentrations O
in O
AN ALLCAPS
were O
3 O
. O
5 O
+/- O
0 O
. O
5 O
versus O
7 O
. O
6 O
+/- O
1 O
. O
2 O
ng O
/ O
ml O
in O
control O
subjects O
. O

Copyright O
1999 NUMERIC
Academic O
Press O
. O

Oligonucleotide RARE
probes O
corresponding O
to O
wild O
- O
type O
and O
mutant O
EpRE LASTCAP
sequences O
were O
used O
in O
gel O
- O
shift O
and O
super RARE
- O
shift O
analyses O
to O
identify O
proteins O
binding O
. O

PKNbeta RARE
had O
high O
sequence O
homology O
with O
PKNalpha RARE
, O
originally RARE
isolated O
PKN I-GENE
, O
especially O
in O
the O
repeats O
of O
charged O
amino O
acid O
- O
rich O
region O
with O
leucine O
- O
zipper O
like O
sequences O
( O
CZ ALLCAPS
region O
/ O
HR1 NUMERIC
), O
in O
the O
carboxyl O
- O
terminal O
catalytic O
domain O
, O
and O
in O
approximately O
130 O
amino O
acid O
stretch O
( O
D O
region O
/ O
HR2 NUMERIC
), O
located O
between O
CZ ALLCAPS
region O
/ O
HR1 NUMERIC
and O
the O
catalytic O
domain O
. O

At O
baseline O
, O
serum O
levels O
of O
lycopene RARE
and O
FLOP ALLCAPS
were O
abnormally RARE
high O
and O
serum O
FLOP ALLCAPS
was O
correlated O
significantly O
with O
plasma O
cyclosporine O
levels O
( O
r O
= O
0 O
. O
646 NUMERIC
, O
p O
= O
0 O
. O
016 NUMERIC
). O

BACKGROUND O
: O
Chronic O
alcohol O
consumption O
has O
been O
demonstrated O
to O
be O
deleterious RARE
to O
bone O
health O
. O

Interestingly O
, O
following O
induction O
of O
stress O
by O
heat O
shock O
, O
high O
salt O
, O
or O
ethanol O
, O
conditions O
under O
which O
most O
mRNA O
export O
is O
blocked O
, O
Npl3p NUMERIC
is O
still O
exported RARE
from O
the O
nucleus O
. O

For O
symptomatic O
relief RARE
and O
inhibition O
of O
the O
growth O
of O
the O
metastases O
interferon I-GENE
- I-GENE
a I-GENE
and O
somatostatin I-GENE
analogues O
can O
be O
employed O
. O

In O
summary O
, O
the O
no O
- O
adverse O
- O
effect O
- O
level O
for O
this O
study O
was O
determined O
to O
be O
1000 O
ppm O
, O
based O
on O
decreased O
weight O
gain O
in O
female O
rats O
, O
and O
on O
slight O
organ O
weight O
changes O
in O
both O
sexes RARE
at O
3000 NUMERIC
ppm O
. O

Some O
of O
them O
produce O
gigantic RARE
sperm O
several O
times O
the O
total O
male O
body O
length O
. O

John RARE
leonard RARE
dawson RARE

PDGF I-GENE
A I-GENE
- I-GENE
chain I-GENE
levels O
increase O
in O
cultured O
vascular O
smooth O
muscle O
cells O
( O
SMCs RARE
) O
exposed O
to O
ATII ALLCAPS
. O

M I-GENE
- I-GENE
Ras I-GENE
interacted O
poorly O
in O
a O
yeast O
two O
- O
hybrid O
assay O
with O
multiple O
Ras I-GENE
effectors O
, O
including O
c I-GENE
- I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
, O
A I-GENE
- I-GENE
Raf I-GENE
, O
B I-GENE
- I-GENE
Raf I-GENE
, O
phosphoinositol RARE
- I-GENE
3 I-GENE
kinase I-GENE
delta I-GENE
, O
RalGDS LASTCAP
, O
and O
Rin1 NUMERIC
. O

Deletion O
mapping O
of O
the O
human I-GENE
presenilin RARE
- I-GENE
1 I-GENE
( O
PS1 NUMERIC
) O
promoter O
delineated RARE
the O
most O
active O
fragment O
from O
- O
118 O
to O
+ O
178 NUMERIC
in O
relation O
to O
the O
transcription O
start O
site O
mapped O
in O
this O
study O
, O
in O
both O
human O
neuroblastoma O
SK ALLCAPS
- O
N O
- O
SH O
and O
hepatoma O
HepG2 O
cells O
. O

Microcirculatory RARE
oxygenation O
and O
shunting RARE
in O
sepsis O
and O
shock O
. O

Analysis O
of O
the O
E2F1 I-GENE
gene I-GENE
promoter I-GENE
showed O
that O
the O
- O
146 NUMERIC
to O
- O
54 O
region O
was O
required O
for O
E2 I-GENE
- O
responsiveness O
in O
transient O
transfection O
assays O
, O
and O
subsequent O
deletion O
/ O
mutation O
analysis O
showed O
that O
a O
single O
upstream O
GC O
- O
rich O
and O
two O
downstream O
CCAAT O
- O
binding O
sites O
were O
required O
for O
transactivation O
by O
E2 I-GENE
. O

In O
the O
course O
of O
investigating RARE
the O
mechanisms O
by O
which O
OF5 NUMERIC
and O
OF3 NUMERIC
regulated O
CYP11A1 NUMERIC
transcription O
, O
we O
found O
that O
OF5 NUMERIC
and O
OF3 NUMERIC
bound O
Sp1 I-GENE
and O
Sp3 I-GENE
in O
JEG ALLCAPS
- O
3 O
cells O
. O

In O
contrast O
, O
the O
differentiation O
of O
neoplastically RARE
transformed O
cells O
does O
not O
repress O
mitogenic O
responsiveness O
or O
junB I-GENE
or O
c I-GENE
- I-GENE
fos I-GENE
inducibility O
. O

Adipocyte RARE
differentiation O
of O
nontransformed RARE
cells O
also O
markedly O
represses O
the O
ability O
of O
SRF I-GENE
to O
bind O
to O
the O
junB I-GENE
SRE O
, O
the O
c I-GENE
- I-GENE
fos I-GENE
SRE O
, O
and O
other O
SREs RARE
, O
as O
determined O
by O
mobility O
shift O
and O
gel O
supershift O
assays O
, O
without O
affecting O
the O
DNA O
binding O
characteristics O
of O
the O
nuclear O
protein O
SP O
- O
1 O
. O

Transformation RARE
blocks O
differentiation O
- O
induced O
inhibition O
of O
serum I-GENE
response I-GENE
factor I-GENE
interactions O
with O
serum O
response O
elements O
. O

The O
core I-GENE
enzyme I-GENE
is O
homologous O
to O
those O
of O
bacteriophages RARE
T3 O
, O
T7 O
and O
SP6 NUMERIC
whereas O
the O
specificity O
factor O
shows O
similarities O
with O
bacterial I-GENE
sigma I-GENE
factors I-GENE
. O

The O
Cr I-GENE
. I-GENE
psbA LASTCAP
- I-GENE
4 I-GENE
ORF I-GENE
contains O
an O
H O
- O
N O
- O
H O
motif O
, O
and O
possibly O
a O
GIY ALLCAPS
- O
YIG ALLCAPS
motif O
. O

The O
interaction O
of O
zf4 NUMERIC
- I-GENE
6 I-GENE
with O
full I-GENE
- I-GENE
length I-GENE
5 I-GENE
S I-GENE
RNA I-GENE
was O
far O
more O
sensitive O
to O
non O
- O
specific O
competitor O
concentration O
than O
was O
the O
zf4 NUMERIC
- I-GENE
7 I-GENE
: O
5 I-GENE
S I-GENE
RNA I-GENE
interaction O
, O
suggesting O
that O
finger O
seven O
contributes O
to O
both O
affinity O
and O
specificity O
in O
this O
protein O
: O
RNA O
interaction O
. O

The O
STAT I-GENE
protein I-GENE
accumulation O
resulting O
from O
C I-GENE
/ I-GENE
EBP I-GENE
expression O
was O
tightly O
coupled O
to O
the O
morphological O
conversion O
of O
fibroblasts O
to O
adipocytes O
and O
represents O
an O
expression O
profile O
identical O
to O
that O
reported O
for O
mature O
adipocytes O
in O
vivo O
. O

The O
median O
durations O
for O
response O
and O
survival O
time O
in O
the O
late O
phase O
II O
trial O
were O
2 O
. O
3 O
months O
and O
5 O
. O
8 O
months O
, O
respectively O
. O

The O
role O
of O
' O
scientific RARE
psychiatry RARE
' O
in O
understanding O
patients O
with O
chronic O
schizophrenia O
or O
severe O
personality RARE
disorder O
. O

Myocardial O
antioxidant O
enzymes O
, O
catalase I-GENE
, O
glutathione I-GENE
peroxidase I-GENE
and O
superoxide I-GENE
dismutase I-GENE
, O
in O
the O
MCT ALLCAPS
- O
treated O
rats O
were O
not O
different O
compared O
to O
control O
rats O
. O

The O
second O
goal O
was O
to O
ascertain RARE
the O
somatotopic RARE
arrangement O
of O
the O
GPi RARE
in O
PD O
. O

These O
overall O
results O
indicate O
that O
there O
is O
generally O
one O
PERV ALLCAPS
copy O
per O
integration O
site O
. O

The O
present O
investigation O
conducted O
in O
a O
population O
of O
258 O
dentally RARE
aware RARE
individuals O
in O
the O
age O
range O
20 O
- O
69 O
years O
, O
was O
initiated O
to O
elucidate O
the O
relationship O
between O
tobacco O
smoking O
and O
supragingival RARE
calculus RARE
, O
taking O
into O
account O
possible O
confounding RARE
factors O
such O
as O
age O
, O
gender O
, O
oral O
hygiene RARE
and O
gingival RARE
inflammation O
. O

OBJECTIVE O
: O
To O
determine O
whether O
administration O
of O
misoprostol RARE
prevents O
gastric O
hemorrhage O
in O
healthy O
dogs O
treated O
with O
high O
doses O
of O
methylprednisolone RARE
sodium O
succinate RARE
( O
MPSS ALLCAPS
). O

Patients O
were O
assessed O
for O
cardiac O
MIBG ALLCAPS
uptake O
, O
circulating O
norepinephrine O
concentration O
, O
LVEF O
, O
peak O
Vo2 NUMERIC
, O
x O
- O
ray O
cardiothoracic RARE
ratio O
, O
M O
- O
mode O
echographic RARE
end O
- O
diastolic O
diameter O
and O
right O
- O
sided RARE
heart O
catheterization RARE
parameters O
. O

Nuclear O
hormone O
receptors O
( O
NRs RARE
) O
are O
ligand O
- O
inducible O
transcription O
factors O
that O
mediate O
critical O
functions O
in O
many O
species O
. O

These O
cells O
were O
able O
to O
present O
influenza O
virus O
particles O
to O
HLA I-GENE
- I-GENE
DR1 I-GENE
- O
restricted O
T O
cell O
clones O
. O

Sequencing O
of O
zebrafish RARE
( O
Danio RARE
rerio RARE
) O
bacterial O
artificial O
chromosome O
and O
P1 O
artificial O
chromosome O
genomic O
clone O
fragments O
and O
of O
cDNA O
clones O
has O
led O
to O
the O
identification O
of O
five O
new O
loci O
coding O
for O
beta O
subunits O
of O
proteasomes RARE
( O
PSMB ALLCAPS
). O

In O
addition O
to O
homologues O
of O
the O
human I-GENE
genes I-GENE
PSMB5 NUMERIC
through O
PSMB9 NUMERIC
, O
two O
new O
genes O
, O
PSMB11 NUMERIC
and O
PSMB12 NUMERIC
, O
have O
been O
found O
for O
which O
there O
are O
no O
known O
corresponding O
genes O
in O
humans O
. O

It O
applies RARE
Udry RARE
' O
s O
biosocial RARE
perspective RARE
, O
which O
attempts O
to O
reconcile RARE
the O
biological O
and O
sociological RARE
models O
of O
premarital RARE
sexual O
and O
reproductive O
behaviour O
. O

Weight RARE
and O
height O
z O
- O
scores O
were O
significantly O
associated O
with O
BMD O
z O
- O
scores O
. O

A O
limited O
sampling O
strategy O
was O
used O
based O
on O
a O
bayesian RARE
parameter O
estimation O
algorithm O
that O
is O
part O
of O
the O
ADAPT ALLCAPS
II O
software RARE
package RARE
. O

Interaction O
of O
HRI ALLCAPS
with O
Hsc70 NUMERIC
was O
required O
for O
the O
transformation O
of O
HRI ALLCAPS
, O
as O
the O
Hsc70 NUMERIC
antagonist O
clofibric RARE
acid O
inhibited O
the O
folding O
of O
HRI ALLCAPS
into O
a O
mature O
- O
competent O
conformation O
. O

The O
amino O
acid O
changes O
D206A NUMERIC
and O
D208A NUMERIC
abolish RARE
singly RARE
or O
in O
combination O
the O
exonuclease O
activity O
in O
vivo O
. O

Previous O
experimental O
evidence O
had O
indicated O
that O
Reg1 NUMERIC
might O
target O
Glc7 NUMERIC
to O
nuclear O
substrates O
such O
as O
the O
Snf1 NUMERIC
kinase I-GENE
complex I-GENE
. O

In O
the O
budding O
yeast O
, O
Saccharomyces O
cerevisiae O
, O
replicators RARE
can O
function O
outside O
the O
chromosome O
as O
autonomously O
replicating O
sequence O
( O
ARS O
) O
elements O
; O
however O
, O
within O
chromosome O
III O
, O
certain O
ARSs RARE
near O
the O
transcriptionally O
silent O
HML I-GENE
locus I-GENE
show O
no O
replication O
origin O
activity O
. O

These O
results O
suggest O
that O
, O
for O
the O
HML I-GENE
ARS O
cluster O
( O
ARS303 NUMERIC
, O
ARS320 NUMERIC
, O
and O
ARS302 NUMERIC
), O
inactivity RARE
of O
origins O
is O
independent O
of O
local O
transcriptional O
silencing O
, O
even O
though O
origins O
and O
silencers RARE
share O
key O
cis O
- O
and O
trans O
- O
acting O
components O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
expression O
of O
TD ALLCAPS
- I-GENE
IkappaBalpha I-GENE
blocked O
phorbol O
myristate O
acetate I-GENE
- I-GENE
phytohemagglutinin I-GENE
or O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
- O
induced O
IkappaBalpha I-GENE
gene I-GENE
transcription O
and O
abolished O
NF I-GENE
- I-GENE
kappaB I-GENE
DNA O
binding O
activity O
, O
due O
to O
the O
continued O
cytoplasmic O
sequestration RARE
of O
RelA I-GENE
( O
p65 I-GENE
) O
by O
TD ALLCAPS
- I-GENE
IkappaBalpha I-GENE
. O

( O
i O
) O
Complete RARE
Grb10 NUMERIC
expression O
from O
cDNA O
with O
an O
ecdysone O
- O
regulated O
transient O
expression O
system O
stimulated O
PDGF I-GENE
- I-GENE
BB I-GENE
-, O
IGF I-GENE
- I-GENE
I I-GENE
, O
and O
insulin I-GENE
- O
but O
not O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
)- O
induced O
DNA O
synthesis O
in O
an O
ecdysone O
dose O
- O
responsive O
fashion O
. O

The O
analysis O
of O
two O
distinct O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathways O
shows O
that O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- O
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
activation O
, O
resulting O
in O
the O
phosphorylation O
of O
ATF I-GENE
- I-GENE
2 I-GENE
, O
c I-GENE
- I-GENE
Jun I-GENE
, O
and O
JunD LASTCAP
, O
is O
required O
not O
only O
for O
the O
IL I-GENE
- I-GENE
1 I-GENE
- O
but O
also O
for O
the O
TPA O
- O
dependent O
induction O
, O
while O
the O
extracellular I-GENE
signal I-GENE
- I-GENE
related I-GENE
kinase I-GENE
1 I-GENE
( O
ERK I-GENE
- I-GENE
1 I-GENE
) O
and O
ERK I-GENE
- I-GENE
2 I-GENE
activation O
is O
involved O
in O
the O
TPA O
- O
but O
not O
in O
the O
IL I-GENE
- I-GENE
1 I-GENE
- O
dependent O
stimulation O
of O
the O
uPA I-GENE
enhancer I-GENE
. O

CONCLUSIONS O
: O
In O
healthy O
individuals O
, O
whole O
body O
insulin I-GENE
sensitivity O
is O
related O
, O
or O
" O
coupled O
, O
" O
to O
the O
anaerobic O
threshold O
. O

Interdomain RARE
signaling O
in O
a O
two O
- O
domain O
fragment O
of O
the O
human I-GENE
glucocorticoid I-GENE
receptor I-GENE
. O

In O
contrast O
, O
the O
xtRNA LASTCAP
( O
Sec RARE
) O
gene O
needs O
the O
binding O
of O
the O
seven O
Staf RARE
zinc I-GENE
fingers I-GENE
, O
but O
not O
Oct I-GENE
- I-GENE
1 I-GENE
, O
for O
optimal O
transcriptional O
capacity O
. O

Collectively O
, O
these O
results O
show O
that O
the O
differential O
utilization O
of O
Staf RARE
zinc I-GENE
finger I-GENE
1 I-GENE
represents O
a O
new O
, O
critical O
determinant O
of O
the O
transcriptional O
activation O
mechanism O
for O
the O
Xenopus I-GENE
tRNA I-GENE
( O
Sec RARE
) O
and O
human I-GENE
U6 I-GENE
snRNA I-GENE
genes I-GENE
. O

In O
B O
cells O
, O
HEF1 I-GENE
is O
phosphorylated O
by O
a O
cytoskeleton O
- O
dependent O
mechanism O
that O
is O
triggered O
by O
integrin I-GENE
ligation O
. O

The O
calcitonin I-GENE
- O
induced O
tyrosine O
phosphorylation O
of O
HEF1 I-GENE
increased O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
. O

Independent RARE
protrudor RARE
muscle O
stimulation O
increased O
VI O
, O
max O
( O
peak O
increase O
61 O
%, O
P O
< O
0 O
. O
05 O
), O
did O
not O
change O
Pcrit RARE
, O
and O
decreased O
Rn RARE
( O
peak O
decrease O
of O
41 O
%, O
P O
< O
0 O
. O
05 O
). O

We O
report O
the O
construction O
of O
an O
approximately O
1 O
. O
7 O
- O
Mb O
sequence O
- O
ready RARE
YAC O
/ O
BAC ALLCAPS
clone O
contig O
of O
8p22 NUMERIC
- O
p23 NUMERIC
. O

The O
human I-GENE
RAD30B NUMERIC
and O
mouse I-GENE
Rad30b NUMERIC
mRNA I-GENE
transcripts I-GENE
, O
like O
many O
repair O
proteins O
, O
are O
highly O
expressed O
in O
the O
testis O
. O

Analysis O
of O
the O
mouse I-GENE
STAP ALLCAPS
gene I-GENE
isolated O
from O
the O
genomic O
library O
revealed O
that O
the O
STAP ALLCAPS
gene I-GENE
spans O
a O
region O
of O
over O
11 O
kb O
and O
comprises O
eight O
exons O
. O

A O
reduced O
matrix O
distribution O
and O
enhanced O
cell O
density O
were O
observed O
as O
the O
biofilm RARE
aged O
. O

After O
10 O
months O
of O
treatment O
with O
the O
conjugated O
estrogen O
, O
both O
his O
height O
and O
weight O
showed O
improvement O
, O
while O
his O
bone O
mineral O
density O
and O
bone O
age O
were O
increased O
. O

Viscosity RARE
experiments O
on O
the O
catalytic O
fragment O
kinase O
reaction O
demonstrated O
that O
the O
chemical O
( O
phosphoryl RARE
transfer O
) O
step O
had O
a O
reduced O
rate O
. O

Velocity RARE
sedimentation O
, O
cross O
- O
linking O
, O
and O
immunoprecipitation O
analyses O
of O
detergent O
- O
solubilized RARE
rat O
brain O
revealed O
that O
the O
32 O
and O
34 O
kDa O
polypeptides O
reside O
within O
heterotetramers RARE
. O

In O
vitro O
expression O
levels O
of O
the O
different O
plasmids O
differed O
by O
as O
much O
as O
tenfold RARE
. O

In O
EEG O
only O
single O
slow O
waves O
above O
left O
temporal O
region O
were O
revealed O
. O

Molecular O
characterization O
of O
type O
- O
specific O
capsular RARE
polysaccharide RARE
biosynthesis O
genes O
of O
Streptococcus O
agalactiae RARE
type O
Ia RARE
. O

( O
1998 O
) O
FASEB ALLCAPS
J O
. O

IL I-GENE
- I-GENE
1beta I-GENE
( O
10 O
ng O
/ O
ml O
) O
drastically RARE
increased O
both O
PDGFalphaR LASTCAP
and O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
delta I-GENE
( O
C I-GENE
/ I-GENE
EBPdelta RARE
) O
mRNA O
levels O
in O
a O
time O
dependent O
manner O
. O

The O
recruitment O
of O
constitutively O
phosphorylated O
p185 NUMERIC
( O
neu I-GENE
) O
and O
the O
activated O
mitogenic O
pathway O
proteins O
to O
this O
membrane O
- O
microfilament RARE
interaction O
site O
provides O
a O
physical O
model O
for O
integrating RARE
the O
assembly O
of O
the O
mitogenic O
pathway O
with O
the O
transmission O
of O
growth O
factor O
signal O
to O
the O
cytoskeleton O
. O

Transient O
tyrosine O
phosphorylation O
of O
Crk I-GENE
in O
fibroblast I-GENE
growth I-GENE
factor I-GENE
- I-GENE
2 I-GENE
- O
stimulated O
endothelial O
cells O
was O
dependent O
on O
the O
juxtamembrane O
tyrosine O
residue O
463 NUMERIC
in O
FGFR I-GENE
- I-GENE
1 I-GENE
, O
and O
a O
Crk I-GENE
SH2 I-GENE
domain I-GENE
precipitated O
FGFR I-GENE
- I-GENE
1 I-GENE
via O
phosphorylated O
Tyr O
- O
463 NUMERIC
, O
indicating O
direct O
complex O
formation O
between O
Crk I-GENE
and O
FGFR I-GENE
- I-GENE
1 I-GENE
. O

ECG O
- O
gated O
myocardial O
Technetium RARE
- O
99m O
sestamibi RARE
SPECT O
is O
a O
useful O
technique O
to O
measure O
myocardial O
perfusion O
and O
function O
simultaneously O
. O

Role O
of O
the O
3 O
' O
untranslated O
region O
of O
baculovirus I-GENE
p10 NUMERIC
mRNA I-GENE
in O
high O
- O
level O
expression O
of O
foreign O
genes O
. O

The O
intron O
RNA O
consists O
of O
2492 NUMERIC
nucleotides O
which O
can O
be O
folded O
into O
a O
secondary O
structure O
with O
all O
the O
expected O
sequence O
motifs O
of O
subgroup O
- O
IIA1 NUMERIC
introns O
( O
Michel RARE
et O
al O
. O

The O
intron O
is O
capable O
of O
splicing O
despite O
the O
fact O
that O
both O
the O
EBS1 NUMERIC
/ O
IBS1 NUMERIC
and O
the O
EBS2 NUMERIC
/ O
IBS2 NUMERIC
sequence O
motifs O
, O
thought O
to O
be O
necessary O
for O
correct O
splicing O
, O
extend O
over O
5 O
instead O
of O
6 O
bp O
. O

The O
Trk RARE
/ I-GENE
Nerve RARE
Growth I-GENE
Factor I-GENE
receptor I-GENE
mediates O
the O
rapid O
activation O
of O
a O
number O
of O
intracellular O
signaling O
proteins O
, O
including O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
). O

The O
controversy RARE
of O
significance O
testing O
: O
misconceptions RARE
and O
alternatives RARE
. O

Chemical O
uptake O
into O
human O
stratum RARE
corneum RARE
in O
vivo O
from O
volatile O
and O
non O
- O
volatile O
solvents RARE
. O

Like O
DNA O
binding O
, O
transcriptional O
enhancement O
required O
amino O
- O
terminally O
located O
basic O
amino O
acid O
residues O
but O
not O
the O
carboxyl O
- O
terminal O
portion O
of O
Hap46 NUMERIC
known O
to O
participate O
in O
hsp70 I-GENE
interaction O
. O

We O
have O
tested O
the O
function O
of O
two O
potential O
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
like I-GENE
sites I-GENE
present O
in O
the O
PAI I-GENE
- I-GENE
2 I-GENE
proximal I-GENE
promoter I-GENE
for O
responsiveness O
to O
TNFalpha RARE
using O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
reporter I-GENE
gene I-GENE
deletion O
and O
mutation O
analyses O
. O

N O
- O
terminal O
sequence O
analysis O
and O
NMR O
measurements O
revealed O
that O
this O
fragment O
originates RARE
from O
the O
C O
- O
terminal O
80 O
residues O
of O
MBF1 NUMERIC
and O
form O
a O
well O
structured O
C O
- O
terminal O
domain O
of O
MBF1 NUMERIC
, O
MBF1CTD NUMERIC
. O

The O
nucleosomal RARE
response O
associated O
with O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
induction O
is O
mediated O
via O
alternative O
MAP I-GENE
kinase I-GENE
cascades I-GENE
: O
MSK1 NUMERIC
as O
a O
potential O
histone I-GENE
H3 I-GENE
/ O
HMG I-GENE
- I-GENE
14 I-GENE
kinase O
. O

The O
arrangement O
of O
these O
cutoff O
- O
levels O
leads O
to O
a O
sensitivity O
of O
85 O
% O
at O
a O
specificity O
of O
55 O
% O
for O
Protein I-GENE
S100 NUMERIC
when O
measured O
by O
RIA ALLCAPS
, O
and O
to O
a O
sensitivity O
of O
77 O
% O
at O
a O
specificity O
of O
61 O
% O
when O
measured O
by O
LIA ALLCAPS
. O

272 O
, O
1904 NUMERIC
]. O

Using O
16 O
strains O
of O
C O
. O
trachomatis RARE
in O
triplicate RARE
assays O
, O
we O
found O
the O
RT O
- O
PCR O
method O
consistently O
more O
sensitive O
than O
the O
conventional O
technique O
for O
all O
eight O
antimicrobials RARE
tested O
, O
with O
resultant RARE
MICs O
determined O
by O
RT O
- O
PCR O
ranging O
from O
1 O
. O
6 O
- O
fold O
higher O
( O
erythromycin RARE
) O
to O
>/= O
195 NUMERIC
- O
fold O
higher O
( O
amoxicillin O
). O

Null RARE
alleles O
of O
SAS4 NUMERIC
and O
SAS5 NUMERIC
bypassed RARE
the O
role O
of O
the O
Abf1p NUMERIC
binding I-GENE
site I-GENE
of O
the O
HMR I-GENE
- I-GENE
E I-GENE
silencer I-GENE
but O
not O
the O
role O
of O
the O
ACS ALLCAPS
or O
Rap1p NUMERIC
binding I-GENE
site I-GENE
. O

Recent O
molecular O
analysis O
has O
revealed O
that O
the O
S I-GENE
locus I-GENE
is O
highly O
polymorphic O
and O
contains O
several O
genes O
, O
i O
. O
e O
., O
SLG ALLCAPS
, O
SRK ALLCAPS
, O
the O
as O
- O
yet O
- O
unidentified O
pollen O
S O
gene O
( O
s O
), O
and O
other O
linked O
genes O
. O

A O
cDNA O
encoding O
a O
putative O
RNA I-GENE
and I-GENE
/ I-GENE
or I-GENE
DNA I-GENE
helicase I-GENE
has O
been O
isolated O
from O
Arabidopsis O
thaliana O
cDNA O
libraries O
. O

In O
vivo O
, O
MyoD I-GENE
requires O
this O
tryptophan O
motif O
to O
evoke RARE
chromatin O
remodeling O
in O
the O
Myogenin RARE
promoter I-GENE
and O
to O
activate O
Myogenin RARE
transcription O
. O

RESULTS O
: O
256 O
Periods RARE
of O
TTP ALLCAPS
or O
PUNP ALLCAPS
were O
reported O
by O
men O
and O
174 NUMERIC
by O
women O
. O

Feed RARE
intake O
and O
BW ALLCAPS
gains RARE
were O
decreased O
( O
P O
< O
0 O
. O
05 O
) O
by O
dietary O
treatments O
containing O
M O
. O

The O
N O
terminus O
of O
beta O
( O
95 O
kDa O
) O
corresponds O
to O
alpha O
with O
the O
integrase I-GENE
domain I-GENE
attached O
to O
the O
C O
terminus O
( O
32 O
kDa O
). O

Skn RARE
- I-GENE
1a I-GENE
lacking O
the O
C O
- O
terminal O
region O
completely O
lost O
transactivation O
ability O
, O
irrespective O
of O
the O
promoter O
tested O
, O
and O
was O
able O
to O
block O
transactivation O
by O
normal O
Skn RARE
- I-GENE
1a I-GENE
in O
competition O
assays O
. O

In O
early O
Xenopus O
embryos O
, O
the O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
member O
activin I-GENE
induces O
the O
gene I-GENE
Mix RARE
. I-GENE
2 I-GENE
by O
stimulating O
the O
formation O
of O
a O
multiprotein RARE
complex O
, O
activin I-GENE
- I-GENE
responsive I-GENE
factor I-GENE
( O
ARF I-GENE
). O

To O
further O
characterize O
the O
structure O
and O
evolutionary O
synthesis O
of O
the O
CMT1A NUMERIC
- O
REP ALLCAPS
repeat O
, O
fluorescent O
in O
situ O
hybridization O
( O
FISH ALLCAPS
) O
analysis O
and O
heterologous O
PCR O
- O
based O
assays O
were O
carried O
out O
for O
a O
series O
of O
primates O
. O

Natl RARE
. O

In O
the O
face O
of O
the O
outbreak O
, O
there O
was O
a O
delay O
before O
vaccination O
was O
able O
to O
stop O
deaths O
. O

Here O
we O
show O
that O
a O
novel O
isoform O
of O
Rapl RARE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
, O
called O
rap1GAPII NUMERIC
, O
binds O
specifically O
to O
the O
alpha O
- O
subunits O
of O
the O
G I-GENE
( I-GENE
i I-GENE
) I-GENE
family I-GENE
of O
heterotrimeric I-GENE
G I-GENE
- I-GENE
proteins I-GENE
. O

The O
B O
- O
oligomer RARE
of O
pertussis I-GENE
toxin I-GENE
deactivates RARE
CC I-GENE
chemokine I-GENE
receptor I-GENE
5 I-GENE
and O
blocks O
entry O
of O
M O
- O
tropic RARE
HIV O
- O
1 O
strains O
. O

Cross O
- O
linking O
the O
B I-GENE
cell I-GENE
Ag I-GENE
receptor I-GENE
( O
BCR I-GENE
) O
to O
surface I-GENE
Fc I-GENE
receptors I-GENE
for O
IgG I-GENE
( O
Fc I-GENE
gamma I-GENE
R I-GENE
) O
inhibits O
G1 O
- O
to O
- O
S O
progression O
; O
the O
mechanism O
by O
which O
this O
occurs O
is O
not O
completely O
known O
. O

Cross O
- O
linking O
the O
B I-GENE
cell I-GENE
Ag I-GENE
receptor I-GENE
( O
BCR I-GENE
) O
to O
surface I-GENE
Fc I-GENE
receptors I-GENE
for O
IgG I-GENE
( O
Fc I-GENE
gamma I-GENE
R I-GENE
) O
inhibits O
G1 O
- O
to O
- O
S O
progression O
; O
the O
mechanism O
by O
which O
this O
occurs O
is O
not O
completely O
known O
. O

TRAF2 I-GENE
is O
a O
potent O
activator O
of O
a O
95 I-GENE
- I-GENE
kDa I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
termed O
germinal RARE
center I-GENE
kinase I-GENE
related I-GENE
( O
GCKR ALLCAPS
, O
also O
referred O
to O
as O
KHS1 NUMERIC
), O
which O
signals O
activation O
of O
the O
SAPK I-GENE
pathway O
. O

An O
activation O
- O
responsive O
element O
in O
single I-GENE
C I-GENE
motif I-GENE
- I-GENE
1 I-GENE
/ O
lymphotactin RARE
promoter O
is O
a O
site O
of O
constitutive O
and O
inducible O
DNA O
- O
protein O
interactions O
involving O
nuclear O
factor O
of O
activated O
T O
cell O
. O

Cytokine RARE
- O
induced O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
DNA O
binding O
activity O
, O
RelA I-GENE
nuclear O
translocation O
, O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
degradation O
, O
I I-GENE
kappa I-GENE
B I-GENE
serine O
32 O
phosphorylation O
, O
and O
I I-GENE
kappa I-GENE
B I-GENE
kinase I-GENE
( O
IKK ALLCAPS
) O
activity O
were O
blocked O
by O
curcumin RARE
treatment O
. O

A O
portion O
of O
p193 NUMERIC
is O
nuclear O
and O
localizes O
to O
the O
mitotic O
spindle O
. O

The O
main O
issues O
are O
the O
need O
to O
explain O
a O
number O
of O
still O
unknown O
mechanisms O
, O
to O
determine O
which O
" O
natural O
diet O
" O
carries O
the O
minimum O
coronary O
risk O
and O
whether O
" O
new O
" O
foods RARE
produced O
by O
modern O
technology O
are O
really RARE
needed O
to O
contrast O
this O
epidemic O
. O

Cotransfection O
of O
the O
coactivator O
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
relieved RARE
the O
transcriptional O
repression O
of O
PPARalphawt RARE
by O
PPARalphatr RARE
, O
suggesting O
that O
the O
dominant O
negative O
effect O
of O
PPARalphatr RARE
might O
occur O
through O
competition O
for O
essential O
coactivators RARE
. O

SF I-GENE
- I-GENE
1 I-GENE
does O
not O
have O
an O
N O
- O
terminal O
AF1 NUMERIC
domain O
. O

To O
estimate O
the O
locations O
of O
sources O
with O
the O
TF O
- O
MUSIC ALLCAPS
algorithm O
, O
we O
first O
set O
the O
target O
region O
on O
the O
spectrogram RARE
of O
the O
somatosensory RARE
responses O
. O

We O
discuss O
these O
results O
in O
terms O
of O
the O
influence O
that O
time O
and O
nutritional O
constraints RARE
have O
on O
odonate RARE
development O
patterns O
and O
fitness O
. O

OBJECTIVE O
: O
1998 O
Surveillance RARE
, O
Epidemiology RARE
, O
and O
End RARE
Results O
( O
SEER ALLCAPS
) O
data O
estimate O
an O
83 O
. O
1 O
% O
5 O
- O
year O
survival O
rate O
for O
corpus RARE
uteri RARE
adenocarcinoma O
FIGO ALLCAPS
stage O
II O
. O

A O
novel O
Drosophila I-GENE
A I-GENE
kinase I-GENE
anchor I-GENE
protein I-GENE
, O
Drosophila I-GENE
A I-GENE
kinase I-GENE
anchor I-GENE
protein I-GENE
200 I-GENE
( O
DAKAP200 NUMERIC
), O
is O
predicted O
to O
be O
involved O
in O
routing RARE
, O
mediating O
, O
and O
integrating RARE
signals O
carried O
by O
cAMP O
, O
Ca O
( O
2 O
+), O
and O
diacylglycerol RARE
( O
Li O
, O
Z O
., O
Rossi RARE
, O
E O
. O

In O
vitro O
transcription O
results O
indicate O
that O
this O
5 O
' O
structure O
functions O
in O
the O
attenuation O
mechanism O
, O
since O
deletion O
of O
the O
stem O
- O
loop O
caused O
an O
increase O
in O
transcription O
readthrough O
. O

A O
5 O
' O
RNA O
stem O
- O
loop O
participates O
in O
the O
transcription O
attenuation O
mechanism O
that O
controls O
expression O
of O
the O
Bacillus I-GENE
subtilis I-GENE
trpEDCFBA LASTCAP
operon I-GENE
. O

Single RARE
- O
alanine O
- O
substitution O
mutations O
had O
minimal O
, O
if O
any O
, O
effects O
on O
S O
- O
induced O
cell O
- O
to O
- O
cell O
fusion O
. O

Furthermore O
, O
we O
demonstrate O
that O
transcription O
from O
the O
MMTV I-GENE
5 I-GENE
' I-GENE
LTR I-GENE
is O
highly O
active O
in O
the O
absence O
of O
Stat5a I-GENE
, O
a O
transcription O
factor O
that O
had O
been O
shown O
previously O
to O
be O
required O
for O
transcription O
from O
the O
MMTV I-GENE
LTR I-GENE
. O

Regional RARE
insertional O
mutagenesis O
of O
specific O
genes O
on O
the O
CIC5F11 NUMERIC
/ O
CIC2B9 NUMERIC
locus O
of O
Arabidopsis O
thaliana O
chromosome O
5 O
using O
the O
Ac I-GENE
/ O
Ds RARE
transposon O
in O
combination O
with O
the O
cDNA O
scanning O
method O
. O

RESULTS O
: O
CK I-GENE
- O
MB I-GENE
elevation O
was O
detected O
in O
313 NUMERIC
patients O
( O
18 O
. O
7 O
%), O
with O
1 O
- O
3x NUMERIC
in O
12 O
. O
8 O
%, O
3 O
- O
5x NUMERIC
in O
3 O
. O
5 O
% O
and O
> O
5x NUMERIC
normal O
in O
2 O
. O
4 O
% O
of O
patients O
. O

Thus O
, O
NART ALLCAPS
- O
R O
performance O
may O
not O
be O
a O
valid RARE
estimate O
of O
baseline O
IQ ALLCAPS
for O
patients O
with O
neurologic O
disorders O
with O
suspected O
language O
impairment O
. O

Activated RARE
areas O
have O
been O
identified O
by O
means O
of O
cross O
- O
correlation O
analysis O
. O

Natural RARE
Haemophilus O
influenzae O
type O
b O
capsular RARE
polysaccharide RARE
antibodies O
in O
412 NUMERIC
infants O
and O
children O
from O
West RARE
Africa RARE
( O
Burkina RARE
- O
Faso RARE
) O
and O
France RARE
: O
a O
cross O
- O
sectional O
serosurvey RARE
. O

In O
this O
study O
, O
we O
identified O
Sp1 I-GENE
and O
Sp3 I-GENE
as O
major O
factors O
binding O
to O
the O
Sp1 I-GENE
sites I-GENE
of O
the O
p21 I-GENE
/ O
WAF1 I-GENE
/ O
Cip1 I-GENE
promoter O
in O
MG63 NUMERIC
cells O
through O
electrophoretic O
mobility O
shift O
assays O
and O
showed O
that O
TSA ALLCAPS
treatment O
did O
not O
change O
their O
binding O
activities O
. O

Galoyan RARE
has O
summarized RARE
the O
results O
of O
his O
discovery O
of O
cardioactive RARE
neurohormones RARE
. O

To O
study O
the O
regulation O
of O
its O
expression O
, O
the O
human I-GENE
aldehyde RARE
reductase I-GENE
gene I-GENE
and O
promoter O
were O
cloned O
and O
characterized O
. O

Immunohistochemical RARE
staining O
with O
MIB ALLCAPS
- I-GENE
1 I-GENE
and O
p53 I-GENE
antibodies I-GENE
showed O
low O
(< O
1 O
%) O
and O
negative O
reaction O
. O

The O
C2C NUMERIC
- O
Prx RARE
is O
encoded O
as O
a O
preprotein RARE
of O
273 NUMERIC
amino O
acids O
containing O
a O
putative O
chloroplast O
- O
targeting O
signal O
of O
65 O
amino O
acids O
at O
its O
N O
- O
terminus O
. O

Immediately RARE
before O
surgery O
patients O
received O
either O
intravenous O
hydrocortisone RARE
100 O
mg O
or O
placebo O
in O
random O
, O
double O
- O
blind O
order O
. O

A O
tyrosine O
- O
based O
sorting O
signal O
in O
the O
beta2 I-GENE
integrin I-GENE
cytoplasmic I-GENE
domain I-GENE
mediates O
its O
recycling RARE
to O
the O
plasma O
membrane O
and O
is O
required O
for O
ligand O
- O
supported O
migration O
. O

The O
injection O
of O
XDRP1 NUMERIC
protein I-GENE
into O
fertilized RARE
Xenopus O
eggs O
blocked O
embryonic O
cell O
division O
. O

Using O
transgenic O
Xenopus O
embryos O
, O
we O
demonstrate O
that O
the O
integrity O
of O
these O
two O
sequences O
is O
necessary O
for O
correct O
spatial O
expression O
of O
a O
Xbra2 NUMERIC
promoter I-GENE
- I-GENE
driven I-GENE
reporter I-GENE
gene I-GENE
. O

In O
order O
to O
screen O
for O
such O
cofactors RARE
, O
we O
have O
used O
a O
transcriptionally O
inactive O
mutant O
of O
Xenopus I-GENE
MEF2D NUMERIC
in O
a O
yeast O
two O
- O
hybrid O
screen O
. O

NuA4 NUMERIC
has O
an O
apparent O
molecular O
mass O
of O
1 O
. O
3 O
MDa RARE
. O

ATF1 NUMERIC
transcription O
is O
negatively O
regulated O
by O
unsaturated RARE
fatty O
acids O
and O
oxygen O
. O

Two O
patients O
with O
recurrent O
tumors O
had O
high O
S O
- O
phase O
fractions O
both O
on O
the O
first O
resected RARE
specimens O
and O
at O
the O
time O
of O
the O
second O
operation O
. O

Mutation O
of O
TTF I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
( I-GENE
TBE ALLCAPS
) I-GENE
1 I-GENE
, I-GENE
3 I-GENE
, I-GENE
and I-GENE
4 I-GENE
in O
combination O
markedly O
decreased O
transcriptional O
activity O
of O
SP I-GENE
- I-GENE
A I-GENE
promoter O
- O
chloramphenicol I-GENE
acetyltransferase I-GENE
constructs O
containing O
SP I-GENE
- I-GENE
A I-GENE
gene I-GENE
sequences O
from O
- O
256 O
to O
+ O
45 O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
I I-GENE
induces O
bcl I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
through O
the O
transcription O
factor O
cAMP I-GENE
- I-GENE
response I-GENE
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

Synthesis RARE
of O
antisense O
RNA O
and O
S O
phase O
- O
dependent O
binding O
of O
E2F I-GENE
complexes I-GENE
in O
intron O
1 O
. O

Identification O
of O
eotaxin RARE
- I-GENE
3 I-GENE
will O
further O
promote O
our O
understanding O
of O
the O
control O
of O
eosinophil O
trafficking O
and O
other O
CCR3 NUMERIC
- O
mediated O
biological O
phenomena O
. O

NF I-GENE
- I-GENE
kappaB I-GENE
plays O
a O
critical O
role O
in O
activation O
of O
HIV O
- O
1 O
gene O
expression O
by O
cytokines O
and O
other O
stimuli O
, O
but O
the O
signal O
transduction O
pathways O
that O
regulate O
the O
switch O
from O
latent O
to O
productive RARE
infection O
have O
not O
been O
defined O
. O

These O
studies O
suggest O
that O
MAPK I-GENE
acts O
by O
stimulating O
AP I-GENE
- I-GENE
1 I-GENE
and O
a O
subsequent O
physical O
and O
functional O
interaction O
of O
AP I-GENE
- I-GENE
1 I-GENE
with O
NF I-GENE
- I-GENE
kappaB I-GENE
, O
resulting O
in O
a O
complex O
that O
synergistically O
transactivates O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
. O

ERK I-GENE
MAP I-GENE
kinase I-GENE
links O
cytokine O
signals O
to O
activation O
of O
latent O
HIV O
- O
1 O
infection O
by O
stimulating O
a O
cooperative O
interaction O
of O
AP I-GENE
- I-GENE
1 I-GENE
and O
NF I-GENE
- I-GENE
kappaB I-GENE
. O

A O
human O
nuclear O
- O
localized O
chaperone RARE
that O
regulates O
dimerization O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
bZIP I-GENE
proteins I-GENE
. O

Clinical O
differentiation O
of O
patients O
with O
mild O
diplegic RARE
cerebral O
palsy RARE
( O
CP O
) O
and O
idiopathic O
toe O
walking RARE
( O
ITW ALLCAPS
) O
can O
be O
difficult O
. O

Sputum RARE
IL I-GENE
- I-GENE
8 I-GENE
and O
MPO ALLCAPS
were O
significantly O
increased O
after O
BPT ALLCAPS
in O
both O
TDI ALLCAPS
- O
and O
grain RARE
dust O
- O
asthma O
( O
P O
< O
0 O
. O
05 O
). O

Montelukast RARE
reduces O
airway O
eosinophilic RARE
inflammation O
in O
asthma O
: O
a O
randomized O
, O
controlled O
trial O
. O

Treatment O
of O
unstable O
angina O
: O
role O
of O
antithrombotic RARE
therapy O
. O

Here O
, O
we O
demonstrate O
that O
kinase O
- O
dead RARE
but O
not O
wild O
- O
type O
forms O
of O
Fyn I-GENE
, O
Lck I-GENE
, O
and O
ZAP I-GENE
- I-GENE
70 I-GENE
block O
70Z NUMERIC
Cbl I-GENE
- O
mediated O
NFAT I-GENE
activation O
. O

Substitutions RARE
of O
region O
I O
with O
synthetic O
sequences O
showed O
that O
no O
specific O
sequence O
but O
rather O
repeats O
of O
three O
or O
more O
consecutive O
adenines RARE
or O
thymines RARE
, O
without O
interruption RARE
by O
guanine O
or O
cytosine O
, O
are O
required O
for O
the O
ARS O
activity O
. O

In O
Saccharomyces O
cerevisiae O
, O
PHO85 NUMERIC
encodes O
a O
cyclin I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
catalytic O
subunit O
with O
multiple O
regulatory O
roles O
thought O
to O
be O
specified O
by O
association O
with O
different O
cyclin I-GENE
partners O
( O
Pcls RARE
). O

Mutants RARE
with O
mild O
lace RARE
alleles I-GENE
grow O
to O
become O
adults O
with O
multiple O
aberrant O
morphologies RARE
in O
the O
appendages RARE
, O
compound O
eye O
, O
and O
bristles RARE
. O

In O
fact O
, O
SPT ALLCAPS
activity O
in O
the O
fly RARE
expressing O
epitope O
- O
tagged O
Lace RARE
was O
absorbed O
by O
epitope O
- O
specific O
antibody O
. O

Mutations O
of O
the O
RET I-GENE
gene I-GENE
, O
encoding O
a O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
, O
have O
been O
associated O
with O
the O
inherited O
cancer O
syndromes O
MEN ALLCAPS
2A O
and O
MEN ALLCAPS
2B O
. O

These O
results O
show O
that O
targeting O
of O
Ras I-GENE
- O
GAP I-GENE
could O
represent O
a O
novel O
anticancer RARE
approach O
. O

EB ALLCAPS
- I-GENE
1 I-GENE
, O
a O
tyrosine I-GENE
kinase I-GENE
signal I-GENE
transduction I-GENE
gene I-GENE
, O
is O
transcriptionally O
activated O
in O
the O
t O
( O
1 O
; O
19 O
) O
subset O
of O
pre O
- O
B O
ALL O
, O
which O
express O
oncoprotein O
E2a NUMERIC
- O
Pbx1 NUMERIC
. O

Protein I-GENE
kinase I-GENE
A I-GENE
- I-GENE
Ialpha RARE
subunit O
- O
directed O
antisense O
inhibition O
of O
ovarian O
cancer O
cell O
growth O
: O
crosstalk RARE
with O
tyrosine I-GENE
kinase I-GENE
signaling O
pathway O
. O

BCL6 NUMERIC
encodes O
a O
POZ I-GENE
/ I-GENE
Zn I-GENE
finger I-GENE
protein I-GENE
, O
a O
structure O
similar O
to O
that O
of O
many O
Drosophila O
developmental O
regulators O
and O
to O
another O
protein O
involved O
in O
a O
human O
hematopoietic O
malignancy O
, O
PLZF I-GENE
. O

Beta RARE
1 I-GENE
integrin I-GENE
- O
and O
proteoglycan O
- O
mediated O
stimulation O
of O
T O
lymphoma O
cell O
adhesion O
and O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
signaling O
by O
thrombospondin RARE
- I-GENE
1 I-GENE
and O
thrombospondin RARE
- I-GENE
1 I-GENE
peptides I-GENE
. O

Optical RARE
CD O
, O
and O
spectral O
and O
activity O
analyses O
were O
used O
to O
examine O
reactivity O
of O
HO ALLCAPS
isozymes RARE
with O
NO O
species O
produced O
by O
NO O
donors O
. O

The O
phosphotransferase O
system O
( O
PTS ALLCAPS
) O
of O
Streptomyces O
coelicolor RARE
identification O
and O
biochemical O
analysis O
of O
a O
histidine I-GENE
phosphocarrier RARE
protein I-GENE
HPr RARE
encoded O
by O
the O
gene O
ptsH LASTCAP
. O

Serum O
concentrations O
of O
bone I-GENE
specific I-GENE
alkaline I-GENE
phosphatase I-GENE
( O
BALP ALLCAPS
) O
and O
osteocalcin RARE
( O
bone I-GENE
Gla RARE
protein I-GENE
, O
BGP ALLCAPS
), O
urinary O
levels O
of O
pyridinoline RARE
( O
Pyr RARE
) O
and O
deoxypyridinoline RARE
( O
Dpyr RARE
) O
and O
computed O
tomography O
( O
CT O
) O
measurements O
of O
the O
cross O
- O
sectional O
areas O
of O
the O
vertebrae RARE
and O
the O
femurs RARE
, O
the O
apparent O
density O
of O
cancellous RARE
bone O
in O
the O
vertebrae RARE
, O
and O
the O
volume O
and O
the O
material O
density O
of O
cortical O
bone O
in O
the O
femurs RARE
were O
determined O
in O
126 O
boys O
and O
143 O
girls O
, O
ages O
7 O
- O
18 O
years O
. O

In O
another O
study O
, O
intravenous O
administration O
of O
devazepide RARE
, O
a O
specific O
cholecystokinin RARE
- I-GENE
A I-GENE
receptor I-GENE
antagonist O
, O
at O
a O
dose O
of O
0 O
. O
1 O
mg O
/ O
kg O
/ O
hr O
was O
begun RARE
15 O
min O
before O
postprandial RARE
saline O
intake O
and O
continued O
for O
1 O
hr O
. O

This O
cluster O
consisted O
of O
four O
apparently O
unrelated O
ESTs O
and O
two O
genes O
, O
pregnancy I-GENE
- I-GENE
associated I-GENE
plasma I-GENE
protein I-GENE
- I-GENE
A I-GENE
( O
PAPP ALLCAPS
- I-GENE
A I-GENE
) O
and O
a O
novel O
gene O
( O
tentatively O
named O
EST I-GENE
- I-GENE
YD1 NUMERIC
). O

Prognostic RARE
value O
of O
a O
treadmill RARE
exercise O
score O
in O
symptomatic O
patients O
with O
nonspecific O
ST O
- O
T O
abnormalities O
on O
resting O
ECG O
. O

Structural O
changes O
in O
the O
C O
- O
terminus O
of O
Ca2 O
+- O
bound O
rat I-GENE
S100B NUMERIC
( O
beta I-GENE
beta I-GENE
) O
upon O
binding O
to O
a O
peptide O
derived O
from O
the O
C O
- O
terminal O
regulatory O
domain O
of O
p53 I-GENE
. O

We O
propose O
that O
Gly84 NUMERIC
is O
part O
of O
a O
putative O
" O
oxyanion RARE
hole RARE
" O
involved O
in O
the O
stabilization O
of O
the O
transition O
state O
similar O
to O
the O
C I-GENE
group I-GENE
of O
the O
esterase I-GENE
/ O
lipase I-GENE
family O
. O

The O
solution O
structure O
of O
the O
adduct RARE
derived O
from O
the O
covalent RARE
bonding RARE
of O
the O
fjord RARE
region O
(+)-( RARE
11S NUMERIC
, O
12R NUMERIC
, O
13R NUMERIC
, O
14S NUMERIC
) O
stereoisomer RARE
of O
anti O
- O
11 O
, O
12 O
- O
dihydroxy RARE
- O
13 O
, O
14 O
- O
epoxy RARE
- O
11 O
, O
12 O
, O
13 O
, O
14 O
- O
tetrahydrobenzo RARE
[ O
g O
] O
chrysene RARE
, O
(+)- O
anti O
- O
B O
[ O
g O
] O
CDE ALLCAPS
, O
to O
the O
exocyclic RARE
N O
( O
6 O
) O
amino O
group O
of O
the O
adenine O
residue O
dA6 NUMERIC
, O
( O
designated O
(+)- O
trans O
- O
anti O
-( O
B O
[ O
g O
] O
C O
) O
dA6 NUMERIC
), O
positioned O
opposite O
a O
thymine RARE
residue O
dT17 NUMERIC
in O
the O
DNA O
sequence O
context O
d O
( O
C1 O
- O
T2 O
- O
C3 O
- O
T4 O
- O
C5 NUMERIC
-( O
B O
[ O
g O
] O
C O
) O
A6 NUMERIC
- O
C7 NUMERIC
- O
T8 NUMERIC
- O
T9 NUMERIC
- O
C10 NUMERIC
- O
C11 NUMERIC
). O
d O
( O
G12 NUMERIC
- O
G13 NUMERIC
- O
A14 NUMERIC
- O
A15 NUMERIC
- O
G16 NUMERIC
- O
T17 NUMERIC
- O
G18 NUMERIC
- O
A19 NUMERIC
- O
G20 NUMERIC
++ RARE
+- O
A21 NUMERIC
- O
G22 NUMERIC
) O
( O
designated O
( O
B O
[ O
g O
] O
C O
) O
dA LASTCAP
. O
dT O
11 O
- O
mer O
duplex O
), O
has O
been O
studied O
using O
structural O
information O
derived O
from O
NMR O
data O
in O
combination O
with O
molecular O
dynamics O
( O
MD ALLCAPS
) O
calculations RARE
. O

Since O
sildenafil RARE
came RARE
on O
the O
market RARE
, O
it O
seems O
that O
the O
place O
of O
MUSE ALLCAPS
is O
reduced O
because O
comparative O
studies O
give O
better O
results O
for O
sildenafil RARE
than O
MUSE ALLCAPS
( O
70 O
% O
vs O
40 O
%) O
and O
of O
course O
with O
a O
better O
acceptance RARE
. O

Serum O
antibodies O
were O
detected O
in O
at O
least O
95 O
% O
of O
the O
infected O
guinea O
pigs O
between O
4 O
- O
30 O
WPI ALLCAPS
and O
rats O
between O
3 O
- O
16 O
WPI ALLCAPS
. O

During O
both O
encephalopathy RARE
episodes O
, O
CSF O
protein O
and O
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
levels O
were O
elevated O
without O
an O
increased O
IgG I-GENE
index O
or O
IgG I-GENE
synthesis O
rate O
. O

CONCLUSIONS O
: O
These O
results O
show O
that O
once O
daily O
oral O
valganciclovir RARE
can O
produce O
exposures O
of O
ganciclovir RARE
( O
AUC24 NUMERIC
) O
exceeding RARE
those O
attained RARE
using O
intravenous O
ganciclovir RARE
10 O
mg O
/ O
kg O
. O

Except RARE
for O
nonperfusion RARE
of O
neurosensory RARE
retinal O
vessels O
at O
a O
light O
dose O
of O
150 O
J O
/ O
cm2 O
, O
no O
other O
adverse O
events O
were O
of O
concern RARE
. O

Except RARE
for O
nonperfusion RARE
of O
neurosensory RARE
retinal O
vessels O
at O
a O
light O
dose O
of O
150 O
J O
/ O
cm2 O
, O
no O
other O
adverse O
events O
were O
of O
concern RARE
. O

The O
healing O
rate O
in O
HIV O
- O
positive O
patients O
was O
66 O
percent O
after O
14 O
weeks O
and O
100 O
percent O
after O
32 O
weeks O
; O
the O
corresponding O
figures RARE
for O
patients O
with O
acquired O
immunodeficiency O
syndrome O
were O
0 O
and O
50 O
percent O
. O

The O
P I-GENE
mRNA I-GENE
also O
contains O
a O
third O
ORF O
for O
the O
V I-GENE
protein I-GENE
, O
although O
it O
is O
unclear O
how O
or O
whether O
this O
ORF O
is O
accessed RARE
. O

A O
genetic O
screen O
in O
yeast O
has O
allowed O
us O
to O
identify O
a O
novel O
transcriptional O
factor O
binding O
to O
the O
GlRE LASTCAP
, O
i O
. O
e O
. O
the O
chicken I-GENE
ovalbumin RARE
upstream I-GENE
promoter I-GENE
- I-GENE
transcription I-GENE
factor I-GENE
II I-GENE
( O
COUP I-GENE
- I-GENE
TFII ALLCAPS
). O

We O
have O
cloned O
the O
single O
- O
copy O
gene O
for O
the O
trans I-GENE
- I-GENE
spliceosomal RARE
U5 I-GENE
snRNA I-GENE
from O
the O
trypanosomatid RARE
species O
Leptomonas RARE
seymouri RARE
, O
using O
U5 I-GENE
RNA I-GENE
affinity O
selection O
and O
cDNA O
cloning O
. O

The O
MMPI O
- O
A O
( O
Butcher RARE
et O
al O
., O
1992 O
), O
like O
the O
older O
MMPI O
( O
Hathaway RARE
& O
McKinley RARE
, O
1983 O
), O
distinguishes RARE
between O
anorexia RARE
and O
bulimia RARE
. O

On O
the O
other O
hand O
, O
phosphatidyl RARE
inositol O
4 O
, O
5 O
bisphosphate RARE
( O
PIP2 O
) O
hydrolysis O
requires O
direct O
phosphorylation O
at O
tyrosine O
residue O
of O
the O
PLC I-GENE
- I-GENE
gamma1 NUMERIC
isozyme RARE
. O

A O
G22V NUMERIC
mutant I-GENE
of O
M I-GENE
- I-GENE
Ras I-GENE
was O
constitutively O
active O
and O
its O
expression O
in O
an O
interleukin I-GENE
- I-GENE
3 I-GENE
( O
IL I-GENE
- I-GENE
3 I-GENE
)- O
dependent O
mast O
cell O
/ O
megakaryocyte RARE
cell O
line O
resulted O
in O
increased O
survival O
in O
the O
absence O
of O
IL I-GENE
- I-GENE
3 I-GENE
, O
increased O
growth O
in O
IL I-GENE
- I-GENE
4 I-GENE
, O
and O
, O
at O
high O
expression O
levels O
, O
in O
factor O
- O
independent O
growth O
. O

Mammalian RARE
M I-GENE
- I-GENE
Ras I-GENE
and O
a O
Caenorhabditis O
elegans O
orthologue RARE
exhibit O
conserved O
structural O
features O
, O
and O
these O
are O
likely O
to O
mediate O
activation O
of O
distinctive O
signaling O
paths RARE
that O
function O
in O
parallel O
to O
those O
downstream O
of O
p21 I-GENE
Ras I-GENE
. O

Taken O
together O
, O
our O
data O
suggest O
that O
PecS LASTCAP
attenuates O
pelD LASTCAP
and O
pelE LASTCAP
expression O
rather O
than O
acting O
as O
a O
true O
repressor O
like O
KdgR LASTCAP
. O

These O
observations O
establish O
that O
RsmC LASTCAP
negatively O
regulates O
rsmB LASTCAP
transcription O
but O
positively O
affects O
RsmA LASTCAP
production O
. O

All O
were O
experienced O
hearing O
aid O
users O
who O
wore RARE
linear O
Class O
D O
instruments O
with O
input O
compression O
limiting O
at O
the O
time O
of O
their O
enrollment RARE
in O
this O
study O
. O

SCOB ALLCAPS
testing O
of O
food O
- O
restricted O
animals O
, O
using O
a O
multiple O
fixed O
ratio O
( O
FR O
)/ O
fixed O
interval O
( O
FI ALLCAPS
) O
schedule O
( O
FR20 NUMERIC
: O
FI120 NUMERIC
), O
was O
conducted O
prior O
to O
each O
exposure O
to O
maintain O
the O
operant RARE
behavior O
; O
the O
data O
from O
Weeks RARE
- O
1 O
, O
4 O
, O
8 O
, O
and O
13 O
were O
evaluated O
for O
evidence O
of O
neurotoxicity O
. O

Ribonuclease RARE
protection O
assays O
revealed O
that O
hmg1 NUMERIC
and O
hmg2 NUMERIC
are O
differentially O
expressed O
in O
a O
developmentally O
- O
and O
spatially O
- O
modulated O
manner O
during O
morphogenesis RARE
of O
specialized O
terpenoid RARE
- O
containing O
pigment RARE
glands O
in O
embryos O
. O

Differential O
expression O
was O
confirmed O
by O
Northern O
blot O
analysis O
employing O
multiple O
normal O
and O
tumor O
cell O
lines O
. O

Inactivation RARE
of O
the O
Neurospora I-GENE
crassa I-GENE
mitochondrial I-GENE
outer I-GENE
membrane I-GENE
protein I-GENE
TOM70 NUMERIC
by O
repeat O
- O
induced O
point O
mutation O
( O
RIP ALLCAPS
) O
causes O
defects O
in O
mitochondrial O
protein O
import O
and O
morphology O
. O

Several O
genes O
or O
transcriptional O
units O
were O
identified O
, O
including O
the O
3 O
' O
end O
of O
ribosomal I-GENE
s6 NUMERIC
kinase I-GENE
( O
Rsk3 NUMERIC
); O
two O
apparently O
intronless O
and O
ORF O
- O
less O
genes O
; O
and O
Gpr31 NUMERIC
, O
an O
intronless O
, O
putative O
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
receptor I-GENE
. O

The O
results O
suggest O
that O
GATA I-GENE
- I-GENE
5 I-GENE
may O
have O
specific O
downstream O
targets O
and O
that O
GATA I-GENE
- I-GENE
4 I-GENE
, I-GENE
- I-GENE
5 I-GENE
, I-GENE
and I-GENE
- I-GENE
6 I-GENE
can O
only O
partially O
substitute O
for O
each O
other O
in O
cardiogenesis RARE
. O

This O
study O
was O
designed O
to O
compare O
the O
efficacy O
of O
efegatran RARE
plus O
streptokinase RARE
versus O
heparin O
plus O
accelerated O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( O
TPA I-GENE
) O
in O
coronary O
reperfusion O
in O
acute O
MI O
. O

Recently O
, O
cell O
- O
surface O
TRAIL ALLCAPS
has O
been O
shown O
to O
be O
expressed O
by O
activated O
human O
and O
mouse O
T O
lymphocytes O
, O
raising RARE
the O
possibility O
that O
TRAIL ALLCAPS
might O
be O
involved O
in O
T O
cell O
- O
mediated O
cytotoxicity O
and O
/ O
or O
immune O
regulation O
. O

A O
panel O
of O
pharmacologic RARE
inhibitors O
was O
used O
to O
investigate O
the O
signal O
transduction O
pathways O
involved O
in O
TRAIL ALLCAPS
gene I-GENE
induction O
following O
T O
lymphocyte O
activation O
. O

From O
February RARE
1991 O
to O
August O
1997 O
, O
124 O
patients O
with O
endometrial O
carcinoma O
were O
treated O
postoperatively O
with O
high O
- O
dose O
- O
rate O
vaginal O
vault RARE
brachytherapy RARE
as O
the O
only O
adjuvant O
treatment O
. O

Twelve RARE
patients O
had O
stage O
IBG3 NUMERIC
, O
14 O
had O
ICG1 NUMERIC
, O
9 O
had O
ICG2 NUMERIC
, O
and O
3 O
had O
ICG3 NUMERIC
disease O
. O

Defective RARE
provirus O
genomes O
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
are O
frequently O
detected O
in O
lymphocytes O
from O
infected O
individuals O
and O
in O
infected O
cell O
lines O
. O

A O
total O
of O
174 NUMERIC
primer O
pairs O
gave O
interpretable RARE
banding RARE
patterns O
, O
137 NUMERIC
( O
79 O
%) O
of O
which O
revealed O
at O
least O
two O
alleles O
on O
native O
polyacrylamide O
gels O
. O

A O
population O
pharmacokinetic O
study O
of O
cyclosporin O
in O
organ O
transplant O
patients O
, O
including O
elderly O
allograft RARE
recipients O
up O
to O
75 O
years O
of O
age O
, O
did O
not O
identify O
age O
as O
a O
covariable RARE
influencing O
cyclosporin O
pharmacokinetics O
. O

Immunofluoresence RARE
data O
indicated O
that O
once O
bound O
to O
the O
mutant O
receptor O
, O
fluorescent O
- O
labeled O
RAP ALLCAPS
co O
- O
localized O
with O
markers O
of O
the O
endosomal RARE
pathway O
, O
whereas O
, O
in O
cells O
expressing O
the O
wild O
- O
type O
receptor O
, O
RAP ALLCAPS
fluorescence O
co O
- O
localized O
with O
lysosomal O
markers O
. O

Interleukin I-GENE
- I-GENE
12 I-GENE
( O
IL I-GENE
- I-GENE
12 I-GENE
) O
is O
a O
cytokine O
produced O
by O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC ALLCAPS
) O
that O
causes O
interferon I-GENE
- I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
production O
and O
enhancement O
of O
cell O
- O
mediated O
cytotoxicity O
. O

IL I-GENE
- I-GENE
12 I-GENE
production O
was O
correlated O
with O
C3a NUMERIC
concentration O
measured O
at O
the O
outlet RARE
of O
hemodialyzer RARE
after O
15 O
min O
of O
dialysis O
( O
r O
= O
0 O
. O
69 O
, O
P O
< O
0 O
. O
01 O
). O

In O
HeLa O
cells O
, O
the O
JNKK2 NUMERIC
- O
JNK1 I-GENE
fusion O
protein O
showed O
significant O
JNK I-GENE
activity O
, O
which O
was O
comparable O
with O
that O
of O
JNK1 I-GENE
activated O
by O
many O
stimuli O
and O
activators O
, O
including O
EGF I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
anisomycin RARE
, O
UV O
irradiation O
, O
MEKK1 NUMERIC
, O
and O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
Rac1 I-GENE
and O
Cdc42Hs NUMERIC
. O

J O
. O

Our O
results O
implicate RARE
TGF I-GENE
- I-GENE
beta I-GENE
RII I-GENE
as O
a O
direct O
target O
of O
EWS I-GENE
- O
FLI1 I-GENE
. O

The O
reduction O
in O
saturated RARE
fatty O
acids O
intake O
led O
to O
modest RARE
( O
but O
in O
group O
1 O
significant O
) O
0 O
. O
15 O
mmol O
/ O
l O
( O
2 O
. O
5 O
%) O
reduction O
in O
total O
serum O
cholesterol O
level O
. O

Secondly RARE
, O
an O
ethanol O
repression O
autoregulation O
( O
ERA ALLCAPS
)/ O
twelve RARE
- O
fold O
TA O
repeat O
( O
TAB ALLCAPS
) O
repressor O
element O
was O
identified O
within O
the O
promoter O
region O
of O
the O
GLK1 NUMERIC
gene I-GENE
. O

A O
crucial O
transcription O
factor O
in O
this O
process O
is O
STAT6 NUMERIC
, O
which O
binds O
to O
a O
specific O
DNA O
element O
upon O
cytokine O
activation O
. O

CONCLUSIONS O
: O
Congenital RARE
horizontal O
tarsal RARE
kink RARE
is O
rare O
and O
its O
cause O
is O
unknown O
. O

A O
local O
, O
high O
- O
density O
, O
single O
- O
nucleotide O
polymorphism O
map O
used O
to O
clone O
Caenorhabditis I-GENE
elegans I-GENE
cdf RARE
- I-GENE
1 I-GENE
. O

This O
machinery O
involves O
a O
secondary O
structure O
, O
SECIS O
element O
, O
in O
the O
selenoprotein RARE
- O
encoding O
mRNA O
, O
directing RARE
selenocysteine O
insertion O
at O
the O
position O
of O
an O
opal RARE
( O
UGA O
) O
codon O
, O
normally O
conferring O
termination O
of O
translation O
. O

High O
- O
level O
expression O
in O
Escherichia O
coli O
of O
selenocysteine O
- O
containing O
rat I-GENE
thioredoxin RARE
reductase I-GENE
utilizing O
gene O
fusions O
with O
engineered O
bacterial O
- O
type O
SECIS O
elements O
and O
co O
- O
expression O
with O
the O
selA LASTCAP
, O
selB LASTCAP
and O
selC LASTCAP
genes I-GENE
. O

In O
Wnt I-GENE
signaling O
, O
beta I-GENE
- I-GENE
catenin I-GENE
and O
plakoglobin I-GENE
transduce RARE
signals O
to O
the O
nucleus O
through O
interactions O
with O
TCF I-GENE
- I-GENE
type I-GENE
transcription I-GENE
factors I-GENE
. O

Assembly RARE
of O
a O
complex O
between O
FAK I-GENE
and O
Src I-GENE
kinases I-GENE
may O
serve O
to O
regulate O
the O
subcellular O
localization O
and O
the O
enzymatic O
activity O
of O
members O
of O
the O
Src I-GENE
family I-GENE
of O
kinases O
. O

For O
EPV ALLCAPS
3 O
, O
10 O
, O
or O
40 O
, O
the O
bias RARE
exceeded RARE
25 O
% O
for O
7 O
, O
3 O
, O
and O
1 O
in O
the O
8 O
- O
predictor O
model O
respectively O
, O
when O
a O
conventional O
selection O
criterion O
was O
used O
( O
alpha O
= O
0 O
. O
05 O
). O

Our O
study O
also O
demonstrated O
significant O
increases O
in O
the O
number O
of O
larger O
myelinated RARE
fibers O
crossing RARE
the O
repair O
site O
in O
comparison O
with O
the O
neonatal O
and O
adult O
groups O
( O
p O
< O
0 O
. O
04 O
). O

Me RARE
( O
2 O
) O
SO ALLCAPS
- O
induced O
neuronal O
differentiation O
of O
N1E NUMERIC
- O
115 O
neuroblastoma O
cells O
increased O
both O
the O
expression O
of O
the O
endogenous I-GENE
Ntr RARE
- I-GENE
1 I-GENE
gene I-GENE
and O
reporter O
genes O
driven O
by O
NTR ALLCAPS
- I-GENE
1 I-GENE
promoter I-GENE
sequences I-GENE
by O
3 O
- O
4 O
- O
fold O
. O

Cortical RARE
dysplasias RARE
, O
genetics RARE
, O
and O
epileptogenesis RARE
. O

In O
the O
work O
reported O
here O
, O
we O
used O
peptide O
mapping O
, O
mass O
spectrometry O
, O
and O
site O
- O
directed O
mutagenesis O
to O
identify O
two O
sets O
of O
pAP LASTCAP
phosphorylation O
sites O
. O

Both O
HERV ALLCAPS
- O
K O
type O
1 O
and O
2 O
clones O
were O
isolated O
. O

Duch RARE
, O
and O
F O
. O

At O
all O
time O
- O
points O
, O
most O
patients O
(>/= RARE
87 O
%) O
were O
receiving O
irbesartan RARE
/ O
HCTZ ALLCAPS
alone O
. O

Modification RARE
of O
dopamine I-GENE
D2 I-GENE
receptor I-GENE
activity O
by O
pergolide RARE
in O
Parkinson O
' O
s O
disease O
: O
an O
in O
vivo O
study O
by O
PET O
. O

High O
- O
affinity O
binding O
sites O
for O
both O
GR I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
nucleoproteins RARE
were O
identified O
at O
adjacent O
elements O
within O
the O
nGRE LASTCAP
. O

When O
the O
73 O
- O
bp O
fragment O
was O
fused O
to O
an O
alpha1 I-GENE
- I-GENE
globin I-GENE
promoter O
- O
CAT I-GENE
construct O
and O
cotransfected O
with O
CCAAT I-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
( O
CTF1 NUMERIC
)/ O
NF1 I-GENE
into O
Drosophila O
Schneider RARE
SL2 NUMERIC
insect O
cells O
( O
which O
lack O
NF1 I-GENE
- I-GENE
like I-GENE
proteins I-GENE
) O
trans O
- O
activation O
of O
CAT I-GENE
activity O
was O
observed O
. O

Western O
blot O
analysis O
showed O
a O
rapid O
corresponding O
increase O
in O
p21WAF1 NUMERIC
/ O
CIP1 NUMERIC
protein O
, O
whereas O
protein O
levels O
of O
another O
member O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor I-GENE
family I-GENE
, O
p27kip1 NUMERIC
, O
were O
unchanged O
. O

Aggregation RARE
of O
vHnf1 NUMERIC
- O
deficient O
embryonic O
stem O
cells O
with O
wild O
- O
type O
tetraploid RARE
embryos O
, O
which O
contribute O
exclusively O
to O
extraembryonic RARE
tissues O
, O
rescues RARE
periimplantation RARE
lethality O
and O
allows O
development O
to O
progress O
to O
early O
organogenesis RARE
. O

nos RARE
- I-GENE
1 I-GENE
and O
nos RARE
- I-GENE
2 I-GENE
, O
two O
genes O
related O
to O
Drosophila I-GENE
nanos RARE
, O
regulate O
primordial RARE
germ O
cell O
development O
and O
survival O
in O
Caenorhabditis O
elegans O
. O

Although O
upstream O
regulators O
of O
Tec RARE
family I-GENE
kinases I-GENE
are O
relatively O
well O
characterized O
, O
little O
is O
known O
of O
the O
downstream O
effectors O
of O
these O
enzymes O
. O

Efficient RARE
phosphorylation O
of O
BRDG1 NUMERIC
by O
Tec RARE
required O
the O
PH I-GENE
and O
SH2 I-GENE
domains I-GENE
as O
well O
as O
the O
kinase O
domain O
of O
the O
latter O
. O

CONCLUSION O
: O
These O
findings O
imply O
that O
eotaxin RARE
either O
is O
mechanistically RARE
involved O
in O
acute O
asthma O
or O
serves O
as O
a O
biomarker RARE
for O
activity O
of O
the O
CCR3 NUMERIC
receptor I-GENE
ligand I-GENE
system O
, O
which O
is O
functionally O
linked O
to O
asthma O
. O

The O
expression O
analysis O
of O
the O
KlHIS4 NUMERIC
gene I-GENE
under O
phosphate O
starvation O
or O
high O
adenine O
supply O
shows O
that O
factors O
, O
such O
as O
Bas1 NUMERIC
or O
Bas2 NUMERIC
, O
involved O
in O
the O
basal O
control O
may O
also O
operate RARE
in O
a O
different O
way O
in O
K O
. O
lactis O
. O

These O
thyroid O
hormone O
changes O
may O
be O
mediated O
in O
part O
by O
cytokines O
or O
other O
inflammatory O
mediators RARE
, O
acting O
at O
the O
level O
of O
the O
hypothalamus O
and O
pituitary O
gland O
, O
the O
thyroid O
gland O
, O
and O
the O
hepatic I-GENE
deiodinase I-GENE
system O
. O

ESS ALLCAPS
type O
1 O
, O
with O
FT3 NUMERIC
low O
and O
FT4 NUMERIC
and O
TSH I-GENE
normal O
, O
is O
the O
most O
frequent O
form O
. O

METHODS O
: O
We O
studied O
20 O
symptomatic O
patients O
with O
HOCM ALLCAPS
( O
12 O
men O
), O
mean O
age O
52 O
+/- O
17 O
years O
, O
before O
and O
after O
septal O
reduction O
using O
echocardiography O
and O
electrocardiogram O
( O
ECG O
). O

Paleoceanographic RARE
data O
from O
the O
Laurentian RARE
Fan RARE
, O
used O
as O
a O
proxy RARE
for O
sea O
surface O
temperature O
, O
reveal O
that O
surface O
slope O
waters RARE
north RARE
of O
the O
Gulf RARE
Stream RARE
experienced O
warming RARE
during O
the O
Little RARE
Ice RARE
Age RARE
of O
the O
16th NUMERIC
to O
19th NUMERIC
centuries RARE
and O
support O
the O
notion O
of O
an O
NAO ALLCAPS
- O
driven O
coupled O
system O
. O

This O
effect O
required O
( O
i O
) O
IR I-GENE
activation O
since O
it O
was O
abrogated O
by O
IR I-GENE
mutation O
at O
tyrosines RARE
1162 NUMERIC
and O
1163 NUMERIC
and O
( O
ii O
) O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
since O
it O
was O
abolished O
by O
overexpression O
of O
dominant I-GENE
- I-GENE
negative I-GENE
IkappaB LASTCAP
- I-GENE
alpha I-GENE
( I-GENE
A32 NUMERIC
/ I-GENE
36 I-GENE
) I-GENE
and O
mimicked O
by O
overexpression O
of O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
c I-GENE
- I-GENE
Rel I-GENE
subunit I-GENE
. O

The O
factor O
designated O
B O
formed O
a O
complex O
centered O
on O
the O
sequence O
TGTGGT ALLCAPS
, O
a O
core O
motif O
recognized O
by O
members O
of O
the O
AML ALLCAPS
/ I-GENE
CBFalpha RARE
transcription I-GENE
factor I-GENE
family I-GENE
. O

Furthermore O
, O
overexpression O
of O
AML3 NUMERIC
/ O
CBFalpha1 NUMERIC
could O
rescue O
the O
AML1 NUMERIC
- O
ETO ALLCAPS
repression O
. O

We O
examined O
Akt I-GENE
activation O
in O
Lyn I-GENE
-, O
Syk RARE
- O
and O
Btk RARE
- O
deficient O
DT40 NUMERIC
cells O
and O
B O
cells O
from O
Lyn I-GENE
(-/-) RARE
mice O
. O

Regulators RARE
of O
G I-GENE
protein I-GENE
signaling I-GENE
( I-GENE
RGS ALLCAPS
) I-GENE
proteins I-GENE
that O
contain O
DEP ALLCAPS
( O
disheveled RARE
, O
EGL ALLCAPS
- I-GENE
10 I-GENE
, O
pleckstrin I-GENE
) O
and O
GGL ALLCAPS
( O
G I-GENE
protein I-GENE
gamma I-GENE
subunit I-GENE
- I-GENE
like I-GENE
) O
domains O
form O
a O
subfamily O
that O
includes O
the O
mammalian I-GENE
RGS ALLCAPS
proteins I-GENE
RGS6 NUMERIC
, O
RGS7 NUMERIC
, O
RGS9 NUMERIC
, O
and O
RGS11 NUMERIC
. O

Cloning O
and O
expression O
of O
a O
specific O
human I-GENE
alpha I-GENE
1 I-GENE
, I-GENE
2 I-GENE
- I-GENE
mannosidase RARE
that O
trims RARE
Man9GlcNAc2 NUMERIC
to O
Man8GlcNAc2 NUMERIC
isomer RARE
B O
during O
N O
- O
glycan RARE
biosynthesis O
. O

The O
ORs RARE
of O
GC O
, O
adjusted O
for O
age O
and O
sex O
, O
varied O
from O
17 O
. O
1 O
, O
for O
those O
with O
baseline O
diagnoses RARE
of O
superficial O
intestinal O
metaplasia RARE
( O
IM O
), O
to O
29 O
. O
3 O
, O
for O
those O
with O
deep O
IM O
or O
mild O
dysplasia O
( O
DYS ALLCAPS
) O
or O
IM O
with O
glandular RARE
atrophy O
and O
neck O
hyperplasia O
, O
to O
104 O
. O
2 O
, O
for O
those O
with O
moderate O
or O
severe O
DYS ALLCAPS
, O
as O
compared O
with O
subjects O
with O
superficial O
gastritis RARE
( O
SG O
) O
or O
chronic O
atrophic RARE
gastritis RARE
( O
CAG ALLCAPS
) O
at O
baseline O
. O

Here O
we O
report O
that O
Dbp5p NUMERIC
and O
Rat7p NUMERIC
interact O
through O
their O
Nterminal RARE
domains O
. O

Thus O
, O
the O
nematode O
genes O
could O
be O
the O
homologs I-GENE
of I-GENE
Hh RARE
molecules I-GENE
in O
other O
phyla RARE
. O

A O
subset O
of O
mutations O
in O
the O
Psi RARE
synthase I-GENE
domain I-GENE
impairs RARE
association O
of O
the O
altered O
Cbf5p NUMERIC
proteins I-GENE
with O
selected O
box O
H I-GENE
/ I-GENE
ACA I-GENE
snoRNAs RARE
, O
suggesting O
that O
the O
functional O
catalytic O
domain O
is O
essential O
for O
that O
interaction O
. O

Although O
the O
Src I-GENE
tyrosine I-GENE
kinase I-GENE
induces O
constitutive O
Stat3 I-GENE
phosphorylation O
on O
tyrosine O
, O
activation O
of O
Stat3 I-GENE
- O
mediated O
gene O
regulation O
requires O
both O
tyrosine O
and O
serine O
phosphorylation O
of O
Stat3 I-GENE
. O

The O
transcription I-GENE
factor I-GENE
CHOP I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
homologous I-GENE
protein I-GENE
10 I-GENE
) O
is O
a O
bZIP I-GENE
protein I-GENE
induced O
by O
a O
variety O
of O
stimuli O
that O
evoke RARE
cellular O
stress O
responses O
and O
has O
been O
shown O
to O
arrest O
cell O
growth O
and O
to O
promote O
programmed O
cell O
death O
. O

Thus O
, O
CHOP I-GENE
not O
only O
is O
a O
negative O
or O
a O
positive O
regulator O
of O
C I-GENE
/ I-GENE
EBP I-GENE
target O
genes O
but O
also O
, O
when O
tethered RARE
to O
AP I-GENE
- I-GENE
1 I-GENE
factors I-GENE
, O
can O
activate O
AP I-GENE
- I-GENE
1 I-GENE
target O
genes O
. O

This O
motif O
, O
first O
described O
for O
the O
Drosophila I-GENE
homeobox I-GENE
activator I-GENE
DEAF ALLCAPS
- I-GENE
1 I-GENE
, O
identifies O
an O
emerging RARE
group O
of O
metazoan O
transcriptional O
modulators RARE
. O

RNase I-GENE
MRP I-GENE
is O
a O
ribonucleoprotein O
endoribonuclease RARE
that O
has O
been O
shown O
to O
have O
roles O
in O
both O
mitochondrial O
DNA O
replication O
and O
nuclear I-GENE
5 I-GENE
. I-GENE
8S NUMERIC
rRNA I-GENE
processing O
. O

We O
have O
examined O
the O
regulation O
of O
the O
FGFR I-GENE
- I-GENE
1 I-GENE
gene I-GENE
( O
cek RARE
- I-GENE
1 I-GENE
) O
in O
avian O
myogenic O
cultures O
by O
immunocytochemistry RARE
and O
Northern O
blot O
analysis O
. O

Regulation O
of O
avian I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
1 I-GENE
( O
FGFR I-GENE
- I-GENE
1 I-GENE
) O
gene O
expression O
during O
skeletal O
muscle O
differentiation O
. O

The O
backbone RARE
dynamics O
of O
residues O
located O
in O
the O
folded O
part O
of O
CRP2 NUMERIC
( O
LIM2 NUMERIC
) O
R122A NUMERIC
have O
been O
characterized O
by O
proton O
- O
detected O
( O
15 O
) O
N O
NMR O
spectroscopy O
. O

Rac I-GENE
causes O
uncapping RARE
of O
actin I-GENE
filaments RARE
( O
F I-GENE
- I-GENE
actin I-GENE
) O
at O
the O
plus O
- O
ends O
, O
through O
phosphatidylinositol O
4 O
, O
5 O
bisphosphate RARE
( O
PIP2 O
), O
and O
eventually RARE
induces O
membrane O
ruffling RARE
. O

However O
, O
a O
specific O
ICE I-GENE
/ O
caspase RARE
- I-GENE
1 I-GENE
inhibitor O
called O
N1445 NUMERIC
completely O
abolished O
the O
CK I-GENE
- O
induced O
apoptosis O
by O
reactivating RARE
PKB I-GENE
, O
but O
without O
affecting O
the O
CK I-GENE
- O
induced O
suppression O
of O
Ras I-GENE
transformation O
. O

OBJECTIVE O
: O
Although O
the O
preponderance RARE
of O
findings O
offer O
support O
for O
transient O
( O
where O
is O
it O
?) RARE
as O
opposed O
to O
sustained O
( O
what O
is O
it O
?) RARE
deficit O
, O
a O
need O
remains O
for O
specific O
depiction RARE
of O
the O
deficit O
. O

The O
AL ALLCAPS
- O
R8 NUMERIC
SI ALLCAPS
: O
the O
next O
generation O
staging RARE
container RARE
for O
plutonium O
pits RARE
at O
the O
USDOE ALLCAPS
Pantex RARE
Plant RARE
. O

RESULTS O
: O
Factors O
associated O
with O
significantly O
( O
P O
<. RARE
05 O
) O
increased O
risk O
of O
treatment O
failure O
in O
a O
Cox O
multivariate O
analysis O
included O
age O
older O
than O
45 O
years O
( O
relative O
hazard RARE
, O
1 O
. O
17 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
], O
1 O
. O
02 O
- O
1 O
. O
33 O
), O
Karnofsky RARE
performance O
score O
less O
than O
90 O
% O
( O
1 O
. O
27 O
; O
95 O
% O
CI O
, O
1 O
. O
07 O
- O
1 O
. O
51 O
), O
absence O
of O
hormone O
receptors O
( O
1 O
. O
31 O
; O
95 O
% O
CI O
, O
1 O
. O
15 O
- O
1 O
. O
51 O
), O
prior O
use O
of O
adjuvant O
chemotherapy O
( O
1 O
. O
31 O
; O
95 O
% O
CI O
, O
1 O
. O
10 O
- O
1 O
. O
56 O
), O
initial O
disease O
- O
free O
survival O
interval O
after O
adjuvant O
treatment O
of O
no O
more O
than O
18 O
months O
( O
1 O
. O
99 O
; O
95 O
% O
CI O
, O
1 O
. O
62 O
- O
2 O
. O
43 O
), O
metastases O
in O
the O
liver O
( O
1 O
. O
47 O
; O
95 O
% O
CI O
, O
1 O
. O
20 O
- O
1 O
. O
80 O
) O
or O
central O
nervous O
system O
( O
1 O
. O
56 O
; O
95 O
% O
CI O
, O
0 O
. O
99 O
- O
2 O
. O
46 O
[ O
approaches O
significance O
]) O
vs O
soft O
tissue O
, O
bone O
, O
or O
lung O
, O
3 O
or O
more O
sites O
of O
metastatic O
disease O
( O
1 O
. O
32 O
; O
95 O
% O
CI O
, O
1 O
. O
13 O
- O
1 O
. O
54 O
), O
and O
incomplete O
response O
vs O
complete O
response O
to O
standard O
- O
dose O
chemotherapy O
( O
1 O
. O
65 O
; O
95 O
% O
CI O
, O
1 O
. O
36 O
- O
1 O
. O
99 O
). O

One O
form O
of O
the O
SBEI ALLCAPS
gene I-GENE
transcript I-GENE
in O
12 O
- O
day O
old O
kernels RARE
contained O
the O
exon O
I O
+ O
II O
+ O
III O
combination O
at O
the O
5 O
' O
end O
, O
whereas O
other O
forms O
differed O
by O
inclusion O
of O
intron O
1 O
or O
exclusion O
of O
exon O
II O
sequences O
. O

In O
PC O
, O
rare O
MNGCs RARE
had O
intranuclear RARE
inclusions RARE
and O
grooves RARE
. O

16 O
percent O
, O
P O
< O
0 O
. O
001 O
), O
and O
sustained O
normalization RARE
of O
serum I-GENE
alanine I-GENE
aminotransferase I-GENE
levels O
( O
41 O
percent O
vs O
. O

Its O
C O
- O
terminal O
catalytic O
domain O
was O
found O
to O
be O
highly O
conserved O
in O
the O
homologues O
p140 NUMERIC
( O
ras I-GENE
- O
GRF ALLCAPS
) O
and O
Sos I-GENE
. O

356 NUMERIC
, O
93 O
- O
98 O
]. O

The O
proteasome O
is O
a O
large O
complex O
consisting O
of O
two O
multisubunit O
structures O
, O
the O
20S I-GENE
and O
19S NUMERIC
( O
PA700 NUMERIC
) O
or O
P28 NUMERIC
complexes I-GENE
, O
that O
combine RARE
to O
form O
the O
26S NUMERIC
particles I-GENE
. O

In O
assays O
with O
purified O
enzymes O
, O
wild O
- O
type O
but O
not O
PTPS ALLCAPS
- O
S19A NUMERIC
was O
a O
specific O
substrate O
for O
the O
cGMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( I-GENE
cGK LASTCAP
) I-GENE
type I-GENE
I I-GENE
and I-GENE
II I-GENE
. O

R O
., O
Fleischmann RARE
, O
R O
., O
Venter RARE
, O
J O
. O

The O
N O
- O
terminal O
domain O
of O
approximately O
70 O
kDa O
exhibits O
11 O
imperfect RARE
amino O
acid O
repeats O
that O
show O
some O
homology O
to O
promastigote RARE
surface O
glycoproteins O
of O
the O
psa2 NUMERIC
/ O
gp46 NUMERIC
complex O
. O

In O
contrast O
to O
previously O
characterized O
proteophosphoglycans RARE
, O
the O
ppg1 NUMERIC
gene O
product O
is O
predominantly O
membrane O
- O
associated O
and O
it O
is O
expressed O
on O
the O
promastigote RARE
cell O
surface O
. O

Most O
important O
, O
infection O
of O
the O
cells O
with O
an O
adenoviral RARE
construct O
expressing O
this O
mutant O
inhibited O
the O
induction O
of O
VEGF I-GENE
mRNA I-GENE
under O
conditions O
that O
mimic O
hypoxia O
. O

Neuregulin RARE
stimulates O
ErbB2 NUMERIC
, O
ErbB3 NUMERIC
, O
and O
ErbB4 NUMERIC
, O
members O
of O
the O
ErbB I-GENE
family I-GENE
of O
receptor I-GENE
tyrosine I-GENE
kinases I-GENE
. O

Our O
results O
suggest O
that O
Anu2p NUMERIC
is O
the O
yeast I-GENE
homologue I-GENE
of I-GENE
mammalian I-GENE
epsilon I-GENE
- I-GENE
COP ALLCAPS
and O
the O
abrupt RARE
accumulation O
of O
the O
ER O
membrane O
caused O
by O
a O
blockage RARE
of O
the O
early O
protein O
transport O
pathway O
leads O
to O
alteration O
of O
nuclear O
morphology O
of O
the O
budding O
yeast O
cells O
. O

In O
PC12 O
cells O
, O
nerve I-GENE
growth I-GENE
factor I-GENE
induces O
neuronal O
differentiation O
and O
repressed O
expression O
of O
nrg RARE
- I-GENE
1 I-GENE
. O

In O
a O
PC12 O
cell O
mutant O
that O
is O
deficient O
in O
protein I-GENE
kinase I-GENE
A I-GENE
activity O
( O
AB ALLCAPS
. O
11 O
), O
all O
three O
differentiating O
agents O
were O
unable O
to O
down O
- O
regulate O
nrg RARE
- I-GENE
1 I-GENE
mRNA I-GENE
. O

TSC1 NUMERIC
mutations I-GENE
include O
two O
nonsense O
mutations O
, O
four O
insertions O
, O
and O
three O
splice O
mutations O
. O

Twelve RARE
patients O
without O
abnormalities O
in O
the O
PTT ALLCAPS
are O
assumed O
to O
harbor O
missense O
mutations O
, O
probably O
in O
TSC2 NUMERIC
. O

The O
first O
algorithm O
, O
FOREPROJ ALLCAPS
, O
is O
a O
fast O
- O
forward RARE
projection RARE
algorithm O
that O
allows O
calculation RARE
of O
the O
3 O
- O
D O
attenuation O
correction O
factors O
( O
ACF ALLCAPS
' O
s O
) O
directly O
from O
a O
two O
- O
dimensional O
( O
2 O
- O
D O
) O
transmission O
scan O
, O
without O
first O
reconstructing RARE
the O
attenuation O
map O
and O
then O
performing RARE
a O
3 O
- O
D O
forward RARE
projection RARE
. O

We O
have O
cloned O
cDNA O
and O
genomic O
DNA O
for O
a O
mouse O
gene O
encoding O
a O
protein O
with O
significant O
sequence O
similarity O
to O
conserved O
domains O
found O
in O
proteins O
of O
the O
Spo11p NUMERIC
family I-GENE
. O

RT O
- O
PCR O
and O
in O
situ O
hybridization O
analyses O
of O
a O
time O
course O
of O
juvenile O
testis O
development O
indicate O
that O
Spo11 NUMERIC
expression O
begins O
in O
early O
meiotic O
Prophase RARE
I O
, O
prior O
to O
the O
pachytene RARE
stage O
, O
with O
increasing O
accumulation O
of O
mRNA O
through O
the O
pachytene RARE
stage O
. O

Animals O
were O
put RARE
to O
death O
8 O
weeks O
later O
and O
the O
grafts O
were O
sterilely RARE
explanted RARE
and O
analyzed O
via O
microbiologic RARE
culture O
and O
standard O
histologic O
procedures O
for O
evidence O
of O
infection O
. O

The O
RMR ALLCAPS
was O
measured O
twice O
in O
each O
phase O
and O
found O
to O
be O
similar O
( O
F O
( O
1 O
, O
18 O
) O
= O
0 O
. O
863 NUMERIC
) O
across O
the O
follicular O
( O
5018 NUMERIC
kJ LASTCAP
/ O
24 O
h O
) O
and O
the O
luteal O
( O
5098 NUMERIC
kJ LASTCAP
/ O
24 O
h O
) O
phases O
. O

Oseltamivir RARE
( O
GS4104 NUMERIC
), O
which O
can O
be O
administered O
orally O
, O
is O
the O
prodrug RARE
of O
GS4071 NUMERIC
, O
a O
potent O
and O
selective O
inhibitor O
of O
influenzavirus RARE
neuraminidases RARE
. O

In O
gel O
mobility O
shift O
assays O
, O
we O
found O
no O
evidence O
for O
VDR I-GENE
- O
TR I-GENE
heterodimer O
interaction O
with O
any O
tested O
element O
. O

The O
relative O
importance O
of O
these O
two O
mechanisms O
differed O
in O
a O
response O
element O
- O
specific O
manner O
. O

After O
14 O
d O
of O
overfeeding RARE
, O
hepatic O
PL O
profiles O
were O
identical O
in O
the O
two O
breeds RARE
and O
similar O
to O
that O
in O
control O
livers RARE
; O
choline RARE
- O
containing O
PL O
accounted RARE
for O
95 O
% O
of O
total O
PL O
. O

C O
- O
SP O
duration O
was O
significantly O
reduced O
in O
ALS ALLCAPS
patients O
compared O
to O
controls O
at O
low O
stimulation O
intensity O
corresponding O
to O
an O
MEP ALLCAPS
threshold O
increased O
by O
15 O
%. O

These O
data O
show O
that O
the O
spv RARE
virulence I-GENE
genes I-GENE
belong O
simultaneously O
to O
several O
regulons RARE
in O
the O
cell O
, O
raising RARE
the O
possibility O
that O
spv RARE
expression O
can O
be O
fine O
- O
tuned RARE
in O
response O
to O
multiple O
environmental O
inputs O
. O

Intensive RARE
synthesis O
of O
PNA ALLCAPS
in O
the O
cells O
of O
microvascular O
wall O
evidenced RARE
of O
their O
high O
functional O
activity O
, O
and O
the O
synthesis O
of O
DNA O
in O
them O
showed O
their O
ability O
for O
proliferation O
, O
i O
. O
g O
.-- RARE
for O
growth O
. O

Tracheal RARE
transsection RARE
combined O
with O
hilar RARE
ligation O
( O
TL ALLCAPS
& O
PL O
) O
effected RARE
a O
reduction O
of O
19 O
. O
9 O
% O
( O
n O
. O
s O
.). O

Kinase RARE
- O
deficient O
erbB I-GENE
proteins I-GENE
reduced O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
)- O
induced O
tyrosine O
phosphorylation O
of O
endogenous O
Shc I-GENE
proteins I-GENE
and O
also O
reduced O
immediate O
and O
sustained O
EGF I-GENE
- I-GENE
induced I-GENE
ERK I-GENE
MAPK I-GENE
activities O
in O
human O
glioblastoma RARE
cells O
, O
although O
basal O
ERK I-GENE
MAPK I-GENE
activities O
were O
unaffected O
. O

Using O
immunolocalization RARE
, O
we O
observe O
that O
ACE3 NUMERIC
, O
a O
440 O
- O
bp O
chorion RARE
element O
that O
contains O
information O
sufficient O
to O
drive O
amplification O
, O
directs O
DmORC LASTCAP
localization O
in O
follicle O
cells O
. O

Therefore O
, O
homozygous O
co O
- O
deletions O
of O
CDKN2A NUMERIC
and O
CDKN2B NUMERIC
rather O
than O
mutations O
targeting O
individual O
transcripts O
are O
frequently O
selected O
for O
in O
these O
tumors O
. O

Here O
, O
we O
show O
that O
aortic O
explants RARE
isolated O
from O
PPARalpha I-GENE
- O
null O
mice O
display O
an O
exacerbated RARE
response O
to O
inflammatory O
stimuli O
, O
such O
as O
lipopolysaccharide O
( O
LPS O
), O
as O
demonstrated O
by O
increased O
IL I-GENE
- I-GENE
6 I-GENE
secretion O
. O

Albumin RARE
expression O
is O
maintained O
in O
the O
liver O
by O
a O
combination O
of O
liver O
- O
enriched O
transcription O
factors O
such O
as O
CAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
) I-GENE
alpha I-GENE
and O
C I-GENE
/ I-GENE
EBPbeta I-GENE
. O

The O
requirement O
for O
proteolytic O
activity O
of O
both O
FVIIa RARE
and O
FXa RARE
suggests O
that O
protease O
- O
activated O
receptors O
may O
be O
involved O
. O

Amyloid RARE
beta I-GENE
- I-GENE
protein I-GENE
( O
Abeta RARE
) O
is O
the O
main O
constituent RARE
of O
amyloid RARE
fibrils RARE
found O
in O
senile O
plaques RARE
and O
cerebral O
vessels O
in O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
and O
is O
derived O
by O
proteolysis O
from O
the O
beta I-GENE
- I-GENE
amyloid RARE
precursor I-GENE
protein I-GENE
( O
APP ALLCAPS
). O

We O
also O
show O
that O
activation O
of O
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
) O
signaling O
is O
sufficient O
to O
down O
- O
regulate O
caveolin RARE
- I-GENE
1 I-GENE
protein I-GENE
expression O
and O
promoter O
activity O
. O

The O
importin RARE
alpha I-GENE
. I-GENE
beta I-GENE
heterodimer I-GENE
mediates O
nuclear O
import O
of O
proteins O
containing O
classical O
nuclear O
localization O
signals O
. O

The O
expressed O
G1 I-GENE
- O
G2 I-GENE
bound O
to O
both O
hyaluronan RARE
and O
link I-GENE
protein I-GENE
indicating O
that O
the O
immunoglobulin I-GENE
- I-GENE
fold I-GENE
motif I-GENE
and O
proteoglycan O
tandem O
repeat O
loops O
of O
the O
G1 I-GENE
domain I-GENE
were O
correctly O
folded O
. O

The O
results O
suggest O
that O
the O
presence O
or O
absence O
per O
se RARE
of O
keratan RARE
sulfate O
on O
native O
G1 O
- O
G2 O
does O
not O
affect O
the O
activity O
of O
atrolysin RARE
C O
toward O
the O
two O
sites O
. O

Despite O
i O
. O
v O
. O
steroid O
therapy O
, O
[ O
NOexh RARE
] O
remained O
elevated O
throughout O
recovery O
( O
37 O
. O
9 O
+/- O
4 O
. O
8 O
ppb O
, O
p O
< O
0 O
. O
001 O
) O
until O
discharge O
( O
40 O
. O
9 O
+/- O
4 O
. O
3 O
ppb O
, O
p O
< O
0 O
. O
001 O
). O

It O
contains O
binding O
sites O
for O
several O
transcription O
factors O
, O
for O
example O
: O
( O
i O
) O
a O
well O
- O
characterized O
binding O
site O
for O
rel I-GENE
/ O
NF I-GENE
- I-GENE
kappaB I-GENE
transcription O
factors O
in O
its O
3 O
'- O
end O
( O
the O
H2TF1 NUMERIC
or O
kappaB1 NUMERIC
element I-GENE
), O
( O
ii O
) O
a O
second O
kappaB I-GENE
site I-GENE
( O
the O
kappaB2 NUMERIC
element I-GENE
), O
which O
is O
located O
immediately O
adjacent O
5 O
' O
to O
the O
H2TF1 NUMERIC
element I-GENE
and O
which O
is O
recognized O
by O
p65 I-GENE
/ O
relA LASTCAP
in O
the O
human I-GENE
HLA I-GENE
system O
, O
and O
( O
iii O
) O
an O
AP I-GENE
- I-GENE
1 I-GENE
/ O
ATF I-GENE
recognition O
sequence O
in O
the O
5 O
' O
end O
( O
EnA LASTCAP
- I-GENE
TRE I-GENE
). O

The O
tumorigenic O
E1A I-GENE
+ O
cHa RARE
- I-GENE
ras I-GENE
cells O
are O
characterized O
by O
high O
and O
constitutive O
DNA O
binding O
activities O
of O
AP I-GENE
- I-GENE
1 I-GENE
, O
in O
contrast O
to O
nontransformed RARE
cells O
and O
the O
E1A I-GENE
cells O
. O

The O
yeast O
C I-GENE
- I-GENE
type I-GENE
cyclin I-GENE
Ume3p NUMERIC
/ O
Srb11p NUMERIC
and O
its O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
Ume5p NUMERIC
are O
required O
for O
the O
full O
repression O
of O
genes O
involved O
in O
the O
stress O
response O
or O
meiosis O
. O

In O
particular O
, O
the O
S1 I-GENE
' I-GENE
specificity I-GENE
site I-GENE
is O
a O
deep O
and O
highly O
hydrophobic O
cavity O
. O

FZD4 NUMERIC
is O
homologous O
to O
FZD9 NUMERIC
and O
FZD10 NUMERIC
, O
and O
overall O
amino O
acid O
identity O
is O
as O
follows O
: O
FZD4 NUMERIC
vs O
FZD9 NUMERIC
, O
51 O
. O
6 O
%; O
FZD4 NUMERIC
vs O
FZD10 NUMERIC
, O
51 O
. O
2 O
%; O
FZD9 NUMERIC
vs O
FZD10 NUMERIC
, O
65 O
. O
7 O
%. O

The O
NF I-GENE
- I-GENE
kappaB I-GENE
responsive O
reporter O
construct O
, O
( O
PRDII ALLCAPS
)( O
4 O
)- O
CAT I-GENE
, O
was O
used O
to O
explore O
transcription O
resulting O
from O
NF I-GENE
- I-GENE
kappaB I-GENE
activated O
by O
Tat I-GENE
. O

The O
RNA O
transcripts O
structurally O
equivalent O
to O
I I-GENE
( I-GENE
2 I-GENE
) I-GENE
sgRNAs RARE
of O
TMV ALLCAPS
U1 I-GENE
and O
crTMV LASTCAP
, O
but O
containing O
a O
hairpin O
structure O
( O
H O
) O
immediately O
upstream O
of O
IRES ALLCAPS
( I-GENE
MP I-GENE
, I-GENE
75 I-GENE
) I-GENE
( I-GENE
HIRES ALLCAPS
( I-GENE
MP I-GENE
), I-GENE
( I-GENE
75 I-GENE
)( I-GENE
CR I-GENE
)- I-GENE
MP I-GENE
- I-GENE
CP I-GENE
- I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
; O
HIRES ALLCAPS
( I-GENE
MP I-GENE
, I-GENE
75 I-GENE
)( I-GENE
U1 I-GENE
)- I-GENE
MP I-GENE
- I-GENE
CP I-GENE
- I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
), O
were O
able O
to O
express O
the O
MP I-GENE
gene I-GENE
in O
vitro O
. O

EIAV ALLCAPS
LTR I-GENE
sequence I-GENE
variability O
is O
confined O
mostly O
to O
a O
small O
portion O
of O
the O
enhancer O
within O
the O
U3 O
segment O
of O
the O
LTR O
. O

Phosphatidylinositol RARE
3 I-GENE
- I-GENE
kinase I-GENE
requirement O
in O
activation O
of O
the O
ras I-GENE
/ O
C I-GENE
- I-GENE
raf I-GENE
- I-GENE
1 I-GENE
/ O
MEK I-GENE
/ O
ERK I-GENE
and O
p70 I-GENE
( O
s6k NUMERIC
) O
signaling O
cascade O
by O
the O
insulinomimetic RARE
agent O
vanadyl RARE
sulfate O
. O

The O
core O
of O
this O
enhancer O
contains O
two O
evolutionarily O
conserved O
binding O
sites O
for O
the O
homeodomain I-GENE
protein I-GENE
Tinman RARE
( O
Tin RARE
), O
expressed O
in O
developing O
cardiac O
, O
somatic O
, O
and O
visceral O
muscle O
lineages O
. O

For O
example O
, O
introduction O
of O
immunogenic RARE
and O
purification O
tag O
sequences O
into O
the O
C O
- O
terminal O
coding O
region O
significantly O
decreased O
bop RARE
gene I-GENE
mRNA I-GENE
and O
protein O
accumulation O
. O

Furthermore O
, O
the O
striking O
ability O
of O
polyoma RARE
middle I-GENE
T I-GENE
antigens I-GENE
to O
promote O
retinoic O
acid O
- O
induced O
differentiation O
appears O
to O
utilize RARE
ERK I-GENE
, O
but O
not O
JNK I-GENE
/ O
SPK I-GENE
or O
p38 I-GENE
signaling O
. O

We O
recommend RARE
that O
paracervical RARE
block O
with O
lignocaine RARE
should O
be O
used O
in O
conjunction O
with O
i O
. O
v O
. O
sedation O
/ O
analgesia O
during O
egg O
collection O
performed O
through O
the O
transvaginal RARE
route O
under O
ultrasound O
guidance RARE
( O
TUGOR ALLCAPS
) O
to O
reduce O
the O
pain O
of O
the O
procedure O
. O

All O
loci O
have O
a O
similar O
organization O
, O
except O
for O
H1 I-GENE
. I-GENE
8 I-GENE
that O
harbors RARE
two O
TcP2beta NUMERIC
genes I-GENE
arranged O
in O
tandem O
and O
separated O
by O
a O
short O
repetitive O
sequence O
, O
named O
SIRE ALLCAPS
( O
short O
interspersed O
repetitive O
element O
), O
which O
is O
also O
found O
upstream O
of O
the O
first O
gene O
of O
the O
tandem O
and O
downstream O
of O
the O
second O
. O

A O
proportion O
of O
APC I-GENE
wild O
- O
type O
colon O
carcinomas O
and O
melanomas O
also O
contains O
constitutive O
nuclear O
Tcf RARE
- I-GENE
4 I-GENE
/ O
beta I-GENE
- I-GENE
catenin I-GENE
complexes O
as O
a O
result O
of O
dominant O
mutations O
in O
the O
N O
terminus O
of O
beta I-GENE
- I-GENE
catenin I-GENE
that O
render RARE
it O
insensitive RARE
to O
downregulation RARE
by O
APC I-GENE
, O
GSK3 NUMERIC
beta I-GENE
, O
and O
Axin RARE
/ O
Conductin RARE
. O

Similar O
mechanisms O
leading O
to O
deregulation RARE
of O
Tcf RARE
target I-GENE
gene I-GENE
activity O
are O
likely O
to O
be O
involved O
in O
melanoma O
and O
other O
forms O
of O
cancer O
. O

This O
report O
describes O
a O
patient O
with O
a O
previous O
inferior O
acute O
myocardial O
infarction O
who O
developed O
right O
ventricular O
infarction O
with O
significant O
anterior O
lead O
ST O
segment O
elevation O
( O
V1 NUMERIC
- O
V4 NUMERIC
) O
caused O
by O
the O
loss O
of O
two O
large O
right O
ventricular O
branches RARE
during O
a O
coronary O
angioplasty RARE
of O
the O
right O
coronary O
artery O
. O

PATIENTS O
AND O
METHODS O
: O
Immediately RARE
before O
radical O
prostatectomy RARE
, O
bone O
marrow O
aspirates RARE
from O
both O
sides O
of O
the O
iliac O
crest RARE
were O
taken O
from O
287 NUMERIC
patients O
. O

PURPOSE O
: O
Previous O
WR O
- O
2721 O
human O
pharmacokinetic O
studies O
were O
limited O
to O
plasma O
levels O
in O
patients O
receiving O
platinum RARE
- O
based O
compounds O
, O
and O
none O
includes O
the O
effects O
of O
WR O
- O
2721 O
on O
endogenous O
thiols RARE
. O

With O
regard O
to O
nonhematologic RARE
toxicities RARE
, O
diarrhea RARE
, O
infection O
and O
elevated O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
of O
grade O
3 O
or O
over O
were O
observed O
in O
2 O
% O
of O
cycles O
, O
but O
were O
tolerable RARE
and O
reversible O
. O

LHbeta RARE
is O
expressed O
in O
pituitary O
gonadotrope RARE
cells O
and O
CGbeta RARE
is O
expressed O
in O
placental O
trophoblast RARE
cells O
. O

Regulation O
of O
HIV O
- O
1 O
transcription O
. O

Human I-GENE
LTBP ALLCAPS
- I-GENE
1 I-GENE
is O
known O
to O
exist O
in O
different O
forms O
. O

In O
an O
earlier O
study O
( O
Kimura RARE
, O
Y O
., O
Kurzydlowski RARE
, O
K O
., O
Tada RARE
, O
M O
., O
and O
MacLennan RARE
, O
D O
. O

It O
consists O
of O
2185 NUMERIC
amino O
acid O
residues O
encoded O
by O
a O
9 O
- O
kilobase O
pair O
mRNA O
; O
several O
splice O
variants O
have O
been O
detected O
in O
human O
and O
rat O
cDNA O
libraries O
. O

Cyclic RARE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
binding O
to O
A I-GENE
- I-GENE
kinase I-GENE
anchoring RARE
proteins O
in O
living O
cells O
by O
fluorescence O
resonance O
energy O
transfer O
of O
green I-GENE
fluorescent I-GENE
protein I-GENE
fusion O
proteins O
. O

CONCLUSIONS O
: O
In O
addition O
to O
the O
superiority RARE
of O
octafluoropropane RARE
- O
filled O
microspheres O
to O
air O
- O
filled O
microspheres O
for O
LV O
opacification RARE
, O
the O
efficacy O
of O
OCTA ALLCAPS
is O
relatively O
unaffected O
by O
impaired O
LV O
function O
and O
is O
less O
susceptible O
to O
the O
effects O
of O
poor O
echogenicity RARE
than O
AIR ALLCAPS
. O

Factor I-GENE
XI ALLCAPS
deficiency O
is O
a O
rare O
hereditary O
bleeding O
disorder O
affecting O
the O
intrinsic O
pathway O
. O

The O
Ishasha RARE
samples O
show O
a O
range O
encompassing O
three O
trophic RARE
levels O
. O

The O
more O
traditional RARE
SERMS ALLCAPS
, O
clomiphene RARE
citrate O
and O
tamoxifen RARE
, O
will O
be O
reviewed O
along O
with O
such O
modern O
drugs O
as O
raloxifene RARE
and O
faslodex RARE
, O
with O
emphasis RARE
upon O
their O
actions O
on O
breast O
, O
uterus RARE
, O
bone O
and O
lipids O
. O

Ti RARE
exhibited O
a O
feather RARE
- O
like O
morphology O
. O

This O
organization O
suggests O
that O
duplication O
events O
that O
have O
generated O
the O
primate O
FUT3 NUMERIC
- O
FUT5 NUMERIC
- O
FUT6 NUMERIC
cluster O
might O
have O
occurred O
through O
a O
long O
- O
interspersed O
- O
nuclear O
- O
element O
- O
based O
mechanism O
of O
unequal RARE
crossing RARE
over O
, O
as O
described O
for O
the O
globin I-GENE
cluster I-GENE
. O

S O
., O
Kim RARE
, O
S O
. O

The O
cop RARE
region I-GENE
also O
harbors RARE
a O
region O
of O
plasmid O
incompatibility RARE
, O
inc RARE
, O
encompassing O
a O
stem O
- O
loop O
structure O
, O
the O
repA LASTCAP
promoter I-GENE
, O
Prep RARE
, O
as O
well O
as O
two O
distinct O
RepA LASTCAP
binding I-GENE
sites I-GENE
, O
BD ALLCAPS
- O
1 O
and O
BD ALLCAPS
- O
2 O
. O

WA ALLCAPS
constructs O
afforded RARE
relaxed RARE
and O
positive O
topoisomers RARE
, O
and O
cyclization RARE
kinetics O
indicated O
slow O
interconversion RARE
of O
precursors O
to O
the O
two O
topoisomers RARE
. O

The O
RFX ALLCAPS
protein I-GENE
family I-GENE
includes O
members O
from O
yeast O
to O
humans O
, O
which O
function O
in O
various O
biological O
systems O
, O
and O
share O
a O
DNA O
- O
binding O
domain O
and O
a O
conserved O
C O
- O
terminal O
region O
. O

Binding O
to O
sulphatides RARE
and O
the O
alpha I-GENE
- I-GENE
dystroglycan RARE
receptor I-GENE
was O
much O
stronger O
and O
required O
at O
least O
two O
LG ALLCAPS
modules I-GENE
. O

Here O
, O
we O
propose O
that O
an O
antagonistic O
, O
BMP I-GENE
/ O
ALK2 NUMERIC
/ O
Smad I-GENE
- O
mediated O
signaling O
pathway O
is O
active O
on O
the O
right O
side O
of O
the O
Xenopus O
embryo O
. O

These O
kinases O
belong O
to O
a O
new O
subfamily O
related O
to O
the O
Trk RARE
subfamily I-GENE
. O

The O
data O
indicate O
that O
etr RARE
- I-GENE
1 I-GENE
is O
essential O
for O
muscle O
development O
in O
C O
. O
elegans O
, O
perhaps O
by O
playing RARE
a O
role O
in O
post O
- O
transcriptional O
processing O
of O
some O
muscle O
component O
, O
and O
thus O
suggesting O
a O
possible O
conservation O
of O
gene O
function O
with O
human I-GENE
CUG ALLCAPS
- I-GENE
bp I-GENE
. O

Gentamicin RARE
given O
by O
DPI ALLCAPS
and O
SVN ALLCAPS
significantly O
decreased O
the O
sputum O
Psa RARE
density O
( O
p O
< O
0 O
. O
05 O
), O
by O
almost O
one O
order O
of O
magnitude O
. O

CONCLUSIONS O
: O
The O
largest O
value O
of O
the O
joint O
space O
may O
be O
used O
when O
evaluating O
rheumatoid O
AC O
joint O
space O
. O

An O
analysis O
of O
sequence O
of O
the O
mutant I-GENE
recN LASTCAP
gene I-GENE
revealed O
a O
G O
: O
C O
to O
T O
: O
A O
transversion O
near O
the O
3 O
' O
end O
of O
the O
coding O
region O
. O

Nevertheless O
, O
in O
view O
of O
the O
potential O
transmission O
rates O
of O
HGV ALLCAPS
and O
the O
lack O
of O
effective O
immunization O
, O
HGV ALLCAPS
should O
be O
regarded O
as O
a O
potential O
occupational RARE
hazard RARE
for O
medical O
and O
dental O
staff RARE
. O

Detection O
of O
poisoning O
by O
Impila RARE
( O
Callilepis RARE
laureola RARE
) O
in O
a O
mother RARE
and O
child O
. O

We O
have O
previously O
identified O
mouse I-GENE
and I-GENE
human I-GENE
cDNAs I-GENE
encoding I-GENE
UNC I-GENE
- I-GENE
51 I-GENE
- I-GENE
like I-GENE
kinase I-GENE
( O
ULK1 NUMERIC
). O

ULKs RARE
and O
UNC I-GENE
- I-GENE
51 I-GENE
share O
a O
typical O
domain O
structure O
of O
an O
amino O
- O
terminal O
kinase O
domain O
, O
a O
central O
proline O
/ O
serine O
rich O
( O
PS O
) O
domain O
, O
and O
a O
carboxy O
- O
terminal O
( O
C O
) O
domain O
. O

These O
results O
suggest O
that O
ULK2 NUMERIC
is O
involved O
in O
a O
previously O
uncharacterized O
signaling O
pathway O
in O
mammalian O
cells O
. O

Connector RARE
enhancer I-GENE
of I-GENE
KSR ALLCAPS
( O
CNK ALLCAPS
) O
is O
a O
multidomain RARE
protein O
required O
for O
RAS ALLCAPS
signaling O
. O

In O
simpler RARE
organisms O
, O
the O
ATP I-GENE
sulfurylase RARE
and O
APS ALLCAPS
kinase I-GENE
reactions O
are O
catalyzed O
by O
separate O
enzymes O
encoded O
by O
two O
or O
three O
genes O
, O
suggesting O
that O
a O
fusion O
of O
separate O
genes O
during O
the O
course O
of O
evolution O
generated O
the O
bifunctional RARE
enzyme O
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
( I-GENE
EBV I-GENE
) I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
( O
LMP1 I-GENE
) O
is O
essential O
for O
EBV O
- O
mediated O
transformation O
of O
primary O
B O
lymphocytes O
. O

The O
amino O
- O
terminal O
half O
of O
1a I-GENE
is O
a O
distant O
homolog I-GENE
of I-GENE
alphavirus RARE
nonstructural RARE
protein I-GENE
nsP1 NUMERIC
, O
which O
has O
been O
implicated O
in O
capping O
viral O
RNAs O
. O

Moreover O
, O
a O
recombinant O
Ad RARE
expressing O
Ad5 I-GENE
E4orf6 NUMERIC
/ I-GENE
7 I-GENE
induced O
apoptosis O
in O
rat O
cells O
when O
coinfected RARE
with O
wild O
- O
type O
p53 I-GENE
- O
expressing O
Ad RARE
. O

In O
HCMV O
( O
Towne RARE
)- O
infected O
HF O
cells O
at O
24 O
to O
48 O
h O
, O
IE2 I-GENE
also O
accumulated O
in O
newly O
formed O
viral O
DNA O
replication O
compartments RARE
containing O
the O
polymerase I-GENE
processivity RARE
factor I-GENE
( O
UL44 NUMERIC
), O
the O
single I-GENE
- I-GENE
stranded I-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
( O
SSB I-GENE
; O
UL57 NUMERIC
), O
the O
UL112 NUMERIC
- I-GENE
113 I-GENE
accessory I-GENE
protein I-GENE
, O
and O
newly O
incorporated O
bromodeoxyuridine RARE
( O
BrdU LASTCAP
). O

Macroscopic RARE
researches RARE
on O
heart O
vascularization RARE
have O
indicated O
that O
the O
angioarchitecture RARE
of O
the O
conducting RARE
system O
differs O
from O
that O
of O
the O
normal O
myocardium O
. O

CONCLUSION O
( O
S O
): O
Measuring RARE
urinary O
LH I-GENE
levels O
is O
an O
excellent O
method O
for O
determining O
ovulation O
. O

However O
, O
reoperation RARE
for O
bulky RARE
cervical O
disease O
( O
group O
3 O
) O
rarely O
results O
in O
normal O
calcitonin I-GENE
levels O
and O
is O
associated O
with O
a O
high O
incidence O
of O
permanent O
hypoparathyroidism RARE
. O

We O
present O
a O
case O
of O
carcinoma O
of O
the O
breast O
presenting O
concurrently RARE
with O
SSc RARE
that O
subsequently O
progressed O
to O
dialysis O
- O
dependent O
renal O
failure O
in O
just O
1 O
month O
. O

PURPOSE O
: O
To O
evaluate O
the O
disease O
- O
free O
survival O
( O
DFS ALLCAPS
) O
and O
overall O
survival O
( O
OS ALLCAPS
), O
prognostic O
factors O
, O
and O
treatment O
- O
related O
mortality O
of O
women O
with O
stage O
IIIB O
inflammatory O
breast O
cancer O
( O
IBC ALLCAPS
) O
treated O
with O
combined O
modality O
therapy O
( O
CMT ALLCAPS
) O
and O
high O
- O
dose O
chemotherapy O
( O
HDCT ALLCAPS
) O
with O
autologous O
stem O
- O
cell O
transplantation O
. O

The O
GPI O
anchor O
moiety RARE
is O
either O
absent O
or O
present O
at O
a O
very O
low O
level O
in O
the O
polypeptide O
expressed O
from O
the O
cDNA O
that O
contained O
both O
the O
signal O
peptide O
and O
GPI O
signal O
sequences O
. O

We O
have O
cloned O
a O
novel O
100 O
- O
kDa O
mammalian O
protein O
, O
which O
was O
recognized O
by O
an O
anti O
- O
peptide O
antibody O
against O
an O
epitope O
- O
containing O
nuclear O
localization O
signal O
of O
NF I-GENE
- I-GENE
kappaB I-GENE
p65 I-GENE
subunit I-GENE
. O

Insulin I-GENE
- O
regulated O
events O
, O
however O
, O
occur O
in O
all O
cells O
. O

Regulatory RARE
regions O
in O
the O
promoter O
and O
third O
intron O
of O
the O
growth I-GENE
hormone I-GENE
gene I-GENE
in I-GENE
rainbow RARE
trout I-GENE
, O
Oncorhynchus RARE
mykiss RARE
walbaum RARE
. O

Although O
most O
SFV O
genes O
have O
homologs O
encoded O
by O
other O
Chordopoxvirinae RARE
, O
the O
SFV O
genome O
lacks O
a O
key O
gene O
required O
for O
the O
production O
of O
extracellular O
enveloped RARE
virus O
. O

They O
self O
- O
completed O
the O
SF O
- O
36 O
questionnaire O
and O
their O
QoL LASTCAP
was O
described O
and O
retrospectively RARE
compared O
to O
that O
of O
historical RARE
controls O
. O

There O
was O
a O
trend O
toward O
an O
association O
between O
IENF ALLCAPS
and O
sural RARE
nerve O
unmyelinated RARE
fiber O
densities RARE
( O
r O
= O
0 O
. O
32 O
, O
p O
= O
0 O
. O
054 NUMERIC
). O

In O
addition O
, O
media O
containing O
F I-GENE
beta I-GENE
alpha I-GENE
/ O
CG I-GENE
beta I-GENE
displayed O
high O
- O
affinity O
binding O
to O
both O
CG I-GENE
and I-GENE
FSH I-GENE
receptors I-GENE
. O

In O
contrast O
, O
AP I-GENE
- I-GENE
2 I-GENE
binding O
activity O
was O
significantly O
greater O
in O
T47D NUMERIC
cells O
, O
and O
Western O
blots O
confirmed O
increased O
AP I-GENE
- I-GENE
2 I-GENE
protein I-GENE
levels O
in O
these O
cells O
. O

N O
. O
van RARE
Hoek RARE
, O
and O
M O
. O

Here O
, O
we O
describe O
a O
tyrosine O
- O
phosphorylated O
nuclear O
protein O
, O
YT521 NUMERIC
- I-GENE
B I-GENE
, O
and O
show O
that O
it O
interacts O
with O
the O
nuclear I-GENE
transcriptosomal RARE
component I-GENE
scaffold RARE
attachment I-GENE
factor I-GENE
B I-GENE
, O
and O
the O
68 I-GENE
- I-GENE
kDa I-GENE
Src I-GENE
substrate O
associated O
during O
mitosis O
, O
Sam68 NUMERIC
. O

These O
mutants O
all O
failed O
to O
interact O
with O
the O
TraR LASTCAP
fusion I-GENE
in O
the O
two O
- O
hybrid O
system O
. O

PhoP LASTCAP
- O
PhoQ LASTCAP
homologues O
in O
Pseudomonas O
aeruginosa O
regulate O
expression O
of O
the O
outer I-GENE
- I-GENE
membrane I-GENE
protein I-GENE
OprH LASTCAP
and O
polymyxin RARE
B O
resistance O
. O

Deletion O
of O
fdsR LASTCAP
revealed O
a O
dual O
regulatory O
effect O
of O
FdsR LASTCAP
on O
the O
fds RARE
operon I-GENE
by O
acting O
as O
transcriptional O
activator O
in O
the O
presence O
of O
formate O
or O
as O
repressor O
in O
the O
absence O
of O
formate O
. O

With O
constructs O
containing O
the O
binding O
site O
of O
one O
gene O
fused O
to O
the O
promoter O
of O
the O
other O
, O
we O
demonstrated O
that O
the O
positional RARE
requirements O
are O
a O
function O
of O
the O
specific O
binding O
site O
, O
not O
the O
promoter O
. O

In O
addition O
, O
all O
three O
Opa RARE
proteins I-GENE
of O
C751 NUMERIC
bind O
equally O
well O
to O
HeLa O
cells O
transfected O
with O
cDNA O
encoding O
the O
carcinoembryonic RARE
antigen I-GENE
[ O
CEA I-GENE
( O
CD66e NUMERIC
)] O
subgroup O
of O
the O
CD66 NUMERIC
family I-GENE
, O
but O
show O
distinct O
tropism RARE
for O
CGM1 NUMERIC
- O
( O
CD66d NUMERIC
) O
and O
NCA ALLCAPS
( O
CD66c NUMERIC
)- O
expressing O
cells O
. O

FISH ALLCAPS
using O
a O
whole O
chromosome O
4 O
paint RARE
demonstrated O
multiple O
rearrangements O
involving O
chromosome O
4 O
in O
MCF ALLCAPS
- O
7 O
AdVp3000 NUMERIC
and O
MCF ALLCAPS
- O
7 O
MX ALLCAPS
, O
while O
S1 O
- O
M1 O
- O
80 O
contained O
only O
a O
simple O
reciprocal O
translocation O
. O

The O
MXR ALLCAPS
gene I-GENE
encodes O
a O
half O
- O
transporter O
and O
the O
absence O
of O
cytogenetic O
evidence O
of O
coamplification RARE
of O
other O
regions O
suggests O
that O
a O
partner O
may O
not O
be O
overexpressed O
, O
and O
instead O
the O
MXR ALLCAPS
half I-GENE
- I-GENE
transporter I-GENE
homodimerizes RARE
to O
mediate O
drug O
transport O
. O

The O
effect O
of O
smoking O
was O
not O
examined O
in O
this O
study O
, O
as O
such O
data O
were O
not O
available O
. O

Serum I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
SD O
score O
increased O
from O
- O
2 O
. O
2 O
and O
- O
4 O
. O
2 O
in O
men O
and O
women O
, O
respectively O
, O
to O
1 O
. O
8 O
and O
- O
0 O
. O
9 O
at O
6 O
months O
and O
0 O
. O
8 O
and O
- O
0 O
. O
7 O
at O
12 O
months O
. O

BACKGROUND O
: O
Measurement O
of O
stereoacuity RARE
at O
varying O
distances O
, O
by O
real O
or O
simulated O
depth O
stereoacuity RARE
tests O
, O
is O
helpful O
in O
the O
evaluation O
of O
patients O
with O
binocular RARE
imbalance RARE
or O
strabismus RARE
. O

Additional RARE
studies O
revealed O
that O
bovine I-GENE
brain I-GENE
Galpha I-GENE
( I-GENE
q I-GENE
/ I-GENE
11 I-GENE
) I-GENE
could O
also O
bind O
to O
an O
N O
- O
terminal O
construct O
of O
GRK2 NUMERIC
, O
while O
no O
binding O
of O
Galpha O
( O
q O
/ O
11 O
), O
Galpha O
( O
s O
), O
Galpha O
( O
i O
), O
or O
Galpha I-GENE
( I-GENE
12 I-GENE
/ I-GENE
13 I-GENE
) I-GENE
to O
comparable O
constructs O
of O
GRK5 NUMERIC
or O
GRK6 NUMERIC
was O
observed O
. O

The O
elm1 NUMERIC
kinase I-GENE
functions O
in O
a O
mitotic O
signaling O
network O
in O
budding O
yeast O
. O

Reverse O
transcription O
( O
RT O
)- O
PCR O
products O
were O
synthesized O
with O
two O
degenerate O
primers O
derived O
from O
the O
conserved O
motifs O
of O
various O
tyrosine I-GENE
kinases I-GENE
. O

In O
addition O
, O
the O
acetyltransferase O
activity O
of O
p300 I-GENE
was O
observed O
to O
be O
distinct O
from O
the O
broadly O
essential O
activation O
function O
of O
the O
CH3 NUMERIC
domain I-GENE
/ O
E1A I-GENE
- O
binding O
region O
. O

The O
proliferation O
- O
specific O
HNF I-GENE
- I-GENE
3 I-GENE
/ O
fork I-GENE
head I-GENE
homolog I-GENE
- I-GENE
11B NUMERIC
protein O
( O
HFH ALLCAPS
- I-GENE
11B NUMERIC
; O
also O
known O
as O
Trident RARE
and O
Win RARE
) O
is O
a O
family O
member O
of O
the O
winged RARE
helix I-GENE
/ O
fork I-GENE
head I-GENE
transcription O
factors O
and O
in O
regenerating RARE
liver O
its O
expression O
is O
reactivated RARE
prior O
to O
hepatocyte O
entry O
into O
DNA O
replication O
( O
S O
phase O
). O

In O
the O
mouse O
, O
CtBP1 NUMERIC
is O
expressed O
from O
embryo O
to O
adult O
, O
but O
CtBP2 NUMERIC
is O
mainly O
expressed O
during O
embryogenesis O
. O

The O
multiple O
functions O
of O
Pmt3p NUMERIC
described O
here O
suggest O
that O
several O
nuclear O
proteins O
are O
regulated O
by O
Pmt3p NUMERIC
conjugation O
. O

The O
role O
of O
transport O
by O
sea O
ice RARE
from O
the O
Kara RARE
Sea RARE
into O
the O
Arctic RARE
Ocean RARE
was O
assessed O
by O
a O
small O
subgroup O
at O
GEOMAR ALLCAPS
. O

We O
determined O
whether O
a O
single O
injection O
of O
slow O
- O
release O
estradiol O
- O
17beta NUMERIC
( O
SRE2 NUMERIC
) O
would O
induce O
pseudopregnancy RARE
in O
gilts RARE
and O
whether O
PGF2alpha NUMERIC
would O
regress RARE
the O
corpora RARE
lutea RARE
( O
CL O
) O
of O
pseudopregnancy RARE
. O

The O
level O
of O
serum I-GENE
creatine I-GENE
kinase I-GENE
was O
significantly O
high O
2 O
days O
after O
ESWIB ALLCAPS
, O
but O
it O
recovered O
in O
a O
week O
. O

Among O
the O
remaining O
22 O
sites O
, O
six O
are O
in O
the O
promoters O
of O
known O
alpha O
- O
specific O
genes O
and O
two O
other O
sites O
have O
an O
alpha2 I-GENE
- O
Mcm1 NUMERIC
- O
dependent O
role O
in O
determining O
the O
direction O
of O
mating O
type O
switching O
. O

Activation O
of O
T O
cells O
via O
the O
TCR I-GENE
and O
other O
costimulatory RARE
receptors O
triggers O
a O
number O
of O
signaling O
cascades O
. O

A O
phylogenetic O
analysis O
with O
the O
TK I-GENE
domains I-GENE
from O
these O
sequences O
and O
a O
fourth O
, O
from O
a O
novel O
scavenger RARE
RTK ALLCAPS
( O
all O
domains O
comprise O
the O
signature RARE
for O
the O
TK I-GENE
class I-GENE
II I-GENE
receptors I-GENE
), O
showed O
that O
they O
are O
distantly O
related O
to O
the O
insulin I-GENE
and O
insulin I-GENE
- I-GENE
like I-GENE
receptors I-GENE
. O

Several O
7SL NUMERIC
RNA I-GENE
- I-GENE
encoding I-GENE
sequences I-GENE
and O
various O
intergenic O
spacers RARE
were O
amplified O
from O
the O
individual O
HindIII I-GENE
fragments I-GENE
of O
about O
1 O
. O
3 O
and O
2 O
. O
8 O
kb O
. O

Results O
confirmed O
that O
stress O
produced O
CA3 O
dendritic RARE
atrophy O
and O
tianeptine RARE
prevented O
it O
. O

We O
have O
isolated O
a O
binding O
partner O
for O
the O
Fanconi RARE
anemia I-GENE
group I-GENE
C I-GENE
protein I-GENE
( O
FANCC ALLCAPS
) O
by O
yeast O
two O
- O
hybrid O
screening O
. O

These O
results O
suggest O
that O
both O
transcription O
activators O
depend O
on O
or O
interact O
with O
different O
subunits O
of O
RNA I-GENE
polymerase I-GENE
, O
although O
their O
role O
in O
formation O
of O
proper O
DNA O
geometry RARE
may O
also O
be O
crucial O
. O

Klebsiella O
oxytoca RARE
can O
assimilate RARE
nitrate O
and O
nitrite O
by O
using O
enzymes O
encoded O
by O
the O
nasFEDCBA LASTCAP
operon I-GENE
. O

Marked O
hemolysis RARE
significantly O
increased O
plasma O
values O
of O
potassium O
, O
phosphorus O
, O
total O
protein O
, O
and O
aspartate I-GENE
aminotransferase I-GENE
. O

Studies O
have O
substantiated RARE
the O
involvement O
of O
numerous O
loci O
on O
certain O
chromosomes O
; O
in O
excess O
of O
10 O
chromosomes O
are O
thought O
to O
be O
involved O
. O

By O
negatively O
regulating O
GRK ALLCAPS
- O
mediated O
receptor O
phosphorylation O
, O
beta I-GENE
- I-GENE
arrestin RARE
- O
mediated O
processes O
such O
as O
Src I-GENE
recruitment O
and O
clathrin I-GENE
- O
mediated O
internalization O
, O
which O
are O
required O
for O
GPCR ALLCAPS
- O
mediated O
ERK I-GENE
activation O
, O
are O
inhibited O
, O
thus O
dampening RARE
further O
ERK I-GENE
activation O
. O

Based O
on O
subcellular O
fractionation O
, O
the O
47 I-GENE
- I-GENE
kDa I-GENE
P I-GENE
- I-GENE
CIP2 NUMERIC
protein I-GENE
is O
mostly O
cytosolic O
. O

Supershift RARE
EMSAs RARE
identified O
that O
upstream I-GENE
stimulatory I-GENE
factor I-GENE
- I-GENE
1 I-GENE
and I-GENE
- I-GENE
2 I-GENE
( O
USF I-GENE
- I-GENE
1 I-GENE
and I-GENE
- I-GENE
2 I-GENE
) O
were O
part O
of O
these O
complexes O
. O

Conversely O
, O
E1A I-GENE
binding O
to O
only O
p300 I-GENE
/ O
CBP I-GENE
results O
in O
an O
increase O
in O
PARP ALLCAPS
enzyme I-GENE
activity O
and O
consequently RARE
in O
cell O
death O
susceptibility O
to O
irradiation O
, O
which O
is O
effectively O
counteracted RARE
by O
the O
PARP ALLCAPS
chemical O
inhibitor O
3 O
- O
aminobenzamide RARE
. O

Analysis O
of O
its O
genomic O
region O
revealed O
that O
the O
13 O
- O
kb O
Cdc6 NUMERIC
gene I-GENE
is O
divided O
into O
12 O
exons O
by O
11 O
introns O
. O

These O
include O
the O
CACCC ALLCAPS
and O
CAAT O
motifs O
. O

Skin RARE
pH O
changes O
associated O
with O
iontophoresis RARE
. O

This O
distinction RARE
was O
based O
upon O
whether O
the O
diagnosis O
provided O
a O
straightforward RARE
range O
of O
prognoses RARE
or O
an O
ambiguous RARE
clinical O
implication RARE
. O

The O
availability O
of O
potent O
regulatory O
DNA O
cassettes RARE
harboring O
the O
murine I-GENE
D1A NUMERIC
gene I-GENE
promoter I-GENE
could O
aid O
testing O
the O
neuronal O
- O
specific O
expression O
of O
transgenes RARE
in O
vivo O
. O

It O
may O
be O
dependent O
on O
location O
of O
a O
focus O
( O
according O
to O
EEG O
) O
as O
well O
as O
on O
the O
character O
and O
manifestation O
of O
the O
accompanying O
neuropsychologic RARE
symptomatology RARE
. O

The O
results O
of O
these O
studies O
demonstrate O
that O
the O
rat O
HDL O
receptor O
SR I-GENE
- I-GENE
BI I-GENE
promoter O
contains O
two O
sterol O
response O
elements O
( O
pSRE LASTCAP
and O
dSRE LASTCAP
) O
through O
which O
SREBP I-GENE
- I-GENE
1a I-GENE
can O
bind O
and O
activate O
transcription O
of O
this O
gene O
. O

Phosphorylation RARE
of O
myosin I-GENE
- I-GENE
binding I-GENE
subunit I-GENE
( O
MBS ALLCAPS
) O
of O
myosin I-GENE
phosphatase I-GENE
by O
Rho I-GENE
- I-GENE
kinase I-GENE
in O
vivo O
. O

Of O
these O
patients O
, O
46 O
, O
164 NUMERIC
were O
placed O
on O
a O
waiting RARE
list RARE
for O
transplantation O
, O
23 O
, O
275 NUMERIC
of O
whom O
received O
a O
first O
cadaveric RARE
transplant O
between O
1991 O
and O
1997 O
. O

In O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
), O
this O
GLUT4 NUMERIC
repressor I-GENE
element I-GENE
( O
G4RE NUMERIC
) O
generated O
specific O
bands O
with O
nuclear O
extracts O
from O
preadipocytes RARE
, O
but O
not O
from O
adipocytes O
. O

Syndromes RARE
of O
abnormal O
fat O
redistribution RARE
and O
metabolic O
complications O
in O
HIV O
- O
infected O
patients O
. O

Cytoprotection RARE
with O
amifostine RARE
in O
radiotherapy O
or O
radio RARE
- O
chemotherapy O
of O
head O
and O
neck O
tumors O

Immunohistochemical RARE
staining O
was O
positive O
for O
S I-GENE
- I-GENE
100 I-GENE
in O
all O
9 O
cases O
stained O
, O
positive O
for O
HMB ALLCAPS
- I-GENE
45 I-GENE
in O
9 O
( O
90 O
%) O
of O
10 O
, O
and O
negative O
for O
cytokeratin RARE
in O
all O
9 O
cases O
in O
which O
myxoid RARE
melanoma O
remained O
in O
the O
block O
after O
previous O
sections O
. O

Patients O
with O
types O
I O
and O
III O
MPGN ALLCAPS
did O
not O
differ O
in O
age O
at O
apparent O
onset O
, O
age O
at O
diagnosis O
, O
or O
interval O
from O
apparent O
onset O
of O
symptoms O
to O
diagnosis O
( O
biopsy O
). O

Residual RARE
urinary O
abnormalities O
were O
significantly O
more O
frequent O
in O
patients O
with O
type O
III O
than O
type O
I O
MPGN ALLCAPS
. O

Taken O
together O
, O
differences O
in O
signaling O
and O
tissue O
expression O
suggest O
that O
the O
human I-GENE
intermediate I-GENE
PRLr RARE
differs O
from O
the O
long I-GENE
PRLr RARE
in O
physiological O
function O
. O

We O
describe O
here O
a O
Drosophila I-GENE
melanogaster I-GENE
FAK I-GENE
homologue I-GENE
, O
DFak56 NUMERIC
, O
which O
maps O
to O
band O
56D NUMERIC
on O
the O
right O
arm O
of O
the O
second O
chromosome O
. O

Because O
the O
Pit I-GENE
- I-GENE
1 I-GENE
sites I-GENE
in O
the O
hGH I-GENE
- I-GENE
N I-GENE
gene I-GENE
promoter I-GENE
are O
insufficient O
for O
such O
gene O
activation O
in O
vivo O
, O
these O
data O
suggested O
a O
unique O
chromatin O
- O
mediated O
developmental O
role O
for O
Pit I-GENE
- I-GENE
1 I-GENE
in O
the O
hGH I-GENE
LCR I-GENE
. O

Recombinant I-GENE
prenylcysteine RARE
lyase I-GENE
was O
produced O
in O
a O
baculovirus O
- O
Sf9 O
expression O
system O
. O

We O
show O
here O
that O
the O
third O
SH3 I-GENE
domain I-GENE
binds O
to O
Sos I-GENE
, O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
for O
Ras I-GENE
and O
Rac I-GENE
, O
both O
in O
vitro O
and O
in O
vivo O
. O

Point RARE
mutations O
in O
the O
third O
SH3 I-GENE
domain I-GENE
abolished O
the O
vinexin RARE
- O
Sos I-GENE
interaction O
. O

In O
gel O
mobility O
shift O
assays O
, O
low O
binding O
activity O
of O
CBF I-GENE
to O
the O
wild I-GENE
- I-GENE
type I-GENE
AtpC LASTCAP
promoter I-GENE
sequence I-GENE
was O
observed O
with O
nuclear O
extracts O
from O
tissue O
with O
low O
AtpC LASTCAP
expression O
levels O
, O
i O
. O
e O
. O
extracts O
from O
etiolated RARE
and O
photobleached RARE
seedlings O
, O
whereas O
high O
binding O
activity O
was O
detectable O
with O
extracts O
from O
tissues O
with O
high O
AtpC LASTCAP
expression O
levels O
, O
i O
. O
e O
. O
extracts O
from O
light O
- O
grown O
seedlings O
and O
etiolated RARE
seedlings O
treated O
with O
cytokinin RARE
. O

Mycoplasma RARE
hominis RARE
infections O
are O
easily O
missed RARE
because O
conventional O
methods O
for O
bacterial O
detection O
may O
fail O
. O

For O
this O
purpose O
, O
we O
used O
a O
series O
of O
plasmid O
constructs O
encoding O
different O
forms O
of O
the O
envelope I-GENE
glycoprotein I-GENE
E I-GENE
of I-GENE
the I-GENE
flavivirus RARE
tick RARE
- I-GENE
borne RARE
encephalitis RARE
virus I-GENE
. O

They O
are O
subdivided RARE
into O
two O
types O
that O
activate O
transduction O
pathways O
via O
different O
cell O
surface O
receptors O
. O

We O
report O
here O
that O
out O
of O
the O
major O
pro O
- O
inflammatory O
cytokines O
examined O
, O
IL I-GENE
- I-GENE
1alpha I-GENE
, O
IL I-GENE
- I-GENE
1beta I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
and O
IL I-GENE
- I-GENE
6 I-GENE
, O
only O
IL I-GENE
- I-GENE
6 I-GENE
was O
generated O
and O
secreted O
in O
PKCeta RARE
- O
expressing O
cells O
without O
any O
additional O
inducer RARE
in O
serum O
- O
supplemented O
cultures O
( O
10 O
% O
FCS ALLCAPS
). O

Demyelinating RARE
diseases O
involving O
the O
grey RARE
matter O
were O
very O
rare O
, O
but O
we O
must O
consider O
the O
presence O
of O
symmetrical RARE
thalamic RARE
involvement O
in O
patients O
with O
ADEM ALLCAPS
. O

To O
define O
the O
minimal O
VDRE O
binding O
domain O
for O
human I-GENE
VDR I-GENE
( O
hVDR LASTCAP
), O
a O
series O
of O
C O
- O
terminally O
truncated O
hVDR LASTCAP
mutants I-GENE
( O
Delta134 NUMERIC
, O
Delta113 NUMERIC
, O
Delta102 NUMERIC
, O
Delta90 NUMERIC
, O
Delta84 NUMERIC
, O
Delta80 NUMERIC
, O
and O
Delta60 NUMERIC
) O
was O
generated O
and O
expressed O
in O
bacteria O
. O

By O
an O
induced O
- O
fit O
mechanism O
, O
contacts O
with O
the O
anticodon RARE
can O
activate O
formation O
of O
a O
robust RARE
transition O
state O
at O
a O
site O
over O
70 O
A O
away RARE
. O

These O
REPs RARE
, O
or O
clusters O
of O
paralogous RARE
loci O
, O
are O
15 O
- O
100 O
kb O
and O
harbor O
at O
least O
four O
ESTs O
and O
an O
expressed O
SH3GL NUMERIC
pseudogene I-GENE
. O

This O
revealed O
a O
minimum O
of O
six O
novel O
OSBP ALLCAPS
- I-GENE
related I-GENE
proteins I-GENE
, O
designated O
ORP ALLCAPS
- I-GENE
1 I-GENE
to O
ORP ALLCAPS
- I-GENE
6 I-GENE
. O

In O
part O
as O
a O
result O
of O
its O
inability RARE
to O
sustain RARE
radiative RARE
loses RARE
, O
the O
BB O
resonator RARE
has O
extremely O
low O
RF ALLCAPS
power O
requirements O
. O

In O
addition O
, O
narZ LASTCAP
expression O
was O
induced O
approximately O
20 O
- O
fold O
intracellularly RARE
in O
Madin RARE
- O
Darby RARE
canine O
kidney O
epithelial O
cells O
and O
16 O
- O
fold O
in O
intracellular O
salts RARE
medium O
, O
which O
is O
believed O
to O
mimic O
the O
intracellular O
milieu RARE
. O

However O
, O
mechanisms O
underlying O
HIV O
- O
1 O
gene O
expression O
in O
the O
CNS O
are O
poorly O
understood O
. O

Is O
radical O
trachelectomy RARE
a O
safe O
alternative O
to O
radical O
hysterectomy O
for O
patients O
with O
stage O
IA O
- O
B O
carcinoma O
of O
the O
cervix O
? O
BACKGROUND O
: O
The O
prognosis O
associated O
with O
lymph O
node O
negative O
, O
early O
stage O
carcinoma O
of O
the O
cervix O
is O
excellent O
, O
with O
5 O
- O
year O
survival O
rates O
greater O
than O
90 O
%. O

A O
key O
event O
in O
this O
process O
is O
the O
selective O
recognition O
of O
the O
target O
membrane O
by O
the O
vesicle O
and O
the O
current O
view O
is O
that O
SNARE ALLCAPS
protein I-GENE
interactions O
likely O
play O
a O
central O
role O
in O
vesicle O
- O
target O
recognition O
and O
or O
membrane O
fusion O
. O

Scapulae RARE
with O
a O
Type O
I O
configuration O
were O
found O
to O
have O
low O
values O
for O
the O
coraco RARE
- O
glenoid RARE
angle O
and O
coracoid RARE
overlap O
, O
which O
are O
known O
to O
be O
associated O
with O
a O
short O
coraco RARE
- O
humeral RARE
distance O
. O

Measurements O
in O
the O
LWS ALLCAPS
p O
. O
a O
. O
, O
LWS ALLCAPS
lat RARE
. O
and O
at O
Ward RARE
' O
s O
triangle RARE
were O
made O
in O
a O
total O
of O
100 O
patients O
. O

A O
group O
of O
66 O
DSM ALLCAPS
- O
IV O
paranoid RARE
schizophrenic O
in O
- O
patients O
were O
assessed O
three O
times O
using O
the O
SAPS ALLCAPS
, O
SANS ALLCAPS
, O
BPRS ALLCAPS
and O
PAS ALLCAPS
. O

In O
conclusion O
: O
( O
i O
) O
TECRA ALLCAPS
kit O
is O
suggested O
to O
be O
used O
for O
screening O
SE O
producing O
strains O
; O
( O
ii O
) O
SET ALLCAPS
- O
RPLA ALLCAPS
and O
RIDASCREEN ALLCAPS
kits RARE
are O
suitable O
for O
epidemiological O
investigation O
of O
SE O
types O
, O
but O
the O
lack O
of O
ability O
for O
detecting O
SEE ALLCAPS
, O
long O
time O
required O
for O
testing O
with O
SET ALLCAPS
- O
RPLA ALLCAPS
kit O
and O
high O
background O
when O
using O
RIDASCREEN ALLCAPS
kit O
must O
be O
overcome O
; O
and O
( O
iii O
) O
because O
of O
the O
complicated O
test O
procedures O
and O
the O
lack O
of O
ability O
for O
detecting O
SEE ALLCAPS
, O
the O
practicality RARE
of O
SET ALLCAPS
- O
EIA O
kit O
in O
screening O
and O
epidemiological O
research O
purposes RARE
is O
low O
. O

Comparison O
of O
immunoassay O
kits RARE
for O
detection O
of O
staphylococcal RARE
enterotoxins RARE
produced O
by O
Staphylococcus O
aureus O

Despite O
the O
high O
frequency O
of O
natural O
infection O
, O
the O
seropositive O
rates O
of O
JEV ALLCAPS
antibody O
still O
correlated O
well O
with O
the O
dose O
of O
vaccine O
received O
, O
i O
. O
e O
., O
67 O
% O
( O
1122 NUMERIC
/ O
1664 NUMERIC
), O
66 O
% O
( O
65 O
/ O
97 O
), O
33 O
% O
( O
4 O
/ O
12 O
) O
and O
40 O
% O
( O
19 O
/ O
47 O
) O
for O
children O
receiving O
3 O
, O
2 O
, O
1 O
, O
and O
0 O
dose O
of O
JE ALLCAPS
vaccines O
, O
respectively O
( O
P O
< O
0 O
. O
0001 O
Chi O
- O
square O
for O
trend O
test O
). O

Furthermore O
, O
in O
vivo O
and O
in O
vitro O
protein O
- O
protein O
interaction O
experiments O
have O
shown O
that O
SR33 NUMERIC
protein I-GENE
interacts O
with O
itself O
and O
with O
SR45 NUMERIC
protein I-GENE
but O
not O
with O
two O
other O
members O
( O
SRZ21 NUMERIC
and O
SRZ22 NUMERIC
) O
of O
the O
SR I-GENE
family I-GENE
that O
are O
known O
to O
interact O
with O
the O
Arabidopsis O
full O
- O
length O
U I-GENE
- I-GENE
70K NUMERIC
only O
. O

In O
summary O
, O
WT1 I-GENE
is O
enriched O
by O
oligo RARE
( O
dT O
) O
chromatography O
, O
as O
are O
U2AF65 NUMERIC
, O
the O
U5 I-GENE
small I-GENE
nuclear I-GENE
RNP I-GENE
- I-GENE
associated I-GENE
protein I-GENE
p116 NUMERIC
and O
hnRNP O
A1 I-GENE
. O

Six O
out O
of O
ten O
hearts O
from O
macerated RARE
stillborn RARE
infants O
showed O
varying O
degrees O
of O
positive O
staining O
. O

Tih1 NUMERIC
maps O
to O
distal O
mouse O
Chr O
1 O
and O
human O
Chr O
1q31 NUMERIC
, O
chromosomal O
regions O
that O
have O
not O
shown O
evidence O
for O
imprinting O
and O
, O
in O
contrast O
to O
Ipl RARE
, O
Tih1 NUMERIC
is O
expressed O
equally O
from O
both O
parental O
alleles O
. O

A O
novel O
pleckstrin I-GENE
homology I-GENE
- I-GENE
related I-GENE
gene I-GENE
family I-GENE
defined O
by O
Ipl RARE
/ O
Tssc3 NUMERIC
, O
TDAG51 NUMERIC
, O
and O
Tih1 NUMERIC
: O
tissue O
- O
specific O
expression O
, O
chromosomal O
location O
, O
and O
parental O
imprinting O
. O

The O
potential O
for O
highly O
reactive O
nanoparticles RARE
( O
RNP O
) O
to O
absorb RARE
destructively RARE
, O
i O
. O
e O
. O
to O
neutralize RARE
highly O
toxic O
substances O
such O
as O
the O
warfare RARE
agents O
GA O
, O
GB ALLCAPS
, O
HD O
and O
VX ALLCAPS
, O
has O
been O
demonstrated O
in O
the O
laboratory O
. O

There O
were O
minimal O
negative O
effects O
on O
hematological RARE
parameters O
, O
acid O
- O
base O
status O
, O
and O
blood O
gases O
. O

Twelve RARE
out O
of O
43 O
renal O
failure O
patients O
had O
troponin RARE
I I-GENE
0 O
. O
13 O
- O
0 O
. O
9 O
microg O
/ O
l O
using O
Axsym RARE
method O
and O
4 O
had O
levels O
of O
0 O
. O
07 O
- O
0 O
. O
13 O
microg O
/ O
l O
using O
Immuno RARE
1 O
. O

Therefore O
, O
we O
propose O
that O
p27 I-GENE
represents O
a O
crucial O
molecule O
in O
HMBA ALLCAPS
signaling O
that O
cannot O
be O
replaced O
by O
p21 I-GENE
. O

Transient O
, O
high O
- O
level O
Ras I-GENE
- O
expression O
induces O
transcriptional O
activation O
of O
p21 I-GENE
mediated O
by O
a O
GC O
- O
rich O
region O
in O
p21 I-GENE
promoter I-GENE
- O
83 O
- O
54 O
bp O
relative O
to O
the O
transcription O
initiation O
site O
containing O
binding O
sites O
for O
Sp1 I-GENE
- I-GENE
family I-GENE
transcription I-GENE
factors I-GENE
. O

The O
RET I-GENE
/ O
PTC3 NUMERIC
rearrangement O
is O
formed O
by O
fusion O
of O
the O
ELE1 NUMERIC
and O
RET I-GENE
genes I-GENE
, O
and O
is O
highly O
prevalent RARE
in O
radiation O
- O
induced O
post O
- O
Chernobyl RARE
papillary RARE
thyroid O
carcinomas O
. O

Apoptosis RARE
of O
small O
cells O
is O
still O
observed O
after O
co O
- O
transfection O
of O
JBD ALLCAPS
and O
LMP1 I-GENE
but O
in O
addition O
a O
few O
apoptotic O
HD O
- O
MyZ LASTCAP
cells O
with O
large O
fused O
nuclear O
masses O
are O
identified O
suggesting O
that O
specific O
inhibition O
of O
JNK I-GENE
leads O
also O
to O
apoptosis O
of O
LMP1 I-GENE
induced O
RS O
cells O
. O

In O
addition O
to O
the O
bZIP I-GENE
protein I-GENE
Opaque2 NUMERIC
( O
O2 I-GENE
), O
there O
are O
other O
maize O
endosperm RARE
nuclear O
proteins O
that O
recognize O
the O
O2 I-GENE
box I-GENE
in O
22 O
kDa O
zein RARE
gene O
promoters O
. O

The O
mEmBP LASTCAP
- I-GENE
1 I-GENE
protein I-GENE
can O
activate O
transcription O
from O
a O
truncated O
promoter O
containing O
a O
pentamer RARE
of O
the O
O2 I-GENE
site I-GENE
in O
yeast O
cells O
; O
however O
, O
it O
inhibited O
regulated O
transcription O
of O
a O
22 I-GENE
kDa I-GENE
zein RARE
promoter I-GENE
in O
a O
transient O
expression O
assay O
using O
cultured O
maize O
endosperm RARE
cells O
. O

GHB ALLCAPS
, O
2 O
CB ALLCAPS
, O
HMB ALLCAPS
, O
are O
some O
of O
these O
recent O
substances O
. O

There O
were O
15 O
deaths O
, O
seven O
of O
which O
were O
felt RARE
to O
be O
avoidable RARE
. O

With O
this O
GH I-GENE
and O
estrogen O
treatment O
regimen O
, O
most O
girls O
with O
TS ALLCAPS
can O
grow O
and O
develop O
much O
more O
in O
conformity RARE
with O
their O
healthy O
peers RARE
. O

We O
propose O
that O
the O
reduced O
responsiveness O
of O
CYP3A2 NUMERIC
is O
the O
result O
of O
preferential O
binding O
of O
COUP I-GENE
- I-GENE
TF I-GENE
at O
the O
CYP3A2 NUMERIC
DexRE LASTCAP
- I-GENE
1 I-GENE
site I-GENE
. O

Higher RARE
CYP3A23 NUMERIC
basal O
activity O
appears O
to O
be O
due O
to O
an O
E O
- O
box O
in O
3A23SiteA NUMERIC
that O
interacts O
with O
USF1 NUMERIC
, O
a O
ubiquitous O
bHLH I-GENE
/ I-GENE
leucine I-GENE
zipper I-GENE
transcription I-GENE
factor I-GENE
. O

The O
first O
one O
is O
a O
TPA O
- O
responsive O
element O
that O
controls O
the O
base O
- O
line O
ST3 NUMERIC
promoter I-GENE
activity O
but O
is O
not O
required O
for O
its O
activation O
. O

To O
understand O
the O
basis O
for O
the O
increased O
cell O
surface O
stability O
compared O
with O
wild O
- O
type O
peptide O
and O
to O
understand O
the O
differences O
in O
T O
cell O
recognition O
between O
I1Y NUMERIC
and O
I1F NUMERIC
, O
we O
determined O
the O
x O
- O
ray O
crystal O
structures O
of O
the O
two O
class I-GENE
I I-GENE
MHC I-GENE
- I-GENE
peptide I-GENE
complexes I-GENE
. O

Redistribution RARE
of O
mannosidase RARE
I I-GENE
was O
also O
observed O
in O
cells O
incubated O
at O
15 O
degrees O
C O
. O

In O
addition O
, O
using O
biochemical O
activity O
assays O
for O
Rho I-GENE
- O
like O
GTPases I-GENE
, O
we O
show O
that O
the O
expression O
of O
beta1A NUMERIC
, O
beta1D NUMERIC
, O
or O
IL2R NUMERIC
- O
beta1A NUMERIC
in O
GE11 NUMERIC
or O
GD25 NUMERIC
cells O
triggers O
activation O
of O
both O
RhoA I-GENE
and O
Rac1 I-GENE
, O
but O
not O
of O
Cdc42 I-GENE
. O

In O
conclusion O
, O
our O
data O
do O
not O
support O
a O
role O
for O
IVIg RARE
in O
the O
remyelination RARE
of O
stable O
multiple O
sclerosis O
lesions O
as O
measured O
by O
central O
conduction O
time O
. O

The O
rhabdomyosarcoma RARE
R1H NUMERIC
growing O
on O
the O
right O
flank O
of O
male O
WAG ALLCAPS
/ O
Rij RARE
rats O
was O
clamped RARE
for O
2 O
or O
4 O
h O
at O
20 O
degrees O
C O
or O
37 O
degrees O
C O
. O

Relative RARE
to O
coherent RARE
control O
words RARE
( O
e O
. O
g O
., O
quick RARE
), O
these O
discourse RARE
- O
dependent O
semantic RARE
anomalies O
elicited O
a O
large O
N400 NUMERIC
effect O
that O
began RARE
at O
about O
200 O
to O
250 O
msec O
after O
word RARE
onset O
. O

These O
synergistic O
effects O
were O
strongly O
Jem RARE
- I-GENE
1 I-GENE
dose O
- O
dependent O
. O

Like O
the O
Tob RARE
protein I-GENE
, O
Tob2 NUMERIC
inhibited O
cell O
cycle O
progression O
from O
the O
G0 NUMERIC
/ O
G1 O
to O
S O
phases O
. O

The O
coordinate O
increase O
in O
cyclin I-GENE
D1 I-GENE
and O
p21 I-GENE
had O
the O
effect O
of O
decreasing O
the O
specific O
but O
not O
absolute O
activity O
of O
cyclin I-GENE
D1 I-GENE
/ O
cdk4 NUMERIC
. O
p53 I-GENE
was O
not O
involved O
since O
CSF I-GENE
- I-GENE
1 I-GENE
induction O
of O
p21 I-GENE
was O
unaffected O
by O
dominant I-GENE
- I-GENE
negative I-GENE
p53 I-GENE
expression O
. O

In O
addition O
, O
SLK ALLCAPS
displays O
high O
homology O
to O
microtubule I-GENE
and I-GENE
nuclear I-GENE
associated I-GENE
protein I-GENE
( O
M I-GENE
- I-GENE
NAP ALLCAPS
) O
and O
AT1 NUMERIC
- I-GENE
46 I-GENE
, O
both O
of O
unknown O
function O
. O

In O
this O
study O
26 O
patients O
( O
20 O
females O
and O
6 O
males O
) O
were O
evaluated O
. O

The O
signalling O
molecules O
Wnt1 NUMERIC
and O
Sonic RARE
hedgehog RARE
, O
implicated O
in O
the O
activation O
of O
Myf5 NUMERIC
in O
myogenic O
progenitor O
cells O
in O
the O
somite RARE
, O
are O
also O
produced O
in O
the O
viscinity RARE
of O
the O
Myf5 NUMERIC
expression I-GENE
domain I-GENE
in O
the O
mesencephalon RARE
. O

STUDY ALLCAPS
DESIGN O
AND O
METHODS O
: O
A O
study O
was O
initiated O
to O
compare O
the O
collection O
of O
PBPCs RARE
with O
the O
new O
device O
, O
the O
AutoPBSC LASTCAP
( O
version O
[ O
V O
] O
6 O
. O
0 O
with O
AutoPBSC LASTCAP
tubing RARE
set O
), O
and O
that O
with O
the O
MNC ALLCAPS
( O
mononuclear O
cell O
) O
procedure O
( O
V4 NUMERIC
. O
7 O
with O
white O
cell O
tubing RARE
set O
), O
for O
patients O
and O
healthy O
donors O
. O

Albumin RARE
dialysis O
: O
effective O
removal O
of O
copper O
in O
a O
patient O
with O
fulminant RARE
Wilson RARE
disease O
and O
successful O
bridging RARE
to O
liver O
transplantation O
: O
a O
new O
possibility O
for O
the O
elimination O
of O
protein O
- O
bound O
toxins RARE
. O

Some O
artificial O
promoter O
constructs O
containing O
multiple O
Sp1 I-GENE
sites I-GENE
were O
highly O
responsive O
to O
ethanol O
, O
but O
others O
were O
not O
, O
suggesting O
that O
the O
organization O
of O
the O
proximal O
promoter O
region O
was O
an O
additional O
factor O
that O
affected O
the O
ethanol O
response O
. O

Overexpression O
of O
CDP I-GENE
/ O
cut I-GENE
in O
ROS O
17 O
/ O
2 O
. O
8 O
osteosarcoma O
cells O
results O
in O
repression O
of O
OC I-GENE
promoter I-GENE
activity O
; O
this O
repression O
is O
abrogated O
by O
mutating RARE
OC I-GENE
box I-GENE
I I-GENE
. O

Injection RARE
of O
double O
- O
stranded O
RNA O
into O
C O
. O
elegans O
results O
in O
embryonic O
lethality O
; O
thus O
, O
the O
SF1 NUMERIC
gene I-GENE
is O
essential O
not O
only O
in O
yeast O
but O
also O
in O
at O
least O
one O
metazoan O
. O

Both O
domains O
were O
required O
for O
specific O
DNA O
binding O
to O
the O
beta I-GENE
- I-GENE
retinoic I-GENE
acid I-GENE
receptor I-GENE
element I-GENE
, O
producing O
a O
DNase I-GENE
I I-GENE
footprint O
covering O
predominantly O
one O
strand O
. O

Snail RARE
family I-GENE
proteins I-GENE
are O
zinc O
finger O
transcriptional O
regulators O
first O
identified O
in O
Drosophila O
which O
play O
critical O
roles O
in O
cell O
fate O
determination O
. O

Consistent O
with O
this O
finding O
, O
beta I-GENE
- I-GENE
catenin I-GENE
interacted O
directly O
with O
the O
RA I-GENE
receptor I-GENE
( O
RAR I-GENE
) O
in O
a O
retinoid O
- O
dependent O
manner O
, O
but O
not O
with O
the O
retinoid I-GENE
X I-GENE
receptor I-GENE
( O
RXR I-GENE
), O
and O
RAR I-GENE
competed RARE
with O
TCF I-GENE
for O
beta I-GENE
- I-GENE
catenin I-GENE
binding O
. O

Sequence O
analysis O
of O
the O
promoter O
region O
showed O
no O
TATA O
box O
but O
identified O
consensus O
binding O
motifs O
for O
Sp1 I-GENE
, O
CREB I-GENE
, O
and O
half O
sites O
of O
the O
estrogen I-GENE
receptor I-GENE
binding I-GENE
site I-GENE
. O

Sak RARE
kinase I-GENE
gene O
structure O
and O
transcriptional O
regulation O
. O

Thrombolysis RARE
was O
followed O
by O
a O
similar O
increase O
of O
platelet O
activity O
with O
maximal O
values O
reached O
at O
the O
3rd NUMERIC
hour O
in O
both O
groups O
( O
196 NUMERIC
+/- O
43 O
IU O
/ O
ml O
in O
Group O
1 O
and O
192 O
+/- O
39 O
in O
Group O
2 O
: O
p O
& O
lt RARE
; O
001versus NUMERIC
baseline O
and O
p O
NS O
between O
the O
groups O
). O

Similar O
to O
Hp140 NUMERIC
, O
isolated O
Hp55 NUMERIC
binds O
DNA O
with O
moderate O
strength O
and O
was O
a O
specificity O
for O
double O
- O
stranded O
primer O
- O
template O
DNA O
. O

Finally O
, O
three O
new O
missense O
mutations O
, O
E138V NUMERIC
, O
R254G NUMERIC
, O
and O
P362R NUMERIC
, O
were O
identified O
in O
the O
human I-GENE
AC I-GENE
gene I-GENE
from O
FD ALLCAPS
patients O
. O

These O
data O
indicate O
that O
the O
interaction O
of O
eIF4A NUMERIC
with O
the O
middle O
region O
of O
eIF4GI NUMERIC
is O
necessary O
for O
translation O
, O
whereas O
the O
interaction O
of O
eIF4A NUMERIC
with O
the O
C O
- O
terminal O
region O
plays O
a O
modulatory RARE
role O
. O

The O
DAP5 NUMERIC
/ O
p86 NUMERIC
apoptotic O
form O
was O
more O
potent O
than O
DAP5 NUMERIC
/ O
p97 NUMERIC
in O
these O
functional O
assays O
. O

12 O
: O
2684 NUMERIC
- O
2697 NUMERIC
, O
1998 O
): O
a O
key O
step O
of O
this O
model O
is O
the O
activation O
of O
the O
MAPK I-GENE
Fus3p NUMERIC
through O
the O
G O
( O
betagamma RARE
)- O
dependent O
relocalization RARE
of O
the O
Ste5p NUMERIC
- O
MAPK I-GENE
cascade O
to O
the O
plasma O
membrane O
. O

Consistent O
with O
this O
finding O
, O
wild I-GENE
- I-GENE
type I-GENE
SAGA ALLCAPS
inhibits O
TBP I-GENE
binding O
to O
the O
HIS3 I-GENE
promoter I-GENE
in O
vitro O
, O
while O
SAGA ALLCAPS
lacking O
Spt3 NUMERIC
or O
Spt8 NUMERIC
is O
not O
inhibitory O
. O

Saccharomyces O
cerevisiae O
contains O
a O
genetically O
and O
biochemically RARE
proven O
CAK I-GENE
gene I-GENE
, O
CAK1 NUMERIC
, O
that O
encodes O
a O
monomeric O
44 I-GENE
- I-GENE
kDa I-GENE
Cak1p NUMERIC
protein I-GENE
unrelated O
to O
Cdk7 NUMERIC
. O

Northern O
blot O
and O
reverse O
transcription O
- O
PCR O
analyses O
of O
human O
mRNA O
samples O
demonstrate O
that O
RNR ALLCAPS
is O
expressed O
exclusively O
in O
the O
retina O
, O
with O
transcripts O
of O
approximately O
7 O
. O
5 O
kb O
, O
approximately O
3 O
. O
0 O
kb O
, O
and O
approximately O
2 O
. O
3 O
kb O
by O
Northern O
blot O
analysis O
. O

Particularly RARE
striking O
was O
the O
conservation O
of O
an O
AP I-GENE
- I-GENE
4 I-GENE
binding I-GENE
site I-GENE
within O
100 O
nucleotides O
upstream O
of O
the O
transcription O
initiation O
site O
in O
both O
Aal RARE
- O
rpL34 NUMERIC
and O
Aal RARE
- O
rpL8 NUMERIC
genes O
. O

Based O
on O
a O
type O
I O
error O
of O
0 O
. O
05 O
, O
our O
study O
had O
a O
power O
greater O
than O
or O
equal O
to O
75 O
% O
to O
detect O
group O
differences O
in O
treatment O
effect O
of O
greater O
than O
or O
equal O
to O
15 O
% O
to O
20 O
%. O

CONCLUSIONS O
: O
Serum O
levels O
of O
S I-GENE
- I-GENE
100beta NUMERIC
are O
reliable O
markers O
for O
adverse O
neurologic O
outcomes O
after O
cardiac O
surgery O
. O

However O
, O
no O
genetic O
alteration O
was O
detected O
in O
any O
of O
the O
cancers O
examined O
. O

All O
problems O
were O
associated O
with O
fractured RARE
or O
lost O
screws RARE
. O

Statins RARE
: O
lower O
lipids O
and O
better O
bones RARE
? O
Although O
statins RARE
are O
widely O
used O
as O
cholesterol O
- O
lowering O
drugs O
, O
a O
recent O
study O
suggests O
that O
these O
compounds O
have O
anabolic RARE
effects O
on O
bone O
and O
could O
be O
developed O
into O
new O
treatments O
for O
common O
metabolic O
bone O
diseases O
such O
as O
osteoporosis RARE

The O
accumulated O
products O
of O
ancient RARE
duplication O
events O
can O
be O
readily O
observed O
among O
the O
genes O
encoding O
voltage O
- O
dependent O
Ca O
( O
2 O
+) O
ion O
channels O
. O

The O
VirR LASTCAP
response I-GENE
regulator I-GENE
from O
Clostridium RARE
perfringens RARE
binds O
independently O
to O
two O
imperfect RARE
direct O
repeats O
located O
upstream O
of O
the O
pfoA LASTCAP
promoter I-GENE
. O

Cloning O
and O
sequencing O
of O
the O
upstream O
region O
of O
pepX LASTCAP
revealed O
the O
presence O
of O
two O
ORFs O
of O
360 NUMERIC
and O
1 O
, O
338 NUMERIC
bp O
that O
were O
shown O
to O
be O
able O
to O
encode O
proteins O
with O
high O
homology O
to O
GlnR LASTCAP
and O
GlnA LASTCAP
proteins I-GENE
, O
respectively O
. O

Objective RARE
: O
To O
evaluate O
endometrial O
thickness O
and O
the O
incidence O
of O
uterine O
bleeding O
in O
postmenopausal RARE
women O
using O
either O
tibolone RARE
2 O
. O
5 O
mg O
or O
continuous O
combined O
2 O
mg O
estradiol O
and O
1 O
mg O
norethisterone RARE
acetate O
( O
E O
+ O
NETA ALLCAPS
) O
daily O
as O
hormone O
replacement O
therapy O
. O

Leukocyte RARE
cultures O
, O
prepared O
from O
blood O
drawn RARE
from O
these O
18 O
children O
at O
6 O
months O
of O
age O
, O
produced O
lower O
yields O
of O
IFN I-GENE
than O
those O
of O
the O
remaining O
53 O
children O
, O
when O
stimulated O
with O
adenovirus O
( O
P O
< O
0 O
. O
001 O
), O
coronavirus O
( O
P O
< O
0 O
. O
001 O
) O
or O
rhinovirus RARE
( O
P O
= O
0 O
. O
002 NUMERIC
). O

In O
the O
BF O
ECT ALLCAPS
group O
the O
- O
age O
based O
dose O
would O
have O
been O
similarly O
dependent O
on O
the O
initial O
seizure O
threshold O
level O
. O

Histological O
analysis O
showed O
that O
the O
neuronal O
loss O
in O
the O
DHED ALLCAPS
- O
treated O
group O
was O
notably RARE
reduced O
in O
the O
hippocampal O
area O
( O
CA1 NUMERIC
) O
of O
ischemic O
rats O
and O
in O
the O
dentate RARE
gyrus O
and O
hippocampal O
area O
( O
CA1 NUMERIC
and O
CA3 O
) O
of O
EC O
- O
lesioned O
rats O
compared O
with O
the O
nontreated RARE
group O
. O

The O
extents RARE
of O
phosphorylation O
of O
Ser44 NUMERIC
and O
Ser64 NUMERIC
were O
1 O
: O
1 O
, O
whereas O
those O
of O
the O
four O
minor O
sites O
all O
together O
were O
< O
30 O
% O
of O
the O
major O
one O
. O

Serum O
HBV O
- O
DNA O
, O
viral O
serology RARE
, O
and O
liver O
enzymes O
were O
measured O
sequentially RARE
; O
liver O
histology RARE
was O
taken O
before O
and O
during O
treatment O
in O
12 O
patients O
. O

Chem O
. O

Maximum RARE
induction O
of O
AP I-GENE
- I-GENE
1 I-GENE
was O
reached O
at O
a O
concentration O
of O
250 O
nmol O
/ O
L O
of O
CalC LASTCAP
. O

Haycocknema RARE
perplexum RARE
n O
. O
g O
., O
n O
. O
sp O
. O

Rams RARE
were O
weighed RARE
and O
testis O
size O
was O
estimated O
by O
orchimetry RARE
at O
each O
time O
period O
. O

Animal RARE
studies O
showed O
that O
beam O
equalization RARE
significantly O
improved O
fluoroscopic RARE
and O
angiographic O
image O
quality O
. O

Role O
of O
estrogen I-GENE
receptor I-GENE
ligand O
and O
estrogen O
response O
element O
sequence O
on O
interaction O
with O
chicken I-GENE
ovalbumin RARE
upstream I-GENE
promoter I-GENE
transcription I-GENE
factor I-GENE
( O
COUP I-GENE
- I-GENE
TF I-GENE
). O

CONCLUSION O
: O
In O
Cdks RARE
functioning O
throughout O
the O
cell O
cycle O
, O
tyrosine O
phosphorylation O
is O
inhibitory O
to O
the O
activation O
of O
kinase O
, O
whereas O
the O
phosphorylation O
of O
threonine O
in O
the O
T O
- O
loop O
is O
essential O
for O
activation O
. O

We O
also O
report O
that O
AHR ALLCAPS
interacts O
with O
COUP I-GENE
- I-GENE
TF I-GENE
in O
transfected O
CV ALLCAPS
- O
1 O
cells O
. O

AB004534 NUMERIC
. O

The O
prevalence O
of O
hepatitis O
C O
virus O
( O
HCV O
) O
infection O
is O
relatively O
low O
in O
childhood O
, O
with O
anti I-GENE
- I-GENE
HCV I-GENE
prevalence O
rates O
of O
0 O
. O
1 O
- O
0 O
. O
4 O
% O
in O
the O
Western O
world O
. O

Clear RARE
and O
evidenced RARE
- O
based O
information O
should O
be O
provided O
to O
patients O
as O
to O
the O
means O
of O
prevention O
with O
special O
attention O
to O
individual O
risk O
groups O
such O
as O
IV O
drug O
abusers RARE
. O

During O
latency O
, O
more O
than O
1 O
% O
of O
neurons O
in O
ganglia RARE
that O
innervate RARE
the O
footpad RARE
expressed O
beta I-GENE
- I-GENE
galactosidase I-GENE
, O
with O
the O
number O
of O
positive O
cells O
remaining O
constant O
for O
at O
least O
5 O
months O
. O

As O
an O
alternative O
approach O
to O
this O
question O
, O
we O
have O
studied O
the O
effects O
of O
ectopically RARE
expressed O
SHIP ALLCAPS
, O
SHP I-GENE
- I-GENE
1 I-GENE
, O
or O
SHP I-GENE
- I-GENE
2 I-GENE
SH2 O
- O
containing O
decoy RARE
proteins O
on O
Fc I-GENE
gamma I-GENE
RIIB1 NUMERIC
signaling O
. O

Compared RARE
to O
those O
with O
normal O
renal O
functions O
, O
these O
patients O
were O
older O
( O
P O
< O
or O
= O
0 O
. O
01 O
), O
had O
significantly O
elevated O
blood O
pressures O
( O
P O
< O
0 O
. O
01 O
or O
P O
= O
0 O
. O
0001 O
), O
and O
in O
the O
case O
of O
Type O
1 O
DM O
, O
with O
a O
higher O
body O
mass O
index O
( O
P O
= O
0 O
. O
0001 O
) O
and O
waist RARE
- O
hip O
ratio O
( O
P O
< O
0 O
. O
01 O
). O

In O
all O
tissues O
examined O
only O
transcripts O
positive O
for O
insert O
3 O
, O
an O
18 O
bp O
insertion O
in O
repeat O
21 O
, O
were O
amplified O
, O
even O
under O
conditions O
in O
which O
a O
30 O
% O
level O
of O
insert O
3 O
negative O
transcript O
could O
be O
easily O
detected O
in O
artificially O
prepared O
control O
samples O
. O

These O
results O
show O
that O
the O
CAAT O
- O
region O
is O
involved O
in O
upregulating RARE
the O
MDR1 NUMERIC
promoter I-GENE
in O
HL60 NUMERIC
/ O
VCR ALLCAPS
cells O
. O

Both O
receptors O
utilize RARE
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
PTKs RARE
) O
for O
the O
phosphorylation O
of O
various O
signaling O
molecules O
, O
a O
process O
that O
is O
critical O
for O
the O
function O
of O
both O
receptors O
. O

Hypothermia RARE
After O
Cardiac O
Arrest RARE
( O
HACA ALLCAPS
) O
Study O
Group O
. O

The O
synergistic O
effect O
due O
to O
the O
5 O
'- O
3 O
' O
cooperation O
was O
at O
least O
fourfold O
greater O
than O
the O
sum O
of O
the O
contributions RARE
of O
the O
individual O
UTRs RARE
. O

We O
demonstrate O
that O
both O
R I-GENE
and O
Z I-GENE
activate O
the O
cellular O
stress O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinases I-GENE
, O
p38 I-GENE
and O
JNK I-GENE
, O
resulting O
in O
phosphorylation O
( O
and O
activation O
) O
of O
the O
cellular I-GENE
transcription I-GENE
factor I-GENE
ATF2 NUMERIC
. O

Two O
US O
commercial O
cultivars RARE
( O
Tehama RARE
and O
Vina RARE
), O
three O
European O
commercial O
cultivars RARE
( O
Esterhazy RARE
, O
139 O
, O
G120 NUMERIC
) O
and O
five O
New O
Zealand RARE
selections RARE
( O
Rex O
, O
Dublin RARE
' O
s O
Glory RARE
, O
Meyric RARE
, O
McKinster RARE
, O
Stanley RARE
) O
were O
evaluated O
. O

Anatomy RARE
of O
the O
uterine O
artery O
. O

However O
, O
activation O
of O
the O
cAMP O
pathway O
, O
which O
is O
known O
to O
regulate O
inhibin RARE
alpha I-GENE
expression O
, O
greatly O
enhanced O
the O
actions O
of O
SF I-GENE
- I-GENE
1 I-GENE
. O

Deletion O
and O
site O
- O
directed O
mutagenesis O
localized O
a O
novel O
SF I-GENE
- I-GENE
1 I-GENE
regulatory I-GENE
element I-GENE
( O
TCA ALLCAPS
GGGCCA ALLCAPS
; O
- O
137 NUMERIC
to O
- O
129 NUMERIC
) O
adjacent O
to O
a O
variant O
cAMP O
- O
response O
element O
( O
CRE O
; O
- O
120 O
to O
- O
114 O
). O

Previously O
, O
we O
showed O
that O
the O
APRE ALLCAPS
is O
a O
cytokine O
[ O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNFalpha RARE
)]- RARE
inducible O
enhancer O
by O
binding O
the O
heterodimeric I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
kappaB I-GENE
( O
NF I-GENE
- I-GENE
kappaB I-GENE
) O
complex O
Rel I-GENE
A I-GENE
x O
NF I-GENE
- I-GENE
kappaB1 NUMERIC
. O

Angiotensin RARE
II I-GENE
induces O
nuclear I-GENE
factor I-GENE
( I-GENE
NF I-GENE
)- I-GENE
kappaB1 NUMERIC
isoforms I-GENE
to O
bind O
the O
angiotensinogen RARE
gene I-GENE
acute O
- O
phase O
response O
element O
: O
a O
stimulus O
- O
specific O
pathway O
for O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

Synthetic RARE
ligands O
have O
been O
identified O
that O
reset RARE
and O
amplify RARE
the O
cycle O
of O
pulsatile RARE
GH I-GENE
secretion O
by O
interacting O
with O
the O
orphan I-GENE
GH I-GENE
- I-GENE
secretagogue RARE
receptor I-GENE
( O
GHS ALLCAPS
- I-GENE
R I-GENE
). O

The O
collection O
of O
mutants O
displaying RARE
TGN ALLCAPS
sorting O
defects O
includes O
members O
with O
mutations O
in O
previously O
identified O
vacuolar I-GENE
protein I-GENE
sorting I-GENE
genes I-GENE
( O
VPS ALLCAPS
), O
including O
the O
dynamin RARE
family O
member O
VPS1 NUMERIC
. O

Also O
in O
the O
spectrum O
of O
mutants O
with O
TGN ALLCAPS
sorting O
defects O
are O
isolates O
with O
mutations O
in O
the O
following O
: O
RIC1 NUMERIC
, O
encoding O
a O
product O
originally RARE
proposed O
to O
participate O
in O
ribosome O
biogenesis O
; O
LUV1 NUMERIC
, O
encoding O
a O
product O
potentially O
involved O
in O
vacuole RARE
and O
microtubule O
organization O
; O
and O
INP53 NUMERIC
, O
encoding O
a O
synaptojanin RARE
- I-GENE
like I-GENE
inositol I-GENE
polyphosphate RARE
5 I-GENE
- I-GENE
phosphatase I-GENE
. O

The O
single O
strandedness RARE
is O
manifested O
as O
a O
terminal O
extension O
of O
the O
G O
- O
rich O
strand O
( O
G O
tails O
) O
that O
can O
occur O
independently O
of O
telomerase I-GENE
, O
suggesting O
that O
cdc17 NUMERIC
/ O
pol1 NUMERIC
mutants O
exhibit O
defects O
in O
telomeric O
lagging RARE
- O
strand O
synthesis O
. O

In O
addition O
, O
CaMig1 NUMERIC
formed O
specific O
complexes O
with O
the O
URS1 NUMERIC
region O
of O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
FBP1 NUMERIC
gene I-GENE
. O

Furthermore O
, O
the O
wide O
distribution O
of O
the O
GFP ALLCAPS
- O
POLO ALLCAPS
protein O
to O
all O
compartments RARE
of O
the O
mitotic O
apparatus O
provides O
a O
valuable O
tool O
for O
future O
studies O
on O
cell O
cycle O
during O
development O
. O

An O
ASIC ALLCAPS
- O
chip RARE
for O
stereoscopic RARE
depth O
analysis O
in O
video RARE
- O
real O
- O
time O
based O
on O
visual O
cortical O
cell O
behavior O
. O

However O
, O
calphostin RARE
C O
, O
a O
specific O
inhibitor O
of O
PKC I-GENE
, O
abolished O
the O
TPA O
- O
induced O
increase O
in O
CFI ALLCAPS
mRNA I-GENE
levels O
. O

Preimmune RARE
IgG I-GENE
, O
anti I-GENE
- I-GENE
GalT LASTCAP
Fab RARE
fragments I-GENE
, O
irrelevant RARE
polymers O
and O
monomeric O
N O
- O
acetylglucosamine RARE
had O
no O
effect O
. O

Arhythmacanthus RARE
Yamaguti RARE
, O
1935 NUMERIC
is O
maintained O
as O
a O
synonym RARE
of O
Heterosentis RARE
because O
the O
distinction RARE
between O
two O
and O
three O
hook RARE
types O
is O
made O
equivocal RARE
when O
the O
transition O
between O
the O
apical RARE
and O
subapical RARE
hooks RARE
is O
gradual RARE
. O

We O
describe O
a O
case O
of O
acetaminophen RARE
overdose RARE
that O
was O
treated O
with O
both O
hemodialysis O
( O
HD O
) O
and O
NAC ALLCAPS
due O
to O
severe O
intoxication RARE
and O
slow O
drug O
clearance O
. O

Following O
conditioning O
, O
a O
single O
coat O
of O
adhesive O
was O
applied O
and O
light O
- O
cured RARE
. O

Downstream RARE
of O
the O
G O
- O
A O
anastomosis O
, O
the O
RD O
, O
CC O
, O
E O
( O
p O
) O
and O
loop O
areas O
were O
significantly O
different O
from O
REF ALLCAPS
, O
but O
significantly O
different O
from O
A O
- O
A O
. O

Induced RARE
expression O
of O
c I-GENE
- I-GENE
myc I-GENE
is O
likely O
to O
contribute O
to O
the O
proliferation O
of O
Stat1 NUMERIC
- O
null O
cells O
in O
response O
to O
IFNs RARE
. O

Eastern RARE
Cooperative RARE
Oncology RARE
Group O
trial O
E3186 NUMERIC
was O
initiated O
to O
explore O
this O
question O
. O

We O
determined O
how O
DNA O
repair O
is O
affected O
by O
TFA1 NUMERIC
conditional O
mutations O
. O

These O
articles RARE
both O
report O
the O
results O
of O
multi O
- O
institutional RARE
, O
randomized O
, O
phase O
3 O
trials O
for O
the O
treatment O
of O
patients O
with O
localized O
( O
T1 O
- O
3 O
N0 NUMERIC
- O
1 O
M0 NUMERIC
) O
esophageal O
squamous O
cell O
carcinoma O
( O
SCC ALLCAPS
) O
or O
esophageal O
adenocarcinoma O
. O

Studies O
of O
MPO ALLCAPS
gene I-GENE
regulation O
can O
help O
to O
elucidate O
the O
mechanism O
of O
normal O
and O
abnormal O
myeloid O
differentiation O
. O

NDRF ALLCAPS
/ O
NeuroD2 NUMERIC
was O
co O
- O
precipitated O
with O
PKN I-GENE
from O
the O
lysate RARE
of O
COS O
- O
7 O
cells O
transfected O
with O
both O
expression O
constructs O
for O
NDRF ALLCAPS
/ O
NeuroD2 NUMERIC
and O
PKN I-GENE
. O

Transient O
transfection O
assays O
using O
P19 O
cells O
revealed O
that O
expression O
of O
NDRF ALLCAPS
/ O
NeuroD2 NUMERIC
increased O
the O
transactivation O
of O
the O
rat I-GENE
insulin I-GENE
promoter I-GENE
element I-GENE
3 I-GENE
( O
RIPE3 NUMERIC
) O
enhancer O
up O
to O
approximately O
12 O
- O
fold O
and O
that O
co O
- O
expression O
of O
catalytically O
active O
form O
of O
PKN I-GENE
, O
but O
not O
kinase O
- O
deficient O
derivative O
, O
resulted O
in O
a O
further O
threefold O
increase O
of O
NDRF ALLCAPS
/ O
NeuroD2 NUMERIC
- O
mediated O
transcription O
. O

Two O
Pax2 NUMERIC
/ I-GENE
5 I-GENE
/ I-GENE
8 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
in O
Engrailed2 NUMERIC
are O
required O
for O
proper O
initiation O
of O
endogenous O
mid O
- O
hindbrain RARE
expression O
. O

Upon O
tyrosine O
phosphorylation O
at O
the O
ITIMs RARE
, O
these O
molecules O
recruit O
SH2 I-GENE
domain O
- O
containing O
phosphatases O
such O
as O
SH2 I-GENE
- O
containing O
tyrosine I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
and O
negatively O
regulate O
cell O
activity O
. O

AF154055 NUMERIC
. O

Alignment RARE
of O
the O
cervical O
spine O
, O
vertebral O
abnormalities O
, O
and O
disc O
changes O
also O
were O
evaluated O
. O

The O
concomitant O
interaction O
of O
mSTI1 NUMERIC
with O
hsp70 I-GENE
and O
hsp90 I-GENE
at O
its O
N O
- O
and O
C O
- O
termini O
respectively O
is O
mediated O
by O
the O
tetratricopeptide RARE
repeat O
( O
TPR O
) O
motifs O
in O
these O
regions O
. O

Competition O
experiments O
demonstrate O
a O
negative O
allosteric RARE
relationship O
between O
these O
RGD ALLCAPS
recognition O
sites O
. O

Sequence O
analysis O
showed O
that O
the O
5 O
'- O
flanking O
region O
upstream O
to O
the O
ATG O
codon O
did O
not O
contain O
a O
conventional O
TATA O
box O
. O

After O
i O
. O
v O
. O
administration O
of O
500 O
mg O
acetazolamide RARE
and O
disinfection RARE
of O
the O
conjunctiva RARE
, O
50 O
micrograms O
rt RARE
- I-GENE
PA I-GENE
in O
0 O
. O
1 O
ml O
( O
BSS ALLCAPS
) O
and O
0 O
. O
5 O
ml O
SF6 NUMERIC
were O
injected O
intravitreally RARE
. O

These O
results O
suggest O
that O
VP1 NUMERIC
was O
efficiently O
transported O
to O
the O
nucleus O
and O
localized O
in O
the O
discrete O
subnuclear RARE
regions O
, O
possibly O
with O
VP2 NUMERIC
and O
VP3 NUMERIC
. O

Differential O
expression O
and O
regulation O
by O
20 O
- O
hydroxyecdysone RARE
of O
mosquito RARE
ultraspiracle RARE
isoforms O
. O

The O
three O
isoforms O
purified O
with O
anti I-GENE
- I-GENE
FLAG ALLCAPS
antibody I-GENE
affinity O
column O
transferred O
sulfate O
to O
heparan RARE
sulfate O
and O
heparin O
but O
not O
to O
other O
glycosaminoglycans RARE
. O

The O
differentiation O
and O
maintenance O
of O
a O
neurotransmitter RARE
phenotype O
is O
guided RARE
by O
the O
interaction O
of O
exogenous O
cues RARE
with O
intrinsic O
genetic O
machinery O
. O

Analysis O
of O
functional O
domains O
of O
Arix RARE
reveals O
an O
N O
- O
terminal O
activation O
domain O
and O
a O
C O
- O
terminal O
repression O
domain O
. O

BACKGROUND O
: O
Left RARE
ventricular O
hypertrophy O
is O
a O
heterogeneous O
disorder O
with O
distinct O
morphologies RARE
. O

Multivariate RARE
predictors O
were O
concentric RARE
remodeling O
( O
P O
< O
0 O
. O
0001 O
; O
odds O
ratio O
, O
13 O
. O
5 O
), O
left O
ventricular O
ejection O
fraction O
> O
2 O
SD O
above O
normal O
( O
P O
< O
0 O
. O
0001 O
), O
and O
single O
- O
vessel O
left O
circumflex RARE
disease O
( O
P O
< O
0 O
. O
0007 NUMERIC
; O
odds O
ratio O
, O
7 O
. O
6 O
). O

The O
case O
for O
completing RARE
the O
lymphadenectomy RARE
when O
positive O
lymph O
nodes O
are O
found O
during O
radical O
hysterectomy O
for O
cervical O
carcinoma O
. O

Overexpression O
of O
ICBP90 NUMERIC
in O
COS O
- O
1 O
- O
transfected O
cells O
induced O
an O
enhanced O
expression O
of O
endogenous I-GENE
topoisomerase I-GENE
IIalpha RARE
. O

The O
RNA O
aptamer RARE
contains O
three O
stems RARE
separated O
by O
a O
pair O
of O
two O
- O
base O
bulges RARE
, O
and O
adopts RARE
an O
unanticipated RARE
fold O
in O
which O
both O
junctional RARE
sites O
are O
anchored O
through O
base O
triple O
formation O
. O

The O
study O
suggests O
the O
presence O
of O
an O
anatomical O
sphincter RARE
at O
the O
RSJ ALLCAPS
which O
seems O
to O
regulate O
the O
passage O
of O
stools RARE
from O
the O
sigmoid RARE
colon O
to O
the O
rectum RARE
. O

Isolation O
of O
cDNAs I-GENE
encoding I-GENE
gibbon RARE
and I-GENE
monkey I-GENE
platelet I-GENE
and I-GENE
T I-GENE
cell I-GENE
activation I-GENE
antigen I-GENE
1 I-GENE
( O
PTA1 NUMERIC
). O

To O
quantify RARE
any O
mechanical O
inhibitory O
effect O
of O
nasal O
intermittent O
positive O
pressure O
ventilation O
( O
IPPV ALLCAPS
) O
on O
inspiratory O
activity O
of O
the O
diaphragm O
we O
ventilated O
five O
conscious O
relaxed RARE
subjects O
on O
two O
occasions RARE
at O
respiratory O
rates O
similar O
to O
quiet RARE
breathing O
( O
QB ALLCAPS
) O
and O
at O
three O
levels O
of O
applied O
pressure O
( O
Pappl RARE
)-- RARE
6 O
, O
9 O
and O
12 O
cmH2O O
, O
each O
during O
hypocapnia RARE
( O
P O
( O
CO2 O
) O
allowed O
to O
decrease O
) O
and O
eucapnia RARE
( O
CO2 O
added O
to O
inspired RARE
gas O
). O

METHODS O
: O
Von RARE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
and O
the O
fibrinolytic RARE
factors O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( O
tPA LASTCAP
), O
measured O
as O
tPA LASTCAP
capacity O
, O
and O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
1 I-GENE
( O
PAI I-GENE
- I-GENE
1 I-GENE
), O
platelets O
, O
fibrinogen I-GENE
, O
and O
inflammatory O
markers O
were O
measured O
in O
74 O
patients O
with O
active O
seropositive O
RA O
. O

Neuronal RARE
signaling O
properties O
are O
largely O
determined O
by O
the O
quantity RARE
and O
combination O
of O
ion O
channels O
expressed O
. O

Treatment O
also O
led O
to O
a O
significant O
dose O
dependent O
reduction O
in O
the O
sum O
of O
ST O
segment O
depression O
at O
both O
trough O
and O
peak O
concentrations O
. O

We O
have O
investigated O
the O
contribution O
of O
specific O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
)- O
TATA O
interactions O
to O
the O
promoter O
activity O
of O
a O
constitutively O
expressed O
silkworm RARE
tRNA I-GENE
( I-GENE
C I-GENE
)( I-GENE
Ala I-GENE
) I-GENE
gene I-GENE
and O
have O
also O
asked RARE
whether O
the O
lack O
of O
similar O
interactions O
accounts RARE
for O
the O
low O
promoter O
activity O
of O
a O
silk RARE
gland I-GENE
- I-GENE
specific I-GENE
tRNA I-GENE
( I-GENE
SG I-GENE
)( I-GENE
Ala I-GENE
) I-GENE
gene I-GENE
. O

The O
sequences O
showed O
extensive O
homologies O
with O
squalene RARE
synthase I-GENE
genes I-GENE
and O
enzymes O
from O
a O
number O
of O
other O
organisms O
and O
extreme O
amino O
acid O
conservation O
within O
the O
binding O
and O
catalytic O
domains O
. O

All O
clones O
and O
strains O
produced O
have O
been O
deposited RARE
in O
the O
EUROFAN ALLCAPS
genetic O
stock RARE
centre RARE
( O
EUROSCARF ALLCAPS
, O
Frankfurt RARE
). O

Two O
episodes O
of O
peritonitis RARE
occurred O
while O
the O
patient O
received O
CAPD ALLCAPS
( O
1 O
episode RARE
/ O
3 O
. O
5 O
patient O
- O
months O
). O

Copyright O
2000 O
The O
Royal RARE
College RARE
of O
Radiologists RARE
. O

Two O
estrogen I-GENE
receptor I-GENE
( O
ER I-GENE
) O
isoforms O
with O
different O
estrogen O
dependencies RARE
are O
generated O
from O
the O
trout I-GENE
ER I-GENE
gene I-GENE
. O

Induction O
was O
reversed O
by O
coexpression O
of O
A I-GENE
- I-GENE
Fos I-GENE
, O
a O
dominant O
negative O
to O
AP I-GENE
- I-GENE
1 I-GENE
. O

In O
myometrial RARE
SMC ALLCAPS
, O
both O
isoforms O
of O
the O
progesterone I-GENE
receptor I-GENE
, O
PR I-GENE
- I-GENE
B I-GENE
and O
PR I-GENE
- I-GENE
A I-GENE
, O
caused O
a O
ligand O
- O
dependent O
activation O
of O
PGDH ALLCAPS
- I-GENE
2368 NUMERIC
/ O
luc3 NUMERIC
. O

Element RARE
B O
(- O
249 NUMERIC
/- O
229 NUMERIC
) O
shows O
more O
than O
80 O
% O
homology O
to O
a O
consensus I-GENE
c I-GENE
- I-GENE
myb I-GENE
element I-GENE
, O
but O
formed O
two O
specific O
complexes O
that O
differed O
from O
that O
of O
c I-GENE
- I-GENE
myb I-GENE
in O
the O
electrophoretic O
mobility O
shift O
assay O
. O

High O
resolution O
computed O
tomography O
of O
the O
lungs O
in O
patients O
with O
rheumatoid O
arthritis O
. O

Stable O
transfection O
of O
the O
truncated O
reduced I-GENE
folate I-GENE
carrier I-GENE
cDNA I-GENE
into O
mouse O
L1210 NUMERIC
leukemia O
cells O
: O
increased O
folate O
accumulation O
, O
decreased O
their O
leucovorin RARE
and O
folic RARE
acid O
growth O
requirements O
, O
and O
increased O
their O
sensitivity O
to O
methotrexate O
. O

Characterization O
of O
a O
human I-GENE
alternatively I-GENE
spliced I-GENE
truncated I-GENE
reduced I-GENE
folate I-GENE
carrier I-GENE
increasing O
folate O
accumulation O
in O
parental O
leukemia O
cells O
. O

Electron RARE
microscopic O
and O
enzymatic O
analyses O
revealed O
that O
the O
A118 NUMERIC
genome O
is O
a O
linear O
, O
circularly RARE
permuted RARE
, O
terminally O
redundant RARE
collection O
of O
double O
- O
stranded O
DNA O
molecules O
. O

Moreover O
, O
increasing O
the O
dosage O
of O
wild I-GENE
- I-GENE
type I-GENE
Fus3 NUMERIC
intensifies RARE
the O
inhibition O
of O
both O
Ty1 I-GENE
transposition RARE
and O
invasive O
growth O
. O

Consistently RARE
, O
activation O
of O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
downstream O
of O
Rho I-GENE
family I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
was O
also O
enhanced O
when O
Dbl RARE
was O
tyrosine O
- O
phosphorylated O
. O

However O
, O
its O
participation O
in O
collagen I-GENE
binding O
has O
not O
been O
shown O
. O

Together O
, O
these O
data O
suggest O
that O
the O
carboxyl O
terminus O
of O
CFTR I-GENE
contains O
a O
tyrosine O
- O
based O
internalization O
signal O
that O
interacts O
with O
the O
endocytic O
adaptor O
complex O
AP I-GENE
- I-GENE
2 I-GENE
to O
facilitate O
efficient O
entry O
of O
CFTR I-GENE
into O
clathrin I-GENE
- O
coated RARE
vesicles O
. O

The O
insulin I-GENE
therapy O
regimen O
did O
not O
affect O
the O
evolution O
of O
the O
patients O
and O
no O
significant O
relationship O
existed O
between O
the O
age O
at O
diagnosis O
, O
duration O
of O
diabetes O
, O
daily O
insulin I-GENE
dosage O
or O
metabolic O
control O
and O
height O
or O
BMI O
. O

Scmh1 NUMERIC
maps O
to O
4D1 NUMERIC
- O
D2 O
. O
1 O
in O
mice O
. O

The O
applicability RARE
of O
laparoscopic O
donor O
nephrectomy RARE
( O
LDN ALLCAPS
) O
has O
not O
been O
assessed O
in O
the O
obese O
donor O
. O

Hyaluronan RARE
treatment O
stimulated O
collagen I-GENE
remodeling O
in O
the O
peripheral O
region O
and O
inhibited O
swelling O
of O
the O
meniscus RARE
repaired RARE
in O
the O
inner O
region O
. O

We O
have O
addressed O
these O
issues O
by O
reconstituting RARE
and O
characterizing O
the O
KRAB I-GENE
: O
KAP ALLCAPS
- I-GENE
1 I-GENE
- O
RBCC ALLCAPS
interaction O
using O
purified O
components O
. O

The O
RING O
finger O
, O
B2 O
box O
, O
and O
coiled O
- O
coil O
region O
are O
required O
for O
oligomerization O
of O
KAP ALLCAPS
- I-GENE
1 I-GENE
- O
RBCC ALLCAPS
and O
KRAB I-GENE
binding O
, O
as O
mutations O
in O
these O
domains O
concomitantly RARE
abolished O
these O
functions O
. O

Actins RARE
show O
two O
different O
forms O
of O
N O
- O
terminal O
processing O
dependent O
on O
their O
N O
- O
terminal O
sequence O
. O

All O
four O
domains O
were O
linked O
via O
proline O
- O
threonine O
- O
rich O
peptides O
. O

JPEG ALLCAPS
53 O
, O
resulting O
in O
a O
compression O
ratio O
of O
1 O
: O
21 O
, O
does O
not O
compromise RARE
the O
diagnostic O
performance O
in O
general O
. O

We O
critically RARE
assess O
current O
systematic O
uncertainties RARE
and O
determine O
the O
primordial RARE
Li O
abundance O
within O
new O
, O
much O
tighter RARE
limits O
: O
& O
amp RARE
; O
parl0 NUMERIC
; O
Li O
& O
amp RARE
; O
solm0 NUMERIC
; O
H O
& O
amp RARE
; O
parr0 NUMERIC
; O
p O
= O
1 O
. O
23 O
+ O
0 O
. O
68 O
- O
0 O
. O
32x10 NUMERIC
- O
10 O
. O

Like O
their O
yeast O
counterpart O
, O
the O
mouse O
GCN2 I-GENE
isoforms O
contain O
HisRS LASTCAP
- I-GENE
related I-GENE
sequences I-GENE
juxtaposed RARE
to O
the O
kinase O
catalytic O
domain O
. O

Five O
women O
( O
15 O
. O
6 O
%) O
met O
criteria O
for O
PMS ALLCAPS
. O

MBI ALLCAPS
and O
MMBI ALLCAPS
showed O
similar O
Cmax RARE
values O
, O
but O
the O
former O
disappeared O
slower O
in O
the O
serum O
than O
the O
latter O
and O
resulted O
in O
its O
larger O
AUC O
values O
. O

Another O
long O
insertion O
in O
the O
cathepsin RARE
X I-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
forms O
a O
beta O
- O
hairpin O
pointing RARE
away RARE
from O
the O
active O
site O
. O

Transfection O
experiments O
demonstrated O
that O
the O
5 O
'- O
flanking O
region O
(- O
1894 NUMERIC
to O
+ O
37 O
) O
of O
the O
mStaf RARE
gene I-GENE
drives RARE
transcription O
in O
mouse O
NMuMG LASTCAP
cells O
and O
that O
a O
construct O
containing O
a O
fragment O
from O
- O
387 NUMERIC
to O
+ O
37 O
showed O
the O
highest O
transcriptional O
activity O
. O

Further O
studies O
in O
T O
- O
24 O
cells O
demonstrated O
that O
HA O
fragments O
also O
induced O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
phosphorylation O
and O
degradation O
, O
kappa I-GENE
B I-GENE
- I-GENE
linked I-GENE
reporter I-GENE
gene I-GENE
expression O
, O
and O
ICAM ALLCAPS
- I-GENE
1 I-GENE
promoter I-GENE
activity O
in O
an O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
- O
dependent O
manner O
. O

Pretreatment RARE
of O
cells O
or O
mouse O
skin O
with O
antisense O
oligonucleotides O
of O
PKCzeta RARE
impaired O
UV O
- O
induced O
activation O
of O
AP I-GENE
- I-GENE
1 I-GENE
in O
JB6 NUMERIC
cells O
as O
well O
as O
in O
AP I-GENE
- I-GENE
1 I-GENE
- O
luciferase I-GENE
transgenic O
mice O
. O

The O
level O
of O
subclinical O
infection O
was O
75 O
% O
among O
seropositive O
dogs O
. O

METHODS O
: O
The O
former O
group O
included O
patients O
who O
had O
been O
treated O
with O
at O
least O
four O
PGE1 NUMERIC
alpha O
- O
ciclodestrina RARE
, O
short O
- O
term O
treatment O
cycles O
per O
year O
while O
the O
latter O
was O
a O
historical RARE
reference O
group O
managed RARE
without O
prostaglandins O
. O

Desmethylferrochloroquine RARE
1a O
and O
didesmethylferrochloroquine RARE
2 O
would O
be O
more O
potent O
against O
schizontocides RARE
than O
CQ ALLCAPS
in O
vitro O
against O
two O
strains O
( O
HB3 NUMERIC
and O
Dd2 NUMERIC
) O
of O
Plasmodium RARE
falciparum O
. O

The O
rrd1 NUMERIC
, I-GENE
2delta NUMERIC
mutant I-GENE
was O
partially O
rescued RARE
by O
inactivation O
of O
HOG1 NUMERIC
or O
PBS2 NUMERIC
, O
suggesting O
an O
interaction O
between O
the O
RRD ALLCAPS
genes I-GENE
and O
the O
Hog1p NUMERIC
signal I-GENE
transduction I-GENE
pathway I-GENE
. O

Members O
of O
the O
JAK ALLCAPS
/ O
Tyk RARE
family O
of O
tyrosine I-GENE
kinases I-GENE
mediate O
phosphorylation O
of O
STAT3 I-GENE
at O
Tyr705 NUMERIC
during O
CNTF ALLCAPS
signaling O
; O
however O
, O
the O
kinase O
responsible O
for O
phosphorylation O
at O
STAT3 I-GENE
Tyr727 NUMERIC
appears O
to O
depend O
on O
both O
the O
extracellular O
stimulus O
and O
the O
cellular O
context O
. O

In O
vivo O
, O
CARbeta RARE
/ O
RXRalpha RARE
activated O
transcription O
from O
an O
HD I-GENE
- O
PPRE ALLCAPS
luciferase I-GENE
reporter I-GENE
construct I-GENE
. O

Zebrafish RARE
cyclops RARE
( O
cyc RARE
) O
encodes O
a O
Transforming RARE
Growth I-GENE
Factor I-GENE
beta I-GENE
( O
TGFbeta RARE
) O
signaling O
factor O
closely O
related O
to O
mouse O
Nodal RARE
. O

Thus O
, O
SOX8 NUMERIC
is O
a O
good O
candidate O
gene O
contributing RARE
to O
the O
mental O
retardation O
phenotype O
seen O
in O
ATR ALLCAPS
- O
16 O
patients O
. O

The O
genome O
organization O
of O
the O
mite O
- O
transmitted O
wheat O
streak RARE
mosaic O
virus O
( O
WSMV ALLCAPS
) O
appears O
to O
parallel O
that O
of O
members O
of O
the O
Potyviridae RARE
with O
monopartite RARE
genomes O
, O
but O
there O
are O
substantial O
amino O
acid O
dissimilarities RARE
with O
other O
potyviral RARE
polyproteins RARE
. O

The O
two O
- O
hybrid O
assay O
was O
then O
performed O
using O
full O
- O
length O
genes O
of O
CI I-GENE
, O
HC ALLCAPS
- I-GENE
Pro I-GENE
, O
P1 I-GENE
, O
P3 I-GENE
, O
and O
CP I-GENE
, O
but O
no O
heterologous O
interactions O
were O
detected O
. O

Diverse RARE
endogenous O
light O
chains O
contribute O
to O
basement RARE
membrane O
reactivity O
in O
nonautoimmune RARE
mice O
transgenic O
for O
an O
anti I-GENE
- I-GENE
laminin RARE
Ig I-GENE
heavy I-GENE
chain I-GENE
. O

Patch RARE
test O
results O
obtained O
with O
corticosteroid O
allergic O
patients O
tested O
with O
a O
large O
corticosteroid O
series O
validated RARE
the O
earlier O
classification O
of O
corticosteroid O
molecules O
in O
four O
groups O
of O
cross O
- O
reacting RARE
molecules O
: O
i O
. O
e O
., O
group O
A O
( O
hydrocortisone RARE
type O
), O
group O
B O
( O
acetonides RARE
), O
group O
C O
( O
betamethasone RARE
type O
- O
non O
esterified RARE
) O
and O
group O
D O
( O
esters O
). O

Mechanisms RARE
of O
tachyphylaxis RARE
in O
regional O
anesthesia O
of O
long O
duration O

An O
increase O
in O
the O
level O
of O
serum O
enzymes O
, O
such O
as O
aspartate I-GENE
transaminase RARE
, O
alkaline I-GENE
phosphatase I-GENE
, O
creatine I-GENE
phosphokinase RARE
, O
lactate I-GENE
dehydrogenase I-GENE
after O
D O
. O
russelli RARE
venom RARE
injection O
in O
albino RARE
rats O
is O
indicative O
of O
cell O
or O
tissue O
damage O
. O

The O
partial O
farm RARE
budget RARE
highlighted RARE
the O
importance O
of O
reducing O
sub O
- O
clinical O
lesions O
in O
a O
feedlot RARE
. O

Surprisingly O
, O
3 O
full I-GENE
- I-GENE
length I-GENE
murine I-GENE
survivin RARE
cDNA I-GENE
clones O
were O
isolated O
, O
predicting O
the O
existence O
of O
3 O
distinct O
survivin RARE
proteins I-GENE
. O

Thus O
, O
the O
induction O
of O
E2F I-GENE
binding O
to O
the O
E2F I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
by O
the O
E4 NUMERIC
- I-GENE
6 I-GENE
/ I-GENE
7 I-GENE
protein I-GENE
observed O
in O
vitro O
correlates O
with O
transactivation O
of O
E2F I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
activity O
in O
vivo O
. O

We O
show O
that O
stabilization O
of O
the O
hairpin O
reduced O
the O
amount O
of O
tRNA O
primer O
that O
is O
annealed RARE
to O
the O
PBS ALLCAPS
. O

Ischemia RARE
- O
induced O
biphasic O
arrhythmias O
were O
suppressed O
in O
both O
zatebradine RARE
and O
propranolol O
groups O
. O

ZK7 NUMERIC
and O
HZF16 NUMERIC
genes I-GENE
appear O
to O
be O
the O
splice O
variants O
transcribed O
from O
the O
same O
gene O
. O

CONCLUSION O
: O
Presence RARE
of O
APOE ALLCAPS
epsilon4 NUMERIC
/* RARE
seems O
to O
increase O
the O
risk O
for O
dementia O
and O
AD O
independently O
of O
its O
effect O
on O
dyslipidemia RARE
and O
atherogenesis RARE
. O

No O
definite O
conclusions O
are O
possible O
because O
of O
the O
small O
number O
of O
patients O
involved O
in O
this O
phase O
II O
trial O
. O

Two O
distinct O
Salmonella I-GENE
fimbrins RARE
, O
AgfA LASTCAP
and O
SefA LASTCAP
, O
comprising RARE
thin O
aggregative RARE
fimbriae RARE
SEF17 NUMERIC
and O
SEF14 NUMERIC
, O
respectively O
, O
were O
each O
genetically O
engineered O
to O
carry O
PT3 NUMERIC
, O
an O
alpha O
- O
helical O
16 O
- O
amino O
acid O
Leishmania O
T O
- O
cell O
epitope O
derived O
from O
the O
metalloprotease RARE
gp63 NUMERIC
. O

In O
marked O
contrast O
to O
AgfA LASTCAP
, O
none O
of O
the O
chimeric I-GENE
SefA LASTCAP
proteins I-GENE
were O
expressed O
or O
assembled O
into O
fimbriae RARE
. O

Productive RARE
growth O
of O
phage O
P22 NUMERIC
in O
wild O
- O
type O
Salmonella O
typhimurium RARE
correlates O
with O
the O
presence O
of O
Abc2 NUMERIC
, O
but O
is O
independent O
of O
the O
absolute O
level O
of O
ATP I-GENE
- I-GENE
dependent I-GENE
nuclease I-GENE
activity O
, O
suggesting O
a O
qualitative O
change O
in O
the O
nature O
of O
Abc2 NUMERIC
- O
modified O
RecBCD LASTCAP
nuclease I-GENE
activity O
relative O
to O
the O
native O
enzyme O
. O

In O
this O
study O
, O
we O
investigated O
the O
molecular O
mechanisms O
underlying O
the O
inducible O
expression O
of O
the O
flt RARE
- I-GENE
1 I-GENE
gene I-GENE
during O
the O
activation O
of O
THP ALLCAPS
- O
1 O
cells O
. O

There O
was O
a O
2 O
. O
4 O
- O
fold O
difference O
in O
CAT I-GENE
produced O
from O
these O
transcripts O
in O
HeLa O
cells O
, O
which O
contain O
a O
greater O
natural O
abundance O
of O
PTB I-GENE
. O

Multiple O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
signaling O
pathways O
connect RARE
the O
cot RARE
oncoprotein I-GENE
to O
the O
c I-GENE
- I-GENE
jun I-GENE
promoter I-GENE
and O
to O
cellular O
transformation O
. O

Dermatology RARE
is O
no O
exception O
. O

4 O
. O

In O
the O
present O
study O
we O
have O
investigated O
the O
regulatory O
mechanism O
for O
CD95L NUMERIC
expression O
. O

Protein O
sequence O
analysis O
reveals O
that O
MAN1 NUMERIC
shares O
a O
conserved O
globular O
domain O
of O
approximately O
40 O
amino O
acids O
, O
which O
we O
term O
the O
LEM ALLCAPS
module RARE
, O
with O
inner O
nuclear O
membrane O
proteins O
lamina RARE
- I-GENE
associated I-GENE
polypeptide I-GENE
2 I-GENE
and O
emerin RARE
. O

Molecular O
cloning O
of O
a O
novel O
human I-GENE
I I-GENE
- I-GENE
mfa RARE
domain I-GENE
- I-GENE
containing I-GENE
protein I-GENE
that O
differently O
regulates O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
and O
HIV O
- O
1 O
expression O
. O

The O
encoded O
amino O
acid O
sequences O
in O
the O
full O
- O
length O
bovine O
and O
porcine O
cDNAs O
were O
identical O
, O
consisting O
of O
209 NUMERIC
amino O
acid O
residues O
, O
and O
were O
nearly O
the O
same O
as O
the O
published O
sequence O
determined O
by O
Edman RARE
degradation O
. O

With O
chemical O
shift O
imaging O
, O
the O
signal O
intensity O
decreased O
on O
the O
out O
- O
of O
- O
phase O
images O
in O
six O
of O
seven O
( O
86 O
%) O
patients O
with O
APA ALLCAPS
and O
in O
eight O
of O
nine O
( O
89 O
%) O
patients O
with O
BAH ALLCAPS
. O

For O
each O
night O
, O
the O
diary RARE
allowed O
the O
subjective RARE
measurement O
of O
bedtime RARE
, O
wake RARE
time O
, O
time O
in O
bed RARE
( O
TIB ALLCAPS
), O
sleep O
efficiency O
, O
number O
of O
minutes O
of O
wake RARE
after O
sleep O
onset O
( O
WASO ALLCAPS
), O
alertness RARE
on O
awakening RARE
, O
and O
percentage O
of O
morning RARE
needing RARE
an O
alarm RARE
( O
or O
a O
person RARE
functioning O
as O
one O
). O

Acad RARE
. O

Copyright O
2000 O
Academic O
Press O
. O

The O
central O
( O
R O
) O
domain O
is O
responsible O
for O
receptor O
- O
binding O
activity O
whereas O
the O
N O
- O
terminal O
( O
T O
) O
domain O
mediates O
translocation O
, O
the O
process O
by O
which O
the O
C O
- O
terminal O
cytotoxic O
domain O
is O
transported O
from O
the O
receptor O
to O
the O
site O
of O
its O
cytotoxicity O
. O

We O
have O
previously O
demonstrated O
that O
expression O
of O
the O
gene O
for O
the O
reproductive O
neuropeptide RARE
, O
GnRH I-GENE
, O
is O
repressed O
by O
the O
glutamate O
/ O
NO O
/ O
cyclic O
GMP ALLCAPS
( O
cGMP O
) O
signal O
transduction O
pathway O
through O
cGMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
in O
the O
hypothalamic RARE
GnRH I-GENE
- O
secreting O
neuronal O
cell O
line O
GT1 NUMERIC
- O
7 O
. O

These O
data O
suggest O
that O
combined O
lesions O
of O
cholinergic O
and O
serotonergic RARE
neurons O
in O
the O
rat O
brain O
do O
not O
alter O
olfactory O
perception RARE
or O
olfactory O
short O
- O
term O
memory O
. O

Extreme RARE
potency O
of O
botulinum I-GENE
toxin I-GENE
. O

In O
contrast O
, O
c I-GENE
- I-GENE
Src I-GENE
activated O
by O
isoproterenol O
led O
to O
tyrosine O
phosphorylation O
of O
Shc I-GENE
and O
subsequent O
Erk RARE
activation O
, O
but O
not O
tyrosine O
phosphorylation O
of O
cortactin RARE
or O
Stat3 I-GENE
. O

MSSPs RARE
are O
believed O
to O
regulate O
DNA O
replication O
, O
transcription O
, O
apopotosis RARE
and O
cell O
cycle O
progression O
by O
interacting O
with O
the O
C I-GENE
- I-GENE
MYC ALLCAPS
protein I-GENE
. O

For O
wild O
type O
MutT LASTCAP
and O
its O
E53D NUMERIC
and O
E44D NUMERIC
mutants I-GENE
, O
plots RARE
of O
log O
( O
k RARE
( O
cat O
)) O
versus O
pH O
exhibited O
a O
limiting O
slope O
of O
1 O
on O
the O
ascending O
limb O
and O
then O
a O
hump RARE
, O
i O
. O
e O
., O
a O
sharply O
defined O
maximum O
near O
pH O
8 O
followed O
by O
a O
plateau RARE
, O
yielding RARE
apparent O
pK LASTCAP
( O
a O
) O
values O
of O
7 O
. O
6 O
+/- O
0 O
. O
3 O
and O
8 O
. O
4 O
+/- O
0 O
. O
4 O
for O
an O
essential O
base O
and O
a O
nonessential RARE
acid O
catalyst RARE
, O
respectively O
, O
in O
the O
active O
quaternary RARE
MutT LASTCAP
- O
Mg O
( O
2 O
+)- O
dGTP LASTCAP
- O
Mg O
( O
2 O
+) O
complex O
. O

Structural O
changes O
in O
the O
kinetically RARE
more O
damaged O
E44D NUMERIC
mutant O
detected O
in O
( O
1 O
) O
H O
-( O
15 O
) O
N O
HSQC ALLCAPS
spectra O
were O
largely O
limited O
to O
the O
loop O
I O
- O
helix O
I O
motif O
, O
suggesting O
that O
Glu O
- O
44 O
stabilizes O
the O
active O
site O
region O
. O

In O
vitro O
expression O
of O
four O
different O
naturally O
occurring O
nonsense O
and O
missense O
mutations O
revealed O
a O
dramatically O
altered O
subcellular O
location O
of O
the O
protein O
in O
cultured O
cells O
. O

After O
i O
. O
v O
. O

Immunity RARE
acquired O
by O
mice O
during O
I O
. O
scapularis RARE
nymphal RARE
activity O
in O
early O
summer O
may O
exclude RARE
a O
large O
proportion O
of O
the O
mouse O
population O
from O
maintaining O
E O
. O
phagocytophila RARE
during O
the O
period O
of O
larval O
activity O
later O
in O
the O
season O
. O

The O
emerging RARE
view O
based O
on O
studies O
in O
yeast O
is O
that O
each O
class O
of O
snoRNPs RARE
is O
composed O
of O
a O
unique O
set O
of O
proteins O
. O

BCR I-GENE
cross O
- O
linking O
also O
led O
to O
increased O
MAPK I-GENE
- O
activated O
protein I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
activity O
, O
an O
enzyme O
that O
lies O
immediately O
downstream O
from O
p38 I-GENE
MAPK I-GENE
; O
MAPK I-GENE
- O
activated O
protein I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
immune O
complexes O
phosphorylated O
a O
peptide O
substrate O
containing O
the O
CREB I-GENE
serine I-GENE
133 I-GENE
phosphoacceptor RARE
motif I-GENE
. O

Activation O
of O
a O
CRE O
- O
dependent O
junB I-GENE
promoter I-GENE
/ O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
reporter O
gene O
by O
the O
BCR I-GENE
was O
also O
blocked O
by O
SB203580 NUMERIC
. O

We O
present O
evidence O
that O
the O
upstream O
open O
reading O
frame O
( O
uORF O
) O
represses O
the O
translation O
of O
the O
downstream O
major O
open O
reading O
frame O
( O
mORF LASTCAP
). O

METHODS O
: O
TBN ALLCAPS
measurements O
were O
performed O
in O
31 O
female O
outpatients RARE
with O
breast O
carcinoma O
who O
were O
undergoing O
standard O
cyclophosphamide O
, O
methotrexate O
, O
and O
5 O
- O
fluorouracil O
( O
CMF ALLCAPS
)- O
based O
chemotherapy O
( O
median O
age O
, O
48 O
years O
; O
range O
, O
26 O
- O
77 O
years O
). O

A O
385 NUMERIC
bp O
Glucocorticoid RARE
Response O
Unit RARE
( O
GRU ALLCAPS
) O
was O
identified O
whose O
glucocorticoid O
induction O
was O
enhanced O
by O
dibutyryl RARE
- O
cAMP O
and O
reduced O
by O
phorbol O
esters O
. O

No O
somatic O
mutations O
were O
found O
in O
any O
of O
the O
samples O
, O
suggesting O
that O
ING1 NUMERIC
is O
not O
a O
tumor O
suppressor O
gene O
target O
in O
head O
and O
neck O
cancer O
. O

Ras I-GENE
- O
GRF1 NUMERIC
transiently O
expressed O
with O
v I-GENE
- I-GENE
Src I-GENE
was O
tyrosine O
- O
phosphorylated O
and O
showed O
significant O
GEF ALLCAPS
activity O
toward O
Rac I-GENE
, O
but O
not O
Rho I-GENE
and O
Cdc42 I-GENE
, O
which O
was O
comparable O
with O
that O
induced O
by O
Gbetagamma I-GENE
. O

As O
no O
complete O
PPARgamma I-GENE
antagonists O
have O
been O
described O
hitherto O
, O
we O
have O
constructed O
a O
dominant O
- O
negative O
mutant O
receptor O
to O
inhibit O
wild O
- O
type O
PPARgamma I-GENE
action O
. O

EMSA O
showed O
that O
nuclear O
proteins O
from O
PC12 O
but O
not O
C6 O
or O
Rat2 NUMERIC
cells O
bind O
the O
CRE O
as O
a O
complex O
containing O
activating I-GENE
transcription I-GENE
factor I-GENE
( I-GENE
ATF I-GENE
)- I-GENE
4 I-GENE
and O
CCAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
beta I-GENE
, O
while O
both O
PC12 O
and O
C6 O
cell O
nuclear O
extracts O
were O
recruited O
by O
the O
CCAAT O
- O
box O
as O
a O
complex O
containing O
nuclear I-GENE
factor I-GENE
Y I-GENE
. O

EMSA O
showed O
that O
nuclear O
proteins O
from O
PC12 O
but O
not O
C6 O
or O
Rat2 NUMERIC
cells O
bind O
the O
CRE O
as O
a O
complex O
containing O
activating I-GENE
transcription I-GENE
factor I-GENE
( I-GENE
ATF I-GENE
)- I-GENE
4 I-GENE
and O
CCAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
beta I-GENE
, O
while O
both O
PC12 O
and O
C6 O
cell O
nuclear O
extracts O
were O
recruited O
by O
the O
CCAAT O
- O
box O
as O
a O
complex O
containing O
nuclear I-GENE
factor I-GENE
Y I-GENE
. O

Despite O
resolution O
of O
the O
solid O
portion O
of O
the O
tumor O
, O
serial O
MRI O
showed O
enlargement O
of O
a O
bilobar RARE
tumor O
cyst O
3 O
years O
after O
the O
original O
diagnosis O
. O

LPO ALLCAPS
and O
SOD I-GENE
levels O
were O
measured O
at O
five O
points O
before O
and O
during O
the O
operation O
. O

Sustained RARE
ventricular O
tachycardia O
and O
its O
successful O
prophylaxis O
during O
high O
- O
dose O
bolus O
interleukin I-GENE
- I-GENE
2 I-GENE
therapy O
for O
metastatic O
renal O
cell O
carcinoma O
. O

Second O
, O
when O
the O
NBF1 NUMERIC
+ I-GENE
R I-GENE
protein I-GENE
, O
the O
NBF2 NUMERIC
protein I-GENE
, O
and O
a O
mixture O
of O
the O
two O
proteins O
were O
folded O
separately O
and O
analyzed O
by O
molecular O
sieve RARE
chomatography RARE
, O
the O
mixture O
was O
found O
to O
elute RARE
prior O
to O
either O
NBF1 NUMERIC
+ I-GENE
R I-GENE
or O
NBF2 NUMERIC
. O

Collectively O
, O
these O
experiments O
demonstrate O
that O
CFTR I-GENE
' I-GENE
s I-GENE
NBF1 NUMERIC
+ I-GENE
R I-GENE
region I-GENE
and O
its O
NBF2 NUMERIC
domain I-GENE
, O
after O
folding O
separately O
as O
distinct O
units O
, O
have O
a O
strong O
propensity O
to O
interact O
and O
that O
this O
interaction O
is O
stable O
in O
the O
absence O
of O
added O
nucleotides O
or O
exogenously RARE
induced O
phosphorylation O
. O

Copyright O
2000 O
Academic O
Press O
. O

Sulfhydryl RARE
titration O
with O
iodoacetamide RARE
, O
monitored O
by O
quantitating RARE
the O
residual O
thiols RARE
after O
reaction O
with O
a O
maleimide RARE
derivative O
of O
biotin RARE
, O
revealed O
a O
striking O
difference O
in O
the O
apparent O
pK LASTCAP
( O
a O
) O
values O
of O
the O
cysteines RARE
at O
the O
two O
splice O
junctions O
. O

After O
nitric O
oxide O
inhalation O
, O
the O
results O
showed O
moderate O
increases O
in O
PaO2 O
and O
SaO2 O
( O
P O
> O
0 O
. O
05 O
) O
and O
a O
significant O
decrease O
in O
Qs RARE
/ O
Q O
tau O
ratio O
( O
P O
< O
0 O
. O
01 O
). O

The O
results O
showed O
that O
MIP O
, O
MMIF ALLCAPS
, O
FIC ALLCAPS
, O
Wimax RARE
, O
P0 NUMERIC
. O
1 O
and O
minute O
ventilation O
( O
Vr RARE
) O
were O
significantly O
increased O
after O
administration O
of O
methylphenidatum RARE
and O
aminophylline RARE
. O

Forty O
4 O
- O
month O
old O
SD O
female O
rats O
were O
randomly O
divided O
into O
four O
groups O
, O
namely O
sham O
operation O
, O
bilateral O
ovariectomy RARE
, O
ovariectomy RARE
plus O
supplementary O
ethinyl RARE
estradiol O
( O
0 O
. O
2 O
microgram O
/ O
100 O
g O
B O
. O

It O
has O
also O
been O
shown O
that O
a O
variety O
of O
extracellular O
factors O
stimulate O
a O
pair O
of O
MAPK O
p44 I-GENE
and O
MAPK O
p42 NUMERIC
of O
MAPK I-GENE
family I-GENE
members I-GENE
. O

Covalent RARE
modification O
of O
the O
transactivator O
protein O
IE2 I-GENE
- O
p86 NUMERIC
of O
human O
cytomegalovirus O
by O
conjugation O
to O
the O
ubiquitin I-GENE
- I-GENE
homologous I-GENE
proteins I-GENE
SUMO ALLCAPS
- I-GENE
1 I-GENE
and O
hSMT3b NUMERIC
. O

73 O
: O
658 NUMERIC
- O
666 NUMERIC
, O
1999 NUMERIC
). O

The O
interaction O
between O
U O
( O
L O
) O
3 O
. O

Protamine RARE
and O
heparin O
doses O
, O
their O
sum O
( O
Sigma RARE
- O
dose O
) O
and O
differential O
( O
Delta O
- O
dose O
) O
doses O
, O
and O
activated O
clotting O
times O
were O
tabulated RARE
. O

In O
this O
study O
, O
a O
common O
mechanism O
has O
been O
identified O
to O
coordinate O
the O
growth O
- O
and O
FC ALLCAPS
- O
dependent O
expression O
of O
caveolin RARE
. O

Comparison O
of O
the O
plant O
nuclear O
tRNA O
3 O
' O
processing O
enzyme O
with O
the O
plant O
mitochondrial O
one O
suggests O
that O
both O
activities O
are O
different O
enzymes O
. O

The O
requirement O
of O
3 O
' O
complementarity O
for O
a O
ligation O
reaction O
is O
reaffirmed RARE
by O
results O
from O
1 O
nt O
insertions O
on O
either O
the O
3 O
'- O
or O
5 O
'- O
side O
of O
the O
nick RARE
. O

NKX2 NUMERIC
. I-GENE
1 I-GENE
is O
a O
member O
of O
the O
NK2 NUMERIC
family I-GENE
of O
homeodomain I-GENE
- I-GENE
containing I-GENE
transcription I-GENE
factors I-GENE
whose O
targeted O
disruption O
in O
mouse O
results O
in O
the O
absence O
of O
thyroid O
tissue O
and O
a O
severely O
abnormal O
lung O
phenotype O
. O

National O
abortion O
laws RARE
usually O
do O
not O
allow O
abortion O
when O
a O
foetus RARE
is O
independently O
viable O
, O
i O
. O
e O
. O
from O
a O
gestational O
age O
of O
about O
24 O
weeks O
. O

Expression O
in O
early O
postnatal O
pituitary O
and O
in O
pre O
- O
somatotrophic RARE
cells O
suggests O
that O
Zn I-GENE
- I-GENE
16 I-GENE
could O
play O
a O
role O
in O
pituitary O
development O
prior O
to O
somatotroph RARE
differentiation O
. O

Mouse RARE
growth I-GENE
hormone I-GENE
transcription I-GENE
factor I-GENE
Zn I-GENE
- I-GENE
16 I-GENE
: O
unique O
bipartite O
structure O
containing O
tandemly O
repeated O
zinc O
finger O
domains O
not O
reported O
in O
rat I-GENE
Zn I-GENE
- I-GENE
15 I-GENE
. O

The O
CCAAT O
core O
sequence O
mutants O
in O
which O
both O
CIII ALLCAPS
and O
CI O
/ O
CII ALLCAPS
were O
abolished O
, O
also O
increased O
the O
promoter O
activity O
. O

Deglutition RARE
is O
considered O
to O
be O
immature O
in O
infants O
and O
to O
mature O
postnatally RARE
. O

This O
repression O
does O
not O
require O
the O
PU I-GENE
. I-GENE
1 I-GENE
transactivation O
or O
PEST ALLCAPS
domains O
and O
cannot O
be O
reversed O
by O
p300 I-GENE
expression O
. O

First O
, O
human O
erythroid O
K562 O
cells O
stably O
integrated O
with O
various O
HS I-GENE
- I-GENE
40 I-GENE
mutants I-GENE
cis O
linked O
to O
a O
human I-GENE
alpha I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
- O
growth I-GENE
hormone I-GENE
hybrid O
gene O
were O
analyzed O
by O
genomic O
footprinting O
and O
expression O
analysis O
. O

Interestingly O
, O
addition O
of O
purified O
CBP I-GENE
to O
the O
nuclear O
extracts O
of O
T47D NUMERIC
cells O
markedly O
stimulated O
progesterone O
- O
and O
PR I-GENE
- O
dependent O
transcription O
from O
a O
nucleosome RARE
- O
free O
, O
progesterone O
response O
element O
( O
PRE ALLCAPS
)- O
linked O
reporter O
DNA O
template O
. O

Its O
cognate O
binding O
protein O
, O
REST ALLCAPS
/ O
NRSF ALLCAPS
, O
is O
an O
essential O
transcription O
factor O
; O
its O
null O
mutations O
result O
in O
embryonic O
lethality O
, O
and O
its O
dominant O
negative O
mutants O
produce O
aberrant O
expression O
of O
neuron O
- O
specific O
genes O
. O

Removal O
of O
all O
core I-GENE
histone I-GENE
tail O
domains O
by O
limited O
trypsin I-GENE
proteolysis O
or O
acetylation O
of O
the O
core I-GENE
histone I-GENE
tails O
significantly O
relieves RARE
this O
inhibition O
and O
allows O
TFIIIA ALLCAPS
to O
exhibit O
high O
- O
affinity O
binding O
to O
nucleosomal RARE
DNA O
. O

Finally O
, O
the O
mechanism O
of O
ASK1 NUMERIC
activation O
involves O
, O
in O
part O
, O
homo RARE
- O
oligomerization O
. O

OUTCOME O
: O
Acetylcholine RARE
receptor I-GENE
antibodies I-GENE
and O
single O
- O
fibre O
electromyogram RARE
were O
useful O
in O
the O
diagnosis O
of O
myasthenia RARE
gravis RARE
. O

Two O
other O
patients O
underwent O
PRFR ALLCAPS
. O

The O
variations O
were O
caused O
by O
opposite O
shifts O
in O
TSH I-GENE
frequency O
distribution O
in O
mothers O
and O
neonates O
. O

Characterization O
of O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
multidrug I-GENE
resistance I-GENE
protein I-GENE
2 I-GENE
( O
MRP2 NUMERIC
) O
gene O
and O
its O
regulation O
in O
comparison O
withthe RARE
multidrug I-GENE
resistance I-GENE
protein I-GENE
3 I-GENE
( O
MRP3 NUMERIC
) O
gene O
. O

However O
, O
such O
a O
mechanism O
was O
not O
detected O
in O
preliminary O
observations O
on O
M O
. O
synoviae RARE
. O

These O
results O
suggest O
that O
the O
M O
. O
jannaschii RARE
as O
well O
as O
related O
archaeal RARE
20S I-GENE
proteasomes RARE
require O
a O
nucleotidase RARE
complex O
such O
as O
PAN ALLCAPS
to O
mediate O
the O
energy O
- O
dependent O
hydrolysis O
of O
folded O
- O
substrate O
proteins O
and O
that O
the O
N O
- O
terminal O
73 O
amino O
acid O
residues O
of O
PAN ALLCAPS
are O
not O
absolutely RARE
required O
for O
this O
reaction O
. O

The O
transcription O
factor O
E2F I-GENE
plays O
an O
important O
role O
in O
G O
( O
1 O
) O
to O
S O
phase O
transition O
in O
the O
higher O
eukaryotic O
cell O
cycle O
. O

In O
two O
- O
field O
nodal O
dissection O
, O
two O
components O
are O
included O
with O
( O
modern O
two O
- O
field O
) O
or O
without O
( O
traditional RARE
two O
- O
field O
) O
nodal O
dissection O
around O
both O
recurrent O
laryngeal RARE
nerve O
chains O
in O
the O
upper O
mediastinum RARE
. O

Of O
the O
153 NUMERIC
patients O
studied O
, O
CK I-GENE
- I-GENE
MB I-GENE
results O
were O
positive O
in O
91 O
( O
59 O
%) O
patients O
; O
ECG O
revealed O
AMI O
in O
72 O
( O
47 O
%) O
patients O
. O

The O
effect O
of O
MIB ALLCAPS
on O
the O
dose O
- O
response O
curve O
of O
externally RARE
applied O
noradrenaline O
was O
also O
studied O
. O

The O
regional O
blockade O
of O
H1R NUMERIC
was O
observed O
mainly O
in O
the O
frontal O
, O
temporal O
and O
anterior O
cingulate RARE
cortices RARE
, O
and O
the O
intravenous O
administration O
of O
d O
- O
chlorpheniramine RARE
as O
a O
therapeutic O
dose O
( O
2 O
mg O
) O
blocked O
over O
60 O
% O
of O
H1R NUMERIC
in O
the O
frontal O
cortices RARE
. O

The O
expression O
of O
the O
yam8 NUMERIC
(+) I-GENE
cDNA I-GENE
in O
the O
mid1 NUMERIC
mutant I-GENE
cells O
partially O
remediated RARE
the O
mid O
phenotype O
and O
resulted O
in O
a O
slight O
increase O
in O
Ca O
( O
2 O
+) O
uptake O
activity O
. O

Linearized RARE
overall O
infection O
rates O
( O
events O
/ O
100 O
patient O
- O
days O
) O
were O
2 O
. O
05 O
+/- O
0 O
. O
33 O
( O
heart O
- O
lung O
) O
and O
2 O
. O
34 O
+/- O
0 O
. O
34 O
( O
double O
- O
lung O
; O
P O
= O
NS O
) O
at O
3 O
months O
. O

Static RARE
and O
dynamic O
compliance O
was O
measured O
after O
induction O
of O
anesthesia O
, O
before O
and O
immediately O
after O
filtration O
in O
the O
operating O
theater RARE
, O
1 O
hour O
after O
return O
to O
the O
pediatric O
intensive O
care O
unit O
, O
and O
24 O
hours O
after O
the O
operation O
. O

Antipyretic RARE
therapy O
: O
physiologic RARE
rationale RARE
, O
diagnostic O
implications O
, O
and O
clinical O
consequences O
. O

There O
is O
no O
correlation O
between O
C2 O
- O
C3 O
disk RARE
morphology O
and O
the O
diskographically RARE
provoked RARE
response O
. O

KFC ALLCAPS
, O
a O
Ste20 NUMERIC
- I-GENE
like I-GENE
kinase I-GENE
with O
mitogenic O
potential O
and O
capability RARE
to O
activate O
the O
SAPK I-GENE
/ O
JNK I-GENE
pathway O
. O

TIP30 NUMERIC
has O
an O
intrinsic O
kinase O
activity O
required O
for O
up O
- O
regulation O
of O
a O
subset O
of O
apoptotic O
genes O
. O

We O
have O
mapped O
the O
human I-GENE
STAG3 NUMERIC
gene I-GENE
to O
the O
7q22 NUMERIC
region O
of O
chromosome O
7 O
; O
six O
human I-GENE
STAG3 NUMERIC
- I-GENE
related I-GENE
genes I-GENE
have O
also O
been O
mapped O
: O
two O
at O
7q22 NUMERIC
near O
the O
functional O
gene O
, O
one O
at O
7q11 NUMERIC
. O
22 O
, O
and O
three O
at O
7q11 NUMERIC
. O
23 O
, O
two O
of O
them O
flanking O
the O
breakpoints O
commonly O
associated O
with O
the O
Williams RARE
- I-GENE
Beuren RARE
syndrome I-GENE
( I-GENE
WBS ALLCAPS
) I-GENE
deletion I-GENE
. O

Reaction RARE
time O
( O
RT O
) O
and O
P300 NUMERIC
were O
collected O
simultaneously O
. O

In O
experiment O
2 O
the O
rats O
had O
free O
access O
to O
two O
bottles RARE
, O
one O
of O
which O
contained O
tap O
water O
, O
and O
the O
other O
contained O
either O
an O
ethanol O
( O
6 O
%) O
or O
a O
sucrose O
( O
5 O
%) O
solution O
. O

Furthermore O
, O
Zelen RARE
' O
s O
method O
is O
used O
to O
balance O
the O
number O
of O
patients O
allocated O
to O
the O
two O
groups O
within O
each O
institution RARE
( O
M O
. O

RESULTS O
: O
In O
this O
group O
of O
patients O
, O
male O
gender O
( O
P O
= O
0 O
. O

Selective O
visual O
attention O
involves O
dynamic O
interplay RARE
between O
attentional RARE
control O
systems O
and O
sensory O
brain O
structures O
. O

The O
patient O
had O
developed O
left O
- O
sided RARE
low O
- O
frequency O
tremor O
and O
hemidystonia RARE
after O
a O
severe O
head O
trauma O
sustained O
at O
15 O
years O
of O
age O
. O

However O
, O
the O
a1 NUMERIC
isoform O
is O
expressed O
most O
heavily RARE
in O
brain O
and O
heart O
, O
a2 NUMERIC
in O
liver O
and O
kidney O
, O
and O
a3 NUMERIC
in O
liver O
, O
lung O
, O
heart O
, O
brain O
, O
spleen O
, O
and O
kidney O
. O

During O
the O
cloning O
by O
reverse I-GENE
transcriptase I-GENE
- O
polymerase O
chain O
reaction O
of O
the O
human I-GENE
HIF I-GENE
- I-GENE
1alpha I-GENE
subunit I-GENE
, O
we O
isolated O
two O
cDNA O
clones O
which O
corresponded O
to O
alternative O
splicing O
of O
the O
HIF I-GENE
- I-GENE
1alpha I-GENE
gene I-GENE
. O

To O
assess O
the O
relationship O
between O
G O
( O
q O
)/ O
G I-GENE
( I-GENE
11 I-GENE
) I-GENE
function O
with O
the O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
dependent O
pathway O
, O
expression O
of O
a O
dominant O
- O
interfering O
p85 I-GENE
regulatory I-GENE
subunit I-GENE
, O
as O
well O
as O
wortmannin O
treatment O
inhibited O
insulin I-GENE
- O
stimulated O
but O
not O
G I-GENE
( I-GENE
q I-GENE
)/ I-GENE
Q209L NUMERIC
- O
stimulated O
GLUT4 NUMERIC
- O
EGFP ALLCAPS
translocation O
. O

In O
endemic RARE
BL ALLCAPS
, O
the O
RB2 NUMERIC
/ O
p130 I-GENE
gene O
is O
mutated O
in O
most O
of O
the O
cases O
, O
and O
the O
protein O
is O
restricted O
to O
the O
cytoplasm O
. O

Together O
, O
these O
data O
identify O
ERK2 I-GENE
as O
a O
specific O
and O
direct O
target O
of O
HePTP LASTCAP
and O
are O
consistent O
with O
a O
model O
in O
which O
HePTP LASTCAP
negatively O
regulates O
ERK2 I-GENE
activity O
as O
part O
of O
a O
feedback RARE
mechanism O
. O

Cross O
- O
reaction O
between O
a O
monoclonal O
antibody O
and O
two O
alpha I-GENE
beta I-GENE
T I-GENE
cell I-GENE
receptors I-GENE
. O

Strontium RARE
nitrate O
mixed O
with O
glycolic RARE
acid O
, O
in O
comparison O
with O
glycolic RARE
acid O
alone O
, O
markedly O
( O
p O
< O
0 O
. O
01 O
) O
shortened O
the O
duration O
of O
the O
irritation RARE
sensation RARE
from O
24 O
. O
4 O
+/- O
4 O
. O
1 O
( O
mean O
+/- O
SEM ALLCAPS
) O
min O
to O
8 O
. O
9 O
+/- O
3 O
. O
7 O
( O
mean O
+/- O
SEM ALLCAPS
) O
min O
, O
and O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
reduced O
the O
mean O
magnitude O
of O
the O
irritation RARE
sensation RARE
at O
all O
time O
points O
( O
overall O
). O

The O
pCMBS LASTCAP
- O
reactive O
sulfhydryl RARE
groups O
were O
located O
exclusively O
in O
the O
exofacial RARE
half O
of O
the O
plasma O
membrane O
and O
, O
when O
presented O
in O
a O
helical O
model O
, O
lie RARE
along O
one O
side O
of O
the O
helices O
. O

Analysis O
of O
1 O
Mb O
of O
published O
sequence O
from O
the O
region O
of O
conserved O
synteny RARE
on O
human O
chromosome O
5q31 NUMERIC
- O
q33 NUMERIC
identified O
45 O
gene O
candidates RARE
, O
including O
35 O
expressed O
genes O
in O
the O
human I-GENE
IL I-GENE
- I-GENE
4 I-GENE
cytokine I-GENE
gene I-GENE
cluster I-GENE
. O

Human I-GENE
AP I-GENE
- I-GENE
2rep NUMERIC
repressed O
both O
reporter O
expression O
from O
a O
transiently O
transfected O
AP I-GENE
- I-GENE
2alpha I-GENE
promoter I-GENE
and O
the O
endogenous O
AP I-GENE
- I-GENE
2alpha I-GENE
gene I-GENE
and O
inversely O
was O
negatively O
regulated O
by O
AP I-GENE
- I-GENE
2alpha I-GENE
. O

In O
order O
to O
gain O
deeper RARE
insight O
into O
the O
role O
of O
the O
amino O
- O
terminal O
domain O
of O
the O
p24 NUMERIC
( O
CA I-GENE
) O
protein O
during O
viral O
replication O
, O
eight O
highly O
conserved O
proline O
residues O
known O
to O
promote O
turns RARE
and O
to O
terminate O
alpha O
- O
helices O
within O
the O
p24 NUMERIC
tertiary O
structure O
were O
replaced O
by O
a O
leucine O
residue O
( O
P O
- O
position O
- O
L O
). O

Clb RARE
/ O
Cdc28 I-GENE
kinases O
promote O
nuclear O
export O
of O
the O
replication I-GENE
initiator I-GENE
proteins I-GENE
Mcm2 NUMERIC
- I-GENE
7 I-GENE
. O

Alternatively RARE
, O
PC12 O
- O
E2 O
cells O
were O
submitted O
to O
treatment O
with O
antibodies O
to O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
( I-GENE
FGF I-GENE
) I-GENE
receptor I-GENE
, O
inhibitors O
of O
the O
nonreceptor RARE
tyrosine I-GENE
kinase I-GENE
p59 NUMERIC
( O
fyn RARE
), O
PLC I-GENE
, O
PKC I-GENE
and O
MEK I-GENE
and O
an O
activator O
of O
PKC I-GENE
, O
phorbol O
- O
12 O
- O
myristate O
- O
13 O
- O
acetate O
( O
PMA O
). O

Cooperative RARE
roles O
of O
Bozozok RARE
/ O
Dharma RARE
and O
Nodal RARE
- I-GENE
related I-GENE
proteins I-GENE
in O
the O
formation O
of O
the O
dorsal O
organizer RARE
in O
zebrafish RARE
. O

Thiopentone RARE
sodium O
administered O
at O
30 O
and O
10 O
min O
before O
or O
5 O
, O
10 O
and O
15 O
min O
after O
exposure O
to O
NOC ALLCAPS
- O
5 O
, O
but O
not O
thereafter O
, O
significantly O
attenuated O
NO O
- O
induced O
neurotoxicity O
compared O
with O
controls O
. O

We O
also O
show O
that O
zygotically RARE
activated O
Xretpos RARE
transcripts O
are O
restricted O
to O
ventro RARE
- O
posterior O
specific O
regions O
and O
induced O
by O
UV O
- O
irradiation O
and O
BMP I-GENE
- I-GENE
4 I-GENE
overexpression O
in O
cycloheximide O
- O
dependent O
way O
. O
genesis RARE
26 O
: O
198 O
- O
207 NUMERIC
, O
2000 O
. O

In O
all O
other O
cases O
, O
vestibular O
neurectomy RARE
or O
chemical O
vestibular O
labyrinthectomy RARE
, O
by O
means O
of O
intratympanic RARE
low O
concentration O
gentamicin RARE
( O
20 O
mg O
/ O
mL O
), O
are O
indicated O
. O

However O
, O
when O
, O
where O
and O
how O
the O
DSPP ALLCAPS
is O
cleaved O
into O
DSP ALLCAPS
and O
DPP ALLCAPS
is O
not O
clear O
. O

It O
has O
a O
grave RARE
prognosis O
with O
> O
70 O
% O
mortality O
in O
3 O
months O
, O
despite O
mechanical O
ventilation O
. O

We O
found O
that O
TCR I-GENE
signaling O
induces O
AP I-GENE
- I-GENE
1 I-GENE
binding O
to O
this O
site O
and O
regulates O
the O
fasl RARE
promoter I-GENE
function O
in O
a O
fashion O
dependent O
on O
NF I-GENE
- I-GENE
kappaB I-GENE
binding O
. O

Thus O
, O
patients O
with O
metastatic O
melanoma O
are O
not O
tolerant RARE
to O
gp100 NUMERIC
Ag I-GENE
based O
on O
the O
detection O
of O
CD8 I-GENE
+ I-GENE
T O
cells O
specific O
for O
multiple O
HLA I-GENE
- I-GENE
A I-GENE
* I-GENE
0201 NUMERIC
- O
restricted O
, O
gp100 NUMERIC
- O
derived O
epitopes O
. O

Approximately O
20 O
% O
of O
ALCLs RARE
that O
express O
ALK ALLCAPS
do O
not O
contain O
the O
t O
( O
2 O
; O
5 O
), O
suggesting O
that O
other O
genetic O
abnormalities O
can O
result O
in O
aberrant O
ALK ALLCAPS
expression O
. O

In O
addition O
, O
expected O
decreases O
in O
ATIC ALLCAPS
enzymatic O
function O
in O
ATIC ALLCAPS
- O
ALK ALLCAPS
- O
containing O
lymphomas O
may O
render RARE
these O
tumors O
more O
sensitive O
to O
antifolate RARE
drugs O
such O
as O
methotrexate O
. O

Following O
the O
observation O
that O
non O
- O
organ O
- O
specific O
antibodies O
are O
related O
with O
pregnancy O
loss O
and O
preeclampsia RARE
, O
the O
role O
of O
organ O
- O
specific O
antibodies O
is O
currently O
being O
extensively O
investigated O
. O

Manganese RARE
ions O
were O
found O
to O
be O
essential O
for O
autophosphorylation O
of O
BGLF4 NUMERIC
, O
and O
magnesium O
can O
stimulate O
the O
activity O
. O

The O
Mif1 NUMERIC
5 I-GENE
' I-GENE
flanking I-GENE
region I-GENE
contains O
a O
functional O
ER O
stress O
- O
responsive O
element O
which O
is O
sufficient O
for O
induction O
by O
tunicamycin RARE
. O

Rigid RARE
point O
feature O
registration RARE
using O
mutual RARE
information O
. O

Methysergide RARE
is O
a O
serotonin O
antagonist O
and O
has O
been O
demonstrated O
to O
reduce O
wound O
blood O
flow O
and O
edema O
formation O
. O

Serum O
leptin I-GENE
concentrations O
in O
women O
during O
gonadotropin I-GENE
stimulation O
cycles O
. O

Valuing RARE
families O
: O
social O
work O
practice O
with O
families O
from O
a O
strengths O
perspective RARE
. O

PURPOSE O
: O
A O
two O
- O
generation O
consanguineous RARE
Pakistani RARE
family O
with O
autosomal RARE
recessive O
Leber RARE
congenital O
amaurosis RARE
( O
LCA ALLCAPS
, O
MIM ALLCAPS
204 NUMERIC
, O
000 O
) O
and O
keratoconus RARE
was O
identified O
. O

Ste18p NUMERIC
was O
targeted O
to O
the O
plasma O
membrane O
even O
in O
the O
absence O
of O
prenylation RARE
or O
thioacylation RARE
. O

Here O
, O
we O
show O
that O
IRF I-GENE
- I-GENE
1 I-GENE
is O
degraded O
via O
the O
ubiquitin I-GENE
- O
proteasome O
pathway O
. O

An O
amino O
- O
acid O
sequence O
comparison O
revealed O
that O
Bacillus I-GENE
YM55 NUMERIC
- I-GENE
1 I-GENE
aspartase RARE
shared O
71 O
% O
homology O
with O
Bacillus I-GENE
subtilis I-GENE
aspartase RARE
and O
49 O
% O
with O
Escherichia O
coli O
and O
Pseudomonas I-GENE
fluorescens RARE
aspartases RARE
. O

Unique RARE
to O
this O
system O
, O
the O
activity O
of O
TraR LASTCAP
is O
negatively O
modulated O
by O
an O
antiactivator RARE
called O
TraM LASTCAP
. O

As O
assessed O
by O
a O
genetic O
assay O
that O
measures O
AAI ALLCAPS
- O
dependent O
DNA O
binding O
, O
TraM LASTCAP
inhibited O
TraR LASTCAP
function O
before O
and O
after O
the O
transcription O
factor O
had O
bound O
to O
its O
DNA O
recognition O
site O
. O

Here O
we O
show O
that O
IIIa RARE
pre O
- O
mRNA O
splicing O
is O
activated O
more O
than O
200 O
- O
fold O
in O
nuclear O
extracts O
prepared O
from O
late O
adenovirus O
- O
infected O
cells O
( O
Ad RARE
- O
NE O
) O
compared O
to O
uninfected RARE
HeLa O
cell O
nuclear O
extracts O
( O
HeLa O
- O
NE O
). O

Inactivation RARE
of O
Ulp2 NUMERIC
also O
suppresses O
several O
ulp1 NUMERIC
( I-GENE
ts I-GENE
) I-GENE
defects O
, O
and O
the O
double O
mutant O
accumulates O
far O
fewer O
Smt3 NUMERIC
- I-GENE
protein I-GENE
conjugates RARE
than O
either O
single O
mutant O
. O

Collectively O
, O
the O
results O
suggest O
that O
ARF I-GENE
binding O
to O
Mdm2 NUMERIC
induces O
a O
conformational O
change O
that O
facilitates RARE
nucleolar O
import O
of O
the O
ARF I-GENE
- O
Mdm2 NUMERIC
complex O
and O
p53 I-GENE
- O
dependent O
cell O
cycle O
arrest O
. O

Cyclin I-GENE
A I-GENE
expression O
is O
repressed O
in O
quiescent RARE
cells O
by O
E2F I-GENE
acting O
in O
conjunction O
with O
its O
pocket O
protein O
partners O
Rb I-GENE
, O
p107 I-GENE
, O
and O
p130 I-GENE
; O
however O
, O
v I-GENE
- I-GENE
Jun I-GENE
overrides RARE
this O
control O
, O
causing O
phosphorylated O
Rb I-GENE
and O
proliferation O
- O
specific O
E2F I-GENE
- O
p107 I-GENE
complexes O
to O
persist RARE
after O
mitogen O
withdrawal O
. O

D I-GENE
- I-GENE
cyclin I-GENE
- O
cdk RARE
activity O
is O
required O
for O
Rb I-GENE
phosphorylation O
in O
v I-GENE
- I-GENE
Jun I-GENE
- O
transformed O
cells O
, O
since O
ectopic O
expression O
of O
the O
cdk4 NUMERIC
- O
and O
cdk6 NUMERIC
- O
specific O
inhibitor O
p16 I-GENE
( O
INK4A NUMERIC
) O
inhibits O
both O
DNA O
synthesis O
and O
cell O
proliferation O
. O

CONCLUSION O
: O
A O
valve O
- O
like O
mechanism O
formed O
by O
the O
capsulorhexis RARE
rim RARE
partially O
adhered RARE
to O
the O
IOL ALLCAPS
optic O
can O
occur O
postoperatively O
. O

The O
protein O
first O
identified O
by O
the O
monoclonal I-GENE
antibody I-GENE
Q18 NUMERIC
is O
encoded O
by O
a O
gene O
located O
in O
57A NUMERIC
on O
polytene RARE
chromosomes O
and O
has O
been O
consequently RARE
named O
Hrb57A NUMERIC
. O

3 O
' O
RNA O
boundary O
experiments O
indicate O
that O
the O
5 O
' O
structure O
reduces O
the O
number O
of O
( O
G O
/ O
U O
) O
AG ALLCAPS
repeats O
required O
for O
stable O
TRAP ALLCAPS
- O
trp RARE
leader O
RNA O
association O
. O

Gene O
silencing O
associated O
with O
repeated O
DNA O
sequences O
has O
been O
reported O
for O
many O
eukaryotes O
, O
including O
plants O
. O

The O
AtERF LASTCAP
genes I-GENE
were O
differentially O
regulated O
by O
ethylene O
and O
by O
abiotic RARE
stress O
conditions O
, O
such O
as O
wounding RARE
, O
cold O
, O
high O
salinity RARE
, O
or O
drought RARE
, O
via O
ETHYLENE ALLCAPS
- I-GENE
INSENSITIVE2 NUMERIC
( O
EIN2 NUMERIC
)- O
dependent O
or O
- O
independent O
pathways O
. O

Animals O
received O
a O
dose O
of O
dexamethasone O
( O
10 O
mg O
/ O
kg O
i O
. O
p O
.) O
prior O
to O
the O
protein O
- O
free O
surfactant O
preparation O
Exosurf RARE
( O
pure O
phospholipids O
containing O
surfactant O
, O
Wellcome RARE
GmbH LASTCAP
, O
Burgwedel RARE
, O
Germany RARE
) O
and O
a O
rSP LASTCAP
- O
C O
based O
surfactant O
, O
respectively O
. O

BACKGROUND O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
response O
rates O
and O
toxicity O
of O
two O
regimens O
containing O
granulocyte I-GENE
- I-GENE
macrophage I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
GM I-GENE
- I-GENE
CSF I-GENE
) O
in O
combination O
with O
interleukin I-GENE
- I-GENE
2 I-GENE
( O
IL I-GENE
- I-GENE
2 I-GENE
) O
in O
the O
treatment O
of O
patients O
with O
metastatic O
renal O
cell O
carcinoma O
. O

We O
show O
, O
by O
injection O
of O
synthetic O
mRNAs O
, O
that O
the O
cis O
- O
acting O
sequences O
responsible O
for O
repression O
of O
cyclin I-GENE
B1 I-GENE
mRNA I-GENE
reside O
within O
its O
3 O
' O
UTR O
. O

These O
data O
indicate O
that O
expansion O
of O
the O
dodecamer RARE
repeat O
located O
in O
the O
proximal O
promoter O
of O
CSTB ALLCAPS
severely O
disrupts RARE
the O
function O
of O
the O
promoter O
and O
thereby O
reduces O
transcription O
of O
CSTB ALLCAPS
. O

Thus O
, O
while O
the O
genomic O
organization O
of O
mHuA LASTCAP
is O
similar O
to O
the O
neural O
- O
restricted O
members O
of O
the O
Elav RARE
family I-GENE
, O
the O
promoter O
element O
differs O
substantially O
both O
by O
sequence O
analysis O
and O
transcriptional O
activity O
in O
non O
- O
neural O
cell O
types O
. O

Analysis O
of O
the O
5 O
' O
end O
of O
the O
mouse I-GENE
Elavl1 NUMERIC
( O
mHuA LASTCAP
) O
gene O
reveals O
a O
transcriptional O
regulatory O
element O
and O
evidence O
for O
conserved O
genomic O
organization O
. O
mHuA LASTCAP
( O
Elavl1 NUMERIC
) O
belongs O
to O
a O
highly O
conserved O
family O
of O
genes O
encoding O
RNA O
- O
binding O
proteins O
and O
has O
been O
linked O
to O
cell O
growth O
and O
proliferation O
through O
its O
regulation O
of O
mRNA O
stability O
. O

Electrophoretic O
mobility O
shift O
assays O
revealed O
that O
Sp1 I-GENE
binds O
to O
two O
different O
regions O
in O
the O
proximal O
promoter O
, O
a O
typical O
Sp1 I-GENE
site I-GENE
located O
at O
(- O
38 O
; O
- O
33 O
) O
and O
a O
G O
/ O
C O
- O
rich O
region O
between O
(- O
67 O
; O
- O
62 O
). O

Fgd3 NUMERIC
and O
FGD1 NUMERIC
share O
a O
high O
degree O
of O
sequence O
identity O
that O
spans O
> O
560 NUMERIC
contiguous O
amino O
acid O
residues O
. O

Molecular O
cloning O
of O
mouse I-GENE
thioredoxin RARE
reductases RARE
. O

The O
HPLC O
method O
involves O
an O
octadecylsilane RARE
column O
at O
55 O
degrees O
C O
, O
a O
mixture O
of O
water O
- O
acetonitrile RARE
- O
orthophosphoric RARE
acid O
( O
779 NUMERIC
: O
220 O
: O
1 O
, O
v O
/ O
v O
) O
as O
mobile O
phase O
and O
detection O
at O
226 NUMERIC
nm O
. O

Eight O
patients O
received O
1 O
. O
5 O
mg O
of O
adefovir RARE
dipivoxil RARE
per O
kg O
of O
body O
weight O
, O
and O
six O
patients O
received O
3 O
. O
0 O
mg O
of O
adefovir RARE
dipivoxil RARE
per O
kg O
. O

CYC2 NUMERIC
encodes O
a O
24 O
- O
kDa O
protein O
that O
has O
sequence O
identity O
to O
the O
Neurospora I-GENE
crassa I-GENE
PREG1 NUMERIC
and O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
PHO80 NUMERIC
cyclin I-GENE
. O

To O
determine O
if O
CYC2 NUMERIC
is O
found O
in O
a O
complex O
with O
previously O
identified O
trypanosome RARE
cdc2 I-GENE
- I-GENE
related I-GENE
kinases I-GENE
( O
CRKs RARE
), O
the O
CYC2 NUMERIC
gene I-GENE
was O
fused O
to O
the O
TY ALLCAPS
epitope I-GENE
tag O
, O
integrated O
into O
the O
trypanosome RARE
genome O
, O
and O
expressed O
under O
inducible O
control O
. O

These O
findings O
indicate O
the O
involvement O
of O
Sp1 I-GENE
and O
an O
Inr RARE
in O
non O
- O
cell O
- O
specific O
regulation O
and O
a O
Kruppel RARE
- I-GENE
like I-GENE
transcription I-GENE
factor I-GENE
and O
Sp1 I-GENE
in O
the O
cell O
- O
specific O
regulation O
of O
the O
LTC ALLCAPS
( I-GENE
4 I-GENE
) I-GENE
S I-GENE
gene I-GENE
. O

Here O
we O
review O
progress O
to O
date O
in O
this O
area O
. O

Additionally O
, O
the O
mouse O
promoter O
contains O
22 O
copies O
of O
a O
CT O
dinucleotide O
repeat O
sequence O
located O
approximately O
155 NUMERIC
bp O
5 O
' O
to O
exon O
1 O
. O

The O
newly O
defined O
region O
contains O
an O
intron O
that O
may O
be O
alternatively O
spliced O
and O
seven O
polyadenylation O
signal O
sequences O
. O

Depleted RARE
and O
enriched O
U3O8 NUMERIC
standard O
reference O
materials O
were O
used O
to O
calibrate RARE
the O
system O
. O

Therefore O
, O
the O
positive O
cAMP O
control O
of O
the O
hypoxic O
SRP1 NUMERIC
and O
HEM13 NUMERIC
genes I-GENE
was O
uncoupled RARE
from O
the O
HOG ALLCAPS
pathway O
. O

Most O
likely O
they O
might O
represent O
regulatory O
RNAs O
or O
transcribed O
transposable RARE
elements O
. O

This O
paper O
reviews RARE
the O
middleware RARE
- O
based O
approach O
adopted O
by O
CEN ALLCAPS
ENV ALLCAPS
12967 NUMERIC
- O
1 O
and O
the O
specialisation RARE
necessary O
for O
the O
healthcare RARE
record O
based O
on O
CEN ALLCAPS
ENV ALLCAPS
12265 NUMERIC
' O
Electronic RARE
Healthcare RARE
Record RARE
Architecture RARE
'. O

Sequence O
analyses O
of O
sos2 NUMERIC
mutant I-GENE
alleles I-GENE
reveal O
that O
both O
the O
N O
- O
terminal O
catalytic O
domain O
and O
the O
C O
- O
terminal O
regulatory O
domain O
of O
SOS2 NUMERIC
are O
functionally O
essential O
. O

A O
mutation O
which O
abrogates RARE
the O
binding O
of O
these O
factors O
reduces O
Wp RARE
reporter I-GENE
activity O
specifically O
in O
B O
cell O
lines O
, O
whereas O
a O
mutation O
which O
converts RARE
the O
site O
to O
a O
consensus O
CREB I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
maintains O
wild O
- O
type O
promoter O
function O
. O

Here O
we O
describe O
the O
cloning O
, O
tissue O
- O
specific O
expression O
pattern O
, O
and O
functional O
characterization O
of O
two O
novel O
TEF I-GENE
- I-GENE
1 I-GENE
isoforms I-GENE
, O
TEF I-GENE
- I-GENE
1beta I-GENE
and O
TEF I-GENE
- I-GENE
1gamma NUMERIC
. O

Therefore O
the O
binding O
sites O
for O
liver O
- O
enriched O
factors O
, O
present O
in O
the O
hamster I-GENE
CYP7A1 NUMERIC
proximal I-GENE
promoter I-GENE
in O
close O
vicinity O
and O
conserved O
between O
species O
, O
constitute O
a O
regulatory O
unit O
important O
for O
basal O
hepatic O
expression O
and O
tissue O
restriction O
of O
the O
action O
of O
hormones O
such O
as O
insulin I-GENE
. O

The O
kinase O
activity O
of O
PfPK6 NUMERIC
is O
sensitive O
to O
CDK I-GENE
inhibitors O
such O
as O
olomoucine RARE
and O
roscovitine RARE
. O

Although O
MAP I-GENE
( I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
) I-GENE
kinases I-GENE
are O
implicated O
in O
cell O
proliferation O
and O
differentiation O
in O
many O
cell O
types O
, O
the O
role O
of O
MAP I-GENE
kinases I-GENE
in O
cardiac O
hypertrophy O
remains O
unclear O
. O

Transfection O
with O
a O
CSF I-GENE
- I-GENE
1R NUMERIC
expression O
plasmid O
permitted O
CSF I-GENE
- I-GENE
1 I-GENE
- O
dependent O
activation O
of O
the O
signalling O
pathway O
targeting O
an O
Ets I-GENE
/ O
AP1 I-GENE
( O
activator I-GENE
protein I-GENE
1 I-GENE
) O
element O
in O
the O
uPA I-GENE
promoter I-GENE
that O
has O
been O
shown O
previously O
to O
be O
a O
target O
of O
oncogenic I-GENE
ras I-GENE
and O
protein O
kinase O
C O
pathways O
. O

Regulation O
of O
urokinase I-GENE
plasminogen I-GENE
activator I-GENE
gene I-GENE
transcription O
in O
the O
RAW264 NUMERIC
murine O
macrophage O
cell O
line O
by O
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
) O
is O
dependent O
upon O
the O
level O
of O
cell O
- O
surface O
receptor O
. O

Molecule RARE
( O
s O
) O
secreted O
by O
neuronal O
cultures O
contribute O
to O
this O
induction O
of O
GLT ALLCAPS
- I-GENE
1 I-GENE
, O
but O
little O
is O
known O
about O
the O
signaling O
pathways O
mediating O
this O
regulation O
. O

Coactivation RARE
of O
endogenous O
or O
exogenous O
G I-GENE
( I-GENE
q I-GENE
)- I-GENE
coupled I-GENE
receptors I-GENE
with O
the O
delta I-GENE
- I-GENE
opioid I-GENE
receptor I-GENE
produced O
strong O
stimulations RARE
of O
PLCbeta RARE
and O
such O
responses O
could O
be O
partially O
blocked O
by O
pertussis I-GENE
toxin I-GENE
. O

Patients O
enrolled O
in O
the O
Integrilin RARE
to O
Minimize RARE
Platelet O
Aggregation RARE
and O
Coronary O
Thrombosis RARE
- O
II O
( O
IMPACT ALLCAPS
- O
II O
) O
trial O
were O
analyzed O
. O

The O
Wnt I-GENE
signaling O
pathway O
functions O
reiteratively RARE
during O
animal O
development O
to O
control O
cell O
fate O
decisions RARE
. O

This O
mutation O
no O
longer O
repressed O
the O
HPV O
- O
11 O
upstream O
regulatory O
region O
- O
controlled O
reporter O
expression O
. O

In O
the O
icosahaedral RARE
MVMi RARE
capsid O
, O
this O
sequence O
forms O
the O
carboxy O
end O
of O
the O
amphipathic RARE
beta O
- O
strand O
I O
( O
betaI LASTCAP
), O
and O
all O
its O
basic O
residues O
are O
contiguously RARE
positioned O
at O
the O
face O
that O
in O
the O
unassembled RARE
subunit O
would O
be O
exposed O
to O
solvent O
. O

The O
two O
contiguous O
IGF2 NUMERIC
( O
human I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
) O
and O
H19 I-GENE
genes I-GENE
are O
reciprocally RARE
imprinted O
in O
both O
human O
and O
mouse O
. O

The O
asymmetric O
methylation O
was O
associated O
with O
tissue O
- O
specific O
disruption O
of O
H19 I-GENE
genomic O
imprinting O
in O
fetal O
brain O
. O

The O
comparison O
of O
the O
expression O
patterns O
of O
the O
known O
Kv4 NUMERIC
family I-GENE
members I-GENE
shows O
subtype O
specificity O
with O
significant O
overlaps RARE
. O

Early O
treatment O
mechanics RARE
of O
the O
Class O
II O
division O
2 O
malocclusion RARE
. O

Preliminary RARE
use O
of O
the O
Nottingham RARE
Eczema RARE
Severity RARE
Score RARE
would O
support O
further O
development O
as O
a O
research O
tool O
for O
a O
simple O
assessment O
of O
disease O
severity O
that O
could O
be O
used O
in O
epidemiological O
studies O
. O

The O
consensus O
highlights RARE
the O
importance O
of O
residues O
other O
than O
the O
eight O
motifs O
that O
are O
often O
associated O
with O
DEAD ALLCAPS
- I-GENE
box I-GENE
RNA I-GENE
helicases RARE
, O
as O
well O
as O
de O
- O
emphasising RARE
the O
importance O
of O
the O
" O
A O
" O
residue O
within O
the O
" O
DEAD ALLCAPS
" O
motif O
. O

Advanced RARE
adenoma RARE
was O
defined O
as O
an O
adenoma RARE
larger O
than O
10 O
mm O
or O
an O
adenoma RARE
of O
any O
size O
with O
villous RARE
component O
, O
high O
- O
grade O
dysplasia O
or O
invasive O
carcinoma O
. O

In O
transient O
assays O
, O
using O
rice O
suspension RARE
- O
cultured O
cells O
transformed O
by O
particle O
bombardment RARE
, O
we O
showed O
previously O
that O
Oshox1 NUMERIC
can O
transcriptionally O
repress O
the O
activity O
of O
reporter O
gene O
constructs O
with O
upstream O
HD I-GENE
- I-GENE
Zip I-GENE
binding O
sites O
. O

Results O
of O
two O
- O
hybrid O
assays O
and O
electrophoretic O
mobility O
shift O
assays O
strongly O
suggest O
that O
all O
HD I-GENE
- I-GENE
Zip I-GENE
proteins I-GENE
of O
families O
I O
and O
II O
can O
form O
homodimers O
and O
also O
heterodimers O
with O
all O
HD I-GENE
- I-GENE
Zip I-GENE
proteins I-GENE
of O
the O
same O
family O
. O

Among O
mammalian I-GENE
HSFs RARE
, O
HSF1 I-GENE
has O
been O
shown O
to O
be O
important O
for O
regulation O
of O
the O
heat O
- O
induced O
stress O
gene O
expression O
, O
whereas O
the O
function O
of O
HSF2 NUMERIC
in O
stress O
response O
is O
unclear O
. O

Importantly RARE
, O
concomitant O
expression O
of O
constitutive O
activated O
Raf I-GENE
and O
V12N38 NUMERIC
Ras I-GENE
results O
in O
almost O
complete O
loss O
of O
TTF I-GENE
- I-GENE
1 I-GENE
activity O
. O

They O
share O
many O
downstream O
targets O
, O
including O
remodeling O
of O
the O
actin I-GENE
cytoskeleton O
, O
activation O
of O
p70 I-GENE
( I-GENE
S6 I-GENE
) I-GENE
kinase I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
), O
and O
regulation O
of O
transcription O
and O
cell O
proliferation O
. O

Expression O
of O
activated O
Cdc42 I-GENE
results O
in O
the O
translocation O
of O
PKClambda RARE
from O
the O
nucleus O
into O
the O
cytosol O
, O
and O
Cdc42 I-GENE
and O
PKClambda RARE
colocalize RARE
at O
the O
plasma O
membrane O
and O
in O
the O
cytoplasm O
. O

Copyright O
2000 O
Academic O
Press O
. O

To O
understand O
whether O
Shc I-GENE
localization O
in O
membrane O
rafts RARE
is O
sufficient O
to O
regulate O
Shc I-GENE
function O
, O
we O
constructed O
a O
Shc I-GENE
chimera I-GENE
containing O
the O
Ras I-GENE
membrane I-GENE
localization I-GENE
motif I-GENE
at O
the O
C O
- O
terminus O
. O

Southern O
blotting O
and O
single O
strand O
conformation O
polymorphism O
analyses O
did O
not O
show O
tumor O
- O
specific O
alterations O
of O
this O
gene O
in O
gliomas RARE
and O
RT O
- O
PCR O
studies O
showed O
expression O
in O
glioma O
cell O
lines O
, O
suggesting O
that O
ANOVA ALLCAPS
is O
not O
the O
chromosome O
19q NUMERIC
glioma O
tumor O
suppressor O
gene O
. O

RegA LASTCAP
is O
a O
positive O
yet O
nonessential RARE
regulator O
of O
tol RARE
- O
oprL LASTCAP
expression O
. O

Enzyme RARE
I I-GENE
of O
the O
phosphoenolpyruvate I-GENE
: I-GENE
sugar I-GENE
phosphotransferase I-GENE
system O
. O

Based O
on O
these O
data O
, O
we O
conclude O
that O
transcription O
of O
prgX LASTCAP
is O
initiated O
from O
the O
Qa RARE
promoter I-GENE
in O
prgQ LASTCAP
, O
and O
PrgX LASTCAP
autoregulates RARE
its O
transcription O
either O
by O
mediating O
transcriptional O
readthrough O
or O
increasing O
mRNA O
stability O
. O

It O
was O
established O
that O
intrathecal RARE
or O
intraperitoneal RARE
PTFL ALLCAPS
, O
elevated O
the O
nociceptive RARE
threshold O
for O
mechanical O
stimuli O
in O
the O
formalin O
test O
in O
rats O
. O

Molecular O
mimicry RARE
of O
human O
cytokine O
and O
cytokine O
response O
pathway O
genes O
by O
KSHV O
. O

Family RARE
environment O
was O
an O
important O
influence O
on O
interpersonal RARE
relationships O
, O
substance RARE
use O
, O
and O
social O
support O
. O

By O
electrophoresis O
mobility O
shift O
assays O
using O
probes O
corresponding O
to O
different O
segments O
of O
the O
putative O
human I-GENE
c I-GENE
- I-GENE
myb I-GENE
intron I-GENE
1 I-GENE
transcription I-GENE
pause RARE
region I-GENE
and O
nuclear O
extracts O
from O
myeloid O
leukemia O
HL O
60 O
and O
fibroblast O
WI ALLCAPS
38 O
cells O
, O
we O
detected O
a O
HL O
- O
60 O
- O
specific O
DNA O
- O
protein O
complex O
with O
a O
123 O
- O
bp O
fragment O
containing O
binding O
sites O
for O
the O
interferon I-GENE
regulatory I-GENE
factors I-GENE
( O
IRFs RARE
) O
nuclear O
proteins O
. O

STUDY ALLCAPS
DESIGN O
: O
Fine RARE
needle RARE
aspiration RARE
cytologic RARE
smears O
from O
21 O
cases O
of O
invasive O
lobular RARE
carcinoma O
( O
ILC ALLCAPS
) O
of O
breast O
were O
subjected O
to O
detailed O
cytomorphologic RARE
analysis O
. O

Electrophile RARE
Response O
Elements RARE
( O
EpREs RARE
), O
located O
in O
5 O
'- O
flanking O
sequences O
of O
both O
the O
GCSh RARE
and O
GCSl RARE
subunit I-GENE
genes I-GENE
, O
are O
hypothesized RARE
to O
at O
least O
partially O
mediate O
gene O
induction O
following O
xenobiotic RARE
exposure O
. O

A O
new O
technique O
to O
create O
an O
artificial O
stenosis O
in O
the O
native O
LAD O
using O
a O
hemoclip RARE
. O

Dll3 NUMERIC
is O
mutated O
in O
the O
X O
- O
ray O
- O
induced O
mouse I-GENE
mutant I-GENE
pudgy RARE
( O
pu RARE
), O
causing O
a O
variety O
of O
vertebrocostal RARE
defects O
similar O
to O
SD O
phenotypes O
. O

Schlegel RARE
, O
J O
. O

TbRAB31 NUMERIC
behaviour O
was O
also O
studied O
during O
the O
cell O
cycle O
; O
TbRAB31 NUMERIC
always O
localised RARE
to O
a O
discrete O
structure O
that O
duplicated O
very O
early O
in O
mitosis O
and O
relocated RARE
to O
daughter O
cells O
in O
a O
coordinate O
manner O
with O
the O
basal O
body O
and O
kinetoplast RARE
, O
suggesting O
the O
involvement O
of O
microtubules RARE
. O

The O
early O
dg RARE
. O
of O
rejection O
and O
especially O
acute O
rejection O
, O
it O
' O
s O
adequate O
management O
, O
decreased O
risk O
for O
the O
future O
chronic O
rejection O
nephropathy O
. O

Invertases RARE
are O
responsible O
for O
the O
breakdown RARE
of O
sucrose O
to O
fructose O
and O
glucose O
. O

To O
investigate O
the O
molecular O
mechanisms O
of O
this O
Tax I-GENE
- O
mediated O
inhibition O
, O
we O
analyzed O
its O
effect O
on O
the O
transcriptional O
activity O
of O
the O
myogenic O
MyoD I-GENE
protein I-GENE
, O
which O
was O
used O
as O
a O
paradigm RARE
of O
bHLH I-GENE
factors I-GENE
. O

The O
human I-GENE
T I-GENE
cell I-GENE
leukemia I-GENE
/ I-GENE
lymphotropic RARE
virus I-GENE
type I-GENE
1 I-GENE
Tax I-GENE
protein I-GENE
represses O
MyoD I-GENE
- O
dependent O
transcription O
by O
inhibiting O
MyoD I-GENE
- O
binding O
to O
the O
KIX ALLCAPS
domain I-GENE
of O
p300 I-GENE
. O

Phosphorylation RARE
and O
spindle O
pole O
body O
localization O
of O
the O
Cdc15p NUMERIC
mitotic I-GENE
regulatory I-GENE
protein I-GENE
kinase I-GENE
in I-GENE
budding I-GENE
yeast I-GENE
. O

Thus O
, O
both O
the O
hyperplasia O
and O
thrombotic O
complications O
which O
often O
follow O
stenting RARE
might O
be O
minimized RARE
by O
employing O
gold RARE
stents RARE
, O
which O
have O
a O
greater O
capacity O
than O
steel RARE
in O
supporting O
a O
functional O
neo O
- O
endothelium O
. O

The O
cell O
cycle O
and O
transcriptional O
defects O
caused O
by O
taf17 NUMERIC
( O
slm7 NUMERIC
- I-GENE
1 I-GENE
) O
are O
consistent O
with O
the O
role O
of O
TAF I-GENE
( I-GENE
II I-GENE
) I-GENE
s I-GENE
as O
modulators RARE
of O
transcriptional O
activation O
and O
may O
reflect O
a O
role O
for O
TAF17 NUMERIC
in O
regulating O
activation O
by O
SBF I-GENE
and O
MBF ALLCAPS
. O

Extracellular RARE
- I-GENE
regulated I-GENE
kinase I-GENE
( O
ERK I-GENE
) O
activation O
and O
molecular O
coupling O
of O
the O
adaptor O
proteins O
p130 I-GENE
Crk I-GENE
- I-GENE
associated I-GENE
substrate I-GENE
( O
CAS I-GENE
) O
and O
c I-GENE
- I-GENE
CrkII LASTCAP
( O
Crk I-GENE
) O
represent O
two O
distinct O
pathways O
that O
induce O
cell O
invasion O
and O
protect O
cells O
from O
apoptosis O
in O
a O
three O
- O
dimensional O
collagen I-GENE
matrix O
. O

Proteolysis RARE
of O
Mbp1 NUMERIC
and O
Swi4 NUMERIC
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
has O
revealed O
the O
extent O
of O
these O
sequences O
, O
and O
C O
- O
terminally O
extended O
molecules O
with O
substantially O
enhanced O
DNA O
binding O
activity O
compared O
to O
the O
core O
domains O
alone O
have O
been O
produced O
. O

The O
evolution O
of O
the O
CCR5 NUMERIC
cis I-GENE
- I-GENE
regulatory I-GENE
region I-GENE
versus O
the O
open O
reading O
frame O
as O
well O
as O
among O
different O
domains O
of O
the O
open O
reading O
frame O
differed O
from O
one O
another O
. O

These O
results O
indicate O
that O
residue O
266 NUMERIC
serves O
as O
a O
" O
protein O
sensor RARE
" O
of O
altered O
minor O
groove O
interactions O
and O
identifies O
which O
base O
pair O
interactions O
are O
altered O
by O
these O
lesions O
. O

The O
recombinant O
enzymes O
exist O
as O
monomers RARE
. O

A O
pathway O
for O
regulation O
of O
B I-GENE
lymphocyte I-GENE
antigen I-GENE
receptor I-GENE
- O
induced O
calcium O
flux RARE
. O

We O
now O
describe O
a O
second O
RIM ALLCAPS
protein I-GENE
, O
called O
RIM2 NUMERIC
, O
that O
is O
highly O
homologous O
to O
RIM1 NUMERIC
and O
also O
expressed O
primarily O
in O
brain O
. O

Inhibitor RARE
- I-GENE
1 I-GENE
( O
I I-GENE
- I-GENE
1 I-GENE
) O
and O
inhibitor I-GENE
- I-GENE
2 I-GENE
( O
I I-GENE
- I-GENE
2 I-GENE
) O
selectively O
inhibit O
type I-GENE
1 I-GENE
protein I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
phosphatases I-GENE
( O
PP1 NUMERIC
). O

Scanning RARE
mutations O
throughout O
the O
AC O
element O
interfered RARE
with O
induction O
but O
allowed O
us O
to O
define O
five O
overlapping O
sites O
for O
regulatory O
factors O
in O
AC O
and O
to O
design O
probes O
binding O
just O
one O
or O
two O
factors O
. O

The O
substrates O
for O
glycan RARE
synthesis O
in O
the O
lumen RARE
of O
the O
Golgi O
are O
nucleotide O
sugars O
that O
must O
be O
transported O
from O
the O
cytosol O
by O
specific O
membrane O
- O
bound O
transporters O
. O

Synaptic RARE
targeting O
of O
the O
postsynaptic RARE
density I-GENE
protein I-GENE
PSD ALLCAPS
- I-GENE
95 I-GENE
mediated O
by O
a O
tyrosine O
- O
based O
trafficking O
signal O
. O

( O
1998 O
) O
J O
. O

Bites RARE
by O
two O
species O
of O
adders RARE
( O
Vipera RARE
aspis RARE
and O
Vipera RARE
berus RARE
) O
can O
lead O
to O
extensive O
swelling O
with O
multiorgan RARE
failure O
. O

Both O
normal O
and O
transforming O
PCPH ALLCAPS
proteins I-GENE
have O
guanosine RARE
diphosphatase RARE
activity O
but O
only O
the O
oncoprotein O
cooperates RARE
with O
Ras I-GENE
in O
activating O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
ERK1 I-GENE
. O

These O
results O
indicate O
that O
virulence O
- O
associated O
genes O
and O
their O
overall O
chromosomal O
arrangement O
are O
relatively O
well O
conserved O
between O
B O
. O
henselae RARE
and O
other O
gram O
- O
negative O
bacteria O
such O
as O
A O
. O
tumefaciens RARE
. O

An O
important O
mechanism O
by O
which O
the O
tumor O
suppressor O
p53 I-GENE
maintains O
genomic O
stability O
is O
to O
induce O
cell O
cycle O
arrest O
through O
activation O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor O
p21 I-GENE
( O
WAF1 I-GENE
/ O
Cip1 I-GENE
) O
gene O
. O

Paxillin RARE
acts O
as O
an O
adaptor O
molecule O
in O
integrin I-GENE
signaling O
. O

Thus O
, O
growth O
factor O
activation O
of O
ER I-GENE
can O
mediate O
transactivation O
vs O
ER I-GENE
/ O
Sp1 I-GENE
binding O
to O
GC O
- O
rich O
sites O
and O
represents O
a O
novel O
pathway O
for O
ligand O
- O
independent O
ER I-GENE
action O
. O

Furthermore O
, O
analysis O
of O
deletion O
promoter O
- O
reporter O
constructs O
found O
that O
the O
basal O
activity O
of O
P2 O
resided RARE
in O
the O
proximal O
region O
of O
P2 O
. O

RESULTS O
: O
Auditory RARE
thresholds RARE
collected O
during O
audiometric RARE
tests O
increased O
gradually O
in O
proportion O
with O
age O
, O
especially O
in O
the O
hypertensive O
group O
( O
p O
< O
0 O
. O
05 O
). O

In O
addition O
, O
the O
transcription O
of O
c I-GENE
- I-GENE
IAP2 NUMERIC
promoter I-GENE
was O
strongly O
up O
- O
regulated O
when O
CD40 I-GENE
or O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
was O
overexpressed O
. O

A O
variety O
of O
professional RARE
and O
self O
- O
applied O
fluoride O
products O
are O
available O
and O
new O
fluoride O
delivery O
systems O
have O
recently O
entered RARE
the O
market RARE
. O

These O
studies O
identify O
several O
of O
the O
signal O
- O
transduction O
events O
involved O
in O
the O
apoptosis O
of O
malignant O
B O
cells O
that O
transpire RARE
following O
ligation O
of O
CD20 NUMERIC
by O
anti I-GENE
- I-GENE
CD20 NUMERIC
antibodies I-GENE
in O
the O
presence O
of O
Fc I-GENE
- I-GENE
receptor I-GENE
- O
expressing O
cells O
or O
secondary O
goat RARE
anti I-GENE
-( I-GENE
mouse I-GENE
Ig I-GENE
) I-GENE
antibodies I-GENE
and O
which O
may O
contribute O
to O
the O
tumor O
regressions RARE
observed O
in O
mouse O
models O
and O
clinical O
trials O
. O

CONCLUSION O
: O
Treatment O
of O
sepsis O
with O
the O
platelet I-GENE
- I-GENE
activating I-GENE
factor I-GENE
antagonist O
BB O
- O
882 NUMERIC
offers O
no O
advantage O
over O
placebo O
on O
survival O
, O
hemodynamic O
status O
, O
respiratory O
function O
, O
or O
organ O
failure O
scores O
. O

Phenazone RARE
potentiates O
the O
local O
anaesthetic RARE
effect O
of O
lidocaine O
in O
mice O
. O

The O
solubility RARE
of O
all O
the O
mutated O
proteins O
was O
remarkably O
reduced O
. O

Recently O
, O
identical O
RBE ALLCAPS
sequences I-GENE
have O
been O
identified O
at O
other O
locations O
in O
the O
human O
genome O
. O

EM O
analysis O
demonstrated O
that O
only O
one O
Rep I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
was O
formed O
on O
ch RARE
- O
19 O
target O
DNA O
. O

The O
protein O
was O
associated O
with O
purified O
vaccinia O
virus O
particles O
and O
with O
membranes O
of O
immature O
and O
mature O
virions O
that O
were O
visualized RARE
by O
electron O
microscopy O
of O
infected O
cells O
. O

In O
vivo O
dimethyl O
sulfate O
footprinting O
of O
the O
cyclin I-GENE
E I-GENE
promoter I-GENE
revealed O
several O
regions O
of O
protection O
and O
hypersensitivity O
that O
were O
unique O
to O
infected O
cells O
. O

A O
total O
of O
194 NUMERIC
STSs RARE
map O
to O
this O
interval O
of O
3 O
Mb O
, O
giving O
an O
average O
marker O
resolution O
of O
approximately O
one O
per O
15 O
kb O
. O

Recently O
, O
a O
mutation O
in O
the O
amino O
- O
terminus O
of O
IB1 NUMERIC
was O
associated O
with O
diabetes O
. O

CONCLUSION O
: O
More O
than O
50 O
% O
of O
patients O
with O
perennial RARE
rhinitis RARE
and O
CRS O
do O
not O
improve O
after O
surgery O
, O
a O
response O
that O
may O
be O
predicted O
by O
more O
cells O
expressing O
IL I-GENE
- I-GENE
5 I-GENE
mRNA I-GENE
in O
the O
ethmoid RARE
sinuses RARE
. O

Biol O
. O

On O
the O
basis O
of O
size O
, O
the O
CRS O
sequence O
to O
which O
it O
binds O
, O
and O
its O
tentative RARE
identification O
as O
a O
zinc I-GENE
finger I-GENE
protein I-GENE
, O
Adx RARE
factor I-GENE
has O
been O
identified O
as O
a O
Kruppel RARE
- I-GENE
like I-GENE
zinc I-GENE
finger I-GENE
protein I-GENE
( O
a O
mouse I-GENE
ZBP ALLCAPS
- I-GENE
89 I-GENE
homologue I-GENE
). O

METHODS O
: O
The O
most O
distal O
muscle O
fibres O
from O
the O
deep O
and O
superficial O
finger O
flexors RARE
were O
measured O
relative O
to O
the O
pisiform RARE
bone O
in O
18 O
cadaveric RARE
specimens O
. O

Here O
we O
report O
on O
the O
isolation O
of O
ICK2 NUMERIC
, O
and O
show O
that O
it O
interacts O
with O
Cdc2aAt NUMERIC
, O
but O
not O
with O
a O
second O
CDK I-GENE
from I-GENE
Arabidopsis I-GENE
, O
Cdc2bAt NUMERIC
. O

Systemic RARE
impact O
of O
risk O
- O
sharing RARE
arrangements RARE
. O

METHODS O
: O
We O
determined O
an O
odds O
ratio O
( O
OR O
), O
as O
a O
measure O
of O
the O
relative O
risk O
of O
being O
exposed O
to O
a O
potential O
interaction O
, O
comparing O
the O
use O
of O
the O
H2 I-GENE
- I-GENE
receptor I-GENE
antagonist O
, O
cimetidine O
, O
with O
that O
of O
the O
noninteracting RARE
agents O
ranitidine O
, O
famotidine RARE
and O
nizatidine RARE
in O
users O
and O
nonusers RARE
of O
warfarin RARE
, O
phenytoin O
and O
theophylline O
. O

The O
prevalence O
of O
malnutrition RARE
was O
30 O
% O
in O
the O
47 O
patients O
without O
CVD ALLCAPS
and O
was O
significantly O
higher O
( O
70 O
%, O
P O
< O
0 O
. O
001 O
) O
in O
the O
70 O
patients O
with O
CVD ALLCAPS
, O
who O
also O
had O
lower O
tHcy RARE
, O
SAlb RARE
, O
plasma I-GENE
IGF I-GENE
- I-GENE
1 I-GENE
, O
serum O
creatinine O
( O
SCr RARE
), O
and O
blood I-GENE
hemoglobin I-GENE
. O

Our O
data O
suggest O
that O
, O
at O
least O
at O
high O
temperature O
, O
a O
critical O
minimal O
level O
of O
Ypt RARE
protein I-GENE
prenylation RARE
is O
required O
for O
maintaining O
vesicle O
polarization RARE
. O

The O
second O
functional O
pair O
of O
CreA LASTCAP
sites I-GENE
is O
located O
between O
the O
two O
transcription O
initiation O
sites O
. O

A O
distinct O
staining O
pattern O
for O
the O
N I-GENE
- I-GENE
utrophin RARE
was O
not O
detectable O
, O
although O
it O
was O
expected O
to O
localise RARE
at O
the O
actin I-GENE
stress O
fibers O
. O

The O
' O
Newcastle RARE
' O
model O
, O
which O
is O
based O
on O
Hotelling RARE
' O
s O
T2 O
statistic RARE
, O
proved O
to O
be O
more O
sensitive O
and O
diagnosed O
a O
systematic O
displacement O
for O
three O
prostate O
patients O
. O

The O
MMA ALLCAPS
, I-GENE
DMA ALLCAPS
, I-GENE
and I-GENE
TMA ALLCAPS
methyltransferases RARE
are O
not O
homologs O
; O
however O
, O
like O
the O
MMA ALLCAPS
methyltransferase I-GENE
gene I-GENE
, O
the O
genes O
encoding O
the O
DMA ALLCAPS
and I-GENE
TMA ALLCAPS
methyltransferases RARE
each O
contain O
a O
single O
in O
- O
frame O
amber RARE
codon O
. O

After O
phosphorylation O
, O
STAT I-GENE
proteins I-GENE
are O
transported O
into O
the O
nucleus O
and O
exhibit O
transcriptional O
activity O
. O

Overexpression O
of O
mcl RARE
- I-GENE
1 I-GENE
is O
sufficient O
to O
protect O
against O
apoptosis O
, O
while O
transfection O
of O
a O
mcl RARE
- I-GENE
1 I-GENE
antisense O
plasmid O
causes O
cell O
death O
. O

Thus O
, O
although O
multiple O
senescence RARE
pathways O
are O
activated O
in O
response O
to O
a O
ras I-GENE
oncogene I-GENE
, O
inactivation O
of O
TGFbeta1 NUMERIC
secretion O
or O
response O
is O
sufficient O
to O
block O
the O
senescence RARE
program O
. O

In O
this O
study O
, O
the O
abilities O
of O
constitutive O
and O
conditional O
forms O
of O
the O
three O
Raf I-GENE
kinases I-GENE
to O
abrogate O
the O
cytokine O
dependency RARE
of O
FDC ALLCAPS
- O
P1 O
cells O
were O
examined O
. O

Application RARE
of O
the O
method O
to O
a O
representative O
set O
of O
50 O
known O
genes O
from O
Arabidopsis O
thaliana O
showed O
significant O
improvement O
in O
prediction O
accuracy O
compared O
to O
previous O
spliced O
alignment O
methods O
. O

The O
complete O
cDNA O
sequence O
of O
human I-GENE
betaV LASTCAP
spectrin I-GENE
is O
available O
from O
GenBank RARE
( O
TM O
) O
as O
accession RARE
number O
. O

Transactivation RARE
of O
naturally O
occurring O
HIV I-GENE
- I-GENE
1 I-GENE
long I-GENE
terminal I-GENE
repeats I-GENE
by O
the O
JNK I-GENE
signaling O
pathway O
. O

These O
data O
show O
that O
the O
alpha O
- O
helix O
domain O
of O
p57 NUMERIC
( O
Kip2 NUMERIC
), O
which O
is O
conserved O
in O
the O
Cip RARE
/ O
Kip RARE
proteins O
, O
is O
implicated O
in O
protein O
- O
protein O
interaction O
and O
confers O
a O
specific O
regulatory O
mechanism O
, O
outside O
of O
their O
Cdk I-GENE
- O
inhibitory O
activity O
, O
by O
which O
the O
p57 NUMERIC
( O
Kip2 NUMERIC
) O
family O
members O
positively O
act O
on O
myogenic O
differentiation O
. O

The O
mode O
of O
resistance O
to O
quinupristin RARE
/ O
dalfopristin RARE
was O
not O
evident O
( O
sat RARE
A O
- O
negative O
by O
PCR O
); O
and O
these O
cases O
illustrate RARE
the O
existence O
of O
streptogramin RARE
- O
resistant O
isolates O
before O
the O
introduction O
of O
this O
antimicrobial O
class O
into O
human O
clinical O
practice O
. O

This O
study O
was O
carried O
out O
to O
analyze O
PRL I-GENE
secretion O
in O
metastatic O
prostate O
cancer O
patients O
both O
at O
basal O
conditions O
and O
in O
response O
to O
L O
- O
Dopa RARE
and O
metoclopramide RARE
, O
which O
represents O
the O
most O
classical O
inhibitory O
and O
stimulatory O
tests O
for O
PRL I-GENE
secretion O
, O
respectively O
. O

Integrin RARE
adhesion I-GENE
receptors I-GENE
transduce RARE
signals O
that O
control O
complex O
cell O
functions O
which O
require O
the O
regulation O
of O
gene O
expression O
, O
such O
as O
proliferation O
, O
differentiation O
and O
survival O
. O

Recombination RARE
, O
replication O
, O
repair O
: O
from O
complexity O
to O
harmony RARE
. O

The O
somatoform RARE
conundrum RARE
: O
a O
question O
of O
nosological RARE
valves RARE
. O

Intra RARE
- O
operative O
ultrasound O
( O
IOUS ALLCAPS
) O
has O
been O
widely O
used O
in O
an O
attempt O
to O
overcome O
these O
difficulties RARE
, O
but O
is O
limited O
by O
its O
two O
- O
dimensional O
nature O
, O
inter RARE
- O
user RARE
variability O
, O
and O
image O
obliteration RARE
with O
ablative RARE
or O
resectional RARE
techniques O
. O

CONCLUSIONS O
: O
This O
randomized O
study O
shows O
that O
Vivostat RARE
fibrin I-GENE
sealant RARE
is O
effective O
in O
preventing O
air O
leakage RARE
after O
small O
lung O
resections RARE
in O
pigs O
, O
even O
at O
high O
inspiratory O
pressures O
. O

Hailey RARE
- O
Hailey RARE
disease O
is O
caused O
by O
mutations O
in O
ATP2C1 NUMERIC
encoding O
a O
novel O
Ca O
( O
2 O
+) O
pump O
. O

Hex RARE
is O
expressed O
in O
the O
developing O
liver O
coincident RARE
with O
the O
forkhead RARE
/ O
winged RARE
helix I-GENE
transcription O
factor O
, O
Hepatocyte RARE
Nuclear I-GENE
Factor I-GENE
3beta NUMERIC
( O
HNF3beta NUMERIC
). O

As O
an O
extension O
of O
our O
structural O
characterization O
of O
the O
exon O
- O
intron O
organization O
of O
the O
mouse I-GENE
Pkr RARE
gene I-GENE
, O
we O
now O
have O
isolated O
and O
characterized O
the O
mouse I-GENE
Pkr RARE
promoter I-GENE
region I-GENE
required O
for O
IFN I-GENE
- O
inducible O
transcription O
. O

The O
CRE O
, O
5 O
'- O
TGACGTCA ALLCAPS
- O
3 O
', O
has O
been O
described O
as O
the O
consensus O
sequence O
for O
the O
cis O
- O
element O
that O
directs O
cAMP O
- O
regulated O
gene O
expression O
. O

Kidney RARE
length O
did O
not O
significantly O
differ O
between O
right O
and O
left O
, O
however O
, O
kidney O
width RARE
, O
cortical O
thickness O
and O
size O
did O
( O
p O
< O
0 O
. O
05 O
). O

The O
clinical O
stage O
was O
I O
( O
T1N0M0 NUMERIC
), O
and O
S2 O
sleeve RARE
segmentectomy RARE
with O
lymph O
node O
dissection O
( O
R O
2 O
b O
) O
was O
performed O
. O

Benztropine RARE
for O
venlafaxine RARE
- O
induced O
night O
sweats RARE
. O

A O
cause O
of O
increase O
of O
alkaline I-GENE
phosphatase I-GENE
in O
children O

The O
physicians O
in O
charge O
of O
all O
patients O
with O
evidence O
of O
acute O
Q O
fever O
( O
seroconversion RARE
and O
/ O
or O
presence O
of O
IgM I-GENE
) O
or O
chronic O
Q O
fever O
( O
prolonged O
disease O
and O
/ O
or O
IgG I-GENE
antibody I-GENE
titer O
to O
phase O
I O
of O
Coxiella RARE
burnetii RARE
> O
or O
= O
800 O
) O
were O
asked RARE
to O
complete O
a O
questionnaire O
, O
which O
was O
computerized O
. O

Copyright O
2000 O
Academic O
Press O
. O

Viral RARE
cell O
- O
to O
- O
cell O
movement O
of O
PVX ALLCAPS
CP I-GENE
mutant I-GENE
was O
complemented O
in O
Nicotiana RARE
tabacum RARE
cv O
. O

Induction O
of O
CD86 NUMERIC
expression O
by O
stimulation O
of O
U937 O
cells O
with O
IFN I-GENE
- I-GENE
gamma I-GENE
revealed O
the O
presence O
of O
two O
functional O
GAS ALLCAPS
( O
gamma I-GENE
- I-GENE
interferon I-GENE
activation I-GENE
site I-GENE
) O
elements O
. O

Significantly O
, O
two O
proximal O
GATA I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
(- O
118 O
/- O
113 O
and O
- O
98 O
/- O
93 O
) O
and O
a O
region O
located O
within O
- O
518 NUMERIC
to O
- O
315bp NUMERIC
of O
the O
mouse I-GENE
ALAS2 NUMERIC
promoter I-GENE
were O
essential O
for O
transcriptional O
activation O
during O
chemically RARE
induced O
differentiation O
of O
MEL ALLCAPS
cells O
, O
implying O
their O
importance O
in O
conferring O
erythroid O
specificity O
to O
the O
ALAS2 NUMERIC
transcriptional O
activation O
. O

SNAP ALLCAPS
- I-GENE
23 I-GENE
plays O
an O
important O
role O
in O
the O
regulation O
of O
vesicle O
trafficking O
in O
mammalian O
cells O
. O

The O
HMG I-GENE
domain I-GENE
of O
both O
HMG20 NUMERIC
proteins I-GENE
is O
most O
similar O
to O
that O
of O
yeast I-GENE
NHP6A NUMERIC
( O
38 O
% O
to O
42 O
%). O

IgM I-GENE
and O
IgG I-GENE
anti I-GENE
A I-GENE
and O
anti I-GENE
B I-GENE
antibody I-GENE
status O
of O
100 O
antenatal RARE
O O
group O
mothers O
( O
who O
had O
non O
O O
group O
husbands RARE
) O
were O
studied O
. O

In O
an O
attempt O
to O
understand O
Wee1 I-GENE
regulation O
during O
cell O
cycle O
, O
yeast O
two O
- O
hybrid O
screening O
was O
used O
to O
identify O
Wee1 O
- O
binding O
protein O
( O
s O
). O

Retroviral RARE
transduction O
of O
T I-GENE
/ I-GENE
T I-GENE
( I-GENE
L I-GENE
) I-GENE
causes O
a O
rapidly O
fatal O
myeloproliferative RARE
disease O
in O
a O
murine O
bone O
marrow O
transplant O
( O
BMT ALLCAPS
) O
model O
, O
whereas O
T I-GENE
/ I-GENE
T I-GENE
( I-GENE
F I-GENE
) I-GENE
causes O
a O
long O
- O
latency O
, O
pre O
- O
B O
- O
cell O
lymphoblastic RARE
lymphoma O
. O

Ab O
- O
MLV ALLCAPS
strains O
expressing O
P70 NUMERIC
/ O
S2 I-GENE
failed O
to O
transform O
NIH O
3T3 O
cells O
and O
demonstrated O
a O
greatly O
reduced O
capacity O
to O
mediate O
signaling O
events O
associated O
with O
the O
Ras I-GENE
- O
dependent O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
pathway O
. O

The O
codon O
usage O
is O
particularly O
marked O
for O
the O
gag I-GENE
, O
pol I-GENE
, O
and O
env I-GENE
genes I-GENE
. O

The O
p53 I-GENE
- I-GENE
homolog I-GENE
p73beta NUMERIC
also O
activated O
the O
PIG3 NUMERIC
promoter I-GENE
, O
but O
in O
contrast O
to O
p53 I-GENE
, O
the O
proline O
- O
rich O
domain O
of O
p73beta NUMERIC
( I-GENE
residues I-GENE
81 I-GENE
- I-GENE
113 I-GENE
) I-GENE
was O
dispensable O
to O
induce O
the O
PIG3 NUMERIC
promoter I-GENE
. O

Results O
from O
transient O
assays O
using O
these O
mutants O
showed O
that O
the O
DE1 NUMERIC
received O
signals O
from O
phytochromes RARE
A I-GENE
and I-GENE
B I-GENE
, O
demonstrating O
that O
this O
element O
is O
indeed O
a O
light O
- O
responsive O
element O
. O

Co O
- O
immunoprecipitation O
and O
DNA O
affinity O
chromatography O
prove O
that O
Sp1 I-GENE
heterodimerizes RARE
with O
ZBP ALLCAPS
- I-GENE
89 I-GENE
when O
bound O
to O
the O
silencer O
element O
to O
yield O
a O
DNA O
- O
protein O
complex O
whose O
mobility O
is O
indistinguishable O
from O
that O
displayed O
by O
HeLa O
nuclear O
extract O
in O
band O
shift O
assays O
. O

The O
ZNF274 NUMERIC
gene I-GENE
is O
mapped O
distal O
to O
marker O
RP O
S28 NUMERIC
1 O
in O
the O
human O
chromosome O
19qter NUMERIC
region O
, O
by O
RH O
mapping O
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
Cdk2 I-GENE
truncations RARE
, O
however O
, O
were O
non O
- O
functional O
in O
these O
strains O
and O
thus O
dependent O
for O
activity O
on O
the O
pho85 NUMERIC
coding I-GENE
region I-GENE
which O
remained O
in O
the O
mutant I-GENE
pho85 NUMERIC
:: O
HIS3 I-GENE
chromosomal I-GENE
locus I-GENE
. O

We O
report O
here O
on O
the O
molecular O
nature O
of O
an O
EMS ALLCAPS
- O
induced O
mutant O
, O
mn1 NUMERIC
- I-GENE
89 I-GENE
, O
a O
leaky RARE
semidominant RARE
allele O
of O
the O
Miniature1 NUMERIC
( O
Mn1 NUMERIC
) O
seed O
locus O
that O
encodes O
a O
seed I-GENE
- I-GENE
specific I-GENE
cell I-GENE
wall I-GENE
invertase RARE
, O
INCW2 NUMERIC
. O

We O
conclude O
that O
, O
both O
in O
atrial O
myocytes RARE
and O
in O
Xenopus O
oocytes O
, O
beta O
- O
adrenergic O
stimulation O
potentiates O
the O
ACh RARE
- O
evoked O
GIRK ALLCAPS
channels I-GENE
via O
a O
pathway O
that O
involves O
PKA I-GENE
- O
catalyzed O
phosphorylation O
downstream O
from O
beta I-GENE
( I-GENE
2 I-GENE
) I-GENE
AR I-GENE
. O

Slap RARE
negatively O
regulates O
Src I-GENE
mitogenic O
function O
but O
does O
not O
revert RARE
Src I-GENE
- O
induced O
cell O
morphology O
changes O
. O

Identification O
of O
a O
novel O
E2F3 NUMERIC
product I-GENE
suggests O
a O
mechanism O
for O
determining O
specificity O
of O
repression O
by O
Rb I-GENE
proteins I-GENE
. O

In O
DNase I-GENE
I I-GENE
footprinting O
protection O
analysis O
, O
both O
SFRE ALLCAPS
and O
ERE ALLCAPS
regions O
were O
protected O
by O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
- O
ERRalpha1 NUMERIC
fusion O
protein O
. O

Overexpressing RARE
the O
coactivator O
, O
SRC1a NUMERIC
or O
GRIP1 NUMERIC
, O
further O
enhances O
ERRalpha1 NUMERIC
- O
induced O
transcriptional O
activity O
. O

Estrogen RARE
receptor I-GENE
- I-GENE
related I-GENE
receptor I-GENE
alpha I-GENE
1 I-GENE
interacts O
with O
coactivator O
and O
constitutively O
activates O
the O
estrogen O
response O
elements O
of O
the O
human I-GENE
lactoferrin RARE
gene I-GENE
. O

We O
examine O
current O
models O
of O
the O
effects O
of O
aging O
on O
mean O
response O
time O
and O
show O
how O
they O
might O
be O
reinterpreted RARE
. O

The O
effects O
of O
these O
mutations O
on O
protein O
function O
require O
further O
examination O
. O

The O
median O
levels O
of O
particles O
with O
50 O
% O
cut O
- O
off O
aerodynamic RARE
diameters O
of O
10 O
( O
PM10 NUMERIC
) O
and O
2 O
. O
5 O
microm O
( O
PM2 NUMERIC
. O
5 O
) O
were O
170 O
( O
range O
103 NUMERIC
- O
613 NUMERIC
) O
and O
95 O
( O
range O
61 O
- O
218 NUMERIC
) O
micro O
x O
m O
- O
3 O
, O
respectively O
. O

Kaposi O
' O
s O
sarcoma O
- O
associated O
herpesvirus O
viral I-GENE
interferon I-GENE
regulatory I-GENE
factor I-GENE
confers O
resistance O
to O
the O
antiproliferative RARE
effect O
of O
interferon I-GENE
- I-GENE
alpha I-GENE
. O

Specific O
and O
heritable RARE
genetic O
interference O
by O
double O
- O
stranded O
RNA O
in O
Arabidopsis O
thaliana O
. O

Comparison O
of O
sequences O
from O
- O
215 O
to O
+ O
1 O
bp O
identified O
consensus O
binding O
sites O
for O
the O
homeodomain I-GENE
transcription I-GENE
factor I-GENE
thyroid I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
TTF I-GENE
- I-GENE
1 I-GENE
). O

Two O
additional O
cis O
- O
acting O
sequences O
, O
conserved O
in O
both O
the O
region O
1 O
and O
3 O
promoters O
, O
were O
identified O
, O
suggesting O
a O
role O
for O
these O
sequences O
in O
the O
coordinate O
regulation O
of O
transcription O
from O
these O
promoters O
. O

Purple RARE
photosynthetic RARE
bacteria O
are O
capable O
of O
generating O
cellular O
energy O
from O
several O
sources O
, O
including O
photosynthesis RARE
, O
respiration O
, O
and O
H O
( O
2 O
) O
oxidation O
. O

An O
analysis O
of O
synthetic O
peptides O
revealed O
a O
minimal O
CTD O
sequence O
that O
is O
sufficient O
to O
bind O
to O
the O
second O
Rsp5 NUMERIC
WW ALLCAPS
domain I-GENE
( O
Rsp5 NUMERIC
WW2 NUMERIC
) O
in O
vitro O
and O
in O
yeast O
two O
- O
hybrid O
assays O
. O

Furthermore O
, O
bone O
marrow O
- O
derived O
macrophages O
from O
LAT ALLCAPS
- O
deficient O
mice O
displayed O
reduced O
phagocytic O
efficiency O
in O
comparison O
to O
the O
macrophages O
from O
wild O
- O
type O
mice O
. O

T1 O
- O
weighted O
MRI O
on O
the O
49th NUMERIC
postoperative O
day O
demonstrated O
bilateral O
and O
symmetrical RARE
hyperintense RARE
lesions O
in O
the O
globus RARE
pallidus RARE
. O

The O
method O
is O
applied O
to O
determine O
aberration RARE
constants O
of O
a O
CM300 NUMERIC
FEG ALLCAPS
/ O
UT O
microscope RARE
with O
correction O
of O
the O
three O
- O
fold O
astigmatism RARE
. O

The O
interaction O
does O
not O
depend O
on O
the O
presence O
of O
the O
correct O
amino O
- O
terminal O
DNA O
binding O
domain O
or O
the O
amino O
acid O
sequences O
between O
the O
DNA O
binding O
domain O
and O
the O
last O
ten O
amino O
acids O
. O

METHOD ALLCAPS
: O
The O
sample O
of O
subjects O
was O
drawn RARE
from O
the O
Suffolk RARE
County RARE
Mental RARE
Health O
Project RARE
, O
a O
longitudinal O
epidemiologic RARE
study O
of O
first O
- O
hospitalized O
subjects O
with O
psychotic RARE
disorders O
; O
the O
present O
study O
focused O
on O
patients O
with O
schizophrenic O
disorders O
. O

Marrow RARE
dysplasia O
is O
a O
major O
characteristic O
of O
patients O
with O
myelodysplastic RARE
syndrome O
( O
MDS ALLCAPS
), O
along O
with O
marrow O
blastosis RARE
, O
cytopenia RARE
and O
cytogenetic O
anomalies O
. O

Eight O
of O
the O
non O
- O
acceptable O
inlays RARE
/ O
onlays RARE
and O
five O
of O
the O
direct O
restorations O
were O
replaced O
, O
while O
the O
other O
ones O
were O
repaired RARE
with O
resin O
composite O
. O

How RARE
plants O
respond O
to O
attack RARE
by O
the O
range O
of O
herbivores RARE
and O
pathogens O
that O
confront RARE
them O
in O
the O
field O
is O
the O
subject O
of O
considerable O
research O
by O
both O
molecular O
biologists RARE
and O
ecologists RARE
. O

CONCLUSION O
: O
The O
probability RARE
of O
cardiopulmonary O
complications O
increases O
significantly O
when O
patients O
develop O
class O
1 O
HELLP ALLCAPS
syndrome O
. O

The O
rate O
- O
limiting O
step O
for O
telomerase I-GENE
activity O
seems O
to O
be O
the O
expression O
of O
the O
catalytic O
subunit O
of O
the O
enzyme O
, O
encoded O
by O
the O
human I-GENE
telomerase I-GENE
reverse I-GENE
transcriptase I-GENE
( O
hTERT LASTCAP
) O
gene O
. O

In O
the O
control O
group O
, O
platelet O
markers O
increased O
1 O
h O
after O
surgery O
. O

However O
, O
the O
element O
proximal O
to O
the O
transcription O
start O
site O
is O
dependent O
on O
the O
SRE O
- O
1 O
. O

AMDA ALLCAPS
white O
paper O
identifies O
ways O
to O
improve O
pharmaceutical RARE
care O
in O
SNFs RARE
. O

Since O
proteins O
containing O
TPR O
elements O
are O
typically O
involved O
in O
multiple O
protein O
- O
protein O
interactions O
, O
we O
suggest O
that O
the O
102kD NUMERIC
protein O
interacts O
within O
the O
tri RARE
- O
snRNP O
with O
both O
the O
U5 I-GENE
and O
U4 I-GENE
/ O
U6 I-GENE
snRNPs O
, O
thus O
bridging RARE
the O
two O
particles O
. O

Antibodies O
raised O
against O
a O
C O
- O
terminal O
portion O
of O
Sec31A NUMERIC
co O
- O
precipitate RARE
Sec13 NUMERIC
and O
inhibit O
ER O
- O
Golgi O
transport O
of O
temperature O
- O
arrested O
vesicular O
stomatitis I-GENE
G I-GENE
protein I-GENE
in O
a O
semi RARE
- O
intact O
cell O
assay O
. O

Regulation O
of O
mitochondrial O
single O
- O
stranded O
DNA O
- O
binding O
protein O
gene O
expression O
links O
nuclear O
and O
mitochondrial O
DNA O
replication O
in O
drosophila RARE
. O

Genetic O
and O
molecular O
complexity O
of O
the O
position O
effect O
variegation RARE
modifier RARE
mod RARE
( O
mdg4 NUMERIC
) O
in O
Drosophila O
. O
mod RARE
( O
mdg4 NUMERIC
), O
also O
known O
as O
E I-GENE
( I-GENE
var I-GENE
) I-GENE
3 I-GENE
- I-GENE
93D NUMERIC
, O
is O
involved O
in O
a O
variety O
of O
processes O
, O
such O
as O
gene O
silencing O
in O
position O
effect O
variegation RARE
( O
PEV ALLCAPS
), O
the O
control O
of O
gypsy RARE
insulator RARE
sequences I-GENE
, O
regulation O
of O
homeotic I-GENE
gene I-GENE
expression O
, O
and O
programmed O
cell O
death O
. O

They O
are O
present O
in O
many O
kinds RARE
of O
living O
things RARE
, O
but O
their O
functions O
, O
especially O
those O
in O
humans O
, O
are O
unclear O
. O

This O
tendency O
is O
likely O
due O
to O
the O
biased RARE
nucleotide O
composition O
of O
the O
asparagus RARE
genome O
, O
rather O
than O
to O
the O
translational O
selection O
for O
specific O
codons O
. O

Transduction RARE
of O
the O
human O
leukemic RARE
cell O
line O
K562 O
showed O
that O
viral O
MRP1 NUMERIC
- O
PG13 NUMERIC
supernatants RARE
routinely RARE
transfer O
the O
MRP1 NUMERIC
gene I-GENE
to O
approximately O
35 O
% O
of O
target O
K562 O
cells O
, O
of O
which O
at O
least O
one O
third O
are O
capable O
of O
proliferating O
in O
the O
presence O
of O
otherwise O
toxic O
concentrations O
of O
etoposide RARE
. O

Regulation O
of O
pituitary O
vasopressin I-GENE
V1b NUMERIC
receptors I-GENE
plays O
a O
critical O
role O
in O
regulating O
pituitary I-GENE
adrenocorticotropic RARE
hormone I-GENE
( O
ACTH I-GENE
) O
secretion O
during O
adaptation O
to O
stress O
. O

Identification O
of O
an O
AfsA LASTCAP
homologue I-GENE
( O
BarX LASTCAP
) O
from O
Streptomyces O
virginiae RARE
as O
a O
pleiotropic O
regulator O
controlling O
autoregulator RARE
biosynthesis O
, O
virginiamycin RARE
biosynthesis O
and O
virginiamycin RARE
M1 O
resistance O
. O

Because O
the O
mutant O
defective O
in O
DNA O
binding O
also O
fails O
to O
stimulate O
Abf1 NUMERIC
ARS1 NUMERIC
DNA O
- O
binding O
activity O
, O
our O
results O
suggest O
that O
Cdc6 NUMERIC
DNA O
- O
binding O
activity O
may O
play O
a O
pivotal O
role O
in O
the O
initiation O
of O
DNA O
replication O
. O

Given RARE
its O
relative O
longevity RARE
on O
the O
Web RARE
, O
TIE ALLCAPS
researchers RARE
have O
been O
in O
a O
unique O
position O
to O
observe O
trends RARE
in O
telemedicine RARE
. O

The O
structural O
study O
of O
peptides O
belonging O
to O
the O
terminal O
domains O
of O
histone I-GENE
H1 I-GENE
can O
be O
considered O
as O
a O
step O
toward O
the O
understanding O
of O
the O
function O
of O
H1 I-GENE
in O
chromatin O
. O

The O
recovery O
rates O
for O
the O
MB O
/ O
BacT LASTCAP
, O
MGIT ALLCAPS
960 NUMERIC
, O
and O
solid O
media O
were O
91 O
. O
6 O
, O
87 O
. O
4 O
, O
and O
54 O
. O
7 O
%, O
respectively O
, O
for O
all O
mycobacteria O
; O
the O
recovery O
rates O
were O
93 O
. O
6 O
, O
88 O
. O
9 O
, O
and O
63 O
. O
4 O
%, O
respectively O
, O
for O
M O
. O
tuberculosis O
complex O
alone O
, O
and O
87 O
. O
5 O
, O
84 O
. O
4 O
, O
and O
37 O
. O
5 O
%, O
respectively O
, O
for O
all O
nontuberculous RARE
mycobacteria O
. O

Cerebral RARE
vasculitis O
secondary O
to O
Crohn O
' O
s O
disease O
seems O
to O
be O
a O
very O
rare O
phenomenon O
. O

SELECTION ALLCAPS
CRITERIA ALLCAPS
: O
Randomised RARE
and O
possibly O
randomised O
trials O
using O
acupuncture RARE
to O
treat O
asthma O
and O
asthma O
- O
like O
symptoms O
. O

SELECTION ALLCAPS
CRITERIA ALLCAPS
: O
Randomised RARE
trials O
comparing O
children O
undergoing O
systematic O
therapy O
focusing O
on O
the O
family O
in O
conjunction O
with O
asthma O
medication O
, O
with O
children O
taking O
asthma O
medication O
only O
. O

To O
test O
the O
hypothesis O
that O
progestin RARE
- O
mediated O
increases O
in O
resting O
core O
temperature O
and O
the O
core O
temperature O
threshold O
for O
sweating RARE
onset O
are O
counteracted RARE
by O
estrogen O
, O
we O
studied O
eight O
women O
( O
24 O
+/- O
2 O
yr O
) O
at O
27 O
degrees O
C O
rest O
, O
during O
20 O
min O
of O
passive O
heating RARE
( O
35 O
degrees O
C O
), O
and O
during O
40 O
min O
of O
exercise O
at O
35 O
degrees O
C O
. O

The O
models O
were O
tested O
by O
studying O
their O
response O
to O
disturbances O
of O
the O
afferent RARE
signal O
from O
the O
bladder O
. O

Our O
data O
show O
also O
that O
phagocytic O
killing RARE
of O
meningococci RARE
is O
probably O
a O
more O
consistent O
assay O
than O
antibody O
titer O
levels O
for O
antimeningococcal RARE
immunity O
, O
especially O
in O
LCC ALLCAPS
- O
deficient O
patients O
. O

These O
studies O
suggest O
an O
additional O
component O
or O
cellular O
environment O
is O
required O
for O
SPRK ALLCAPS
activation O
by O
Cdc42 I-GENE
. O

M O
. O

Jkappa RARE
DNA I-GENE
- I-GENE
binding I-GENE
sites I-GENE
were O
not O
required O
for O
this O
activation O
, O
and O
a O
mutant I-GENE
EBNA I-GENE
- I-GENE
3C I-GENE
protein I-GENE
unable O
to O
bind O
Jkappa RARE
activated O
transcription O
as O
efficiently O
as O
wild I-GENE
- I-GENE
type I-GENE
EBNA I-GENE
- I-GENE
3C I-GENE
, O
indicating O
that O
EBNA I-GENE
- I-GENE
3C I-GENE
can O
regulate O
transcription O
through O
a O
mechanism O
that O
is O
independent O
of O
Jkappa RARE
. O

Thus O
, O
both O
YY1 I-GENE
and O
CDP I-GENE
appear O
to O
be O
negative O
regulators O
of O
the O
differentiation O
- O
induced O
HPV I-GENE
- I-GENE
6 I-GENE
E1 I-GENE
promoter I-GENE
and O
thereby O
the O
HPV O
life O
cycle O
. O

Sequential RARE
cleavage O
by O
metallopeptidases RARE
and O
proteasomes RARE
is O
involved O
in O
processing O
HIV I-GENE
- I-GENE
1 I-GENE
ENV ALLCAPS
epitope I-GENE
for O
endogenous O
MHC I-GENE
class I-GENE
I I-GENE
antigen I-GENE
presentation O
. O

Cloning O
and O
characterization O
of O
human I-GENE
Lnk RARE
, O
an O
adaptor O
protein O
with O
pleckstrin I-GENE
homology O
and O
Src I-GENE
homology I-GENE
2 I-GENE
domains I-GENE
that O
can O
inhibit O
T O
cell O
activation O
. O

Vancomycin RARE
data O
were O
analyzed O
according O
to O
a O
one O
- O
compartment O
open O
model O
with O
use O
of O
NONMEM ALLCAPS
population O
pharmacokinetic O
software RARE
. O

Finally O
, O
Cas I-GENE
existed O
mainly O
in O
cytosol O
and O
membrane O
cytoskeleton O
fractions O
in O
the O
resting O
state O
, O
and O
remained O
unchanged O
during O
platelet O
aggregation O
, O
when O
FAK I-GENE
translocated RARE
to O
the O
cytoskeletal O
fraction O
. O

We O
also O
show O
that O
p65 I-GENE
binds O
to O
these O
targets O
with O
almost O
equal O
affinity O
and O
that O
different O
residues O
have O
variable O
roles O
in O
binding O
different O
kappaB I-GENE
targets I-GENE
. O

Transcriptional O
regulation O
of O
the O
yeast I-GENE
PHO8 NUMERIC
promoter I-GENE
in O
comparison O
to O
the O
coregulated RARE
PHO5 NUMERIC
promoter I-GENE
. O

The O
Siglecs RARE
are O
a O
subfamily O
of O
I I-GENE
- I-GENE
type I-GENE
lectins RARE
( O
immunoglobulin I-GENE
superfamily I-GENE
proteins I-GENE
that O
bind O
sugars O
) O
that O
specifically O
recognize O
sialic RARE
acids O
. O

Our O
data O
provide O
a O
biochemical O
explanation O
for O
the O
similarity O
in O
phenotype O
between O
A O
- O
T O
and O
NBS ALLCAPS
. O

PATIENTS O
OR O
OTHER ALLCAPS
PARTICIPANTS ALLCAPS
: O
Twenty O
children O
met O
the O
criteria O
for O
being O
learning O
disabled RARE
. O

Update RARE
on O
maternal O
- O
fetal O
infections O
by O
hepatitis O
C O
, O
HIV O
and O
cytomegalovirus O

In O
the O
present O
study O
, O
we O
characterized O
cis O
- O
elements O
of O
the O
human I-GENE
PCI I-GENE
gene I-GENE
required O
for O
expression O
in O
the O
hepatoma O
- O
derived O
cell O
line O
, O
HepG2 O
cells O
, O
and O
also O
evaluated O
rat I-GENE
PCI I-GENE
mRNA I-GENE
expression O
, O
particularly O
on O
the O
effect O
of O
androgen O
in O
rat O
reproductive O
tissues O
. O

In O
the O
study O
on O
PCI I-GENE
mRNA I-GENE
expression O
in O
the O
reproductive O
organs O
, O
we O
first O
cloned O
rat I-GENE
PCI I-GENE
cDNA I-GENE
and O
then O
evaluated O
the O
effect O
of O
androgen O
on O
the O
PCI I-GENE
mRNA I-GENE
expression O
. O

To O
illustrate RARE
its O
performance O
, O
measurements O
of O
photoluminescence RARE
in O
GaAs RARE
/ O
AlGaAs RARE
heterostructures RARE
are O
presented O
. O

The O
stoichiometry RARE
of O
the O
complexes O
formed O
with O
the O
dodeca RARE
- O
satellite O
C O
strand O
suggests O
that O
, O
in O
DDP1 NUMERIC
, O
the O
15 O
consecutive O
KH ALLCAPS
domains O
are O
organized O
such O
that O
they O
define O
two O
nucleic O
acid O
binding O
surfaces RARE
. O

Mutational O
analysis O
of O
mammalian I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
5 I-GENE
( O
eIF5 NUMERIC
): O
role O
of O
interaction O
between O
the O
beta O
subunit O
of O
eIF2 NUMERIC
and O
eIF5 NUMERIC
in O
eIF5 NUMERIC
function O
in O
vitro O
and O
in O
vivo O
. O

Much RARE
evidence O
indicates O
that O
p38 I-GENE
is O
an O
activator O
of O
MyoD I-GENE
: O
( O
i O
) O
p38 I-GENE
kinase I-GENE
activity O
is O
required O
for O
the O
expression O
of O
MyoD I-GENE
- O
responsive O
genes O
, O
( O
ii O
) O
enforced RARE
induction O
of O
p38 I-GENE
stimulates O
the O
transcriptional O
activity O
of O
a O
Gal4 I-GENE
- O
MyoD I-GENE
fusion O
protein O
and O
allows O
efficient O
activation O
of O
chromatin O
- O
integrated O
reporters RARE
by O
MyoD I-GENE
, O
and O
( O
iii O
) O
MyoD I-GENE
- O
dependent O
myogenic O
conversion O
is O
reduced O
in O
mouse O
embryonic O
fibroblasts O
derived O
from O
p38alpha NUMERIC
(-/-) RARE
embryos O
. O

This O
activity O
is O
stimulated O
by O
complex O
formation O
with O
the O
other O
eIF2B NUMERIC
subunits I-GENE
. O

Our O
analysis O
of O
nonsense O
mutations O
indicates O
that O
the O
C O
terminus O
of O
eIF2Bepsilon NUMERIC
( I-GENE
residues I-GENE
518 NUMERIC
to I-GENE
712 NUMERIC
) I-GENE
is O
required O
for O
both O
catalytic O
activity O
and O
interaction O
with O
eIF2 NUMERIC
. O

In O
contrast O
, O
mutations O
affecting O
the O
other O
two O
Nim1p NUMERIC
- I-GENE
related I-GENE
kinases I-GENE
in O
S O
. O
cerevisiae O
, O
Hsl1p NUMERIC
and O
Kcc4p NUMERIC
, O
produce O
no O
detectable O
effect O
on O
septin RARE
organization O
. O

CONCLUSIONS O
: O
Physiologic RARE
pacing O
provides O
little O
benefit O
over O
ventricular O
pacing O
for O
the O
prevention O
of O
stroke O
or O
death O
due O
to O
cardiovascular O
causes O
. O

Among O
non O
- O
cirrhotics RARE
, O
lack O
of O
portal O
vein O
visualisation RARE
had O
a O
90 O
% O
sensitivity O
, O
88 O
% O
specificity O
, O
94 O
% O
negative O
predictive O
value O
, O
and O
83 O
% O
positive O
predictive O
value O
in O
the O
diagnosis O
of O
pre O
- O
sinusoidal RARE
portal O
hypertension O
. O

D5 NUMERIC
/ I-GENE
D1 I-GENE
( I-GENE
CT I-GENE
) I-GENE
or O
D5 NUMERIC
/ I-GENE
D1D NUMERIC
( I-GENE
CT I-GENE
) I-GENE
tail O
substitution O
mutants O
displayed O
a O
rank RARE
order O
of O
potency O
and O
agonist O
affinities O
virtually O
mimicking RARE
wild I-GENE
- I-GENE
type I-GENE
( I-GENE
wt I-GENE
) I-GENE
D1 I-GENE
receptors I-GENE
, O
as O
indexed RARE
by O
both O
ligand O
binding O
and O
dopamine O
- O
stimulated O
cAMP O
accumulation O
assays O
, O
and O
, O
similar O
to O
wt O
D1 I-GENE
receptors I-GENE
, O
did O
not O
exhibit O
receptor O
constitutive O
activity O
or O
responsiveness O
to O
inverse RARE
agonists O
. O

Modeling RARE
also O
revealed O
a O
very O
hydrophobic O
surface O
due O
to O
the O
absence O
of O
H12 NUMERIC
, O
exposing RARE
residues O
from O
H3 O
, O
loop O
3 O
- O
4 O
, O
H4 O
, O
and O
H11 NUMERIC
. O

The O
serine I-GENE
- I-GENE
threonine I-GENE
kinase I-GENE
gene I-GENE
is O
likely O
functional O
, O
whereas O
the O
zinc O
finger O
motif O
is O
likely O
nonfunctional RARE
. O

Stat I-GENE
activation O
in O
response O
to O
GH I-GENE
and O
IL I-GENE
- I-GENE
6 I-GENE
was O
determined O
by O
reporter O
gene O
induction O
. O

HFA ALLCAPS
134a NUMERIC
had O
a O
greater O
tendency O
to O
take O
up O
moisture RARE
from O
the O
environment O
than O
did O
HFA ALLCAPS
227 NUMERIC
. O

RESULTS O
: O
Abnormal O
color O
perception RARE
was O
found O
in O
32 O
% O
of O
the O
epilepsy O
patients O
treated O
with O
vigabatrin RARE
monotherapy RARE
and O
28 O
% O
of O
the O
epilepsy O
patients O
treated O
with O
carbamazepine RARE
monotherapy RARE
. O

In O
the O
SPP2 NUMERIC
screening O
test O
, O
a O
few O
plates O
were O
not O
seen O
in O
both O
groups O
. O

Mitogen RARE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
phosphatase I-GENE
- I-GENE
3 I-GENE
( O
MKP I-GENE
- I-GENE
3 I-GENE
) O
is O
a O
dual O
specificity O
phosphatase O
that O
inactivates RARE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
( O
ERK I-GENE
) O
MAP I-GENE
kinases I-GENE
. O

Consistent O
with O
this O
, O
we O
show O
that O
peptides O
representing O
docking RARE
sites O
within O
the O
target O
substrates O
Elk I-GENE
- I-GENE
1 I-GENE
and O
p90 NUMERIC
( O
rsk RARE
) O
inhibit O
ERK I-GENE
- O
dependent O
activation O
of O
MKP I-GENE
- I-GENE
3 I-GENE
. O

HPLC O
phosphopeptide O
mapping O
, O
amino O
acid O
sequencing O
, O
and O
site O
- O
directed O
mutagenesis O
determined O
that O
NCLK ALLCAPS
phosphorylates O
Ser O
( O
67 O
) O
of O
I I-GENE
- I-GENE
1 I-GENE
. O

When O
the O
entire O
diet O
consisted O
of O
SBF O
, O
voluntary RARE
feed O
intake O
was O
reduced O
, O
indicating O
that O
SBF O
should O
not O
be O
fed O
to O
ponies RARE
as O
the O
sole RARE
dietary O
ingredient RARE
. O

Hepatitis O
C O
virus O
infection O
and O
lymphoproliferative RARE
diseases O
in O
France RARE
: O
a O
national O
study O
. O

The O
immune O
system O
is O
closely O
integrated O
with O
the O
neuroendocrine RARE
system O
, O
and O
infection O
- O
induced O
increases O
in O
cytokines O
such O
as O
IL I-GENE
- I-GENE
1 I-GENE
, O
IL I-GENE
- I-GENE
6 I-GENE
and O
TNF I-GENE
have O
numerous O
effects O
on O
the O
central O
nervous O
system O
. O

Interestingly O
, O
a O
decreased O
transcription O
from O
the O
endogenous O
c I-GENE
- I-GENE
Myb I-GENE
promoter I-GENE
was O
observed O
in O
several O
HTLV O
- O
I O
transformed O
T O
- O
cell O
lines O
. O

H19 I-GENE
and O
Igf2 NUMERIC
monoallelic RARE
expression O
is O
regulated O
in O
two O
distinct O
ways O
by O
a O
shared O
cis O
acting O
regulatory O
region O
upstream O
of O
H19 I-GENE
. O

C O
. O
elegans O
KLP ALLCAPS
- I-GENE
11 I-GENE
/ O
OSM ALLCAPS
- I-GENE
3 I-GENE
/ O
KAP ALLCAPS
- I-GENE
1 I-GENE
: O
orthologs RARE
of O
the O
sea I-GENE
urchin I-GENE
kinesin RARE
- I-GENE
II I-GENE
, O
and O
mouse O
KIF3A NUMERIC
/ O
KIFB ALLCAPS
/ O
KAP3 NUMERIC
kinesin RARE
complexes O
. O

Flavonoids RARE
from O
Brosimum RARE
acutifolium RARE
. O

BACKGROUND O
: O
Hepatic RARE
encephalopathy RARE
is O
a O
neuropsychiatric RARE
syndrome O
associated O
with O
acute O
liver O
failure O
, O
chronic O
parenchymal RARE
liver O
disease O
or O
portal O
systemic O
anastomosis O
. O

These O
natural O
antisense O
S I-GENE
transcripts I-GENE
co O
- O
exist O
with O
several O
less O
abundant O
sense O
S I-GENE
transcripts I-GENE
. O

Nor RARE
is O
such O
adjustment O
possible O
unless O
one O
posits RARE
a O
model O
that O
relates RARE
the O
missing O
observations O
to O
other O
observed O
information O
for O
each O
subject O
- O
models O
that O
are O
inherently RARE
untestable RARE
. O

However O
, O
the O
presence O
of O
effacement RARE
seems O
to O
be O
a O
more O
reliable O
and O
practical RARE
parameter O
that O
will O
be O
preferred O
in O
that O
prediction O
. O

The O
data O
are O
compatible O
with O
the O
idea O
that O
YLL031c NUMERIC
transfers RARE
the O
ethanolaminephosphate RARE
to O
the O
inner O
alpha1 O
- O
2 O
- O
linked O
mannose RARE
, O
i O
. O
e O
. O
the O
group O
that O
links O
the O
GPI O
lipid O
anchor O
to O
proteins O
, O
whereas O
Mcd4p NUMERIC
and O
Gpi7p NUMERIC
transfer O
ethanolaminephosphate RARE
onto O
the O
alpha1 O
- O
4 O
- O
and O
alpha1 O
- O
6 O
- O
linked O
mannoses RARE
of O
the O
GPI O
anchor O
, O
respectively O
. O

The O
C O
terminus O
of O
TRBP ALLCAPS
binds O
to O
CBP I-GENE
/ O
p300 I-GENE
and O
DRIP130 NUMERIC
, O
a O
component O
of O
the O
DRIP ALLCAPS
/ O
TRAP ALLCAPS
/ O
ARC I-GENE
complex O
, O
which O
suggests O
that O
TRBP ALLCAPS
may O
activate O
transcription O
by O
means O
of O
such O
interactions O
. O

The O
patients O
who O
presented O
with O
mucocutaneous RARE
disease O
also O
had O
low O
CD4 I-GENE
+ I-GENE
T O
lymphocyte O
counts O
, O
and O
most O
of O
them O
had O
AIDS O
defining RARE
illnesses RARE
. O

Increased O
dietary O
energy O
decreased O
PAB ALLCAPS
and O
the O
use O
of O
added O
dietary O
CO O
rather O
than O
PF ALLCAPS
decreased O
PSHL ALLCAPS
in O
broiler RARE
breeders RARE
between O
26 O
and O
47 O
wk O
of O
age O
. O

The O
gene O
amplification O
model O
of O
Coquelle RARE
et O
al O
. O

Hierarchy RARE
of O
protein I-GENE
tyrosine I-GENE
kinases I-GENE
in O
interleukin I-GENE
- I-GENE
2 I-GENE
( O
IL I-GENE
- I-GENE
2 I-GENE
) O
signaling O
: O
activation O
of O
syk RARE
depends O
on O
Jak3 NUMERIC
; O
however O
, O
neither O
Syk RARE
nor O
Lck I-GENE
is O
required O
for O
IL I-GENE
- I-GENE
2 I-GENE
- O
mediated O
STAT I-GENE
activation O
. O

Immobilized RARE
dimers O
of O
N I-GENE
- I-GENE
cadherin I-GENE
- O
Fc I-GENE
chimera O
mimic O
cadherin O
- O
mediated O
cell O
contact O
formation O
: O
contribution O
of O
both O
outside O
- O
in O
and O
inside RARE
- O
out O
signals O
. O

Although O
the O
OC I-GENE
promoter I-GENE
is O
activated O
in O
a O
C O
terminus O
dependent O
manner O
, O
the O
MDR ALLCAPS
, O
LTR O
and O
BSP I-GENE
promoters I-GENE
are O
repressed O
by O
three O
distinct O
mechanisms O
, O
either O
independent O
of O
or O
involving O
the O
AML ALLCAPS
C I-GENE
terminus I-GENE
, O
or O
requiring O
only O
the O
conserved O
C O
- O
terminal O
pentapeptide RARE
VWRPY ALLCAPS
. O

The O
monoclonal O
immunoglobulin I-GENE
products O
of O
plasma O
cell O
neoplasm RARE
can O
give O
rise O
to O
a O
variety O
of O
manifestations O
including O
hyperviscosity RARE
, O
amyloidosis RARE
, O
cryoglobulinemia RARE
, O
neuropathy O
, O
and O
renal O
failure O
. O

Investigation RARE
of O
the O
structural O
basis O
of O
the O
interaction O
between O
human I-GENE
Igs RARE
and O
gp120 I-GENE
shows O
that O
the O
viral I-GENE
gp120 I-GENE
SAg RARE
can O
interact O
only O
with O
a O
subset O
of O
human I-GENE
V I-GENE
( I-GENE
H I-GENE
) I-GENE
3 I-GENE
+ I-GENE
Igs RARE
. O

Double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
. O

Here O
, O
it O
is O
shown O
that O
TAFII250 NUMERIC
, O
the O
largest O
subunit O
of O
TFIID I-GENE
, O
contains O
two O
tandem O
bromodomain RARE
modules O
that O
bind O
selectively O
to O
multiply RARE
acetylated RARE
histone I-GENE
H4 I-GENE
peptides I-GENE
. O

Endostatin RARE
treatment O
for O
10 O
minutes O
or O
24 O
hours O
induced O
tyrosine O
phosphorylation O
of O
Shb RARE
and O
formation O
of O
multiprotein RARE
complexes O
. O

Therefore O
, O
analogs RARE
of O
vitamin O
D3 O
have O
been O
investigated O
in O
a O
number O
of O
trials O
showing O
improvement O
of O
psoriasis O
. O

The O
transcript O
was O
initially O
identified O
as O
a O
partial O
cDNA O
sequence O
in O
the O
course O
of O
constructing RARE
a O
transcript O
map O
of O
the O
region O
between O
markers O
D11S1765 NUMERIC
and O
uteroglobin RARE
known O
to O
encompass RARE
the O
gene O
causing O
Best RARE
disease O
. O

The O
real O
challenge O
for O
the O
future O
will O
be O
the O
management O
of O
patients O
who O
do O
not O
respond O
to O
first O
- O
line O
treatment O
. O

Iodine RARE
deficiency O
disorders O
in O
Bangladesh RARE
. O

The O
network O
evolution O
was O
interpreted O
by O
an O
approach O
based O
on O
the O
Flory RARE
model O
. O

RESULTS O
: O
Soluble RARE
CD23 I-GENE
levels O
were O
significantly O
higher O
in O
women O
with O
endometriosis RARE
before O
treatment O
than O
in O
ten O
normal O
controls O
. O

CONCLUSION O
: O
Our O
findings O
suggest O
that O
endometriosis RARE
increases O
soluble O
CD23 I-GENE
levels O
, O
which O
can O
be O
suppressed O
with O
either O
danazol RARE
or O
leuprolide RARE
acetate O
injection O
. O

To O
isolate O
this O
gene O
, O
a O
P O
- O
1 O
artificial O
chromosome O
( O
PAC ALLCAPS
) O
library O
was O
screened O
with O
a O
full I-GENE
length I-GENE
UGT2B7 NUMERIC
probe O
and O
a O
clone O
of O
approximately O
100 O
kb O
in O
length O
was O
isolated O
. O

Age RARE
>/= O
50 O
years O
( O
odds O
ratio O
[ O
OR O
], O
14 O
. O
1 O
), O
BMI O
>/= O
28 O
kg O
/ O
m O
( O
2 O
) O
( O
OR O
, O
5 O
. O
7 O
), O
triglycerides O
>/= O
1 O
. O
7 O
mmol O
/ O
L O
( O
OR O
, O
5 O
), O
and O
alanine I-GENE
aminotransferase I-GENE
( O
ALT ALLCAPS
) O
>/= O
2N NUMERIC
( O
OR O
, O
4 O
. O
6 O
) O
were O
independently O
associated O
with O
septal O
fibrosis O
. O

Biologically RARE
significant O
amounts O
of O
platelet I-GENE
activating I-GENE
factor I-GENE
were O
eluted RARE
from O
the O
sorbent RARE
during O
the O
entire O
treatment O
time O
. O

However O
, O
the O
elderly O
group O
showed O
significantly O
longer O
mean O
residence RARE
times O
( O
MRTs RARE
) O
and O
lower O
plasma O
clearance O
of O
lidocaine O
during O
the O
period O
compared O
with O
the O
adult O
group O
( O
P O
< O
. O
05 O
). O

Here O
, O
we O
show O
that O
the O
zinc I-GENE
finger I-GENE
protein I-GENE
Gis1 NUMERIC
acts O
as O
a O
dosage O
- O
dependent O
suppressor O
of O
the O
rim15Delta NUMERIC
defect O
in O
nutrient O
limitation O
- O
induced O
transcriptional O
derepression O
of O
SSA3 NUMERIC
. O

The O
so O
- O
called O
" I-GENE
SH3 I-GENE
" I-GENE
segment I-GENE
of O
the O
linker O
domain O
, O
in O
contrast O
, O
shows O
species O
- O
specific O
sequence O
identity O
in O
all O
but O
one O
amino O
acid O
residues O
in O
both O
factors O
, O
in O
cattle O
, O
human O
, O
and O
mouse O
. O

No O
differences O
in O
total O
cholesterol O
levels O
were O
observed O
between O
mapuches RARE
and O
aymaras RARE
. O

Up RARE
to O
95 O
% O
of O
the O
total O
UV O
exposure O
received O
is O
in O
the O
UV O
- O
A O
waveband RARE
( O
320 NUMERIC
- O
400 O
nm O
). O

To O
begin O
to O
characterize O
the O
role O
of O
the O
RNA O
subunits O
in O
enzyme O
function O
and O
substrate O
specificity O
, O
we O
swapped RARE
two O
hairpin O
structures O
( O
MRP3 NUMERIC
and O
P3 O
) O
between O
RNase I-GENE
MRP I-GENE
RNA I-GENE
and O
RNase I-GENE
P I-GENE
RNA I-GENE
of I-GENE
S I-GENE
. I-GENE
cerevisiae I-GENE
. O

Among O
genes O
induced O
by O
added O
pMesogenin1 NUMERIC
is O
Xwnt RARE
- I-GENE
8 I-GENE
, O
a O
signaling O
factor O
that O
induces O
a O
similar O
repertoire RARE
of O
marker O
genes O
and O
a O
similar O
cellular O
phenotype O
. O

Accordingly RARE
, O
no O
Ha I-GENE
- I-GENE
ras I-GENE
codon I-GENE
12 I-GENE
mutations O
are O
found O
in O
the O
EtNU LASTCAP
- O
induced O
mammary O
tumors O
. O

False RARE
positive O
PET O
FDG O
corresponded O
to O
lung O
infection O
, O
degenerative RARE
bone O
disease O
, O
and O
reconstruction O
artifact RARE
. O

Tumor O
stages O
were O
IIB ALLCAPS
( O
T3 O
N0 NUMERIC
) O
in O
52 O
%, O
IIIA ALLCAPS
in O
15 O
%, O
and O
IIIB O
in O
27 O
% O
of O
patients O
. O

Similarly O
, O
comparison O
of O
percentage O
reductions O
of O
heart O
rate O
at O
supine O
, O
sitting RARE
and O
exercise O
by O
repeated O
measure O
analysis O
showed O
the O
Malays RARE
to O
have O
significantly O
higher O
change O
compared O
to O
the O
Chinese O
( O
p O
= O
0 O
. O
040 NUMERIC
). O

Consistent O
with O
our O
model O
, O
CTCF I-GENE
binding O
is O
abolished O
by O
DNA O
methylation O
. O

OBJECTIVE O
: O
To O
determine O
the O
efficacy O
and O
safety O
of O
amphotericin O
B O
oral O
suspension RARE
( O
ABOS ALLCAPS
) O
for O
the O
treatment O
of O
fluconazole RARE
refractory O
oral O
candidiasis O
in O
persons O
with O
HIV O
infection O
. O

Mucin RARE
gene I-GENE
expression O
has O
been O
shown O
to O
be O
altered O
in O
many O
intestinal O
diseases O
and O
especially O
cancers O
of O
the O
gastrointestinal O
tract O
. O

The O
experimentally O
mapped O
regions O
of O
RPB5 NUMERIC
involved O
in O
these O
interactions O
correspond O
to O
distinct O
and O
surface O
- O
exposed O
alpha O
- O
helical O
structures O
. O

The O
model O
indicates O
that O
a O
0 O
. O
076 NUMERIC
% O
reduction O
in O
cigarette RARE
consumption O
is O
associated O
with O
the O
availability O
of O
nicotine O
patches RARE
after O
1992 O
. O

Paper RARE
alert RARE
. O

The O
tryptase RARE
locus I-GENE
also O
contains O
at O
least O
four O
tryptase RARE
- I-GENE
like I-GENE
pseudogenes RARE
, O
including O
mastin RARE
, O
a O
gene O
expressed O
in O
dogs O
but O
not O
in O
humans O
. O

The O
cellular O
part O
of O
the O
third O
chimeric O
clone O
shows O
significant O
homology O
to O
an O
exon O
of O
the O
human I-GENE
tyrosine I-GENE
phosphatase I-GENE
1 I-GENE
gene I-GENE
, O
although O
oriented RARE
in O
the O
antisense O
direction O
compared O
to O
the O
adjacent O
LTR O
. O

OBJECTIVE O
: O
This O
study O
was O
conducted O
to O
assess O
the O
relative O
roles O
of O
99mTc O
- O
sestamibi RARE
scintimammography RARE
and O
sonography RARE
in O
the O
evaluation O
of O
breast O
lesions O
that O
are O
indeterminate RARE
or O
suspicious RARE
on O
mammography RARE
or O
clinical O
examination O
. O

Mutational O
analyses O
showed O
that O
in O
- O
frame O
stop O
codons O
introduced O
into O
five O
of O
seven O
RNA I-GENE
2 I-GENE
ORFs I-GENE
did O
not O
affect O
accumulation O
of O
progeny RARE
LIYV ALLCAPS
RNA I-GENE
1 I-GENE
or O
RNA I-GENE
2 I-GENE
, O
confirming O
that O
RNA I-GENE
2 I-GENE
does O
not O
encode O
proteins O
necessary O
for O
LIYV ALLCAPS
RNA O
replication O
. O

Role O
of O
NH ALLCAPS
( O
2 O
)- O
and O
COOH O
- O
terminal O
domains O
of O
the O
P I-GENE
protein I-GENE
of O
human O
parainfluenza RARE
virus O
type O
3 O
in O
transcription O
and O
replication O
. O

Phosphorylation RARE
of O
tyrosine O
residues O
in O
the O
kinase O
domain O
and O
juxtamembrane O
region O
regulates O
the O
biological O
and O
catalytic O
activities O
of O
Eph RARE
receptors I-GENE
. O

RESULTS O
: O
Fournier RARE
' O
s O
gangrene RARE
occurs O
worldwide RARE
. O

Genomic O
DNA O
sequencing O
in O
the O
vicinity O
of O
methylmalonyl RARE
- I-GENE
CoA I-GENE
mutase RARE
gene I-GENE
( O
mutAB LASTCAP
) O
from O
a O
rifamycin RARE
SV O
- O
producing O
Amycolatopsis RARE
mediterranei RARE
U32 NUMERIC
allowed O
us O
to O
clone O
, O
sequence O
, O
and O
identify O
a O
gene O
encoding O
a O
novel O
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
( O
amk RARE
). O

IL I-GENE
- I-GENE
2 I-GENE
is O
accepted O
as O
a O
standard O
treatment O
used O
alone O
, O
or O
in O
combination O
with O
chemotherapy O
or O
biotherapy RARE
in O
the O
management O
of O
metastatic O
melanoma O
and O
metastatic O
renal O
cell O
carcinoma O
. O

Moreover O
, O
expression O
of O
antisense I-GENE
Ha I-GENE
- I-GENE
Ras I-GENE
or O
dominant I-GENE
negative I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
abrogated O
the O
mitogenic O
effect O
of O
TGF I-GENE
- I-GENE
beta1 I-GENE
in O
TSU ALLCAPS
- O
Pr1 NUMERIC
, O
and O
the O
TGF I-GENE
- I-GENE
beta1 I-GENE
inhibition O
of O
DU145 NUMERIC
was O
switched RARE
to O
stimulation O
by O
V12Ha NUMERIC
- I-GENE
Ras I-GENE
transfection O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
prostate O
carcinomas O
with O
the O
Ras I-GENE
/ O
MAPK I-GENE
pathway O
activation O
might O
have O
a O
selective O
growth O
advantage O
by O
autocrine O
TGF I-GENE
- I-GENE
beta1 I-GENE
production O
. O

Vbeta RARE
segments O
are O
appended RARE
to O
DJbeta RARE
rearrangements O
, O
with O
little O
or O
no O
direct O
Vbeta RARE
to O
Jbeta RARE
joining O
, O
despite O
12 O
/ O
23 O
compatibility O
of O
Vbeta RARE
23 I-GENE
- I-GENE
RSSs RARE
and O
Jbeta12 NUMERIC
- I-GENE
RSSs RARE
. O

For O
oral O
administration O
, O
AUC0 NUMERIC
- O
infinity RARE
was O
58 O
. O
47 O
+/- O
16 O
. O
37 O
microg O
x O
h O
/ O
ml O
, O
t1 O
/ O
2beta NUMERIC
was O
18 O
. O
39 O
+/- O
0 O
. O
06 O
hours O
, O
maximum O
concentration O
( O
Cmax RARE
) O
was O
2 O
. O
12 O
+/- O
00 O
. O
51 O
microg O
/ O
ml O
, O
time O
to O
Cmax RARE
was O
2 O
. O
20 O
+/- O
2 O
. O
17 O
hours O
, O
mean O
absorption O
time O
was O
2 O
. O
09 O
+/- O
0 O
. O
51 O
hours O
, O
and O
bioavailability RARE
was O
42 O
+/- O
0 O
. O
42 O
%. O

In O
experiment O
2 O
, O
no O
difference O
in O
gastric O
emptying O
of O
40 O
% O
peptone RARE
or O
25 O
% O
glucose O
was O
found O
between O
rats O
receiving O
TPN O
and O
those O
receiving O
intragastric RARE
nutrition O
for O
10 O
to O
12 O
days O
. O

In O
contrast O
, O
H I-GENE
- I-GENE
NS I-GENE
negative O
regulation O
operated O
only O
in O
the O
absence O
of O
Fur I-GENE
. O

Thus O
, O
SAG ALLCAPS
appears O
to O
control O
cell O
cycle O
progression O
in O
yeast O
by O
promoting O
ubiquitination O
and O
degradation O
of O
cell O
cycle O
regulatory O
proteins O
. O

E2F I-GENE
- I-GENE
1 I-GENE
is O
a O
transcription O
factor O
that O
regulates O
cell O
cycle O
progression O
into O
S O
- O
phase O
. O

It O
brings RARE
about O
fatigue RARE
, O
negative O
moods RARE
, O
and O
impaired O
health O
, O
sleep O
, O
safety O
, O
and O
working O
capacity O
. O

This O
demonstrates O
that O
treatment O
of O
the O
graft O
recipient O
for O
a O
relatively O
short O
period O
during O
and O
after O
surgery O
has O
a O
favorable RARE
effect O
on O
the O
survival O
of O
grafted RARE
dopaminergic O
neurons O
. O

The O
relationships O
among O
blood O
concentrations O
of O
thyroid O
hormones O
and O
selenium O
, O
zinc O
, O
retinol O
, O
and O
alpha O
- O
tocopherol RARE
were O
studied O
in O
44 O
healthy O
Northern O
Italian O
oldest RARE
- O
old O
subjects O
( O
age O
range O
, O
90 O
- O
107 NUMERIC
yr O
), O
selected O
by O
the O
criteria O
of O
the O
SENIEUR ALLCAPS
protocol O
. O

Chinese O
Spring RARE
( O
CS O
) O
carrying O
the O
Q I-GENE
gene I-GENE
to O
those O
of O
a O
chromosome O
deletion O
line O
of O
CS O
, O
namely O
, O
q5 NUMERIC
, O
which O
lacks O
15 O
% O
of O
5AL NUMERIC
including O
the O
Q I-GENE
gene I-GENE
. O

Investigations RARE
using O
hippocampal O
slices RARE
maintained O
in O
vitro O
have O
demonstrated O
that O
bursts RARE
of O
oscillatory RARE
field O
potentials O
in O
the O
gamma O
frequency O
range O
( O
30 O
- O
80 O
Hz O
) O
are O
followed O
by O
a O
slower O
oscillation RARE
in O
the O
beta O
1 O
range O
( O
12 O
- O
20 O
Hz O
). O

Karger RARE
AG ALLCAPS
, O
Basel RARE

During O
surgery O
bone O
cysts O
were O
excised RARE
and O
filled O
by O
bone O
grafts O
. O

Urinary RARE
LTE4 NUMERIC
increased O
after O
both O
challenges RARE
the O
rise O
being O
higher O
following O
oral O
as O
compared O
to O
inhalation O
provocation RARE
( O
p O
= O
0 O
. O
0001 O
). O

Basal O
FVR ALLCAPS
was O
reduced O
by O
approximately O
18 O
% O
by O
ERT ALLCAPS
and O
HRT ALLCAPS
, O
but O
FVR ALLCAPS
responses O
to O
noradrenaline O
, O
angiotensin I-GENE
II I-GENE
, O
acetylcholine O
and O
nitroprusside RARE
were O
unaffected O
. O

Three O
FGF I-GENE
- I-GENE
AS I-GENE
cDNAs I-GENE
were O
isolated O
; O
the O
full I-GENE
- I-GENE
length I-GENE
FGF I-GENE
- I-GENE
AS I-GENE
mRNA I-GENE
and O
two O
alternative O
splice O
variants O
lacking O
exon O
2 O
or O
exons O
2 O
and O
3 O
of O
the O
FGF I-GENE
- I-GENE
AS I-GENE
sequence I-GENE
. O

Taken O
together O
, O
these O
results O
indicate O
that O
MAP I-GENE
kinase I-GENE
stimulates O
the O
hPL LASTCAP
- I-GENE
B I-GENE
enhancer I-GENE
by O
an O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
- O
dependent O
pathway O
. O

Characterization O
of O
polymorphic O
TNRs RARE
in O
novel O
and O
even O
known O
genes O
expressed O
in O
human O
spinal O
cord O
is O
likely O
to O
help O
in O
the O
identification O
of O
new O
candidates RARE
for O
genes O
involved O
in O
neurodegenerative RARE
disorders O
. O

Finally O
, O
in O
situ O
RNA O
hybridization O
studies O
revealed O
a O
very O
specific O
pattern O
of O
EphA8 NUMERIC
gene I-GENE
expression O
restricted O
to O
the O
rostral RARE
region O
of O
midbrain RARE
tectum RARE
during O
embryonic O
development O
. O

Transfection O
of O
cDNAs O
for O
three O
mutant O
enzymes O
into O
FPGS ALLCAPS
- O
null O
Chinese O
hamster O
ovary O
cells O
restored O
a O
reduced O
level O
of O
clonal RARE
growth O
, O
whereas O
a O
T339I NUMERIC
mutant O
supported O
growth O
at O
a O
level O
comparable O
to O
that O
of O
the O
wild O
- O
type O
enzyme O
. O

SETTING O
: O
University O
of O
Paris RARE
VII O
hospital O
. O
Patient RARE
( O
s O
): O
Nine RARE
women O
had O
embolization RARE
for O
symptomatic O
myoma RARE
, O
with O
12 O
pregnancies RARE
observed O
. O

Improving RARE
fissure RARE
sealant RARE
quality O
: O
mechanical O
preparation O
and O
filling O
level O
. O

The O
Menopause RARE
- O
Rating RARE
- O
Scale O
( O
MRS O
I O
) O
was O
used O
in O
clinical O
practice O
since O
1992 O
. O

The O
MRS O
II O
meets RARE
a O
high O
methodological RARE
standard O
as O
an O
instrument O
standardized O
in O
the O
population O
. O

The O
protein O
encoded O
by O
the O
fruA LASTCAP
transcript I-GENE
is O
well O
conserved O
with O
the O
D I-GENE
. I-GENE
melanogaster I-GENE
type I-GENE
A I-GENE
protein I-GENE
, O
particularly O
the O
BTB I-GENE
protein I-GENE
- O
protein O
- O
binding O
domain O
, O
which O
is O
encoded O
by O
exons O
I O
and O
II O
and O
is O
100 O
% O
conserved O
. O

In O
addition O
, O
the O
mouse O
ortholog RARE
( O
Mharp RARE
/ O
Smarcal1 NUMERIC
) O
was O
cloned O
, O
and O
the O
Caenorhabditis O
elegans O
ortholog RARE
( O
CEHARP ALLCAPS
) O
was O
identified O
in O
the O
GenBank RARE
database O
. O

Sparfloxacin RARE
and O
clinafloxacin RARE
were O
evaluated O
against O
Enterococcus RARE
faecium RARE
SF2149 NUMERIC
and O
Enterococcus RARE
faecalis RARE
WH245 NUMERIC
, O
respectively O
. O

ECP ALLCAPS
and O
tryptase RARE
levels O
in O
serum O
were O
measured O
before O
and O
after O
the O
last O
oral O
challenge O
. O

Tolterodine RARE
users O
were O
7 O
. O
5 O
times O
more O
likely O
to O
have O
received O
another O
spasmolytic RARE
drug O
( O
RR O
7 O
. O
5 O
, O
95 O
% O
CI O
4 O
. O
8 O
to O
11 O
. O
9 O
). O

For O
an O
unsupervised RARE
program O
, O
the O
costs O
were O
estimated O
at O
$ RARE
311 NUMERIC
for O
the O
first O
year O
and O
$ RARE
73 O
for O
all O
additional O
years O
. O

The O
presence O
of O
such O
a O
putative O
RNA O
- O
binding O
domain O
suggests O
a O
mechanism O
for O
the O
observed O
autoregulation O
of O
bacteriophage O
T4 I-GENE
DNA I-GENE
polymerase I-GENE
synthesis O
by O
binding O
to O
its O
own O
mRNA O
. O

Deletion O
and O
mutational O
analyses O
revealed O
two O
positive O
cis O
- O
regulatory O
elements O
in O
this O
region O
that O
are O
essential O
for O
CSX1 NUMERIC
expression O
in O
cardiomyocytes RARE
. O

Functional O
studies O
which O
introduced O
a O
mutation O
in O
the O
AP2 I-GENE
core I-GENE
binding I-GENE
region I-GENE
as O
well O
as O
cotransfection O
experiments O
using O
an O
AP2 I-GENE
expression O
vector O
revealed O
that O
AP2 I-GENE
exerts O
a O
repressive O
role O
on O
the O
HGF I-GENE
gene I-GENE
promoter I-GENE
activity O
. O

Using O
adenoviral RARE
transfer O
of O
IkappaBalpha I-GENE
( O
IkappaBalpha I-GENE
overexpression O
), O
the O
production O
of O
TNF I-GENE
- I-GENE
alpha I-GENE
induced O
by O
whole O
GBS ALLCAPS
was O
inhibited O
by O
only O
20 O
%. O

In O
reconstitution RARE
experiments O
, O
we O
first O
showed O
that O
expression O
in O
the O
RAW ALLCAPS
264 O
. O
7 O
cell O
line O
of O
C I-GENE
- I-GENE
terminal I-GENE
Src I-GENE
kinase I-GENE
( O
Csk I-GENE
) O
inhibited O
and O
that O
of O
a O
membrane O
- O
anchored O
, O
gain O
- O
of O
- O
function O
Csk I-GENE
abolished O
the O
Fc I-GENE
gamma I-GENE
R I-GENE
- O
mediated O
signaling O
that O
leads O
to O
phagocytosis RARE
in O
a O
kinase O
- O
dependent O
manner O
. O

In O
contrast O
, O
c I-GENE
- I-GENE
Src I-GENE
- I-GENE
derived I-GENE
construct I-GENE
( O
a I-GENE
- I-GENE
Src I-GENE
), O
that O
was O
excluded O
from O
detergent O
- O
resistant O
membranes O
, O
could O
not O
restore RARE
the O
series O
of O
phagocytosis RARE
signaling O
. O

The O
delta I-GENE
srb10 NUMERIC
mutation I-GENE
also O
influenced O
on O
the O
transcript O
levels O
of O
meiosis O
- O
inducing O
genes O
called O
IME1 I-GENE
and O
IME2 NUMERIC
: O
the O
mutation O
elevated O
the O
transcript O
level O
of O
IME1 I-GENE
but O
reduced O
that O
of O
IME2 NUMERIC
, O
resulting O
in O
partial O
defects O
in O
premeiotic RARE
DNA O
synthesis O
and O
meiosis O
. O

We O
also O
found O
that O
environmental O
conditions O
for O
meiosis O
finely RARE
regulate O
the O
transcript O
levels O
of O
KIN28 NUMERIC
and O
CCL1 NUMERIC
, O
such O
that O
nitrogen O
starvation O
first O
elevates RARE
them O
but O
subsequent O
alkalization RARE
of O
medium O
decreases O
them O
. O

The O
pJR LASTCAP
vectors O
differ O
among O
them O
in O
: O
( O
a O
) O
the O
selectable O
marker O
( O
Saccharomyces O
cerevisiae O
LEU ALLCAPS
2 I-GENE
gene I-GENE
, O
which O
complements RARE
S I-GENE
. I-GENE
pombe I-GENE
leu1 NUMERIC
- I-GENE
gene I-GENE
and O
S O
. O
pombe O
ura4 NUMERIC
+ I-GENE
and O
his3 NUMERIC
+ I-GENE
genes I-GENE
); O
( O
b O
) O
the O
thiamine RARE
- O
repressible RARE
nmt1 NUMERIC
promoter I-GENE
( O
3X NUMERIC
, O
41X NUMERIC
and O
81X NUMERIC
with O
extremely O
high O
, O
moderate O
or O
low O
transcription O
efficiency O
, O
respectively O
); O
and O
( O
c O
) O
the O
multiple O
cloning O
site O
( O
two O
multiple O
cloning O
sites O
, O
with O
12 O
restriction O
sites O
each O
). O

( O
GUT ALLCAPS
) O
Sera RARE
of O
30 O
montoux RARE
negative O
healthy O
adults O
( O
age O
/ O
sex O
matched O
) O
were O
taken O
as O
control O
by O
detecting O
IgG I-GENE
anti I-GENE
bodies I-GENE
to O
A60 NUMERIC
antigen I-GENE
. O

The O
effect O
of O
acute O
, O
mid O
- O
cervical O
spinal O
cord O
lesions O
on O
neuronal O
and O
reflex O
activity O
evoked O
by O
the O
noxious RARE
visceral O
stimulus O
, O
colorectal RARE
distension RARE
( O
CRD ALLCAPS
; O
80 O
mmHg O
, O
20 O
s O
), O
was O
determined O
in O
halothane O
- O
anesthetized O
rats O
. O

Franz RARE
Schubert RARE
-- O
his O
life O
, O
music RARE
and O
diseases O

The O
results O
suggest O
that O
the O
role O
of O
S O
. O
argyrostoma RARE
in O
the O
dissemination RARE
of O
Trichinella RARE
larvae O
in O
nature O
is O
limited O
in O
comparison O
to O
the O
role O
played O
by O
mammals O
with O
scavenger RARE
and O
cannibalistic RARE
behavior O
. O

The O
equilibrium O
dissociation O
binding O
constant O
for O
the O
interaction O
of O
TnrA LASTCAP
with O
the O
nrgAB LASTCAP
promoter I-GENE
fragment I-GENE
was O
7 O
. O
7 O
nM O
under O
the O
conditions O
used O
here O
. O

These O
results O
demonstrate O
that O
N O
- O
glycans RARE
flanking O
the O
receptor O
- O
binding O
site O
of O
the O
HA I-GENE
molecule I-GENE
are O
potent O
regulators O
of O
influenza O
virus O
growth O
, O
with O
the O
glycan RARE
at O
Asn149 NUMERIC
being O
dominant O
and O
that O
at O
Asn123 NUMERIC
being O
less O
effective O
. O

RESULTS O
: O
The O
introduction O
of O
the O
PAIP ALLCAPS
resulted O
in O
a O
significant O
( O
p O
< O
0 O
. O
001 O
) O
reduction O
in O
contaminating RARE
WBCs RARE
( O
median O
, O
30 O
, O
000 O
) O
from O
the O
numbers O
seen O
with O
FIP ALLCAPS
( O
median O
, O
2 O
, O
300 O
, O
000 O
) O
while O
maintaining O
the O
separation O
efficacy O
( O
47 O
%) O
and O
separation O
time O
. O

All O
were O
tested O
for O
serum O
ferritin I-GENE
( O
SF I-GENE
), O
hemoglobin I-GENE
( O
Hb I-GENE
) O
level O
and O
asked RARE
for O
detailed O
histories RARE
of O
donations RARE
and O
iron O
supplementation O
. O

Vascular RARE
endothelial I-GENE
growth I-GENE
factor I-GENE
( O
VEGF I-GENE
), O
a O
potent O
agonist O
secreted O
by O
virtually O
all O
cells O
, O
controls O
migration O
and O
division O
of O
vascular O
endothelial O
cells O
. O

The O
antioxidant O
agent O
pyrrolidine RARE
dithiocarbamate RARE
( O
PDTC ALLCAPS
) O
has O
been O
shown O
to O
protect O
endothelial O
cells O
( O
EC O
) O
from O
pro O
- O
inflammatory O
- O
induced O
and O
pro O
- O
oxidant RARE
- O
induced O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

We O
further O
studied O
the O
effects O
of O
SIE ALLCAPS
- I-GENE
1 I-GENE
hypermethylation RARE
on O
p21WAF1 NUMERIC
induction O
by O
STAT I-GENE
activation O
. O

Phd RARE
antibody O
- O
immunoreactive O
peptides O
are O
seen O
in O
light O
- O
adapted O
mouse O
retinal O
cytosolic O
and O
nuclear O
extracts O
. O

In O
the O
pRb I-GENE
(-) RARE
SAOS ALLCAPS
- O
2 O
cell O
line O
transiently O
transfected O
with O
a O
reporter O
plasmid O
containing O
six O
tal I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
, O
pRb I-GENE
enhances O
the O
transcriptional O
activity O
of O
tal I-GENE
- I-GENE
1 I-GENE
- O
E12 I-GENE
- O
Lmo2 NUMERIC
and O
tal I-GENE
- I-GENE
1 I-GENE
- O
E12 I-GENE
- O
Lmo2 NUMERIC
- O
Ldb1 NUMERIC
complexes O
but O
not O
that O
of O
a O
tal I-GENE
- I-GENE
1 I-GENE
- O
E12 I-GENE
heterodimer O
. O

This O
effect O
was O
not O
seen O
in O
conjunction O
with O
oxycodone RARE
, O
a O
morphine I-GENE
- I-GENE
like I-GENE
mu I-GENE
- I-GENE
receptor I-GENE
agonist O
. O

In O
contrast O
to O
the O
morphological O
criteria O
, O
the O
few O
data O
available O
from O
recent O
studies O
at O
the O
genetic O
level O
have O
suggested O
that O
EPVs RARE
infecting RARE
different O
insect O
orders RARE
are O
phylogenetically RARE
distant O
. O

Neurofibromatosis RARE
of O
the O
breast O
in O
a O
patient O
with O
Morbus RARE
von O
Recklinghausen RARE

In O
the O
premating RARE
period O
male O
rate O
of O
aggression O
was O
not O
significantly O
correlated O
with O
testosterone O
level O
. O

These O
results O
support O
the O
hypothesis O
that O
in O
the O
presence O
of O
tryptophan O
the O
ribosome O
translating RARE
tnaC LASTCAP
blocks O
Rho I-GENE
' O
s O
access O
to O
the O
boxA LASTCAP
and O
rut RARE
sites I-GENE
, O
thereby O
preventing O
transcription O
termination O
. O

In O
situ O
hybridization O
with O
the O
antisense O
RNA O
probes O
further O
supported O
the O
expression O
changes O
of O
these O
six O
clones O
and O
localized O
the O
changes O
in O
multiple O
germ O
cell O
stages O
as O
well O
as O
other O
cell O
types O
( O
Sertoli RARE
, O
interstitial O
and O
peritubular RARE
cells O
). O

The O
administration O
of O
the O
GnRH I-GENE
agonist O
reduced O
the O
bone O
mineral O
density O
in O
the O
whole O
femur O
to O
91 O
. O
0 O
% O
of O
that O
in O
the O
control O
group O
. O

Prevention O
, O
differential O
diagnosis O
and O
therapy O
of O
travel RARE
diarrhea RARE

This O
study O
shows O
that O
C I-GENE
/ I-GENE
EBPbeta I-GENE
is O
the O
predominant O
C I-GENE
/ I-GENE
EBP I-GENE
isoform I-GENE
found O
in O
activated O
stellate RARE
cells O
and O
that O
increased O
C I-GENE
/ I-GENE
EBPbeta I-GENE
protein I-GENE
and O
C I-GENE
/ I-GENE
EBPbeta I-GENE
binding O
to O
a O
proximal O
C I-GENE
/ I-GENE
EBP I-GENE
binding I-GENE
site I-GENE
in O
the O
promoter O
mediates O
the O
activating O
effect O
of O
acetaldehyde RARE
. O

Mutation O
analysis O
demonstrates O
that O
the O
motif O
TCCCCT ALLCAPS
is O
critical O
for O
PyRo1 NUMERIC
interaction O
. O

As O
with O
VP16 I-GENE
, O
the O
transactivation O
function O
of O
Luman RARE
is O
also O
regulated O
by O
HCF ALLCAPS
. O

After O
two O
successive O
rounds RARE
of O
selection O
by O
focus O
formation O
assay O
, O
a O
transforming O
ribozyme RARE
( O
Rz007 NUMERIC
) O
was O
identified O
. O

G O
., O
and O
Hyde RARE
, O
C O
. O

Our O
results O
suggest O
that O
proteasome O
inhibition O
leads O
to O
upregulation RARE
of O
specific O
members O
of O
transcription O
factor O
families O
controlling O
cellular O
stress O
response O
and O
proliferation O
. O

The O
ATR ALLCAPS
- O
X O
syndrome O
results O
from O
mutations O
of O
the O
XH2 NUMERIC
gene I-GENE
, O
located O
on O
the O
X O
chromosome O
( O
Xq13 NUMERIC
. O
3 O
) O
and O
coding O
for O
a O
transacting RARE
factor O
which O
regulates O
gene O
expression O
. O

AIMS ALLCAPS
: O
To O
evaluate O
the O
role O
of O
environmental O
intra O
- O
uterine O
factors O
in O
determining O
the O
birthweights RARE
of O
twins RARE
with O
increased O
susceptibility O
to O
diabetes O
and O
discordant RARE
for O
abnormal O
responses O
to O
the O
oral O
glucose O
tolerance O
test O
( O
OGTT ALLCAPS
) O
and O
verify RARE
the O
possible O
association O
of O
within O
- O
pair O
birthweight RARE
differences O
and O
metabolic O
abnormalities O
in O
adult O
life O
. O

In O
NASCIS ALLCAPS
III O
, O
a O
randomization RARE
imbalance RARE
occurred O
that O
allocated O
a O
disproportionate RARE
number O
of O
patients O
with O
no O
motor O
deficit O
( O
and O
therefore O
no O
chance RARE
for O
recovery O
) O
to O
the O
lower O
dose O
control O
group O
. O

Penicillin RARE
acylase RARE
( O
PA I-GENE
) O
from O
Escherichia O
coli O
ATCC11105 NUMERIC
is O
a O
periplasmic RARE
heterodimer O
consisting O
of O
a O
24 O
kDa O
small O
subunit O
and O
a O
65 O
kDa O
large O
subunit O
. O

A O
murine O
expressed O
sequence O
tag O
( O
EST O
) O
showing O
homology O
with O
erythropoietin I-GENE
receptor I-GENE
( O
EPOR ALLCAPS
) O
was O
identified O
in O
the O
EST O
database O
. O

When O
the O
LCx RARE
was O
partially O
occluded O
, O
mild O
PM ALLCAPS
- O
induced O
tachycardia O
resulted O
in O
decreased O
AoP LASTCAP
( O
P O
= O
0 O
. O
045 NUMERIC
) O
as O
well O
as O
in O
decreased O
SV O
( O
P O
= O
0 O
. O
048 NUMERIC
); O
the O
LVEDP ALLCAPS
remained O
high O
( O
P O
= O
0 O
. O
002 NUMERIC
). O

Activation O
of O
nuclear I-GENE
factor I-GENE
( I-GENE
NF I-GENE
)- I-GENE
kappaB I-GENE
and O
subsequent O
proinflammatory RARE
gene O
expression O
in O
human O
airway O
epithelial O
cells O
can O
be O
evoked O
by O
oxidative O
stress O
. O

GAP O
JUNCTIONS ALLCAPS
IN ALLCAPS
THE ALLCAPS
BRAIN ALLCAPS
: O
PREFACE ALLCAPS
. O

We O
have O
isolated O
and O
functionally O
characterized O
the O
mouse O
gene O
for O
the O
C2 O
subunit O
of O
the O
20S I-GENE
proteasome I-GENE
. O

Furthermore O
, O
as O
in O
the O
human O
gene O
, O
the O
3 O
' O
end O
of O
the O
Cacna1f NUMERIC
gene I-GENE
maps O
within O
5 O
kb O
of O
the O
5 O
' O
end O
of O
the O
mouse I-GENE
synaptophysin RARE
gene I-GENE
in O
a O
region O
orthologous RARE
to O
Xp11 NUMERIC
. O
23 O
. O

With O
the O
human I-GENE
Rhotekin RARE
cDNA I-GENE
as O
a O
probe O
, O
Northern O
hybridization O
revealed O
that O
a O
4 O
. O
0 O
- O
kb O
transcript O
was O
expressed O
at O
a O
high O
level O
in O
prostate O
and O
at O
a O
middle O
level O
in O
13 O
of O
16 O
tissues O
examined O
, O
but O
it O
cannot O
be O
detected O
in O
liver O
and O
lung O
tissues O
. O

Similarly O
, O
co O
- O
expression O
of O
a O
dominant O
- O
negative O
mutant O
of O
p38alpha NUMERIC
, O
but O
not O
of O
ERK1 I-GENE
, O
ERK2 I-GENE
, O
JNK1 I-GENE
, O
or O
JNK2 NUMERIC
, O
reduces O
basal O
and O
cadmium O
- O
induced O
pE1 NUMERIC
- I-GENE
luc RARE
activity O
. O

BACKGROUND O
: O
Gamma RARE
knife RARE
radiosurgery RARE
( O
GKR ALLCAPS
) O
is O
a O
safe O
and O
effective O
alternative O
to O
surgery O
for O
intracranial RARE
lesions O
. O

In O
hemodialyzed RARE
patients O
( O
Epo I-GENE
and O
Non O
- O
Epo I-GENE
group O
) O
leptin I-GENE
levels O
were O
significantly O
higher O
when O
compared O
to O
CAPD ALLCAPS
patients O
( O
Epo I-GENE
and O
Non O
- O
Epo I-GENE
group O
, O
respectively O
). O

It O
is O
mainly O
transcribed O
in O
neural O
structures O
and O
in O
developing O
organs O
characterized O
by O
epithelial O
- O
mesenchymal O
interactions O
. O

CONCLUSION O
: O
The O
alpha2 O
- O
adrenergic O
antagonist O
idazoxan RARE
increases O
glucose O
- O
induced O
sympathetic O
activity O
but O
not O
energy O
expenditure O
in O
obese O
subjects O
. O

ID ALLCAPS
- O
PaGIA LASTCAP
diphtheria RARE
toxin I-GENE
polymer RARE
particle O
diagnostic O
agent O
manufactured RARE
by O
DiaMed RARE
AG ALLCAPS
, O
Switzerland RARE
, O
was O
tried RARE
at O
bacteriological RARE
laboratory O
of O
Institute O
of O
Childhood RARE
Infections RARE
in O
St RARE
. O

Next RARE
, O
we O
show O
that O
two O
EMS ALLCAPS
- O
induced O
mutations O
, O
previously O
shown O
to O
interact O
genetically O
with O
zipper O
( O
Ebr RARE
), O
disrupt O
the O
RhoA I-GENE
locus I-GENE
. O

Therefore O
, O
the O
results O
indicate O
that O
repeated O
exposure O
to O
amphetamine O
or O
apomorphine RARE
overcomes RARE
the O
context O
- O
dependent O
component O
of O
sensitization O
of O
amphetamine O
- O
or O
apomorphine RARE
- O
induced O
stereotyped RARE
behavior O
. O

Testing RARE
for O
serum I-GENE
IgM I-GENE
binding O
to O
GM1 NUMERIC
ganglioside RARE
in O
clinical O
practice O
. O

Objective RARE
responses O
also O
occurred O
in O
studies O
that O
explored O
sequential O
use O
of O
exemestane RARE
after O
failure O
of O
aminoglutethimide RARE
( O
26 O
% O
with O
exemestane RARE
200 O
mg O
/ O
day O
) O
or O
other O
nonsteroidal RARE
aromatase I-GENE
inhibitors O
( O
6 O
. O
6 O
% O
with O
exemestane RARE
25 O
mg O
/ O
day O
). O

Topics RARE
reviewed O
here O
include O
: O
data O
supporting O
the O
association O
of O
myositis O
with O
cancer O
and O
the O
appropriate O
evaluations RARE
for O
malignancy O
in O
a O
myositis O
patient O
; O
an O
approach O
to O
the O
assessment O
of O
patients O
with O
dermatomyositis RARE
sine RARE
myositis O
; O
the O
usefulness RARE
of O
the O
clinicopathological RARE
and O
serological O
classifications RARE
; O
a O
discussion O
of O
whether O
childhood O
and O
adult O
myositis O
are O
the O
same O
or O
different O
entities RARE
; O
a O
review O
of O
those O
prognostic O
factors O
to O
consider O
in O
the O
clinical O
management O
of O
myositis O
patients O
; O
current O
approaches O
and O
their O
limitations O
for O
assessing O
disease O
activity O
and O
damage O
. O

The O
science RARE
of O
tissue O
engineering RARE
. O

Endonuclease RARE
III I-GENE
( O
Nth RARE
) O
of O
Escherichia O
coli O
is O
a O
DNA I-GENE
glycosylase I-GENE
essential O
for O
the O
removal O
of O
oxidised RARE
pyrimidine O
base O
residues O
from O
DNA O
. O

The O
duration O
of O
reactive O
hyperemia RARE
decreased O
with O
aging O
, O
but O
the O
difference O
between O
males O
and O
females O
was O
not O
significant O
at O
any O
age O
. O

Acquired RARE
bile O
duct O
blockage RARE
: O
entry O
of O
hepatobiliary RARE
agent O
into O
an O
intrahepatic O
abscess O
. O

Furthermore O
, O
this O
study O
looks RARE
at O
the O
impact O
of O
synthesis O
conditions O
on O
block O
length O
and O
crystallinity RARE
, O
and O
the O
impact O
of O
the O
blocking O
on O
both O
, O
crystallinity RARE
and O
solubility RARE
of O
the O
polymers O
. O

However O
, O
little O
was O
understood O
about O
the O
normal O
function O
of O
CREB I-GENE
- I-GENE
2 I-GENE
in O
mammalian O
development O
or O
organ O
physiology O
. O

The O
outer O
diameter O
and O
the O
thickness O
of O
the O
rotor RARE
are O
60 O
mm O
and O
8 O
mm O
, O
respectively O
. O

Both O
the O
MVBF ALLCAPS
and O
the O
maximum O
EMG O
activity O
in O
the O
right O
masseter RARE
and O
the O
left O
anterior O
temporalis RARE
muscles O
were O
significantly O
decreased O
during O
muscle O
pain O
when O
the O
subjects O
bit RARE
on O
the O
painful RARE
side O
. O

CONCLUSIONS O
: O
There O
is O
a O
relation O
in O
the O
topography RARE
of O
some O
visual O
field O
areas O
assessed O
by O
SWAP ALLCAPS
and O
the O
inferotemporal RARE
neuroretinal RARE
rim RARE
area O
, O
which O
may O
play O
a O
role O
in O
the O
diagnosis O
and O
follow O
- O
up O
of O
suspected O
glaucoma O
. O

The O
total O
alkaloids RARE
contained O
in O
the O
peel RARE
of O
Atzimba RARE
, O
Lopez RARE
, O
Marciana RARE
, O
Montsama RARE
, O
Murca RARE
, O
and O
Puebla RARE
was O
lower O
than O
the O
limits O
recommended O
for O
food O
safety O
. O

The O
detection O
success O
rate O
was O
determined O
for O
different O
markers O
using O
this O
MEK I-GENE
. O

Herein RARE
, O
we O
show O
that O
Smad3 NUMERIC
physically O
interacts O
with O
the O
HMG I-GENE
box O
domain O
of O
LEF1 NUMERIC
and O
that O
TGFbeta RARE
and O
Wnt I-GENE
pathways O
synergize RARE
to O
activate O
transcription O
of O
the O
Xenopus O
homeobox O
gene O
twin RARE
( O
Xtwn RARE
). O

The O
transmembrane O
topology O
of O
Na O
(+)/ RARE
H O
(+) O
exchanger RARE
NHE3 NUMERIC
has O
been O
studied O
using O
in O
vitro O
transcription O
/ O
translation O
of O
two O
types O
of O
fusion O
vectors O
designed O
to O
test O
membrane O
insertion O
properties O
of O
cDNA O
sequences O
encoding O
putative O
NHE3 NUMERIC
membrane O
spanning O
domains O
( O
msds RARE
). O

ACE I-GENE
- I-GENE
2 I-GENE
has O
a O
hydrophobic O
C O
terminus O
of O
H O
type O
. O

Members O
of O
the O
titin RARE
/ O
myosin I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
family O
play O
an O
essential O
role O
in O
the O
organization O
of O
the O
actin I-GENE
/ O
myosin I-GENE
cytoskeleton O
, O
especially O
in O
sarcomere RARE
assembly O
and O
function O
. O

We O
concluded O
that O
activation O
of O
c I-GENE
- I-GENE
fosER LASTCAP
mediated O
transcriptional O
inhibition O
of O
p21 I-GENE
( O
Cip1 I-GENE
/ O
WAF1 I-GENE
) O
through O
a O
previously O
uncharacterized O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
, O
revealing RARE
an O
important O
role O
for O
c I-GENE
- I-GENE
fos I-GENE
in O
negative O
control O
of O
cell O
cycle O
regulatory O
genes O
. O

Furthermore O
, O
a O
pTyr317 NUMERIC
Shc I-GENE
phosphopeptide I-GENE
selectively O
recognized O
Grb2 I-GENE
, O
Sos1 NUMERIC
, O
SHIP ALLCAPS
, O
and O
the O
p85 I-GENE
subunit I-GENE
of O
phosphatidylinositol I-GENE
3 I-GENE
' I-GENE
kinase I-GENE
from O
mast O
cells O
, O
as O
characterized O
by O
mass O
spectrometry O
. O

Although O
increased O
expression O
of O
the O
HMG I-GENE
- I-GENE
I I-GENE
/ I-GENE
Y I-GENE
proteins I-GENE
is O
associated O
with O
cellular O
proliferation O
, O
neoplastic O
transformation O
, O
and O
several O
human O
cancers O
, O
the O
role O
of O
these O
proteins O
in O
the O
pathogenesis O
of O
malignancy O
remains O
unclear O
. O

The O
naltrexone O
/ O
lofexidine RARE
combination O
was O
associated O
with O
a O
more O
rapid O
resolution O
of O
the O
opiate O
withdrawal O
syndrome O
than O
a O
7 O
- O
day O
lofexidine RARE
- O
only O
treatment O
schedule O
, O
without O
substantial O
increases O
in O
withdrawal O
symptoms O
or O
hypotensive O
side O
- O
effects O
. O

The O
first O
symptoms O
of O
enzootic RARE
calcinosis RARE
were O
noted O
in O
March RARE
1998 O
, O
when O
some O
of O
the O
cows O
developed O
locomotor O
abnormalities O
. O

Screening RARE
, O
counseling RARE
, O
and O
treatment O
for O
alcohol O
and O
illicit RARE
drug O
use O
should O
be O
essential O
components O
in O
comprehensive RARE
HBP ALLCAPS
care O
. O

Transcriptional O
regulation O
of O
the O
mouse I-GENE
cytosolic I-GENE
chaperonin RARE
subunit I-GENE
gene I-GENE
Ccta RARE
/ I-GENE
t I-GENE
- I-GENE
complex I-GENE
polypeptide I-GENE
1 I-GENE
by O
selenocysteine I-GENE
tRNA I-GENE
gene I-GENE
transcription I-GENE
activating I-GENE
factor I-GENE
family I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
. O

The O
unfolded RARE
protein O
response O
regulates O
multiple O
aspects O
of O
secretory O
and O
membrane O
protein O
biogenesis O
and O
endoplasmic O
reticulum O
quality O
control O
. O

PNRC ALLCAPS
: O
a O
proline O
- O
rich O
nuclear O
receptor O
coregulatory RARE
protein O
that O
modulates RARE
transcriptional O
activation O
of O
multiple O
nuclear O
receptors O
including O
orphan O
receptors O
SF1 NUMERIC
( O
steroidogenic RARE
factor I-GENE
1 I-GENE
) O
and O
ERRalpha1 NUMERIC
( O
estrogen I-GENE
related I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
1 I-GENE
). O

Studies O
using O
a O
reporter O
plasmid O
with O
a O
functionally O
disrupted O
sterol O
- O
responsive O
element O
( O
SRE O
)- O
1 O
revealed O
a O
reduced O
stimulatory O
response O
to O
IL I-GENE
- I-GENE
6 I-GENE
. O

However O
, O
there O
is O
still O
a O
subset O
of O
tumors O
that O
displayed O
no O
changes O
in O
these O
genes O
. O

We O
have O
shown O
that O
the O
epidural RARE
( O
EPI ALLCAPS
) O
delivery O
of O
morphine O
encapsulated RARE
in O
multivesicular RARE
liposomes O
( O
DepoFoam RARE
drug O
delivery O
system O
) O
produces O
a O
sustained O
clearance O
of O
morphine O
and O
a O
prolonged O
analgesia O
. O

Following O
EPI ALLCAPS
- O
C0401 NUMERIC
, O
but O
not O
saline O
or O
DepoFoam RARE
vehicle O
, O
there O
were O
transient O
(< O
72 O
hr O
) O
decreases O
in O
food O
consumption O
, O
arousal RARE
, O
hindlimb RARE
muscle O
tone O
, O
and O
body O
temperature O
. O

Bailey RARE
Instruments RARE
and O
Owen RARE
Mumford RARE
filaments RARE
were O
the O
most O
accurate O
with O
100 O
% O
buckling RARE
within O
+/- O
1 O
. O
0 O
g O
of O
10 O
g O
. O

PARTICIPANTS ALLCAPS
: O
Convenience RARE
sample O
of O
ambulatory O
outpatients RARE
with O
hereditary O
motor O
and O
sensory O
neuropathy O
, O
type O
I O
( O
n O
= O
9 O
), O
myotonic RARE
muscular O
dystrophy O
( O
n O
= O
10 O
), O
and O
able O
- O
bodied RARE
controls O
( O
n O
= O
11 O
). O

The O
effect O
of O
water O
deprivation O
for O
19 O
h O
on O
renal O
Na O
excretion O
of O
conscious O
adrenalectomized RARE
( O
ADX ALLCAPS
) O
sheep O
maintained O
on O
a O
constant O
intravenous O
infusion O
of O
aldosterone O
and O
cortisol O
( O
ADX ALLCAPS
- O
constant O
steroid O
sheep O
) O
was O
investigated O
. O

Neither O
is O
it O
a O
major O
cause O
of O
rehydration RARE
- O
induced O
renal O
Na O
retention O
. O

CONCLUSION O
: O
Rheumatic RARE
fever O
in O
the O
Nazareth RARE
area O
is O
still O
manifest O
. O

Antithrombin RARE
III I-GENE
deficiency O
: O
when O
substitute O
, O
when O
heparin O
? O
Thrombosis RARE
ABC ALLCAPS
, O
3 O
: O
The O
role O
of O
antithrombin I-GENE
III I-GENE

Specific O
class I-GENE
I I-GENE
and I-GENE
II I-GENE
histone I-GENE
deacetylases RARE
( O
HDACs RARE
) O
interact O
in O
vivo O
with O
BCoR LASTCAP
, O
suggesting O
that O
BCoR LASTCAP
may O
functionally O
link O
these O
two O
classes O
of O
HDACs RARE
. O

This O
is O
the O
first O
example O
of O
a O
eukaryotic O
transcription O
factor O
complex O
containing O
both O
a O
MADS I-GENE
- I-GENE
box I-GENE
and O
a O
forkhead RARE
protein I-GENE
, O
and O
it O
has O
important O
implications O
for O
the O
regulation O
of O
mammalian O
gene O
expression O
. O

After O
screening O
the O
Berkeley RARE
Drosophila O
Genome RARE
Project RARE
database O
with O
sequences O
from O
a O
recently O
characterized O
Leu I-GENE
- I-GENE
rich I-GENE
repeats I-GENE
- I-GENE
containing I-GENE
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
( O
LGR ALLCAPS
) O
from O
Drosophila O
( O
DLGR ALLCAPS
- I-GENE
1 I-GENE
), O
we O
identified O
a O
second O
gene O
for O
a O
different O
LGR ALLCAPS
( O
DLGR ALLCAPS
- I-GENE
2 I-GENE
) O
and O
cloned O
its O
cDNA O
. O

Degenerate RARE
primers O
homologous O
to O
highly O
conserved O
regions O
of O
known O
CYP3A NUMERIC
sequences I-GENE
were O
used O
for O
initial O
RT O
- O
PCRs RARE
. O

When O
cells O
were O
microinjected RARE
with O
TFOs RARE
designed O
to O
bind O
to O
a O
30 O
- O
bp O
polypurine RARE
site O
situated O
between O
the O
two O
TK I-GENE
genes I-GENE
, O
recombination O
was O
observed O
at O
frequencies O
in O
the O
range O
of O
1 O
%, O
2 O
, O
500 O
- O
fold O
above O
the O
background O
. O

Methyllevamisole RARE
was O
used O
as O
the O
internal O
standard O
. O

Resistance O
ratios O
for O
the O
other O
field O
strains O
obtained O
by O
comparison O
with O
the O
R5 NUMERIC
strain O
ranged O
from O
24 O
. O
5 O
to O
239 O
for O
topical RARE
application O
and O
from O
1 O
. O
2 O
to O
9 O
. O
8 O
for O
the O
glass O
jar RARE
method O
. O

Only O
transcripts O
specific O
for O
TSGF ALLCAPS
- I-GENE
2 I-GENE
are O
detected O
in O
ovary O
and O
testes O
tissues O
of O
adults O
as O
well O
as O
in O
puparia RARE
, O
while O
neither O
gene O
is O
expressed O
during O
the O
larval O
developmental O
stages O
. O

In O
a O
gel O
retardation O
assay O
using O
HepG2 O
nuclear O
extracts O
, O
the O
5 O
' O
flanking O
sequence O
from O
- O
74 O
to O
- O
46 O
showed O
a O
shifted O
band O
. O

Reliability RARE
of O
cervical O
range O
of O
motion O
using O
the O
OSI ALLCAPS
CA O
6000 NUMERIC
spine O
motion O
analyser RARE
on O
asymptomatic O
and O
symptomatic O
subjects O
. O

Coimmunoprecipitation RARE
experiments O
performed O
in O
transfected O
cells O
showed O
that O
BCMA ALLCAPS
associates O
with O
TNFR ALLCAPS
- I-GENE
associated I-GENE
factor I-GENE
( I-GENE
TRAF ALLCAPS
) I-GENE
1 I-GENE
, O
TRAF2 I-GENE
, O
and O
TRAF3 NUMERIC
adaptor I-GENE
proteins I-GENE
. O

Since O
the O
RINX ALLCAPS
gene I-GENE
is O
likely O
an O
ortholog RARE
of O
the O
goldfish RARE
Vsx1 NUMERIC
gene I-GENE
, O
it O
has O
been O
named O
VSX1 NUMERIC
by O
the O
Human O
Gene O
Nomenclature RARE
Committee O
. O

The O
chromosomal O
localization O
on O
distal O
chromosome O
7 O
places RARE
it O
in O
a O
cluster O
of O
imprinted O
genes O
, O
flanked O
by O
the O
previously O
described O
Tapa1 NUMERIC
and O
Kcnq1 NUMERIC
genes I-GENE
. O

Activation O
of O
PKA I-GENE
by O
8 O
- O
bromo RARE
- O
cyclic O
AMP O
or O
forskolin O
, O
and O
inhibition O
of O
PKC I-GENE
by O
calphostin RARE
C O
, O
resulted O
in O
a O
significant O
decrease O
in O
3TP NUMERIC
activity O
as O
well O
as O
in O
vitro O
ERK I-GENE
kinase I-GENE
activity O
in O
CRAC ALLCAPS
. O

The O
present O
study O
was O
designed O
to O
evaluate O
the O
sensitivity O
and O
specificity O
of O
AMP O
CT O
( O
Gen RARE
- O
Probe RARE
Incorporated RARE
, O
San RARE
Diego RARE
, O
CA O
, O
USA ALLCAPS
) O
on O
urogenital RARE
specimens O
taken O
from O
symptomatic O
patients O
and O
on O
first O
void RARE
urine O
( O
FVU ALLCAPS
) O
specimens O
from O
asymptomatic O
patients O
. O

Mus81p NUMERIC
also O
shares O
homology O
with O
motifs O
found O
in O
the O
XPF ALLCAPS
endonuclease I-GENE
superfamily I-GENE
. O

Double O
mutant O
analysis O
suggests O
that O
Rad54p NUMERIC
and O
Mus81p NUMERIC
act O
in O
one O
pathway O
for O
the O
repair O
of O
, O
or O
tolerance O
to O
, O
UV O
- O
induced O
DNA O
damage O
. O

The O
linear O
plasmid O
pCLU1 NUMERIC
from O
the O
yeast O
Kluyveromyces RARE
lactis O
normally O
replicates RARE
in O
the O
cytoplasm O
, O
with O
the O
aid O
of O
the O
helper RARE
linear O
plasmid O
pGKL2 NUMERIC
, O
using O
terminal I-GENE
protein I-GENE
( O
TP ALLCAPS
) O
as O
a O
primer O
. O

The O
repetitive O
ETn RARE
( O
early I-GENE
transposon I-GENE
) O
family O
of O
sequences O
represents O
an O
active O
" O
mobile O
mutagen RARE
" O
in O
the O
mouse O
genome O
. O

The O
two O
main O
experimental O
variables O
were O
the O
attended RARE
hemifield RARE
( O
left O
or O
right O
) O
and O
the O
proportion O
of O
trials O
requiring O
a O
shift O
within O
that O
hemifield RARE
( O
20 O
% O
or O
80 O
%). O

The O
measurement O
of O
NO O
in O
biological O
systems O
using O
chemiluminescence RARE
. O

Biochemical O
examinations O
of O
calcium O
- O
phosphorus O
metabolism O
included O
ions O
and O
PTH I-GENE
concentrations O
in O
blood O
serum O
, O
and O
the O
activity O
of O
bone O
isoenzyme RARE
of O
AP I-GENE
. O

Atorvastatin RARE
was O
the O
most O
cost O
- O
effective O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
inhibitor O
. O

Pharmacoeconomic RARE
assessment O
of O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
inhibitor O
therapy O
: O
an O
analysis O
based O
on O
the O
CURVES ALLCAPS
study O
. O

Interestingly O
, O
although O
E O
domains O
of O
these O
two O
receptors O
are O
much O
less O
conserved O
, O
replacement O
of O
this O
domain O
in O
rtER LASTCAP
by O
its O
human O
counterpart O
resulted O
in O
higher O
estradiol O
sensitivity O
but O
no O
increase O
in O
the O
magnitude O
of O
transactivation O
. O

G O
- O
DNA O
is O
a O
four O
- O
stranded O
DNA O
structure O
with O
diverse O
putative O
biological O
roles O
. O

The O
effectiveness O
of O
NRT ALLCAPS
appears O
to O
be O
largely O
independent O
of O
the O
intensity O
of O
additional O
support O
provided O
to O
the O
smoker RARE
. O

SELECTION ALLCAPS
CRITERIA ALLCAPS
: O
All O
controlled O
trials O
where O
adults O
with O
schizophrenia O
or O
similar O
illnesses RARE
were O
randomised O
to O
quetiapine RARE
, O
placebo O
or O
other O
neuroleptic O
drugs O
and O
where O
clinically O
relevant O
outcomes O
were O
reported O
. O

8 O
% O
( O
95 O
% O
CI O
, O
21 O
. O
3 O
- O
44 O
. O
3 O
%). O

In O
contrast O
, O
the O
action O
of O
GLP ALLCAPS
- I-GENE
1 I-GENE
at O
the O
CRE O
was O
not O
blocked O
by O
cotransfection O
with O
M1 I-GENE
- I-GENE
CREB I-GENE
, O
an O
isoform O
that O
lacks O
a O
consensus O
serine O
residue O
serving RARE
as O
substrate O
for O
PKA I-GENE
- O
mediated O
phosphorylation O
. O

Because O
all O
PDGFbetaR LASTCAP
fusions I-GENE
described O
thus O
far O
result O
in O
splicing O
to O
a O
common O
exon O
of O
this O
gene O
, O
we O
performed O
5 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
PCR O
on O
patient O
RNA O
. O

CONCLUSIONS O
: O
In O
essential O
hypertension O
an O
acute O
protein O
load O
induces O
a O
decrease O
in O
GFR O
that O
may O
normalize RARE
under O
antihypertensive O
treatment O
. O

This O
finding O
suggested O
that O
the O
PI3K NUMERIC
- O
Akt I-GENE
activation O
pathway O
plays O
some O
role O
in O
the O
antiapoptotic RARE
effect O
of O
EPO I-GENE
. O

Nine RARE
DNA O
fragments O
that O
were O
specifically O
recognized O
and O
bound O
by O
histidine O
- O
tagged O
AdpA LASTCAP
were O
isolated O
by O
cycles O
of O
a O
gel O
mobility O
shift O
- O
PCR O
method O
. O

To O
determine O
whether O
the O
NTP ALLCAPS
- O
binding O
motif O
is O
important O
for O
Rad24 NUMERIC
function O
, O
we O
mutated O
the O
conserved O
lysine O
( O
115 O
) O
residue O
in O
this O
motif O
. O

The O
carboxyl O
- O
terminal O
proline O
- O
rich O
domain O
of O
SOS1 NUMERIC
is O
involved O
in O
the O
interaction O
with O
the O
PLC I-GENE
- I-GENE
gamma1 NUMERIC
SH3 I-GENE
domain I-GENE
. O

From O
transient O
expression O
studies O
, O
we O
could O
demonstrate O
that O
the O
SH3 I-GENE
domain I-GENE
of O
PLC I-GENE
- I-GENE
gamma1 NUMERIC
is O
necessary O
for O
the O
association O
with O
SOS1 NUMERIC
in O
vivo O
. O

Six O
distinct O
Ets I-GENE
mRNAs I-GENE
were O
identified O
: O
Ets2 NUMERIC
, O
Fli1 NUMERIC
, O
GABPalpha RARE
, O
SAP1 NUMERIC
, O
Elk1 NUMERIC
, O
and O
PE1 NUMERIC
. O

A O
2 O
kb O
transcript O
was O
isolated O
from O
brain O
that O
encodes O
a O
approximately O
57 O
kDa O
protein O
; O
the O
predicted O
protein O
contains O
the O
known O
N I-GENE
- I-GENE
terminal I-GENE
Ets I-GENE
domain I-GENE
of O
PE1 NUMERIC
and O
a O
novel O
C O
- O
terminal O
domain O
with O
signficant RARE
homology O
to O
murine I-GENE
ERF ALLCAPS
. O

Twenty O
eligible RARE
patients O
with O
cirrhosis O
were O
randomized O
into O
two O
groups O
: O
10 O
patients O
treated O
with O
6 O
million O
units O
of O
natural O
IFN I-GENE
- I-GENE
beta I-GENE
twice O
a O
week O
for O
36 O
months O
and O
10 O
patients O
without O
IFN I-GENE
therapy O
. O

Wnt I-GENE
- I-GENE
1 I-GENE
overexpression O
in O
mammary O
epithelial O
cells O
induced O
cyclin I-GENE
D1 I-GENE
mRNA I-GENE
and O
targeted O
overexpression O
of O
Wnt I-GENE
- I-GENE
1 I-GENE
in O
the O
mammary O
gland O
of O
transgenic O
mice O
increased O
both O
ILK I-GENE
activity O
and O
cyclin I-GENE
D1 I-GENE
levels O
. O

Intravenous O
versus O
oral O
administration O
of O
amitriptyline RARE
in O
patients O
with O
major O
depression O
. O

Deletion O
of O
the O
RVH ALLCAPS
domain I-GENE
resulted O
in O
loss O
of O
Ca O
( O
2 O
+)- O
dependent O
activation O
. O

Logistic RARE
regression O
analysis O
revealed O
that O
physicians O
were O
3 O
. O
6 O
times O
more O
likely O
to O
detect O
thin O
lesions O
(</= RARE
0 O
. O
75 O
mm O
) O
compared O
with O
nonphysician RARE
detectors RARE
( O
95 O
% O
confidence O
interval O
[ O
95 O
% O
CI O
], O
2 O
. O
1 O
, O
6 O
. O
5 O
; O
P O
= O
0 O
. O
0001 O
). O

Erythema RARE
exsudativum RARE
multiforme RARE
induced O
by O
granulocyte I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
in O
an O
allogeneic RARE
peripheral O
blood O
stem O
cell O
donor O
. O

VaI LASTCAP
and O
VaII LASTCAP
co O
- O
immunoprecipitated O
with O
ErbB2 NUMERIC
, O
but O
not O
with O
ErbB1 NUMERIC
, O
ErbB3 NUMERIC
, O
or O
ErbB4 NUMERIC
. O

While O
interactions O
of O
WT ALLCAPS
and O
variant O
TGF I-GENE
- I-GENE
alpha I-GENE
with O
the O
ErbBs RARE
all O
result O
in O
ErbB2 NUMERIC
activation O
, O
they O
produce O
different O
biological O
consequences O
, O
suggesting O
that O
the O
various O
TGF I-GENE
- I-GENE
alpha I-GENE
precursors I-GENE
differentially O
modulate O
ErbB I-GENE
signaling O
. O

It O
is O
now O
well O
accepted O
that O
the O
p53 I-GENE
C I-GENE
- I-GENE
terminus I-GENE
plays O
a O
central O
role O
in O
controlling O
the O
activity O
of O
the O
wild O
- O
type O
molecule O
. O

In O
contrast O
to O
full I-GENE
- I-GENE
length I-GENE
E2F I-GENE
- I-GENE
3 I-GENE
, O
which O
is O
expressed O
only O
at O
the O
G1 O
/ O
S O
boundary O
, O
E2F I-GENE
- I-GENE
3B NUMERIC
is O
detected O
throughout O
the O
cell O
cycle O
with O
peak O
levels O
in O
GO ALLCAPS
where O
it O
is O
associated O
with O
Rb I-GENE
. O

The O
transcription O
factor O
Jun I-GENE
( O
c I-GENE
- I-GENE
Jun I-GENE
) O
functions O
as O
a O
recipient O
of O
extracellular O
growth O
signals O
and O
converts RARE
them O
into O
patterns O
of O
gene O
expression O
. O

Developmental RARE
toxicity O
of O
the O
class O
III O
antiarrhythmic O
agent O
almokalant RARE
in O
mice O
. O

This O
compound O
is O
the O
main O
bioactive RARE
metabolite O
of O
trimebutine RARE
II O
( O
Debridat RARE
, O
CAS O
39133 NUMERIC
- O
31 O
- O
8 O
), O
an O
antispasmodic RARE
widely O
used O
for O
intestinal O
diseases O
since O
1969 NUMERIC
. O

In O
addition O
to O
its O
effect O
in O
augmenting RARE
the O
neutrophil O
response O
to O
eccentric RARE
exercise O
, O
vitamin O
E O
causes O
a O
greater O
increase O
in O
circulating O
creatine I-GENE
kinase I-GENE
activity O
, O
perhaps O
indicating O
increased O
skeletal O
muscle O
repair O
. O

This O
enabled RARE
the O
formation O
of O
stem O
- O
loop O
templates O
with O
the O
fusion O
point O
of O
the O
chimeric O
transcript O
in O
the O
loop O
and O
the O
use O
of O
MLL ALLCAPS
primers O
in O
two O
- O
sided RARE
PCR O
. O

CONCLUSION O
: O
The O
authors O
emphasize RARE
that O
the O
initial O
management O
of O
primary O
STS ALLCAPS
should O
be O
adequate O
and O
suggest O
that O
safty RARE
margin O
of O
> O
or O
= O
2 O
cm O
should O
be O
adhered RARE
to O
. O

Measurements O
were O
compared O
with O
two O
computerised RARE
treatment O
planning O
systems O
-- O
Theraplan RARE
VO5B NUMERIC
and O
ADAC ALLCAPS
Pinnacle3 NUMERIC
V4 NUMERIC
. O
0b NUMERIC
. O

Activation O
was O
biphasic O
; O
peaking RARE
at O
5 O
- O
10 O
min O
and O
24 O
h O
after O
treatment O
. O

Whereas O
MARTA1 NUMERIC
is O
clearly O
detectable O
in O
crude O
lysates O
, O
cytosolic O
and O
ribosomal O
salt O
- O
wash RARE
fractions O
, O
and O
in O
nuclear O
extracts O
, O
MARTA2 NUMERIC
is O
preferentially O
found O
in O
the O
ribosomal O
salt O
- O
wash RARE
preparation O
. O

It O
contains O
25 O
exons O
coding O
for O
a O
4 O
. O
7kb NUMERIC
transcript O
including O
large O
5 O
'- O
and O
3 O
'- O
( O
1218bp NUMERIC
and O
701bp NUMERIC
, O
respectively O
) O
untranslated O
regions O
( O
UTRs RARE
). O

Five O
of O
the O
PDP1 NUMERIC
isoforms I-GENE
differ O
by O
the O
substitution O
or O
insertion O
of O
amino O
acids O
at O
or O
near O
the O
N O
- O
terminal O
of O
the O
protein O
. O

The O
optimum RARE
technique O
for O
the O
pathological O
examination O
of O
sentinel RARE
lymph O
nodes O
( O
SLNs RARE
) O
is O
still O
under O
debate RARE
. O

Partial O
correction O
of O
anemia O
with O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
likely O
reduces O
left O
ventricular O
mass O
and O
volume O
. O

This O
study O
demonstrated O
that O
the O
PFA ALLCAPS
- O
100 O
analyzer RARE
can O
accurately O
assess O
vWF I-GENE
- O
dependent O
platelet O
function O
and O
detect O
other O
platelet O
defects O
under O
high O
shear O
stress O
in O
complex O
patient O
populations O
. O

We O
recently O
reported O
the O
molecular O
cloning O
of O
a O
PL I-GENE
scramblase RARE
of O
human O
( O
HuPLSCR1 NUMERIC
) O
and O
mouse O
origin O
, O
respectively O
. O

To O
analyze O
the O
regulatory O
activity O
of O
Gtx RARE
, O
we O
first O
identified O
the O
optimal O
Gtx RARE
- I-GENE
binding I-GENE
sequence I-GENE
using O
an O
in O
vitro O
DNA O
- O
binding O
assay O
. O

Using O
an O
oligomer RARE
duplex O
5 O
'- O
A O
( O
GGGTTA ALLCAPS
)( O
5 O
)- O
3 O
'/ RARE
5 O
'-( RARE
TAACCC ALLCAPS
)( O
5 O
) O
T O
- O
3 O
' O
as O
a O
template O
- O
primer O
, O
we O
show O
that O
both O
the O
Klenow RARE
fragment I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
and O
HIV I-GENE
reverse I-GENE
transcriptase I-GENE
could O
expand RARE
telomere O
DNA O
sequences O
as O
well O
, O
giving O
products O
greater O
than O
the O
size O
of O
the O
template O
DNA O
. O

Cdk2 I-GENE
and O
MAPK I-GENE
precipitates RARE
from O
untreated O
tumor O
lysates O
phosphorylated O
recombinant I-GENE
wild I-GENE
- I-GENE
type I-GENE
p27 I-GENE
but O
not O
the O
T187A NUMERIC
mutant O
in O
vitro O
. O

The O
loss O
of O
avirulence RARE
activity O
because O
of O
mutations O
in O
the O
acidic O
transcriptional O
activation O
domain O
was O
restored O
by O
addition O
of O
the O
activation O
domain O
from O
the O
herpes I-GENE
simplex I-GENE
viral I-GENE
protein I-GENE
VP16 I-GENE
. O

Mutations O
in O
the O
RP2 NUMERIC
locus I-GENE
at I-GENE
Xp11 NUMERIC
. I-GENE
3 I-GENE
were O
found O
in O
a O
further O
10 O
- O
20 O
% O
of O
XLRP ALLCAPS
patients O
, O
as O
predicted O
from O
linkage O
studies O
. O

The O
limit O
between O
the O
cecum RARE
and O
the O
ascending O
colon O
was O
externally RARE
marked O
by O
the O
sulcus RARE
cecocolicus RARE
dorsalis RARE
and O
ventralis RARE
. O

Subsequently RARE
, O
HD O
inhibited O
healing O
because O
it O
significantly O
delayed O
epithelialization RARE
and O
caused O
protracted RARE
inflammation O
. O

The O
effectiveness O
of O
the O
haemodialysate RARE
Solcoseryl RARE
for O
second O
- O
intention RARE
wound O
healing O
in O
horses O
and O
ponies RARE
. O

Although O
there O
is O
little O
evidence O
that O
diet O
composition O
plays O
a O
clinically O
important O
role O
in O
the O
absorption O
or O
expenditure O
of O
energy O
, O
it O
does O
appear O
to O
play O
a O
role O
in O
food O
intake O
. O

These O
findings O
were O
reinforced O
by O
an O
analysis O
that O
was O
restricted O
to O
living O
donor O
transplants RARE
without O
acute O
rejection O
. O

These O
results O
further O
support O
an O
important O
role O
for O
CBF2 I-GENE
in O
mediating O
EBNA2 I-GENE
transactivation O
; O
they O
identify O
the O
hnRNP I-GENE
protein I-GENE
AUF1 NUMERIC
as O
a O
major O
component O
of O
CBF2 I-GENE
and O
are O
also O
the O
first O
evidence O
of O
a O
cis O
- O
acting O
sequence O
other O
than O
a O
CBF1 I-GENE
binding I-GENE
element I-GENE
that O
is O
able O
to O
confer O
responsiveness O
to O
EBNA2 I-GENE
. O

The O
genome O
of O
the O
human O
herpesvirus O
8 O
( O
HHV ALLCAPS
- O
8 O
) O
contains O
a O
cluster O
of O
open O
reading O
frames O
( O
ORFs O
) O
encoding O
proteins O
with O
homology O
to O
the O
cellular O
transcription O
factors O
of O
the O
interferon I-GENE
regulatory I-GENE
factor I-GENE
( O
IRF I-GENE
) O
family O
. O

Despite O
these O
limitations O
the O
CHIME ALLCAPS
monitor O
provides O
an O
opportunity RARE
to O
record O
physiological O
data O
previously O
unavailable RARE
in O
the O
home O
. O

DATA ALLCAPS
SYNTHESIS ALLCAPS
: O
Intracoronary RARE
ultrasound O
has O
been O
shown O
to O
improve O
upon O
demonstrated O
weaknesses RARE
of O
coronary O
angiography O
. O

TB O
bone O
area O
( O
p O
< O
0 O
. O
001 O
), O
height O
( O
p O
< O
0 O
. O
01 O
), O
years O
in O
present O
colony O
( O
p O
= O
0 O
. O
03 O
), O
and O
menses RARE
( O
p O
< O
0 O
. O
01 O
) O
predicted O
TB O
BMC ALLCAPS
. O

CREST ALLCAPS
syndrome O
; O
a O
changing O
clinical O
significance O

Troglitazone RARE
also O
induced O
an O
endogenous I-GENE
PPARgamma I-GENE
target I-GENE
gene I-GENE
in O
T24 NUMERIC
cells O
, O
adipocyte RARE
- I-GENE
type I-GENE
fatty I-GENE
acid I-GENE
binding I-GENE
protein I-GENE
( O
A I-GENE
- I-GENE
FABP ALLCAPS
), O
the O
expression O
of O
which O
correlates O
with O
bladder O
cancer O
differentiation O
. O

Viruses RARE
were O
isolated O
from O
9 O
lungs O
: O
7 O
with O
PI O
- O
3V NUMERIC
, O
1 O
with O
NCP ALLCAPS
BVDV ALLCAPS
type O
1 O
, O
and O
1 O
with O
both O
BVHV ALLCAPS
- O
1 O
and O
BVDV ALLCAPS
. O

The O
RS447 NUMERIC
human I-GENE
megasatellite RARE
tandem I-GENE
repetitive I-GENE
sequence I-GENE
encodes O
a O
novel O
deubiquitinating RARE
enzyme O
with O
a O
functional O
promoter O
. O

Previous O
experience O
and O
contextual RARE
cues RARE
are O
essential O
elements O
in O
the O
generation O
of O
a O
subjective RARE
prediction O
. O

To O
characterize O
this O
effect O
, O
we O
looked RARE
for O
targets O
of O
NS1 I-GENE
influenza I-GENE
virus I-GENE
protein I-GENE
among O
cellular O
translation O
factors O
. O

Collectively O
, O
these O
and O
previously O
published O
data O
suggest O
a O
model O
where O
NS1 I-GENE
recruits RARE
eIF4GI NUMERIC
specifically O
to O
the O
5 O
' O
untranslated O
region O
( O
5 O
' O
UTR O
) O
of O
the O
viral O
mRNA O
, O
allowing O
for O
the O
preferential O
translation O
of O
the O
influenza O
virus O
messengers RARE
. O

Eukaryotic RARE
translation I-GENE
initiation I-GENE
factor I-GENE
4GI NUMERIC
is O
a O
cellular O
target O
for O
NS1 I-GENE
protein I-GENE
, O
a O
translational O
activator O
of O
influenza O
virus O
. O

Splicing RARE
of O
the O
K I-GENE
- I-GENE
SAM ALLCAPS
alternative O
exon O
of O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
2 I-GENE
gene I-GENE
is O
heavily RARE
dependent O
on O
the O
U O
- O
rich O
sequence O
IAS1 NUMERIC
lying RARE
immediately O
downstream O
from O
its O
5 O
' O
splice O
site O
. O

( O
iii O
) O
In O
these O
cells O
, O
PKCbeta RARE
plays O
a O
unique O
Ras I-GENE
- O
independent O
role O
in O
mediating O
insulin I-GENE
but O
not O
EGF I-GENE
or O
other O
growth O
factor O
mitogenic O
signals O
. O

However O
, O
it O
is O
not O
known O
whether O
the O
recently O
identified O
isoforms O
Vav2 NUMERIC
and O
Vav3 NUMERIC
, O
which O
are O
broadly O
expressed O
, O
can O
couple RARE
with O
similar O
classes O
of O
receptors O
, O
nor O
is O
it O
known O
whether O
all O
Vav RARE
isoforms I-GENE
possess O
identical O
functional O
activities O
. O

Transcriptional O
regulation O
of O
fbp1 NUMERIC
promoter I-GENE
constructs I-GENE
containing O
only O
UAS1 O
or O
UAS2 NUMERIC
confirms RARE
that O
the O
PKA I-GENE
and O
MAPK I-GENE
regulation O
is O
targeted O
to O
both O
sites O
. O

X O
- O
ray O
crystallographic RARE
data O
show O
that O
the O
PLZF I-GENE
BTB I-GENE
/ O
POZ O
domain O
forms O
an O
obligate RARE
homodimer O
via O
an O
extensive O
interface O
. O

The O
ability O
of O
SMRT I-GENE
to O
associate O
with O
these O
transcription O
factors O
and O
thereby O
to O
mediate O
repression O
is O
strongly O
inhibited O
by O
activation O
of O
tyrosine I-GENE
kinase I-GENE
signaling O
pathways O
, O
such O
as O
that O
represented O
by O
the O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
. O

In O
addition O
, O
the O
ketamine RARE
- O
treated O
rats O
had O
more O
neurons O
and O
glial RARE
cells O
surrounding O
the O
ventricles O
. O

The O
differences O
were O
as O
follows O
: O
for O
overall O
response O
rate O
p O
= O
0 O
. O
004 NUMERIC
; O
power O
( O
for O
p O
= O
0 O
. O
05 O
) O
85 O
%; O
for O
survival O
p O
= O
0 O
. O
09 O
; O
for O
grade O
IV O
granulocytopenia RARE
p O
= O
0 O
. O
3 O
; O
and O
for O
febrile RARE
neutropenia O
p O
= O
0 O
. O
61 O
. O

Patients O
were O
randomly O
assigned O
to O
treatment O
with O
the O
ACE I-GENE
inhibitor O
perindopril RARE
( O
and O
the O
diuretic O
indapamide RARE
for O
those O
with O
no O
definite O
indication O
for O
or O
contraindication RARE
to O
treatment O
with O
a O
diuretic O
) O
or O
matching RARE
placebo O
( O
s O
). O

The O
results O
indicate O
that O
the O
open O
- O
section O
effect O
decreases O
the O
torsional RARE
stiffness O
and O
stress O
concentration O
effects O
decrease O
the O
torsional RARE
strength O
of O
a O
long O
bone O
with O
a O
longitudinal O
defect O
. O

These O
regions O
may O
be O
differentially O
involved O
in O
tissue O
- O
specificity O
, O
and O
/ O
or O
circadian O
regulation O
, O
of O
the O
human I-GENE
hPer1 NUMERIC
gene I-GENE
transcription O
. O

Additionally O
, O
putative O
CF1 NUMERIC
/ O
USP ALLCAPS
and O
Broad RARE
Complex RARE
Z2 NUMERIC
transcription O
factor O
elements O
were O
found O
in O
the O
upstream O
regions O
of O
MIH ALLCAPS
and O
MO ALLCAPS
- I-GENE
IH ALLCAPS
genes O
respectively O
. O

Sequence O
analysis O
reveals O
that O
the O
newly O
discovered O
oasA2 NUMERIC
gene I-GENE
represents O
a O
pseudogene O
that O
is O
still O
transcribed O
, O
but O
is O
not O
functionally O
translated O
. O

Genomic O
and O
functional O
characterization O
of O
the O
oas RARE
gene I-GENE
family I-GENE
encoding O
O I-GENE
- I-GENE
acetylserine RARE
( I-GENE
thiol RARE
) I-GENE
lyases RARE
, O
enzymes O
catalyzing RARE
the O
final O
step O
in O
cysteine O
biosynthesis O
in O
Arabidopsis O
thaliana O
. O

Two O
distinct O
recessive O
susceptibility O
loci O
for O
vasculitis O
were O
mapped O
on O
chromosome O
( O
Chr O
) O
4 O
at O
D4Mit89 NUMERIC
and O
D4Mit147 NUMERIC
in O
both O
progenies RARE
. O

During O
treatment O
, O
the O
phosphorylation O
state O
of O
Rb I-GENE
shifted O
to O
a O
hypophosphorylated RARE
form O
. O
mRNA O
for O
the O
HPV O
E6 I-GENE
/ O
E7 I-GENE
genes O
decreased O
; O
however O
, O
significant O
changes O
in O
the O
E7 I-GENE
protein I-GENE
were O
not O
observed O
, O
while O
increased O
levels O
of O
Rb I-GENE
immunoprecipitated O
with O
anti I-GENE
- I-GENE
E7 I-GENE
antibodies I-GENE
were O
observed O
. O

Further O
characterization O
of O
these O
putative O
Hoxa RARE
- I-GENE
1 I-GENE
target I-GENE
genes I-GENE
will O
aid O
in O
delineating RARE
the O
functions O
of O
the O
Hoxa RARE
- I-GENE
1 I-GENE
protein I-GENE
in O
the O
differentiation O
processes O
which O
occur O
during O
embryogenesis O
. O

The O
ability O
of O
U6 I-GENE
- O
U57 NUMERIC
mutants O
to O
influence O
the O
fidelity O
of O
both O
branch O
site O
and O
3 O
' O
splice O
site O
recognition O
suggests O
that O
this O
nucleotide O
may O
participate O
in O
the O
formation O
of O
the O
active O
site O
( O
s O
) O
of O
the O
spliceosome O
. O

We O
have O
determined O
the O
structure O
of O
the O
WNT ALLCAPS
- I-GENE
2B I-GENE
gene I-GENE
. O

The O
role O
of O
daunorubicin RARE
in O
induction O
therapy O
for O
adult O
acute O
myeloid O
leukemia O

Five O
of O
the O
Aeromonas RARE
strains O
and O
one O
of O
V O
cholerae O
non O
- O
O1 NUMERIC
were O
positive O
for O
enterotoxin O
activity O
. O

TNF I-GENE
- I-GENE
alpha I-GENE
induced O
a O
dose O
- O
and O
time O
- O
dependent O
increase O
in O
cyclooxygenase RARE
- I-GENE
2 I-GENE
( O
COX ALLCAPS
- I-GENE
2 I-GENE
) O
expression O
and O
PGE2 O
formation O
in O
human O
NCI ALLCAPS
- O
H292 NUMERIC
epithelial O
cells O
. O

The O
therapy O
time O
to O
deliver RARE
the O
NCS ALLCAPS
therapeutic O
dose O
of O
10000 NUMERIC
RBE ALLCAPS
- O
cGy RARE
, O
is O
27 O
times O
longer O
when O
157Gd NUMERIC
is O
used O
instead O
of O
10B NUMERIC
. O

Mis3 NUMERIC
is O
needed O
for O
the O
formation O
of O
18S NUMERIC
ribosome I-GENE
RNA I-GENE
, O
and O
may O
hence O
direct O
the O
level O
of O
proteins O
required O
for O
the O
coupling O
. O

Losartan RARE
Intervention RARE
For O
Endpoint RARE
. O

CONCLUSION O
: O
Vitrectomy RARE
for O
vitreous O
hemorrhage O
in O
Terson RARE
syndrome O
is O
a O
safe O
and O
effective O
procedure O
, O
offering RARE
a O
rapid O
and O
prolonged O
improvement O
in O
vision O
. O

RNA O
in O
situ O
hybridization O
on O
brain O
sections O
of O
normal O
human O
embryos O
revealed O
a O
strong O
labeling O
in O
restricted O
areas O
of O
the O
cerebral O
cortex O
. O

To O
facilitate O
manipulation RARE
of O
large O
genomic O
sequences O
, O
we O
developed O
a O
method O
of O
converting O
Escherichia O
coli O
P1 O
artificial O
chromosomes O
( O
PACs RARE
) O
into O
yeast O
artificial O
chromosomes O
( O
YACs O
). O

After O
gamma O
- O
irradiation O
, O
the O
majority O
of O
F9 O
cells O
undergo O
apoptosis O
implying O
that O
wt I-GENE
- I-GENE
p53 I-GENE
likely O
triggers O
pro O
- O
apoptotic O
gene O
expression O
in O
DNA O
damaged O
cells O
. O

Mobilization RARE
with O
cyclophosphamide O
and O
granulocyte I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
was O
effective O
in O
terms O
of O
CD34 I-GENE
+ I-GENE
cell O
shift O
to O
peripheral O
blood O
and O
the O
good O
quality O
autograft RARE
reliably RARE
led O
to O
haematopoetic RARE
recovery O
after O
megachemotherapy RARE
. O

This O
suggests O
that O
cardiovascular O
magnetic O
resonance O
is O
the O
preferred O
technique O
for O
volume O
and O
ejection O
fraction O
estimation O
in O
heart O
failure O
patients O
, O
because O
of O
its O
3D NUMERIC
approach O
for O
non O
- O
symmetric RARE
ventricles O
and O
superior O
image O
quality O
. O

A O
degenerate O
DNA O
transposon O
, O
Pat RARE
, O
was O
identified O
in O
the O
genomes O
of O
various O
wild O
- O
type O
strains O
of O
the O
filamentous O
fungus O
Podospora RARE
anserina RARE
. O

However O
, O
the O
presence O
of O
Tax I-GENE
I I-GENE
increased O
the O
extent O
and O
altered O
the O
profile O
of O
proteins O
binding O
TRE I-GENE
- I-GENE
2 I-GENE
in O
vivo O
. O

We O
have O
also O
identified O
a O
functional O
domain O
in O
the O
ORF O
50 O
protein O
, O
an O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
product I-GENE
that O
is O
mainly O
encoded O
by O
ORF O
50 O
. O

A O
2 O
. O
3 O
- O
kb O
full O
- O
length O
cDNA O
clone O
of O
an O
Atlantic RARE
halibut RARE
Mx RARE
gene I-GENE
was O
isolated O
from O
a O
liver O
cDNA O
library O
. O

PLUS ALLCAPS
- O
3 O
is O
a O
new O
Swedish RARE
protocol O
of O
natural O
speech O
in O
3 O
- O
year O
- O
old O
children O
. O

Once O
HIT ALLCAPS
II O
is O
suspected O
, O
heparin O
( O
and O
low O
- O
molecular O
- O
weight O
heparins RARE
) O
should O
be O
stopped O
immediately O
. O

The O
reduced O
efficiency O
in O
the O
glycosylase I-GENE
activity O
is O
also O
reflected O
in O
a O
reduced O
ability O
of O
S120K NUMERIC
MutY LASTCAP
to O
prevent O
DNA O
mutations O
in O
vivo O
. O

METHODS O
AND O
RESULTS O
: O
We O
prospectively RARE
compared O
the O
automated O
measurements O
of O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
and O
volumes O
from O
rest O
- O
injected O
gated O
Technetium RARE
99m O
( O
Tc99m NUMERIC
) O
perfusion O
SPECT O
with O
equilibrium O
radionuclide RARE
angiocardiography RARE
( O
ERNA ALLCAPS
) O
in O
62 O
patients O
and O
the O
assessment O
of O
regional O
function O
with O
echocardiography O
in O
22 O
patients O
. O

The O
2 O
cDNAs O
differed O
in O
the O
length O
of O
their O
respective O
3 O
' O
untranslated O
regions O
, O
of O
577 NUMERIC
bp O
in O
Cp I-GENE
. I-GENE
F6 NUMERIC
and O
72 O
bp O
in O
Cp I-GENE
. I-GENE
F10 NUMERIC
, O
in O
both O
of O
which O
a O
putative O
polyadenylation O
signal O
was O
identified O
. O

This O
intracellular O
signaling O
, O
known O
as O
the O
unfolded RARE
protein O
response O
( O
UPR ALLCAPS
), O
is O
mediated O
by O
the O
cis O
- O
acting O
ER O
stress O
response O
element O
( O
ERSE ALLCAPS
) O
in O
mammals O
. O

A O
Y I-GENE
. I-GENE
lipolytica RARE
Kar2p NUMERIC
mutant I-GENE
was O
isolated O
that O
restored O
interaction O
with O
an O
Sls1p NUMERIC
mutant I-GENE
, O
suggesting O
that O
the O
interaction O
with O
Sls1p NUMERIC
could O
be O
nucleotide O
and O
/ O
or O
conformation O
dependent O
. O

We O
have O
carried O
out O
a O
comprehensive RARE
and O
systematic O
mutagenesis O
of O
the O
Cse4p NUMERIC
N I-GENE
terminus I-GENE
to O
analyze O
its O
function O
. O

The O
spacing RARE
of O
the O
essential O
N O
- O
terminal O
domain O
( O
END ALLCAPS
) O
relative O
to O
the O
HFD ALLCAPS
can O
be O
changed O
significantly O
without O
an O
apparent O
effect O
on O
Cse4p NUMERIC
function O
. O

The O
bases O
of O
this O
comparison O
are O
reviewed O
and O
discussed O
. O

In O
invertebrates RARE
, O
Fhit RARE
is O
encoded O
as O
a O
fusion O
protein O
with O
Nit RARE
, O
a O
member O
of O
the O
nitrilase RARE
superfamily I-GENE
. O

Platelet O
counts O
and O
function O
as O
well O
as O
fibrinogen I-GENE
and O
von I-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
levels O
were O
determined O
in O
each O
sample O
. O

The O
manifestations O
often O
include O
a O
moderate O
thrombocytopenia O
and O
, O
less O
commonly O
, O
hemolysis RARE
. O

A O
beta2 I-GENE
RARE ALLCAPS
reporter I-GENE
construct I-GENE
in O
which O
the O
methylation O
- O
susceptible O
cytosines RARE
in O
the O
sense O
strand O
were O
replaced O
by O
thymine RARE
displayed O
marked O
loss O
of O
activity O
in O
a O
replicated RARE
chromatin O
- O
dependent O
manner O
. O

Non O
- O
poliomyelitis RARE
AFP O
rate O
had O
increased O
from O
0 O
. O
9 O
in O
1997 O
to O
2 O
. O
8 O
in O
1998 O
. O

Consciousness RARE
is O
connected O
with O
attention O
, O
working O
memory O
and O
perception RARE
. O

Multiparity RARE
had O
a O
protective O
effect O
with O
0 O
. O
66 O
less O
risk O
( O
95 O
% O
CI O
0 O
. O
44 O
- O
0 O
. O
99 O
). O

Picture RARE
the O
smell RARE
. O

The O
aim O
of O
our O
study O
was O
to O
evaluate O
the O
level O
of O
oxidative O
stress O
in O
healthy O
controls O
( O
CTL O
) O
compared O
with O
CRF O
and O
HD O
patients O
before O
( O
pre O
- O
HD O
) O
and O
after O
( O
post O
- O
HD O
) O
the O
dialysis O
session O
, O
carried O
out O
on O
a O
high O
biocompatible RARE
polyacrylonitrile RARE
membrane O
AN69 NUMERIC
. O

Indirect RARE
plasma O
parameters O
such O
as O
vitamin O
E O
, O
thiol RARE
and O
uric O
acid O
levels O
were O
also O
quantified RARE
. O

Only O
two O
of O
27 O
participants RARE
( O
7 O
. O
4 O
%) O
with O
definite O
POAG ALLCAPS
had O
been O
previously O
diagnosed O
and O
treated O
, O
and O
66 O
. O
7 O
% O
of O
the O
previously O
undiagnosed RARE
had O
IOP O
less O
than O
22 O
mmHg O
. O

Taken O
together O
, O
they O
uphold RARE
the O
emerging RARE
concern RARE
that O
women O
with O
ER I-GENE
(+) I-GENE
cancers O
may O
not O
benefit O
significantly O
from O
endocrine O
treatment O
if O
the O
tumors O
also O
overexpress RARE
HER ALLCAPS
- I-GENE
2 I-GENE
. O

Promoter O
activity O
was O
dose O
- O
dependently O
inhibited O
by O
cotransfection O
with O
either O
ras I-GENE
or O
mos I-GENE
oncogenes I-GENE
, O
but O
oncogene O
inhibition O
was O
reversed O
and O
the O
overall O
activity O
increased O
when O
cells O
were O
treated O
with O
the O
MAP I-GENE
kinase I-GENE
kinase I-GENE
( O
MKK ALLCAPS
) O
inhibitor O
PD98059 O
. O

Our O
results O
indicate O
that O
the O
expression O
of O
Cktsf1b1 NUMERIC
, O
a O
gene O
associated O
with O
early O
development O
and O
cell O
transformation O
, O
is O
sensitive O
to O
MKK ALLCAPS
levels O
and O
may O
be O
regulated O
via O
multiple O
transcription O
factor O
complexes O
. O

INTERVENTIONS ALLCAPS
: O
Subcutaneous RARE
tissue O
PO2 O
and O
PCO2 O
tensions RARE
were O
measured O
directly O
in O
patients O
with O
necrotising RARE
fasciitis RARE
and O
in O
healthy O
volunteers O
during O
normobaric RARE
and O
hyperbaric RARE
conditions O
. O

Because O
GH I-GENE
- O
induced O
Akt I-GENE
activation O
was O
completely O
inhibited O
in O
both O
cells O
by O
the O
same O
concentration O
of O
LY294002 NUMERIC
, O
these O
findings O
indicate O
that O
the O
wortmannin O
sensitivity O
of O
both O
the O
IRS I-GENE
- I-GENE
1 I-GENE
- O
independent O
and O
- O
dependent O
GH I-GENE
- O
induced O
MAP I-GENE
kinase I-GENE
activation O
may O
reflect O
the O
activity O
of O
another O
wortmannin O
- O
sensitive O
target O
( O
s O
) O
in O
addition O
to O
PI3K NUMERIC
in O
mediation RARE
of O
GH I-GENE
- O
induced O
MAP I-GENE
kinase I-GENE
activation O
in O
these O
cells O
. O

Insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
- O
mediated O
enhancement O
of O
growth I-GENE
hormone I-GENE
- O
induced O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
activation O
. O

Functional O
magnetic O
resonance O
imaging O
( O
fMRI LASTCAP
) O
has O
been O
increasingly RARE
used O
in O
studying O
human O
brain O
function O
given O
its O
non O
- O
invasive O
feature O
and O
good O
spatial O
resolution O
. O

After O
declamping RARE
of O
the O
aorta O
, O
there O
were O
also O
severe O
edema O
, O
local O
fibre O
necrosis O
, O
and O
adhesion O
of O
leucocytes RARE
, O
whereas O
muscle O
fibre O
areas O
became O
3 O
, O
935 NUMERIC
. O
18 O
micro O
531 NUMERIC
microm O
( O
2 O
) O
for O
type O
I O
and O
5 O
, O
804 NUMERIC
+/- O
1 O
, O
075 NUMERIC
microm O
( O
2 O
) O
for O
type O
II O
. O

The O
results O
indicate O
that O
the O
relationship O
between O
comprehension RARE
and O
production O
is O
different O
at O
different O
stages O
in O
development O
. O

It O
was O
found O
that O
increase O
in O
the O
RH O
level O
boosts RARE
the O
current O
values O
by O
2 O
- O
3 O
orders RARE
of O
magnitude O
; O
contrariwise RARE
, O
the O
voltage O
values O
rise O
by O
about O
three O
times O
with O
drop O
in O
the O
RH O
. O

On O
long O
- O
term O
follow O
- O
up O
, O
there O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
hospitalizations RARE
( O
1 O
per O
2 O
. O
1 O
vs O
. O

Genomic O
libraries O
were O
stored O
as O
frozen RARE
cultures O
in O
a O
96 O
- O
well O
format RARE
, O
each O
well O
containing O
approximately O
300 O
- O
600 O
colonies O
( O
12 O
plates O
for O
small O
library O
, O
four O
for O
medium O
- O
size O
library O
and O
four O
for O
large O
library O
). O

In O
several O
cell O
lines O
, O
mTOR LASTCAP
or O
its O
downstream O
targets O
can O
be O
regulated O
by O
phosphatidylinositol I-GENE
( I-GENE
PI I-GENE
) I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
; O
protein I-GENE
kinases I-GENE
A I-GENE
, I-GENE
B I-GENE
, I-GENE
and I-GENE
C I-GENE
; O
heterotrimeric I-GENE
G I-GENE
- I-GENE
proteins I-GENE
; O
a O
PD98059 O
- O
sensitive O
kinase O
or O
calcium O
; O
as O
well O
as O
by O
amino O
acids O
. O

The O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
p53 I-GENE
is O
involved O
in O
maintaining O
genomic O
stability O
. O

Abrogation RARE
of O
p53 I-GENE
function O
by O
E6 I-GENE
resulted O
in O
an O
increase O
in O
the O
spontaneous O
mutation O
frequencies O
at O
the O
heterozygous RARE
thymidine I-GENE
kinase I-GENE
( O
TK I-GENE
) O
locus O
but O
not O
at O
the O
hemizygous RARE
hypoxanthine RARE
phosphoribosyl RARE
transferase I-GENE
( O
HPRT ALLCAPS
) O
locus O
. O

Cytogenetic RARE
analysis O
of O
LOH ALLCAPS
mutants O
by O
chromosome O
painting RARE
indicated O
a O
mosaic O
of O
chromosomal O
aberrations RARE
involving O
chromosome O
17 O
, O
in O
which O
partial O
chromosome O
deletions O
, O
amplifications RARE
, O
and O
multiple O
translocations RARE
appeared O
heterogeneously RARE
in O
a O
single O
mutant O
. O

These O
results O
support O
a O
model O
in O
which O
p53 I-GENE
protein I-GENE
contributes O
to O
the O
maintenance O
of O
genomic O
integrity O
through O
recombinational RARE
repair O
. O

The O
importance O
of O
this O
new O
epidemiological O
profile O
of O
schistosomiasis RARE
in O
the O
State O
of O
Pernambuco RARE
relies RARE
on O
the O
fact O
that O
it O
can O
be O
related O
with O
the O
drastic RARE
human O
interference O
on O
the O
environment O
. O

In O
patients O
with O
type O
II O
tumors O
, O
the O
pattern O
of O
lymphatic RARE
spread O
was O
primarily O
directed O
toward O
the O
paracardial RARE
, O
lesser O
curvature RARE
, O
and O
left O
gastric O
artery O
nodes O
; O
esophagectomy RARE
offered O
no O
survival O
benefit O
over O
extended O
gastrectomy RARE
in O
these O
patients O
. O

RESULTS O
: O
No O
significant O
deformation RARE
in O
vertebral O
artery O
flow O
was O
noted O
in O
the O
flexion RARE
- O
distraction RARE
Stage O
I O
injuries O
within O
the O
physiologic RARE
range O
of O
cervical O
flexion RARE
. O

We O
screened O
a O
K562 O
cDNA O
library O
and O
identified O
novel O
transcripts O
, O
MZF1B NUMERIC
and O
MZF1C NUMERIC
. O

The O
human O
cDNA O
clone O
NFBD1 NUMERIC
( O
previously O
designated O
KIAA0170 NUMERIC
) O
encodes O
a O
novel O
protein O
( O
2089 NUMERIC
amino O
acids O
in O
length O
; O
calculated O
molecular O
mass O
226 NUMERIC
, O
440 O
D O
) O
with O
possible O
BRCT ALLCAPS
domains I-GENE
at O
its O
carboxy O
terminus O
( O
amino O
acid O
residues O
1894 NUMERIC
- O
2089 NUMERIC
). O

RESULTS O
: O
Neither O
basal O
FSH I-GENE
level O
nor O
stimulated O
FSH I-GENE
level O
alone O
were O
statistically O
significant O
predictors O
of O
IVF ALLCAPS
success O
; O
however O
, O
no O
patient O
with O
a O
day O
3 O
FSH I-GENE
level O
> O
11 O
. O
1 O
mIU LASTCAP
/ O
ml O
or O
a O
stimulated O
day O
10 O
FSH I-GENE
level O
> O
13 O
. O
5 O
mIU LASTCAP
/ O
ml O
conceived RARE
and O
carried O
a O
pregnancy O
. O

Parathyroid RARE
hormone I-GENE
regulation O
of O
bone I-GENE
sialoprotein RARE
( O
BSP I-GENE
) O
gene O
transcription O
is O
mediated O
through O
a O
pituitary I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
Pit I-GENE
- I-GENE
1 I-GENE
) O
motif O
in O
the O
rat I-GENE
BSP I-GENE
gene I-GENE
promoter I-GENE
. O

Recent O
target O
BP O
goals RARE
promulgated RARE
by O
the O
Sixth RARE
Report RARE
from O
the O
Joint RARE
National O
Committee O
( O
JNC ALLCAPS
VI O
) O
are O
based O
on O
the O
premise RARE
that O
the O
intensity O
of O
treatment O
directly O
corresponds O
to O
the O
magnitude O
of O
pretreatment O
risk O
. O

Linking RARE
continuous O
community O
- O
based O
morbidity O
recording O
of O
influenza O
- O
like O
illness O
( O
ILI ALLCAPS
) O
with O
virological RARE
sampling O
has O
consistently O
proved O
its O
value O
as O
one O
of O
the O
earliest RARE
indicators O
of O
circulating O
influenza O
activity O
. O

The O
muskox RARE
is O
a O
new O
host O
record O
for O
T O
. O
gondii RARE
. O

These O
include O
NPF ALLCAPS
repeats O
, O
a O
leucine O
heptad O
repeat O
enriched O
in O
charged O
residues O
, O
and O
a O
proline O
- O
rich O
SH3 I-GENE
- I-GENE
like I-GENE
and O
/ O
or O
WW ALLCAPS
domain O
- O
binding O
site O
in O
the O
N O
- O
terminal O
domain O
, O
which O
is O
followed O
by O
a O
membrane O
core O
containing O
four O
putative O
transmembrane O
spans O
and O
three O
amphiphilic RARE
segments O
that O
are O
the O
most O
highly O
conserved O
structural O
elements O
. O

We O
show O
here O
that O
this O
difference O
is O
due O
to O
the O
presence O
of O
a O
Mot3 NUMERIC
binding I-GENE
site I-GENE
in O
OpA LASTCAP
. O

The O
article O
deals RARE
with O
the O
diagnosing RARE
and O
correction O
of O
reversible O
ischemia O
of O
the O
intestine O
. O

Mucosal RARE
application O
of O
NCX ALLCAPS
- O
4016 NUMERIC
, O
however O
, O
did O
not O
cause O
PD O
reduction O
and O
luminal O
H O
+ O
loss O
, O
but O
produced O
a O
marked O
hyperemia RARE
, O
resulting O
in O
no O
damage O
in O
the O
stomach O
of O
both O
normal O
and O
STZ ALLCAPS
- O
diabetic O
rats O
. O

Functional O
recognition O
of O
5 O
' O
splice O
site O
by O
U4 I-GENE
/ O
U6 I-GENE
. O
U5 I-GENE
tri RARE
- O
snRNP O
defines O
a O
novel O
ATP O
- O
dependent O
step O
in O
early O
spliceosome O
assembly O
. O

As O
control O
, O
the O
cells O
were O
transfected O
with O
DNA O
mixtures RARE
containing O
vector O
mU6 NUMERIC
- O
C1 O
or O
mU6 NUMERIC
- O
C2 O
. O

The O
amino O
acid O
sequence O
of O
matrilysin RARE
- I-GENE
2 I-GENE
also O
contains O
a O
threonine O
residue O
adjacent O
to O
the O
Zn O
- O
binding O
site O
that O
has O
been O
defined O
as O
a O
specific O
feature O
of O
matrilysin RARE
. O

In O
this O
regard O
, O
we O
have O
recently O
observed O
that O
a O
constitutively O
active O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
( O
GPCR ALLCAPS
) O
encoded O
by O
the O
Kaposi O
' O
s O
sarcoma O
- O
associated O
herpes O
virus O
( O
KSHV O
)/ O
human O
herpes O
virus O
8 O
is O
oncogenic O
and O
stimulates O
angiogenesis O
by O
increasing O
the O
secretion O
of O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
( O
VEGF I-GENE
), O
which O
is O
a O
key O
angiogenic RARE
stimulator RARE
and O
a O
critical O
mitogen O
for O
the O
development O
of O
Kaposi O
' O
s O
sarcoma O
. O

No O
specific O
subgroup O
of O
clients RARE
benefited RARE
more O
from O
URD ALLCAPS
, O
although O
a O
prospective O
study O
employing O
random O
assignment O
might O
be O
more O
successful O
in O
identifying O
such O
a O
group O
. O

In O
the O
lattice RARE
, O
23 O
% O
of O
the O
sites O
are O
occupied O
, O
95 O
% O
of O
the O
atoms RARE
are O
in O
the O
lowest O
energy O
magnetic O
sublevel RARE
, O
and O
37 O
% O
are O
in O
the O
lowest O
3D NUMERIC
vibrational RARE
state O
. O

Coexisting RARE
vertical O
and O
horizontal O
one O
and O
a O
half O
syndromes O
. O

As O
in O
the O
other O
three O
members O
whose O
gene O
expression O
is O
altered O
during O
tumorigenesis O
, O
PI12 NUMERIC
expression O
was O
found O
to O
be O
down O
- O
regulated O
in O
tumor O
brain O
tissues O
and O
in O
two O
brain O
cancer O
cell O
lines O
: O
U O
- O
87 O
MG ALLCAPS
and O
H4 O
. O

Regarding RARE
" O
the O
relation O
between O
sexual O
orientation O
and O
penile RARE
size O
," O
by O
A O
. O

This O
slope O
was O
further O
significantly O
decreased O
at O
5 O
min O
ischemia O
(- O
26 O
. O
5 O
+/- O
8 O
. O
8 O
microm O
/ O
mmHg O
) O
but O
returned O
toward O
control O
values O
in O
short O
- O
term O
hibernating RARE
myocardium O
at O
90 O
min O
ischemia O
(- O
17 O
. O
2 O
+/- O
6 O
. O
6 O
microm O
/ O
mmHg O
). O

Whereas O
both O
MAP O
and O
MSNA ALLCAPS
increase O
during O
SHG ALLCAPS
, O
the O
transition O
from O
SHG ALLCAPS
to O
PHI ALLCAPS
is O
characterized O
by O
a O
transient O
reduction O
in O
MAP O
but O
sustained O
elevation O
in O
MSNA ALLCAPS
, O
facilitating O
separation O
of O
these O
factors O
in O
vivo O
. O

Analysis O
of O
Standard RARE
Reference RARE
Material RARE
1846 NUMERIC
, O
Infant RARE
Formula RARE
, O
gave O
a O
mean O
value O
of O
0 O
. O
95 O
+/- O
0 O
. O
088 NUMERIC
mg O
vitamin O
K O
/ O
kg O
( O
K O
or O
K1 O
?) RARE
( O
n O
= O
31 O
) O
with O
a O
coefficient O
of O
variation O
of O
9 O
. O
26 O
. O

We O
have O
recently O
discovered O
that O
CCAAAT ALLCAPS
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
beta I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
beta I-GENE
) O
induces O
gene O
transcription O
through O
a O
novel O
IFN I-GENE
response I-GENE
element I-GENE
called O
the O
gamma I-GENE
- I-GENE
IFN I-GENE
- I-GENE
activated I-GENE
transcriptional I-GENE
element I-GENE

Northern O
blot O
analysis O
demonstrated O
that O
the O
STORP ALLCAPS
gene I-GENE
has O
a O
ubiquitous O
pattern O
of O
expression O
similar O
to O
that O
of O
the O
PML ALLCAPS
gene I-GENE
. O

In O
the O
TLE ALLCAPS
patients O
the O
NAA ALLCAPS
: O
Cr O
ratios O
were O
reduced O
in O
the O
seizure O
focus O
, O
while O
in O
the O
FLE ALLCAPS
patients O
they O
were O
not O
always O
reduced O
in O
the O
seizure O
focus O
. O

The O
Spo0F NUMERIC
residues I-GENE
making O
up O
the O
hydrophobic O
patch O
are O
very O
similar O
in O
all O
response O
regulators O
suggesting O
that O
the O
binding O
is O
initiated O
through O
the O
same O
residues O
in O
all O
interacting O
response O
regulator O
- O
kinase O
pairs O
. O

The O
psychologic RARE
factors O
associated O
wth RARE
serious O
illness O
, O
terminal O
prognoses RARE
, O
and O
dying RARE
complicate RARE
the O
scenario RARE
even O
more O
as O
compared O
with O
that O
of O
nonmalignant RARE
pain O
. O

However O
, O
if O
the O
spatial O
resolution O
is O
not O
critical O
and O
interest O
is O
to O
compare O
a O
pathologic O
area O
with O
a O
contralateral O
VOI ALLCAPS
, O
then O
the O
acquisition O
of O
two O
single O
- O
voxel RARE
spectra O
may O
be O
preferred O
. O

Quantitative O
evaluation O
of O
magneto RARE
- O
optical O
parameters O
is O
necessary O
in O
order O
to O
apply RARE
scanning O
near O
- O
field O
optical O
microscope RARE
( O
SNOM ALLCAPS
) O
technology O
to O
the O
study O
of O
magnetism RARE
on O
the O
mesoscopic RARE
scale O
. O

We O
found O
that O
the O
amplitude O
of O
the O
cortical O
evoked O
potentials O
( O
amplitude O
of O
the O
N2 O
/ O
P2 O
peak O
) O
increased O
from O
5 O
. O
1 O
+/- O
0 O
. O
7 O
microV LASTCAP
at O
5 O
mA LASTCAP
to O
16 O
. O
3 O
+/- O
1 O
. O
1 O
microV LASTCAP
at O
20 O
mA LASTCAP
. O

While O
mutations O
in O
K I-GENE
- I-GENE
Rev I-GENE
that O
inactivate RARE
any O
one O
of O
these O
properties O
also O
blocked O
K I-GENE
- I-GENE
Rev I-GENE
- O
dependent O
nuclear O
RNA O
export O
, O
several O
K I-GENE
- I-GENE
Rev I-GENE
mutants I-GENE
were O
comparable O
to O
wild O
type O
when O
assayed O
for O
any O
of O
these O
individual O
activities O
yet O
nevertheless RARE
defective O
for O
RNA O
export O
. O

LMP I-GENE
- I-GENE
1 I-GENE
is O
targeted O
to O
the O
plasma O
membrane O
, O
where O
it O
binds O
TRAF ALLCAPS
, O
TRADD ALLCAPS
, O
and O
JAK ALLCAPS
molecules I-GENE
to O
activate O
NF I-GENE
- I-GENE
kappaB I-GENE
-, O
AP I-GENE
- I-GENE
1 I-GENE
-, O
and O
STAT I-GENE
- O
dependent O
pathways O
as O
does O
CD40 I-GENE
. O

Identification O
of O
an O
enhancer O
and O
an O
alternative O
promoter O
in O
the O
first O
intron O
of O
the O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
gene I-GENE
. O

Studying RARE
intracellular O
signaling O
pathways O
, O
which O
may O
be O
involved O
in O
malignant O
transformation O
of O
Ret RARE
- I-GENE
9bp NUMERIC
expressing O
NIH3T3 O
cells O
, O
we O
could O
demonstrate O
Ret RARE
- I-GENE
9bp NUMERIC
dependent O
phosphorylation O
of O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
2 I-GENE
( O
IRS I-GENE
- I-GENE
2 I-GENE
) O
with O
consecutive O
activation O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
) O
and O
protein I-GENE
kinase I-GENE
B I-GENE
( O
PKB I-GENE
/ O
AKT ALLCAPS
). O

METHODS O
: O
In O
the O
current O
study O
the O
authors O
reported O
on O
PPB ALLCAPS
cases O
from O
a O
national O
retrospective O
search O
performed O
in O
18 O
Italian O
Associations RARE
for O
Pediatric RARE
Hematology RARE
and O
Oncology RARE
centers O
. O

Phylogenetic RARE
analysis O
showed O
that O
the O
ToLCV LASTCAP
isolates O
from O
Bangalore RARE
constitute O
a O
group O
of O
viruses O
separated O
from O
those O
of O
Northern O
India RARE
. O

Mutating RARE
the O
Fcp1p NUMERIC
- O
binding O
motif O
KEFGK ALLCAPS
in O
the O
RAP74 NUMERIC
( O
Tfg1p NUMERIC
) O
subunit O
of O
TFIIF ALLCAPS
to O
EEFGE ALLCAPS
led O
to O
both O
synthetic O
phenotypes O
in O
certain O
fcp1 NUMERIC
tfg1 NUMERIC
double O
mutants O
and O
a O
reduced O
ability O
of O
Fcp1p NUMERIC
to O
activate O
transcription O
when O
it O
is O
artificially O
tethered RARE
to O
a O
promoter O
. O

These O
results O
suggest O
that O
Cdc42p NUMERIC
is O
in O
fact O
required O
for O
pheromone O
response O
and O
that O
interaction O
with O
the O
PAK ALLCAPS
Ste20p NUMERIC
is O
critical O
for O
that O
role O
. O

Deletion O
of O
an O
intergenic O
DNA O
- O
binding O
site O
for O
this O
complex O
from O
a O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
locus I-GENE
construct I-GENE
results O
in O
delayed O
human I-GENE
gamma I-GENE
- I-GENE
to I-GENE
beta I-GENE
- I-GENE
globin I-GENE
switching O
in O
transgenic O
mice O
, O
suggesting O
that O
the O
PYR ALLCAPS
complex I-GENE
acts O
to O
facilitate O
the O
switch O
. O

The O
product O
of O
rat I-GENE
gene I-GENE
33 I-GENE
was O
identified O
as O
an O
ErbB I-GENE
- I-GENE
2 I-GENE
- I-GENE
interacting I-GENE
protein I-GENE
in O
a O
two O
- O
hybrid O
screen O
employing O
the O
ErbB I-GENE
- I-GENE
2 I-GENE
juxtamembrane I-GENE
and I-GENE
kinase I-GENE
domains I-GENE
as O
bait RARE
. O

Studies O
suggest O
that O
the O
DGOR ALLCAPS
without O
acid O
reflux O
may O
result O
in O
symptoms O
but O
unless O
acid O
reflux O
is O
present O
simultaneously O
, O
it O
does O
not O
cause O
oesophagitis RARE
. O

Symptoms RARE
, O
however O
, O
appear O
to O
correlate O
poorly O
with O
oesophagitis RARE
; O
hence O
, O
severe O
symptoms O
do O
not O
indicate O
there O
is O
greater O
oesophageal RARE
damage O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
relationship O
between O
blood O
flow O
in O
the O
tumor O
assessed O
by O
color O
Doppler O
ultrasound O
, O
microvessel RARE
density O
, O
and O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
levels O
in O
endometrial O
carcinoma O
. O

These O
results O
demonstrate O
Ras I-GENE
- O
and O
Raf I-GENE
- O
independent O
ERK I-GENE
MAPK O
activation O
maintains O
cell O
viability O
following O
heat O
shock O
. O

Three O
cDNAs O
encoding O
basic I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
bZIP I-GENE
)- I-GENE
type I-GENE
ABRE ALLCAPS
- I-GENE
binding I-GENE
proteins I-GENE
were O
isolated O
by O
using O
the O
yeast O
one O
- O
hybrid O
system O
and O
were O
designated O
AREB1 NUMERIC
, O
AREB2 NUMERIC
, O
and O
AREB3 NUMERIC
( O
ABA I-GENE
- I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
protein I-GENE
). O

Recombinant O
AROM ALLCAPS
- O
p64 NUMERIC
displayed O
high O
binding O
to O
single O
- O
stranded O
DNA O
and O
poly O
( O
A O
) O
homopolymers RARE
suggesting O
that O
this O
protein O
could O
play O
a O
role O
in O
mRNA O
maturation O
/ O
metabolism O
. O

The O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinase I-GENE
fer RARE
associates O
with O
signaling O
complexes O
containing O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
and O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

The O
variable O
phenotype O
of O
the O
allotetraploids RARE
could O
not O
be O
explained O
by O
cytological RARE
abnormalities O
. O

In O
the O
PMR ALLCAPS
target O
area O
but O
not O
in O
the O
nontreated RARE
area O
an O
improvement O
in O
regional O
myocardial O
flow O
reserve O
occurs O
in O
wall O
segments O
with O
initially O
severely O
or O
moderately O
reduced O
stress O
perfusion O
. O

Analysis O
of O
intron O
/ O
exon O
boundaries O
of O
the O
genomic O
BAC ALLCAPS
clones O
demonstrate O
that O
junctin RARE
, O
junctate RARE
, O
and O
aspartyl RARE
beta I-GENE
- I-GENE
hydroxylase I-GENE
result O
from O
alternative O
splicing O
of O
the O
same O
gene O
. O

It O
is O
now O
estimated O
that O
inactivation O
mutants O
of O
PTEN ALLCAPS
exist O
in O
60 O
% O
of O
all O
forms O
of O
solid O
tumors O
. O

We O
have O
demonstrated O
that O
the O
activity O
of O
ILK I-GENE
is O
constitutively O
elevated O
in O
PTEN ALLCAPS
mutant I-GENE
cells O
. O

The O
growth I-GENE
factor I-GENE
receptor I-GENE
- I-GENE
bound I-GENE
protein I-GENE
2 I-GENE
( O
Grb2 I-GENE
) O
adaptor O
when O
complexed O
with O
Sos I-GENE
( O
Son RARE
of I-GENE
sevenless RARE
), O
the O
exchange O
factor O
of O
Ras I-GENE
, O
conveys RARE
the O
signal O
induced O
by O
tyrosine I-GENE
kinase I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
to O
Ras I-GENE
by O
recruiting RARE
Sos I-GENE
to O
the O
membrane O
, O
allowing O
activation O
of O
Ras I-GENE
. O

Mutations O
in O
genes O
encoding O
PR65 NUMERIC
/ I-GENE
A I-GENE
subunits I-GENE
have O
been O
identified O
in O
several O
different O
human O
cancers O
and O
the O
PP2A I-GENE
inhibitor O
, O
termed O
fostriecin RARE
, O
is O
being O
tested O
as O
an O
anticancer RARE
drug O
. O

For O
this O
purpose O
, O
a O
segment O
of O
dxr RARE
was O
amplified O
from O
Synechococcus RARE
leopoliensis RARE
SAUG ALLCAPS
1402 NUMERIC
- O
1 O
DNA O
via O
PCR O
using O
oligonucleotides O
for O
conserved O
regions O
. O

Perceptual RARE
learning O
for O
a O
pattern O
discrimination O
task O
. O

The O
detector O
has O
the O
advantage O
of O
finding O
both O
ST O
segment O
deviations RARE
and O
entire O
ST O
- O
T O
complex O
changes O
thereby O
providing O
a O
wider RARE
characterization O
of O
the O
potential O
ischemic O
events O
. O

While O
this O
Saccharomyces O
cerevisiae O
SIN4 NUMERIC
gene I-GENE
product I-GENE
is O
a O
component O
of O
a O
mediator RARE
complex O
associated O
with O
RNA I-GENE
polymerase I-GENE
II I-GENE
, O
various O
studies O
suggest O
the O
involvement O
of O
Sin4 NUMERIC
in O
the O
alteration O
of O
higher O
- O
order O
chromatin O
structure O
. O

Primary O
adrenal O
hypersensitivity O
to O
ACTH I-GENE
drive O
in O
obesity O
has O
also O
been O
suggested O
. O

In O
addition O
, O
a O
noncanonical RARE
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
binding I-GENE
site I-GENE
within O
the O
Gadd45gamma NUMERIC
promoter I-GENE
where O
C I-GENE
/ I-GENE
EBPbeta I-GENE
and O
C I-GENE
/ I-GENE
EBPdelta RARE
could O
bind O
, O
was O
identified O
by O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
and O
reporter O
gene O
analysis O
. O

Src I-GENE
activation O
induced O
by O
FGF1 NUMERIC
was O
blocked O
by O
the O
SH2 I-GENE
domain I-GENE
of O
Src I-GENE
and O
PP2 NUMERIC
, O
a O
specific O
inhibitor O
of O
Src I-GENE
. O

The O
use O
of O
the O
PLCgamma RARE
inhibitory I-GENE
peptide I-GENE
, O
neomycin O
and O
the O
calcium O
chelator RARE
BAPTA ALLCAPS
- O
AM O
on O
oocytes O
expressing O
FGFR1 NUMERIC
or O
the O
stimulation O
by O
PDGF I-GENE
- I-GENE
BB I-GENE
of O
oocytes O
expressing O
PDGFR ALLCAPS
- O
FGFR1 NUMERIC
mutated O
on O
the O
PLCgamma RARE
binding I-GENE
site I-GENE
, O
prevented O
GVBD ALLCAPS
and O
ERK2 I-GENE
phosphorylation O
. O

Multiple O
transcription O
start O
sites O
were O
revealed O
by O
primer O
extension O
analysis O
of O
the O
mouse O
gene O
, O
and O
transfection O
constructs O
containing O
the O
prospective O
promoter O
generated O
transcriptional O
activity O
comparable O
to O
that O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

From O
two O
inhibitor O
scaffolds RARE
, O
we O
have O
identified O
potent O
and O
selective O
inhibitors O
for O
sensitized RARE
kinases O
from O
five O
distinct O
subfamilies RARE
. O

To O
determine O
whether O
interaction O
of O
arsenite RARE
with O
the O
hormone O
- O
binding O
domain O
results O
in O
receptor O
activation O
, O
COS O
- O
1 O
cells O
were O
transiently O
cotransfected O
with O
the O
chimeric I-GENE
receptors I-GENE
GAL ALLCAPS
- I-GENE
ER I-GENE
, O
which O
contains O
the O
hormone O
- O
binding O
domain O
of O
ERalpha RARE
and O
the O
DNA O
- O
binding O
domain O
of O
the O
transcription O
factor O
GAL4 I-GENE
, O
and O
a O
GAL4 I-GENE
- O
responsive O
CAT I-GENE
reporter I-GENE
gene I-GENE
. O

By O
progressive O
5 O
'- O
deletion O
studies O
, O
we O
have O
identified O
a O
248 NUMERIC
- O
bp O
DNA O
fragment O
(- O
1018 NUMERIC
to O
- O
771 NUMERIC
, O
relative O
to O
the O
translation O
start O
site O
) O
at O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
GnRHR LASTCAP
gene I-GENE
that O
is O
responsible O
for O
the O
GnRHa RARE
- O
mediated O
down O
- O
regulation O
of O
human I-GENE
GnRHR LASTCAP
promoter I-GENE
activity O
. O

The O
mean O
day O
of O
diagnosis O
of O
periventricular RARE
echodensities RARE
was O
3 O
+/- O
2 O
days O
( O
range O
1 O
- O
11 O
days O
), O
and O
of O
cystic O
PVL ALLCAPS
21 O
+/- O
8 O
days O
( O
range O
2 O
- O
47 O
days O
). O

The O
LAMMER ALLCAPS
protein O
kinase O
encoded O
by O
the O
Doa RARE
locus I-GENE
of O
Drosophila O
is O
required O
in O
both O
somatic O
and O
germline O
cells O
and O
is O
expressed O
as O
both O
nuclear O
and O
cytoplasmic O
isoforms O
throughout O
development O
. O

We O
have O
mutated O
to O
cysteine O
, O
one O
at O
a O
time O
, O
21 O
consecutive O
residues O
in O
the O
fourth O
TMS ALLCAPS
( O
TM4 NUMERIC
). O

( O
1995 O
) O
J O
. O

HYPOTHESIS ALLCAPS
: O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
oxidative O
susceptibility O
of O
apolipoprotein I-GENE
B I-GENE
- I-GENE
containing I-GENE
lipoproteins I-GENE
and O
antioxidant O
status O
in O
patients O
with O
acute O
coronary O
syndromes O
and O
chronic O
stable O
angina O
pectoris O
. O

In O
group O
B O
37 O
MBq O
in O
150 O
microL LASTCAP
of O
99mTc O
- O
HSA ALLCAPS
nanocolloid RARE
was O
additionally O
injected O
intradermally RARE
18 O
h O
before O
surgery O
( O
3 O
- O
6 O
aliquots RARE
injected O
perilesionally RARE
). O

Post O
- O
operative O
functional O
outcome O
is O
related O
to O
pre O
- O
operative O
functional O
status O
. O

We O
cloned O
a O
DNA O
fragment O
encoding O
the O
N O
- O
terminal O
part O
of O
a O
protein O
with O
significant O
similarity O
to O
members O
of O
the O
LysR LASTCAP
family I-GENE
of I-GENE
transcriptional I-GENE
regulators I-GENE
( O
LTTRs RARE
). O

AGO1 NUMERIC
is O
similar O
to O
QDE ALLCAPS
- I-GENE
2 I-GENE
required O
for O
quelling RARE
and O
RDE ALLCAPS
- I-GENE
1 I-GENE
required O
for O
RNAi RARE
. O

Intracellular RARE
localization O
studies O
using O
the O
mDAP LASTCAP
- I-GENE
3 I-GENE
/ O
EGFP ALLCAPS
fusion O
protein O
, O
cell O
fractionation O
and O
protease O
protection O
experiments O
localized O
mDAP LASTCAP
- I-GENE
3 I-GENE
to O
the O
mitochondrial O
matrix O
. O

We O
could O
demonstrate O
the O
involvement O
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKA I-GENE
) O
in O
the O
phosphorylation O
of O
CDC25Mm NUMERIC
in O
fibroblasts O
overexpressing O
this O
RasGEF LASTCAP
as O
well O
as O
in O
mouse O
brain O
synaptosomal RARE
membranes O
. O

Reporter RARE
gene O
expression O
analyses O
indicate O
that O
both O
WASP ALLCAPS
promoters I-GENE
show O
high O
levels O
of O
expression O
in O
different O
hematopoietic O
cell O
lines O
. O

We O
find O
that O
3T1 NUMERIC
- O
3T2 NUMERIC
mixing RARE
has O
a O
pronounced O
effect O
on O
the O
line O
shape O
and O
radiative RARE
decay O
rate O
of O
emission O
from O
the O
3T2 NUMERIC
state O
and O
that O
the O
extent O
of O
mixing RARE
depends O
critically RARE
on O
the O
magnitude O
of O
nontetrahedral RARE
distortions RARE
. O

A O
total O
of O
576 NUMERIC
1 O
- O
day O
- O
old O
Ross RARE
broiler RARE
chicks O
were O
housed RARE
in O
six O
treatment O
groups O
[ O
six O
replicates RARE
of O
16 O
each O
; O
control O
, O
CLI ALLCAPS
( O
15 O
g O
kg O
(- O
1 O
) O
diet O
), O
50 O
parts O
per O
billion RARE
( O
ppb O
) O
AF I-GENE
, O
50 O
ppb O
AF I-GENE
plus O
CLI ALLCAPS
, O
100 O
ppb O
AF I-GENE
, O
100 O
ppb O
AF I-GENE
plus O
CLI ALLCAPS
] O
for O
42 O
days O
. O

The O
cost O
per O
test O
is O
less O
than O
those O
for O
CC O
, O
kEIA LASTCAP
and O
PACE2 NUMERIC
. O

Altogether O
these O
results O
suggest O
that O
, O
in O
KG1a NUMERIC
cells O
, O
TNFalpha RARE
can O
stimulate O
in O
parallel O
PC I-GENE
- I-GENE
PLC I-GENE
and O
PLD ALLCAPS
, O
whose O
lipid O
products O
activate O
in O
turn O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAP I-GENE
kinase I-GENE
) O
and O
NF I-GENE
- I-GENE
kappaB I-GENE
signalling O
respectively O
. O

Concurrently RARE
, O
we O
monitored O
weather RARE
conditions O
and O
used O
time O
- O
activity O
budget RARE
data O
of O
free O
- O
living O
birds O
and O
laboratory O
data O
on O
resting O
metabolic O
rate O
to O
construct O
time O
- O
activity O
laboratory O
( O
TAL ALLCAPS
) O
estimates O
of O
daily O
energy O
expenditure O
( O
DEE ALLCAPS
) O
and O
to O
partition RARE
the O
verdins RARE
' O
energy O
budget RARE
into O
thermoregulatory RARE
, O
activity O
and O
basal O
components O
. O

L O
/ O
H O
> O
0 O
. O
61 O
( O
chi RARE
( O
2 O
)= RARE
10 O
. O
8 O
; O
P O
:< RARE
0 O
. O
001 O
) O
and O
a O
restrictive O
filling O
pattern O
( O
chi RARE
( O
2 O
)= RARE
3 O
. O
6 O
; O
P O
:< RARE
0 O
. O
05 O
) O
were O
independent O
predictors O
of O
events O
. O

The O
high O
selectivity O
of O
arrestins RARE
for O
this O
particular O
functional O
form O
of O
receptor O
ensures RARE
their O
timely RARE
binding O
and O
dissociation O
. O

When O
cotransfected O
in O
fibroblasts O
with O
a O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
expression O
vector O
, O
reporter O
gene O
expression O
increased O
3 O
- O
fold O
only O
in O
the O
wild O
- O
type O
constructs O
. O

Expression O
of O
a O
dominant I-GENE
negative I-GENE
Smad2 NUMERIC
significantly O
reduces O
the O
level O
of O
luciferase I-GENE
reporter I-GENE
activity O
induced O
by O
nodal O
treatment O
. O

Normal RARE
alpha1 I-GENE
( I-GENE
I I-GENE
) I-GENE
collagen I-GENE
mRNA I-GENE
showed O
no O
significant O
reduction O
when O
AR O
or O
IR O
was O
expressed O
from O
the O
pHbetaAPr RARE
- O
1 O
- O
neo O
vector O
and O
a O
small O
( O
10 O
- O
20 O
%) O
but O
significant O
reduction O
when O
either O
ribozyme RARE
was O
expressed O
from O
the O
pCI LASTCAP
. O
neo O
vector O
. O

Nature RARE
398 NUMERIC
, O
828 NUMERIC
- O
830 NUMERIC
) O
that O
the O
amino O
acid O
sequences O
of O
peptide O
fragments O
obtained O
from O
a O
polypeptide O
found O
in O
a O
complex O
of O
proteins O
that O
alters O
chromatin O
structure O
( O
ARC I-GENE
) O
are O
identical O
to O
portions O
of O
the O
deduced O
open O
reading O
frame O
of O
TIG ALLCAPS
- I-GENE
1 I-GENE
mRNA I-GENE
. O

Abnormalities RARE
of O
plasma I-GENE
cholecystokinin RARE
were O
observed O
only O
in O
patients O
with O
delayed O
gastric O
emptying O
. O

5 O
( O
Sunset RARE
Yellow RARE
FCF ALLCAPS
) O
were O
determined O
using O
liquid O
chromatography O
/ O
mass O
spectrometry O
( O
LC ALLCAPS
/ O
MS O
) O
with O
electrospray RARE
ionization RARE
. O

Polysome RARE
and O
40S NUMERIC
ribosome I-GENE
fractions O
were O
severely O
decreased O
in O
the O
krr1 NUMERIC
mutant I-GENE
and O
Kri1p NUMERIC
- O
depleted O
cells O
. O

They O
also O
negatively O
modulate O
the O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
catalytic O
activity O
but O
to O
different O
extents RARE
, O
dependent O
on O
the O
unique O
N O
- O
terminal O
structure O
of O
each O
isoform O
. O

Cam RARE
kinase I-GENE
II I-GENE
induces O
in O
vivo O
phosphorylation O
of O
Smad2 NUMERIC
and O
Smad4 NUMERIC
and O
, O
to O
a O
lesser O
extent O
, O
Smad3 NUMERIC
. O

The O
Drosophila I-GENE
melanogaster I-GENE
suppressor I-GENE
of I-GENE
sable RARE
gene I-GENE
, O
su RARE
( O
s O
), O
encodes O
a O
novel O
, O
150 O
- O
kDa O
nuclear O
RNA O
binding O
protein O
, O
SU O
( O
S O
), O
that O
negatively O
regulates O
RNA O
accumulation O
from O
mutant O
alleles O
of O
other O
genes O
that O
have O
transposon O
insertions O
in O
the O
5 O
' O
transcribed O
region O
. O

As O
a O
result O
, O
we O
have O
defined O
two O
arginine O
- O
rich O
motifs O
( O
ARM1 NUMERIC
and O
ARM2 NUMERIC
) O
that O
mediate O
the O
RNA O
binding O
activity O
of O
SU O
( O
S O
). O

This O
interaction O
inhibits O
the O
histone I-GENE
acetyltransferase I-GENE
activity O
of O
p300 I-GENE
, O
resulting O
in O
drastic RARE
reduction O
of O
nucleosomal RARE
histone I-GENE
acetylation O
and O
alteration O
of O
chromatin O
structure O
. O

Recombinant I-GENE
BRI1 NUMERIC
- I-GENE
KD ALLCAPS
autophosphorylated RARE
on O
serine O
( O
Ser O
) O
and O
threonine O
( O
Thr O
) O
residues O
with O
p O
- O
Ser O
predominating RARE
. O

Flow RARE
cytomery RARE
was O
used O
for O
cell O
cycle O
analysis O
. O

Further O
research O
is O
required O
to O
better O
measure O
treatment O
effects O
, O
modification O
of O
MS O
natural O
history O
, O
and O
net RARE
societal RARE
costs O
of O
IFN I-GENE
beta I-GENE
- I-GENE
1b I-GENE
in O
RRMS ALLCAPS
. O

Cost RARE
- O
effectiveness O
of O
interferon I-GENE
beta I-GENE
- I-GENE
1b I-GENE
in O
slowing RARE
multiple O
sclerosis O
disability RARE
progression O
. O

Both O
the O
Cmax RARE
and O
AUC O
values O
were O
almost O
doubled RARE
with O
doubling RARE
the O
dose O
. O

Hyperactivation RARE
of O
Cdc2 I-GENE
in O
fission O
yeast O
causes O
cells O
to O
undergo O
a O
lethal O
premature O
mitosis O
called O
mitotic O
catastrophe RARE
. O

Diary RARE
. O

Cells RARE
differentiate O
in O
response O
to O
various O
extracellular O
stimuli O
. O

Transforming RARE
growth I-GENE
factor I-GENE
- I-GENE
beta1 I-GENE
( O
TGF I-GENE
- I-GENE
beta1 I-GENE
) O
can O
act O
as O
a O
tumor O
suppressor O
or O
a O
tumor O
promoter O
depending O
on O
the O
characteristics O
of O
the O
malignant O
cell O
. O

Vasoactive RARE
intestinal I-GENE
peptide I-GENE
and O
pituitary I-GENE
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
inhibit O
nuclear I-GENE
factor I-GENE
- I-GENE
kappa I-GENE
B I-GENE
- I-GENE
dependent I-GENE
gene I-GENE
activation O
at O
multiple O
levels O
in O
the O
human O
monocytic O
cell O
line O
THP ALLCAPS
- O
1 O
. O

Mn2 NUMERIC
+ O
increased O
both O
the O
junction O
binding O
and O
cleaving RARE
activities O
of O
the O
mutant O
proteins O
. O

While O
Pt RARE
; I-GENE
cycH LASTCAP
; I-GENE
1 I-GENE
and O
Os RARE
; I-GENE
cycH LASTCAP
; I-GENE
1 I-GENE
were O
expressed O
in O
all O
tissues O
examined O
, O
the O
transcripts O
accumulated O
abundantly O
in O
dividing RARE
cells O
. O

Moreover O
, O
an O
in O
vitro O
pull RARE
- O
down O
assay O
showed O
that O
Os RARE
; I-GENE
CycH LASTCAP
; I-GENE
1 I-GENE
specifically O
bound O
to O
R2 I-GENE
but O
not O
to O
other O
rice I-GENE
CDKs RARE
. O

In O
transient O
analysis O
using O
particle O
bombardment RARE
of O
tobacco O
leaf O
sections O
, O
a O
tetramer O
of O
the O
distB LASTCAP
ABRE ALLCAPS
( O
abscisic RARE
acid O
- O
responsive O
element O
) O
mediated O
transactivation O
by O
ABI3 NUMERIC
and O
ABI3 NUMERIC
- O
dependent O
response O
to O
ABA O
, O
whereas O
a O
tetramer O
of O
the O
composite O
RY ALLCAPS
/ O
G O
complex O
, O
containing O
RY ALLCAPS
repeats O
and O
a O
G O
- O
box O
, O
mediated O
only O
ABA O
- O
independent O
transactivation O
by O
ABI3 NUMERIC
. O

The O
major O
neurological O
manifestations O
of O
brain O
injury O
in O
these O
babies O
are O
spastic RARE
motor O
deficits O
. O

Spores RARE
from O
Rhizopus RARE
stolonifer RARE
were O
suspended RARE
in O
distilled RARE
water O
( O
1 O
x O
10 O
( O
6 O
) O
spores RARE
/ O
mL O
) O
and O
used O
as O
starter RARE
. O

Overexpression O
of O
Trdpm1 NUMERIC
in O
a O
dpm1 NUMERIC
(+):: RARE
his7 NUMERIC
/ I-GENE
dpm1 NUMERIC
(+) I-GENE
S O
. O
pombe O
diploid O
resulted O
in O
a O
4 O
- O
fold O
increase O
in O
specific O
DPM ALLCAPS
synthase I-GENE
activity O
. O

The O
LMW ALLCAPS
FGF I-GENE
- I-GENE
2 I-GENE
up O
- O
regulated O
the O
PKC I-GENE
epsilon I-GENE
levels O
by O
1 O
. O
6 O
- O
fold O
; O
by O
contrast O
the O
HMW ALLCAPS
isoform I-GENE
down O
- O
regulated O
the O
level O
of O
this O
PKC I-GENE
isotype RARE
by O
about O
3 O
- O
fold O
and O
increased O
the O
amount O
of O
PKC I-GENE
delta I-GENE
by O
1 O
. O
7 O
- O
fold O
. O

Helicobacter RARE
pylori O
and O
stomach O
diseases O
: O
from O
clinical O
point O
of O
view O

For O
this O
purpose O
, O
the O
writhing RARE
test O
, O
capsaicin RARE
and O
formalin O
induced O
- O
pain O
in O
mice O
were O
used O
. O

2000 O
update RARE
of O
recommendations RARE
for O
the O
use O
of O
hematopoietic I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
: O
evidence O
- O
based O
, O
clinical O
practice O
guidelines O
. O

Prominent RARE
findings O
were O
chronic O
pancreatitis O
with O
acinar RARE
and O
ductal RARE
plugs RARE
, O
granulomatous RARE
and O
necrotizing RARE
peripancreatic RARE
steatitis RARE
, O
degenerative RARE
myopathy RARE
, O
testicular O
atrophy O
, O
candidiasis O
and O
bacterial O
necrotizing RARE
glossitis RARE
. O

Taken O
together O
, O
our O
data O
indicate O
that O
multiple O
survival O
pathways O
are O
triggered O
via O
this O
receptor O
, O
whereas O
NF I-GENE
- I-GENE
kappaB I-GENE
/ O
Rel I-GENE
and O
PI I-GENE
- I-GENE
3K NUMERIC
are O
crucial O
for O
CD40 I-GENE
- O
induced O
proliferation O
. O

In O
vitro O
, O
Arix RARE
and O
NBPhox RARE
form O
DNA O
- O
independent O
multimers RARE
and O
exhibit O
cooperative O
binding O
to O
the O
DB1 NUMERIC
regulatory I-GENE
element I-GENE
, O
which O
contains O
two O
homeodomain I-GENE
recognition I-GENE
sites I-GENE
. O

We O
conclude O
from O
this O
study O
that O
Arix RARE
and O
NBPhox RARE
exhibit O
indistinguishable O
and O
independent O
transcriptional O
regulatory O
properties O
on O
the O
DBH ALLCAPS
promoter I-GENE
. O

METHODS O
AND O
RESULTS O
: O
Studies O
were O
undertaken O
in O
9 O
isolated O
guinea O
pig O
hearts O
, O
which O
demonstrated O
reverse O
use O
- O
dependent O
prolongation O
of O
cardiac O
repolarization RARE
by O
100 O
nmol O
/ O
L O
domperidone RARE
. O

The O
N O
- O
terminal O
small O
segment O
of O
yeast I-GENE
TAF145 NUMERIC
( O
yTAF145 NUMERIC
) O
binds O
to O
TBP I-GENE
and O
thereby O
inhibits O
TBP I-GENE
function O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
overall O
performance O
of O
a O
new O
oscillometric RARE
wrist O
blood O
pressure O
monitor O
( O
Braun RARE
PrecisionSensor RARE
, O
Braun RARE
GmbH LASTCAP
, O
Kronberg RARE
, O
Germany RARE
) O
as O
defined O
by O
the O
ANSI ALLCAPS
/ O
AAMI ALLCAPS
SP10 NUMERIC
- O
1992 O
guidelines O
, O
and O
to O
analyze O
the O
data O
for O
the O
optimized RARE
selection O
of O
the O
algorithm O
that O
derives RARE
the O
blood O
pressure O
values O
from O
the O
oscillometric RARE
blood O
pressure O
curves O
. O

Following O
the O
results O
of O
toxicological O
experiments O
in O
the O
target O
animals O
" O
Toxicological RARE
Drinking RARE
Water RARE
Standards RARE
for O
Animals O
" O
can O
be O
established O
. O

An O
increase O
in O
hypothalamic RARE
expression O
of O
at O
least O
two O
of O
the O
erbB I-GENE
receptors I-GENE
is O
initiated O
before O
the O
pubertal RARE
augmentation RARE
of O
gonadal RARE
steroid O
secretion O
and O
is O
completed O
on O
the O
day O
of O
the O
first O
preovulatory RARE
surge RARE
of O
gonadotropins RARE
. O

Dsh RARE
is O
required O
for O
two O
different O
pathways O
, O
the O
Wnt I-GENE
pathway O
and O
planar RARE
polarity O
pathway O
in O
Drosophila O
. O

Catch RARE
- O
up O
growth O
and O
craniofacial RARE
dimensions O
following O
administration O
of O
the O
antineoplastic RARE
agent O
vincristine O
to O
young O
rats O
. O

CONCLUSIONS O
: O
LSCC ALLCAPS
malformation RARE
, O
like O
other O
inner O
ear O
malformations O
such O
as O
large O
vestibular O
aqueduct RARE
and O
X O
- O
linked O
mixed O
deafness RARE
with O
perilymph RARE
gusher RARE
, O
can O
be O
associated O
with O
CHL ALLCAPS
, O
SNHL ALLCAPS
, O
or O
normal O
hearing O
. O

Escalation RARE
to O
180 O
mg O
/ O
m2 O
was O
to O
be O
carried O
out O
if O
white O
blood O
cell O
nadir RARE
count O
was O
> O
2 O
. O
0 O
x O
10 O
( O
9 O
)/ O
l O
and O
platelet O
nadir RARE
count O
was O
> O
75 O
x O
10 O
( O
9 O
)/ O
l O
. O

Methyl RARE
formate O
was O
used O
as O
the O
solvent O
of O
biodegradable RARE
oligoesters RARE
for O
the O
fabrication RARE
of O
microspheres O
with O
encapsulated RARE
bovine I-GENE
serum I-GENE
albumin I-GENE
( O
BSA ALLCAPS
). O

The O
small I-GENE
monomeric I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
of O
the O
RAB ALLCAPS
subfamily I-GENE
are O
key O
regulatory O
elements O
of O
the O
machinery O
that O
controls O
membrane O
traffic RARE
in O
eukaryotic O
cells O
. O

Furthermore O
, O
loss O
of O
methylation O
also O
greatly O
reduced O
the O
association O
of O
another O
yeast O
B O
- O
type O
subunit O
, O
Rts1p NUMERIC
. O

Thus O
, O
methylation O
of O
Pph21p NUMERIC
is O
important O
for O
formation O
of O
PP2A I-GENE
trimeric RARE
and I-GENE
dimeric I-GENE
complexes I-GENE
, O
and O
consequently RARE
, O
for O
PP2A I-GENE
function O
. O

The O
purpose O
of O
this O
study O
was O
to O
analyze O
the O
temporal O
characteristics O
and O
the O
spatial O
mapping O
of O
the O
independent O
components O
identified O
by O
ICA ALLCAPS
when O
the O
subject O
performs RARE
a O
finger O
- O
tapping RARE
task O
. O

The O
authors O
present O
the O
only O
two O
studies O
that O
have O
proved O
successful O
in O
treating RARE
animal O
models O
of O
osteoarthritis RARE
using O
gene O
therapy O
, O
and O
propose O
an O
overview RARE
of O
several O
strategies O
for O
the O
development O
of O
gene O
therapy O
in O
osteoarthritis RARE
treatment O
in O
the O
future O
. O

Together O
, O
these O
results O
indicate O
that O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
induces O
VEGF I-GENE
gene I-GENE
expression O
at O
both O
transcriptional O
and O
post O
- O
transcriptional O
levels O
, O
and O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
evokes RARE
p38 I-GENE
MAPK O
and O
JNK I-GENE
signalings RARE
, O
which O
in O
turn O
stimulate O
the O
transcription O
of O
the O
VEGF I-GENE
gene I-GENE
through O
Sp1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

Binding O
of O
NusA LASTCAP
to O
RNA O
in O
the O
presence O
of O
alpha O
or O
N O
involves O
an O
amino I-GENE
- I-GENE
terminal I-GENE
S1 I-GENE
homology I-GENE
region I-GENE
that O
is O
otherwise O
inactive O
in O
full I-GENE
- I-GENE
length I-GENE
NusA LASTCAP
. O

The O
subjects O
were O
diagnosed O
on O
the O
basis O
of O
DSM ALLCAPS
- O
IV O
pathological O
gambling RARE
criteria O
and O
completed O
the O
Turkish RARE
Version RARE
of O
South RARE
Oaks RARE
Gambling RARE
Screen RARE
( O
SOGS ALLCAPS
). O

Lys O
( O
193 O
) O
and O
Arg O
( O
194 NUMERIC
), O
located O
at O
the O
COOH O
- O
terminal O
end O
of O
HD I-GENE
, O
are O
essential O
for O
dimerization O
. O

Elevation RARE
of O
intracellular O
Ca O
( O
2 O
+) O
levels O
are O
also O
involved O
because O
treatment O
with O
receptor O
- O
associated O
protein O
, O
nifedipine O
, O
MK801 NUMERIC
, O
removal O
of O
Ca O
( O
2 O
+) O
from O
the O
medium O
and O
dantrolene RARE
all O
served RARE
to O
inhibit O
calcium O
elevation O
and O
attenuate RARE
the O
activation O
of O
CREB I-GENE
. O

The O
present O
study O
shows O
that O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
- O
dependent O
p38 I-GENE
kinase I-GENE
activation O
regulates O
Akt I-GENE
phosphorylation O
and O
activity O
in O
human O
neutrophils O
. O

When O
BFDS ALLCAPS
was O
taken O
as O
the O
reference O
, O
W O
/ O
A O
Z O
scores O
showed O
consistent O
positive O
increments RARE
, O
from O
birth O
in O
girls O
and O
1 O
mo O
in O
boys O
. O

These O
probable O
border RARE
sequences O
are O
closely O
related O
to O
those O
of O
other O
known O
T O
- O
regions O
and O
define O
a O
second O
T O
- O
region O
of O
pTiChry5 NUMERIC
, O
called O
T O
- O
right O
( O
TR O
), O
that O
confers O
production O
of O
the O
Amadoriopines RARE
. O

Using O
purified O
recombinant I-GENE
HMG I-GENE
I I-GENE
, O
we O
have O
identified O
several O
high O
- O
affinity O
binding O
sites O
which O
overlap O
important O
transcription O
factor O
binding O
sites O
. O

High I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
protein I-GENE
I I-GENE
can O
modulate O
binding O
of O
transcription O
factors O
to O
the O
U5 I-GENE
region I-GENE
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
proviral I-GENE
promoter I-GENE
. O

Another O
cis O
- O
acting O
element O
, O
exonic RARE
splicing O
suppressor O
1 O
( O
ESS1 NUMERIC
), O
represses O
use O
of O
the O
nt O
3225 NUMERIC
3 O
' O
splice O
site O
. O

Leptinaemia RARE
does O
not O
correlate O
with O
the O
actual O
or O
mean O
blood O
pressure O
reading O
nor O
with O
stage O
of O
hypertension O
according O
to O
the O
WHO ALLCAPS
classification O
. O

5 O
'- O
RACE O
analysis O
suggested O
a O
single O
transcription O
initiation O
site O
187 NUMERIC
bp O
upstream O
from O
the O
translational O
start O
site O
. O

Thus O
, O
diamide RARE
treatment O
of O
nuclear O
extracts O
strongly O
reduces O
the O
binding O
of O
NFI ALLCAPS
proteins I-GENE
, O
and O
the O
addition O
of O
higher O
concentrations O
of O
dithiothreitol RARE
to O
nuclear O
extracts O
from O
TG I-GENE
- O
treated O
cells O
restores O
NFI ALLCAPS
- I-GENE
DNA I-GENE
binding O
to O
levels O
in O
extracts O
from O
untreated O
cells O
. O

LMP2A NUMERIC
enhances O
Lyn I-GENE
and O
Syk RARE
ubiquitination O
in O
vivo O
in O
a O
fashion O
that O
depends O
on O
the O
activity O
of O
Nedd4 NUMERIC
family O
members O
and O
correlates O
with O
destabilization RARE
of O
the O
Lyn I-GENE
tyrosine I-GENE
kinase I-GENE
. O

Further O
, O
Tax I-GENE
- O
mediated O
apoptosis O
was O
effectively O
prevented O
by O
ectopic O
expression O
of O
the O
p300 I-GENE
coactivator I-GENE
. O

Our O
results O
, O
however O
, O
were O
obtained O
for O
Z O
itself O
and O
not O
for O
[ O
Z O
]. O

Fisher RARE
' O
s O
exact RARE
test O
or O
Pearson RARE
' O
s O
chi2 NUMERIC
test O
were O
used O
for O
statistical O
analysis O
. O

RESULTS O
: O
In O
the O
pregnant O
group O
, O
serum O
PP14 NUMERIC
concentrations O
were O
markedly O
increased O
after O
ET O
, O
and O
a O
significant O
difference O
between O
the O
pregnant O
group O
and O
the O
nonpregnant RARE
group O
was O
observed O
8 O
days O
following O
ET O
( O
p O
< O
0 O
. O
01 O
). O

Thromboelastography RARE
is O
a O
test O
that O
could O
potentially O
correlate O
with O
the O
degree O
of O
anticoagulation RARE
produced O
by O
low O
molecular O
weight O
heparin O
. O

High O
expression O
of O
the O
peroxisome I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
alpha I-GENE
( O
PPARalpha I-GENE
) O
differentiates RARE
brown O
fat O
from O
white O
, O
and O
is O
related O
to O
its O
high O
capacity O
of O
lipid O
oxidation O
. O

This O
- O
2485 NUMERIC
/- O
2458 NUMERIC
element O
bound O
PPARalpha I-GENE
and O
PPARgamma I-GENE
from O
brown O
fat O
nuclei O
. O

These O
results O
provide O
direct O
evidence O
for O
differential O
susceptibility O
to O
endonuclease O
- O
mediated O
mRNA O
decay O
resulting O
from O
the O
differential O
affinity O
of O
a O
RNA O
- O
binding O
protein O
for O
cis O
- O
acting O
stability O
determinants O
. O

RESULTS O
: O
Twenty O
- O
two O
( O
26 O
%) O
patients O
had O
PHG ALLCAPS
before O
( O
group O
A O
) O
and O
64 O
( O
74 O
%) O
developed O
PHG ALLCAPS
after O
variceal RARE
eradication O
( O
group O
B O
). O

Response O
was O
extremely O
poor O
in O
African O
Americans RARE
and O
those O
with O
HCV O
genotype RARE
1 O
. O

Aspirin RARE
causes O
peptic RARE
ulcers O
predominately RARE
by O
reducing O
gastric I-GENE
mucosal I-GENE
cyclooxygenase RARE
( O
COX ALLCAPS
) O
activity O
and O
prostaglandin O
synthesis O
. O

A O
total O
of O
1060 NUMERIC
clones O
were O
randomly O
selected O
for O
sequencing O
of O
one O
end O
. O

Expression O
of O
a O
hybrid O
protein O
containing O
the O
cytoplasmic O
C O
- O
terminal O
half O
of O
UhpB LASTCAP
fused O
to O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
) O
also O
interfered RARE
with O
Uhp RARE
signaling O
. O

CONCLUSIONS O
: O
The O
surgical O
or O
multimodality RARE
treatment O
of O
MSGT ALLCAPS
has O
provided O
a O
good O
locoregional RARE
control O
( O
78 O
%) O
and O
68 O
% O
10 O
- O
year O
survival O
in O
a O
series O
of O
patients O
treated O
at O
the O
oncology RARE
department RARE
of O
a O
general O
hospital O
in O
Quito RARE
, O
Ecuador RARE
. O

RESULTS O
: O
Glaucoma RARE
suspects RARE
were O
divided O
into O
two O
groups O
according O
to O
their O
SWAP ALLCAPS
results O
: O
high O
risk O
( O
with O
SWAP ALLCAPS
abnormalities O
) O
and O
low O
risk O
( O
with O
normal O
SWAP ALLCAPS
result O
). O

The O
gene O
is O
separated O
into O
four O
exons O
by O
three O
short O
introns O
, O
and O
the O
open O
reading O
frame O
consists O
of O
6660 NUMERIC
base O
pairs O
( O
bp O
) O
capable O
of O
encoding O
a O
polypeptide O
of O
2220 NUMERIC
amino O
acid O
residues O
. O

Like O
the O
p190 I-GENE
- I-GENE
B I-GENE
exon O
, O
the O
first O
exon O
of O
p190 I-GENE
- I-GENE
A I-GENE
is O
extremely O
large O
( O
3 O
. O
7 O
kb O
in O
length O
), O
encoding O
both O
the O
GTPase I-GENE
and O
middle O
domains O
( O
residues O
1 O
- O
1228 NUMERIC
), O
but O
not O
the O
remaining O
GAP I-GENE
domain I-GENE
, O
suggesting O
a O
high O
conservation O
of O
genomic O
structure O
between O
two O
p190 I-GENE
genes I-GENE
. O

The O
entire O
human I-GENE
teneurin RARE
- I-GENE
1 I-GENE
( O
TEN1 NUMERIC
) O
gene O
is O
contained O
in O
eight O
PAC ALLCAPS
clones O
representing O
part O
of O
the O
chromosomal O
locus O
Xq25 NUMERIC
. O

The O
plexiform RARE
neurofibroma RARE
and O
multiple O
localized O
neurofibromas RARE
are O
characteristic O
of O
NF1 I-GENE
. O

In O
general O
lookback RARE
, O
all O
patients O
who O
received O
blood O
before O
being O
tested O
for O
hepatitis O
C O
are O
advised RARE
to O
undergo O
testing O
. O

The O
proposed O
algorithm O
consists O
of O
several O
steps O
. O

It O
contained O
seven O
extra O
amino O
acids O
of O
FVVLNLQ ALLCAPS
; O
this O
short O
stretch O
of O
extra O
sequence O
was O
found O
between O
Gln O
( O
421 NUMERIC
) O
and O
Phe O
( O
422 NUMERIC
) O
within O
the O
SET ALLCAPS
( O
Suvar3 NUMERIC
- I-GENE
9 I-GENE
, O
Enhancer RARE
- I-GENE
of I-GENE
- I-GENE
zeste RARE
, O
Trithorax RARE
) O
interacting O
domain O
( O
SID ALLCAPS
) O
of O
rMTM LASTCAP
. O

MED1 NUMERIC
has O
a O
weak O
glycosylase I-GENE
activity O
on O
the O
mutagenic RARE
adduct RARE
3 O
, O
N O
( O
4 O
)- O
ethenocytosine RARE
, O
a O
metabolite O
of O
vinyl O
chloride O
and O
ethyl O
carbamate RARE
. O

There O
were O
no O
instances O
of O
major O
flap O
necrosis O
although O
two O
flaps RARE
showed O
tip O
ischaemia O
. O

These O
results O
suggest O
that O
XAB1 NUMERIC
is O
a O
novel O
cytoplasmic I-GENE
GTPase I-GENE
involved O
in O
nuclear O
localization O
of O
XPA ALLCAPS
. O

One O
of O
these O
factors O
, O
IRF I-GENE
- I-GENE
2 I-GENE
, O
was O
initially O
cloned O
as O
an O
antagonistic O
counterpart O
to O
IRF I-GENE
- I-GENE
1 I-GENE
with O
oncogenic O
potential O
. O

Among O
the O
total O
CDSs RARE
, O
8 O
. O
8 O
% O
match O
sequences O
of O
proteins O
found O
only O
in O
Bacillus O
subtilis O
and O
66 O
. O
7 O
% O
are O
widely O
conserved O
in O
comparison O
with O
the O
proteins O
of O
various O
organisms O
, O
including O
B O
. O
subtilis O
. O

Tobramycin RARE
- O
loaded RARE
SLN ALLCAPS
administered O
i O
. O
v O
. O
showed O
a O
prolonged O
circulation O
time O
compared O
to O
the O
i O
. O
v O
. O
administered O
tobramycin RARE
solution O
. O

Bacteriol RARE
. O

Terminal RARE
deoxynucleotidyl RARE
transferase I-GENE
- O
mediated O
nick RARE
end O
labeling O
assays O
revealed O
that O
hormonal O
activation O
of O
the O
PAX3 NUMERIC
repressors RARE
induced O
extensive O
apoptosis O
that O
correlated O
with O
down O
- O
regulation O
of O
BCL I-GENE
- I-GENE
X I-GENE
( I-GENE
L I-GENE
) I-GENE
expression O
. O

VEGF I-GENE
promoter I-GENE
activity O
in O
transient O
transfections O
was O
decreased O
by O
either O
pharmacological O
or O
genetic O
inhibition O
of O
EGFR I-GENE
, O
Ras I-GENE
, O
or O
phosphatidylinositol I-GENE
3 I-GENE
'- I-GENE
kinase I-GENE
[ O
PI O
( O
3 O
) O
kinase O
]. O

Epidermal RARE
growth I-GENE
factor I-GENE
receptor I-GENE
transcriptionally O
up O
- O
regulates O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
expression O
in O
human O
glioblastoma RARE
cells O
via O
a O
pathway O
involving O
phosphatidylinositol I-GENE
3 I-GENE
'- I-GENE
kinase I-GENE
and O
distinct O
from O
that O
induced O
by O
hypoxia O
. O

Thus O
, O
IHHNV ALLCAPS
is O
closely O
related O
to O
densoviruses RARE
of O
the O
genus O
Brevidensovirus RARE
in O
the O
family O
Parvoviridae RARE
, O
and O
we O
therefore O
propose O
to O
rename RARE
this O
virus O
Penaeus RARE
stylirostris RARE
densovirus RARE
( O
PstDNV LASTCAP
). O

Stress RARE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
1 I-GENE
( O
SAPK1 NUMERIC
), O
also O
called O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
), O
becomes O
activated O
in O
vivo O
in O
response O
to O
pro O
- O
inflammatory O
cytokines O
or O
cellular O
stresses O
. O

Catalytic RARE
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
by O
binding O
to O
p38 I-GENE
MAP I-GENE
kinase I-GENE
: O
critical O
role O
of O
the O
p38 I-GENE
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
in O
its O
negative O
regulation O
. O

Thus O
, O
the O
class I-GENE
C I-GENE
- O
Vps RARE
complex O
directs O
multiple O
reactions O
during O
the O
docking RARE
and O
fusion O
of O
vesicles O
with O
the O
vacuole RARE
, O
each O
of O
which O
contributes O
to O
the O
overall O
specificity O
and O
efficiency O
of O
this O
transport O
process O
. O

Combined O
intravenous O
and O
intra O
- O
arterial O
recombinant O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
in O
acute O
ischemic O
stroke O
. O

To O
begin O
to O
understand O
this O
role O
, O
we O
overexpressed O
ATF I-GENE
- I-GENE
2 I-GENE
in O
a O
human O
cancer O
cell O
line O
. O

Signal RARE
transduction O
via O
modulation O
of O
phosphorylation O
after O
selective O
inhibition O
of O
protein I-GENE
phosphatase I-GENE
( I-GENE
PP I-GENE
) I-GENE
1 I-GENE
and O
/ O
or O
PP2A I-GENE
appears O
to O
play O
a O
role O
in O
okadaic RARE
acid O
( O
OA ALLCAPS
)- O
mediated O
effects O
. O

Botulinum RARE
toxin I-GENE
A I-GENE
in O
the O
treatment O
of O
hemiplegic RARE
spastic RARE
foot O
drop O
-- O
clinical O
and O
functional O
outcomes O
. O

Exon RARE
A O
is O
located O
approximately O
7 O
kb O
5 O
' O
to O
the O
HSL ALLCAPS
translation I-GENE
start I-GENE
site I-GENE
. O

NF I-GENE
- I-GENE
kappaB I-GENE
is O
a O
redox RARE
- O
sensitive O
transcription O
factor O
known O
to O
be O
activated O
by O
oxidative O
stress O
as O
well O
as O
chemical O
and O
biological O
reductants RARE
. O

Cardiovascular RARE
risk O
factors O
and O
antihypertensive O
treatment O
. O

What RARE
to O
look RARE
for O
during O
a O
compliance O
review O
: O
10 O
common O
mistakes RARE
made O
by O
SNFs RARE
. O

CONCLUSIONS O
: O
EBCT ALLCAPS
technology O
allows O
minimally RARE
invasive O
evaluation O
of O
intramyocardial RARE
microcirculatory RARE
function O
and O
permits O
assessment O
of O
microvascular O
BV ALLCAPS
distribution O
in O
different O
functional O
components O
. O

These O
two O
mAbs RARE
used O
the O
same O
V O
( O
H O
) O
and O
J O
( O
H O
) O
gene O
segments O
, O
but O
different O
D O
, O
Vkappa RARE
, O
and O
Jkappa RARE
genes O
. O

SSF ALLCAPS
experiments O
were O
carried O
out O
in O
bench RARE
- O
scale O
bioreactors RARE
( O
equipped RARE
with O
CO2 O
and O
volatile O
organic O
traps RARE
) O
containing O
a O
mixture O
of O
lignocellulosic RARE
materials O
and O
a O
radiolabeled O
pesticide RARE
. O

Characterization O
of O
a O
Xenopus I-GENE
laevis I-GENE
CXC ALLCAPS
chemokine I-GENE
receptor I-GENE
4 I-GENE
: O
implications O
for O
hematopoietic O
cell O
development O
in O
the O
vertebrate O
embryo O
. O

Patients O
had O
to O
have O
adequate O
liver O
, O
renal O
, O
and O
marrow O
functions O
. O

Inhibition O
of O
RNA2 NUMERIC
translation O
was O
selective O
, O
with O
no O
effect O
on O
general O
cellular O
translation O
or O
translation O
of O
BMV ALLCAPS
RNA1 NUMERIC
- O
encoded O
replication I-GENE
factor I-GENE
1a I-GENE
, O
and O
was O
independent O
of O
p20 NUMERIC
, O
a O
cellular O
antagonist O
of O
DED1 NUMERIC
function O
in O
translation O
. O

Abbreviations RARE
: O
CAS I-GENE
, O
CRK ALLCAPS
- I-GENE
associated I-GENE
substrate I-GENE
; O
CH ALLCAPS
, O
calponin RARE
- I-GENE
homology I-GENE
domain I-GENE
; O
CSK ALLCAPS
, O
C I-GENE
- I-GENE
terminal I-GENE
SRC I-GENE
kinase I-GENE
; O
E6 I-GENE
, O
Papillomavirus RARE
E6 I-GENE
protein I-GENE
; O
FAK I-GENE
, O
focal I-GENE
adhesion I-GENE
kinase I-GENE
; O
GIT ALLCAPS
, O
GRK ALLCAPS
interacter RARE
; O
GPCR ALLCAPS
, O
heterotrimeric I-GENE
- I-GENE
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
; O
GRK ALLCAPS
, O
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
- I-GENE
receptor I-GENE
kinase I-GENE
; O
MAPK I-GENE
, O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
ERK I-GENE
, O
p38 I-GENE
, O
JNK I-GENE
); O
PAK ALLCAPS
, O
p21 I-GENE
- I-GENE
activated I-GENE
kinase I-GENE
; O
PBS ALLCAPS
, O
paxillin I-GENE
- I-GENE
binding I-GENE
subdomain I-GENE
; O
PIX ALLCAPS
, O
PAK ALLCAPS
- I-GENE
interacting I-GENE
exchange I-GENE
factor I-GENE
; O
PKL ALLCAPS
, O
paxillin I-GENE
kinase I-GENE
linker I-GENE
; O
POR1 NUMERIC
, O
partner I-GENE
of I-GENE
Rac I-GENE
; O
PS O
, O
phosphoserine RARE
; O
PT O
, O
phosphothreonine RARE
; O
PY ALLCAPS
, O
phosphotyrosine O
; O
RTK ALLCAPS
, O
growth I-GENE
factor I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
; O
SH I-GENE
, O
SRC I-GENE
- I-GENE
homology I-GENE
domain I-GENE
. O

In O
15 O
ventilator RARE
- O
dependent O
, O
SB ALLCAPS
, O
and O
actively O
expiring RARE
patients O
, O
we O
found O
that O
the O
difference O
PEEP ALLCAPS
( O
i O
), O
dyn RARE
- O
Pga RARE
, O
total O
decay O
( O
mean O
+/- O
SD O
, O
5 O
. O
7 O
+/- O
1 O
. O
9 O
cm O
H O
( O
2 O
) O
O O
) O
was O
quite O
similar O
to O
PEEP ALLCAPS
( O
i O
), O
dyn RARE
ref RARE
( O
5 O
. O
3 O
+/- O
1 O
. O
9 O
cm O
H O
( O
2 O
) O
O O
). O

Of O
208 NUMERIC
eligible RARE
subjects O
, O
82 O
received O
supervised RARE
IPT ALLCAPS
at O
a O
dose O
of O
900 NUMERIC
mg O
twice O
weekly O
for O
6 O
mo O
( O
Regimen RARE
A O
), O
73 O
received O
unsupervised RARE
IPT ALLCAPS
900 NUMERIC
mg O
twice O
weekly O
for O
6 O
mo O
( O
Regimen RARE
B O
), O
and O
53 O
received O
unsupervised RARE
IPT ALLCAPS
300 O
mg O
daily O
for O
6 O
mo O
( O
Regimen RARE
C O
). O

There O
were O
122 O
cases O
of O
tuberculosis O
over O
an O
average O
10 O
. O
3 O
yr O
of O
follow O
- O
up O
( O
crude O
annual O
incidence O
, O
76 O
. O
2 O
/ O
100 O
, O
000 O
). O

These O
results O
suggested O
that O
BACH1t NUMERIC
recruits RARE
BACH1 NUMERIC
to O
the O
nucleus O
through O
BTB I-GENE
domain O
- O
mediated O
interaction O
. O

The O
U17 NUMERIC
/ O
U16 NUMERIC
and O
the O
U16 NUMERIC
+ I-GENE
gene I-GENE
products I-GENE
transactivated O
the O
HIV I-GENE
LTR I-GENE
. O

Transcription O
of O
the O
six O
EBNA I-GENE
genes I-GENE
, O
which O
are O
expressed O
in O
EBV O
- O
immortalized RARE
primary O
B O
cells O
, O
arises RARE
from O
one O
of O
two O
promoters O
, O
Cp I-GENE
and O
Wp RARE
, O
located O
near O
the O
left O
end O
of O
the O
viral O
genome O
. O

The O
Cili RARE
- I-GENE
2 I-GENE
sequences I-GENE
possess O
similarity O
to O
the O
RNaseH LASTCAP
domain I-GENE
of O
Lian RARE
- O
Aa1 NUMERIC
, O
a O
mosquito RARE
non I-GENE
- I-GENE
LTR I-GENE
retrotransposon I-GENE
. O

This O
dynamic O
response O
strongly O
suggests O
that O
the O
p53 I-GENE
and O
Rb I-GENE
tumor O
suppressor O
pathways O
are O
intact O
in O
HeLa O
cells O
and O
that O
repression O
of O
HPV I-GENE
E6 I-GENE
and O
E7 I-GENE
mobilizes RARE
these O
pathways O
in O
an O
orderly RARE
fashion O
to O
deliver RARE
growth O
inhibitory O
signals O
to O
the O
cells O
. O

Thus O
, O
blocks O
in O
the O
RARalpha RARE
- O
specific O
pathway O
of O
retinoid O
- O
induced O
differentiation O
may O
be O
bypassed RARE
during O
retinoid O
induction O
of O
FR I-GENE
- I-GENE
beta I-GENE
expression O
. O

Is O
more O
better O
? O
About RARE
dose O
levels O
of O
ACE I-GENE
inhibitors O
in O
chronic O
heart O
failure O
. O

To O
test O
whether O
or O
not O
SOCS ALLCAPS
- I-GENE
3 I-GENE
also O
binds O
to O
the O
IGFIR ALLCAPS
, O
we O
cloned O
human I-GENE
SOCS ALLCAPS
- I-GENE
3 I-GENE
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
from O
human O
skeletal O
muscle O
mRNA O
. O

A O
protein O
lacking O
the O
SH2 I-GENE
and O
RING O
finger O
domains O
has O
no O
activity O
, O
but O
a O
chimeric O
protein O
with O
the O
SH2 I-GENE
and O
RING O
finger O
domains O
of O
SLI ALLCAPS
- I-GENE
1 I-GENE
replaced O
by O
the O
equivalent O
domains O
of O
c I-GENE
- I-GENE
Cbl I-GENE
has O
activity O
. O

To O
evaluate O
the O
effects O
of O
HRT ALLCAPS
on O
those O
factors O
in O
end O
- O
stage O
renal O
disease O
( O
ESRD ALLCAPS
) O
patients O
, O
we O
evaluated O
the O
changes O
of O
lipid O
profile O
, O
coagulation O
and O
fibrinolysis RARE
markers O
, O
and O
plasma O
homocysteine RARE
levels O
after O
treatment O
. O

There O
was O
a O
weak O
significant O
correlation O
between O
TGF I-GENE
beta I-GENE
1 I-GENE
levels O
and O
normal O
cell O
radiosensitivity RARE
( O
lymphocyte O
SF2 NUMERIC
). O

Acute O
feasibility O
and O
safety O
of O
a O
smoking O
reduction O
strategy O
for O
smokers O
with O
schizophrenia O
. O

Tightly RARE
ordered RARE
proteasomal RARE
degradation O
of O
proteins O
critical O
for O
cell O
cycle O
control O
implies RARE
a O
role O
of O
the O
proteasome O
in O
maintaining O
cell O
proliferation O
and O
cell O
survival O
. O

The O
sixth RARE
nucleotide O
was O
bulged RARE
out O
to O
allow O
stacking RARE
of O
this O
U O
. O
G O
pair O
on O
the O
adjacent O
helical O
region O
. O

Functional O
analysis O
of O
the O
mutant I-GENE
desmin RARE
in O
SW13 NUMERIC
( O
vim RARE
-) O
cells O
showed O
aggregation O
of O
abnormal O
coarse RARE
clumps RARE
of O
desmin RARE
positive O
material O
dispersed RARE
throughout O
the O
cytoplasm O
. O

Patients O
with O
lesions O
affecting O
the O
PRC ALLCAPS
but O
sparing RARE
the O
PHC ALLCAPS
, O
and O
patients O
with O
lesions O
affecting O
both O
PRC ALLCAPS
and O
PHC ALLCAPS
, O
performed O
an O
oculomotor RARE
delayed O
response O
task O
with O
unpredictably RARE
varied O
memory O
delays RARE
of O
up O
to O
30 O
s O
. O

In O
addition O
, O
26 O
amino O
acid O
residues O
, O
K69 NUMERIC
, O
D88 NUMERIC
, O
E94 NUMERIC
, O
D134 NUMERIC
, O
R154 NUMERIC
, O
K169 NUMERIC
, O
H197 NUMERIC
, O
D233 NUMERIC
, O
G235 NUMERIC
, O
G236 NUMERIC
, O
G237 NUMERIC
, O
F238 NUMERIC
, O
E274 NUMERIC
, O
G276 NUMERIC
, O
R277 NUMERIC
, O
Y278 NUMERIC
, O
K294 NUMERIC
, O
Y323 NUMERIC
, O
Y331 NUMERIC
, O
D332 NUMERIC
, O
C360 NUMERIC
, O
D361 NUMERIC
, O
D364 NUMERIC
, O
G387 NUMERIC
, O
Y389 NUMERIC
, O
and O
F397 NUMERIC
( O
mouse O
ODC ALLCAPS
numbering RARE
), O
all O
of O
which O
are O
implicated O
in O
the O
formation O
of O
the O
pyridoxal RARE
phosphate O
- O
binding O
domain O
and O
the O
substrate O
- O
binding O
domain O
and O
in O
dimer O
stabilization O
with O
the O
eukaryotic O
ODCs RARE
, O
were O
also O
conserved O
in O
S O
. O
ruminantium RARE
LDC ALLCAPS
. O

The O
Psc2 NUMERIC
cDNA I-GENE
contained O
an O
open O
reading O
frame O
homologous O
to O
CP2 NUMERIC
family I-GENE
proteins I-GENE
. O

Our O
results O
indicate O
that O
Shh RARE
can O
drive O
continued O
cycling RARE
in O
immature O
, O
proliferating O
CGNPs RARE
. O

The O
QT O
interval O
was O
related O
to O
various O
components O
of O
the O
insulin I-GENE
resistance O
syndrome O
, O
including O
BP O
and O
insulin I-GENE
sensitivity O
. O

The O
wavenumbers RARE
corresponding O
to O
the O
normal O
modes O
of O
vibration O
were O
calculated O
using O
the O
DFT ALLCAPS
( O
B3LYP NUMERIC
/ O
6 O
- O
31G NUMERIC
**) RARE
approximation RARE
and O
their O
agreement O
with O
the O
measured O
values O
improved O
after O
scaling RARE
of O
the O
associated O
force O
field O
. O

The O
data O
provide O
strong O
evidence O
that O
ThlA LASTCAP
is O
involved O
in O
the O
metabolism O
of O
both O
acid O
and O
solvent O
formation O
, O
whereas O
the O
physiological O
function O
of O
ThlB LASTCAP
has O
yet O
to O
be O
elucidated RARE
. O

In O
addition O
, O
npm3 NUMERIC
, O
which O
is O
usually O
coactivated RARE
with O
fgf8 NUMERIC
by O
MMTV O
insertion O
, O
was O
not O
up O
- O
regulated O
by O
androgens RARE
in O
SC O
- O
3 O
cells O
. O

Experiments O
with O
epitope O
- O
tagged O
proteins O
show O
that O
UEV1A NUMERIC
is O
a O
nuclear O
protein O
, O
whereas O
both O
Kua RARE
and O
Kua RARE
- O
UEV ALLCAPS
localize O
to O
cytoplasmic O
structures O
, O
indicating O
that O
the O
Kua RARE
domain I-GENE
determines RARE
the O
cytoplasmic O
localization O
of O
Kua RARE
- O
UEV ALLCAPS
. O

Stoichiometric RARE
phosphorylation O
of O
human I-GENE
p53 I-GENE
at O
Ser315 NUMERIC
stimulates O
p53 I-GENE
- O
dependent O
transcription O
. O
p53 I-GENE
protein I-GENE
activity O
as O
a O
transcription O
factor O
can O
be O
activated O
in O
vivo O
by O
antibodies O
that O
target O
its O
C O
- O
terminal O
negative O
regulatory O
domain O
suggesting O
that O
cellular O
enzymes O
that O
target O
this O
domain O
may O
play O
a O
role O
in O
stimulating O
p53 I-GENE
- O
dependent O
gene O
expression O
. O

Interestingly O
, O
this O
mutant O
cell O
line O
lacks O
expression O
of O
the O
IKK ALLCAPS
regulatory I-GENE
protein I-GENE
, O
IKKgamma RARE
. O

The O
Tax I-GENE
/ O
IKKgamma RARE
interaction O
serves O
to O
recruit O
Tax I-GENE
to O
the O
IKK ALLCAPS
catalytic I-GENE
subunits I-GENE
, O
IKKalpha RARE
and O
IKKbeta RARE
, O
and O
this O
recruitment O
appears O
to O
be O
an O
essential O
mechanism O
by O
which O
Tax I-GENE
stimulates O
the O
activity O
of O
IKK ALLCAPS
. O

An O
anchored O
AFLP ALLCAPS
- O
and O
retrotransposon O
- O
based O
map O
of O
diploid O
Avena RARE
. O

In O
addition O
, O
we O
identified O
a O
novel O
type O
of O
inhibitory O
domain O
in O
the O
N O
- O
terminal O
60 O
amino O
acids O
of O
IRF I-GENE
- I-GENE
1 I-GENE
which O
strongly O
inhibits O
its O
transcriptional O
activity O
. O

Effects O
of O
spatial O
and O
temporal O
smoothing RARE
on O
stimulated O
brillouin RARE
scattering RARE
in O
the O
independent O
- O
hot O
- O
spot RARE
model O
limit O
The O
influence O
of O
laser O
beam O
smoothing RARE
on O
stimulated O
Brillouin RARE
backscattering RARE
( O
SBBS ALLCAPS
) O
is O
studied O
analytically RARE
in O
the O
limit O
of O
the O
independent O
hot O
spot RARE
model O
. O

Simultaneous RARE
determination O
of O
theophylline O
and O
its O
metabolites O
by O
HPLC O
] O
A O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
method O
has O
been O
developed O
for O
the O
simultaneous O
determination O
of O
theophylline O
and O
its O
metabolites O
, O
with O
caffeine O
and O
its O
metabolites O
. O

Ten O
males O
performed O
both O
test O
conditions O
and O
oxygen O
uptake O
VO2 O
, O
heart O
rate O
, O
minute O
ventilation O
VE O
, O
perceived O
exertion RARE
and O
spinal O
shrinkage RARE
were O
recorded O
. O

CONCLUSION O
: O
SPT ALLCAPS
is O
more O
useful O
than O
WST ALLCAPS
in O
differentiating O
patients O
predisposed RARE
to O
aspiration RARE
. O

Studied RARE
groups O
were O
( O
1 O
) O
untreated O
control O
, O
n O
= O
12 O
; O
( O
2 O
) O
FK O
- O
1 O
, O
n O
= O
8 O
; O
( O
3 O
) O
FK O
- O
3 O
, O
n O
= O
8 O
. O

DNA O
binding O
and O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
pull RARE
- O
down O
assays O
demonstrate O
that O
binding O
requires O
Elk I-GENE
- I-GENE
1 I-GENE
( I-GENE
1 I-GENE
- I-GENE
212 NUMERIC
) I-GENE
but O
not O
the O
C O
- O
terminal O
transactivation O
domain O
. O

Unexpectedly RARE
, O
ALK7 NUMERIC
signaling O
produced O
a O
remarkable O
change O
in O
cell O
morphology O
characterized O
by O
cell O
flattening RARE
and O
elaboration RARE
of O
blunt RARE
, O
short O
cell O
processes O
. O

The O
swa2 NUMERIC
- I-GENE
1 I-GENE
allele I-GENE
recovered O
from O
the O
original O
screen O
carries O
a O
point O
mutation O
in O
its O
tetratricopeptide RARE
repeat O
( O
TPR O
) O
domain O
, O
a O
motif O
not O
found O
in O
auxilin RARE
but O
known O
in O
other O
proteins O
to O
mediate O
interaction O
with O
heat I-GENE
- I-GENE
shock I-GENE
proteins I-GENE
. O

Association O
of O
stress O
during O
delivery O
with O
increased O
numbers O
of O
nucleated RARE
cells O
and O
hematopoietic O
progenitor O
cells O
in O
umbilical RARE
cord O
blood O
. O

In O
slightly O
older O
embryos O
, O
the O
expression O
was O
skewed RARE
to O
one O
side O
of O
the O
embryo O
and O
by O
E6 O
. O
5 O
, O
at O
the O
onset O
of O
gastrulation RARE
, O
expression O
was O
seen O
in O
the O
epiblast RARE
, O
visceral O
endoderm O
, O
nascent RARE
mesoderm O
, O
and O
the O
primitive RARE
streak RARE
. O

Transformation RARE
of O
the O
sconC3 NUMERIC
mutant I-GENE
with O
sconB LASTCAP
+ I-GENE
restores O
the O
wild O
- O
type O
phenotype O
. O

The O
authors O
proposed O
that O
the O
highly O
convergent RARE
inputs O
to O
the O
entorhinal RARE
cortex O
indicate O
this O
region O
may O
be O
particularly O
important O
for O
selecting RARE
or O
compressing RARE
information O
. O

Influence O
of O
oil O
emulsions RARE
and O
diphenyl RARE
on O
post O
- O
harvest RARE
physiconutritional RARE
changes O
in O
Kagzi RARE
limes RARE
( O
Citrus RARE
aurantifolia RARE
) O
was O
studied O
. O

Detailed RARE
analysis O
of O
alpha1 I-GENE
, I-GENE
3GT NUMERIC
transcripts I-GENE
revealed O
two O
major O
alternative O
splicing O
patterns O
in O
the O
5 O
'- O
untranslated O
region O
( O
5 O
'- O
UTR O
) O
and O
evidence O
for O
minor O
splicing O
activity O
that O
occurs O
in O
a O
tissue O
- O
specific O
manner O
. O

A O
thermal O
Kubo RARE
- O
Martin RARE
- O
Schwinger RARE
condition O
arises RARE
due O
to O
the O
coupling O
of O
a O
computer O
to O
a O
strong O
periodic O
source O
, O
namely O
, O
the O
daily O
and O
weekly O
usage O
patterns O
of O
the O
system O
. O

The O
non O
- O
homologous O
sequences O
in O
the O
5 O
' O
untranslated O
regions O
might O
be O
acquired O
at O
or O
after O
transcription O
during O
retrotransposition RARE
of O
the O
ATLN ALLCAPS
elements O
. O

The O
time O
course O
of O
RNA1 NUMERIC
replication O
and O
RNA3 NUMERIC
synthesis O
in O
induced O
yeast O
paralleled RARE
that O
in O
yeast O
transfected O
with O
natural O
FHV ALLCAPS
virion O
RNA O
. O

The O
transcription O
and O
alternative O
splicing O
of O
human I-GENE
ORL1 NUMERIC
and O
GAIP ALLCAPS
are O
cell O
- O
type O
specific O
. O

RESULTS O
: O
The O
main O
effect O
of O
muscle O
pain O
, O
compared O
to O
non O
- O
painful RARE
stimulation O
, O
was O
a O
significant O
and O
long O
- O
lasting O
increase O
of O
delta O
( O
1 O
- O
3 O
Hz O
) O
power O
and O
an O
alpha O
- O
1 O
( O
9 O
- O
11 O
Hz O
) O
power O
increase O
over O
the O
contralateral O
parietal RARE
locus O
. O

The O
extraction O
was O
subsequently O
rated RARE
as O
' O
easy RARE
' O
or O
' O
difficult O
'. O
Taking RARE
Pell RARE
- O
Gregory RARE
class O
C O
as O
a O
predictor O
of O
a O
' O
difficult O
' O
extraction O
, O
specificity O
was O
88 O
% O
but O
sensitivity O
was O
low O
at O
15 O
%. O

In O
addition O
, O
our O
results O
show O
that O
ERKs I-GENE
and O
PI3Ks NUMERIC
can O
synergise RARE
to O
convert RARE
ectoderm RARE
into O
mesoderm O
. O

Based O
on O
16S NUMERIC
rRNA I-GENE
gene I-GENE
sequence I-GENE
analysis O
, O
the O
11 O
species O
having O
two O
tuf RARE
genes I-GENE
all O
have O
a O
common O
ancestor O
, O
while O
the O
six O
species O
having O
only O
one O
copy O
diverged O
from O
the O
enterococcal RARE
lineage O
before O
that O
common O
ancestor O
. O

Nevertheless O
, O
protein I-GENE
kinase I-GENE
A I-GENE
stimulation O
induces O
CREMalpha RARE
to O
activate O
the O
complex O
native O
promoter O
in O
the O
phosphoenolpyruvate I-GENE
carboxykinase RARE
( O
PEPCK I-GENE
) O
gene O
. O

Another O
putative O
HNF3 NUMERIC
site I-GENE
in O
close O
apposition RARE
to O
a O
NF1 I-GENE
/ O
CTF ALLCAPS
site O
was O
localized O
upstream O
of O
the O
silencer O
- O
like O
element O
. O

This O
transcriptional O
regulation O
occurs O
through O
modulation O
of O
the O
forkhead RARE
transcription I-GENE
factor I-GENE
FKHR ALLCAPS
- I-GENE
L1 I-GENE
, O
and O
IL I-GENE
- I-GENE
3 I-GENE
inhibited O
FKHR ALLCAPS
- I-GENE
L1 I-GENE
activity O
in O
a O
PI3K NUMERIC
- O
dependent O
manner O
. O

Taken O
together O
, O
these O
observations O
indicate O
that O
inhibition O
of O
p27 I-GENE
( O
KIP1 NUMERIC
) O
transcription O
through O
PI3K NUMERIC
- O
induced O
FKHR ALLCAPS
- I-GENE
L1 I-GENE
phosphorylation O
provides O
a O
novel O
mechanism O
of O
regulating O
cytokine O
- O
mediated O
survival O
and O
proliferation O
. O

DNase I-GENE
I I-GENE
genomic O
footprinting O
revealed O
that O
the O
c I-GENE
- I-GENE
Myb I-GENE
site I-GENE
is O
occupied O
in O
a O
tissue O
- O
specific O
fashion O
in O
vivo O
. O

We O
conclude O
that O
c I-GENE
- I-GENE
Myb I-GENE
regulates O
the O
RAG ALLCAPS
- I-GENE
2 I-GENE
promoter I-GENE
in O
T O
cells O
by O
binding O
to O
this O
consensus I-GENE
c I-GENE
- I-GENE
Myb I-GENE
binding I-GENE
site I-GENE
. O

A O
recently O
reported O
new O
member O
of O
the O
Vav RARE
family I-GENE
proteins I-GENE
, O
Vav3 NUMERIC
has O
been O
identified O
as O
a O
Ros RARE
receptor I-GENE
protein I-GENE
tyrosine I-GENE
kinase I-GENE
( O
RPTK ALLCAPS
) O
interacting O
protein O
by O
yeast O
two O
- O
hybrid O
screening O
. O

Subsequently RARE
, O
we O
show O
that O
the O
reexpression RARE
of O
the O
r I-GENE
- I-GENE
PTPeta RARE
gene I-GENE
in O
highly O
malignant O
rat O
thyroid O
cells O
transformed O
by O
retroviruses RARE
carrying O
the O
v I-GENE
- I-GENE
mos I-GENE
and O
v I-GENE
- I-GENE
ras I-GENE
- I-GENE
Ki RARE
oncogenes I-GENE
suppresses O
their O
malignant O
phenotype O
. O

Induced RARE
expression O
of O
Rnd3 NUMERIC
is O
associated O
with O
transformation O
of O
polarized RARE
epithelial O
cells O
by O
the O
Raf I-GENE
- O
MEK I-GENE
- O
extracellular O
signal O
- O
regulated O
kinase O
pathway O
. O

The O
activity O
of O
the O
transcription I-GENE
factor I-GENE
CREB I-GENE
is O
regulated O
by O
extracellular O
stimuli O
that O
result O
in O
its O
phosphorylation O
at O
a O
critical O
serine O
residue O
, O
Ser133 NUMERIC
. O

RESULTS O
: O
Average RARE
age O
at O
symptom RARE
onset O
was O
41 O
. O
2 O
years O
. O

When O
10 O
fields O
were O
analysed O
, O
a O
strong O
relationship O
was O
found O
between O
the O
presence O
of O
bacteria O
on O
Gram O
staining O
and O
the O
final O
diagnosis O
of O
VAP ALLCAPS
( O
for O
PSB ALLCAPS
and O
PTC ALLCAPS
respectively O
: O
sensitivity O
74 O
and O
81 O
%, O
specificity O
94 O
and O
100 O
%, O
positive O
predictive O
value O
91 O
and O
100 O
%, O
negative O
predictive O
value O
82 O
and O
88 O
%). O

Unlike O
the O
mammalian O
proteins O
, O
XFGF3 NUMERIC
is O
efficiently O
secreted O
as O
a O
Mr O
31 O
, O
000 O
glycoprotein O
, O
gp31 NUMERIC
, O
which O
undergoes O
proteolytic O
cleavage O
to O
produce O
an O
NH2 O
- O
terminally O
truncated O
product O
, O
gp27 NUMERIC
. O

NH2 O
- O
terminal O
trimming RARE
of O
Xenopus O
and O
mammalian I-GENE
FGF3s NUMERIC
may O
therefore O
be O
a O
prerequisite O
of O
optimal O
biological O
activity O
. O

Here O
, O
we O
identified O
three O
cis O
- O
elements O
required O
for O
replication O
within O
the O
200 O
bp O
promoter O
, O
using O
autonomously O
replicating O
plasmids O
carrying O
various O
mutations O
and O
deletions O
. O

Tranilast RARE
in O
the O
Therapy RARE
of O
Coronary O
Artery RARE
Disease RARE
. O

The O
objectives RARE
of O
the O
present O
study O
were O
to O
evaluate O
the O
effects O
of O
adding O
Equex RARE
to O
a O
TRIS ALLCAPS
- O
extender RARE
, O
diluting RARE
the O
semen O
in O
1 O
or O
2 O
steps O
, O
freezing RARE
according O
to O
2 O
methods O
, O
thawing RARE
at O
2 O
rates O
, O
and O
the O
interactions O
between O
these O
treatments O
, O
on O
the O
post O
- O
thaw RARE
survival O
of O
dog O
spermatozoa O
at O
38 O
degrees O
C O
. O

This O
study O
is O
a O
further O
and O
more O
extensive O
validation RARE
of O
the O
clinician RARE
rated RARE
NIMH ALLCAPS
- O
LCM ALLCAPS
- O
p O
. O

The O
Aie1 NUMERIC
locus I-GENE
was O
mapped O
to O
mouse O
chromosome O
7A2 NUMERIC
- O
A3 O
by O
fluorescent O
in O
situ O
hybridization O
. O

Psychiatric RARE
disorders O
in O
children O
and O
adolescents RARE
carry O
considerable O
morbidity O
, O
impede RARE
development O
, O
and O
carry O
a O
significant O
mortality O
by O
suicide O
. O

Molecular O
cloning O
and O
expression O
of O
human I-GENE
UDP ALLCAPS
- I-GENE
d I-GENE
- I-GENE
Xylose RARE
: I-GENE
proteoglycan I-GENE
core I-GENE
protein I-GENE
beta I-GENE
- I-GENE
d I-GENE
- I-GENE
xylosyltransferase RARE
and O
its O
first O
isoform I-GENE
XT ALLCAPS
- I-GENE
II I-GENE
. O

Thyrotoxicosis RARE
due O
to O
amiodarone RARE
is O
difficult O
to O
treat O
and O
is O
further O
complicated O
by O
the O
pro O
- O
arrhythmic RARE
potential O
of O
thyrotoxicosis RARE
and O
the O
fading RARE
antiarrhythmic O
effect O
after O
amiodarone RARE
withdrawal O
. O

Chaperones RARE
/ O
HSPs RARE
thus O
play O
important O
roles O
within O
cell O
cycle O
processes O
. O

Oncogenic RARE
signalling O
by O
E2F1 I-GENE
has O
recently O
been O
linked O
to O
stabilization O
and O
activation O
of O
the O
tumour O
suppressor O
p53 I-GENE
( O
refs RARE
1 O
, O
3 O
, O
4 O
). O

This O
study O
allows O
us O
to O
draw RARE
conclusions O
about O
the O
identity O
of O
proteins O
required O
for O
the O
development O
of O
the O
nervous O
system O
in O
Drosophila O
and O
provides O
an O
example O
of O
a O
molecular O
approach O
to O
characterize O
en O
masse RARE
transposon O
- O
tagged O
mutations O
identified O
in O
genetic O
screens RARE
. O

We O
describe O
the O
identification O
and O
initial O
characterization O
of O
neurobeachin RARE
, O
a O
neuron O
- O
specific O
multidomain RARE
protein O
of O
327 NUMERIC
kDa O
with O
a O
high O
- O
affinity O
binding O
site O
( O
K O
( O
d O
), O
10 O
nm O
) O
for O
the O
type I-GENE
II I-GENE
regulatory I-GENE
subunit I-GENE
of I-GENE
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
RII I-GENE
). O

Children O
with O
ADD ALLCAPS
showed O
an O
attenuated O
frontal O
CNV O
- O
1 O
amplitude O
and O
a O
trend O
towards O
increased O
CNV O
- O
1 O
and O
CNV O
- O
2 O
occipital RARE
amplitudes O
. O

Where RARE
UMDNJ ALLCAPS
is O
headed RARE
. O

Overexpression O
of O
c I-GENE
- I-GENE
Myc I-GENE
in O
serum O
- O
starved RARE
human O
or O
mouse O
embryonic O
cells O
leads O
to O
apoptosis O
which O
is O
significantly O
reduced O
in O
the O
presence O
of O
growth O
factor O
- O
containing O
serum O
. O
c I-GENE
- I-GENE
Myc I-GENE
- O
induced O
apoptosis O
appears O
to O
be O
deficient O
in O
bax RARE
- O
null O
as O
compared O
with O
bax RARE
- O
wild O
- O
type O
mouse O
embryonic O
fibroblasts O
. O

Antimicrobial RARE
Susceptibility RARE
of O
Klebsiella O
pneumoniae O
Producing RARE
Extended RARE
- I-GENE
Spectrum RARE
beta I-GENE
- I-GENE
lactamase I-GENE
( O
ESBL ALLCAPS
) O
Isolated RARE
in O
Hospitals RARE
in O
Brazil RARE
. O

CONCLUSION O
: O
Our O
results O
suggest O
that O
AIF ALLCAPS
peak O
saturation O
leads O
to O
a O
significant O
systematic O
error O
in O
the O
determination O
of O
CBV ALLCAPS
and O
CBF O
values O
and O
has O
necessarily O
to O
be O
taken O
into O
account O
for O
dynamic O
contrast O
- O
enhanced O
MR O
perfusion O
studies O
. O

METHODS O
: O
T2 O
*- RARE
weighted O
, O
three O
- O
dimensional O
gradient O
- O
echo O
images O
were O
acquired O
by O
exploiting RARE
the O
magnetic O
susceptibility O
difference O
between O
oxygenated RARE
and O
deoxygenated RARE
hemoglobin I-GENE
in O
the O
vasculature RARE
and O
microvasculature RARE
. O

In O
the O
COPD O
patients O
, O
the O
variability O
of O
Delta O
- O
inst RARE
Rrs RARE
( O
30 O
%) O
was O
greater O
than O
that O
of O
FOT ALLCAPS
Rrs RARE
( O
21 O
%). O

Toward RARE
this O
end O
, O
we O
prepared O
synthetic O
proteins O
with O
either O
the O
catalytic O
domain O
of O
FAP ALLCAPS
- I-GENE
1 I-GENE
( I-GENE
C I-GENE
- I-GENE
terminal I-GENE
399 NUMERIC
amino I-GENE
acids I-GENE
) I-GENE
or O
its O
inactive O
form O
( O
Cys2408 NUMERIC
--> O
Ser O
) O
fused O
to O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
). O

Thus O
, O
Pet111p NUMERIC
could O
play O
dual O
roles O
in O
both O
membrane O
localization O
and O
regulation O
of O
Cox2p NUMERIC
synthesis O
within O
mitochondria O
. O

Furthermore O
, O
transfection O
of O
cells O
with O
the O
spacer O
- O
RING O
domain O
alone O
suppressed O
the O
antiapoptotic RARE
function O
of O
the O
N O
- O
terminal O
BIR ALLCAPS
domain O
of O
c I-GENE
- I-GENE
IAP1 NUMERIC
and O
induced O
apoptosis O
. O

The O
determination O
of O
the O
double O
bounds RARE
in O
blood O
serum O
lipids O
by O
titration O
with O
ozone RARE
: O
the O
pathophysiology O
and O
diagnostic O
significance O
] O
In O
this O
article O
the O
method O
of O
definition O
of O
double O
binders RARE
in O
lipids O
of O
blood O
serum O
in O
patients O
with O
different O
diseases O
basically RARE
atherosclerosis O
and O
ischemic O
heart O
disease O
, O
with O
use O
titration O
by O
ozone RARE
is O
given O
. O

Ang RARE
II I-GENE
- O
induced O
fibronectin I-GENE
mRNA O
was O
not O
affected O
by O
PKC I-GENE
inhibitors O
or O
PKC I-GENE
depletion O
, O
whereas O
specific O
inhibition O
of O
EGF I-GENE
- I-GENE
R I-GENE
function O
by O
a O
dominant I-GENE
negative I-GENE
EGF I-GENE
- I-GENE
R I-GENE
mutant I-GENE
and O
tyrphostin RARE
AG1478 NUMERIC
abolished O
induction O
of O
fibronectin I-GENE
mRNA I-GENE
. O

Acoust RARE
. O

Video RARE
images O
of O
the O
nostrils RARE
were O
captured RARE
and O
then O
analyzed O
for O
area O
, O
perimeter RARE
, O
centroid RARE
, O
principal O
axis O
, O
moments RARE
about O
the O
major O
and O
minor O
axes RARE
( O
I11 NUMERIC
, O
I22 NUMERIC
), O
anisometry RARE
, O
bulkiness RARE
, O
lateral O
offset RARE
, O
internostril RARE
angle O
, O
and O
rotational RARE
angle O
. O

MS O
characteristics O
of O
coumarins RARE
, O
psoralens RARE
and O
polymethoxylated RARE
flavones RARE
with O
different O
substitution O
patterns O
were O
determined O
on O
the O
basis O
of O
the O
response O
obtained O
with O
the O
APcI LASTCAP
interface O
. O

Young RARE
fish O
( O
Oreochromis RARE
mossambicus RARE
) O
were O
exposed O
to O
microgravity RARE
( O
micro O
g O
) O
for O
9 O
to O
10 O
days O
during O
space O
missions RARE
STS ALLCAPS
- O
55 O
and O
STS ALLCAPS
- O
84 O
, O
or O
to O
hypergravity RARE
( O
hg RARE
) O
for O
9 O
days O
. O

S6K2 NUMERIC
is O
highly O
homologous O
to O
S6K1 NUMERIC
in O
the O
core O
kinase O
and O
linker O
regulatory O
domains O
but O
differs O
from O
S6K1 NUMERIC
in O
the O
N O
- O
and O
C O
- O
terminal O
regions O
and O
is O
differently O
localized O
primarily O
to O
the O
nucleus O
because O
of O
a O
C O
- O
terminal O
nuclear O
localization O
signal O
unique O
to O
S6K2 NUMERIC
. O

Pretreatment RARE
of O
cells O
with O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
- I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
kinase I-GENE
( O
MEK I-GENE
) O
inhibitor O
U0126 NUMERIC
inhibited O
S6K2 NUMERIC
activation O
to O
a O
greater O
extent O
than O
S6K1 NUMERIC
. O

T O
cells O
express O
two O
isoforms O
of O
S6k1 NUMERIC
: O
a O
70 O
kDa O
cytoplasmic O
kinase O
and O
an O
85 O
kDa O
isoform O
that O
has O
a O
classic RARE
nuclear O
localisation RARE
. O

Ketanserin RARE
, O
a O
hypotensive O
drug O
with O
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
antagonism RARE
, O
when O
administered O
by O
topical RARE
infusion O
of O
a O
0 O
. O
25 O
% O
w O
/ O
v O
solution O
by O
corneal O
and O
scleral RARE
applications O
, O
was O
found O
to O
lower O
intraocular RARE
pressure O
with O
four O
times O
more O
activity O
than O
its O
metabolite O
, O
ketanserinol RARE
. O

A O
prospectively RARE
gated O
2D NUMERIC
axial O
sequence O
with O
velocity O
encoding O
in O
the O
craniocaudal RARE
direction O
in O
the O
cervical O
region O
was O
set O
at O
a O
velocity O
of O
+/- O
10 O
cm O
/ O
s O
. O

It O
was O
subsequently O
shown O
that O
Tip60 NUMERIC
had O
histone I-GENE
acetyltransferase I-GENE
( O
HAT ALLCAPS
) O
activity O
. O

Our O
data O
show O
that O
multiple O
MLSN1 NUMERIC
transcripts I-GENE
, O
both O
constitutively O
expressed O
and O
inducible O
, O
are O
present O
in O
cultured O
pigmented RARE
melanoma O
cells O
, O
and O
suggest O
that O
MLSN1 NUMERIC
expression O
can O
be O
regulated O
at O
the O
level O
of O
both O
transcription O
and O
mRNA O
processing O
. O

Copyright O
2000 O
Academic O
Press O
. O

Plectin RARE
and O
desmoplakin RARE
have O
GSR ALLCAPS
- O
containing O
domains O
at O
their O
C O
- O
termini O
and O
we O
further O
demonstrate O
that O
the O
GSR ALLCAPS
- O
containing O
domain O
of O
plectin RARE
, O
but O
not O
desmoplakin RARE
, O
can O
bind O
to O
MTs RARE
in O
vivo O
. O

Characterization O
of O
the O
microtubule O
binding O
domain O
of O
microtubule I-GENE
actin I-GENE
crosslinking RARE
factor I-GENE
( O
MACF ALLCAPS
): O
identification O
of O
a O
novel O
group O
of O
microtubule I-GENE
associated I-GENE
proteins I-GENE
. O

These O
results O
also O
suggest O
the O
involvement O
of O
additional O
elements O
in O
the O
UPR ALLCAPS
. O

We O
show O
that O
in O
contrast O
to O
SRC1 NUMERIC
, O
direct O
binding O
of O
CBP I-GENE
to O
the O
estrogen I-GENE
receptor I-GENE
is O
weak O
, O
suggesting O
that O
SRC1 NUMERIC
functions O
primarily O
as O
an O
adaptor O
to O
recruit O
CBP I-GENE
and O
p300 I-GENE
. O

Remarkably RARE
, O
a O
construct O
corresponding O
to O
residues O
631 NUMERIC
to O
970 NUMERIC
, O
which O
contains O
only O
the O
LXXLL ALLCAPS
motifs O
and O
the O
AD1 NUMERIC
region O
of O
SRC1 NUMERIC
, O
retained O
strong O
coactivator O
activity O
in O
our O
assays O
. O

Since O
MEK I-GENE
acts O
as O
a O
cytoplasmic O
anchor O
for O
the O
ERKs I-GENE
, O
the O
lack O
of O
a O
MEK I-GENE
interaction O
resulted O
in O
the O
aberrant O
nuclear O
localization O
of O
ERK2 I-GENE
- O
Delta19 NUMERIC
- I-GENE
25 I-GENE
mutants O
in O
serum O
- O
starved RARE
cells O
. O

Pmt2 NUMERIC
is O
a O
member O
of O
a O
six O
- O
protein O
family O
in O
yeast O
that O
catalyzes O
the O
first O
step O
in O
O O
mannosylation RARE
of O
target O
proteins O
. O

Fecal RARE
samples O
were O
collected O
at O
the O
beginning O
and O
end O
of O
each O
trial O
period O
and O
were O
analyzed O
for O
gastrointestinal O
nematode O
eggs O
and O
Giardia RARE
cyst O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
risk O
factors O
for O
background O
diabetic O
retinopathy RARE
( O
BDR ALLCAPS
) O
and O
PDR ALLCAPS
by O
following O
394 NUMERIC
Japanese O
patients O
with O
early O
- O
onset O
type O
2 O
diabetes O
diagnosed O
before O
30 O
years O
of O
age O
( O
mean O
age O
27 O
, O
mean O
blood O
pressure O
at O
entry O
116 NUMERIC
/ O
73 O
mm O
Hg O
). O

Of O
the O
21 O
quadrants RARE
positive O
in O
the O
controls O
, O
17 O
were O
correlated O
with O
previously O
detected O
jaw O
pathoses RARE
. O

Four O
cases O
of O
synovial O
chondromatosis RARE
are O
presented O
. O

Previous O
studies O
have O
shown O
that O
the O
pro O
- O
inflammatory O
cytokines O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
and O
interferon I-GENE
gamma I-GENE
reduce O
the O
expression O
of O
the O
cystic I-GENE
fibrosis I-GENE
transmembrane I-GENE
conductance I-GENE
regulator I-GENE
( O
CFTR I-GENE
) O
gene O
( O
CFTR I-GENE
) O
in O
HT O
- O
29 O
and O
T84 NUMERIC
cells O
by O
acting O
post O
- O
transcriptionally O
. O

Regulation O
of O
RhoA I-GENE
is O
required O
to O
maintain O
adhesion O
in O
stationary O
cells O
, O
but O
is O
also O
critical O
for O
cell O
spreading RARE
and O
migration O
[ O
3 O
]. O

Here O
we O
show O
in O
mouse O
fibroblasts O
stably O
transformed O
by O
v I-GENE
- I-GENE
Src I-GENE
that O
mRNA O
and O
protein O
levels O
of O
p21 I-GENE
( O
WAF1 I-GENE
/ O
CIP1 NUMERIC
), O
cyclin I-GENE
D1 I-GENE
, O
and O
cyclin I-GENE
E I-GENE
are O
elevated O
. O

ORFA ALLCAPS
and O
ccdA LASTCAP
were O
constitutively O
cotranscribed O
as O
determined O
by O
primer O
extension O
analysis O
. O

Mouse RARE
Impact RARE
is O
a O
paternally RARE
expressed O
gene O
encoding O
an O
evolutionarily O
conserved O
protein O
of O
unknown O
function O
. O

These O
cells O
produced O
P2Y NUMERIC
( I-GENE
11 I-GENE
) I-GENE
mRNA I-GENE
during O
culture O
. O

Coexpression RARE
studies O
indicate O
that O
insulin I-GENE
and O
PKB I-GENE
suppress O
transactivation O
by O
C I-GENE
/ I-GENE
EBPbeta I-GENE
, O
but O
not O
C I-GENE
/ I-GENE
EBPalpha RARE
, O
and O
that O
N O
- O
terminal O
transactivation O
domains O
in O
C I-GENE
/ I-GENE
EBPbeta I-GENE
are O
required O
. O

Among O
eight O
graminaceous RARE
species O
tested O
, O
Ids3 NUMERIC
expression O
was O
observed O
only O
in O
Fe RARE
- O
deficient O
roots O
of O
H O
. O
vulgare RARE
and O
Secale RARE
cereale RARE
. O
which O
not O
only O
secrete RARE
2 O
'- O
deoxymugineic RARE
acid O
( O
DMA ALLCAPS
), O
but O
also O
mugineic RARE
acid O
( O
MA O
) O
and O
3 O
- O
epihydroxymugineic RARE
acid O
( O
epiHMA LASTCAP
, O
H O
. O
vulgare RARE
), O
and O
3 O
- O
hydroxymugineic RARE
acid O
( O
HMA ALLCAPS
, O
S O
. O
cereale RARE
). O

In O
contrast O
, O
high O
COUP I-GENE
- I-GENE
TFI I-GENE
expression O
impeded RARE
the O
neuronal O
differentiation O
of O
P19 O
cells O
induced O
with O
RA O
, O
resulting O
in O
cell O
cultures O
lacking O
neurons O
. O

Because O
PET O
is O
also O
useful O
for O
the O
pretreatment O
and O
follow O
- O
up O
evaluation O
, O
the O
use O
of O
stereotactic RARE
PET O
in O
these O
patients O
can O
enable RARE
an O
accurate O
comparison O
of O
PET O
- O
based O
metabolic O
data O
with O
MR O
- O
based O
anatomical O
data O
. O

Therefore O
, O
in O
our O
in O
vitro O
model O
, O
the O
localization O
of O
the O
mutation O
in O
the O
K I-GENE
- I-GENE
ras I-GENE
gene I-GENE
predisposes RARE
to O
a O
different O
level O
of O
aggressiveness RARE
in O
the O
transforming O
phenotype O
. O

Here O
, O
we O
describe O
the O
isolation O
of O
MdPin1 NUMERIC
, O
a O
Pin1 NUMERIC
homologue O
from O
the O
plant O
species O
apple RARE
( O
Malus RARE
domestica RARE
) O
and O
show O
that O
it O
has O
the O
same O
phosphorylation O
- O
specific O
substrate O
specificity O
and O
can O
be O
inhibited O
by O
juglone RARE
in O
vitro O
, O
as O
is O
the O
case O
for O
Pin1 NUMERIC
. O

Differential O
association O
of O
products O
of O
alternative O
transcripts O
of O
the O
candidate O
tumor I-GENE
suppressor I-GENE
ING1 NUMERIC
with O
the O
mSin3 NUMERIC
/ O
HDAC1 NUMERIC
transcriptional O
corepressor RARE
complex O
. O

These O
and O
other O
data O
presented O
suggest O
that O
TAg RARE
' O
re O
- O
models O
' O
host O
cell O
transcription O
factors O
that O
are O
used O
early O
in O
viral O
infection O
, O
and O
thereby O
mimics RARE
an O
event O
that O
naturally O
occurs O
during O
transformation O
. O

This O
sensitivity O
analysis O
showed O
that O
the O
practical RARE
limits O
of O
the O
accuracy O
of O
the O
used O
screening O
test O
jeopardize RARE
the O
estimation O
of O
the O
true O
herd O
prevalence O
within O
reasonable O
confidence O
limits O
, O
because O
the O
within O
- O
herd O
PTB O
true O
prevalence O
was O
low O
. O
For O
this O
reason RARE
we O
augmented O
the O
herd O
specificity O
for O
herds RARE
with O
larger O
adult O
herd O
size O
(> O
5 O
). O

ORFK10 NUMERIC
. I-GENE
5 I-GENE
encodes O
a O
protein O
, O
latency I-GENE
- I-GENE
associated I-GENE
nuclear I-GENE
antigen I-GENE
2 I-GENE
( O
LANA2 NUMERIC
), O
which O
is O
expressed O
in O
KSHV O
- O
infected O
hematopoietic O
tissues O
, O
including O
PEL ALLCAPS
and O
CD O
but O
not O
KS O
lesions O
. O

As O
hypothesized RARE
, O
believers RARE
showed O
relatively O
higher O
right O
hemispheric RARE
activation O
and O
reduced O
hemispheric RARE
asymmetry O
of O
functional O
complexity O
. O

In O
Xenopus O
, O
BMPs RARE
act O
as O
epidermal O
inducers RARE
and O
also O
as O
negative O
regulators O
of O
neurogenesis RARE
. O

Presently RARE
four O
unique O
variants O
carrying O
distinct O
GAF ALLCAPS
sequences I-GENE
in O
the O
N O
- O
terminal O
region O
have O
been O
identified O
. O

Genomic O
organization O
of O
the O
human O
phosphodiesterase I-GENE
PDE11A NUMERIC
gene I-GENE
. O

The O
present O
findings O
revealed O
that O
the O
rib RARE
- I-GENE
2 I-GENE
protein I-GENE
was O
a O
unique O
alpha1 I-GENE
, I-GENE
4 I-GENE
- I-GENE
N I-GENE
- I-GENE
acetylglucosaminyltransferase RARE
involved O
in O
the O
biosynthetic O
initiation O
and O
elongation O
of O
heparan RARE
sulfate O
. O

Inhibition O
of O
the O
Mek RARE
/ O
Erk RARE
pathway O
in O
Rat1 NUMERIC
/ O
ras I-GENE
cells O
, O
using O
the O
Mek RARE
inhibitor O
, O
PD98059 O
, O
resulted O
in O
complete O
cytoskeletal O
recovery O
, O
indistinguishable O
from O
that O
induced O
by O
HR12 NUMERIC
. O

The O
transcription O
factor O
CHOP I-GENE
/ O
GADD153 NUMERIC
gene O
is O
induced O
by O
cellular O
stress O
and O
is O
involved O
in O
mediating O
apoptosis O
. O

Addition O
of O
synthetic O
tyrosine O
- O
phosphorylated O
peptides O
derived O
from O
betac RARE
cytoplasmic O
tyrosines RARE
prior O
to O
GM I-GENE
- I-GENE
CSF I-GENE
stimulation O
inhibited O
the O
in O
vitro O
activation O
of O
STAT5 I-GENE
. O

MAIN O
OUTCOME O
MEASURES ALLCAPS
: O
Percentage RARE
change O
in O
the O
apnea O
- O
hypopnea RARE
index O
( O
AHI ALLCAPS
; O
apnea O
events O
+ O
hypopnea RARE
events O
per O
hour O
of O
sleep O
) O
and O
odds O
of O
developing O
moderate O
- O
to O
- O
severe O
SDB ALLCAPS
( O
defined O
by O
an O
AHI ALLCAPS
> O
or O
= O
15 O
events O
per O
hour O
of O
sleep O
), O
with O
respect O
to O
change O
in O
weight O
. O

Paraneoplastic RARE
rheumatic RARE
syndromes O
. O

This O
article O
reviews RARE
recent O
information O
on O
the O
frequency O
, O
characteristics O
, O
and O
possible O
pathogenic O
mechanisms O
of O
the O
vasculitides RARE
occurring O
in O
patients O
with O
the O
main O
connective O
tissue O
diseases O
. O

Tec RARE
kinase I-GENE
signaling O
in O
T O
cells O
is O
regulated O
by O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
the O
Tec RARE
pleckstrin I-GENE
homology I-GENE
domain I-GENE
. O

Current O
evidence O
for O
this O
type O
of O
DNA O
supercoiling RARE
- O
dependent O
transcriptional O
coupling O
, O
based O
largely O
on O
the O
in O
vivo O
activities O
of O
promoters O
contained O
in O
engineered O
DNA O
constructs O
, O
suggests O
that O
the O
transcription O
complex O
must O
be O
physically O
hindered RARE
to O
generate O
DNA O
supercoils RARE
and O
to O
prevent O
their O
diffusion O
throughout O
the O
DNA O
duplex O
. O

The O
structure O
of O
the O
free O
SH2 I-GENE
domain I-GENE
has O
been O
compared O
to O
that O
of O
the O
SH2 I-GENE
complexed O
with O
a O
doubly RARE
phosphorylated O
peptide O
derived O
from O
polyomavirus RARE
middle I-GENE
T I-GENE
antigen I-GENE
( O
MT ALLCAPS
). O

We O
have O
identified O
three O
binding O
sites O
for O
protein O
complexes O
: O
a O
palindrome O
, O
a O
direct O
repeat O
, O
and O
a O
C O
+ O
T O
sequence O
that O
corresponds O
to O
seven O
GAGA ALLCAPS
motifs O
on O
the O
transcribed O
strand O
. O

Copyright O
2000 O
Academic O
Press O
. O

Nucleotide O
sequence O
, O
genome O
organization O
and O
phylogenetic O
analysis O
of O
pineapple RARE
mealybug RARE
wilt RARE
- O
associated O
virus O
- O
2 O
. O

Patients O
underwent O
pretreatment O
cystoscopy RARE
and O
detailed O
tumor O
mapping O
, O
and O
were O
treated O
with O
75 O
mg O
. O
/ O
m O
. O
2 O
cisplatin O
on O
day O
1 O
and O
1 O
gm RARE
./ RARE
m O
. O
2 O
daily O
, O
5 O
- O
fluorouracil O
on O
days O
1 O
to O
4 O
and O
definitive O
radiotherapy O
. O

All O
9 O
untreated O
patients O
underwent O
laparoscopy RARE
, O
which O
identified O
3 O
intra O
- O
abdominal O
, O
3 O
vanished RARE
and O
2 O
peeping RARE
testes O
, O
and O
1 O
atrophic RARE
testis O
in O
the O
inguinal RARE
canal RARE
. O

This O
philosophy RARE
was O
instituted RARE
for O
the O
compound O
RP O
73401 NUMERIC
, O
a O
specific O
phosphodiesterase I-GENE
IV I-GENE
inhibitor O
, O
that O
was O
being O
developed O
simultaneously O
for O
delivery O
by O
both O
oral O
and O
pulmonary O
routes O
of O
administration O
. O

Increased O
levels O
of O
anticardiolipin RARE
immunoglobulin I-GENE
G I-GENE
may O
also O
cause O
bleeding O
. O

RESULTS O
: O
Prevalence RARE
of O
obesity O
( O
BMI O
SDS O
> O
2 O
. O
0 O
) O
was O
< O
2 O
% O
at O
diagnosis O
, O
but O
increased O
to O
16 O
% O
at O
3y NUMERIC
. O

One O
of O
the O
sequelae RARE
of O
the O
antiphospholipid RARE
- O
antibodies O
is O
an O
impaired O
uteroplacental RARE
circulation O
. O

Bupropion RARE
to O
aid O
smoking O
cessation O
. O

Using O
a O
natural O
dominant O
negative O
for O
AP I-GENE
- I-GENE
1 I-GENE
transcriptional O
activity O
in O
ROS O
17 O
/ O
2 O
. O
8 O
cells O
, O
we O
then O
showed O
that O
AP I-GENE
- I-GENE
1 I-GENE
transcription I-GENE
factors I-GENE
mediated O
TGF I-GENE
- I-GENE
beta1 I-GENE
- O
and O
BMP I-GENE
- I-GENE
2 I-GENE
- O
regulated O
expression O
of O
the O
( I-GENE
alpha1 I-GENE
) I-GENE
collagen I-GENE
I I-GENE
gene I-GENE
as O
well O
as O
TGF I-GENE
- I-GENE
beta1 I-GENE
- O
regulated O
expression O
of O
the O
parathyroid I-GENE
hormone I-GENE
( O
PTH I-GENE
)/ O
PTH I-GENE
- I-GENE
related I-GENE
peptide I-GENE
( I-GENE
PTHrP LASTCAP
) I-GENE
receptor I-GENE
. O

PM ALLCAPS
12 O
or O
18 O
mg O
/ O
kg O
daily O
plus O
a O
standard O
dose O
of O
SB ALLCAPS
for O
21 O
days O
was O
statistically O
more O
effective O
than O
SB ALLCAPS
in O
producing O
a O
final O
cure O
for O
patients O
with O
VL ALLCAPS
in O
Bihar RARE
, O
India RARE
. O

Adjuvant RARE
therapy O
for O
colon O
cancer O
] O
Surgery RARE
alone O
may O
fail O
to O
cure O
a O
considerable O
number O
of O
locally O
advanced O
colon O
cancers O
. O

There O
were O
significant O
differences O
( O
p O
< O
0 O
. O
05 O
) O
between O
the O
fracture O
and O
nonfracture RARE
groups O
in O
the O
total O
femur O
BMD O
( O
13 O
%), O
trabecular RARE
BMD O
in O
the O
distal O
radius RARE
( O
4 O
%), O
and O
the O
fractal RARE
dimension RARE
in O
the O
radiographs O
( O
FD2 NUMERIC
) O
( O
3 O
%). O

BACKGROUND O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
and O
compare O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
levels O
in O
gingival RARE
crevicular RARE
fluid O
( O
GCF ALLCAPS
) O
and O
clinical O
periodontal O
findings O
in O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
and O
adult O
periodontitis RARE
( O
AP O
). O

In O
a O
prospective O
, O
multicentre RARE
trial O
the O
efficacy O
of O
an O
Vitex RARE
agnus RARE
castus RARE
L O
extract O
Ze RARE
440 O
was O
investigated O
in O
50 O
patients O
with O
pre O
- O
menstrual O
syndrome O
( O
PMS ALLCAPS
). O

Studies O
are O
necessary O
to O
assess O
the O
source O
of O
contamination O
and O
potential O
role O
of O
MRSA ALLCAPS
- O
contaminated O
milk O
in O
the O
transmission O
of O
MRSA ALLCAPS
to O
neonates O
. O

Effects O
of O
Trypanosoma O
vivax RARE
on O
pregnancy O
of O
Yankasa RARE
sheep O
and O
the O
results O
of O
homidum RARE
chloride O
chemotherapy O
. O

NF I-GENE
kappa I-GENE
B I-GENE
was O
activated O
to O
a O
much O
greater O
extent O
by O
roscovitine RARE
in O
the O
WT ALLCAPS
cells O
than O
in O
Y8 NUMERIC
cells O
. O

Depending RARE
on O
treatment O
exposures O
, O
this O
at O
- O
risk O
population O
may O
experience O
life O
- O
threatening RARE
late O
effects O
, O
such O
as O
cirrhosis O
secondary O
to O
hepatitis O
C O
or O
late O
- O
onset O
anthracycline RARE
- O
induced O
cardiomyopathy O
, O
or O
life O
- O
changing O
late O
effects O
, O
such O
as O
cognitive O
dysfunction O
. O

The O
presence O
of O
locus O
- O
specific O
residues O
throughout O
the O
entire O
promoter O
region O
strongly O
suggests O
that O
the O
various O
HLA I-GENE
class I-GENE
I I-GENE
loci I-GENE
are O
differentially O
regulated O
. O

Because O
the O
number O
of O
parameters O
required O
by O
a O
Volterra RARE
series O
grows RARE
rapidly O
with O
both O
the O
length O
of O
its O
memory O
and O
the O
order O
of O
its O
nonlinearity RARE
, O
methods O
for O
identifying O
these O
models O
from O
measurements O
of O
input O
/ O
output O
data O
are O
limited O
to O
low O
- O
order O
systems O
with O
relatively O
short O
memories RARE
. O

The O
standard O
method O
for O
calculating RARE
the O
composite O
score O
on O
the O
S O
- O
B O
IV O
excludes RARE
subtests RARE
with O
a O
raw RARE
score O
of O
0 O
, O
which O
overestimates RARE
cognitive O
functioning O
in O
young O
biologically O
high O
risk O
children O
. O

NiCl RARE
( O
2 O
)- O
induced O
MCP ALLCAPS
- I-GENE
1 I-GENE
synthesis O
required O
activation O
of O
NF I-GENE
- I-GENE
kappaB I-GENE
since O
mutation O
of O
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
binding I-GENE
sites I-GENE
in O
the O
promoter O
resulted O
in O
complete O
loss O
of O
inducible O
promoter O
activity O
. O

Engagement RARE
of O
human I-GENE
CD2 NUMERIC
by O
mitogenic O
pairs O
of O
anti I-GENE
- I-GENE
CD2 NUMERIC
mAb I-GENE
induces O
tyrosine O
phosphorylation O
of O
a O
number O
of O
intracellular O
proteins O
including O
a O
120 O
kDa O
phosphoprotein O
that O
we O
identify O
as O
the O
proto I-GENE
- I-GENE
oncogene I-GENE
c I-GENE
- I-GENE
Cbl I-GENE
. O

Validity RARE
of O
NIR ALLCAPS
spectroscopy O
for O
quantitatively RARE
measuring O
muscle O
oxidative O
metabolic O
rate O
in O
exercise O
. O

Previous O
studies O
have O
demonstrated O
that O
tissue O
- O
restricted O
transcription O
factors O
including O
PU I-GENE
. I-GENE
1 I-GENE
and O
PU I-GENE
. I-GENE
1 I-GENE
interaction I-GENE
partner I-GENE
( O
PIP ALLCAPS
) O
function O
synergistically O
with O
c I-GENE
- I-GENE
Fos I-GENE
plus O
c I-GENE
- I-GENE
Jun I-GENE
to O
stimulate O
the O
kappaE3 NUMERIC
'- I-GENE
enhancer I-GENE
in O
3T3 O
cells O
. O

The O
murine I-GENE
int I-GENE
- I-GENE
6 I-GENE
locus I-GENE
, O
identified O
as O
a O
frequent O
integration O
site O
of O
mouse O
mammary O
tumor O
viruses O
, O
encodes O
the O
48 I-GENE
- I-GENE
kDa I-GENE
eIF3e NUMERIC
subunit I-GENE
of I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
eIF3 I-GENE
. O

An O
int6 NUMERIC
deletion I-GENE
( O
int6Delta NUMERIC
) O
mutant O
was O
viable O
but O
grew RARE
slowly O
in O
minimal O
medium O
. O

Additionally O
, O
MIP I-GENE
- I-GENE
2A I-GENE
antagonizes RARE
cell O
growth O
regulatory O
role O
of O
MBP I-GENE
- I-GENE
1 I-GENE
. O

We O
produced O
transgenic O
plants O
expressing O
the O
antisense I-GENE
Arabidopsis I-GENE
HD I-GENE
( O
AtHD1 NUMERIC
) O
gene O
. O

3 O
. O
04 O
+/- O
1 O
. O
2 O
, O
P O
< O
0 O
. O
0001 O
), O
large O
accelerations RARE
/ O
30 O
min O
( O
1 O
. O
46 O
+/- O
1 O
. O
96 O
vs O
. O

Four O
transcription O
initiation O
sites O
have O
been O
identified O
by O
full O
- O
length O
RNA I-GENE
ligase I-GENE
- O
mediated O
rapid O
amplification O
of O
cDNA O
ends O
( O
RLM ALLCAPS
- O
RACE O
) O
between O
- O
61 O
and O
- O
32 O
bp O
from O
the O
translation O
initiation O
codon O
. O
Reverse O
transcription O
- O
PCR O
analysis O
revealed O
that O
PFK I-GENE
- I-GENE
A I-GENE
, O
PFK I-GENE
- I-GENE
B I-GENE
and O
PFK I-GENE
- I-GENE
C I-GENE
genes I-GENE
were O
expressed O
, O
in O
all O
mouse O
tissues O
tested O
, O
at O
varying O
levels O
. O

PFK I-GENE
- I-GENE
A I-GENE
mRNA O
was O
more O
abundantly O
expressed O
in O
all O
tissues O
than O
were O
the O
PFK I-GENE
- I-GENE
B I-GENE
and O
PFK I-GENE
- I-GENE
C I-GENE
genes I-GENE
. O

We O
used O
the O
Toshiba RARE
IIDR ALLCAPS
system O
, O
which O
is O
composed O
of O
an O
X O
- O
ray O
TV ALLCAPS
system O
and O
a O
digital O
image O
managing RARE
circuit O
. O

In O
whole O
sardine RARE
, O
domoic RARE
acid O
was O
detected O
in O
levels O
exceeding RARE
sometimes RARE
the O
regulatory O
limit O
. O

In O
addition O
, O
we O
identified O
two O
mutations O
, O
Delta O
M1281 NUMERIC
and O
IVS51 NUMERIC
+ O
5G NUMERIC
--> O
A O
, O
in O
a O
German RARE
USH1 NUMERIC
patient O
. O

Closeup RARE
: O
a O
resource O
for O
nurses RARE
who O
smoke O
. O

[ O
18F O
](+)- RARE
4 O
- O
fluorobenzyltrozamicol RARE
( O
FBT ALLCAPS
), O
which O
selectively O
binds O
to O
the O
vesicular O
acetylcholine I-GENE
transporter I-GENE
in O
the O
presynaptic RARE
cholinergic O
neuron O
, O
has O
previously O
been O
shown O
to O
be O
a O
useful O
ligand O
for O
the O
study O
of O
cholinergic O
terminal O
density O
in O
the O
basal O
ganglia RARE
with O
PET O
. O

We O
demonstrate O
that O
the O
protein O
is O
a O
murine I-GENE
homologue I-GENE
of I-GENE
SAF ALLCAPS
- I-GENE
A I-GENE
which O
has O
been O
shown O
to O
bind O
selectively O
to O
MARs RARE
and O
is O
responsible O
for O
the O
satMa RARE
- O
binding O
activity O
in O
the O
chromatographic O
fractions O
. O

The O
molecular O
associations O
dictating RARE
INCENP ALLCAPS
behavior O
during O
mitosis O
are O
currently O
unknown O
. O

Ang RARE
II I-GENE
significantly O
induced O
Ang2 NUMERIC
mRNA I-GENE
accumulations RARE
without O
affecting O
Ang1 NUMERIC
or O
Tie2 NUMERIC
expression O
, O
which O
was O
inhibited O
by O
protein I-GENE
kinase I-GENE
C I-GENE
inhibitors O
and O
by O
intracellular O
Ca O
( O
2 O
+) O
chelating RARE
agents O
. O

Promoter O
analysis O
demonstrated O
that O
the O
sequence O
identical O
to O
consensus O
cAMP O
- O
responsive O
element O
( O
CRE O
) O
located O
at O
- O
481 NUMERIC
of O
the O
SMemb RARE
promoter I-GENE
was O
critical O
for O
Hex RARE
responsiveness O
. O

LH I-GENE
/ I-GENE
CG I-GENE
receptor I-GENE
activation O
of O
ARNO ALLCAPS
is O
not O
mediated O
by O
activation O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
) O
or O
by O
G I-GENE
protein I-GENE
beta I-GENE
gamma I-GENE
subunits I-GENE
. O

Deletion O
analysis O
showed O
that O
the O
- O
321 NUMERIC
/+ RARE
41 O
sequence O
was O
sufficient O
for O
both O
the O
constitutive O
promoter O
activity O
and O
auto RARE
- O
activation O
and O
electrophoretic O
mobility O
shift O
assays O
identified O
the O
interaction O
of O
C I-GENE
/ I-GENE
EBPs RARE
and O
Sp1 I-GENE
to O
this O
region O
. O

Termination RARE
of O
induced O
VT O
on O
the O
first O
attempt O
was O
comparable O
with O
BV ALLCAPS
pacing O
( O
87 O
. O
4 O
%) O
versus O
RV O
pacing O
( O
89 O
. O
6 O
%). O

We O
compare O
the O
results O
of O
this O
algorithm O
with O
the O
results O
obtained O
with O
two O
other O
algorithms RARE
, O
the O
optimal O
algorithm O
for O
monochannel RARE
nonoverlapping RARE
noise O
and O
the O
optimal O
algorithm O
for O
multichannel RARE
additive O
noise O
, O
and O
we O
show O
that O
in O
both O
cases O
improvement O
can O
be O
obtained O
. O

Changes O
in O
stimulation O
levels O
over O
time O
in O
nucleus O
22 O
cochlear O
implant O
users O
. O

Nuclease RARE
probing RARE
and O
structure O
- O
directed O
mutagenesis O
revealed O
that O
the O
105 O
- O
nt O
TE ALLCAPS
( O
TE105 NUMERIC
) O
forms O
a O
cruciform RARE
secondary O
structure O
containing O
four O
helices O
connected O
by O
single O
- O
stranded O
regions O
. O

Tele RARE
- O
Talk RARE
has O
the O
extra O
capability RARE
of O
operating O
in O
live O
conference RARE
situations O
using O
microphone RARE
input O
. O

A O
marked O
decrease O
in O
the O
type I-GENE
1 I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
( I-GENE
IGF I-GENE
) I-GENE
receptor I-GENE
( O
IGF I-GENE
- I-GENE
IR I-GENE
) O
occurs O
in O
prostate O
epithelial O
cells O
during O
transformation O
from O
the O
benign O
to O
the O
metastatic O
state O
. O

The O
P69 NUMERIC
cell O
line O
was O
derived O
by O
immortalization RARE
of O
human O
primary O
prostate O
epithelial O
cells O
with O
simian I-GENE
virus I-GENE
- I-GENE
40 I-GENE
T I-GENE
antigen I-GENE
and O
is O
rarely O
tumorigenic O
. O

We O
determined O
whether O
the O
human I-GENE
StAR LASTCAP
promoter I-GENE
is O
responsive O
to O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
SREBPs RARE
). O

Expression O
of O
SREBP I-GENE
- I-GENE
1a I-GENE
stimulated O
StAR LASTCAP
promoter I-GENE
activity O
in O
the O
context O
of O
COS O
- O
1 O
cells O
and O
human O
granulosa RARE
- O
lutein RARE
cells O
. O

Because O
the O
high I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
receptor I-GENE
( O
HDL I-GENE
- I-GENE
R I-GENE
) O
is O
a O
key O
element O
in O
cholesterol O
homeostasis RARE
and O
a O
potential O
therapeutic O
target O
for O
hypercholesterolemic RARE
drugs O
, O
an O
understanding O
of O
HDL I-GENE
- I-GENE
R I-GENE
regulation O
is O
essential O
. O

IFN I-GENE
- I-GENE
stimulated I-GENE
gene I-GENE
factor I-GENE
- I-GENE
3 I-GENE
and O
STAT1 I-GENE
homodimers I-GENE
formed O
and O
bound O
an O
IFN I-GENE
- I-GENE
stimulated I-GENE
response I-GENE
element I-GENE
( O
ISRE ALLCAPS
) O
and O
gamma I-GENE
- I-GENE
activated I-GENE
sequence I-GENE
( O
GAS ALLCAPS
) O
element O
, O
respectively O
. O

We O
have O
therefore O
studied O
the O
molecular O
mechanisms O
of O
TGF I-GENE
- I-GENE
beta1 I-GENE
action O
on O
thyroglobulin RARE
( O
TG I-GENE
) O
gene O
expression O
by O
focusing O
our O
attention O
on O
TGF I-GENE
- I-GENE
beta1 I-GENE
regulation O
of O
thyroid O
- O
specific O
transcription O
factors O
. O

The O
epitope O
- O
protected O
lysine O
( O
K O
) O
was O
present O
in O
a O
30 I-GENE
- I-GENE
aa I-GENE
TPO ALLCAPS
fragment I-GENE
that O
, O
by O
N O
- O
terminal O
sequencing O
, O
was O
found O
to O
be O
K713 NUMERIC
. O

To O
understand O
the O
molecular O
regulation O
of O
these O
genes O
in O
thyroid O
cells O
, O
the O
effect O
of O
thyroid I-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
( O
TTF I-GENE
- I-GENE
1 I-GENE
) O
and O
the O
paired I-GENE
domain I-GENE
- I-GENE
containing I-GENE
protein I-GENE
8 I-GENE
( O
Pax I-GENE
- I-GENE
8 I-GENE
) O
on O
the O
transcriptional O
activity O
of O
the O
deiodinase I-GENE
promoters I-GENE
were O
studied O
. O

